<SEC-DOCUMENT>0000875045-21-000010.txt : 20210203
<SEC-HEADER>0000875045-21-000010.hdr.sgml : 20210203
<ACCEPTANCE-DATETIME>20210203163007
ACCESSION NUMBER:		0000875045-21-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		205
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210203
DATE AS OF CHANGE:		20210203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		21586576

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>biib-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:93645b15-c187-4b47-82bf-4dd611d6b978,g:f6c0263a-8ffa-4fd3-a952-6de1d776d19e,d:efe8f1adeafa45df8da4a5beded16de5--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:biib="http://www.biogenidec.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV80L2ZyYWc6Y2JmZmIzYzQ2YTI3NGIzZjkwYjk3ZGExZWNmZmU4YjAvdGFibGU6MGYzNTNiY2MxZmE4NDdhNTg3ZDQ2ZjI5ZTUwNzQ4ZTgvdGFibGVyYW5nZTowZjM1M2JjYzFmYTg0N2E1ODdkNDZmMjllNTA3NDhlOF8xLTEtMS0xLTA_0b496f3a-fed4-4e1a-a133-5d793a6c5767">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV80L2ZyYWc6Y2JmZmIzYzQ2YTI3NGIzZjkwYjk3ZGExZWNmZmU4YjAvdGFibGU6MGYzNTNiY2MxZmE4NDdhNTg3ZDQ2ZjI5ZTUwNzQ4ZTgvdGFibGVyYW5nZTowZjM1M2JjYzFmYTg0N2E1ODdkNDZmMjllNTA3NDhlOF8zLTEtMS0xLTA_12273ac1-ce7e-4f4a-b09b-78e5e1b57e48">2020</ix:nonNumeric><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV80L2ZyYWc6Y2JmZmIzYzQ2YTI3NGIzZjkwYjk3ZGExZWNmZmU4YjAvdGFibGU6MGYzNTNiY2MxZmE4NDdhNTg3ZDQ2ZjI5ZTUwNzQ4ZTgvdGFibGVyYW5nZTowZjM1M2JjYzFmYTg0N2E1ODdkNDZmMjllNTA3NDhlOF80LTEtMS0xLTA_ad8605b8-e8bc-4451-af0b-10ef0573f0cc">FY</ix:nonNumeric><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV80L2ZyYWc6Y2JmZmIzYzQ2YTI3NGIzZjkwYjk3ZGExZWNmZmU4YjAvdGFibGU6MGYzNTNiY2MxZmE4NDdhNTg3ZDQ2ZjI5ZTUwNzQ4ZTgvdGFibGVyYW5nZTowZjM1M2JjYzFmYTg0N2E1ODdkNDZmMjllNTA3NDhlOF81LTEtMS0xLTA_6ece283e-cb61-4e71-94c3-5af2a0c840cf">false</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzEtMS0xLTEtMA_0467173a-da5d-472f-9329-91ddcf11f0a3">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzEtMy0xLTEtMA_42e23e41-83c6-43cf-9e13-6898f679ca19">0.001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzItMS0xLTEtMA_5e727e9b-da1c-4acd-84c3-927c1bfa27bc">0.0005</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzItMy0xLTEtMA_dfa4d726-6e4e-4b08-b1d2-01b787269381">0.0005</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzMtMS0xLTEtMA_6aa56020-140b-41e5-ba34-7e5b580f53a9">23.8</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzMtMy0xLTEtMA_627d7927-871d-4650-bbaf-679bdf4ed356">23.8</ix:nonFraction><ix:nonNumeric contextRef="i20d53eeb6bac423daeed8dd6132359a9_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4NDA_d52adc0a-d056-48aa-8b93-a252ffbfe552">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="id1d08429d1c347878b82c18df8d582c9_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzItMS0xLTEtMA_ad4af409-6257-4ea9-b3d3-ccf967af7fb2">15</ix:nonNumeric><ix:nonNumeric contextRef="i434f35407e6e4c099ce33b8a068afd74_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzMtMS0xLTEtMA_4bff1514-1ae1-4e6b-a173-1486c952833c">40</ix:nonNumeric><ix:nonNumeric contextRef="i33ed7c967da142e892cae01133c8613e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzUtMS0xLTEtMA_a84410ae-3a67-4ef9-ba77-6a5bc6c42685">5</ix:nonNumeric><ix:nonNumeric contextRef="ie335a67b286c4619b0b5b87a19532f5a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzYtMS0xLTEtMA_b5830636-fc30-4f33-9693-e72e0cd18a82">7</ix:nonNumeric><ix:nonNumeric contextRef="i31173508fedd4169a632723f6c55327a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzgtMS0xLTEtMA_e34daa41-0aaf-41d5-9215-985cd67eec58">5</ix:nonNumeric><ix:nonNumeric contextRef="i68ae650937b24214a80dedf08e192bef_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzktMS0xLTEtMA_65586f9a-9daf-45a5-a519-b67f443aac6b">20</ix:nonNumeric><ix:nonNumeric contextRef="i20d53eeb6bac423daeed8dd6132359a9_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzExLTEtMS0xLTA_d522d9ed-79da-4f79-b808-2ce8de6a9d78">3</ix:nonNumeric><ix:nonNumeric contextRef="i1b4148f6f0e64fcc8d46dde21febd1df_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzEyLTEtMS0xLTA_1ed127fe-8322-4504-9fbf-d2bcead1f7cf">5</ix:nonNumeric><ix:nonNumeric contextRef="ic69589c021a84ef3b51246299f3819f4_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTkvZnJhZzo3OTM1YmRlYzEyNGY0ZWY3YmMyMjVhNDIxMDcyZGY1MS90YWJsZTplYmYxYjYwMTM2ODY0ZmE2OWI0ODc4Yjg3MDU3NWExMi90YWJsZXJhbmdlOmViZjFiNjAxMzY4NjRmYTY5YjQ4NzhiODcwNTc1YTEyXzMtMS0xLTEtMA_ce455bcf-7b18-423d-aa4d-df4701d94a1c">4</ix:nonNumeric><ix:nonNumeric contextRef="i6ece1a557c614598b419f009a522970e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTkvZnJhZzo3OTM1YmRlYzEyNGY0ZWY3YmMyMjVhNDIxMDcyZGY1MS90YWJsZTplYmYxYjYwMTM2ODY0ZmE2OWI0ODc4Yjg3MDU3NWExMi90YWJsZXJhbmdlOmViZjFiNjAxMzY4NjRmYTY5YjQ4NzhiODcwNTc1YTEyXzQtMS0xLTEtMA_6a0af5d0-7c4a-4499-89a9-99ccd191037f">28</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i21ab402dc3c540aaaa74ab88707cd06e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzItMS0xLTEtMA_bab008c1-85e5-49a8-8d17-62f301c653e3">2.900</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i777e7a0559ef48fd8038247a2da5c7c3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzMtMS0xLTEtMA_9f3dd0b6-fefe-4df2-b4be-810de88acdea">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if4f6df13a0ab4a20800b6bd00a5f821d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzQtMS0xLTEtMA_e89d515f-8350-4753-a174-a9d0bc4c4064">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i665e4e826ccd4df0a58a999910a2c5ce_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzUtMS0xLTEtMjQxODg_fa30f618-dde3-40dc-ba90-b2e4a6def973">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic5513569ac924bcd810dcccb4b75c1ca_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzUtMS0xLTEtMA_ab6645bf-a8c6-4423-9ca7-74ff251e6ce1">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i55d717cfc9ad47b288a5e9b60459b22c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzctMS0xLTEtMjQxODg_7ef7ae7d-815f-42b1-844d-34d42ada0080">3.150</ix:nonFraction><ix:nonNumeric contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMS0xLTEtMTMxMzU_4631686e-fcd9-443b-a344-b69d241e1c2d">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i21ab402dc3c540aaaa74ab88707cd06e_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl8yLTEtMS0xLTI0Mjgy_416f1f93-333a-42c0-91da-a300950a4cb2">2.900</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i777e7a0559ef48fd8038247a2da5c7c3_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl8zLTEtMS0xLTI0Mjgy_153276d6-3964-4550-9736-2093a173dce2">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if4f6df13a0ab4a20800b6bd00a5f821d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl80LTEtMS0xLTI0Mjgy_3abae926-ffdd-4d49-9992-75bc58879f22">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i665e4e826ccd4df0a58a999910a2c5ce_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl81LTEtMS0xLTI0Mjgy_cacfe58f-1820-4e9a-8a04-6ef078ee7946">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic5513569ac924bcd810dcccb4b75c1ca_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl82LTEtMS0xLTI0Mjgy_4685ffdc-563a-47ee-8d8c-71039fd5fb32">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i55d717cfc9ad47b288a5e9b60459b22c_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl83LTEtMS0xLTI0Mjgy_92f792b3-aa89-49c0-b3ab-031409a819f4">3.150</ix:nonFraction><ix:nonNumeric contextRef="id1c47bb693114834bbe5ba4a44e2234c_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNzA_dabd3a6a-1cff-45b6-8845-824a093e53e1">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNTQ_9f998ee0-5669-4526-a3e7-3980eafec54f">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNjU_9f998ee0-5669-4526-a3e7-3980eafec54f">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i0f3c645fd7d74b17a26a9b8652d2a6f9_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzItMS0xLTEtMA_9c8696cf-9be0-4b1e-89eb-e1c924aa1669">37.8</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic4a97d152e6b454f8ff1a1aaed64c1b2_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzItMy0xLTEtMA_7f393da7-a1a5-4ff5-a20d-9e9c9468bd24">31.2</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia726ac01887c4e3f8b260b50fdc0036c_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzItNS0xLTEtMA_0668fbaf-73ca-4776-9748-9045b9c15fd6">27.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i73be9e1394774290a72930a5f26e75a7_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzMtMS0xLTEtMA_2a2db1f8-6860-45c1-8fa7-b506f7306c32">44.1</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1a8d0fe496fa4437a1c3009ee5b30517_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzMtMy0xLTEtMA_30fba259-5dd7-49b5-9e88-4a66323727af">33.6</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia220992660254d9a81341091dce24aa9_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzMtNS0xLTEtMA_4b9f938a-6224-4b0e-a0d9-73b7cb554fbc">32.4</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzQtMS0xLTEtMA_25cb13bf-5839-40bd-9432-eeb2ce0f9198">1.41</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzQtMy0xLTEtMA_12d1e6da-7b2d-4b2d-8ba1-1876378ff37a">2.46</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzQtNS0xLTEtMA_fb455ca9-4847-4e30-be6b-26095ccbcabd">1.90</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzUtMS0xLTEtMA_cdff5667-66f1-433c-acb0-2bed149a72a1">1.48</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzUtMy0xLTEtMA_752a2d0d-4c0c-4526-b06e-e4a6a3ad2edd">2.53</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzUtNS0xLTEtMA_922966ac-244d-4428-b6f6-2fb088665f93">2.30</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="2" name="biib:AverageStockPriceOnGrantDateInDollarsMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzYtMS0xLTEtMA_7c0e90cb-6c57-42df-98bf-c6b718505e5d">257.83</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231" decimals="2" name="biib:AverageStockPriceOnGrantDateInDollarsMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzYtMy0xLTEtMA_b3b885ec-1bed-4dad-ac98-528f7a58506e">228.59</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231" decimals="2" name="biib:AverageStockPriceOnGrantDateInDollarsMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzYtNS0xLTEtMA_d22e304e-e521-470e-b43c-5272b70ad2fe">279.47</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="2" name="biib:AverageStockPriceOnGrantDateInDollarsMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzctMS0xLTEtMA_9e54c945-79d8-4fc3-9a27-404c09e7b202">325.40</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231" decimals="2" name="biib:AverageStockPriceOnGrantDateInDollarsMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzctMy0xLTEtMA_44a83221-bea1-42bf-b758-9c7d2bef7ddb">331.18</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231" decimals="2" name="biib:AverageStockPriceOnGrantDateInDollarsMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzctNS0xLTEtMA_03fef00a-5b76-40c0-8c11-032422e292a6">346.76</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ifad8db8e19694c21869ab3526b232850_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTplY2VmYzNjNTA5NzI0OGNkYjAyNDJlZjVlYTQwNDJkZS90YWJsZXJhbmdlOmVjZWZjM2M1MDk3MjQ4Y2RiMDI0MmVmNWVhNDA0MmRlXzAtMC0xLTEtMTM4MDg_0d6479ff-6b5a-4ac5-bb36-5c4d6816289c">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ibe08502e6aa446d09a87c817d769e4d4_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTplY2VmYzNjNTA5NzI0OGNkYjAyNDJlZjVlYTQwNDJkZS90YWJsZXJhbmdlOmVjZWZjM2M1MDk3MjQ4Y2RiMDI0MmVmNWVhNDA0MmRlXzEtMC0xLTEtMTM4MDg_f5a7102f-29f2-4763-8aee-963250bb27c4">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia976a78ea31f4adeb3848c2680c1fb1a_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTplY2VmYzNjNTA5NzI0OGNkYjAyNDJlZjVlYTQwNDJkZS90YWJsZXJhbmdlOmVjZWZjM2M1MDk3MjQ4Y2RiMDI0MmVmNWVhNDA0MmRlXzItMC0xLTEtMTM4MDg_0294f2fd-afa3-41b6-bbd1-b05c48076192">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i40f86ad979b04ab6b1c5dbf39dc6ca3a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if78e92be0e5f40fa8335c122c201e968_I20210202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b7b9a353c2419ca9a01532a522a0d0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2514a987784410a8165984f87269d3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2987b04d4c240d88b84a50c04ca2df1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fe07a7c7dc0443dbe2b2303dcf1a9ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic832cd7b75cb4db1947131a9ca6ada7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947f2882d6404d2ebbe95236b59c95ef_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf0372b542a4a81867022b7653fddbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b225a61fc749cf835625b8fa6246b6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba23f55f1d1462cb337f7f348d52f17_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7685594c21ff48f6aa4a4ab8e67bd590_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3565d89e31c04fe69d700b215cbfe265_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36a6dbaa4344c37a9dc77f2cda681cf_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic116ea7c17b449929c5b3e40bf3fc147_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacfecdd3de364249bf6dd9e13df58609_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9808ec312874199952c2b8c5ee0b580_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id82ee39d50af4f5587e19230de06cf02_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9925b2c3e594ae0812001969da2a99b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idae041b402f34f1db7c9617616121bba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c314d6d1f964bfe879cbff831677e6d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b238312a99c4acda7452e34a406431c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8631cd953f3488583e5a99f0aa067ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideb28add0da94e2984281d36c212a6b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieafb8a83622d4c7d83aa7f731407ace6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32b478b02b043de86c4b4db94343ae7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia04b4d5aa1794922b920009486d15ab9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59c8c0fefae64f87b0c7f553d3c884e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9730f32121bf4c97a3efb7cd327a3f8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7b0512c1ef74ccf9a55f06a601135a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02dd29564939484da19f114c7ad6568e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba1e5d98e494036a7bb6347485e7fd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dfc1fefbed7417cbbc28aa6ac0dd8b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead28cb9adf24fb08e016c9daa3a77d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ed583992094d77bff487c7db1d1673_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id631f87e609f40da8cd804801bbf81b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd77c6e9bea747df9f7e454828986d8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399ba008e6b14b85b6ac84920d61a3c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f98217bbb834e0f8ebd6c2398b7661d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a84661ca7648508fd93941bcbb997d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79397f44d5c042f496ceeab9b494a03a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b33fe470a0f4f07ae856080b1a72e21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id652954848994c64a952bdd912f71f14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if56588187b87454685183cbffc3ada80_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e4e6dae85540218e42aba08c3a9ecc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7957fd5108f041cf86733aef419c0487_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdeb7d5b926d493e962de8b221ba05e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccbf67b67a6f4ef8b20a95e69c600436_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1a9b4290144caba8998988eecf9b58_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004794513a2f4fcd8eace5db98fbe94d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fbbd190dd9349c684025d6612613087_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10bc4925779c4c62a721fcebc24cc43a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd9ccd986ede408889b471271b8b92ab_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71879223335b46f3bb3d2e9c89f29739_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0408f46008684d05830c8aaf3c8d10a9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1627e985e4343de929ab7dfd5658901_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70263815613a400b92f377b89a761d52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743aafca54fa41abb7393b53cca04663_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if23b90bc2339453c813e349dde6eb88c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5788dc676f14d319251454a02fc807d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918c175a6348429f80750ffad3e51592_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i561f5ec343c3430f81b526c7ba3bf33d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i127bbeecda744fa68a10a6e33a60cd1a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if96513171bce497b9a51c54f048f8529_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77516ed4d6a7476c85c01147c2202ad8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a8269e77864460833b3ae44b188fbe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff528a7cfce4bd8a0366f490246b62e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60b675c71ae45dcba471a7e7fe41934_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d567bbbce0486f8cfdae0a70a3f4ee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b12db8472d48b2b53334bb866cc37b_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de8222bfb764bc7976ec9ac1b1fcfee_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32099e94310245729c8234363676b11a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01ad07778ac849c8b2b4e37c57f5c8cc_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e785004dde49f0a56829b6f56ed277_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ca3a2e6fcb04f20be394cdde7a54e82_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878381e1afac4f80a13bd087ea6d9e3c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb9c26e9c2e84acbaf8ec47d303849df_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6054bf321ca4765a1d083cac2ace95d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60249b902884484cb11d0cb33e879fff_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide6cf3bb3d4e468189726437ef50fcc4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e22ca2059f4f898210fe8a9df07b93_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81db584ecd34c3fb0bcfcd6b6c8bef2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481a6d5bdbbe43a5980efa84e275da23_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8450111dafb6479dad6f805a7b7d9e08_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084deb1b42c44169a52d93eca76466ef_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d4919f13974879958994e93ea3e69e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1acabe726ab40d4b398592903594e20_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837a6587aeba49309a36ff845c583cc1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa3981c364664bbf965221342c3e8296_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26657d5aeb394760be302cf4583f264d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158387b1a5ea437bb6564f068f16da94_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8870b4b39a7c4f5db82e81c17a5045ae_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie609bb78211648bbb28efbdf966eede3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946db844720d4aa7917f3e015d7ad5f5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic69589c021a84ef3b51246299f3819f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ece1a557c614598b419f009a522970e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b527baa2064e4abdfd753f227e1770_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20d53eeb6bac423daeed8dd6132359a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b4148f6f0e64fcc8d46dde21febd1df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e23f9e905c04daca8cae6b8673c5e1f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:context id="id202dc9d694b43e7bb188183306ef1be_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredIncomeTaxChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62315bf96a414f8f8bf19b192b4c0951_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ed6ef3bd55540debba7f93c76913164_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d08429d1c347878b82c18df8d582c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i434f35407e6e4c099ce33b8a068afd74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33ed7c967da142e892cae01133c8613e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie335a67b286c4619b0b5b87a19532f5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31173508fedd4169a632723f6c55327a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ae650937b24214a80dedf08e192bef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia457a1bccc154fcd8ff6932b1456cb83_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d25f7562934bc8a1eebaf7750912d2_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibef78125dd7d4a94a4efe455cc442105_I20190607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i931745da9c9741a7bcb5a4292c51f87a_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f95102445b94a5183bbd60ea00497d5_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0b20812b1ae4a52b980e45bc1c13af9_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675123ee33df46f18f7d302db7babd89_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ed3b5c3c244392982bf3e4a342675d_I20190607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b0a4756e001463da2b40b89dfd99ab3_I20190607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i217e491a4a2945fda8b6a3fb6e69f33c_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ba7bb298ba4551bfaf50b04a063a19_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0826dcdf451640cfa9e62b8a90ea7c7c_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe928ba270d49608bb021eb1ec31bd8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38b01edc61441248c76861d6096cd34_D20180701-20180730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5655172610c049b7b1d99d51a603c7f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida412b4bccf941a7af64620b69dcf1ef_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae2c3b5bd774a9bb73adaf4ac185c0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9e587add174faba8df37c45bf81a84_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6599810683224f4f8d5b5a4cec91c8ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a89db2076b46d08a583b581aa591ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ec4e78cdf14e27b10a96f705b49b62_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c7c39b59484f68a74bc30138f093c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8bc356d23184fcebc37ba9a22520399_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f2c1d75d0244adbaf0ce60ba6f10c6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4671dcaaccbb4c73bc88e30c9c3ef796_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i611243e9e12c42aa8073bc846cf26e10_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89219f9fbe1b4c1dbf921ccb2d9beab4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d646b3f2acc46cfa9c025734b83a62d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676dac9dfca9459aa08e07ccbde07b0d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38907cded92a4460972fcfcc8fc9a8e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0479de2c47942988bc6c58b22051c05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i239b75ed62774dddb59a70525b80aa50_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad45c8aa37643dda100435c30ec9812_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie627c15061db491694d9896f93024ce7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808ab222eb14472a9a5315190f9d73f9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a5bf5f3c2f4bbfb702fcd685c5350f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdcf0cf7d9d84f1b9a94c5e3ddfaf245_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04860cd441c6444f8d0547cddbe88ec1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef7c311e0124c438791428e3b4b41a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc945d8f6294b06ab322c83d51a8139_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e8798dae8a4b08812a89a53e77047c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ac014fbb4e4c6db8de2f58e8127e65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e79a9c192ab4345a8831a1ec2ea4c7b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2acaf2f4edd94d2aa5d30476174c8ff1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9161ee6ab1b24fa0a4b4fb0e50c29fab_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc147b15e5c42138dac645bea65a6e3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51cecc234a1c499e81996ec359a83235_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc67fa6b68546999e25a409116223a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6055a732a3c42339f265cbba96a4237_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b8355cc290044cc90da4d1eb56c12fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic228d3e552df4464b29306fc6585aa80_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25bb90461ed2438a995263720a6ed66d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793c32241e6a44aa9d8cbcf846f1608e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21e1cbb7e7fd41b196a67213d407f8da_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7dc62500324422c8b3e284eaa458c65_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3153e9337f7f46b180a951e086f83f04_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30a842196f14402bb07dc592bab78e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0009c1183e6246eeb2ee54a841d184b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea2097d09a44a509b495c405a069070_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd129491fd544708255c0bf9443922c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48d69c93cae04d3491b6586590a557f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ee1ffeca9640ecb4a25fa543737c80_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92af91a220a14e519e257472f7b4627c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7dc974c8cf545aaa99c23d6995ccf0e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b5853b0a7b4b75b8a727674c5976cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6420df982c54462fac44de3494b1078a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92992eed3334e24956317197eb6249d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfe618b1b7444265baadef360f6cfe7f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3274395ada7440579bbf98e82e662536_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4163b71d3ebf4640b1af4d523043b9d5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b1f3407fd84deab1332035a3a31964_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f67a8c0aea4ef7ba8c99f1f5292a0e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fbdc5541c854505baa5fe73b8b9fb16_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic369938897d44097803fd74cc0bf646d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b7d190fad4b4287ba2080a56db09bb6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e67ce0006534c9d90964417d4f29f9a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8cbfde1864b4ae69989d769e587d576_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85145d7d92464b108b60ca4e887113f9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2352931d6f4d8980b86773c3e2523a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7979d3870a264dd0a1528aafe4e9a00c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib08fe27eb1d045de9c81dadf75845b7e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3882c6c7e44816881d6d48c711cdb8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9ada749a894e289113c4d61f405d38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie042a2edd31046aca7dde1c59f969ab3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5a0d587886c43a485b4a1beaf2cb9a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5ea019d4fd4c2f897fe2644f7c7ed2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef4f9926f8d4814a9d013cf79e963e9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d98281f667b40a595d97292a3d7d21e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i181d0ab423b0468a8a6f8b139f105d1d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c81e1552b61450e83a94056dc340dbc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ebf7dfae7004c2da140bd5817f77ab2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f197d8686c4e44bbee78953032d413_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23cac88653144474aa6d28fad81d8ecf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d5709855edc4dafb39167708c8ba135_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2c2f06527b4022a893fa9bcb7e4e52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22cdd79b3cf74f248c1f7221acba2a23_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec8554a2c2be4400a7226435515b1cff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i466f28f7b774412c92456ab39ec8c2a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31933ce497d64be0899c42e590f33e49_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7a44b1f0d049cabc406d3d7fb76dfa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc3ca49c80e494caf1f76203a66f71e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i836a100e66ca48e8a1e7ddee36e17253_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b4ad0dba054423b82e1cc5bf4358871_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28387800191b42c088cd25c6a9466a12_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3f5c2e8409c4870834b30b67f6c99d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbd96336b17c48759b92af5b727a614d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c35b9c4f72240cb91164b21f3abd0a2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e2ed02bfb06451f9fb5ae7fddafa907_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f93424eda7546c9a3ac40bcfbfaa106_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3ea9446ace44e788ee54818d9b37f3a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fbc92ecd2ec466bb430e6dce8b804a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf1efb62ce514836b55d3ee7a4ac1a5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26bd8f41008941b1be219ee8aba377f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib76e8e2921bd486fa43cf0f7bf709125_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc2e1129ed148b29526834ea34cc7e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5517906d4a214fd5a371d6c53ae66e73_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66448bf19334d99863e008bc96d2313_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b62d124ddb34cf3809af9802c175ace_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0132327259a94fb1975abd835ed78152_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c90e682e5e417a967657ac50fbacf1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43014c84e32d490e8ca9d7d907dff83b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d4c2a4027e3422ea87ff6cc3b986145_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6560ddf1da469783c308fbc59328d7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c11246cbbfa46648ee949251e0eb821_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d7562d98124ce596c58c5c77f902a5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3f610d2c9e746d5ba0b20b191ecff82_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7ac8b29bb24df09106e8a94a348a10_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f99591bb1b0401b8000095a52fab6f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bb76f2658274da7b4345880031c2273_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c66309e53f467ab518b51c5bce54f4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c98110a133446d0bd61f9284d0e58f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c311f0cc16744aeb4492070360e76b3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa69ae482814ac8bcd343ae4a224389_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="i6838460bdaca49d7b136d868993f4d08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ff66c8950bb4a7e88affcf110449d1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea5f27bc85f4fddb4469f05a3b00215_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4f9dcae88cc43e891f75bf74e4bf5c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2a9f19b6d9f4f4a995ece66958a61eb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0863980b999348b5a5e8c88dcfc46890_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd820ada82d04297b57bc8a5f70af4b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i112f6f59416148d2a921ea8b21ca66ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e510eea4c8c4271a8fe6ae31a7211f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c42c0c7a42943d7a9ffc85aa01e8a61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400709e4fbb2431a8c60b9f0001721f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb52c820db94f3aa2e279e49e3f772a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia91f6946981c4e79a74688a13b7b6cae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib09a186083b44003b3551748e372ab96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i913629824c8f4387b3fa3d219d942aff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e8aacd727c4737ad050b96fdf9c8af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6a7b631471438e8fee99a379470ccb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8cb46beb3d4d47884b9ee3730ccea5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb4285e484a4003bbfb3010fd8b052b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc03c10e08964a88b663a184122907a2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica5f21c6cd2348a196b1a5aabce51c96_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9f7171e7754520b8801272436020bd_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77265ab5c594a27b0736ca509460655_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f40d69597314563b8de93e06ec34c1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195b915d47274fca99fe4a792ac7ea69_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45223ed4352840169e55fb7523bb7c45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f4c36386654c569a449f1f90ca2232_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9559172621a745278ce2779747432dec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6b5a9481f349908c730396c050643d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd59c1996ba049328473d73e6ebc2376_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29bfccabbb4483d896c6bb788ec20c3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c7287b63dc4cd3a1a2ec95a9d031bb_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd5d205fed849349f4c94a2eb02cdd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:OtherRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a785963e61a4b4e817f15fa26f0d819_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:OtherRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf5ae537bd74ff9a59f2b74a8161266_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:OtherRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e510b249bf46dc94c9604a2b8b9a69_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c0819a2f984821bb989e9609805bb8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e58e40285c848e296a601009ac7f815_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ef21a6d03740f8aa272b7fdb22b854_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ea9f4eaaa24324b4547475bd116c88_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb160e00a5f449ca3dc21f07ab9ba0f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3976604c455244a68c5f8bc26ebe6514_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6054a3521e4fad899551ca7aeb3026_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18053bf504534e879bf5029dbb2066e7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d72ff5a209c4e3b8fd84b931863f9d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609fe60df7e64f54a5f65e6a8167f50a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ContractManufacturingCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if028deb520d34a2aa081b6f9c3dac0e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16eea92696684f6f8f01944879fe877c_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d271b53e29411abc2a151b7350aeb7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c498e3888a34f50a02f1bb18e32ad14_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0293853038ec4dbf8d988ed6233a88a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie292720cdee34fa4a2f50bd921742df8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e983ff4043d40f0913bb5c532a2f59c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb36452ab02142988e739a2d7605d7ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB054Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i101d5553f62a4ad998a4e79cfea8fca3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1193619aae94660913bc904c7ad0ebd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68ac17ffb634d7ea358cffd1d2ff11c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1c8b3e3b2804596ba415198766ed335_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f7617347de84315b946e8a49e9bd554_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia56ada61d04148c9aa29b83378b86afa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i725b0e19a3884b52a34ffa0720d25883_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f3a2917b0f4c51b7e1a5f8612047eb_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB054Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ad3e4569ba84e3ab10d4fb4ff676171_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e82735011b489487c0fe39eb2af15c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife7148cb77ec48c4a82e74afba1044e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b88845b78404eafbfca745c512904b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a386c121b94d3285b2e93991eee966_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31de162949914248aef0218bfb3cae08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia30b12536469448f9255d5e1df2de125_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa11cb31d8024230a65d4ab2be7a7509_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib868142b7926459283806400925364f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d4400d07ebb429faf284232b75c3fad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1295c3d9fdcd4cd6bd7a06e54f915289_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b1a4978f65a4ad194d0e7fd7c37d454_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia05d20dd706c4482ac970a02c04378de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i728ad60c42494777a77a89260395a79e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5360f78fa9cf47a49f8eb29cf63a6bb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1e4d4d27f141faaceb13587dfc5353_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109944c309984c92ba371b3ed38bc32c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i687ce2197ff242fb8d9744823666b4a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e264b8e2f86435888156e14e7e26af2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e51f6583c34ffea8242489d150dcac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9faf10577b784e7f8fe0df2ba091b6df_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5ca70e7a0449ef9804d477da976c90_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6ed8b6d39d4f95be135a06386353e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f12a8b2a02a45b5a3b5d20a2203d529_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7b0ff43002742d382a430a6b312ac29_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i078713d9a8a24ed788012f01caca7e4c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f29144216246c0ba14b7f3d524b07d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37c27cce50943f586fccbb1bf987550_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ee55d0301d4a5296dbfd62c35d349f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic10b6933b9ab4178884a89b8aeef21e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50c85d1b3eb3432491fd04d440130a03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia29e9f9c6a0f4c099a0d0b872c4ab3e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0afc7497a10045ec82e92ec6f6142457_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892b13c4cafa42ecb4c07f03ecf1b9af_I20190607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f77918266b4800a5e937031d200d33_D20200608-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-08</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib982081d33b9432380d458461cb24794_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4596e7576e6f4acea88a866738dcf7c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bbc25a9c5ac47fbbfd534ee97a1d39c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d8fda27d15472886e7714ecfd74f13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i801a46869f664fecb61055c870823b33_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc1b899a302148ca9891b0255cc8aa0d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b6dd5c2efe4f5396abf0aff9bfeccf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c421dee5311428bb63a943e6edd3b3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ff588847a4742dbb38528249abffe4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddd13c0f2522452cb9725ea76f4505d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0204ca1f1214960bd167eb5e80b1a81_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic30eadf1122f4f10b6945f7d760771bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83bcad67dce847b8b91749bab6735d86_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925b36a148674fc19a08cbd449595002_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92764f5eb5834b79ae55dff4c1df9d03_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic89f75651f684c4e8666f45255e68b39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a9f448c619444ab4fff72a5de9ba77_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9f5fdb4ff554001875fedb563688ba3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe586d2389a346e4b21234342c93c79a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if183ac868dc34ca58fc0c53525b4c288_D20150201-20150228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-02-01</xbrli:startDate><xbrli:endDate>2015-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i648eef4285664a8dac0cdbc16d4a15eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7237b9cff6a4464cb92770b4bf1cbbc2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51282ea551b1459695602c42c153aa71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90382b76ddef440099125efad57c3a58_D20101201-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-12-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cc1602563fe4003b79c44b2d4563182_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc66d48ef7a8480184a55afd9eb1ca13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff949adf9ab740fbb27bef3b64e6be50_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff8fc3255cf42698cf5d8a08d11df44_I20120331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8be1727d99e64340bb2d309e36968ac8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5ad52311e434feca77f912a91898714_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a46f2c40caf49ea87719f6b7a9ee5bf_I20150228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2afce0b61c084d69ab3183af171ee801_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ab402dc3c540aaaa74ab88707cd06e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777e7a0559ef48fd8038247a2da5c7c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4f6df13a0ab4a20800b6bd00a5f821d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i665e4e826ccd4df0a58a999910a2c5ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5513569ac924bcd810dcccb4b75c1ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d717cfc9ad47b288a5e9b60459b22c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a1894f77974cf2b8aedcc04b6c5f86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3e9fb1cd6824fbb85da3d9df004f1ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a84817f64104c25b845cd16a8f0ab52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9959b5f071814b32bb44c12f7979e4f8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368be994479c4748a98800a90058bb03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia668578daa974ee2b66900846a7f2aa4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8420ca71f3b4038bcfda28fcd31dc62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e3d526e5639439988a6a4d0a1596dbc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1444a522fb044ee7a105512067bac273_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff8968812da45e2a9aa27638fc19580_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cd740912ac448feb53d1e58c59635f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f3019ec63604b1e9670c0bddc262a57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43d6eeff5022443a911867c6740b0321_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1018d5a2a449484ca302a3ba827164ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f82abfdb08f42288d72dca49fe6886a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9549e6582b0842b0bb8b80335d95f5c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6123894aef18412c8778f35bebcb4b94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17d3f0012ad49839eb5e30af562ce46_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c6df684829d457191dd58d3cd5cdf67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dfeca1a2e48493283b2d3282a9abbda_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8344f64bdd4767b10aa2100406065d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if324696bb41c43df9e57bee9ea0785b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29edf7836e8242968b86b1318f81fb38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c9faf0348614580b6500e84022870f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i745ea53017d44a209cd4871e1fc8dbb3_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58da0dc381ad4518baba0871c615c8cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8cbdc550c74ee4ae87ae5b4bc3ac20_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ccffca563b74d8792d57e3f776ccc3d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0ec7fb81814c1188c3590687864a65_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4877a3944c7c442fb949a47bf0f67c40_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7391238241af432e81e836c4866c9d90_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1533362d92634f39ba4a401c3f7026f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8686b81ecb37418dbc5bcc179b1e109c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i265b3873c6154df1b98c0e68348adf62_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304cadf22e1f4d51a2a058761d61f7e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9548c02f9465476885ffa4b8feb4449a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d0fec390494bbf9e3fa14a10590ee3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72fd8f14ca0e40fdb0a695a13b9d715f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0f26f772ded49dea5267467d918765a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfac85de776a4ccdb1c2c9949959fc1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba1524cdf8b541d993f6af6346716c26_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3984a0ac91e341979ac9c6a390e24ddb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2454550ae594d8ab5f93ecc8828eb34_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e5d7ed77346446bbda233cc544e7a56_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51c2fde97ce4501afc27d5c5035c4e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970be973b11946e2ba4be4af29d27f00_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff4e5d22d10f47a4be988b01f0b8f5ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5015e8fef3747c89a3ecb45e4b014c9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a829cf79dbf4cf18de8842f672ff28c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2da81af0f6824d0fbb5054283dac56b3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2e5836ef2c4728bf3267af3cd05975_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341bf7c7b22846c3a15d2ca347a2a5e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i150073ed6ed44a05be7690bce055038b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4fc26110cbb49bb95e0d829274d6717_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e5f86d5a26a4fb599b079a5ce05a6ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie623c4bf0a334923b7419fe9e4036c4d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie26d559169994ab2bee2cc026fd0802f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5bb44b7dbe04121b65a77c399136416_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3026bb704ae34186986b2cc13a1fa4af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed04fdf163840848076059cbd6be57d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5681d70ef5e4ab1a40f14225017e26b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eb0b3093eab4e4fbf121e5a890af5ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a22865ae984cd9a1584ed794eb45f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeea6c57cc5b4032abf11ed3fd20204a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ad3e74dab6043a0ab76c58210d1d2c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1921cf5b564c24a5b92cac02448a78_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b97f0e94db4a76838c9d49661b0f65_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i394788312749438ca5a0088d46557b6b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c9fc7dc1c74381a2af78f961d3d49a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifff3562287364307b49c65b486ab7f1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad27b646ce224aeab760a794d241f6b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b4b25460674afd905c8bebb6f7495f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f77bb62e04422484e61cd37ab61ae5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5747821ef74aea809d0a7f45d8bd8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44254b6ac97b42949dbeef89bda488f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef2acb849c6486f8fab7daf104f20fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia14add4a287f45888b55667cd3541758_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93f0f42e415041f8bcef0f0de00298ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib105aece693d4b43a0c52e39570beb9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe741caa88b64940868b7b3ab24c4a52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3844e07d48c84ee491e1b9f71aa66a47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd0d7ea7b3a4afa9b4461ff7b726aba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c6f6c468f64ddcb921d54c39e33bcb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f6909c22acb465098440df5033cb0c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i249f9f4c4b124dd8b673e35fc4455624_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia87d29e7890540bb8654a68a1d34708c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i28e6c2c7dcef4706a9e8c029a70b1b66_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbaabb3c8c67456798b662d69d200f72_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib34a3983473240ca94309b2221293726_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ea75f6631c448f8f22c298bec0c951_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i214f8c61e02b4bc78c01086f27fa4760_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f537e57d89f4823b4442dbfdb55895c_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13d06bfb1ac54344bc9084f8e1ea171e_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4652a3a2e7940719a658dd16032604d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50d29a2be0b04648b7d97ec27df8f046_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i828bc1c45a6d4a98b00274ffc1f8eeda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:SubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i787eed6e9a344d8c908c09867efa7395_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:SubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b65f5d0f33646d9bc123cea10741758_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf080c13135547c8af17c3b9569fb595_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa108c2a221547038bfc56b7a2800e00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i849ff223eb2f4be899ee0be3b39ab50f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d80f95e39cb4bfaba1e47004246e9e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e69090a5bf6448aacee4bfd8770c3e3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b85566626e4d3abc15fda2e07b56a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i923409ff6b114d4ab014bcd315beca62_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id224660fdd0047b996983e6ee2775abe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib639369018004754a9231ea3cb196a74_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib182bbc8abc342c796c4fe1951e63578_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda291dcf88445d79798c83baf0cdab6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied6fc4314ff74454a352c1254c20f4a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id270cfd00e264906938aa37712a47c2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie63cee825d9047dc912cec33b6578d0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb111e31f6244de805aec691711dc6b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aadbc751f6142fb9d7d9b181bf75a09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c681c490eb24f0888c2d4a13e77ad8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i947c924e348b4937945183baa80b4090_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61dd7a223a64fd789d0d20d60918b24_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2020SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e5df66246e4242a351e934e5d881a9_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i262058cabfd94b5ab32927e2ab5d4b39_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ddb930bb2d6431ea44a09daf6837686_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98decbb03ea4472c94a12ac0b39c7793_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2020SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1c876d462a421f884f7da02f35aeb6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2015SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie421a618f95e4d26993d33169587ef01_I20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07e15711c4c4d72879f1d4eddbaa8f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522bc71323b84dfaa650873976042d71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121fec5eb0a442788b9b201aa33e7063_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d9dc2f9e5647a79094565b056378cc_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4870972449f45cca77c7f81269fdbe0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51e142f8c61e4ef9aa6fcc66964b20a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51bbbbb29365442693577108f0597733_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:SeriesXPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic43dbda8223e4c34ae49a143d781adf8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0070294a197c45399f314f23509957dc_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41af7ab14acc4fb1987d804ec0919188_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbfd0586c39547f4bd2e2e1a5234c516_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5af4399029492c96f8e3642a945612_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice49d2ad46424ef199c6cb123804c5a5_I20160731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b72acd0c624e9a9e5f85ff7919818a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f24d77b87bc4232984dc260a26c171e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709cfa41571a4ab8b7d4914c6efb00b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d68ba226474425a9ad91c1d2d03c1a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d8c73e458441d994c3c13f19832ae9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5acc9340a88745fd84cac5a88b2066cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdcecbf126d4b8099f5e7acda25fb2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c3ebcbd89841a28e7480e4337c4988_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f5a43994a74e30bc2c24fc58be7a8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38457c7073c148078d40e136da416dc2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f346c927114584bd6128c5a5e41d52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53527d45eb34a6b993b46ac83917155_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id971167191384986aec4598f9022d212_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b64d0eaf4c246fab3031182b58a6d37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf2db733a844ed99dc8f7222b3ccc49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bba1fded9e7415e8f0eecc9fc01fa37_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d78be56f2654da88b7ee62f039e7477_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863cc533cc0841c9a1fb1ddedc5d0abc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i520d25d1349b439588d438faa148525c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2706b4a26f7244ee86167f45ad4d537d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05757bf43f664f91b75e8330e6981029_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic378ba6b90b54eb49686f7fbcd8d7d26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c50d1ee35d466596e1a0bd0485826b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd9d8887f184f03b4f51f5d658bd9bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3946e2ed691746eea6486da676e10065_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89cc1e0b559548e1b327e6f439fb19d6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05064dd261bf486d8e3bf1bba3b6c47e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0edbe632efef45cc957628ebc1d33d42_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa22ea433e141458d8691d0f27355c1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide4cbacbf5734ef695d22154b1428d52_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id59744b4317a46d5ab82e7521aa6b11e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia35f6885c958490aa4fa10a11e2ca2e6_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i903a5c782a9b41dc9edce0003cd86d67_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6757062bd137442ea0f58c866b089bcd_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ba77a8a8704925bcd95ae5bd41be65_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20addfea8892477996faeb680a08f153_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d0da88784044139ae3b0627adb1073e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieedbbfb7ec1f47d98f528e19bea4741a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc4fdfb6dc344f2ba410b5f056357e3a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i255daee7862543c69e18f60f9dab28fa_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib03e8eced8bc40769f89224b7a3917b7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0835e29a53b74d32a686b04bc1b1b198_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib755e31f5e76447187fce9bda9cb4342_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d38cf0e172d4e26924af47f88ae37cd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c99beb651874e9494da14b27703de21_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a66bdab7bd472bae2b3efc40fee57c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c58c66b4a842ac9ad5f192b2a0e90b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5eb4853f6f4dfe9344661c9aa220db_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d3de7bccd345f7a075fd96f73db36f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98dca11e646a476986ce2b76bb838960_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629d97b930eb4709852d599b96bd1336_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca0c44aac904794a5af072f3936f72c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i268b5aee503541a1b2d10eb88d72b0fb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id83a5eaf6567467eb34c2a56b8b9b544_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1029aaf02d1e4e45bfea6b6f58c10380_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48908e834b734ebebfa2eebf3d33b0be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8750b469f74471190cc2cf6076d21ef_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i286d43c7e7e34e99a914f5aa626a428b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60b5c10ba06457f95296998f5fab4fb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ef982cfbdf41d3b4a5ae5f59e4bf33_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c767930933407ba05e420ac12e8ead_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe0551d164a4cf2b1e3b5a93ddbac8b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553c1568915b41bd8a1f0a03726da4b5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie00db9b8e16a4be5b4796014ce7b9775_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2afb74941ee472f98e6628b9fc75769_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0fbc5a8e674148b9ed9389f86047fa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51da93958ce045aa9a3723e4939788a8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978a8bf34b8a4498a033dbbeb035725f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d9eb1cb8dad4f7bb71554081970672c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d9a8ab9362146acb873dbfa9866ab42_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d7efd2d47c945e197f5e3a194b14857_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf69f103a98a40ce90631e9f60d5754b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5182146502648bf94e1be9dce89213b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f97fac7edf9426d88a1e76bb48ad55c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f109ebcb514632b195259b16d76186_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d29238f9c3f411fa88ad3fefaaacf57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d37f597e713494d9d43394bf06bab30_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7350a4e642e945d4b5a1646e257127f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf98ae6877747fc9a91fc7dc00a358e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib997cdf3cb144617bb5d6ff4986095ba_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05aa73c81db48f6b204fa3c972243e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3653e8c908ef47bc8ad1352fd466e75e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba5bec6196eb4910ac31bcec98a0c3a9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3480fbb97844462e9008fb8c307b45ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a25527f05454792b6c3a170ae578dc8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54cf49ddedf140a0ab09a33fe768f730_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0df0e7d12e4abda01cacd276a69d0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e0d61fcfcf945bea2cf06b84ae730ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db7fc9d86d84cb6b0b36baee4a3643f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a840f55f6d64ab182ff63fbceb3665a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i321f27bc93f84527866eb088a9a13ab8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a7d16eb3f9c4249b12a16fbbf180e21_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0769ffe96e9e4c938ce1cbd317e37f42_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0390833128a4361842fcc8dc5e28d8f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a49c0b0d08f4220b68f83ed9492b788_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>biib:Plan</xbrli:measure></xbrli:unit><xbrli:context id="i4952db151b244967ad310f4684e13d15_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:DirectorsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e20d08747494db199b88c431d14e928_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0d36998038a4ff1aeee3c3273f7a37f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c47bb693114834bbe5ba4a44e2234c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82e3cb95d2d4a44b7a01995c91159a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c1ad961cd346de9af30e39027d96bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a2350cc1a754e1e8af5bc26001a39ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="increment"><xbrli:measure>biib:Increment</xbrli:measure></xbrli:unit><xbrli:context id="i8f065e3287da460f99889b0a7d3e9327_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a8afaf854c4785ba7b167d54f6f8a0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i307bf919a041463693eb52f82fe704dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1af180b9ceba4128805321de34545ed8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i180576e386e14660b3b217b13f520f3a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b626c65959246e09aa12e28314bba0c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if59b671ae4d44f3b97a43ee65c799fc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb57f7f3d44e42c4a8e598bf54a94075_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d7f7d4fdc14cd4a16f3d306b79e0d5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d4a650ffa44c1998500b69da6939ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a25395b7a6043aca656dfaf91b50a0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b2d203f7de418d8494c28ba590c318_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef74f21f78441ffa5960a07e5974a49_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b2e6ab84a14827b284ec4a34e34ebd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f58504b3d04073a49321e74a6c17bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b88b6b11d44635858d6a6d1dd65fd2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5279dcf6d19435dbf4f97f6c1923185_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db70ce0acff40ddb1a8049995563df4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife7a28c7abae4f1c93ca334525d03c5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6556dcd7cdf41ecbef4a10fc43d3f45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307d77a2fa40438aa59c8269e8e9b25d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibec2bce1b2964c0f98ad9f65944dee76_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if188b16b7c0a45a1a919112de323694b_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf6d89d5466147cd8f697b7487932bfb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2396dcccc314478d8ad44cb90e14d1e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eed89417d914c45a6644792efcd83e5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f3c645fd7d74b17a26a9b8652d2a6f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a97d152e6b454f8ff1a1aaed64c1b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia726ac01887c4e3f8b260b50fdc0036c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73be9e1394774290a72930a5f26e75a7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8d0fe496fa4437a1c3009ee5b30517_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia220992660254d9a81341091dce24aa9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad8db8e19694c21869ab3526b232850_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe08502e6aa446d09a87c817d769e4d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia976a78ea31f4adeb3848c2680c1fb1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeae6620ceef4b6da93e2b0ac949cf2a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e408385075494cbe602b5be6d1c8e3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e9fc07f4dfc4bc081d7e510e678bca7_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:ForeignearningsintheformofcashandcashequivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c4584fb70e4f31996559b7c3214b24_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:OtherForeignEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib21ba4f090344f2f9805e82e16811047_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fe3f12d8cdc4e1fb91fee9506338b3f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9237ad9c6c14888837dc3e87c024939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5daca379673646cba7a409b1982cb5ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie04b35230b3a4c1b86938c22cf535263_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DeferredTaxAssetLiabilityTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0192f21805fe4e158b7667cad4964a5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d86e21f739f482d80d94fd171cf33bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26628f1182184eba96d1f455922e58af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c55c5c3bbab4bcc915d94071853367e_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5c5a093a604074b379ddadcb4304e8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8217e2c7737e464790a37fff8a75e2cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliAndSangamoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44ba7c8ceb14c93b89739486052b804_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36bea0a273e042b4977e70b6d39dce99_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f7c1fc4a6c450c9505e7b20773c69c_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2fc03f67f5645f1b013252212df9935_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i771406e8a3b34c93b5f87c9b46df7655_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ec1427e45649d2851751c0d45cf674_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7585b972767d4bd6bbbd279b2e88eee9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e00ac4fc24f4e0bb5ded9386aef6231_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74714c45267446986d21e121eec440b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c2a5bc4c964df2a0221f7f66aec154_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97799a59fdcc43b1bfbf8aa1dcd16b3a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fce10d195874216b12663411fa5c489_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1662495653e1435689b93551c68ae54e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffff7fb793694c20a0248c1ea9b22dfe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dfe4622e95f4be3b13eb7b4eb5d7421_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id28d5f3f841240659df55d6cebaa2341_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1a76b88c18540f5b28ba2e5fbc3f6f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bdb2b3168704d7e945362a0cc289715_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i747f7303e31143ec8231dc760b0cb79a_D20121201-20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71eb4f6064534d02b9b523b950ef4cb5_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45dbe435f7fd469798d0b243da615ec6_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105821a34e0b4347b7fd8ae515422218_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9331add6801a4df791250e423365aaea_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d15cdc79395436f8ea70d371389138c_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c9ea4c44b047fab182bf1e93960612_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff10bbc1b7204f9a899f2b15e8f5bb57_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b01dc3119ea40eaaabda1c48b7c9107_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465d3d459afa478c9e3119d88d5627e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if47126e2c5154b45ab4cbefbf186b118_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5d541771094deaba1fa696b580448f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if223f76ca1884559bc1cd766f260b0eb_D20130901-20130930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-09-01</xbrli:startDate><xbrli:endDate>2013-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95a0cc3cf2744b12b943e07433857c3a_I20130930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9dc60a6f69e48f5a2a97af95fa37fb4_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5554faf4f05643a08aa9972d0ca3320a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66010d191b2a4b168f86fe9538abfa3b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0993650b5ce4b56ba73d7e6d491c39c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cbeeb58208f422997188aaf6d96b19c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912e90e415414b2eb40263d0228aebbd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46b16525b4ff43abb6399861bedb691a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be23a7aefd749b688f0ea9bc6153af4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib08f91138dfb4499a6873f325caac5c6_D20190101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a519048d3946d6b1cae8db3bf6ea2b_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d3846e76534a968aa79c696280f29f_D20180401-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f4b4db6bca74ad38b22a985c9cf4c8c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cf41e8e7ce64d6b9af4dccfbd954c2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i685eb05651d54eb487dd05db4f014285_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i523d958a043b46abb2bf95ddabf9e48d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6770bed0636946adb09e5741c30e183e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07e06dea69a4477c83eaaab76c26a1c0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6011115c7277467e81a492d53cc5c2de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204866d0c938473fb367812907152221_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8095992b920b4752bea7ed0e25a7dec6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307bd3b52c544217a250d6bec5afed5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0259bfa32ec47deb51fdd95ffd65e06_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5afe9f2f08fd4c56a2b406c9f04b9941_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aed9a151f27413aad9ecb189295574d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c7eb5801004aad9c424b58efad93ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i062dfb826bb543c0ab344580c2bc9f39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i329e830c9d924ad1abde877010ab5c13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie615c033847a4fdc95860b4e0bfd4d64_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18853d4d37eb4076a332a07be0132022_D20170601-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74db4b324cc4118b5cddd07bff2bc26_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc638e4ad114ce2ad08351d98ed22df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7e2e7e20d974dde8d37743caeeb08eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ee0bf055a24fd6888b5ed314a45afe_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie154ef82e19b42d287f8709039383fa3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice90a1eb84854ab6838871533abeea35_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a57dff6854d41af89281f848dc03341_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02062df52254e2a96f48ca5db08b037_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i238f01dc6276416eac270e2a8e9978df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4675956b4c7541689880490a770cb247_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64566178ee6240c4bca091bed9507fe4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a2842d092548499069b826f6c1c638_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6856a51b4454c25b01425f5b605c021_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ee863c764240e8b24a01061fc43c1e_I20120229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef12f56eff74ffba6abbdbbf71ce00c_D20120201-20120229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-01</xbrli:startDate><xbrli:endDate>2012-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64dc4d43b5394b6b882e494448859c7b_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a6f7ae45f34f16a1e64ef99614a3f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d919fabed9048039865137149827503_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i295fd62c9b9a44a19b8f2c9cf5993d16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f272ab6a3b3497a8d35a3bdbf2a7afa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897172e0b7bd4edda63f02e0d50f23aa_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id583b49771574491a9a38091b81e5d33_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40f71161d18144578dd8f72012056ddf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa950bc28fd44ad8df6891d4c6166ca_D20131201-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if35d8e291e634b4fb356e7dd2eb4e57e_D20131201-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55970ae847c94b61adb418c71761c6c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idced215bef924766890054dea8e163a5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d07f2e384e64708858924ad5f63049d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14fe65b9d9ce412f9b5cb080d3a88a3d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic52a2fe62f214111bf27f2241c15e13d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b079cbb95c4416897c5c9f868e8ecbe_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b3ae17c9254af097d228dac7821a3c_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47c03e6e7be46888ccb47d76183eca4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ExpectedPaymentTimelineofMilestoneAxis">biib:TwelvemonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22a68eca818d4bfd974767e6d650ecec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:NeurimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77448f6c2bef4b2ea4eb496e64cae04e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957831cfe2a145bab834e81558efd05e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AducanumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i933bc3e4859e442d998a3136c487cd85_D20191101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd0b9db93464b41b789d3e1ca413b78_I20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f1d1f107eb4341ad1613ad1b5d5759_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a1d60eac014ca3be868d71ce1a4a4f_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd3d46d9dd249b28b950c8de7e4732c_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7513df5070046c28b340530835d8133_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d03ca4620f4c52999c7becc617b0ff_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeaee754376e4c77898d464920110368_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i751bdf5f146846a0a2d59925aa237c7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aa757dc6dcd456f86823b48006f5e50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if55055ac245a4373b369623a07552bcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AducanumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43fa46a959704893ae8c17cdf1fcca1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia620d874c26f4526a51976fe0e5fd937_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766a717009a042eab70c1b33dd98c33d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eaae0c3c53245ed91bba34207199327_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd5e42a67c414bde9ae4844e15f78b39_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic085e896635e45e896872f4b67d23b0b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b27f85445594281810d4e11521c4fb0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1ee455bd644649ba9f949ccefc1a95_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib255acebc8bb4cbf9289671a4d33b082_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6eab3ca24d4a599f6a591c887c3592_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a552a264841456ba32e800303b29c4b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a170e3656544b4d848f8f7740a81d09_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79fdfce753a6425b8f9b7ca88002a439_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifececb28512c40ee8412eff5d4625c9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7150facb4e24d09a7ef6a2fee36dfc9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3da3923fab24d76b979d1adf1a4a146_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc247cbbe7443509ae3adc1934e986c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24be31960c444fa3abc4b582746b9496_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc07ab871bb4356b9e093f779247007_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2baef659c2bc4c41a82832bd90ac2e36_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff57345bf2b4431834e26681459d492_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9af8365f4d94f16920edbde69e7cbb7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f46388dff4463e9fde50c812857bbd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe68292fbbe8447c8b94adbca7e5c270_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0916ba417dd84c7ba1d88322f8285810_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4626ac9e1499406f9c21d3df61161c1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a3e7b4381945be8628c8dda3f341b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4af3774c88a4c69bdfb4f0b296748c4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbd9ea049fb349888e438f5bf876864b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6587b6a9e7a4af3bde2b30568b9afb3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6988263d2c4242e89b4c6e3d6b3dffad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c353d1945748a9b24ca8847773877e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13dba24b1b3b499ea5f5844129e61ac2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1973b2051d3340b1824cfc6b74a8aaa9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c819a830ca44238bc2e36f8b20fd54c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia331aa05ae08401980f6ff67ad3d9568_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77580efa84d475392dddda68bff7041_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b205643e3ea42fcb8a65c552825bb63_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aeffaf17ea24cf680dcae3471e1b7f9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444f2f75d3b2489ab262daa8b78df9ba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98fe9583334144ef942f3d12e08913b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6db9e6fd2a649c9889b826888da6372_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3ac83089e884263a9d4ae9da7e3efde_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d9eb2f85dd546a4ae15fc642f85d8af_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4630fecb0f6c47b2b848f15327791e4f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002c6070bf8846dc9140030a63f37dac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i674d0e91669c40ff82a76bedb27e4e67_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0172f7c5c8b3448bb8ca832a1116f3aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib563770ab8184507a232435bea87086a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d67a017c4d1439bbfdeb2055dacff9b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388f07fba6354ae6b12a5c8a48d28304_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c94a7c202e7466686a893e6fda06193_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4342c229637d452dafa8e4a45cb1a216_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9714a1b144e4e9b81457f7ce371bbea_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe36228fc3c43b182afc7bd39a2d6bd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd05e22171d4dad869c4a37eb52a7f5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e85dcda379e4e348325696cd2ec9cf6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f84620186bd48dfaa02b13846091e74_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf10b7ffe1994abcbd958c90d5c06301_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16aea428adb4ba5ae3e7d508536706d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67b659127c9421f89dad74f1278c337_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745cdf1e889c4c16afb442fe563d25a2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id49704cf795948148f16dbae680341c9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cfd775f332e45ac808c12b6838e769e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbdc67c11df94e509edd9a7f39c16d8e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e40021e4994fcbb8133c1d5d3f6f27_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c4f2b0a6a9c49f48c35940d82b38a6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e096fa0fb0473683e284201e92aaca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e2b3b8ba24b4036880ba37d5422da63_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae776ffb778432e982088a179ebb204_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fca2b687f2f4872a9a845bb672960a5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5dfc91e9f8241d894aa02ab5409f041_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ae9621a79ec4f2a81baf7fc485474c2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c705be761834645b8c5978e3818b771_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f55339914bb4b2ab51133f2c27b01c7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87a96b308944207b0abf485235389d9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ce7f756f854eff83de1460d06439a0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3a2e9422f744e57a659fdc96c0a0d84_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie805016a199a4e4eafdf82e66b43ecd8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2d9c146e8546eb8940919a230b2410_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f37a240cd2462496769361d7d6aa4c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc07ea8987844bbae9f16026aa3eeb2_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7776337c87847de857073085287b7df_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee7c83511ad4b4a994502e07e77195c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dc031b722984deaaab7026bf6193aab_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5416e51b85274f0bb17370851e4a3b1b_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ad278057bef48a7b7423fcd6a012b35_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87d95cb80ee488f95f41a5044d1b98c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61172312032a4a168fbce9685cffadb9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1244a258e99d4f4bbccf06fe8dd8b6f8_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9edea67901754dfca2b56005c22d377d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5380e1ba1c7b486290cfbe6457fb3bd7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7ea2df93e7492991c4ca15c3f6e098_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d05a3ba448a4750b45bb2d906497144_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNy0xLTEtMA_bb7f955b-8dd2-4259-afc2-d669fdf6b779 id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtOS0xLTEtMA_4eace0b0-5459-443b-adf4-f41a5aee20ae id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNy0xLTEtMA_01e50ece-7e7b-4921-9bbd-d7faebc2bd59 id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMS0xLTEtMA_868f3bcf-bd41-4cd0-874e-b9e7a6eac3a3 id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMS0xLTEtMA_39dfce08-102f-4ec0-a97c-6fe195f05d8a id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtOS0xLTEtMA_e605553e-fb73-480b-b14d-4ace6cf47e83 id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMy0xLTEtMA_e02a9e0f-13e0-4819-a172-c922d853149c id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMy0xLTEtMA_f12fa61f-347d-4d6e-b8f0-8dce21f1c03b id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNS0xLTEtMA_c67cd457-35c2-4bdc-98e3-c6fac4fc50f3 id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNS0xLTEtMA_8ecba11c-83af-4c5b-9efe-71417b9f874c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMS0xLTEtMA_3d7def81-fe0f-4338-b42f-f9e4c5d0aac7 id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMy0xLTEtMA_d535a514-8b7c-44b1-935b-6f83ea384d26 id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyODE2_c2dfd109-d8fa-4cb8-b3c4-ad01329efc84" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg2_aca5d24a-146b-4dbc-aa83-d2e4f12e6dfa" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMy0xLTEtMA_5e5cc007-b27e-4389-873d-5a05fde0a71e id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMS0xLTEtMA_a453c414-1392-406f-a3c6-6be569fd62aa" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzM4_565199ff-dcec-4c09-87e4-87594327fc27" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMS0xLTEtMA_94bb0b7a-efc2-49dd-9afd-60ee50e69cdc id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMy0xLTEtMA_31107894-bc5a-4a7a-9cf9-547a7e070226" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzc4_f2233f5e-fe16-49c0-8d02-0bd274729343" order="1"></ix:relationship></ix:resources></ix:header></div><div id="iefe8f1adeafa45df8da4a5beded16de5_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:100%">Form&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA2_50cbf961-19b8-4a0b-8235-e3f98dff2617">10-K</ix:nonNumeric> </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6OWNkNWQ1NmI3YmE5NDY3ZDk1ZDc0OGJmMGJjOTU1YmMvdGFibGVyYW5nZTo5Y2Q1ZDU2YjdiYTk0NjdkOTVkNzQ4YmYwYmM5NTViY18wLTAtMS0xLTA_9b3675a6-db9d-4691-948f-062b96ec2962">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18xMTk_9c269e76-0d83-4ae5-a4a5-7c4fe8c1ae35"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18xMTk_e6fc9ab1-243e-4489-948d-2a9e7845d0c4">December 31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">or</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6ZTQ2N2IyMTM0MDk5NDZhNDgxZjRjNTg2ZWI0ZGY4NWYvdGFibGVyYW5nZTplNDY3YjIxMzQwOTk0NmE0ODFmNGM1ODZlYjRkZjg1Zl8wLTAtMS0xLTA_724f1d48-49ca-4058-91c1-802de5c4abca">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission file number:&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTAy_1758d416-8e9a-4f8e-b1ed-091e9590317c">0-19311</ix:nonNumeric> </span></div><div style="text-align:center"><img src="biib-20201231_g1.jpg" alt="biib-20201231_g1.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:128px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA4_cdcb5014-6cb0-48d5-bab9-958ffc0a1097">BIOGEN INC.</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6YjNjNGJkODJjYmZlNDBlMDlhYTNmYjIwNWRmMDQ4NzcvdGFibGVyYW5nZTpiM2M0YmQ4MmNiZmU0MGUwOWFhM2ZiMjA1ZGYwNDg3N18wLTAtMS0xLTA_e26a7735-6a13-48b8-bf41-6dea5a11dce5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6YjNjNGJkODJjYmZlNDBlMDlhYTNmYjIwNWRmMDQ4NzcvdGFibGVyYW5nZTpiM2M0YmQ4MmNiZmU0MGUwOWFhM2ZiMjA1ZGYwNDg3N18wLTItMS0xLTA_56a881eb-b98a-4211-8137-e7f42f42d05a">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk3_900c1f78-a12f-4cd3-b9f8-4a4eb5a8703a">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk1_107de00e-67a6-4db1-9ed3-976b515c63df">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTAx_747b4280-9f53-4a81-9065-090664567a41">MA</ix:nonNumeric> <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk4_b98d751f-21a6-4d89-9d6b-b972cfbbdd6c">02142</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTAz_5cfccb7c-62e3-40a3-85c2-ab45ba8f12fe">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk5_80c13a0e-7876-47c8-b588-19aa825e6f41">679-2000</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.583%"><tr><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Each Exchange Where Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6NTBhZDhkYWI2YzJlNGI2M2E2MjFlODhmZDI1NjZmZGIvdGFibGVyYW5nZTo1MGFkOGRhYjZjMmU0YjYzYTYyMWU4OGZkMjU2NmZkYl8xLTAtMS0xLTA_822adaad-8b4b-49d4-97a7-77538321637b">Common Stock, $0.0005&#160;par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6NTBhZDhkYWI2YzJlNGI2M2E2MjFlODhmZDI1NjZmZGIvdGFibGVyYW5nZTo1MGFkOGRhYjZjMmU0YjYzYTYyMWU4OGZkMjU2NmZkYl8xLTItMS0xLTA_ade6adf8-ad2e-4948-bc5d-93048cb8bff7">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6NTBhZDhkYWI2YzJlNGI2M2E2MjFlODhmZDI1NjZmZGIvdGFibGVyYW5nZTo1MGFkOGRhYjZjMmU0YjYzYTYyMWU4OGZkMjU2NmZkYl8xLTUtMS0xLTA_fbc4abab-47dd-4c29-9931-1ae9a355f88c">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">None</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTAw_5ae4364e-c961-4363-ba1f-c492dd8c1d40">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA0_2417c1ee-fd5b-4cb3-949c-9fa5b98a7588">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA3_7725f27b-0387-4b7f-b839-e1c2252ec95d">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA1_48928c16-0ca7-451b-8fd0-0bf035e907e1">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6Nzk2MjA1ZjhiOWVkNDQxOGFmNDQ2MGI2MDRjYmQ1YzgvdGFibGVyYW5nZTo3OTYyMDVmOGI5ZWQ0NDE4YWY0NDYwYjYwNGNiZDVjOF8wLTAtMS0xLTA_acdcb982-ac2d-4451-a7e5-5fa19ae14242">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6Nzk2MjA1ZjhiOWVkNDQxOGFmNDQ2MGI2MDRjYmQ1YzgvdGFibGVyYW5nZTo3OTYyMDVmOGI5ZWQ0NDE4YWY0NDYwYjYwNGNiZDVjOF8xLTQtMS0xLTA_08a8425b-d0d3-43d8-b2c0-77f2cb932909">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6Nzk2MjA1ZjhiOWVkNDQxOGFmNDQ2MGI2MDRjYmQ1YzgvdGFibGVyYW5nZTo3OTYyMDVmOGI5ZWQ0NDE4YWY0NDYwYjYwNGNiZDVjOF8yLTQtMS0xLTA_d9b89398-9a28-41b6-b34b-ae8bde70b393">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N180Mzk4MDQ2NTE0NDI5_3163de4a-148e-43c5-8885-d8f49292387d">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk2_052ea60b-046a-4f61-a12d-881594b67d28">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was $<ix:nonFraction unitRef="usd" contextRef="i40f86ad979b04ab6b1c5dbf39dc6ca3a_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N180Mzk4MDQ2NTE0NDM3_d4667d0c-3952-4057-8c0c-f915d7bce113">42,102,640,463</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of February&#160;2, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="if78e92be0e5f40fa8335c122c201e968_I20210202" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N180Mzk4MDQ2NTE0NDQx_6d8fa414-0501-42bc-9213-b467b606531a">152,335,731</ix:nonFraction> shares of common stock, $0.0005&#160;par value, outstanding.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N181NDk3NTU4MTQyMjAw_8eab54a4-64ee-4d2d-b378-9f7c3e5d448a" escape="true">Portions of the definitive proxy statement for our 2021 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this report.</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_7"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM&#160;10-K</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2020 </span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_19">PART&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_22">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_22">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_64">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_64">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_64">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_67">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_67">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_67">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_70">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_70">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_70">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_73">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_73">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_73">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_76">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_76">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_76">48</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_79">PART&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_82">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_82">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_82">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_85">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_85">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_85">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_88">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_88">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_166">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_166">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_166">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_169">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_169">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_169">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_172">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_172">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_172">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_175">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_175">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_175">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_178">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_178">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_178">83</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_181">PART&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_184">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_184">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_184">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_187">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_187">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_187">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_190">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_190">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_190">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_193">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_193">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_193">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_196">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_196">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_196">84</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_199">PART&#160;IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_202">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_202">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_202">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_205">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_205">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_205">85</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_211">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_211">89</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_214">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_214">1</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our core and emerging growth areas as well as implementation of our corporate strategy;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of certain business development transactions;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expenses, supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the Solothurn manufacturing facility to be partially operational;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) departure from the European Union (E.U.);</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws, regulatory requirements, judicial decisions and accounting standards.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_13"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:9pt;padding-left:36pt;padding-right:18pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_16"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AVONEX</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PLEGRIDY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RITUXAN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RITUXAN HYCELA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SPINRAZA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TECFIDERA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TYSABRI</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ZINBRYTA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are registered trademarks of Biogen. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BENEPALI</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FLIXABI</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FUMADERM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMRALDI</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Healthy Climate, Healthy Lives</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are trademarks of Biogen. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ENBREL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EYLEA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GAZYVA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HUMIRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LUCENTIS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, OCREVUS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, REMICADE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_22"></div><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1. &#160;&#160;&#160;&#160;Business</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="biib-20201231_g2.jpg" alt="biib-20201231_g2.jpg" style="height:211px;margin-bottom:5pt;vertical-align:text-bottom;width:405px"/></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on developing next generation treatments for MS. We introduced the first approved treatment for SMA and are continuing to pursue research and development for potential advancements in the treatment of SMA. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including Alzheimer's disease, ALS, Parkinson's disease, choroideremia (CHM), major depressive disorder, postpartum depression, X-linked retinitis pigmentosa (XLRP), systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), cognitive impairment associated with schizophrenia (CIAS), stroke and neuropathic pain.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell  BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Key Business Developments</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of key developments affecting our business since the beginning of 2020. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisitions, collaborative and other relationships discussed below, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, Collaborative and Other Relationships</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder (ISWRD) in Parkinson&#8217;s disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we closed a collaboration and license agreement with Sangamo Therapeutics, Inc. (Sangamo) to develop and commercialize ST-501 for tauopathies, including Alzheimer&#8217;s disease; ST-502 for synucleinopathies, including, Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. In connection with the closing of this transaction, we purchased $225.0&#160;million of Sangamo common stock, or approximately 24&#160;million shares at approximately $9.21 per share.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 we closed a collaboration and license agreement with Denali Therapeutics Inc. (Denali) to co-develop and co-commercialize Denali&#8217;s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson&#8217;s disease. In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta (Abeta) program and a second program utilizing its Transport Vehicle technology. Further, we have a right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $465.0&#160;million </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020 we closed a global collaboration and license agreement with Sage Therapeutics, Inc. (Sage) to jointly develop and commercialize zuranolone (SAGE-217) for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for the potential treatment of essential tremor and other neurological disorders. In connection with the closing of this transaction we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share.</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Key Developments</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab (A&#946; mAb)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 we completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease that we are developing in collaboration with Eisai Co., Ltd. (Eisai). In August 2020 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date on March 7, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 the FDA held a virtual meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (the Advisory Committee) to review data supporting the BLA for aducanumab and to vote on questions presented at the meeting. A majority of the Advisory Committee members voted against each of the questions presented at the meeting.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 the FDA extended the review period for the BLA for aducanumab by three months. The updated PDUFA action date is June 7, 2021. As part of the ongoing review, we submitted a response to an information request by the FDA, including additional analyses and clinical data, which the FDA considered a Major Amendment to the application that will require additional time for review.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for aducanumab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application for aducanumab.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SB11 (referencing LUCENTIS)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the EMA accepted for review the MAA for SB11 and in November 2020 the FDA accepted the BLA for SB11. We have exclusive rights to commercialize SB11 in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia, pursuant to our 2019 agreement with Samsung Bioepis.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Share Repurchase Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0&#160;billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthy Climate, Healthy Lives</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 we announced Healthy Climate, Healthy Lives, a $250.0&#160;million, 20-year initiative to eliminate our fossil fuels across our operations and collaborate with renowned institutions with the aim to improve health, especially for the world's most vulnerable populations.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Changes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 we announced the appointment of Michael R. McDonnell as Executive Vice President and Chief Financial Officer.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our executive officers, please read the subsection entitled "Information about our Executive Officers" included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_28"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product and Pipeline Developments</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Core Growth Areas</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiple Sclerosis and Neuroimmunology</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI (natalizumab)</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In March 2020 we made a regulatory submission to the EMA for a subcutaneous (SC) formulation of TYSABRI (natalizumab). In June 2020 we submitted a Supplemental Biologics License Application for a SC formulation of natalizumab to the FDA. The filings are supported by data from the DELIVER and REFINE studies, which demonstrated that natalizumab 300 mg SC every 4 weeks (Q4W) was comparable to standard 300 mg intravenous Q4W dosing with respect to clinical and magnetic resonance imaging (MRI) efficacy, pharmacokinetics/pharmacodynamics, immunogenicity and safety.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2020, through the 2020 American Academy of Neurology (AAN) Science Highlights virtual platform, an analysis of TYSABRI contributed to data demonstrating the reduced risk of progressive multifocal leukoencephalopathy (PML) through extended interval dosing (approximately every six weeks) as compared to the currently approved Q4W dosing.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2020, at MSVirtual2020, the eighth joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), we presented new real-world MRI data suggesting that the effectiveness of extended interval dosing of TYSABRI is similar to the approved Q4W dosing.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY (diroximel fumarate; DRF)</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2020, through the 2020 AAN Science Highlights virtual platform, we announced new data that support VUMERITY as an important oral treatment option in RMS.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2020, at MSVirtual2020, the eighth joint meeting of ACTRIMS-ECTRIMS, we presented new data further defining the effectiveness and safety profile of VUMERITY.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In November 2020 we submitted a MAA for VUMERITY to the EMA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLEGRIDY (peginterferon beta-1a)</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In December 2020 the European Commission (EC) approved a new intramuscular (IM) injection route of administration for PLEGRIDY for the treatment of relapsing-remitting MS (RRMS).</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In January 2021 the FDA approved a new IM injection route of administration for PLEGRIDY for the treatment of RRMS.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alzheimer's Disease and Dementia</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab (A&#946; mAb)</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In March 2020 the first patient was dosed in the aducanumab re-dosing study, EMBARK, which is a global re-dosing clinical study designed to evaluate aducanumab in eligible Alzheimer&#8217;s disease patients who were actively enrolled in aducanumab studies (PRIME, EVOLVE, EMERGE and ENGAGE) in March 2019.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In November 2020 we presented on the study design of the ongoing EMBARK re-dosing study of aducanumab at the 2020 Clinical Trials on Alzheimer's Disease digital conference.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BAN2401 (lecanemab)</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2020 the first patient was dosed in the Phase 3 AHEAD 3-45 clinical study of BAN2401, an anti-amyloid beta antibody, in individuals with preclinical Alzheimer&#8217;s disease who have intermediate or elevated levels of amyloid in their brains. We are collaborating with Eisai on the development of BAN2401.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuromuscular Disorders</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA (nusinersen)</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In March 2020 the first patient was dosed in the global DEVOTE study, which is evaluating the safety, tolerability and potential for even greater efficacy of SPINRAZA when administered at a higher dose than currently approved for the treatment of SMA.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In March 2020 a study on the efficacy and safety of SPINRAZA in teen and adult patients was published in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lancet Neurology</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, showing clinically meaningful improvements in motor function in a real-world cohort. This study included 139 teens and adults with later-onset SMA (age 16-65 years) from 10 neuromuscular treatment centers in Germany. Patients were followed for 6-14 months and experienced statistically significant increases in HFMSE (Hammersmith Functional Motor Scale Expanded) scores compared to baseline at 6 months, 10 months and 14 months. Clinically meaningful improvements (&#8805;3 points increase) in HFMSE scores were seen in 28% of patients at 6 months, 35% of patients at 10 months and 40% of patients at 14 months. The most frequent adverse events were headache, back pain and nausea.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2020 we announced new results from NURTURE, the longest study of presymptomatic patients with SMA. In infants genetically diagnosed with SMA, new data demonstrated that early and sustained treatment with SPINRAZA for up to 4.8 years enabled unprecedented survival. Patients continued to maintain and make progressive gains in motor function compared to the natural course of the disease. These results were presented at the virtual Cure SMA Research &amp; Clinical Care Meeting.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2020, through the 2020 AAN Science Highlights virtual platform, we announced additional data from the SPINRAZA clinical development program that further demonstrated the sustained efficacy and longer-term safety of SPINRAZA in a broad range of patients with SMA. The SHINE open-label extension study (NCT02594124) has enrolled 292 patients (infants through teenagers) from 5 previous SPINRAZA clinical studies, including ENDEAR. New findings from the SHINE study show that treatment with SPINRAZA resulted in motor function improvement or disease stabilization in toddlers, children and young adults who were treated continuously, some for up to six and a half years.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB067 (tofersen) - ALS</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2020 positive results from a Phase 1/2 study of tofersen for the potential treatment of superoxide dismutase 1 (SOD1) ALS were published in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Final Phase 1/2 study results demonstrated proof-of-concept and proof-of-biology of tofersen.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB105 (ataxin-2 ASO) - ALS</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2020 the first patient in a Phase 1 study of BIIB105, an antisense oligonucleotide (ASO) targeting ataxin-2 in ALS, was dosed.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movement Disorders</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB101 (ION464) - Multiple System Atrophy</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2020 the first patient in the Phase 1 study of BIIB101, an ASO targeting alpha synuclein in multiple system atrophy, was dosed.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Areas</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunology</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dapirolizumab Pegol (anti-CD40L) - SLE</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In August 2020 the first patient was dosed in the Phase 3 program for dapirolizumab pegol in patients with active SLE despite being treated by standard of care therapies. Dapirolizumab pegol is being developed in collaboration with UCB Pharma S.A.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB059 (anti-BDCA2) - CLE/SLE</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2020 we shared positive data from the 16-week CLE portion of the Phase 2 LILAC study. The study evaluated the efficacy and safety of BIIB059, a fully humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) expressed on plasmacytoid dendritic cells (pDCs). The data were presented at the European E-Congress of Rheumatology (EULAR).</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In November 2020 we shared positive data from the 24-week SLE portion of the Phase 2 LILAC study (part A) demonstrating that BIIB059 was associated with a statistically significant reduction in total active joint count. These data, along with the previously reported findings from the CLE portion of the LILAC study, were presented at the American College of Rheumatology&#8217;s virtual ACR Convergence 2020.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung Bioepis - Biogen's Joint Venture with Samsung BioLogics</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In May 2020 Samsung Bioepis announced that the primary endpoints were met in the randomized, double-masked, Phase 3 trial comparing the efficacy, safety and immunogenicity of SB11 to the reference product (LUCENTIS). Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2020 Samsung Bioepis initiated a Phase 3 study for SB15, a proposed aflibercept biosimilar referencing EYLEA. EYLEA is widely used to treat ophthalmologic conditions such as neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME) and diabetic retinopathy in patients with DME.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Programs</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In March 2020 we announced that the Phase 2 OPUS study investigating natalizumab as an adjunctive therapy in adults with drug-resistant focal epilepsy did not meet its primary endpoint. Safety data were in-line with the known safety profile of natalizumab. Based on these results, we discontinued development of natalizumab in drug-resistant focal epilepsy.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In October 2020 we announced that the Phase 2 AFFINITY study of opicinumab (anti-LINGO) in MS did not meet its primary or secondary endpoints. Based on these results, we discontinued development of opicinumab.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In February 2021 we announced that the Phase 2 SPARK study of BIIB054 (cinpanemab) in Parkinson's disease did not meet its primary or secondary endpoints. Based on these results, we discontinued development of BIIB054.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketed Products</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows our revenues by product and revenues from anti-CD20 therapeutic programs for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:9pt;padding-left:22.5pt"><img src="biib-20201231_g3.jpg" alt="biib-20201231_g3.jpg" style="height:508px;margin-bottom:5pt;vertical-align:text-bottom;width:666px"/></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Interferon includes AVONEX and PLEGRIDY.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> For 2020, 2019 and 2018 other includes FAMPYRA, FUMADERM, BENEPALI, IMRALDI and FLIXABI. For 2020 and 2019 other also includes VUMERITY, which became commercially available in the U.S. in November 2019. For 2018 other also includes ZINBRYTA, which was voluntary withdrawn from the market in March 2018.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Anti-CD20 therapeutic programs include RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales for TECFIDERA, AVONEX, TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenues for the years ended December&#160;31, 2020, 2019 and 2018. For additional financial information about our product and other revenues and geographic areas where we operate, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Revenues,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 24, Segment Information, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in this report and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;6. Selected Financial Data </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report. A discussion of the risks attendant to our operations is set forth in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis and Neuroimmunology</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. Patients with active RMS experience an uneven pattern of disease progression characterized by periods of stability that are interrupted by flare-ups of the disease after which the patient may return to a lower baseline of functioning. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MS products we market and our major markets are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaborator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g4.jpg" alt="biib-20201231_g4.jpg" style="height:37px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RMS in the U.S.<br/>RRMS in the E.U.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.<br/>France<br/>Germany<br/>Italy<br/>Japan<br/>Spain<br/>U.K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g5.jpg" alt="biib-20201231_g5.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:140px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RMS in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g6.jpg" alt="biib-20201231_g6.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:134px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RMS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.<br/>France<br/>Germany<br/>Italy<br/>Japan<br/>Spain<br/></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g7.jpg" alt="biib-20201231_g7.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:128px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RMS in the U.S.<br/>RRMS in the E.U.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.<br/>France<br/>Germany<br/>Italy<br/>Spain<br/>U.K.<br/></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g8.jpg" alt="biib-20201231_g8.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:114px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RMS<br/>RRMS in the E.U.<br/>Crohn's disease in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.<br/>France<br/>Germany<br/>Italy<br/>Spain<br/>U.K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img src="biib-20201231_g9.jpg" alt="biib-20201231_g9.jpg" style="height:37px;margin-bottom:5pt;vertical-align:text-bottom;width:133px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walking ability for patients with MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acorda Therapeutics, Inc. (Acorda)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France<br/>Germany</span></td></tr></table></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neuromuscular Disorders</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SMA is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness. Ultimately, individuals with the most severe type of SMA can become paralyzed and have difficulty performing the basic functions of life, like breathing and swallowing. Due to a deletion or mutations in the SMN1 gene, people with SMA do not produce enough survival motor neuron (SMN) protein, which is critical to the survival of the neurons that control muscles. The severity of SMA correlates with the amount of SMN protein. People with Type 1 SMA, the most severe life-threatening form, produce very little SMN protein and do not achieve the ability to sit without support, and typically do not live beyond two years of age without respiratory support and nutritional interventions. People with Type 2 and Type 3 SMA produce greater amounts of SMN protein and have less severe, but still life-altering, forms of SMA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SMA product and major markets are as follows: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaborator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><img src="biib-20201231_g10.jpg" alt="biib-20201231_g10.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"/><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SMA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ionis Pharmaceuticals Inc. (Ionis)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.<br/>Brazil<br/>Canada<br/>France<br/>Germany<br/>Italy<br/>Japan<br/>Spain<br/>Turkey</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilars are a group of biologic medicines that are similar to currently available biologic therapies developed by companies known as "originators". Under our agreements with Samsung Bioepis, we commercialize three anti-tumor necrosis factor (TNF) biosimilars in certain countries in Europe: BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE. We also have an option to acquire exclusive rights to commercialize BENEPALI, IMRALDI and FLIXABI in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current biosimilar products and major markets are as follows: </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:30.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g11.jpg" alt="biib-20201231_g11.jpg" style="height:74px;margin-bottom:5pt;vertical-align:text-bottom;width:173px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis<br/>Juvenile idiopathic arthritis<br/>Psoriatic arthritis<br/>Axial spondyloarthritis<br/>Plaque psoriasis<br/>Paediatric plaque psoriasis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France<br/>Germany<br/>Italy<br/>Spain<br/>U.K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g12.jpg" alt="biib-20201231_g12.jpg" style="height:89px;margin-bottom:5pt;vertical-align:text-bottom;width:173px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis<br/>Juvenile idiopathic arthritis<br/>Axial spondyloarthritis<br/>Psoriatic arthritis<br/>Psoriasis<br/>Paediatric plaque psoriasis<br/>Hidradenitis suppurativa <br/>Adolescent hidradenitis suppurativa<br/>Crohn&#8217;s disease<br/>Paediatric Crohn's disease<br/>Ulcerative colitis<br/>Uveitis<br/>Paediatric Uveitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France<br/>Germany<br/>U.K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img src="biib-20201231_g13.jpg" alt="biib-20201231_g13.jpg" style="height:85px;margin-bottom:5pt;vertical-align:text-bottom;width:162px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rheumatoid arthritis<br/>Crohn&#8217;s disease<br/>Paediatric Crohn&#8217;s disease<br/>Ulcerative colitis<br/>Paediatric ulcerative colitis<br/>Ankylosing spondylitis<br/>Psoriatic arthritis<br/>Psoriasis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France<br/>Germany<br/>Italy</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Relationships</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with Genentech that entitle us to certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and other potential anti-CD20 therapies. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current anti-CD20 therapeutic programs and major markets are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:27.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g14.jpg" alt="biib-20201231_g14.jpg" style="height:46px;margin-bottom:5pt;vertical-align:text-bottom;width:128px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Hodgkin's lymphoma<br/>CLL<br/>Rheumatoid arthritis<br/>Two forms of ANCA-associated vasculitis<br/>Pemphigus vulgaris</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.<br/>Canada</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g15.jpg" alt="biib-20201231_g15.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:165px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Hodgkin's lymphoma<br/>CLL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="biib-20201231_g16.jpg" alt="biib-20201231_g16.jpg" style="height:73px;margin-bottom:5pt;vertical-align:text-bottom;width:97px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In combination with chlorambucil for previously untreated CLL<br/>Follicular lymphoma<br/><br/>In combination with chemotherapy followed by GAZYVA alone for previously untreated follicular lymphoma</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img src="biib-20201231_g17.jpg" alt="biib-20201231_g17.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:165px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RMS<br/>PPMS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.<br/>Australia<br/>Germany<br/>Switzerland</span></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaborator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Markets</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img src="biib-20201231_g18.jpg" alt="biib-20201231_g18.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:116px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderate to severe plaque psoriasis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td></tr></table></div><div id="iefe8f1adeafa45df8da4a5beded16de5_34"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patient Support and Access</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We interact with patients, advocacy organizations and healthcare societies in order to gain insights into unmet needs. The insights gained from these engagements help us support patients with services, programs and applications that are designed to help patients lead better lives. Among other things, we provide customer service and other related programs for our products, such as disease and product specific websites, insurance research services, financial assistance programs and the facilitation of the procurement of our marketed products. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to helping patients obtain access to our therapies. Our patient representatives have access to a suite of financial assistance tools. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With those tools, we help patients understand their insurance coverage and, if needed, help patients compare and select new insurance options and programs. In the U.S., we have established programs that provide co-pay assistance or free marketed product for qualified uninsured or underinsured patients, based on specific eligibility criteria. We also provide charitable contributions to independent charitable organizations that assist patients with out-of-pocket expenses associated with their therapy.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe all healthcare stakeholders have a shared responsibility to ensure patients have equitable access to new, innovative medicines. We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. In appropriate situations, patients may have access to investigational therapies through Early Access Programs, single patient access or emergency use based on humanitarian or compassionate grounds.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Marketing and Distribution</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Force and Marketing</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote our marketed products worldwide, including in the U.S., Europe and Japan, primarily through our own sales forces and marketing groups. In some countries, particularly in areas where we continue to expand into new geographic areas, we partner with third parties. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS are marketed by the Roche Group and its sublicensees.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize BENEPALI, IMRALDI and FLIXABI pursuant to our agreement with Samsung Bioepis in certain countries in Europe.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our sales and marketing efforts on specialist physicians in private practice or at major medical centers. We use customary industry practices to market our products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Arrangements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We distribute our products in the U.S. principally through wholesale and specialty distributors of pharmaceutical products and specialty pharmacies, mail order specialty distributors or shipping service providers. In other countries, the distribution of our products varies from country to country, including through wholesale distributors of pharmaceutical products and third-party distribution partners who are responsible for most marketing and distribution activities.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS are distributed by the Roche Group and its sublicensees.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We distribute BENEPALI, IMRALDI and FLIXABI in certain countries in Europe and have an option to acquire exclusive rights to distribute these products in China.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product sales to two wholesale distributors each accounted for more than 10.0% of our total revenues for the years ended December&#160;31, 2020, 2019 and 2018, and on a combined basis, accounted for approximately 45.8%, 47.0% and 50.0% of our gross product revenues for the years ended December&#160;31, 2020, 2019 and 2018, respectively. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Revenues</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_37"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patents and Other Proprietary Rights</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are important to obtaining and protecting exclusive rights in our products and product candidates. We regularly seek patent protection in the U.S.&#160;and in selected countries outside the U.S.&#160;for inventions originating from our research and development efforts and those we license or acquire. In addition, we license rights to various patents and patent applications. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.&#160;patents, as well as most foreign patents, are generally effective for 20&#160;years from the date the earliest application was filed; however, U.S.&#160;patents that issue on applications filed before June&#160;8, 1995,&#160;may be effective until 17&#160;years from the issue date, if that is later than the 20-year date. In some cases, the patent term may be extended to recapture a portion of the term lost during regulatory review of the claimed therapeutic or, in the case of the U.S., because of U.S.&#160;Patent and Trademark Office (USPTO) delays in prosecuting the application. Specifically, in the U.S., under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, a patent that covers a drug approved by the FDA may be eligible for patent term extension (for up to 5 years, but not beyond a total of 14 years from the date of product approval) as compensation for patent term lost during the FDA regulatory review process. The duration and extension of the term of foreign patents varies, in accordance with local law. For example, supplementary protection certificates (SPCs) on some of our products have been granted in a number of European countries, compensating in part for delays in obtaining marketing approval.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory exclusivity, which may consist of regulatory data protection and market protection, also can provide meaningful protection for our products. Regulatory data protection provides to the holder of a drug or biologic marketing authorization, for a set period of time, the exclusive use of the proprietary pre-clinical and clinical data that it created at </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant cost and submitted to the applicable regulatory authority to obtain approval of its product. After the period of exclusive use, third parties are permitted to reference such data in abbreviated applications for approval and to market (subject to any applicable market protection) their generic drugs and biosimilars. Market protection provides the holder of a drug or biologic marketing authorization the exclusive right to commercialize its product for a period of time, thereby preventing the commercialization of another product containing the same active ingredient(s) during that period. Although the World Trade Organization's agreement on trade-related aspects of intellectual property rights (TRIPS) requires signatory countries to provide regulatory exclusivity to innovative pharmaceutical products, implementation and enforcement varies widely from country to country.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon other forms of unpatented confidential information to remain competitive. We protect such information principally through refraining from public disclosure and confidentiality agreements with our employees, consultants, outside scientific collaborators, scientists whose research we sponsor and other advisers. In the case of our employees, these agreements also provide, in compliance with relevant law, that inventions and other intellectual property conceived by such employees during their employment are our exclusive property.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks are important to us and are generally covered by trademark applications or </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registrations in the USPTO and the patent or trademark offices of other countries. We also use trademarks licensed from third parties, such as the trademark FAMPYRA, which we license from Acorda. Trademark protection varies in accordance with local law, and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Patent Portfolio </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes our patents in the U.S. and Europe that we currently consider of primary importance to our marketed products, including the territory, patent number, general subject matter and expected expiration dates. Except as otherwise noted, the expected expiration dates include any granted patent term extensions and issued SPCs. In some instances, there are later-expiring patents relating to our products directed to, among other things, particular forms or compositions, methods of manufacturing or use of the drug in the treatment of particular diseases or conditions. We also continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patent No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">General Subject Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patent </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,399,514</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1131065</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of dialkyl fumarates and their use for treating autoimmune diseases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2137537</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of use</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,446,173</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Polymer conjugates of interferon beta-1a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,524,660</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,017,733</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Polymer conjugates of interferon beta-1a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1656952</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Polymer conjugates of interferon-beta-1a and uses thereof</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1476181</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Polymer conjugates of interferon-beta-1a and uses thereof</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,807,167</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,493,567</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1485127</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of use </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2676967</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of use</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1732548</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sustained-release aminopyridine compositions for increasing walking speed in patients with MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2377536</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sustained-release aminopyridine compositions for treating MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,669,281</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds and pharmaceutical compositions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,090,558</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,080,733</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystalline forms, pharmaceutical compositions and methods of treatment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,101,993</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oligonucleotides containing 2&#8217;-O-modified purines</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,838,657</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMA treatment via targeting of SMN2 splice site inhibitory sequences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,110,560</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMA treatment via targeting of SMN2 splice site inhibitory sequences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,361,977</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,980,853</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,717,750</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,926,559</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2034</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,266,822</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SMA treatment via targeting of SMN2 splice site inhibitory sequences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,436,802</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods for Treating Spinal Muscular Atrophy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2035</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1910395</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2548560</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3305302</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3308788</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3449926</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compositions and methods for modulation of SMN2 splicing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030</span></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Footnotes follow on next page.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">In addition to patent protection, certain of our products are entitled to regulatory exclusivity in the U.S. and the E.U. expected until the dates set forth below:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:46.345%"><tr><td style="width:1.0%"></td><td style="width:20.035%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.035%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expected Expiration</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E.U.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E.U.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E.U.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E.U.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td></tr></table></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">For additional information as to the validity of this patent, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2024. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">This patent was revoked in a European opposition. This decision is being appealed. This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2029.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2024.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2028.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.22pt">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2031.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:1.82pt">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2031.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existence of patents does not guarantee our right to practice the patented technology or commercialize the patented product. Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes, such as those that cover our existing products, compounds and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Litigation, interferences, oppositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We also face challenges to our patents, regulatory exclusivities or other proprietary rights covering our products by third-parties, such as manufacturers of generics, biosimilars, prodrugs and products approved under abbreviated regulatory pathways. A discussion of certain risks and uncertainties that may affect our patent position, regulatory exclusivities or other proprietary rights is set forth in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report, and the discussion of legal proceedings related to certain patents described above is set forth in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition in the biopharmaceutical industry is intense. There are many companies, including biotechnology and pharmaceutical companies, engaged in developing products for the indications our approved products are approved to treat and the therapeutic areas we are targeting with our research and development activities. Some of our competitors may have substantially greater financial, marketing, research and development and other resources than we do.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that competition and leadership in the industry is based on managerial and technological excellence and innovation as well as establishing patent and other proprietary positions through research and development. The achievement of a leadership position also depends largely upon our ability to maximize the approval, acceptance and use of our product candidates and the availability of adequate financial resources to fund facilities, equipment, personnel, clinical testing, manufacturing and marketing. Another key aspect of remaining competitive in the industry is recruiting and retaining leading scientists and technicians to conduct our research activities and advance our development programs, including with the commercial expertise to effectively market our products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition among products approved for sale may be based, among other things, on patent position, product efficacy, safety, patient convenience, delivery devices, reliability, availability, reimbursement and price. In addition, early entry of a new pharmaceutical product into the market may have important advantages in gaining product acceptance and market share. Accordingly, the relative speed with which we can develop products, complete the testing and approval process and supply commercial quantities of products will have a significant impact on our competitive position.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The introduction of new products or technologies, including the development of new processes or technologies by competitors or new information about existing products or technologies, results in increased competition for our marketed products and pricing pressure on our marketed products. The development of new or improved treatment options or standards of care or cures for the diseases our products treat reduces and could eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negatively impact future sales of our existing products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face increased competitive pressures from the introduction of generic versions, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products, which may significantly reduce both the price that we are able to charge for our products and the volume of products we sell. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenues in a short period of time. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our long-term competitive position depends upon our success in discovering and developing innovative, cost-effective products that serve unmet medical needs, along with our ability to manufacture products efficiently and to launch and market them effectively in a highly competitive environment.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about the competition that our marketed products face is set forth below and in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Factors included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and VUMERITY each compete with one or more of the following products as well as generic and biosimilar versions of such products: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.685%"><tr><td style="width:1.0%"></td><td style="width:47.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Competing Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Competitor</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUBAGIO (teriflunomide)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BETASERON/BETAFERON (interferon-beta-1b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bayer Group</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COPAXONE <br/>(glatiramer acetate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Teva Pharmaceuticals Industries Ltd.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EXTAVIA <br/>(interferon-beta-1b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novartis AG</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILENYA (fingolimod)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novartis AG</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GLATOPA (glatiramer acetate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sandoz, a division of Novartis AG</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LEMTRADA (alemtuzumab)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MAVENCLAD (cladribine)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EMD Serono</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MAYZENT (siponimod)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novartis AG</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS (ocrelizumab)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genentech</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">REBIF <br/>(interferon-beta-1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EMD Serono</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZEPOSIA (ozanimod)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BMS</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BAFIERTAM (monomethyl fumarate)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Banner Life Sciences</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KESIMPTA (ofatumumab)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novartis AG</span></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the year ended December 31, 2020, and is expected to have a </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FAMPYRA is indicated as a treatment to improve walking in adult patients with MS who have a walking disability and is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS. FAMPYRA is currently the only therapy approved to improve walking in patients with MS. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition in the MS market is intense.&#160;Along with us, a number of companies are working to develop additional treatments for MS that may in the future compete with our MS products. One such product that was approved in the U.S. in 2017 and in the E.U. in 2018 is OCREVUS, a treatment for RMS and PPMS that was developed by Genentech. While we have a financial interest in OCREVUS, future sales of our MS products may be adversely affected if OCREVUS continues to gain market share, or if other MS products that we or our competitors are developing are commercialized</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:8pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spinal Muscular Atrophy</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from a gene therapy product that was approved in the U.S. and the E.U. and a new oral product that was approved in the U.S. and has been accepted for review in the E.U. We expect that we will experience competition from both products in additional jurisdictions in the future. Additionally, we are aware of other products now in development that, if launched, may also compete with SPINRAZA. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products.</span></div><div style="margin-top:8pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Psoriasis</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FUMADERM competes with several different types of therapies in the psoriasis market within Germany, including oral systemics such as methotrexate and cyclosporine.</span></div><div style="margin-top:8pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BENEPALI, IMRALDI and FLIXABI, the three biosimilar products we currently commercialize in certain countries in Europe for Samsung Bioepis, compete with their reference products, ENBREL, HUMIRA and REMICADE, respectively, as well as other biosimilars of those reference products. </span></div><div style="margin-top:8pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Relationships in Other Indications</span></div><div style="margin-top:8pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN, RITUXAN HYCELA and GAZYVA in Oncology</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RITUXAN, RITUXAN HYCELA and GAZYVA compete with a number of therapies in the oncology market, including TREANDA (bendamustine HCL), ARZERRA (ofatumumab), IMBRUVICA (ibrutinib) and ZYDELIG (idelalisib). </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that over time RITUXAN HYCELA and GAZYVA will increasingly compete with RITUXAN in the oncology market. In addition, we are aware of several other anti-CD20 molecules, including biosimilar products, that have recently been approved and are expected to compete with RITUXAN, RITUXAN HYCELA and GAZYVA in the oncology market. In November 2019, January 2020 and Janu</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ary 2021 bi</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">osimilar products referencing RITUXAN were launched in the U.S and are being offered at lower prices. This competition has adversely affected the pre-tax profits of our collaboration arrangements with Genentech and could have a significant adverse affect our co-promotion profits in the U.S. in future years.</span></div><div style="margin-top:8pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN in Rheumatoid Arthritis</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RITUXAN competes with several different types of therapies in the rheumatoid arthritis market, including, among others, traditional disease-modifying anti-rheumatic drugs such as steroids, methotrexate and cyclosporine, TNF inhibitors, ORENCIA (abatacept), ACTEMRA (tocilizumab) and XELJANZ (tofacitinib).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of other products, including biosimilars, in development that, if approved, may compete with RITUXAN in the rheumatoid arthritis market. </span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_43"></div><div style="margin-top:12pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Research and Development Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A commitment to research is fundamental to our mission. Our research efforts are focused on better understanding the underlying biology of diseases so we can discover and deliver treatments that have the potential to make a real difference in the lives of patients with high unmet medical needs. By applying our expertise in biologics and our growing capabilities in small molecule, antisense, gene therapy, gene editing and other technologies, we target specific medical needs where we believe new or better treatments are needed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated. As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products and technologies and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our research and development expense included in our consolidated statements of income, please read</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below highlights our current research and development programs that are in clinical trials and the current phase of such programs. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report. </span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.344%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="39" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Core Growth Areas</span></td><td colspan="3" rowspan="5" style="background-color:#40aeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MS and Neuroimmunology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB061 (oral remyelination) - MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB091 (BTK inhibitor) - MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB107 (anti-VLA4) - MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="9" style="background-color:#bfe4ff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alzheimer's Disease and Dementia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aducanumab (A&#946; mAb)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> - Alzheimer's</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filed in U.S., E.U. and Japan</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BAN2401 (lecanemab)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> - Alzheimer's</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#1c5a7d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB092 (gosuranemab) - Alzheimer's</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB076 (anti-tau mAb) - Alzheimer's</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB080 (tau ASO) - Alzheimer's</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="9" style="background-color:#40aeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuromuscular Disorders, <br/>including SMA and ALS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB067 (tofersen) - ALS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#1c5a7d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB078 (IONIS-C9</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:1.12pt;vertical-align:baseline">Rx</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">#</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> - ALS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB105 (ataxin-2 ASO)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">#</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> - ALS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB100 (XP01 inhibitor) - ALS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB110 (ActRIIA/B ligand trap) - SMA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="9" style="background-color:#bfe4ff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Parkinson's Disease and<br/> Movement Disorders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB124 (SAGE-324)* - Essential Tremor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB094 (ION859)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">#</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> - Parkinson's</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB118 (CK1 inhibitor) - ISWRD in Parkinson's</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB101 (ION464)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">#</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> - Multiple System Atrophy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB122 (DNL151)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> - Parkinson's</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="background-color:#40aeff;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ophthalmology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB111 (timrepigene emparvovec) - CHM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#1c5a7d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#40aeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB112 (RPGR gene therapy) - XLRP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2/3</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="background-color:#bfe4ff;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuropsychiatry</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB125 (zuranolone)* - PPD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#1c5a7d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB125 (zuranolone)* - MDD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#1c5a7d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB104 (AMPA PAM) - CIAS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="16" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Emerging Growth Areas</span></td><td colspan="3" rowspan="3" style="background-color:#def3c0;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#def3c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dapirolizumab pegol (anti-CD40L)* - SLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#1c5a7d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#def3c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB059 (anti-BDCA2) - CLE/SLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#bbdc7f;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acute Neurology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bbdc7f;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB093 (glibenclamide IV) - LHI</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#94;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Stroke</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#1c5a7d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bbdc7f;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TMS-007</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">#</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> - Acute Ischemic Stroke</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#bbdc7f;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB093 (glibenclamide IV) - Brain Contusion</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="5" style="background-color:#def3c0;border-left:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuropathic Pain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#def3c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB074 (vixotrigine) - Trigeminal Neuralgia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#def3c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB074 (vixotrigine) - Small Fiber Neuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#2573ba;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#def3c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BIIB095 (Nav 1.7) - Neuropathic Pain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#77afe4;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="background-color:#acacac;border-left:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#acacac;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SB11 (referencing LUCENTIS)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filed in U.S. and E.U.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#acacac;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SB15 (referencing EYLEA)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#1c5a7d;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Collaboration program</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"># Option agreement</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#94; Large Hemispheric Infarction (LHI); postpartum depression (PPD); major depressive disorder (MDD)</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about certain of our agreements with collaborators and other third parties, please read the subsection entitled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Relationships</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we establish business relationships, including entering into licenses, joint ventures and collaborative arrangements with other companies, universities and medical research institutions, to assist in the clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies, universities and medical research institutions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a brief description of certain business relationships and collaborations that expand our pipeline and provide us with certain rights to existing and potential new products and technologies. For additional information on certain of these relationships, including their ongoing financial and accounting impact on our business, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acorda Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Acorda to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alkermes</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive license and collaboration agreement with Alkermes for VUMERITY, which was approved for the treatment of RMS in the U.S. in October 2019 and became commercially available in the U.S. in November 2019. Under this agreement, we have an exclusive, worldwide license to develop and commercialize VUMERITY. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092 (gosuranemab), a Phase 2 investigational therapy in Alzheimer's disease. Under this agreement, we received worldwide rights to gosuranemab and are responsible for the full development and potential commercialization of gosuranemab in Alzheimer's disease. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Denali to co-develop and co-commercialize Denali&#8217;s small molecule inhibitors of LRRK2 for Parkinson&#8217;s disease. In the LRRK2 collaboration, we and Denali share responsibility and costs for global development as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China, we are responsible for commercialization and pay Denali tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle: Abeta program and a second program utilizing its Transport Vehicle technology. Further, we have a right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize BAN2401, an Eisai product candidate for the potential treatment of Alzheimer's disease. Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a collaboration agreement with Eisai to jointly develop and commercialize aducanumab (the Aducanumab Collaboration Agreement). Under the Aducanumab Collaboration Agreement, the two companies will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have collaboration arrangements with Genentech which entitle us to certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and other potential anti-CD20 therapies. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ionis Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive, worldwide option and collaboration agreement with Ionis relating to the development and commercialization of antisense therapeutics for up to three gene targets. Under a </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separate collaboration and license agreement with Ionis, we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA. We also have a 10-year exclusive collaboration agreement with Ionis to develop novel ASO drug candidates for a broad range of neurological diseases.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have research collaboration agreements with Ionis under which both companies perform discovery level research and will develop and commercialize new ASO drug candidates for the potential treatment of SMA and additional antisense or other therapeutics for the potential treatment of neurological diseases.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all licensed products.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Samsung BioLogics established a joint venture, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;We also have an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-TNF biosimilar product candidates in certain countries in Europe and, in the case of BENEPALI, Japan.&#160;Under this agreement, we are commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in certain countries in Europe and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our joint venture and commercialization agreements with Samsung Bioepis, we license certain of our proprietary technology to Samsung Bioepis in connection with Samsung </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bioepis' development, manufacture and commercialization of its biosimilar products.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a global collaboration and license agreement with Sage to jointly develop and commercialize zuranolone for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for the potential treatment of essential tremor and other neurological disorders. We and Sage share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea with respect to zuranolone, and will pay Sage tiered royalties.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer&#8217;s disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. Sangamo will perform early research activities, costs for which will be shared by the companies, and we will assume responsibility and costs beyond the early research activities.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_49"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Regulatory</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and contemplated activities and the products, technologies and processes that result from such activities are subject to substantial government regulation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Pharmaceuticals</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Approval and Post-Approval Regulation in the U.S.</span></div><div style="margin-top:9pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APPROVAL PROCESS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before new pharmaceutical products may be sold in the U.S., preclinical studies and clinical trials of the products must be conducted and the results submitted to the FDA for approval. With limited exceptions, the FDA requires companies to register both pre-approval and post-approval clinical trials and disclose clinical trial results in public databases. Failure to register a trial or disclose study results within the required time periods could result in penalties, including civil monetary penalties. Clinical trial programs must establish efficacy, determine an </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appropriate dose and dosing regimen and define the conditions for safe use. This is a high-risk process that requires stepwise clinical studies in which the candidate product must successfully meet predetermined endpoints. The results of the preclinical and clinical testing of a product are then submitted to the FDA in the form of a BLA or a New Drug Application (NDA). In response to a BLA or NDA, the FDA may grant marketing approval, request additional information or deny the application if it determines the application does not provide an adequate basis for approval.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development and receipt of regulatory approval takes a number of years, involves the expenditure of substantial resources and depends on a number of factors, including the severity of the disease in question, the availability of suitable alternative treatments, potential safety signals observed in preclinical or clinical tests and the risks and benefits of the product as demonstrated in clinical trials. The FDA has substantial discretion in the product approval process, and it is impossible to predict with any certainty whether and when the FDA will grant marketing approval. The agency may require the sponsor of a BLA or NDA to conduct additional clinical studies or to provide other scientific or technical information about the product, and these additional requirements may lead to unanticipated delays or expenses. Furthermore, even if a product is approved, the approval may be subject to limitations based on the FDA's interpretation of the existing pre-clinical and/or clinical data. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has developed four distinct approaches intended to facilitate the development and expedite the regulatory review of therapeutically important drugs, especially when the drugs are the first available treatment or have advantages over existing treatments: accelerated approval, fast track, breakthrough therapy and priority review.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Accelerated Approval</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The FDA may grant &#8220;accelerated approval&#8221; to products that treat serious or life-threatening illnesses and that provide meaningful therapeutic benefits to patients over existing treatments. Under this pathway, the FDA may approve a product based on surrogate endpoints or clinical endpoints other than survival or irreversible morbidity. When approval is based on surrogate endpoints or clinical endpoints other than survival or morbidity, the sponsor will be required to provide the FDA with confirmatory data post-approval to verify and describe clinical benefit. Under the FDA's accelerated approval regulations, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it may require </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain post-marketing restrictions to assure safe use. In addition, for products approved under accelerated approval, sponsors may be required to submit all copies of their promotional materials, including advertisements, to the FDA at least 30 days prior to initial dissemination. The FDA may withdraw approval if, for instance, post-marketing studies fail to verify clinical benefit, it becomes clear that restrictions on the distribution of the product are inadequate to ensure its safe use or if a sponsor fails to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Fast Track</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The FDA may grant "fast track" status to products that treat a serious condition and have data demonstrating the potential to address an unmet medical need or a drug that has been designated as a qualified infectious disease product.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Breakthrough Therapy</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The FDA may grant &#8220;breakthrough therapy&#8221; status to drugs designed to treat, alone or in combination with another drug or drugs, a serious or life-threatening disease or condition and for which preliminary clinical evidence suggests a substantial improvement over existing therapies based on a clinically significant endpoint. Breakthrough therapy status entitles the sponsor to earlier and more frequent meetings with the FDA regarding the development of nonclinical and clinical data and permits the FDA to offer product development or regulatory advice for the purpose of shortening the time to product approval. Breakthrough therapy status does not guarantee that a product will be eligible for priority review and does not ensure FDA approval.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Priority Review</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: &#8220;Priority review&#8221; only applies to applications (original or efficacy supplement) for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, diagnosis or prevention of a serious condition. Priority review may also be granted for any supplement that proposes a labeling change due to studies completed in response to a written request from the FDA for pediatric studies, for an application for a drug that has been designated as a qualified infectious disease product or for any application or supplement for a drug submitted with a priority review voucher.</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016 the FDA issued a rare pediatric disease priority review voucher to us in connection with the approval of SPINRAZA. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">POST-MARKETING STUDIES</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the approval pathway employed, the FDA may require a sponsor to conduct additional post-marketing studies as a condition of approval to provide data on safety and effectiveness. If a sponsor fails to conduct the required studies, the FDA may withdraw its approval. In addition, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it can mandate post-marketing restrictions to assure safe use. In such a case, the sponsor may be required to establish rigorous systems to assure use of the product under safe conditions. These systems are usually referred to as Risk Evaluation and Mitigation Strategies (REMS). The FDA can impose financial penalties for failing to comply with certain post-marketing commitments, including REMS. In addition, any changes to an approved REMS must be reviewed and approved by the FDA prior to implementation.</span></div><div style="margin-top:9pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADVERSE EVENT REPORTING</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor information on side effects and adverse events reported during clinical studies and after marketing approval and report such information and events to regulatory agencies. Non-compliance with the FDA's safety reporting requirements may result in civil or criminal penalties. Side effects or adverse events that are reported during clinical trials can delay, impede or prevent marketing approval. Based on new safety information that emerges after approval, the FDA can mandate product labeling changes, impose a new REMS or the addition of elements to an existing REMS, require new post-marketing studies (including additional clinical trials) or suspend or withdraw approval of the product. These requirements may affect our ability to maintain marketing approval of our products or require us to make significant expenditures to obtain or maintain such approvals.</span></div><div style="margin-top:9pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APPROVAL OF CHANGES TO AN APPROVED PRODUCT</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we seek to make certain types of changes to an approved product, such as adding a new indication, making certain manufacturing changes or changing manufacturers or suppliers of certain ingredients or components, the FDA will need to review and approve such changes in advance. In the case of a new indication, we are required to demonstrate with additional clinical data that the product is safe and effective for a use other than what was initially approved. FDA regulatory review may result in denial or modification of the planned changes, or requirements to conduct additional tests or evaluations that can substantially delay or increase the cost of the planned changes.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">REGULATION OF PRODUCT ADVERTISING AND PROMOTION</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates all advertising and promotion activities and communications for products under its jurisdiction both before and after approval. Pursuant to FDA guidance, a company can make safety and efficacy claims either in or consistent with the product label. However, physicians may prescribe legally available drugs for uses that are not described in the drug's labeling. Such off-label prescribing is common across medical specialties, and often reflects a physician's belief that the off-label use is the best treatment for patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers' communications regarding off-label uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising and the full range of civil and criminal penalties available to the government.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Combination Products</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Combination products are defined by the FDA to include products comprising two or more regulated components (e.g., a biologic and a device). Biologics and devices each have their own regulatory requirements, and combination products may have additional requirements. Some of our marketed products meet this definition and are regulated under this framework and similar regulations outside the U.S., and we expect that some of our pipeline product candidates may be evaluated for regulatory approval under this framework as well. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017 new regulations governing medical devices (MDR) and in-vitro diagnostic medical devices (IVDR) entered into force in the E.U. although these are not expected to fully apply until May 2021 with respect to the MDR regulations and May 2022 with respect to the IVDR regulations. All products covered by these regulations will be required to comply with them at the end of the transitional periods. These regulations introduce new requirements, including for clinical investigation of certain classifications of medical devices, require increased regulatory scrutiny, enhance the requirements for post market surveillance and vigilance and provide for greater transparency. These regulations also change the requirements for assessment of the medical device components of integral drug-device combination products, necessitating assessment of the device components under both the medical device and medicinal product regulatory regimes.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Approval and Post-Approval Regulation Outside the U.S.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our products in numerous jurisdictions outside the U.S. Most of these jurisdictions have product approval and post-approval regulatory processes that are similar in principle to those in the U.S. In Europe, for example, where a substantial part of our ex-U.S. efforts are focused, there are several routes for marketing approval, depending on the type of product for which approval is sought. Under the centralized procedure, a company submits a single application to the EMA. The marketing authorization application is similar to the NDA or BLA in the U.S. and is evaluated by the Committee for Medicinal Products for Human Use (CHMP), the expert scientific committee of the EMA responsible for human medicines. If the CHMP determines that the marketing authorization application fulfills the requirements for quality, safety and efficacy and that the medicine has a positive benefit risk balance, it will adopt a positive opinion recommending the granting of the marketing authorization by the EC. The CHMP opinion is not binding, but is typically adopted by the EC. A MAA approved by the EC is valid in all member states of the E.U. The centralized procedure is required for all biological products, orphan medicinal products and new treatments for neurodegenerative disorders, and it is available for certain other products, including those which constitute a significant therapeutic, scientific or technical innovation.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the centralized procedure, the European regulatory framework includes the following options for regulatory review and approval in E.U. member states: </span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">a national procedure, where the first application is made to the competent authority in one E.U. country only; </span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">a decentralized procedure, where applicants submit identical applications to several E.U. countries and receive simultaneous approval, if the medicine has not yet been authorized in any E.U. country; and </span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">a mutual recognition procedure, where applicants that have a medicine authorized in one E.U. country can apply for mutual recognition of this authorization in other E.U. countries. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the U.S., the E.U. also has distinct approaches intended to optimize the regulatory pathways for therapeutically important drugs, including the Priority Medicines Evaluation Scheme (PRIME), accelerated assessment and conditional marketing authorization. PRIME is intended to provide additional support to medicine developers throughout the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development process. Regulatory review timelines in the E.U. may be truncated under accelerated assessment for products that address an unmet medical need. In addition, conditional marketing  authorizations may be granted for such products in the interest of public health, where the benefit of immediate availability outweighs the risk of less comprehensive data than normally required. Conditional marketing authorizations are valid for one year and can be renewed annually. The marketing authorization holder is required to complete specific obligations (ongoing or new studies and, in some cases, additional activities) with a view to providing comprehensive data confirming that the benefit risk balance is positive. Once comprehensive data on the product have been obtained, the marketing authorization may be converted into a standard marketing authorization.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aside from the U.S. and E.U., there are countries in other regions where it is possible to receive an "accelerated" review whereby the national regulatory authority will commit to truncated review timelines for products that meet specific medical needs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the E.U. there is detailed legislation on pharmacovigilance and extensive guidance on good pharmacovigilance practices. A failure to comply with E.U. pharmacovigilance obligations may result in significant financial penalties for the marketing authorization holder.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the approval process employed, various parties share responsibilities for the monitoring, detection and evaluation of adverse events post-approval, including national competent authorities, the EMA, the EC and the marketing authorization holder. The EMA&#8217;s Pharmacovigilance Risk Assessment Committee is responsible for assessing and monitoring the safety of human medicines and makes recommendations on product safety issues. Marketing authorization holders have an obligation to inform regulatory agencies of any new information which may influence the evaluation of benefits and risks of the medicinal product concerned. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., E.U. and other jurisdictions, regulatory agencies, including the FDA, conduct periodic inspections of NDA, BLA and marketing authorization holders to assess their compliance with pharmacovigilance obligations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Good Manufacturing Practices</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory agencies regulate and inspect equipment, facilities and processes used in the manufacturing and testing of pharmaceutical and biologic products prior to approving a product. If, after receiving approval from regulatory agencies, a </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company makes a material change in manufacturing equipment, location or process, additional regulatory review and approval may be required. We also must adhere to current Good Manufacturing Practices (cGMP) and product-specific regulations enforced by regulatory agencies following product approval. The FDA, the EMA and other regulatory agencies also conduct periodic visits to re-inspect equipment, facilities and processes following the initial approval of a product. If, as a result of these inspections, it is determined that our equipment, facilities or processes do not comply with applicable regulations and conditions of product approval, regulatory agencies may seek civil, criminal or administrative sanctions or remedies against us, including significant financial penalties and the suspension of our manufacturing operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Good Clinical Practices</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, the EMA and other regulatory agencies promulgate regulations and standards for designing, conducting, monitoring, auditing and reporting the results of clinical trials to ensure that the data and results are accurate and that the rights and welfare of trial participants are adequately protected (commonly referred to as current Good Clinical Practices (cGCP)). Regulatory agencies enforce cGCP through periodic inspections of trial sponsors, principal investigators and trial sites, contract research organizations (CROs) and institutional review boards. If our studies fail to comply with applicable cGCP guidelines, the clinical data generated in our clinical trials may be deemed unreliable and relevant regulatory agencies may require us to perform additional clinical trials before approving our marketing applications. Noncompliance can also result in civil or criminal sanctions. We rely on third parties, including CROs, to carry out many of our clinical trial-related activities. Failure of such third parties to comply with cGCP can likewise result in rejection of our clinical trial data or other sanctions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2014 the EC adopted a new Clinical Trial Regulation, which was effective in June 2014 but is not expected to apply until 2021. The regulation harmonizes the procedures for assessment and governance of clinical trials throughout the E.U. and will require that information on the authorization, conduct and results of each clinical trial conducted in the E.U. be publicly available.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act (PPACA) amended the Public Health Service Act (PHSA) to authorize the FDA to approve biological products, referred to as biosimilars or follow-on biologics, that are shown to be "highly similar" to previously approved biological products based upon potentially abbreviated data packages.&#160;The biosimilar </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">must show it has no clinically meaningful differences in terms of safety and effectiveness from the reference product, and only minor differences in clinically inactive components are allowable in biosimilar products. The approval pathway for biosimilars does, however, grant a biologics manufacturer a 12-year period of exclusivity from the date of approval of its biological product before biosimilar competition can be introduced. There is uncertainty, however, as the approval framework for biosimilars originally was enacted as part of the PPACA. There have been, and there are likely to continue to be, federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. If the PPACA is repealed, substantially modified or invalidated, it is unclear what, if any, impact such action would have on biosimilar regulation.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biosimilars approval pathway has been in place in the E.U. since 2003. The EMA has issued a number of scientific and product specific biosimilar guidelines, including requirements for approving biosimilars containing monoclonal antibodies. In the E.U., biosimilars are generally approved under the centralized procedure. The approval pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on reliance on the clinical trial data of an innovator product to which the biosimilar has been demonstrated, through comprehensive comparability studies, to be &#8220;similar.&#8221; In many cases, this allows biosimilars to be brought to market without conducting the full complement of clinical trials typically required for novel biologic drugs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Act</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.S.&#160;Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a &#8220;rare disease or condition,&#8221; which generally is a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;If a product which has an orphan drug designation subsequently receives an initial FDA approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, i.e., the FDA may not approve any other applications to market the same drug for the same indication for a period of seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Legislation similar to the U.S.&#160;Orphan Drug Act has been enacted in other countries to encourage the research, development and marketing of medicines to treat, prevent or diagnose rare diseases. In the E.U., medicinal products that receive and maintain an orphan designation are entitled to 10 years of market exclusivity following approval, protocol assistance and access to the centralized procedure for marketing </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorization. SPINRAZA has been granted orphan drug designation in the U.S., E.U. and Japan.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Pertaining to Pricing and Reimbursement</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of our products depend, to a significant extent, on the availability and amount of reimbursement by third-party payors, including governments, private health plans and other organizations. Substantial uncertainty exists regarding the pricing and reimbursement of our products, and drug prices continue to receive significant scrutiny. Governments may regulate coverage, reimbursement and pricing of our products to control cost or affect utilization of our products. Challenges to our pricing strategies, by either government or private stakeholders, could harm our business. The U.S.&#160;and foreign governments have enacted and regularly consider additional reform measures that affect health care coverage and costs. Private health plans may also seek to manage cost and utilization by implementing coverage and reimbursement limitations. Other payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities and private health insurers, seek price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, may impose restrictions on access, coverage or pricing of particular drugs based on perceived value.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Within the U.S.</span></div><div style="margin-top:5pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Medicaid</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program, we are required to pay a rebate for each unit of product reimbursed by the state Medicaid programs. The amount of the rebate is established by law and is adjusted upward if the average manufacturer price (AMP) increases more than inflation (measured by the Consumer Price Index&#160;- Urban). The rebate amount is calculated each quarter based on our report of current AMP and best price for each of our products to the Centers for Medicare&#160;&amp; Medicaid Services (CMS). The requirements for calculating AMP and best price are complex. We are required to report any revisions to AMP or best price previously reported within a certain period, which revisions could affect our rebate liability for prior quarters. In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the statute governing the Medicaid Drug Rebate Program provides for civil monetary penalties.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Medicare</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Medicare is a federal program that is administered by the federal government. The program covers individuals age&#160;65 and over as well as those with certain disabilities. Medicare Part&#160;B generally covers drugs that must be administered by physicians or other health care practitioners, are provided in connection with certain durable medical equipment or are certain oral anti-cancer drugs and certain oral immunosuppressive drugs. Medicare Part B pays for such drugs under a payment methodology based on the average sales price (ASP) of the drugs. Manufacturers, including us, are required to provide ASP information to the CMS on a quarterly basis. The manufacturer-submitted information is used to calculate Medicare payment rates. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, the governing statute provides for civil monetary penalties.</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 CMS issued an interim final rule that seeks to lower prescription drug costs by paying no more for certain Medicare Part B drugs than the lowest price paid for such drugs in certain other countries (the "most favored nation" rule). One of the drugs subject to the rule is TYSABRI. Under the rule, the lower payment rates for affected drugs would be phased in over a period of four years, beginning in 2021. Although the rule is being challenged by industry associations on a number of grounds, if the challenges are unsuccessful, the rule could harm our business. In addition, if the rule were expanded to include other drugs or to include Medicare Part D, such expansions could cause additional harm.</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that are not administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government. Each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time-to-time. The prescription drug plans negotiate pricing with manufacturers and pharmacies, and may condition formulary placement on the availability of manufacturer discounts. In addition, manufacturers, including us, are required to provide to the CMS a discount of up to 70% on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries reach the coverage gap in their drug benefits.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Federal Agency Discounted Pricing</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our products are subject to discounted pricing when </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchased by federal agencies via the Federal Supply Schedule (FSS). FSS participation is required for our products to be covered and reimbursed by the Veterans Administration (VA), Department of Defense, Coast Guard and Public Health Service (PHS). Coverage under Medicaid, Medicare and the PHS pharmaceutical pricing program is also conditioned upon FSS participation. FSS pricing is intended not to exceed the price that we charge our most-favored non-federal customer for a product. In addition, prices for drugs purchased by the VA, Department of Defense (including drugs purchased by military personnel and dependents through the TriCare retail pharmacy program), Coast Guard and PHS are subject to a cap on pricing equal to 76% of the non-federal average manufacturer price (non-FAMP). An additional discount applies if non-FAMP increases more than inflation (measured by the Consumer Price Index&#160;- Urban). In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the governing statute provides for civil monetary penalties.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">340B Discounted Pricing</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: To maintain coverage of our products under the Medicaid Drug Rebate Program and Medicare Part B, we are required to extend significant discounts to certain covered entities that purchase products under Section 340B of the PHS pharmaceutical pricing program. Purchasers eligible for discounts include hospitals that serve a disproportionate share of financially needy patients, community health clinics and other entities that receive certain types of grants under the PHSA. For all of our products, we must agree to charge a price that will not exceed the amount determined under statute (the &#8220;ceiling price&#8221;) when we sell outpatient drugs to these covered entities. In addition, we may, but are not required to, offer these covered entities a price lower than the 340B ceiling price. The 340B discount formula is based on AMP and is generally similar to the level of rebates calculated under the Medicaid Drug Rebate Program. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outside the U.S.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., our products are paid for by a variety of payors, with governments being the primary source of payment. Governments may determine or influence reimbursement of products and may also set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i.e., referencing prices in other countries and using those reference prices to set a price). Budgetary pressures in many countries are continuing to cause governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates and expanded generic substitution and patient cost-sharing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Pertaining to Sales and Marketing</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. There is therefore a possibility that our practices might be challenged under anti-kickback or similar laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third-party payors (including Medicare and Medicaid), claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal civil False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include federal &#8220;sunshine&#8221; provisions. The sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to physicians and certain other healthcare practitioners or to </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">teaching hospitals. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements. Given the lack of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulations</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Anti-Corruption</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the U.S.&#160;Foreign Corrupt Practices Act (FCPA), which prohibits U.S.&#160;companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws to which we are subject also include the U.K. Bribery Act 2010 (Bribery Act), which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the U.K. generally will be subject to the Bribery Act. Penalties under the Bribery Act include significant fines for companies and criminal sanctions for corporate officers under certain circumstances.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NIH Guidelines</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to conduct research at our U.S. facilities in compliance with the current U.S.&#160;National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). By local ordinance, we are required to, among other things, comply with the NIH Guidelines in relation to our facilities in Research Triangle Park (RTP), NC and are required to operate pursuant to certain permits.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Laws</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to data privacy and protection, safe working conditions, laboratory practices, the experimental use of animals and the purchase, storage, movement, import, export and use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research work are or may be applicable to our activities. Certain agreements entered into by us involving exclusive license rights may be subject to national or international antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Parliament and the Council of the European Union adopted a comprehensive general data privacy regulation (GDPR) in 2016 to replace the current E.U. Data Protection Directive and related country-specific legislation. The GDPR took effect in May 2018 and governs the collection and use of personal data in the E.U. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the E.U. to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20.0 million or 4.0% of the annual global revenues of the infringer, whichever is greater.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_52"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to comply in all material respects with applicable laws and regulations concerning the environment. While it is impossible to predict accurately the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our operations or competitive position.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_55"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capabilities, processes and facilities. We believe that our manufacturing facilities, together with the third-party contract manufacturing organizations we outsource to, currently provide sufficient capacity for our products and to Samsung Bioepis, our joint venture that develops, manufactures and markets biosimilar products, and other strategic contract manufacturing partners. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Facilities</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug substance manufacturing facility includes:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.685%"><tr><td style="width:1.0%"></td><td style="width:48.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Drug Substance Manufactured</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RTP, NC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVONEX<br/>PLEGRIDY<br/>TYSABRI<br/>Other*</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* Other includes products manufactured for contract manufacturing partners.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our drug substance manufacturing facility, we have a drug product manufacturing facility and supporting infrastructure in RTP, NC, including a parenteral facility and an oral solid dose products manufacturing facility. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parenteral facility adds capabilities and capacity for filling biologics into vials and is principally used for filling product candidates. The oral solid dose products facility can supplement our outsourced small molecule manufacturing capabilities, including the manufacture of TECFIDERA.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have an oligonucleotide synthesis manufacturing facility in RTP, NC. This facility gives us the capability to manufacture ASO drugs like SPINRAZA as well as our other ASO candidates currently in our clinical pipeline.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational during the first half of 2021. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech is responsible for all worldwide manufacturing activities for bulk RITUXAN, RITUXAN HYCELA and GAZYVA and has sourced the manufacture of certain bulk RITUXAN, RITUXAN HYCELA and GAZYVA requirements to a third party. Acorda supplies FAMPYRA to us pursuant to its supply agreement with Alkermes, Inc. and Ionis supplies the active pharmaceutical ingredient (API) for SPINRAZA. Alkermes currently supplies VUMERITY to us pursuant </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to a supply agreement. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by us or our designee.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-Party Suppliers and Manufacturers</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We principally use third parties to manufacture the API and the final product for our small molecule products and product candidates, including TECFIDERA and FUMADERM, and the final drug product for our large molecule products and, to a lesser extent, product candidates. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source all of our fill-finish and the majority of final product assembly and storage operations for our products, along with a substantial part of our label and packaging operations, to a concentrated group of third-party contract manufacturing organizations. Raw materials, delivery devices, such as syringes and auto-injectors, and other supplies required for the production of our products and product candidates are procured from various third-party suppliers and manufacturers in quantities adequate to meet our needs. Continuity of supply of such raw materials, devices and supplies is assured using a strategy of dual sourcing where possible or by a risk-based inventory strategy. Our third-party service providers, suppliers and manufacturers may be subject to routine cGMP inspections by the FDA or comparable agencies in other jurisdictions and undergo assessment and certification by our quality management group.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_2967"></div><div style="margin-top:12pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had approximately 9,100 employees worldwide. Approximately 5,675 employees were employed in the U.S. and approximately 3,425 employees were employed in foreign countries. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity and Inclusion</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Biogen, prejudice, racism and intolerance are unacceptable. We are committed to Diversity, Equity and Inclusion (DE&amp;I) across all aspects of our organization, including hiring, promotion and development practices. As of December 31, 2020, 28% of Biogen&#8217;s director-level and above positions were held by ethnic or racial minorities in the U.S. Our policies and practices are global, but the laws in many countries outside the U.S. do not permit us to collect ethnic or racial data on our employees. Globally, 48% </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Biogen&#8217;s positions at director-level and above were held by women. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 we introduced an updated DE&amp;I strategy that outlines actionable steps to deepen our commitment across the business, building upon a strong foundation. This plan includes a four-part strategy to build our talent and leadership pipeline, improve health outcomes for the African American, Black, Latinx and other minority communities in the disease areas we treat and expand sourcing with minority-owned businesses. We plan to create greater awareness and capability in our organization through leadership accountability and transparency. To establish and progress this strategy, we rely on a cross-company governing body of employees known as the Diversity, Equity &amp; Inclusion Strategic Council.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are honored to be recognized as a company of choice. We scored 100.0% on the 2020 Disability Equality Index, which measures our policies and practices related to disability inclusion, for the third consecutive year. Additionally, for the seventh consecutive year, we were recognized as a Best Place to Work for LGBTQ Equality by the Human Rights Campaign, scoring 100.0% on their Corporate Equality Index. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Philosophy on Pay Equity</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to ensuring our employees receive equal pay for equal work. We establish components and ranges of compensation based on market and benchmark data. Within this context, we strive to pay all employees equitably within a reasonable range, taking into consideration factors such as role; market data; internal equity; job location; relevant experience; and individual, business unit and company performance. In addition, we are committed to providing flexible benefits designed to allow our diverse global workforce to have reward opportunities that meet their varied needs so that they are inspired to perform their best on behalf of patients and stockholders each day.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review our compensation practices and analyze the equity of compensation decisions, for individual employees and our workforce as a whole. If we identify employees with pay gaps, we review and take appropriate action to ensure fidelity between our stated philosophy and actions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We institute measures, such as communications and trainings, to recognize, interrupt and prevent bias in hiring, performance management and compensation decisions and we provide resources to further develop managers and leaders to help them make equitable decisions about pay.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent and Development</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are encouraged to take advantage of an array of professional development resources. Managers coach employees for performance, and also engage in employee development discussions to support growth and learning.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our employees access to over 8,000 on-demand learning modules in English, French, German, Spanish, Japanese and Portuguese. Additionally, we have a wide selection of courses and trainings that are offered through Biogen University, our global validated learning management system.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To create and sustain a workplace as diverse and inclusive as the patients we serve, we offer programs that invest in our talent pipeline and in our current leaders, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">Activate, Reflect and Co-Create: Preparing top talent for the rigors of executive roles.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">Women&#8217;s Leadership Program: Addressing the unique challenges faced by female leaders to increase influence and impact.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">Executive Leadership Retreat: Immersing leaders in topics designed to help them shape culture and build resilience.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">The Partnership, Inc's BioDiversity Fellows Program: To continue to bolster our talent pipeline with a diverse mix of leaders, high potential, mid-career, underrepresented minorities participate in this program, which we helped create.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Employee Resource Networks (ERNs) provide invaluable opportunities for employees to share knowledge and build connections. Our current ERNs include:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">IGNITE: Brings together early-career professionals and their advocates.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">AccessAbility: Supports employees with disabilities and employees who are caretakers of individuals with disabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">Biogen Veterans Network: Encourages veterans and allies of veterans to connect and support one another.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">Mosaic: Fosters awareness and appreciation of different cultural backgrounds, in addition to promoting networking and development opportunities for members.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">ReachOUT: Supports a best-in-class working environment for LGBTQ employees and embraces all LGBTQ employees and their allies.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">Women&#8217;s Innovation Network: Creates networking, mentoring and learning opportunities for women and allies worldwide.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.5pt">ourIMPACT: Advances climate, health and equity at work, in employees' personal lives and in the communities where we live and work.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Creating a culture where all colleagues feel supported and valued is paramount to our corporate mission. The ongoing COVID-19 pandemic has led to unique challenges, and we are striving to ensure the health, safety and general well-being of our employees. We continue to evolve our programs to meet our employees&#8217; health and wellness needs, which we believe is essential to attract and retain employees of the highest caliber. For example, we have refreshed our flexible working arrangement policies to allow for more flexibility around work hours to help employees balance the demands of their work and home lives, shifted many of our on-site wellness services to virtual, including virtual behavior health, nutrition, fitness and overall well-being classes and counseling, rolled out the Headspace meditation app globally at no cost, provided workshops and programming to help employees cope with stress, isolation and building resilience, along with financial planning workshops and counseling sessions, expanded our child- and back-up care services to meet the growing childcare needs of our employees and provided additional holidays and time off for recharging, voting and volunteering.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee surveys</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize an employee survey program to pulse employees through email and mobile apps as well as provide an opportunity for commentary and facilitate feedback to questions. The survey is designed to empower managers and leaders with anonymous information on their practices related to building culture, performance and an engaged workforce, allowing them to create plans and measure efficacy for continuous improvement. We care deeply about employee feedback and are building an analytics community across Human Resources to bring more rigor and sophistication to the collection and analysis of employee opinions. We use their perspectives to guide us to take actions that improve engagement and support and help maintain our reputation as a great place to work for all of our employees. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Succession planning </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year we conduct a talent review across our global enterprise that includes, among other important topics, a review of succession plans for many of our roles. To help ensure the long-term continuity of our business, we actively manage the development of </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">talent to fill the roles that are most critical to the on-going success of our company. In addition, each year our Board of Directors reviews the succession plan for our executives.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Workplace Health and Safety</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The well-being of our employees is a top priority, and we believe each and every employee plays a role in creating a safe and healthy workplace. Our employees have varied roles and functions, which is why we empower them to promote a safe working environment, regardless of whether work happens in the lab, in an office or in a manufacturing plant. Our policies and practices are intended to protect not only our employees, but also the surrounding communities in which we operate.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 we continued to make significant progress integrating Human Performance into our Environment, Health and Safety programs. We believe that, when it comes to safety, workers are part of the solution. We encourage employees to collaboratively engage in proactive problem solving through practices such as Open Reporting and Work Observation and Risk Conversations. We also utilize &#8220;After Action Reviews&#8221; following the completion of a project. These reviews enable us to not only focus on areas for improvement, but also to learn and apply good practices from what goes well. By engaging and empowering our employees through such programs, we believe that we can help change how the entire industry approaches safety performance and risk management.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Information about our Executive Officers (as of February&#160;3, 2021)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Joined Biogen</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Michel Vounatsos</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Susan H. Alexander</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, Chief Legal Officer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2006</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Michael R. McDonnell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Alphonse Galdes, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, Pharmaceutical Operations and Technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1995</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ginger Gregory, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President and Chief Human Resources Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chirfi Guindo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, Global Product Strategy and Commercialization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Robin C. Kramer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Vice President, Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Alfred W. Sandrock, Jr., M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, Research and Development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1998</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michel Vounatsos</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Experience</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Vounatsos has served as our Chief Executive Officer and as a member of our Board of Directors since January 2017. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck &amp; Co., Inc. (Merck), a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line and Merck Customer Centricity. In this role, he led Merck&#8217;s global primary care business unit, a role which encompassed Merck&#8217;s cardiology-metabolic, general medicine, women&#8217;s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company&#8217;s relationships with key constituents, including the most significant providers, payors and retailers and the world&#8217;s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos currently serves on the advisory board of Tsinghua University School of Pharmaceutical Sciences, on the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, on the board of directors of N-Lorem Foundation and as a member of the MIT Presidential CEO Advisory Board.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Public Company Boards</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PerkinElmer, Inc., a global scientific technology and life science research company</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Education</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Universite Victor Segalen, Bordeaux II, France, C.S.C.T. Certificate in Medicine</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HEC School of Management - Paris, M.B.A.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Susan H. Alexander</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Experience</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Alexander has served as our Executive Vice President, Chief Legal Officer and Secretary since April 2018. Prior to that, Ms. Alexander served as our Executive Vice President, Chief Legal, Corporate Services and Secretary from March 2017 to March 2018, as our Executive Vice President, Chief Legal Officer and Secretary from December 2011 to March 2017 and as our Executive Vice President, General Counsel and Corporate Secretary from 2006 to December 2011. Prior to joining Biogen, Ms.&#160;Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms.&#160;Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms.&#160;Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms.&#160;Alexander was a partner at the law firms of Hinckley, Allen&#160;&amp; Snyder and Fine&#160;&amp; Ambrogne. </span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Public Company Boards</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Invacare Corporation, a medical and healthcare product company</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Education</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellesley College, B.A.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boston University School of Law, J.D.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Experience</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mr. McDonnell has served as our Executive Vice President and Chief Financial Officer since August 2020. Prior to joining Biogen, Mr. McDonnell served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, from December 2015 until July 2020. Prior to that, Mr. McDonnell served as the Executive Vice President and Chief Financial Officer of Intelsat, a leading global provider of satellite services, from November 2008 to December 2015, as Executive Vice President and Chief Financial Officer of MCG Capital Corporation, a publicly-held commercial finance company, from September 2004 until October 2008 and as MCG Capital Corporation&#8217;s Chief Operating Officer from August 2006 until October 2008. Before joining MCG Capital Corporation, Mr. McDonnell served as Executive Vice President and Chief Financial Officer for EchoStar Communications Corporation (f/k/a DISH Network Corporation), a direct-to-home satellite television operator, from July 2004 until August 2004 and as its Senior Vice President and Chief Financial Officer from August 2000 to July 2004. Mr. McDonnell spent 14 years at PricewaterhouseCoopers LLP, including 4 years as a partner. Mr. McDonnell has a Bachelor of Science degree in accounting from Georgetown University and is a certified public accountant.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Education</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgetown University, B.S. Accounting</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Alphonse Galdes, Ph.D.</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Experience</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Galdes has served as our Executive Vice President, Pharmaceutical Operations and Technology since September 2019. Since joining Biogen in 1995, Dr. Galdes has held several senior executive positions, including most recently as Senior Vice President, Asset Development and Portfolio Management from November 2015 to September 2019 and Senior Vice President, Technical Development from October 2010 to November 2015. Dr. Galdes was a Rhodes Scholar at Oxford University and performed post-doctoral research work at the Department of Biological Chemistry at Harvard Medical School.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Education</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University of Malta, B.Sc. Chemistry and Biology</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University of Malta, M.Sc. Biochemistry</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxford University, Ph.D. Biochemistry</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ginger Gregory, Ph.D.</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Experience</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Gregory has served as our Executive Vice President and Chief Human Resources Officer since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin&#8217; Brands Group Inc., a restaurant holding company, where she served as Chief Human Resource Officer, Novartis AG, a pharmaceutical company, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People &amp; Organization at the company&#8217;s headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resources generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen &amp; Hamilton, an information technology consulting company, in the area of organization change and effectiveness.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Education</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">University of Massachusetts, B.A. Psychology</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The George Washington University, Ph.D. Psychology</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:3.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chirfi Guindo</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Experience</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Guindo has served as our Executive Vice President, Global Product Strategy and Commercialization since February 2019. Prior to that, Mr. Guindo served as our Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation from November 2017 to February 2019. Prior to joining Biogen, Mr. Guindo spent 27 years in the global pharmaceutical industry and held several leadership positions at Merck, a pharmaceutical company, in Canada, the U.S., France, Africa and the Netherlands. He worked in several disciplines including Finance, Sales &amp; Marketing, General Management and Global Strategy/Product Development in specialty, acute and hospital care. Most recently Mr. Guindo was Vice President and Managing Director and President and Managing Director of Merck Canada from October 2014 to November 2017. From January 2011 to October 2014 he was Vice President and General Manager, Global HIV Franchise at Merck.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Education</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ecole Central de Paris (France), Engineering</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stern School of Business, New York University, M.B.A. Finance/Economics</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:3.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robin C. Kramer</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Experience</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Kramer has served as our Senior Vice President, Chief Accounting Officer since December 2020. Prior to that, Ms. Kramer served as our Vice President, Chief Accounting Officer from November 2018 to December 2020. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte &amp; Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007 Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst &amp; Young LLP and Arthur Anderson LLP. Ms. Kramer is a licensed certified public accountant (CPA) in Massachusetts. She is a member of the Massachusetts Society of CPAs and the American Institute of CPAs. Ms. Kramer currently serves on the board of directors of Samsung Bioepis and on the board of directors of the Center for Women and Enterprise. Ms. Kramer previously served as a Board Member for the Massachusetts State Board of Accountancy from September 2011 to December 2015 and Probus Insurance Company Europe DAC from 2016 to 2018.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Public Company Boards</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Armata Pharmaceuticals, Inc., a biotechnology company</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Education</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salem State University, B.B.A. Accounting</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Alfred W. Sandrock, Jr., M.D., Ph.D.</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Experience</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Sandrock has served as our Executive Vice President, Research and Development since September 2019. Prior to that, Dr. Sandrock served as our Chief Medical Officer from October 2017 to January 2020, as our Executive Vice President, Chief Medical Officer Neurology and Neurodegeneration from October 2015 to October 2017, as our Chief Medical Officer and Group Senior Vice President from April 2013 to October 2015 and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several other senior executive positions since joining Biogen in 1998, including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Education</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stanford University, B.A. Human Biology</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvard Medical School, M.D. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harvard University, Ph.D. Neurobiology</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:6pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts General Hospital, internship in Medicine, residency and chief residency in Neurology and clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography)</span></td></tr></table></div><div id="iefe8f1adeafa45df8da4a5beded16de5_61"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 225 Binney Street, Cambridge, MA 02142 and our telephone number is (617)&#160;679-2000. Our website address is www.biogen.com. We make available free of charge through the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and all amendments to those reports as soon as reasonably practicable after such material is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">electronically filed with or furnished to the U.S. Securities and Exchange Commission. We include our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website. The contents of our website are not incorporated into this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;&#160;1A. &#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenues from our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues depend upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenues are concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction or greater acceptance of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third parties;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, regulatory or legislative developments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products and technologies from our research and development activities or our licenses or acquisitions from third parties, including our commercialization agreements with Samsung Bioepis, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the ASO platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies. In addition, clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to pursue other opportunities in our pipeline. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may also not meet investor expectations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market during the year ended December 31, 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenues in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business could be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of generic versions of branded MS products, including our own products, biosimilars, follow-on products, prodrugs or products approved under abbreviated regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our MS products, generic or biosimilars of our MS products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</span></div><div style="margin-top:9pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the SMA market, we face competition from a gene therapy product that was approved the U.S. and the E.U. and a new oral product that was approved in the U.S. and has been accepted for review in the E.U. We expect that we will experience competition from both products in additional jurisdictions in the future. Additionally, we are aware of other products now in development that, if launched, may compete with SPINRAZA. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products as well as the delay of SPINRAZA doses due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="margin-top:9pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have in the past made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons and we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenues to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators, joint venture partners and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of significant collaborative, joint venture and other third-party relationships for revenues and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third parties. Reliance on third parties subjects us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators, joint venture partners or third parties devote to our programs, products or product candidates;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators, joint venture partners or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators, joint venture partners or other third parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators, joint venture partners or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenues from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the PPACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the expansion of the number of hospitals eligible for discounts under Section 340B of the PHSA. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing public attention on the costs of prescription drugs and there have been, are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in such activities, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If Samsung Bioepis or other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet higher than anticipated demand. We are dependent on a third-party for the manufacture of biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Legal and Regulatory Requirements.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Any improper conduct or actions on the part of Samsung Bioepis or our joint venture partner, Samsung BioLogics, could damage our reputation and be distracting to management. The former chief executive officer (the incumbent chairman of the board) and the chief financial officer of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that may impact its operations and business or divert the attention of the Samsung Bioepis management team from its ongoing operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with cGCP. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing PML in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time.</span></div><div style="margin-top:9pt;text-indent:22.3pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:9pt;text-indent:22.3pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of patent and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenues may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, could require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be materially adversely affected, directly or indirectly, by the ongoing COVID-19 pandemic. National, state and local governments in affected regions have implemented and may continue to implement safety precautions, including quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns, business closures and other measures. These measures may disrupt normal business operations both in and outside of affected areas and may have significant negative impacts on businesses and financial markets worldwide.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including limiting travel and working from home. We have also suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings. This limits our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prolonged remote working arrangements could impact employees&#8217; productivity and morale, strain our technology resources and introduce operational risks. Operating requirements may continually change due to the COVID-19 pandemic and we may experience unpredictability in our expenses, employee productivity and employee work culture. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third parties we rely on. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability due to the COVID-19 pandemic, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. Furthermore, delays and disruptions experienced by our collaborators, joint venture partners or other third parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to continue our existing clinical trials or to initiate new clinical trials may be adversely affected, directly or indirectly, by the COVID-19 pandemic. For example, our Phase 3 study of BIIB093 for LHI has been delayed as this study involves administration of BIIB093 in an acute hospital setting. Restrictions on travel and/or transport of clinical materials as well as diversion of hospital staff and resources to COVID-19 infected patients could disrupt trial operations and recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. We may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020 and is aimed at providing emergency assistance and health care for individuals, families and businesses and generally supporting the U.S. economy. We expect that additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. The COVID-19 pandemic may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication of on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will have on our business, operations, employees, customers, suppliers or collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. Further, the COVID-19 pandemic has caused us to modify our business practices, including the requirement that most of our office-based employees in the U.S. and our other key markets work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). A breakdown, invasion, corruption, destruction or breach of our technology systems, including our cloud technologies, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks could also include supply chain attacks, which could cause a delay in the manufacturing of our products or products produced for contract manufacturing. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s GDPR established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA), and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions  with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information we submitted to the government. We cannot ensure that our compliance controls, policies and procedures will protect us from acts committed by our employees, collaborators or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenues. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the Bribery Act, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the effects of the U.K.'s departure from the E.U., known as Brexit;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our international operations are subject to regulation under U.S. law. For example, the FCPA prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the Solothurn facility to be partially operational during the first half of 2021; however, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. We have had delays, and if there are additional delays, in bringing the Solothurn facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control, including the impact of the COVID-19 pandemic. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with cGMP.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors. In addition, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational during the first half of 2021. However, there can be no assurance that we will be able to meet our expected timeline or that there will not be any direct or indirect delays resulting from the COVID-19 pandemic. We have had delays, and if there are additional delays, in bringing the Solothurn facility online, we may not have sufficient large-scale manufacturing capacity to meet our long-term manufacturing requirements.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk Relating to Government Actions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act, which may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. Further, the new administration could introduce new tax laws or revise or issue new interpretations of the 2017 Tax Act.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Swiss Federal Act on Tax Reform and AHV Financing (TRAF) resulted in significant changes to the Swiss cantonal income tax system. Final interpretation of the transitional and new regimes of the TRAF may require further adjustments and changes in our estimates, which could have a significant adverse effect on our business, results of operations or financial condition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="margin-top:9pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stoc</span><span style="color:#008080;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">k</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including in-process research and development (IPR&amp;D) and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expenses and increased bad debt reserves; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_67"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;&#160;1B. &#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_70"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;&#160;2. &#160;&#160;&#160;&#160;Properties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our owned and leased properties as of December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Cambridge, MA we own approximately 508,000&#160;square feet of real estate space, consisting of a building that houses a research laboratory and a cogeneration plant totaling approximately 263,000&#160;square feet and a building that contains research, development and quality laboratories totaling approximately 245,000&#160;square feet.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we lease a total of approximately 1,169,000&#160;square feet in Massachusetts, which is summarized as follows:</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">800,000&#160;square feet in Cambridge, MA, which is comprised of offices for our corporate headquarters and other administrative and development functions and laboratories, of which 265,000 square feet is subleased by multiple companies for general office space, laboratories and manufacturing facilities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">357,000&#160;square feet of office space in Weston, MA, of which 174,000 square feet is subleased through the remaining term of our lease agreement; and</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">12,000 square feet of office space in Waltham, MA.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Massachusetts lease agreements expire at various dates through the year 2028.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">North Carolina</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In RTP, NC we own approximately 1,040,000&#160;square feet of real estate space, which is summarized as follows:</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">357,000&#160;square feet of laboratory and office space;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">206,000 square foot multi-purpose facility, including an ASO manufacturing suite and administrative space;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">175,000&#160;square feet related to a large-scale biologics manufacturing facility;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">105,000&#160;square feet related to a small-scale biologics manufacturing facility;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">84,000&#160;square feet of warehouse space and utilities;&#160;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">70,000 square feet related to a parenteral fill-finish facility; and</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">43,000&#160;square feet related to a large-scale purification facility.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we lease approximately 65,000 square feet of warehouse space and 103,000 square feet of office space in Durham, NC. Our North Carolina lease agreements expire at various dates through the year 2031.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Switzerland</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space.  </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other International</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office space in Baar, Switzerland, our international headquarters; the U.K.; Germany; France; Japan; Canada and numerous other countries. Our international lease agreements expire at various dates through the year 2030.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_73"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;&#160;3. &#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal matters as of December&#160;31, 2020, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_76"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;&#160;4. &#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_82"></div><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Market and Stockholder Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on The Nasdaq Global Select Market under the symbol &#8220;BIIB.&#8221; As of February&#160;2, 2021, there were approximately 505 shareholders of record of our common stock.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid cash dividends since our inception. While we historically have not paid cash dividends and do not have a current intention to pay cash dividends, we continually review our capital allocation strategies, including, among other things, payment of cash dividends, share repurchases and acquisitions.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity during the fourth quarter of 2020:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:18.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be<br/>Purchased Under<br/>Our Programs ($ in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2020</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 2020</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2020</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,620,969&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.77&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,600.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,620,969&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.77&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.6 million shares of our common stock at a cost of approximately $400.0 million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 16.7 million shares of our common stock at a cost of approximately $5.0 billion during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million and 14.7 million shares of our common stock at a cost of approximately $1.3 billion and $3.7 billion during the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018 our Board of Directors authorized a program to repurchase up to $3.5 billion of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately 8.9 million and 4.3 million shares of our common stock at a cost of approximately $2.1 billion and $1.4 billion during the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately 10.5 million shares of common stock at a cost of approximately $3.0 billion during the year ended December&#160;31, 2018.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance graph below compares the five-year cumulative total stockholder return on our common stock, the Nasdaq Pharmaceutical Index, the S&amp;P 500 Index and the Nasdaq Biotechnology Index.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. In connection with the spin-off, each Biogen shareholder received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. For additional information on the spin-off of our hemophilia business, please read</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 3, Hemophilia Spin-Off</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance graph below assumes the investment of $100.00 on December&#160;31, 2015, in our common stock and each of the three indexes, with dividends being reinvested. Our stock prices have been adjusted for the effect of the spin-off of our hemophilia business. The five-year cumulative total stockholder return for Biogen does not reflect the reinvestment by Biogen shareholders of the distribution they received in connection with the spin-off of our hemophilia business or any subsequent increase or decrease in value of Bioverativ stock subsequent to the spin-off. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock price performance in the graph below is not necessarily indicative of future price performance.</span></div><div><img src="biib-20201231_g19.jpg" alt="biib-20201231_g19.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:26.440%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$92.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$112.74</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$106.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$105.01</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$86.65</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nasdaq Pharmaceutical Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$98.91</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$117.83</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$127.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$145.65</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$160.97</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$111.96</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$136.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$130.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$171.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$203.04</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nasdaq Biotechnology Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$78.65</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$95.69</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$87.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$109.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$137.94</span></td></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included under the heading </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Graph</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is &#8220;furnished&#8221; and not &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be &#8220;soliciting material&#8221; subject to Regulation&#160;14A or incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6. &#160;&#160;&#160;&#160;Selected Financial Data</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Our results of operations are summarized as follows:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,886.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,354.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,817.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,559.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,314.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,444.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,377.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,452.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,273.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,448.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expenses</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,894.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,335.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,564.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,928.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,297.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,550.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,042.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,345.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,151.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,047.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,125.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,899.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,128.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,933.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">992.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,158.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,425.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,458.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,237.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,060.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,474.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,670.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,695.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,430.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,539.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,702.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Diluted Earnings Per Share</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.80&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Our financial condition is summarized as follows:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Financial Condition</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,382.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,884.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,913.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,746.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,724.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,618.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,234.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,288.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,652.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,876.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable, less current portion</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,459.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,936.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,935.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,512.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,700.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,343.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,039.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,612.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,140.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data included within the tables above should be read in conjunction with our consolidated financial statements and related notes and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and our previously filed Annual Reports on Form&#160;10-K.</span></div><div style="margin-top:8pt;padding-left:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;7. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our consolidated financial statements and the accompanying notes beginning on page&#160;F-1 of this report. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our discussion of the year ended December&#160;31, 2019, compared to the year ended December&#160;31, 2018, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> located in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include MS and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including SMA and ALS; movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis, our joint venture with Samsung BioLogics, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to our patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland, which we expect to be partially operational during the first half of 2021. We believe that the Solothurn manufacturing facility will provide us with the ability to further expand if our future growth and drug development plans increase.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues depend upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Environment</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion on our business environment, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report. For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Hatch-Waxman Act in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the year ended December 31, 2020, and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition. For additional information, please read the discussion under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations - Product Revenues - Multiple Sclerosis (MS) - Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Update Regarding COVID-19</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently continuing the clinical trials we have underway in sites across the globe, </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future. For example, our Phase 3 study of BIIB093 for LHI, a severe form of ischemic stroke, has been delayed as this study involves administration of BIIB093 in an acute hospital setting. To help mitigate the impact of the COVID-19 pandemic to our clinical trials, we are pursuing innovative approaches such as remote monitoring, remote patient visits and supporting home infusions. These alternative measures have resulted in an immaterial increase to the cost of the clinical trials underway.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brexit</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 31, 2020, the U.K. ceased to be a member state of the E.U., a process known as Brexit, and began a transition period, which expired on December 31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 the U.K. and the E.U. agreed on a trade and cooperation agreement, under which the E.U. and the U.K. will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement covers the general objectives and framework of the relationship between the U.K. and the E.U., including as it relates to trade, transport and visas. Notably, under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire E.U. single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the E.U. Depending on the application of the terms of the trade and cooperation agreement, we could face new regulatory costs and challenges.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect Brexit to have a material impact on our consolidated results of operations as less than 4.0% of our total product revenues in 2020, 2019 and 2018 were derived from U.K. sales. However, we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replace or replicate, including U.K. competition laws. Therefore, we will continue to monitor for developments in this area and assess any potential impacts on our business and results of operations.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share attributable to Biogen Inc. were $24.80 for 2020, representing a decrease of 21.1% as compared to $31.42 in the same period in 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the year ended December&#160;31, 2020, compared to the year ended December&#160;31, 2019, reflects the following:</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total revenues were $13,444.6 million for 2020, representing a decrease of 6.5% as compared to $14,377.9 million in 2019.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Product revenues, net totaled $10,692.2 million for 2020, representing a decrease of 6.0% as compared to $11,379.8 million in 2019. This decrease was primarily due to a $697.2 million, or 8.2%, decrease in MS product revenues and a $44.9 million, or 2.1%, decrease in revenues from SPINRAZA, partially offset by a $57.5 million, or 7.8%, increase in revenues from our biosimilar business. Product revenues, net, compared to the same period in 2019, further reflects the unfavorable impact of foreign currency exchange of $111.6&#160;million.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in MS product revenues was primarily due to a decrease in TECFIDERA demand and price as a result of multiple TECFIDERA generic entrants entering the U.S. market during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Revenues from anti-CD20 therapeutic programs totaled $1,977.8 million for 2020, representing a decrease of 13.6% as compared to $2,290.4 million in 2019. This decrease was primarily due to a $490.7&#160;million, or 31.7%, decrease in RITUXAN revenues, partially offset by a $157.9&#160;million, or 23.0%, increase in royalty revenues on sales of OCREVUS. Sales of RITUXAN have been adversely affected primarily by the onset of biosimilars competition in the U.S.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.34pt">Other revenues totaled $774.6 million for 2020, representing an increase of 9.5% over $707.7 million in 2019. This increase was due to higher contract manufacturing revenues, primarily resulting from $346.2&#160;million in revenues related to the delivery of the license for certain of our manufacturing-related intellectual property to a contract manufacturing customer.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expenses</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total cost and expenses were $8,894.5 million for 2020, representing an increase of 21.3% from $7,335.3 million in 2019. This increase was primarily due to a $1,710.3 million, or 75.0%, increase in research and development expense.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The increase in research and development expense was primarily due to $1,893.3&#160;million in charges recognized in connection with upfront payments associated with entering into our collaborations with Sangamo, Denali and Sage.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This increase was partially offset by:</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">a 5.1% decrease in amortization and impairment of acquired intangible assets; and </span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">a $92.5 million gain recognized in 2020 associated with the divestiture of our Hiller&#248;d, Denmark manufacturing operations. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition, Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We generated $4,229.8 million of net cash flows from operations for 2020. </span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Cash, cash equivalents and marketable securities totaled approximately $3,382.2 million as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We repurchased and retired approximately 22.4&#160;million shares of our common stock at a cost of approximately $6.7&#160;billion during 2020 under our 2020, December 2019 and March 2019 Share Repurchase Programs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, Collaborative and Other Relationships</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisitions, collaborative and other relationships discussed below, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118, a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer. We are developing BIIB118 for the potential treatment of ISWRD in Parkinson&#8217;s disease and plan to develop </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BIIB118 for the potential treatment of sundowning in Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of BIIB118, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we closed a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 we closed a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of LRRK2 for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle: Abeta program and a second program utilizing its Transport Vehicle technology. Further, we have a right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 we closed a global collaboration and license agreement with Sage to jointly develop and commercialize zuranolone for the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for the potential treatment of essential tremor and other neurological disorders.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Key Developments</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab (AB mAb)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. In August 2020 the FDA accepted the BLA and granted Priority Review with a PDUFA action date on March 7, 2021. In November 2020 the FDA held a virtual meeting of the Advisory Committee to review data supporting the BLA for aducanumab and to vote on questions presented at the meeting. A majority of the Advisory Committee members voted against each of the questions presented at the meeting.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021 the FDA extended the review period for the BLA for aducanumab by three months. The updated PDUFA action date is June 7, 2021. As part of the ongoing review, we submitted a response to an information request by the FDA, including additional analyses and clinical data, which the FDA considered a Major Amendment to the application that will require additional time for review.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the EMA accepted for review the MAA for aducanumab.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application for aducanumab.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Share Repurchase Program</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0&#160;billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,713.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,800.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(813.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,792.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,666.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,086.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,886.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(687.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(312.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,444.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,377.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,452.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(933.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,905.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,438.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,274.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(532.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,101.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,363.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(224.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,946.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZINBRYTA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm   </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS product revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,832.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,529.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,595.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(697.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,052.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,097.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,724.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm   </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilar product revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">795.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">738.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,886.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(687.6)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis (MS)</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumarate</span></div><div><img src="biib-20201231_g20.jpg" alt="biib-20201231_g20.jpg" style="height:306px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fumarate revenues include sales from TECFIDERA and VUMERITY. In October 2019 the FDA approved VUMERITY for the treatment of RMS and VUMERITY became commercially available in the U.S. in November 2019.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the 17.2% decrease in U.S. Fumarate revenues was primarily due to a decrease in TECFIDERA demand and price as a result of multiple TECFIDERA generic entrants entering the U.S. market during the year ended December 31, 2020. This decrease was partially offset by an increase of approximately $60.0&#160;million in VUMERITY sales, which became commercially available in the U.S. in November 2019.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the 3.3% increase in rest of world Fumarate revenues was primarily due to an increase in TECFIDERA sales volumes of 8.6%, partially offset by pricing reductions in certain European countries and the unfavorable impact of foreign currency exchange. The increase in volumes was primarily due to continued strong patient growth in our E.U. direct markets, including Italy, Spain and the U.K., as well as growth in Japan and Brazil.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Hatch-Waxman Act in West Virginia and Delaware. We have appealed the judgments in both actions.</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the year ended December&#160;31, 2020, and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate an increase in TECFIDERA sales volume in rest of world in 2021, compared to 2020, notwithstanding the increasing competition from additional treatments for MS and potential disruptions due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect an increase in VUMERITY sales volume in the U.S., mostly driven by the continued launch of VUMERITY.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interferon</span></div><div style="margin-top:9pt;text-indent:13.5pt"><img src="biib-20201231_g21.jpg" alt="biib-20201231_g21.jpg" style="height:306px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the 10.7% decrease in U.S. Interferon revenues was primarily due to a decrease in Interferon sales volumes of 12.0%. The net decline in sales volumes reflects the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the 10.5% decrease in rest of world Interferon revenues was primarily due to a decrease in Interferon sales volumes of 7.1%, which negatively impacted comparative revenue of $48.1&#160;million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that Interferon revenues will continue to decline in both the U.S. and rest of world markets in 2021, compared to 2020, as a result of increasing </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competition from our other MS products as well as other treatments for MS, including biosimilars, and pricing reductions in certain European markets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AVONEX</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, 2019 and 2018 U.S. AVONEX revenues totaled $1,083.4&#160;million, $1,202.1&#160;million and $1,420.2&#160;million, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, 2019 and 2018 rest of world AVONEX revenues totaled $408.5&#160;million, $463.8&#160;million and $495.3&#160;million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLEGRIDY</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, 2019 and 2018 U.S. PLEGRIDY revenues totaled $190.1&#160;million, $224.5&#160;million and $248.1&#160;million, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, 2019 and 2018 rest of world PLEGRIDY revenues totaled $195.5&#160;million, $211.4&#160;million and $199.4&#160;million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div><img src="biib-20201231_g22.jpg" alt="biib-20201231_g22.jpg" style="height:306px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the 5.3% increase in U.S. TYSABRI revenues was primarily due to an increase in TYSABRI sales volume of 1.0% and price increases, partially offset by higher discounts and allowance rates. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, rest of world TYSABRI revenues remained flat, with stable volume and pricing.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate TYSABRI sales volume to modestly increase on a global basis in 2021, compared to 2020, despite increasing competition from additional treatments for MS, including OCREVUS. We believe that some TYSABRI infusions may be delayed due, directly or indirectly, to the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic. We expect to continue to face price reductions in certain European markets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spinal Muscular Atrophy (SMA)</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="text-indent:13.5pt"><img src="biib-20201231_g23.jpg" alt="biib-20201231_g23.jpg" style="height:306px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the 15.6% decrease in U.S. SPINRAZA revenues was primarily due to a decrease in sales volumes of 15.0%, resulting from increased competition as well as lower loading and maintenance doses due to the impact of site of care closures as a result of the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the 8.7% increase in rest of world SPINRAZA revenues was primarily due to a net increase in sales volumes of 16.8%, which was reflective of the impact of a shift from loading to maintenance doses and the impact of site of care closures as a result of the COVID-19 pandemic.  This increase was partially lower net prices and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect that SPINRAZA revenues will be subject to increased competition resulting in higher discontinuations and a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months and lower prices in certain rest of world countries. We believe that some SPINRAZA doses may continue to be delayed due, directly or indirectly, to the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from a gene therapy product that was approved in the U.S. and the E.U. and a new oral product that was approved in the U.S. and has been accepted for review in the E.U. We expect that we will experience competition from both products in additional jurisdictions in the future. Additionally, we are aware of other products now in development that, </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if launched, may also compete with SPINRAZA. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BENEPALI, IMRALDI and FLIXABI</span></div><div><img src="biib-20201231_g24.jpg" alt="biib-20201231_g24.jpg" style="height:306px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the 7.8% increase in biosimilar revenues was primarily due to higher sales volumes and a favorable foreign currency impact, partially offset by the unfavorable impact of price decreases.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect modest to moderate revenue growth for our biosimilars business depending on the impact of the COVID-19 pandemic. We expect growth to be primarily driven by the continued launch of IMRALDI in Europe, partially offset by price reductions in certain European countries.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilars, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. In October 2020 the EMA accepted for review the MAA for SB11 and in November 2020 the FDA accepted the BLA for SB11. We also acquired an option to extend our existing commercial agreement with Samsung Bioepis for BENEPALI, IMRALDI and FLIXABI in certain countries in </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe and obtained an option to acquire exclusive rights to commercialize these products in China. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_97"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech (Roche Group)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><img src="biib-20201231_g25.jpg" alt="biib-20201231_g25.jpg" style="height:366px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,334.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,747.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,484.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">622.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">669.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,901.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,124.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,814.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in U.S.&#160;product revenues, net was primarily due to a decrease in sales volumes of RITUXAN in the U.S. of 26.7%, due to the onset of competition from multiple biosimilars, and we believe RITUXAN was adversely impacted by the COVID-19 pandemic.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, product revenues, net also reflects increases in GAZYVA sales volumes of 24.7%.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in collaboration costs and expenses was primarily due to lower cost of sales on RITUXAN.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several other anti-CD20 molecules, including biosimilar products, that have recently been approved and are expected to compete with RITUXAN and GAZYVA in the oncology market. In November 2019, January 2020 and January 2021 biosimilar products referencing RITUXAN were launched in the U.S. and are being offered at lower prices. This competition has adversely affected the pre-tax profits of our collaboration arrangements with Genentech and could have a significant adverse affect on our co-promotion profits in the U.S. in future years.</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the increase in other revenues from anti-CD20 therapeutic programs was primarily due to sales growth of OCREVUS. Royalty revenues recognized on sales of OCREVUS for the years ended December&#160;31, 2020, 2019 and 2018, totaled $845.4&#160;million, $687.5&#160;million and $478.3&#160;million, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenues are based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_100"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues are summarized as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.512%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.7)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">753.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Collaborative and Other Relationships</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from collaborative and other relationships primarily include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM Corporation (FUJIFILM) assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completed after the Hiller&#248;d, Denmark manufacturing operations divestiture date under our technical development services and manufacturing agreements with Samsung Bioepis.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, we recognized $20.9 million and $106.2 million, respectively, related to the services described above provided to Samsung Bioepis.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Royalty and Corporate Revenues</span></div><div><img src="biib-20201231_g26.jpg" alt="biib-20201231_g26.jpg" style="height:306px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result, we are entitled to $500.0&#160;million in a series of three payments. The first payment became due upon regulatory approval of such product and was received during the second quarter of 2020. Subsequent payments are due on the first and second anniversaries of the regulatory approval.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other corporate revenues for the year ended December&#160;31, 2020, reflect $346.2&#160;million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $153.8&#160;million of the $500.0&#160;million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demand for supply and the fair value of comparable manufacturing and development services.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the increase in other royalty and corporate revenues was due to higher contract manufacturing revenues, primarily resulting from $346.2&#160;million in revenues related to the delivery of the license for certain of our manufacturing-related intellectual property to a contract manufacturing customer, as discussed above.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_103"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</span></div><div style="text-align:center"><img src="biib-20201231_g27.jpg" alt="biib-20201231_g27.jpg" style="height:328px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, reserves for discounts and allowances as </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a percentage of gross product revenues were 27.1%, 24.3% and 23.7%, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discounts</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the increase in discounts was primarily driven by an increase in gross biosimilar sales in our international markets as well as increases in discount percentages in certain countries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Adjustments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, VA and PHS discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the increase in contractual adjustments was primarily due to higher pharmacy rebates and governmental rebates in the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. as well as higher governmental rebates and allowances in the rest of world, due in part to an increase in SPINRAZA sales volumes worldwide.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Returns</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns expected to be made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenues are recognized, resulting in a reduction to product sales. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, return reserves were relatively consistent. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Revenues,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_106"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cost and Expenses</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expenses is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.951%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,805.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,816.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,990.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,280.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,597.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,710.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(316.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,504.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,374.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,106.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">464.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">489.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">747.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(257.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(147.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,894.5&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,335.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,564.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,559.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(229.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20201231_g28.jpg" alt="biib-20201231_g28.jpg" style="height:306px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales, as a percentage of total revenues, were 13.4%, 13.6% and 13.5% for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in product cost of sales was primarily due to lower cost of sales from contract manufacturing agreements, primarily resulting from the sale of hemophilia inventory, with a cost basis of $173.5&#160;million, to Bioverativ in the first quarter of 2019 and FUJIFILM assuming responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis during the third quarter of 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons totaled $26.6 million, $52.2 million and $41.9 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Cost of Sales</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in royalty cost of sales was primarily due to lower royalties payable on lower sales of AVONEX and SPINRAZA.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_112"></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span><img src="biib-20201231_g29.jpg" alt="biib-20201231_g29.jpg" style="height:365px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20201231_g30.jpg" alt="biib-20201231_g30.jpg" style="height:693px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the increase in research and development expense was primarily due to approximately $1,084.0&#160;million, $601.3&#160;million and $208.0&#160;million of upfront payments made in connection with entering into our collaborations with Sage, Denali and Sangamo, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 we recorded significant upfront payments related to our new collaborations as part of research and development expense. Excluding upfront payments, we expect our core research and development expense to increase in 2021, driven by continued investment in our pipeline, including significant investments related to the new assets in the Sage collaboration. We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we capitalized approximately $93.8&#160;million of pre-launch inventory for aducanumab. If aducanumab does not receive regulatory approval in the U.S., we would expense this inventory as research and development expense and, under the terms of the Aducanumab Collaboration Agreement, Eisai would reimburse us for 45.0% of the costs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone and Upfront Expenses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for 2020 includes:</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1,084.0&#160;million charge to research and development expense in connection with the upfront payment associated with entering into our collaboration with Sage in the fourth quarter of 2020;</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$601.3&#160;million charge to research and development expense in connection with the upfront payment associated with entering into our collaboration with Denali in the third quarter of 2020; and</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$208.0&#160;million charge to research and development expense in connection with the upfront payment associated with entering into our collaboration with Sangamo in the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for 2019 includes:</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$63.0&#160;million charge to research and development expense in connection with our agreement with Samsung Bioepis to secure the exclusive rights to commercialize two potential ophthalmology biosimilar products; and</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$45.0&#160;million charge to research and development expense upon the exercise of our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB080 (tau ASO) for the potential treatment of Alzheimer's disease.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront payments associated with these collaborations are classified as research and development expense as the programs they relate to had not achieved regulatory approval as of the payment date.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about these collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stage Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in spending related to our early stage programs was primarily due to a decrease in costs associated with:</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of gosuranemab in progressive supraneuclear palsy;</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of toferson in ALS into late stage; and</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of the Phase 2b study of BG00011 for the potential treatment of idiopathic pulmonary fibrosis (IPF).</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by an increase in costs associated with:</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">spending in the development of BIIB112 (RPGR gene therapy) in XLRP;</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">spending in the development of BIIB080 in Alzheimer's disease; and</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">spending in the development of gosuranemab in Alzheimer's disease.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late Stage Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in spending associated with our late stage programs was primarily due to:</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">a decrease in spending related to the discontinuation of the global Phase 3 trials of aducanumab, net of reimbursement from our collaboration partner Eisai in the first quarter of 2019;</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">a decrease in spending related to the discontinuation of the global Phase 3 trials, MISSION AD1 and MISSION AD2, of elenbecestat (development code: E2609) in patients with early Alzheimer's disease in the third quarter of 2019; and</span></div><div style="margin-top:5pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">a decrease in spending related to VUMERITY, which was approved by the FDA in the fourth quarter of 2019.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by an increase in spending due to the advancement of toferson in ALS into late stage, an increase in spending related to BAN2401 in early Alzheimer's disease, our EMBARK redosing study for aducanumab and BIIB111 (timrepigene emparvovec) in CHM.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following a futility analysis, we accrued approximately $45.0&#160;million related to the termination of clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred by the collaboration for the advancement of aducanumab.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. In August 2020 the FDA accepted the BLA and granted Priority Review with a PDUFA action date on March 7, 2021. In January 2021 the FDA extended the review period for the BLA for aducanumab by three months. The updated PDUFA action date is June 7, 2021.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 Eisai initiated a global Phase 3 trial for the development of BAN2401 in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div><img src="biib-20201231_g31.jpg" alt="biib-20201231_g31.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the increase in selling, general and administrative expenses was primarily due to increased commercial and medical investments in support of pre-launch activities associated with the potential regulatory approval of aducanumab.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we expect selling, general and administrative costs, including headcount and commercial infrastructure, to significantly increase as we support activities associated with the potential regulatory approvals of aducanumab in the U.S. and rest of world markets.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_115"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20201231_g32.jpg" alt="biib-20201231_g32.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $115.0&#160;million impairment charge related to BIIB111, which was obtained as part of our acquisition of Nightstar Therapeutics plc (NST), a $75.4&#160;million impairment charge related to BIIB054 and a $19.3&#160;million impairment charge related to one of our other IPR&amp;D intangible assets.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, amortization and impairment of acquired intangible assets reflects the impact of a $215.9&#160;million impairment charge related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 for the potential treatment of IPF, which was discontinued in the third quarter of 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets, excluding impairment charges, totaled $255.1 million, $274.0 million and $381.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in amortization of acquired intangible assets, excluding impairment charges, was primarily due to a lower rate of amortization for acquired intangible assets.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we began experiencing third-party manufacturing delays that may impact our timeline for a potential filing of a BLA for BIIB111 for regulatory approval by up to one year. In addition, we determined that forecasted costs associated with advancing the BIIB111 program through Phase 3 development and potential commercialization will exceed our original estimates. We reassessed the fair value of the program based on these changes in assumptions and determined that the program was partially impaired. We recognized an impairment charge of $115.0&#160;million during the fourth quarter of 2020, which resulted in a reduction of the IPR&amp;D asset from $480.0&#160;million to $365.0&#160;million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB054</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021 we announced that we discontinued development of BIIB054 as a potential treatment of Parkinson's disease as our Phase 2 SPARK study did not meet its primary or secondary endpoints. Although we made this determination in February 2021, it was based on conditions that existed as of December&#160;31, 2020. As a result, we recognized an impairment charge of approximately $75.4&#160;million during the fourth quarter of 2020 to reduce the fair value of the related IPR&amp;D intangible asset to zero.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine (BIIB074), there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of trigeminal neuralgia (TGN) as we engaged with the FDA regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of December&#160;31, 2020, the carrying value associated with our vixotrigine IPR&amp;D assets was $177.5&#160;million.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_118"></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Profit (Loss) Sharing</span></div><div><img src="biib-20201231_g33.jpg" alt="biib-20201231_g33.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit (loss) sharing primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020, 2019 and 2018 we recognized a net profit-sharing expense of $266.5 million, $241.6 million and $187.4 million, respectively, to reflect Samsung Bioepis&#8217; 50.0% sharing of the net collaboration profits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended 2020, we also recognized net profit-sharing income of $33.8&#160;million to reflect Eisai's 45.0% share of the $75.0&#160;million milestone expense related to the completed submission of the BLA for the approval of aducanumab to the FDA.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="text-indent:11.25pt"><img src="biib-20201231_g34.jpg" alt="biib-20201231_g34.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 we entered into a share purchase agreement with FUJIFILM to sell all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark. The transaction closed in August 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, we recognized a total net loss of approximately $124.2 million related to the transaction in our consolidated statements of income. This loss included a pre-tax loss of $55.3 million, which was recorded in loss on divestiture of Hiller&#248;d, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately $11.2 million and our estimate of the fair value of adverse commitments of approximately $74.0 million, primarily associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. We also recorded a tax expense of $68.9 million related to this transaction.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, we reduced our estimate of the fair value of the adverse commitment associated with the guarantee of future batch production by approximately $62.0&#160;million based on our current manufacturing forecasts. Additionally, we recorded a reduction to our pre-tax loss of approximately $30.5&#160;million due to a refund of interest paid associated with a tax matter.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_124"></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div><img src="biib-20201231_g35.jpg" alt="biib-20201231_g35.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The gain on fair value remeasurement of contingent consideration for 2020 was primarily due to the remeasurement of the contingent consideration associated with our BIIB054 program as well as changes in the probability and the expected timing of the achievement of certain remaining developmental milestones, changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on fair value remeasurement of contingent consideration for 2019 was primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF as well as changes in the probability and expected timing of achievement of certain developmental milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our IPR&amp;D intangible assets, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development</span></div><div><img src="biib-20201231_g36.jpg" alt="biib-20201231_g36.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 from Pfizer for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases. In connection with this acquisition, we made an upfront payment of $75.0&#160;million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB118 has not yet reached technological feasibility.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of BIIB118, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_130"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div><img src="biib-20201231_g37.jpg" alt="biib-20201231_g37.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the change in other income (expense), net primarily reflects an increase in our net unrealized gains on our holdings in equity securities, partially offset by higher interest expense.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, net unrealized and realized gains on our holdings in equity securities were approximately $681.8&#160;million and $12.1&#160;million, respectively, compared to net unrealized and realized gains of $150.1&#160;million and $50.0&#160;million in 2019. The net unrealized gains recognized during the year ended December&#160;31, 2020, primarily reflects an increase in the fair value of Denali and Sangamo common stock of approximately $703.9&#160;million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, net interest expense was $180.5 million as compared to $67.4 million in 2019. This increase was primarily due to additional borrowings in 2020 and lower interest income earned on our investments in 2020 as compared to 2019. On April 30, 2020, we issued our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion (2020 Senior Notes).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest expense will increase in 2021, as our 2020 Senior Notes will be outstanding for the entire year.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our 2020 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_133"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income Tax Provision</span></div><div><img src="biib-20201231_g38.jpg" alt="biib-20201231_g38.jpg" style="height:338px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, as compared to 2019, the increase in our effective tax rate was primarily due to the income tax expense related to the establishment of a valuation allowance against certain net deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., partially offset by the benefit recognized on the effective settlement of certain tax matters. Additionally, our 2019 effective tax rate benefited from an internal reorganization of certain intellectual property rights and the enactment of a new taxing regime in the country and certain cantons of Switzerland, partially offset by tax expense related to the divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write-off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our uncertain tax positions and income tax rate reconciliation for 2020, 2019 and 2018, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_136"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity in (Income) Loss of Investee, Net of Tax</span></div><div><img src="biib-20201231_g39.jpg" alt="biib-20201231_g39.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018. As of December&#160;31, 2020, our ownership percentage remained at approximately 49.9%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in (income) loss of investee, net of tax in our consolidated statements of income. We recognize amortization on certain basis differences resulting from our November 2018 investment. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The former chief executive officer (the incumbent chairman of the board) and the chief financial officer of our joint venture partner, Samsung BioLogics, are currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, equity in (income) loss of investee, net of tax reflects our share of income totaling $45.3 million and amortization of basis differences totaling $40.0 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, equity in (income) loss of investee, net of tax reflects our share of losses totaling $1.2 million and amortization of basis differences totaling $78.2 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Noncontrolling Interests, Net of Tax</span></div><div><img src="biib-20201231_g40.jpg" alt="biib-20201231_g40.jpg" style="height:240px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 net income (loss) attributable to noncontrolling interests, net of tax, was primarily due to the $75.0&#160;million milestone payment related to the completed submission of the BLA for the approval of aducanumab to the FDA.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_142"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Condition, Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:57.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,913.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,382.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,884.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,459.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,954.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working Capital:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,887.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,381.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,742.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,863.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,144.9&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,518.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_145"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, certain significant cash flows were as follows:</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$4.2 billion in net cash flows provided by operating activities, which reflected $1.9&#160;billion of upfront payments and the premium on stock purchases made in connection with entering into our collaborations with Sage, Denali and Sangamo and recognized as research and development expenses; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$6.7 billion used for share repurchases;</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$3.0&#160;billion in proceeds received from the issuance of our 2020 Senior Notes;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5&#160;billion payment made for the redemption of our 2.90% Senior Notes due September 15, 2020, prior to their maturity;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$906.7 million</span><span style="color:#0f243e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in total net payments for income taxes;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$441.0&#160;million used to purchase Sage common stock;</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$423.7&#160;million used to purchase Denali common stock;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$141.8&#160;million used to purchase Sangamo common stock; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$424.8 million used for purchases of property, plant and equipment.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, certain significant cash flows were as follows:</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$7.1 billion in net cash flows provided by operating activities;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0f243e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$5.9 billion used for share repurchases;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.1 billion in total net payments for income taxes;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$923.7&#160;million in proceeds received on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, including the sale of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$744.4&#160;million payment made for our acquisition of NST, net of cash acquired;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$514.5 million used for purchases of property, plant and equipment;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$479.3&#160;million in proceeds received on sales of strategic investments;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$300.0 million for the final contingent payment made to former shareholders of Fumapharm AG and holders of their rights; and</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$155.0&#160;million in payments made to Alkermes following the FDA's approval of VUMERITY.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. On April 30, 2020, we issued our 2020 Senior Notes for an aggregate principal amount of $3.0&#160;billion. We expect our operating expenditures, particularly those related to research and development, clinical trials, commercialization of new products and international expansion to continue to grow. However, we expect to continue funding our current and planned operating requirements primarily through our cash flows earned from our operations as well as our existing cash resources and proceeds received from the issuance of our 2020 Senior Notes. Generic competition for TECFIDERA in the U.S. has begun and we believe that this competition will reduce our cash flow from operations in 2021 and will have a significant adverse impact on our future cash flows from operations. We believe that our existing funds, when combined with </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. In August 2020 the FDA accepted the BLA and granted Priority Review with a PDUFA action date on March 7, 2021. In January 2021 the FDA extended the review period for the BLA for aducanumab by three months. The updated PDUFA action date is June 7, 2021. If we do not receive regulatory approval or are unable to successfully commercialize aducanumab, our financial condition, business and operations may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">isk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. In March 2020 there was a severe liquidity crisis in the capital markets, particularly with respect to securities with maturities of less than one year, due to the COVID-19 pandemic. This issue impacted pricing of securities in our portfolio as we attempted to decrease our marketable securities level and increase cash, leading to approximately $8.2&#160;million in realized losses for the year ended December&#160;31, 2020. We believe that actions taken by the U.S. Federal Reserve to enhance liquidity have stabilized the capital markets for the time being.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had cash, cash equivalents and marketable securities totaling approximately $3.4&#160;billion compared to approximately $5.9&#160;billion as of December&#160;31, 2019. The net decrease in cash, cash equivalents and marketable securities at December&#160;31, 2020, from December&#160;31, 2019, was primarily due to cash used for share repurchases, the redemption of our 2.90% Senior Notes due September 15, 2020, upfront payments and stock purchases totaling $2.9&#160;billion made in connection with entering into our collaborations with Sage, Denali and Sangamo and net purchases of property, plant and equipment, partially offset by cash flows from operations and net proceeds from the issuance of our 2020 Senior Notes.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and other assets in our consolidated balance sheet as of December&#160;31, 2020 and 2019, include the carrying value of our investment in Samsung Bioepis of $620.2 million and $580.2 million, respectively. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis may be limited and we may realize significantly less than the value of such investment. The investment is also subject to foreign currency exchange fluctuations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration with Sangamo, we purchased approximately 24&#160;million shares of Sangamo common stock in April 2020. As of December&#160;31, 2020, the fair value of this investment was $333.7&#160;million. In connection with our collaboration with Denali, we purchased approximately 13&#160;million shares of Denali common stock in September 2020. As of December&#160;31, 2020, the fair value of this investment was $935.7&#160;million. In connection with our collaboration with Sage, we purchased approximately 6.2&#160;million shares of Sage common stock in December 2020. As of December&#160;31, 2020, the fair value of this investment was $433.9&#160;million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in Ionis common stock had a fair value of $249.1&#160;million and $329.6&#160;million as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, Samsung Bioepis, Sangamo, Denali and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we issued our 2020 Senior Notes for an aggregate principal amount of $3.0&#160;billion, consisting of the following:</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5&#160;billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5&#160;billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior secured notes issued in 2015 (2015 Senior Notes):</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes and our 2015 Senior Notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020 we redeemed our 2.90% Senior Notes due September 15, 2020, with an aggregate principal amount of $1.5&#160;billion.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair values of our outstanding borrowings as of December&#160;31, 2020 and 2019, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Credit Facility</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0&#160;billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility entered into in August 2015. As of December&#160;31, 2020, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Working capital was $3.1 billion and $3.5 billion as of December&#160;31, 2020 and December&#160;31, 2019, respectively. The change in working capital reflects a decrease in total current assets of approximately $1.5&#160;billion and a decrease in total current liabilities of approximately $1.1&#160;billion. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total current assets was primarily driven by a decrease in net cash, cash equivalents and marketable securities due to cash used for share repurchases, the redemption of our 2.90% Senior Notes due September 15, 2020, upfront payments and stock purchases totaling $2.9&#160;billion made in connection with entering into our collaborations with Sage, Denali and Sangamo and net purchases of property, plant and equipment, partially offset by cash flows from operations and net proceeds from the issuance of our 2020 Senior Notes.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net decrease in current liabilities was primarily due to the redemption of our 2.90% Senior Notes due September 15, 2020, which were classified within current liabilities as of December 31, 2019, partially offset by an increase in accrued expenses and other.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.6 million shares of our common stock at a cost of approximately $400.0 million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized our December 2019 Share Repurchase Program, which was a program to repurchase up to </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0&#160;billion of our common stock that was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 16.7 million shares of our common stock at a cost of approximately $5.0 billion during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized our March 2019 Share Repurchase Program, which was a program to repurchase up to $5.0 billion of our common stock that was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million and 14.7 million shares of our common stock at a cost of approximately $1.3 billion and $3.7 billion during the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which was a program to repurchase up to $3.5 billion of our common stock that was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately 8.9 million and 4.3 million shares of our common stock at a cost of approximately $2.1 billion and $1.4 billion during the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_148"></div></div></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.003%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020<br/>vs.<br/>2019</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019<br/>vs.<br/>2018</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flows provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,229.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,078.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,187.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flows provided by (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(608.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">470.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,046.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(229.4)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flows used in financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,272.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,860.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,472.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_151"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="text-indent:24.75pt"><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in net cash flows provided by operating activities was primarily due to lower net income as well as increases in certain working capital asset balances. Net income in 2020 reflected approximately $1,084.0&#160;million, $601.3&#160;million and $208.0&#160;million of upfront payments made in connection with entering into our collaborations with Sage, Denali and Sangamo, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the increase in net cash flows used in investing activities was primarily </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to the purchases of the common stock of Sangamo, Denali and Sage totaling $1.0&#160;billion during 2020 and proceeds of $923.7 million received in 2019 related to the divestiture of our Hiller&#248;d, Denmark manufacturing operations, partially offset by higher proceeds received from the sale of investments as compared to the prior year. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2020 compared to 2019, the decrease in net cash flows used in financing activities was primarily due to the net proceeds received from the issuance of our 2020 Senior Notes offset by a higher amount spent on shares repurchased in 2020 as compared to the comparative period in 2019 and the redemption of our 2.90% Senior Notes due September 15, 2020. </span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_154"></div></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations as of December&#160;31, 2020, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1 to 3<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3 to 5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After<br/>5&#160;Years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cancellable operating leases </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt obligations </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,853.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,512.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,218.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,843.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase and other obligations </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,248.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Defined benefit obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,640.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">747.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,056.5&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,732.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,103.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="iefe8f1adeafa45df8da4a5beded16de5_157"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We lease properties and equipment for use in our operations. Amounts reflected within the table above detail future minimum rental commitments under non-cancelable operating leases as of December&#160;31 for each of the periods presented. In addition to the minimum rental commitments, these leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Obligations are presented net of sublease income expected to be received for our vacated small-scale biologics manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Long-term debt obligations are related to our 2015 Senior Notes and our 2020 Senior Notes, including principal and interest payments. </span></div><div style="margin-bottom:12pt;margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Purchase and other obligations include $697.0 million related to the remaining payments on a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) and $217.2 million related to the fair value of net liabilities on derivative contracts. </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18.0% on annual worldwide net sales up to $2.0 billion and 25.0% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence Pharmaceuticals Ltd. we agreed to make additional payments based upon the achievement of certain milestone events. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to these acquisitions.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of December&#160;31, 2020, we could trigger potential future milestone payments to third parties of up to approximately $10.2 billion, including approximately $1.9 billion in development milestones, approximately $1.3 billion in regulatory milestones and approximately $7.0 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of December&#160;31, 2020, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingent on the successful achievement of certain development, regulatory or commercial milestones. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to $86.2&#160;million in milestones in 2021 under our current agreements. Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $200.0 million in milestones to Neurimmune in 2021, which includes $100.0&#160;million if launched in the U.S., $50.0&#160;million if launched in three or more countries within the E.U. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, we paid Neurimmune $75.0&#160;million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests for the year ended December&#160;31, 2020. In addition, for the year ended December&#160;31, 2020, we recognized net profit-sharing income of $33.8&#160;million to reflect Eisai's 45.0% share of the $75.0&#160;million milestone expense.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $21.7 million in our consolidated balance sheet for expenditures incurred by CROs as of December&#160;31, 2020. We have approximately $593.0 million in cancellable future commitments based on existing CRO contracts as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December&#160;31, 2020, we have approximately $79.6 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, included in other long-term liabilities we have accrued approximately $697.0 million, respectively, under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of December&#160;31, 2020, $62.0 million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue interest.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Off-Balance Sheet Arrangements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_160"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards  please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_2978"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal matters as of December&#160;31, 2020, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_163"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates. Other significant accounting policies are outlined in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under Financial Accounting Standards Board (FASB) Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenues, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Revenues</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this report.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired Intangible Assets, including IPR&amp;D</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we purchase a business, the acquired IPR&amp;D is measured at fair value, capitalized as an intangible asset and tested for impairment at least annually, as of October 31, until commercialization, after which time the IPR&amp;D is amortized over its estimated useful life. If we acquire an asset or group of assets that do not meet the definition of a </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business under applicable accounting standards, the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired, and expect to continue to acquire, intangible assets through the acquisition of biotechnology companies or through the consolidation of variable interest entities. These intangible assets primarily consist of technology associated with human therapeutic products and IPR&amp;D product candidates. When significant identifiable intangible assets are acquired, we generally engage an independent third-party valuation firm to assist in determining the fair values of these assets as of the acquisition date. Management will determine the fair value of less significant identifiable intangible assets acquired. Discounted cash flow models are typically used in these valuations, and these models require the use of significant estimates and assumptions including but not limited to:</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">estimating the timing of and expected costs to complete the in-process projects;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">projecting regulatory approvals;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">estimating future cash flows from product sales resulting from completed products and in process projects;&#160;and</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">developing appropriate discount rates and probability rates by project.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the fair values assigned to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these projects are not successfully developed, the sales and profitability of the company may be adversely affected in future periods. Additionally, the value of the acquired intangible assets may become impaired. No assurance can be given that the underlying assumptions used to estimate expected project sales, development costs or profitability, or the events associated with such projects, will transpire as estimated.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment and Amortization of Long-lived Assets and Accounting for Goodwill</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-lived Assets Other than Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used include property, plant and equipment as well as intangible assets, including IPR&amp;D and trademarks. Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review our intangible assets </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing our impairment assessment, we calculate the fair value using the same methodology as described above under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangible Assets, including IPR&amp;D</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in the estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have previously been impaired, including our vixotrigine program for the potential treatment of neuropathic pain, such as TGN, could become further impaired in the future.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most significant intangible assets are our acquired and in-licensed rights and patents. Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY or TECFIDERA (rest of world) products.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the impairment charges related to our long-lived assets during 2020, 2019 and 2018, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill relates largely to amounts that arose in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003 and amounts that were paid in connection with the acquisition of Fumapharm AG. Our goodwill balances represent the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess our goodwill balance within our single reporting unit annually, as of October&#160;31, and whenever events or changes in circumstances indicate the carrying value of goodwill may not be </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recoverable to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed our required annual impairment test in the fourth quarters of 2020, 2019 and 2018 and determined in each of those periods that the carrying value of goodwill was not impaired. In each year, the fair value of our reporting unit, which includes goodwill, was significantly in excess of the carrying value of our reporting unit.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue the remaining obligations and record increases or decreases in their fair value as an adjustment to contingent consideration expense in our consolidated statements of income. Changes in the fair value of our contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and achievement and timing of any cumulative sales-based and development milestones or changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above, could have a material impact on the amount of contingent consideration expense we record in any given period.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare and file income tax returns based on our interpretation of each jurisdiction&#8217;s tax laws and regulations. In preparing our consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. Upon our election in the fourth quarter of 2018 to record deferred taxes for global intangible low-taxed income (GILTI), we have included amounts related to GILTI taxes within temporary difference. Significant management </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and the effects of tax planning strategies. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions using a &#8220;more likely than not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished, through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the &#8220;more likely than not&#8221; threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews, we have no plans to appeal or litigate any aspect of the tax position and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_166"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and pricing pressures worldwide as well as changes in economic conditions in the markets in which we </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operate as a result of the COVID-19 pandemic. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina&#8217;s economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of December&#160;31, 2020, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Expense Hedging Program</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 24 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in this report.  </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Risk Management Hedging Program</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of December&#160;31, 2020 and 2019, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $458.2&#160;million and $265.0&#160;million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedge Program</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of our approximately 49.9% ownership interest in Samsung Bioepis. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next 10 months. As of December&#160;31, 2020 and 2019, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $56.9&#160;million and $43.0&#160;million, respectively. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates, including changes resulting from the impact of the COVID-19 pandemic. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of December&#160;31, 2020 and 2019, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $13.2&#160;million and $21.0&#160;million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing Pressure</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country but may also adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">throughout Europe may also lead to higher levels of parallel trade.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition in many markets from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways.&#160;Such products are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenues. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenues in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the year ended December 31, 2020, and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions, including as a result of the COVID-19 pandemic, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of December&#160;31, 2020 and 2019. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_169"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;8 is contained on pages F-1 through F-80 of this report and is incorporated herein by reference.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_172"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_175"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of December&#160;31, 2020. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission's rules and forms; and </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S.&#160;GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</span></div><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S.&#160;GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;&#160;and</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2020. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control&#160;&#8212; Integrated Framework.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, our management has concluded that, as of December&#160;31, 2020, our internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2020, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their attestation report, which is included herein.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_178"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_184"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information concerning our executive officers is set forth under the heading </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Information about our Executive Officers</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Item 1 of this report. The text of our code of business conduct, which includes the code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions, is posted on our website, www.biogen.com, under the &#8220;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; subsection of the &#8220;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section of the site. We intend to make all required disclosures regarding any amendments to, or waivers from, provisions of our code of business conduct at the same location of our website. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to the remainder of this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposal&#160;1&#160;- Election of Directors,&#8221; &#8220;Corporate Governance at Biogen&#8221; </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and &#8220;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Miscellaneous&#160;- Stockholder Proposals</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; contained in the proxy statement for our 2021 annual meeting of stockholders.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_187"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation Matters</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Corporate Governance at Biogen&#8221;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contained in the proxy statement for our 2021 annual meeting of stockholders.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_190"></div><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Stock Ownership&#8221;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Equity Compensation Plan Information&#8221;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contained in the proxy statement for our 2021 annual meeting of stockholders.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_193"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships and Related Person Transactions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Corporate Governance at Biogen</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; contained in the proxy statement for our 2021 annual meeting of stockholders.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_196"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto in the section entitled &#8220;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proposal&#160;2&#160;- Ratification of the Selection of our Independent Registered Public Accounting Firm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; contained in the proxy statement for our 2021 annual meeting of stockholders.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_202"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;15. &#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a. &#160;&#160;&#160;&#160;(1)&#160;Consolidated Financial Statements:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial statements are filed as part of this report:</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;Number</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-79</span></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain totals may not sum due to rounding.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;(2) Exhibits</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed on the Exhibit&#160;Index beginning on page&#160;86, which is incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;(3) Financial Statement Schedules</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements and notes thereto.</span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_205"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;16. &#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:5pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504513000010/apa.htm">Asset Purchase Agreement among Biogen Idec International Holding Ltd., Elan Pharma International Limited and Elan Pharmaceuticals, Inc., dated as of February 5, 2013. Filed as Exhibit 2.1 to our Current Report on Form 8-K/A filed on February 12, 2013.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000007/ex21_separationxagreement.htm">Separation Agreement between Biogen Inc. and Bioverativ Inc. dated as of January 31, 2017. Filed as Exhibit 2.1 to our Current Report on Form 8-K filed on February 2, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000119312512312222/d362642dex31.htm">Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000008/biib-2015x327xexhibit31.htm">Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on March 27, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000119312517200127/d406783dex31.htm">Fourth Amended and Restated Bylaws. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on June 9, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-20201231xex44.htm">Second Supplemental Indenture, dated April 30, 2020, between Biogen Inc. and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit B, respectively, thereto. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on April 30, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000119312512312222/d362642dex31.htm">Reference is made to Exhibit 3.1 for a description of the rights, preferences and privileges of our Series A Preferred Stock and Series X Junior Participating Preferred Stock.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex41.htm">Indenture between Biogen Inc. and U.S. Bank National Association, dated as of September 15, 2015. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex42.htm">First Supplemental Indenture between Biogen Inc. and U.S. Bank National Association, dated September 15, 2015. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on September 16, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-20201231xex44.htm">Description of Securities.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000028/creditagreement2015biogen.htm">Credit Agreement between Biogen Inc., Bank of America, N.A., Goldman Sachs Bank USA and other lenders party thereto, dated August 28, 2015. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 1, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000119312520022940/d854655dex101.htm">Credit Agreement, dated as of January 28, 2020, among Biogen Inc., Bank of America, N.A., as administrative agent, swing ling lender and the L/C issuer, and the other lenders party thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 3, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311009300/b83162exv10w5.htm">Second Amended and Restated Collaboration Agreement between Biogen Idec Inc. and Genentech, Inc., dated as of October 18, 2010. Filed as Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2010.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311009300/b83162exv10w6.htm">Letter Agreement regarding GA101 financial terms between Biogen Idec Inc. and Genentech, Inc., dated October 18, 2010. Filed as Exhibit 10.6 to our Annual Report on Form 10-K for the year ended December 31, 2010.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095015717000082/ex10-1.htm">Settlement and License Agreement, dated January 17, 2017, between Biogen Swiss Manufacturing GmbH, Biogen International Holdings ltd., Forward Pharma A/S and other parties thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000119312517139450/d43428ddef14a.htm#toc43428_63">Biogen Inc. 2017 Omnibus Equity Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on April 26, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit102.htm">Form of restricted stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit103.htm">Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit104.htm">Form of performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit105.htm">Form of cash-settled performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.5 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1010.htm">Form of performance stock units award agreement (cash-settled) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.10 to our Annual Report on Form 10-K for the year ended December 31, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1011.htm">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.11 to our Annual Report on Form 10-K for the year ended December 31, 2017.</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex101.htm">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex102.htm">Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex103.htm">Form of restricted stock unit award agreement (2018 one-time transition grant) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000029/biib-2019630xex101.htm">Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000029/biib-2019630xex102.htm">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000029/biib-2019630xex103.htm">Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019). Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex101.htm">Biogen Idec Inc. 2008 Amended and Restated Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex102.htm">Form of performance unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex103.htm">Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508005246/b71469biexv10w1.htm">Form of restricted stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 1, 2008.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508005246/b71469biexv10w2.htm">Form of nonqualified stock option award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed on August 1, 2008.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095012310036233/b79987exv10w1.htm">Form of cash-settled performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000014/biib-2015331xex101.htm">Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515159387/d786327ddef14a.htm#toc786327_57">Biogen Inc. 2015 Employee Stock Purchase Plan. Filed as Appendix A to our Definitive Proxy Statement on Schedule 14A filed on April 30, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508003542/b67068dfdefc14a.htm#152">Biogen Idec Inc. 2008 Performance-Based Management Incentive Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on May 8, 2008.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.28*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000017/biib-2019331xex101.htm">Biogen Inc. 2019 Form of Performance-Based Management Incentive Plan.&#160;Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095013504001180/b48790biexv10w13.txt">Biogen Idec Inc. Voluntary Executive Supplemental Savings Plan, as amended and restated effective January 1, 2004. Filed as Exhibit 10.13 to our Annual Report on Form 10-K for the year ended December 31, 2003.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1023.htm">Biogen Idec Inc. Supplemental Savings Plan, as amended. Filed as Exhibit 10.23 to our Annual Report on Form 10-K for the year ended December 31, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1024.htm">Biogen Idec Inc. Voluntary Board of Directors Savings Plan, as amended. Filed as Exhibit 10.24 to our Annual Report on Form 10-K for the year ended December 31, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000029/biib-2019630xex104.htm">Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective June 19, 2019. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit101-severancepo.htm">Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as ame</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit101-severancepo.htm">nded effective July 13, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit101-severancepo.htm">. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit101-severancepo.htm">September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit101-severancepo.htm"> 30, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504519000041/biib-2019930xex101.htm">Annual Retainer Summary for Board of Directors (effective January 1, 2020). Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311057276/b86869exv10w1.htm">Form of indemnification agreement for directors and executive officers. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 7, 2011.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000076/biogenemploymentagreementf.htm">Employment Agreement between Biogen Inc. and Michel Vounatsos dated December 18, 2016 and effective as of January 6, 2017. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on December 19, 2016.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit102-mcdonnellof.htm">Letter regarding employment arrangement of Michael McDonnell dated July 16, 2020. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit102-mcdonnellof.htm">September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit102-mcdonnellof.htm"> 30, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000095012310010528/b77985exv10w58.htm">Letter regarding employment arrangement of Susan Alexander dated December 13, 2005. Filed as Exhibit 10.58 to our Annual Report on Form 10-K for the year ended December 31, 2009.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504513000027/biib-2013630xex101.htm">Letter regarding employment arrangement of Alfred W. Sandrock, Jr. dated May 7, 2013. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1037.htm">Letter regarding employment arrangement of Alfred Sandrock dated October 19, 2015. Filed as Exhibit 10.37 to our Annual Report on Form 10-K for the year ended December 31, 2015.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.41*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-20201231xex1041.htm">Letter regarding employment arrangement of Chirfi Guindo dated October 12, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1031.htm">Letter regarding employment arrangement of Jeffrey Capello dated November 14, 2017. Filed as Exhibit 10.31 to our Annual Report on Form 10-K for the year ended December 31, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit103-capellosepa.htm">Separation Agreement between Biogen Inc. and Jeffrey Capello dated July 16, 2020. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit103-capellosepa.htm">September </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/875045/000087504520000036/exhibit103-capellosepa.htm">30, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1033.htm">Letter regarding employment arrangement of Michael Ehlers dated April 16, 2016. Filed as Exhibit 10.33 to our Annual Report on Form 10-K for the year ended December 31, 2017.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-20201231xex21.htm">Subsidiaries.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-20201231xex23.htm">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-20201231xex311.htm">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-20201231xex312.htm">Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-20201231xex321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Equity and (vi) Notes to Consolidated Financial Statements.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted or requested with respect to portions of this exhibit.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;++</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:237.00pt"><tr><td style="width:1.0pt"></td><td style="width:36.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:196.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHEL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> V</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OUNATSOS</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;3, 2021 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Capacity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHEL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> V</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OUNATSOS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director&#160;and&#160;Chief&#160;Executive&#160;Officer (principal&#160;executive&#160;officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHAEL</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> R. M</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ONNELL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive&#160;Vice&#160;President and Chief Financial Officer (principal financial officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;R</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBIN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. K</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RAMER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Accounting Officer (principal accounting officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robin C. Kramer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TELIOS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> P</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">APADOPOULOS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director&#160;and&#160;Chairman&#160;of&#160;the&#160;Board&#160;of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stelios Papadopoulos</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LEXANDER </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ENNER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Alexander J. Denner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;C</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AROLINE</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D. D</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORSA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline D. Dorsa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;W</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ILLIAM</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. H</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AWKINS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William A. Hawkins</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;N</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANCY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. L</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EAMING</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nancy L. Leaming</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESUS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. M</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANTAS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jesus B. Mantas</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;R</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICHARD </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ULLIGAN</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard C. Mulligan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;R</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBERT</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. P</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANGIA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert W. Pangia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;B</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RIAN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> S. P</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OSNER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian S. Posner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;E</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RIC</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K. R</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OWINSKY</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric K. Rowinsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TEPHEN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. S</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HERWIN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 3, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen A. Sherwin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-80</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:225pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_217"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMtMS0xLTEtMA_6a0ed653-9f36-475f-9118-4e9e085a0ddc">10,692.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMtMy0xLTEtMA_d75d01e0-2541-47b7-82d2-700b1f3acdd5">11,379.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b7b9a353c2419ca9a01532a522a0d0_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMtNS0xLTEtMA_bb196343-62ed-4852-b40e-5d323d7ffdd8">10,886.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzQtMS0xLTEtMA_e3a3e877-3c54-42fc-9aaa-9086bd0f6877">1,977.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzQtMy0xLTEtMA_efc48f75-a41c-42d6-aa19-8d9dc2a10c11">2,290.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2514a987784410a8165984f87269d3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzQtNS0xLTEtMA_c740096a-486f-479a-83c4-68cba75c904b">1,980.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzUtMS0xLTEtMA_f947fba1-0902-48f9-b07d-8c0a0bf47db8">774.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzUtMy0xLTEtMA_c79804dd-b7ce-41a3-9472-2c58fa646b08">707.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2987b04d4c240d88b84a50c04ca2df1_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzUtNS0xLTEtMA_c90658c4-4d94-447b-9994-0cd1981ebb49">585.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzYtMS0xLTEtMA_dbab5c81-4baa-4401-be65-4e1e8f4108fc">13,444.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzYtMy0xLTEtMA_91199dfd-96fd-45c5-92a9-72a7831cb3ce">14,377.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzYtNS0xLTEtMA_6f681e2d-1e3a-4251-a6b9-06f704c62b6e">13,452.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzgtMS0xLTEtMA_eef6523a-b8b6-4ee6-a006-553625085322">1,805.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzgtMy0xLTEtMA_71b2c323-16ce-4bb3-b00e-77a5ecce6e12">1,955.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzgtNS0xLTEtMA_858b18d8-74c2-4d7b-a345-d8981b130e54">1,816.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzktMS0xLTEtMA_56f8f66e-b6e2-463a-9f1f-74d4fa9331ef">3,990.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzktMy0xLTEtMA_2f7b9b2f-922c-44a2-9064-114bc5c8b105">2,280.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzktNS0xLTEtMA_c8b3a1b1-31bc-478b-af12-458d5312879a">2,597.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEwLTEtMS0xLTA_493d001a-31d5-448d-9eef-8a8cbf2b93e4">2,504.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEwLTMtMS0xLTA_4e5f88d7-79be-4ced-b3b4-1e81c4875036">2,374.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEwLTUtMS0xLTA_89157830-5e01-4c03-a866-cee49f428590">2,106.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzExLTEtMS0xLTA_1ac5d9c5-36b8-4c39-b95a-140896767d61">464.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzExLTMtMS0xLTA_8b31c47d-fba5-48bb-8733-fac9a2d3ebd8">489.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzExLTUtMS0xLTA_04b25b28-b92d-481d-98b0-838dae1accfa">747.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="biib:CollaborationProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEyLTEtMS0xLTA_4cc55e99-f6a2-4ac4-9a36-a22dcfbc7d82">232.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="biib:CollaborationProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEyLTMtMS0xLTA_19047871-4441-4705-9043-97710f99b907">241.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="biib:CollaborationProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEyLTUtMS0xLTA_3e10c045-5a9b-4952-af17-09e75395fc8f">185.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEzLTEtMS0xLTA_ad47f4d4-d55c-435a-b56c-80b0f46f5d82">92.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEzLTMtMS0xLTA_a02358aa-eca5-40aa-a64e-6f9516d2e872">55.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEzLTUtMS0xLTA_8f616f62-ee96-4de8-9e2a-b4dbbd6b4cd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE0LTEtMS0xLTA_12ef2c84-5bf3-43fe-8e4c-a3b74b560779">86.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE0LTMtMS0xLTA_78e12663-3168-4f52-ae7e-d17196e32575">63.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE0LTUtMS0xLTA_0ad70e9d-a678-46b8-a71e-137ca12ada96">12.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE1LTEtMS0xLTA_662bc6db-6d0b-4a8c-a0e2-f0f6aa7cd824">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE1LTMtMS0xLTA_f1fadb9a-c5e4-497e-8133-789926d14f01">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE1LTUtMS0xLTA_21dda23a-239e-47da-9f04-b2b8d3ac7ce5">112.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE2LTEtMS0xLTA_b9f9831f-2a96-4510-a4ed-eeeb49b8ecf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE2LTMtMS0xLTA_66288863-9f27-419c-9bf7-e1d0d612db53">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE2LTUtMS0xLTA_ab88dba6-a715-4149-a097-615ce683ebaa">12.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE3LTEtMS0xLTA_da22813f-66ce-49da-ad05-576c9c66bfee">8,894.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE3LTMtMS0xLTA_0156f7b3-4eca-4e2f-96ca-49619d18fc41">7,335.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE3LTUtMS0xLTA_5250c2dd-762e-49a2-ad92-dde4b970e035">7,564.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE4LTEtMS0xLTA_f1b6f877-f5cb-4cb7-87b2-f7bb9eb620cb">4,550.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE4LTMtMS0xLTA_aaf2f99b-701b-48b8-a268-fad53fd08199">7,042.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE4LTUtMS0xLTA_5da4dba7-872c-4af2-a074-707b41942b7e">5,888.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE5LTEtMS0xLTA_d631a5ad-0f99-419a-9708-f8882a1bd5df">497.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE5LTMtMS0xLTA_cb31198c-5afb-4b79-ae46-82fa17c9ba26">83.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE5LTUtMS0xLTA_6d62b742-5690-403f-b523-31c8b5833b3e">11.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIwLTEtMS0xLTA_de91a2f4-19eb-430b-a3a4-94b95e640379">5,047.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIwLTMtMS0xLTA_e061a02b-dbe1-4f2c-b30b-b23750e0e3d3">7,125.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIwLTUtMS0xLTA_ac052457-374f-4b5a-acca-d0b90f75b22b">5,899.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIxLTEtMS0xLTA_d5c80daf-ad4d-4e58-a691-bb3ec1a6e7c9">992.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIxLTMtMS0xLTA_001fd664-fa1d-4311-9e67-9ffc8420a40b">1,158.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIxLTUtMS0xLTA_655cb870-fba3-4264-ae03-49fe45df790b">1,425.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (income) loss of investee, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIyLTEtMS0xLTA_874c1b90-9013-4e90-b149-21ccec4c57ce">5.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIyLTMtMS0xLTA_c6c2a85e-4fd8-43de-ab38-1e8b35f54ad9">79.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIyLTUtMS0xLTA_9de92976-7de5-4631-a0c0-d8e7f86ea466">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIzLTEtMS0xLTA_0c3f9af9-8954-48ca-b3b4-64e5692abfe5">4,060.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIzLTMtMS0xLTA_23e4385f-0da2-423a-932d-457932858469">5,888.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIzLTUtMS0xLTA_a264a1a7-39aa-4fc3-b41f-0354abc3522d">4,474.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI0LTEtMS0xLTA_d73666b1-d083-4444-a42f-2d721496835c">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI0LTMtMS0xLTA_16f6adea-9953-4ff0-8e63-caa8643c6083">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI0LTUtMS0xLTA_39696b29-8b71-4168-b1d4-6fb7a1aa9066">43.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI1LTEtMS0xLTA_7d30276c-2f36-42fe-8d56-a35e9c945746">4,000.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI1LTMtMS0xLTA_02b38495-3b55-4d5e-b123-c81f06e42aa7">5,888.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI1LTUtMS0xLTA_a4055183-d607-42de-ac78-50653ae3a2da">4,430.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI3LTEtMS0xLTA_0d399f58-471c-4b6b-906b-ef38d59f11fe">24.86</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI3LTMtMS0xLTA_801767ff-68ab-4415-9270-0fe64143be88">31.47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI3LTUtMS0xLTA_d74ad986-b3f4-41ac-90a3-98948130bc39">21.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI4LTEtMS0xLTA_dd96bb7e-4dc5-4d5b-88e1-2e020536282d">24.80</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI4LTMtMS0xLTA_b0ab0aab-559c-4eed-b34f-d325eeae5dac">31.42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI4LTUtMS0xLTA_51743bd1-8b4c-47a2-a297-e85b4ed077de">21.58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMwLTEtMS0xLTA_79556e69-4273-48cc-961d-bc083d8cef82">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMwLTMtMS0xLTA_6f35df45-1fef-4c87-8bb4-40177a6b55e0">187.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMwLTUtMS0xLTA_c97aa078-df90-44fc-ad10-c34f1711293c">204.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMxLTEtMS0xLTA_497ba59f-3ad3-419f-84bf-981fd717cfdb">161.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMxLTMtMS0xLTA_90c26f62-f30f-4616-8a5b-416126a1b026">187.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMxLTUtMS0xLTA_262b1bc5-76d0-49d9-a25b-5337bb89c94d">205.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:90pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzItMS0xLTEtMA_1f1a4227-36e6-46de-92d0-f5889ba8f287"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzItMS0xLTEtMA_bd351670-df4f-46c1-8529-9f70297623f1">4,000.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzItMy0xLTEtMA_82156a64-df9f-4f0f-96c8-b85976149037">5,888.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzItNS0xLTEtMA_39e0b859-211c-4cfc-b6ca-da4637599341">4,430.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzctMS0xLTEtMA_70f2c868-48f2-4f8f-aa26-9278f649dfcc">2.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzctMy0xLTEtMA_0027d693-3e40-4257-92d7-cbd208fb52e0">8.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzctNS0xLTEtMA_b222add3-e57b-4105-9e36-bb226912b88c">3.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzExLTEtMS0xLTA_a1e73acd-374d-4d47-b8f7-3455c1cf5aa2">186.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzExLTMtMS0xLTA_021efb02-a2a5-443e-8c36-7678ac9b5b15">26.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzExLTUtMS0xLTA_8683b4c2-9f94-4665-bec6-69cff99c40ff">139.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE1LTEtMS0xLTA_e1f31523-a79c-4b42-b17c-694eb87c3e61">33.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE1LTMtMS0xLTA_e5a4c352-6b0d-4095-8329-9ceb3e2db0f0">21.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE1LTUtMS0xLTA_e5a66552-6b50-41a3-a139-6c7b4998473c">3.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE2LTEtMS0xLTA_637eb254-3905-434c-8843-682ebd1303c1">33.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE2LTMtMS0xLTA_34bfaafa-e942-4fea-85c4-b78b72e5fd68">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE2LTUtMS0xLTA_64ab6763-eb43-4e4d-89a3-5994ef8c35a2">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE3LTEtMS0xLTA_b658834b-84e5-4f36-81d7-3db2791fb83f">92.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE3LTMtMS0xLTA_dcf31c51-2534-49f9-a5ee-156563793286">103.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE3LTUtMS0xLTA_3694e81e-87c0-4eaa-a264-48ce1f70f68c">67.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE4LTEtMS0xLTA_d207f341-f57d-4622-a0b2-a8062d316320">163.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE4LTMtMS0xLTA_b9be0ff1-a292-4143-a2e8-1559cd369d67">105.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE4LTUtMS0xLTA_c897683d-fb17-44f5-8d90-ad6240e120d6">76.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE5LTEtMS0xLTA_ee1fdc85-4f85-49e2-8b78-effdcf2bcedd">3,836.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE5LTMtMS0xLTA_4dad0fe7-dab7-4cc8-924c-06864afc1b4b">5,993.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE5LTUtMS0xLTA_28d14a00-a0d0-4421-855a-a36756e584b6">4,507.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIwLTEtMS0xLTA_787bc7bb-4204-4c2e-aabd-0a6e2bde7598">60.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIwLTMtMS0xLTA_c378b798-2f48-4bdf-a267-02839761fe53">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIwLTUtMS0xLTA_cac08277-8e12-4f1a-8e1d-ab13b7906337">42.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIxLTEtMS0xLTA_1ec2703b-17fd-411f-902e-597d33abecaa">3,897.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIxLTMtMS0xLTA_49e055d6-e655-43ec-bf66-7c8cb3833c3d">5,993.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIxLTUtMS0xLTA_59b1107e-3897-447a-a346-d47e82b8d207">4,550.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_223"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQtMS0xLTEtMA_b1ef6ec9-2269-4bc6-aa4b-16e20f669f9a">1,331.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQtMy0xLTEtMA_f2ab034b-1d26-4a21-bf5d-fe211cba581a">2,913.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzUtMS0xLTEtMA_99d0ee14-a1b0-4902-a3c6-23dbe96b5e04">1,278.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzUtMy0xLTEtMA_1ee8c363-2923-4df0-8312-9132261bf082">1,562.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzYtMS0xLTEtMA_b5be3808-c102-47f8-a474-7861428f70f2">1,913.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzYtMy0xLTEtMA_adc00297-4535-47ea-9742-6e05a7d1fed1">1,880.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="biib:DueFromUnconsolidatedJointBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzctMS0xLTEtMA_10d01db8-ed9a-42c4-944d-58e32af077f6">413.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="biib:DueFromUnconsolidatedJointBusiness" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzctMy0xLTEtMA_59aceeff-3129-4e90-b339-73c73f99435d">590.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzgtMS0xLTEtMA_e653f7c1-f03b-4a4c-ac3d-f9dd14dca079">1,068.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzgtMy0xLTEtMA_8868d1dc-1c66-40b5-86b0-ba757f6234e2">804.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzktMS0xLTEtMA_8daf8a86-434f-4566-8447-654b608e7ba6">881.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzktMy0xLTEtMA_fca07f8d-31df-48e0-beea-ace91f4e7572">631.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEwLTEtMS0xLTA_7b839713-7e0a-41b4-a83d-eff486d67d49">6,887.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEwLTMtMS0xLTA_c80b196a-bb23-4226-bab9-c2c1bff6c6d1">8,381.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzExLTEtMS0xLTA_1a422415-77f5-48a2-ab15-91e0f19a1de7">772.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzExLTMtMS0xLTA_e70db56a-4cf2-413b-b2e2-da25fe96d8cb">1,408.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEyLTEtMS0xLTA_4b4acb3d-26b8-4742-8893-42557fb2fb21">3,411.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEyLTMtMS0xLTA_ca3da1d3-b66a-4ea7-ab3f-adcc70bb5821">3,247.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEzLTEtMS0xLTA_40cf13fc-a08a-47c5-8452-2da32ed84d88">433.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEzLTMtMS0xLTA_f4db3866-c81a-44cd-88e9-d5b08eac4348">427.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE0LTEtMS0xLTA_8456b4aa-3dee-4405-af78-e6e5673d1670">3,084.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE0LTMtMS0xLTA_b60aeaf6-0586-4e4a-a082-04b00dc87cc6">3,527.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE1LTEtMS0xLTA_a77c347d-93bb-422a-8003-f229c3b6995b">5,762.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE1LTMtMS0xLTA_e6db83e6-e5aa-40cb-b276-048351308adc">5,757.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE2LTEtMS0xLTA_60d3d9d2-222c-405c-ad36-4e355ad8ff0f">1,369.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE2LTMtMS0xLTA_155fd86f-fa01-49d8-873b-a332ad51cfc0">3,232.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE3LTEtMS0xLTA_2589f4c8-d412-4d4d-8dcd-d6fdb1db0f14">2,899.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE3LTMtMS0xLTA_a00fca2d-5db8-45b7-ae7f-b0002884de59">1,252.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE4LTEtMS0xLTA_faa9e37f-da62-402a-a4c3-8bf0c7e5f982">24,618.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE4LTMtMS0xLTA_4c3bfbb9-731d-4a3b-a946-1a752dbc3de8">27,234.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIxLTEtMS0xLTA_782c6424-0211-4dff-a35c-9f9f923a784c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIxLTMtMS0xLTA_0ff4b27b-2e25-488c-9256-d7edf77b5427">1,495.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIyLTEtMS0xLTA_140ca0ec-4250-4770-8edb-ebe5cfaff837">142.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIyLTMtMS0xLTA_ddc5a544-c843-4592-8ef7-19214d974b42">71.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIzLTEtMS0xLTA_20372949-0c89-4fec-a0c8-ed490fe03ed4">454.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIzLTMtMS0xLTA_3a279423-543a-4efb-ab2e-1c6af18ce8e0">530.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI0LTEtMS0xLTA_d7991e02-8133-4de2-a4a4-735905bf19ee">3,145.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI0LTMtMS0xLTA_030c49a0-dec2-46fa-be85-fa67757854bf">2,765.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI1LTEtMS0xLTA_e0b21e58-b8b5-4290-bd4f-f4b98edacb1f">3,742.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI1LTMtMS0xLTA_6ca31f47-fcf4-42a8-9670-a932f0185a89">4,863.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI2LTEtMS0xLTA_4c96d10f-26fd-4078-876c-1ddcbef3085e">7,426.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI2LTMtMS0xLTA_493900fe-052a-4fe0-9d8a-7854720a1b53">4,459.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI3LTEtMS0xLTA_e07459c7-22bd-4353-816f-e0ddf286a9fb">1,032.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI3LTMtMS0xLTA_b68f8627-2bdc-4513-8d5e-f3b5a0c41b3c">2,810.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI4LTEtMS0xLTA_0f3e01ef-aa3e-4beb-a8eb-8bd227597d17">402.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI4LTMtMS0xLTA_4fff9cc2-fae6-402e-8c54-e0c32b16b397">412.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI5LTEtMS0xLTA_741a9778-b152-47d3-951a-71e87093a261">1,329.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI5LTMtMS0xLTA_d8c41ac3-757e-4c28-935b-72792430b02b">1,348.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzMwLTEtMS0xLTA_d38a796e-3e65-42f8-beca-b05d8bf96a8f">13,932.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzMwLTMtMS0xLTA_1c137325-246d-4b3f-b535-f9f3a0219d16">13,895.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments, contingencies and guarantees (Notes 21 and 22)</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzMxLTEtMS0xLTA_8d3d3595-0381-4bfd-9404-ece022b41964"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzMxLTMtMS0xLTA_e107d668-bf4b-4363-8ad0-da57244c217d"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM0LTEtMS0xLTA_92e92c83-381d-4397-abda-9366bf3e47eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM0LTMtMS0xLTA_0d15d2dd-674d-4c72-b969-afa8595a1b54">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM1LTEtMS0xLTA_5919609e-77e5-4e59-a219-a6636d599344">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM1LTMtMS0xLTA_d55e24fe-01b9-439f-8bd8-68708ad5c891">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM2LTEtMS0xLTA_269205ae-1c89-4b02-96c1-7050e85f7c67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM2LTMtMS0xLTA_2ecc3cca-b8f2-46fb-87fb-766257ec50a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM3LTEtMS0xLTA_5e63fb09-1653-41b5-9dc2-d35926845fe6">299.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM3LTMtMS0xLTA_b3019de6-5b63-4eb1-a70f-d10f4d7cb89e">135.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM4LTEtMS0xLTA_f778d447-7cac-41ec-971d-27a6f38282e6">13,976.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM4LTMtMS0xLTA_69f368b9-17b8-4dea-854b-846e8d875120">16,455.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM5LTEtMS0xLTA_3b336f2a-e52e-4224-8cc0-2f98a887f47b">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM5LTMtMS0xLTA_17c77a46-7b49-4546-a9b6-424d471d87f2">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQwLTEtMS0xLTA_dc774520-ddf3-4748-b1b1-a6064e19556c">10,700.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQwLTMtMS0xLTA_4b2a5c87-3a73-48f3-93fc-22ac9e63ae2b">13,343.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQxLTEtMS0xLTA_e9949627-91e4-441b-a4ce-48224b4578ad">14.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQxLTMtMS0xLTA_ed48a5b9-51c0-4b9b-a68b-0bdbe5dfcd1f">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQyLTEtMS0xLTA_69e6b8cf-d4ce-401a-a1dd-3a2c12f293c8">10,686.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQyLTMtMS0xLTA_5b720d50-9863-4d41-ba53-1fae1cd3828f">13,339.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQzLTEtMS0xLTA_adf00792-8c40-44e1-8b8a-42fc88872972">24,618.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQzLTMtMS0xLTA_3be81fb2-aac7-4502-9c5d-6aa2eefc90eb">27,234.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_229"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMtMS0xLTEtMA_b86eddd3-7fe7-446b-8bde-cec12b3fcc35">4,060.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMtMy0xLTEtMA_f3c1a507-cb6a-4bcf-8d7f-51f880d92bf5">5,888.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMtNS0xLTEtMA_2f799ea2-82fc-4b82-a6f8-3c4d75e06ea7">4,474.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flows from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzUtMS0xLTEtMA_7eb482ab-bc35-45e1-91b9-6f0e90ce2507">457.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzUtMy0xLTEtMA_df35fbfe-6a43-4159-b866-da90a88715f7">464.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzUtNS0xLTEtMA_f296fdbb-0f27-4945-916e-686d448438f2">650.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtMS0xLTEtMjE2Nzg_90adba3e-5a47-43db-baf5-004027d3873b">209.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtMy0xLTEtMjE2Nzg_e954b077-19ac-4ba7-b274-6979fbc6ecd0">215.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtNS0xLTEtMjE2Nzg_a262c99c-097a-45e7-b9b0-2257db73bc87">366.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtMS0xLTEtMA_63355d92-b5fd-412c-8707-de5b818afaa9">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtMy0xLTEtMA_dd4357fe-c29b-49d6-85e4-9b14806e08a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtNS0xLTEtMA_1d2d0ceb-dabc-4ab9-9914-f027f71ea5de">112.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzctMS0xLTEtMA_7d3c922b-d393-4132-9bf9-7682d5cdc865">198.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzctMy0xLTEtMA_8337dcda-6431-4103-934b-7aed2d69a823">182.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzctNS0xLTEtMA_78175732-930e-4d2d-b79a-bed56132a6b0">157.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzgtMS0xLTEtMA_37c67447-f12a-4f27-b7a2-e525c794058e">86.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzgtMy0xLTEtMA_74f7befe-bb19-42bb-a94f-5ae3d062cc79">63.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzgtNS0xLTEtMA_f77cdf18-cffc-4687-9d07-9dec17c4b193">12.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain)/loss on divestiture of Hillerod, Denmark manufactuing operations</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzktMS0xLTEtMA_77c6d651-0c5d-4984-8c1d-c8b46cfa0ef4">92.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzktMy0xLTEtMA_7d935ce7-66ca-4aa7-9c76-92e430822a8b">55.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzktNS0xLTEtMA_328240c4-afe2-4994-9245-be4966bf97cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTEtMS0xLTM2NQ_f34621e5-e3ed-463f-8ed0-4407e3485c99">149.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTMtMS0xLTM2NQ_8db84ea4-58cd-4df1-b871-852fae018865">67.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTUtMS0xLTM2NQ_3f50fa7e-6b06-4710-860a-4bdf370299d1">108.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTEtMS0xLTM2NQ_88060e66-885b-49d8-9454-20a16635273b">681.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTMtMS0xLTM2NQ_790c3b25-4a17-45ed-a870-55b73607ed9b">147.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTUtMS0xLTM2NQ_26ccf3cd-f383-4626-b6a9-0ca12c908718">124.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on equity method investment</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTEtMS0xLTA_30cb7239-3611-488e-9568-1a41dd14f35e">3.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTMtMS0xLTA_6b04d078-7607-4c26-a869-e8e597e1ef48">77.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTUtMS0xLTA_391ebe2d-540e-4793-8510-f6de8d7838b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTEtMS0xLTA_c21fdc8f-5537-4931-8c79-50b6771779a3">131.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTMtMS0xLTA_125ec36b-46cd-45e0-9251-7c2005a66680">139.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTUtMS0xLTA_f910a181-a802-47d2-8c0b-33386d1d5ae6">55.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEzLTEtMS0xLTA_ff790642-19e4-49a6-b535-1e653b1eddf2">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEzLTMtMS0xLTA_0e7a01e1-6ef5-495e-98be-d26467e79a5f">68.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEzLTUtMS0xLTA_70dc3a63-ff89-4927-b81c-16b8e3ab9b9c">205.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE0LTEtMS0xLTA_7acce0be-21e2-4c4c-a9cb-e8abc1a5f102">176.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE0LTMtMS0xLTA_af708612-518f-464a-95b0-b98379c9ace6">63.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE0LTUtMS0xLTA_bdb08695-9aee-470d-8743-5726611bd40e">5.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE1LTEtMS0xLTA_2aadddde-f59b-4849-8c38-73511f8d87ae">316.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE1LTMtMS0xLTA_e5ea0823-a9b7-406b-ba16-cc478eb6c679">19.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE1LTUtMS0xLTA_bc65de68-59ca-4ccd-ae56-e4d1b9be2c72">52.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE2LTEtMS0xLTA_1977d2ab-dca4-47a0-9b71-e4587a5fb60c">154.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE2LTMtMS0xLTA_b9f9e3cd-6191-4abc-aa06-dfe8462f3453">240.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE2LTUtMS0xLTA_e3d2e145-d06a-49ec-9ae0-88fc7522fdc1">465.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE3LTEtMS0xLTA_453c84d8-5e67-487b-b34b-a5746f3457eb">67.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE3LTMtMS0xLTA_31c5c724-9207-4126-9e52-57c0612d17a8">16.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE3LTUtMS0xLTA_d3ae9f64-1303-4d63-bbbb-6dee289d51c0">321.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE4LTEtMS0xLTA_e511d5df-f020-45f4-a424-108ead068106">137.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE4LTMtMS0xLTA_76605f8c-3a61-482a-8f2a-aaa4723779fe">43.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE4LTUtMS0xLTA_b3fdd135-6de7-404e-85de-5b675c156d0a">135.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flows provided by operating activities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE5LTEtMS0xLTA_b0eaa635-4317-466e-9ec5-fafa85af9042">4,229.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE5LTMtMS0xLTA_abd0cb1e-48f9-427b-bb6a-68800ada09cd">7,078.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE5LTUtMS0xLTA_39eb8c9c-144b-4b68-a579-2c8021d43d20">6,187.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIxLTEtMS0xLTA_8dc6c6f4-c9a2-49dc-9d43-46c24e3f3cb5">7,299.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIxLTMtMS0xLTA_7c093993-588b-4a23-a138-fa031ffc7c41">6,007.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIxLTUtMS0xLTA_9dbcf1c5-0779-4aa2-947f-fb383d9289a9">9,173.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIyLTEtMS0xLTA_4da23522-817c-4e7a-91b1-d1fcc94c0438">6,397.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIyLTMtMS0xLTA_64c5dd73-8784-457c-b25e-1f9677d8a3f1">5,252.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIyLTUtMS0xLTA_08c16bd7-4d0b-4573-84e7-f73c634ee7fc">7,694.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration paid related to Fumapharm AG acquisition</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIzLTEtMS0xLTA_8d0a459d-1024-4b8b-a043-4e4bbd41392f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIzLTMtMS0xLTA_b2809460-6941-4605-a048-56b227bd0b6b">300.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIzLTUtMS0xLTA_cf8570ee-b6f9-4040-b978-7b9e12ab9a7a">1,500.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of Nightstar Therapeutics plc, net of cash acquired</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI0LTEtMS0xLTA_3c3d81d7-1819-49c4-b384-0bf45d66ad0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI0LTMtMS0xLTA_f497bf42-0610-4176-97ef-c623285c8968">744.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI0LTUtMS0xLTA_833011aa-e426-4670-968a-9b19d59943d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of Ionis Pharmaceuticals, Inc. stock</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe07a7c7dc0443dbe2b2303dcf1a9ed_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTEtMS0xLTk3Mjk_8f9bd5dc-19b0-4dd7-979e-8a05d008e0bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic832cd7b75cb4db1947131a9ca6ada7d_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTMtMS0xLTk3Mjk_902fa7b3-57f3-4b36-93e4-40628cf9e4f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i947f2882d6404d2ebbe95236b59c95ef_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTUtMS0xLTk3Mjk_f48aa1d4-e61b-4716-a5be-3ecc7a088b87">462.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of Sangamo Therapeutics, Inc. stock</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcf0372b542a4a81867022b7653fddbb_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTEtMS0xLTMyMA_12f7a1c5-cada-4566-90fa-0279cfde40b2">141.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b225a61fc749cf835625b8fa6246b6_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTMtMS0xLTMyMA_f2bd6a26-c947-4cb5-bb20-82308d58c601">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba23f55f1d1462cb337f7f348d52f17_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTUtMS0xLTMyMA_0a93753b-a6dd-428d-a3e9-98fc0eefacc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of Denali Therapeutics Inc. stock</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7685594c21ff48f6aa4a4ab8e67bd590_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTEtMS0xLTMyMA_30c1fed3-e3b1-4cd1-af0d-cba65c926c51">423.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3565d89e31c04fe69d700b215cbfe265_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTMtMS0xLTMyMA_6ba37d53-e254-4804-ba28-2bef0bfc5784">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36a6dbaa4344c37a9dc77f2cda681cf_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTUtMS0xLTMyMA_f498cbc7-b481-4168-b2dd-d8417d2cf249">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of Sage Therapeutics, Inc. stock</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic116ea7c17b449929c5b3e40bf3fc147_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI5LTEtMS0xLTIyMDA_257ba48c-c7f4-4c7e-9e6a-84815d5399df">441.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacfecdd3de364249bf6dd9e13df58609_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI5LTMtMS0xLTIyMDA_cbdf4517-8511-44b5-8b1e-7fa8909a7601">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9808ec312874199952c2b8c5ee0b580_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI5LTUtMS0xLTIyMDA_733f4f55-eab9-465c-aee3-eaea830f4feb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from divesiture of Hillerod, Denmark manufacturing operations</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTEtMS0xLTA_144bc972-cfee-43c4-8cbe-1ea89bf98bde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTMtMS0xLTA_b4c5c68e-e88e-4053-9ce0-937997c12150">923.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTUtMS0xLTA_946bce5d-2563-4e01-9633-64c69584bf5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTEtMS0xLTA_0028c75f-e279-4886-9645-c4079546f49e">424.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTMtMS0xLTA_108cba38-fc41-49df-a42f-ff09d9e30703">514.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTUtMS0xLTA_b85de27f-8dbd-4198-a2cb-1f550107a6a0">770.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTEtMS0xLTA_74723211-625c-4624-9b0e-1ed819569cdb">75.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTMtMS0xLTA_9bc3a2b8-f49e-4202-a91a-8b2698649062">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTUtMS0xLTA_db9e763b-4d39-441d-9b6c-dabdbca6b341">112.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI4LTEtMS0xLTA_5f83b703-46b4-4674-8156-9cdc9fa85706">52.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI4LTMtMS0xLTA_a66bb1bc-e648-485f-b084-e680ba4ebb99">155.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI4LTUtMS0xLTA_5c450535-86ac-4048-bd30-7208537b4beb">3.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMwLTEtMS0xLTA_91f56fda-5823-45c2-919a-b2762a680e64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMwLTMtMS0xLTA_f351d8af-89ee-4536-9360-266ac5669201">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMwLTUtMS0xLTA_48328eb6-b067-4244-abca-95d78b6a9d98">676.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMxLTEtMS0xLTA_ea794243-fb5a-4982-a419-5e69cf6201a0">74.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMxLTMtMS0xLTA_c397f5f7-7e5d-451d-a289-9aee695faedd">479.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMxLTUtMS0xLTA_1158e27b-6b17-45bf-a7d0-80cdcb479cdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMyLTEtMS0xLTA_eb6e40a8-156f-4299-b59f-ddb636cf1cbe">26.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMyLTMtMS0xLTA_10d8f971-8279-468d-8291-0abe59e4c2d2">27.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMyLTUtMS0xLTA_c6dd2196-44de-4187-add5-e845855fb4c0">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flows provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMzLTEtMS0xLTA_a5b3efd3-2b71-41df-a7ad-7514fd7f6e92">608.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMzLTMtMS0xLTA_593e2a15-f316-41b0-874c-7d5f14ec9c1c">470.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMzLTUtMS0xLTA_2a5d2f14-e8d1-43a0-966b-56b95ea36856">2,046.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM1LTEtMS0xLTA_4d9da11d-e28d-468f-ae2b-459690e7b909">6,679.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM1LTMtMS0xLTA_0a7fb270-65df-4f5c-bde4-69791569fc35">5,868.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM1LTUtMS0xLTA_5b2f390a-ac1d-4211-9526-e4677d612181">4,352.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM2LTEtMS0xLTA_424c5030-1a6e-4a33-8bfa-e1d96d1d7016">4.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM2LTMtMS0xLTA_12694025-4383-40d6-87f2-c3164b859bd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM2LTUtMS0xLTA_fa88a4d1-57be-4833-8f24-b9317ee4fac8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM3LTEtMS0xLTA_1d20679e-e6dd-400d-b36d-efa1fff11eeb">2,967.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM3LTMtMS0xLTA_b72595d8-71eb-4788-a6ed-64642316432d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM3LTUtMS0xLTA_388aa909-686d-459e-a7ae-4c6fd4f7694b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of borrowings</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTEtMS0xLTM0Ng_759cc718-e0da-4c40-8f01-44f6a204112e">1,500.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTMtMS0xLTM0Ng_5480068b-800b-452c-ba8b-65f893313fcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTUtMS0xLTM0Ng_f5f9c264-e095-412c-879a-0c3e6222740c">3.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net contribution (distribution) to noncontrolling interest</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfCapitalDistribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM4LTEtMS0xLTA_da31919f-b8f9-4118-9516-a52006fa132e">71.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM4LTMtMS0xLTA_ea032372-6c19-4327-8459-b9c92e612d6f">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:PaymentsOfCapitalDistribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM4LTUtMS0xLTA_3450eb10-c6ea-4129-8d1b-342cb6dccd0f">36.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM5LTEtMS0xLTA_42cc4b83-805b-496f-b901-37a25ad0be7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM5LTMtMS0xLTA_9a7fd22d-2538-40c7-889f-1155659519ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM5LTUtMS0xLTA_6e66d137-aa8a-4456-8fef-afa47f54fd48">58.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTEtMS0xLTA_add76988-1a77-4e6c-b882-d48263f1af34">14.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTMtMS0xLTA_37cfddd3-690c-442c-8b85-a6229932011d">3.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTUtMS0xLTA_c8a41fef-4f74-42c3-9d3e-5d488d1bc012">21.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flows (used in) financing activities</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQxLTEtMS0xLTA_286574d9-799f-44e3-a7f9-4af9527b940c">5,272.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQxLTMtMS0xLTA_e3743575-64a7-4f6b-9bb9-ce90f4bd44bc">5,860.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQxLTUtMS0xLTA_eafb6660-1ebc-4de2-867c-1e3703a423d4">4,472.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQyLTEtMS0xLTA_dc16848b-a616-4216-bd04-0781beba92ff">1,651.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQyLTMtMS0xLTA_d93868fa-758a-4baf-a9b9-e15f9c99895e">1,688.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQyLTUtMS0xLTA_f15a2700-3309-4adb-a123-fa56b952dd22">330.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQzLTEtMS0xLTA_21d461e5-a5ee-4cf0-bd37-dc52771bc65b">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQzLTMtMS0xLTA_f28d2e34-dd2a-4915-87b6-0f328ed44ae7">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQzLTUtMS0xLTA_671a4e5a-0a50-4a22-ab33-5f3e3047c0ac">18.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the year</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ0LTEtMS0xLTA_e3df1643-c781-4311-80e2-11b479d7048b">2,913.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ0LTMtMS0xLTA_cad7d86f-d8ea-4615-a56a-3c343d543221">1,224.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9925b2c3e594ae0812001969da2a99b_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ0LTUtMS0xLTA_13fc22c8-0393-477d-aee4-97a6c5f28b6e">1,573.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the year</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ1LTEtMS0xLTA_ad4da943-c52e-4d02-af63-b8ab8ecebee8">1,331.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ1LTMtMS0xLTA_dbbaf1d4-ec84-49a3-a27b-2ee89db8fad6">2,913.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ1LTUtMS0xLTA_6cca8dba-2e9a-4ffb-81e6-52f5642a017f">1,224.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_232"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.164%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idae041b402f34f1db7c9617616121bba_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMS0xLTEtMA_d3b7d754-bf1e-4306-b1db-87fc25ed9067">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae041b402f34f1db7c9617616121bba_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMy0xLTEtMA_5edb59d7-16c8-4c1a-a7df-6f78426f18d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c314d6d1f964bfe879cbff831677e6d_I20191231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItNS0xLTEtMA_e646cc9b-65a2-47df-ba0c-a1428d0f4ea3">198.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c314d6d1f964bfe879cbff831677e6d_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItNy0xLTEtMA_fa9cf6e0-ca76-4517-94d8-afd5a1555c26">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b238312a99c4acda7452e34a406431c_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItOS0xLTEtMA_f3f1f7ce-3b5b-4903-a348-70dd9dd28e86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8631cd953f3488583e5a99f0aa067ea_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTEtMS0xLTA_680897c9-9d7f-4b20-9a46-ac0604e43e64">135.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb28add0da94e2984281d36c212a6b5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTMtMS0xLTA_c9fcef3d-43f8-49d9-a781-08c19be2a4d0">16,455.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieafb8a83622d4c7d83aa7f731407ace6_I20191231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTUtMS0xLTA_34e86bdd-5bc9-478b-8338-ebbf26baba08">23.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieafb8a83622d4c7d83aa7f731407ace6_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTctMS0xLTA_db09ed42-4a36-4497-96a8-5b9b1fd61c16">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32b478b02b043de86c4b4db94343ae7_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTktMS0xLTA_8876fcae-fa64-4171-81fa-fd00cf9ed984">13,343.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04b4d5aa1794922b920009486d15ab9_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMjEtMS0xLTA_5143037d-5937-463b-b6a2-dbd9dd24fa34">4.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMjMtMS0xLTA_0c79558d-873f-417b-b1e5-bdb6dec2f832">13,339.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c8c0fefae64f87b0c7f553d3c884e9_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzMtMTMtMS0xLTA_442c2379-bf23-409b-845e-4cbbd1587d59">4,000.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzMtMTktMS0xLTA_09455b8c-3930-497c-af59-8ca9ae655015">4,000.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzMtMjEtMS0xLTA_bb404fca-c899-4f90-91f1-42b3d7a3d4b4">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzMtMjMtMS0xLTA_eab893d0-a794-4c95-9166-2db821fac8f3">4,060.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9730f32121bf4c97a3efb7cd327a3f8b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzQtMTEtMS0xLTA_33b1e0e2-460e-4f2f-b769-8c6c62e922f2">163.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzQtMTktMS0xLTA_5f1b4f09-5dc7-436c-8a1b-edfa929df531">163.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzQtMjEtMS0xLTA_1f36ed60-57b2-497c-a0cc-e9ff76f98bbe">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzQtMjMtMS0xLTA_9f6f46e1-f41d-47ee-a350-7c2d8d106051">162.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMjEtMS0xLTE1NDY5_25621e69-1ce0-4f77-a7dd-9b659a6c6638">75.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMjMtMS0xLTE1NDY5_ecd0f5d3-cb72-49d0-84d3-db812a8ce82a">75.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMTktMS0xLTA_cdb39b5f-e7cf-4979-9c1b-7f67b4875022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMjEtMS0xLTA_4b8a9a2f-f2e4-4d33-b5d5-aaee12fb379a">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMjMtMS0xLTA_f55bce22-6eba-4c8c-a31b-bec4dc79b7d3">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTUtMS0xLTIyMDg_4608c08a-7084-45d5-8460-044d2ecce6ea">1.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTctMS0xLTIyMDg_293c7642-0453-4a51-a439-0b7f8385e26a">400.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7b0512c1ef74ccf9a55f06a601135a6_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTktMS0xLTIyMDg_98cbce5f-362e-486e-b835-4c14f26adfba">400.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMjMtMS0xLTIyMDg_c2d2b4ce-f2d8-412c-8a19-116a8c42c14a">400.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i02dd29564939484da19f114c7ad6568e_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctNS0xLTEtMjIwOA_d45b1d75-d281-4cca-a647-03b6e0949b95">1.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifba1e5d98e494036a7bb6347485e7fd7_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctOS0xLTEtMjIwOA_91659103-59ec-4672-ae77-2d2a4879dfa3">60.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5dfc1fefbed7417cbbc28aa6ac0dd8b8_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTMtMS0xLTIyMDg_1d9e2b2f-434e-4195-add6-47484dda89d3">339.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTUtMS0xLTIyMDg_9238072c-8b33-4c7d-a58c-bc0fefe6bf1c">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTctMS0xLTIyMDg_72a084c1-62e3-4ad5-9eb8-0273039b1d7d">400.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMjMtMS0xLTIyMDg_25bcad78-fd1f-4e3c-80ee-30affa49d745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTUtMS0xLTA_673d7f7a-0b54-4944-bd62-f24d5a929866">16.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTctMS0xLTA_dcbfd9bf-7a19-4e11-821f-73a0fbc3c6a6">5,000.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iead28cb9adf24fb08e016c9daa3a77d5_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTktMS0xLTA_7e0d5074-7e1d-412e-8cc5-665111aad021">5,000.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMjMtMS0xLTA_b888cc7a-c51e-41ca-8ee1-01c648ed74db">5,000.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the December 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20ed583992094d77bff487c7db1d1673_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctNS0xLTEtMA_f78b97f6-7720-41c3-805f-93c45f13daa7">16.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id631f87e609f40da8cd804801bbf81b7_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctOS0xLTEtMA_fd37426a-5e69-4a46-82b6-80ecc93845fc">121.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd77c6e9bea747df9f7e454828986d8a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTMtMS0xLTA_1c58b9b6-73fd-4919-a45b-209642294fa2">4,878.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTUtMS0xLTA_3268b655-d41d-480b-8098-cd69d044a19e">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTctMS0xLTA_b665eced-c700-4568-90b1-a9b4ba3a52b9">5,000.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead28cb9adf24fb08e016c9daa3a77d5_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTktMS0xLTA_3d5a4eae-4a17-4ed4-9c57-ad98b65fc9e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMjMtMS0xLTA_d683476b-0e2e-4fa4-b8b1-db2841e6146c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzgtMTUtMS0xLTA_3d0705bb-e888-4591-b3e4-5a4b81a39856">4.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzgtMTctMS0xLTA_ced32f7d-2176-4175-881d-c3e254176547">1,279.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i399ba008e6b14b85b6ac84920d61a3c7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzgtMTktMS0xLTA_e6a54007-4c8a-4f52-a9eb-41bc55638983">1,279.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzgtMjMtMS0xLTA_5ac702e5-d086-4ffb-91d9-a8d4fa67fd5b">1,279.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2f98217bbb834e0f8ebd6c2398b7661d_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktNS0xLTEtMA_42f5e1ed-1613-4251-94e5-e412026cc662">4.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79a84661ca7648508fd93941bcbb997d_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktOS0xLTEtMA_9f05c2b5-186a-436a-b15d-d26c31ba0f5c">71.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79397f44d5c042f496ceeab9b494a03a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMTMtMS0xLTA_0b0c7eab-0ec4-4f34-960e-e8fb2bb5a3c7">1,208.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMTUtMS0xLTA_a8ba6ac1-9f95-4ec9-83d1-dd5eb3209b61">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMTctMS0xLTA_b68e96d0-30cb-4bc9-bfb1-f05692cdd03c">1,279.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i399ba008e6b14b85b6ac84920d61a3c7_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMTktMS0xLTA_50141fb1-8170-4287-9180-4a8fa43d2554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMjMtMS0xLTA_88b01fbb-20aa-4a35-8ab6-d90611cfaac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b33fe470a0f4f07ae856080b1a72e21_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTUtMS0xLTA_cf3c7bbb-a775-477b-89b0-7308da57de38">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTktMS0xLTA_cfc8aeb7-98d1-4991-a949-0f70513ba71b">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c8c0fefae64f87b0c7f553d3c884e9_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTEzLTEtMS0w_869e9f5e-9e2f-4f2b-91b3-29adde72841d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTE5LTEtMS0w_d27bd5e5-e2f2-4741-9242-ea7ff46186f5">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTIzLTEtMS0w_e14c7b66-b721-49b9-8317-f402f0ce0491">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b33fe470a0f4f07ae856080b1a72e21_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTUtMS0xLTA_3c9c1c87-8f6c-493c-880f-17a8fb7f7b28">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTktMS0xLTA_65be729a-a762-4487-a466-0c71a1d7c2fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59c8c0fefae64f87b0c7f553d3c884e9_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTEzLTEtMS0w_6ad377c5-2193-436a-a40a-0183c79f33bd">53.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTE5LTEtMS0w_30ac9815-e8f7-4bb7-bd75-f33ebe6da24e">53.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTIzLTEtMS0w_08234b98-9916-4c8e-9113-1b643358b9af">53.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation expense related to share-based payments</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEyLTktMS0xLTA_005553b8-08bc-4171-8aad-9fdac794ae3b">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEyLTE5LTEtMS0w_8f2340b9-74d5-43bb-ab30-8e9431b75d5c">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEyLTIzLTEtMS0w_f4a34f6d-403d-47c6-8537-98f94cda6b05">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzE1LTktMS0xLTE0NzMz_669ee8b9-14dc-48ed-80f1-4876ae3f458f">0.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzE1LTE5LTEtMS0xNDczMw_bdf5dd36-711b-4666-a805-d20432c1ada7">0.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzE1LTIzLTEtMS0xNDczMw_38450888-ef17-4bb7-be33-acfbccd8a382">0.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id652954848994c64a952bdd912f71f14_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTEtMS0xLTA_29cd5ffe-900d-4943-aec0-085d934c8478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id652954848994c64a952bdd912f71f14_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTMtMS0xLTA_d8ff432f-88ac-4d54-a6d6-c1f7e5f36db3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if56588187b87454685183cbffc3ada80_I20201231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTUtMS0xLTA_823532f9-2cd5-4fb9-92cf-9f09b2beaf3f">176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if56588187b87454685183cbffc3ada80_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTctMS0xLTA_b5633b01-1053-4435-8098-874dd1b4ddb9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e4e6dae85540218e42aba08c3a9ecc_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTktMS0xLTA_63ce514a-422a-4caa-88b1-a02a149cc1a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7957fd5108f041cf86733aef419c0487_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTExLTEtMS0w_b804ce9f-c924-422e-a6f9-41978432873b">299.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdeb7d5b926d493e962de8b221ba05e5_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTEzLTEtMS0w_ab7c2492-8550-482c-bba0-d7962d9740d5">13,976.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iccbf67b67a6f4ef8b20a95e69c600436_I20201231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTE1LTEtMS0w_0db8a8c4-c360-4a73-8546-3da8c842d0b9">23.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccbf67b67a6f4ef8b20a95e69c600436_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTE3LTEtMS0w_a799dbcb-ada9-4b31-98d0-dc6f8fd95ab2">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1a9b4290144caba8998988eecf9b58_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTE5LTEtMS0w_12c60f49-4698-4911-a1a0-4af6e0c069b2">10,700.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i004794513a2f4fcd8eace5db98fbe94d_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTIxLTEtMS0w_388daf79-76f3-4033-bb79-f3755feec8e9">14.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTIzLTEtMS0w_5ed4ac4a-da3f-4b01-a678-f978ed2e6a90">10,686.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.164%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMS0xLTEtMA_ef583f0f-beec-4596-96b5-c59651fc82bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMy0xLTEtMA_ad1e98e7-0668-4190-980e-34b52a828018">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fbbd190dd9349c684025d6612613087_I20181231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItNS0xLTEtMA_c1ede944-c5c2-48db-9c95-39d4809062c7">221.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbbd190dd9349c684025d6612613087_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItNy0xLTEtMA_0ff4814b-78ba-4619-af15-99a02da2e0df">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10bc4925779c4c62a721fcebc24cc43a_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItOS0xLTEtMA_8695d8f2-c139-43fc-b2e3-ce8200e6fc9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTEtMS0xLTA_dae4eeb5-7eda-442c-a15c-5f12d5f63186">240.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9ccd986ede408889b471271b8b92ab_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTMtMS0xLTA_6cdfe49d-679a-4cc9-a560-35a058889a24">16,257.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i71879223335b46f3bb3d2e9c89f29739_I20181231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTUtMS0xLTA_6932990a-d044-4fc2-b711-768064c5a0ee">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71879223335b46f3bb3d2e9c89f29739_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTctMS0xLTA_2b243290-f148-41ad-9a91-a7208ea2cc98">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0408f46008684d05830c8aaf3c8d10a9_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTktMS0xLTA_07f01686-881b-4f2c-9370-1abd19c38012">13,039.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1627e985e4343de929ab7dfd5658901_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMjEtMS0xLTA_6a4dbbfc-023a-4780-b8ae-0adba6d784e5">8.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMjMtMS0xLTA_d9b99a8e-8582-41ac-abe7-5d5f2d339d7b">13,031.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70263815613a400b92f377b89a761d52_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzMtMTMtMS0xLTA_375d88e1-b531-4f98-9a4d-31ea4457e3a2">5,888.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzMtMTktMS0xLTA_485b417c-b4af-4800-a972-0d51a0a8b4dc">5,888.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzMtMjMtMS0xLTA_fe1e728f-7a17-42ce-b8e1-0fd28c666ffb">5,888.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743aafca54fa41abb7393b53cca04663_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzQtMTEtMS0xLTA_ea90ce5a-8c9e-4e96-b0ba-124f2df4385c">105.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzQtMTktMS0xLTA_2ce38e9f-7500-4e74-bb0a-35f1e401efcb">105.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if23b90bc2339453c813e349dde6eb88c_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzQtMjEtMS0xLTA_2ef1327e-9ff0-4b04-97bb-5cd118545943">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzQtMjMtMS0xLTA_99778351-eaf0-4c7f-9990-7c2ed3de5bc0">104.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzUtMTktMS0xLTA_164faa2c-2e4c-4225-898a-d7993bf5c884">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if23b90bc2339453c813e349dde6eb88c_D20190101-20191231" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzUtMjEtMS0xLTA_da71c9a4-2f6b-4a6b-99a3-ef1dd00b7af4">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzUtMjMtMS0xLTA_2ef80d20-7889-4a69-9278-c85ad08bcff1">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzctMTUtMS0xLTA_3a00dafd-b552-4ad5-9c08-e69ee52a2c1e">14.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzctMTctMS0xLTA_851107dc-6e95-495a-a1e2-cda626d18d40">3,720.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5788dc676f14d319251454a02fc807d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzctMTktMS0xLTA_d8e045e9-663c-460d-98fa-0d35f3a6a76b">3,720.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzctMjMtMS0xLTA_bf12aca1-4f5a-46a1-b92f-7b2b0e598f03">3,720.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the March 2019 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i918c175a6348429f80750ffad3e51592_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtNS0xLTEtMA_879ee7ad-0d98-414a-96b1-0d1dfdaab3aa">14.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i918c175a6348429f80750ffad3e51592_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtNy0xLTEtMA_e3d94417-1784-4d16-bd8f-f14b74404e0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i561f5ec343c3430f81b526c7ba3bf33d_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtOS0xLTEtMA_a71ca01f-3251-4674-b281-a72d55dc6e0f">121.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i127bbeecda744fa68a10a6e33a60cd1a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMTMtMS0xLTA_22d9775d-bd25-4a2e-8da7-a4f8b01a855b">3,599.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMTUtMS0xLTA_c27bd346-a3ad-4ac2-9a19-4d2fd3650900">14.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMTctMS0xLTA_2d683fcb-5a8a-41da-b571-fabfda36bdce">3,720.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5788dc676f14d319251454a02fc807d_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMTktMS0xLTA_4d935214-2477-4137-909e-e5d1b279a656">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMjMtMS0xLTA_1709d07e-16ff-4a7b-a040-6e0fd4f5fd59">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if96513171bce497b9a51c54f048f8529_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzktMTUtMS0xLTA_564c8af5-e47a-4cfe-ac1f-78523c8007e9">8.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if96513171bce497b9a51c54f048f8529_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzktMTctMS0xLTA_2f75c3a4-5993-45ff-b74c-7f717c5a18f6">2,147.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77516ed4d6a7476c85c01147c2202ad8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzktMTktMS0xLTA_00b20804-fff2-42c4-93e2-4da025a0417e">2,147.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzktMjMtMS0xLTA_05597185-3777-4e46-a2f9-775c8aa4acc6">2,147.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic1a8269e77864460833b3ae44b188fbe_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTUtMS0xLTA_d60e559a-651b-49ab-a1e3-15fdfc81163d">8.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a8269e77864460833b3ae44b188fbe_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTctMS0xLTA_e00fc764-4f4f-4810-9427-7af59b6d3f67">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icff528a7cfce4bd8a0366f490246b62e_D20190101-20191231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTktMS0xLTA_11c36647-d4d1-486f-a2ff-c23da0055103">110.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id60b675c71ae45dcba471a7e7fe41934_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTEzLTEtMS0w_c8c39bff-d80f-4280-83f5-f58d3c8e1f60">2,036.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if96513171bce497b9a51c54f048f8529_D20190101-20191231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTE1LTEtMS0w_a0be81ff-9882-451f-ae30-6384e892a0eb">8.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if96513171bce497b9a51c54f048f8529_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTE3LTEtMS0w_32565517-e590-41fc-99e8-bbbd4b28f9ef">2,147.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77516ed4d6a7476c85c01147c2202ad8_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTE5LTEtMS0w_aed2259f-1ddd-446b-a55e-3e26a07cfa46">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTIzLTEtMS0w_5606dde9-c17f-406b-adc6-02960af91ab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTUtMS0xLTA_3180426e-1358-4c04-8e3a-3d8787852b8d">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTctMS0xLTA_df546d13-a892-4a78-8b8f-caeedd73629b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d567bbbce0486f8cfdae0a70a3f4ee_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTktMS0xLTA_e6bf00b2-7369-4498-a244-2a979bacc558">40.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTE5LTEtMS0w_0c08a876-c6b5-43ea-ab07-7198a7d056a4">40.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTIzLTEtMS0w_6cdad9be-1f48-4075-ad2e-af2d42258694">40.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTUtMS0xLTA_4e40a7d8-6145-4a4d-b9a6-c0c70c52ca3a">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTctMS0xLTA_9f322c7f-a6bb-4609-8321-9bd16d444432">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70263815613a400b92f377b89a761d52_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTEzLTEtMS0xNDc_93d98a0a-7134-4f62-a9e0-9cd47052e94d">53.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTE5LTEtMS0w_5721b31e-155c-4e99-babc-20fca467b6dd">53.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTIzLTEtMS0w_36435a32-4a61-4a68-a19d-918e5843f4e5">53.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d567bbbce0486f8cfdae0a70a3f4ee_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEzLTktMS0xLTA_1704913e-3c04-4119-bcfb-ad0746ca65cd">191.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEzLTE5LTEtMS0w_98ba6799-64a7-4bd8-a74f-89771154d2f8">191.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEzLTIzLTEtMS0w_7cde9fd8-2e7f-4c0b-ad81-ee07b5a5fb36">191.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idae041b402f34f1db7c9617616121bba_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTEtMS0xLTA_c69b4b5f-ea40-4305-9621-13b948791b0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae041b402f34f1db7c9617616121bba_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTMtMS0xLTA_7d79ef2b-eb74-4c97-9252-b21d4c1447b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c314d6d1f964bfe879cbff831677e6d_I20191231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTUtMS0xLTA_97762a7e-df6d-49b5-92d9-748ff28b665f">198.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c314d6d1f964bfe879cbff831677e6d_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTctMS0xLTA_b9e56e35-3de5-4c0f-b7a7-2e6086fe6c70">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b238312a99c4acda7452e34a406431c_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTktMS0xLTA_bbcff1df-c46e-4430-96aa-a86610cd6e1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8631cd953f3488583e5a99f0aa067ea_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTExLTEtMS0w_680897c9-9d7f-4b20-9a46-ac0604e43e64">135.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideb28add0da94e2984281d36c212a6b5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTEzLTEtMS0w_7cc4456d-1cbb-4dae-84c4-ae6cf59b94e9">16,455.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieafb8a83622d4c7d83aa7f731407ace6_I20191231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTE1LTEtMS0w_23cfc941-0d81-4313-90ad-16f023092ee5">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieafb8a83622d4c7d83aa7f731407ace6_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTE3LTEtMS0w_5311d5d2-40ad-47cd-a10a-b404e54f8fa2">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia32b478b02b043de86c4b4db94343ae7_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTE5LTEtMS0w_85d8fd1f-997f-45e4-aee6-2df8dcb1282b">13,343.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia04b4d5aa1794922b920009486d15ab9_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTIxLTEtMS0w_54d8c824-74dc-4c62-9bbf-cfd90e474c00">4.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTIzLTEtMS0w_97f8e8d4-1e4a-4232-80e5-81be9a0a0537">13,339.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of </a><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.164%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2017</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23b12db8472d48b2b53334bb866cc37b_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMS0xLTEtMA_e6bc581b-4803-4494-9246-066f2cef2ad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b12db8472d48b2b53334bb866cc37b_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMy0xLTEtMA_75de622d-7480-4d46-954c-29eb13427643">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6de8222bfb764bc7976ec9ac1b1fcfee_I20171231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItNS0xLTEtMA_657aae1f-f69f-4ce4-a5af-fe31a2c566da">235.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de8222bfb764bc7976ec9ac1b1fcfee_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItNy0xLTEtMA_2d04f6fd-09fe-4556-8771-46c5af042a37">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32099e94310245729c8234363676b11a_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItOS0xLTEtMA_9a0a79d6-83df-4e8d-880e-4cfd752451ba">97.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01ad07778ac849c8b2b4e37c57f5c8cc_I20171231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTEtMS0xLTA_0200f2f6-8498-4642-b6e3-34eb1a59288b">318.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e785004dde49f0a56829b6f56ed277_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTMtMS0xLTA_87a973b7-c3ae-4f99-a7a6-4d0954c293a1">15,810.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4ca3a2e6fcb04f20be394cdde7a54e82_I20171231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTUtMS0xLTA_a0d9e9c9-b4fb-4785-87ae-71f0e4246d67">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ca3a2e6fcb04f20be394cdde7a54e82_I20171231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTctMS0xLTA_5435908d-c2ea-49dc-b533-b1ba6ee3bc22">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878381e1afac4f80a13bd087ea6d9e3c_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTktMS0xLTA_a207a9b0-f506-4073-8745-cef0f374fea0">12,612.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb9c26e9c2e84acbaf8ec47d303849df_I20171231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMjEtMS0xLTA_30eed16d-b071-4d59-90be-de1f3618d488">14.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9925b2c3e594ae0812001969da2a99b_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMjMtMS0xLTA_7e19166c-4b4c-466c-8e03-5b11db24b928">12,598.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6054bf321ca4765a1d083cac2ace95d_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzMtMTMtMS0xLTA_964d916b-36f0-460f-869a-dba582027670">4,430.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzMtMTktMS0xLTA_c071d6fb-b218-434c-aa22-c3a9dc952921">4,430.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60249b902884484cb11d0cb33e879fff_D20180101-20181231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzMtMjEtMS0xLTA_f90dc29e-f74b-435c-b49c-20e56134cc50">43.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzMtMjMtMS0xLTA_3428b721-de58-4cf1-a5f8-47d5f06e69c7">4,474.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6cf3bb3d4e468189726437ef50fcc4_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzQtMTEtMS0xLTA_ceadda8c-6340-463c-8fbb-95d687793842">76.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzQtMTktMS0xLTA_f0af5b3d-139c-43d0-b75a-48d0f1bb62e2">76.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60249b902884484cb11d0cb33e879fff_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzQtMjEtMS0xLTA_7cd5df1c-5a22-40c5-87c8-65e70048c0fe">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzQtMjMtMS0xLTA_965db46e-57c2-40b8-b3a3-1d9d46af661b">76.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzUtMTktMS0xLTA_32a923d2-5668-4b65-875a-94ead912ff12">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60249b902884484cb11d0cb33e879fff_D20180101-20181231" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzUtMjEtMS0xLTA_3c956a60-7e9c-47f8-8610-460ac560c7f6">13.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="biib:Noncontrollinginterestincreasedecreaseother" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzUtMjMtMS0xLTA_f907af7f-fee5-4c6e-a4db-bc9cf4d1459b">13.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzYtMTktMS0xLTA_96cdb74b-5be5-49f8-af7a-cdd595cda473">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60249b902884484cb11d0cb33e879fff_D20180101-20181231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzYtMjEtMS0xLTA_494ddb35-c3ed-4370-9966-c26d7ca206eb">50.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzYtMjMtMS0xLTA_38f05d48-362b-4c0a-8e34-a58f66dfff19">50.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzctMTUtMS0xLTA_b860f7cb-0521-4e65-806e-2426171084f1">4.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzctMTctMS0xLTA_58f2f848-898a-4c63-9e07-f86c3902dd14">1,352.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6e22ca2059f4f898210fe8a9df07b93_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzctMTktMS0xLTA_3fa734bb-2f3f-487e-b23b-63cd773f4b9e">1,352.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzctMjMtMS0xLTA_1392a74a-4b36-4d55-80bb-64cf055e9a75">1,352.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie81db584ecd34c3fb0bcfcd6b6c8bef2_D20180101-20181231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtNS0xLTEtMA_1b3a786f-fba4-4cec-b4fe-296df1d22d1a">4.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81db584ecd34c3fb0bcfcd6b6c8bef2_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtNy0xLTEtMA_74fddc02-57a5-4d6e-84fe-c8d991c8fdca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i481a6d5bdbbe43a5980efa84e275da23_D20180101-20181231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtOS0xLTEtMA_6b4da7db-c269-4165-9458-3778aa72e4a1">92.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8450111dafb6479dad6f805a7b7d9e08_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMTMtMS0xLTA_0fc4b517-c6b8-40d2-9e90-4264b8540338">1,259.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMTUtMS0xLTA_808035ff-3459-4aa3-ab5d-15ecd083f4c7">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMTctMS0xLTA_f3b90551-ad87-41f8-9fb0-1de16f55b1e7">1,352.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e22ca2059f4f898210fe8a9df07b93_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMTktMS0xLTA_72211748-95c5-4401-bd4e-3aafcd7ab2ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMjMtMS0xLTA_9c8546cb-e9ff-434d-b45b-17c1179248d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzktMTUtMS0xLTA_35a6e638-fe7d-4c7f-91b0-ae2e21d75d08">10.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzktMTctMS0xLTA_ad877bef-0b2f-4f12-86c5-36edbed262e1">3,000.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i084deb1b42c44169a52d93eca76466ef_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzktMTktMS0xLTA_bcd74fed-ef17-46bf-8a68-57c73e0711a5">3,000.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzktMjMtMS0xLTA_07cda3c4-4bef-48f7-b7e5-aee37181146b">3,000.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib5d4919f13974879958994e93ea3e69e_D20180101-20181231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTUtMS0xLTIwNQ_27ba7549-0344-4401-9d57-2f9230711d46">10.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d4919f13974879958994e93ea3e69e_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTctMS0xLTIwNQ_0c4b7db5-563a-4714-bfa6-90ee574b9a5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1acabe726ab40d4b398592903594e20_D20180101-20181231" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTktMS0xLTIwNQ_8547ba76-dbab-4efb-824a-3c6e2da12d99">171.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i837a6587aeba49309a36ff845c583cc1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTEzLTEtMS0yMDU_1ca84c1d-004a-4391-adb8-320f20e600e5">2,828.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTE1LTEtMS0yMDU_0fe9b87e-a133-4d65-ad1d-ce2449c14161">10.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTE3LTEtMS0yMDU_ffcf4020-8af9-4a34-bd66-001c0aa6043d">3,000.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084deb1b42c44169a52d93eca76466ef_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTE5LTEtMS0yMzM1_2c9477fe-ac36-4b69-9b86-170a22d5e497">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTIzLTEtMS0yMzM1_577d6faa-8e33-4a7f-b245-6023e1b9992c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa3981c364664bbf965221342c3e8296_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTUtMS0xLTA_19aeff9b-cbd3-4778-9a71-571809ddb0c7">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa3981c364664bbf965221342c3e8296_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTctMS0xLTA_50444105-8102-45b7-8061-ab25c150617b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26657d5aeb394760be302cf4583f264d_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTktMS0xLTA_e94cd8a3-2d3e-4119-a72f-a7d4f603b3f3">41.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTE5LTEtMS0w_d55c5bc6-222f-4186-b889-c3c7969e20e3">41.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTIzLTEtMS0w_0d5bc2f0-0f02-444e-b799-8157ae711b69">41.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa3981c364664bbf965221342c3e8296_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTUtMS0xLTA_f8a00b2b-8f66-41e7-9daf-0d31f9516045">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa3981c364664bbf965221342c3e8296_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTctMS0xLTA_8d8c33b2-2181-47dd-9572-446a1506fbb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26657d5aeb394760be302cf4583f264d_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTktMS0xLTA_0c2df6d9-d813-462a-a7f5-4e3b743175ad">43.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTE5LTEtMS0w_3ce8ad74-81c2-4fdb-bcf0-00457557e0a4">43.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTIzLTEtMS0w_9b7398b5-182d-44fd-91f4-436148f4eabc">43.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation expense related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26657d5aeb394760be302cf4583f264d_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEyLTktMS0xLTA_15c6b168-60e1-4e8c-829f-5ff3e3d9e873">168.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEyLTE5LTEtMS0w_aa844d86-ae7b-4d68-8ed9-e18b73194146">168.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEyLTIzLTEtMS0w_de831df0-d1ac-41db-8ce7-8861ab445c94">168.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption of new accounting guidance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158387b1a5ea437bb6564f068f16da94_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEzLTExLTEtMS0xODQ_51d4ebb0-7483-4061-b470-f1bd4424189d">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8870b4b39a7c4f5db82e81c17a5045ae_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEzLTEzLTEtMS0xODQ_d3c72766-3faa-4e00-a09c-8238a8808666">104.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie609bb78211648bbb28efbdf966eede3_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEzLTE5LTEtMS0xODQ_16cdf586-fde8-41ac-833e-f7e0550ca2ab">106.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946db844720d4aa7917f3e015d7ad5f5_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEzLTIzLTEtMS0xODQ_8843c909-a768-4a11-9fd0-9326ebd8301c">106.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTEtMS0xLTA_b745bdf7-d07b-462a-b005-da4392c82e12">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTMtMS0xLTA_d614b71f-cef5-4f51-883c-cf46e9981a90">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fbbd190dd9349c684025d6612613087_I20181231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTUtMS0xLTA_d2c86544-59a6-4a79-b163-9736341dddb3">221.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fbbd190dd9349c684025d6612613087_I20181231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTctMS0xLTA_8182654e-2d6f-45f4-8308-8604f89a7a24">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10bc4925779c4c62a721fcebc24cc43a_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTktMS0xLTA_f335a532-431f-46ed-b38a-57af5c999295">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTExLTEtMS0w_3abc8fe4-7921-4898-8f7e-7a0838ca76e1">240.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9ccd986ede408889b471271b8b92ab_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTEzLTEtMS0w_68054bec-3c30-4832-8d70-3658e02a921e">16,257.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i71879223335b46f3bb3d2e9c89f29739_I20181231" decimals="-5" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTE1LTEtMS0w_99f49d47-385e-4b2a-a62c-09dec8081228">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71879223335b46f3bb3d2e9c89f29739_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTE3LTEtMS0w_176e9862-7127-4ef3-83c6-4ea9ba457bff">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0408f46008684d05830c8aaf3c8d10a9_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTE5LTEtMS0w_902f12b3-6712-4b5f-b969-0b310f9b1d26">13,039.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1627e985e4343de929ab7dfd5658901_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTIxLTEtMS0w_364379e7-cefc-4515-8868-1a7eb5494041">8.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTIzLTEtMS0w_2f872f9b-e059-47b0-b188-f636e6fd83c8">13,031.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_235"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_238"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5NDA2_3e3ba89d-5044-41b7-98a9-e1f0f50ca0ac" continuedAt="i954bb6bc04ea4219916e59a9971421be" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i954bb6bc04ea4219916e59a9971421be" continuedAt="idb972b2ff8cd4571ab55e56558118921"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:BusinessOverviewPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjM0_b5a8f45b-dd72-4290-ad89-1035b37ea196" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODY3OTk_60896451-0a1c-4fd9-94c5-d6bf9accd589">two</ix:nonFraction> potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjQ1_a9400040-e0b0-493c-a8f6-c1f3849335d9" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzM0Mjg_28af3133-99b2-4f88-b5fd-f92b3f0c6dcd">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="idb972b2ff8cd4571ab55e56558118921" continuedAt="i7cf5b4491b89460088b85d808d804e0b"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjY2_59972f05-e39d-4198-a149-21d25a4a3869" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU0OTc1NTgyMTM1NzM_259bf04e-96db-4452-8236-a4c0f645de16" continuedAt="i20e4bf3b3af64f4aa9752b5d6bc98bbf" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This standard became effective for us on January 1, 2018, and was adopted using the modified retrospective method. The adoption of this standard as of January 1, 2018, did not change our revenue recognition.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i7cf5b4491b89460088b85d808d804e0b" continuedAt="i3e670024f095415ca716b7022a40c667"><ix:continuation id="i20e4bf3b3af64f4aa9752b5d6bc98bbf" continuedAt="i07069c0afd6c4e0894750288c4dd5014"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the coverage patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Pharmacy rebates represent our estimated obligations resulting from contractual commitments to sell products to specific pharmacies. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from contracted discounts on product purchased or product dispensed. The calculation of the accrual for these rebates is based on an </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i3e670024f095415ca716b7022a40c667" continuedAt="i55384e503c7b44d8860b3b0bd986c014"><ix:continuation id="i07069c0afd6c4e0894750288c4dd5014" continuedAt="i4cbfce5f93c24573936a831263b88576"><div style="margin-top:9pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimate of the pharmacy&#8217;s buying or dispensing patterns and the resulting applicable contractual rebate rate(s) to be earned over the contractual period.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration with Genentech is within the scope of ASC 808, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs consist of:</span></div><div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</span></div><div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#160;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech and the Roche Group. Pre-tax co-promotion profits consist of net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA include estimates that are based on information received from Genentech and the Roche Group. These estimates are subject to change and actual results may differ. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize royalty revenues on sales of OCREVUS based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our relationship with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize royalty revenues related to sales by our licensees of products covered under patents that we own. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i55384e503c7b44d8860b3b0bd986c014" continuedAt="i76f0f71b733949b98c3d13840dceca54"><ix:continuation id="i4cbfce5f93c24573936a831263b88576"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Corporate Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjQ5_7ad44380-f86c-4523-bd1c-ef79a6d1b75c" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;1</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;3</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Liabilities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzY0_2e5d5272-8e36-442d-b427-eebcb24e1835" escape="true">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of December&#160;31, 2020 and 2019, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i76f0f71b733949b98c3d13840dceca54" continuedAt="i4c56c82a5d89460a987292643075c88b"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjI4_ec6af531-39af-4b3e-aa0a-5ae37f7d2374" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within <ix:nonNumeric contextRef="ic69589c021a84ef3b51246299f3819f4_D20200101-20201231" format="ixt-sec:durday" name="biib:PaymentTermsOfAccountsReceivable" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4MDc_cf128f8e-9d6e-4752-9288-9a0aec9b4a4e">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i6ece1a557c614598b419f009a522970e_D20200101-20201231" format="ixt-sec:durday" name="biib:PaymentTermsOfAccountsReceivable" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4MTM_71f63176-744d-44cd-ad86-bc1a7de79347">90</ix:nonNumeric> days.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzQ4_c591bf7e-2396-4d4a-a6e3-c5d7eb84bded" continuedAt="ied244fba73d24c0eae75d7b1d80e41cf" escape="true">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ied244fba73d24c0eae75d7b1d80e41cf">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Other Investments</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mzk1_d59ebbb5-1679-4b6d-8809-e3030f6d029c" continuedAt="i41cfa59e817946d49ff3b0fcb5fc2789" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net on a specific identification basis.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Equity Securities and Venture Capital Funds</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i4c56c82a5d89460a987292643075c88b" continuedAt="idde714536daa4ffcb2cabf6d1dd1b635"><ix:continuation id="i41cfa59e817946d49ff3b0fcb5fc2789"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Marketable Equity Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluating Marketable Debt Securities for Other-than-Temporary Impairments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method of Accounting</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mjc2_b9c1a171-1aa0-4654-b5e6-85427aeae4fc" escape="true">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjA3_0fe9c434-2d1a-467b-b0b5-413193359619" continuedAt="ief27d65151ec454c91d008b6c9321b1c" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalization of Inventory Costs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="idde714536daa4ffcb2cabf6d1dd1b635" continuedAt="i502b3fbcd58f4ac198834399fd8cb77f"><ix:continuation id="ief27d65151ec454c91d008b6c9321b1c"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="ic0b527baa2064e4abdfd753f227e1770_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryCapitalizedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzI3NDg3NzkxNTU2NzQ_2717c0de-c735-4a8f-bc7c-3ac471158acc">93.8</ix:nonFraction>&#160;million of pre-launch inventory for aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease that we are developing in collaboration with Eisai Co., Ltd. (Eisai). If aducanumab does not receive regulatory approval in the U.S., we would expense this inventory as research and development expense and, under the terms of our collaboration agreement with Eisai to jointly develop and commercialize aducanumab, Eisai would reimburse us for <ix:nonFraction unitRef="number" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="3" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1OTczNTY_6c061fe6-9f12-4a31-a184-dd1c57d61518">45.0</ix:nonFraction>% of the costs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obsolescence and Unmarketable Inventory</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mzky_2f829e09-ec0a-4385-8235-4bf22424b151" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4NDA_d52adc0a-d056-48aa-8b93-a252ffbfe552">three</span> to <ix:nonNumeric contextRef="i1b4148f6f0e64fcc8d46dde21febd1df_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4MzU_698569d9-3710-4191-8984-92812aa8260e">five years</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU0OTc1NTgyMTM1NzQ_4b018080-ba44-4a95-8956-6d810b8be49e" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 to 40&#160;years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the useful life or the term of the respective lease</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and Fixtures</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7&#160;years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 20&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer&#160;Software&#160;and&#160;Hardware</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5&#160;years</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i502b3fbcd58f4ac198834399fd8cb77f" continuedAt="i07d0f525b48e408c831cc637d9f8bd4e"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzIw_2be119f9-856d-4f39-bb0c-02b8a242a8d1" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016 the FASB issued ASU No. 2016-02, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-10, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-11, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Targeted Improvements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-20, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Narrow-Scope Improvement for Lessors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASU No. 2019-01, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Codification Improvements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately $<ix:nonFraction unitRef="usd" contextRef="i4e23f9e905c04daca8cae6b8673c5e1f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzM2ODc3_39757ca5-c5d8-409d-9e83-4601966959bf">463.0</ix:nonFraction> million and a corresponding operating lease liability of approximately $<ix:nonFraction unitRef="usd" contextRef="i4e23f9e905c04daca8cae6b8673c5e1f_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzM2OTQz_d498f1e3-d324-45a9-b8ec-7ba2fa2a11cd">526.0</ix:nonFraction> million, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the adoption of the new leasing standards, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i07d0f525b48e408c831cc637d9f8bd4e" continuedAt="ied54d03d89e346c8868823d794510441"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjYw_4a896550-497b-4920-b0af-ca144a75dc6a" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include other amounts related to our other marketed products and programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to trademarks, trade names and IPR&amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-process Research and Development (IPR&amp;D)</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzIz_f2e39568-67d1-4926-8c62-a989bc2c18ec" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ied54d03d89e346c8868823d794510441" continuedAt="i607bc3af326e491c8af6337c92fffd8e"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjIx_e256d958-0834-4107-9f0e-d918dbc803ca" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 24, Segment Information,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements, we operate in <ix:nonFraction unitRef="segment" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODY4MDc_cf82a576-3514-4296-9f1e-9b76339dc95d">one</ix:nonFraction> operating segment, which is our only reporting unit.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjAw_d8d95880-bef7-4447-9ceb-f162f3579d77" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mzgz_656d3064-fb07-42ce-b075-9f3f7b90cd17" continuedAt="i5df958310a84414994167afbb400dbd6" escape="true">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5df958310a84414994167afbb400dbd6">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjAx_904f0851-431c-4a37-8a5d-078446ba52dd" continuedAt="i7cf565cad872460e84a4169a57753451" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow and Fair Value Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i607bc3af326e491c8af6337c92fffd8e" continuedAt="ie8249d8e7e0f45b488bc3346388de51f"><ix:continuation id="i7cf565cad872460e84a4169a57753451"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our derivative instruments and hedging activities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Derivative Instruments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currencies</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzEw_d6a6690e-470b-49ff-8fa4-e7ee03962473" escape="true">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Cost of Sales</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:RoyaltyCostofSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5NDE5_16d7c647-61d0-4247-9e2d-27a37dfebe82" escape="true">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Share-Based Compensation</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjE1_1fd444c1-3dc1-4094-ba01-be31f3bc7f82" continuedAt="ifc348487a4364c5a8fdd84d491c3b190" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ie8249d8e7e0f45b488bc3346388de51f" continuedAt="i081097a4274747eca0d6d3f876c004aa"><ix:continuation id="ifc348487a4364c5a8fdd84d491c3b190"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzA0_35a35adf-9f89-4480-8104-913d94e90d2a" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5NDA1_d34e3c74-a0c0-408c-bf04-3f0c45dd1ee1" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. For the years ended December&#160;31, 2020, 2019 and 2018, advertising costs totaled $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU5NDMw_8b23c5cf-a4b7-46e3-90c1-b446a5962c57">111.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU5NDM0_6ddca70c-016d-489d-bf2c-ced1d108b36f">79.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU5NDQx_93651b4a-d5cb-4c25-b044-ca49e81b37fb">90.2</ix:nonFraction> million, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i081097a4274747eca0d6d3f876c004aa" continuedAt="i9a6a6f016a1843ecba7d0f3cf159bdf1"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mjg0_3c6cf1a0-aaed-48c5-a38d-f6db15a5b904" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016 the FASB issued ASU No. 2016-16,&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="id202dc9d694b43e7bb188183306ef1be_I20171231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzYxMjgw_9fcc3ae3-1973-4a83-bdb8-132f4918f0da">0.5</ix:nonFraction> billion, offset by a corresponding net increase to retained earnings of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i62315bf96a414f8f8bf19b192b4c0951_I20171231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzYxMzYx_00a76af0-39dd-4079-b424-f60077cde2a3">0.5</ix:nonFraction> billion. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;$<ix:nonFraction unitRef="usd" contextRef="i8ed6ef3bd55540debba7f93c76913164_I20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzYxNTMw_99760498-26fd-4739-b339-416dde29066e">0.4</ix:nonFraction> billion&#160;with a corresponding reduction to our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions using a &#8220;more likely than not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzE2_96c1cd8a-c252-41fc-bdcb-f9928ea4a1d7" escape="true">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. Legal costs associated with legal proceedings are expensed when incurred.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjQw_f28e0c4f-365c-494f-97c6-21882e2074dc" escape="true">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU0OTc1NTgyMTM1NzI_dfc745a3-2bcb-4ce9-a890-06d04be3d35d" continuedAt="i48ce17a0d56540939fbb48f300fae32a" escape="true">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i9a6a6f016a1843ecba7d0f3cf159bdf1" continuedAt="i61427e961ead4b4d8cfda0340a17e496"><ix:continuation id="i48ce17a0d56540939fbb48f300fae32a" continuedAt="i15e161ffd62d4630a2a340005cf0e131"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards did not have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard did not have a material impact on our disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This standard makes targeted improvements for collaborative arrangements as follows: </span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Adds unit-of-account guidance to ASC 808, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i61427e961ead4b4d8cfda0340a17e496"><ix:continuation id="i15e161ffd62d4630a2a340005cf0e131"><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.</span></div></ix:continuation></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_244"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzg5NTE_a686c6aa-3b7c-442c-a906-bfb4f7ac4a43" continuedAt="i687e146a5b3e450a8feebf95485fbfcb" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="i687e146a5b3e450a8feebf95485fbfcb" continuedAt="i27bf5f39f4594e7c87cd9a59093c508a"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson&#8217;s disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia457a1bccc154fcd8ff6932b1456cb83_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEwOTk1MTE2NDQzMjU_39730354-366c-4a60-937a-dd2c89d05e60">75.0</ix:nonFraction>&#160;million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $<ix:nonFraction unitRef="usd" contextRef="ia457a1bccc154fcd8ff6932b1456cb83_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEwOTk1MTE2NDQzNDA_0531ea6c-aa5a-4fb7-99ee-961954ec1c2e">635.0</ix:nonFraction>&#160;million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Nightstar Therapeutics plc</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added <ix:nonFraction unitRef="product" contextRef="i74d25f7562934bc8a1eebaf7750912d2_D20190601-20190630" decimals="INF" format="ixt-sec:numwordsen" name="biib:ClinicalAssetsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzQzOTgwNDY1Mjc3MDM_4e3efba6-2183-4876-9c72-853d02d7a437">two</ix:nonFraction> mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the acquisition, we paid NST shareholders $<ix:nonFraction unitRef="usdPerShare" contextRef="ibef78125dd7d4a94a4efe455cc442105_I20190607" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzk1Ng_bc60674e-cbff-4490-b998-b33e5222fc32">25.50</ix:nonFraction> in cash for each issued and outstanding NST share, which totaled $<ix:nonFraction unitRef="usd" contextRef="i931745da9c9741a7bcb5a4292c51f87a_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEwMjQ_7778c170-0ef3-4569-ac47-386165ea2bf6">847.6</ix:nonFraction> million. In addition, we paid $<ix:nonFraction unitRef="usd" contextRef="i931745da9c9741a7bcb5a4292c51f87a_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEwNDk_e5f7895e-1282-464a-b9fe-ae5dccd883b7">4.6</ix:nonFraction> million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was $<ix:nonFraction unitRef="usd" contextRef="i9f95102445b94a5183bbd60ea00497d5_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEyOTU_f57741b5-7d74-424f-9ef4-7d24b0d1c3ce">26.2</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ib0b20812b1ae4a52b980e45bc1c13af9_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEzMDg_3286c908-e46f-44a3-978f-7e9617b455ba">18.4</ix:nonFraction> million was recognized as a charge to selling, general and administrative expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="i675123ee33df46f18f7d302db7babd89_D20190601-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzE0MDQ_1dc1afff-e60b-46b0-83de-a1f69ecfd540">7.8</ix:nonFraction> million as a charge to research and development expense in our consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of <ix:nonFraction unitRef="number" contextRef="ibef78125dd7d4a94a4efe455cc442105_I20190607" decimals="INF" name="biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzIxMjA_d0ca0f64-2da1-4129-8089-7bb6861808a8">12.5</ix:nonFraction>%. We recorded IPR&amp;D assets for BIIB111 and BIIB112 at their initial fair values of $<ix:nonFraction unitRef="usd" contextRef="i12ed3b5c3c244392982bf3e4a342675d_I20190607" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzIyNDE_0f51b0ce-63db-4b0b-b7e8-2b071bd6884f">480.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b0a4756e001463da2b40b89dfd99ab3_I20190607" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzIzMTA_c5bedb9e-550f-4ada-8732-a35055dcfa50">220.0</ix:nonFraction> million, respectively. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reco</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gnized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for GILTI. Goodwill that is tax deductible for GILTI purposes is approximately $<ix:nonFraction unitRef="usd" contextRef="ibef78125dd7d4a94a4efe455cc442105_I20190607" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzMzMDg_880d2913-7eb5-46e2-95e8-51ed9998597c">60.9</ix:nonFraction> million as of December 31, 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i27bf5f39f4594e7c87cd9a59093c508a" continuedAt="i22b42757e3064506b1fffc3a6e04f469"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our consolidated statements of income. Subsequent to June 7, 2019, the acquisition date, our results of operations include the results of operations of NST.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB100 Acquisition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018 we acquired BIIB100 (XP01 inhibitor) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 investigational oral compound for the potential treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i217e491a4a2945fda8b6a3fb6e69f33c_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzQyNjM_9fe5e89b-d5da-488f-b97e-0d6d16d968e1">10.0</ix:nonFraction> million to Karyopharm, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB100 had not yet reached technological feasibility. We may also pay Karyopharm up to $<ix:nonFraction unitRef="usd" contextRef="ic3ba7bb298ba4551bfaf50b04a063a19_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzQ0NTA_6710f79e-291e-4d6d-b3e2-147239c035ec">207.0</ix:nonFraction> million in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB104 Acquisition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018 we acquired BIIB104 (AMPA) from Pfizer. BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0826dcdf451640cfa9e62b8a90ea7c7c_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzUyMjI_c707b1f1-893e-4bcc-8f22-d781a328de39">75.0</ix:nonFraction> million to Pfizer, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB104 had not yet reached technological feasibility. We may also pay Pfizer up to $<ix:nonFraction unitRef="usd" contextRef="iefe928ba270d49608bb021eb1ec31bd8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzU0MDE_a59e64e4-e1fb-4754-8554-2a2e6e32c389">515.0</ix:nonFraction> million in total development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB110 Acquisition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 we acquired BIIB110 (ActRIIA/B ligand trap) and ALG-802 from AliveGen Inc. (AliveGen).&#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. </span></div></ix:continuation><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i22b42757e3064506b1fffc3a6e04f469">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="if38b01edc61441248c76861d6096cd34_D20180701-20180730" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzczNDI_f833d29f-1da1-46f6-8e97-eec4a9d1ec5c">27.5</ix:nonFraction> million to AliveGen, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB110 had not yet reached technological feasibility. We may also pay AliveGen up to $<ix:nonFraction unitRef="usd" contextRef="i5655172610c049b7b1d99d51a603c7f4_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzc1MjU_d33d2298-286d-470c-b117-5287a74a652b">535.0</ix:nonFraction> million in additional development and commercialization milestones.</ix:continuation> </span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_247"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzM0OTM_b1398559-a71d-43c6-b308-cb5133ec1f7d" continuedAt="i3ba9bf784ecf4f1b857008e65418c452" escape="true">Divestitures</ix:nonNumeric></span></div><ix:continuation id="i3ba9bf784ecf4f1b857008e65418c452" continuedAt="ic0c3ae3f36d2446f8b262135f538f19c"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="ida412b4bccf941a7af64620b69dcf1ef_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzMzOQ_b10e716e-6e10-47b5-bb95-4b07599dad62">881.9</ix:nonFraction> million in cash, which may be adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ic0c3ae3f36d2446f8b262135f538f19c"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, we recognized a total net loss of approximately $<ix:nonFraction unitRef="usd" contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzIwOTc_6c4ba329-9d99-48b2-9b4e-40d7732533aa">124.2</ix:nonFraction> million related to the transaction in our consolidated statements of income. This loss included a pre-tax loss of $<ix:nonFraction unitRef="usd" contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzIxNzk_f85438b9-a7d3-466c-b322-17935072b662">55.3</ix:nonFraction> million, which was recorded in loss on divestiture of Hiller&#248;d, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately $<ix:nonFraction unitRef="usd" contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzI0NzY_17622505-1878-4f80-a8cd-03fc4cb28fb6">11.2</ix:nonFraction> million and our estimate of the fair value of adverse commitments of approximately $<ix:nonFraction unitRef="usd" contextRef="i7ae2c3b5bd774a9bb73adaf4ac185c0f_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzI1NTY_a78b8dd8-3a7d-4cf8-8ee8-36c8781ccd48">74.0</ix:nonFraction> million, primarily associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. We also recorded a tax expense of $<ix:nonFraction unitRef="usd" contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzI4MDg_1ea877b7-eb9d-4bee-8957-63fd4e10b864">68.9</ix:nonFraction> million related to this transaction.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the closing of this transaction, we sold to FUJIFILM $<ix:nonFraction unitRef="usd" contextRef="i2e9e587add174faba8df37c45bf81a84_I20190831" decimals="-5" format="ixt:numdotdecimal" name="biib:InventoryrawmaterialssoldtoFUJIFILM" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzEwOTk1MTE2MzI2MTg_f3070b7c-9d6e-4f94-85fa-5d048d7296e7">41.8</ix:nonFraction> million of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we reduced our estimate of the fair value of the adverse commitment associated with the guarantee of future batch production by approximately $<ix:nonFraction unitRef="usd" contextRef="i6599810683224f4f8d5b5a4cec91c8ab_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PurchaseCommitmentReductionOfAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzEwOTk1MTE2MzIzMTY_82569bf4-5249-459e-b563-886230b6eb15">62.0</ix:nonFraction>&#160;million based on our current manufacturing forecasts. Additionally, we recorded a reduction to our pre-tax loss of approximately $<ix:nonFraction unitRef="usd" contextRef="i6599810683224f4f8d5b5a4cec91c8ab_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzEwOTk1MTE2MzIzMDE_f5bc465c-0653-4def-bdf9-ef07b5217610">30.5</ix:nonFraction>&#160;million due to a refund of interest paid associated with a tax matter.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the fair value of the adverse commitments is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_250"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NDA_9377a03a-39ab-441c-b6b9-5f61c5fc5677" continuedAt="i255da0a1b83248ddb76bbefd18be5580" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="i255da0a1b83248ddb76bbefd18be5580" continuedAt="ibb3c5f3bb2fe42a58692c5fcaa53db29"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NDQ_069a296d-09c5-4543-842d-f9069094bfdb" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by product are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a89db2076b46d08a583b581aa591ef_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMS0xLTEtMA_764a1af1-625f-403f-a56d-04e6a4ba8fcd">2,742.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ec4e78cdf14e27b10a96f705b49b62_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMy0xLTEtMA_37a7c0f4-eaa1-4823-b45f-ac6c55593e5d">1,163.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c7c39b59484f68a74bc30138f093c8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtNS0xLTEtMA_8c31f0c5-b44c-4615-b66c-3b798b492e3c">3,905.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8bc356d23184fcebc37ba9a22520399_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtNy0xLTEtMA_a42169fe-9e4e-4764-b760-846b7ff9e371">3,312.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9f2c1d75d0244adbaf0ce60ba6f10c6_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtOS0xLTEtMA_fb1b50a7-1429-4c02-af1f-ea0384650de2">1,126.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4671dcaaccbb4c73bc88e30c9c3ef796_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMTEtMS0xLTA_cf1b9545-0dc3-492e-8c8d-7e75676b8b09">4,438.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611243e9e12c42aa8073bc846cf26e10_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMTMtMS0xLTA_4e619517-1ec1-4fc1-8c97-aec366076b47">3,253.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89219f9fbe1b4c1dbf921ccb2d9beab4_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMTUtMS0xLTA_bb3a58fa-813b-459f-9145-b8264bb02a7a">1,020.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d646b3f2acc46cfa9c025734b83a62d_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMTctMS0xLTA_c327372a-710a-4a97-9817-9c00ebe6dbd6">4,274.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676dac9dfca9459aa08e07ccbde07b0d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMS0xLTEtMA_4862dabd-3164-43e7-90af-17b9dfbcb00e">1,273.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38907cded92a4460972fcfcc8fc9a8e6_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMy0xLTEtMA_761009a0-9d2b-4d54-a1b5-f07d94259c62">604.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0479de2c47942988bc6c58b22051c05_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtNS0xLTEtMA_1ddce796-d666-45c5-a3c2-d3a1b941a0ae">1,877.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i239b75ed62774dddb59a70525b80aa50_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtNy0xLTEtMA_77c8e186-7af7-4842-93e6-6acee6b8748e">1,426.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ad45c8aa37643dda100435c30ec9812_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtOS0xLTEtMA_37995d0e-0986-4481-a0ce-9d8422f6e0a5">675.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie627c15061db491694d9896f93024ce7_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMTEtMS0xLTA_020cf5e5-6c01-4e09-8a09-46c7800b7943">2,101.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808ab222eb14472a9a5315190f9d73f9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMTMtMS0xLTA_540a8738-caa4-479d-90f9-c31748d136b9">1,668.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a5bf5f3c2f4bbfb702fcd685c5350f_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMTUtMS0xLTA_925b53fd-9daf-41f0-91c6-8ecd44d011dd">694.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdcf0cf7d9d84f1b9a94c5e3ddfaf245_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMTctMS0xLTA_3742db96-54b6-4383-9587-e2df648391e0">2,363.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04860cd441c6444f8d0547cddbe88ec1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMS0xLTEtMA_61e3f0a7-347d-4685-a3ed-6be8cb829b16">1,096.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef7c311e0124c438791428e3b4b41a4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMy0xLTEtMA_345f1f74-c72f-4609-8010-0c1dabcb3c7d">849.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc945d8f6294b06ab322c83d51a8139_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtNS0xLTEtMA_adb077bb-1c8b-4279-8b2e-92286e5c5b60">1,946.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e8798dae8a4b08812a89a53e77047c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtNy0xLTEtMA_549d9958-b61d-49e5-9f5e-c90483c2b953">1,041.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ac014fbb4e4c6db8de2f58e8127e65_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtOS0xLTEtMA_8f54e5b3-cf16-4add-955d-d844501706d7">850.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e79a9c192ab4345a8831a1ec2ea4c7b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMTEtMS0xLTA_ed16613a-a131-4feb-be5a-310321d5c781">1,892.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2acaf2f4edd94d2aa5d30476174c8ff1_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMTMtMS0xLTA_3ac78977-439e-447c-84c6-c60f57ae1a83">1,025.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9161ee6ab1b24fa0a4b4fb0e50c29fab_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMTUtMS0xLTA_84d9ca70-eaf5-4b0f-8731-82e5ca0f5a1c">839.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc147b15e5c42138dac645bea65a6e3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMTctMS0xLTA_fd8e9f08-c5a4-4849-a9c9-efb24b5ad06f">1,864.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51cecc234a1c499e81996ec359a83235_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMS0xLTEtMA_6ddeb7ae-9dbc-4422-939b-5dd5ba9d2bdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc67fa6b68546999e25a409116223a5_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMy0xLTEtMA_c42b42de-2611-48da-88af-dc3190a6a7b7">103.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6055a732a3c42339f265cbba96a4237_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtNS0xLTEtMA_8085cfef-146a-409e-9194-8ad7be88d200">103.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8355cc290044cc90da4d1eb56c12fe_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtNy0xLTEtMA_e43c32b0-0a71-49aa-9778-d660f7dc96be">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic228d3e552df4464b29306fc6585aa80_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtOS0xLTEtMA_ee654e49-9d6b-40bf-b709-732fe0a364bc">97.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25bb90461ed2438a995263720a6ed66d_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMTEtMS0xLTA_f392bbd6-ac18-4869-9ca8-aee948887abf">97.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793c32241e6a44aa9d8cbcf846f1608e_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMTMtMS0xLTA_258156f3-36bd-41ee-8c5b-44ac3f49fa06">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21e1cbb7e7fd41b196a67213d407f8da_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMTUtMS0xLTA_49b33b9b-d9a6-42a0-a9c3-fda89179fb63">92.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7dc62500324422c8b3e284eaa458c65_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMTctMS0xLTA_0bdd13ff-e874-42d3-aac0-2a2500e9b8af">92.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZINBRYTA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3153e9337f7f46b180a951e086f83f04_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMS0xLTEtMA_b8ce3e19-c50d-4d12-85f9-cbace98e57e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30a842196f14402bb07dc592bab78e7_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMy0xLTEtMA_0fd8706d-84b9-4821-942d-6966b5a4124c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0009c1183e6246eeb2ee54a841d184b3_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktNS0xLTEtMA_7c01e63c-567c-48d0-9d66-6a5528b326b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea2097d09a44a509b495c405a069070_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktNy0xLTEtMA_66b6166a-cd3e-4575-98e2-11abd93e6954">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd129491fd544708255c0bf9443922c_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktOS0xLTEtMA_c0e9bae6-e727-484b-8bf4-83968d34a421">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d69c93cae04d3491b6586590a557f3_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMTEtMS0xLTA_be2f2f9c-358d-4ad2-b38a-75ef1fed0d7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ee1ffeca9640ecb4a25fa543737c80_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMTMtMS0xLTA_569f869f-157a-4754-8c7a-d2c02f2ac88a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92af91a220a14e519e257472f7b4627c_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMTUtMS0xLTA_fde52ed3-5591-4e45-838d-af9b43183dc4">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7dc974c8cf545aaa99c23d6995ccf0e_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMTctMS0xLTA_8a107742-3c22-46c3-b125-95c6dda5582a">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b5853b0a7b4b75b8a727674c5976cd_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTEtMS0xLTA_4ef8447f-c383-4d2a-bb25-80ed01d3f2d1">5,112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6420df982c54462fac44de3494b1078a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTMtMS0xLTA_49156896-4008-4856-897a-adf116d596b9">2,719.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if92992eed3334e24956317197eb6249d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTUtMS0xLTA_592ca3a8-a344-42cd-bed8-b086370bc136">7,832.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe618b1b7444265baadef360f6cfe7f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTctMS0xLTA_6425a6c7-e330-48a6-baba-10dd1a7bb337">5,780.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3274395ada7440579bbf98e82e662536_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTktMS0xLTA_bb5e8faa-ab08-4469-8929-d391c72a08ba">2,748.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4163b71d3ebf4640b1af4d523043b9d5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTExLTEtMS0w_646540a7-26ff-4689-8de6-cfcdcc065fee">8,529.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b1f3407fd84deab1332035a3a31964_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTEzLTEtMS0w_0e5faee1-595f-4d94-bb2c-08b20a505dc2">5,946.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f67a8c0aea4ef7ba8c99f1f5292a0e_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTE1LTEtMS0w_c819ec60-2f58-484b-a0bf-9a040974b70c">2,648.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fbdc5541c854505baa5fe73b8b9fb16_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTE3LTEtMS0w_0fa396e1-cdcb-4e6e-8b0a-db3943fcbc36">8,595.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic369938897d44097803fd74cc0bf646d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTEtMS0xLTA_93906e60-bdae-4a41-af44-24d5c0b05f1a">787.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7d190fad4b4287ba2080a56db09bb6_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTMtMS0xLTA_2ef82cd8-0d54-4bec-945e-a460e2d987d4">1,264.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e67ce0006534c9d90964417d4f29f9a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTUtMS0xLTA_20641709-b1ba-4ea7-ac84-bf6ebf0d0a82">2,052.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8cbfde1864b4ae69989d769e587d576_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTctMS0xLTA_0b80143e-22cd-4264-b9ce-5e1f536cfd9e">933.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85145d7d92464b108b60ca4e887113f9_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTktMS0xLTA_96ac0b28-dec1-4961-b66b-50b901a3bcdb">1,163.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2352931d6f4d8980b86773c3e2523a_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTExLTEtMS0w_abd0bb54-6479-420d-a997-2537bdc7fd67">2,097.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7979d3870a264dd0a1528aafe4e9a00c_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTEzLTEtMS0w_c6d4cdd0-6465-4833-bc0b-966e266a4a79">854.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib08fe27eb1d045de9c81dadf75845b7e_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTE1LTEtMS0w_6472ffb0-4de6-4e92-9333-8265db4542cf">870.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3882c6c7e44816881d6d48c711cdb8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTE3LTEtMS0w_95247915-0e8d-42ef-810f-1c806bb98121">1,724.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9ada749a894e289113c4d61f405d38_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTEtMS0xLTA_90978123-1c48-4cef-b1e1-115af2db40ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie042a2edd31046aca7dde1c59f969ab3_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTMtMS0xLTA_2739814d-a4f3-4ca0-a4c8-96f9bcfb3b15">481.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a0d587886c43a485b4a1beaf2cb9a7_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTUtMS0xLTA_bb369f5e-2bdd-401d-be35-8f71924c2c2f">481.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5ea019d4fd4c2f897fe2644f7c7ed2_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTctMS0xLTA_38814209-49c1-4719-871e-5307cd222e19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef4f9926f8d4814a9d013cf79e963e9_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTktMS0xLTA_9ec6f78d-de9f-4fe2-9a1a-1281ec6d7398">486.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d98281f667b40a595d97292a3d7d21e_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTExLTEtMS0w_400a93bc-8de3-4035-8945-f89ad8ba1fd7">486.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181d0ab423b0468a8a6f8b139f105d1d_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTEzLTEtMS0w_e6927094-cb87-4d6a-8af7-b1abea55c2de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c81e1552b61450e83a94056dc340dbc_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTE1LTEtMS0w_861e5298-eaca-46b4-b896-e77b8d76b768">485.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebf7dfae7004c2da140bd5817f77ab2_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTE3LTEtMS0w_83937202-e4ad-432b-88a4-9e9e885879ed">485.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f197d8686c4e44bbee78953032d413_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTEtMS0xLTA_fad11740-b25c-4d16-9f9f-0fc1eb6b0e7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23cac88653144474aa6d28fad81d8ecf_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTMtMS0xLTA_90f627c3-8fce-4b1d-940b-da80ad01198b">216.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d5709855edc4dafb39167708c8ba135_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTUtMS0xLTA_e8a5cb4b-1f52-4f3a-b2f6-23e41e466a18">216.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d2c2f06527b4022a893fa9bcb7e4e52_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTctMS0xLTA_9d15fdb6-7089-4043-89b1-d09ab2ad3955">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cdd79b3cf74f248c1f7221acba2a23_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTktMS0xLTA_708d4d47-0147-4a45-a7df-2e69f7b2069b">184.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8554a2c2be4400a7226435515b1cff_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTExLTEtMS0w_0f386a0b-33e7-4c4f-adba-c7acf44ecbce">184.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466f28f7b774412c92456ab39ec8c2a6_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTEzLTEtMS0w_ac963c24-3a97-4428-8bb0-65780b8c38a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31933ce497d64be0899c42e590f33e49_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTE1LTEtMS0w_f407821a-6dc1-47cf-ba16-52bcda5c0f15">16.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7a44b1f0d049cabc406d3d7fb76dfa_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTE3LTEtMS0w_85f47ba4-28d5-49b2-9ae8-712a6eae364b">16.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc3ca49c80e494caf1f76203a66f71e_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTEtMS0xLTA_11fc8292-1c0e-4c99-9978-8a97342c01c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i836a100e66ca48e8a1e7ddee36e17253_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTMtMS0xLTA_b26d1e7a-cf45-4048-8531-9f0a72ca64ab">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4ad0dba054423b82e1cc5bf4358871_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTUtMS0xLTA_6a028fdf-2d81-476b-9a13-d4819b7af961">97.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28387800191b42c088cd25c6a9466a12_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTctMS0xLTA_d1f33aef-dd91-4040-aca3-cea227811c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f5c2e8409c4870834b30b67f6c99d0_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTktMS0xLTA_571235eb-f912-439c-b5c1-1e14aa0f0b2d">68.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd96336b17c48759b92af5b727a614d_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTExLTEtMS0w_52630954-3540-453b-b961-4b000691bbff">68.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c35b9c4f72240cb91164b21f3abd0a2_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTEzLTEtMS0w_c762baa8-4ade-4418-9df6-cb291b3d0570">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2ed02bfb06451f9fb5ae7fddafa907_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTE1LTEtMS0w_788b1ee6-5713-4e38-af9c-02afd380ebec">43.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f93424eda7546c9a3ac40bcfbfaa106_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTE3LTEtMS0w_bf3a1aa0-7b82-4c90-a87e-f7518db9f845">43.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ea9446ace44e788ee54818d9b37f3a_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTEtMS0xLTA_670ed588-0dfd-46e0-80f7-9c485719ab20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fbc92ecd2ec466bb430e6dce8b804a3_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTMtMS0xLTA_9b4ed0e0-e41b-4cf4-88a7-fd651d9899a7">795.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1efb62ce514836b55d3ee7a4ac1a5d_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTUtMS0xLTA_b6006044-8e8b-4a5c-8725-6fd12f3175d4">795.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26bd8f41008941b1be219ee8aba377f2_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTctMS0xLTA_80832e08-0db6-4655-918d-a544123f1bfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76e8e2921bd486fa43cf0f7bf709125_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTktMS0xLTA_c8fb6d37-1d0b-4c13-87e7-b25f72f539bb">738.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc2e1129ed148b29526834ea34cc7e6_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTExLTEtMS0w_b518221e-7b2b-43bd-9ecc-346cacba998e">738.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5517906d4a214fd5a371d6c53ae66e73_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTEzLTEtMS0w_393838c3-4152-441d-8e08-460a368688b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if66448bf19334d99863e008bc96d2313_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTE1LTEtMS0w_c634192d-4558-4869-959e-faf1c3dc81d5">545.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b62d124ddb34cf3809af9802c175ace_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTE3LTEtMS0w_25b63534-c175-4029-9f1b-aa52bebe70b2">545.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0132327259a94fb1975abd835ed78152_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTEtMS0xLTA_f627db12-9f34-4edb-b142-07c8094fc4b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c90e682e5e417a967657ac50fbacf1_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTMtMS0xLTA_397a9049-d4d5-4a8c-8c67-d4a882294901">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43014c84e32d490e8ca9d7d907dff83b_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTUtMS0xLTA_4a3485ad-b30b-4b7a-8993-6373b5a9a181">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d4c2a4027e3422ea87ff6cc3b986145_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTctMS0xLTA_6e94d53c-3017-4f66-b145-6dd55610f896">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6560ddf1da469783c308fbc59328d7_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTktMS0xLTA_e3cc6c77-b140-4ca5-a62d-c0f5dd06e9bf">15.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c11246cbbfa46648ee949251e0eb821_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTExLTEtMS0w_e032558a-5fe8-435e-9d3e-2a904a9fd125">15.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d7562d98124ce596c58c5c77f902a5_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTEzLTEtMS0w_162861b6-0ee2-4a36-8ca0-8062a46187cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f610d2c9e746d5ba0b20b191ecff82_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTE1LTEtMS0w_f703e3e5-0ee3-41ca-a730-f2e893cbd744">22.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7ac8b29bb24df09106e8a94a348a10_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTE3LTEtMS0w_be69dd7e-4140-4ab2-b703-72349970c983">22.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f99591bb1b0401b8000095a52fab6f8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTEtMS0xLTA_57556a95-019f-4a1d-9e1a-095ed7da5852">5,900.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb76f2658274da7b4345880031c2273_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTMtMS0xLTA_f2d309d2-3cb8-4c65-9f7c-34b5ccacb577">4,792.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTUtMS0xLTA_4be2e776-979c-4e71-98eb-f0b269373661">10,692.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c66309e53f467ab518b51c5bce54f4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTctMS0xLTA_50938e99-5dfa-4d91-94c0-ae72d49c5560">6,713.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98110a133446d0bd61f9284d0e58f2_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTktMS0xLTA_f314675e-181c-44cb-8e20-47ae85562958">4,666.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTExLTEtMS0w_adcd602e-29b6-476c-9263-13500cfb8d20">11,379.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c311f0cc16744aeb4492070360e76b3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTEzLTEtMS0w_0d4b7386-ad4d-44d2-82c9-1a7a9d788d3c">6,800.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa69ae482814ac8bcd343ae4a224389_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTE1LTEtMS0w_a1f9f802-5c54-41f9-8a1a-22306b2399f8">4,086.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b7b9a353c2419ca9a01532a522a0d0_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTE3LTEtMS0w_53371154-bf3c-489c-8be6-00fbb9d44f1a">10,886.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenues from <ix:nonFraction unitRef="wholesaler" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzQzOTgwNDY1MTc0MDQ_a642b5b4-3eb8-4a2d-9740-0d220391f9a0">two</ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="i6838460bdaca49d7b136d868993f4d08_D20200101-20201231" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzQwOTE_c5919aef-e09f-4da8-bf61-c6da87ac0549">30.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3ff66c8950bb4a7e88affcf110449d1d_D20200101-20201231" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzQwOTY_795e0241-9165-4a66-8d2a-f44380a9b60d">15.3</ix:nonFraction>% of gross product revenues in 2020, <ix:nonFraction unitRef="number" contextRef="i0ea5f27bc85f4fddb4469f05a3b00215_D20190101-20191231" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzIzMA_cbec50b4-4149-4d0e-9578-784aa7f15e78">30.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id4f9dcae88cc43e891f75bf74e4bf5c0_D20190101-20191231" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzIzNw_23df41f6-f27f-4ecc-86be-c2eb4d7ec55a">17.2</ix:nonFraction>% of gross product revenues in 2019 and <ix:nonFraction unitRef="number" contextRef="ib2a9f19b6d9f4f4a995ece66958a61eb_D20180101-20181231" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3Ng_cde651ec-427b-4602-a72e-eb21b54566a1">32.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0863980b999348b5a5e8c88dcfc46890_D20180101-20181231" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI4Mw_d511ed4e-0faa-4fa2-84a6-c2808e1065a9">18.4</ix:nonFraction>% of gross product revenues in 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, <ix:nonFraction unitRef="wholesaler" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfWholesalers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzQzOTgwNDY1MTc0MTM_2ad83e7e-b33d-4149-8613-4d6257c4905f">two</ix:nonFraction> wholesale distributors individually accounted for approximately <ix:nonFraction unitRef="number" contextRef="ifd820ada82d04297b57bc8a5f70af4b9_I20201231" decimals="3" name="biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzQxMDE_d70e84e0-f177-49ba-8e1a-f29160564bd3">21.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i112f6f59416148d2a921ea8b21ca66ca_I20201231" decimals="3" name="biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzQxMDU_3f9c4b73-5cd7-4f46-bea3-6632e926faa2">8.5</ix:nonFraction>% of net accounts receivable associated with our product sales, as compared to <ix:nonFraction unitRef="number" contextRef="i6e510eea4c8c4271a8fe6ae31a7211f5_I20191231" decimals="3" name="biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzQ5OA_e521bee5-66ef-40eb-af19-075855c9f0a5">24.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3c42c0c7a42943d7a9ffc85aa01e8a61_I20191231" decimals="3" name="biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzUwNQ_6c9321c5-8aa7-472e-9490-b894efcc4235">13.9</ix:nonFraction>% as of December&#160;31, 2019, respectively.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NjU_f54b9a46-53bb-430f-9c49-5b44608ea767" continuedAt="i16109f00cfc6413297c99730ffab7a2f" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400709e4fbb2431a8c60b9f0001721f4_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzItMS0xLTEtMA_e4e69378-f0c3-4a09-923f-6c7ef8ebe61a">131.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb52c820db94f3aa2e279e49e3f772a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzItMy0xLTEtMA_d0083026-32cf-40ee-83d0-d806b56bfd55">1,027.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91f6946981c4e79a74688a13b7b6cae_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzItNS0xLTEtMA_d10a0f2e-f68a-4a8f-b2ed-389d8d27e6aa">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzItNy0xLTEtMA_df111f75-a68b-41de-bddf-b6f4e85fac24">1,198.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzMtMS0xLTEtMA_505b5a7d-9877-47ec-b685-0fdbeae3dc15">774.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzMtMy0xLTEtMA_588f90a8-1fb4-4d9c-b994-5b206cfb8ea9">3,308.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzMtNS0xLTEtMA_254fc8cb-6c80-480f-855f-36977ad6a4c2">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzMtNy0xLTEtMA_b9b59cbb-073d-45c4-bb22-100f10ea3ede">4,102.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzQtMS0xLTEtMA_07f089d6-f9d2-4ea1-9d13-78d7be5c8147">1.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzQtMy0xLTEtMA_caca5277-2c38-439b-a6a5-b5ee0d7d21ea">54.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzQtNS0xLTEtMA_7e66e104-fd9f-4e8f-912d-efbb682859f2">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzQtNy0xLTEtMA_8ce8de4f-4a27-4ad2-b28b-9f76b540a7f1">53.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzUtMS0xLTEtMA_122c91d0-d8c3-4e44-8439-b47169235ac7">635.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzUtMy0xLTEtMA_d0f4547c-ae09-481e-bd4e-d4875122c74e">2,426.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzUtNS0xLTEtMA_af217259-9f96-4e17-94e3-8488a7e1f068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzUtNy0xLTEtMA_6b658ddd-975e-40da-ba38-f7424e5a8404">3,061.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzYtMS0xLTEtMA_d40119dc-7b5c-4eb8-b651-8562b44c6a73">128.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzYtMy0xLTEtMA_27873341-0bef-4495-9cb7-202e3fab1a4e">763.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzYtNS0xLTEtMA_7fd28032-ee8e-4cc2-9ea2-84a7449be3ed">19.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzYtNy0xLTEtMA_c85f4120-1a09-4d27-85c2-9aa054e875e9">910.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib09a186083b44003b3551748e372ab96_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzctMS0xLTEtMA_addd70c2-511e-4080-8375-6b9ff8501b31">141.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913629824c8f4387b3fa3d219d942aff_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzctMy0xLTEtMA_11e764da-52bb-492f-bc21-588e74e4981a">1,093.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e8aacd727c4737ad050b96fdf9c8af_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzctNS0xLTEtMA_25f1b91e-b4c4-429c-85ab-da371a7a808f">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzctNy0xLTEtMA_c6d47f82-3614-4a19-9c62-226b3ba16e06">1,276.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ibb3c5f3bb2fe42a58692c5fcaa53db29" continuedAt="if2f4925195dc4bf5b6f07267f874fd86"><ix:continuation id="i16109f00cfc6413297c99730ffab7a2f"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6a7b631471438e8fee99a379470ccb_I20181231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzItMS0xLTEtMA_63405e7a-ca9d-40ec-8e36-7071340cc70c">127.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8cb46beb3d4d47884b9ee3730ccea5_I20181231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzItMy0xLTEtMA_9b9c81b5-6cf3-4efd-a5c1-17a03a1b000c">888.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb4285e484a4003bbfb3010fd8b052b_I20181231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzItNS0xLTEtMA_db3c6bad-d281-445b-9868-a6cffd460656">34.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzItNy0xLTEtMA_c1ffe047-8d3b-4492-b345-78b54f974201">1,051.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc03c10e08964a88b663a184122907a2_D20190101-20191231" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzMtMS0xLTEtMA_07a32b69-a31e-40a0-a781-26ba26e3ddff">666.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzMtMy0xLTEtMA_744f5ea4-1c7b-4686-bcdb-eb68ff1a3d88">3,011.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzMtNS0xLTEtMA_ca05e07c-fed8-40b8-bd9f-009e44395b3e">20.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzMtNy0xLTEtMA_a9376dea-6398-44f7-8833-a927fcaeac87">3,698.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc03c10e08964a88b663a184122907a2_D20190101-20191231" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzQtMS0xLTEtMA_981a731b-0e44-4792-8a7b-dee375978143">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzQtMy0xLTEtMA_3feb6c55-0e1c-4a43-a3a3-e17de2a6d377">54.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzQtNS0xLTEtMA_70cfebe9-c746-48a9-944f-2a807b81bf83">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzQtNy0xLTEtMA_10f554eb-149f-4bf8-8458-f3f024ce9527">48.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc03c10e08964a88b663a184122907a2_D20190101-20191231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzUtMS0xLTEtMA_c3c798a4-5b31-4d22-b5b4-dc9576ee751f">535.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzUtMy0xLTEtMA_d2706b15-49d8-40ff-afc0-f0b6674777d3">2,242.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzUtNS0xLTEtMA_c5ac30b7-b752-4755-8f4f-ec19738e5e56">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzUtNy0xLTEtMA_5f15d09e-fd84-41a8-b66e-6bb3eec11cba">2,778.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc03c10e08964a88b663a184122907a2_D20190101-20191231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzYtMS0xLTEtMA_bc79dffe-6998-4dd1-9890-c767ffb545a4">127.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzYtMy0xLTEtMA_39db9c88-0b5a-4a08-a6ff-69bc1a7b144d">576.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzYtNS0xLTEtMA_2908969c-55b9-46d6-b145-173155dc63db">20.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzYtNy0xLTEtMA_f38f302b-3904-48e7-b4ee-063b1c53b10d">724.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400709e4fbb2431a8c60b9f0001721f4_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzctMS0xLTEtMA_5349bcb0-7243-4753-8bf4-c5351755d231">131.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb52c820db94f3aa2e279e49e3f772a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzctMy0xLTEtMA_8050f4b4-b1e2-4e93-98fa-cc3374ff4b25">1,027.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91f6946981c4e79a74688a13b7b6cae_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzctNS0xLTEtMA_552717de-3cf1-498d-af8b-c1d5a7b24cb1">40.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzctNy0xLTEtMA_ec4c1f0c-23e1-4018-a919-7bbef428c58e">1,198.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica5f21c6cd2348a196b1a5aabce51c96_I20171231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzItMS0xLTEtMA_9f2936b1-ba68-4d40-a086-0d5ee6788128">109.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9f7171e7754520b8801272436020bd_I20171231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzItMy0xLTEtMA_9334e934-5ad7-4d9e-bb99-c27b4c58d6a1">606.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic77265ab5c594a27b0736ca509460655_I20171231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzItNS0xLTEtMA_2178b9b1-6a25-4fe6-b571-50a28af5bd75">46.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9925b2c3e594ae0812001969da2a99b_I20171231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzItNy0xLTEtMA_0a44aff4-e1c3-4d29-917d-9a9c1a8101bf">761.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzMtMS0xLTEtMA_87de97ff-467b-425c-8be6-855d6f92ca61">679.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzMtMy0xLTEtMA_db66a322-ff0c-4276-998d-53a91f2221af">2,686.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzMtNS0xLTEtMA_a17e7462-79ac-4c2e-83f6-f1986d886593">23.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzMtNy0xLTEtMA_5faf8977-5ddf-4312-93fa-7875eb8c590d">3,389.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzQtMS0xLTEtMA_a35201b1-b91b-4d65-8b40-64b8ff7707c2">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzQtMy0xLTEtMA_1b55bed4-f87b-42dd-897f-2d9f74772a84">10.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzQtNS0xLTEtMA_a16344d1-25df-446d-84fb-4f0af6439748">1.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzQtNy0xLTEtMA_6faebd2a-4f5a-4968-a845-97836530fc10">12.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzUtMS0xLTEtMA_03680e2e-a29c-4461-aaf4-be7ece07336a">551.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzUtMy0xLTEtMA_21d8d10e-7355-4736-8a51-ccb284a14b91">1,887.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzUtNS0xLTEtMA_783de352-e1d3-4d36-9ab6-fe778a133c14">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzUtNy0xLTEtMA_f58bc350-3f78-42cf-a2ef-13894f1c6443">2,440.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzYtMS0xLTEtMA_ad79539f-1547-40da-b9a7-e5d540933d97">109.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzYtMy0xLTEtMA_887c648d-995f-4bcb-9394-04d42755cd18">506.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzYtNS0xLTEtMA_288ca3ff-110f-44b2-bdf4-b7e5e67e25f2">31.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzYtNy0xLTEtMA_406c20b4-8c97-4b7e-bdd0-de617ccf156d">646.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6a7b631471438e8fee99a379470ccb_I20181231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzctMS0xLTEtMA_083dc12e-5bd3-4f62-9814-8c2dae343f54">127.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8cb46beb3d4d47884b9ee3730ccea5_I20181231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzctMy0xLTEtMA_d9da0d68-3424-4cd7-a24a-3cbe2836895e">888.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb4285e484a4003bbfb3010fd8b052b_I20181231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzctNS0xLTEtMA_bd2bbacc-9c50-458c-9908-146fec39a9cd">34.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzctNy0xLTEtMA_20bfdee0-d737-44d4-96f0-b9988c35d5be">1,051.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NjM_301b2447-00de-4f72-99a2-777ffd5f6f3a" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f40d69597314563b8de93e06ec34c1c_I20201231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzItMS0xLTEtMA_94bf24c9-e5cd-48ea-a672-4e700dc17687">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195b915d47274fca99fe4a792ac7ea69_I20191231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzItMy0xLTEtMA_043e833d-fb68-419b-81df-a0ae7684d0e0">197.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expenses and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzMtMS0xLTEtMA_2305c86f-ff12-4ae1-ad38-469d71fb56f2">1,080.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzMtMy0xLTEtMA_a7db5ddc-265a-4c9a-8560-4b4a59b39277">1,001.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzQtMS0xLTEtMA_7586686f-bc25-44cb-b1cb-986c4482ea53">1,276.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzQtMy0xLTEtMA_a5e0c81f-868c-4aa8-9106-c1c07ca960e7">1,198.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NTQ_76315981-623f-4a6c-ae43-8ee110d52442" continuedAt="i8f25078f7b0749f19a2896fc64c068ba" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9559172621a745278ce2779747432dec_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzItMS0xLTEtMA_ebec6446-e5a7-463a-ab56-bd96dcff1338">1,080.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6b5a9481f349908c730396c050643d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzItMy0xLTEtMA_c93cb881-346b-4e1c-84cd-0e8e13ed01ac">1,542.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzItNS0xLTEtMA_97df85a1-a3e1-4b41-a47e-a87f40dfdb03">1,431.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9559172621a745278ce2779747432dec_D20200101-20201231" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzMtMS0xLTEtMA_77f15f1d-626f-41db-8e72-648836461ee1">897.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6b5a9481f349908c730396c050643d_D20190101-20191231" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzMtMy0xLTEtMA_df0dc30c-3e83-4c77-9284-018a02519d6a">748.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzMtNS0xLTEtMA_4b06ae48-ce42-4306-a8b6-5592978f7d91">548.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzQtMS0xLTEtMA_e1834f38-5293-4fab-acbd-e6878c145f15">1,977.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzQtMy0xLTEtMA_213fea8b-1e43-4d14-a8db-917c757778bb">2,290.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2514a987784410a8165984f87269d3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzQtNS0xLTEtMA_c5f5cbd4-885e-4f47-8744-3b8023bcfe49">1,980.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" name="biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzk3OA_0a92c5be-03d9-47c4-9446-c747a4548611">14.7</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" name="biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzk4Mg_87ebe664-d74a-41d7-af60-5223cd39b7f1">15.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" name="biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzk4OQ_54bdfad5-84c6-4181-913c-32e4e63da4fc">14.7</ix:nonFraction>% of our total revenues in 2020, 2019 and 2018, respectively, were derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="if2f4925195dc4bf5b6f07267f874fd86"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:OtherrevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NDk_b88bce9c-de1f-4a2d-a385-e1209a98891d" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd59c1996ba049328473d73e6ebc2376_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtMi0xLTEtMjA3ODQ_a5b00f64-559a-420c-aad6-72bf8b417e70">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia29bfccabbb4483d896c6bb788ec20c3_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtNC0xLTEtMjA3ODQ_d5eb398d-ba15-4464-939f-175521476cde">106.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c7287b63dc4cd3a1a2ec95a9d031bb_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtNi0xLTEtMjA3ODQ_f5c5fa51-5370-45b1-9c7a-f05a32a72c85">96.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd5d205fed849349f4c94a2eb02cdd4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtMS0xLTEtMA_7a6ceeed-6476-43f4-8735-623b90a204d4">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a785963e61a4b4e817f15fa26f0d819_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtMy0xLTEtMA_e2ec88aa-7593-4510-8532-a1c7cc4b74e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddf5ae537bd74ff9a59f2b74a8161266_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtNS0xLTEtMA_db1feb82-b271-4b31-88a5-df409d300b93">8.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e510b249bf46dc94c9604a2b8b9a69_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzctMS0xLTEtMA_acbfa933-be31-443f-bc8b-62f6fef06e43">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c0819a2f984821bb989e9609805bb8_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzctMy0xLTEtMA_e0b43d4e-471a-42ec-b9bb-2bd7059bf985">17.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58e40285c848e296a601009ac7f815_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzctNS0xLTEtMA_14be323f-e546-4cff-9e2e-1ebdef22ddb0">38.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ef21a6d03740f8aa272b7fdb22b854_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzgtMS0xLTEtMA_fdbb93dc-5475-4dd8-b5c9-276823e776fa">719.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ea9f4eaaa24324b4547475bd116c88_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzgtMy0xLTEtMA_b7927810-f885-4dae-80ff-e9d0faa52d39">584.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb160e00a5f449ca3dc21f07ab9ba0f_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzgtNS0xLTEtMA_9b517738-c901-4c5c-bec5-de7a9f6d6db1">459.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzktMS0xLTEtMA_ee75e8df-b447-41ee-8728-3ff134a6ee74">774.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzktMy0xLTEtMA_b2efdc22-c05d-4242-bd9b-36570a1dfde2">707.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2987b04d4c240d88b84a50c04ca2df1_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzktNS0xLTEtMA_5e230af7-184d-48b7-942a-18e4a3fcb63e">585.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended December&#160;31, 2020, 2019 and 2018, we recognized $<ix:nonFraction unitRef="usd" contextRef="i3976604c455244a68c5f8bc26ebe6514_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzE1NzA_39468b56-5d48-4ac1-b4c4-d9c95bd6c99d">48.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5a6054a3521e4fad899551ca7aeb3026_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzE1NzQ_bd9f306f-abda-4400-9fe8-257272655be9">383.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18053bf504534e879bf5029dbb2066e7_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzE1ODE_dccc3ce4-06b3-4e83-8da7-7c6281972cf6">206.7</ix:nonFraction> million, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result we are entitled to $<ix:nonFraction unitRef="usd" contextRef="i9d72ff5a209c4e3b8fd84b931863f9d2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzE5OTU_0a0781f1-d232-41c0-b38a-0faf9bd9b8ff">500.0</ix:nonFraction> million in a series of three payments. The first payment became due upon a regulatory approval of such product and was received during the second quarter of 2020. Subsequent payments are due on the first and second anniversaries of the regulatory approval.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other corporate revenues for the year ended December&#160;31, 2020, reflect $<ix:nonFraction unitRef="usd" contextRef="i609fe60df7e64f54a5f65e6a8167f50a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzI4NDM_0a9c2d7e-3b7a-4aa8-85c1-fdadb80a0cd7">346.2</ix:nonFraction>&#160;million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="if028deb520d34a2aa081b6f9c3dac0e9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzI4Mjk_1f2e7a0e-ea29-40fc-8a5c-5ea97ab6f4bd">153.8</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i9d72ff5a209c4e3b8fd84b931863f9d2_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzIwNzQ_0a0781f1-d232-41c0-b38a-0faf9bd9b8ff">500.0</ix:nonFraction> million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_253"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzE0MDc_2345aea0-01f8-46f1-af1b-165d9639928c" continuedAt="ib448f10bfef4409ebbdb6cd67d379294" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ib448f10bfef4409ebbdb6cd67d379294" continuedAt="i446a945afbdb48999d28be5e339b0885"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzE0MTQ_50e7d367-7ea3-4450-9a97-4ae220acbd14" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzItMS0xLTEtMA_98fe41ff-0f92-499f-99cd-35d13715067b">314.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzItMy0xLTEtMA_7ee1bd99-51ec-4b99-9d20-4e58a3bad222">169.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzMtMS0xLTEtMA_608a9028-2a0a-420b-b858-69fa1e0808e7">544.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzMtMy0xLTEtMA_97132928-0910-419e-adb7-5fe72dcadeee">460.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzQtMS0xLTEtMA_9739c56e-f188-46ff-adc5-299e4403616a">209.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzQtMy0xLTEtMA_2bfe87aa-b66e-4271-9ea2-c2bb8f505fe5">174.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzUtMS0xLTEtMA_82f4c293-f6be-49ee-a421-8fd01380fc22">1,068.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="biib:Inventorynetcurrentandnoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzUtMy0xLTEtMA_ade985f6-d2d5-474f-8ee5-abc8ca0e5318">804.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzY0Nw_7d7d572b-77fd-4509-ad4f-485ddb5f7cfa">26.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzY1MQ_f9b83923-0487-48a9-90f2-528aa56abfdb">52.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzY1OA_a46e44db-6492-44f3-95b9-e6ec34689ed0">41.9</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i446a945afbdb48999d28be5e339b0885"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included the sale of $<ix:nonFraction unitRef="usd" contextRef="i16eea92696684f6f8f01944879fe877c_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2Xzk3OQ_af585e43-8104-46ef-856d-cd41696eca44">14.0</ix:nonFraction> million of work in process inventory.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we sold to FUJIFILM approximately $<ix:nonFraction unitRef="usd" contextRef="i2e9e587add174faba8df37c45bf81a84_I20190831" decimals="-5" format="ixt:numdotdecimal" name="biib:InventoryrawmaterialssoldtoFUJIFILM" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzEwNTk_f3070b7c-9d6e-4f94-85fa-5d048d7296e7">41.8</ix:nonFraction> million of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_256"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwNjE1_a0cafe9f-72ab-4657-b5b2-9f091dc66842" continuedAt="i4b131f344aa8411eab0f86eedc4e8d99" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i4b131f344aa8411eab0f86eedc4e8d99" continuedAt="i9b7cce9bd14b422dba80550108687d25"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwNTk1_98f6a7e9-0a7d-44dc-b47f-c9ba0e007b65" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItMy0xLTEtMA_aa29a957-6997-4fee-954a-66da855b7553">7,394.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItNS0xLTEtMA_1f48612d-f674-48e9-9857-4ab0e67de144">5,136.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItNy0xLTEtMA_a00f6831-5605-4775-be5c-343be50dcb74">2,257.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItOS0xLTEtMA_67af51b8-ace1-4c68-b1b0-9761bb7d6100">7,379.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItMTEtMS0xLTA_af61b18e-4cb4-4b30-802f-1bcd1075d050">4,881.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItMTMtMS0xLTA_bd70cae0-794c-45e7-8e4d-113c6ac7858a">2,497.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d271b53e29411abc2a151b7350aeb7_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzMtMy0xLTEtMA_edb25d0a-8e10-4eaa-9c51-ee7f7cf20763">762.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d271b53e29411abc2a151b7350aeb7_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzMtNy0xLTEtMA_f60f44f2-3509-45b2-9d78-8db0ef95be43">762.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c498e3888a34f50a02f1bb18e32ad14_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzMtOS0xLTEtMA_3b447a55-7f1c-4e70-9c3f-e80bca7a601c">965.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c498e3888a34f50a02f1bb18e32ad14_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzMtMTMtMS0xLTA_acada7d8-dded-48e1-836a-59662e239958">965.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0293853038ec4dbf8d988ed6233a88a0_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzQtMy0xLTEtMA_21cb51b7-a16b-4e8b-baec-779b9e9e3dc4">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0293853038ec4dbf8d988ed6233a88a0_I20201231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzQtNy0xLTEtMA_a40400c7-b413-435b-9e1a-04bba1484ba0">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie292720cdee34fa4a2f50bd921742df8_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzQtOS0xLTEtMA_860016a7-1eb9-4ee6-b050-0d0cba9b3f6a">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie292720cdee34fa4a2f50bd921742df8_I20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzQtMTMtMS0xLTA_1a2dd759-52ec-4333-b120-49480e5694d3">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtMy0xLTEtMA_770df6ba-4ec5-4eff-b01d-7c3b84004ad1">8,220.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtNS0xLTEtMA_7a5caff6-2e2e-4f72-83dd-183959e00ad0">5,136.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtNy0xLTEtMA_4759a84b-6103-465e-868f-211e5d39b12a">3,084.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtOS0xLTEtMA_375e558c-9594-453d-8c21-705cd15d4f2e">8,408.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtMTEtMS0xLTA_1ac9ea54-a0b8-41fa-ae4b-72e15a8d44e7">4,881.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtMTMtMS0xLTA_151afb73-51c6-4c27-ba5a-3d96f250ff3e">3,527.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization and impairments of acquired intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NTIwMTU_d1dc8568-13a6-4cfe-8ace-2bb33ca69898">464.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzI3Nw_384ad337-d19a-4e1b-8296-1c00b94cd6ed">489.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzI4NA_7edde50b-a6e5-4343-a068-a9b819871453">747.3</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets, excluding impairment charges, totaled $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NTIwMjQ_e2efbc13-9e47-499a-929a-98087c7e35c0">255.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzQyMg_d9b9b274-a674-4a2b-b66d-4e82f6b0fce2">274.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzQyOQ_62eb7af9-9cf4-487d-9abd-5aaf00cff507">381.2</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The decrease in amortization of acquired intangible assets, excluding impairment charges, over the three years was primarily due to a low</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">er rate of amortization for acquired intangible assets.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="i6e983ff4043d40f0913bb5c532a2f59c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NTIwOTk_f60e8281-8e6f-4aa7-b5d6-850c67baf59e">115.0</ix:nonFraction>&#160;million impairment charge related to BIIB111, which was obtained as part of our acquisition of NST, a $<ix:nonFraction unitRef="usd" contextRef="idb36452ab02142988e739a2d7605d7ff_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzQzOTgwNDY1NDU1ODE_d78c5c66-8764-4863-9562-93b33c00451f">75.4</ix:nonFraction>&#160;million impairment charge related to BIIB054 (cinpanemab) and a $<ix:nonFraction unitRef="usd" contextRef="i101d5553f62a4ad998a4e79cfea8fca3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:AmortizationandImpairmentofAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2Mzg2NDg_8af83f93-a30f-4fa6-9924-58773b46a712">19.3</ix:nonFraction>&#160;million impairment charge related to one of our other IPR&amp;D intangible assets.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, amortization and impairments of acquired intangible assets reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="ic1193619aae94660913bc904c7ad0ebd_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzgyMg_8990040d-1e3e-4486-b294-5c0b8b099880">215.9</ix:nonFraction> million impairment charge related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF), which was discontinued in the third quarter of 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2018, amortization and impairments of acquired intangible assets reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="ia68ac17ffb634d7ea358cffd1d2ff11c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzExNTI_8c45346b-ede7-458e-88d3-cd5573c1fefc">189.3</ix:nonFraction> million impairment charge related to certain IPR&amp;D assets associated with our vixotrigine program, as discussed below, and a $<ix:nonFraction unitRef="usd" contextRef="ic1c8b3e3b2804596ba415198766ed335_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NDA4MTE_2c180697-775e-4e73-8026-9212a2f0a2eb">176.8</ix:nonFraction>&#160;million impairment charge related to our U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan as well as other amounts related to our other marketed products and programs acquired through business combinations. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i9b7cce9bd14b422dba80550108687d25" continuedAt="i98589fb03c7f4b5abe73297491ffa743"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of December&#160;31, 2020 and 2019, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST and</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Convergence Pharmaceuticals Holdings Ltd. (Convergence). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;D programs with an estimated fair value of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ibef78125dd7d4a94a4efe455cc442105_I20190607" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzYzNjk_7f8a7755-8ff7-4a1c-bd48-d89d1f9166a5">585.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For additional information on our acquisition of NST, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we began experiencing third-party manufacturing delays that may impact our timeline for a potential filing of a Biologics License Application (BLA) for BIIB111 for regulatory approval by up to one year. In addition, we determined that forecasted costs associated with advancing the BIIB111 program through Phase 3 development and potential commercialization will exceed our original estimates. We reassessed the fair value of the program based on these changes in assumptions and determined that the program was partially impaired. We recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i1f7617347de84315b946e8a49e9bd554_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NTE5ODA_83422eaa-0811-4406-b540-37f9fe387596">115.0</ix:nonFraction>&#160;million during the fourth quarter of 2020, which resulted in a reduction of the IPR&amp;D asset from $<ix:nonFraction unitRef="usd" contextRef="ia56ada61d04148c9aa29b83378b86afa_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NjM0NjQ_bae548d0-2ca2-4605-ac91-356db2c02e9a">480.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i725b0e19a3884b52a34ffa0720d25883_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NjM0ODA_8f76828b-5a23-41d2-a08b-1b9fac6d8d77">365.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB054</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021 we announced that we discontinued development of BIIB054 as a potential treatment of Parkinson's disease as our Phase 2 SPARK study did not meet its primary or secondary endpoints. Although we made this determination in February 2021, it was based on conditions that existed as of December&#160;31, 2020. As a result, we recognized an impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i14f3a2917b0f4c51b7e1a5f8612047eb_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzQzOTgwNDY1NDU2MjY_c4cf34cb-89d8-4357-9c80-1c555315b338">75.4</ix:nonFraction>&#160;million during the fourth quarter of 2020 to reduce the fair value of the related IPR&amp;D intangible asset to zero.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D impairment charges were included in amortization and impairment of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. The fair value of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of December&#160;31, 2020, the carrying value associated with our vixotrigine IPR&amp;D assets was $<ix:nonFraction unitRef="usd" contextRef="i2ad3e4569ba84e3ab10d4fb4ff676171_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NDg5NzU_809ed8cb-282e-44ee-b2ed-d923b11194ae">177.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span><span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzU0OTc1NTgxNjE1MjE_2c3d5f4f-33b0-4c37-bdde-b5775c7340a8" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzEtMS0xLTEtMA_d6dbd4be-e7a3-4787-8e0b-b3c709ed82bd">205.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzItMS0xLTEtMA_9f1e120a-6251-4a41-820a-edcf96d0acdf">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzMtMS0xLTEtMA_6c8ec636-6880-4660-8d70-b36d8445a148">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzQtMS0xLTEtMA_672614af-84e0-4f7e-ad6a-3b60801cdce8">225.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzUtMS0xLTEtMA_89a8e58f-fb79-4b8d-a41b-d7d59621527f">220.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i98589fb03c7f4b5abe73297491ffa743" continuedAt="i95c1c74047304113b4dc572dbd769ae4"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwNjEy_726bfb6c-edc7-4664-84c9-6bef49e1e7b0" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzItMS0xLTEtMA_0d214b9e-8f14-4776-8a00-e6199d7ca258">5,757.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzItMy0xLTEtMA_fcb78abf-d953-4b06-8030-fc92d4e6ad6d">5,706.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase to goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzMtMS0xLTEtMA_0e6da53a-9acb-46dc-995b-0fc55b1dacb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzMtMy0xLTEtMA_24c962d8-76b1-4f8d-a1f2-786b2eb8ab3f">117.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzQtMS0xLTEtMA_f94dcae0-bd4e-4189-ac9e-7c1400ac30fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzQtMy0xLTEtMA_fbb38be8-c18f-44b1-870a-5785e793f7ac">69.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzUtMS0xLTEtMA_cf336443-8245-4bf7-9dcf-50341769390a">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzUtMy0xLTEtMA_dc823ad9-f096-41b1-8f62-e178195b22b3">3.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, end of year</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzYtMS0xLTEtMA_9afb556f-da5a-4fe1-8909-fb1df33fcb51">5,762.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzYtMy0xLTEtMA_648a8b2f-d7d8-4033-b8b8-358ba91b93d8">5,757.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i95c1c74047304113b4dc572dbd769ae4">As of December&#160;31, 2020, we had <ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwNDU3_2ff12343-4caa-4581-9984-35afdb920d93">no</ix:nonFraction> accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_262"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzcxMjI_c91bdaed-1393-4694-97ac-a9bfaa4e0da0" continuedAt="ib2fb7fe749124de1a8e3124b220bdbd9" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib2fb7fe749124de1a8e3124b220bdbd9" continuedAt="iad8244891e274271a820a3e2d7553243"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzcxMTI_e67bfd95-2327-4981-922b-162810cab444" continuedAt="ia87a10cebbd04ff98d6f380a9418c910" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzItMS0xLTEtMA_cd10f8c5-effe-418e-a071-35e265ab5a17">626.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzItMy0xLTEtMA_d3fecf93-746e-4ef5-80ae-83b0213ad154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88845b78404eafbfca745c512904b0_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzItNS0xLTEtMA_42b8428a-26f6-4dfd-9803-8bd2c8d3e7b6">626.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a386c121b94d3285b2e93991eee966_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzItNy0xLTEtMA_2472dbde-c2e6-4d80-9589-1dd065827023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31de162949914248aef0218bfb3cae08_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzQtMS0xLTEtMA_cb535667-a42a-4d73-abc5-93551f7f9161">1,301.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30b12536469448f9255d5e1df2de125_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzQtMy0xLTEtMA_41f656d8-9589-4427-b668-56bf07ae5724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa11cb31d8024230a65d4ab2be7a7509_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzQtNS0xLTEtMA_e2a6a92e-d5d6-4934-a18a-014fedd9651b">1,301.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib868142b7926459283806400925364f0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzQtNy0xLTEtMA_3ba78d98-b3bd-471f-ae80-1acb69ec42df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4400d07ebb429faf284232b75c3fad_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzUtMS0xLTEtMA_a95e83ff-3c92-4b91-9d78-873d3fef5691">627.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1295c3d9fdcd4cd6bd7a06e54f915289_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzUtMy0xLTEtMA_65b7dd96-5d21-4aef-9471-ea242485d491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1a4978f65a4ad194d0e7fd7c37d454_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzUtNS0xLTEtMA_c18acad9-61f7-43b8-a088-8679584e12f2">627.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05d20dd706c4482ac970a02c04378de_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzUtNy0xLTEtMA_749794b3-b021-46d9-a2e8-72c6463076ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728ad60c42494777a77a89260395a79e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzYtMS0xLTEtMA_c49a4464-530b-4370-869f-f9f9f2d8d424">122.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5360f78fa9cf47a49f8eb29cf63a6bb6_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzYtMy0xLTEtMA_e18d95b0-4167-4724-9b57-061e9c2fec6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1e4d4d27f141faaceb13587dfc5353_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzYtNS0xLTEtMA_24aa0bd6-9fab-44f1-8ab4-6bf4f8ab7469">122.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109944c309984c92ba371b3ed38bc32c_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzYtNy0xLTEtMA_4c1be5d5-2442-4be6-8da5-38754456edbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzctMS0xLTEtMA_46711f17-aa3f-42b6-bea3-9d34a29e7d79">1,974.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzctMy0xLTEtMA_33c1bfa4-626a-4e62-8e35-059605ed120a">271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88845b78404eafbfca745c512904b0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzctNS0xLTEtMA_e4510895-7423-4a00-94da-6d8431c3f6b8">1,703.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a386c121b94d3285b2e93991eee966_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzctNy0xLTEtMA_11300379-eb07-4e3d-ab1f-1cea378bf1c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzgtMS0xLTEtMA_d84f7b2e-dd70-4850-8ca3-6c862b156222">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzgtMy0xLTEtMA_b502ef48-55a4-4a0f-a48b-cb66955eeb77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88845b78404eafbfca745c512904b0_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzgtNS0xLTEtMA_34c8080d-25b1-4c02-a8c3-778db3800133">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a386c121b94d3285b2e93991eee966_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzgtNy0xLTEtMA_a89f711c-1a0c-40a4-aaf3-e643d1682483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzktMS0xLTEtMA_806a739b-3782-4330-8ddf-bd46e3d8342d">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzktMy0xLTEtMA_74245496-3957-4144-98d5-6f2ceffdb65c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88845b78404eafbfca745c512904b0_I20201231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzktNS0xLTEtMA_3ed6fedb-c232-4e7e-be29-11e23520b106">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a386c121b94d3285b2e93991eee966_I20201231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzktNy0xLTEtMA_13f798d5-795c-4a8f-9832-39af49a0ef9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEwLTEtMS0xLTA_71d467a1-d888-4283-84fd-8efa540f00d9">4,700.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEwLTMtMS0xLTA_5d4773d3-7bdc-4950-aecc-99d347908d3d">271.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88845b78404eafbfca745c512904b0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEwLTUtMS0xLTA_828966f6-bc35-4b48-b87f-b33ae18e184a">4,429.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a386c121b94d3285b2e93991eee966_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEwLTctMS0xLTA_39a78fa1-edf5-48d2-944f-63870bf5edfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEyLTEtMS0xLTA_7526de6f-a085-4280-bc0f-ffe704a30bb0">217.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEyLTMtMS0xLTA_0565a44b-d47b-457b-b40d-77a6a8901c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88845b78404eafbfca745c512904b0_I20201231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEyLTUtMS0xLTA_e3da15e0-9ad6-4fe2-8a02-18e03717e0eb">217.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a386c121b94d3285b2e93991eee966_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEyLTctMS0xLTA_ec2e0f78-ee39-430c-9fab-98edead7d5f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEzLTEtMS0xLTA_1b640dbe-d2ee-4e4e-bf33-4b9b2d4a2147">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEzLTMtMS0xLTA_8380f8e1-2d07-42ca-b29e-0552737bc9ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88845b78404eafbfca745c512904b0_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEzLTUtMS0xLTA_0d0198ff-54eb-44e9-b355-54ca6a728f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a386c121b94d3285b2e93991eee966_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEzLTctMS0xLTA_6c4357a2-a244-44d1-88b9-b8021244f495">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzE0LTEtMS0xLTA_efcfe6b6-88f4-4170-bd08-864f6882629c">477.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzE0LTMtMS0xLTA_e4b2ee19-228b-45f1-a033-24a3bc4ede10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88845b78404eafbfca745c512904b0_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzE0LTUtMS0xLTA_862f2072-8c81-46a7-bca2-c0cff111429e">217.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a386c121b94d3285b2e93991eee966_I20201231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzE0LTctMS0xLTA_5c63bbbb-3844-4c9a-9a83-8b8f4aea178a">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="iad8244891e274271a820a3e2d7553243" continuedAt="ieede186bae3c40fe8096bb911d2cc313"><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ia87a10cebbd04ff98d6f380a9418c910"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzItMS0xLTEtMA_f7c598ff-f750-46e0-a98f-8421ff68151a">2,541.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzItMy0xLTEtMA_80c7b3d5-5ad3-4b0d-8d2c-6826585476e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzItNS0xLTEtMA_a0afe955-c0a4-4c48-b44e-f8178ec2822c">2,541.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzItNy0xLTEtMA_9df591c0-ec7f-4c7b-8399-fe2899d75f3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e51f6583c34ffea8242489d150dcac_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzQtMS0xLTEtMA_9cd6e147-f286-4282-982c-a0250653e228">1,695.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9faf10577b784e7f8fe0df2ba091b6df_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzQtMy0xLTEtMA_3f4505c2-2445-4cae-a0ad-2d92307a1fb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5ca70e7a0449ef9804d477da976c90_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzQtNS0xLTEtMA_fcffbf16-57e5-4a6e-8f1e-f2d7fbe39140">1,695.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6ed8b6d39d4f95be135a06386353e2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzQtNy0xLTEtMA_67a20bde-809f-41ff-88dc-c71ce8a948ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f12a8b2a02a45b5a3b5d20a2203d529_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzUtMS0xLTEtMA_d79c8c30-3697-4b70-8c92-f1bed4b2dbcb">1,013.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b0ff43002742d382a430a6b312ac29_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzUtMy0xLTEtMA_23180ad5-6378-41f3-a32f-21c979ac5bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078713d9a8a24ed788012f01caca7e4c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzUtNS0xLTEtMA_79fe2fcd-7dde-4c7a-9963-eede67c8e49e">1,013.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f29144216246c0ba14b7f3d524b07d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzUtNy0xLTEtMA_2e4dbf76-eeb9-46a3-a613-90181013ec19">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37c27cce50943f586fccbb1bf987550_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzYtMS0xLTEtMA_66a6a4b3-0e5d-456f-9d18-59e2e1f5aa29">261.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ee55d0301d4a5296dbfd62c35d349f_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzYtMy0xLTEtMA_60cdb715-232b-4ced-87a9-7d563e1878cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10b6933b9ab4178884a89b8aeef21e2_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzYtNS0xLTEtMA_7d14fda0-4a1c-4363-871e-931012b8f3a9">261.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c85d1b3eb3432491fd04d440130a03_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzYtNy0xLTEtMA_f7b3f347-d038-4047-b3d2-898fec93d84b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzctMS0xLTEtMA_901b6218-93a2-44f5-b389-dbc159336cf0">337.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzctMy0xLTEtMA_f8dae1b1-6702-4c2f-80fa-05fed76ebfa2">7.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzctNS0xLTEtMA_7334c420-638a-4aa9-9ec8-449b74dbf6bd">329.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzctNy0xLTEtMA_ed04b452-fdeb-41f0-a93d-babbf5f48be1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzgtMS0xLTEtMA_f697a99b-5cc6-4b60-b7d7-1e99da8533c2">43.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzgtMy0xLTEtMA_45cba3c8-5738-410e-b36a-33c73c5b9eb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzgtNS0xLTEtMA_6dec33c2-ca5c-4d9c-b757-f8d468eb931f">43.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzgtNy0xLTEtMA_44a92d08-9b36-46ac-afe7-761c18505a48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzktMS0xLTEtMA_aabe7f96-a7d0-45d6-b49d-58199b622cfc">27.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzktMy0xLTEtMA_16c97557-acf9-40ef-b6f0-c088e3b03814">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzktNS0xLTEtMA_99995520-5b09-4b9e-b5fe-74b32ffaea1b">27.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231" decimals="-5" format="ixt:zerodash" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzktNy0xLTEtMA_c1fada28-cf4e-497a-8a05-4f3f5f2d1dce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEwLTEtMS0xLTA_4fafd492-fb22-44ac-bdce-11588d4e4872">5,920.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEwLTMtMS0xLTA_2d11687f-6915-4c15-a27a-63da7340a82a">7.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEwLTUtMS0xLTA_636d71da-528d-4a53-8244-f1af92d5fa20">5,912.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEwLTctMS0xLTA_543fbce6-ae96-4e09-99f0-0dd8249aca4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEyLTEtMS0xLTA_fc7293f6-0da5-445b-b56d-5858ac79fdf1">8.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEyLTMtMS0xLTA_bab018a0-7372-4eb4-9bed-e33141eda53b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEyLTUtMS0xLTA_f72e2141-d173-4586-ab55-54f03d766716">8.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEyLTctMS0xLTA_b5566199-e0d0-4452-84d6-ff33992809e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEzLTEtMS0xLTA_65ed69df-1fba-4704-a7ee-880967f4be50">346.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEzLTMtMS0xLTA_5d9a3961-7948-402c-bde3-3d953909cfdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEzLTUtMS0xLTA_dea46ec7-7145-47ef-ba73-9a63ada8c973">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEzLTctMS0xLTA_0bfd2987-3d18-4176-a684-3c412938ee76">346.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzE0LTEtMS0xLTA_aaaa7f39-3b99-4dff-9bbf-b79c62664f35">354.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzE0LTMtMS0xLTA_8cef8566-1021-4cb5-81b0-19edaf96816a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzE0LTUtMS0xLTA_295c41a5-18e7-448d-802e-29218e7a25c8">8.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzE0LTctMS0xLTA_d043b114-5d45-44ac-b413-9dfe7a06f249">346.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value during the years ended December&#160;31, 2020 and 2019. In addition, there have been no changes in valuation techniques during the years ended December&#160;31, 2020 and 2019. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in Sangamo Therapeutics, Inc. (Sangamo) common stock, Denali Therapeutics Inc. (Denali) common stock and Sage Therapeutics, Inc. (Sage) common stock and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Financial Instruments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares of Ionis common stock were initially subject to certain holding period restrictions that have since expired. The fair value of this investment was a Level 1 measurement as of December&#160;31, 2020. For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzU0OTc1NTgxNTY0MTA_dab0d7a2-f8a0-4512-a0d1-059c6cd87d23" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphYWE1NTNlYjkxZmM0NGZlOTI0YTljNzVkNTViZjI4Zi90YWJsZXJhbmdlOmFhYTU1M2ViOTFmYzQ0ZmU5MjRhOWM3NWQ1NWJmMjhmXzMtMi0xLTEtMTEyMDc_1ca42066-20f6-4711-8d39-c9d64e12d0cd">259.8</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia29e9f9c6a0f4c099a0d0b872c4ab3e0_I20201231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphYWE1NTNlYjkxZmM0NGZlOTI0YTljNzVkNTViZjI4Zi90YWJsZXJhbmdlOmFhYTU1M2ViOTFmYzQ0ZmU5MjRhOWM3NWQ1NWJmMjhmXzMtOC0xLTEtMTE3NTg_2e9f7f93-e4e1-480f-8891-c93ee53c1dd3">0.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0afc7497a10045ec82e92ec6f6142457_I20201231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphYWE1NTNlYjkxZmM0NGZlOTI0YTljNzVkNTViZjI4Zi90YWJsZXJhbmdlOmFhYTU1M2ViOTFmYzQ0ZmU5MjRhOWM3NWQ1NWJmMjhmXzMtMTAtMS0xLTExMjA5_4d408373-abd7-4a3a-8f1e-d710793854a7">0.60</ix:nonFraction>%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from <ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" name="biib:TechnologicalAndRegulatorySuccessProbability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NDU1MTg_cbfefd24-33b9-4887-8532-a0e0624ed260">39.9</ix:nonFraction>% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ieede186bae3c40fe8096bb911d2cc313" continuedAt="ied150512f1774a538855ef917fad6586"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to assets and liabilities that are recorded at fair value on a recurring basis, we record assets and liabilities at fair value on a nonrecurring basis as required by accounting principles generally accepted in the U.S. (U.S. GAAP). Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzQzOTgwNDY1MzA5MTc_9c8269b0-7b55-402c-8c06-144e7f202a2f" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:38.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Book Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Book Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB111 intangible asset</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892b13c4cafa42ecb4c07f03ecf1b9af_I20190607" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo3NjBmN2Q3NjIxMzU0ZjAyODRlZjFlNGE0NjMwYmJmMy90YWJsZXJhbmdlOjc2MGY3ZDc2MjEzNTRmMDI4NGVmMWU0YTQ2MzBiYmYzXzItMi0xLTEtMTg1NTY_2615cb68-341e-4d0d-b058-1d4db120e513">480.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31f77918266b4800a5e937031d200d33_D20200608-20201231" decimals="-5" sign="-" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo3NjBmN2Q3NjIxMzU0ZjAyODRlZjFlNGE0NjMwYmJmMy90YWJsZXJhbmdlOjc2MGY3ZDc2MjEzNTRmMDI4NGVmMWU0YTQ2MzBiYmYzXzItNC0xLTEtMTg1NTg_e2d6c847-4965-4aea-b485-30f77a17ad1d">115.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib982081d33b9432380d458461cb24794_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo3NjBmN2Q3NjIxMzU0ZjAyODRlZjFlNGE0NjMwYmJmMy90YWJsZXJhbmdlOjc2MGY3ZDc2MjEzNTRmMDI4NGVmMWU0YTQ2MzBiYmYzXzItNi0xLTEtMTg1NjA_fdd0b994-d7fd-4c8a-8751-342596968717">365.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, we recorded a partial impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i6e983ff4043d40f0913bb5c532a2f59c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NDc1NjQ_f60e8281-8e6f-4aa7-b5d6-850c67baf59e">115.0</ix:nonFraction>&#160;million related to BIIB111. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzU0OTc1NTgxNTY0MDk_b7b6a68a-e584-4864-966e-af47fcdaf294" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.900% Senior Notes due September 15, 2020</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzItMS0xLTEtMA_ae316169-1bd0-43ab-adef-cee443feaaa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bbc25a9c5ac47fbbfd534ee97a1d39c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzItMy0xLTEtMA_3f4d0c16-f073-4743-85ce-3e0066869c2b">1,509.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d8fda27d15472886e7714ecfd74f13_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzMtMS0xLTEtMA_0be07fc1-54e6-4f10-886e-e1d12beaf941">1,054.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i801a46869f664fecb61055c870823b33_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzMtMy0xLTEtMA_f02abd31-fb0a-40ff-95b4-ae4a4fc8ab46">1,038.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1b899a302148ca9891b0255cc8aa0d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzQtMS0xLTEtMA_6d4d41c9-6536-42c2-8951-06c7e8daba7a">2,003.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6b6dd5c2efe4f5396abf0aff9bfeccf_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzQtMy0xLTEtMA_ddf2fe0e-3b7e-4531-9c2e-5cb6069c1a3f">1,897.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c421dee5311428bb63a943e6edd3b3b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzUtMi0xLTEtMjkxMg_f71a1839-dc9d-450f-b544-9df548237199">1,557.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff588847a4742dbb38528249abffe4a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzUtNC0xLTEtMjkxMg_820c3b85-0d0b-42c2-95ee-a01aeaa5adda">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd13c0f2522452cb9725ea76f4505d0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzUtMS0xLTEtMA_54312191-7dc0-4a38-8689-9a8ea9246911">2,365.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0204ca1f1214960bd167eb5e80b1a81_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzUtMy0xLTEtMA_99b0fd1c-2211-4953-9b36-d29b042413be">2,107.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic30eadf1122f4f10b6945f7d760771bf_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzctMi0xLTEtMjkxNQ_1dde538d-2009-4bee-bb5c-888a92ac0c3f">1,536.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83bcad67dce847b8b91749bab6735d86_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzctNC0xLTEtMjkxNQ_c5c9dccb-5ea7-4495-8c5c-426011a5350d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzYtMS0xLTEtMA_388da5f9-88f1-4930-8c15-57f6bdb48c26">8,515.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzYtMy0xLTEtMA_7a414a27-24d7-461e-9989-f9947152b4aa">6,553.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzQzOTgwNDY1Mjg2Mzk_09e91436-dfc1-4f2f-90d8-f5879528c60a">2.900</ix:nonFraction>% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i925b36a148674fc19a08cbd449595002_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzQzOTgwNDY1Mjg2NDc_db24c87b-bb74-410d-a171-f925441a0348">3.0</ix:nonFraction>&#160;billion. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen International Neuroscience GmbH (BIN)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzcxMzQ_ed743172-c1a7-4933-91af-82278cd776c8" continuedAt="i36d7099ba18b49ac961cfb1c35f01294" escape="true">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i36d7099ba18b49ac961cfb1c35f01294"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzItMS0xLTEtMA_4a37cd2b-1f2c-454a-9e85-5dd1286bc835">346.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92764f5eb5834b79ae55dff4c1df9d03_I20181231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzItMy0xLTEtMA_6d15f948-aaf9-4f6e-a2a9-3a09ffbd9319">409.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic89f75651f684c4e8666f45255e68b39_D20200101-20201231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzMtMS0xLTEtMA_33cb6d2b-14f8-4e62-8ebf-130425588dbb">86.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56a9f448c619444ab4fff72a5de9ba77_D20190101-20191231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzMtMy0xLTEtMA_b4436dd2-ec16-4bdf-aecf-c371b2ef5957">63.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89f75651f684c4e8666f45255e68b39_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzQtMS0xLTEtMA_0f97119d-7f62-4613-bb7b-8504320db8a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a9f448c619444ab4fff72a5de9ba77_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzQtMy0xLTEtMA_e54f4883-a28a-423d-b80a-894e15e48db0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of year</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzUtMS0xLTEtMA_08ce28d3-d2a8-474e-9179-eb012939b565">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzUtMy0xLTEtMA_c57f8659-ef3d-4b64-bf7d-60dee7cdad3a">346.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, approximately $<ix:nonFraction unitRef="usd" contextRef="if9f5fdb4ff554001875fedb563688ba3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzE2OTE_e6b70ddf-2cdd-489c-9b96-5052c76a6ae2">110.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibe586d2389a346e4b21234342c93c79a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzE2OTg_5c668cee-c7dd-4739-9df4-a3f717f356a9">197.7</ix:nonFraction> million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, changes in the fair value of our contingent consideration obligations were primarily due to our discontinuing development of BIIB054 for the potential treatment of Parkinson's disease, resulting in a reduction of our contingent consideration obligations of $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzI3NDg3NzkwOTQ0NTY_71d9d030-d487-471d-b094-6ac318e83554">51.0</ix:nonFraction>&#160;million as well as other changes in the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ied150512f1774a538855ef917fad6586"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probability and the expected timing of the achievement of certain remaining developmental milestones, changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzE2NDkyNjc0NTQ5NzA_dc245a5a-9968-441f-a779-03102080009b">61.2</ix:nonFraction>&#160;million as well as other changes in the probability and expected timing of achievement of certain developmental milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convergence Pharmaceuticals Holdings Limited</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of $<ix:nonFraction unitRef="usd" contextRef="if183ac868dc34ca58fc0c53525b4c288_D20150201-20150228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM1NzI_7b947eb3-5c44-4bf6-8dba-d3fa1412aa74">274.5</ix:nonFraction> million. As of December&#160;31, 2020 and 2019, the fair value of this contingent consideration obligation was $<ix:nonFraction unitRef="usd" contextRef="i648eef4285664a8dac0cdbc16d4a15eb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM2NTY_4cdea13c-0125-49ec-b123-788f380f327a">259.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7237b9cff6a4464cb92770b4bf1cbbc2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM2NjM_e04c3c66-9fdd-48ba-affa-64e38bab20b1">244.6</ix:nonFraction> million, respectively. Our most recent valuation was determined based upon net cash flow projections of $<ix:nonFraction unitRef="usd" contextRef="i648eef4285664a8dac0cdbc16d4a15eb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM3NjI_ccd7782b-242c-4d2e-8158-bbf0a5dd98d0">400.0</ix:nonFraction> million, probability weighted and discounted using a rate of <ix:nonFraction unitRef="number" contextRef="i51282ea551b1459695602c42c153aa71_I20201231" decimals="3" name="biib:FairValueMeasurementInputs" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM4MTg_6f324ac4-40af-462f-8c22-2be3df826f42">0.6</ix:nonFraction>%, which is a measure of the credit risk associated with settling the liability. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen International Neuroscience GmbH</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of $<ix:nonFraction unitRef="usd" contextRef="i90382b76ddef440099125efad57c3a58_D20101201-20101231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzUwMzk_dada9aa0-60d5-49aa-abbe-7b8f56aea2c4">81.2</ix:nonFraction> million. We discontinued further development of BIIB054 for the potential treatment of Parkinson's disease based on the results of a Phase 2 study of BIIB054. Additionally, during the third and fourth quarters of 2020 we discontinued other programs related to our acquisition of BIN for which we had immaterial contingent consideration obligations. As a result, the fair value of the contingent consideration obligations related to our acquisition of BIN has been adjusted to <ix:nonFraction unitRef="usd" contextRef="i2cc1602563fe4003b79c44b2d4563182_D20200101-20201231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTMwNzU_46961842-6998-4ffc-99c0-3a7bc1827efa">zero</ix:nonFraction>, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="idc66d48ef7a8480184a55afd9eb1ca13_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzcxNDY4MjU2MDMyMjk_0dc688e3-b55c-480f-8df6-98f86a6160ec">101.5</ix:nonFraction> million for the year ended December&#160;31, 2020. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired IPR&amp;D</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the acquired IPR&amp;D assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. These assets are tested for impairment annually until commercialization, after which time the acquired IPR&amp;D will be amortized over its estimated useful life using the economic consumption method. In connection with our acquisition of BIN, we recognized a $<ix:nonFraction unitRef="usd" contextRef="iff949adf9ab740fbb27bef3b64e6be50_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTM3NTQ_80c9737e-c5f5-4b38-ace6-b07b813bbc87">110.9</ix:nonFraction>&#160;million acquired IPR&amp;D intangible asset. We discontinued further development of BIIB054 for the potential treatment of Parkinson's disease and recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="idb36452ab02142988e739a2d7605d7ff_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTIxNTA_f975ab37-3474-4b9a-9354-554e328307e5">75.4</ix:nonFraction>&#160;million during the fourth quarter of 2020 to reduce the fair value of the IPR&amp;D intangible asset to <ix:nonFraction unitRef="usd" contextRef="i76d271b53e29411abc2a151b7350aeb7_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTIxNzE_3e9afb41-8d01-46ad-b79a-4fbb9c1d2b4d">zero</ix:nonFraction>. In connection with our acquisition of Stromedix Inc., we recognized a $<ix:nonFraction unitRef="usd" contextRef="ibff8fc3255cf42698cf5d8a08d11df44_I20120331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzYzNTY_7fff92f8-b897-42a8-a1d6-a06cd7eedb5c">219.2</ix:nonFraction> million acquired IPR&amp;D intangible asset. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF and recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i8be1727d99e64340bb2d309e36968ac8_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTM4NTU_7f925496-803b-4590-ae9d-edea0c2a6b49">215.9</ix:nonFraction>&#160;million to reduce the fair value of the IPR&amp;D intangible asset to <ix:nonFraction unitRef="usd" contextRef="ib5ad52311e434feca77f912a91898714_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzQzOTgwNDY1Mjg4MTQ_2d5c0b5c-b7f5-4462-a776-8e59a80642f7">zero</ix:nonFraction>. In connection with our acquisition of Convergence, we recognized a $<ix:nonFraction unitRef="usd" contextRef="i8a46f2c40caf49ea87719f6b7a9ee5bf_I20150228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzY3MDE_8933ca5e-134f-4bd1-9790-d72a831b2ea5">424.6</ix:nonFraction> million acquired IPR&amp;D intangible asset. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling $<ix:nonFraction unitRef="usd" contextRef="i2afce0b61c084d69ab3183af171ee801_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTM4MjQ_f91e83e3-3f6c-40ba-861a-5e68cae11d3b">189.3</ix:nonFraction>&#160;million. For additional information on our IPR&amp;D intangible assets, including a discussion of our most significant assumptions, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_268"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ4MDg_84e4fbf9-b3a6-48fd-9572-604565369629" continuedAt="i4c5fbfdff4f34e97ac6829c9b35dff3d" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i4c5fbfdff4f34e97ac6829c9b35dff3d" continuedAt="i552ec2d775294a0ea8f6134ec851ad7c"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ4MDY_d3ce39b3-ec6e-4bc5-877f-274be2f1f324" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a1894f77974cf2b8aedcc04b6c5f86_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzItMS0xLTEtMA_faa4430b-1f73-4f9a-afd1-6793e60b7f78">61.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e9fb1cd6824fbb85da3d9df004f1ff_I20191231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzItMy0xLTEtMA_59db27d4-ddad-4d86-936d-d158390d597c">384.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a84817f64104c25b845cd16a8f0ab52_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzMtMS0xLTEtMA_933dae92-835b-47f2-a01e-d57e0223aff4">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9959b5f071814b32bb44c12f7979e4f8_I20191231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzMtMy0xLTEtMA_d4711a54-2718-4d75-84d2-bd49ec4575c8">368.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i368be994479c4748a98800a90058bb03_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzQtMS0xLTEtMA_225dab2e-a1c9-47a6-90aa-2ead15fd7569">505.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia668578daa974ee2b66900846a7f2aa4_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzQtMy0xLTEtMA_f4e3ba69-7acc-488b-901c-2e0b38cfef84">1,628.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8420ca71f3b4038bcfda28fcd31dc62_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzUtMS0xLTEtMA_a1e936af-ba65-40f5-a352-32eb8dc65051">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3d526e5639439988a6a4d0a1596dbc_I20191231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzUtMy0xLTEtMA_942e779b-6d2a-49c4-b2bc-d0c4733841a7">159.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzYtMS0xLTEtMA_7c92d76c-f3d4-4d2a-beb4-4833bb3af4cf">626.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzYtMy0xLTEtMA_1d6495e5-b58f-4739-8f97-43ed328b158a">2,541.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ3OTc_17e5332b-67bc-4324-90b0-382d9b5dff6e" continuedAt="i0e45fdcd9f274e799b6be9553f13c319" escape="true">The following tables summarize our marketable debt and equity securities, classified as available for sale:</ix:nonNumeric></span></div><ix:continuation id="i0e45fdcd9f274e799b6be9553f13c319"><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1444a522fb044ee7a105512067bac273_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzItMS0xLTEtMA_048d9713-c352-46a2-a9c0-187e525e0e59">897.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1444a522fb044ee7a105512067bac273_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzItMy0xLTEtMA_b5e8ed2e-25cb-42c5-b976-4eec3d41d586">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1444a522fb044ee7a105512067bac273_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzItNS0xLTEtMA_6f81d0ce-e50a-45fb-b621-c7488ff475b6">0.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1444a522fb044ee7a105512067bac273_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzItNy0xLTEtMA_ee73f516-ed49-46b0-bd05-0b5292ff505f">898.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff8968812da45e2a9aa27638fc19580_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzMtMS0xLTEtMA_2837cdb1-a78b-40a9-ac75-1e2c008ea100">402.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff8968812da45e2a9aa27638fc19580_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzMtMy0xLTEtMA_abc4001d-1dd9-46e4-b3d3-2eeff0317281">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ff8968812da45e2a9aa27638fc19580_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzMtNS0xLTEtMA_35dea5d0-044c-4612-8cad-84107dfd524b">0.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff8968812da45e2a9aa27638fc19580_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzMtNy0xLTEtMA_4aca9a76-eb57-4100-ad82-9a2c2e896932">403.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd740912ac448feb53d1e58c59635f4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzUtMS0xLTEtMA_bfdb930e-5ee2-4aee-a58f-ea79837081bb">380.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd740912ac448feb53d1e58c59635f4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzUtMy0xLTEtMA_9a0773e0-bb32-4691-9e9e-6145abdcf57c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd740912ac448feb53d1e58c59635f4_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzUtNS0xLTEtMA_c262957b-fa6f-4d0b-8449-36b56749d49d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd740912ac448feb53d1e58c59635f4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzUtNy0xLTEtMA_cc7b1bab-1613-45fb-8df7-417e6b726dbf">380.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3019ec63604b1e9670c0bddc262a57_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzYtMS0xLTEtMA_0a20bc88-573d-4d4a-9602-9d965cc22b9c">245.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3019ec63604b1e9670c0bddc262a57_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzYtMy0xLTEtMA_19254ca9-1705-485a-afc9-682d45d8f3ac">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3019ec63604b1e9670c0bddc262a57_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzYtNS0xLTEtMA_db836fcd-8bd3-4ccb-8ef2-14083eed59b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3019ec63604b1e9670c0bddc262a57_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzYtNy0xLTEtMA_a4921b25-872a-4369-868c-b257454dbaae">246.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzgtMS0xLTEtMA_bf239143-ec45-447c-92ec-6be5d07a913f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzgtMy0xLTEtMA_54c311ea-105a-41b7-8cd7-32c67ea46e11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzgtNS0xLTEtMA_eb6a79e1-da28-4c03-bf0f-282898318abf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzgtNy0xLTEtMA_2539bbc1-6ffc-4345-9f2a-6752399704c4">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6eeff5022443a911867c6740b0321_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzktMS0xLTEtMA_72de1db6-b630-4308-b01d-e806ac457920">122.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6eeff5022443a911867c6740b0321_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzktMy0xLTEtMA_6fb92f38-cfd0-48cf-a776-534dbc338de0">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43d6eeff5022443a911867c6740b0321_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzktNS0xLTEtMA_c730e091-1c9f-4f2d-bcc7-c5da7afe0363">0.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d6eeff5022443a911867c6740b0321_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzktNy0xLTEtMA_33c8be34-ed99-4579-99d6-0ad8763ffa83">122.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEwLTEtMS0xLTA_0af4fbff-690d-4c1d-95fa-cc4d4a8a5f50">2,049.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEwLTMtMS0xLTA_986213fd-2342-4c62-b149-491679cbf6e6">2.3</ix:nonFraction></span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEwLTUtMS0xLTA_b40b5b8d-c837-4735-834e-4e344a58aa7c">0.4</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEwLTctMS0xLTA_c8c85aac-78c3-4218-a7a1-d01b0384d975">2,051.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1018d5a2a449484ca302a3ba827164ca_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEyLTItMS0xLTE0NDY3_e6cf92dd-c1b9-4e92-ba1d-8e357a117cbc">70.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1018d5a2a449484ca302a3ba827164ca_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEyLTQtMS0xLTE0NDgx_fd30cf38-1b04-4bc2-9268-c8138e99c71a">15.9</ix:nonFraction></span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1018d5a2a449484ca302a3ba827164ca_I20201231" decimals="-5" format="ixt:zerodash" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEyLTYtMS0xLTE0NDcy_4c18484b-4297-499b-b29f-8367f20957e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1018d5a2a449484ca302a3ba827164ca_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEyLTgtMS0xLTE0NDc2_a60066eb-c773-4678-adb2-f77b870d9936">86.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f82abfdb08f42288d72dca49fe6886a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzExLTEtMS0xLTA_3eb82ad1-a597-4045-9fc3-d9f05c726567">1,168.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f82abfdb08f42288d72dca49fe6886a_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzExLTMtMS0xLTA_bf1c383c-43e7-4421-be11-b39e95223c11">733.8</ix:nonFraction></span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f82abfdb08f42288d72dca49fe6886a_I20201231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzExLTUtMS0xLTA_0698e527-27a8-4de9-b5f0-58f70958ad00">14.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f82abfdb08f42288d72dca49fe6886a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzExLTctMS0xLTA_216a392b-19e9-4000-91c5-f5c00f59952d">1,887.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9549e6582b0842b0bb8b80335d95f5c2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzItMS0xLTEtMA_aada3a26-47ad-4f05-a529-076d1dea900a">1,057.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9549e6582b0842b0bb8b80335d95f5c2_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzItMy0xLTEtMA_a63b9992-774b-4b77-b4b8-e28b7fecb477">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9549e6582b0842b0bb8b80335d95f5c2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzItNS0xLTEtMA_0dbd5d1e-97c5-4f03-8dc9-30ae67b83f5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9549e6582b0842b0bb8b80335d95f5c2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzItNy0xLTEtMA_23c9519a-0c4a-422e-ad5c-43efd5749ada">1,058.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6123894aef18412c8778f35bebcb4b94_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzMtMS0xLTEtMA_faabe316-ec61-4d42-8c67-d342bce04cc0">633.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6123894aef18412c8778f35bebcb4b94_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzMtMy0xLTEtMA_24940404-5d58-48b1-bead-befb1699c4d1">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6123894aef18412c8778f35bebcb4b94_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzMtNS0xLTEtMA_c0815a2d-2f74-4fae-a2aa-607f8a8a9af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6123894aef18412c8778f35bebcb4b94_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzMtNy0xLTEtMA_17931a23-a66e-4643-a269-5b007f39301d">636.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17d3f0012ad49839eb5e30af562ce46_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzUtMS0xLTEtMA_37494188-ad0c-4e48-89f9-e4df6f37006a">502.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17d3f0012ad49839eb5e30af562ce46_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzUtMy0xLTEtMA_f0daffd8-6ec4-449a-bb6e-d304621320e5">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17d3f0012ad49839eb5e30af562ce46_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzUtNS0xLTEtMA_a3594abd-4e24-43f2-8c49-02727d467b15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17d3f0012ad49839eb5e30af562ce46_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzUtNy0xLTEtMA_63b94350-6588-4c43-9564-d5f07218d84a">503.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6df684829d457191dd58d3cd5cdf67_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzYtMS0xLTEtMA_ecde79a8-769f-4e03-a540-a51a5bae50c4">510.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6df684829d457191dd58d3cd5cdf67_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzYtMy0xLTEtMA_0a2eb670-699a-4b86-bba6-0e7684bdcd42">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c6df684829d457191dd58d3cd5cdf67_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzYtNS0xLTEtMA_71bfa28f-a129-440c-90d1-707d2f39906a">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6df684829d457191dd58d3cd5cdf67_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzYtNy0xLTEtMA_621eff17-b499-4bd0-a5a7-1ef5e250dcc5">510.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dfeca1a2e48493283b2d3282a9abbda_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzgtMS0xLTEtMA_ceb0d758-cc5c-438b-b834-45ac82f7f871">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dfeca1a2e48493283b2d3282a9abbda_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzgtMy0xLTEtMA_06b8b529-6501-4007-befa-5892ceefb11e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dfeca1a2e48493283b2d3282a9abbda_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzgtNS0xLTEtMA_ac2dd39e-c74b-4ceb-bed4-11b43b015cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dfeca1a2e48493283b2d3282a9abbda_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzgtNy0xLTEtMA_b6ae0944-c366-44df-8e8f-ae2d21716b25">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8344f64bdd4767b10aa2100406065d_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzktMS0xLTEtMA_639eb2ca-8ab6-479f-9a49-20429416724c">260.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8344f64bdd4767b10aa2100406065d_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzktMy0xLTEtMA_3474daf0-fbfd-4234-8f49-7676e2f19564">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb8344f64bdd4767b10aa2100406065d_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzktNS0xLTEtMA_225bd31b-6b4f-4099-a438-3eccb64ce32d">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8344f64bdd4767b10aa2100406065d_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzktNy0xLTEtMA_1df68c8d-557a-4765-9ded-5e551370cf9f">260.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzEwLTEtMS0xLTA_337c4a24-3536-43b5-90fa-5b3c2a1a6014">2,965.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzEwLTMtMS0xLTA_ed6826c3-cacb-4079-831d-f445e01d1bd8">6.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzEwLTUtMS0xLTA_58737955-afdc-43e0-a496-7c37575f3561">0.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzEwLTctMS0xLTA_b236fda0-639d-424e-82f6-bfde061ce4fb">2,970.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if324696bb41c43df9e57bee9ea0785b5_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzExLTEtMS0xLTA_52a799bb-aa76-4f07-b3aa-b1275b623288">218.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if324696bb41c43df9e57bee9ea0785b5_I20191231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzExLTMtMS0xLTA_3fe60171-7bb0-4d1f-ac0f-459917141732">132.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if324696bb41c43df9e57bee9ea0785b5_I20191231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzExLTUtMS0xLTA_4699352a-8d44-4da5-8931-504a23a51da1">13.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if324696bb41c43df9e57bee9ea0785b5_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzExLTctMS0xLTA_16c2f777-5402-4179-ba4d-758813ec6e9a">337.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i552ec2d775294a0ea8f6134ec851ad7c" continuedAt="i134b252487f148e79f635652e05c6a0e"><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ3ODQ_7fac16c8-fabe-42e6-bad3-a20af2fe5b46" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.299%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzItMS0xLTEtMA_84c06e90-8e04-4fc1-942f-84c0177539f4">1,278.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzItMy0xLTEtMA_f955f0f1-4b93-4eaf-9353-8340726d8c50">1,278.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzItNS0xLTEtMA_1a677462-a289-4729-a60d-ec353f685bdf">1,562.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzItNy0xLTEtMA_4d33e1ff-205b-45cd-96c0-205b36b26ecd">1,560.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzMtMS0xLTEtMA_9c2dec4d-20c5-4ee4-a609-ece229a0594f">722.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzMtMy0xLTEtMA_73508834-3896-488b-a2a2-8aaa27d9e54b">721.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzMtNS0xLTEtMA_4aa31144-c843-4db0-98e6-73034be571f1">1,234.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzMtNy0xLTEtMA_84d4b89b-59ff-4004-bc72-0e28cda05334">1,230.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzQtMS0xLTEtMA_1fa4372b-9734-461c-bfc1-b89f9809766f">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzQtMy0xLTEtMA_56314755-f215-4c14-b437-02b59d2d0c60">49.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzQtNS0xLTEtMA_4a6a3c1c-ff45-4213-841c-40ba34b14de1">173.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzQtNy0xLTEtMA_c418a184-fc72-4e10-a115-c26da79438b3">173.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzUtMS0xLTEtMA_ae0a0c79-2bda-4ea7-9f00-434399ca68f5">2,051.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzUtMy0xLTEtMA_e44ad2ca-d376-484f-8471-c1c57b5dcda8">2,049.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzUtNS0xLTEtMA_66d4f8b0-c8d8-4522-92b0-6966e5a36870">2,970.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzUtNy0xLTEtMA_136bcdb4-aaf2-41e2-a8de-f2a1fc916b9e">2,965.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of December&#160;31, 2020 and 2019, was approximately <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzEwMTE_1d2e15c4-84f1-43aa-9769-a2472d53a2ba">11</ix:nonNumeric>&#160;months and <ix:nonNumeric contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" format="ixt-sec:durmonth" name="biib:AverageMaturityOfMarketableSecurities" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzEwMjU_85a82449-444e-4996-b17b-3812f710efd8">14</ix:nonNumeric> months, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ4MDI_9b5d8941-6d5a-4e54-ac20-2884bf6f4db3" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzItMS0xLTEtMA_ef5b6bf4-eaf5-4c12-a805-80628d9f3d8c">7,299.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzItMy0xLTEtMA_b4680c3c-0165-4e42-8c3a-56a29f0be997">6,007.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzItNS0xLTEtMA_f2845eb3-0415-463e-a627-17722f3c563d">9,173.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzMtMS0xLTEtMA_c6be72f2-1b86-4037-93fc-711957530bbf">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzMtMy0xLTEtMA_22538285-1876-4457-90c1-fd1b4e2aa5d6">6.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzMtNS0xLTEtMA_ef2c5aac-d211-445f-b746-8ca01f2f97ea">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzQtMS0xLTEtMA_41e0410e-4f6d-424b-8a09-bff9278ff6d4">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzQtMy0xLTEtMA_e38c02f2-6ca6-4dc8-87b3-adbd8c32434c">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzQtNS0xLTEtMA_ec7349fc-f280-46f7-a08a-c41ed2f2e738">11.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the year ended December&#160;31, 2020, 2019 and 2018, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="i29edf7836e8242968b86b1318f81fb38_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzE4ODM_23aaf3f6-4096-4b68-b7cd-26545ea1306c">2,024.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8c9faf0348614580b6500e84022870f6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:StrategicInvestmentPortfolio" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzE4OTA_affa72ba-c14d-42ab-89a8-ff9466fff7be">393.9</ix:nonFraction> million, respectively, which are included in investments and other assets in our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our strategic investment portfolio for the year ended December&#160;31, 2020, was primarily due to our purchases of Sage, Denali and Sangamo common stock, as discussed below. These purchases were reflected as net cash flows used in investing activities within the consolidated statement of cash flows.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this collaboration in December 2020 we purchased approximately <ix:nonFraction unitRef="shares" contextRef="i745ea53017d44a209cd4871e1fc8dbb3_I20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInCommonStockSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzEwOTk1MTE2Mzk0ODA_e6fd7435-74b1-433c-85c0-339b71aa100b">6.2</ix:nonFraction>&#160;million shares of Sage common stock. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i58da0dc381ad4518baba0871c615c8cc_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQzOTgwNDY1Mjg2MTc_0d88afb3-4c9f-42a2-833a-00e15683a2e5">zero</ix:nonFraction> based upon the fact that Sage and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i134b252487f148e79f635652e05c6a0e"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately <ix:nonFraction unitRef="shares" contextRef="i4c8cbdc550c74ee4ae87ae5b4bc3ac20_I20200930" decimals="-6" format="ixt:numdotdecimal" name="biib:InvestmentInCommonStockSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzEwOTk1MTE2Mzk1Njc_d6a6c5c9-c4bf-4e95-9413-b86614c6e882">13</ix:nonFraction>&#160;million shares of Denali common stock in September 2020. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i9ccffca563b74d8792d57e3f776ccc3d_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQzOTgwNDY1Mjg2MjY_e589b041-9bd7-4c5f-9f53-37961ee61e79">zero</ix:nonFraction> based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased approximately <ix:nonFraction unitRef="shares" contextRef="i5d0ec7fb81814c1188c3590687864a65_I20200430" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInCommonStockSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzE2NDkyNjc0NTE3Nzk_21b24d69-43d7-4cba-a361-ac0166801c8c">24</ix:nonFraction>&#160;million shares of Sangamo common stock. This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo common stock and a dividend yield of <ix:nonFraction unitRef="number" contextRef="i4877a3944c7c442fb949a47bf0f67c40_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:DividendYieldPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQzOTgwNDY1Mjg2MzU_454ee840-8f4d-4796-b28f-8b8e70896fbe">zero</ix:nonFraction> based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="i7391238241af432e81e836c4866c9d90_I20180630" decimals="3" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQxNzc_758b1eb1-33a4-42cb-adb5-2863cfeb4110">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQxOTc_f8f3f1b7-eea6-4a9c-9328-961f4718561c">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQyOTA_4c88c01a-ed83-4c5d-9abb-d950650aea32">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQzMTE_3e883ba5-3f22-40bd-8003-27ba98c7c4f4">676.6</ix:nonFraction> million) to Samsung BioLogics. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ0MTk_d492f79b-9e7c-49d4-be30-f1e3eeb713af">673.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ0NDA_3b4657d4-f201-42f2-8f06-8cbc5485339f">620.2</ix:nonFraction> million) and <ix:nonFraction unitRef="krw" contextRef="i8686b81ecb37418dbc5bcc179b1e109c_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ0NDg_7ff763be-99ac-491f-b185-7f1cde51bf5a">670.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i8686b81ecb37418dbc5bcc179b1e109c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ0Njk_e41505a1-9d47-4e47-98da-bf916f11ea5b">580.2</ix:nonFraction> million), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_271"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwODM_e50ecbdb-b046-49b7-9e85-9d401507af14" continuedAt="i1f94f45aa282478f9382777fcf8ecd54" escape="true">Derivative Instruments</ix:nonNumeric></span></div><ix:continuation id="i1f94f45aa282478f9382777fcf8ecd54" continuedAt="iaeb136d33933472086a3402c7b2170be"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of December&#160;31, 2020 and 2019, had durations of <ix:nonNumeric contextRef="ic69589c021a84ef3b51246299f3819f4_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzY0Nw_226d5997-76a1-4a3a-9005-9cc2b2052d41">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i6ece1a557c614598b419f009a522970e_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzY1Mw_4d0d5d76-c365-42f5-970c-fc529c9539e9">24</ix:nonNumeric> months and <ix:nonNumeric contextRef="i265b3873c6154df1b98c0e68348adf62_D20190101-20191231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzY2MA_320a2abc-a60e-48ed-aa97-4186a3f294a7">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i304cadf22e1f4d51a2a058761d61f7e7_D20190101-20191231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzY2Ng_8f823e1e-f869-4af6-a595-ff14e70a6d7a">15</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="iaeb136d33933472086a3402c7b2170be" continuedAt="ibff806b8ad9c4985946c536bf923b0a5"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and fair value changes of excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwNzM_bba846e2-c9fc-4927-a698-68128fb9bf4a" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount<br/>As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9548c02f9465476885ffa4b8feb4449a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzItMS0xLTEtMA_1bf47532-d900-4372-8ac6-7eb5f95ef7ba">2,979.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d0fec390494bbf9e3fa14a10590ee3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzItMy0xLTEtMA_2e5389e8-5321-4421-b216-25ca16daed71">1,892.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72fd8f14ca0e40fdb0a695a13b9d715f_I20201231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzMtMS0xLTEtMA_e1b49c8b-dc2f-47fa-9831-f70b6ebf776b">250.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f26f772ded49dea5267467d918765a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzMtMy0xLTEtMA_970f279a-9b3b-4504-963b-7b88e7a0a1e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfac85de776a4ccdb1c2c9949959fc1e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzctMS0xLTEtMA_c79e7d7d-7bbe-4e71-9a67-b114fb31f39c">3,229.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba1524cdf8b541d993f6af6346716c26_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzctMy0xLTEtMA_b69bb3ef-e023-4f9f-989f-56cf789da41e">1,892.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $<ix:nonFraction unitRef="usd" contextRef="i3984a0ac91e341979ac9c6a390e24ddb_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE3OTg_3a0de465-8c05-4139-bab2-b5b8fcc29d07">212.5</ix:nonFraction> million as of December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net gains of $<ix:nonFraction unitRef="usd" contextRef="ib2454550ae594d8ab5f93ecc8828eb34_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE4MjQ_399f306e-2ac3-4876-bd27-9a42c608f5c6">0.5</ix:nonFraction> million as of December&#160;31, 2019, and net gains of $<ix:nonFraction unitRef="usd" contextRef="i9e5d7ed77346446bbda233cc544e7a56_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE4NTU_01edcace-cd75-4c9f-9833-dc2d925f8815">27.3</ix:nonFraction> million as of December&#160;31, 2018. We expect the net losses of $<ix:nonFraction unitRef="usd" contextRef="i3984a0ac91e341979ac9c6a390e24ddb_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE4OTU_3a0de465-8c05-4139-bab2-b5b8fcc29d07">212.5</ix:nonFraction> million to be settled over the next <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE5MjY_64c15284-1351-48d8-a5e8-d75993d3975a">24</ix:nonNumeric> months, of which $<ix:nonFraction unitRef="usd" contextRef="if51c2fde97ce4501afc27d5c5035c4e1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE5Mzk_26d2e484-8a2d-40cf-abf0-ca58ffe97d2d">175.2</ix:nonFraction> million of these losses are expected to be settled over the next <ix:nonNumeric contextRef="if51c2fde97ce4501afc27d5c5035c4e1_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE5OTg_833cf68d-edee-4422-bff8-8ccf745b404c">12</ix:nonNumeric> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of December&#160;31, 2020 and 2019, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwNzQ_b285fdb8-564d-4119-bcfc-431e8d7c6d6d" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="45" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassified from AOCI into Operating Income</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970be973b11946e2ba4be4af29d27f00_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtMi0xLTEtMA_2563533b-0a08-4991-9e45-123d65623031">18.3</ix:nonFraction></span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4e5d22d10f47a4be988b01f0b8f5ef_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtNC0xLTEtMA_dca48a69-9a5c-4400-b930-8f9b785f834e">118.6</ix:nonFraction></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5015e8fef3747c89a3ecb45e4b014c9_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtNi0xLTEtODMx_4e686734-38e2-4b8e-a446-f15c0cd87e08">42.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a829cf79dbf4cf18de8842f672ff28c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtOC0xLTEtMA_5d83ffec-caa3-4836-8728-6f6e35f090eb">9.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2da81af0f6824d0fbb5054283dac56b3_D20190101-20191231" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtMTAtMS0xLTA_a4a0a8ee-7316-49c1-8f2c-5ef2f45ecbef">2.9</ix:nonFraction></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2e5836ef2c4728bf3267af3cd05975_D20180101-20181231" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtMTQtMS0xLTMxNjg_37544215-f3e6-407a-a947-27fd4da3115d">10.8</ix:nonFraction></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341bf7c7b22846c3a15d2ca347a2a5e5_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtMi0xLTEtMA_85cc5b84-5a43-430e-9e00-1709bf82b09d">3.3</ix:nonFraction></span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i150073ed6ed44a05be7690bce055038b_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtNC0xLTEtMA_bbfac936-48f7-4b50-bb7e-6c331e34e950">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4fc26110cbb49bb95e0d829274d6717_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtNi0xLTEtODMx_0295d74d-b540-4c15-868f-f3ff0452b676">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e5f86d5a26a4fb599b079a5ce05a6ee_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtOC0xLTEtMA_0249bfdb-ca2b-4618-b6dc-fc959076faa3">&#8212;</ix:nonFraction></span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie623c4bf0a334923b7419fe9e4036c4d_D20190101-20191231" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtMTAtMS0xLTA_247c96bb-2e43-47fe-8bc4-cea910d68ea9">0.2</ix:nonFraction></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie26d559169994ab2bee2cc026fd0802f_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtMTQtMS0xLTMxNjg_5820fda7-e127-4bb7-826f-0833dd13eefe">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Contracts - Hedging Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Contracts</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of our <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzI3NDg3NzkwNzc3ODg_c3339563-92a8-4c0c-a117-9617e38d57bf">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="ic5bb44b7dbe04121b65a77c399136416_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzMwODA_f315ac0f-ba54-4685-8564-9f8539d1fad5">675.0</ix:nonFraction> million, which were set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzI3NDg3NzkwNzc4MTY_c3339563-92a8-4c0c-a117-9617e38d57bf">2.90</ix:nonFraction>% Senior Notes attributable to changes in interest rates. The carrying value of our <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzI3NDg3NzkwNzc4MDI_c3339563-92a8-4c0c-a117-9617e38d57bf">2.90</ix:nonFraction>% Senior Notes as of December&#160;31, 2019, included approximately $<ix:nonFraction unitRef="usd" contextRef="i3026bb704ae34186986b2cc13a1fa4af_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzEwOTk1MTE2MzQ5MjQ_63514ab6-7338-4fb8-aed7-8263ac0318ea">2.3</ix:nonFraction> million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQzOTgwNDY1MTk3MTA_c3339563-92a8-4c0c-a117-9617e38d57bf">2.90</ix:nonFraction>% Senior Notes, resulting in a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="ifed04fdf163840848076059cbd6be57d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzEwOTk1MTE2MzU4NjQ_27a45fb0-bb3e-4034-9f8c-df953ce565c7">3.3</ix:nonFraction>&#160;million for the year ended December&#160;31, 2020, which was recorded as a component of interest expense in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="i7391238241af432e81e836c4866c9d90_I20180630" decimals="3" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQyNjI_758b1eb1-33a4-42cb-adb5-2863cfeb4110">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQyODI_f8f3f1b7-eea6-4a9c-9328-961f4718561c">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQzNzU_4c88c01a-ed83-4c5d-9abb-d950650aea32">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQzOTY_3e883ba5-3f22-40bd-8003-27ba98c7c4f4">676.6</ix:nonFraction> million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of December&#160;31, 2020, had remaining durations of <ix:nonNumeric contextRef="ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQ3NzA_886ddcbf-145f-4ca0-ab54-f00a477a2573">10</ix:nonNumeric> months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ibff806b8ad9c4985946c536bf923b0a5"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $<ix:nonFraction unitRef="usd" contextRef="if5681d70ef5e4ab1a40f14225017e26b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzUxMjQ_41c2cfee-f8f5-4952-bbba-5cc8bf03f42c">21.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7eb0b3093eab4e4fbf121e5a890af5ae_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzUxMzE_345bc5b5-19a7-4214-9a69-b2db5eb7a2c3">1.5</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $<ix:nonFraction unitRef="usd" contextRef="id6a22865ae984cd9a1584ed794eb45f1_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzU1NTY_15667cb0-5637-436d-8859-a8ffb62431f4">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifeea6c57cc5b4032abf11ed3fd20204a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzU1NjM_a104fa99-8ba4-4fab-b78f-9ac448eba0cb">2.9</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwNzA_bdeffa37-0bd1-46c5-99a2-097fc52c53de" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedges in our consolidated financial statements:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMi0xLTEtMA_b8fd0578-6cc2-4f4c-870e-f521bdd32a02">35.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad3e74dab6043a0ab76c58210d1d2c0_D20190101-20191231" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtNC0xLTEtMA_6648a8f7-7844-4a23-86f3-c0df73ff1d3f">25.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f1921cf5b564c24a5b92cac02448a78_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtNi0xLTEtODc1_3e89dd5e-45a4-4e18-bc89-915d08bc9ef5">3.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtOC0xLTEtMA_416bcbee-420a-47b0-9852-d5f5a2a39517">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad3e74dab6043a0ab76c58210d1d2c0_D20190101-20191231" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMTAtMS0xLTA_11ae10ad-39ab-4305-841e-0a4f8dcb814d">3.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1921cf5b564c24a5b92cac02448a78_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMTQtMS0xLTg3OQ_9afdc7ad-a571-47f4-a447-beb6570a23a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b97f0e94db4a76838c9d49661b0f65_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMTQtMS0xLTA_15cbfa92-41c8-4876-9f70-70829395f846">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394788312749438ca5a0088d46557b6b_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMTYtMS0xLTA_f46c4cb5-a05d-4a35-ab92-ef30a3f6e537">7.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c9fc7dc1c74381a2af78f961d3d49a_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMjItMS0xLTg4Mw_8a8fbc1b-ea67-4f14-b068-727e6f7c6cfa">1.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency contracts was $<ix:nonFraction unitRef="usd" contextRef="ifff3562287364307b49c65b486ab7f1b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzEwOTk1MTE2MzY0MDE_9088903c-9048-411d-be16-91986ef8f607">1,158.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iad27b646ce224aeab760a794d241f6b3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzYzMjE_61be0b74-ec3f-4895-b490-3b621c0cd774">793.8</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. Net gains of $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzEwOTk1MTE2MzYzOTQ_a5deaed4-a867-473d-b5a8-5ad4dab92034">30.1</ix:nonFraction> million, net losses of $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzYzNzM_1344491a-5a8d-44b3-bc6b-11db9b134141">5.9</ix:nonFraction> million and net gains of $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzYzODA_23fa5cc7-656f-4fd8-b054-40a5a8e3914e">2.0</ix:nonFraction> million related to these contracts were recorded as a component of other income (expense), net for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. </span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwNzU_566a05df-32ff-49f1-a328-5b18562bc421" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:27.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;Sheet&#160;Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b4b25460674afd905c8bebb6f7495f_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzItNC0xLTEtMA_b9517fc2-9857-4e40-aae2-4b86ee77c202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f77bb62e04422484e61cd37ab61ae5_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzItNi0xLTEtMA_4587a403-dbda-4b35-87f5-117953bad560">33.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd5747821ef74aea809d0a7f45d8bd8a_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzMtNC0xLTEtMA_de55dc16-b9cc-4c60-8a30-0d18b0c69eb7">157.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44254b6ac97b42949dbeef89bda488f5_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzMtNi0xLTEtMA_6664fe97-7605-47e0-a473-aa3c54a5b671">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef2acb849c6486f8fab7daf104f20fe_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzQtNC0xLTEtMA_92f237a2-e300-48bc-acfb-54bb25cc5b30">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14add4a287f45888b55667cd3541758_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzQtNi0xLTEtMA_2de8e332-8a7b-42e1-8d03-0b9cc6b2e707">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f0f42e415041f8bcef0f0de00298ff_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzYtNC0xLTEtMA_59a89ffe-4e93-4a36-84a2-c913f9a87bce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib105aece693d4b43a0c52e39570beb9c_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzYtNi0xLTEtMA_10e0adf4-ed1f-4cda-8242-c4192ea127e1">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe741caa88b64940868b7b3ab24c4a52_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzktNC0xLTEtMTk2Nzg_f8825752-1847-4c96-aae1-2629c822accf">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3844e07d48c84ee491e1b9f71aa66a47_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzktNi0xLTEtMTk2ODI_e90597da-db69-4210-87a2-f3e9eb94d407">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Fair Value Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd0d7ea7b3a4afa9b4461ff7b726aba_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzgtNC0xLTEtMA_138668af-fa6a-4fc7-9943-cd95dde26c3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3026bb704ae34186986b2cc13a1fa4af_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzgtNi0xLTEtMA_63514ab6-7338-4fb8-aed7-8263ac0318ea">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c6f6c468f64ddcb921d54c39e33bcb_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzExLTQtMS0xLTA_23ae9b7a-6a51-478b-9fd4-0ff2a5caee81">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6909c22acb465098440df5033cb0c7_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzExLTYtMS0xLTA_25de18df-96ca-458f-be8a-0741db7263ea">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i249f9f4c4b124dd8b673e35fc4455624_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzEyLTQtMS0xLTA_2a818dfe-9d4c-4141-bc24-f91ad1d3df1c">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87d29e7890540bb8654a68a1d34708c_I20191231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzEyLTYtMS0xLTA_045e4567-d49a-4e1d-813a-70f1c7fa72cb">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_277"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE3OTM_ff6e4828-0f5a-4d26-b7fe-df76edec1d2f" continuedAt="i69b2ad4c396e49ed99a291a2b53de77a" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="i69b2ad4c396e49ed99a291a2b53de77a"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE3ODU_f0e050db-e3cb-4e04-a622-4c7d3f35dc37" continuedAt="i7eb3ccf563d34294b45e67d932cf5864" escape="true">Components of property, plant and equipment, net are summarized as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i7eb3ccf563d34294b45e67d932cf5864"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzItMS0xLTEtMA_d777a3c3-7230-4cc8-9a5f-6ea4c2daaabc">119.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzItMy0xLTEtMA_967a6445-d869-47af-9e4b-e121f4b311b0">118.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzMtMS0xLTEtMA_402c70ff-2909-42e4-90d0-27d37909ba2b">1,025.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:BuildingsAndImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzMtMy0xLTEtMA_049aa6f2-0fa4-44df-bc42-a0d367dc42fe">835.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzQtMS0xLTEtMA_e4f13eec-cc72-4e9a-b807-f2059caa45a6">104.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzQtMy0xLTEtMA_9564dbe0-0bc6-4bb0-bbd5-ba99a70e119b">99.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzUtMS0xLTEtMA_86d9610c-2bd2-4b87-8237-0a4daa68d41a">1,027.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzUtMy0xLTEtMA_fbf2ab3a-b9e0-483d-a92b-c970b9ca1439">844.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software and hardware</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="biib:ComputerSoftwareAndHardware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzYtMS0xLTEtMA_1f68c328-4e5a-4582-8965-71e349031fb1">903.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="biib:ComputerSoftwareAndHardware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzYtMy0xLTEtMA_85d0909a-72b6-49bd-8d51-4df5b3fdbae2">798.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:FurnitureAndFixturesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzctMS0xLTEtMA_d30d893e-b924-44be-97b6-75d3f7a8eee0">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:FurnitureAndFixturesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzctMy0xLTEtMA_42293d20-c16c-40ca-9f56-3f47f4c6f13c">58.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzgtMS0xLTEtMA_beee5636-0dd9-4331-892d-54d473f535d0">1,950.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzgtMy0xLTEtMA_44a66542-163a-4a5a-b024-e1e545979a88">2,084.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzktMS0xLTEtMA_88438297-2ac6-483f-a8e3-88a6cb3721a6">5,193.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzktMy0xLTEtMA_9ce2514d-bc2b-4aa6-97ce-0d59652f5ea8">4,838.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzEwLTEtMS0xLTA_539f33eb-8f8a-4a46-8dab-c0da66194042">1,782.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzEwLTMtMS0xLTA_01b29436-89b5-44df-afff-0892fc3a3120">1,590.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzExLTEtMS0xLTA_ff79fd69-b206-4811-8c4a-8632e4e660c1">3,411.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzExLTMtMS0xLTA_018495b2-75af-463f-a0c8-811a02dda1c2">3,247.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzI0NA_4cc560f5-8d71-43af-9d00-48f0314265c6">201.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzI0OA_faf49de7-9581-4e6a-bf11-4d78cbe3780f">190.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzI1NQ_2a52569f-91b6-4899-a08f-0a69c48b3268">269.4</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we capitalized interest costs related to construction in progress totaling approximately $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzM5OA_73346dad-10ad-4aa1-88af-845ed2774634">65.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzQwMg_83a7cf6b-109d-438d-a706-5234eb5b7aa7">68.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzQwOQ_cb1e8c78-65c4-43ff-83a2-c6f99cad89c5">54.0</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include <ix:nonFraction unitRef="sqft" contextRef="i28e6c2c7dcef4706a9e8c029a70b1b66_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzEwOTk1MTE2Mjk5ODY_29e02d5b-e648-4239-be99-e8ff10ee9ae7">393,000</ix:nonFraction>&#160;square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="ifbaabb3c8c67456798b662d69d200f72_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzEwOTk1MTE2Mjk5OTU_c041e163-8ecf-40f6-a46b-24c485e8a606">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="ib34a3983473240ca94309b2221293726_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="biib:NumberOfSquareFeet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzEwOTk1MTE2MzAwODQ_4cb029af-c4fa-49c3-9f6d-8ee271519381">51,000</ix:nonFraction> square feet of administrative space. As of December&#160;31, 2020 and 2019, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i82ea75f6631c448f8f22c298bec0c951_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzExMzU_81d8ee76-dd98-4373-a9a7-a9e5e0b1535d">1.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i214f8c61e02b4bc78c01086f27fa4760_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ConstructionInProgressGross" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzExNDI_7ec21d95-4214-4013-b83e-75a529900574">1.9</ix:nonFraction> billion, respectively, capitalized as construction in progress related to this facility. For the year ended December&#160;31, 2020, we placed approximately $<ix:nonFraction unitRef="usd" contextRef="i82ea75f6631c448f8f22c298bec0c951_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzEwOTk1MTE2Mjk5NTE_97fc6c05-f191-4016-b857-9453d6692d2a">256.8</ix:nonFraction>&#160;million of fixed assets in service related to this facility.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included $<ix:nonFraction unitRef="usd" contextRef="ida412b4bccf941a7af64620b69dcf1ef_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE0ODM_e7a7e150-7b47-4b80-b17f-202fdcd25435">631.5</ix:nonFraction> million of property, plant and equipment, which was primarily comprised of $<ix:nonFraction unitRef="usd" contextRef="i2f537e57d89f4823b4442dbfdb55895c_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE1NTM_805b6fb6-b543-4e5f-841e-868f1c39ed60">312.5</ix:nonFraction> million for buildings and $<ix:nonFraction unitRef="usd" contextRef="i13d06bfb1ac54344bc9084f8e1ea171e_I20190831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE1NzQ_c85932be-655a-4767-90e8-9b8c8bea4ac8">287.3</ix:nonFraction> million for machinery and equipment. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_280"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5Njc_3525e829-3652-42df-ad36-329684347d50" continuedAt="iac7a409b564e4e508a5a3f10c1b53258" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="iac7a409b564e4e508a5a3f10c1b53258" continuedAt="i721b4c52405947188ba89f70b5e3b093"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real estate, including laboratory and office space, and certain equipment. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases have remaining lease terms ranging from less than <ix:nonNumeric contextRef="ic4652a3a2e7940719a658dd16032604d_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE2NA_c369b594-109c-454d-a866-a690e3afdac0">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i50d29a2be0b04648b7d97ec27df8f046_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE3MA_988fc76d-d6b2-41ab-bef3-ec722ac5cd9a">ten years</ix:nonNumeric>. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from <ix:nonNumeric contextRef="ic4652a3a2e7940719a658dd16032604d_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzMxNg_d2e5f957-e28e-40f5-bb68-8d7816b5b42b">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i50d29a2be0b04648b7d97ec27df8f046_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzMyMg_df172522-d9bc-4b08-80a5-60bd8b6775e9">six years</ix:nonNumeric>.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from <ix:nonNumeric contextRef="i828bc1c45a6d4a98b00274ffc1f8eeda_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzQ5Mg_cbf5e195-e3c1-48a5-846b-eeb00b0f266d">four years</ix:nonNumeric> to <ix:nonNumeric contextRef="i787eed6e9a344d8c908c09867efa7395_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzQ5OA_cc96ef11-a56e-41b8-bfb1-44d4febc7cd4">eight years</ix:nonNumeric>. Our subleases do not include an option to renew as they are coterminous with our operating leases.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i721b4c52405947188ba89f70b5e3b093" continuedAt="i17a2e5a6be134b98a6e4688bb8d0a3b1"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:LesseeLeaseTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5Njg_c7c78c0a-fca1-4ec3-987d-12da9e081b03" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b65f5d0f33646d9bc123cea10741758_I20201231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzItMy0xLTEtMA_6ccc50f1-3a06-4593-94aa-4e3e41e7b7ee">433.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf080c13135547c8af17c3b9569fb595_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzMtNS0xLTEtNzQ4_e34ee2df-af0d-4c37-b40c-fff774f173ac">427.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMS0xLTEtMTMxMzU_4631686e-fcd9-443b-a344-b69d241e1c2d">Accrued expenses and other</span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa108c2a221547038bfc56b7a2800e00_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzUtMy0xLTEtMA_66eaff0e-5389-4240-a8b7-ada5fb179541">83.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849ff223eb2f4be899ee0be3b39ab50f_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtNS0xLTEtNzUy_2f5b7223-189b-4d8c-800d-7ae31fd0cef5">73.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d80f95e39cb4bfaba1e47004246e9e4_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMy0xLTEtMA_4dca9f86-5b28-40a8-9228-f3c2d3e678a8">402.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e69090a5bf6448aacee4bfd8770c3e3_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzctNS0xLTEtNzUy_530591e2-334a-4f9f-80f8-c3adafe5d886">412.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzctMy0xLTEtMA_2cb8d196-65a0-4306-9387-807b659244d3">485.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzgtNS0xLTEtNzUy_122dfe5a-9dc0-43db-b752-91abedb1a762">486.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5Njk_2ae0a62e-dfbf-4497-bda9-7b186ae5f13d" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of lease costs in our consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b85566626e4d3abc15fda2e07b56a5_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzItMy0xLTEtMA_5ab3a945-4909-4542-b225-601bedcc709b">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923409ff6b114d4ab014bcd315beca62_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzItNS0xLTEtNzg3_811f764f-2d72-4684-b770-6ecff1a3d11c">6.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224660fdd0047b996983e6ee2775abe_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzMtMy0xLTEtMA_0a3e6430-f57a-4b51-944e-b1ad77ee4b5e">93.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzMtNS0xLTEtNzg3_f7b4040e-5c8e-4c42-b181-3e8ae327ce4a">84.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b85566626e4d3abc15fda2e07b56a5_D20200101-20201231" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzQtMy0xLTEtMA_183bcd31-a33a-433e-985b-3deb3f7a90fd">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923409ff6b114d4ab014bcd315beca62_D20190101-20191231" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzQtNS0xLTEtNzg3_273b6793-eca4-430b-896f-325574c9fbe7">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224660fdd0047b996983e6ee2775abe_D20200101-20201231" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzUtMy0xLTEtMA_0179b361-789c-4283-8881-16d18fe93029">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzUtNS0xLTEtNzg3_d7c31323-4a9e-4f25-9aaf-d93d0887ad05">23.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id224660fdd0047b996983e6ee2775abe_D20200101-20201231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzYtMy0xLTEtMA_dc867004-2621-48e3-9712-f0a0b1c7ff7c">24.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzYtNS0xLTEtNzg3_847b396b-5a08-4e80-a586-cf77463cfb27">25.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib639369018004754a9231ea3cb196a74_D20200101-20201231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzctMy0xLTEtMA_3a90691e-c453-4e83-a939-1c18607173bd">3.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib182bbc8abc342c796c4fe1951e63578_D20190101-20191231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzctNS0xLTEtNzg3_4f614f5b-6e19-45f4-83c5-5ebe6ec84d61">3.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzgtMy0xLTEtMA_58ea32c2-ee86-4266-9b86-74da2298eeab">92.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzgtNS0xLTEtNzg3_ef1db634-c3c3-4bfe-af74-46846748088e">86.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost primarily related to operating expenses, taxes and insurance associated with our operating leases. As these costs are generally variable in nature, they are not included in the measurement of the operating lease asset and related lease liability.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5NzA_4cd12a0c-a48c-4429-9d2e-fb1ff4d98a55" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzEtMS0xLTEtMA_2b7ef118-4971-41cc-922c-fc2485e32aab">95.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzItMS0xLTEtMA_11d09ecf-3c3d-4cbc-a97a-b8f5b2ac144d">93.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzMtMS0xLTEtMA_8129a822-5d90-4e92-8493-de2005d77021">82.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzQtMS0xLTEtMA_428a893c-79ac-4340-b392-8148c8ce15bd">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzUtMS0xLTEtMA_aecb219e-1065-4d93-a584-29c9f01afa0d">56.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzYtMS0xLTEtMA_90728556-dff9-4c26-a8b5-e58172d23f26">129.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzctMS0xLTEtMA_53cec26c-88e1-4b35-953f-5935bb3d7812">533.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzgtMS0xLTEtMA_7444dd40-ef29-4bf7-8bf7-9795330506d6">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzktMS0xLTEtMA_d61ec27f-dd33-4eeb-ba32-9acf76c13871">485.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5NjU_7db86546-97fd-4320-a85e-fb9163defc41" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo3NjMzNWQ2MmIzZjU0MDExYWRkMzY3ODY2NDU1YTRiMS90YWJsZXJhbmdlOjc2MzM1ZDYyYjNmNTQwMTFhZGQzNjc4NjY0NTVhNGIxXzEtMS0xLTEtMA_f96ba46e-712d-443a-994b-fb2d25b9fb90">6.30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo3NjMzNWQ2MmIzZjU0MDExYWRkMzY3ODY2NDU1YTRiMS90YWJsZXJhbmdlOjc2MzM1ZDYyYjNmNTQwMTFhZGQzNjc4NjY0NTVhNGIxXzItNC0xLTEtOTI5_d15ce488-38bd-4a50-b3ac-03589262cdc9">7.07</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo3NjMzNWQ2MmIzZjU0MDExYWRkMzY3ODY2NDU1YTRiMS90YWJsZXJhbmdlOjc2MzM1ZDYyYjNmNTQwMTFhZGQzNjc4NjY0NTVhNGIxXzItMS0xLTEtMA_8b69baa3-4e3d-4e09-9826-b2297a345509">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo3NjMzNWQ2MmIzZjU0MDExYWRkMzY3ODY2NDU1YTRiMS90YWJsZXJhbmdlOjc2MzM1ZDYyYjNmNTQwMTFhZGQzNjc4NjY0NTVhNGIxXzMtNC0xLTEtOTI5_2d00c353-2438-455f-a64e-a2b602e6008a">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i17a2e5a6be134b98a6e4688bb8d0a3b1"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5NjY_266eb514-2bcc-4eb6-a411-650bd7437e68" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo5ZTM5NGMzMjY2MDQ0YjY0Yjg5OTdjNTUwMmE3ZDBhZi90YWJsZXJhbmdlOjllMzk0YzMyNjYwNDRiNjRiODk5N2M1NTAyYTdkMGFmXzItMS0xLTEtMA_fdd67f30-f988-49a6-b45f-20638fd5221e">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo5ZTM5NGMzMjY2MDQ0YjY0Yjg5OTdjNTUwMmE3ZDBhZi90YWJsZXJhbmdlOjllMzk0YzMyNjYwNDRiNjRiODk5N2M1NTAyYTdkMGFmXzItNC0xLTEtOTUy_88b274a9-9da5-4d64-9b5f-84d2c10e9d3b">93.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets obtained in exchange for lease obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo5ZTM5NGMzMjY2MDQ0YjY0Yjg5OTdjNTUwMmE3ZDBhZi90YWJsZXJhbmdlOjllMzk0YzMyNjYwNDRiNjRiODk5N2M1NTAyYTdkMGFmXzMtMS0xLTEtMA_3f6440f1-af04-4904-8eec-41a8dc5bff1b">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo5ZTM5NGMzMjY2MDQ0YjY0Yjg5OTdjNTUwMmE3ZDBhZi90YWJsZXJhbmdlOjllMzk0YzMyNjYwNDRiNjRiODk5N2M1NTAyYTdkMGFmXzMtNC0xLTEtOTUy_793b41e9-7572-4b62-b447-914ba8aaf55e">35.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_283"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI2ODA_14349d57-aa25-4dc4-959a-93dfe4ed2645" continuedAt="i68886393396b4f56967ef8cf710b1b86" escape="true">Indebtedness</ix:nonNumeric></span></div><ix:continuation id="i68886393396b4f56967ef8cf710b1b86" continuedAt="i332e42cc38974e1f8df670f1d9a7e410"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQ5NDc4MDIzMzUyNTE_d0cf9d22-c9c3-4811-b419-d9f58cac6afc" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.900% Senior Notes due September 15, 2020</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ab402dc3c540aaaa74ab88707cd06e_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzMtMS0xLTEtMA_a228b473-0fb2-4f24-a223-d5f9aa8c2c00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda291dcf88445d79798c83baf0cdab6_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzMtMy0xLTEtMA_3cc1b249-0233-44a1-9017-8e4a2018026f">1,495.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6fc4314ff74454a352c1254c20f4a6_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzQtMS0xLTEtMA_28f11399-52c0-436d-b494-edb785e34269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id270cfd00e264906938aa37712a47c2c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzQtMy0xLTEtMA_3c8f9736-f36a-452b-811a-bb64f0833262">1,495.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777e7a0559ef48fd8038247a2da5c7c3_I20201231" decimals="-5" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzctMS0xLTEtMA_630adc71-8221-4070-815a-3dd6b66fd145">997.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63cee825d9047dc912cec33b6578d0d_I20191231" decimals="-5" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzctMy0xLTEtMA_8caa189a-0887-46e8-8e54-3b3a491e405b">996.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f6df13a0ab4a20800b6bd00a5f821d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzgtMS0xLTEtMA_aedda25e-d4f6-4d85-969c-c0199f6f7c55">1,741.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb111e31f6244de805aec691711dc6b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzgtMy0xLTEtMA_d52ee1ab-13f9-4bc1-81fb-3f67dccb9a42">1,739.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i665e4e826ccd4df0a58a999910a2c5ce_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzgtMi0xLTEtODAyNg_cd4685e3-bb07-4da6-858f-22bd30f0728a">1,491.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aadbc751f6142fb9d7d9b181bf75a09_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzgtNC0xLTEtODAyNg_67eb6412-fee1-4100-a8bb-778502a75a43">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5513569ac924bcd810dcccb4b75c1ca_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzktMS0xLTEtMA_b4656ddb-d15e-4894-830a-d119a4df6e84">1,723.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c681c490eb24f0888c2d4a13e77ad8c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzktMy0xLTEtMA_cf40f960-afd1-40d5-805b-67f1d34ad217">1,722.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d717cfc9ad47b288a5e9b60459b22c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzEwLTItMS0xLTgwMzA_67ef809f-f32e-4bb4-a23a-c657e221a970">1,472.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947c924e348b4937945183baa80b4090_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzEwLTQtMS0xLTgwMzA_6f06ec52-b530-42ae-b035-c33f154eae33">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6fc4314ff74454a352c1254c20f4a6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzEwLTEtMS0xLTA_d3cd11a7-f468-4f0d-81b8-16b4bad83945">7,426.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id270cfd00e264906938aa37712a47c2c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzEwLTMtMS0xLTA_7d7bfdfe-f67a-400d-8822-d7cebec68bde">4,459.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQzOTgwNDY1MjEzNjc_94bd5063-44ea-49c2-a9cf-55398e14d767">2.900</ix:nonFraction>% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="if61dd7a223a64fd789d0d20d60918b24_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2Mzc5NDg_3d3ea11d-6835-4cff-b5a7-a4f5f15a644a">3.0</ix:nonFraction>&#160;billion, as discussed below.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Senior Notes</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="if61dd7a223a64fd789d0d20d60918b24_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyMjA_3d3ea11d-6835-4cff-b5a7-a4f5f15a644a">3.0</ix:nonFraction>&#160;billion (2020 Senior Notes) as of December&#160;31, 2020, consisting of the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$<ix:nonFraction unitRef="usd" contextRef="i58e5df66246e4242a351e934e5d881a9_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxNjA_81c4b681-bdbb-4a0c-8fc6-57ac7e29fca7">1.5</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i58e5df66246e4242a351e934e5d881a9_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxNzQ_ccec51e5-0594-4e90-a6f5-7c90221563d5">2.25</ix:nonFraction>% Senior Notes due May 1, 2030, valued at <ix:nonFraction unitRef="number" contextRef="i58e5df66246e4242a351e934e5d881a9_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyMDI_2237045b-cd57-493a-a697-5cdcde4ae89e">99.973</ix:nonFraction>% of par; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$<ix:nonFraction unitRef="usd" contextRef="i262058cabfd94b5ab32927e2ab5d4b39_I20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxODE_8f1f1dd2-13ab-40d7-a31a-9017c31897ad">1.5</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i262058cabfd94b5ab32927e2ab5d4b39_I20200430" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxOTU_b69590da-c0e1-4140-9f91-b4b8eab2768d">3.15</ix:nonFraction>% Senior Notes due May 1, 2050, valued at <ix:nonFraction unitRef="number" contextRef="i262058cabfd94b5ab32927e2ab5d4b39_I20200430" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyMTE_c58b0e48-1cd7-4593-8a08-4ffe0d7481fb">99.174</ix:nonFraction>% of par.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at <ix:nonFraction unitRef="number" contextRef="i6ddb930bb2d6431ea44a09daf6837686_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyNjI_4dbeba2b-0eb7-4598-ab5d-43578f31fee1">100.0</ix:nonFraction>% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="i6ddb930bb2d6431ea44a09daf6837686_D20200101-20201231" decimals="INF" name="biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyNTY_b3350545-1d21-42ec-89c3-4c95b7385509">101.0</ix:nonFraction>% of the principal amount plus accrued and unpaid interest to the date of repurchase.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i98decbb03ea4472c94a12ac0b39c7793_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxNDU_cb4d3ebe-2779-4e21-82fb-3847c909386c">24.4</ix:nonFraction>&#160;million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable May 1 and November 1 of each year, commencing November 1, 2020.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Senior Notes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior secured notes issued in 2015 (the 2015 Senior Notes) as of December&#160;31, 2020:</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$<ix:nonFraction unitRef="usd" contextRef="i43d8fda27d15472886e7714ecfd74f13_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI0OQ_ca8f5619-aa0f-4d9b-9fa1-fccca2cd3295">1.0</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i43d8fda27d15472886e7714ecfd74f13_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI4Mg_136d69aa-b140-432e-bae5-fe60c7c9f299">3.625</ix:nonFraction>% Senior Notes due September 15, 2022, valued at <ix:nonFraction unitRef="number" contextRef="i43d8fda27d15472886e7714ecfd74f13_I20201231" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzMzMg_ea40e7fc-9160-4502-a501-28084129669a">99.920</ix:nonFraction>% of par;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i332e42cc38974e1f8df670f1d9a7e410"><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$<ix:nonFraction unitRef="usd" contextRef="ifc1b899a302148ca9891b0255cc8aa0d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzM0Mw_82985a06-b923-4d54-89fc-dcac79ed039c">1.75</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ifc1b899a302148ca9891b0255cc8aa0d_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzM3Ng_6264740e-6a9f-4a55-adc4-a44ca060a375">4.05</ix:nonFraction>% Senior Notes due September 15, 2025, valued at <ix:nonFraction unitRef="number" contextRef="ifc1b899a302148ca9891b0255cc8aa0d_I20201231" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQyNg_f8c4ac70-26bc-4557-8871-ddd1553084f3">99.764</ix:nonFraction>% of par; and</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$<ix:nonFraction unitRef="usd" contextRef="iddd13c0f2522452cb9725ea76f4505d0_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQ0MQ_105b2fcd-15f1-4cd9-a8b9-35c83c830f72">1.75</ix:nonFraction> billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iddd13c0f2522452cb9725ea76f4505d0_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQ3NA_bb163ea2-61dd-4a61-ad86-28af61a7e5b9">5.20</ix:nonFraction>% Senior Notes due September 15,&#160;2045, valued at <ix:nonFraction unitRef="number" contextRef="iddd13c0f2522452cb9725ea76f4505d0_I20201231" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzUyNA_8fc89b40-042f-460c-9212-6b9cbcf4dbcb">99.294</ix:nonFraction>% of par.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original costs associated with this offering of approximately $<ix:nonFraction unitRef="usd" contextRef="i3b1c876d462a421f884f7da02f35aeb6_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzU5NA_6801e629-414d-4008-bc4e-7fee3f07243b">47.5</ix:nonFraction> million have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheets. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2015 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at <ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzk4OA_188b790b-d7e3-4aed-ab5a-412b4d877be0">100.0</ix:nonFraction>% of the principal amount plus accrued interest and a specified make-whole amount. Our 2015 Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to <ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" name="biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzExOTE_16e81ced-747b-4fbf-ab36-e18cefc1e949">101.0</ix:nonFraction>% of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="ie421a618f95e4d26993d33169587ef01_I20150915" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzk0MDU_42f74c5c-f203-4300-a024-bc04f12116de">1.5</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzkzNjI_c3339563-92a8-4c0c-a117-9617e38d57bf">2.90</ix:nonFraction>% Senior Notes due September 15, 2020, at <ix:nonFraction unitRef="number" contextRef="ie421a618f95e4d26993d33169587ef01_I20150915" decimals="INF" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzk0MTk_d0f7bd9f-e738-4e6a-944d-657a2ef77ecb">99.792</ix:nonFraction>% of par. Our <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzkzNzQ_c3339563-92a8-4c0c-a117-9617e38d57bf">2.90</ix:nonFraction>% Senior Notes were senior unsecured obligations. In connection with the <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzkzNzc_c3339563-92a8-4c0c-a117-9617e38d57bf">2.90</ix:nonFraction>% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our <ix:nonFraction unitRef="number" contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzkzOTE_c3339563-92a8-4c0c-a117-9617e38d57bf">2.90</ix:nonFraction>% Senior Notes prior to their maturity and recognized a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ic07e15711c4c4d72879f1d4eddbaa8f6_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzMyNDU_3a5695aa-df9a-4b62-a9f7-b87c90c38007">9.4</ix:nonFraction>&#160;million upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our consolidated statements of income for the year ended December&#160;31, 2020, reflects the payment of a $<ix:nonFraction unitRef="usd" contextRef="i522bc71323b84dfaa650873976042d71_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzMyMzA_1d6e0086-d534-414a-97dc-0937c67f9647">12.7</ix:nonFraction>&#160;million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $<ix:nonFraction unitRef="usd" contextRef="ifed04fdf163840848076059cbd6be57d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzMyMTQ_caca74ee-280a-4fed-865c-c4ad7492f23f">3.3</ix:nonFraction>&#160;million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate contracts, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Derivative Instruments, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Credit Facility</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $<ix:nonFraction unitRef="usd" contextRef="i121fec5eb0a442788b9b201aa33e7063_I20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzk1OTQ_705efd68-8450-449b-b096-b99d513d37c0">1.0</ix:nonFraction> billion, <ix:nonNumeric contextRef="i02d9dc2f9e5647a79094565b056378cc_D20200101-20200131" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQzOTgwNDY1MjEzODI_2f9c9bca-a5a4-4756-bc19-939161cbf58a">five-year</ix:nonNumeric> senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility that we entered into in August 2015. As of December&#160;31, 2020, we had <ix:nonFraction unitRef="usd" contextRef="if4870972449f45cca77c7f81269fdbe0_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzU1Mjk_e631bbec-e501-4132-8caa-c12e5ec5d773">no</ix:nonFraction> outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Maturity</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI2NjU_6568f297-eb3f-46d4-83a8-7b26e9f2c13b" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross payments due under our debt arrangements are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:78.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzEtMS0xLTEtMA_b5662a46-1cd1-47a2-bb59-956ca0c43b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzItMS0xLTEtMA_351bd4ff-a075-4610-9976-31673cccbc4e">1,000.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzMtMS0xLTEtMA_eedb4833-6503-4fa0-88db-ae69200ddc6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzQtMS0xLTEtMA_613fa663-9ef5-4089-90a0-393760a54b0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzUtMS0xLTEtMA_d9fa1f37-3741-4242-bac7-f885db7ca303">1,750.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzYtMS0xLTEtMA_cf3315af-fa08-4ca4-b45a-ce2151a5c462">4,750.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzctMS0xLTEtMA_4b879dea-ae73-4fbb-9559-759ada22df6b">7,500.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our debt is disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_286"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzMzNzE_d542b0ed-9365-482e-ad81-9663e3dfe203" continuedAt="ic471bc562b7a406e9b0eb5598e2c6b80" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="ic471bc562b7a406e9b0eb5598e2c6b80" continuedAt="ie1fa1e9bdb58463da2336af743ac1dca"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="shares" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQy_1b3ca3c7-b22e-49fd-b9ff-66bb63bdbb14">8.0</ix:nonFraction> million&#160;shares of Preferred Stock authorized, of which <ix:nonFraction unitRef="shares" contextRef="i51e142f8c61e4ef9aa6fcc66964b20a3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzky_846a36e1-4782-4e9d-aa00-3e34c72e9a0b">1.75</ix:nonFraction> million shares are authorized as Series A, <ix:nonFraction unitRef="shares" contextRef="i51bbbbb29365442693577108f0597733_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEzMA_d3369243-5d20-44d3-8c61-1c21e1fd8eb4">1.0</ix:nonFraction> million shares are authorized as Series X junior participating and <ix:nonFraction unitRef="shares" contextRef="ic43dbda8223e4c34ae49a143d781adf8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzE5Mg_b31e8388-7a3c-4446-9b80-30fc01b84765">5.25</ix:nonFraction> million shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences and the relative, participating, optional or other special rights of the shares of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ie1fa1e9bdb58463da2336af743ac1dca" continuedAt="i264c1fd9a0ce4188b29990cdac8670cb"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. <ix:nonFraction unitRef="shares" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_196c85ef-7a42-47f1-9946-f26388ccdd41"><ix:nonFraction unitRef="shares" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_228eadd2-80a6-4b34-90e1-c2e7bf43a7d1"><ix:nonFraction unitRef="shares" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_23a365f6-2ed2-441e-9eb6-140c8ed3568d"><ix:nonFraction unitRef="shares" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_69eacadf-6c1d-4bc5-8a7c-2fefc3cc7af3"><ix:nonFraction unitRef="shares" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_c8f90d7c-a626-449a-9ad0-d98b92c994ab"><ix:nonFraction unitRef="shares" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_daf5a04a-912d-4249-8c73-7864883fd80d">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Preferred Stock were issued and outstanding during 2020, 2019 and 2018.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:SummaryOfCommonStockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzMzNjk_3d4551b8-2cb1-45f7-8e06-560f9db901a5" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes the number of shares authorized, issued and outstanding of our common stock as of December&#160;31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:13.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.569%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMS0xLTEtMA_5e027624-37fd-4f4c-a690-1d0b29c38923">1,000.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMy0xLTEtMA_ac92d319-c791-4e58-b9eb-560534394f5b">176.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItNS0xLTEtMA_3d6023cc-b507-48c1-bf99-6d5815954c24">152.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItNy0xLTEtMA_01d8c0c7-904a-40a5-995e-1644556378a4">1,000.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItOS0xLTEtMA_3f2de498-02a5-4d34-8fdf-98ae2fe6a50e">198.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMTEtMS0xLTA_f4b7b4aa-baf5-4a3d-9aec-4550989243a8">174.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMTMtMS0xLTA_552cd5f8-51dd-4412-83f1-a22d74e2f0ad">1,000.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMTUtMS0xLTA_6f4fbae2-902c-456d-a5f3-f27de77a4e46">221.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMTctMS0xLTA_d29ef585-07af-444f-9d81-dcd6d6749efd">197.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i0070294a197c45399f314f23509957dc_I20201031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzIzMjg_fdbb6385-1e84-44a9-a66f-8e9fab3cf514">5.0</ix:nonFraction> billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzIzMzI_b2843ce5-0654-4480-9b15-568918e524a7">1.6</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzIzOTI_31c85977-d498-4e25-913a-73b0149c15e8">400.0</ix:nonFraction> million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i41af7ab14acc4fb1987d804ec0919188_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzE0NzA_dbebcadb-a653-49d1-ae63-bced7392d33e">5.0</ix:nonFraction> billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzE3MTA_0ce08ffa-af55-48a9-8b90-94f6a9ef86cf">16.7</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzE3NzA_16aa521b-7ba2-40a8-8cb8-0c60e487de4b">5.0</ix:nonFraction> billion during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="idbfd0586c39547f4bd2e2e1a5234c516_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzE1NDY_7354644a-ecde-4f6b-8993-1551e5de0f8f">5.0</ix:nonFraction> billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzE4NTU_837ebcf7-8736-4cf8-af6a-9e41aeaf3e4d">4.1</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzEzOTQ_9ee8abb6-98d5-4d64-941b-8499afe439ac">14.7</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzE5MTI_0c31ae72-2ed3-40da-896e-c357740d3a1a">1.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzE0MDM_ada0edec-0be7-45e0-be7d-24a919d4da6a">3.7</ix:nonFraction> billion during the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i8f5af4399029492c96f8e3642a945612_I20180831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzI1MDQ_7663cc42-d1f6-4ed5-8eda-4b01e729a059">3.5</ix:nonFraction> billion of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzIyODI_6db39d19-22ab-4d01-a4dd-3313d2bb7977">8.9</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzI1MTQ_2b5d9353-15b4-4794-b151-fab0146187af">4.3</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzIzNDY_934597d2-d68e-4428-a497-d75e03ab19ea">2.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzI1MjU_32b3148f-221a-4842-b395-9c340c37e44c">1.4</ix:nonFraction> billion during the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ice49d2ad46424ef199c6cb123804c5a5_I20160731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzI0NzQ_0c4a80c6-83f8-4f49-9ab7-edfbb915dd6a">5.0</ix:nonFraction> billion of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzI3Mjk_5a5e1e44-480a-497b-9fc2-4bebe50f805a">10.5</ix:nonFraction> million shares of common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzI3ODk_1afd1849-1802-4451-a210-1be0dcd1cb92">3.0</ix:nonFraction> billion during the year ended December&#160;31, 2018.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i264c1fd9a0ce4188b29990cdac8670cb" continuedAt="ic0affd82f7f740708bf07b9da2832ce7"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzMzNzU_b8c9e755-3b8a-47da-8838-35f4ad691fcc" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b72acd0c624e9a9e5f85ff7919818a_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtMS0xLTEtMA_24318b88-3103-4cc0-a1cc-35b750f95a97">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f24d77b87bc4232984dc260a26c171e_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtMy0xLTEtMA_4f60efd0-899c-456f-ba7b-77b5174740a9">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709cfa41571a4ab8b7d4914c6efb00b3_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtNS0xLTEtMA_f7103ebc-dc3a-415c-aed7-5b3a56814bcb">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5d68ba226474425a9ad91c1d2d03c1a_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtNy0xLTEtMA_7604451e-4277-4a0b-9f4f-fcd5bcf8d2cb">32.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25d8c73e458441d994c3c13f19832ae9_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtOS0xLTEtMA_7fff9054-d927-4e06-a24a-f94e3e927cd6">139.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8631cd953f3488583e5a99f0aa067ea_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtMTEtMS0xLTA_1b9fc7e3-d875-4c94-8655-b800b8e494b7">135.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5acc9340a88745fd84cac5a88b2066cd_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItMS0xLTEtMA_97974a58-c819-4f5f-a4ac-aec2b97d5cbf">9.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdcecbf126d4b8099f5e7acda25fb2d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItMy0xLTEtMA_f0826394-d8ba-4186-b930-0937a7ba661d">165.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c3ebcbd89841a28e7480e4337c4988_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItNS0xLTEtMA_54759a1e-25a3-4d1a-bef3-0c20a43e9029">30.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f5a43994a74e30bc2c24fc58be7a8b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItNy0xLTEtMA_822c7e73-a6fe-4ec8-9a07-39bd42b7b9ee">33.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38457c7073c148078d40e136da416dc2_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItOS0xLTEtMA_7267fff9-1c4b-497e-ae04-1d58809eb62e">92.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItMTEtMS0xLTA_683d1f02-53c4-4010-aa7b-d27153965d95">145.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5acc9340a88745fd84cac5a88b2066cd_D20200101-20201231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtMS0xLTEtMA_f35915e5-e00b-4c45-847f-32ea0a691417">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdcecbf126d4b8099f5e7acda25fb2d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtMy0xLTEtMA_d62e28c4-3881-40e8-a772-f6e7d213b52f">21.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c3ebcbd89841a28e7480e4337c4988_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtNS0xLTEtMA_11171f38-9a7c-4626-aa8f-9694a9df930e">2.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f5a43994a74e30bc2c24fc58be7a8b_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtNy0xLTEtMA_3ca34fcd-75f8-45a7-9045-b213f70af084">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38457c7073c148078d40e136da416dc2_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtOS0xLTEtMA_576bef2e-9117-454c-b92c-8a1c4513208c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtMTEtMS0xLTA_18c4819f-d79a-4d57-a3f7-127cccc2b434">18.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5acc9340a88745fd84cac5a88b2066cd_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtMS0xLTEtMA_beed4971-539d-4ff7-8cd5-1e9f23f07381">2.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdcecbf126d4b8099f5e7acda25fb2d_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtMy0xLTEtMA_60d99351-b99d-49ae-8e48-01689fbd52ef">186.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c3ebcbd89841a28e7480e4337c4988_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtNS0xLTEtMA_2630fab3-063d-4ece-bce5-b4fda26f15cf">33.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6f5a43994a74e30bc2c24fc58be7a8b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtNy0xLTEtMA_44180549-8518-450e-83c1-bbd0c826792c">33.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38457c7073c148078d40e136da416dc2_D20200101-20201231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtOS0xLTEtMA_21ab571e-e143-4331-8722-33906309c154">92.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtMTEtMS0xLTA_d6685044-af8d-4dd2-8cf0-9250e3658e75">163.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f346c927114584bd6128c5a5e41d52_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtMS0xLTEtMA_955f4369-15ba-422f-8828-ab3b3d7424b9">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie53527d45eb34a6b993b46ac83917155_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtMy0xLTEtMA_ea9ad750-29a5-4bc9-ac85-f9da764056c2">179.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id971167191384986aec4598f9022d212_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtNS0xLTEtMA_521f57f0-908d-43ac-be06-66f4077fe99e">8.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b64d0eaf4c246fab3031182b58a6d37_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtNy0xLTEtMA_153f9498-45f2-441d-898c-f21e81af9e74">66.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cf2db733a844ed99dc8f7222b3ccc49_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtOS0xLTEtMA_d70f3a8a-40d0-4038-9a69-10d5e803d246">46.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7957fd5108f041cf86733aef419c0487_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtMTEtMS0xLTA_65eb87a7-cecc-4015-94fe-c77bfecdd7e1">299.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bba1fded9e7415e8f0eecc9fc01fa37_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtMS0xLTEtMA_d72d0134-4bbe-44a2-9c6e-4e2b536f3a28">4.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d78be56f2654da88b7ee62f039e7477_I20181231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtMy0xLTEtMA_6835301d-12ed-4f03-95de-5b38308dd3b1">34.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cc533cc0841c9a1fb1ddedc5d0abc_I20181231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtNS0xLTEtMA_42cc7443-0d5d-48cc-b903-5d010ba120dc">3.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i520d25d1349b439588d438faa148525c_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtNy0xLTEtMA_0a290f5e-a37d-44c6-abd6-9df878aeaf9e">31.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2706b4a26f7244ee86167f45ad4d537d_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtOS0xLTEtMA_85acd05f-bb2a-431b-aa09-4cfb65286bcc">243.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtMTEtMS0xLTA_6204ab3b-11a7-42ac-bff5-ffdbfd79ce7b">240.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05757bf43f664f91b75e8330e6981029_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtMS0xLTEtMA_592bdb65-3a50-4ecb-8ae9-17f2b9f8e579">11.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic378ba6b90b54eb49686f7fbcd8d7d26_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtMy0xLTEtMA_51de001c-ec1f-4f5b-b746-344d5450e8b7">88.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c50d1ee35d466596e1a0bd0485826b_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtNS0xLTEtMA_7e9fb173-a7b0-4af4-b2f2-91f545f9966e">28.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd9d8887f184f03b4f51f5d658bd9bb_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtNy0xLTEtMA_c693b1a7-c14c-48bd-9d3a-a18fcd8cd6f2">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3946e2ed691746eea6486da676e10065_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtOS0xLTEtMA_749c25a2-3ddd-478c-b2e5-2caf60fd9dfd">103.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtMTEtMS0xLTA_495c77a1-3d35-4ffb-8a49-e2f7d7056a63">230.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05757bf43f664f91b75e8330e6981029_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtMS0xLTEtMA_58453029-b5e6-49a2-ac23-d46d6e7338c4">3.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic378ba6b90b54eb49686f7fbcd8d7d26_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtMy0xLTEtMA_b178f72d-f179-4b47-8573-770cc86ad392">115.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14c50d1ee35d466596e1a0bd0485826b_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtNS0xLTEtMA_61df676c-2a7e-4216-a37b-7872a2326384">7.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd9d8887f184f03b4f51f5d658bd9bb_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtNy0xLTEtMA_0b175fa5-27fd-4746-be29-67215fd1eb78">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3946e2ed691746eea6486da676e10065_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtOS0xLTEtMA_b5ebdd41-1898-4fa3-9308-00974743dc28">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtMTEtMS0xLTA_041e67ae-414e-4f2b-8587-38c5b0ffdc31">125.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05757bf43f664f91b75e8330e6981029_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtMS0xLTEtMA_0e2a3bdb-7971-4668-946c-429bf2b44807">8.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic378ba6b90b54eb49686f7fbcd8d7d26_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtMy0xLTEtMA_3ad08913-7995-4c94-9a89-2b1e3aa80337">26.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c50d1ee35d466596e1a0bd0485826b_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtNS0xLTEtMA_e36dfed1-d1ef-42de-9407-722b362d767d">21.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcd9d8887f184f03b4f51f5d658bd9bb_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtNy0xLTEtMA_3031d161-fb22-425f-a2fb-d30d743989df">1.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3946e2ed691746eea6486da676e10065_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtOS0xLTEtMA_3748b95a-623f-4679-8974-3e3ca39c2279">103.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtMTEtMS0xLTA_e61af562-7ce3-40f0-a272-a7a551b09070">105.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b72acd0c624e9a9e5f85ff7919818a_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctMS0xLTEtMA_c1636e75-49b4-4a16-8722-b96eaf6a8e6c">4.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f24d77b87bc4232984dc260a26c171e_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctMy0xLTEtMA_b6bd3a83-d025-447a-a610-969f7c645e84">7.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709cfa41571a4ab8b7d4914c6efb00b3_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctNS0xLTEtMA_ad31c5f7-5e19-4e85-bf39-47c464a89fee">25.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5d68ba226474425a9ad91c1d2d03c1a_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctNy0xLTEtMA_dae35d9e-6f69-402e-8899-71f32ce7103c">32.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25d8c73e458441d994c3c13f19832ae9_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctOS0xLTEtMA_c6c0d0e9-fd0d-453a-b305-b41e70d921e6">139.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8631cd953f3488583e5a99f0aa067ea_I20191231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctMTEtMS0xLTA_164cc4f5-439b-4b11-b277-4f42d73e3b60">135.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89cc1e0b559548e1b327e6f439fb19d6_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtMS0xLTEtMA_f7db62ab-ca7b-4c73-93e7-f9903746e8b3">1.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05064dd261bf486d8e3bf1bba3b6c47e_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtMy0xLTEtMA_ea8ea291-b042-4928-931e-d56f924f4a60">104.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edbe632efef45cc957628ebc1d33d42_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtNS0xLTEtMA_c08c5b49-7e3e-4f25-8bc9-bd33db96504f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fa22ea433e141458d8691d0f27355c1_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtNy0xLTEtMA_f75c267d-596f-46ef-bb34-2af85cf6585d">36.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide4cbacbf5734ef695d22154b1428d52_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtOS0xLTEtMA_74f67370-eb7f-4013-89f2-661440e85177">175.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01ad07778ac849c8b2b4e37c57f5c8cc_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtMTEtMS0xLTA_3cd0dd4b-7609-43e2-829a-ac2e33081933">318.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount reclassified, net of tax, upon adoption of ASU 2016-01</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59744b4317a46d5ab82e7521aa6b11e_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMS0xLTEtMTAwMw_8988b8d8-9d36-4e43-87ef-9daad52878a9">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia35f6885c958490aa4fa10a11e2ca2e6_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMy0xLTEtMTAwMw_2407194e-90b1-447d-b19e-363cba83d3b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i903a5c782a9b41dc9edce0003cd86d67_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItNS0xLTEtMTAwMw_ff5b7c36-9982-4a78-a9c0-f7010ca4e1c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6757062bd137442ea0f58c866b089bcd_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItNy0xLTEtMTAwMw_8038da5f-c6f1-4e76-a9f8-e33d34fbc1f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ba77a8a8704925bcd95ae5bd41be65_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItOS0xLTEtMTAwMw_268b1162-cda5-4738-8951-373f068f66d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158387b1a5ea437bb6564f068f16da94_I20171231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMTItMS0xLTExNDE3_6aad2be1-dc2b-4dc0-ac9a-5e7d3b3e0a62">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20addfea8892477996faeb680a08f153_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMS0xLTEtMTAwMw_8908fac1-fd2e-4b4c-ac65-f76cf38cb526">0.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d0da88784044139ae3b0627adb1073e_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMy0xLTEtMTAwMw_09bea457-843a-4714-9f06-75e7175f52e6">104.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedbbfb7ec1f47d98f528e19bea4741a_I20171231" decimals="-5" format="ixt:zerodash" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtNS0xLTEtMTAwMw_5e326e94-a603-4dc3-b5fe-f67f7e029b25">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc4fdfb6dc344f2ba410b5f056357e3a_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtNy0xLTEtMTAwMw_d938600b-8eaf-4f89-a525-8b6f64431110">36.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i255daee7862543c69e18f60f9dab28fa_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtOS0xLTEtMTAwMw_81c75975-54ee-4136-8f3e-4b601284efee">175.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib03e8eced8bc40769f89224b7a3917b7_I20171231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtMTItMS0xLTExNDE3_f33707c8-1dba-4b61-9644-51593f71878f">316.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0835e29a53b74d32a686b04bc1b1b198_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMS0xLTEtMA_c89347dc-7d1e-4781-8e41-d9f222aa2054">10.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib755e31f5e76447187fce9bda9cb4342_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMy0xLTEtMA_8f4ec711-8759-4d3e-9a6b-248c3d69849d">97.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d38cf0e172d4e26924af47f88ae37cd_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItNS0xLTEtMA_3348eaa4-0446-4e8c-8616-0f92810ab539">5.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c99beb651874e9494da14b27703de21_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItNy0xLTEtMA_155b21eb-c37b-4f88-be9d-b00baffc9e24">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87a66bdab7bd472bae2b3efc40fee57c_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItOS0xLTEtMA_3ce58842-431b-4c70-af89-4f152885badc">67.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMTEtMS0xLTA_7cf0d96f-8e5b-47cb-a215-5daf42af4b91">29.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0835e29a53b74d32a686b04bc1b1b198_D20180101-20181231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMS0xLTEtMA_d31d91b1-a7e6-4000-bfd4-7f600de28cf9">6.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib755e31f5e76447187fce9bda9cb4342_D20180101-20181231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMy0xLTEtMA_bfe99960-2d31-4641-8091-b578e3ab8ed7">41.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d38cf0e172d4e26924af47f88ae37cd_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtNS0xLTEtMA_81388eb2-eb2a-4369-b2c2-01933db0c722">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c99beb651874e9494da14b27703de21_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtNy0xLTEtMA_542ac343-9e8f-4783-bcee-5ff2dd444d1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87a66bdab7bd472bae2b3efc40fee57c_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtOS0xLTEtMA_f493bf50-80dc-47de-a7f7-2db148c3ccf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMTEtMS0xLTA_3a0b7b9a-e93f-446f-9e68-11edd0f6f412">47.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0835e29a53b74d32a686b04bc1b1b198_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtMS0xLTEtMA_95da6103-d98b-4801-af92-690841dcfee6">3.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib755e31f5e76447187fce9bda9cb4342_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtMy0xLTEtMA_6b320a39-0b8c-4dc1-b042-f4c805a551df">139.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d38cf0e172d4e26924af47f88ae37cd_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtNS0xLTEtMA_b5d6630a-986d-4876-badc-c7a23933fba1">3.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c99beb651874e9494da14b27703de21_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtNy0xLTEtMA_32b8b893-ce60-456d-8fb9-5a9e21065410">5.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87a66bdab7bd472bae2b3efc40fee57c_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtOS0xLTEtMA_3c9f4451-0e64-4a81-83f3-11c3a78f0883">67.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtMTEtMS0xLTA_477d4aa8-3681-425f-af68-302c28fa1519">76.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bba1fded9e7415e8f0eecc9fc01fa37_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtMS0xLTEtMA_bf290bb0-4274-4a78-987d-d358066d17e4">4.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d78be56f2654da88b7ee62f039e7477_I20181231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtMy0xLTEtMA_613a1a21-4ffd-40a2-a5a6-f4140f2b3b5f">34.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863cc533cc0841c9a1fb1ddedc5d0abc_I20181231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtNS0xLTEtMA_3577fdca-c0b8-4a8c-abfb-8e9684a59a39">3.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i520d25d1349b439588d438faa148525c_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtNy0xLTEtMA_12d83d84-6ab4-44b7-bdfa-bb2d5ccd0cf4">31.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2706b4a26f7244ee86167f45ad4d537d_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtOS0xLTEtMA_014a974f-8ae8-48ed-8f4d-e7f57e5cc5d9">243.3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtMTEtMS0xLTA_b78d68ca-f589-45a0-afc5-018216b27185">240.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ic0affd82f7f740708bf07b9da2832ce7"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzMzNzY_071d84a3-887e-42bc-9dc9-7b4d5ed607d6" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from<br/>Accumulated Other Comprehensive Income</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45c58c66b4a842ac9ad5f192b2a0e90b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzMtNC0xLTEtMA_6e203272-cffb-4cbd-87a7-6083e9050d5b">8.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5eb4853f6f4dfe9344661c9aa220db_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzMtNi0xLTEtMA_f38d5e7b-f39f-433f-8770-e8850ca1fa2e">4.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70d3de7bccd345f7a075fd96f73db36f_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzMtOC0xLTEtMA_84d6671d-f4ba-4826-a9b1-27436e0877d3">8.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c58c66b4a842ac9ad5f192b2a0e90b_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzQtNC0xLTEtMA_c929ac09-74c9-4ce8-b02c-41c10ccdaa85">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae5eb4853f6f4dfe9344661c9aa220db_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzQtNi0xLTEtMA_d263d1eb-9c49-49d9-a954-f79d950d6935">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d3de7bccd345f7a075fd96f73db36f_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzQtOC0xLTEtMA_239931d8-a532-4205-b87d-c2941eb98771">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dca11e646a476986ce2b76bb838960_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzYtNC0xLTEtMA_976d1b44-b95b-44dc-9f9e-14890d7e6e54">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629d97b930eb4709852d599b96bd1336_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzYtNi0xLTEtMA_1cbaa7f7-fb26-4316-a650-08342b4e56c5">118.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzYtOC0xLTEtMA_da8a68d4-7622-481e-b9e0-35a3a61992d1">42.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dca11e646a476986ce2b76bb838960_D20200101-20201231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzctNC0xLTEtMA_485fdf31-fa25-46ca-a724-2f63d7f1676d">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i629d97b930eb4709852d599b96bd1336_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzctNi0xLTEtMA_e32584c6-b396-4d73-b8dc-39e74c87e7ee">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzctOC0xLTEtMA_7e46103b-1ac6-46b4-80e6-30f54525ed4d">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dca11e646a476986ce2b76bb838960_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzgtNC0xLTEtMA_d10e10ba-da21-4936-be50-f05595749a9b">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629d97b930eb4709852d599b96bd1336_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzgtNi0xLTEtMA_573fe434-1462-41df-af6d-91497e25bf12">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzgtOC0xLTEtMA_d8d1fd23-48de-460b-972a-edb907f7e381">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98dca11e646a476986ce2b76bb838960_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzktNC0xLTEtMA_2ef39db8-3abd-457b-9063-26f5ac9bb809">0.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i629d97b930eb4709852d599b96bd1336_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzktNi0xLTEtMA_d51b998a-47a7-43d6-b022-9c55803cf7c0">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzktOC0xLTEtMA_19930005-8653-4b9d-98fa-85591f467791">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Income (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca0c44aac904794a5af072f3936f72c_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzExLTQtMS0xLTA_4a96c621-0628-44e2-a5e5-c822bf01d00e">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268b5aee503541a1b2d10eb88d72b0fb_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzExLTYtMS0xLTA_a0d4c407-2238-4f72-b38f-a52fbe8f72cd">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83a5eaf6567467eb34c2a56b8b9b544_D20180101-20181231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzExLTgtMS0xLTA_3cc36891-b104-4db7-b108-cf224a09cbc5">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1029aaf02d1e4e45bfea6b6f58c10380_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzEzLTQtMS0xLTA_6e0a504b-f8df-47b6-994a-2245c388b1af">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48908e834b734ebebfa2eebf3d33b0be_D20190101-20191231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzEzLTYtMS0xLTA_259dc929-8b8a-45a3-bb48-9ca0531fa047">125.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8750b469f74471190cc2cf6076d21ef_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzEzLTgtMS0xLTA_c74c6b50-ec9f-4034-bebb-7e0628718fd9">47.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-indent:24.75pt"><span><br/></span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_289"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzQ5NDc4MDIzMjYxMjA_4b94b38a-5d16-42a9-869f-cecce3a2fbc7" continuedAt="i5f3b82bd409744b9a4fa54e8b682bbbc" escape="true">Earnings&#160;per Share</ix:nonNumeric></span></div><ix:continuation id="i5f3b82bd409744b9a4fa54e8b682bbbc"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzQ4NQ_5cd6a47a-95b5-44d6-b2c8-e0d51c10d995" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzMtMS0xLTEtMA_1f1a4227-36e6-46de-92d0-f5889ba8f287"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzMtMS0xLTEtMA_bd351670-df4f-46c1-8529-9f70297623f1">4,000.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzMtMy0xLTEtMA_b01ca025-1e67-4c5c-9900-7ab2eb6ab097">5,888.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzMtNS0xLTEtMA_b218b854-b800-4a75-bd2e-31d7dc822922">4,430.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzUtMS0xLTEtMA_8a3cbff3-1050-4688-8ded-33e7ef045cfb">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzUtMy0xLTEtMA_6e0f2cef-ae63-425d-9949-696ebecc7bc2">187.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzUtNS0xLTEtMA_8fac122e-1a81-4156-89ee-552ca859b843">204.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i286d43c7e7e34e99a914f5aa626a428b_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzgtMS0xLTEtMA_22f0f8eb-b149-4aa9-9d94-8a5cbb421a82">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie60b5c10ba06457f95296998f5fab4fb_D20190101-20191231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzgtMy0xLTEtMA_8a196795-6df2-42ae-920a-ac9adc85c240">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87ef982cfbdf41d3b4a5ae5f59e4bf33_D20180101-20181231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzgtNS0xLTEtMA_af8924c6-7d34-4712-b662-90d8224f66bf">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7c767930933407ba05e420ac12e8ead_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzktMS0xLTEtMA_c197aa5a-e20e-4cd4-8713-ecff5b19c3fa">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabe0551d164a4cf2b1e3b5a93ddbac8b_D20190101-20191231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzktMy0xLTEtMA_831beaf0-2fc6-4b6b-97e0-831ad2e606b0">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i553c1568915b41bd8a1f0a03726da4b5_D20180101-20181231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzktNS0xLTEtMA_f62e92b2-16e7-48f7-bd1d-839034b0ae7d">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie00db9b8e16a4be5b4796014ce7b9775_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEwLTEtMS0xLTA_65430343-8f75-41d8-a613-e9f874158236">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2afb74941ee472f98e6628b9fc75769_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEwLTMtMS0xLTA_6e7bb9dd-c6b3-481f-8d3d-1545b260dede">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c0fbc5a8e674148b9ed9389f86047fa_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEwLTUtMS0xLTA_160c3903-3c31-4be1-9daf-a3eb3a091899">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzExLTEtMS0xLTA_337a0fa6-1623-46ae-b17b-b6920ce485b4">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzExLTMtMS0xLTA_b08d945b-4910-4718-98fa-187743ca923c">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzExLTUtMS0xLTA_490ad376-38f2-4b95-9473-a44318896128">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEyLTEtMS0xLTA_7576f9c4-ca1a-4cc1-a947-c226eb9ffece">161.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEyLTMtMS0xLTA_194e9bb4-2d0a-477f-a6fc-8e3e21239d3d">187.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEyLTUtMS0xLTA_e1017e95-d10f-477f-9353-4e52faf915a8">205.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share for the years ended December&#160;31, 2020, 2019 and 2018, reflects the repurchase of approximately <ix:nonFraction unitRef="shares" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzEwOTk1MTE2Mjg4OTE_13b4db34-9405-4749-a88a-6ad622310341">22.4</ix:nonFraction>&#160;million shares, <ix:nonFraction unitRef="shares" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzEwOTk1MTE2Mjg4NjM_217e794f-d88e-4446-87a1-236cc2653e2b">23.6</ix:nonFraction>&#160;million shares and <ix:nonFraction unitRef="shares" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzEwOTk1MTE2Mjg4Nzc_a9ae3497-e5c4-4669-a956-b575cea1248c">14.8</ix:nonFraction>&#160;million shares of our common stock, respectively, under our share repurchase programs. For additional information on our share repurchase programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Equity</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_292"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzE5_09e5e619-255f-43e9-8818-39f61e6305d8" continuedAt="i6a2f22d7515149dd871b85fae7db4120" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="i6a2f22d7515149dd871b85fae7db4120" continuedAt="i4ba10bb1529d4e48a312b2aec8b15081"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzUx_1fbd6c4a-b4c4-4f41-845d-fcac90c192f6" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b85566626e4d3abc15fda2e07b56a5_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzItMS0xLTEtMA_872107f9-fb7c-4d75-b62e-5ad323375294">80.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923409ff6b114d4ab014bcd315beca62_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzItMy0xLTEtMA_356007b8-bf9c-4e0d-af81-7ef431d9972c">77.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51da93958ce045aa9a3723e4939788a8_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzItNS0xLTEtMA_ee41d05e-2c6d-4609-87ec-01fb83d9052a">75.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id224660fdd0047b996983e6ee2775abe_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzMtMS0xLTEtMA_b76b65eb-fdd5-4f07-a48c-fb13dd599817">131.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzMtMy0xLTEtMA_2939f3dd-92fb-451b-a9ab-5e52f8d651cf">148.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978a8bf34b8a4498a033dbbeb035725f_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzMtNS0xLTEtMA_22d57325-900f-49e7-9897-c3f6c79d70f9">105.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzQtMS0xLTEtMA_3db51c15-026d-4a25-a021-8c8320b2a845">211.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzQtMy0xLTEtMA_586b627c-79f1-42c8-821c-7e9e22f21306">225.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzQtNS0xLTEtMA_05c749c6-5e0e-492d-be78-fc21e5448d84">181.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzUtMS0xLTEtMA_a73f53ae-309c-4657-81dd-e3b26e6ff730">6.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzUtMy0xLTEtMA_58d3105f-b232-4a15-bf7f-3386bf67d9ce">8.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzUtNS0xLTEtMA_f9f50be5-e21e-473c-afdf-8edf790da9cc">11.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzYtMS0xLTEtMA_e04e4a60-bf22-448b-a8e5-499d525edbd9">205.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzYtMy0xLTEtMA_fc871b1a-d9e0-4581-8949-4dc6628bb8f0">216.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzYtNS0xLTEtMA_52d447bd-3ad9-4161-9553-2303ffe940b4">170.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzctMS0xLTEtMA_d9b20451-75af-4d8b-b0a3-25276dc01116">33.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzctMy0xLTEtMA_cdb35e5c-1d4d-42c3-ab08-257ba8a48d7f">35.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzctNS0xLTEtMA_d935bdd4-f912-42ca-b7b5-803eb2c5581f">27.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d9eb1cb8dad4f7bb71554081970672c_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzgtMS0xLTEtMA_ba9bf324-a40f-46bf-a07a-110c3715b855">171.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9a8ab9362146acb873dbfa9866ab42_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzgtMy0xLTEtMA_8a31bf67-f0ae-411c-bcbb-2f848ee25efd">180.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7efd2d47c945e197f5e3a194b14857_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzgtNS0xLTEtMA_d9663201-bbf8-45c6-a8be-47e85cc746e6">142.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzE2_b708e430-94fb-47a3-8221-084058ff22ec" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf69f103a98a40ce90631e9f60d5754b_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzItMS0xLTEtMA_a2c5ab0c-78ad-4b48-bed9-c3a0930c76ed">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5182146502648bf94e1be9dce89213b_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzItMy0xLTEtMA_a2794652-a626-48a1-905a-274160b7a5b7">30.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f97fac7edf9426d88a1e76bb48ad55c_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzItNS0xLTEtMA_00f6b293-1683-46dc-874d-a799102a8972">27.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f109ebcb514632b195259b16d76186_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzMtMS0xLTEtMA_ab927330-40c2-453a-acfc-6a0f0fa8e5e7">142.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d29238f9c3f411fa88ad3fefaaacf57_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzMtMy0xLTEtMA_d12d68c4-98d1-4791-aed1-7e5552fcd73d">134.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d37f597e713494d9d43394bf06bab30_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzMtNS0xLTEtMA_5eb2efb2-1e9e-4e3c-b94e-5b0059d44467">126.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7350a4e642e945d4b5a1646e257127f3_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzQtMS0xLTEtMA_896085c2-effd-46a8-b46d-bd6bd4dfe8f7">1.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf98ae6877747fc9a91fc7dc00a358e_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzQtMy0xLTEtMA_c8dbc5d4-6529-45e8-baf6-795e92c96da9">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib997cdf3cb144617bb5d6ff4986095ba_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzQtNS0xLTEtMA_a8d8cbdd-3067-4e77-a58b-514752a16d8a">7.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia05aa73c81db48f6b204fa3c972243e7_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzUtMS0xLTEtMA_b3ce81f9-806c-435c-a8d4-b353bad2d16a">0.1</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3653e8c908ef47bc8ad1352fd466e75e_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzUtMy0xLTEtMA_efbcf3c2-cfe9-4f97-ba3f-8f4eb1febb17">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba5bec6196eb4910ac31bcec98a0c3a9_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzUtNS0xLTEtMA_ce1a22a1-a323-432e-8f3a-10decd7bc1f4">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3480fbb97844462e9008fb8c307b45ef_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzYtMS0xLTEtMA_22bc35a9-3ce7-4e57-9c41-981580e9a268">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a25527f05454792b6c3a170ae578dc8_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzYtMy0xLTEtMA_46bc10bd-3721-4bd7-85b4-e2f6d197e22f">15.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54cf49ddedf140a0ab09a33fe768f730_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzYtNS0xLTEtMA_1c64a297-27f0-4cda-aff3-6fefe715c7b0">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0df0e7d12e4abda01cacd276a69d0a_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzctMS0xLTEtMA_e0d5a578-0690-46bc-8038-b2b7f1cda04b">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0d61fcfcf945bea2cf06b84ae730ce_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzctMy0xLTEtMA_c5a8e841-0e76-459d-8123-51decadd3c31">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db7fc9d86d84cb6b0b36baee4a3643f_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzctNS0xLTEtMA_fed6e50d-8fb2-466f-b483-d107f7d0dcae">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a840f55f6d64ab182ff63fbceb3665a_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzgtMS0xLTEtMA_90b354bc-ca7f-48d0-96b9-5992955199ef">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i321f27bc93f84527866eb088a9a13ab8_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzgtMy0xLTEtMA_3ad61b0f-ea50-4ec0-8de1-4f8695102120">11.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7d16eb3f9c4249b12a16fbbf180e21_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzgtNS0xLTEtMA_f68ee06c-67b0-490a-943f-814b74510a50">10.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NST stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0769ffe96e9e4c938ce1cbd317e37f42_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzktMS0xLTEtMA_d261de34-aa8e-405f-9bb7-a194aa82d0c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0390833128a4361842fcc8dc5e28d8f_D20190101-20191231" decimals="-5" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzktMy0xLTEtMA_a50cf45a-b687-4348-a2cf-5b1a39839eaf">26.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a49c0b0d08f4220b68f83ed9492b788_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzktNS0xLTEtMA_596dc9dc-2587-42d6-9e90-56a29b9fa249">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEwLTEtMS0xLTA_f03a3e57-abbb-478f-b365-73fdfd736af7">211.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEwLTMtMS0xLTA_5d74052e-28c5-441e-b906-6353303dac46">225.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEwLTUtMS0xLTA_808208f8-5066-4858-ba1a-74bfb2e12682">181.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzExLTEtMS0xLTA_492bd998-d809-409b-b6de-8ae62a3030c6">6.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzExLTMtMS0xLTA_ad276ed7-0381-448f-af52-a035e7a68ffe">8.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzExLTUtMS0xLTA_b351e9a0-2d6a-48a1-9be7-4082edd8dc19">11.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEyLTEtMS0xLTA_a5336553-ca03-4639-97a2-d34c99f9e0f1">205.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEyLTMtMS0xLTA_e0d71895-ce9c-456e-b6fb-24bd75961d0a">216.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEyLTUtMS0xLTA_ee6fe59b-7dff-415b-b2db-36ba7685f2f5">170.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, unrecognized compensation cost related to unvested share-based compensation was approximately $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQxNA_222b4fb0-5dc3-4159-9019-fc5cee5dea45">207.6</ix:nonFraction> million, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" format="ixt-sec:duryear" name="biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzUzOQ_e5ab694f-a496-47f8-acf8-89005aa3dc36">1.9</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Plans</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="plan" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzU4OA_6e076e54-6489-4b9d-8271-68a0d55206ea">three</ix:nonFraction> share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors Plan</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2006 Directors Plan. We have reserved a total of <ix:nonFraction unitRef="shares" contextRef="i4952db151b244967ad310f4684e13d15_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:NumberOfSharesOfCommonStockForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzNjY_14eda07b-1ea2-42eb-b1d4-1fc8f37f0773">1.6</ix:nonFraction> million shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a <ix:nonFraction unitRef="number" contextRef="i4952db151b244967ad310f4684e13d15_D20200101-20201231" decimals="INF" name="biib:RatioOfNumberOfSharesReservedUnderPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxMzk_c8aa51f5-99c3-449f-8b90-e91cdcdeeb46">1.5</ix:nonFraction>-to-1 ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i4ba10bb1529d4e48a312b2aec8b15081" continuedAt="i3ef2cdd55ab344bb929718c69cf0e05f"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omnibus Plan</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2017 Omnibus Equity Plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;<ix:nonFraction unitRef="shares" contextRef="i6e20d08747494db199b88c431d14e928_I20170630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzIzMDQ_a04f4747-7efe-4fa8-8365-dd7a988a5229">8.0</ix:nonFraction> million&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under the Biogen Idec Inc. 2008 Omnibus Equity Plan (2008 Omnibus Equity Plan) as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;<ix:nonFraction unitRef="number" contextRef="if0d36998038a4ff1aeee3c3273f7a37f_D20200101-20201231" decimals="INF" name="biib:RatioOfNumberOfSharesReservedUnderPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNDU_7da8c143-0e15-4bc8-9a8d-9269c0e689b7">1.5</ix:nonFraction>-to-1&#160;ratio.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a <ix:nonNumeric contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNTc_83737e29-df8b-4cb6-9649-17845c7d9fd7">10</ix:nonNumeric>-year term and vest over a period of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNzA_dabd3a6a-1cff-45b6-8845-824a093e53e1">one</span> and <ix:nonNumeric contextRef="ia82e3cb95d2d4a44b7a01995c91159a4_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxODM_4b148e88-174b-4bde-b263-761b665a0057">four years</ix:nonNumeric>, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. As of December&#160;31, 2020, all outstanding options were exercisable.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzNDAz_fbef932f-ac6b-475f-b79e-50f7bbf4191c" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock option activity:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c1ad961cd346de9af30e39027d96bf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzEtMS0xLTEtMA_b02f0139-0176-43f4-87ca-e2de704d66c5">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7c1ad961cd346de9af30e39027d96bf_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzEtMy0xLTEtMA_0383d6ce-51ac-471d-b3ac-aa7c70a72ad7">58.46</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzItMS0xLTEtMA_09e592d6-d590-4253-8452-893be2d5efa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzItMy0xLTEtMA_0e622b1e-1534-4caa-8805-ef5cc81a6569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzMtMS0xLTEtMA_64bf1d96-9eb2-4c90-9cdd-34253d1c7738">12,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzMtMy0xLTEtMA_f2309b64-1afb-41c9-93e1-058ab900e141">58.46</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzQtMS0xLTEtMA_5773816e-640e-493d-99ba-d010e2061560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzQtMy0xLTEtMA_b12ac261-8123-439d-8d1b-4443df1d8627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a2350cc1a754e1e8af5bc26001a39ec_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzUtMS0xLTEtMA_9ed7b50a-486d-4074-8156-adb75d0f61d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a2350cc1a754e1e8af5bc26001a39ec_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzUtMy0xLTEtMA_8c792990-3a60-49ce-91d4-f45fa66425d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic values of options exercised in 2020, 2019 and 2018 totaled $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzM4NjY_a8fd1a90-f02d-4b22-8e70-d7fd9ef64851">2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzM4NzA_74475ab0-9b97-4352-a35e-98cb2c946bc7">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzM4Nzc_76dd7364-0b13-4da6-aa1a-f127f845ff84">4.0</ix:nonFraction> million, respectively. </span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg4_8347a6c1-c9b2-440a-929e-1acf53fedf9c" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit realized for stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzItMS0xLTEtMA_4d51f2b4-6d87-404a-a740-6f783166c54c">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzItMy0xLTEtMA_5ae565b2-a5b1-49d2-be1e-a9bb8d2c1703">2.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzItNS0xLTEtMA_8081da3c-d115-421f-8096-ddb8d8a276bf">2.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzMtMS0xLTEtMA_d83c0cef-19aa-4598-8e14-9f1b2d1d0a61">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzMtMy0xLTEtMA_2c3eb78a-27d8-482f-8fb4-45278c627980">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzMtNS0xLTEtMA_4b557bad-46e4-49db-8dce-52af84d260f0">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Stock Units (MSUs)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSUs awarded to employees prior to 2014 vested in <ix:nonFraction unitRef="increment" contextRef="i8f065e3287da460f99889b0a7d3e9327_D20130101-20131231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfEqualAnnualIncrements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQyODQ_34cd242e-6492-4aec-a772-00ebb6002fbb">four</ix:nonFraction> equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between <ix:nonFraction unitRef="number" contextRef="i8f065e3287da460f99889b0a7d3e9327_D20130101-20131231" decimals="INF" format="ixt-sec:numwordsen" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ0MDY_653d53ee-8389-42ae-aea7-94ca5c6b565d">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="i8f065e3287da460f99889b0a7d3e9327_D20130101-20131231" decimals="INF" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ0MTM_6df86ee4-4bd0-4f63-a700-a5f8cd816840">150.0</ix:nonFraction>% of the target number of units granted based on actual stock performance. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSUs awarded to employees in 2014 and thereafter vest in <ix:nonFraction unitRef="increment" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfEqualAnnualIncrements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ1NDc_ab54c65c-d390-42b1-8eae-da397a4b58a8">three</ix:nonFraction> equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between <ix:nonFraction unitRef="number" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ2NzM_22d0141d-e1ad-4b82-813f-733aa39d288d">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="INF" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ2ODA_8b01c210-815e-422a-9505-9dbf79140255">200.0</ix:nonFraction>% of the target number of units granted based on actual stock performance. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i3ef2cdd55ab344bb929718c69cf0e05f" continuedAt="i4da0c3988ce74e87aa2dfd21da6ce242"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. </span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:ScheduleOfMarketStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjQ_93470bbc-0b51-49fb-88b7-deaaad326c96" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our MSU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant&#160;Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28a8afaf854c4785ba7b167d54f6f8a0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzEtMS0xLTEtMA_55e16e0f-e55b-4b30-ba19-4e191752975d">183,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i28a8afaf854c4785ba7b167d54f6f8a0_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzEtMy0xLTEtMA_866b3c26-d20a-49aa-a6c4-268f9025f255">378.09</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMS0xLTEtMA_a453c414-1392-406f-a3c6-6be569fd62aa">133,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMy0xLTEtMA_5e5cc007-b27e-4389-873d-5a05fde0a71e">398.61</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzMtMS0xLTEtMA_3f169860-689d-4559-abb2-824084e628a2">82,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzMtMy0xLTEtMA_52ce774d-8bb5-46b9-96c5-1f1e7d8694df">375.42</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzQtMS0xLTEtMA_b51ffc6e-8030-4410-bc3e-e11a318a8a4c">33,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzQtMy0xLTEtMA_c2aa2a97-6cf3-4077-9498-8aac2ebc1b43">402.62</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i307bf919a041463693eb52f82fe704dd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzUtMS0xLTEtMA_badf11df-d9a6-4e83-acb9-1453b1b6ad38">201,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i307bf919a041463693eb52f82fe704dd_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzUtMy0xLTEtMA_4eae62b8-bc3e-45bc-98be-21f27b394f70">388.98</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzM4_565199ff-dcec-4c09-87e4-87594327fc27" footnoteRole="http://www.xbrl.org/2003/role/footnote">MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.</ix:footnote></span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the <ix:nonNumeric contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" format="ixt-sec:durday" name="biib:NumberOfDaysForCalculationOfAverageClosingStockPrice" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzU5NDg_758825a3-7995-4475-99a1-75c800ccde7f">30</ix:nonNumeric> calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjM_ae06a7a5-d16b-4685-b30c-4b6de6133f04" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in our valuation are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzItMS0xLTEtMA_8ae4c2ee-ea98-4ef9-83e6-0d025b6f957b">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzItMy0xLTEtMA_39d63b28-742d-4554-a464-774d5a9cdfa5">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzItNS0xLTEtMA_a8e43bf2-e795-436d-baf8-98d4c2d1a574">&#8212;</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range of expected stock price volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8% - 44.1%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2% - 33.6%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5% - 32.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range of risk-free interest rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.41% - 1.48%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.46% - 2.53%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9% - 2.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 calendar day average stock price on grant date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$257.83 - $325.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$228.59 - $331.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$279.47 - $346.76</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average per share grant date fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzYtMS0xLTEtMA_9322999c-3c96-4187-a79f-85f04ed4f813">398.61</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzYtMy0xLTEtMA_c6b16dfa-4707-4137-adf7-5c604d89497d">378.08</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzYtNS0xLTEtMA_6f632a87-9af1-4fb0-a6e1-c14290da8c77">378.85</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of MSUs vested in 2020, 2019 and 2018 totaled $<ix:nonFraction unitRef="usd" contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzYyNDE_7207434b-313e-47b5-ac38-07e165874697">26.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzYyNDU_21455c02-9a4d-4e0a-bd7c-3c330c571210">32.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzYyNTI_c5cc2003-6877-4291-8d01-b72ef7a7e46e">26.9</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Settled Performance Units (CSPUs)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CSPUs awarded to employees vest in <ix:nonFraction unitRef="increment" contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfEqualAnnualIncrements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzYzNDQ_da065e3b-c3e9-493a-a944-aaeab21d6398">three</ix:nonFraction> equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between <ix:nonFraction unitRef="number" contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzY4Mzg_5db1b7d1-ecb4-4483-af16-764b509ba0c2">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231" decimals="INF" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzY4NDU_4680e2b7-42fe-4836-bc6b-0c50b07bf301">200.0</ix:nonFraction>% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the <ix:nonNumeric contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231" format="ixt-sec:durday" name="biib:NumberOfDaysForCalculationOfAverageClosingStockPrice" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzcxNzg_da15c251-2a74-4fa1-aebb-3e7bfb4c7b50">30</ix:nonNumeric> calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzNDA5_527570b4-b964-4167-885c-e31d08ee3f24" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our CSPU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b626c65959246e09aa12e28314bba0c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzEtMS0xLTEtMA_5b472672-cb87-46f1-b8cf-745b508212a1">13,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzItMS0xLTEtMA_f50de499-1433-4dd7-83ea-d2ff737baa3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzMtMS0xLTEtMA_e7f49a8e-596f-4fbe-82c9-ace15aefa078">13,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzQtMS0xLTEtMA_a909bdeb-1ba7-4a13-af3b-9b10bb5f699c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if59b671ae4d44f3b97a43ee65c799fc1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzUtMS0xLTEtMA_d902520a-6105-46d3-b7d2-3e4c52963b71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash paid in settlement of CSPUs vested in 2020, 2019 and 2018 totaled $<ix:nonFraction unitRef="usd" contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzc0OTM_4628d1fe-e70b-4081-bd84-4682aef84c95">3.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ifb57f7f3d44e42c4a8e598bf54a94075_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzc0OTc_9027fa0c-3213-4044-acc1-630ec32be4bc">10.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6d7f7d4fdc14cd4a16f3d306b79e0d5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzc1MDQ_fb7197b3-8d4b-467e-8d3b-25cb787dcf82">15.1</ix:nonFraction> million, respectively.&#160; </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i4da0c3988ce74e87aa2dfd21da6ce242" continuedAt="i18ab19f310a84dee9023602b3a0ad60d"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-vested Restricted Stock Units (PUs)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in <ix:nonFraction unitRef="increment" contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfEqualAnnualIncrements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzc4Nzk_cc62e94f-9e75-499a-a907-fb1b8635a125">three</ix:nonFraction> equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between <ix:nonFraction unitRef="number" contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzgyNDg_318568f5-5459-4999-ab63-317d5b370267">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231" decimals="INF" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzgyNTU_86574ddf-1f3f-4d01-8aae-e76bf10418f5">200.0</ix:nonFraction>% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the <ix:nonNumeric contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231" format="ixt-sec:durday" name="biib:NumberOfDaysForCalculationOfAverageClosingStockPrice" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzg1NDA_072f8a58-36b2-4a9d-80c9-5abbdb8e7c84">30</ix:nonNumeric> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:PerformanceunitsactivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMjk5_e13b08f8-2cf0-4101-bb65-0075390dca8c" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94d4a650ffa44c1998500b69da6939ac_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzEtMS0xLTEtMA_598330fc-0c26-435a-9bec-6e7c7507bd4b">11,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzItMS0xLTEtMA_efa5b434-1e52-4e0d-9bcf-8f96bee6fd43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzMtMS0xLTEtMA_70f3266e-e168-4c24-98e8-e6c37e37a8d3">11,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzQtMS0xLTEtMA_de16597d-59fe-43af-82de-14d409b40dbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a25395b7a6043aca656dfaf91b50a0b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzUtMS0xLTEtMA_b202f552-9522-41f7-a9c7-5ffb9a9f85bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All PUs that vested in 2020, 2019 and 2018 were settled in cash totaling $<ix:nonFraction unitRef="usd" contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzg3ODc_ce08f8f0-a25a-48f0-a8bc-9b86716b3584">3.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i01b2d203f7de418d8494c28ba590c318_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzg3OTE_65cf3805-b0b9-4a69-b740-77fb2d1a97bd">10.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ef74f21f78441ffa5960a07e5974a49_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzg3OTg_8d3959c0-9252-4aa4-a16a-7b369f12fe30">17.0</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units (PSUs)</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PSUs Settled in Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a <ix:nonNumeric contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNDM_5031c6ae-45ff-457e-8965-0f50a124b1cb">three-year</ix:nonNumeric> performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative <ix:nonNumeric contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNDQ_910bc494-a21d-4ae5-9889-8bc47afd48ef">three-year</ix:nonNumeric> performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants may ultimately earn between <ix:nonFraction unitRef="number" contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzk1MjQ_a7579045-bb2b-4b73-81c1-c864784ea4f7">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" decimals="INF" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzk1MzE_cdeaef3e-2976-4521-8d86-08a4e27d6464">200.0</ix:nonFraction>% of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:PerformanceStockUnitsSettledinStockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjI_d3775cf5-32d8-4526-8364-335d20dabf6a" continuedAt="i1f6c7fc3f8ec42a599ff7f0e4e33bc64" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSUs that settle in stock activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78b2e6ab84a14827b284ec4a34e34ebd_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzEtMS0xLTEtMA_2029c077-d898-4daf-aab8-6a5bc76d624a">111,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i78b2e6ab84a14827b284ec4a34e34ebd_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzEtMy0xLTEtMA_1c22ef4a-e4ae-4e45-b7ee-c720ef00cdff">316.39</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMS0xLTEtMA_94bb0b7a-efc2-49dd-9afd-60ee50e69cdc">73,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMy0xLTEtMA_31107894-bc5a-4a7a-9cf9-547a7e070226">293.35</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzMtMS0xLTEtMA_f411736e-ca46-465a-8160-72e097f4d125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzMtMy0xLTEtMA_51769a62-d490-4ce8-94a6-a1703d9a6d06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzQtMS0xLTEtMA_f9f2f502-085e-4c5e-b7e8-1558c07b8a87">29,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzQtMy0xLTEtMA_72efb7ca-06b0-49d4-8729-e94bfaab2f40">323.42</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43f58504b3d04073a49321e74a6c17bd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzUtMS0xLTEtMA_30b05869-42c7-490e-84a2-1f1f3c829cf7">155,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i43f58504b3d04073a49321e74a6c17bd_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzUtMy0xLTEtMA_a62a60ee-dfa1-4352-adb3-f83f27f0b04c">304.19</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i1f6c7fc3f8ec42a599ff7f0e4e33bc64" continuedAt="i7f7345328d0943e79671423f11430d7c">(1)</ix:continuation></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i7f7345328d0943e79671423f11430d7c"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzc4_f2233f5e-fe16-49c0-8d02-0bd274729343" footnoteRole="http://www.xbrl.org/2003/role/footnote">PSUs settled in stock granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</ix:footnote></ix:continuation> </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PSUs Settled in Cash</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNTQ_9f998ee0-5669-4526-a3e7-3980eafec54f">three</span> performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i18ab19f310a84dee9023602b3a0ad60d" continuedAt="i066a38387a394338a6611a2ef1bc92fe"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNjU_9f998ee0-5669-4526-a3e7-3980eafec54f">three</span> annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants may ultimately earn between <ix:nonFraction unitRef="number" contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEwODM1_54226def-f0db-4d98-a529-6622cf730834">zero</ix:nonFraction> and <ix:nonFraction unitRef="number" contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231" decimals="INF" name="biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEwODQy_5a651a61-34b1-449f-8d42-0c2d201f0f22">200.0</ix:nonFraction>% of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the <ix:nonNumeric contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231" format="ixt-sec:durday" name="biib:NumberOfDaysForCalculationOfAverageClosingStockPrice" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzExMTgy_a9c423e1-bbab-4885-b20a-ef894270349c">30</ix:nonNumeric> calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:PerformanceStockUnitsSettledinCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjE_21d7bf13-0ea7-4af8-8921-abd9e649952e" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSUs that settle in cash activity:</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2b88b6b11d44635858d6a6d1dd65fd2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzEtMS0xLTEtMA_8bb35e31-5311-44dc-8899-166ade73ec5e">82,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzItMS0xLTEtMA_cde2cbee-7ac0-4c30-a5e8-a40ead4a07d0">63,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzMtMS0xLTEtMA_6ec535f1-6633-4e20-8259-74c2f8c90395">2,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzQtMS0xLTEtMA_3ec9a252-63de-4b54-a2b2-5fcb4a0eb160">23,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5279dcf6d19435dbf4f97f6c1923185_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzUtMS0xLTEtMA_230c8d1d-34c8-440d-9646-28f3216390c8">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> PSUs settled in cash granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Vested Restricted Stock Units (RSUs)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded to employees generally vest no sooner than one-third per year over <ix:nonNumeric contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyMDQ_94133f5e-4f96-4abd-8240-0d3fde2c97a5">three years</ix:nonNumeric> on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. </span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjA_974550b1-1890-43d6-9114-ab8e93418d84" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3db70ce0acff40ddb1a8049995563df4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzEtMS0xLTEtMA_86722fb9-d9c8-4f54-91cf-8b2d5b4a20eb">938,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3db70ce0acff40ddb1a8049995563df4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzEtMy0xLTEtMA_d1d81716-1e32-425f-9583-ff0113126032">306.55</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMS0xLTEtMA_3d7def81-fe0f-4338-b42f-f9e4c5d0aac7">620,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMy0xLTEtMA_d535a514-8b7c-44b1-935b-6f83ea384d26">318.87</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzMtMS0xLTEtMA_7010cb1d-3592-424e-b750-4b7bd0d71e87">440,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzMtMy0xLTEtMA_35ec7f97-ea96-429e-98fa-589afb023a73">304.45</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzQtMS0xLTEtMA_9b252fad-ca1e-47ac-ba73-319a1f4109a6">100,000</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzQtMy0xLTEtMA_be4d12fe-8c39-49ba-9dfa-cba10bc563e5">314.46</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife7a28c7abae4f1c93ca334525d03c5b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzUtMS0xLTEtMA_96716473-78d8-413a-a12c-1806e448235e">1,018,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife7a28c7abae4f1c93ca334525d03c5b_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzUtMy0xLTEtMA_a906ceb5-cf55-4e84-82fc-e1e924e51b6b">314.46</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg2_aca5d24a-146b-4dbc-aa83-d2e4f12e6dfa" footnoteRole="http://www.xbrl.org/2003/role/footnote">RSUs granted in 2020 primarily represent RSUs granted in conjunction with our annual awards made in February 2020 and awards made in conjunction with the hiring of new employees. RSUs granted in 2020 also include approximately <ix:nonFraction unitRef="shares" contextRef="ic6556dcd7cdf41ecbef4a10fc43d3f45_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyODE2_c2dfd109-d8fa-4cb8-b3c4-ad01329efc84">10,000</ix:nonFraction> RSUs granted to our Board of Directors.</ix:footnote></span></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted in 2019 and 2018 had weighted average grant date fair values of $<ix:nonFraction unitRef="usdPerShare" contextRef="i307d77a2fa40438aa59c8269e8e9b25d_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyOTMy_742c265b-390a-4f8c-8d38-fdc2cc39547c">304.44</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ibec2bce1b2964c0f98ad9f65944dee76_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyOTM5_3a81c85f-fb97-4295-a8ff-cde984d1d702">316.32</ix:nonFraction>, respectively.</span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of RSUs vested in 2020, 2019 and 2018 totaled $<ix:nonFraction unitRef="usd" contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMDEz_82b7001b-03ea-453d-8f63-d400bea8d42d">140.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i307d77a2fa40438aa59c8269e8e9b25d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMDE3_7a3a79bb-fbc9-4884-9b87-0f1aaac7ab5e">131.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibec2bce1b2964c0f98ad9f65944dee76_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMDI0_f03c27c7-c709-4016-9061-d7637fd2af8d">111.7</ix:nonFraction> million, respectively.&#160; </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (ESPP)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015 our shareholders approved the 2015 ESPP. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is <ix:nonFraction unitRef="shares" contextRef="if188b16b7c0a45a1a919112de323694b_D20150601-20150630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMjM4_fc79e5bd-e327-4117-84b9-e1b3cf9dd837">6.2</ix:nonFraction> million. </span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzIy_363a0a87-4d0a-4332-9562-bc63bff23f2e" continuedAt="i99c6ca4a5b1a4a7faf22c19fcb5c2838" escape="true">The following table summarizes our ESPP activity:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i066a38387a394338a6611a2ef1bc92fe"><ix:continuation id="i99c6ca4a5b1a4a7faf22c19fcb5c2838"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued under the 2015 ESPP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf6d89d5466147cd8f697b7487932bfb_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzItMS0xLTEtMA_0a1aa64b-06d3-4a97-b366-8305284f495f">212,000</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2396dcccc314478d8ad44cb90e14d1e7_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzItMy0xLTEtMA_9e0f9180-82b4-4b45-a339-b282c9c899d9">204,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3eed89417d914c45a6644792efcd83e5_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzItNS0xLTEtMA_841f55a7-0d69-4823-a229-ed2687e3f703">170,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received under the 2015 ESPP</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6d89d5466147cd8f697b7487932bfb_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzMtMS0xLTEtMA_2b710ac7-45ce-4ae8-9f05-3ab208549983">48.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2396dcccc314478d8ad44cb90e14d1e7_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzMtMy0xLTEtMA_f4d6a91a-0d0f-4a2a-975d-02dc7b055462">40.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eed89417d914c45a6644792efcd83e5_D20180101-20181231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzMtNS0xLTEtMA_c1ceb1d0-a3e0-4fbb-8ff3-c41369daa2d7">40.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="iefe8f1adeafa45df8da4a5beded16de5_298"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzExMDgx_5109a545-e8e3-4d69-a1cf-1fe138dde481" continuedAt="if814b0460e7c472186355c0f9df53c02" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="if814b0460e7c472186355c0f9df53c02" continuedAt="ia970a111ddb34803b3303e16e61f065f"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzExMDkz_89c69bac-b3e4-4450-bbee-ca10e8d591b2" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income tax expense and the income tax expense consist of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income before income taxes (benefit):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzMtMS0xLTEtMA_2cce673d-37a0-4cdb-8dae-44c34432c10d">3,290.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzMtMy0xLTEtMA_12f357f5-1129-47c5-9277-b233865b968e">4,725.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzMtNS0xLTEtMA_fbce5d74-bdd2-4f5b-8b53-8bc673d8de84">3,877.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzQtMS0xLTEtMA_4e626d9a-8e1a-4c17-b09c-96399377d963">1,757.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzQtMy0xLTEtMA_02d515a0-734f-4ec4-9b93-b64cf6bc5406">2,400.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzQtNS0xLTEtMA_21f771f1-029b-4d61-9176-114c295ea297">2,022.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzUtMS0xLTEtMA_a382e42b-a76f-4db7-bfac-0a0114a8bf13">5,047.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzUtMy0xLTEtMA_7e524576-0d36-4bc0-b2ec-4f2f14f02b9f">7,125.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzUtNS0xLTEtMA_f5105d03-4e0e-4970-9465-c5805d8981b7">5,899.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income tax expense (benefit):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzgtMS0xLTEtMA_f8123e42-1013-4610-8980-797e99fbb70f">647.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzgtMy0xLTEtMA_367b0b4a-41a3-4a78-95cb-25b7585aaeda">947.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzgtNS0xLTEtMA_8eb7384f-2abf-4be8-b3ea-7fe570dc0bd5">1,131.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzktMS0xLTEtMA_33b0cd9b-0a39-4b16-8ada-9c70f054a117">41.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzktMy0xLTEtMA_11c38630-19a2-4b38-b5f3-93d5e4a2902b">59.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzktNS0xLTEtMA_a18c6a7b-ee34-4265-9c0e-9cbf6ad41553">45.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEwLTEtMS0xLTA_f06e2975-e34d-405b-9e88-b3b7f92920be">155.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEwLTMtMS0xLTA_eb3dfd45-71a2-477a-8883-2d5a43ba394f">84.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEwLTUtMS0xLTA_6e9f9ddb-c4e0-42a0-9de6-eee5366b2dcb">140.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzExLTEtMS0xLTA_e63e4adb-e8f1-46da-9f06-fa3402a322e1">843.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzExLTMtMS0xLTA_40d63c35-0e93-45b0-827a-e20793de75e7">1,090.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzExLTUtMS0xLTA_556ab62f-eb16-4214-8b36-c3724686dfc9">1,317.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEzLTEtMS0xLTA_7fcdf067-d3fd-4005-a40a-b4230ca4b4ad">1,749.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEzLTMtMS0xLTA_b10ba749-6ba8-4734-8dd0-1a42a03e8565">1,143.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEzLTUtMS0xLTA_028b88d2-a7c6-4e3d-a63d-adb932c3ea82">62.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE0LTEtMS0xLTA_f54e17b3-b002-4eab-979d-e924073b80f7">6.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE0LTMtMS0xLTA_e4555b88-c20b-473a-988e-af65be4515e0">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE0LTUtMS0xLTA_4fabe6e4-24f8-4cdd-8e97-a0a14050cabf">7.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE1LTEtMS0xLTA_e64fb48b-d4f7-40d6-829a-622a804a33bc">1,905.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE1LTMtMS0xLTA_ea8cc356-dd56-4b17-b66f-514d9a6974b1">1,074.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE1LTUtMS0xLTA_c8c61484-5fdf-4d98-95b4-bcc066363aca">177.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE2LTEtMS0xLTA_98e5aaec-f643-4bd1-9c32-fdccfd4cf3c6">149.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE2LTMtMS0xLTA_df7fe3ca-38e3-473f-9af2-fd6542d9ab6c">67.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE2LTUtMS0xLTA_faac5568-c663-4e78-a47d-0f093346d6a1">108.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE3LTEtMS0xLTA_32ffeb87-c4b3-45ab-801b-42ea83fdeb20">992.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE3LTMtMS0xLTA_db02bbd2-8a79-421c-bd9f-fac5840e22e1">1,158.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE3LTUtMS0xLTA_f7bd9145-51df-4597-b5e9-145cc743be13">1,425.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Tax Act</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 35.0% to 21.0%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as GILTI or Subpart F income, includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) and base erosion prevention measures on U.S. earnings and reduces the effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, we recognized a net reduction of $<ix:nonFraction unitRef="usd" contextRef="ibeae6620ceef4b6da93e2b0ac949cf2a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:Reductionindeferredtaxliabilityundistributedforeignearnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzE2MjE_0ce9a972-0c34-43a4-8537-1386610e72af">34.6</ix:nonFraction> million in our estimated Transition Toll Tax, an expense of $<ix:nonFraction unitRef="usd" contextRef="ibeae6620ceef4b6da93e2b0ac949cf2a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzE2NzY_55738949-f871-4dea-a83c-26fac3a4d409">12.7</ix:nonFraction> million to remeasure our deferred tax balances, an expense of $<ix:nonFraction unitRef="usd" contextRef="i13e408385075494cbe602b5be6d1c8e3_I20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:DeferredtaxliabilitiesGILTItaxcalculation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzE3MzM_83bea6b3-fe96-4504-a527-ee3752eb110a">135.8</ix:nonFraction> million related to establishing deferred taxes for GILTI and an expense of $<ix:nonFraction unitRef="usd" contextRef="ibeae6620ceef4b6da93e2b0ac949cf2a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzE4MDM_02d8d52a-b2e2-4696-9c76-0264cadcef63">11.0</ix:nonFraction> million to reflect other aspects of the 2017 Tax Act.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transition Toll Tax</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="i8e9fc07f4dfc4bc081d7e510e678bca7_I20171231" decimals="INF" name="biib:TransitionTollTaxRepatriationTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzIyMjQ_1f019e00-8fdb-4c1d-b070-f003aed7efca">15.5</ix:nonFraction>% and all other earnings were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="i60c4584fb70e4f31996559b7c3214b24_I20171231" decimals="INF" name="biib:TransitionTollTaxRepatriationTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzIyNzQ_502ea6ec-0de3-494b-9a04-c3dcc0a6f2f3">8.0</ix:nonFraction>%.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we have accrued income tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="ib21ba4f090344f2f9805e82e16811047_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzIzMzc_29dd9b65-0cfa-45fa-a027-d8a9c9135f5c"><ix:nonFraction unitRef="usd" contextRef="i8fe3f12d8cdc4e1fb91fee9506338b3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzIzMzc_f74ad078-794a-4a0b-aa50-3bc757625071">697.0</ix:nonFraction></ix:nonFraction> million under the Transition Toll Tax. Of the amounts accrued as of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzI0Nzk_cabd9074-3cab-4f5c-ba6c-c1819442dcee">62.0</ix:nonFraction> million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ia970a111ddb34803b3303e16e61f065f" continuedAt="ib199ff44c8a843d294872c3e5702e564"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unremitted Earnings</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we considered our earnings not to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences of approximately $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-8" format="ixt:numdotdecimal" name="biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzMwNTY_6e6b3b4f-2e58-4f33-97e1-6e6fe9b55a7b">1.5</ix:nonFraction> billion as of December&#160;31, 2020, primarily arising through the impacts of purchase accounting. These permanently reinvested basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which were considered probable as of December&#160;31, 2020. The residual U.S. tax liability, if these differences reverse, would be between $<ix:nonFraction unitRef="usd" contextRef="ic4652a3a2e7940719a658dd16032604d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzM0Mjc_7efe14ab-3289-4624-bf51-ad02bcd7223e">300.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i50d29a2be0b04648b7d97ec27df8f046_I20201231" decimals="-6" format="ixt:numdotdecimal" name="biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzM0MzQ_050f1378-a306-4919-8294-2d267ea103c4">400.0</ix:nonFraction> million as of December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act adjusted a number of provisions of the tax code, including the calculation and eligibility of certain deductions and the treatment of net operating losses and tax credits. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the year ended December&#160;31, 2020, or to our net deferred tax assets as of December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TECFIDERA</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the year ended December&#160;31, 2020, and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the net value of certain deferred tax assets by approximately $<ix:nonFraction unitRef="usd" contextRef="ic9237ad9c6c14888837dc3e87c024939_I20201231" decimals="-8" format="ixt:numdotdecimal" name="biib:DeferredTaxAssetsValueReductionInValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDE5OTk_bdb3475e-e769-4051-8195-ad16df7ecbf9">1.7</ix:nonFraction>&#160;billion and reduced the net value of deferred tax liabilities associated with GILTI and tax credits by approximately $<ix:nonFraction unitRef="usd" contextRef="ic9237ad9c6c14888837dc3e87c024939_I20201231" decimals="-8" format="ixt:numdotdecimal" name="biib:DeferredTaxLiabilitiesValueReductionInValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDIwMTM_48b3dea3-7a1a-4c53-b080-f5077016e101">1.6</ix:nonFraction>&#160;billion. For the year ended December&#160;31, 2020, the income tax expense associated with these reductions was approximately $<ix:nonFraction unitRef="usd" contextRef="i5daca379673646cba7a409b1982cb5ce_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDIwMjc_714639f4-197a-48f2-995b-1f31f378b60c">90.3</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ib199ff44c8a843d294872c3e5702e564" continuedAt="i1f9b1b930b9541338cf67c774a49132a"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets and Liabilities</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ5NDc4MDIzNDE2NDU_3e55b79c-9ed7-4d9b-9a0e-bbdcc73b051a" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzMtMS0xLTEtMA_e28c51d6-7418-4a0e-8e51-24a69b614877">113.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzMtMy0xLTEtMA_555581fb-312c-4124-aa5d-60687d6a9a19">106.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory, other reserves and accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzQtMS0xLTEtMA_574317a9-8f35-4e8e-a51f-e04df271029c">165.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzQtMy0xLTEtMA_959e5889-bd34-4af0-b177-8cf8546747aa">162.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzUtMS0xLTEtMA_39a8eae9-59e0-43b8-b94e-e4e2ed5cfd69">1,546.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzUtMy0xLTEtMA_551fd103-dbc8-48bd-9be5-3b65db366981">3,380.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzYtMS0xLTEtMA_f561ce05-8ed3-4a18-aac7-9e28285ae247">2,080.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzYtMy0xLTEtMA_6afce0aa-c244-4448-bdd0-5bb44079dc1d">130.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzctMS0xLTEtMA_4b455a2a-357f-4892-b8f7-3986c4fe256e">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzctMy0xLTEtMA_05887139-66f0-4368-9bb2-8a49ddfb63e6">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzgtMS0xLTEtMA_50fb21e1-4079-4a1f-b336-8d62d6dba776">103.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzgtMy0xLTEtMA_47e5a22a-a834-44a9-925e-a66ea8de950f">103.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzktMS0xLTEtMA_5d9d636c-e6b9-4f36-b328-34cfc80c4685">1,753.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzktMy0xLTEtMA_4f127311-63ec-414b-a06f-3091d3e0f92f">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEwLTEtMS0xLTA_113f09f6-d356-47db-b0b4-6f955406245e">2,278.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEwLTMtMS0xLTA_68307762-2008-44ea-9b87-e483a626c6a8">3,905.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEyLTEtMS0xLTA_28ae4b41-86d7-4151-8cb6-8fd64fa8afa1">396.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEyLTMtMS0xLTA_3f627932-9aea-4ae6-a9b4-9e0094e3b8b7">350.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:DeferredtaxliabilitiesGILTItaxcalculation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEzLTEtMS0xLTA_8483b184-6c2c-44da-b3aa-7f022a14f837">1,143.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:DeferredtaxliabilitiesGILTItaxcalculation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEzLTMtMS0xLTA_20cdc451-3325-4d8f-983e-44089e79382e">1,381.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" sign="-" name="biib:DeferredTaxLiabilitiesTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE0LTEtMS0xLTA_365d4acb-cccb-4d09-adad-2ec148552f97">174.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="biib:DeferredTaxLiabilitiesTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE0LTMtMS0xLTA_bea08f46-049b-476f-a23f-65d9181126eb">1,617.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation, amortization and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="biib:DeferredTaxLiabilitiesDepreciationAmortizationOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE1LTEtMS0xLTA_eaf7d7db-94a7-4026-b8f0-906b3ea04740">227.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="biib:DeferredTaxLiabilitiesDepreciationAmortizationOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE1LTMtMS0xLTA_93cefbc3-436e-49b2-85c3-aa1bed98bbf8">135.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE2LTEtMS0xLTA_220adcb7-994c-4155-b903-65a109a74bf1">1,941.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE2LTMtMS0xLTA_c8c43e2b-99c8-4189-9a67-46f3aa417878">3,484.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance between December&#160;31, 2020 and 2019, was primarily related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to deferred tax assets and liabilities, we have recorded deferred charges related to intra-entity sales of inventory. As of December&#160;31, 2020 and 2019, the total deferred charges were $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:Totaldeferredchargesandprepaidtaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ2MTE_7aaebb25-02b3-4646-ba56-c0c75481eb84">142.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:Totaldeferredchargesandprepaidtaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ2MTg_5db8a125-23fb-47f4-ac12-369e61e82e5f">243.8</ix:nonFraction> million, respectively. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ5NDc4MDIzNDE2NDY_4fb0fe2b-1e1e-4e54-aa77-a822d9bea350" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzItMS0xLTEtMA_0b1541c4-6457-4701-ae63-90d29e64609b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzItMy0xLTEtMA_16595c6a-3072-45a4-b21b-74c2fe50aab4">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzItNS0xLTEtMA_f1755ad9-1948-43ff-8e9e-382982ac0ff8">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzMtMS0xLTEtMA_52cbaf73-f35a-4642-9acd-999c90d5cf40">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzMtMy0xLTEtMA_b514c663-8bf3-4cbd-9cc4-9ad1ebd5cfb6">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzMtNS0xLTEtMA_12439c51-c24f-439c-a5e4-7cf0b71f4597">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzQtMS0xLTEtMA_624373b4-e49b-4f72-99b5-454533935750">3.3</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzQtMy0xLTEtMA_fc8dcff9-996b-4cf5-87d6-91efcf686f7e">4.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzQtNS0xLTEtMA_a4233754-96c1-4a33-a8d8-dfc8f178be06">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Credits and net operating loss utilization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzUtMS0xLTEtMA_5bd2afda-5e23-47b1-bee7-114225394177">1.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzUtMy0xLTEtMA_e2afdcd6-e999-4576-b883-1e4e0fffb6f6">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzUtNS0xLTEtMA_d5bd9ee7-7dd8-4435-aa1b-1961d949d62c">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzYtMS0xLTEtMA_227fc717-7fcb-461d-8b84-9487cd5609df">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzYtMy0xLTEtMA_95d9410a-20f8-4e66-8c95-d7fe164667cd">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzYtNS0xLTEtMA_c36fc0a2-08cb-4fa7-8709-c3811b0f6292">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divestiture of Denmark manufacturing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzctMS0xLTEtMA_94f716fb-68a2-42ff-9253-2648e7785a49">0.4</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzctMy0xLTEtMA_c0798c3e-d661-4451-99fa-068dd2e87391">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzctNS0xLTEtMA_60e427b4-f92b-4ba8-995b-11760a68b618">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal reorganization of certain intellectual property rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" format="ixt:zerodash" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzgtMS0xLTEtMA_004ef53c-5272-4b9a-a310-e934a7720e73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" sign="-" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzgtMy0xLTEtMA_bb03c83e-e828-49c4-91ab-24ec3c944ffa">2.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" format="ixt:zerodash" name="biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzgtNS0xLTEtMA_bc5c8772-32ee-4a9f-bb72-38ad93ae0ef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktMi0xLTEtMTkyOTM_0ccd4b96-4d6e-4a1c-941c-77bc7af54655">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktNC0xLTEtMTkyOTM_875bb0b0-d2e9-4574-99e0-108176b0d426">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktNi0xLTEtMTkyOTM_9090f7aa-21ce-498a-a109-0fff6c258332">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktMS0xLTEtMA_34d99505-ac79-43b5-9d24-34deaeedde08">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktMy0xLTEtMA_1f41fb2b-4096-4228-aeb0-455a074a2bc4">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktNS0xLTEtMA_004cc1c9-bd8e-4f08-8fb2-44d0ab6467ff">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. tax reform</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzExLTEtMS0xLTA_b14e5385-2467-48c4-a5c9-6e4205c64bac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzExLTMtMS0xLTA_bec9903c-c3f4-4516-ac3a-dcc00dfd96ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzExLTUtMS0xLTA_8646970b-299f-4678-80fe-4e86eb60c502">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss tax reform</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" format="ixt:zerodash" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzEyLTEtMS0xLTA_3cd18454-b54d-4f57-973f-7b9ea1e887ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" sign="-" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzEyLTMtMS0xLTA_5bd84823-9ab0-433f-ad15-d619bf46bd00">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" format="ixt:zerodash" name="biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzEyLTUtMS0xLTA_65fd0937-286f-4d2d-a1ba-a4ad2a9a1812">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE1LTEtMS0xLTA_d9c189bf-f8ff-47d6-9d05-5e69dd4a3093">0.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE1LTMtMS0xLTA_ba4c9310-81d6-47fe-82ef-94844dc85960">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE1LTUtMS0xLTA_1fb461ec-7fe5-4bb0-a60b-391a348a783b">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE2LTEtMS0xLTA_ecb72ebc-8556-4fb1-bdb6-1ca4305772c3">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE2LTMtMS0xLTA_0251d717-e518-452c-8b90-c6cd27f46d44">16.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE2LTUtMS0xLTA_b559fd49-8bd2-4b7f-9074-ad372d19d28f">24.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, our effective tax rate was primarily increased by the income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above, and partially offset by the benefit recognized on the effective settlement of certain tax matters. Additionally, our 2019 effective tax rate benefited from </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i1f9b1b930b9541338cf67c774a49132a" continuedAt="i5fd28e15881047898724ba4ca4983b9a"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an internal reorganization of certain intellectual property rights and the enactment of a new taxing regime in the country and certain cantons of Switzerland, which we refer to as Swiss Tax Reform, partially offset by tax expense related to the divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write-off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the 2019 internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of $<ix:nonFraction unitRef="usd" contextRef="ie04b35230b3a4c1b86938c22cf535263_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzU4Njk_687cbc23-5f00-4034-a9ad-168fb25dbe7d">754.1</ix:nonFraction> million and a deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="ie04b35230b3a4c1b86938c22cf535263_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzU5MDQ_1db464e2-dea8-44e4-be6b-25e0d3c36052">603.3</ix:nonFraction> million as of December&#160;31, 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, as compared to 2018, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of the Swiss Tax Reform. This decrease was partially offset by a $<ix:nonFraction unitRef="usd" contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDQzMzM_7aafadec-9573-4d13-9537-6de7a1802c7f">68.9</ix:nonFraction>&#160;million tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from the unfavorable effects of the 2017 Tax Act and our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Attributes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had net operating losses and general business credit carry forwards for U.S. federal income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i0192f21805fe4e158b7667cad4964a5f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzY3NDY_96ec8b03-edbd-451a-b919-973ec42df9f6">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0192f21805fe4e158b7667cad4964a5f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzY3NTM_01dcdd69-6303-4289-9730-620301cbc382">1.3</ix:nonFraction> million, respectively, which begin to expire in 2026. For U.S. state income tax purposes, we had research and investment credit carry forwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i0d86e21f739f482d80d94fd171cf33bf_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzcwMzk_224e5d43-9cc0-4f83-bfa1-f6bee991322c">142.4</ix:nonFraction> million that begin to expire in 2022. For foreign income tax purposes, we had $<ix:nonFraction unitRef="usd" contextRef="i0192f21805fe4e158b7667cad4964a5f_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzcxMTI_0eea5fa2-01cf-47af-999c-e0e577aa3292">18.0</ix:nonFraction> billion of Swiss federal net operating loss carryforwards that begin to expire in 2025 and $<ix:nonFraction unitRef="usd" contextRef="i26628f1182184eba96d1f455922e58af_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NTE1MDY_c866c90a-7ada-458a-add5-47b2fac74a3a">16.8</ix:nonFraction>&#160;billion of Swiss cantonal net operating loss carryforwards that begin to expire in 2025.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries, net of the recorded valuation allowance. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to adjust or establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ5NDc4MDIzNDE2NDc_1dec2e5c-4cd8-49af-a439-274d29eb4ced" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance at January 1,</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzItMS0xLTEtMA_c1424111-be85-40c9-8bfd-1cb0ac5b4fb5">129.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzItMy0xLTEtMA_516ffc6e-de73-448c-ad60-065e3ce21614">114.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9925b2c3e594ae0812001969da2a99b_I20171231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzItNS0xLTEtMA_bdbd233d-57f1-46b4-835e-7d69cc9d72d3">66.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzMtMS0xLTEtMA_531562fa-afcb-4581-9a97-5cdc47bbb67b">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzMtMy0xLTEtMA_713d5649-fb96-422a-b241-20553bea2c68">5.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzMtNS0xLTEtMA_6f6016b5-b2e1-43d4-b5b9-f85ea1df5db2">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions of prior periods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzQtMS0xLTEtMA_d6aef71b-cd66-4542-a15e-7a16b850b33e">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzQtMy0xLTEtMA_6a092c46-342d-42b8-9091-4369b129d041">17.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzQtNS0xLTEtMA_cef2b627-3cd7-41c4-aef1-800107db3b63">58.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reductions for tax positions of prior periods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzUtMS0xLTEtMA_7cd23ff4-b89d-4730-882b-29150356efbf">63.6</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzUtMy0xLTEtMA_37176cf1-c50c-46d8-b26f-ac4ebc2d5586">10.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzUtNS0xLTEtMA_811a9c27-7b24-4094-8782-599e5900d409">13.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statute expirations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzYtMS0xLTEtMA_41d2db41-986c-44b6-a03b-dc0178ba7952">7.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzYtMy0xLTEtMA_bebde395-90ae-4d7a-839f-dafcdac1d6ab">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzYtNS0xLTEtMA_3aeea948-b71f-4328-a8df-3c2659c67b95">2.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement refund (payment)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzctMS0xLTEtMA_b2fdc9cf-0230-4fe1-b0df-4a25101de4ac">35.9</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzctMy0xLTEtMA_f30c2261-f00c-4e06-bb3a-36221086f86c">3.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzctNS0xLTEtMA_abb00245-e817-4985-ab3b-53ffe464ab61">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance ar December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzgtMS0xLTEtMA_c9b63bdf-36df-4de5-9380-b5d8a4102473">75.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzgtMy0xLTEtMA_019e9a28-a358-4509-af7c-2632b45a7fb6">129.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzgtNS0xLTEtMA_fdf6db14-40a2-4339-9ffc-258b18f0693c">114.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 activity reflects the impact of the effective settlement of certain tax matters. We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i5fd28e15881047898724ba4ca4983b9a" continuedAt="iccb7edfd7bda4a7ca4f1855cdb2910b2"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits as of December&#160;31, 2020, 2019 and 2018, are $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzkzMzc_a0f3bcc4-2f23-4e42-8a3e-cbdd1818ba12">68.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzkzNDE_8b39d484-941e-44c7-b326-2683cf662140">122.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzkzNDg_c2583366-3bda-4f28-bed0-5c92f9563acf">109.1</ix:nonFraction> million (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize potential interest and penalties related to unrecognized tax benefits in income tax expense. In 2020, 2019 and 2018 we recognized a net interest and penalty expense of $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk2ODc_103faacb-ecdf-4cb3-afdd-0af4e8882a06">1.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk2OTE_8b70672d-9018-4269-9e0c-b084a8fff327">4.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk2OTg_6afc62f6-16ae-4555-9e89-1ad8c9f13e47">2.2</ix:nonFraction> million, respectively. We have accrued $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk3MzI_92f47816-19a9-432a-a32d-add6bf058133">21.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk3Mzk_85a65f7f-86a1-4d3e-8e5f-af8556ca93fd">20.0</ix:nonFraction> million for the payment of interest and penalties as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal and State Uncertain Tax Positions</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDk0NDk_1d8f1985-a805-4744-8fc5-de79cd848031">25.0</ix:nonFraction> million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Bioverativ Spin-off</span></div></ix:continuation><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iccb7edfd7bda4a7ca4f1855cdb2910b2">On February 1, 2017, in connection with the spin-off of our hemophilia business, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders pursuant to a separation agreement. In March 2018 Bioverativ was acquired by Sanofi S.A. (Sanofi) and is now an indirect wholly-owned subsidiary of Sanofi. The spin-off of our hemophilia business was intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Our 2017 tax return position remains open to audit. Bioverativ and Sanofi agreed to indemnify us for certain potential liabilities that may arise.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span><br/></span></div><div id="iefe8f1adeafa45df8da4a5beded16de5_301"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwMzg_f1c585f1-52ed-4f26-9ab8-2fe5c588c03c" continuedAt="i1dfd69c9174f4417b8152bbdf53a7ef3" escape="true">Other Consolidated Financial Statement Detail</ix:nonNumeric></span></div><ix:continuation id="i1dfd69c9174f4417b8152bbdf53a7ef3" continuedAt="ie56f6afec0224458b865e83afbc2441c"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Cash Flow Information</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwNDM_7874a6d8-726e-4220-aef3-b95099c1763f" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information for the years ended December&#160;31, 2020, 2019 and 2018, is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzMtMS0xLTEtMA_4cb0aee1-60bb-4322-b811-acc5be7e183e">272.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzMtMy0xLTEtMA_440525d3-1b0e-4c2d-af9e-5675ce3928c3">244.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzMtNS0xLTEtMA_dab59983-c832-4d66-a038-44e4e954bc9d">243.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzQtMS0xLTEtMA_4a868fb5-1d90-4145-b1c3-dcb6a3fade54">906.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzQtMy0xLTEtMA_e481a6d5-dc5e-4448-b86f-140a399842d7">1,064.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzQtNS0xLTEtMA_02a656d0-5816-42e1-b7a1-865b5ee3b52b">1,007.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-cash Operating, Investing and Financing Activity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2018 we accrued $<ix:nonFraction unitRef="usd" contextRef="i9c55c5c3bbab4bcc915d94071853367e_D20181001-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzI4Nw_613b93ee-e48b-4eee-ab6e-082e6bb0bc26">300.0</ix:nonFraction> million upon reaching $<ix:nonFraction unitRef="usd" contextRef="i2a5c5a093a604074b379ddadcb4304e8_I20181231" decimals="-8" format="ixt:numdotdecimal" name="biib:CumulativeSalesLevel" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzMwNA_edb8f4e3-56e7-43d2-80ee-d3fd0567aed2">20.0</ix:nonFraction> billion in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately $<ix:nonFraction unitRef="usd" contextRef="i82ea75f6631c448f8f22c298bec0c951_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzk2OQ_15f3ff55-c198-4522-ab49-ef44bed6173f">12.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i214f8c61e02b4bc78c01086f27fa4760_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzk3Ng_7d830099-b385-46dc-a56e-3b4fac243183">50.0</ix:nonFraction> million in our consolidated balance sheets as of December&#160;31, 2020 and 2019, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Property, Plant and Equipment,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ie56f6afec0224458b865e83afbc2441c"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwNDk_61ff71fa-78fe-4cb9-aa50-52651e8c25b5" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzItMS0xLTEtMA_9e38a9f4-1c5f-4cd7-b130-3fb36eac1d5c">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzItMy0xLTEtMA_dfbe32b7-08fc-4d95-9b5a-fc19c9c6f80c">120.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzItNS0xLTEtMA_db9d422e-f3f7-45a8-8e5b-84a5bb9002e4">112.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzMtMS0xLTEtMA_c0baeaf7-1f09-407a-ba48-96f79505e29f">222.5</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzMtMy0xLTEtMA_aab9263a-f788-4204-97ac-5a42406f5f34">187.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzMtNS0xLTEtMA_4b0f50b6-1d24-4fce-bc80-da9f38aaf1fc">200.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzQtMS0xLTEtMA_b8e27167-c2ac-4cef-9677-45150c04dfa2">685.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzQtMy0xLTEtMA_21d773ec-5e19-4839-a2e4-cbd664244991">204.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:GainLossOnSaleOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzQtNS0xLTEtMA_3c98e586-0863-482b-8f61-f2cf42aca6cc">119.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzUtMS0xLTEtMA_923d826c-38dc-4c39-b43b-01a0fc6eaaaa">10.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzUtMy0xLTEtMA_ab4c268f-a2f2-43c9-9b19-18eb3ff08016">7.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzUtNS0xLTEtMA_329498c9-aef6-425c-9ab2-cb97e098fc01">9.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzYtMS0xLTEtMA_f702b790-63ba-4ffa-bf01-4607916839d6">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzYtMy0xLTEtMA_fb491de4-7c60-4a58-8c42-df9454776f8b">47.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzYtNS0xLTEtMA_a363a3fa-b663-4f91-aa28-eb559e260e72">10.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzctMS0xLTEtMA_4e82753e-bf4b-48a2-87c4-c49092212e23">497.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzctMy0xLTEtMA_3da5f00f-c8af-4e5c-947d-62112bcb58a9">83.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzctNS0xLTEtMA_d44380c0-cce7-45de-94a4-46e33fde72e1">11.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, net unrealized and realized gains on our holdings in equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0MDc_83f53fb5-9c13-448f-a45f-18b630f9e1ce">681.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0MTM_d4208bf4-90ab-4537-a5ae-0ddb50bfc0b3">12.1</ix:nonFraction>&#160;million, respectively, compared to net unrealized and realized gains of $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0MTk_b3bcae8b-1416-4c06-ac88-f3769549dfdc">150.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0MjU_27bcd029-fae0-4142-815a-9f0d501991e3">50.0</ix:nonFraction>&#160;million in 2019. The net unrealized gains recognized during the year ended December&#160;31, 2020, primarily reflects an increase in the fair value of Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i8217e2c7737e464790a37fff8a75e2cc_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0NDM_6bc0d37d-721b-4334-9cda-a4f72f064a3f">703.9</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwNTA_916dc73d-3fcf-4538-9833-ef25935ad233" escape="true"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of December&#160;31, 2020, 2019 and 2018:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzItMS0xLTEtMA_3168bac0-1012-49ac-a61d-98e4187ee3fa">693.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzItMy0xLTEtMA_47975338-2791-41f0-87ec-304cb34cc8c7">200.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzItNS0xLTEtMA_f00d2e2d-7c8b-4deb-8a60-a00fe1d96d17">127.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzMtMS0xLTEtMA_227e4f61-01ad-4f2d-8f22-30805179bc73">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzMtMy0xLTEtMA_467cc4d4-319a-44a9-9c03-628b91a24b7f">50.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzMtNS0xLTEtMA_0bf44139-5f6d-4e69-820b-74514460f349">0.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzQtMS0xLTEtMA_d7baec62-9325-4607-ac7f-7d8c9d03a1f0">681.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzQtMy0xLTEtMA_d9f8d033-065b-4138-8a55-b2b74dd23078">150.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzQtNS0xLTEtMA_21bff74d-9bcb-45c5-8640-14f5aa8135b5">128.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwMzY_9d481d7d-147e-4025-9b04-5ac6e85cc22e" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzItMS0xLTEtMA_b3cf638e-75b1-4de2-bf0f-ba0b35c0cb42">1,080.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzItMy0xLTEtMA_187cc441-2bd2-4fe7-b9c8-f84f4f7760e2">1,001.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzMtMi0xLTEtMjA1MTI_51b6b06b-0c24-4015-9819-bcd010560991">389.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzMtNC0xLTEtMjA1MTI_4111b44f-d6a4-4cd7-8d52-21ffab855b3e">281.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzMtMS0xLTEtMA_3a2aa1ab-246f-4cbd-83f1-4afe7c79aebc">333.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzMtMy0xLTEtMA_b72c2da2-10e1-4ec4-beda-a28badac91c6">309.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzUtMS0xLTEtMA_62d4ae27-e3a7-45c4-8aad-cb867a9b329a">218.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzUtMy0xLTEtMA_4abd140d-3786-4649-b6ec-da490c8b92b8">220.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzYtMi0xLTEtMjEwNzk_9aa96f42-9ff1-4c24-aed8-d3e6633e3c1c">181.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzYtNC0xLTEtMjEwNzk_fe1112dd-6afe-4cdd-83f9-cf3225261529">6.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzYtMS0xLTEtMA_5f6179b8-2ed6-42bf-8823-ffc33a6dd87c">149.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzYtMy0xLTEtMA_a01ad3eb-877f-462b-8736-c64da223959e">148.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzgtMS0xLTEtMA_92aff3c0-a80c-44a5-85c4-f77204cdc159">791.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzgtMy0xLTEtMA_b27034a1-ea16-4776-955b-9a1fb3821003">798.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzktMS0xLTEtMA_9ea83f1b-140f-460b-8119-90c8b22b2111">3,145.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzktMy0xLTEtMA_9e494ad9-8bd2-4de6-9516-48952f2fceda">2,765.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzE5MjM_741a9778-b152-47d3-951a-71e87093a261">1,329.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzE5MzA_d8c41ac3-757e-4c28-935b-72792430b02b">1,348.9</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively, and include accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwMDY_92d65717-6d60-452a-975b-95135f7cf01b">709.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwMTM_5324ea8a-d1a0-4390-824e-04cbcb0a2139">803.3</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_304"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDQ1_37a1803e-fa68-4bca-be06-8422939d9f24" continuedAt="i200d4fcdc46d49778b926c79e7567cce" escape="true">Collaborative and Other Relationships</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i200d4fcdc46d49778b926c79e7567cce" continuedAt="i4de6dc2185454763bf369dffb6f1caa7">In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i4de6dc2185454763bf369dffb6f1caa7" continuedAt="i778128acc91947f389f3af96b92fc8b1"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our collaboration partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to OCREVUS and any other collaboration anti-CD20 products in development in exchange for a royalty as well as our rights to GAZYVA in exchange for the compensation described in the collaboration arrangement. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from <ix:nonFraction unitRef="number" contextRef="id44ba7c8ceb14c93b89739486052b804_D20170301-20170331" decimals="3" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyMTc_9731b810-0398-453c-8c67-da8235ee38bd">13.5</ix:nonFraction>% and increasing up to <ix:nonFraction unitRef="number" contextRef="i36bea0a273e042b4977e70b6d39dce99_D20170301-20170331" decimals="3" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyNDE_9c372f91-413c-4c4f-a426-f64cd2f90fa2">24.0</ix:nonFraction>% if annual net sales exceed $<ix:nonFraction unitRef="usd" contextRef="ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331" decimals="-5" format="ixt:numdotdecimal" name="biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyNzE_9c7ee0bb-03e2-4035-b6ea-78ad2522452a">900.0</ix:nonFraction> million. There will be a <ix:nonFraction unitRef="number" contextRef="ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331" decimals="INF" name="biib:Reductioninroyaltyrate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyOTE_e5f3f39e-0d52-4a45-8330-6fa88dc00e38">50.0</ix:nonFraction>% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross <ix:nonFraction unitRef="number" contextRef="i31f7c1fc4a6c450c9505e7b20773c69c_D20170301-20170331" decimals="3" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0MDc_e35cf9b5-bc03-437b-bb84-ae373bd0de4b">3.0</ix:nonFraction>% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting <ix:nonNumeric contextRef="ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331" format="ixt-sec:duryear" name="biib:PeriodOfCollaborationAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0OTI_684dd954-eb0c-44a1-ba9b-bf6da395605f">11</ix:nonNumeric> years from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i778128acc91947f389f3af96b92fc8b1" continuedAt="i89dc76f41c8c4ba393d9f5a3006e3f4a"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN Profit Share</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a <ix:nonFraction unitRef="number" contextRef="id2fc03f67f5645f1b013252212df9935_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ0NDI_95f4dacc-787c-45a0-976b-dd305db45c76">30.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ0NjQ_16c4b3b7-1bb5-4780-ad5b-84b3996044d1">50.0</ix:nonFraction> million of co-promotion operating profits earned each calendar year. <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:CoPromotionProfitSharingFormulaTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDU3_05fb4274-8ad4-4bdf-8247-b6f33b67df0a" continuedAt="if06c97bec4ad4744b4d89e9193e0820e" escape="true">Our share of annual co-promotion profits in excess of $<ix:nonFraction unitRef="usd" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ1ODI_16c4b3b7-1bb5-4780-ad5b-84b3996044d1">50.0</ix:nonFraction> million varies, as summarized in the table below, upon the following events:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="if06c97bec4ad4744b4d89e9193e0820e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until GAZYVA First Non-CLL FDA Approval</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2fc03f67f5645f1b013252212df9935_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTphNzUyMDZjOWEyMjQ0ZWZlYThlYWU3MjljOWJjZmU0ZS90YWJsZXJhbmdlOmE3NTIwNmM5YTIyNDRlZmVhOGVhZTcyOWM5YmNmZTRlXzAtMS0xLTEtMA_8001e1e5-42de-4d63-bf7c-10ce5bc39224">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2fc03f67f5645f1b013252212df9935_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTphNzUyMDZjOWEyMjQ0ZWZlYThlYWU3MjljOWJjZmU0ZS90YWJsZXJhbmdlOmE3NTIwNmM5YTIyNDRlZmVhOGVhZTcyOWM5YmNmZTRlXzEtMS0xLTEtMA_1d3cb2f8-42bd-46e6-adde-9ffd51993049">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2fc03f67f5645f1b013252212df9935_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTphNzUyMDZjOWEyMjQ0ZWZlYThlYWU3MjljOWJjZmU0ZS90YWJsZXJhbmdlOmE3NTIwNmM5YTIyNDRlZmVhOGVhZTcyOWM5YmNmZTRlXzItMS0xLTEtMA_87861230-5b59-407b-9a80-2359cc41a56c">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2fc03f67f5645f1b013252212df9935_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTphNzUyMDZjOWEyMjQ0ZWZlYThlYWU3MjljOWJjZmU0ZS90YWJsZXJhbmdlOmE3NTIwNmM5YTIyNDRlZmVhOGVhZTcyOWM5YmNmZTRlXzMtMS0xLTEtMA_8dcfcc70-c408-4384-bc48-398b9af946f6">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Non-CLL GAZYVA FDA Approval</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least $<ix:nonFraction unitRef="usd" contextRef="i79ec1427e45649d2851751c0d45cf674_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ5NTc_ddf7d63d-a276-49d4-a007-c3f57a7c1aac">150.0</ix:nonFraction> million or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="i79ec1427e45649d2851751c0d45cf674_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzUxNDY_b162e53a-0ac0-4226-a234-1b6fddfbaf14">150.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="i79ec1427e45649d2851751c0d45cf674_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:SalesTriggerGrossSalesThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzUzMDg_847ac47b-4d6e-415f-ac51-e7ec2f1213b5">500.0</ix:nonFraction> million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN pre-tax profits in the U.S. in excess of $<ix:nonFraction unitRef="usd" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODc2Mjg_d6c9aaa5-d1af-40ae-a082-219330cd0974">50.0</ix:nonFraction>&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, was <ix:nonFraction unitRef="number" contextRef="i7585b972767d4bd6bbbd279b2e88eee9_D20190101-20191231" decimals="3" name="biib:Futurepercentageofcopromotionoperatingprofits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODc1ODc_37580f78-937e-4050-bc64-98e343be26f5"><ix:nonFraction unitRef="number" contextRef="i8e00ac4fc24f4e0bb5ded9386aef6231_D20200101-20201231" decimals="3" name="biib:Futurepercentageofcopromotionoperatingprofits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODc1ODc_caa37035-f1fc-463b-82d5-7ed85f14bd87"><ix:nonFraction unitRef="number" contextRef="ib74714c45267446986d21e121eec440b_D20180101-20181231" decimals="3" name="biib:Futurepercentageofcopromotionoperatingprofits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODc1ODc_edf8b72d-9a18-4a2b-9332-fcd2a860cd4f">37.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>%.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between <ix:nonFraction unitRef="number" contextRef="i59c2a5bc4c964df2a0221f7f66aec154_D20200101-20201231" decimals="3" name="biib:Futurepercentageofcopromotionoperatingprofits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzU4NTc_45fd4880-2950-4af0-b8d9-48f22cc5f951">30.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i97799a59fdcc43b1bfbf8aa1dcd16b3a_D20200101-20201231" decimals="3" name="biib:Futurepercentageofcopromotionoperatingprofits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzU4NjQ_9772353d-1645-42dd-be24-5d02c5c131a0">37.5</ix:nonFraction>% based on certain events.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a <ix:nonFraction unitRef="number" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzU5ODA_5c93600a-816d-486f-8b47-d6ce3e923e77">35.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYwMDI_16c4b3b7-1bb5-4780-ad5b-84b3996044d1">50.0</ix:nonFraction> million of operating profits earned each calendar year. <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:PretaxProfitSharingFormulaTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDU4_aa76c2f6-54c9-4f6b-a5ad-fc71e78276bb" continuedAt="ia511f4cc5cf84884b416f7d74dae0dfa" escape="true">Our share of annual profits in excess of $<ix:nonFraction unitRef="usd" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYwOTQ_16c4b3b7-1bb5-4780-ad5b-84b3996044d1">50.0</ix:nonFraction> million varies, as summarized in the table below, upon the following events:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="ia511f4cc5cf84884b416f7d74dae0dfa"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until First GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpjNmFhOGM4YTViYTY0MGZjOWY1MzdmY2I4ZDZiOGExMS90YWJsZXJhbmdlOmM2YWE4YzhhNWJhNjQwZmM5ZjUzN2ZjYjhkNmI4YTExXzAtMS0xLTEtMA_d89542a8-52aa-4b44-abcb-733b444a6d99">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpjNmFhOGM4YTViYTY0MGZjOWY1MzdmY2I4ZDZiOGExMS90YWJsZXJhbmdlOmM2YWE4YzhhNWJhNjQwZmM5ZjUzN2ZjYjhkNmI4YTExXzEtMS0xLTEtMA_9c8914a9-8952-4dfa-b8dd-03f7a86c5f78">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpjNmFhOGM4YTViYTY0MGZjOWY1MzdmY2I4ZDZiOGExMS90YWJsZXJhbmdlOmM2YWE4YzhhNWJhNjQwZmM5ZjUzN2ZjYjhkNmI4YTExXzItMS0xLTEtMA_c4fafca9-b18f-40b4-8d71-8638087820ef">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of GAZYVA pre-tax profits in excess of $<ix:nonFraction unitRef="usd" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTcxMjY_d6c9aaa5-d1af-40ae-a082-219330cd0974">50.0</ix:nonFraction>&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, was <ix:nonFraction unitRef="number" contextRef="i4fce10d195874216b12663411fa5c489_I20181231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYyMjc_26046e1f-570f-48a1-bd8d-4dcf47addc5a"><ix:nonFraction unitRef="number" contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYyMjc_8cfba6f4-dc29-4bc8-99c3-b7f2de282680"><ix:nonFraction unitRef="number" contextRef="i1662495653e1435689b93551c68ae54e_I20191231" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYyMjc_9a266c46-f1bc-4146-b07a-9af9d5b7484b">37.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>%. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Anti-CD20 Therapeutic Programs</span></div><ix:continuation id="i8f25078f7b0749f19a2896fc64c068ba"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9559172621a745278ce2779747432dec_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzItMS0xLTEtMA_10ccf37c-5bff-4ae0-b9ad-acbfa08b48d8">1,080.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6b5a9481f349908c730396c050643d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzItMy0xLTEtMA_245f921d-5531-43ac-8dde-756c0c4e9b49">1,542.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzItNS0xLTEtMA_87aa97c1-ac53-477f-af57-7ba72cc9a7ec">1,431.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9559172621a745278ce2779747432dec_D20200101-20201231" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzMtMS0xLTEtMA_9d167efb-1f44-4876-908e-64ff2ac38f1f">897.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6b5a9481f349908c730396c050643d_D20190101-20191231" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzMtMy0xLTEtMA_559d2a22-0dfc-4ecc-8ae3-b5831e43d442">748.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzMtNS0xLTEtMA_4ba8e667-766e-4c40-85ef-fe66087cd189">548.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzQtMS0xLTEtMA_4765fed5-a2d4-4c2d-b129-51609f8cfa02">1,977.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzQtMy0xLTEtMA_66e3a679-5f8a-41a2-9d85-7ad2b4120fce">2,290.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2514a987784410a8165984f87269d3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzQtNS0xLTEtMA_e29e3db0-2702-4582-9e42-99833c771f99">1,980.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i89dc76f41c8c4ba393d9f5a3006e3f4a" continuedAt="i53fafaab7f3345e2ae9a96c2550c3e52"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ionis Pharmaceuticals, Inc. </span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2012 we entered into a collaboration and license agreement with Ionis pursuant to which we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between <ix:nonFraction unitRef="number" contextRef="iffff7fb793694c20a0248c1ea9b22dfe_D20200101-20201231" decimals="INF" name="biib:PercentageOfRoyaltiesAsPerCollaboration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc2Mzk_40feffb2-3620-493e-acf5-89ddcfe6dfcc">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3dfe4622e95f4be3b13eb7b4eb5d7421_D20200101-20201231" decimals="INF" name="biib:PercentageOfRoyaltiesAsPerCollaboration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc2NDY_92165359-6573-4a7b-9fda-71c5553e74ad">15.0</ix:nonFraction>%, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended December&#160;31, 2020, 2019 and 2018, totaled $<ix:nonFraction unitRef="usd" contextRef="id28d5f3f841240659df55d6cebaa2341_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc4Mjg_134e39c2-92fa-40c8-817c-0d69df77434a">286.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ib1a76b88c18540f5b28ba2e5fbc3f6f0_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc4MzI_b12d4185-36f5-4151-99cd-ce73e816015a">293.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5bdb2b3168704d7e945362a0cc289715_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc4Mzk_3829156e-9c03-4827-a0d2-1409c229a8d4">238.0</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Ionis Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three gene targets. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, Ionis is responsible for global development of any product candidate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to $<ix:nonFraction unitRef="usd" contextRef="i747f7303e31143ec8231dc760b0cb79a_D20121201-20121231" decimals="-5" format="ixt:numdotdecimal" name="biib:LicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzg1NzI_31d91ab5-7208-48ac-9b71-75d6985f1dac">70.0</ix:nonFraction> million to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i71eb4f6064534d02b9b523b950ef4cb5_I20121231" decimals="-5" format="ixt:numdotdecimal" name="biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzg3MDE_2d42367d-f546-49bd-a74a-3ddd4de662a5">130.0</ix:nonFraction> million in additional milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if we successfully develop the product candidate after option exercise. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i71eb4f6064534d02b9b523b950ef4cb5_I20121231" decimals="-5" format="ixt:numdotdecimal" name="biib:Upfrontpaymentforcollaborationagreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzg5NjY_cf435754-65a6-4d90-b4ba-73e8f645dddb">30.0</ix:nonFraction> million to Ionis and agreed to make potential additional payments, prior to licensing, of up to $<ix:nonFraction unitRef="usd" contextRef="i747f7303e31143ec8231dc760b0cb79a_D20121201-20121231" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzkwNTc_d36967df-fd6e-4852-a0ac-4d7150dc2617">10.0</ix:nonFraction> million based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this $<ix:nonFraction unitRef="usd" contextRef="i45dbe435f7fd469798d0b243da615ec6_D20150101-20151231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzkyMjc_a3a6c3cd-7807-4b39-9e74-e8fd7b23217c">10.0</ix:nonFraction> million developmental milestone upon the selection of BIIB080 (tau ASO), which is currently in Phase 1 development for the potential treatment of Alzheimer's disease. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080. In connection with the option exercise, we made a payment of&#160;$<ix:nonFraction unitRef="usd" contextRef="i105821a34e0b4347b7fd8ae515422218_D20191201-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzk1ODU_8971fa7d-d32d-484d-bdd6-19fb86383237">45.0</ix:nonFraction> million&#160;to Ionis, which was recorded as research and development expense in our consolidated statements of income. Future payments may include additional milestone payments of up to&#160;$<ix:nonFraction unitRef="usd" contextRef="i105821a34e0b4347b7fd8ae515422218_D20191201-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzk3NjI_6709da2c-ddfb-4659-997d-70091f690863">155.0</ix:nonFraction> million&#160;and royalties on future sales in the low- to mid-teens if we successfully develop the product candidate after option exercise.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Ionis Agreement</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 we closed a <ix:nonNumeric contextRef="i9331add6801a4df791250e423365aaea_D20180601-20180630" format="ixt-sec:duryear" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDU5_15122d5c-5355-44e1-88d9-6166c8cd8424">10</ix:nonNumeric>-year exclusive collaboration agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (2018 Ionis Agreement) for a total payment of $<ix:nonFraction unitRef="usd" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-8" format="ixt:numdotdecimal" name="biib:Totalpaymenttoentercollaborationagreement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMTQ4_7a94b565-d1c5-4d1c-8ece-9b9a7461eab0">1.0</ix:nonFraction> billion, consisting of an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:Upfrontpaymentforcollaborationagreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMTg4_856159c7-606c-4cb9-b41a-3d434f78e5ac">375.0</ix:nonFraction> million and the purchase of approximately <ix:nonFraction unitRef="shares" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInCommonStockSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMjI1_270ad68f-6234-4578-905f-f9820028f2eb">11.5</ix:nonFraction> million shares of Ionis common stock at a cost of $<ix:nonFraction unitRef="usd" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:Purchaseofcommonstock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMjcw_21fae514-9e0d-4062-bb78-4019589e015f">625.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing, we recorded $<ix:nonFraction unitRef="usd" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMzAw_58367cc1-e21c-4dd5-82b5-05019999036f">50.9</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:Upfrontpaymentforcollaborationagreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMzEw_856159c7-606c-4cb9-b41a-3d434f78e5ac">375.0</ix:nonFraction> million upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining $<ix:nonFraction unitRef="usd" contextRef="i9331add6801a4df791250e423365aaea_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwNDEz_5126ab12-3ef3-4365-9d39-1b9f08e660af">324.1</ix:nonFraction> million as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="shares" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInCommonStockSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwNjkw_270ad68f-6234-4578-905f-f9820028f2eb">11.5</ix:nonFraction> million shares of Ionis common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of $<ix:nonFraction unitRef="usd" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:Investmentincommonstockvalue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzExMDgw_8862d66b-b817-45f3-8cfc-95c90d2d402b">462.9</ix:nonFraction> million in investments and other assets in our consolidated balance sheets reflecting the fair value of the Ionis common stock as of the purchase date and a charge of $<ix:nonFraction unitRef="usd" contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:Premiumonpurchaseofcommonstock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzExMjM2_961cd8e5-e52e-4bba-ac75-c98f338e212f">162.1</ix:nonFraction> million to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the Ionis common stock. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i53fafaab7f3345e2ae9a96c2550c3e52" continuedAt="ia3555894633140f7a90c30d47ac8133d"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in Ionis common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the option to license therapies arising out of the 2018 Ionis Agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to $<ix:nonFraction unitRef="usd" contextRef="ia2c9ea4c44b047fab182bf1e93960612_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyMDY0_348d1175-eded-4ef3-a2fb-43dacd60ffbc">125.0</ix:nonFraction> million or $<ix:nonFraction unitRef="usd" contextRef="iff10bbc1b7204f9a899f2b15e8f5bb57_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyMDcw_66262bb0-0c65-4209-a0e7-8f5a4d00b308">270.0</ix:nonFraction> million for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, we incurred milestones of $<ix:nonFraction unitRef="usd" contextRef="i8b01dc3119ea40eaaabda1c48b7c9107_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODQyMDQ_8dae4b77-ad4c-4cb0-afdd-4839b093ce62">11.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i465d3d459afa478c9e3119d88d5627e7_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyMjU1_aa532543-9ad4-40b5-81c5-c5329d49fe68">30.0</ix:nonFraction> million, respectively, related to the advancement of neurological targets identified under the 2018 Ionis Agreement.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 SMA Collaboration Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of such therapies.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this agreement, we made a $<ix:nonFraction unitRef="usd" contextRef="if47126e2c5154b45ab4cbefbf186b118_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyNzQ1_8cb3ece3-33cf-4ed7-bd9f-3bdb1dd740c5">25.0</ix:nonFraction> million upfront payment to Ionis and we may pay Ionis up to $<ix:nonFraction unitRef="usd" contextRef="if47126e2c5154b45ab4cbefbf186b118_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyODAw_cff9c08d-7285-4672-80db-937e33daa8e1">260.0</ix:nonFraction> million in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to $<ix:nonFraction unitRef="usd" contextRef="i1e5d541771094deaba1fa696b580448f_I20171231" decimals="-5" format="ixt:numdotdecimal" name="biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyOTY5_963b475e-c8d6-41a1-971d-3bbf0d9b46ac">800.0</ix:nonFraction> million in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Long-term Strategic Research Agreement</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 we entered into a <ix:nonNumeric contextRef="if223f76ca1884559bc1cd766f260b0eb_D20130901-20130930" format="ixt-sec:durwordsen" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0MTM_19b9ee4f-cf70-440a-a151-abd1aad6ed8f">six-year</ix:nonNumeric> research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the potential treatment of neurological diseases.&#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the agreement. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-ALS antisense product candidates, Ionis is responsible for global development through the completion of a Phase 2 trial and we provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a $<ix:nonFraction unitRef="usd" contextRef="if223f76ca1884559bc1cd766f260b0eb_D20130901-20130930" decimals="-5" format="ixt:numdotdecimal" name="biib:LicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE0MzA1_207d9a92-4a48-49d0-b262-8397910c7ed0">70.0</ix:nonFraction> million license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i95a0cc3cf2744b12b943e07433857c3a_I20130930" decimals="-5" format="ixt:numdotdecimal" name="biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE0NTE1_426b0c7d-f3d2-4f44-b75f-820883af586b">130.0</ix:nonFraction> million, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (tofersen), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made a payment of $<ix:nonFraction unitRef="usd" contextRef="ic9dc60a6f69e48f5a2a97af95fa37fb4_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1MDM1_4d281cae-668c-4bde-817b-999f606ab6be">35.0</ix:nonFraction> million to Ionis, which was recorded as research and development in our consolidated statements of income. Future payments may include potential post-licensing milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic9dc60a6f69e48f5a2a97af95fa37fb4_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1MjE4_004c3b67-5b11-4e28-bf3a-cb09ea318210">55.0</ix:nonFraction> million and royalties in the low- to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of tofersen following the option exercise. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ending December&#160;31, 2020, 2019 and 2018, we incurred milestones of $<ix:nonFraction unitRef="usd" contextRef="i5554faf4f05643a08aa9972d0ca3320a_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1NTM3_ab758885-1b5d-44d6-8f63-dd653cb21f48">28.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i66010d191b2a4b168f86fe9538abfa3b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1NTQx_eb5d6db6-4463-483f-8457-bff329c17ab4">20.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia0993650b5ce4b56ba73d7e6d491c39c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1NTQ4_7be06651-c5e2-4161-a0f0-0b9fa60b5516">18.0</ix:nonFraction> million, respectively, related to the advancement of programs under this agreement, which were recorded as research and development expense in our consolidated statements of income.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ia3555894633140f7a90c30d47ac8133d" continuedAt="i0799be8d2f1c417295045d76bcc63bab"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BAN2401 Collaboration</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, <ix:nonFraction unitRef="product" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfProductCandidates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0MTk_269f0318-ba5f-4925-938f-e5f6c2a9f5a8">two</ix:nonFraction> Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BAN2401 Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (the Aducanumab Collaboration Agreement). </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDI4_206eb8cb-3ce0-4534-9b9e-6c3410a0cb56" escape="true"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expenses related to the BAN2401 Collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:55.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzItMS0xLTEtMA_8e8405d7-47f3-4459-8128-808bef4fa2ab">219.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzItMy0xLTEtMA_2dd2e0c4-1d9a-42e2-aa0b-09403bdfb7b4">348.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzItNS0xLTEtMA_00890c12-2119-467e-b97c-19c9ac326b2b">232.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzMtMS0xLTEtMA_07bd447e-a709-4b46-9c31-6c88ce65915a">109.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzMtMy0xLTEtMA_e338a6d8-e821-4533-bf8b-8c93e6133e18">174.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzMtNS0xLTEtMA_fc69d1aa-db1b-4b8f-8511-557c07c25fbd">116.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbeeb58208f422997188aaf6d96b19c_D20200101-20201231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzUtMS0xLTEtMA_c91d3147-f0e9-4ad4-b464-c023cbb13345">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912e90e415414b2eb40263d0228aebbd_D20190101-20191231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzUtMy0xLTEtMA_8cb3b2bc-7b9f-4934-b245-12a3a21c8b16">32.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b16525b4ff43abb6399861bedb691a_D20180101-20181231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzUtNS0xLTEtMA_392133c4-5028-4d5d-a763-048135b65b31">10.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbeeb58208f422997188aaf6d96b19c_D20200101-20201231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzYtMS0xLTEtMA_516f7151-ef36-4819-95cc-e985ad104cd2">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912e90e415414b2eb40263d0228aebbd_D20190101-20191231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzYtMy0xLTEtMA_5f1eddbc-1dfe-4ae0-a771-922280c74acb">16.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b16525b4ff43abb6399861bedb691a_D20180101-20181231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzYtNS0xLTEtMA_62fe7c4c-7097-4eb6-80a8-52feac4f337c">5.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab Collaboration Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $<ix:nonFraction unitRef="usd" contextRef="i3be23a7aefd749b688f0ea9bc6153af4_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossOnContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODQ4NjA_39325114-56a2-4ce0-85c3-1af5d6cef4f6">45.0</ix:nonFraction> million related to the termination of various clinical trials and research and development contracts net of the expected <ix:nonFraction unitRef="number" contextRef="ib08f91138dfb4499a6873f325caac5c6_D20190101-20201231" decimals="3" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODQ5Nzc_2e526ad1-57d1-48d8-b972-4528f6c7a7f2">45.0</ix:nonFraction>% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period through March 31, 2018, we were responsible for <ix:nonFraction unitRef="number" contextRef="i12a519048d3946d6b1cae8db3bf6ea2b_D20180101-20180331" decimals="INF" name="biib:PercentageOfDevelopmentCostsIncurred" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODAxNzg_d414d757-ec4f-46a8-9f9d-ac021869fbcb">100.0</ix:nonFraction>% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for <ix:nonFraction unitRef="number" contextRef="i04d3846e76534a968aa79c696280f29f_D20180401-20181231" decimals="3" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5MDM1_b798471a-3b3e-44dd-aca4-ca643be20e14">15.0</ix:nonFraction>% of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for <ix:nonFraction unitRef="number" contextRef="ib08f91138dfb4499a6873f325caac5c6_D20190101-20201231" decimals="3" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5MTM0_2e526ad1-57d1-48d8-b972-4528f6c7a7f2">45.0</ix:nonFraction>% of aducanumab development expense incurred. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i0799be8d2f1c417295045d76bcc63bab" continuedAt="ief70b74c040e481998addb4e05d3863e"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzQ1NTc_dab8a7a4-5de1-4a49-9779-49a52ce20f97">33.8</ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="ib08f91138dfb4499a6873f325caac5c6_D20190101-20201231" decimals="3" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzQ1OTA_2e526ad1-57d1-48d8-b972-4528f6c7a7f2">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzQ1NzI_6632ab0a-8912-445d-9d01-541f58959466">75.0</ix:nonFraction>&#160;million milestone expense related to the submission of the BLA for the approval of aducanumab to the FDA.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a <ix:nonFraction unitRef="number" contextRef="i3f4b4db6bca74ad38b22a985c9cf4c8c_D20200101-20201231" decimals="3" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5NzA1_d44c64b3-0077-4211-a730-6592dee8289a">55.0</ix:nonFraction>% share of the potential profits (losses) in the U.S., a <ix:nonFraction unitRef="number" contextRef="i7cf41e8e7ce64d6b9af4dccfbd954c2a_D20200101-20201231" decimals="3" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5NzYz_25ac23c8-44f8-4f97-9000-526bd2109ddb">68.5</ix:nonFraction>% share of the potential profits (losses) in the European Union (E.U.) and a <ix:nonFraction unitRef="number" contextRef="i685eb05651d54eb487dd05db4f014285_D20200101-20201231" decimals="3" name="biib:Biogenshareofcopromotionprofitsorlosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5ODI0_6dd5b7a1-39fb-4624-bce5-20c72ed1f513">20.0</ix:nonFraction>% share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDM0_095c05f5-8847-4510-837c-26e6d644f18a" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i523d958a043b46abb2bf95ddabf9e48d_D20200101-20201231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzItMS0xLTEtMA_fd4fb3ae-ebdb-4292-8a6a-93a4028158d8">152.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6770bed0636946adb09e5741c30e183e_D20190101-20191231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzItMy0xLTEtMA_16fd3ebd-890a-4f27-8439-1b67042a5da0">179.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e06dea69a4477c83eaaab76c26a1c0_D20180101-20181231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzItNS0xLTEtMA_02828500-2072-44f4-83db-52c473c22658">264.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i523d958a043b46abb2bf95ddabf9e48d_D20200101-20201231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzMtMS0xLTEtMA_df7f2676-51bb-4751-9cc6-ff97a792200e">83.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6770bed0636946adb09e5741c30e183e_D20190101-20191231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzMtMy0xLTEtMA_80b77197-32b8-4dae-8311-913800fc8056">98.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e06dea69a4477c83eaaab76c26a1c0_D20180101-20181231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzMtNS0xLTEtMA_cd13ee18-02ec-42ac-afff-51cfd82040f9">234.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6011115c7277467e81a492d53cc5c2de_D20200101-20201231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzUtMS0xLTEtMA_47170db8-251b-42aa-93d3-a552fd6b4fbb">353.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204866d0c938473fb367812907152221_D20190101-20191231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzUtMy0xLTEtMA_56f66db2-abff-4b0d-b28b-df5d5321fd56">27.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8095992b920b4752bea7ed0e25a7dec6_D20180101-20181231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzUtNS0xLTEtMA_a0b9e56a-700c-4d1e-8bd7-d0f41b74a99b">50.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6011115c7277467e81a492d53cc5c2de_D20200101-20201231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtMS0xLTEtMA_9b9cc419-a8b1-4a51-8d54-fb0ebaebcad4">193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204866d0c938473fb367812907152221_D20190101-20191231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtMy0xLTEtMA_b77fde18-a31f-4c76-9a08-bd876d5c2b74">15.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8095992b920b4752bea7ed0e25a7dec6_D20180101-20181231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtNS0xLTEtMA_0a65e195-44b0-43b8-a0b4-bf27a5fcd947">27.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab collaboration third party milestone expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtMi0xLTEtNTUzMQ_a3f63e1f-aea4-4a75-86ca-6b6fab2fcfcf">75.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtNC0xLTEtNTUzMQ_a7a4ccc3-f5b8-4fa7-b80d-1b3d0659c6c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtNi0xLTEtNTUzMQ_b9a9d93a-1a10-4e0c-bd93-fe957f09910d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzctMi0xLTEtNTUzMQ_c1527754-73ce-4021-8053-726f05069c69">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzctNC0xLTEtNTUzMQ_9c8cd6f7-36b5-4434-b11f-8b3cd903518e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzctNi0xLTEtNTUzMQ_03173601-ab19-42cb-a036-35eeb0418f84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB Pharma S.A.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. <ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ5NDc4MDIzNzc0MTI_09ade21f-fd1b-4912-9eab-ecc3046916af" continuedAt="i1cba0e518e0c440abf41850355b2a5b2" escape="true">A summary of development expense related to the UCB collaboration agreement is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt"><ix:continuation id="i1cba0e518e0c440abf41850355b2a5b2"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307bd3b52c544217a250d6bec5afed5a_D20200101-20201231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzItMi0xLTEtMTE3ODk_8cd79765-e8c8-4d3d-ac70-19738b6887e4">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0259bfa32ec47deb51fdd95ffd65e06_D20190101-20191231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzItNC0xLTEtMTE3OTE_05eaec45-3fa4-42b8-9729-8be986bfa58e">31.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5afe9f2f08fd4c56a2b406c9f04b9941_D20180101-20181231" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzItNi0xLTEtMTE3OTM_b4cdb2be-f7a6-4540-a5cf-9860d44b7bbf">29.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307bd3b52c544217a250d6bec5afed5a_D20200101-20201231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzMtMi0xLTEtMTE3ODk_86512dce-6bc8-4823-9b25-3e3ef9512e0f">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0259bfa32ec47deb51fdd95ffd65e06_D20190101-20191231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzMtNC0xLTEtMTE3OTE_8d63dae0-26e3-438d-a0eb-513a4650f37a">16.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5afe9f2f08fd4c56a2b406c9f04b9941_D20180101-20181231" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzMtNi0xLTEtMTE3OTM_7580b524-995a-436a-9bef-0b8a265d0886">14.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alkermes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for VUMERITY, a novel fumarate for the treatment of RMS. In October 2019 the FDA approved VUMERITY in the U.S. for the treatment of RMS. In November 2019 VUMERITY became commercially available in the U.S.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we received an exclusive, worldwide license to develop and commercialize VUMERITY and we pay Alkermes a royalty of <ix:nonFraction unitRef="number" contextRef="i8aed9a151f27413aad9ecb189295574d_D20200101-20201231" decimals="2" name="biib:PercentageOfRoyaltiesAsPerCollaboration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIxMjg2_fa5c945c-8f57-4236-bb10-19a01aa6201d">15.0</ix:nonFraction>% on worldwide net commercial sales of VUMERITY. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of <ix:nonNumeric contextRef="i8aed9a151f27413aad9ecb189295574d_D20200101-20201231" format="ixt-sec:durwordsen" name="biib:RoyaltiesPayablePeriodPostFDAApproval" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0ODU_0d7e4aca-1085-4a71-96aa-900bdcb8cde4">five years</ix:nonNumeric> following FDA approval. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ief70b74c040e481998addb4e05d3863e" continuedAt="idf1f2bfccad1434886770473b8584eb0"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates, other than VUMERITY, developed under the exclusive license from Alkermes. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2019, following the FDA's approval of VUMERITY, we paid Alkermes $<ix:nonFraction unitRef="usd" contextRef="ib4c7eb5801004aad9c424b58efad93ad_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIyNDg1_b56775d5-7684-4c44-a91f-6556a6f4ac5c">155.0</ix:nonFraction> million in milestone payments, which were recorded in intangible assets in our consolidated balance sheets and will be amortized over the useful life of the product. For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $<ix:nonFraction unitRef="usd" contextRef="i062dfb826bb543c0ab344580c2bc9f39_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIyNjkz_15824e69-db6d-489a-90f7-565803483cc4">32.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i329e830c9d924ad1abde877010ab5c13_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIyNjk3_ae5ffee2-2357-4807-91fb-f8fcaff60c88">53.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie615c033847a4fdc95860b4e0bfd4d64_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIyNzA0_9406c5d0-242e-4e1f-9d62-edfd1a4dede0">68.7</ix:nonFraction> million, respectively, in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alkermes currently supplies VUMERITY to us pursuant to a supply agreement. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by us or our designee.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092 (gosuranemab), an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with Alzheimer's disease. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we received worldwide rights to gosuranemab and are responsible for the full development and potential commercialization of gosuranemab in Alzheimer's disease and progressive supranuclear palsy (PSP). </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we announced that the Phase 2 PASSPORT study investigating gosuranemab in individuals with PSP did not meet its primary endpoint. Based on these results, we discontinued development of gosuranemab in PSP and other primary tauopathies. We will continue our ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease, given differences in disease pathology.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this agreement, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i18853d4d37eb4076a332a07be0132022_D20170601-20170630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTU3NDQ_fa58931d-cb3c-4fb3-927c-d902a466f084">300.0</ix:nonFraction> million to BMS and assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. We may pay BMS up to $<ix:nonFraction unitRef="usd" contextRef="id74db4b324cc4118b5cddd07bff2bc26_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI0ODg1_52a6c494-84b9-4d97-a93f-8da0d70d45dc">360.0</ix:nonFraction> million in additional milestone payments, and potential royalties, and we may pay the former shareholders of iPierian up to $<ix:nonFraction unitRef="usd" contextRef="iecc638e4ad114ce2ad08351d98ed22df_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI1MDA0_867ac744-6385-47b4-8c17-f466732ed1e8">370.0</ix:nonFraction> million in remaining milestone payments as well as potential royalties on net commercial sales.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $<ix:nonFraction unitRef="usd" contextRef="id74db4b324cc4118b5cddd07bff2bc26_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI1MTM4_3c2f9613-e0cf-4c0e-acdd-38c6788dcdf2">62.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic7e2e7e20d974dde8d37743caeeb08eb_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI1MTQ1_d565ccdb-b9de-4a4c-a8d9-4f98f4a6440f">144.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i68ee0bf055a24fd6888b5ed314a45afe_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODUxMzE_e429d05b-7394-49e8-8f3c-4871a2998cc6">97.0</ix:nonFraction> million, respectively, in research and development expense in our consolidated statements of income related to this agreement.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acorda Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone of $<ix:nonFraction unitRef="usd" contextRef="ie154ef82e19b42d287f8709039383fa3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2MDI0_670250c3-4479-49e4-a41b-8788b08fdee6">15.0</ix:nonFraction> million, due if ex-U.S. net sales reach $<ix:nonFraction unitRef="usd" contextRef="ice90a1eb84854ab6838871533abeea35_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:ForeignSalesRequiredToTriggerMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2MDU5_72a80487-2c63-44fe-809b-78653d7e4071">100.0</ix:nonFraction> million over a period of four consecutive quarters, was recognized during the third quarter of 2020 and capitalized within intangible assets, net in our consolidated balance sheet. Royalty payments are recognized in cost of sales within our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes Inc., who acquired Elan Drug Technologies, the original party to the license with Acorda. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="idf1f2bfccad1434886770473b8584eb0" continuedAt="ia8b829b8787c45dcb747505ffe6ff0d2"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ending December&#160;31, 2020, 2019 and 2018, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were $<ix:nonFraction unitRef="usd" contextRef="ice90a1eb84854ab6838871533abeea35_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2NzA0_0fc014db-e6b5-4ada-ba9e-9b06c9dcba82">44.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i1a57dff6854d41af89281f848dc03341_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2NzA4_59f88629-1063-4b37-979b-5a8f2590e54f">42.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib02062df52254e2a96f48ca5db08b037_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2NzE1_b6f9a976-6d85-4e89-acb9-46ba26c46fe7">36.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize zuranolone (SAGE-217) for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for the potential treatment of essential tremor and other neurological disorders. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection of the closing of this transaction in December 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0OTM_0fd0aadb-d546-4252-b45b-790d9b32918b">650.0</ix:nonFraction>&#160;million of Sage common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0ODA_fbf7a00b-06fe-4675-870a-c60759490e0c">6.2</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130" decimals="INF" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA1MDk_2d4a5125-898e-493d-8dd7-98cdd05a17e5">104.14</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0MzQ_b1dd96df-daf6-455f-bd88-c4c6eee043e2">209.0</ix:nonFraction>&#160;million to research and development expense in our consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0NTA_76f19706-7523-44d5-9442-2ed6770dfa2f">875.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also pay Sage development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0NjY_72335eb4-6c4a-42ac-8a87-c828e2675b0a">1.6</ix:nonFraction>&#160;billion if all the specified milestones set forth in this agreement are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and will pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATV enabled anti-amyloid beta</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program and a second program utilizing its Transport Vehicle technology. Further, we have a right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $<ix:nonFraction unitRef="usd" contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NjkwMTE_a5b51fc6-8f44-4caf-b3fd-c465fbf6eb97">465.0</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Denali common stock in September 2020, or approximately <ix:nonFraction unitRef="shares" contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5OTk_72c2412d-7e12-4406-a7dc-f47b6985dc44">13</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930" decimals="2" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5OTE_2d2ae93a-fd5f-42ad-baef-1c2a810975fc">34.94</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5NzY_b8776bc2-975f-43a5-a7a2-f32d76d469e8">41.3</ix:nonFraction>&#160;million to research and development expense in our consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5NjA_e4e1c05e-c579-4286-a1a7-915d08c17776">560.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Denali development and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5NDY_3e6d07c9-3889-4565-96fe-437d5c77e7db">1.1</ix:nonFraction>&#160;billion if the milestones related to the LRRK2 program are achieved. Under this agreement, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and will pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i238f01dc6276416eac270e2a8e9978df_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODUxNzE_9a3f3425-0354-41ee-8a21-7377e8324d5a">8.8</ix:nonFraction>&#160;million in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a <ix:nonNumeric contextRef="i4675956b4c7541689880490a770cb247_D20200101-20201231" format="ixt-sec:durwordsen" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ4Njc_e146dbc8-596a-4222-a3ef-dd7d3450c644">five-year</ix:nonNumeric> period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction in April 2020 we purchased $<ix:nonFraction unitRef="usd" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc4ODg_7404330e-454f-4cc8-b095-0bc21aaba5f3">225.0</ix:nonFraction>&#160;million of Sangamo common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="-6" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementSharesPurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc4NzY_d602a7b1-9ffa-4749-a4ba-acea14a8bad6">24</ix:nonFraction>&#160;million shares at approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="2" name="biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5MDQ_6fa915b5-f93f-46e0-95c8-7bcbba833805">9.21</ix:nonFraction> per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5MTE_d9eb94f3-a29c-48d8-91c7-65554e2ade40">83.0</ix:nonFraction>&#160;million to research </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ia8b829b8787c45dcb747505ffe6ff0d2" continuedAt="ic5f8a3671aca4a0083b0218ec0504f57"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development expense in our consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5MjY_5a3beab3-0b80-416e-853e-1f3de7c41655">125.0</ix:nonFraction>&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5NDI_ebfa9e7c-b532-456d-9443-af9fc5d5825d">2.4</ix:nonFraction>&#160;billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $<ix:nonFraction unitRef="usd" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5NTY_5647a580-c9c6-483b-9c40-c40a3ca29053">80.0</ix:nonFraction>&#160;million relates to the selection of targets, $<ix:nonFraction unitRef="usd" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="-8" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5NzE_e85e6192-3d45-46ff-a68b-b903e0909d6c">1.9</ix:nonFraction>&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $<ix:nonFraction unitRef="usd" contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="biib:GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5ODU_6c7a67ba-f625-4f1a-882b-2a74597f62c4">380.0</ix:nonFraction>&#160;million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we will pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, we recorded $<ix:nonFraction unitRef="usd" contextRef="i4675956b4c7541689880490a770cb247_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODUyMDE_b88da1cf-3e33-42b2-ab93-59564849e473">6.4</ix:nonFraction>&#160;million in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $<ix:nonFraction unitRef="usd" contextRef="i64566178ee6240c4bca091bed9507fe4_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwMjAx_4daf2c37-9750-45c2-ae9c-804861320be5">92.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i32a2842d092548499069b826f6c1c638_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwMjA1_f25d5cfb-e61f-4d1b-9b45-783c2b959ef2">77.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie6856a51b4454c25b01425f5b605c021_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwMjEy_42eed90c-a657-4599-a61e-7f460c9fb4a8">48.6</ix:nonFraction> million, respectively, as research and development expense in our consolidated statements of income related to other research and discovery related arrangements. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;Samsung BioLogics contributed <ix:nonFraction unitRef="krw" contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229" decimals="-8" format="ixt:numdotdecimal" name="biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNTc4_a2b4b062-c53a-4395-a0d1-d17ac91e5b50">280.5</ix:nonFraction> billion South Korean won (approximately $<ix:nonFraction unitRef="usd" contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNjEz_65759413-b0ab-46ac-a13a-faf969cd809e">250.0</ix:nonFraction> million) for an <ix:nonFraction unitRef="number" contextRef="i3ef12f56eff74ffba6abbdbbf71ce00c_D20120201-20120229" decimals="INF" name="biib:JointVentureOwnerShipPercentageByThirdParty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNjI0_24606996-6a60-491a-bfc0-c266afd49523">85.0</ix:nonFraction>% ownership interest in Samsung Bioepis and we contributed <ix:nonFraction unitRef="krw" contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNjcx_5de001cc-74cc-494a-8572-0dc12533fa93">49.5</ix:nonFraction> billion South Korean won (approximately $<ix:nonFraction unitRef="usd" contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNzA2_857ebb98-4fbd-4c7d-8db3-8ba840deaf76">45.0</ix:nonFraction> million) for the remaining <ix:nonFraction unitRef="number" contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNzI4_0dbcf831-05e9-4043-b75c-dd66d87f05ab">15.0</ix:nonFraction>% ownership interest.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="i7391238241af432e81e836c4866c9d90_I20180630" decimals="3" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwODk3_758b1eb1-33a4-42cb-adb5-2863cfeb4110">5.0</ix:nonFraction>%, which reflected the effect of previous equity financings in which we did not participate, to approximately <ix:nonFraction unitRef="number" contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMxMDA4_f8f3f1b7-eea6-4a9c-9328-961f4718561c">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, we paid <ix:nonFraction unitRef="krw" contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMxMTAx_4c88c01a-ed83-4c5d-9abb-d950650aea32">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMxMTIy_3e883ba5-3f22-40bd-8003-27ba98c7c4f4">676.6</ix:nonFraction> million) to Samsung BioLogics.&#160;As of December&#160;31, 2020, our ownership percentage remained at approximately <ix:nonFraction unitRef="number" contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMxMjA5_f8f3f1b7-eea6-4a9c-9328-961f4718561c">49.9</ix:nonFraction>%.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $<ix:nonFraction unitRef="usd" contextRef="i64dc4d43b5394b6b882e494448859c7b_I20181130" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyMjEz_4543adb0-9141-469f-b6dc-bf7657d00ae7">675.0</ix:nonFraction> million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="ib4a6f7ae45f34f16a1e64ef99614a3f6_D20200101-20201231" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyNTk3_ed765be2-9e0c-43f7-bcfd-8964c771da0d">1.5</ix:nonNumeric> years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i6d919fabed9048039865137149827503_D20200101-20201231" format="ixt-sec:duryear" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyNjEw_02dd501f-091e-47e9-bc54-a58687d06b49">15</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The former chief executive officer (the incumbent chairman of the board) and the chief financial officer of our joint venture partner, Samsung BioLogics, is currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="ic5f8a3671aca4a0083b0218ec0504f57" continuedAt="i431905e5633b418aab97a62803c5e113"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, we recognized net income on our investment of $<ix:nonFraction unitRef="usd" contextRef="i295fd62c9b9a44a19b8f2c9cf5993d16_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMTA4_8098ee5b-badd-49c0-ae2b-bcdb533148cc">5.3</ix:nonFraction> million, reflecting our share of income totaling $<ix:nonFraction unitRef="usd" contextRef="i295fd62c9b9a44a19b8f2c9cf5993d16_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTE4MTI_d9aa4793-e4cb-45a1-8cd3-041e769cf367">45.3</ix:nonFraction> million offset by amortization of basis differences totaling $<ix:nonFraction unitRef="usd" contextRef="i295fd62c9b9a44a19b8f2c9cf5993d16_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTE4MTc_25ea6838-05de-477f-bd3f-2342edda8e7f">40.0</ix:nonFraction> million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, we recognized net losses on our investment of $<ix:nonFraction unitRef="usd" contextRef="i3f272ab6a3b3497a8d35a3bdbf2a7afa_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTIzNDA_d64bab69-4f07-4b16-a621-db3623b0eb2a">79.4</ix:nonFraction> million, reflecting our share of losses totaling $<ix:nonFraction unitRef="usd" contextRef="i3f272ab6a3b3497a8d35a3bdbf2a7afa_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTIzOTQ_d61b332a-06d8-4214-8992-8015a337fbb6">1.2</ix:nonFraction> million and amortization of basis differences totaling $<ix:nonFraction unitRef="usd" contextRef="i3f272ab6a3b3497a8d35a3bdbf2a7afa_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTI0NDY_f02d17fa-41ca-4d4c-93f5-2a5a08819b19">78.2</ix:nonFraction> million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMjk3_d492f79b-9e7c-49d4-be30-f1e3eeb713af">673.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMzE4_3b4657d4-f201-42f2-8f06-8cbc5485339f">620.2</ix:nonFraction> million) and <ix:nonFraction unitRef="krw" contextRef="i8686b81ecb37418dbc5bcc179b1e109c_I20191231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMzI2_7ff763be-99ac-491f-b185-7f1cde51bf5a">670.8</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i8686b81ecb37418dbc5bcc179b1e109c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMzQ3_e41505a1-9d47-4e47-98da-bf916f11ea5b">580.2</ix:nonFraction> million), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Transaction</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjY5MDQ_ac8b1eeb-f90f-46db-8390-29c9ff08f61d">two</ix:nonFraction> potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i897172e0b7bd4edda63f02e0d50f23aa_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzOTQ5_9e8323fb-9e6c-4c3b-9669-f40af5733d03">100.0</ix:nonFraction> million to Samsung Bioepis in January 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i897172e0b7bd4edda63f02e0d50f23aa_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzOTk3_45b94ea1-06f7-473d-9391-495bccd3fa48">63.0</ix:nonFraction> million was recorded as research and development expense in 2019 and $<ix:nonFraction unitRef="usd" contextRef="id583b49771574491a9a38091b81e5d33_I20200131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0MDk0_51b48939-7503-4545-8b42-06b9f6e32aad">37.0</ix:nonFraction> million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $<ix:nonFraction unitRef="usd" contextRef="i40f71161d18144578dd8f72012056ddf_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0Mjk3_512054c7-aae0-4ac6-839f-480b241039d3">15.0</ix:nonFraction> million development milestone, which was included in research and development expense in our consolidated statements of income. We may pay Samsung Bioepis up to $<ix:nonFraction unitRef="usd" contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0MjQ_2a4fe2dc-ed2d-4282-9dbb-ee54a7672018">195.0</ix:nonFraction>&#160;million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231" format="ixt-sec:durwordsen" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0NDc_b8140c70-e96b-452e-ba75-8d44fe57407d">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:ContractOptionExerciseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0NTUw_1de3efd1-8862-4799-88b5-c705ec1b1e21">60.0</ix:nonFraction> million, and obtained an option to acquire exclusive rights to commercialize these products in China. </span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2013 we entered into an agreement with Samsung Bioepis to commercialize, over a <ix:nonNumeric contextRef="icfa950bc28fd44ad8df6891d4c6166ca_D20131201-20131231" format="ixt-sec:duryear" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjUxNDY_f5d577f7-fc22-40d0-9d58-1833a2fd801f">10</ix:nonNumeric>-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&#160;As discussed above, we have an option to extend this agreement by an additional <ix:nonNumeric contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231" format="ixt-sec:durwordsen" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0NjY_72f1aee6-923c-4297-93c9-2b6aef4b17f1">five years</ix:nonNumeric>. Under this agreement, we have made upfront and clinical development milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="icfa950bc28fd44ad8df6891d4c6166ca_D20131201-20131231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM1MTM5_cee5674d-c968-4fd1-b68c-fe3a5bdbe352">46.0</ix:nonFraction> million, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of $<ix:nonFraction unitRef="usd" contextRef="if35d8e291e634b4fb356e7dd2eb4e57e_D20131201-20131231" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM1MzY1_edc0b1c3-d00c-4f32-a40b-ec6df05d82dc">25.0</ix:nonFraction> million upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="if35d8e291e634b4fb356e7dd2eb4e57e_D20131201-20131231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM1Nzkz_4654bfae-0663-4bd6-87f3-af1481948c88">75.0</ix:nonFraction> million as intangible assets, net in our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie Inc. (AbbVie) related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in Europe in the fourth quarter of 2018.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM2Nzcx_ced8e982-5425-4d28-a3cd-14bde7734e20">50</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended December&#160;31, 2020, 2019 and 2018, we recognized a net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:CollaborationProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM3MDM2_2cdfccac-d3c5-479f-8084-ca7ff4cfdbae">266.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i55970ae847c94b61adb418c71761c6c4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:CollaborationProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM3MDQw_513d1368-60bf-49bb-937c-7007bb618375">241.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idced215bef924766890054dea8e163a5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="biib:CollaborationProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM3MDQ3_6811010b-fb19-4a38-b5ef-e55fdbb3f001">187.4</ix:nonFraction> million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM3MDkz_ced8e982-5425-4d28-a3cd-14bde7734e20">50</ix:nonFraction>% sharing of the net collaboration profits. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i431905e5633b418aab97a62803c5e113"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the technical development services agreement, we provided Samsung Bioepis technical development and technology transfer services, which included, but were not limited to, cell culture development, purification process development, formulation development and analytical development. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under the manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recognized $<ix:nonFraction unitRef="usd" contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM4ODA1_448408e1-dce9-4ff3-a7d3-55156f8ac0a8">20.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i55970ae847c94b61adb418c71761c6c4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM4ODA5_7b858023-fd0a-470a-aa89-03b393f6cde1">106.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idced215bef924766890054dea8e163a5_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM4ODE2_9c01f35d-8f08-49c7-b294-35dc449fcc7e">96.4</ix:nonFraction> million, respectively, in revenues under the license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="i2d07f2e384e64708858924ad5f63049d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5MTY0_4bdd9ed7-337a-49e7-b8fd-01bd3f66ebd6">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i14fe65b9d9ce412f9b5cb080d3a88a3d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5MTcy_c3c2393a-01be-4d0e-90b6-0476363da0e5">85.0</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. Amounts payable to Samsung Bioepis as of December&#160;31, 2020, were $<ix:nonFraction unitRef="usd" contextRef="i2d07f2e384e64708858924ad5f63049d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODIwMDE_569e75de-cc16-425f-916d-2966cdea5db9">99.0</ix:nonFraction>&#160;million. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the $<ix:nonFraction unitRef="usd" contextRef="i14fe65b9d9ce412f9b5cb080d3a88a3d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5MjY4_138fd414-6a6d-474e-a268-92ec5a29ee99">100.0</ix:nonFraction> million upfront payment related to the transaction we completed in December 2019, as discussed above.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_310"></div><div style="margin-top:9pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzQ3NTI_02d5dd16-f18a-4740-bd9e-2e0351c835b5" continuedAt="i76a12932b68b4939a8f049dd7bb41141" escape="true">Investments in Variable Interest Entities</ix:nonNumeric></span></div><ix:continuation id="i76a12932b68b4939a8f049dd7bb41141" continuedAt="i1d1685e815514f6aba687345bfab2bfa"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="ic52a2fe62f214111bf27f2241c15e13d_D20200101-20201231" format="ixt-sec:duryear" name="biib:Termofcollaborationagreement" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzQzOTgwNDY1MTY2NjY_b17abb04-2273-4a84-a082-9fed3cacceeb">12</ix:nonNumeric> years from the first commercial sale of a licensed product. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="ic52a2fe62f214111bf27f2241c15e13d_D20200101-20201231" decimals="INF" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzMzMTY_8fab0968-4d7a-43f9-820a-e6a53e579736">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017 we amended the terms of the Neurimmune Agreement and made a $<ix:nonFraction unitRef="usd" contextRef="i1b079cbb95c4416897c5c9f868e8ecbe_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEzNjk_b6d585f6-885f-43c5-939e-18b68561a30e">150.0</ix:nonFraction> million payment to Neurimmune in exchange for a <ix:nonFraction unitRef="number" contextRef="i1b079cbb95c4416897c5c9f868e8ecbe_D20171001-20171031" decimals="INF" name="biib:Reductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzE0MTI_51627e0e-684d-48b2-9943-079494e37b36">15.0</ix:nonFraction>% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $<ix:nonFraction unitRef="usd" contextRef="i36b3ae17c9254af097d228dac7821a3c_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzE2Mzc_a9f4f579-8bc4-45f4-b0bb-33f9f3d8f064">50.0</ix:nonFraction> million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i1d1685e815514f6aba687345bfab2bfa"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalties payable on potential commercial sales of aducanumab, by an additional <ix:nonFraction unitRef="number" contextRef="i36b3ae17c9254af097d228dac7821a3c_D20180501-20180531" decimals="INF" name="biib:Additionalreductioninroyaltyratepayableoncommercialsales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzE4NzI_a466904e-5854-41c3-b972-210b4acc272e">5.0</ix:nonFraction>%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzM0MTE_6632ab0a-8912-445d-9d01-541f58959466">75.0</ix:nonFraction>&#160;million upon the regulatory filing with the FDA for the approval of aducanumab. During the second quarter of 2020, we paid Neurimmune $<ix:nonFraction unitRef="usd" contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQ1Njg_6632ab0a-8912-445d-9d01-541f58959466">75.0</ix:nonFraction>&#160;million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests for the year ended December&#160;31, 2020. In addition, for the year ended December&#160;31, 2020, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQ1ODY_dab8a7a4-5de1-4a49-9779-49a52ce20f97">33.8</ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231" decimals="3" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQ1OTI_884b702e-be41-41da-ba2b-01da507bd8d5">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQ1OTg_6632ab0a-8912-445d-9d01-541f58959466">75.0</ix:nonFraction>&#160;million milestone expense.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="ic47c03e6e7be46888ccb47d76183eca4_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzM5Nzc_d00c53eb-d401-4be2-b184-aa9d27294146">200.0</ix:nonFraction> million in milestones to Neurimmune in 2021, which includes $<ix:nonFraction unitRef="usd" contextRef="i22a68eca818d4bfd974767e6d650ecec_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzM5ODk_69c3cbea-0752-4bbc-b93a-000836476c7a">100.0</ix:nonFraction>&#160;million if launched in the U.S., $<ix:nonFraction unitRef="usd" contextRef="i77448f6c2bef4b2ea4eb496e64cae04e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzM5OTU_73dd4e2f-6ccc-4ed3-a28d-8bd7c5b742a3">50.0</ix:nonFraction>&#160;million if launched in three or more countries within the E.U. and $<ix:nonFraction unitRef="usd" contextRef="i957831cfe2a145bab834e81558efd05e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQwMDE_4350c760-9f90-4e02-9f12-d3e8d011924b">50.0</ix:nonFraction>&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending December&#160;31, 2020, 2019 and 2018, amounts reimbursed were immaterial.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzQxNzg_5ee157fe-6c43-4489-ae4c-f978d12465bd">12.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzQxODU_e2160faa-fb2a-40ea-a647-c0e944d4a76e">22.7</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_313"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTMvZnJhZzplOWI4N2M4MjNjYjI0NWU4ODI3YjczYzUzOGZmYTk1Yi90ZXh0cmVnaW9uOmU5Yjg3YzgyM2NiMjQ1ZTg4MjdiNzNjNTM4ZmZhOTViXzQ5NDc4MDIzNTc3NTY_8e889dff-bab9-4c2c-8d44-687f77e43610" continuedAt="id6f6c8b884b84c469ca9c0e6ada3a3e2" escape="true">Litigation</ix:nonNumeric></span></div><ix:continuation id="id6f6c8b884b84c469ca9c0e6ada3a3e2" continuedAt="i3f38ba782e7640499e767f9a1b00d707"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i3f38ba782e7640499e767f9a1b00d707" continuedAt="i3f1de2890ed646548b46e62cbe7d485c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and an action filed by a shareholder on January 5, 2021, in the U.S. District Court for the District of Massachusetts. Both actions allege violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and are seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction. Fresenius Kabi has appealed that decision and was permitted to add a claim of infringement of the Danish counterpart of the &#8216;510 patent, and the appeal is pending. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#8217;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing has been set for August 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i3f1de2890ed646548b46e62cbe7d485c" continuedAt="i158753bfaa554c279c1a28dcadfcca1b"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $<ix:nonFraction unitRef="usd" contextRef="i933bc3e4859e442d998a3136c487cd85_D20191101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTMvZnJhZzplOWI4N2M4MjNjYjI0NWU4ODI3YjczYzUzOGZmYTk1Yi90ZXh0cmVnaW9uOmU5Yjg3YzgyM2NiMjQ1ZTg4MjdiNzNjNTM4ZmZhOTViXzQ5NDQ_a7a57173-6e53-4cf1-860f-f8dee9ef0693">200.0</ix:nonFraction> million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Dispute with Jacobs Switzerland GmbH</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claimed additional payments were due for construction costs. We have reached an agreement in principle to resolve the claim.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Petition for Inter Partes Review</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Office Oppositions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018 the EPO revoked Forward Pharma's European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. A hearing was held in January 2021 and a decision is pending. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#8216;263 Patent. No hearing has been set in this matter.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i158753bfaa554c279c1a28dcadfcca1b"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) have each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#8217;s and Mylan Ireland&#8217;s respective applications to market a generic version of TECFIDERA. The EMA&#8217;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma. That case was heard in July 2020 and we are awaiting a decision. We intend to seek leave to intervene in support of the EMA in the case brought by Mylan Ireland. No hearing has been set in that matter.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_316"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzY2OTg_d1f79889-3deb-4b25-9d00-cb5ba99699e7" continuedAt="i19b48095be2b4117a6655d485a8ed7ec" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i19b48095be2b4117a6655d485a8ed7ec" continuedAt="i1ee0b07320b943af8768fa6ca4f885df"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of <ix:nonFraction unitRef="number" contextRef="i5cd0b9db93464b41b789d3e1ca413b78_I20131231" decimals="INF" name="biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzI3Mw_53509aad-6e97-40ca-931f-7a724162c540">18.0</ix:nonFraction>% on annual worldwide net commercial sales up to $<ix:nonFraction unitRef="usd" contextRef="i5cd0b9db93464b41b789d3e1ca413b78_I20131231" decimals="-8" format="ixt:numdotdecimal" name="biib:FutureContingentPaymentThreshold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzMyMw_9a4d4af0-26f2-4a74-91f5-2373b306745a">2.0</ix:nonFraction> billion and <ix:nonFraction unitRef="number" contextRef="i5cd0b9db93464b41b789d3e1ca413b78_I20131231" decimals="INF" name="biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzMzMA_ca61d727-6a45-41d0-a182-72649e3ed546">25.0</ix:nonFraction>% on annual worldwide net commercial sales that exceed $<ix:nonFraction unitRef="usd" contextRef="i5cd0b9db93464b41b789d3e1ca413b78_I20131231" decimals="-8" format="ixt:numdotdecimal" name="biib:FutureContingentPaymentThreshold" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzM4Ng_e551ef41-2b53-4e35-b822-ec706b24c115">2.0</ix:nonFraction> billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net commercial sales of SPINRAZA using a tiered royalty rate between <ix:nonFraction unitRef="number" contextRef="i16f1d1f107eb4341ad1613ad1b5d5759_D20160101-20161231" decimals="INF" name="biib:PercentageOfRoyaltiesAsPerCollaboration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzkyNw_62b16b8a-0766-4205-9cb5-fa86de3c5cf3">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i91a1d60eac014ca3be868d71ce1a4a4f_D20160101-20161231" decimals="INF" name="biib:PercentageOfRoyaltiesAsPerCollaboration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzkzNA_48ad354a-fcdb-4c3b-b0eb-7620ecb19b63">15.0</ix:nonFraction>%, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of <ix:nonFraction unitRef="number" contextRef="i2dd3d46d9dd249b28b950c8de7e4732c_D20191001-20191031" decimals="INF" name="biib:PercentageOfRoyaltiesAsPerCollaboration" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzE0MTI_2190628d-d2c3-4844-a8cb-3caadd9d55f3">15.0</ix:nonFraction>%, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of <ix:nonNumeric contextRef="i8aed9a151f27413aad9ecb189295574d_D20200101-20201231" format="ixt-sec:durwordsen" name="biib:RoyaltiesPayablePeriodPostFDAApproval" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzQzOTgwNDY1MTgwNzg_0d7e4aca-1085-4a71-96aa-900bdcb8cde4">five years</ix:nonNumeric> following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i1ee0b07320b943af8768fa6ca4f885df" continuedAt="id69251fca53248a084459918d004c9f9"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the acquisition of Convergence occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with this transaction at their fair value on the acquisition date and revalue the remaining obligations each reporting period. We may pay up to approximately $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzIzODA_f884f67e-fcd6-40f4-b87d-0aac02b9fad7">400.0</ix:nonFraction> million in remaining milestones related to these acquisitions.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumapharm AG</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We were required to make contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached $<ix:nonFraction unitRef="usd" contextRef="id7513df5070046c28b340530835d8133_I20201231" decimals="INF" format="ixt:numdotdecimal" name="biib:CumulativeSalesLevel" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzI5MjI_3c1f6f48-6786-430c-8e15-6ccd8e9a0d0f">20.0</ix:nonFraction> billion, at which time no further contingent payments were due. During the first quarter of 2019 we paid the final $<ix:nonFraction unitRef="usd" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzQ2MTg_ead357e7-99b2-44b0-aede-721223124c7d">300.0</ix:nonFraction>&#160;million contingent payment as we achieved the $<ix:nonFraction unitRef="usd" contextRef="i65d03ca4620f4c52999c7becc617b0ff_I20181231" decimals="INF" format="ixt:numdotdecimal" name="biib:CumulativeSalesLevel" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzMwNzE_f6c438af-90f1-4eb8-9db0-46b027ab0e0b">20.0</ix:nonFraction> billion cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2018.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of December&#160;31, 2020, we could trigger potential future milestone payments to third parties of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-8" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzU2Njk_4f5236c1-bd05-4404-ac36-6fd6909a3f30">10.2</ix:nonFraction> billion, including approximately $<ix:nonFraction unitRef="usd" contextRef="ifeaee754376e4c77898d464920110368_I20201231" decimals="-8" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzU2NzU_155bb991-1990-42ef-8537-29f44551cd98">1.9</ix:nonFraction> billion in development milestones, approximately $<ix:nonFraction unitRef="usd" contextRef="i751bdf5f146846a0a2d59925aa237c7e_I20201231" decimals="-8" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzU2ODE_3c5817c9-7bb4-4830-8544-4323eb79ffea">1.3</ix:nonFraction> billion in regulatory milestones and approximately $<ix:nonFraction unitRef="usd" contextRef="i4aa757dc6dcd456f86823b48006f5e50_I20201231" decimals="-8" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzU2ODc_42506cf6-c549-4775-a74e-428d2fc8a479">7.0</ix:nonFraction> billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of December&#160;31, 2020, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to $<ix:nonFraction unitRef="usd" contextRef="if55055ac245a4373b369623a07552bcf_I20211231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgxODQ_deff9409-bc86-4692-8634-2901b10012ff">86.2</ix:nonFraction>&#160;million in milestones in 2021 under our current agreements. Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $<ix:nonFraction unitRef="usd" contextRef="ic47c03e6e7be46888ccb47d76183eca4_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgxOTI_d00c53eb-d401-4be2-b184-aa9d27294146">200.0</ix:nonFraction> million in milestones to Neurimmune in 2021, which includes $<ix:nonFraction unitRef="usd" contextRef="i22a68eca818d4bfd974767e6d650ecec_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgyMDQ_69c3cbea-0752-4bbc-b93a-000836476c7a">100.0</ix:nonFraction>&#160;million if launched in the U.S., $<ix:nonFraction unitRef="usd" contextRef="i77448f6c2bef4b2ea4eb496e64cae04e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgyMTA_73dd4e2f-6ccc-4ed3-a28d-8bd7c5b742a3">50.0</ix:nonFraction>&#160;million if launched in three or more countries within the E.U. and $<ix:nonFraction unitRef="usd" contextRef="i957831cfe2a145bab834e81558efd05e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgyMTY_4350c760-9f90-4e02-9f12-d3e8d011924b">50.0</ix:nonFraction>&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020 we paid Neurimmune $<ix:nonFraction unitRef="usd" contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzYwNTM_6632ab0a-8912-445d-9d01-541f58959466">75.0</ix:nonFraction>&#160;million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzcxNjk_b357a2b9-71a1-409d-8632-1807bf3c0279">21.7</ix:nonFraction> million in our consolidated balance sheet for expenditures incurred by CROs as of December&#160;31, 2020. We have approximately $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzcxODE_0e0b1d10-8f74-4409-a421-5fd2003d6023">593.0</ix:nonFraction> million in cancellable future commitments based on existing CRO contracts as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December&#160;31, 2020, we have approximately $<ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2Mzc1MTY_8071a6dc-a612-4bd9-af3a-c4de672e413f">79.6</ix:nonFraction> million of liabilities associated with uncertain tax positions.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="id69251fca53248a084459918d004c9f9"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we have accrued income tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="ib21ba4f090344f2f9805e82e16811047_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzU4NDk_29dd9b65-0cfa-45fa-a027-d8a9c9135f5c"><ix:nonFraction unitRef="usd" contextRef="i8fe3f12d8cdc4e1fb91fee9506338b3f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzU4NDk_f74ad078-794a-4a0b-aa50-3bc757625071">697.0</ix:nonFraction></ix:nonFraction> million, respectively, under the Transition Toll Tax. Of the amounts accrued as of December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2Mzc4Mjk_cabd9074-3cab-4f5c-ba6c-c1819442dcee">62.0</ix:nonFraction> million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue interest. For additional information on the Transition Toll Tax, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. As of December&#160;31, 2020, we had contractual commitments of approximately $<ix:nonFraction unitRef="usd" contextRef="i82ea75f6631c448f8f22c298bec0c951_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzQzOTgwNDY1MjE5NDU_c992e45d-2438-4f60-8102-b76a4382ec5e">9.3</ix:nonFraction>&#160;million related to the construction of this facility.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_319"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:GuaranteesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTkvZnJhZzo5Yjg0YWExMTEyY2I0N2FjOTc1ZjA1MzE5ZDM5ZGEyZi90ZXh0cmVnaW9uOjliODRhYTExMTJjYjQ3YWM5NzVmMDUzMTlkMzlkYTJmXzk4Ng_902531e6-8b4a-4f7e-94c8-e5b42845f419" continuedAt="id021be40dffc44b78518a1f9f8ae8c9f" escape="true">Guarantees</ix:nonNumeric></span></div><ix:continuation id="id021be40dffc44b78518a1f9f8ae8c9f"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we did not have significant liabilities recorded for guarantees.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of December&#160;31, 2020 and 2019.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_322"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM2MDI_106919c7-c840-4e77-9900-e130503d0e23" continuedAt="i80be5bdbf0d24292b9e258e514207af3" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i80be5bdbf0d24292b9e258e514207af3" continuedAt="i2bf92762f86843f485dfb0fb3aac5c15"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Savings Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of <ix:nonNumeric contextRef="i43fa46a959704893ae8c17cdf1fcca1d_D20200101-20201231" format="ixt-sec:duryear" name="biib:MinimumQualifyingAgeForEmployeeBenefitPlan" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzQyMg_8d243a4c-b3c7-417a-8a8f-edc36ec020bf">21</ix:nonNumeric>. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense related to our 401(k) Savings Plan totaled $<ix:nonFraction unitRef="usd" contextRef="i43fa46a959704893ae8c17cdf1fcca1d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5Xzk0Mw_455bc355-00a8-4f80-ad47-3359d37b4e9b">44.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia620d874c26f4526a51976fe0e5fd937_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5Xzk0Nw_5a0a9104-3e39-4e2e-a930-e7a66518b5aa">44.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i766a717009a042eab70c1b33dd98c33d_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5Xzk1NA_9ef5b34d-327d-4e74-9dd4-3203fd39c307">42.2</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of December&#160;31, 2020 and 2019, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i8eaae0c3c53245ed91bba34207199327_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzE2MzM_2b3fa562-9b4d-4902-917a-72886591b883">120.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifd5e42a67c414bde9ae4844e15f78b39_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzE2NDA_8da99fee-c1d4-49a2-bdae-2efb47c3843a">114.6</ix:nonFraction> million, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension Plans</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="i2bf92762f86843f485dfb0fb3aac5c15"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was <ix:nonFraction unitRef="number" contextRef="ic085e896635e45e896872f4b67d23b0b_D20190101-20191231" decimals="INF" name="biib:PercentageOfMinimumInvestmentReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzI1Mjc_16b5ab52-81c5-42a4-a39d-53a64c5eda3a"><ix:nonFraction unitRef="number" contextRef="i9b27f85445594281810d4e11521c4fb0_D20180101-20181231" decimals="INF" name="biib:PercentageOfMinimumInvestmentReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzI1Mjc_4264082c-e6cc-4f92-8b10-30584bbef1d2"><ix:nonFraction unitRef="number" contextRef="i4e1ee455bd644649ba9f949ccefc1a95_D20200101-20201231" decimals="INF" name="biib:PercentageOfMinimumInvestmentReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzI1Mjc_e20e9ddb-d513-43b3-a7da-8e751aa5c5ed">1.00</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2020, 2019 and 2018. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. As of December&#160;31, 2020 and 2019, the Swiss plan had an unfunded net pension obligation of $<ix:nonFraction unitRef="usd" contextRef="ib255acebc8bb4cbf9289671a4d33b082_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMwMjU_f5725191-ab46-4610-bf4c-a9b4ca651b1d">75.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac6eab3ca24d4a599f6a591c887c3592_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMwMzI_0c3e50af-9e6f-4c5d-bb3b-b8377d0c0ad0">42.9</ix:nonFraction> million, respectively, and plan assets that totaled $<ix:nonFraction unitRef="usd" contextRef="ib255acebc8bb4cbf9289671a4d33b082_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMwNzk_1dd5b7c6-8110-4323-ae8e-c2cc48381d16">170.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac6eab3ca24d4a599f6a591c887c3592_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMwODY_0c6e6e6a-e699-4bd2-94ab-43ed83598335">127.1</ix:nonFraction> million, respectively. In 2020, 2019 and 2018 we recognized expense totaling $<ix:nonFraction unitRef="usd" contextRef="i4e1ee455bd644649ba9f949ccefc1a95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMxNTI_dfdeed07-5e06-4593-bafe-7735b020f775">15.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic085e896635e45e896872f4b67d23b0b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMxNTY_bd6a0608-92a3-4dfb-8080-273330c3d72f">14.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9b27f85445594281810d4e11521c4fb0_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMxNjM_ba0d41fa-5938-4e36-9ee8-9e3790b26a14">14.8</ix:nonFraction> million, respectively, related to our Swiss plan, of which $<ix:nonFraction unitRef="usd" contextRef="i0a552a264841456ba32e800303b29c4b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMyMTc_38dcaa74-2633-4f8b-b97a-a0241c468fef">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7a170e3656544b4d848f8f7740a81d09_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMyMjE_dfeaa615-3741-41fd-9cfb-379e3942f7be">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i79fdfce753a6425b8f9b7ca88002a439_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PensionExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMyMjg_a513a291-21c8-4955-9884-4dc402ae0960">1.3</ix:nonFraction> million, respectively, was included in other income (expense), net.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the German plans are unfunded and totaled $<ix:nonFraction unitRef="usd" contextRef="ifececb28512c40ee8412eff5d4625c9c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMzNTU_b39b01fa-736a-4eb0-ab38-b37b3b22c731">75.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic7150facb4e24d09a7ef6a2fee36dfc9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMzNjI_ac1476c8-8834-4d3b-b9d7-304005213fba">59.6</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively. Net periodic pension cost related to the German plans totaled $<ix:nonFraction unitRef="usd" contextRef="ib3da3923fab24d76b979d1adf1a4a146_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM0NTg_8eb68162-61c3-41d7-ac1c-843e1d0257b0">6.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0cc247cbbe7443509ae3adc1934e986c_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM0NjI_48b97008-61b3-4073-9cd6-0d9284e6021d">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i24be31960c444fa3abc4b582746b9496_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM0Njk_8bcae3f7-e9b1-40d6-bf2f-fa768f6d4271">5.3</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i6cc07ab871bb4356b9e093f779247007_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM1MzA_e436f49e-1f2e-45b9-854f-161058051220">2.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2baef659c2bc4c41a82832bd90ac2e36_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM1MzQ_98dd41d6-0b7e-418b-8a53-d93cb66ff9dc">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibff57345bf2b4431834e26681459d492_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM1NDE_1c78aa01-625d-4bb2-b8b2-2479ee8a404a">1.5</ix:nonFraction> million, respectively, was included in other income (expense), net.</span></div></ix:continuation><div id="iefe8f1adeafa45df8da4a5beded16de5_328"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzI3OTM_73a849f3-da4a-4d42-aef1-9e2625ad6834" continuedAt="i8836068faa7740bdbdac5a94a6012d71" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="i8836068faa7740bdbdac5a94a6012d71" continuedAt="id491ee91f5b741b3830b7dc6696e75c3"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzQ1_613ed554-f42e-4db5-a417-2fa64e6f8a7e">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><ix:continuation id="id491ee91f5b741b3830b7dc6696e75c3"><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzI4MDc_570ada3f-938c-4d4e-96aa-fe85f3f8dacc" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain certain financial information by geographic area:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f99591bb1b0401b8000095a52fab6f8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtMS0xLTEtMA_056c46c8-71db-45cb-a0a8-9a5d69ffd2ce">5,900.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9af8365f4d94f16920edbde69e7cbb7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtMy0xLTEtMA_3dfe5870-74d6-40e5-a7dc-7f4e9fb66c7d">3,656.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f46388dff4463e9fde50c812857bbd_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtNS0xLTEtMA_e7d64cc4-3a6f-4616-99e8-f036acfa9d9c">596.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe68292fbbe8447c8b94adbca7e5c270_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtNy0xLTEtMA_47881383-7451-416c-abbd-bbb66cabe69f">539.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtOS0xLTEtMA_60db6cab-c3b0-446d-9035-4afc2dfa53f9">10,692.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0916ba417dd84c7ba1d88322f8285810_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItMS0xLTEtMA_468d3a62-4ad2-40a5-abd3-ca3b32c96323">1,897.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4626ac9e1499406f9c21d3df61161c1c_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItMy0xLTEtMA_27652e49-f523-4ada-964e-9c266b6aa06a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a3e7b4381945be8628c8dda3f341b6_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItNS0xLTEtMA_f8e47b85-e8e1-4a0e-a8b5-d95fc4f1054f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4af3774c88a4c69bdfb4f0b296748c4_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItNy0xLTEtMA_44260df2-48fc-4e01-a952-d9c651905d7a">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItOS0xLTEtMA_41886a0d-b3f7-4e5d-b492-84b8cdd153c6">1,977.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd9ea049fb349888e438f5bf876864b_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtMS0xLTEtMA_3b62a454-8b90-4e7a-9877-3b9f22cc1ddb">733.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6587b6a9e7a4af3bde2b30568b9afb3_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtMy0xLTEtMA_8d2cc2e9-8ec8-4f6b-9d1f-b19cf8d2d857">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6988263d2c4242e89b4c6e3d6b3dffad_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtNS0xLTEtMA_526c9d36-b939-4e0b-ba5b-2767c617fc88">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c353d1945748a9b24ca8847773877e_D20200101-20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtNy0xLTEtMA_cf0fa50a-174d-4ae5-b862-e6071b96b91f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtOS0xLTEtMA_d65f3d28-cfe5-42c8-928d-c7ec20ee936e">774.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dba24b1b3b499ea5f5844129e61ac2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtMS0xLTEtMA_cf588b41-4c05-40bf-a3e3-8f6ce2ec807c">1,496.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1973b2051d3340b1824cfc6b74a8aaa9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtMy0xLTEtMA_06109185-9935-4bc3-877b-41e6e4bd3ac3">2,321.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c819a830ca44238bc2e36f8b20fd54c_I20201231" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtNS0xLTEtMA_6b727bd8-67bb-459b-99f4-c94eefcb8683">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia331aa05ae08401980f6ff67ad3d9568_I20201231" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtNy0xLTEtMA_db51943f-f06c-46e6-ac7d-236eb210dc62">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtOS0xLTEtMA_c520a758-90ca-4f0e-8425-45fba92d514d">3,844.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c66309e53f467ab518b51c5bce54f4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctMS0xLTEtMA_9fe10ff5-eed4-476d-9853-444f294edfcf">6,713.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77580efa84d475392dddda68bff7041_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctMy0xLTEtMA_3cbfcc49-08d4-486b-9408-3f70987ebfad">3,794.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b205643e3ea42fcb8a65c552825bb63_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctNS0xLTEtMA_85ad0a99-cea7-400b-88a7-cbcebc71d19b">320.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aeffaf17ea24cf680dcae3471e1b7f9_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctNy0xLTEtMA_b57107b6-bc6a-494f-9a8d-7ed3c041a844">551.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctOS0xLTEtMA_0240376b-ff5d-4057-9fb0-33b6169a03ca">11,379.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444f2f75d3b2489ab262daa8b78df9ba_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtMS0xLTEtMA_0874b523-99da-4bee-ba19-5105fd7f83d7">2,211.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98fe9583334144ef942f3d12e08913b9_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtMy0xLTEtMA_e3845dd9-3e71-4fd9-9126-91d2c282535b">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6db9e6fd2a649c9889b826888da6372_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtNS0xLTEtMA_23834a88-0a5a-439c-8362-05ee2b7a6d8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ac83089e884263a9d4ae9da7e3efde_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtNy0xLTEtMA_82c506fd-9b9d-4128-8f2b-18d8b904eba5">78.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtOS0xLTEtMA_435a3ff0-7291-4d4c-8a8a-cc4b5beb362d">2,290.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9eb2f85dd546a4ae15fc642f85d8af_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktMS0xLTEtMA_97befc69-bb53-4d55-8225-7d6ea1a99869">585.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4630fecb0f6c47b2b848f15327791e4f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktMy0xLTEtMA_c7b738c5-a95a-4357-a262-461c5c6fbf3e">9.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002c6070bf8846dc9140030a63f37dac_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktNS0xLTEtMA_a685abde-f015-484a-9cad-606fcbb86209">112.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674d0e91669c40ff82a76bedb27e4e67_D20190101-20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktNy0xLTEtMA_6d1ef973-bf0f-4e8d-b4af-d81a17a5e696">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktOS0xLTEtMA_fdcb858d-69a0-46a3-b9d3-71845a2ca5f8">707.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0172f7c5c8b3448bb8ca832a1116f3aa_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTEtMS0xLTA_e3c82dcf-9dfc-4760-84fa-5276e2aa3f36">1,493.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib563770ab8184507a232435bea87086a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTMtMS0xLTA_bb59b502-b03e-4b3c-89e6-0125d6e4938a">2,162.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d67a017c4d1439bbfdeb2055dacff9b_I20191231" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTUtMS0xLTA_e4746b36-7760-486d-8a68-9574e3fcb132">6.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388f07fba6354ae6b12a5c8a48d28304_I20191231" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTctMS0xLTA_327a2fb1-223d-49e5-adfb-2f9cc9be589e">12.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTktMS0xLTA_be4c6992-1c10-4a00-935a-2dbfdbb2963b">3,674.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c311f0cc16744aeb4492070360e76b3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTEtMS0xLTA_df7af581-5657-44ca-8726-1859e7c8ffb8">6,800.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c94a7c202e7466686a893e6fda06193_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTMtMS0xLTA_da3b7e29-276f-4438-a052-04c8cb377a68">3,370.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4342c229637d452dafa8e4a45cb1a216_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTUtMS0xLTA_7c3bd239-9d41-4aa5-9ed7-62932e39f71c">281.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9714a1b144e4e9b81457f7ce371bbea_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTctMS0xLTA_c9d74227-c450-40eb-ac95-fee5a23cf31b">434.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b7b9a353c2419ca9a01532a522a0d0_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTktMS0xLTA_58bedd33-0fda-463e-a0d3-03d57d96f6b1">10,886.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe36228fc3c43b182afc7bd39a2d6bd_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTEtMS0xLTA_49b1cb1c-9621-4295-89a4-fac81e599957">1,903.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd05e22171d4dad869c4a37eb52a7f5_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTMtMS0xLTA_4f92c4e7-b503-4236-9d0a-57b231fad7f6">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e85dcda379e4e348325696cd2ec9cf6_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTUtMS0xLTA_07df315c-6825-4c12-8965-e1bc1e99f613">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f84620186bd48dfaa02b13846091e74_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTctMS0xLTA_2c1c6bc9-bc30-479a-82b6-8e2ec18afe6a">76.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2514a987784410a8165984f87269d3_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTktMS0xLTA_c8ea9db9-fa2e-42fe-a136-fcad49017f27">1,980.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf10b7ffe1994abcbd958c90d5c06301_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTEtMS0xLTA_245818e3-6ea2-43cf-9e3b-b91494730dce">457.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic16aea428adb4ba5ae3e7d508536706d_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTMtMS0xLTA_7eb76c79-faa5-45d4-8d60-1bdc75e5a3c5">32.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67b659127c9421f89dad74f1278c337_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTUtMS0xLTA_411d5046-00e0-48b9-8170-fa779f4b3c82">96.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745cdf1e889c4c16afb442fe563d25a2_D20180101-20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTctMS0xLTA_41582e17-0e50-45da-93e5-4fe779665ccd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2987b04d4c240d88b84a50c04ca2df1_D20180101-20181231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTktMS0xLTA_18928a99-90c0-4c0d-b583-8a6c150a5cbe">585.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49704cf795948148f16dbae680341c9_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTEtMS0xLTA_3743daa7-7bff-4484-9ca9-b1f1ab64e035">1,152.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cfd775f332e45ac808c12b6838e769e_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTMtMS0xLTA_2bb9c8fd-951f-4928-918b-f44b39a00fbf">2,442.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdc67c11df94e509edd9a7f39c16d8e_I20181231" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTUtMS0xLTA_ec34e315-3bec-4e31-8485-c8a3a6b89043">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e40021e4994fcbb8133c1d5d3f6f27_I20181231" decimals="-5" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTctMS0xLTA_5b24fe3c-b415-4f04-be89-873ddd606e5b">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTktMS0xLTA_f690185d-9ec3-407e-a1ff-d5f99856dae1">3,601.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, 2019 and 2018, approximately $<ix:nonFraction unitRef="usd" contextRef="i4c4f2b0a6a9c49f48c35940d82b38a6b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzE5MzM_440f846b-0db3-4743-b8fb-306953b4533e">2,180.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie6e096fa0fb0473683e284201e92aaca_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzE5Mzc_af7a3f61-18c1-42e2-9774-0fab4aace640">2,028.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8e2b3b8ba24b4036880ba37d5422da63_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzE5NDQ_a6ef2421-feb3-4c0c-b4fc-a6dc8a971cb2">1,748.5</ix:nonFraction> million, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. As of December&#160;31, 2018, approximately $<ix:nonFraction unitRef="usd" contextRef="i8ae776ffb778432e982088a179ebb204_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzIzMDk_6e4ef595-cd69-4994-8bc5-242400cc7964">646.5</ix:nonFraction> million of our long-lived assets were related to our manufacturing facility in Hiller&#248;d, Denmark.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Property, Plant and Equipment,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-77</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_331"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU0MjY_87d47e3e-2616-4e2e-b6cb-7b1b0bfd62e9" continuedAt="ic4c80f649e194e668d1ac81825f11ab8" escape="true">Quarterly Financial Data (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="ic4c80f649e194e668d1ac81825f11ab8"><ix:nonNumeric contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1Mjc_1ae74079-c50d-4dae-bbe2-abf5e1616a44" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:36.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Year</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fca2b687f2f4872a9a845bb672960a5_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItMS0xLTEtMA_07db04aa-7c4f-436a-8831-3689946eb245">2,904.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5dfc91e9f8241d894aa02ab5409f041_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItMy0xLTEtMA_7cc23f95-b663-4243-943e-860d1ee15340">2,795.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae9621a79ec4f2a81baf7fc485474c2_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItNS0xLTEtMA_58ebeeb9-f1b9-4a45-a9c9-1a424ed3e44a">2,690.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c705be761834645b8c5978e3818b771_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItNy0xLTEtMA_4da0a5b7-7955-4c8a-8efd-b6fb33388ecb">2,301.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItOS0xLTEtMA_3e29a612-ef6c-47b0-a2e3-cbe3399c40f8">10,692.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f55339914bb4b2ab51133f2c27b01c7_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtMS0xLTEtMA_af8f582c-5a3e-43ec-a878-b0949c87a832">520.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87a96b308944207b0abf485235389d9_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtMy0xLTEtMA_d40f3a05-8261-46f2-9e99-4835df0d5b29">478.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ce7f756f854eff83de1460d06439a0_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtNS0xLTEtMA_66db4928-6e58-4280-bc4c-c4d55a4e1a5f">560.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a2e9422f744e57a659fdc96c0a0d84_D20201001-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtNy0xLTEtMA_2b516a46-3f6d-4f26-85f3-4c03735a43f4">419.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtOS0xLTEtMA_5fe7707a-abf5-4f86-a258-8ada778d206b">1,977.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie805016a199a4e4eafdf82e66b43ecd8_D20200101-20200331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtMS0xLTEtMA_1ca6cd10-04d4-49dc-acc2-099fa11c24d6">109.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2d9c146e8546eb8940919a230b2410_D20200401-20200630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtMy0xLTEtMA_c9aaa2d3-b292-45eb-9b96-b945f82d2e9f">407.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f37a240cd2462496769361d7d6aa4c_D20200701-20200930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtNS0xLTEtMA_4e7d009a-b04c-4889-b0db-197fd3619e1f">125.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc07ea8987844bbae9f16026aa3eeb2_D20201001-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtNy0xLTEtMA_bc9888a5-fb98-4114-a668-5e13ffb40c6d">132.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtOS0xLTEtMA_a565085f-d711-4a13-b9c1-2a7f9068d70c">774.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtMS0xLTEtMA_0cd08d92-cfb2-4a0c-a192-e9d2a6cf98b9">3,534.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtMy0xLTEtMA_4cc71007-fa59-4408-a199-ecc6db9d57e0">3,681.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtNS0xLTEtMA_d110f119-31e2-4d66-a03f-e9a1062b98f4">3,376.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtNy0xLTEtMA_ac2859d2-b1f0-4cca-932c-fffd22044c2d">2,852.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtOS0xLTEtMA_61082424-b793-4f04-83c9-93edb2ec88d9">13,444.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMS0xLTEtMA_868f3bcf-bd41-4cd0-874e-b9e7a6eac3a3">3,080.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMy0xLTEtMA_e02a9e0f-13e0-4819-a172-c922d853149c">3,270.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNS0xLTEtMA_8ecba11c-83af-4c5b-9efe-71417b9f874c">2,927.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNy0xLTEtMA_bb7f955b-8dd2-4259-afc2-d669fdf6b779">2,361.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtOS0xLTEtMA_4eace0b0-5459-443b-adf4-f41a5aee20ae">11,639.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctMS0xLTEtMA_1e3e3715-5ec3-4624-992e-85bd57369a05">1,392.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctMy0xLTEtMA_83770c2e-67a3-4572-9320-0f440d558e76">1,606.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctNS0xLTEtMA_b54912fa-b9d3-4e0f-8d2f-d57302b9f6bd">703.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctNy0xLTEtMA_00ce2a1c-7afa-460e-a535-ff97e4050823">357.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctOS0xLTEtMA_9cf5b0d5-c61c-49f6-87a4-0e7d6bb4ca15">4,060.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtMS0xLTEtMA_d37c962d-8421-43dc-a784-c1000ce6aded">1,399.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtMy0xLTEtMA_113433d1-7b59-47d7-80e0-9d388dbba293">1,542.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtNS0xLTEtMA_7a539bd9-bc6c-482b-9d8b-f4f197b2e89f">701.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtNy0xLTEtMA_da690fae-ed6a-4c6d-82a8-76105c268a30">357.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtOS0xLTEtMA_1b9a353a-aff5-4a4b-ac40-f031b6bb4f68">4,000.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTEtMS0xLTA_8fe4956e-fda9-4bfd-a01b-851184711ad5">8.10</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTMtMS0xLTA_354ddb90-c628-41be-949c-4a93051ff777">9.60</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTUtMS0xLTA_10615ec0-c93c-48ae-b122-0a9e14e255ee">4.47</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTctMS0xLTA_4991197b-a43a-45d2-86ec-cacf19e99ee7">2.33</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTktMS0xLTA_c03fb85b-07eb-4a9d-8a10-878992c597b9">24.86</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTEtMS0xLTA_9373be3e-ee83-487d-ab67-63d295f81edc">8.08</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTMtMS0xLTA_2cf8e39d-7df1-413a-9c96-79b5806e174f">9.59</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTUtMS0xLTA_98a8ece2-c75b-4fad-aa99-6892ff3ae07d">4.46</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTctMS0xLTA_94c2e1ef-7fac-416e-85af-52aa1df4b6ba">2.32</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTktMS0xLTA_860fa633-d142-441c-adba-d3065eb39a08">24.80</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTEtMS0xLTA_9a441885-c2af-4d5e-a1df-9fbb1dd1dffe">172.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTMtMS0xLTA_932075fb-fd36-4233-b17e-37bb5a916f97">160.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTUtMS0xLTA_7656fdde-77ef-44e5-ba13-df6b793617bb">156.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTctMS0xLTA_a95b6aee-4502-4933-bf1a-381001562d88">153.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTktMS0xLTA_c1350c07-82b9-4c59-a56f-3972d0321bfe">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTEtMS0xLTA_ab44a510-694c-45c7-a740-dd4b550f19e8">173.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTMtMS0xLTA_3f83a59b-f25a-45ec-8299-ccbb41606f09">160.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTUtMS0xLTA_774a0777-9c4f-4176-ac7c-df39db02b595">157.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTctMS0xLTA_fa52f10a-7391-44f5-880d-cc9a32626b14">154.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTktMS0xLTA_b174a4f4-6dc2-4717-9230-70d4d46e5fb9">161.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:36.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Year</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7776337c87847de857073085287b7df_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItMS0xLTEtMA_b39f318d-340d-44f6-9bc2-36108985cbcc">2,680.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee7c83511ad4b4a994502e07e77195c_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItMy0xLTEtMA_64c7dcde-cc30-4608-a7f2-f2afd1d968f0">2,880.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc031b722984deaaab7026bf6193aab_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItNS0xLTEtMA_12afd31f-e7d1-43ae-af21-20c2b06a0aae">2,894.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5416e51b85274f0bb17370851e4a3b1b_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItNy0xLTEtMA_7e8cc5ed-b5fe-49b1-bc88-c549b45f756f">2,924.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItOS0xLTEtMA_3af431e4-2bb0-4eb4-a47e-b9b1819b2aaf">11,379.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad278057bef48a7b7423fcd6a012b35_D20190101-20190331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtMS0xLTEtMA_4100c309-0a98-4c03-9393-ee9bb55b564c">517.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87d95cb80ee488f95f41a5044d1b98c_D20190401-20190630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtMy0xLTEtMA_de2b9391-c567-4f64-be49-35341f2625f6">576.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61172312032a4a168fbce9685cffadb9_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtNS0xLTEtMA_7a328d97-7a39-498d-bcc5-96c63702302b">595.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1244a258e99d4f4bbccf06fe8dd8b6f8_D20191001-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtNy0xLTEtMA_316de687-e86a-4801-9555-540cc6e7d575">600.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtOS0xLTEtMA_62bdc50d-e6b8-4f09-81be-2b125a7febb5">2,290.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edea67901754dfca2b56005c22d377d_D20190101-20190331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtMS0xLTEtMA_5e36c376-11bb-49c6-a776-502acf2a2301">292.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5380e1ba1c7b486290cfbe6457fb3bd7_D20190401-20190630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtMy0xLTEtMA_3d5b24dc-b363-4a36-bbe1-e7f25810b15a">160.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd7ea2df93e7492991c4ca15c3f6e098_D20190701-20190930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtNS0xLTEtMA_46f62ca6-e13a-46a2-9ced-7b6078026daf">109.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d05a3ba448a4750b45bb2d906497144_D20191001-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtNy0xLTEtMA_39638832-cb23-49d2-8596-c54db9de4085">145.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtOS0xLTEtMA_ae3a9bfa-fdbd-4ae1-a435-c7e65cf7f5dc">707.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtMS0xLTEtMA_cf82b7e8-eca2-4721-9593-d7a80fa7bb8f">3,489.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtMy0xLTEtMA_79f07107-6644-4550-9404-e82067c8224a">3,616.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtNS0xLTEtMA_cbde5114-c05b-4d19-9c78-2508f402a89e">3,600.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtNy0xLTEtMA_7e587a73-4db7-4afb-894f-84a207ca2e1d">3,671.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtOS0xLTEtMA_b539c8ef-9322-4de6-be5f-6ea1e0b711fd">14,377.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMS0xLTEtMA_39dfce08-102f-4ec0-a97c-6fe195f05d8a">2,887.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMy0xLTEtMA_f12fa61f-347d-4d6e-b8f0-8dce21f1c03b">3,140.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNS0xLTEtMA_c67cd457-35c2-4bdc-98e3-c6fac4fc50f3">3,170.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNy0xLTEtMA_01e50ece-7e7b-4921-9bbd-d7faebc2bd59">3,224.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtOS0xLTEtMA_e605553e-fb73-480b-b14d-4ace6cf47e83">12,422.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctMS0xLTEtMA_e6c0231f-1435-4772-b340-d9153187d369">1,408.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctMy0xLTEtMA_e1acee11-0bda-4ca7-bbd2-86c9de4e3cfe">1,494.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctNS0xLTEtMA_4de51ec7-07c9-4498-afb1-7b0c38e4a06d">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctNy0xLTEtMA_9fa8f7f8-1a49-4b73-86e0-56d5fec4c1bf">1,439.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctOS0xLTEtMA_6db6a3c4-5afd-4af9-96ff-c1e1adcba63a">5,888.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtMS0xLTEtMA_1b9ce59d-9045-4c4a-a21d-d157b2c3bc09">1,408.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtMy0xLTEtMA_e01817c7-7015-483a-b98f-3d1d0ca346b2">1,494.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtNS0xLTEtMA_0a2e2f99-aa72-4b8f-a18a-6073c2c4986d">1,545.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtNy0xLTEtMA_fbd9fc7f-257d-4a2f-a51e-a306ac0211c4">1,439.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtOS0xLTEtMA_8c20aace-b061-4213-8dc4-89838383bbb8">5,888.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTEtMS0xLTA_88396a64-d3e4-4ddb-975d-6680fde2583d">7.17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTMtMS0xLTA_24bfc3af-3031-430b-aac6-3d30f369783c">7.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTUtMS0xLTA_0c49bc7b-79ea-497e-bb5b-911f199d903a">8.40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTctMS0xLTA_ec2fb9ed-a56e-4b4d-83a6-578a587a3d44">8.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTktMS0xLTA_95aa40fd-37c4-49f3-aeda-092f941b515c">31.47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTEtMS0xLTA_d9d20560-cf66-4ee8-b23c-98954e749a84">7.15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTMtMS0xLTA_81c5dbbb-2efe-49b8-9309-4c33a904fa44">7.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTUtMS0xLTA_3e6e0735-a76c-488f-bc50-39dbf797f597">8.39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTctMS0xLTA_01f79033-3606-47b7-8973-8375371e2471">8.08</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTktMS0xLTA_b1f4c0b6-d103-4c37-bac6-518c034083b9">31.42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTEtMS0xLTA_3bf747e0-20ef-41ce-ba6f-92751b87d95a">196.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTMtMS0xLTA_b52df3b5-6243-4979-a07b-e81601db9da7">190.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTUtMS0xLTA_dacb3659-a160-436d-919f-f9d4b718ac3c">184.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTctMS0xLTA_597f65b9-78ad-4f4a-8fbb-27b71b0da696">177.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTktMS0xLTA_b8d9c632-aff0-4499-8988-9d7a33bcd820">187.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTEtMS0xLTA_69cbf493-a28a-43c7-8a16-22465a25d64e">197.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTMtMS0xLTA_c3db8313-4e2d-49ec-bd01-08e618f17d85">190.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTUtMS0xLTA_20fb6800-c66d-4f2d-953f-5f7a59ed497b">184.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTctMS0xLTA_db6c3451-0cea-4cdf-9f94-f003ca5cbe07">178.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTktMS0xLTA_93256996-10e1-4701-8776-7e39007827ae">187.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644" continuedAt="i865063bb75a24c428a4a5f6bb0149dbf" footnoteRole="http://www.xbrl.org/2003/role/footnote">(1)</ix:footnote></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i865063bb75a24c428a4a5f6bb0149dbf"> Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets</ix:continuation>.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-78</span></div></div></div><div id="iefe8f1adeafa45df8da4a5beded16de5_337"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:14pt;text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">To the Board of Directors and Shareholders of Biogen Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited the accompanying consolidated balance sheets of Biogen Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, and the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2020, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in Accounting Principles</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed in Note 1 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019 and the manner in which it accounts for income taxes for intra-entity transfers of assets other than inventory in 2018.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iefe8f1adeafa45df8da4a5beded16de5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reserves for Medicaid and Managed Care Rebates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described in Notes 1 and 4 to the consolidated financial statements, the Company recognized revenue from product sales net of reserves, including Medicaid and managed care rebates. Within Accrued expenses and other, total contractual adjustments amounted to $1,093.0 million as of December 31, 2020. This balance primarily includes provisions for Medicaid and managed care rebates in the US. Medicaid rebates relate to the Company&#8217;s estimated obligations to states under established reimbursement arrangements. The Company&#8217;s liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end. Managed care rebates represent the Company&#8217;s estimated obligations to third parties, primarily pharmacy benefit managers.  Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities.  These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying coverage patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.  As disclosed by management, the Medicaid and managed care estimates reflect historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal considerations for our determination that performing procedures relating to reserves for Medicaid and managed care rebates is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing these reserves, as the reserves are based on assumptions developed using historical experience, current contractual requirements, specific known market events and payment patterns, which in turn led to a high degree of auditor judgment, subjectivity and effort in applying procedures related to these assumptions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements.  These procedures included testing the effectiveness of controls relating to the reserves for Medicaid and managed care rebates, including controls over the assumptions used to estimate these rebate reserves. These procedures also included, among others, (i) developing an independent estimate of the rebate reserves by utilizing third-party data related to product demand, data related to price changes, the terms of the specific rebate programs, the historical trend of actual rebate claims paid and consideration of contractual requirement changes and market events; (ii) comparing the independent estimate to management&#8217;s estimate, and (iii) testing rebate claims paid by the Company, including evaluating the claims for consistency with the contractual terms of the Company&#8217;s rebate agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/PricewaterhouseCoopers LLP</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;3, 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2003.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-80</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>biib-20201231xex44.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0a24c3ea5c154f1faa3a0db899985bf0_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 4.4</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTERED PURSUANT TO SECTION 12 OF THE </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of December 31, 2020, Biogen Inc. (the &#8220;Company&#8221;) has six classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#58; (1) Common Stock&#59; (2) 3.625% Senior Notes due 2022&#59; (3) 4.050% Senior Notes due 2025&#59; (4) 2.250% Senior Notes due 2030&#59; (5) 5.200% Senior Notes due 2045 and (6) 3.150% Senior Notes due 2050.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Common Stock</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our Common Stock is a summary and does not purport to be complete. It is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), and our Fourth Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.4 is a part. We encourage you to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">read our Certificate of Incorporation, our Bylaws and the applicable provisions of the General Corporation Law of Delaware for additional information.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized Capital Stock</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital stock consists of 1,000,000,000 shares of Common Stock, par value $0.0005 per share, and 8,000,000 shares of Preferred Stock, par value $0.001 per share.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voting Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Common Stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors. Our Common Stock does not have cumulative voting rights.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the rights of holders of all classes of stock at the time outstanding having prior rights as to dividends, if any, the holders of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Board of Directors in its discretion out of funds legally available for the payment of dividends.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidation Rights</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any preferential rights of outstanding shares of Preferred Stock, if any, holders of Common Stock will share ratably in all assets legally available for distribution to our stockholders in the event of liquidation, dissolution or winding up of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Rights and Preferences</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Stock has no sinking fund or redemption provisions or preemptive, conversion or exchange rights. Holders of Common Stock may act by unanimous written consent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Listing</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Common Stock is traded on The Nasdaq Stock Market LLC under the trading symbol &#8220;BIIB.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Notes Due 2022, 2025 and 2045</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our 3.625% Senior Notes due 2022 (the &#8220;notes due 2022&#8221;), the 4.050% Senior Notes due 2025 (the &#8220;notes due 2025&#8221;) and the 5.200% Senior Notes due 2045 (the &#8220;notes due 2045&#8221; and together with the notes due 2020, the notes due 2022 and the notes due 2025, the &#8220;notes&#8221;), is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the indenture, dated as of September 15, 2015 (the &#8220;Base Indenture&#8221;), between Biogen Inc. and U.S. Bank National Association, as trustee, as supplemented by the first supplemental indenture dated as of September 15, 2015 (the Base Indenture, as supplemented by the fist supplemental indentures, the &#8220;Indenture&#8221;), which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.4 is a part.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encourage you to read the above referenced Indenture, as supplemented, for additional information.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Description of Notes, the terms &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and other similar references refer only to Biogen Inc. and not to any of its subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The notes due 2022 were initially limited to $1,000,000,000 aggregate principal amount. The maturity date of the notes due 2022 is September 15, 2022.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The notes due 2025 were initially limited to $1,750,000,000 aggregate principal amount. The maturity date of the notes due 2025 is September 15, 2025.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The notes due 2045 were initially limited to $1,750,000,000 aggregate principal amount. The maturity date of the notes due 2045 is September 15, 2045.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time, without notice to or the consent of the holders or beneficial owners of the notes, create and issue additional notes of any of the series having the same ranking and the same interest rate, maturity and other terms as the notes of the applicable series. Any additional notes and the notes of such series will generally constitute a single series under the Indenture, provided that if the additional notes are not fungible with the notes of such series for U.S. federal income tax purposes, the additional notes will have a separate CUSIP number.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest and Principal</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes due 2022 bear interest at a fixed interest rate of 3.625%. The notes due 2025 bear interest at a fixed interest rate of 4.050%. The notes due 2045 bear interest at a fixed interest rate of 5.200%. Interest on the notes is payable semiannually on March 15 and September 15 of each year to holders of record at the close of business on the March 1 or September 1, whether or not a business day, immediately before the applicable interest payment date. The amount of interest payable on the notes is computed on the basis of a 360-day year consisting of twelve 30-day months.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes were issued only in fully registered form, without coupons, in denominations of $2,000 and integral multiples of $1,000 in excess thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any interest payment date or the maturity date of the notes is not a business day, then the related payment of interest and&#47;or principal payable on such date will be paid on the next succeeding business day with the same force and effect as if made on such interest payment date or maturity date and no further interest will accrue in respect of the delay. The term &#8220;business day&#8221; means any day other than a Saturday, a Sunday or any other day on which banking institutions in The City of New York are authorized or required by law, regulation or executive order to close.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ranking</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are senior unsecured obligations and rank equal in right of payment with our other existing and future senior unsecured obligations, and senior in right of payment to any of our future subordinated indebtedness.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are effectively subordinated to any secured obligations of ours to the extent of the value of the assets securing such obligations. The notes are structurally subordinated to all existing and future obligations of our subsidiaries, including claims with respect to trade payables. This means that holders of the notes have a junior position to the claims of creditors of our direct and indirect subsidiaries on the assets and earnings of such subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Optional Redemption</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Optional redemption of notes due 2022</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time and from time to time, the notes due 2022 are redeemable, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2022, at a redemption price equal to the greater of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100% of principal amount of the notes due 2022 to be redeemed, or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sum of the present values of the remaining scheduled payments of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate plus 25 basis points,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Optional redemption of notes due 2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time and from time to time prior to June 15, 2025 (the date that is three months prior to maturity), the notes due 2025 are redeemable, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2025, at a redemption price equal to the greater of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100% of principal amount of the notes due 2025 to be redeemed, or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sum of the present values of the remaining scheduled payments of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate plus 30 basis points,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 15, 2025 (the date that is three months before maturity), the notes due 2025 may be redeemed, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2025, at a redemption price equal to 100% of the principal amount of the notes due 2025 to be redeemed on the redemption date plus accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Optional redemption of notes due 2045</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time and from time to time prior to March 15, 2045 (the date that is six months prior to maturity), the notes due 2045 are redeemable, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2045, at a redemption price equal to the greater of&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100% of principal amount of the notes due 2045 to be redeemed, or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sum of the present values of the remaining scheduled payments of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate plus 35 basis points,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after March 15, 2045 (the date that is six months before maturity), the notes due 2045 may be redeemed, as a whole or in part, at our option, on at least 30 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2045, at a redemption price equal to 100% of the principal amount of the notes due 2045 to be redeemed on the redemption date plus accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Treasury Issue&#8221; means the United States Treasury security or securities selected by an Independent Investment Banker (as defined below) as having an actual or interpolated maturity comparable to the remaining term of the notes of the applicable series to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of a comparable maturity to the remaining term of such notes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Treasury Price&#8221; means, with respect to any notes of a series on any redemption date, (A)&#160;the average of the Reference Treasury Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (B)&#160;if the Independent Investment Banker obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such quotations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Independent Investment Banker&#8221; means one of the Reference Treasury Dealers (as defined below) appointed by us.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reference Treasury Dealer&#8221; means each of Goldman, Sachs&#160;&#38; Co. and Merrill Lynch, Pierce, Fenner&#160;&#38; Smith Incorporated or their respective affiliates, which are primary U.S. Government securities dealers in The City of New York, and their respective successors plus three other primary U.S. Government securities dealers in The City of New York selected by us&#59; provided, however, that if any of the foregoing or their affiliates shall cease to be a primary U.S. Government securities dealer in The City of New York (a &#8220;Primary Treasury Dealer&#8221;), we will substitute therefor another Primary Treasury Dealer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reference Treasury Dealer Quotations&#8221; means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the applicable Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the trustee by the Reference Treasury Dealers at 3&#58;30 p.m. New York time on the third business day preceding such redemption date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Treasury Rate&#8221; means, with respect to any redemption date, the rate per annum equal to the semiannual equivalent yield to maturity or interpolated (on a day count basis) of the Comparable Treasury Issue, assuming a price for the applicable Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Comparable Treasury Price for such redemption date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On and after the redemption date for the notes of the applicable series, interest will cease to accrue on the notes of that series or any portion thereof called for redemption, unless we default in the payment of the redemption price. On or before the redemption date for the notes of that series, we will deposit with a paying agent, or the trustee, funds sufficient to pay the redemption price of and accrued and unpaid interest on such notes to be redeemed on such date. If less than all of the notes of a series are to be redeemed, the notes of that series to be redeemed will be selected by DTC (as defined below) in accordance with its standard procedures. If the notes to be redeemed are not global notes then held by DTC, or DTC prescribes no method of selection, the trustee will select the notes to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeemed on a pro rata basis, by lot, or by any other method the trustee deems fair and appropriate and subject to and otherwise in accordance with the procedures of DTC.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change of Control</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a Change of Control Triggering Event (as defined below) occurs with respect to the notes of a series, unless we have exercised our option to redeem the notes of such series as described above, we will be required to make an offer (the &#8220;Change of Control Offer&#8221;) to each holder of the notes of such series to repurchase all or any part of that holder&#8217;s notes of such series on the terms set forth in such notes. In the Change of Control Offer, we will be required to offer payment in cash equal to 101% of the aggregate principal amount of notes repurchased, plus accrued and unpaid interest, if any, on the notes repurchased to but not including the date of repurchase (the &#8220;Change of Control Payment&#8221;). With respect to the notes of each series, within 30 days following any Change of Control Triggering Event or, at our option, prior to any Change of Control (as defined below), but after public announcement of the transaction that constitutes or may constitute the Change of Control, a notice will be mailed to holders of the notes of the applicable series describing the transaction that constitutes or may constitute the Change of Control Triggering Event and offering to repurchase the notes of such series on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such notice is mailed or, if the notice is mailed prior to the Change of Control, no earlier than 30 days and no later than 60 days from the date on which the Change of Control Triggering Event occurs (the &#8220;Change of Control Payment Date&#8221;). The notice will, if mailed prior to the date of consummation of the Change of Control, state that the offer to purchase is conditioned on the Change of Control Triggering Event occurring on or prior to the Change of Control Payment Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Change of Control Payment Date, we will, to the extent lawful&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accept for payment all notes or portions of notes properly tendered pursuant to the Change of Control Offer&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deposit with the paying agent an amount equal to the Change of Control Payment in respect of all notes or portions of notes properly tendered&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deliver or cause to be delivered to the trustee the notes properly accepted together with an officers&#8217; certificate stating the aggregate principal amount of notes or portions of notes being repurchased.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not be required to make a Change of Control Offer upon the occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by us and the third party repurchases all notes properly tendered and not withdrawn under its offer. In addition, we will not repurchase any notes if there has occurred and is continuing on the Change of Control Payment Date an event of default under the Indenture, other than a default in the payment of the Change of Control Payment upon a Change of Control Triggering Event.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will comply in all material respects with the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the notes as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with the Change of Control Offer provisions of the notes, we will comply with those securities laws and regulations and will not be deemed to have breached our obligations under the Change of Control Offer provisions of the notes by virtue of any such conflict.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Change of Control Offer provisions of the notes, the following terms will be applicable&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Change of Control&#8221; means the occurrence of any of the following&#58; (1)&#160;the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) (other than us or one of our Subsidiaries (as defined below)) becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of our Voting Stock (as defined below) or other Voting Stock into which our Voting Stock is reclassified, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated, exchanged or changed, measured by voting power rather than number of shares&#59; provided, however, that a Person (as defined below) shall not be deemed beneficial owner of, or to own beneficially, (A)&#160;any securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of such Person&#8217;s affiliates until such tendered securities are accepted for purchase or exchange thereunder, or (B)&#160;any securities if such beneficial ownership (i)&#160;arises solely as a result of a revocable proxy delivered in response to a proxy or consent solicitation made pursuant to the applicable rules and regulations under the Exchange Act, and (ii)&#160;is not also then reportable on Schedule&#160;13D (or any successor schedule) under the Exchange Act&#59; (2)&#160;the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of our assets and the assets of our Subsidiaries, taken as a whole, to one or more &#8220;persons&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) (other than to us or one of our Subsidiaries) (a &#8220;Transferee&#8221;), provided, however, that none of the circumstances in this clause&#160;(2) will be a Change of Control if the persons that beneficially own our Voting Stock immediately prior to the transaction own, directly or indirectly, shares representing a majority of the total Voting Stock as measured by voting power rather than number of shares of the Transferee&#59; (3)&#160;we consolidate with, or merge with or into, any &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) or any such Person consolidates with, or merges with or into, us, in either case, pursuant to a transaction in which any of our outstanding Voting Stock or the Voting Stock of such other Person is converted into or exchanged for cash, securities or other property, other than pursuant to a transaction in which shares of our Voting Stock outstanding immediately prior to the transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving Person immediately after giving effect to such transaction&#59; or (4)&#160;the adoption of a plan relating to our liquidation or dissolution.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Change of Control Triggering Event&#8221; means the occurrence of both a Change of Control and a Rating Event (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Investment Grade Rating&#8221; means a rating equal to or higher than Baa3 (or the equivalent) by Moody&#8217;s (as defined below) and BBB- (or the equivalent) by S&#38;P (as defined below), and the equivalent investment grade credit rating from any additional rating agency or Rating Agencies (as defined below) selected by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Moody&#8217;s&#8221; means Moody&#8217;s Investors Service, Inc., or any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Rating Agencies&#8221; means (1)&#160;each of Moody&#8217;s and S&#38;P and (2)&#160;if any of Moody&#8217;s and S&#38;P ceases to rate the notes or fails to make a rating of the notes publicly available for reasons outside of our control, a &#8220;nationally recognized statistical rating organization&#8221; within the meaning of Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act selected by us (as certified by a resolution of our board of directors) and which is reasonably acceptable to the trustee as a replacement agency for Moody&#8217;s or S&#38;P, or both of them, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Rating Event&#8221; means (A)&#160;with respect to the notes due 2020, the rating on such notes is lowered by each of the Rating Agencies and such notes are rated below an Investment Grade Rating by each of the Rating Agencies, (B)&#160;with respect to the notes due 2022, the rating on such notes is lowered by each of the Rating Agencies and such notes are rated below an Investment Grade Rating by each of the Rating Agencies, (C)&#160;with respect to the notes due 2025, the rating on such notes is lowered by each of the Rating Agencies and such notes are rated below an Investment Grade Rating by each of the Rating Agencies and (D)&#160;with respect to the notes due 2045, the rating on such notes is lowered by each of the Rating Agencies and such notes are rated below an Investment Grade Rating by each of the Rating Agencies, in each case, on any day during the period commencing on the earlier of the date of the first public notice of the occurrence of a Change of Control or our intention to effect a Change of Control and ending 60 days following consummation of such Change of Control (which period will be extended so long as the rating of the applicable series of notes is under publicly announced consideration for a possible downgrade by any of the Rating Agencies).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;S&#38;P&#8221; means Standard&#160;&#38; Poor&#8217;s Rating Services, a Standard&#160;&#38; Poor&#8217;s Financial Services LLC business, or any successor thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Voting Stock&#8221; means, with respect to any specified &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) as of any date, the capital stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sinking Fund</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are not be entitled to the benefit of any sinking fund.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation on Liens</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as provided under &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions,&#8221; we will not, and will not permit any Subsidiary of ours to, create or assume any Indebtedness (as defined below) secured by any Lien (as defined below) on any of our or their respective Properties (as defined below) unless the notes are secured by such Lien equally and ratably with, or prior to, the Indebtedness secured by such Lien. This restriction does not apply to Indebtedness that is secured by&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens existing on the date of the issuance of the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens securing only the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens on Property or shares of stock in respect of Indebtedness of a Person existing at the time such Person becomes a Subsidiary of ours or is merged into or consolidated with, or its assets are acquired by, us or any Subsidiary of ours (provided that such Lien was not incurred in anticipation of such transaction and was in existence prior to such transaction) so long as such Lien does not extend to any other Property and the Indebtedness so secured is not increased&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens to secure Indebtedness incurred for the purpose of all or any part of a Property&#8217;s purchase price or cost of construction or additions, repairs, alterations or other improvements&#59; provided that (1)&#160;the principal amount of any Indebtedness secured by such Lien does not exceed 100% of such Property&#8217;s purchase price or cost, (2)&#160;such Lien does not extend to or cover any other Property other than the Property so purchased, constructed or on which such additions, repairs, alterations or other improvements were so made and (3)&#160;such Lien is incurred prior to or within 270 days after the acquisition of such Property or the completion of construction or such additions, repairs, alterations or other improvements and the full operation of such Property thereafter&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens in favor of the U.S. or any state thereof, or any instrumentality of either, to secure certain payments pursuant to any contract or statute&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens for taxes or assessments or other governmental charges or levies which are not overdue for a period exceeding 60 days unless such Liens are being contested in good faith and for which adequate reserves are being maintained, to the extent required by generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">title exceptions, easements, licenses, leases and other similar Liens that are not consensual and that do not materially impair the use of the Property subject thereto&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens to secure obligations under worker&#8217;s compensation laws, unemployment compensation, old-age pensions and other social security benefits or similar legislation&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens arising out of legal proceedings, including Liens arising out of judgments or awards&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warehousemen&#8217;s, materialmen&#8217;s, carrier&#8217;s, landlord&#8217;s and other similar Liens for sums not overdue for a period exceeding 60 days unless such Liens are being contested in good faith and for which adequate reserves are being maintained, to the extent required by generally accepted accounting principles&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens incurred to secure the performance of statutory obligations, surety or appeal bonds, performance or return-of-money bonds, insurance, self-insurance or other obligations of a like nature incurred in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens that are rights of set-off relating to the establishment of depository relations with banks not given in connection with the issuance of Indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens on the assets of a special purpose Subsidiary resulting from securitization transactions with respect to accounts receivable, royalties and similar assets included in such securitization transactions&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens upon specific items of inventory or other goods and proceeds of any Person securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances issued or created for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens securing reimbursement obligations with respect to letters of credit that encumber documents and other Property relating to such letters of credit and the products and proceeds thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens on key-man life insurance policies granted to secure our Indebtedness against the cash surrender value thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens encumbering customary initial deposits and margin deposits and other Liens in the ordinary course of business, in each case securing Hedging Obligations (as defined below) and forward contract, option, futures contracts, futures options or similar agreements or arrangements designed to protect us or any of our Subsidiaries from fluctuations in interest rates, currencies or the price of commodities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by us or any of our Subsidiaries in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens in our favor or the favor of any of our Subsidiaries&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens to secure any extension, renewal, refinancing or refunding (or successive extensions, renewals, refinancings or refundings), in whole or in part, of any Indebtedness secured by Liens referred to in the foregoing bullets or Liens created in connection with any amendment, consent or waiver relating to such Indebtedness, so long as such Lien does not extend to any other Property and the Indebtedness so secured does not exceed the fair market value (as determined by our board of directors) of the assets subject to such Liens at the time of such extension, renewal, refinancing or refunding, or such amendment, consent or waiver, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation on Sale and Leaseback Transactions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as provided under &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions,&#8221; we will not, and will not permit any of our Subsidiaries to, enter into any Sale and Leaseback Transaction (as defined below) with respect to any of our or their respective Properties, the acquisition or completion of construction and commencement of full operations of which has occurred more than 270 days prior thereto, unless&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such transaction was entered into prior to the first issue date of the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such transaction was for the sale and leasing back to us of any Property by one of our Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or such Subsidiary would be entitled to incur Indebtedness secured by a mortgage on the Property to be leased in an amount equal to the Attributable Debt (as defined below) with respect to such Sale and Leaseback Transaction without equally and ratably securing the notes pursuant to the first paragraph of &#8220;&#8212;Limitation on Liens&#8221; above&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lease is for a period not in excess of five years, including renewal rights&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the Subsidiary, prior to or within 270 days after the sale of such Property in connection with the Sale and Leaseback Transaction is completed, applies the net cash proceeds of the sale of the Property leased to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">the retirement of the notes or debt of ours ranking equally with the notes or to the retirement of any debt of a Subsidiary of ours, or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the acquisition of different property, facilities or equipment or the expansion of our existing business, including the acquisition of other businesses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exempted Liens and Sale and Leaseback Transactions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the restrictions described under the headings &#8220;&#8212;Limitation on Liens&#8221; or &#8220;&#8212;Limitation on Sale and Leaseback Transactions,&#8221; we or any Subsidiary of ours may create or assume any Liens or enter into any Sale and Leaseback Transactions not otherwise permitted as described above, if the sum of the following does not exceed 10% of Consolidated Total Assets (as defined below)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outstanding Indebtedness secured by such Liens (not including any Liens permitted under &#8220;&#8212;Limitation on Liens&#8221; which amount does not include any Liens permitted under the provisions of this &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions&#8221;)&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all Attributable Debt in respect of such Sale and Leaseback Transaction entered into (not including any Sale and Leaseback Transactions permitted under &#8220;&#8212;Limitation on Sale and Leaseback Transactions&#8221; which amount does not include any Sale and Leaseback Transactions permitted under the provisions of this &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions&#8221;),</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured, in each case, at the time such Lien is incurred or any such Sale and Leaseback Transaction is entered into by us or such Subsidiary of ours.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merger, Consolidation or Sale of Assets</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may merge or consolidate with another Person and may sell, transfer or lease all or substantially all of our assets to another Person if all the following conditions are met&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the merger, consolidation or sale of assets must not cause an event of default. See &#8220;&#8212;Events of Default.&#8221; An event of default for this purpose would also include any event that would be an event of default if the notice or time requirements were disregarded&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we are not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all of our assets to, must be organized under the laws of the U.S., any state thereof or the District of Columbia&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we are not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all of our assets to, must expressly assume by supplemental Indenture all of our obligations under the notes and the Indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deliver specific certification and documents to the trustee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;event of default&#8221; in respect of each series of the notes means any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we do not pay the principal of or any premium on the notes of that series on its due date&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we do not pay interest on the notes of that series within 30 days of its due date whether at maturity, upon redemption or upon acceleration (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent for application to pay such interest prior to the expiration of the 30-day period)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we remain in breach of a covenant in respect of the notes of that series for 90 days after we receive a written notice of default in accordance with the provisions of the Indenture stating we are in breach and requiring that we remedy the breach&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain events of bankruptcy, insolvency or reorganization occur with respect to us or any significant Subsidiary of ours.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default (other than due to certain events in bankruptcy, insolvency or reorganization) with respect to the notes of a series has occurred and has not been cured, the trustee or the holders of at least 25% in aggregate principal amount of the notes of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare the entire principal amount (and premium, if any) of, and all the accrued and unpaid interest on the notes of that series to be due and immediately payable. This is called a declaration of acceleration of maturity. If an event of default with respect to the notes of any of the series occurs because of certain events in bankruptcy, insolvency or reorganization relating to us, the principal amount of the notes of that series will be automatically accelerated, without any action by the trustee or any holder. Holders of a majority in aggregate principal amount of the notes of a series may also waive certain past defaults under the Indenture on behalf of all of the holders of the notes of that series. A declaration of acceleration of maturity with respect to the notes of a series may be canceled, under specific circumstances, by the holders of at least a majority in aggregate principal amount of the notes of that series.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any securities are outstanding under the Indenture, the Indenture requires us, within 120&#160;days after the end of each fiscal year, to furnish to the trustee a statement as to our compliance with the Indenture. The trustee will generally give the holders of notes notice within 90&#160;days of the occurrence of an event of default known to the trustee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the Indenture at the request of any of the holders unless the holders offer the trustee indemnity or security satisfactory to it. If indemnity or security satisfactory to the trustee is provided, the holders of a majority in aggregate principal amount of the notes of the applicable series may, with respect to the notes of that series, direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. The trustee may refuse to follow those directions in certain circumstances. No delay or omission in exercising any right or remedy will be treated as a waiver of the right, remedy or event of default.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before you are allowed to bypass the trustee and bring a lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating to the notes of the applicable series, the following must occur&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">you must give the trustee written notice that an event of default has occurred and remains uncured&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the holders of at least 25% in aggregate principal amount of the outstanding notes of that series must make a written request that the trustee take action because of the default and must offer the trustee indemnity or security satisfactory to it against the cost and other liabilities of taking that action&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">holders of a majority in aggregate principal amount of the notes of that series must not have given the trustee a direction inconsistent with the above notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, you are entitled at any time to bring a lawsuit for the payment of money due on your notes on or after the due date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defeasance</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Full Defeasance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Internal Revenue Service issues a ruling or there is a change in applicable U.S. federal tax law, as described below, we can legally release ourselves from any payment or other obligations on the notes, called &#8220;full defeasance,&#8221; if we put in place the following other arrangements for you to be repaid&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deposit in trust for your benefit and the benefit of all other registered holders of the notes, money, U.S. government or U.S. government agency notes or bonds or a combination thereof that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates including, possibly, their earliest redemption date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deliver to the trustee a legal opinion confirming that you will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the full defeasance and that you will not be taxed on the notes any differently than if the full defeasance had not occurred.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish full defeasance, as described above, you would have to rely solely on the trust deposit for repayment on the notes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You could not look to us for repayment in the unlikely event of any shortfall</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever become bankrupt or insolvent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Defeasance.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can be released from the restrictive covenants in the notes if we make the arrangements described below</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This is called &#8220;covenant defeasance.&#8221; In that event, the registered holders of the notes would lose the protection of those restrictive covenants but would gain the protection of having money and securities set aside in trust to repay the notes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to achieve covenant defeasance, we must do the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deposit in trust for your benefit and the benefit of all other registered holders of the notes, money, U.S. government or U.S. government agency notes or bonds or a combination thereof that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates, including their earliest possible redemption date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deliver to the trustee a legal opinion confirming that under current U.S. federal income tax law the registered holders of the notes will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the covenant defeasance and that the registered holders of the notes will not be taxed on the notes any differently than if the covenant defeasance had not occurred.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish covenant defeasance, the following provisions of the Indenture and the notes would no longer apply unless otherwise specified&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our promises regarding conduct of our business and other matters and any other covenants applicable to the series of notes&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the definition of an event of default as a breach of such covenants.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish covenant defeasance, you can still look to us for repayment of the notes if there were a shortfall in the trust deposit</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fact, if one of the remaining events of default occurred (such as our bankruptcy) and the notes become immediately due and payable, there may be such a shortfall</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the event causing the default, of course, you may not be able to obtain payment of the shortfall.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to exercise either full defeasance or covenant defeasance, we must comply with certain conditions, and no event or condition can exist that would prevent us from making payments of principal, premium and interest, if any, on the notes of such series on the date the irrevocable deposit is made or at any time during the period ending on the 91</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after the deposit date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notices</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the notes, we and the trustee will send notices regarding the notes only to registered holders, using their addresses as listed in the list of registered holders.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modification or Waiver</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally may modify and amend the Indenture with the consent of the holders of at least a majority in aggregate principal amount of the outstanding notes of the affected series. However, we may not make any modification or amendment without the consent of each holder of the notes of the affected series if such action would&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the stated maturity of, or the principal of or premium or interest on, the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce any amounts due on the notes or payable upon acceleration of the maturity of the notes following a default&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely affect any right of repayment at the holder&#8217;s option&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the place (except as otherwise described in this prospectus supplement) or currency of payment on the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modify the notes to contractually subordinate the notes in right of payment to other Indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the percentage of holders of notes whose consent is needed to modify or amend the Indenture&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the percentage of holders of notes whose consent is needed to waive compliance with certain provisions of the Indenture or to waive certain defaults&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modify any other aspect of the provisions of the Indenture dealing with modification and waiver except to increase the voting requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for certain specified provisions, the holders of at least a majority in aggregate principal amount of the outstanding notes of the affected series may, on behalf of the holders of all the notes of that series, waive our compliance with certain provisions of the Indenture. The holders of a majority in aggregate principal amount of the outstanding notes of the affected series may, on behalf of the holders of all the notes of such series, waive any past default under the Indenture with respect to that series and its consequences, except a default in the payment of the principal of or premium or interest on any notes of that series or in respect of a covenant or provision which cannot be modified or amended without the consent of the holder of each outstanding note of that series&#59; provided however that the holders of a majority in aggregate principal amount of the outstanding notes of the affected series may rescind an acceleration and its consequences, including any payment default that resulted from such acceleration.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, without the consent of any holder of notes of a series, we may amend or supplement the Indenture or the notes for among other reasons&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to cure any ambiguity, defect or inconsistency provided such amendment or supplement does not adversely affect the rights of any holder of notes of that series&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to comply with the covenant described under &#8220;&#8212;Merger, Consolidation or Sale of Assets&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to appoint a successor trustee with respect to the notes and to add to or change any of the provisions of the Indenture necessary to provide for the administration of the trusts in the Indenture by more than one trustee&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to comply with the requirements of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) in order to maintain the qualification of the Indenture under the Trust Indenture Act of 1939&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to make any change that would not adversely affect the rights of any holder of notes of that series&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to provide for the issuance of any additional notes as permitted by the Indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to conform the Indenture or the notes to the description thereof set forth in the prospectus supplement and in the accompanying prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Satisfaction and Discharge</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture will cease to be of further effect, and we will be deemed to have satisfied and discharged the Indenture with respect to the notes, when the following conditions have been satisfied&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all notes not previously delivered to the trustee for cancellation have become due and payable or will become due and payable at their stated maturity or on a redemption date within one year&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we deposit with the trustee, in trust, funds sufficient to pay the entire indebtedness on the notes that had not been previously delivered for cancellation, for the principal and interest to the date of the deposit (for notes that have become due and payable) or to the stated maturity or the redemption date, as the case may be (for notes that have not become due and payable)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have paid or caused to be paid all other sums payable under the Indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have delivered to the trustee an officers&#8217; certificate and opinion of counsel, each stating that we have complied with all these conditions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain obligated to provide for registration of transfer and exchange and to provide notices of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Trustee</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trustee is U.S. Bank National Association. U.S. Bank National Association is also the initial paying agent and registrar for the notes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture provides that, except during the continuance of an event of default under the Indenture, the trustee under the Indenture will perform only such duties as are specifically set forth in the Indenture</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Indenture, the holders of a majority in outstanding aggregate principal amount of the notes will have the right to direct the time, method and place of conducting any proceeding or exercising any remedy available to the trustee under the Indenture, subject to certain exceptions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default has occurred and is continuing, the trustee under the Indenture will exercise such rights and powers vested in it under the Indenture and is obligated to use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such person&#8217;s own affairs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture and provisions of the Trust Indenture Act incorporated by reference in the Indenture contain limitations on the rights of the trustee under such Indenture, should it become a creditor of our company, to obtain payment of claims in certain cases or to realize on certain Property received by it in respect of any such claims, as security or otherwise</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trustee under the Indenture is permitted to engage in other transactions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, if the trustee under the Indenture acquires any prohibited conflicting interest, it must eliminate the conflict or resign.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trustee may resign or be removed and a successor trustee may be appointed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Indenture and the notes will be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definitions</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following definitions are applicable to this Description of Notes&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Attributable Debt&#8221; means, with respect to a Sale and Leaseback Transaction, an amount equal to the lesser of (1)&#160;the fair market value of the Property (as determined in good faith by our board of directors)&#59; and (2)&#160;the present value of the total net amount of rent payments to be made under the lease during its remaining term, discounted at the rate of interest set forth or implicit in the terms of the lease, compounded semi-annually. The calculation of the present value of the total net amount of rent payments is subject to adjustments specified in the Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Capitalized Lease&#8221; means any obligation of a Person to pay rent or other amounts incurred with respect to real property or equipment acquired or leased by such Person and used in its business that is required to be recorded as a capital lease in accordance with generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Consolidated Total Assets&#8221; means, with respect to any Person as of any date, the amount of total assets as shown on the consolidated balance sheet of such Person for the most recent fiscal quarter for which financial statements have been filed with the SEC, prepared in accordance with accounting principles generally accepted in the United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Hedging Obligations&#8221; means, with respect to any specified Person, the obligations of such Person under&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">interest rate swap agreements (whether from fixed to floating or from floating to fixed), interest rate cap agreements and interest rate collar agreements&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">other agreements or arrangements designed to manage interest rates or interest rate risk&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">other agreements or arrangements designed to protect such Person against fluctuations in currency exchange rates or commodity prices.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Indebtedness&#8221; of any Person means, without duplication (1)&#160;any obligation of such Person for money borrowed, (2)&#160;any obligation of such Person evidenced by bonds, debentures, notes or other similar instruments, (3)&#160;any reimbursement obligation of such Person in respect of letters of credit or other similar instruments which support financial obligations which would otherwise become Indebtedness, and (4)&#160;any obligation of such Person under Capitalized Leases&#59;&#160;provided, however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;that &#8220;Indebtedness&#8221; of such Person shall not include any obligation of such Person to any Subsidiary of such Person or to any Person with respect to which such Person is a Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Lien&#8221; means any pledge, mortgage, lien, encumbrance or other security interest.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Person&#8221; means any individual, corporation, limited liability company, partnership, joint venture, association, joint stock company, trust, unincorporated organization or government or any agency or political subdivision thereof or other similar entity.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Property&#8221; means any property or asset, whether real, personal or mixed or tangible or intangible.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Sale and Leaseback Transaction&#8221; means any arrangement with any Person providing for the leasing by us or any Subsidiary of ours of any Property that has been or is to be sold or transferred by us or such Subsidiary, as the case may be, to such Person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Subsidiary&#8221; of any Person means (1)&#160;a corporation, a majority of the outstanding Voting Stock of which is, at the time, directly or indirectly, owned by such Person by one or more Subsidiaries of such Person, or by such Person and one or more Subsidiaries thereof or (2)&#160;any other Person (other than a corporation), including, without limitation, a partnership or joint venture, in which such Person, one or more Subsidiaries thereof or such Person and one or more Subsidiaries thereof, directly or indirectly, at the date of determination thereof, has at least majority ownership interest entitled to vote in the election of directors, managers or trustees thereof (or other Person performing similar functions).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Notes&#58; Book-Entry System</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Global Notes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes of each series is represented by one or more fully registered global notes, without interest coupons, was deposited upon issuance with the trustee as custodian for The Depository Trust Company (&#8220;DTC&#8221;), and registered in the name of Cede&#160;&#38; Co. or its nominee, in each case, for credit to an account of a direct or indirect participant as described below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below, the global notes may be transferred, in whole and not in part, only to another nominee of DTC or to a successor of DTC or its nominee. Beneficial interests in the global notes may not be</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchanged for definitive notes in registered certificated form (&#8220;certificated notes&#8221;) except in limited circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers of beneficial interests in the global notes are subject to the applicable rules and procedures of DTC and its direct or indirect participants, which may change.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes may be presented for registration of transfer and exchange at the offices of the trustee as set forth in the Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Book Entry Procedures for the Global Notes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All interests in the global notes will be subject to the operations and procedures of DTC, Euroclear Bank, S.A.&#47;N.V. and Clearstream Luxembourg,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;soci&#233;t&#233; anonyme</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Notes Due 2030 and 2050</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our 2.250% Senior Notes due 2030 (the &#8220;notes due 2030&#8221;) and the 3.150% Senior Notes due 2050 (the &#8220;notes due 2050&#8221; and, together with the notes due 2030, the &#8220;notes&#8221;), is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the indenture dated as of September&#160;15, 2015, between Biogen Inc. and U.S. Bank National Association, as trustee, as supplemented by a supplemental indenture, dated as of April 30, 2020, between Biogen Inc. and the trustee, as the &#8220;indenture.&#8221; The terms of the notes include those stated in the indenture and those made part of the indenture by reference to the Trust Indenture Act of 1939. A copy of the indenture is available for inspection at the office of the trustee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We encourage you to read the above referenced Indenture, as supplemented, for additional information.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Description of Notes, the terms &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and other similar references refer only to Biogen Inc. and not to any of its subsidiaries.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The notes due 2030 were initially limited to $1,500,000,000 aggregate principal amount. The maturity date of the notes due 2030 is May 1, 2030.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The notes due 2050 were initially limited to $1,500,000,000 aggregate principal amount. The maturity date of the notes due 2050 is May 1, 2050.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time, without notice to or the consent of the holders or beneficial owners of the notes, create and issue additional notes of any of the series having the same ranking and the same interest rate, maturity and other terms as the notes of the applicable series. Any additional notes having such similar terms, together with that series of notes, could be considered part of the same series of notes under the indenture&#59; provided that if the additional notes are not fungible with the notes of such series for U.S. federal income tax purposes, the additional notes will have a separate CUSIP number.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest and Principal</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes due 2030 bear interest at a fixed rate of 2.250%. The notes due 2050 bear interest at a fixed interest rate of 3.150%. Interest will be payable semiannually on November 1 and May 1 of each year, beginning November 1, 2020. Interest on the notes is paid to holders of record at the close of business on the October&#160;15 or April 15, whether or not a business day, immediately before the applicable interest payment date. The amount of interest payable on the notes is computed on the basis of a&#160;360-day&#160;year consisting of twelve&#160;30-day&#160;months.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes were issued only in fully registered form, without coupons, in denominations of $2,000 and integral multiples of $1,000 in excess thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any interest payment date or the maturity date of the notes is not a business day, then the related payment of interest and&#47;or principal payable on such date will be paid on the next succeeding business day with the same force and effect as if made on such interest payment date or maturity date and no further interest will accrue in respect of the delay. The term &#8220;business day&#8221; means any day other than a Saturday, a Sunday or any other day on which banking institutions in The City of New York are authorized or required by law, regulation or executive order to close.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ranking</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are senior unsecured obligations and rank equal in right of payment with our other existing and future senior unsecured obligations and senior in right of payment to any of our future subordinated indebtedness.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are effectively subordinated to all of our existing and future secured indebtedness and other secured liabilities to the extent of the value of the assets securing such indebtedness and liabilities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are structurally subordinated to all existing and future obligations of our subsidiaries, including claims with respect to trade payables. This means that holders of the notes have a junior position to the claims of creditors of our direct and indirect subsidiaries on the assets and earnings of such subsidiaries. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Optional Redemption</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time prior to the Par Call Date (as defined below) for the notes due 2030, and from time to time, the notes due 2030 are redeemable as a whole or in part, at our option, on at least 10 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2030 at a redemption price equal to the greater of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100% of principal amount of the notes due 2030 to be redeemed, or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sum of the present values of the remaining scheduled payments (through the Par Call Date for the notes due 2030 assuming for such purpose that such notes matured on the Par Call Date for the notes due 2030) of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate (as defined below) plus 25 basis points, in the case of notes due 2030.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after the Par Call Date for the notes due 2030, the notes due 2030 may be redeemed, as a whole or in part, at our option, on at least 10 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes to be redeemed (or otherwise delivered in accordance with the applicable procedures of DTC), at a redemption price equal to 100% of the principal amount of the notes to be redeemed on the redemption date plus accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Optional redemption of notes due 2050</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time prior to the Par Call Date for the notes due 2050, and from time to time, the notes due 2050 are redeemable as a whole or in part, at our option, on at least 10 days, but not more than 60 days, prior notice mailed to the registered address of each holder of the notes due 2050 at a redemption price equal to the greater of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">100% of principal amount of the notes due 2050 to be redeemed, or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sum of the present values of the remaining scheduled payments (through the Par Call Date for the notes due 2050 assuming for such purpose that such notes matured on the Par Call Date for the notes due 2050) of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the date of redemption) discounted to the date of redemption on a semiannual basis, assuming a 360-day year consisting of twelve 30-day months, at the Treasury Rate (as defined below) plus 30 basis points, in the case of notes due 2050.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus, in either case, accrued and unpaid interest to, but not including, the date of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Treasury Issue&#8221; means the U.S. Treasury security or securities selected by an Independent Investment Banker (as defined below) as having an actual or interpolated maturity comparable to the remaining term of the notes of the applicable series (&#8220;Remaining Life&#8221;) to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of a comparable maturity to the remaining term of such notes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Comparable Treasury Price&#8221; means, with respect to any notes of a series on any redemption date, (A)&#160;the average of the Reference Treasury Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (B)&#160;if the Independent Investment Banker obtains fewer than four such Reference Treasury Dealer Quotations, the average of all such quotations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Independent Investment Banker&#8221; means one of the Reference Treasury Dealers (as defined below) appointed by us.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8220;Par Call Date&#8221; means&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">with respect to the notes due 2030, February 1, 2030 (three months prior to the maturity date of the notes due 2030)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">with respect to the notes due 2050, November 1, 2049 (six months prior to the maturity date of the notes due 2050).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reference Treasury Dealer&#8221; means each of Goldman Sachs&#160;&#38; Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, or their respective affiliates, which are primary U.S. Government securities dealers in The City of New York, and their respective successors plus three other primary U.S. Government securities dealers in The City of New York selected by us&#59; provided, however, that if any of the foregoing or their affiliates shall cease to be a primary U.S. Government securities dealer in The City of New York (a &#8220;Primary Treasury Dealer&#8221;), we will substitute therefor another Primary Treasury Dealer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reference Treasury Dealer Quotations&#8221; means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the applicable Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the trustee by the Reference Treasury Dealers at 3&#58;30&#160;p.m. New York time on the third business day preceding such redemption date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Treasury Rate&#8221; means, with respect to any redemption date&#58; (1)&#160;the rate per annum equal to the yield, under the heading which represents the average for the immediately preceding week, appearing in the most recently published statistical release designated &#8220;H.15(519)&#8221; or any successor publication which is published weekly by the Board of Governors of the Federal Reserve System and which establishes yields on actively traded U.S. Treasury securities adjusted to constant maturity under the caption &#8220;Treasury Constant Maturities&#8221; for the maturity corresponding to the Comparable Treasury Issue&#59; provided that, if no maturity is within three months before or after the Remaining Life of the notes to be redeemed, yields for the two published maturities most closely corresponding to the Comparable Treasury Issue shall be determined and the Treasury Rate shall be interpolated or extrapolated from those yields on a straight-line basis, rounding to the nearest month&#59; or (2)&#160;if such release (or any successor release) is not published during the week preceding the calculation date or does not contain such yields, the rate per year equal to the semiannual equivalent yield to maturity or interpolated (on a day count basis) of the Comparable Treasury Issue, assuming a price for the applicable Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Comparable Treasury Price for such redemption date. The Treasury Rate shall be calculated on the third business day preceding the redemption date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On and after the redemption date for the notes of the applicable series, interest will cease to accrue on the notes of that series or any portion thereof called for redemption, unless we default in the payment of the redemption price. On or before the redemption date for the notes of that series, we will deposit with a paying agent, or the trustee, funds sufficient to pay the redemption price of and accrued and unpaid interest on such notes to be redeemed on such date. If less than all of the notes of a series are to be redeemed, the notes of that series to be redeemed will be selected by DTC in accordance with its standard procedures. If the notes to be redeemed are not global notes then held by DTC, or DTC prescribes no method of selection, the trustee will select the notes to be redeemed on a pro rata basis, by lot, or by any other method the trustee deems fair and appropriate and subject to and otherwise in accordance with the procedures of DTC. Any redemption or notice of redemption may, at our discretion, be subject to one or more conditions precedent, and, at our discretion, the redemption date may be delayed until such time as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any or all such conditions shall be satisfied. We will provide written notice to the trustee prior to the close of business two business days prior to the redemption date if any such redemption has been rescinded or delayed, and upon receipt the trustee shall provide such notice to each holder of the notes in the same manner in which the notice of redemption was given.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change of Control</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a Change of Control Triggering Event (as defined below) occurs with respect to the notes of a series, unless we have exercised our option to redeem the notes of such series as described above, we will be required to make an offer (the &#8220;Change of Control Offer&#8221;) to each holder of the notes of such series to repurchase all or any part of that holder&#8217;s notes of such series on the terms set forth in such notes. In the Change of Control Offer, we will be required to offer payment in cash equal to 101% of the aggregate principal amount of notes repurchased, plus accrued and unpaid interest, if any, on the notes repurchased to but not including the date of repurchase (the &#8220;Change of Control Payment&#8221;). With respect to the notes of each series, within 30 days following any Change of Control Triggering Event or, at our option, prior to any Change of Control (as defined below), but after public announcement of the transaction that constitutes or may constitute the Change of Control, a notice will be mailed (or otherwise delivered in accordance with the applicable procedures of DTC) to holders of the notes of the applicable series describing the transaction that constitutes or may constitute the Change of Control Triggering Event and offering to repurchase the notes of such series on the date specified in the notice, which date will be no earlier than 10 days and no later&#160;than 60 days from the date such notice is mailed (or otherwise delivered in accordance with the applicable procedures of DTC) or, if the notice is mailed (or otherwise delivered) prior to the Change of Control, no earlier than 10 days and no later than 60 days from the date on which the Change of Control Triggering Event occurs (the &#8220;Change of Control Payment Date&#8221;). The notice will, if mailed (or otherwise delivered) prior to the date of consummation of the Change of Control, state that the offer to purchase is conditioned on the Change of Control Triggering Event occurring on or prior to the Change of Control Payment Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Change of Control Payment Date, we will, to the extent lawful&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accept for payment all notes or portions of notes properly tendered pursuant to the Change of Control Offer&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deposit with the paying agent an amount equal to the Change of Control Payment in respect of all notes or portions of notes properly tendered&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deliver or cause to be delivered to the trustee the notes properly accepted together with an officers&#8217; certificate stating the aggregate principal amount of notes or portions of notes being repurchased.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not be required to make a Change of Control Offer upon the occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by us and the third party repurchases all notes properly tendered and not withdrawn under its offer. In addition, we will not repurchase any notes if there has occurred and is continuing on the Change of Control Payment Date an event of default under the indenture, other than a default in the payment of the Change of Control Payment upon a Change of Control Triggering Event.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will comply in all material respects with the requirements of Rule&#160;14e-1&#160;under the Exchange Act and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the notes as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with the Change of Control Offer provisions of the notes, we will comply with those securities laws and regulations and will not be deemed to have breached our obligations under the Change of Control Offer provisions of the notes by virtue of any such conflict.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the Change of Control Offer provisions of the notes, the following terms will be applicable&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Change of Control&#8221; means the occurrence of any of the following&#58; (1)&#160;the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) (other than us or one of our Subsidiaries (as defined below)) becomes the beneficial owner (as defined in Rules&#160;13d-3&#160;and&#160;13d-5&#160;under the Exchange Act), directly or indirectly, of more than 50% of our Voting Stock (as defined below) or other Voting Stock into which our Voting Stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares&#59; provided, however, that a Person (as defined below) shall not be deemed beneficial owner of, or to own beneficially, (A)&#160;any securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of such Person&#8217;s affiliates until such tendered securities are accepted for purchase or exchange thereunder, or (B)&#160;any securities if such beneficial ownership (i)&#160;arises solely as a result of a revocable proxy delivered in response to a proxy or consent solicitation made pursuant to the applicable rules and regulations under the Exchange Act, and (ii)&#160;is not also then reportable on Schedule&#160;13D (or any successor schedule) under the Exchange Act&#59; (2)&#160;the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of our assets and the assets of our Subsidiaries, taken as a whole, to one or more &#8220;persons&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) (other than to us or one of our Subsidiaries) (a &#8220;Transferee&#8221;), provided, however, that none of the circumstances in this clause&#160;(2) will be a Change of Control if the persons that beneficially own our Voting Stock immediately prior to the transaction own, directly or indirectly, shares representing a majority of the total Voting Stock as measured by voting power rather than number of shares of the Transferee&#59; (3)&#160;we consolidate with, or merge with or into, any &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) or any such Person consolidates with, or merges with or into, us, in either case, pursuant to a transaction in which any of our outstanding Voting Stock or the Voting Stock of such other Person is converted into or exchanged for cash, securities or other property, other than pursuant to a transaction in which shares of our Voting Stock outstanding immediately prior to the transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving Person immediately after giving effect to such transaction&#59; or (4)&#160;the adoption of a plan relating to our liquidation or dissolution.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Change of Control Triggering Event&#8221; means the occurrence of both a Change of Control and a Rating Event (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Fitch&#8221; means Fitch Inc., or any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Investment Grade Rating&#8221; means a rating equal to or higher than Baa3 (or the equivalent) by Moody&#8217;s (as defined below) and&#160;BBB-&#160;(or the equivalent) by S&#38;P (as defined below) or Fitch, and the equivalent investment grade credit rating from any additional rating agency or Rating Agencies (as defined below) selected by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Moody&#8217;s&#8221; means Moody&#8217;s Investors Service, Inc., or any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Rating Agencies&#8221; means (1)&#160;each of Fitch, Moody&#8217;s and S&#38;P and (2)&#160;if any of Fitch, Moody&#8217;s and S&#38;P ceases to rate the notes or fails to make a rating of the notes publicly available for reasons outside of our control, a &#8220;nationally recognized statistical rating organization&#8221; within the meaning of Rule&#160;15c3-1(c)(2)(vi)(F)&#160;under the Exchange Act selected by us (as certified by a resolution of our board of directors) and which is reasonably acceptable to the trustee as a replacement agency for Fitch, Moody&#8217;s or S&#38;P, or all of them, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Rating Event&#8221; means with respect to either series of notes, the rating on such notes is lowered by at least two of the three Rating Agencies and such notes are rated below an Investment Grade Rating by at least two of the three Rating Agencies, on any day during the period commencing on the earlier of the date of the first public notice of the occurrence of a Change of Control or our intention to effect a Change of Control and ending 60 days following consummation of such Change of Control (which period will be extended so long as the rating of the applicable series of notes is under publicly announced consideration for a possible downgrade by any of the Rating Agencies).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;S&#38;P&#8221; means Standard&#160;&#38; Poor&#8217;s Rating Services, a Standard&#160;&#38; Poor&#8217;s Financial Services LLC business, or any successor thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Voting Stock&#8221; means, with respect to any specified &#8220;person&#8221; (as that term is used in Section&#160;13(d) of the Exchange Act) as of any date, the capital stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sinking Fund</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes are not entitled to the benefit of any sinking fund.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation on Liens</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as provided in this section or as provided under &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions,&#8221; we will not, and will not permit any Subsidiary of ours to, create or assume any Indebtedness (as defined below) secured by any Lien (as defined below) on any of our or their respective Principal Properties (as defined below) unless the notes are secured by such Lien (as defined below) equally and ratably with, or prior to, the Indebtedness secured by such Lien. This restriction does not apply to Indebtedness that is secured by&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens existing on the date of the issuance of the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens securing only the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens on property or shares of stock in respect of Indebtedness of a Person existing at the time such Person becomes a Subsidiary of ours or is merged into or consolidated with, or its assets are acquired by, us or any Subsidiary of ours (provided that such Lien was not incurred in anticipation of such transaction and was in existence prior to such transaction) so long as such Lien does not extend to any other property and the Indebtedness so secured is not increased&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens to secure Indebtedness incurred for the purpose of all or any part of a property&#8217;s purchase price or cost of construction or additions, repairs, alterations, or other improvements&#59; provided that (1) the principal amount of any Indebtedness secured by such Lien does not exceed 100% of such property&#8217;s purchase price or cost, (2) such Lien does not extend to or cover any other property other than the property so purchased, constructed or on which such additions, repairs, alterations or other improvements were so made and (3) such Lien is incurred prior to or within 270 days after the acquisition of such property or the completion of construction or such additions, repairs, alterations or other improvements and the full operation of such property thereafter&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens in favor of the U.S. or any state thereof, or any instrumentality of either, to secure certain payments pursuant to any contract or statute&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens for taxes or assessments or other governmental charges or levies which are not overdue for a period exceeding 60 days unless such Liens are being contested in good faith and for which adequate reserves are being maintained, to the extent required by generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">title exceptions, easements, licenses, leases and other similar Liens that are not consensual and that do not materially impair the use of the property subject thereto&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens to secure obligations under worker&#8217;s compensation laws, unemployment compensation, old-age pensions and other social security benefits or similar legislation&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens arising out of legal proceedings, including Liens arising out of judgments or awards&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warehousemen&#8217;s, materialmen&#8217;s, carrier&#8217;s, landlord&#8217;s and other similar Liens for sums not overdue for a period exceeding 60 days unless such Liens are being contested in good faith and for which adequate reserves are being maintained, to the extent required by generally accepted accounting principles&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens incurred to secure the performance of statutory obligations, surety or appeal bonds, performance or return-of-money bonds, insurance, self-insurance or other obligations of a like nature incurred in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens that are rights of set-off relating to the establishment of depository relations with banks not given in connection with the issuance of Indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens arising out of conditional sale, title retention, consignment or similar arrangements for the sale of goods entered into by us or any of our Subsidiaries in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens in our favor or the favor of any of our Subsidiaries&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Liens to secure any extension, renewal, refinancing or refunding (or successive extensions, renewals, refinancings or refundings), in whole or in part, of any Indebtedness secured by Liens referred to in the foregoing bullets or Liens created in connection with any amendment, consent or waiver relating to such Indebtedness, so long as such Lien does not extend to any other Principal Property and the Indebtedness so secured does not exceed the fair market value (as determined by our board of directors) of the assets subject to such Liens at the time of such extension, renewal, refinancing or refunding, or such amendment, consent or waiver, as the case may be.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitation on Sale and Leaseback Transactions</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as provided under &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions,&#8221; we will not, and will not permit any of our Subsidiaries to, enter into any Sale and Leaseback Transaction (as defined below) with respect to any of our or their respective Principal Properties, the acquisition or completion of construction and commencement of full operations of which has occurred more than 270 days prior thereto, unless&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such transaction was entered into prior to the first issue date of the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such transaction was for the sale and leasing back to us of any property by one of our Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or such Subsidiary would be entitled to incur Indebtedness secured by a mortgage on the property to be leased in an amount equal to the Attributable Debt (as defined below) with respect to such Sale and Leaseback Transaction without equally and ratably securing the notes pursuant to the first paragraph of &#8220;&#8212;Limitation on Liens&#8221; above&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lease is for a period not in excess of five years, including renewal rights&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the Subsidiary, prior to or within 270 days after the sale of such property in connection with the Sale and Leaseback Transaction is completed, applies the net cash proceeds of the sale of the property leased to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">the retirement of the notes or debt of ours ranking equally with the notes or to the retirement of any debt of a Subsidiary of ours, or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the acquisition of another Principal Property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exempted Liens and Sale and Leaseback Transactions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the restrictions described under the headings &#8220;&#8212;Limitation on Liens&#8221; or &#8220;&#8212;Limitation on Sale and Leaseback Transactions,&#8221; we or any Subsidiary of ours may create or assume any Liens or enter into any Sale and Leaseback Transactions not otherwise permitted as described above, if the sum of the following does not exceed 15% of Consolidated Total Assets (as defined below)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outstanding Indebtedness secured by such Liens (not including any Liens permitted under &#8220;&#8212;Limitation on Liens&#8221; which amount does not include any Liens permitted under the provisions of this &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions&#8221;)&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all Attributable Debt in respect of such Sale and Leaseback Transaction entered into (not including any Sale and Leaseback Transactions permitted under &#8220;&#8212;Limitation on Sale and Leaseback Transactions&#8221; which amount does not include any Sale and Leaseback Transactions permitted under the provisions of this &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions&#8221;),</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">measured, in each case, at the time such Lien is incurred or any such Sale and Leaseback Transaction is entered into by us or such Subsidiary of ours.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merger, Consolidation or Sale of Assets</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may merge or consolidate with another Person and may sell, transfer or lease all or substantially all of our assets to another Person if all the following conditions are met&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the merger, consolidation or sale of assets must not cause an event of default. See &#8220;&#8212;Events of Default.&#8221; An event of default for this purpose would also include any event that would be an event of default if the notice or time requirements were disregarded&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we are not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all of our assets to, must be organized under the laws of the U.S., any state thereof or the District of Columbia&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we are not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all of our assets to, must expressly assume by supplemental indenture all of our obligations under the notes and the indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deliver specific certification and documents to the trustee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;event of default&#8221; in respect of each series of the notes means any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we do not pay the principal of or any premium on the notes of that series on its due date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we do not pay interest on the notes of that series within 30 days of its due date whether at maturity, upon redemption or upon acceleration (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent for application to pay such interest prior to the expiration of the&#160;30-day&#160;period)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we remain in breach of a covenant in respect of the notes of that series for 90 days after we receive a written notice of default in accordance with the provisions of the indenture stating we are in breach and requiring that we remedy the breach&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain events of bankruptcy, insolvency or reorganization occur with respect to us or any significant Subsidiary of ours.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default (other than due to certain events in bankruptcy, insolvency or reorganization) with respect to the notes of a series has occurred and has not been cured, the trustee or the holders of at least 25% in</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate principal amount of the notes of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare the entire principal amount (and premium, if any) of, and all the accrued and unpaid interest on the notes of that series to be due and immediately payable. This is called a declaration of acceleration of maturity. If an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">event of default with respect to the notes of any of the series occurs because of certain events in bankruptcy, insolvency or reorganization relating to us, the principal amount of the notes of that series will be automatically accelerated, without any action by the trustee or any holder. Holders of a majority in aggregate principal amount of the notes of a series may also waive certain past defaults under the indenture on behalf of all of the holders of the notes of that series. A declaration of acceleration of maturity with respect to the notes of a series may be canceled, under specific circumstances, by the holders of at least a majority in aggregate principal amount of the notes of that series.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any securities are outstanding under the indenture, the indenture requires us, within 120&#160;days after the end of each fiscal year, to furnish to the trustee a statement as to our compliance with the indenture. The trustee will generally give the holders of notes notice within 90&#160;days of the occurrence of an event of default known to the trustee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the indenture at the request of any of the holders unless the holders offer the trustee indemnity and&#47;or security satisfactory to it. If indemnity or security satisfactory to the trustee is provided, the holders of a majority in aggregate principal amount of the notes of the applicable series may, with respect to the notes of that series, direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. The trustee may refuse to follow those directions in certain circumstances. No delay or omission in exercising any right or remedy will be treated as a waiver of the right, remedy or event of default.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before you are allowed to bypass the trustee and bring a lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating to the notes of the applicable series, the following must occur&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">you must give the trustee written notice that an event of default has occurred and remains uncured&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the holders of at least 25% in aggregate principal amount of the outstanding notes of that series must make a written request that the trustee take action because of the default and must offer the trustee indemnity and&#47;or security satisfactory to it against the cost and other liabilities of taking that action&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity and&#47;or security&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">holders of a majority in aggregate principal amount of the notes of that series must not have given the trustee a direction inconsistent with the above notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, you are entitled at any time to bring a lawsuit for the payment of money due on your notes on or after the due date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defeasance</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Full Defeasance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Internal Revenue Service issues a ruling or there is a change in applicable U.S. federal tax law, as described below, we can legally release ourselves from any payment or other obligations on the notes, called &#8220;full defeasance,&#8221; if we put in place the following other arrangements for you to be repaid&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deposit in trust for your benefit and the benefit of all other registered holders of the notes, money, U.S. government or U.S. government agency notes or bonds or a combination thereof that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates including, possibly, their earliest redemption date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deliver to the trustee a legal opinion confirming that you will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the full defeasance and that you will not be taxed on the notes any differently than if the full defeasance had not occurred.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish full defeasance, as described above, you would have to rely solely on the trust deposit for repayment on the notes. You could not look to us for repayment in the unlikely event of any shortfall</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever become bankrupt or insolvent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Defeasance. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can be released from the restrictive covenants in the notes if we make the arrangements described below</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This is called &#8220;covenant defeasance.&#8221; In that event, the registered holders of the notes would lose the protection of those restrictive covenants but would gain the protection of having money and securities set aside in trust to repay the notes</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to achieve covenant defeasance, we must do the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deposit in trust for your benefit and the benefit of all other registered holders of the notes, money, U.S. government or U.S. government agency notes or bonds or a combination thereof that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates, including their earliest possible redemption date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we must deliver to the trustee a legal opinion confirming that under current U.S. federal income tax law you will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the covenant defeasance and that you will not be taxed on the notes any differently than if the covenant defeasance had not occurred.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish covenant defeasance, the following provisions of the indenture and the notes would no longer apply unless otherwise specified&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our promises regarding conduct of our business and other matters and any other covenants applicable to the series of notes&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the definition of an event of default as a breach of such covenants.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we accomplish covenant defeasance, you can still look to us for repayment of the notes if there were a shortfall in the trust deposit</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fact, if one of the remaining events of default occurred (such as our bankruptcy) and the notes become immediately due and payable, there may be such a shortfall</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the event causing the default, of course, you may not be able to obtain payment of the shortfall.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to exercise either full defeasance or covenant defeasance, we must comply with certain conditions, and no event or condition can exist that would prevent us from making payments of principal, premium and interest, if any, on the notes of such series on the date the irrevocable deposit is made or at any time during the period ending on the 91</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after the deposit date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notices</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the notes, we and the trustee will send notices regarding the notes only to registered holders, using their addresses as listed in the list of registered holders.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modification or Waiver</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally may modify and amend the indenture with the consent of the holders of at least a majority in aggregate principal amount of the outstanding notes of the affected series. However, we may not make any modification or amendment without the consent of each holder of the notes of the affected series if such action would&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the stated maturity of, or the principal of or premium or interest on, the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce any amounts due on the notes or payable upon acceleration of the maturity of the notes following a default&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely affect any right of repayment at the holder&#8217;s option&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change the place (except as otherwise described in this prospectus supplement) or currency of payment on the notes&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modify the notes to contractually subordinate the notes in right of payment to other Indebtedness&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the percentage of holders of notes whose consent is needed to modify or amend the indenture&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the percentage of holders of notes whose consent is needed to waive compliance with certain provisions of the indenture or to waive certain defaults&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modify any other aspect of the provisions of the indenture dealing with modification and waiver except to increase the voting requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for certain specified provisions, the holders of at least a majority in aggregate principal amount of the outstanding notes of the affected series may, on behalf of the holders of all the notes of that series, waive our compliance with certain provisions of the indenture. The holders of a majority in aggregate principal amount of the outstanding notes of the affected series may, on behalf of the holders of all the notes of such series, waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of or premium or interest on any notes of that series or in respect of a covenant or provision which cannot be modified or amended without the consent of the holder of each outstanding note of that series&#59; provided however that the holders of a majority in aggregate principal amount of the outstanding notes of the affected series may rescind an acceleration and its consequences, including any payment default that resulted from such acceleration.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, without the consent of any holder of notes of a series, we may amend or supplement the indenture or the notes for among other reasons&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to cure any ambiguity, defect or inconsistency provided such amendment or supplement does not adversely affect the rights of any holder of notes of that series&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to comply with the covenant described under &#8220;&#8212;Merger, Consolidation or Sale of Assets&#59;&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to appoint a successor trustee with respect to the notes and to add to or change any of the provisions of the indenture necessary to provide for the administration of the trusts in the indenture by more than one trustee&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to comply with the requirements of the SEC in order to maintain the qualification of the indenture under the Trust Indenture Act of 1939&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to make any change that would not adversely affect the rights of any holder of notes of that series&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to provide for the issuance of any additional notes as permitted by the indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to conform the indenture or the notes to the description thereof set forth in this prospectus supplement and in the accompanying prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Satisfaction and Discharge</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture will cease to be of further effect, and we will be deemed to have satisfied and discharged the indenture with respect to the notes, when the following conditions have been satisfied&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all notes not previously delivered to the trustee for cancellation have become due and payable or will become due and payable at their stated maturity or on a redemption date within one year&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we deposit with the trustee, in trust, funds sufficient to pay the entire indebtedness on the notes that had not been previously delivered for cancellation, for the principal and interest to the date of the deposit (for notes that have become due and payable) or to the stated maturity or the redemption date, as the case may be (for notes that have not become due and payable)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have paid or caused to be paid all other sums payable under the indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have delivered to the trustee an officers&#8217; certificate and opinion of counsel, each stating that we have complied with all these conditions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain obligated to provide for registration of transfer and exchange and to provide notices of redemption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Trustee</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trustee is U.S. Bank National Association. U.S. Bank National Association is also the initial paying agent and registrar for the notes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture provides that, except during the continuance of an event of default under the indenture, the trustee under the indenture will perform only such duties as are specifically set forth in the indenture</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the indenture, the holders of a majority in outstanding aggregate principal amount of the notes will have the right to direct the time, method and place of conducting any proceeding or exercising any remedy available to the trustee under the indenture, subject to certain exceptions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an event of default has occurred and is continuing, the trustee under the indenture will exercise such rights and powers vested in it under the indenture and is obligated to use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such person&#8217;s own affairs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture and provisions of the Trust Indenture Act incorporated by reference in the indenture contain limitations on the rights of the trustee under such indenture, should it become a creditor of our company, to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claims, as security or otherwise</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trustee under the indenture is permitted to engage in other transactions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, if the trustee under the indenture acquires any prohibited conflicting interest, it must eliminate the conflict or resign.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trustee may resign or be removed and a successor trustee may be appointed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture and the notes will be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following definitions are applicable to this Description of Notes&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Attributable Debt&#8221; means, with respect to a Sale and Leaseback Transaction, an amount equal to the lesser of (1)&#160;the fair market value of the property (as determined in good faith by our board of directors)&#59; and (2)&#160;the present value of the total net amount of rent payments to be made under the lease during its remaining term, discounted at the rate of interest set forth or implicit in the terms of the lease, compounded semi-annually. The calculation of the present value of the total net amount of rent payments is subject to adjustments specified in the indenture.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Consolidated Total Assets&#8221; means, with respect to any Person as of any date, the amount of total assets as shown on the consolidated balance sheet of such Person for the most recent fiscal quarter for which financial statements have been filed with the SEC, prepared in accordance with accounting principles generally accepted in the U.S.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Indebtedness&#8221; of any Person means, without duplication (1)&#160;any obligation of such Person for money borrowed, (2)&#160;any obligation of such Person evidenced by bonds, debentures, notes or other similar instruments, (3)&#160;any reimbursement obligation of such Person in respect of letters of credit or other similar instruments which support financial obligations which would otherwise become Indebtedness, and (4)&#160;any obligation of such Person under any lease&#59;&#160;provided, however,&#160;that &#8220;Indebtedness&#8221; of such Person shall not include any obligation of such Person to any Subsidiary of such Person or to any Person with respect to which such Person is a Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Lien&#8221; means any pledge, mortgage, lien, encumbrance or other security interest.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Person&#8221; means any individual, corporation, limited liability company, partnership, joint venture, association, joint stock company, trust, unincorporated organization or government or any agency or political subdivision thereof or other similar entity.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Principal Property&#8221; means (1)&#160;any manufacturing facility, together with the land upon which it is erected and fixtures comprising a part thereof, owned or leased by us or any Subsidiary and located within the continental U.S. and having a net book value which, on the date the determination as to whether a property is a Principal Property is being made, exceeds 1% of our Consolidated Total Assets other than any such facility or a portion thereof which our board of directors determine in good faith, at any time on or prior to such date, is not of material importance to the total business conducted, or assets owned, by us and our Subsidiaries as an entirety or (2)&#160;any shares of stock or Indebtedness of any Subsidiary owning a Principal Property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Sale and Leaseback Transaction&#8221; means any arrangement with any Person providing for the leasing by us or any Subsidiary of ours of any property that has been or is to be sold or transferred by us or such Subsidiary, as the case may be, to such Person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Subsidiary&#8221; of any Person means (1)&#160;a corporation, a majority of the outstanding Voting Stock of which is, at the time, directly or indirectly, owned by such Person by one or more Subsidiaries of such Person, or by such Person and one or more Subsidiaries thereof or (2)&#160;any other Person (other than a corporation), including, without limitation, a partnership or joint venture, in which such Person, one or more Subsidiaries thereof or such Person and one or more Subsidiaries thereof, directly or indirectly, at the date of determination thereof, has at least majority ownership interest entitled to vote in the election of directors, managers or trustees thereof (or other Person performing similar functions).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Notes&#58; Book-Entry System</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Global Notes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes of each series is represented by one or more fully registered global notes, without interest coupons, was deposited upon issuance with the trustee as custodian for DTC, and registered in the name of Cede&#160;&#38; Co. or its nominee, in each case, for credit to an account of a direct or indirect participant as described below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below, the global notes may be transferred, in whole and not in part, only to another nominee of DTC or to a successor of DTC or its nominee. Beneficial interests in the global notes may not be exchanged for definitive notes in registered certificated form (&#8220;certificated notes&#8221;) except in limited circumstances.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers of beneficial interests in the global notes are subject to the applicable rules and procedures of DTC and its direct or indirect participants, which may change.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes may be presented for registration of transfer and exchange at the corporate trust offices of the trustee as set forth in the indenture.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain Book Entry Procedures for the Global Notes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All interests in the global notes will be subject to the operations and procedures of DTC, Euroclear Bank, S.A.&#47;N.V. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">425387_1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>3
<FILENAME>biib-20201231xex1041.htm
<DESCRIPTION>EX-10.41
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i53e37a60cb32430a99134f6cd91e422e_1"></div><div style="min-height:68pt;width:100%"><div><font style="color:#2d9ced;font-family:'Arial',sans-serif;font-size:25pt;font-weight:700;line-height:7%">Biogen</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.5pt;text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 10.41</font></div><div style="margin-top:4.75pt;padding-left:17.1pt;padding-right:362.55pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:256%">October 12, 2017 </font></div><div style="padding-right:362.55pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chirfi Guindo</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;address&#93;</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;address&#93;</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:17.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dear Chirfi,</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:16.45pt;padding-right:15.3pt;text-indent:0.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:140%">I am pleased to extend you this offer of employment to join Biogen with the job title of EVP, Global Commercial. This position will report to Michel Vounatsos, Chief Executive Officer. Please note that neither this letter nor any other materials constitute a contract of employment with Biogen. Your employment at Biogen is employment at-will. This means that just as you are free to leave your employment at any time, with or without cause or notice, Biogen also has the same right to terminate your employment at any time, with or without cause or notice. The specific terms of our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:140%">offer </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:140%">are listed below&#59; please take the time to review the offer, sign and return to me by October 15, 2017.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The position will be based at our Cambridge, MA facility.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:16.55pt;padding-right:15.3pt;text-indent:-0.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:143%">Salary&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:143%">This is a full-time, exempt position and your starting annual salary will be $500,000.00, and which will be paid biweekly in accordance with our standard payroll policies.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:15.8pt;padding-right:15.25pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:128%">Sign-On Bonus&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:128%">Upon employment , you will receive $250,000.00 as a one-time cash bonus. The bonus will be paid to you within two pay periods after your start date provided that you sign the enclosed Cash Sign-On Bonus Agreement, which describes the terms and conditions of the cash sign-on bonus.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:15.5pt;padding-right:15.3pt;text-indent:0.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:140%">Annual Bonus Plan&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:140%">You will be eligible to participate in the Biogen Annual Bonus Plan, beginning in 2018, with a target bonus opportunity of 70% of your annual base salary. Eligibility details and other terms of the Plan are included in the current year's Plan document, which will be made available upon your employment with the Company.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:15.25pt;padding-right:15.3pt;text-indent:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:141%">Long-Term Incentive (LTI) Plan&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:141%">Provided that you commence employment before December 1, 2017, you will be granted Restricted-Stock Units (RSU) and Market Stock Units (MSU) in connection with the commencement of your employment. The approximate grant date value of your RSU award will be</font></div><div style="padding-left:14.8pt;padding-right:14.35pt;text-indent:0.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:140%">$750,000.00. The number of RSU shares granted to you will be calculated by dividing the approximate grant date value by the closing price of Biogen stock (NASDAQ) on the date of grant, with the resulting number of shares rounded to the nearest five shares. The approximate grant date value of your MSU award will be $750,000.00. The number of MSU shares granted to you will be calculated by dividing the approximate grant date value by the closing price of Biogen stock (NASDAQ) and the MSU accounting valuation factor effective at the time of grant, with the resulting number of shares rounded to the nearest five shares. Your RSU and MSU awards will be granted on the first trading day of the month following your start date. The grant of RSU and MSU awards described above are contingent upon you starting employment at Biogen prior to December 1, 2017.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:14.3pt;padding-right:11.4pt;text-indent:0.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">The actual terms of your RSU and MSU awards will be communicated to you following the grant date. Your grants will be awarded under the Biogen Inc. 2017 Omnibus Equity Plan (the &#34;2017 Plan&#34;). You are considered a &#34;designated employee,&#34; as defined in the Plan. The Plan and Prospectus are available to you on Biogen's benefits website at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%;text-decoration:underline">&#91;website&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:139%">. Please read these documents for information about your LTl grants.</font></div><div><font><br></font></div><div style="height:57pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#7cbfeb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">225 </font><font style="color:#67b5eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">Binney St1eel, Cambridge</font><font style="color:#9ec6df;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">, </font><font style="color:#67b5eb;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:7%">MA </font><font style="color:#67b5eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">02142 </font><font style="color:#5ba1e4;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">&#8226; </font><font style="color:#67b5eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">Phone 781-464-2000 </font><font style="color:#5ba1e4;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">&#8226; </font><font style="color:#67b5eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">www</font><font style="color:#9ec6df;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">.</font><font style="color:#67b5eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">biogen </font><font style="color:#9ec6df;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">.</font><font style="color:#7cbfeb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">com</font></div><div><font><br></font></div></div></div><div id="i53e37a60cb32430a99134f6cd91e422e_4"></div><hr style="page-break-after:always"><div style="min-height:69pt;width:100%"><div><font style="color:#2d97eb;font-family:'Arial',sans-serif;font-size:25pt;font-weight:700;line-height:7%">Biogen</font><font style="color:#90cff2;font-family:'Arial',sans-serif;font-size:25pt;font-weight:700;line-height:7%">.</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:18.05pt;padding-right:11.4pt;text-indent:0.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:143%">Each year, typically in February, you will be eligible to receive an annual Long Term Incentive (LTl) award which will be based on the planning range in effect at the time of grant. A current planning reference value for your role is $1,500,000 and our current annual performance-based LTI vehicles have a maximum payout of 200% of the target grant. Actual LTl award values, amounts, delivery vehicles and payout percentages and metrics will be determined by the Compensation and Management Development Committee of the Board of Directors (CMDC) in its sole discretion based upon performance, future contribution expectations and other considerations. Your first eligible annual grant will be February 2019.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:17.7pt;padding-right:11.4pt;text-indent:0.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:140%">Employee Benefits&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:140%">Biogen offers a robust and highly competitive employee benefits program. As an employee, you will be able to choose from a menu of options through our flexible benefits program. These benefits include a 401(k) savings plan&#59; group health care, including medical, dental, prescription drug and vision coverage&#59; life, dependent life and disability insurance&#59; as well as flexible spending accounts for eligible medical and dependent care expenses.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.15pt;padding-right:14.35pt;text-indent:0.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:140%">You are also entitled to up to 20 vacation days (160 hours) per year (pro-rated if you work part-time). Additional benefit offerings include an Employee Stock Purchase Plan (ESPP) and work&#47;life benefits such as a concierge service and access to subsidized back-up dependent care. Please visit Biogen's Benefits website using the below link and login information to familiarize yourself with Biogen's complete benefit plan offerings.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:63pt;padding-right:148.55pt;text-indent:0.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:130%">URL&#58; &#91;website&#93;</font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Username&#58; &#91;username&#93;</font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Password&#58; &#91;password&#93;</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:17.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional Executive Benefits</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:34.5pt;padding-right:11.4pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:140%">Supplemental Savings Plan&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:140%">You will be entitled to participate in Biogen's Supplemental Savings Plan (SSP). This plan has two features . The first allows you to make pre-tax deferrals of up to 80% of your base salary and up to 100% of your Annual Bonus payment and certain other eligible incentive payments. Your contributions to this plan may be limited by your contributions towards other plans (e.g., 401(k), ESPP, medical, etc.). The second feature is a Company contribution of 6% of certain eligible compensation such as salary and annual bonus that is above the IRS maximum compensation limit of the 401(k) plan. You will be provided with SSP enrollment information upon your employment with the Company.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:34.25pt;padding-right:13.75pt;text-indent:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:141%">Life Insurance&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:141%">You will be provided life insurance coverage equal to three times your annual base salary, subject to meeting the medical standards stated in the group term life insurance policy for U.S. employees. Biogen pays the premium for this insurance. The IRS requires employers to impute the value of company-paid life insurance for coverage over $50,000. This imputed income will be displayed on your pay stub.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:34.35pt;padding-right:13.75pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:140%">Severance&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:140%">You will be entitled to severance benefits in accordance with the Severance Plan for U.S. Executive Vice Presidents effective January 1, 2014 as such plan may be amended from time to time.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:34.25pt;text-indent:-0.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:143%">Tax </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:143%">&#38; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:143%">Financial Planning and Executive Physicals&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:143%">You are eligible for annual reimbursement of expenses for qualified services such as federal and state income tax planning and&#47;or preparation, financial and estate planning services, and the purchase of tax and&#47;or financial planning tools.</font></div><div style="margin-top:6pt;padding-left:34pt;padding-right:10.4pt;text-indent:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:137%">Additionally, the Company will reimburse you for the expenses of an annual comprehensive physical exam when coordinated by the Executive Health Services team at Mass. General Hospital (MGH). The combined annual reimbursement you are eligible to receive is $7,500 per calendar year (January 1 - December 31), subject to the guidelines of the Tax </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:137%">&#38; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:137%">Financial Planning and Executive Physical Reimbursement Program. The details of these benefits are available upon your employment with the Company.</font></div><div style="height:56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#64afe8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">225 B11mey Street, Cambridge</font><font style="color:#8eaed1;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">, </font><font style="color:#64afe8;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:7%">MA </font><font style="color:#64afe8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">02142 &#8226; Phone 781-464-2000 &#8226; www.biogen</font><font style="color:#90cff2;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">.</font><font style="color:#64afe8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">com</font></div><div><font><br></font></div></div></div><div id="i53e37a60cb32430a99134f6cd91e422e_7"></div><hr style="page-break-after:always"><div style="min-height:71pt;width:100%"><div><font style="color:#2d97ed;font-family:'Arial',sans-serif;font-size:25pt;font-weight:700;line-height:7%">Biogen</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:20.2pt;padding-right:3.05pt;text-indent:0.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Stock Trading Plan&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Upon employment with the Company , you will become subject to Biogen's Global Insider Trading Policy, a copy of which will be provided to you. The Biogen Global Insider Trading Policy sets forth guidelines designed to promote compliance with applicable federal and state securities laws that prohibit persons who are aware of material nonpublic information about the company from trading in securities of the company or providing material nonpublic information to other persons who may trade on the basis of that information. Upon your employment, you will be assigned, based on your job, to a specific trading group that will determine your obligations and restrictions under the policy, and you will be required to complete training on the policy.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:20pt;padding-right:7.8pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Share Ownership Requirement&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">A key objective of our long-term incentive plans is to ensure strong alignment between the interests of our senior executives and those of our stockholders. It is expected that through our annual long-term incentive grants, you will accumulate and retain Biogen shares in an amount equivalent to 3x salary through the first 5 years of employment.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:20.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">You are required to satisfy the following contingencies prior to employment at Biogen.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:54.95pt;padding-right:11.7pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%;padding-left:14.15pt">Pre-employment screening&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Employment at Biogen is contingent upon your successful completion and passing of both a background check and drug screen. Biogen's background check includes verificat ion of employment history, educational and professional licenses, degrees and&#47;or credentials , a criminal records check, a Social Security Number search and verification of any other professional qualifications that your position responsibilities at Biogen may warrant. Completion of your online Application for Employment authorizes Biogen to conduct these background checks. If you have any questions about the background check, please contact </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%;text-decoration:underline">HRConnect&#64;biogen.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:54.8pt;padding-right:5.85pt;text-align:justify;text-indent:-17.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:123%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:123%;padding-left:14.05pt">Signed Employee Proprietary Information and Inventions and Non-Compete Agreement (&#34;PII Agreement&#34;)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Prior to and as a condition of employment with Biogen you will be required to sign Biogen's PII Agreement. This is required to, among other things, protect Biogen's substantial investment in creating and maintaining its confidential and proprietary information, and to maintain goodwill with our customers , vendors and other business partners. You will receive an email shortly that contains a link to this agreement for your review and electronic signature .</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:54.7pt;padding-right:17.35pt;text-indent:-17.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:132%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:132%;padding-left:14.45pt">Authorization to Work in the United States&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:132%">Please note that Biogen is an E-Verify employer. The Federal government requires you to provide proper identi fication verifying your eligibility to work in the United States.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:54.65pt;padding-right:40.25pt;text-indent:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:132%">If you will be working at one of our office locations&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:132%">Please complete Section 1 of the Employment Eligibility Verification Form 1-9, electronically as specified in your emails from</font></div><div style="padding-left:54.55pt;padding-right:14.35pt;text-indent:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:132%">Guardian. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:132%;text-decoration:underline">On your first day of employment,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:132%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:132%">please bring original and unexpired documents and a scanned copy of your documents to complete the 1-9 process. A list of acceptable documents can be found on the last page of the Form 1-9 packet.</font></div><div style="padding-right:14.35pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:54pt;text-indent:0.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:141%">If you are a field employee&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:141%">You will receive a separate email from HR Operations providing you with instructions to complete your 1-9 form. Please complete per instructions with in 3 days of receipt.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#6eb6eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">225 Binney St</font><font style="color:#4da5e8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">r</font><font style="color:#6eb6eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">ee</font><font style="color:#4da5e8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">t</font><font style="color:#8cc3e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">, </font><font style="color:#6eb6eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">Cambridg </font><font style="color:#8cc3e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">e</font><font style="color:#6eb6eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">, MA 02</font><font style="color:#bac8e4;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">&#183;</font><font style="color:#4da5e8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">1 </font><font style="color:#6eb6eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">4</font><font style="color:#8cc3e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">2 </font><font style="color:#4da5e8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">&#8226; </font><font style="color:#6eb6eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">Phone 781-464 </font><font style="color:#bac8e4;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">-</font><font style="color:#6eb6eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">2000 &#8226; www.biogen </font><font style="color:#8cc3e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">.</font><font style="color:#6eb6eb;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">corn</font></div><div><font><br></font></div></div></div><div id="i53e37a60cb32430a99134f6cd91e422e_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#2b97ed;font-family:'Arial',sans-serif;font-size:25pt;font-weight:700;line-height:7%">Biogen</font><font style="color:#8ecce8;font-family:'Arial',sans-serif;font-size:25pt;font-weight:700;line-height:7%">.</font></div><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chirti, we are excited at the prospect of your joining Biogen. To confirm your acceptance of this offer of employment, please sign and return this letter by October 15, 2017 and keep the other copy for your records. We would anticipate your first day of employment to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">be November 1, 2017</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. If you have any questions , please feel free to contact me.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:22.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Best Regards,</font></div><div><font><br></font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ginger Gregory&#160;&#160;&#160;&#160;</font></div><div style="padding-left:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Ginger Gregory&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:21.35pt;padding-right:336.85pt;text-indent:0.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:250%">EVP, Human Resources </font></div><div style="padding-left:22.5pt;padding-right:336.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cc&#58; Michel Vounatsos</font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:21.4pt;padding-right:3.05pt;text-indent:-0.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">I </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%">accept this offer of employment and acknowledge the contingencies of employment described above, including the at-will nature of my employment.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:39.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACCEPTED&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Chirfi Guindo&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Signature</font></div><div><font><br></font></div><div style="height:55pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#74b8e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">225 Binney Street. Cambridge, </font><font style="color:#5dace8;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:7%">MA </font><font style="color:#74b8e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">02142 </font><font style="color:#5dace8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">&#8226; </font><font style="color:#74b8e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">Phone 781 </font><font style="color:#8ecce8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">-</font><font style="color:#74b8e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">464</font><font style="color:#a8b8d8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">-</font><font style="color:#74b8e9;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">2000 </font><font style="color:#5dace8;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:7%">&#8226; www.biogen.com</font></div><div><font><br></font></div></div></div><div id="i53e37a60cb32430a99134f6cd91e422e_13"></div><hr style="page-break-after:always"><div style="min-height:61pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.4pt;padding-left:13.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Guindo, Chirfi</font></div><div style="margin-top:0.45pt;padding-left:13.35pt;padding-right:292.6pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">US Domestic Relocation Addendum </font></div><div style="padding-left:13.5pt;padding-right:292.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 10, 2017</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:158.27pt;padding-right:158.27pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Supplemental  Relocation Benefits</font></div><div><font><br></font></div><div style="padding-left:13.5pt;padding-right:18.15pt;text-align:justify;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">In addition to the benefits provided to you pursuant to the U.S. Domestic Relocation Policy, Executive Level, (the &#34;Policy&#34;), Biogen will supplement those benefits as described, and in accordance with, the terms below (&#34;Supplemental Relocation Benefits&#34;) .</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:13.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Relocation Terms</font></div><div style="margin-top:0.85pt;padding-left:13pt;padding-right:18.5pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Please note that these Supplemental Relocation Benefits are contingent on you moving to the Boston, MA area within one (2) years from the date you start your new position (&#34;Effective Date of Transfer&#34;), and by signing and returning the Biogen Relocation Repayment Agreement. The standard relocation timeline </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:123%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">being extended by one (1) year to accommodate your son's completion of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:123%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">high school requirements.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:13.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Expatriate Housing</font></div><div style="margin-top:0.6pt;padding-left:13.1pt;padding-right:18.6pt;text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">In addition to the Temporary &#47;Duplicate Housing and Return Trip provisions as indicated in the Policy, the Company will cover the costs of your expatriate housing in Canada, inclusive of rent of 6,500 CAD per month and utilities up to 250 CAD per month if utilities are not included in your rent. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:124%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">coverage will be provided for up to ten (10) months. All expenses will be paid or reimbursed through Biogen's Mobility Program.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:13.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Dependent Schooling</font></div><div style="margin-top:0.65pt;padding-left:12.85pt;padding-right:18.65pt;text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">The Company will cover the costs of your son's tuition and book fees through the end of the 2017&#47;2018 Canadian school year. All expenses will be paid directly or reimbursed through Biogen's Mobility Program.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:13.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Final Move location</font></div><div style="margin-top:0.85pt;padding-left:12.75pt;padding-right:19.05pt;text-align:justify;text-indent:0.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:124%">The Company will provide benefits to support your final move from the Montreal, Canada area in addition to the home sale benefits from your primary residence in New Jersey. These final move benefits include, lease cancellation support, final trip expenses (flights or mileage reimbursement) and house hold goods shipment.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:13.05pt;padding-right:18.75pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">Except for the Supplemental Relocation Benefits described above, all other terms of the Policy apply, and the Biogen Relocation Repayment Agreement governs the terms of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:123%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">relocation benefits provided to you. Furthermore, nothing in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:123%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:123%">document alters the terms and conditions of your offer .</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:13.15pt;padding-right:15.3pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:247%">My signature below acknowledges that I understand and agree to the terms of this agreement. </font></div><div style="padding-left:13.5pt;padding-right:15.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acknowledged and Agreed&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-top:0.4pt;padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Chirfi Guindo&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chirfi Guindo</font></div><div><font><br></font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Oct. 14, 2017&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date</font></div><div style="padding-left:12.75pt"><font style="color:#604d52;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:108%">&#160;&#160;&#160;&#160;</font><font style="color:#8c6e8c;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:108%">'</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>4
<FILENAME>biib-20201231xex21.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6ceafa666b2f450599ab9f91c270caa1_32"></div><div style="min-height:31.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 21</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following is a list of subsidiaries of Biogen Inc. as of December 31, 2020, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.</font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUBSIDIARY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:115%">STATE OR OTHER JURISDICTION OF<br>INCORPORATION OR ORGANIZATION</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Foundation Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen MA Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Realty Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Realty Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen U.S. Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen U.S. Limited Partnership</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen (RTP) Realty LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Chesapeake LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Holding I LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Holding II LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Manufacturing Holding LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen New Ventures Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen SRO Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen U.S. Pacific LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen U.S. West Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Conforma Therapeutics Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stromedix, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nightstar, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen (Argentina) SRL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Australia PTY Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Austria GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Belgium N.V.&#47;S.A.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen International Holding Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen (Bermuda) Technologies Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Brasil Produtos Farmaceuticos LTDA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Canada Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Chile SpA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chile</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Biotechnology (Shanghai) Co., Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BIIB Colombia S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Colombia<br></font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Pharma d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Croatia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen (Czech Republic) s.r.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen (Denmark) A&#47;S</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Estonia OU</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estonia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Finland OY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen France S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Hong Kong Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hong Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Hungary KFT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hungary</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Idec Biotech India Pvt. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Idec (Ireland) Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ireland</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:31.5pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nightstar Europa Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Italia S.R.L.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Japan Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Korea LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Latvia SIA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Latvia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Lithuania UAB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lithuania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Luxembourg Holding S.a.r.l.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Mexico Servicios S. de R.L. de C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen NZ Biopharma Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Norway AS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Poland Sp. z.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Portugal Sociedade Farmaceutica, Unipessoal Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Slovakia s.r.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Slovak Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Pharma, farmacevtska in biotehnoloska druzba, d.o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Slovenia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Spain, S.L.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Sweden AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen International GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen International Neuroscience GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Management Services GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Swiss Investments GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Swiss Manufacturing GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Switzerland AG</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Switzerland Holdings GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Eidetica Biopharma GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Taiwan Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taiwan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Idec Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Idec Research Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convergence Pharmaceuticals Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convergence Pharmaceuticals Holdings Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Old Convergence Pharmaceuticals Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Silver Acquisition Co. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nightstar Therapeutics Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NightstaRx Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tungsten Bidco Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biogen Idec Uruguay SA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Uruguay</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>biib-20201231xex23.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i23761550e2bb4c89a234dd2044d1376b_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23</font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-237819) and Form S-8 (Nos. 333-218799, 333-205254, 333-128339, 333-152456, 333-140817 and 333-170133) of Biogen Inc. of our report</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">dated February 3, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div style="margin-top:60pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP </font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 3, 2021</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>biib-20201231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i239a431da10643a3a76a4bf6895c7135_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michel Vounatsos, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this annual report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 3, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>biib-20201231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i21a939a019544cbeaa7f9bb7dd965e9b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this annual report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 3, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>biib-20201231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2130b329f38b474089af2d627a11e15e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report on Form 10-K for the year ended December 31, 2020 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 3, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 3, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>biib-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:93645b15-c187-4b47-82bf-4dd611d6b978,g:f6c0263a-8ffa-4fd3-a952-6de1d776d19e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>000010001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofIncome">
        <link:definition>100010002 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>100020003 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome_1" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome_1">
        <link:definition>100020003 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets">
        <link:definition>100030004 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040005 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>100050006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofEquity">
        <link:definition>100060007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>210011001 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>220022001 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>230033001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>240044001 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails">
        <link:definition>240054002 - Disclosure - Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>210061002 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails">
        <link:definition>240074003 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Divestitures" roleURI="http://www.biogenidec.com/role/Divestitures">
        <link:definition>210081003 - Disclosure - Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DivestituresDetails" roleURI="http://www.biogenidec.com/role/DivestituresDetails">
        <link:definition>240094004 - Disclosure - Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>210101004 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>230113002 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails">
        <link:definition>240124005 - Disclosure - Revenues - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>240134006 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails">
        <link:definition>240144007 - Disclosure - Revenues - Reserves for Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTotalReservesforDiscountsandAllowancesDetails" roleURI="http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails">
        <link:definition>240154008 - Disclosure - Revenues - Total Reserves for Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>240164009 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>240174010 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>210181005 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>230193003 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>240204011 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails">
        <link:definition>240214012 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>210221006 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>230233004 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails">
        <link:definition>240244013 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>240254014 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails">
        <link:definition>240264015 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillChangesinGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails">
        <link:definition>240274016 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>210281007 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>230293005 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails">
        <link:definition>240304017 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails">
        <link:definition>240314018 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>240324019 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails">
        <link:definition>240334020 - Disclosure - Fair Value Measurements - Gains and Losses on Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails">
        <link:definition>240344021 - Disclosure - Fair Value Measurements - Summary of Fair and Carrying Value of Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails">
        <link:definition>240354022 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>210361008 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>230373006 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails">
        <link:definition>240384023 - Disclosure - Financial Instruments - Summary of Financial Assets with Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofMarketableSecuritiesDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails">
        <link:definition>240394024 - Disclosure - Financial Instruments - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofContractualMaturitiesDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails">
        <link:definition>240404025 - Disclosure - Financial Instruments - Summary of Contractual Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails">
        <link:definition>240414026 - Disclosure - Financial Instruments - Proceeds from Marketable Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>240424027 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>210431009 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>230443007 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsNarrativeDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails">
        <link:definition>240454028 - Disclosure - Derivative Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails">
        <link:definition>240464029 - Disclosure - Derivative Instruments - Foreign Currency Forward Contracts Entered into Hedge Forecasted Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails">
        <link:definition>240474030 - Disclosure - Derivative Instruments - Summary of the Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails">
        <link:definition>240484031 - Disclosure - Derivative Instruments - Summary of the Effect of Derivatives Designated as Net Investment Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails">
        <link:definition>240494032 - Disclosure - Derivative Instruments - Summary of the Fair Value for our Outstanding Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>210501010 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentTables">
        <link:definition>230513008 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>240524033 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>240534034 - Disclosure - Property, Plant and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biogenidec.com/role/Leases">
        <link:definition>210541011 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.biogenidec.com/role/LeasesTables">
        <link:definition>230553009 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.biogenidec.com/role/LeasesNarrativeDetails">
        <link:definition>240564035 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeasesDetails" roleURI="http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails">
        <link:definition>240574036 - Disclosure - Leases - Schedule of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseCostsDetails" roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails">
        <link:definition>240584037 - Disclosure - Leases - Operating Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseLiabilityMaturityDetails" roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails">
        <link:definition>240594038 - Disclosure - Leases - Operating Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseLiabilityMaturityDetails_1" roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1">
        <link:definition>240594038 - Disclosure - Leases - Operating Lease Liability Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails" roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails">
        <link:definition>240604039 - Disclosure - Leases - Operating Lease Weighted Average Remaining Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails" roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails">
        <link:definition>240614040 - Disclosure - Leases - Operating Lease Supplemental Cash Flow Disclosure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>210621012 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessTables" roleURI="http://www.biogenidec.com/role/IndebtednessTables">
        <link:definition>230633010 - Disclosure - Indebtedness (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessSummaryofIndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails">
        <link:definition>240644041 - Disclosure - Indebtedness - Summary of Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessNarrativeDetails" roleURI="http://www.biogenidec.com/role/IndebtednessNarrativeDetails">
        <link:definition>240654042 - Disclosure - Indebtedness - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessTotalDebtMaturitiesDetails" roleURI="http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails">
        <link:definition>240664043 - Disclosure - Indebtedness - Total Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>210671013 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>230683011 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.biogenidec.com/role/EquityNarrativeDetails">
        <link:definition>240694044 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofCommonStockDetails" roleURI="http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails">
        <link:definition>240704045 - Disclosure - Equity - Summary of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>240714046 - Disclosure - Equity - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>240724047 - Disclosure - Equity - Reclassification out of Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>210731014 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>230743012 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareBasicandDilutedEarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails">
        <link:definition>240754048 - Disclosure - Earnings per Share - Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareNarrativeDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareNarrativeDetails">
        <link:definition>240764049 - Disclosure - Earnings per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>210771015 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>230783013 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails">
        <link:definition>240794050 - Disclosure - Share-Based Payments - Share-based Compensation Expense Included in Consolidation Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails">
        <link:definition>240804051 - Disclosure - Share-Based Payments - Summary of Share-based Compensation Expense Associated with Each Share-based Compensating Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsNarrativeDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails">
        <link:definition>240814052 - Disclosure - Share-Based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsStockOptionActivityDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails">
        <link:definition>240824053 - Disclosure - Share-Based Payments - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails">
        <link:definition>240834054 - Disclosure - Share-Based Payments - Tax Benefit and Cash Received from Stock Option Exercises (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsMarketStockUnitsActivityDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails">
        <link:definition>240844055 - Disclosure - Share-Based Payments - Market Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails">
        <link:definition>240854056 - Disclosure - Share-Based Payments - Assumptions Used in Valuation of Market Based Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails">
        <link:definition>240864057 - Disclosure - Share-Based Payments - Cash Settled Performance Shares Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsPerformanceUnitsActivityDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails">
        <link:definition>240874058 - Disclosure - Share-Based Payments - Performance Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails">
        <link:definition>240884059 - Disclosure - Share-Based Payments - Performance Stock Units Settled in Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails">
        <link:definition>240894060 - Disclosure - Share-Based Payments - Performance Stock Units Settled in Cash Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails">
        <link:definition>240904061 - Disclosure - Share-Based Payments - Time-Vested Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails">
        <link:definition>240914062 - Disclosure - Share-Based Payments - Shares Issued Under Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>210921016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>230933014 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails">
        <link:definition>240944063 - Disclosure - Income Taxes - Income Before Income Tax Provision and the Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>240954064 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>240964065 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxRateDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails">
        <link:definition>240974066 - Disclosure - Income Taxes - Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails">
        <link:definition>240984067 - Disclosure - Income Taxes - Accounting for Uncertainty in Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>210991017 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>231003015 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails">
        <link:definition>241014068 - Disclosure - Other Consolidated Financial Statement Detail - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailNarrativeDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails">
        <link:definition>241024069 - Disclosure - Other Consolidated Financial Statement Detail - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails">
        <link:definition>241034070 - Disclosure - Other Consolidated Financial Statement Detail - Other Income (Expense), Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails">
        <link:definition>241044071 - Disclosure - Other Consolidated Financial Statement Detail - Gain (Loss) on Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails">
        <link:definition>241054072 - Disclosure - Other Consolidated Financial Statement Detail - Accrued Expenses and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>211061018 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>231073016 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOCREVUSDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails">
        <link:definition>241084073 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails">
        <link:definition>241094074 - Disclosure - Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsProfitSharingDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails">
        <link:definition>241104075 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails">
        <link:definition>241114076 - Disclosure - Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>241124077 - Disclosure - Collaborative and Other Relationships - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsIonisDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails">
        <link:definition>241134078 - Disclosure - Collaborative and Other Relationships - Ionis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEisaiDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails">
        <link:definition>241144079 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails">
        <link:definition>241154080 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails">
        <link:definition>241164081 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Aducanumab Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails">
        <link:definition>241174082 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsAlkermesDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails">
        <link:definition>241184083 - Disclosure - Collaborative and Other Relationships - Alkermes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsBristolMyersSquibbDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails">
        <link:definition>241194084 - Disclosure - Collaborative and Other Relationships - Bristol Myers Squibb (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsAcordaDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails">
        <link:definition>241204085 - Disclosure - Collaborative and Other Relationships - Acorda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOtherArrangementsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails">
        <link:definition>241214086 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSamsungBioepisDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails">
        <link:definition>241224087 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>211231019 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>241244088 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>211251020 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationNarrativeDetails" roleURI="http://www.biogenidec.com/role/LitigationNarrativeDetails">
        <link:definition>241264089 - Disclosure - Litigation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.biogenidec.com/role/CommitmentsandContingencies">
        <link:definition>211271021 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>241284090 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Guarantees" roleURI="http://www.biogenidec.com/role/Guarantees">
        <link:definition>211291022 - Disclosure - Guarantees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans">
        <link:definition>211301023 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansNarrativeDetails" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails">
        <link:definition>241314091 - Disclosure - Employee Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.biogenidec.com/role/SegmentInformation">
        <link:definition>211321024 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.biogenidec.com/role/SegmentInformationTables">
        <link:definition>231333017 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails">
        <link:definition>241344092 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationGeographicInformationDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails">
        <link:definition>241354093 - Disclosure - Segment Information - Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>211361025 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>231373018 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>241384094 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" abstract="false" name="AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ZINBRYTAMember" abstract="true" name="ZINBRYTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_TGNMember" abstract="true" name="TGNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MajorDistributorDomain" abstract="true" name="MajorDistributorDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageOfDevelopmentCostsIncurred" abstract="false" name="PercentageOfDevelopmentCostsIncurred" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" abstract="false" name="DeferredTaxLiabilitiesDepreciationAmortizationOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB111Member" abstract="true" name="BIIB111Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredTaxAssetsValueReductionInValue" abstract="false" name="DeferredTaxAssetsValueReductionInValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ForeignearningstypeDomain" abstract="true" name="ForeignearningstypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DirectorsPlanMember" abstract="true" name="DirectorsPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InventoryrawmaterialssoldtoFUJIFILM" abstract="false" name="InventoryrawmaterialssoldtoFUJIFILM" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CumulativeSalesLevel" abstract="false" name="CumulativeSalesLevel" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" abstract="false" name="IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredtaxliabilityMember" abstract="true" name="DeferredtaxliabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OtherRelationshipsMember" abstract="true" name="OtherRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryOfCommonStockTableTextBlock" abstract="false" name="SummaryOfCommonStockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_StromedixMember" abstract="true" name="StromedixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Totaldeferredchargesandprepaidtaxes" abstract="false" name="Totaldeferredchargesandprepaidtaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="biib_NightstarMember" abstract="true" name="NightstarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SeriesXPreferredStockMember" abstract="false" name="SeriesXPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" abstract="false" name="NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Noncontrollinginterestincreasedecreaseother" abstract="false" name="Noncontrollinginterestincreasedecreaseother" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Reductionindeferredtaxliabilityundistributedforeignearnings" abstract="false" name="Reductionindeferredtaxliabilityundistributedforeignearnings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" abstract="false" name="PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FairValueMeasurementInputs" abstract="false" name="FairValueMeasurementInputs" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ComputerSoftwareAndHardware" abstract="false" name="ComputerSoftwareAndHardware" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DivestituresAbstract" abstract="true" name="DivestituresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_Purchaseofcommonstock" abstract="false" name="Purchaseofcommonstock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Inventorynetcurrentandnoncurrent" abstract="false" name="Inventorynetcurrentandnoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OthercorporaterevenuesMember" abstract="true" name="OthercorporaterevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CumulativeSalesLevelAxis" abstract="true" name="CumulativeSalesLevelAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" abstract="false" name="GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SangamoTherapeuticsIncAgreementMember" abstract="true" name="SangamoTherapeuticsIncAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" abstract="false" name="PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" abstract="true" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_VUMERITYMember" abstract="true" name="VUMERITYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OCREVUSMember" abstract="true" name="OCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DenaliAndSangamoMember" abstract="true" name="DenaliAndSangamoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A2015ESPPMember" abstract="true" name="A2015ESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CommercialMilestonesMember" abstract="true" name="CommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" abstract="false" name="TimeVestedRestrictedStockUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_A2015SeniorNotesMember" abstract="true" name="A2015SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" abstract="false" name="WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A225SeniorNotesDueMay12030Member" abstract="true" name="A225SeniorNotesDueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashTableTextBlock" abstract="false" name="PerformanceStockUnitsSettledinCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_A2020SeniorNotesMember" abstract="true" name="A2020SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ClinicalAssetsAcquired" abstract="false" name="ClinicalAssetsAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" abstract="false" name="InvestmentsByThirdPartyInJointVentureAsPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockTableTextBlock" abstract="false" name="PerformanceStockUnitsSettledinStockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_SolothurnMember" abstract="true" name="SolothurnMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" abstract="false" name="GlobalLicensingCollaborationAgreementPurchasePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_A2017OmnibusEquityPlanMember" abstract="true" name="A2017OmnibusEquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareRepurchaseProgram2Member" abstract="true" name="ShareRepurchaseProgram2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpectedPaymentTimelineofMilestoneDomain" abstract="true" name="ExpectedPaymentTimelineofMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" abstract="false" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_PercentageOfMinimumInvestmentReturn" abstract="false" name="PercentageOfMinimumInvestmentReturn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SOD1Member" abstract="true" name="SOD1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MajorDistributorAxis" abstract="true" name="MajorDistributorAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EachAdditionalOneBillionUpToTwentyBillionMember" abstract="true" name="EachAdditionalOneBillionUpToTwentyBillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_RituxanMember" abstract="true" name="RituxanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NumberOfSharesOfCommonStockForIssuance" abstract="false" name="NumberOfSharesOfCommonStockForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesValueReductionInValue" abstract="false" name="DeferredTaxLiabilitiesValueReductionInValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" abstract="false" name="DeferredTaxLiabilitiesTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GAZYVAMember" abstract="true" name="GAZYVAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredtaxliabilitiesGILTItaxcalculation" abstract="false" name="DeferredtaxliabilitiesGILTItaxcalculation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_TwelvemonthsMember" abstract="true" name="TwelvemonthsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CumulativeSalesLevelDomain" abstract="true" name="CumulativeSalesLevelDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ExpectedPaymentTimelineofMilestoneAxis" abstract="true" name="ExpectedPaymentTimelineofMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_CollaborationProfitSharing" abstract="false" name="CollaborationProfitSharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" abstract="false" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_RoyaltyCostofSalesPolicyTextBlock" abstract="false" name="RoyaltyCostofSalesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ForeignearningstypeAxis" abstract="true" name="ForeignearningstypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_BIIB112Member" abstract="true" name="BIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementAmountSharesPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" abstract="false" name="SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TechnologicalAndRegulatorySuccessProbability" abstract="false" name="TechnologicalAndRegulatorySuccessProbability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Upfrontpaymentforcollaborationagreement" abstract="false" name="Upfrontpaymentforcollaborationagreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" abstract="false" name="ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentPaymentThreshold" abstract="false" name="FutureContingentPaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" abstract="true" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Premiumonpurchaseofcommonstock" abstract="false" name="Premiumonpurchaseofcommonstock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_AliveGenMember" abstract="true" name="AliveGenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UndesignatedPreferredStockMember" abstract="false" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB118Member" abstract="true" name="BIIB118Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BiogenIdecInternationalNeuroscienceMember" abstract="false" name="BiogenIdecInternationalNeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" abstract="false" name="ExpectedLicenseFeeAndRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" abstract="false" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_CashSettledPerformanceSharesMember" abstract="true" name="CashSettledPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CoPromotionProfitSharingFormulaAbstract" abstract="true" name="CoPromotionProfitSharingFormulaAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_DeferredTaxAssetLiabilityTypeAxis" abstract="true" name="DeferredTaxAssetLiabilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_WorkinprocessMember" abstract="true" name="WorkinprocessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_TwentybillionMember" abstract="true" name="TwentybillionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Totalpaymenttoentercollaborationagreement" abstract="false" name="Totalpaymenttoentercollaborationagreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DenmarkManufacturingOperationsMember" abstract="true" name="DenmarkManufacturingOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AducanumabMember" abstract="true" name="AducanumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" abstract="false" name="GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BioverativMember" abstract="true" name="BioverativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" abstract="false" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_LongtermoperatingleaseliabilitiesMember" abstract="true" name="LongtermoperatingleaseliabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PostacquisitionequitycompensationMember" abstract="true" name="PostacquisitionequitycompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AverageStockPriceOnGrantDateInDollarsMinimum" abstract="false" name="AverageStockPriceOnGrantDateInDollarsMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" abstract="false" name="ScheduleOfMarketStockUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_EquityMethodInvestmentsExpectedProfitShare" abstract="false" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" abstract="false" name="FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_RoyaltiesPayablePeriodPostFDAApproval" abstract="false" name="RoyaltiesPayablePeriodPostFDAApproval" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MinimumQualifyingAgeForEmployeeBenefitPlan" abstract="false" name="MinimumQualifyingAgeForEmployeeBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" abstract="false" name="OperatingleasesupplementalcashflowdisclosureTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_A315SeniorNotesDueMay12050Member" abstract="true" name="A315SeniorNotesDueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SangamoCommonStockMember" abstract="true" name="SangamoCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" abstract="false" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_JointVentureOwnerShipPercentageByThirdParty" abstract="false" name="JointVentureOwnerShipPercentageByThirdParty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetDomain" abstract="true" name="ResearchanddevelopmentassetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" abstract="false" name="MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_DividendYieldPercentage" abstract="false" name="DividendYieldPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NumberOfEqualAnnualIncrements" abstract="false" name="NumberOfEqualAnnualIncrements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareRepurchaseProgram5Member" abstract="true" name="ShareRepurchaseProgram5Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_InvestmentInCommonStockSharesPurchased" abstract="false" name="InvestmentInCommonStockSharesPurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_AmortizationandImpairmentofAcquiredIntangibleAssets" abstract="false" name="AmortizationandImpairmentofAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" abstract="false" name="ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_PerformanceUnitsMember" abstract="true" name="PerformanceUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ConvergencePharmaceuticalsMember" abstract="true" name="ConvergencePharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_RatioOfNumberOfSharesReservedUnderPlan" abstract="false" name="RatioOfNumberOfSharesReservedUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" abstract="false" name="MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_KaryopharmMember" abstract="true" name="KaryopharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_UCBPharmaSAMember" abstract="true" name="UCBPharmaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" abstract="false" name="Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GlobalLicensingCollaborationAgreementSharesPurchased" abstract="false" name="GlobalLicensingCollaborationAgreementSharesPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" abstract="false" name="FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_U.S.2017TaxActMember" abstract="true" name="U.S.2017TaxActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareRepurchaseProgram3Member" abstract="true" name="ShareRepurchaseProgram3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OperatingleaseassetsMember" abstract="true" name="OperatingleaseassetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Termofcollaborationagreement" abstract="false" name="Termofcollaborationagreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_AcordaMember" abstract="false" name="AcordaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DueFromUnconsolidatedJointBusiness" abstract="false" name="DueFromUnconsolidatedJointBusiness" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FUMADERMMember" abstract="true" name="FUMADERMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_LesseeLeaseTableTableTextBlock" abstract="false" name="LesseeLeaseTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" abstract="false" name="AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" abstract="false" name="ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_DeferredTaxAssetLiabilityTypeDomain" abstract="true" name="DeferredTaxAssetLiabilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" abstract="false" name="RevenuesInPercentageFromAntiCD20TherapeuticPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" abstract="false" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Futurepercentageofcopromotionoperatingprofits" abstract="false" name="Futurepercentageofcopromotionoperatingprofits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PerformanceunitsactivityTableTextBlock" abstract="false" name="PerformanceunitsactivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_FumapharmAgMember" abstract="true" name="FumapharmAgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_BIIB054Member" abstract="true" name="BIIB054Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" abstract="false" name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" abstract="false" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_PretaxProfitSharingFormulaTableTextBlock" abstract="false" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_AlkermesMember" abstract="true" name="AlkermesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Biogenshareofcopromotionprofitsorlosses" abstract="false" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DisputedClaimsRelatingToConstructionCosts" abstract="false" name="DisputedClaimsRelatingToConstructionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_Reductioninroyaltyrate" abstract="false" name="Reductioninroyaltyrate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ContractManufacturingCustomerMember" abstract="true" name="ContractManufacturingCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareRepurchaseProgram1Member" abstract="true" name="ShareRepurchaseProgram1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NewAntiCd20Member" abstract="true" name="NewAntiCd20Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" abstract="false" name="FairValueIndefiniteLivedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_Investmentincommonstockvalue" abstract="false" name="Investmentincommonstockvalue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_Reductioninroyaltyratepayableoncommercialsales" abstract="false" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_PurchaseCommitmentReductionOfAmountCommitted" abstract="false" name="PurchaseCommitmentReductionOfAmountCommitted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_PeriodOfCollaborationAgreement" abstract="false" name="PeriodOfCollaborationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PaymentTermsOfAccountsReceivable" abstract="false" name="PaymentTermsOfAccountsReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_SubleaseMember" abstract="true" name="SubleaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ForeignSalesRequiredToTriggerMilestone" abstract="false" name="ForeignSalesRequiredToTriggerMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" abstract="true" name="SegmentGeographicalGroupsOfCountriesGroupOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageParValueOfSeniorNotes" abstract="false" name="PercentageParValueOfSeniorNotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" abstract="false" name="NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_IPerianMember" abstract="true" name="IPerianMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_IonisPharmaceuticalsMember" abstract="true" name="IonisPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_SalesTriggerGrossSalesThreshold" abstract="false" name="SalesTriggerGrossSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" abstract="false" name="Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PercentageOfRoyaltiesAsPerCollaboration" abstract="false" name="PercentageOfRoyaltiesAsPerCollaboration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherForeignEarningsMember" abstract="true" name="OtherForeignEarningsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_ShareRepurchaseProgram4Member" abstract="true" name="ShareRepurchaseProgram4Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" abstract="false" name="OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" abstract="false" name="EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_LicenseFee" abstract="false" name="LicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" abstract="false" name="NumberOfDaysForCalculationOfAverageClosingStockPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_ForeignearningsintheformofcashandcashequivalentsMember" abstract="true" name="ForeignearningsintheformofcashandcashequivalentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_AverageStockPriceOnGrantDateInDollarsMaximum" abstract="false" name="AverageStockPriceOnGrantDateInDollarsMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TransitionTollTaxRepatriationTaxRate" abstract="false" name="TransitionTollTaxRepatriationTaxRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="biib_DevelopmentMilestonesMember" abstract="true" name="DevelopmentMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>biib-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:93645b15-c187-4b47-82bf-4dd611d6b978,g:f6c0263a-8ffa-4fd3-a952-6de1d776d19e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_248a82de-07fa-42b3-b7bb-ddaffdc67e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a0dcfa4a-8888-45d0-83e5-08a646158d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_248a82de-07fa-42b3-b7bb-ddaffdc67e8c" xlink:to="loc_us-gaap_Revenues_a0dcfa4a-8888-45d0-83e5-08a646158d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9fe216db-49b6-449c-aec1-9a2287a124dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_248a82de-07fa-42b3-b7bb-ddaffdc67e8c" xlink:to="loc_us-gaap_CostsAndExpenses_9fe216db-49b6-449c-aec1-9a2287a124dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_33cb4f7b-2e5c-4997-8fe3-8b7e123b45f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_33cb4f7b-2e5c-4997-8fe3-8b7e123b45f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_69554c2b-ea4d-4614-a8ad-34c3b8d9fc92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_69554c2b-ea4d-4614-a8ad-34c3b8d9fc92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fc538bcd-ec7b-45de-8a95-6ec666a5152d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fc538bcd-ec7b-45de-8a95-6ec666a5152d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_33a90853-aee2-4ca5-8c72-b23f75ceb84e" xlink:href="biib-20201231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_33a90853-aee2-4ca5-8c72-b23f75ceb84e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_e6b1ade9-64a1-4799-8f55-58c691e84060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_e6b1ade9-64a1-4799-8f55-58c691e84060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharing_d0c094e9-7203-4f31-a403-9c2dc60cb7b6" xlink:href="biib-20201231.xsd#biib_CollaborationProfitSharing"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_biib_CollaborationProfitSharing_d0c094e9-7203-4f31-a403-9c2dc60cb7b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_ae60cbb3-b690-4474-9eab-d887a112e573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_ae60cbb3-b690-4474-9eab-d887a112e573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_18d183fe-6d83-4d41-a3e3-cdfb4bbbefe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_18d183fe-6d83-4d41-a3e3-cdfb4bbbefe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0fd89379-627d-4e42-a364-dc9f8485071b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fffedd04-d599-4aad-ac8a-dbdae8ca3a72" xlink:to="loc_us-gaap_RestructuringCharges_0fd89379-627d-4e42-a364-dc9f8485071b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bb4b51a9-ead1-4bcd-b857-9b1ad36cd77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cdb6f332-e8a6-4053-9565-3f4507dfe1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bb4b51a9-ead1-4bcd-b857-9b1ad36cd77d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_cdb6f332-e8a6-4053-9565-3f4507dfe1d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a31a317c-1c4d-4de4-8fdb-40d998d7b5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bb4b51a9-ead1-4bcd-b857-9b1ad36cd77d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a31a317c-1c4d-4de4-8fdb-40d998d7b5e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0bbc2927-3eea-4d91-8d8d-2980f17e2337" xlink:href="biib-20201231.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bb4b51a9-ead1-4bcd-b857-9b1ad36cd77d" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0bbc2927-3eea-4d91-8d8d-2980f17e2337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_632b8f51-313d-4f6a-b2f4-7cb0e2cffdf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_abb577c0-cf3a-41c5-a154-1e8ffa84630b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_632b8f51-313d-4f6a-b2f4-7cb0e2cffdf1" xlink:to="loc_us-gaap_OperatingIncomeLoss_abb577c0-cf3a-41c5-a154-1e8ffa84630b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_71b3af28-8dd5-4777-84a8-842670271a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_632b8f51-313d-4f6a-b2f4-7cb0e2cffdf1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_71b3af28-8dd5-4777-84a8-842670271a9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_99c47d94-9bb0-4f73-8562-8cfb6c0b3ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b4186d44-286c-4154-a0d7-4f77db47586b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_99c47d94-9bb0-4f73-8562-8cfb6c0b3ce3" xlink:to="loc_us-gaap_ProfitLoss_b4186d44-286c-4154-a0d7-4f77db47586b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5a46f0cd-7117-449e-84a8-efdd31c5366e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_99c47d94-9bb0-4f73-8562-8cfb6c0b3ce3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5a46f0cd-7117-449e-84a8-efdd31c5366e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f18bc8ca-1eff-44d2-90af-187e3b17302a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_dbd58cd8-da65-4b18-8745-f31801ea78bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f18bc8ca-1eff-44d2-90af-187e3b17302a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_dbd58cd8-da65-4b18-8745-f31801ea78bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d14d2fce-e702-4a7b-88e0-c5ccc56a6920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f18bc8ca-1eff-44d2-90af-187e3b17302a" xlink:to="loc_us-gaap_NetIncomeLoss_d14d2fce-e702-4a7b-88e0-c5ccc56a6920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_69c9b968-2392-4317-8687-c8f4da822cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_78c6fa39-d32a-4f17-88ed-b5dd2a36bfde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_69c9b968-2392-4317-8687-c8f4da822cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_78c6fa39-d32a-4f17-88ed-b5dd2a36bfde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_13742393-3143-4469-99ad-7144d4ee4378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_69c9b968-2392-4317-8687-c8f4da822cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_13742393-3143-4469-99ad-7144d4ee4378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2d68a0f4-7350-4318-90ec-120b09827152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_69c9b968-2392-4317-8687-c8f4da822cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2d68a0f4-7350-4318-90ec-120b09827152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_1718096f-4b17-4e0b-9fa1-ba64b927c024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_69c9b968-2392-4317-8687-c8f4da822cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_1718096f-4b17-4e0b-9fa1-ba64b927c024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5df62027-0746-4582-a5dd-649f2823308b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_69c9b968-2392-4317-8687-c8f4da822cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5df62027-0746-4582-a5dd-649f2823308b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_51818859-ee03-465d-a6fc-b75aaf0e7e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e6db4b94-9ebb-408c-9282-9d277f1b042e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51818859-ee03-465d-a6fc-b75aaf0e7e75" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e6db4b94-9ebb-408c-9282-9d277f1b042e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_639dab1a-8bf5-4e83-b1e9-3d90d34d00ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51818859-ee03-465d-a6fc-b75aaf0e7e75" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_639dab1a-8bf5-4e83-b1e9-3d90d34d00ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_809823c9-9b5f-406f-9163-0e0a472e6d15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d5fa27e9-a413-4803-82db-50ed12501219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_809823c9-9b5f-406f-9163-0e0a472e6d15" xlink:to="loc_us-gaap_AccountsPayableCurrent_d5fa27e9-a413-4803-82db-50ed12501219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_cdf38368-8dcf-49d2-bcc2-1ea69e04f5a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_809823c9-9b5f-406f-9163-0e0a472e6d15" xlink:to="loc_us-gaap_TaxesPayableCurrent_cdf38368-8dcf-49d2-bcc2-1ea69e04f5a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_36275bac-adf8-4eae-b3c0-7a635c115746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_809823c9-9b5f-406f-9163-0e0a472e6d15" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_36275bac-adf8-4eae-b3c0-7a635c115746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_40885c7f-bdd1-4919-b3c8-db492155b3d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_809823c9-9b5f-406f-9163-0e0a472e6d15" xlink:to="loc_us-gaap_DebtCurrent_40885c7f-bdd1-4919-b3c8-db492155b3d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b9cfba9-23b1-448d-bb77-8da24b465ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8d8443a2-2c37-4e34-b733-11118655a3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9cfba9-23b1-448d-bb77-8da24b465ccf" xlink:to="loc_us-gaap_PreferredStockValue_8d8443a2-2c37-4e34-b733-11118655a3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9cb17acd-1845-408b-a825-6dfd884291e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9cfba9-23b1-448d-bb77-8da24b465ccf" xlink:to="loc_us-gaap_CommonStockValue_9cb17acd-1845-408b-a825-6dfd884291e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3091a90d-308c-40b4-bb17-dd46ee233227" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9cfba9-23b1-448d-bb77-8da24b465ccf" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3091a90d-308c-40b4-bb17-dd46ee233227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33185ba7-774f-49d9-86f1-ac6666e91be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9cfba9-23b1-448d-bb77-8da24b465ccf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_33185ba7-774f-49d9-86f1-ac6666e91be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a537b3f3-07e7-4952-b1a4-50d609903ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9cfba9-23b1-448d-bb77-8da24b465ccf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a537b3f3-07e7-4952-b1a4-50d609903ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_bebd4e8a-b908-4704-b141-d15d1fc873a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9cfba9-23b1-448d-bb77-8da24b465ccf" xlink:to="loc_us-gaap_TreasuryStockValue_bebd4e8a-b908-4704-b141-d15d1fc873a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_83c30164-edeb-40d1-9b17-fdcee053b534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cabe7dd0-aa9f-4ea8-9f3b-3e4f95b34179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_83c30164-edeb-40d1-9b17-fdcee053b534" xlink:to="loc_us-gaap_InventoryNet_cabe7dd0-aa9f-4ea8-9f3b-3e4f95b34179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e678429-abb1-4ea6-894b-c5a43ecdd18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_83c30164-edeb-40d1-9b17-fdcee053b534" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e678429-abb1-4ea6-894b-c5a43ecdd18a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_30b6902d-b7eb-4674-91e8-911cbfe89cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_83c30164-edeb-40d1-9b17-fdcee053b534" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_30b6902d-b7eb-4674-91e8-911cbfe89cd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_fe340722-c11c-4adc-867f-7b0a10e234a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_83c30164-edeb-40d1-9b17-fdcee053b534" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_fe340722-c11c-4adc-867f-7b0a10e234a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_c14d3443-1644-4446-a09c-51237bf9aad4" xlink:href="biib-20201231.xsd#biib_DueFromUnconsolidatedJointBusiness"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_83c30164-edeb-40d1-9b17-fdcee053b534" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_c14d3443-1644-4446-a09c-51237bf9aad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_30c207a2-2e03-4451-a582-29bfda15255b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_83c30164-edeb-40d1-9b17-fdcee053b534" xlink:to="loc_us-gaap_OtherAssetsCurrent_30c207a2-2e03-4451-a582-29bfda15255b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a6925fb8-6b87-4fff-a42a-37ea50e33eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_701cc661-4dbe-470f-8166-e448779131ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a6925fb8-6b87-4fff-a42a-37ea50e33eee" xlink:to="loc_us-gaap_LiabilitiesCurrent_701cc661-4dbe-470f-8166-e448779131ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_356a3625-30dc-440f-a715-0c5f43b585dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a6925fb8-6b87-4fff-a42a-37ea50e33eee" xlink:to="loc_us-gaap_LongTermDebt_356a3625-30dc-440f-a715-0c5f43b585dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2d9265f1-e539-44d4-b5ff-3eda05adde01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a6925fb8-6b87-4fff-a42a-37ea50e33eee" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2d9265f1-e539-44d4-b5ff-3eda05adde01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9adfd7c9-56df-4a9e-93be-2b1bd27e9d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a6925fb8-6b87-4fff-a42a-37ea50e33eee" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9adfd7c9-56df-4a9e-93be-2b1bd27e9d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f871e6d7-8ec3-42b8-9a21-fa07df34d2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a6925fb8-6b87-4fff-a42a-37ea50e33eee" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f871e6d7-8ec3-42b8-9a21-fa07df34d2c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f87ca32c-f79c-4864-b32b-54f57a803d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87ad13ee-0949-4586-b0d9-b5afbe08107b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f87ca32c-f79c-4864-b32b-54f57a803d97" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87ad13ee-0949-4586-b0d9-b5afbe08107b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a41f189e-e515-428d-b707-5330ef03049a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f87ca32c-f79c-4864-b32b-54f57a803d97" xlink:to="loc_us-gaap_Liabilities_a41f189e-e515-428d-b707-5330ef03049a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_72828f87-c3ea-4774-8df7-e038aa97bb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f87ca32c-f79c-4864-b32b-54f57a803d97" xlink:to="loc_us-gaap_CommitmentsAndContingencies_72828f87-c3ea-4774-8df7-e038aa97bb9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_994af582-5344-46c4-b0fb-1d544713eacf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:to="loc_us-gaap_AssetsCurrent_994af582-5344-46c4-b0fb-1d544713eacf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_023431dc-a591-44ad-a086-a4061943ef21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_023431dc-a591-44ad-a086-a4061943ef21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f77fc357-7fb6-43af-83fc-e8f05f7d3f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f77fc357-7fb6-43af-83fc-e8f05f7d3f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c02f3643-61c7-4d03-8e48-9a97f3fafaf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c02f3643-61c7-4d03-8e48-9a97f3fafaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_07cc0aaa-5da2-4e0b-9291-afca52410ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_07cc0aaa-5da2-4e0b-9291-afca52410ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_77c19028-3665-40e6-ba6a-3fa046c78a46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:to="loc_us-gaap_Goodwill_77c19028-3665-40e6-ba6a-3fa046c78a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_31ca4603-830d-44ab-a85c-c4b7a778ff39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_31ca4603-830d-44ab-a85c-c4b7a778ff39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9565b385-9442-47db-8d8e-076c1252463b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_05628ea5-0202-4944-8dd0-642ab32ff66e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9565b385-9442-47db-8d8e-076c1252463b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d92afffa-51b0-4c53-a2ec-b0fcfc5133a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cbec10bf-35c3-47e6-9301-7196231fe1a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d92afffa-51b0-4c53-a2ec-b0fcfc5133a5" xlink:to="loc_us-gaap_StockholdersEquity_cbec10bf-35c3-47e6-9301-7196231fe1a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_38c3fd7e-a6d9-439f-869c-f3301d87da16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d92afffa-51b0-4c53-a2ec-b0fcfc5133a5" xlink:to="loc_us-gaap_MinorityInterest_38c3fd7e-a6d9-439f-869c-f3301d87da16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_efc97c09-e7a9-4803-be35-bff848ad896b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03980d7a-a0aa-4c48-b300-b7e52bd742a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_efc97c09-e7a9-4803-be35-bff848ad896b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03980d7a-a0aa-4c48-b300-b7e52bd742a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0c2dfb1d-4663-488d-8f75-cf920f0a3dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_efc97c09-e7a9-4803-be35-bff848ad896b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0c2dfb1d-4663-488d-8f75-cf920f0a3dc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1cee76a1-98e3-43b2-a64e-d841c49046d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_efc97c09-e7a9-4803-be35-bff848ad896b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1cee76a1-98e3-43b2-a64e-d841c49046d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_182a971f-ab10-43bd-8b87-62ddd7838826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_182a971f-ab10-43bd-8b87-62ddd7838826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_28149448-73d8-4c6f-be76-806f605046a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_28149448-73d8-4c6f-be76-806f605046a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dff2168a-2092-4454-83ed-bebeb9888a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dff2168a-2092-4454-83ed-bebeb9888a37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8878ffec-9418-4c18-9492-2e056f4b9536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8878ffec-9418-4c18-9492-2e056f4b9536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_78d990ba-5059-4070-b982-62f1c09c9a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_78d990ba-5059-4070-b982-62f1c09c9a82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_a33ef52b-675e-4e29-9c1b-2afcb95ab30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_a33ef52b-675e-4e29-9c1b-2afcb95ab30a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_29b48af5-596d-48a9-b0fc-a13db919ad4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_29b48af5-596d-48a9-b0fc-a13db919ad4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7b0c0914-e955-4d4c-a319-dc076e82be33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7b0c0914-e955-4d4c-a319-dc076e82be33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_85c9665f-4538-4f0d-b0cd-57bc48b8e0a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_85c9665f-4538-4f0d-b0cd-57bc48b8e0a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_75a4339a-b3bd-4af3-b9a6-1611c4d9b135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_75a4339a-b3bd-4af3-b9a6-1611c4d9b135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b8daf188-537d-4d7d-bd54-2cd8807f1177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b8daf188-537d-4d7d-bd54-2cd8807f1177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1f0176f2-e680-4d4d-9e28-929c9af6c83c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50ee9fbd-4ec0-4722-b377-5c915e5d822b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1f0176f2-e680-4d4d-9e28-929c9af6c83c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_f973e5de-8664-48d4-a143-2d36de5f7589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:to="loc_us-gaap_RepaymentsOfDebt_f973e5de-8664-48d4-a143-2d36de5f7589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6c30e8de-1bbc-479e-9c88-a3dcac88f8d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6c30e8de-1bbc-479e-9c88-a3dcac88f8d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_260d184e-109e-47e4-9c1c-3f8ed7823fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_260d184e-109e-47e4-9c1c-3f8ed7823fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4bad9e2f-1b3a-47a2-bff4-e656f47efb89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4bad9e2f-1b3a-47a2-bff4-e656f47efb89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_24b2e056-5aed-47c8-9982-e8273aed8943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_24b2e056-5aed-47c8-9982-e8273aed8943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d30daec-4ced-463b-b143-7595903f30f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d30daec-4ced-463b-b143-7595903f30f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_5a683ede-fdf1-4c94-a4d9-9eee4954f5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_5a683ede-fdf1-4c94-a4d9-9eee4954f5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_36012e31-cbbc-461a-8c38-7bcbb5f7a906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80d0cfd1-2b4e-44f4-acb9-57aa8ce8a6dd" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_36012e31-cbbc-461a-8c38-7bcbb5f7a906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_b9d2ca91-0825-4b1f-a667-7f9250ddf9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_b9d2ca91-0825-4b1f-a667-7f9250ddf9b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6ad9ec64-ebaa-46ef-9b96-a3b592408d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_ShareBasedCompensation_6ad9ec64-ebaa-46ef-9b96-a3b592408d10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b2890c7a-06a1-4a11-8fac-d9497f7acd7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b2890c7a-06a1-4a11-8fac-d9497f7acd7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1e3581ff-58f0-4908-a23d-f6d7ce259539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1e3581ff-58f0-4908-a23d-f6d7ce259539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_871702db-a6c9-41c7-b5a2-3e4d1830d6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_ProfitLoss_871702db-a6c9-41c7-b5a2-3e4d1830d6c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_f05bfa8c-1796-4f86-97f8-c47fd5f51f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_f05bfa8c-1796-4f86-97f8-c47fd5f51f5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_105eca2b-4104-4cd6-a7ac-781bba5965ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_105eca2b-4104-4cd6-a7ac-781bba5965ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4f3f6467-afae-49a0-b1db-4e28ddb75c2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4f3f6467-afae-49a0-b1db-4e28ddb75c2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_b734b0ea-7549-45a0-b872-be79d5aedc1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_b734b0ea-7549-45a0-b872-be79d5aedc1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e2f3f405-59fe-4970-b1f2-9bd4515192b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e2f3f405-59fe-4970-b1f2-9bd4515192b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d0c8bc7e-c6aa-49a2-b5a8-dfd5db9dc2b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d0c8bc7e-c6aa-49a2-b5a8-dfd5db9dc2b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b80c2684-9703-4cd8-908f-86b0c87ab045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b80c2684-9703-4cd8-908f-86b0c87ab045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a2f33320-5152-4c35-88fe-55e1373583de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a2f33320-5152-4c35-88fe-55e1373583de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_daca0b9a-3b89-48d6-836a-0c01c69e48e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_daca0b9a-3b89-48d6-836a-0c01c69e48e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6341e282-7ab9-477e-b4d0-b99048d62817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6341e282-7ab9-477e-b4d0-b99048d62817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e8fe7d03-a4ee-4b9c-ba93-7e05d57358de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e8fe7d03-a4ee-4b9c-ba93-7e05d57358de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3da42075-f5b0-428c-9c9c-db6561816da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f90681a7-1f5a-4e32-82ad-9f3da9e1db56" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3da42075-f5b0-428c-9c9c-db6561816da3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofEquity"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20201231.xsd#Acquisitions"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Divestitures" xlink:type="simple" xlink:href="biib-20201231.xsd#Divestitures"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Divestitures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DivestituresDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20201231.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesRevenuesbyProductDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesReservesforDiscountsandAllowancesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesTotalReservesforDiscountsandAllowancesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5b1c9cc4-30ec-4889-9568-2414f97d0f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_5b69e173-4d87-49db-bd2b-e1280a6ed75c" xlink:href="biib-20201231.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5b1c9cc4-30ec-4889-9568-2414f97d0f3e" xlink:to="loc_biib_ShareOfCoPromotionProfits_5b69e173-4d87-49db-bd2b-e1280a6ed75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_45ea0bda-4504-4f66-bda2-d208af76f097" xlink:href="biib-20201231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5b1c9cc4-30ec-4889-9568-2414f97d0f3e" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_45ea0bda-4504-4f66-bda2-d208af76f097" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesOtherRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20201231.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_455d139e-6369-4694-b2cd-d251cbb40250" xlink:href="biib-20201231.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4d2c71a4-2aa0-4b13-88b6-dc9e08ec588f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_455d139e-6369-4694-b2cd-d251cbb40250" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4d2c71a4-2aa0-4b13-88b6-dc9e08ec588f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b5d02875-c7d0-4e1f-a660-e9d287fd3ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_455d139e-6369-4694-b2cd-d251cbb40250" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b5d02875-c7d0-4e1f-a660-e9d287fd3ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2565b43a-6df7-4443-9b40-ec431100adc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_455d139e-6369-4694-b2cd-d251cbb40250" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2565b43a-6df7-4443-9b40-ec431100adc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwill"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_272484ff-39b0-4a43-b131-7f22e69245e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15617f6d-b2d4-4deb-9bab-f32a0248ec88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_272484ff-39b0-4a43-b131-7f22e69245e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_15617f6d-b2d4-4deb-9bab-f32a0248ec88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f40758c-8009-46db-99fd-a81c1005e2e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_272484ff-39b0-4a43-b131-7f22e69245e0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f40758c-8009-46db-99fd-a81c1005e2e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_01f5c60d-6808-432d-91d5-19253cd4452d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_db5881ff-896e-4abc-bb45-60ddcef18840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_01f5c60d-6808-432d-91d5-19253cd4452d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_db5881ff-896e-4abc-bb45-60ddcef18840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4f3d61e5-495f-43e4-bd0c-9e76a62768ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_01f5c60d-6808-432d-91d5-19253cd4452d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4f3d61e5-495f-43e4-bd0c-9e76a62768ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38d84584-2236-4000-a590-794817137cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_174349a2-f81c-48f2-a61c-a1fa9392e14b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38d84584-2236-4000-a590-794817137cba" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_174349a2-f81c-48f2-a61c-a1fa9392e14b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_46257bf0-ca12-424e-b459-a0447c755485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_38d84584-2236-4000-a590-794817137cba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_46257bf0-ca12-424e-b459-a0447c755485" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_f6216112-ea75-4ed9-952f-2e6817b58792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_319f5a6a-0ebf-4c35-abb1-89baaca01764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_f6216112-ea75-4ed9-952f-2e6817b58792" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_319f5a6a-0ebf-4c35-abb1-89baaca01764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_03f9e94f-fa21-4749-9940-b97a546ea2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_f6216112-ea75-4ed9-952f-2e6817b58792" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_03f9e94f-fa21-4749-9940-b97a546ea2d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_fe727873-3155-4596-a75d-b4a44e3f07a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_ae21665d-7a05-40eb-873c-d2b2b0b74e98" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_fe727873-3155-4596-a75d-b4a44e3f07a6" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_ae21665d-7a05-40eb-873c-d2b2b0b74e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_6065d162-e34b-4cc6-9dcb-d9a6e685a6ab" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_fe727873-3155-4596-a75d-b4a44e3f07a6" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_6065d162-e34b-4cc6-9dcb-d9a6e685a6ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_58cef0f2-a91f-4aea-a583-0323ca302f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_fe727873-3155-4596-a75d-b4a44e3f07a6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_58cef0f2-a91f-4aea-a583-0323ca302f42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e52df2f-e1f9-4183-ab0e-d4b677ca9750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2290c6f6-bdc7-4a19-861b-f93f3d9ff182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e52df2f-e1f9-4183-ab0e-d4b677ca9750" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2290c6f6-bdc7-4a19-861b-f93f3d9ff182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_261aacb7-5e39-44d5-91fe-cafc54bef409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e52df2f-e1f9-4183-ab0e-d4b677ca9750" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_261aacb7-5e39-44d5-91fe-cafc54bef409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e4d6338-422b-472c-b175-7dfcf209d631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5e52df2f-e1f9-4183-ab0e-d4b677ca9750" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e4d6338-422b-472c-b175-7dfcf209d631" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_eff1a512-40fa-46cb-a155-c23a515c7ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_d92643c0-bb91-4227-a54b-45b36c451cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_eff1a512-40fa-46cb-a155-c23a515c7ebe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_d92643c0-bb91-4227-a54b-45b36c451cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_10641553-440f-4fed-855e-913f37278bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_eff1a512-40fa-46cb-a155-c23a515c7ebe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_10641553-440f-4fed-855e-913f37278bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_e816d0d8-9888-42ba-9929-b15ec5108e37" xlink:href="biib-20201231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_eff1a512-40fa-46cb-a155-c23a515c7ebe" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_e816d0d8-9888-42ba-9929-b15ec5108e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d9fdd7cc-0351-4568-a792-d0e8963a44de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f283014f-45b6-4658-8368-9d4f12ad6771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d9fdd7cc-0351-4568-a792-d0e8963a44de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f283014f-45b6-4658-8368-9d4f12ad6771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f8828813-c6a3-4879-95a3-74cf9566a4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d9fdd7cc-0351-4568-a792-d0e8963a44de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f8828813-c6a3-4879-95a3-74cf9566a4a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_820cfb10-5479-4e86-a6cd-0dcef37fda63" xlink:href="biib-20201231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d9fdd7cc-0351-4568-a792-d0e8963a44de" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_820cfb10-5479-4e86-a6cd-0dcef37fda63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstruments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipment"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4dd63fc5-f60e-42a7-90ba-85eb1bf5e13d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12c7da22-2602-4192-b6db-c5583a09bee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4dd63fc5-f60e-42a7-90ba-85eb1bf5e13d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12c7da22-2602-4192-b6db-c5583a09bee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eb2b5d6a-6504-4d6b-aa11-708d07f70e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4dd63fc5-f60e-42a7-90ba-85eb1bf5e13d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eb2b5d6a-6504-4d6b-aa11-708d07f70e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_44a5da03-37aa-423e-be1e-871c6fe87b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_99a1e845-7f1e-491d-9c80-2c479aa27e11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_44a5da03-37aa-423e-be1e-871c6fe87b98" xlink:to="loc_us-gaap_Land_99a1e845-7f1e-491d-9c80-2c479aa27e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_263fe387-2baf-4e74-a0ad-8bc42ff3d566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_44a5da03-37aa-423e-be1e-871c6fe87b98" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_263fe387-2baf-4e74-a0ad-8bc42ff3d566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_54ef0db1-6e97-4628-9bad-ac0134f1a2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_44a5da03-37aa-423e-be1e-871c6fe87b98" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_54ef0db1-6e97-4628-9bad-ac0134f1a2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_8bc16fd4-9d6c-4ae1-aa60-902057f0751a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_44a5da03-37aa-423e-be1e-871c6fe87b98" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_8bc16fd4-9d6c-4ae1-aa60-902057f0751a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ComputerSoftwareAndHardware_06b08e55-4df0-4f19-80d2-28c2f5b22bc1" xlink:href="biib-20201231.xsd#biib_ComputerSoftwareAndHardware"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_44a5da03-37aa-423e-be1e-871c6fe87b98" xlink:to="loc_biib_ComputerSoftwareAndHardware_06b08e55-4df0-4f19-80d2-28c2f5b22bc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_6d41dfbf-67c2-4c8e-9fcf-98ad6c52078e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_44a5da03-37aa-423e-be1e-871c6fe87b98" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_6d41dfbf-67c2-4c8e-9fcf-98ad6c52078e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_da0b4e9c-526d-4b86-9856-e761b679e5b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_44a5da03-37aa-423e-be1e-871c6fe87b98" xlink:to="loc_us-gaap_ConstructionInProgressGross_da0b4e9c-526d-4b86-9856-e761b679e5b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:type="simple" xlink:href="biib-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesScheduleofOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseLiabilityMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c1e3019-3bee-4b3f-a5b0-dca7d25567d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_220cfb3c-2040-4ae1-8f3b-0759c30f03a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c1e3019-3bee-4b3f-a5b0-dca7d25567d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_220cfb3c-2040-4ae1-8f3b-0759c30f03a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8ed51d92-edda-4aa2-9914-7fec829756a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c1e3019-3bee-4b3f-a5b0-dca7d25567d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8ed51d92-edda-4aa2-9914-7fec829756a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a2632a38-4514-4487-96d4-347bb6c42182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c1e3019-3bee-4b3f-a5b0-dca7d25567d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a2632a38-4514-4487-96d4-347bb6c42182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3314ff83-9687-494f-9312-2b480756dc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c1e3019-3bee-4b3f-a5b0-dca7d25567d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3314ff83-9687-494f-9312-2b480756dc7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1e431ffb-5246-47f3-ba56-c3bf6fc04ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c1e3019-3bee-4b3f-a5b0-dca7d25567d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1e431ffb-5246-47f3-ba56-c3bf6fc04ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0cb98112-72fb-4700-b01b-dbdf1e540c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4c1e3019-3bee-4b3f-a5b0-dca7d25567d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0cb98112-72fb-4700-b01b-dbdf1e540c92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3834157b-87bc-4cec-b01b-c7d238f07c16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_74dc6338-1366-4162-9eb9-c616090f481b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3834157b-87bc-4cec-b01b-c7d238f07c16" xlink:to="loc_us-gaap_OperatingLeaseLiability_74dc6338-1366-4162-9eb9-c616090f481b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_29fa2d3e-94f4-46a5-a846-57dced43d5c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3834157b-87bc-4cec-b01b-c7d238f07c16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_29fa2d3e-94f4-46a5-a846-57dced43d5c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20201231.xsd#Indebtedness"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessSummaryofIndebtednessDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessTotalDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_70bf0002-ead5-4fc5-bf91-856657201d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_357fe37d-73f5-42ca-ba82-cf9bd96e4974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_70bf0002-ead5-4fc5-bf91-856657201d8f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_357fe37d-73f5-42ca-ba82-cf9bd96e4974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d9c80e4f-e8d0-433a-aa93-2a1a595f3242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_70bf0002-ead5-4fc5-bf91-856657201d8f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d9c80e4f-e8d0-433a-aa93-2a1a595f3242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_779167fa-36ab-4266-9fc4-f95fa6a2e237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_70bf0002-ead5-4fc5-bf91-856657201d8f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_779167fa-36ab-4266-9fc4-f95fa6a2e237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_80e16965-00bb-40cb-9566-0bd26800f0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_70bf0002-ead5-4fc5-bf91-856657201d8f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_80e16965-00bb-40cb-9566-0bd26800f0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_de3569a4-19a0-4872-98f2-c155a5cee427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_70bf0002-ead5-4fc5-bf91-856657201d8f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_de3569a4-19a0-4872-98f2-c155a5cee427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_f0981af2-4358-4dd8-8194-9b0208eea692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_70bf0002-ead5-4fc5-bf91-856657201d8f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_f0981af2-4358-4dd8-8194-9b0208eea692" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20201231.xsd#Equity"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquitySummaryofCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShare"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareBasicandDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_be11c468-bcef-439b-972c-eb07080f5442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1880c167-1bd0-4434-a2f5-ddb8e46aa448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_be11c468-bcef-439b-972c-eb07080f5442" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1880c167-1bd0-4434-a2f5-ddb8e46aa448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7069d300-6ce2-45f3-9e1a-b0a80e85f22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3e48b82b-ea5c-4f9a-a579-39d5f21866e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7069d300-6ce2-45f3-9e1a-b0a80e85f22c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3e48b82b-ea5c-4f9a-a579-39d5f21866e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5db32d7f-5582-4ddf-a804-60d9d8733342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7069d300-6ce2-45f3-9e1a-b0a80e85f22c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_5db32d7f-5582-4ddf-a804-60d9d8733342" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPayments"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsMarketStockUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e40acd3e-c0b3-497f-b2d9-aab1e13bd648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1e97dfac-f38a-4442-ba82-3a984a67214a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e40acd3e-c0b3-497f-b2d9-aab1e13bd648" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1e97dfac-f38a-4442-ba82-3a984a67214a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f236be55-4861-49f4-a53a-36bd60cf5c1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e40acd3e-c0b3-497f-b2d9-aab1e13bd648" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_f236be55-4861-49f4-a53a-36bd60cf5c1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c17968cb-6013-4dff-8e0e-4a11d1343fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5125c5bf-8429-49f5-bd9c-adac14c859aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c17968cb-6013-4dff-8e0e-4a11d1343fd1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5125c5bf-8429-49f5-bd9c-adac14c859aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_81860f1e-7b27-465b-b68a-f265a3e4bc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_c17968cb-6013-4dff-8e0e-4a11d1343fd1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_81860f1e-7b27-465b-b68a-f265a3e4bc77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_de22dc11-f4d6-4b46-a50f-af87cf31ab59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_289c3dcd-98db-4246-a827-699821d45a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_de22dc11-f4d6-4b46-a50f-af87cf31ab59" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_289c3dcd-98db-4246-a827-699821d45a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b8d19338-5aa0-4576-9da5-cab751be70c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_de22dc11-f4d6-4b46-a50f-af87cf31ab59" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b8d19338-5aa0-4576-9da5-cab751be70c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_eab33c68-bce2-4dd7-b186-7ec479bc21f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_de22dc11-f4d6-4b46-a50f-af87cf31ab59" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_eab33c68-bce2-4dd7-b186-7ec479bc21f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20b6a6bf-7f0d-488b-8407-0f0f6ab42400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_84083052-9016-4fe3-ad11-ce2f2f9e5857" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20b6a6bf-7f0d-488b-8407-0f0f6ab42400" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_84083052-9016-4fe3-ad11-ce2f2f9e5857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_242a8372-59a8-4eb0-b234-350a10e56228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20b6a6bf-7f0d-488b-8407-0f0f6ab42400" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_242a8372-59a8-4eb0-b234-350a10e56228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_989576d7-4efc-4fb7-a4ae-773071ac639b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20b6a6bf-7f0d-488b-8407-0f0f6ab42400" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_989576d7-4efc-4fb7-a4ae-773071ac639b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ce6be6f6-7705-4c37-94f9-2585a750d5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0da0c594-bb55-4213-ba54-a05733ac237f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ce6be6f6-7705-4c37-94f9-2585a750d5b5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0da0c594-bb55-4213-ba54-a05733ac237f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_89a6ec9a-945f-43d9-a6d0-b1cd3b388998" xlink:href="biib-20201231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ce6be6f6-7705-4c37-94f9-2585a750d5b5" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_89a6ec9a-945f-43d9-a6d0-b1cd3b388998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_78f925ae-c6e4-4454-85e1-51ad7d1d72a8" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ce6be6f6-7705-4c37-94f9-2585a750d5b5" xlink:to="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_78f925ae-c6e4-4454-85e1-51ad7d1d72a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_982f2235-3143-45ed-89a8-f477273d9431" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ce6be6f6-7705-4c37-94f9-2585a750d5b5" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_982f2235-3143-45ed-89a8-f477273d9431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_bdf871fa-0ec0-46c3-8b48-27c0847bf0d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4769ce5d-354a-47e1-abd7-c28290a4fbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bdf871fa-0ec0-46c3-8b48-27c0847bf0d1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4769ce5d-354a-47e1-abd7-c28290a4fbb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_0ebd7620-db97-42cf-a7f0-1de1bca60a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bdf871fa-0ec0-46c3-8b48-27c0847bf0d1" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_0ebd7620-db97-42cf-a7f0-1de1bca60a4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d3f9ccfc-d45c-4c9b-b56f-7ae9d211d0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bdf871fa-0ec0-46c3-8b48-27c0847bf0d1" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_d3f9ccfc-d45c-4c9b-b56f-7ae9d211d0e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f3c62643-c56f-4b35-b6d0-542efd70e639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bdf871fa-0ec0-46c3-8b48-27c0847bf0d1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f3c62643-c56f-4b35-b6d0-542efd70e639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f48290df-85ec-4a44-a407-213ac61642d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bdf871fa-0ec0-46c3-8b48-27c0847bf0d1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f48290df-85ec-4a44-a407-213ac61642d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_92fe4d6a-cf42-4d87-b818-5daf5a6032cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bdf871fa-0ec0-46c3-8b48-27c0847bf0d1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_92fe4d6a-cf42-4d87-b818-5daf5a6032cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7fb8da67-4c85-4831-9020-9b6f3ae64174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_bdf871fa-0ec0-46c3-8b48-27c0847bf0d1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7fb8da67-4c85-4831-9020-9b6f3ae64174" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d559e2f7-1765-4662-b763-4c2d2cb59e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d559e2f7-1765-4662-b763-4c2d2cb59e9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_adf546bd-6175-463f-9687-6f23bf03a2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_adf546bd-6175-463f-9687-6f23bf03a2b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7e5391a3-70f8-4af5-bfd2-c9b2062c0371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7e5391a3-70f8-4af5-bfd2-c9b2062c0371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0610a8d6-e67f-44f9-8eb1-a768f2e986a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0610a8d6-e67f-44f9-8eb1-a768f2e986a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_e8d0eac8-dc2c-4996-b8ba-82b2fb5c48d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_e8d0eac8-dc2c-4996-b8ba-82b2fb5c48d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_aa695b33-4f03-4772-b07d-adc2e730ab57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_aa695b33-4f03-4772-b07d-adc2e730ab57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_94ea7c20-fa68-4d4b-a6e6-b6d2da57f2a1" xlink:href="biib-20201231.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_94ea7c20-fa68-4d4b-a6e6-b6d2da57f2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_ea23178d-33f2-4d5c-aaaa-858e6b79b385" xlink:href="biib-20201231.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_ea23178d-33f2-4d5c-aaaa-858e6b79b385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_3ebfe05d-d564-443d-818a-67abbaf30249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_3ebfe05d-d564-443d-818a-67abbaf30249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_cddb7ead-fce0-44ba-9885-5f84659f82c2" xlink:href="biib-20201231.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_cddb7ead-fce0-44ba-9885-5f84659f82c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_47b1b563-f694-44f6-8eb3-45c70aa87d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_47b1b563-f694-44f6-8eb3-45c70aa87d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9a4a0445-1d19-4012-8cc1-d7d07dae78f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_58b8c111-0602-48b3-b8ea-9bcab0b111a6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9a4a0445-1d19-4012-8cc1-d7d07dae78f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_591ed283-fd8a-4b0e-abe7-8fb4dc66047e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_99b29778-2be7-4819-b752-4bc9ef1cd0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_591ed283-fd8a-4b0e-abe7-8fb4dc66047e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_99b29778-2be7-4819-b752-4bc9ef1cd0c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f9fdb0c8-3d2a-44e5-80ef-e783415aa1c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_591ed283-fd8a-4b0e-abe7-8fb4dc66047e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f9fdb0c8-3d2a-44e5-80ef-e783415aa1c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5dda12f2-e5e6-4d52-b669-1dd8488546ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_591ed283-fd8a-4b0e-abe7-8fb4dc66047e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5dda12f2-e5e6-4d52-b669-1dd8488546ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9f4b9a57-4534-4505-a5f4-eb4381987a7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_591ed283-fd8a-4b0e-abe7-8fb4dc66047e" xlink:to="loc_us-gaap_InterestExpense_9f4b9a57-4534-4505-a5f4-eb4381987a7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_d68e0028-ef12-4c2d-ad83-ebdf504bfa1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_591ed283-fd8a-4b0e-abe7-8fb4dc66047e" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_d68e0028-ef12-4c2d-ad83-ebdf504bfa1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_9a9d53e4-ef15-4485-b51c-dba17663b39a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_db2ccaf9-bb7b-4f01-91dd-3ed4f1799ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_9a9d53e4-ef15-4485-b51c-dba17663b39a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_db2ccaf9-bb7b-4f01-91dd-3ed4f1799ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0f110a71-0ed1-4c03-9c96-2c134d21f341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_9a9d53e4-ef15-4485-b51c-dba17663b39a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0f110a71-0ed1-4c03-9c96-2c134d21f341" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_64966505-f864-4dbc-80c0-9bdeaaa25cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_24efb082-5ffd-40a9-97dd-04a335790169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_64966505-f864-4dbc-80c0-9bdeaaa25cf3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_24efb082-5ffd-40a9-97dd-04a335790169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_be922224-d156-4c92-8ce8-f3cc22d550e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_64966505-f864-4dbc-80c0-9bdeaaa25cf3" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_be922224-d156-4c92-8ce8-f3cc22d550e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_c95b7098-410d-4039-b7b8-d140d2006270" xlink:href="biib-20201231.xsd#biib_Collaborationexpensesaccrual"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_64966505-f864-4dbc-80c0-9bdeaaa25cf3" xlink:to="loc_biib_Collaborationexpensesaccrual_c95b7098-410d-4039-b7b8-d140d2006270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f21a48eb-e116-4fcc-b27a-cfeccf2b09db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_64966505-f864-4dbc-80c0-9bdeaaa25cf3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f21a48eb-e116-4fcc-b27a-cfeccf2b09db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_59501315-5728-49ed-bc12-acc5a870b1b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_64966505-f864-4dbc-80c0-9bdeaaa25cf3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_59501315-5728-49ed-bc12-acc5a870b1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_dfb61ce1-0f8a-484b-b1a2-f84a4db41181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_64966505-f864-4dbc-80c0-9bdeaaa25cf3" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_dfb61ce1-0f8a-484b-b1a2-f84a4db41181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_b9827892-6fa8-49e4-9f16-d579028765f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_64966505-f864-4dbc-80c0-9bdeaaa25cf3" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_b9827892-6fa8-49e4-9f16-d579028765f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationships"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsIonisDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsAlkermesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsBristolMyersSquibbDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsAcordaDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20201231.xsd#InvestmentsinVariableInterestEntities"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20201231.xsd#Litigation"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LitigationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="biib-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:type="simple" xlink:href="biib-20201231.xsd#Guarantees"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="biib-20201231.xsd#EmployeeBenefitPlans"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformation"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationGeographicInformationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnauditedDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>biib-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:93645b15-c187-4b47-82bf-4dd611d6b978,g:f6c0263a-8ffa-4fd3-a952-6de1d776d19e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended" id="ib7420eb9417a435595cbe4b0ec124963_CoverPage"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofIncome" xlink:type="extended" id="i39cd38b5949444f9aa82fd72e39b528a_ConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_974bc8bc-63d3-4285-a1c8-902bfbe0e383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_Revenues_974bc8bc-63d3-4285-a1c8-902bfbe0e383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ef6f2e88-6768-430e-b297-e604a9ff749d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ef6f2e88-6768-430e-b297-e604a9ff749d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_db9b6a11-a5b1-4caa-8bf0-c36d554f9d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_db9b6a11-a5b1-4caa-8bf0-c36d554f9d14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_60fdc397-78d1-447a-bf25-090d7cbdbf65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_60fdc397-78d1-447a-bf25-090d7cbdbf65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_5c5cd0d2-c3f2-4c3d-9be9-fa9115e979ab" xlink:href="biib-20201231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_5c5cd0d2-c3f2-4c3d-9be9-fa9115e979ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharing_e3a15d62-8ec5-49a4-8682-4882f719ae73" xlink:href="biib-20201231.xsd#biib_CollaborationProfitSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_biib_CollaborationProfitSharing_e3a15d62-8ec5-49a4-8682-4882f719ae73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6f481756-c2bd-4ceb-af56-619487dfa05c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6f481756-c2bd-4ceb-af56-619487dfa05c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_42d53ae0-dca6-434a-ade0-b4b251c53bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_42d53ae0-dca6-434a-ade0-b4b251c53bd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a0e50ada-952f-4605-a6cc-005748537e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a0e50ada-952f-4605-a6cc-005748537e82" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bbef4075-4314-4b75-b7da-f3dfaff5595b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_RestructuringCharges_bbef4075-4314-4b75-b7da-f3dfaff5595b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8377a40b-6cb2-4420-97ac-e9a6e9fe5273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_CostsAndExpenses_8377a40b-6cb2-4420-97ac-e9a6e9fe5273" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dac2f759-214a-48ba-9d12-3d42f4f7a909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_OperatingIncomeLoss_dac2f759-214a-48ba-9d12-3d42f4f7a909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_df1d388b-af58-4f75-91be-6979f331d1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_df1d388b-af58-4f75-91be-6979f331d1b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_faa2dd6c-cdf0-4519-b609-3044a5d2f46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_faa2dd6c-cdf0-4519-b609-3044a5d2f46b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_790d2458-fd88-4697-84c0-8189a6c2d63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_790d2458-fd88-4697-84c0-8189a6c2d63c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0be755a6-63fe-4fc7-a25e-106e776ccab2" xlink:href="biib-20201231.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0be755a6-63fe-4fc7-a25e-106e776ccab2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ff3d7a07-333e-40cb-a189-b83627b4f5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_ProfitLoss_ff3d7a07-333e-40cb-a189-b83627b4f5e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83d6b0bc-74d7-45e7-8c43-7e8155a14afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83d6b0bc-74d7-45e7-8c43-7e8155a14afc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6267873c-2744-410d-b7bf-bb6431c7dd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_NetIncomeLoss_6267873c-2744-410d-b7bf-bb6431c7dd8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_40d9a254-ccbf-4a5f-a999-3d081e622c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_40d9a254-ccbf-4a5f-a999-3d081e622c71" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9140dd08-f06d-4f1f-95b7-2946310294a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_40d9a254-ccbf-4a5f-a999-3d081e622c71" xlink:to="loc_us-gaap_EarningsPerShareBasic_9140dd08-f06d-4f1f-95b7-2946310294a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_914c6c08-78a7-46f3-a2ff-a09bf58bdda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_40d9a254-ccbf-4a5f-a999-3d081e622c71" xlink:to="loc_us-gaap_EarningsPerShareDiluted_914c6c08-78a7-46f3-a2ff-a09bf58bdda9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c098e1ab-eb34-4a85-80cd-5f5ad0d9ea50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c098e1ab-eb34-4a85-80cd-5f5ad0d9ea50" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ef278d3-03e5-44a3-9ab1-d8da7f58256c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c098e1ab-eb34-4a85-80cd-5f5ad0d9ea50" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ef278d3-03e5-44a3-9ab1-d8da7f58256c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a37dc7e6-7366-47d9-82cf-7ec561312fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c098e1ab-eb34-4a85-80cd-5f5ad0d9ea50" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a37dc7e6-7366-47d9-82cf-7ec561312fd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2649009d-b09b-4775-92b1-18f6f1ab060d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_StatementTable_2649009d-b09b-4775-92b1-18f6f1ab060d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d380f2fb-deb5-4400-8fca-08f174012815" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2649009d-b09b-4775-92b1-18f6f1ab060d" xlink:to="loc_srt_ProductOrServiceAxis_d380f2fb-deb5-4400-8fca-08f174012815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d380f2fb-deb5-4400-8fca-08f174012815_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d380f2fb-deb5-4400-8fca-08f174012815" xlink:to="loc_srt_ProductsAndServicesDomain_d380f2fb-deb5-4400-8fca-08f174012815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d380f2fb-deb5-4400-8fca-08f174012815" xlink:to="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7b58e73b-5429-4850-b0ce-c163a04ea887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:to="loc_us-gaap_ProductMember_7b58e73b-5429-4850-b0ce-c163a04ea887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_1b7ea3d4-dd69-48ab-8f30-87c89488292c" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_1b7ea3d4-dd69-48ab-8f30-87c89488292c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_4e131b1d-9b9c-4c90-a9a5-5ee9aeaa6fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_4e131b1d-9b9c-4c90-a9a5-5ee9aeaa6fcb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="i2a68abcbfe184e8595ea3c0180e30a2d_ConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i3d3bbf6917974270a30658543d83cd40_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i74639510a73b45e7b84124f4e6f6f73e_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i9abf3b6f65d14f3684a9299ccdf2e18b_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077a3ea8-1e52-4aad-a847-47c14eadc3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077a3ea8-1e52-4aad-a847-47c14eadc3f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_952f3246-240a-4a24-8551-55170e9f71ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077a3ea8-1e52-4aad-a847-47c14eadc3f6" xlink:to="loc_us-gaap_ProfitLoss_952f3246-240a-4a24-8551-55170e9f71ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077a3ea8-1e52-4aad-a847-47c14eadc3f6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_79e77d5c-4db4-4548-943c-6a19bc048684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_79e77d5c-4db4-4548-943c-6a19bc048684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_b863f702-0bb5-466b-a532-b5d9af36d18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_b863f702-0bb5-466b-a532-b5d9af36d18d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1ef30184-ef4b-4968-ac85-de7b70034493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1ef30184-ef4b-4968-ac85-de7b70034493" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5bc57893-ccd8-4017-a28e-0ff73b23a9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_ShareBasedCompensation_5bc57893-ccd8-4017-a28e-0ff73b23a9ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_64d62cee-4eaa-4514-af97-ea7a0d576dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_64d62cee-4eaa-4514-af97-ea7a0d576dfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_433502e2-2c32-411c-9903-e025ec48795b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_433502e2-2c32-411c-9903-e025ec48795b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6fc08dc3-d816-4265-96fd-c53883521e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6fc08dc3-d816-4265-96fd-c53883521e76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_493e9f8a-63e7-44c2-bcd2-8c8243715ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_493e9f8a-63e7-44c2-bcd2-8c8243715ead" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0576092f-d311-4941-a9a6-cf698eaf271b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0576092f-d311-4941-a9a6-cf698eaf271b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1e479511-76e5-4e5c-ac85-03205404b1be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1e479511-76e5-4e5c-ac85-03205404b1be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f23ff5c7-7ae9-4d5a-acf1-85225402d504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f23ff5c7-7ae9-4d5a-acf1-85225402d504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_67b19d6d-2ead-4b15-9c47-986da0cd0fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_67b19d6d-2ead-4b15-9c47-986da0cd0fc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_043eff47-dca3-47b2-b54b-4c69aed7a313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_043eff47-dca3-47b2-b54b-4c69aed7a313" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8d318d9e-8933-46fc-bb17-c69d62474695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8d318d9e-8933-46fc-bb17-c69d62474695" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9ddb1c91-aa04-494c-9800-2592344c9f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9ddb1c91-aa04-494c-9800-2592344c9f06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_948fbda5-b8f2-44b8-aa0c-e693cc545973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_948fbda5-b8f2-44b8-aa0c-e693cc545973" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b006fcc0-23bf-4180-bda2-4d842260a912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b006fcc0-23bf-4180-bda2-4d842260a912" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9a220f77-5c42-4b1c-ad86-068097865690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9a220f77-5c42-4b1c-ad86-068097865690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_87e8d145-3b51-419a-ba3f-bf666ac7c309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_87e8d145-3b51-419a-ba3f-bf666ac7c309" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_e6ce8e96-111f-4622-a6d9-f56c06d31068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_e6ce8e96-111f-4622-a6d9-f56c06d31068" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_1c6c4bb9-6c76-427a-98d8-9378d474bcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_1c6c4bb9-6c76-427a-98d8-9378d474bcf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_ce4f7bcf-d62a-49b8-aa40-5d72f8d9e215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_ce4f7bcf-d62a-49b8-aa40-5d72f8d9e215" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c4cfbeed-157d-4ff3-a375-9b8a68e393c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c4cfbeed-157d-4ff3-a375-9b8a68e393c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09c7444f-299e-47ce-b97f-38e80d72db58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09c7444f-299e-47ce-b97f-38e80d72db58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b04bc166-d3cf-45bb-b7b1-dff27fc7f990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b04bc166-d3cf-45bb-b7b1-dff27fc7f990" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ba89cb90-0aad-4601-a8e8-60982bc3f1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ba89cb90-0aad-4601-a8e8-60982bc3f1b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_931a9528-e427-42e3-b7b9-fa6484cbfb96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_931a9528-e427-42e3-b7b9-fa6484cbfb96" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_814ab5ef-07a7-4574-88bb-f38217edf6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_814ab5ef-07a7-4574-88bb-f38217edf6bb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_77b8151f-dc28-4049-bcd5-38330dc98a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_77b8151f-dc28-4049-bcd5-38330dc98a91" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8c9ceb2c-80ad-45d9-9035-5c270d2f2d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8c9ceb2c-80ad-45d9-9035-5c270d2f2d33" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_956c94f9-a7a4-417f-9159-c8294537d6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_956c94f9-a7a4-417f-9159-c8294537d6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_805accc2-a1ad-43d5-ad85-b05f52621811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_805accc2-a1ad-43d5-ad85-b05f52621811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16ec0ca9-3ccd-41d7-803a-33d1e9997e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16ec0ca9-3ccd-41d7-803a-33d1e9997e8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_f97daab5-61c3-4c83-ad49-7feb10089ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_RepaymentsOfDebt_f97daab5-61c3-4c83-ad49-7feb10089ce6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_cba674a2-cf4f-44b7-be98-c2f509d0c875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_cba674a2-cf4f-44b7-be98-c2f509d0c875" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_c4573011-f6b2-4142-8342-c93bfc699e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_c4573011-f6b2-4142-8342-c93bfc699e53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_d4b464f0-6e2b-49a0-92f8-28af55afb3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_d4b464f0-6e2b-49a0-92f8-28af55afb3ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1f980e8f-70c2-47ad-b396-366bdbecfbc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1f980e8f-70c2-47ad-b396-366bdbecfbc7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d947b0e-bab3-4dfd-8fe2-afacf9dfff2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d947b0e-bab3-4dfd-8fe2-afacf9dfff2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_33561356-5fef-4609-9166-2513f8811ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_33561356-5fef-4609-9166-2513f8811ad7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6de166ea-1e65-43a4-901d-5c34d1abf31a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6de166ea-1e65-43a4-901d-5c34d1abf31a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4cac0747-594b-42a8-9e9a-5ccf49baf455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4cac0747-594b-42a8-9e9a-5ccf49baf455" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ddeda97-53ad-41a2-bd53-7cc0ecd0fa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f097e07c-e9ff-41fd-8252-b8327202f0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_StatementTable_f097e07c-e9ff-41fd-8252-b8327202f0d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64941f8d-8f53-45d6-a93d-338c8db6e865" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f097e07c-e9ff-41fd-8252-b8327202f0d9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64941f8d-8f53-45d6-a93d-338c8db6e865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_64941f8d-8f53-45d6-a93d-338c8db6e865_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64941f8d-8f53-45d6-a93d-338c8db6e865" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_64941f8d-8f53-45d6-a93d-338c8db6e865_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64941f8d-8f53-45d6-a93d-338c8db6e865" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_8c9fada5-987e-4c1a-8250-b97958040b38" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:to="loc_biib_IonisPharmaceuticalsMember_8c9fada5-987e-4c1a-8250-b97958040b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsIncAgreementMember_877aefc6-396a-42ee-a304-72c7ed2964e9" xlink:href="biib-20201231.xsd#biib_SangamoTherapeuticsIncAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:to="loc_biib_SangamoTherapeuticsIncAgreementMember_877aefc6-396a-42ee-a304-72c7ed2964e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_f92ec65d-dd56-4aed-8af4-38c1b11b87c3" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:to="loc_biib_DenaliTherapeuticsIncMember_f92ec65d-dd56-4aed-8af4-38c1b11b87c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_d8aa5749-56ad-44e4-8738-d2e2c49d7dc4" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:to="loc_biib_SageTherapeuticsIncMember_d8aa5749-56ad-44e4-8738-d2e2c49d7dc4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i3082974aed074301a3740d745ec4eb16_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3251b9cc-fd96-4a50-a6b1-149d0c3f9c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3251b9cc-fd96-4a50-a6b1-149d0c3f9c7b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5a2c9fe0-f328-4621-bbdc-81075be94f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_SharesIssued_5a2c9fe0-f328-4621-bbdc-81075be94f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30530b2f-96eb-4350-8eeb-e46943fd9434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30530b2f-96eb-4350-8eeb-e46943fd9434" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_99776daa-458d-4ff7-88c1-4f3fc45926d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_ProfitLoss_99776daa-458d-4ff7-88c1-4f3fc45926d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_67098f3b-8ff4-4548-aae4-5e1add3b2736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_67098f3b-8ff4-4548-aae4-5e1add3b2736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_dbb6786b-86d0-45e5-99e8-4adbc2b08932" xlink:href="biib-20201231.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_dbb6786b-86d0-45e5-99e8-4adbc2b08932" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_16c1810f-1433-4e16-aed8-222ccac50473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_16c1810f-1433-4e16-aed8-222ccac50473" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_eb5fc851-f8cc-4fe4-840c-0fe414e4d924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_eb5fc851-f8cc-4fe4-840c-0fe414e4d924" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e819c447-f170-4e80-b0da-d199d1762162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e819c447-f170-4e80-b0da-d199d1762162" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f974687d-ec2e-42f9-8eb6-0521b3d1a979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f974687d-ec2e-42f9-8eb6-0521b3d1a979" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_b009f283-30a8-4252-b9a6-55d888dcc10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_b009f283-30a8-4252-b9a6-55d888dcc10c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_437e52ac-60f0-484f-9040-d335a7973d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_437e52ac-60f0-484f-9040-d335a7973d04" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e0612a67-17a9-4dcb-9f42-8e1411231b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e0612a67-17a9-4dcb-9f42-8e1411231b4e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26f69f83-8dd3-4fdf-a863-3e2379af5e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26f69f83-8dd3-4fdf-a863-3e2379af5e37" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_157e6627-b964-49ae-b572-ce8801417ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_157e6627-b964-49ae-b572-ce8801417ce6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_22f3b21e-7b8f-4ddf-9864-37c32ab2e8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_22f3b21e-7b8f-4ddf-9864-37c32ab2e8dd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_78373f6c-9688-497a-8966-52be71cc5fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockholdersEquityOther_78373f6c-9688-497a-8966-52be71cc5fa5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1a63fd84-2e7b-4592-b26a-e79b0f5ab4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73a88d13-627f-48aa-9a98-ce8fceac25eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3251b9cc-fd96-4a50-a6b1-149d0c3f9c7b" xlink:to="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9aa8a4c7-be9d-4e59-a0c7-734fec853e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9aa8a4c7-be9d-4e59-a0c7-734fec853e81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9aa8a4c7-be9d-4e59-a0c7-734fec853e81_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9aa8a4c7-be9d-4e59-a0c7-734fec853e81" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9aa8a4c7-be9d-4e59-a0c7-734fec853e81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9aa8a4c7-be9d-4e59-a0c7-734fec853e81" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram5Member_66198519-dc66-47f9-bc8d-4c76e5b304dd" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram5Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram5Member_66198519-dc66-47f9-bc8d-4c76e5b304dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram4Member_3ea8210e-7100-4f03-ab65-942ab5682c54" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram4Member_3ea8210e-7100-4f03-ab65-942ab5682c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram3Member_d475dd07-b96c-4c0f-bb47-51b00116023b" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram3Member_d475dd07-b96c-4c0f-bb47-51b00116023b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram2Member_53c3a684-82b3-4e27-a711-af03839e748f" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram2Member_53c3a684-82b3-4e27-a711-af03839e748f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram1Member_ae77935e-bb40-45d8-955d-75e750b6e8de" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram1Member_ae77935e-bb40-45d8-955d-75e750b6e8de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e848e69d-a487-4fa4-bb0f-425708769a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e848e69d-a487-4fa4-bb0f-425708769a63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e848e69d-a487-4fa4-bb0f-425708769a63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e848e69d-a487-4fa4-bb0f-425708769a63" xlink:to="loc_us-gaap_EquityComponentDomain_e848e69d-a487-4fa4-bb0f-425708769a63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e848e69d-a487-4fa4-bb0f-425708769a63" xlink:to="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_8fc2075b-3625-4ad0-bac9-f432f8e15667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_PreferredStockMember_8fc2075b-3625-4ad0-bac9-f432f8e15667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d260b1c3-af87-4bdd-8d4a-11f0453ddd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_CommonStockMember_d260b1c3-af87-4bdd-8d4a-11f0453ddd9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b2c01739-2a5e-43d1-b430-851916122f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b2c01739-2a5e-43d1-b430-851916122f48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_055783e5-a66c-4849-a1d4-22d7262614c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_055783e5-a66c-4849-a1d4-22d7262614c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_74ef5d5c-e949-4ecb-b387-c07848cf01dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_RetainedEarningsMember_74ef5d5c-e949-4ecb-b387-c07848cf01dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_3035680f-15fc-4f48-a219-30d24cfe2704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_TreasuryStockMember_3035680f-15fc-4f48-a219-30d24cfe2704" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_51bb2560-f8bb-4964-920a-203cfb55d1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_ParentMember_51bb2560-f8bb-4964-920a-203cfb55d1e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a0e257b1-f635-412b-bdb9-f8203cd82725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a0e257b1-f635-412b-bdb9-f8203cd82725" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_21d58001-253f-4ce6-8d20-240a5e47a519" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_21d58001-253f-4ce6-8d20-240a5e47a519" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_21d58001-253f-4ce6-8d20-240a5e47a519_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_21d58001-253f-4ce6-8d20-240a5e47a519" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_21d58001-253f-4ce6-8d20-240a5e47a519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f61247d-b671-42b7-adbc-1c44f7ea1320" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_21d58001-253f-4ce6-8d20-240a5e47a519" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f61247d-b671-42b7-adbc-1c44f7ea1320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f23e32d3-9298-49c1-bb85-c45264e49015" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f61247d-b671-42b7-adbc-1c44f7ea1320" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f23e32d3-9298-49c1-bb85-c45264e49015" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="id30fcf2fec7f40e88f385882d2f91a36_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i7aff4b2fbb9f44d3a2832d8543bc0537_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ia572139d0698479a9ed14e610ab0ab1a_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i3a25149b7b354dff94e8ae272f53351f_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_bbd0069c-82a7-4ed5-8fd6-0194022dca8e" xlink:href="biib-20201231.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_bbd0069c-82a7-4ed5-8fd6-0194022dca8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_68b481e7-e18e-4d2d-9988-b023bab785d8" xlink:href="biib-20201231.xsd#biib_InterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_biib_InterestInSubsidiary_68b481e7-e18e-4d2d-9988-b023bab785d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_f5dda052-a6a2-4421-8efa-a16eff561e52" xlink:href="biib-20201231.xsd#biib_PaymentTermsOfAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_biib_PaymentTermsOfAccountsReceivable_f5dda052-a6a2-4421-8efa-a16eff561e52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryCapitalizedCosts_b5e8ef1c-321c-4563-9472-4cffd7cc84fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryCapitalizedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_OtherInventoryCapitalizedCosts_b5e8ef1c-321c-4563-9472-4cffd7cc84fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_9f8f416a-8a4f-418e-bb2b-5118ebef034c" xlink:href="biib-20201231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_9f8f416a-8a4f-418e-bb2b-5118ebef034c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54ecaca2-c2dd-4e0d-a8a8-0ba40c9613a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54ecaca2-c2dd-4e0d-a8a8-0ba40c9613a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a5fe87e1-97d3-4a28-88a8-a56c87b80132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a5fe87e1-97d3-4a28-88a8-a56c87b80132" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41f4983d-f278-4e17-8b0d-17237c223081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_OperatingLeaseLiability_41f4983d-f278-4e17-8b0d-17237c223081" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b19f608d-0c13-4f0e-89dd-4e3283dc84b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b19f608d-0c13-4f0e-89dd-4e3283dc84b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_3556b347-c3a9-4adb-9f1a-a220eb6510b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_AdvertisingExpense_3556b347-c3a9-4adb-9f1a-a220eb6510b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fdf29610-3833-4d3e-b3f5-fefb86ed55eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fdf29610-3833-4d3e-b3f5-fefb86ed55eb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_981db929-793b-4ca4-a9ed-9840b213e279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:to="loc_us-gaap_DeferredIncomeTaxChargesMember_981db929-793b-4ca4-a9ed-9840b213e279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_61acedbe-448c-41b2-80bc-e85453d75b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:to="loc_us-gaap_RetainedEarningsMember_61acedbe-448c-41b2-80bc-e85453d75b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilityMember_4ff28533-4c73-4150-bb8f-ccd468096f46" xlink:href="biib-20201231.xsd#biib_DeferredtaxliabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:to="loc_biib_DeferredtaxliabilityMember_4ff28533-4c73-4150-bb8f-ccd468096f46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_697eb4a9-afe1-4303-9d03-93cf7db80ccc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_srt_RangeAxis_697eb4a9-afe1-4303-9d03-93cf7db80ccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_697eb4a9-afe1-4303-9d03-93cf7db80ccc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_697eb4a9-afe1-4303-9d03-93cf7db80ccc" xlink:to="loc_srt_RangeMember_697eb4a9-afe1-4303-9d03-93cf7db80ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_499d393d-72f0-486b-b203-a007e76942ba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_697eb4a9-afe1-4303-9d03-93cf7db80ccc" xlink:to="loc_srt_RangeMember_499d393d-72f0-486b-b203-a007e76942ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b1b5ed59-b16e-4092-93b2-b78e090ff7ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_499d393d-72f0-486b-b203-a007e76942ba" xlink:to="loc_srt_MinimumMember_b1b5ed59-b16e-4092-93b2-b78e090ff7ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_291c4ffb-cd7e-495f-8037-03677570a0d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_499d393d-72f0-486b-b203-a007e76942ba" xlink:to="loc_srt_MaximumMember_291c4ffb-cd7e-495f-8037-03677570a0d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75543b4d-614a-406b-91ba-315ba06f4381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75543b4d-614a-406b-91ba-315ba06f4381" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75543b4d-614a-406b-91ba-315ba06f4381_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75543b4d-614a-406b-91ba-315ba06f4381" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_75543b4d-614a-406b-91ba-315ba06f4381_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a267e6d9-2001-40e5-b237-b31956ff3602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75543b4d-614a-406b-91ba-315ba06f4381" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a267e6d9-2001-40e5-b237-b31956ff3602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_286c9853-934f-464f-b6ca-045ec1ead6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a267e6d9-2001-40e5-b237-b31956ff3602" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_286c9853-934f-464f-b6ca-045ec1ead6b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_981417be-868f-4523-b0dc-069c1299c847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_981417be-868f-4523-b0dc-069c1299c847" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_981417be-868f-4523-b0dc-069c1299c847_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_981417be-868f-4523-b0dc-069c1299c847" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_981417be-868f-4523-b0dc-069c1299c847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6658ef1d-fd0e-4d7d-83f8-06f6b791077d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_981417be-868f-4523-b0dc-069c1299c847" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6658ef1d-fd0e-4d7d-83f8-06f6b791077d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3914d5dc-b8ae-4b9e-bde2-eaed590df261" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6658ef1d-fd0e-4d7d-83f8-06f6b791077d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3914d5dc-b8ae-4b9e-bde2-eaed590df261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_027c1b25-c4d5-4ae3-8e04-7c24ae507895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_027c1b25-c4d5-4ae3-8e04-7c24ae507895" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_027c1b25-c4d5-4ae3-8e04-7c24ae507895_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_027c1b25-c4d5-4ae3-8e04-7c24ae507895" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_027c1b25-c4d5-4ae3-8e04-7c24ae507895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7726203-3c1f-4890-8db3-cbc7298afcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_027c1b25-c4d5-4ae3-8e04-7c24ae507895" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7726203-3c1f-4890-8db3-cbc7298afcb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_fc275dd3-47da-4a0e-8b30-295c4711f298" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7726203-3c1f-4890-8db3-cbc7298afcb1" xlink:to="loc_biib_EisaiMember_fc275dd3-47da-4a0e-8b30-295c4711f298" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails" xlink:type="extended" id="ie989214e82684ac7965234aacff7c129_SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05c333d5-114c-48d3-86b0-3515d624d7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b219677-e396-430a-8419-9cc662d79ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05c333d5-114c-48d3-86b0-3515d624d7f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b219677-e396-430a-8419-9cc662d79ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05c333d5-114c-48d3-86b0-3515d624d7f3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d24c6eaa-99ba-44cd-bd65-eda5ff058d33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:to="loc_srt_RangeAxis_d24c6eaa-99ba-44cd-bd65-eda5ff058d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d24c6eaa-99ba-44cd-bd65-eda5ff058d33_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d24c6eaa-99ba-44cd-bd65-eda5ff058d33" xlink:to="loc_srt_RangeMember_d24c6eaa-99ba-44cd-bd65-eda5ff058d33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9103697-33a1-49df-ac6e-c6c5864461d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d24c6eaa-99ba-44cd-bd65-eda5ff058d33" xlink:to="loc_srt_RangeMember_e9103697-33a1-49df-ac6e-c6c5864461d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70a1fb1d-3d45-4161-a9a6-246c1ea4c46c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e9103697-33a1-49df-ac6e-c6c5864461d8" xlink:to="loc_srt_MinimumMember_70a1fb1d-3d45-4161-a9a6-246c1ea4c46c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2f7d0222-cfdf-4952-a2ff-bc53104f0bd3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e9103697-33a1-49df-ac6e-c6c5864461d8" xlink:to="loc_srt_MaximumMember_2f7d0222-cfdf-4952-a2ff-bc53104f0bd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4661db16-3248-4172-86bd-97b5af15acea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4661db16-3248-4172-86bd-97b5af15acea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4661db16-3248-4172-86bd-97b5af15acea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4661db16-3248-4172-86bd-97b5af15acea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4661db16-3248-4172-86bd-97b5af15acea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4661db16-3248-4172-86bd-97b5af15acea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_fb802884-06c7-4a01-ac15-daafe34e5ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:to="loc_us-gaap_BuildingMember_fb802884-06c7-4a01-ac15-daafe34e5ac7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7ad6df91-47b3-42b6-a5b7-72be22659fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7ad6df91-47b3-42b6-a5b7-72be22659fbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_51bd44f5-552f-4cd9-bee3-017036f83c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_51bd44f5-552f-4cd9-bee3-017036f83c06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6a9ea247-095e-4163-8bb9-75f2463684e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6a9ea247-095e-4163-8bb9-75f2463684e0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20201231.xsd#Acquisitions"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" id="if6c9ab08042a45b3955de7d06e2641be_Acquisitions"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="ia888803dec64412ba1f6cc8cec796f53_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_da3a14a6-951f-42e4-a4a5-37e06c6a5d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_da3a14a6-951f-42e4-a4a5-37e06c6a5d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_47a2ef02-72ee-4e39-bcbc-28a3b27650bb" xlink:href="biib-20201231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_47a2ef02-72ee-4e39-bcbc-28a3b27650bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalAssetsAcquired_b4dcb68c-f90d-4e8d-8d84-a74812aa8d0a" xlink:href="biib-20201231.xsd#biib_ClinicalAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_biib_ClinicalAssetsAcquired_b4dcb68c-f90d-4e8d-8d84-a74812aa8d0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_73b4c0c6-2be1-481e-bfca-d74f0092e958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_73b4c0c6-2be1-481e-bfca-d74f0092e958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_58c2c003-d539-4480-9a30-b4f436abca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_58c2c003-d539-4480-9a30-b4f436abca0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_43bff1f0-cb05-4d7b-a262-a95f6eef9e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_43bff1f0-cb05-4d7b-a262-a95f6eef9e50" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_1a0ba02b-bba8-4d5a-aa6e-891bbb092150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_1a0ba02b-bba8-4d5a-aa6e-891bbb092150" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_a61d9ec2-d279-4dac-91c5-f59927031c8c" xlink:href="biib-20201231.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_a61d9ec2-d279-4dac-91c5-f59927031c8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1a00494e-2e68-4014-b046-4bf70d02c21f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1a00494e-2e68-4014-b046-4bf70d02c21f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_d149b3c8-1466-4068-a859-8a7a89270733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_d149b3c8-1466-4068-a859-8a7a89270733" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6993fbc4-9e55-4efa-807d-ea0db599e8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6993fbc4-9e55-4efa-807d-ea0db599e8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6993fbc4-9e55-4efa-807d-ea0db599e8fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6993fbc4-9e55-4efa-807d-ea0db599e8fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6993fbc4-9e55-4efa-807d-ea0db599e8fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6993fbc4-9e55-4efa-807d-ea0db599e8fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_cff57adb-ab12-49de-a3f0-15705f64d49b" xlink:href="biib-20201231.xsd#biib_BIIB118Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_BIIB118Member_cff57adb-ab12-49de-a3f0-15705f64d49b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_61b7a795-af78-496e-94b1-25e3a6965102" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_NightstarMember_61b7a795-af78-496e-94b1-25e3a6965102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_KaryopharmMember_cfc3b005-37e0-49f3-aaec-1b252814880e" xlink:href="biib-20201231.xsd#biib_KaryopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_KaryopharmMember_cfc3b005-37e0-49f3-aaec-1b252814880e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PfizerMember_324a6128-658b-4b09-9eae-c81da18d204a" xlink:href="biib-20201231.xsd#biib_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_PfizerMember_324a6128-658b-4b09-9eae-c81da18d204a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AliveGenMember_62b71589-618a-4ddf-a8dd-41b20625a0aa" xlink:href="biib-20201231.xsd#biib_AliveGenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_AliveGenMember_62b71589-618a-4ddf-a8dd-41b20625a0aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_411ea80a-fea7-4c54-b1cf-2b63259e25d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_411ea80a-fea7-4c54-b1cf-2b63259e25d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_411ea80a-fea7-4c54-b1cf-2b63259e25d4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_411ea80a-fea7-4c54-b1cf-2b63259e25d4" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_411ea80a-fea7-4c54-b1cf-2b63259e25d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_bd4c9701-152b-4b7c-950a-80544cc1a777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_411ea80a-fea7-4c54-b1cf-2b63259e25d4" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_bd4c9701-152b-4b7c-950a-80544cc1a777" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PostacquisitionequitycompensationMember_574711b5-d617-43c2-ac19-3bddfc7d0505" xlink:href="biib-20201231.xsd#biib_PostacquisitionequitycompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_bd4c9701-152b-4b7c-950a-80544cc1a777" xlink:to="loc_biib_PostacquisitionequitycompensationMember_574711b5-d617-43c2-ac19-3bddfc7d0505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cef9709b-442e-479d-84b9-3bf89e82b206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cef9709b-442e-479d-84b9-3bf89e82b206" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cef9709b-442e-479d-84b9-3bf89e82b206_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cef9709b-442e-479d-84b9-3bf89e82b206" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cef9709b-442e-479d-84b9-3bf89e82b206_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8efe998c-dba6-443a-b99e-501e3794bcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cef9709b-442e-479d-84b9-3bf89e82b206" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8efe998c-dba6-443a-b99e-501e3794bcc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_96cb2073-0e92-4bdf-93b4-c51bb753ecf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8efe998c-dba6-443a-b99e-501e3794bcc8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_96cb2073-0e92-4bdf-93b4-c51bb753ecf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fbaf2787-dc07-4879-a62a-62dee2cbe84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8efe998c-dba6-443a-b99e-501e3794bcc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fbaf2787-dc07-4879-a62a-62dee2cbe84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_fdf64819-9d05-4d56-9327-54a51ad51e47" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_fdf64819-9d05-4d56-9327-54a51ad51e47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_fdf64819-9d05-4d56-9327-54a51ad51e47_default" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_fdf64819-9d05-4d56-9327-54a51ad51e47" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_fdf64819-9d05-4d56-9327-54a51ad51e47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_c5c4d776-786d-4a78-acce-b67fd4eaca6a" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_fdf64819-9d05-4d56-9327-54a51ad51e47" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_c5c4d776-786d-4a78-acce-b67fd4eaca6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_1d0dc14f-379d-4301-929f-f416942c176b" xlink:href="biib-20201231.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_c5c4d776-786d-4a78-acce-b67fd4eaca6a" xlink:to="loc_biib_BIIB111Member_1d0dc14f-379d-4301-929f-f416942c176b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_1dd4fb33-10f2-4390-bbcf-f32d66bf20f6" xlink:href="biib-20201231.xsd#biib_BIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_c5c4d776-786d-4a78-acce-b67fd4eaca6a" xlink:to="loc_biib_BIIB112Member_1dd4fb33-10f2-4390-bbcf-f32d66bf20f6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Divestitures" xlink:type="simple" xlink:href="biib-20201231.xsd#Divestitures"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Divestitures" xlink:type="extended" id="i0e2b03bf833742b1b6bc6b48e6aa5d78_Divestitures"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DivestituresDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="extended" id="i856c51e4a883441ea012e13c92b1ca97_DivestituresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_09c91d4f-2538-441a-a5f3-e352b6b1c09c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_09c91d4f-2538-441a-a5f3-e352b6b1c09c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_696d942c-48ea-499b-a299-e878bb6d6a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_696d942c-48ea-499b-a299-e878bb6d6a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_cde71995-f617-4bd4-a45a-171652dac125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_cde71995-f617-4bd4-a45a-171652dac125" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f119d2c6-da00-4a8b-aafa-d6902b3215a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f119d2c6-da00-4a8b-aafa-d6902b3215a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9b60e565-bdc9-4821-a25f-76baf5391782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9b60e565-bdc9-4821-a25f-76baf5391782" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_40b10ab1-5856-44a4-8c89-89863ca43336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_40b10ab1-5856-44a4-8c89-89863ca43336" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_921dfee6-6eb8-49f9-987c-ab09629e9b4c" xlink:href="biib-20201231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_921dfee6-6eb8-49f9-987c-ab09629e9b4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PurchaseCommitmentReductionOfAmountCommitted_6ca194f3-3db6-4299-969f-7a7a924544f9" xlink:href="biib-20201231.xsd#biib_PurchaseCommitmentReductionOfAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_biib_PurchaseCommitmentReductionOfAmountCommitted_6ca194f3-3db6-4299-969f-7a7a924544f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_aa7c93f7-122a-4478-a23d-98af5aac3fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_aa7c93f7-122a-4478-a23d-98af5aac3fcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9aef2f98-1549-46fb-a312-33c2295d6c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_aa7c93f7-122a-4478-a23d-98af5aac3fcd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9aef2f98-1549-46fb-a312-33c2295d6c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9aef2f98-1549-46fb-a312-33c2295d6c23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9aef2f98-1549-46fb-a312-33c2295d6c23" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9aef2f98-1549-46fb-a312-33c2295d6c23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e5779860-1a09-4dbc-9cd8-e59f66cac7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9aef2f98-1549-46fb-a312-33c2295d6c23" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e5779860-1a09-4dbc-9cd8-e59f66cac7a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_942f6de4-74fb-447a-a288-c6ab4aaa5bf6" xlink:href="biib-20201231.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e5779860-1a09-4dbc-9cd8-e59f66cac7a2" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_942f6de4-74fb-447a-a288-c6ab4aaa5bf6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20201231.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended" id="i6af6ee46c9b249d6a193d27c2434e080_Revenues"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" id="i1d5e01b4d49744b68bca369096f55868_RevenuesTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesRevenuesbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails" xlink:type="extended" id="id9bbea46458845f4a3cf18999e77023b_RevenuesRevenuesbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3caa7f51-06cf-45de-915d-5b25304f0efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2d8b50a3-833d-444e-b439-052d70f7da1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3caa7f51-06cf-45de-915d-5b25304f0efc" xlink:to="loc_us-gaap_Revenues_2d8b50a3-833d-444e-b439-052d70f7da1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3caa7f51-06cf-45de-915d-5b25304f0efc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7786e8c0-5bc8-4653-ab25-4a867f53e4d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:to="loc_srt_StatementGeographicalAxis_7786e8c0-5bc8-4653-ab25-4a867f53e4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7786e8c0-5bc8-4653-ab25-4a867f53e4d9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7786e8c0-5bc8-4653-ab25-4a867f53e4d9" xlink:to="loc_srt_SegmentGeographicalDomain_7786e8c0-5bc8-4653-ab25-4a867f53e4d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ededc21b-c3ab-41e5-bffe-5a87c29a1ebd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7786e8c0-5bc8-4653-ab25-4a867f53e4d9" xlink:to="loc_srt_SegmentGeographicalDomain_ededc21b-c3ab-41e5-bffe-5a87c29a1ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_866e6e99-ddeb-4721-91b2-4413d9e95fb7" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ededc21b-c3ab-41e5-bffe-5a87c29a1ebd" xlink:to="loc_country_US_866e6e99-ddeb-4721-91b2-4413d9e95fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b673e7a6-64f9-45fa-a263-77752cc95eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ededc21b-c3ab-41e5-bffe-5a87c29a1ebd" xlink:to="loc_us-gaap_NonUsMember_b673e7a6-64f9-45fa-a263-77752cc95eca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe316a9d-90a3-47f2-b995-6e486353c760" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:to="loc_srt_ProductOrServiceAxis_fe316a9d-90a3-47f2-b995-6e486353c760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe316a9d-90a3-47f2-b995-6e486353c760_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fe316a9d-90a3-47f2-b995-6e486353c760" xlink:to="loc_srt_ProductsAndServicesDomain_fe316a9d-90a3-47f2-b995-6e486353c760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fe316a9d-90a3-47f2-b995-6e486353c760" xlink:to="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_2a609a07-72fc-4c7f-a34b-65cdfcad97f6" xlink:href="biib-20201231.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_FumarateMember_2a609a07-72fc-4c7f-a34b-65cdfcad97f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_242f2710-cfba-470e-803a-44f6be02e0a9" xlink:href="biib-20201231.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_InterferonMember_242f2710-cfba-470e-803a-44f6be02e0a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_72d3d32a-4d22-48b0-89f1-fe7fed62efc2" xlink:href="biib-20201231.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_TysabriProductMember_72d3d32a-4d22-48b0-89f1-fe7fed62efc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_ff01b125-c232-4a9d-8924-bbc1b53d6c1a" xlink:href="biib-20201231.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_FAMPYRAMember_ff01b125-c232-4a9d-8924-bbc1b53d6c1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_2c91287d-f1c2-4c46-b90e-be19c4964c8a" xlink:href="biib-20201231.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_ZINBRYTAMember_2c91287d-f1c2-4c46-b90e-be19c4964c8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_ddc425ed-f1fe-4e76-a845-6065d7eff6a8" xlink:href="biib-20201231.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_MSProductRevenuesMember_ddc425ed-f1fe-4e76-a845-6065d7eff6a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_15ac5c07-962b-4a3c-9d11-662ab8b98eff" xlink:href="biib-20201231.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_SPINRAZAMember_15ac5c07-962b-4a3c-9d11-662ab8b98eff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_0269fa8d-a7de-4edd-9ef4-d51abc0fe106" xlink:href="biib-20201231.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_BENEPALIMember_0269fa8d-a7de-4edd-9ef4-d51abc0fe106" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_72952523-6395-4193-af7f-c5d80b49d871" xlink:href="biib-20201231.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_IMRALDIMember_72952523-6395-4193-af7f-c5d80b49d871" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_512b99a6-0747-4b80-bab5-c204a39081af" xlink:href="biib-20201231.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_FLIXABIMember_512b99a6-0747-4b80-bab5-c204a39081af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_37e19f49-df8b-48c2-8278-0c20fba851a9" xlink:href="biib-20201231.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_BiosimilarsMember_37e19f49-df8b-48c2-8278-0c20fba851a9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_cdccace6-4225-4bfa-a43e-ed8bb9bea438" xlink:href="biib-20201231.xsd#biib_FUMADERMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_FUMADERMMember_cdccace6-4225-4bfa-a43e-ed8bb9bea438" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_79e1192b-7455-404c-a87d-7c209e1317cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_us-gaap_ProductMember_79e1192b-7455-404c-a87d-7c209e1317cc" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i6bc665ea1797463ab508616537a63116_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_e2bf50a8-803c-43a1-b795-bd6792a77240" xlink:href="biib-20201231.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_biib_NumberOfWholesalers_e2bf50a8-803c-43a1-b795-bd6792a77240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_863b0626-2a5b-4cbd-92c0-730d1c1ee8e1" xlink:href="biib-20201231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_863b0626-2a5b-4cbd-92c0-730d1c1ee8e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_3f24b077-9827-43fa-b0f9-91fd850ea9a4" xlink:href="biib-20201231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_3f24b077-9827-43fa-b0f9-91fd850ea9a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_59b81a5c-8a7f-4759-915e-3caa1ff7fe07" xlink:href="biib-20201231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_59b81a5c-8a7f-4759-915e-3caa1ff7fe07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_47f8cd2a-9314-4939-9402-c2b40f4db8bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_us-gaap_Revenues_47f8cd2a-9314-4939-9402-c2b40f4db8bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f69d963c-82b7-4434-98c6-3758d9cf516b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f69d963c-82b7-4434-98c6-3758d9cf516b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MajorDistributorAxis_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042" xlink:href="biib-20201231.xsd#biib_MajorDistributorAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:to="loc_biib_MajorDistributorAxis_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MajorDistributorDomain_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042_default" xlink:href="biib-20201231.xsd#biib_MajorDistributorDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042" xlink:to="loc_biib_MajorDistributorDomain_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MajorDistributorDomain_b874a20d-95d1-46fb-a8e4-eaccf47371e4" xlink:href="biib-20201231.xsd#biib_MajorDistributorDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042" xlink:to="loc_biib_MajorDistributorDomain_b874a20d-95d1-46fb-a8e4-eaccf47371e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_86ad889b-c65d-4c0f-8be1-ac19a2071489" xlink:href="biib-20201231.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_b874a20d-95d1-46fb-a8e4-eaccf47371e4" xlink:to="loc_biib_DistributorOneMember_86ad889b-c65d-4c0f-8be1-ac19a2071489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_23ef4067-9213-4fd7-bba8-dbe08b74be23" xlink:href="biib-20201231.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_b874a20d-95d1-46fb-a8e4-eaccf47371e4" xlink:to="loc_biib_DistributorTwoMember_23ef4067-9213-4fd7-bba8-dbe08b74be23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_faf9c9ac-864f-428b-8207-2d9696559a57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:to="loc_srt_MajorCustomersAxis_faf9c9ac-864f-428b-8207-2d9696559a57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_faf9c9ac-864f-428b-8207-2d9696559a57_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_faf9c9ac-864f-428b-8207-2d9696559a57" xlink:to="loc_srt_NameOfMajorCustomerDomain_faf9c9ac-864f-428b-8207-2d9696559a57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_650bca0e-12b8-4bb9-839b-4671676f7738" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_faf9c9ac-864f-428b-8207-2d9696559a57" xlink:to="loc_srt_NameOfMajorCustomerDomain_650bca0e-12b8-4bb9-839b-4671676f7738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BioverativMember_52fad878-eb5c-47ef-839a-5cba10be327f" xlink:href="biib-20201231.xsd#biib_BioverativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_650bca0e-12b8-4bb9-839b-4671676f7738" xlink:to="loc_biib_BioverativMember_52fad878-eb5c-47ef-839a-5cba10be327f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingCustomerMember_f218d9f0-4886-4b03-af19-20dbece299b8" xlink:href="biib-20201231.xsd#biib_ContractManufacturingCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_650bca0e-12b8-4bb9-839b-4671676f7738" xlink:to="loc_biib_ContractManufacturingCustomerMember_f218d9f0-4886-4b03-af19-20dbece299b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b9ed688f-8a01-4bcf-81e1-371fb7eea788" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:to="loc_srt_ProductOrServiceAxis_b9ed688f-8a01-4bcf-81e1-371fb7eea788" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b9ed688f-8a01-4bcf-81e1-371fb7eea788_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b9ed688f-8a01-4bcf-81e1-371fb7eea788" xlink:to="loc_srt_ProductsAndServicesDomain_b9ed688f-8a01-4bcf-81e1-371fb7eea788_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b8440aa-6d03-4d12-893c-031016a96d70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b9ed688f-8a01-4bcf-81e1-371fb7eea788" xlink:to="loc_srt_ProductsAndServicesDomain_1b8440aa-6d03-4d12-893c-031016a96d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b75d798a-5486-4a3c-962a-aaa53fabe7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1b8440aa-6d03-4d12-893c-031016a96d70" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b75d798a-5486-4a3c-962a-aaa53fabe7ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_5f692e69-dd7f-45ef-b9ea-f5027b1c74ef" xlink:href="biib-20201231.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1b8440aa-6d03-4d12-893c-031016a96d70" xlink:to="loc_biib_OthercorporaterevenuesMember_5f692e69-dd7f-45ef-b9ea-f5027b1c74ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesReservesforDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails" xlink:type="extended" id="iba8e72073d314018bad647b80768f2dd_RevenuesReservesforDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_70f4ca55-d0f0-4c8e-a124-f6ffee87578d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_70f4ca55-d0f0-4c8e-a124-f6ffee87578d" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a2799d0c-dfce-47e5-ac75-2b8e5b9ed78e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a2799d0c-dfce-47e5-ac75-2b8e5b9ed78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_23e61ae6-a865-4a93-a260-777e6d813db9" xlink:href="biib-20201231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_23e61ae6-a865-4a93-a260-777e6d813db9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_1cbfa6f4-4d7f-4aa7-8668-27f4149fea64" xlink:href="biib-20201231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_1cbfa6f4-4d7f-4aa7-8668-27f4149fea64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_e1381edd-f7f4-4610-ab8c-0b3fca84baf0" xlink:href="biib-20201231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_e1381edd-f7f4-4610-ab8c-0b3fca84baf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_d565ba11-486e-4dee-aa7f-8b34755093ac" xlink:href="biib-20201231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_d565ba11-486e-4dee-aa7f-8b34755093ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d61bc7a2-928e-473c-b4eb-5703c27ff3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2782970-4b3a-4a8c-848f-6b9bee3d4c40" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_70f4ca55-d0f0-4c8e-a124-f6ffee87578d" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2782970-4b3a-4a8c-848f-6b9bee3d4c40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7dd753b9-2bfd-44a9-b682-0c39af223d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2782970-4b3a-4a8c-848f-6b9bee3d4c40" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7dd753b9-2bfd-44a9-b682-0c39af223d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7dd753b9-2bfd-44a9-b682-0c39af223d47_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7dd753b9-2bfd-44a9-b682-0c39af223d47" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7dd753b9-2bfd-44a9-b682-0c39af223d47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7dd753b9-2bfd-44a9-b682-0c39af223d47" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_cc35c3ae-0d28-4d50-9f1f-d09a6921954f" xlink:href="biib-20201231.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:to="loc_biib_ReserveforCashDiscountsMember_cc35c3ae-0d28-4d50-9f1f-d09a6921954f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_5375e095-37a5-4e4c-adfb-eb399901f9a5" xlink:href="biib-20201231.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:to="loc_biib_ContractualAdjustmentsMember_5375e095-37a5-4e4c-adfb-eb399901f9a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_b00270b2-ce10-496b-b8ee-c911cfb99319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_b00270b2-ce10-496b-b8ee-c911cfb99319" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesTotalReservesforDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails" xlink:type="extended" id="i2135923b937747198fd715ccf911af26_RevenuesTotalReservesforDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6a50eedb-73b6-4853-927d-3a15514e16d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ed8c43b5-ee14-4ebb-8fbf-c23941e2066f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6a50eedb-73b6-4853-927d-3a15514e16d5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ed8c43b5-ee14-4ebb-8fbf-c23941e2066f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_82f81e39-b98e-41b6-839f-f53fcb258596" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6a50eedb-73b6-4853-927d-3a15514e16d5" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_82f81e39-b98e-41b6-839f-f53fcb258596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_08493d29-3dd1-4277-b88e-e332ce677617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_82f81e39-b98e-41b6-839f-f53fcb258596" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_08493d29-3dd1-4277-b88e-e332ce677617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_08493d29-3dd1-4277-b88e-e332ce677617_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08493d29-3dd1-4277-b88e-e332ce677617" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_08493d29-3dd1-4277-b88e-e332ce677617_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a7322223-14f7-4893-999f-b13a94c4285a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08493d29-3dd1-4277-b88e-e332ce677617" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a7322223-14f7-4893-999f-b13a94c4285a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0dcb529b-7387-46b4-8060-7ea7a07353a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a7322223-14f7-4893-999f-b13a94c4285a" xlink:to="loc_us-gaap_AccountsReceivableMember_0dcb529b-7387-46b4-8060-7ea7a07353a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0e52f656-52e0-474d-a455-3ce02de0887c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a7322223-14f7-4893-999f-b13a94c4285a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_0e52f656-52e0-474d-a455-3ce02de0887c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="i6ad6de491f6841d583fd465a0039f8ca_RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_2c5519bd-6784-4c54-88e4-1f6b2b41c08d" xlink:href="biib-20201231.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:to="loc_biib_ShareOfCoPromotionProfits_2c5519bd-6784-4c54-88e4-1f6b2b41c08d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_312ad5a0-eb87-410d-96dd-38a749ee17f5" xlink:href="biib-20201231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_312ad5a0-eb87-410d-96dd-38a749ee17f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_597ce7c8-dfe1-4b66-ac33-88d5b692ccd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:to="loc_us-gaap_Revenues_597ce7c8-dfe1-4b66-ac33-88d5b692ccd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4b20f65f-dca1-451c-b7b4-deea470be791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:to="loc_srt_MajorCustomersAxis_4b20f65f-dca1-451c-b7b4-deea470be791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4b20f65f-dca1-451c-b7b4-deea470be791_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4b20f65f-dca1-451c-b7b4-deea470be791" xlink:to="loc_srt_NameOfMajorCustomerDomain_4b20f65f-dca1-451c-b7b4-deea470be791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f47597bf-42c7-42bc-879f-5bab0114fad0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4b20f65f-dca1-451c-b7b4-deea470be791" xlink:to="loc_srt_NameOfMajorCustomerDomain_f47597bf-42c7-42bc-879f-5bab0114fad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_d5729c2f-f8f7-4e72-9155-2d6e60c92c4c" xlink:href="biib-20201231.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f47597bf-42c7-42bc-879f-5bab0114fad0" xlink:to="loc_biib_RocheGroupGenentechMember_d5729c2f-f8f7-4e72-9155-2d6e60c92c4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5b49ef01-5ada-4fab-9dcc-0e15df8e0973" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:to="loc_srt_ProductOrServiceAxis_5b49ef01-5ada-4fab-9dcc-0e15df8e0973" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b49ef01-5ada-4fab-9dcc-0e15df8e0973_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5b49ef01-5ada-4fab-9dcc-0e15df8e0973" xlink:to="loc_srt_ProductsAndServicesDomain_5b49ef01-5ada-4fab-9dcc-0e15df8e0973_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec582985-72c1-4f73-8e09-3d029928b56d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5b49ef01-5ada-4fab-9dcc-0e15df8e0973" xlink:to="loc_srt_ProductsAndServicesDomain_ec582985-72c1-4f73-8e09-3d029928b56d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_f8510afd-3eeb-489d-8838-fa46c4875a5a" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ec582985-72c1-4f73-8e09-3d029928b56d" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_f8510afd-3eeb-489d-8838-fa46c4875a5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" id="i388790ba11a64419bff3f1ed19e6df48_RevenuesOtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d1d8686a-cf99-4c4a-b2ad-1075a9054cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e5bf5fde-4e27-43de-92d0-f22d8a4ffda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d1d8686a-cf99-4c4a-b2ad-1075a9054cb1" xlink:to="loc_us-gaap_Revenues_e5bf5fde-4e27-43de-92d0-f22d8a4ffda9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d1d8686a-cf99-4c4a-b2ad-1075a9054cb1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4471be72-6a2b-43ac-bea8-0a4977142cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4471be72-6a2b-43ac-bea8-0a4977142cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4471be72-6a2b-43ac-bea8-0a4977142cb5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4471be72-6a2b-43ac-bea8-0a4977142cb5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4471be72-6a2b-43ac-bea8-0a4977142cb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7cdb474-d594-4b21-a644-9f52554c1f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4471be72-6a2b-43ac-bea8-0a4977142cb5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7cdb474-d594-4b21-a644-9f52554c1f5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ea1a4095-8a46-4a51-bfff-acef5f4d7014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7cdb474-d594-4b21-a644-9f52554c1f5d" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ea1a4095-8a46-4a51-bfff-acef5f4d7014" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:to="loc_srt_ProductOrServiceAxis_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4" xlink:to="loc_srt_ProductsAndServicesDomain_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4" xlink:to="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_39a10c66-ad2b-4a42-8061-385f2eca5967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:to="loc_us-gaap_RoyaltyMember_39a10c66-ad2b-4a42-8061-385f2eca5967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_a5f9e280-2b08-4649-8808-a85ad4a93667" xlink:href="biib-20201231.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:to="loc_biib_OthercorporaterevenuesMember_a5f9e280-2b08-4649-8808-a85ad4a93667" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6878fce4-e992-41c8-a891-5e0112abbd0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6878fce4-e992-41c8-a891-5e0112abbd0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_988c2a03-e3a4-4a76-80cd-17d6c04ada9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:to="loc_srt_MajorCustomersAxis_988c2a03-e3a4-4a76-80cd-17d6c04ada9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_988c2a03-e3a4-4a76-80cd-17d6c04ada9e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_988c2a03-e3a4-4a76-80cd-17d6c04ada9e" xlink:to="loc_srt_NameOfMajorCustomerDomain_988c2a03-e3a4-4a76-80cd-17d6c04ada9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ec35216b-afc7-421b-bb61-ec079b3d8fd6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_988c2a03-e3a4-4a76-80cd-17d6c04ada9e" xlink:to="loc_srt_NameOfMajorCustomerDomain_ec35216b-afc7-421b-bb61-ec079b3d8fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_ba7d780e-3a35-4e85-b11a-118babcda81d" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec35216b-afc7-421b-bb61-ec079b3d8fd6" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_ba7d780e-3a35-4e85-b11a-118babcda81d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherRelationshipsMember_86489641-d46f-4d5c-ac53-90b26b5bf5ef" xlink:href="biib-20201231.xsd#biib_OtherRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec35216b-afc7-421b-bb61-ec079b3d8fd6" xlink:to="loc_biib_OtherRelationshipsMember_86489641-d46f-4d5c-ac53-90b26b5bf5ef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20201231.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" id="i58fd7f12deaa4f04907a99a15f1f7824_Inventory"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" id="ibf0182af4a3b4a5288434fbc3abfe1cf_InventoryTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryComponentsofInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended" id="i5ec05248f6764b1f97ce6a4441982727_InventoryComponentsofInventoryDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended" id="i0a4c0848d24b4d8f8f61ed6ecf922a75_InventoryNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_901a8af3-db26-4de6-8cdd-ee5beb6d97a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:to="loc_us-gaap_InventoryWriteDown_901a8af3-db26-4de6-8cdd-ee5beb6d97a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0feb2697-aa66-4d83-a1b5-865dc54061fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0feb2697-aa66-4d83-a1b5-865dc54061fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_30d30a40-cf7c-4ce4-8eb8-18ee07fccca4" xlink:href="biib-20201231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_30d30a40-cf7c-4ce4-8eb8-18ee07fccca4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_66f3b2d0-6c1f-481d-a7bb-703800b5592c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_66f3b2d0-6c1f-481d-a7bb-703800b5592c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_66f3b2d0-6c1f-481d-a7bb-703800b5592c" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e6d5d99-1716-4f71-85fa-053d9dada9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e6d5d99-1716-4f71-85fa-053d9dada9eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkinprocessMember_df723935-b375-4d29-8b4d-eb90aaa9329f" xlink:href="biib-20201231.xsd#biib_WorkinprocessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e6d5d99-1716-4f71-85fa-053d9dada9eb" xlink:to="loc_biib_WorkinprocessMember_df723935-b375-4d29-8b4d-eb90aaa9329f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwill"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended" id="i5d1d79a2fab94334b66c5d51380ae285_IntangibleAssetsandGoodwill"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended" id="i40841b42abaa4387b33910a76cfe6388_IntangibleAssetsandGoodwillTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended" id="iac15b55d9b284c2d90d09bbbf7837072_IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b4068342-54dd-42a7-b290-5f77e734f594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b4068342-54dd-42a7-b290-5f77e734f594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_70a2d717-01bf-444a-8eac-0cf09ec291d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_70a2d717-01bf-444a-8eac-0cf09ec291d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ded8585a-0bd9-40ce-9222-1dc20cf81c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ded8585a-0bd9-40ce-9222-1dc20cf81c00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_705c5f61-6d24-47c6-a6fa-361569e5f9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_705c5f61-6d24-47c6-a6fa-361569e5f9c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9f33e26-55f5-4de8-a630-48e34468e3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9f33e26-55f5-4de8-a630-48e34468e3ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97fcffe7-c3e5-4cf0-9b8b-fb435102b51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97fcffe7-c3e5-4cf0-9b8b-fb435102b51f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_676ce1e8-8ac5-4343-9e3b-976ef35c5220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_676ce1e8-8ac5-4343-9e3b-976ef35c5220" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_288eaecf-cd21-4110-8d22-ec8bcb724d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_288eaecf-cd21-4110-8d22-ec8bcb724d52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_288eaecf-cd21-4110-8d22-ec8bcb724d52_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_288eaecf-cd21-4110-8d22-ec8bcb724d52" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_288eaecf-cd21-4110-8d22-ec8bcb724d52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6514d6d-ebb6-4149-bc52-229f3197b5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_288eaecf-cd21-4110-8d22-ec8bcb724d52" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6514d6d-ebb6-4149-bc52-229f3197b5fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_59b980c0-6fa0-4bf3-a697-702e12a8e1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6514d6d-ebb6-4149-bc52-229f3197b5fc" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_59b980c0-6fa0-4bf3-a697-702e12a8e1d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_d4fabce5-0e98-4269-b358-4e6955199f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6514d6d-ebb6-4149-bc52-229f3197b5fc" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_d4fabce5-0e98-4269-b358-4e6955199f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_286aea6a-5111-45b7-a779-e9dafbc12d8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:to="loc_srt_RangeAxis_286aea6a-5111-45b7-a779-e9dafbc12d8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_286aea6a-5111-45b7-a779-e9dafbc12d8c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_286aea6a-5111-45b7-a779-e9dafbc12d8c" xlink:to="loc_srt_RangeMember_286aea6a-5111-45b7-a779-e9dafbc12d8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_457543b5-08e3-47e7-b505-2b5397987ede" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_286aea6a-5111-45b7-a779-e9dafbc12d8c" xlink:to="loc_srt_RangeMember_457543b5-08e3-47e7-b505-2b5397987ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37f59a09-069f-4d58-8e9c-9fbee26136ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_457543b5-08e3-47e7-b505-2b5397987ede" xlink:to="loc_srt_MinimumMember_37f59a09-069f-4d58-8e9c-9fbee26136ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f0ab84a6-d9d1-4c23-8a09-14ce326bb9e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_457543b5-08e3-47e7-b505-2b5397987ede" xlink:to="loc_srt_MaximumMember_f0ab84a6-d9d1-4c23-8a09-14ce326bb9e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="ic4e65621727a478782ad571eb9761277_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_7140a184-9735-4d8a-88b3-c8fcb9826668" xlink:href="biib-20201231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_7140a184-9735-4d8a-88b3-c8fcb9826668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f5d1c1ff-01e9-4cbb-ab69-e2a521b459e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f5d1c1ff-01e9-4cbb-ab69-e2a521b459e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e36df39f-6dc2-48bf-8433-b7f160d1d992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e36df39f-6dc2-48bf-8433-b7f160d1d992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1c69e442-b0e7-4559-a5a0-948992f9023f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1c69e442-b0e7-4559-a5a0-948992f9023f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_403fe8d2-0ed5-4b68-8b22-47d3ca16ee86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_403fe8d2-0ed5-4b68-8b22-47d3ca16ee86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6adc714e-a320-476c-affa-399be848fd95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6adc714e-a320-476c-affa-399be848fd95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1872cbd2-a6e0-48a2-820f-16b21b34fd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1872cbd2-a6e0-48a2-820f-16b21b34fd46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d9a528cb-1348-46eb-925e-0e036458db7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d9a528cb-1348-46eb-925e-0e036458db7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d9a528cb-1348-46eb-925e-0e036458db7c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d9a528cb-1348-46eb-925e-0e036458db7c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d9a528cb-1348-46eb-925e-0e036458db7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036f7af8-4207-4075-848d-d0caf5fd34f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d9a528cb-1348-46eb-925e-0e036458db7c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036f7af8-4207-4075-848d-d0caf5fd34f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_d6554c34-86b5-4335-86b3-46c3763d81f7" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036f7af8-4207-4075-848d-d0caf5fd34f3" xlink:to="loc_biib_NightstarMember_d6554c34-86b5-4335-86b3-46c3763d81f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_8d5fa3f7-6000-4db7-b996-68ff844c48e5" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_8d5fa3f7-6000-4db7-b996-68ff844c48e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_8d5fa3f7-6000-4db7-b996-68ff844c48e5_default" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_8d5fa3f7-6000-4db7-b996-68ff844c48e5" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_8d5fa3f7-6000-4db7-b996-68ff844c48e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_8d5fa3f7-6000-4db7-b996-68ff844c48e5" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_45b8dca6-690e-43a4-8f58-1cad9d507ee8" xlink:href="biib-20201231.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:to="loc_biib_BIIB111Member_45b8dca6-690e-43a4-8f58-1cad9d507ee8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB054Member_22c9b8d2-4ed0-4a87-9115-622a20a7b1f3" xlink:href="biib-20201231.xsd#biib_BIIB054Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:to="loc_biib_BIIB054Member_22c9b8d2-4ed0-4a87-9115-622a20a7b1f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_e5cf2990-fa8d-4457-9968-d9883b9a7bac" xlink:href="biib-20201231.xsd#biib_TGNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:to="loc_biib_TGNMember_e5cf2990-fa8d-4457-9968-d9883b9a7bac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_683b1c88-3854-40f3-8639-b4eedd3c9583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_683b1c88-3854-40f3-8639-b4eedd3c9583" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_683b1c88-3854-40f3-8639-b4eedd3c9583_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_683b1c88-3854-40f3-8639-b4eedd3c9583" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_683b1c88-3854-40f3-8639-b4eedd3c9583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_73b559dd-45b6-464f-849c-ceb62abb1041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_683b1c88-3854-40f3-8639-b4eedd3c9583" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_73b559dd-45b6-464f-849c-ceb62abb1041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5e922b40-5d54-4c37-9ee4-e8736189bb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_73b559dd-45b6-464f-849c-ceb62abb1041" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5e922b40-5d54-4c37-9ee4-e8736189bb39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_daedb89d-3ae3-4896-82f8-00645dd1d6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_daedb89d-3ae3-4896-82f8-00645dd1d6bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_daedb89d-3ae3-4896-82f8-00645dd1d6bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_daedb89d-3ae3-4896-82f8-00645dd1d6bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_daedb89d-3ae3-4896-82f8-00645dd1d6bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a722d43-b3fd-4bb0-b450-8af336e9cab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_daedb89d-3ae3-4896-82f8-00645dd1d6bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a722d43-b3fd-4bb0-b450-8af336e9cab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3141c0e9-ca66-4e8e-9dc6-af2ab656b0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a722d43-b3fd-4bb0-b450-8af336e9cab9" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_3141c0e9-ca66-4e8e-9dc6-af2ab656b0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_24d29a6d-ae17-404b-b6a7-9a562c858b4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_srt_ProductOrServiceAxis_24d29a6d-ae17-404b-b6a7-9a562c858b4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_24d29a6d-ae17-404b-b6a7-9a562c858b4c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_24d29a6d-ae17-404b-b6a7-9a562c858b4c" xlink:to="loc_srt_ProductsAndServicesDomain_24d29a6d-ae17-404b-b6a7-9a562c858b4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_feb829f9-346a-436d-a989-7ea098c56535" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_24d29a6d-ae17-404b-b6a7-9a562c858b4c" xlink:to="loc_srt_ProductsAndServicesDomain_feb829f9-346a-436d-a989-7ea098c56535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_3d44da65-c0da-433b-9aad-785271ca9f62" xlink:href="biib-20201231.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_feb829f9-346a-436d-a989-7ea098c56535" xlink:to="loc_biib_TECFIDERAMember_3d44da65-c0da-433b-9aad-785271ca9f62" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended" id="i13d1853c7d9641a486ea674ddbdef7a9_IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="extended" id="id852b9f123084e958fe21094c72e4f72_IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" id="i002b8c99591143649dfa95716246d32a_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i8ab424c609b44a7c85ce18082d9716cb_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended" id="if42260e2970144b992050991b1276e3c_FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3420f409-860e-4623-85fc-f1621231166e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3420f409-860e-4623-85fc-f1621231166e" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_359ce423-3702-450e-ab04-9fe733a6b267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_359ce423-3702-450e-ab04-9fe733a6b267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_097e609f-736f-4b07-a7d7-fb86f2144756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_097e609f-736f-4b07-a7d7-fb86f2144756" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4e071ade-4b73-437e-80b7-6b34b3cb7e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4e071ade-4b73-437e-80b7-6b34b3cb7e71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_60837d0c-3c3b-4569-a95d-80a8ed7abee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_60837d0c-3c3b-4569-a95d-80a8ed7abee9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_213e8f01-aa38-4b01-8e56-bca3566b804d" xlink:href="biib-20201231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_213e8f01-aa38-4b01-8e56-bca3566b804d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ea4d291c-5823-4ea2-b4d3-036662867c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ea4d291c-5823-4ea2-b4d3-036662867c08" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3420f409-860e-4623-85fc-f1621231166e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cbf4f905-0e02-40a4-b4a2-8accec5ee5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cbf4f905-0e02-40a4-b4a2-8accec5ee5ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_997e4918-a3ba-4f73-9d63-196cebbe712f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_997e4918-a3ba-4f73-9d63-196cebbe712f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_205a82c4-3b0a-4a28-a77a-9927509287bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_205a82c4-3b0a-4a28-a77a-9927509287bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3420f409-860e-4623-85fc-f1621231166e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a13b6cc-3754-4cbe-8189-3c628f613261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a13b6cc-3754-4cbe-8189-3c628f613261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a13b6cc-3754-4cbe-8189-3c628f613261_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a13b6cc-3754-4cbe-8189-3c628f613261" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1a13b6cc-3754-4cbe-8189-3c628f613261_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a13b6cc-3754-4cbe-8189-3c628f613261" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_63b51eb1-afe8-45b0-bc3c-514374451263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_63b51eb1-afe8-45b0-bc3c-514374451263" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6f38dd68-cf5e-4832-8afc-dcdba83a7b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6f38dd68-cf5e-4832-8afc-dcdba83a7b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d8e40d82-dba2-46bd-a0bb-830ec81b4f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d8e40d82-dba2-46bd-a0bb-830ec81b4f9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7f8057c3-a6b6-42ef-97ef-da358e284b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7f8057c3-a6b6-42ef-97ef-da358e284b51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f8057c3-a6b6-42ef-97ef-da358e284b51_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7f8057c3-a6b6-42ef-97ef-da358e284b51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7f8057c3-a6b6-42ef-97ef-da358e284b51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4392907e-96d0-4d8e-8e5e-bd09782f3005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7f8057c3-a6b6-42ef-97ef-da358e284b51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4392907e-96d0-4d8e-8e5e-bd09782f3005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f477bcaa-5065-432e-9533-12a595cbe88a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4392907e-96d0-4d8e-8e5e-bd09782f3005" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f477bcaa-5065-432e-9533-12a595cbe88a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_527eb9f1-7beb-415b-aae8-60bd1fdc0181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_527eb9f1-7beb-415b-aae8-60bd1fdc0181" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_527eb9f1-7beb-415b-aae8-60bd1fdc0181_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_527eb9f1-7beb-415b-aae8-60bd1fdc0181" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_527eb9f1-7beb-415b-aae8-60bd1fdc0181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_527eb9f1-7beb-415b-aae8-60bd1fdc0181" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9977ebd8-38f0-4ffc-b896-adab7738d79f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9977ebd8-38f0-4ffc-b896-adab7738d79f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_c7a90e18-9866-4cc0-bd2a-f0b63bffc21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_c7a90e18-9866-4cc0-bd2a-f0b63bffc21a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_96f246aa-f07e-4a70-9610-426d60d50f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_96f246aa-f07e-4a70-9610-426d60d50f05" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails" xlink:type="extended" id="ide1c2bba057e4874a2bdfaf4869f2d44_FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d718f0d6-336e-4610-9619-4a4089a7baee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3d5fc7cc-a781-4ae4-8478-a65e4be399fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d718f0d6-336e-4610-9619-4a4089a7baee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3d5fc7cc-a781-4ae4-8478-a65e4be399fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_87d01c78-8a48-4fa0-b327-4e086a231d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d718f0d6-336e-4610-9619-4a4089a7baee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_87d01c78-8a48-4fa0-b327-4e086a231d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d718f0d6-336e-4610-9619-4a4089a7baee" xlink:to="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feee4eda-ffd2-4c7e-be84-994a1d9093c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feee4eda-ffd2-4c7e-be84-994a1d9093c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_feee4eda-ffd2-4c7e-be84-994a1d9093c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feee4eda-ffd2-4c7e-be84-994a1d9093c1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_feee4eda-ffd2-4c7e-be84-994a1d9093c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_206982a1-6703-4d2c-9cad-41f1f7939d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feee4eda-ffd2-4c7e-be84-994a1d9093c1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_206982a1-6703-4d2c-9cad-41f1f7939d0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b8a1867d-d9b9-41aa-a4df-6842152ce020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_206982a1-6703-4d2c-9cad-41f1f7939d0c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b8a1867d-d9b9-41aa-a4df-6842152ce020" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_473b6e1a-ba9b-40de-b065-3053923d841e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:to="loc_srt_RangeAxis_473b6e1a-ba9b-40de-b065-3053923d841e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_473b6e1a-ba9b-40de-b065-3053923d841e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_473b6e1a-ba9b-40de-b065-3053923d841e" xlink:to="loc_srt_RangeMember_473b6e1a-ba9b-40de-b065-3053923d841e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3364ea4e-66ad-4fdc-aeb2-dbbe8c7cb5b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_473b6e1a-ba9b-40de-b065-3053923d841e" xlink:to="loc_srt_RangeMember_3364ea4e-66ad-4fdc-aeb2-dbbe8c7cb5b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_daad5ddf-8d92-4ba6-8889-b33bca8f07ff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3364ea4e-66ad-4fdc-aeb2-dbbe8c7cb5b0" xlink:to="loc_srt_WeightedAverageMember_daad5ddf-8d92-4ba6-8889-b33bca8f07ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3919afe2-b25b-4062-aea0-aecdd606de13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3919afe2-b25b-4062-aea0-aecdd606de13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3919afe2-b25b-4062-aea0-aecdd606de13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3919afe2-b25b-4062-aea0-aecdd606de13" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3919afe2-b25b-4062-aea0-aecdd606de13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3283b5e3-9f8f-44b7-b1ab-bb8b2d17692a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3919afe2-b25b-4062-aea0-aecdd606de13" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3283b5e3-9f8f-44b7-b1ab-bb8b2d17692a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_6cabeb04-f410-4e4a-b465-4515f0da6e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3283b5e3-9f8f-44b7-b1ab-bb8b2d17692a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_6cabeb04-f410-4e4a-b465-4515f0da6e81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i9a3d8c3d25fc4e77aba96382a39f48d8_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_9548c71c-36eb-407a-9307-d84313241e8b" xlink:href="biib-20201231.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_9548c71c-36eb-407a-9307-d84313241e8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc1bfdc1-5374-4520-8160-10c4b423a06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc1bfdc1-5374-4520-8160-10c4b423a06e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7cab26fd-4e65-4f38-b800-1f7867b5cc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7cab26fd-4e65-4f38-b800-1f7867b5cc3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_20feea6f-5cb6-45ac-a1da-ab0e3e478819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_20feea6f-5cb6-45ac-a1da-ab0e3e478819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_a9f1b2f3-cb59-43b4-83cb-5a3cc7af33b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_a9f1b2f3-cb59-43b4-83cb-5a3cc7af33b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_389fffe7-8abc-4c3e-a407-ff1b3e6b15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_389fffe7-8abc-4c3e-a407-ff1b3e6b15e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_66eefede-89e8-4a37-8694-e85caca8a387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_66eefede-89e8-4a37-8694-e85caca8a387" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_106838dd-d99e-402e-88be-d7a8ed133310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_106838dd-d99e-402e-88be-d7a8ed133310" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueMeasurementInputs_94bc8471-7741-4acc-a7a0-c8f7a3b12158" xlink:href="biib-20201231.xsd#biib_FairValueMeasurementInputs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_biib_FairValueMeasurementInputs_94bc8471-7741-4acc-a7a0-c8f7a3b12158" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_211382df-bd0a-4949-a3cc-280af3a42033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_211382df-bd0a-4949-a3cc-280af3a42033" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_89fd1bd4-a903-48f7-9e30-abe38a520927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_89fd1bd4-a903-48f7-9e30-abe38a520927" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1854fd57-76bf-4bfe-be12-2b0120016520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_1854fd57-76bf-4bfe-be12-2b0120016520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_1854fd57-76bf-4bfe-be12-2b0120016520_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1854fd57-76bf-4bfe-be12-2b0120016520" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_1854fd57-76bf-4bfe-be12-2b0120016520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_39b9eeca-49a2-45b4-8d8a-f4cb2da5fe41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1854fd57-76bf-4bfe-be12-2b0120016520" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_39b9eeca-49a2-45b4-8d8a-f4cb2da5fe41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fae047da-412f-4267-b3a7-5bd145b47930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_39b9eeca-49a2-45b4-8d8a-f4cb2da5fe41" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fae047da-412f-4267-b3a7-5bd145b47930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_40361c96-1960-4915-8998-cd3596b75e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_40361c96-1960-4915-8998-cd3596b75e13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_40361c96-1960-4915-8998-cd3596b75e13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_40361c96-1960-4915-8998-cd3596b75e13" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_40361c96-1960-4915-8998-cd3596b75e13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4a034d6a-b6b0-4621-a104-a675e49f5102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_40361c96-1960-4915-8998-cd3596b75e13" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4a034d6a-b6b0-4621-a104-a675e49f5102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d5e50cfa-23be-44a7-9c88-db4069c31d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4a034d6a-b6b0-4621-a104-a675e49f5102" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d5e50cfa-23be-44a7-9c88-db4069c31d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b1d1e30-275c-429f-89a3-27968c8cc341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b1d1e30-275c-429f-89a3-27968c8cc341" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b1d1e30-275c-429f-89a3-27968c8cc341_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b1d1e30-275c-429f-89a3-27968c8cc341" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b1d1e30-275c-429f-89a3-27968c8cc341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b1d1e30-275c-429f-89a3-27968c8cc341" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_8b7fd576-550d-469e-b42e-0f6eef5a3317" xlink:href="biib-20201231.xsd#biib_ConvergencePharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_8b7fd576-550d-469e-b42e-0f6eef5a3317" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_147e8160-56be-4372-9556-974cecc9236d" xlink:href="biib-20201231.xsd#biib_BiogenIdecInternationalNeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_147e8160-56be-4372-9556-974cecc9236d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StromedixMember_ec65d060-dd53-4fc3-a8c1-d3e1211707bc" xlink:href="biib-20201231.xsd#biib_StromedixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:to="loc_biib_StromedixMember_ec65d060-dd53-4fc3-a8c1-d3e1211707bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_e5412ef3-caf3-4fb0-9ca0-b1f490f51ca7" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:to="loc_biib_NightstarMember_e5412ef3-caf3-4fb0-9ca0-b1f490f51ca7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5d0e5130-99c8-405a-ace2-f2e5d643431c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5d0e5130-99c8-405a-ace2-f2e5d643431c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5d0e5130-99c8-405a-ace2-f2e5d643431c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5d0e5130-99c8-405a-ace2-f2e5d643431c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5d0e5130-99c8-405a-ace2-f2e5d643431c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d3726d67-5b41-476e-a323-4da5ac65bca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5d0e5130-99c8-405a-ace2-f2e5d643431c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d3726d67-5b41-476e-a323-4da5ac65bca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_ca7a4b9d-5864-495e-9eb9-3621bd35c3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d3726d67-5b41-476e-a323-4da5ac65bca3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_ca7a4b9d-5864-495e-9eb9-3621bd35c3fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_4cadf0a8-c386-4185-9e71-987ede2c0415" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_4cadf0a8-c386-4185-9e71-987ede2c0415" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_4cadf0a8-c386-4185-9e71-987ede2c0415_default" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_4cadf0a8-c386-4185-9e71-987ede2c0415" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_4cadf0a8-c386-4185-9e71-987ede2c0415_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_da98b281-5a44-4050-ba93-99ca1e14645d" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_4cadf0a8-c386-4185-9e71-987ede2c0415" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_da98b281-5a44-4050-ba93-99ca1e14645d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB054Member_113ee29e-8ca6-4911-81af-b1226aeeed83" xlink:href="biib-20201231.xsd#biib_BIIB054Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_da98b281-5a44-4050-ba93-99ca1e14645d" xlink:to="loc_biib_BIIB054Member_113ee29e-8ca6-4911-81af-b1226aeeed83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails" xlink:type="extended" id="ieb6c983eebfd47e8a10170c128468dcf_FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a61cb901-b9b4-4460-96e3-5a2ce5110742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a61cb901-b9b4-4460-96e3-5a2ce5110742" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_34822b12-8131-45ed-9cd6-e23c00de9ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_34822b12-8131-45ed-9cd6-e23c00de9ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f8fb7552-d076-41e1-a9c9-3c66014105a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f8fb7552-d076-41e1-a9c9-3c66014105a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_471b5a06-ec58-44e2-808c-54d090ea67fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_471b5a06-ec58-44e2-808c-54d090ea67fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a61cb901-b9b4-4460-96e3-5a2ce5110742" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_e2adaf99-c88a-4617-8ae2-10a3304f4ab9" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_e2adaf99-c88a-4617-8ae2-10a3304f4ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_e2adaf99-c88a-4617-8ae2-10a3304f4ab9_default" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e2adaf99-c88a-4617-8ae2-10a3304f4ab9" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_e2adaf99-c88a-4617-8ae2-10a3304f4ab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_b2c2d031-df6f-459a-98f9-25b01c661b2a" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e2adaf99-c88a-4617-8ae2-10a3304f4ab9" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_b2c2d031-df6f-459a-98f9-25b01c661b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_2755731a-926d-41cf-8d3e-3ea43019ffc4" xlink:href="biib-20201231.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_b2c2d031-df6f-459a-98f9-25b01c661b2a" xlink:to="loc_biib_BIIB111Member_2755731a-926d-41cf-8d3e-3ea43019ffc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9ba40494-dfcf-442b-9dd4-7072d3a37679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9ba40494-dfcf-442b-9dd4-7072d3a37679" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9ba40494-dfcf-442b-9dd4-7072d3a37679_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9ba40494-dfcf-442b-9dd4-7072d3a37679" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9ba40494-dfcf-442b-9dd4-7072d3a37679_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_943837c4-bd11-4171-ac82-d4247b8f9b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9ba40494-dfcf-442b-9dd4-7072d3a37679" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_943837c4-bd11-4171-ac82-d4247b8f9b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_275bfa9f-0c24-4cb2-9cea-3af191ea4436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_943837c4-bd11-4171-ac82-d4247b8f9b6a" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_275bfa9f-0c24-4cb2-9cea-3af191ea4436" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails" xlink:type="extended" id="if3fb074354ac457b98620e8cf0b566f6_FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_ff5919c7-de9d-4807-b443-9528d4c7ef7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_ff5919c7-de9d-4807-b443-9528d4c7ef7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb582de9-1321-4614-b710-63e912b30619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb582de9-1321-4614-b710-63e912b30619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6fa46c94-e02c-4b21-8718-464f946d6df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6fa46c94-e02c-4b21-8718-464f946d6df0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:to="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a001890-1cec-4ae4-9f07-277d7fcf600a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a001890-1cec-4ae4-9f07-277d7fcf600a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a001890-1cec-4ae4-9f07-277d7fcf600a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a001890-1cec-4ae4-9f07-277d7fcf600a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a001890-1cec-4ae4-9f07-277d7fcf600a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a001890-1cec-4ae4-9f07-277d7fcf600a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_b08d0a7b-ee97-4788-8a2e-12cd9b9bc30c" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_b08d0a7b-ee97-4788-8a2e-12cd9b9bc30c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_7e65b7f1-062b-4ba0-a9e5-e622caf54583" xlink:href="biib-20201231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_7e65b7f1-062b-4ba0-a9e5-e622caf54583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_17e9b4ef-2127-4d2b-a067-131f7332128e" xlink:href="biib-20201231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_17e9b4ef-2127-4d2b-a067-131f7332128e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A225SeniorNotesDueMay12030Member_847b9f4c-0425-4f8b-8b08-4f9c1cff02e4" xlink:href="biib-20201231.xsd#biib_A225SeniorNotesDueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_A225SeniorNotesDueMay12030Member_847b9f4c-0425-4f8b-8b08-4f9c1cff02e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8409bfb9-beeb-4133-b5e0-d32a31c441b9" xlink:href="biib-20201231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8409bfb9-beeb-4133-b5e0-d32a31c441b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A315SeniorNotesDueMay12050Member_9ad37f76-5f2d-4194-b480-238839c3a2dd" xlink:href="biib-20201231.xsd#biib_A315SeniorNotesDueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_A315SeniorNotesDueMay12050Member_9ad37f76-5f2d-4194-b480-238839c3a2dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05382fcc-f1da-4c7e-bc96-ab68a16667cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05382fcc-f1da-4c7e-bc96-ab68a16667cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_05382fcc-f1da-4c7e-bc96-ab68a16667cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05382fcc-f1da-4c7e-bc96-ab68a16667cc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_05382fcc-f1da-4c7e-bc96-ab68a16667cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80d8d4b7-afc0-4733-ba79-2af3873cb5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05382fcc-f1da-4c7e-bc96-ab68a16667cc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80d8d4b7-afc0-4733-ba79-2af3873cb5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3ad07abe-34bd-4eef-b5ff-98da7553760b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80d8d4b7-afc0-4733-ba79-2af3873cb5b2" xlink:to="loc_us-gaap_SeniorNotesMember_3ad07abe-34bd-4eef-b5ff-98da7553760b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails" xlink:type="extended" id="i01f6864aafd04107a6807d64e0997873_FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0d9e1bba-b32e-4b9a-a5c7-6ee5395a9d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0d9e1bba-b32e-4b9a-a5c7-6ee5395a9d92" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1d6b3d24-f150-45e7-85ee-92bab2228c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1d6b3d24-f150-45e7-85ee-92bab2228c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4f0d2e7c-1ae7-4b76-909e-c6b385e5535c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4f0d2e7c-1ae7-4b76-909e-c6b385e5535c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e8ffe46c-1910-4b4e-b16d-7cd5f971c27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e8ffe46c-1910-4b4e-b16d-7cd5f971c27e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a5385f2-6a3a-4106-aaac-81cb8dea958b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8ac234a7-531a-4adf-9513-763bb4dc0745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0d9e1bba-b32e-4b9a-a5c7-6ee5395a9d92" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8ac234a7-531a-4adf-9513-763bb4dc0745" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_606afcdc-435b-4410-aa14-1499c78dbb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8ac234a7-531a-4adf-9513-763bb4dc0745" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_606afcdc-435b-4410-aa14-1499c78dbb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_606afcdc-435b-4410-aa14-1499c78dbb00_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_606afcdc-435b-4410-aa14-1499c78dbb00" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_606afcdc-435b-4410-aa14-1499c78dbb00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_829f3ff4-ea29-40c4-ac55-9c4bc834d674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_606afcdc-435b-4410-aa14-1499c78dbb00" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_829f3ff4-ea29-40c4-ac55-9c4bc834d674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e91b37c0-6f5e-4b9c-a95a-dedf266cb3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_829f3ff4-ea29-40c4-ac55-9c4bc834d674" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e91b37c0-6f5e-4b9c-a95a-dedf266cb3b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" id="i7fc0168e789c432490398c2d076ff52a_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" id="id594b8829e2e474fbb43d607229afd7f_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails" xlink:type="extended" id="i3b93a02a3a894a2ba12e0a5d7322f3dd_FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_f0cf80d8-b0a9-4ddd-98f8-192a9cf49cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_692ad504-c60c-43dd-9e15-a1b8c14fad65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_f0cf80d8-b0a9-4ddd-98f8-192a9cf49cab" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_692ad504-c60c-43dd-9e15-a1b8c14fad65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_18555f7a-78fd-4a97-9a54-683dbccbd608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_f0cf80d8-b0a9-4ddd-98f8-192a9cf49cab" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_18555f7a-78fd-4a97-9a54-683dbccbd608" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0eb06655-8d0f-4d4f-b4e3-21574271b8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_18555f7a-78fd-4a97-9a54-683dbccbd608" xlink:to="loc_us-gaap_InvestmentTypeAxis_0eb06655-8d0f-4d4f-b4e3-21574271b8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0eb06655-8d0f-4d4f-b4e3-21574271b8a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0eb06655-8d0f-4d4f-b4e3-21574271b8a4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0eb06655-8d0f-4d4f-b4e3-21574271b8a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0eb06655-8d0f-4d4f-b4e3-21574271b8a4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_54c9c507-9c1a-4a45-ae0e-4b682fdb4d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:to="loc_us-gaap_CommercialPaperMember_54c9c507-9c1a-4a45-ae0e-4b682fdb4d64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_ab8952c4-78e3-46f9-b00e-381dfe5e72da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_ab8952c4-78e3-46f9-b00e-381dfe5e72da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e75d8c92-6b0a-4e19-bd69-e92f8252b941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e75d8c92-6b0a-4e19-bd69-e92f8252b941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_ad13d060-2bcf-4a60-b1d2-d054428136e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:to="loc_us-gaap_DebtSecuritiesMember_ad13d060-2bcf-4a60-b1d2-d054428136e4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails" xlink:type="extended" id="i6a8c63992a1c4d13bb2f90dab1a856d1_FinancialInstrumentsSummaryofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f87081e6-a564-4717-894c-d02570183f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f87081e6-a564-4717-894c-d02570183f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6af72a4a-252b-4203-81ac-f1d2db23aea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6af72a4a-252b-4203-81ac-f1d2db23aea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c5bcc6b8-c164-43dc-811d-55b6d70e8a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c5bcc6b8-c164-43dc-811d-55b6d70e8a7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c699f965-a209-4fb3-a659-dd6dbd1492e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c699f965-a209-4fb3-a659-dd6dbd1492e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_c3d706c0-dad0-41e3-a7f6-930ef9ec9454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_c3d706c0-dad0-41e3-a7f6-930ef9ec9454" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_1fa63bc0-f2da-4c33-9201-8912c99f7994" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_1fa63bc0-f2da-4c33-9201-8912c99f7994" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e43cf13b-0522-4188-809d-2c67f3812ab8" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e43cf13b-0522-4188-809d-2c67f3812ab8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_931cb3b6-1aa2-4dde-bfbf-d2fbe666a526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_931cb3b6-1aa2-4dde-bfbf-d2fbe666a526" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_324b2356-9380-49bc-bc18-ddadbdb4a522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_324b2356-9380-49bc-bc18-ddadbdb4a522" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_81ceec3c-b540-48ad-9414-354ce5a1c76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_324b2356-9380-49bc-bc18-ddadbdb4a522" xlink:to="loc_us-gaap_FinancialInstrumentAxis_81ceec3c-b540-48ad-9414-354ce5a1c76b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81ceec3c-b540-48ad-9414-354ce5a1c76b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_81ceec3c-b540-48ad-9414-354ce5a1c76b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81ceec3c-b540-48ad-9414-354ce5a1c76b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_81ceec3c-b540-48ad-9414-354ce5a1c76b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_9991ae29-b37a-43a8-98b0-ff8421fde85a" xlink:href="biib-20201231.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_9991ae29-b37a-43a8-98b0-ff8421fde85a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_d9b7494a-92f4-4950-a114-4a5ff4f94931" xlink:href="biib-20201231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_d9b7494a-92f4-4950-a114-4a5ff4f94931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_8962eba2-c19e-4305-b51c-96290b5738fb" xlink:href="biib-20201231.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_8962eba2-c19e-4305-b51c-96290b5738fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_e86997a7-0462-4998-b1d5-b1876cf13400" xlink:href="biib-20201231.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_e86997a7-0462-4998-b1d5-b1876cf13400" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_c2319c60-a240-43bd-a354-c641bb6491ec" xlink:href="biib-20201231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_c2319c60-a240-43bd-a354-c641bb6491ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_c4092a42-c0de-4db4-8acf-506389d70821" xlink:href="biib-20201231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_c4092a42-c0de-4db4-8acf-506389d70821" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_befc0af8-abe0-45e6-b406-0827d612fd32" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_EquitySecuritiesCurrentMember_befc0af8-abe0-45e6-b406-0827d612fd32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_36d6d4c0-2c7e-4332-8f1c-4ce02ca9f251" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_36d6d4c0-2c7e-4332-8f1c-4ce02ca9f251" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofContractualMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="extended" id="i942c19a7b2964b64a491143fa377728e_FinancialInstrumentsSummaryofContractualMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails" xlink:type="extended" id="i9b60bfa1c37a4ce2818b1ca47a8a2708_FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i2b1d9eff58a44093811617b75def6e93_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_3ef35663-26f4-4be3-8eb6-e95dcef6d5d8" xlink:href="biib-20201231.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_3ef35663-26f4-4be3-8eb6-e95dcef6d5d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_2ac07800-8e85-4a93-88c6-68b67f98ef34" xlink:href="biib-20201231.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_StrategicInvestmentPortfolio_2ac07800-8e85-4a93-88c6-68b67f98ef34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInCommonStockSharesPurchased_61722914-e5db-48fd-a04c-c25aa22617b5" xlink:href="biib-20201231.xsd#biib_InvestmentInCommonStockSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_InvestmentInCommonStockSharesPurchased_61722914-e5db-48fd-a04c-c25aa22617b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_4bb93233-ed71-449d-9377-99d91f7cc1d0" xlink:href="biib-20201231.xsd#biib_DividendYieldPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_DividendYieldPercentage_4bb93233-ed71-449d-9377-99d91f7cc1d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_722f86f4-f3c4-41fb-b26a-210b4c561c7b" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_722f86f4-f3c4-41fb-b26a-210b4c561c7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_47e6b1a2-7f05-4642-87fa-8f32fd8515b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_47e6b1a2-7f05-4642-87fa-8f32fd8515b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_99e19853-6d9e-47eb-ace9-8b0925352c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_99e19853-6d9e-47eb-ace9-8b0925352c70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_13212ea8-5585-43a9-a307-70c084063580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_us-gaap_EquityMethodInvestments_13212ea8-5585-43a9-a307-70c084063580" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d4845c01-675a-4b33-98dc-3576b356159a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d4845c01-675a-4b33-98dc-3576b356159a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2e3e2cbf-2ec0-4872-b41a-6e42966582d4" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d4845c01-675a-4b33-98dc-3576b356159a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_2e3e2cbf-2ec0-4872-b41a-6e42966582d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_00cfd88b-cca1-48ca-8424-a69cdf1243ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_us-gaap_TypeOfArrangementAxis_00cfd88b-cca1-48ca-8424-a69cdf1243ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_00cfd88b-cca1-48ca-8424-a69cdf1243ce_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_00cfd88b-cca1-48ca-8424-a69cdf1243ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_00cfd88b-cca1-48ca-8424-a69cdf1243ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e1704eea-f43c-4813-98a9-fe3d710f52a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_00cfd88b-cca1-48ca-8424-a69cdf1243ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e1704eea-f43c-4813-98a9-fe3d710f52a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_f7020e0d-ec52-458e-99cf-f2afb1a6d960" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e1704eea-f43c-4813-98a9-fe3d710f52a7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_f7020e0d-ec52-458e-99cf-f2afb1a6d960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_us-gaap_FinancialInstrumentAxis_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5704aa82-c363-4bdf-b185-4de13dd604e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5704aa82-c363-4bdf-b185-4de13dd604e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_dccdf17e-bec6-4976-ad51-e4d4bdd60ac9" xlink:href="biib-20201231.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5704aa82-c363-4bdf-b185-4de13dd604e6" xlink:to="loc_biib_StrategicInvestmentsMember_dccdf17e-bec6-4976-ad51-e4d4bdd60ac9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3453034c-54ec-46f3-a6e3-8d2ee11231ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_dei_LegalEntityAxis_3453034c-54ec-46f3-a6e3-8d2ee11231ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3453034c-54ec-46f3-a6e3-8d2ee11231ae_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3453034c-54ec-46f3-a6e3-8d2ee11231ae" xlink:to="loc_dei_EntityDomain_3453034c-54ec-46f3-a6e3-8d2ee11231ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3453034c-54ec-46f3-a6e3-8d2ee11231ae" xlink:to="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_6a5dcbc9-7d8c-489b-87d8-a02df0c96690" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:to="loc_biib_SageTherapeuticsIncMember_6a5dcbc9-7d8c-489b-87d8-a02df0c96690" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_024fdfca-d90d-4d56-98f9-4facf5fd1316" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:to="loc_biib_DenaliTherapeuticsIncMember_024fdfca-d90d-4d56-98f9-4facf5fd1316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_664aa4fa-a3b2-46b4-9128-a49db28a7177" xlink:href="biib-20201231.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:to="loc_biib_SangamoCommonStockMember_664aa4fa-a3b2-46b4-9128-a49db28a7177" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fc0c609-c99f-4711-9d35-e92834029c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fc0c609-c99f-4711-9d35-e92834029c9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fc0c609-c99f-4711-9d35-e92834029c9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fc0c609-c99f-4711-9d35-e92834029c9e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2fc0c609-c99f-4711-9d35-e92834029c9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7a3c38b-c110-4498-a614-fc04c3462c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fc0c609-c99f-4711-9d35-e92834029c9e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7a3c38b-c110-4498-a614-fc04c3462c0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_97862ba8-80d6-4ed4-b35d-0a0c5aaeb854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7a3c38b-c110-4498-a614-fc04c3462c0a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_97862ba8-80d6-4ed4-b35d-0a0c5aaeb854" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstruments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" id="ieb3c58bb23944834838d02f2c0069d09_DerivativeInstruments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" id="i2e7032a1d2e24741b02d340b590c4fc7_DerivativeInstrumentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended" id="i6a5167f2aae74308acfef7ca523c0b21_DerivativeInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_f58ccf00-6ab5-43cd-b152-6303cf95760d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_f58ccf00-6ab5-43cd-b152-6303cf95760d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_b3a7aae4-de55-4900-9c9c-9f3b601033cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_b3a7aae4-de55-4900-9c9c-9f3b601033cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ca61d7b-ac0d-4058-9186-1715af6f776a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ca61d7b-ac0d-4058-9186-1715af6f776a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_a23ba5b3-3da4-44b3-a1e1-04a3464abf98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DerivativeNotionalAmount_a23ba5b3-3da4-44b3-a1e1-04a3464abf98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3d81ed74-edb9-4262-b340-f99a2f4d3ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3d81ed74-edb9-4262-b340-f99a2f4d3ae2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_dc82f495-ce37-47e3-ad69-43b175461bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_dc82f495-ce37-47e3-ad69-43b175461bfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7b7e41ee-9112-43fa-84df-794336ad1e6f" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7b7e41ee-9112-43fa-84df-794336ad1e6f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0cbd61af-ecf0-4b0b-8deb-acab83bd9176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0cbd61af-ecf0-4b0b-8deb-acab83bd9176" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a0c68d92-4946-404d-9fe1-8b0d80135d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a0c68d92-4946-404d-9fe1-8b0d80135d81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_d871659d-a7dd-47ef-9373-015503dab292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DerivativeTermOfContract_d871659d-a7dd-47ef-9373-015503dab292" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_c5d6f9e6-49a5-4193-970e-e2d267443ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_c5d6f9e6-49a5-4193-970e-e2d267443ac1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bf790aee-75bb-4b60-b259-c26240d6f29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bf790aee-75bb-4b60-b259-c26240d6f29f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e86db838-0d3b-4e3e-9da1-ea744aa86484" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_srt_RangeAxis_e86db838-0d3b-4e3e-9da1-ea744aa86484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e86db838-0d3b-4e3e-9da1-ea744aa86484_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e86db838-0d3b-4e3e-9da1-ea744aa86484" xlink:to="loc_srt_RangeMember_e86db838-0d3b-4e3e-9da1-ea744aa86484_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eeaed2e0-a068-452b-9264-ac376a55fd0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e86db838-0d3b-4e3e-9da1-ea744aa86484" xlink:to="loc_srt_RangeMember_eeaed2e0-a068-452b-9264-ac376a55fd0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7748ac3e-f191-44cf-99a6-6cd747d11fd9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eeaed2e0-a068-452b-9264-ac376a55fd0a" xlink:to="loc_srt_MinimumMember_7748ac3e-f191-44cf-99a6-6cd747d11fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e52f6c6d-0524-401e-b3e8-f5d09508723f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eeaed2e0-a068-452b-9264-ac376a55fd0a" xlink:to="loc_srt_MaximumMember_e52f6c6d-0524-401e-b3e8-f5d09508723f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_768ee315-fe96-4b07-8ae9-15b24a326da0" xlink:href="biib-20201231.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_biib_DerivativeMaturityAxis_768ee315-fe96-4b07-8ae9-15b24a326da0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_768ee315-fe96-4b07-8ae9-15b24a326da0_default" xlink:href="biib-20201231.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_768ee315-fe96-4b07-8ae9-15b24a326da0" xlink:to="loc_biib_DerivativeMaturityDomain_768ee315-fe96-4b07-8ae9-15b24a326da0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_f47d29c4-df0b-4a2d-a3f4-0bb810a54df7" xlink:href="biib-20201231.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_768ee315-fe96-4b07-8ae9-15b24a326da0" xlink:to="loc_biib_DerivativeMaturityDomain_f47d29c4-df0b-4a2d-a3f4-0bb810a54df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_db041322-78c8-4e69-bb0c-f68f670e7f49" xlink:href="biib-20201231.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_f47d29c4-df0b-4a2d-a3f4-0bb810a54df7" xlink:to="loc_biib_ShorttermderivativeMember_db041322-78c8-4e69-bb0c-f68f670e7f49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cb1387eb-bbc4-4650-b273-40f832e971a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cb1387eb-bbc4-4650-b273-40f832e971a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cb1387eb-bbc4-4650-b273-40f832e971a8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb1387eb-bbc4-4650-b273-40f832e971a8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cb1387eb-bbc4-4650-b273-40f832e971a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fa01ece8-7d7d-4e45-8da3-0b622184d1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb1387eb-bbc4-4650-b273-40f832e971a8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fa01ece8-7d7d-4e45-8da3-0b622184d1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_5f161f88-ca55-4a06-ad60-b660b48d422d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa01ece8-7d7d-4e45-8da3-0b622184d1c6" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_5f161f88-ca55-4a06-ad60-b660b48d422d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_cfdbcb4c-4edd-4253-8b6e-f123c6d24437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa01ece8-7d7d-4e45-8da3-0b622184d1c6" xlink:to="loc_us-gaap_InterestRateSwapMember_cfdbcb4c-4edd-4253-8b6e-f123c6d24437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_DebtInstrumentAxis_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_850362ea-a837-4625-ac35-915537ebe4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_850362ea-a837-4625-ac35-915537ebe4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_8deb7190-67f0-4a85-97a7-302935fbcd99" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_850362ea-a837-4625-ac35-915537ebe4a4" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_8deb7190-67f0-4a85-97a7-302935fbcd99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_31c6aafe-b756-4152-8d41-5e94f3bfe711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_HedgingDesignationAxis_31c6aafe-b756-4152-8d41-5e94f3bfe711" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_31c6aafe-b756-4152-8d41-5e94f3bfe711_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_31c6aafe-b756-4152-8d41-5e94f3bfe711" xlink:to="loc_us-gaap_HedgingDesignationDomain_31c6aafe-b756-4152-8d41-5e94f3bfe711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_921acd4a-bb6c-4e44-ba92-3b9a3bd902dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_31c6aafe-b756-4152-8d41-5e94f3bfe711" xlink:to="loc_us-gaap_HedgingDesignationDomain_921acd4a-bb6c-4e44-ba92-3b9a3bd902dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2bc81bfc-03cb-46f9-8614-5507651a34db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_921acd4a-bb6c-4e44-ba92-3b9a3bd902dc" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2bc81bfc-03cb-46f9-8614-5507651a34db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c330fc9d-ecac-427d-be0b-f87365c42ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_921acd4a-bb6c-4e44-ba92-3b9a3bd902dc" xlink:to="loc_us-gaap_NondesignatedMember_c330fc9d-ecac-427d-be0b-f87365c42ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81e1ccf7-653b-433e-b24e-807b07d0509b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81e1ccf7-653b-433e-b24e-807b07d0509b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_81e1ccf7-653b-433e-b24e-807b07d0509b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81e1ccf7-653b-433e-b24e-807b07d0509b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_81e1ccf7-653b-433e-b24e-807b07d0509b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_799d49ce-45ae-49b6-af4c-4612667b92d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81e1ccf7-653b-433e-b24e-807b07d0509b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_799d49ce-45ae-49b6-af4c-4612667b92d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_6e23851a-5966-49c7-b158-555da8d1fef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_799d49ce-45ae-49b6-af4c-4612667b92d3" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_6e23851a-5966-49c7-b158-555da8d1fef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_741ebb8c-8343-4c9a-b54d-c86730662d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_741ebb8c-8343-4c9a-b54d-c86730662d26" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_741ebb8c-8343-4c9a-b54d-c86730662d26_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_741ebb8c-8343-4c9a-b54d-c86730662d26" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_741ebb8c-8343-4c9a-b54d-c86730662d26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9fd4adfb-ce86-429c-a118-4f24a8d03501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_741ebb8c-8343-4c9a-b54d-c86730662d26" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9fd4adfb-ce86-429c-a118-4f24a8d03501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_01646f5e-658d-46df-b745-5926639411a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9fd4adfb-ce86-429c-a118-4f24a8d03501" xlink:to="loc_us-gaap_InterestExpenseMember_01646f5e-658d-46df-b745-5926639411a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bcb165f2-c9f1-4ffe-a91a-d3907c05768a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bcb165f2-c9f1-4ffe-a91a-d3907c05768a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bcb165f2-c9f1-4ffe-a91a-d3907c05768a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bcb165f2-c9f1-4ffe-a91a-d3907c05768a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bcb165f2-c9f1-4ffe-a91a-d3907c05768a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ca9c6b3-1901-4f1d-8d7d-2d9ce6df7b6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bcb165f2-c9f1-4ffe-a91a-d3907c05768a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ca9c6b3-1901-4f1d-8d7d-2d9ce6df7b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_53731420-b3bb-4984-9cbd-b2fe50163d11" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ca9c6b3-1901-4f1d-8d7d-2d9ce6df7b6f" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_53731420-b3bb-4984-9cbd-b2fe50163d11" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails" xlink:type="extended" id="i6953b5ce965e4deaaf8596621c641ce7_DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ec2df105-5eab-49a5-a306-7372d752d989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4f76f33e-8dd0-4f10-82d8-78afb1e11919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec2df105-5eab-49a5-a306-7372d752d989" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4f76f33e-8dd0-4f10-82d8-78afb1e11919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec2df105-5eab-49a5-a306-7372d752d989" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_fa6415ef-a3cc-401a-978c-99eb4c39aa9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:to="loc_srt_CurrencyAxis_fa6415ef-a3cc-401a-978c-99eb4c39aa9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_fa6415ef-a3cc-401a-978c-99eb4c39aa9f_default" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_fa6415ef-a3cc-401a-978c-99eb4c39aa9f" xlink:to="loc_currency_AllCurrenciesDomain_fa6415ef-a3cc-401a-978c-99eb4c39aa9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_c5943b58-6247-4ae3-bdae-33f5b2dbdef5" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_fa6415ef-a3cc-401a-978c-99eb4c39aa9f" xlink:to="loc_currency_AllCurrenciesDomain_c5943b58-6247-4ae3-bdae-33f5b2dbdef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_4c40d89a-4923-4d86-aa69-c2d8dd09758b" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_c5943b58-6247-4ae3-bdae-33f5b2dbdef5" xlink:to="loc_currency_EUR_4c40d89a-4923-4d86-aa69-c2d8dd09758b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_77d9d0d5-13d7-4d73-9199-33976be4d89b" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_c5943b58-6247-4ae3-bdae-33f5b2dbdef5" xlink:to="loc_currency_GBP_77d9d0d5-13d7-4d73-9199-33976be4d89b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5069f938-7656-4a9e-89f0-6580710de586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:to="loc_us-gaap_HedgingDesignationAxis_5069f938-7656-4a9e-89f0-6580710de586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5069f938-7656-4a9e-89f0-6580710de586_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5069f938-7656-4a9e-89f0-6580710de586" xlink:to="loc_us-gaap_HedgingDesignationDomain_5069f938-7656-4a9e-89f0-6580710de586_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_80734e46-b795-47c2-9de5-e25f6f461343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5069f938-7656-4a9e-89f0-6580710de586" xlink:to="loc_us-gaap_HedgingDesignationDomain_80734e46-b795-47c2-9de5-e25f6f461343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b53378ba-0149-4409-92cf-072d62a3baae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_80734e46-b795-47c2-9de5-e25f6f461343" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b53378ba-0149-4409-92cf-072d62a3baae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails" xlink:type="extended" id="ie85761d539174171afb59eb24cb7b8ea_DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_23e8d2c6-cc6e-43e7-8626-d15024d7b6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1176f1bb-a541-422a-a808-1ef6354328be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_23e8d2c6-cc6e-43e7-8626-d15024d7b6cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1176f1bb-a541-422a-a808-1ef6354328be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6daf7efc-afe9-43ec-935c-ef1daae0a2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_23e8d2c6-cc6e-43e7-8626-d15024d7b6cd" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6daf7efc-afe9-43ec-935c-ef1daae0a2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_23e8d2c6-cc6e-43e7-8626-d15024d7b6cd" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d569b78b-b362-4c38-abec-dfb5a408c0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d569b78b-b362-4c38-abec-dfb5a408c0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d569b78b-b362-4c38-abec-dfb5a408c0e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d569b78b-b362-4c38-abec-dfb5a408c0e6" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d569b78b-b362-4c38-abec-dfb5a408c0e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f865cd14-36b2-4930-9498-d647a7b82e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d569b78b-b362-4c38-abec-dfb5a408c0e6" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f865cd14-36b2-4930-9498-d647a7b82e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_0a44ced4-8e6f-43c3-ae68-2deb60a67f6c" xlink:href="biib-20201231.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f865cd14-36b2-4930-9498-d647a7b82e27" xlink:to="loc_biib_CashflowsrevenueMember_0a44ced4-8e6f-43c3-ae68-2deb60a67f6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_7f8d77a8-aaa0-40e9-b48f-943e87018786" xlink:href="biib-20201231.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f865cd14-36b2-4930-9498-d647a7b82e27" xlink:to="loc_biib_CashflowsoperatingexpensesMember_7f8d77a8-aaa0-40e9-b48f-943e87018786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_dca25627-c09c-44e8-830a-6c85ef3e069e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_dca25627-c09c-44e8-830a-6c85ef3e069e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dca25627-c09c-44e8-830a-6c85ef3e069e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_dca25627-c09c-44e8-830a-6c85ef3e069e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dca25627-c09c-44e8-830a-6c85ef3e069e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_741a8035-dea3-4f8c-b84d-b369a0c3f14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_dca25627-c09c-44e8-830a-6c85ef3e069e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_741a8035-dea3-4f8c-b84d-b369a0c3f14f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f18270b4-2891-4052-a5d0-a180640335ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_741a8035-dea3-4f8c-b84d-b369a0c3f14f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f18270b4-2891-4052-a5d0-a180640335ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b4da75cd-6f52-4bc3-997e-05f3be38d834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b4da75cd-6f52-4bc3-997e-05f3be38d834" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b4da75cd-6f52-4bc3-997e-05f3be38d834_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4da75cd-6f52-4bc3-997e-05f3be38d834" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b4da75cd-6f52-4bc3-997e-05f3be38d834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_93d975a2-9f12-48c2-90cc-00b499c3098f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4da75cd-6f52-4bc3-997e-05f3be38d834" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_93d975a2-9f12-48c2-90cc-00b499c3098f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_b971479f-ba9f-424a-aeab-241baae1e56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_93d975a2-9f12-48c2-90cc-00b499c3098f" xlink:to="loc_us-gaap_SalesMember_b971479f-ba9f-424a-aeab-241baae1e56e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_7035e7f7-e308-4b61-a333-42a6337767f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_93d975a2-9f12-48c2-90cc-00b499c3098f" xlink:to="loc_us-gaap_OperatingExpenseMember_7035e7f7-e308-4b61-a333-42a6337767f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails" xlink:type="extended" id="ib66f1e0ebe4f4a7e81eb330f00a08f45_DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_3fdf442d-6872-465d-b788-ee304f755f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_3fdf442d-6872-465d-b788-ee304f755f44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c2d67b06-2ec8-4d0b-acd7-5b24ca944aad" xlink:href="biib-20201231.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c2d67b06-2ec8-4d0b-acd7-5b24ca944aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aab3f96d-1a6e-4741-893f-17c1d35538ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aab3f96d-1a6e-4741-893f-17c1d35538ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d9104d5a-a7e9-41b7-bf00-b6baeba25727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d9104d5a-a7e9-41b7-bf00-b6baeba25727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_b7ddefa9-dca8-45de-936c-9dab3ffeb51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d9104d5a-a7e9-41b7-bf00-b6baeba25727" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_b7ddefa9-dca8-45de-936c-9dab3ffeb51c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0870eefe-1156-4129-a943-d852ea068a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0870eefe-1156-4129-a943-d852ea068a77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0870eefe-1156-4129-a943-d852ea068a77_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0870eefe-1156-4129-a943-d852ea068a77" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0870eefe-1156-4129-a943-d852ea068a77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_041111d4-cd9f-4295-824a-698d21317548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0870eefe-1156-4129-a943-d852ea068a77" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_041111d4-cd9f-4295-824a-698d21317548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_585da510-faf9-4d0e-b378-b8fea56ee670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_041111d4-cd9f-4295-824a-698d21317548" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_585da510-faf9-4d0e-b378-b8fea56ee670" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails" xlink:type="extended" id="i5ab60ab750654b059ca49d911b621eae_DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f978637c-2236-4717-9210-545642968cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_dad56fb3-e1f1-414e-9a0e-c4c544c00cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f978637c-2236-4717-9210-545642968cba" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_dad56fb3-e1f1-414e-9a0e-c4c544c00cf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_354470d2-014d-4612-ae90-34e09a2d4be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f978637c-2236-4717-9210-545642968cba" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_354470d2-014d-4612-ae90-34e09a2d4be2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f978637c-2236-4717-9210-545642968cba" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a2afd269-1760-43ce-a723-cf7bfff0686e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a2afd269-1760-43ce-a723-cf7bfff0686e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a2afd269-1760-43ce-a723-cf7bfff0686e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2afd269-1760-43ce-a723-cf7bfff0686e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a2afd269-1760-43ce-a723-cf7bfff0686e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2afd269-1760-43ce-a723-cf7bfff0686e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_07b9db5e-8001-40d0-b771-caf66117a5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_07b9db5e-8001-40d0-b771-caf66117a5a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_ddde8957-3fbb-48eb-837c-5ffc0c72aa0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_ddde8957-3fbb-48eb-837c-5ffc0c72aa0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5e359cc2-f8fd-4f5b-9049-21a848303415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5e359cc2-f8fd-4f5b-9049-21a848303415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9b400794-96c1-4d91-af25-9ec2d0235d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9b400794-96c1-4d91-af25-9ec2d0235d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9b400794-96c1-4d91-af25-9ec2d0235d48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9b400794-96c1-4d91-af25-9ec2d0235d48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9b400794-96c1-4d91-af25-9ec2d0235d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ec90be79-52a6-4335-bf20-4707bb49eecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9b400794-96c1-4d91-af25-9ec2d0235d48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ec90be79-52a6-4335-bf20-4707bb49eecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ad3a06b3-1b38-4be1-a56b-6b5ca842c910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec90be79-52a6-4335-bf20-4707bb49eecb" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ad3a06b3-1b38-4be1-a56b-6b5ca842c910" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_75fa14cf-c13b-46ee-8c2c-f1f1b5f0d501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec90be79-52a6-4335-bf20-4707bb49eecb" xlink:to="loc_us-gaap_InterestRateSwapMember_75fa14cf-c13b-46ee-8c2c-f1f1b5f0d501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_1a93a5d8-cdac-4ea8-b9c9-ce62262070a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:to="loc_us-gaap_CashFlowHedgingMember_1a93a5d8-cdac-4ea8-b9c9-ce62262070a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_65d91f1c-a6fe-46f6-b1fb-ac0abc155b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_65d91f1c-a6fe-46f6-b1fb-ac0abc155b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_18b561fd-cf64-4360-a76a-8277da3b2e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:to="loc_us-gaap_FairValueHedgingMember_18b561fd-cf64-4360-a76a-8277da3b2e30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_HedgingDesignationAxis_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6" xlink:to="loc_us-gaap_HedgingDesignationDomain_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7755c73a-1e1b-4c82-8d97-137f5286d4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6" xlink:to="loc_us-gaap_HedgingDesignationDomain_7755c73a-1e1b-4c82-8d97-137f5286d4ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9f10eb31-5b8c-4c22-a39a-7ec6406cd473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7755c73a-1e1b-4c82-8d97-137f5286d4ff" xlink:to="loc_us-gaap_NondesignatedMember_9f10eb31-5b8c-4c22-a39a-7ec6406cd473" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipment"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended" id="i0fcaa104a7be49dfac5ed36b356e26a7_PropertyPlantandEquipment"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentTables" xlink:type="extended" id="i7a5262a20c07442aad3e87f6ae604cc9_PropertyPlantandEquipmentTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="i6e7648e52060484e9fd38f045e1fb7ad_PropertyPlantandEquipmentDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended" id="ia1b7446af92d495ab22b33d2850c45ad_PropertyPlantandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9317d6cb-5f38-429e-879e-501500eb93c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_Depreciation_9317d6cb-5f38-429e-879e-501500eb93c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_4a915ed6-dd43-4295-b659-4940be113707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_InterestCostsCapitalized_4a915ed6-dd43-4295-b659-4940be113707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_8e37ade0-a1c8-4427-b634-79085aa833f8" xlink:href="biib-20201231.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_biib_NumberOfSquareFeet_8e37ade0-a1c8-4427-b634-79085aa833f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_044d53b3-9433-43b4-badc-d3745fd6aed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_ConstructionInProgressGross_044d53b3-9433-43b4-badc-d3745fd6aed1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ae000ab0-d615-49f7-89f2-6dc28cd88dde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ae000ab0-d615-49f7-89f2-6dc28cd88dde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_924ccf94-3665-41a5-ae10-237c1c002bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_924ccf94-3665-41a5-ae10-237c1c002bf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_a5233d6a-77e3-413a-85b7-78516d8ecb67" xlink:href="biib-20201231.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_biib_FacilityTypeAxis_a5233d6a-77e3-413a-85b7-78516d8ecb67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_a5233d6a-77e3-413a-85b7-78516d8ecb67_default" xlink:href="biib-20201231.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_a5233d6a-77e3-413a-85b7-78516d8ecb67" xlink:to="loc_biib_FacilityTypeDomain_a5233d6a-77e3-413a-85b7-78516d8ecb67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:href="biib-20201231.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_a5233d6a-77e3-413a-85b7-78516d8ecb67" xlink:to="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_3c4d3756-6666-44cc-b952-6a4a2f907a4d" xlink:href="biib-20201231.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:to="loc_biib_BiologicsManufacturingMember_3c4d3756-6666-44cc-b952-6a4a2f907a4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_2ee4e5d9-36dc-445e-9833-01e5e22a39a4" xlink:href="biib-20201231.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_2ee4e5d9-36dc-445e-9833-01e5e22a39a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_f59f5812-c621-429b-896b-0befa73491b0" xlink:href="biib-20201231.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:to="loc_biib_AdministrativeSpaceMember_f59f5812-c621-429b-896b-0befa73491b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_b46b629e-3a10-4fc6-acda-a2c7720d1c1e" xlink:href="biib-20201231.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_biib_FacilityLocationAxis_b46b629e-3a10-4fc6-acda-a2c7720d1c1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_b46b629e-3a10-4fc6-acda-a2c7720d1c1e_default" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_b46b629e-3a10-4fc6-acda-a2c7720d1c1e" xlink:to="loc_biib_FacilityLocationDomain_b46b629e-3a10-4fc6-acda-a2c7720d1c1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_78360f80-5421-4752-a10a-6dd976f8b346" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_b46b629e-3a10-4fc6-acda-a2c7720d1c1e" xlink:to="loc_biib_FacilityLocationDomain_78360f80-5421-4752-a10a-6dd976f8b346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember_1330b5d4-f385-41ff-a6b9-f9fa0cb00f02" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_78360f80-5421-4752-a10a-6dd976f8b346" xlink:to="loc_biib_SolothurnMember_1330b5d4-f385-41ff-a6b9-f9fa0cb00f02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a43b739a-849a-4c83-b5de-b65d3f4bbaea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a43b739a-849a-4c83-b5de-b65d3f4bbaea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a43b739a-849a-4c83-b5de-b65d3f4bbaea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a43b739a-849a-4c83-b5de-b65d3f4bbaea" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a43b739a-849a-4c83-b5de-b65d3f4bbaea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_251eee64-f5b4-4cd0-a21a-adf10539e6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a43b739a-849a-4c83-b5de-b65d3f4bbaea" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_251eee64-f5b4-4cd0-a21a-adf10539e6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_dfb9f979-86ed-4cbe-a5bf-be2b566b7d3d" xlink:href="biib-20201231.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_251eee64-f5b4-4cd0-a21a-adf10539e6e8" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_dfb9f979-86ed-4cbe-a5bf-be2b566b7d3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52c069f4-c9b5-4e2d-873c-3b2c024320e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52c069f4-c9b5-4e2d-873c-3b2c024320e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52c069f4-c9b5-4e2d-873c-3b2c024320e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52c069f4-c9b5-4e2d-873c-3b2c024320e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52c069f4-c9b5-4e2d-873c-3b2c024320e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1d9278c-08cc-450c-8fff-537bc8009e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52c069f4-c9b5-4e2d-873c-3b2c024320e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1d9278c-08cc-450c-8fff-537bc8009e1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_e8ffec2d-2055-4ca9-8acb-2a3709e844ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1d9278c-08cc-450c-8fff-537bc8009e1e" xlink:to="loc_us-gaap_BuildingMember_e8ffec2d-2055-4ca9-8acb-2a3709e844ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c5c21d3b-de03-4d45-9f4d-eadb8d6a7275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1d9278c-08cc-450c-8fff-537bc8009e1e" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c5c21d3b-de03-4d45-9f4d-eadb8d6a7275" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:type="simple" xlink:href="biib-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended" id="i5ed7ab9495e143068e214e102f58c3a3_Leases"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended" id="ic23284113ee44a5e916c14dec5f9b9e9_LeasesTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ic101190da703493baeb382a047ddfead_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_dec024a3-bbf2-4436-8382-222b065f90be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_93f4b904-6cab-41b6-8e27-fe87d17e5f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_dec024a3-bbf2-4436-8382-222b065f90be" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_93f4b904-6cab-41b6-8e27-fe87d17e5f66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_71f3549f-65cb-40a3-84ba-e73ab1c00b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_dec024a3-bbf2-4436-8382-222b065f90be" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_71f3549f-65cb-40a3-84ba-e73ab1c00b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_dec024a3-bbf2-4436-8382-222b065f90be" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:to="loc_srt_RangeAxis_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c" xlink:to="loc_srt_RangeMember_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6ce3503-7375-43dc-bc77-2b80b2949623" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c" xlink:to="loc_srt_RangeMember_a6ce3503-7375-43dc-bc77-2b80b2949623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b17171a4-2baa-491f-b614-04a7064311de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6ce3503-7375-43dc-bc77-2b80b2949623" xlink:to="loc_srt_MinimumMember_b17171a4-2baa-491f-b614-04a7064311de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f77c0202-1ddc-4dd5-99d7-a0b38e7bdc94" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6ce3503-7375-43dc-bc77-2b80b2949623" xlink:to="loc_srt_MaximumMember_f77c0202-1ddc-4dd5-99d7-a0b38e7bdc94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_bce44dda-4fea-4e64-8d39-5c81cf746273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:to="loc_us-gaap_LeaseContractualTermAxis_bce44dda-4fea-4e64-8d39-5c81cf746273" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_bce44dda-4fea-4e64-8d39-5c81cf746273_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_bce44dda-4fea-4e64-8d39-5c81cf746273" xlink:to="loc_us-gaap_LeaseContractualTermDomain_bce44dda-4fea-4e64-8d39-5c81cf746273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f4aa55fa-132c-4c88-a760-bd7199f45e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_bce44dda-4fea-4e64-8d39-5c81cf746273" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f4aa55fa-132c-4c88-a760-bd7199f45e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SubleaseMember_e14914c8-4e5e-47eb-abba-8cc7de374a31" xlink:href="biib-20201231.xsd#biib_SubleaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f4aa55fa-132c-4c88-a760-bd7199f45e69" xlink:to="loc_biib_SubleaseMember_e14914c8-4e5e-47eb-abba-8cc7de374a31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesScheduleofOperatingLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails" xlink:type="extended" id="ifb219193ed8442dfb50e92e0fea26904_LeasesScheduleofOperatingLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_57aa6a5d-9b0c-45a2-bcce-f3b545918108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_57aa6a5d-9b0c-45a2-bcce-f3b545918108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ab63834-e567-4d4a-93d3-51d225288c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ab63834-e567-4d4a-93d3-51d225288c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_776a3888-710b-481e-bae4-cd1838a4d645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_776a3888-710b-481e-bae4-cd1838a4d645" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b1c000d1-3211-431c-9453-50a4e54cf45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b1c000d1-3211-431c-9453-50a4e54cf45c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1f711a84-f89f-4341-bfa3-59b8e21cf030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseLiability_1f711a84-f89f-4341-bfa3-59b8e21cf030" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ed379d1-c138-49ba-a61b-72442e901215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_StatementTable_8ed379d1-c138-49ba-a61b-72442e901215" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8ed379d1-c138-49ba-a61b-72442e901215" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingleaseassetsMember_5d3c0fdc-fce1-4fc4-ad1c-62b28302e086" xlink:href="biib-20201231.xsd#biib_OperatingleaseassetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:to="loc_biib_OperatingleaseassetsMember_5d3c0fdc-fce1-4fc4-ad1c-62b28302e086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_8b0de4ff-faa7-42fb-b4bb-1caab5372e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_8b0de4ff-faa7-42fb-b4bb-1caab5372e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_94d1bd89-5b36-4e3c-bc6a-19e562df161d" xlink:href="biib-20201231.xsd#biib_LongtermoperatingleaseliabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_94d1bd89-5b36-4e3c-bc6a-19e562df161d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseCostsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails" xlink:type="extended" id="i24220fcbdc2f484cb3b0036cc1a3d359_LeasesOperatingLeaseCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3ce5a47d-f423-43fa-99a3-d82d3bf623ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_OperatingLeaseCost_3ce5a47d-f423-43fa-99a3-d82d3bf623ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0f8baa92-d7ba-402e-9eeb-fec56b9257a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_VariableLeaseCost_0f8baa92-d7ba-402e-9eeb-fec56b9257a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_a305e9a4-8b22-4e4b-8e99-e8f54bc103d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_SubleaseIncome_a305e9a4-8b22-4e4b-8e99-e8f54bc103d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ab14625b-d9da-4e01-b26e-6ec6c339e894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_LeaseCost_ab14625b-d9da-4e01-b26e-6ec6c339e894" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_668ecbe7-e07c-4530-9556-b0cebc9b6dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_StatementTable_668ecbe7-e07c-4530-9556-b0cebc9b6dd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f859a6de-b4fc-49d1-a02e-4a6998a516f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_668ecbe7-e07c-4530-9556-b0cebc9b6dd8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f859a6de-b4fc-49d1-a02e-4a6998a516f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f859a6de-b4fc-49d1-a02e-4a6998a516f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f859a6de-b4fc-49d1-a02e-4a6998a516f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f859a6de-b4fc-49d1-a02e-4a6998a516f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f859a6de-b4fc-49d1-a02e-4a6998a516f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b79e394b-5fae-42a8-a360-9949628f661f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b79e394b-5fae-42a8-a360-9949628f661f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_68d2685d-03f0-4ea3-85f7-137b27c175a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_68d2685d-03f0-4ea3-85f7-137b27c175a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_beceef7d-b92f-43dd-8ff4-84ff3c455ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_beceef7d-b92f-43dd-8ff4-84ff3c455ee4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseLiabilityMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="extended" id="ic872befde31a4f5b866829841935c52c_LeasesOperatingLeaseLiabilityMaturityDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="extended" id="ia048f10a5dbe4dce9427db80abc6651c_LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails" xlink:type="extended" id="i30b11be36cf74e878a65d1e3fec225f8_LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20201231.xsd#Indebtedness"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" id="if4ab055dd8bc4fdd87a3f278ebf18fb2_Indebtedness"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" id="i19fec66f1aea486ab2451a7bd3ef4d7a_IndebtednessTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessSummaryofIndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails" xlink:type="extended" id="ie91cc01aa796416d957c4fbbc5ea6d9e_IndebtednessSummaryofIndebtednessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_dd6bf653-5b8f-492a-a0c5-412671b588f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_dd6bf653-5b8f-492a-a0c5-412671b588f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f39e9421-2766-4329-a3a4-2c2fe845215a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_dd6bf653-5b8f-492a-a0c5-412671b588f7" xlink:to="loc_us-gaap_NotesPayableCurrent_f39e9421-2766-4329-a3a4-2c2fe845215a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_349eea79-7ea4-4fa5-91d2-208d1819d1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_dd6bf653-5b8f-492a-a0c5-412671b588f7" xlink:to="loc_us-gaap_DebtCurrent_349eea79-7ea4-4fa5-91d2-208d1819d1c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_728f4448-16c0-41a0-9611-cf99ab83bdeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_728f4448-16c0-41a0-9611-cf99ab83bdeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_600567b8-5eed-4302-83cb-1e746c96070a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_728f4448-16c0-41a0-9611-cf99ab83bdeb" xlink:to="loc_us-gaap_LongTermNotesPayable_600567b8-5eed-4302-83cb-1e746c96070a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_256eb1c7-e603-4c3d-921e-fbda2b608114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_728f4448-16c0-41a0-9611-cf99ab83bdeb" xlink:to="loc_us-gaap_LongTermDebt_256eb1c7-e603-4c3d-921e-fbda2b608114" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_35d0be45-db0f-47df-9320-30debe53da07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_35d0be45-db0f-47df-9320-30debe53da07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0bfcfb17-7580-46c0-91b2-7aaaf279cf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0bfcfb17-7580-46c0-91b2-7aaaf279cf99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:to="loc_us-gaap_DebtInstrumentAxis_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_f645299b-13a5-4ecc-bce6-cbef000d2d7e" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_f645299b-13a5-4ecc-bce6-cbef000d2d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_e27c39c4-fd5d-45e0-911f-874108022c32" xlink:href="biib-20201231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_e27c39c4-fd5d-45e0-911f-874108022c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_aaf2cd11-cb0f-4290-8b67-47a0bc4af2ff" xlink:href="biib-20201231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_aaf2cd11-cb0f-4290-8b67-47a0bc4af2ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A225SeniorNotesDueMay12030Member_2b75f7f2-7a1d-4fef-8c81-fc860fa4e820" xlink:href="biib-20201231.xsd#biib_A225SeniorNotesDueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_A225SeniorNotesDueMay12030Member_2b75f7f2-7a1d-4fef-8c81-fc860fa4e820" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ae0d8d53-12bf-49a2-b88a-621d39c06e9f" xlink:href="biib-20201231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ae0d8d53-12bf-49a2-b88a-621d39c06e9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A315SeniorNotesDueMay12050Member_91f16640-25d6-46c7-8074-b11b5860fce0" xlink:href="biib-20201231.xsd#biib_A315SeniorNotesDueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_A315SeniorNotesDueMay12050Member_91f16640-25d6-46c7-8074-b11b5860fce0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8de84685-c14f-4328-a869-fdad9eca116e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8de84685-c14f-4328-a869-fdad9eca116e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8de84685-c14f-4328-a869-fdad9eca116e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8de84685-c14f-4328-a869-fdad9eca116e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8de84685-c14f-4328-a869-fdad9eca116e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_19e770ce-e88e-45e9-8f51-ecd8fe4d2eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8de84685-c14f-4328-a869-fdad9eca116e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_19e770ce-e88e-45e9-8f51-ecd8fe4d2eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_74572205-4327-4b76-99af-8a1a0e7eef52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_19e770ce-e88e-45e9-8f51-ecd8fe4d2eac" xlink:to="loc_us-gaap_SeniorNotesMember_74572205-4327-4b76-99af-8a1a0e7eef52" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="extended" id="i9786db0572474794b09050ba6db5b528_IndebtednessNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6eb7649f-53f0-479e-9899-847361970193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6eb7649f-53f0-479e-9899-847361970193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b8e990c1-313c-4d90-b746-2c6682106023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b8e990c1-313c-4d90-b746-2c6682106023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_2a0ef3e9-2081-41d4-a868-f654f5ef088e" xlink:href="biib-20201231.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_2a0ef3e9-2081-41d4-a868-f654f5ef088e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_ddc99c4b-817b-46c8-962d-560952c197c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_ddc99c4b-817b-46c8-962d-560952c197c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_b211284a-b70d-43e4-9701-f831679eab09" xlink:href="biib-20201231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_b211284a-b70d-43e4-9701-f831679eab09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_b8b3a6ff-d3cd-4bba-b5a5-79f92c6f4e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_b8b3a6ff-d3cd-4bba-b5a5-79f92c6f4e4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain_6031092a-97f2-4245-b672-c5b3ad973ca4" xlink:href="biib-20201231.xsd#biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain_6031092a-97f2-4245-b672-c5b3ad973ca4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_eace1f79-4c10-4b92-9186-951db7cc97a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_eace1f79-4c10-4b92-9186-951db7cc97a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_41c6225a-f792-4367-bc06-b762060dddc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_41c6225a-f792-4367-bc06-b762060dddc8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_634c3736-9ff2-408d-8438-004700f594e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentTerm_634c3736-9ff2-408d-8438-004700f594e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_5e40d65d-35d8-488b-b525-1dd750c72354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_LineOfCredit_5e40d65d-35d8-488b-b525-1dd750c72354" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_39b26e58-17b4-4fee-8d36-3cad5b2aef98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_39b26e58-17b4-4fee-8d36-3cad5b2aef98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_39b26e58-17b4-4fee-8d36-3cad5b2aef98_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_39b26e58-17b4-4fee-8d36-3cad5b2aef98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_39b26e58-17b4-4fee-8d36-3cad5b2aef98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c35adb5-ea1b-4004-bc34-1aa9947045a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_39b26e58-17b4-4fee-8d36-3cad5b2aef98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c35adb5-ea1b-4004-bc34-1aa9947045a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_aa040e1b-dbe9-4c10-a17a-b0449a612d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c35adb5-ea1b-4004-bc34-1aa9947045a6" xlink:to="loc_us-gaap_SeniorNotesMember_aa040e1b-dbe9-4c10-a17a-b0449a612d50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_44d352a1-893c-438f-bcaf-8bc0a054f118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c35adb5-ea1b-4004-bc34-1aa9947045a6" xlink:to="loc_us-gaap_LineOfCreditMember_44d352a1-893c-438f-bcaf-8bc0a054f118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_347a4d98-4292-4461-afd6-f07ab6538cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_DebtInstrumentAxis_347a4d98-4292-4461-afd6-f07ab6538cf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_347a4d98-4292-4461-afd6-f07ab6538cf3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_347a4d98-4292-4461-afd6-f07ab6538cf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_347a4d98-4292-4461-afd6-f07ab6538cf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_347a4d98-4292-4461-afd6-f07ab6538cf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020SeniorNotesMember_1dafe62a-5c75-4389-9d14-3308601ab260" xlink:href="biib-20201231.xsd#biib_A2020SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:to="loc_biib_A2020SeniorNotesMember_1dafe62a-5c75-4389-9d14-3308601ab260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A225SeniorNotesDueMay12030Member_3dcbea78-2dd5-4406-ae9b-b276b1639b81" xlink:href="biib-20201231.xsd#biib_A225SeniorNotesDueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_A2020SeniorNotesMember_1dafe62a-5c75-4389-9d14-3308601ab260" xlink:to="loc_biib_A225SeniorNotesDueMay12030Member_3dcbea78-2dd5-4406-ae9b-b276b1639b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A315SeniorNotesDueMay12050Member_2fa087de-cfde-468b-b4d6-1a882f88f9f8" xlink:href="biib-20201231.xsd#biib_A315SeniorNotesDueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_A2020SeniorNotesMember_1dafe62a-5c75-4389-9d14-3308601ab260" xlink:to="loc_biib_A315SeniorNotesDueMay12050Member_2fa087de-cfde-468b-b4d6-1a882f88f9f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:href="biib-20201231.xsd#biib_A2015SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:to="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6cd413ac-392c-4d53-81d0-3e017d25b60c" xlink:href="biib-20201231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6cd413ac-392c-4d53-81d0-3e017d25b60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_43e800d8-d395-47b2-8c7e-683a4f3b7447" xlink:href="biib-20201231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_43e800d8-d395-47b2-8c7e-683a4f3b7447" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_d4402dc9-b033-4177-87fe-d235f42ade1e" xlink:href="biib-20201231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_d4402dc9-b033-4177-87fe-d235f42ade1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_448284f8-535c-436b-8f73-b2e2e8cd4a3d" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_448284f8-535c-436b-8f73-b2e2e8cd4a3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b06c0773-5a0a-4664-977a-e020a57e4cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b06c0773-5a0a-4664-977a-e020a57e4cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_cc643072-ed7e-49e2-a90b-36e168295c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b06c0773-5a0a-4664-977a-e020a57e4cf4" xlink:to="loc_us-gaap_InterestExpenseMember_cc643072-ed7e-49e2-a90b-36e168295c53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_590e0ca3-68a4-4d0c-bb76-8623a626fa6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_590e0ca3-68a4-4d0c-bb76-8623a626fa6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_590e0ca3-68a4-4d0c-bb76-8623a626fa6c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_590e0ca3-68a4-4d0c-bb76-8623a626fa6c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_590e0ca3-68a4-4d0c-bb76-8623a626fa6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6be3e80a-f165-493a-aa2e-efeead469afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_590e0ca3-68a4-4d0c-bb76-8623a626fa6c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6be3e80a-f165-493a-aa2e-efeead469afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_57e62732-3f82-4b55-aced-1adb5184fdc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6be3e80a-f165-493a-aa2e-efeead469afb" xlink:to="loc_us-gaap_InterestRateSwapMember_57e62732-3f82-4b55-aced-1adb5184fdc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3ee42229-d685-44ac-9d11-9cb84022c825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_CreditFacilityAxis_3ee42229-d685-44ac-9d11-9cb84022c825" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3ee42229-d685-44ac-9d11-9cb84022c825_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_3ee42229-d685-44ac-9d11-9cb84022c825" xlink:to="loc_us-gaap_CreditFacilityDomain_3ee42229-d685-44ac-9d11-9cb84022c825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f5b00691-fb3a-4ef2-adda-41c8ba76ae01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_3ee42229-d685-44ac-9d11-9cb84022c825" xlink:to="loc_us-gaap_CreditFacilityDomain_f5b00691-fb3a-4ef2-adda-41c8ba76ae01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_18206528-1440-4650-b2f3-fa255d3777bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f5b00691-fb3a-4ef2-adda-41c8ba76ae01" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_18206528-1440-4650-b2f3-fa255d3777bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessTotalDebtMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails" xlink:type="extended" id="ieb7883787a294ab1a8d093d673db0da7_IndebtednessTotalDebtMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20201231.xsd#Equity"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" id="if4d50c8054ec47208aae53f907ce0355_Equity"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" id="i799c912ec088407782b226be3d2109a5_EquityTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="extended" id="i56043bbdf9b94ec2bebc017a07e7564d_EquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_88db0c92-52c3-4404-9a06-2c87da7c3a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_88db0c92-52c3-4404-9a06-2c87da7c3a3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_61af3ce8-9ccc-4fa1-b200-f69e88dc3873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_PreferredStockSharesIssued_61af3ce8-9ccc-4fa1-b200-f69e88dc3873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fb91e72b-8c38-4459-aa06-f9d43937bbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fb91e72b-8c38-4459-aa06-f9d43937bbce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8e81d236-c6b8-4fa7-911a-2b9675e136cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8e81d236-c6b8-4fa7-911a-2b9675e136cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a0e0df9a-d1a4-4be7-af6a-f16f844ef10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a0e0df9a-d1a4-4be7-af6a-f16f844ef10d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_715fc4b3-44c6-471d-9696-fc3b6fa40abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_715fc4b3-44c6-471d-9696-fc3b6fa40abd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram5Member_0e4dfd25-11c1-4354-a1ab-5d5fb572ebf0" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram5Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram5Member_0e4dfd25-11c1-4354-a1ab-5d5fb572ebf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram4Member_e388e2fa-ae1c-4053-8401-496900ca2611" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram4Member_e388e2fa-ae1c-4053-8401-496900ca2611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram3Member_8eb00b00-ce5a-4ea2-9fde-5a9670a07ca1" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram3Member_8eb00b00-ce5a-4ea2-9fde-5a9670a07ca1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram2Member_c9a2c0a9-b5f6-4f30-853c-004d13b00e7f" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram2Member_c9a2c0a9-b5f6-4f30-853c-004d13b00e7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram1Member_77e1b905-3ff8-44ee-bfc8-90533d4a7a26" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram1Member_77e1b905-3ff8-44ee-bfc8-90533d4a7a26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_953c919a-f8e6-44fd-be4c-acc8760f3334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:to="loc_us-gaap_StatementClassOfStockAxis_953c919a-f8e6-44fd-be4c-acc8760f3334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_953c919a-f8e6-44fd-be4c-acc8760f3334_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_953c919a-f8e6-44fd-be4c-acc8760f3334" xlink:to="loc_us-gaap_ClassOfStockDomain_953c919a-f8e6-44fd-be4c-acc8760f3334_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_953c919a-f8e6-44fd-be4c-acc8760f3334" xlink:to="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a8873750-7438-48af-b10a-723794d5a472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a8873750-7438-48af-b10a-723794d5a472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeriesXPreferredStockMember_f05214d1-256f-4177-a2a3-9ad865eaf862" xlink:href="biib-20201231.xsd#biib_SeriesXPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:to="loc_biib_SeriesXPreferredStockMember_f05214d1-256f-4177-a2a3-9ad865eaf862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UndesignatedPreferredStockMember_20f0d02b-4ff1-4475-b821-120adaed3e55" xlink:href="biib-20201231.xsd#biib_UndesignatedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:to="loc_biib_UndesignatedPreferredStockMember_20f0d02b-4ff1-4475-b821-120adaed3e55" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquitySummaryofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails" xlink:type="extended" id="i7f193a03ea2142c49327895fcb29355b_EquitySummaryofCommonStockDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="id998a13d0dd545a5a2c61df3c4b20847_EquityAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_97c5e346-d5d8-49d3-a34c-dff087a71d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_97c5e346-d5d8-49d3-a34c-dff087a71d6f" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c05308db-ba56-40e0-8f21-866b7e81f029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c05308db-ba56-40e0-8f21-866b7e81f029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec27d1fe-932f-4eff-aacd-2911d2a025b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec27d1fe-932f-4eff-aacd-2911d2a025b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_96b4022a-9e61-409b-b9ee-d5077ad1aa12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_96b4022a-9e61-409b-b9ee-d5077ad1aa12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6761dc6e-e6cf-4f7c-bd0b-d4578caeeb69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6761dc6e-e6cf-4f7c-bd0b-d4578caeeb69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3a3632db-c2ea-4add-8dbd-4e18eabe3fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3a3632db-c2ea-4add-8dbd-4e18eabe3fb6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_478e476a-496a-4f87-a395-ea2543fa8e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_97c5e346-d5d8-49d3-a34c-dff087a71d6f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0592dc2c-0f07-4d2b-bca7-921060cae3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0592dc2c-0f07-4d2b-bca7-921060cae3ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0592dc2c-0f07-4d2b-bca7-921060cae3ae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0592dc2c-0f07-4d2b-bca7-921060cae3ae" xlink:to="loc_us-gaap_EquityComponentDomain_0592dc2c-0f07-4d2b-bca7-921060cae3ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c19fda53-7fad-4076-848c-af187c61b81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0592dc2c-0f07-4d2b-bca7-921060cae3ae" xlink:to="loc_us-gaap_EquityComponentDomain_c19fda53-7fad-4076-848c-af187c61b81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c19fda53-7fad-4076-848c-af187c61b81e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5fcdd61d-843f-4229-a88c-5996eb620f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5fcdd61d-843f-4229-a88c-5996eb620f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_07f60c3a-3319-421f-8ade-3c12aa10be30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_07f60c3a-3319-421f-8ade-3c12aa10be30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8cd45b13-4059-4b7a-92d3-e0f4f849e614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8cd45b13-4059-4b7a-92d3-e0f4f849e614" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e79f7d90-9894-4a20-81be-4ff36147eb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e79f7d90-9894-4a20-81be-4ff36147eb3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a8ca47a6-30ff-4f4b-ab05-adb5855c7eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a8ca47a6-30ff-4f4b-ab05-adb5855c7eb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_406b6412-f244-46c5-8dac-e0964aaf2b57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_406b6412-f244-46c5-8dac-e0964aaf2b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f987d875-20c1-4f9d-9d33-1ec966319979" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_406b6412-f244-46c5-8dac-e0964aaf2b57" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f987d875-20c1-4f9d-9d33-1ec966319979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_a74907b7-0065-430f-bd1f-5997dea40110" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_406b6412-f244-46c5-8dac-e0964aaf2b57" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_a74907b7-0065-430f-bd1f-5997dea40110" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="ia71f386c30f04775b51b91edcb7cefd3_EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_25b38934-3fb0-4b65-b9c5-a3459d5911cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_25b38934-3fb0-4b65-b9c5-a3459d5911cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8e32a234-aa58-4240-baad-ed62ec931240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8e32a234-aa58-4240-baad-ed62ec931240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ec02fb2a-24e7-4af2-89e9-188169777736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_Revenues_ec02fb2a-24e7-4af2-89e9-188169777736" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a399ccbb-e054-4685-8c2e-a06d4608cf82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_OperatingExpenses_a399ccbb-e054-4685-8c2e-a06d4608cf82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1bc5ef5c-931e-4a92-b7d8-12ff2e1f1ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_NetIncomeLoss_1bc5ef5c-931e-4a92-b7d8-12ff2e1f1ef5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b924f2b4-36c3-4bb9-87df-65e561270c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b924f2b4-36c3-4bb9-87df-65e561270c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b924f2b4-36c3-4bb9-87df-65e561270c66_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b924f2b4-36c3-4bb9-87df-65e561270c66" xlink:to="loc_us-gaap_EquityComponentDomain_b924f2b4-36c3-4bb9-87df-65e561270c66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b924f2b4-36c3-4bb9-87df-65e561270c66" xlink:to="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6e466670-5204-4336-80dc-b0a34de73e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6e466670-5204-4336-80dc-b0a34de73e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5dd38bf4-4499-443a-83da-e25aa0b382ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5dd38bf4-4499-443a-83da-e25aa0b382ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_1116af78-1b25-4722-a455-b29198e451e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_1116af78-1b25-4722-a455-b29198e451e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_777357c2-bf41-4437-8bcd-da0d05233263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_777357c2-bf41-4437-8bcd-da0d05233263" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_777357c2-bf41-4437-8bcd-da0d05233263_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_777357c2-bf41-4437-8bcd-da0d05233263" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_777357c2-bf41-4437-8bcd-da0d05233263_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cc45a7d7-f942-4a15-a719-fd4a088ffb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_777357c2-bf41-4437-8bcd-da0d05233263" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cc45a7d7-f942-4a15-a719-fd4a088ffb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d5e28f58-53c7-4f49-a912-1626822372cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cc45a7d7-f942-4a15-a719-fd4a088ffb08" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d5e28f58-53c7-4f49-a912-1626822372cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShare"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended" id="i42f120f4c03f47fb935e72ba066ce441_EarningsperShare"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended" id="i5e2de7d22b3d4b858ec832cf8d840e66_EarningsperShareTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareBasicandDilutedEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="extended" id="i85ba7bcc6e6e425a8ecf4af39c0bd3ec_EarningsperShareBasicandDilutedEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e2cbf605-3e72-44fc-91f4-5012f78bec86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumeratorAbstract_4afee3d1-458d-475f-b71e-c6ce761f01dc" xlink:href="biib-20201231.xsd#biib_NumeratorAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e2cbf605-3e72-44fc-91f4-5012f78bec86" xlink:to="loc_biib_NumeratorAbstract_4afee3d1-458d-475f-b71e-c6ce761f01dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc1b8930-42e7-4418-8d08-55dd2c4ee07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_NumeratorAbstract_4afee3d1-458d-475f-b71e-c6ce761f01dc" xlink:to="loc_us-gaap_NetIncomeLoss_bc1b8930-42e7-4418-8d08-55dd2c4ee07a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:href="biib-20201231.xsd#biib_DenominatorAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e2cbf605-3e72-44fc-91f4-5012f78bec86" xlink:to="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fd4622a-412a-45ab-b914-6a0cd4078be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fd4622a-412a-45ab-b914-6a0cd4078be5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_45794874-29d0-4c93-b680-0b55d1091523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_45794874-29d0-4c93-b680-0b55d1091523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4b572ba7-8b47-40a8-a3d9-4bb6e9ca8cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_45794874-29d0-4c93-b680-0b55d1091523" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4b572ba7-8b47-40a8-a3d9-4bb6e9ca8cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2007c5d9-9dcf-49f8-9a68-dee5e54abef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_45794874-29d0-4c93-b680-0b55d1091523" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2007c5d9-9dcf-49f8-9a68-dee5e54abef8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6f46b73b-a01b-4fd5-9328-e73abc0bc792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6f46b73b-a01b-4fd5-9328-e73abc0bc792" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a3dff39d-5e2a-4758-8f77-888245eaba6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e2cbf605-3e72-44fc-91f4-5012f78bec86" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a3dff39d-5e2a-4758-8f77-888245eaba6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ece9e540-b307-4f2d-9383-07f74c5f9c21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a3dff39d-5e2a-4758-8f77-888245eaba6b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ece9e540-b307-4f2d-9383-07f74c5f9c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ece9e540-b307-4f2d-9383-07f74c5f9c21_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ece9e540-b307-4f2d-9383-07f74c5f9c21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ece9e540-b307-4f2d-9383-07f74c5f9c21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ece9e540-b307-4f2d-9383-07f74c5f9c21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_11372b96-751a-425c-9cc9-619abbed1f06" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_11372b96-751a-425c-9cc9-619abbed1f06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_330ba4d3-5145-4e42-896d-28cb821389a7" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:to="loc_biib_MarketStockUnitsMember_330ba4d3-5145-4e42-896d-28cb821389a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_6980af51-717d-4813-94e7-7775c07be05b" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_6980af51-717d-4813-94e7-7775c07be05b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareNarrativeDetails" xlink:type="extended" id="i75c3910af9bf406b9da74ecd066583a8_EarningsperShareNarrativeDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPayments"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" id="i5d12ae7d93784ff59082c63e0334dea9_ShareBasedPayments"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" id="i133216772f704f3fa8a520a1517509dc_ShareBasedPaymentsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails" xlink:type="extended" id="i9fc988ee049841d8af2162cdc5a5d43e_ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_afa33c55-b9d7-4981-9f43-bf149f4c5139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_afa33c55-b9d7-4981-9f43-bf149f4c5139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_57307698-1bbb-41a0-94b1-b0d530250d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_57307698-1bbb-41a0-94b1-b0d530250d3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0565d352-27c4-4278-b7a2-1e0d1af3c21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0565d352-27c4-4278-b7a2-1e0d1af3c21d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_d612613d-1bb3-46b2-b2be-dcf1e4aafcf7" xlink:href="biib-20201231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_d612613d-1bb3-46b2-b2be-dcf1e4aafcf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f8e3e0b8-9bb7-45dd-8325-06e47f2855f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f8e3e0b8-9bb7-45dd-8325-06e47f2855f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c27e5396-42af-4806-ac09-982c9d87e06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c27e5396-42af-4806-ac09-982c9d87e06d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b626346-2c60-4547-a671-0bfb21dc64f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c27e5396-42af-4806-ac09-982c9d87e06d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b626346-2c60-4547-a671-0bfb21dc64f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3b626346-2c60-4547-a671-0bfb21dc64f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b626346-2c60-4547-a671-0bfb21dc64f0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3b626346-2c60-4547-a671-0bfb21dc64f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b626346-2c60-4547-a671-0bfb21dc64f0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7109e070-8b27-4530-9cab-60d0b77191d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7109e070-8b27-4530-9cab-60d0b77191d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1330a744-4474-4733-af0b-a273e65e073a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1330a744-4474-4733-af0b-a273e65e073a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_7efa43d0-aa80-446a-bb24-39a552d1f7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:to="loc_us-gaap_ParentMember_7efa43d0-aa80-446a-bb24-39a552d1f7a1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails" xlink:type="extended" id="i4a62f346270e44008927906dfdab4f4a_ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f0635ab-02fc-4507-83c4-2679923a4358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f0635ab-02fc-4507-83c4-2679923a4358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_00b34deb-11ad-40d9-a0fd-f52d20d2977d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_00b34deb-11ad-40d9-a0fd-f52d20d2977d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2ab0d11a-a957-42d9-a427-503b48622671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2ab0d11a-a957-42d9-a427-503b48622671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9e52852c-3e16-4d20-b6d6-0ab4da308c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9e52852c-3e16-4d20-b6d6-0ab4da308c4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2d419dfb-2b60-4d18-9142-e659b7812a35" xlink:href="biib-20201231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2d419dfb-2b60-4d18-9142-e659b7812a35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b9c49ceb-c642-4192-9df7-e70b85abbc94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b9c49ceb-c642-4192-9df7-e70b85abbc94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9c49ceb-c642-4192-9df7-e70b85abbc94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b9c49ceb-c642-4192-9df7-e70b85abbc94" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9c49ceb-c642-4192-9df7-e70b85abbc94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2349652f-c047-48cf-9abf-9be3673969a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b9c49ceb-c642-4192-9df7-e70b85abbc94" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2349652f-c047-48cf-9abf-9be3673969a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_fcb78912-a411-480e-9b04-fa0eeaf89013" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2349652f-c047-48cf-9abf-9be3673969a5" xlink:to="loc_biib_NightstarMember_fcb78912-a411-480e-9b04-fa0eeaf89013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4166a0b7-ba36-42a0-b5ae-31086977bccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:to="loc_us-gaap_AwardTypeAxis_4166a0b7-ba36-42a0-b5ae-31086977bccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4166a0b7-ba36-42a0-b5ae-31086977bccc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4166a0b7-ba36-42a0-b5ae-31086977bccc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4166a0b7-ba36-42a0-b5ae-31086977bccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b25851-5c3e-4f6f-8b5b-cae7d67c8cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4166a0b7-ba36-42a0-b5ae-31086977bccc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b25851-5c3e-4f6f-8b5b-cae7d67c8cfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b0620e73-8a80-4f45-800e-860af30fb76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b25851-5c3e-4f6f-8b5b-cae7d67c8cfc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b0620e73-8a80-4f45-800e-860af30fb76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8c3920e3-bb29-4ff2-9988-0987d3795995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:to="loc_us-gaap_PlanNameAxis_8c3920e3-bb29-4ff2-9988-0987d3795995" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8c3920e3-bb29-4ff2-9988-0987d3795995_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8c3920e3-bb29-4ff2-9988-0987d3795995" xlink:to="loc_us-gaap_PlanNameDomain_8c3920e3-bb29-4ff2-9988-0987d3795995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8c3920e3-bb29-4ff2-9988-0987d3795995" xlink:to="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_bc1d37cb-0668-4926-8008-77606b50bfc2" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_MarketStockUnitsMember_bc1d37cb-0668-4926-8008-77606b50bfc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_60c18376-18cd-4796-93f6-600730f35c6f" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_60c18376-18cd-4796-93f6-600730f35c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_1888a4cc-1c17-4512-9f72-8fdc8dc0510d" xlink:href="biib-20201231.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_CashSettledPerformanceSharesMember_1888a4cc-1c17-4512-9f72-8fdc8dc0510d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceUnitsMember_8dae1201-dd55-4475-b5ba-6a0510dfc47f" xlink:href="biib-20201231.xsd#biib_PerformanceUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_PerformanceUnitsMember_8dae1201-dd55-4475-b5ba-6a0510dfc47f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_386b3197-b139-4f45-8e13-db4825dc1cbb" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_386b3197-b139-4f45-8e13-db4825dc1cbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_c23cc7ce-6e89-4e58-b67c-e0d6fdf4970b" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_c23cc7ce-6e89-4e58-b67c-e0d6fdf4970b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_4d52e59c-95bc-4761-8f1d-9d14d387782b" xlink:href="biib-20201231.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_4d52e59c-95bc-4761-8f1d-9d14d387782b" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended" id="i51e5183dc98146daaeb4625c93c4b98a_ShareBasedPaymentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0feb7f5a-7827-4832-85a3-1350455c0fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0feb7f5a-7827-4832-85a3-1350455c0fc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_b2e6420f-704f-4c44-b4e9-2375959bbb81" xlink:href="biib-20201231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_b2e6420f-704f-4c44-b4e9-2375959bbb81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_6f97da3f-af8b-4149-b338-3976559cad4b" xlink:href="biib-20201231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_6f97da3f-af8b-4149-b338-3976559cad4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_15e9af5e-1120-4982-bec6-7682ae076ec0" xlink:href="biib-20201231.xsd#biib_NumberOfSharesOfCommonStockForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_15e9af5e-1120-4982-bec6-7682ae076ec0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_92a70b21-f6a0-447c-be24-648f435e86cc" xlink:href="biib-20201231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_92a70b21-f6a0-447c-be24-648f435e86cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67755505-9123-4fb1-b4ce-02838a389a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67755505-9123-4fb1-b4ce-02838a389a02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b72b1280-2556-41c4-a207-98570308fc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b72b1280-2556-41c4-a207-98570308fc79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54fcf64b-f10a-4670-a177-a7af18977be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54fcf64b-f10a-4670-a177-a7af18977be0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_20c84e2c-db44-4ddc-bf05-a35e5e6c6dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_20c84e2c-db44-4ddc-bf05-a35e5e6c6dcd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_403e8565-cb00-4d78-b60c-b559d0bfcbe3" xlink:href="biib-20201231.xsd#biib_NumberOfEqualAnnualIncrements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_403e8565-cb00-4d78-b60c-b559d0bfcbe3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_4b42bd2b-c600-4e54-9285-ce2b166906ff" xlink:href="biib-20201231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_4b42bd2b-c600-4e54-9285-ce2b166906ff" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_3a645019-c02a-4ca8-9589-5af40144c3d4" xlink:href="biib-20201231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_3a645019-c02a-4ca8-9589-5af40144c3d4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_61da919a-ae0c-4ea2-b8d7-10504a719b9d" xlink:href="biib-20201231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_61da919a-ae0c-4ea2-b8d7-10504a719b9d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0bcb20f2-338b-4bc0-a3f6-d4b8bc84b8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0bcb20f2-338b-4bc0-a3f6-d4b8bc84b8a7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_8f4715c9-36b2-4cca-85a3-f92a36657ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_8f4715c9-36b2-4cca-85a3-f92a36657ebd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0afa1553-c220-4230-befa-e60642a79d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0afa1553-c220-4230-befa-e60642a79d1c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51009b9a-0359-4b7a-99cf-019d78152c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51009b9a-0359-4b7a-99cf-019d78152c8c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_68aa25e0-0693-4881-963a-4219d8119760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_68aa25e0-0693-4881-963a-4219d8119760" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e99c5599-ea4c-493f-b094-cad79c992c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_us-gaap_PlanNameAxis_e99c5599-ea4c-493f-b094-cad79c992c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e99c5599-ea4c-493f-b094-cad79c992c70_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e99c5599-ea4c-493f-b094-cad79c992c70" xlink:to="loc_us-gaap_PlanNameDomain_e99c5599-ea4c-493f-b094-cad79c992c70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89fe3fbb-4045-4955-9a2e-4463023acb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e99c5599-ea4c-493f-b094-cad79c992c70" xlink:to="loc_us-gaap_PlanNameDomain_89fe3fbb-4045-4955-9a2e-4463023acb5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DirectorsPlanMember_54c466a5-ec14-46c3-8dd8-b3186b0062dc" xlink:href="biib-20201231.xsd#biib_DirectorsPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_89fe3fbb-4045-4955-9a2e-4463023acb5b" xlink:to="loc_biib_DirectorsPlanMember_54c466a5-ec14-46c3-8dd8-b3186b0062dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_4230c8b5-9f80-4244-b22e-dfdb1cc15abe" xlink:href="biib-20201231.xsd#biib_A2017OmnibusEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_89fe3fbb-4045-4955-9a2e-4463023acb5b" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_4230c8b5-9f80-4244-b22e-dfdb1cc15abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_us-gaap_AwardTypeAxis_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_e8f5b587-e13a-4be7-a6b7-f1673157a17a" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_biib_MarketStockUnitsMember_e8f5b587-e13a-4be7-a6b7-f1673157a17a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_6884c8ee-a595-4121-bf73-9021517d9d1f" xlink:href="biib-20201231.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_biib_CashSettledPerformanceSharesMember_6884c8ee-a595-4121-bf73-9021517d9d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f9c450e7-6e13-49e7-a47b-d3374d52d0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_us-gaap_PerformanceSharesMember_f9c450e7-6e13-49e7-a47b-d3374d52d0b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_36d2e1f3-740f-4e79-b487-92e1f9d41bd2" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_f9c450e7-6e13-49e7-a47b-d3374d52d0b1" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_36d2e1f3-740f-4e79-b487-92e1f9d41bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_37c57cd2-53b7-4612-aa99-855b4aefb64d" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_f9c450e7-6e13-49e7-a47b-d3374d52d0b1" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_37c57cd2-53b7-4612-aa99-855b4aefb64d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_114c1b03-c615-4d01-bddb-5e0e655c7ab2" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_114c1b03-c615-4d01-bddb-5e0e655c7ab2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d0f94288-ba1c-4540-954f-c4915afbda57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d0f94288-ba1c-4540-954f-c4915afbda57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bdb0104b-05cc-40ab-9894-4a72c8053d44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_srt_RangeAxis_bdb0104b-05cc-40ab-9894-4a72c8053d44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bdb0104b-05cc-40ab-9894-4a72c8053d44_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bdb0104b-05cc-40ab-9894-4a72c8053d44" xlink:to="loc_srt_RangeMember_bdb0104b-05cc-40ab-9894-4a72c8053d44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27e45392-c97f-47e6-a94a-c7f81405d9c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bdb0104b-05cc-40ab-9894-4a72c8053d44" xlink:to="loc_srt_RangeMember_27e45392-c97f-47e6-a94a-c7f81405d9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96e965e3-933a-4cf9-9303-990465a6af7e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27e45392-c97f-47e6-a94a-c7f81405d9c5" xlink:to="loc_srt_MinimumMember_96e965e3-933a-4cf9-9303-990465a6af7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a70d8185-0366-43e5-b5ba-9fc6b2850e57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27e45392-c97f-47e6-a94a-c7f81405d9c5" xlink:to="loc_srt_MaximumMember_a70d8185-0366-43e5-b5ba-9fc6b2850e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_08825167-ce1c-492b-a709-cb6311836d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_us-gaap_VestingAxis_08825167-ce1c-492b-a709-cb6311836d19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_08825167-ce1c-492b-a709-cb6311836d19_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_08825167-ce1c-492b-a709-cb6311836d19" xlink:to="loc_us-gaap_VestingDomain_08825167-ce1c-492b-a709-cb6311836d19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_08825167-ce1c-492b-a709-cb6311836d19" xlink:to="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8052736a-6172-47f0-ad05-3f5779491815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8052736a-6172-47f0-ad05-3f5779491815" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_86a3ccff-9e25-4612-bd22-777a6aeab07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_86a3ccff-9e25-4612-bd22-777a6aeab07b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_12904ff9-c0df-455e-a7bb-d4ff11cd58b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_12904ff9-c0df-455e-a7bb-d4ff11cd58b0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="extended" id="if35c92e9c0cb42beb04c44aba692120f_ShareBasedPaymentsStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f46287b-76c2-4d7c-b327-9fdbd5af57f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f46287b-76c2-4d7c-b327-9fdbd5af57f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c408e199-ec8f-4397-b2de-f3964dde9cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c408e199-ec8f-4397-b2de-f3964dde9cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8a86cf16-595a-4f03-b0f7-77c563decee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8a86cf16-595a-4f03-b0f7-77c563decee4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3f5c687d-802a-4284-81ef-c71e2ee1416f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3f5c687d-802a-4284-81ef-c71e2ee1416f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9d281cdf-0dae-446e-b06f-2bf2af05b581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9d281cdf-0dae-446e-b06f-2bf2af05b581" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_616d4a55-6a5b-4978-81dc-f6dbb3ba72c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f46287b-76c2-4d7c-b327-9fdbd5af57f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c549f9f2-6187-49af-9b19-f84181477734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c549f9f2-6187-49af-9b19-f84181477734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f8130a7-a0ab-4b88-afb7-23e96f2ded6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f8130a7-a0ab-4b88-afb7-23e96f2ded6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a87349d1-dbd6-4cc0-b8ca-13fdb0f6c961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a87349d1-dbd6-4cc0-b8ca-13fdb0f6c961" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40f93fa7-1467-4a6b-b60b-d346514db0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40f93fa7-1467-4a6b-b60b-d346514db0b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4df58c32-5995-42b5-b6e8-88b55f27166f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f28c302e-ab0b-4a3a-83bc-b70be230c1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f46287b-76c2-4d7c-b327-9fdbd5af57f0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f28c302e-ab0b-4a3a-83bc-b70be230c1e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_197d78e0-581e-44b8-ae4d-a7a907cb7adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f28c302e-ab0b-4a3a-83bc-b70be230c1e6" xlink:to="loc_us-gaap_AwardTypeAxis_197d78e0-581e-44b8-ae4d-a7a907cb7adf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_197d78e0-581e-44b8-ae4d-a7a907cb7adf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_197d78e0-581e-44b8-ae4d-a7a907cb7adf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_197d78e0-581e-44b8-ae4d-a7a907cb7adf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c888c51-0319-4187-a9ce-7ca44251da8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_197d78e0-581e-44b8-ae4d-a7a907cb7adf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c888c51-0319-4187-a9ce-7ca44251da8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_06d0c666-03a0-4d5d-8071-97593be604c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c888c51-0319-4187-a9ce-7ca44251da8a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_06d0c666-03a0-4d5d-8071-97593be604c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails" xlink:type="extended" id="ibc2feed2215e46ba967a34e841f795e4_ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsMarketStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails" xlink:type="extended" id="ice7026060a1741bd8cd2ec2c91bc6edf_ShareBasedPaymentsMarketStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46170e7-ce25-4e22-b48a-db91d8972429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46170e7-ce25-4e22-b48a-db91d8972429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_489b32fb-3e9b-4f94-b597-63a624dcf403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_489b32fb-3e9b-4f94-b597-63a624dcf403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3bdf6635-fbc7-4ff0-9ca2-993c9435406c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3bdf6635-fbc7-4ff0-9ca2-993c9435406c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_43130105-208a-4e82-a156-9d4983e206a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_43130105-208a-4e82-a156-9d4983e206a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d47aada0-d9a2-4a15-97f9-8ba4b1782f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d47aada0-d9a2-4a15-97f9-8ba4b1782f0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e172a721-d8f8-47e3-913a-f60e2e099245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46170e7-ce25-4e22-b48a-db91d8972429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39d832ef-aa12-4c46-9232-5e07d738f122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39d832ef-aa12-4c46-9232-5e07d738f122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34b1e4b8-b532-4f68-8428-a5334af240da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34b1e4b8-b532-4f68-8428-a5334af240da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a95fc537-4f86-4456-804f-7c895f0fc684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a95fc537-4f86-4456-804f-7c895f0fc684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab273951-b9ae-48f3-8d89-afc32cac12ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab273951-b9ae-48f3-8d89-afc32cac12ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e977ec09-8fdb-475f-865d-a2b667960429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_245d5888-b2ef-4920-9cae-9e5d260791ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46170e7-ce25-4e22-b48a-db91d8972429" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_245d5888-b2ef-4920-9cae-9e5d260791ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d973dcc-10b4-4ad1-865e-ad084b750918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_245d5888-b2ef-4920-9cae-9e5d260791ce" xlink:to="loc_us-gaap_AwardTypeAxis_9d973dcc-10b4-4ad1-865e-ad084b750918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d973dcc-10b4-4ad1-865e-ad084b750918_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9d973dcc-10b4-4ad1-865e-ad084b750918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d973dcc-10b4-4ad1-865e-ad084b750918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7f6cd35-ae03-4b0f-bd2d-49dca31ed19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9d973dcc-10b4-4ad1-865e-ad084b750918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7f6cd35-ae03-4b0f-bd2d-49dca31ed19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_af645d7f-7729-4dbc-8bf7-caf9b2a4a5a9" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7f6cd35-ae03-4b0f-bd2d-49dca31ed19e" xlink:to="loc_biib_MarketStockUnitsMember_af645d7f-7729-4dbc-8bf7-caf9b2a4a5a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails" xlink:type="extended" id="ic6b08300b5944b6c8351ee0ab9d0c147_ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f1dd94eb-79a5-4ff9-b122-17801e7c8874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f1dd94eb-79a5-4ff9-b122-17801e7c8874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_49776252-ea04-4ec5-910b-9b6e36778a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_49776252-ea04-4ec5-910b-9b6e36778a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8f4c94e2-d4ec-4a93-9751-a83d61c886c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8f4c94e2-d4ec-4a93-9751-a83d61c886c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_028e72ba-c36c-40d0-bb3c-697031b08854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_028e72ba-c36c-40d0-bb3c-697031b08854" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_d5e144ea-533b-443d-83e2-961bb4a43252" xlink:href="biib-20201231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_d5e144ea-533b-443d-83e2-961bb4a43252" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_383a3a64-3e45-40d0-8509-868270c52f44" xlink:href="biib-20201231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_383a3a64-3e45-40d0-8509-868270c52f44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4d16634d-c983-4ebe-9bd2-cc36b1aaaad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4d16634d-c983-4ebe-9bd2-cc36b1aaaad2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7d21aede-7f8d-4424-a8c4-ae966c418d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:to="loc_us-gaap_AwardTypeAxis_7d21aede-7f8d-4424-a8c4-ae966c418d63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d21aede-7f8d-4424-a8c4-ae966c418d63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7d21aede-7f8d-4424-a8c4-ae966c418d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d21aede-7f8d-4424-a8c4-ae966c418d63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dfb7e45-8a67-489a-89ab-ea74c812d59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7d21aede-7f8d-4424-a8c4-ae966c418d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dfb7e45-8a67-489a-89ab-ea74c812d59d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_cc9dc459-6459-40c6-a28d-f14f8ac30cf0" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dfb7e45-8a67-489a-89ab-ea74c812d59d" xlink:to="loc_biib_MarketStockUnitsMember_cc9dc459-6459-40c6-a28d-f14f8ac30cf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be059d4f-9c16-4ec3-a512-b01539f73ede" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:to="loc_srt_RangeAxis_be059d4f-9c16-4ec3-a512-b01539f73ede" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be059d4f-9c16-4ec3-a512-b01539f73ede_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_be059d4f-9c16-4ec3-a512-b01539f73ede" xlink:to="loc_srt_RangeMember_be059d4f-9c16-4ec3-a512-b01539f73ede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cea9526-38a6-47d6-be0e-261192f0df52" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_be059d4f-9c16-4ec3-a512-b01539f73ede" xlink:to="loc_srt_RangeMember_1cea9526-38a6-47d6-be0e-261192f0df52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4faaad7-a9be-40db-b660-22a72ce07aa4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cea9526-38a6-47d6-be0e-261192f0df52" xlink:to="loc_srt_MinimumMember_b4faaad7-a9be-40db-b660-22a72ce07aa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c8eabee-cbfb-41e5-a680-cbb51d64b13a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cea9526-38a6-47d6-be0e-261192f0df52" xlink:to="loc_srt_MaximumMember_1c8eabee-cbfb-41e5-a680-cbb51d64b13a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails" xlink:type="extended" id="icd456c34e4da43cc85a55f9b0caeef13_ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7697acdb-537d-4a1e-83d0-ad0735892b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7697acdb-537d-4a1e-83d0-ad0735892b48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4fa36056-1063-42c4-b1ca-5c1af45efbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4fa36056-1063-42c4-b1ca-5c1af45efbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_959295ea-172b-4e75-97b5-ae5ccc4e0eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_959295ea-172b-4e75-97b5-ae5ccc4e0eb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ffd77ea8-0c18-4ab2-9944-51d8dfe52946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ffd77ea8-0c18-4ab2-9944-51d8dfe52946" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6420680e-8cda-4062-bf17-db387b29d321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6420680e-8cda-4062-bf17-db387b29d321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5291ef9a-ce8f-44be-91fd-673c9abe8c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf66c853-d1f8-4220-9934-1678389bb02d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7697acdb-537d-4a1e-83d0-ad0735892b48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf66c853-d1f8-4220-9934-1678389bb02d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf66c853-d1f8-4220-9934-1678389bb02d" xlink:to="loc_us-gaap_AwardTypeAxis_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d3752a9-2abd-4e58-922d-f2c44e4b8c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d3752a9-2abd-4e58-922d-f2c44e4b8c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_ce1d763b-362a-4b9c-a74f-d5e1ba468ab7" xlink:href="biib-20201231.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d3752a9-2abd-4e58-922d-f2c44e4b8c58" xlink:to="loc_biib_CashSettledPerformanceSharesMember_ce1d763b-362a-4b9c-a74f-d5e1ba468ab7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails" xlink:type="extended" id="ie0f75c0078174cbaa0bd5de76ccb19af_ShareBasedPaymentsPerformanceUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4af1aa84-dda3-444e-b54b-836537b28c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4af1aa84-dda3-444e-b54b-836537b28c86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07342568-cea8-439f-8f4c-8dd98829d2cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07342568-cea8-439f-8f4c-8dd98829d2cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_774ba374-2e93-4e82-86e0-86b5eda9b533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_774ba374-2e93-4e82-86e0-86b5eda9b533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc1b260e-01f5-4a50-b186-197e1370b941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc1b260e-01f5-4a50-b186-197e1370b941" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d343372a-6fcf-4f26-ac2d-b77edd8841c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d343372a-6fcf-4f26-ac2d-b77edd8841c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e3f164bc-c0e3-4787-9945-523c94996027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c83c0b2-de6b-45d9-852f-da8048facc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4af1aa84-dda3-444e-b54b-836537b28c86" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c83c0b2-de6b-45d9-852f-da8048facc7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c83c0b2-de6b-45d9-852f-da8048facc7e" xlink:to="loc_us-gaap_AwardTypeAxis_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06df0f82-000b-4ecd-9a15-8a41b63cb9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06df0f82-000b-4ecd-9a15-8a41b63cb9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ff44ba80-5600-4501-9a86-d7f50ed25bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06df0f82-000b-4ecd-9a15-8a41b63cb9bf" xlink:to="loc_us-gaap_PerformanceSharesMember_ff44ba80-5600-4501-9a86-d7f50ed25bb6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails" xlink:type="extended" id="i63fdf2f9ab1a40078e5417a860c28f0d_ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a6f54ce-84b2-4afc-bc4f-4f7161cd74b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a6f54ce-84b2-4afc-bc4f-4f7161cd74b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3d57a46-86e6-4996-9369-253c8191c381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3d57a46-86e6-4996-9369-253c8191c381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_287d24db-df27-4d24-8791-ebd4c857b33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_287d24db-df27-4d24-8791-ebd4c857b33e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_44f7bf11-645c-4f70-a5da-b76d1e30e2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_44f7bf11-645c-4f70-a5da-b76d1e30e2ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_576ad693-9593-430d-8df1-d9289b5dde59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_576ad693-9593-430d-8df1-d9289b5dde59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d951a90b-2af7-414d-9e5b-0ef968ad30a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a6f54ce-84b2-4afc-bc4f-4f7161cd74b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8a293a44-8c40-472c-ac45-7ae59e5e29dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8a293a44-8c40-472c-ac45-7ae59e5e29dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_593470ce-74da-49b0-b78e-40acda6d0021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_593470ce-74da-49b0-b78e-40acda6d0021" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b892b332-5be9-4c8c-890a-2d34a81fa3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b892b332-5be9-4c8c-890a-2d34a81fa3da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_03a23ca4-6c25-4024-a0fd-158c826c988f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_03a23ca4-6c25-4024-a0fd-158c826c988f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe94b7f0-f057-4559-bca2-5a3f59b5253a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6a62a1-ff6f-48d8-a329-0f6eab1996bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a6f54ce-84b2-4afc-bc4f-4f7161cd74b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6a62a1-ff6f-48d8-a329-0f6eab1996bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e78f3af-e33e-491a-9ab6-aaa0ed91b165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6a62a1-ff6f-48d8-a329-0f6eab1996bc" xlink:to="loc_us-gaap_AwardTypeAxis_0e78f3af-e33e-491a-9ab6-aaa0ed91b165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e78f3af-e33e-491a-9ab6-aaa0ed91b165_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0e78f3af-e33e-491a-9ab6-aaa0ed91b165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e78f3af-e33e-491a-9ab6-aaa0ed91b165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0a4a1f-a36e-4d96-b5ce-3e70ea3feaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0e78f3af-e33e-491a-9ab6-aaa0ed91b165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0a4a1f-a36e-4d96-b5ce-3e70ea3feaa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_b1243678-e649-462f-a8d1-08a4afcad400" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0a4a1f-a36e-4d96-b5ce-3e70ea3feaa7" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_b1243678-e649-462f-a8d1-08a4afcad400" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails" xlink:type="extended" id="i3e0ea8ee6c144977933ea8fa113fdce3_ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d74b745e-8359-4038-bd27-63df9a8191ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d74b745e-8359-4038-bd27-63df9a8191ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17ed22ad-badb-4913-8221-a45171e12908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17ed22ad-badb-4913-8221-a45171e12908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_caa4ed25-787d-4722-9b59-a196687f5d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_caa4ed25-787d-4722-9b59-a196687f5d58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6a248aff-6b70-4ce0-b873-1289ef2de2db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6a248aff-6b70-4ce0-b873-1289ef2de2db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_746d3c96-45c9-4da3-8b09-3392dec4a835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_746d3c96-45c9-4da3-8b09-3392dec4a835" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3cfb827c-55f3-4d9f-960c-648ca32245f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac0d471b-b1e4-49ec-83f2-22b725211125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d74b745e-8359-4038-bd27-63df9a8191ff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac0d471b-b1e4-49ec-83f2-22b725211125" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac0d471b-b1e4-49ec-83f2-22b725211125" xlink:to="loc_us-gaap_AwardTypeAxis_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ed0b4b4-a627-49f2-bbdd-507c08478786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ed0b4b4-a627-49f2-bbdd-507c08478786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_45f4db86-a247-4d45-8e73-dd174855febd" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ed0b4b4-a627-49f2-bbdd-507c08478786" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_45f4db86-a247-4d45-8e73-dd174855febd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i90de5c87df654869b08e47a31e6f18e5_ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_963edc36-e7b4-43b7-9af5-119c2420c618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_963edc36-e7b4-43b7-9af5-119c2420c618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3700e10a-224a-43c3-bfec-889e116589a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3700e10a-224a-43c3-bfec-889e116589a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0c75bb0e-51a1-4e82-9ac6-acd6383f495e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0c75bb0e-51a1-4e82-9ac6-acd6383f495e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be5e5772-bcca-4b2f-905b-875458d1ab75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be5e5772-bcca-4b2f-905b-875458d1ab75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9ca80b53-6098-4f67-a36b-0563904a84b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e20feed-07d5-42d4-915a-07eedafe6f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e20feed-07d5-42d4-915a-07eedafe6f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a277c521-66e0-434b-8c24-acc2ec2ff327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a277c521-66e0-434b-8c24-acc2ec2ff327" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9363ea41-c272-4c80-ab6e-5cd87faf80b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9363ea41-c272-4c80-ab6e-5cd87faf80b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39f8c88a-e134-465e-8ca5-f05054119e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39f8c88a-e134-465e-8ca5-f05054119e35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2006140a-b0c7-412b-8666-b1b727020556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d3bfcec-7873-4aa6-9462-7ebed665b7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_88497b92-a90b-46d0-aaeb-e191c132292b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:to="loc_us-gaap_AwardTypeAxis_88497b92-a90b-46d0-aaeb-e191c132292b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88497b92-a90b-46d0-aaeb-e191c132292b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_88497b92-a90b-46d0-aaeb-e191c132292b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88497b92-a90b-46d0-aaeb-e191c132292b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d74a94-e476-4da6-9588-3c425a7e1c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_88497b92-a90b-46d0-aaeb-e191c132292b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d74a94-e476-4da6-9588-3c425a7e1c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_030cad97-7041-4015-93d4-620be09bb142" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d74a94-e476-4da6-9588-3c425a7e1c67" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_030cad97-7041-4015-93d4-620be09bb142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_77216e71-93b0-4f64-93d5-446bebc1da57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:to="loc_srt_TitleOfIndividualAxis_77216e71-93b0-4f64-93d5-446bebc1da57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_77216e71-93b0-4f64-93d5-446bebc1da57_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_77216e71-93b0-4f64-93d5-446bebc1da57" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_77216e71-93b0-4f64-93d5-446bebc1da57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7ce3e591-9a0b-4af5-89fa-dbdcb4676bbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_77216e71-93b0-4f64-93d5-446bebc1da57" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7ce3e591-9a0b-4af5-89fa-dbdcb4676bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_7b0e3dcc-ea34-464e-8861-f1e710846e07" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7ce3e591-9a0b-4af5-89fa-dbdcb4676bbc" xlink:to="loc_srt_DirectorMember_7b0e3dcc-ea34-464e-8861-f1e710846e07" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails" xlink:type="extended" id="id4399d32b28842a2b665ce0035e130ca_ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_b58f4398-7a0d-4530-903c-6a62baef2385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_38da3084-90f5-4d4c-95f1-911d871c69ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_b58f4398-7a0d-4530-903c-6a62baef2385" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_38da3084-90f5-4d4c-95f1-911d871c69ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1e519bce-711d-4bbb-92a4-4ca36185159f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_b58f4398-7a0d-4530-903c-6a62baef2385" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1e519bce-711d-4bbb-92a4-4ca36185159f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_bfd44136-1247-4cc4-8a6c-3771f3988056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_b58f4398-7a0d-4530-903c-6a62baef2385" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_bfd44136-1247-4cc4-8a6c-3771f3988056" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ea21e8e1-1c2e-48d2-aba5-e8a55f913597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_bfd44136-1247-4cc4-8a6c-3771f3988056" xlink:to="loc_us-gaap_PlanNameAxis_ea21e8e1-1c2e-48d2-aba5-e8a55f913597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ea21e8e1-1c2e-48d2-aba5-e8a55f913597_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ea21e8e1-1c2e-48d2-aba5-e8a55f913597" xlink:to="loc_us-gaap_PlanNameDomain_ea21e8e1-1c2e-48d2-aba5-e8a55f913597_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_39edd8a9-b8fd-4dcf-9f2a-617925801656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ea21e8e1-1c2e-48d2-aba5-e8a55f913597" xlink:to="loc_us-gaap_PlanNameDomain_39edd8a9-b8fd-4dcf-9f2a-617925801656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2015ESPPMember_08524d1a-fb18-47f8-aeee-cf2248fc1c61" xlink:href="biib-20201231.xsd#biib_A2015ESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_39edd8a9-b8fd-4dcf-9f2a-617925801656" xlink:to="loc_biib_A2015ESPPMember_08524d1a-fb18-47f8-aeee-cf2248fc1c61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" id="iad8fdbecb1ee485997c03e42035ec13f_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" id="i50e87408aa6245579d3809e68988ee82_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails" xlink:type="extended" id="i6040f177b0a44d02aff3efd4ee40ec48_IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ifa60256019cb477d92f6a43154cf2ff9_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_c8b02f04-0523-4237-b373-fac2b8b12ad6" xlink:href="biib-20201231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_c8b02f04-0523-4237-b373-fac2b8b12ad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_827a91a6-ddc1-4cce-9941-a8fd429032dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_827a91a6-ddc1-4cce-9941-a8fd429032dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_587c6a7b-04c9-4429-83cc-287f1ea32e27" xlink:href="biib-20201231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_587c6a7b-04c9-4429-83cc-287f1ea32e27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_e343d40b-5a8e-4e21-a7bb-6e37366c000a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_e343d40b-5a8e-4e21-a7bb-6e37366c000a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_e3086eb3-3be0-430c-85ba-99b86370fd33" xlink:href="biib-20201231.xsd#biib_TransitionTollTaxRepatriationTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_e3086eb3-3be0-430c-85ba-99b86370fd33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_f79df3ab-1c31-4247-930f-3e265cab9e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_f79df3ab-1c31-4247-930f-3e265cab9e06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_3b575a0a-4a03-4bb8-8a8a-d3b6ed154b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_IncomeTaxesPaid_3b575a0a-4a03-4bb8-8a8a-d3b6ed154b33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_30298ab7-39e6-4ad4-8a44-562c96a2d7eb" xlink:href="biib-20201231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_30298ab7-39e6-4ad4-8a44-562c96a2d7eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_30619bae-c58e-42f9-8d39-4e4e23d6f99d" xlink:href="biib-20201231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_30619bae-c58e-42f9-8d39-4e4e23d6f99d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductionInValue_9b141631-be31-4d06-87a0-710247bc3531" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetsValueReductionInValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_DeferredTaxAssetsValueReductionInValue_9b141631-be31-4d06-87a0-710247bc3531" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductionInValue_3dc2e353-28f8-4de9-a22a-d95538894bc2" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesValueReductionInValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductionInValue_3dc2e353-28f8-4de9-a22a-d95538894bc2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet_461db798-f4c7-4f65-b2e2-030206986f76" xlink:href="biib-20201231.xsd#biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet_461db798-f4c7-4f65-b2e2-030206986f76" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_c168ee1d-a2cc-407e-9ba5-472c0baacaad" xlink:href="biib-20201231.xsd#biib_Totaldeferredchargesandprepaidtaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_c168ee1d-a2cc-407e-9ba5-472c0baacaad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_01b42a75-770d-4ef2-a8eb-095612b5dc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_01b42a75-770d-4ef2-a8eb-095612b5dc3a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_53af6cd1-77a1-4cd9-bd88-2e64ed0b5bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_53af6cd1-77a1-4cd9-bd88-2e64ed0b5bf6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_28211097-b48d-46e0-ab14-7d7ef09a0f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_28211097-b48d-46e0-ab14-7d7ef09a0f70" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3318b3be-746c-4472-9aec-52d740b8af90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3318b3be-746c-4472-9aec-52d740b8af90" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_cb1fb71a-5f1e-4b34-abb8-16229a580d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_cb1fb71a-5f1e-4b34-abb8-16229a580d7e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_27ba8056-bb16-4aa5-84c0-6dc780f859d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_27ba8056-bb16-4aa5-84c0-6dc780f859d5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_be87990f-5ada-489a-819a-7dde709fbfa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_be87990f-5ada-489a-819a-7dde709fbfa6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ab21fe35-1abb-4547-aa1f-199b8c8f0d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ab21fe35-1abb-4547-aa1f-199b8c8f0d26" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_025f78d7-9fd4-4908-8154-550f6fbb42ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_025f78d7-9fd4-4908-8154-550f6fbb42ef" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_74394800-0907-4b26-bfb7-65f9d1ca2aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_74394800-0907-4b26-bfb7-65f9d1ca2aaa" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_157797ac-7f79-455b-ab7a-8f3e5e979486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_157797ac-7f79-455b-ab7a-8f3e5e979486" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_aa0e1740-0d71-44fd-98b8-a59c1e614f99" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetLiabilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeAxis_aa0e1740-0d71-44fd-98b8-a59c1e614f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_aa0e1740-0d71-44fd-98b8-a59c1e614f99_default" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetLiabilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_aa0e1740-0d71-44fd-98b8-a59c1e614f99" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_aa0e1740-0d71-44fd-98b8-a59c1e614f99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_d368bfad-e9d7-4068-886d-991eafc8e289" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetLiabilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_aa0e1740-0d71-44fd-98b8-a59c1e614f99" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_d368bfad-e9d7-4068-886d-991eafc8e289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_c00a00c2-94d8-4996-8921-f4bd9e806f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_d368bfad-e9d7-4068-886d-991eafc8e289" xlink:to="loc_us-gaap_IntellectualPropertyMember_c00a00c2-94d8-4996-8921-f4bd9e806f59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd7ee87b-aa2f-442d-92e7-f442b27d04cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_srt_ProductOrServiceAxis_fd7ee87b-aa2f-442d-92e7-f442b27d04cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd7ee87b-aa2f-442d-92e7-f442b27d04cb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fd7ee87b-aa2f-442d-92e7-f442b27d04cb" xlink:to="loc_srt_ProductsAndServicesDomain_fd7ee87b-aa2f-442d-92e7-f442b27d04cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8892a711-629e-499f-8676-479d661c4829" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fd7ee87b-aa2f-442d-92e7-f442b27d04cb" xlink:to="loc_srt_ProductsAndServicesDomain_8892a711-629e-499f-8676-479d661c4829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_71c4f5d9-9d4a-45ab-be90-a40fd3b8ccb4" xlink:href="biib-20201231.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8892a711-629e-499f-8676-479d661c4829" xlink:to="loc_biib_TECFIDERAMember_71c4f5d9-9d4a-45ab-be90-a40fd3b8ccb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_97fae0aa-38a6-4364-8a6b-627ac2b23221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_97fae0aa-38a6-4364-8a6b-627ac2b23221" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97fae0aa-38a6-4364-8a6b-627ac2b23221_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_97fae0aa-38a6-4364-8a6b-627ac2b23221" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_97fae0aa-38a6-4364-8a6b-627ac2b23221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52dc1819-7c6e-477f-a73a-c19d640da23b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_97fae0aa-38a6-4364-8a6b-627ac2b23221" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52dc1819-7c6e-477f-a73a-c19d640da23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_d7b6ae41-9945-4da2-841b-4063e3f7f707" xlink:href="biib-20201231.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52dc1819-7c6e-477f-a73a-c19d640da23b" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_d7b6ae41-9945-4da2-841b-4063e3f7f707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c6c70b7-d7ff-4e90-80a8-a290945e4119" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_srt_RangeAxis_9c6c70b7-d7ff-4e90-80a8-a290945e4119" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c6c70b7-d7ff-4e90-80a8-a290945e4119_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9c6c70b7-d7ff-4e90-80a8-a290945e4119" xlink:to="loc_srt_RangeMember_9c6c70b7-d7ff-4e90-80a8-a290945e4119_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efe9fb03-630e-4600-9579-39f17f8d7941" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9c6c70b7-d7ff-4e90-80a8-a290945e4119" xlink:to="loc_srt_RangeMember_efe9fb03-630e-4600-9579-39f17f8d7941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_29135378-9c93-4c85-af04-62e02fdb8897" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_efe9fb03-630e-4600-9579-39f17f8d7941" xlink:to="loc_srt_MinimumMember_29135378-9c93-4c85-af04-62e02fdb8897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a0c3bd21-6e0a-459f-bf2c-5af6446ee46b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_efe9fb03-630e-4600-9579-39f17f8d7941" xlink:to="loc_srt_MaximumMember_a0c3bd21-6e0a-459f-bf2c-5af6446ee46b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningstypeAxis_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52" xlink:href="biib-20201231.xsd#biib_ForeignearningstypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_biib_ForeignearningstypeAxis_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningstypeDomain_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52_default" xlink:href="biib-20201231.xsd#biib_ForeignearningstypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ForeignearningstypeAxis_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52" xlink:to="loc_biib_ForeignearningstypeDomain_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningstypeDomain_d7669ce3-67da-4f48-8ffa-e777d253538a" xlink:href="biib-20201231.xsd#biib_ForeignearningstypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ForeignearningstypeAxis_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52" xlink:to="loc_biib_ForeignearningstypeDomain_d7669ce3-67da-4f48-8ffa-e777d253538a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_3eac8023-b7a3-4ec3-85f7-a69b6d82f968" xlink:href="biib-20201231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_d7669ce3-67da-4f48-8ffa-e777d253538a" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_3eac8023-b7a3-4ec3-85f7-a69b6d82f968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherForeignEarningsMember_0f2ef6b8-f12a-4f1a-89d8-11b9c7960322" xlink:href="biib-20201231.xsd#biib_OtherForeignEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_d7669ce3-67da-4f48-8ffa-e777d253538a" xlink:to="loc_biib_OtherForeignEarningsMember_0f2ef6b8-f12a-4f1a-89d8-11b9c7960322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2dba818e-fc7f-4c1b-b835-26eeddd1116c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2dba818e-fc7f-4c1b-b835-26eeddd1116c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2dba818e-fc7f-4c1b-b835-26eeddd1116c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2dba818e-fc7f-4c1b-b835-26eeddd1116c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2dba818e-fc7f-4c1b-b835-26eeddd1116c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_57c7beb1-6469-4c9e-8450-8eb29f7a385d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2dba818e-fc7f-4c1b-b835-26eeddd1116c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_57c7beb1-6469-4c9e-8450-8eb29f7a385d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember_70e4b020-2570-48e7-801f-c91bd2b43d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_57c7beb1-6469-4c9e-8450-8eb29f7a385d" xlink:to="loc_us-gaap_GeneralBusinessMember_70e4b020-2570-48e7-801f-c91bd2b43d3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_b5398989-caf7-4055-8121-428530f504da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_57c7beb1-6469-4c9e-8450-8eb29f7a385d" xlink:to="loc_us-gaap_ResearchMember_b5398989-caf7-4055-8121-428530f504da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_U.S.2017TaxActMember_b40e73bc-1990-41b7-88f5-271592df0f84" xlink:href="biib-20201231.xsd#biib_U.S.2017TaxActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:to="loc_biib_U.S.2017TaxActMember_b40e73bc-1990-41b7-88f5-271592df0f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ee45ea20-8513-46e3-9f0c-5ea053462f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:to="loc_us-gaap_DomesticCountryMember_ee45ea20-8513-46e3-9f0c-5ea053462f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9d601de3-bdc7-490b-bd81-d35a17b5ae2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9d601de3-bdc7-490b-bd81-d35a17b5ae2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_9d16a7e2-a58b-4cf6-a92d-be7db3ef3df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:to="loc_us-gaap_ForeignCountryMember_9d16a7e2-a58b-4cf6-a92d-be7db3ef3df1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="i97fdbd3bbb734b1b8e7f2e13b0c70b46_IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="extended" id="i7d5592632d374161b34346dc050999f4_IncomeTaxesTaxRateDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails" xlink:type="extended" id="i85dac09de22a49299f6147204cd0ec13_IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" id="ie517369abecf40ffa12313036cc28016_OtherConsolidatedFinancialStatementDetail"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" id="i72bed71b7c7849e4bbbd9e54d4e1e0e9_OtherConsolidatedFinancialStatementDetailTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails" xlink:type="extended" id="i2af8c5b5ab714e80912f9b2479b9f1ec_OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails" xlink:type="extended" id="ie99affa2342f4a3cacefb421f2a89c32_OtherConsolidatedFinancialStatementDetailNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_ce6f713f-1c2f-4c13-a485-9e3818e52fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_ce6f713f-1c2f-4c13-a485-9e3818e52fa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevel_8d827ff5-e077-4fa9-bd5b-a3df67f61415" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevel"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_biib_CumulativeSalesLevel_8d827ff5-e077-4fa9-bd5b-a3df67f61415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_0f90c44b-6f06-4c5c-ada0-8e9cae9b5b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_0f90c44b-6f06-4c5c-ada0-8e9cae9b5b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_ed51fb86-e4e5-4ec6-bd24-4501232fc6da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_ed51fb86-e4e5-4ec6-bd24-4501232fc6da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8fc63f40-ccc5-4fc0-b2f7-919c8044078c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_8fc63f40-ccc5-4fc0-b2f7-919c8044078c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_03967a8d-7682-4971-82bc-30b10a00948a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_03967a8d-7682-4971-82bc-30b10a00948a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7d28c5f1-a377-4693-8115-1d039da25a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7d28c5f1-a377-4693-8115-1d039da25a29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_16b2fe17-1963-47b0-885e-f97289c56601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_16b2fe17-1963-47b0-885e-f97289c56601" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dc20802d-98a9-42ae-8d18-a06136ba96b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_srt_ProductOrServiceAxis_dc20802d-98a9-42ae-8d18-a06136ba96b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc20802d-98a9-42ae-8d18-a06136ba96b2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dc20802d-98a9-42ae-8d18-a06136ba96b2" xlink:to="loc_srt_ProductsAndServicesDomain_dc20802d-98a9-42ae-8d18-a06136ba96b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d05160ad-4e98-4e48-89f4-dd20e4bb326b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dc20802d-98a9-42ae-8d18-a06136ba96b2" xlink:to="loc_srt_ProductsAndServicesDomain_d05160ad-4e98-4e48-89f4-dd20e4bb326b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_c3001e1e-88d4-43d7-bcdc-9c3b889e696d" xlink:href="biib-20201231.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d05160ad-4e98-4e48-89f4-dd20e4bb326b" xlink:to="loc_biib_FumarateMember_c3001e1e-88d4-43d7-bcdc-9c3b889e696d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8e8b7019-0540-46db-bb62-b79ab5034cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8e8b7019-0540-46db-bb62-b79ab5034cfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e8b7019-0540-46db-bb62-b79ab5034cfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e8b7019-0540-46db-bb62-b79ab5034cfe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e8b7019-0540-46db-bb62-b79ab5034cfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe451116-a16d-4055-a46b-065eefe867e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e8b7019-0540-46db-bb62-b79ab5034cfe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe451116-a16d-4055-a46b-065eefe867e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumapharmAgMember_e46ad566-b289-4df1-a190-b84070848f88" xlink:href="biib-20201231.xsd#biib_FumapharmAgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe451116-a16d-4055-a46b-065eefe867e6" xlink:to="loc_biib_FumapharmAgMember_e46ad566-b289-4df1-a190-b84070848f88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_0ee487e1-3bbc-459a-873d-1f7a02f4ac40" xlink:href="biib-20201231.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_biib_FacilityLocationAxis_0ee487e1-3bbc-459a-873d-1f7a02f4ac40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_0ee487e1-3bbc-459a-873d-1f7a02f4ac40_default" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_0ee487e1-3bbc-459a-873d-1f7a02f4ac40" xlink:to="loc_biib_FacilityLocationDomain_0ee487e1-3bbc-459a-873d-1f7a02f4ac40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_3551ba7b-e95f-4725-9caf-35f274d6cd67" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_0ee487e1-3bbc-459a-873d-1f7a02f4ac40" xlink:to="loc_biib_FacilityLocationDomain_3551ba7b-e95f-4725-9caf-35f274d6cd67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember_7c629d90-8a76-4887-a2c1-ed02b28138de" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_3551ba7b-e95f-4725-9caf-35f274d6cd67" xlink:to="loc_biib_SolothurnMember_7c629d90-8a76-4887-a2c1-ed02b28138de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelAxis_2ea42160-9302-4b00-80ef-b742c3d09b34" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_biib_CumulativeSalesLevelAxis_2ea42160-9302-4b00-80ef-b742c3d09b34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelDomain_2ea42160-9302-4b00-80ef-b742c3d09b34_default" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_2ea42160-9302-4b00-80ef-b742c3d09b34" xlink:to="loc_biib_CumulativeSalesLevelDomain_2ea42160-9302-4b00-80ef-b742c3d09b34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelDomain_35f7a420-4e5b-43a0-9726-f814cb9b8ec3" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_2ea42160-9302-4b00-80ef-b742c3d09b34" xlink:to="loc_biib_CumulativeSalesLevelDomain_35f7a420-4e5b-43a0-9726-f814cb9b8ec3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwentybillionMember_ab489002-2c6d-4c04-ac6d-ed21267781ea" xlink:href="biib-20201231.xsd#biib_TwentybillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_35f7a420-4e5b-43a0-9726-f814cb9b8ec3" xlink:to="loc_biib_TwentybillionMember_ab489002-2c6d-4c04-ac6d-ed21267781ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6e9d6f0f-b3ed-4dcb-95dc-71b06d46ab39" xlink:href="biib-20201231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_35f7a420-4e5b-43a0-9726-f814cb9b8ec3" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6e9d6f0f-b3ed-4dcb-95dc-71b06d46ab39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3bc14176-abc3-46a1-ac74-fcdbf53cfb69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_dei_LegalEntityAxis_3bc14176-abc3-46a1-ac74-fcdbf53cfb69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3bc14176-abc3-46a1-ac74-fcdbf53cfb69_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3bc14176-abc3-46a1-ac74-fcdbf53cfb69" xlink:to="loc_dei_EntityDomain_3bc14176-abc3-46a1-ac74-fcdbf53cfb69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3bc14176-abc3-46a1-ac74-fcdbf53cfb69" xlink:to="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_a570a7ca-cd0d-4ec7-a670-96eecf73b38e" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_DenaliTherapeuticsIncMember_a570a7ca-cd0d-4ec7-a670-96eecf73b38e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_c5b9feeb-38e5-423c-86de-dce6a734b209" xlink:href="biib-20201231.xsd#biib_SangamoCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_SangamoCommonStockMember_c5b9feeb-38e5-423c-86de-dce6a734b209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_34b388ec-38b7-4bec-b770-87e663ad5315" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_IonisPharmaceuticalsMember_34b388ec-38b7-4bec-b770-87e663ad5315" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_17877662-1339-4707-8451-a05c9f5b3dbf" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_SageTherapeuticsIncMember_17877662-1339-4707-8451-a05c9f5b3dbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliAndSangamoMember_feeeccc9-4f36-40c8-94e7-defea07252e7" xlink:href="biib-20201231.xsd#biib_DenaliAndSangamoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_DenaliAndSangamoMember_feeeccc9-4f36-40c8-94e7-defea07252e7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" xlink:type="extended" id="i5ee252eeef394b0b8ea264a31abae83f_OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails" xlink:type="extended" id="i532a5aaf40fc481287149b562c16e6b2_OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails" xlink:type="extended" id="i94c042bd99b74ed5b09ba6d1a1486224_OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_56d18388-0b0a-434d-bae2-e609091adbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_56d18388-0b0a-434d-bae2-e609091adbbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_e0190e19-477e-4c0d-8f54-67e170ea5b26" xlink:href="biib-20201231.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_biib_Collaborationexpensesaccrual_e0190e19-477e-4c0d-8f54-67e170ea5b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bb45a56e-c61c-454a-b310-0fe326608ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bb45a56e-c61c-454a-b310-0fe326608ed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c960a44e-fa65-4322-ac50-d0b7502f9533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c960a44e-fa65-4322-ac50-d0b7502f9533" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_cb25ab7b-b588-445b-ac68-42d40736d2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_cb25ab7b-b588-445b-ac68-42d40736d2d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f49a043c-fc41-4e9f-bf8b-866ad0825f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f49a043c-fc41-4e9f-bf8b-866ad0825f57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4be6edcd-35d4-4544-b55c-c4cba817ce10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4be6edcd-35d4-4544-b55c-c4cba817ce10" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5cbf1621-e633-41c2-b1bf-5c3e98964e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5cbf1621-e633-41c2-b1bf-5c3e98964e2c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1feee384-5b47-48d6-b41f-a168f87ab572" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1feee384-5b47-48d6-b41f-a168f87ab572" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f2c9c109-ef78-4b79-84f7-d9517f2be4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1feee384-5b47-48d6-b41f-a168f87ab572" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f2c9c109-ef78-4b79-84f7-d9517f2be4d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f2c9c109-ef78-4b79-84f7-d9517f2be4d2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f2c9c109-ef78-4b79-84f7-d9517f2be4d2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f2c9c109-ef78-4b79-84f7-d9517f2be4d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_016ee5f7-5052-4e1f-8abe-0d3142397a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f2c9c109-ef78-4b79-84f7-d9517f2be4d2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_016ee5f7-5052-4e1f-8abe-0d3142397a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_4f395225-8a3f-4f39-977d-2ffa3c7ab287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_016ee5f7-5052-4e1f-8abe-0d3142397a8c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_4f395225-8a3f-4f39-977d-2ffa3c7ab287" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationships"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended" id="ie6602333c763403a8b10a3813e2561fb_CollaborativeandOtherRelationships"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended" id="ie781ef8af0524124a16def320a25ead2_CollaborativeandOtherRelationshipsTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended" id="if88146e9c7ad4b38adca0ea32fa8f740_CollaborativeandOtherRelationshipsOCREVUSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_f00e6159-b1e5-427f-9b24-1e2d14c2ab5e" xlink:href="biib-20201231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_f00e6159-b1e5-427f-9b24-1e2d14c2ab5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_5aeb2718-a856-4baa-b659-462a59a912a4" xlink:href="biib-20201231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_5aeb2718-a856-4baa-b659-462a59a912a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_cf2eb553-c793-4993-8a71-a190f0516662" xlink:href="biib-20201231.xsd#biib_Reductioninroyaltyrate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_biib_Reductioninroyaltyrate_cf2eb553-c793-4993-8a71-a190f0516662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_199892d1-ba16-4a9d-a2c2-6f0529503f6b" xlink:href="biib-20201231.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_biib_PeriodOfCollaborationAgreement_199892d1-ba16-4a9d-a2c2-6f0529503f6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_68e0e224-612b-4322-84ab-38284d0e8e0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:to="loc_srt_ProductOrServiceAxis_68e0e224-612b-4322-84ab-38284d0e8e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68e0e224-612b-4322-84ab-38284d0e8e0c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_68e0e224-612b-4322-84ab-38284d0e8e0c" xlink:to="loc_srt_ProductsAndServicesDomain_68e0e224-612b-4322-84ab-38284d0e8e0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa49be79-da88-4e63-8cd2-59e3844d94a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_68e0e224-612b-4322-84ab-38284d0e8e0c" xlink:to="loc_srt_ProductsAndServicesDomain_aa49be79-da88-4e63-8cd2-59e3844d94a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_f3f6a2db-9e2c-4f21-98a5-e7305d4d282a" xlink:href="biib-20201231.xsd#biib_OCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_aa49be79-da88-4e63-8cd2-59e3844d94a6" xlink:to="loc_biib_OCREVUSMember_f3f6a2db-9e2c-4f21-98a5-e7305d4d282a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0dec9123-5782-4243-9d59-aff1292ab085" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:to="loc_srt_RangeAxis_0dec9123-5782-4243-9d59-aff1292ab085" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dec9123-5782-4243-9d59-aff1292ab085_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0dec9123-5782-4243-9d59-aff1292ab085" xlink:to="loc_srt_RangeMember_0dec9123-5782-4243-9d59-aff1292ab085_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_735637df-5a4f-4d85-b960-60448d97f032" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0dec9123-5782-4243-9d59-aff1292ab085" xlink:to="loc_srt_RangeMember_735637df-5a4f-4d85-b960-60448d97f032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c2cf4ef2-678e-49ee-94f9-c70fe1edb4f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_735637df-5a4f-4d85-b960-60448d97f032" xlink:to="loc_srt_MinimumMember_c2cf4ef2-678e-49ee-94f9-c70fe1edb4f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ecf2981a-19df-405b-9169-254844c532aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_735637df-5a4f-4d85-b960-60448d97f032" xlink:to="loc_srt_MaximumMember_ecf2981a-19df-405b-9169-254844c532aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b693c264-64f5-4cad-b8f0-d0106bbbd041" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:to="loc_srt_StatementGeographicalAxis_b693c264-64f5-4cad-b8f0-d0106bbbd041" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b693c264-64f5-4cad-b8f0-d0106bbbd041_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b693c264-64f5-4cad-b8f0-d0106bbbd041" xlink:to="loc_srt_SegmentGeographicalDomain_b693c264-64f5-4cad-b8f0-d0106bbbd041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2863bfd2-fc19-4be2-b3a6-ce07d0a26377" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b693c264-64f5-4cad-b8f0-d0106bbbd041" xlink:to="loc_srt_SegmentGeographicalDomain_2863bfd2-fc19-4be2-b3a6-ce07d0a26377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_6e937367-8be6-42bb-9554-82683492f0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2863bfd2-fc19-4be2-b3a6-ce07d0a26377" xlink:to="loc_us-gaap_ForeignCountryMember_6e937367-8be6-42bb-9554-82683492f0db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="extended" id="i00cfcd2869ba48bfb61efe53f9983b73_CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3aa07837-c660-4ce1-a072-dfde29497a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_a464d0e1-9f55-4f9b-9c7e-d14863b9d5d9" xlink:href="biib-20201231.xsd#biib_CoPromotionProfitSharingFormulaAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3aa07837-c660-4ce1-a072-dfde29497a0a" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_a464d0e1-9f55-4f9b-9c7e-d14863b9d5d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_38f6e3ce-bcbe-4773-a374-a0f0b6116b28" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_a464d0e1-9f55-4f9b-9c7e-d14863b9d5d9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_38f6e3ce-bcbe-4773-a374-a0f0b6116b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_a464d0e1-9f55-4f9b-9c7e-d14863b9d5d9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_575e9bfa-b542-4f6f-bc92-b17f13f02b7a" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_575e9bfa-b542-4f6f-bc92-b17f13f02b7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_22224d5a-80c0-4bf1-a38d-77516cacff97" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_22224d5a-80c0-4bf1-a38d-77516cacff97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_e875d5fe-a0ef-4198-a094-8489abe8c1ed" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_e875d5fe-a0ef-4198-a094-8489abe8c1ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4faea19-fee9-4c95-aa6f-84dc7d6faece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3aa07837-c660-4ce1-a072-dfde29497a0a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4faea19-fee9-4c95-aa6f-84dc7d6faece" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3a02249-a10d-48bc-af5e-29edb5286d23" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4faea19-fee9-4c95-aa6f-84dc7d6faece" xlink:to="loc_srt_ProductOrServiceAxis_e3a02249-a10d-48bc-af5e-29edb5286d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e3a02249-a10d-48bc-af5e-29edb5286d23_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e3a02249-a10d-48bc-af5e-29edb5286d23" xlink:to="loc_srt_ProductsAndServicesDomain_e3a02249-a10d-48bc-af5e-29edb5286d23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_42b2a2a2-dbd4-4f37-8656-a10196f8b2f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e3a02249-a10d-48bc-af5e-29edb5286d23" xlink:to="loc_srt_ProductsAndServicesDomain_42b2a2a2-dbd4-4f37-8656-a10196f8b2f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_136ad607-9e9d-4aea-a6a7-6fe026a9e2bb" xlink:href="biib-20201231.xsd#biib_RituxanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_42b2a2a2-dbd4-4f37-8656-a10196f8b2f8" xlink:to="loc_biib_RituxanMember_136ad607-9e9d-4aea-a6a7-6fe026a9e2bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended" id="i18d5ead22eac4ac7a4b5a9b44a08c158_CollaborativeandOtherRelationshipsProfitSharingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_657b96fe-38c1-457f-97f1-f310307b97a8" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_657b96fe-38c1-457f-97f1-f310307b97a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_2e351f1b-9b7b-485d-ba2d-2b2ef58ded70" xlink:href="biib-20201231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_2e351f1b-9b7b-485d-ba2d-2b2ef58ded70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_782d3908-d20f-47cd-8e86-fc6456e31620" xlink:href="biib-20201231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_782d3908-d20f-47cd-8e86-fc6456e31620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_589ec4ae-0d98-4b84-b80f-68136c7476ff" xlink:href="biib-20201231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_589ec4ae-0d98-4b84-b80f-68136c7476ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_0be03236-02eb-4cc6-89ad-c7b1b7d1bad4" xlink:href="biib-20201231.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_0be03236-02eb-4cc6-89ad-c7b1b7d1bad4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_414fd7c4-46a7-417a-987d-85905b44ce45" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_414fd7c4-46a7-417a-987d-85905b44ce45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_fe878147-3388-4e75-8920-a9975944a4b9" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_fe878147-3388-4e75-8920-a9975944a4b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_8a90727d-4f3a-417e-9a81-3542d697658a" xlink:href="biib-20201231.xsd#biib_Futurepercentageofcopromotionoperatingprofits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_8a90727d-4f3a-417e-9a81-3542d697658a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dfce8ef2-bfb4-4005-938b-764463084275" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:to="loc_srt_ProductOrServiceAxis_dfce8ef2-bfb4-4005-938b-764463084275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dfce8ef2-bfb4-4005-938b-764463084275_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dfce8ef2-bfb4-4005-938b-764463084275" xlink:to="loc_srt_ProductsAndServicesDomain_dfce8ef2-bfb4-4005-938b-764463084275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dfce8ef2-bfb4-4005-938b-764463084275" xlink:to="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_b3a3f48c-5f81-48ee-abe6-993129797fe0" xlink:href="biib-20201231.xsd#biib_RituxanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:to="loc_biib_RituxanMember_b3a3f48c-5f81-48ee-abe6-993129797fe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_7064a8e3-6742-4de6-9255-08d3bdd8b8e9" xlink:href="biib-20201231.xsd#biib_GAZYVAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:to="loc_biib_GAZYVAMember_7064a8e3-6742-4de6-9255-08d3bdd8b8e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NewAntiCd20Member_727f73a0-47ac-4466-bc25-99876bb77a07" xlink:href="biib-20201231.xsd#biib_NewAntiCd20Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:to="loc_biib_NewAntiCd20Member_727f73a0-47ac-4466-bc25-99876bb77a07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_002d01e6-ee16-4527-aee9-5d0393b603e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:to="loc_srt_RangeAxis_002d01e6-ee16-4527-aee9-5d0393b603e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_002d01e6-ee16-4527-aee9-5d0393b603e3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_002d01e6-ee16-4527-aee9-5d0393b603e3" xlink:to="loc_srt_RangeMember_002d01e6-ee16-4527-aee9-5d0393b603e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e454cb9-0019-4f90-9d4a-560cea32725b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_002d01e6-ee16-4527-aee9-5d0393b603e3" xlink:to="loc_srt_RangeMember_6e454cb9-0019-4f90-9d4a-560cea32725b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_38da6ecb-8dc0-492c-b17c-50ad63e84253" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e454cb9-0019-4f90-9d4a-560cea32725b" xlink:to="loc_srt_MinimumMember_38da6ecb-8dc0-492c-b17c-50ad63e84253" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b62d9b4-8180-4f9d-8e1e-43500be7c4b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e454cb9-0019-4f90-9d4a-560cea32725b" xlink:to="loc_srt_MaximumMember_0b62d9b4-8180-4f9d-8e1e-43500be7c4b5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="extended" id="i0bb7d3edb5fb4fdfa0cf7cc2eded4013_CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a56949e-36d8-4381-918d-40610d0196f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_990773a8-53ed-4a8a-a0bc-54400146fac3" xlink:href="biib-20201231.xsd#biib_CoPromotionProfitSharingFormulaAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a56949e-36d8-4381-918d-40610d0196f9" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_990773a8-53ed-4a8a-a0bc-54400146fac3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_8114de4a-a25f-4913-bd76-bc2492be6e00" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_990773a8-53ed-4a8a-a0bc-54400146fac3" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_8114de4a-a25f-4913-bd76-bc2492be6e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_2e7e5e28-4427-4b2c-b575-07dc2432eb72" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_990773a8-53ed-4a8a-a0bc-54400146fac3" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_2e7e5e28-4427-4b2c-b575-07dc2432eb72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_f857f16e-60bd-46bf-81b5-7fce16b58b2b" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_2e7e5e28-4427-4b2c-b575-07dc2432eb72" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_f857f16e-60bd-46bf-81b5-7fce16b58b2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_43769371-c4ec-4feb-9d84-ec8dee29c7e4" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_2e7e5e28-4427-4b2c-b575-07dc2432eb72" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_43769371-c4ec-4feb-9d84-ec8dee29c7e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e5b06d56-5a78-4a26-94e5-42d5c47ce84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a56949e-36d8-4381-918d-40610d0196f9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e5b06d56-5a78-4a26-94e5-42d5c47ce84d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca44a3e6-c992-4bac-98db-40075b4162a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e5b06d56-5a78-4a26-94e5-42d5c47ce84d" xlink:to="loc_srt_ProductOrServiceAxis_ca44a3e6-c992-4bac-98db-40075b4162a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ca44a3e6-c992-4bac-98db-40075b4162a0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ca44a3e6-c992-4bac-98db-40075b4162a0" xlink:to="loc_srt_ProductsAndServicesDomain_ca44a3e6-c992-4bac-98db-40075b4162a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32bb198a-6240-4e31-8378-9c02f22278ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ca44a3e6-c992-4bac-98db-40075b4162a0" xlink:to="loc_srt_ProductsAndServicesDomain_32bb198a-6240-4e31-8378-9c02f22278ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_3aa11955-6680-4e37-b300-4a61924e42be" xlink:href="biib-20201231.xsd#biib_GAZYVAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32bb198a-6240-4e31-8378-9c02f22278ad" xlink:to="loc_biib_GAZYVAMember_3aa11955-6680-4e37-b300-4a61924e42be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="ibe7a40be802b468eae09deedbd0fa6be_CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_48f9361c-4088-4480-9fcb-f4ca082d5fb5" xlink:href="biib-20201231.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:to="loc_biib_ShareOfCoPromotionProfits_48f9361c-4088-4480-9fcb-f4ca082d5fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_80079cc4-591f-4e49-8405-162f93a222eb" xlink:href="biib-20201231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_80079cc4-591f-4e49-8405-162f93a222eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_11df3cd4-c546-489e-86f7-6acbbecc83bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:to="loc_us-gaap_Revenues_11df3cd4-c546-489e-86f7-6acbbecc83bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:to="loc_srt_MajorCustomersAxis_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b" xlink:to="loc_srt_NameOfMajorCustomerDomain_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_94f2064e-c58f-4364-ace7-602a74ed944f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b" xlink:to="loc_srt_NameOfMajorCustomerDomain_94f2064e-c58f-4364-ace7-602a74ed944f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_88697d12-1db4-4718-bdf4-b0cf31c6545e" xlink:href="biib-20201231.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_94f2064e-c58f-4364-ace7-602a74ed944f" xlink:to="loc_biib_RocheGroupGenentechMember_88697d12-1db4-4718-bdf4-b0cf31c6545e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f91eb7d4-7a45-44ed-b820-ed23aa495088" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:to="loc_srt_ProductOrServiceAxis_f91eb7d4-7a45-44ed-b820-ed23aa495088" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f91eb7d4-7a45-44ed-b820-ed23aa495088_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f91eb7d4-7a45-44ed-b820-ed23aa495088" xlink:to="loc_srt_ProductsAndServicesDomain_f91eb7d4-7a45-44ed-b820-ed23aa495088_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7b5dc85d-4619-4bc1-8418-063f9e17d78a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f91eb7d4-7a45-44ed-b820-ed23aa495088" xlink:to="loc_srt_ProductsAndServicesDomain_7b5dc85d-4619-4bc1-8418-063f9e17d78a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_02a9bcc5-d8be-44d9-a0e9-adf182306942" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7b5dc85d-4619-4bc1-8418-063f9e17d78a" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_02a9bcc5-d8be-44d9-a0e9-adf182306942" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsIonisDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails" xlink:type="extended" id="i7fc4ea439adb49dc89159db8d14975d4_CollaborativeandOtherRelationshipsIonisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_fd1d102a-5c30-4426-b645-018740c37609" xlink:href="biib-20201231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_fd1d102a-5c30-4426-b645-018740c37609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fb8b275e-5d34-408e-b680-82d3412284f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fb8b275e-5d34-408e-b680-82d3412284f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LicenseFee_02214c00-8fdb-45a8-aa9c-c1c759fc188d" xlink:href="biib-20201231.xsd#biib_LicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_LicenseFee_02214c00-8fdb-45a8-aa9c-c1c759fc188d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_013a0dd5-1c04-48c9-a95c-13debd9d517f" xlink:href="biib-20201231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_013a0dd5-1c04-48c9-a95c-13debd9d517f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_933ab5b9-d73c-422f-8067-56925accdb42" xlink:href="biib-20201231.xsd#biib_Upfrontpaymentforcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Upfrontpaymentforcollaborationagreement_933ab5b9-d73c-422f-8067-56925accdb42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_857cd9eb-94ba-4788-9bda-62e535300c65" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_AdditionalMilestonePayment_857cd9eb-94ba-4788-9bda-62e535300c65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8943f8df-7ba3-4974-92c3-357fa310a6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8943f8df-7ba3-4974-92c3-357fa310a6ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_18b21e31-df1d-490a-9522-5a8310390d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_18b21e31-df1d-490a-9522-5a8310390d23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_bd4ba266-d692-4518-84de-2b0bd72c6fad" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Termofcollaborationagreement_bd4ba266-d692-4518-84de-2b0bd72c6fad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_da77451c-d9ca-44b8-96de-d3fb42e989f1" xlink:href="biib-20201231.xsd#biib_Totalpaymenttoentercollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_da77451c-d9ca-44b8-96de-d3fb42e989f1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInCommonStockSharesPurchased_5860131d-4147-456b-a0fe-3e3ac3bdbd31" xlink:href="biib-20201231.xsd#biib_InvestmentInCommonStockSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_InvestmentInCommonStockSharesPurchased_5860131d-4147-456b-a0fe-3e3ac3bdbd31" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Purchaseofcommonstock_e561253b-98b2-4a91-a42c-0b4d0da40088" xlink:href="biib-20201231.xsd#biib_Purchaseofcommonstock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Purchaseofcommonstock_e561253b-98b2-4a91-a42c-0b4d0da40088" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1450cf76-03b9-4ae1-857a-38e7ec8e89d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1450cf76-03b9-4ae1-857a-38e7ec8e89d0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstockvalue_b78a528e-4b22-4e0b-a186-80e604d7f3f4" xlink:href="biib-20201231.xsd#biib_Investmentincommonstockvalue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Investmentincommonstockvalue_b78a528e-4b22-4e0b-a186-80e604d7f3f4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_ebc7286d-4884-4c60-915a-51f2638c6a1e" xlink:href="biib-20201231.xsd#biib_Premiumonpurchaseofcommonstock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_ebc7286d-4884-4c60-915a-51f2638c6a1e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_2aaffb73-0b9e-4876-93b8-97750f57f740" xlink:href="biib-20201231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_2aaffb73-0b9e-4876-93b8-97750f57f740" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_845a369b-7233-40b3-b6f6-99e23b97b64d" xlink:href="biib-20201231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_845a369b-7233-40b3-b6f6-99e23b97b64d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_b17f3e59-1ec2-4964-a8bf-f229fd71e1d4" xlink:href="biib-20201231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_b17f3e59-1ec2-4964-a8bf-f229fd71e1d4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b4622271-6e88-4be6-8fbf-a39301bce97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b4622271-6e88-4be6-8fbf-a39301bce97d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4622271-6e88-4be6-8fbf-a39301bce97d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b4622271-6e88-4be6-8fbf-a39301bce97d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b4622271-6e88-4be6-8fbf-a39301bce97d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38da71d4-816d-4176-bf67-0f3a367117c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b4622271-6e88-4be6-8fbf-a39301bce97d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38da71d4-816d-4176-bf67-0f3a367117c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_094f3681-8325-4c9b-8f71-b11f911e2cb0" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38da71d4-816d-4176-bf67-0f3a367117c1" xlink:to="loc_biib_IonisPharmaceuticalsMember_094f3681-8325-4c9b-8f71-b11f911e2cb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_23ae7265-2527-489a-a722-6750135ed6c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:to="loc_srt_RangeAxis_23ae7265-2527-489a-a722-6750135ed6c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23ae7265-2527-489a-a722-6750135ed6c5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_23ae7265-2527-489a-a722-6750135ed6c5" xlink:to="loc_srt_RangeMember_23ae7265-2527-489a-a722-6750135ed6c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a8238ee-a375-442f-89ef-372681eb9003" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_23ae7265-2527-489a-a722-6750135ed6c5" xlink:to="loc_srt_RangeMember_9a8238ee-a375-442f-89ef-372681eb9003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_869946ca-2b86-403f-87d9-8a22d06aa6ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a8238ee-a375-442f-89ef-372681eb9003" xlink:to="loc_srt_MinimumMember_869946ca-2b86-403f-87d9-8a22d06aa6ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6885a453-be24-4b68-b817-ce38d8404794" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a8238ee-a375-442f-89ef-372681eb9003" xlink:to="loc_srt_MaximumMember_6885a453-be24-4b68-b817-ce38d8404794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:to="loc_srt_ProductOrServiceAxis_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540" xlink:to="loc_srt_ProductsAndServicesDomain_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c4b9ac21-64df-4035-868c-a4eeecc6805d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540" xlink:to="loc_srt_ProductsAndServicesDomain_c4b9ac21-64df-4035-868c-a4eeecc6805d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SOD1Member_23c02415-e593-4893-b7b2-da0b49cf9ec9" xlink:href="biib-20201231.xsd#biib_SOD1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c4b9ac21-64df-4035-868c-a4eeecc6805d" xlink:to="loc_biib_SOD1Member_23c02415-e593-4893-b7b2-da0b49cf9ec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_4657551d-1d99-40c2-acce-af416d775ddc" xlink:href="biib-20201231.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c4b9ac21-64df-4035-868c-a4eeecc6805d" xlink:to="loc_biib_SPINRAZAMember_4657551d-1d99-40c2-acce-af416d775ddc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended" id="i1d9aaac370d44148af1c0a492587fe70_CollaborativeandOtherRelationshipsEisaiDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_6ffec08c-6c69-492c-9aa1-34cbba82c4d1" xlink:href="biib-20201231.xsd#biib_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_NumberOfProductCandidates_6ffec08c-6c69-492c-9aa1-34cbba82c4d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_4093d1f1-613a-4c28-8698-6172a4bd66ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_us-gaap_LossOnContractTermination_4093d1f1-613a-4c28-8698-6172a4bd66ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_b47b7a94-a55c-47db-a2bd-4646cc48b1d4" xlink:href="biib-20201231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_b47b7a94-a55c-47db-a2bd-4646cc48b1d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfDevelopmentCostsIncurred_8e0604e5-d96f-44d4-a32f-e5b9fe9079a6" xlink:href="biib-20201231.xsd#biib_PercentageOfDevelopmentCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_PercentageOfDevelopmentCostsIncurred_8e0604e5-d96f-44d4-a32f-e5b9fe9079a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0c837a94-9e93-4f72-8f97-b030a794509c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0c837a94-9e93-4f72-8f97-b030a794509c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_591d9718-b3e2-48cc-80ea-27216a73b65c" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_AdditionalMilestonePayment_591d9718-b3e2-48cc-80ea-27216a73b65c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_53db99c2-2d95-4c16-b55d-a3a1b4e65c48" xlink:href="biib-20201231.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_53db99c2-2d95-4c16-b55d-a3a1b4e65c48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_07628a40-fae8-42fb-a30a-b91d5ed63564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_07628a40-fae8-42fb-a30a-b91d5ed63564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07628a40-fae8-42fb-a30a-b91d5ed63564_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07628a40-fae8-42fb-a30a-b91d5ed63564" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_07628a40-fae8-42fb-a30a-b91d5ed63564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_049137c7-dfb5-4347-a5da-cc0fa7c5c999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07628a40-fae8-42fb-a30a-b91d5ed63564" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_049137c7-dfb5-4347-a5da-cc0fa7c5c999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_25de5ffa-bc3f-434e-8697-786a84f39e62" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_049137c7-dfb5-4347-a5da-cc0fa7c5c999" xlink:to="loc_biib_EisaiMember_25de5ffa-bc3f-434e-8697-786a84f39e62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:to="loc_srt_StatementGeographicalAxis_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8" xlink:to="loc_srt_SegmentGeographicalDomain_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8" xlink:to="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_11851801-2699-42d5-a463-10ce1aef8629" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:to="loc_country_US_11851801-2699-42d5-a463-10ce1aef8629" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_f0271d8a-6f45-4ec2-8c4b-f889e9918881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:to="loc_us-gaap_EuropeanUnionMember_f0271d8a-6f45-4ec2-8c4b-f889e9918881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_8f45da52-a116-42b2-b424-34eb744b2e97" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:to="loc_country_JP_8f45da52-a116-42b2-b424-34eb744b2e97" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended" id="i5d03193e195041a4a2d8cd13e34cb87c_CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_a4a33a73-f6e3-4c28-9279-181d786f06e4" xlink:href="biib-20201231.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:to="loc_biib_ExpenseIncurredByCollaboration_a4a33a73-f6e3-4c28-9279-181d786f06e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_150d77d0-1521-4f6b-bae3-f4eb73c19787" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_150d77d0-1521-4f6b-bae3-f4eb73c19787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_b567f3f5-0a09-40a1-ac84-db243a4a0065" xlink:href="biib-20201231.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:to="loc_biib_Expenseincurredbythecollaboration_b567f3f5-0a09-40a1-ac84-db243a4a0065" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d6461cfd-04a2-40b9-8ba0-cfc5b14f31cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d6461cfd-04a2-40b9-8ba0-cfc5b14f31cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fa517bac-e686-4376-ae06-719395c92dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d6461cfd-04a2-40b9-8ba0-cfc5b14f31cf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fa517bac-e686-4376-ae06-719395c92dd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ae09aa7b-1e43-45ee-821a-544a62f8d0e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:to="loc_srt_ProductOrServiceAxis_ae09aa7b-1e43-45ee-821a-544a62f8d0e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ae09aa7b-1e43-45ee-821a-544a62f8d0e0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ae09aa7b-1e43-45ee-821a-544a62f8d0e0" xlink:to="loc_srt_ProductsAndServicesDomain_ae09aa7b-1e43-45ee-821a-544a62f8d0e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea6dd408-6457-46cd-8b20-70ed8d959f9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ae09aa7b-1e43-45ee-821a-544a62f8d0e0" xlink:to="loc_srt_ProductsAndServicesDomain_ea6dd408-6457-46cd-8b20-70ed8d959f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_11ff651c-d2cd-4064-911e-9b4c76a28a2d" xlink:href="biib-20201231.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ea6dd408-6457-46cd-8b20-70ed8d959f9a" xlink:to="loc_biib_E2609andBAN2401Member_11ff651c-d2cd-4064-911e-9b4c76a28a2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9ced479-6495-423a-9e48-d006ddfc6f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9ced479-6495-423a-9e48-d006ddfc6f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_4987650b-c66a-465e-97ec-184004df200d" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9ced479-6495-423a-9e48-d006ddfc6f37" xlink:to="loc_biib_EisaiMember_4987650b-c66a-465e-97ec-184004df200d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails" xlink:type="extended" id="ie4645e3e12144adea11d9102bc9ca9c7_CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_8af67c51-c5a1-4705-a035-76ba4d6d5289" xlink:href="biib-20201231.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_biib_Expenseincurredbythecollaboration_8af67c51-c5a1-4705-a035-76ba4d6d5289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_c3e08587-fd0d-4b46-ba6d-38d14be5322f" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_c3e08587-fd0d-4b46-ba6d-38d14be5322f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_4aa619b0-aa80-46f6-b962-ea79687818d2" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_biib_AdditionalMilestonePayment_4aa619b0-aa80-46f6-b962-ea79687818d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_696eff19-2abd-4bd8-a8da-095dbd78fa64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_696eff19-2abd-4bd8-a8da-095dbd78fa64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_94817869-9548-4abe-a1d3-8459f3d9db4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:to="loc_srt_ProductOrServiceAxis_94817869-9548-4abe-a1d3-8459f3d9db4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_94817869-9548-4abe-a1d3-8459f3d9db4e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_94817869-9548-4abe-a1d3-8459f3d9db4e" xlink:to="loc_srt_ProductsAndServicesDomain_94817869-9548-4abe-a1d3-8459f3d9db4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_93152bc9-42ab-4081-991c-230db6f32df0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_94817869-9548-4abe-a1d3-8459f3d9db4e" xlink:to="loc_srt_ProductsAndServicesDomain_93152bc9-42ab-4081-991c-230db6f32df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_3b66bb62-0cd6-49fe-8c13-d7575715c608" xlink:href="biib-20201231.xsd#biib_AducanumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_93152bc9-42ab-4081-991c-230db6f32df0" xlink:to="loc_biib_AducanumabMember_3b66bb62-0cd6-49fe-8c13-d7575715c608" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8bca9c45-11a1-468a-8415-d305e337d508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8bca9c45-11a1-468a-8415-d305e337d508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8bca9c45-11a1-468a-8415-d305e337d508_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8bca9c45-11a1-468a-8415-d305e337d508" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8bca9c45-11a1-468a-8415-d305e337d508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9e6cfb7-f21d-4a29-aba7-a32e2232edc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8bca9c45-11a1-468a-8415-d305e337d508" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9e6cfb7-f21d-4a29-aba7-a32e2232edc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e8aec1a5-9f4d-4bd3-9b9b-64cb15cdafe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9e6cfb7-f21d-4a29-aba7-a32e2232edc5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e8aec1a5-9f4d-4bd3-9b9b-64cb15cdafe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e632635f-081d-40f6-b5a0-3abe47cb3ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9e6cfb7-f21d-4a29-aba7-a32e2232edc5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e632635f-081d-40f6-b5a0-3abe47cb3ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd138343-ce07-478b-a0b8-7b9bc205f105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd138343-ce07-478b-a0b8-7b9bc205f105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_63047803-2ee4-4763-adbe-7d867a48f77a" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd138343-ce07-478b-a0b8-7b9bc205f105" xlink:to="loc_biib_EisaiMember_63047803-2ee4-4763-adbe-7d867a48f77a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended" id="if7c0521c90d8437ab4505e4de8a84ecc_CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bc3bf1-f94d-4914-9cfd-e50bffdbae6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_b4fa8de5-1269-46e4-9daf-4a625202ab83" xlink:href="biib-20201231.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bc3bf1-f94d-4914-9cfd-e50bffdbae6c" xlink:to="loc_biib_Expenseincurredbythecollaboration_b4fa8de5-1269-46e4-9daf-4a625202ab83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_84347a1d-777d-420e-a30c-3eb62a157d55" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bc3bf1-f94d-4914-9cfd-e50bffdbae6c" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_84347a1d-777d-420e-a30c-3eb62a157d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bc3bf1-f94d-4914-9cfd-e50bffdbae6c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_48564390-18ce-4fa9-8387-e2dd50ca5ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_48564390-18ce-4fa9-8387-e2dd50ca5ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bb50b754-5158-47b1-832e-5bc08c8a888f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48564390-18ce-4fa9-8387-e2dd50ca5ed2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bb50b754-5158-47b1-832e-5bc08c8a888f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_943ccb4f-592f-4dcd-8e00-db03e11568e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_943ccb4f-592f-4dcd-8e00-db03e11568e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_943ccb4f-592f-4dcd-8e00-db03e11568e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_943ccb4f-592f-4dcd-8e00-db03e11568e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_943ccb4f-592f-4dcd-8e00-db03e11568e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c48d46c-caab-4e58-bcb4-1b5e5ec53f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_943ccb4f-592f-4dcd-8e00-db03e11568e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c48d46c-caab-4e58-bcb4-1b5e5ec53f50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaSAMember_c68e55a9-d0e2-4b67-8823-08a3be3aa2e6" xlink:href="biib-20201231.xsd#biib_UCBPharmaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c48d46c-caab-4e58-bcb4-1b5e5ec53f50" xlink:to="loc_biib_UCBPharmaSAMember_c68e55a9-d0e2-4b67-8823-08a3be3aa2e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsAlkermesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails" xlink:type="extended" id="icd9cfe10d9d54f2382189c0d65eeb87a_CollaborativeandOtherRelationshipsAlkermesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_3ed00ae1-5afe-4d20-93e7-1bd62e10c9d3" xlink:href="biib-20201231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_3ed00ae1-5afe-4d20-93e7-1bd62e10c9d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltiesPayablePeriodPostFDAApproval_25595cab-53d4-4aa3-a867-fe9885841108" xlink:href="biib-20201231.xsd#biib_RoyaltiesPayablePeriodPostFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_biib_RoyaltiesPayablePeriodPostFDAApproval_25595cab-53d4-4aa3-a867-fe9885841108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a482ff2-708d-468d-bccd-b33eb3d35677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a482ff2-708d-468d-bccd-b33eb3d35677" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_1ae966ec-e99b-4254-b10f-7936b9f3248b" xlink:href="biib-20201231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_1ae966ec-e99b-4254-b10f-7936b9f3248b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea1ade1e-8179-4305-834e-943802bee899" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:to="loc_srt_ProductOrServiceAxis_ea1ade1e-8179-4305-834e-943802bee899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea1ade1e-8179-4305-834e-943802bee899_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ea1ade1e-8179-4305-834e-943802bee899" xlink:to="loc_srt_ProductsAndServicesDomain_ea1ade1e-8179-4305-834e-943802bee899_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a4d2c34-9159-4b96-911b-026fd41b3625" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ea1ade1e-8179-4305-834e-943802bee899" xlink:to="loc_srt_ProductsAndServicesDomain_5a4d2c34-9159-4b96-911b-026fd41b3625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_77c32eaa-46ff-4c4d-a9d8-6f9708c50834" xlink:href="biib-20201231.xsd#biib_VUMERITYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a4d2c34-9159-4b96-911b-026fd41b3625" xlink:to="loc_biib_VUMERITYMember_77c32eaa-46ff-4c4d-a9d8-6f9708c50834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_43f16a9e-0d02-4090-b45b-8bd18c529962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:to="loc_us-gaap_TypeOfArrangementAxis_43f16a9e-0d02-4090-b45b-8bd18c529962" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_43f16a9e-0d02-4090-b45b-8bd18c529962_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43f16a9e-0d02-4090-b45b-8bd18c529962" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_43f16a9e-0d02-4090-b45b-8bd18c529962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22f65f24-5143-4c1a-942c-e38dcd867f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43f16a9e-0d02-4090-b45b-8bd18c529962" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22f65f24-5143-4c1a-942c-e38dcd867f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlkermesMember_7f555040-ef3a-4c72-b9fe-dce2c12a9fc2" xlink:href="biib-20201231.xsd#biib_AlkermesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22f65f24-5143-4c1a-942c-e38dcd867f59" xlink:to="loc_biib_AlkermesMember_7f555040-ef3a-4c72-b9fe-dce2c12a9fc2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsBristolMyersSquibbDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails" xlink:type="extended" id="if5dd2038b11d41ab9e8c96026469bb62_CollaborativeandOtherRelationshipsBristolMyersSquibbDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d68b25da-004b-4d30-8a07-f445a86f9a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75c22e7a-5855-409f-9afc-186e5a5f0314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d68b25da-004b-4d30-8a07-f445a86f9a40" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75c22e7a-5855-409f-9afc-186e5a5f0314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_ca58ea3a-6605-497d-a533-2b7d8be5d9ac" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d68b25da-004b-4d30-8a07-f445a86f9a40" xlink:to="loc_biib_AdditionalMilestonePayment_ca58ea3a-6605-497d-a533-2b7d8be5d9ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b237ec1d-8691-41b5-9f43-c3ee7d485b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d68b25da-004b-4d30-8a07-f445a86f9a40" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b237ec1d-8691-41b5-9f43-c3ee7d485b00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6ac3f691-e062-47a0-9059-18f21065174c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b237ec1d-8691-41b5-9f43-c3ee7d485b00" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6ac3f691-e062-47a0-9059-18f21065174c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ac3f691-e062-47a0-9059-18f21065174c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ac3f691-e062-47a0-9059-18f21065174c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ac3f691-e062-47a0-9059-18f21065174c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c67c9be-2ada-45d4-8592-7de3e24f137e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ac3f691-e062-47a0-9059-18f21065174c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c67c9be-2ada-45d4-8592-7de3e24f137e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BristolMyersSquibbMember_8192b5ca-3778-4c9e-90f7-ff0d0801d5fe" xlink:href="biib-20201231.xsd#biib_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c67c9be-2ada-45d4-8592-7de3e24f137e" xlink:to="loc_biib_BristolMyersSquibbMember_8192b5ca-3778-4c9e-90f7-ff0d0801d5fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IPerianMember_310a5398-0e46-459d-82e9-9dfedf120c35" xlink:href="biib-20201231.xsd#biib_IPerianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c67c9be-2ada-45d4-8592-7de3e24f137e" xlink:to="loc_biib_IPerianMember_310a5398-0e46-459d-82e9-9dfedf120c35" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsAcordaDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails" xlink:type="extended" id="ic56b632b70c24bb69cbb5dc09f8ea0a8_CollaborativeandOtherRelationshipsAcordaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_a1f1c31f-9393-4413-9f80-9ac7914382dd" xlink:href="biib-20201231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_a1f1c31f-9393-4413-9f80-9ac7914382dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_1a31550e-7d47-47f9-87fc-46e038120a05" xlink:href="biib-20201231.xsd#biib_ForeignSalesRequiredToTriggerMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_1a31550e-7d47-47f9-87fc-46e038120a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_504e0502-306b-4309-a060-ea8115a81bb7" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_504e0502-306b-4309-a060-ea8115a81bb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e6773d8-749d-4a06-831e-f9d6a0ff2588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e6773d8-749d-4a06-831e-f9d6a0ff2588" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_486a9648-fb17-4ef9-b9f6-5dfbf599d96b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e6773d8-749d-4a06-831e-f9d6a0ff2588" xlink:to="loc_us-gaap_TypeOfArrangementAxis_486a9648-fb17-4ef9-b9f6-5dfbf599d96b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_486a9648-fb17-4ef9-b9f6-5dfbf599d96b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_486a9648-fb17-4ef9-b9f6-5dfbf599d96b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_486a9648-fb17-4ef9-b9f6-5dfbf599d96b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecd2a0eb-73cf-403e-b528-6b6f508cd503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_486a9648-fb17-4ef9-b9f6-5dfbf599d96b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecd2a0eb-73cf-403e-b528-6b6f508cd503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcordaMember_f66bc794-c18a-4d04-84df-da62c7068a1a" xlink:href="biib-20201231.xsd#biib_AcordaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecd2a0eb-73cf-403e-b528-6b6f508cd503" xlink:to="loc_biib_AcordaMember_f66bc794-c18a-4d04-84df-da62c7068a1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended" id="i73497df73d2f4b298868ee391a9713d4_CollaborativeandOtherRelationshipsOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_95146adc-66d5-4681-9b07-f9d5bf82f07f" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_95146adc-66d5-4681-9b07-f9d5bf82f07f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_ca10d08c-4b79-42df-a2e4-fed3b44679db" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_ca10d08c-4b79-42df-a2e4-fed3b44679db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_8809023e-7fd3-4d0d-aded-29776bde3cc9" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_8809023e-7fd3-4d0d-aded-29776bde3cc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0b3120f3-4011-4d15-9660-a5e2afbea3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0b3120f3-4011-4d15-9660-a5e2afbea3ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_164d3518-8d7a-408a-a1ac-30e61cc9c9ca" xlink:href="biib-20201231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_164d3518-8d7a-408a-a1ac-30e61cc9c9ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments_05f70fb6-7c8f-4ede-acb4-9b1c6f27b23d" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments_05f70fb6-7c8f-4ede-acb4-9b1c6f27b23d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6dbdd03e-34e0-4914-8b7f-f88a148d149c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6dbdd03e-34e0-4914-8b7f-f88a148d149c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_f57d4754-4416-47f4-85da-0ab8519efafc" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_Termofcollaborationagreement_f57d4754-4416-47f4-85da-0ab8519efafc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets_d420c579-8658-46af-88bc-dd9085120bb0" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets_d420c579-8658-46af-88bc-dd9085120bb0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones_259c23d2-bcf6-441f-98ed-ca9ae5cad943" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones_259c23d2-bcf6-441f-98ed-ca9ae5cad943" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones_32113f91-8319-4bc8-ad5b-cfb3efc7cc9f" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones_32113f91-8319-4bc8-ad5b-cfb3efc7cc9f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfa11061-f73f-4cfa-9464-a28553a9072c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfa11061-f73f-4cfa-9464-a28553a9072c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8cae34c5-4719-4738-af56-f6d45e9ec69d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfa11061-f73f-4cfa-9464-a28553a9072c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8cae34c5-4719-4738-af56-f6d45e9ec69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8cae34c5-4719-4738-af56-f6d45e9ec69d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8cae34c5-4719-4738-af56-f6d45e9ec69d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8cae34c5-4719-4738-af56-f6d45e9ec69d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8cae34c5-4719-4738-af56-f6d45e9ec69d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_894c407d-6f3f-47ed-b4aa-050ce734f43e" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:to="loc_biib_SageTherapeuticsIncMember_894c407d-6f3f-47ed-b4aa-050ce734f43e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_d39fbe7b-4f2a-4a58-854d-719d923c8422" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:to="loc_biib_DenaliTherapeuticsIncMember_d39fbe7b-4f2a-4a58-854d-719d923c8422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsIncAgreementMember_b7bdb236-922f-4d45-96a2-8070da010d33" xlink:href="biib-20201231.xsd#biib_SangamoTherapeuticsIncAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:to="loc_biib_SangamoTherapeuticsIncAgreementMember_b7bdb236-922f-4d45-96a2-8070da010d33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_c6982e9c-2427-4047-867d-ceae920ff728" xlink:href="biib-20201231.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:to="loc_biib_OtherresearchanddiscoveryMember_c6982e9c-2427-4047-867d-ceae920ff728" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended" id="i1612fa2d76cc4fc0a1259195cd568045_CollaborativeandOtherRelationshipsSamsungBioepisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_bd14298b-9b09-4ca8-8e85-4b29c131ed74" xlink:href="biib-20201231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_bd14298b-9b09-4ca8-8e85-4b29c131ed74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_560bc23f-100e-464d-aebc-89a3229d1f3d" xlink:href="biib-20201231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_560bc23f-100e-464d-aebc-89a3229d1f3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_49a3a4bf-7c01-4ab4-ae40-5cda093a35bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_EquityMethodInvestments_49a3a4bf-7c01-4ab4-ae40-5cda093a35bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d77d9d7c-82f8-44bf-b629-5617af6756fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d77d9d7c-82f8-44bf-b629-5617af6756fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_d9e2756c-c088-4c15-8fd3-7e7b72c04869" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_d9e2756c-c088-4c15-8fd3-7e7b72c04869" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1d081ff7-8d64-463b-aadf-4c5f328ef074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1d081ff7-8d64-463b-aadf-4c5f328ef074" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_df1a8b4c-f7f3-40f1-bc32-0980ac417416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_df1a8b4c-f7f3-40f1-bc32-0980ac417416" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_ec42ba88-5327-4e23-9eb3-e20759856c4f" xlink:href="biib-20201231.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_ec42ba88-5327-4e23-9eb3-e20759856c4f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d693074d-2492-4785-98bf-b264ab0265cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d693074d-2492-4785-98bf-b264ab0265cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_436a25ad-b24f-4889-bd76-75fd377e2233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_436a25ad-b24f-4889-bd76-75fd377e2233" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_8351574f-df30-4818-924e-0289722cddb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_AdjustmentForAmortization_8351574f-df30-4818-924e-0289722cddb4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_ce57cfad-0bb7-4e39-8d5d-de26c3e5770d" xlink:href="biib-20201231.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_ce57cfad-0bb7-4e39-8d5d-de26c3e5770d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_7faa2776-26cf-4b41-87bd-344d578a66e1" xlink:href="biib-20201231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_7faa2776-26cf-4b41-87bd-344d578a66e1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a542bd31-bbdb-4d41-b79e-b4196eaf3e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a542bd31-bbdb-4d41-b79e-b4196eaf3e3a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_d3e05db2-50e9-4a21-b5b2-09d8366860a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_d3e05db2-50e9-4a21-b5b2-09d8366860a2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_54b55a9d-7d6a-4e97-b0c7-6f679a7c897c" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_AdditionalMilestonePayment_54b55a9d-7d6a-4e97-b0c7-6f679a7c897c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1896cb1b-426c-4daf-8c88-fb4d1bd60407" xlink:href="biib-20201231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1896cb1b-426c-4daf-8c88-fb4d1bd60407" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_998589cd-6804-4d55-a575-04f4be72fafc" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_Termofcollaborationagreement_998589cd-6804-4d55-a575-04f4be72fafc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_12650b74-2b48-4453-8497-5320e619a56c" xlink:href="biib-20201231.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_ContractOptionExerciseFee_12650b74-2b48-4453-8497-5320e619a56c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_feb39590-d44d-4a6d-8a12-f36ce5ddbd72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_feb39590-d44d-4a6d-8a12-f36ce5ddbd72" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_dc343c30-e09a-41fc-aca4-40d6c2aea0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_dc343c30-e09a-41fc-aca4-40d6c2aea0a6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_12a6978b-38a6-424e-b3de-f259fde33445" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_12a6978b-38a6-424e-b3de-f259fde33445" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharing_fd1cf573-f735-43fe-a1b6-f3358183db18" xlink:href="biib-20201231.xsd#biib_CollaborationProfitSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_CollaborationProfitSharing_fd1cf573-f735-43fe-a1b6-f3358183db18" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8f5a9ab2-df19-4d1f-a52e-03ecc9bb4ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_Revenues_8f5a9ab2-df19-4d1f-a52e-03ecc9bb4ad3" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_b6094939-83b1-4e5d-b18a-b908c37b5d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_DueFromRelatedParties_b6094939-83b1-4e5d-b18a-b908c37b5d04" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_af7a9f0a-7f01-44b2-8bc2-64db74b73603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_af7a9f0a-7f01-44b2-8bc2-64db74b73603" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17c560f4-2dca-4f42-bdd3-be634b13477a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17c560f4-2dca-4f42-bdd3-be634b13477a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_17c560f4-2dca-4f42-bdd3-be634b13477a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17c560f4-2dca-4f42-bdd3-be634b13477a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_17c560f4-2dca-4f42-bdd3-be634b13477a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_80e36ada-d35d-41de-886e-04ec757261a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17c560f4-2dca-4f42-bdd3-be634b13477a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_80e36ada-d35d-41de-886e-04ec757261a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_09e6fe5d-f70e-48bd-b939-47d3ca55b5c1" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_80e36ada-d35d-41de-886e-04ec757261a5" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_09e6fe5d-f70e-48bd-b939-47d3ca55b5c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b36725c2-1281-42c4-a5c0-c769a5ae17fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b36725c2-1281-42c4-a5c0-c769a5ae17fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b36725c2-1281-42c4-a5c0-c769a5ae17fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b36725c2-1281-42c4-a5c0-c769a5ae17fe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b36725c2-1281-42c4-a5c0-c769a5ae17fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7650ea3f-5ad7-4b69-8fcc-225ae30abc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b36725c2-1281-42c4-a5c0-c769a5ae17fe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7650ea3f-5ad7-4b69-8fcc-225ae30abc3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_b49fcf13-b0be-402e-9912-ad3eca143b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7650ea3f-5ad7-4b69-8fcc-225ae30abc3e" xlink:to="loc_us-gaap_InventoriesMember_b49fcf13-b0be-402e-9912-ad3eca143b77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6663c11c-942c-4df5-b56e-a2d8b1026864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7650ea3f-5ad7-4b69-8fcc-225ae30abc3e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6663c11c-942c-4df5-b56e-a2d8b1026864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9831e065-481b-4287-8482-69c472ef75db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9831e065-481b-4287-8482-69c472ef75db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9831e065-481b-4287-8482-69c472ef75db_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9831e065-481b-4287-8482-69c472ef75db" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9831e065-481b-4287-8482-69c472ef75db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_393d3ce2-0a01-46a5-96f0-a61aee981d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9831e065-481b-4287-8482-69c472ef75db" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_393d3ce2-0a01-46a5-96f0-a61aee981d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_c3b88be9-8c0c-486b-aa08-b0599196aac2" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_393d3ce2-0a01-46a5-96f0-a61aee981d79" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_c3b88be9-8c0c-486b-aa08-b0599196aac2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_b323bd75-3988-4987-a3b7-6c599a15dc2c" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_b323bd75-3988-4987-a3b7-6c599a15dc2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_b323bd75-3988-4987-a3b7-6c599a15dc2c_default" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_b323bd75-3988-4987-a3b7-6c599a15dc2c" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_b323bd75-3988-4987-a3b7-6c599a15dc2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_c7df7b24-c7ec-4517-8942-e5848731ec36" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_b323bd75-3988-4987-a3b7-6c599a15dc2c" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_c7df7b24-c7ec-4517-8942-e5848731ec36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DevelopmentMilestonesMember_3a78686e-05fa-4a14-a384-fe96e7975319" xlink:href="biib-20201231.xsd#biib_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_c7df7b24-c7ec-4517-8942-e5848731ec36" xlink:to="loc_biib_DevelopmentMilestonesMember_3a78686e-05fa-4a14-a384-fe96e7975319" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20201231.xsd#InvestmentsinVariableInterestEntities"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended" id="i3312b19574c34c3e9354c7c8b2a7b165_InvestmentsinVariableInterestEntities"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended" id="i8ca29dcf43a04d6b9c11a1468e259c3d_InvestmentsinVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_d593f10b-530a-4b0f-8b86-55cbece88a3c" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_Termofcollaborationagreement_d593f10b-530a-4b0f-8b86-55cbece88a3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_13812641-fb08-41fd-a2b4-152b4afccbe9" xlink:href="biib-20201231.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_13812641-fb08-41fd-a2b4-152b4afccbe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_65a86394-1e5c-4d75-9d17-9d13b23d75f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_65a86394-1e5c-4d75-9d17-9d13b23d75f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_481a24c3-f701-4588-bc0d-c31bdda3227a" xlink:href="biib-20201231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_481a24c3-f701-4588-bc0d-c31bdda3227a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_498cffa2-6397-48dd-bb30-a54247088a5f" xlink:href="biib-20201231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_498cffa2-6397-48dd-bb30-a54247088a5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_1f278902-584c-4ab7-950c-e357715df4bd" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_AdditionalMilestonePayment_1f278902-584c-4ab7-950c-e357715df4bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c6aeed39-85bf-4d0e-8399-c8225ffcf7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c6aeed39-85bf-4d0e-8399-c8225ffcf7f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_bcd10b04-c6ab-4d4c-841a-619ec5df5d3d" xlink:href="biib-20201231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_bcd10b04-c6ab-4d4c-841a-619ec5df5d3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0a59bd82-858f-4826-9561-0fdba0d0a01d" xlink:href="biib-20201231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0a59bd82-858f-4826-9561-0fdba0d0a01d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_679389de-cde7-4c65-9552-7d90a6431692" xlink:href="biib-20201231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_679389de-cde7-4c65-9552-7d90a6431692" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2984f4f2-2f91-4873-8e90-160ad7a29de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2984f4f2-2f91-4873-8e90-160ad7a29de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2984f4f2-2f91-4873-8e90-160ad7a29de5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2984f4f2-2f91-4873-8e90-160ad7a29de5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2984f4f2-2f91-4873-8e90-160ad7a29de5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2984f4f2-2f91-4873-8e90-160ad7a29de5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_0964d227-0a17-4f03-a673-e160fd29483e" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:to="loc_biib_EisaiMember_0964d227-0a17-4f03-a673-e160fd29483e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_fa64a230-b402-427c-8a3d-264f8453bb14" xlink:href="biib-20201231.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:to="loc_biib_NeurimmuneMember_fa64a230-b402-427c-8a3d-264f8453bb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_2cbd6e64-7eab-447c-85e3-4eaed32fa15a" xlink:href="biib-20201231.xsd#biib_AducanumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:to="loc_biib_AducanumabMember_2cbd6e64-7eab-447c-85e3-4eaed32fa15a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38_default" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_9b987cb9-03f8-480b-b9d5-810dbd359546" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_9b987cb9-03f8-480b-b9d5-810dbd359546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_26ba04a6-9051-4ec1-b9cc-48f2cb9b175e" xlink:href="biib-20201231.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_9b987cb9-03f8-480b-b9d5-810dbd359546" xlink:to="loc_biib_RegulatoryMilestonesMember_26ba04a6-9051-4ec1-b9cc-48f2cb9b175e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8f69ed98-c5d2-4a7c-a12d-baad649086da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8f69ed98-c5d2-4a7c-a12d-baad649086da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8f69ed98-c5d2-4a7c-a12d-baad649086da_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8f69ed98-c5d2-4a7c-a12d-baad649086da" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8f69ed98-c5d2-4a7c-a12d-baad649086da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1afc4c36-697a-4368-9526-91ef191b0fa0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8f69ed98-c5d2-4a7c-a12d-baad649086da" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1afc4c36-697a-4368-9526-91ef191b0fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_4affa25f-8203-4dcb-9908-012fa4148ca6" xlink:href="biib-20201231.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1afc4c36-697a-4368-9526-91ef191b0fa0" xlink:to="loc_biib_NeurimmuneMember_4affa25f-8203-4dcb-9908-012fa4148ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_3abf07ba-4501-4bc7-b9e4-5387adb101ae" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_3abf07ba-4501-4bc7-b9e4-5387adb101ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_3abf07ba-4501-4bc7-b9e4-5387adb101ae_default" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_3abf07ba-4501-4bc7-b9e4-5387adb101ae" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_3abf07ba-4501-4bc7-b9e4-5387adb101ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_e36a670c-1ed6-4cb9-b240-f07460869ee5" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_3abf07ba-4501-4bc7-b9e4-5387adb101ae" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_e36a670c-1ed6-4cb9-b240-f07460869ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwelvemonthsMember_b778a927-d7a0-4000-8b4a-dfb4e5fe3d78" xlink:href="biib-20201231.xsd#biib_TwelvemonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_e36a670c-1ed6-4cb9-b240-f07460869ee5" xlink:to="loc_biib_TwelvemonthsMember_b778a927-d7a0-4000-8b4a-dfb4e5fe3d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_srt_StatementGeographicalAxis_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2" xlink:to="loc_srt_SegmentGeographicalDomain_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_92f5467b-ef9b-49de-a24f-b0a83e9cadd4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2" xlink:to="loc_srt_SegmentGeographicalDomain_92f5467b-ef9b-49de-a24f-b0a83e9cadd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_21188f03-a576-4ef2-a10d-d7bd79e1de89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_92f5467b-ef9b-49de-a24f-b0a83e9cadd4" xlink:to="loc_us-gaap_EuropeanUnionMember_21188f03-a576-4ef2-a10d-d7bd79e1de89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_f9b8aa59-635e-4b17-995f-c85a6451a023" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_92f5467b-ef9b-49de-a24f-b0a83e9cadd4" xlink:to="loc_country_JP_f9b8aa59-635e-4b17-995f-c85a6451a023" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20201231.xsd#Litigation"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" id="i74466774f2a349ee9cd4f4859c07d6bb_Litigation"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LitigationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationNarrativeDetails" xlink:type="extended" id="i1d220c20a22641deaa209b6b9c95ffe9_LitigationNarrativeDetails"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="biib-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsandContingencies" xlink:type="extended" id="ic26a935ba17e473cb9ce48758a489a74_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i00406bca21c245a8934fee74f2233d09_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1e9c39d4-6075-4171-b857-31be6f2795fb" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1e9c39d4-6075-4171-b857-31be6f2795fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentThreshold_3771b990-7f32-4211-9d23-f74b1a477821" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_FutureContingentPaymentThreshold_3771b990-7f32-4211-9d23-f74b1a477821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_0a652f74-a332-45b8-b9c6-a11b08a4f4fc" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_0a652f74-a332-45b8-b9c6-a11b08a4f4fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_20de4e35-4f97-4c0c-9798-e46202ec79b5" xlink:href="biib-20201231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_20de4e35-4f97-4c0c-9798-e46202ec79b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltiesPayablePeriodPostFDAApproval_ee90dc9b-5575-4905-9b2d-2027b9531ede" xlink:href="biib-20201231.xsd#biib_RoyaltiesPayablePeriodPostFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_RoyaltiesPayablePeriodPostFDAApproval_ee90dc9b-5575-4905-9b2d-2027b9531ede" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_166181ce-b9b3-4594-904d-5d64cf933a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_166181ce-b9b3-4594-904d-5d64cf933a56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevel_bb137a5a-9a59-4e09-a604-d77629e64263" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevel"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_CumulativeSalesLevel_bb137a5a-9a59-4e09-a604-d77629e64263" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e4b9049f-a708-4a73-a609-d3a2a775c7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e4b9049f-a708-4a73-a609-d3a2a775c7aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0fbce738-fdf1-4cd8-9f39-81698d1c9065" xlink:href="biib-20201231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0fbce738-fdf1-4cd8-9f39-81698d1c9065" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_271e03be-2ba2-42c8-a481-0d67c417696e" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_AdditionalMilestonePayment_271e03be-2ba2-42c8-a481-0d67c417696e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_eb4f61d8-7ed7-4f53-9a4e-0067b8e1dcea" xlink:href="biib-20201231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_eb4f61d8-7ed7-4f53-9a4e-0067b8e1dcea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_889ebbe0-e1a1-4a52-b0b7-57559441ad46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_OtherCommitment_889ebbe0-e1a1-4a52-b0b7-57559441ad46" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4a97823a-28ce-4ebc-af47-dd4f4f528833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4a97823a-28ce-4ebc-af47-dd4f4f528833" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_9947daa3-6c92-45f1-b68f-1d6b849fca54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_9947daa3-6c92-45f1-b68f-1d6b849fca54" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_4ee81bde-3da5-4fa1-88d3-1e7c69d76a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_4ee81bde-3da5-4fa1-88d3-1e7c69d76a9d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_3a351639-7e8e-4572-bf2e-bcb1c58b1884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_IncomeTaxesPaid_3a351639-7e8e-4572-bf2e-bcb1c58b1884" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_108d73a7-b804-4218-8c3e-2d7a09775273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_ContractualObligation_108d73a7-b804-4218-8c3e-2d7a09775273" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fb01a886-a9e6-46fb-840e-f85aebedefb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fb01a886-a9e6-46fb-840e-f85aebedefb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb01a886-a9e6-46fb-840e-f85aebedefb8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fb01a886-a9e6-46fb-840e-f85aebedefb8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb01a886-a9e6-46fb-840e-f85aebedefb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9141dfa-79e0-4f96-ad03-b4f1dd3b8091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fb01a886-a9e6-46fb-840e-f85aebedefb8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9141dfa-79e0-4f96-ad03-b4f1dd3b8091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_3fdc6dcc-44c0-48f7-ad59-1114e410edf7" xlink:href="biib-20201231.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9141dfa-79e0-4f96-ad03-b4f1dd3b8091" xlink:to="loc_biib_TysabriProductMember_3fdc6dcc-44c0-48f7-ad59-1114e410edf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumapharmAgMember_cbd5622b-9b6a-4b30-9e12-a8b4abb6b923" xlink:href="biib-20201231.xsd#biib_FumapharmAgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9141dfa-79e0-4f96-ad03-b4f1dd3b8091" xlink:to="loc_biib_FumapharmAgMember_cbd5622b-9b6a-4b30-9e12-a8b4abb6b923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c74a9c83-ffc7-4231-b02a-9b074356f268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c74a9c83-ffc7-4231-b02a-9b074356f268" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c74a9c83-ffc7-4231-b02a-9b074356f268_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c74a9c83-ffc7-4231-b02a-9b074356f268" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c74a9c83-ffc7-4231-b02a-9b074356f268_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c74a9c83-ffc7-4231-b02a-9b074356f268" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_8481ae3c-359c-48f8-8e16-b6a1a5c2e7fe" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:to="loc_biib_IonisPharmaceuticalsMember_8481ae3c-359c-48f8-8e16-b6a1a5c2e7fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlkermesMember_d281b132-30af-474b-a5f2-57688ff0a0b0" xlink:href="biib-20201231.xsd#biib_AlkermesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:to="loc_biib_AlkermesMember_d281b132-30af-474b-a5f2-57688ff0a0b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_03d9fb76-884f-4341-8dfa-445632f34c8c" xlink:href="biib-20201231.xsd#biib_AducanumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:to="loc_biib_AducanumabMember_03d9fb76-884f-4341-8dfa-445632f34c8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_a4fbd942-f463-41da-a1ac-8e9e13af84f8" xlink:href="biib-20201231.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:to="loc_biib_NeurimmuneMember_a4fbd942-f463-41da-a1ac-8e9e13af84f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96fb0a7e-ba28-449a-a3be-79256e5137a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_srt_RangeAxis_96fb0a7e-ba28-449a-a3be-79256e5137a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_96fb0a7e-ba28-449a-a3be-79256e5137a5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_96fb0a7e-ba28-449a-a3be-79256e5137a5" xlink:to="loc_srt_RangeMember_96fb0a7e-ba28-449a-a3be-79256e5137a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c32b8a60-d4ab-488a-b26a-3a029d5c3e8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_96fb0a7e-ba28-449a-a3be-79256e5137a5" xlink:to="loc_srt_RangeMember_c32b8a60-d4ab-488a-b26a-3a029d5c3e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36793aee-1ffc-4395-9c16-fc6c9be506cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c32b8a60-d4ab-488a-b26a-3a029d5c3e8f" xlink:to="loc_srt_MinimumMember_36793aee-1ffc-4395-9c16-fc6c9be506cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d34ff36c-cb24-4be0-b171-a60cf74f3856" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c32b8a60-d4ab-488a-b26a-3a029d5c3e8f" xlink:to="loc_srt_MaximumMember_d34ff36c-cb24-4be0-b171-a60cf74f3856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3f1a42b-4ca9-43f4-8729-2df9404e26af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_srt_ProductOrServiceAxis_a3f1a42b-4ca9-43f4-8729-2df9404e26af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a3f1a42b-4ca9-43f4-8729-2df9404e26af_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a3f1a42b-4ca9-43f4-8729-2df9404e26af" xlink:to="loc_srt_ProductsAndServicesDomain_a3f1a42b-4ca9-43f4-8729-2df9404e26af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a3f1a42b-4ca9-43f4-8729-2df9404e26af" xlink:to="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_bbdcb41c-98b7-47b2-b42f-793b9955bb81" xlink:href="biib-20201231.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:to="loc_biib_SPINRAZAMember_bbdcb41c-98b7-47b2-b42f-793b9955bb81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_6c12265a-3831-4daf-8891-0bc15ac55fad" xlink:href="biib-20201231.xsd#biib_VUMERITYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:to="loc_biib_VUMERITYMember_6c12265a-3831-4daf-8891-0bc15ac55fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_9ddb8ccf-dab8-4dfd-b6fd-0fe5ba8c0068" xlink:href="biib-20201231.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:to="loc_biib_FumarateMember_9ddb8ccf-dab8-4dfd-b6fd-0fe5ba8c0068" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelAxis_c03a535c-c3e1-4711-990d-3cdb45ae4be4" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_biib_CumulativeSalesLevelAxis_c03a535c-c3e1-4711-990d-3cdb45ae4be4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelDomain_c03a535c-c3e1-4711-990d-3cdb45ae4be4_default" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_c03a535c-c3e1-4711-990d-3cdb45ae4be4" xlink:to="loc_biib_CumulativeSalesLevelDomain_c03a535c-c3e1-4711-990d-3cdb45ae4be4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelDomain_de67de13-3c9f-42b7-ac97-965845708dcf" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_c03a535c-c3e1-4711-990d-3cdb45ae4be4" xlink:to="loc_biib_CumulativeSalesLevelDomain_de67de13-3c9f-42b7-ac97-965845708dcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwentybillionMember_52c95eae-0e47-420f-a450-176813db3e43" xlink:href="biib-20201231.xsd#biib_TwentybillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_de67de13-3c9f-42b7-ac97-965845708dcf" xlink:to="loc_biib_TwentybillionMember_52c95eae-0e47-420f-a450-176813db3e43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5843417f-b4b5-4802-9479-ccfd8f7b8c9d" xlink:href="biib-20201231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_de67de13-3c9f-42b7-ac97-965845708dcf" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5843417f-b4b5-4802-9479-ccfd8f7b8c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_f6a44953-c885-45fc-b2c6-5cce43a04ede" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_f6a44953-c885-45fc-b2c6-5cce43a04ede" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_f6a44953-c885-45fc-b2c6-5cce43a04ede_default" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f6a44953-c885-45fc-b2c6-5cce43a04ede" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_f6a44953-c885-45fc-b2c6-5cce43a04ede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f6a44953-c885-45fc-b2c6-5cce43a04ede" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DevelopmentMilestonesMember_a49a7c41-8131-49cb-860a-d584fae160ae" xlink:href="biib-20201231.xsd#biib_DevelopmentMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:to="loc_biib_DevelopmentMilestonesMember_a49a7c41-8131-49cb-860a-d584fae160ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_312524fd-2a0f-488d-b173-4399353e438e" xlink:href="biib-20201231.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:to="loc_biib_RegulatoryMilestonesMember_312524fd-2a0f-488d-b173-4399353e438e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CommercialMilestonesMember_9134a862-b869-4684-b1f9-bf4b3718af49" xlink:href="biib-20201231.xsd#biib_CommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:to="loc_biib_CommercialMilestonesMember_9134a862-b869-4684-b1f9-bf4b3718af49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_8a0234e7-4422-49b5-95f3-1cf562e39971" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_8a0234e7-4422-49b5-95f3-1cf562e39971" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_8a0234e7-4422-49b5-95f3-1cf562e39971_default" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_8a0234e7-4422-49b5-95f3-1cf562e39971" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_8a0234e7-4422-49b5-95f3-1cf562e39971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_61a2f7c9-5e74-4c3a-af1e-e52d3deb07f0" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_8a0234e7-4422-49b5-95f3-1cf562e39971" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_61a2f7c9-5e74-4c3a-af1e-e52d3deb07f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwelvemonthsMember_90d704ee-1680-4ab3-8a09-f5374b113b59" xlink:href="biib-20201231.xsd#biib_TwelvemonthsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_61a2f7c9-5e74-4c3a-af1e-e52d3deb07f0" xlink:to="loc_biib_TwelvemonthsMember_90d704ee-1680-4ab3-8a09-f5374b113b59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5546c1b1-7c8e-4425-ad35-209bc9161bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5546c1b1-7c8e-4425-ad35-209bc9161bc7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5546c1b1-7c8e-4425-ad35-209bc9161bc7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5546c1b1-7c8e-4425-ad35-209bc9161bc7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5546c1b1-7c8e-4425-ad35-209bc9161bc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_32ba86a1-7bbc-4f80-8ce6-80aff8ebed96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5546c1b1-7c8e-4425-ad35-209bc9161bc7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_32ba86a1-7bbc-4f80-8ce6-80aff8ebed96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_U.S.2017TaxActMember_426dc3a5-f946-4a0e-bed8-c711dcfb0ebb" xlink:href="biib-20201231.xsd#biib_U.S.2017TaxActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_32ba86a1-7bbc-4f80-8ce6-80aff8ebed96" xlink:to="loc_biib_U.S.2017TaxActMember_426dc3a5-f946-4a0e-bed8-c711dcfb0ebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf" xlink:href="biib-20201231.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_biib_FacilityLocationAxis_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf_default" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf" xlink:to="loc_biib_FacilityLocationDomain_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_8a404f06-6141-404f-8274-258e241db7d8" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf" xlink:to="loc_biib_FacilityLocationDomain_8a404f06-6141-404f-8274-258e241db7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember_6ac3610d-045a-4f1d-be7c-882369a004a4" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_8a404f06-6141-404f-8274-258e241db7d8" xlink:to="loc_biib_SolothurnMember_6ac3610d-045a-4f1d-be7c-882369a004a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_srt_StatementGeographicalAxis_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc" xlink:to="loc_srt_SegmentGeographicalDomain_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_27a88e66-1668-4c7e-9cc2-c016b1d82587" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc" xlink:to="loc_srt_SegmentGeographicalDomain_27a88e66-1668-4c7e-9cc2-c016b1d82587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_35dc20fd-1b59-41bc-9bc3-e6c2b5ed4a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_27a88e66-1668-4c7e-9cc2-c016b1d82587" xlink:to="loc_us-gaap_EuropeanUnionMember_35dc20fd-1b59-41bc-9bc3-e6c2b5ed4a05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_428c41a6-de5d-4517-8b24-394e23093ec9" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_27a88e66-1668-4c7e-9cc2-c016b1d82587" xlink:to="loc_country_JP_428c41a6-de5d-4517-8b24-394e23093ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_befc5051-2d57-496d-a2ed-7d4a0220033a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_srt_StatementScenarioAxis_befc5051-2d57-496d-a2ed-7d4a0220033a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_befc5051-2d57-496d-a2ed-7d4a0220033a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_befc5051-2d57-496d-a2ed-7d4a0220033a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_befc5051-2d57-496d-a2ed-7d4a0220033a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a3e30c54-9f1c-4514-bcfc-34e171688b0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_befc5051-2d57-496d-a2ed-7d4a0220033a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a3e30c54-9f1c-4514-bcfc-34e171688b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1c525a72-6294-42bc-a632-a7e24357376f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a3e30c54-9f1c-4514-bcfc-34e171688b0c" xlink:to="loc_srt_ScenarioForecastMember_1c525a72-6294-42bc-a632-a7e24357376f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:type="simple" xlink:href="biib-20201231.xsd#Guarantees"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" id="i52861972f5dd49c39588d6f8c35bdda2_Guarantees"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="biib-20201231.xsd#EmployeeBenefitPlans"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" id="i9fb4b69441244d8089783a90cbfb3859_EmployeeBenefitPlans"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended" id="i328603ef0c4847d798c78a0ed456a2e6_EmployeeBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_e67fe865-17ee-4f5b-99dd-b1c54d0de62a" xlink:href="biib-20201231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_e67fe865-17ee-4f5b-99dd-b1c54d0de62a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_058b9cdd-a249-4cd3-9401-4739b432d54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_058b9cdd-a249-4cd3-9401-4739b432d54d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_6038d415-92e0-4e4e-b701-5ad83882ddc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_6038d415-92e0-4e4e-b701-5ad83882ddc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_ca580932-514f-443a-9911-34df3af6abbd" xlink:href="biib-20201231.xsd#biib_PercentageOfMinimumInvestmentReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_ca580932-514f-443a-9911-34df3af6abbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_4359019c-bfda-4e3d-8410-5ff7638ac59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_4359019c-bfda-4e3d-8410-5ff7638ac59f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1fe396c7-deef-4a78-b03a-e742baf99210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1fe396c7-deef-4a78-b03a-e742baf99210" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense_5efab0c9-fc15-496c-83b1-c807fe5689bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_PensionExpense_5efab0c9-fc15-496c-83b1-c807fe5689bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44bb18f1-612c-4c6b-a1c3-7b0d1104ec78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44bb18f1-612c-4c6b-a1c3-7b0d1104ec78" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bca3eb83-5548-4880-8540-f284c2a95b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bca3eb83-5548-4880-8540-f284c2a95b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bca3eb83-5548-4880-8540-f284c2a95b72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bca3eb83-5548-4880-8540-f284c2a95b72" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bca3eb83-5548-4880-8540-f284c2a95b72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_12483314-2e75-4347-863c-04d97bb63498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bca3eb83-5548-4880-8540-f284c2a95b72" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_12483314-2e75-4347-863c-04d97bb63498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_5cd4461d-22bd-4703-b363-0cadd437ad86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_12483314-2e75-4347-863c-04d97bb63498" xlink:to="loc_us-gaap_DomesticPlanMember_5cd4461d-22bd-4703-b363-0cadd437ad86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3e9e5e1f-7fa7-423d-ba9b-180d6a7c9db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_12483314-2e75-4347-863c-04d97bb63498" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3e9e5e1f-7fa7-423d-ba9b-180d6a7c9db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7f6186b1-3877-42bf-9daf-d8300cc7dbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7f6186b1-3877-42bf-9daf-d8300cc7dbe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f6186b1-3877-42bf-9daf-d8300cc7dbe7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7f6186b1-3877-42bf-9daf-d8300cc7dbe7" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f6186b1-3877-42bf-9daf-d8300cc7dbe7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a409865-20c8-42d8-a8cd-3f6ca15b8ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7f6186b1-3877-42bf-9daf-d8300cc7dbe7" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a409865-20c8-42d8-a8cd-3f6ca15b8ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6a7304b9-d4dc-4def-8cfd-227fe59df3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a409865-20c8-42d8-a8cd-3f6ca15b8ea4" xlink:to="loc_us-gaap_ForeignPlanMember_6a7304b9-d4dc-4def-8cfd-227fe59df3bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_d6228a28-5b1f-49cb-8301-a90a8bedc360" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_6a7304b9-d4dc-4def-8cfd-227fe59df3bf" xlink:to="loc_country_CH_d6228a28-5b1f-49cb-8301-a90a8bedc360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_1c38f16b-57bd-4555-b70f-b2225640e931" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_6a7304b9-d4dc-4def-8cfd-227fe59df3bf" xlink:to="loc_country_DE_1c38f16b-57bd-4555-b70f-b2225640e931" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d6d108db-02c4-43a4-a5d6-c5718ee5b42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d6d108db-02c4-43a4-a5d6-c5718ee5b42b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d6d108db-02c4-43a4-a5d6-c5718ee5b42b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6d108db-02c4-43a4-a5d6-c5718ee5b42b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d6d108db-02c4-43a4-a5d6-c5718ee5b42b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16544506-ac2c-43e3-8a92-7d2c8b0e101e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6d108db-02c4-43a4-a5d6-c5718ee5b42b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16544506-ac2c-43e3-8a92-7d2c8b0e101e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_5ec44b24-9e8d-4996-baae-2b2253e8ae8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16544506-ac2c-43e3-8a92-7d2c8b0e101e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_5ec44b24-9e8d-4996-baae-2b2253e8ae8e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformation"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" id="i23c7df27297743899c37a0bdf30c6c51_SegmentInformation"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" id="ic76116d977674b769d48dc596f95a651_SegmentInformationTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i8348da7981004b9f9fe28fb063277d3c_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f12fbba-a466-4b35-9638-7e8f85838aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_76dbf572-d408-49a3-890a-46633e3fbdc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f12fbba-a466-4b35-9638-7e8f85838aa9" xlink:to="loc_us-gaap_NumberOfReportableSegments_76dbf572-d408-49a3-890a-46633e3fbdc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_955d58fb-9b91-427c-a3de-01b95e486f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f12fbba-a466-4b35-9638-7e8f85838aa9" xlink:to="loc_us-gaap_NoncurrentAssets_955d58fb-9b91-427c-a3de-01b95e486f41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_519642fe-2c47-4b2a-9e4a-e68eb4fdb349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f12fbba-a466-4b35-9638-7e8f85838aa9" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_519642fe-2c47-4b2a-9e4a-e68eb4fdb349" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ffc1e024-da4c-4982-a2a7-13089760197e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_519642fe-2c47-4b2a-9e4a-e68eb4fdb349" xlink:to="loc_srt_StatementGeographicalAxis_ffc1e024-da4c-4982-a2a7-13089760197e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ffc1e024-da4c-4982-a2a7-13089760197e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ffc1e024-da4c-4982-a2a7-13089760197e" xlink:to="loc_srt_SegmentGeographicalDomain_ffc1e024-da4c-4982-a2a7-13089760197e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8eb1f2cd-b091-4d11-9604-8250f69eb9b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ffc1e024-da4c-4982-a2a7-13089760197e" xlink:to="loc_srt_SegmentGeographicalDomain_8eb1f2cd-b091-4d11-9604-8250f69eb9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember_ddae30e1-a55e-46d0-9a1a-a00f8fc3977c" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8eb1f2cd-b091-4d11-9604-8250f69eb9b6" xlink:to="loc_biib_SolothurnMember_ddae30e1-a55e-46d0-9a1a-a00f8fc3977c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DK_e0e1746b-a5c4-455b-8399-c82806234fd8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DK"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8eb1f2cd-b091-4d11-9604-8250f69eb9b6" xlink:to="loc_country_DK_e0e1746b-a5c4-455b-8399-c82806234fd8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationGeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails" xlink:type="extended" id="i3064aee8070f4e68865c1edcffd0caec_SegmentInformationGeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_289fd566-451d-4d8c-b2e9-f3c6213722bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_89c1d85e-295f-44eb-bd21-80c472a1f6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_289fd566-451d-4d8c-b2e9-f3c6213722bd" xlink:to="loc_us-gaap_Revenues_89c1d85e-295f-44eb-bd21-80c472a1f6c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_4b18a471-04cc-462e-917c-242c87f61dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_289fd566-451d-4d8c-b2e9-f3c6213722bd" xlink:to="loc_us-gaap_NoncurrentAssets_4b18a471-04cc-462e-917c-242c87f61dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_289fd566-451d-4d8c-b2e9-f3c6213722bd" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3880c126-593d-47f6-bb88-93c0556cac4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:to="loc_srt_ProductOrServiceAxis_3880c126-593d-47f6-bb88-93c0556cac4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3880c126-593d-47f6-bb88-93c0556cac4b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3880c126-593d-47f6-bb88-93c0556cac4b" xlink:to="loc_srt_ProductsAndServicesDomain_3880c126-593d-47f6-bb88-93c0556cac4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3880c126-593d-47f6-bb88-93c0556cac4b" xlink:to="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ee837fed-696c-44a8-9567-aae5538b7238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:to="loc_us-gaap_ProductMember_ee837fed-696c-44a8-9567-aae5538b7238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_45638ae4-5cde-42e9-9c8e-1dcc885da781" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_45638ae4-5cde-42e9-9c8e-1dcc885da781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_c527a49f-7e01-47b0-88be-2d61eae73eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_c527a49f-7e01-47b0-88be-2d61eae73eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5a54324a-59e0-482b-b764-81976b81ef9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:to="loc_srt_StatementGeographicalAxis_5a54324a-59e0-482b-b764-81976b81ef9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5a54324a-59e0-482b-b764-81976b81ef9e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5a54324a-59e0-482b-b764-81976b81ef9e" xlink:to="loc_srt_SegmentGeographicalDomain_5a54324a-59e0-482b-b764-81976b81ef9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5a54324a-59e0-482b-b764-81976b81ef9e" xlink:to="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1719ab03-53bb-4147-82ed-c9753d8113e3" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:to="loc_country_US_1719ab03-53bb-4147-82ed-c9753d8113e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_3135b915-2df1-4e62-b32e-cc9745a1c7c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:to="loc_srt_EuropeMember_3135b915-2df1-4e62-b32e-cc9745a1c7c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaMember_b921ae27-b6df-4942-a44c-625e0f5b4929" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:to="loc_srt_AsiaMember_b921ae27-b6df-4942-a44c-625e0f5b4929" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_02d76c26-1a78-424d-a016-d2f1e2075cee" xlink:href="biib-20201231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_02d76c26-1a78-424d-a016-d2f1e2075cee" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" id="ic845091fcb744c118c80ed1d6b241053_QuarterlyFinancialDataUnaudited"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" id="ic364ba1bcdf44c188767ff672cba5973_QuarterlyFinancialDataUnauditedTables"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnauditedDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" id="i2ad2644fedf54d30b7e495163ea5879d_QuarterlyFinancialDataUnauditedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_132c4802-b9eb-4d18-8d1f-17ecfe71389c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_132c4802-b9eb-4d18-8d1f-17ecfe71389c" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a0121eaf-3db0-4989-9b3c-3ddd0202b31e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_Revenues_a0121eaf-3db0-4989-9b3c-3ddd0202b31e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_36a0f0a1-16ea-4c9f-8e49-25679d1fecad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_GrossProfit_36a0f0a1-16ea-4c9f-8e49-25679d1fecad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_326e872d-ba51-45fe-a4de-9a76fa03b545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_ProfitLoss_326e872d-ba51-45fe-a4de-9a76fa03b545" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_10124cbb-fd82-4098-a4d8-f9c65750ad9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_NetIncomeLoss_10124cbb-fd82-4098-a4d8-f9c65750ad9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_140ab18c-317d-4eba-af8f-3d497bf3179f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_140ab18c-317d-4eba-af8f-3d497bf3179f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_71cff9bc-3477-413b-9df7-4c85c5efe1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_140ab18c-317d-4eba-af8f-3d497bf3179f" xlink:to="loc_us-gaap_EarningsPerShareBasic_71cff9bc-3477-413b-9df7-4c85c5efe1a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1e3adba6-52cf-4be9-b976-f3f8c933f20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_140ab18c-317d-4eba-af8f-3d497bf3179f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1e3adba6-52cf-4be9-b976-f3f8c933f20c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d94f160c-6057-4ca6-a4d8-adee53a21e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d94f160c-6057-4ca6-a4d8-adee53a21e86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08aa7bba-5aaa-407d-a402-1497cf26281b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d94f160c-6057-4ca6-a4d8-adee53a21e86" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08aa7bba-5aaa-407d-a402-1497cf26281b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e7f1e406-a2c2-4b3e-a745-08f8cc58df8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d94f160c-6057-4ca6-a4d8-adee53a21e86" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e7f1e406-a2c2-4b3e-a745-08f8cc58df8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bd2c8c4f-caf5-4f74-93a7-22c0d9a8ac6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_132c4802-b9eb-4d18-8d1f-17ecfe71389c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bd2c8c4f-caf5-4f74-93a7-22c0d9a8ac6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b720ecde-a6ac-437c-8592-eb2a76d435c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd2c8c4f-caf5-4f74-93a7-22c0d9a8ac6f" xlink:to="loc_srt_ProductOrServiceAxis_b720ecde-a6ac-437c-8592-eb2a76d435c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b720ecde-a6ac-437c-8592-eb2a76d435c6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b720ecde-a6ac-437c-8592-eb2a76d435c6" xlink:to="loc_srt_ProductsAndServicesDomain_b720ecde-a6ac-437c-8592-eb2a76d435c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b720ecde-a6ac-437c-8592-eb2a76d435c6" xlink:to="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4ee91fdf-4432-45d8-9805-502ca189cf82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:to="loc_us-gaap_ProductMember_4ee91fdf-4432-45d8-9805-502ca189cf82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_348a1d1d-342e-4816-9067-a85ffde72234" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_348a1d1d-342e-4816-9067-a85ffde72234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e6e53dd1-3f7f-40f3-9cc1-83cf9b5e5fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e6e53dd1-3f7f-40f3-9cc1-83cf9b5e5fbe" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>biib-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:93645b15-c187-4b47-82bf-4dd611d6b978,g:f6c0263a-8ffa-4fd3-a952-6de1d776d19e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_73b0320f-d4a7-4cd2-89a6-7014484c7d40_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c2696955-366a-41ee-b806-c013abe4722e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6dd0dcfd-c61f-43c1-8a38-98d4e1f88f28_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_53faf1b0-4792-4de7-89d7-01f44b0f4827_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_8a9af05c-7401-4632-8c4e-9f0cde259fa8_terseLabel_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_label_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_documentation_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement" xlink:href="biib-20201231.xsd#biib_Totalpaymenttoentercollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totalpaymenttoentercollaborationagreement" xlink:to="lab_biib_Totalpaymenttoentercollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_3d3f2c1b-d07f-41be-bd7d-be67018f9cbb_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20201231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e811f76b-b720-46ba-80cc-6a8d487cbb09_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_275ef13f-a7f1-47ff-81ed-846698c90923_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliAndSangamoMember_7c2dfc34-8cce-4601-a3e2-63b9e1c2040e_terseLabel_en-US" xlink:label="lab_biib_DenaliAndSangamoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali and Sangamo</link:label>
    <link:label id="lab_biib_DenaliAndSangamoMember_label_en-US" xlink:label="lab_biib_DenaliAndSangamoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali and Sangamo [Member]</link:label>
    <link:label id="lab_biib_DenaliAndSangamoMember_documentation_en-US" xlink:label="lab_biib_DenaliAndSangamoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali and Sangamo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliAndSangamoMember" xlink:href="biib-20201231.xsd#biib_DenaliAndSangamoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliAndSangamoMember" xlink:to="lab_biib_DenaliAndSangamoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_8803d826-fd84-430f-b227-170ee278c443_terseLabel_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and regulatory success, probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_label_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_documentation_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:href="biib-20201231.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:to="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_1b91e969-b268-457f-aa55-6c6a2efa5ef3_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_441e9ca5-6434-4e46-b3a8-eb8110bb5269_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_58e704f7-e8c7-40af-8133-57b156f00ce7_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities associated with uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZINBRYTAMember_079ac8fc-7afa-4618-91f6-da698497b241_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_label_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember" xlink:href="biib-20201231.xsd#biib_ZINBRYTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember" xlink:to="lab_biib_ZINBRYTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_ed5606d9-75da-4bf7-8a4f-570fe48aed18_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_37ed54e6-ea36-458b-9d0a-3c4871bb4b77_verboseLabel_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equal annual increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_label_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Equal Annual Increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_documentation_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equal annual increments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfEqualAnnualIncrements" xlink:href="biib-20201231.xsd#biib_NumberOfEqualAnnualIncrements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfEqualAnnualIncrements" xlink:to="lab_biib_NumberOfEqualAnnualIncrements" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeriesXPreferredStockMember_890ac7c4-6b33-4672-89eb-7d8fea5e66ff_terseLabel_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X junior participating</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_label_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_documentation_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeriesXPreferredStockMember" xlink:href="biib-20201231.xsd#biib_SeriesXPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeriesXPreferredStockMember" xlink:to="lab_biib_SeriesXPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain_59532a21-476d-43b8-9fd7-6bf1f181b4fa_terseLabel_en-US" xlink:label="lab_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax charge</link:label>
    <link:label id="lab_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain_label_en-US" xlink:label="lab_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:label id="lab_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain_documentation_en-US" xlink:label="lab_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" xlink:href="biib-20201231.xsd#biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" xlink:to="lab_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_17322a59-04ff-43e3-8bc8-3e41b8be66eb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherForeignEarningsMember_24a35e76-11d7-41f0-a52b-330e02ce27b5_terseLabel_en-US" xlink:label="lab_biib_OtherForeignEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Earnings</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_label_en-US" xlink:label="lab_biib_OtherForeignEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_documentation_en-US" xlink:label="lab_biib_OtherForeignEarningsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherForeignEarningsMember" xlink:href="biib-20201231.xsd#biib_OtherForeignEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherForeignEarningsMember" xlink:to="lab_biib_OtherForeignEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bff72af9-5925-46f9-bac7-f6fb11d3a0eb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e88be661-9d54-40eb-8f4f-ba9bd4db7338_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_8695b2c0-53e6-4047-a9a8-3e08516b8cce_terseLabel_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_label_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_documentation_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement" xlink:href="biib-20201231.xsd#biib_Upfrontpaymentforcollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Upfrontpaymentforcollaborationagreement" xlink:to="lab_biib_Upfrontpaymentforcollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d013f1d0-9a64-4d20-9c3e-32a6614fe32a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d8c8c0f5-494b-43bc-b33d-125bbac8b6d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_d7703cfe-33b7-4b9b-961e-07220e8e2d06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of subsidiaries and affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_22b027f5-f85a-4c1a-8786-133336b40a0c_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis Pharmaceuticals</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember" xlink:to="lab_biib_IonisPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_94b67e1a-d834-4834-b161-afa801e9d9b3_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_425c6cab-0d06-4741-91ef-37eefd6cb06e_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_92aedea1-292b-474e-b1a8-9364ab2116da_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_e9ded57d-a20a-4cc0-9021-ce5996721538_terseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage to be received</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:href="biib-20201231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ForeignearningstypeDomain_88efa70a-1891-44d3-bbfb-bcd529c0b664_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_label_en-US" xlink:label="lab_biib_ForeignearningstypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Foreign earnings type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningstypeDomain" xlink:href="biib-20201231.xsd#biib_ForeignearningstypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeDomain" xlink:to="lab_biib_ForeignearningstypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_2fc38575-569e-4e6e-a1a4-1f5603428556_terseLabel_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease supplemental cash flow disclosure</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_label_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_documentation_en-US" xlink:label="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease supplemental cash flow disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:href="biib-20201231.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:to="lab_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_6ef5a350-b70d-4f88-ba13-18b5b6b8d427_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash activity</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_3496f1b2-d4d4-46a9-8f96-a727761b9c73_terseLabel_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_label_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_documentation_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes" xlink:href="biib-20201231.xsd#biib_Totaldeferredchargesandprepaidtaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totaldeferredchargesandprepaidtaxes" xlink:to="lab_biib_Totaldeferredchargesandprepaidtaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DK_8836b72c-71be-4b3a-b6fb-209b82d50452_terseLabel_en-US" xlink:label="lab_country_DK" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DENMARK</link:label>
    <link:label id="lab_country_DK_label_en-US" xlink:label="lab_country_DK" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DENMARK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DK" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DK"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DK" xlink:to="lab_country_DK" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_c1a50650-d388-44da-a953-d553870abc7d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_3b911e86-8a43-4e6c-b665-00900b45715e_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares activity</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_label_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_documentation_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:href="biib-20201231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:to="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_3aea7c8d-dd55-4b11-a518-c20f38f776b2_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20201231.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_638bf260-de37-47d6-905d-6a27e1c4034b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_ffbad9ac-0339-44ca-9245-2056776b045c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to the share repurchase program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d847fe25-32d5-482e-9a4a-a97a3c65fec6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3bb0fc32-b968-48a4-90d2-3987895dc41f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_626aa038-206d-4e2a-a908-e685135e61e9_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_02039f00-9efc-43e2-a4e0-0edf234082bf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e7e14713-1177-4a26-ac7a-8d568db6340b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_527be494-745b-4322-be85-64cb24182f08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryCapitalizedCosts_07acac74-1f69-4088-88b3-1e53d9c1e878_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryCapitalizedCosts_label_en-US" xlink:label="lab_us-gaap_OtherInventoryCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Capitalized Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryCapitalizedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryCapitalizedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryCapitalizedCosts" xlink:to="lab_us-gaap_OtherInventoryCapitalizedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7541e5bf-4867-4d63-a77a-86c3291aaa0d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8ec5384c-fcfb-4f17-a124-240304968cbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7db72076-f323-47b5-aaf9-187f74c89ef6_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02bdcd14-50ea-4e3b-bc75-101fb5084bb1_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_78067d70-ae23-45f2-b8f5-ca3bae455128_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_56f1c54b-2fd3-4d90-a71b-418adf18f312_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_fcd2da01-9eb2-4e1f-9653-32e13dc15489_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Nightstar Therapeutics plc, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_4d715417-1c48-4962-91b7-8bb5cdc847db_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain" xlink:to="lab_biib_ResearchanddevelopmentassetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_55e94acf-1774-4f80-8254-106e7b2fef37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2b1a9f03-5bd5-4612-8fd6-541eaaee6e4b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_8770f1cb-b990-4ac4-b55e-d2bf65116d0e_terseLabel_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_label_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_documentation_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits" xlink:href="biib-20201231.xsd#biib_Futurepercentageofcopromotionoperatingprofits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futurepercentageofcopromotionoperatingprofits" xlink:to="lab_biib_Futurepercentageofcopromotionoperatingprofits" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaSAMember_a85aa317-5b48-4bae-bffd-0d8d2f659787_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A.</link:label>
    <link:label id="lab_biib_UCBPharmaSAMember_label_en-US" xlink:label="lab_biib_UCBPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaSAMember_documentation_en-US" xlink:label="lab_biib_UCBPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaSAMember" xlink:href="biib-20201231.xsd#biib_UCBPharmaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaSAMember" xlink:to="lab_biib_UCBPharmaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A315SeniorNotesDueMay12050Member_a196e27d-dedd-48a4-a4a9-b6696b582214_terseLabel_en-US" xlink:label="lab_biib_A315SeniorNotesDueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A315SeniorNotesDueMay12050Member_label_en-US" xlink:label="lab_biib_A315SeniorNotesDueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A315SeniorNotesDueMay12050Member_documentation_en-US" xlink:label="lab_biib_A315SeniorNotesDueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A315SeniorNotesDueMay12050Member" xlink:href="biib-20201231.xsd#biib_A315SeniorNotesDueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A315SeniorNotesDueMay12050Member" xlink:to="lab_biib_A315SeniorNotesDueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MajorDistributorAxis_51ab9d4c-ce02-47a5-840a-e05d48b96657_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_label_en-US" xlink:label="lab_biib_MajorDistributorAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_documentation_en-US" xlink:label="lab_biib_MajorDistributorAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MajorDistributorAxis" xlink:href="biib-20201231.xsd#biib_MajorDistributorAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorAxis" xlink:to="lab_biib_MajorDistributorAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_2a852770-621f-4dde-ac7e-e65baabdc297_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3e9343f8-625d-438e-94d0-46ac13d258ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_71062055-e165-4c35-b3f3-de9bbbcd3ed2_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock pursuant to the share repurchase program, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_bf932111-6275-4350-adf0-ceb952c5a9e5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_0a12f0b0-aff8-4efb-a64f-c479be3a0282_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable securities, excluding strategic investments</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5cb950b4-947f-4cca-b16f-c86bff94b964_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d8d8d5fb-0373-4d50-a496-439a0ae64aec_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8b32562c-7c50-4b74-8536-72cc266a7f6f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f6689c61-fd5d-435b-9deb-46477a4c327e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ef02fc2d-ad9c-4ced-b35d-a5e8ad016bed_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to unvested share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_9783bc0c-a0b2-4369-b5d2-20414ba7c332_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_a33384f3-4ccf-41b0-8e3f-cbe5b710f905_verboseLabel_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares of common stock for issuance (in shares)</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_label_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Of Common Stock For Issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_documentation_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares of common stock for issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance" xlink:href="biib-20201231.xsd#biib_NumberOfSharesOfCommonStockForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSharesOfCommonStockForIssuance" xlink:to="lab_biib_NumberOfSharesOfCommonStockForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_f6632d22-0f08-4216-8d06-c2521adf741f_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8424137e-d2d6-4800-86e8-b1ea742660ff_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_f4acc44d-4deb-4d86-8a66-210424519104_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f337f690-67d6-407d-b06d-826efe1f293c_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_73f12513-ddf0-421b-8325-a8e0dc4a9fd3_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20201231.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CH_265f4c80-a107-4b7e-9ce9-32ea4cc3415d_terseLabel_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SWITZERLAND</link:label>
    <link:label id="lab_country_CH_label_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_ddd596ef-78ba-4985-931f-cde20af6641b_negatedTerseLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20201231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f791d337-6d82-475d-a927-3d3e7f15db18_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_cf0f6925-31e4-457f-9a87-b3fedfce2bf7_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f5f17f45-54e7-4dba-b7f8-9570f33289a1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_15918a33-cfff-4d6c-a12e-87ff27e297c0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_dd51d2bf-4fc9-4bc9-819c-971f170e8ed8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_c9594403-33ce-4344-b8a7-5167bbbe0deb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RoyaltiesPayablePeriodPostFDAApproval_34ebe7c2-fb61-43cf-9788-abee0b633e48_terseLabel_en-US" xlink:label="lab_biib_RoyaltiesPayablePeriodPostFDAApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable period, post FDA approval</link:label>
    <link:label id="lab_biib_RoyaltiesPayablePeriodPostFDAApproval_label_en-US" xlink:label="lab_biib_RoyaltiesPayablePeriodPostFDAApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Payable Period, Post FDA Approval</link:label>
    <link:label id="lab_biib_RoyaltiesPayablePeriodPostFDAApproval_documentation_en-US" xlink:label="lab_biib_RoyaltiesPayablePeriodPostFDAApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Payable Period, Post FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltiesPayablePeriodPostFDAApproval" xlink:href="biib-20201231.xsd#biib_RoyaltiesPayablePeriodPostFDAApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltiesPayablePeriodPostFDAApproval" xlink:to="lab_biib_RoyaltiesPayablePeriodPostFDAApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_19a4be11-fad0-40e8-a697-b0290a7f472f_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_48162fef-8ac9-4687-99d2-d84816c922b5_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Senior Notes due September 15, 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20201231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_d6e4e838-176a-42d2-9889-b2a314b46e29_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_6765e23c-8985-475c-abde-2ce3aecbc9a0_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_adad4f3d-d10a-4dd3-9901-11fbf742824d_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_5b1478d1-62e2-4e79-a4fe-7940c781d88a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_cb49ec5e-3423-4d7e-a3fb-b17dff92badb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_4ec87765-b525-475f-a002-30099a5ba0b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_8daf8b3a-04d4-481d-bcd0-55a89ea67d2a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e186b839-5ee0-42ec-bea1-fd0a2aa81756_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based payment arrangement, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6f418591-8ede-4860-beef-b4fd59e36d34_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_9bd509e3-7dea-4c5c-b611-d9e2794f8a65_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_774e281b-74c0-49f1-9cd1-2818363d4359_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_1348812a-7847-412f-a72e-cebfea760a67_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestiture of Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_0cffe1f9-a302-4c4b-bb7e-c77a92a6b06e_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20201231.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_0a9720d8-6da7-4bf9-aa07-e4fd651ae83f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_6121b6fa-769c-4348-84d3-64f5d6642477_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bf952e53-cf7f-48c7-8984-96bd5410e0a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_8bdcfbe3-714a-4978-935a-34db39667f6d_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20201231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_2a50b344-a4a0-4f3f-9e4c-1830e4f0957a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b528bfaf-0168-42fc-a824-844c12fff126_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_52019da4-d07d-4856-8a87-51d7c5a00089_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_57c1ebd0-a794-459d-b2b4-c92bceba7814_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20201231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_4347fe6e-1cbf-4e71-a43e-bd951765e3cd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. tax reform</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_bed7bac9-03ce-4b9a-b0b7-639251733a27_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition toll tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_3800aa5c-9bf9-49d4-8f26-940695f5f1be_verboseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional milestone payments when certain sales threshold is met</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Additional Milestone Payments When Meeting Certain Sales Threshold</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional milestone payments when meeting certain sales threshold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:href="biib-20201231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_cc47e5be-da8f-4098-8a2b-f3b78d57b9fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_4f658368-162a-4e89-90f9-0d812b6d64cf_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_96ea5b8c-07e7-42c3-bac4-980db725c0e1_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20201231.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_124b645a-446e-4a3f-bb42-a0b6e71feb7d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5fcd91d9-35b2-428e-98c4-ed2d7010f6f5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c6d956b7-c266-4275-b588-22f75490c1e6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_646373d2-4986-4976-a8ba-04d00577e335_verboseLabel_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign sales required to trigger milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_label_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Sales Required To Trigger Milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_documentation_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign sales required to trigger milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone" xlink:href="biib-20201231.xsd#biib_ForeignSalesRequiredToTriggerMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignSalesRequiredToTriggerMilestone" xlink:to="lab_biib_ForeignSalesRequiredToTriggerMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_ad49b71e-45fa-416f-b468-fca3202f2840_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da34b4cf-3458-4cde-97c9-65ed9ce76a36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_34f810ec-e8b8-4e8a-8b14-78b35ff9f516_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_9631cebc-0b25-45c5-afbf-9c63135bc2cb_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20201231.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_f3b9f3a6-706c-4115-9fcb-82ebec983c65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2874b2bd-6826-45e9-9fed-028c1c9708db_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_edd5685e-355a-469e-8f6c-229aa20c23cd_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60d7c038-0390-4790-aa13-5a961d353e24_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_79fce2d7-4921-49e7-a13e-ba94a7538057_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_75e394da-99a9-40a1-b9ed-759215520179_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a8bdbf72-319b-41cb-afed-ddb39f5f56bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Plan number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ab8c98cd-ac69-4c23-b793-fb86677bafb9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_6edf43c8-2a6e-416c-8bc3-e67089a605bc_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum batch production for Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_5b8af4d6-a8fc-46ac-bc93-d32877e9e8b0_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due September 15, 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20201231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7c044be9-e7cb-4588-b8d4-1adf0e3814e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareRepurchaseProgram3Member_62171cab-fb50-4bcd-bcf2-b6faba38630c_terseLabel_en-US" xlink:label="lab_biib_ShareRepurchaseProgram3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram3Member_label_en-US" xlink:label="lab_biib_ShareRepurchaseProgram3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 3 [Member]</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram3Member_documentation_en-US" xlink:label="lab_biib_ShareRepurchaseProgram3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram3Member" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareRepurchaseProgram3Member" xlink:to="lab_biib_ShareRepurchaseProgram3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_bf62be4b-b61d-4c8e-b369-01b6f49474ab_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting for Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e21ee240-2e33-484d-9377-bebf53d51279_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_6edce25d-1726-4315-a06c-f059dc365148_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_c5d506cf-dd8c-4f6d-b40b-d278e02cd865_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method of Accounting</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_5cf6cc9e-fede-4160-90a1-2be6adabf266_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20201231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_373e37e4-4901-404c-9ea8-c9d9f943ed34_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset/Liability Type [Domain]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_label_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset/Liability Type [Domain]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeDomain_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetLiabilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain" xlink:to="lab_biib_DeferredTaxAssetLiabilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_b4b21240-be96-48f3-aef0-7ed375d60718_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_726c96ec-0c3a-4188-b1c8-0e5621b802b4_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumapharmAgMember_9bce05ed-7ced-4b5d-8e96-443d06b99d3c_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_label_en-US" xlink:label="lab_biib_FumapharmAgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumapharmAgMember" xlink:href="biib-20201231.xsd#biib_FumapharmAgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember" xlink:to="lab_biib_FumapharmAgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_df62fa71-9448-4142-b5f5-8fd2f1e38ab6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_2cac9dee-8acb-4853-a80c-b01b9e9e27bb_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In-process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_c54931b7-6bbe-4eff-ad6c-10535fa78386_terseLabel_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum qualifying age for employee benefit plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_label_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_documentation_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum qualifying age for employee benefit plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:href="biib-20201231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:to="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_b0b22114-3837-4bd8-844f-1da19cedea2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_6daabaca-b0dc-4ca0-942e-00e0bd7470eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2ebd950f-ef44-4a01-86f9-65de0432037d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_6d2593a7-77b3-4473-9ba2-c8f00b555785_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ae179664-3e3f-4459-869e-bc67afc27058_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cfa82ec4-a40e-4b70-95ad-265164bf7d64_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9884aa2b-2ab0-4a8a-9d03-959ad3ab32a7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_b0d33f9e-afb0-4c8e-806d-117c22ca888d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_d3112840-4c99-4f44-b7ea-38228a9eae60_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_62cf333c-e4c5-4ae8-8524-0d2ecc0b465c_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Gains/(Losses) Recognized in Other Comprehensive Income (Effective Portion) (in millions)</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2f8bd1d5-7635-4a5d-b8d4-f7d6228a3e7b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_03ec7bc4-8271-4367-9be3-ce65c81e7f18_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_183cc52b-bf28-4560-8c9f-8e32a551ba89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_497980f5-9d40-4fb0-a1a9-096083c2414f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_01a127be-0041-489c-8959-02cccafa0680_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e24cd1b-9617-4742-9b75-52e83c0233e7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_59c31f03-606b-4d72-8868-02ed0302365f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMMember_b93e0de5-b2d5-4e04-aa4a-d706c42f0c2d_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_label_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember" xlink:href="biib-20201231.xsd#biib_FUMADERMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember" xlink:to="lab_biib_FUMADERMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_6d51bd0a-bca6-4491-a4d0-89494f9ff987_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross" xlink:to="lab_us-gaap_FurnitureAndFixturesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_4089dddc-4c7b-4707-befc-bc0dc84df342_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_505ce0db-9ab1-4d9d-8202-2352ed615d30_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_52974745-2a89-4562-9a62-2c14cbc335bc_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b4b69bb1-bf32-4524-a858-7750f009582e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c662cef4-b3e9-415d-afd0-a81746378f35_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_d7281121-36ef-4d8d-b8d9-e04d8bc960f4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0c566035-d482-4801-9679-87ba54741e59_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_389288b9-0c47-4c14-b9d7-24f39f3fe6ad_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_ade82b5d-3a4a-4594-9916-cfb6cf9b887b_verboseLabel_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of total number of shares reserved under the plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_label_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_documentation_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of total number of shares reserved under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:href="biib-20201231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:to="lab_biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SOD1Member_3eb9cb98-dc38-470f-8863-930acafb0ccd_terseLabel_en-US" xlink:label="lab_biib_SOD1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOD1</link:label>
    <link:label id="lab_biib_SOD1Member_label_en-US" xlink:label="lab_biib_SOD1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:label id="lab_biib_SOD1Member_documentation_en-US" xlink:label="lab_biib_SOD1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SOD1Member" xlink:href="biib-20201231.xsd#biib_SOD1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SOD1Member" xlink:to="lab_biib_SOD1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_aa5393ac-4b83-43c8-ac28-831be28fb302_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_29d8a967-a1c7-4396-9a0f-2d10874db887_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceUnitsMember_551e5b1a-6cd2-493d-a5a8-bedd6788fb63_terseLabel_en-US" xlink:label="lab_biib_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_label_en-US" xlink:label="lab_biib_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_documentation_en-US" xlink:label="lab_biib_PerformanceUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceUnitsMember" xlink:href="biib-20201231.xsd#biib_PerformanceUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceUnitsMember" xlink:to="lab_biib_PerformanceUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55c008e6-b360-47f5-a21e-b47a5100a0e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, unvested shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a801403b-3353-46f8-b774-96d20290b688_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, unvested shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_e14d1a42-e304-4f41-a2f9-2d225a869af8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_e4842603-32d7-41c2-b05b-db6753c28104_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IPerianMember_e1dab21c-ed6b-429b-bb17-8ba21d63ba0f_terseLabel_en-US" xlink:label="lab_biib_IPerianMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">iPerian</link:label>
    <link:label id="lab_biib_IPerianMember_label_en-US" xlink:label="lab_biib_IPerianMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">iPerian [Member]</link:label>
    <link:label id="lab_biib_IPerianMember_documentation_en-US" xlink:label="lab_biib_IPerianMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">iPerian [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IPerianMember" xlink:href="biib-20201231.xsd#biib_IPerianMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IPerianMember" xlink:to="lab_biib_IPerianMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_230ef21a-16d6-41d2-8311-f234d29f385f_verboseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes" xlink:href="biib-20201231.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes" xlink:to="lab_biib_PercentageParValueOfSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86e5944c-7998-4def-89e5-308e307cb565_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_54a91c8f-c8ab-4906-8c90-640d906c7b29_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_edb56d89-d27d-4142-a0d0-0e114b6e181d_verboseLabel_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_label_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_documentation_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:href="biib-20201231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:to="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6d2b8a0f-efb9-4b62-9521-4681bcdebbb0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_eba3bee5-2db2-46e6-8a13-a6b197db4ce8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_ee8b5b1d-ac14-457e-aada-c5b7d8ec4f2c_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20201231.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_5148667b-e457-4140-ac3d-d26daf198e0c_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20201231.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_aa2eabaf-b599-416f-8026-d8667a82fcda_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_48156f90-b29f-41e1-a92e-07f8605e8934_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_c2d2e76f-d002-42dc-8c71-225d921b92ac_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_53cb6143-ae7c-48ef-9753-76f7bea3eccb_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_03515b7d-beb3-4560-a380-e4b1c9fde1c3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims asserted</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_74004cf1-b43c-46e0-aff3-02620b0893f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e84c303d-0e98-4ae2-b166-8862a0191db0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_728f0f2c-b27b-4313-bd54-9c23eb470bf9_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of minimum investment return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_label_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Minimum Investment Return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_documentation_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of minimum investment return.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn" xlink:href="biib-20201231.xsd#biib_PercentageOfMinimumInvestmentReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMinimumInvestmentReturn" xlink:to="lab_biib_PercentageOfMinimumInvestmentReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_1054be72-5747-4e03-82d8-f2314592ee9c_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, gross unrealized gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_1d04c6e8-6e93-42a7-9b09-a0eedbf83913_terseLabel_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-acquisition equity compensation</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_label_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:label id="lab_biib_PostacquisitionequitycompensationMember_documentation_en-US" xlink:label="lab_biib_PostacquisitionequitycompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-acquisition equity compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PostacquisitionequitycompensationMember" xlink:href="biib-20201231.xsd#biib_PostacquisitionequitycompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PostacquisitionequitycompensationMember" xlink:to="lab_biib_PostacquisitionequitycompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4b169c10-0b28-4ba8-91ea-ff2b92c96c7e_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheet</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20201231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26ec325b-d075-4bbd-8e96-de2153476ae4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_4876cec0-6f4f-4348-8d2d-73ad2d82b6d0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ee5e9850-daed-4765-9266-824e490ff227_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_88d2b5dc-acb6-4410-8a9b-ccd8d183a6c4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_96112713-ee50-4905-80f3-f6fa866b66b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_e52078ae-7a98-4ab0-af08-1428e33603a8_verboseLabel_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_label_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from unconsolidated joint business</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_documentation_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness" xlink:href="biib-20201231.xsd#biib_DueFromUnconsolidatedJointBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DueFromUnconsolidatedJointBusiness" xlink:to="lab_biib_DueFromUnconsolidatedJointBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_b5234c92-5a12-4122-9ddc-5afab8ebdf21_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20201231.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e2fdb6-b725-4afa-9dbb-65e53637c953_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1bbd3594-5b6b-4a9a-8942-3064f09d5631_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_328a4468-cb83-422c-b1ac-fff2adeeede9_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20201231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_fceff018-b8c7-4c84-87b7-aa3effa7972f_negatedTerseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Depreciation Amortization Other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities depreciation amortization other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:to="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f46b87b1-c30d-4dd7-a3af-1aeda774e3d3_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_d647888f-7cc7-4b36-abae-62038da31b54_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_c51ad250-1970-4d27-af17-ffb0a673938a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_c30bf428-de9f-42b1-bc29-c261ac824ec1_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_5bd71e39-13e9-4b17-bfdd-4ef1f9349663_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_7285229d-3808-4ad1-8703-da950aaaa937_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_c1f5e67c-6393-4721-9471-1f28d34ce4f5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StromedixMember_a1cbb0e7-80c5-43bc-923c-fbc1e51ad34b_verboseLabel_en-US" xlink:label="lab_biib_StromedixMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stromedix, Inc.</link:label>
    <link:label id="lab_biib_StromedixMember_label_en-US" xlink:label="lab_biib_StromedixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stromedix [Member]</link:label>
    <link:label id="lab_biib_StromedixMember_documentation_en-US" xlink:label="lab_biib_StromedixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stromedix.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StromedixMember" xlink:href="biib-20201231.xsd#biib_StromedixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StromedixMember" xlink:to="lab_biib_StromedixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5b3964c7-7645-4a6c-9931-d94203f28972_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_2f8852a6-5527-42e9-9d9e-b8678381b7a8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_b3d304c0-2f22-4ee7-98b0-def3d82fdc4e_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_f47f5c4b-e1f8-432f-9354-f2f10e52bfc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_fa3e1c43-c422-4bd9-8fa0-bbdf202bd516_verboseLabel_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_label_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Geographical Groups Of Countries Group Other [Member]</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_documentation_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment geographical groups of countries group other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:href="biib-20201231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:to="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_017f4b81-a9e9-4c74-9bcd-55aaf2178899_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_cd15c3cf-6def-4970-997b-030e3a39bda0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_fa316c7a-a18b-43c6-bc74-43212539ca3b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_9c983b40-b2a4-45e3-8cab-8ee6469ca2eb_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5f7fedee-629a-4dfb-99a1-b382fa6e8323_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_563f8190-7faf-4c9d-a6d5-39eb031fb942_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_ce976e65-e9d9-4393-9ac6-81603925e2ac_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20201231.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_4d3f32f8-d3d3-4bcd-b8df-0b660d8aa3e7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts duration</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_329e43e2-c7f0-4597-8023-78334a757f1d_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5568d295-29cf-44ea-8852-7b227856d162_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_78edd3a5-ab1e-4457-b6bc-d4a7a64c8a53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_156dc984-d6ee-40f3-9232-519aa5401375_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity related to the UCB collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:href="biib-20201231.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_913b6380-1ef7-4070-8aaa-537e080750dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_b0779b73-bfab-4a7c-8a2c-73608fb6739e_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_987fd810-4e88-4ade-8bbc-b3d724959d5e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_408162d9-caa9-463c-9285-af61cebdc8f0_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0a038beb-e5b0-4b16-a9c2-b8bbfb13dbb4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1d316850-6dfd-4b9f-b60b-c7b5bdbe6797_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_f44ec30a-ee76-46ab-86e0-ed27427eac1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_4cf7d0a8-a111-420d-927e-c7a019b29c07_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded net pension</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Purchaseofcommonstock_dce5ea9d-8c20-4934-acc6-03660fbcddda_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Purchaseofcommonstock" xlink:href="biib-20201231.xsd#biib_Purchaseofcommonstock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock" xlink:to="lab_biib_Purchaseofcommonstock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_45e4753c-e31d-4e83-976e-95314f58e1be_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_56e1baf4-0381-4eb0-badf-3bfbe27c1591_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_9f91581a-73b2-486b-9922-9d7afd999380_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20201231.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fd763b8-1022-4933-b6f3-ccabf4573392_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9cc86cba-148f-4f46-bce2-40c84cf55337_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ccded08d-7489-4ff3-83ff-27a19cd82f6a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a5a3aefd-25a7-4666-ac45-c1f856c7f4ef_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_c5770106-802c-4929-8425-09be4f9cff31_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_0f7836f2-c308-465c-afb5-357bbd001f3c_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20201231.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_99613c73-5f89-47cc-a54d-4391f16141dd_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20201231.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_3955f6d8-cf57-45c2-8844-0bbec6a0a52b_terseLabel_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_label_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Under Employee Stock Purchase Plan [Table Text Block]</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_documentation_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:href="biib-20201231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:to="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_185b610a-56c7-4e52-987f-ddc666494320_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e9622d3-0cac-4f8d-bb91-97913d85354b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6699c9f5-5a15-4427-b00a-435834e44889_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_665225bf-0652-48ac-ba1c-678d0528b725_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_734d0936-4dfa-41a3-a273-a146a7f603f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7ead4aae-c784-4d62-b1c9-8d72169eb21f_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer&#160;Software&#160;and&#160;Hardware</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_aeee2aa2-6f6b-4ec9-825a-fbb908c85c02_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TwelvemonthsMember_cf6f5260-3eaf-495a-8f96-f4738abfbcac_terseLabel_en-US" xlink:label="lab_biib_TwelvemonthsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve months</link:label>
    <link:label id="lab_biib_TwelvemonthsMember_label_en-US" xlink:label="lab_biib_TwelvemonthsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve months [Member]</link:label>
    <link:label id="lab_biib_TwelvemonthsMember_documentation_en-US" xlink:label="lab_biib_TwelvemonthsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve months [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwelvemonthsMember" xlink:href="biib-20201231.xsd#biib_TwelvemonthsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TwelvemonthsMember" xlink:to="lab_biib_TwelvemonthsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_3f4fac20-00f4-4a60-84da-8b7d1889aa08_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock activity</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_d44729a3-829e-4bbd-9edf-5baa59d2c3db_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized investment gains (losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_ef89fca5-8a95-494a-b912-5207124e920c_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04ccc544-27f4-47dd-90da-b4e11ee6f2ae_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_67f8c027-d37e-4821-8b52-1bea8473ee42_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_dde43a8a-8f0f-4315-ac3f-107aa2fdf0ee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_97a088c9-aea6-40d3-8226-7b8bd06b42a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of year</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b3db1238-f855-4b9c-a505-691de6fbbd13_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of year</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4148837f-321c-49e5-bdd5-02255123a195_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_95a254dc-5283-4e69-8a28-3e5fc667c187_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_c191e23b-6d4a-4274-8d95-d94d5e106d9e_terseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20201231.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_6f7c713c-e8bc-4177-8965-2a02e618ba95_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity related to BAN2401 and Elenbecestat collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:href="biib-20201231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_976b4767-8dc4-4f08-b5b0-62e7230a793a_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_87db9eb3-ab82-4e48-a3ee-d36cfc27beca_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20201231.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_d0291cd1-c70b-4b17-8d28-371a330c3739_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ac85e9e1-d9e7-4fb7-bac1-76ba36b74b2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_ccb41835-9bc8-414c-946a-2a57d49f957f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_9dbfc5d3-eaa1-44dd-952f-31c07cef4174_terseLabel_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_label_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_documentation_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:to="lab_biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_26cb6b67-8fe5-4490-9948-81756ab35a4e_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20201231.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c23753cf-29ce-4676-8a05-e64689295085_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_4686458b-faba-41f5-bd00-4d5492ae5fc0_terseLabel_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_label_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_documentation_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software and hardware</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ComputerSoftwareAndHardware" xlink:href="biib-20201231.xsd#biib_ComputerSoftwareAndHardware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ComputerSoftwareAndHardware" xlink:to="lab_biib_ComputerSoftwareAndHardware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_cef9302c-302d-4524-90ba-47f5b1c72c59_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a1dab75c-619b-4a18-af05-4ac4ed756901_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_98c9e243-6ca9-455d-ac9b-409ba5bc0b3f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_dea8a51a-7602-4c3a-b4b4-db117751a88b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a96a7724-fc9a-45e6-8283-5442da4d4cd5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_b9544a27-c1bb-4842-b59f-40d3a6ff3de1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_071cdeb8-daf6-4054-9e85-1642a974987d_terseLabel_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit and cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Proceeds Received and Tax Benefit from Share-based Payment Awards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:to="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_525afba1-c126-45bf-991c-ee5bf297929c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_d87686e5-0157-48e2-b41f-a21ff3d0091e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_846cf8c1-4e17-4c2d-9a57-fa8f9b611d97_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfDevelopmentCostsIncurred_73e7146a-de82-43fd-8a45-e18a35e59a16_terseLabel_en-US" xlink:label="lab_biib_PercentageOfDevelopmentCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs incurred</link:label>
    <link:label id="lab_biib_PercentageOfDevelopmentCostsIncurred_label_en-US" xlink:label="lab_biib_PercentageOfDevelopmentCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Development Costs Incurred</link:label>
    <link:label id="lab_biib_PercentageOfDevelopmentCostsIncurred_documentation_en-US" xlink:label="lab_biib_PercentageOfDevelopmentCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Development Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfDevelopmentCostsIncurred" xlink:href="biib-20201231.xsd#biib_PercentageOfDevelopmentCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfDevelopmentCostsIncurred" xlink:to="lab_biib_PercentageOfDevelopmentCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_3489e4a4-9cc0-4190-950d-766bb0b69554_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b25f357a-5bca-45a9-a256-df463deba78a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_a24d5e9c-5447-460a-a7d5-54b3d1613c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_d8d24150-f7dc-4486-ab0d-ea83556501eb_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20201231.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_933f498b-7531-41af-aee1-a1a69a826d50_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20201231.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_bb18101c-3c7c-4466-a7bf-bd836cbb74a8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_f60d42f7-9994-4a51-9165-fbfe2c4152bd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_c78b592c-1c92-483a-8fc5-fda7303d4b32_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20201231.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_d69b348f-fc6d-48a7-8ecc-04d5f33d88cf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7026b3dc-85ed-439f-b2ee-253ae1ee784a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TwentybillionMember_188106e0-805c-4ca0-b048-352db01603de_terseLabel_en-US" xlink:label="lab_biib_TwentybillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty billion</link:label>
    <link:label id="lab_biib_TwentybillionMember_label_en-US" xlink:label="lab_biib_TwentybillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty billion [Member]</link:label>
    <link:label id="lab_biib_TwentybillionMember_documentation_en-US" xlink:label="lab_biib_TwentybillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty billion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwentybillionMember" xlink:href="biib-20201231.xsd#biib_TwentybillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TwentybillionMember" xlink:to="lab_biib_TwentybillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_8d1d15c2-f2ee-432f-bbd3-164e7a5dd9bf_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20201231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_357b5546-7d1b-40d1-909f-eb4c0820770c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2e61aee9-dd9b-4bf9-b328-7952c8a59df9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b27bef48-0fcd-4a0e-9eb1-50b2c8f0d7ed_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_a3ca42e7-a6aa-444f-aee4-fcf7dc2d2d2d_terseLabel_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_label_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_documentation_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:href="biib-20201231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:to="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_c1490195-fd80-44a7-acbb-96bcbbaf7d20_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_d6768546-ae7f-44b1-9045-ac967c74d7f4_negatedLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20201231.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce9ffc86-7721-4629-82a5-9519e65ba226_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_c383ecb7-016c-4844-9811-a4c4e213fae9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing) (in millions)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_583e7378-04a4-4172-88ab-621560484ae5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net contribution (distribution) to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_label_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Capital Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfCapitalDistribution" xlink:to="lab_us-gaap_PaymentsOfCapitalDistribution" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_2d05d471-ad8a-404c-83ef-d9f0c7a1a10d_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4b65bb1e-04ef-4f87-ab11-56cdc492806f_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e8008225-f65d-4e6f-a1e8-459fec0041ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_8248b5eb-5f25-4aa6-9e77-89e53aa74bfe_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as cash flow hedging instruments on our consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dbc93f0f-3df2-4d1a-a6d2-9c01eaded445_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_b5a76eb9-7e66-44f1-9edd-35108c06bee3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1b5d8095-9170-4f0b-9863-1549c052bf5b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the fair value for our outstanding derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_77b8f9cc-5171-4ea5-942b-495bcaa78eb7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_901c4992-e041-430e-be1a-86090dd582c2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_3188af6a-eec3-4c2d-93d6-48e1ad2c839e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_ab0f6af7-e951-4d27-bed1-b4dbac3c21a0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_01130c35-1de5-43ef-a959-26e9d0909189_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_cff1adf3-bd4b-49a6-b7dd-ed027e244a7e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_d927aa36-0143-496c-8377-7f5ae7b05f89_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_0fddb2a3-1e20-432d-98a4-276f0348a985_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal reorganization of certain intellectual property rights</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:href="biib-20201231.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4bea8ec1-3510-428e-8180-d2d8dcc51e24_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_5fa80c42-3854-4433-b883-ac94de95154a_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelAxis" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelAxis" xlink:to="lab_biib_CumulativeSalesLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_489e19ff-0d30-4a9b-a6b8-4e99f697c918_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A225SeniorNotesDueMay12030Member_80a859d9-bfbb-4502-8b99-1e3f77547b0f_terseLabel_en-US" xlink:label="lab_biib_A225SeniorNotesDueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A225SeniorNotesDueMay12030Member_label_en-US" xlink:label="lab_biib_A225SeniorNotesDueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A225SeniorNotesDueMay12030Member_documentation_en-US" xlink:label="lab_biib_A225SeniorNotesDueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A225SeniorNotesDueMay12030Member" xlink:href="biib-20201231.xsd#biib_A225SeniorNotesDueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A225SeniorNotesDueMay12030Member" xlink:to="lab_biib_A225SeniorNotesDueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f87ebe7a-1109-4885-b892-28d671bf6254_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_fccc0f81-761b-4530-85c9-24b845163432_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a69ee8fa-079d-4cbe-a987-824f7702a9eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_f173bfd9-08ac-4957-97ef-742468f45fa1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d1923a55-7bbb-4ce2-911f-730b00c6af69_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_93977d1c-4dd0-4d7e-9335-475a7ff2fdd8_verboseLabel_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days for calculation of average closing stock price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_label_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Days For Calculation Of Average Closing Stock Price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_documentation_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days for calculation of average closing stock price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:href="biib-20201231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:to="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoTherapeuticsIncAgreementMember_01ce77f5-c8d4-40ba-bfee-09369444bffb_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsIncAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsIncAgreementMember_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsIncAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsIncAgreementMember_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsIncAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsIncAgreementMember" xlink:href="biib-20201231.xsd#biib_SangamoTherapeuticsIncAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsIncAgreementMember" xlink:to="lab_biib_SangamoTherapeuticsIncAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_1ef7d563-9498-4b3b-9474-6a8898a9ad43_terseLabel_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Manufacturing Operations</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_label_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:label id="lab_biib_DenmarkManufacturingOperationsMember_documentation_en-US" xlink:label="lab_biib_DenmarkManufacturingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denmark Manufacturing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember" xlink:href="biib-20201231.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenmarkManufacturingOperationsMember" xlink:to="lab_biib_DenmarkManufacturingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d5f81c45-5893-4991-9ab4-b358e0ee75f3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2711045e-b923-45f5-a9db-f97fe51414c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_5252581f-912a-4a92-8e6f-074783426ac7_verboseLabel_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms of accounts receivable arising from product sales</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_label_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms Of Accounts Receivable</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_documentation_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms of accounts receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable" xlink:href="biib-20201231.xsd#biib_PaymentTermsOfAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentTermsOfAccountsReceivable" xlink:to="lab_biib_PaymentTermsOfAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_6431eae7-e32e-4ac4-bac3-f9dba28504ff_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8dec08fc-dfe2-4cb7-b1d6-939360e1e25a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets_03547b1c-a153-4371-ad6e-416afca0bd3d_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration, payment, selection of targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Selection of Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_6e92abd3-3555-404f-a170-6ac97140a76d_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_34ca9ac4-ed16-417c-816c-571524f8f942_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SubleaseMember_92c9ba5d-8521-42cd-bd9f-c69ade8b4059_terseLabel_en-US" xlink:label="lab_biib_SubleaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease</link:label>
    <link:label id="lab_biib_SubleaseMember_label_en-US" xlink:label="lab_biib_SubleaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease [Member]</link:label>
    <link:label id="lab_biib_SubleaseMember_documentation_en-US" xlink:label="lab_biib_SubleaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SubleaseMember" xlink:href="biib-20201231.xsd#biib_SubleaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SubleaseMember" xlink:to="lab_biib_SubleaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a4c8b4df-0511-453f-b6ae-6348d61d46ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_37d678e4-e453-4a00-b873-0d7d5df1832d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3b4539e3-4768-4de0-93a0-97b65f03a70d_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_b7f2df8d-e943-4ca5-a93b-3a83854a0899_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_a6db9214-8b44-42a9-a304-125041e80444_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity related to Aducanumab collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20201231.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c7adc890-d023-4367-aaff-2bd9b02621e3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_b93e35b8-a4cd-4f64-88b0-0958f7fcb088_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_e7d25de1-f5b3-462b-87f0-6bddb432b92b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherTaxExpenseBenefit" xlink:to="lab_us-gaap_OtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_52dcbf64-f7c2-4f7c-8413-4f25d3aad3d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Net Investment Hedge, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_3c7328c5-5e6f-4222-91e6-b13e0ea24f52_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8ae94dea-48e5-4336-83bd-78a0e340f127_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_56638983-c6e0-4f7e-b048-747ab6c0f1d0_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of year</link:label>
    <link:label id="lab_us-gaap_Goodwill_e89f2116-2372-44bf-8fea-1b7ae5d0b927_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of year</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a3b1158c-0149-4d1b-b99d-d9f601b05e0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_996d68ae-963d-4af9-86bf-e16d75f1fdef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b71ce0cf-e594-40e8-87e7-35511506d6a9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4976579c-733a-415c-929c-c76ed08d183a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CumulativeSalesLevel_23f36751-6e4d-4cb4-962e-29289265c4b6_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevel" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_label_en-US" xlink:label="lab_biib_CumulativeSalesLevel" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevel" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative sales level</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevel" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevel"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevel" xlink:to="lab_biib_CumulativeSalesLevel" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_31322771-6d64-4f85-82c3-46f783b876fe_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_db0f413b-0e45-4e9f-93f4-e1f5584f7c6a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement refund (payment)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4fec66fd-cdf7-4042-ba71-fb99da107b5d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d4b125d9-63d7-4fb8-9c14-f0ad4e2b0d2e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_8675df56-1e95-4c6f-92f9-129b2c13d2cc_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20201231.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_54ed2be2-a3d8-4549-88c2-72bcba88942f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_b18d8fcc-4845-4561-909b-7048c59199ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_adffd823-a709-483e-ae6a-9a9a2239da31_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_147c145a-b494-4fb6-ae53-b7e4ccf78544_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet_1aa9acaf-e12a-4cf2-850a-6f4227ea368d_terseLabel_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense, reduction in deferred tax assets and liabilities, net</link:label>
    <link:label id="lab_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</link:label>
    <link:label id="lab_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet_documentation_en-US" xlink:label="lab_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" xlink:href="biib-20201231.xsd#biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" xlink:to="lab_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_130691b9-8811-4552-94b2-12ded6ce37cf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_aba8776b-1ea6-47e0-9322-73278400ed7c_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20201231.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_23d79cbb-da46-42f0-82ff-1ba113ec0eb2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_2f861087-f9cd-4a0a-ba11-b35f0834431b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b9ba8bc3-1293-4bba-9bd5-12c7f644d133_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5a26ef7a-755d-4451-b988-1094484e7c1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_10f661b2-c9d4-4711-bac7-4961c6defdaa_terseLabel_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ophthalmolgy biosimilar products</link:label>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_label_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</link:label>
    <link:label id="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_documentation_en-US" xlink:label="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:href="biib-20201231.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:to="lab_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_11ae819a-e3c5-4d24-9e27-e7e22ec00276_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_a40bed70-ad62-4478-8a80-71359cf1dcd3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_50c5caa9-78c3-4219-9da9-5301d86201d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_0e8839ae-0aad-410c-a165-2784536b7e1d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_e531fe14-6381-4b89-83ef-9589b870522f_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumeratorAbstract_aa57518c-3f8f-42dc-8b55-9e115c1b80da_verboseLabel_en-US" xlink:label="lab_biib_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_biib_NumeratorAbstract_label_en-US" xlink:label="lab_biib_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_biib_NumeratorAbstract_documentation_en-US" xlink:label="lab_biib_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumeratorAbstract" xlink:href="biib-20201231.xsd#biib_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumeratorAbstract" xlink:to="lab_biib_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8239d957-528b-4d22-81f9-c0dbba95682f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GAZYVAMember_733316a3-60f9-4eb1-8b2c-4ea08e63943b_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_label_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_documentation_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember" xlink:href="biib-20201231.xsd#biib_GAZYVAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember" xlink:to="lab_biib_GAZYVAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ff27f4d2-f1bf-42cb-952c-a39f0cd28386_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ae4c2c5e-a22e-4629-bb41-2a5f3e1fe833_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0f8dc3a1-6486-4885-bab0-52c050081460_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc. (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90c0cf02-5387-4847-9877-e656fdd5f2e7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc. (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_cdb78530-526e-4437-af97-9daca6e1be1d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_684211c5-8934-4e05-902d-7bbc0d525553_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3361a8b5-10ab-4685-8b07-f07856db09b2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_37f9726e-941c-4757-84fb-5722775fa945_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_KaryopharmMember_23bdde44-34c1-43e1-b2cc-3d295e10ce0a_terseLabel_en-US" xlink:label="lab_biib_KaryopharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karyopharm</link:label>
    <link:label id="lab_biib_KaryopharmMember_label_en-US" xlink:label="lab_biib_KaryopharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:label id="lab_biib_KaryopharmMember_documentation_en-US" xlink:label="lab_biib_KaryopharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_KaryopharmMember" xlink:href="biib-20201231.xsd#biib_KaryopharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_KaryopharmMember" xlink:to="lab_biib_KaryopharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_911a0e9b-31ea-42ca-9685-b4c547b4499b_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_label_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:label id="lab_biib_DeferredTaxAssetLiabilityTypeAxis_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetLiabilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset/Liability Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetLiabilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis" xlink:to="lab_biib_DeferredTaxAssetLiabilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_074fe545-d52f-4fdd-b456-c1c0d7963f98_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoCommonStockMember_38885cab-a376-4846-abdb-f61209f3ea03_terseLabel_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_label_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock [Member]</link:label>
    <link:label id="lab_biib_SangamoCommonStockMember_documentation_en-US" xlink:label="lab_biib_SangamoCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember" xlink:href="biib-20201231.xsd#biib_SangamoCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoCommonStockMember" xlink:to="lab_biib_SangamoCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0c53ae8-d1f2-4aed-9eba-11527441853d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_8059ab9d-833a-45c8-844e-23e3cb1fa89f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory work-in-process sold to FUJIFILM</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_d3e46384-131d-4ae2-b93b-0dc40be94bcc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_7c779bd6-f248-4f6f-9cb9-4082e47f7341_verboseLabel_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_label_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_documentation_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:href="biib-20201231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:to="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_8419d325-b227-4699-bb9b-c55da539b966_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining term and discount rate</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_label_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_documentation_en-US" xlink:label="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease weighted average remaining term and discount rate [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:href="biib-20201231.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:to="lab_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f0102748-4e4c-4f67-b345-1eaab3c3301d_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance at January 1,</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_58f052a3-caba-419e-ae9f-2cc1abc8c589_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance ar December 31,</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_144f8b82-5bdf-414f-b7a8-b2e5948aca7b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_131dce24-2b9c-45ad-951b-3ad1f11f5dce_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_514d59d1-653a-4db5-83c5-696d8d034d5c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_40a3dcfd-c1d1-4b4e-b92c-a5bb604cfaa6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8b500edd-dbb8-4b98-ab28-1b2796c325bd_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_b0307ae7-e54c-41d9-8cf0-34d710f10c52_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20201231.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_8a6b76b0-5a46-4b71-8e3e-195fd422a825_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_a6aa9e5c-e925-4f36-86ce-dd4a42b7f0f4_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plan obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_27a5a6ac-1aa5-427c-8b06-1e0b0ba7fe4b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement refund (payment)</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_03994ba1-c34c-454a-b41d-b6d799169114_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3576d778-c501-4e7e-89ac-c14132d90931_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_dc8c7fdd-b231-4ac5-b031-6476913f26c6_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_6f597410-0cea-41b8-b9e0-e7c6368f18a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_2215bfe2-9df3-48f7-942c-4d19eb88550a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_ec1082f3-5b37-438a-b70c-6c2a0bdadc69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_bd350f4d-846f-41a3-9e84-1b8014051c7d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_292c642a-65b4-4764-93f3-266eb82e60ec_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3e0a97c6-0a33-4ba7-abc5-cc60d031d4a7_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_55d40ef4-fc3f-4cc2-b4d4-3693a620be16_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_431cbcf5-f88e-4546-bb58-46bfa76ebd68_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_e0f6bacc-536b-4840-8201-ff3fc1061cdc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_61d7cf53-a4c9-4228-ba49-abdcb831bc99_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6955fdb7-9327-46a9-be70-513ad9e00e92_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_85485844-5d18-477f-8199-9ccecd9ac9e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_54a46f8a-9920-4a3b-802d-8b5d13fc8cbd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_94f32174-ab1d-4318-9e10-795218d51d99_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20201231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_57d8574e-d8ab-4996-b529-ecf8b4923840_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:href="biib-20201231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_00868ca7-e18f-4970-bd5e-735621a7c910_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_97670429-bead-4e45-899c-06cea53f4020_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_bdce44d0-830c-4db8-9dc8-9b1bb1a79e7e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_199bf6da-2331-4d97-94f5-bb07de9d6d72_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_59ee80b2-dd1d-486b-863f-ab3cb00326e9_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_7481ea8f-eb24-4407-b39a-267bf1b1e383_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_label_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentThreshold" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentThreshold" xlink:to="lab_biib_FutureContingentPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_c16cc150-b810-4ab6-ba85-fe78f9bb20e6_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20201231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_9d88a73d-d91a-417e-b5f4-2095484df9df_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaMember_5a140379-db98-45b0-a090-ba2688283d9d_terseLabel_en-US" xlink:label="lab_srt_AsiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia</link:label>
    <link:label id="lab_srt_AsiaMember_label_en-US" xlink:label="lab_srt_AsiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaMember" xlink:to="lab_srt_AsiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_9dc20f68-8207-480b-94fa-cee575e201f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_660f6de3-a65a-4581-8de4-cb99e7f73bd2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6f4a2d9b-dcf0-45cb-a38b-c5a48aee5371_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RituxanMember_b5d8380d-78d9-41e9-80f0-34aabb20c192_terseLabel_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_label_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_documentation_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember" xlink:href="biib-20201231.xsd#biib_RituxanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember" xlink:to="lab_biib_RituxanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_56e7c9f2-8174-45b3-adad-19aa8b8b837a_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20201231.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_264842fc-e39d-4779-87b0-b87605af8af5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_45f0f950-a52f-4a97-a942-23b21d61ce1d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_44e94d75-ed01-4f8b-ac29-5fe6651e33cc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6b93dc34-0a9e-4d31-bf54-e0a4c9e87dd5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_bed09bd8-d8e6-4c9e-aab4-69cd91a7d690_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_8c283420-a730-4071-a1fe-e84a12e78c85_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_29c565a4-2853-494b-89a4-c5bb1e63be0d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bc8db232-148f-49bc-9112-5da83893fd95_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_10ab2e46-4802-4677-a18b-3f406146d6da_terseLabel_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property</link:label>
    <link:label id="lab_us-gaap_IntellectualPropertyMember_label_en-US" xlink:label="lab_us-gaap_IntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember" xlink:to="lab_us-gaap_IntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ee245994-9b89-4023-965e-312917993201_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_d4b46321-b361-4ed8-905a-dc693c19560e_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co Promotion Profit Sharing Formula [Abstract]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract" xlink:href="biib-20201231.xsd#biib_CoPromotionProfitSharingFormulaAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract" xlink:to="lab_biib_CoPromotionProfitSharingFormulaAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_c4c7d617-b8bc-4aba-b893-f156e99adc8a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_7369f5d9-c823-4eba-98ca-6ec55552bbf8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_18b1903f-46c9-43b7-a05d-9cdecded52cf_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_4d9b3a17-393e-424e-8fdb-53e966afdb5a_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20201231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_36689ecb-1913-4272-8c73-cd3107cd6f5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_10dfd4e8-22ed-4cab-af96-62083904f315_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0715ac36-c0ba-4590-a29e-0937b7624935_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_9abe9200-1775-4644-bece-6daa5aeb4e3b_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20201231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a9d6eab3-5da1-4a95-9205-5b635e7c2323_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fa07ace1-384d-4883-b976-10ae8aaf265b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_78e21d1c-d5cf-4bd5-a774-83d020d4adfa_terseLabel_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_label_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_documentation_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions used in valuation of market based stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:href="biib-20201231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:to="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_20f6ded5-598c-447f-bf0a-18cd1278bf38_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_746a9b79-675f-4728-b07e-5a1549bf496c_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20201231.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8f8ab27a-4020-456d-b001-6bc3f1a95d3a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c0e92ccc-6f9c-4e53-8116-56b88233d684_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_4803d44e-4190-4e3b-b44f-ac8f35ed3cd2_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_f05eed3d-ebbf-4d8f-aec1-9313ae7e7cf0_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_c57e3213-c838-48ae-b775-532e8068cb9d_terseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20201231.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_54038912-799c-4bb3-811b-7a9ddb99f425_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6870b0eb-bf7f-4807-8beb-c16d9553221b_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_a8c43292-c283-489b-8b9a-7fed6007291a_verboseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NewAntiCd20Member_cec47755-d36b-47c0-b6c9-2ae5b838553a_terseLabel_en-US" xlink:label="lab_biib_NewAntiCd20Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Anti Cd20</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_label_en-US" xlink:label="lab_biib_NewAntiCd20Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Anti Cd20 [Member]</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_documentation_en-US" xlink:label="lab_biib_NewAntiCd20Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Anti-CD20.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NewAntiCd20Member" xlink:href="biib-20201231.xsd#biib_NewAntiCd20Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NewAntiCd20Member" xlink:to="lab_biib_NewAntiCd20Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_6cd5614c-56a2-4356-a8bd-a63959c0537c_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6727008f-8220-4a42-a812-6de30049b3b3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_36dd376e-caf2-4570-8364-0e38e1f2bbd1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5a95d6ae-434e-416f-8f72-8842f6f129dd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_88d02f6a-a9f1-4a31-8660-cd4dd4dbe8b0_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_428bd97b-94b6-4da2-a624-d7987bd70562_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ba7d1615-a9f7-43e4-ae2b-7ae672cbc783_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a8c6bc65-279f-4193-94e1-b49f4c3c8750_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_29efcdc7-dd01-41d9-879c-3de5683c365e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a6b40541-01fa-4183-934a-741f6524b445_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_48d3bbf1-3b87-474e-bbea-305615ee7560_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f69ab8f6-c4ea-4650-b517-b78bba3a967c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2ad838cf-a869-4e88-acc4-d606620dbb07_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_f67d54e6-397f-4c90-8d2b-f24b0922a1ee_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20201231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_b23c8460-3042-40f0-960c-78eb60119a29_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20201231.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_85d98b64-9cf4-4388-95d7-ab3b52904121_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Status of Postretirement Benefit Plans, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08c3c991-64fb-426b-9d0d-a1d408c1a005_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_7f0da418-5945-4cae-b491-4f0f7f458cf1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_524191ca-2d4c-46d8-9986-3f91018aa5ce_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionExpense_76c0356f-db38-486f-b633-6bac9998b9d6_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension cost (reversal)</link:label>
    <link:label id="lab_us-gaap_PensionExpense_label_en-US" xlink:label="lab_us-gaap_PensionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense" xlink:to="lab_us-gaap_PensionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcordaMember_783bd631-a6e4-4d7e-840e-0da29b051bd7_terseLabel_en-US" xlink:label="lab_biib_AcordaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acorda</link:label>
    <link:label id="lab_biib_AcordaMember_label_en-US" xlink:label="lab_biib_AcordaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acorda [Member]</link:label>
    <link:label id="lab_biib_AcordaMember_documentation_en-US" xlink:label="lab_biib_AcordaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acorda.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcordaMember" xlink:href="biib-20201231.xsd#biib_AcordaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcordaMember" xlink:to="lab_biib_AcordaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d1c3d072-51ed-4e75-863e-bf8ac29af38f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9c1dbe76-6061-48c0-a7fd-32d6ab8caa14_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_0131506c-109c-4b98-82c6-fae2be9b5f31_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average stock price on grant date maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average stock price on grant date in dollars maximum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:href="biib-20201231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_5aff4e13-0504-4918-bada-be7cc726beaa_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_808ea99f-0d1d-497d-b76e-3f3e6a418500_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_label_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, GILTI tax calculation</link:label>
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, GILTI tax calculation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:href="biib-20201231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:to="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_c45276e4-d3f4-45a6-be61-32760954ac04_terseLabel_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:href="biib-20201231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_634b0e01-db9c-4472-a292-bdcd5dc1866e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemptions percentage of 2015 notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_0707c21d-87c6-4c42-8a95-a3a6e792b06d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9e63067a-af16-485a-9f10-d7c53cee5128_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e61fe33d-521d-4877-a995-482b64dd9053_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_45d48baa-4b93-46aa-bb90-bcfd8d7a1d41_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_52f27c33-d84b-43f6-810a-07956289e44e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0b51211d-4624-4dd5-b472-dd56c5df5825_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_0c8e4ff1-9689-409f-9265-d7777c7739da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_25ca9512-8b13-4e61-b3d9-41c7979ba9b6_terseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement" xlink:href="biib-20201231.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement" xlink:to="lab_biib_PeriodOfCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_651f58a5-717e-48d2-b490-2de822acdc0b_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_8cce07a7-b288-4495-adc2-3c02b381d4e4_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales trigger gross sales threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold" xlink:href="biib-20201231.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_d041e6de-d0dd-4c09-a649-db6acf4164ca_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_183652b0-269d-48a0-b7b9-0ae5430505b4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to savings plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_905ed638-1ad9-432a-a524-dab1e75911f7_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20201231.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4b247bf5-a0c2-4261-ae51-6dbd24b32f05_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_c1ba45c6-664a-4f7b-8bae-d34d9950a12d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_69a9ebb2-2400-4be7-b983-56a45ee30184_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative qualifying as hedge, excluded component, after tax</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_9ee55a34-e669-4de5-9c76-fbf67d0fab89_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnMember_b35bd44c-9825-4129-a2ba-b1acfa01a22f_terseLabel_en-US" xlink:label="lab_biib_SolothurnMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn</link:label>
    <link:label id="lab_biib_SolothurnMember_label_en-US" xlink:label="lab_biib_SolothurnMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:label id="lab_biib_SolothurnMember_documentation_en-US" xlink:label="lab_biib_SolothurnMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnMember" xlink:to="lab_biib_SolothurnMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_af954212-8685-433a-8743-7b52411e3bb1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_25744618-8d16-474a-9f20-ce837562b3df_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_e274bb28-b190-47fe-899a-cc8aa78cfb14_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution from noncontrolling interest</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother" xlink:href="biib-20201231.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones_3ae98bd2-d200-4a95-8035-44fb06cbf58f_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration, payment, sales based milestone</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_35f71755-7e79-4322-99f2-5ae57c2c756d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_13f18c2c-4d0d-4025-b0f8-61bbf82bdb8a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_251db0aa-17c3-4db4-89e4-4f35c6f48f86_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8838b289-1cf2-4df2-ab2f-a9ecd2679209_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AliveGenMember_c3ff5706-dd2e-40b8-8604-2eddbec00288_terseLabel_en-US" xlink:label="lab_biib_AliveGenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AliveGen</link:label>
    <link:label id="lab_biib_AliveGenMember_label_en-US" xlink:label="lab_biib_AliveGenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AliveGen [Member]</link:label>
    <link:label id="lab_biib_AliveGenMember_documentation_en-US" xlink:label="lab_biib_AliveGenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AliveGen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AliveGenMember" xlink:href="biib-20201231.xsd#biib_AliveGenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AliveGenMember" xlink:to="lab_biib_AliveGenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_26279f22-984e-43d1-b612-c6f988130c9d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8c11ee52-9fdc-47be-bed8-10331fda75e0_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4f561597-9e0e-4d8f-b3bf-989605a7fca0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d3607165-d384-4709-891a-2cb931eacac9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_3c719364-8fd4-41e8-8962-1d5ac99313b3_terseLabel_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition toll tax repatriation tax rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_label_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_documentation_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate" xlink:href="biib-20201231.xsd#biib_TransitionTollTaxRepatriationTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TransitionTollTaxRepatriationTaxRate" xlink:to="lab_biib_TransitionTollTaxRepatriationTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_c4bc1ac2-6ce4-4272-95cd-08f17ff7e60d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_78e9054c-42f7-486e-86a6-2f75c89eafd9_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_835042b3-3992-4ef9-8417-1c9b4ddc6d12_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlement of awards upon vesting</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_352393c0-fdb1-4daf-a1ed-0c2f2d7461d3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f8d2d4e4-2b7c-4ebf-9c3b-29a038e0e8d0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_03073e10-7f7a-4e0e-87c9-1f1f3b6e4b08_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c81587e1-ef56-41a5-80f7-e4bb2724a8da_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20201231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f451af8e-ad14-44a3-b406-10cdd772cf67_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_77aafe7f-ff03-4bf3-a873-f3e53ce3a3bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_cb4fe90f-49ab-4cbb-a483-e324e7e2f2a9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d98425da-2e5d-4d9a-8a24-cf6482600aec_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_baec3e94-9930-4ab7-b35b-bfbf11e1690f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d99b92c5-63c8-4667-a0f5-d9446a1f35c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9619ccd7-d499-4c04-8664-3682bd4169ae_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4f5bccaa-cec1-42b4-8e71-a59dbf3bbf4e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount reclassified, net of tax, upon adoption of ASU 2016-01</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_11778c2b-08f7-45a2-b87c-815ef9da18a8_terseLabel_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Domain]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_label_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Payment Timeline of Milestone [Domain]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_documentation_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:to="lab_biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_b46c6ca0-3ec7-4fb5-92f2-6e0fac0f22b0_terseLabel_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units activity</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_label_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_documentation_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock" xlink:href="biib-20201231.xsd#biib_PerformanceunitsactivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceunitsactivityTableTextBlock" xlink:to="lab_biib_PerformanceunitsactivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_c44f6c95-1a87-40d5-9e92-41d5e86b3bcc_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal: MS</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20201231.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2d9ef15c-a2d8-4c14-a222-c287655e14f8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_898c5b34-9af3-43de-aa93-5a64acbd8d3e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f661511e-52d4-4bd9-a21a-2f791cd3915e_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_68bb140a-f40b-4ca7-8c48-1e04c18c3944_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_3bb1a02c-9a8c-4777-b983-41de18988935_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_8b86b77c-383d-478a-9c79-89eb2cc7cca0_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_2c5fe237-3ff6-4700-a107-cdbedeeee5c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_ca850d27-adde-45d8-b6ad-0e6e2cf0cdd8_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Credit Carryforwards</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:to="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_dd379003-2d3a-415a-a049-9b4ac090c65d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_8bca4397-be7f-473d-a6ac-89e022a82e51_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2bae1ec4-2f9b-475b-8e19-3273f5655235_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_4526b8d3-4923-4a24-9561-09d619aa49e1_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average stock price on grant date minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average stock price on grant date in dollars minimum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:href="biib-20201231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_34a1b979-c487-41cb-8c31-a4113e4377fa_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_62a62a41-91fc-4efe-91b2-e9e3decc681f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_b67c2bd7-5a3e-431c-a198-c36ddbd7dbad_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_6045663a-6501-46e3-80e6-e06fbd19edeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of beginning and ending amount of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_549a2080-8c81-4d87-a825-86dc4d845089_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforward, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8bfe5d99-028f-48ce-b9a8-4b5535a35436_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesAbstract_946a0201-0013-4c12-b361-bcc1f6e2a2b0_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:label id="lab_us-gaap_GuaranteesAbstract_label_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesAbstract" xlink:to="lab_us-gaap_GuaranteesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d0bbf076-752a-4bd7-b7fc-fbbf7addcfda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_bd6cda0e-e7e8-4d62-88f2-e4428f782bf2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of indebtedness</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_10357721-7ce3-4d8e-a282-d63b69cbffb7_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b038bcbc-d554-45f5-9cb5-b857e69b1955_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f0fb554b-969f-46fc-8159-b4cf10f72951_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_738a8e19-f5ca-4eef-a042-495e9d01fc77_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8cfd94af-e6c7-4632-8a3e-9fa53e72fa4e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a89011fd-5810-4610-8124-a7e3f0a3182f_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f0b919b8-84f4-455f-aca0-aa0b9ab34b69_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6fc9ebd5-86e7-46a6-a0d7-797243ab5865_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0c7aa18a-7af6-4cac-a1f2-8ea414033af4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_46e138ab-668f-4990-843f-9dbe5276206a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, fair value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_777f1c46-8636-45f1-8fdc-f8d9da84aa87_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_d3cb467b-2989-488b-8e5f-737493466ca4_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c423a550-422c-410c-a184-93d8d6a8994f_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_374195ef-4dd5-46c6-b8ae-33068d108596_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:href="biib-20201231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8e50e1a6-17a8-4dd3-9867-74b496291ce4_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_bc64293f-a240-4db3-ad6a-04e4b94a6d46_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_17e7824f-fae7-4cbb-a3f7-379e401a0b5f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_0866b7ee-887e-44a7-bdb0-e655499e2061_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fc53e4b9-ef63-4c3d-945d-5d96af5bbe78_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_8e78631f-4f7c-4e57-a288-ad03ae2e84df_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20201231.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9b9daadb-5690-479b-9f27-e11c8d0e5318_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e91d6d71-8dc3-4044-ace1-ce5b58a23ad5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2015SeniorNotesMember_59b26b60-d4ad-423e-8c7f-e61bab226425_terseLabel_en-US" xlink:label="lab_biib_A2015SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Senior Notes</link:label>
    <link:label id="lab_biib_A2015SeniorNotesMember_label_en-US" xlink:label="lab_biib_A2015SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Senior Notes [Member]</link:label>
    <link:label id="lab_biib_A2015SeniorNotesMember_documentation_en-US" xlink:label="lab_biib_A2015SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2015SeniorNotesMember" xlink:href="biib-20201231.xsd#biib_A2015SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015SeniorNotesMember" xlink:to="lab_biib_A2015SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2c6d3a2-0320-4408-b304-737ab4d4bdd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_453fe218-b0ef-4c41-a2e1-be3271eeb9e7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_1e31869c-a951-4bb2-8251-179415f60d3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ce99dd13-79ab-433a-9ef5-bbcb49708a6b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_17d719e1-ad27-4325-b3b9-abf42bfeec5b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5e29fdcf-0522-4777-a983-0e59848118d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_16b18006-5795-4a6a-8335-fde036efe0c6_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After First GA101 Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_684c03ab-24a2-4130-8c80-71d7e8b7095b_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, non-current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_0258f070-4fec-4148-adae-d01adc2cc5d8_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec International Neuroscience GmbH</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_label_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec International Neuroscience Member</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_documentation_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen idec international neuroscience.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember" xlink:href="biib-20201231.xsd#biib_BiogenIdecInternationalNeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecInternationalNeuroscienceMember" xlink:to="lab_biib_BiogenIdecInternationalNeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_78837f40-37f2-4e1f-9774-9412fc4d4005_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f51af26-179a-481b-ac56-291be95fffa2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_90d5d3a3-1f9b-4347-8e54-12bc06e4b731_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:href="biib-20201231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3cb590a6-b205-4389-bd3b-4fa554af822f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_308fb939-2866-4069-8b9e-105792b0c3c4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_c13fb0f6-05b4-4fbc-a993-b5eff7ec0f1c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, measurements, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_759c10eb-36c8-4716-8f9a-83d3ebc4564d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c670397e-69e0-48c4-8294-f82b340134d4_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Gains/(Losses) Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20201231.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_078dfd04-4b2a-46ff-aa56-2cd3d6ef9013_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_508c5c87-7691-42d6-8a45-9ec55284d205_verboseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total sales and marketing expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_cdcb4f5a-3a3b-4a22-ac06-69af686d07cb_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total UCB development expense</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20201231.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0921bb74-b30a-46cb-bf2b-d488d85ce264_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2cd5c1b7-0d21-4b13-9eef-a16eb79dc623_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_5bf229d1-fddf-446c-a599-a9b499809873_terseLabel_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings in the form of cash and cash equivalents</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_label_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_documentation_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:href="biib-20201231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:to="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_cf80149a-cbb1-4424-87ca-b112af3b7b63_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_789b5c35-55da-40b8-ad1e-2388b368ca13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_20df7f9b-d25e-4a7a-9ef6-e737eb858864_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected costs to sell disposal group</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LicenseFee_88d5f718-a453-4f33-a4cc-145491a52f67_terseLabel_en-US" xlink:label="lab_biib_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee</link:label>
    <link:label id="lab_biib_LicenseFee_label_en-US" xlink:label="lab_biib_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_documentation_en-US" xlink:label="lab_biib_LicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LicenseFee" xlink:href="biib-20201231.xsd#biib_LicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LicenseFee" xlink:to="lab_biib_LicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_4f57cbe6-9abf-49e3-9a3f-171973a2305f_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0f460c4c-795e-4e4a-8c8a-07d7d4ebc87a_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_4ca4d400-ebd6-4cf2-82a3-5ed764085b65_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fa9a1ac8-4919-4eb0-a8a8-7439afe3b2df_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_036aa96a-f9e7-42a0-a249-2735c228855f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_4ad4d6fe-aa4b-44ba-ad73-8695ad2bff8e_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_10101fda-ab23-4478-bc70-8dc363073200_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_c63b481b-5bdd-4e4a-bcdb-ce28de190846_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-downs on excess, obsolete, unmarketable or other inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_cf68f51f-f0b5-431f-8fa6-a3776a5cff21_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_0aae47c1-68cb-422d-9602-8700f6434a46_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_cee83510-ba55-4cb1-bdf3-6228dd48114a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_89eac5f0-cce4-4abd-aa35-1832c2655d64_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_41f2b480-a663-4ba8-884b-22475b13040f_negatedTerseLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/returns relating to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20201231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e6cad2c9-8213-4513-99d7-49b213177e43_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_069c1bee-aef7-45a9-96d2-820f7fe4b4e5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_b86bc8d9-2c74-438e-980b-2da4741acf3a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_ee34fa82-2f26-4ee3-854d-ff682e1dc21f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4e01401d-0a42-4dab-84ef-a978193ef124_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1faecdab-27d6-4f5e-8891-8615994b3742_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5822f2c1-dfcd-4ec2-90f4-ed9fa0d369a9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_67d3f9ad-7f2a-4aef-971a-b8c9e89e206c_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Book Value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareRepurchaseProgram5Member_bebfef3d-8994-4716-9c67-dc701b321362_terseLabel_en-US" xlink:label="lab_biib_ShareRepurchaseProgram5Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram5Member_label_en-US" xlink:label="lab_biib_ShareRepurchaseProgram5Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 5 [Member]</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram5Member_documentation_en-US" xlink:label="lab_biib_ShareRepurchaseProgram5Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 5</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram5Member" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram5Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareRepurchaseProgram5Member" xlink:to="lab_biib_ShareRepurchaseProgram5Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_7a71de5c-37ca-4c4b-a0a5-bec9b82b0c58_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f11cd156-5b4f-4f5b-ade8-b5c4b85aee3d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_4eb54e00-5dc8-40b8-a386-ea29ae7838dc_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20201231.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_053ebdab-8ace-4ee3-8caf-a6626cd1b2d9_terseLabel_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected license fee and regulatory milestone payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_label_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected license fee and regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:href="biib-20201231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:to="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductionInValue_22a01efc-6803-4c79-8730-03ef23128314_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductionInValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, value, reduction in value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductionInValue_label_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductionInValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxAssetsValueReductionInValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxAssetsValueReductionInValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductionInValue" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetsValueReductionInValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxAssetsValueReductionInValue" xlink:to="lab_biib_DeferredTaxAssetsValueReductionInValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_042750ba-923b-4d4b-b857-00fea004154b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_dfd160fb-7456-44ce-9ce0-07b2c2f4ec8c_verboseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_82bb16bd-930d-46e3-bd8a-077d8b543306_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20201231.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Investmentincommonstockvalue_92ed9f0b-7279-41ee-b97e-02619693ab4b_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstockvalue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:label id="lab_biib_Investmentincommonstockvalue_label_en-US" xlink:label="lab_biib_Investmentincommonstockvalue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:label id="lab_biib_Investmentincommonstockvalue_documentation_en-US" xlink:label="lab_biib_Investmentincommonstockvalue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstockvalue" xlink:href="biib-20201231.xsd#biib_Investmentincommonstockvalue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstockvalue" xlink:to="lab_biib_Investmentincommonstockvalue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c5c3fba4-b28e-44ce-9c31-9a296c0eb255_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ac648bc7-4508-48cb-a351-806a29e34937_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, contingencies and guarantees (Notes 21 and 22)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_58550d85-6b1c-474b-934d-c4f9aefee348_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c2c0f0de-b97f-4ed1-893f-1ccb909e4065_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0f58a8fb-4609-4c68-befa-5eebb24bc484_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_409d8e2c-a4dc-4b7a-85e2-7c087015367a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb4a24df-99b1-46b2-b4bf-04f8176a18de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_074d386c-a012-449f-b6a1-e98b0b38a841_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_108910c8-4759-4ddd-9c13-33672e04e3aa_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_7b85f447-5102-4657-9c9a-3159b0f7a214_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7d903eb9-9c22-4a6a-bb21-8c1b64c67eab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b2e7d11b-4cca-4810-b0b1-f69d545564c2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_724adfe1-7c94-4ed6-bd79-1985a6e1462d_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_2efc629a-becc-4e56-a816-00b1c7d59ac9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_c1d3317e-2767-4817-88a7-474cb9c92a42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2af0db36-f120-4cef-8bf6-bc2a102ecfdf_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_356a5e0c-ca77-4970-8708-505a209d1552_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_528be8ba-6b0d-4b71-9d25-a193b0744be0_terseLabel_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_label_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_documentation_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:href="biib-20201231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:to="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_d5708ef3-fb58-42a6-8131-3c291a27b401_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89727369-63ba-4437-8763-ad4ed7266b0e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_47d0dbce-dadd-4a40-9304-762307daaed6_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20201231.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_19e7260c-cf16-4883-b20b-9e93e4adc3b0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_0517e301-fbd8-410f-851a-5969c9563417_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_c11b12d6-10ea-4c4e-9d68-69136b8dc027_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_6f540e7b-f7f1-4a9a-8276-d5f082a1e2c4_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis, ownership percentage before additional purchase transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_f1190882-7908-475c-8369-ecc93de0af6e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_216b709f-3a0a-488c-ad03-a077478a489c_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_07fd37cf-d153-401a-8d22-48931ebfab7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_e09dc662-65e5-4388-b15e-ebebc357b68b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to increase investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_e7ab82c0-f08c-4a1a-a8a9-1205e39ccf30_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Market Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_documentation_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Market Stock Units Activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:href="biib-20201231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:to="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_e3cdb265-b4e3-4cab-9431-7a9d5eaddb7e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with the senior Nnotes offerings</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2015ESPPMember_29c559bb-76f6-419a-b070-488a338fc032_terseLabel_en-US" xlink:label="lab_biib_A2015ESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_biib_A2015ESPPMember_label_en-US" xlink:label="lab_biib_A2015ESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:label id="lab_biib_A2015ESPPMember_documentation_en-US" xlink:label="lab_biib_A2015ESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2015ESPPMember" xlink:href="biib-20201231.xsd#biib_A2015ESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015ESPPMember" xlink:to="lab_biib_A2015ESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_28641cd0-3153-434d-ae58-704e6f7917c4_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_69a42c15-7367-4377-ab7d-8cf0aea0295a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_9a82e28c-6190-462e-9078-754feb4d5b27_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_44c34418-d9aa-42b6-a986-25d6868772f0_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20201231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_d6ee6d24-49bf-40a7-ab81-e0278bbec575_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_8da365d7-9302-41fe-8c42-a41d6cbddd79_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_944dbffa-db64-4b27-aee2-b402d0525f8c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_6170d92e-35bd-4c9c-8ad9-685b96bed772_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_9bf32d33-6741-473b-9d69-4d310cbec769_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_a1018214-9f78-4f35-ab81-e1d860eabd40_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Other Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyrate_aef7d9f2-a51d-4fd9-8704-fa9edc43afca_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate" xlink:href="biib-20201231.xsd#biib_Reductioninroyaltyrate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate" xlink:to="lab_biib_Reductioninroyaltyrate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1dfa85f8-14eb-450e-99bf-853693ad7210_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f48e8f98-c72b-4490-ad12-7113bf4c8111_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total cost and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20201231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9d3ec2dc-0eea-45c6-a1fd-b46868dff8fe_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_33d8d23a-5286-4818-9fa4-39e3c620ce35_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e07c4cb2-5701-4755-9bc3-47538f3a5a02_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ede62673-4c8b-4e32-b3fe-66f99bdcc67e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_e8efa081-2815-4427-a1d1-3c201718a24a_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_5c2b4564-3e95-4df6-85e8-5cd1763ba338_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e66652b8-87f8-4c32-8cae-c986ae3d1d2a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c7aa9f78-890f-467e-ba79-203d7e2a5cc6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_b52284de-077b-4fcf-b218-7cdc3a135836_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_f8b26519-5ed2-4bda-a338-c05dbae28941_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_94449cb3-62c1-4363-8166-f2f43ac5ee10_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_2a611082-4abb-438c-910f-f669b8f61ec0_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BristolMyersSquibbMember_9bc151ce-308f-4f17-ba5e-5bbf571b41c0_terseLabel_en-US" xlink:label="lab_biib_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_label_en-US" xlink:label="lab_biib_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_biib_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BristolMyersSquibbMember" xlink:href="biib-20201231.xsd#biib_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BristolMyersSquibbMember" xlink:to="lab_biib_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_f39de710-2027-40c8-9e6f-fe283675d996_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_a2c57fc7-56c4-4ad2-8977-4324d9801e6d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductionInValue_5e248283-99e3-4bf6-96e4-3c0b17f2b0fb_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductionInValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, value, reduction in value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductionInValue_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductionInValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesValueReductionInValue_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesValueReductionInValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Value, Reduction in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductionInValue" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesValueReductionInValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesValueReductionInValue" xlink:to="lab_biib_DeferredTaxLiabilitiesValueReductionInValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb6df369-1aec-4aee-9c47-d9d75490bec4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_864fceb6-20dd-4dab-9ae4-e50bcd28f4e0_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20201231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_70991be2-7cbc-4842-9325-7ce16c5a1cc9_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:href="biib-20201231.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_27990bfb-4ac3-4d61-a3b7-872c6e851b9c_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20201231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1890b388-2e90-49d2-9c23-24ec892fccef_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1a4591eb-c9b9-4975-8ee1-1869f2acfb7d_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_56f8cf9d-71d2-4d0d-9568-0ea0bfd8cd59_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption percentage for change in control provision</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:href="biib-20201231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_d59de590-1ba9-4233-a3a5-d1ff8dc0fcb2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_549df318-8d76-47f3-b336-79635e70d30f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_d0a09d5e-16a7-4c99-97dd-672194b5fd49_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9fadd031-41e7-4c77-98a5-7b779acf281a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_4ac8c19e-e730-443e-bc0f-630f31073e4f_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_8f33f487-6501-4bff-a3a1-26b28daf5255_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_a9c85a6f-0935-45e0-b874-d0993a2c9943_terseLabel_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_label_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_documentation_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Premiumonpurchaseofcommonstock" xlink:href="biib-20201231.xsd#biib_Premiumonpurchaseofcommonstock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Premiumonpurchaseofcommonstock" xlink:to="lab_biib_Premiumonpurchaseofcommonstock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_c3a0d733-413d-472f-a36e-7f2bc7fe5b3b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_cbce8ff4-effe-4cf5-844b-e256aa835f3b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_bab11d69-e24a-4968-bcfd-f51103ffde32_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20201231.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_670d6149-be3d-47b7-930e-b7ac8fc2dd02_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20201231.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b930c723-d86e-44ed-9022-1ccf48611ee2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6d778a27-54c0-4f08-a7b6-1105486f71f5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_30d6080f-db71-4afd-aee7-2de542cd9812_terseLabel_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, in-process research and development, discount rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Indefinite Lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:href="biib-20201231.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:to="lab_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_908d82ca-47c7-48da-9f8a-82be80c92d96_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1d2c8b60-6b3c-4d1f-8a11-9dcdef2ac228_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_77556b6d-3b0d-4a35-8fab-cbbba8ccce8a_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_b9469c28-7639-4339-86ba-7251e8479be3_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected profit share percentage</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_e382eeaf-f828-431e-ba13-db906f10740c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7cfc867-8ca6-4629-878f-dca5785734b7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_bdf675a6-723e-436a-8d2f-4bf4b048933c_terseLabel_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties as per collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_label_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_documentation_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties as per collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:href="biib-20201231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:to="lab_biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_05f44ab6-669f-4a2b-b833-dfd15e52a4f2_terseLabel_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Each additional one billion up to twenty billion</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_label_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_documentation_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:href="biib-20201231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:to="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_e92f078e-9b3e-4eae-af5d-3d031357fa40_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_ce02315d-2932-440b-b4ec-dc89eb398c0c_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_8900ea81-d4da-4eae-960f-a6c22c075a01_verboseLabel_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_label_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_documentation_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:href="biib-20201231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:to="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d8d03733-e8a6-45cb-8a8a-019dd9dcc7f0_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AlkermesMember_87e4e86d-de16-4b3b-b976-e1ebb648ae0f_terseLabel_en-US" xlink:label="lab_biib_AlkermesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alkermes</link:label>
    <link:label id="lab_biib_AlkermesMember_label_en-US" xlink:label="lab_biib_AlkermesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alkermes [Member]</link:label>
    <link:label id="lab_biib_AlkermesMember_documentation_en-US" xlink:label="lab_biib_AlkermesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alkermes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlkermesMember" xlink:href="biib-20201231.xsd#biib_AlkermesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AlkermesMember" xlink:to="lab_biib_AlkermesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_06b5f0ef-0aeb-42ca-8d54-934f8ee01095_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20201231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c66e092d-aa42-404a-bf7b-bb82bdf02839_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DivestituresAbstract_c7399563-2e0b-45f9-9939-a6255ad252a5_terseLabel_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_label_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract" xlink:href="biib-20201231.xsd#biib_DivestituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract" xlink:to="lab_biib_DivestituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_19a3a6bb-a190-4f00-a802-6a6f7670b7f0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_307be8bc-e006-4bbd-99e6-2ad125260960_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8875595e-821d-48bf-bbb4-7dadd78f56f9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_80508218-48a4-4dcf-afec-61229b71d8ba_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest costs capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fb29e8e9-f3c7-4c42-be9f-975edae13e09_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_e68ff4a2-3385-491f-b1e1-daf7f3eb1e29_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ac1befbf-b820-4329-9ee4-e626ecb1b1fd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_5d75d2b4-0da8-4473-b9c7-89d619e82a88_verboseLabel_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize the cost of unvested awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_label_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Period To Recognize Cost Of Nonvested Awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_documentation_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize the cost of nonvested awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:href="biib-20201231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:to="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_4b4856ce-27cf-4df5-bd7a-c88ed6bf9045_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7c8a4078-947a-4287-9c69-9cbac52626a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and equity securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_200c6400-eb19-4567-8eaa-b3dd884d37fa_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_f1226d2c-b08d-4107-bac2-4b5272a2d3b4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_6136fb41-95ba-4a3f-a592-7b919f47b600_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_79a9925b-25a7-42df-9c6c-9265c03f9392_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_912ca37a-6be3-490b-b1f9-c36cfbdf7d6b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_31d03508-7285-4f0f-8278-b9152cdafe09_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20201231.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BioverativMember_d9a35048-3caf-4d58-b7fc-7876b0aaa49c_terseLabel_en-US" xlink:label="lab_biib_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_label_en-US" xlink:label="lab_biib_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_documentation_en-US" xlink:label="lab_biib_BioverativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BioverativMember" xlink:href="biib-20201231.xsd#biib_BioverativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember" xlink:to="lab_biib_BioverativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_7b280c3f-496e-4df2-88f5-b1cf76b3e0d4_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_be837c50-c5f5-4bbd-8e63-dd30ca45ba68_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfProductCandidates_32b2b309-d779-4731-913e-2a2a873c0821_terseLabel_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_label_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:label id="lab_biib_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_biib_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates" xlink:href="biib-20201231.xsd#biib_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfProductCandidates" xlink:to="lab_biib_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_6bed03c6-8d3f-42e1-8f12-d8a92c11e354_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_5411d171-44de-4e8b-863a-0b712c33ce66_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_6e1f644a-e6b5-44df-a96a-453483a8cbbe_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:href="biib-20201231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b2a2a640-9b6c-4683-b63a-b06e07718a97_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5e1f4faf-9d47-46c9-93a5-88c7edc40dd1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_27b708ae-6bd4-4e8e-9170-2b0e85f1c051_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_dfb1e90f-ce1e-462c-add6-23f379c814ad_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_0710f211-6e29-4950-82fe-ebf250a671ad_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets related to operations in Denmark</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_0a8c5b64-164c-4814-91ea-0c4b3e513bed_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_729212b9-122c-440f-bb40-cfa24da7e59d_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_3ae5f2ec-26d1-42a1-b774-6010c18a0879_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_17f3edb4-1c30-4ae4-900a-7a23295941ee_verboseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20201231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_bb3eadcb-c02e-4b99-9933-bd98a281b7d8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_8b15a434-83b3-4b11-9122-85ab713a9dab_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_dcad5ea5-74ac-4aa1-8d8f-b962576b9c99_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_6e373ed9-4e96-4c02-88db-3f2a2415f886_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_946328ea-50eb-47c8-bb69-17e6955f27b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b732ac40-1e75-4ab4-947f-0b8bfe6aed5e_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8fadfe40-1a46-4d14-8889-5f40c9ce3835_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax provision and the income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB118Member_42d8db4d-6be5-4a15-8ab3-490a8751f24f_terseLabel_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118</link:label>
    <link:label id="lab_biib_BIIB118Member_label_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118 [Member]</link:label>
    <link:label id="lab_biib_BIIB118Member_documentation_en-US" xlink:label="lab_biib_BIIB118Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB118</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member" xlink:href="biib-20201231.xsd#biib_BIIB118Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB118Member" xlink:to="lab_biib_BIIB118Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_217a3e56-ccac-448a-a025-40859467886f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_6519647f-0f62-462e-b229-c688f3d7ade2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_32daa1da-d0a3-413b-b2ac-0ac33a4bc934_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent" xlink:href="biib-20201231.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_ee33ccc1-88ef-4f92-b12c-6ad7adffa5a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_1ae70bb0-ef67-4ced-9c49-17a7d2ebe93f_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_eb87853e-2f87-4de1-be27-3e6024589ec9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_8f866fc3-e19f-4d95-9b0d-238bc611b5cc_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20201231.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_c805f7ed-7359-4ce8-b3d9-85c1cb2c2d09_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total basis difference</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_9270f81f-5b5f-475a-8431-e3c61e5ca43d_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_76a0c24f-a332-4b66-94f8-5137cb6322fd_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Cumulative sales level [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelDomain" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelDomain" xlink:to="lab_biib_CumulativeSalesLevelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0c15aae4-6d8b-4a0a-8313-1c48679c0e34_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_71663d59-98bf-49a9-a087-0b2d9125dd26_terseLabel_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total revenues</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_label_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_documentation_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:href="biib-20201231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:to="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_c0ef388f-41be-4ec2-80e1-ec706a5272e0_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Senior Notes due September 15, 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_d487f113-2e29-4ea0-9d1c-7010362910de_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_1ab0e2c7-70a1-4641-a42e-e8202e80c0fa_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on derivative instruments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_f6285960-3043-4fea-914a-eb4faa0dd365_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b0d570d1-f4e9-40c2-acda-2b0dd9548101_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_3e8232a8-6c6b-4cba-98e6-8c017795ff6d_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20201231.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_f6186276-69cc-45ce-a5a1-de24ae5b7c7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value hedge</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_19cf74b8-fb46-40c9-adac-923ddf5d9fee_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_f4d39242-75af-497b-b6fa-eccf93933dee_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_88755fe3-95b6-4d7f-be8f-a7aa3d647d8a_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a1b2c6ff-cd67-4a82-b334-29f92a471bb3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_d9aa8425-bec0-41f7-ac54-d523919a55ef_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1558d36f-9ee7-4745-8890-3fefb9233df7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_a03d907f-5d33-4b14-a3e3-097356bb1cbb_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock pursuant to the share repurchase program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_6258501e-666d-42f8-8296-a78d392db8ad_terseLabel_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Cost of Sales</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_label_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock" xlink:href="biib-20201231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyCostofSalesPolicyTextBlock" xlink:to="lab_biib_RoyaltyCostofSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c0749348-e5df-4439-a253-962d42916f46_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_4d87dcd2-ea2e-4b66-9d43-0d2f5eea08b1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_e4a37b29-ca1a-4767-8db1-4db3e0132060_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, other reserves and accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_50281159-aa88-4783-9217-16160d260920_verboseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OCREVUSMember_40720117-e6e9-4ab8-8adb-5e859d0fdd8b_terseLabel_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCREVUS</link:label>
    <link:label id="lab_biib_OCREVUSMember_label_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCREVUS [Member]</link:label>
    <link:label id="lab_biib_OCREVUSMember_documentation_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember" xlink:href="biib-20201231.xsd#biib_OCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OCREVUSMember" xlink:to="lab_biib_OCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_322084cb-040a-4b49-bc6c-0ca8fa0a174d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_c21b5106-e932-45a2-946e-10bf3b7a9dce_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:href="biib-20201231.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b3a1cd6d-6505-4148-b179-4a026d11fa4a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense asset acquired</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ClinicalAssetsAcquired_23afdb0f-853e-449d-a769-67f5d4396634_terseLabel_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical assets acquired</link:label>
    <link:label id="lab_biib_ClinicalAssetsAcquired_label_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:label id="lab_biib_ClinicalAssetsAcquired_documentation_en-US" xlink:label="lab_biib_ClinicalAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalAssetsAcquired" xlink:href="biib-20201231.xsd#biib_ClinicalAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ClinicalAssetsAcquired" xlink:to="lab_biib_ClinicalAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingleaseassetsMember_a2decad5-2949-4827-8b4a-e666320acec1_terseLabel_en-US" xlink:label="lab_biib_OperatingleaseassetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_label_en-US" xlink:label="lab_biib_OperatingleaseassetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:label id="lab_biib_OperatingleaseassetsMember_documentation_en-US" xlink:label="lab_biib_OperatingleaseassetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingleaseassetsMember" xlink:href="biib-20201231.xsd#biib_OperatingleaseassetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingleaseassetsMember" xlink:to="lab_biib_OperatingleaseassetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5aeb1596-9cd7-4895-9b24-991b5a897293_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Country</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_c9d6abc1-08fa-4bf1-af73-291ba91ea49a_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20201231.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_7d37030b-cac6-48d4-b1dd-3197539730a3_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2020SeniorNotesMember_b29dacae-a1da-4614-82af-677379c1b69f_terseLabel_en-US" xlink:label="lab_biib_A2020SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Senior Notes</link:label>
    <link:label id="lab_biib_A2020SeniorNotesMember_label_en-US" xlink:label="lab_biib_A2020SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Senior Notes [Member]</link:label>
    <link:label id="lab_biib_A2020SeniorNotesMember_documentation_en-US" xlink:label="lab_biib_A2020SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020SeniorNotesMember" xlink:href="biib-20201231.xsd#biib_A2020SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2020SeniorNotesMember" xlink:to="lab_biib_A2020SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_bf0f6c8b-4736-4a0b-9dad-9135767ba3bc_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, gross unrealized losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_52218dc6-6c27-4729-bd86-fa0431dda149_terseLabel_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of operating leases</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_label_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:label id="lab_biib_LesseeLeaseTableTableTextBlock_documentation_en-US" xlink:label="lab_biib_LesseeLeaseTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Table [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock" xlink:href="biib-20201231.xsd#biib_LesseeLeaseTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LesseeLeaseTableTableTextBlock" xlink:to="lab_biib_LesseeLeaseTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_beb7966a-0600-4db5-bea2-927be6fa9ad2_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration, shares purchased, amount</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Amount, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_ebc07649-f92e-49e4-b7b0-3d918116c19d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_8a8df7b9-4e17-4ae3-8e1e-90793829f658_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20201231.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_ea23cef1-a8af-4aa2-9c8e-c1b8db58b875_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_34ef7700-13dc-4f13-b137-ee84f38492d0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_ef5c4446-e376-4781-8337-76e2d53d2e0b_terseLabel_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_label_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_documentation_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:href="biib-20201231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:to="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3123105c-6d9c-478a-b22c-332834345473_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_22b61f2f-4878-4304-a4bd-b651267693aa_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20201231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_6735de6a-3b44-41ee-9b77-5475e131be1a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair-value post-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_4c66e833-37c3-4a44-a995-5ee91e9a0089_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NST stock options</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_c03771a6-fd60-4753-8e6f-b11fae535ee9_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_456f2c2b-92fe-43f8-8bff-426324ab5e9a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_91e23b8b-5dc3-491f-93bf-39837f9fb6c9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_4e46132a-a1ff-46ac-baa3-6673812684a1_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones_1a0ac5e5-53f2-4c44-9796-1f559d964315_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration, payment,first milestone</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_eff946cc-c9d0-4c42-96d9-8270a44ac6ff_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c3ab780d-2e51-426b-bc22-04e45b3cbcbd_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_a7334b15-3ec5-4682-997c-cb1a6121b6ee_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_6aeda24d-b445-483c-a906-42e0b7193b04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_bb378ec2-b1df-4bc5-bd83-fe2cb9cdb220_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_6215ca69-00b5-4e7b-a8d3-765be46162f3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_823c90b1-50d1-47ee-adf3-b3fac643f80b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_eadbd075-e2cc-4c82-83d7-9df14a0f5709_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9ac1a4bb-8543-412e-8839-b3d9bfb20f37_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_8dd1eecf-341f-45b8-98e1-340518159054_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e64382dd-25a8-408b-b714-5cb5bd757570_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7f38980b-4484-4e13-bf20-251d604a0118_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_9e5281aa-2763-49d2-af3b-4cf5e9d05fa5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_e040dbee-c6ca-4ff5-b4d8-749cddb0c885_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1a69a8f8-dc71-4734-99db-e9f9ed9a5c3c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_b76bc071-92ba-4e7f-b463-5ba68d00551d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bf0c8c3c-9848-48a0-9f7a-a6296844e6a2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_2742f728-6bd3-414d-8160-8f3ab5e162ce_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_67bc3351-432a-450f-8abc-d8ac907245c1_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment hedge</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_cb3c2347-4a60-49e9-8112-406f5fa43a14_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount of share repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_b03b1a8a-c01f-4d15-ba47-d6be373d041b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on derivative instruments, net, pretax</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_94dacd78-9338-446f-ac5b-26d5c1a111cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_d3ba014b-67c6-444a-98d4-ca676078c83c_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_4c49aac8-efe4-4728-b0fe-2ce369979756_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_fe085b69-4730-484f-9481-dbfee0d8136c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_05ed46a9-f31f-45e1-a16f-1f7032c32309_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4d93a16a-8a36-4373-8cc5-22b54bdd339c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1d123ac0-48a1-4ddb-8a87-0cfc104f4b4c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, contract term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_e6b96ad4-a639-4544-b2eb-617a73fe8cb2_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration, purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Purchase Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInCommonStockSharesPurchased_4cf8f1c0-3eb6-4127-ae31-07d5543f2f8e_terseLabel_en-US" xlink:label="lab_biib_InvestmentInCommonStockSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in common stock, shares purchased (in shares)</link:label>
    <link:label id="lab_biib_InvestmentInCommonStockSharesPurchased_label_en-US" xlink:label="lab_biib_InvestmentInCommonStockSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Common Stock, Shares Purchased</link:label>
    <link:label id="lab_biib_InvestmentInCommonStockSharesPurchased_documentation_en-US" xlink:label="lab_biib_InvestmentInCommonStockSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Common Stock, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInCommonStockSharesPurchased" xlink:href="biib-20201231.xsd#biib_InvestmentInCommonStockSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInCommonStockSharesPurchased" xlink:to="lab_biib_InvestmentInCommonStockSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxChargesMember_66df0f5a-e0a0-45df-b20f-6a21bbd011d1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Charge</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxChargesMember_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Charge [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxChargesMember" xlink:to="lab_us-gaap_DeferredIncomeTaxChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4718b805-26b1-44fc-9618-37c77e309dd7_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_75e3896c-7042-440e-88aa-d39257e6f3c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1c12ae52-66ee-4e78-b4b1-5e7c236fe252_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_2a4eb7b8-fceb-476a-8beb-ed43a526df01_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d92f5880-2552-46d9-93d1-2b987938fe70_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_03a39f06-942d-4a13-91da-7e3983b2b797_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_50395e61-1bde-4b1d-9d11-fa21c7a29071_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_76f22679-1434-4bc0-9f70-ae9469be72f2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3f202756-4991-4931-af59-ce8d2f35ab42_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to the share repurchase program, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_50c06f31-556a-41e4-9472-618fd7aa94cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_edda6ee7-1821-43c9-b1f3-e5781f3b5abb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_389cd38d-6d67-4f4a-8f2b-7bc59fde093d_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_bdfcadab-a082-4b0a-a147-572e9829e863_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20201231.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_192f947c-e227-413a-8eeb-49eadc4a653e_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_8a107010-89e4-45cd-9005-dfbc1af5e5e0_terseLabel_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_label_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_documentation_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undesignated preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UndesignatedPreferredStockMember" xlink:href="biib-20201231.xsd#biib_UndesignatedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UndesignatedPreferredStockMember" xlink:to="lab_biib_UndesignatedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_6f5c389f-bfd2-4940-b807-6fbd6f949adf_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_a284ac7a-14f5-49d4-a77b-936bfc565bee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_76263cae-fe32-4b63-b689-8cf6706f73d5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_18b5c5d2-3c52-4589-8b35-a8a7cbfd5423_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationProfitSharing_5e106c77-c870-4831-aee2-6de052027629_terseLabel_en-US" xlink:label="lab_biib_CollaborationProfitSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_label_en-US" xlink:label="lab_biib_CollaborationProfitSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_documentation_en-US" xlink:label="lab_biib_CollaborationProfitSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharing" xlink:href="biib-20201231.xsd#biib_CollaborationProfitSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationProfitSharing" xlink:to="lab_biib_CollaborationProfitSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_117dd0d4-7c79-466c-854e-8f2d2a50ca20_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_012487aa-1951-4080-bf0f-1f1b831cb579_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MajorDistributorDomain_c733deed-f4d2-45ec-abf2-bf3d26ebc692_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_label_en-US" xlink:label="lab_biib_MajorDistributorDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_documentation_en-US" xlink:label="lab_biib_MajorDistributorDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MajorDistributorDomain" xlink:href="biib-20201231.xsd#biib_MajorDistributorDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorDomain" xlink:to="lab_biib_MajorDistributorDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_005e4406-229a-4027-81f9-ae109da0b39f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_0f591288-429b-4742-964a-50c5e9f79187_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5958fa6c-b064-4309-8232-105f09b49120_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_c758498a-f314-4106-9c8f-eecca9b34241_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3cac8ae0-ed1c-4756-8064-5933e52bef28_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralBusinessMember_902b203b-20b3-40ec-b4db-63ae628d8b71_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Business</link:label>
    <link:label id="lab_us-gaap_GeneralBusinessMember_label_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralBusinessMember" xlink:to="lab_us-gaap_GeneralBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_72bdc799-8e84-441e-be9e-07208ac7156f_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Termofcollaborationagreement_31643ee4-e537-4120-b382-0f01d76efd9f_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement" xlink:to="lab_biib_Termofcollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_9443dd05-c08a-442f-9940-5a5347b1ad4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DisputedClaimsRelatingToConstructionCosts_55302c1a-7b20-4eb2-b21d-fc56141940c7_terseLabel_en-US" xlink:label="lab_biib_DisputedClaimsRelatingToConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disputed claims</link:label>
    <link:label id="lab_biib_DisputedClaimsRelatingToConstructionCosts_label_en-US" xlink:label="lab_biib_DisputedClaimsRelatingToConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disputed Claims Relating to Construction Costs</link:label>
    <link:label id="lab_biib_DisputedClaimsRelatingToConstructionCosts_documentation_en-US" xlink:label="lab_biib_DisputedClaimsRelatingToConstructionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disputed Claims Relating to Construction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DisputedClaimsRelatingToConstructionCosts" xlink:href="biib-20201231.xsd#biib_DisputedClaimsRelatingToConstructionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DisputedClaimsRelatingToConstructionCosts" xlink:to="lab_biib_DisputedClaimsRelatingToConstructionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a2c0e2f-32f0-457d-a291-73f914cdb95c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_4fdb6e6b-1813-4f63-ad58-19751336fa31_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e57a31b5-8c0b-462d-ba1f-2af169b19649_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_bc0d6420-d129-412c-8960-580c73975c97_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic pension cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_42ba8a3a-b86b-4563-ab23-b64a4f4d5466_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_bc442a8b-df8d-49eb-8bf8-5757c583609d_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_801786d5-fd22-4b9b-964e-cc6a51b510e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_727b79ed-a7ad-406b-a4d0-b849167095d0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5a8dcf33-03a4-4895-8806-82bce746080a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ef3ba2d0-4875-40dd-b8d4-a8f6aad14d5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_43ae0a88-d558-4096-b91b-c2107ca85bb2_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_69ade3c0-ee80-4747-bed8-05d189488836_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_295b51f7-f59c-418f-885a-d0b34f4845e0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_1bdaa951-5223-414d-998d-5da0714d80f1_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal: Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20201231.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f7e1e148-7fea-4268-98d1-5ef46e77cc0d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments_b88b2bf6-c0ba-45d0-8fb7-907ecc200969_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration, development and commercial milestone payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_3768f3cd-2af5-4d18-a85a-399ea1307175_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3efb6ca5-0cd8-4898-8a82-25a4ba8f71b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divesiture of Hillerod, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fcb3edf4-5ee4-4632-8e77-2084c2fb608d_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f2145b36-7a95-4625-b126-f10d2cd052ba_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Book Value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b7bc286f-4a9a-4530-90e6-c7c890482ea4_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_3e4303b2-6f87-42e7-a63f-0bc140c998c5_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_4c4edd31-8314-4dc2-83b7-adfbe0a0d171_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_63308a0b-04bd-4040-96e9-cb96e09e0faf_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment estimated useful lives</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property plant and equipment useful lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:href="biib-20201231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_3c86f0a6-67ec-4a0c-a553-b85d51140a98_terseLabel_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_label_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Omnibus Equity Plan [Member]</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_documentation_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2017OmnibusEquityPlanMember" xlink:href="biib-20201231.xsd#biib_A2017OmnibusEquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2017OmnibusEquityPlanMember" xlink:to="lab_biib_A2017OmnibusEquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_e64fad22-067a-436b-a9d3-202f0b15c50e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d373117c-98a1-4508-b3c9-1d660c9b9c6d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NightstarMember_9ebcab58-26e5-4cee-adb1-95bf1d63da1c_terseLabel_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar</link:label>
    <link:label id="lab_biib_NightstarMember_label_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:label id="lab_biib_NightstarMember_documentation_en-US" xlink:label="lab_biib_NightstarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nightstar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NightstarMember" xlink:to="lab_biib_NightstarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_e847b502-9872-43a7-a81b-961892790763_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_51d02215-4476-4221-b047-c726680b9090_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_8d9beec6-6fd5-4b02-9bbb-91244484050b_terseLabel_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convergence Pharmaceuticals</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_label_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_documentation_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ConvergencePharmaceuticalsMember" xlink:href="biib-20201231.xsd#biib_ConvergencePharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConvergencePharmaceuticalsMember" xlink:to="lab_biib_ConvergencePharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a4231670-16d3-4f4c-bded-6e5b7dcaeed1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dcc879d9-d719-4998-974a-0243502a1adb_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_e6f1aaeb-76a3-495f-b6c8-2a82d6d343e2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_c7b79fee-ce1b-492d-99cf-7855928b6c92_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_b95baecd-b5d4-4151-91a7-0aff91142dd1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_2399b0f7-60bc-413b-bf1f-535fc203a8fa_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20201231.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_f3b2f0fc-23b6-40c0-be05-19b7b429321b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_9ad249a9-b84c-4939-8d96-8831543b1396_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_ecca3525-9cdc-47a3-9737-9cf9f6d3f4a8_verboseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20201231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4ffb0f66-53a3-4e0f-9fa1-15c2ef78343b_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c96c69f7-ff35-4146-90e0-f8040c6f5a23_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net profits on investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_U.S.2017TaxActMember_54478025-ad40-47da-9049-63dc5ce25b30_terseLabel_en-US" xlink:label="lab_biib_U.S.2017TaxActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_label_en-US" xlink:label="lab_biib_U.S.2017TaxActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. 2017 Tax Act [Member]</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_documentation_en-US" xlink:label="lab_biib_U.S.2017TaxActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. 2017 Tax Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_U.S.2017TaxActMember" xlink:href="biib-20201231.xsd#biib_U.S.2017TaxActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_U.S.2017TaxActMember" xlink:to="lab_biib_U.S.2017TaxActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a300786b-8ce2-42fd-a205-c129b4b0fb07_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_bb216517-e8e4-42b3-94f7-b0055b60f126_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20201231.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_799ca436-3a2b-45c1-9eb5-b2f6f3910c9e_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due September 15, 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20201231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_20ec8a15-561a-4353-a556-67eb3c99fb70_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_ebcb960b-37a0-4b75-af63-878d4bc197fb_verboseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment, approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20201231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_5cb24e7f-316d-46b4-b897-4808891cad41_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareRepurchaseProgram1Member_bfa12cc0-78de-4775-9ca3-7f3633a4deb7_terseLabel_en-US" xlink:label="lab_biib_ShareRepurchaseProgram1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram1Member_label_en-US" xlink:label="lab_biib_ShareRepurchaseProgram1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 1 [Member]</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram1Member_documentation_en-US" xlink:label="lab_biib_ShareRepurchaseProgram1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram1Member" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareRepurchaseProgram1Member" xlink:to="lab_biib_ShareRepurchaseProgram1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_713bba16-6fa2-4283-8429-afb5987bfb3b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e7181593-175d-4778-ac94-13d18fed0faf_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_b71d5577-b47e-4ebf-9be1-10a2ff6b515b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6f8119e1-9e03-43c7-afd8-a17439700d90_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f6118234-14b2-4a79-b35a-87eb1667d77b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_71f53792-123c-49f6-bab8-08e70828713d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit realized for stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_d921f6a0-f18a-4ecf-ade7-512ebf92c309_verboseLabel_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_label_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses On Funding Commitment Related To Clinical Research</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_documentation_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses on funding commitment related to clinical research.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:href="biib-20201231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:to="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_6355a6c2-2b0e-4d1d-bd1b-6ab49d32cbcf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_2e48bbb2-e9aa-49d3-b08a-a84cb27b0707_terseLabel_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_label_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture OwnerShip Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_documentation_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture owner ship percentage by third party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty" xlink:href="biib-20201231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_JointVentureOwnerShipPercentageByThirdParty" xlink:to="lab_biib_JointVentureOwnerShipPercentageByThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9f8f612c-a463-4560-9209-5e2a5ce7f821_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_ea5382a8-617d-4f7e-baeb-1be8cac5979b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received for sale of Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ForeignearningstypeAxis_399dc34e-a678-4535-96c4-95bb56e069bd_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_label_en-US" xlink:label="lab_biib_ForeignearningstypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningstypeAxis" xlink:href="biib-20201231.xsd#biib_ForeignearningstypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeAxis" xlink:to="lab_biib_ForeignearningstypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_bf106d62-a5bc-4fb4-8d9b-de5edd934a32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of gains or losses on assets measured at fair value, nonrecurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_4d86fd09-a461-4204-b58b-66d1c1d36fbe_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ade1c97a-c964-4ce4-b979-0c5434f504ef_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareRepurchaseProgram4Member_ca99e6ab-12f3-4654-8e22-fae318900a1e_terseLabel_en-US" xlink:label="lab_biib_ShareRepurchaseProgram4Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Share Repurchase Program</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram4Member_label_en-US" xlink:label="lab_biib_ShareRepurchaseProgram4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 4 [Member]</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram4Member_documentation_en-US" xlink:label="lab_biib_ShareRepurchaseProgram4Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram4Member" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram4Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareRepurchaseProgram4Member" xlink:to="lab_biib_ShareRepurchaseProgram4Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_c707dd9d-f361-4473-9aec-e5085cc88da4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_9f12dbb7-94d3-4ade-bae3-d7c18d66dc99_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:href="biib-20201231.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e20a0a1b-0df7-45b6-a49d-629e15f644e5_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_5850eb55-0fc8-4b2c-91d8-4efb9c43332d_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_7c0ba71a-e1a6-4bc0-89c5-6d9633b18359_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de80d518-e8e6-4904-b956-39cb7455c684_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_06d7e910-74cc-4e37-9894-8f8fe770637e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_9c8c2e79-a375-4ae8-9e6d-7304535b0771_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_8c0d61fc-3727-47ff-83ac-0ec53b6acd00_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss tax reform</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:href="biib-20201231.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WorkinprocessMember_5a7a2fe3-673b-4024-a4a2-620222ffd5b2_terseLabel_en-US" xlink:label="lab_biib_WorkinprocessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_biib_WorkinprocessMember_label_en-US" xlink:label="lab_biib_WorkinprocessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_biib_WorkinprocessMember_documentation_en-US" xlink:label="lab_biib_WorkinprocessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkinprocessMember" xlink:href="biib-20201231.xsd#biib_WorkinprocessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkinprocessMember" xlink:to="lab_biib_WorkinprocessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_281697ef-da98-4e9b-965c-c4b2309bb087_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VUMERITYMember_bcd174f7-b30e-4249-9db0-94a6e18f1b3a_terseLabel_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY</link:label>
    <link:label id="lab_biib_VUMERITYMember_label_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:label id="lab_biib_VUMERITYMember_documentation_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember" xlink:href="biib-20201231.xsd#biib_VUMERITYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VUMERITYMember" xlink:to="lab_biib_VUMERITYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_d7be0436-db98-430d-b375-10bf86e0f17c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2c5e232a-cf49-400f-b104-9508e52b331f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_4ecf78a7-40ad-4ee5-8fc1-b58f3a141eb6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_251f749c-658e-435b-966f-ba3b79cc4273_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangible asset</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_53a4bb40-55bf-46d9-aa42-9096f9261163_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net contribution (distribution) to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b86aaee5-ac75-4625-af39-b80ab377ebd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6dd38d34-c28a-4f13-b593-496285eb7166_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_c1980583-6a63-41d2-b296-290a9be47a97_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_73c30d07-383b-4294-b713-9ba11e7266eb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_52461b31-087e-496c-8b3e-fb160e956100_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received under the 2015 ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_451801ff-37ea-4644-9ef6-1edf568f5b93_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_37bd43e5-465b-4705-b64a-60db637b7870_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OthercorporaterevenuesMember_991c665b-f27c-45c3-ac0b-92e117b9b119_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember" xlink:href="biib-20201231.xsd#biib_OthercorporaterevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember" xlink:to="lab_biib_OthercorporaterevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1e149fdb-b7ee-4ba2-894a-f0374e661f7b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_8c782813-b0d5-407d-80be-a8c50755fc15_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_cd71a749-1af6-4ef9-b005-86c28909a3c8_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_99abebc4-1c27-4d59-91c9-e84d96609030_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_84583c6f-6873-428f-b458-19e52bcd70b1_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_dc5e7679-f147-402b-b850-cde0f32113a3_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_093da251-caf2-4658-8214-24aa8b1f4110_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_3cbd6dd5-28d6-455d-bf0c-edbcdc68a072_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PurchaseCommitmentReductionOfAmountCommitted_158f3cf9-7809-4e23-b240-d2d838d49df6_terseLabel_en-US" xlink:label="lab_biib_PurchaseCommitmentReductionOfAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, reduction</link:label>
    <link:label id="lab_biib_PurchaseCommitmentReductionOfAmountCommitted_label_en-US" xlink:label="lab_biib_PurchaseCommitmentReductionOfAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Reduction of Amount Committed</link:label>
    <link:label id="lab_biib_PurchaseCommitmentReductionOfAmountCommitted_documentation_en-US" xlink:label="lab_biib_PurchaseCommitmentReductionOfAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Reduction of Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PurchaseCommitmentReductionOfAmountCommitted" xlink:href="biib-20201231.xsd#biib_PurchaseCommitmentReductionOfAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PurchaseCommitmentReductionOfAmountCommitted" xlink:to="lab_biib_PurchaseCommitmentReductionOfAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_138a14f0-c26a-403e-ae96-a08d329e2029_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_7153148f-da44-4524-a532-09b313ef4ff0_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_55578b06-9b98-464b-95a8-edfec9617019_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions by third party</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_label_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_documentation_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments by third party in joint venture as per agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:href="biib-20201231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:to="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eeee8580-94f2-4fd2-8e04-b02c2487f267_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_085238ef-6a54-4ddc-8cac-e51903489a83_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1eee6f7-d5be-4d64-872e-65713b806a18_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_742fb55b-4f0a-4e73-b65c-a1919d8cb677_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_3f57b7c0-697f-4371-b553-7e2500bc5f10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_d6c36294-9ad8-4107-bf70-8294b296c4b0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_861fd825-a4e5-4191-8008-664389e1e56d_negatedTerseLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/returns relating to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20201231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_ce0c77da-e906-465a-871b-dec1f11d715b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e49a384-c11a-4122-9f25-d7211cce7432_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_0fff5be2-bc0c-4b12-9477-c18ad8bfa49b_terseLabel_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_label_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:label id="lab_biib_LongtermoperatingleaseliabilitiesMember_documentation_en-US" xlink:label="lab_biib_LongtermoperatingleaseliabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember" xlink:href="biib-20201231.xsd#biib_LongtermoperatingleaseliabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongtermoperatingleaseliabilitiesMember" xlink:to="lab_biib_LongtermoperatingleaseliabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_a094b085-0c2e-47de-95c9-e542858b2723_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c90f2d24-0be9-4a4d-b196-8b20bd24624d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_214d7645-a422-421f-9123-44fd2345b4e8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_da06eb8b-946c-4657-9c1a-ddf02e9c5ce1_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance units</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember" xlink:href="biib-20201231.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember" xlink:to="lab_biib_CashSettledPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_55f36c17-aae4-4691-be66-4fb145c24af5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_0ff1d3f1-d14e-4cbe-a72a-b8d03bea5608_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b3c9ed68-ad04-4d80-9045-60d3b7ef5455_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f6629bb-bbbb-4aee-a31d-3322fb7613aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96156a53-06a6-41da-8702-2356afdd3afb_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_380c3baf-fb7d-4880-b824-78f42beac7c5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DevelopmentMilestonesMember_b9aa56a2-28c4-4b1c-b2bf-2318d0a01974_terseLabel_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_label_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_documentation_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DevelopmentMilestonesMember" xlink:href="biib-20201231.xsd#biib_DevelopmentMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentMilestonesMember" xlink:to="lab_biib_DevelopmentMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_a27d50c0-d7be-4789-9055-8abb260764ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statute expirations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2e5044ce-7088-4a5e-9ff7-a4f6198b9d0f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_ffa2c8e3-7f03-435d-866f-8cc68c7650e6_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20201231.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_b4946642-c662-4a6f-9da4-3bcfb81f9c93_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5b415c40-9ac8-406c-95ce-1d7a9f46b025_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_4b9e2d82-c5ce-42ca-8420-1b77f68ad7ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_15e52c22-f8a4-46b8-8e0e-31dde81af989_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_633c68ad-2214-442a-8540-c2cee0549cd8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dcca1829-4129-440f-93ff-39f9dce6fe51_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d3ea2802-9354-440c-9223-1c0486230efd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_91b87746-f5b6-46aa-84c7-62d44ad56e45_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6a47398e-d7c8-4c37-a314-a622179e1688_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_57afc7d7-9048-41ff-88b8-c8fd4e7586e2_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_547424bf-bc71-43f1-aff7-a89c8f133b33_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20201231.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_87c03ded-b0a0-4c61-8bff-a2ca8e6b816d_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2da39902-510b-4a6b-8523-6fd47b004236_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4f836eac-bb74-4698-86c7-004bbd866843_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_cec6c67a-b1fb-410b-8281-35e34211b5b1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_adb60957-a8df-486d-b343-86705086d9ee_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_150cf7f0-a846-4f72-9c65-ee9d43a89d9f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bacd2504-45cb-4ebf-b0dd-a875f7e5dc16_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_06086d45-64b7-446f-b438-e21c1bf15111_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_d78b86b8-4e4a-4121-a6f3-65c37143d281_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities, current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7b044ea4-6a03-41f1-8ef9-857b05033d58_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_92deebf2-9b38-4f9f-bb30-8eac1ceadd55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_d901efb2-a281-43fd-b909-4a4c0136f073_terseLabel_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Common Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock" xlink:href="biib-20201231.xsd#biib_SummaryOfCommonStockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfCommonStockTableTextBlock" xlink:to="lab_biib_SummaryOfCommonStockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_5842d781-9e24-48db-8002-2db5965993df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_47a48dca-1b6a-4158-a855-4ede0c0a02f8_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to Neurimmune</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6eba6647-ea90-47d8-9a53-b615fd28f22a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_7cb478a9-9ec2-4745-8730-4ceab4bf18f9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1724c73e-6514-41f0-a5c0-21314727215b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_025c8f04-2fe8-4f43-b686-8fa17f984edd_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_8a1beedd-370a-4081-8c36-59f718364b93_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total aducanumab collaboration third party milestone expense</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1a305ba0-2e65-45eb-9606-6e8e119f287b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment sold to Fujifilm</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TGNMember_63fd2c72-e8e4-48df-b314-febbd2a4bab5_terseLabel_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:label id="lab_biib_TGNMember_label_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_documentation_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember" xlink:href="biib-20201231.xsd#biib_TGNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember" xlink:to="lab_biib_TGNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryMilestonesMember_35fbfe88-a673-414b-b30d-8b46f591c4ff_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember" xlink:href="biib-20201231.xsd#biib_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember" xlink:to="lab_biib_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DirectorsPlanMember_c46bb82e-1614-4d68-87c6-069d7022a534_verboseLabel_en-US" xlink:label="lab_biib_DirectorsPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors Plan</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_label_en-US" xlink:label="lab_biib_DirectorsPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors Plan [Member]</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_documentation_en-US" xlink:label="lab_biib_DirectorsPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DirectorsPlanMember" xlink:href="biib-20201231.xsd#biib_DirectorsPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DirectorsPlanMember" xlink:to="lab_biib_DirectorsPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DividendYieldPercentage_a2c7ae1a-68c5-4f0c-87a1-02c4d956c4d5_terseLabel_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_label_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:label id="lab_biib_DividendYieldPercentage_documentation_en-US" xlink:label="lab_biib_DividendYieldPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage" xlink:href="biib-20201231.xsd#biib_DividendYieldPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DividendYieldPercentage" xlink:to="lab_biib_DividendYieldPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_e6464cb7-1baa-4c2f-ba20-cd0b8edfa98b_verboseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_label_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantees [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesTextBlock" xlink:to="lab_us-gaap_GuaranteesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_8a6c3123-bce7-4b79-8d2d-265a47ce63bd_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c6d9f26a-2856-446a-a67f-8e25117d4f51_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f74c52be-b2e8-42e9-bfb4-67b42cc5fb89_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f61fd3ab-2bdf-41df-8b86-048ee6028e06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareRepurchaseProgram2Member_823492f0-ec10-4844-aaad-63bd662ef4e4_terseLabel_en-US" xlink:label="lab_biib_ShareRepurchaseProgram2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram2Member_label_en-US" xlink:label="lab_biib_ShareRepurchaseProgram2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 2 [Member]</link:label>
    <link:label id="lab_biib_ShareRepurchaseProgram2Member_documentation_en-US" xlink:label="lab_biib_ShareRepurchaseProgram2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram2Member" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareRepurchaseProgram2Member" xlink:to="lab_biib_ShareRepurchaseProgram2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_a5e9eb4b-c7d3-4c8e-94b7-2ec37151f2ed_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_52c97886-f711-4db0-92c7-49a06c55fc9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_3f87a1d0-8e44-4edb-a280-63eeee11f628_terseLabel_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_label_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:label id="lab_biib_InventoryrawmaterialssoldtoFUJIFILM_documentation_en-US" xlink:label="lab_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory raw materials sold to FUJIFILM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:href="biib-20201231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:to="lab_biib_InventoryrawmaterialssoldtoFUJIFILM" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f1b4d136-1dc2-4183-a62b-f8abc00b683d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_eb0073fa-e35d-4de4-8aef-0c479b47b42d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under the 2015 ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1218f296-d790-4039-b690-a23a9daf8089_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_fc5afd13-4224-49b0-b901-bd1de1d71711_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenominatorAbstract_a50316df-5c8d-4732-b273-b1375fc36208_verboseLabel_en-US" xlink:label="lab_biib_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_biib_DenominatorAbstract_label_en-US" xlink:label="lab_biib_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_biib_DenominatorAbstract_documentation_en-US" xlink:label="lab_biib_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenominatorAbstract" xlink:href="biib-20201231.xsd#biib_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenominatorAbstract" xlink:to="lab_biib_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6597cbab-1d66-4498-92aa-6cb4de4b9194_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_183d9c2a-f5dc-47bb-a9ec-071dbb74b942_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_8c63c511-b9df-457c-a45c-8d2fd595bd67_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111Member_a4cca7e6-c83f-4d74-be6a-f516682153cc_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_label_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_documentation_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member" xlink:href="biib-20201231.xsd#biib_BIIB111Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member" xlink:to="lab_biib_BIIB111Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EuropeanUnionMember_dce97811-817e-4320-9ea7-f66354437d27_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember" xlink:to="lab_us-gaap_EuropeanUnionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e995a761-1e4e-4738-99bc-e777987a2e33_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_9d1d8cea-3b9d-4b27-b0fe-37abc53430ee_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20201231.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB112Member_5aa50350-41f9-48a4-96c3-bd6ce24118c3_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_label_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member" xlink:href="biib-20201231.xsd#biib_BIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member" xlink:to="lab_biib_BIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_abff14af-93a8-4eeb-8bbf-28beafc163dc_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7cfa5d8c-5be5-4c76-bd10-106a0ac3092b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossOnContractTermination_402a83c6-a72e-41a1-8a70-a619f29403a5_terseLabel_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on contract termination</link:label>
    <link:label id="lab_us-gaap_LossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_LossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossOnContractTermination" xlink:to="lab_us-gaap_LossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3d3d4194-94ab-456d-afae-f550de310a89_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fa754262-ccbd-4e65-a942-85dc8b9cb485_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_daf99c29-7a5c-4cbb-8eb7-3c0d7d38f97d_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_bc02931e-9a14-44e9-b9bc-b3db1c7cd474_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_af5487bc-e4d5-4a52-9ebf-4cc828fa1bbc_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20201231.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_cb6fa2df-2ad1-49ed-af06-3d4fabe450dc_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB054Member_887c229d-1005-466d-9d28-fe10b784aa6c_terseLabel_en-US" xlink:label="lab_biib_BIIB054Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB054</link:label>
    <link:label id="lab_biib_BIIB054Member_label_en-US" xlink:label="lab_biib_BIIB054Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB054 [Member]</link:label>
    <link:label id="lab_biib_BIIB054Member_documentation_en-US" xlink:label="lab_biib_BIIB054Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB054</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB054Member" xlink:href="biib-20201231.xsd#biib_BIIB054Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB054Member" xlink:to="lab_biib_BIIB054Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CommercialMilestonesMember_f39681ff-96e6-4b6b-a4ec-a02292882430_terseLabel_en-US" xlink:label="lab_biib_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_label_en-US" xlink:label="lab_biib_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_documentation_en-US" xlink:label="lab_biib_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CommercialMilestonesMember" xlink:href="biib-20201231.xsd#biib_CommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommercialMilestonesMember" xlink:to="lab_biib_CommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_cb25d975-e899-43fb-a56f-f7b01b60cf4d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_c187b8fe-fe7d-4f76-971b-af490ec000cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ee48be98-a315-4c70-8481-f34311b98b44_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_9e1bce89-faa8-4d24-bc63-0e49bd100f07_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_81ab0cb3-7e91-4bd4-b52f-aed3cd1bf1cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DeferredtaxliabilityMember_9b6048f0-69d4-48fc-8bd3-d94f043ebc2a_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilityMember" xlink:href="biib-20201231.xsd#biib_DeferredtaxliabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember" xlink:to="lab_biib_DeferredtaxliabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FairValueMeasurementInputs_5ed0ee50-44aa-4a4d-bec2-2fdcd37a4504_terseLabel_en-US" xlink:label="lab_biib_FairValueMeasurementInputs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement and measurement inputs, recurring and nonrecurring</link:label>
    <link:label id="lab_biib_FairValueMeasurementInputs_label_en-US" xlink:label="lab_biib_FairValueMeasurementInputs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs</link:label>
    <link:label id="lab_biib_FairValueMeasurementInputs_documentation_en-US" xlink:label="lab_biib_FairValueMeasurementInputs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueMeasurementInputs" xlink:href="biib-20201231.xsd#biib_FairValueMeasurementInputs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueMeasurementInputs" xlink:to="lab_biib_FairValueMeasurementInputs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b61725d7-f516-4df1-b99d-d447c299e4f6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc. (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dc8b2bd8-15be-4ada-8320-f25783e7b32e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_b2e5bc7d-0e09-407b-a4dc-a717261cdf1e_terseLabel_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_label_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_documentation_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:href="biib-20201231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:to="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_f827b343-356f-4cfd-a39f-0b88a4ca0213_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedge</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_6195b088-b06f-4126-9b9d-851670d694a0_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4f23cbb9-aa8f-4daa-a8d6-35e885879ce3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_96ba32ec-753c-4710-9d98-92eeba15e8a4_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_876258d0-08ea-4323-acbf-50c16ac5cb54_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_83a835b9-0259-490e-8e1d-03f260c9cf9d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_41b66521-74d4-429b-92b3-0fab1cd2fbaf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_ab5b88fb-51d8-464e-9d6e-367dbefe5af5_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3edac010-c230-4dc6-82d3-18167b330608_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_83605447-0b74-4b5f-b24d-c1fb359afd12_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_acf92595-7291-4547-9ac1-a89f5e95d866_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_27ed2dfa-b346-4e6b-853f-fd0be44a2c6d_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20201231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_eac86c6d-1ece-4f8e-a96c-77d107055d78_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_523975e1-300b-4e98-b672-41aaa2d230f3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_80f1badd-8048-4701-8479-125835f5b4ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_385014d2-7ad6-4438-9af2-044ff840c3e5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf1bd4c1-53f8-4183-8e39-a7382a853c33_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_383d333c-eca5-48bf-a39b-b4bcf6ef7c85_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5bcfb3dc-e978-4f29-82c3-387abf5740ba_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ec89ab47-a86b-41e4-bcf0-a48e30160527_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_30c11841-0e3b-4eb0-97e3-80c25ff3b07f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_7216b760-a814-4cdd-a8a8-1a4c15e4b7a1_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_96392f12-c042-4575-8fd2-6bdf94e5322b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8669beb7-4076-4cc1-a453-47e23ddda98f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e8a38b63-630e-43f3-816b-5cf6943a952d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_81d91f58-aff9-4df5-8cb5-057bcbab2f56_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c11a88e7-8d14-4b86-8969-7ff7b8fd5142_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_045b2e7f-c9bb-4ed9-aca9-200e45d3dada_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_41b79a7d-3611-421e-9d85-7f88dcd4044d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8423043f-0ce0-4db1-817c-1eba9a692b3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_e422814b-2a67-4cd3-8e55-d1686e23dd54_terseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units activity</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units Activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_51cdf801-a3f1-4497-9139-b966859588cc_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense on disposal group</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_bc6582ae-f40f-4133-9bfa-506c6a65b369_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractManufacturingCustomerMember_a3c4ba1f-9784-4a44-a8f1-231f291adde6_terseLabel_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing Customer</link:label>
    <link:label id="lab_biib_ContractManufacturingCustomerMember_label_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing Customer [Member]</link:label>
    <link:label id="lab_biib_ContractManufacturingCustomerMember_documentation_en-US" xlink:label="lab_biib_ContractManufacturingCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Manufacturing Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingCustomerMember" xlink:href="biib-20201231.xsd#biib_ContractManufacturingCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractManufacturingCustomerMember" xlink:to="lab_biib_ContractManufacturingCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_83135f1b-cb0d-456e-985b-39c4f31447ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PfizerMember_2348aaa8-7ba3-446a-9618-bb7ccd937085_terseLabel_en-US" xlink:label="lab_biib_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_biib_PfizerMember_label_en-US" xlink:label="lab_biib_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_biib_PfizerMember_documentation_en-US" xlink:label="lab_biib_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PfizerMember" xlink:href="biib-20201231.xsd#biib_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PfizerMember" xlink:to="lab_biib_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1e897c96-57aa-4c9e-8189-e6af35dd96a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_4856e652-4832-48ed-880a-a92e11b8ec1c_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20201231.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6844aac9-2c1d-43cf-b104-57b86039cb39_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_9a0c27fe-40e5-498c-88a8-0fe5be9a3638_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for pre-combination equity compensation</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_714aeb93-1bab-40f7-b4fa-d5a83ce3d17c_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_e8542560-9d48-4c45-a9cf-d752a9739839_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contingent consideration in the form of development and approval milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_25b7bcd8-9c67-4886-86ba-e3de6af702bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0ad0f65b-c5cc-48c2-bf61-fb21dba4bad1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8980a8ae-1ae0-4be2-8505-40764771b4af_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior unsecured revolving credit facility maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_29d84d48-07f2-428d-a22f-ec9c2e4a5e02_terseLabel_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_label_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_documentation_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:href="biib-20201231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:to="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_05be3343-cf42-45f9-84a9-7fbc8bcf68c6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_0b6daee2-6ceb-4c97-b30c-351dbfa2349e_terseLabel_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global licensing collaboration, shares purchased (in shares)</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_label_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:label id="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased_documentation_en-US" xlink:label="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Licensing Collaboration Agreement, Shares, Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:to="lab_biib_GlobalLicensingCollaborationAgreementSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f7651afc-fd29-4650-afcd-15ad46f33080_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant&#160;Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_544a9af2-b49a-4c16-a9aa-aabdd6f3003b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and discovery services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_b4abe7ca-8b09-4b17-91db-852bac040116_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_17a30e4f-36cc-46bc-be46-bf028e5fc42d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AducanumabMember_29cf8364-34de-48c5-8e6d-35de440627dd_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_label_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_documentation_en-US" xlink:label="lab_biib_AducanumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember" xlink:href="biib-20201231.xsd#biib_AducanumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember" xlink:to="lab_biib_AducanumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a0842811-4f6a-4990-b1d9-98ec0ecb86d9_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_07390d14-367b-4a4b-b444-bcbb8b168fe6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6ac6665c-4408-4029-8a29-c53e932875ce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_e5033876-a0c3-4017-a0ff-1819180fcef7_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ce59c8f3-da17-4472-b533-6a8dfe6e4063_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a413324b-c28b-45bf-af7e-d6bd8b68684a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent payment</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_60a2b95a-081f-460b-90b6-482f8e4eb85c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9883edae-3e5b-471f-af6c-90a40532858c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_b22ba243-4776-49e7-8b68-d5614a9b3a0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain)/loss on divestiture of Hillerod, Denmark manufactuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_184c3949-f52e-4541-b2ce-7a97bbb57d67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherRelationshipsMember_ab924231-ca5d-403f-ae92-6c4e7225cb62_terseLabel_en-US" xlink:label="lab_biib_OtherRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Relationships</link:label>
    <link:label id="lab_biib_OtherRelationshipsMember_label_en-US" xlink:label="lab_biib_OtherRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Relationships [Member]</link:label>
    <link:label id="lab_biib_OtherRelationshipsMember_documentation_en-US" xlink:label="lab_biib_OtherRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherRelationshipsMember" xlink:href="biib-20201231.xsd#biib_OtherRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherRelationshipsMember" xlink:to="lab_biib_OtherRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_895061bc-aa97-4439-99ae-7dd8a1c2ce52_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_a228258b-a464-4211-bb3b-8a02c6d1dab8_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Senior Notes due September 15, 2020</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_8677d663-2bb5-434c-b442-f98c7a64a3cf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellable future commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7c689837-755a-48fc-a3cb-88aa3d79be40_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_7f85fdaf-911f-4e14-9add-22e586ce1b19_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_890e21f3-966c-4b5a-af23-a259b885a95a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b4c6e8b6-f998-4d36-bb62-8d4bc06c61e2_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c1b82697-9633-4efc-a995-1b472bb78c8a_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_707da836-5d08-4c3c-8064-10a2bcb5d54d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_374b3543-939d-4b1f-a9a5-b30720b68594_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6a31d19a-f569-4271-9b61-01834adab144_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_1221737f-e8aa-4d6d-8b79-ae83045ca491_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2e5e4bef-a542-4a24-b69b-241aee378325_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_055d6e6d-7f4c-48e6-bd5b-9fb66a2f2e04_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>biib-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:93645b15-c187-4b47-82bf-4dd611d6b978,g:f6c0263a-8ffa-4fd3-a952-6de1d776d19e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6428e22c-4a45-43a1-81bc-1a9f7956b43b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_DocumentType_6428e22c-4a45-43a1-81bc-1a9f7956b43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_72abcb36-1112-4fbf-93a6-5c9f3386ff3a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_DocumentAnnualReport_72abcb36-1112-4fbf-93a6-5c9f3386ff3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6e229e58-cf8c-4ef5-bbc8-1464b5eb20e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_DocumentPeriodEndDate_6e229e58-cf8c-4ef5-bbc8-1464b5eb20e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_de1c185c-1d9b-4bde-aba4-d8cf969536f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_CurrentFiscalYearEndDate_de1c185c-1d9b-4bde-aba4-d8cf969536f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_765ba386-3415-49a8-8384-93918f618db8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_DocumentTransitionReport_765ba386-3415-49a8-8384-93918f618db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_da1039ff-f04c-4fe4-942c-bd8b254b4d58" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityFileNumber_da1039ff-f04c-4fe4-942c-bd8b254b4d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8d554518-1127-4063-9646-62de20e74dbe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityRegistrantName_8d554518-1127-4063-9646-62de20e74dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_829ccb3a-ab0b-4f66-8de1-4ab20f9f750f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityIncorporationStateCountryCode_829ccb3a-ab0b-4f66-8de1-4ab20f9f750f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8d947214-7999-4414-82f0-fc88ff73a4e2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityTaxIdentificationNumber_8d947214-7999-4414-82f0-fc88ff73a4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_69e334a1-0636-488e-b157-79586cd32512" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityAddressAddressLine1_69e334a1-0636-488e-b157-79586cd32512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_aac58ef0-95b3-4863-8ea5-7e779ce2106f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityAddressCityOrTown_aac58ef0-95b3-4863-8ea5-7e779ce2106f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5efba3a4-0584-4e09-92ec-51748ae0b334" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityAddressStateOrProvince_5efba3a4-0584-4e09-92ec-51748ae0b334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_92e7e4ac-bd06-4e8c-8d04-d945ec57b95c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityAddressPostalZipCode_92e7e4ac-bd06-4e8c-8d04-d945ec57b95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fccea179-ff08-48f0-b566-7a7842643d97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_CityAreaCode_fccea179-ff08-48f0-b566-7a7842643d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0feaa2ef-247f-4b82-b3e3-0f7e1ad4df99" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_LocalPhoneNumber_0feaa2ef-247f-4b82-b3e3-0f7e1ad4df99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8fcff568-4880-4109-be6e-c7e09c9ed147" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_Security12bTitle_8fcff568-4880-4109-be6e-c7e09c9ed147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_59d90be3-a0de-40c5-b570-967194d8478b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_TradingSymbol_59d90be3-a0de-40c5-b570-967194d8478b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2e182185-f72a-4c71-806e-5a52d3443fbc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_SecurityExchangeName_2e182185-f72a-4c71-806e-5a52d3443fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_cec67d21-97ca-4786-9089-79ca38810ab9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_cec67d21-97ca-4786-9089-79ca38810ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d353a688-9b29-4e24-ba50-e0d1acf0d8f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityVoluntaryFilers_d353a688-9b29-4e24-ba50-e0d1acf0d8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_cf8ed025-c85d-46f8-90f6-d87730c103bb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityCurrentReportingStatus_cf8ed025-c85d-46f8-90f6-d87730c103bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_89f9fdff-395c-48be-81a4-3e3c70854b00" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityInteractiveDataCurrent_89f9fdff-395c-48be-81a4-3e3c70854b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_583f74fb-23c4-4b73-8665-148467083ce1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityFilerCategory_583f74fb-23c4-4b73-8665-148467083ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9c70cf9e-2336-4ef9-b7f4-0ed2686c5d0b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntitySmallBusiness_9c70cf9e-2336-4ef9-b7f4-0ed2686c5d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_46f38ab9-0326-414e-8c0c-8e5f732b84c9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityEmergingGrowthCompany_46f38ab9-0326-414e-8c0c-8e5f732b84c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_0b140c57-0ec8-45ea-bf5d-c7a6e1d2ae0e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_IcfrAuditorAttestationFlag_0b140c57-0ec8-45ea-bf5d-c7a6e1d2ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1356eb41-a746-4155-ab38-75f8373a87b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityShellCompany_1356eb41-a746-4155-ab38-75f8373a87b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_077c2878-267a-436a-aef0-7f2eb18e6f20" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityPublicFloat_077c2878-267a-436a-aef0-7f2eb18e6f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f5676d55-c261-46e2-8177-ae4304bbdd6d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f5676d55-c261-46e2-8177-ae4304bbdd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e80eb938-7b0a-4f1d-b0f5-68748b3c78e4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e80eb938-7b0a-4f1d-b0f5-68748b3c78e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9d4b8b6d-e767-4c97-b17d-7d33bdd406fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_EntityCentralIndexKey_9d4b8b6d-e767-4c97-b17d-7d33bdd406fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c2bd0fff-c113-4642-8243-9bb16586210f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_DocumentFiscalYearFocus_c2bd0fff-c113-4642-8243-9bb16586210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1df16a2c-2831-4f10-8299-484318494c98" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1df16a2c-2831-4f10-8299-484318494c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_76850043-f9fb-4300-8f8e-eb9591bc2fb8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1bab47c0-279e-42e4-b721-3f3fa0c1cd62" xlink:to="loc_dei_AmendmentFlag_76850043-f9fb-4300-8f8e-eb9591bc2fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5be1ac2e-2688-4786-8126-09523237d8d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2649009d-b09b-4775-92b1-18f6f1ab060d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5be1ac2e-2688-4786-8126-09523237d8d3" xlink:to="loc_us-gaap_StatementTable_2649009d-b09b-4775-92b1-18f6f1ab060d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d380f2fb-deb5-4400-8fca-08f174012815" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2649009d-b09b-4775-92b1-18f6f1ab060d" xlink:to="loc_srt_ProductOrServiceAxis_d380f2fb-deb5-4400-8fca-08f174012815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d380f2fb-deb5-4400-8fca-08f174012815" xlink:to="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7b58e73b-5429-4850-b0ce-c163a04ea887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:to="loc_us-gaap_ProductMember_7b58e73b-5429-4850-b0ce-c163a04ea887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_1b7ea3d4-dd69-48ab-8f30-87c89488292c" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_1b7ea3d4-dd69-48ab-8f30-87c89488292c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_4e131b1d-9b9c-4c90-a9a5-5ee9aeaa6fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_56691514-5aea-47dc-b37c-2d4ec861514c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_4e131b1d-9b9c-4c90-a9a5-5ee9aeaa6fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2649009d-b09b-4775-92b1-18f6f1ab060d" xlink:to="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_974bc8bc-63d3-4285-a1c8-902bfbe0e383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_Revenues_974bc8bc-63d3-4285-a1c8-902bfbe0e383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ef6f2e88-6768-430e-b297-e604a9ff749d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ef6f2e88-6768-430e-b297-e604a9ff749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_db9b6a11-a5b1-4caa-8bf0-c36d554f9d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_db9b6a11-a5b1-4caa-8bf0-c36d554f9d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_60fdc397-78d1-447a-bf25-090d7cbdbf65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_60fdc397-78d1-447a-bf25-090d7cbdbf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_5c5cd0d2-c3f2-4c3d-9be9-fa9115e979ab" xlink:href="biib-20201231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_5c5cd0d2-c3f2-4c3d-9be9-fa9115e979ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharing_e3a15d62-8ec5-49a4-8682-4882f719ae73" xlink:href="biib-20201231.xsd#biib_CollaborationProfitSharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_biib_CollaborationProfitSharing_e3a15d62-8ec5-49a4-8682-4882f719ae73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6f481756-c2bd-4ceb-af56-619487dfa05c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_6f481756-c2bd-4ceb-af56-619487dfa05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_42d53ae0-dca6-434a-ade0-b4b251c53bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_42d53ae0-dca6-434a-ade0-b4b251c53bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a0e50ada-952f-4605-a6cc-005748537e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a0e50ada-952f-4605-a6cc-005748537e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_bbef4075-4314-4b75-b7da-f3dfaff5595b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_RestructuringCharges_bbef4075-4314-4b75-b7da-f3dfaff5595b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8377a40b-6cb2-4420-97ac-e9a6e9fe5273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1f452080-ef32-45ad-9145-b694902042ee" xlink:to="loc_us-gaap_CostsAndExpenses_8377a40b-6cb2-4420-97ac-e9a6e9fe5273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dac2f759-214a-48ba-9d12-3d42f4f7a909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_OperatingIncomeLoss_dac2f759-214a-48ba-9d12-3d42f4f7a909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_df1d388b-af58-4f75-91be-6979f331d1b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_df1d388b-af58-4f75-91be-6979f331d1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_faa2dd6c-cdf0-4519-b609-3044a5d2f46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_faa2dd6c-cdf0-4519-b609-3044a5d2f46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_790d2458-fd88-4697-84c0-8189a6c2d63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_790d2458-fd88-4697-84c0-8189a6c2d63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0be755a6-63fe-4fc7-a25e-106e776ccab2" xlink:href="biib-20201231.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_0be755a6-63fe-4fc7-a25e-106e776ccab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ff3d7a07-333e-40cb-a189-b83627b4f5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_ProfitLoss_ff3d7a07-333e-40cb-a189-b83627b4f5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83d6b0bc-74d7-45e7-8c43-7e8155a14afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83d6b0bc-74d7-45e7-8c43-7e8155a14afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6267873c-2744-410d-b7bf-bb6431c7dd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_NetIncomeLoss_6267873c-2744-410d-b7bf-bb6431c7dd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_40d9a254-ccbf-4a5f-a999-3d081e622c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_40d9a254-ccbf-4a5f-a999-3d081e622c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9140dd08-f06d-4f1f-95b7-2946310294a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_40d9a254-ccbf-4a5f-a999-3d081e622c71" xlink:to="loc_us-gaap_EarningsPerShareBasic_9140dd08-f06d-4f1f-95b7-2946310294a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_914c6c08-78a7-46f3-a2ff-a09bf58bdda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_40d9a254-ccbf-4a5f-a999-3d081e622c71" xlink:to="loc_us-gaap_EarningsPerShareDiluted_914c6c08-78a7-46f3-a2ff-a09bf58bdda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c098e1ab-eb34-4a85-80cd-5f5ad0d9ea50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a08450d-6b46-464f-8f74-39b1d50fad1e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c098e1ab-eb34-4a85-80cd-5f5ad0d9ea50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ef278d3-03e5-44a3-9ab1-d8da7f58256c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c098e1ab-eb34-4a85-80cd-5f5ad0d9ea50" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8ef278d3-03e5-44a3-9ab1-d8da7f58256c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a37dc7e6-7366-47d9-82cf-7ec561312fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c098e1ab-eb34-4a85-80cd-5f5ad0d9ea50" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a37dc7e6-7366-47d9-82cf-7ec561312fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_647a17d9-1662-423e-8471-55bffb441f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f34195e4-6652-4aa5-8f5b-fa41759540a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_647a17d9-1662-423e-8471-55bffb441f84" xlink:to="loc_us-gaap_NetIncomeLoss_f34195e4-6652-4aa5-8f5b-fa41759540a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_647a17d9-1662-423e-8471-55bffb441f84" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a0bdffe6-005d-4372-8f47-8ee9453e7830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a0bdffe6-005d-4372-8f47-8ee9453e7830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_7776c3bb-f93c-4b3a-b2e3-9220a816f071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_7776c3bb-f93c-4b3a-b2e3-9220a816f071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_060c00df-b09c-46d9-afe1-c697edb46f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_060c00df-b09c-46d9-afe1-c697edb46f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_64cca6dd-316a-4e1e-83ea-f7e1a3e43dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_64cca6dd-316a-4e1e-83ea-f7e1a3e43dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f99873b3-a72f-4999-bb21-fea3545c0fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f99873b3-a72f-4999-bb21-fea3545c0fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2e618238-67c3-4a1d-afcf-884a505faff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2e618238-67c3-4a1d-afcf-884a505faff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8125c8a9-0a3b-453b-9a90-a6085b804aad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8125c8a9-0a3b-453b-9a90-a6085b804aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9358e597-0645-49bc-a392-db2166c6be2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9358e597-0645-49bc-a392-db2166c6be2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6a59081f-75b9-461f-8305-8e44da740bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_23e124eb-1439-4307-b73e-2f9896a09719" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6a59081f-75b9-461f-8305-8e44da740bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofComprehensiveIncome_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ebd9ab9a-c8e5-4f94-9f76-5bd8804c689b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ebd9ab9a-c8e5-4f94-9f76-5bd8804c689b" xlink:to="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19b59c81-6511-445c-9bf4-d924fb7463f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_19b59c81-6511-445c-9bf4-d924fb7463f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c2d4bbe4-a0d3-4d02-8ded-62719d503a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c2d4bbe4-a0d3-4d02-8ded-62719d503a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c11bd796-b36c-4f70-a879-5819764bbd56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c11bd796-b36c-4f70-a879-5819764bbd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_4c069065-9e3f-47ed-b8c1-56d3e71b1a69" xlink:href="biib-20201231.xsd#biib_DueFromUnconsolidatedJointBusiness"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_4c069065-9e3f-47ed-b8c1-56d3e71b1a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_eadb2382-fb3f-4535-bb7a-e2cba4660256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:to="loc_us-gaap_InventoryNet_eadb2382-fb3f-4535-bb7a-e2cba4660256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c354e91c-8e3b-4671-b0ae-ed6a1a84975f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:to="loc_us-gaap_OtherAssetsCurrent_c354e91c-8e3b-4671-b0ae-ed6a1a84975f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d41fdf19-7d99-44ac-849b-eabc0ba7008b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cba121c8-bb1d-4d03-88f4-e5e8ed7974cc" xlink:to="loc_us-gaap_AssetsCurrent_d41fdf19-7d99-44ac-849b-eabc0ba7008b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2ad8e63d-153f-483b-8e81-42f307b3a81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2ad8e63d-153f-483b-8e81-42f307b3a81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5154052b-8b75-4e11-82f1-2c9c9b757e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5154052b-8b75-4e11-82f1-2c9c9b757e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_07fadcdc-873f-42bd-9825-af54ed22c1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_07fadcdc-873f-42bd-9825-af54ed22c1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8b8186c0-3974-4515-a086-1cc7950e7068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8b8186c0-3974-4515-a086-1cc7950e7068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_61b29bd3-df58-4707-ab64-0000852add1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_Goodwill_61b29bd3-df58-4707-ab64-0000852add1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_4e37d330-80d0-46c1-9954-d69b5beec5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_4e37d330-80d0-46c1-9954-d69b5beec5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dc50ce6d-d0b5-4798-89ab-9d3af2af2fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dc50ce6d-d0b5-4798-89ab-9d3af2af2fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_de4efdcb-69dd-4eb1-be32-fb5c6d69f8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c1994e4-6524-4cfe-ad10-057be1e93c40" xlink:to="loc_us-gaap_Assets_de4efdcb-69dd-4eb1-be32-fb5c6d69f8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ebd9ab9a-c8e5-4f94-9f76-5bd8804c689b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a4d3c2a4-609f-403e-b347-cee5f6a6ebd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a4d3c2a4-609f-403e-b347-cee5f6a6ebd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_721341a5-4dee-4b4f-b4b5-c47a83f1ff13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a4d3c2a4-609f-403e-b347-cee5f6a6ebd5" xlink:to="loc_us-gaap_DebtCurrent_721341a5-4dee-4b4f-b4b5-c47a83f1ff13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_27e040c5-5012-444e-b9b7-d093fd0a2c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a4d3c2a4-609f-403e-b347-cee5f6a6ebd5" xlink:to="loc_us-gaap_TaxesPayableCurrent_27e040c5-5012-444e-b9b7-d093fd0a2c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d43055fa-9f8e-46dd-bc70-f8a275c15701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a4d3c2a4-609f-403e-b347-cee5f6a6ebd5" xlink:to="loc_us-gaap_AccountsPayableCurrent_d43055fa-9f8e-46dd-bc70-f8a275c15701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a5d9982b-56d9-4fb3-b0f4-789bb357c263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a4d3c2a4-609f-403e-b347-cee5f6a6ebd5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a5d9982b-56d9-4fb3-b0f4-789bb357c263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f9e5fb5c-f526-45ef-ad83-47cf12cceb38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a4d3c2a4-609f-403e-b347-cee5f6a6ebd5" xlink:to="loc_us-gaap_LiabilitiesCurrent_f9e5fb5c-f526-45ef-ad83-47cf12cceb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d2f1f3fc-bba6-4d54-8ecb-c7a173aaa7a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_LongTermDebt_d2f1f3fc-bba6-4d54-8ecb-c7a173aaa7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_147bc434-da42-4b0c-a1dc-1e84d42001bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_147bc434-da42-4b0c-a1dc-1e84d42001bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_302ae2b6-1db1-41be-9e86-8a320f7c48d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_302ae2b6-1db1-41be-9e86-8a320f7c48d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5c15320a-c33d-49fc-b410-42042e7ea35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5c15320a-c33d-49fc-b410-42042e7ea35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d2a86bc3-34e2-4f93-91cd-d33691ae0972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_Liabilities_d2a86bc3-34e2-4f93-91cd-d33691ae0972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f2b0f5a4-9547-47bd-8ee0-b8ed9802405a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f2b0f5a4-9547-47bd-8ee0-b8ed9802405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5132600a-a379-42e0-8466-14fd4b7566b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5132600a-a379-42e0-8466-14fd4b7566b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5132600a-a379-42e0-8466-14fd4b7566b8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2ad3e9c4-c1f9-45ca-9566-ff90f36c3488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:to="loc_us-gaap_PreferredStockValue_2ad3e9c4-c1f9-45ca-9566-ff90f36c3488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e2a233d0-e0e8-4424-904a-c02b0debc490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:to="loc_us-gaap_CommonStockValue_e2a233d0-e0e8-4424-904a-c02b0debc490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dda18776-a4f9-46cd-8457-28e90f305964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dda18776-a4f9-46cd-8457-28e90f305964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_98d63883-e4c5-476c-a6ae-328351828fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_98d63883-e4c5-476c-a6ae-328351828fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e750f3f8-f5af-45b7-860e-584c2ee33d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e750f3f8-f5af-45b7-860e-584c2ee33d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_19b08f56-5300-4f91-8fc7-8412d3b7eddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:to="loc_us-gaap_TreasuryStockValue_19b08f56-5300-4f91-8fc7-8412d3b7eddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8586fa22-31b8-44cc-b11c-9bc9c0915444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8c5922b-7fc2-45df-a1d4-c1e6c989e45a" xlink:to="loc_us-gaap_StockholdersEquity_8586fa22-31b8-44cc-b11c-9bc9c0915444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_651de7df-e8fb-4103-a709-abf1b95add97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5132600a-a379-42e0-8466-14fd4b7566b8" xlink:to="loc_us-gaap_MinorityInterest_651de7df-e8fb-4103-a709-abf1b95add97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cd08e80b-bfd0-46df-9891-deb910998541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5132600a-a379-42e0-8466-14fd4b7566b8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cd08e80b-bfd0-46df-9891-deb910998541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32a21dea-4a37-43e6-b7c3-afd38dbcdd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b650374f-c8e3-4dfe-bed5-24797d842651" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32a21dea-4a37-43e6-b7c3-afd38dbcdd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_394510c3-1fd1-44f9-bb59-56cc5a744b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12d47dbc-632f-42c3-aed8-b2553d960f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_394510c3-1fd1-44f9-bb59-56cc5a744b33" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_12d47dbc-632f-42c3-aed8-b2553d960f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_28bb51ad-a61b-4199-945a-4636d150cdfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_394510c3-1fd1-44f9-bb59-56cc5a744b33" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_28bb51ad-a61b-4199-945a-4636d150cdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_9409975f-7b1a-4f11-a0a0-49750c0d4a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_394510c3-1fd1-44f9-bb59-56cc5a744b33" xlink:to="loc_us-gaap_TreasuryStockShares_9409975f-7b1a-4f11-a0a0-49750c0d4a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8ec8d0f0-2952-495d-b5d2-4dd1c19d6de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f097e07c-e9ff-41fd-8252-b8327202f0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ec8d0f0-2952-495d-b5d2-4dd1c19d6de5" xlink:to="loc_us-gaap_StatementTable_f097e07c-e9ff-41fd-8252-b8327202f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64941f8d-8f53-45d6-a93d-338c8db6e865" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f097e07c-e9ff-41fd-8252-b8327202f0d9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64941f8d-8f53-45d6-a93d-338c8db6e865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64941f8d-8f53-45d6-a93d-338c8db6e865" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_8c9fada5-987e-4c1a-8250-b97958040b38" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:to="loc_biib_IonisPharmaceuticalsMember_8c9fada5-987e-4c1a-8250-b97958040b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsIncAgreementMember_877aefc6-396a-42ee-a304-72c7ed2964e9" xlink:href="biib-20201231.xsd#biib_SangamoTherapeuticsIncAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:to="loc_biib_SangamoTherapeuticsIncAgreementMember_877aefc6-396a-42ee-a304-72c7ed2964e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_f92ec65d-dd56-4aed-8af4-38c1b11b87c3" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:to="loc_biib_DenaliTherapeuticsIncMember_f92ec65d-dd56-4aed-8af4-38c1b11b87c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_d8aa5749-56ad-44e4-8738-d2e2c49d7dc4" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_689067c7-8b1c-4a75-ae2c-9229d4dbb30b" xlink:to="loc_biib_SageTherapeuticsIncMember_d8aa5749-56ad-44e4-8738-d2e2c49d7dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f097e07c-e9ff-41fd-8252-b8327202f0d9" xlink:to="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077a3ea8-1e52-4aad-a847-47c14eadc3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077a3ea8-1e52-4aad-a847-47c14eadc3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_952f3246-240a-4a24-8551-55170e9f71ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077a3ea8-1e52-4aad-a847-47c14eadc3f6" xlink:to="loc_us-gaap_ProfitLoss_952f3246-240a-4a24-8551-55170e9f71ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_077a3ea8-1e52-4aad-a847-47c14eadc3f6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_79e77d5c-4db4-4548-943c-6a19bc048684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_79e77d5c-4db4-4548-943c-6a19bc048684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_b863f702-0bb5-466b-a532-b5d9af36d18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_b863f702-0bb5-466b-a532-b5d9af36d18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1ef30184-ef4b-4968-ac85-de7b70034493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1ef30184-ef4b-4968-ac85-de7b70034493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5bc57893-ccd8-4017-a28e-0ff73b23a9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_ShareBasedCompensation_5bc57893-ccd8-4017-a28e-0ff73b23a9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_64d62cee-4eaa-4514-af97-ea7a0d576dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_64d62cee-4eaa-4514-af97-ea7a0d576dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_433502e2-2c32-411c-9903-e025ec48795b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax_433502e2-2c32-411c-9903-e025ec48795b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6fc08dc3-d816-4265-96fd-c53883521e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6fc08dc3-d816-4265-96fd-c53883521e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_493e9f8a-63e7-44c2-bcd2-8c8243715ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_493e9f8a-63e7-44c2-bcd2-8c8243715ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0576092f-d311-4941-a9a6-cf698eaf271b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0576092f-d311-4941-a9a6-cf698eaf271b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1e479511-76e5-4e5c-ac85-03205404b1be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1e479511-76e5-4e5c-ac85-03205404b1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f23ff5c7-7ae9-4d5a-acf1-85225402d504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f23ff5c7-7ae9-4d5a-acf1-85225402d504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_67b19d6d-2ead-4b15-9c47-986da0cd0fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_67b19d6d-2ead-4b15-9c47-986da0cd0fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_043eff47-dca3-47b2-b54b-4c69aed7a313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_043eff47-dca3-47b2-b54b-4c69aed7a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8d318d9e-8933-46fc-bb17-c69d62474695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8d318d9e-8933-46fc-bb17-c69d62474695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9ddb1c91-aa04-494c-9800-2592344c9f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9ddb1c91-aa04-494c-9800-2592344c9f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_948fbda5-b8f2-44b8-aa0c-e693cc545973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cd099dc5-c645-4901-8d8b-6794f5d9b3e0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_948fbda5-b8f2-44b8-aa0c-e693cc545973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b006fcc0-23bf-4180-bda2-4d842260a912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db105dce-b16c-4b36-bd24-4edf3e0c3967" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b006fcc0-23bf-4180-bda2-4d842260a912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9a220f77-5c42-4b1c-ad86-068097865690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9a220f77-5c42-4b1c-ad86-068097865690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_87e8d145-3b51-419a-ba3f-bf666ac7c309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_87e8d145-3b51-419a-ba3f-bf666ac7c309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_e6ce8e96-111f-4622-a6d9-f56c06d31068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_e6ce8e96-111f-4622-a6d9-f56c06d31068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_1c6c4bb9-6c76-427a-98d8-9378d474bcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_1c6c4bb9-6c76-427a-98d8-9378d474bcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_ce4f7bcf-d62a-49b8-aa40-5d72f8d9e215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_ce4f7bcf-d62a-49b8-aa40-5d72f8d9e215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c4cfbeed-157d-4ff3-a375-9b8a68e393c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_c4cfbeed-157d-4ff3-a375-9b8a68e393c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09c7444f-299e-47ce-b97f-38e80d72db58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09c7444f-299e-47ce-b97f-38e80d72db58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b04bc166-d3cf-45bb-b7b1-dff27fc7f990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_b04bc166-d3cf-45bb-b7b1-dff27fc7f990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ba89cb90-0aad-4601-a8e8-60982bc3f1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ba89cb90-0aad-4601-a8e8-60982bc3f1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_931a9528-e427-42e3-b7b9-fa6484cbfb96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_931a9528-e427-42e3-b7b9-fa6484cbfb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_814ab5ef-07a7-4574-88bb-f38217edf6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_814ab5ef-07a7-4574-88bb-f38217edf6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_77b8151f-dc28-4049-bcd5-38330dc98a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_77b8151f-dc28-4049-bcd5-38330dc98a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8c9ceb2c-80ad-45d9-9035-5c270d2f2d33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_00f341fc-e399-4917-be8a-07d8c722e886" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8c9ceb2c-80ad-45d9-9035-5c270d2f2d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_956c94f9-a7a4-417f-9159-c8294537d6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_956c94f9-a7a4-417f-9159-c8294537d6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_805accc2-a1ad-43d5-ad85-b05f52621811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_805accc2-a1ad-43d5-ad85-b05f52621811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16ec0ca9-3ccd-41d7-803a-33d1e9997e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16ec0ca9-3ccd-41d7-803a-33d1e9997e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_f97daab5-61c3-4c83-ad49-7feb10089ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_RepaymentsOfDebt_f97daab5-61c3-4c83-ad49-7feb10089ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_cba674a2-cf4f-44b7-be98-c2f509d0c875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_cba674a2-cf4f-44b7-be98-c2f509d0c875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_c4573011-f6b2-4142-8342-c93bfc699e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_c4573011-f6b2-4142-8342-c93bfc699e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_d4b464f0-6e2b-49a0-92f8-28af55afb3ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_d4b464f0-6e2b-49a0-92f8-28af55afb3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1f980e8f-70c2-47ad-b396-366bdbecfbc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1f980e8f-70c2-47ad-b396-366bdbecfbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d947b0e-bab3-4dfd-8fe2-afacf9dfff2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_08e8bfcf-9f0e-4830-8a13-65f2ac58ff78" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d947b0e-bab3-4dfd-8fe2-afacf9dfff2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_33561356-5fef-4609-9166-2513f8811ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_33561356-5fef-4609-9166-2513f8811ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6de166ea-1e65-43a4-901d-5c34d1abf31a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6de166ea-1e65-43a4-901d-5c34d1abf31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4cac0747-594b-42a8-9e9a-5ccf49baf455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4cac0747-594b-42a8-9e9a-5ccf49baf455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ddeda97-53ad-41a2-bd53-7cc0ecd0fa5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_327082ea-f07b-4ccd-9b87-ed74ffb2a298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ddeda97-53ad-41a2-bd53-7cc0ecd0fa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="biib-20201231.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6f93b180-f2e8-4b42-906b-cdd8eefdaa8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6f93b180-f2e8-4b42-906b-cdd8eefdaa8d" xlink:to="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9aa8a4c7-be9d-4e59-a0c7-734fec853e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9aa8a4c7-be9d-4e59-a0c7-734fec853e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9aa8a4c7-be9d-4e59-a0c7-734fec853e81" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram5Member_66198519-dc66-47f9-bc8d-4c76e5b304dd" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram5Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram5Member_66198519-dc66-47f9-bc8d-4c76e5b304dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram4Member_3ea8210e-7100-4f03-ab65-942ab5682c54" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram4Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram4Member_3ea8210e-7100-4f03-ab65-942ab5682c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram3Member_d475dd07-b96c-4c0f-bb47-51b00116023b" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram3Member_d475dd07-b96c-4c0f-bb47-51b00116023b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram2Member_53c3a684-82b3-4e27-a711-af03839e748f" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram2Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram2Member_53c3a684-82b3-4e27-a711-af03839e748f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram1Member_ae77935e-bb40-45d8-955d-75e750b6e8de" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7b7d5bb1-a17e-4a35-8250-7243112c7884" xlink:to="loc_biib_ShareRepurchaseProgram1Member_ae77935e-bb40-45d8-955d-75e750b6e8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e848e69d-a487-4fa4-bb0f-425708769a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e848e69d-a487-4fa4-bb0f-425708769a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e848e69d-a487-4fa4-bb0f-425708769a63" xlink:to="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_8fc2075b-3625-4ad0-bac9-f432f8e15667" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_PreferredStockMember_8fc2075b-3625-4ad0-bac9-f432f8e15667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d260b1c3-af87-4bdd-8d4a-11f0453ddd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_CommonStockMember_d260b1c3-af87-4bdd-8d4a-11f0453ddd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b2c01739-2a5e-43d1-b430-851916122f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b2c01739-2a5e-43d1-b430-851916122f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_055783e5-a66c-4849-a1d4-22d7262614c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_055783e5-a66c-4849-a1d4-22d7262614c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_74ef5d5c-e949-4ecb-b387-c07848cf01dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_RetainedEarningsMember_74ef5d5c-e949-4ecb-b387-c07848cf01dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_3035680f-15fc-4f48-a219-30d24cfe2704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_TreasuryStockMember_3035680f-15fc-4f48-a219-30d24cfe2704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_51bb2560-f8bb-4964-920a-203cfb55d1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_ParentMember_51bb2560-f8bb-4964-920a-203cfb55d1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a0e257b1-f635-412b-bdb9-f8203cd82725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bdca7673-f5f7-4320-accb-f2c16ed9a527" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a0e257b1-f635-412b-bdb9-f8203cd82725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_21d58001-253f-4ce6-8d20-240a5e47a519" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_21d58001-253f-4ce6-8d20-240a5e47a519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f61247d-b671-42b7-adbc-1c44f7ea1320" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_21d58001-253f-4ce6-8d20-240a5e47a519" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f61247d-b671-42b7-adbc-1c44f7ea1320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f23e32d3-9298-49c1-bb85-c45264e49015" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f61247d-b671-42b7-adbc-1c44f7ea1320" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f23e32d3-9298-49c1-bb85-c45264e49015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3251b9cc-fd96-4a50-a6b1-149d0c3f9c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_43542d88-f7ce-4904-baff-3e46a538f874" xlink:to="loc_us-gaap_StatementLineItems_3251b9cc-fd96-4a50-a6b1-149d0c3f9c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3251b9cc-fd96-4a50-a6b1-149d0c3f9c7b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_5a2c9fe0-f328-4621-bbdc-81075be94f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_SharesIssued_5a2c9fe0-f328-4621-bbdc-81075be94f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30530b2f-96eb-4350-8eeb-e46943fd9434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_30530b2f-96eb-4350-8eeb-e46943fd9434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_99776daa-458d-4ff7-88c1-4f3fc45926d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_ProfitLoss_99776daa-458d-4ff7-88c1-4f3fc45926d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_67098f3b-8ff4-4548-aae4-5e1add3b2736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_67098f3b-8ff4-4548-aae4-5e1add3b2736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_dbb6786b-86d0-45e5-99e8-4adbc2b08932" xlink:href="biib-20201231.xsd#biib_Noncontrollinginterestincreasedecreaseother"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_dbb6786b-86d0-45e5-99e8-4adbc2b08932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_16c1810f-1433-4e16-aed8-222ccac50473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_16c1810f-1433-4e16-aed8-222ccac50473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_eb5fc851-f8cc-4fe4-840c-0fe414e4d924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_eb5fc851-f8cc-4fe4-840c-0fe414e4d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e819c447-f170-4e80-b0da-d199d1762162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e819c447-f170-4e80-b0da-d199d1762162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f974687d-ec2e-42f9-8eb6-0521b3d1a979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f974687d-ec2e-42f9-8eb6-0521b3d1a979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_b009f283-30a8-4252-b9a6-55d888dcc10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_b009f283-30a8-4252-b9a6-55d888dcc10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_437e52ac-60f0-484f-9040-d335a7973d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_437e52ac-60f0-484f-9040-d335a7973d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e0612a67-17a9-4dcb-9f42-8e1411231b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_e0612a67-17a9-4dcb-9f42-8e1411231b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26f69f83-8dd3-4fdf-a863-3e2379af5e37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26f69f83-8dd3-4fdf-a863-3e2379af5e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_157e6627-b964-49ae-b572-ce8801417ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_157e6627-b964-49ae-b572-ce8801417ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_22f3b21e-7b8f-4ddf-9864-37c32ab2e8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_22f3b21e-7b8f-4ddf-9864-37c32ab2e8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_78373f6c-9688-497a-8966-52be71cc5fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockholdersEquityOther_78373f6c-9688-497a-8966-52be71cc5fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1a63fd84-2e7b-4592-b26a-e79b0f5ab4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_SharesIssued_1a63fd84-2e7b-4592-b26a-e79b0f5ab4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73a88d13-627f-48aa-9a98-ce8fceac25eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3589f5de-8e61-45a8-b909-598e8ea58e9a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_73a88d13-627f-48aa-9a98-ce8fceac25eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_44a91a65-e9c7-4e7e-ad41-386810f5821b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_537002ed-8b2a-4f95-9d7f-361c5418bffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_44a91a65-e9c7-4e7e-ad41-386810f5821b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_537002ed-8b2a-4f95-9d7f-361c5418bffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_b64cdc3d-6b0c-43e8-80f1-ce92f87789c5" xlink:href="biib-20201231.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_b64cdc3d-6b0c-43e8-80f1-ce92f87789c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ed304f01-fec2-4df0-ae42-090de6ff4134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ed304f01-fec2-4df0-ae42-090de6ff4134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_37f9cd39-7375-4f9f-9902-0c039f094078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_UseOfEstimates_37f9cd39-7375-4f9f-9902-0c039f094078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_af9867d2-f26b-4187-8acc-ada6d956b613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_af9867d2-f26b-4187-8acc-ada6d956b613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_0f7536b5-1c02-4337-b195-e76aa9f6e536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_0f7536b5-1c02-4337-b195-e76aa9f6e536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a5e9c1be-5522-4cf5-ae69-21f4346a955d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a5e9c1be-5522-4cf5-ae69-21f4346a955d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_084b7837-1722-464f-8bac-233f92b5e2b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_084b7837-1722-464f-8bac-233f92b5e2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_69f4c20e-d83a-495e-9b16-0c233d136319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_69f4c20e-d83a-495e-9b16-0c233d136319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_edd5f9b9-44cc-4cde-b98b-0d33ab9f1e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_edd5f9b9-44cc-4cde-b98b-0d33ab9f1e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_3d50b067-e622-463b-9bb8-0497aa669f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_3d50b067-e622-463b-9bb8-0497aa669f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_a90310e9-0679-43ca-8764-dfa57390bfba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_a90310e9-0679-43ca-8764-dfa57390bfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9df6f03c-55d0-4314-b8a3-888abd2b45ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9df6f03c-55d0-4314-b8a3-888abd2b45ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_eb70b43c-38eb-4ffa-b5fd-96d137c40955" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_eb70b43c-38eb-4ffa-b5fd-96d137c40955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_964fad6f-1905-475d-bb70-835eba07f746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_964fad6f-1905-475d-bb70-835eba07f746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_aac1a7d9-675c-4278-8afa-59a563cbdd3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_aac1a7d9-675c-4278-8afa-59a563cbdd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f992c09d-6b8f-4744-a797-9a9cb84e74e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f992c09d-6b8f-4744-a797-9a9cb84e74e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7d963b1d-75db-43a1-84bc-cf26d8b64172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7d963b1d-75db-43a1-84bc-cf26d8b64172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2aef8b7c-4c26-40bb-8d52-ee0142e970d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2aef8b7c-4c26-40bb-8d52-ee0142e970d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_366aa8ce-f4bd-4c29-9ccc-3dc5d2c8fb0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_366aa8ce-f4bd-4c29-9ccc-3dc5d2c8fb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5c056269-c005-4455-af18-7605ead38437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5c056269-c005-4455-af18-7605ead38437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_4a61b0fc-69ef-4b12-89fa-ce562bc10206" xlink:href="biib-20201231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_biib_RoyaltyCostofSalesPolicyTextBlock_4a61b0fc-69ef-4b12-89fa-ce562bc10206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_1ffb56bf-5461-4502-9abc-e888fef0ed08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_1ffb56bf-5461-4502-9abc-e888fef0ed08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_ef091fad-ff1d-4e8b-b396-0d34a4b96fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_ef091fad-ff1d-4e8b-b396-0d34a4b96fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_fda2ef03-49c9-44db-aaac-1536453e4e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_fda2ef03-49c9-44db-aaac-1536453e4e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0225e1f0-e9ae-4edf-968e-14bcdde8a55e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0225e1f0-e9ae-4edf-968e-14bcdde8a55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1a870aa2-8fc0-4fb7-bb55-565ce73a334f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1a870aa2-8fc0-4fb7-bb55-565ce73a334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_36b43074-63bb-45f1-810a-15a3fb8fdd50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_36b43074-63bb-45f1-810a-15a3fb8fdd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20b1850d-b06d-4770-8d49-08e53a0ca8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c433ae5-8f79-441a-914f-aa829a905996" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_20b1850d-b06d-4770-8d49-08e53a0ca8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e5340d70-9a25-4ef1-9c2b-c200c34a74b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_e6078e71-3db0-4edb-823d-a442aa776727" xlink:href="biib-20201231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e5340d70-9a25-4ef1-9c2b-c200c34a74b2" xlink:to="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_e6078e71-3db0-4edb-823d-a442aa776727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d3e0a2fe-cf40-4421-bc91-d61280649ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3e0a2fe-cf40-4421-bc91-d61280649ddc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4b3bc81a-9c78-47ec-8b0b-079ad7c10f77" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_981db929-793b-4ca4-a9ed-9840b213e279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:to="loc_us-gaap_DeferredIncomeTaxChargesMember_981db929-793b-4ca4-a9ed-9840b213e279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_61acedbe-448c-41b2-80bc-e85453d75b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:to="loc_us-gaap_RetainedEarningsMember_61acedbe-448c-41b2-80bc-e85453d75b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilityMember_4ff28533-4c73-4150-bb8f-ccd468096f46" xlink:href="biib-20201231.xsd#biib_DeferredtaxliabilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_357a68e4-d0ce-425a-9c4a-3385fa762695" xlink:to="loc_biib_DeferredtaxliabilityMember_4ff28533-4c73-4150-bb8f-ccd468096f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_697eb4a9-afe1-4303-9d03-93cf7db80ccc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_srt_RangeAxis_697eb4a9-afe1-4303-9d03-93cf7db80ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_499d393d-72f0-486b-b203-a007e76942ba" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_697eb4a9-afe1-4303-9d03-93cf7db80ccc" xlink:to="loc_srt_RangeMember_499d393d-72f0-486b-b203-a007e76942ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b1b5ed59-b16e-4092-93b2-b78e090ff7ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_499d393d-72f0-486b-b203-a007e76942ba" xlink:to="loc_srt_MinimumMember_b1b5ed59-b16e-4092-93b2-b78e090ff7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_291c4ffb-cd7e-495f-8037-03677570a0d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_499d393d-72f0-486b-b203-a007e76942ba" xlink:to="loc_srt_MaximumMember_291c4ffb-cd7e-495f-8037-03677570a0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75543b4d-614a-406b-91ba-315ba06f4381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75543b4d-614a-406b-91ba-315ba06f4381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a267e6d9-2001-40e5-b237-b31956ff3602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_75543b4d-614a-406b-91ba-315ba06f4381" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a267e6d9-2001-40e5-b237-b31956ff3602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_286c9853-934f-464f-b6ca-045ec1ead6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a267e6d9-2001-40e5-b237-b31956ff3602" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_286c9853-934f-464f-b6ca-045ec1ead6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_981417be-868f-4523-b0dc-069c1299c847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_981417be-868f-4523-b0dc-069c1299c847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6658ef1d-fd0e-4d7d-83f8-06f6b791077d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_981417be-868f-4523-b0dc-069c1299c847" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6658ef1d-fd0e-4d7d-83f8-06f6b791077d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3914d5dc-b8ae-4b9e-bde2-eaed590df261" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_6658ef1d-fd0e-4d7d-83f8-06f6b791077d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3914d5dc-b8ae-4b9e-bde2-eaed590df261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_027c1b25-c4d5-4ae3-8e04-7c24ae507895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_027c1b25-c4d5-4ae3-8e04-7c24ae507895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7726203-3c1f-4890-8db3-cbc7298afcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_027c1b25-c4d5-4ae3-8e04-7c24ae507895" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7726203-3c1f-4890-8db3-cbc7298afcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_fc275dd3-47da-4a0e-8b30-295c4711f298" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d7726203-3c1f-4890-8db3-cbc7298afcb1" xlink:to="loc_biib_EisaiMember_fc275dd3-47da-4a0e-8b30-295c4711f298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bb9eaf67-7128-43c4-86d9-e540e8cc91e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_bbd0069c-82a7-4ed5-8fd6-0194022dca8e" xlink:href="biib-20201231.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_bbd0069c-82a7-4ed5-8fd6-0194022dca8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_68b481e7-e18e-4d2d-9988-b023bab785d8" xlink:href="biib-20201231.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_biib_InterestInSubsidiary_68b481e7-e18e-4d2d-9988-b023bab785d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_f5dda052-a6a2-4421-8efa-a16eff561e52" xlink:href="biib-20201231.xsd#biib_PaymentTermsOfAccountsReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_biib_PaymentTermsOfAccountsReceivable_f5dda052-a6a2-4421-8efa-a16eff561e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryCapitalizedCosts_b5e8ef1c-321c-4563-9472-4cffd7cc84fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryCapitalizedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_OtherInventoryCapitalizedCosts_b5e8ef1c-321c-4563-9472-4cffd7cc84fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_9f8f416a-8a4f-418e-bb2b-5118ebef034c" xlink:href="biib-20201231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_9f8f416a-8a4f-418e-bb2b-5118ebef034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54ecaca2-c2dd-4e0d-a8a8-0ba40c9613a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_54ecaca2-c2dd-4e0d-a8a8-0ba40c9613a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a5fe87e1-97d3-4a28-88a8-a56c87b80132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a5fe87e1-97d3-4a28-88a8-a56c87b80132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41f4983d-f278-4e17-8b0d-17237c223081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_OperatingLeaseLiability_41f4983d-f278-4e17-8b0d-17237c223081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b19f608d-0c13-4f0e-89dd-4e3283dc84b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b19f608d-0c13-4f0e-89dd-4e3283dc84b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_3556b347-c3a9-4adb-9f1a-a220eb6510b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_AdvertisingExpense_3556b347-c3a9-4adb-9f1a-a220eb6510b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fdf29610-3833-4d3e-b3f5-fefb86ed55eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_360a55f7-47f7-41af-92b3-5bf8dbaabe85" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fdf29610-3833-4d3e-b3f5-fefb86ed55eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cdde3fe6-2f44-49d1-934d-4edfbac3f5dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cdde3fe6-2f44-49d1-934d-4edfbac3f5dd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d24c6eaa-99ba-44cd-bd65-eda5ff058d33" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:to="loc_srt_RangeAxis_d24c6eaa-99ba-44cd-bd65-eda5ff058d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9103697-33a1-49df-ac6e-c6c5864461d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d24c6eaa-99ba-44cd-bd65-eda5ff058d33" xlink:to="loc_srt_RangeMember_e9103697-33a1-49df-ac6e-c6c5864461d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70a1fb1d-3d45-4161-a9a6-246c1ea4c46c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e9103697-33a1-49df-ac6e-c6c5864461d8" xlink:to="loc_srt_MinimumMember_70a1fb1d-3d45-4161-a9a6-246c1ea4c46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2f7d0222-cfdf-4952-a2ff-bc53104f0bd3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e9103697-33a1-49df-ac6e-c6c5864461d8" xlink:to="loc_srt_MaximumMember_2f7d0222-cfdf-4952-a2ff-bc53104f0bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4661db16-3248-4172-86bd-97b5af15acea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4661db16-3248-4172-86bd-97b5af15acea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4661db16-3248-4172-86bd-97b5af15acea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_fb802884-06c7-4a01-ac15-daafe34e5ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:to="loc_us-gaap_BuildingMember_fb802884-06c7-4a01-ac15-daafe34e5ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7ad6df91-47b3-42b6-a5b7-72be22659fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7ad6df91-47b3-42b6-a5b7-72be22659fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_51bd44f5-552f-4cd9-bee3-017036f83c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_51bd44f5-552f-4cd9-bee3-017036f83c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6a9ea247-095e-4163-8bb9-75f2463684e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9ccf935-845f-4033-a5cc-df7728f7537c" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_6a9ea247-095e-4163-8bb9-75f2463684e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05c333d5-114c-48d3-86b0-3515d624d7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_21d6ac88-8918-4b05-981b-a80d9850d82c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05c333d5-114c-48d3-86b0-3515d624d7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b219677-e396-430a-8419-9cc662d79ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05c333d5-114c-48d3-86b0-3515d624d7f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b219677-e396-430a-8419-9cc662d79ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20201231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b655b424-5695-4290-8acc-e04a8287cbbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d23535d3-9b2e-49b6-a0b9-d1e0c502a692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b655b424-5695-4290-8acc-e04a8287cbbf" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d23535d3-9b2e-49b6-a0b9-d1e0c502a692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_91b32013-36fe-4362-8147-790e787573a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_91b32013-36fe-4362-8147-790e787573a3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6993fbc4-9e55-4efa-807d-ea0db599e8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6993fbc4-9e55-4efa-807d-ea0db599e8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6993fbc4-9e55-4efa-807d-ea0db599e8fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB118Member_cff57adb-ab12-49de-a3f0-15705f64d49b" xlink:href="biib-20201231.xsd#biib_BIIB118Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_BIIB118Member_cff57adb-ab12-49de-a3f0-15705f64d49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_61b7a795-af78-496e-94b1-25e3a6965102" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_NightstarMember_61b7a795-af78-496e-94b1-25e3a6965102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_KaryopharmMember_cfc3b005-37e0-49f3-aaec-1b252814880e" xlink:href="biib-20201231.xsd#biib_KaryopharmMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_KaryopharmMember_cfc3b005-37e0-49f3-aaec-1b252814880e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PfizerMember_324a6128-658b-4b09-9eae-c81da18d204a" xlink:href="biib-20201231.xsd#biib_PfizerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_PfizerMember_324a6128-658b-4b09-9eae-c81da18d204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AliveGenMember_62b71589-618a-4ddf-a8dd-41b20625a0aa" xlink:href="biib-20201231.xsd#biib_AliveGenMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f22c8590-168f-49b7-873e-d218dcf88e92" xlink:to="loc_biib_AliveGenMember_62b71589-618a-4ddf-a8dd-41b20625a0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_411ea80a-fea7-4c54-b1cf-2b63259e25d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_411ea80a-fea7-4c54-b1cf-2b63259e25d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_bd4c9701-152b-4b7c-950a-80544cc1a777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_411ea80a-fea7-4c54-b1cf-2b63259e25d4" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_bd4c9701-152b-4b7c-950a-80544cc1a777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PostacquisitionequitycompensationMember_574711b5-d617-43c2-ac19-3bddfc7d0505" xlink:href="biib-20201231.xsd#biib_PostacquisitionequitycompensationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_bd4c9701-152b-4b7c-950a-80544cc1a777" xlink:to="loc_biib_PostacquisitionequitycompensationMember_574711b5-d617-43c2-ac19-3bddfc7d0505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cef9709b-442e-479d-84b9-3bf89e82b206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cef9709b-442e-479d-84b9-3bf89e82b206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8efe998c-dba6-443a-b99e-501e3794bcc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cef9709b-442e-479d-84b9-3bf89e82b206" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8efe998c-dba6-443a-b99e-501e3794bcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_96cb2073-0e92-4bdf-93b4-c51bb753ecf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8efe998c-dba6-443a-b99e-501e3794bcc8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_96cb2073-0e92-4bdf-93b4-c51bb753ecf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fbaf2787-dc07-4879-a62a-62dee2cbe84a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8efe998c-dba6-443a-b99e-501e3794bcc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_fbaf2787-dc07-4879-a62a-62dee2cbe84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_fdf64819-9d05-4d56-9327-54a51ad51e47" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_fdf64819-9d05-4d56-9327-54a51ad51e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_c5c4d776-786d-4a78-acce-b67fd4eaca6a" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_fdf64819-9d05-4d56-9327-54a51ad51e47" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_c5c4d776-786d-4a78-acce-b67fd4eaca6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_1d0dc14f-379d-4301-929f-f416942c176b" xlink:href="biib-20201231.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_c5c4d776-786d-4a78-acce-b67fd4eaca6a" xlink:to="loc_biib_BIIB111Member_1d0dc14f-379d-4301-929f-f416942c176b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_1dd4fb33-10f2-4390-bbcf-f32d66bf20f6" xlink:href="biib-20201231.xsd#biib_BIIB112Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_c5c4d776-786d-4a78-acce-b67fd4eaca6a" xlink:to="loc_biib_BIIB112Member_1dd4fb33-10f2-4390-bbcf-f32d66bf20f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5d000a18-f0b5-41c9-bd11-5f6fb6adcf12" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_da3a14a6-951f-42e4-a4a5-37e06c6a5d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_da3a14a6-951f-42e4-a4a5-37e06c6a5d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_47a2ef02-72ee-4e39-bcbc-28a3b27650bb" xlink:href="biib-20201231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_47a2ef02-72ee-4e39-bcbc-28a3b27650bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalAssetsAcquired_b4dcb68c-f90d-4e8d-8d84-a74812aa8d0a" xlink:href="biib-20201231.xsd#biib_ClinicalAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_biib_ClinicalAssetsAcquired_b4dcb68c-f90d-4e8d-8d84-a74812aa8d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_73b4c0c6-2be1-481e-bfca-d74f0092e958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_73b4c0c6-2be1-481e-bfca-d74f0092e958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_58c2c003-d539-4480-9a30-b4f436abca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_58c2c003-d539-4480-9a30-b4f436abca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_43bff1f0-cb05-4d7b-a262-a95f6eef9e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_43bff1f0-cb05-4d7b-a262-a95f6eef9e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_1a0ba02b-bba8-4d5a-aa6e-891bbb092150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_1a0ba02b-bba8-4d5a-aa6e-891bbb092150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_a61d9ec2-d279-4dac-91c5-f59927031c8c" xlink:href="biib-20201231.xsd#biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate_a61d9ec2-d279-4dac-91c5-f59927031c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1a00494e-2e68-4014-b046-4bf70d02c21f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1a00494e-2e68-4014-b046-4bf70d02c21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_d149b3c8-1466-4068-a859-8a7a89270733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e467534b-5e51-4eb5-8e8f-1f87251b8c7b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_d149b3c8-1466-4068-a859-8a7a89270733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Divestitures" xlink:type="simple" xlink:href="biib-20201231.xsd#Divestitures"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Divestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_cac68bd8-601e-4e33-a80e-1cd184a02592" xlink:href="biib-20201231.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_768aaa28-e754-4ae2-b248-e7e67ec7f016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_cac68bd8-601e-4e33-a80e-1cd184a02592" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_768aaa28-e754-4ae2-b248-e7e67ec7f016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DivestituresDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_60b72ee9-d850-45b8-a07b-6da8ae8fc655" xlink:href="biib-20201231.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_aa7c93f7-122a-4478-a23d-98af5aac3fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_60b72ee9-d850-45b8-a07b-6da8ae8fc655" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_aa7c93f7-122a-4478-a23d-98af5aac3fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9aef2f98-1549-46fb-a312-33c2295d6c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_aa7c93f7-122a-4478-a23d-98af5aac3fcd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9aef2f98-1549-46fb-a312-33c2295d6c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e5779860-1a09-4dbc-9cd8-e59f66cac7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9aef2f98-1549-46fb-a312-33c2295d6c23" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e5779860-1a09-4dbc-9cd8-e59f66cac7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_942f6de4-74fb-447a-a288-c6ab4aaa5bf6" xlink:href="biib-20201231.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e5779860-1a09-4dbc-9cd8-e59f66cac7a2" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_942f6de4-74fb-447a-a288-c6ab4aaa5bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_aa7c93f7-122a-4478-a23d-98af5aac3fcd" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_09c91d4f-2538-441a-a5f3-e352b6b1c09c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_09c91d4f-2538-441a-a5f3-e352b6b1c09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_696d942c-48ea-499b-a299-e878bb6d6a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_696d942c-48ea-499b-a299-e878bb6d6a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_cde71995-f617-4bd4-a45a-171652dac125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_cde71995-f617-4bd4-a45a-171652dac125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f119d2c6-da00-4a8b-aafa-d6902b3215a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f119d2c6-da00-4a8b-aafa-d6902b3215a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9b60e565-bdc9-4821-a25f-76baf5391782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9b60e565-bdc9-4821-a25f-76baf5391782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_40b10ab1-5856-44a4-8c89-89863ca43336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_40b10ab1-5856-44a4-8c89-89863ca43336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_921dfee6-6eb8-49f9-987c-ab09629e9b4c" xlink:href="biib-20201231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_921dfee6-6eb8-49f9-987c-ab09629e9b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PurchaseCommitmentReductionOfAmountCommitted_6ca194f3-3db6-4299-969f-7a7a924544f9" xlink:href="biib-20201231.xsd#biib_PurchaseCommitmentReductionOfAmountCommitted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_9eadab30-fbed-4969-918e-e9237c3884e4" xlink:to="loc_biib_PurchaseCommitmentReductionOfAmountCommitted_6ca194f3-3db6-4299-969f-7a7a924544f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20201231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0fbd003f-63c9-4c58-be72-fdaf2d5dd86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_93d8fd42-4983-4f7e-af9b-cb86638743c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0fbd003f-63c9-4c58-be72-fdaf2d5dd86f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_93d8fd42-4983-4f7e-af9b-cb86638743c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5c6371ef-4476-4a39-a90b-7089791c4adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4d850e80-4a6b-48cd-8d4a-8a29dacf02b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5c6371ef-4476-4a39-a90b-7089791c4adb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4d850e80-4a6b-48cd-8d4a-8a29dacf02b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_3df2edb6-2361-422a-bf73-dfad40ec461a" xlink:href="biib-20201231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5c6371ef-4476-4a39-a90b-7089791c4adb" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_3df2edb6-2361-422a-bf73-dfad40ec461a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4a201689-2655-4384-8268-eb4fa8556db4" xlink:href="biib-20201231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5c6371ef-4476-4a39-a90b-7089791c4adb" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4a201689-2655-4384-8268-eb4fa8556db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_903bc99c-6996-41af-b47e-ad0ca1a81f7b" xlink:href="biib-20201231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5c6371ef-4476-4a39-a90b-7089791c4adb" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_903bc99c-6996-41af-b47e-ad0ca1a81f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_ff76b5ea-beeb-4461-b174-6d3f537a427f" xlink:href="biib-20201231.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5c6371ef-4476-4a39-a90b-7089791c4adb" xlink:to="loc_biib_OtherrevenuesTableTextBlock_ff76b5ea-beeb-4461-b174-6d3f537a427f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesRevenuesbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7485b8b0-fb15-4f1e-bc7d-372f533b1af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7485b8b0-fb15-4f1e-bc7d-372f533b1af1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7786e8c0-5bc8-4653-ab25-4a867f53e4d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:to="loc_srt_StatementGeographicalAxis_7786e8c0-5bc8-4653-ab25-4a867f53e4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ededc21b-c3ab-41e5-bffe-5a87c29a1ebd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7786e8c0-5bc8-4653-ab25-4a867f53e4d9" xlink:to="loc_srt_SegmentGeographicalDomain_ededc21b-c3ab-41e5-bffe-5a87c29a1ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_866e6e99-ddeb-4721-91b2-4413d9e95fb7" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ededc21b-c3ab-41e5-bffe-5a87c29a1ebd" xlink:to="loc_country_US_866e6e99-ddeb-4721-91b2-4413d9e95fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b673e7a6-64f9-45fa-a263-77752cc95eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ededc21b-c3ab-41e5-bffe-5a87c29a1ebd" xlink:to="loc_us-gaap_NonUsMember_b673e7a6-64f9-45fa-a263-77752cc95eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe316a9d-90a3-47f2-b995-6e486353c760" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:to="loc_srt_ProductOrServiceAxis_fe316a9d-90a3-47f2-b995-6e486353c760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fe316a9d-90a3-47f2-b995-6e486353c760" xlink:to="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_2a609a07-72fc-4c7f-a34b-65cdfcad97f6" xlink:href="biib-20201231.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_FumarateMember_2a609a07-72fc-4c7f-a34b-65cdfcad97f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_242f2710-cfba-470e-803a-44f6be02e0a9" xlink:href="biib-20201231.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_InterferonMember_242f2710-cfba-470e-803a-44f6be02e0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_72d3d32a-4d22-48b0-89f1-fe7fed62efc2" xlink:href="biib-20201231.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_TysabriProductMember_72d3d32a-4d22-48b0-89f1-fe7fed62efc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_ff01b125-c232-4a9d-8924-bbc1b53d6c1a" xlink:href="biib-20201231.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_FAMPYRAMember_ff01b125-c232-4a9d-8924-bbc1b53d6c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_2c91287d-f1c2-4c46-b90e-be19c4964c8a" xlink:href="biib-20201231.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_ZINBRYTAMember_2c91287d-f1c2-4c46-b90e-be19c4964c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_ddc425ed-f1fe-4e76-a845-6065d7eff6a8" xlink:href="biib-20201231.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_MSProductRevenuesMember_ddc425ed-f1fe-4e76-a845-6065d7eff6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_15ac5c07-962b-4a3c-9d11-662ab8b98eff" xlink:href="biib-20201231.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_SPINRAZAMember_15ac5c07-962b-4a3c-9d11-662ab8b98eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_0269fa8d-a7de-4edd-9ef4-d51abc0fe106" xlink:href="biib-20201231.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_BENEPALIMember_0269fa8d-a7de-4edd-9ef4-d51abc0fe106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_72952523-6395-4193-af7f-c5d80b49d871" xlink:href="biib-20201231.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_IMRALDIMember_72952523-6395-4193-af7f-c5d80b49d871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_512b99a6-0747-4b80-bab5-c204a39081af" xlink:href="biib-20201231.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_FLIXABIMember_512b99a6-0747-4b80-bab5-c204a39081af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_37e19f49-df8b-48c2-8278-0c20fba851a9" xlink:href="biib-20201231.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_BiosimilarsMember_37e19f49-df8b-48c2-8278-0c20fba851a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_cdccace6-4225-4bfa-a43e-ed8bb9bea438" xlink:href="biib-20201231.xsd#biib_FUMADERMMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_biib_FUMADERMMember_cdccace6-4225-4bfa-a43e-ed8bb9bea438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_79e1192b-7455-404c-a87d-7c209e1317cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_599978cd-63c7-4f9b-8ca1-d1cbd8a6c398" xlink:to="loc_us-gaap_ProductMember_79e1192b-7455-404c-a87d-7c209e1317cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3caa7f51-06cf-45de-915d-5b25304f0efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3bb2ec93-a46b-40e3-9e16-648898c7d79a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3caa7f51-06cf-45de-915d-5b25304f0efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2d8b50a3-833d-444e-b439-052d70f7da1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3caa7f51-06cf-45de-915d-5b25304f0efc" xlink:to="loc_us-gaap_Revenues_2d8b50a3-833d-444e-b439-052d70f7da1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9e9adc18-a569-42a2-b851-a9b5b93342f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9e9adc18-a569-42a2-b851-a9b5b93342f8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MajorDistributorAxis_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042" xlink:href="biib-20201231.xsd#biib_MajorDistributorAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:to="loc_biib_MajorDistributorAxis_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MajorDistributorDomain_b874a20d-95d1-46fb-a8e4-eaccf47371e4" xlink:href="biib-20201231.xsd#biib_MajorDistributorDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_c04dda6e-f0ec-4dbc-a5b3-c7f4891e9042" xlink:to="loc_biib_MajorDistributorDomain_b874a20d-95d1-46fb-a8e4-eaccf47371e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_86ad889b-c65d-4c0f-8be1-ac19a2071489" xlink:href="biib-20201231.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_b874a20d-95d1-46fb-a8e4-eaccf47371e4" xlink:to="loc_biib_DistributorOneMember_86ad889b-c65d-4c0f-8be1-ac19a2071489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_23ef4067-9213-4fd7-bba8-dbe08b74be23" xlink:href="biib-20201231.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_b874a20d-95d1-46fb-a8e4-eaccf47371e4" xlink:to="loc_biib_DistributorTwoMember_23ef4067-9213-4fd7-bba8-dbe08b74be23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_faf9c9ac-864f-428b-8207-2d9696559a57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:to="loc_srt_MajorCustomersAxis_faf9c9ac-864f-428b-8207-2d9696559a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_650bca0e-12b8-4bb9-839b-4671676f7738" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_faf9c9ac-864f-428b-8207-2d9696559a57" xlink:to="loc_srt_NameOfMajorCustomerDomain_650bca0e-12b8-4bb9-839b-4671676f7738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BioverativMember_52fad878-eb5c-47ef-839a-5cba10be327f" xlink:href="biib-20201231.xsd#biib_BioverativMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_650bca0e-12b8-4bb9-839b-4671676f7738" xlink:to="loc_biib_BioverativMember_52fad878-eb5c-47ef-839a-5cba10be327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingCustomerMember_f218d9f0-4886-4b03-af19-20dbece299b8" xlink:href="biib-20201231.xsd#biib_ContractManufacturingCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_650bca0e-12b8-4bb9-839b-4671676f7738" xlink:to="loc_biib_ContractManufacturingCustomerMember_f218d9f0-4886-4b03-af19-20dbece299b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b9ed688f-8a01-4bcf-81e1-371fb7eea788" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:to="loc_srt_ProductOrServiceAxis_b9ed688f-8a01-4bcf-81e1-371fb7eea788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b8440aa-6d03-4d12-893c-031016a96d70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b9ed688f-8a01-4bcf-81e1-371fb7eea788" xlink:to="loc_srt_ProductsAndServicesDomain_1b8440aa-6d03-4d12-893c-031016a96d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_b75d798a-5486-4a3c-962a-aaa53fabe7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1b8440aa-6d03-4d12-893c-031016a96d70" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_b75d798a-5486-4a3c-962a-aaa53fabe7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_5f692e69-dd7f-45ef-b9ea-f5027b1c74ef" xlink:href="biib-20201231.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1b8440aa-6d03-4d12-893c-031016a96d70" xlink:to="loc_biib_OthercorporaterevenuesMember_5f692e69-dd7f-45ef-b9ea-f5027b1c74ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_2069a559-d570-434d-a5d1-9056c35f054a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_e2bf50a8-803c-43a1-b795-bd6792a77240" xlink:href="biib-20201231.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_biib_NumberOfWholesalers_e2bf50a8-803c-43a1-b795-bd6792a77240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_863b0626-2a5b-4cbd-92c0-730d1c1ee8e1" xlink:href="biib-20201231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_863b0626-2a5b-4cbd-92c0-730d1c1ee8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_3f24b077-9827-43fa-b0f9-91fd850ea9a4" xlink:href="biib-20201231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_3f24b077-9827-43fa-b0f9-91fd850ea9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_59b81a5c-8a7f-4759-915e-3caa1ff7fe07" xlink:href="biib-20201231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_59b81a5c-8a7f-4759-915e-3caa1ff7fe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_47f8cd2a-9314-4939-9402-c2b40f4db8bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_us-gaap_Revenues_47f8cd2a-9314-4939-9402-c2b40f4db8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f69d963c-82b7-4434-98c6-3758d9cf516b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b9a5042a-9548-4a1d-b9ec-61a08ec9c2ca" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f69d963c-82b7-4434-98c6-3758d9cf516b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesReservesforDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6a13f79-28ec-42da-8ba6-7304efcb0f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2782970-4b3a-4a8c-848f-6b9bee3d4c40" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a6a13f79-28ec-42da-8ba6-7304efcb0f22" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2782970-4b3a-4a8c-848f-6b9bee3d4c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7dd753b9-2bfd-44a9-b682-0c39af223d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2782970-4b3a-4a8c-848f-6b9bee3d4c40" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7dd753b9-2bfd-44a9-b682-0c39af223d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_7dd753b9-2bfd-44a9-b682-0c39af223d47" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_cc35c3ae-0d28-4d50-9f1f-d09a6921954f" xlink:href="biib-20201231.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:to="loc_biib_ReserveforCashDiscountsMember_cc35c3ae-0d28-4d50-9f1f-d09a6921954f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_5375e095-37a5-4e4c-adfb-eb399901f9a5" xlink:href="biib-20201231.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:to="loc_biib_ContractualAdjustmentsMember_5375e095-37a5-4e4c-adfb-eb399901f9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_b00270b2-ce10-496b-b8ee-c911cfb99319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ca9cdd48-72a3-4223-87b1-cd7828f0a757" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_b00270b2-ce10-496b-b8ee-c911cfb99319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_70f4ca55-d0f0-4c8e-a124-f6ffee87578d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a2782970-4b3a-4a8c-848f-6b9bee3d4c40" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_70f4ca55-d0f0-4c8e-a124-f6ffee87578d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_70f4ca55-d0f0-4c8e-a124-f6ffee87578d" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a2799d0c-dfce-47e5-ac75-2b8e5b9ed78e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a2799d0c-dfce-47e5-ac75-2b8e5b9ed78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_23e61ae6-a865-4a93-a260-777e6d813db9" xlink:href="biib-20201231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_23e61ae6-a865-4a93-a260-777e6d813db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_1cbfa6f4-4d7f-4aa7-8668-27f4149fea64" xlink:href="biib-20201231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_1cbfa6f4-4d7f-4aa7-8668-27f4149fea64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_e1381edd-f7f4-4610-ab8c-0b3fca84baf0" xlink:href="biib-20201231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_e1381edd-f7f4-4610-ab8c-0b3fca84baf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_d565ba11-486e-4dee-aa7f-8b34755093ac" xlink:href="biib-20201231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_d565ba11-486e-4dee-aa7f-8b34755093ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d61bc7a2-928e-473c-b4eb-5703c27ff3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0976042d-b2d3-44ec-9051-69e2c3df5da1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d61bc7a2-928e-473c-b4eb-5703c27ff3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesTotalReservesforDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee3d9c07-00b3-42d3-879f-64c9b287f1b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_82f81e39-b98e-41b6-839f-f53fcb258596" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ee3d9c07-00b3-42d3-879f-64c9b287f1b0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_82f81e39-b98e-41b6-839f-f53fcb258596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_08493d29-3dd1-4277-b88e-e332ce677617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_82f81e39-b98e-41b6-839f-f53fcb258596" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_08493d29-3dd1-4277-b88e-e332ce677617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a7322223-14f7-4893-999f-b13a94c4285a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_08493d29-3dd1-4277-b88e-e332ce677617" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a7322223-14f7-4893-999f-b13a94c4285a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0dcb529b-7387-46b4-8060-7ea7a07353a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a7322223-14f7-4893-999f-b13a94c4285a" xlink:to="loc_us-gaap_AccountsReceivableMember_0dcb529b-7387-46b4-8060-7ea7a07353a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_0e52f656-52e0-474d-a455-3ce02de0887c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a7322223-14f7-4893-999f-b13a94c4285a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_0e52f656-52e0-474d-a455-3ce02de0887c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6a50eedb-73b6-4853-927d-3a15514e16d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_82f81e39-b98e-41b6-839f-f53fcb258596" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6a50eedb-73b6-4853-927d-3a15514e16d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ed8c43b5-ee14-4ebb-8fbf-c23941e2066f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_6a50eedb-73b6-4853-927d-3a15514e16d5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ed8c43b5-ee14-4ebb-8fbf-c23941e2066f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8b06dea6-9558-453e-8795-aa1708ff6938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8b06dea6-9558-453e-8795-aa1708ff6938" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4b20f65f-dca1-451c-b7b4-deea470be791" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:to="loc_srt_MajorCustomersAxis_4b20f65f-dca1-451c-b7b4-deea470be791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f47597bf-42c7-42bc-879f-5bab0114fad0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4b20f65f-dca1-451c-b7b4-deea470be791" xlink:to="loc_srt_NameOfMajorCustomerDomain_f47597bf-42c7-42bc-879f-5bab0114fad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_d5729c2f-f8f7-4e72-9155-2d6e60c92c4c" xlink:href="biib-20201231.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f47597bf-42c7-42bc-879f-5bab0114fad0" xlink:to="loc_biib_RocheGroupGenentechMember_d5729c2f-f8f7-4e72-9155-2d6e60c92c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5b49ef01-5ada-4fab-9dcc-0e15df8e0973" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:to="loc_srt_ProductOrServiceAxis_5b49ef01-5ada-4fab-9dcc-0e15df8e0973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec582985-72c1-4f73-8e09-3d029928b56d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5b49ef01-5ada-4fab-9dcc-0e15df8e0973" xlink:to="loc_srt_ProductsAndServicesDomain_ec582985-72c1-4f73-8e09-3d029928b56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_f8510afd-3eeb-489d-8838-fa46c4875a5a" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ec582985-72c1-4f73-8e09-3d029928b56d" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_f8510afd-3eeb-489d-8838-fa46c4875a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_685c64dd-f520-45cd-9b68-82882b3b5db8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_2c5519bd-6784-4c54-88e4-1f6b2b41c08d" xlink:href="biib-20201231.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:to="loc_biib_ShareOfCoPromotionProfits_2c5519bd-6784-4c54-88e4-1f6b2b41c08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_312ad5a0-eb87-410d-96dd-38a749ee17f5" xlink:href="biib-20201231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_312ad5a0-eb87-410d-96dd-38a749ee17f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_597ce7c8-dfe1-4b66-ac33-88d5b692ccd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2142f983-2d32-4ac9-a70e-9083c21f9bbf" xlink:to="loc_us-gaap_Revenues_597ce7c8-dfe1-4b66-ac33-88d5b692ccd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_504a3351-d4cc-4096-9fef-f94f00307a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_504a3351-d4cc-4096-9fef-f94f00307a6e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4471be72-6a2b-43ac-bea8-0a4977142cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4471be72-6a2b-43ac-bea8-0a4977142cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7cdb474-d594-4b21-a644-9f52554c1f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4471be72-6a2b-43ac-bea8-0a4977142cb5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7cdb474-d594-4b21-a644-9f52554c1f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_ea1a4095-8a46-4a51-bfff-acef5f4d7014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f7cdb474-d594-4b21-a644-9f52554c1f5d" xlink:to="loc_us-gaap_CollaborativeArrangementMember_ea1a4095-8a46-4a51-bfff-acef5f4d7014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:to="loc_srt_ProductOrServiceAxis_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a27cf1f6-025c-4857-bb17-5c0cfaf0aad4" xlink:to="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_39a10c66-ad2b-4a42-8061-385f2eca5967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:to="loc_us-gaap_RoyaltyMember_39a10c66-ad2b-4a42-8061-385f2eca5967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_a5f9e280-2b08-4649-8808-a85ad4a93667" xlink:href="biib-20201231.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:to="loc_biib_OthercorporaterevenuesMember_a5f9e280-2b08-4649-8808-a85ad4a93667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_6878fce4-e992-41c8-a891-5e0112abbd0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e5772de0-b4e1-4d01-a0bc-aa5538a4fdfb" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_6878fce4-e992-41c8-a891-5e0112abbd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_988c2a03-e3a4-4a76-80cd-17d6c04ada9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:to="loc_srt_MajorCustomersAxis_988c2a03-e3a4-4a76-80cd-17d6c04ada9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ec35216b-afc7-421b-bb61-ec079b3d8fd6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_988c2a03-e3a4-4a76-80cd-17d6c04ada9e" xlink:to="loc_srt_NameOfMajorCustomerDomain_ec35216b-afc7-421b-bb61-ec079b3d8fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_ba7d780e-3a35-4e85-b11a-118babcda81d" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec35216b-afc7-421b-bb61-ec079b3d8fd6" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_ba7d780e-3a35-4e85-b11a-118babcda81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherRelationshipsMember_86489641-d46f-4d5c-ac53-90b26b5bf5ef" xlink:href="biib-20201231.xsd#biib_OtherRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ec35216b-afc7-421b-bb61-ec079b3d8fd6" xlink:to="loc_biib_OtherRelationshipsMember_86489641-d46f-4d5c-ac53-90b26b5bf5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_d1d8686a-cf99-4c4a-b2ad-1075a9054cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_02e11ff3-534e-41db-b16f-6a170ea9826f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_d1d8686a-cf99-4c4a-b2ad-1075a9054cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e5bf5fde-4e27-43de-92d0-f22d8a4ffda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_d1d8686a-cf99-4c4a-b2ad-1075a9054cb1" xlink:to="loc_us-gaap_Revenues_e5bf5fde-4e27-43de-92d0-f22d8a4ffda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20201231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_cd8c0ed7-1ed8-4b76-ac82-c48d1d9d95e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_a1f2fea6-b664-4eaf-8590-fe7df1b68550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_cd8c0ed7-1ed8-4b76-ac82-c48d1d9d95e4" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_a1f2fea6-b664-4eaf-8590-fe7df1b68550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8e8b3e88-6af9-448d-a168-4931c506eb63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8db108c0-e4eb-4d82-9dbc-75baf10fb930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8e8b3e88-6af9-448d-a168-4931c506eb63" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8db108c0-e4eb-4d82-9dbc-75baf10fb930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_21e4d3ea-2076-4c7c-b2e6-607a8e932971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_fefa1568-e50f-486c-8f44-08736257ab31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_21e4d3ea-2076-4c7c-b2e6-607a8e932971" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_fefa1568-e50f-486c-8f44-08736257ab31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d0b993eb-e238-45f1-9649-f99a20a02fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_21e4d3ea-2076-4c7c-b2e6-607a8e932971" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d0b993eb-e238-45f1-9649-f99a20a02fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_75e9c8fe-1923-4c54-8943-19c3cb02ef64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_21e4d3ea-2076-4c7c-b2e6-607a8e932971" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_75e9c8fe-1923-4c54-8943-19c3cb02ef64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_2932c51f-ef1d-4bdb-a336-f4016c68213c" xlink:href="biib-20201231.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_21e4d3ea-2076-4c7c-b2e6-607a8e932971" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_2932c51f-ef1d-4bdb-a336-f4016c68213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_dc45761a-c3c2-4f42-84ef-c0541f851fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_66f3b2d0-6c1f-481d-a7bb-703800b5592c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dc45761a-c3c2-4f42-84ef-c0541f851fb3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_66f3b2d0-6c1f-481d-a7bb-703800b5592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_66f3b2d0-6c1f-481d-a7bb-703800b5592c" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e6d5d99-1716-4f71-85fa-053d9dada9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_a32e768b-bbe1-43d3-9d97-0aae5ccfa1c8" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e6d5d99-1716-4f71-85fa-053d9dada9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkinprocessMember_df723935-b375-4d29-8b4d-eb90aaa9329f" xlink:href="biib-20201231.xsd#biib_WorkinprocessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e6d5d99-1716-4f71-85fa-053d9dada9eb" xlink:to="loc_biib_WorkinprocessMember_df723935-b375-4d29-8b4d-eb90aaa9329f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_66f3b2d0-6c1f-481d-a7bb-703800b5592c" xlink:to="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_901a8af3-db26-4de6-8cdd-ee5beb6d97a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:to="loc_us-gaap_InventoryWriteDown_901a8af3-db26-4de6-8cdd-ee5beb6d97a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0feb2697-aa66-4d83-a1b5-865dc54061fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_0feb2697-aa66-4d83-a1b5-865dc54061fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_30d30a40-cf7c-4ce4-8eb8-18ee07fccca4" xlink:href="biib-20201231.xsd#biib_InventoryrawmaterialssoldtoFUJIFILM"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_a795e18c-a9d2-4838-aa23-df0c62231a6e" xlink:to="loc_biib_InventoryrawmaterialssoldtoFUJIFILM_30d30a40-cf7c-4ce4-8eb8-18ee07fccca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6faff00f-9daf-41bc-8f94-e48fd4867996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_41815526-4f48-493f-872e-131d8822572e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6faff00f-9daf-41bc-8f94-e48fd4867996" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_41815526-4f48-493f-872e-131d8822572e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cb9d7084-649e-4a19-9d72-51b2c24f92a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_3cb626c6-c281-42d5-8f9d-47c4b4de43f7" xlink:href="biib-20201231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cb9d7084-649e-4a19-9d72-51b2c24f92a1" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_3cb626c6-c281-42d5-8f9d-47c4b4de43f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b589c951-298e-45e1-8575-4c5f453d3c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cb9d7084-649e-4a19-9d72-51b2c24f92a1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b589c951-298e-45e1-8575-4c5f453d3c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_f2c3dfb0-1a47-4b72-95a6-84e980648e47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cb9d7084-649e-4a19-9d72-51b2c24f92a1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_f2c3dfb0-1a47-4b72-95a6-84e980648e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6d3fde7-4326-4436-b9fb-082cd2754e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6d3fde7-4326-4436-b9fb-082cd2754e91" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_288eaecf-cd21-4110-8d22-ec8bcb724d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_288eaecf-cd21-4110-8d22-ec8bcb724d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6514d6d-ebb6-4149-bc52-229f3197b5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_288eaecf-cd21-4110-8d22-ec8bcb724d52" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6514d6d-ebb6-4149-bc52-229f3197b5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_59b980c0-6fa0-4bf3-a697-702e12a8e1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6514d6d-ebb6-4149-bc52-229f3197b5fc" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_59b980c0-6fa0-4bf3-a697-702e12a8e1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_d4fabce5-0e98-4269-b358-4e6955199f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c6514d6d-ebb6-4149-bc52-229f3197b5fc" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_d4fabce5-0e98-4269-b358-4e6955199f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_286aea6a-5111-45b7-a779-e9dafbc12d8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:to="loc_srt_RangeAxis_286aea6a-5111-45b7-a779-e9dafbc12d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_457543b5-08e3-47e7-b505-2b5397987ede" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_286aea6a-5111-45b7-a779-e9dafbc12d8c" xlink:to="loc_srt_RangeMember_457543b5-08e3-47e7-b505-2b5397987ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37f59a09-069f-4d58-8e9c-9fbee26136ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_457543b5-08e3-47e7-b505-2b5397987ede" xlink:to="loc_srt_MinimumMember_37f59a09-069f-4d58-8e9c-9fbee26136ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f0ab84a6-d9d1-4c23-8a09-14ce326bb9e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_457543b5-08e3-47e7-b505-2b5397987ede" xlink:to="loc_srt_MaximumMember_f0ab84a6-d9d1-4c23-8a09-14ce326bb9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_34c62291-4d47-44d9-9394-12559ccf8ab4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b4068342-54dd-42a7-b290-5f77e734f594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b4068342-54dd-42a7-b290-5f77e734f594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_70a2d717-01bf-444a-8eac-0cf09ec291d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_70a2d717-01bf-444a-8eac-0cf09ec291d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ded8585a-0bd9-40ce-9222-1dc20cf81c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_ded8585a-0bd9-40ce-9222-1dc20cf81c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_705c5f61-6d24-47c6-a6fa-361569e5f9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_705c5f61-6d24-47c6-a6fa-361569e5f9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9f33e26-55f5-4de8-a630-48e34468e3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e9f33e26-55f5-4de8-a630-48e34468e3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97fcffe7-c3e5-4cf0-9b8b-fb435102b51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97fcffe7-c3e5-4cf0-9b8b-fb435102b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_676ce1e8-8ac5-4343-9e3b-976ef35c5220" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d98b14e1-7c37-4169-b817-426dc5e33936" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_676ce1e8-8ac5-4343-9e3b-976ef35c5220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_48f6118e-8acb-44aa-8449-72777aa52646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_48f6118e-8acb-44aa-8449-72777aa52646" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d9a528cb-1348-46eb-925e-0e036458db7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d9a528cb-1348-46eb-925e-0e036458db7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036f7af8-4207-4075-848d-d0caf5fd34f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d9a528cb-1348-46eb-925e-0e036458db7c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036f7af8-4207-4075-848d-d0caf5fd34f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_d6554c34-86b5-4335-86b3-46c3763d81f7" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_036f7af8-4207-4075-848d-d0caf5fd34f3" xlink:to="loc_biib_NightstarMember_d6554c34-86b5-4335-86b3-46c3763d81f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_8d5fa3f7-6000-4db7-b996-68ff844c48e5" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_8d5fa3f7-6000-4db7-b996-68ff844c48e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_8d5fa3f7-6000-4db7-b996-68ff844c48e5" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_45b8dca6-690e-43a4-8f58-1cad9d507ee8" xlink:href="biib-20201231.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:to="loc_biib_BIIB111Member_45b8dca6-690e-43a4-8f58-1cad9d507ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB054Member_22c9b8d2-4ed0-4a87-9115-622a20a7b1f3" xlink:href="biib-20201231.xsd#biib_BIIB054Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:to="loc_biib_BIIB054Member_22c9b8d2-4ed0-4a87-9115-622a20a7b1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_e5cf2990-fa8d-4457-9968-d9883b9a7bac" xlink:href="biib-20201231.xsd#biib_TGNMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_67a869f9-7368-49f5-840e-cb920923deb9" xlink:to="loc_biib_TGNMember_e5cf2990-fa8d-4457-9968-d9883b9a7bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_683b1c88-3854-40f3-8639-b4eedd3c9583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_683b1c88-3854-40f3-8639-b4eedd3c9583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_73b559dd-45b6-464f-849c-ceb62abb1041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_683b1c88-3854-40f3-8639-b4eedd3c9583" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_73b559dd-45b6-464f-849c-ceb62abb1041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5e922b40-5d54-4c37-9ee4-e8736189bb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_73b559dd-45b6-464f-849c-ceb62abb1041" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5e922b40-5d54-4c37-9ee4-e8736189bb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_daedb89d-3ae3-4896-82f8-00645dd1d6bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_daedb89d-3ae3-4896-82f8-00645dd1d6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a722d43-b3fd-4bb0-b450-8af336e9cab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_daedb89d-3ae3-4896-82f8-00645dd1d6bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a722d43-b3fd-4bb0-b450-8af336e9cab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3141c0e9-ca66-4e8e-9dc6-af2ab656b0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7a722d43-b3fd-4bb0-b450-8af336e9cab9" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_3141c0e9-ca66-4e8e-9dc6-af2ab656b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_24d29a6d-ae17-404b-b6a7-9a562c858b4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_srt_ProductOrServiceAxis_24d29a6d-ae17-404b-b6a7-9a562c858b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_feb829f9-346a-436d-a989-7ea098c56535" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_24d29a6d-ae17-404b-b6a7-9a562c858b4c" xlink:to="loc_srt_ProductsAndServicesDomain_feb829f9-346a-436d-a989-7ea098c56535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_3d44da65-c0da-433b-9aad-785271ca9f62" xlink:href="biib-20201231.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_feb829f9-346a-436d-a989-7ea098c56535" xlink:to="loc_biib_TECFIDERAMember_3d44da65-c0da-433b-9aad-785271ca9f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_262c6cf3-173f-46fc-9fe3-b52e9c998111" xlink:to="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_7140a184-9735-4d8a-88b3-c8fcb9826668" xlink:href="biib-20201231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_7140a184-9735-4d8a-88b3-c8fcb9826668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f5d1c1ff-01e9-4cbb-ab69-e2a521b459e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f5d1c1ff-01e9-4cbb-ab69-e2a521b459e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e36df39f-6dc2-48bf-8433-b7f160d1d992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e36df39f-6dc2-48bf-8433-b7f160d1d992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1c69e442-b0e7-4559-a5a0-948992f9023f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_1c69e442-b0e7-4559-a5a0-948992f9023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_403fe8d2-0ed5-4b68-8b22-47d3ca16ee86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_403fe8d2-0ed5-4b68-8b22-47d3ca16ee86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6adc714e-a320-476c-affa-399be848fd95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6adc714e-a320-476c-affa-399be848fd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1872cbd2-a6e0-48a2-820f-16b21b34fd46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_653715b4-25ba-4bea-83bd-9d326fe995c6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1872cbd2-a6e0-48a2-820f-16b21b34fd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b31f5806-9c5b-463e-82ce-1ea230a43aa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c73a1b29-2d9d-46fd-8c9c-404ec622e20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b31f5806-9c5b-463e-82ce-1ea230a43aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c73a1b29-2d9d-46fd-8c9c-404ec622e20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_eb41213d-a7df-4b1c-bc50-58140eb7f0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b31f5806-9c5b-463e-82ce-1ea230a43aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_eb41213d-a7df-4b1c-bc50-58140eb7f0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1c27217f-7a27-4db1-a638-4f6b3d7b97ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b31f5806-9c5b-463e-82ce-1ea230a43aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1c27217f-7a27-4db1-a638-4f6b3d7b97ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6d028fc0-7043-4760-aa90-40a7f470325b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b31f5806-9c5b-463e-82ce-1ea230a43aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6d028fc0-7043-4760-aa90-40a7f470325b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_26b6e20e-1654-4ff1-87fa-beec51c4defa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b31f5806-9c5b-463e-82ce-1ea230a43aa5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_26b6e20e-1654-4ff1-87fa-beec51c4defa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21465802-59a3-43a4-8ef9-8014e8d254ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_353d2c8d-c603-4468-a6a1-c943643a7fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21465802-59a3-43a4-8ef9-8014e8d254ef" xlink:to="loc_us-gaap_GoodwillRollForward_353d2c8d-c603-4468-a6a1-c943643a7fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3ba17931-aa1d-4c32-ad17-7d0a8de5a933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_353d2c8d-c603-4468-a6a1-c943643a7fcf" xlink:to="loc_us-gaap_Goodwill_3ba17931-aa1d-4c32-ad17-7d0a8de5a933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b4e35a79-7226-438f-b638-172317fcd845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_353d2c8d-c603-4468-a6a1-c943643a7fcf" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b4e35a79-7226-438f-b638-172317fcd845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_69977d9d-f0e1-491a-9aad-836950462209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_353d2c8d-c603-4468-a6a1-c943643a7fcf" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_69977d9d-f0e1-491a-9aad-836950462209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_cae7d7bc-a4ac-443a-9484-54b880e89cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_353d2c8d-c603-4468-a6a1-c943643a7fcf" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_cae7d7bc-a4ac-443a-9484-54b880e89cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_78a81e01-f704-4fdc-8e69-c366d87a075b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_353d2c8d-c603-4468-a6a1-c943643a7fcf" xlink:to="loc_us-gaap_Goodwill_78a81e01-f704-4fdc-8e69-c366d87a075b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_51b665f9-110d-4e90-b641-ab56843ed078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_90aaa819-9e0b-4c3c-a7f2-17df2bb1ed5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_51b665f9-110d-4e90-b641-ab56843ed078" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_90aaa819-9e0b-4c3c-a7f2-17df2bb1ed5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_26eeb577-1731-4d23-b187-e406f1bbb57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8d5a87b1-5354-4afc-aaa2-e47bc12906b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26eeb577-1731-4d23-b187-e406f1bbb57d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8d5a87b1-5354-4afc-aaa2-e47bc12906b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1b5ca0db-0012-41a8-b5e0-6a1a5aed9423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26eeb577-1731-4d23-b187-e406f1bbb57d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1b5ca0db-0012-41a8-b5e0-6a1a5aed9423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_daf8d987-3298-4891-ba61-b6891856857f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26eeb577-1731-4d23-b187-e406f1bbb57d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_daf8d987-3298-4891-ba61-b6891856857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_457f6d38-a1e2-43dc-95de-f1f60b2b3580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26eeb577-1731-4d23-b187-e406f1bbb57d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_457f6d38-a1e2-43dc-95de-f1f60b2b3580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8f04a0ff-bfa9-4b41-b16f-661ef7962b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26eeb577-1731-4d23-b187-e406f1bbb57d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8f04a0ff-bfa9-4b41-b16f-661ef7962b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2f465f65-0249-4f58-9285-80e75d7b6350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2f465f65-0249-4f58-9285-80e75d7b6350" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a13b6cc-3754-4cbe-8189-3c628f613261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a13b6cc-3754-4cbe-8189-3c628f613261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1a13b6cc-3754-4cbe-8189-3c628f613261" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_63b51eb1-afe8-45b0-bc3c-514374451263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_63b51eb1-afe8-45b0-bc3c-514374451263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6f38dd68-cf5e-4832-8afc-dcdba83a7b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6f38dd68-cf5e-4832-8afc-dcdba83a7b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d8e40d82-dba2-46bd-a0bb-830ec81b4f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5566d6c-a573-4c05-a4aa-86857b9b3a24" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d8e40d82-dba2-46bd-a0bb-830ec81b4f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7f8057c3-a6b6-42ef-97ef-da358e284b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7f8057c3-a6b6-42ef-97ef-da358e284b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4392907e-96d0-4d8e-8e5e-bd09782f3005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7f8057c3-a6b6-42ef-97ef-da358e284b51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4392907e-96d0-4d8e-8e5e-bd09782f3005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f477bcaa-5065-432e-9533-12a595cbe88a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4392907e-96d0-4d8e-8e5e-bd09782f3005" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f477bcaa-5065-432e-9533-12a595cbe88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_527eb9f1-7beb-415b-aae8-60bd1fdc0181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_527eb9f1-7beb-415b-aae8-60bd1fdc0181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_527eb9f1-7beb-415b-aae8-60bd1fdc0181" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9977ebd8-38f0-4ffc-b896-adab7738d79f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9977ebd8-38f0-4ffc-b896-adab7738d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_c7a90e18-9866-4cc0-bd2a-f0b63bffc21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_c7a90e18-9866-4cc0-bd2a-f0b63bffc21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_96f246aa-f07e-4a70-9610-426d60d50f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bc22573-7932-40ec-9fb5-57332646a964" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_96f246aa-f07e-4a70-9610-426d60d50f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3420f409-860e-4623-85fc-f1621231166e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_31aacc6a-7eb5-445d-8e00-1c4fc0cdf0b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3420f409-860e-4623-85fc-f1621231166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3420f409-860e-4623-85fc-f1621231166e" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_359ce423-3702-450e-ab04-9fe733a6b267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_359ce423-3702-450e-ab04-9fe733a6b267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_097e609f-736f-4b07-a7d7-fb86f2144756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_097e609f-736f-4b07-a7d7-fb86f2144756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4e071ade-4b73-437e-80b7-6b34b3cb7e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4e071ade-4b73-437e-80b7-6b34b3cb7e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_60837d0c-3c3b-4569-a95d-80a8ed7abee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_60837d0c-3c3b-4569-a95d-80a8ed7abee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_213e8f01-aa38-4b01-8e56-bca3566b804d" xlink:href="biib-20201231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_213e8f01-aa38-4b01-8e56-bca3566b804d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ea4d291c-5823-4ea2-b4d3-036662867c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_9ac4ce9c-9ab6-4e5b-8d6d-a49f797a2f0f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ea4d291c-5823-4ea2-b4d3-036662867c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3420f409-860e-4623-85fc-f1621231166e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cbf4f905-0e02-40a4-b4a2-8accec5ee5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_cbf4f905-0e02-40a4-b4a2-8accec5ee5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_997e4918-a3ba-4f73-9d63-196cebbe712f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_997e4918-a3ba-4f73-9d63-196cebbe712f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_205a82c4-3b0a-4a28-a77a-9927509287bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5c44ca42-0e18-4aee-9a82-bbcb55920c15" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_205a82c4-3b0a-4a28-a77a-9927509287bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ab95646-2750-4209-aeeb-9e8a9b09d98f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ab95646-2750-4209-aeeb-9e8a9b09d98f" xlink:to="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feee4eda-ffd2-4c7e-be84-994a1d9093c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feee4eda-ffd2-4c7e-be84-994a1d9093c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_206982a1-6703-4d2c-9cad-41f1f7939d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_feee4eda-ffd2-4c7e-be84-994a1d9093c1" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_206982a1-6703-4d2c-9cad-41f1f7939d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b8a1867d-d9b9-41aa-a4df-6842152ce020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_206982a1-6703-4d2c-9cad-41f1f7939d0c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b8a1867d-d9b9-41aa-a4df-6842152ce020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_473b6e1a-ba9b-40de-b065-3053923d841e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:to="loc_srt_RangeAxis_473b6e1a-ba9b-40de-b065-3053923d841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3364ea4e-66ad-4fdc-aeb2-dbbe8c7cb5b0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_473b6e1a-ba9b-40de-b065-3053923d841e" xlink:to="loc_srt_RangeMember_3364ea4e-66ad-4fdc-aeb2-dbbe8c7cb5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_daad5ddf-8d92-4ba6-8889-b33bca8f07ff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3364ea4e-66ad-4fdc-aeb2-dbbe8c7cb5b0" xlink:to="loc_srt_WeightedAverageMember_daad5ddf-8d92-4ba6-8889-b33bca8f07ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3919afe2-b25b-4062-aea0-aecdd606de13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3919afe2-b25b-4062-aea0-aecdd606de13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3283b5e3-9f8f-44b7-b1ab-bb8b2d17692a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3919afe2-b25b-4062-aea0-aecdd606de13" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3283b5e3-9f8f-44b7-b1ab-bb8b2d17692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_6cabeb04-f410-4e4a-b465-4515f0da6e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3283b5e3-9f8f-44b7-b1ab-bb8b2d17692a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_6cabeb04-f410-4e4a-b465-4515f0da6e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d718f0d6-336e-4610-9619-4a4089a7baee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d833fc04-55dc-4255-963f-83eae6fae1e4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d718f0d6-336e-4610-9619-4a4089a7baee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3d5fc7cc-a781-4ae4-8478-a65e4be399fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d718f0d6-336e-4610-9619-4a4089a7baee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3d5fc7cc-a781-4ae4-8478-a65e4be399fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_87d01c78-8a48-4fa0-b327-4e086a231d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d718f0d6-336e-4610-9619-4a4089a7baee" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_87d01c78-8a48-4fa0-b327-4e086a231d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fa73e30d-3b76-4290-b086-7b5b71570da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fa73e30d-3b76-4290-b086-7b5b71570da2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1854fd57-76bf-4bfe-be12-2b0120016520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_1854fd57-76bf-4bfe-be12-2b0120016520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_39b9eeca-49a2-45b4-8d8a-f4cb2da5fe41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1854fd57-76bf-4bfe-be12-2b0120016520" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_39b9eeca-49a2-45b4-8d8a-f4cb2da5fe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fae047da-412f-4267-b3a7-5bd145b47930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_39b9eeca-49a2-45b4-8d8a-f4cb2da5fe41" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_fae047da-412f-4267-b3a7-5bd145b47930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_40361c96-1960-4915-8998-cd3596b75e13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_40361c96-1960-4915-8998-cd3596b75e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4a034d6a-b6b0-4621-a104-a675e49f5102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_40361c96-1960-4915-8998-cd3596b75e13" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4a034d6a-b6b0-4621-a104-a675e49f5102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d5e50cfa-23be-44a7-9c88-db4069c31d08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4a034d6a-b6b0-4621-a104-a675e49f5102" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d5e50cfa-23be-44a7-9c88-db4069c31d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b1d1e30-275c-429f-89a3-27968c8cc341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b1d1e30-275c-429f-89a3-27968c8cc341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b1d1e30-275c-429f-89a3-27968c8cc341" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_8b7fd576-550d-469e-b42e-0f6eef5a3317" xlink:href="biib-20201231.xsd#biib_ConvergencePharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_8b7fd576-550d-469e-b42e-0f6eef5a3317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_147e8160-56be-4372-9556-974cecc9236d" xlink:href="biib-20201231.xsd#biib_BiogenIdecInternationalNeuroscienceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_147e8160-56be-4372-9556-974cecc9236d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StromedixMember_ec65d060-dd53-4fc3-a8c1-d3e1211707bc" xlink:href="biib-20201231.xsd#biib_StromedixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:to="loc_biib_StromedixMember_ec65d060-dd53-4fc3-a8c1-d3e1211707bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_e5412ef3-caf3-4fb0-9ca0-b1f490f51ca7" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dcfdf691-5581-4b44-bcd7-ac5731e18cf8" xlink:to="loc_biib_NightstarMember_e5412ef3-caf3-4fb0-9ca0-b1f490f51ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5d0e5130-99c8-405a-ace2-f2e5d643431c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5d0e5130-99c8-405a-ace2-f2e5d643431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d3726d67-5b41-476e-a323-4da5ac65bca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5d0e5130-99c8-405a-ace2-f2e5d643431c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d3726d67-5b41-476e-a323-4da5ac65bca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_ca7a4b9d-5864-495e-9eb9-3621bd35c3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d3726d67-5b41-476e-a323-4da5ac65bca3" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_ca7a4b9d-5864-495e-9eb9-3621bd35c3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_4cadf0a8-c386-4185-9e71-987ede2c0415" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_4cadf0a8-c386-4185-9e71-987ede2c0415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_da98b281-5a44-4050-ba93-99ca1e14645d" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_4cadf0a8-c386-4185-9e71-987ede2c0415" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_da98b281-5a44-4050-ba93-99ca1e14645d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB054Member_113ee29e-8ca6-4911-81af-b1226aeeed83" xlink:href="biib-20201231.xsd#biib_BIIB054Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_da98b281-5a44-4050-ba93-99ca1e14645d" xlink:to="loc_biib_BIIB054Member_113ee29e-8ca6-4911-81af-b1226aeeed83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_26f7420d-5d35-45d2-8a1e-a8b2241aa44f" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_9548c71c-36eb-407a-9307-d84313241e8b" xlink:href="biib-20201231.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_9548c71c-36eb-407a-9307-d84313241e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc1bfdc1-5374-4520-8160-10c4b423a06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc1bfdc1-5374-4520-8160-10c4b423a06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7cab26fd-4e65-4f38-b800-1f7867b5cc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7cab26fd-4e65-4f38-b800-1f7867b5cc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_20feea6f-5cb6-45ac-a1da-ab0e3e478819" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_20feea6f-5cb6-45ac-a1da-ab0e3e478819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_a9f1b2f3-cb59-43b4-83cb-5a3cc7af33b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_a9f1b2f3-cb59-43b4-83cb-5a3cc7af33b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_389fffe7-8abc-4c3e-a407-ff1b3e6b15e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_389fffe7-8abc-4c3e-a407-ff1b3e6b15e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_66eefede-89e8-4a37-8694-e85caca8a387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_66eefede-89e8-4a37-8694-e85caca8a387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_106838dd-d99e-402e-88be-d7a8ed133310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_106838dd-d99e-402e-88be-d7a8ed133310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FairValueMeasurementInputs_94bc8471-7741-4acc-a7a0-c8f7a3b12158" xlink:href="biib-20201231.xsd#biib_FairValueMeasurementInputs"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_biib_FairValueMeasurementInputs_94bc8471-7741-4acc-a7a0-c8f7a3b12158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_211382df-bd0a-4949-a3cc-280af3a42033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_211382df-bd0a-4949-a3cc-280af3a42033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_89fd1bd4-a903-48f7-9e30-abe38a520927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3042a2f8-d936-4544-a353-722b219a0a37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_89fd1bd4-a903-48f7-9e30-abe38a520927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f6cd7c8d-2a5d-42b2-94e3-d0ed9109c1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f6cd7c8d-2a5d-42b2-94e3-d0ed9109c1dc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_e2adaf99-c88a-4617-8ae2-10a3304f4ab9" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_e2adaf99-c88a-4617-8ae2-10a3304f4ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_b2c2d031-df6f-459a-98f9-25b01c661b2a" xlink:href="biib-20201231.xsd#biib_ResearchanddevelopmentassetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e2adaf99-c88a-4617-8ae2-10a3304f4ab9" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_b2c2d031-df6f-459a-98f9-25b01c661b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_2755731a-926d-41cf-8d3e-3ea43019ffc4" xlink:href="biib-20201231.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_b2c2d031-df6f-459a-98f9-25b01c661b2a" xlink:to="loc_biib_BIIB111Member_2755731a-926d-41cf-8d3e-3ea43019ffc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9ba40494-dfcf-442b-9dd4-7072d3a37679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9ba40494-dfcf-442b-9dd4-7072d3a37679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_943837c4-bd11-4171-ac82-d4247b8f9b6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9ba40494-dfcf-442b-9dd4-7072d3a37679" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_943837c4-bd11-4171-ac82-d4247b8f9b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_275bfa9f-0c24-4cb2-9cea-3af191ea4436" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_943837c4-bd11-4171-ac82-d4247b8f9b6a" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_275bfa9f-0c24-4cb2-9cea-3af191ea4436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a61cb901-b9b4-4460-96e3-5a2ce5110742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cbbc8d57-9e29-4d68-b338-e93ebcaf4282" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a61cb901-b9b4-4460-96e3-5a2ce5110742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a61cb901-b9b4-4460-96e3-5a2ce5110742" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_34822b12-8131-45ed-9cd6-e23c00de9ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_34822b12-8131-45ed-9cd6-e23c00de9ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f8fb7552-d076-41e1-a9c9-3c66014105a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f8fb7552-d076-41e1-a9c9-3c66014105a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_471b5a06-ec58-44e2-808c-54d090ea67fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_45f0b952-bc59-4f50-8822-3a1dcae198f4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_471b5a06-ec58-44e2-808c-54d090ea67fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e67a4506-23eb-4ee5-8937-60a510a84490" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e67a4506-23eb-4ee5-8937-60a510a84490" xlink:to="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a001890-1cec-4ae4-9f07-277d7fcf600a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a001890-1cec-4ae4-9f07-277d7fcf600a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a001890-1cec-4ae4-9f07-277d7fcf600a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_b08d0a7b-ee97-4788-8a2e-12cd9b9bc30c" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_b08d0a7b-ee97-4788-8a2e-12cd9b9bc30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_7e65b7f1-062b-4ba0-a9e5-e622caf54583" xlink:href="biib-20201231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_7e65b7f1-062b-4ba0-a9e5-e622caf54583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_17e9b4ef-2127-4d2b-a067-131f7332128e" xlink:href="biib-20201231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_17e9b4ef-2127-4d2b-a067-131f7332128e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A225SeniorNotesDueMay12030Member_847b9f4c-0425-4f8b-8b08-4f9c1cff02e4" xlink:href="biib-20201231.xsd#biib_A225SeniorNotesDueMay12030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_A225SeniorNotesDueMay12030Member_847b9f4c-0425-4f8b-8b08-4f9c1cff02e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8409bfb9-beeb-4133-b5e0-d32a31c441b9" xlink:href="biib-20201231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8409bfb9-beeb-4133-b5e0-d32a31c441b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A315SeniorNotesDueMay12050Member_9ad37f76-5f2d-4194-b480-238839c3a2dd" xlink:href="biib-20201231.xsd#biib_A315SeniorNotesDueMay12050Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65014b8f-42d6-44c2-8fbc-053061c1a850" xlink:to="loc_biib_A315SeniorNotesDueMay12050Member_9ad37f76-5f2d-4194-b480-238839c3a2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_05382fcc-f1da-4c7e-bc96-ab68a16667cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_05382fcc-f1da-4c7e-bc96-ab68a16667cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80d8d4b7-afc0-4733-ba79-2af3873cb5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_05382fcc-f1da-4c7e-bc96-ab68a16667cc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80d8d4b7-afc0-4733-ba79-2af3873cb5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3ad07abe-34bd-4eef-b5ff-98da7553760b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80d8d4b7-afc0-4733-ba79-2af3873cb5b2" xlink:to="loc_us-gaap_SeniorNotesMember_3ad07abe-34bd-4eef-b5ff-98da7553760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6d789540-2820-4f3b-84fe-b4fb9888dbf5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_ff5919c7-de9d-4807-b443-9528d4c7ef7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_ff5919c7-de9d-4807-b443-9528d4c7ef7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb582de9-1321-4614-b710-63e912b30619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_eb582de9-1321-4614-b710-63e912b30619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6fa46c94-e02c-4b21-8718-464f946d6df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2b5a34e7-75d6-4756-82a1-5d43705a16cd" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6fa46c94-e02c-4b21-8718-464f946d6df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e4abe31f-6c84-4978-989e-089fcdceee5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8ac234a7-531a-4adf-9513-763bb4dc0745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e4abe31f-6c84-4978-989e-089fcdceee5b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8ac234a7-531a-4adf-9513-763bb4dc0745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_606afcdc-435b-4410-aa14-1499c78dbb00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8ac234a7-531a-4adf-9513-763bb4dc0745" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_606afcdc-435b-4410-aa14-1499c78dbb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_829f3ff4-ea29-40c4-ac55-9c4bc834d674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_606afcdc-435b-4410-aa14-1499c78dbb00" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_829f3ff4-ea29-40c4-ac55-9c4bc834d674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e91b37c0-6f5e-4b9c-a95a-dedf266cb3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_829f3ff4-ea29-40c4-ac55-9c4bc834d674" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e91b37c0-6f5e-4b9c-a95a-dedf266cb3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0d9e1bba-b32e-4b9a-a5c7-6ee5395a9d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_8ac234a7-531a-4adf-9513-763bb4dc0745" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0d9e1bba-b32e-4b9a-a5c7-6ee5395a9d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_0d9e1bba-b32e-4b9a-a5c7-6ee5395a9d92" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1d6b3d24-f150-45e7-85ee-92bab2228c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1d6b3d24-f150-45e7-85ee-92bab2228c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4f0d2e7c-1ae7-4b76-909e-c6b385e5535c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4f0d2e7c-1ae7-4b76-909e-c6b385e5535c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e8ffe46c-1910-4b4e-b16d-7cd5f971c27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e8ffe46c-1910-4b4e-b16d-7cd5f971c27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a5385f2-6a3a-4106-aaac-81cb8dea958b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8f442df0-8b91-432a-b383-31abe4649274" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3a5385f2-6a3a-4106-aaac-81cb8dea958b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4bae20fb-f484-47da-b265-9a4c76a4a50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_e740514e-52fc-40fb-a85c-424331831b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_4bae20fb-f484-47da-b265-9a4c76a4a50d" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_e740514e-52fc-40fb-a85c-424331831b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_567addea-c2d7-43ab-8df2-21d40d80d42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_be66de74-a855-429b-8986-284b956d49d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_567addea-c2d7-43ab-8df2-21d40d80d42a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_be66de74-a855-429b-8986-284b956d49d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_065218e7-a864-4d4d-a875-60ad51a67add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_567addea-c2d7-43ab-8df2-21d40d80d42a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_065218e7-a864-4d4d-a875-60ad51a67add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e8ecc94e-3ec7-44cd-958e-52cd22dec573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_567addea-c2d7-43ab-8df2-21d40d80d42a" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e8ecc94e-3ec7-44cd-958e-52cd22dec573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_62b3ca21-a775-41d5-b0b9-0ae0963360a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_567addea-c2d7-43ab-8df2-21d40d80d42a" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_62b3ca21-a775-41d5-b0b9-0ae0963360a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_07a5373c-7b0d-4196-9bed-bd42d280cf4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_18555f7a-78fd-4a97-9a54-683dbccbd608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_07a5373c-7b0d-4196-9bed-bd42d280cf4f" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_18555f7a-78fd-4a97-9a54-683dbccbd608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0eb06655-8d0f-4d4f-b4e3-21574271b8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_18555f7a-78fd-4a97-9a54-683dbccbd608" xlink:to="loc_us-gaap_InvestmentTypeAxis_0eb06655-8d0f-4d4f-b4e3-21574271b8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0eb06655-8d0f-4d4f-b4e3-21574271b8a4" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_54c9c507-9c1a-4a45-ae0e-4b682fdb4d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:to="loc_us-gaap_CommercialPaperMember_54c9c507-9c1a-4a45-ae0e-4b682fdb4d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_ab8952c4-78e3-46f9-b00e-381dfe5e72da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_ab8952c4-78e3-46f9-b00e-381dfe5e72da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e75d8c92-6b0a-4e19-bd69-e92f8252b941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e75d8c92-6b0a-4e19-bd69-e92f8252b941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_ad13d060-2bcf-4a60-b1d2-d054428136e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_2fcf6ce6-e3d2-4703-83ed-417c7116a656" xlink:to="loc_us-gaap_DebtSecuritiesMember_ad13d060-2bcf-4a60-b1d2-d054428136e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_f0cf80d8-b0a9-4ddd-98f8-192a9cf49cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_18555f7a-78fd-4a97-9a54-683dbccbd608" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_f0cf80d8-b0a9-4ddd-98f8-192a9cf49cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_692ad504-c60c-43dd-9e15-a1b8c14fad65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_f0cf80d8-b0a9-4ddd-98f8-192a9cf49cab" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_692ad504-c60c-43dd-9e15-a1b8c14fad65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b7d5d437-5c2c-42a5-ac08-c5918345617a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_324b2356-9380-49bc-bc18-ddadbdb4a522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b7d5d437-5c2c-42a5-ac08-c5918345617a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_324b2356-9380-49bc-bc18-ddadbdb4a522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_81ceec3c-b540-48ad-9414-354ce5a1c76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_324b2356-9380-49bc-bc18-ddadbdb4a522" xlink:to="loc_us-gaap_FinancialInstrumentAxis_81ceec3c-b540-48ad-9414-354ce5a1c76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_81ceec3c-b540-48ad-9414-354ce5a1c76b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_9991ae29-b37a-43a8-98b0-ff8421fde85a" xlink:href="biib-20201231.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_9991ae29-b37a-43a8-98b0-ff8421fde85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_d9b7494a-92f4-4950-a114-4a5ff4f94931" xlink:href="biib-20201231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_d9b7494a-92f4-4950-a114-4a5ff4f94931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_8962eba2-c19e-4305-b51c-96290b5738fb" xlink:href="biib-20201231.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_8962eba2-c19e-4305-b51c-96290b5738fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_e86997a7-0462-4998-b1d5-b1876cf13400" xlink:href="biib-20201231.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_e86997a7-0462-4998-b1d5-b1876cf13400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_c2319c60-a240-43bd-a354-c641bb6491ec" xlink:href="biib-20201231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_c2319c60-a240-43bd-a354-c641bb6491ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_c4092a42-c0de-4db4-8acf-506389d70821" xlink:href="biib-20201231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_c4092a42-c0de-4db4-8acf-506389d70821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_befc0af8-abe0-45e6-b406-0827d612fd32" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_EquitySecuritiesCurrentMember_befc0af8-abe0-45e6-b406-0827d612fd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_36d6d4c0-2c7e-4332-8f1c-4ce02ca9f251" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7da700d5-a389-41ee-bf31-f27ef2266358" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_36d6d4c0-2c7e-4332-8f1c-4ce02ca9f251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_324b2356-9380-49bc-bc18-ddadbdb4a522" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f87081e6-a564-4717-894c-d02570183f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f87081e6-a564-4717-894c-d02570183f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6af72a4a-252b-4203-81ac-f1d2db23aea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6af72a4a-252b-4203-81ac-f1d2db23aea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c5bcc6b8-c164-43dc-811d-55b6d70e8a7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c5bcc6b8-c164-43dc-811d-55b6d70e8a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c699f965-a209-4fb3-a659-dd6dbd1492e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c699f965-a209-4fb3-a659-dd6dbd1492e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_c3d706c0-dad0-41e3-a7f6-930ef9ec9454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_c3d706c0-dad0-41e3-a7f6-930ef9ec9454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_1fa63bc0-f2da-4c33-9201-8912c99f7994" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_1fa63bc0-f2da-4c33-9201-8912c99f7994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e43cf13b-0522-4188-809d-2c67f3812ab8" xlink:href="biib-20201231.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e43cf13b-0522-4188-809d-2c67f3812ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_931cb3b6-1aa2-4dde-bfbf-d2fbe666a526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2a77806d-2d55-4903-8a82-274b6f3e0512" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_931cb3b6-1aa2-4dde-bfbf-d2fbe666a526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsSummaryofContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_92ff5a9a-3187-48ca-a9b1-7ad3a56894b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e50bab48-37b4-409c-8655-9b1dbcbffe5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_92ff5a9a-3187-48ca-a9b1-7ad3a56894b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e50bab48-37b4-409c-8655-9b1dbcbffe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2bc37210-7013-4bc7-8326-9c412f1d3eff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e50bab48-37b4-409c-8655-9b1dbcbffe5f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2bc37210-7013-4bc7-8326-9c412f1d3eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e194acfb-27a1-462c-ab44-c1e16c082f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e50bab48-37b4-409c-8655-9b1dbcbffe5f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e194acfb-27a1-462c-ab44-c1e16c082f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_01e39c52-a91a-4166-a5de-7f25c9a673c3" xlink:href="biib-20201231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e50bab48-37b4-409c-8655-9b1dbcbffe5f" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_01e39c52-a91a-4166-a5de-7f25c9a673c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0ea38c5-4bd8-4b0b-a9ed-945a1697af97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e50bab48-37b4-409c-8655-9b1dbcbffe5f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0ea38c5-4bd8-4b0b-a9ed-945a1697af97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_f70968b4-1008-498d-ab91-20de041c674f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_92ff5a9a-3187-48ca-a9b1-7ad3a56894b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_f70968b4-1008-498d-ab91-20de041c674f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0305cadb-c5a3-465d-baf7-9b175e82ef31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_f70968b4-1008-498d-ab91-20de041c674f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0305cadb-c5a3-465d-baf7-9b175e82ef31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e73e54e8-2bb2-4b32-96f8-1b1ffdfb0287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_f70968b4-1008-498d-ab91-20de041c674f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e73e54e8-2bb2-4b32-96f8-1b1ffdfb0287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_8b89ab24-0cc7-404a-8e71-5d6b28034fbc" xlink:href="biib-20201231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_f70968b4-1008-498d-ab91-20de041c674f" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_8b89ab24-0cc7-404a-8e71-5d6b28034fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1a2b156f-e9f0-4c0e-afc2-8e4c98e5c61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_f70968b4-1008-498d-ab91-20de041c674f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1a2b156f-e9f0-4c0e-afc2-8e4c98e5c61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0f71ec3d-fe09-4a72-b540-98f5f960d2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b227bf89-ccd8-4a26-b9a1-b0e730ca1440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0f71ec3d-fe09-4a72-b540-98f5f960d2a0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b227bf89-ccd8-4a26-b9a1-b0e730ca1440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_86743b72-1b63-452a-ae69-87f3a3705e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0f71ec3d-fe09-4a72-b540-98f5f960d2a0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_86743b72-1b63-452a-ae69-87f3a3705e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_f4223035-e098-46ed-9b1d-38ec0f9e44d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0f71ec3d-fe09-4a72-b540-98f5f960d2a0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_f4223035-e098-46ed-9b1d-38ec0f9e44d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0af0df22-3ba2-4a94-819f-a09937f8d695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_0af0df22-3ba2-4a94-819f-a09937f8d695" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d4845c01-675a-4b33-98dc-3576b356159a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fb3c8d47-6b1a-4ad7-a920-eb045eb7183c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d4845c01-675a-4b33-98dc-3576b356159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2e3e2cbf-2ec0-4872-b41a-6e42966582d4" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d4845c01-675a-4b33-98dc-3576b356159a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_2e3e2cbf-2ec0-4872-b41a-6e42966582d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_00cfd88b-cca1-48ca-8424-a69cdf1243ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_us-gaap_TypeOfArrangementAxis_00cfd88b-cca1-48ca-8424-a69cdf1243ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e1704eea-f43c-4813-98a9-fe3d710f52a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_00cfd88b-cca1-48ca-8424-a69cdf1243ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e1704eea-f43c-4813-98a9-fe3d710f52a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_f7020e0d-ec52-458e-99cf-f2afb1a6d960" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e1704eea-f43c-4813-98a9-fe3d710f52a7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_f7020e0d-ec52-458e-99cf-f2afb1a6d960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_us-gaap_FinancialInstrumentAxis_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5704aa82-c363-4bdf-b185-4de13dd604e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_637da2bf-3da8-4e60-aac9-e7a1fc58e9ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5704aa82-c363-4bdf-b185-4de13dd604e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_dccdf17e-bec6-4976-ad51-e4d4bdd60ac9" xlink:href="biib-20201231.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5704aa82-c363-4bdf-b185-4de13dd604e6" xlink:to="loc_biib_StrategicInvestmentsMember_dccdf17e-bec6-4976-ad51-e4d4bdd60ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3453034c-54ec-46f3-a6e3-8d2ee11231ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_dei_LegalEntityAxis_3453034c-54ec-46f3-a6e3-8d2ee11231ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3453034c-54ec-46f3-a6e3-8d2ee11231ae" xlink:to="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_6a5dcbc9-7d8c-489b-87d8-a02df0c96690" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:to="loc_biib_SageTherapeuticsIncMember_6a5dcbc9-7d8c-489b-87d8-a02df0c96690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_024fdfca-d90d-4d56-98f9-4facf5fd1316" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:to="loc_biib_DenaliTherapeuticsIncMember_024fdfca-d90d-4d56-98f9-4facf5fd1316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_664aa4fa-a3b2-46b4-9128-a49db28a7177" xlink:href="biib-20201231.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3f86e00b-86df-4ed2-beec-3f02f80cf818" xlink:to="loc_biib_SangamoCommonStockMember_664aa4fa-a3b2-46b4-9128-a49db28a7177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fc0c609-c99f-4711-9d35-e92834029c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fc0c609-c99f-4711-9d35-e92834029c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7a3c38b-c110-4498-a614-fc04c3462c0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2fc0c609-c99f-4711-9d35-e92834029c9e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7a3c38b-c110-4498-a614-fc04c3462c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_97862ba8-80d6-4ed4-b35d-0a0c5aaeb854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e7a3c38b-c110-4498-a614-fc04c3462c0a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_97862ba8-80d6-4ed4-b35d-0a0c5aaeb854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f0c170f6-5125-41fb-b7f7-681244c60803" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_3ef35663-26f4-4be3-8eb6-e95dcef6d5d8" xlink:href="biib-20201231.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_3ef35663-26f4-4be3-8eb6-e95dcef6d5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_2ac07800-8e85-4a93-88c6-68b67f98ef34" xlink:href="biib-20201231.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_StrategicInvestmentPortfolio_2ac07800-8e85-4a93-88c6-68b67f98ef34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInCommonStockSharesPurchased_61722914-e5db-48fd-a04c-c25aa22617b5" xlink:href="biib-20201231.xsd#biib_InvestmentInCommonStockSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_InvestmentInCommonStockSharesPurchased_61722914-e5db-48fd-a04c-c25aa22617b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DividendYieldPercentage_4bb93233-ed71-449d-9377-99d91f7cc1d0" xlink:href="biib-20201231.xsd#biib_DividendYieldPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_DividendYieldPercentage_4bb93233-ed71-449d-9377-99d91f7cc1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_722f86f4-f3c4-41fb-b26a-210b4c561c7b" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_722f86f4-f3c4-41fb-b26a-210b4c561c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_47e6b1a2-7f05-4642-87fa-8f32fd8515b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_47e6b1a2-7f05-4642-87fa-8f32fd8515b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_99e19853-6d9e-47eb-ace9-8b0925352c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_99e19853-6d9e-47eb-ace9-8b0925352c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_13212ea8-5585-43a9-a307-70c084063580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a0b93ba7-1a56-4e90-a201-9d5c0d010101" xlink:to="loc_us-gaap_EquityMethodInvestments_13212ea8-5585-43a9-a307-70c084063580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9a35d6f7-fc7d-471b-88bd-5b8f8f7f10d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c1aaa10a-d385-4189-bb52-045658a8d801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9a35d6f7-fc7d-471b-88bd-5b8f8f7f10d1" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c1aaa10a-d385-4189-bb52-045658a8d801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28c41591-7415-40c3-9661-4999e4dd4b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_4af7ffed-c04b-4cf8-940f-bf143223c3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28c41591-7415-40c3-9661-4999e4dd4b80" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_4af7ffed-c04b-4cf8-940f-bf143223c3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_cc42e067-a5c4-4564-8065-9508822da007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28c41591-7415-40c3-9661-4999e4dd4b80" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_cc42e067-a5c4-4564-8065-9508822da007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c8ea6332-3394-4372-9447-f4fce81b5b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28c41591-7415-40c3-9661-4999e4dd4b80" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c8ea6332-3394-4372-9447-f4fce81b5b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_d272edd0-bffc-45e6-a835-67c798fdc269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_28c41591-7415-40c3-9661-4999e4dd4b80" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_d272edd0-bffc-45e6-a835-67c798fdc269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4d6d0a19-4f95-4d53-82ec-a2c86dcfe4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4d6d0a19-4f95-4d53-82ec-a2c86dcfe4ac" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e86db838-0d3b-4e3e-9da1-ea744aa86484" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_srt_RangeAxis_e86db838-0d3b-4e3e-9da1-ea744aa86484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eeaed2e0-a068-452b-9264-ac376a55fd0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e86db838-0d3b-4e3e-9da1-ea744aa86484" xlink:to="loc_srt_RangeMember_eeaed2e0-a068-452b-9264-ac376a55fd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7748ac3e-f191-44cf-99a6-6cd747d11fd9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eeaed2e0-a068-452b-9264-ac376a55fd0a" xlink:to="loc_srt_MinimumMember_7748ac3e-f191-44cf-99a6-6cd747d11fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e52f6c6d-0524-401e-b3e8-f5d09508723f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eeaed2e0-a068-452b-9264-ac376a55fd0a" xlink:to="loc_srt_MaximumMember_e52f6c6d-0524-401e-b3e8-f5d09508723f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_768ee315-fe96-4b07-8ae9-15b24a326da0" xlink:href="biib-20201231.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_biib_DerivativeMaturityAxis_768ee315-fe96-4b07-8ae9-15b24a326da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_f47d29c4-df0b-4a2d-a3f4-0bb810a54df7" xlink:href="biib-20201231.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_768ee315-fe96-4b07-8ae9-15b24a326da0" xlink:to="loc_biib_DerivativeMaturityDomain_f47d29c4-df0b-4a2d-a3f4-0bb810a54df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_db041322-78c8-4e69-bb0c-f68f670e7f49" xlink:href="biib-20201231.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_f47d29c4-df0b-4a2d-a3f4-0bb810a54df7" xlink:to="loc_biib_ShorttermderivativeMember_db041322-78c8-4e69-bb0c-f68f670e7f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cb1387eb-bbc4-4650-b273-40f832e971a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cb1387eb-bbc4-4650-b273-40f832e971a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fa01ece8-7d7d-4e45-8da3-0b622184d1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb1387eb-bbc4-4650-b273-40f832e971a8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fa01ece8-7d7d-4e45-8da3-0b622184d1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_5f161f88-ca55-4a06-ad60-b660b48d422d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa01ece8-7d7d-4e45-8da3-0b622184d1c6" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_5f161f88-ca55-4a06-ad60-b660b48d422d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_cfdbcb4c-4edd-4253-8b6e-f123c6d24437" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fa01ece8-7d7d-4e45-8da3-0b622184d1c6" xlink:to="loc_us-gaap_InterestRateSwapMember_cfdbcb4c-4edd-4253-8b6e-f123c6d24437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_DebtInstrumentAxis_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_850362ea-a837-4625-ac35-915537ebe4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f88ebe24-2f02-4a6a-ab76-3f0d98d7eb3d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_850362ea-a837-4625-ac35-915537ebe4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_8deb7190-67f0-4a85-97a7-302935fbcd99" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_850362ea-a837-4625-ac35-915537ebe4a4" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_8deb7190-67f0-4a85-97a7-302935fbcd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_31c6aafe-b756-4152-8d41-5e94f3bfe711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_HedgingDesignationAxis_31c6aafe-b756-4152-8d41-5e94f3bfe711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_921acd4a-bb6c-4e44-ba92-3b9a3bd902dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_31c6aafe-b756-4152-8d41-5e94f3bfe711" xlink:to="loc_us-gaap_HedgingDesignationDomain_921acd4a-bb6c-4e44-ba92-3b9a3bd902dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2bc81bfc-03cb-46f9-8614-5507651a34db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_921acd4a-bb6c-4e44-ba92-3b9a3bd902dc" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2bc81bfc-03cb-46f9-8614-5507651a34db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_c330fc9d-ecac-427d-be0b-f87365c42ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_921acd4a-bb6c-4e44-ba92-3b9a3bd902dc" xlink:to="loc_us-gaap_NondesignatedMember_c330fc9d-ecac-427d-be0b-f87365c42ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81e1ccf7-653b-433e-b24e-807b07d0509b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81e1ccf7-653b-433e-b24e-807b07d0509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_799d49ce-45ae-49b6-af4c-4612667b92d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_81e1ccf7-653b-433e-b24e-807b07d0509b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_799d49ce-45ae-49b6-af4c-4612667b92d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_6e23851a-5966-49c7-b158-555da8d1fef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_799d49ce-45ae-49b6-af4c-4612667b92d3" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_6e23851a-5966-49c7-b158-555da8d1fef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_741ebb8c-8343-4c9a-b54d-c86730662d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_741ebb8c-8343-4c9a-b54d-c86730662d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9fd4adfb-ce86-429c-a118-4f24a8d03501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_741ebb8c-8343-4c9a-b54d-c86730662d26" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9fd4adfb-ce86-429c-a118-4f24a8d03501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_01646f5e-658d-46df-b745-5926639411a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9fd4adfb-ce86-429c-a118-4f24a8d03501" xlink:to="loc_us-gaap_InterestExpenseMember_01646f5e-658d-46df-b745-5926639411a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bcb165f2-c9f1-4ffe-a91a-d3907c05768a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bcb165f2-c9f1-4ffe-a91a-d3907c05768a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ca9c6b3-1901-4f1d-8d7d-2d9ce6df7b6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_bcb165f2-c9f1-4ffe-a91a-d3907c05768a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ca9c6b3-1901-4f1d-8d7d-2d9ce6df7b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_53731420-b3bb-4984-9cbd-b2fe50163d11" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ca9c6b3-1901-4f1d-8d7d-2d9ce6df7b6f" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_53731420-b3bb-4984-9cbd-b2fe50163d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d499d8d2-c354-422f-9850-06923596419c" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_f58ccf00-6ab5-43cd-b152-6303cf95760d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_f58ccf00-6ab5-43cd-b152-6303cf95760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_b3a7aae4-de55-4900-9c9c-9f3b601033cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_b3a7aae4-de55-4900-9c9c-9f3b601033cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ca61d7b-ac0d-4058-9186-1715af6f776a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ca61d7b-ac0d-4058-9186-1715af6f776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_a23ba5b3-3da4-44b3-a1e1-04a3464abf98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DerivativeNotionalAmount_a23ba5b3-3da4-44b3-a1e1-04a3464abf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3d81ed74-edb9-4262-b340-f99a2f4d3ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3d81ed74-edb9-4262-b340-f99a2f4d3ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_dc82f495-ce37-47e3-ad69-43b175461bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_dc82f495-ce37-47e3-ad69-43b175461bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7b7e41ee-9112-43fa-84df-794336ad1e6f" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_7b7e41ee-9112-43fa-84df-794336ad1e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0cbd61af-ecf0-4b0b-8deb-acab83bd9176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0cbd61af-ecf0-4b0b-8deb-acab83bd9176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a0c68d92-4946-404d-9fe1-8b0d80135d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a0c68d92-4946-404d-9fe1-8b0d80135d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_d871659d-a7dd-47ef-9373-015503dab292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_DerivativeTermOfContract_d871659d-a7dd-47ef-9373-015503dab292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_c5d6f9e6-49a5-4193-970e-e2d267443ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_c5d6f9e6-49a5-4193-970e-e2d267443ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bf790aee-75bb-4b60-b259-c26240d6f29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7288d739-65f4-4820-8f21-7441b247a243" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_bf790aee-75bb-4b60-b259-c26240d6f29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0f99ddbc-b224-4fbb-b7ce-f85492c00ac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0f99ddbc-b224-4fbb-b7ce-f85492c00ac4" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_fa6415ef-a3cc-401a-978c-99eb4c39aa9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:to="loc_srt_CurrencyAxis_fa6415ef-a3cc-401a-978c-99eb4c39aa9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_c5943b58-6247-4ae3-bdae-33f5b2dbdef5" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_fa6415ef-a3cc-401a-978c-99eb4c39aa9f" xlink:to="loc_currency_AllCurrenciesDomain_c5943b58-6247-4ae3-bdae-33f5b2dbdef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_4c40d89a-4923-4d86-aa69-c2d8dd09758b" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_c5943b58-6247-4ae3-bdae-33f5b2dbdef5" xlink:to="loc_currency_EUR_4c40d89a-4923-4d86-aa69-c2d8dd09758b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_77d9d0d5-13d7-4d73-9199-33976be4d89b" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_c5943b58-6247-4ae3-bdae-33f5b2dbdef5" xlink:to="loc_currency_GBP_77d9d0d5-13d7-4d73-9199-33976be4d89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5069f938-7656-4a9e-89f0-6580710de586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:to="loc_us-gaap_HedgingDesignationAxis_5069f938-7656-4a9e-89f0-6580710de586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_80734e46-b795-47c2-9de5-e25f6f461343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5069f938-7656-4a9e-89f0-6580710de586" xlink:to="loc_us-gaap_HedgingDesignationDomain_80734e46-b795-47c2-9de5-e25f6f461343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b53378ba-0149-4409-92cf-072d62a3baae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_80734e46-b795-47c2-9de5-e25f6f461343" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b53378ba-0149-4409-92cf-072d62a3baae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_ec2df105-5eab-49a5-a306-7372d752d989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ae6413e9-20d0-45bc-9d65-951ef096ef43" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_ec2df105-5eab-49a5-a306-7372d752d989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4f76f33e-8dd0-4f10-82d8-78afb1e11919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_ec2df105-5eab-49a5-a306-7372d752d989" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4f76f33e-8dd0-4f10-82d8-78afb1e11919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2e4afa67-55b0-434f-976b-266e7fb9e5f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2e4afa67-55b0-434f-976b-266e7fb9e5f6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d569b78b-b362-4c38-abec-dfb5a408c0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d569b78b-b362-4c38-abec-dfb5a408c0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f865cd14-36b2-4930-9498-d647a7b82e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d569b78b-b362-4c38-abec-dfb5a408c0e6" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f865cd14-36b2-4930-9498-d647a7b82e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_0a44ced4-8e6f-43c3-ae68-2deb60a67f6c" xlink:href="biib-20201231.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f865cd14-36b2-4930-9498-d647a7b82e27" xlink:to="loc_biib_CashflowsrevenueMember_0a44ced4-8e6f-43c3-ae68-2deb60a67f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_7f8d77a8-aaa0-40e9-b48f-943e87018786" xlink:href="biib-20201231.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f865cd14-36b2-4930-9498-d647a7b82e27" xlink:to="loc_biib_CashflowsoperatingexpensesMember_7f8d77a8-aaa0-40e9-b48f-943e87018786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_dca25627-c09c-44e8-830a-6c85ef3e069e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_dca25627-c09c-44e8-830a-6c85ef3e069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_741a8035-dea3-4f8c-b84d-b369a0c3f14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_dca25627-c09c-44e8-830a-6c85ef3e069e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_741a8035-dea3-4f8c-b84d-b369a0c3f14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_f18270b4-2891-4052-a5d0-a180640335ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_741a8035-dea3-4f8c-b84d-b369a0c3f14f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_f18270b4-2891-4052-a5d0-a180640335ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b4da75cd-6f52-4bc3-997e-05f3be38d834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b4da75cd-6f52-4bc3-997e-05f3be38d834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_93d975a2-9f12-48c2-90cc-00b499c3098f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4da75cd-6f52-4bc3-997e-05f3be38d834" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_93d975a2-9f12-48c2-90cc-00b499c3098f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_b971479f-ba9f-424a-aeab-241baae1e56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_93d975a2-9f12-48c2-90cc-00b499c3098f" xlink:to="loc_us-gaap_SalesMember_b971479f-ba9f-424a-aeab-241baae1e56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_7035e7f7-e308-4b61-a333-42a6337767f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_93d975a2-9f12-48c2-90cc-00b499c3098f" xlink:to="loc_us-gaap_OperatingExpenseMember_7035e7f7-e308-4b61-a333-42a6337767f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_23e8d2c6-cc6e-43e7-8626-d15024d7b6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_3e142b7f-67f1-47b2-b566-64c0eab4f494" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_23e8d2c6-cc6e-43e7-8626-d15024d7b6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1176f1bb-a541-422a-a808-1ef6354328be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_23e8d2c6-cc6e-43e7-8626-d15024d7b6cd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_1176f1bb-a541-422a-a808-1ef6354328be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6daf7efc-afe9-43ec-935c-ef1daae0a2ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_23e8d2c6-cc6e-43e7-8626-d15024d7b6cd" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6daf7efc-afe9-43ec-935c-ef1daae0a2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_74bd4003-9b44-496f-8fcf-ac30dfc6c42c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_74bd4003-9b44-496f-8fcf-ac30dfc6c42c" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d9104d5a-a7e9-41b7-bf00-b6baeba25727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_05dbcdfe-0bff-40a9-9ab9-55210a23f9f0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d9104d5a-a7e9-41b7-bf00-b6baeba25727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_b7ddefa9-dca8-45de-936c-9dab3ffeb51c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d9104d5a-a7e9-41b7-bf00-b6baeba25727" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_b7ddefa9-dca8-45de-936c-9dab3ffeb51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0870eefe-1156-4129-a943-d852ea068a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0870eefe-1156-4129-a943-d852ea068a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_041111d4-cd9f-4295-824a-698d21317548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0870eefe-1156-4129-a943-d852ea068a77" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_041111d4-cd9f-4295-824a-698d21317548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_585da510-faf9-4d0e-b378-b8fea56ee670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_041111d4-cd9f-4295-824a-698d21317548" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_585da510-faf9-4d0e-b378-b8fea56ee670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_16101f93-5617-46c4-8535-18f74a4156ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_3fdf442d-6872-465d-b788-ee304f755f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_3fdf442d-6872-465d-b788-ee304f755f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c2d67b06-2ec8-4d0b-acd7-5b24ca944aad" xlink:href="biib-20201231.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_c2d67b06-2ec8-4d0b-acd7-5b24ca944aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aab3f96d-1a6e-4741-893f-17c1d35538ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_7ed9bfca-240b-49e9-a3da-4a65772cefe9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aab3f96d-1a6e-4741-893f-17c1d35538ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f15fff4d-3244-4b2e-bdb7-f5b3e95b2dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f15fff4d-3244-4b2e-bdb7-f5b3e95b2dd7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a2afd269-1760-43ce-a723-cf7bfff0686e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a2afd269-1760-43ce-a723-cf7bfff0686e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2afd269-1760-43ce-a723-cf7bfff0686e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_07b9db5e-8001-40d0-b771-caf66117a5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_07b9db5e-8001-40d0-b771-caf66117a5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_ddde8957-3fbb-48eb-837c-5ffc0c72aa0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_ddde8957-3fbb-48eb-837c-5ffc0c72aa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5e359cc2-f8fd-4f5b-9049-21a848303415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4c3574e3-41cc-48e9-b574-fbcc4286b531" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_5e359cc2-f8fd-4f5b-9049-21a848303415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9b400794-96c1-4d91-af25-9ec2d0235d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9b400794-96c1-4d91-af25-9ec2d0235d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ec90be79-52a6-4335-bf20-4707bb49eecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9b400794-96c1-4d91-af25-9ec2d0235d48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ec90be79-52a6-4335-bf20-4707bb49eecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ad3a06b3-1b38-4be1-a56b-6b5ca842c910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec90be79-52a6-4335-bf20-4707bb49eecb" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ad3a06b3-1b38-4be1-a56b-6b5ca842c910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_75fa14cf-c13b-46ee-8c2c-f1f1b5f0d501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ec90be79-52a6-4335-bf20-4707bb49eecb" xlink:to="loc_us-gaap_InterestRateSwapMember_75fa14cf-c13b-46ee-8c2c-f1f1b5f0d501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6886f92e-4f8d-4c4c-bf2f-b49b7543ed4e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_1a93a5d8-cdac-4ea8-b9c9-ce62262070a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:to="loc_us-gaap_CashFlowHedgingMember_1a93a5d8-cdac-4ea8-b9c9-ce62262070a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_65d91f1c-a6fe-46f6-b1fb-ac0abc155b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_65d91f1c-a6fe-46f6-b1fb-ac0abc155b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_18b561fd-cf64-4360-a76a-8277da3b2e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4e61a1eb-8b87-41ac-90fc-be81113a6e54" xlink:to="loc_us-gaap_FairValueHedgingMember_18b561fd-cf64-4360-a76a-8277da3b2e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_HedgingDesignationAxis_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7755c73a-1e1b-4c82-8d97-137f5286d4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_4babb68a-7b00-4f4f-a5b7-796ee44c7fd6" xlink:to="loc_us-gaap_HedgingDesignationDomain_7755c73a-1e1b-4c82-8d97-137f5286d4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9f10eb31-5b8c-4c22-a39a-7ec6406cd473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7755c73a-1e1b-4c82-8d97-137f5286d4ff" xlink:to="loc_us-gaap_NondesignatedMember_9f10eb31-5b8c-4c22-a39a-7ec6406cd473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f978637c-2236-4717-9210-545642968cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_d87902ce-d855-46e7-b98d-a382356a558a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f978637c-2236-4717-9210-545642968cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_dad56fb3-e1f1-414e-9a0e-c4c544c00cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f978637c-2236-4717-9210-545642968cba" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_dad56fb3-e1f1-414e-9a0e-c4c544c00cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_354470d2-014d-4612-ae90-34e09a2d4be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_f978637c-2236-4717-9210-545642968cba" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_354470d2-014d-4612-ae90-34e09a2d4be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6a9487ed-50a9-46ee-98cc-372fefbd4ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_84b0efbf-9668-4997-abf5-044ef559b5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6a9487ed-50a9-46ee-98cc-372fefbd4ef9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_84b0efbf-9668-4997-abf5-044ef559b5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_51ea0141-4dd7-4c52-b54e-c086c88d1e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_23e956b9-74a2-4e1c-b081-c7fabffbb83e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_51ea0141-4dd7-4c52-b54e-c086c88d1e02" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_23e956b9-74a2-4e1c-b081-c7fabffbb83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_86c2da8f-2e67-48a7-82ae-127b736c76d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_Land_86c2da8f-2e67-48a7-82ae-127b736c76d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_55a8ab37-c8a6-43c2-afaf-df97b38ee1db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_55a8ab37-c8a6-43c2-afaf-df97b38ee1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_fde67e65-4fce-48ba-aeb8-0747a75824bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_fde67e65-4fce-48ba-aeb8-0747a75824bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_fe53282f-3fbc-4936-be4e-4836b2715283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_fe53282f-3fbc-4936-be4e-4836b2715283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ComputerSoftwareAndHardware_71598b44-5f0c-4796-b60d-23ce3090d447" xlink:href="biib-20201231.xsd#biib_ComputerSoftwareAndHardware"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_biib_ComputerSoftwareAndHardware_71598b44-5f0c-4796-b60d-23ce3090d447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_0b0e461a-2b95-4506-b474-1d9877f8fbc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_0b0e461a-2b95-4506-b474-1d9877f8fbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e38660a7-2b6b-4034-8aab-7cdfc7500930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_ConstructionInProgressGross_e38660a7-2b6b-4034-8aab-7cdfc7500930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bbdb0df2-aa3b-4930-bf74-15c145f56a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bbdb0df2-aa3b-4930-bf74-15c145f56a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69513623-538d-4bad-818b-0ab6d8f942f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69513623-538d-4bad-818b-0ab6d8f942f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fc174835-7ecb-4b0b-9732-3774eb6cc044" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7e8e7825-c526-420f-91ad-b02f86ad829d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fc174835-7ecb-4b0b-9732-3774eb6cc044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_06bc5543-8a33-4a62-a507-4d8fc96ae2b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_06bc5543-8a33-4a62-a507-4d8fc96ae2b9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_a5233d6a-77e3-413a-85b7-78516d8ecb67" xlink:href="biib-20201231.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_biib_FacilityTypeAxis_a5233d6a-77e3-413a-85b7-78516d8ecb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:href="biib-20201231.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_a5233d6a-77e3-413a-85b7-78516d8ecb67" xlink:to="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_3c4d3756-6666-44cc-b952-6a4a2f907a4d" xlink:href="biib-20201231.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:to="loc_biib_BiologicsManufacturingMember_3c4d3756-6666-44cc-b952-6a4a2f907a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_2ee4e5d9-36dc-445e-9833-01e5e22a39a4" xlink:href="biib-20201231.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_2ee4e5d9-36dc-445e-9833-01e5e22a39a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_f59f5812-c621-429b-896b-0befa73491b0" xlink:href="biib-20201231.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_1b2e78f1-c49a-4100-ad6d-adcf2ea16a43" xlink:to="loc_biib_AdministrativeSpaceMember_f59f5812-c621-429b-896b-0befa73491b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_b46b629e-3a10-4fc6-acda-a2c7720d1c1e" xlink:href="biib-20201231.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_biib_FacilityLocationAxis_b46b629e-3a10-4fc6-acda-a2c7720d1c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_78360f80-5421-4752-a10a-6dd976f8b346" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_b46b629e-3a10-4fc6-acda-a2c7720d1c1e" xlink:to="loc_biib_FacilityLocationDomain_78360f80-5421-4752-a10a-6dd976f8b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember_1330b5d4-f385-41ff-a6b9-f9fa0cb00f02" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_78360f80-5421-4752-a10a-6dd976f8b346" xlink:to="loc_biib_SolothurnMember_1330b5d4-f385-41ff-a6b9-f9fa0cb00f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a43b739a-849a-4c83-b5de-b65d3f4bbaea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a43b739a-849a-4c83-b5de-b65d3f4bbaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_251eee64-f5b4-4cd0-a21a-adf10539e6e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a43b739a-849a-4c83-b5de-b65d3f4bbaea" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_251eee64-f5b4-4cd0-a21a-adf10539e6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_dfb9f979-86ed-4cbe-a5bf-be2b566b7d3d" xlink:href="biib-20201231.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_251eee64-f5b4-4cd0-a21a-adf10539e6e8" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_dfb9f979-86ed-4cbe-a5bf-be2b566b7d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52c069f4-c9b5-4e2d-873c-3b2c024320e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52c069f4-c9b5-4e2d-873c-3b2c024320e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1d9278c-08cc-450c-8fff-537bc8009e1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52c069f4-c9b5-4e2d-873c-3b2c024320e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1d9278c-08cc-450c-8fff-537bc8009e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_e8ffec2d-2055-4ca9-8acb-2a3709e844ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1d9278c-08cc-450c-8fff-537bc8009e1e" xlink:to="loc_us-gaap_BuildingMember_e8ffec2d-2055-4ca9-8acb-2a3709e844ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_c5c21d3b-de03-4d45-9f4d-eadb8d6a7275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f1d9278c-08cc-450c-8fff-537bc8009e1e" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_c5c21d3b-de03-4d45-9f4d-eadb8d6a7275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_38872d1d-f777-4f6c-971d-4d3914c72352" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9317d6cb-5f38-429e-879e-501500eb93c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_Depreciation_9317d6cb-5f38-429e-879e-501500eb93c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_4a915ed6-dd43-4295-b659-4940be113707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_InterestCostsCapitalized_4a915ed6-dd43-4295-b659-4940be113707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_8e37ade0-a1c8-4427-b634-79085aa833f8" xlink:href="biib-20201231.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_biib_NumberOfSquareFeet_8e37ade0-a1c8-4427-b634-79085aa833f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_044d53b3-9433-43b4-badc-d3745fd6aed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_ConstructionInProgressGross_044d53b3-9433-43b4-badc-d3745fd6aed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ae000ab0-d615-49f7-89f2-6dc28cd88dde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ae000ab0-d615-49f7-89f2-6dc28cd88dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_924ccf94-3665-41a5-ae10-237c1c002bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c178d138-6321-4cbb-a362-b24fdd3e0ed3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_924ccf94-3665-41a5-ae10-237c1c002bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:type="simple" xlink:href="biib-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_640db76f-58f0-411b-915f-5abc0bb6306a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_74a240a8-2cae-4738-a7b4-ec8a84dde703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_640db76f-58f0-411b-915f-5abc0bb6306a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_74a240a8-2cae-4738-a7b4-ec8a84dde703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a43e34ad-23f9-4a5c-99ad-e3f3a3827932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LesseeLeaseTableTableTextBlock_27a1d05f-5031-449c-a27b-f1e87767eab2" xlink:href="biib-20201231.xsd#biib_LesseeLeaseTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a43e34ad-23f9-4a5c-99ad-e3f3a3827932" xlink:to="loc_biib_LesseeLeaseTableTableTextBlock_27a1d05f-5031-449c-a27b-f1e87767eab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_d6746b3b-b3aa-441d-95b0-0d9ee8f805fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a43e34ad-23f9-4a5c-99ad-e3f3a3827932" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_d6746b3b-b3aa-441d-95b0-0d9ee8f805fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0ee9402e-3196-48ed-a0be-1a0fdbfa21ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a43e34ad-23f9-4a5c-99ad-e3f3a3827932" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0ee9402e-3196-48ed-a0be-1a0fdbfa21ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_c9623b92-5482-426c-9226-f77793576285" xlink:href="biib-20201231.xsd#biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a43e34ad-23f9-4a5c-99ad-e3f3a3827932" xlink:to="loc_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock_c9623b92-5482-426c-9226-f77793576285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_c97fc426-0c2c-4e1f-96c4-e9ecae0473bb" xlink:href="biib-20201231.xsd#biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a43e34ad-23f9-4a5c-99ad-e3f3a3827932" xlink:to="loc_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock_c97fc426-0c2c-4e1f-96c4-e9ecae0473bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c64f906e-c796-4a5c-8a8c-00ed0bb9cfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c64f906e-c796-4a5c-8a8c-00ed0bb9cfb8" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:to="loc_srt_RangeAxis_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6ce3503-7375-43dc-bc77-2b80b2949623" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e5fbf3d0-5be2-4717-a36e-5a2c2f291f6c" xlink:to="loc_srt_RangeMember_a6ce3503-7375-43dc-bc77-2b80b2949623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b17171a4-2baa-491f-b614-04a7064311de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6ce3503-7375-43dc-bc77-2b80b2949623" xlink:to="loc_srt_MinimumMember_b17171a4-2baa-491f-b614-04a7064311de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f77c0202-1ddc-4dd5-99d7-a0b38e7bdc94" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6ce3503-7375-43dc-bc77-2b80b2949623" xlink:to="loc_srt_MaximumMember_f77c0202-1ddc-4dd5-99d7-a0b38e7bdc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_bce44dda-4fea-4e64-8d39-5c81cf746273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:to="loc_us-gaap_LeaseContractualTermAxis_bce44dda-4fea-4e64-8d39-5c81cf746273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f4aa55fa-132c-4c88-a760-bd7199f45e69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_bce44dda-4fea-4e64-8d39-5c81cf746273" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f4aa55fa-132c-4c88-a760-bd7199f45e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SubleaseMember_e14914c8-4e5e-47eb-abba-8cc7de374a31" xlink:href="biib-20201231.xsd#biib_SubleaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f4aa55fa-132c-4c88-a760-bd7199f45e69" xlink:to="loc_biib_SubleaseMember_e14914c8-4e5e-47eb-abba-8cc7de374a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_dec024a3-bbf2-4436-8382-222b065f90be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_61f4fa23-b746-4ab1-bfeb-d5160069fb78" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_dec024a3-bbf2-4436-8382-222b065f90be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_93f4b904-6cab-41b6-8e27-fe87d17e5f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_dec024a3-bbf2-4436-8382-222b065f90be" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_93f4b904-6cab-41b6-8e27-fe87d17e5f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_71f3549f-65cb-40a3-84ba-e73ab1c00b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_dec024a3-bbf2-4436-8382-222b065f90be" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_71f3549f-65cb-40a3-84ba-e73ab1c00b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesScheduleofOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9dc84db8-9d0b-4fbe-a6cb-e1513d3cede8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ed379d1-c138-49ba-a61b-72442e901215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dc84db8-9d0b-4fbe-a6cb-e1513d3cede8" xlink:to="loc_us-gaap_StatementTable_8ed379d1-c138-49ba-a61b-72442e901215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ed379d1-c138-49ba-a61b-72442e901215" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_15ab3f5c-03e4-4533-a8ba-71ac4bf5ddd9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingleaseassetsMember_5d3c0fdc-fce1-4fc4-ad1c-62b28302e086" xlink:href="biib-20201231.xsd#biib_OperatingleaseassetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:to="loc_biib_OperatingleaseassetsMember_5d3c0fdc-fce1-4fc4-ad1c-62b28302e086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_8b0de4ff-faa7-42fb-b4bb-1caab5372e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_8b0de4ff-faa7-42fb-b4bb-1caab5372e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongtermoperatingleaseliabilitiesMember_94d1bd89-5b36-4e3c-bc6a-19e562df161d" xlink:href="biib-20201231.xsd#biib_LongtermoperatingleaseliabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_88a2ab09-4060-4766-984b-68efaa2d1fe9" xlink:to="loc_biib_LongtermoperatingleaseliabilitiesMember_94d1bd89-5b36-4e3c-bc6a-19e562df161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ed379d1-c138-49ba-a61b-72442e901215" xlink:to="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_57aa6a5d-9b0c-45a2-bcce-f3b545918108" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_57aa6a5d-9b0c-45a2-bcce-f3b545918108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ab63834-e567-4d4a-93d3-51d225288c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1ab63834-e567-4d4a-93d3-51d225288c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_776a3888-710b-481e-bae4-cd1838a4d645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_776a3888-710b-481e-bae4-cd1838a4d645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b1c000d1-3211-431c-9453-50a4e54cf45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b1c000d1-3211-431c-9453-50a4e54cf45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1f711a84-f89f-4341-bfa3-59b8e21cf030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5238e23c-f9ba-4ea3-bf0c-bab4ee7b21bb" xlink:to="loc_us-gaap_OperatingLeaseLiability_1f711a84-f89f-4341-bfa3-59b8e21cf030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fac63e50-09a3-4d3b-88a2-e1a5ff13d001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_668ecbe7-e07c-4530-9556-b0cebc9b6dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fac63e50-09a3-4d3b-88a2-e1a5ff13d001" xlink:to="loc_us-gaap_StatementTable_668ecbe7-e07c-4530-9556-b0cebc9b6dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f859a6de-b4fc-49d1-a02e-4a6998a516f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_668ecbe7-e07c-4530-9556-b0cebc9b6dd8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f859a6de-b4fc-49d1-a02e-4a6998a516f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f859a6de-b4fc-49d1-a02e-4a6998a516f6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b79e394b-5fae-42a8-a360-9949628f661f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b79e394b-5fae-42a8-a360-9949628f661f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_68d2685d-03f0-4ea3-85f7-137b27c175a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_68d2685d-03f0-4ea3-85f7-137b27c175a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_beceef7d-b92f-43dd-8ff4-84ff3c455ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6fa77ca1-12a7-4332-a3d2-6e4eb172dad7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_beceef7d-b92f-43dd-8ff4-84ff3c455ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_668ecbe7-e07c-4530-9556-b0cebc9b6dd8" xlink:to="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3ce5a47d-f423-43fa-99a3-d82d3bf623ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_OperatingLeaseCost_3ce5a47d-f423-43fa-99a3-d82d3bf623ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0f8baa92-d7ba-402e-9eeb-fec56b9257a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_VariableLeaseCost_0f8baa92-d7ba-402e-9eeb-fec56b9257a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_a305e9a4-8b22-4e4b-8e99-e8f54bc103d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_SubleaseIncome_a305e9a4-8b22-4e4b-8e99-e8f54bc103d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_ab14625b-d9da-4e01-b26e-6ec6c339e894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6dc0ef6a-f377-446e-95b1-f4d0e41f4b2e" xlink:to="loc_us-gaap_LeaseCost_ab14625b-d9da-4e01-b26e-6ec6c339e894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseLiabilityMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_78bee7b0-aa49-4e82-9dcf-47080dbb1f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_78bee7b0-aa49-4e82-9dcf-47080dbb1f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5b13cdd-5b3e-4ed8-a8ad-2e12ce9b1353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c5b13cdd-5b3e-4ed8-a8ad-2e12ce9b1353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5a9d31f3-d606-4e0f-a877-6c539ec0d755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5a9d31f3-d606-4e0f-a877-6c539ec0d755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a72e9dd8-d3dd-4399-a9c6-8fdf64b15e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a72e9dd8-d3dd-4399-a9c6-8fdf64b15e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_830ceb6e-56e3-4238-b6cc-447d6aed9f88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_830ceb6e-56e3-4238-b6cc-447d6aed9f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3ce5781c-b119-4b0f-afc2-f6f385f6d1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3ce5781c-b119-4b0f-afc2-f6f385f6d1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cfc005d1-af68-4a72-94cd-db7d980b8e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cfc005d1-af68-4a72-94cd-db7d980b8e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2bded38c-7007-4090-8bae-d130c82d0cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2bded38c-7007-4090-8bae-d130c82d0cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a79c7ba0-d047-4207-ba4d-97ff7ba3d7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cc0ef2fc-c7c4-42dc-b01e-0d12a92547cc" xlink:to="loc_us-gaap_OperatingLeaseLiability_a79c7ba0-d047-4207-ba4d-97ff7ba3d7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ee8d4246-3289-4ac3-b9e1-74f13d987a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fe7d31fb-27fc-456e-bee1-4179c5a0b634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ee8d4246-3289-4ac3-b9e1-74f13d987a84" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fe7d31fb-27fc-456e-bee1-4179c5a0b634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3f321b22-3380-4e4e-b594-7a9bd7f76f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ee8d4246-3289-4ac3-b9e1-74f13d987a84" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3f321b22-3380-4e4e-b594-7a9bd7f76f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5b1e72e2-07af-4d55-83a2-fa725c97f6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_77198506-a43d-4524-937c-c76029cc608c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5b1e72e2-07af-4d55-83a2-fa725c97f6b9" xlink:to="loc_us-gaap_OperatingLeasePayments_77198506-a43d-4524-937c-c76029cc608c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_678fb901-9a8b-4350-8632-9f810723dfbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5b1e72e2-07af-4d55-83a2-fa725c97f6b9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_678fb901-9a8b-4350-8632-9f810723dfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20201231.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_44b47a2d-08a9-4a16-8b9d-b8877fbda6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_efec2f82-1235-4666-9394-e68d263814a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_44b47a2d-08a9-4a16-8b9d-b8877fbda6c3" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_efec2f82-1235-4666-9394-e68d263814a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c369130f-0894-4fd9-b14d-c5fc4a4eaed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_d3972302-d9e6-4211-b499-c44e6585bb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c369130f-0894-4fd9-b14d-c5fc4a4eaed5" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_d3972302-d9e6-4211-b499-c44e6585bb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_aee19258-bf3c-46ed-9c71-9cf51b7dbdb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c369130f-0894-4fd9-b14d-c5fc4a4eaed5" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_aee19258-bf3c-46ed-9c71-9cf51b7dbdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessSummaryofIndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6f872b1-d10d-4695-b69c-de174b150324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6f872b1-d10d-4695-b69c-de174b150324" xlink:to="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:to="loc_us-gaap_DebtInstrumentAxis_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_606fbc41-aaf3-4fa7-b80c-63e470fa8e0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_f645299b-13a5-4ecc-bce6-cbef000d2d7e" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_f645299b-13a5-4ecc-bce6-cbef000d2d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_e27c39c4-fd5d-45e0-911f-874108022c32" xlink:href="biib-20201231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_e27c39c4-fd5d-45e0-911f-874108022c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_aaf2cd11-cb0f-4290-8b67-47a0bc4af2ff" xlink:href="biib-20201231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_aaf2cd11-cb0f-4290-8b67-47a0bc4af2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A225SeniorNotesDueMay12030Member_2b75f7f2-7a1d-4fef-8c81-fc860fa4e820" xlink:href="biib-20201231.xsd#biib_A225SeniorNotesDueMay12030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_A225SeniorNotesDueMay12030Member_2b75f7f2-7a1d-4fef-8c81-fc860fa4e820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ae0d8d53-12bf-49a2-b88a-621d39c06e9f" xlink:href="biib-20201231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ae0d8d53-12bf-49a2-b88a-621d39c06e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A315SeniorNotesDueMay12050Member_91f16640-25d6-46c7-8074-b11b5860fce0" xlink:href="biib-20201231.xsd#biib_A315SeniorNotesDueMay12050Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf6e5511-be1b-4c56-970f-61a05b5799aa" xlink:to="loc_biib_A315SeniorNotesDueMay12050Member_91f16640-25d6-46c7-8074-b11b5860fce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8de84685-c14f-4328-a869-fdad9eca116e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8de84685-c14f-4328-a869-fdad9eca116e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_19e770ce-e88e-45e9-8f51-ecd8fe4d2eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8de84685-c14f-4328-a869-fdad9eca116e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_19e770ce-e88e-45e9-8f51-ecd8fe4d2eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_74572205-4327-4b76-99af-8a1a0e7eef52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_19e770ce-e88e-45e9-8f51-ecd8fe4d2eac" xlink:to="loc_us-gaap_SeniorNotesMember_74572205-4327-4b76-99af-8a1a0e7eef52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e71adcb0-bc31-4049-a91c-85d73d5a471c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_dd6bf653-5b8f-492a-a0c5-412671b588f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_dd6bf653-5b8f-492a-a0c5-412671b588f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_f39e9421-2766-4329-a3a4-2c2fe845215a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_dd6bf653-5b8f-492a-a0c5-412671b588f7" xlink:to="loc_us-gaap_NotesPayableCurrent_f39e9421-2766-4329-a3a4-2c2fe845215a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_349eea79-7ea4-4fa5-91d2-208d1819d1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_dd6bf653-5b8f-492a-a0c5-412671b588f7" xlink:to="loc_us-gaap_DebtCurrent_349eea79-7ea4-4fa5-91d2-208d1819d1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_728f4448-16c0-41a0-9611-cf99ab83bdeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_728f4448-16c0-41a0-9611-cf99ab83bdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_600567b8-5eed-4302-83cb-1e746c96070a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_728f4448-16c0-41a0-9611-cf99ab83bdeb" xlink:to="loc_us-gaap_LongTermNotesPayable_600567b8-5eed-4302-83cb-1e746c96070a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_256eb1c7-e603-4c3d-921e-fbda2b608114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_728f4448-16c0-41a0-9611-cf99ab83bdeb" xlink:to="loc_us-gaap_LongTermDebt_256eb1c7-e603-4c3d-921e-fbda2b608114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_35d0be45-db0f-47df-9320-30debe53da07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_35d0be45-db0f-47df-9320-30debe53da07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0bfcfb17-7580-46c0-91b2-7aaaf279cf99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_22825faa-e9ee-4d2f-9d95-fc864819c07c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0bfcfb17-7580-46c0-91b2-7aaaf279cf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4e8a6db4-e7f9-43ad-a677-dcdd87d71722" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4e8a6db4-e7f9-43ad-a677-dcdd87d71722" xlink:to="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_39b26e58-17b4-4fee-8d36-3cad5b2aef98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_39b26e58-17b4-4fee-8d36-3cad5b2aef98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1c35adb5-ea1b-4004-bc34-1aa9947045a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_39b26e58-17b4-4fee-8d36-3cad5b2aef98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1c35adb5-ea1b-4004-bc34-1aa9947045a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_aa040e1b-dbe9-4c10-a17a-b0449a612d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c35adb5-ea1b-4004-bc34-1aa9947045a6" xlink:to="loc_us-gaap_SeniorNotesMember_aa040e1b-dbe9-4c10-a17a-b0449a612d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_44d352a1-893c-438f-bcaf-8bc0a054f118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1c35adb5-ea1b-4004-bc34-1aa9947045a6" xlink:to="loc_us-gaap_LineOfCreditMember_44d352a1-893c-438f-bcaf-8bc0a054f118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_347a4d98-4292-4461-afd6-f07ab6538cf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_DebtInstrumentAxis_347a4d98-4292-4461-afd6-f07ab6538cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_347a4d98-4292-4461-afd6-f07ab6538cf3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020SeniorNotesMember_1dafe62a-5c75-4389-9d14-3308601ab260" xlink:href="biib-20201231.xsd#biib_A2020SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:to="loc_biib_A2020SeniorNotesMember_1dafe62a-5c75-4389-9d14-3308601ab260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A225SeniorNotesDueMay12030Member_3dcbea78-2dd5-4406-ae9b-b276b1639b81" xlink:href="biib-20201231.xsd#biib_A225SeniorNotesDueMay12030Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_A2020SeniorNotesMember_1dafe62a-5c75-4389-9d14-3308601ab260" xlink:to="loc_biib_A225SeniorNotesDueMay12030Member_3dcbea78-2dd5-4406-ae9b-b276b1639b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A315SeniorNotesDueMay12050Member_2fa087de-cfde-468b-b4d6-1a882f88f9f8" xlink:href="biib-20201231.xsd#biib_A315SeniorNotesDueMay12050Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_A2020SeniorNotesMember_1dafe62a-5c75-4389-9d14-3308601ab260" xlink:to="loc_biib_A315SeniorNotesDueMay12050Member_2fa087de-cfde-468b-b4d6-1a882f88f9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:href="biib-20201231.xsd#biib_A2015SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:to="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6cd413ac-392c-4d53-81d0-3e017d25b60c" xlink:href="biib-20201231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6cd413ac-392c-4d53-81d0-3e017d25b60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_43e800d8-d395-47b2-8c7e-683a4f3b7447" xlink:href="biib-20201231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_43e800d8-d395-47b2-8c7e-683a4f3b7447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_d4402dc9-b033-4177-87fe-d235f42ade1e" xlink:href="biib-20201231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_A2015SeniorNotesMember_e89e62a5-e3ab-4508-81fd-27943e82ef5d" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_d4402dc9-b033-4177-87fe-d235f42ade1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_448284f8-535c-436b-8f73-b2e2e8cd4a3d" xlink:href="biib-20201231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2cfd65e2-eddb-4c0d-b8f0-1844d7e1b596" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_448284f8-535c-436b-8f73-b2e2e8cd4a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b06c0773-5a0a-4664-977a-e020a57e4cf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9fe34dfc-8327-4c7f-9b4b-0dc8af6df9eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b06c0773-5a0a-4664-977a-e020a57e4cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_cc643072-ed7e-49e2-a90b-36e168295c53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b06c0773-5a0a-4664-977a-e020a57e4cf4" xlink:to="loc_us-gaap_InterestExpenseMember_cc643072-ed7e-49e2-a90b-36e168295c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_590e0ca3-68a4-4d0c-bb76-8623a626fa6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_590e0ca3-68a4-4d0c-bb76-8623a626fa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6be3e80a-f165-493a-aa2e-efeead469afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_590e0ca3-68a4-4d0c-bb76-8623a626fa6c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6be3e80a-f165-493a-aa2e-efeead469afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_57e62732-3f82-4b55-aced-1adb5184fdc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_6be3e80a-f165-493a-aa2e-efeead469afb" xlink:to="loc_us-gaap_InterestRateSwapMember_57e62732-3f82-4b55-aced-1adb5184fdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3ee42229-d685-44ac-9d11-9cb84022c825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_CreditFacilityAxis_3ee42229-d685-44ac-9d11-9cb84022c825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f5b00691-fb3a-4ef2-adda-41c8ba76ae01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_3ee42229-d685-44ac-9d11-9cb84022c825" xlink:to="loc_us-gaap_CreditFacilityDomain_f5b00691-fb3a-4ef2-adda-41c8ba76ae01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_18206528-1440-4650-b2f3-fa255d3777bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f5b00691-fb3a-4ef2-adda-41c8ba76ae01" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_18206528-1440-4650-b2f3-fa255d3777bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02e0c684-0c99-42db-99b5-ec9757d81ea9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6eb7649f-53f0-479e-9899-847361970193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6eb7649f-53f0-479e-9899-847361970193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b8e990c1-313c-4d90-b746-2c6682106023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b8e990c1-313c-4d90-b746-2c6682106023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_2a0ef3e9-2081-41d4-a868-f654f5ef088e" xlink:href="biib-20201231.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_2a0ef3e9-2081-41d4-a868-f654f5ef088e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_ddc99c4b-817b-46c8-962d-560952c197c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_ddc99c4b-817b-46c8-962d-560952c197c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_b211284a-b70d-43e4-9701-f831679eab09" xlink:href="biib-20201231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_b211284a-b70d-43e4-9701-f831679eab09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_b8b3a6ff-d3cd-4bba-b5a5-79f92c6f4e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_b8b3a6ff-d3cd-4bba-b5a5-79f92c6f4e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain_6031092a-97f2-4245-b672-c5b3ad973ca4" xlink:href="biib-20201231.xsd#biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain_6031092a-97f2-4245-b672-c5b3ad973ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_eace1f79-4c10-4b92-9186-951db7cc97a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_eace1f79-4c10-4b92-9186-951db7cc97a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_41c6225a-f792-4367-bc06-b762060dddc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_41c6225a-f792-4367-bc06-b762060dddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_634c3736-9ff2-408d-8438-004700f594e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_DebtInstrumentTerm_634c3736-9ff2-408d-8438-004700f594e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_5e40d65d-35d8-488b-b525-1dd750c72354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cc837248-a590-4668-a54e-aa80940b7ec1" xlink:to="loc_us-gaap_LineOfCredit_5e40d65d-35d8-488b-b525-1dd750c72354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IndebtednessTotalDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fd777724-f060-416e-a115-e7a3ba9b383d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_267cf663-b834-4292-bf90-5516549873e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd777724-f060-416e-a115-e7a3ba9b383d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_267cf663-b834-4292-bf90-5516549873e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_326a992f-7ee1-4014-8d89-c8f14c9e8b10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd777724-f060-416e-a115-e7a3ba9b383d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_326a992f-7ee1-4014-8d89-c8f14c9e8b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3e3a4c93-cc55-4574-8b91-c6e3159a2699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd777724-f060-416e-a115-e7a3ba9b383d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3e3a4c93-cc55-4574-8b91-c6e3159a2699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ea98b271-ca38-40f3-84c4-e1db83e01f54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd777724-f060-416e-a115-e7a3ba9b383d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ea98b271-ca38-40f3-84c4-e1db83e01f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_928610a4-2788-4664-97c2-eba7e1d5b9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd777724-f060-416e-a115-e7a3ba9b383d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_928610a4-2788-4664-97c2-eba7e1d5b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_17026f87-fd53-4a9e-b32e-1aeb6140a039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd777724-f060-416e-a115-e7a3ba9b383d" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_17026f87-fd53-4a9e-b32e-1aeb6140a039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_db0babc5-9ebc-4c48-86d1-62183cea4230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fd777724-f060-416e-a115-e7a3ba9b383d" xlink:to="loc_us-gaap_LongTermNotesPayable_db0babc5-9ebc-4c48-86d1-62183cea4230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20201231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a4e6bcd8-8d8e-423e-b03c-bab9ef984c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1c2d0782-9b1b-4c07-9bb5-901fdf8b8d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a4e6bcd8-8d8e-423e-b03c-bab9ef984c68" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1c2d0782-9b1b-4c07-9bb5-901fdf8b8d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_27ed700c-6338-4a4a-b30c-8357cadef5d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_0adb35a8-f47c-45ef-8ff7-2a3e1bbd2ffe" xlink:href="biib-20201231.xsd#biib_SummaryOfCommonStockTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27ed700c-6338-4a4a-b30c-8357cadef5d1" xlink:to="loc_biib_SummaryOfCommonStockTableTextBlock_0adb35a8-f47c-45ef-8ff7-2a3e1bbd2ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d213f090-c450-48e3-adc4-9b6a55cdf317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27ed700c-6338-4a4a-b30c-8357cadef5d1" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_d213f090-c450-48e3-adc4-9b6a55cdf317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_69066b18-ddb0-44f8-8033-32bdeb4a35c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27ed700c-6338-4a4a-b30c-8357cadef5d1" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_69066b18-ddb0-44f8-8033-32bdeb4a35c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c91e8edc-9a46-4b20-bddb-61eb75926fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c91e8edc-9a46-4b20-bddb-61eb75926fc1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_d98c1ba8-92cd-4ae6-a691-f04e1c6a9988" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram5Member_0e4dfd25-11c1-4354-a1ab-5d5fb572ebf0" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram5Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram5Member_0e4dfd25-11c1-4354-a1ab-5d5fb572ebf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram4Member_e388e2fa-ae1c-4053-8401-496900ca2611" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram4Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram4Member_e388e2fa-ae1c-4053-8401-496900ca2611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram3Member_8eb00b00-ce5a-4ea2-9fde-5a9670a07ca1" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram3Member_8eb00b00-ce5a-4ea2-9fde-5a9670a07ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram2Member_c9a2c0a9-b5f6-4f30-853c-004d13b00e7f" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram2Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram2Member_c9a2c0a9-b5f6-4f30-853c-004d13b00e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareRepurchaseProgram1Member_77e1b905-3ff8-44ee-bfc8-90533d4a7a26" xlink:href="biib-20201231.xsd#biib_ShareRepurchaseProgram1Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b53a6c74-db02-4bd0-8845-c0ef0a16c35e" xlink:to="loc_biib_ShareRepurchaseProgram1Member_77e1b905-3ff8-44ee-bfc8-90533d4a7a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_953c919a-f8e6-44fd-be4c-acc8760f3334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:to="loc_us-gaap_StatementClassOfStockAxis_953c919a-f8e6-44fd-be4c-acc8760f3334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_953c919a-f8e6-44fd-be4c-acc8760f3334" xlink:to="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a8873750-7438-48af-b10a-723794d5a472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a8873750-7438-48af-b10a-723794d5a472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeriesXPreferredStockMember_f05214d1-256f-4177-a2a3-9ad865eaf862" xlink:href="biib-20201231.xsd#biib_SeriesXPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:to="loc_biib_SeriesXPreferredStockMember_f05214d1-256f-4177-a2a3-9ad865eaf862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UndesignatedPreferredStockMember_20f0d02b-4ff1-4475-b821-120adaed3e55" xlink:href="biib-20201231.xsd#biib_UndesignatedPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5f0e29df-76d9-43bf-81d7-bad86d2faf65" xlink:to="loc_biib_UndesignatedPreferredStockMember_20f0d02b-4ff1-4475-b821-120adaed3e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c9d8a2cd-4f7a-42c2-a8c0-28554995dc32" xlink:to="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_88db0c92-52c3-4404-9a06-2c87da7c3a3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_88db0c92-52c3-4404-9a06-2c87da7c3a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_61af3ce8-9ccc-4fa1-b200-f69e88dc3873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_PreferredStockSharesIssued_61af3ce8-9ccc-4fa1-b200-f69e88dc3873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fb91e72b-8c38-4459-aa06-f9d43937bbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fb91e72b-8c38-4459-aa06-f9d43937bbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8e81d236-c6b8-4fa7-911a-2b9675e136cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8e81d236-c6b8-4fa7-911a-2b9675e136cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a0e0df9a-d1a4-4be7-af6a-f16f844ef10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a0e0df9a-d1a4-4be7-af6a-f16f844ef10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_715fc4b3-44c6-471d-9696-fc3b6fa40abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6e241575-4400-4122-96ab-d27125b64292" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_715fc4b3-44c6-471d-9696-fc3b6fa40abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquitySummaryofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_aff385dc-a83c-4724-97e2-3101b2b3c7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_91ae6a8f-d696-4201-8f1b-6430c147cd1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aff385dc-a83c-4724-97e2-3101b2b3c7fe" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_91ae6a8f-d696-4201-8f1b-6430c147cd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0091fdc7-3588-4533-bcd7-6042aa901d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aff385dc-a83c-4724-97e2-3101b2b3c7fe" xlink:to="loc_us-gaap_CommonStockSharesIssued_0091fdc7-3588-4533-bcd7-6042aa901d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_aa0f7032-123f-496f-bc33-7d87f9fd8884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_aff385dc-a83c-4724-97e2-3101b2b3c7fe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_aa0f7032-123f-496f-bc33-7d87f9fd8884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_438c73c7-e38f-4ed1-8af0-e1a3fb83b398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_438c73c7-e38f-4ed1-8af0-e1a3fb83b398" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0592dc2c-0f07-4d2b-bca7-921060cae3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0592dc2c-0f07-4d2b-bca7-921060cae3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c19fda53-7fad-4076-848c-af187c61b81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0592dc2c-0f07-4d2b-bca7-921060cae3ae" xlink:to="loc_us-gaap_EquityComponentDomain_c19fda53-7fad-4076-848c-af187c61b81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c19fda53-7fad-4076-848c-af187c61b81e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5fcdd61d-843f-4229-a88c-5996eb620f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5fcdd61d-843f-4229-a88c-5996eb620f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_07f60c3a-3319-421f-8ade-3c12aa10be30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_07f60c3a-3319-421f-8ade-3c12aa10be30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8cd45b13-4059-4b7a-92d3-e0f4f849e614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8cd45b13-4059-4b7a-92d3-e0f4f849e614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e79f7d90-9894-4a20-81be-4ff36147eb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_e79f7d90-9894-4a20-81be-4ff36147eb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a8ca47a6-30ff-4f4b-ab05-adb5855c7eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9350347b-b584-405d-ba99-b7a710c21230" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_a8ca47a6-30ff-4f4b-ab05-adb5855c7eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_406b6412-f244-46c5-8dac-e0964aaf2b57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5d6b2b79-4532-48fe-aa6f-8c800d33c7fe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_406b6412-f244-46c5-8dac-e0964aaf2b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f987d875-20c1-4f9d-9d33-1ec966319979" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_406b6412-f244-46c5-8dac-e0964aaf2b57" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_f987d875-20c1-4f9d-9d33-1ec966319979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_a74907b7-0065-430f-bd1f-5997dea40110" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_406b6412-f244-46c5-8dac-e0964aaf2b57" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_a74907b7-0065-430f-bd1f-5997dea40110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_97c5e346-d5d8-49d3-a34c-dff087a71d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ecd36a66-dfda-493d-877b-56d625ef9e44" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_97c5e346-d5d8-49d3-a34c-dff087a71d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_97c5e346-d5d8-49d3-a34c-dff087a71d6f" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c05308db-ba56-40e0-8f21-866b7e81f029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c05308db-ba56-40e0-8f21-866b7e81f029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec27d1fe-932f-4eff-aacd-2911d2a025b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec27d1fe-932f-4eff-aacd-2911d2a025b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_96b4022a-9e61-409b-b9ee-d5077ad1aa12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_96b4022a-9e61-409b-b9ee-d5077ad1aa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6761dc6e-e6cf-4f7c-bd0b-d4578caeeb69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6761dc6e-e6cf-4f7c-bd0b-d4578caeeb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3a3632db-c2ea-4add-8dbd-4e18eabe3fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3a3632db-c2ea-4add-8dbd-4e18eabe3fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_478e476a-496a-4f87-a395-ea2543fa8e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c9b1a6b-1e28-4f59-8e06-bbbe2e052324" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_478e476a-496a-4f87-a395-ea2543fa8e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c1ac97a2-0352-4dd2-81ea-6933bdc04e90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c1ac97a2-0352-4dd2-81ea-6933bdc04e90" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b924f2b4-36c3-4bb9-87df-65e561270c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b924f2b4-36c3-4bb9-87df-65e561270c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b924f2b4-36c3-4bb9-87df-65e561270c66" xlink:to="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6e466670-5204-4336-80dc-b0a34de73e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_6e466670-5204-4336-80dc-b0a34de73e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5dd38bf4-4499-443a-83da-e25aa0b382ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5dd38bf4-4499-443a-83da-e25aa0b382ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_1116af78-1b25-4722-a455-b29198e451e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dbd44773-edf4-4ee9-9e88-61178d0793a0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_1116af78-1b25-4722-a455-b29198e451e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_777357c2-bf41-4437-8bcd-da0d05233263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_777357c2-bf41-4437-8bcd-da0d05233263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cc45a7d7-f942-4a15-a719-fd4a088ffb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_777357c2-bf41-4437-8bcd-da0d05233263" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cc45a7d7-f942-4a15-a719-fd4a088ffb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d5e28f58-53c7-4f49-a912-1626822372cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cc45a7d7-f942-4a15-a719-fd4a088ffb08" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_d5e28f58-53c7-4f49-a912-1626822372cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_b42433bf-9e52-4e88-908d-2fa1a0b93106" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_25b38934-3fb0-4b65-b9c5-a3459d5911cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_25b38934-3fb0-4b65-b9c5-a3459d5911cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8e32a234-aa58-4240-baad-ed62ec931240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8e32a234-aa58-4240-baad-ed62ec931240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ec02fb2a-24e7-4af2-89e9-188169777736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_Revenues_ec02fb2a-24e7-4af2-89e9-188169777736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a399ccbb-e054-4685-8c2e-a06d4608cf82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_OperatingExpenses_a399ccbb-e054-4685-8c2e-a06d4608cf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1bc5ef5c-931e-4a92-b7d8-12ff2e1f1ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_c32472eb-714c-40d4-a3cb-49a301c905d5" xlink:to="loc_us-gaap_NetIncomeLoss_1bc5ef5c-931e-4a92-b7d8-12ff2e1f1ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e97fb46a-9783-43c1-ada5-0bf04efc611d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6d01c904-9575-46e7-bc81-9b5b44c41681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e97fb46a-9783-43c1-ada5-0bf04efc611d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6d01c904-9575-46e7-bc81-9b5b44c41681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ccc8800-3176-41c4-97c9-eb0681d0f67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9db4965d-cf95-45a7-ba8a-b9905f9b62d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ccc8800-3176-41c4-97c9-eb0681d0f67c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9db4965d-cf95-45a7-ba8a-b9905f9b62d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareBasicandDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2c866d5a-3b2f-473c-913a-de5c6f0f690b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a3dff39d-5e2a-4758-8f77-888245eaba6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2c866d5a-3b2f-473c-913a-de5c6f0f690b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a3dff39d-5e2a-4758-8f77-888245eaba6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ece9e540-b307-4f2d-9383-07f74c5f9c21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a3dff39d-5e2a-4758-8f77-888245eaba6b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ece9e540-b307-4f2d-9383-07f74c5f9c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ece9e540-b307-4f2d-9383-07f74c5f9c21" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_11372b96-751a-425c-9cc9-619abbed1f06" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_11372b96-751a-425c-9cc9-619abbed1f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_330ba4d3-5145-4e42-896d-28cb821389a7" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:to="loc_biib_MarketStockUnitsMember_330ba4d3-5145-4e42-896d-28cb821389a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_6980af51-717d-4813-94e7-7775c07be05b" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6aba26dd-5050-4578-96c0-2f453ff430fc" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_6980af51-717d-4813-94e7-7775c07be05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e2cbf605-3e72-44fc-91f4-5012f78bec86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a3dff39d-5e2a-4758-8f77-888245eaba6b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e2cbf605-3e72-44fc-91f4-5012f78bec86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumeratorAbstract_4afee3d1-458d-475f-b71e-c6ce761f01dc" xlink:href="biib-20201231.xsd#biib_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e2cbf605-3e72-44fc-91f4-5012f78bec86" xlink:to="loc_biib_NumeratorAbstract_4afee3d1-458d-475f-b71e-c6ce761f01dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc1b8930-42e7-4418-8d08-55dd2c4ee07a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_NumeratorAbstract_4afee3d1-458d-475f-b71e-c6ce761f01dc" xlink:to="loc_us-gaap_NetIncomeLoss_bc1b8930-42e7-4418-8d08-55dd2c4ee07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:href="biib-20201231.xsd#biib_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e2cbf605-3e72-44fc-91f4-5012f78bec86" xlink:to="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fd4622a-412a-45ab-b914-6a0cd4078be5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fd4622a-412a-45ab-b914-6a0cd4078be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_45794874-29d0-4c93-b680-0b55d1091523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_45794874-29d0-4c93-b680-0b55d1091523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4b572ba7-8b47-40a8-a3d9-4bb6e9ca8cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_45794874-29d0-4c93-b680-0b55d1091523" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4b572ba7-8b47-40a8-a3d9-4bb6e9ca8cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2007c5d9-9dcf-49f8-9a68-dee5e54abef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_45794874-29d0-4c93-b680-0b55d1091523" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_2007c5d9-9dcf-49f8-9a68-dee5e54abef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6f46b73b-a01b-4fd5-9328-e73abc0bc792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_8507947b-38be-4722-ae90-4c0dc03ad090" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6f46b73b-a01b-4fd5-9328-e73abc0bc792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EarningsperShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_80694f28-620c-4779-95fb-9f4068268243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_e1bb5358-b360-4df9-9725-6b51f88ff194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_80694f28-620c-4779-95fb-9f4068268243" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_e1bb5358-b360-4df9-9725-6b51f88ff194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33263f7c-3cac-4b4f-b35e-db1bf86946f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d06773bf-ded1-4d68-8651-2893ffc86749" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_33263f7c-3cac-4b4f-b35e-db1bf86946f6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d06773bf-ded1-4d68-8651-2893ffc86749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e6277927-7204-402b-8237-f062bf836403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e6277927-7204-402b-8237-f062bf836403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ae2223c2-3ce8-4f22-8573-619522c7a110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ae2223c2-3ce8-4f22-8573-619522c7a110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_12fe6be3-3e70-456b-8d4d-bd314c8d770f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_12fe6be3-3e70-456b-8d4d-bd314c8d770f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_5bfaaf15-6ab5-4ae4-a88e-4215e570eb88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_5bfaaf15-6ab5-4ae4-a88e-4215e570eb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_924bac9a-ea6f-4823-b6e1-24e55355c1fb" xlink:href="biib-20201231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_924bac9a-ea6f-4823-b6e1-24e55355c1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_92752cfe-76ee-4883-ad24-0325e6f3111f" xlink:href="biib-20201231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_92752cfe-76ee-4883-ad24-0325e6f3111f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_4080bb6b-6695-43ad-8394-c116e8ebdf65" xlink:href="biib-20201231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_4080bb6b-6695-43ad-8394-c116e8ebdf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_ca09932f-c317-4408-9a33-9140334c8153" xlink:href="biib-20201231.xsd#biib_PerformanceunitsactivityTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_biib_PerformanceunitsactivityTableTextBlock_ca09932f-c317-4408-9a33-9140334c8153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_54ffda38-a315-4324-921d-d1a935e1dcae" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_54ffda38-a315-4324-921d-d1a935e1dcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_1d879104-048c-4020-b79b-0dfe541b2678" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_1d879104-048c-4020-b79b-0dfe541b2678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_e30340b6-8774-47cd-bc9c-a2e3dddb3f92" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_e30340b6-8774-47cd-bc9c-a2e3dddb3f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_08b0f4cd-119d-4d0f-8c45-246695d3760b" xlink:href="biib-20201231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_397302d9-319c-48c0-bc3b-f678990ef558" xlink:to="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_08b0f4cd-119d-4d0f-8c45-246695d3760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a611d05-9c4d-4ef6-94c7-2db12a565620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c27e5396-42af-4806-ac09-982c9d87e06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a611d05-9c4d-4ef6-94c7-2db12a565620" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c27e5396-42af-4806-ac09-982c9d87e06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b626346-2c60-4547-a671-0bfb21dc64f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c27e5396-42af-4806-ac09-982c9d87e06d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b626346-2c60-4547-a671-0bfb21dc64f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b626346-2c60-4547-a671-0bfb21dc64f0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7109e070-8b27-4530-9cab-60d0b77191d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7109e070-8b27-4530-9cab-60d0b77191d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1330a744-4474-4733-af0b-a273e65e073a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1330a744-4474-4733-af0b-a273e65e073a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_7efa43d0-aa80-446a-bb24-39a552d1f7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1f08e6ea-d0ae-4110-bedc-373377556fcd" xlink:to="loc_us-gaap_ParentMember_7efa43d0-aa80-446a-bb24-39a552d1f7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c27e5396-42af-4806-ac09-982c9d87e06d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_afa33c55-b9d7-4981-9f43-bf149f4c5139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_afa33c55-b9d7-4981-9f43-bf149f4c5139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_57307698-1bbb-41a0-94b1-b0d530250d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_57307698-1bbb-41a0-94b1-b0d530250d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0565d352-27c4-4278-b7a2-1e0d1af3c21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0565d352-27c4-4278-b7a2-1e0d1af3c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_d612613d-1bb3-46b2-b2be-dcf1e4aafcf7" xlink:href="biib-20201231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_d612613d-1bb3-46b2-b2be-dcf1e4aafcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f8e3e0b8-9bb7-45dd-8325-06e47f2855f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86066035-0558-4dfe-99bb-22a7d96991e2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f8e3e0b8-9bb7-45dd-8325-06e47f2855f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0312e424-e903-4d4a-94e6-5df53e300e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0312e424-e903-4d4a-94e6-5df53e300e71" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b9c49ceb-c642-4192-9df7-e70b85abbc94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b9c49ceb-c642-4192-9df7-e70b85abbc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2349652f-c047-48cf-9abf-9be3673969a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b9c49ceb-c642-4192-9df7-e70b85abbc94" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2349652f-c047-48cf-9abf-9be3673969a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NightstarMember_fcb78912-a411-480e-9b04-fa0eeaf89013" xlink:href="biib-20201231.xsd#biib_NightstarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2349652f-c047-48cf-9abf-9be3673969a5" xlink:to="loc_biib_NightstarMember_fcb78912-a411-480e-9b04-fa0eeaf89013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4166a0b7-ba36-42a0-b5ae-31086977bccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:to="loc_us-gaap_AwardTypeAxis_4166a0b7-ba36-42a0-b5ae-31086977bccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b25851-5c3e-4f6f-8b5b-cae7d67c8cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4166a0b7-ba36-42a0-b5ae-31086977bccc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b25851-5c3e-4f6f-8b5b-cae7d67c8cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b0620e73-8a80-4f45-800e-860af30fb76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b25851-5c3e-4f6f-8b5b-cae7d67c8cfc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b0620e73-8a80-4f45-800e-860af30fb76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8c3920e3-bb29-4ff2-9988-0987d3795995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:to="loc_us-gaap_PlanNameAxis_8c3920e3-bb29-4ff2-9988-0987d3795995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8c3920e3-bb29-4ff2-9988-0987d3795995" xlink:to="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_bc1d37cb-0668-4926-8008-77606b50bfc2" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_MarketStockUnitsMember_bc1d37cb-0668-4926-8008-77606b50bfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_60c18376-18cd-4796-93f6-600730f35c6f" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_60c18376-18cd-4796-93f6-600730f35c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_1888a4cc-1c17-4512-9f72-8fdc8dc0510d" xlink:href="biib-20201231.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_CashSettledPerformanceSharesMember_1888a4cc-1c17-4512-9f72-8fdc8dc0510d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceUnitsMember_8dae1201-dd55-4475-b5ba-6a0510dfc47f" xlink:href="biib-20201231.xsd#biib_PerformanceUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_PerformanceUnitsMember_8dae1201-dd55-4475-b5ba-6a0510dfc47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_386b3197-b139-4f45-8e13-db4825dc1cbb" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_386b3197-b139-4f45-8e13-db4825dc1cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_c23cc7ce-6e89-4e58-b67c-e0d6fdf4970b" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_c23cc7ce-6e89-4e58-b67c-e0d6fdf4970b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_4d52e59c-95bc-4761-8f1d-9d14d387782b" xlink:href="biib-20201231.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b57f4256-20ab-49d4-9eb5-18a2cce635de" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_4d52e59c-95bc-4761-8f1d-9d14d387782b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cd675c20-1084-440d-8536-c9d1a4327ebf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f0635ab-02fc-4507-83c4-2679923a4358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f0635ab-02fc-4507-83c4-2679923a4358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_00b34deb-11ad-40d9-a0fd-f52d20d2977d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_00b34deb-11ad-40d9-a0fd-f52d20d2977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2ab0d11a-a957-42d9-a427-503b48622671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2ab0d11a-a957-42d9-a427-503b48622671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9e52852c-3e16-4d20-b6d6-0ab4da308c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9e52852c-3e16-4d20-b6d6-0ab4da308c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2d419dfb-2b60-4d18-9142-e659b7812a35" xlink:href="biib-20201231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ab016274-8fe3-49d9-a679-a436b7b32e50" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2d419dfb-2b60-4d18-9142-e659b7812a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c07eb1e7-6814-42d4-b63e-decbbab1fb09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c07eb1e7-6814-42d4-b63e-decbbab1fb09" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e99c5599-ea4c-493f-b094-cad79c992c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_us-gaap_PlanNameAxis_e99c5599-ea4c-493f-b094-cad79c992c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89fe3fbb-4045-4955-9a2e-4463023acb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e99c5599-ea4c-493f-b094-cad79c992c70" xlink:to="loc_us-gaap_PlanNameDomain_89fe3fbb-4045-4955-9a2e-4463023acb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DirectorsPlanMember_54c466a5-ec14-46c3-8dd8-b3186b0062dc" xlink:href="biib-20201231.xsd#biib_DirectorsPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_89fe3fbb-4045-4955-9a2e-4463023acb5b" xlink:to="loc_biib_DirectorsPlanMember_54c466a5-ec14-46c3-8dd8-b3186b0062dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_4230c8b5-9f80-4244-b22e-dfdb1cc15abe" xlink:href="biib-20201231.xsd#biib_A2017OmnibusEquityPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_89fe3fbb-4045-4955-9a2e-4463023acb5b" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_4230c8b5-9f80-4244-b22e-dfdb1cc15abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_us-gaap_AwardTypeAxis_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_51c8385f-67a0-4fd8-b7c5-3ebd3d3fda96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_e8f5b587-e13a-4be7-a6b7-f1673157a17a" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_biib_MarketStockUnitsMember_e8f5b587-e13a-4be7-a6b7-f1673157a17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_6884c8ee-a595-4121-bf73-9021517d9d1f" xlink:href="biib-20201231.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_biib_CashSettledPerformanceSharesMember_6884c8ee-a595-4121-bf73-9021517d9d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f9c450e7-6e13-49e7-a47b-d3374d52d0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_us-gaap_PerformanceSharesMember_f9c450e7-6e13-49e7-a47b-d3374d52d0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_36d2e1f3-740f-4e79-b487-92e1f9d41bd2" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_f9c450e7-6e13-49e7-a47b-d3374d52d0b1" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_36d2e1f3-740f-4e79-b487-92e1f9d41bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_37c57cd2-53b7-4612-aa99-855b4aefb64d" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_f9c450e7-6e13-49e7-a47b-d3374d52d0b1" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_37c57cd2-53b7-4612-aa99-855b4aefb64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_114c1b03-c615-4d01-bddb-5e0e655c7ab2" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_114c1b03-c615-4d01-bddb-5e0e655c7ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d0f94288-ba1c-4540-954f-c4915afbda57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2cf24af3-907e-45a1-a27c-5c0a3e77525f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d0f94288-ba1c-4540-954f-c4915afbda57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bdb0104b-05cc-40ab-9894-4a72c8053d44" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_srt_RangeAxis_bdb0104b-05cc-40ab-9894-4a72c8053d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27e45392-c97f-47e6-a94a-c7f81405d9c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bdb0104b-05cc-40ab-9894-4a72c8053d44" xlink:to="loc_srt_RangeMember_27e45392-c97f-47e6-a94a-c7f81405d9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_96e965e3-933a-4cf9-9303-990465a6af7e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27e45392-c97f-47e6-a94a-c7f81405d9c5" xlink:to="loc_srt_MinimumMember_96e965e3-933a-4cf9-9303-990465a6af7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a70d8185-0366-43e5-b5ba-9fc6b2850e57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27e45392-c97f-47e6-a94a-c7f81405d9c5" xlink:to="loc_srt_MaximumMember_a70d8185-0366-43e5-b5ba-9fc6b2850e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_08825167-ce1c-492b-a709-cb6311836d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_us-gaap_VestingAxis_08825167-ce1c-492b-a709-cb6311836d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_08825167-ce1c-492b-a709-cb6311836d19" xlink:to="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8052736a-6172-47f0-ad05-3f5779491815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8052736a-6172-47f0-ad05-3f5779491815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_86a3ccff-9e25-4612-bd22-777a6aeab07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_86a3ccff-9e25-4612-bd22-777a6aeab07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_12904ff9-c0df-455e-a7bb-d4ff11cd58b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_6555705d-774a-477c-a8aa-ed631442fe93" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_12904ff9-c0df-455e-a7bb-d4ff11cd58b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e7ac7dd-8960-47fb-8232-767081e34f93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0feb7f5a-7827-4832-85a3-1350455c0fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0feb7f5a-7827-4832-85a3-1350455c0fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_b2e6420f-704f-4c44-b4e9-2375959bbb81" xlink:href="biib-20201231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_b2e6420f-704f-4c44-b4e9-2375959bbb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_6f97da3f-af8b-4149-b338-3976559cad4b" xlink:href="biib-20201231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_6f97da3f-af8b-4149-b338-3976559cad4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_15e9af5e-1120-4982-bec6-7682ae076ec0" xlink:href="biib-20201231.xsd#biib_NumberOfSharesOfCommonStockForIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_15e9af5e-1120-4982-bec6-7682ae076ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_92a70b21-f6a0-447c-be24-648f435e86cc" xlink:href="biib-20201231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_92a70b21-f6a0-447c-be24-648f435e86cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67755505-9123-4fb1-b4ce-02838a389a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_67755505-9123-4fb1-b4ce-02838a389a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b72b1280-2556-41c4-a207-98570308fc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b72b1280-2556-41c4-a207-98570308fc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54fcf64b-f10a-4670-a177-a7af18977be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_54fcf64b-f10a-4670-a177-a7af18977be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_20c84e2c-db44-4ddc-bf05-a35e5e6c6dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_20c84e2c-db44-4ddc-bf05-a35e5e6c6dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_403e8565-cb00-4d78-b60c-b559d0bfcbe3" xlink:href="biib-20201231.xsd#biib_NumberOfEqualAnnualIncrements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_403e8565-cb00-4d78-b60c-b559d0bfcbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_4b42bd2b-c600-4e54-9285-ce2b166906ff" xlink:href="biib-20201231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_4b42bd2b-c600-4e54-9285-ce2b166906ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_3a645019-c02a-4ca8-9589-5af40144c3d4" xlink:href="biib-20201231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_3a645019-c02a-4ca8-9589-5af40144c3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_61da919a-ae0c-4ea2-b8d7-10504a719b9d" xlink:href="biib-20201231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_61da919a-ae0c-4ea2-b8d7-10504a719b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0bcb20f2-338b-4bc0-a3f6-d4b8bc84b8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0bcb20f2-338b-4bc0-a3f6-d4b8bc84b8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_8f4715c9-36b2-4cca-85a3-f92a36657ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_8f4715c9-36b2-4cca-85a3-f92a36657ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0afa1553-c220-4230-befa-e60642a79d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0afa1553-c220-4230-befa-e60642a79d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51009b9a-0359-4b7a-99cf-019d78152c8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51009b9a-0359-4b7a-99cf-019d78152c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_68aa25e0-0693-4881-963a-4219d8119760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ec12ad5-f88b-49a8-8bc0-d67277f73c68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_68aa25e0-0693-4881-963a-4219d8119760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68a20699-63f0-4d4f-82e9-9def587b784f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f28c302e-ab0b-4a3a-83bc-b70be230c1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68a20699-63f0-4d4f-82e9-9def587b784f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f28c302e-ab0b-4a3a-83bc-b70be230c1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_197d78e0-581e-44b8-ae4d-a7a907cb7adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f28c302e-ab0b-4a3a-83bc-b70be230c1e6" xlink:to="loc_us-gaap_AwardTypeAxis_197d78e0-581e-44b8-ae4d-a7a907cb7adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c888c51-0319-4187-a9ce-7ca44251da8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_197d78e0-581e-44b8-ae4d-a7a907cb7adf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c888c51-0319-4187-a9ce-7ca44251da8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_06d0c666-03a0-4d5d-8071-97593be604c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c888c51-0319-4187-a9ce-7ca44251da8a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_06d0c666-03a0-4d5d-8071-97593be604c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f46287b-76c2-4d7c-b327-9fdbd5af57f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f28c302e-ab0b-4a3a-83bc-b70be230c1e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f46287b-76c2-4d7c-b327-9fdbd5af57f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f46287b-76c2-4d7c-b327-9fdbd5af57f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c408e199-ec8f-4397-b2de-f3964dde9cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c408e199-ec8f-4397-b2de-f3964dde9cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8a86cf16-595a-4f03-b0f7-77c563decee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8a86cf16-595a-4f03-b0f7-77c563decee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3f5c687d-802a-4284-81ef-c71e2ee1416f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3f5c687d-802a-4284-81ef-c71e2ee1416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9d281cdf-0dae-446e-b06f-2bf2af05b581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9d281cdf-0dae-446e-b06f-2bf2af05b581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_616d4a55-6a5b-4978-81dc-f6dbb3ba72c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4008db2-74ef-4511-95aa-4d40e7d6d419" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_616d4a55-6a5b-4978-81dc-f6dbb3ba72c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f46287b-76c2-4d7c-b327-9fdbd5af57f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c549f9f2-6187-49af-9b19-f84181477734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c549f9f2-6187-49af-9b19-f84181477734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f8130a7-a0ab-4b88-afb7-23e96f2ded6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2f8130a7-a0ab-4b88-afb7-23e96f2ded6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a87349d1-dbd6-4cc0-b8ca-13fdb0f6c961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a87349d1-dbd6-4cc0-b8ca-13fdb0f6c961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40f93fa7-1467-4a6b-b60b-d346514db0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40f93fa7-1467-4a6b-b60b-d346514db0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4df58c32-5995-42b5-b6e8-88b55f27166f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bd4d8022-773c-4624-976d-b20320dd0416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4df58c32-5995-42b5-b6e8-88b55f27166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab6a83a6-2be4-43cf-b096-f72369458289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_16b42b1f-87ee-4ab4-8a4f-57724d659a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab6a83a6-2be4-43cf-b096-f72369458289" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_16b42b1f-87ee-4ab4-8a4f-57724d659a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6128ccd9-3ecb-4cf9-8b00-6ca1d023b993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab6a83a6-2be4-43cf-b096-f72369458289" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6128ccd9-3ecb-4cf9-8b00-6ca1d023b993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsMarketStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef24df20-c0f2-4abc-a0b0-f744d1c4d029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_245d5888-b2ef-4920-9cae-9e5d260791ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef24df20-c0f2-4abc-a0b0-f744d1c4d029" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_245d5888-b2ef-4920-9cae-9e5d260791ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d973dcc-10b4-4ad1-865e-ad084b750918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_245d5888-b2ef-4920-9cae-9e5d260791ce" xlink:to="loc_us-gaap_AwardTypeAxis_9d973dcc-10b4-4ad1-865e-ad084b750918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7f6cd35-ae03-4b0f-bd2d-49dca31ed19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9d973dcc-10b4-4ad1-865e-ad084b750918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7f6cd35-ae03-4b0f-bd2d-49dca31ed19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_af645d7f-7729-4dbc-8bf7-caf9b2a4a5a9" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7f6cd35-ae03-4b0f-bd2d-49dca31ed19e" xlink:to="loc_biib_MarketStockUnitsMember_af645d7f-7729-4dbc-8bf7-caf9b2a4a5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46170e7-ce25-4e22-b48a-db91d8972429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_245d5888-b2ef-4920-9cae-9e5d260791ce" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46170e7-ce25-4e22-b48a-db91d8972429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46170e7-ce25-4e22-b48a-db91d8972429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_489b32fb-3e9b-4f94-b597-63a624dcf403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_489b32fb-3e9b-4f94-b597-63a624dcf403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3bdf6635-fbc7-4ff0-9ca2-993c9435406c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3bdf6635-fbc7-4ff0-9ca2-993c9435406c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_43130105-208a-4e82-a156-9d4983e206a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_43130105-208a-4e82-a156-9d4983e206a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d47aada0-d9a2-4a15-97f9-8ba4b1782f0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d47aada0-d9a2-4a15-97f9-8ba4b1782f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e172a721-d8f8-47e3-913a-f60e2e099245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_97aeef0f-42bc-4b33-b09c-1a51b36e964c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e172a721-d8f8-47e3-913a-f60e2e099245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46170e7-ce25-4e22-b48a-db91d8972429" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39d832ef-aa12-4c46-9232-5e07d738f122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_39d832ef-aa12-4c46-9232-5e07d738f122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34b1e4b8-b532-4f68-8428-a5334af240da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34b1e4b8-b532-4f68-8428-a5334af240da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a95fc537-4f86-4456-804f-7c895f0fc684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a95fc537-4f86-4456-804f-7c895f0fc684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab273951-b9ae-48f3-8d89-afc32cac12ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ab273951-b9ae-48f3-8d89-afc32cac12ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e977ec09-8fdb-475f-865d-a2b667960429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_57aa6aa7-c3cd-407c-ba35-1a2ba40014ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e977ec09-8fdb-475f-865d-a2b667960429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72a218f0-fd14-4f45-aa7b-1eaf290144e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72a218f0-fd14-4f45-aa7b-1eaf290144e0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7d21aede-7f8d-4424-a8c4-ae966c418d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:to="loc_us-gaap_AwardTypeAxis_7d21aede-7f8d-4424-a8c4-ae966c418d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dfb7e45-8a67-489a-89ab-ea74c812d59d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7d21aede-7f8d-4424-a8c4-ae966c418d63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dfb7e45-8a67-489a-89ab-ea74c812d59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_cc9dc459-6459-40c6-a28d-f14f8ac30cf0" xlink:href="biib-20201231.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6dfb7e45-8a67-489a-89ab-ea74c812d59d" xlink:to="loc_biib_MarketStockUnitsMember_cc9dc459-6459-40c6-a28d-f14f8ac30cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be059d4f-9c16-4ec3-a512-b01539f73ede" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:to="loc_srt_RangeAxis_be059d4f-9c16-4ec3-a512-b01539f73ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cea9526-38a6-47d6-be0e-261192f0df52" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_be059d4f-9c16-4ec3-a512-b01539f73ede" xlink:to="loc_srt_RangeMember_1cea9526-38a6-47d6-be0e-261192f0df52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4faaad7-a9be-40db-b660-22a72ce07aa4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cea9526-38a6-47d6-be0e-261192f0df52" xlink:to="loc_srt_MinimumMember_b4faaad7-a9be-40db-b660-22a72ce07aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c8eabee-cbfb-41e5-a680-cbb51d64b13a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cea9526-38a6-47d6-be0e-261192f0df52" xlink:to="loc_srt_MaximumMember_1c8eabee-cbfb-41e5-a680-cbb51d64b13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ca8d669-b171-4af0-9766-787d0ce59a92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f1dd94eb-79a5-4ff9-b122-17801e7c8874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f1dd94eb-79a5-4ff9-b122-17801e7c8874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_49776252-ea04-4ec5-910b-9b6e36778a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_49776252-ea04-4ec5-910b-9b6e36778a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8f4c94e2-d4ec-4a93-9751-a83d61c886c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8f4c94e2-d4ec-4a93-9751-a83d61c886c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_028e72ba-c36c-40d0-bb3c-697031b08854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_028e72ba-c36c-40d0-bb3c-697031b08854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_d5e144ea-533b-443d-83e2-961bb4a43252" xlink:href="biib-20201231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_d5e144ea-533b-443d-83e2-961bb4a43252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_383a3a64-3e45-40d0-8509-868270c52f44" xlink:href="biib-20201231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_383a3a64-3e45-40d0-8509-868270c52f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4d16634d-c983-4ebe-9bd2-cc36b1aaaad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adeaf76b-9780-4c05-b191-370759e57354" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4d16634d-c983-4ebe-9bd2-cc36b1aaaad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8698a0f1-214e-4e3f-869f-2371c5eb86b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf66c853-d1f8-4220-9934-1678389bb02d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8698a0f1-214e-4e3f-869f-2371c5eb86b1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf66c853-d1f8-4220-9934-1678389bb02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf66c853-d1f8-4220-9934-1678389bb02d" xlink:to="loc_us-gaap_AwardTypeAxis_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d3752a9-2abd-4e58-922d-f2c44e4b8c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3cd98123-f5f4-4fb0-9b2a-a4157c3d07de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d3752a9-2abd-4e58-922d-f2c44e4b8c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashSettledPerformanceSharesMember_ce1d763b-362a-4b9c-a74f-d5e1ba468ab7" xlink:href="biib-20201231.xsd#biib_CashSettledPerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d3752a9-2abd-4e58-922d-f2c44e4b8c58" xlink:to="loc_biib_CashSettledPerformanceSharesMember_ce1d763b-362a-4b9c-a74f-d5e1ba468ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7697acdb-537d-4a1e-83d0-ad0735892b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bf66c853-d1f8-4220-9934-1678389bb02d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7697acdb-537d-4a1e-83d0-ad0735892b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7697acdb-537d-4a1e-83d0-ad0735892b48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4fa36056-1063-42c4-b1ca-5c1af45efbf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4fa36056-1063-42c4-b1ca-5c1af45efbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_959295ea-172b-4e75-97b5-ae5ccc4e0eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_959295ea-172b-4e75-97b5-ae5ccc4e0eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ffd77ea8-0c18-4ab2-9944-51d8dfe52946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ffd77ea8-0c18-4ab2-9944-51d8dfe52946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6420680e-8cda-4062-bf17-db387b29d321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6420680e-8cda-4062-bf17-db387b29d321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5291ef9a-ce8f-44be-91fd-673c9abe8c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_13ddb311-080a-487e-b99b-c1b91a17014f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5291ef9a-ce8f-44be-91fd-673c9abe8c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8955724c-ba5e-435f-b112-cba6695c4c18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c83c0b2-de6b-45d9-852f-da8048facc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8955724c-ba5e-435f-b112-cba6695c4c18" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c83c0b2-de6b-45d9-852f-da8048facc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c83c0b2-de6b-45d9-852f-da8048facc7e" xlink:to="loc_us-gaap_AwardTypeAxis_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06df0f82-000b-4ecd-9a15-8a41b63cb9bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_84a35cf4-d76e-4a01-9ec2-3f268d1ab4a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06df0f82-000b-4ecd-9a15-8a41b63cb9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ff44ba80-5600-4501-9a86-d7f50ed25bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06df0f82-000b-4ecd-9a15-8a41b63cb9bf" xlink:to="loc_us-gaap_PerformanceSharesMember_ff44ba80-5600-4501-9a86-d7f50ed25bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4af1aa84-dda3-444e-b54b-836537b28c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2c83c0b2-de6b-45d9-852f-da8048facc7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4af1aa84-dda3-444e-b54b-836537b28c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4af1aa84-dda3-444e-b54b-836537b28c86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07342568-cea8-439f-8f4c-8dd98829d2cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_07342568-cea8-439f-8f4c-8dd98829d2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_774ba374-2e93-4e82-86e0-86b5eda9b533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_774ba374-2e93-4e82-86e0-86b5eda9b533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc1b260e-01f5-4a50-b186-197e1370b941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc1b260e-01f5-4a50-b186-197e1370b941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d343372a-6fcf-4f26-ac2d-b77edd8841c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d343372a-6fcf-4f26-ac2d-b77edd8841c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e3f164bc-c0e3-4787-9945-523c94996027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6e04430b-71e6-42fc-9a41-267941d67d6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e3f164bc-c0e3-4787-9945-523c94996027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5711709b-423a-4ecc-b91a-0e5061f7b0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6a62a1-ff6f-48d8-a329-0f6eab1996bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5711709b-423a-4ecc-b91a-0e5061f7b0f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6a62a1-ff6f-48d8-a329-0f6eab1996bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0e78f3af-e33e-491a-9ab6-aaa0ed91b165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6a62a1-ff6f-48d8-a329-0f6eab1996bc" xlink:to="loc_us-gaap_AwardTypeAxis_0e78f3af-e33e-491a-9ab6-aaa0ed91b165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0a4a1f-a36e-4d96-b5ce-3e70ea3feaa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0e78f3af-e33e-491a-9ab6-aaa0ed91b165" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0a4a1f-a36e-4d96-b5ce-3e70ea3feaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_b1243678-e649-462f-a8d1-08a4afcad400" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e0a4a1f-a36e-4d96-b5ce-3e70ea3feaa7" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_b1243678-e649-462f-a8d1-08a4afcad400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a6f54ce-84b2-4afc-bc4f-4f7161cd74b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae6a62a1-ff6f-48d8-a329-0f6eab1996bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a6f54ce-84b2-4afc-bc4f-4f7161cd74b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a6f54ce-84b2-4afc-bc4f-4f7161cd74b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3d57a46-86e6-4996-9369-253c8191c381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3d57a46-86e6-4996-9369-253c8191c381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_287d24db-df27-4d24-8791-ebd4c857b33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_287d24db-df27-4d24-8791-ebd4c857b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_44f7bf11-645c-4f70-a5da-b76d1e30e2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_44f7bf11-645c-4f70-a5da-b76d1e30e2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_576ad693-9593-430d-8df1-d9289b5dde59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_576ad693-9593-430d-8df1-d9289b5dde59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d951a90b-2af7-414d-9e5b-0ef968ad30a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f1d7f34f-b4d9-4378-bc57-c2ab0d2efcd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d951a90b-2af7-414d-9e5b-0ef968ad30a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a6f54ce-84b2-4afc-bc4f-4f7161cd74b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8a293a44-8c40-472c-ac45-7ae59e5e29dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8a293a44-8c40-472c-ac45-7ae59e5e29dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_593470ce-74da-49b0-b78e-40acda6d0021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_593470ce-74da-49b0-b78e-40acda6d0021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b892b332-5be9-4c8c-890a-2d34a81fa3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b892b332-5be9-4c8c-890a-2d34a81fa3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_03a23ca4-6c25-4024-a0fd-158c826c988f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_03a23ca4-6c25-4024-a0fd-158c826c988f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe94b7f0-f057-4559-bca2-5a3f59b5253a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bf718466-572b-4e47-a3cd-7c2c990f4f21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fe94b7f0-f057-4559-bca2-5a3f59b5253a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_932cdc86-f15c-433d-9f97-54930293bc66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac0d471b-b1e4-49ec-83f2-22b725211125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_932cdc86-f15c-433d-9f97-54930293bc66" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac0d471b-b1e4-49ec-83f2-22b725211125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac0d471b-b1e4-49ec-83f2-22b725211125" xlink:to="loc_us-gaap_AwardTypeAxis_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ed0b4b4-a627-49f2-bbdd-507c08478786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1cdf5fd5-3a9d-4fb6-ab7d-df23e6aad3f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ed0b4b4-a627-49f2-bbdd-507c08478786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_45f4db86-a247-4d45-8e73-dd174855febd" xlink:href="biib-20201231.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ed0b4b4-a627-49f2-bbdd-507c08478786" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_45f4db86-a247-4d45-8e73-dd174855febd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d74b745e-8359-4038-bd27-63df9a8191ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac0d471b-b1e4-49ec-83f2-22b725211125" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d74b745e-8359-4038-bd27-63df9a8191ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d74b745e-8359-4038-bd27-63df9a8191ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17ed22ad-badb-4913-8221-a45171e12908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17ed22ad-badb-4913-8221-a45171e12908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_caa4ed25-787d-4722-9b59-a196687f5d58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_caa4ed25-787d-4722-9b59-a196687f5d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6a248aff-6b70-4ce0-b873-1289ef2de2db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6a248aff-6b70-4ce0-b873-1289ef2de2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_746d3c96-45c9-4da3-8b09-3392dec4a835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_746d3c96-45c9-4da3-8b09-3392dec4a835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3cfb827c-55f3-4d9f-960c-648ca32245f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e27c440a-0227-41ff-923a-b2141752467e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3cfb827c-55f3-4d9f-960c-648ca32245f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b763e1cb-51b1-490f-896b-f0887321ae4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b763e1cb-51b1-490f-896b-f0887321ae4c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_88497b92-a90b-46d0-aaeb-e191c132292b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:to="loc_us-gaap_AwardTypeAxis_88497b92-a90b-46d0-aaeb-e191c132292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d74a94-e476-4da6-9588-3c425a7e1c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_88497b92-a90b-46d0-aaeb-e191c132292b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d74a94-e476-4da6-9588-3c425a7e1c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_030cad97-7041-4015-93d4-620be09bb142" xlink:href="biib-20201231.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3d74a94-e476-4da6-9588-3c425a7e1c67" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_030cad97-7041-4015-93d4-620be09bb142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_77216e71-93b0-4f64-93d5-446bebc1da57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:to="loc_srt_TitleOfIndividualAxis_77216e71-93b0-4f64-93d5-446bebc1da57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7ce3e591-9a0b-4af5-89fa-dbdcb4676bbc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_77216e71-93b0-4f64-93d5-446bebc1da57" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7ce3e591-9a0b-4af5-89fa-dbdcb4676bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_7b0e3dcc-ea34-464e-8861-f1e710846e07" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7ce3e591-9a0b-4af5-89fa-dbdcb4676bbc" xlink:to="loc_srt_DirectorMember_7b0e3dcc-ea34-464e-8861-f1e710846e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d23d128d-d20f-4ac0-8e07-5a63a3c882d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_963edc36-e7b4-43b7-9af5-119c2420c618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_963edc36-e7b4-43b7-9af5-119c2420c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3700e10a-224a-43c3-bfec-889e116589a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3700e10a-224a-43c3-bfec-889e116589a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0c75bb0e-51a1-4e82-9ac6-acd6383f495e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0c75bb0e-51a1-4e82-9ac6-acd6383f495e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be5e5772-bcca-4b2f-905b-875458d1ab75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be5e5772-bcca-4b2f-905b-875458d1ab75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9ca80b53-6098-4f67-a36b-0563904a84b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7b222888-96cd-4302-89a4-5780f07915a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9ca80b53-6098-4f67-a36b-0563904a84b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e20feed-07d5-42d4-915a-07eedafe6f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e20feed-07d5-42d4-915a-07eedafe6f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a277c521-66e0-434b-8c24-acc2ec2ff327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a277c521-66e0-434b-8c24-acc2ec2ff327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9363ea41-c272-4c80-ab6e-5cd87faf80b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9363ea41-c272-4c80-ab6e-5cd87faf80b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39f8c88a-e134-465e-8ca5-f05054119e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_39f8c88a-e134-465e-8ca5-f05054119e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2006140a-b0c7-412b-8666-b1b727020556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_be8eff8a-5e47-4fc8-a7e8-46d720fcf032" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2006140a-b0c7-412b-8666-b1b727020556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d3bfcec-7873-4aa6-9462-7ebed665b7f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5c34c0b-9ee6-4c5f-9669-2dfc0f73d71e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9d3bfcec-7873-4aa6-9462-7ebed665b7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_487e3514-ad62-4753-a78a-251f056288d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_bfd44136-1247-4cc4-8a6c-3771f3988056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_487e3514-ad62-4753-a78a-251f056288d3" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_bfd44136-1247-4cc4-8a6c-3771f3988056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ea21e8e1-1c2e-48d2-aba5-e8a55f913597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_bfd44136-1247-4cc4-8a6c-3771f3988056" xlink:to="loc_us-gaap_PlanNameAxis_ea21e8e1-1c2e-48d2-aba5-e8a55f913597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_39edd8a9-b8fd-4dcf-9f2a-617925801656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ea21e8e1-1c2e-48d2-aba5-e8a55f913597" xlink:to="loc_us-gaap_PlanNameDomain_39edd8a9-b8fd-4dcf-9f2a-617925801656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2015ESPPMember_08524d1a-fb18-47f8-aeee-cf2248fc1c61" xlink:href="biib-20201231.xsd#biib_A2015ESPPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_39edd8a9-b8fd-4dcf-9f2a-617925801656" xlink:to="loc_biib_A2015ESPPMember_08524d1a-fb18-47f8-aeee-cf2248fc1c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_b58f4398-7a0d-4530-903c-6a62baef2385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_bfd44136-1247-4cc4-8a6c-3771f3988056" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_b58f4398-7a0d-4530-903c-6a62baef2385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_38da3084-90f5-4d4c-95f1-911d871c69ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_b58f4398-7a0d-4530-903c-6a62baef2385" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_38da3084-90f5-4d4c-95f1-911d871c69ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1e519bce-711d-4bbb-92a4-4ca36185159f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_b58f4398-7a0d-4530-903c-6a62baef2385" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1e519bce-711d-4bbb-92a4-4ca36185159f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9bcf9ce9-04dd-4d6d-ae1b-3ac809cc2728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5102b11e-7e81-4027-9d93-b0338ad17681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9bcf9ce9-04dd-4d6d-ae1b-3ac809cc2728" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5102b11e-7e81-4027-9d93-b0338ad17681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fab7bdba-0f22-467e-af63-be0ae1bc569d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d8c6bc9a-f46a-4185-9993-fbd9b84af6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fab7bdba-0f22-467e-af63-be0ae1bc569d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d8c6bc9a-f46a-4185-9993-fbd9b84af6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3ac4678d-390c-40a3-83c9-dc2190ad5cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fab7bdba-0f22-467e-af63-be0ae1bc569d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3ac4678d-390c-40a3-83c9-dc2190ad5cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2167bcc1-98b0-44ab-a00e-8987ef728a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fab7bdba-0f22-467e-af63-be0ae1bc569d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2167bcc1-98b0-44ab-a00e-8987ef728a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d0c95a06-685f-4558-9fc2-7bb8a55be6ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fab7bdba-0f22-467e-af63-be0ae1bc569d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d0c95a06-685f-4558-9fc2-7bb8a55be6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d0b9e2d6-b3bb-450f-98e4-3081e51c31fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_c08d6e1d-4ccf-446d-a321-69f1191e0670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0b9e2d6-b3bb-450f-98e4-3081e51c31fc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_c08d6e1d-4ccf-446d-a321-69f1191e0670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_03ecb0fd-4de6-4248-b6fe-136cba083241" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_c08d6e1d-4ccf-446d-a321-69f1191e0670" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_03ecb0fd-4de6-4248-b6fe-136cba083241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_92eae173-d2cc-406a-9a5d-29dfb01b6acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_03ecb0fd-4de6-4248-b6fe-136cba083241" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_92eae173-d2cc-406a-9a5d-29dfb01b6acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b98dc757-be60-4e60-bfe8-42d999b1c4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_03ecb0fd-4de6-4248-b6fe-136cba083241" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b98dc757-be60-4e60-bfe8-42d999b1c4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ca41bfe-dcfe-4eb1-8812-66b5c4fdf29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_03ecb0fd-4de6-4248-b6fe-136cba083241" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ca41bfe-dcfe-4eb1-8812-66b5c4fdf29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4901ca92-d486-4784-8fcb-c446633b753e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_c08d6e1d-4ccf-446d-a321-69f1191e0670" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4901ca92-d486-4784-8fcb-c446633b753e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaaa59c7-3473-4ef7-9b05-b050e7368faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4901ca92-d486-4784-8fcb-c446633b753e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaaa59c7-3473-4ef7-9b05-b050e7368faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_22ecb6f5-deed-4dad-bcb3-6f90f3168c01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaaa59c7-3473-4ef7-9b05-b050e7368faf" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_22ecb6f5-deed-4dad-bcb3-6f90f3168c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_45dbd27c-0c53-459e-ad14-f248b661a1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaaa59c7-3473-4ef7-9b05-b050e7368faf" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_45dbd27c-0c53-459e-ad14-f248b661a1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1c951731-8c7e-445e-b020-a81e689a556a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaaa59c7-3473-4ef7-9b05-b050e7368faf" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1c951731-8c7e-445e-b020-a81e689a556a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_23b8540e-3c4c-47c4-810f-f35d9f4c0734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaaa59c7-3473-4ef7-9b05-b050e7368faf" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_23b8540e-3c4c-47c4-810f-f35d9f4c0734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_dfdc77b4-4881-4203-a1be-ed6906631d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_4901ca92-d486-4784-8fcb-c446633b753e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_dfdc77b4-4881-4203-a1be-ed6906631d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b84a690c-a12e-4a54-b917-2d75d4004bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_dfdc77b4-4881-4203-a1be-ed6906631d1a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b84a690c-a12e-4a54-b917-2d75d4004bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0dcc01ca-5b6a-4b83-b08d-0b2c1ccf5bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_dfdc77b4-4881-4203-a1be-ed6906631d1a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0dcc01ca-5b6a-4b83-b08d-0b2c1ccf5bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6ac8aeb2-5dbc-4a01-a662-c4bf4d0b8e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_dfdc77b4-4881-4203-a1be-ed6906631d1a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6ac8aeb2-5dbc-4a01-a662-c4bf4d0b8e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e9a9126-79bc-4c38-8e19-50243e1e9ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_dfdc77b4-4881-4203-a1be-ed6906631d1a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e9a9126-79bc-4c38-8e19-50243e1e9ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_90f05395-208f-4394-ab48-9df5bebe90ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_c08d6e1d-4ccf-446d-a321-69f1191e0670" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_90f05395-208f-4394-ab48-9df5bebe90ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a200eff2-52e4-4270-b86c-fbbf7e648ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a200eff2-52e4-4270-b86c-fbbf7e648ca2" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeAxis_aa0e1740-0d71-44fd-98b8-a59c1e614f99" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetLiabilityTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeAxis_aa0e1740-0d71-44fd-98b8-a59c1e614f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetLiabilityTypeDomain_d368bfad-e9d7-4068-886d-991eafc8e289" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetLiabilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeAxis_aa0e1740-0d71-44fd-98b8-a59c1e614f99" xlink:to="loc_biib_DeferredTaxAssetLiabilityTypeDomain_d368bfad-e9d7-4068-886d-991eafc8e289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntellectualPropertyMember_c00a00c2-94d8-4996-8921-f4bd9e806f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DeferredTaxAssetLiabilityTypeDomain_d368bfad-e9d7-4068-886d-991eafc8e289" xlink:to="loc_us-gaap_IntellectualPropertyMember_c00a00c2-94d8-4996-8921-f4bd9e806f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd7ee87b-aa2f-442d-92e7-f442b27d04cb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_srt_ProductOrServiceAxis_fd7ee87b-aa2f-442d-92e7-f442b27d04cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8892a711-629e-499f-8676-479d661c4829" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fd7ee87b-aa2f-442d-92e7-f442b27d04cb" xlink:to="loc_srt_ProductsAndServicesDomain_8892a711-629e-499f-8676-479d661c4829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_71c4f5d9-9d4a-45ab-be90-a40fd3b8ccb4" xlink:href="biib-20201231.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8892a711-629e-499f-8676-479d661c4829" xlink:to="loc_biib_TECFIDERAMember_71c4f5d9-9d4a-45ab-be90-a40fd3b8ccb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_97fae0aa-38a6-4364-8a6b-627ac2b23221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_97fae0aa-38a6-4364-8a6b-627ac2b23221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52dc1819-7c6e-477f-a73a-c19d640da23b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_97fae0aa-38a6-4364-8a6b-627ac2b23221" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52dc1819-7c6e-477f-a73a-c19d640da23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenmarkManufacturingOperationsMember_d7b6ae41-9945-4da2-841b-4063e3f7f707" xlink:href="biib-20201231.xsd#biib_DenmarkManufacturingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_52dc1819-7c6e-477f-a73a-c19d640da23b" xlink:to="loc_biib_DenmarkManufacturingOperationsMember_d7b6ae41-9945-4da2-841b-4063e3f7f707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c6c70b7-d7ff-4e90-80a8-a290945e4119" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_srt_RangeAxis_9c6c70b7-d7ff-4e90-80a8-a290945e4119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_efe9fb03-630e-4600-9579-39f17f8d7941" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9c6c70b7-d7ff-4e90-80a8-a290945e4119" xlink:to="loc_srt_RangeMember_efe9fb03-630e-4600-9579-39f17f8d7941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_29135378-9c93-4c85-af04-62e02fdb8897" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_efe9fb03-630e-4600-9579-39f17f8d7941" xlink:to="loc_srt_MinimumMember_29135378-9c93-4c85-af04-62e02fdb8897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a0c3bd21-6e0a-459f-bf2c-5af6446ee46b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_efe9fb03-630e-4600-9579-39f17f8d7941" xlink:to="loc_srt_MaximumMember_a0c3bd21-6e0a-459f-bf2c-5af6446ee46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningstypeAxis_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52" xlink:href="biib-20201231.xsd#biib_ForeignearningstypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_biib_ForeignearningstypeAxis_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningstypeDomain_d7669ce3-67da-4f48-8ffa-e777d253538a" xlink:href="biib-20201231.xsd#biib_ForeignearningstypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeAxis_a7a1048a-a6ed-4a9c-8efe-e6b901d9cb52" xlink:to="loc_biib_ForeignearningstypeDomain_d7669ce3-67da-4f48-8ffa-e777d253538a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_3eac8023-b7a3-4ec3-85f7-a69b6d82f968" xlink:href="biib-20201231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_d7669ce3-67da-4f48-8ffa-e777d253538a" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_3eac8023-b7a3-4ec3-85f7-a69b6d82f968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherForeignEarningsMember_0f2ef6b8-f12a-4f1a-89d8-11b9c7960322" xlink:href="biib-20201231.xsd#biib_OtherForeignEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_d7669ce3-67da-4f48-8ffa-e777d253538a" xlink:to="loc_biib_OtherForeignEarningsMember_0f2ef6b8-f12a-4f1a-89d8-11b9c7960322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2dba818e-fc7f-4c1b-b835-26eeddd1116c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2dba818e-fc7f-4c1b-b835-26eeddd1116c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_57c7beb1-6469-4c9e-8450-8eb29f7a385d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2dba818e-fc7f-4c1b-b835-26eeddd1116c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_57c7beb1-6469-4c9e-8450-8eb29f7a385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralBusinessMember_70e4b020-2570-48e7-801f-c91bd2b43d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_57c7beb1-6469-4c9e-8450-8eb29f7a385d" xlink:to="loc_us-gaap_GeneralBusinessMember_70e4b020-2570-48e7-801f-c91bd2b43d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_b5398989-caf7-4055-8121-428530f504da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_57c7beb1-6469-4c9e-8450-8eb29f7a385d" xlink:to="loc_us-gaap_ResearchMember_b5398989-caf7-4055-8121-428530f504da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_29de6a2c-7e68-4a81-9cf4-1d09ffae3aed" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_U.S.2017TaxActMember_b40e73bc-1990-41b7-88f5-271592df0f84" xlink:href="biib-20201231.xsd#biib_U.S.2017TaxActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:to="loc_biib_U.S.2017TaxActMember_b40e73bc-1990-41b7-88f5-271592df0f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ee45ea20-8513-46e3-9f0c-5ea053462f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:to="loc_us-gaap_DomesticCountryMember_ee45ea20-8513-46e3-9f0c-5ea053462f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9d601de3-bdc7-490b-bd81-d35a17b5ae2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9d601de3-bdc7-490b-bd81-d35a17b5ae2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_9d16a7e2-a58b-4cf6-a92d-be7db3ef3df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_69d4fdf7-522a-490b-a139-35d1e77ca1c4" xlink:to="loc_us-gaap_ForeignCountryMember_9d16a7e2-a58b-4cf6-a92d-be7db3ef3df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_804c3ed4-acb5-4bcd-b5fd-a41ef545651b" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_c8b02f04-0523-4237-b373-fac2b8b12ad6" xlink:href="biib-20201231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_c8b02f04-0523-4237-b373-fac2b8b12ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_827a91a6-ddc1-4cce-9941-a8fd429032dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_827a91a6-ddc1-4cce-9941-a8fd429032dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_587c6a7b-04c9-4429-83cc-287f1ea32e27" xlink:href="biib-20201231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_587c6a7b-04c9-4429-83cc-287f1ea32e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_e343d40b-5a8e-4e21-a7bb-6e37366c000a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_e343d40b-5a8e-4e21-a7bb-6e37366c000a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_e3086eb3-3be0-430c-85ba-99b86370fd33" xlink:href="biib-20201231.xsd#biib_TransitionTollTaxRepatriationTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_e3086eb3-3be0-430c-85ba-99b86370fd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_f79df3ab-1c31-4247-930f-3e265cab9e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_f79df3ab-1c31-4247-930f-3e265cab9e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_3b575a0a-4a03-4bb8-8a8a-d3b6ed154b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_IncomeTaxesPaid_3b575a0a-4a03-4bb8-8a8a-d3b6ed154b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_30298ab7-39e6-4ad4-8a44-562c96a2d7eb" xlink:href="biib-20201231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_30298ab7-39e6-4ad4-8a44-562c96a2d7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_30619bae-c58e-42f9-8d39-4e4e23d6f99d" xlink:href="biib-20201231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_30619bae-c58e-42f9-8d39-4e4e23d6f99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxAssetsValueReductionInValue_9b141631-be31-4d06-87a0-710247bc3531" xlink:href="biib-20201231.xsd#biib_DeferredTaxAssetsValueReductionInValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_DeferredTaxAssetsValueReductionInValue_9b141631-be31-4d06-87a0-710247bc3531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesValueReductionInValue_3dc2e353-28f8-4de9-a22a-d95538894bc2" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesValueReductionInValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_DeferredTaxLiabilitiesValueReductionInValue_3dc2e353-28f8-4de9-a22a-d95538894bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet_461db798-f4c7-4f65-b2e2-030206986f76" xlink:href="biib-20201231.xsd#biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet_461db798-f4c7-4f65-b2e2-030206986f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_c168ee1d-a2cc-407e-9ba5-472c0baacaad" xlink:href="biib-20201231.xsd#biib_Totaldeferredchargesandprepaidtaxes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_c168ee1d-a2cc-407e-9ba5-472c0baacaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_01b42a75-770d-4ef2-a8eb-095612b5dc3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_01b42a75-770d-4ef2-a8eb-095612b5dc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_53af6cd1-77a1-4cd9-bd88-2e64ed0b5bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_53af6cd1-77a1-4cd9-bd88-2e64ed0b5bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_28211097-b48d-46e0-ab14-7d7ef09a0f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_28211097-b48d-46e0-ab14-7d7ef09a0f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3318b3be-746c-4472-9aec-52d740b8af90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3318b3be-746c-4472-9aec-52d740b8af90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_cb1fb71a-5f1e-4b34-abb8-16229a580d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_cb1fb71a-5f1e-4b34-abb8-16229a580d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_27ba8056-bb16-4aa5-84c0-6dc780f859d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_27ba8056-bb16-4aa5-84c0-6dc780f859d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_be87990f-5ada-489a-819a-7dde709fbfa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_be87990f-5ada-489a-819a-7dde709fbfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ab21fe35-1abb-4547-aa1f-199b8c8f0d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ab21fe35-1abb-4547-aa1f-199b8c8f0d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_025f78d7-9fd4-4908-8154-550f6fbb42ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_025f78d7-9fd4-4908-8154-550f6fbb42ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_74394800-0907-4b26-bfb7-65f9d1ca2aaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_74394800-0907-4b26-bfb7-65f9d1ca2aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_157797ac-7f79-455b-ab7a-8f3e5e979486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_3667fdef-d230-473b-b142-5e9513466fa4" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_157797ac-7f79-455b-ab7a-8f3e5e979486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_853e7df2-0971-46c2-99a9-55cd67f787ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_853e7df2-0971-46c2-99a9-55cd67f787ed" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f9a2344e-1104-47f9-b415-5c534338473a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f9a2344e-1104-47f9-b415-5c534338473a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_308257ef-b3c9-423e-8828-bce801bdc1ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_308257ef-b3c9-423e-8828-bce801bdc1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_812ed26b-2509-42ad-b9f1-4de1b5e23690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_812ed26b-2509-42ad-b9f1-4de1b5e23690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0027248c-a6ce-4f35-8eb2-dd6318a42d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0027248c-a6ce-4f35-8eb2-dd6318a42d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ccf4e37b-fa44-4356-ad3a-9f8604fe0cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ccf4e37b-fa44-4356-ad3a-9f8604fe0cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5b651ca7-3933-4036-b78b-31fb11a0a32e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5b651ca7-3933-4036-b78b-31fb11a0a32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6c26ac53-b7fa-4a9e-b836-5d37bbfe6f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6c26ac53-b7fa-4a9e-b836-5d37bbfe6f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1b0a5cf7-d523-4938-9e36-e007fc655ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_159f009b-69dd-458d-a71c-284d12e3b0d9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1b0a5cf7-d523-4938-9e36-e007fc655ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_77230b35-3d4e-4142-92af-f8fd52684664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_853e7df2-0971-46c2-99a9-55cd67f787ed" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_77230b35-3d4e-4142-92af-f8fd52684664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9acef724-6a25-4c5f-8f29-cdb6fa377fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_77230b35-3d4e-4142-92af-f8fd52684664" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9acef724-6a25-4c5f-8f29-cdb6fa377fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_ef8d8c6b-3d1a-4f11-912e-be43e53205b0" xlink:href="biib-20201231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_77230b35-3d4e-4142-92af-f8fd52684664" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_ef8d8c6b-3d1a-4f11-912e-be43e53205b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_d4623efd-1681-4a6b-a919-1490eb30e4d3" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_77230b35-3d4e-4142-92af-f8fd52684664" xlink:to="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_d4623efd-1681-4a6b-a919-1490eb30e4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_505ee1bd-7964-4df6-9e73-cd19e8fb47bf" xlink:href="biib-20201231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_77230b35-3d4e-4142-92af-f8fd52684664" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_505ee1bd-7964-4df6-9e73-cd19e8fb47bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_57e93d1a-5224-4e88-b320-ebd4040bab0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_77230b35-3d4e-4142-92af-f8fd52684664" xlink:to="loc_us-gaap_DeferredTaxLiabilities_57e93d1a-5224-4e88-b320-ebd4040bab0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90b6bfa3-46e9-4d85-b21f-c786cc9938df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90b6bfa3-46e9-4d85-b21f-c786cc9938df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_cff3b8d6-5934-4d07-bf7a-bb178017ada4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_cff3b8d6-5934-4d07-bf7a-bb178017ada4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_34beffaf-b45c-4e85-859d-8c31df4f1e3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_34beffaf-b45c-4e85-859d-8c31df4f1e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_82b87757-0d23-47e9-a5bf-f888cef53541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_82b87757-0d23-47e9-a5bf-f888cef53541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_a20a24dd-4b23-43fe-8a41-fc590331f134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_a20a24dd-4b23-43fe-8a41-fc590331f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_10501f92-c184-4ac7-a162-2f32b2ca099a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets_10501f92-c184-4ac7-a162-2f32b2ca099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_ddc9f2d6-4fa6-414d-a9d0-a57401fc8b05" xlink:href="biib-20201231.xsd#biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization_ddc9f2d6-4fa6-414d-a9d0-a57401fc8b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_462d5294-7254-4d13-9340-3f78d83f5f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_462d5294-7254-4d13-9340-3f78d83f5f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_489c7aab-6c7f-4e73-a90a-6142d2c1ab4e" xlink:href="biib-20201231.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_489c7aab-6c7f-4e73-a90a-6142d2c1ab4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_281a913c-bd46-4fe8-a86d-3037d3234147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_281a913c-bd46-4fe8-a86d-3037d3234147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_effab5d6-ca74-47bb-a0a6-11381d66d827" xlink:href="biib-20201231.xsd#biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent_effab5d6-ca74-47bb-a0a6-11381d66d827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d709d955-9f38-4133-b5af-edb31c2fdfec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d709d955-9f38-4133-b5af-edb31c2fdfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3a8b5f4-75cf-445a-aa62-045d284d1d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73b6b8ba-7046-4be6-9aff-cc25925b898a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c3a8b5f4-75cf-445a-aa62-045d284d1d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f87af72b-6e0e-498f-8226-48d06c4b2f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f87af72b-6e0e-498f-8226-48d06c4b2f96" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_23922e77-4b69-4f88-8f67-5181e45663e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_23922e77-4b69-4f88-8f67-5181e45663e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_84dab2c6-e061-4342-a018-10c6691364ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_84dab2c6-e061-4342-a018-10c6691364ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_149c0dc5-1fab-41c3-8959-10d91f6cf612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_149c0dc5-1fab-41c3-8959-10d91f6cf612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6227080b-7575-4157-81a1-74436b76c908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6227080b-7575-4157-81a1-74436b76c908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_98482734-4cf6-4312-aea3-8259de219f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_98482734-4cf6-4312-aea3-8259de219f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_9b8eb5cf-f695-48eb-ad15-489fd349bc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_9b8eb5cf-f695-48eb-ad15-489fd349bc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f3cdd860-b621-4e70-a862-072983be95a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f3cdd860-b621-4e70-a862-072983be95a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_52d1e2ac-980a-4088-8adf-4e96fc2f46ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5070b8e0-ec13-48a8-8f1c-f8f50de5c6ad" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_52d1e2ac-980a-4088-8adf-4e96fc2f46ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_841d6202-2b1a-4b9d-8aeb-1dded88cc0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_b78d0bcb-dbf2-4e74-ada4-c2931156d9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_841d6202-2b1a-4b9d-8aeb-1dded88cc0bd" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_b78d0bcb-dbf2-4e74-ada4-c2931156d9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6d35ac0-5ec6-402f-a020-4e171b4a4fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_fa8676db-b2a4-46fd-8336-0b8d533cbe47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6d35ac0-5ec6-402f-a020-4e171b4a4fb7" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_fa8676db-b2a4-46fd-8336-0b8d533cbe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_03695c75-e67d-4e17-a9d5-7031ae5df977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6d35ac0-5ec6-402f-a020-4e171b4a4fb7" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_03695c75-e67d-4e17-a9d5-7031ae5df977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_38d83beb-00f3-451d-984c-703c867e1458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6d35ac0-5ec6-402f-a020-4e171b4a4fb7" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_38d83beb-00f3-451d-984c-703c867e1458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8a446db9-ee88-4705-8215-0f8f3ff6e0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6d35ac0-5ec6-402f-a020-4e171b4a4fb7" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8a446db9-ee88-4705-8215-0f8f3ff6e0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eef7d154-1cc8-44fc-8fe0-98964007e29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fc119dff-3f2b-461c-a9ca-4dc0dc3e7134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eef7d154-1cc8-44fc-8fe0-98964007e29c" xlink:to="loc_us-gaap_InterestPaidNet_fc119dff-3f2b-461c-a9ca-4dc0dc3e7134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_a131ff50-4b69-4edb-9da7-a5781d443bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eef7d154-1cc8-44fc-8fe0-98964007e29c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_a131ff50-4b69-4edb-9da7-a5781d443bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_32cc4468-8827-4902-a003-036cabe86f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_32cc4468-8827-4902-a003-036cabe86f9a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dc20802d-98a9-42ae-8d18-a06136ba96b2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_srt_ProductOrServiceAxis_dc20802d-98a9-42ae-8d18-a06136ba96b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d05160ad-4e98-4e48-89f4-dd20e4bb326b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dc20802d-98a9-42ae-8d18-a06136ba96b2" xlink:to="loc_srt_ProductsAndServicesDomain_d05160ad-4e98-4e48-89f4-dd20e4bb326b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_c3001e1e-88d4-43d7-bcdc-9c3b889e696d" xlink:href="biib-20201231.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d05160ad-4e98-4e48-89f4-dd20e4bb326b" xlink:to="loc_biib_FumarateMember_c3001e1e-88d4-43d7-bcdc-9c3b889e696d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8e8b7019-0540-46db-bb62-b79ab5034cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8e8b7019-0540-46db-bb62-b79ab5034cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe451116-a16d-4055-a46b-065eefe867e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8e8b7019-0540-46db-bb62-b79ab5034cfe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe451116-a16d-4055-a46b-065eefe867e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumapharmAgMember_e46ad566-b289-4df1-a190-b84070848f88" xlink:href="biib-20201231.xsd#biib_FumapharmAgMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fe451116-a16d-4055-a46b-065eefe867e6" xlink:to="loc_biib_FumapharmAgMember_e46ad566-b289-4df1-a190-b84070848f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_0ee487e1-3bbc-459a-873d-1f7a02f4ac40" xlink:href="biib-20201231.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_biib_FacilityLocationAxis_0ee487e1-3bbc-459a-873d-1f7a02f4ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_3551ba7b-e95f-4725-9caf-35f274d6cd67" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_0ee487e1-3bbc-459a-873d-1f7a02f4ac40" xlink:to="loc_biib_FacilityLocationDomain_3551ba7b-e95f-4725-9caf-35f274d6cd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember_7c629d90-8a76-4887-a2c1-ed02b28138de" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_3551ba7b-e95f-4725-9caf-35f274d6cd67" xlink:to="loc_biib_SolothurnMember_7c629d90-8a76-4887-a2c1-ed02b28138de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelAxis_2ea42160-9302-4b00-80ef-b742c3d09b34" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_biib_CumulativeSalesLevelAxis_2ea42160-9302-4b00-80ef-b742c3d09b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelDomain_35f7a420-4e5b-43a0-9726-f814cb9b8ec3" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_2ea42160-9302-4b00-80ef-b742c3d09b34" xlink:to="loc_biib_CumulativeSalesLevelDomain_35f7a420-4e5b-43a0-9726-f814cb9b8ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwentybillionMember_ab489002-2c6d-4c04-ac6d-ed21267781ea" xlink:href="biib-20201231.xsd#biib_TwentybillionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_35f7a420-4e5b-43a0-9726-f814cb9b8ec3" xlink:to="loc_biib_TwentybillionMember_ab489002-2c6d-4c04-ac6d-ed21267781ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6e9d6f0f-b3ed-4dcb-95dc-71b06d46ab39" xlink:href="biib-20201231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_35f7a420-4e5b-43a0-9726-f814cb9b8ec3" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_6e9d6f0f-b3ed-4dcb-95dc-71b06d46ab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3bc14176-abc3-46a1-ac74-fcdbf53cfb69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_dei_LegalEntityAxis_3bc14176-abc3-46a1-ac74-fcdbf53cfb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3bc14176-abc3-46a1-ac74-fcdbf53cfb69" xlink:to="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_a570a7ca-cd0d-4ec7-a670-96eecf73b38e" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_DenaliTherapeuticsIncMember_a570a7ca-cd0d-4ec7-a670-96eecf73b38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoCommonStockMember_c5b9feeb-38e5-423c-86de-dce6a734b209" xlink:href="biib-20201231.xsd#biib_SangamoCommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_SangamoCommonStockMember_c5b9feeb-38e5-423c-86de-dce6a734b209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_34b388ec-38b7-4bec-b770-87e663ad5315" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_IonisPharmaceuticalsMember_34b388ec-38b7-4bec-b770-87e663ad5315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_17877662-1339-4707-8451-a05c9f5b3dbf" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_SageTherapeuticsIncMember_17877662-1339-4707-8451-a05c9f5b3dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliAndSangamoMember_feeeccc9-4f36-40c8-94e7-defea07252e7" xlink:href="biib-20201231.xsd#biib_DenaliAndSangamoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_30393019-79fa-44bc-a0f8-35560b0a8535" xlink:to="loc_biib_DenaliAndSangamoMember_feeeccc9-4f36-40c8-94e7-defea07252e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6249cfca-670c-4ae7-8fec-e930b68bf1c6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_ce6f713f-1c2f-4c13-a485-9e3818e52fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_ce6f713f-1c2f-4c13-a485-9e3818e52fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevel_8d827ff5-e077-4fa9-bd5b-a3df67f61415" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevel"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_biib_CumulativeSalesLevel_8d827ff5-e077-4fa9-bd5b-a3df67f61415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_0f90c44b-6f06-4c5c-ada0-8e9cae9b5b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_0f90c44b-6f06-4c5c-ada0-8e9cae9b5b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_ed51fb86-e4e5-4ec6-bd24-4501232fc6da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_ed51fb86-e4e5-4ec6-bd24-4501232fc6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8fc63f40-ccc5-4fc0-b2f7-919c8044078c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_8fc63f40-ccc5-4fc0-b2f7-919c8044078c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_03967a8d-7682-4971-82bc-30b10a00948a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_03967a8d-7682-4971-82bc-30b10a00948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7d28c5f1-a377-4693-8115-1d039da25a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7d28c5f1-a377-4693-8115-1d039da25a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_16b2fe17-1963-47b0-885e-f97289c56601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ca3d8d16-72bd-418f-a2ab-b4b6a22ef054" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_16b2fe17-1963-47b0-885e-f97289c56601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4269825-d9b8-4d53-a316-05ea05c60c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7838e938-17f6-41de-84e5-b874ddefd82e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4269825-d9b8-4d53-a316-05ea05c60c32" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7838e938-17f6-41de-84e5-b874ddefd82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8c474c4d-97b2-425f-9cd4-c9344c080f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4269825-d9b8-4d53-a316-05ea05c60c32" xlink:to="loc_us-gaap_InterestExpense_8c474c4d-97b2-425f-9cd4-c9344c080f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_accfe076-60df-4041-9f2b-d9ae520e1959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4269825-d9b8-4d53-a316-05ea05c60c32" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_accfe076-60df-4041-9f2b-d9ae520e1959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a8737fde-34e4-4648-a6f0-c47927f22562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4269825-d9b8-4d53-a316-05ea05c60c32" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a8737fde-34e4-4648-a6f0-c47927f22562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dc1d364c-7a3b-4b1b-96d7-9383bbbdec3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4269825-d9b8-4d53-a316-05ea05c60c32" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dc1d364c-7a3b-4b1b-96d7-9383bbbdec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9da62743-517a-4c28-9a66-afc9fb810ef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4269825-d9b8-4d53-a316-05ea05c60c32" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9da62743-517a-4c28-9a66-afc9fb810ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74b23c7f-0026-4ca7-8670-d7f15e09b983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_85e314da-89f7-4faf-a515-0d053cab294e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74b23c7f-0026-4ca7-8670-d7f15e09b983" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_85e314da-89f7-4faf-a515-0d053cab294e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d54cde66-e081-4283-8a17-3abc6b7ed2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74b23c7f-0026-4ca7-8670-d7f15e09b983" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d54cde66-e081-4283-8a17-3abc6b7ed2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2bc7d954-4f5f-4abf-a916-4975c6e59abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74b23c7f-0026-4ca7-8670-d7f15e09b983" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2bc7d954-4f5f-4abf-a916-4975c6e59abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c70131aa-df69-4f07-8f97-96ca3a22f91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1feee384-5b47-48d6-b41f-a168f87ab572" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c70131aa-df69-4f07-8f97-96ca3a22f91e" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1feee384-5b47-48d6-b41f-a168f87ab572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f2c9c109-ef78-4b79-84f7-d9517f2be4d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1feee384-5b47-48d6-b41f-a168f87ab572" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f2c9c109-ef78-4b79-84f7-d9517f2be4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_016ee5f7-5052-4e1f-8abe-0d3142397a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f2c9c109-ef78-4b79-84f7-d9517f2be4d2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_016ee5f7-5052-4e1f-8abe-0d3142397a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_4f395225-8a3f-4f39-977d-2ffa3c7ab287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_016ee5f7-5052-4e1f-8abe-0d3142397a8c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_4f395225-8a3f-4f39-977d-2ffa3c7ab287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1feee384-5b47-48d6-b41f-a168f87ab572" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_56d18388-0b0a-434d-bae2-e609091adbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_56d18388-0b0a-434d-bae2-e609091adbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_e0190e19-477e-4c0d-8f54-67e170ea5b26" xlink:href="biib-20201231.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_biib_Collaborationexpensesaccrual_e0190e19-477e-4c0d-8f54-67e170ea5b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bb45a56e-c61c-454a-b310-0fe326608ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bb45a56e-c61c-454a-b310-0fe326608ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c960a44e-fa65-4322-ac50-d0b7502f9533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c960a44e-fa65-4322-ac50-d0b7502f9533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_cb25ab7b-b588-445b-ac68-42d40736d2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_cb25ab7b-b588-445b-ac68-42d40736d2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f49a043c-fc41-4e9f-bf8b-866ad0825f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f49a043c-fc41-4e9f-bf8b-866ad0825f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4be6edcd-35d4-4544-b55c-c4cba817ce10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4be6edcd-35d4-4544-b55c-c4cba817ce10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5cbf1621-e633-41c2-b1bf-5c3e98964e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_818df981-96b0-421b-b035-334e75fa12bd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5cbf1621-e633-41c2-b1bf-5c3e98964e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d19cc2a0-b7be-4980-9d72-7551d24918f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_cf16694e-11a6-4ab3-99c5-3714625d1507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d19cc2a0-b7be-4980-9d72-7551d24918f0" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_cf16694e-11a6-4ab3-99c5-3714625d1507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac1ad11f-6d33-45f7-9b30-8f488c6d737c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_a6be9115-7dfd-4d38-af16-cd515e567378" xlink:href="biib-20201231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac1ad11f-6d33-45f7-9b30-8f488c6d737c" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_a6be9115-7dfd-4d38-af16-cd515e567378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_c0ed6a51-1fb5-4373-b73f-3cbb64f1bc83" xlink:href="biib-20201231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac1ad11f-6d33-45f7-9b30-8f488c6d737c" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_c0ed6a51-1fb5-4373-b73f-3cbb64f1bc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_b93aa1db-051e-4f9c-b787-cb52d3b6e823" xlink:href="biib-20201231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac1ad11f-6d33-45f7-9b30-8f488c6d737c" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_b93aa1db-051e-4f9c-b787-cb52d3b6e823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_bdd821b0-e54e-42b9-b250-56b4fe219a34" xlink:href="biib-20201231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac1ad11f-6d33-45f7-9b30-8f488c6d737c" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_bdd821b0-e54e-42b9-b250-56b4fe219a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_ca22c615-e7f1-47fe-b9a2-af2cebc7363d" xlink:href="biib-20201231.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac1ad11f-6d33-45f7-9b30-8f488c6d737c" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_ca22c615-e7f1-47fe-b9a2-af2cebc7363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_b83a6670-f628-4af8-8b2a-308b80c1673f" xlink:href="biib-20201231.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac1ad11f-6d33-45f7-9b30-8f488c6d737c" xlink:to="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_b83a6670-f628-4af8-8b2a-308b80c1673f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d17b434-60c3-4f3c-80d1-3c3f83bcd12f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0d17b434-60c3-4f3c-80d1-3c3f83bcd12f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_68e0e224-612b-4322-84ab-38284d0e8e0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:to="loc_srt_ProductOrServiceAxis_68e0e224-612b-4322-84ab-38284d0e8e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aa49be79-da88-4e63-8cd2-59e3844d94a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_68e0e224-612b-4322-84ab-38284d0e8e0c" xlink:to="loc_srt_ProductsAndServicesDomain_aa49be79-da88-4e63-8cd2-59e3844d94a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_f3f6a2db-9e2c-4f21-98a5-e7305d4d282a" xlink:href="biib-20201231.xsd#biib_OCREVUSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_aa49be79-da88-4e63-8cd2-59e3844d94a6" xlink:to="loc_biib_OCREVUSMember_f3f6a2db-9e2c-4f21-98a5-e7305d4d282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0dec9123-5782-4243-9d59-aff1292ab085" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:to="loc_srt_RangeAxis_0dec9123-5782-4243-9d59-aff1292ab085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_735637df-5a4f-4d85-b960-60448d97f032" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0dec9123-5782-4243-9d59-aff1292ab085" xlink:to="loc_srt_RangeMember_735637df-5a4f-4d85-b960-60448d97f032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c2cf4ef2-678e-49ee-94f9-c70fe1edb4f2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_735637df-5a4f-4d85-b960-60448d97f032" xlink:to="loc_srt_MinimumMember_c2cf4ef2-678e-49ee-94f9-c70fe1edb4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ecf2981a-19df-405b-9169-254844c532aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_735637df-5a4f-4d85-b960-60448d97f032" xlink:to="loc_srt_MaximumMember_ecf2981a-19df-405b-9169-254844c532aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b693c264-64f5-4cad-b8f0-d0106bbbd041" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:to="loc_srt_StatementGeographicalAxis_b693c264-64f5-4cad-b8f0-d0106bbbd041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2863bfd2-fc19-4be2-b3a6-ce07d0a26377" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b693c264-64f5-4cad-b8f0-d0106bbbd041" xlink:to="loc_srt_SegmentGeographicalDomain_2863bfd2-fc19-4be2-b3a6-ce07d0a26377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_6e937367-8be6-42bb-9554-82683492f0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2863bfd2-fc19-4be2-b3a6-ce07d0a26377" xlink:to="loc_us-gaap_ForeignCountryMember_6e937367-8be6-42bb-9554-82683492f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab8ba67c-227e-4acc-980b-7d994fa98a22" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_f00e6159-b1e5-427f-9b24-1e2d14c2ab5e" xlink:href="biib-20201231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_f00e6159-b1e5-427f-9b24-1e2d14c2ab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_5aeb2718-a856-4baa-b659-462a59a912a4" xlink:href="biib-20201231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_5aeb2718-a856-4baa-b659-462a59a912a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_cf2eb553-c793-4993-8a71-a190f0516662" xlink:href="biib-20201231.xsd#biib_Reductioninroyaltyrate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_biib_Reductioninroyaltyrate_cf2eb553-c793-4993-8a71-a190f0516662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_199892d1-ba16-4a9d-a2c2-6f0529503f6b" xlink:href="biib-20201231.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_630d1636-be37-4ee9-9892-52049cc421b6" xlink:to="loc_biib_PeriodOfCollaborationAgreement_199892d1-ba16-4a9d-a2c2-6f0529503f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74a34411-f9d0-4759-b0f7-d1f2280d6888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4faea19-fee9-4c95-aa6f-84dc7d6faece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74a34411-f9d0-4759-b0f7-d1f2280d6888" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4faea19-fee9-4c95-aa6f-84dc7d6faece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3a02249-a10d-48bc-af5e-29edb5286d23" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4faea19-fee9-4c95-aa6f-84dc7d6faece" xlink:to="loc_srt_ProductOrServiceAxis_e3a02249-a10d-48bc-af5e-29edb5286d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_42b2a2a2-dbd4-4f37-8656-a10196f8b2f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e3a02249-a10d-48bc-af5e-29edb5286d23" xlink:to="loc_srt_ProductsAndServicesDomain_42b2a2a2-dbd4-4f37-8656-a10196f8b2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_136ad607-9e9d-4aea-a6a7-6fe026a9e2bb" xlink:href="biib-20201231.xsd#biib_RituxanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_42b2a2a2-dbd4-4f37-8656-a10196f8b2f8" xlink:to="loc_biib_RituxanMember_136ad607-9e9d-4aea-a6a7-6fe026a9e2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3aa07837-c660-4ce1-a072-dfde29497a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e4faea19-fee9-4c95-aa6f-84dc7d6faece" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3aa07837-c660-4ce1-a072-dfde29497a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_a464d0e1-9f55-4f9b-9c7e-d14863b9d5d9" xlink:href="biib-20201231.xsd#biib_CoPromotionProfitSharingFormulaAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3aa07837-c660-4ce1-a072-dfde29497a0a" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_a464d0e1-9f55-4f9b-9c7e-d14863b9d5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_38f6e3ce-bcbe-4773-a374-a0f0b6116b28" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_a464d0e1-9f55-4f9b-9c7e-d14863b9d5d9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_38f6e3ce-bcbe-4773-a374-a0f0b6116b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_a464d0e1-9f55-4f9b-9c7e-d14863b9d5d9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_575e9bfa-b542-4f6f-bc92-b17f13f02b7a" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_575e9bfa-b542-4f6f-bc92-b17f13f02b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_22224d5a-80c0-4bf1-a38d-77516cacff97" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_22224d5a-80c0-4bf1-a38d-77516cacff97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_e875d5fe-a0ef-4198-a094-8489abe8c1ed" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_b42a2321-b9c5-4b53-8e65-291085cad584" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_e875d5fe-a0ef-4198-a094-8489abe8c1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca6b9f99-2582-4e94-9875-eb686d5c91f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca6b9f99-2582-4e94-9875-eb686d5c91f8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dfce8ef2-bfb4-4005-938b-764463084275" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:to="loc_srt_ProductOrServiceAxis_dfce8ef2-bfb4-4005-938b-764463084275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dfce8ef2-bfb4-4005-938b-764463084275" xlink:to="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_b3a3f48c-5f81-48ee-abe6-993129797fe0" xlink:href="biib-20201231.xsd#biib_RituxanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:to="loc_biib_RituxanMember_b3a3f48c-5f81-48ee-abe6-993129797fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_7064a8e3-6742-4de6-9255-08d3bdd8b8e9" xlink:href="biib-20201231.xsd#biib_GAZYVAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:to="loc_biib_GAZYVAMember_7064a8e3-6742-4de6-9255-08d3bdd8b8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NewAntiCd20Member_727f73a0-47ac-4466-bc25-99876bb77a07" xlink:href="biib-20201231.xsd#biib_NewAntiCd20Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b0696348-1444-48f5-af7e-1da6df207b4c" xlink:to="loc_biib_NewAntiCd20Member_727f73a0-47ac-4466-bc25-99876bb77a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_002d01e6-ee16-4527-aee9-5d0393b603e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:to="loc_srt_RangeAxis_002d01e6-ee16-4527-aee9-5d0393b603e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e454cb9-0019-4f90-9d4a-560cea32725b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_002d01e6-ee16-4527-aee9-5d0393b603e3" xlink:to="loc_srt_RangeMember_6e454cb9-0019-4f90-9d4a-560cea32725b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_38da6ecb-8dc0-492c-b17c-50ad63e84253" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e454cb9-0019-4f90-9d4a-560cea32725b" xlink:to="loc_srt_MinimumMember_38da6ecb-8dc0-492c-b17c-50ad63e84253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0b62d9b4-8180-4f9d-8e1e-43500be7c4b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e454cb9-0019-4f90-9d4a-560cea32725b" xlink:to="loc_srt_MaximumMember_0b62d9b4-8180-4f9d-8e1e-43500be7c4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_be37fbd8-b033-4a28-aa38-54c7301cc54f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_657b96fe-38c1-457f-97f1-f310307b97a8" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_657b96fe-38c1-457f-97f1-f310307b97a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_2e351f1b-9b7b-485d-ba2d-2b2ef58ded70" xlink:href="biib-20201231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_2e351f1b-9b7b-485d-ba2d-2b2ef58ded70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_782d3908-d20f-47cd-8e86-fc6456e31620" xlink:href="biib-20201231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_782d3908-d20f-47cd-8e86-fc6456e31620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_589ec4ae-0d98-4b84-b80f-68136c7476ff" xlink:href="biib-20201231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_589ec4ae-0d98-4b84-b80f-68136c7476ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_0be03236-02eb-4cc6-89ad-c7b1b7d1bad4" xlink:href="biib-20201231.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_0be03236-02eb-4cc6-89ad-c7b1b7d1bad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_414fd7c4-46a7-417a-987d-85905b44ce45" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_414fd7c4-46a7-417a-987d-85905b44ce45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_fe878147-3388-4e75-8920-a9975944a4b9" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_fe878147-3388-4e75-8920-a9975944a4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_8a90727d-4f3a-417e-9a81-3542d697658a" xlink:href="biib-20201231.xsd#biib_Futurepercentageofcopromotionoperatingprofits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e92b19ac-6a3c-4cb9-ae71-4978cdad317d" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_8a90727d-4f3a-417e-9a81-3542d697658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26b63493-8c66-420e-bedd-23b343003c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e5b06d56-5a78-4a26-94e5-42d5c47ce84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_26b63493-8c66-420e-bedd-23b343003c7d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e5b06d56-5a78-4a26-94e5-42d5c47ce84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ca44a3e6-c992-4bac-98db-40075b4162a0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e5b06d56-5a78-4a26-94e5-42d5c47ce84d" xlink:to="loc_srt_ProductOrServiceAxis_ca44a3e6-c992-4bac-98db-40075b4162a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32bb198a-6240-4e31-8378-9c02f22278ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ca44a3e6-c992-4bac-98db-40075b4162a0" xlink:to="loc_srt_ProductsAndServicesDomain_32bb198a-6240-4e31-8378-9c02f22278ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_3aa11955-6680-4e37-b300-4a61924e42be" xlink:href="biib-20201231.xsd#biib_GAZYVAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32bb198a-6240-4e31-8378-9c02f22278ad" xlink:to="loc_biib_GAZYVAMember_3aa11955-6680-4e37-b300-4a61924e42be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a56949e-36d8-4381-918d-40610d0196f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e5b06d56-5a78-4a26-94e5-42d5c47ce84d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a56949e-36d8-4381-918d-40610d0196f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_990773a8-53ed-4a8a-a0bc-54400146fac3" xlink:href="biib-20201231.xsd#biib_CoPromotionProfitSharingFormulaAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9a56949e-36d8-4381-918d-40610d0196f9" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_990773a8-53ed-4a8a-a0bc-54400146fac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_8114de4a-a25f-4913-bd76-bc2492be6e00" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_990773a8-53ed-4a8a-a0bc-54400146fac3" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_8114de4a-a25f-4913-bd76-bc2492be6e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_2e7e5e28-4427-4b2c-b575-07dc2432eb72" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_990773a8-53ed-4a8a-a0bc-54400146fac3" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_2e7e5e28-4427-4b2c-b575-07dc2432eb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_f857f16e-60bd-46bf-81b5-7fce16b58b2b" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_2e7e5e28-4427-4b2c-b575-07dc2432eb72" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_f857f16e-60bd-46bf-81b5-7fce16b58b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_43769371-c4ec-4feb-9d84-ec8dee29c7e4" xlink:href="biib-20201231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_2e7e5e28-4427-4b2c-b575-07dc2432eb72" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_43769371-c4ec-4feb-9d84-ec8dee29c7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4cb188be-4971-47ec-8310-e399799e4bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4cb188be-4971-47ec-8310-e399799e4bf0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:to="loc_srt_MajorCustomersAxis_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_94f2064e-c58f-4364-ace7-602a74ed944f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_63eb8fb3-6c7d-49d2-be30-5435f2f3b67b" xlink:to="loc_srt_NameOfMajorCustomerDomain_94f2064e-c58f-4364-ace7-602a74ed944f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_88697d12-1db4-4718-bdf4-b0cf31c6545e" xlink:href="biib-20201231.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_94f2064e-c58f-4364-ace7-602a74ed944f" xlink:to="loc_biib_RocheGroupGenentechMember_88697d12-1db4-4718-bdf4-b0cf31c6545e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f91eb7d4-7a45-44ed-b820-ed23aa495088" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:to="loc_srt_ProductOrServiceAxis_f91eb7d4-7a45-44ed-b820-ed23aa495088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7b5dc85d-4619-4bc1-8418-063f9e17d78a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f91eb7d4-7a45-44ed-b820-ed23aa495088" xlink:to="loc_srt_ProductsAndServicesDomain_7b5dc85d-4619-4bc1-8418-063f9e17d78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_02a9bcc5-d8be-44d9-a0e9-adf182306942" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7b5dc85d-4619-4bc1-8418-063f9e17d78a" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_02a9bcc5-d8be-44d9-a0e9-adf182306942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0ad2c8c1-324d-4cb2-8d91-b18aeab7a1ad" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_48f9361c-4088-4480-9fcb-f4ca082d5fb5" xlink:href="biib-20201231.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:to="loc_biib_ShareOfCoPromotionProfits_48f9361c-4088-4480-9fcb-f4ca082d5fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_80079cc4-591f-4e49-8405-162f93a222eb" xlink:href="biib-20201231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_80079cc4-591f-4e49-8405-162f93a222eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_11df3cd4-c546-489e-86f7-6acbbecc83bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8a00abea-f75e-4291-9b58-07c848cb898c" xlink:to="loc_us-gaap_Revenues_11df3cd4-c546-489e-86f7-6acbbecc83bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsIonisDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46d389fa-6a9b-4250-8f80-5135e63c875b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46d389fa-6a9b-4250-8f80-5135e63c875b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b4622271-6e88-4be6-8fbf-a39301bce97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b4622271-6e88-4be6-8fbf-a39301bce97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38da71d4-816d-4176-bf67-0f3a367117c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b4622271-6e88-4be6-8fbf-a39301bce97d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38da71d4-816d-4176-bf67-0f3a367117c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_094f3681-8325-4c9b-8f71-b11f911e2cb0" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38da71d4-816d-4176-bf67-0f3a367117c1" xlink:to="loc_biib_IonisPharmaceuticalsMember_094f3681-8325-4c9b-8f71-b11f911e2cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_23ae7265-2527-489a-a722-6750135ed6c5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:to="loc_srt_RangeAxis_23ae7265-2527-489a-a722-6750135ed6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a8238ee-a375-442f-89ef-372681eb9003" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_23ae7265-2527-489a-a722-6750135ed6c5" xlink:to="loc_srt_RangeMember_9a8238ee-a375-442f-89ef-372681eb9003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_869946ca-2b86-403f-87d9-8a22d06aa6ca" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a8238ee-a375-442f-89ef-372681eb9003" xlink:to="loc_srt_MinimumMember_869946ca-2b86-403f-87d9-8a22d06aa6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6885a453-be24-4b68-b817-ce38d8404794" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a8238ee-a375-442f-89ef-372681eb9003" xlink:to="loc_srt_MaximumMember_6885a453-be24-4b68-b817-ce38d8404794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:to="loc_srt_ProductOrServiceAxis_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c4b9ac21-64df-4035-868c-a4eeecc6805d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5a36e379-c5e6-4cfd-a83b-cfe2a0a8d540" xlink:to="loc_srt_ProductsAndServicesDomain_c4b9ac21-64df-4035-868c-a4eeecc6805d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SOD1Member_23c02415-e593-4893-b7b2-da0b49cf9ec9" xlink:href="biib-20201231.xsd#biib_SOD1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c4b9ac21-64df-4035-868c-a4eeecc6805d" xlink:to="loc_biib_SOD1Member_23c02415-e593-4893-b7b2-da0b49cf9ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_4657551d-1d99-40c2-acce-af416d775ddc" xlink:href="biib-20201231.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c4b9ac21-64df-4035-868c-a4eeecc6805d" xlink:to="loc_biib_SPINRAZAMember_4657551d-1d99-40c2-acce-af416d775ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_47fe8be4-6fd5-496f-97b9-42d5afd436de" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_fd1d102a-5c30-4426-b645-018740c37609" xlink:href="biib-20201231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_fd1d102a-5c30-4426-b645-018740c37609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fb8b275e-5d34-408e-b680-82d3412284f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fb8b275e-5d34-408e-b680-82d3412284f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LicenseFee_02214c00-8fdb-45a8-aa9c-c1c759fc188d" xlink:href="biib-20201231.xsd#biib_LicenseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_LicenseFee_02214c00-8fdb-45a8-aa9c-c1c759fc188d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_013a0dd5-1c04-48c9-a95c-13debd9d517f" xlink:href="biib-20201231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_013a0dd5-1c04-48c9-a95c-13debd9d517f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_933ab5b9-d73c-422f-8067-56925accdb42" xlink:href="biib-20201231.xsd#biib_Upfrontpaymentforcollaborationagreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Upfrontpaymentforcollaborationagreement_933ab5b9-d73c-422f-8067-56925accdb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_857cd9eb-94ba-4788-9bda-62e535300c65" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_AdditionalMilestonePayment_857cd9eb-94ba-4788-9bda-62e535300c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8943f8df-7ba3-4974-92c3-357fa310a6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8943f8df-7ba3-4974-92c3-357fa310a6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_18b21e31-df1d-490a-9522-5a8310390d23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_18b21e31-df1d-490a-9522-5a8310390d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_bd4ba266-d692-4518-84de-2b0bd72c6fad" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Termofcollaborationagreement_bd4ba266-d692-4518-84de-2b0bd72c6fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_da77451c-d9ca-44b8-96de-d3fb42e989f1" xlink:href="biib-20201231.xsd#biib_Totalpaymenttoentercollaborationagreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_da77451c-d9ca-44b8-96de-d3fb42e989f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInCommonStockSharesPurchased_5860131d-4147-456b-a0fe-3e3ac3bdbd31" xlink:href="biib-20201231.xsd#biib_InvestmentInCommonStockSharesPurchased"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_InvestmentInCommonStockSharesPurchased_5860131d-4147-456b-a0fe-3e3ac3bdbd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Purchaseofcommonstock_e561253b-98b2-4a91-a42c-0b4d0da40088" xlink:href="biib-20201231.xsd#biib_Purchaseofcommonstock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Purchaseofcommonstock_e561253b-98b2-4a91-a42c-0b4d0da40088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1450cf76-03b9-4ae1-857a-38e7ec8e89d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1450cf76-03b9-4ae1-857a-38e7ec8e89d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Investmentincommonstockvalue_b78a528e-4b22-4e0b-a186-80e604d7f3f4" xlink:href="biib-20201231.xsd#biib_Investmentincommonstockvalue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Investmentincommonstockvalue_b78a528e-4b22-4e0b-a186-80e604d7f3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_ebc7286d-4884-4c60-915a-51f2638c6a1e" xlink:href="biib-20201231.xsd#biib_Premiumonpurchaseofcommonstock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_ebc7286d-4884-4c60-915a-51f2638c6a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_2aaffb73-0b9e-4876-93b8-97750f57f740" xlink:href="biib-20201231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_2aaffb73-0b9e-4876-93b8-97750f57f740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_845a369b-7233-40b3-b6f6-99e23b97b64d" xlink:href="biib-20201231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_845a369b-7233-40b3-b6f6-99e23b97b64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_b17f3e59-1ec2-4964-a8bf-f229fd71e1d4" xlink:href="biib-20201231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_318770bc-d48a-4b86-963f-73cd768be847" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_b17f3e59-1ec2-4964-a8bf-f229fd71e1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e51e92c-85b5-45cd-9093-3d1f0b20d686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e51e92c-85b5-45cd-9093-3d1f0b20d686" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_07628a40-fae8-42fb-a30a-b91d5ed63564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_07628a40-fae8-42fb-a30a-b91d5ed63564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_049137c7-dfb5-4347-a5da-cc0fa7c5c999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_07628a40-fae8-42fb-a30a-b91d5ed63564" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_049137c7-dfb5-4347-a5da-cc0fa7c5c999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_25de5ffa-bc3f-434e-8697-786a84f39e62" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_049137c7-dfb5-4347-a5da-cc0fa7c5c999" xlink:to="loc_biib_EisaiMember_25de5ffa-bc3f-434e-8697-786a84f39e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:to="loc_srt_StatementGeographicalAxis_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_58d20b8b-e2c1-4930-b6d1-a0c19dfbaed8" xlink:to="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_11851801-2699-42d5-a463-10ce1aef8629" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:to="loc_country_US_11851801-2699-42d5-a463-10ce1aef8629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_f0271d8a-6f45-4ec2-8c4b-f889e9918881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:to="loc_us-gaap_EuropeanUnionMember_f0271d8a-6f45-4ec2-8c4b-f889e9918881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_8f45da52-a116-42b2-b424-34eb744b2e97" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_51e4e7a9-1079-4ee0-8883-fab394921877" xlink:to="loc_country_JP_8f45da52-a116-42b2-b424-34eb744b2e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4a59544d-3dbd-43ae-bfb8-0480474eedd1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfProductCandidates_6ffec08c-6c69-492c-9aa1-34cbba82c4d1" xlink:href="biib-20201231.xsd#biib_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_NumberOfProductCandidates_6ffec08c-6c69-492c-9aa1-34cbba82c4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossOnContractTermination_4093d1f1-613a-4c28-8698-6172a4bd66ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_us-gaap_LossOnContractTermination_4093d1f1-613a-4c28-8698-6172a4bd66ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_b47b7a94-a55c-47db-a2bd-4646cc48b1d4" xlink:href="biib-20201231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_b47b7a94-a55c-47db-a2bd-4646cc48b1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfDevelopmentCostsIncurred_8e0604e5-d96f-44d4-a32f-e5b9fe9079a6" xlink:href="biib-20201231.xsd#biib_PercentageOfDevelopmentCostsIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_PercentageOfDevelopmentCostsIncurred_8e0604e5-d96f-44d4-a32f-e5b9fe9079a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0c837a94-9e93-4f72-8f97-b030a794509c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0c837a94-9e93-4f72-8f97-b030a794509c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_591d9718-b3e2-48cc-80ea-27216a73b65c" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_AdditionalMilestonePayment_591d9718-b3e2-48cc-80ea-27216a73b65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_53db99c2-2d95-4c16-b55d-a3a1b4e65c48" xlink:href="biib-20201231.xsd#biib_Biogenshareofcopromotionprofitsorlosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c8a2be2-0a89-4a6c-96c0-03cb1a0fc99e" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_53db99c2-2d95-4c16-b55d-a3a1b4e65c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c2beab5-67ac-45ed-8199-2eab49df51e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c2beab5-67ac-45ed-8199-2eab49df51e9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d6461cfd-04a2-40b9-8ba0-cfc5b14f31cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_356a1ff2-d05e-4c1c-80b8-8fcae694ec4f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d6461cfd-04a2-40b9-8ba0-cfc5b14f31cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fa517bac-e686-4376-ae06-719395c92dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d6461cfd-04a2-40b9-8ba0-cfc5b14f31cf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fa517bac-e686-4376-ae06-719395c92dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ae09aa7b-1e43-45ee-821a-544a62f8d0e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:to="loc_srt_ProductOrServiceAxis_ae09aa7b-1e43-45ee-821a-544a62f8d0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ea6dd408-6457-46cd-8b20-70ed8d959f9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ae09aa7b-1e43-45ee-821a-544a62f8d0e0" xlink:to="loc_srt_ProductsAndServicesDomain_ea6dd408-6457-46cd-8b20-70ed8d959f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_11ff651c-d2cd-4064-911e-9b4c76a28a2d" xlink:href="biib-20201231.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ea6dd408-6457-46cd-8b20-70ed8d959f9a" xlink:to="loc_biib_E2609andBAN2401Member_11ff651c-d2cd-4064-911e-9b4c76a28a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9ced479-6495-423a-9e48-d006ddfc6f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bcbc09e5-cfc0-4a49-bacd-8c0c26e50381" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9ced479-6495-423a-9e48-d006ddfc6f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_4987650b-c66a-465e-97ec-184004df200d" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f9ced479-6495-423a-9e48-d006ddfc6f37" xlink:to="loc_biib_EisaiMember_4987650b-c66a-465e-97ec-184004df200d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e8937403-1cfb-42c3-8bcb-b03760937faa" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_a4a33a73-f6e3-4c28-9279-181d786f06e4" xlink:href="biib-20201231.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:to="loc_biib_ExpenseIncurredByCollaboration_a4a33a73-f6e3-4c28-9279-181d786f06e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_150d77d0-1521-4f6b-bae3-f4eb73c19787" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_150d77d0-1521-4f6b-bae3-f4eb73c19787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_b567f3f5-0a09-40a1-ac84-db243a4a0065" xlink:href="biib-20201231.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_33bcf18f-92ff-4ea2-9233-40b3e9826318" xlink:to="loc_biib_Expenseincurredbythecollaboration_b567f3f5-0a09-40a1-ac84-db243a4a0065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613fd981-7dcb-481a-985e-74b3cc606743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_613fd981-7dcb-481a-985e-74b3cc606743" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_94817869-9548-4abe-a1d3-8459f3d9db4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:to="loc_srt_ProductOrServiceAxis_94817869-9548-4abe-a1d3-8459f3d9db4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_93152bc9-42ab-4081-991c-230db6f32df0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_94817869-9548-4abe-a1d3-8459f3d9db4e" xlink:to="loc_srt_ProductsAndServicesDomain_93152bc9-42ab-4081-991c-230db6f32df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_3b66bb62-0cd6-49fe-8c13-d7575715c608" xlink:href="biib-20201231.xsd#biib_AducanumabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_93152bc9-42ab-4081-991c-230db6f32df0" xlink:to="loc_biib_AducanumabMember_3b66bb62-0cd6-49fe-8c13-d7575715c608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8bca9c45-11a1-468a-8415-d305e337d508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8bca9c45-11a1-468a-8415-d305e337d508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9e6cfb7-f21d-4a29-aba7-a32e2232edc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8bca9c45-11a1-468a-8415-d305e337d508" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9e6cfb7-f21d-4a29-aba7-a32e2232edc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e8aec1a5-9f4d-4bd3-9b9b-64cb15cdafe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9e6cfb7-f21d-4a29-aba7-a32e2232edc5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e8aec1a5-9f4d-4bd3-9b9b-64cb15cdafe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e632635f-081d-40f6-b5a0-3abe47cb3ced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a9e6cfb7-f21d-4a29-aba7-a32e2232edc5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e632635f-081d-40f6-b5a0-3abe47cb3ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd138343-ce07-478b-a0b8-7b9bc205f105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3dcdc5f3-7e36-4580-9c6d-9d7d8d5e0aa9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd138343-ce07-478b-a0b8-7b9bc205f105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_63047803-2ee4-4763-adbe-7d867a48f77a" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dd138343-ce07-478b-a0b8-7b9bc205f105" xlink:to="loc_biib_EisaiMember_63047803-2ee4-4763-adbe-7d867a48f77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d5f6026-12ab-4a8a-b127-d8c283488447" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_8af67c51-c5a1-4705-a035-76ba4d6d5289" xlink:href="biib-20201231.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_biib_Expenseincurredbythecollaboration_8af67c51-c5a1-4705-a035-76ba4d6d5289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_c3e08587-fd0d-4b46-ba6d-38d14be5322f" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_c3e08587-fd0d-4b46-ba6d-38d14be5322f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_4aa619b0-aa80-46f6-b962-ea79687818d2" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_biib_AdditionalMilestonePayment_4aa619b0-aa80-46f6-b962-ea79687818d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_696eff19-2abd-4bd8-a8da-095dbd78fa64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23617e28-bdf3-4ef1-a752-6027e19fe4a8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_696eff19-2abd-4bd8-a8da-095dbd78fa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ccac78a9-8b5c-473e-99f2-a7d74919cd31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ccac78a9-8b5c-473e-99f2-a7d74919cd31" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_48564390-18ce-4fa9-8387-e2dd50ca5ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac9c5385-7f71-4e82-a6d6-538a7bec5b8b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_48564390-18ce-4fa9-8387-e2dd50ca5ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bb50b754-5158-47b1-832e-5bc08c8a888f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48564390-18ce-4fa9-8387-e2dd50ca5ed2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_bb50b754-5158-47b1-832e-5bc08c8a888f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_943ccb4f-592f-4dcd-8e00-db03e11568e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_943ccb4f-592f-4dcd-8e00-db03e11568e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c48d46c-caab-4e58-bcb4-1b5e5ec53f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_943ccb4f-592f-4dcd-8e00-db03e11568e8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c48d46c-caab-4e58-bcb4-1b5e5ec53f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaSAMember_c68e55a9-d0e2-4b67-8823-08a3be3aa2e6" xlink:href="biib-20201231.xsd#biib_UCBPharmaSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c48d46c-caab-4e58-bcb4-1b5e5ec53f50" xlink:to="loc_biib_UCBPharmaSAMember_c68e55a9-d0e2-4b67-8823-08a3be3aa2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bc3bf1-f94d-4914-9cfd-e50bffdbae6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccc27087-85b4-4aaf-91f5-903f7a297c6a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bc3bf1-f94d-4914-9cfd-e50bffdbae6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_b4fa8de5-1269-46e4-9daf-4a625202ab83" xlink:href="biib-20201231.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bc3bf1-f94d-4914-9cfd-e50bffdbae6c" xlink:to="loc_biib_Expenseincurredbythecollaboration_b4fa8de5-1269-46e4-9daf-4a625202ab83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_84347a1d-777d-420e-a30c-3eb62a157d55" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c5bc3bf1-f94d-4914-9cfd-e50bffdbae6c" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_84347a1d-777d-420e-a30c-3eb62a157d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsAlkermesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b287fba-0a20-4ea3-8a51-4e06ca97b8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b287fba-0a20-4ea3-8a51-4e06ca97b8bc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ea1ade1e-8179-4305-834e-943802bee899" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:to="loc_srt_ProductOrServiceAxis_ea1ade1e-8179-4305-834e-943802bee899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a4d2c34-9159-4b96-911b-026fd41b3625" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ea1ade1e-8179-4305-834e-943802bee899" xlink:to="loc_srt_ProductsAndServicesDomain_5a4d2c34-9159-4b96-911b-026fd41b3625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_77c32eaa-46ff-4c4d-a9d8-6f9708c50834" xlink:href="biib-20201231.xsd#biib_VUMERITYMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a4d2c34-9159-4b96-911b-026fd41b3625" xlink:to="loc_biib_VUMERITYMember_77c32eaa-46ff-4c4d-a9d8-6f9708c50834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_43f16a9e-0d02-4090-b45b-8bd18c529962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:to="loc_us-gaap_TypeOfArrangementAxis_43f16a9e-0d02-4090-b45b-8bd18c529962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22f65f24-5143-4c1a-942c-e38dcd867f59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43f16a9e-0d02-4090-b45b-8bd18c529962" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22f65f24-5143-4c1a-942c-e38dcd867f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlkermesMember_7f555040-ef3a-4c72-b9fe-dce2c12a9fc2" xlink:href="biib-20201231.xsd#biib_AlkermesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_22f65f24-5143-4c1a-942c-e38dcd867f59" xlink:to="loc_biib_AlkermesMember_7f555040-ef3a-4c72-b9fe-dce2c12a9fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f73da3bf-98d9-460a-b5f9-28583eb41030" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_3ed00ae1-5afe-4d20-93e7-1bd62e10c9d3" xlink:href="biib-20201231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_3ed00ae1-5afe-4d20-93e7-1bd62e10c9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltiesPayablePeriodPostFDAApproval_25595cab-53d4-4aa3-a867-fe9885841108" xlink:href="biib-20201231.xsd#biib_RoyaltiesPayablePeriodPostFDAApproval"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_biib_RoyaltiesPayablePeriodPostFDAApproval_25595cab-53d4-4aa3-a867-fe9885841108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a482ff2-708d-468d-bccd-b33eb3d35677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4a482ff2-708d-468d-bccd-b33eb3d35677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_1ae966ec-e99b-4254-b10f-7936b9f3248b" xlink:href="biib-20201231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c3cd96a7-7f8b-4610-8084-6f4b37e6f46b" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_1ae966ec-e99b-4254-b10f-7936b9f3248b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsBristolMyersSquibbDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7948609d-3c2c-473c-a744-bf316b4cf0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b237ec1d-8691-41b5-9f43-c3ee7d485b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7948609d-3c2c-473c-a744-bf316b4cf0e2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b237ec1d-8691-41b5-9f43-c3ee7d485b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6ac3f691-e062-47a0-9059-18f21065174c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b237ec1d-8691-41b5-9f43-c3ee7d485b00" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6ac3f691-e062-47a0-9059-18f21065174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c67c9be-2ada-45d4-8592-7de3e24f137e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ac3f691-e062-47a0-9059-18f21065174c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c67c9be-2ada-45d4-8592-7de3e24f137e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BristolMyersSquibbMember_8192b5ca-3778-4c9e-90f7-ff0d0801d5fe" xlink:href="biib-20201231.xsd#biib_BristolMyersSquibbMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c67c9be-2ada-45d4-8592-7de3e24f137e" xlink:to="loc_biib_BristolMyersSquibbMember_8192b5ca-3778-4c9e-90f7-ff0d0801d5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IPerianMember_310a5398-0e46-459d-82e9-9dfedf120c35" xlink:href="biib-20201231.xsd#biib_IPerianMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9c67c9be-2ada-45d4-8592-7de3e24f137e" xlink:to="loc_biib_IPerianMember_310a5398-0e46-459d-82e9-9dfedf120c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d68b25da-004b-4d30-8a07-f445a86f9a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b237ec1d-8691-41b5-9f43-c3ee7d485b00" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d68b25da-004b-4d30-8a07-f445a86f9a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75c22e7a-5855-409f-9afc-186e5a5f0314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d68b25da-004b-4d30-8a07-f445a86f9a40" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_75c22e7a-5855-409f-9afc-186e5a5f0314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_ca58ea3a-6605-497d-a533-2b7d8be5d9ac" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d68b25da-004b-4d30-8a07-f445a86f9a40" xlink:to="loc_biib_AdditionalMilestonePayment_ca58ea3a-6605-497d-a533-2b7d8be5d9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsAcordaDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_669aae8a-2e42-481e-8608-da1c5e7086d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e6773d8-749d-4a06-831e-f9d6a0ff2588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_669aae8a-2e42-481e-8608-da1c5e7086d9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e6773d8-749d-4a06-831e-f9d6a0ff2588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_486a9648-fb17-4ef9-b9f6-5dfbf599d96b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e6773d8-749d-4a06-831e-f9d6a0ff2588" xlink:to="loc_us-gaap_TypeOfArrangementAxis_486a9648-fb17-4ef9-b9f6-5dfbf599d96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecd2a0eb-73cf-403e-b528-6b6f508cd503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_486a9648-fb17-4ef9-b9f6-5dfbf599d96b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecd2a0eb-73cf-403e-b528-6b6f508cd503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcordaMember_f66bc794-c18a-4d04-84df-da62c7068a1a" xlink:href="biib-20201231.xsd#biib_AcordaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecd2a0eb-73cf-403e-b528-6b6f508cd503" xlink:to="loc_biib_AcordaMember_f66bc794-c18a-4d04-84df-da62c7068a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9e6773d8-749d-4a06-831e-f9d6a0ff2588" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_a1f1c31f-9393-4413-9f80-9ac7914382dd" xlink:href="biib-20201231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_a1f1c31f-9393-4413-9f80-9ac7914382dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_1a31550e-7d47-47f9-87fc-46e038120a05" xlink:href="biib-20201231.xsd#biib_ForeignSalesRequiredToTriggerMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_1a31550e-7d47-47f9-87fc-46e038120a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_504e0502-306b-4309-a060-ea8115a81bb7" xlink:href="biib-20201231.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_11ebec4b-d5bb-4a66-b6c2-a0d1096d2215" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_504e0502-306b-4309-a060-ea8115a81bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08d3f8be-265f-412a-862a-b4d1d20ce9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfa11061-f73f-4cfa-9464-a28553a9072c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08d3f8be-265f-412a-862a-b4d1d20ce9d2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfa11061-f73f-4cfa-9464-a28553a9072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8cae34c5-4719-4738-af56-f6d45e9ec69d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfa11061-f73f-4cfa-9464-a28553a9072c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8cae34c5-4719-4738-af56-f6d45e9ec69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8cae34c5-4719-4738-af56-f6d45e9ec69d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_894c407d-6f3f-47ed-b4aa-050ce734f43e" xlink:href="biib-20201231.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:to="loc_biib_SageTherapeuticsIncMember_894c407d-6f3f-47ed-b4aa-050ce734f43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_d39fbe7b-4f2a-4a58-854d-719d923c8422" xlink:href="biib-20201231.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:to="loc_biib_DenaliTherapeuticsIncMember_d39fbe7b-4f2a-4a58-854d-719d923c8422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsIncAgreementMember_b7bdb236-922f-4d45-96a2-8070da010d33" xlink:href="biib-20201231.xsd#biib_SangamoTherapeuticsIncAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:to="loc_biib_SangamoTherapeuticsIncAgreementMember_b7bdb236-922f-4d45-96a2-8070da010d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_c6982e9c-2427-4047-867d-ceae920ff728" xlink:href="biib-20201231.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb44c35b-5e1b-4a79-8526-eca0143f8427" xlink:to="loc_biib_OtherresearchanddiscoveryMember_c6982e9c-2427-4047-867d-ceae920ff728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dfa11061-f73f-4cfa-9464-a28553a9072c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_95146adc-66d5-4681-9b07-f9d5bf82f07f" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased_95146adc-66d5-4681-9b07-f9d5bf82f07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_ca10d08c-4b79-42df-a2e4-fed3b44679db" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementSharesPurchased_ca10d08c-4b79-42df-a2e4-fed3b44679db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_8809023e-7fd3-4d0d-aded-29776bde3cc9" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare_8809023e-7fd3-4d0d-aded-29776bde3cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0b3120f3-4011-4d15-9660-a5e2afbea3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0b3120f3-4011-4d15-9660-a5e2afbea3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_164d3518-8d7a-408a-a1ac-30e61cc9c9ca" xlink:href="biib-20201231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_164d3518-8d7a-408a-a1ac-30e61cc9c9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments_05f70fb6-7c8f-4ede-acb4-9b1c6f27b23d" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments_05f70fb6-7c8f-4ede-acb4-9b1c6f27b23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6dbdd03e-34e0-4914-8b7f-f88a148d149c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6dbdd03e-34e0-4914-8b7f-f88a148d149c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_f57d4754-4416-47f4-85da-0ab8519efafc" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_Termofcollaborationagreement_f57d4754-4416-47f4-85da-0ab8519efafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets_d420c579-8658-46af-88bc-dd9085120bb0" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets_d420c579-8658-46af-88bc-dd9085120bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones_259c23d2-bcf6-441f-98ed-ca9ae5cad943" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones_259c23d2-bcf6-441f-98ed-ca9ae5cad943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones_32113f91-8319-4bc8-ad5b-cfb3efc7cc9f" xlink:href="biib-20201231.xsd#biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_801c6ec7-9aac-4243-8b5e-de901e7e16a3" xlink:to="loc_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones_32113f91-8319-4bc8-ad5b-cfb3efc7cc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14a1d034-0e9b-44ff-9f2b-1e78a96a39a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14a1d034-0e9b-44ff-9f2b-1e78a96a39a6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17c560f4-2dca-4f42-bdd3-be634b13477a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17c560f4-2dca-4f42-bdd3-be634b13477a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_80e36ada-d35d-41de-886e-04ec757261a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_17c560f4-2dca-4f42-bdd3-be634b13477a" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_80e36ada-d35d-41de-886e-04ec757261a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_09e6fe5d-f70e-48bd-b939-47d3ca55b5c1" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_80e36ada-d35d-41de-886e-04ec757261a5" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_09e6fe5d-f70e-48bd-b939-47d3ca55b5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b36725c2-1281-42c4-a5c0-c769a5ae17fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b36725c2-1281-42c4-a5c0-c769a5ae17fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7650ea3f-5ad7-4b69-8fcc-225ae30abc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b36725c2-1281-42c4-a5c0-c769a5ae17fe" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7650ea3f-5ad7-4b69-8fcc-225ae30abc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_b49fcf13-b0be-402e-9912-ad3eca143b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7650ea3f-5ad7-4b69-8fcc-225ae30abc3e" xlink:to="loc_us-gaap_InventoriesMember_b49fcf13-b0be-402e-9912-ad3eca143b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6663c11c-942c-4df5-b56e-a2d8b1026864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7650ea3f-5ad7-4b69-8fcc-225ae30abc3e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6663c11c-942c-4df5-b56e-a2d8b1026864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9831e065-481b-4287-8482-69c472ef75db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9831e065-481b-4287-8482-69c472ef75db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_393d3ce2-0a01-46a5-96f0-a61aee981d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9831e065-481b-4287-8482-69c472ef75db" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_393d3ce2-0a01-46a5-96f0-a61aee981d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_c3b88be9-8c0c-486b-aa08-b0599196aac2" xlink:href="biib-20201231.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_393d3ce2-0a01-46a5-96f0-a61aee981d79" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_c3b88be9-8c0c-486b-aa08-b0599196aac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_b323bd75-3988-4987-a3b7-6c599a15dc2c" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_b323bd75-3988-4987-a3b7-6c599a15dc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_c7df7b24-c7ec-4517-8942-e5848731ec36" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_b323bd75-3988-4987-a3b7-6c599a15dc2c" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_c7df7b24-c7ec-4517-8942-e5848731ec36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DevelopmentMilestonesMember_3a78686e-05fa-4a14-a384-fe96e7975319" xlink:href="biib-20201231.xsd#biib_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_c7df7b24-c7ec-4517-8942-e5848731ec36" xlink:to="loc_biib_DevelopmentMilestonesMember_3a78686e-05fa-4a14-a384-fe96e7975319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a2a8dfa9-cea0-4907-99a5-02313bdf852e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_bd14298b-9b09-4ca8-8e85-4b29c131ed74" xlink:href="biib-20201231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_bd14298b-9b09-4ca8-8e85-4b29c131ed74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_560bc23f-100e-464d-aebc-89a3229d1f3d" xlink:href="biib-20201231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_560bc23f-100e-464d-aebc-89a3229d1f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_49a3a4bf-7c01-4ab4-ae40-5cda093a35bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_EquityMethodInvestments_49a3a4bf-7c01-4ab4-ae40-5cda093a35bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d77d9d7c-82f8-44bf-b629-5617af6756fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d77d9d7c-82f8-44bf-b629-5617af6756fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_d9e2756c-c088-4c15-8fd3-7e7b72c04869" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_d9e2756c-c088-4c15-8fd3-7e7b72c04869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1d081ff7-8d64-463b-aadf-4c5f328ef074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1d081ff7-8d64-463b-aadf-4c5f328ef074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_df1a8b4c-f7f3-40f1-bc32-0980ac417416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_df1a8b4c-f7f3-40f1-bc32-0980ac417416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_ec42ba88-5327-4e23-9eb3-e20759856c4f" xlink:href="biib-20201231.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_ec42ba88-5327-4e23-9eb3-e20759856c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d693074d-2492-4785-98bf-b264ab0265cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_d693074d-2492-4785-98bf-b264ab0265cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_436a25ad-b24f-4889-bd76-75fd377e2233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_436a25ad-b24f-4889-bd76-75fd377e2233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_8351574f-df30-4818-924e-0289722cddb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_AdjustmentForAmortization_8351574f-df30-4818-924e-0289722cddb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_ce57cfad-0bb7-4e39-8d5d-de26c3e5770d" xlink:href="biib-20201231.xsd#biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights_ce57cfad-0bb7-4e39-8d5d-de26c3e5770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_7faa2776-26cf-4b41-87bd-344d578a66e1" xlink:href="biib-20201231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_7faa2776-26cf-4b41-87bd-344d578a66e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a542bd31-bbdb-4d41-b79e-b4196eaf3e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a542bd31-bbdb-4d41-b79e-b4196eaf3e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_d3e05db2-50e9-4a21-b5b2-09d8366860a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_d3e05db2-50e9-4a21-b5b2-09d8366860a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_54b55a9d-7d6a-4e97-b0c7-6f679a7c897c" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_AdditionalMilestonePayment_54b55a9d-7d6a-4e97-b0c7-6f679a7c897c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1896cb1b-426c-4daf-8c88-fb4d1bd60407" xlink:href="biib-20201231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_1896cb1b-426c-4daf-8c88-fb4d1bd60407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_998589cd-6804-4d55-a575-04f4be72fafc" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_Termofcollaborationagreement_998589cd-6804-4d55-a575-04f4be72fafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_12650b74-2b48-4453-8497-5320e619a56c" xlink:href="biib-20201231.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_ContractOptionExerciseFee_12650b74-2b48-4453-8497-5320e619a56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_feb39590-d44d-4a6d-8a12-f36ce5ddbd72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_feb39590-d44d-4a6d-8a12-f36ce5ddbd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_dc343c30-e09a-41fc-aca4-40d6c2aea0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_dc343c30-e09a-41fc-aca4-40d6c2aea0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_12a6978b-38a6-424e-b3de-f259fde33445" xlink:href="biib-20201231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_12a6978b-38a6-424e-b3de-f259fde33445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationProfitSharing_fd1cf573-f735-43fe-a1b6-f3358183db18" xlink:href="biib-20201231.xsd#biib_CollaborationProfitSharing"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_biib_CollaborationProfitSharing_fd1cf573-f735-43fe-a1b6-f3358183db18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8f5a9ab2-df19-4d1f-a52e-03ecc9bb4ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_Revenues_8f5a9ab2-df19-4d1f-a52e-03ecc9bb4ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_b6094939-83b1-4e5d-b18a-b908c37b5d04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_DueFromRelatedParties_b6094939-83b1-4e5d-b18a-b908c37b5d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_af7a9f0a-7f01-44b2-8bc2-64db74b73603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8252208c-eba5-4402-97a7-c3f7b5996834" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_af7a9f0a-7f01-44b2-8bc2-64db74b73603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20201231.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_07799fd0-8e18-411e-a4c7-04c77706024d" xlink:href="biib-20201231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_babac30f-489c-44ba-8c21-357247281eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_07799fd0-8e18-411e-a4c7-04c77706024d" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_babac30f-489c-44ba-8c21-357247281eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_c86ed0ff-4b77-446f-8e02-9d4b342ceec0" xlink:href="biib-20201231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_c86ed0ff-4b77-446f-8e02-9d4b342ceec0" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2984f4f2-2f91-4873-8e90-160ad7a29de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2984f4f2-2f91-4873-8e90-160ad7a29de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2984f4f2-2f91-4873-8e90-160ad7a29de5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_0964d227-0a17-4f03-a673-e160fd29483e" xlink:href="biib-20201231.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:to="loc_biib_EisaiMember_0964d227-0a17-4f03-a673-e160fd29483e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_fa64a230-b402-427c-8a3d-264f8453bb14" xlink:href="biib-20201231.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:to="loc_biib_NeurimmuneMember_fa64a230-b402-427c-8a3d-264f8453bb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_2cbd6e64-7eab-447c-85e3-4eaed32fa15a" xlink:href="biib-20201231.xsd#biib_AducanumabMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bf3cb16d-0592-461d-a538-79f790e9f968" xlink:to="loc_biib_AducanumabMember_2cbd6e64-7eab-447c-85e3-4eaed32fa15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_9b987cb9-03f8-480b-b9d5-810dbd359546" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_c65e98f8-2edf-4f6e-a74b-e4aedda9cc38" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_9b987cb9-03f8-480b-b9d5-810dbd359546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_26ba04a6-9051-4ec1-b9cc-48f2cb9b175e" xlink:href="biib-20201231.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_9b987cb9-03f8-480b-b9d5-810dbd359546" xlink:to="loc_biib_RegulatoryMilestonesMember_26ba04a6-9051-4ec1-b9cc-48f2cb9b175e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8f69ed98-c5d2-4a7c-a12d-baad649086da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8f69ed98-c5d2-4a7c-a12d-baad649086da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1afc4c36-697a-4368-9526-91ef191b0fa0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8f69ed98-c5d2-4a7c-a12d-baad649086da" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1afc4c36-697a-4368-9526-91ef191b0fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_4affa25f-8203-4dcb-9908-012fa4148ca6" xlink:href="biib-20201231.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1afc4c36-697a-4368-9526-91ef191b0fa0" xlink:to="loc_biib_NeurimmuneMember_4affa25f-8203-4dcb-9908-012fa4148ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_3abf07ba-4501-4bc7-b9e4-5387adb101ae" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_3abf07ba-4501-4bc7-b9e4-5387adb101ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_e36a670c-1ed6-4cb9-b240-f07460869ee5" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_3abf07ba-4501-4bc7-b9e4-5387adb101ae" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_e36a670c-1ed6-4cb9-b240-f07460869ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwelvemonthsMember_b778a927-d7a0-4000-8b4a-dfb4e5fe3d78" xlink:href="biib-20201231.xsd#biib_TwelvemonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_e36a670c-1ed6-4cb9-b240-f07460869ee5" xlink:to="loc_biib_TwelvemonthsMember_b778a927-d7a0-4000-8b4a-dfb4e5fe3d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_srt_StatementGeographicalAxis_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_92f5467b-ef9b-49de-a24f-b0a83e9cadd4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e02a2da8-0a7a-458b-8e4f-642c25b2f6a2" xlink:to="loc_srt_SegmentGeographicalDomain_92f5467b-ef9b-49de-a24f-b0a83e9cadd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_21188f03-a576-4ef2-a10d-d7bd79e1de89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_92f5467b-ef9b-49de-a24f-b0a83e9cadd4" xlink:to="loc_us-gaap_EuropeanUnionMember_21188f03-a576-4ef2-a10d-d7bd79e1de89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_f9b8aa59-635e-4b17-995f-c85a6451a023" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_92f5467b-ef9b-49de-a24f-b0a83e9cadd4" xlink:to="loc_country_JP_f9b8aa59-635e-4b17-995f-c85a6451a023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c832da2e-dee3-4e3f-a013-e295293b7fbd" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_d593f10b-530a-4b0f-8b86-55cbece88a3c" xlink:href="biib-20201231.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_Termofcollaborationagreement_d593f10b-530a-4b0f-8b86-55cbece88a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_13812641-fb08-41fd-a2b4-152b4afccbe9" xlink:href="biib-20201231.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_13812641-fb08-41fd-a2b4-152b4afccbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_65a86394-1e5c-4d75-9d17-9d13b23d75f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_65a86394-1e5c-4d75-9d17-9d13b23d75f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_481a24c3-f701-4588-bc0d-c31bdda3227a" xlink:href="biib-20201231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_481a24c3-f701-4588-bc0d-c31bdda3227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_498cffa2-6397-48dd-bb30-a54247088a5f" xlink:href="biib-20201231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_498cffa2-6397-48dd-bb30-a54247088a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_1f278902-584c-4ab7-950c-e357715df4bd" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_AdditionalMilestonePayment_1f278902-584c-4ab7-950c-e357715df4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c6aeed39-85bf-4d0e-8399-c8225ffcf7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c6aeed39-85bf-4d0e-8399-c8225ffcf7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_bcd10b04-c6ab-4d4c-841a-619ec5df5d3d" xlink:href="biib-20201231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_bcd10b04-c6ab-4d4c-841a-619ec5df5d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0a59bd82-858f-4826-9561-0fdba0d0a01d" xlink:href="biib-20201231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0a59bd82-858f-4826-9561-0fdba0d0a01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_679389de-cde7-4c65-9552-7d90a6431692" xlink:href="biib-20201231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_c060e1df-1568-4537-a3c3-acddfe360ea8" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_679389de-cde7-4c65-9552-7d90a6431692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20201231.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_5cf6b027-1dc8-42a7-b1c1-deefabdafec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4eb1624d-8632-4eaa-8de1-c4c846da333e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_5cf6b027-1dc8-42a7-b1c1-deefabdafec6" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4eb1624d-8632-4eaa-8de1-c4c846da333e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#LitigationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_69286e0a-6ab2-4bfa-bfd7-7bf424b0f760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_c50302ab-a361-4465-ae5a-9006edb1c798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_69286e0a-6ab2-4bfa-bfd7-7bf424b0f760" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_c50302ab-a361-4465-ae5a-9006edb1c798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DisputedClaimsRelatingToConstructionCosts_b6cf1a23-d733-471b-9a50-0a5d2804b9eb" xlink:href="biib-20201231.xsd#biib_DisputedClaimsRelatingToConstructionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_69286e0a-6ab2-4bfa-bfd7-7bf424b0f760" xlink:to="loc_biib_DisputedClaimsRelatingToConstructionCosts_b6cf1a23-d733-471b-9a50-0a5d2804b9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="biib-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91db1297-df31-4000-b64f-2f80d6de0c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f997b928-1135-4730-89b2-1601a5c408a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91db1297-df31-4000-b64f-2f80d6de0c04" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f997b928-1135-4730-89b2-1601a5c408a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_704bb4a0-846a-41b2-b2b4-51a4c33cbd6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_704bb4a0-846a-41b2-b2b4-51a4c33cbd6c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fb01a886-a9e6-46fb-840e-f85aebedefb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fb01a886-a9e6-46fb-840e-f85aebedefb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9141dfa-79e0-4f96-ad03-b4f1dd3b8091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fb01a886-a9e6-46fb-840e-f85aebedefb8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9141dfa-79e0-4f96-ad03-b4f1dd3b8091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_3fdc6dcc-44c0-48f7-ad59-1114e410edf7" xlink:href="biib-20201231.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9141dfa-79e0-4f96-ad03-b4f1dd3b8091" xlink:to="loc_biib_TysabriProductMember_3fdc6dcc-44c0-48f7-ad59-1114e410edf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumapharmAgMember_cbd5622b-9b6a-4b30-9e12-a8b4abb6b923" xlink:href="biib-20201231.xsd#biib_FumapharmAgMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9141dfa-79e0-4f96-ad03-b4f1dd3b8091" xlink:to="loc_biib_FumapharmAgMember_cbd5622b-9b6a-4b30-9e12-a8b4abb6b923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c74a9c83-ffc7-4231-b02a-9b074356f268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c74a9c83-ffc7-4231-b02a-9b074356f268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c74a9c83-ffc7-4231-b02a-9b074356f268" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsMember_8481ae3c-359c-48f8-8e16-b6a1a5c2e7fe" xlink:href="biib-20201231.xsd#biib_IonisPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:to="loc_biib_IonisPharmaceuticalsMember_8481ae3c-359c-48f8-8e16-b6a1a5c2e7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlkermesMember_d281b132-30af-474b-a5f2-57688ff0a0b0" xlink:href="biib-20201231.xsd#biib_AlkermesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:to="loc_biib_AlkermesMember_d281b132-30af-474b-a5f2-57688ff0a0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AducanumabMember_03d9fb76-884f-4341-8dfa-445632f34c8c" xlink:href="biib-20201231.xsd#biib_AducanumabMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:to="loc_biib_AducanumabMember_03d9fb76-884f-4341-8dfa-445632f34c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_a4fbd942-f463-41da-a1ac-8e9e13af84f8" xlink:href="biib-20201231.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2287a959-5143-44dc-8687-d251a51cea8c" xlink:to="loc_biib_NeurimmuneMember_a4fbd942-f463-41da-a1ac-8e9e13af84f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96fb0a7e-ba28-449a-a3be-79256e5137a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_srt_RangeAxis_96fb0a7e-ba28-449a-a3be-79256e5137a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c32b8a60-d4ab-488a-b26a-3a029d5c3e8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_96fb0a7e-ba28-449a-a3be-79256e5137a5" xlink:to="loc_srt_RangeMember_c32b8a60-d4ab-488a-b26a-3a029d5c3e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_36793aee-1ffc-4395-9c16-fc6c9be506cd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c32b8a60-d4ab-488a-b26a-3a029d5c3e8f" xlink:to="loc_srt_MinimumMember_36793aee-1ffc-4395-9c16-fc6c9be506cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d34ff36c-cb24-4be0-b171-a60cf74f3856" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c32b8a60-d4ab-488a-b26a-3a029d5c3e8f" xlink:to="loc_srt_MaximumMember_d34ff36c-cb24-4be0-b171-a60cf74f3856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3f1a42b-4ca9-43f4-8729-2df9404e26af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_srt_ProductOrServiceAxis_a3f1a42b-4ca9-43f4-8729-2df9404e26af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a3f1a42b-4ca9-43f4-8729-2df9404e26af" xlink:to="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_bbdcb41c-98b7-47b2-b42f-793b9955bb81" xlink:href="biib-20201231.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:to="loc_biib_SPINRAZAMember_bbdcb41c-98b7-47b2-b42f-793b9955bb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_6c12265a-3831-4daf-8891-0bc15ac55fad" xlink:href="biib-20201231.xsd#biib_VUMERITYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:to="loc_biib_VUMERITYMember_6c12265a-3831-4daf-8891-0bc15ac55fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_9ddb8ccf-dab8-4dfd-b6fd-0fe5ba8c0068" xlink:href="biib-20201231.xsd#biib_FumarateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e8c1b475-67b5-487e-81f3-12e04a911c42" xlink:to="loc_biib_FumarateMember_9ddb8ccf-dab8-4dfd-b6fd-0fe5ba8c0068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelAxis_c03a535c-c3e1-4711-990d-3cdb45ae4be4" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_biib_CumulativeSalesLevelAxis_c03a535c-c3e1-4711-990d-3cdb45ae4be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevelDomain_de67de13-3c9f-42b7-ac97-965845708dcf" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_c03a535c-c3e1-4711-990d-3cdb45ae4be4" xlink:to="loc_biib_CumulativeSalesLevelDomain_de67de13-3c9f-42b7-ac97-965845708dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwentybillionMember_52c95eae-0e47-420f-a450-176813db3e43" xlink:href="biib-20201231.xsd#biib_TwentybillionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_de67de13-3c9f-42b7-ac97-965845708dcf" xlink:to="loc_biib_TwentybillionMember_52c95eae-0e47-420f-a450-176813db3e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5843417f-b4b5-4802-9479-ccfd8f7b8c9d" xlink:href="biib-20201231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_de67de13-3c9f-42b7-ac97-965845708dcf" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_5843417f-b4b5-4802-9479-ccfd8f7b8c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_f6a44953-c885-45fc-b2c6-5cce43a04ede" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_f6a44953-c885-45fc-b2c6-5cce43a04ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:href="biib-20201231.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f6a44953-c885-45fc-b2c6-5cce43a04ede" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DevelopmentMilestonesMember_a49a7c41-8131-49cb-860a-d584fae160ae" xlink:href="biib-20201231.xsd#biib_DevelopmentMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:to="loc_biib_DevelopmentMilestonesMember_a49a7c41-8131-49cb-860a-d584fae160ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_312524fd-2a0f-488d-b173-4399353e438e" xlink:href="biib-20201231.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:to="loc_biib_RegulatoryMilestonesMember_312524fd-2a0f-488d-b173-4399353e438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CommercialMilestonesMember_9134a862-b869-4684-b1f9-bf4b3718af49" xlink:href="biib-20201231.xsd#biib_CommercialMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_479219e3-c1a4-4a2d-8b65-89972257db24" xlink:to="loc_biib_CommercialMilestonesMember_9134a862-b869-4684-b1f9-bf4b3718af49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_8a0234e7-4422-49b5-95f3-1cf562e39971" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_8a0234e7-4422-49b5-95f3-1cf562e39971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_61a2f7c9-5e74-4c3a-af1e-e52d3deb07f0" xlink:href="biib-20201231.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_8a0234e7-4422-49b5-95f3-1cf562e39971" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_61a2f7c9-5e74-4c3a-af1e-e52d3deb07f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TwelvemonthsMember_90d704ee-1680-4ab3-8a09-f5374b113b59" xlink:href="biib-20201231.xsd#biib_TwelvemonthsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_61a2f7c9-5e74-4c3a-af1e-e52d3deb07f0" xlink:to="loc_biib_TwelvemonthsMember_90d704ee-1680-4ab3-8a09-f5374b113b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5546c1b1-7c8e-4425-ad35-209bc9161bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5546c1b1-7c8e-4425-ad35-209bc9161bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_32ba86a1-7bbc-4f80-8ce6-80aff8ebed96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5546c1b1-7c8e-4425-ad35-209bc9161bc7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_32ba86a1-7bbc-4f80-8ce6-80aff8ebed96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_U.S.2017TaxActMember_426dc3a5-f946-4a0e-bed8-c711dcfb0ebb" xlink:href="biib-20201231.xsd#biib_U.S.2017TaxActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_32ba86a1-7bbc-4f80-8ce6-80aff8ebed96" xlink:to="loc_biib_U.S.2017TaxActMember_426dc3a5-f946-4a0e-bed8-c711dcfb0ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf" xlink:href="biib-20201231.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_biib_FacilityLocationAxis_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_8a404f06-6141-404f-8274-258e241db7d8" xlink:href="biib-20201231.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_478c63e4-c6d3-4d7a-8e56-0780d00a0ecf" xlink:to="loc_biib_FacilityLocationDomain_8a404f06-6141-404f-8274-258e241db7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember_6ac3610d-045a-4f1d-be7c-882369a004a4" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_8a404f06-6141-404f-8274-258e241db7d8" xlink:to="loc_biib_SolothurnMember_6ac3610d-045a-4f1d-be7c-882369a004a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_srt_StatementGeographicalAxis_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_27a88e66-1668-4c7e-9cc2-c016b1d82587" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2b8b5bc8-d739-4028-b783-bc5f0ea5adcc" xlink:to="loc_srt_SegmentGeographicalDomain_27a88e66-1668-4c7e-9cc2-c016b1d82587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_35dc20fd-1b59-41bc-9bc3-e6c2b5ed4a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_27a88e66-1668-4c7e-9cc2-c016b1d82587" xlink:to="loc_us-gaap_EuropeanUnionMember_35dc20fd-1b59-41bc-9bc3-e6c2b5ed4a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_428c41a6-de5d-4517-8b24-394e23093ec9" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_27a88e66-1668-4c7e-9cc2-c016b1d82587" xlink:to="loc_country_JP_428c41a6-de5d-4517-8b24-394e23093ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_befc5051-2d57-496d-a2ed-7d4a0220033a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_srt_StatementScenarioAxis_befc5051-2d57-496d-a2ed-7d4a0220033a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a3e30c54-9f1c-4514-bcfc-34e171688b0c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_befc5051-2d57-496d-a2ed-7d4a0220033a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a3e30c54-9f1c-4514-bcfc-34e171688b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1c525a72-6294-42bc-a632-a7e24357376f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a3e30c54-9f1c-4514-bcfc-34e171688b0c" xlink:to="loc_srt_ScenarioForecastMember_1c525a72-6294-42bc-a632-a7e24357376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_960360ac-79e1-4a40-8207-46320b194563" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1e9c39d4-6075-4171-b857-31be6f2795fb" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_1e9c39d4-6075-4171-b857-31be6f2795fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentThreshold_3771b990-7f32-4211-9d23-f74b1a477821" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_FutureContingentPaymentThreshold_3771b990-7f32-4211-9d23-f74b1a477821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_0a652f74-a332-45b8-b9c6-a11b08a4f4fc" xlink:href="biib-20201231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_0a652f74-a332-45b8-b9c6-a11b08a4f4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_20de4e35-4f97-4c0c-9798-e46202ec79b5" xlink:href="biib-20201231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_20de4e35-4f97-4c0c-9798-e46202ec79b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltiesPayablePeriodPostFDAApproval_ee90dc9b-5575-4905-9b2d-2027b9531ede" xlink:href="biib-20201231.xsd#biib_RoyaltiesPayablePeriodPostFDAApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_RoyaltiesPayablePeriodPostFDAApproval_ee90dc9b-5575-4905-9b2d-2027b9531ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_166181ce-b9b3-4594-904d-5d64cf933a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_166181ce-b9b3-4594-904d-5d64cf933a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CumulativeSalesLevel_bb137a5a-9a59-4e09-a604-d77629e64263" xlink:href="biib-20201231.xsd#biib_CumulativeSalesLevel"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_CumulativeSalesLevel_bb137a5a-9a59-4e09-a604-d77629e64263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e4b9049f-a708-4a73-a609-d3a2a775c7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e4b9049f-a708-4a73-a609-d3a2a775c7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0fbce738-fdf1-4cd8-9f39-81698d1c9065" xlink:href="biib-20201231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0fbce738-fdf1-4cd8-9f39-81698d1c9065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_271e03be-2ba2-42c8-a481-0d67c417696e" xlink:href="biib-20201231.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_AdditionalMilestonePayment_271e03be-2ba2-42c8-a481-0d67c417696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_eb4f61d8-7ed7-4f53-9a4e-0067b8e1dcea" xlink:href="biib-20201231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_eb4f61d8-7ed7-4f53-9a4e-0067b8e1dcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_889ebbe0-e1a1-4a52-b0b7-57559441ad46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_OtherCommitment_889ebbe0-e1a1-4a52-b0b7-57559441ad46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4a97823a-28ce-4ebc-af47-dd4f4f528833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4a97823a-28ce-4ebc-af47-dd4f4f528833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_9947daa3-6c92-45f1-b68f-1d6b849fca54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_9947daa3-6c92-45f1-b68f-1d6b849fca54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_4ee81bde-3da5-4fa1-88d3-1e7c69d76a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_4ee81bde-3da5-4fa1-88d3-1e7c69d76a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_3a351639-7e8e-4572-bf2e-bcb1c58b1884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_IncomeTaxesPaid_3a351639-7e8e-4572-bf2e-bcb1c58b1884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_108d73a7-b804-4218-8c3e-2d7a09775273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f1f5d72f-c4a3-4247-9532-f427d090da78" xlink:to="loc_us-gaap_ContractualObligation_108d73a7-b804-4218-8c3e-2d7a09775273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:type="simple" xlink:href="biib-20201231.xsd#Guarantees"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesAbstract_b6f750ab-493a-4140-907a-fc33807ed50e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesTextBlock_de795e82-e0f1-4b56-a608-e142da9cfa23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_b6f750ab-493a-4140-907a-fc33807ed50e" xlink:to="loc_us-gaap_GuaranteesTextBlock_de795e82-e0f1-4b56-a608-e142da9cfa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="biib-20201231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d7bc58ab-0250-49e0-bf9b-62ab3f1a91e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1ffb4749-d8e6-4924-b1d9-9f1e84d54610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d7bc58ab-0250-49e0-bf9b-62ab3f1a91e5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1ffb4749-d8e6-4924-b1d9-9f1e84d54610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#EmployeeBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a8cebfeb-383f-4f4f-ad6b-6cf11648db3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a8cebfeb-383f-4f4f-ad6b-6cf11648db3f" xlink:to="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bca3eb83-5548-4880-8540-f284c2a95b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bca3eb83-5548-4880-8540-f284c2a95b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_12483314-2e75-4347-863c-04d97bb63498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bca3eb83-5548-4880-8540-f284c2a95b72" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_12483314-2e75-4347-863c-04d97bb63498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_5cd4461d-22bd-4703-b363-0cadd437ad86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_12483314-2e75-4347-863c-04d97bb63498" xlink:to="loc_us-gaap_DomesticPlanMember_5cd4461d-22bd-4703-b363-0cadd437ad86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3e9e5e1f-7fa7-423d-ba9b-180d6a7c9db7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_12483314-2e75-4347-863c-04d97bb63498" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_3e9e5e1f-7fa7-423d-ba9b-180d6a7c9db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7f6186b1-3877-42bf-9daf-d8300cc7dbe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7f6186b1-3877-42bf-9daf-d8300cc7dbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a409865-20c8-42d8-a8cd-3f6ca15b8ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7f6186b1-3877-42bf-9daf-d8300cc7dbe7" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a409865-20c8-42d8-a8cd-3f6ca15b8ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_6a7304b9-d4dc-4def-8cfd-227fe59df3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a409865-20c8-42d8-a8cd-3f6ca15b8ea4" xlink:to="loc_us-gaap_ForeignPlanMember_6a7304b9-d4dc-4def-8cfd-227fe59df3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_d6228a28-5b1f-49cb-8301-a90a8bedc360" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CH"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_6a7304b9-d4dc-4def-8cfd-227fe59df3bf" xlink:to="loc_country_CH_d6228a28-5b1f-49cb-8301-a90a8bedc360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_1c38f16b-57bd-4555-b70f-b2225640e931" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_6a7304b9-d4dc-4def-8cfd-227fe59df3bf" xlink:to="loc_country_DE_1c38f16b-57bd-4555-b70f-b2225640e931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d6d108db-02c4-43a4-a5d6-c5718ee5b42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d6d108db-02c4-43a4-a5d6-c5718ee5b42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_16544506-ac2c-43e3-8a92-7d2c8b0e101e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d6d108db-02c4-43a4-a5d6-c5718ee5b42b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_16544506-ac2c-43e3-8a92-7d2c8b0e101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_5ec44b24-9e8d-4996-baae-2b2253e8ae8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_16544506-ac2c-43e3-8a92-7d2c8b0e101e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_5ec44b24-9e8d-4996-baae-2b2253e8ae8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_78d8c3eb-d6ca-47b0-9c38-3b27d3880a4e" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_e67fe865-17ee-4f5b-99dd-b1c54d0de62a" xlink:href="biib-20201231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_e67fe865-17ee-4f5b-99dd-b1c54d0de62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_058b9cdd-a249-4cd3-9401-4739b432d54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_058b9cdd-a249-4cd3-9401-4739b432d54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_6038d415-92e0-4e4e-b701-5ad83882ddc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_6038d415-92e0-4e4e-b701-5ad83882ddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_ca580932-514f-443a-9911-34df3af6abbd" xlink:href="biib-20201231.xsd#biib_PercentageOfMinimumInvestmentReturn"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_ca580932-514f-443a-9911-34df3af6abbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_4359019c-bfda-4e3d-8410-5ff7638ac59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_4359019c-bfda-4e3d-8410-5ff7638ac59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1fe396c7-deef-4a78-b03a-e742baf99210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_1fe396c7-deef-4a78-b03a-e742baf99210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionExpense_5efab0c9-fc15-496c-83b1-c807fe5689bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_PensionExpense_5efab0c9-fc15-496c-83b1-c807fe5689bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44bb18f1-612c-4c6b-a1c3-7b0d1104ec78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_83ebb9df-58a3-4887-b44c-4989788cf8e9" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44bb18f1-612c-4c6b-a1c3-7b0d1104ec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f2f887a6-98fd-4862-a36d-e1c47d120739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_e766bc05-534c-47f1-aaad-8232f048c746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f2f887a6-98fd-4862-a36d-e1c47d120739" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_e766bc05-534c-47f1-aaad-8232f048c746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_09017c34-3a5f-4f72-a364-20c77c5415d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_12bf8c7a-407b-490e-9a9d-8a892d91c45d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_09017c34-3a5f-4f72-a364-20c77c5415d4" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_12bf8c7a-407b-490e-9a9d-8a892d91c45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1abe42e4-3c42-45b0-a1f3-d8b3d6d92a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_519642fe-2c47-4b2a-9e4a-e68eb4fdb349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1abe42e4-3c42-45b0-a1f3-d8b3d6d92a25" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_519642fe-2c47-4b2a-9e4a-e68eb4fdb349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ffc1e024-da4c-4982-a2a7-13089760197e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_519642fe-2c47-4b2a-9e4a-e68eb4fdb349" xlink:to="loc_srt_StatementGeographicalAxis_ffc1e024-da4c-4982-a2a7-13089760197e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8eb1f2cd-b091-4d11-9604-8250f69eb9b6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ffc1e024-da4c-4982-a2a7-13089760197e" xlink:to="loc_srt_SegmentGeographicalDomain_8eb1f2cd-b091-4d11-9604-8250f69eb9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnMember_ddae30e1-a55e-46d0-9a1a-a00f8fc3977c" xlink:href="biib-20201231.xsd#biib_SolothurnMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8eb1f2cd-b091-4d11-9604-8250f69eb9b6" xlink:to="loc_biib_SolothurnMember_ddae30e1-a55e-46d0-9a1a-a00f8fc3977c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DK_e0e1746b-a5c4-455b-8399-c82806234fd8" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DK"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8eb1f2cd-b091-4d11-9604-8250f69eb9b6" xlink:to="loc_country_DK_e0e1746b-a5c4-455b-8399-c82806234fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f12fbba-a466-4b35-9638-7e8f85838aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_519642fe-2c47-4b2a-9e4a-e68eb4fdb349" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f12fbba-a466-4b35-9638-7e8f85838aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_76dbf572-d408-49a3-890a-46633e3fbdc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f12fbba-a466-4b35-9638-7e8f85838aa9" xlink:to="loc_us-gaap_NumberOfReportableSegments_76dbf572-d408-49a3-890a-46633e3fbdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_955d58fb-9b91-427c-a3de-01b95e486f41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_3f12fbba-a466-4b35-9638-7e8f85838aa9" xlink:to="loc_us-gaap_NoncurrentAssets_955d58fb-9b91-427c-a3de-01b95e486f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#SegmentInformationGeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3582b347-6453-4eff-9c39-1ec0711d25fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3582b347-6453-4eff-9c39-1ec0711d25fc" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3880c126-593d-47f6-bb88-93c0556cac4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:to="loc_srt_ProductOrServiceAxis_3880c126-593d-47f6-bb88-93c0556cac4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3880c126-593d-47f6-bb88-93c0556cac4b" xlink:to="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ee837fed-696c-44a8-9567-aae5538b7238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:to="loc_us-gaap_ProductMember_ee837fed-696c-44a8-9567-aae5538b7238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_45638ae4-5cde-42e9-9c8e-1dcc885da781" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_45638ae4-5cde-42e9-9c8e-1dcc885da781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_c527a49f-7e01-47b0-88be-2d61eae73eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d644dc1b-93ac-4548-8177-433a6dcef5ce" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_c527a49f-7e01-47b0-88be-2d61eae73eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5a54324a-59e0-482b-b764-81976b81ef9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:to="loc_srt_StatementGeographicalAxis_5a54324a-59e0-482b-b764-81976b81ef9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5a54324a-59e0-482b-b764-81976b81ef9e" xlink:to="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1719ab03-53bb-4147-82ed-c9753d8113e3" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:to="loc_country_US_1719ab03-53bb-4147-82ed-c9753d8113e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_3135b915-2df1-4e62-b32e-cc9745a1c7c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:to="loc_srt_EuropeMember_3135b915-2df1-4e62-b32e-cc9745a1c7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaMember_b921ae27-b6df-4942-a44c-625e0f5b4929" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AsiaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:to="loc_srt_AsiaMember_b921ae27-b6df-4942-a44c-625e0f5b4929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_02d76c26-1a78-424d-a016-d2f1e2075cee" xlink:href="biib-20201231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c7eadeb6-b25a-4a8b-92b8-319ae136cc20" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_02d76c26-1a78-424d-a016-d2f1e2075cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_289fd566-451d-4d8c-b2e9-f3c6213722bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6386b4a-4fef-4940-b000-1eda6671ae78" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_289fd566-451d-4d8c-b2e9-f3c6213722bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_89c1d85e-295f-44eb-bd21-80c472a1f6c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_289fd566-451d-4d8c-b2e9-f3c6213722bd" xlink:to="loc_us-gaap_Revenues_89c1d85e-295f-44eb-bd21-80c472a1f6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_4b18a471-04cc-462e-917c-242c87f61dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_289fd566-451d-4d8c-b2e9-f3c6213722bd" xlink:to="loc_us-gaap_NoncurrentAssets_4b18a471-04cc-462e-917c-242c87f61dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_65698768-bf6b-4782-af26-3dc9fa0ffbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_f4727937-a38a-4a6f-96b8-b993cf7bdc2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_65698768-bf6b-4782-af26-3dc9fa0ffbb3" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_f4727937-a38a-4a6f-96b8-b993cf7bdc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3a707aa4-34d4-43b0-bd18-f11ef04d3ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_04453c29-30dc-41cd-bf37-4b7647cc9637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3a707aa4-34d4-43b0-bd18-f11ef04d3ed7" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_04453c29-30dc-41cd-bf37-4b7647cc9637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="biib-20201231.xsd#QuarterlyFinancialDataUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b983759b-143d-40ba-8565-463ba18cf82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bd2c8c4f-caf5-4f74-93a7-22c0d9a8ac6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b983759b-143d-40ba-8565-463ba18cf82f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bd2c8c4f-caf5-4f74-93a7-22c0d9a8ac6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b720ecde-a6ac-437c-8592-eb2a76d435c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd2c8c4f-caf5-4f74-93a7-22c0d9a8ac6f" xlink:to="loc_srt_ProductOrServiceAxis_b720ecde-a6ac-437c-8592-eb2a76d435c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b720ecde-a6ac-437c-8592-eb2a76d435c6" xlink:to="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_4ee91fdf-4432-45d8-9805-502ca189cf82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:to="loc_us-gaap_ProductMember_4ee91fdf-4432-45d8-9805-502ca189cf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_348a1d1d-342e-4816-9067-a85ffde72234" xlink:href="biib-20201231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_348a1d1d-342e-4816-9067-a85ffde72234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_e6e53dd1-3f7f-40f3-9cc1-83cf9b5e5fbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ac4ae39-c21b-46d1-b6f5-a4c5f008785c" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_e6e53dd1-3f7f-40f3-9cc1-83cf9b5e5fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_132c4802-b9eb-4d18-8d1f-17ecfe71389c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd2c8c4f-caf5-4f74-93a7-22c0d9a8ac6f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_132c4802-b9eb-4d18-8d1f-17ecfe71389c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_132c4802-b9eb-4d18-8d1f-17ecfe71389c" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a0121eaf-3db0-4989-9b3c-3ddd0202b31e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_Revenues_a0121eaf-3db0-4989-9b3c-3ddd0202b31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_36a0f0a1-16ea-4c9f-8e49-25679d1fecad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_GrossProfit_36a0f0a1-16ea-4c9f-8e49-25679d1fecad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_326e872d-ba51-45fe-a4de-9a76fa03b545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_ProfitLoss_326e872d-ba51-45fe-a4de-9a76fa03b545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_10124cbb-fd82-4098-a4d8-f9c65750ad9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_NetIncomeLoss_10124cbb-fd82-4098-a4d8-f9c65750ad9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_140ab18c-317d-4eba-af8f-3d497bf3179f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_140ab18c-317d-4eba-af8f-3d497bf3179f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_71cff9bc-3477-413b-9df7-4c85c5efe1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_140ab18c-317d-4eba-af8f-3d497bf3179f" xlink:to="loc_us-gaap_EarningsPerShareBasic_71cff9bc-3477-413b-9df7-4c85c5efe1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1e3adba6-52cf-4be9-b976-f3f8c933f20c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_140ab18c-317d-4eba-af8f-3d497bf3179f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1e3adba6-52cf-4be9-b976-f3f8c933f20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d94f160c-6057-4ca6-a4d8-adee53a21e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_53dd9254-f6cc-43f3-bebd-44a7627cce9e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d94f160c-6057-4ca6-a4d8-adee53a21e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08aa7bba-5aaa-407d-a402-1497cf26281b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d94f160c-6057-4ca6-a4d8-adee53a21e86" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08aa7bba-5aaa-407d-a402-1497cf26281b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e7f1e406-a2c2-4b3e-a745-08f8cc58df8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d94f160c-6057-4ca6-a4d8-adee53a21e86" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e7f1e406-a2c2-4b3e-a745-08f8cc58df8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20201231_g1.jpg
<TEXT>
begin 644 biib-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "  8$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4*Y[QAXW
MTOP1IXN=2F(,A(B@C&Z24@9(49^G)( R,GD5/XK\2V_A319M0G^?;\L<08 R
MN>BC^9P#@ G'%?-WB.ZO_%6H2ZEJ,GFSR<*/X(U&<*HSP!D\=222223GT,+A
M?;N\M(HX,3B/8JT=9":U^T)XGN/$EGJ$6RUTVVE#_P!FQ'Y95^8$.Y&22K'G
M&T$*0H(S6=\3_P!L?5)+B;3O"EA_9$:\-?WJK+.>%(*QY*)SN'S;\@@_*1BN
M7UJQ\O/&*\Q\<:7YMJ]U&/WMN"3C RG4Y/MR1^/&37UBP.&E:2CM_6I\S+%U
MXWCS;DFL_$CQ#XO=TUG7;_48Y)#+Y,\[&,,<_=3.U>I    Z# XK+KCX]0R>
MM='I=\+R/:?]8HYYZCUK\^XFRA0_VR@M.O\ F81E*3]YW9WGAKXN>,_";Q_V
M9XCOXDC3RT@EE\Z%5X.!')N4=., $<X(R:^C_AA^U=::]<1:?XKM8])NI'"I
M?VQ/V8DDXWAB6C ^49RPZDE0*^2[> L:VK&T/'%?!TL?5PS]UW78]/#UJM-Z
M/0_1N&5+B-)(W5T8!E93D$=00>]25\Q? 'XE3^&KJ/0M3N3_ &-.?W#R<BVD
M)SP>RL3R.@)!XRQKZ=K[+!XR&,I\\-UN?2TYJI&X4445WF@4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >$_$[7CXB\9_V?&P:ST[]V K @RD N>!
MU'"X.<%3TR14=QH(BTP2$<$<5QNBZLVI:M<7\^U9;F9IG"\#<S%CCVR37=ZG
MKBMI21 \ 5]0Z;HJ--=#YY355RFSR3Q1"$9Z\ZU,?,:]!\47(=W.:\[U)OF-
M?0X:]E<\'$6OH>)>)[4Z#KTMN.(7Q+%S_"2>.I/!!'/)QGO5G1]3:WG20<X/
M*YZCN*U_BQ9@V6GW@.&CE,6T#J&&<Y]MGZFN1TQCQ6&(I1J<U*?PL(OF@GU/
M:M-A6>-)$.48!@<=B,@UTVFZ?NQQ7,?"V.75[&6V2-I'MV'(' 5LD9/U#=?:
MO6M+T$6X!E()_NKT_$U_-V;47E^+J8=]'_PWX'O86GSQ4K:#]#T??@D;5[G^
ME?47P\UQM<\-PM,Q>XMSY$C,<EL 8;))R2",D]\UX#90@8 7 Z  5ZO\([CR
M;N]MMO\ K8UDW?[IQC'ON_2M<CK2IXI1;TD>Y3BHJR/3J***_2C4**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /C#2[B33YW@E4QRQ,4=&&""#@@C
MU!&*V;O7"T.-W:JOQ?TJ3PO\2=8B/F"&ZD^VQ/)CYED^9L8[!RZCO\OXUR$V
MJ;EQG-??4XJM&-1=4?%RDZ4G!]!VN7WF%N:Y"\DW-^-6]8U:*VC,D\JQIZL>
MI] .I/'0<UYSXA\67-[F*QW6\>2#+_&PQCCT[\CGITY%>C&U-'G3_>/0ROB/
MK"ZC=0:= X>.W8O*R]-^" ,^H!.<'&3@\BL33K<KBI(=-P>E>E?"WX.:W\2+
MY!90&WTQ) EQJ4J_NHAC) &06;&,*.Y&2H.1P5Z\**=6L[(Z*<'*T(*[.F^
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M=&O]8DB ,BV%J\Y3.<9V@X!P<9]#5/4--O-'OI;._M)[*\A($EO<QF.1"0"
M5(!!P0>1T-?5_P"J.';Y%B/>72R_S/B?]><7%*I+#>[ZO\['[$9W<CD45^;7
MP1_:E\3_  KU*RM-1O;K7?"B_NI=.G??)"F%4&!FY7:%&$R$ZC"D[E_0_P +
M^*-+\::!9ZUHU['?Z9>1B2&>+.",D$$'D$$$%2 0000"#7QN:9/B,JFE5UB]
MFMF?H&2Y]ALZ@W2TDMT_ZV-9C@9)P*;YB?WU_.O&_P!L3_DW;Q5];3_TKAK\
MU*]'*.'WFM"595>6SMM?HGW\SR,]XH_L7$QP_L>>ZO>]NK79]C]D>#[UB^(O
M&6@^#X89=<UK3]&CF;9&]_=)"KD#) +$9..U?-WC7]H(?!W]G7P%8:/-"_BO
M4="L_LZ/A_LT7D(#.R].H(7=P3DX8*RGXHU[7M2\4:M<ZIJU[-J&H7+;Y;FX
M?>[$  <GL   !P     !6V5\-U<<I5*D^6"=K]6<V;\7TLOY:=*'-4:3:OHK
M_J?JKI7Q:\%:[J$-AIOB[0[^]F.V*WMM0ADD<X)PJALG@$\5UF=W0Y%?C?7T
M5^S5^U+J?P\U:T\/^)KR;4?"EP4@22=R\FF]%5E)/^J  #)G"@97&"K=V8<)
M5</2=7#SY[;JUG\NYP97QQ2Q-94<7#DOL[Z?/_,_0BBD5@R@CH:6OSX_5 HH
MHH **** "HYK>.X7;+&LB^C $5)12<4U9@8=QX0L9FR#+$,8VHV<_F#55O =
MHS<W$^WL 0#^>*Z:BN*6!P\M7 =V85GX-TVU8$QM<,#D&9L_A@8!'U!K;CC6
M) B*%11@*!@#'0 4ZBMZ=&G15J<;""BBBMP.0^+W_)*O&/\ V![O_P!$O7Y.
M?PU^L?Q>_P"25>,?^P/=_P#HEZ_)S^&OU+@S^'6]5^I^*^('\:AZ,]*^#?QZ
MU_X'MJ[:'::?='4Q")OM\;OM\O?MV[77'^L.<YZ"O2S^WQ\0/^@3X>_\!Y__
M (]7D'PW^#?BOXM_V@/#&GI?_P!GB/[1NN$BV;]VW&XC.=C=.F*[;_AC7XK_
M /0OP_\ @?!_\77O8VCDLJ\I8MQY^MWK^?8^8R_$9_##1C@E/V?2RNM_3N=/
M)^WM\0FX73/#RG_KVG/X_P"NKP_Q5XN\2_%3Q.E_K-W<Z[K5SLMH@L8+'LL<
M<:  <DG:H&68GDDD^C2?L<_%B.,D>&XY#V5;^WR?SD _6O-/&7@77_A_K#:9
MXATFXTJ]7Y@DRC#C^\C E77W4D9R.N:VP%/*:<W]1<.=]FF_S.;,JN=5*:_M
M%3Y/--+_ "/>/@+^QUKGB_5+75O&MG+HWAQ#YAL928[J[P<;"HYB0D'<3AL#
M"CY@Z_?$<20QJD:A54 *H& /8"OS0^%/[47C?X77$,7V^37M%7:CZ9J4K.%0
M8&(G/S1D*"!U49SM/%?H?X \<Z9\2/"&F^(](:1K&^C+HLJ[70@E61AG&58%
M>"1P<$CFOS[B6CF"K*IBW>'V;;?\.?JG!]?+'0='!IJIO*^[_P"!^1\K?\%#
MO^/KP'_N7W\[>OCK^&OL7_@H=_Q]> _]R^_G;U\=?PU]YP[_ ,BFG_V]^;/S
M3BO_ )'E7_MW\D?L<K!85)Z!<_I7YA?M%?%RX^+WQ(U"]CN7?0K*1K;3(-Y*
M"($ R $+@R$;SD;A\JDD**_0?XTZX_AOX0>+-1ANGLKB'2I_)N(W*LDK1E8R
MI'(.\KC'?%?E0*^7X0PD9SJ8J2NUHOGN?9<=XZ<*=+!Q>CU?Z?J=C\(_ACJ'
MQ>\=6/AW3Y!!YN9;BZ9"RV\*XWN0.IY"@=V902 <C]$?"/[-OPZ\'Z3!8P^%
MM/U!XQ\UYJ=NES/(VT L7<'&<?=4!1DX45X9_P $^_"H73_%OB26*%O-FBT^
M"; ,B;%,DJ@]E;S(>!P2H]!7V#7F\39I6J8R6'A*T(:67<];A#)L/3P,<75A
M><^_1?UJ>*?%+]E/P-X\\/RPZ;HUGX=U:.-S:WFF0K  Y' D5  ZY ZC(&<$
M9K\Y=8TF[T#5K[3-0B\B_LIY+:>'<&V2(VUUR"0<$$9!(..,U^POX5^<_P"V
MQX?&B?':]NEDW_VM96]Z5Q@(0##CW_U.[/\ M&O0X4S&K*O+"59735UZH\OC
M;*:%/#QQM&/+).SMU1V/["OQ5FTGQ5=>!KR;-AJ8>ZL4(SLN$7+J"!P&C4L=
MQP/+&,%CGV7]M[Q1<>'_ ()O9VZ_\A>_ALI'#$%$P\IQZY\H*0>,,:^%OAGX
M@3PK\1/#&L2RR06]CJ5O/-)"3N\H2*9!P1G*[@1T()!ZU^B/[37PUG^*/PAU
M.PL;<7&KVA6^L4+$9D3[RC'5FC:10#QEATZAYSAZ.#SFAB)*T9--^J>_Y$Y#
MBL1CL@Q&%@[S@FEZ-;?G8_,GG%?H+^Q-\/-'T7X3V?B>*VWZUK+3>?<R@%EC
MCF=%C3CA?D#$=R<DX"@?GUBOL[]C_P#:*\-Z'X+A\%^)M0MM%FLII#8W5R?+
MAFB=FD8/(3M5PQ?KM!!0#)S7T7%%.O5P"]@KJ]W;M_EL?+<&U<-0S.^*:6C2
MOWT_2Y]A>V.*^/\ ]OGP#I4.B:)XPA@$&K->+IT[Q@ 3QM'(ZEO4KY9 /HQ!
MS@8^L;S7M-TW2WU&ZU"VMM/1/,>ZEE58E7&=Q8G &.]?$'[9GQXT3XA+I7AC
MPU>QZG8V-PUU>7D2$QM,H9$6-^C !I"2 0=RX/!K\\X=HXB684Y4D[)Z]K=3
M]2XJQ&$CE=2%5J[6BZW\CY<K]6/@IXJN/&7PE\+ZU=RM/>7%A']HE< %Y57;
M(V !C+*3P .:_+71-%O?$FL66E:;;M=:A>3+!;PJ0"[L0 ,D@#J,DD #DX'-
M?IEXDT]_A+^SGJ5A:7PAN=%\/2017L:B$F9("JR 9.&9\'&3R>]?7<7<E3V%
M%?&W^!\-P.ZE%XC$/X$M?7?\KGPG^T=\6I_BU\2M0NTN6DT.QD:UTR$.3&(E
M.#*!@<R$;B<9P54D[16I^RW\#X/C/XWN!JOF?\(]I*)/>+$P4S,S$1PYR&4-
MM<EE!("$94LK#Q?K7NOP _:<B^!?AS4=-7PI'K,]Y=_:7O/MOV=]NQ56,_NF
MR%(8\G'SGZU]%C,/7PV6_5LNC[UDE:R?F_ZZGRF Q6&Q>;?6LTE[K;;W?HM.
MGZ'Z':/HFG^']/AL-,LK>PL81MCM[6)8XT'7"JH '/\ .N=^)'PK\.?%;0)=
M*U_3XYU9&6&Z10)[9C@[XG()4Y53Z'&&!!(KYD'_  4.?.?^$!7/_88/_P 8
MH_X>(/\ ]""O_@X_^T5^91R'.(352--I]^9?YG[#4XFR"I2=&=1.+Z<K_P C
MY=^(W@>[^&OCC6?#-^=]QI\YC$O \V,@-&^ 3C<C*V"21NP>0:^C/V#_ (H2
M:=XBU'P->3 VNH*U[8*[ ;9T \Q%&,G<@#=< 1' RQ->(?'#XJ0?&/QL?$D6
MA1Z!(]M'!/%'.)C,ZE@)&;8N3M*KR"<(.>@J+X$ZQ<Z'\9O!5S9OY4S:M;V[
M'&?DE<1./Q1V'XU^E8W#U,9E+ABE::C?_MY'Y%E^*IY?G4:F#E>GS67G%OS\
MOQ/N_P#;$_Y-U\5?6T_]*X:_-7^&OTI_;#_Y-T\4_6T_]*X:_-;^&O+X/_W&
MI_B?Y(]SCQ_\*--_W%^;/8/A'\.=<_:6\=6EE>7DEMI6DZ?;VUQ=*C,MO;Q(
ML<<48)*AWVDX) R9&P<8/VSX8_9>^&?AG2?L2>%K342R*LMUJ:?:9I&"X+;F
M^X3C.$"C)X KD?V'_"<6A_!:'55=9)]:O)KECY0#1JC&%4+9RPS&S9[>81CN
M?H7FOC,[S2M/%2P]&3C3@[)+3;J?><-Y)AJ>#AB<1!3J5%=MZ[[?@?G]^UM^
MSGI7PE.G^(O#1:WT*^F%I)82R-(;>;864H[$LRLJ,2&.5(."0P"_.':OTH_;
M$4-^SOXH) )5K0@XZ?Z5%7YK5^@<,XRKC<"_;N[B[?+3_,_,>+\!1R_,K8=6
MC)*5NSU7Z'ZF?L]>*&\8?!;PEJ;R2S2M9);RRSN7=Y(28G8D\DED8Y/7->C5
MXQ^QW_R;MX5^MW_Z5S5[/7Y!CH1IXNK".RDU^)^\Y74E5P-"I+=QC^04445Q
M'J!1112$%%%% !1110 4444 %%%% '(?%[_DE7C'_L#W?_HEZ_)S^&OUC^+W
M_)*O&/\ V![O_P!$O7Y.?PU^I<&?PZWJOU/Q7Q _C4/1GV-_P3O_ -;X^_W;
M#^=S7V97QG_P3O\ ];X^_P!VP_G<U]F5\EQ)_P C6M\O_24?=<(_\B6A_P!O
M?^E,*\\^.WPR@^+'PTU?16A1[\1&>PD8J#'<J"8R&(. 3\K$#.UF ZUZ'7FW
MQ[^*UI\)_AQJFIM=K#JTT30:;#A6=[AAA"%)&54D,WH >IP#XN#]J\1!4/CN
MK'OY@Z"PE3ZS\%G?T/RVKZ]_X)_^.)8]3\2>$)&=X)8EU6W4(NU&4K'*2<9)
M8-#@$X 0XQSGY#]J^GOV ]'NKCXFZ]J<<>;*UTHV\LF>CRRQL@Q[B)_RK]IX
MBA"665.?I;[[H_GOA:<X9Q2]EU;^ZQTW_!0[_CZ\!_[E]_.WKXZ_AK[%_P""
MAW_'UX#_ -R^_G;U\=?PU'#O_(II_P#;WYLTXK_Y'E7_ +=_)'Z=?M0:1-K?
M[/\ XM@@^_':)<GC/RQ2)*W_ (ZAK\Q>M?KOXJ\.P^+O">JZ'<N\=OJ5E):2
M/&1N59$*$C(/.">HK\D]6TNZT/5+W3;Z$P7ME,]O/"2"4D1BK*2"0<$$9!(X
MKPN#JR=*M1OJG?[]/T/H^/,.U6H8BVCC;[M?U/NC]@&2-OA7KD88&1=:D8J#
MR 8( "1Z<$9]J^GJ^#?V#?'EMH/CW5_#5R AUV!'MY"3_K8-[;  /XD=VR2,
M>7CDD5]Y=J^.X@P\J&8U%+9ZKYGW_"F)AB,II<KUCH_E_P #4*_/_P#;U(/Q
MFTP9Z:)"/_(\]?H S!5)/05^7'[1GCB#XA?&3Q'JUI,9]/686EJWFB1#'$H3
M<A!QL9E9QCCY\]2:]+A.C*IC_:+:*?\ D>1QSB(T\M5)[RDOP//M-LI]3U"U
ML[6)YKJXE6**.,$LS,0  !U))  '<U^N7B+Q)IO@_P /7>L:S=I8Z;9Q>;//
M)G"CZ 9)S@  $DD 9)Q7YJ?LS^#YO&?QN\+6T8D$5G=+J,TT<9<1K!^\&[T#
M.J)GL7'? /T;_P % O%-]IWAOPMH$$GEV6I3S7%SM8@OY(C"(<'!7,I8@@\H
MI&,5[W$%)9CF6'P*?>_S_P" CYGA>N\JRG%9BU?9+U_X=GSE\>?'7AGXG^/I
M+_PCX9;25GD/FS9/FZA*VWYS""50[L\+DMN+,<G ?=?LO_%*UT7^TY/!]XUK
ML63;%+%)-AL8_<JYDSSRNW([XP:YOX1^)--\'_$[PUK6L6HN],LKV.69"6^0
M X$F%R24)#X'78!WK]3M!\2:5XHTJ#4M(U"UU&PF'R7%K*LB-@X(!!(X((/N
M,5U9MF5?(HTL/AH7A;>5W\CBR3*<-Q)*MB<74Y9WVC9?.UOZZGY8_P#"G_'@
M_P"9)\1_^"FX_P#B*[;PA^R/\3?%WV>7^PQHUG,&(N=6F$.W&1AHQF4$D=T]
M#T.:_2G?%_>3\Q2^8@_B4?C7SL^+L9*-H4XI]SZJEP/@5.]6M*2^2/&?@;^R
M]X<^#)&H-)_;GB3#+_:<\6P1*QQMBCR0GRX!.2QRW.#M&C^U3I=QK'P!\7P6
MPS)';I<'G'R12I(Y_P"^4:O5E8-T8'Z&L3QQX=_X3#P7KNA&;[-_:5C/9^=M
MW;/,C9=V.^-V<5\M'&U:F+AB:\KR33U]3[6674*.7U,'AHI1<6M/-'Y%^G:O
M>?@%^RR_QR\)WNMKXF&BBWOGLO(-AY^[;'&^[=YJX^_C&.WOQX7=V<VGW4UK
M=026UU [12PS*5>-E)!5@0"""""".""*^PO^"?\ XXAC3Q)X0N)8HYBZ:G:1
M[&WR9 CFRWW<+M@P.#\S'GM^R9YB<1A\ \1A'9JSOOH?@/#N%PN*S*.&QL;Q
M=UVU$_X=WO\ ]#\O_@G/_P ?H_X=WO\ ]#\O_@G/_P ?K[+HK\N_UDS7_G]^
M$?\ (_:/]4<E_P"?'_DTO\SXT_X=X/C_ )'Y<?\ 8'_^WUK>#?V#W\*>+=$U
ML^-ENAIE]!>>0-*V>9Y<BOMW>><9VXS@XST-=7\9_P!L*Q^$OQ ?PS#X?;6S
M;Q1/>7"7?DF!G^;8%,9#$(4;.X#Y\=0<:/PU_; \*_$[QCIGAK3M(UJ#4;[>
M$>XBA$2E49VRPE)QA3V]*]*IB^()X;VLVW3DKWM';[CQ:6!X7AB_802]I%VM
M>6_W]S1_;#X_9U\4CWM/_2N&OS6_AK]*OVQ/^3=?%7UM/_2N&OS5_AKZG@[_
M '&?^)_DCX[CW_D8T_\  OS9^E7['?\ R;KX5^MW_P"E<U>SUXQ^QW_R;KX5
M^MW_ .E<U>SU^8YE_OM;_%+\S]DR?_D78?\ P1_)'C'[8G_)NOBKZVG_ *5P
MU^:O\-?I5^V)_P FZ^*OK:?^E<-?FK_#7Z=P=_N,_P#$_P D?CG'W_(RI_X%
M^;/TJ_8[_P"3=?"OUN__ $KFKV>O&/V._P#DW7PK];O_ -*YJ]GK\QS+_?:W
M^*7YG['D_P#R+L/_ ((_D@HHHKS3UPHHHH **** "BBB@ HHHH **** .0^+
MW_)*_&/_ &![O_T2]?DY7ZZ>.M#G\3^"=?TBU:..ZO[">UC:4D(&>-E!8@'
MR1T!XKX=_P"&"OB)T_M/PY_X$S__ !FOT'A?,<+@855B)\MVK'Y3QGE>,S"K
M1>&IN22=SQ_X>_%[Q;\*C?GPMJ_]E&^\L7'^CQ2^9LW;?]8K8QO;ICK]*[#_
M (:\^+?_ $-S?^"^T_\ C5=A_P ,%?$3_H)^'/\ P*G_ /C-'_#!/Q#Z_P!I
M^'/_  )G_P#C-?4U<?D->;J5>24GU:_X!\71RWB3#TU3HJI&*Z)V_4X__AKS
MXM]/^$N;_P %]I_\:KS3Q-XLUGQIJKZEKNJW6K7S CSKJ4N54L6VJ,X506;"
MJ !G@"O>_P#A@KXB?]!/PY_X$S__ !FM?P[_ ,$_O$UU+-_;GB?3-,C !B:Q
MADNRQYR&#"/;CC&,Y]J=/,LBPOOTG&+\HZ_@@JY3Q'C%[.LIR7G+3\6?+EI:
MSZC=0VMK#)<W4[K%%#"A=Y'8@*JJ 2220  "22,5^D_[+?P9F^#_ ,.UBU.&
M-/$.IR?:K_858Q]HX=P'(5>2,D!G?!(.:D^$/[,'@[X/W2:E913:KKJA@-2O
MV#/&&4!A&@ 5._."V'8%B#BO8:^*S[/UF*5##JU._P!__ /T3ACAB652^M8I
MWJ/9=O\ @GQC_P %#_\ CY\!_P"Y??SMZ^.Z_0[]JOX ^(OC=-X:?0;K3;<:
M:MR)O[0ED3=YABV[=B-G[ASG'45X'_PP3\0_^@GX<'_;S<?_ !FOH\DS?!87
M+H4:U1*2O^;/D>(LCS#%YM4KT:3<7;7Y(^_8_P#5)]!7Q!^VY\$WT?6!X_TF
M _8+YEBU2.*,XAFZ+,3T"N,*>  P!R2]?<*+M11Z#%5KZPM]5L9[.\MXKNTN
M(VBFMYT#I(C##*RGJ""1@]>:_.\MS"IEN)5>&O==T?JV;973S;!O#5-'T?9G
MX_6=W/I]U!=6L\EK=0.LL4\+E7C=2"K*P/!! P00<@$5]1>#OV^O$.CZ4EKX
MA\.6OB"[3"K>0W/V0N  "74(X+$Y.5VCG  KK_BI^P?9:G=SW_@74H])+!<:
M3J&]X <@$K+\SJ,9."K9)P"!@#Q#4/V.OBQ9WDL$7AR.]C1L+<6]_;B-QZ@/
M(K8^J@^U?J%3&Y)G,$\1))KO[K7E?_)GXU3R_B'(*LEA8NS_ )5S)_+7\4;'
MQB_;&\3_ !.T:?1-/L8_#&DW2!+E8)VEN)ASN0RX7","H*A<G!!8JQ6O 8H7
MN)DBA1I99&"JB EF).  !R23P *][\,?L1_$K7)B-0M[#P_$K@%KVZ61BI/)
M40[P<#/#%<GOWKZF^"?[*OAGX/W2:K)(^O\ B(*56_N8PJ0@YR8H\D(<8&XE
MFZ@$!B*RGF^4Y-1=/!6;[+7[V;4\CSO/\0JN.O%=Y:?=$S_V3?@"_P )?#,N
MKZPBGQ+J\:F6-D&;.'JL(/7<<@OC R%'.P,>A_:6^#<7QB^'KVT4L=KK&G,U
MW8SR!0I8*0T3,1D(XZD$8948YVX/KE?!/[9WQOU+Q%XPO? VG7*P^'M,=!=+
M;OG[7/@,0Y!^[&3C9V=23DA=OQ&7_7,VS-5H2M._,WV2_JQ^C9K]0R/)WAZD
M+PM9+N_7\;GS3/"UO-+"[(6C<H3&X=20<'#*2"..""01R"146*^@?V1?@7H?
MQBUK7+OQ$9)]-TB.)?L$4AC\]Y?, 9G4A@%"$X&-Q(YPI#>XS?L ^"6CQ#KW
MB"-^QDE@8?EY0K])Q?$&"P==X:O?F5KNVA^28'AC,,PPZQ>'MRRO97UT/@WZ
MT?A7W5_P[]\*?]#+K/\ Y"_^(JGJ?_!/G0Y;4C3_ !7J-M<<;9+FWCF0<\Y4
M;,_G6"XFRMO65O\ MUG5+@_.4KJ-_P#MY'R;X+^*_B_X>2POX>\17^F1Q,SK
M;)*7MRS @EH6RC'!ZE>" 1@@$??/[-_[1EK\;M+N;2]@@TWQ)8JK7%K')E)D
M/'FQ@G.W=P1D[<KDG<,_"/Q>^$^K_!OQC)H.JM'."@GM;J'[EQ"20'QU4Y4@
MJ>A!P2,,=/\ 9Q\47'A+XV^$;NW!<7%]'82Q[RJNDQ\HY /.-X8 \94'M49M
MEV#S/!2Q5%+FMS)KK;H_ZT'D>;8[)\PCA*[?*VDXOIT_JVYZI^V=\#+GPSXH
MF\<:/9LVA:DP:_\ * Q:W1."Y  PLF0=QS\Y;)&Y0?G/P[XCU+PGKEEK.CWD
MNGZE9R>9#<0D90C@Y'.002"""""01@D']=;_ $^VU:QGL[RWBNK2XC:*:"=
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M^&=)FMX+^],!CDNV98ALGCD.2JL1PAQ@=<?6OD+_ (8*^(G_ $$_#G_@3/\
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20201231_g10.jpg
<TEXT>
begin 644 biib-20201231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[@ .061O8F4 9      !_^$0C$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    )    '(!,@ "    %    ):':0 $
M 0   *H   $N  K\@   )Q  "OR    G$$%D;V)E(%!H;W1O<VAO<"!#0R R
M,#$U("A-86-I;G1O<V@I #(P,38Z,3 Z,C@@,#@Z-# Z-#,   >0 P "
M%    020!  "    %    1B2D0 "     S P  "2D@ "     S P  "@ 0 #
M     0 !  "@ @ $     0   >"@ P $     0   /      ,C Q-CHQ,#HR
M." P.#HT,#HP,  R,#$V.C$P.C(X(# X.C0P.C P      8! P #     0 &
M   !&@ %     0   7P!&P %     0   80!*  #     0 "   " 0 $
M 0   8P" @ $     0  #O<         2     $   !(     ?_8_^T #$%D
M;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(  A$! Q$!_]T
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M[1AB4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M.$))300Z      $+    $     $       MP<FEN=$]U='!U=     4
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ !(     0 ! $@    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300        "   X0DE-! (       (
M #A"24T$,        0$ .$))300M       &  $    ".$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      U<
M   &              #P   !X    !$ 4P!0 $D 3@!2 $$ 6@!! %\ ; !O
M &< ;P!? &X 90!W     0                         !
M  '@    \                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    \     !29VAT;&]N9P   >     &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /      4F=H
M=&QO;F<   '@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3004       $     SA"24T$
M#      /$P    $   "@    4    >   )8    .]P 8  '_V/_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 4 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M300A      !=     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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M>W/Z>QY[ZC_D+;5_TL4_ZLS]9(_W9'_3[>>/_%1N/^[EM?5.'\I_CY-[T_\
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M 2B#$3.B_I#GW+?L/S-#[.>UUCR1>V;7V\Q7-U*9(B$@;QYGD05D/B JK!6
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MYD_Y[I?^/=?3U]WG_IQ?LQ_XKMA_U:7K:(_EL?\ ,H?C7_X@7$?^X-'[Q_\
MNT_^)>\P_P#-'=O^/6_7%_[W/_*^>\'_ (L\O_'VZMB]];.L(NOGB_(8?\9=
M[[ ^O^DWM>Q'UO\ WJSQ%O\ 8^\"-T_Y6+<_^>Z3_JZ>OJO]JO\ E1?;&O#]
MS;;_ -HT/5W'S(^&F2^1'3&VOD-U9CUJ>S^K.D]C9+>&W,=0U-3E>T.N8-LX
MJL;^&PT<<CU6\]CK)//2HR,^1HG:D2TJPGWCC]VZVYAWK<?='ERUG66PVUI+
MU(2',FHW+Q3"&@(TE0KM&:%G"Z!4MUSF^[_]X&U]JO</>/:OG:\*<G;US%>1
MVMP[JL>W7YN)4'B%R MI>41)#4""51.W87ZK-^"/RYROQ%[KQ6]Q7RS=6[N;
M&8KLVAI2]5"F'5Y!A]]T%-&P%37;4^\D>94]=7BYIX@=7CM*^]VF[F39N9N4
MIUBYWV>8W-A(20DA*Z9K28@]UO>1DQLIP'*N*$ C,/[R_L18^^WMW>\O&T5>
M=+ 22;>[40F6@\6S=C\*7.@*I.([E8I.&JM[7\['<&,[!^$?46\MN5-/E,/+
MW]LG*-68^IBJZ04>1ZT[0@@J8ZE/3/25+5\#0R*/W8ID<#2P/O(CF3W V?W3
M]H^6^;]EJBON*I<0L?U+6YCCGCGMI@:%9(I.W*@LI5P-+J>N:?\ =V;9><K?
M>+Y[V#=HFAOARO=QZ74HVJ/<-N9E*GX67PW#J?A9&4Y'517\I_\ [*;WI_X@
M?='_ +U&UN/]A[P>^\7_ ,J'M?\ TMXO^K4O6=?WX?\ ISO+_P#XLMO_ -H]
MQUN,];_\>%M+_M1T/_6H>^DWW??^G)>UW_2FMO\ C@ZX$\V_\K-OG_/2_P#A
MZH5_X4!_\>=\8/\ P^]^_P#O'I[#_OW_ +B<L_\ ->7_ *MCKIM_=<_\K![R
M#_I&67_:4>J4/B/\G8OBMO+>^[)=AU78"[SV90;0_AM-N*GVW)C#19^/.G)-
M55./R*522^+P^((I%]1)^GO"KW+]OS[B[5M>UIO LVMKEY=1B,NK5$8]- RT
M(K6M?E3KHE[Z^S+^]FP<N;$G,R;6VW[@]UXC0-<"37 8?#T*\96E=6HD@\*>
M?5O.Z/Y]0AZ\_@76/Q[RV'WU'B*;&8_-[XW;AJ_;&)F6E%.<D,?@8I<GG)J-
M@)(J:3[**<BTDD8X.6&R^[G]7>3]DY:V[:B^X65C#;B9V C8Q1+'X@C%6H2M
M0A(]"<=8(;-_=D&3FH;ESC[J07'+9G,DD-G:S)<2@MJ\/7,1'"&^%I!XK)7L
M1^/5%.-Q/;?R3[<JJ+ T62[&[>[-W!7YW)5#1@+/D<K5FHS&[-T5R(E%@-MX
M]Y#)4U,OC@@@011"X1/<&<R\R6&U6NY<T<T;B(K4,7ED;XG=LZ(UXO+(31(T
M!\J@**CI7>7_ ")[1<B0W&Y74.T\B;-:I#&M>"1+IBMK9#5YKB3X8XU#.[DN
MY^)NMM_X5=&4G4FW^INI\)5G,T/6&':JW!N%(I(H<SG:AZS(9O,HDGKABS&Y
M\BYID<ZQ2HH/*M;'O[O-CO'NU]Y;:N:ELVCL;.Y>_G\Q!;PQ-#:Q,PQK:0Q
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MK(6=_EZ]S^4;?EC>9_H!_B1N9XOD'AD9"1Z!U :G &M,4 )5_.@_[=_=F?\
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M2]0K -)FV*$#[$&3%WWBYQ_>E]_5C;Y0=OM7K,0?CF'X/]+#Y^LF*=F>V?\
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M2/\ [^+97O/+WC_Y4+<O^:]M_P!I$?4T_P!WO_XE'R=_TKMW_P"[5=]:R?\
M+_\ ^RSNB?\ M8;R_P#>&SOOGK[R5_UL.;?])#_U?3KL1]Z3_P 1[]RO^:-I
M_P!IL/6ZQT'_ ,RZHOZ#*YNW^'^Y"4\?[$^\H?N0$_ZP6T GAN>X?]I3_P"7
MKYX?<W_E:YZ\? A_ZMCH9_>774?=>]^Z]U[W[KW6@K\T_P#LK;Y0_P#B;>R?
M_=W4C_>_>"?-W_*W<R?\]TO_ !X]?3[]WK_IQ?LQ_P"*[8?]65ZVB/Y;'_,H
MOC7_ .(%P_\ [@TGO'_[M/\ XE[S"?+P=V_X];]<7_O<_P#*^^\'_BSR_P#'
MVZMB]];.L(NOGC_(/_F<'?/_ (D_M7_WJ\]_Q3W@/NG_ "L.Y_\ /=+_ -76
MZ^JWVM_Y4+VS_P"E+MO_ &C0];E/P@_XL76W_B =F?\ NFV5[A7[E]/^".Y^
M_P"E1N?_ '<[#KY^OO%U_>G-W_BSW?\ U>N^C4?(3HK8WR3Z@WKTUV%2-/M[
M>&,:F6L@ &0P&9IG6KP6YL1(2OBRVW\M#%50$G0[1Z'#1LZGJ5O^R67,6TWN
MS[@M;>9:5'%6&5=?Z2M0C[*'!/4,>UGN5S)[1<^<O>X'*LX7=;";5H;X)HF&
MF:WE'G%/$6C?S ;4I#!2-$/O7I;?'QW[;WOTUV)2&FW1LG+/125<4$T..W#A
MJC5-M_=V#,X#S8+<^,TU,!NQA<R4[GRP2 8.;YLM[R_NU[L^X+2YA:E:4#KQ
M21?577(]#53E3U]+_MK[A\N>Z_(O+GN!RG/JV;<8 P4L&>"5<36LU.$UO)5'
MX!AHE4:)$).I_*?_ .RF]Z?X=#[I_P!@!NC:W^\ >\<OO%?\J%M9_P"DO%_U
M:EZQV^_#_P!.<Y>_\66W_P"T>XZW&>M_^/"VE_VHZ'_K4/?2?[OO_3DO:[_I
M36W_ !P=<"N;?^5FWS_GI?\ P]4*_P#"@/\ X\_XP?\ A][^_P#>.7_B?9![
M\_[B<L_\UY?^K8ZZ;?W7/_*P>\G_ $K++_M*/5?/\I _\9A[O_\ $-8('_7_
M -(%*??.?[RW_*K\LD\/WC-_VC-UE+]^JO\ 4+VZ_P#%@F_[0FZVULEL3:W:
M'3]3UUO?%0YS:.]MB#;6XL5.71*W$Y?#K1U<2RQ,DU/.(Y=4<L;+)%(%=&#*
M".J/MY8VNY^U')>W7L0>TFV.U1U/FK6Z _8?0C(.1GKAI:<R[UR;S[#S7R[>
MM;;]MVY?402"A*2Q2ZU-#4,*BC*P*LI*L""1UHJ?+#XX;F^+7>&_.C=X--7P
MX2H^^VIN"51 =Y=>YJ6HDVINN,0,5@K:BFII*:M1+"GRM)4*GH6-CBSS+L%W
MRIOUYM-RQ)B;5&Y_T2)JZ'(_I95QP#*PX4Z^E3V/]W-G]Z/;?ECW(V$+%+<+
MHN8!W?2WL047-L:Y9 S+)"3F2WEB+=Q<#9/_ )1/S6?NWK>3J7L#-?==H=;P
M8_&9*IK'7[K<^$FO2;9WF&+WEFRL4'V.2-O3E8!(QO6)[3>Q?. ]KN?F]M]Q
MD\/D'F.=YMJ)^"TW$]]S8%JT1+FIFMA2FO5&#K< \A_OV_=W7VYYO7GGE;;@
MG)F[M))&J?#;S#NN+3A@1EO&MQYVSE1BW;JS/Y0=TXWX[_'WMON?)Z6386S,
MIE,=2LY0Y+<50BXW:V'B8*_^49G<E=2TL0L;R3 >\V>9MYCY?V#=MYEX00LP
M'J_!%^UG*J/F>L/?9KV]N_=7W2Y&]OK.H;<]PCCD:E?#@!\2XE/#MB@221OZ
M*GK09QN*W7V-NW'82.IGS>^^R-VTF,-;*WGJLMN[>N:"U>1F:0ZI9)LID9*J
M0L;E W/O :_W*.QM=PWK=)JQ0123S,?/2#(Y/^F((KZGKZ>[R]V/E+8;O<6A
M6VY:VBQ:30  L5M:152, <*1HL8^9'6Y_P#'WH?:,6*P76N/Q]#3;2ZVV;A=
MN4]?28; R5U4V)IJ?&4M1)55V(K4FFRL]-4U4CNK.;\\F_O&/[OGM+)]XGG_
M )JFYGW?<;798H7N[B2VD"2":XF_Q>%#*DL2@J)21H)"PT6FJO7SV>Z7N;OL
MM_N7-UU=ROOF[W\L[*TLP1?$8R,H5)4H(PR1J!0#^71G$^->P(Y$D#UA:-U<
M7Q.RB"4-P&']T[%3^1[S,_X 7VLI3^O/-G_959_]L'4/-[N\T.K*0E"*?VMW
M_P!M/6G5_,9^-]-\6_EEV!L7!1U$>Q]U1T7:/7XF"6I<%O&HKFRN(B:*"G@9
M,#N['Y"&-57T4KP W/);YLY.'(FYV_+<=Y/<VL5K$(IIBIEE0+HU2LB1QF6J
M$,41 : Z02>N^GW3?=N;WI]CN5^9-T=3S%9,VVWU*]TUJJ>%*02QK-;/ S$G
M,@DI08%PO\E+OE<OUS)U;DZTODNJ\W-M(022$R?W!WK4U&?V+5A>%2DPNXEK
M\8I)9M+J386]Q9R#O9]LOO+\O[O(Q3EWG"T-E/Y*+Q"OANV::BZQY(P+ASZ]
M8#_WB'MDVW\W+SI9V]+/>[<7.H#'UMHJP7BUXEIH/!N#3%0?.O5C?\ROY*;I
M^+7Q1WCO[8M.3OC<&3P_76TLNXIWI=J9C=[5-,=VU5/4!UK#M^@IYYZ>#0ZS
MUBPI)IB9W7H%[C\QW/+'*UY?V*_X[(RPQMBB-)4>(0>.@ D#S:@.*GK$W[H7
MM#LOO1[W<O\ +',LO_(;M8I;ZZB[@US%:Z6^E5EH4\=V1)'J"D1D9:N%4Z/4
MAEE\I-1.\\OFDDK*F0U57-53L\LU94S3$O5U<\\C22NY)DD8L3S[PL4YU,"<
MUSFM>))XU.:G\^OH]70ACTQ*(EH J@*H4"@10/A4* J@?"H '#JSGIC^9?DN
MDMD[$ZUVW\;.MZC8VR*6*F./;L#>5'E=P/-.:S/Y7+90X6L@.=W/D9)*BIJ&
MIIE!?0$,:*ON&KKV5V;>>;QS;S3S!=[BKW22SVK1Q1PS1(PI::@6>. H/".@
M%@A8\6)ZPV]P?N>V?N+S)S+SAN_N_NZ\R;BY;Q/H;1HX !I@CBC\92(;= J1
MH)$)"ZBP9B>CM)_PH#WLB*D?Q+V='&BA(XU[VS2JB+Z4557I<!551P!;CWF[
M%[ZW%O'';P\H0)"BA55;@A54"@4 6X  %  !0>76.S?W7'+KDLWOG?EB:DG9
MHJD^I_W:]'Y^"O\ -#J?EM6]EIO3J'&=58K8#[4@BRF&WW7;Z6NJ=R0Y>HD^
M^@JME;1?'P44&-!U1_<EM1)"@<A_>?O9\M<G[SR_9<\;,]EM%^DQ^IBD,ZP&
M(H"TR>&C^$0Q)=-;+IRA4DKC!]Y7[FD/L7!R>>7N?)M[O=T%RQCELDLRBVYB
M4:"MW="0N9"*-X8%!0DGHU7SW^0)^-WQ+[;[1Q=9'3[G.W#MCK^4QM.&WQO1
MDV_MBJ6%'C:6/&5F0%;(+@>&F8GWD'SKS''L?*&X[S:S R/"!"W$%Y:+&P]0
M-0?[!U"GW8_:[_7;]\>1>3+RW+[-]7]1>BM/\3M 9[A:T-#(B>"N#W2#K1]Z
MQZZR7:W8G7?4^(,[UV_MUX':*U!>62H@QU94QKFLA--:2:0T6$@J)Y7-VLA8
M_D^\#M]WF#EO8=WY@N?[&RM7ESFK*I\,9\V<J/F2.OH[YSYKM.1^4N:^>+[2
M+;:[*>Y*BBJSJI\)%& -4Q1%'#( QUNI=/=.[3W0*S$Q8NAQ>U-I8S%83#+C
ML+M\SF.D@%'CZ<U-=A:U)D@QM$K.2/(S.I)Y-\?_ +LOL3![][KS??\ -N^[
MI;;19)&6EM90DDEW<.[E-4T4\6A$4LX50]7CR%X_/#SYS]OFS>!?/>R3;W?3
M2S2ZYI]-6.MVTI,A!+N0/P@ BGH.0^,_7?TD6JGB97CE@EQ.S#%-#*C1302A
M=J*QCFB<J;$&QX(//O+_ /X ;VNP1SWS:&!J"+NSJ".!'^(<>HX/N_S53L**
MXR");NH(-01_C-*@Y&*>M>M*SYJ?')OBQ\E>T.F(EJY=KXS)19_8E97MY9LA
MU_NZ#^+[?9IA3TR5$F+:2HQ<TBJ%-5CY;<>V>;.7IN5-_N]E>=Y4A"%)7"ZY
M8RHTN^E4362"'T*J:PVE0,=?0Y]WCW:'O7[0\F>X$C(-ZEA,%XJ"@2]M3X4P
M JQ4242Y4$U$<R=;#/\ )N[_ 'WWT?MO9V8KFJ,_U[-4]19E7=?(U)@X&S?7
M&2DA5BR1UFU*F2D25_7*](U[VXC_ -D=\'MK]Y3<N7I&9.7><[/Q8^.@7L6M
MR*< 2PG!(X>+&N12G*G[_P![7#ECW(W??MOM@FU;JJ[G%0&@:8B*_C!/$K<J
M)2HPJRBG'J\#WTKZYR]>]^Z]U[W[KW7O?NO=?__7W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0?_.'_F$8WKO:&;^*/3V>IJSLK>N-?&]M
MYO&3>9>OMD96E=:K;*5E-.JT^]MW4<H1H3K:BQ<KRR*CSTVJ;_:;D.3<;N'F
M;=H2NW0M6!6QXL@.'H>,:'-?Q. !@-UA?]ZCWPM^7=HN_;GEB]1^8KQ-%VZF
MOTUNX.J.H(I-*#32<K$2Q'<O6F)\E,M75&W-M]7;:HILKNOL7+P&EPM"O^4G
M X"5:BHGE (CI\?/DA#')))ICCCB=R;+[R/W%F9(X$4F>1N ]%XU^T^OV]8K
M?=RVJQM-^W[W)Y@NXK3E7E^T96GDP@NKI="*OFTB0ZV1$J[.Z(!W='?_ )='
M\N?M'O+<T/7G6U+$U=7UE))W'W-6XRMJ=C[ H88OO/X6DT7@;*U&/IY/]Q^)
MCFAJ,I6RI).]-3,:B(.<P\R[/R3MCW=_)KO''9$I&N0^06OPH#\3D8 ) 8T4
MGUQ;<[?>EY[M;/8;.6RY%L'*1/*"4@C/]I<SZ:*]Y,H 2%3V+HBU(NN3K?>^
M.GQ_Z^^,'4&TNF.LZ2IAVUM2FFU5V1>";-;@S%?.];F=QYZJIJ>D@JLSF:^9
MYIG2.-!<(BJBJHP\W_?+_F/=;K=]Q<&YE/ 5TJH%%502:*HP,GU.2>NEW(_)
M>R>W_+.V<J[!$5V^V4BK4+R.QJ\CD  N[$DD #R   '0W>R?H6]>]^Z]T53Y
M,_"SXZ?+;&4U-W-L"BRN>QE&U!@-]X>63 []V]2-,]2*3&;HQQBKVQJU4C2_
M95!GHFD9F:$EB2"><N1-HYSM=%T[V^YHI$=S$%\1/.A#JR2)6M8Y%9<DKI8U
MZFSV>^\-[L>Q=Y+-[?<T20;9-('FLY0)K*=@ NJ2WDJGB:0%\5-$P4 "0 "E
M,W87\@W'4];-4=9]\[QBQ%M4=!N';NVMQY5;?6/[G[C;,;_X&Y)_I[Q&YK]K
M_?+EJ2XEV3EO9^9-N4$J8+E]ONC_ $6MI_%@)I^)+H:C6D2#KH%RM_>>WLEO
M'%S?[8[>U]P+P3W$$9^>G3<$?ZL](W;7\C;[.M$F]^R^T]R4 /JQVU=J[1VC
M/)<>D/F*K*[C94O]=,0X_/T]P]N,7WE67PMK]@)8)^&J2=)U_8DL8_/50>?0
M@W?^\B-Q 4Y=Y0V6SN?]^7-S=72C[(EB@J1\VSZ=6A?'_P"#&W.F<%+MCKG9
M&*ZSP61G@GW'EJZL;/[TW144=E@K,_EY)ZG(9B2%6;[>*6>&EIB;QP@?4/[3
M]U;[PGNQN]KN7N1=1;1MR,5!G:.1XDJ-0M;*V9HP7%>Z66,D@%]8P<,_=+[R
M6[>X.YKO7-O,<^\[G$A6"-$\"TME;)2"(*J1 FFME1I)*=SGRL3VOMC%[1P]
M/A<3&4IX2TDLLA#3U=3);S550X URRE1_@J@*. /?33VV]NN6_:SE.PY0Y7M
MRMC#5G=J&2:9J>)-*P J[T'  *H5% 50!BEO.\7N^7\NX7SUE;  X*HX*H\@
M/YFI.3T!GRV^-&W?EST;N3HW=.Y=P[1Q.X<IM7,MG=L?P\Y6EK=G[EQ>ZL;&
M$R=)6TLE'4Y#$QQU"Z%=H68(Z-9PMYZY;N>;>6-QV2ROH[:]DTM'))&98P\;
MAT\2,/&S(64!@LB-0G2P/4D^QGO!NWL5[D;1[D;+M%K?7]I#<Q"&XU^&R75O
M);2&L;(P=4E9D-2 X!966JFIWJ+^3YCN@^W=J]J;5W/VANO,[%JLI+BZ3*Y+
M8*[;RIR^'K,/,U4(XL9E_'%35[,HM&PE4 W7Z\V^?O;#[T6]V&_\FO[5;=<;
M9,57ZJUN[<*ZHZR*T0N;N.0 D ,)8E([@ 0 QS>Y\^_K>>Y_(F]\D[SLVS6-
MAN21B1XX[TW$?A2K* M3)%ED /Q=I)%#PNFZ?P&8VULFEQ>=HFQ^03(96=Z5
MYJ:=DBJ*V62%C)233P'7&00 Q(!YL>/>8GW4^2.:_;WV>VWEOG3:&L=^2_O9
M&A,D4A"2W#O&=4$DL9U*0U Y(K1J&H'/7GO=+'=^89KW;KCQ;4Q1@-1AE4 (
MHP4X..'V8Z%#WD?T#>O>_=>Z][]U[JASO_\ DI[$[([/[ [2I.S^VZRI[+WA
MN'>&6Q&/JMBTYP]?N.MEKJJDH3D,-11S8NF>8I 7D,Z(JAS(UW]X1>\GMY[V
M[=OUSO?MOR_M>_;7=SLYB=_I[J!V.JC&2>."6*M:.K1R*  8W)U]=,?:_P#O
M#^9N4>3>5^2Y^3=BCAVBP@M8Y76\/BI H17?PY6(D8"KT 4DDJ$';T?[XM=!
M[DZ-H^OMER8_*R;8Z_V)_<W'9S,UV"J,G6P4,--#1SY*/$UCQFMJ0C%S%$L8
M(_'N,?NZ>S?O-R[[^R^X?/G(C;;MES:7YD=;BSEC26<PE$58KF66C:6 .DTI
MW$5ZQ=]Y_<[:O<BXYJYA6ZA&\[KN?U<D,2S"-&<L76,RJ#H6HIJ8M3C7H\OO
MI7UCAUK\=N_R-.O]R[OW=NG&]I]R95-\;AW'N*MIJ2KV#!58RKW'D:O)U<"F
MOPN/IY:6*:M98F!+Z5 9;^HX)>ZWMU[Z[%O[W_MWRSM7,.RW,SR ,XMKJ%BV
MLK,)KB*&136BR1.K&E&B7XFZD\B_WDG-6S[#L6R7?)7+\+;;:P0(S+>E9%MX
MTC4]DLC!B$!8'%34&F!:9\<^I=T=85.'Q64Q=93X7;G7F/V9C\C75N)J*NM7
M"K@*&BEJX\;5SJ*NIH\69)"J+&'N!86'L)?=1]F/=KD;W?YDYPY]Y-;;=LO-
MHNT#_46DJ^//>6<XC58+B9Z:8Y""PH H!-3UA5[K\\[/SE%?WUG>(VX7>ZO=
MNB+*JJ93.[A3(H.E7D 4$EJ<:GHW?OHUU!?5>?SA_ES=2?-N;:6XMS9G<NQ]
M^[)HZ_&8_=.T)<;!4YS UK"I&VMQQ9+'Y&"KQ])D :BDE55GI99)-+&.66-X
MF]U?;^_YQVOZSEN>UAYLMD;P3<(SP2CCX,VAE=5+?#*I8QDDZ'4LARI^[C][
M'GK[NB;[M6S;?9[CRSN+I(]M="0K#,G;]1 8W0J[IV2J24E54J Z(ZD_^.O\
MK>/XO]@9CL'9-=V9NK,93:.4V//2;KR^Q'PRXS(Y+'Y&6NI%QG\.K?O5FQB"
M,N0FAFU+>UN<?/WM/]Z+GC;AR_N7M%;I907@E62WNK.KM&'0$>+>U\-@U15%
M:E,+D=3S[L??1D]YN5K#E7F.UV>RL8;^.\#6T5Z)?$2-T"-XFM-%)#JH*U H
M:5K=#L6@K<7L_;F.R-.U)7T6)I*>KIG>*1H9XH]+H9())87((^JL1[Z4>S&R
M;MRU[4\@;!OU@UKO-GMD,4T19&,<B+1E+1LZ-0^:LP/D3USXYDNK>]W[=KNU
ME#VTD[,K $5!.#0@$?F!T33YV_ _:?SBV_L+&[DWSN[9E5UOELUF\+_=EL0*
M?+5&:QJ8NII<M_%,;D'6..G4F%HBFB0W8.OI]HO=[DGF'G'88?ZJ7EI'O]HS
M/$ETCM!-J6AC=HV5XB?PR .%/Q1L#C('[M/WF-\^[ANO,UYL_+=AN$.[P10R
M_4"75$L4AD5HO#D05+'N#5JN!I.>B;?&S^6-4?%K=&\-U;+KNQ-VUV[]K4VT
M*^EW;D]B#'TU#C\VF<AKL?\ PN6BJ#5S5,00^2Z^(_I#>^;ON![/?>AY]L+7
M:=R]GX(H;2XDD5[>\LOU&*&+_1+[X".Y>U6X5 X=3][O??&B]ZMEV#9>8K;:
MK&WL+UKI&M8[S6SO$82DGBAUT!37MSJ\Z=72[;IJBCV]@Z2KB:"JI<3CZ>HA
M9HW:*>&EBCEC9XGDC8HZD75B#^#[ZE^WNW7VT<A\F;5NEL8=RMMKMHI8R58I
M(D**ZED9D)5@15693Q!(SUSVW>:*XW3<9X'U0O.[*<BH+$@T(!R/4 ]$E^<'
M\O[JOYP8S9<F\,UN79F\.OI\H=O;MVC+C(:^JQ&9AC&3VOFTRF-R4-9A*BMI
M:>K30L<]/4P QN$DGCE(_<WD.XYSVE'V>XMX.9+8,8'F1GA8-\44P1E?0Q (
M9#J1@" P+*V17W<?O1\[?=QO.8DV#;[/<-AW58_'M;H2%%EA)\.XA,<D9694
M:2(U+(\;D,I98V2O_I?^4A6?'GM7;_:O7>_^Y7W!MF2LI9:2JR77;;?W3@ZY
M!%DMO9F-(J&NEQ-<R1S(Z".>"HACEC*NH]\\>;/;G[T>_P!C?\O7?LY8O"LR
M-%<V]Y;JT4\+AXKJV>6\C8.C+5&>-20>Y!PZR@]POOT0^ZO).Z<D\U\K\OC:
M[Q58,L=\)[:9,QSQ$EU$J592#J1XV='JK=6%_*;XK9'YL=#X3JKL'=N\^K9,
M5NK%;IS,&UY=M3Q[NKMNTM?'B*3*S5%+F8UPXR%7%D%2(Q21UU+"S:ECTMF3
M%MGN[[A^SVVV/,6U1;-[D6K#QHKLQ3VUX\*D*^NSG;PTF)60$$M#**-$ZJ*X
MK^ROO7:_=V]S-QYVY7V+;]Z6:RDMHC<"<&U2=D,K1!6B/BZ%: EM2M#)(!1F
MJ*[.F_Y/N%Z0[5VIVKB,EV?O',;%J\C6X+%;FRO7PV_)EJG'U6+I,Q,M */(
M/-B4JGGI>4M*59AQ;WAGS?[=_>MYEV;>.6)O:*UCLK@A'F@O+/4R(X8B/Q;X
M=DND5+(K%3E5)(&5ON#]_7<O<CDC>^2-PL]FL-OW)(UFEMX[[QQ&KK(\0UZD
MI*5"2'-5J <UZN>Z9V97;0VQ.,Q2?99K*Y":JK:=I*>9Z>"G I*& S4LU1 X
M,,1E]+$!IB/K?WEM]TCVCWGVI]NKY>:]K^DYNW._DFGB+12-%''^C;QF2&26
M-AX:&;M<Z6G8'->N?//_ #!;[]O$1L)O$V^"(*C48!F/<[48*1DZ<C@HZ%[W
ME1T!>J\OG3_+OZV^;[[%SFY=S[KV9N[KJCS^.Q.3VK-B(5S>(STF.JIL/G/X
MGB<FS0T==C5EI)(]!@>::X<2&T/^[W(>^\W[3%><HSV2<TVBOX2W2N8)E:A,
M3O&0\1U*"DH$@2K:HW!QE5]VO[UO-_W<EYEVW9]GL=PV/=I())8[D2GP98 Z
MB6'PY(Z%TD*RJU=86.A4H*E"^-_\L&N^+6_LKV!U[G^V,W7YC;=1M;)X?<^8
MV"^ KJ0Y"ERE!D6BQWV-6N4PV0HUEI9;^@.ZE;,??.OG3VN^]-SG96FWW?M!
M!;RVEXMQ!<6]W9B6.2.H4H9+TT4X.4!JJFE1U.ONW]\F#WIY8LN5^:MKV.WM
MK>\6YCEMHKT3HVAHWCK)K4Q2QN5D6F:*:U'5@_RN^+&+^:G0N-ZIW]N#=/7<
MHSVV]Y3U6VGPD]?#G-OQ5B)CJQJVBRE'/C)Y:UV?P&.0E4*N!J5NBNY;)S;[
MA>UNSP;E;IM'.SV\,LL-P%N(X[I%I)'+]/( T9;51X9, JPK0J<6_9'WJO?N
M\^YMWSMROM=ENJ?37%JJW F"&&<K61-#QN) $ &NJY8%3@BGNH_D5;5AFEA3
M?7=54L;Z!44V3ZT^WFTBQD@-324M08F/TUQHW]0/>$-[RI][&SO+FUB]F]KN
M8XV*B6*\@\*2GXH_&O(92IX@R11MZJ.L]H_[RO?)8TD;EGEU"PKI:/<*CY'2
MS+7[&(^?6'_AB[;'_/9=X?\ GSZM_P"C/:;^KGWM/_"'V/\ V66?_>PZM_R<
MGWO_ *9_EO\ YQ[EU[_AB[;'_/9=X?\ GSZM_P"C/?OZN?>T_P#"'V/_ &66
M?_>PZ]_R<GWO_IG^6_\ G'N71L_C'_+OR'Q8Q^^<7L]-[[KA["R^WLGF:K>.
M4V3]QCQM^@J\73TV-_@U52**:>"ODDEUAGU@:;>X[Y\]COO,>Y%QLK;[[1I;
MP6JO%2&\L,QS.ID9M5\34 &FGR^?4&^\?WK+;WKNN6[S?_W;8OM4$\<2VL=Y
MI?QW61FD\56.H,@5:4&DFM3T:SYR_"7'?-;8NRMGYOL7>6R,9L?.3;HAP>U_
MX"E#N+,'%38JB;+U.4Q.2JHVQ--5S_;>)UB$DQ:17*H4Z1^[?)O.7,W*-E;<
MDW%BF[V8UK;78?P)V$>D1F:-M<++D(^F1*GO0BC"%?NW?>*NON\<R<P[]MW*
M>W[C=[E;"V,UQXQ>"+Q!(_A+'(BGQ65/$U*6TK12H+!B%?'_ /E.T'QU[-I.
MU-MU'96[]PXO"Y["8BEW;EMA+B<:^?IDH*S-TZ8F2CJGRD..$D,!9@B+.Y(O
M;WSYYS]L?O5<Z;)/R[>>T,%O823([O#>66MQ$Q94.N_/Z;-1B* G2 :=9->Z
M'WX;OW8Y/GY)WB':+#:Y[F&65[6.]\200,72)C(&41F32[T%3H4<*]7,=3[3
MGVALZCH:^G^URU;//DLK"7BE:*IG*QQ0-)!)-"QIZ.&)#H9EU V)O[SG^[![
M7WOM5[4;7M&]V!M^:+V:2[O4+([)-)1$C+QL\9,4$<2'0[+J#$$UJ>?O.^^1
M;]O\]S:RZ[*-1'&:$549)H0#W.6.0#0C'0E^\AN@AU6A\Z_Y:O6WS4W'M'L+
M,;JWCL[>VR]MY#:RMM2HPE/3;IP53D8\O0T68.7Q.19:K!UK51H9$>.-!7U
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M]1-!-63N7UL"3<RCN/-G*NQ1".]WBUB5!I$:,'84'PB./45]!4 #UZQAY?\
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MIIV9HB8G4 %0205!^*F:4X'UQY]<?DIOW([GVW\+_DG+U+WCB]B==?),;V[
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M\KAG;^6I\!6=F=S\./CCJ9F+,3_HCVI]6:Y/MCFT4YIYB X?73?]7&ZMM/\
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M3PTE'3P4M+31)#3TU-%'!3P0QJ%CBAAB58XHHU%@J@ #Z>VB2Q)8U)ZL
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..[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20201231_g11.jpg
<TEXT>
begin 644 biib-20201231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
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M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
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M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
M?4:&U9;]:XIYSY4?;0)KF9-I;F=<19';;[]+O)![<08YOH^!<B<E>(]V<L@+
M+I$8<D4  (  @ "&()5(<]MX[I.(=*5JTI'9=61;>Y!1=AY+#([U=M0Y+HWZ
M=W0E#HW4=[L+'([(=WT  (  @ "%2).P?!9W_I'\?$QIS)!=?'-:IH[:?)=*
M2XV,?, XD8R4?.4DG(Q8?.8+ 8R\?0P  (  @ "$;Y)=A%EW*I"QA =H^(\8
M@Z%9QHV:@S%)J(Q!@LDX!8M1@H<D.(K^@F<*[8KQ@>X  (  @ "#NI%'C,AV
M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
M@ "#)I!TE41U\8[=D_!GO(T[DF)8AHNHD,5(:XI-CV@W%(E"CI@CGHBRCL8*
MQH@=ATD  (  @ ""L8_6G<YU=HY"G 5G.HR7F>]8!(KVE\Q'ZHF3EAHVCXB,
ME6LC-(?IE!4*MH<0ASX  (  @ ""6H]DIH1U%HW.I%MFRXP7H<=7D8IGGR]'
MA(CWG5(V/(?EG' B[H<YEYX*E89&AR@  (  @ !ZD**E8G!N$Z F9)5@JYWN
M9J!2()OG:(I"6)H>:DXPXIC^:\,<@9G!;#\#WYBA;+X  (  ?]!Y_*%!:GMM
MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
M>A^,'7,;:K5^O70);'EP>W3C;AU@Y76[;Z)0,G:/<1(^&G==<ETJ"W?M<T40
M/7D0<LL  (  ?;6*U7"3<[)]:W&H=,!O*7*A=:U?Z'.-=H=/3W1Z=TL]9W5/
M=_LICG6]>&D0 W;L=_   (  @ ")DVYK?*Y\4&^9?19N"W"I?5=>N'&E?7I.
M77*>?9H\BG-]?;HHW7/&?<,/H74E?9X  (  @ "(B6RDA;9[1VWCA7IM#F[_
MA0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH  (  @ "'LFLLCKIZ
M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
M@ "'#&H"E[EYS6M8ED1KE6Q\E(%<76V)DJE,(VZ.D0\ZJF];C_8G@&\GC^P/
M '%0BB4  (  @ "&EVDDH+-Y3VI_GK1K"FN>G%%;T&RAF=Y+IVV=E](Z16Y?
MEJXG%6X)E64.IW"1B>@  (  @ "!UX&+6%UU6(%86Y=GQH%:7J%8[(%]87=(
MP8&X9!LW X(G9G$BT8,=9_@(YX2D9]\  (  >7. RWZV8.)T:'[*8U]FU'[M
M9;58%W\>9^=("W]@:?(V<'_*:[DB9X"$;,D(WX'I;)H  (  ?09_NGP-:5US
M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
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M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
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M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
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M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
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M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
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MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
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M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
M@ !RLTYPDIIG+5'MD:):L%3UD$M-+U>"CN(^F%EAC=(NBEF4C7D<0%N>C1D&
MG733A'D  (  @ !PT7%S3>)E!G*34:18>'/-555*T74&6-X[S78M7" JYW=#
M7MD6G7@P8!8 IW[F8EH  (  >-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[
M#7)J8= J4G-:9 ,60W0)9-< SGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC
M8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@
M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
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MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
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M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
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MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
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M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
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M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
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MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
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M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
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MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
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M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
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MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
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MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
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M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
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M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
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M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
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MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
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M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
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M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
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M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
M '_? @!Y_Q$!;_\9 F?_(@1@_RP'6O\T#%3_/ ]/_T,32O])%4?_3Q=#_U49
M0/];&S[_81P[_V8>.?]M'S;_=" T_WTA,?^&(R__D20M_YLE+/^E)BO_KR8J
M_[LG*?^^)RG_OB<I_[XG*?^^)RG_OB<I_[XGIK8  )C"  "+S@  ?ML  '7Y
M!P!K_P\!8O\6 EO_'@-4_R8%3O\N!DG_-0A%_SP+0?]##3[_2 X[_TX0./]3
M$37_6!(S_UX3,?]D%"[_:A4L_W(6*O]Z%R?_@Q@E_XX9)/^8&B/_H!HB_ZH;
M(?^M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;FKX  (O*  !^UP  <.,  &?_! !>
M_PT 5O\2 4__&0))_R #0_\G!#__+@4Z_S0&-_\Z!S/_/P<P_T0(+O])"2S_
M3@DI_U,*)_]8"B7_7@LC_V0+(?]L#!__= T=_WT.&_^'#AG_CP\8_YD/&/^;
M$!C_FQ 8_YL0&/^;$!C_FQ 8_YL0_TPJ _](,P7_3S0&_U0W"/]:00[_7$H6
M_UI4'?]78"3_5&LJ_U!X+_]-A#/_2H\V_T>9.?]&H3O_1:D\_T2P/O]#MS__
M0L __T+)0/]!U4'_0>1!_T'N0O]!]D+_0?U"_T+_0?E$_T'T1O]"[T?_0N]'
M_T+O1_]"[T?_0N]'_T+O1_]"_TTI _]*,@3_43(&_U<V"/]</P[_7DD6_UU3
M'?]:7B3_5VDJ_U-U+_]0@33_38TW_TJ7.O](GSS_1Z<]_T:N/_]%M4#_1+U!
M_T3&0O]#T4+_0^)#_T/L0_]#]4/_0_Q#_$3_0_5'_T/O2/]$ZTG_1.M)_T3K
M2?]$ZTG_1.M)_T3K2?]$_TTI _],, 3_5#$%_UDT"/]?/0[_84<6_V!2'?]=
M7"3_6F<K_U9S,/]3?S3_3XHX_TV4._]+G3W_2J0__TBL0/](LT'_1[M"_T;#
M0_]&SD3_1=]$_T7J1?U%\T7[1?M%]T;_1/!)_T7J2O]&Y4O_1^5+_T?E2_]'
MY4O_1^5+_T?E2_]'_TXI _]/+@3_5RX%_UTR!_]C.P[_9486_V50'?]A623_
M760K_UIP,/]6?#7_4X<Y_U"1//].FC__3:) _TNI0O]*L$/_2K=$_TG 1?](
MRD;]2-M&^DCG1_A(\D?U2/I&\4G_1^I+_TCC3/])WDW_2MY-_TK>3?]*WDW_
M2MY-_TK>3?]*_T\H _]2+ 3_6BP%_V$O!_]G.@[_:D05_VI.'/]G5R3_8F$K
M_UYM,?];>#;_5X,Z_U2-/?]2ED#_4)Y"_D^E1/Q.K47[3;1'^DR\2/E,QTCV
M2]1)\TOE2?!+\$GM3/E(Z4S_2N%._TO:3_],TU#_3=-0_TW34/]-TU#_3=-0
M_TW34/]-_U H _]5*@3_72D%_V4M!_]L. W_;T(4_V]+'/]L52/_:%XJ_V-I
M,?]?=#;]7'\[^UF)/_E6DD+W5)I$]5.B1O12J4CR4;%)\5"Y2N]/PTON3\]+
MZT_B2^=/[DOD3_A-WT_^3M51_T_.4O]0R5/_4,E3_U#)4_]0R5/_4,E3_U#)
M4_]0_U$G _]8)P3_82<$_VHL!O]Q-@S_=$ 3_W1)&O]R4B+_;ELI_6AD,/EE
M<#;V87L[\UZ%0/!;CD/N699&[%>>2.I5IDKH5*U,YU.U3>53OT[C4\Q.X5/?
M3MU3[4_84O=1T5/]4LI4_E/$5O]3OU?_4[]7_U._5_]3OU?_4[]7_U._5_]3
M_U(G _];)0/_920$_VXJ!O]V- O_>CT1_WI&&/]X3R#[=%@H]F]A+_%K;#;M
M9W8\Z6. 0.9@BD7D79)(X5N:2M]9HDW=6*I/VE>R4-A6O%'55<A2TE7;4\Y6
MZU/+5O95QE;]5K]8_5:Z6?U7MEK]5[9:_5>V6OU7MEK]5[9:_5>V6OU7_U,F
M _]?(@/_:2$#_W,H!?][,@K_?SL0_X!$%OM^3![T>U0E[G9=+>EQ:#3D;7([
MX&E\0=QEA4;88HY*U%^63=%=G5#.7*52S%JM5,E9ME;'6<)7QEG05\)9YEB_
M6?-9NUK[6;5;^UJP7?M:K5W[6:U=^UFM7?M9K5W[6:U=^UFM7?M9_U8D _]B
M( /_;2 #_W<F!/]_, C_A#D-_89!%/6%21ON@E$BYWU:*N%X9#+<<VXZU&YW
M0=!J@$?,9HE,R&214,5BF%/#8*!5P%ZH6+Y=L5F[7;Q;N5S)7+=<X%RT7>]<
ML%[Y7:M?^5VH8/E<I6'Y7*5A^5RE8?E<I6'Y7*5A^5RE8?E<_U@B _]E'@/_
M<1\#_WLD _^$+@?_B38+^(L^$>^+1A?HB$X>X817)ME^83'1>&HZRW-S0L9O
M?$C";(1-OFF,4;MFDU6X9)M8M6.C6K-AK%RP8+=>KF#$7ZQ@V%^I8>M?IV'W
M7Z)C]U^?9/=?G63X7IUD^%Z=9/A>G63X7IUD^%Z=9/A>_UL@ O]H' +_=!T"
M_WXC _^(*P7]C30)\Y [#NJ00Q3BCTH:VHI4)="#73#)?F<ZPWAO0KYT>$BY
M<8!.M6Z(4K)KCU:O:9=:K&>?7*EEJ%^F9+)AI&2_8J)DT&*@9.=BGF7U8IIF
M]6&89_9@EFCV8)9H]F"6:/9@EFCV8)9H]F"6:/9@_UT? O]J&@+_=QP"_X(A
M O^+*03YD3$'[Y4X"^:6/Q#=E$<7THY1),J(6R_"@V0YO'YL0;=Y=$BR=7Q.
MKG*$4ZIOBU>F;9-;HVN;7J!JI&"=:*YCFVBZ9)EHRV67:.-DE6GS9)-J]&.1
M:_5BD&OU89!K]6&0:_5AD&OU89!K]6&0:_5A_U\= O]M& +_>AL"_X4? O^.
M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
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M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
M/>HN #KK-@$X[#X!-NQ& C/M30,Q[54#+^Y=!"WN904K[G %*>][!BCOB0<F
M\)<')?"G""3QN @C\<P((O+E""+P\P@B[_4((N_U""+O]0@B[_4(GJ8  )&O
M  "$N   =\$  &K)  !=T   4=<  $;=   _Z@4 //8. #GV%P V]R  ,_<H
M #'X,  N^38!*_D] 2GZ1 $G^DH")?M2 B/[6@(@_&,#'OQN QS]>P,;_HD$
M&?Z8!!C_J 07_[<$%O_(!!;_X 06_^0$%O_D!!;_Y 06_^0$DZX  (6W  !X
MP   :LD  %W2  !0V0  1-\  #KD   U]P, ,O\, "[_$@ K_QH */\A ";_
M)P C_RT (/\S ![_.0$<_S\!&?]% 1?_30$5_U4!$_]? 1'_:@(0_W@"#O^'
M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
M_PY' ?\-4P'_"U\!_PIK ?\*=0'_"G\!_PJ' ?\*C@'_"I4!_PJ; ?\)H '_
M":4 _PFK /\)L0#_";@ _PG! /X)S #\"=X ^0GK /4)]@#S"?\ \@K_ /$*
M_P'Q"_\!\0O_ ?$+_P'Q"_\!_Q\C /\?(0#_'B$ _QDD /\7+ #_%3< _Q-$
M /\14 '_$%P!_PYG ?\.<@'_#GL!_PZ$ ?\.BP'_#I(!_PZ8 ?\.G0'_#J,!
M_@ZH ?P.K@'[#K4 ^@Z^ /@.R0#U#ML \@[J .X.]0#L#O\!ZP__ >H/_P'J
M$/\!Z1#_ >D0_P'I$/\!_R(? /\B' #_(1P _Q\@ /\?*0#_'#0 _QI  /\7
M3 '_%5@!_Q1C ?\3;@'_$W<!_A.  ?P3B 'Z$HX!^1*5 ?@2F@'V$J !]1*F
M ?02K 'S$K,!\1*\ ? 2QP'M$M@!Z1/H >83]0'D%/\!XA3_ N$5_P+A%?\"
MX!7_ N 5_P+@%?\"_R4; /\F%P#_)!8 _R4< /\F)0#_)#  _R$[ /\?2 #_
M'50!_1M? ?D::0'W&G,!]!E\ ?(9A 'Q&8L![QF1 >X9EP'L&9T!ZQFC >D9
MJ@'H&;$!YQFZ >49Q0'C&=4!WQKH =P;]0+8&_\"U1S_ ]0<_P/3'/\$TAS_
M!-(<_P32'/\$_RD7 /\J$P#_*1( _RP8 /\L(0#_+"L _RDW /TG0P#W)4\!
M\R-: >\B9 'L(6X!Z2%W ><A?P'E(88!Y"&- >(@E 'A()H!WR"@ =X@IP'<
M(:\!VB&X M@APP+5(=,"T2+G LTB] /*(_\$R"/_!<<C_P;&(_\&QB/_!L8C
M_P;&(_\&_RP2 /\N#P#_,!  _S,4 /\S&P#_,B4 ^C P /(N/ #L+$D YRI5
M >,J7P'@*6D!W2ER =HH>@'7*(("U2B) M,HD +1*)8#SRB< \XHHP/,**L#
MRBBS \DHO@3'*,P$Q2GB!,$J\0:^*OX'O"K_"+HJ_PBZ*O\(N2K_";DJ_PFY
M*O\)_S / /\R"P#_-@T _S@0 /\Y%0#Y-QX [S4H .<S-0#@,D( VS)/ -4Q
M6@'0,60"S3!M LLP=0/),'P#QR^#!,4OB@3$+Y$%PB^7!<$OG@:_+Z8&O2^O
M!KPON0>Z+\<'N##=![4P[@FR,/L*L##_"ZXP_PNN,/\+K3#_"ZTP_PNM,/\+
M_S,, /\V!@#_/ D _SX, /T]$ #O/!4 Y#D? -LY+0#2.CP S3I) <@Y5 '$
M.5X"P3AG [\W;P2]-W8%NS9]!KDVA >W-HL'MC62"+0UF@FS-:$)L36J"J\U
MM NN-<$+K#74"ZDVZ@RF-O@-I3;_#J,W_PZB-_\.HC?_#J(W_PZB-_\._S<'
M /\[ @#_0 , \D(% .E""0#E/PX V#X6 ,Y )P#'038 PD%$ ;U!3P*Y0%D#
MMC]A!+0^:0:Q/7$'KSUX"*X\?PFL/(8*JCN-"ZD[E0RG.YT-I3NF#:,ZL ZB
M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
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M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
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M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
M7T5' %U%30!;150 6D9; 5E&8P%71FP!5D9V E1&@0-31HX#4D><!%!'JP10
M1[T$3T?6!4]'[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+
M  !_2@  >$8  '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T 64E$
M %=)2@!625$ 54I9 51*80%22FD!44IT D]*?P-.2HP#34J;!$Q+J@1+2[P$
M2DO3!4I+[@1+2_T$2TK_ TM*_P-+2O\#P4@  +)0  "@3P  D4\  (5.  ![
M30  <TD  &Q*  !G2P0 8DP. %],%P!<32$ 6DTJ %A-,@!633H 5$U! %-.
M2 !23D\ 4$Y7 4].7P%.3F<!3$YR DM.?0))3HL#2$Z9!$=/J 1&3[H$1D_1
M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
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M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
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MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
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MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
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M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
MDF;2@Y-ETH649-&'E&/0BI5BT(Z68M".EF+0CI9BT(Z68M".EF+0CI9BT(Z6
M8M".EF+0CI9BT(Z68M".EM'"!@'-RPD%NMH'&:C^#C&9_QU#CO\O487Z/UQ^
M]$UD>?!8:G/L7V]MZF-S:>=I=F?E;GEEY')[8^-V?6+B>7Y@X7Q_7^!^@%[?
M@8%=WX."7-Z&@UO=B81:W8V%6MV-A5K=C85:W8V%6MV-A5K=C85:W8V%6MV-
MA5K=C85:W8V%6MV-A<O$!@"[T08'J><&&IK_$RN._R0YA?\V1'[_1$UY_U%5
M<?M76VOW76!E]&)D8O)H9U_P;6I=[W%L6^UU;5KM>&]9['MP6.M^<5?J@7)6
MZH1R5>F'<U3IBG13Z(YU4^B.=5/HCG53Z(YU4^B.=5/HCG53Z(YU4^B.=5/H
MCG53Z(YU4^B.=;S)!0"KVP$(FO\+%H__&2.%_RLM?O\Y-WC_1D!P_TY':?]4
M36+_6E)>_F%66OQF65C[:UM5^7!=5/AT7E+W>%]1]WM@4/9^84_U@6)/]81C
M3O2'9$WTBV5,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,
M\Y!F3/.09O^@& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-
MAZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJ
MO,!XKKS =[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[
MO'BTN_^@& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-AZ+,
MC(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!X
MKKS =[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BT
MN_^@& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-AZ+,C(VJ
MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
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M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
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MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
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M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
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M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
M (S9  "!]0, >?\0 6[_%@-E_Q\&7O\G"U?_, ]1_S<32_\^%T;_11E!_TP;
M/?]2'3G_6!\V_U\A-/]F(C'_;B0O_W<E+?^ )BO_C"@I_Y<I*/^B*B?_K2LF
M_[DL)O_)+2;_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+:JW  ":Q0  B],  'WB
M  !U_P4 :?\, 5__$0)7_Q<#4/\?!4G_)@=$_RX)/_\V"SO_/0TW_T,/,_])
M$3#_3Q(N_U43+/];%"K_8A4G_VD6)?]R%R/_>Q@A_X89'_^1&A[_G!L>_Z4<
M'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@  ?-X  '#U  !E
M_P  6O\& 5'_#0%)_Q$"0_\7 SW_'P0X_R8%-/\M!C#_,P<M_SD'*O\^""?_
M0P@E_TD)(_]."2'_5 D?_UH*'?]A"AO_:0L9_W(,%_]\#1;_A@T4_X\.%/^:
M#Q3_F@\4_YH/%/^:#Q3_F@\4_YH/%/^:#_]<' +_5R8#_U$R!O]./ C_5T40
M_UM.&?]<6"+_6V,K_UEO,O]7>CC_5(4]_U*00?]0F47_3Z!'_TZG2?]-KDO_
M3+1,_TN[3?]*PT[_2<U/_TG=4/](Z5#_2/)0^TGV4/9+^5#P3?M/ZD_[4.=/
M_%#G3_Q0YT_\4.=/_%#G3_Q0YT_\4/]<' +_6"8#_U(R!O]1.@C_6D,0_U]-
M&?]?5R/_7F$K_UQM,_]9>3K_5X0__U2.0_]2ET?_4)])_T^F2_].K4W_3;1/
M_TR[4/]+PU'_2\Y2_TK?4O])ZE/]2O)3^$OV4_%-^%+K3_I2Y5#Z4^)1^E/B
M4?I3XE'Z4^)1^E/B4?I3XE'Z4_]=&P+_628#_U,Q!O]4.0C_74(0_V)+&O]B
M52/_8%\L_U]K-/]<=SO_68) _U:,1?]4E4C_4IY+_U&E3O]0K$__3[-1_TZ[
M4O]-Q%/_3,]4_TO@5?]+ZU7Z3/)5]$WV5>Q0^%3F4?A5WU+Y5MQ3^5;<4_E6
MW%/Y5MQ3^5;<4_E6W%/Y5O]>&P+_6B4#_U0Q!O]8-PC_84 1_V5)&O]F4R/_
M9%TM_V)H-?]?=#S_7']"_UF*1_]6DTO_5)Q._U.D4/]1JU+_4+-4_T^Z5?].
MQ%;_3=!7_TWB6/Q,[5CV3O)8[E#U6.93]EC?5/=9UU7X6=-5^%G35?A9TU7X
M6=-5^%G35?A9TU7X6?]?&@+_6R4#_U4P!O]<- C_93T1_VI'&O]K423_:5HM
M_V9D-O]C<#W_7WQ#_UR'2?]9D4W_5YI0_U6B4_]3JE7_4K)7_U&Z6?]0Q5K_
M3]);_$[D6_A/[5SP4?);YU3T6]Y5]5S55O9=SECW7<M8]UW+6/==RUCW7<M8
M]UW+6/==RUCW7?]@&@+_7"0#_U8O!?]@,@C_:CL0_V]$&O]P3B/_;U<M_VMA
M-O]G;#[_8WA%_V"#2_]<CD__6IA3_U>@5O]6J5G_5+%;_U.Z7/Y1QE[\4-9?
M^5#G7_)2[E_G5?%?W5?R8-)8\V'+6?5BQ5OU8L-;]6+#6_5BPUOU8L-;]6+#
M6_5BPUOU8O]A&0+_72,#_UHM!?]E+PC_;S@0_W1!&?]V2R/_=50M_W%=-O]L
M9S__:'-&_V1_3/]@BE+_7956_UJ>6?]8IUS^5K!?_52Z8/Q3QV+Y4MQC\U/H
M8^E5[F/>6/!DT%KQ9<A<\F;"7?)FO5[R9KM>\F:[7O)FNU[R9KM>\F:[7O)F
MNU[R9O]B&0+_7B,#_UXJ!?]I+0C_=#4/_WH^&/]\2"+_>U$L_WA:-O]S8S__
M;6U'_VEZ3O]DAE3_8)%8_UV<7/U:I6#[6+!B^E:[9?A5RF;U5.!G[%;J9]]:
M[6?07.]IQEWO:K]?[VJY8.]JM6'O:K-A[VJS8>]JLV'O:K-A[VJS8>]JLV'O
M:O]C& +_8"(#_V(G!?]N*@?_>3(._W\\%_^"1B'_@D\K_W]8-?][8#[_=6E'
M_V]T3OMJ@57X9HQ;]6*77_-?H6/P7*MF[EJV:>Q9Q&KI6-IKX5KJ:]!=[&W%
M7^QNO&'K;[9B[&^Q8^QNK63L;JMD[6VK9.UMJV3M;:MD[6VK9.UMJV3M;?]D
M& +_82(#_V8E!/]R)P?_?C -_X4[%O^(11__B$TI_X95,_^"7CW[?69&]G9P
M3O)R?%7N;8=<ZFB28N9DG&;C8:9JX%^R;=U=OV_:7=-PTE[J<,1@Z7*Z8NAS
MLV3H<ZUEZ7.I9NERIF?J<:1GZG"D9^IPI&?J<*1GZG"D9^IPI&?J</]E%P+_
M8B$#_VDC!/]W)0;_@B\,_XHY%/^.0QW_CTPF_XU3,/F*6SKSA6-$[7]L3>AY
M=U7C=()=WFZ-8]EIEVG39J%NSV.L<<MAN73(8<IUQ6'E=KEDYG>P9N5WJFCF
M=Z5IYG:B:N=UGVKH<YYKZ7.>:^ESGFOI<YYKZ7.>:^ESGFOI<_]F%P'_8R$#
M_VT@!/][(P7_ARX+_X\X$O^301K_E4HC^I11+?.163?LC6!!Y8=I2M^!=%/6
M>GY=SW2(9<IOD6S%:YMQP6BF=;UFLGBZ9<)ZMV7=>ZYHXWNG:N-[HFOD>IYL
MY7B;;>5WF6WG=IANYW68;N=UF&[G=9ANYW68;N=UF&[G=?]G%@'_9" #_W >
M _]^(@7_BRP)_Y,W$/^80!C]FD@@])I.*>R853/EE5T\W8]F1].(;U/+@7E>
MQ7N#9K]UC&ZY<99TM6ZA>+!KK'RM:KM^JFK2?Z1LX'Z>;>%]FF_B?)=PXWJ5
M<.1YDW#E=Y-QYG>3<>9WDW'F=Y-QYG>3<>9WDW'F=_]H%@'_9" #_W,< _^!
M( 3_CBL(_Y<U#O^=/A7XGT0<[Z!+)>>?4BW?G5HWTY5C1LJ.;%/#AW5>NX%^
M9[5[B&^O=Y%UJG.<>J5PJ'ZA;[:!GF_*@IMPWH&6<=^ DW+A?I%SXGR0<^-Z
MCG/D>8YSY7B.<^5XCG/E>(YSY7B.<^5XCG/E>/]I%@'_9AX#_W8: _^$'P/_
MDBH'_YLT#/Z@.Q+SHT$8ZJ9((.*G3R?8HE8VS)I@1<.3:5*[C7)>LX9Z9ZR!
MA&^F?8UVH'F8?)MVHX"7=+&#E'3%A)%UW8./=MZ!C7;@?XMWX7V*=^)[B7;D
M>HEVY'F)=N1YB7;D>8EVY'F)=N1YB7;D>?]I%0'_:1T#_W@9 O^''@/_E2@&
M_YXR"OJD-P_OJ#T4YJQ$&MVM2R30IE0UQI]>1+R99E*TDF]=K(QW9Z2'@&^>
M@HIWF'Z4?9)[H(&->JV$BGG A8AZW(2'>MV"AGK?@(9ZX'Z%>N)\A7GC>H5Y
MY'F%>>1YA7GD>85YY'F%>>1YA7GD>?]J%0'_:QL"_WL7 O^*' +_F"8%_Z(P
M"/6H,PSKKCD0XK-!%-:Q1R/*JU(TP*1<0[:>9%&MF&Q<I9)T9IV-?6^6B(9V
MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
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M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
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M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
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M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
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M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
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MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
MP9<I [F4.0NQD$86J8U0(**)6BJ<A6(REH)J.9%_<C^,?'I%AWJ#2H-XC4Y_
M=IA1>W6D5'ATLU9V=,A6=73H575U_5-U=/]1=7/_3W9R_TUV<?],=G'_3'9Q
M_TQV<?],=G'_3/]9$ #_9@< _W,$ .%_ 0#6B 0 SY & ,J6" #$FA( O)LF
M K28-PFLE404I)%.'YV.5RB6BF QD(=H.(N$<#^&@GA$@7^!27U]BTUX>Y91
M='JB5'%YL59O><56;GKF56YZ_%-O>?]1<'?_3W%V_TUQ=?],<77_3'%U_TQQ
M=?],<77_3/];#@#_:00 ]G<  -V"  #0BP, R9,% ,29!@"^GA  MI\D JZ=
M- BFFD$3GY9,'9B352>1D%XOBXUE-X6*;3V B'5#>X5^2':#B$QR@I-0;H"@
M4VM_KE5H?\)69W_C56B ^E-I?O]1:GS_3VM[_TUL>?],;'G_3&QY_TQL>?],
M;'G_3/]># #_; $ YGH  -:&  #+CP( Q)<$ +Z=! "XH@X L:,A :FB,@>A
MGS\1F9Q*&Y*94R6+EEPMA9-C-7^1:SMZCG-!=8Q\1G"*A4MKB)%/9X>=4F2&
MK%1BAK]588;A5&&&^5)CA/]098'_3V9__TUG?O],9W[_3&=^_TQG?O],9W[_
M3/]A"@#_;P  X'X  -")  #&DP$ OYL# +BA @"QI@L JJ@> :.G+P6;I3T/
ME*)(&8R?42*%G%DK?YIA,GF8:3ETE7$_;Y-Y1&J2@TAED(Y,88^;3UZ.JE);
MCKU26H[>4EN-^%!<B_]/7HC_3F"%_TQA@_]+88/_2V&#_TMA@_]+88/_2_]D
M!0#U=   VH(  ,N.  #!EP  N)X! +&E  "IJP< HZT: )RL+ 25JSH,C:A%
M%H:F3Q]_I%<H>:)?+W.@9C5MGFX[:)QW0&.:@45?F8Q)6YB93%>7J$Y5E[M/
M5)?<3E26]DY5E/]-6)#_3%F-_TM;BO]*6XK_2EN*_TI;BO]*6XK_2O]H  #E
M>0  T8<  ,62  "[G   L:(  *FI  "AL0( F[,5 )6S* *.LC8)AK!"$G^N
M3!MXK%0C<JI<*FRH9#%GIVPV8J5U.UVD?T!9HXI#5:*71U&AITE/H;I*3J+9
M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
M +>=  "LI   HJL  )BS  ".NP$ A<$, ('"'0![PBT#=<$Z"6_ 11%IOT\8
M8[Y7'EZ]7R-9O&@H5;MQ+5&[>S!-NH<T2KJ5-T>ZI3E%NK@Z1+K7.4.X]3M"
MMO\]0K/_/D2N_SY%J?\^1:G_/D6I_SY%J?\^1:G_/N!]  #)C0  NYH  *ZB
M  "CJ0  F+$  (ZY  "$P0( ><D' '3+% !PS"8!:\LU!67+0 I@RDL06\I4
M%E?)71I2R64?3LAO(TO(>B9'R(8I1,B4+$+(I"Y R+@O/\G7+S_']3 ]Q/\S
M.\/_-3R^_S8]N/\W/;C_-SVX_S<]N/\W/;C_-]&&  # E0  LI\  *6G  ":
MKP  CK<  (._  !XQP, ;L\' &77#0!CV!T 8-@M EO8.@17V$8)4]A0#4_8
M61%+UV(51]=L&$37=QM!UX0>/MB3(#S8HR$[V;<B.MK5(CK6\B,WU/\G-M+_
M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
M **"  "8@0  D8,/ (V%'P"(A2X"@X0[!7Z#10IZ@4X/=8!6%'%_7AAN?68<
M:GQM(&=[=B-C>H G8'F+*EUXF"Q:=Z8N6'>X+U=WT2]7=_$N6';_+%AV_RI9
M=?\I6G3_*%IT_R=:=/\G6G3_)^U9  #79@  Q7$  +EZ  "O@   IH0  )V&
M  "1AP  BHD, (:*&P""BRL!?8HX!'B)0@ATB$P-;X=4$FR%6Q9HA&,:9(-K
M'F&"="%=@7TD6H")*%=_EBI5?J0L4GZV+5%^SBU1?>\L4GW_*U)\_RE3>_\H
M5'K_)U1Z_R=4>O\G5'K_)^A>  #0:P  P'8  +1^  "KA0  H8D  )>+  ")
MC0  @X\( 'Z0%P![D2<!=I$T W*0/P9MCTD+:8Y1#V6-61-BC& 77HMH&UN*
M<1Y7B7LA5(B&)%&'E"=/AJ(I38:T*DN&S"I+A>XI3(3_*4R#_RA,@_\G38'_
M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
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M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
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M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
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M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
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M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
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M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
M 0(#! 4&!P@)"@L,#0X/$!$2$Q05%A<8&1H;'!T>'R A(B,D)28G*"DJ*RPM
M+B\P,3(S-#4V-S@Y.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!14E-455976%E:
M6UQ=7E]@86)C9&5F9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!@H.$A8:'
MB(F*BXR-CH^0D9*3E)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.T
MM;:WN+FZN[R]OK_ P<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>W^#A
MXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_  $! @(# P0$!08&!P<(
M" D)"@L+# P-#0X/#Q 0$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?(" A(B(C
M)"0E)B8G*"DI*BLL+2TN+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&2$E*3$U/
M4%)355=86EQ>8&)D9FAJ;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&CI:>HJJRM
MK["RL[6VM[FZN[R]O\#!PL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6U]C9V=K;
MV]S=W=[?W^#AX>+CX^3EY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T]?;V
M]_?X^/GY^OO[_/S]_?[^_P ! 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.#P\0
M$!$1$A,3%!05%A87%Q@9&1H:&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK+"TM
M+B\P,3(R,S0U-C<X.3H[/#T^/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B9&9H
M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
MP<+#Q,7&Q\C)RLO,S<W.S]#1TM+3U-76UM?8V=G:V]O<W=W>W]_@X>'BX^/D
MY>7FYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^
M_O__I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)T
MJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_
MI24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K
M=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&
M_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]
MIGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P
M#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"
MMZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F
M.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]
MR[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_
ML4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=
M@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C
M_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.K
MFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+
M,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!
M547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^
MPUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:
M\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E
M<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3"
M;(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7
MNG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9
MS+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)T
MJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_
MI24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K
M=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_IB4&
M_Z0P#O^G.AC_LD,B_[Q+,O_#5$7\QEU:\<AD<>/&:H?6P&^;R[ARK,*Q=+J[
MK7?$M*E[S:NC?]2BGH7;F9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:
MCN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN'_IB4&_Z4P
M#O^H.A?_LT,B_[Y+,?_%5$7YR5Q;[\UC<>/,:8C5QFV<R;]PKKVV<KJTL'7#
MJZIXRJ*E?-&9H8'8D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0
MG8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=W_IB4&_Z4P#O^J
M.A?_M4,B_\!+,?W(4T7VS5M;[=%A<N'09XG1RVN=PL!NK;:W<;BLL7/!HZQV
MR)JH><Z2I'[4B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78
MB:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=C_IR4&_Z4P#O^K.A?_
MMD,A_\%+,?K+4D3ST5I:ZME@<M[698G+S&J<N\%MJZ^Y<+:EM'*^G*]TQ)2K
M=\J+IWO/A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!
MU(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=3_IR4&_Z8P#O^M.A;_N$(A
M_L1*,/?.4D3PUEA:Y^!><M;:9(C$S6F:M,-LJ*B[;[*>MG"ZEK)RP(ZN=L:&
MJGK*?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G
M?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\[_J"4&_Z<P#O^N.1;_ND(@^\9*
M+_3344/KW5=:X^9<<<[;9(>]SVF8KL5KI:*^;J^8N6^VD+5QO(BQ=,&!KGC%
M>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[
MK'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<G_J"0&_Z<P#?^P.17_O4(?]\E*+^_8
M4$+FXU59W.A;<,;=8X6VT6B5I\AKH9S!;:J3O&^QBKEQMH2U=+M]LG>_=[!\
MPG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"
M=[!\PG>P?,)WL'S"=[!\PG>P?,+_J20%_Z@P#?^S.13^P$(>\\U*+>G=3T#A
MZ5-9T^I;;[_?8X*OTV>1H<MJG9;%;:6-P&^KAKUQL'^Z<[5ZMW>X=+5[NW2U
M>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[
MNW2U>[MTM7N[=+5[NW2U>[O_JB0%_ZDO#?^V.!/YQ$$=[=))*^+C34#;[U)8
MRNU:;;?A8G^HUF>-F\]JEY');9^(Q6^E@L)QJ7N_=*UVO7>P<;M[LW&[>[-Q
MNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[
M>[-QNWNS<;M[LW&[>[/_JR0%_ZLO#?^Z.!+SR4$;Y-I)*-CH3$#.\U%7P.]9
M:Z[D87J@W&>&E-1KD(O/;I>$S'"<?<ESH'C&=:-SQ'BF;L)\J6["?*ENPGRI
M;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*EN
MPGRI;L)\J6["?*G_K20%_[ O"_O . _JT$$7VN)&*,SN3$'#^5!5M?-89J7I
M8727X6=^C=MKAH77;XQ_U'*1>M%UE'7/>)=QS7N:;,Q^G&S,?IQLS'Z<;,Q^
MG&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<
M;,Q^G&S,?IS_KR,$_[8M"?'(-@S=W#T3S>I&*L'V2T"V_T]1JO=88)OO86N/
MZ&ATA>1M>W_@<8!YWG2#==QXAG+:>XENV'Z+:]:"C6O6@HUKUH*-:]:"C6O6
M@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"
MC6O6@HW_L2,$^K\L!N/4+P?.YCL6P?-%*[3_23VH_TY,GOU76)'V86&&\6EI
M?^UO;GGJ=')UZ'=U<>=Z=V[E?7EKY(![:>.$?&GCA'QIXX1\:>.$?&GCA'QI
MXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GC
MA'S_M2(#Z\LB M#C)P?"\3H9M/Y"*J;_1CF;_TU%DO]63X;^8E9^^FI<=_=P
M8'/U=6-O\WAE;?)\9VKQ?VAH\()J9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K
M9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6OV
MPAL!U-\1 <+O)@NU_#H:I_\^)YG_1#.-_TL]A?]517S_84MU_VI/</]P4FS_
M=51J_GE6:/U\5V;\?UAD_():8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&
M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
ME:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:
M_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'
M?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA'
M)O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQ
MQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N
M433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>
MM<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_
MKUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)V
MH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y<K"_^7-A+_H3X:_ZI&)?^P4#3_L5I%
M_[!D5_>L;6GLIW=[X9Y]BMF6@Y?1CHFBRXB.J\>"D['$?I>WP7J<N[YWHK^\
M=:K"M7&NP[-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-R
MK\&S<J_!LW*OP;-RK\'_F1\%_Y<J"O^8-1+_HST:_ZQ&)?^S3S3_M%E&_[1C
M6/:Q;&OJK75]WZ-[C=6;@9S-DH:HQXN*L<*%C[F_@)2^NWR:P[EYH<>U=JG*
MK76LQJMVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K
M=JW$JW:MQ*MVK<3_FA\$_Y@J"O^:-!+_I3T9_ZY&)?^U3C3_MUA&_[=A6?6U
M:FSILG-_W:AXD-.??J#*EH*LQ(Z'M[Z(C+^Z@Y'%MW^8R[1\H<^K>*7/I7FJ
MR*1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&
MI'FLQJ1YK,;_FA\$_Y@J"O^;-!'_ICT9_Z]%)?^W3C3_NE=&_[M@6?2Y:6WG
MMG&!W*QVD]"D>Z/(FG^QP).$O+N,B<6WB)#+M(:9SK*&I-&D?*31GWVIRIY]
MJLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJ
MR)Y]JLC_FQ\$_YDJ"O^<-!'_ISP9_[%%)/^Y333_O%=&_KY?6?2]9V[GNF^"
MVK%TE<^H>:;%GWVTOI>!P+F4BL:UD9++KXV8SZJ*H=*>@J/3F8&HS)B"J<J8
M@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"
MJ<K_FQ\$_YDJ"O^=-!'_J3P8_[)%)/^[33/_OU9&_<%>6O/!9F_FOVV#V;9S
ME\VM=ZC$I7NWOJ&#P+:;B<:NE8_,J)&5SZ*.GM*9AZ+3E(:GS9.&J,N3AJC+
MDX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,O_
MFQ\$_YDJ"O^>,Q'_JCP8_[-%)/^\3#/_P55&^\1=6O/%96_EPVR$V+MQF,RR
M=:O#K7RVN:6!O[">AL:HF8S+H962T)N2F].4CJ+4CXJFSH^*J,N/BJC+CXJH
MRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,O_FQ\$
M_YHJ"O^?,Q#_JSP8_[5$(_^^3#/^PU5%^<=<6O')9&_ER&J%UL%OFLJY=*J^
ML'JVLZE_OZJBA,:BG8K+FYJ0SY67F=*/E*+4BI"FSHJ/J,R*CZC,BH^HS(J/
MJ,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,S_G!\$_YHJ
M"O^@,Q#_K#P8_[9$(_^_3#+\QE1%]LI<6N_-8G#DS6B&T\5MFL6\<ZJYM'BU
MKJU]OJ6G@L6=HHC+E9^.SX^<EM*+G*+3AI6FSH:4I\R&E*?,AI2GS(:4I\R&
ME*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\S_G!\$_YHI"O^B
M,Q#_K3L7_[=$(__!3#+YR5-%\\U:6NS28'#@T&:&SLALFL"_<:FTN'>UJ;%\
MOI^L@<67J(;*D*2,SHJBE=&%HJ'2@9RFSH&:I\R!FJ?,@9JGS(&:I\R!FJ?,
M@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\S_G!X$_YLI"O^C,Q#_
MKSL7_[E$(OW#2S'VS%)$\-)96>C:7W#;U62&R<QJF;K#;ZBMNW2THK1YO9BO
M?<.0K(/(B:F)S(.GD<]^IIS0?:2FS7RBJ,M\HJC+?**HRWRBJ,M\HJC+?**H
MRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,O_G1X$_YLI"O^E,@__L3L6
M_[Q$(?K&2S'ST5%#Z]I76>/?76_3VV.%PL]IE['$;:>DO'"RF+5TNXZQ>,*&
MK7W&@*N"RGJIBLUVJ)3.=JFCS'>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>K
MJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,K_G1X$_YPI"O^G,@__LSL6_[Y#
M(/7*2R_NUE!"YN%65]SD6V[+WF.#NM%HE*G';*.;OFZND+AQMX:T=+U^L'C"
M=ZY\QG*L@\EMJXS*;:N9R6ZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\=N
MK)_';JR?QVZLG\=NK)_';JR?QVZLG\?_GAX$_YTI"?^I,@[_MCH4^L)#'_#.
M2B[GW4] XNE25]+H6FW!X&* L=1GD:'*:YZ4PVZHB;UQL("Y=+9YMG>Z=+1[
MO6ZR@<!JL(C"9["2PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#
M9K"6PV:PEL-FL);#9K"6PV:PEL/_GQX$_YXI"?^M,0W_NCH3],="'>C52BO?
MY$P_U^Q15LGN66NWXV%\J-AGBYK/:Y>-R6Z@@\1QIWO =*QUO7BP<+M[LVRY
M@+9HN(:X9+>/N6.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1
MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
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M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
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M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
M_I\8 .ZJ' 'BLR$!U;<J!<FS.Q.^KD@BM*A2,*NC6CVBGF)'FYEI4)25<%B.
MDG=>B(]^9(.-AFE^BX]M>8F8<7:'HW-RAJ]U<(:_=F^'UW5SB>UM<XCR9G2'
M]F!TA_=?=(?W7W2']U]TA_=?=(?W7W2']U__:14!_WH0 ?^*$0#_EQ( ^:,4
M .JN%0#=N1< S[HH!,2W.1&YLD8@KZQ0+Z:G6#N=HV!&E9]G3XZ;;E:(F'5=
M@I5\8WV3A&AXD8QL<X^6<&^.H')LC:UT:HV]=6F-TG5LD.UM;8[Q9VZ,]F!N
MC/=?;HSW7VZ,]U]NC/=?;HSW7VZ,]U__;!,!_WT/ ?^-$ #_FQ  ]*@/ .6U
M#0#5OQ  RKXF [^[-Q"TMD0>JK%.+:&M5SF8J5Y$D*5E38FB;%6"GW-;?)QZ
M87>:@69RF(IJ;9:4;FF5GG%FE*MS8Y2Z<V*5SW-FE^QL9Y7Q9FB3]F!HDO=?
M:)+W7VB2]U]HDO=?:)+W7VB2]U__;Q$!_X$. /^1#@#RH P VJT) -.X"@#.
MPPX Q,(C [F_-0ZONT(<I+=,*INS53>2KUQ!BJQC2H.I:E)\IG%9=J1X7G"B
M?V-KH(AG9YZ1:V.=G6Y?G:EP79VY<%R=S7!?G^MK89WR96*:]F!BF?=>8IGW
M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
M_Y$8 ?29'0'GH","W:4K!,^A.P_%G$@=O)93*K207#6LBV0_IH=L1Z"#<TV;
M@'I3EGV"5Y)ZBER.>))@BG:<8X=UIF:$=+)H@G3":(!TVVB#>/)@A'K[681Y
M_U2$>?]/A'G_3X1Y_T^$>?]/A'G_3X1Y_T__814!_W 0 ?]^$0#_BA( _Y05
M /"=&0#CI1X!UZ@H \NE.0[!GT8;MYI1*:^56C2GD&(^H8MJ1IN'<4R5A'A2
MD(%_5XQ_AUR(?9!@A'N98X!ZHV9]>;!H>WF_:7IYUFE\?/!A?G[Z6GY]_E5^
M??]1?GW_47Y]_U%^??]1?GW_47Y]_U'_8Q0!_W(/ ?^!$ #_C1$ _)@2 .RA
M$P#?JA8 T:PF \>H-PV\HT0:LYY/)ZJ96#.CE& ]G)!H19:,;TR0B792BX9]
M5X:$A5N"@HY??H"78WI_H69W?JUH=7Z]:7-^TFEV@>YB>(+Z6WB"_E9Y@?]1
M>8'_47F!_U%Y@?]1>8'_47F!_U'_91,!_W4. /^##@#_D X ]9L. .BF#@#9
MKP\ S*\D L*K-0RXIT,9KJ).)J:=5C&>F5X[EY5F1)"1;4N+CG11AHQ[5H&)
M@UM\AXM?>(:58G2$GV5Q@ZMH;H.Z:6V#SFEOANMC<H?Y7'.&_59SA?]2<X7_
M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
M_QO^0/\;_D#_&_Y _QO_0"H"_T,L _])+ /_32\$_T\U!O]0/@C_3DD,_TQ6
M#_]*9!+_2'(5_T=_&/]&BQG_198;_T2?'/]$IQW_0ZX>_T.U'_]"O1__0L8@
M_T+1(/]"XB'_0NTA_T+U(?]"_2']0O\A^T/_(/I#_Q_Y0_\>^4/_'OE#_Q[Y
M0_\>^4/_'OE#_Q[_02D"_T8J _],*0/_42P$_U,R!O]4/ C_5$<,_U%2#_]/
M8!/_36\7_TQ\&?]*B!S_29(>_TB;'_]'HR'_1ZLB_T:R(_]&NB/_1L,D_T7-
M)?]%WB7_1>HF_$7T)OE%_";V1?\F]4;_)/1&_R/S1_\A\T?_(?-'_R'S1_\A
M\T?_(?-'_R'_0B@"_TDG O]0)@/_52@$_U@O!?]:.0C_6D0,_U=/$/]57!3_
M4VH8_U%W&_]/@Q__3HXA_TV7(_],GR7_2Z<F_TJN)_]*MBG^2;XJ_4G)*OI(
MV2OW2.<L]$CR+/%(^RSO2?\J[4K_*.Q*_R?K2_\EZTS_)>M,_R7K3/\EZTS_
M)>M,_R7_0R@"_TTD O]4(P/_6B4#_UXL!?]@-@?_8$$+_UY,$/];5Q7_6689
M_U=R'O]5?B+^4XDE_%&3*/I0FRKY3Z,L]TZJ+O9-LB_T3+HP\TS$,O)+T3/N
M2^0TZDKP-.=+^C/E3?\PY$[_+>)/_ROA4/\IX5#_*>%0_RGA4/\IX5#_*>%0
M_RG_1B4"_U A O]8( +_7R$#_V0J!/]F,P?_9CT+_V5($/]B4Q7_8&$;_%UM
M(/A:>27U6(0I\U:-+?!4EC#N4IXS[5&E->M0K3?I3K4YYTZ_.^9-S#SC3. ]
MWTWN/-Q/^3G94?\UUE+_,M13_S#35/\MTU7_+=-5_RW35?\MTU7_+=-5_RW_
M2B,"_U0> O]<' +_9!\"_VDG!/]L, ;_;3H*_VQ$#_UJ3Q7X9UP<\V-H(N]@
M="CK77XNZ%J(,^57D3?C59DZX%.@/MY2J$#<4;%!V5"[0M90R$/34-Q$SU#L
M0\Q2^#_+5?\[R5?_-\A8_S3'6?\RQEG_,<99_S'&6?\QQEG_,<99_S'_32 "
M_U<; O]@&0+_:1T"_V\E _]R+07_=#<(_7-!#O9Q2Q3P;E@<ZFID).5E;BO@
M87DSW%Z".-A<BSS36I0_T%B<0LY7HT3+5:Q&R56U1\=4P$G%5-!)PE/F2<!6
M]46^6?] O5O_/+Q<_SF[7?\UNEW_-;I=_S6Z7?\UNEW_-;I=_S7_4!X"_UL9
M ?]D%@'_;1L"_W0B O]X*@3_>C,']GH]#.]X1Q/G=50;X7!?)=IK:BW39W0T
MSF1].LIAAC_'7XY"Q%V61<%;GDB_6J9*O%FO3+I8NDVX6,A.MEC?3K19\$NS
M7/U%LE__0+)@_SRP8?\YL&'_.+!A_SBP8?\XL&'_.+!A_SC_4AL!_UX6 ?]H
M% '_<AD!_WD? O]^)P/Y@# %\($Y"N> 0Q'@?% :UG=;),]R9B[);6\UQ&IX
M.\!G@4"\9(E$N6*12+9@F4JS7Z%-L5VJ3ZY<M%&L7,%2JES44JA=ZU"H8/I)
MJ&/_1*AD_T"F9?\\IF7_.Z9E_SNF9?\[IF7_.Z9E_SO_51D!_V$4 ?]L$@'_
M=A<!_WT< ?^#(P+TABP$ZH@U!^&'0 [6@DP9S7U8),9W8BW <VLUNV]T/+=L
M?$&S:81&KV>,2:QEE$RI8YQ/IF*E4:1AKU.B8+Q5H&#-59Y@YE2>9/=-GV?_
M1Y]I_T.>:?\_G6G_/9UI_SV=:?\]G6G_/9UI_SW_5Q<!_V,2 ?]O$0'_>10!
M_X$9 ?N'( 'OC"<"Y(XP!=J-/0S/ATH8QX)5([]]7RVY>&@ULW1P/*]Q>$*K
M;H!&IVR(2J1ID$Z@:)A1G6:A4YMEJU689+A7EF3(6)1DX5B5:/10EFO_2I=L
M_T66;?]!EFW_0)9M_T"6;?] EFW_0)9M_T#_614!_V80 ?]R$ #_?1( _X46
M /:,&P'JD2(!WY0K ].1.@O)C$<7P(=3(KF"7"RR?64UK7EM/*AU=4*C<WU'
MH'"$2YQNC$Z9;)52E6N>5))IJ%>0:;19CFC#68QHW%J-;/)3CV[_3)!P_T>/
M<?]#CW'_08]Q_T&/<?]!CW'_08]Q_T'_6Q0!_V@/ /]U#P#_@!$ _XD3 /*0
M%P#EEAP V9DF LV5. K$D$46NXM1(;.&6BRM@F,TIWYK.Z%Z<D&==WI&F76!
M2Y5SB4^2<9%2CF^;58MNI5B(;;!:AFR_6X1MU5N&;^]5B'+]3HET_TF)=/]$
MB'3_0XAT_T.(=/]#B'3_0XAT_T/_71(!_VL. /]X#@#_@P\ _8P0 .V4$@#@
MFA4 TYPD LB9-@F_E$,5MH]/(*Z*6"NGAF$SH8)H.YQ_<$&7?'=&DWE^2X]W
MAD^+=8]2B'.85H1RHEB!<:Y:?W&\7'UQT%Q_<^Q6@7;[3X-X_TJ#>/]%@GC_
M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
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M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
M )V1  "3DP  A98  'Z7"P!YEQD =9<H 7&7-0-LEC\&:)5("F244 UADU<1
M79)>%5J19AA7D&X;5(]W'E&.@2!.CHTC2XV:)4F-J29(C;LG1XW4)T>,\"1(
MC/\B28O_($J+_QY*B_\>2HO_'DJ+_Q[5;@  PWL  +>%  "LC0  HI(  )>6
M  ",F0  ?YP  '6>!0!PGQ, ;9\C &F?, %EGCL$89Y%!UV=30I:G%0-5YM<
M$52:8Q11FFL73IET&4N8?QQ(F(L>19>9($.7J"%"E[HB09?3(D&6[R!"E?X>
M0I7_'4.4_QQ#E/\<0Y3_'$.4_QS,=0  O($  +&,  "FD@  FY<  )&;  "%
MGP  >:,  &JG  !EIPX 8Z@< &"H*P%=J#8"6:= !%:G2093IE$)4*99#$VE
M8 Y*I6D11Z1R%$2D?19"HXD8/Z.7&CVCIQL\H[D<.Z/2&SNB[QL[H/X:.Y__
M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
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M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
M0;4& #ZV$0 ]MAX .[8I #JW-  YMSX -[=' #:W4 $TMUH!,K=D C"W;P,N
MMWP$++>+!2JWG 4IMZX&*+C%!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R
M_PBOC0  HI0  )>:  "+H   ?J8  '&K  !EL   6;0  $VW  !"NP  .+X!
M "_""0 MPQ( +,,> "O#*0 JQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!
M(L:& 2#&F $?QJL!'L?! 1[&Y $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2E
ME   FIH  (ZA  "!IP  <ZX  &>T  !:N0  3KT  $+    XPP  +\<  ";+
M!  >T H &]$1 !K2&@ 9TB4 &-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\
M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
MQ#Q- < \6 *\.V$#N3MJ!;8Z<@:T.GH'LCF!"+ YB FO.9 *K3B8"JLXH0NI
M.*H,J#BV#:8XQ0VD.-X.H3GQ#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ
M_PG_.P( _SX  /=$  #F1P  WT@! -I&!@#90 L S4(9 ,5$*P"^1#L N41(
M ;5#4P.Q0EP$KD)E!JM!; >I0'0)ID!["J0_@PNC/XH-H3Z3#I\^G ^=/J40
MFSZQ$9H^OQ&8/M02EC_M$90__ ^30/\.DD#_#))!_PN20?\+DD'_"Y)!_PO_
M/0  _T,  .E)  #>3@  TT\  ,U. P#*20@ PDD4 +M*)@"U2S8 KTM# JM*
M3@.G25<%I$A@!Z%'9PF>1F\*G$9V#)I%?0Z8184/ED2.$)1$EQ*20Z$3D$.L
M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
M .H^  #?0@  U4(  ,\_ P#-. @ Q3@5 +TZ)@"W.S8 LCQ# *X\3@&J.U<"
MISM@ Z4Z9P.C.F\$H3IV!9\Y?0:=.84'FSF-!YDXE@B8.* )ECBK"I0XN J3
M.<H+D3GE"X\Z]PJ-.O\)C#O_"(P[_P>,._\'C#O_!XP[_P?_.   \3X  .-%
M  #420  RTH  ,5'  #!000 NC\1 +-!(0"M0C$ J$,^ *1#20&@0E,"G4%;
M YM!8@280&H%ED!Q!I0_> >2/W\(D#^("H\^D0N-/IL,BSZF#8D^LPV(/L0.
MAC_@#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/   ZT,  -Q*  #,
M3P  PU   +Q.  "W20$ L48. *I(' "D22P H$DZ )M)10&82$X"E$=7 Y)'
M7@6/1F4&C49L!XM%<PF)17L*AT2#"X5$C0R#1)<.@4.B#W]#KQ!^0\ 0?$3:
M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
MR!9K ,46<P##%WL P1>" , 8B0"^&)  O!B8 +L9H "Y&:D MQFT +4:P@"T
M&M8 L!OM :T<_ &K'?\!J1W_ :D=_P&H'?\!J!W_ :@=_P'_*   _R<  /XJ
M  #O*@  YR<! .<B"0#D'1  V1L= ,\=+0#)'CP Q"!) +\@4P"\(5T N2%E
M +<B;0"U(G0 LR)\ +$B@P&P(HH!KB*2 :PCFP&K(Z0!J2.O :<CO &F),X!
MHR3H J E^0*>)?\"G27_ IPE_P*;)?\"FR7_ ILE_P+_+   _RT  .TR  #B
M-   VC,  -,N P#2)0H R247 ,$G)P"[*38 MBI# +(K3@"O*U< K"M@ *HK
M9P&H*V\!IBMV :0K?0&C*X0"H2N- I\KE0*>*Y\"G"NJ YHKM@.9+,<#ERSB
M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
M8D4W &%%/P!?148 745- %M%5 !:1EL!649C 5=&; )61G<"5$:# U-&D0-1
M1J$$4$>Q!$]'QP1.1^<$3D?[!$Y'_P-.1_\#3T?_ T]'_P/,1@  NTX  *]4
M  "D5P  FE@  )%7  "&5   >TX  '!*  !I2 T 94@6 &))(0!?22L 74DT
M %M)/ !924, 5TE* %9)4@!52ED!5$IA 5)*:@%12G4"3TJ! TY*CP-,2Y\$
M2TNP!$I+Q01)2^8$24OZ!$E+_P-*2_\#2DO_ TI+_P/(20  N%$  *Q7  "A
M6P  F%P  (Y<  "#60  =E,  &M.  !D30H 7TP3 %Q-'@!:32@ 6$TQ %9-
M.@!434$ 4TY( %).3P!03E<!3TY? 4U.: %,3G,"2D]_ DE/C0-'3YT$1D^N
M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
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M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( ( !*0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M6^+QC\1^)(YH/#4;_N( 2CZFPX//58P1@D<DY QR1YI^S=\'Y/CA\7--T/\
M>+99-Q?R+P8[=,%^>Q.0H/JXK]+=+TNWT33;>SLX8[>UM8UAABC7:D2*,*H'
M8  "O)\,^"J69U'F&.5Z4'91>TI;Z]TM-.K=MDT\<OPJJ/GGLANBZ)9^&]*@
ML=/M;>RLK5 D,$,82.-?0 <"K5%%?TI&,8Q48JR1[P4455U?5[/P[I%UJ&H7
M5M8V%C"]Q<W-Q*(H;>) 6=W=B JJH)))P "35>2 DOK&'4[.6WN88KBWG4I)
M%*@=)%/4$'@@^AJGX3\+6G@O1(M-T]9([&V)$$+.66!"<A%)YVCL"3@8 P
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M>I6Y*M#=EA]I4-TW+<!G*\_),F<AJ_0W]C;]M7P/_P %B/V?X?#NM75GX?\
MC#X=MS-=6:IM!884W5N"3YEN_P H= =T9.#QL=OD?%C@%Y[EL<PP"]^*YEZM
M>]%^MM^DEK9,\G$TO;1Y'\2V.T_X)C_$.*P\1^(/#,\@5M0B2^M03C<T>5D
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M;%7C8'(92.00>01SFM'Q!XZUSQ7!'%JFL:KJ4<3;T2ZNY)E0],@,3@U],_\
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M!LXI\?G,3QQS]:[<1AX5<ZIM[Q@W^+2_,MI.JO0\_P#^":W[!E]^W_\ '_\
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M &B/9G>%.%;A0>>E>CD.)HX?&QK5W9*^NKW373U.BC)*5V?D?_P3@_:^TO\
M8>_:7M_'NK:#>>(H;;3KFSCMK:Y6"17E 4/E@00!N&#_ 'L]J^GOV\/^"]MS
M^T[\!=6\!>#O!MUX5@\21&UU34+R_6>8VY(WPQHB@#>!M9B3\I8 <Y'1:G_P
M;->,(;=?L?Q2\-W$F[!6;2IH5"\\Y#MSTXQ^-7/"'_!LMK]Q=Q_V_P#%?1[.
M ,=XT_19+ERO;!>6, GGJ#CWK[/$8[)*M98JK).4=OBZ;:6.J4J3?,S\[/V>
MO@EK'[1_QM\,^!]"ADFU+Q)?QV:E5+"!"<R3-C^".,,['LJ$U^VO_!;OX&-X
MB_X)F:I9Z);L8? -Q8:E% H+,+:$_9VQC^Y%*SDGC:C>U>D_L+_\$QOAK^P9
M9SW7ANWO-8\3WT7DW>O:FRO=,G!,<04!8HRPSM49.!N9L#'T'JFF6VMZ;<65
M[;P7EG>1-#/!-&)(YHV!#(RGAE()!!&"#7S^;<0QKXRG5HKW:;NK]=K_ (*R
M,*E:\DULC^8']G/XTW?[.GQX\)^.K&UAOKGPKJ<.H"VE;:MP$8%HR>J[ER,\
MXSG'&*_64?\ !RQ\+_["AD/@#QZ-28'S8 UIY"''\,OF[FYXYC''/M5+]HG_
M (-N_"/C;Q1>:I\._&UYX-M[J0R#2+ZQ_M"V@)/*Q2^8DBH!T#^8>V['3RO1
M?^#9KQ=/?[=1^*GANUM=X DMM)FN)-N>3L9T&0.V[D]QUKVL7CLDQ_+4Q$M5
M_B3]-/T-92I3U9]P?\$V_P#@I;;_ /!19_&TECX-NO"MCX0:R1);C4ENGOFN
M/M!(VK&OE[!"IZMGS.VWGX?_ .#F7Q2UW\7OA9HN_*Z?H][>A-P^4SSQH3CJ
M,_9QSWQ[5]V?\$V_^"<>G_\ !.OP7XCTVU\3W'BJ[\37,-S<W4M@MF$\I&55
M50[G'SL>6/7ZYXG_ (*,?\$@[7_@H1\8M'\677C^\\+C2-&CTA+.+2%NU?;/
M-*9=YE0@GS0NW'&S.>:\# XK 8?-?;4W:DMMWTMZ[W,8R@JEUL?$O_!MAH/V
MG]KSQMJ6TD6?A"2WSD84RWEJW3KG$1Y'OZBOK[_@X8\1MHO_  3X-L&VC6/$
MMA:$9'S +--C_P @YXYX],UV?_!-K_@E3I__  3M\3>*M4MO&-QXLF\36L%K
M^]TM;/[*L;NQP1(Y;<6'''W>_;L?^"C/[!R?\%!_A'HWA&X\5W'A6TTG6$U=
MI(M/6\,[K#+$JX+H5P)G.0>_3H1>*S+#U<XCBE+W%;6SZ+M:^_D.52+J*70_
M$#_@E_X=;Q1_P4(^$-LJEC'XDMKS (&! 3,3SZ"//KZ<U^@__!S%\-+[6/A9
M\+?%T$+/8Z#J5]IETZC_ %;7<<+QY]O]$<9Z D#J17H'[&'_  0DTK]D#]I;
MPU\1D^(UWXDD\-FX9-/FT-+=)FEMI8 2_G/MV^;O&%/*CIUK[6^+_P (/#OQ
M[^&NK>$?%FEV^L>']<A\B[M9L@.,AE8$8*LK ,K*059000173F6?4'F5+%4'
MS1BM=&M[I[VZ,=2LN=21_/'_ ,$Y/VV)OV"?VD[?QM_9<FM:;<6$VE:G913"
M&6:VE9'RC$$;EDBC8 \';C(SD?I#KO\ P<K_  O@LHVTWP#X^O+@QJ72Z-I;
MHK_Q*&660E0.C%03Z"N+^+?_  ;/6MWK-Q<>!?B=+9V,A9H;'6M+\Z2+T!N(
MG7<,\9\H$#GFN<\)_P#!LMXBN;A?[=^+&BV,6[G[!HLMTQ7C'WY8\$\COC@\
M]*]'&8G(L9)5Z\M;?WE^"1I*5&3YF?H5_P $_P#]LC_ANOX CQXOAM_"T$NI
M7%C#:/??;&=8MH\POY<8&69AM .-O4YP/QQ_X+MZY_:O_!3#QM;G_F&6FF6P
MXQUL()?Q_P!;7[1_L2_LHV'[%7[.6B_#W3]4N-;CTF2XFDOYXA"]R\TSRD[
M6"@;@H )X7/4FOP:_P""IGB#_A)O^"AOQ<N./W?B&:TX7;_J0L/_ +3Z]ZX^
M&8TGF56=#X$G;?:ZMOJ30M[1N.Q[3_P2)_X*>^!?^"?'@WQQ8^*O#_BC5KWQ
M-<07%O)I,4#J/)1U5)#)*A )D8Y ./0YX\I_X*5?\%%-:_X*%_%:PU2;3O[
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M (-F/$C^(O+O_BOHD.D C]_!HLLERWMY;2JH[C.\^OM7TY=?\$#O@F_[.?\
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M?VSXI\4>'H;[4[W[/%;_ &F9BV6\N)4C7.!PJ@>U>^T %%%% !1110 4444
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M!?\ V!9O_2RXKC?^"'TD=WXN_;+N)IIIM4;]HWQ3#+YK,S+;I]G$ &?X0-X
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20201231_g12.jpg
<TEXT>
begin 644 biib-20201231_g12.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
M3['?BL\O4*W<BJP;WZO0BS %@:DD@[D  (,>@ ![.<8EE^1M5,":E9!>][L?
MDXY0 [75D?9 3[#ND.PO8:S2D0$<%:JFD L%Y*?A@_L  (,=@ ![%\6$GW5M
M1[_JG+->][I@FD=0"K4,F&9 6[ EEUTO>:P EWD<2ZFCDR$&.Z;.A#<  (,=
M@ !Z]L4&IS!M/[];H_U>_+G!H2Q0%K1AGQ1 9Z]UGEDOC:M6G-,<>*C@DT &
MAZ7KA&H  (,<@ !ZW,2=KSYM/K[AJY-?";DXJ%M0*K/,IC- A:[7I,XON:JP
MH$4<LZ@QDV<&R*5&A)8  (,<@ #F'W9P<QC0&W=+<_&Y@'@?=,RB*GCJ=:^*
M)'FR=J%Q8WI_=Z-7AGM/>)\[+WPQ>986G7TA>>CD#W2'?FC.:W6)?ANW^G9\
M?>6@RW=E?<J(W7A+?<UP+GDS?>166WH5??DZ!WKO?A(5('M4?<'B,7+PB=+,
MFG0"B&2V7W4*AQ*?1G8*A?V'?G<(A1%N\W@&A$)5/GCV@WDX^7G$@L03Q'G5
M@@O@:7&3E3C*S7*NDK^TG'/ D&R=L731CDR&$77FC'9MLG;VBL)4*G?RB2$W
M_GBRA[<2E'B+A>S>R7!UH)W),G&2G2^S G*KF>><*W/%EM6$KG3ED_AL?'8'
MD6E3(W<+COHW%7>[C/X1CW=QB3_=;&^8K W'V7"TI[JQJG'+HW^:VW+HGWJ#
M=W0/F[1K6'4UF#-2+G9!E0\V0G;ADL40M':$BTO<3F[KMXS&P7 $LENPBW$5
MK3&9OG(PJ#R"<G-=HYIJ<G2*GTQ16G64FW4UCW8EF24/_G6_BM#;;VYMPQ[%
MY6^!O16OHW"(MP28RW&;L2.!A7+)JZQII'/]IK90KW4)HGLT]'6%GK4/:G4?
MBFS:RVX;SL;%1&\IQ^2NZW AP/.7_W$GNC: NW)/L_QHZW.#KGU0"G2.JDDT
M8W3]HR@.]'2?BAS6%7\.<;;!Y7\0<LJL]'\=<\^7'W\U=-& =7]6==UH[G^(
M=O90,7_/> @TFH!9>0</6('R>3S4C'U1?'_ LGUS?'JKSGV7?'R5_GW ?(]_
M4WWS?+EGTWXW?/=/'GZ-?30SD'\2?7(.08!(?8/3 'O2AU"_!WP"AD*J07PS
MA424@7QQA&]]_GR[@[UFHGT5@R9."WUV@I@RDWWM@B4-3'[2@8/1;GJ&DAB]
M97J\D!FHH7KWCC"3#7M C&E\JGNABMUE>'P,B7)-"7QVB"$QK7S>AQX,>'V-
MA/S/\WERG.F[[WFJF@NG+7GMET&1I'H_E)A[9GJEDAQD6WLBC^=,&7N3C>$P
MW'OJC'\+PGQWA_/.LWB;I]*ZLWC4I!^E\GD5H'&0<GEJG.9Z2GG6F9%C5GI3
MEH1+/GK,D^8P(7L5DH(+*7N-AXO-KG?QLM.YL'@JKDZDZGAEJ;^/;'BYI51Y
M6GDLH31BA7FNG7%*A'HAFDLO@WI<F'(*JGK+AS;,Y'=SO?&XXW>JN*"D$'?<
MLS6.BW@GK>MX@7B;J0EAQ'DGI+=)Y7F<H6LN_'G!G4X*0GHMAO#,57<>R3ZX
M2G=1PR.C7W=WO."-RW>UML)WR'@DL2]A('BPK'M)5'DGJ/(N?7E!GV\)\'FO
MAKC&?H@8<(JS_(<S<;Z@DH9R<MJ,&X71<^YVMX5'=0M@7(3<=C5(M(2>=U4M
MQ83T>%((W(9/>6#%1H: >KBRZH6[>NJ?<X4,>QN+!X1U>U=UJH/Y>Z=?6X.<
M? E'NH-H?&DLV(.R?, (+X2J?77$$H4.A/FQJ(1<A#&>7X.S@W*)V8,L@M)T
MAX*Z@E1>48)K@?-&QX)$@9\K^X*%@6X'F(,Y@0O"K8/'CRJP,8,6C8V<R8)\
MB_>(<8( BGQS0H&HB39=-8%KB!)%U8%*AQ,K+(%XAGX'%('XA"C!5(*]F6&N
MV((-EOV;=8%ZE)V'*8$%DE%R&X"PD"U<-8"$CE1% (!HC+PJ>("$C D&HX#F
MA'W ,('MH[ZMN(% H)::5X"KG62&%( XFD5Q''_GEUI;47^VE,)$1'^ADK0I
MUW^PDA,&1'_^A#V_1(%)KC>LRX"?JDZ99( %IDN%('^.HEMP/7]$GKA:DG\8
MFX)#IG[VF2(I47[XET(%]G\_A B^D(#.N-JL$( FM#*8F7^$KV"$3G\"JI]O
M<WZWIDY9V'Z5HJE##'YWH' HWWY>FX(%MGZC@]R^%(!XP\&K@G_3OF.7['\D
MN,&#DWZ3LS5NQGY KDE917X@JG-"DWX'IS H>7WFFUX%@WXF@[JW7)%7;[&F
M-8^><.V4(8X<<A* ](S)<RYLRXN8=%17DXJ5=89 [XG@=J0F@8H[=X$#*HHD
M>;VV6(_A>5.E0XY'>9Z3'HS4>>E_^8N'>C]KUHI?>JE6JHEF>R1 "HBU>Y@E
MLHCZ>_0"VXB$?6FU28Z+@NJD#(T"@EV2 XN2@=-^UXI3@6EJS(DW@1E5NXA*
M@.,_-H>>@+HD^H?.@+@"E8<6@**T+(U-C)6BU(O+BSZ0MHIJB>A]N8DJB+1I
MO8@?AZQ4SH<^AL<^:X:8A@TD4(:VA>8"6879@9:S!8Q+EDFAPHK+E#B/G(EO
MDBU\BX@ZD#=HL(<QCFM3WX9AC.4]I86]BZ\CLX7$B[D")83*@7.R!HN%H!^@
MOHH)G5F.F(BLFH][DH=YE]IGRH9QE5M3$H68DS$\_H3WD:XC+(3LD2$!^8/E
M@5:Q-8KIJ@Z?ZXEQII:-P(@/HPUZO(;9GYUG!875G'M2:H3]F=0\=81*F#XB
MP(0PE9T!U8,G@3VPDHIRM">?0(C^L *-"8>6J[YZ H96IY=F4850H^%1QH2#
MH/0[\(/.GU\B88.4ES\!N(*-@2FP((H:OHN>O(BJN<*,;H<[M,9Y787OK^YE
MN83BJ\!11(03J.8[?X-DI3$A_X,BEOP!H((2@1FHFYKI;PB8CIAS<$&'I98\
M<6EUL)0\<HQBM9)H<[=.DI#5=.<XU(_"=?0>HY"&=H0  (IR>T6GRIF=>">7
MTI<]>("&UY4.>-UTY),->4=AZY$[><5-T(^L>E X&8Z5>LP>!H\U>PL  (C9
M?I.F[YA7@3N6T98)@,J%Z9/;@&5S[9'E@!QA!9 =?_%- 8Z8?]\W8XV!?]8=
M=XW^?_,  (=R@ "E]9<VBD"5PI3JB1^$QI+'B UR]I#-AP]@&X\3AD%,.8V6
MA94VP(Q^A1L<_(S=A68  (8[@ "E"Y8NDW&4SI/LD:.#RY'0C^)Q]H_<CC-?
M1HX6C+-+?HREBWTV*HN,BJX<CXO0BN,  (4P@ "D-)5OG,:4#9,OFE&#"I$.
ME]YQ)(\:E89>=XU:DVA*RHO?D:XUF(K%D,<<(XKRCY$  (1/@ "C@93:IBZ3
M4I*>HQF"2I!ZG_IP:(Z!G/Q=R8S#FE-*-HM&F#\U)8H6EY0;T8HLDL\  (.5
M@ "B\91IK[N2O9(QK N!JY 'J$9OQXX$I*==+8Q$H8I)IHK/GV0TM(F8G=D;
MBXF'DI\  (+]@ "BBI06N9J22)'@M5N!(X^NL/-O.(VAK+]<JHO8J5))-XI@
MIT@T4HDPHM<;-XD8DF<  (*$@ ":4J3;;H2+/*&Z;Z][69[=<-)J>YPX<?18
ME9G&<QM%;I>O=#\P<I9E=2@5_YA-=2@  (8@?FF9LJ.[=RZ*M*"D=X5ZPYW!
M=^EIY)L1>%Y7_)B;>.=$W9:">7HOZI4J>>T5II;4>=P  (4 @ "9"Z*&?\&)
MZI]]?UYZ"IR6?PUI'YGM?N!71I=Z?M!$.Y5F?MDO8I0'?N@55)5X?P@  (0$
M@ "82J%EB$J)#9YCAT1Y&)N&AE-H3IC9A816@)9SA.-#DY1DA&HNWI+_A"L5
M!Y0^A(   (,H@ "7?J!\D-V(0YU\CT)X1YJAC;UG=)?WC%A5T96!BQI"_)-[
MBC4N;)(,B=$4RI,;B4   ()L@ "6UY^PF:N'EYRYEWIWEYG?E5=FR9<ODU-5
M+Y2WD8U">Y*;D$ N#)$GD X4DI(4C48  ('.@ "61I\<HH^'&)PHG\]W%9E$
MG0UF.9:*FG14G905F$%!_Y'\ELDMM)!MEH4489$XC<@  (%+@ "5SIZQJY>&
MG9N]J$YVDIC2I/EEMI8.H==4'I.5GU%!AY&"GA M6(_IF^ 4.9"$C:P  (#@
M@ "5=9YBM/"&.YMKL2EV(IAXK49E096JJ:Y3M),JIPY!+Y$2I3HM#H]]GG84
M I ,C8<  ("+@ ",G*\T;@!^5ZM[;Q=O7:@#<"]?>:3 <4M.C*&[<F@\09\W
M<W<GS9WW="0-+Z"X<\4  ()_@ ",+*XY=D%^!JIZ=HYO *;M=O)?&J.5=VQ.
M*Z"#=_L[Z)WT>(PGA)R9>.0-.I[B>-$  ('%@ "+NJT-?EU]<ZE8??]N?*7"
M?;M>BZ)I?:)-IY]6?:@[>9S'?<8G,YM7?=X-/YTV?CL  ($A@ "+,*OJAF=\
MSZ@ZA7=MPZ2KA*)=ZZ%-@_E-$9Y#@X$[ )NT@S8FX)HU@RT-/YNU@Q$  ("3
M@ "*FZKYCH-\-*=-C0UM'J/!B[1=0:!BBH%,B9U,B8DZC9K!B.PFE)DQB/\-
M/YI<AST  ( :@ "*$*I!EL1[KJ:6E,ULF*,%DNQ<NI^AD3E,"9R%C]$Z,IG=
MCO0F6Y@_CUL-0IDGB/<  (  @ ")J*F>GR![0*7XG*ML)J)DFD9<2)[]F!A+
MH9O>EEPYXYDNE88F-I=>E-P-2I@1B/P  (  @ ")2ZDTIZ=[!:6*I+UKYZ'D
MH<Y;^)YBGR-+2ILYG3DYBIB9G*PE\Y;+F7(-2I<YB/P  (  @ ") ZCHL()Z
MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
M@ !U1*[TA>%H?ZM8A2Y;!:?/A(=,MZ1M@_,]<J%D@X\LD)\R@VL8V9[W@[\"
M[9H[@?L  (  @ !TY*X3C8IH**IUC'):KZ;CBUA,7Z-YBE@]'J!HB9HL7YX8
MB6@8TIVVB8,#(YBV@A\  (  @ !TE*UEE3UGYJG!D\I:;J8CDD-,&**MD-X\
MU)^:C^XL,)T[D <8VIR5CED#5I=J@D(  (  @ !T7:S7G0)GL:DMFSM:,J6&
MF59+V*(&EZ,\E)[LEK4KZYR3EG88NYO&D+D#B993@F0  (  @ !T+JQ^I1=G
MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
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M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
M@ "4T8\,8Y*&\HV=9?%W\(QY:"!GGXN):B=6&XJ[;!5#/8HJ;>$N=HHI;T<3
MR(R;;Q0  (  >D"4$(TM;'J&*XOW;?YW#HKE;VAFRXGT<,!568DE<@M"D8B3
M<S\MWXA]=!X38HI]<ZP  (  ?;:3,8M?=4>%'(I-=@YV&(E(=L1EU(AD=W!4
M?8>?>!I!UX<3>+DM28;N>1\3 XA_>)H  (  @ "2+(FX??N$"XBR?B1T\H?!
M?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (  @ "1,(A,ALR#
M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
M@ "05X<[C[Z"5(9*CK)S0X5@C7=C(H2%C"=2)(/,BO _\H-$B@ KTH+]B9X2
M'X-GB#H  (  @ "/J(9BF+6!FH5XEQ=RA82)E3EB9X.IDT91;8+RD8H_58)E
MD$(K;X'[D!T1Y8(>C!D  (  @ "/((6\H;Z!"839GY9QZ8/AG1MAS(+TFHM0
MU8(WF%H^N8&REO0J\($ZED81LH$1B_<  (  @ ".OH5%JO> EX1EJ%=Q8X-B
MI45A/X)BHB%06(&7GY@^5H$*GF4JFX".FS41<8!%B\L  (  @ "'?)B=8Q5Z
M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
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M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
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M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
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M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
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M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
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M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
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MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
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M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
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M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
M@ !JXV$C;D9?N&-F;Z13NV5D<.U&RF<7<A8XHVAN<R(H;6C#<^<5&VK)<]H!
M$WXN=QX  (  @ !IQ5X#=H!>R&!V=U!2YV*6=_]%]&1<>) WS66C>1$GV66J
M>7@4KFB:>6<!$GXP>_0  (  @ !HW%M+?JM=[5WC?O12&V ??PQ%-F'R?PLW
M&V,K?Q,G1V+>?R\4<6:[?V8!)'X3?_H  (  @ !H)5D#AL!=1%N[AH]1>5X+
MAA=$H%_CA8DVB6$(A2DFM&!AA284!F54A40!,'W^@,X  (  @ !GGE<MCL9<
MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
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M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
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MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
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M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
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M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
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MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
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M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
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MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
M@C)SIB-L@L]X087Y?M!BN'JI?NAE:6Z'?PYH"V')?T%JKE2??X)M8T=F?]IP
M/3JF@$IS0"Y\@.IVCB.L@;5Z+H3^?&!JTGF7?+-LR&V@?0)NM&#S?5QPG5/S
M?<ARF4;I?E%TL3I>?O1VZ"YP?\5Y52/C@+U[]H/S>BYRRWB)>JAT%&R/>QYU
M36 N>YAV?E-+?#1WND9T?.QY"CH??;]Z;BYG?L%[]203?^1]EX+R>$1ZO7>0
M>.![66NF>75[V%]5>@]\15+(>L=\ND83>ZY].SGM?*U]R"YC?=U^9B0\?RI_
M#H(5=KR"GG;8=W&"D6L >!F"4UZI>,F!]5(F>9R!F$6I>IV!1CFJ>\. ^2Y0
M?1N JB1??HV 6(%A=7J*3G8F=D&)E6I7=O:(E%X/=[B':E&<>*.&/$5">;Z%
M$CE\>OF#ZBY(?'6"LR1[?@N!=(#5='F1P'6>=4^06VG1=@V.E5V4=M>,F%$L
M=]2*ED3?>0J(E#E >ER&DBY!>^V$?"22?:&"9(!L<[>8[W4T=)>6Y&EB=5F4
M5%TK=B61?%#7=RF.H$2D>&Z+Q3D0>=J(YRXF>X:%_"2D?4R#*7MYB<%::7#D
MB.9=S66VB#1A*5GMAXYDB$W*AN!H 4&EAC5KJ38%A91O@BL'A1)SN2%DA+=X
M3WJ;AUQB'G NAL%DSF4*AB]G>EEBA9]J+TUBA1!L_4%CA(QO\S7NA!9S$BLC
M@\)V?"&]@Y%Z*7G$A0MIMV]&A*5KO&1,A#9MOUBT@\=OQTS>@UUQYD$,@P9T
M)37)@KUVA2LU@I9Y'"(*@H][W7CA@N]Q-&Y;@JQRF&-@@E]S\E@$@A%U3DQ,
M@=)VN4"J@:5X/#6:@8EYU2L]@8][E2)-@:Y]:G@'@2)XG6V.@/IY9&*;@,=Z
M%E=%@)-ZO4O9@&Q[;4!5@&Q\+S5R@'A\_BM&@*=]X2*&@.Y^S'=&?YM_]&S=
M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
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MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
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MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
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M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
MOI@F4P&-<(L"5P^,/'T_6ON*XF[E7O>)=& ^8S"("%&59ZZ&G4-N;&R%,#7'
M<8"#LRE\=K>"(Y=B4866,8I-5;"4(GR56;>1WFY-7="/@U^S8BR-+%$:9M:*
MTT,;:[V(<#6G</.%[BE_=DV#59;=4&J>CXG*5*>;HWP26+V8<VW37.>5*E]/
M85J1ZE#09B&.ID+9:RF+3S5Z<(.'U"F!=?F$4I5;:S555HB4;0195GLG;NI=
M/6T$<.=A%EYG<P-D^T^I=4QI!T%3=\1M23-V>HUQ\2;9?:)W*Y/F9Z->:H=B
M:==AD'H(; EDHVP.;DQGL%V9<+%JR4\(<TEN!$#C=A-Q:S-&>2]U)R;X?(UY
M49*!9&%G>(8)9NIIQGC^:6%L!VL7:^1N0ES3;HUPBDYU<7!R[D"(=(AU=#,C
M=_)X/"<3>YA[4Y$'871P882?9$!QXW>49O1S5VGY:;1TPEO<;*AV-4VW;]-W
MOT )<S1Y8C+K=N-[,2<J>L%]+H^M7NEY+H-;8>IYZW9F9-5ZD&CC9\Q[)5L8
M:O=[P$T9;F=\;#^D<@E])C+#=?5]^"<^>@A^WHZ/7,:!Y()27_*!VW5W8PF!
MK&@)9C&!9UI9:8R!(DR9;2N Z3]2<0: N3*@=2F BR=/>6N 78VI6OZ*:8%[
M7DV)F'2Q88:(D6=79-2';5FZ:%V&24PA;"B%*3\4<"J$##**='V"XB==>.B!
MJXSY69"2K(#47/J1$G008$R/+V;$8[6-)UDS9V"+(4NK:U6)'#[);WV'%#)T
M<^^$]2=I>'V"QHQ_6'R:E8!96_F8-W.07UF5=F9*8M*2AEC09I*/FTMD:J*,
MLCZ*;NR)P#)+<X*&MB=R>">#L8H'<K95@'Y,<]Y9<7'G=2E=3V30=HYA(U=&
M> ME"$FF>:QI&3QZ>W5M82_7?85R$22!?]1W1XBY;T]>!7TU<-EA+W#E<FQD
M2F/U= YG8E:6=<UJBDDC=[=MUSPG><MQ4B_"?"9U(B2W?K5Y5H=];#1F>WOP
M;@YHXV_>;]YK/V,'<;YMEU7:<[YO_4B;=>YR@CO8>$IU*B^O>NQX$R3F?;A[
M0(8V:6)NXWJP:WUPC6ZN;8AR)V(T;YYSOE4L<=]U6D@E=%%W#CN:=O%XW2^D
M>=5ZVB4/?-Q] H3]9O5W,7FD:4)X)6VM:W]X_V$O;<9YR51P<#QZF4>+<O![
M?#LY=<Q\;B^$>.A]>B4R?!U^F8/Z9.I_9WBN9UY_I&S,:<)_MV!D;#=_LE/#
M;ME_KD<<<;=_MSKV=,I_RR]P>!M_Y25/>WV  (,I8S:':7?K9<J&[VP9:$V&
M.%_":N2%7U,S;:^$AT:R<+>#M#K(<^V"Z"]G=VR"%"5H>O>!-X*&8=6/*W=1
M9(2-^VN#9QZ,=E\Z:<V*Q%*W;+B)$T9&;^>'9CJ&<T"%O2];=MR$ 25[>HJ"
M/X(18,>6FW;=8XJ4O&L+9C*29U[(:.^/UU);:^V-2D8&;S:*PCI.<K"(."\Y
M=F^%H"6+>C.#&'[2>GQ5GW0$>P%9?6B;>[!=45R/?'-A)5 @?4-E$$.H?BQI
M*C>Q?S1M>RQ7@'5R-")8@>=W7WVF=TI=G7,3>"M@QV>_>19CZ%O=>@UG#4^7
M>Q9J1T-+?$!MJ3>$?8MQ.BQB?Q%U'R*D@+UY6'R,=%)ECW'R=8!H!F;2=J9J
M=UL(=]-LZ$[P>1AO;4+6>H1R$S='?!%TWBQC?=5WZ2+G?[=[+'MP<:1M9W#8
M<PIO,V6]=&5P]%I&=<-RLDY-=TAT?$)J>/%V7S<2>KYX7BQD?+YZBB,A?M-\
MUWI<;TQU-6_2<.)V5&3.<FIW8%EL<_9X7DW0=:AY9T(1=XUZ@S;K>9)[L2QL
M>\E\^R-3?@]^5WEQ;5E\[V\0;Q=]:&0C<,%]NEC <G-]\TTS=$U^,4&M=EI^
M@3:Q>)!^W2QA>OI_0B-\?6I_J'BQ:[>$=&Y:;9.$16-\;UJ#V5@J<2R#2TRO
M<RF"P$%/=5R"0#:-=[*!R"QB>DB!3".>?.& RW@::F2+M6W-;%J*X6+U;C:)
MM5>R<!V(6TQ#<C>' T#P=(Z%LC98=P2$:BQB>;6#%B.Z?'*!P7>I:5R2KFU@
M:V:1.V*';5&/35=,;T6-($OS<7"*]4"\<]Z(U#8L=G6&MRQ+>4>$E2//?!F"
MBG/,@HQ5FFG?@G%99U]L@GM=-%1L@H]A#4D;@J%E!#W1@K]I,#,6@O%MD2D+
M@T]R5"!C@]1W<W*^?Y)='&D,?\I@1EZO@ 9C;U/9@$-FI4BR@(1I]CV4@-MM
M=#,*@4EQ'RDT@>-U&R#&@IUY67'*?+YDD&@2?3QG%EWG?:QIG5,G?AEL+$@N
M?I!NTCU!?R)QGC+M?\QTD"E0@*!WOR$;@8U[&'#3>BUK[F<9>MYMU5ST>WUO
MMU)U?!MQGD>>?,MSECSC?9=UJS+%?GMWW"E@?X9Z.B%E@*%\KF_H=_)S.&9!
M>,UT@UPJ>91UP%&S>EMV]D<P>S-X.3R6?#=YE#*G?5![ 2ER?HY\B2&D?]9^
M&6\4=@MZ<V5]=PY[(5M[=_=[L%$F>-Y\+$:]>=M\L#QI>P!]2S*:?$A]\RF$
M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
M-$2W9C> /#<5;/J 4RKH<\V >9?B0$R)O8L-1F&(PGVD3#Z'R6^14AN&T6$/
M6#&%W%*#7I6$ZD1T94&#]S;S;$."_"KL<TJ!_I;?/A^2LXHY1'J0QGS]2I:.
MX&\/4*N- V"B5OJ+*U(?79F)3$0L9'V'8C;8:ZV%7BKO<MZ#2Y8H/'6;(8F>
M0P"8.WR!24>5:FZR3X:2LF!A5?Z0 U'T7,>-0T0$8]>*:S:[:S2':BKR<HB$
M89=D765/_HH98&%4:7QM8W-8T6X[9JE=-U^<:A!AJU#=;;9F14*)<9EK&#2T
M==QP5B@O>F=V,)5Z6,=9:HC'7$E<_WM;7\U@CVU;8VMD'E[B9SMGM5!,:TYK
M;D(F;Z%O6#2+=%ASJ"A,>4]X?9.Z5)IBS(<86))E@WGN7'QH-FP-8'UJZEW,
M9+-MJD]R:3%PBD&/;?!SDC1&<PUV["AE>%=ZII((4-)L$(5_53)M['AS67=O
MR&KI7=%QI%S28FMSBDZU9TMUBT$4;&UWJS00<>9Z""A[=WU\II!V375U-X0<
M4C!V/W<S5LYW0VG!6WMX0UP(8&AY34X39:1Z;$"L:QY[GS/F<.A\^2B.=L%^
M>8\C2HY^/(+U3Y=^<78X5(-^FFCH67Y^O5M*7K5^Y4V:9#A_'4!=:?]_8C/$
M<!!_MRB>=B& &8X/2!2'"X(&36.&:'5M4I"%LF@[5\V$]5JQ74>$/4TF8PJ#
MC4 D:0R"XS.N;UF"-2BK=9V!A(TY1@R/BX%+2Y..$'3+4/:,>6>S5F>*V%H[
M7!:)0$R\8A2'JS_?:$J&%C.<;L.$;BBU=3""NXRB1'J7EH#!2BN52'1.3[22
MSV=)54N03EGK6R&-VTR&84>+9C^O9ZJ(Z3-\;DZ&42B^=-F#O(R^9%U08X!P
M9LE4MW.Z:519#F9^; %=:%C>;MAAU4LE<>AF;3W@=3%K/S$E>-=P@"7 ?+UV
M6(KL7_A9,G\78N5<R'*19=M@6F6':.AC[E@0;"1GD4J&;YYK6SUV<U)O6#$!
M=U]SMB7Q>YMXBXE46_%B#7VG7U-DV'%]8JEGH&219A%J:%=/::AM/TGZ;81P
M-CTD<9US5S#K=@MVRB8<>IQZF8?"6%%JSGPO7!1LSW 37\!NSV-Z8WUPS59@
M9W=RU4E(:[)T^CRS<"AW/S#"=.MYP29!>;Q\?H9851IS='KD62UTL&[G72MU
MXV)J83IW$56J98-X2DBX:A=YF#Q=;N!Z_#"H<^U\B29A>/Q^-H4J4E-[_'G7
M5JU\=&W\6O)\V&&:7TI],E3X8]I]DDA*:+%^!3P;;<-^B#"3<Q1_'29[>%E_
MO80V3_>$37C]5(R$ FT\60V#DV#R7:2#%%1D8G2"G4?=9XB",COM;-"!TC")
M<EN!<B:1=]&!$(-Y3@:,5'A44LV+1FR@5W^* F!K7$6(IU/K84F'5T=T9I:&
M$#NM;!"$T#!_<<2#@R:C=V*",(+T3(*3]'?747*2,&PG5D:0%E_\6R^-W5.5
M8%>+LD<Z9<N)D#MZ:W*'<#!?<5&%0B:Q=PJ#'X(;:XY0PW:V;6U4_FKN;W!9
M0UZK<8]=E%(.<\YA_D5E=CYFESD\>-]K:BVM>])PKR-[?OAV>X!B9V%9 '5Q
M:;A<DFG?;!M@)5W.;I-COU%=<2]G;D3D= )K1SCO=P=O4RVC>EESP"/ ?<QX
MEG[O8XMA2'059DYD(VC/:0IF_ES>:]=IW%"C;LQLSD1@<?UOXSBF=6!S(RV:
M>0EVL2/\?,-ZBWV(8 UIB7+"8RUKJ&>:9CMMQUP.:59OZD_[;*1R%D/R<"MT
M8#AS<^1VS"V;=]]Y=B0Q>]U\5GPZ7/QQL7&I8&=S&6:58\!T>EL,9R9UUD])
M:L!W/T-D;IUXP#@?<J1Z6"V(=N1\&21=>Q9]]7LG6E-YNW"M7?UZ<&6U89A[
M#EI&941[H$ZD:2%\/$,";3Q\[3?J<8E]KRU_=@A^A22">F]_8WI(6 Z!CF_E
M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
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MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
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M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
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M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
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M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
M:/\1 &'_&@%:_R,#5/\K!$__,P9*_SL(1O]""T/_20U _T\./?]5$#K_6Q$X
M_V$3-?]H%#/_;Q4P_W@6+O^"%RS_C1DJ_YD:*?^D&BC_KQLG_[H<)O_''";_
MQQPF_\<<)O_''";_QQPF_\<<H;0  )._  "&R@  >-8  &SB  !C_ < 7/\/
M %7_%@%/_QX"2?\F T3_+@1 _S0%//\[!CG_00<V_T8(,_],"#'_40DN_U<*
M+/]="BK_9 LH_VP,)?]U#2/_?PXA_XH/(/^5$![_H! >_Z@1'?^Q$1W_L1$=
M_[$1'?^Q$1W_L1$=_[$1E;P  (;'  !YTP  :^   %[M  !6_P, 3_\, $G_
M$@%#_QD!/O\@ CG_)P,U_RT#,O\S!"[_. 0K_ST%*/]"!2;_1P4D_TP&(O]1
M!B#_5P8=_UX'&_]E!QG_;@@7_W@(%?^#"!/_C0D3_Y8)$O^>"1+_G@D2_YX)
M$O^>"1+_G@D2_YX)_T(M _]",@3_2#($_TPV!O]./ C_4$<._U!2%?].7QK_
M2VL?_TAW)/]%@R?_0HXJ_T&7+/\_H"[_/Z<O_SZN,/\]M3'_/;PR_SS%,O\\
MSC/_.]\S_SOJ-/\[\S3_._LT_SS_,_X\_S/\/?\T]C__-?4__S7U/_\U]3__
M-?4__S7U/_\U_T,L _]$, 3_2C $_TXT!O]1.@C_4T8._U)1%?]171K_3FD@
M_TMT)/](@"C_18LK_T.5+?]"G2__0:4P_T"L,?\_LS+_/[HS_S["-/\^S#3_
M/MPU_SWH-?\]\37_/OHU_3[_-?L__S3X/_\V\D'_-_!!_S?P0?\W\$'_-_!!
M_S?P0?\W_T0L _]'+@/_32X$_U$R!?]4.0C_5T0._U9/%?]46AO_468@_TYR
M)?]+?2G_2(@L_T:2+O]%FS#_1*(R_T.I,_]"L#3_0K<U_T&_-O]!R3;_0-<W
M_T#E-_U \#?Z0/@W]T'_-O9!_S?R0?\X[$/_.>I$_SGJ1/\YZD3_.>I$_SGJ
M1/\Y_T4K _])+ /_4"P$_U4O!?]9-PC_7$(._UM-%?]85QO_5F,@_U)O)?]/
M>BK_3(4M_TJ/,/](F#+_1Y\T_T:F-?]%K3;_1;0W_T2\./Y$QCC\1-(Y^4/B
M.?9$[CGS1/<Y\43_.>]$_SKK1?\[Y$;_/.-&_SSC1O\\XT;_/.-&_SSC1O\\
M_T8K _]-*0/_5"D$_UDL!?]>-0?_84 -_V%*%/]>5!K_6E\@_U=K)O]4=BK_
M48$N_TZ+,?Y,E#3\2YPU^TJC-_I)JCCX2+$Y]TBY.O9'PCOU1\T[\D??.^Y'
M[#OK2/8[Z4?_/>='_S[A2/\_VDK_0-A*_T#82O] V$K_0-A*_T#82O] _T<J
M _]0)P/_6"8#_UXJ!/]C,P?_9CT-_V9'$_]D41K_8%L@_UQG)OU9<BOZ5GTO
M^%.',_91D#7T4)@W\DZ?.?%-ICOO3*T\[DRU/>Q+OCWK2\H^Z4O</N5,ZCWB
M2_4_WTO^0=Q*_T+43/]#S4W_0\M._T/+3O]#RT[_0\M._T/+3O]#_THH _]4
M) /_7",#_V,H!/]H, ;_;#L+_VQ$$O]J3AG^9E@?^6%B)?5>;2OR6W@P[UB"
M-.Q6BS?J5)0YZ%.;.^91HSWE4:H^XU"R/^%/NT#@3\= WD_80=E/Z$'43_1#
MT$[^1<Y._T;(4/]&PE'_1\!1_T? 4?]'P%'_1\!1_T? 4?]'_TTE O]7(0+_
M8" #_V@F _]N+@7_<C@*_W)!$/UP2Q?W;50=\FA>).UD:2KI870PY5Y^-.);
MASC@68\[W5>7/MM5GT#85*9"U5.N0])2MT304L)%SE+01LM2Y4;(4O)(Q5+]
M2<)2_TJ\5/]*MU7_2K95_TJV5?]*ME7_2K95_TJV5?]*_U C O];'@+_9!X"
M_VTD _]S*P3_=S4(_G@^#O9W1Q3P=% ;ZF]:(N1K92G@9V\OVV-Y-=9@@CK2
M78H^SUN20<Q9FD/*6*%%R%>I1\96LDG$5KQ*PE7)2[]5WTN\5NY,N5;Z3;=6
M_TVR6/]-KEG_3:Q9_TVL6?]-K%G_3:Q9_TVL6?]-_U,@ O]>' +_:!P"_W$B
M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
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M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
MM_\W0+?_-T"W_S= M_\WSHL  +^8  "RH0  IZD  )RP  "1N   AL " 'O(
M!P!TRQ( <,PB 6O+, -FRSP'8<M%#%S*3A%8RE855,I=&5')9!Q.R6P?2\ET
M(DC(?B1%R(@G0\B5*$'(HBH_R+$K/LG$*S[)X2H^Q_(K/<;\+3S%_RX\Q?\N
M/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP  >\<# '#/!P!G
MU@T 9-<: &#8*@%<V#8#6-A!!E382@I0V%(-3=A:$$K78A-'UVD61==R&$+7
M?!I V(<</=B3'CS8H1\ZV; @.=G#(#G9WR YU^\@.-7Y(C?4_R,WU/\C-]3_
M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
M!/]$3 ;_05@(_S]D"_L^;P[Y/'D0]CN#$?0ZBQ/S.9,4\3F9%/ XH!7N.*86
M[3BM%NPXM!;J.+T6Z3C)%N<XVQ;C.>H6X#CU&-TX_QK;-_\<V3?_'=<W_QW6
M-_\>UC?_'M8W_Q[6-_\>_SL@ ?]!' '_11H!_TL@ ?]-* '_3C("_TT\!/]*
M1P;Z2%,(]D9?"_)$:@[O0G01[$%^$^I AQ3H/XX5YCZ6%N4^G!?C/:,8XCVJ
M&. ]LAC?/;L9W3W&&=L]V!K6/>D:TCWU'<X]_A_,//\@RSS_(<D\_R')//\A
MR3S_(<D\_R')//\A_S\< ?]%%P'_2Q<!_U = ?]3) '_5"T"_U,W _=10@7Q
M3DT([$Q:"^A*90_E2&\1XD=Y%-]%@A;=1(H7VD.1&=A"F1K50I\;TT&F'-%!
MKAW/0;<>SD'!'LQ!T!_)0N4?Q4+S(<)!_B/ 0?\DOD'_)+U!_R6]0?\EO4'_
M);U!_R6]0?\E_T(8 ?])$P#_4!0 _U89 /]9( '_6B@!]UHR N]8/03H54D'
MXU-5"MY18 [93FH2U$QT%M!+?!C.280;S$B,',I'DQ[(1YH?QD:A(<1&J2+"
M1;$CP46\([]%R22]1M\EN4;O)K9&^R>T1O\HLT;_*+)&_RBQ1O\HL4;_*+%&
M_RBQ1O\H_T85 /]-$0#_51( _UL6 /]>&P#Y8",![V L >9>-@/?7$0%V%E0
M"M%76P_,5&44R%)N&,50=QO#3W\=P$Z&'[Y-CB&\3)4CNDN<)+A*I":V2JPG
MM$JV*+-)PRFQ2=8IKDKJ*JM*^"NI2O\KJ$O_*Z=+_RNG2_\KITO_*Z=+_RNG
M2_\K_TD2 /]0#@#_61  _U\2 /]C%@#R91T YV4E -YD,0'48C\%S6!+"L==
M5@_"6F 5OEAI&;M6<1RX5'D?ME.!(K-2B"2Q4) FKU"7**U/GRFK3J@KJ4ZR
M+*=.OBVF3LXNHT[F+J%/]2Z?3_\NGD__+IU/_RZ=4/\NG5#_+IU0_RZ=4/\N
M_TP0 /]4#0#_70X _V,/ /EG$0#K:14 WVH< --J+ '+:#L$Q65'";]B4@^Z
M8%P5MEUE&;);;1VO674AK%A\(ZI6@R:G58LHI523*J-3FRRA4Z,NGU*M+YU2
MN3";4LDQF5+B,9=3\C&64_\QE53_,914_S"45/\PE%3_,)14_S"45/\P_T\.
M /]8"P#_8 L ^V8, /!K#0#D;0X UFX6 ,QO* '$;3<$O6M$";=H3P^R95@5
MKF)A&JI@:1ZG7G AI%UX):%;?R>?6H<JG%F.+)I8ERZ85Z PE5:J,I-6M3.1
M5L4TD%;=-(Y7\#2-5_TSC%C_,XQ8_S*,6/\QC%C_,8Q8_S&,6/\Q_U$, /];
M"0#_8P@ ZVH' -UN" #8<0H SW(3 ,9S)0&^<C0#MW!!"+%M3 ZL:E44IV=>
M&:-E91Z@8VTBG&%T)9I@>RB77H,KE%V++9)<DS"/6YPRC5JF-(M:LC6)6L$V
MAUK6-H9;[3:%6_LUA5S_-(1<_S.$7/\SA%S_,X1<_S.$7/\S_U,* /]=!@#U
M9@0 WVT# -5R!@#0=0D R781 ,!W(@"X=C$#L70^!ZMQ20ZF;E(4H6Q;&9UI
M8AV99VHBEF9Q)9-D>"B08W\KC6&'+HI@D#"(7YDSA5^C-8->KS:!7KXX@%[1
M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
MXE\# -IB!@#48PD S6,2 ,1E(P"\93("MF- !;%A2PFL7E0.J%Q=$J5;91:A
M66P8GUAS&YQ6>AZ:58(@F%2*(I54DB234YLFD5*E)X]2L"F-4KXJC%+0*HI3
MZ2J)4_DIB%3_*8=4_RB'5/\HAU3_*(=4_RB'5/\H_TP% /]6 0#I70  W&,"
M -%G!0#,: < QF@0 +UJ( "V:2\!L&@\!*IE1PFE8U$-H6%:$IU?81::7FD9
MEUQP')5;=QZ26GXAD%F&(XU8CB6+5Y<GB5>A*896K2N%5KHL@U;,+()7YBR!
M5_<K@%C_*H!8_RJ 6/\I@%C_*8!8_RF 6/\I_T\" /U9  #B8   U6<  ,QJ
M P#&; 4 P&P. +=M'0"P;BP!JFPY!*5J1 B@:$X-FV97$9=D7A648F49D6!L
M'(Y?<QZ+7GLAB5V")(9<BR:$6Y0H@5N>*G]:JBQ]6K<M?%K)+GI:XRYZ6_4M
M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
M_TL, /I,#P#L3!0 X4H= -9*+ #.2SL!R4I( L1(4P3 1UT'O$9F";I$;@NW
M0W8-M4-]#K-"A!"Q08L1L$&2$JY FA.L0*(4JD"K%:E MA:G0,07ID#9%Z-!
M[1B@0?L8GT'_&9Y!_QF=0?\9G4+_&)U"_QB=0O\8_T ) /]&!0#_3 4 \4\'
M .90"0#C3PT U4\5 ,Q1)P#%438!OU!# KI/3@6V35@(LTQA"K!*:0VM27 /
MJTAX$:E'?Q*G1X84I4:-%:-&E1:A19X8GT6G&9Y%LAJ<1;\:FD71&YA%Z1N6
M1O@<E4;_&Y1&_QN31O\;DT?_&Y-'_QN31_\;_T(% /]* 0#R4   X50! -E6
M!0#350D S%42 ,-6(@"\5S(!MU8_ K)42@6M4U0(JE%="Z=09 ZD3FP0HDUS
M$I],>A2=3($6FTN)%YE*D1F72ID:E4FC&Y-)KAV22;L>D$G,'HY*Y1Z-2O8>
MBTO_'HM+_QV*2_\=BDO_'8I+_QV*2_\=_T4  /]-  #E5   V5D  ,]; P#*
M6P8 Q%H/ +M;'@"U7"X!KUL[ JI:1@6F6% (HE99"Y]58 Z<4V@1F5)O$Y=1
M=A654'T7DU"$&9!/C1J.3I8<C$Z?'HI.JA^(3K<@AT[((85.XB&$3_,@@T__
M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
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M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
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M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
M/7%1 #QQ60$Z<6(!.'%L C9P> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q
M;OL$,6W_!#%L_P0Q;/\$KV0  *%I  "/:   @6@  '5I  !K:0  8&L  %5N
M  !-<0  1G,  $)U"P _=A( /7<< #QW)0 Z>"T .7@U #AY/0 W>44 -GE-
M #5Y50 S>5X ,7EH 3!Y= $N>8,"+7F2 BMXHP(J>+4"*GC, BIWZ@(J=OD#
M*G7_ RIT_P,J=/\#JFH  )IM  ");   ?&T  '!M  !F;@  6W$  %!U  !(
M>   07L  #I^!0 V?PX -( 6 #.!(  R@2@ ,($P "^".  N@D  +8)( "R"
M4  K@EH *H)D "B"<  F@G\!)8*/ 22"H $C@K(!(H+) 2*!YP$B?_<!(G[_
M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
M7T5' %U%30!;150 6D9; 5E&8P%71FP!5D9V E1&@0-31HX#4D><!%!'JP10
M1[T$3T?6!4]'[P1/1_T$3T?_ T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+
M  !_2@  >$8  '%'  !L1P< :$@0 &1(&@!A220 7TDM %U)-0!;23T 64E$
M %=)2@!625$ 54I9 51*80%22FD!44IT D]*?P-.2HP#34J;!$Q+J@1+2[P$
M2DO3!4I+[@1+2_T$2TK_ TM*_P-+2O\#P4@  +)0  "@3P  D4\  (5.  ![
M30  <TD  &Q*  !G2P0 8DP. %],%P!<32$ 6DTJ %A-,@!633H 5$U! %-.
M2 !23D\ 4$Y7 4].7P%.3F<!3$YR DM.?0))3HL#2$Z9!$=/J 1&3[H$1D_1
M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
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M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
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M_/[______________________________________________________P
M                   ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@(2(D)28H
M*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA96UQ=7F!A
M8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3E)66F)F:
MG)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,S<_0T=+4
MU=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^________________
M______________________________________\
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M_VUF=#$      P0A   !                     0
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MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
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MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
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M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
M=[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN_^@
M& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-AZ+,C(VJQXJ1
ML<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS =[2[
MO'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN_^@& /_
MHBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-AZ+,C(VJQXJ1L<2(
ME+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS =[2[O'BT
MN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN_^A& /_HRL0
M_Z Z)?^<2#S_EU93^)-C:.R2:7KAD7.*V(]\F-".A*3*CHRMQHV0M,2*D[?#
MAI6XPH28N<&!F[K!?YV[P'V@O,![I+S >J>]P'FLO<!XL+V]>+.\N'BSO+AX
ML[RX>+.\N'BSO+AXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO/^A& /_HRH0_Z$Y
M)?^=2#W_F%54]Y1A:>N49GO@DF^,UI%XFLZ0@J;(CXFPQ(^/ML.+D;?"B)2Y
MP827NL""FKS ?YV]OWV@OK][I+Z^>JB_OGBMO[UXL;ZX>+*^M'FSO;1YL[VT
M>;.]M'FSO;1YL[VT>;.]M'FSO;1YL[VT>;.]M'FSO?^B& /_I"D0_Z$X)?^=
M1SW_F554]Y9>:>N58WO@E&R-U9)UG,V1?ZC'D8>RQ)&.ML.-D+C!B9.ZP(:6
MO+^"F;V_?YR^OGV@O[U[I<"]>:K O7BPP+AYL,"T>;&_KWJRO:]ZLKVO>K*]
MKWJRO:]ZLKVO>K*]KWJRO:]ZLKVO>K*]KWJRO?^C& /_I"D0_Z(X)?^>1CW_
MF515]Y=<:>N78'S?EFF-U9-RG<R2?*K%DH6TQ)*,ML*/C[G!BY*[P(>5O;Z#
MF+^]@)S O7V@P;Q[I<*\>:O"N7FOPK1YK\&P>K# K'NROJQ[LKZL>[*^K'NR
MOJQ[LKZL>[*^K'NROJQ[LKZL>[*^K'NROO^C& +_I2@0_Z(W)?^?1CW_FE-5
M]YE::>N97GS?EV6.U)5OG<N4>:O%DX*TQ)2*M\*1CKG C)"\OXB3OKV$E\"\
M@)O"NWV@P[M[IL2Z>JW%M'JNQ*]ZK\*L>[# J'RQOZA\L;^H?+&_J'RQOZA\
ML;^H?+&_J'RQOZA\L;^H?+&_J'RQO_^D& +_I2@0_Z,V)?^?13W_FE-5]YI7
M:>N;6WS?F6*.U)=KGLN5=JS%E("TPY6(M\&3C;K CH^]OHF2P+R%E<*[@9K$
MN7V@QKE[J,>T>JO'KWNMQ:M[KL.G?*_!I'VQOZ1]L;^D?;&_I'VQOZ1]L;^D
M?;&_I'VQOZ1]L;^D?;&_I'VQO_^D& +_IB<0_Z,V)?^@1#W_FU)6]YQ5:>N<
M6'S?FUZ.U)EGGLJ7<ZS%EGRTPY>%M\&6B[N_D8V^O8N0P;N&E,2Y@9G'MWZ@
MR;9\J<JN>ZK(JGRLQJ9]K<2C?J_!H'ZQOZ!^L;^@?K&_H'ZQOZ!^L;^@?K&_
MH'ZQOZ!^L;^@?K&_H'ZQO_^E& +_IB8/_Z0U)?^@1#W_G%%6]YY3:>N>57O?
MGEJ-U)MDGLJ9;ZS%F'FTPYF"N,&9BKN^E(R_O(Z.P[F(DL>W@IC+M7ZAS:]\
MI\VI?:G*I7ZKQZ)_K<2??Z_"G8"QOYV L;^=@+&_G8"QOYV L;^=@+&_G8"Q
MOYV L;^=@+&_G8"QO_^F& +_IR8/_Z0U)?^@0S[_G5!5]Y]1:.N@4WO@H%>-
MU)Y?GLJ;:ZS%FW6TPYM^N,";A[R]EXK NI&,Q;>*D,JTA)?/LH"CTJA_I<^C
M@*C+H("KQYV!K<6;@:_"F8*QOYF"L;^9@K&_F8*QOYF"L;^9@K&_F8*QOYF"
ML;^9@K&_F8*QO_^F& +_IR4/_Z4T)?^A0S[_GDY5^*%.:.RB4'K@HU*,U:%;
MG<N>9JS&G7&TPYYZN,">A+R\FXC"N96*Q[6-C<ZPAI;4J8*@UJ&"I-"=@JC+
MFH.JR)F#K<67A*_"EH2PP):$L,"6A+# EH2PP):$L,"6A+# EH2PP):$L,"6
MA+# EH2PP/^F& +_IR4/_Z4T)?^A0C[_GTQ5^*),9^RE37GAIDZ+U:16G,RA
M8:K&H6RSPZ)VM\"B@+V\H(?#MYJ(RK*3BM*LBY3;H(>?V)J&I-&7AJ?,E8:J
MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
M>9^QOWN<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO?^@$ '_
MI"0)_Z,R'/^H-"O_LR\T^;\M/.G-+T#9WB]*RN<T7[WJ.G.OWD&#H=-1D9?+
M8)V0Q&ZFC+]ZK8:[@;-_N(>X>K:-NW>UE;QUM9^\<K2HO6ZSLKYQK+*^=*>R
MOG:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO?^A$ '_I2,)
M_Z0Q'/^M+B?_N2DO[L@F,]K<)C?*YRQ/O?(R8Z_H.76AW4*$EM13D(_-8IJ*
MQW"BAL-ZJ("_@*U[O86Q=KN+M'.YDK5QN9JV<+FCM6VYJ[9JN+2X:[*VN&ZL
MMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZLMKANK+:X;JRVN/^C$ '_IR()_Z4O
M&_^S)R+TPB$FW=@=),OG(SR]\BI3K_,R9J'G.W:5WD:#C=96C8?09):$RW&<
M?\AXH7K%?J5VPH.I<L&)JV^_CZULOY:N:[Z=KFJ_IJYHOZZN9;VXL&6YN[!E
MN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[!EN;NP9;F[L/^E$ '_J" (_ZPF%_R[
M'1KCT1,9S.49*;WR(D&O_2I5H?,T9I;I/W2,X4M_A=M9B(#59H]\T6^4=\YV
MF7/+?)QPR8&?;<B'H6K'C*-HQI*D9L69I63%H*5DQ:BE8\:RI&#$NZ9@Q+NF
M8,2[IF#$NZ9@Q+NF8,2[IF#$NZ9@Q+NF8,2[IO^H$ #_JAX(_[,=$>S)#@_.
MXPX5OO(8+:_^(D.A_RU5EO0Y9(SL16^$Y5%Y?N!<@'G<9X9TV6Z*<-9TCFS3
M>9%ITG^39]"$E63/BI=BSH^88,V5F5_-G)I>S:*;7<VKFUS-M)I<S;2:7,VT
MFES-M)I<S;2:7,VTFES-M)I<S;2:7,VTFO^K#P#_K1H'\L -",[3"@:^\ X:
MK_X9,*'_)$.5_S)2B_@_7H/Q2VA][%9P=^A?=G'D97ILX6Q^:=]R@6;=>(1C
MW'V&8=N"B%_:AXE=V8R+6]B2C%G7F(U8UIZ-5]:ECE;5K(Y6U:R.5M6LCE;5
MK(Y6U:R.5M6LCE;5K(Y6U:R.5M6LCO^O#0#_MPX#S<D( ;[8"0FN_1 <H?\<
M+Y7_*3^+_S=,@OY%5GSY4%YU]%ED;O%?:6CN9&UDZVIP8>IP<U_H=75=YWIW
M6^9_>%GEA'E8Y(E[5N..?%7BDWU4XIA^4N&>?E'AI7]1X:5_4>&E?U'AI7]1
MX:5_4>&E?U'AI7]1X:5_4>&E?_&T" #.P 8 O<X' :[@!PN@_Q(<E/\@*XK_
M+SB!_SU#>O])2W/_4E%L_E=79?M=6V'Y8UY>]VA@6_5M8ECT<F16\W=F5?)[
M9U/Q@&A1\(1I4/"):D_OCFM.[I-L3.Z9;4OMGVY+[9]N2^V?;DOMGVY+[9]N
M2^V?;DOMGVY+[9]N2^V?;M&Y P"\Q04 K=8# 9_X"PN3_Q88B?\D)(#_-"]Y
M_T$W</](/FC_3T-B_U5'7?]:2UG_8$U6_V504_]J45'_;E-/_W)43O]V54S^
M>U9+_7]72?V$6$C\B%E'^XU:1ON36T7ZF%Q%^IA<1?J87$7ZF%Q%^IA<1?J8
M7$7ZF%Q%^IA<1?J87+V] P"MS0$ GM\  9+_#0B'_QD2?O\I&W7_-2-L_SPJ
M9/]#+U[_2C18_U W5/]6.E'_6SQ._V ^2_]D0$K_:$%(_VQ"1O]P0T7_=$1$
M_WA%0O]]1D'_@4= _X9(/_^,23W_D4H]_Y%*/?^12CW_D4H]_Y%*/?^12CW_
MD4H]_Y%*/?^12J[%  ">UP  C_4  8;_#P1\_QL+<?\D$6?_+!=?_S4<6?\]
M(53_129/_TLI3/]2+$C_5R]&_UTP1/]A,D+_9C- _VHU/_]N-CW_<S<\_W<X
M._]\.3K_@3HX_X8Z-_^,.S;_DCPV_Y(\-O^2/#;_DCPV_Y(\-O^2/#;_DCPV
M_Y(\-O^2//^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z
M@&_N=XAWZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:Z
MD=QEP9+<9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1
MSFC2D?^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N
M=XAWZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QE
MP9+<9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2
MD?^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N=XAW
MZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QEP9+<
M9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D?^$
M$P'_A2(&_X8U%/^$1B3_@%4T_X1=0_^%95#_@VU=^(!U:/)]?G'L>H9YZ'>-
M?^5UDX7B<IB)X'"=C-]NHH[=;*:0W&NKDMMIKY3::+65VF>[E=IFPY;:9LR6
MTVC/ELQISY7(:L^6R&K/ELAJSY;(:L^6R&K/ELAJSY;(:L^6R&K/EO^%$@'_
MAR(&_X<U%/^%1B3_A%0U_XA<0_^(9%'^AVM>]X-R:?& ?'/K?85[YWJ,@N-W
MDH?@=)>,WG*<C]QPH9+;;J:4V6RJEMEJL)C8:;:9UVB]F==HQIK3:,R:S&K,
MF<9KS)K";,R:PFS,FL)LS)K";,R:PFS,FL)LS)K";,R:PFS,FO^&$@'_B"$&
M_X@U%/^&1B7_AU,U_XM;0_^,8E'^BFI>]H=Q:O"$>G3J@(-]Y7V*A.)ZD(K>
M=I:/W'2;DMIQH)78;Z68UFVKFM5KL)O5:K><U&F_G=1IR9W,:\J=QFS)G<!M
MR9V];LF=O6[)G;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G?^'$@'_B2$&_XHU
M%/^(1B7_BE(U_XY:0_^/85'^CFA>]HMO:N^'>'7IA(%^Y("(AN!\CXS=>921
MVG::E=ASGYG5<*6;U&ZJGM-ML9_2:[B@TFO"H<ULQZ'&;L>AP&['H;MOQZ&X
M<,>AN'#'H;APQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H?^($0'_BB$&_XLU%/^)
M1B7_C5$U_Y)80_^27E'^D&5>]HYL:^^+=7;HAWZ XX2&B-Y_C8_;>Y.4V'B9
MF=5UGIS3<J2?T7"JHM!NLJ/0;;JDSFS$I<9OQ*2_<,2ENG'$I;5QQ*6R<L2D
MLG+$I+)RQ*2R<L2DLG+$I+)RQ*2R<L2DLG+$I/^)$0'_BR$&_XPT%/^*1B7_
MD$\T_Y160_^46U'^DV%>]I%H:^Z.<';HBWN XH>#B=V#BI'9?I&7U7J7G--W
MG:#0=*2CSW&JILYOLZ?-;KVHQW#"J+YQP:FX<L&IM'/!J:]TPJBM=,*GK73"
MIZUTPJ>M=,*GK73"IZUTPJ>M=,*GK73"I_^*$0'_C"$&_XTT%/^+1B;_DTXT
M_Y930O^76%#^EEY>]I1D:NZ2;';GCW:!X8R BMR'B)+8@H^9TWV5G]!YG*/.
M=:.GS'*KJLMPM*O(<+^LOW.^K+=TOJVR=;ZLKG:_K*IVOZNH=\"JJ'? JJAW
MP*JH=\"JJ'? JJAWP*JH=\"JJ'? JO^+$0'_C2 &_XXT%/^-12;_EDTS_YE0
M0?^:54__FEI=]YA@:>^5:'7HDG" X8][BMR+A)/6AHR:TH"3H<Y[FJ;,=Z*J
MRG2KKLARN*_ =+ROMW6\L+!VO+"K=[ROJ'B]KZ5YOJVC>;ZMHWF^K:-YOJVC
M>;ZMHWF^K:-YOJVC>;ZMHWF^K?^+$ '_CB &_X\T%/^/1"7_F$HS_YM-0/^=
M44[_G5=;^)Q<:/":8W3HEVI_XI-UBMR/@)/6BHF;T820H\U^F*G)>:*NQW6M
ML<1TNK.W=KFSKWBYLZIYNK.F>KJRHWN[L:![O+"??+VNGWR]KI]\O:Z??+VN
MGWR]KI]\O:Z??+VNGWR]KO^,$ '_CR &_Y T%/^20R7_FD@R_YU*/_^?3DW_
MH%-:^:!89O&?7W+JG&5]XYAOB-R3>I+6CX2;T(B-H\N!EJO'>Z&QQ7:PM;IW
MM[:O>;>VJ'JXMJ-\N+2@?+FSGGVZLIQ^N[&;?KRPFWZ\L)M^O+";?KRPFWZ\
ML)M^O+";?KRPFWZ\L/^-$ '_CR &_Y$T%/^40R3_FT8Q_Z!(/O^B2TO_I%!8
M^J159/.D6G#KHF%[Y)]IA=Z:<Y#7E7Z9T(Z(H\J%DZS$?:"TO7BPN:]YM;FF
M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
M@N$  'C_  !L_P@!8/\- E?_$0-/_Q@%2/\@!D/_*0@__S$*._\X##C_/@XU
M_T0/,O])$##_3A$N_U,2+/]8$RK_710I_V,5)_]I%B7_;Q<D_W<7(O]^&"'_
MA1D?_X\:'_^1&A__D1H?_Y$:'_^1&A__D1H?_Y$:'_^1&O]H&0+_9",$_U\O
M!O]>0!#_8TL:_V=4)?]H72__9F<Y_V1R0?]B?4C_8(=._UV04O];F%;_6IY9
M_UBD6_]7JEW^5K!?_56U8/Q4O&'\5,1B^U/-8_E2W&/V4N9C\5/J8^Q4[6/F
M5N]BX%?P8^!7\&/@5_!CX%?P8^!7\&/@5_!CX%?P8_]I& +_92,$_V N!O]?
M0!#_9DD:_VI3)?]K7##_:64Z_V=P0O]D>TG_8H5/_U^.5/]=EEC_6YU;_UJC
M7?U8J5_\5Z]A^U:U8OI5O&3Z5<1E^53.9?=3W6;S4^9F[E7J9N=6[67A6.YE
MVUGO9MM9[V;;6>]FVUGO9MM9[V;;6>]FVUGO9O]J& +_9B($_V$N!_]@/Q#_
M:4@;_VU1)O]N6S#_;&0Z_VEN0_]G>4O_9(-1_V&,5O]?E5K_79Q=_5NB8/M:
MJ6+Z6:]D^5BU9?E7O&?X5L5H]U7/:/54X&GP5>9IZ5?J:.)9[&C;6NUITUON
M:=-;[FG36^YITUON:=-;[FG36^YITUON:?]J& +_9R($_V(N!_]C/A#_;$8;
M_W%0)O]R63'_<&([_VQK1/]I=DS_9X%2_V2+6/]ADUS]7YM@^UVA8OI;J&7Y
M6JYG^%FU:/=8O&GV5\9J]5;1:_)5X6SL5^=LY%GI:]Q;ZVO47.QLS5WM;,U=
M[6S-7>ULS5WM;,U=[6S-7>ULS5WM;/]K%P+_:"$#_V,M!_]G/!#_<$4;_W1.
M)O]V5S'_=& [_W!I1?]M<TW_:GY4_V:(6OYCD5[[89EB^5^@9?A=IVCV7*UJ
M]5JT;/19O6WT6,=N\E?4;^Y7XF_F6>9OW5SI;M-=ZF_-7NMPQU_K<,=?ZW#'
M7^MPQU_K<,=?ZW#'7^MPQU_K</]L%P+_:2$#_V4M!_]K.A#_=$,;_WE,)O]Z
M53'_>5T\_W5F1?]P<$[_;7M6_VJ%7/QFCV'Z9)=E]V&?:/9?IFOT7:UM\URT
M;_):O7'Q6<ER[UC:<^A:XW/>7>9RTU[H<\M?Z'3&8.ATP6'H=,%AZ'3!8>AT
MP6'H=,%AZ'3!8>ATP6'H=/]M%@+_:B #_V8M!_]O.!#_>$$:_WU*)?]_4C'_
M?EL\_WMC1O]V;$__<7=7_FV"7OMJC&/X9I5H]62=;/-AI&_R7ZQQ\%VT<^]<
MOW7N6\MVZEO==^!=XW;38.5WRF'E>,1BY7B^8^5XNF3E>+IDY7BZ9.5XNF3E
M>+IDY7BZ9.5XNF3E>/]N%@+_:R #_V@L!_]S-A#_?3\:_X)')?^$4##_A%@[
M_X%@1?]\:4__=G)7_G%]7_EMB&7V:I)J\V:;;_%CHW+O8:MU[5^U>.Q=P7GL
M7-!ZXUW?>]1AXGO*8N)\PF3A?;QEX7VW9N)\LV?B?+-GXGRS9^)\LV?B?+-G
MXGRS9^)\LV?B?/]P%0'_;!\#_VDL!_]W- __@3P9_X=%)/^*32__B54Z_X==
M1?^"94__?&Y8_79X8/ARA&?U;8YM\6F8<N]FH7;L8ZMYZV"V?.E>Q'[G7MA_
MV&'??LICWX#!9=Z!N6?>@;1HWH&P:=^ K&G??ZQIWW^L:=]_K&G??ZQIWW^L
M:=]_K&G??_]Q%0'_;1\#_VLK!_][,@__ACH8_XQ#(O^/2RW_CU,X_XU:0_^)
M8DW_@VE7_7QR8/AV?V?T<8IN\&R5=.UHGWGJ9*I]Z&&W@.9?R(+=8=N#S&3<
MA,!FW(6X:-N%L6K;A:UKW(2I;-V#IFS=@J9LW8*F;-V"IFS=@J9LW8*F;-V"
MIFS=@O]R% '_;QX#_V\I!_]_, [_BC@7_Y%!(?^42BS_E5$V_Y-80?^08$O[
MBV=5]81O7_!]>F?K=X5OYW*0=N-MFWS>:*:!VF6SA-5CQ(;/9-J'P6?9B+=I
MV(FO:]B)JFW9B*9NVH>C;MJ&H&_;A:!OVX6@;]N%H&_;A:!OVX6@;]N%H&_;
MA?]R% '_<!X#_W(H!_^"+@W_CC86_Y5 '_^92"G_F4\T_YA5/OJ67$GTDF13
M[8QK7>>%=F;A?X%OVWB,=]-REG[-;:&$R6JMB<5HNXO!:-",MFO5C:YMU8VG
M;]:,HW#6BY]QV(J=<=F)FW+:AYMRVH>;<MJ'FW+:AYMRVH>;<MJ'FW+:A_]S
M% '_<!T#_W4F!O^&+ W_D385_YE '?^<1B?_G4PQ_)U2._2<647MF6!/YI1H
M6=^.<V/5AGUNS7^'>,9XD8# <YN'NV^GC+9MM(^S;,B1K&[2D:5PTY"@<M2/
MG'/5C9ETUHR7=-B*EG79B99UV8F6==F)EG79B99UV8F6==F)EG79B?]T$P'_
M<1T#_W@D!O^)*PS_E343_YP^&_^@0R3_HDDN]Z-0-^^B5D'GH5U*WYUG5-25
M;V++C7ANPX6">;M_C(*U>9:)KW6ACJIRKY*F<<&4H7/0E)QTT9*8=M*1EG?3
MCY1WU8V2=]:,D7C8BI%XV(J1>-B*D7C8BI%XV(J1>-B*D7C8BO]U$P'_<AP#
M_WLC!O^,*0O_F#02_Y\\&?^C02+[ID8J\JA-,^JI5#SBJ5M$UZ-C4\R:;&+"
MDW5NNHM^>;*%AX.J?Y&*I'N<D)YXJI2:=KN6EW?/EI1YT)21>M&2CWK3D(YZ
MU(^->M6-C'K7BXQZUXN,>M>+C'K7BXQZUXN,>M>+C'K7B_]U$P'_<QP#_WTA
M!?^.*0K_FS00_Z(Y%_^F/A_WJD0F[JY*+N6Q4C7<KUE!SZAA4L6@:6&[F')N
ML9%Z>:F+@X.AA8V+FH&8D91^I9:0?+:8C7W-EXQ^SY6*?M"3BG[2D8E^TX^)
M?=6-B'W6BXA]UHN(?=:+B'W6BXA]UHN(?=:+B'W6B_]V$@'_=!P#_X @!?^1
M* G_GC,/_Z0W%?ZJ.QOSKT$BZK1(*.*Y4"[4M%9 R:U?4;ZE9V"TGF]MJI=W
M>*&1@(*9C(J+D8>5D8N$HI:&@[*9@X3+F(2#SI:$@]"4A(+2DH2!TY"$@=2.
MA(#6C(2 UHR$@-:,A(#6C(2 UHR$@-:,A(#6C/]W$@'_=!L#_X(>!/^4)PC_
MH#(-_Z<T$_JN.!COM3T<YKQ&(=R_3"S.N50_P[%=4+>J95^MI&QLHYUT=YF8
M?(&1DX:*B8^2D8*,GY9]BJ^8>HO'F'R)SI9]B-"4?H;2DG^%TY!_A-2.@(/6
MC("#UHR @]:,@(/6C("#UHR @]:,@(/6C/]X$@'_=1L#_X4<!/^7)@?_HR\+
M_ZLP$/6S-!3KNSH7XL1$&-7$2"O(O5,]O+9;3K&P8UVFJFIJG*1Q=I*?>H")
MFH.)@9:.D'F3G)5TDJR7<9+#F'.1SY9VCM"4>(O2D7F*TY!ZB-6.>X?6C'N'
MUHQ[A]:,>X?6C'N'UHQ[A]:,>X?6C/]X$@'_=AL#_X@; _^:)0;_IBL)_J\L
M#/&Y+P[FPS8/W<T\%L[(1RG"PE$[MKQ93*JV85N?L&AHE:MO=(NF=WZ!HH"&
M>9^+C7&<F9)LFZF5:9N_EFN9T)1NE-&2<9'2D7./U(]UC=6-=HO6BW:+UHMV
MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
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M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
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M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
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MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
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M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
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M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
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M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
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M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
M_UX" /]L @#_? , _XT# /^= P#_K , _[4# /^U P#_M0, _[4# /^U _\Y
M)P+_,S("_S4T _\X-@/_.#L$_S9#!?\S3@?_,5L)_R]H#?\M=A'_*X04_RF1
M%O\IFQC_**09_RBM&O\HM1O_)[X<_R?('/\GU!W_)^0=_R?O'O\G^1[_)_\>
M_R?_'O\G_QW_*/\=_RO_'O\M_Q_\+_\?_"__'_PO_Q_\+_\?_"__'_\Z)P+_
M-#$"_S@Q _\[- /_.SD$_SI!!?\W2P?_-5@*_S-E#O\Q<Q+_+X$5_RV.%_\M
MF!G_+*$;_RRJ'/\KLAW_*[L>_RO$'_\KT!__*N$@_RKM(/\J]R#_*O\@_RO_
M(/\K_Q__+/\?_R__(?PQ_R+W,_\B]S/_(O<S_R+W,_\B]S/_(O\[)@+_-3 "
M_SLO O\^,0/_/S8$_SX]!?\\2 ?_.U4+_SEB#_\W;Q/_-7T7_S.*&?\RE1O_
M,9X=_S"G'O\PKQ__,+<@_R_ (?\ORR+_+]PB_R_J(_\O]2/_+_XC_R__(O\P
M_R+_,/\C^S/_)?4U_R7P-_\F\#?_)O W_R;P-_\F\#?_)O\\)@+_.2T"_S\L
M O]#+0/_1#($_T,Y!?]#10?_0E(+_T!?$/\^:Q7_.W@8_SF%&_\WD![_-YH@
M_S:C(?\UJR+_-;,C_S2\)/\TQB7_--0E_S3F)O\T\2;_-/LF_S7_)?XU_R;Z
M-O\H\SC_*>PZ_RGF//\JYCS_*N8\_RKF//\JYCS_*O\])0+_/2H"_T,H O]'
M*0/_22T$_THV!?]*00?_24T,_T=:$?]%9Q;_0G0:_T" '?\^C"#_/94B_SR>
M)/\[IB;_.ZXG_SJW*/\ZP2C_.LTI_SKA*?XZ[BG[.ODI]SO_*?8Z_ROP._\M
MZ#W_+N$__R[;0?\NVT'_+MM!_R[;0?\NVT'_+O\^)0+_028"_T@D O],)0+_
M3RD#_U(S!?]1/@?_44D,_T]6$O],8A?_2F\<_T=[(/]%AB/_0Y$E_T*:)_]!
MHBG_0:HJ_4"R*_Q O"S[/\@M^#_;+?1 ZRWP0/<M[4#_+^L__S'D0?\RVT/_
M,]%$_S/+1O\SRT;_,\M&_S/+1O\SRT;_,_] ) +_12,"_TP@ O]2(0+_5B8#
M_UDO!/]9.@?_648,_U91$O]471C_46H=_DYU(?Q,@27Y2HLH]TF5*_5'G2SS
M1Z8N\D:N+_!%N##O1<0Q[473,>A&Z#'E1O8RXD7_-=]$_S;31_\WRDC_.,1*
M_SB_2_\WOTO_-[]+_S>_2_\WOTO_-_]!(P'_21\!_U$< ?]7' +_7","_V L
M _]@-@;_8$$+_UY-$?U;6!CX6&0=]%5P(_%3?"?N4(8KZT^0+NE-F3#G3*$R
MY4RJ,^-+M#3B2\ UX$O/-=M+YC;52O0XT4K_.LY*_SS$3/\\O4W_/+A/_SRT
M3_\[M$__.[1/_SNT3_\[M$__._]"(@'_3!P!_U48 ?]<&0'_8R "_V8H _]H
M,@7_:#T)^F9($/1C4Q?N8%\=ZEUK(^9:=BCB5X$MWU6+,-Q3E#/949TVU5"F
M.--/KSK03[L[SD[)/,M/X3W'3_(^PT__0,!/_T&W4?]!L5+_0*U3_T"J5/\_
MJE3_/ZI4_S^J5/\_JE3_/_]&'P'_4!D!_UD5 ?]B%P'_:!T!_VPD O]O+@/Y
M;S@'\6Y$#NMK3A7E:%L<WV1G(]I@<2K477LOT%N%-,Q8CCC)5Y<[QU6@/<14
MJ3_"4[1!OU/"0KU3UD.Y4^U$ME/]1;-4_T6L5O]$IU?_1*18_T.A6/]"H5C_
M0J%8_T*A6/]"H5C_0O]('0'_4Q8!_UT2 ?]F% '_;1D!_W(A ?MU*0+R=C,%
MZ78^"^)S2A+;;U<:TFMB(\UG;"O(9'8QQ&%_-\!>B3N]7)(^NEN:0;=9I$2U
M6*Y&LE>[1[!7S4BM6.A(JECZ2:=9_TBA6O](G5O_1YM<_T:97/]%F5S_19E<
M_T697/]%F5S_1?]+&@'_5Q,!_V$0 /]K$@#_<A8 _W@< ?5[) 'K?2T#XGXY
M!]E[1A#0=E,:R7%>),-M:"R^:G$SNF=[.+9D@SVR8HQ!KV"51:Q>GT>I7:E*
MIERV2Z1<QTRB7.)-GUWW3)Q>_TR87_]*E6#_29-@_TB18/]'D6#_1Y%@_T?_
MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
M ,UG  ##;   NV\  +5P  "O;PH J'$: *-R*P&=<CD$F'!%"9-N3PZ/;5@4
MBVM@&(=I9QR$:&\@@6=W(WUF@"9Z9(HI=V.4+'5CH2YR8J\O<&+!,&]BWS!N
M8_<N;V/_+&]C_RIO8_\H;V+_)V]B_R=O8O\G;V+_)_]-  #K6   V6,  ,EJ
M  "_<   MW,  +!T  "I= < HW87 )YW* &8=C<$DW5""(YS3 Z)<543A7!=
M&(%N91Q^;6P?>VQT(WAJ?29T:8<I<6B2+&YGGBYL9ZPP:F>^,6EGW#!I9_4N
M:6?_+&EG_RIJ9_\I:F;_*&IF_R=J9O\G:F;_)_]0  #G6P  TV8  ,5N  "[
M<P  LW<  *MY  "D> , G7H4 )A[)0&3>S0#CGI !XEX2@V$=E,2@'5;%WQS
M8AMX<FH?=7%R(G)O>R9O;H4I;&V0+&ELG"YF;*HP9&R\,6-LV3!C;/0O8VS_
M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
M=6(N ')B.0%O8D,";&%+ VIA4P5G85H'96!B"6-@:@M@7W,-7EY]#UM>B1%9
M79825UVE$U5=MA147<X45%WN$U1=_Q%57/\055S_#E5;_PY66_\-5EO_#=Y,
M  #'5@  N%\  *UD  "@90  DV0  (EC  !_80  >6(# '5D$0!R91X ;V8K
M &QG-P%J9T "9V9) V5F401B95@&8&5@"%UD9PI;9' ,66-[#E9CAA!48I02
M4F*C$U!BM!-/8LP33V+M$D]A_Q%/8?\04&#_#E!@_PY08/\-4&#_#=E/  ##
M6@  M&,  *EI  ";:   CV<  (1G  !Y90  <V<  &]I#@!L:AL :6LH &=L
M- !D;#T!8FQ& E]K3@1=:U8%6FI=!UAJ90E6:6X+4VEX#5%HA ].:)(03&>A
M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
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M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
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M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
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M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
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M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
MQ.T2 K7[)@VH_S89F?\[(XS_02R _THT>/]3.G'_7S]L_VE#:/]O167_=$=C
M_W=(8O][26'_?DI?_X%*7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_
MA$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$O_GR(%_YTM
M#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2Q
MPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>
M.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(
MN;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_
MJ$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(
MC+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>
M_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z
M@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)
M*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%
MMW^7R[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V
M4SS_N%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7
MR[1]H,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_
MN%U/^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]
MH,^N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/
M^[9F8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F
M8^ZT;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT
M;W?BK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?B
MK'6)V*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)
MV*1[F<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-'_GR(%_YTM#/^>.!7_J$$>_[%)*_^V4SS_N%U/^[9F8^ZT;W?BK'6)V*1[
MF<Z;?Z;(DX2QPHV(N;Z(C+^Z@Y'%MW^7R[1]H,^N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-'_
MGR(%_YTM#/^?.!7_JD >_[-)*_^Y4CS_NUQ/^KIE9.VX;7CAL'.+U:AYG,R?
M?:K%EX&UOY&%OKJ,B<6VAX_,LH.6TJ^!H-:G?J+3IWZBTZ=^HM.G?J+3IWZB
MTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM/_GR(%
M_YXM#/^@-Q3_JT >_[1)*_^[4CS_O5M0^KYD9.R\;'G@M7*-TZUWGLJD>JW"
MG'ZYO):"P[>0A\JRBXS2KH>5V*:#G=JA@J'5H8*AU:&"H=6A@J'5H8*AU:&"
MH=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=7_H"(%_YXM
M#/^A-Q3_K$ =_[9(*_^]43S_P%I0^L%C9>S!:GK>N7"/TK%UH<BH>+# H7N\
MN9M_Q[26A,^PE(W5JY&7VJ")G-R:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:
MB*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H-?_H"(%_YXM#/^B
M-Q3_K4 =_[=(*O^_43S_PEI0^<1B9>O%:7O>OFZ0T;9SH\:N=K.^IWG N*-_
MR;2AAL^LG(W5HY:4VIJ1G-R5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8
ME8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]C_H"(%_Y\M#/^C-Q3_
MKD =_[A(*O_!4#S^Q5E0]\A@9NO*9WS=PVV1S[QQI<6T=+6]L'G MJQ_R*ZG
MA<^EH8K5G)R1VI69G-R/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?
MV(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]C_H2(%_Y\M#/^D-Q3_L#\<
M_[I(*O_#4#O[R%A0]<M?9NG/9GS<R6N2SL-OIL&Z<K6VLG; K*Q[R*2H?\Z<
MI(74E*"-V(V?F=N*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<
MG]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]C_H2(%_Z M#/^F-A/_L3\<_[M(
M*?[&3SOXRU=0\M!>9N?49'W:SVF3R,5MIKJ[<+2MLW._HZUVQYJH>LV2I7_2
MBJ*&UX2@D=F$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$
MHIS7A**<UX2BG->$HIS7A**<UX2BG-?_H2(%_Z M#/^G-A/_LS\<_[U'*?S(
M3COUSE9/[M5=9N3:8GW3TFB2P<9LI+.\;[&FM7*\G*]TQ).K=\J+IWO/@Z2!
MU'VBB]9[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75
M>Z.5U7NCE=5[HY75>Z.5U7NCE=7_HB$%_Z M#/^H-A+_M#\;_[]'*/G+3CKR
MTU5/ZMQ;9N#@87W,TV>1N\AKHJR^;J^@MW"XE;)SP(VN=L6%JGK*?JA_SGBF
MA]%UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/
MTG6EC])UI8_2=:6/TG6EC]+_HB$%_Z$L"_^J-A+_MCX;_<)'*/7-3CGNV51.
MYN-99=CB8'O%U6:/M,IJGZ7!;:N9NF^TD+5RNXBQ=<"!KGC%>JQ]R72JA,MQ
MJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&I
MB\QQJ8O,<:F+S'&IB\S_HR$%_Z(L"_^L-1'_N3X:^<5')_#133CIX%),XNE7
M9,[D7WJ]UV:,K<QJFY_$;*>3OF^OBKEQM8.V=+I\LW>^=K%\PG&O@L1NKH?&
M;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9N
MKH?&;JZ'QFZNA\;_I"$%_Z,L"_^O-1#_O#X8],E&)>K833;BYT],W.]58\;F
M7WBTVF6)I=!IEIC(;*&-PV^HA;]QKGZ[=+)XN7>V<[=[N6ZU@+QKM(6^:[2%
MOFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^
M:[2%OFNTA;[_I2$$_Z0L"_^S-0_[P3X7[<]&(N'?2S38ZT],S_-48KSH7G2K
MWF2$G=1ID)'.;9F'R6^@@,5RI7K"=*ETP'BL<+Y[KVN\@+)HNX2S:+N$LVB[
MA+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$
MLVB[A+/_IB$$_Z@K"O^X- WSQST4Y-A%'M;F237+\4Y,Q/=37['L77"AXF1]
ME=MIAXK5;H^"T'&5>\UTFG;+=YUQR7F@;<=]HFG%@:5FQ(6F9L2%IF;$A:9F
MQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$
MA:;_J" $_ZXJ"/R_,POISSP0U^%"'LKM236_^$U*M_M26Z;Q76F8Z65TC.)J
M?8/=;X1\VG.)=]=WC'/5>H]OTWV1;-& E&C0A)9ESX>79<^'EV7/AY=ESX>7
M9<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY?_
MJB #_[4I!O#(,0?:W3,,R^I"(;[V2#6R_TQ&J?]159OW76".\&5JA>ML<7WG
M<79WY'9Z<^)Y?6_A?']LWX"!:=Z#@V?=AX5EW(F&9=R)AF7<B89EW(F&9=R)
MAF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B8;_K1\#
M^;\E ]_6(@++Z#(/OO1!(K#_13.D_TI!G/]138_^75:%^69>??1N9';R<VAR
M[WAK;NY\;6SM?V]J[()P9^J%<F7JB7-CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/I
MC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'3_MAP"Z,T4
M <SF'02^\S$2L?\^(J/_0B^6_T@ZC?]01(3_7$M[_V=1=/YN5F_\<UEL^WA;
M:?E\76?X?UYF^(-?9/>&8&+VB6%A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A
M]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&+SQ \ SMH+ +WS
M'0>Q_S(4H_\Z'Y7_/RJ)_T8S@/]/.GC_6T!Q_V9%;/]M2&C_<TIF_W=,9/][
M36+_?TYA_X)/8/^%4%[_B5%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM1
M7O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU',RPD ON8, :__'@FD
M_S 3E?\U'(?_/"1\_T0K<_]-,6S_6#7_XGT024-#7U!23T9)3$4 #1)G_V,Y
M8_]K.V'_<3U?_W4^7?]Y/US_?$!;_W]!6O^"05G_AD)8_XA"6/^(0EC_B$)8
M_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_
MB$+_F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_
MA]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__
MF1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2
MA934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%
M_Y8K"_^5-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934
MBXR>SX61ILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K
M"_^5-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>
MSX61ILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5
M-A+_H#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61
MILN E:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_
MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
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M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
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M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
M +*L  "GM0  G,   )'* P"'U@< @.D1 'GI( )RZ2P%:^DV"F3I/P]>Z4@4
M6>E1&57H6AQ1Z6(@3NEK(TOI="5(Z7TG1NF(*D/IDRM!ZJ M0.JO+C[KP"X]
M[-LN/>KO+CWH_"X]Y_\M/>?_+3WG_RT]Y_\M/>?_+3WG_RW%GP  M:D  *BQ
M  "<O   D,<  (32 0!ZWP8 =/03 &WT( )F]"H$7_0T"%KU/0M4]44/3_5,
M$DSU511)]ET71O9E&$3V;AI!]G<</_>!'3WWC1\[]YD@.?BF(3CXM2(W^<@B
M-OGC(C;X\R(V]_PB-O?\(C;W_"(V]_PB-O?\(C;W_"*WI@  J:X  )RY  "0
MQ   @\\  '?;  !O]@H 9_\3 6#_'0):_R<#5/\P!4__. A*_T *1O](#$/_
M3PY _U8//?]>$#O_91(X_VX3-O]W%#3_@A4R_X\6,/^;%R__J1<N_[<8+?_(
M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
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M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
M//(1 #GS&P V\R4 -/0N #'T-P$N]3\!+/5' 2GV3P(G]E<")?=A R/W; ,A
M^'H$'_B)!![YF@4<^:L%&_K !1KZW@4:^?(%&O?]!1GV_P49]O\%&?;_!1GV
M_P6>I@  D:\  (.Y  !UP@  9\L  %K3  !-V@  0M\  #CE   U^P< ,?\/
M "[_%@ K_Q\ *?\F "7_+0 C_S0 (/\[ 1[_0P$;_TL!&?]3 1;_70(4_VH"
M$O]X A'_B (0_YH"$/^K P[_O@,._]4##O_M P[_\ ,.__ ##O_P P[_\ .3
MK@  A+@  ';"  !GS   6M4  $S<   _X0  ->8  "WT   J_P( )O\+ "/_
M$0 @_Q< '?\= !G_(P 6_RD %/\O !+_-0 0_ST #O]% 0S_3@$*_U@!!_]E
M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
M=\$  &C,  !:UP  2]X  #[D   RZ0  )^T  "/_   ?_P  &_\% !?_#  4
M_Q  $?\4  __&  -_QT "_\B  C_*  %_RX  O\U  #_/0  _T<  /]2  #_
M7@  _VT  /]^ 0#_C@$ _YL! /^I 0#_JP$ _ZL! /^K 0#_JP'_*BT!_RXK
M ?\P*P'_,"X"_RXU O\I/0/_)4D$_R-7!/\A9 7_'W(&_QU_!O\=B@;_'90&
M_QV<!_\<HP?_'*H'_QRQ!_\<N ;_'+\&_QS)!O\<U@;_'>4&_QWO!O\=^07_
M'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_+"L!_S H ?\S
M* '_,RL"_S$Q O\M.@/_*T<$_RA4!?\F807_)&\&_R)\!_\BAP?_(I$'_R&9
M!_\AH0C_(:<(_R&N"/\AM0C_(;P(_R'&!_\AT0?_(>('_R+M!_\B]P?_(O\&
M_2+_!OPB_P;\(O\&_"+_!OLB_P;[(O\&^R+_!OLB_P;_+B@!_S,E ?\V)0'_
M-R<!_S4M O\T. /_,D0$_R]1!?\L7@;_*FL'_REW!_\H@PC_)XT(_R>6"?\G
MG0G_)Z0)_R>K"?\GL@G_)[D)_R?""?\GS0G_)]X)_R?K"?PG]@CY*/X(]RC_
M"/8H_PCU*/\(]2C_"/4H_PCU*/\(]2C_"/4H_PC_,B4!_S<B ?\Z(0'_.R,!
M_SLI O\[- +_.4 $_S9-!?\T6@;_,68'_S!S"/\N?PG_+HD*_RZ2"O\MF0O_
M+:$+_RVG"_\MK@O_+;4,_RV^#/XMR0S[+=D,^"WH"_0N] OQ+OX+[R[_"^XN
M_POM+O\+["[_"NPN_PKL+O\*["[_"NPN_PK_-2(!_SL> ?\_'0'_0!\!_T(F
M ?]",0+_0#P#_SY(!?\[50;_.6((_S=N"O\V>0O_-80,_32-#?PTE0WZ-)P.
M^3.C#O<SJ@_V,[(/]3.Z#_,SQ0_R,](/[C/E#^HT\@_G-/T/Y33_#^0T_P[B
M-?\.XC7_#>$U_PWA-?\-X37_#>$U_PW_.1X!_S\: ?]#& '_1AH!_TDC ?])
M+0+_2#@#_T5$!?]#4 ?_0%T)^SYI"_@]= WU/'\.\SN(#_$[D!#O.I@1[3J?
M$NPYIA/J.:X3Z3FV%.<YP13F.<X5XCGC%=XY\17;.OP4V#K_$]4[_Q+3._\2
MTCO_$=([_Q#2._\0TCO_$-([_Q#_/1L!_T,6 /](% #_3!<!_T\? ?]0* '_
M3S,"_TT_!/M*2@;U1U<)\49D#.U$;P[I0WD1YT*#$^1!BQ3B0),6X#^;%]\_
MHAC=/JH9VSZS&M@^O1K6/LH;TC[?&\X^[QO+/_L:R4#_&,= _Q?&0?\5Q4'_
M%,1!_Q3$0?\4Q$'_%,1!_Q3_01< _T<2 /],$ #_4A0 _U8; /]7) '_5BX"
M^%0Y _%110;K3U()YDU>#.%+:1#=2703V4A]%M5&AAC218X:T$66',Y$G1W,
M1*4>RD.M'\A#MB#&0\,AQ4/3(<%#Z2&^1/<?O$7_';I&_QNY1_\9N$?_&+A'
M_Q>X1_\7N$?_%[A'_Q?_1!0 _TL0 /]1#@#_5Q$ _UL6 /]='@#Y72@![ULS
M N=9/P3@5TT(VE19#=-29!+.4&X6RDYW&<=,@!S%2X@>PDJ0(,!*ER&^29\C
MO$BG)+I(L"6X2+PFMTC+)[1'XR>R2?,EL$K_(JY+_Q^N3/\=K4S_&ZU-_QJM
M3?\:K4W_&JU-_QK_1Q$ _T\- /]6# #_7 X _V 2 /UB& #P8R$ YF(L =Y@
M.@/47D@'S5M4#<=87Q/#5FD7OU1R&[Q2>AZY48(AME"*([1/D26R3IDGL$VB
M**Y-JRJL3+8KJDS$+*A,VRRF3>\JI$_])J10_R.C4?\@HU+_'J)2_QVB4O\=
MHE+_':)2_QW_2@\ _U(* /]:"0#_8 L _V4. /5G$0#H:!@ W6<D -)F-0+*
M9$0'PV%0#;U>6Q.Y7&08M5IM'+%8=2"N5WTCK%6$):E4C"BG4Y0JI5*=+*-2
MIBVA4;$OGU&^,)U1T3";4>HOFE/Z*II5_R:95O\CF5;_(9E7_Q^95_\?F5?_
M'YE7_Q__30T _U4& /]=!0#[9 < [VD) .EK# #A;!  TVT> ,EL,0+":D '
MNV=,#;5D5Q.P86 9K%]I':A=<2&E7'@DHEJ )Z!9ARJ=6) LFU>8+IE6HC"6
M5:PRE%6Y,Y-5RC.15>4SD5?W+9%9_RF16O\ED5O_(Y%;_R&16_\AD5O_(9%;
M_R'_3PL _U<" /]A @#J: $ WFT$ -AP" #5< L RW(; ,)Q+@*Z;ST&M&Q)
M#:YI5!.I9UT9I&1E':%B;2&=870EFE]\*)A>@RN578LMDEN4,)!;GC*-6J@T
MBUFU-8I9QC:(6>$VB%ST,(A=_RN)7O\HB5__)8E?_R.)7_\CB5__(XE?_R/_
M40D _UH  /5D  #@;   UW$# -!T!@#-=0D Q'87 +QV*@&T=#H%KG%&#*=N
M41*B:UH8GFEB'9IG:2&697$EDV1X*)!B@"N-88@NBV"1,8A?FC.&7J4U@UZR
M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
M +EX  "R>   JW@- *1Y'0">>"T!EW<Z!9)U10J,<DX.B'!6$X1O7A> ;60:
M?6QK'7IK<R!W:GLC=&F#)G)HC2EO9YDL;&:E+FIFLR]I9L8P:&;D+VIH]REK
M:?\E;&G_(FQJ_R!L:O\@;&K_(&QJ_R#_5P  Y&(  -)L  #&<P  O7@  +5[
M  "M?   I7P* )]]&@"9?"H!DWLX!(UY0PF(=TP.@W54$G]S6Q9[<F(9>'!I
M'75O<"!R;G@C;VV!)FQLBREJ;)<L9VNC+F5KLB]D:\0P8FOA+V1L]BIF;?\F
M9FW_(V=N_R!G;O\@9V[_(&=N_R#V60  X&4  ,YO  #"=@  N7P  +%_  "I
M@   H( ' )F!%P"4@2@!CH U XA^00B#?$H-?GI2$7IX615V=V 9<W9G''!T
M;A]M<W8C:G)_)F=QB2ED<94K8G"A+6!PL"]><,(O77#?+U]Q]2I@<?\F87+_
M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
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M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
M 'IY!P!U>10 <GHC &YZ+P%K>3H":'E# V1X2P5A=U((7W=9"EQV8 Q9=6@/
M5W1P$51T>A-2<X863W.3&$URH1E,<K$:2G+&&DIRY1I+<OD73'+_%4QR_Q--
M<O\237+_$DUR_Q+48   PFL  +5T  "K>P  HG\  )>!  ",@0  >GX  '-_
M @!N?Q$ :X > &B + !E@#<!8H!  U]_2 1<?E &67Y7"%=]7@M4?&8-47QN
M#T][>!%,>X,42GJ1%DAZGQ=&>J\817K$&$1ZY!A%>?@61GG_%$9X_Q)'>/\1
M1WC_$4=X_Q'-90  O7   +%Y  "G@   G(0  )*&  "&A@  =X8  &N&  !F
MAPT 8X<9 &"()P!>B#,!6X@\ EB'10-6ATT$4X94!E"&6PA.A6,*2X1L#$F$
M=@]&@X$11(./$T*#G11 @JX5/X/"%3Z"XA4_@?<3/X'_$D" _Q% @/\00(#_
M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
M .H^  #?0@  U4(  ,\_ P#-. @ Q3@5 +TZ)@"W.S8 LCQ# *X\3@&J.U<"
MISM@ Z4Z9P.C.F\$H3IV!9\Y?0:=.84'FSF-!YDXE@B8.* )ECBK"I0XN J3
M.<H+D3GE"X\Z]PJ-.O\)C#O_"(P[_P>,._\'C#O_!XP[_P?_.   \3X  .-%
M  #420  RTH  ,5'  #!000 NC\1 +-!(0"M0C$ J$,^ *1#20&@0E,"G4%;
M YM!8@280&H%ED!Q!I0_> >2/W\(D#^("H\^D0N-/IL,BSZF#8D^LPV(/L0.
MAC_@#H0_] V#0/\+@T#_"H) _PF"0?\(@D'_"()!_PC_/   ZT,  -Q*  #,
M3P  PU   +Q.  "W20$ L48. *I(' "D22P H$DZ )M)10&82$X"E$=7 Y)'
M7@6/1F4&C49L!XM%<PF)17L*AT2#"X5$C0R#1)<.@4.B#W]#KQ!^0\ 0?$3:
M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
MK!EU *L9? "I&80 J!J, *8:E "D&IX HQNH *$;M "?',4 GAS? )H=\P&8
M'O\!EQ[_ 98?_P&5'_\!E1__ 94?_P'_)@  ]"<  .8M  #:+P  SRT  ,HG
M  #''P@ P1P3 +H>(@"T'S$ KR ] *LA2 "H(E( IB): *,C8@"A(VD H"-O
M )XC=P"<(WX FR.& )DDCP&7))D!EB2C 90DL &2);\!D276 8XF[P&,)_\"
MBR?_ HHG_P*))_\"B2?_ 8DG_P'Z*0  [#   -TV  #-.   Q#<  +XR  "Z
M*P( M24. *XG'0"H*2L I"HX * J0P"=*TP FBM5 )@K7 "6*V, E"MJ 9(K
M<0&0+'@!CRR! 8TLB@&++)0"BBR? H@LJP*&++H"A2W. X,NZ@.!+OP#@"[_
M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
ME!M_ )(<B "0')( CQR= (T=J0"+';< BA[* (@?YP"&(/H A"#_ 8,@_P&#
M(/\!@B#_ 8(@_P'U)   Y2P  -,Q  #&,P  O#$  +8M  "P)0  K!T, *8>
M& "A("8 G"$R )DB/0"5(D< DR-/ )$C5@"/(UT C21D (LD:P"))'( B"1Z
M (8D@P"$)8T @R68 8$EI & )K(!?B;% 7TGX@%[)_<!>2C_ 7@H_P%X*/\!
M>"C_ 7@H_P'O*P  W3,  ,HY  "^.P  M#H  *TV  "F+P  H2@' )LG$P"6
M*"  D2DM (XJ. "+*T( B"M* (8K4@"$*U@ @BQ? ( L9@!_+&T ?2QU 'LL
M?@%Z+(@!>"R4 78MH %U+:X"="W  G(NW0)Q+O0"<"__ F\O_P)O+_\!;B__
M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
M;S [ &TP0P!K,4H :3%1 &<Q5P!F,5X 9#%F &,R;P!A,GD 8#*% 5\RD@%=
M,Z$!7#.Q 5LTQ@%:-.8!637[ 5DU_P%9-/\!633_ 5DT_P'2.   P$   +-%
M  "H2   GD@  )5&  "+0   @CL  'DU! !S,Q  ;S0: &PT)0!I-2\ 9S4W
M &4V/P!C-D8 8C9- & V5 !?-EL 73=C %PW:P!;-W8!63>" 5@XCP%6.)X!
M53BO E0YPP)3.>0"4SKY 5,Y_P%2.?\!4SG_ 5,Y_P'-/   O$0  *])  "D
M3   FDP  )%+  "'1@  ?4   ',[  !L. T :#D7 &4Y(@!C.BL 8#HT %XZ
M/ !=.D, 6SI* %H[4 !8.U@ 5SM@ %8[: !5/',!4SQ_ 5(\C0%0/9P!3SVL
M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
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M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( (<!! ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MU.*E'9GI87%4L31AB*#O":4D^Z:NGKW044451T!1110 4444 %%%% !1110
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MWSFOH6OB[]I;X@ZW^RG_ ,$7]#O?#6H7&B^(M)\+^'K&UO+==LD4KM:)*W<
ME#+Z\FOSK^ W_!8?XS_"GXE6NMZ_XJU;QMIMO;W*-I.H7&VWGD>!UB9BH!PD
MI1R!U"D @D$=7U^&'4*4ET6I]IC..LNX=^J95C8R3]G!W23C%?#KK?3E=[)Z
M;'[RT5_/#\7O^"D_QR^-6NW%[JGQ*\46,<['%EI%])IMG&N<A!% 5# 8&"^Y
MN,DDY)]!_8[_ ."OOQ5_9Y^)EC<>*O%'B+QYX0FE":IIVJWC7UQY1/,D$LI+
MK(O)"EPC=#C@K,<YIN5G%V/(P_C5E%3%*C.E.,&[<[MIYM)MV]&WY'[NT5^#
M?[4G_!8CXS?M!^+KN71_$VJ> ?#GF?Z%IFA736LL2 \&2Y3;+(Y&,_,%]% K
M@/A+_P %&_C=\&O$-I?Z7\2O%EY':N&^PZKJ,NH64JYR4:&9F4!N<E<-SP0>
M:4LZI\UE%V%B/&K*(8GV4*4Y0O;F5E\U%N]O6S\C^B.BOF?Q-^V+)\3?^"66
MN?&#0W_L74[[P?>7,#12_P#(/OU22!MC$<F.X5MI(YVCUK\H_A)_P5M^-G@/
MXEZ'K.M^./$?B;2--NTGN])FNDCCU&-3\T+-L;:&'&<$C.<5OB,RITG%6O=7
M^1]/G_B)EF4U*$:ZE*-:*DI12:47U=VGMKHF[>9^^E%?@GXK_P""EWQR_:J^
M-^CVMQXZU[P_8ZSJL%G#I7AVYET^VBCEE5/+Q"PDE&&Q^\9B?7IC].O^"J7_
M  4=7]A/X=Z?8Z';VNH^//%"R?V=%<#=#80KP]S(H.6PQ"HIP&.XYPA!*>9T
MYQE-JRC;\195XBY9CL+B<?9PHT+)REO*][62ON[)+=W6B/K*BOYO_B?^VQ\7
M/C)J\E[XB^(WBZ^DD;?Y2:C);VT9_P!B&,K&G_ 5%8.C_M$_$#P]?)=:?XZ\
M96-U&<K-;ZU<Q2+SGAE<'J!^5<CSM7TAIZ_\ ^+J>.6!4[0PLW'NY)/[M?S/
MZ7J_#3_@NQXA_MK_ (*%ZY;>9N_LC2=/M"-P.S,(FQ[?Z[.#ZY[U]G?\$&/C
M_P#$#X]_#_X@3>./%>M>*+?2+NQMM.;491-) 2DS2_O"/,8M^[SO)^Z,8R<_
MGM_P5H\0MXF_X*)_%"Y8L3'J,-IR .(;6&$=/^N?U]>:G,<0JN&C-=7^5T9^
M)>?T\RX3P^-HQ<8UJBT=KI)3[-K=:>1]_?\ !NCX>6V_98\;:KA=UYXJ:U/)
MSB*TMV''3_EL>GO[5^A%?&/_  0:T+^R?^"?NGW&,?VIKE_<]<YPZQ?A_JNG
M^-<3_P %4_\ @L'>?LP^,9OAS\-H[&Z\76\*OJNK7"":'1V<!EACC/RR3;2&
M8ME$#*,,Q8)UX>O"AA(RF?99#G&#R+A3"XK'2M'DCLKMN2YDDNKU_-NR/T$K
M\8?^#AK7CJ7[:?A^S4R>7IOA&V4JP&-[W5VQ(^JE!SW'XGYJ\:_M]_&WXA7<
MTVJ?%7QXXN#F2&WUF:TMSSG_ %43+&.?1>*\V\7>.-:^(&K_ -H:]K&J:Y?;
M!%]IO[J2YFV#.%WN2<#)XSWKS<;F2KPY(QL?DO'/B=A<[RZ67X:C*-Y)W;6R
MUV5_S/TQ_P"#;7P^QN/B[JK!@JKI5I&0PVMG[8SY'7(PF.W)Z]O9?VQ/^")N
MF_M>_M&>(OB%=?$/4-%FU_[,#8QZ0LZ6XAMHH!AS*I.?*W=!RQKD?^#<OPZ;
M;]G7Q]JVWY;WQ&EH&V]?)MHWQGOCS^G;/O7QO_P4&_;2^*FB_ML?$W3]!^)W
MQ T?2=-UZXLK:RL/$5W;VUNL)\LJD<<@51E3P!USGG-:QE2A@X*K&Z;?EW/H
M8XS*LNX*P*S:@ZT)2;4;VLVYN^C6R;7S/U7_ .">O[ 5A^P%X'\0:-9^)+KQ
M,WB"^2]DGFM!:^4%C"! H=L]SG(Z^U<IX?\ ^":<EK^R5X1^&.I^)+&^&E^,
MXO%6N72V#)'JT8O)+B2W5=Y9"R,B;RS$;>XXK3_X(]^)_$/CS]@7PCKWB?7M
M8\1:MK%SJ$SWNIW\U[<LJ7DT*JSRDM@"+@ XQCN37T[7IT</2G2CI96T7KJ?
MJN3Y;EN*RS#U*5+EIRI^[&[TC4Y9-;ZWLM?6VC9\>^$_^"1'A?PIJ6NBWU&.
M'2[R^233;2.VWFQM8[6WMTB9Y"[2/^Y+%\C)?H**^PJ*G^R\-_*>A3R#+Z<>
M2%)):_B[GQ3_ ,%)?A%)HGCFQ\86T9-GK4:VMVP'W+B,84G_ 'HP /\ KF?:
MOF6OU2^)GPZTWXL>"-0T'5HC)9W\>TD?>B8<JZGLRL 1]/2OS9^,_P &]8^!
MWC>XT75X6RI+6UP%Q'>19^61?KW'4'(-?SKXI<*U,%CGF=%7I57=_P!V;WO_
M (MT^]T8YCAW&?M%L_S,OP!XZU#X:>,M/UW2I?)OM-E$L9/*MV*L.ZLI*D=P
M37Z4?!'XSZ3\<_ EMK6ER*K, EU;%@9+.7NC?S![C!K\OZZSX._&C7O@;XL3
M5M#N?+9L+<6\F6ANTS]UU[^Q&".Q%>1P'QM/(L0Z=:\J$_B2W3_F7GW75>B,
M\'BW1=GLS[*_;-_8B@_;GN_#N@^+O$6H6?PUT:<:CJ.@:<##-XANE)\M9[C.
M4MXQD[$&YV<G<IC0UZY\-?AGX?\ @[X'TWPUX6T?3]!T'28A!:6-G$(X85'H
M!U).26.2Q)))))KA_@)^U[X5^.=M#;QW"Z3KS !]-NG 9V_Z9-P)![#YN.5%
M>K5_4^ SJAF.%C4PE53I]+;7\UNGWOKT/H(3C-<T HHHKJ*/+?VWO$'_  B_
M[&OQ6O\ *JUOX1U0Q[EW#>;20("/0L17\XMK;27MS'#"C22S,$15'+,3@ 5_
M0-_P5<U__A'/^">/Q2N-WE^9I:6N?,\O_73Q0XS[[\8[YQWK\*OV;/#1\9_M
M%> ='51(=6\1Z=9A2H;=YES&F,'@]>AXKYO.&W6C%=OU9_./C/\ O\WP>$OO
M'_TJ5OT/UP_X+M3Q> ?^"=NE:+$RK%<:]IVEQ@(5#".&:0  <#B'.#QQZXK\
MEOV7_@?<?M)_M">$? MM-]F;Q)J4=K+..L$/WI9 .Y6-78#N1BOTZ_X../$7
MV;X"_#O2=V/MNOS7>W)Y\FW9,XZ<>?\ K]:^0?\ @AWH']L_\%&?"5Q_T";'
M4;H<XZV<L/X_ZVL\;%2QBI]-%^1R\>8>.8<;4,#45X_NH-?W6[O\&S]-/VL_
MV.?A7\,O^">WQ$T;2_!?AJPL_#WA*_N;&8V<7VE+F&V=X9C,1O:4R*N6)+,3
MC)S7X)U_07_P59\1?\(Q_P $]/BE=;_+\S2EM,E@O^OGBAQGW\S&.^<5^!WP
MW\.CQA\1-!TDKY@U34;>T*X/S>9*J8XY[]N:,VC&-11BK:!XR8:DLSPF%P\5
M%\EDDDM')I+3HK:'[K?L ?\ !.GP+^SK^S=HEGJ_A70]8\5:U917>O7FHV4=
MU))-(@9H 7!VQ1[M@48!VEB,L37XD?M/>'=*\(?M*_$/2=!B$.AZ7XFU*TTZ
M,9Q';QW4B1+SSP@4<\U_2O7\Q/Q(\1#QA\1->U8-Y@U34;B[#<_-YDK/GGGO
MWYK;-:,*4(0BN_Z'I>,6!PF R[ X/#045%R2LE>R4;_>VF^[U/TN\(ZM-X-_
MX-P-0N9)@QU+SX+=#)M(677?)91GV\QL#J,^YK\SOA_X*OOB5X\T3PYI:"34
MO$%_!IMHA_BFFD6-!^+,*_2G]JR7_A ?^" ?PQTW>%_MR73AC>/G\UY[S'/^
M[G Z8] :^,O^"9WA[_A)_P!OKX3VQC\SR_$,%WC:&QY.9L\^GEYSVQFN/$KF
ME3C_ '8_U^)\KQAA?;YEE662>GL:$'ZR=G^%C]N?V>/V$?AG^SG\+M(\-:7X
M3T&_;31'+-J-]I\4UY?7*D,;AW8$[]XW* <)A0N HQ^./_!8KXKS?%;_ (*"
M^.6:1FM/#LD.A6B,<^4EO&!(![&=IF_X'7[Y5_-K^V'JSZ[^UO\ %*]D&U[O
MQ=JLI4'(7=>2G ]ATKT,VC&G3C""M_P/^'/OO&14\'DV'P6&BH0<]EHK1B[+
MTUO\C],O^"!O[(6@Z7\";GXJ:QI5GJ&O^(K^6WTF>X@60V-K WELT1.=K/,)
M S#G$:CUKY(_X+I:[_:__!1#Q%;[@W]EZ9IUK@/NVYMUEQC^'_6YQ[Y[U^GO
M_!(6VCM/^"<GPQ6-%C5K.Z<A1U9KVX8G\22?QK\=?^"F/Q2M/C+^WA\3->L+
MB.[LI-5^Q03I@I*EK%':AE(X*GR<@]Q@\YS6.*C&&#IQ6[L_P_X)Y/&]&A@.
M"<#A**2<W!OS;@Y2?G[S7WH_1G_@W5\/?8_V3O&&J%=K7WBR2W'R8++%:6Q!
MSW&96'L0:_,+]MWQ!_PE/[9/Q6O^=EQXNU0QY7:0@NY F1Z[0*_7/_@@YH?]
MD?\ !/W3;CY1_:FMW]SP<YPZQ?A_JNG^-?BEX]UY?%7CK6M47;MU*_GNAM4J
M,/(S< \CKWK'%Z8:E%>?]?B>-QQ^YX4RG#W^*+E_Y*G_ .W'[I_\$NKNW^$'
M_!+'P3JEXK+:Z7H^H:S/EADH;FYN#R./NGCN!C/(K\+OB#XWU#XF>/-:\1ZK
M*9]3UZ^GU&[D/\<LLC2.?^^F-?MYJ&G3> ?^"(#V\8\N;_A4_P"\4IMV&?3L
MR#'J/,89]>:_"V"-9IT5I%B5F +L#M0>IP"<#V!-5F$FH4J;Z17]?@7XJ5)4
ML'EF7K2,:2?SM&*^ZWXG[P?\$S?^"??@O]G?]FWPS?ZEX;TG4?&WB&PBU'5=
M0O+5+B>%YE$@MT9@=B1@JI"X#,I8YS7Y*_\ !3F2Q/[>WQ.CTVUM;*SM-7^R
M1P6R!(H_*BCB("@ #E#P!US7]!US<VGA[29)I7@L[&QA+N[$1Q01H,DGH%55
M'T %?S7_ +2OQ(A^,/[1/CSQ9:F0VGB3Q!?:G;^83N6*:X=XQSSPK*,=L5MF
ME.%*E"G$^@\7<+A<NR7!Y9AHJ*4KI*UVHQ:;?=MR5WU>Y^OW_! 3P]_8O[!C
MW.S;_:WB6^N\X(WX2"'/O_JL<>E?D-^U)KY\5_M-_$;5&+,VI>)]3NB2NTG?
M=RMT' Z]*_:S_@CEIT/@S_@FAX"N;@B-9(]1O[AP2PVF^N2#CVC"\#N*_"#6
M-3DUO5KJ\FV^=>3/,^W.-S$DXSSU-8X[3#T8^3?Y'S_B':CPWE&&ZN'-_P"2
M0O\ C(_H+_X)<:%_PCO_  3[^%=O_P ]-%6ZZY_USO+_ .S_ (5[[7G?[(GA
M[_A$_P!E#X8Z6R[6T_PII=N_ !++:1*2<<9)!->B5]%AX\M**\E^1_1V4T71
MP-&D_LPBONBD%%%%;'H!7*_%KX-Z#\;/"[Z3KUF)XN6AF3Y9K5_[\;=C[<@]
M""*ZJBL,5A:6(I2H5XJ49*S35TT*44U9GP!\;/V#O&'PRN)KG28)/$VCJ25E
MM$S<Q#T>+K^*;A].E>(3P/;2M'(K1R1G:RL,,I]"*_6ZL'Q?\+?#?C[/]M:#
MI&J,0!ON;5))%QZ,1N'X&OQS.O!S#U9NIEE;V?\ =DKKY/=+U4O4\RKE<6[T
MW8_*Y6*-D<$<@CM7JWPU_;3^(/PTCCABUC^UK./I;:FIN%QZ!\B0#V# 5]E3
M?L9_#&>5G;PE8@MV6:91^0?%;OA?]GOP/X-E633?"NAV\RXVRFT621?H[ L/
MP->3E?A7GN#K^TH8N-/SBYW^ZR3]&[&=/+ZT'>,[>AYW^S]^U!XU^,\D D^'
M<D%BQ'F:K]M-O:@>JJ\9+_1&8_SKW:BBOVS*<%B<+0]GBJ[K2_F:C'[E%+\6
MWYGJ4XRBK2=SY$_X+CZ\='_X)T^*[?=M_M6_TZU(VYW8NXIL>W^JSGVQWK\G
M/^"9_AS_ (2G]OGX46OEB3RO$-O>8*AO]1F?//IY><]L9ZU^_7Q1^$?ACXU^
M&/[%\7:%I?B+2?.6?[)?P":'S%SM;:>,C)Y]ZY'P'^Q-\(_A?XLL]>\._#CP
M?HNM:<Q>UO;338XYH"5*DJP&0=K$?C48K 5*M=5$U;0_-.*. L1FV?8?-E4B
MH4^1.+3NU&;D_+6]C\^_^#DCQ+YWB+X2Z.K8^S6^IWCJ'/S>8UJBDCIQY;X/
MN?Q\W_X-YO#O]J?MH^(+YE;R]+\)7+*P(XD>ZM4 (ZX*E^GH/H?U6^-G[(OP
MU_:-U>RO_''@_2?$MYIT)@MI+M6+0H6W%1@CJ>:/@I^R'\-?V<M8O-0\#^#M
M'\-WNH0BWN9K1&#2QAMP4Y)XR ?PI2R^I+%>W;5K_/3Y&6(X Q5;BM9_*K'V
M:E%\NO-[L%%=+;J_H>#_ /!=#Q$=#_X)W>([7=M_MC4].M",CYL7*38_\@YX
M]/3-?D'^PSX=_P"$L_;/^%-@P#1S>+=,,H)(S&MU&SC(YSM4X]_3K7]"'QB^
M!_A/]H#PFN@^,]#L?$.CK<+="UN@3&)5#!7X(Y 9OSKA? 7_  3U^"OPO\8Z
M?X@\/_#KP_I6M:3,)[2[A1Q) XX##+=>:,9E]2M6]HFK:;W_ ,A<7>'^*SC.
MZ&9QJ1C"FH)IWNU&3D[:6UOH>B?%WQ$?!_PG\4:L',9TO2;J\#ARFWRX7?.1
MR,8ZBOYD:_J#\1>'K/Q9X?OM*U*W2ZT_4[>2UNH7SMFBD4JZG'."I(XKQ#_A
MUO\ L^_]$K\+_P#?N3_XJJS# U*\DX-67?\ X8W\1.!L7Q%*@\/4C!4^;XKZ
M\W+V3['Q9_P6%<^"O^"9/[//A3<VV./3202K9^S:5Y62>O\ RV[<<_2OFS_@
MB=X;_P"$@_X*.^!Y67?'I<&H7C IN'%C.BGVPSJ0?4#UK]HOC#^RS\/?C_I.
MDV'C+PII?B"ST'<-/ANE8K:[E53MP1U"*/PK)^$G[#OPE^ _C*/Q!X/\"Z'X
M?UJ.)X5N[5&$BHXPR\L1@UG/+JKKJI=65OPMY''F/AWB,3Q%0S>-2*ITG3]W
M6_[NWE;='JU?SZ_\%3?@9J7P)_;E\?6]Y:R0V7B+5)]?TV4IMCN(+J1IODQQ
MA'9X\=C&:_H*KC?C'^S[X)_:$T&/3?&WA;1?$UG"Q:%;ZV61K=CP6C?[T9(X
MRI!KLQ^$=>"479H^DX[X/7$.!CAX3Y)PES1;5UM9I^3[]TC\!?AY_P % /B]
M\)_@7<?#?P[XTOM+\(W'FC[-#!#YL*R[C*D<Q3S8U=F+$*PP22,;FSP?Q*^"
MWBOX.QZ&WBC0=0T,>)-/35=-%W'L-U;.S*L@'49*G@X."#C# G]^/AS_ ,$V
M?@5\*?$<6K:)\,O#<.H6[*\,US&]Z86!R'03,X5@>0R@$>M>F?$OX.^$_C/H
MRZ=XN\,Z#XFL8R6CAU2PBNUB8C!90ZG:WN,&O-63U91]^6O3=H_-O^(.YAB<
M+R8_&\TX)*FO>E&*[:V:5M$HI6\]C\]/^#>[XN>+?B!\-/'W@>ZU(?\ ",^$
M(;<Z4%B42V$MY)=.^&&&8%D9L$\'/3-?E9XF\.7W@[Q)J&D:E;R6>HZ7<R6E
MU!(-KPRQL4=2/4,"/PK^D[X1?LZ^!?@$NH#P3X1T'PM_:QC-Y_9MFEO]I\O=
MLW[0,[=[XSTW'UKG?BM^PY\(?CAXGDUKQ5\//"^L:Q-CSKV2S"7%Q@ #S'3#
M.0  "Q.  *TJY74E1A"^JOWMJ>OG'AAC,?DV#P,L0O:X?G5W=IQDU9+JN5**
M6FWR/SG_ ."4GQ&^(W[:OPQ^*WPG\0>++K4/#=GX ?1-%M;B*-8]/ED'DV[;
MU4.0BKC#$Y'TK\[?%7A;4? _B6_T?5[.XT[5-+N'M;NUG3;);RH2K(P[$$$5
M_2-\&?V9?A_^SQ'=+X'\'Z#X9:_5$N9+"T6.2Y"YVAW^\P&XXR3U-<C^T-_P
M3U^#O[4VMG5/&G@FPU#6&0(=1MYIK*Z< 87>\+H9,#@;]P  ]*FIE525-*ZY
ME^1CG7A7C<=E6&H2Q"EB*/,G*3DXRBW=*^K7*M%IY=C\9/B-_P %2OCA\:?@
MI#\-]2\2^=H]Q!'I]P;2S6.^U.( *(I95&Y@W 8+@OT;<"0?G[Q%X=O_  CK
M]]I6J6=QI^I:;.]M=6MQ&8Y;>5&*NC*>0P(((/<5_0I\!O\ @F_\%/V;-;AU
M;PGX#TNWUBV8/%J%Y)+?W4#XQOC>=G\MO>/;U/K4WC3_ ()U_!'XB^+=1U[7
M/AOX=U+6-7N'NKRZF1S)<2N<LY^;J36<LIKR5Y23?FV>3C?"/.L?3C5Q^-4Z
MRLM7*245T3:O>_DEONV<3^SL6^%O_!(70[UF:$V'PUDU7<TH7:&L7N =P^Z/
MFSZ@=>17X(P0274Z11(TDDC!411N9B>  .Y-?TY)\-M!3X<CP@-)L3X873?[
M'_LQHP;8V?E>3Y!4\%/+^7'IQ7FUM_P3P^!EG<1S1?"CP+'+$P='728@48'(
M(X[5TXO+9U%!0:]U6U/K.,O#O%9U3PE*E5C%48\KNGJ_=3:_\!/5O"VAKX8\
M,Z;IL>WR]/M8K9=J[5PB!1@=AQTJ_117L15E9'ZPE9604444P"BBB@ HHHH
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M5$KH"P($A?#;?E]>_P"&1_VP?^CQO"__ (9:S_\ EA0,[/\ X)9_M3Q_M/\
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M"MG_ (*0?\I*/V&_^QL\1?\ IF>O%O\ @IC_ ,$UO@;^QK^RK8^)/"GA%/\
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M[\"_^P+-_P"EEQ0,\-\._L>>#_$7_!QOXXFNK&&70[7P'IGQ"DT-X]VGW/B
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MR]$L?!FABY0,!<3C3I99!G&"R,S*P'0!/6ONR@ HHHH **** "BBB@ HHHH
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;+6VW?-]G@10B;NY8@*"%'TM110(**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20201231_g13.jpg
<TEXT>
begin 644 biib-20201231_g13.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
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M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
M@ ">.WZPB7V/)'Y]B,]_!WY0A_]MY'XKAQU;UGX>ADI(D7XRA9DSLGY"A0T:
M.7Y9A0P  (  @ "=1'V0DNZ.)'UED95^"GTZD ]L\GT9CG=:]7T.C/A'UWT9
MB[$S''TDBMT9QWS[BF8  (  @ "<?7RJG&>-67R&FFE]/7Q7F"YL)GPTE>1:
M-'PND\E'-'PXD@HRI7PKD289<7O'CMD  (  @ ";Y7O[I?.,MGO<HU5\CGNG
MH&MK=WMYG7)9B7MQFLE&CWN#F,,R'WMME_D9('K$D/T  (  @ ";?7M_KY^,
M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
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M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
M@ "#)I!TE41U\8[=D_!GO(T[DF)8AHNHD,5(:XI-CV@W%(E"CI@CGHBRCL8*
MQH@=ATD  (  @ ""L8_6G<YU=HY"G 5G.HR7F>]8!(KVE\Q'ZHF3EAHVCXB,
ME6LC-(?IE!4*MH<0ASX  (  @ ""6H]DIH1U%HW.I%MFRXP7H<=7D8IGGR]'
MA(CWG5(V/(?EG' B[H<YEYX*E89&AR@  (  @ !ZD**E8G!N$Z F9)5@JYWN
M9J!2()OG:(I"6)H>:DXPXIC^:\,<@9G!;#\#WYBA;+X  (  ?]!Y_*%!:GMM
MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
M@ "'2H!6@(MY_8 ;@*-KPG_?@)9<BW^F@&Y,9W][@$DZJ']]@"TFW'^.@! -
M4G_^?^@  (  @ "&:'\'B4]Y-G[8B--K GZ;B"-;PGY>AU9+C7XWAI<Y_7XL
MA@DF47XDA=D-#7YZA*,  (  @ "%L7WSDA%X>7W,D09J1WV-C[=;#7U.CE!*
MW'TIC0\Y9GT6C"PE]7SCC#H,ZGTRB)8  (  @ "%(GT=FM5WYWS[F41IL'RW
MEU]:>7QOE6)*27Q&D[(XTWPTDK$E@GOFDDH,RWPGB*8  (  @ "$N'Q_H[%W
M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
M@ !^0Y'Y769QVI"18!ID:8]Q8J95NHZ#90=%OHW#9SDT'XUR:1L?THY6:A<&
M3HZ9:A0  (  ?,M]>X_H9:AQ*HZP9Z!CLHV9:7]5&8RD:T-%-HO<;.4SM8M]
M;D4?CHPG;N &:HOV;O   (  ?]Y\KHW7;=%P.HS%;R-BY(N\<&)43HK0<8Y$
MBXH-<J,S+HFI<X8?-HHC<\P&=XF?="L  (  @ ![R8OM=>EO1(KN=JIAWHGY
M=U13A8D3=_%#UXA=>'LRHX?V>.<>W8A&>.T&?(>2>;\  (  @ !ZZ8I*?@5N
M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
M>A^,'7,;:K5^O70);'EP>W3C;AU@Y76[;Z)0,G:/<1(^&G==<ETJ"W?M<T40
M/7D0<LL  (  ?;6*U7"3<[)]:W&H=,!O*7*A=:U?Z'.-=H=/3W1Z=TL]9W5/
M=_LICG6]>&D0 W;L=_   (  @ ")DVYK?*Y\4&^9?19N"W"I?5=>N'&E?7I.
M77*>?9H\BG-]?;HHW7/&?<,/H74E?9X  (  @ "(B6RDA;9[1VWCA7IM#F[_
MA0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH  (  @ "'LFLLCKIZ
M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
M@ !^F'FF<<IR#GH-<O=DEGIH= 56+GJ[=/=&6WL@==,U%WN'=H@A='O4=M (
MLGUP=PL  (  @ !]@'>)>DMP^7@+>MQCC'AY>TE5+'C:>YE%M'D_>^$TBWFI
M?!LA&7G ?" (JGNA?)8  (  @ !\CW77@MYP+'9K@M]BS7;A@JU47W=&@EQ$
MY7>L@A S\G@"@=\@GW?C@=4(@WH?@5P  (  @ ![RW1QBVIO9G40BMYB#'6)
MBA!3I77QB2A$-'98B%TS7':@A]D@2G8[B \(<GC8A54  (  @ ![,7-2D_!N
MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
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M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
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M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
M@ !S#FL8?)YG;VR/?1-:VFW/?5I-,F[B?7X^:F_.?9PN '!2?;T:X6^(?<($
MF'@\?H(  (  @ !R.FDSA/EFH6J^A.1:%FP*A)%,>&TEA"(]NFX0@\0M;FYU
M@Y<:F&V(@]X$FG@X@H,  (  @ !QDF>GC49F &E#C+%9>&J6B\U+Y&NPBLX]
M*&R3B@8LW&S?B;H:*VOVB<P$F7@Z@QP  (  @ !Q%69QE8UEA&@:E(Y8]VEP
MDR)+96J#D9X\O6M8D( LBFN%D%\9T&JTCH@$;'B'@OT  (  @ !LQ8+94GMA
M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
M@ ">^U/53=6/R%<(4AV !%HB5E!O7%TL6F-=I6 97E%*OV*U8A$V<61C98$>
M7V.69_0!>WV :QF<T4Z%6 B.%%(N6V]^A%6R7KYN"%D18?)<;UQ#909)JU\'
M9_8U@&"8:I\=K6 R;'8!BWUD;\^:VDFL8CZ,.TW 9+E\[U&<9R)LBE5!:7M;
M(%BH:[Y(C5N*;>@TFESS;]H=#EU*<20!FGU+=.*8Z$4\;&2*:TFS;?E[,DW4
M;XAK'U&Y<0U9VE56<H5'?EA.<_ SR%F%=30<?UK:=@8!IGTV>8N7"D$V=GB(
MRT8*=SAYODIY=_5IO4Z/>*I8V%)<>5Y&G%5H>A S%U9F>K,<"EC3>RH!L7TD
M?8B59SVI@'Z':T+4@&QXFT>+@%QHPTO<@$M7[T_&@#Y%]U+>@$,RD5.@@%@;
MJU<I@*@!NGT4@.64"CJ6BG&&2D /B8AWL44&B*=H 4F)A]17.TV3AQ5%7%"M
MAGLR+E$UAB$;9U7*AI(!PGT(@3"2]3@&E#^%93W DG9V^4+MD,1G;D>8CS56
MN4N[C=9$W$[4C+8QPT\8C!L;,52OB\L!R'S]@322,S8/G;2$OCORFP=V<4%"
MF(9G!$8)EDM6;$H_E&-$I4U9DN,QB4U>DE :]U//C_ !S7SU@3B3@UJ^3>Z%
M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
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MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
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M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
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M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
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MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
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M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
M.O8[[3SC/=L^TS_+0,1!O4*W0[)$K$6F1J%'G$B7291*D$N.3(M-BDZ)3XA0
MB%&)4HA3B%2(58A6B5>*6(M9C5J/6Y%<DUV67IA?FV"=89]BH&.A9*-EI&:F
M9Z=HJ&FI:JIKJFRK;:MNJV^K<*EQJ'*E<Z-TH'6==IEWE7B1>8QZAWN"?'Q]
M=GYO?VF 88%:@E&#2(0^A36&*X<AB!>)#(H"BO>+[8SBC=B.S8_#D+F1KY*E
MDYR4DI6)EH"7>)APF6J:8YM>G%F=59Y2GU"@3Z%/HE"C4J15I5FF7Z=FJ&ZI
M>*J"JXZLG*VKKKNOS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/ 9<&'
MPJK#SL3QQA7'.<A>R8+*ILO*S.W.$,\RT%31=-*4T[+4S]7KUP;8'MDVVDS;
M8=QTW8?>F-^GX+/AON+'X\WDT>72YM#GS.C$Z;KJK.N;[(?M;^Y8[USP6_%6
M\DSS/?0J]1+U]O;6][/XC?EB^B_Z]/NQ_&;]$?VS_DW^X?]Q__\   '9 XT%
M"094!W\(E@FA"J0+GPR3#8(.< ]?$$P1-Q(A$PD3\!36%;L6GQ>#&($9?1IT
M&V8<51U!'BP?%R  (.HATR*](Z8DD"5Z)F0G3B@Y*24J$"K]*^HLURW$+K$O
MGC",,7DR9S-5-$0U,C8B-Q$X 3CQ.>(ZTSO$/+4]ICZ8/XI ?4%O0F)#541)
M13Q&,$<C2!=)"TG_2O-+Z$S<3=!.Q4^Y4*U1H5*54XA4>E5M5E]745A#635:
M)EL87 E<^EWK7MQ?S&"]8:QBFV.)9'AE9F949T)H,&D>:@MJ^&OE;-)MOFZJ
M;Y9P@G%L<E9S0'0I=1)U^W;D=\UXMGF>>H9[;GQ6?3Y^)7\-?_2 VX'"@JB#
MC81RA5>&.X<@B 6(ZHG/BK.+F(Q]C6*.1X\MD!*0^)'>DL23JI21E7B68)='
MF"^9&)H!FNJ;U)R_G:J>EI^#H'&A7Z)/HS^D,*4BIA6G"*?]J/.IZJKBJ]NL
MU:W0KLNOQ[#$L<*RP;/!M,*UQ;;(M\VXT[G;NN.[[;SXO@2_$< @P3#"0,-2
MQ&;%>L:/QZ;(OLG6RO',#,TJSD?/8]" T9_2O]/@U0/6)]=,V'/9F]K$V^_=
M&MY&WW/@H>'/XP+D3>69YN?H-NF&ZMCL*^V [M?P,?&0\N_T3?6J]P3X6OFK
M^O;\.OU[_KO___\ @ "  .9/?\Y_6,V9?ZA^S;3:?YE^>9P4?Z-^98-,?\9^
MA6J%?_Y^P%&_@&-_/3D @1* #_S%?GR+-.2U?F.);,Q ?EV'S+.:?FZ&9IK8
M?IB%0X(8?MF$3VE:?R^#9U"N?Z^"H3@4@':!YOJ\?3:6<>+[?3"3DLK+?3Z0
MS[(Z?6F.7IF3?:R,+(#O?@>*(FA.?G6($T_!?PR& #=!?^B#K/CC?"ZAM^%!
M?#.=O\DS?$V9\+#"?(665YA%?-^3&G_+?4^/\V=6?=&,M4[O?GR)33:'?V>%
M7/<W>V.M ]^E>V:GZ\>J>X>C"J]@>\F>:9;X?"N9^'ZR?*^5MV9N?4.104XN
M??V,>S7E?O2&[_6\>LJX5=XO>L>R%,9#>N2L%*X9>RRF897<>YF@VGVD?"2;
M6665?,B5J$V"?9&/@35;?I&(7_1W>E+#JMSL>D:\,L4)>EVU"JSY>J>N.Y3I
M>Q^GFWS9>[:@Z&38?&"9W4SM?3624#3H?CV)I_-C>??/ =O8>>/&0,/Z>?*]
MY*OW>CJU[)0">KBN)'P@>UNF0&1(?!"=Y4QO?.J4XS2)??>*Q?)U>;3:6MKK
M>9?0,L,/>9_&E*L8>>.]:I,[>F2T:GMW>PVK0&/">\RAEDP)?*^7,S0]?;Z+
MMNY3B-M^-M>&A\1]PL"?AL-]<*F,A>9]59)2A2I]=7L'A(9]QF/$@_%^-4R/
M@WA^Z362@RB  .P]AWV(R]84AG"'0+]KA8.%XZACA+N$P9$>A!N#WWG4@Y2#
M+6*<@QV"C4N2@L."%C38@I"!P>IZAD>39=1TA4V0VKW\A&^.<Z<+@\2,6(_M
M@SF*=WC*@LJ(O6&V@FF' TK-@B:%3#0S@@>#;^C;A4^=_M+@A%^:=+QZ@XZ7
M%*6K@N>3Z(ZT@G*1"W>[@A6.06#6@<>+9$H8@9>(:#.B@8N%!.=<A(NHH-%L
M@YVD%;L0@M2?NJ1;@C>;E(V @<*7E7:Z@7B3NV (@3F/LDEU@1J+93,D@1^&
M>^8 @_&S2] ;@P2MNKG-@CJH6*,R@:.C+8Q[@3:>('7(@.Z9%%]*@+Z3VTCD
M@*^..C*Y@,&'S^35@W.]^,[Z@H>W5KBU@;RPXJ(O@2:JJ(N?@,2DBG41@(.>
M55ZG@%27T4AI@%.0V3)@@'*(^^/6@P[(I<X%@B3 XK?&@5>Y4Z%*@+^Q^HK0
M@&&JNW1K@"ZC7%XI@ >;E4@"@ >3.S(7@#")_N, @KW35,TW@=;*6;;Z@0?!
MFJ"(@&ZY$XHC@!&PHG/:?^*H!EVW?\:>_4>K?]"55C'<?_N*U]X2D>)\L,CN
MC_%\8[.QCAA\.IX[C&A\1XB-BMY\CW+%B6E]"ET1A_Q]J$=[AIE^DS)1A3E_
M\=PJD+2&E\>4CL&%4K*2C/2$/)TVBU>#6X>.B>2"MG'2B(B"/5PKAS.!V$:Y
MA>F!HC'+A**!G=JCCXZ0E<8YC:B.5[%RB]V,/IP5BE>*<(9XB/B(V7#0A[6'
M:%M(AG>%_$8%A4:$GS%4A!F#--E"CIN:E\38C+^7;+ 'BP>4:YK(B8*1I(52
MB#F/'6_9AP6,J%J#A=B*)D5OA+J'CS#L@Z"$K]?NC>&DE,.'C F@@:ZZBEN<
MFYF/B-Z8Y(0ZAXV53V[PAFN1U5G.A4J.-$3HA#V*6S"1@S6&"]:UC4NNG,)<
MBW>IG:V9B<JDQ)B"B%*@%X-,APB;?FX:A>&6XEDKA,Z2'41S@]",_S!%@MJ'
M1-6GC-"XH\%<BO^RL*RAB5&LVI>;A]VG*H*&AINABFUWA7J;T%BAA&*5T$02
M@W./;# %@HV(5M3"C&K"IL"&BIV[LJO/B/&TU);1AWNN$H'.ACVG6VSCA2F@
M@E@VA!:93D/!@R>1G"_1@DZ)0=0$C!/,J;_5BDW$H*L?B*.\I98GARVTOH$W
MA?&LWFQGA."DU5?4@]F<;4-X@O23A2^G@AN*!<Y/FQM[@+JBF%E[4:;OE:Q[
M1I,*DR=[<W[HD,9[VFJHCG5\=U:(C")].4*6B<)^4"]"AT)_XLR=F@^$TKF!
MESR#OJ8&E)>"U9(TDB"")'X3C].!K6G:C9B!8U7&BUF!,4'\B1&!-R[OAJ:!
M>LM"F1&.(;A$ED6,+J3YDYV*6I$ND3>(U7T@COJ'?6D"C-&&2E4.BJ6%'T%T
MB'"$"BZEAAN"^LHAF!Z7CK<8E6.4N:/+DLF2 9 ;D%>/C'P=CBV-46@@C!2+
M*518B?F(^4#RA]N&P2YEA9^$7LC_EV:@]K8'E*V=1**ODAN9OX[ZC[V6:7L@
MC8F3,V=1BW^0$5.^B6V,S4"*AUV)82XNA32%H<?LEMBJ8+3^E"*EUZ&ND9*A
M<(X+CSF=,7I,C0F9 F:7BOB4SE,VB/"0=$ PAN^+TRW_A-B&P<;[EF2SO[0@
MDZZN5J#7D1^I!8U!CLBCT7F>C*&>IV8*BI.98U+&B(*3XC_GAH^.#2W8A(R'
MN\8NE@.]&;-EDTZVQ* AD,"P?(R2CFFJ1'C^C$:D$66)BD2=NE)KB#:7%C^J
MAD&0"RVXA$R(D,6%E:_&<;+-DOR_')^)D'*WQHO^CAVP=WA[B_NI*&4@B?ZA
MLE(:A_V9[#]PAA&1PBV?A!J)0+\@I(=ZK:S)H/IZC9I_G7QZEH@4FA]ZV'5R
MEMY[5F*TDZ5\#% JD%M\Z3WAC.Y^("QJB3M_T[VBHYR#<*OBG_*"?)G.G'.!
MM8=NF1^!)73%E>^ TF(*DL> KD^)CX^ ICUNC#6 W"Q)B)>!6;R#HJF,-JK<
MGP:*;ICLFX6(SX:,F$&'=7/SE1R&4&%2D@.%4$[SCMF$6ST*BY"#A2PLB 6"
MQ+N"H=V4[*G0GD226Y?9FLR/^865EWZ-PG,3E&2+S6"8D52)YDYFCC2'^CRR
MBON&$"P3AX2$$;JEH1J=PZCIG8Z:99;GFB&7-(2AEMJ4)G(\DZF1/U_FD*F.
M:TWAC92+?3QABF^(=BO]AQ6%/;F\H(^FFJ@>G/VB:98DF8R>8(/?EDF:?W&(
MDRN6KU]-D"*2VDUVC16.XSPBB?Z*MROJAK>&1;CMH""O6J=@G(JJ6)5NF1JE
M<8,UE=N@JG#WDL2;ZU[7C[^7%4T>C*>2"SOPB9N,P"O;AFB'*K@WG\>X":;!
MG"VR)Y36F+RL6(*EE7ZFG'!SDFN@Y%YMCW";#$S7C%F4\SO'B4N.C"O/ABB'
MZ[>@GWG M*8^F]FYWI16F&JS#H(IE3"L2G (DB"EB5X:CRJ>I$R9C""7@3N?
MB1R0%"O%A?2(B;"=KBAZ)I^*J<UZ"8Z.I7YZ&WV H4AZ:FQ*G2%Z^%L%F/![
MP$H)E*!\L3EJD!%]_RG0BQQ_Q*]<K5*"9I[4J-F!@HX&I(2 T'S^H%" 6FN_
MG#* (EI]F ^ '4F-D\J -CDACTN DRG@BFN!.:YWK&N*GYX"I_>(]XU2HYV'
M>WQ'GW.&1VL3FUV%2%GIET6$<TD:DPN#KCCDCIN#$"GNB<^"D:VTJYN2SYTN
MIS20:HQSHN..,GM[GK&,-6I<FJ.*<%E4EI*(P4BPDF"'$CBOC?Z%;BGZB4>#
MR:SMJOV:]9QJII:7U(NJHDF4YWJTGAF2+&FPF?F/@UC-E?*,^$A4D<6*5CB"
MC7&'I2H$B-&$X*Q$JF*C-YO)I?V?4HL+H;";F7H:G828"&DCF6:4A5A6E5&1
M!4@"D3"-:SA:C/")KRH-B&Z%U*N>J>^K7IM$I8"FJ(J.H2VB&'F=G0"=KVBS
MF.^95%?]E.:4Y4?%D+N033@^C(B+ARH4B!R&I:L&J9>S:)K#I1^MVHH9H,JH
M;'DQG)ZC'VA4F).=VU>PE)68?$>3D&J2[#@JC#6-)2H9A]B'5*J#J4R[9)I7
MI,FTZ(FTH'6NA7C5G$VH06@'F$:B"5=XE$N;M4=ND"^5,S@7C ..@BH>AZ.'
MXZ+AM_QYQY,!LLQYHX,\K:IYN'-UJ)9Z$6.9HWUZK%._GDA[@T1&F-]\AC5*
MDQQ]YR=_C-E_MJ'DMRV!C9)WL>B L(+6K+R #',1IZ-_J&,KHHQ_AU-8G5U_
MGD/QE_I_UC4LDD2 52>\C!F!'*$_MD:)0I';L0F'L()/J]B&37*$IL*%.6*H
MH:Z$7%+KG(:#KD.EERJ#%#46D8."J"?RBW""8J"WM7*0YI%$L#Z.I8&IJQ*,
ME7'LI?**Q&(@H.>)+5*!F\:'L4-@EG&&.C4%D-F$VB@ABMZ#B* LM,>8AY"W
MKY*5E($9JFF2V7%;I4R03V&FH#.-Z5(CFQR+FT,GE<Z)0#3XD$.&Y"A(BF&$
MC9^;M$*@)9 WKP2<>8"CJ=:9 G#NI+J5O&%$GZ22B5'5FGZ/54+YE3B,%#3M
MC[^(P2AIB?>%;I\NL[JGL(_6KGJC0(!)J4R? W"<I#6:\F#]GR66[E&AF@*2
MVT+6E*N.JC3ECT:*9BB%B:"&+YZWLURO&8^-K@RIS8 .J-*DM'!>H[&?S6#"
MGJ6:^E%QF9J6$4*\E%21!33ECNZ+VBB;B5F&SYY-LPJV9X\\K:ZP-'_+J'.J
M,' HHU>D9&"<GE">M%%;F4B8[T*TE!"3#33JCK:-$BBMB2"'497LP?UY?X<R
MN_)Y4'B1M?AY8FG\K_]YPEMGJ>MZ:$SLHZ%[3S[KG0Y\8C&%E@5]TR5TCF]_
MJ94\P2: V(;1NQA_^7A%M11_7&FNKP]_!UL5J/-^_$RFHJ=_+#Z]G!-_@#&3
ME1: 'R7<C9V! 939P#*(#X9KNC.&BW?KM"N%.VE-KB*$05J\J .#A$QBH;R"
M^CZ:FRV"B3&EE$""2R8VC.:".)21OU"/+H84N52-"'>"LT^+&6CMK3R);5IH
MIR6( DPEH.6&M3Y^FE^%=#&XDX2$4R:$C$B#3I1"OI.62(7&N)*3>7<SLHJ0
MZFB9K'J.DUHEIEB,94OXH">*5#YKF:R(/#'+DN*&,R;'B\*$0I/DO?V=785[
MM_"9W';UL>&6FVAFJ]*3DEGVI;60I4O6GWV-P3Y?F0V*TS'=DE6'YB;^BU*%
M%9.)O8.D3H4ZMVB@#W;$L5&<$&@_JT&82UG8I2^4HDO$GOR0\3Y8F(.-+3'L
MD=R)92<LBO6%QI--O0&K$X4.MN6F"G:GL,VA1F@LJK^<OUG)I+.84DNZGI&3
MU3Y5F!F/1#'ZD7&*KR=1BJF&6I, O**QM83RMG2KOW:?L%&F$F@GJCF@N5G,
MI"R;CDO'GA*65SYNE[J1$3(8D3"+QB=OBFZ&T8F5S"1Y<'OUQ39Y*&YFOFAY
M+V#LMXYYCU.0L'AZ/$9IJ0E[+CG:H3=\3"X&F-1]R2.DC^%_G(E)RRJ 97N_
MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
MEM:!_"2PCC:"$XDOR1V-OGN)PF>+IVWHNY")SV!JM(B(0%,?K5R&^D8PI?"%
MUSGWGBR$Q2ZYE@6#W24;C8V#&HDCR$*44'N"P8"1FFWFNI^/+F!?LYJ- E,=
MK&J+!48ZI1*)*CH1G6"'42[NE5&%E25UC/V$ (D)QX2:V'M[P+:7=VWPN<V4
M9&!ULLF1E5,OJZ2.YT90I$V,23HOG*^)JR\?E+F'("7!C(6$Q8CLQN&A+WMV
MP J=&&W]N1J95&".LAB5VE-+JP"2?T9NH[6/)SI0G!F+R"]+E#F(>27_C"*%
M:HC-QE2G4'MQOW>B=FX-N(*=^&"JL8"9RE-KJG"5PD:/HSF1MCIRFZJ-I"]T
MD]&)H28RB]*%\XBQQ="M,GMQOO&GAVXEM_JB/6#2L/F=5U.;J?"8HT;#HL63
M[CJDFTN/-R^ADX>*EB9:BY.&8?+/>V-YL-O=>[QYTL2H?!QZ!ZTE?(-Z7I5Q
M?/=ZW7VM?7Q[@F7P?A5\/DY$?ME]-#;+?^E^??"R>;F$S]HM>C2#RL,J>K."
MZ*O/>SN",I0T>]"!JGR(?':!0F3A?2Z XTU5?A" GS8!?SJ :.[,>%F0 MAJ
M>.6-VL&?>7B+TJI>>AF*$)+J>LF(?7MD>XN'!6/D?%^%ADQ]?5N#_C5,?IN"
M/^T&=S.;,=:N=\B7[[_X>&B4V*C@>1F1\I&8>>&/5'I!>KN,PV+R>Z>*&DNX
M?+F'1S2M?@R#_>MI=D>F5=4;=MZB [YR=X6=WJ=W>$&9[)!->1:6'7DH>@:2
M<F(->P:.EDL"?"R*;S0D?8V%G>H$=9.Q;]._=B>L$;T>=LVFUZ8W=X^ASX\O
M>&Z<YG@?>6F7_6$Y>GR2ZTI?>[*-;3.O?1^'%^C:=06\>]*==96V#KO_=C>O
MNJ4D=ONIE(X]=^2CC7=1>.J=<V"!>@:7#$G4>TN0,S--?,*(:.?G=)S'<=&P
M=2>_[KL0=<*X>Z0W=H*Q*XU@=W&I^':;>(.BKE_R>:J:_$E>>O:2NS+\?'2)
MC.<G=%720=#V=-G)F[I,=6K _Z-N=B2X@(RB=Q.P%77T>"NGB%]J>5N>CDCY
M>K&4^C*\?#:*@>*9A!%X&\V-@X5X>+@<@PYXX:(X@JMY9(P)@EQZ#'6\@A]Z
MV5^ @?![PTE5@>)\[#-\@@1^=>#A@HZ"J<Q<@A>!YK<2@;.!/Z$H@66 P8KI
M@2N :W2@@0F .5YS@/Z &4AU@16 'S+@@5J 2=]1@4&-0<K!@-F+;K66@(*)
MN)_%@$V(/HFR@"Z&\'.4@"F%OEV/@#6$BD>Z@&2#6#)6@+^"!]V_@"B7Q<DE
M?\>4]+0!?WR20IY<?U"/N8AT?TN-;G*'?UR+,5RW?W^(XT<3?\6&=#'=@#2#
MK-Q$?T*B0<>S?N*>>[*:?J":TIT'?H"72H=!?H*3W7&)?JJ0DUOO?N"-($9[
M?SF);3%T?[J%,-KZ?I"LOL9T?C&H!+%C?>ZC6)OC?=.>Q88]?=^:2'">?@R5
MT%LY?E:1-D7T?L*,.S$;?U&&CMGH?@*W,L5L?:2Q?K!<?5ZKQYKD?4.F(85>
M?5J@D6_F?9*:\EJ>?>&5%T6!?ER.T3#0?OF'P]D-?9?!F,26?3JZXJ]_?.VT
M%IH&?,VM3821?.>FFV\Y?2V?UUH:?8>8PT4A?@B1*S"3?J^(SMAF?4K+[L/N
M?.[$)Z[%?)B\-9E$?&^T.X/@?(BL6&ZF?-6D8%FL?3N<%$33?<B3/3!C?G2)
MK=+OC.MVV;^2BWQW5ZN]BBUWW9=?B/YX?(*IA^9Y0VW1AMYZ-%D8A=Y[1D1[
MA/%\H3!:A!I^:]%UBY2 P;YDBC6 /*JCB/1_T99:A]5_AH&OAM)_96SHA>-_
M9UA A/U_>T/,A"Q_NB_N@VZ *M FBE2*N;T6B06)-:F#A\F'RI4TAK^&DX";
MA="%@VOQA/F$D5=MA"R#HD,K@W>"OR^-@M2!TL[.B4*4I;NTA_B2-Z@0ALZ/
MXI/IA<N-LW]VA/6+M&KZA#.)PE:J@WR'PT*=@MN%KR\Y@DN#7<V!B&F>A+IH
MAR*;-*;)A@"7^I*RA0:4V7YDA#&1SFH6@X6.VE7Z@MZ+Q$(?@E"(>2[Q@=.$
MQLQ;A[ZH:;E,AGJD-J6TA5>@"9&LA&*;[7UY@Y67WVE'@NF3SE5=@E2/G$&R
M@=B+%RZS@6R&"\MFAS.R1+A>A?*M)Z3'A,ZG_Y#)@]JBWWRR@Q>=RFBD@G.8
MH%39@=V3/4%7@7*-?BZ @1:')\J@AL>\#[><A8JV :0 A&.OU9 $@VJIH7O\
M@JJC=V@+@A2=,E1I@8>6I4$+@1Z/IRY6@,Z(&LH*AG7%S;<#A3R^P*-9A!"W
M?8]9@Q*P)7MB@E&HU&>-@<"A:%0&@3^9L$#%@.&1B"XT@)6(Y,.[E?AUWK'*
MD[)V<I]OD9!W$(R4CY%WR7E<C:EXJF7^B\MYN%++B>MZZC_$B U\:RUIAB1^
M8,)\E,%_-+#0DH-^V)Z$D&U^DXNVCGI^<GB%C*)^>64UBME^I5(4B0]^YS\[
MAT=_6RTKA72 #,%9DZ*(?Z^BD6^'0)U[CUJ&$HJOC7>%&W>6B["$1&1EB?R#
MBE%HB$:"US[!AI2"-BSTA->!G<!%DI.1V*Y\D&R/NIQ+CF6-JHFGC'V+QW:>
MBLR*#6.1B2F(8E#"AX>&KSY0A>^$\BS%A$N#$+\GD;Z;)JUTCYB8,9L\C9>5
M48B+B\"2B76HB@Z/UV+%B("--5 IANV*=CWMA62'D"R<@]*$8KXGD1ND<ZQV
MCOB@JYI"C/B<Z(>ABR69-737B7B5BV(2A^>1W$^FAF*.#CV9A.N)_BQY@VN%
MCKU.D)BMKJNECGBI#9ESC':D8(;:BJ2?MG0HB/Z;$F&%AW.66$\YA>F1;#U5
MA(*,-2Q<@Q6&DKR?D#&VV:KZCA.Q5YC#C!"KM88MBCFF!W.(B):@6F#_AQ>:
ME$[;A924CCT;A"R.+BQ%@LZ'<+P9C]^_]ZIRC<:YAI@NB\"RVX66B>6L%W,!
MB$&E4V"3AL:>=$Z&A4^753SA@_./WRPR@I6()[4.GSUU,J1CG"AUSI-BF3=V
M>H'QEF5W17 LDZ-X.EY&D.%Y7DR=CA%ZJ#LVBRQ\1"JMB!Y^5+0'GBE]_*.C
MFQ1]MY*NF"=]CH%$E5M]BF]^DJ1]LEVCC_)^ 4P*C3)^:CK4BF!_"RJ=AV5_
M[K,=G1>&O**MF@V%H)'1ER"$H(!DE&*#T6ZRD;F#*5SSCQF"GTM^C&F"'SI]
MB:F!NRJ/AL&!:[(IG"F/8J&JF26-?Y#"ED&+O'][DWZ*%&W=D.2(G%Q%CE&'
M+4K]B[&%O#HQB02$2BJ#AC&"R+%,FTN8'Z#%F%&5=(_7E7:2XGZ/DKN08FT7
MD!2-^UN@C92+I4J%BP.).#GLB&R&LBIYA;2$ [!TFJN@VJ &E["=98\=E-*9
M^GW.DAF6H6QBCX"34EL*C/R/_TH;BG>,D3FPA^^(\BIPA4J%&*^[FBZI>9]1
MES6E.HYIE%6@\WTED9V<LFO.CPF8=5J3C(F4)DG%B?V/K#F"AX2*^2IIA/*&
M"*\AF<ZQ_IZ]EM2LZXW4D_*GOGR3D3:BB&M(CJ2=5%HCC"Z8!TEZB:62ASE;
MARN,Q"ICA*J&TJZJF8&Z=IY&EHBT@8U4DZ.N67P2D..H'&K7CE"AX5G+B]V;
MCDDVB6&5"CDPAO*.22I>A'"'>*<!J+ITP9=^I-QU6X>XH1YV#'>;G75VXF<Y
MF<YWYE;$EAEY'$:ADD5Z>#;@CD1\*B@OB?Y^2*8RI\1]"I;SH^!\SX<VH!U\
MMW<:G'-\R6:UF-%]"U9)E2=]>$8WD5Y^ 3:HC6U^R"A+B3A_T:5_IK^%/98S
MHN2$.H:-GQZ#6'9JFWR"K&84E^."*E7!E$>!RD71D(R!>C9XC*N!3"ADB(J!
M.Z3&I<^-6Y5FH?R+GH6QGCZ* '6JFIF(CF5GEPZ'1E4WDWV&$$5QC]"$VS9,
MB_^#KRAZA_*"A:0$I1&5:I2FH3^2^(3NG860I73GF>..<63(EDJ,2E2YDLB*
M.T4=CR6(&#8HBV2%ZBB-AW"#JZ-CI&.=CY0'H)B:8(1/G-Z70W1.F3R4.60\
ME::1-U1*DAF..$34CH.+)S8(BMF']2B<AP&$K*+/H^6EEI.*H!>AI(/4G%:=
MM'//F*^9SF/&E2*5\E/MD9^2"427C@*. #7OBF>)SRBIAJ:%B:).HXBM>I,1
MG[>HP(-=F_*C]7-=F$:?*V-?E+J:9U.8D4&5D$1@C:>0EC7;B@N+;BBTAEN&
M0J'HHS^U2)*NGVJON(+VFZ&I_W+XE_*D/F,)E&6>AU-7D.Z8OT0SC5^2US7$
MB<^,RBB\AA^&V9FLLFQT:8L\K<=T^GR=J3IUK6V^I+-VC%ZPH!IWG4^BFV!X
MXD#^EG9Z3S+<D41\%"7VB[=^/)D:L8M\/(KEK-Q\ 7Q*J$)[]&UIH[%\&%Y6
MGQ=\<D]1FF-\^T"_E8!]HS+1D%M^C"8\BN-_MIBAL(F#ZHI=J^*"]GO2IT*"
M*FSHHK2!G5WAGB"!/D[SF7>!!D""E)^ XC+'CXJ YR9ZBBF!$)@BKY:+>XG)
MJO2)VWLNIEJ(8FQ9H<>'&UUBG3^& TZ2F*&% 4!'D]2$!C*_CM*#'R:OB8B"
M1Y>8KLZ3 XD\JB^0NGJ<I9>.EVO'H0:,EESMG'6*L4XZE^2(X4 3DR&'!S*X
MCBZ%+R;<B/Z#6Y<0KC6:AHB^J9.7D'HCI/>4M&M5H&61]%R'F]2/0DWPES6,
MD3_JDGV)V#*SC9Z'$"<"B(J$2Y:KK:6A\(A:J0:>17G"I&J:J&KYG]B7'5PX
MFTJ3F4VXEJZ0"S_-D>:,:C*PC1R(NB<AB"J%%Y9'K4:I-X@:J*"DS'F&H_6@
M66JUGU&;\5OUFL*7F4U^ECJ3.#^KD8..P3*OC+N*,B<[A]R%PI7TK/RP88?0
MJ$VK*7D]HYREU&IQGO6@AEN_FF6;44U:E=Z6%#^8D320QS*OC'F+;"=/AYV&
M3(T1O%)T''^BMN-TH'(6L81U461DK!=V-U:<IG]W5$CKH*YXJSN\FIAZ*B\P
ME"-\ B0!C4E^,(R_NWA[@G]]M@%[0G'PL(U[.V0YJPU[;U9MI6Q[WTC&GYU\
MA3NKF8M]3"]2DR-^5R1NC&1_GHR$NFZ"LG\NM/^!QW&IKX2!#&/IJ@* FE8F
MI&. 74B4GIR 33N8F)6 5"]PDC^ C"3-BYV Z8Q!N6R)OG[5M &(-7$_KHJ&
MVF..J0*%NE77HVZ$T$A?G;*$ 3N%E[>#/R^*D76"G"4?BO&"$8OON)60OGZ"
MLRJ.F'#GK;*,H&,RJ"N*TE64HI")*$@QG..'F#MVEO2&!B^BD,:$@R5DBE^#
M%8N7M_&7N'XTLG^4\'"AK0&22V+SIWB/R55;H=Z-7D@.G"F*_SMJED>(G"^V
MD"V&/"6?B>2#]HM%MW">C'WSL?>;&W!IK&^7OF*_IN"4?U4PH4R15D?TFYR.
M*SMEE:^*]R_(CZB'PR7.B7^$M(L0MO:E,GW%L7RA#W _J_&<]F*;IE^8\U40
MH,V5 T?:FRF1#3M<E3R-$"_9CS6)$R7UB2V%4HK4MJ:KO7VQL1ZFTW QJX&A
MVF*%I=N<^E4"H#^80T?9FJ&3D#MJE-..WB_PCNN*+R84B.N%T8$-QF1S]G2*
MP#1T9&?^N@5U"UMILZQU\T[<K0=W&D*"I@MX?S;#GK1Z#BO*EN5[]2)%CK9^
M)8$'Q7]Z^729OT]ZIV@$N09ZGEMGLI%ZVT[8J]Q[7D*+I-Q\'3;CG8=] "P:
ME<E^*B+7C<!_AX$0Q&"!L'2'OCN P6?PM^R #5M*L6U_L4[#JK9_D$*)H[Y_
MI3;^G'1_UBQ@E,V .R-5C.J Q8$/PT2(-W1PO2"&NF?&MM*%=%LIL%"$=$ZL
MJ:*#M$*%HK>#%3<6FWV"BBR>D_"")2/ C#.!WX#[PE..KW1;O"J,HV>PM=>*
MSUL,KU:)+4Z@J*:'N4*)H<V&93<OFJ2%&"S6DS"#YB0<BYB"UH#<P925'W1+
MNV"2?F>JM020"5L-KH&-PDZ@I]:+F$*4H/R)@S=*F>:'=2T'DHR%>R1HBQ:#
MJH"]P/F;8G1 NKJ8(V>JM%.5!5L3K<Z2$$ZIIRN/-4*DH%J,9#=EF4.)ERTS
MD@&&W22GBJR$7("?P'ZA<G0YNC.=C&>OL\*9NUL<K366#DZSII>2@4*RG]>.
M^C=\F,J+>2U8D9"(#B3:BE6$[X"'P!FG4'0XN<"BLV>ZLT2>'ELMK+*9M$[)
MIA65<D+/GUV1/3>:F&.-$RUXD3V)""4"BA&%9>:W=K%S:-%5=Y-T2[N&>'!U
M-*4Z>4AV*HZA>B1W.7?O>P]X96%/? ]YJDK/?3U[*#2O?KM\_^2U=-=^<\^S
M=>%^*[H/=N!]^J/M=]M]YXUP>-M]]';:>>I^&F!3>PY^2DGW?%]^EC0&??M^
M_.+E<TV)BLWQ=&F(&KB%=7^&Q*)]=I6%J(PK=[.$KW6_>.*#RU]D>B:"XDDT
M>Y6!]3-P?4R Y.$H<?R4C<PS<R.2"+;4=$:/I:#]=7&-:XK8=JR+:G2@=_>)
M<UY]>5>':4B >N&%/#+L?*^"LM^4<.B?>LJF<A.;\[5+<T&8B)^,='B50HF/
M=<22%W.+=RJ/"EVB>**+U4?;>D.(7S)Z?"2$7MY!<!.J5<E9<3^EU[0"<FZA
M89Y.<ZR=!HAP=028P'*'=G>4?%S7> :0&$=&>;R+5C(9>ZV%X]TK;VVU&<A*
M<)BOI;+O<<*J()U!<P*DJ8=_=&6?1W&[=>:9U5PG=X&4)4;(>4J.%3')>T>'
M.]Q2;O._NL=V<!NY3;(1<3ZRMIQ<<GFL&8:D<^&ECG$#=7">\EN:=QB8 $9<
M>.N0E#&&>O.(9MNS;J7*(\;:;\;"LK%A<-V[ IN<<@ZS.X7J<W6K?G!@=0JC
MIUL3=KV;=T7W>)R2QC%1>J^)8=<@?Q5R&L.:?QES.:^ ?RAT3IK)?T!U:(6J
M?V1VEW!B?Y9WY5LS?]AY3D8>@#YZ]3%^@-Y\_=6C?69\F<)R?8M\FJYH?;-\
MHYFX?>)\P82>?AY\^V]I?FU]3UI1?M%]LD5F?UU^-S$ @"%^Y-0C>_.'%,#7
M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
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M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
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MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
MH)=_9UWPG19_3U+MF7)_.D?NE;9_03T4D>]_7C+LC@Y_A2F6BB1_OB&UAE5_
M_W+AHON&'FANGZ"%A5VCG!V$SU*CF'F$#D>OE,*#6CSXD/^"N#+LC3."("FT
MB6B!CB'WA;R!!'*2HC>,CV@OGMN+=5UJFU**'%)HEZJ(ID=VD_J'.CS9D$&%
MV3+TC':$@RG2B,:#*B(MA3V!X7)9H9F2Q6?[GCR1(ETRFJ^/)%(QEP*,]D=$
MDU2*SSRICZN(KS+EB^2&H2GPB#^$D")9A->"F7(KH3"8U6?]G<B6O5TOFB:4
M!%(<EF"0_$<[DJ:.##RTCP.+-#+VBUZ(=2H$A]J%N2)\A(6#+VH)LM=C:E_\
MKNAEJ57AJKEH#4NPIB1JFT& H2MM6#>)F^AP32X]EG1S:R6]D-EVTQZ@BUQZ
M8&F8L?)J0%_7K=)KRU76J6EMB4NZI+%O>$&<GZYQFS>YFG1S\RZ%E0]V<"8H
MCXUY*!\VBC![]6E;L(1PPE^3K&!QNU6LI_)RVTN9HS5T-T&2GCQUP3?+F15W
M>BZXD\=Y42:"CF-[5A^WB2M]9&DDKOEW"%]/JMMW@U5?IG9X&DMKH<AXWT%V
MG.%YT#?-E])ZXR[=DI]\#B;,C5Q]6R GB$M^JFCJK:)].5\<J8M]054MI2E]
M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
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M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
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MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
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M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
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MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
ML&ONAIB*=6*:A>R)Q%B^A0&(JDZ4@_2'541U@P:&$SJ*@DF$YS%+@9Z#TBC#
M@2J"JR&9@."!@FN8A>&0OV))A3F/BEAMA%.-NDY-@TB+G$1!@EN)F#IM@::'
MK3%&@0^%URC1@+B#]B&X@(>"+67>FS%9H5SGF0A<Y5.9EN=@04GME)]COT 9
MDB)G:#9FCXEK3"U7C.=O7R4#BE=SQQX'A_QX8F4BF4=@?5QKES]C*5,NE1IE
M\4FEDLQHVC_UD%AKZ39JC=EO*RV$BU=RER5;B.YV2AZ,AKMZ'624ER=G+%O4
ME3]I3%*WDS-K@$D]D/EMUC^TCJ%P2C96C$1RZBV?B>EUK"6DAZQXIA\ A:-[
ML&0$E1IMMULXDTMO4%(6D5EP]TC-CSURM3]DC0ITCC8RBM5VARVJB*1XFB7<
MAI%ZV!]CA+)]&V-SDU=T,UJPD:)U25&:C\!V8$A8C;9W>C\DBZ!XL#8/B9%Z
M BVLAX=[9"8'A9Q\XA^W@^1^6V+PD>IZI5H]D$M[.E$WCG5[N$@%C'=\*S[B
MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
MWT>^BVV ICZAB7: ?C78AXV ;BV[A;. ;B9(A!2 :2 W@JF 7V(JC\^&\%F.
MCE.&A%";C(Z%P4=]BIB$USYNB*B$ #6FAM6#/2VIA0F"DB9H@WV!W2!F@C:!
M)&'ECQB,TUEOC:>+^%!_B^.*A$=FB=V(RSYRA^2'.#7&AAB%QRW,A&R$<2:%
M@P:#$2"+@=J!Q5N3I%Q8^5-0H91<,4KEGJ9?D4)(FVEC)CF<E^!F^#$GE"QK
M"RE?D&MO3")>C+USTQREB5YX:%K:HJQ?<%+4G_1B'DI]G/9D^D($F:MH!CF%
MEB!K1S$]DGQNP"FDCM-R8"+/BT=V.AT^B ]Z%EIKH*)EM5)>G?UGYDHAFQ1J
M.$&XE]9LOCE>E&1O;3%!D.!R32G7C5IU2R,MB?AX=QW"ANQ[G%H*GI9KU5'S
MG 1MBTFOF3%O6T%PEA-Q4CDQDL)S<3$\CV-UM"G\C =X#B-ZB-%ZBQXTA?)\
M^%FEG,MQZ%&5FE-S)DE>EXYT<D$CE']US3D6D4QW5#$ZCA)X^BH;BMUZK2.[
MA])\=AZ4A1Y^+%E&FU1W]%%+F/%XODDEECAY?$#ZDS-Z/#CZD ][&#%%C.A\
M%RHZB=A](R/QAO=^-A[DA&Q_-5CVFB)]T%$1E\]^)TC\E1U^44#9DB%^<3C?
MCPQ^J3%"B_I^^RI<B/A_8"0BACY_PA\F@]F %EBUF2^#>E#GEN>#6TC>E#B"
M[D#%D3V"93C0CC&!]3$PBSB!GBI?B$N!7R1*A:6!&A];@V. T5B+F&^(]5#-
MEBF(84C)DWZ'4T"YD(6&&3C6C7J$_#%%BHV#_2ITA[:#%21CA2R"-!^%@P2!
M::Q_7.-5*YTR7_U9)HV%8Q%=%7U,9C!@^VR?:71DYUO$;.IH[TL[<)5M*#L0
M=)EQNRP'>/IVY:J+6.U?89NP7&]B8(PS7]]E5WPG8U=H3&N<9O1K25KH:L9N
M84J,;M!QHCJE<S1U-"OW=_)Y/JB]56=I@)G]63YK@(K$7/]M?GK18,-O@VIX
M9*]QEEG\:-5SP4G>;3=V##I <?5XEBOJ=P=[=J;R4CUS<YA+5F-T@HDF6F1U
ME'F 7FQVJVE38J9WTED49QMY#4DZ:\YZ73GE<-Y[V2O>=C=]B*5"3W=]0I;+
M4^!];H?%6")]F7@T7&1]Q&A;8-Q]^%A)99M^/DBK:I9^CCF6;^Q^]"O3=8-_
M;J/432"&\96+4<*&/8:O5CB%?W<]6K&$NV=]7UV#^U>H9%&#14@X:8V"DCE4
M;R"!W2O*=.F!(J*I2RF0<Y2)3_N.UX7/5)N-*G9Z64"+=6;-7AZ)Q%<:8T.(
M$4?>:*V&5CDB;G2$ARO#=&F"H:'$29>9L)/"3HZ7)(4A4TV4@G7B6!"1VF9$
M71./-U:?8F6,C4>$9_N)SSCY;>:&ZRN]= "#Z:$K2'"B@9,W37N>]X2@4DN;
M7'5P5R&7Q67G7#N4.%988:J0G4=$9V*,Y#C*;7*(^BNY<ZN$^Z#58_-5-9+4
M9FE9.H1):.==)W49:WAA!F5Q;BQD[E6B<1!H^48O="AM-S<K=Y5QUBE;>UAW
M"I\K8#!>Y9&C8P]A^X-%9>!E G0\:+QH F2T:[UK"E4*;O5N,47#<F5Q@C;S
M=B]U*BEC>DMY29V*7,YH>9 !8 !JI8';8QMLQW+N9D%NYV.;:8]Q$U0J;1ES
M6D4A<-UUPC:>=/AX:REJ>5M[99OJ6<1QY8YO73US-(!=8)=T>G' 8_UUNV*6
M9YAW!U-?:VUX:$27;WYYX398<^5[ABEO>(E]6YIH5QM[-8T/6M![KW\77F=\
M&7"-8@5\>6&X9=M\WU*J:?A]6$0=;DY]W#8=<O9^=BET=]-_)9DH5-^$:HOM
M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
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M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
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M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
MH'F;5BZ)&6])6D"(;F1Q7C^'?EDI8E&&<$VI9IN%;D(^:R>$>3>/;]2#D"U]
M=+*"H"2Z>7.!K7D>5+202F[66.V._6/^70Z-15B^84"+8$U59:N)B4(':EV'
MP3=@;S>& BUC=$"$/B3.>1B"BG=L<P91!6SQ=%=5*V(<=<Q99%;5=U5=L4M"
M>/!B'3^R>K%FO32O?)AKF"I7?L1PX"%D@1-VF778;QA8O6O/<-5<3&$N<IY?
MXE8;='-CA4JV=F)G0S]6>'YK,#2&>L%O3RIL?41SRR&]?]IXG72':W%@@FJ4
M;9)C:F T;ZUF5E5!<=%I2TH.=!-L6#[C=H9OC#1/>2%R["IU>_)VEB(*?LAZ
M>W-,:!YH.6EG:I)J=5\7;/ELM51\;V1N^TEL<?QQ4SY[=,)SRS0A=ZYV92I_
M>LEY.")-?=E\+W(?92EOXVA29^5Q<UX@:I!S %.B;4)TBTCV<!YV*3XJ<S)W
MX30$=F9YL"J0><1[J2*%?0Q]MW$A8IQW=F>"99=X85UP:']Y-U+Z:W!Z!$A>
M;HEZWCW1<=A[TC/5=4M\V"J0>.9]\B*U?&!_#W!38&M^TF;%8YQ_&5S'9KE_
M-5)E:>!_0$??;3%_5SUY<+5_@C.Z=%=_O2J9>"A__2+<>]& .&^P7IF%Y68T
M8?>%C5Q!94&$[U'P:).$,T=X;!&#A#TA;\F"YS.-<Y6"62J@=XJ!QR+\>UV!
M,F\Y722,JF7'8*J+OUO69!:*95&.9XB(VT<N:R6'8#SS;P"%^3-G<OB$GRJ.
M=Q>#1B,5>P"!_VS2>LU1%6-*>X=5+EEM?&)98$\I?45=KT2D?BUB)3HP?RUF
MU3!5@$IKOB<X@9IQ#A^ @P1VLFMH=Q]856)$>#Q;Y5B5>5Y?@TZ$>H)C-40O
M>[-G"3GN?01K#S!*?G)O1R=H@!)SUA_L@;]XHFI <Z=?H&$M=1]BEU>[=HME
MF$W&=_1HJ$.E>7!KUCF:>Q)O+S P?-!RLB>*?KEV>R!)@*%Z:VDH<'IFWV =
M<CUI.%:[<^UKETT-=9YN!$,1=VAPB3D]>5=S,3 ->V%U^B>A?8UX^""9?ZI\
M"F@D;:1N"U\S;ZEOQE7D<9EQ@DQ&<XQS0T*D=95U&#CS=\YW#B_V>AMY&2>Z
M?(9[2"#>?M=]?&<[:RIU)EY?;6UV1%4M;YEW5$NW<<1X84(U= =Y?3C-=G)Z
MN2_R>/I\!B?4>Z!]9B$7?B5^P69\:0=\$5W#:X=\F%2K;>=\^$M&<$%]2T'.
M<K5]L#B$=51^+B_D> 5^OB?G>MY_3R%&?9)_UV7D9SV"N5TY:>Z"K%0O;'R"
M7$K>;OZ!\D%V<9R!G#@Z=&J!7"_ =T*!+B?U>C^ ^R%L?1J P65R9<N)'%S0
M:*2(@U/+:UB'@$J';?N&4T$X<+>%.S@7<Z6$.R^I=J6#3"?Q><B"7R&+?+J!
M@&*$@MQ0X5GT@O%4]U$4@R!9*D?3@TM=@SY;@VYB#34#@YMFUBQ-@]MKV"1B
MA$-Q-1W5A,1VQV%#?VI7MUD#?]U;3U!'@$I>^T<V@*IBQ#WT@0AFMC35@7MJ
MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
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M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
M  $                    !                     0    $" P0%!@<(
M"0H+# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$R,S0U
M-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)35%565UA96EM<75Y?8&%B
M8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/
MD)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKJ^PL;*SM+6VM[BYNKN\
MO;Z_P,'"P\3%QL?(R<K+S,W.S]#1TM/4U=;7V-G:V]S=WM_@X>+CY.7FY^CI
MZNOL[>[O\/'R\_3U]O?X^?K[_/W^_P ! 0(" P,$! 4&!@<'" @)"0H+"PP,
M#0T.#P\0$!$1$A,3%!05%A87%Q@9&1H:&QP<'1X>'R @(2(B(R0D)28F)R@I
M*2HK+"TM+B\P,3(R,S0U-C<X.3H[/#T^/T!"0T1%1DA)2DQ-3U!24U576%I<
M7F!B9&9H:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>Y
MNKN\O;_ P<+#Q,7&Q\C)RLO,S<W.S]#1TM+3U-76UM?8V=G:V]O<W=W>W]_@
MX>'BX^/DY>7FYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[
M^_S\_?W^_O\  0$" @,#! 0%!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04
M%186%Q<8&1D:&AL<'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T
M-38W.#DZ.SP]/C] 0D-$149(24I,34]04E-55UA:7%Y@8F1F:&IM;W%T=GE\
M?H&#AHF+CI"2E9>9FYV?H:.EIZBJK*VOL+*SM;:WN;J[O+V_P,'"P\3%QL?(
MR<K+S,W-SL_0T=+2T]35UM;7V-G9VMO;W-W=WM_?X.'AXN/CY.7EYN;GZ.CI
MZ>KKZ^SL[>[N[^_P\/'R\O/S]/3U]O;W]_CX^?GZ^_O\_/W]_O[__Z8Y,O^B
M1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'
MR[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]
MH$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@
MA]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@
M\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"O
MG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,
M<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6
MJYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G
M3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+
MW:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:
MJ%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6
MSZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99
MIL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E
M9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$
MIV^VP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^V
MP:=XN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=X
MN[VG@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7F_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG
M@<"ZI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
M_Z8Y,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"Z
MI8?&MJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y
M,O^B1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&
MMJ.'R[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B
M1DK]H$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'
MR[.@A]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B1DK]
MH$U@\:1,<N:G3(3:J%"6SZ99IL>E9+'$IV^VP:=XN[VG@<"ZI8?&MJ.'R[.@
MA]"OG8C6JYJ+W:67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F_Z8Y,O^B14K]H4Q@
M\J5+<>:I2H/:JDV5SZE6I<BH8;#%JFNUPJQUNKZK?;^ZJH/%MJB'RK*FA]"K
MHH?6I)Z)W)J:C^&:FH_AFIJ/X9J:C^&:FH_AFIJ/X9J:C^&:FH_AFIJ/X9J:
MC^&:FH_AFIJ/X9J:C^&:FH_AFIJ/X9J:C^&:FH_A_Z8X,O^C14K]HDM@\J9)
M<>:J2(+;K4J3T*Q2H\FL7:_&KV>SP[%QN+^S>;VXKX'$LJJ'RZRFAM"EHX;5
MG9^&VI.=B]Z3G8O>DYV+WI.=B]Z3G8O>DYV+WI.=B]Z3G8O>DYV+WI.=B]Z3
MG8O>DYV+WI.=B]Z3G8O>DYV+WI.=B]Z3G8O>_Z<X,O^C14K]HDI?\J=(<.>L
M1H'<KT>2TK!.H<JQ5ZW(MF*PQ;ILM;JS>+ZRKH'%K:J'RZ>GA<^@I(33F*&%
MUX^?B-J/GXC:CY^(VH^?B-J/GXC:CY^(VH^?B-J/GXC:CY^(VH^?B-J/GXC:
MCY^(VH^?B-J/GXC:CY^(VH^?B-J/GXC:_Z<X,O^C1$O^HTE?\ZE&;^BN1(#=
MLT.0T[9(G\RW4:K*P%RLO;ALM[.R>,"MKH'&J:J&RJ*HA,Z;I831E*.$U(RA
MA]>,H8?7C*&'UXRAA]>,H8?7C*&'UXRAA]>,H8?7C*&'UXRAA]>,H8?7C*&'
MUXRAA]>,H8?7C*&'UXRAA]>,H8?7_Z<W,O^C1$O^I4=>\ZI$;NFQ07_?N#Z.
MUKU"F\_#2J3"OEROMK=LN:ZQ>,&IKH'&I:N%R9ZIA,R8IX//D:6$THJCAM2*
MHX;4BJ.&U(JCAM2*HX;4BJ.&U(JCAM2*HX;4BJ.&U(JCAM2*HX;4BJ.&U(JC
MAM2*HX;4BJ.&U(JCAM2*HX;4_Z@W,O^D1$O^ID9>]*U";>JT/GWAO3N+VL8\
MELK&2*2YO%RRK[9MNZFQ><&EKH+%H:R$R)NJ@\N5J8/-CZ>$SXFFAM&)IH;1
MB::&T8FFAM&)IH;1B::&T8FFAM&)IH;1B::&T8FFAM&)IH;1B::&T8FFAM&)
MIH;1B::&T8FFAM&)IH;1_Z@W,O^D0TO_J$-=]:\_;.RX.GKDPS>'W=,UD,'$
M2:>QNEZUJ;5NO*2Q>L"BKX+$G:V$QYBLA,F2JH3+C:F%S8BHALZ(J(;.B*B&
MSHBHALZ(J(;.B*B&SHBHALZ(J(;.B*B&SHBHALZ(J(;.B*B&SHBHALZ(J(;.
MB*B&SHBHALZ(J(;._ZDV,O^E0DO_JD%<]K([:NZ]-G?HRS. T-(SD[C#2ZBJ
MN6"VI+5PO*&R>\">L(/#FJZ$Q96MA,>0K(3)BZN%RH>JALR'JH;,AZJ&S(>J
MALR'JH;,AZJ&S(>JALR'JH;,AZJ&S(>JALR'JH;,AZJ&S(>JALR'JH;,AZJ&
MS(>JALR'JH;,_ZDU,O^E0DO_K#U:^+<W9_'$,7'?URQ[Q= UE;#"3JFDN&.W
MG[5RO)VS?+^;L8/!EZ^$PY*NA,6.K87&BJR&R(>LA\F'K(?)AZR'R8>LA\F'
MK(?)AZR'R8>LA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>LA\F'K(?)AZR'R8>L
MA\F'K(?)_ZHT,O^F0$O_L#E8^;TQ8N?.+6G0X"1_N<\WEZ?"4JF>NF:UFK5S
MNYBS?;Z7LH/ E+&%P9"PA<.-KX7$B:Z&Q8:NA\:&KH?&AJZ'QH:NA\:&KH?&
MAJZ'QH:NA\:&KH?&AJZ'QH:NA\:&KH?&AJZ'QH:NA\:&KH?&AJZ'QH:NA\:&
MKH?&_ZLS,O^J.TG_MC)3\,<J6MC>(6;"WR2"K<X\F)_#5J>9O&BREK=UN)2T
M?;V3LX.^D;*%OXZRAL"+L8;!B+"'PH:PB,.&L(C#AK"(PX:PB,.&L(C#AK"(
MPX:PB,.&L(C#AK"(PX:PB,.&L(C#AK"(PX:PB,.&L(C#AK"(PX:PB,.&L(C#
M_ZTQ,O^P,T7XP"E,W]8C3<?H(&JSWB:$H<]!EI?&6:23P&JLD+QULH^Y?;:/
MMX.XC+:$NHJUA;R(M(:]AK.'OH2SB+^$LXB_A+.(OX2SB+^$LXB_A+.(OX2S
MB+^$LXB_A+.(OX2SB+^$LXB_A+.(OX2SB+^$LXB_A+.(OX2SB+^$LXB__Z\O
M,O^Y*3_HSAX_S.8;4K?N(6VEWBR#E])%DI#+6YV,Q6NEB\)UJHJ_?*V'OG^P
MA+R L8.\@K*!NX.S?[J$M'ZZAK5^NH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZAK5^
MNH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZAK5^NH:U?KJ&M7ZZAK5^NH:U_[(J,O'&
M'#/1XA0ZO/,;5JCN)FV8X35_CMA*C(C0796&S&N;A,ETH(''>*-^Q7NE?,1]
MIGO$?J=YPX"H>,*"J7?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J
M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
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M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
M95'T@&51](!E4?2 95'T@&51](!E_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@
M]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)
M=Z6OR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA
M;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6O
MR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5
M:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6I
ML,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GE
MDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=T
MKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$
MWX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''
M<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\
MCMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''<[.R
MQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NR_Y8S%/^50R7_DU$W_Y=31?^95E+]F5M@]9A@;>V69WGEDW&$WY![CMJ-
MA);5B(J<T820HL^ E:;,?9FIRWN=K,EYH:[(=Z6OR':JL<=TKK+'<[2RQ'2Z
MLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JR
M_Y8S%/^60R7_E5 W_YE11/^;5%+^G%A?]9M=;.V99'CFEFR#WY-VC=J/@);4
MC(B=T8>.H\V#DZC+@)BKR7V<KLAZH;'&>*6RQG>JM,5UL+7%=+BUO7>XM;AW
MN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BU_Y<S
M%/^60R7_EDXW_YI/1/^=4E'^GE5>]IY::NZ<8';GFF>"X)9RC-J2>Y74CH2=
MT(J+H\V&D:G*@I:MR'Z;L,9[H+/%>::UQ'>LML-VL[>^=[>WMWBVN+)YMKBR
M>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:X_Y@S%/^7
M0R7_ETTW_YM-0_^?4%#_H%-=]Z!8:>^?777HG62 X9INB]N6=Y35D8"<T(Z)
MH\R)CZG)A)6NQX":LL5]H+7#>J>WPGBNN<!WM;FX>+6YL7FUN:QZM;FL>K6Y
MK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6Y_Y@S%/^80R7_
MF$PV_YQ,0_^@3D__HE%<^*-5:/"B6W3IH6%_XIYJB=R:<Y/6E7R;T9&%H\R,
MC*G)AY.OQH*9L\-^H+?">JBYP7BQN[EXL[RQ>;.[JWJTNZ=[M;JG>[6ZIWNU
MNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6Z_YDS%/^80R7_F4LV
M_YY+0O^A3$[_I$];^:539O&E6'+JI%Y]XZ)FA]V><)'7F7B9TI6!H<V/B:G)
MBI&OQ8.8M,)_G[B]?*>[NGJPO;)ZLKZK>[*]IGRSO*-]M+JC?;2ZHWVTNJ-]
MM+JC?;2ZHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2Z_YDS%/^80R;_F4HV_Y]*
M0O^C2T[_IDY9^JA19?*H5G#KJ%Q[Y:=BA=^C;([9GW67TYI^G\V3AJC%C8VO
MOX>4M;F#G+FU?Z.\L7VLOJQ\L;^E?+&_H7ZSO9Y^M+N>?K2[GGZTNYY^M+N>
M?K2[GGZTNYY^M+N>?K2[GGZTNYY^M+N>?K2[_YDS%/^90R;_FDDU_Z!(0?^D
M24W_ITQ8^JI09/.K5&[MK%IYYJQ@@N"J:8O:IG.4SY]\G<:7@ZB^D(JPN(N1
MMK*&F+JM@Z"]J8&HOZ6 L,"??[# G("RO9J!L[N:@;.[FH&SNYJ!L[N:@;.[
MFH&SNYJ!L[N:@;.[FH&SNYJ!L[N:@;.[_YHS%/^90R;_FT@U_Z%'0?^E2$S_
MJ4I7^ZQ.8O6O4FSNL%AVZ+%>?]^P:(C5K'20RJ-ZG<";@:BXE(>PL8^.MJN*
ME;NFAYV^HH6EP)^$K\&9@:_!EX*ROI6#L[R5@[.\E8.SO)6#L[R5@[.\E8.S
MO)6#L[R5@[.\E8.SO)6#L[R5@[.\_YHS%/^90R;_G$<U_Z)&0/^G1TO_JTE6
M_:],8/:R46KNM%=SY;=>?-VV:H//KW*0Q:9XG;N>?J>RF(6PJY.+MJ6.D[N?
MBYJ^FXFBP9B(K,*3A:_"DH:QOY&&L[R1AK.\D8:SO)&&L[R1AK.\D8:SO)&&
ML[R1AK.\D8:SO)&&L[R1AK.\_YHS%/^90B;_G$8T_Z-%0/^H14K_K4=5_K%*
M7_6U4&CKN59PX[U>=]F[:H#+LG"0P*EVG;:B?*>MG(*OI9>)MIZ3D+N9CYB^
ME(V@P9&,J<*-BJ["C8FQOXV)LKV-B;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-
MB;*]C8FRO8V)LKV-B;*]_YLS%/^:0B;_G44T_Z1$/_^J1$G_KT53_+1)7?*Y
M3V7IOE9LX<-@<M.^:8#&M6Z/NZUTG+"F>J>GH("OGYN&M9B7CKN3E96^CI*=
MP8J2I\*(D*["B(ZPP(B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]
MB(VRO8B-LKV(C;*]_YLS%/^:0B;_GD0S_Z5"/O^K0DC_L412^K=(6O"]3F'F
MQ%9GWLEB;<[!9W_!N6V.MK%RFZNJ>*:BI7ZNF:"$M9*=B[J,FI.^AYB;P(27
MI,*"EJ_"@Y.PP(21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&R
MOH21LKZ$D;*^_YLS%/^:02;_GT(S_Z9 /?^M0$?_M$)/][M'5^W#35WDS%A@
MV<U@;,G%9GZ\O6N-L+5QFJ6O=J6<JGRMDZ:"M(RBB;F&H)"]@9Z9OWV>HL%[
MGJ_!?9FPP'^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6
MLKY_EK*^_YPS%/^:02;_H$$R_Z@_//^P/D7_MT%-],!%4^K)3E;BU5I7TM%>
M:\3)9'VVP6J,JKMOF9^U=*26L'JLC:R LH:IA[=_IXZ[>J:6OG>EH+]TIJV_
M=Z&QOWJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZ
MG;*^_YTS%/^;02;_HC\Q_ZH\.O^S/$+[NSY)\,9$3>;23TW<W%=6S-5=:K[-
M8WNPQVB+I,%MEYF\<Z*/N'BJAK1^L'^RA;5YL(RX=*^5NW&NG[QNKZN]<:JS
MO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\
M_YTS%/^;0";_I#PP_ZTY./^V.3_UP3Q#Z<Y$1-[=34?2X%-8Q=M<:+?387JI
MS6:)G,AKE9'$<9^(P':G?[U]K7B[A+%SNHNT;[B4MVRWG;AJMZBY:;:VN&VO
MM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y_YXR
M%/^=/B7_ISDN_[$V-?N\-CKMR3H\X-I$.M+B1TS'XDU>N=Y4;JS96WR?U&*(
ME-!HDXK,;YN"QW>B?,-^J'; A*QROHJO;[R1L6V\F+)KNZ&S:KNMLF>ZMK1G
MNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T_Y\R%/^@
M.B3_JC0L_[4R,?/#,C/CU#@PT^$\/\;H0E*YY4ACK.)-<I_?5'^3V5V*B=)G
MDX/-<)I]R7>?>,9]I'3$@Z=PPHBI;L&.JVS E*QJOYNM:;^EK6B_KJUHOZZM
M:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM_Z P%/^C-B+_
MKS H^[PM*^C-+"C5X# PQ^DX1+GL/E>LZ45GGN=+=9+@4X")V5Z)@M1HD7S0
M<99XS'>;=,I]GG#(@J%NQX>C:\6+I6G$D*9HQ):G9L.>J&7#I:AEPZ6H9<.E
MJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H_Z$O%/^H+Q__M2HB
M\,8D(=C=(R#(Z2TUNO(U2:SQ/%J>\$-IDNA,=8CA57^!VV&'>]=JC7;3<9%R
MT7>5;\]\EVS-@)IJS(6;:,N)G6;*C9YER9*?8\F8H&+(GJ%BR)ZA8LB>H6+(
MGJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA_Z,M%/^N*1KXOR :WM88
M$\GH(B6Z]"LZK/@T39[W/%R2\49IB.E0<W_C67MZWV2"=-QKAG#9<8IMUG:-
M:M5[CVC3?Y%FTH.29-&'E&/1BI5AT(^68,^4EU[/F9A>SYF87L^9F%[/F9A>
MSYF87L^9F%[/F9A>SYF87L^9F%[/F9A>SYF8_Z<H$O^W'Q+FSA$-R^85%KOT
M(2JL_BL^GO\T3I+Z/UR(\DIF?^Q5;WGH7G5RY&1[;N%K?FK?<(%HWG6$9=QY
MA6/;?8=BVH&(8-J$B5_9AXI=V(N+7->0C%O6E(U;UI2-6]:4C5O6E(U;UI2-
M6]:4C5O6E(U;UI2-6]:4C5O6E(U;UI2-_[ >"^W&#@C-VPL(N_,5&JS_(2Z>
M_RP_DO\W38?]1%A_]D]A>/%9:''M7VUJZV1Q9^AJ=&3G;W=BY71Y8.1X>E_C
M>WM=XWY\7.*!?5OAA'Y:X8A_6>",@%C@CX%8X(^!6."/@5C@CX%8X(^!6."/
M@5C@CX%8X(^!6."/@5C@CX%8X(^!\[T-!,S/"0&]Y0P,K/\7'I[_)"^2_R\]
MA_\]27__25)X_%1:</A:7VGT7V1D\F5G8?!J:5[O;FM<[G)M6^UV;EKL>6]8
M['QP5^M^<%;K@7%5ZH1R5.J(<U/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/I
MBW13Z8MT4^F+=%/IBW13Z8MTS,8( +W4" .M]0X/G_\:'Y/_)RV(_S0Y?O]"
M0W?_34IN_U-09_]956+\7EA>^V1;6_EH75GX;%Y7]W!@5O=S857V=F)4]7AB
M4_5[8U+T?611](!D4/.#94_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/
M\X9F3_.&9D_SAF9/\X9FO<L& *[;!@2?_Q 0D_\='8C_*BA^_S@R=O]$.FW_
M2T%E_U%&7_]725O_74Q8_V).5?]F4%/_:E%2_VU24/]P4T__<E1._W543?]W
M54W_>55,_GM62_Y^5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]@5=*_8%7
M2OV!5TK]@5=*_8%7_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOO
MC7)VZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)M
MLZ'1;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&
MHLANQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)V
MZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1
M;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLAN
MQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\
M?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FB
MT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(
M;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\?^2%
MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
M_ULH/O]?*3S_8RHZ_V<K.?]K+#?_;RPV_W0M-?]X+C3_?2XR_X(O,?^(,#'_
MBC Q_XHP,?^*,#'_BC Q_XHP,?^*,#'_BC Q_XHP_VHD!/]I,@K_;#X4_W9&
M'O][32G_?%4S_WI=/?]V9D;_<6Y-_VUY5/]JA%K^9HU?^V.58OEAG&7X7Z)H
M]UZH:O9<K6OU6[-L]%JY;O-9P6[S6,EO\EC4<.]8X'#I6>1PXUKF<-Q=Z'#<
M7>APW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>AP_VHD!/]I,@K_;#X4_W9&'O][
M32G_?%4S_WI=/?]V9D;_<6Y-_VUY5/]JA%K^9HU?^V.58OEAG&7X7Z)H]UZH
M:O9<K6OU6[-L]%JY;O-9P6[S6,EO\EC4<.]8X'#I6>1PXUKF<-Q=Z'#<7>AP
MW%WH<-Q=Z'#<7>APW%WH<-Q=Z'#<7>AP_VHC!/]I,0K_;CX4_W=%'O]\32C_
M?E0S_WQ<//]Y9$7_<VU._V]X5?]K@EK]:(M?^V648_EBFV;W8*%I]EZG:_5=
MK6ST7+-N\UJZ;_)9P7#R6<IQ\5C8<>Q9X7'F6N1QX%SG<=A=Z''87NAQV%[H
M<=A>Z''87NAQV%[H<=A>Z''87NAQ_VLC!/]J,0K_<3P4_WI#'?^ 2RC_@5,R
M_X!://]\8D7_=VI._W%T5?]N?UO]:HE@^F:29/ADF6CV8:!K]5^G;?->K6_R
M7+-P\ENZ<?%:PW+P6<US[EG=<^A:XG3A7.5SV5[F<]!?YW307^=TT%_G=-!?
MYW307^=TT%_G=-!?YW307^=T_VPC!/]K,0K_<SL4_WU"'?^"2B?_A%$R_X-9
M._^ 8$7_>VA-_W1Q5?]P?%O\;(=A^6B09O=EF&GU8Y]L\V&F;_)?K''Q7;-R
M\%R[=.];Q77O6M!UZEK?=N)<XG;;7^5UT6#F=LIAY7?*8>5WRF'E=\IAY7?*
M8>5WRF'E=\IAY7?*8>5W_VTB!/]L,0O_=CH4_X!!'?^%2"?_B$\Q_X=7._^$
M7D3_?V9-_WAN5?]S>5S\;H1B^6J-9_9GEFOT9)YN\F*E<?%@K'/O7K1U[EV\
M=NY;QW?M6]9XY5S@>-Q?XWC28.1XRV'D><1CXWK$8^-ZQ&/C>L1CXWK$8^-Z
MQ&/C>L1CXWK$8^-Z_VXB!/]M,0O_>#@3_X,_'/^)1R;_BTXP_XM5.?^(7$/_
M@V-,_WUK5/]V=5S\<H!B^&V*9_5IE&SS9IQP\6.D<^]AK'7N7[1W[5V^>>Q<
MRWKH7-QZWE_A>M)AXWO*8N)\Q&/B?;YEX7V]9>%]O67A?;UEX7V]9>%]O67A
M?;UEX7V]9>%]_VXB!/]N, O_>S<3_X8^'/^,127_CTPN_X]3./^-6D'_B&%+
M_X-I4_I\<5OW=GQB\W&':/!MD&WM:9EQZF:A=>ACJ7CF8;)ZY&"[>^)?QWS@
M7]I]U&+A?<ICX'[#9.!_O6;?@+=GWX"W9]^ MV??@+=GWX"W9]^ MV??@+=G
MWX"W9]^ _V\A!/]O, O_?C82_XD\&_^01"3_DTPM_Y-2-O^264#_CF!)^8AF
M4O2";EKO?'EAZW>#:.=RC&[D;95SX&J==]UGIGK:9:Y\UF.X?M-BPX#18M.!
MRF3?@<%EWH*[9]V"M6C=@[!IW8.P:=V#L&G=@[!IW8.P:=V#L&G=@[!IW8.P
M:=V#_W A!/]R+PO_@302_XP[&O^30R+_ETLK_Y=1-/^65SWZDUU&\XYD3^Z(
M:UCH@G5@XWQ_:-YWB6[9<I%TTVZ9>=!KH7W,:*F R6:R@L=EO8/%9<N$P6;<
MA+EHVX6S:=N%KFO;A:ELVX6I;-N%J6S;A:ELVX6I;-N%J6S;A:ELVX6I;-N%
M_W$A!/]T+@K_A#,1_X\Z&?^60R'_FDDI_YI.,OR:5#OUF%M$[I1B3>>/:57A
MB7->VX)\9M-\A6_-=XUUR7*5>L5OG7_!;*6"OFJMA;MIN(>Y:<2(MVG8B+!K
MV8BK;-F(IVW9B*-OVH>C;]J'HV_:AZ-OVH>C;]J'HV_:AZ-OVH>C;]J'_W$@
M!/]V+ K_AC(1_Y(Z&/^90B#_G$<G_YY,+_B>4CCPG5A Z9I?2>*59U+:CW!<
MT8=X9LJ!@6_%?(EVP'>0?+MTF("W<:"$M&^IA[%MLXFN;+^*K&S/BZANUXND
M;]B*H'#8BIUQV8F=<=F)G7'9B9UQV8F=<=F)G7'9B9UQV8F=<=F)_W(@!/]X
M*PK_B# 0_Y0Y%_^;01[_GT4E_:%*+?2B4#3LHE8\Y*!<1=R;94_2DVU<RHQU
M9L.&?6^]@85VMWR-?;-XE(&N=9R&JW.EB:=QKHNE<+J-HW#)C:!QU8V<<]:,
MFG36BY=TV(J7=-B*EW38BI=TV(J7=-B*EW38BI=TV(J7=-B*_W,@!/]Z*@G_
MBR\/_Y8Y%O^=/QS_H4,C^J1(*O&F3C'HIU0XX:=<0-6?8D[+F&M;PY%R9KR+
M>F^VA8)WL(&)?:M]D8*F>9F&HG>ABI]UJXV<=+:.FG3%CYAUU(Z5=M6-DW?5
MC9)WUHN2=]:+DG?6BY)WUHN2=]:+DG?6BY)WUHN2=]:+_W,@!/]\*0G_C2\/
M_Y@X%?^?/1O_I$$A]ZA&)^VK3"WEK5(SW*I9/]"C84W&G&E:OI5P9;:/=V^O
MBG]VJ86&?:2!CH*??I:'FWN>BY=YJ(Z4>+./DGC!D)!YTY"/>M2/CGK5C8Q[
MUHR,>]:,C'O6C(Q[UHR,>]:,C'O6C(Q[UHR,>]:,_W0?!/]^* G_CBX._YLX
M%/^A/!G_IS\?]*M$).JO2BGBLU$NUJY7/LNG7TW!H&=:N9EN9;&3=6ZJCGQV
MHXJ#?9Z&BX*9@Y.'E(";BY!^I8Z-?;"0BGV]D8E^T)&(?M./B'[4CH=^U8V'
M?M6-AW[5C8=^U8V'?M6-AW[5C8=^U8V'?M6-_W0?!/^ )PC_D"X._YTW$_^C
M.AC\J3T<\:]"(.>T2"3?MTXLT;%5/<>J7DR]HV59M)UL9*N7<VZDDWIVGHZ!
M?)B+B(*2AY"'CH69BXF#HHZ&@JV0@X*[D8*"S)&"@M.0@H+4CX*!U8V"@=6-
M@H'5C8*!U8V"@=6-@H'5C8*!U8V"@=6-_W4?!/^")@C_DBT-_Y\V$O^E.!;Y
MK#L:[K,_'>6Y1A_:NTLKS;14/,*N7$NXIV-8KZ%J8Z:<<6V?EW=UF)-^?)*0
MAH*,C8Z'AXJ6BX.(H(Y_AZN0?8>XD7N'R9%\A].0?(;4CWV%U8U]A=6-?875
MC7V%U8U]A=6-?875C7V%U8U]A=6-_W4?!/^$)0C_E"T,_Z U$/^H-A3VKS@7
MZ[<]&.*_11G5ODDJR+A3.[VQ6TJSJV)7JJ9H8J&A;VR9G'5TDIA\>XR5@X&&
MDHN&@9"4BWR.GHYYC:B0=HRUD72-QI%UC=.0=HO4CWB)U8UXB=6->(G5C7B)
MU8UXB=6->(G5C7B)U8UXB=6-_W8> _^&) ?_ERP+_Z(R#_^K,Q'RLS43Z+PZ
M$][%/Q?0P4@IQ+M1.;FU64BNL&!5I:IG89RF;6N4HG1SC9YZ>H:;@8" F(F%
M>Y:2B7:4FXURDZ:/;Y.SD&Z3PY!ND]./<)'4CG*.U8URCM6-<H[5C7*.U8UR
MCM6-<H[5C7*.U8URCM6-_W<> _^)(@?_F2P*_Z4P#?RN+P[ON#$.Y,,W#=G*
M.Q;+Q48GO[]0.+.Z6$>IM5]4G[!E7Y:L:VF.J')QAJ5X>("B?WYZGX>#=)V/
MB&^;F8MLFJ2-:9JPCF>;P(YGF]6.:9C5C6R4UHQLE-:,;)36C&R4UHQLE-:,
M;)36C&R4UHQLE-:,_W@> _^,(0;_G2L(_Z@L"OBS*@OJORL)X,PR!M'..17%
MR44EN<1.-JZ_5D6CNUU2F;9C79"R:6>'KW!O@*QV=GFI?7QSIX2!;J6-A6FD
MEXAEHZ**8Z.NC&&COHQ@I-*+8Z#7BV6<V(IEG-B*99S8BF6<V(IEG-B*99S8
MBF6<V(IEG-B*_WH= _^/( 7_H"D'_ZPG!_*X) ;EQR0$V=4G!<O3-Q._SD,C
ML\I,-*?%5$*<P5M/DKUB6HFZ:&2!MVYL>;1T<G.R>WAML(-]:*^+@6.NE81?
MK:"&7:VMAUNMO(=:KM"'7*K:AU^EVH=?I=J'7Z7:AU^EVH=?I=J'7Z7:AU^E
MVH=?I=J'_WX: _^4'P3_I28%_;$@!.S!&@/?TQ<!T-PE!,39-1"XU4$AK-!+
M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
M:/\1 &'_&@%:_R,#5/\K!$__,P9*_SL(1O]""T/_20U _T\./?]5$#K_6Q$X
M_V$3-?]H%#/_;Q4P_W@6+O^"%RS_C1DJ_YD:*?^D&BC_KQLG_[H<)O_''";_
MQQPF_\<<)O_''";_QQPF_\<<H;0  )._  "&R@  >-8  &SB  !C_ < 7/\/
M %7_%@%/_QX"2?\F T3_+@1 _S0%//\[!CG_00<V_T8(,_],"#'_40DN_U<*
M+/]="BK_9 LH_VP,)?]U#2/_?PXA_XH/(/^5$![_H! >_Z@1'?^Q$1W_L1$=
M_[$1'?^Q$1W_L1$=_[$1E;P  (;'  !YTP  :^   %[M  !6_P, 3_\, $G_
M$@%#_QD!/O\@ CG_)P,U_RT#,O\S!"[_. 0K_ST%*/]"!2;_1P4D_TP&(O]1
M!B#_5P8=_UX'&_]E!QG_;@@7_W@(%?^#"!/_C0D3_Y8)$O^>"1+_G@D2_YX)
M$O^>"1+_G@D2_YX)_T(M _]",@3_2#($_TPV!O]./ C_4$<._U!2%?].7QK_
M2VL?_TAW)/]%@R?_0HXJ_T&7+/\_H"[_/Z<O_SZN,/\]M3'_/;PR_SS%,O\\
MSC/_.]\S_SOJ-/\[\S3_._LT_SS_,_X\_S/\/?\T]C__-?4__S7U/_\U]3__
M-?4__S7U/_\U_T,L _]$, 3_2C $_TXT!O]1.@C_4T8._U)1%?]171K_3FD@
M_TMT)/](@"C_18LK_T.5+?]"G2__0:4P_T"L,?\_LS+_/[HS_S["-/\^S#3_
M/MPU_SWH-?\]\37_/OHU_3[_-?L__S3X/_\V\D'_-_!!_S?P0?\W\$'_-_!!
M_S?P0?\W_T0L _]'+@/_32X$_U$R!?]4.0C_5T0._U9/%?]46AO_468@_TYR
M)?]+?2G_2(@L_T:2+O]%FS#_1*(R_T.I,_]"L#3_0K<U_T&_-O]!R3;_0-<W
M_T#E-_U \#?Z0/@W]T'_-O9!_S?R0?\X[$/_.>I$_SGJ1/\YZD3_.>I$_SGJ
M1/\Y_T4K _])+ /_4"P$_U4O!?]9-PC_7$(._UM-%?]85QO_5F,@_U)O)?]/
M>BK_3(4M_TJ/,/](F#+_1Y\T_T:F-?]%K3;_1;0W_T2\./Y$QCC\1-(Y^4/B
M.?9$[CGS1/<Y\43_.>]$_SKK1?\[Y$;_/.-&_SSC1O\\XT;_/.-&_SSC1O\\
M_T8K _]-*0/_5"D$_UDL!?]>-0?_84 -_V%*%/]>5!K_6E\@_U=K)O]4=BK_
M48$N_TZ+,?Y,E#3\2YPU^TJC-_I)JCCX2+$Y]TBY.O9'PCOU1\T[\D??.^Y'
M[#OK2/8[Z4?_/>='_S[A2/\_VDK_0-A*_T#82O] V$K_0-A*_T#82O] _T<J
M _]0)P/_6"8#_UXJ!/]C,P?_9CT-_V9'$_]D41K_8%L@_UQG)OU9<BOZ5GTO
M^%.',_91D#7T4)@W\DZ?.?%-ICOO3*T\[DRU/>Q+OCWK2\H^Z4O</N5,ZCWB
M2_4_WTO^0=Q*_T+43/]#S4W_0\M._T/+3O]#RT[_0\M._T/+3O]#_THH _]4
M) /_7",#_V,H!/]H, ;_;#L+_VQ$$O]J3AG^9E@?^6%B)?5>;2OR6W@P[UB"
M-.Q6BS?J5)0YZ%.;.^91HSWE4:H^XU"R/^%/NT#@3\= WD_80=E/Z$'43_1#
MT$[^1<Y._T;(4/]&PE'_1\!1_T? 4?]'P%'_1\!1_T? 4?]'_TTE O]7(0+_
M8" #_V@F _]N+@7_<C@*_W)!$/UP2Q?W;50=\FA>).UD:2KI870PY5Y^-.);
MASC@68\[W5>7/MM5GT#85*9"U5.N0])2MT304L)%SE+01LM2Y4;(4O)(Q5+]
M2<)2_TJ\5/]*MU7_2K95_TJV5?]*ME7_2K95_TJV5?]*_U C O];'@+_9!X"
M_VTD _]S*P3_=S4(_G@^#O9W1Q3P=% ;ZF]:(N1K92G@9V\OVV-Y-=9@@CK2
M78H^SUN20<Q9FD/*6*%%R%>I1\96LDG$5KQ*PE7)2[]5WTN\5NY,N5;Z3;=6
M_TVR6/]-KEG_3:Q9_TVL6?]-K%G_3:Q9_TVL6?]-_U,@ O]>' +_:!P"_W$B
M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
M0_\> 3__)@(Z_RT"-_\S S/_.0,P_S\$+O]$!"O_2@4I_U %)_]6!B3_708B
M_V4'(/]N!QW_>0@;_X4(&O^2"1G_G@D8_Z@)%_^S"1?_MPD7_[<)%_^W"1?_
MMPD7_[<)D+H  (+%  !TT   9]P  %CC  !-\   1_\" $+_#  \_Q$ ./\8
M 33_'P$P_R4!+/\K BG_, (E_S4"(_\Z B#_/P,>_T0#'/]) QG_3P,7_U8$
M%?]>!!+_: 01_W(%#_]^!0[_B@4._Y0%#?^>!0W_H@4-_Z(%#?^B!0W_H@4-
M_Z(%_SDO O\\, /_03$#_T0T!/]$.@;_1$4(_T51#/]#71'_06D6_SYV&?\\
M@1S_.HP>_SF6(/\XGB'_-Z4C_S>K(_\VLB3_-KDE_S; )?\URB;_-=<F_S7E
M)O\U[R;_-?@F_S;_)OXV_R;\-O\F_#;_)_HV_RCZ-O\H^C;_*/HV_RCZ-O\H
M_SDO O\^+P/_1"\#_T8R!/](. ;_2$,(_TA/#?]'6Q+_1&<6_T)S&O\_?QW_
M/8H?_SR3(?\[FR/_.J(D_SFI)?\YL";_.+8F_SB^)_\XQR?_.-,H_SCC*/\X
M[2C^./<H^SC^)_DY_R?X./\I^#C_*O8X_RKV./\J]CC_*O8X_RKV./\J_SHO
M O]!+ /_1BP#_THO!/],-P7_34$(_TQ,#?]+6!+_2&07_T9P&_]#?![_08<@
M_S^0(_\^F"3_/: E_SVF)O\\K2?_/+0H_SN[*?\[Q"G_.\\I_CO@*OL[ZRKX
M._4I]CS^*?0\_RKS._\K\CO_+.\[_RWO._\M[SO_+>\[_RWO._\M_SPM O]$
M*0+_2BD#_TXL!/]1- 7_4CX(_U)*#?]051+_36$7_TIM&_](>!__18,B_T.-
M)/]"E2;_09TG_T"C*/] JBG^/[$J_3^X*_P_P2OZ/\LK]S_<+/4_Z2SQ/_0K
M[S_]+.T__RWL/O\OZS[_,.<__S#G/_\PYS__,.<__S#G/_\P_T J O]()@+_
M3B8#_U(I _]6,@7_5SP'_U='#/]541+_4ET7_U!I'/]-="#_2G\C_4B))OM'
MD2CZ1IDI^$6@*O=$IROU1*TL]$.U+?-#O2WR0\@N\$/7+NQ#YR[I1/,MYD/\
M,.1"_S'C0O\RX4+_,]Q#_S3<0_\TW$/_--Q#_S3<0_\T_T,G O]+(P+_4B("
M_U@G _]<+P3_73D'_UY##/];3A'_6%@7_E5D'/I2;R#W4'HD]$V$)_),C2GP
M2I4K[TF<+>U)HR[L2*HOZD>Q+^E'NC#G1\4PYD?2,.)(Y3#?1_(RVT?[--A&
M_S751O\VTD;_-\U(_S?-2/\WS4C_-\U(_S?-2/\W_T8D O]/( +_5A\"_UTD
M _]A+ 3_8S4&_V1 "_]B2A#Z7E06]5M?'/%8:R#N574EZU-_*.A1B"OF3Y$M
MY$Z8+^)-H##A3*<QWTRN,MU+MS/;2\(TV4K/-=5+Y#702_ VS4K[.,I*_SK(
M2O\ZQDO_.\%,_SO!3/\[P4S_.\%,_SO!3/\[_THA O]3'0+_6QP"_V(B O]G
M*0/_:3(%_VH\"?EH1@_R95 5[6%;&NA>9B#D6W$EX5A[*=Y6A"S;5(POV%*4
M,M11FS324*,UT$^J-\Y.LCC,3KPYRD[).LA.W3K$3^T[P4[Y/;Y._SV\3O\^
MND__/K90_SZV4/\^ME#_/K90_SZV4/\^_TT> O]6&@'_7QH!_V<@ O]L)@+_
M;RX$^7 X!_)O0@SK;$L2Y6E7&=]E8A_:86PEU%UV*M!;?B_-68<RRE>/-<A6
MEC?&5)TYQ%.E.\%3K3R_4K<^O5+#/[Q2TS^Y4N@_M5+V0;-2_T&Q4_]!KU/_
M0:Q4_T&L5/]!K%3_0:Q4_T&L5/]!_U < ?]:%P'_9!@!_VP= ?]Q(P+]=2H#
M\W8S!>MV/0KC<T</W&]3%]1K7A_.9F<FRF-Q*\9@>3#"7H$TOUR)-[U:D3JZ
M69@\N%B@/K97J$"T5K)"LE:]0[!5S$.M5N-$JU;S1*A7_D2G5_]$I5C_1*)8
M_T2B6/]$HEC_1*)8_T2B6/]$_U,9 ?]=% '_:!8!_W : ?]V( 'W>B8"[7PN
M ^1\. ?<>D0-TG5/%LMP6A[&;&,FP6AL++UF=3&Y8WTUMF&$.;-?C#RP790_
MKER;0:M;I$.I6JU%IUJX1J59QT>C6MY'H5KO1Y];_$>=6_]'FUS_1II<_T::
M7/]&FES_1II<_T::7/]&_U47 ?]@$@'_:Q0!_W07 /]Z' 'R?R(!YX$I MZ"
M,P33?T ,RWI,%<1V5AZ^<6 EN6YH++1K<3*Q:'DVK6: .JIDB#VG8H] I6"7
M0Z)?H$6?7JE'G5ZT29M=PDJ97=9*EU[L2I9?^DF57_])DV#_2))@_T>28/]'
MDF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M@QT XH<C =:'+@/,
M@ST+Q7])%+U[4QVW=ETELG-E+*UO;3*I;74WIFI\.Z)HA#Z?9HQ!G&641)EC
MG$>78J9)E&*P2Y)AODR08=!,CV+H3(YC^$N-8_]*C&3_28MD_TF+9/])BV3_
M28MD_TF+9/])_UH3 ?]F$ #_<1$ _WH2 />"% #HAQ< W8L< -"++ /'B#L*
MOX1'$[A_41RQ>UHDK'=B*Z=T:C&C<7(VGV]Y.YMM@#^8:XA"E6F019)HF4B/
M9J)*C&:M3(IENDV(9<Q.AV;F3H9G]DR&9_]+A6C_2X1H_TJ$:/]*A&C_2H1H
M_TJ$:/]*_UP2 ?]H#P#_=!  _WT0 /.%$ #DBQ$ UH\7 ,N.*@+"C#@)NHA$
M$K.$3QNL?U@CIWQ@*Z%X:#&==6\VF7-V.Y5Q?3^2;X5"CFV-18MLEDB(:Z!+
MA6JJ38-IMTZ!:<A/@&KC3X!K]$Y_:_],?VO_2W]K_TM_:_]+?VO_2W]K_TM_
M:_]+_UX0 ?]K#@#_=@X ^X - .J(#0#;CPP T)(5 ,>2)P*^CS8(MHQ"$:Z(
M31JHA%8BHH!>*IQ]93"7>FPUDW=S.H]U>SZ,<X)"B'*+1H5PDTF";YU,?VZH
M3GUNM4][;<90>F[@4'EO\DYY;_Y->6__3'EO_TMY;_]+>6__2WEO_TMY;_]+
M_V / /]M#0#_>0P [H,+ -N+"0#4D0H S)43 ,*5)0*YDS0'L8]!$*J,2QFC
MB%0AG81<*9>!8R^2?FHUCGQQ.8IZ>#V&>(!"@W:(17]UD4E\<YM,>7*F3G9R
MLU!U<L-0<W+=4'1S\$]T<_U-='/_3'1S_TQT<_],='/_3'1S_TQT<_],_V(.
M /]O# #\>PH WH8& -6." #/E D QY@1 +Z8(P&UEC(&K9,_#Z:021B?C%(@
MF(E:*).&82Z.@V@TB8%O.85_=CV!?7Y!?7N&17IYCTEV>)E,<W>D3G%WL5!O
M=L%0;G?94&YW[T]N=_Q.;G?_36]W_TQO=_],;W?_3&]W_TQO=_],_V0- /]R
M"@#P?@8 VH@% -"0!P#*EP@ PIL0 +F;(0&QFC &J9<]#J&41Q>:D5 ?E(U8
M)XZ+7RV)B&8SA(9M.("$=#U[@GM!>("$171_C4AQ?9=+;7RB3FM\KT]I>[Y0
M:'S54&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_3&I[_TQJ>_],_V8* /]U" #A
M@0( U(L% ,N3!@#$F@8 O9X. +6?'P&LGBX%I)L[#)V81166E4X>CY-6)8F0
M72R$CF0R?XMK-WJ*<CQVB'E <H:!1&^%BD=K@Y5*:(*@366!K$YC@;Q/8H'1
M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
M@U\@ ']?+ ![7S<!=UY  G1>2 -Q74\$;UQ6!6Q<7 =J6V,):%MK"V9:<PUD
M6GP/8EJ'$6!9DQ)>6: 475FN%5M9OQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9
M_Q)<6?\2W%   ,=9  "Z8   KV0  *1E  "99   D&   (AA!@""8A$ ?F,=
M 'IC*@!V8S0!<V(] 6]B1@)L84T$:F%4!6=@6@=E8&$(8U]I"F%?<0Q?7GH.
M75Z%$%M>D1)979X46%VL%5==O1967=465EWN%5==_!177?\35UW_$E==_Q)7
M7?\2UE,  ,1<  "W8P  K&@  *!H  "59P  BF,  (-E @!]9@\ >&8: '1G
M)P!Q9S( ;F<[ 6MF0P)H9DL#9652!6-E609A9%\(7F1G"EQC;PQ:8W@.6&.#
M$%9BCQ)48IP34V*J%5)BNQ518M(546'M%5)A^Q128?\34V'_$E-A_Q)38?\2
MT58  ,!?  "S9@  J6L  )QK  "0:@  A6<  'UI  !W:@T <VL7 &]K) !L
M;"\ :6PX 69K00)C:TD#86M0!%YJ5P9<:ET'6FEE"5AI;0M5:'8-4VB!#U%G
MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
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M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
M<TDZ '!)0@!N24D!;$A0 6I(5@%H2%T"9DAD F5(; -C2'4$84=_!6!'B@9>
M2)<'74BE"%M(M A;2,<)6DCD"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],
M  "R4@  HU$  )=0  "-3@  ADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV
M &I,/P!H3$8 9DQ- 61,4P%B3%H"84QA E],:0->3'($7$Q\!5I,B 993)4'
M5TRC"%9,L@A53,8)54SB"55,]0A53/\'54S_!U9,_P963/\&S$@  +Q0  "O
M50  H%0  )-3  ")40  @4T  'I.  !U3PP <$\5 &U0( !J4"H 9U S &50
M/ !C4$, 85!* 5]040%=4%@"7%!? EI09P-94' $5U!Z!550A@944),'4E"A
M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
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M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
M5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,
M-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS
M  !E,@( 83(- %XR% !<,QX 6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310
M % U6 !.-6  339J $PV=0!+-X( 2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!
M1SC_ 4<X_P%'./\!MSL  *(\  "1/   @SP  '@\  !P.@  :C<  &0V  !@
M-@  7#8+ %DW$@!6-QH 5#<C %(W*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY
M50!).5X 2#IH $<Z<P!&.X  13N. $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_
M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
M  $    ! @,$!08'" @)"@L,#0X/$!$2$Q05%A<8&1H:&QP='A\@(2(C)"4F
M)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,34Y/4%%2
M4U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\?7Y_
M@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNL
MK:ZPL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1T]35UM?8V=K;
MW-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\  0$" @,#! 0%
M!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<'!T>'A\@
M("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C] 0D-$149(
M24I,34]04E-55UA:7%Y@8F1F:&IM;W%T=GE\?H&#AHF+CI"2E9>9FYV?H:.E
MIZBJK*VOL+*SM;:WN;J[O+V_P,'"P\3%QL?(R<K+S,W-SL_0T=+2T]35UM;7
MV-G9VMO;W-W=WM_?X.'AXN/CY.7EYN;GZ.CIZ>KKZ^SL[>[N[^_P\/'R\O/S
M]/3U]O;W]_CX^?GZ^_O\_/W]_O[_  $! @(# P0$!08&!P<(" D)"@L+# P-
M#0X/#Q 0$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?(" A(B(C)"0E)B8G*"DI
M*BLL+2TN+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&2$E*3$U/4%)355=86EQ>
M8&)D9FAJ;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&CI:>HJJRMK["RL[6VM[FZ
MN[R]O\#!PL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6U]C9V=K;V]S=W=[?W^#A
MX>+CX^3EY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T]?;V]_?X^/GY^OO[
M_/S]_?[^_]K+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.E
MA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&P
MHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5
MK9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+
M"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(
MV:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OH
MS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=
MB=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZ
MZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJ
MG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P0
M8-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>
MJ)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(
M#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-
MX:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++
MNC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9
MC^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*L
MQK=0M,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0
MM,"S:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S
M:+R[KGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[
MKGO$M:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$
MM:B(R[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(
MR[.EA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.E
MA]&PHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YMK+"1OHS0XZZ<P08-S(#I++NC*LQK=0M,"S:+R[KGO$M:B(R[.EA]&P
MHH?5K9^(V:N=B=RJG(O>J)J-X:>9C^.EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYMG+"1OGS@TYZ,T08-S)#9++NS"KQKA/M,"S9[V[KGO$M:F(R[*FA]&OHX?5
MK:"(V:N>B=RIG(K>IYN,X*69C^.AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2A
MF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y-G+
M"1KDS@TYY\X.8-K*#)++O"ZKQ;E-M,"T9KVZKGK%M:F'R[&FA]&NHX?5K*"(
MV:J>B=RGG(K>I9N+X**:C>*>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_C
MGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/X]C+"1KA
MSPPYY<\.8-G*#)'+OBRKQ;E,M;ZT9[VYKGO%M*J'S+"FA]&MHX?5JZ"(V:B>
MB-NEG8G=HYR*WY^:B^&;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.
MXIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XMC+"1K<T LY
MX] -8-C+"Y'+ORNKQ+I,M;VS9[ZXKGO%M*F'S+"FA]&LHX?5J:"'V*:?B-NC
MG8C=H)R)WIV;BN"8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:
MC>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X=?,"1K:T0LXWM$,
M7];+"Y'+P"FLPKE-MKRS:+ZWKGO&LZF'S*^FA]&JHX;5IZ&'V*2?A]JAGH?<
MGIV(W9J<B=Z5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5
MFXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X-;,"1G9T0LXVM,,7]3,
M"Y')P"FMP+E.MKJS:;^UKGS&LJF'S*VFAM&IHX;4I:&&UZ*@AMF?GX;:FYZ'
MW)>=B-V3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>
MDYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WM7,"1G8T@LWV-,+7M+,"Y/'
MORNMOKA0M[FR:K^TK7S&L*F'S*NFAM"GI(74HZ*%UI^AA=B<H(79F)^&VI2>
MA]R0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*
MW9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W=3-"1G6T@LWUM0+7M#+"I7$OBVN
MO+A1N+>R:L"SK7S&KJF'S*FFAM"EI(73H*.$U9VBA-:9H878E:"%V9&?A]J.
MGHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>
MB=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)V]/-"AC5TPLVU-0+7\[+"9?!OC"ONK=3
MN+6R;,"PK7W'K*J&RZ>GA<^BI831GJ2$TYJCA-66HH36DZ&%UX^@AMB+H(G9
MBZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+
MH(G9BZ")V8N@B=F+H(G9BZ")V=+."A?3U LUT=,*8LO,"9F^O3.QM[=5N;*Q
M;<&MK7W&JJJ&RZ2HA,Z?IX30FZ6#TI>D@].3HX34D*.%U8RBAM:)H8C7B:&(
MUXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7
MB:&(UXFAB->)H8C7B:&(U]#/"A;1U LWSM,*9<;*"YVYO#BRM+98NJVQ;L&J
MKGW&IZN%R:&IA,R<J(/.EZ>#SY.F@]&0I832C:6%TXJDAM.'HXC4AZ.(U(>C
MB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(
MU(>CB-2'HXC4AZ.(U,[0"A7.U HZRM,*:,#(#Z&UNSZTK;5;NZFQ;\&FKWW$
MHZV$QYVK@\J8JH/+DZF#S9"HA,Z-IX3/BJ>%SX>FA]"%IHC1A::(T86FB-&%
MIHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86F
MB-&%IHC1A::(T<S0"1C*U H^Q=,*;;C%%J6NN42UI[5>NZ.R<,"AL'W#GZZ$
MQ9FM@\>4K(3)D*N$RHVJA<N*JH7+B*F&S(6IA\V#J(G-@ZB)S8.HB<V#J(G-
M@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#
MJ(G-@ZB)S<C1"1O%U0I"O],*<K'$'J>EN4FVH;9@NYZS<+Z=L7W!F["$PY6O
MA,21KH3&C:V%QXJMAL>(K(;(AJR'R(2KB<F"JXK)@JN*R8*KBLF"JXK)@JN*
MR8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)
M@JN*R<32""# U@E(N-0*>*G/%YB>OD>NFK9BNIBU<;R7LWR^E[*$P)*QA<*-
ML(7#BJ^&Q(BOA\2&KXC%A*Z)Q8.NBL6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&N
MB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+
MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
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MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
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M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
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M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
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MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
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M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
M]]]@0^[L8$?C\5](V_%A2=+R8TG2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8_Z5
M  #4J0  PK4# +7! P"JSP4 H.<+ 9C]&@:/_BD0AO\U&W[_0"5T_T8M:_],
M-6/_4CI<_UD_5O]@0U#_:$=,_W%*1_][3$/_ATY _Y10/O^A4CW_L%0[_\-5
M._[A53SY\%5 \/150^?W5$/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5-NA  #%
ML   M;H" *C' @"=U@0 D_P. 8O_'0:#_RL/>O\U%W'_/!]H_T(F8/])+%G_
M3S%3_U8U3O]=.$G_93M%_VT]0?]V/S[_@$$[_XM#.?^813C_I$8V_[)'-?_$
M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
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MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
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M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
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M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
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M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
M );! @",RP< A-4- (#5'@%YU2X%<M0\#&S31Q1ETE ;7]%9(5K18B=5T&LL
M4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J.D#-_3X^R_] 0,/_0D&]_T-"
MN?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@M   E;X  (O(
M P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<X$T45^!6&5/@7QU/X&DB2^!S
M)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?^C$YWO\T.=G_-CK0_S@[S/\Y
M.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@  *&Q  "5NP  B<4  '[/ @!T
MV@8 ;NL1 &CK'@%BZRH#7>PU!E?L/PM2[$@/3>Q1$TKM6A9&[6,90^UM'$#M
M>!X][H4A.NZ3(SCOHR0V\+8F-?'2)C3O\R8T[/\F,NO_*#+G_RLSY/\L,^3_
M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
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MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
M &O/  !?U@  5-X$ %'P$ !-\!L 2O F 4;Q, )"\CH#/O)#!#OS2P4X\U0'
M-O1="#/T: DP]70++O6!#"SVD0XJ]J(/*/>W$"?XUA$G]O01)O/_$2;Q_Q$E
M\?\3)?'_$R7Q_Q,E\?\3)?'_$ZVA  "@J0  DK,  (2\  !VQ@  :<\  %W8
M  !1WP  2>X$ $;\#@!"_1< /OXA #O^*@$W_S,"-/\Z C#_0@,M_TH#*_]3
M!"C_7 4E_V8%(O]S!B#_@P<?_Y0('?^F"!S_O @;_^()&O_Y"1K__PD9__\)
M&?__"1G__PD9__\)&?__":*G  "3L0  A;L  ';&  !IT   6]H  $[@  !#
MY0  /OL! #K_#  V_Q, ,O\; "__(P K_RH!*/\Q 23_-P$A_S\"'_]& AS_
M3@(9_U@#%O]C Q/_< ,2_X$$$?^3!!#_IP0/_[T%#O_@!0[_]@4.__\%#O__
M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
M_QU- ?\;60'_&64!_AEP ?P8>@'Y&(,!]QB, ?88DP'T&)H!\QBA ?$9J 'P
M&; "[AFZ NT9Q@+J&MD"YAKK >(;^0+@&_\#WAS_!-T<_P7<'/\%W!S_!=L<
M_P7;'/\%VQS_!?\J&0#_+1, _RT1 /\M$0#_+AD _RTB /\L+@#_*3H _R9'
M ?HD5 'V(V !\B)K >\B=0+M(GX"ZR*' NDBCP+G(I8"Y2*> N0BI0+B(JT"
MX2.W M\CPP+=(]8"V"3J ](D^07/)?\&S27_!\LE_PC*)?\(RB3_",HD_PC*
M)/\(RB3_"/\N% #_,1  _S(- /\T#@#_-10 _S4< /\S)P#Z,30 \R]! .XM
M3@'I+%H!Y2QE N(L< +?*WD"W2N" ]HKBP/8*Y($U2N:!-,KH@31*ZH%SRNS
M!<TKOP;,+,\&R"WG!\0M]PG!+?\*ORW_"[TM_PR\+?\,O"S_#+LL_PR[+/\,
MNRS_#/\Q$0#_-0P _S8' /\Z"P#_/!  _SL5 /@Y'P#O-RL YS8Y .$U1P#<
M-50!U35@ M$U:@/.-',$S#1\!<HTA0;(-(T'QC.4",0SG G",Z4)P3.N"K\S
MN0N],\@+NS3A"[<T\PVT-/\/L33_#[ T_Q"O-/\0KC3_#ZXT_P^N-/\/KC3_
M#_\U#@#_. < _SP" /] !@#_00L ^D$/ .T_%@#C/"( VCTQ -(^00#,/D\"
MR#Y: \0]9 7!/6X'OSQV"+P\?@JZ.X<+N#N/#+<[EPVU.I\.LSJI#[$ZM!"O
M.L(1KCK9$:H[[Q*G._\3I3O_%*0[_Q.C._\3HCO_$Z([_Q*B._\2HCO_$O\X
M"@#_/   _T$  /5%  #F1@( X44' .-"#0#50QD S$4L ,9'/ '!1TD"O$95
M!+E%7P:U1&@)LT-Q"[!#>0VN0H$/K$*)$*I!D1*H09H3IT"D%*5 KQ6C0+P6
MH4#0%IY!ZA><0?P7FD'_%YA!_Q>80?\6ET'_%9=!_Q670?\5ET'_%?\[!@#_
M/P  ^48  .5+  #<3@  TTT$ -%*"0#*2A0 PDTG +Q.-P&W3D4"LDU0!:],
M6@BK2V,*J$IL#:9)= ^D27P1H4B$$Y]'C!6=1Y47FT:?&)E&JAF71K@:ED;*
M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
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M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
MKQJ  *X:B "L&Y  JQN9 *D;HP"G'*X IAR\ *0=SP"A'NH!GA[\ 9P?_P&;
M'_\!FA__ 9H>_P&9'O\!F1[_ ?\B  #_(0  ["<  . J  #4*0  S20  ,H<
M" #$&1( O1PB +<>,0"S(#X KR%) *TB4P"J(UP J"1D *8D; "D)', HR1Z
M *$E@@&@)8L!GB64 9TEG@&;)JH!F2:W 9@FR0*5)^8"DB?Y I H_P*/*/\"
MCB?_ HXG_P*.)_\"CB?_ O\F  #R*0  XS$  -(T  #(-   P#   +LI @"X
M(PX L28< *PH*P"H*C@ I"M$ *$L3@"?+5< G2U? )LM9P&9+6X!F"YU 98N
M?0*4+H8"DRZ0 I$NF@./+J8#C2ZS XPNQ0.*+^$$AR_V!(4O_P2$+_\#A"__
M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
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M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
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M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
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M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
MY)   -^Q                       ! P0%!@@)"@L-#@\1$A,4%A<8&AL<
M'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U15
M5UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/
MD)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(
MR<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^____
M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
ME:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:
M_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'
M?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA'
M)O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQ
MQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N
M433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>
MM<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_
MKUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)V
MH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y<K"_^7-A+_H3X:_ZI&)?^P4#3_L5I%
M_[!D5_>L;6GLIW=[X9Y]BMF6@Y?1CHFBRXB.J\>"D['$?I>WP7J<N[YWHK^\
M=:K"M7&NP[-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-R
MK\&S<J_!LW*OP;-RK\'_F1\%_Y<J"O^8-1+_HST:_ZQ&)?^S3S3_M%E&_[1C
M6/:Q;&OJK75]WZ-[C=6;@9S-DH:HQXN*L<*%C[F_@)2^NWR:P[EYH<>U=JG*
MK76LQJMVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K
M=JW$JW:MQ*MVK<3_FA\$_Y@J"O^:-!+_I3T9_ZY&)?^U3C3_MUA&_[=A6?6U
M:FSILG-_W:AXD-.??J#*EH*LQ(Z'M[Z(C+^Z@Y'%MW^8R[1\H<^K>*7/I7FJ
MR*1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&
MI'FLQJ1YK,;_FA\$_Y@J"O^;-!'_ICT9_Z]%)?^W3C3_NE=&_[M@6?2Y:6WG
MMG&!W*QVD]"D>Z/(FG^QP).$O+N,B<6WB)#+M(:9SK*&I-&D?*31GWVIRIY]
MJLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJ
MR)Y]JLC_FQ\$_YDJ"O^<-!'_ISP9_[%%)/^Y333_O%=&_KY?6?2]9V[GNF^"
MVK%TE<^H>:;%GWVTOI>!P+F4BL:UD9++KXV8SZJ*H=*>@J/3F8&HS)B"J<J8
M@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"
MJ<K_FQ\$_YDJ"O^=-!'_J3P8_[)%)/^[33/_OU9&_<%>6O/!9F_FOVV#V;9S
ME\VM=ZC$I7NWOJ&#P+:;B<:NE8_,J)&5SZ*.GM*9AZ+3E(:GS9.&J,N3AJC+
MDX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,O_
MFQ\$_YDJ"O^>,Q'_JCP8_[-%)/^\3#/_P55&^\1=6O/%96_EPVR$V+MQF,RR
M=:O#K7RVN:6!O[">AL:HF8S+H962T)N2F].4CJ+4CXJFSH^*J,N/BJC+CXJH
MRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,O_FQ\$
M_YHJ"O^?,Q#_JSP8_[5$(_^^3#/^PU5%^<=<6O')9&_ER&J%UL%OFLJY=*J^
ML'JVLZE_OZJBA,:BG8K+FYJ0SY67F=*/E*+4BI"FSHJ/J,R*CZC,BH^HS(J/
MJ,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,S_G!\$_YHJ
M"O^@,Q#_K#P8_[9$(_^_3#+\QE1%]LI<6N_-8G#DS6B&T\5MFL6\<ZJYM'BU
MKJU]OJ6G@L6=HHC+E9^.SX^<EM*+G*+3AI6FSH:4I\R&E*?,AI2GS(:4I\R&
ME*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\S_G!\$_YHI"O^B
M,Q#_K3L7_[=$(__!3#+YR5-%\\U:6NS28'#@T&:&SLALFL"_<:FTN'>UJ;%\
MOI^L@<67J(;*D*2,SHJBE=&%HJ'2@9RFSH&:I\R!FJ?,@9JGS(&:I\R!FJ?,
M@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\S_G!X$_YLI"O^C,Q#_
MKSL7_[E$(OW#2S'VS%)$\-)96>C:7W#;U62&R<QJF;K#;ZBMNW2THK1YO9BO
M?<.0K(/(B:F)S(.GD<]^IIS0?:2FS7RBJ,M\HJC+?**HRWRBJ,M\HJC+?**H
MRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,O_G1X$_YLI"O^E,@__L3L6
M_[Q$(?K&2S'ST5%#Z]I76>/?76_3VV.%PL]IE['$;:>DO'"RF+5TNXZQ>,*&
MK7W&@*N"RGJIBLUVJ)3.=JFCS'>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>K
MJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,K_G1X$_YPI"O^G,@__LSL6_[Y#
M(/7*2R_NUE!"YN%65]SD6V[+WF.#NM%HE*G';*.;OFZND+AQMX:T=+U^L'C"
M=ZY\QG*L@\EMJXS*;:N9R6ZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\=N
MK)_';JR?QVZLG\=NK)_';JR?QVZLG\?_GAX$_YTI"?^I,@[_MCH4^L)#'_#.
M2B[GW4] XNE25]+H6FW!X&* L=1GD:'*:YZ4PVZHB;UQL("Y=+9YMG>Z=+1[
MO6ZR@<!JL(C"9["2PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#
M9K"6PV:PEL-FL);#9K"6PV:PEL/_GQX$_YXI"?^M,0W_NCH3],="'>C52BO?
MY$P_U^Q15LGN66NWXV%\J-AGBYK/:Y>-R6Z@@\1QIWO =*QUO7BP<+M[LVRY
M@+9HN(:X9+>/N6.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1
MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
MRO%15;[R6&BMYF%WGMUGA)+5;(^'SV^6?LMSG'C(=J%RQGFD;L1\IVG"@:EF
MP(:L8K^-K6&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_
MCZYAOX^N8;^/KF&_CZ[_HAT#_Z8G!_^W+PGRQS@-X=A!%-+F1BK'\$Q OOA0
M4[+U5V.BZV%PE>-G>XK=;82!V'&+>M1UD'32>9-PT'R6;,Y_F6C,@YMDRXB=
M8<J-GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@
MR8^?8,F/GV#)CY__I!T#_ZTF!?N^+0;FT#0(T^(\%L?N1BN[^4H^L/Y/3Z;Z
M5UR8\6%HC.MH<8/F;GA[XG-]==]X@7'=>X1MVW^':MJ#B6?9AHIDUXN,8=:0
MCF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.
M8-61CF#5D8[_IQP#_[4C ^[))@/5WRD'Q^P\&;KX1"NM_T@[H_]-29K_5U2-
M^6%=A/1J97SP<&IV[79N<>MZ<6WI?G1KZ()V:.:%=V;EB'ECY(QZ8>.1?&#C
MDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2
M?&#CDGS_JQL"]\ = =G<$@''ZR@*NO<[&JS_02F@_T8VE?],08W_5DN#_V%2
M>_UK5W3Z<5QO^'9?;/9[86GU?V-G](-D9?.&9F/RBF=A\8YH7_"2:5_PDVI?
M\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_P
MDVK_MQ4!UL\+ ,?J$P*Y]RD-K/\Y&I[_/B:2_T0PA_]+.8#_5$!X_V%&<O]J
M2FS_<$UI_W909O][463_?U-C_X-48?^&56#^B59>_HU77?V26%S]DUA<_9-8
M7/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUC6
MQ @ QM0) +CW% 2K_RD.GO\T&)#_.B&$_T$I>O]),'+_4C9L_UXZ:/]H/63_
M;T!A_W1!7_]Y0U[_?41=_X!%7/^$15O_AT9:_XI'6/^/1UC_D$A8_Y!(6/^0
M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
MM]L' :G_%@:?_RH-D/\P%8/_-AQW_SXB;O]'*&;_4"QA_UHO7?]D,5O_;#-9
M_W$U6/]U-E;_>396_WPW5?]_-U3_@CA3_X4Y4O^).5+_BCE2_XHY4O^*.5+_
MBCE2_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCG_DAT$_Y I
M"?^--1#_F#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+
MW("5D]A\FYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^-
M-1#_F#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5
MD]A\FYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_
MF#L7_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\
MFYG4>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_F#L7
M_Z!$(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\FYG4
M>*">T76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_F#L7_Z!$
M(?^F3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\FYG4>*">
MT76DHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_F#L7_Z!$(?^F
M3BW_IUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\FYG4>*">T76D
MHL]SJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_F#L7_Z!$(?^F3BW_
MIUD\_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\FYG4>*">T76DHL]S
MJ:7-<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[_DAT$_Y I"?^--1#_F#L7_Z!$(?^F3BW_IUD\
M_Z5D3/^A;EOWFWAJ[I6!=^>.B8+AAH^+W("5D]A\FYG4>*">T76DHL]SJ:7-
M<:ZHS&^UJLIMOJW#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[_DQT$_Y I"?^/-!#_FCL7_Z)$(/^I32W_JE@\_ZAB
M3/^D;%SUGW9L[)E_>N21AX;>B8V0V(.3F--^F9_0>IVDS7:BJ<MTIZS)<:VO
MQV^TLL%LN;2\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\
M;+NQO&R[L;QLN['_E!T$_Y$H"?^1,Q#_G#H6_Z1#(/^L3"W_K58]_ZU@3?ZI
M:E[TI71NZI]]?>&6@XO9CHJ6TX>0H,Z!E:?*?)JMQWB?LL1UI;;"<JNYP'"T
MN[=NM;FS;[BULV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM;-ON+6S;[BU
MLV^XM;-ON+7_E!T$_Y(H"?^3,@__GCH6_Z=#(/^N2RW_L54]_[!?3OVN:%_R
MJG)PYZ1Z@=Z:@(_5DH><SHN,ILF$D:_$?I>UP7F<N[YVH[^\=*O"M&^NPZYR
ML[RK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.V
MN*MSMKC_E1P$_Y(H"?^5,@__H#H6_ZE"'_^P2BW_M%0]_[1>3OVS9V#QKW!R
MYJEX@]N??I/2EX.ARXZ)K,2&CK7 @)2]O'N:P[IZH\6W>:O'K'.LQJ=UL;^E
M=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5W
MM;K_E1P$_Y,H"?^6,0__H3D5_ZI"'_^R2BS_ME,\_[==3ONV96'PM&YTY*UU
MAMFD>Y;/FX"EQY*%L<&*B[N]AY3 NX6=Q+:"I,>P?JK(I7>JR*%YL,&?>K.\
MGWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[S_
ME1P$_Y,H"?^7,0__HSD5_ZQ"'_^T2BS_N5,\_[I<3OBZ9&+ON&QUX[)SB-BI
M>9G-GWZIQ9B$M+^3C+RXC9/!LXF9Q:Z&H<BJA*G)GWRIRIM]KL*9?K*]F7ZR
MO9E^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKW_EAP$
M_Y,H"?^8, [_I#D5_ZU!'O^U22S_NU(\_;U;3O:]8V+NO6MVXK9QB=6N=YO+
MI7RJPIV#M+F6B;RRD9#!K(R6QJ>)G<BCAZ;*F8"HRY:!KL25@;&^E8&QOI6!
ML;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;[_EAP$_Y0G
M"?^9, [_I3D4_ZY!'O^W22O_O5$\_+]:3O3!8F+LP6EWX;MPB]*Q=)W'J'NJ
MO*"!M+2:A[RLE(W"II"4QJ"-F\F<BZ3+E8:HRY&%K<60A;&_D(6QOY"%L;^0
MA;&_D(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%L;__EAP$_Y0G"/^:
M, [_IC@4_[!!'?^X22O_OU$\^L)93O+$86/IQ6AWW;YMC,VT<YW"JWFJMZ1^
MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
MCJ.+Q(BADL>#GYK)@*"GRGV:K,9]F*_!?9BOP7V8K\%]F*_!?9BOP7V8K\%]
MF*_!?9BOP7V8K\%]F*_!?9BOP7V8K\'_F!L#_Y8G"/^@+PW_K#<2_[= &_W!
M2"CVRTXY[]-43.;96F+8U&%WQ\MGBKG#;)JMO'*GH;9WL9BQ?;B/K8*^B*J)
MPX*HD,9]IYG(>J>ER7>BK,5XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!
M>)^PP7B?L,%XG[#!>)^PP7B?L,'_F!L#_Y<F"/^B+PS_KC<2_[D_&OG$1R?Q
MSDTXZMM32^#?66#0VE]VP=!EB;/):YFFPG"EF[UUKY&X>[:(M8"\@;*&P'NP
MC<-VKI;%<ZZAQG*MK<1RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFP
MP'*IL,!RJ;# <JFPP'*IL,#_F1L#_Y@F"/^D+@O_L381_KT_&?3(1R7KU$TV
MY>-02=GC5U_)WUYTNM=DAJS/:9:=QVVCD<!QK(:[=;-^MWJY=[1_O7*RA;]M
ML8W!:K"7PFFQI<%LM+*];+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO6RT
MLKULM+*];+2RO6RTLKW_FAL#_YDF"/^G+0K_M38/^<$_%^[.1B/DW$PRW>=/
M2<_H5E[ Y%URLMYD@J/4:9&5RVV<B<5PI7_ <ZQWO'>Q<+E\M6NW@;AGMH>Z
M8[60NV&UF[QCMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKEC
MMZ:Y8[>FN6.WIKG_FQL#_YLE!_^K+0G_N34-\L<^%>751A_:XTDSS^M.2<;M
M5%VWZEQNJ.)C?9K9:8J.TFV4A,QQFWO(=:%SQ'BF;L)\J6G @:QEOH>N8KV.
ML%^]E[%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ
M7KR>L5Z\GK'_G!H#_Z D!O^P+ CYP#0+Z<\]$-K?0AW.Z4DSQ/%.2+OR4EJM
M\%MIGN=C=I+@:8&'VF^)?M1SD'?1=Y5QSGN9;,Q_G&C*@YYDR8B@8<>.HE[&
ME:1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;
MI%S&FZ3_GAH#_Z4C!?^W*@7PR#('W-LU#,[G0A_"\4@TN/E,1J_W456B]5MB
ME>UD;8KG:W: XG!]>=YU@G/;>H=NV7Z*:]>"C&?5AHYDU(N08=.0DE[1EI1<
MT9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1
MFY7_H1D"_ZTA _B_)@/BU"4#SN4S#\+P0B&V^D<SJ_Y+0J+^4$^7^UM:B_5E
M8X+P;&IZ[')P=.EX=&_G?'=LY8%Z:..$?&;BB'UCX8Q_8."1@5[?EH)<WIJ#
M7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH/_
MHQD"_[8= >G,%P'/XQX#PO S$K7Z0"*I_T0PG?])/97_4$B+_UM0@OUE5WKY
M;5UT]G-A;_1Y9&OR?F=H\8)I9O"&:F3OBFQB[HYM8.V2;EWLEW!<ZYMQ7.N;
M<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW'_K!4!
M\\,0 -':"P#![Q\&M/LS$ZC_/"";_T(LD/](-H?_3S]__UI&>/]E2W'_;4]L
M_W-2:?]Y56;^?E=D_8)88OR&66'[BEI?^HY;7OJ27%SYEUU;^)M>6_B;7EOX
MFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFU[ZN0X S<L)
M ,#F#0&R_" (I_\S$YK_.1V-_S\F@O]&+GK_3C5S_U@Z;?]C/VG_;$)E_W)$
M8O]W1F#_?$=?_X%(7?^%25S_B$I;_XQ+6O^03%C_E4U7_YE-5_^935?_F4U7
M_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4W-P08 OM ' +'V
M#@*E_R$)F?\N$HS_-!F _SL@=O]#)VW_3"QF_U0P8O]@,U[_:35<_V\W6O]T
M.%G_>3E8_WTZ5_^ .U;_A#M5_X<\5/^+/5/_D#U2_Y,^4O^3/E+_DSY2_Y,^
M4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSZ]Q04 L-<% */_$ .9
M_R()B_\I#W[_,!5S_S@::?] 'V+_22-;_U$F5_]:*%7_8BI2_VDK4?]O+%#_
M<RU/_W<N3O]Z+D[_?2]-_X O3/^$,$O_B#!+_XLP2_^+,$O_BS!+_XLP2_^+
M,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS#_BQP$_X@H"/^$- [_CSH4
M_Y="'/^>2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A
M=*.*WW&HCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="
M'/^>2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*
MWW&HCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>
M2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&H
MCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_
MGE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUO
MKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_GE<T
M_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUOKI';
M;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_GE<T_YUB
M0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUOKI';;;.4
MVFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO_BQP$_XDH"/^%,P[_D#D4_YA"'/^>2R?_GU8T_YYA0O^:
M;5#_E7==]X^!:/&)BW+K@Y)[YWV8@N-XG8C@=*.,W7*HD-MOK9/:;K.6V&RZ
MF-9KPIO1:<J<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<
MRF;*G,IFRIS_C!P#_XDG"/^(,@[_DS@4_YM!'/^B2B?_I%0T_Z)?0_^?:E']
MFG1?]91^;.V.B'CGAX^!XH"5BMU[FI#:=Z"6UG2FFM1QK)[2;[*AT&VYH\]L
MPZ;%9\.FP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'
MH<!IQZ'_C1P#_XHG"/^*,0W_EC<3_YY &_^E22?_IU,T_Z==0_^D:%/\H')B
M\II\<.J4A7WCBXN(W822D=A^F)C3>IZ?T'6DI,URJJC+;["KR6VXKL)IO+"\
M:\"JMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=M
MQ*7_C1L#_XLG"/^,, W_F#<3_Z! &_^G2";_JU(T_ZM<1/^I9E3ZI7!D\)]Y
M<^>8@H'?CXB-V8B/E]*!E:#.>YNGRG:AK<=SJ+'%<*^UP6VWM[EKN+6S;KVN
ML'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:C_
MCAL#_XLF"/^., W_FC82_Z(_&O^I2";_KE$T_ZY;1/^L9%7YJFYE[Z5W=N6=
M?X7<E(62U(R,G<Z$DJ?)?9BOQ'B>M<)UI[G!=+&[N'"SN[%OMKBL<;NQJ7._
MJZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZO_CAL#
M_XPF"/^0+PW_FS82_Z0_&O^K1R;_L5 T_[%91/RP8U7VKFQG[:IU>..A?(C9
MF(.6T9")H\J'CZW%@I>TPG^@N+Y\J+N[>K"]L72RO:ERM+NF=+FSHW:^K:-V
MOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJW_CQL#_XPF
M!_^1+@S_G382_Z8^&O^M1R7_LT\T_[181/JT85;SLFIH[*]S>N&F>HO6G8":
MS92&I\:-C:^_AY2UNH*<N;5_I+RR?:R^JWFQOZ-VLKV@>+BUGGF]KYYYO:^>
M>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:__CQL#_XTF!_^3
M+@S_GC41_Z@^&?^O1B7_MDXS_K=71/>W8%;PMFAIZ+-P>]ZJ=XW0GWR=QY>#
MI[^0BJ^XBY&VLH:8NJV#H+VI@:F_I7ZPP)QYL;^:>[>WF'V[L)A]N["8?;NP
MF'V[L)A]N["8?;NPF'V[L)A]N["8?;NPF'V[L)A]N[#_D!H#_XTF!_^4+0S_
MH#41_ZD^&?^Q1B3_N$TS_+M61/6[7U;MNV=IX[5N?=:L<X_*HWJ=P9N I[B4
MA["QCXZVJXJ5NZ:'G;ZBA:7 GX2OP99^L,&4?[:XDX"[LI. N[*3@+NRDX"[
MLI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[+_D!H#_XXF!_^5+0S_H341
M_ZL]&/^S1B3_NDTS^KY51/._75;JOV5JW[AK?M"O<8_%IGB<NY]^I[*8A:^K
MDXNVI8Z3NY^+FKZ;B:+!F(BLPI""K\*/@[6YCX2ZLX^$NK./A+JSCX2ZLX^$
MNK./A+JSCX2ZLX^$NK./A+JSCX2ZLX^$NK/_D!H#_XXE!_^6+ O_HC40_ZP]
M&/^U12/_O$PR^,%40_##7%;GPV-JVKMI?LRR<(_ JG:<MJ)\IZV<@J^EEXFV
MGI.0NYF/F+Z4C:#!D8RIPHN(KL**B+2ZBHBYM(J(N;2*B+FTBHBYM(J(N;2*
MB+FTBHBYM(J(N;2*B+FTBHBYM(J(N;3_D1H#_X\E!_^8+ O_I#00_ZX]&/^W
M12/_OTPR]L530^[(6U;CQF%JU+]H?L>V;HZ[K72<L:9ZIJ>@@*^?FX:UF)>.
MNY.5E;Z.DIW!BI*GPH:.KL*$C;2[A8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FT
MA8RYM(6,N;2%C+FTA8RYM(6,N;3_D1H#_X\E!_^9+ O_IC0/_[ \%_^Y1"+\
MP4LQ],E20NO-657?R6!JS\)F?<*Y;(VVL7*;JZMXIJ*E?JZ9H(2UDIV+NHR:
MD[Z'F)O A)>EPH"6K\)_DK.\@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&X
MM8"1N+6 D;BU@)&XM8"1N+7_DAH#_Y E!_^;+ K_IS0/_[(\%O^[1"'YQ4LP
M\<Y10>?26%3:SEYIRL9E?+V]:XRPMG":I;!VI9RJ?*V3IH*TC*.)N8:@D+V!
MGIF_?9ZBP7N>K\%YF;.\>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7
MN+5ZE[BU>I>XM7J7N+7_DAD#_Y E!_^=*PK_JC,._[4\%?R_1"#TR$HN[=-0
M/^/85E/3TEUHQ<IC>[?":8NJNV^8G[9THY6Q>JR-K8"RA:J'MW^GCKMZII>^
M=Z:@OW2FK;]SH;2[=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5T
MGKBU=)ZXM72>N+7_DQD#_Y$D!_^?*PG_K#,-_[@[%/C#0Q[OS4HLY]I//=W>
M55'-V%MGOL]B>K#(9XFDPFV7F;QRH8^X>*F&M7ZP?[*%M7FPC+ATKY6[<*^?
MO&ZOK+QMJ[6Y;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT
M;J>YM&ZGN;3_E!D#_Y(D!_^B*@C_L#(,_KPZ$O+'0ASHTTDIX>%,.]3C4U'&
MW5IEM]5@>*G/9H>=R6N4D<5PGH?!=J9_OGRL>+R$L7*ZB[1MN9.V:KB<N&>W
MI[AGM[>V:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[
ML6BRN['_E1@#_Y4C!O^E*0?_M#$*^,$Z$.O.0AC@W4<EU>5+.\OG45"]XUEC
MK]Y?=*+898.6TVJ/BLYOF7_(<Z%UQ'BG;L%]JVF^A*YEO8NQ8;R3LE^\G;)?
MO*RQ8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_
MOJW_EA@#_YDA!?^J* ;_N3 (\,@X#>'80!/4XT4FRNM+.\'L3T^SZ%=@IN5?
M;YKB9GR.W&R&A-5QCWK0=95SS7J;;,I_GV?'A*)CQHJD7\21IES$F:=:PZ2G
M6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*?_
MF!<"_YX@!/^O)@7XP"X&YM S"-7A/!3)ZD4HO_)*.[7Q3DRI[U9;G>U?:)+J
M9W.'XVU\?MYR@G;:>(APUWV,:]2"D&;2AY)CT8R57\^2EES.F9A9SJ*96,VK
MFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYK_FA<"
M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
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M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
ME\X  (G>  !__P<!=/\0 FG_%0-?_QP%5_\D"%#_+ I*_S,,1?\[#D'_00\]
M_T<0.O]-$3C_4A$V_U<2-/]<$S+_81,Q_V84+_]K%"[_<14M_W<5+/]]%2K_
M@Q8I_XL6*?^.%BG_CA8I_XX6*?^.%BG_CA8I_XX6*?^.%BG_CA;_9B #_V$J
M!?]A,PC_:38+_VX]#_]Q1A7_<U$<_W->(_]P;2G_;GPP_VN)-?]IECG_9Z$]
M_V:J0/]DLD+_8[E$_V'"1O]@R$?_7LU(_US42O];WDO[6>1,]UCJ3/17[TWP
M5O--[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-[%7X3>Q5^$W_9B #_V$J!?]A
M,PC_:38+_VX]#_]Q1A7_<U$<_W->(_]P;2G_;GPP_VN)-?]IECG_9Z$]_V:J
M0/]DLD+_8[E$_V'"1O]@R$?_7LU(_US42O];WDO[6>1,]UCJ3/17[TWP5O--
M[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-[%7X3>Q5^$W_9B #_V(J!?]C,0C_
M:S4+_W \#_]S117_=4\<_W9=(_]S;"K_<'HQ_VV'-O]KE#O_:9\__VBH0O]F
ML$7_9+A'_V/ 2?]AQTK_7\Q,_UW33?Q<WD[Y6N1/]5GJ4/%8[U'M5_11Z5?Y
M4.E7^5#I5_E0Z5?Y4.E7^5#I5_E0Z5?Y4.E7^5#_9Q\#_V,J!?]E, C_;C,+
M_W0Z#_]W0Q7_>4X<_WI:)/]W:"O_='8S_W&$.?]ND#__;)M#_VJE1_]HK4K_
M9[9,_V6^3O]CQ5#_8<M2_5_25/E=W57T6^16\%KJ5^M8\%CG6/57XUGZ5.-9
M^E3C6?I4XUGZ5.-9^E3C6?I4XUGZ5.-9^E3_:!\#_V,I!?]H+@?_<3(*_W<X
M#_][0A7_?4P<_WY8)/][9BW_=W,U_W2 //]QC$+_;Y='_VRA2_]JJD__:+)2
M_V>[5/]EQ%;^8LI8^6#16O5>W%SP7.1=ZEKK7N99\5_B6O5;W%OY5]Q;^5?<
M6_E7W%OY5]Q;^5?<6_E7W%OY5]Q;^5?_:1X#_V0I!?]K+0?_=# *_WLW#O]_
M017_@4H<_X)5)?]_8R[_>W V_WA\/O]UB47_<91+_V^>4/]LIE3_:JY8_6BW
M6_QFP%WZ9,E@]6'08O!>W&/J7.5EY5OL9MY:\&/86_1@T5WX6]%=^%O17?A;
MT5WX6]%=^%O17?A;T5WX6]%=^%O_:1X#_V4H!?]N*P?_>"X*_W\V#O^#/Q3_
MA4@<_X=3)?^$8"__@&PX_WQY0?]XA4G^=)!0^W&95OENHEKX:ZI?]FBR8O1F
MNV7S9,5H\&+0:^I?W6WC7>=NVUOJ;=-<[VC-7O-DR%_W7\A?]U_(7_=?R%_W
M7\A?]U_(7_=?R%_W7\A?]U__:AX#_V8H!?]Q*0?_>RP)_X,U#?^'/A3_BD<;
M_XQ0)?^)72__A6DZ_8%U1/I\@$WW>(M5]'.57/%OG6+O;*5G[6FM:^MFMF_H
M8\!RYF',=>-@WW?67.1XSE[I<LE?[6W$8/!HOV+T8[]B]&._8O1COV+T8[]B
M]&._8O1COV+T8[]B]&/_:QT#_V<G!?]T)P;_?RL(_X<S#?^,/!/_CT4;_Y%.
M)?^/6C#\BV8[^(9Q1O.!?%'O?(=:[':08NAQF&GE;*!PX6BH==YDL'K;8KI^
MV&''?]1AVG_+7^%^Q&'E=[]BZ7*[8^UMMF3Q9[9D\6>V9/%GMF3Q9[9D\6>V
M9/%GMF3Q9[9D\6?_;!T#_VHF!?]W)@;_@BH(_XHR#/^0.Q+_DT,:_Y9,)/V5
M5S#WD6(\\HQM2>R&>%3G?X%?XGB*:=QRDG+6;9IXTFJB?,YGJW_+9K2!R66_
M@\=DSH3!8]V#NF3B?+9FYG:R9^IQKFCO:JYH[VJN:.]JKFCO:JYH[VJN:.]J
MKFCO:JYH[VK_;1P#_VPD!?]Z) 7_A2D'_XXQ"_^4.1'_F$(9_YM*)/B;5##R
MEU\]ZY)J2^6*<UC>@GQDU7R%;L]VC77*<I5ZQFZ=?L-LI8*_:J^$O6FYAKIH
MQX>W:-J'L6C>@:UIXWJI:^ATIFOL;:9L[6VF;.UMIFSM;:9L[6VF;.UMIFSM
M;:9L[6W_;1P#_VXC!/]](@7_B"@'_Y$P"O^8.!#_G$ 8^Y])(_2A4B_MG5P]
MY99F3-V.;UK3AWAES(&!;L9[B7;!=Y%[O'.9@+APH82U;JJ'LFVTB:]LP8JM
M;-**J&S<A:5MX7ZB;N5WGV_K<)]OZW"?;^MPGV_K<)]OZW"?;^MPGV_K<)]O
MZW#_;AP#_W$B!/]_(07_BR<&_Y0O"?^;-P__H#\7^*1'(?"G3R[HHEH]WYMC
M3=24;%K+C'5EQ(9];[Z A7:X?(U\LWB5@:]UG86K<J6)J'&OBZ5PNXRC<,N-
MH''9B)UQWX&;<N1ZF7/I<IESZ7*9<^ERF7/I<IESZ7*9<^ERF7/I<IESZ7+_
M;QL#_W,@!/^"( 3_CB8&_Y<N"/^?-@[]I#X5]*A&(.RL32WCIU@\V:!A3,V8
M:EG%D7)EO8MZ;K:%@G:P@(E]JWV1@J=YF8:C=Z**GW6KC9QTMXZ:=,:/F'76
MBY9VW8.4=N)\DW;G=))VZ'22=NATDG;H=))VZ'22=NATDG;H=))VZ'3_;QL"
M_W4?!/^$'P3_D"4%_YHM"/^B-0SZJ#T4\:Q%'NBP3"O?JU<[TJ1?2\B<:%F_
ME6]DMX]W;K"*?W:JA89]I(&.@I]^EH>;>YZ+EWFHCI1XLX^2>,*0D7K5C8]Z
MVX6.>N%^C7KF=HUZYG:->N9VC7KF=HUZYG:->N9VC7KF=HUZYG;_<!L"_W8>
M _^&'@3_DR4%_YTL!_^E- OWJSP2[K%#'.6T2RG:KU4ZS:A>2L*@9EBYFFUD
ML9-U;JJ.?':CBH-]GH:+@IF"DX>4@)N+D'ZECHU]L)"*?;Z1BG_3CXE^VH>(
M?M]_AW[E=X=^Y7>'?N5WAW[E=X=^Y7>'?N5WAW[E=X=^Y7?_<!L"_W@= _^(
M'@/_E20$_Z K!O^H,@KTKSH1Z[5"&N&X2B?4LU,YR*M<2;ZD9%>TGFMCK)AR
M;:23>76>CH%\F(N(@I*'D(>-A9F+B8.BCH:"KI&#@KR1@H/.D8.#V8B"@M^!
M@H+D>8*"Y'B"@N1X@H+D>(*"Y'B"@N1X@H+D>(*"Y'C_<1H"_WH< _^*'0/_
MER,$_Z(I!?RL,0GQLSD/Z+I %]V\2"7/ME(XPZ];2+FH8E:OHFIBIYQP;)^7
M=W68DWY\DI"&@HR-CH>'BI>+@XB@CG^'JY%\A[F1>X?+D7R(V(E]A]Z"?8;D
M>GV&Y'E]AN1Y?8;D>7V&Y'E]AN1Y?8;D>7V&Y'G_<1H"_WP: _^-' /_FB(#
M_Z4H!/FO+P?NN#<,Y+\_%-C 1B3*NE WO[-91[2L856JIFAAH:%N:YF<=722
MF'Q[C)6#@8:2BX:!D)2+?(Z>CGB-J9!VC+:1=(W(D7:.V(IWC-V"=XKC>G>*
MXWIWBN-Z=XKC>G>*XWIWBN-Z=XKC>G>*XWK_<AH"_W\9 O^/&P+_G2 #_ZDF
M _:S+07JO34)X,8\$-+$1"/%O4\UNK=81J^Q7U2EJV9@G*9M:I2B<W.,GGIZ
MAIN!@("8B85ZEI*)=92;C7*3IH]OD[20;93%D'"5V(IPDMV#<9#C>W&0XWMQ
MD.-[<9#C>W&0XWMQD.-[<9#C>W&0XWO_<QD"_X(7 O^2&@+_H!\"_ZTD O*X
M*@3FPS$&V\PU#\S(0B' PDTTM+Q61*FV7E*?L61>EJQK:(ZI<7&&I7AX?Z)_
M?GF@AX-TG8^(;YR9BVN;I(UHF[*.9YO"CFF=V(IJF=V":Y;C>VN6XWMKEN-[
M:Y;C>VN6XWMKEN-[:Y;C>VN6XWO_=!D"_X45 O^6& '_I!P!^[(@ >V_)0+A
MS"H#U-$R#<?,01^ZQTPQKL%40J.\7%"9MV)<D+-I9H>P;VZ K79U>:I]>W.H
MA(!MIHV%:*67B&6DHXIBI+"+8*3!BV*FV8ACHMZ!99[C>F6>XWIEGN-Z99[C
M>F6>XWIEGN-Z99[C>F6>XWK_=A@"_XD3 ?^:%@'_J1@!]K@; >?'&@';V1P!
MS=8P"\#2/QVTS4HOJ,A2/YW#6DV2OV%8B;MG8H"X;6MYMG1Q<K-[=VRQ@WQG
ML(R 8J^6@UZNH89<KJ^'6J^_AUNPVH1=K.!_7J?E>%ZGY7A>I^5X7J?E>%ZG
MY7A>I^5X7J?E>%ZGY7C_>A4"_XX2 ?^?$P#_L!, [\ 0 -G4# #.WQP!Q-TO
M";G9/1JMTT@LH<]0.Y7+6$F+QU]4@L1E7GG";&9RP')L:[YZ<F:]@G9ANXMZ
M7+N5?5FZH7]7NJ^ 5;N_@%6\V7]6N.-Z6++G=5BRYW18LN=T6++G=%BRYW18
MLN=T6++G=%BRYW3_@!(!_Y00 /^F#P#CN L TL8* ,S7"P##XQX"N>(Q"J_@
M/1BDW48GF=E.-XW45D2#T5U/>L]D6'+-:E]KRW)E9<IY:F#)@F];R8MR5\B6
M=53(HG=2R*]X4<G >%#*VW=1QNAS4L#K;U*_[&]2O^QO4K_L;U*_[&]2O^QO
M4K_L;U*_[&__APX!_YL- -^N!P#0O @ Q\D( ,';"P"WZ" #K><Q#:3F/1F9
MY$0FCN),,X3@5#Y[WEQ'<]UC3VO<:E9EVG)<8-IZ8%O9@V17V8QG4]F7:E#9
MHVQ.V;%M3=K";4S;W&Q-V.QJ3L_P9T[/\&=.S_!G3L_P9T[/\&=.S_!G3L_P
M9T[/\&?_CPL Z:0$ -&T!@#%OP8 O,T( +3I#@&J[B(%HNXS#I?M.QF-[$(D
M@^M)+GOJ4S9SZ5P^;.ED1&?I;$EBZ'1-7NA\45KHA516Z(Y64^F865'IHUI.
MZ;!<3>J^7$SKTEU+ZNE=2N/S7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7$KC
M\USYF0, U*P" ,6W! "YPP4 L-(( *?V$0&>]20&E?4R#HKU.A>!]4$@>/5(
M)W#U4"YJ]%HT9?1C.&#T:SQ=]70_6?5\0E?UA$14]8U&4?:72$_VH4I-]JQ+
M2_>Y3$KWR$U)^.!-2/?S34CW]$U(]_1-2/?T34CW]$U(]_1-2/?T34CW]$W:
MHP  Q[$" +B[ P"MR00 H]D' )K]% *2_2<'A_XO#7W^-Q1T_S\;;/]'(&;_
M3B5@_U<I7/]@+5G_:3!6_W$R4_]X-%'_@#9/_XDW3?^2.4O_G#I)_Z8[2/^Q
M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
M )_)  "3V0  B?P+ 8#_%P)V_R %;/\H"63_, U=_S@05_] $U'_1Q9-_TX8
M2O]6&4?_7!I$_V,<0O]I'4#_<!X__W@>/?^ 'SO_B" Z_Y$A./^;(C?_I"(V
M_ZTC-?^X(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2.MM@  G\0  )+2
M  "$X0  ??\- 7+_$P)H_QL$7_\C!EC_*PE1_S,+3/\Z#4?_00]#_T@10/].
M$CW_5!,[_UH4.?]?%#?_914U_VL6,_]R%C'_>A<O_X(7+O^+&"S_DQ@K_YP9
M*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQFAOP  DLP  (3<  !X
M]P  ;O\* 6/_$ ):_Q4#4O\=!$O_) 9&_RP(0?\S"3S_.@HY_T +-?]%##+_
M2@TP_U -+O]4#BS_60XJ_UX/*/]D#R;_:@\E_W$0(_]X$"+_@!$@_X@1'_^1
M$1__D1$?_Y$1'_^1$1__D1$?_Y$1'_^1$1__D1'_7"(#_U<M!?]8,P?_7S8)
M_V,]#?]E1A+_9E 7_V5>'/]D;B+_87PG_U^**_]>EB[_7*$Q_UNJ,_]:LC7_
M6;HV_UC#-_]8S3G_5]@Y_U;@.O]5YCO_5.P\_U/Q//Q2]3WX4OD]]5']/?-1
M_SWS4?\]\U'_/?-1_SWS4?\]\U'_/?-1_SW_7"(#_U<L!?]:,@?_834)_V4\
M#?]G11+_:$\7_VA<'?]F;2+_8WLH_V&(+/]?E"__7I\R_UVI-?];L3?_6KDX
M_UK!.O]9RSO_6-4\_U??/?]6YC[_5>L^_53P/_E3]3_V4OE \U+]0/!2_S[P
M4O\^\%+_/O!2_S[P4O\^\%+_/O!2_S[_72$#_U@L!?]<, ?_9#,)_V@Z#?]K
M0Q+_;$X7_VQ:'?]J:B3_9W@I_V2%+O]BD3+_89PV_U^F./]>KCK_7;8\_UR^
M/O];R#__6M)!_UG=0O]7Y4/]5NI$^57P1/54]47Q5/I%[E3^1.Q4_T+L5/]"
M[%3_0NQ4_T+L5/]"[%3_0NQ4_T+_7B$#_UDL!?]?+@;_9C()_VPX#/]O01'_
M;TP7_W%7'O]N9R7_:W4K_VB",/]ECC7_9)DY_V*C//]@JS[_7[-!_UZ[0O]=
MQ$3_7,Y&_UK<1_Y9Y$CZ5^I)]5;P2O!5]DKM5?I*Z5;^1^=6_T7G5O]%YU;_
M1>=6_T7G5O]%YU;_1>=6_T7_7B$#_UDK!?]B+0;_:C (_V\V#/]R0!'_=$H8
M_W55'O]R9";_;W(M_VQ_,_]IBSC_9I8\_V6@0/]CJ$/_8;!&_V"X2/]>P4K_
M7<M+_US:3?I:XT[U6>I/\%?Q4.M6]E'G5_M.Y%C_2^%9_TGA6?])X5G_2>%9
M_TGA6?])X5G_2>%9_TG_7R #_UHK!?]E*P;_;2X(_W,U#/]W/A'_>$@7_WE2
M'_]W8"?_=&XN_W![-?]MASO_:I)!_V>;1?]EI$G^8ZQ,_6&T3OM@O%'Z7L93
M^5W45?5;XU;O6NI8Z5CR6>59]U;@6OM3VUO_3]=;_TW76_]-UUO_3==;_TW7
M6_]-UUO_3==;_TW_8" #_UTI!?]H*0;_<2L'_W@S"_]\/!#_?487_WY0'_]]
M72C_>6HP_W5V./]Q@C_\;8U%^FJ72_AGGT_V9:=3]&*O5O-@N%GQ7\%<\%W-
M7NU<X&#H6NQAX5KR8-I;]EO37/I7SUW]4\Q>_U',7O]1S%[_4<Q>_U',7O]1
MS%[_4<Q>_U'_81\#_V G!/]K)@7_=2D'_WPQ"O^!.A#_@T07_X1-'_^#62C_
M?V8R_'IR._AU?D/U<8A+\FV24>]IFE;M9J);ZF.J7^A@LF/F7KQFY%S(:>%;
MVFO=6NIKTUSP9LU>]6'(7_E<Q&#\6,%A_E7!8?Y5P6'^5<%A_E7!8?Y5P6'^
M5<%A_E7_8A\#_V,E!/]O) 7_>2@&_X$P"O^%.0__B$(6_XE+'O^)5BCZA6(S
M]8!N/?!Z>4?L=8-0Z7",6.5KE5[A9IUDWF.D:=M@K6W77[=OU%[#<-%>TG'-
M7>=QQU_N:\)A\F:^8O9ANF/Y7+=C_%BW8_Q8MV/\6+=C_%BW8_Q8MV/\6+=C
M_%C_8Q\#_V8C!/]R(@3_?2<&_X4N"?^*-P[_C4 5_X])'OJ/4RCTC%\T[H9J
M/^E_=$OC>'Y5WG*&7MAMCV73:IAJSV>@;<QEJ'#)8[%SQF*\=,1AR77!8>!V
MO&/J<;=D[VJT9?-EL&;V8*YG^5RN9_E<KF?Y7*YG^5RN9_E<KF?Y7*YG^5S_
M8QX#_V@A!/]U( 3_@24%_XDM"/^/-0S_DCX4_)1''?663RCND5LTYXMF0>"$
M;T[9?7E8T7>"8,QSBF?';Y-LQ&R;<,!IHW.]9ZQVNF:V>+AEPGFV9=5YLF;F
M=O_B?1!)0T-?4%)/1DE,10 .$JYH[&^J:?!IJ&GT8Z9J]U^F:O=?IFKW7Z9J
M]U^F:O=?IFKW7Z9J]U__9!X#_VL@ _]X'@3_A"0%_XTL!_^3- O_ESP2^)E%
M&_";32?HEUDTX9!B0M>);$[.@W58R'U^8<-XAFB^=(YMN7"6<K9NGG6R;*=X
MKVJQ>ZUIO7RJ:<U]J&KC>J5LZ7*B;.ULH&WR9IYN]6*>;O5BGF[U8IYN]6*>
M;O5BGF[U8IYN]6+_91T"_VT> _]['0/_AR,$_Y J!O^7,@K]G#L0])]#&>RA
M2R7CG%8SVI9@0<^.:4['B')8P()Z8;I]@FBU>8INL762<ZQRFG>I<*-ZIFZL
M?:-MN'ZA;<=_GV[@?IQPYW6:<.MOF7'P:)=Q\V27<?-DEW'S9)=Q\V27<?-D
MEW'S9)=Q\V3_91T"_V\= _]^' /_BB($_Y,I!?^;,0GYH#D/\*-!&.>F22/>
MH50QTII>0,B39TW C&]8N8=W8;."?VBN?8=NJ7J.<Z1WEGB@=)][G7.H?IIQ
MM("8<<*!EG+8@95TY7B3=.IQDG7O:Y%U\F:1=?)FD77R9I%U\F:1=?)FD77R
M9I%U\F;_9AT"_W$; _^ &P/_C"$#_Y8H!?^>+PCVI#<-[*@_%>.K2"#8IE(P
MS)Y<0,.794V[D6U7LXMT8:V&?&BG@H-NHGZ+=)U[DWB9>9Q\E7>E?Y)VL(&0
M=;Z"CG;1@HYXXWJ->.ASC'CM;(MX\6B+>/%HBWCQ:(MX\6B+>/%HBWCQ:(MX
M\6C_9QP"_W,: O^"&@+_CR #_YDF!/ZB+@;SJ#4+Z:T]$]^O1A[2J5$OQZ):
M/[Z;8TRUE6I7KH]R8*>+>6BAAX%NG(.(=)> D'B2?9E\CGRB@(MZK8*(>KN#
MAWK-@X=\XGR'?.=UAGSL;H9\\&F&?/!IAGSP:89\\&F&?/!IAGSP:89\\&G_
M9QP"_W49 O^%&0+_DA\"_YPE _NE+ 7PK#0)YK([$-NS1!W-K4\NPZ99/KF?
M84NPF6A6J)1P7Z&/=V>;BWYNEHB&<Y"%CGB,@I9\B("@@(1_JX*!?[B#?W_*
MA(&!X7V!@>9V@8#K;X" [VJ @.]J@(#O:H" [VJ @.]J@(#O:H" [VK_:!P"
M_W@7 O^'& +_E!T"_Y\C _BI*@3LL3$'XK<Y#=6W0AS)L$XMOJI7/;2C7TJK
MGF=5HYAN7YR4=6:6D'QMD(V#<XN*BWB&B)1\@8:>@'V$J()[A+6$>83'A'J&
MX'][A>9W>X7K<'N$[FM[A.YK>X3N:WN$[FM[A.YK>X3N:WN$[FO_:1L"_WH6
M O^*%P+_EQP"_Z,A O2M)P/HM2X%WKTU"M"Z0!O$M$PLNJY6.Z^H7DFFHF54
MGIUL79>9<V:0E7ELBI*!<H60B7=_C9)\>XN;?W>*IH)TB;.#<HK$@W2,X']T
MB^5X=8GJ<7:([6QVB.UL=HCM;':([6QVB.UL=HCM;':([6S_:QH"_WT4 O^-
M%@'_FAH!_Z8> ?"Q(P+DNRD#V<(P"<N]/QG N$HJM;)4.JJL7$>AIV-2F:-J
M7)&?<62*FW=KA)A_<7Z6AG9YDX][=)*9?G"0I(%MD+&":Y#!@FV2W7]ND>5X
M;X_J<7".[6QPCNUL<([M;'".[6QPCNUL<([M;'".[6S_;A@"_X 2 ?^0%0'_
MGA<!^ZL: >RW'@'@PR$!TL8M",;!/1BZO$DHK[=2.*6R6D6<K6%1DZEH6HNE
M;V*$HG5I?I]\;WB=A'1SFXUY;IF6?&J8HG]GEZZ 99B_@669V']HF.5X:9;J
M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
M ,B9  "]HP  LJL  *FR  "@NP( E\0) )+%&P"+Q"P$@\(Z#'O!1!5TOTX=
M;KU6)&B\72ICNV0P7[IL-%JY=#E6N'P\4[>'/T^WDD),MI]$2K:M1DBVP$9(
MM]U%2;;R0TJU_T%+M?\^2[3_/4NT_SU+M/\]2[3_/4NT_SWB@P  S9(  ,&?
M  "TIP  JJ\  *"X  "6P , C,H' (;-% "!S28">LPU"'/+00]LRDH79LE3
M'6'(6R-<QV(H6,9J+%3&<C!0Q7PS3<6&-DK$DCE'Q)\[1<2N/$3%P3Q#Q=\\
M1,3S.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP  Q9H  +>D  "K
MK   H+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ ECUD807M90%5G5
M6!I5U& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5PC$_U>$P/]/R
M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
M(_\. "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!"O\^ 0C_1@$%
M_T\! ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@( _Z8" /^F @#_
MI@+_+B\"_S,L O\W+0+_.# "_S<V _\T/P3_,4L&_R]8!_\L9@C_*G0)_RF!
M"O\HC0O_*)<+_RB?"_\HI@S_)ZT,_R>T#/\GNPS_)\0,_R?.#/\HW@O_*.D+
M_RCS"_\H^PO_*/\*_RG_"O\I_PK_*?\*_RC_"O\H_PK_*/\*_RC_"O\H_PK_
M,"T"_S8J O\Y*@+_.RX"_SHT _\X/ 3_-DD&_S-6!_\Q8PG_+W$*_RU^"_\M
MB@S_+)0,_RR<#?\LI W_+*L-_RRQ#?\LN0W_*\$-_RS+#?\LV@W_+.<-_RSQ
M#?\L^@W_+/\,_BW_#/TM_PS]+?\,_2S_"_TL_PO]+/\+_2S_"_TL_PO_,BL!
M_SDH O\]* +_/RH"_SXP _\].@3_/$8&_SE3"/\W8 G_-6T+_S-Z#/\RA@W_
M,9 ._S&9#O\QH0__,:@/_S"N#_\PM0__,+T0_S#'$/\PU!#_,.00_S'O$/XQ
M^0_[,?\/^3'_#_@Q_P[W,?\.]S'_#O8Q_P[V,?\.]C'_#O8Q_P[_-2@!_SPE
M ?] ) +_0R<"_T,L _]$-P3_0D,&_T!/"/\]7 K_.VD,_SEV#?\X@@__-XP0
M_S>5$?\VG1'_-J02_S:K$O\VLA/_-;H3_S7#$_\USQ/\->$3^3;M$_8V]Q/S
M-O\3\3;_$O V_Q+P-_\1[S?_$>\W_Q#O-_\0[S?_$.\W_Q#_.24!_T A ?]%
M( '_1R("_TDI O]*- 3_23\%_T9+"/]$6 K_0F4-_T!Q#_\^?1'_/8<2_SV1
M%/X\F17]/* 5_#NG%OH[KA?Y.[87^#N_%_8[RACT.]P8\#OJ&.T[]ACJ._\7
MZ#S_%^<\_Q;F/?\5Y3W_%.4]_Q3E/?\4Y3W_%.4]_Q3_/2(!_T0> ?])' '_
M31X!_U F O]1, /_4#L%_TY&"/]+4PO_2& ._T9L$?M%>!/X1((5]D.,%_1"
ME!CS09P9\4&C&^] JAON0+(<[3^['>L_QA[I/]4>Y3_H'^) ]![?0/X=W4'_
M&]M"_QK90O\8V$+_%]A"_Q?80O\7V$+_%]A"_Q?_0!\!_T@: ?].& '_4AL!
M_U8C O]8+ /_5S<$_U5"!_]230OY4%H.]4UG$O%,<A;N2GT8ZTB&&^E'CQWG
M1I<?Y46>(.-$IB+A1*XCX$.W)-Y#PB7<0] FUT/E)M-$\R301?XBS4;_(,Q'
M_Q[*1_\<R4C_&\E(_QO)2/\;R4C_&\E(_QO_1!L!_TP6 ?]2% '_6!@!_UT?
M ?]?* +_7C(#_5T]!O9:20KP5U4/ZE5B$^92;1CB4'<<WTZ!']Q,BB+92Y(D
MU4J:)M-)H2C12:DISTBR*LU(O"O+2,DLR$C?+,5([RO"2OPHP$O_);],_R*^
M3?\@O4W_'[U-_QZ]3?\>O4W_'KU-_Q[_1Q@!_T\3 ?]6$0#_7A4 _V(< ?]E
M) '^92T"]&0X!>UA0PGF7U$.X%Q=%-I8:!K45G(>T%1[(LQ2A";*4(PHQT^4
M*L5.FRS#3J,NP4VL+[],MC"]3,(QNTS3,KA,Z3&V3O@MM%#_*K-1_R>S4O\D
MLE+_(K)2_R*R4O\BLE+_(K)2_R+_2A4!_U,1 /];#P#_8A( _V@7 /]J'P'V
M:R@![&LR ^1I/@?<9DP-TV)8%,U?8QO(7&T@Q%IV),%8?BB^5H8KNU6.+KE3
MEC"V4IXRM%*F,[)1L#6P4;PVKE#+-ZQ0XS>J4O0SJ53_+JA6_RNH5_\HJ%?_
M):A7_R6H5_\EJ%?_):A7_R7_31, _U8. /]?#0#_9Q  _VP3 /MP&0#O<2(!
MY'$L MMP.@71;$@,R6A4%,-E7QN^8F@ANE]Q)K9=>2JS6X$ML%J),*Y8D3.K
M5YDUJ5:A-Z=6JSBE5;8ZHU7%.Z%5W3N?5O WGUC^,I]:_RZ>6_\KGES_*)Y<
M_RB>7/\HGES_*)Y<_RC_4!$ _UD, /]C# #_:PT _W 0 /5T$P#H=AH W7<E
M =%V-@3(<D0,P6Y0%+MK6QNV9V0AL65M)ZUB=2NJ8'POIU^$,J1=C#2B7)0W
MGUN=.9U:ICN:6;$]F%F_/I=9TSZ56NP[E5W[-99>_S&67_\MEF#_*I9@_RJ6
M8/\JEF#_*I9@_RK_4@\ _UP* /]F"0#_;@H ]G0, .]X#@#A>Q( U'P@ ,I[
M,P3!=T$+NG1-$[1P6!NN;&$AJ6II)Z9G<2NB97@OGV2 ,YQBB#:989 XEE^9
M.Y1>HCV17JT_CUV[0(U=S4&,7N@_C6'Y.(UB_S..9/\PCF3_+(YE_RR.9?\L
MCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9?PP S8$= ,1_, .[
M?#\*M'A+$JUU51JH<5XAHVYF)I]L;BN;:G4OF&A],Y5GA#:298PYCV25/(QC
MGSZ)8JI AV&W0H5AR4*$8N1!A63W.X9F_S6'9_\QAVC_+H=I_RV':?\MAVG_
M+8=I_RW_5PP _V$$ /YL P#D=0$ VWL% -. " #0@PH QX4: +Z$+0.V@3P)
MKWU($JAY4AFB=EL@G7-C)IEP:RN5;G(OD6UY,XYK@3:+:8DZB&B2/(5GG#^"
M9J=!@&:T0WYFQ41\9N%#?FCU/']J_S> :_\S@6S_+X%L_R^!;/\O@6S_+X%L
M_R__60L _V,! /1O  #?>   U'\$ ,Z#!@#*AP@ PH@8 +F'*P*QA3H(JH%&
M$:-^4!B=>ED?F'=A)9-U:"J/<V\OBW%W,XAO?C:%;H8Z@FR//7]KF4!\:J5"
M>6JQ1'=JPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P?'#_,'QP_S#_
M6P@ _V8  .=R  #:>P  SX(# ,F'!0#$B@8 O(P5 +2+* *LB3@'I85$$)Z"
M3AB8?U<>DWQ?)(YY9BJ*=VTNAG5T,H)T?#9_<H0Y?'&-/7EPET!V;Z)"<VZO
M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
M?;@  '&^!@!NOQ4 :K\F 6:_,P-AOC\'7;Y("UF]40]5O5D34;Q@%TZ\:!I+
MNW$=2+M['T6ZAR)"NI0D0+JB)CZZLR8]NL@F/;KH)CVX^24]M_\D/;;_(SVV
M_R,]MO\C/;;_(SVV_R/'B   N94  *R=  "AI   EJL  (JR  !_N0  <[\!
M &C&!0!@R@X 7LH= %O*+ %7RC@#5,I#!5#*3 A-R54+2LE=#D?)9A%$R6\4
M0<EY%C_(A1@\R),:.LBB&SG)LQPXR<D<.,CH'#?'^1PWQ?\<-L3_'#;$_QPV
MQ/\<-L3_'#;$_QR^D0  L)L  *2C  "8J@  C+(  ("Y  !TP   :,<  %W-
M!0!3TPH 3]<2 $W8(@!+V#  2=@\ D;81@-$V4\$0=E8!C_980@\V6L*.MEV
M##?9@@XUVI /--J@$#+:L1$QV\<1,=KG$3#8]A(PUO\3+]3_$R_4_Q,OU/\3
M+]3_$R_4_Q.SF@  IJ$  )JI  "-L0  @+H  '3!  !HR0  7,\  %+5 P!(
MW @ 1>42 $/E'@!!YBH /N8U 3OG/@$YYT<"-^=0 S3H600RZ&(%,.AM!B[I
M>0<LZ8<(*^J6"2GJIPHHZKH*)^O6"B?I\ HGY_T))N;_"B;F_PHFYO\*)N;_
M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
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M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
MQ#Q- < \6 *\.V$#N3MJ!;8Z<@:T.GH'LCF!"+ YB FO.9 *K3B8"JLXH0NI
M.*H,J#BV#:8XQ0VD.-X.H3GQ#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ
M_PG_.P( _SX  /=$  #F1P  WT@! -I&!@#90 L S4(9 ,5$*P"^1#L N41(
M ;5#4P.Q0EP$KD)E!JM!; >I0'0)ID!["J0_@PNC/XH-H3Z3#I\^G ^=/J40
MFSZQ$9H^OQ&8/M02EC_M$90__ ^30/\.DD#_#))!_PN20?\+DD'_"Y)!_PO_
M/0  _T,  .E)  #>3@  TT\  ,U. P#*20@ PDD4 +M*)@"U2S8 KTM# JM*
M3@.G25<%I$A@!Z%'9PF>1F\*G$9V#)I%?0Z8184/ED2.$)1$EQ*20Z$3D$.L
M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
M09,J $"3-  _DST /9-% #N330$ZDU8!.)-? C:3:0,TDW4#,I*#!#"2DP4N
MDJ0&+9*W!BR2T08LD>\&*X__!BN._P8KC?\'*XW_!RN-_P>S>   IX(  )R(
M  "1C   AY   'J3  !ME0  89<  %69  !)FP  /YP! #F=#@ WG1< -IXB
M #2>+  SGC4 ,IX^ #&>1P PGU  +I]: "V?9 $KGW$!*9Y_ B>>D (FGJ$"
M))ZU B.>S@(CG>X#(YO^ R*:_P0BF?\$(IG_!"*9_P2L@0  H(@  )6.  "+
MD@  ?Y8  '*:  !EG0  6:   $ZC  !"I   -Z8  "ZH!0 IJ0\ **D8 ">J
M(@ FJBP ):HU "2J/P CJD@ (JM3 "&K7@ @JVH 'JMY !VKBP ;JYT &JNQ
M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
M25A$ $A82P!'6%, 15A; 4189 %"6&X!0%A[ C]8B0(]6)D#/%BJ SM9OP,Z
M6> #.ECW SI8_P,[5_\#.U?_ SM7_P.\5   KEP  *-C  "99P  D&D  (5I
M  !Y9P  :V(  &!@  !570  3EL, $M;% !)7!\ 1UPH $9=,0!%73D 0UU!
M $)=2 !!7E  0%Y8 #Y>80$\7FP!.UYX CE>AP(W7I<"-EZI S5>O0,T7]T#
M-%[U S5=_P(U7?\"-5S_ C5<_P*X60  JF$  *!G  "6;   C&X  (%N  !V
M;   9VD  %QF  !19   2&() $1B$0!"8AL 06,D #]C+0 ^8S4 /60] #QD
M10 [9$T .615 #AD7P V9&D!-61V 3-DA0$Q994",&6G B]ENP(N9=H"+F3T
M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
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M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( (<!  ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MP%H=QMW*#K$\;=CR+<'Z8+_4+_>%>\?M)_&>'X%_">_UH[&OG_T;3XFZ2W#
M[<CN% +'V4U^:FIZE<:SJ-Q>74TEQ=74C2S2R-N:1V.2Q/<DG-?C?BMQ;+"4
M%E.%=IU%>;72/;UEU\O4\S,<3R1]G'=_D>L_L1_"(?%;XXV+7,7F:7H(_M&Z
MR,JY4CRT/U?!QW"M7Z(5X%_P3O\ AF/!WP1.L31[;SQ-.;@DC#"!"4C'Y[V'
MLXKWVOHO#/)%E^2PJ27OUO??H_A7_@-GZMF^!H\E)=WJ%%%%?H1V!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?E?\ \%4_
MAW^TI^P1JUS\5O@[\5OB!JOP[9_,U/2=4U!]</AMBWWMMWYN^U).-QRT? )*
MX(\[_9*_X.;];TR]M=+^,_A&UU2Q8K&^N>'5\BZB'=Y+9V,<F3@GRWCP <*Q
MXK]BM;T6S\2:->:=J%K!>Z??0O;7-O.@DBN(G4JZ.IX964D$'@@U_.!_P5Y_
MX)^R?L"?M1W&GZ7#<-X%\5*^I^')W!(CCW?O;0MW>%B!U)*/$QY8U]ADL\+C
MX_5<7!<Z6DEHVO5=5^)SUN:'OQ/Z%?@-^T)X+_:=^'=IXK\!^(M/\2:'=_*M
MQ:O\T3X!,<J'#Q2 $91P&&1D<BNTK^6_]B7]N3QU^P?\7[7Q5X-OW^SLZKJF
MD32-]BUF 9S'*H[@$[7'S(3D=P?Z+?V</VVO!W[47[*\?Q6\-7&_2H[.6:^M
M)&'GZ;<PQ[Y;67T=>.>C!E89# GR,^RAY:G6;O3[]K:Z_P!:E4ZRFM3YR_X*
M'_%IO&WQ?70+>0MI_AB/RF /RO<. TA_ ;5]BK>M>%:#HL_B/7++3[5=US?S
MI;1+ZN[!5'YD4:]K=QXEUR\U&\D\RZOYWN)G_O.[%F/YDUZ5^Q1X3'B[]I3P
MW&X_=6,KW[\=/*1F7_Q\)7\.8C$5<^SSGGO6J)+R3:27R5E\CYV4G6K7?5GZ
M%^%?#MOX0\,:=I-JNVUTVVCM8AC^%%"C]!6A117]CTZ<814(*R6B7DCZ@***
M*L HK\<_V]/C]XP@_;"\?V^F^+/$EC8V>IM:Q6]MJL\<47EHL9"JK #E3P!U
MKR+_ (:#\??]#OXO_P#!S<?_ !=?FN*\1J5&M.E[!OE;5^;>SMV/WC+O O%8
MK"4L5];C'GC&5N1Z<R3MOTN?O317X+?\-!^/O^AW\7_^#FX_^+K[=_:S^(OB
M'X?_ /!*_P"$<T.O:U;Z]K=S9SRWJW4T=U-%);7,QS(&W$?-'U/(P<>G5@>/
M*>(IUJGL6E3CS?%OJE;;K<\W./!S$8"OA<.\3&3KSY%:+5M&V]]4K'Z&45^1
MO_!-+XF^,O'W[:W@O3]0\6>)KZPWW4]Q#/J<TL3JEI,X#*S$$%@HZ=Z^U/\
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MG?Y^/>N/,*GL\+4J/I&3^Y'H910]MCJ-%?:G%??)(_#FOT1^'G_!$[P_XP\
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MKEYIUVGEW5A.]M,G]UT8JP_ @UZE^PWXK'A7]I;0-[[(=2\VQDY^]OC.P?\
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M\ T8X)X-U7K)2O9=$U;\3[JMXR8N>;0S58:-X4Y04>9M>]*+;O9:^[8^!?\
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MH_\ !7GX.>/?BS^U!I]SX?\ !7B[7M,T_0+>T6YT[2+FZ@+^=/(PW(A7</,
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MZZ>D%%%% !7P9_P6&_Y.O_8A_P"ROP_^D[5]YU\&?\%AO^3K_P!B'_LK\/\
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MR<$[6,%U)-;3Q[ASM>*1@1T/RGJ!72?LK?\ *<C]K#_L4_!O_HBZH_X+J?\
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MV"?^"5_B+_@GUX\^)_AWPAXNT&;X(>.FEU"QT>ZTZ:77=/OWMH+?+W9EV21
M1,3E-SEP21@Y**FXSA?V5O\ @E3\=/\ @F3\)M+TG]G_ .)'PZU::\M5_P"$
MIT+QMI-Y'HNJ:@A95U&UDM9#-:3/"(8I%(D1_*5\9&*];_9'_8"\>:)^U%J?
MQZ^/GCK1_'?Q2FTHZ#H5AH%E+8^'O"%@Q#S16D<C-)))*XRTLGS8RO(Z%%4(
(^MZ*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20201231_g14.jpg
<TEXT>
begin 644 biib-20201231_g14.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!<17AI9@  34T *@    @ ! ,"  (
M   6    /E$0  $    ! 0   %$1  0    !   7$E$2  0    !   7$@
M  !0:&]T;W-H;W @24-#('!R;V9I;&4 _^(,6$E#0U]04D]&24Q%  $!   ,
M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@
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M,"#P?4'U![BK_LZ,H7C*_P"1'UZ2E:4;'UA/J%E:S1PW%Y;PRR?<224*S=N
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MCF?;\O\ ,.5=_P RQ15?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFCF?;\O\
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20201231_g15.jpg
<TEXT>
begin 644 biib-20201231_g15.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        !(     0   $@    !  .@ 0 #     0 !  "@
M @ $     0   2R@ P $     0   %<     _^T .%!H;W1O<VAO<" S+C
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M\SGP;9Q$0>4]-BQPN=N+IMXWRX'H&NCNGJ.G]L;H^'#TT)8A*5\NSH_\=S#
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M0A#R'#[J6_A;E*/#IP\U$47\.3-=[FH&\IKX9#D0KV[U<1( 2#'>6$ <@B/
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M=!#P '/B4%D_,:"(EQQXL%"01(A_7_'".J Q> A?[O !\!_%"8HJH9F0Z^*
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>Q5X9LX" 0E6/-E!(M0E%Z#W<0B< C(X&_P#[(?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20201231_g16.jpg
<TEXT>
begin 644 biib-20201231_g16.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^_9:WC/HS\ZS#()X=.MA/?ANX]5Z=SVY'5P&4@J1D$<@CVK4^&:<79Z-=!U
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MH0!V/>L)QMJC]1R+,_:Q^IXF7O17N2;W7:YXC_9]S_SRD_[X;_"LC[?VE/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P!V/)_I5G@2WT.OH)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y+QIX9C\4:;):$8E W1-
MW#CD#Z'O4M75CU\NQDL!7C67P[27D_\ (^(K^QETV=[:=2DD3%6!]17+MH?N
M5.I&M"-6F[QDKHI]*1H>F>!OB-=>%'$$N9K-C\R$\K[IZ?2M(RY?0^:S+*:>
M8+VD+0K+9]'ZGU+H/BW3?$48>SF4L1DQDX9?8BMTT]C\JQ.!KX*3C6@TNDK:
M,Z4'TJCS-@H :SJ@RQ"@>IQ0-)O1(\[\3_$S2_#R,L;BYN.0(T.<'MN/I4.2
M1]'@LGQ&,:;BX4_YI:77D?(OBOQ%>>*;IKN\;/9$'W47T K"]S]%I8"G@J?L
MJ2]7U;.,EBJC@JTCUOX.>!FU_4QJ%PG^B69#<CAW[*/IU-:1/D,PFJ*Y%\3_
M  /M@#' K0^4"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#Q[XE_#M?$,9U"P4+>1CYE
M' E4=O\ >';UK.4;ZK<^RR?-G@I?5L0[T9/1_P K?Z'RA/;R6KF*52CH<,I&
M"#Z$5S;'ZS&49Q4X-.+U36Q#043P7,MLVZ%VC;U5B#^AH)E&,U:<5)>:N=E9
M?$;7=/4)#<O@>H#?SJ^9H\:IE."JN\Z6OD[%UOBKXA88-R1]%4?THYF8K),
MO^77_DS.<U#Q9JFI_P#'Q<2,/0,5'Z8I79Z-+ X;#_PJ<5ZI,YYG+G+$DGKF
MI/0VT6B[(85S03*-]#IO"7@B[\6W2PPJ5A!_>2D?*H[\^OM6D5?8^7S'$4\#
M!RFUSOX8]3[7\/Z#;>'+-+&S4*D8Y/0L>['W-="5M#\DK595YNI/=_@;5,YP
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2^=CIHWO>]/0X]2[&;GO2T*U+J&3O2 G%(84 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 &* # H ,"@ QB@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^A4]?TS7H+5'F[.W8^SO VO#Q!I4-P3F55"2?[X'-<$X\KL>C!W5SKZS- H
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MES+S.2<>1V6QZ9\%O$7^LTB4_P#32/)Z8X*C\>:QJQ^T;4I?9/H6N4ZPH *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M/S'^\.2,>E>EBY^QKQFDG9;'S&3T'C,!4P[DX\TOBZHD_P"%=X_Y>3_WS_\
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MA^-?+SBX2<'T=C]6HU57IQK1VDDRU4'0% !0 4 % !0 4 % !0 4 % !0 4
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M_(T_'O\ R"G_ -]/YUA@?XR]&>AGW^XS_P 4?U(/ G_()/\ UTE_G5X[^/\
M)&&0_P"X?]O3.1\,?\AQ_J_\S7H8G_=H^B/G,K_Y&53U9Z?XA_Y!UQ_US/\
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MTB5[BY5WD(PN%)QZG/J:Z<51J5DH4](K<\S*L;A\#.5?$:S>WEYG>CX@6?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
8 * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20201231_g17.jpg
<TEXT>
begin 644 biib-20201231_g17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "D A\# 2(  A$! Q$!_\0
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M000I'(Z<+@ZV)J*C0BY2?1?UIZF=2I&$>:;LCZ#=UC1F8A549))X KYN^/\
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M%8G_  N/PC_T-7AO_P &</\ \53C3G)7BFQ<R6YTE%<W_P +C\(_]#5X;_\
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M3KXY_ 'PG^T=X%N/#WB[2;?4[&96\IV4">S<C EA?&8W'J.O0@@D'\3?VO\
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M^:]@')0^K+U7\1W&/4^CCX_XC(\72X5X@J.6#F^6G.3UHR;LHMO_ )=MZ:_
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MB\5&X81*JJL;$<;B6(!.-IP1F_M2_P#!&?5OV>_@EK'C#2?&G_"6-H:K/=6
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MZQ^]?YH_=;0/$%CXKT6UU+2[RUU'3[V,36]S;2K+#.AZ,K*2&!]0:N5^2?\
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MAYUZL:-/XI-)>K=D?7'[*OP07X#_  3L8;J+R_$'B18]2U0E,/"I4^3!_P
M1CD<$.\JGH*^OOV9_A!''9P^)-1AW2,/^)=')SY:\YE(Z9.>/0#/<&O+_!?A
MAOBO\0;.V/F^5=3YGF)_>,B@LY/49Q@9]2#C)KZTM;:.RMHX846.&%0B(HX5
M0, #Z5_G#P#@ZW&O%.,XWSA<T5/]VGJE)6Y4K]*<>6W]YJ2=T?O6?UX9/EE'
M)L([.WO/K;K_ .!.]_+3J24445_2A^;A1110 4444 %%%% !1110!X=^U1\(
ME:!O%&GQA67"W\:C[P/ E^O0'\#V->$5]Q:A80ZK836MQ&LL%PACD1NC*1@B
MOC7Q[X3E\#>,-0TJ7)-G*51C_&AY1OQ4@_C7\7_2 X'IY=CX9Y@XVIUVU-+9
M5-[_ /;ZN_6,GU/V/@+.I8B@\%6=Y4]O\/;Y/\&NQ\"_MK? E?A9X]75M.CV
MZ+K[-(J@?+;3]73V!SN7ZL!]VO%:^_/VP_ !^('P&U=(TW76D@:E!QWBR7Q[
MF,N![D5\!U_<7T9N/Z_$_!L%CI\V(PLG2DWNTDG"3[MQ:BWU<6WJ?D'B)D<,
MNS9NBK0J+F79-_$E\];=$T=]^RW\:)_V>_V@_"?C"&1DCT;4(WN@HR9+9ODG
M3'^U$SCZD5^^5I=QW]K'/#(LL,R!XW0Y5U(R"#Z$5_.?7[<?\$R?BTWQ@_8K
M\%WD\QFOM)MVT:Z).Y@ULQC3)[DQ")CGGYOQK[[Q!P-X4\8NCY7\]5^OWGSN
M3U=94WZGSA_P7)_9EN-8TO0_BGI=NTG]EQC2-:"+]R(N6@F/L'=T8GGYXQT%
M?$G[(/[3.I_LE_'32_&&GQFZMX0;74;/=M^W6CD>9'GL>%93T#HI.1D']V?$
MGARQ\8>'[W2=4M(;[3=2@>VN;>9=T<\;@JRL/0@D5^3G[=/_  2=\3_ G6+[
MQ!X#L[SQ-X)D8R^1"IFOM('4HZ#YI(QVD4$@#Y@,;FSX5SS#5L+_ &7CFNJ5
M]FGTOW73\-45F&%G&I[>E\_\S]0/@A\=_"_[1/@&T\2>$]4AU+3[I1O4$":U
M?&3%*G5''<'ZC(()["OY[?AW\5?%'P<U\ZAX8U[6/#NH+\KR6-R\#.!_"X4C
M<.ORMD>U>R+_ ,%6/C\MA]F_X6%/Y87;DZ38>9C_ '_(W9]\YKGQGA_7]I_L
MM2/+_>NFON3O^!=/.(6_>)W\C]A/C)\:_#/P!\"7?B3Q9JUMI.EV@^](W[R=
M\9$<:=7<XX5<G\ 37XE_MG?M1:A^UU\=]2\674<EK88%II5FY!-G:(3L4XXW
M$LSMU&YVQQBN,^)/Q<\5?&?7EU+Q5X@U?Q%? %8Y+ZY>8Q G.U 3A5S_  J
M/:OIK]B#_@D]XL^/VKV>N>-K2^\)^"D82,LZ&*_U1>#MBC891"/^6C#H?E#<
MD>YE>3X/(:;Q>,J)S:M?](K=M]_RU.3$8FIBY*G36G];GK__  0V_9ENK-]<
M^*FJ6[107$3:/HN]?]:-P:XF'L"JQ@CJ?-';G]&*S_"GA73? WAFPT;1[.#3
M]+TN!+:UMH5VQP1J,*H'L!6A7YGG&9RQ^+EB9:7V79+9?Y^9[F&H*C34$?BO
M_P %0/V9[C]G/]J;6)(;=D\.^+I9-8TJ0#Y!YC9FA'8&.1B,=D:,_P 5=Q_P
M2>_;SL?V9_%MYX/\777V7P;XDG$\=X^3'I5WM"[V Z1R*%5C_"50G W&OTG_
M &J/V6_#7[6WPLN/#/B*)HV!,UA?Q >?IT^"!(GJ.<,IX8<<'!'XZ?M2_L/>
M/_V2M=FC\1:3+<:*9-MKK=FADL;D$_+EO^6;G^X^&X.,CD_HV39GA,XP']G8
MQVG9+S=MI+S[K]#Q<30J8:K[:GM_6C/W.TW4[?6=/@O+.XANK6ZC66&:%Q)'
M*C#(96'!!'((X-35^"7P<_:\^)GP MOL_A'QEK6CV>[>+,2":U#=R(9 T8)[
MD+SWKL_%?_!3SX\>,]*>SO/B)J44,@()LK2UL9,'_II!$CC\#7BU/#[%JI:G
M4BX]W=/[K-?B=4<XIVUB[GZA_M5_\%#_ (?_ +)'B31]'UZXN=1U34I@+FTT
MX+--IL!!_?RKD8&<87.YAD@''/K?PW^)F@?%_P 'V?B#PSJUGK6CWR[H;FV?
M<I]5(ZJPZ%6 8'@@&OP'\(^#/$OQK\<)IVCV.J>)/$&J2E_+B5KB>=B<L['D
M]3DLQP.I-?K?_P $R?V#=2_8]\%W^H>(M4FF\3>(T3[5I]O=,UAIZ#E5VCY9
M)O[TF"!RJG&6?#B#AS Y=A(OVO[WM_-\NB7?]2\'C:M:H_=]W\O\S8_X*T_\
MH^OB!_W#O_3E:U^3W['?_)W'PL_[&_2?_2V&OUA_X*T_\H^OB!_W#O\ TY6M
M?D]^QW_R=Q\+/^QOTG_TMAKW>#?^1-7_ ,4O_2(G)F7^\Q]%^;/WIOK*'4[*
M:VN(HY[>X1HI8Y%W+(K#!4@]00<8K\-OV]/V7IOV3OVC-7\.QI)_8=X?[0T6
M5B6WVDC-M4GNT9#1D]RF>XK]SJ^8?^"K'[*!_:3_ &<[C4=+M?.\4^"Q)J.G
MA!E[B' ^T0#N2R*& '):-0.M?)\(YQ]2QJA-^Y/1^3Z/Y/\ !L]#,</[6E=;
MH\=_X(I_M@_\))X;N/A+KUWNOM)1[S0'E;YIK;.9;<$]3&274<G8S#@1U^@%
M?SS_  T^(NK?"/Q]I/B;0KIK/5M%N4NK:4= RGHP[JPRI'0@D=Z_=S]F;X_:
M3^TW\%-#\9:00D6IPXN+?=EK.X7Y986_W6!P>Z[6Z$5Z'&V2_5\1]<I+W)[^
M4O\ @[^MS+*\5SP]G+=?D>%_\%H?^3(;[_L,67_H35^<O_!.G_D][X;?]AA/
M_06K]&O^"T/_ "9#??\ 88LO_0FK\B/#GB74O!^N6VJ:3J%[I>I6;^9;W=G.
MT$\#?WD=2&4^X-?1<'476R:I27VG)?>DCBS*7+B5+M;\S^B>BOP1_P"&Q/BY
M_P!%3^(W_A2WO_QRC_AL3XN?]%3^(W_A2WO_ ,<KQ?\ B'N(_P"?L?N9U?VQ
M#^5G[W45^&'PJ_:X^*VH_%#PW;W'Q.^(4]O/JEK')')XCO&213*H*D&3!!'!
M!K]SZ^=S[(*F5RA&I-2YK[>5O\SLPF,5=-I6L%?F+_P72^ ']@_$'PW\2+.'
M;;:]%_9.I,H^47,0+0L?]IXMR_2WK].J\D_;F^ O_#2/[+GBOPS##YVIO:F\
MTS^\+N']Y$!Z;R"A]G-9<.YC]2Q].L_AO9^CT_#?Y%8RC[6BX]>A^0'PQ_:N
MU7X9_LM_$#X:VWF_9_&UU:3+*K[?LJH3]H'OYJI"A_V5;UKTG_@D9^SY_P +
MM_:ST_5+NW\[1? Z#6+DL/E,X.+9/KYGS_2%J^771HW*LI5E."".0:_8;_@C
MW^S_ /\ "G/V3[77+JW\O6/'DO\ :TI8?,+8#;;+_NE,R#_KN:_4>*,53R_
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M@%RH!9O=LFNCK%^(WQ$T?X3>!]2\2>(+S^S]%T>$SW=QY3R^4@(&=J*S'J.
M":/AS\1-'^+/@?3?$GA^\_M#1=8A$]I<>4\7FH21G:ZJPZ'@@&N2<:LX^VG=
MJ]KN^_:_<T3BGRK[BQXM\':1X_\ #UQI.O:5INM:3=[?/LK^V2YMYMK!UW1N
M"K89589'!4'J*Y/1_P!E3X7^'=7M=0T_X;^ ;&_L9DN+:YM_#]I%-;RHP9'1
MUC!5E8 @@@@@$5WU%$,15A'EA)I>38.,6[M!1116)1YW-^R%\)KB9I)/A?\
M#N220EF9O#=F68GJ2?+KJ/ ?PS\-_"S2Y;'PQX?T/PY93RF>6WTNQBLXI)"
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MNI-&9HX,G SNCC7OT+@GL#7TI\&OC;X7_: \#6_B/PCJUOK&DW!*>9'E7A<
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M .W_ (UY2MT/N\_I0CBO:4_AFE)/R>R^7P_(****^X/$"BBB@ HHHH ****
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M>#/$T%TB/#>:=.&,<BE2&4_,C#K@\J0>Q(KZ,/B*R_9=^,4?B#3;%M4^%WQ
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M)[<X*GAA[@$?.?AKX*_M;_LY6::%X5\7>#/'WANT416#ZTK)<V\2\*K9PPP
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ME>BVTLDEHK66Q:P\$DET=PKP']M#]@W2_P!JB73?$&F:I<>$?B!X?VG3-=M
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M 3L/(85M(^/NN>$M9_M+PG=6%XUQ)YES!%:?9)+O_KXLU)BW8'W[;!QRS9)
M_%O$SP-S'.,+*OP[BG1K2C:4)-NC57]Z+3Y)_P![EWW7,Y3/L.'.,,/A*BAC
MZ7/!.ZDOCCZ-6NO*^W6UD?HIX9^._BCPGA+;59YK=>!%=8G4#TRW(_ BNZT7
M]LN^A55U#1;6X/=K>9HOT8-_.OC/]GK]KNQ^-]V^GS:7-INJ01>8X6=)(I1T
M.P$B0GO@*V!U->MVNIV][(T<4T;R)]Y,_.GU7J/QK^&,RSCQ X(QLLJQM:I2
MG32;C)QJ12>S5^>*3Z6/VBA@LASFBL52A&2EU2<7?SM9W]3Z1M?VQM"<?O\
M2]6C]=@C?^;"DN?VQ]#7=Y.EZK)Z;_+7/Y,:^=J*V_XCWQ?R\OM87[^SC?\
M*WX&?^HN47OR/_P)GM&N?MDWTZ,NFZ-:VS= ]Q,9OQP O\S7G/C'XK^(/'F5
MU+4II83_ ,L$Q'%_WRN ?J<FN=K-E\7:>K,L5Q]LD1MK1VJFX=#_ +00';]6
MP*^3S?CKBG/HNEB\34J1ZQC[L?G&"2?S1ZF$R/+,"U*E3C%]&]7\F[O[C2K'
M\:>-K3P1IJS3I/<W$[>7:V=LGF7%Y)_<C7OZDG 49)( S61XU\>MX;TQKG4M
M0TWPG8]//O94DN7]0D8)3=W!W/[I7DWB3X^V]E827WA]DT6SO(R'\5^(59I[
MQ1VL[;'F3<]-JK$C?>"@YKZ'P_\ "7.>),1'ZI0=6%]6G:GZ2K6<5_AA[2H[
M64$]5QYYQ1A,OIOVLU%^>LOE#=^LN6/6YN>-?$MSI.MZ??>(;,:YXRNB6\.^
M$+%O/2S?G$TA ^9U ),IPJ@-L'!:O!?C1\8FT9M5T^QU9-:\4:Y&;;Q'KD!!
MMXXLY_LZQ8$_Z.,8DE&/-(PI\O+2\UX[^-KWG]HVGA]]2MX=54QZGJE[+NU3
M6U/\,K*<10G _<1G;P [2E58>?5_I?X7^$>$X7HJO7M/$.*BVH\L81O?V=*+
M;<::>KNW.I+]Y5DY64?YWXDXHJYE/DA>-.][-W;>W-)]96T6B45[L4EN5^B'
M_!'+]A![R^M_B]XLL2L%N3_PC-I.G^M?HUZ0>R\B//4Y?C:A/GO_  37_P""
M9%[^T%J%CXX\;6\MCX&M9EEMK.1"LNOE><#H5@SC+?Q\A>[#]8+"P@TJQAM;
M6&&VM;:-8H88D"1Q(HPJJHX     X %?0<8<31C"6 PK]YZ2:Z+LO-]>VV^W
MFY;@6W[:IMT_S)J***_+3W@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20201231_g18.jpg
<TEXT>
begin 644 biib-20201231_g18.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P 8H^N4?YG_ . 3_P#D0^L4OYOPE_D'_"56'_3Q_P" EW_\8H^N4?YG_P"
M3_\ D0^L4OYOPE_D'_"56'_3Q_X"7?\ \8H^N4?YG_X!/_Y$/K%+^;\)?Y!_
MPE5A_P!/'_@)=_\ QBCZY1_F?_@$_P#Y$/K%+^;\)?Y!_P )58?]/'_@)=__
M !BCZY1_F?\ X!/_ .1#ZQ2_F_"7^0?\)58?]/'_ ("7?_QBCZY1_F?_ (!/
M_P"1#ZQ2_F_"7^0?\)58?]/'_@)=_P#QBCZY1_F?_@$__D0^L4OYOPE_D'_"
M56'_ $\?^ EW_P#&*/KE'^9_^ 3_ /D0^L4OYOPE_D'_  E5A_T\?^ EW_\
M&*/KE'^9_P#@$_\ Y$/K%+^;\)?Y&U:W45Y$EQ VZ.55=#@C*L RG! (R"#@
M@$=QFNV,E-*<=4TFO1ZHZ4U)*2V:NOF<9XID*W5H.PF8_P#DO<#^M>9COX</
M\:_])F<&+^!?XE^3*GFBO!/&#S10 >:* #S10 >:* #S10 >:* #S10 >:*
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MMNG%::;6;T_$SHT8U%!MN\IRCI;HFUT\B6*RLY?)*R3 7081@A,AESDMVQZ
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MT4 'V2+^Z* #[)%_=% !]DB_NB@ ^R1?W10 ?9(O[HH /LD7]T4 'V2+^Z*
C#[)%_=% !]DB_NB@ ^R1?W10 HM(O[HH O1(J#"C H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20201231_g19.jpg
<TEXT>
begin 644 biib-20201231_g19.jpg
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEI>NSZW9;[W3H)W_ -$QR\:L>,\=:TOL7C?_ *#=E_X#'_&HOA=_R3/P[_V
MK3_T2E;M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
M8_V+QO\ ]!NR_P# 8_XU5BN/&,VK2Z0NKVH>&)9&8VW!!_&NBK'LO^1WO?\
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M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C572+CQCK%LUU!J]JH65HR'MN<J<>M=
M%6/X'_Y!$O\ U^S?^A4 'V+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &79VGBU+I'OM6M7B
M#?O$2W()'L:U*** "BBB@ HHHH R? G@/P7\,/"&G^ /AWX7LM%T32K<0:;I
M6FVZQ06T8)(1$7A1DG@>M:U%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P
M"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_
MR3/P[_V K3_T2E;M !1110 4444 %%%% !1110 5CV7_ ".][_UY1?S-;%8]
ME_R.][_UY1?S- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7Z?\ T$UL4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XE_P"0
MOH__ %^G_P!!-;%8_B7_ )"^C_\ 7Z?_ $$T ;%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!F^,?^18O?\ K@:N:=_R#X/^
MN*_R%4_&/_(L7O\ UP-7-._Y!\'_ %Q7^0H FHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *S?&/_ "+%[_UP-:59OC'_ )%B]_ZX
M&@"YIW_(/@_ZXK_(5-4.G?\ (/@_ZXK_ "%34 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6/X'_P"01+_U^S?^A5L5C^!_^01+
M_P!?LW_H5 &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^
MAK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%
M% !1110 4444 %8]E_R.][_UY1?S-;%8]E_R.][_ ->47\S0!L4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XE_P"0OH__
M %^G_P!!-;%8_B7_ )"^C_\ 7Z?_ $$UL4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !6/XE_Y"^C_]?I_]!-;%8_B7_D+Z/_U^
MG_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%8_B7_D+Z/\ ]?I_]!-;% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V
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M0T;PEJFHZ9X?NF;8(;V^M;:2WMW#?*RL^8V!#[,&@#ZYHK"N/B?\.+7X;/\
M&2X\>Z.GA%-$.L/XG;4HOL T[RO.^U^?N\OR?*_>>9G;MYSCFOF;X%?\%RO^
M"9/[1GQ?T;X)?#/]H2<ZOXGNWM?"%WK?A'5-,T_Q%.AVM%8WEW;1P7#[OE55
M?+D@(&R* /K:BBB@ KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]
M#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH ***
M* "BBB@ HHHH *Q[+_D=[W_KRB_F:V*Q[+_D=[W_ *\HOYF@#8HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q+_P A?1_^
MOT_^@FMBL?Q+_P A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Q_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_^@F@
M#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2'\-_$[X4_LI?M5_\%'(OA;<^ ]$^,_BW7?B'\+_  #=6HCFL]*ALI&M;R6
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M=_R3/P[_ -@*T_\ 1*5NT 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44
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M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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MZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\
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M3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H **** "BBB@ HHHH ****
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M8O?^N!K2K-\8_P#(L7O_ %P- %S3O^0?!_UQ7^0J:H=._P"0?!_UQ7^0J:@
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MC0C2N[WD]V]W_DO(****ZS8*Q_ __((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\
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M_(L7O_7 U<T[_D'P?]<5_D*I^,?^18O?^N!JYIW_ "#X/^N*_P A0!-1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F^,?^18O?\
MK@:TJS?&/_(L7O\ UP- %S3O^0?!_P!<5_D*FJ'3O^0?!_UQ7^0J:@ HHHH
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M#IA3A2BHQ5D@HHHK4L**** "L?P/_P @B7_K]F_]"K8K'\#_ /((E_Z_9O\
MT*@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#NOA=
M_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@
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M*LWQC_R+%[_UP- %S3O^0?!_UQ7^0J:H=._Y!\'_ %Q7^0J:@ HHHH ****
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MQHSKOFK;=(]/GW?X+\0HHHKU#K"BBB@ HHHH **** "L?P/_ ,@B7_K]F_\
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M** "BBB@ HHHH **** ,WQC_ ,BQ>_\ 7 U<T[_D'P?]<5_D*I^,?^18O?\
MK@:N:=_R#X/^N*_R% $U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6;XQ_Y%B]_ZX&M*LWQC_P BQ>_]<#0!<T[_ )!\'_7%?Y"I
MJAT[_D'P?]<5_D*FH **** "BBB@ HHHH *J:YKNC>&=(GU[Q#JD%E96L9>X
MN;F0(D:^I)_R:P?BG\7_  =\(](2_P#$ES)+=73>7INE6:>9=7LO0)&@Y/)
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MY"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_ -!- &Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 9OC'_D6+W_K@:N:=_R#X/\
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M44 %8_@?_D$2_P#7[-_Z%6Q6/X'_ .01+_U^S?\ H5 &Q1110 4444 %%%%
M!1110 4444 %%%% !1110 444C,J*7=@ !DDG@"@!:*XW]GWX[> ?VF?@WH'
MQU^&%Q<2Z%XDL1=:<;R(1S!"2,.@)VMQTS7BW[7_ /P61_X)G?L%^.'^&?[5
MO[5^C>%_$<4$4\V@QZ7?ZC>11RC=&[PV-O,Z!E((+ <<]* /INBLRS\9>'-0
M\&1?$&SU$OI$^F+J,5V(7&ZV,?F!]A&_[ASMQN[8SQ7Q%)_P<R_\$3HD:67]
ML._55!+,WPG\5  >I_XE= 'WA17AVD_\%(?V,-<_8C?_ (*-:;\8G?X-)83W
MK>,7\-:DA\B&\>RD?[&UL+L@7",@_<Y8#<,J0Q\B^$7_  <&_P#!(WX[_%'P
MY\&/A7^U->ZGXD\6:U;:3H&GM\,_$ENMU=W$BQ0QF6?3DBC#.RC>[*HSDD#F
M@#[.HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH
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M<UO]DGQAH=I=Z2T<^K7UQ 8;5=R_.X4YQ]/6OK:O*/VY_P#DT?Q[_P!@%_\
MT-: .@^%?B?6&^&'AQCX.O03H-F2"R\?N$K?_P"$EU?_ *%"]_[Z6HOA=_R3
M/P[_ -@*T_\ 1*5NT 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\
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M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#E
M-<US49]1TV23PW<QF.Y+(C,N9#MZ"M/_ (275_\ H4+W_OI:/$O_ "%]'_Z_
M3_Z":V* ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?
M^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^E
MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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M%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M6'CLM7Z_\!?F=)\(/%VD> _B;HOB[7]'@O[*ROT>[MIX1(#&>"P4]64'<O\
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MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
MHE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%%% !6/9?\CO>
M_P#7E%_,UL5CV7_([WO_ %Y1?S- &Q1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?
M_036Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_R")?\ K]F_]"H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ K'\2_\ (7T?_K]/_H)K8K'\2_\
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MZV_X;I_97_Z*E_Y1+[_XQ6;X5_;:_9BTW3I(+WXF;':YD<#^Q;T\%L@\0U\
M45]Q_J'D_P#S\J??'_Y$^-_UVS7^2'W2_P#DC]*/ O[5_P  ?B7XJM?!/@GQ
M[]MU.]W_ &6V_LJZCW[$:1OFDB51A58\D=/6O1*_.[]A;_DZCPM_V_?^D-Q7
MZ(U\/Q-E&&R;'QH4&VG%2]ZU[WDNB78^RX=S3$9M@I5JR2:DUI>UK)]6^X44
M45\Z>\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?
M^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %8]
ME_R.][_UY1?S-;%8]E_R.][_ ->47\S0!L4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &/XE_P"0OH__ %^G_P!!-;%8_B7_
M )"^C_\ 7Z?_ $$UL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6/XE_Y"^C_]?I_]!-;%8_B7_D+Z/_U^G_T$T ;%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F^,?\ D6+W
M_K@:N:=_R#X/^N*_R%4_&/\ R+%[_P!<#5S3O^0?!_UQ7^0H FHHHH ****
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M3XWB[$U*^6P_=N,>=:RT;]V7V=_OMZ'GE%%%?IQ^='K?["W_ "=1X6_[?O\
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M?5FU*E"C#EC_ ,/YOS"BBBMS0**** "LWQC_ ,BQ>_\ 7 UI5F^,?^18O?\
MK@: +FG?\@^#_KBO\A4U0Z=_R#X/^N*_R%34 %%%% !1110 4444 %%%% !1
M110 445SOC_XM_#3X6V?VWQ_XUL-,4KN2*>;,L@_V(UR[_\  0:NG2J5IJ%.
M+;?1*[(J5*=*#G-I)=7HCHJ*\>/[0_Q.^(_[CX _!.^NK=^$\1>*B;&RQ_?1
M#^\F7_=P?:@_LY?$3XC'S_V@?C5J&H6[\OX=\- V%CC^X[#]Y,ONV#[UZ']F
M^QUQ510\OBE_X"MO^WG$X?[0]KIAJ;GY_#'_ ,">_P#VZI'0>/?VH/@UX!O?
M[$N/$_\ :NK,VV/1= B-Y=._]S;'D*WLQ6N?_P"$Q_:L^*?R>"? 5AX#TQ^F
MI^)W^T7Q7^\ELGRHW^S)Q[UZ#X#^%7PX^&%E]@\ ^#+#2T*[7>V@'F2#_;D.
M7?\ X$3704?6L#A_X%+F?\T]?NBO=7SY@^K8VO\ QJG*NT-/OD]?NY3R;2OV
M1_"&IW\>O_&;Q7K'CK4HVW*VMW)6TB;_ *9VR$(H_P!D[A7J&D:+H_A_3X])
MT'2;:QM8AB*VM(%CC0>RJ !5FBN;$8W%8JRJS;2V6R7HEHODCHH83#8:_LHI
M-[OJ_5O5_-A7G?CK]E#X _$OQ5=>-O&W@+[;J=[L^U7/]JW4>_8BQK\L<JJ,
M*JC@#IZUZ)148?$XG"SYZ$W![7BVG;MH77P^'Q,.6M!26]FDU?YGDG_#"W[*
M_P#T2W_RMWW_ ,?K-\*_L2_LQ:EITD][\,][K<R(#_;5Z. V .)J]MK'\#_\
M@B7_ *_9O_0JZ_[9SC_H(J?^!R_S.7^R<J_Z!X?^ 1_R.3\"_LH? 'X:>*K7
MQMX)\!?8M3LM_P!EN?[5NI-F]&C;Y9)64Y5F'(/7UKT2BBN3$8G$XJ?/7FYO
M:\FV[=M3JH8?#X:'+1@HK>R22O\ (****P-@HHHH **** "BBB@ HHHH ***
M* "BBD9E12[L  ,DD\ 4 +17&_L^_';P#^TS\&] ^.OPPN+B70O$EB+K3C>1
M".8(21AT!.UN.F:\6_:__P""R/\ P3._8+\</\,_VK?VK]&\+^(XH(IYM!CT
MN_U&\BCE&Z-WAL;>9T#*006 XYZ4 ?3=%4_#VO:3XJT"Q\4:#=^?8ZE9Q75E
M/Y;+YD,B!T;:P!&5(." 1GD5\2:M_P ')_\ P1<T36;W0-0_; O!=:=>RVEX
MD/PM\42JDT3E'7<FF%6PRD9!(XX- 'W/17*Z%\;OA3XA^"=E^T=9^-K2W\$7
M_A>+Q'#XBU0-901Z7);"Y6ZE^T!&@00D.WF!2@SN"D$#YS^!7_!<K_@F3^T9
M\7]&^"7PS_:$G.K^)[M[7PA=ZWX1U33-/\13H=K16-Y=VT<%P^[Y557RY("!
MLB@#ZVHHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH [K
MX7?\DS\._P#8"M/_ $2E;M87PN_Y)GX=_P"P%:?^B4K=H **** "BBB@ HHH
MH **** "L>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F: -BBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$O_(7T?_K]/_H)
MK8K'\2_\A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M78:$U.:<Y=Y.[^71?)(****\\[@HHHH **** "BBB@ K'\#_ /((E_Z_9O\
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MCX.O03H-F2"R\?N$K?\ ^$EU?_H4+W_OI:B^%W_),_#O_8"M/_1*5NT 8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8_
M_"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM9EKK
MFHKXINKI?#=RSO;1JT 9=R@$\FNKK'LO^1WO?^O*+^9H /\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
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MYD.WH*ZNL?Q+_P A?1_^OT_^@F@ _P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M+W_OI:/^$EU?_H4+W_OI:V**W-#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M^@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Q_$O_(7T?\ Z_3_ .@FMBL?Q+_R%]'_ .OT_P#H)H V**** "BBB@ HHHH
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MZ<8W8],"O0J**Z\/AZ6%I*G36GXM]6WU;ZLVI4H48<L?Z\WYA1116YH%%%%
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M **** "BBB@ HHHH **** "BBB@#'\2_\A?1_P#K]/\ Z":V*Q_$O_(7T?\
MZ_3_ .@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOH__ %^G_P!!-;%8_B7_ )"^C_\ 7Z?_ $$UL4 %%%% !1110 4444 %%%%
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MB]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#X/\ KBO\A4U !1110 4444 %%%%
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MB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\
M8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H ****
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MD!37IE%%=F'PM#"PY::M?=[MONV]6_-G12HTZ,;07^;]7U"L?Q+_ ,A?1_\
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M.&'BZC\MEZR>GR5WY'3?$?\ :4^%7PVO_P#A'[K5Y=6UQVVP^']!@-W>2/\
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M#_\ ((E_Z_9O_0J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**J:%K^A>*='M_$/AC6K34;"[CWVM]87*S0S+_>1T)5A[@U;H ***IOXAT"/
M65\.OKEFNH/'O2Q-R@F9?[P3.XC@\X[4 7**** "BBB@ KRC]N?_ )-'\>_]
M@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[
M_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@ HHHH *Q[+_D=[W_KRB_F:V*Q
M[+_D=[W_ *\HOYF@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.
MT_\ Y\8?^_0H_L[3_P#GQA_[]"@#G]>\2Z#<ZGIDT&J1,L-T6E8'[HV]36I_
MPF/AC_H-0?\ ?55/$=E9IJNDJEI$ UX0P$8Y&TUK_P!G:?\ \^,/_?H4 4_^
M$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG_P#/C#_WZ% %
M/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?V=I_
M_/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G
M:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JR_B)\0/AI\*M&.N>
M.M3L[*)LB"-HPTL[?W8T W.?H..^!7GHM_C3^T%_QXZ?)\/O"4O_ "W>%?[8
MOX_]D=+92._WNXW UQ8C'4Z,_903G/\ E6_J^D5YNWE<YZF(A"7(ES2[+]>R
M]3H/B-^T]X \%W0\.>'A+XC\02\0:)I/S,#ZRO\ =B4=R>0.<8KEK3P#K'Q@
MNH]>_:1\=6_V)7$EMX)T6X9+.+'(^T2#YIV'IG /0X.*]*^'GP=^'/PMTG^R
M?!_AF"'?S<74J^9/<-_>DD;YF.><=!G@"NA_L[3_ /GQA_[]"L5@JV*?-C'=
M?R+X?GUG\[1_N]2/83K:UW=?RK;Y]_GIY&5I.M> ]!TZ'1]#N+&SM+=-D%M;
M1A(XU] JC %6?^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A
M7I)**LCJ225D4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_
M9VG_ //C#_WZ%,93_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^JR]>\2Z#<ZGIDT&J1,L-T6E8'
M[HV]370?V=I__/C#_P!^A61XCLK--5TE4M(@&O"& C'(VF@"W_PF/AC_ *#4
M'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#
M4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/A
MC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H
M I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0KGO%WQ(^$/@
M(-_PF7C'0M-9>L-W=Q)(?HF=Q_ 5=.E4JRY81;?9*Y$ZE.E'FFTEYZ&K_P )
MCX8_Z#4'_?5'_"8^&/\ H-0?]]5YC-^UQ\)-4F:T^&O@WQ#XPF!*X\/>')'0
M-[O($ 'OR*9_PF7[4WC'CPA^S_X?\-PM_J[OQ9JPE8CU,-N-RGV-=ZRG&Q_B
MI4_\;47]S=_N1Q?VI@Y:4VY_X4Y?BE;[V>H_\)CX8_Z#4'_?50:A\1/ VDVY
MO-5\565M"O66XG"*/Q/%>:_\*$^.OBX[OB)^T7-90M]ZP\(:-%9[/7;.V9#^
M(J]HW[&/P&L+I=2\0:!>^(KT=;SQ%JDMR[?520A_[YH^K9?2_B5[^4(M_C+D
M_"X?6,=4_AT;?XY)?A'F_0F\0_MD?L[:!,;.+X@1ZI=$XCM=%M9;II#Z QJ5
M_P#'JPI?VK?'/B4^7\,_V?-8E1N%O/$U]#IJ*/[VQBS,/I@UZOH/@7P3X6M_
MLGAGP?I>G18QY=CI\<2_DJBK_P#9VG_\^,/_ 'Z%'UC+:7\.BY?XY/\ */+^
M;#V&85/CK*/^&*_.7-^2/%OM?[47C+G6OC%X.\(0/_RST+2WOIU'H6N,+GW6
M@?LY?#7Q#^\^*_QI\4^+2W^LM=0UQXK4_P"[%%MVC_@5>T_V=I__ #XP_P#?
MH4?V=I__ #XP_P#?H4?VMBX?P;4_\,4G_P"!6YOQ#^S,++^+>?\ BDVON^'\
M#A?"'PV_9Q\![7\)^#- M)$^[<?8U>8?]M'!?]:_-.OUF_L[3_\ GQA_[]"O
M*O\ AA;]E?\ Z);_ .5N^_\ C]?0<-\24<KE6EB^>;GRV:UVYKWNUW/#X@X?
MJYE&E'"\L%#FO?3>UK63['YW45^@?B7]B+]E_3]"NKVT^&.R6.(E&_MJ].#]
M#-5JR_8:_9:ELXI9/A=EFB4L?[;ON21_UWKZC_7S)_\ GW4^Z/\ \D?-_P"I
M.:_SP^^7_P B>/\ _!,;6-+TG_A-_P"TKU(?,_LW9O/7'VK/\Q7U;_PF/AC_
M *#4'_?58/PR^ 7PC^#OV[_A77@]+#^T?*^V;[N:?S/+W[/]<[[<;VZ8SGG.
M!75?V=I__/C#_P!^A7YYGN/HYGFM3$TDU&5K7WTBET;[=S[S)<%5R[+:>'J-
M.4;[;:R;ZI=RG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[
M.T__ )\8?^_0KR#U"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
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M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
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M'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\
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M **** "BBB@ HHHH **** "BBB@#'\2_\A?1_P#K]/\ Z":V*Q_$O_(7T?\
MZ_3_ .@FMB@ HHHH **** "BBO._B'^T3X=\+ZT? O@?2;CQ7XI?(31-((;R
M3ZSR\K"H[YR1W '-88C$T,+#GJRLOQ;[);M^2U,ZE6G1CS3=OZZ=SOM1U'3]
M(L9=3U6^AMK:!"\]Q<2!$C4=2S'@#W->47_QX\9_%2]E\-?LU^'%O(D<QW?C
M'5HVCT^V/0^4"-T[CV& <<$'-+I_P&\9?%*^B\3?M*>)%O8T<26G@[2G:/3K
M8]1YASNG<>I..HRP.*]6T_3[#2;*+3=+L8;:V@0)#;V\01(U'0*HX ]A7%_M
MV-[TH?\ D[_-17WR_P +,/\ :,1_<C_Y,_\ +\7Z'!?#S]G?PWX5UD>.?&NJ
MW'BKQ2^#)KFK@-Y)]((^5A4=L<CL<<5Z'117;A\-0PL.2E&R_/S;W;\WJ;TZ
M5.C'E@K?UU[A1116YH%%%% !1110 4444 %%%% !6/XE_P"0OH__ %^G_P!!
M-?E717Z1_P 0^_ZB?_)/_MS\_P#]>O\ J'_\G_\ M3];**_).OK;_@EK_P S
MU_W#/_;NO-S?@[^RLNGBO;\W+;3EM>[2WYGW['H95Q9_:>/AAO8\O-?7FOLF
M]N5=NY];45E^)?&_@SP9;_:_%_BW3=+CQD/J%]'"#]-Y&:\^U/\ ;+^",=XV
ME^$KW5?%%ZO6S\,Z/-<N?3#85#^#5\I0P.-Q*O2IRDNZ3M]^Q]/6QN$PSM5J
M)/LVK_=N>JT5Y%_PN+]I#Q=\OP__ &;'TV%ON7_B_5TM]O\ O6Z9D_(T?\*T
M_:M\8_-XU^/FF>'X6_UEEX1T3=GV$\YWK]<5O_9KI_QJL(?]O<S^Z'-^-C#^
MT%/^#3G+Y<J^^?+^%SUJYNK:R@:ZO+B.*)!EY)7"JH]23P*X+Q9^U/\ L^^#
M',&K_%+3)9@<?9]-D-W)N_N[80V#]<5BVO[&GPIOIUOOB'JWB/Q?<J=PE\2:
M]-* WLJ%!CV.17>^$_AC\.? B!/!G@72=+(&-]E81QN?JP&3^)HY<II;RG/T
M2@OO?,__ "5!S9I5VC&"\VY/[ERK_P F9Y__ ,-0>)_$_P GPG_9U\7ZT#_J
M[O4H$TVUD]UEE)R/P%'E?MI>,_OW/@WP7;-T\M)-1NT^N<1&O7:*/K]"G_!H
M17G*\W^+Y?\ R4/J5>I_%K2?E&T5^"YO_)CR+_AEC6/$WS_%C]H'QCK^[_66
MEI=KI]I)]88@?_0JZ#PC^S!\ /!!630OA7I1E4Y%Q?0FZD!]0\Q8@_2N]HJ*
MF:9A4CR^T:CVC[J^Z-E^!4,MP-.7-[--]W[S^^5W^(V&&&VB6"WA6-$&$1%
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MVY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\
MHE*W: "BBB@ HHHH **** "BBB@ K'LO^1WO?^O*+^9K8K'LO^1WO?\ KRB_
MF: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]'_Z_3_Z":V* "BBJVKZQI.@:;-K&
MN:G!9VENF^>YNI1''&OJ6;@4FU%78FTE=EFN;^)/Q:\ _"?2AJGC;7H[<R<6
MMH@WW%RW3;'&/F8YP,]!GDBN$N_C;\0OC#=2:%^SAX?"V"N8[GQOK4#):1XX
M/V>,C,[#U(P#U&#FNA^&W[/7A/P-JI\9:_>W/B3Q/*,W'B'63YDH/I$IR(5'
M( 7D XR17FO&UL4^7!JZ_G?P_+K/Y6C_ 'NAR^WG6TH+3^9[?+O^7F<V+3X\
M?M!_-J+W?P^\)2?\NT3#^U[^,_WFZ6RD=OO=CN!S7H?P]^&'@7X5Z*-"\#>'
MH;&$X,TBC=+.W]Z1SEG/U/'; K?HK;#X&E1G[6;<Y_S/?T72*\E;SN:4\/&$
MN=N\N[_3LO0****[3<**** "BBB@ HHHH **** "BBB@ HJMK&M:/X>TV76-
M?U6VLK2!=TUU=SK''&/4LQ %>5:A^U%=^-;V7P_^SC\/KWQ?<HQ276)0;72[
M=O\ :F<#S".NU<9'0FNK#8+$XJ[IQT6[>D5ZMV2^\YL1C,/AK*<M7LEJWZ):
MO[C\\:***_H8_" KZ(_8)^$[_%3_ (2NVG^(GB/0[2T^P_:;?P]J'V8WF_[1
M@2-@DA=IP!_?-?.]?6W_  2U_P"9Z_[AG_MW7@<45JF'R*M4INS7+_Z5$]SA
MNE3KYU2A-73YO_26>V^&OV1?V>O#-Q]N'PZMM2NF.9+K6Y7O7D;U(F++GZ 5
MZ#IFE:7HMHNGZ/IMO:0)]R"VA6-%^@4 "K%%?BU?%XK%.]:HY>K;_,_7:.%P
MV&5J4%'T204445SFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M;XQ_Y%B]_P"N!JYIW_(/@_ZXK_(53\8_\BQ>_P#7 U<T[_D'P?\ 7%?Y"@":
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8_\
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M%_PF\'7VO:_JTXBL--T^+<\A[D]D4#)9V(50"20 37]%_P#P37_8ETS]A?\
M91TOX*7\]M?:W>S2:GXOO(5S%<7\RJKJN>L:1I'$I(&X1[L L17?_ ;]E+]G
M#]F#2I=(^ /P9T'PNEP@2ZGTVR N+E1T$L[9EE [;V.*]!KR\ZS^>9Q5*G'E
M@M?-OS_R/7X?X:AD\G6J2YJC5M-DO+U[GFGC[]C+]D;XI%W^(?[,?@+6)9/O
M7-[X3M&F'TE\O>/P->0ZY_P1=_X)[WFH'7/!_P )=3\(:D>FI>#_ !=J-C(O
MT43&,8]EKZIHKQJ>-QE)6A4DOFSWJN7X"N[U*46_.*/DG_AV-\4_!7S? O\
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M^"J'P=_X)Z>'K;2-0TQO$OCG5[8S:-X4M;D1;(<E?M-S)AO)BW A>"SE2%&
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M?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%%
M!6/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S- &Q1110 4444 %%%% !1110
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M=L,;DM80&D([NWWG/NQ)K:HHKSIU)U9N<VVWNWJST(0A3BHP5DNB"BN#^/\
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M-IVZ:<CZ6MJ]#ZTHKY,_X<T?LK6W_($^('Q8TW'^K^P_$V^78>Y&YCR:0_\
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MW"K)-CKL4G+8[XH M4455M-<T6_O[C2K'6+6:ZM"/M=M%<*TD.>F]0<KGWH
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M2WQR 8U5MO!9J^@*U]K@\-_"CSR[RV^4?_DF_1&/L<=BOXTN2/\ +%Z_.?\
M\BE_B9\Y_ +_ ()C_L\?!_Q;_P +?^(;ZI\4?B+(ZR7'CSXBW/\ :%VCCD?9
MXWS';*ISMV+N4<;R*^C***Y:U>MB)<U25W_6W9>AV4,-0PL.6E%)?GYON_-Z
MA1116)N%%%% !1110 5C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!- &Q111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\I_\ !2O_
M ()3_"3_ (*%:%;:^^K?\(QX]TBV,.D^*(+7S5FAR6%M=1@J98\DE6!#1EB1
MD%D;ZLHK?#XFOA*RJTI6DCGQ6$P^-H.C7CS1?0_G\^(__!!#_@I'X#U2:UTC
MX9:)XEL86_Y"VB^++..%E_O;;N2&7\-F?K7O/[%O_!N1\1M8\26'C;]M/Q9I
M^F:%"Z3/X1\/7IGO+[OY4UPH$<"'C)C,C$9 *'##]>/&/_(L7O\ UP-7-._Y
M!\'_ %Q7^0KW*O%.:U:7(FH^:6OYO\CYRAP;DU&M[1J4O)O3\$G][*_ACPSX
M>\%>'+#PAX2T6VTW2]+M([73M/LX1'%;0QJ%2-%'"J%   ]*O445\ZVV[L^J
M225D%%%%(84444 %%%% !1110 4444 %%%87CWXE^!?AAI!UOQSXDMM/A.?+
M65LR2D?PH@RSGV - &[7,?$CXQ_#SX46:W'C+Q!'#--_QZZ?"/,N;@YP D2_
M,<GC/3U(KB/^$S^/7QO_ '/PWT1O!7AZ3@^(=<MP]]<)ZP6_1 1T9CR#D$'B
MNG^&_P  /A_\-[QM?@MI]5UV8[KKQ!K,OVB[E8]2&;[GIA0..N: .8%U^T/\
M<>+*&3X>>&Y/^6TRA]7ND]EZ6^?^^AVR*[+X:_!/X=_"F)Y/"VB9O9L_:]6O
M7\Z[N">I>5N>3R0,#/:NLHH **** /QQ_P"#CO\ 8V\4:-\4M)_;2\):-)<:
M%K6GP:3XLFAC+?8KZ'*6\TA[)+$4C!Z!H "<NH/Y>U_5_P"+?"/A?Q[X9OO!
M?C;P]9ZMI&IVS6^HZ;J%NLL%S$PPR.C A@?0U^<O[2G_  ;@?LU>*+Z]\8_
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MB@ K'\#_ /((E_Z_9O\ T*MBL?P/_P @B7_K]F_]"H V**** "BBB@ HHHH
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
MSXP_]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J\H_;=\2Z%J'[+_B>TLM4
MBDE?[%M13R<7L!/Z"O8_[.T__GQA_P"_0KR;]N6RLXOV6?%$D5I$K#[%AEC
M(_TZWKTLF_Y'&'_Z^0_]*1Y^;?\ (JQ'^"?_ *2SX#T2=BK6[=!RI_I5^J5A
M";>($CYCR:N;AMW=L5Y68\2Y9G/$&-^KV4*<M^DDE:4_1R3?HT^IY'#&*;RU
M4JKU@O\ R7_@;?<5-5NUB"PM#NSSR>*]?_9T^-G['FE:=9^%/&_P[U?Q-XQL
M&=;ZTM4BO(K</(TD:K;M<#:#&R,0T>222,@Y/D=P5EC(EA#@<@=_PKU/P+^S
M;^PY\2_A=I.K_M7?LA6-S;ZD9DA^(<,$B/>8GD0+<SVC),C)M\M2Q/RQKC
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M%L/[[4[CP)]OTU/7%S;,V['LE/ZI@I?!1<O\-:#_  Y&_P !_7\1'^)64?\
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MVZ,C1+(8/X0\_C0!]Y?\)CX8_P"@U!_WU1_PF/AC_H-0?]]5\)?\-B?M%?\
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MAVX).*^G?AY\??@K\6O#,/C/X8?%#1=?TJX'[J_TF^2>,G'*DJ3M8=U.".A
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M_"6C:S>>(M'\+Z=::AJ!!O[ZVLHXYKDCIYCJ S_B36C10 4444 %>4?MS_\
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M9O\ T*MBL?P/_P @B7_K]F_]"H V**** "BBB@ HHHH **** "BBB@ HHHH
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M^,_,T]6+-X.\12M+:XZD02YWQ'T!."3DFM3P?^TIX8O]83P9\2](NO!WB$X
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M110 4444 %%%% !1110 45D^+_'7@WP#IIU?QIXFL],M^=KW<X3>1V4=6/L
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M4GOMP/:NSHH *\;_ &IOV?K'XS:]X3O(W6">'4A;:A,#AGLF.YP#_>4@[?\
M?:O9*Q_$O_(7T?\ Z_3_ .@F@#3L;&STRQATW3[=(;>WB6*"&,85$4850/0
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M3TQ@GKBO0JQ/'?PW\#?$S2#HGCGPU;:C!SY?G)\\1/='&&0^ZD4 ;=%>0_\
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M -!-;%8_B7_D+Z/_ -?I_P#030!L4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'P)^US\(/^%2?%V[BTZU\O2M7S>Z9M&%0,
M?GB'^Z^0!_=*^M?4_P"R!\(E^%/P@M'O[;9JFM!;[421\R;A^[B/^ZF,CLS-
M6W\=_A/X6^)V@V5WXB@W/H=\+VV8 ?-@8:(_[#?*2/\ 9%=GIW_(/@_ZXK_(
M4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9OC
M'_D6+W_K@:TJS?&/_(L7O_7 T 7-._Y!\'_7%?Y"IJAT[_D'P?\ 7%?Y"IJ
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MBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\
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M;##GC.,$]":Z>N(^(_[/_P /OB/>KX@GM9]*UV$[K;Q!HTQM[N-AT)9?O_\
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M%% !1110 4444 %%%% !1110 4444 %8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\
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M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0
M!3_X3'PQ_P!!J#_OJLNT\2Z"GBV[O7U2(1/:QJDF>"03D5T']G:?_P ^,/\
MWZ%9%G969\9WL1M(MHLXR%\L8!R: +?_  F/AC_H-0?]]4?\)CX8_P"@U!_W
MU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0
M?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P )
MCX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'
M_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?
M]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0
M?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/
M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* /.-9\&?#A_C58_&6TO8CJ/V46EQM^Z ,_O3_ +6W"9_NC%=W_P )CX8_
MZ#4'_?55/$=E9IJNDJEI$ UX0P$8Y&TUK_V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
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M30:I$RPW1:5@?NC;U-=!_9VG_P#/C#_WZ%9'B.RLTU7252TB :\(8",<C::
M+?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\
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M FRA),*Y)C'H* (?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
M4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ
M% %:V\4>'[R=;6UU6)Y'.$13R35^HDL;*-@\=G$K#H5C (J6@ HHHH ****
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^)?\ D+Z/_P!?I_\
M036Q6/XE_P"0OH__ %^G_P!!-;% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!- &
MQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9
MOC'_ )%B]_ZX&KFG?\@^#_KBO\A5/QC_ ,BQ>_\ 7 U<T[_D'P?]<5_D* )J
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQC_R+
M%[_UP-:59OC'_D6+W_K@: +FG?\ (/@_ZXK_ "%35#IW_(/@_P"N*_R%34 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X'_Y!
M$O\ U^S?^A5L5C^!_P#D$2_]?LW_ *%0!L4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:U
MZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\
MV K3_P!$I6[0 4444 %%%% !1110 4444 %8]E_R.][_ ->47\S6Q6/9?\CO
M>_\ 7E%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!-;% !1110 4444
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M*_R%35#IW_(/@_ZXK_(5-0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8_@?_D$2_\ 7[-_Z%6Q6/X'_P"01+_U^S?^A4 ;%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=
M_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 5C
MV7_([WO_ %Y1?S-;%8]E_P CO>_]>47\S0!L4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &/XE_Y"^C_ /7Z?_036Q6/XE_Y
M"^C_ /7Z?_036Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7Z?\ T$T ;%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F^,?^18O
M?^N!JYIW_(/@_P"N*_R%4_&/_(L7O_7 U<T[_D'P?]<5_D* )J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQC_ ,BQ>_\ 7 UI
M5F^,?^18O?\ K@: +FG?\@^#_KBO\A4U0Z=_R#X/^N*_R%34 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X'_ .01+_U^S?\
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M!-;%8_B7_D+Z/_U^G_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!F^,?\ D6+W_K@:N:=_R#X/^N*_R%4_&/\ R+%[
M_P!<#5S3O^0?!_UQ7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *S?&/_(L7O_7 UI5F^,?^18O?^N!H N:=_P @^#_KBO\
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MA:S%F^&N@$DY).C0<_\ CM)_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\
MHO&B?]]2?_$4?\-W?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"
MIOA7_P!$T\/_ /@F@_\ B* .%_X;N_9#_P"B\:)_WU)_\11_PW=^R'_T7C1/
M^^I/_B*[K_A4WPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(H X7
M_AN[]D/_ *+QHG_?4G_Q%'_#=W[(?_1>-$_[ZD_^(KNO^%3?"O\ Z)IX?_\
M!-!_\11_PJ;X5_\ 1-/#_P#X)H/_ (B@#A?^&[OV0_\ HO&B?]]2?_$4?\-W
M?LA_]%XT3_OJ3_XBNZ_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F
M@_\ B* .%_X;N_9#_P"B\:)_WU)_\1639_MS?LEKXQO+AOCCI C:TC"R$2[2
M03P#LP37J'_"IOA7_P!$T\/_ /@F@_\ B*\3\"_#SP!-^WEX[T:;P-H[V</@
MC2Y(;1M,B,:.9&RP7;@$]R* .R_X;N_9#_Z+QHG_ 'U)_P#$4?\ #=W[(?\
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MX?\ _!-!_P#$4?\ "IOA7_T33P__ .":#_XB@#A?^&[OV0_^B\:)_P!]2?\
MQ%'_  W=^R'_ -%XT3_OJ3_XBNZ_X5-\*_\ HFGA_P#\$T'_ ,11_P *F^%?
M_1-/#_\ X)H/_B* .%_X;N_9#_Z+QHG_ 'U)_P#$4?\ #=W[(?\ T7C1/^^I
M/_B*[K_A4WPK_P"B:>'_ /P30?\ Q%'_  J;X5_]$T\/_P#@F@_^(H X7_AN
M[]D/_HO&B?\ ?4G_ ,11_P -W?LA_P#1>-$_[ZD_^(KNO^%3?"O_ *)IX?\
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MN_9#_P"B\:)_WU)_\17=?\*F^%?_ $33P_\ ^":#_P"(H_X5-\*_^B:>'_\
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M (BC_A4WPK_Z)IX?_P#!-!_\10!PO_#=W[(?_1>-$_[ZD_\ B*/^&[OV0_\
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MOV0_^B\:)_WU)_\ $4?\-W?LA_\ 1>-$_P"^I/\ XBNZ_P"%3?"O_HFGA_\
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MB:>'_P#P30?_ !%'_"IOA7_T33P__P"":#_XB@#A?^&[OV0_^B\:)_WU)_\
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MA_\ 1>-$_P"^I/\ XBNZ_P"%3?"O_HFGA_\ \$T'_P 11_PJ;X5_]$T\/_\
M@F@_^(H X7_AN[]D/_HO&B?]]2?_ !%'_#=W[(?_ $7C1/\ OJ3_ .(KNO\
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M (;N_9#_ .B\:)_WU)_\11_PW=^R'_T7C1/^^I/_ (BNZ_X5-\*_^B:>'_\
MP30?_$4?\*F^%?\ T33P_P#^":#_ .(H X7_ (;N_9#_ .B\:)_WU)_\11_P
MW=^R'_T7C1/^^I/_ (BNZ_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^
M":#_ .(H X7_ (;N_9#_ .B\:)_WU)_\11_PW=^R'_T7C1/^^I/_ (BNZ_X5
M-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_ .(H X7_ (;N_9#_ .B\
M:)_WU)_\11_PW=^R'_T7C1/^^I/_ (BNZ_X5-\*_^B:>'_\ P30?_$4?\*F^
M%?\ T33P_P#^":#_ .(H X7_ (;N_9#_ .B\:)_WU)_\11_PW=^R'_T7C1/^
M^I/_ (BNZ_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^":#_ .(H X7_
M (;N_9#_ .B\:)_WU)_\11_PW=^R'_T7C1/^^I/_ (BNZ_X5-\*_^B:>'_\
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MN^CP$L3"I))*\FMO_A4WPK_Z)IX?_P#!-!_\10!PO_#=W[(?_1>-$_[ZD_\
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M\-W?LA_]%XT3_OJ3_P"(H_X;N_9#_P"B\:)_WU)_\17=?\*F^%?_ $33P_\
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M_1>-$_[ZD_\ B*/^&[OV0_\ HO&B?]]2?_$5W7_"IOA7_P!$T\/_ /@F@_\
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M%UM\'_V7D^+/BGXK_$FW\&Z!X:?QO%H %W/!-+&YN9;:=.6B"88(!NR6&,$
M^I:*^7_V2/VI?^"F/Q>^+0\(_M6_\$J;3X/>%/[,FF/C"'X\Z5XC87*E?+M_
MLEK;1R?/EOWF["[>1S7U!0 4444 %%%% !1110 4444 %%%% !1110 4444
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MKJ"XO?#_ (-2Y%VLVH#)VWEU,!.8NL(=E)^?:F%_P0",S_$?]N)_$6S^W_\
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M_#'PRCT6]\93V;;K8:M<BXD C##=)%$H$A.<JP5U /T,HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,7XC?$;P'\(? >K_%'XH^+M/T#P[H&GRWV
MM:UJMRL-O9V\:EGDD=N%4 5^??[(FB?$G_@K-_P4$\*_\%9?&/A+4/"OP0^$
M6CZKI?[-ND:O:M!J/BF?48OL]_XCGB;F"UDA4)!&PW.JQR87;\_JW_!83_@E
MW\6_^"I?@GP/\,/"'[9)^&?A?PUKDFK>*/#5SX"37K'Q7.CV[V27<37EL##
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M4]=^%VG7EM\+O"GA/P0-$T?1[J[C$5SJ<J&:5[FZ>,!1G:L94,N2%V@'>?\
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MG[%'[.OA3]EWX!Z VG>%?"&FBTTV*:0/-,Q9I);B9P 'FEE>25V  +R,0 ,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOM'CTSXM07.K6!FVBR75;;[$#:1SN\2-)'YS6[R*)(\;F7W?]I/_ (*C:+\
M_P!GGX0>/O#?P,U?QO\ $SX[P6$7PQ^$F@ZI$EQJ5[/9QW<JR7DJJD%K;QN#
M+=,F$!5B@!. #ZLHKXK^&_\ P4O_ &I?AO\ M)^ _P!G+_@H[^Q'8?"M/BO>
M2Z=\._&OA/XA1^(=*N=62(S#2KO%O ]K.Z*WEOADE8;5Z,1E?$K_ (*U_M$7
MG[>WQ:_X)T?LJ?L"3_$#QK\-M,T/4+?7KWX@0Z7I$MI?V*7,LUY+);$VAB>6
M&*.&/SWN"SL!$L3D 'W317R__P $ZO\ @H;XL_;!\4_%#X!?'K]GN?X5_%_X
M,ZU96/COP:=>CU2U,%[ T]C?6MVB()89XT=@"H*X&2=P->@_\%"?^3!?CA_V
M1_Q-_P"FJYH ]?HK\P/V>_\ @H;IG_!,7_@W>_9Q_:=UKX6S>+[,>'O#.BW>
MF6^JFTDBBO)#&UPK+!,9&C +"(*"Y^7<N<UZ'XU_X*W?MD?L\^._ GC']LG_
M ()HS_#SX-?$3QE8>&K#Q@OQ+M-1U?P]<WS;+.75=.AAVP*Y_P!8L<S^3RI9
MWVJX!]^45\K_ +<__!237_V</C?X,_8W_9F_9QO_ (P_&[QYI5QK&F>#+;7H
MM)LM*T>%S')J>HWTJ.MO!YBLB (QD>-D!5BH;L_V0/C/^W/\1M:U_P ,?MG?
ML8Z+\-'TRWMYM$U[PS\2(=?L-:\QI!)$%\B":VDB"H3YBE7$@*MPP ![K111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXIV^@W_C-;65HIIM+LGM9<1>9&ZQR3NGF$8PC!E'9>.?^"S'PNMO^"<W@O\
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MO OCN&RU'7?#NDZS';L)].GN[.*X$9.")(V8'!.!\R^U)X_TOQ=K?@36]%\
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MZO#G@7P1X/FN+CPEX-TK2Y+M]]V^G:=% 9VZY<HHW'D\FM6@#X/_ &*E5?\
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MA?3M)MY)#(]OIEE' C.>K%4 !/O0!^%/_!.UO^"?_P  /V:=._9A_P""@O\
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MI<?'[Q#\)=#>P\.Q>''@4+%?-%&EJ\LK"95V EG*;B6$6WL=+^(_['O[(_\
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M  4A_8_\:>'?'&L:>MOXC^(WB[0?%FG:!=7\DTAC'VR&9+908S&-ZJL8P26
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MMXE^$G[.'PJU73;OXB6MK(NG:GXEU8M"UA:2NH%QY=J_F,Z952"#]Y"_Z=4
M?E#_ ,$?/VD?^&/?^"-O[1O[4_\ PAG_  D7_"O_ (P?$+7?["_M'[)]O^SS
M+)Y/G^7)Y6[;C?L?&<[37<^)O^"V'[;6F_LP:9_P4+T/_@E%?3? ,>'K/6]<
MUJ[^*%K#KXTV1(S<:A:Z:;?,EK&6=HVD>-YXD68I"CY7YV_93_Y5M?VU/^QP
M^*%?7WQ[C2+_ (-I/$$42!57]B\A548 '_"+CB@#T[]M7_@I]X)_9E^"7PU\
M=?!SX9ZA\5?&/QOU&RL/@SX$T:^2RD\0RW,"W"S27$JLMK;1PNKR3,K! ZY
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MND=[ ,K./LRX3>$\S]C/V4_VH?@Y^V?^SYX7_::^ GB9=5\+^+-,6[L)N!+
MW*R6\R@GRYHI \<B9^5T8<]: /0J*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKSSQ3\&O'VO^(;O6=,_:!\1:7;W$I>+3[6&(QP#^ZN1G% 'H
M=%>6_P#"@OB9_P!'/^*O^_$'^%'_  H+XF?]'/\ BK_OQ!_A0!ZBRJZE'4$$
M8((X(K\^/VH?A$WP=^+=]HEG;E-,O3]LTD@<"%R?D'^XP9?7 ![U];?\*"^)
MG_1S_BK_ +\0?X5YY^TE^ROXSU7X>77BRZ^+&K^)+W0H'N+:TU&VCYCX,H4J
M,@[5W8YSM H ^2*^L_\ @GM\(/L&D7OQCUBUQ+>[K/2-XZ1*?WL@_P!Y@%!_
MV&]:^:/AOX$U?XF>.=,\"Z(/W^HW2Q^9MR(DZO(1Z*H9C]*^T]$_9H\;^&](
MM]!T+]H_Q):6=I$(K:W@M8%2-1T &* /7:*\M_X4%\3/^CG_ !5_WX@_PH_X
M4%\3/^CG_%7_ 'X@_P * /4J*\M_X4%\3/\ HY_Q5_WX@_PKT/PMI%]H'AZT
MT;4]>N-4N+>+9+J%T ))S_>;'&: /SZ_X.H[*'4O^",WCK3K@MY<_BOPS&^T
MX.&UFU!Q^=7?^".OQ6\>?"#P=\4_^"1'[1/B"6]\=_LWE[3PKJMZ<2>)/!%P
MC/I%^O9C'&1;2!,K%LA0G<35?_@Z4_Y0Z>-/^QP\+_\ IZM*3_@M]\/?&7[,
MOBCP'_P68^!.@7%YKOP;CET/XM:1IX_>>(? 5\^R[C89^=[25Q=1@_*I:21N
M(Q0!0_X(*>.OB9\-/^#=SX1>-O@W\%[GXA^)[+2=7_L;P9::U;Z<^IS/XDOH
M]ANKC]U JAR[.V0%1N"< ]EJW_!4+]MW]F?XC^!X/^"B/_!//2/ 7P]^('BZ
MS\,V?C[P1\5HO$":!J=XYCM(M0MS:0,L4CX4W"$HAZ@E@*^,/@-\6OV@/@I_
MP:+_  L\=?L_>)?$F@.FH26_C7Q3X-B9]7T'PW)XKODU&^M-JEEE2$X\Q1F-
M6=P5V;AX]_P5$NO^"/4/P%\$)_P3J^)?C+XJ^.V^)/AF^\1>+U^*GB;7;;1-
M/;4(Q]IU$75VUE%<33F*)(FB67<[LJKY9( /UF_:X_X*(_'3P#^U_I/[ O[%
MG[*=I\3_ (EW/@(^-/$,_B/QK'H.D:%HQO#9Q2O,89I+B5YU9?*C0%058D@D
M#L?A]^U]\;/AS^S-X_\ VA?^"C7[.VF?!V'X=V]S?7YT3QQ#XAM=3TV"V69K
MNW>.&%T8MOB6WD02%U&,AUKYQ_X*J_\ #FKQI^U1H>C?MC?M<ZY\"?CAX;\)
M1R>&?B)X4\87OAC54T>>:8B&+4 AM9T$R2MY3[V1F)"J)#N^<?AK_P -?_\
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M+Q_'X@T?5;VTA^T3Z?,?L\$MI.(060LI60_*O-6?VC/^"E?QWB_;'U/]@_\
M8!_9(M/BUXX\'>'[36?B;J^O^-DT'1O"T-V"]G:R3&"=YKJ>,>8L:H,(P;+
M/L_.7QT?^"8]O_P56_8VTW_@FEJ7B3Q?96?Q:E7QI\07^(7B#7]'6X>R8V]A
M#-J5W-;O<E!-+(+< QJ(PY_> #ZC\"?M)_!O_@EM_P %E_VG?^&X/&-KX#\+
M_M"6WA?Q/\,/'VNQO%I>H_V=ISV=]I\ES@I%/%(X*QL1E#GC>@8 ]S_8-_X*
MP^+?VP?VR_B3^Q'\2?V0]5^%_BWX5>%K"_\ %D.K^*(KYDOKB3:UM$(H%26W
M\LQ3172R$31S(?+C.0/IS]H3_D@?CC_L3]3_ /262OS>_P""8/[2G@?]K?\
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M--\/7UMXI\+ZG\.;G5+JX>34+IT@8)92+.SQO'@;B/F XQQK_ 7P#\</A_\
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M"=G\*3\7;?4/^%9>*?#GQ'A\0V=S>V</GS:==E+>$P3>3RKC*NQ55!Y9?/\
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M,?CC>_%2]U>8[K>\^'4?EZEI6D/DDRJ=2NVMY6X 98POW2!^[5 'YP_M,?\
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MAAC"I&H& J@<  =A4E% &?9>%/"VG:Y=>)]/\-:?!J=Z@2]U&&S19[A1T#R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20201231_g2.jpg
<TEXT>
begin 644 biib-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #3 94# 2(  A$! Q$!_\0
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M_C+]CCXG_#FSDU3P%X]U+6F@7<;-+F6TN6 Y^3#E'/L<9[5]6_&SXP:3\#_
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M;.MQ;R=1O!X!'<'D$=P2*;K7B2]\8ZQ>Z[J5PUWJ&HS-<W$S=6=CD_0#H!V
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M//$NI>(M5N&NM0U*9KB60^_11Z*HPH'8 5RNN386.(=_F-3:--YEJ4/6,X_
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M^JS%[J.)>+"Y8Y.0.D;GD'H&)'<5^A6F:9::+IUM86%M%9V5M&L4-O"H5(T
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M_,Z:&'J8B7+31F?L5_LY3>.O$%MXZ\06I7PWILN^PAF7B^N%/#X/6-#SGH6
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M%>",&IK%S'?6SCJLBG]10!Z91115$W"BBBF%PHHHH"X4444!<**** N%%%%
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MU- '>44459 4444 %%%% !1110 4444 %%%% !1110 ^BBBH+"BBB@ HHHH
M**** "BBB@ HHHH K:E9+J%C-;MQO7 /H>QKS6:%[>9XI%VNAVL/>O4ZYSQ1
MH)O%-W;KF91\Z#^,>H]Z .,HHHH **** "BBD)H 'MS>*8 -S2?* /4]*$L'
MTL&UD&)(SA_KZUU_A;03;XO;A<2$?NT/\(]3[U/XFT$Z@GVF!<W"#!7^^O\
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M%%% $<G7\*CHHJB'N(W2FT452$PIIZT44Q"$!A@@$>A&:6BB@3&'N#R*3H
M,#T%%% A:;"Q)<$]#Q113%U)<T9HHI%AFC-%% !FC-%% "$FHFD;)YHHJD1(
M;N/K1DT44R0R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R
,:,FBB@ R:*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-20201231_g20.jpg
<TEXT>
begin 644 biib-20201231_g20.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M9 )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M["<Q-=VX).$D7:2 2H??MP, ?6- !1110 4444 %%%% !1110 4444 %%%%
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M/X^\8>([-0P^&^@63%Y+R>9>8+B<2(L4.09 5SC?$6_3.@#Y)_9E_P""Z/\
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M#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M_KU_U#_^3_\ VI^JG_"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5^5=%'_$/O\
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MWUS\.OC[\)/".C7GQ/TOPQX@\(V,FGW-MKJR)!=6^[,<L<B*WS #!4C))/0
M$]^95:U-4^5N,6_><5=I6=M+/=V3=G;RW.++Z=&HY\R4I)>ZF[)NZOK=;*[2
MNK_@<%\8/A'<_"O4=/EM-?@UG1M;L1>Z'K-M$T:74).#E&Y1U/#(22,BN/KZ
M!_:DMO!NG?LX_"S2O"FLOJ,%L=1CM;^2 Q&Y59$$LBHWS*AD^[GG;BOGZGE6
M)J8O!*<][R6JLWRR<;M:6;MJK*S%F>'IX7%N$-K1>CNES13LGU2OH^Q[?_P3
MV_Y.3LO^P7=_^BZ^_:^ O^">W_)R=E_V"[O_ -%U]^U^9<<_\CI?X%^;/T3@
MS_D4/_&_R04445\:?6A1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/
M>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 > _M"?MR_P#"A_B3/\/?^%7?
MVKY-K%-]L_MOR,[USC9Y#]/7-</_ ,/2O^J%_P#ES_\ W-7G'_!0G_DY.]_[
M!=I_Z+KQ"OUS*>&,CQ664:M6C>4HIM\TMVO*1^79IQ'G.'S&K2IU;1C)I+EC
MLGYH^MO^'I7_ %0O_P N?_[FH_X>E?\ 5"__ "Y__N:ODFBO0_U1X>_Y\_\
MDT__ )(X/]:<^_Y_?^2Q_P#D3ZV_X>E?]4+_ /+G_P#N:C_AZ5_U0O\ \N?_
M .YJ^2:*/]4>'O\ GS_Y-/\ ^2#_ %IS[_G]_P"2Q_\ D3ZV_P"'I7_5"_\
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M *+K[]KX"_X)[?\ )R=E_P!@N[_]%U]^U^0\<_\ (Z7^!?FS]3X,_P"10_\
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M$_A5*LWPIT[Q!%XJ\9Z)H3BUM--A\-/;3K=7*H%#7MY(C*LAW22!WQD$U?\
M'GQQ_P""K7[</[:/QA^ 7[#'QM^'GP6\ ?!'5[#0-3\4>)?!QU[6-?U:XL8K
MR0QP2.L,-O&DR*"?F.=V6W%8_3?V7/V9_P#@L-\/OCMH7B_]J?\ X*;^#_B%
MX#M/M7]N^#]*^"]GI,^H;[65(-MW'(6BV3M#*<#YA&5Z-0!]?T444 >%_P#!
M/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 ? 7_!0G_DY.
M]_[!=I_Z+KQ"O;_^"A/_ "<G>_\ 8+M/_1=>(5^]9#_R)</_ ((_D?B6=?\
M(WK_ ..7YA1117K'F!1110 4444 %%%% !1110 4444 %%%% !1110 5^L6A
M?\@.S_Z](_\ T$5^3M?K%H7_ " [/_KTC_\ 017YSX@_!AO^W_\ VT^^X%^/
M$?\ ;O\ [<6J***_-3]""OYZ/VZO^3T_BS_V4;6?_2V6OZ%Z_GH_;J_Y/3^+
M/_91M9_]+9:_5/"K_D98C_ O_2C\Q\3O^1?A_P#&_P CRJBBBOW _&0HHHH
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M .-4?\-2?';_ *'K_P IEK_\:KS^BCZMAOY%]R#ZSB?YW][/0/\ AJ3X[?\
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MWQE_R*&J_P#8-G_]%M5T_P"(O4BI\#]#^:6BBBO[!/Y."BBB@ HHHH ****
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M .;<^&/_ )'KT#]ES]LO_@K#\5_CMH7@#]I?_@B__P *F\$W_P!J_MOX@?\
M#1>A:]_96RUEDA_T&UA6:?S9DB@^4C9YV\_*A% 'U_1110!X7_P3W_Y(GJW_
M &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 ?BA_P7#_Y/ZU?_L7=
M,_\ 1-?(5?7O_!</_D_K5_\ L7=,_P#1-?(5?U-PM_R3F$_Z]Q_)'\S<2_\
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M117XT?KH5_/1^W5_R>G\6?\ LHVL_P#I;+7]"]?ST?MU?\GI_%G_ +*-K/\
MZ6RU^J>%7_(RQ'^!?^E'YCXG?\B_#_XW^1Y51117[@?C(4444 %%%% !1110
M 4444 %%%% !1110 4444 %>J_L*_P#)Z?PF_P"RC:-_Z6Q5Y57JO["O_)Z?
MPF_[*-HW_I;%7%F?_(MK?X)?DSLR[_D84?\ ''\T?T+T445_)!_5 5F^,O\
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M_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH _%#_@N'_R?UJ__ &+NF?\
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MO-*BBBOQH_70K^>C]NK_ )/3^+/_ &4;6?\ TMEK^A>OYZ/VZO\ D]/XL_\
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M_;=\)^&K[Q+>_"&*Z_LNW,^J:9I/B&QO;ZTC R6>W@F:0_102/3K7S[7U/\
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M\$OR9RY=_P C"C_CC^:/Z!?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M HHHH **** "BBB@ K^EKP;_ ,BAI7_8-@_]%K7\TM?TM>#?^10TK_L&P?\
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M $H_,?$[_D7X?_&_R/*J***_<#\9"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KU7]A7_D]/X3?]E&T;_P!+8J\JKU7]A7_D]/X3?]E&T;_TMBKBS/\
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M,_\ 1-?(5?U-PM_R3F$_Z]Q_)'\S<2_\E!BO^ODOS"BBBO>/$"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K^EKP;_R*&E?]@V#_ -%K7\TM?TM>#?\
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M5_8)_)P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'U[_P $//\
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M?\1>I%3X'Z'\TM%%%?V"?R<%%%% !1110 4444 %%%% !1110 4444 %%%%
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MH_\ Z'SX6?GK'_Q5'_#@G]H__H?/A9^>L?\ Q5?K#11_K%Q!_P!!E7_P9/\
MS#^P,B_Z!*7_ (+C_D?D]_PX)_:/_P"A\^%GYZQ_\51_PX)_:/\ ^A\^%GYZ
MQ_\ %5^L-%'^L7$'_095_P#!D_\ ,/[ R+_H$I?^"X_Y'Y/?\."?VC_^A\^%
MGYZQ_P#%5QWQ*_X(U?'/X;>+?"'A+5?%OPYFF\7:PVGV3VHU4I$XC+[I-S@[
M<#^')K]DJ\@_:/\  OB[Q9\6/A)K?AS09[NTT/QA)=:M/" 5M83 RAVYZ9XH
M_P!8N(/^@RK_ .#)_P"8?V!D7_0)2_\ !<?\C\_?^'!/[1__ $/GPL_/6/\
MXJC_ (<$_M'_ /0^?"S\]8_^*K]8:*/]8N(/^@RK_P"#)_YA_8&1?] E+_P7
M'_(_)[_AP3^T?_T/GPL_/6/_ (JC_AP3^T?_ -#Y\+/SUC_XJOUAHH_UBX@_
MZ#*O_@R?^8?V!D7_ $"4O_!<?\C\GO\ AP3^T?\ ]#Y\+/SUC_XJC_AP3^T?
M_P!#Y\+/SUC_ .*K]8:*/]8N(/\ H,J_^#)_YA_8&1?] E+_ ,%Q_P C\GO^
M'!/[1_\ T/GPL_/6/_BJ/^'!/[1__0^?"S\]8_\ BJ_6&BC_ %BX@_Z#*O\
MX,G_ )A_8&1?] E+_P %Q_R/R>_X<$_M'_\ 0^?"S\]8_P#BJ^E[+X%_\%I=
M/LXK"S_;$^%B101+'$G_  B1.U5& ,FVR>!7V517'B\QS#'V^M5IU+;<TG*U
M][7;M>QUX7+\!@;_ %:E&%]^6*C>VU[)7/CG_A2__!:W_H\CX6?^$C_]S4?\
M*7_X+6_]'D?"S_PD?_N:OL:BN([#XY_X4O\ \%K?^CR/A9_X2/\ ]S5\\^._
M^"('[6_Q+\:ZM\1/&WQ/^%E[K&NZC-?ZK>>3JL?GW$KEY'V1E47+,3A0 ,\
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M\+/SUC_XJOUAHH_UBX@_Z#*O_@R?^8?V!D7_ $"4O_!<?\C\GO\ AP3^T?\
M]#Y\+/SUC_XJM7P+_P $0/VM_AIXUTGXB>"?B?\ "RRUC0M1AO\ 2KSR=5D\
MBXB</&^R0LC890<,"#CD$5^IE%3+B#/IQ<98NJT]U[27^94<BR2$E*.%IIK^
MY'_(^.?^%+_\%K?^CR/A9_X2/_W-1_PI?_@M;_T>1\+/_"1_^YJ^QJ*\@]4^
M.?\ A2__  6M_P"CR/A9_P"$C_\ <U1WOP+_ ."TNH6<MA>?MB?"QXIXFCE3
M_A$B-RL,$9%MD<&OLJBA-IAN?D]_PX)_:/\ ^A\^%GYZQ_\ %4?\."?VC_\
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MN?3+[Q5\<?CK)JFN_P#"QWUBZ6\\*'[9<1:=%I>R4+;16RQ12)&!C)*'*!5
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MM*TJ/PR%N+J30G\7#_C_ #HQN22T*KO$S1_)YC1J"46,#]1: "BBB@ HHHH
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ML?"]UI_A_2KN"+28;VWGC0$7,4;2NX$KLY+,[;F=BS$GXV_X)E?\%;/V8_\
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M*A_M>7WPX_;,_:HT_P"'7[+OPK\1 V_P]O[#4&U#XK:O;OE+G4%MH7$&E0N
MR6SD/*P#2*#\L/W?^W/9_"'_ (+$?\$4OBGX._8#\66'BW2?$/AB2W\&'2;*
M6UANK[2KJ&YCL8HYHXRF9;185RH4%ASCFON2B@#\A/VE/^"U/[-_[3'_  1\
MO_V6_@SK5]K?[1OQ/^'2_#G_ (4C::1<+KUGKUW;#3[^&:!HQY,<.ZY<ROM0
MJ@Y!; ^Y_#7Q+_9Z_P""0O\ P3L^%OAW]K;XNV/ACP_X!\&Z!X0O/$$]M<3P
MS7\-C'!PL,;O\[0R,#MQ]*^@X?"'A.V\12^+[?POIT>K3Q"*?5$LHQ<2(,85
MI -Q' X)QQ6C0!^.?_!O?_P5%_8*TGQI\>?@-J/[1>FQ>+OB]^V9XOU[X<:*
M=-O2^MZ=?K8BSN$80[$$ABDP)&1AMY XKI/VB/B9^S-^SK_P7Y\:?$W_ (*R
MV6GV_@#6_A1I-I^SEXJ\>Z0;SP[IDB*IU:VC9XWAMKR2?>Y=@K>7P6 EC#?K
M15+7_#?AWQ7ICZ+XIT&RU*SD(,EIJ%JDT3$=,JX(/Y4 ?ES_ ,$M_&/PA^-/
M_!;;XV_&W_@F_H\=M^S?-\([#3O&6J>'M&>Q\/:WXZ2^1DGLH]J1R2I9^:DD
MD:X)W,=WFH[?JG5?2=(TG0--AT?0M+M[*TMUVP6MI L<<:^BJH  ^E6* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ^%_^#@?_ ),T\,_]E.LO_3=J-?CW7["?\' __)FGAG_LIUE_Z;M1
MK\>Z_H?PV_Y)B/\ CD?@?B%_R4DO\,?R"OV$_P"#?C_DS3Q-_P!E.O?_ $W:
M=7X]U^PG_!OQ_P F:>)O^RG7O_INTZCQ(_Y)B7^*/YAX>?\ )1Q_PR/NBBBB
MOYX/WP**** / /VA_P!N?_A0G[=G[.G[%/\ PJ[^UO\ A?W_  EW_%3?VWY'
M]A?V'I<=_P#\>_D/]J\_S/+_ -9%Y>-WSYVT?\%1_P!N?_AVO^PGXY_;6_X5
M=_PFG_"%_P!F?\4S_;?]G?;/MFJ6EA_Q\>1/Y>S[5YG^K;=LV\;MP^?/^"B]
MS;VG_!=3_@G3+<S+&ID^+2!F. 6;PU:JH^I8@#W-)_P=*WEK;?\ !"WXVPW$
MRJ]Q+X9C@4_QL/$NEO@?\!5C^% 'WWI-_P#VII5MJ?E>7]IMTEV;L[=R@XSW
MZTFF:UHVM"8Z/JUK=BWF,-P;:=9/*D'5&VD[6'<'FOS"_P""N_P*L/VC?^"I
MG_!._P"!GB3Q+K6C:;KEM\3(=<ET/4I;*ZGL8_#^GRW5D)HBLD27$,<MM(49
M7$<[[64X(C\8?L@_L]_\$O\ _@M1^R3;_L,> (_A]HGQMT[QMX=^)?AG1KV?
M[!K$&G:5'>V4SQ22,HFCG8G>!D@ <<D@'WU\*O&7[4NM_M)_%?PA\6/@_H^B
M_#/1/["_X5+XLLM62:[\1^=9N^J?:8%E9K?[/<A(DW)'O5BPW 9K$_X)Z?MN
M>"_^"B7[*.@?M9?#[P;JF@:5X@OM2MK?2]9DC:XB:SOI[-RQC)7#/ S#!Z,,
M\U\E_LC_  J^'OQR_P""QO\ P4R^#OQ8\+V^M^&?$NF?"C3M=TBZ9A'>6LOA
M:Z62)BI#8921P0:\Q_X-D/\ @G!^Q!?_ +!_PK_;AO/V=]%D^*]EX@\2_9?&
MIEG^U1^5J^H6<>!YGE\6X$?W>GOS0!^L6IZ]H>BR00ZQK-I:/=2^7:K<W"QF
M9_[JAB-QY' YJW7X%_L+:E\"/^"B'P@US]MG]O\ _P""1O[1/[2/C;XG>(]6
MD@\5Z+IEA>:)H6E17DMO;:5I EUJU>U2!8BK,(8Y#*7.]@%8^E^+OC1_P4#_
M &7O^"$?Q"^%/C"T^)'PXU2?X[0_#WX1>)?B-+&GB+3/ ^I7MH+2XN)89I0+
MB*":YM?,60^7L78_R*0 ?H__ ,%0/VV]5_8:_8*^*'[67PQTK1/$NM_#ZQMI
M5T6_NV,#2RWL%N4F\I@Z$+*QQD'*BO>/!FN3^)O!^D^)+F%(Y-0TR"YDC3.U
M6DC5R!GL":_'O_@N5_P1B_8;_8Z_X(Z_$'XF?LF^ I? ?B;P?H^F0:EX@L=8
MN//\5V4NHVD%Q:ZJ6<K>^8SK.I=<I/#$4V#(/Z[?";_DE?AG_L7[+_T0E 'S
M'^VC_P %,_B1\'OVI=!_8)_8T_91NOC+\9-9\)/XIU+2I_%,&B:3X=T03FW6
M]O;R5).6E&U843<V1R"Z!NG_ &0OVE?^"A7Q%^+U]\*?VS?^">%G\,M.A\.S
M:EIGCWPW\3[77]+OYTG@C^PF)88I[>8I,TBEP5987P<BO-?V[?\ @F/^TS\0
M/VP=)_X*,?\ !.[]J[3OA?\ %RS\$?\ "(^(+#Q3X<74]$\2Z2+@W$<4Z\O
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M\8/N?_@FG_R074O^QKN/_2>VKZ%KYZ_X)I_\D%U+_L:[C_TGMJ^A:_"N(_\
MD>8C_$?M&0?\B:A_A"BBBO$/8"OC_P#X*5_\%-/B_P#L2?'OX%_LT? /]CZ#
MXN^+_CI<^((-%L+GXBQ>'4LWTN&SF8&66TN$?>ERYRQCV^3CYB_'V!7Y7_\
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MAT&]\06,-]<#-O92W:++*.?NH3ENAZ#M7Y@_\$TOAI\0/@C_ ,%.;H_LE_\
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MUKVFBNK XRK@,7#$4TG*+NK[?H<V,PM/'865"HVE)6=M_P!3\[O^&%OVJ/\
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MWM^R+'3:>M>_T44 ?%_[+7_!&[P5^S!_P5#^+?\ P4BTOXQ7&J1?$F"\;2?
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-20201231_g21.jpg
<TEXT>
begin 644 biib-20201231_g21.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
M_P!B'_@GW\%_&&K>-[KQ"-:\4Z=?Z2(XM,O&MA;B(2JS@P1&>X>6X;;&B(C$
MG+!0#]A?VM/V'_ '_!<#]D;X/^)?&7QT^(?P\\+ZSHUEXKN]-\ :O':S:E#?
MV$4J6T[RHZ%$$F1NC;GL*_-/_@RDT6T\-_%_]J[P[8/(T%A+X:MH6E(+%$N-
M94$D  G &>*_2[]JC_@H)^RG_P $(OV0_@]X)_:1'BK4M)M=#L?"&B7'A;2(
M[J21]/T^*,O(LLT>U2D8/4G)K\,O^#<+_@L+^R;_ ,$W/C?\;M1_:%T[Q=-'
M\6=6T6/PM_PCFCQ7)0Q7.H%O/WSQ^7_Q]Q8QNZ-Z<@'UK_P=J^&?C%JO[8?[
M/=W^T#X@\9:;^R+<2:=9>/K_ ,,>8\%E?MJDIU"66.,,#<?V?Y!MS(C',<WE
MJQWJ?!?V'_AM\'?#7_!PI\.-+_X-^OB#XU\0_""SLM,N_BY?O+>G3;>R,DRZ
MC#.]S'&98#;^28O.!_TJ3$9RBX];_P"#FB/Q!\-?^"QW[/O[07[:7PVU_P 7
M?LNZ/9Z6+K3[>U>XTP3)>S/J$#QY$;7#+]GD:-R#/$B1Y(4A?(=5^*7[.G[:
M/_!PM^S_ /$'_@@S\&[GPQH>@3Z(?B%J7A'P8VA::UO'J$CZC<3VL:QK';FP
M802,ZQ^<WR ,Q4L ?TP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH B2QL
MHV#QV<2L.A6, BI:** "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\ R1/5
MO^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_B9\0?#OP
ME^'&O_%/Q?)*FE>&M%NM4U-H$#.+>WB:63:I(W-M0X&1DX%;E?C_ /\ !??P
MI=1?M93?$/\ ;2^"7Q \=_LZ6_[.^K6O@,>%-/O+_1?#OC\S3,M_J]K:MD?N
M/*6.>56B4XPN5=D /UN\&^*]'\=^$M+\;>'IC)8:OI\-Y9NP )CD0.N0"<'!
M&1V-?'OQ0_X.$O\ @D[\)?'NM?#WQ#^T??WUSX8U"2R\4ZCX>\!ZUJ5AHT\;
ME'2XNK:T>(;6!!VLV,'-9'_!$&W_ ."1VH_##4_''_!,77/#8U/5-#TB'XE:
M-H&IWL307D,4FV673;I@;1F>2<>:D2"7;C+^6-OOO[8'[2?[*O\ P3E_94\0
M?%WXN:;I.C>$[*.:.V\,Z7IT*/KU_<;RNGVMLH GN+ARPVXP<N[D*KL #TOX
M2?%WX8_'KX:Z-\8O@QXZTSQ-X7\062W>BZ[H]TLUO=Q$D;E8=P05*G!5E*D
M@@9O[17[1/P9_9-^#&N?M"_M!^-XO#G@[PW#%+K6LRVD\XMUDF2"/]W CR.6
MEEC0*BL26'%?,'_! ']E/XP?LB?\$V_#O@GXX^%1X:U[Q'XAU7Q2?!2L2OAB
MVU"Y,T&F@'[ACCVLR8!1Y'4C*DG[1GM[>Z017,"2*'5PLB@@,K!E//<$ @]B
M : /D#X(?\%Y/^"8/Q[^+NC? WPO\>]0T?Q'XFN1;^%[;QIX*U;0XM9E+!5C
MMY[ZVBB=V9E54+!W9U502<5]'_M ?M#_  0_96^%&J_'']HGXFZ3X1\)Z+&'
MU'6]8N/+BC+'"HH&6DD9B%6- SNQ 4$G%?E%_P %A/VJ_B)^U_)\,OV1OVH/
MV,?%7[.WP^U#XS:3<W/Q]^)02ZL=/DM;AS%#9MIZ3K;7-T,JDMS+!&J%]Y"Y
M9>C_ ."\OQF\7R?\%3_V.OV==.^ L_Q5LTGUOQ/HGPP.H16MGXA\1K%]GTV6
M]EF#)%;V;"6Y>0H^U/-^4YX /LK]DK_@LE^P%^VS\6(?@C\!/B=KMQXEO=.G
MU#2;#7? 6KZ4NI6<(!DG@EN[6..10&4XW!L,#MZXK_M1?\%I_P#@GK^R#\9-
M4_9\^+WQ3UZ3QGH<-O-KN@^&O &L:L^G13PK/$\TEI:O$H:)U<#>6P>E<)\)
M_P#@I1^UA\,OVU? G[%'_!3']E3PGX)U+XJV=]-\*O'?P]\72ZMI%_?6D7F7
M&G3BX@BEMYQ$PP_*N9%10=V1[S^V9^TQ\7/V6O#>F^(O@M^Q+XW^,MWJ]S/_
M &A8>!;FRAELC'$FR6<W,B;@^ @V!V^3IT% '1?LG_MB_LS_ +<GPEA^.7[*
M?Q=TSQEX9FNGM7O]/$D;VUP@5F@GAE5);>4*Z,8Y$5MKJV,,"?2G=(T,DC!5
M499B< "OS9_X-YKKP]\1O$/[3W[3=_-8>%_''Q&^,/VSQQ\%+>SNK>Z^'LT4
M4B16MZES! SW<VZ6229(_*=E.UB5<+[[_P %POB?XI^#W_!)#X_^._!5]-:Z
MG%\.;RSM[JW8K) +O;:/(C#E65)V(8<@@$=* ,.W_P""^G_!*2Z^*B?"N']J
M.+]YKW]B1>+&\,ZD/#CZENV_9AJYM_L1/^WYOE_[=?8P((R#7P7XU_91^#$7
M_!N'??LXCPE8'P_9?LM-=P1QVZE1J$6B_;EOP,8,WVQ1<[^\A+=Z]?\ ^".'
MQ0\5?&;_ ()7? +XC>.+RXNM6OOA?I4=_>71)EN9(8%@,SD_>9_+WENY;/>@
M#Z5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['
MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH ****
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M(WF8!'E5^E?[+?P!\+_LJ_LV^ _V:?!=S)/I?@/PCI^A6=U,@5[E;6W2'SG
MX#N5+M[L:[RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^
M">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BO!?^"@W[=V@_L'?#'PWXCC^%^K>._%WCWQM8>#_ (=^!M$NHK>;6]:O
M-YAA:>8^7;1!8W9YGRJ #@Y%>%_\$Z/VN?\ @IG\2/B3K7A3]H?]A^RB\)7?
MQ3\26&I>-M+^,5MJ3^$6@DF9+![.2T@DN((Y$2W2:%C_ *Q6**N< 'W=17RS
M^UC^R[_P4E_:"^-4D_P2_P""CT'P5^&EMI5NEMI'A;X<V.JZSJ%[ES-)/=7P
M*P1CY J1*2P!W$5YE_P30_:@_;)T#]NKXS_\$O\ ]M'XNZ5\5-4^&GA_2?$G
MA7XI:=H$&E7-]IMZ /LM_:V_[F.X0LFTH 64.S%LJ0 ?>=%%?EU\4_B]_P %
M@_V6O^"F'[-'P_\ V@_VX?!^N^!OC5\0-;TR_P#A_P"#?AG:6MO:V5I:>?&&
MOKE9+IW/F1Y*&/!0\D'  /U%HKYR_P""L7[<UW_P3I_8/\;?M1>'_#$.N>(M
M-BMM/\(:)<;C'>ZM>7$=M;*X4AF17D\UU!#,D3 $$@U\>_M.^*_^"N__  2?
M^ 6A?\%%?C[^WBGQDT/1=8TK_A>GPIN/A_IMC8VFGWMS%;2OH]S:QK.LEM+.
MBH7)64?O)!\I0@'ZGT5X-^V5X*_;H^-'@[PQ;?L _M.^#/ALMY+)/X@\4^(O
M!W]N3/:/&A@-G [K$6R6),AP05QWKR7_ (($_M2_M&?M@_\ !.[3?C#^U1\3
MO^$P\8CQIKVEW>O?V+9Z?]HAM+Z2&+]Q9Q1Q)A5'1<^I)YH ^TZ**_,'X!>,
M_P#@I/\ \%7/CG^T%XB\!?\ !0N]_9^\)?![XRZK\/?"G@;PK\/]+U&]FET\
M1DZGJ,E^CNZS>8I6)2J?)(HQMW, ?I]17QY_P1-_;+^/W[97[+WBZZ_:;N](
MU3QC\,OBYKWP_P!3\7>'[,6]CXH_LTP[=4AC7Y$63SMI"?(6B8J%!VK]AT %
M%%% !1110 5%?W7V*QFO=F[R8F?;G&<#.*EJKKO_ " [S_KTD_\ 03515Y)"
MD[19\I_\/2O^J%_^7/\ _<U'_#TK_JA?_ES_ /W-7R317[5_JCP]_P ^?_)I
M_P#R1^0?ZTY]_P _O_)8_P#R)];?\/2O^J%_^7/_ /<U'_#TK_JA?_ES_P#W
M-7R311_JCP]_SY_\FG_\D'^M.??\_O\ R6/_ ,B?6W_#TK_JA?\ Y<__ -S4
M?\/2O^J%_P#ES_\ W-7R311_JCP]_P ^?_)I_P#R0?ZTY]_S^_\ )8__ ")]
M;?\ #TK_ *H7_P"7/_\ <U'_  ]*_P"J%_\ ES__ '-7R311_JCP]_SY_P#)
MI_\ R0?ZTY]_S^_\EC_\B?6W_#TK_JA?_ES_ /W-1_P]*_ZH7_Y<_P#]S5\D
MT4?ZH\/?\^?_ ":?_P D'^M.??\ /[_R6/\ \B?6W_#TK_JA?_ES_P#W-1_P
M]*_ZH7_Y<_\ ]S5\DT4?ZH\/?\^?_)I__)!_K3GW_/[_ ,EC_P#(GUM_P]*_
MZH7_ .7/_P#<U'_#TK_JA?\ Y<__ -S5\DT4?ZH\/?\ /G_R:?\ \D'^M.??
M\_O_ "6/_P B?6W_  ]*_P"J%_\ ES__ '-1_P /2O\ JA?_ )<__P!S5\DT
M4?ZH\/?\^?\ R:?_ ,D'^M.??\_O_)8__(GUM_P]*_ZH7_Y<_P#]S4?\/2O^
MJ%_^7/\ _<U?)-%'^J/#W_/G_P FG_\ )!_K3GW_ #^_\EC_ /(GW=^SW^W+
M_P +X^),'P]_X5=_97G6LLWVS^V_/QL7.-GD)U]<U[]7P%_P3V_Y.3LO^P7=
M_P#HNOOVOSGBO+\'EN9JEAH\L>5.UV];ONV??\,X[%9AESJXB7-+F:O9+2R[
M)!1117S)]"%%%% !1110 4444 %%%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2
M:]TKYZ_8+MO$DOP<U9M)U*WBB_X3C6<K+"6.?M+<YKVW[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#
M'_&C[%XW_P"@W9?^ Q_QH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_Q
MH V**Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QH \@_;__ &+O@)^W=\,M
M!^#/QE\<:OX7U?3_ !5;:_\ #OQ/X6UU-/UK1]<LTD>*[L9&#;I41I"5*L-I
M)P"JLOYR? GXU_\ !0#_ ()B_%[PA:^*_P!JG2?C/\,OBG^V!J/PQU;POXE\
M)V]CXEMK^ZO94;6[>ZM2!<C='YDR.FU-P50-X=/TV_:8_8S^!?[:/@6T^&W[
M6'PMT3QGI&GZFFHZ8EP]Q;3V%TJL@G@GMW26&0*[ .CJ<,>:^?OV"_\ @BU^
MS5^Q_P"/-=^-L?P:T:X\>Q>/=?N?!?B?6_$.IZ[<:3HES=.;2.%M0GD\BX^S
ML$DD4>8V6W2/DD@';_\ !27_ (*.']CZV\._ ?X!^ A\1?V@?B;,UE\+OAI:
MS >8_(?4[]@0;;3X,,\DK%=VQE#*!))'/_P3,_X)Z7G[%7A/Q3\2_C1\0SX]
M^.'Q8U6/6_B_\07C*K?WBJ1#96J$#RK*V5FCA3 XR=J K&E7]I__ ((O?\$Y
MOVT/C4_[1_[2_P"SU/KWCF?2H-.N-?L?B!KVELUM""$C$=C>PQ@#)Z+D]R:Z
M#]D/_@EA^Q)^P?XVU+XB?LK?"&_\.:QK&F#3M2N[[Q_KFKK):^:DI01:A>3Q
MH=T:G<JAN,9P2" >YZ!X^\"^+-9U7PYX6\:Z3J6H:%.L&MV&GZE%--I\K E8
MYT1BT+$ D!P"0#7P/_P5M_Y2H?\ !/;_ +*AXI_]-4%>\_L)_L(ZW^R9XY^-
MGQG\4>*].U?QC\;?BY?>*=:NK..18+72PS1Z;IR;@,M# 3ODV_-)*_4!:\[\
M>?\ !O#_ ,$B_B;XXO/B3XY_98U*_P!;O]4N-1GOF^+?BE"MS.Y>62-4U(+%
MN9C\J!5 X   % '&?\'/'AO6[S_@EI>?$;3+"YNK3P!\2?#'B76X+1"SFQ@U
M!(I6P.H7SU<^@4D\ FI_^#CGXN>!-7_X(C?$!O"NO6^L2?$^+P_I7@"+391*
MVO7-YJ=G- EL!_K2T"23 +U2,D5]9?#']D?X+?!G]GNV_9(^'OP\L!\,;?2K
MS39/">OWUUJR7%K=22R7$,LM[)++,CF>0%9&<8;;]T #PWX)?\$*?^"<G[/7
MQ6T+XQ_#KX+:C<ZCX0O&N_ FE>)_'&JZMI7ABX8[O-L;*ZG>*%PV&5L$HP#(
M5(! !]0?!GPCJ/P_^#_A3P'K$_FW>B>&K&PNI-^[?)#;I&QSWR5/-?"W_!K_
M /\ **^T_P"RH>+/_3K-7U-^UA^P=^SI^W?X+TKP'^UUX#F\3Z?HFJ-?Z7%I
MOBK5-',4[1F,L7T^XA=_E9AM9BO.<9&:\U_9=_X(D_\ !-K]BGXIZ;\;?V7/
MV>+KPQXHT9+H:5>O\1O$-]!";B&2&4FVN[Z6"0LDKC+(2"<@A@" #Z<L?'W@
M75/%]]\/M,\:Z3<Z_I<$<^IZ'!J43WEI%( 4DEA#;XU8$8+  YXK\B?V%/V(
M?AI_P6C^('[0O[:_[2'Q6\9^"O$L_P 5=7\!-X.^$6OIX:.FZ9IP2. :F]I&
M)=2O&60DRW1=< *JA $7].O"_P"R+\%/ W[1/BW]KWP;X"M[+XG>.]%L=*\5
M^)FU6\E6^M;156"/[,\I@BVJ@&8T5C_$6[^)_'3_ ((??\$_OV@?B]KGQY\0
M_#;7_#'BOQ8V[QG?_#SQ_JN@Q^(3SN-W#9S)'*S$L6?:'8L2S,3F@#SO_@WI
M^)FM3_ 7XL_LCFXT+5O#W[//QLUKP#X.\7>'M#MM/BUS3;=EDCEFCM$2!KH&
M0^;+&!YA=7;<[-(_Z!5Y?^SG^RE\(_V.OA#IGP#_ &4?AQH?@GPAI)=K72;"
M.24O(YR\LLLC&2:5L#=)(S.<#+' KN/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&@#8HK'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&@#8JKKO\ R [S_KTD_P#035'[%XW_ .@W9?\ @,?\:JZW9>-1HMX6
MUJS(^RR9 MC_ '3[U4/C1,OA9^6M%%%?T<?@(4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'M_\ P3V_Y.3LO^P7=_\ HNOOVOS[_8(CU&7]HFS3
M2[B.*;^S+K#RIN&-G/%?=GV+QO\ ]!NR_P# 8_XU^0\<_P#(Z7^!?FS]3X,_
MY%#_ ,;_ "1L45EV=IXM2Z1[[5K5X@W[Q$MR"1[&M2OC3ZT**** "BBB@ HH
MHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CW
MK/\ Z4FO=* "BBB@ HHKS7]LSXY:]^S)^R/\3OVC/"W@\^(-3\"^ M6U[3]%
M&[%[-:6DDZ1-M^8(60;BO(7)'- 'H US16UIO#:ZO:G44M1<O8"X7SU@+%1*
M4SN"%E*AL8R",\5:K\>_V+=!_P""@?[;_P 9]%_:)\"?\%C[&#QEXL_9ZT;Q
M#=3^%?A;H.H:)I(N=0NF.@/;.OG,MO(65Y'F2Y+[PQ7 5?TN_:V_9"^'O[:_
MP6C^!GQG\3^*;+1WU"WO-1;P;XCGTF>\:(,#"\T!#^2Q8ED!&<+SQ0!ZM17Y
MD_\ !NE\'?A_^SW\1/VSO@=\*=(EL/#?A3]IB^TS1+.>^FN7AMHK:-$5I9F:
M20X'+.Q8GDFOTVH JZQKFB>'K,ZCK^L6MC;A@IGO+A8DR>@W,0,U8BEBGB6:
M&171U#(ZG(8'H0>XK\?/VJO!'[&&H?\ !:'XMZM_P74NK4?#F?P?H(_9<;Q]
M?7,'A4VRVO\ Q.TB9&6 7RW7EDK*?,*R%@"IC(]8_P""!7@738=<_:;TOX K
MK\_[(^J^-K&+]GF+6I[HVTL1M9TUPZ<;D^<; W)B2)P=C;'*DL)#0!^EM%?C
M?_P60_X(V?\ !%;]@K_@GKX[^.'P_P#V%;!O'%W;1:!\.;6/Q?KLTL^O7[BW
MM#'$U\1*T9=I_+((98&&#G%?:_[-W_!)3]G/P_\ \$H/A[_P3'_:6^'T'BOP
MQHOAVR;Q3I1U*YMXKK5_M!U"ZE66VECD"_;I)9% ?&, Y% 'US17X;?\%)O^
M")/_  2[TO\ ;9_9E_X)]?LA_LIV/AWQ5\1?&,OB3XAZQ;^)=5NWL/!NF1L]
MW&R7-W)'&;IMT<<FW(> J/O8/[DT %%?C5_P6L^'_P"QWXV_X+5_#NY_;Q_9
MK\:_$[X=V?[-UR3HO@GP]JVH7$>I-K4WD2,NELDJJ(UN#EF"<'.3BOK3_@B;
MHW_!&ZV\#>.=?_X))^%X/#_VO4K.U^)/AZ[N=635+"ZMQ.+>.[M=4E>6#'FW
M 5D 1R' 9BAV@'W#1110 4444 %%%% !117YC?M%?\E\\:?]C3??^CWKW\@R
M/^W*\Z?M.3E5]K]?5'AYYG/]C483]GS\SMO;]&?IS17Y)T5]3_Q#[_J)_P#)
M/_MSYO\ UZ_ZA_\ R?\ ^U/ULHK\DZ*/^(??]1/_ ))_]N'^O7_4/_Y/_P#:
MGZV45^2=%'_$/O\ J)_\D_\ MP_UZ_ZA_P#R?_[4_6RBOR3HH_XA]_U$_P#D
MG_VX?Z]?]0__ )/_ /:GZV45^2=%'_$/O^HG_P D_P#MP_UZ_P"H?_R?_P"U
M/ULHK\DZ*/\ B'W_ %$_^2?_ &X?Z]?]0_\ Y/\ _:GZV45^2=%'_$/O^HG_
M ,D_^W#_ %Z_ZA__ "?_ .U/ULHK\DZ*/^(??]1/_DG_ -N'^O7_ %#_ /D_
M_P!J?K917Y)UV?[.O_)?/!?_ &--C_Z/2LJ_ 7L:$JGUF_*F_@[+_$:4>-O;
M5HT_J]KM+X^__;I^G-%%%?GA]X%5==_Y =Y_UZ2?^@FK55==_P"0'>?]>DG_
M *":J'QHF7PL_)VBBBOZ./P$**** "BBB@ HK2U;PIJ^C:%I?B*]C06VL12R
M695LG$<C1MGCCYE/X4>$?!_BCQYK\'A;P=H=QJ.H7+8AMK9,L<<DGL !R2<
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MS<**** "BBB@ HHHH **** "BBB@ HHHH **** "NS_9U_Y+YX+_ .QIL?\
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MH[;OYR;?S"BBBO1. ]O_ .">W_)R=E_V"[O_ -%U]^U\!?\ !/;_ ).3LO\
ML%W?_HNOOVOR'CG_ )'2_P "_-GZGP9_R*'_ (W^2"BBBOC3ZT**** "BBB@
M HHKS#]K?]E#P#^V?\*5^"/Q5\6>+=.\,W&J0W.NV'A'Q)-I3ZU;(KAM/N9H
M")3:R;P9$C=&;8HW 9! /,OCW_P6?_X)6_LR>))_!GQF_;I\ :=K%I(8[W2K
M#5CJ5S:R X*3162RM$P_NN ?:NV_9C_X*)?L+_MFRO9?LN?M6^"/&E]'&9)=
M(T?78C?QH!DNUHY6=5_VB@'!YXKF?V=/V4?^"6GPCUCQ'\"?V;?V?_A!INK>
M 8[./QAI6D>';&2^TO[3!YUN;Z5D:4O)"/,#2L69?FR1S7SEX?T;_@W4_P""
MM/Q<UGX-_!%_AOJ_Q-\*>9=IK_PYT^?P[KUFT+A?MECJ5M%;M=K$Y5@\,DT0
M)!((;D _1FBL?X>>$I? '@#0_ D_BO5]>?1-'MK!]<U^Z$]_J)AB6,W-S(%4
M232;=[N% 9F8X&<5L4 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3
MU;_L>]9_]*37NE ' ?$+]J+X%?"KQ*_A#Q[XY^P:C'$DCV_]F74N%894[HXF
M7D>]8?\ PW3^RO\ ]%2_\HE]_P#&*^7?^"A/_)R=[_V"[3_T77B%?IF6<&97
MC,OI5YSFG**;LXVU73W3\[S#BW,L)CJE&$(6C)I73OH_\1^B/_#=/[*__14O
M_*)??_&*/^&Z?V5_^BI?^42^_P#C%?G=17=_J'D__/RI]\?_ )$X_P#7;-?Y
M(?=+_P"2/T1_X;I_97_Z*E_Y1+[_ .,4?\-T_LK_ /14O_*)??\ QBOSNHH_
MU#R?_GY4^^/_ ,B'^NV:_P D/NE_\D?HC_PW3^RO_P!%2_\ *)??_&*/^&Z?
MV5_^BI?^42^_^,5^=U%'^H>3_P#/RI]\?_D0_P!=LU_DA]TO_DC]$?\ ANG]
ME?\ Z*E_Y1+[_P",4?\ #=/[*_\ T5+_ ,HE]_\ &*_.ZBC_ %#R?_GY4^^/
M_P B'^NV:_R0^Z7_ ,D?HC_PW3^RO_T5+_RB7W_QBC_ANG]E?_HJ7_E$OO\
MXQ7YW44?ZAY/_P _*GWQ_P#D0_UVS7^2'W2_^2/T1_X;I_97_P"BI?\ E$OO
M_C%'_#=/[*__ $5+_P HE]_\8K\[J*/]0\G_ .?E3[X__(A_KMFO\D/NE_\
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M?NX55UW_ ) =Y_UZ2?\ H)JU577?^0'>?]>DG_H)JH?&B9?"S\G:***_HX_
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M@FJA\:)E\+/R=HHHK^CC\!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ]O_ .">W_)R=E_V"[O_ -%U]^U\!?\ !/;_ ).3LO\ L%W?_HNOOVOR
M'CG_ )'2_P "_-GZGP9_R*'_ (W^2"BBBOC3ZT**** "BBB@ HHHH _.[]I?
M]@7_ (*6^%OVY?B'^VY^RE_P4>^''PC\.>-K'3++5=!U_P"'Z74%VMI:I#%+
M>/+*(Y+E6\T).H23RF2)F98U ]'_ &/_ (0?\%>;'XQ>'OB%^T1_P4?^%GQ)
M^&<?VK^V="\)?#&*RFU#-M,D/E7<<K!-EP8I&QG<L;+WKP+3_P!CK]FK_@K#
M_P %6/VCO#O_  4/N[WQDOP2U;1='^&?P<O/$=U9Z?I6E7&EP7+ZT;:WEC:X
MDN9IG'FL2H"A#G$81;3]D7]G/_@E%_P5U_9X^'O_  3UOK_PEI_QQ_X2*P^*
M7P=M?$=S>Z?=:?9Z7+=6^MK!<22-:R17$2Q^9D*X9D3;F7< ?J-1110!\]?L
M%ZQ?V'P<U:"VT"XN5_X3C63YD1&,_:6XYKVW_A)=7_Z%"]_[Z6O(_P#@GO\
M\D3U;_L>]9_]*37NE 'Y]_M[W<]]^T3>7%Q8R6S'3+4>5*1D?)UXKQ>O;_\
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M616->K$3IP*Y"NS_ &=?^2^>"_\ L:;'_P!'I7+CO]RJ_P"&7Y,Z<%_OE/\
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M>3P;_P + LO#>RT9)#)=?:[U&C.QEC7R\;F\S(^Z: /SU_X*]?&?_@WC\?\
M[4]YX+_;F\<^,/"OQH\!VT&GW'BWX?Z!XBM-3MK>6!+F. WFGVSPW*>7.K -
MYFS>R@J2PJS_ ,$>/C1_P;W^!OVH8/AS^P3XU\6^)_C+\0+2YM!XK\?>'_$5
MSJE[;6UM)=RP?;=0MDAMX_*MF<JIC\PQH#N(0#UK_AX?_P %U_\ I75_\VY\
M,?\ R/7H'[+G[9?_  5A^*_QVT+P!^TO_P $7_\ A4W@F_\ M7]M_$#_ (:+
MT+7O[*V6LLD/^@VL*S3^;,D4'RD;/.WGY4(H ^OZ*** /"_^">__ "1/5O\
ML>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH ^ O^"A/_)R=[_V"[3_
M -%UXA7M_P#P4)_Y.3O?^P7:?^BZ\0K]ZR'_ )$N'_P1_(_$LZ_Y&]?_ !R_
M,****]8\P*=#YQF3[/N\S<-FSKG/&,=Z;3HI)(9%FA<JZ,"K*<$$=#0P6Y]#
MZ)\;_#OQ)\!>([CXZ_""'4KZ*]TNTU2]T>62SOKQ\S(DCJ,J\J;2,8 ;.#C
MJ[\#_!'AKX'?MWR_#)=4-W9&WFMK2:Z W'SK43+&^ !NP=AX&3V&<5P^C?MB
M?%^T\&ZM9:AXVFEUB6:T_LS4&TNU>5$3S/-W2F/>6PR;222.<$9.?+I?$GB"
M?Q ?%<^MW3ZF;K[2=0:=C-YV[=YF_.=V><]<U\Q3RC$SCB*3M3A.+BDI.2NX
MQLTFE91LUIO>WV4?15,TP\)4*JO.<6I7<5%V3E=.S=V[K?:U^K/H#X ?&3XQ
M_$3]HH?#3Q]<S7^BZJ]W9ZUX9NH0;2U@6-\HL>,1",JH&,'C!ZUA^#;2TU+]
ME[XI^$/"[_:6TGQ!9WZ!3N>2T$I3S!CJ%"%B>PYKEM;_ &L_CEKVC76CW7B>
MWB:_M_(U"_L]+@ANKJ/&-KS(@<C'7!!/>N3^'WQ(\:?"WQ"OBCP+K;V-V(FB
MD8(KI+&V-T;HP*NIP."#T!Z@5I'*L1:4XQA!_NVHQ;Y6X2O=OE5K_#LVDKN^
MQ#S.@N6$I2FO?3DTKI3C:RU>V^Z3>BMN>D? Y6T#]FCXK>*-2C"6M[;:?IMF
MSCB:X:5B57U*JRL?0'-:=UI/P<USX*^&_A[H7[0&C:'%Y*:EXD@N]-NGFN=1
M=.5<HF"D2G8H!Q]X]3FO-_B1\<_B/\5+&UT;Q3JL"Z=92&2UTS3[*.VMXW/5
M]D:@%N3R<D9.,9-<A73'+:U6<JM2?))SYK1LTK145\4==%?;=^29SRS"C2C&
ME3CS14>6\KIN\G)_"]-7;?9>;1[W^WMX:\/V7Q*C\06GC>TNKZ6PLX9='CMY
M!+%&MN,3%B-I5L# !S\U<3^S?)/X%_:.\(S^*K&:QQJT2LMY"T942@HK$,!@
M98'/2N2\<^/O%OQ)UX^)O&NK?;;XP1PF?R(X_D10JC;&JC@ #.,^M.\=?$/Q
MC\2M>7Q/XUUDWE\MO' LX@CBQ&@P@Q&JC@=\9JL-@,12RR.#J237(XM]M+*V
MBNM][/;<G$8ZA4S&6+IQ:?,I)=];N^KL]MKK?8[O2_ GB-?VRH?!IL93>1^/
M SAD)/E+=>89?]WRQOSZ<U@?M(:W8>(OCUXMU?3)$>WDUVX6*2/[KA7*;AZ@
M[<Y[YK4D_:W^/$FBG26\7Q^<UI]E;5AIT(OFAQC8;C9YGXYW>]>:DDG)-7@\
M-BUB%5KV3C%15FW?6[>J5KV5EKZD8K$89T'2HW:<N9W25M+):-WW=WIZ!111
M7JGFA7ZQ:%_R [/_ *](_P#T$5^3M?K%H7_(#L_^O2/_ -!%?G/B#\&&_P"W
M_P#VT^^X%^/$?]N_^W%JBBBOS4_0@K\QOVBO^2^>-/\ L:;[_P!'O7Z<U^8W
M[17_ "7SQI_V--]_Z/>OON /]]K?X5^9\/QQ_NE+_$_R.,HHHK]2/S<****
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M_P#VBC_ANC_JEW_E;_\ M%?/]%']G8/^7\7_ )A_:.,_F_!?Y'T!_P -T?\
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M5_R,L1_@7_I1^8^)W_(OP_\ C?Y'E5%%%?N!^,A1110 4444 %%%% !1110
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M4?F/B=_R+\/_ (W^1Y91117[@?C(4444 %%%% !1110 4444 %%%% !1110
M4444 %>J_L*_\GI_";_LHVC?^EL5>55ZG^PY/#;?MF_"FXN) B1_$/1V=CT
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M]Q_.1^Z^''_)/R_Z^2_*)I450MO%'A^\G6UM=5B>1SA$4\DU?K\[/OPHHHH
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MRL&5E)!!!!P:N4 >#_\ !/RTM9_@KJSS6T;G_A.M9&60$_\ 'R:]R_L[3_\
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M?^B:^0J_J;A;_DG,)_U[C^2/YFXE_P"2@Q7_ %\E^84445[QX@4444 %%%%
M!1110 4444 %%%% !1110 4444 %?TM>#?\ D4-*_P"P;!_Z+6OYI:_I:\&_
M\BAI7_8-@_\ 1:U^0>+'P8/UJ?\ MA^K^%WQXOTA_P"WFE1117XT?KH5_/1^
MW5_R>G\6?^RC:S_Z6RU_0O7\]'[=7_)Z?Q9_[*-K/_I;+7ZIX5?\C+$?X%_Z
M4?F/B=_R+\/_ (W^1Y51117[@?C(4444 %%%% !1110 4444 %%%% !1110
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M:^0J_J;A;_DG,)_U[C^2/YFXE_Y*#%?]?)?F%%%%>\>(%%%% !1110 4444
M%%%% !1110 4444 %%%% !7]+7@W_D4-*_[!L'_HM:_FEK^EKP;_ ,BAI7_8
M-@_]%K7Y!XL?!@_6I_[8?J_A=\>+](?^WFE1117XT?KH5_/1^W5_R>G\6?\
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M((R"#6&'S# 8NI*G0JQG*.Z4DVO6S-J^ QV%IJ=:E*,7LVFD_O,JBO>O O\
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M3^+/_91M9_\ 2V6OZ%Z_GH_;J_Y/3^+/_91M9_\ 2V6OU3PJ_P"1EB/\"_\
M2C\Q\3O^1?A_\;_(\JHHHK]P/QD*ELC:+>0MJ"NT E7SUB(W%,\XSWQFHJEL
MA9F\A&HF06_FKYYA WA,_-MSQG&<9I/8:W/U4\::A^U+XJ^'?C'Q%_P3C^(F
MC:EX)A7P^_PY\/>!+RRCFTFU2&87T-S:2 /Y[/M9ED#N_']TJOYG>//%7Q3L
M_B[K/B[Q?)?Z)XO;6+B;5O*MCI]Q;7;NWG#RXPGD'+,"BA0,D8 XKZG^$OPN
M_9 T#X*>.]<\)?MSZC9Z+_PD/AZ[FOU\!W\&K:4T3WC11 1DQO,^6"R))M4Q
MEFVY /CW[47QE^&_[8G[:^M?%.[U=_!?A?Q'JEM"VJW^GO<R6=M#;Q6_VF6&
MWRSNPBWLB9(+8!.,GXCAZE'!XNM2C3YJ:6LW2E">D86C*Z]]RNV[*]TVU[Z/
MLL^JRQ>%HU)5+3;T@JD90UE.[C9^XHV25W:S23]QG=_M!7MYJ/\ P2U^!=]J
M%W+/-+XR\2M)--(69SY_4D\DU\K5]N_$6']@KQC^R+X"_9KM?^"@-C%<^"=7
MU2_?5#\,M:*WOVM]XC">4-A7IDL<^U?/OP"^ '@OXE_!3XJ_&+Q[XKO-)MO
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MM6-,U;5=%NQ?Z-J=Q:3J,+-;3-&X'U4@ULZ&-I4G"C46BBH\T6[6WO:2;O\
M*SUUV,57P=2JIUJ;U<G+EDEOM:\7:WSOY'V9XE^&WC?]D/\ X)C^./A)^TP8
MM*\1>/\ Q9I=SX'\&W-]'+=V:V\J/<WS1(S>2KQH8B3@Y"@XW#/Q74U_J.H:
MK=OJ&J7TUS/*<R3W$I=W/J2>34-3EV!J8*-1U)*4ZDG.32LKV2LE=V5HK=N[
MN^I688R&+E35.+C&$5%7=W:[=V[*[NWT5E9= K^EKP;_ ,BAI7_8-@_]%K7\
MTM?TA>#_  3I+>$M+8W-YSIT!XNV_P">:U^8^+'P8/UJ?^V'Z/X7?'B_2'_M
MYU5%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5^-'ZZ;%?ST?MU?\GI_%G_L
MHVL_^ELM?O\ _P#"#Z1_S\WO_@6U?S^_MPVZ6G[9?Q5M8RQ6/XAZPJEFR<"\
MEZGO7ZIX5?\ (RQ'^!?^E'YCXG?\B_#_ .-_D>6T445^X'XR%%%% %VS\2:_
MI^A7OAFQUBXBT_4I89+^RCE(CN'BW>4SKT8KO?&>FX^M4J**2BDVTMQMMI)]
M JS'K&KQ:5+H,6J7*V,TZ3362SL(I)5#!79,X+ ,P!(R Q]35:BAI/<$VM@H
MHHIB"BBB@ HHHH **** "O5?V%?^3T_A-_V4;1O_ $MBKRJO4OV'K=+O]LOX
M56LA8+)\0]'5BK8.#>1=#VKBS/\ Y%M;_!+\F=F7?\C"C_CC^:/Z&J*Q_P#A
M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ_D@_J@V*S?&7_(H:K_ -@V?_T6U0_\
M(/I'_/S>_P#@6U9OC#P3I*^$M487-YQITYYNV_YYM5T_XB]2*GP/T/YO:***
M_L$_DX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z]_X(>?\G]:
M1_V+NI_^B:_:^OQ)_P"")VG0:I^WAI-I</(JGP]J1S$Y4\0^HK]GO^$'TC_G
MYO?_  +:OY_\3O\ DHX_]>X_G(_=?#C_ ))^7_7R7Y1-BBLNS\):;8W27<-Q
M=%HVRH>Y8C\16I7YV??A1110 4444 %%%% !1110 4444 >%_P#!/?\ Y(GJ
MW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 ?BA_P %P_\ D_K5_P#L
M7=,_]$U\A5]>_P#!</\ Y/ZU?_L7=,_]$U\A5_4W"W_).83_ *]Q_)'\S<2_
M\E!BO^ODOS"BBBO>/$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^EK
MP;_R*&E?]@V#_P!%K7\TM?TM>#?^10TK_L&P?^BUK\@\6/@P?K4_]L/U?PN^
M/%^D/_;S2HHHK\:/UT*_GH_;J_Y/3^+/_91M9_\ 2V6OZ%Z_GH_;J_Y/3^+/
M_91M9_\ 2V6OU3PJ_P"1EB/\"_\ 2C\Q\3O^1?A_\;_(\JHHHK]P/QD****
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M;/\ ^BVJZ?\ $7J14^!^A_-+1117]@G\G!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?7O_  0\_P"3^M(_[%W4_P#T37[7U^*'_!#S_D_K2/\
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M "BBB@ HHHH *]5_85_Y/3^$W_91M&_]+8J\JKU7]A7_ )/3^$W_ &4;1O\
MTMBKBS/_ )%M;_!+\F=F7?\ (PH_XX_FC^A>BBBOY(/ZH"LWQE_R*&J_]@V?
M_P!%M6E6;XR_Y%#5?^P;/_Z+:KI_Q%ZD5/@?H?S2T445_8)_)P4444 %%%%
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MK#11_K%Q!_T&5?\ P9/_ ##^P,B_Z!*7_@N/^1^3W_#@G]H__H?/A9^>L?\
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MV+H.>H!KU^C_ %BX@_Z#*O\ X,G_ )A_8&1?] E+_P %Q_R/R>_X<$_M'_\
M0^?"S\]8_P#BJ/\ AP3^T?\ ]#Y\+/SUC_XJOUAHH_UBX@_Z#*O_ (,G_F']
M@9%_T"4O_!<?\C\GO^'!/[1__0^?"S\]8_\ BJ/^'!/[1_\ T/GPL_/6/_BJ
M_6&BC_6+B#_H,J_^#)_YA_8&1?\ 0)2_\%Q_R/R>_P"'!/[1_P#T/GPL_/6/
M_BJ/^'!/[1__ $/GPL_/6/\ XJOUAHH_UBX@_P"@RK_X,G_F']@9%_T"4O\
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M#(O^@2E_X+C_ )'Y^_\ #@G]H_\ Z'SX6?GK'_Q5'_#@G]H__H?/A9^>L?\
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M+Q#H$^KR>'X-<LWOXDWRV*7*&9%X^8IG<!R.<=ZN5^0O_!77_@D'_P $I?V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^%_^#@?_DS3PS_V4ZR_]-VHU^/=?L)_P<#_ /)FGAG_ +*=9?\
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MS:EIGCWPW\3[77]+OYTG@C^PF)88I[>8I,TBEP5987P<BO-?V[?^"8_[3/Q
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M)&$@)EVJS+A?,Q^E= !1110 5\Z?\%,_^2(:-_V-</\ Z37-?1=?.G_!3/\
MY(AHW_8UP_\ I-<U[G#?_(]H?XOT9XW$'_(EK_X?U/AZBBBOW0_&#[G_ .":
M?_)!=2_[&NX_])[:OH6OGK_@FG_R074O^QKN/_2>VKZ%K\*XC_Y'F(_Q'[1D
M'_(FH?X0HHHKQ#V KX__ ."E?_!33XO_ +$GQ[^!?[-'P#_8^@^+OB_XZ7/B
M"#1;"Y^(L7AU+-]+ALYF!EEM+A'WI<N<L8]ODX^8OQ]@5^5__!=C4_CKH_\
MP55_X)^:E^S1X6\.:WXYBUGXAGP_I?BW4I;/3KB3^SM+#B::%'= (RY!53E@
MHZ'- 'NOP*_X*V_%L_MB>$_V&_V_OV"]:^ _C/XBZ?>W7PVU"/QW8^)=&\0-
M9QF2X@6\M8XO)F5,'RV3/*@[2\>_[7O+RTT^UDOK^ZC@@B0O+-,X5$4=22>
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M9"T)_#'PM_:?\#>+K+Q]\,;*^F;2(;_1[#[9%J<,#NPMY9$(MSLVJ5#<98T
M>WVW[>'[<?[17[=_Q*_9B_8K^"OPL'@WX):]HVE?$7Q;\2_%.H07>H37D"W4
MR:;;65M( T,19<SLJNX'(!./M>OR"_X)*?\ !+7_ ()_VW_!3+]JR_@_9CT)
M9O@M\8_#S_"V037.?#S#3UN@8?WO/[Y0_P ^[D>G%?JQ\9_A9X:^.?P>\5_!
M/QG%YFC^,/#5]HFJIMSNMKNW>"48/7Y)&H Z6BOP2M9?'O\ P48_X);_ ++W
M_!%W5O$<EAXX;XA>*?!_Q%>";/V"U\$VEUY<4F1D*6ET7!8?>P/>O8_@;^T+
MJ?\ P4T^+7_!.#X+:VTMS/X)\(ZE\4?BQ:3\R0ZMX?1M"M)G4\JW]KI=9SR,
MC&30!^P&L:YHGAZT%_K^L6MC 7"":\N%B0L>BY8@9..E65974.C @C((/!%?
MEC^S7^RA\$?^"M__  4*_:I^,/[?GA1/B'I?PD^)K?#GX8^ M;OICI?AZRM;
M96N+R.V5U5I[IW#F5@2"K;2 %VY'[)EKJO[+^N?\%$?^"77A/Q3JNJ?"_P"$
M7@6WUOX866JZA)=OX<M=:\.W5W/I2RREG$$;A/*0L2%#L26=C0!^KMWK&D:?
M=V^GW^JVT$]VQ6T@FG57F(&2$!.6('I7SK_P2R_;<\:?M\_L[ZY\9O'?@W2]
M#O-*^)7B#PU%9Z3)(T3P:?=M!'*3(2=[ 9;MGI7RI_P0-_X)<?LH3?L)_ ']
ML_XK^!I?&7Q7/ABSU71?&6OZK<S2Z' N];.RL8_,$5M!#!M78JX=S([[B]?/
M/PV_:6^*G[)O_!MA^T1\7/@GK\VC^)V^.GB;1M+UN"0H^F?VCXE@L9+E'7F-
MTBN)"CCE7V,.10!^JW_!0+]K&\_9&_8M^*_[2O@&STC7=<^'/A.YU5-%O;HF
M-Y8UW+',(V#H#^!KTGX,^-[WXF?!_P *?$C4K**VN/$'AJQU*XMX"2D3SVZ2
MLBYYP"Y SS@5^4__  5C_P""(W[$'[(G_!(#XE?$#]G+PK=>%?B#X,\"L^H?
M$.VUBY&H>*$=HTU"'4RTA6[2[5Y28W!5)6C:,+L K]/OV3_^36?AI_V3_1O_
M $AAH [^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ^4?^"PO[-7QK_:F_9GT/X?? ?P7_;NKV?CJVU&YM/[2MK79;)97L;2
M;[B2-3AYHQ@'/S9Q@$C\W/\ ASE_P4>_Z-S_ /+OT?\ ^2Z_=&BOLLDXXS;(
M<"L)AX0<4V_>4F]?227X'R&<\%Y7GF->*KSFI-)>ZXI:>L7^9^%W_#G+_@H]
M_P!&Y_\ EWZ/_P#)=?I'_P $>OV:OC7^RS^S/KGP^^/'@O\ L+5[SQU<ZC;6
MG]I6UUOMGLK*-9-]O)(HR\,@P3GY<XP03]744\[XYS;/L \)B(046T_=4D]/
M637X#R;@O*\CQJQ5"<W))KWG%K7TBOS"BBBOC#ZX**** /FW_@HW_P $[-*_
M;R\/>"O$?A3XPZI\-?B?\+?$PU_X8?$C1]/CO)=&O"H66.6VE(2ZMI55!)"6
M4-Y:9. RMX;XN_X)1?MS_ME^)?"6@_\ !3S]OSP_XW^&7A#Q+:Z[)\-_A]\-
M%T2+Q->6S;K<ZC<O<2N80W+01J%;/5656'Z"44 > ?M#_L,?\+[_ &[/V=/V
MUO\ A:/]D_\ "@?^$N_XIG^Q//\ [=_MS2X[#_CX\]/LOD>7YG^KE\S.WY,;
MJ/VEOV&/^&B/VSOV>?VN_P#A:/\ 8_\ PH74/$EU_P (]_8GVC^W?[6TY++;
MY_GI]E\K9OSY<N_.W"?>KW^B@#P#]GC]AC_A0G[=G[1?[:W_  M'^UO^%_?\
M(C_Q3/\ 8GD?V%_8>ER6'_'QY[_:O/\ ,\S_ %<7EXV_/G=7EG[#O_!,+]IK
M]@3Q?:> /@S_ ,% ([GX"6'B?5-5LOA'K'PGM9;VWAO99IVM$UE;M7")<3>8
M&,!) *]&R/M*B@#X+T#_ ()<_MK?L@>./%@_X)B?MQ^'?!?PY\9^([G7KCX6
M_$?X=_VW9:!J%R=US)IMQ%<P2Q0NWS"V;*(<D$[C7J?C?_@G;XM_:B_8)\7_
M +%__!0+]I.Z^*&H^-)I)[OQII7A6VT%M+E62*6S-E;0M(L?V:6&-U+L[2'=
MO+!B*^H:* /S2_:/_P"",W_!1G]NK]ER]_8\_;,_X*MZ;J?A*UMK==)O?#/P
MC6VO=8NK>1&@NM89K[_20@4MY$+1!YO+E=V\O:WZ.^$]"_X1?PKIGAG[5Y_]
MG:?#:^?LV^9Y:!-V,G&<9QDX]:T** /E_P#:P_9A_P""BWC#XUK\9OV+/^"A
M]EX"T^31K>RU'X;^,OAQ!KNCW,T3R-]KCE\Z*>UD82!6$9(8(I/(%<5^S#_P
M2Z^.FG_MHZ?_ ,%#/^"@7[7T?Q9^(_AKPY<Z)X TGP]X0CT+0_"UM<AEN7AA
M6622XFD1W4RR,#MD8$-MC*?:M% 'QAX6_P""8G[2GP(_:X\=_'O]D7]OM/!7
M@KXI>/X/%WC_ .&NN?"JUUL7=]B-+S[-?M=0R6HN$CQ]R3RR01G&#@2?\$Q?
MVX/@+^T5\4_B/_P3^_;R\/> O!WQJ\6R^*?%WAKQC\,4UV?1];G14NK[3Y?M
M,*L9=BGRIE9%*@?,*^[J* /D7_@G]_P29\,_L1?"GXU_!WQ/\=-:^(^F_&OQ
MCJ&N:YJ&N6(M]0_TZRCMKI9YUE<7$TC+)*TRI$-TI C4**K?L!_\$X/VG_V,
M/"VG?L]>//V\K+XF_!#0O#5UH>B?#K5_A#:65Y':2'$23ZE%=L;A41G0@P*'
M##.,<_8=% 'Y_P#PG_X)@_\ !1S]BCP[-\!OV /^"COAW2_A%%>W$OA7PM\4
M?A?_ &Y?^$H9I6E:UM;V.[A-S"KNY19U^4';D]3[3XY_9E_X*'O^SKX*\%_"
MO_@I'!:?$OPWJ-S=>*/'7B+X3V-U9^+HY7F86LVGQ31K91IYD81H'WJL"@EM
MS9^EZ* /C'X!_P#!.#]IG6/VT_#/[>W_  4!_:LT'Q]XM^'_ (<U'1_AWX;\
M"^!O[$TG1EOE$=W=2-)///=2R1_( S*J#) )QC[.HHH **** "O%OVYOA-\0
M/C%\+--\-_#C0/[1O;?Q!'<S0_:XH=L0@G4MF5U!^9U& <\_6O::*ZL#C*N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-20201231_g22.jpg
<TEXT>
begin 644 biib-20201231_g22.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
MF\$&\?Q')I.K/J+2M=&^C^S&<N4/[N79][+YVUH?\%-/^"'_ /P\7_;E^"O[
M9_\ PT[_ ,(=_P *?N+"7_A&_P#A"O[0_M?[-J8OL?:/ML/V?=CR_P#5R8^]
MS]VOO>B@#\\_^"H7_!!;3?VV/VG?#O[?/[+7[4&M? _XY^&X(84\6Z1IWVN#
M45A1HXFEC62)TE$3&$R!F5X<1O&X IW[)O\ P2J_X*:^%?VE?!_[0W[<G_!9
M+Q5\3-.\&7DUQ:?#O1/"ZZ3I6H2/;RPJ]WY4RI-L\TN T)(900PK]"J* "OE
MC_@L+_P30_X>P_L?-^RC_P +J_X0'=XHL=8_M_\ X1O^U?\ CW$H\KR/M-O]
M[S/O;^-O0YX^F-)\4^&->N9[/0O$=A>S6QQ<Q6EXDC1'.,,%)*\@CGTJ_0!Y
M!^P'^RE_PPW^QM\/?V2?^$]_X2C_ (0/P^FF?\)!_9?V+[=M=F\SR/-E\K[V
M-OF-TZU\*?M"_P#!NW\5_"_[:?BC]O+_ ()6_M^ZO\ O%GCF6XF\7Z$WAU-1
MTZ[FN)1+<,@,BA8WE'FF&2.51(2R-& JK^GVF>(= UN:>WT;7+.[DM9-ETEK
M<I(86_NL%)VG@\'TJS<W-M9V[W=Y<)%%&I:261PJJ!U))X H ^'_ -B7_@E9
M^U/\,?$WCKQM_P %!_\ @I-XL^/\OCSP'=>%+KPS=Z2=,TC3;.Y9#.T$"3N@
ME=4V&1(XCM8@@X!KY8_9M_X-@_VG_P!F-/&_[/WPQ_X*Y>*]#^ GCNXGD\1>
M"]#\)1PZEJD<D7D^1+<F8K"6BVQRRP!#-&FTH@(V?K_HOB#0?$=J;[P]K=G?
MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *5]XBT339_LM_J4<4@ .QCSBHO\ A,?#'_0:@_[ZKR#]@VYN==^#FJWN
MN7#WDR^-M7C66[<R,$6Y(5<MDX Z#M7M?]G:?_SXP_\ ?H4 4_\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0
M:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H5YK^V7\8K_\ 9C_9'^)W[1GA
M7P%%K^I^!/ 6K:]I^BB(XO9K2TDG2)MOS!"R#<5Y"Y(YH []?%WA=[QM.3Q!
M:&Z6S%VUH)U,PMRY02E/O;"RE0V,9!&>*GL-;TO5"RZ=>+-MQN,8) ^I[5^0
MO[%F@?\ !0+]M_XSZ+^T3X#_ ."QUA;^,O%?[/6C>(;J?PK\+=!U#1-)%SJ%
MTQT![9U\YEMY"RO(\R7)?>&*X"K^EG[67['OPW_;2^"Z_ WXQ^(O$]AH\NHV
M][J3>#/$,VD3WK1!@89)H"'\EBQ+(",X7GB@#U*_U&RTR#[3?W"Q1[L;VZ9J
MG_PF/AC_ *#4'_?5?FS_ ,&ZWP8^'7P!^(7[9WP+^%^AO9>&?"G[3-]IFB6-
MS>2W3PV\-M&B*TL[/)(V!RSL6)Y)K],O[.T__GQA_P"_0H K7GBKPWIVG+J^
MIZ[:6MH[A$N;N=8HV8] &? )X/Y4^]\0:-IL@BOM02)F7<H?(R/4>M?E;^S_
M /LM_ /_ (*M?\%5?VMKS_@H7X87Q^/@OXHTOPI\-/AWK=_.NG>'=(EM7D-]
M':HZJTET\>_S6!/RM@X*@=A_P1&^(VC_  L_;2_:R_X)9>#/&%YKWPZ^"?B[
M3;WX71ZGJ,E\^AV5] YO-'2:5F?R;6Y01HK,2#YF3F@#])M/U73]51I=.NEF
M53AF3H#Z4R?7=)MKT:=/?*LY(Q%@[CGI@=Z_%'_@X)\;>)?^"B'[,OQ^\0>
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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MO^"5WP"^(WCB\N+K5K[X7Z5'?WET29;F2&!8#,Y/WF?R]Y;N6SWH ^E:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\
MTI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* . ^(7[47P*^%7B5_"'CWQS]@U
M&.))'M_[,NI<*PRIW1Q,O(]ZP_\ ANG]E?\ Z*E_Y1+[_P",5\N_\%"?^3D[
MW_L%VG_HNO$*_3,LX,RO&9?2KSG-.44W9QMJNGNGYWF'%N983'5*,(0M&32N
MG?1_XC]$?^&Z?V5_^BI?^42^_P#C%'_#=/[*_P#T5+_RB7W_ ,8K\[J*[O\
M4/)_^?E3[X__ ")Q_P"NV:_R0^Z7_P D?HC_ ,-T_LK_ /14O_*)??\ QBC_
M (;I_97_ .BI?^42^_\ C%?G=11_J'D__/RI]\?_ )$/]=LU_DA]TO\ Y(_1
M'_ANG]E?_HJ7_E$OO_C%'_#=/[*__14O_*)??_&*_.ZBC_4/)_\ GY4^^/\
M\B'^NV:_R0^Z7_R1^B/_  W3^RO_ -%2_P#*)??_ !BC_ANG]E?_ **E_P"4
M2^_^,5^=U%'^H>3_ //RI]\?_D0_UVS7^2'W2_\ DC]$?^&Z?V5_^BI?^42^
M_P#C%'_#=/[*_P#T5+_RB7W_ ,8K\[J*/]0\G_Y^5/OC_P#(A_KMFO\ )#[I
M?_)'Z(_\-T_LK_\ 14O_ "B7W_QBC_ANG]E?_HJ7_E$OO_C%?G=11_J'D_\
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MV$[S]DOQS\<?C/XW\3V>L^,?C=\6+_Q1JMUIR.L%GIH9H],T]0X&XPVY.]\
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M_!NA_P $>-6\2ZOXNN/V5M4BU#7=4GU'5IK+XK^*;<7-U,Y>24I%J:J"68G
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M?6W_  ]*_P"J%_\ ES__ '-1_P /2O\ JA?_ )<__P!S5\DT4?ZH\/?\^?\
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M^J%_^7/_ /<U'_#TK_JA?_ES_P#W-7R311_JCP]_SY_\FG_\D'^M.??\_O\
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MA_X]9/\ ED/[IK0JKKO_ " [S_KTD_\ 0350^-$R^%GY.T445_1Q^ A1110
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M:XHYC@9J;C43Y-9:K1)7;]/UT.N6 QL'!.FUS[:;MNUO4Y.BO9-(_9Q^%7Q
MU&[\&?"+X[-K'B2UMY9+:QN] >V@U Q@EEAEWM@X!(R.>O R1X_:6EU?W45C
M96[S332+'#%&I9G8G 4 =22<8J\/C,/B7)0;O&UTTXNSV=I).SL]?)DU\)7P
MZ3FE9WLTU)76ZNF]5=:>:(Z*]/\ C=^S9/\ !3P3H7B>^\:0:A>:I<2VU_I]
MO:X6PN(E4R1>;O(D*L2IPHP5-)X<^!7@W3OA]IGQ(^,WQ+?P]:ZZ\@T.PLM*
M:[N;F-#M:9@&41H#P,Y)R#6,<TP4Z$:T)7C)M*R;;:O=)6N]GTM97V-7EV,C
M6=*4;-)-W:22=K7=[+===]-SS&BNP^,'PCN/A9J&GSV7B"#6=%UNQ%YH>LVT
M31K=0DX(*-S&ZGAD).,BN9T2SLM1UFTT_4]42QMI[J..XO9(RZVZ,P#2%5Y8
M*"3@<G%=5*O2K455@[Q?K^6]_+>^AS5*-6C5=.:L_P"NNUO/8JT5['X;^ 7P
M*^(.K1^"_AW^T8]UKUR&73XM1\+S6MM=R $A Y<E,XX)!],9.*\DU72[[1-4
MN=%U. Q7-G</!<1$\HZ,58?@0:RP^-H8F;A"Z:ULXRB[/9VDEIH:5\)6P\5*
M5FGI=-25UTNF]2O11176<P5^L6A?\@.S_P"O2/\ ]!%?D[7ZQ:%_R [/_KTC
M_P#017YSX@_!AO\ M_\ ]M/ON!?CQ'_;O_MQ:HHHK\U/T(*_,;]HK_DOGC3_
M +&F^_\ 1[U^G-?F-^T5_P E\\:?]C3??^CWK[[@#_?:W^%?F?#\<?[I2_Q/
M\CC****_4C\W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KL_P!G7_DO
MG@O_ +&FQ_\ 1Z5QE=G^SK_R7SP7_P!C38_^CTKEQW^Y5?\ #+\F=."_WRG_
M (E^:/TYHHHK^>3]W"JNN_\ (#O/^O23_P!!-6JJZ[_R [S_ *])/_0350^-
M$R^%GY.T445_1Q^ A1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
MW_\ !/;_ ).3LO\ L%W?_HNOOVO@+_@GM_R<G9?]@N[_ /1=??M?D/'/_(Z7
M^!?FS]3X,_Y%#_QO\D%%%%?&GUH4444 %%%% !1110 4444 %%%% 'SU^P7K
M%_8?!S5H+;0+BY7_ (3C63YD1&,_:6XYKVW_ (275_\ H4+W_OI:\C_X)[_\
MD3U;_L>]9_\ 2DU[I0!^??[>]W/??M$WEQ<6,ELQTRU'E2D9'R=>*\7KV_\
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M;"C KUR[+TQFJ>@?M!?!7X<:Q-X[^%'P+N;'Q&T4BV$VI:\;BUTYW4J7CCV
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M89<$D\\#!\4IX;%K$N47%QE'=.U]5=;-JS]18C#/#J,E)2C+9J]M'9[I.Z]
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MO%'PI^%/P*UCX.?#WQP?%.J^*+^VEUK4X+&2"UMH8'$B1IYG+MN'WAQ@GI@
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M_P#0350^-$R^%GY.T445_1Q^ A1110 5O_#+QMXO^''C2T\;^!\_;].WR@&
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M *+K[]KX"_X)[?\ )R=E_P!@N[_]%U]^U^0\<_\ (Z7^!?FS]3X,_P"10_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#V_\ X)[?\G)V7_8+N_\
MT77W[7P%_P $]O\ DY.R_P"P7=_^BZ^_:_(>.?\ D=+_  +\V?J?!G_(H?\
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M )$N'_P1_(_$LZ_Y&]?_ !R_,****]8\P**** "BBB@ HHHH **** "BBB@
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M0!]?T444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4
M? 7_  4)_P"3D[W_ +!=I_Z+KQ"O0_\ @IO\<OA;X#_:LU#P]XK\4?9;Q-'L
MG:'[%/)A6CR#E$(_6OGS_AJ3X$_]#U_Y3+K_ .-5_0&08>O+),.U!VY(]'V/
MPW/,10CG&(3FK\\NJ[GH%%>?_P##4GP)_P"AZ_\ *9=?_&J/^&I/@3_T/7_E
M,NO_ (U7K_5L3_(_N9Y7UG#?SK[T>@45Y_\ \-2? G_H>O\ RF77_P :H_X:
MD^!/_0]?^4RZ_P#C5'U;$_R/[F'UG#?SK[T>@45Y_P#\-2? G_H>O_*9=?\
MQJC_ (:D^!/_ $/7_E,NO_C5'U;$_P C^YA]9PW\Z^]'H%%>?_\ #4GP)_Z'
MK_RF77_QJC_AJ3X$_P#0]?\ E,NO_C5'U;$_R/[F'UG#?SK[T>@45Y__ ,-2
M? G_ *'K_P IEU_\:H_X:D^!/_0]?^4RZ_\ C5'U;$_R/[F'UG#?SK[T>@45
MY_\ \-2? G_H>O\ RF77_P :H_X:D^!/_0]?^4RZ_P#C5'U;$_R/[F'UG#?S
MK[T>@45Y_P#\-2? G_H>O_*9=?\ QJC_ (:D^!/_ $/7_E,NO_C5'U;$_P C
M^YA]9PW\Z^]'H%%>?_\ #4GP)_Z'K_RF77_QJC_AJ3X$_P#0]?\ E,NO_C5'
MU;$_R/[F'UG#?SK[T>@5^L6A?\@.S_Z](_\ T$5^+O\ PU)\"?\ H>O_ "F7
M7_QJOV@\.RQS^'[":)LJ]G$RG'4%!7YKXB4JE.&&YXM?'NO\)^A<!U:=2>(Y
M))_#L_\ $7****_,C]%"OS&_:*_Y+YXT_P"QIOO_ $>]?IS7YC?M%?\ )?/&
MG_8TWW_H]Z^^X _WVM_A7YGP_''^Z4O\3_(XRBBBOU(_-PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *[/\ 9U_Y+YX+_P"QIL?_ $>E<979_LZ_\E\\
M%_\ 8TV/_H]*Y<=_N57_  R_)G3@O]\I_P")?FC].:***_GD_=PJKKO_ " [
MS_KTD_\ 035JJNN_\@.\_P"O23_T$U4/C1,OA9^3M%%%?T<?@(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'M__  3V_P"3D[+_ +!=W_Z+K[]K
MX"_X)[?\G)V7_8+N_P#T77W[7Y#QS_R.E_@7YL_4^#/^10_\;_)!1117QI]:
M%%%% !1110 5Y/\ MD_"[]JKXN_"./PI^QY^U/:?"#Q:NL0SR>++WP/;>($>
MS5)!);?9;EE0%V:-O,SE?+P/O&O6*\O_ &L_V/\ X(_ML?#BQ^%/Q\TO5+O1
MM.\06VM6L6DZ[<Z?(+NW#B-C);.CLH\QLH3M/&0<"@#Y0_X82_X+X?\ 2>7P
M_P#^(NZ)_P#'Z] _9<_9-_X*Z?#/X[:%XW_:?_X*UZ/\3O UE]J_MSP/:_ ;
M2]%DU+?:RQPXO()6DA\N=XIOE!W"(H>&-?./_!5CX(_\&Z_@7]IO5OB=_P %
M&_CY?^'?B+XMBMKO4=)TWXAZ_P"?Y:01V\,AL-,=_LZ-'"N"8U#E6;DY-<U_
MP3"/_!M%_P -R>!_^'?O[07B37/B[_Q,_P#A$M+O]=\6S0S?\2R[^U;DU!!;
M'%I]I8>8>"H*_,%H _7*BBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_
M .2)ZM_V/>L_^E)KW2@#\4/^"X?_ "?UJ_\ V+NF?^B:^0J^O?\ @N'_ ,G]
M:O\ ]B[IG_HFOD*OZFX6_P"2<PG_ %[C^2/YFXE_Y*#%?]?)?F%%%%>\>(%%
M%% !1110 4444 %%%% !1110 4444 %%%% !7]+7@W_D4-*_[!L'_HM:_FEK
M^EKP;_R*&E?]@V#_ -%K7Y!XL?!@_6I_[8?J_A=\>+](?^WFE1117XT?KH5^
M8W[17_)?/&G_ &--]_Z/>OTYK^>C]NK_ )/3^+/_ &4;6?\ TMEK])\-<+]:
MS"O&]K17YGYYXAXKZK@:,K7O)_D?5=%?G_17[#_8_P#?_#_@GY1_;']S\?\
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M *I=_P"5O_[11_PW1_U2[_RM_P#VBC^SL9_+^*_S#^T<'_-^#_R/H"BOG_\
MX;H_ZI=_Y6__ +11_P -T?\ 5+O_ "M__:*/[.QG\OXK_,/[1P?\WX/_ "/H
M"BOG_P#X;H_ZI=_Y6_\ [11_PW1_U2[_ ,K?_P!HH_L[&?R_BO\ ,/[1P?\
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M3$4$A&YAD@*,D@4 ?7]%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\
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MJXLS_P"1;6_P2_)G9EW_ ",*/^./YH_H7HHHK^2#^J K-\9?\BAJO_8-G_\
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M?#OA_P (>'['PGX3T.STS2M+LXK33--T^V6&WM+>- D<,4: +&BJH554
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MW4__ $37[7U_/_B=_P E''_KW'\Y'[KX<?\ )/R_Z^2_*(4445^=GWX4444
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MUB[N=$L'M;*2YD:TM9)?,:&(L2B%C]X@8&>^,U]"_L5?!OX(ZK\&OBQ^T_\
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M72G_ ,)CX8_Z#4'_ 'U7\_'[<<\-S^V;\5KBWD#I)\0]89&'0@WDN#7]"?\
M9VG_ //C#_WZ%?SW?MT*J?MH_%A$4 #XBZR  .!_IDM?JGA5_P C+$?X%_Z4
M?F/B=_R+\/\ XW^1Y51117[@?C(4444 %%3PZ9J5Q8SZI;Z?/);6S(MS<)$3
M'$7SL#,!A2VUL9ZX..E04KIA9H****8!13[:VN+R=+6TMWEED;;''&A9F/H
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M'_?5?C!_P1!BBF_;WTE)HU=?^$=U+AAD?ZFOVK_L[3_^?&'_ +]"OY_\3O\
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M)?\ DH,5_P!?)?F%%%%>\>(%%%% !1110 4444 %%%% !1110 4444 %%%%
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MY!XL?!@_6I_[8?J_A=\>+](?^WFE1117XT?KH5_/1^W5_P GI_%G_LHVL_\
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M77A,?CL!)RPU65-O=QDXW];-'+BL%@L=%1Q-*,TMN:*E;[TS\GO^'!/[1_\
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M_P (D1N5A@C(MLC@U]E44)M,-S\GO^'!/[1__0^?"S\]8_\ BJ/^'!/[1_\
MT/GPL_/6/_BJ_6&BO9_UBX@_Z#*O_@R?^9Y']@9%_P! E+_P7'_(_)[_ (<$
M_M'_ /0^?"S\]8_^*H_X<$_M'_\ 0^?"S\]8_P#BJ_6&BC_6+B#_ *#*O_@R
M?^8?V!D7_0)2_P#!<?\ (_)[_AP3^T?_ -#Y\+/SUC_XJC_AP3^T?_T/GPL_
M/6/_ (JOUAHH_P!8N(/^@RK_ .#)_P"8?V!D7_0)2_\ !<?\C\GO^'!/[1__
M $/GPL_/6/\ XJC_ (<$_M'_ /0^?"S\]8_^*K]8:*/]8N(/^@RK_P"#)_YA
M_8&1?] E+_P7'_(_)[_AP3^T?_T/GPL_/6/_ (JN.^"/_!&KXY_&WPE<^+=
M\6_#FWAMM8N]/=+\:J'+P2%&8;'(VDCCOZU^R5>0?L4^!?%WP^^$^I:)XTT&
M?3KN;QAJEU'!< !FADG+(_!Z$<BC_6+B#_H,J_\ @R?^8?V!D7_0)2_\%Q_R
M/S]_X<$_M'_]#Y\+/SUC_P"*H_X<$_M'_P#0^?"S\]8_^*K]8:*/]8N(/^@R
MK_X,G_F']@9%_P! E+_P7'_(_)[_ (<$_M'_ /0^?"S\]8_^*H_X<$_M'_\
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M:?$/X8Z?J4TFG6][9Q&33M7BMY'803221M;EEVJR1R<9+$@'ZN4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %.[\0Z!8:G!HM]KEG#>70)M;26Y1
M99@/[J$Y;IV%7*_/?X\?\$$?^",/@OX->/?BY^T3\,;QIET^^UOQ3\6O$WC?
M49=8L657E:]2X:;9$\6 R(D80E5!1LD'Q[]G[]NC]K_]GC_@U1G_ &R_BUX@
MU:Z^(6E^!+V'PAXBU\&2_EMKK53I^D7\V_/F.L4]O*K-N\Q$C=B^\D@'ZOQZ
MYHDVK2:!#K%J]_#&)););A3,B'&&*9W <CG'>K5?D!^T9_P1:^ ?[,'_  2.
MOOVQ/@TFM:/^TS\-/AXGQ%G^-\/B&[EUK4-;M;87^H//(\K+-#,JW$9B<,@1
MAD$@D_:]U\&_A7_P60_X)Z?![Q7\=]3\5:3H_C#P[H/C;4=-\%>*+G2#<SW&
MELSV4\L#"1[8&[<F,,,M%&V?EY /JBJ^J:MI>B63ZGK6I6]G;1X\RXNIEC1<
MG RS$ <U^;G_  ;)?#GPA\'O@;^U#\)/A[IC66@>%OVT_&VD:'9/<R3&WL[:
MVTJ&&,R2LSR%8T4;G8L<9)))-<'_ ,%,/!G[-^K_ /!9'0]5_P""Q=VZ_LV2
M?"-8?@^?$M]<P^$E\5BZS>)>M"PC2]-N79#.0C1A<$LB@ 'ZQV=[9ZC:QWVG
MW<4\$J!HIH9 R.IZ$$<$5)7Y=?\ !$/PI\.M%_;V_:%U/_@G7=:DW['\VE:5
M'X9"W%U)H3^+A_Q_G1C<DEH57>)FC^3S&C4$HL8'ZBT %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)QQFV0X%83#P@XIM^\I-Z^DDOP/D,YX+RO/,:\57G-2:2]UQ2T]8O\S\+O\
MASE_P4>_Z-S_ /+OT?\ ^2Z_2/\ X(]?LU?&O]EG]F?7/A]\>/!?]A:O>>.K
MG4;:T_M*VNM]L]E91K)OMY)%&7AD&"<_+G&""?JZBGG?'.;9]@'A,1""BVG[
MJDGIZR:_ >3<%Y7D>-6*H3FY)->\XM:^D5^84445\8?7!1110!\V_P#!1O\
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M^R^5]GW9\N7?OQA,9/T?10!\X?\ !2O_ ()[6O\ P4!^&GA+3_#/Q8D^'GQ
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-20201231_g23.jpg
<TEXT>
begin 644 biib-20201231_g23.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK_P5-_9=^&GA?X(?![_@L5X3T7P5X4M8;33?#NG?LHZ5$@MT.64R?VD6+O\
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M^?=3[H__ "8?ZSX#^67W+_Y(^L:*^3O^&E_C;_T.O_E-MO\ XW1_PTO\;?\
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M-2:BHRUTV7^9],T445]P?0!1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"4VV_^-T?\-+_&W_H=?_*;;?\ QNN$HKRO[<SK_H)J?^!R_P SB_M#'_\
M/V7_ ($_\SN_^&E_C;_T.O\ Y3;;_P"-T?\ #2_QM_Z'7_RFVW_QNN$HH_MS
M.O\ H)J?^!R_S#^T,?\ \_9?^!/_ #.[_P"&E_C;_P!#K_Y3;;_XW1_PTO\
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M_P"&E_C;_P!#K_Y3;;_XW1_PTO\ &W_H=?\ RFVW_P ;KA**/[<SK_H)J?\
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M;#?[S#U7YGV?16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U?TJ?JQL45C_\
M"#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\
M_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?
M\_-[_P"!;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO
M_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\ "#Z1_P _
M-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;
M4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!
M;4?\(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q1
M679^$M-L;I+N&XNBT;94/<L1^(K4H **** "BBB@ HHHH **** "BBB@#PO_
M ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@#Y;_:L_Y*
M_<_]>4'_ *#7F]>D?M6?\E?N?^O*#_T&O-Z_G?B'_D>XG_'+\S\QS/\ Y&%7
M_$_S"BBBO'.$**** "BBB@ HHHH **** "BBB@ HHHH **** "ON72_^0;;_
M /7!/_017PU7W+I?_(-M_P#K@G_H(K]-\-_CQ/I#_P!N/K.%OBJ_]N_J3T44
M5^IGV 5\:?%G_DJ'B+_L-W7_ *-:OLNOC3XL_P#)4/$7_8;NO_1K5^=>(W^X
MT/\ $_R/E^*/]VI^OZ'/4445^2'Q84444 %%%% !1110 4444 %%%% !1110
M 4444 %=#\)O^2H>'?\ L-VO_HU:YZNA^$W_ "5#P[_V&[7_ -&K77E_^_TO
M\4?S1MAO]YAZK\S[+HHHK^E3]6"BBB@ HHHH ***^=O^"A'_  4P_9C_ .">
MOP^N+OXM?$NQM_&>IZ!J%WX'\'1V%W?WNL3V\#NO^C64<DRP;P%>=@L:#)+C
M!P ?1-%>!_L+?\%&_P!F;]OKP[>+\%/&MU<^(_#NEZ?<>,O#^H^&-2TJXTN2
M[1S'^[OX(F>-FAF"R)N4^6?FKYZ_;0_X+0_M%_L@?&K3?".I?\$M_&%S\/M0
M^*FF^!HOBGX@\<V>E6EU<WDWEQW%I:B&>>YB(#N"0BD)@LN10!^@-%%>>?M2
M_$7]H#X5?!G4?&O[,7[.$7Q8\8V]Q;II_@B;QG;: MY&\JK*_P!MN8Y(X_+C
M+/@J=VW:,$YH ]#HK\Q?VEO^"V7_  5$_9"TWPIJG[0'_!#NQT5/''C2Q\)^
M%HH/VH-*O9]0U>\+""WCAM=.DD);8V6V[1CDC(S]8_MJ_M1?MF_!KQ;X>^&_
M[&O_  3_ -1^,>JZW8SW6H:W>^-;7P_HNAHCJBB>YG1S+*Q8D0QJ6*J3P* /
MHFBOC3]CW_@J-\6?B)^UY=_\$_/VZ/V0;CX+_%E_"K>)/"T5EXLAUW1_$^F)
M)Y<LEM=Q1Q[)4(.864G$;DD8"GW/]MK]KKP)^Q!^SIK?Q]\;Z7=:M+:-#8^&
M_"^F'-[XBUBY<0V6F6J@$M-/,R(,*VT%G(VH: /6**^;_P#@E1^W_??\%+_V
M0=/_ &I=4^"Y\ 7-WK^IZ5<>&3XB&J_9Y+.Y:!F^T"" -N*DX"#'3)ZU[%\>
M_B5XB^#WP:\1_$_PC\*]:\<:IHFER7.G^$/#JJ;[5IA]RWAW?*&8D#)X R3T
MH ZZBOSG^+G_  5Z_P""D'[(?@Q?VD?VXO\ @D&_A#X/V]Y;Q^)];\*?&.PU
M[5_#5O-*D2W-Q9Q0(LZAG4,(W 7=RW'/Z%>&?$FA^,O#>G^+_#&I1WNF:K8Q
M7FG7D).R>"5 \<BY[,K CZT 7J*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH
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M#,!>^_M&&2Z =I&(=0#OP0<"@#[^HKYOC\)?MO?L[_L(?$\_%?\ :$N?CO\
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MHHK^E3]6"BBHK^5X;&::)L,D3,IQT(%)NRN#T):*^3O^&E_C;_T.O_E-MO\
MXW1_PTO\;?\ H=?_ "FVW_QNOA/^(AY+_P ^ZGW1_P#DSYS_ %GP'\LON7_R
M1]8T5\G?\-+_ !M_Z'7_ ,IMM_\ &Z/^&E_C;_T.O_E-MO\ XW1_Q$/)?^?=
M3[H__)A_K/@/Y9?<O_DCZQHKY._X:7^-O_0Z_P#E-MO_ (W1_P -+_&W_H=?
M_*;;?_&Z/^(AY+_S[J?='_Y,/]9\!_++[E_\D?6-%?)W_#2_QM_Z'7_RFVW_
M ,;H_P"&E_C;_P!#K_Y3;;_XW1_Q$/)?^?=3[H__ "8?ZSX#^67W+_Y(^L:*
M^3O^&E_C;_T.O_E-MO\ XW1_PTO\;?\ H=?_ "FVW_QNC_B(>2_\^ZGW1_\
MDP_UGP'\LON7_P D?6-%?)W_  TO\;?^AU_\IMM_\;H_X:7^-O\ T.O_ )3;
M;_XW1_Q$/)?^?=3[H_\ R8?ZSX#^67W+_P"2/K&BOD[_ (:7^-O_ $.O_E-M
MO_C='_#2_P ;?^AU_P#*;;?_ !NC_B(>2_\ /NI]T?\ Y,/]9\!_++[E_P#)
M'UC17R=_PTO\;?\ H=?_ "FVW_QNC_AI?XV_]#K_ .4VV_\ C='_ !$/)?\
MGW4^Z/\ \F'^L^ _EE]R_P#DCZQHKY._X:7^-O\ T.O_ )3;;_XW1_PTO\;?
M^AU_\IMM_P#&Z/\ B(>2_P#/NI]T?_DP_P!9\!_++[E_\D?6-%>"?L_?&GXF
M>-_B/#H/BCQ+]JM'M97:+['"F65<@Y1 ?UKWNOI\GS?#9WA'B*":C=KWK)W5
MNS?<]? XVECZ/M:::5[:_P# ;"BBBO5.P**** "BBB@ HHHH **** "BBB@#
MPO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH ^6_VK/\
MDK]S_P!>4'_H->;UZ1^U9_R5^Y_Z\H/_ $&O-Z_G?B'_ )'N)_QR_,_,<S_Y
M&%7_ !/\PHHHKQSA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[ETO_
M )!MO_UP3_T$5\-5]RZ7_P @VW_ZX)_Z"*_3?#?X\3Z0_P#;CZSA;XJO_;OZ
MD]%%%?J9]@%?&GQ9_P"2H>(O^PW=?^C6K[+KXT^+/_)4/$7_ &&[K_T:U?G7
MB-_N-#_$_P CY?BC_=J?K^ASU%%%?DA\6%%%% !1110 4444 %%%% !1110
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MWP5IOC&ZTOP!K]SX4T_2OM&GZ?YHN=1"642Y28LH"LS[?LS $9.>/^!FN?\
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M_P!E/_DK]M_UY3_^@U]25^T>'_\ R(G_ (Y?E$^\X:_Y%[_Q/\D%%%%?<'T
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M_##]E[_@J[^T3\'?A#IMY:Z+8^"/"\T:ZAJD][.\LT1DD=Y9W9V+.Q/7 S@
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M4^;WDVN6-TDFU[TKJVJZ)V5F]T:+!-855I7U3:LKJU[:NZM^/<^ZZZ'X3?\
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M .T!X_\ V=/[4^'.EZ;X%^(FJZ'!+;V/BC&H6^BWCA&EAF-N=L_EY=<H=K,
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M]EB**;XNVZ31JZ_8I^&&1]VOJ#^SM/\ ^?&'_OT*^8?V4_\ DK]M_P!>4_\
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MXV^)_C/_ (2[XK?$/4$U7XE>,W3:+RZ"D1VT"D#R[6!6,<28'&3A00B_&?\
MP2A_8$_9L^*WBK]H32?VJ_ASIOC/Q3X3^,^L:-;Z'XE4W$.DZ?(5F2ZMX')6
M(W+O*?. W,(%VMP:^W_V;/\ @G[^R=^R+XJO_&OP ^'%_HVI:GI_V&]GNO%V
MJZBKP;UDVA+VZE13N13N4!N,9P2*R_V@_P#@FI^R5^TI\19?B[X[\':MIWB>
M[LELM5USPIXFO=)GU.V4 "&Z-K*@G4* N7!8* H.  .ZEFT(U*\?:S2J*/OJ
M*4DXO1<JE91MII+16TMH=,,9%3J+GE:=M4DFK=+)[6TT9\D_L@^*_P!I7X=_
ML<?M3_!O]AZROO&)^'GQ7U#PW\$HYK]939V\LT,<T,$T[A)%LTE>= S88CN&
MQ7DO[8?BKXP?!O\ 8P^#O[/47_!/3QYX0TKPQ\7_  ]>1Z]X@\3Z7<RZ_J8F
MFDD$AAF9OM-U,\CEV^0$D9  %?J[\#_@3\(_V;?AKIWP?^!W@2R\.>'-+5A9
MZ;8AB S'+.[L2\CL>6=RS,>234'QP_9Z^#_[1^@:3X8^,_A#^V;'0_$5IKNE
MP?VA<6_DZA;%C!-N@D0MM+-\C$H<\J:WI9_AZ>/=1TKP<^:^O,[1M=VDDWN]
M;V<I:EPS*E'$.3A>-[];[6Z-+N_5L/!/Q@2[^%FB?$+XT>'E^'-[JY6*;0?$
MVL6PEM+EG94MS*C^7)(P7("$YS[&KWQ:^''A;XT> =6^$GBK5=1MK36+0)=M
MHNK265XD>\$-'-$PDCY7&Y2.XK.^//[.7P9_::\,:;X-^-_@W^V]-TC7[76M
M.MO[1N+;RKZW+&&;=;R(S;=S?*Q*G/(-<I^U#^P=^S=^U_JFD>(_C+X:U5M9
MT"WF@T;6]"\2WNFW5I%*5:1 UM*@96*J<.&Z<8KPZ4L+[6,W*4-6W97Y?Y;7
MDF_.[T\SSX.CSJ3;CJ]E>W:VO]>9\H?#_P"#OA7_ ()U?\%:?AU\'_@+XKO?
M$6G?'+PUK+>-].\53IJ6KZ,-/MS/;7:7[K]I6WE=&C\J1V0M'(>6V;?T1KQ7
M]F'_ ()[_LH_LAZ_J/C7X,_#B1/$FKP"#5/%6N:M<ZEJ5Q%D'R_M%S([(A*J
M2B;58HI()48]JK;-<93QM:$HMR<8I.323DTWJTF]DU%:O1)LTQE>-><6FW96
M;>C>^O7I9?(*^Y=+_P"0;;_]<$_]!%?#5?<NE_\ (-M_^N"?^@BONO#?X\3Z
M0_\ ;CZ'A;XJO_;OZD]%%%?J9]@%?&GQ9_Y*AXB_[#=U_P"C6K[+KXT^+/\
MR5#Q%_V&[K_T:U?G7B-_N-#_ !/\CY?BC_=J?K^ASU%%%?DA\6%%%% !1110
M 4444 %%%% !1110 4444 %%%% !70_";_DJ'AW_ +#=K_Z-6N>KH?A-_P E
M0\._]ANU_P#1JUUY?_O]+_%'\T;8;_>8>J_,^RZ***_I4_5@J#5/^0;<?]<'
M_P#034]0:I_R#;C_ *X/_P"@FIG\#$]CX:HHHK^83\D"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ](_93_ .2OVW_7E/\ ^@U]25\M_LI_\E?M
MO^O*?_T&OJ2OVCP__P"1$_\ '+\HGWG#7_(O?^)_D@HHHK[@^@"BBB@ HHHH
M **** /S)_X*2?L0_ #X:_M;:Q^WG\8O^"W?CK]G+5O&>G6^E6&FZ;XJT[3(
MIK*VB1?LL22+YMY&LF^?:PD$;SN1MW5V'_!,_P"!7AKQQ\6--_:$^"W_  7H
M^)'[1/A_PP]PFM^#+KQ;IM_I\K3VL\,:WD5N@EB*LXF0-MRT*GD9KSCX<:)^
MP-XK_P""TO[3$7_!3*V\"WOQ+M+C0$^#EA\6Q;-8)X0_LN)E?2$OOW#R&[-T
M9C&#(K[^F9<KXFT3]@_PI_P7$_9SA_X)DVG@BS\<7>G^)D^.EC\)1;+IG_"+
MC3&:!]52Q_<)+]N%MY)8"1GV;LCRJ /U,HHHH \+_P"">_\ R1/5O^Q[UG_T
MI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH ^6_VK/^2OW/_7E!_P"@UYO7I'[5
MG_)7[G_KR@_]!KS>OYWXA_Y'N)_QR_,_,<S_ .1A5_Q/\PHHHKQSA"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K[ETO_D&V_P#UP3_T$5\-5]RZ7_R#
M;?\ ZX)_Z"*_3?#?X\3Z0_\ ;CZSA;XJO_;OZD]%%%?J9]@%?&GQ9_Y*AXB_
M[#=U_P"C6K[+KXT^+/\ R5#Q%_V&[K_T:U?G7B-_N-#_ !/\CY?BC_=J?K^A
MSU%%%?DA\6%%%% !1110 4444 %%%% !1110 4444 %%%% !70_";_DJ'AW_
M +#=K_Z-6N>KH?A-_P E0\._]ANU_P#1JUUY?_O]+_%'\T;8;_>8>J_,^RZ*
M**_I4_5@J#5/^0;<?]<'_P#034]0:I_R#;C_ *X/_P"@FIG\#$]CX:HHHK^8
M3\D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ](_93_ .2OVW_7
ME/\ ^@U]25\M_LI_\E?MO^O*?_T&OJ2OVCP__P"1$_\ '+\HGWG#7_(O?^)_
MD@HHHK[@^@"BBB@ HHHH *\O_:S_ &D]3_9:^'%C\0M*_9U^(WQ-DO?$%MI;
M:!\,= 74M0MUF#DW<D1D3;;Q[,.^>-Z\'->H5Y/^V3_PW+_PJ./_ (=\?\*G
M_P"$\_MB'SO^%R_VG_9']G[)/-Q_9O[[S]_E;<_)C?GG% 'QS_P5!^._[,7Q
M.^+VH_ +]I[_ ((.?'_X^V_A%XH])\=^&/@]#J5A*LT$4[BPOQ<QS! 7\N0*
M5'F1,"#M!J?_ ();?'G]FGX>?%S3_P!G3]F+_@A1\??V?K+Q89_[6\<^*O@_
M#I>FQ_9[6:X07]_]HDF8,8S%$'+#S)E48W$UL?\ '4U_U8!_Y>]>@?LN?\/]
M/^%[:%_PVM_PR!_PK+_2O^$F_P"%6_\ "4_V[_QZR_9_LOV__1_^/GR-^_\
MY9>9M^;;0!]?T444 >%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_
M $I->Z4 ?+?[5G_)7[G_ *\H/_0:\WKTC]JS_DK]S_UY0?\ H->;U_._$/\
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M":GJ#5/^0;<?]<'_ /034S^!B>Q\-4445_,)^2!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >D?LI_\E?MO^O*?_P!!KZDKY;_93_Y*_;?]>4__
M *#7U)7[1X?_ /(B?^.7Y1/O.&O^1>_\3_)!1117W!] %%%% !1110 5X5_P
M4,^&'@7XN_ BU\'_ ! _;=\7_ &S?Q):R0^-_!/CJW\/7L\P254L?M5PI5DD
MW%C$!N8Q*1]TU[K7&_'#]GGX&?M+>$[;P'^T#\)]!\8Z+9ZI#J5KI?B'3DNH
M(KR(,(IU1P0'4.V&ZC<: /SI\=?\$\OV>_A?XKN_ GQ+_P"#F3]I;P[KFGL@
MO]&UW]I[2K2[MBR*ZB2&6%73*,K#(&0P/0BO0?V'OV9/V</A[^U%X8\8> O^
M"^?Q@^->K6?VW[)\,O%/[0FF:Y8:SOLIT;S;&!!)/Y*,UPNT_(T"N>%-<?\
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MKK_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\
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M%% !1110 4444 %%%% !1110 4444 %?<NE_\@VW_P"N"?\ H(KX:K[ETO\
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M .-4?\-=_M#_ /10O_*3:?\ QJO-J*/JN%_Y]Q^Y![&C_*ON/2?^&N_VA_\
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M'A/_ %2+_P K_P#]ST?V9COY/Q7^8?4\1_+^*/I*BOFW_AX3_P!4B_\ *_\
M_<]'_#PG_JD7_E?_ /N>C^S,=_)^*_S#ZGB/Y?Q1])45\V_\/"?^J1?^5_\
M^YZ/^'A/_5(O_*__ /<]']F8[^3\5_F'U/$?R_BCZ2HKYM_X>$_]4B_\K_\
M]ST?\/"?^J1?^5__ .YZ/[,QW\GXK_,/J>(_E_%'TE17S;_P\)_ZI%_Y7_\
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M/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 ?DA_P %@/\
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MGPS_ .Q[TK_TKCK?"_[S#U7YFE'^+'U1^X]%%%?KI]H%4/%7_(L:E_UX3?\
MH!J_5#Q5_P BQJ7_ %X3?^@&D]A/8_G^HHHK\</B HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /J'_@C_\ \GJZ9_V M0_]%5^M]?DA_P $?_\
MD]73/^P%J'_HJOUOK]!X7_Y%K_Q/\D?293_NK]7^@4445]&>H%%%% !1110
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M?E6:_P#(RK?XG^9\?C/]ZGZL****X#G"BBG0037,Z6UO&7DD<*B*,EB3@ 4
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M*M_V[^I[>3;S^7ZE^BBBOM#W0K\./VR/^3M/B9_V/>J_^E<E?N/7X<?MD?\
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M $KDKY3BO_=J?K^AXV<?PH^IYM1117PQX 4444 %%%% !1110 4444 %%%%
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M5P'.%%%% !1110 4444 %%%% !1110 4444 %%%% !7] /A7_D6--_Z\(?\
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M**_'#X@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZA_P""/_\
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MG[77_14?A9_WYU6OU*HKB_L[+_\ GS#_ ,!7^1A]5PW\B^Y'Y:_\.1/VNO\
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MT1QC"2OC&* /TFT[7-%UB6XATG6+6Z>UE,5TEM<*YA?^ZX4G:?8\U:K\C_\
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M+F*-I7<"5V<EF=MS.Q9B3\;?\$RO^"MG[,?_  3$_P""<'_#%O[='B:3P?\
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M:3H&FPZ/H6EV]E:6Z[8+6T@6..-?154  ?2K% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=8UFTM'NI?+M5N;A8S,_]U0Q&X\C@<U;K\"_V%M2^!'_  40^$&N?ML_M_\
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MJT.@WOB"QAOK@9M[*6[1991S]U"<MT/0=J_,'_@FE\-/B!\$?^"G-T?V2_\
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M[Q;\/_#FHZ/\._#?@7P-_8FDZ,M\HCN[J1I)YY[J62/Y &9509(!.,?9U%%
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-20201231_g24.jpg
<TEXT>
begin 644 biib-20201231_g24.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M9 )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
M/VFOB3^V+^R/X2_:.^+O[-FN?"'Q%XC^W_VA\._$DLSWND_9[^XM8_,::VMG
M/FQP).NZ%/EF7&X89O6[_6M&TNXM[34]6M;:6\E\NTBGG5&G?^Z@)RQY' K\
MC_\ @X4TC]IK0/\ @V^31OVR_%.E:W\4;?5_#J>-=6T2.-+2ZO?[0&YXA'%$
MH7;MZ1J..E?G7\?O^"1/@&Q_X-R?!W_!5#QY\=O'FM_$O2]+T=M T^YU=&T?
M2M'GU=+&'3[>W,>Z()'*LY=7&9MYQ\QH _J-KX^_X+/_ /!2WQ3_ ,$UOV#]
M2_:W^#'A;P[XQU"P\4Z?I!T_4[QS:_OW97W- P8.N!QGOS7Y0?\ !2S_ (*.
M_M4VO_!L'^S));_$W6(]=^+4TF@^-?%$=ZXO+_3-/-W%]GDFSO+3B&W\U\[I
M%CD5BPD?/GW_  5/_P"")7P1_P""?G_!$+P7^TS\$/CIXU;7?%C>&7^(^E7F
MN*^C>)'N[<W"O':JBB-X)B#"V6(B\P$L6+4 ?OY_P3R_:7\2?MD_L0_##]J;
MQAX=L=(U3QWX1M=7OM,TUW:WMI)5R4C+DL5'N<UZS8>(O#^JWUQI>EZ[9W-S
M:'%W;6]TCR0GIAU!RO0]:_G>_P""G7[;GQ]_9@_X-N_V-_@S\#/&>H^&X_BE
MX12W\3ZSI%PT%R]A9VT;&R65<-&DSW"%]I!982A)1W4_,7Q2_9QOOA%\/_AK
M\3?^"5?_  3D_;F^'OQO\):A;3ZS\0-?\$WQM=9B\AC-*J6ZOY3&81E8U7RF
MB:1) ^0: /ZQ[JZMK*VDO+VXCAAB0O++*X544#)))X  [U^='_!?W_@M;\4O
M^"1O@+X6>-?@?\+_  IXUC^(.H:I!</KEY/Y4*6L=LR-$UNXW;C.V<DCY1BO
MSW_X.#/VJ?VG_P!LKQE^Q-^P=\1M2UGX;:?\9O!?A?7OB7H\EM+9"+6=6O([
M*2*ZADVMBR=)F$,@&UI<L-RKM\/_ .#FC_@E3\'/^"5?@CX(> OV;/BQXVO?
M!7BBYUV>3P?XNUY;V*RU*V2P66_M@(T$;3I.BRA0%)@C([  ']25?G9_P6W_
M ."^%S_P1V^(_P //AU9?LBR?$V;Q]I=Y=Q2Q>.3I+6K0311"((+"Y,Q<R<$
M%<8Q@YK]$Z_GQ_X/*?\ D]#]ES_L'WW_ *<;.@#WW2/^#NFR^%7CW2?"?[?_
M /P2O^+?P3LM5DVIJ5]<2W4D:Y ,HM[NRL7DC4,"WE[F /"L< _KA\)OBQ\-
M_CM\,]"^,GP@\8V7B#POXETR+4-#UG3Y-T-W;R*&1US@C@X*D!E(*L 00/AC
M_@Z+C^"#_P#!&'XH/\95TTW:3:8?!)O-OV@:U]NA$7V;/S>9Y7G[MO/D^=GY
M=U?D_P"'_P!MG]K#]C?_ (--/ T?PL\6ZUX>NOB%\;=5\,Z1XCLYWAGL=!;[
M9<W"VLRX:)I+JVN(]RD$*T^"#@@ _I<M_$7A^ZU:70+77;.2_@7=/91W2&:,
M<<L@.X#D=1WJY7\CVK_LR:!:_LC> ?B+^Q!_P3O_ &WM'_:)L?[.UN7XQ)X4
MOFTK5YI4$EQ+;-;;GCA)<O;RQC>RA=[-O+#[ _X+S_\ !2C]OS5O^":7[(_P
M2\=:GK_PT\4_&7PW>3_&(W-M-H][=W%D]K9B&=-J26\,KS27$L. &W1C&T8(
M!_0IIOB7PYK-W/I^CZ_97<]J<7,%M=)(\)Z88*25_&I-6UG1]!LFU+7=5MK*
MV0@/<7<ZQHI/ RS$ 5^<W[%G_!L%^P7^PY\6_AO^T7\)_B!\1)/'W@&Z6ZN=
M8NM<A-KK<C0/%,DUL(<1Q-YC%5C8%<+N9\'=^0?[0?[1+_\ !1[_ (+2?&*/
M]NW]G_X_?&WX??#;7M;TCP?\)O@I9S7#Z3#9ZA]B@DFCC8&"(HC/+(FUY)Y$
M!;:-M ']3=K=6U[;I>6=Q'-#*@:.6)PRNIZ$$<$4EW=VEA:R7M]<QPPPH7EF
ME<*J*!DDD\ #UK\%O^#<#4/VS_V<O^"E7C+]G7PI^S-^T%X0_9?\8Z?J-]X8
MTCXQ>$+VW'AZZB"30,9WC$$<K 30-L8><&C9@608^8_^"+G_  3+\ _\%1?V
M]OVI?@S\</BOXST/P!I>K7=]K6A^#=72S?6;TZM=)9FX9XY%>*',\@0K@R&,
M_P ." ?T_OKFBII'_"0/K%J+#R?-^VFX40^7C._?G;M]\XK!^+GQ!D\ ?!;Q
M/\5- CM[Y]$\+WNJV2-)F*X,-L\R LIY5MHY!Z'BOYGO^#?O_@G))_P59LOC
M#^Q5^T?^TY\1K7X/_"6Z2^T3P9X<UM;>VDUR_DN($OGCD2166-+%W$6,;Y,@
MC,F_Z'_X-0OC;\2O&7_!-3]KCX(^)_%5Y?>'?!F@B\\-6-U<-(NGM?Z9J8N(
MXMQ/EQLUI&^Q<+O9VQEV) /T"_X(*_\ !8CXB?\ !6']GGQ[\;?CG\/?"W@E
MO!_BZ+2(5T:\F$$D;VT<N^1KASAMS[>"!TK[^AFBN(EG@E5T=0R.C9# \@@C
MJ*_F-_X-P/\ @C=\#O\ @JY^RI\5H?VE?C)XZM- \/>+(K?P[X4\+:XMK:VN
MIRV0+ZK-$R.L\H011QA@ H24'=O^7J?^"(G_  4H_:E_9&_X)O?MK?"C1_'$
M_B!/@7X:CU'X8WE[F>+1;NXN;FQD:)9-P\CS!#<K#]P-'*<'S&H _H_N_$7A
M_3]3@T2_UVS@O;H9MK2:Z199A_LH3ENAZ#M5ROY"_P!G#X3?"S]JC]D;QI\9
MOCK^Q#^V3\9?CIXON]1N/#GQD\&:-<ZEHUG>Q@K;;I06:Z(G7]^7W, 2D>PJ
M&/WHWQ:_;E^('_!I=\?O O[?7@3QWI/BKP+KVEZ-H-]\0]#N[+4-1T?^UM%F
M@=S=HLD_EO)-")#GY8T4DE30!^^^HZSH^D- NK:K;6IN9UAMA<3JGFR'HB[B
M-S'L!S5FOP/_ .#?/_@A1\+?VO?V-?@3_P %!OVC?VB_B-=ZGX/\73ZG\*/"
M>CZK;1:3H5KIOB*XF:!XIK>5G\^_@N99"CQY68 88;J_?"@#\L?VIO\ @NE_
MP4Y^$/Q,^(FG?!W_ ((3_$+Q/X#^'?B;5],D\>7>KWD,6LVMA<RPMJ%O$NG$
M^0ZQ-(K(TJ[3G=P:^@/^",/_  6?^$'_  6/^$?B7QEX*^&NH^"_$W@F^M;;
MQ9X6O]02\2W%RDK6T\-RJ1^=%)Y$Z_-&C!H6!7&UFY;_ (*^_#[_ (+S^.-<
MN;;_ ()8?$WX9Z1X(G\!"WU73]=VIX@GU<S70F-G)/;O!&K6[6JHSR)AU<_+
MPQ^/?^#+SXA_LTI\%/BW\%/!7PPUK0?BGI6JZ=>?$'5M5U5;F/6K?_28K7[.
MBQ1_9D@<7"M"V]MT^_S7W[(P#JOVT_\ @[%\=?LA^-[[3+G_ ()'?$67PO#X
MBO\ 1M*\9>,O$LF@VFLSVDI21K0G3;B.=< /\LA(5E) S7Z_^$]=_P"$H\*Z
M9XF^R^1_:.GPW7D;]WE^8@?;G SC.,X&?2OQ!_X/@O\ D@/P"_['#6O_ $EM
MZ_:WX4,J?"GPT[L !X>LR23P!Y"4 =#14%CJ>FZFC2:;J,%PJG#-!,K@'WP:
MGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *_/C_ ((H?\$(O^'/'C_XG>.?^&I_^%B_\+'M["+[+_P@_P#9']G?
M9I;F3.[[=<^=N^T8Z)C9GG/'Z#T4 <?^T%\!_AC^U!\$?%/[//QF\/C5/"WC
M'19]+UNQWE&>"52I*,.4=3AE<<JRJPY K\A(/^#67]M+X;?#GQ-^R/\ L\_\
M%D_$?A_X#>+[^2;6/!=[X2>28PR;1)$WE7:)*75560IY*2@?,F.*_:NB@#X/
MU+_@@U\#?#7_  1U\2_\$B_@-\3+SPO8^*VMKO6O'VIZ.NHW5WJ27UI=37DM
MNLT"L76SCA5%=1'&J#+;/F]Y_P""9?[$W_#NC]ASP'^QC_PLS_A,?^$)M[Z+
M_A)/[&_L_P"V_:+^YO,_9_.F\O;]HV?ZQL[,\9P/=Z* "OR?^.7_  ;+_$B]
M_;F^(?[</[#O_!5#QM\!]6^)>H7E]XBL=$\*/=RF:\N%NKM!<PZC:DP/<#S1
M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M*N__ (U1_P -9_L_?]#_ /\ E*N__C5']F9E_P ^9_\ @+_R#^V<G_Z"*?\
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M!/ _BC4;;6/$O@W2M1N[(YL[J^TZ*:2 YS\C.I*\\\8KCO\ AK/]G[_H?_\
MRE7?_P :H_X:S_9^_P"A_P#_ "E7?_QJC^S,R_Y\S_\  7_D']LY/_T$4_\
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MNKA?$^M^$;_Q)81^4/):RM+JTMILOG(?S+R+"XY4.<_+6!^UY^VC^S7^P?\
M"F/XW?M4_$*;PSX8EU:'3(]1AT"_U(FZE21XX_*L8)I1E8G.[9M&.2,C/X._
MLSZ#_P $C_"/Q\^'?PR_X+"?!#Q/X)^(5Q\+->M?B]KOQTM=9AN=:\9OJVEM
M;ZC#JJN1Y1MTO3%<1RQQHC8+;G#/_0Q\,;'P;I?PV\/:9\.M6CO_  ];:':1
M:%?Q:B;Q;FS6%!!()RS>>&C"L)-S;\[LG.: /C;P_P#\'(__  1C\4^)]*\&
MZ%^US?3ZGK>I0:?I-H?A7XH1KFZF<)%$I;3 -S,P Y[U[/\ MG?\%.OV,OV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&RGEAEFMU?&1&\EO [+T)B0]A6O_ ,)CX8_Z#4'_ 'U0!\??\$6_V/\ X_\
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M$L<>I&6>W1WT\+< L[*)&V'!R![Y_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M?F7^V[\1_P#@J[_P5*_9P\0_L%^"/^"4FK?".T\?)!IWB[XC_$_Q_I<^GZ%8
MB>.2:2"WM&>6\D.S:NP<9W8[C])OA/\ #ZP^$OPL\-?"K2K^:ZM?#/A^RTFV
MNKC'F31VT"0J[8XW$("?<U>_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T
M&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_
MX3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T
M&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^J -*BJ%MXH\/WDZVMKJL3R.<(BGDFK] !1110 4444
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MC\@S?_D:5O\ $_S"BBBNP\X**** "BBB@ HHHH **** "BBB@ HHHH ****
M"OVW\-_\B[8?]>47_H K\2*_;?PW_P B[8?]>47_ * *^6XFVI?]O?H?;<&_
M%7_[=_\ ;B[1117RA]T%?CU^U7_R<U\0?^QSU+_TIDK]A:_'K]JO_DYKX@_]
MCGJ7_I3)7TG#?^\3]/U/CN,?]UI?XG^1P%%%%?8'P 4444 %%%0S:CI]O>PZ
M;/?PI<W"NUO;O* \H3&XJIY8#<,XZ9'K0&Y-1110 44DDB1(TLKA54$LS'
M]34=E?V.I0"ZTZ]BGB)($D,@=21[B@"6BBB@ HHJ$:A8&]_LT7L/V@)O,'F#
M?M]=O7'O0!-1110 5W_[*G_)S7P^_P"QSTW_ -*8ZX"N_P#V5/\ DYKX??\
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M+_@%\/-*\._%/4M(\1Z=\5-4T= D_B73X/#9FU*?4'0_Z0!?^0\3/D*Y54P
M  #]3_AYI'B_P_X T/0?B#XP3Q#K]CH]M;ZYK\6G)9KJ=XD2K-="W0E8!)(&
M?RU)";MH) S6Q110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_[
M'O6?_2DU[I0!^8O_  5)_P"3MM0_[ UC_P"BZ^=:^BO^"I/_ "=MJ'_8&L?_
M $77SK7Z1EW^X4O\*_(_(,W_ .1I6_Q/\PHHHKL/."F71MA;2&]*>3L/F^;C
M;MQSG/&,4^FSP0W,+VUQ$LD<BE9$<9#*1@@CN* /BSQ7^REXU^!WQ?\ !-E^
MR5^TK<Z%I5QI7B#4= TKQ-;0ZGI6F1XMI988G;#QV\I<$MEBFW<"2QS[A^SC
M^UCI?Q'_ &.])_:G^,)L?#5N=.N9M<E#,+>,P7$D#21Y)8J[1Y1?F8[PHW'&
M>1\4?\$SOV;-2^)WAW5='^%=M!X9MK;4?[=T9-?OXX)99/(,&RW6;RU3*R[E
M4*K97<&P,>N?$G]F_P""7Q;^%<'P1\=> +:?PI;&#[-HEE/+9Q0B'_5JOV9X
MV55[*#CVKS,/A\31G-Q22Z*[:O96Z:):[=_)'M8K%83$4Z<9MR=]9<J4K7E=
M;ZMW3U?2_5GC'PL\'^-OVW/B9HO[3_QBT*XT;X?>';K[9\+O!=XN)KZ;^#6+
MU<X#8YAC_A!!Z?-+]/5X-9?\$S?V+-/N(KJS^%6HH\#J\1_X3;62%*G(X-W@
M].E>B_&O]GOX2?M$:+9^'_B[X;N-2M+"Z-Q:QV^L7=F4D*E22UM+&S<$\$D>
MU;X>GB*5.7,DY/K=ZOS]W3R23.7%5<+7JQ4924%I;E7NKR]YW;ZMM'CG_!)O
M_DT2'_L;=9_]+'KS?X/_ +-7PP^(W_!1KXYZ-\>?#UOK8M)-.U?PYH&JYDM+
MB.YA(DN_))VRM&!'%N(.TR,.#7O_ ,(?V"_V5/@/XQM/'WPH^&MQI6J6(E^R
MS?\ "3:E.B>8C1O^ZFN'C8E789*G&<C! -;'QN_9/^"?[0.K6'B;Q_X>NH]:
MTN)H=/U[1M4GL+V&)B28O.@=69"23M;(!8D $FN=8.J\-2C-)N#VOH]+=OGL
M]CKEF%!8NM.G*2C46]DFG=/^;5:6W6YX]^QGHVE?"C]LCXT? #X4S.O@/28=
M*U&UTF.9I+?1]1N(B9H8B2=@?EBG;8!QMKZ:TCQ3X9\0:<=8T#Q%87UHLIC-
MU9WB2QAP<%=RDC(/&.N:YWX*? +X3?L\^%Y?"/PD\(QZ7:W%RUS>R&9YI[N<
M]99II&9Y&/JQ..@P.*I>'?V8?@7X4^$6I_ ?0O BP^$]9:Y;4M)?4+F03&<Y
ME_>/(9%W'T88[8KIP]*M0I*-EU>^UW=):;+;\D<>+KX?$UG.[^RKV5W96;>N
M[M>VOF^IX3^WI^R-\+=,^&_BW]J!/'VM:?XA\.I+X@TV/6=5^W:5)>QC=';F
MRN@\.)& C55489U(SC!^B?@5XXUGXF_!/PA\1_$>EK8ZAK_AFQU"^LT4A899
MK=)'4!N0 6. ><=:\MTO_@F=^R+8ZO;:GJG@O5M9@L9EEL=*U_Q1?7ME PZ8
MAEE*N .,.&&.U>^1QQPQK%%&JHJ@*JC  '0 5.'H3A6E4<5&_1.]WWV16+Q-
M.IAX4E)R<6]6K65EHM7Z_D+1117:><%?MOX;_P"1=L/^O*+_ - %?B17[;^&
M_P#D7;#_ *\HO_0!7RW$VU+_ +>_0^VX-^*O_P!N_P#MQ=HHHKY0^Z"OQZ_:
MK_Y.:^(/_8YZE_Z4R5^PM?CU^U7_ ,G-?$'_ +'/4O\ TIDKZ3AO_>)^GZGQ
MW&/^ZTO\3_(X"BBBOL#X **** "N?UWX=Z7KWQ$\/_$>YOKA+KP[:7UO:P)M
M\N1;H0ARV1G(\E<8(ZG.:Z"BE**DK,J,I0=U_5] HHHIDC+BW@NX'MKJ!)8Y
M%*R1R*&5@>H(/45#I>C:1H=M]BT32K:SAW%O)M8%C7)ZG"@#-6:*+*]QW=K!
M1110(*K#1=&75#K@TFV%Z4V&\$"^:5_N[\9Q[9JS10%V@HHHH *[_P#94_Y.
M:^'W_8YZ;_Z4QUP%=_\ LJ?\G-?#[_L<]-_]*8ZRQ'\"?H_R.C"?[W3_ ,2_
M,_86BBBOS _: HHHH **** "BBB@#S_]I?\ 96_9Z_;%^&3_  <_:9^%>F^+
M_#;WL5XFFZCO7R;F,,(YXI(V62*50S .C*PW'!Y-?+O[$W_!#S]CW]F'X^^-
M/CWK7P(T[4]:M_B.^I_"C4];\5ZIKDNB:8=+TZ)2%U">58[H74-VPFPTH0Q
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MXEC2IM4TGQMXMNX9=1U"UL(H/[3"1(#:SD P.H9XY4@B<HLA9S[!^RY\3/\
M@MYX@^.VA:1^U]^S)\!_#WP[F^U?\)#K'@SQI?W>I6^+65H/)BE4(^ZX$*MD
M\(SD<@4 ?7]%%% 'A?\ P3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>
M]9_]*37NE 'YB_\ !4G_ ).VU#_L#6/_ *+KYUKZ*_X*D_\ )VVH?]@:Q_\
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M_A9_P3.O?VP=:^,WA[_@L9:?LK_'Q-,M-+\=3>&?B=IMD^L6Z0H]JNJZ;<R
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M%W?%#_H9_P#R2@_^(KX<HH_M&IY_>']DTO+[C[C_ .%W?%#_ *&?_P DH/\
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MB*ZGFOM0N5UV#P_!;RH;J5I ,,9"=A88R^#M' Z5X%16KQ:=13:U5UOWM?\
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M70<@4444 %%%% !1110 4444 %%%% !1110 4444 %?TU>#?^10TK_L&P?\
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M<A_W%_XG^2"BBBO+/;"BBB@ HHHH **** /R O\ QA_P2%^%?_!9/]IG3?\
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MF?\ HFOCVOL,'_NL/1'Y]F'^_5/\3_,****Z#D"BBB@ HHHH **** "BBB@
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MLWQE_P BAJO_ &#9_P#T6U-;B>Q_,K1117VY^:!1110 4444 %%%% !1110
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MKH.0**** "BBB@ HHHH **** "BBB@ HHHH **** "OZ:O!O_(H:5_V#8/\
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M&%EXU'A+5"VM69']G3Y MC_SS;WIK<3V/YK:***^W/S0**** "BBB@ HHHH
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M>L?L'?\ )[/PD_[*/HW_ *6Q5%7^%+T9KA_X\/5?F?T24445\4?HX5F^,O\
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M_P#04T7_ ,*&S_\ CM?NAX9_X*Q?\$\-/\.:?87G[3^BI+!8Q1RI]BNSM94
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M+7N<>,P-+'14:C:MV_X9G\YW_"*W_P#T%-%_\*&S_P#CM'_"*W__ $%-%_\
M"AL__CM?T8_\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S3_T;QX%_\)*S_P#C
M5=G]KXGLOQ_S/._U?P?\TOO7^1_.=_PBM_\ ]!31?_"AL_\ X[1_PBM__P!!
M31?_  H;/_X[7]&/_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2
ML_\ XU1_:^)[+\?\P_U?P?\ -+[U_D?SG?\ "*W_ /T%-%_\*&S_ /CM'_"*
MW_\ T%-%_P#"AL__ ([7]&/_  R_^S3_ -&\>!?_  DK/_XU1_PR_P#LT_\
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MT7_PH;/_ ..U_1C_ ,,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\
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M'_#+_P"S3_T;QX%_\)*S_P#C5']KXGLOQ_S#_5_!_P TOO7^1_.=_P (K?\
M_04T7_PH;/\ ^.T?\(K?_P#04T7_ ,*&S_\ CM?T8_\ #+_[-/\ T;QX%_\
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MG_\ ':/^$5O_ /H*:+_X4-G_ /':_HQ_X9?_ &:?^C>/ O\ X25G_P#&J/\
MAE_]FG_HWCP+_P"$E9__ !JC^U\3V7X_YA_J_@_YI?>O\C^<[_A%;_\ Z"FB
M_P#A0V?_ ,=H_P"$5O\ _H*:+_X4-G_\=K^C'_AE_P#9I_Z-X\"_^$E9_P#Q
MJC_AE_\ 9I_Z-X\"_P#A)6?_ ,:H_M?$]E^/^8?ZOX/^:7WK_(_G._X16_\
M^@IHO_A0V?\ \=H_X16__P"@IHO_ (4-G_\ ':_HQ_X9?_9I_P"C>/ O_A)6
M?_QJC_AE_P#9I_Z-X\"_^$E9_P#QJC^U\3V7X_YA_J_@_P":7WK_ "/YSO\
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MHG[/GP#\,ZM;Z_X<^"'A#3[ZTD$EK>V/AJUBFA<=&1UC!4^X-=?6!U!1110
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M_8?C_;NU2:^\2^&=8TS3;CP5IN@P[KSQ+/J*H;"VMD;&7F$BMR/E0.Q!VXH
M^@:*^#O"?_!5_P#:T^#WQJ^&OP^_X*5?\$^(O@[X:^,6OQ:!X)\9Z'\2;?Q!
M;V&MSH7MM+U-(X(C;RRX*K(A9"X(QM5W3[QH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBOCGX[?MI?\ !4JU^,WB;X>?LD_\$F_^$L\->&+W[.OC
MKQQ\6;+P_!KCB-786-JT,DKQY;:)G*H2I':@#[&HKYO_ .";7_!1CPU_P4(^
M'?BJ^O\ X2ZS\.?'OPY\5S^&OB7\._$%RD]QH6IQ#)59XPJW$+#.R4*N[8_R
M@ $_/"_\%I?VM_C1X<\:?M(_L,_\$T9_B=\"? FK7]G/XYNOB/!IFI>*$L6*
MWEUI&GM;2&>&/:Y0LX:8J54*X9% /O/3/A3X1TCXHZI\8+.&<:UJ^FP6-Z[3
MDQF&(DH G8Y/7O725X7X9_;M\&_%_P#8-L/V\_V8/AKXE^)>EZYX;BU7P[X2
M\/01C5=0=I!$]H$=MB312^8D@+$*89.2!SY+_P $\?\ @J=\9OVQOVK?BC^R
M3\>_V%M0^"WB+X:^'])U>6UU7Q[;:Q<W4.H!FA$D=M L=NVP*^!+(?FP0I!H
M ^SJ*^7?^"@7_!1[4OV2/B#\._V9_@3\ KWXL_&GXL7%VO@KP'::U'IEO':6
ML?F76H7M[(CK;6\:G/W69RK!<;21A?LK?\%*OC#XH_:Q'[!W[>'[*4?P?^)V
MJ^&)?$/@>32?&,6NZ-XJL(6VW(MKE(HFCN83DM;NA;8C/G&W(!]?T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !17P5XQ_X*)_\ !8"*UUCXE?#K
M_@B-=7?@G19;AX[?7OC/86?B+6+2(MF>#3EMY#$Y52RP.QD?@*,L*]R_9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BOQR_X.%?^3T/#'_9+[+_TXZE7PA7K
MT,J]M14^>U_+_@G@8K//JV(E2]G>WG_P#^GRBOY@Z_HM_8B_Y,O^$/\ V2_0
M/_3=!6&,P/U2*?->_E;]3IR[-/K\Y1Y.6R[W_1'I]%%%>>>L%%%% !17P?\
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M/M7F?ZMMVS;QNW#V_P )Z[_PE'A73/$WV7R/[1T^&Z\C?N\OS$#[<X&<9QG
MSZ4 :%%%% !1110 4444 %%%>'?\%(O^3+O&?_<._P#3C:UK0I>WKQIWMS-+
M[W8PQ5;ZMAIUK7Y4W;O97/<:*_#NBOI?]6?^GO\ Y+_]L?'?ZY_]./\ R;_[
M4_<2BOAW_@C+_P U(_[@_P#[?5]Q5X&-POU/%2HWO:VNVZ3/JLMQO]H8*&(Y
M>7FOI>^S:WLNP4445R'<%%%?/'_!1K]O;_A@#P9\,_%W_"J?^$M_X6+\:-!\
M ?9_[=^P?V?_ &D9Q]MW>1-YOE^3_J<)OW??7'(!]#T5\(_\%6_^"W>C_P#!
M++]HGX4?!WQ7^SE<>*] \?PR7OB7Q;;>*/LC>&-.AO+>WN+LVOV27[4L:3F4
MCS(N$P2 2P^A_P!OS]LSPQ^P?^R#XM_:LU?PQ)XE.@V<"Z%X;L[WR9==U&YG
MCM[.RBD"2%3+/-&N\(Y52S;6VXH ]GHKX<^"/_!9J?XP?\$;O$O_  5HNOV:
M#I,GAS2M;NY/AV?&7G^<VG7<MN8_M_V-=N\Q[L^0=N<8;&:\[U[_ (+=_MT?
M!WX :/\ ME_M,_\ !&O5]"^"]_I&GZOJ7C3P9\;M,\07FFZ;>+&T5T^G?9;>
M4KME0M\PV9^8K0!^D]%9'P_\=^%/BCX#T3XF^!-8CU#0_$6D6VJ:-?Q A;FT
MN(EEAE (! 9'5AD9YKXL_90_X+A^ ?VI?^"EGC3]@&R^"%WHNC:-=:W8>!?B
M;/KWG6OC'4=&>V34[2"W^SJ(S#Y[N'6:4,D);Y=P  /NJBOG#_@HK_P4$_X8
M$_X4Q_Q:3_A+/^%N_'#0_AY_R'_L']D_VCYO^G?ZB;S_ "_*_P!3^[W;O]8N
M.?H^@ HK\[?!_P#P6(_;[^/'QR^,OPM_9%_X)(67Q"T?X,_$_4?!>K^()OV@
M[#1Y;RXM9642I;7>GC;O0!]OF,%SMWG&:]<_8X_X*R^$_P!H?]H;4/V*OVA/
MV>/&/P,^-VGZ.=6B\ >-W@N(M8L02'N=-O[9FAOD0@[MNT_*Y4,(Y"@!];45
M\\? W]O;_A<__!0WXY_L%_\ "J?[-_X4OH_AN_\ ^$K_ +=\[^V/[6L_M.S[
M+Y"_9_*^[GS9-_7"=*^AZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:Q^R3JNJZ]^T0DJ,8[G5/#5RVD>'5\QAB;SI&2]8'.\)NP<;J_1GXP_L%?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?#OAV^CAT^TU?5K:.)-.MY[EHXPBB"/+L50.[@,5 =@#[&_X)E?\HW/V?/\
MLA_A/_TSVM>WUY7^PO\ #?QI\'/V)?@[\(OB/HW]G>(O"OPK\/:/KVG_ &B.
M;[+>VVFV\,\7F1,R/MD1EW(S*<9!((->J4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-20201231_g25.jpg
<TEXT>
begin 644 biib-20201231_g25.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
M9[UC_@X(\5V/P[TRS2PLAH/@7R=6^Q(NQ(1="[6>/Y %!\]]HQU Q7ZRT4 ?
MG[_P5P_X(*?#K_@I[\$_ASH&G_&O4?!WQ'^%.FQV7A;Q\]C]K:[@"1!XKN-9
M(V8L\*2+(KAHG+D!@[ _,/[1W_!J9^T?^VWX.\,:K^V!_P %B?%GB_QYH'G6
MR:SK7@8ZA8VVGE4V6UM =0A9)-ZL\MPS,TV8P57RRS_M!10 5^=G_!;?_@@?
M<_\ !8GXC_#SXBV7[74GPRF\ Z7>6D447@8ZLUTT\T4HE#B_MC"4,?  ;.<Y
M&*_1.B@#\:M/_P"#1F^^+GCG2?$/_!0#_@K-\6OC7I.D3;K?2;VRFMI=A(+1
M+<7E_?&-6QAO+56(Z%3@C[__ &N?^"4'[(/[7'[!<7_!._6_!(\,^!-)L[5/
M!R^' L<WAVXM5(M[FW+A@S@,ZOOW&1990QRY:OH+QGXW\%_#CPU<^,_B'XOT
MO0='L]GVS5M:U".UMH-[K&F^65E5=SLJC)Y9@!R12^#_ !IX.^(?ARV\8^ /
M%FF:YI%Z&-GJNCW\=S;3A6*,4EC)5L,K*<$X*D=10!^4GPR_X(2?\%C?A#\/
M;']FCX<_\%^/$6A_"_2+466CPZ=\/@-3LK)>$@AF-WYL(5?E4)< (  H  4?
M0W[=O_!"7X&_M_\ [!GPX_8^^,?Q?\1R>)_A5HEO:>$OBQ/$MSJ37"6T4%Q-
M=1R-BX2Y\J-Y4WJS.B$2 KD_=%4=*\4>&=>N9[/0_$5A>S6QQ<Q6EVDC1'./
MF"DE>0>M 'YO?L-_\$=O^"H_[.WQH\ :S\?_ /@M#XG\>_#;X=W@EL_ ":#/
M$-8B2%XH;>ZF:[+&--R.%D\\ QJ !@,*?[7/_!O3X]U?]N'6O^"BO_!,[]N;
M6/@!\1_%1F?Q=:1Z$NH:?J<TY5KB0+YB;1*Z++)%(DR-*/, 0@5^G=4],\0Z
M!K<UQ;:-KEG=R6DFRZCM;E)&A;GY7"D[3P>#Z4 ?&'_!/3_@FM^W-^SO^T)>
M?M-?MO?\%3/%GQOU2?PK<:+8>$FT/^S-$TWSIK>5[E($G:-IO]'"!UBC.UV!
MS6'_ ,$E_P#@B!_PZX_:2^,G[0G_  T[_P )S_PMNX$O]D?\(5_9G]E?Z9/<
MX\W[;/Y_^OV_<C^[GO@?>]% 'P1_P1B_X(?_ /#HCQ_\7O'/_#3O_"PO^%JW
M&GR_9?\ A"O[)_LO[++>R8W?;;CS]WVS'1,>7GG=QS__  2-_P"" W_#K#X+
M_'#X0_\ #6/_  G?_"YM'M;'^T?^$$_LO^Q_)MK^#?Y?VZ?[1G[;NQNCQY6,
MG=E?T3NKJUL;9[R]N8X88E+22RN%5 .I)/ %0:-K^A>([0W_ (>UNTOX Q4S
M65RLJ9';*DC- 'XT? __ (-5OVIOV./A+XE\._L<?\%E?%WA#Q-XLG\CQ#=:
M7X,?3M.U+3A'M2&2&._ED2XC9IF2Z1]P65D"C)>OK#_@EW_P0,_9G_X)Y?L;
M^/\ ]EKQGK+?$>\^+UD]I\4=>O;'[$FI6IAEACLX(ED=H(HDGF*MO:0R2N^Y
M?D5/O*B@#\A?A/\ \&[O_!1O]B4ZS\,O^"<?_!:37? ?PRUK5)+T>&M=\#0W
M\]@[@*61S)Y;2%54-+$EN6VKD< U]'>*/^"-OQ)^(W_!)SQ]_P $V_C!^WOX
MH\;>)OB'JZ:EK'Q?\6Z&]]<I*M]9W6Q;1[S/E!;-8U3[1A ^1P M?=E% '@'
M_!+C]AC_ (=K_L)^!OV*?^%H_P#":?\ "%_VG_Q4W]B?V=]L^V:I=W__ ![^
M?/Y>S[5Y?^L;=LW<;MH]_HHH _([Q;_P0<_X+$:=%JGP_P#A#_P< ^.K7P1J
M4TXAT_5='O#=V%M*Q_T>*87SN%53M78\8P.%7H/IW_@C+_P1/^"/_!'3X<>(
M])\%_$'4O&OC'QI-;/XK\7ZG9):K,EN)/)M[>W5G\B)3+(Q!DD=F?+,0J*OV
MI10!^//[='_!KY^U/^W[\0M3\1?'+_@M-XKU?PZ?%&HZMX4\(Z]\-I=0MO#L
M=U*S"V@+ZRHPD>R+<$7(C'RCH/HSX"_L8?M8_P#!-#]B?X_ZQ^T+^WKX]_:>
MFNOA]/+X1T6_\,7,5UIS6EA>K]CLXOMEXTKW+2P( H7!B3AL_+]]44 ?F!_P
M:G?\$\OC3^PQ^P'J?C#X_:5=:+X@^*^OQZ]#X5O[1H;K2;&.$0VXN%?#)-(-
MTIC(!1'C#8;<H_3^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF[_@J'_P
M3D\-_P#!4/X Z/\ LV>.?C-XE\%^';?QG:ZSXAG\)LBW>J6D-O<Q&Q#OE(U=
MIT<LZ2J#"/D)(9?I&OC/_@NS_P %1==_X)+?L,O^T/X*^'L/B/Q-X@\40>%_
M"L%]+ML[.^N+2[N5NKD AI(HTM)#Y:$%V*+N4$LH!^)7_!>3_@FG\ /^"(OQ
ML^!_C7_@F5\=?'NB?$W7[JZ<:"/$(NM2A$+P+;7</DQI(JS2O)$8W#),5*JN
M$D4_8G_!US_P4 _:E^$/[)GP,_9'\':_=^%?%?QBTV2]^)9T*[:&;;;PVD;:
M<KH=PAEN;J3>%QN6V"'*NZGX,_X)??\ !6G_ ()M_!;]HG5O^"B/_!4C0?C=
M\:OVA]3U1[K3=2@\-:3<:/X>P<1RVHGU.$O,%P$/E1QVZA4B0%1(?N?_ (.M
M?V;?B7^VA^R!\ _^"GO[,?@76]2TSPMI#:EKFGQV6^_L-)U2"SO;6\ECA9]J
MP/$5E*,X0SAL[%9P ?.W_!7[_@F%I_\ P;G:1\!?VWO^">?QT\:Z?XM37CHW
MBV[U35%D@U2[2W6Y5C%&D8^SR^5<));/O1D*#@ABWZM?MC?\$L_@1_P7>\'?
M S]HKXX_%SQIH7@:/P(FM1>!_"E[' NIR:G#:743SSR*ZXB5=N%BW'>2'3&#
M^4__  65_P""HGAC_@X=T;X!?L0_\$\?@]XRU7QA<^(3K'BBPU+2?*BTR[>W
M6W6,R(S@PP^=</+<,%C1%5LG+!?LW_@OA_P51^+/_!$W]CCX0_L*?LJ6")XP
MUKX>Q:/8_$"Y52NBV&FV]O9F6WA.0UT_!5G^2, G#L1M /A[6_V:K?\ X))_
M\'*OPC_99_X)4?&/Q3K&GZ]J?AX>//#$NK_:3:07-U(-2TV],2JLL4=@@O-T
MB%H5F5\[HPU>]?\ !?GXM?%+_@H+_P %K_@W_P $5[3XGZUX<^&$]SI#>.++
M0KHQOJ-Q=EKJ>60<K(8K)(_)$BLL<CNY!S7DG_! W_@J/_P1W_8R\?:%I^J_
M#'XZ>//VC/B[X@M-*\3_ !4\1^&])DCBN]0ND1H8)'U9YH[;SI TLQ5IIR"[
MC[D2>K?\%]?AC\2/^">?_!<'X,_\%G9?AQK6N_"W[7HZ>,]1T6U\QM/N;3=:
M3P.>%1I+)HVA\QE61TD3(VDT >=_&'X7I_P;9_\ !=CX*^!_V0/B9XL/PB^+
M5KI"^,O"WB#5_M$4T-UJ,NG70<*J)*T($=S"Y&]')7=L)#?T9U_.5\=OBQI_
M_!R#_P %X/@CXE_8T\!>*)_A3\*;/1W\9^*-;T@V\5O;VVHRZA=2/RPB,JF.
MVB5OF>0$[2H)'Z<_M2?\%M-;_9U_X+$_#+_@E-I?[-$6O1?$*TTR>;QHOBEH
M9-.6ZEN5?_0Q:OY@C6WWDF5<ACG &2 ??E?GW^W%_P &[/[*_P#P4=_:^UO]
MJC]K3XR?$'4[2ZTBRL/#_@G0=4CLK'2EA@$<DA9TE:1W<%_D\I1G#!SS7Z"5
M^"/_  ='?\%R?CC\*?C;J7_!+?X$W^I>!M&&G6+_ !+\>:4%EU2]M+R!)C:6
M2>9&(XQ#(-Y,B/*V8]T:;C( <%_P;\Z;X\_96_X."/BA^P[^QS\9=<\;? /1
MQKL7B&::^$]F+>V0"VNG\L"%KF.\,5KY\:IY@:0C"MMJSXG\+7__  <-?\'%
MWQ+_ &1/VEOB5XH@^#/P5BUV'2O"?A[5/(B":5=PZ8\J$JZ+)<7DWFO-M+F/
M;&& ";?<?^#=#_@IK_P1G^'?C?PA_P $U?V$O@)\8;/QQX_%U-KGQ!\=>&](
MA;6[NRT^YO9)+J6WU*:2*,1P3+#!'&R(7 ZO)*?"]5\:'_@WL_X.//B?^U-^
MU%X \2CX/_&F#7Y]'\6:'I9GA>/5;N#4W2,957>"[A\F2'.]4VR!2K)N .K_
M ."/WC7Q_P#\$H?^#A[Q]_P1@\.?$[7]<^$?B&2[7PYI'B"]\T:;<?V0NMVE
MR@ "I*;??;R,BHLQ9&9<HFU__!UO_P $K/ _P[^#'C#_ (*3ZS^T1\1?$'B3
MQ!\1=,L]+\'ZGJT;:%HMK- Z.D$!1G#?N 01(J_.WRG/$'_!(7PMXS_X*P_\
M'&'Q _X+(^#/AUKND_"+PQ+='0M:UVR\I=0N?[&71+2V7DJTWV?=<NJ,PAVH
M&(+INT?^#L;_ (*V?LL?$_X,>+?^"7?AO3_%:_$KPAX_T>\U:>YTB)=,,:6S
M3GRYQ,78[+F/@QCG=Z<@'Z=?\$A]:U#PU_P1=^!'B+2=)>_NM/\ @9I=S;6,
M>=US(E@K+&,<Y8@#\:_#S_@D1^R3^SQ_P7:;]IK]J_\ X*L?M(>(+SQOX=LX
M;O3[U_%0LX] M)H[N62]6)]P%M T:(D0 AC52I4[EQ^F7_!N!_P5Y_93_:G^
M 'PX_P""=?PRT[Q;'X_^%_P4M+CQ+-JFCQ1:>R636=E-Y,RS,SGS;J+;E%RN
MX\8P?SX_;G^*G_!JAXA^-/Q"^*OC+]G+XNV?Q,TGQ+J4&M?#'P^9M,T_6]7@
MG>.3+1RO%;0RRJ26A>,A6+"+>=I /J'_ (,W?^"@7QI_:&^"OQ)_9%^-GC74
M/$*?#-]-O_!FHZM=M/<0:==^?')9&1R6,4,D"-&"3M$[*,*B*/V.^)_B^^^'
MWPU\0^/=+\+W>N7.AZ'=ZA;Z+IZDSZA)#"\BV\8"L2\A4(N 3EAP>E?D=_P:
M(?\ !.KXR_LR?!;XD?M??';X<7/A"Z^+=W8Q>$/#=_;O#/;Z1:F>3[08I/GC
MCFDN (P_S%+=7Y616;]%?^"H'BW]H[P'_P $]?C!XQ_9&L;RX^(^G>!KV;PJ
MFFVWG723A/FD@CP?,G2/S'C4 EG50 Q." ?!/Q;_ ."^_P#P5H^!?PUO/VD/
MBW_P0!\5>'OAMI<0N-7O]1^)(%Y96V0#+-$+#S(0-RDEX@%YR1@D?2/C/_@M
MU\(C_P $;-2_X+"_!3X6WOBC1M.L+=Y?!&IZNNFW4=VVJ0Z=/:RSK%.(VBDE
M9PPC82*JD8#@C^>/P3\2/V/?CU_P3C^(OBSX[_'C]I7XC_M62P:E<OX>.N7M
MSHUG8Q.&_M"[E=75[:.'>\OFR;C( @0 AC]E_LZ_\J4_Q=_['!O_ %)=*H ^
M@-9_X.V_C;KG[+6G_M;?"/\ X) ^-=3\':9=M:_$3Q3>>*I1H>B79NFBAM(;
M]-.(G9XFMG:1TB$4ERL6USM=_MO7?^"Y?[*/AO\ X)*:7_P5PU;2=63POK5@
M(]-\)JT9U"?6/M$EHVF*Q(7<MQ#,#+T\J)I<$84_ 'P,LK-/^#(?472TB!F\
M)^())2(QEW'C2[ 8^I 51D]E'H*^?+W]E;XP_M1?\&>7P[N/@QX<OM9O/AY\
M7]3\6:OI.FPM+//IT5WJUI.Z1J"S^5]L69L9Q'%(W:@#MO\ @I__ ,%SOVB/
MV]O^"-'Q'TCXW_\ !,3QM\,/!GQ+?1D^&OQ*AU&34=(U":VUVQNV@G=[6#R@
MT%K<&.8;EE:,J%'6OTP_X-E_^4'/P(_[!^M_^G_4:_)3]K#_ (+:?L[_ +5'
M_!N1I7[ WPG^#WC"Z\<^$/ _@_1_'=P/#_\ Q*_#EKI=[I\(U%KI6*A+F:&"
M&-<!MUV5.,?-^M?_  ;+_P#*#GX$?]@_6_\ T_ZC0!Z]_P %0_\ @G-X>_X*
MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@W[5&G?%3XB>'/#$^@?#S2?#7A :+HGA6UN#_I4\,1EEDFNIERC2L1A'9,,
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M@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\
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MH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\
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M;_@H=_T<'_Y:>D__ ")1_P /=O\ @H=_T<'_ .6GI/\ \B4?\0EXC_Y^TO\
MP*?_ ,K#_B8/@S_H'Q'_ (!3_P#EI^VU%?B3_P /=O\ @H=_T<'_ .6GI/\
M\B4?\/=O^"AW_1P?_EIZ3_\ (E'_ !"7B/\ Y^TO_ I__*P_XF#X,_Z!\1_X
M!3_^6G[;45^)/_#W;_@H=_T<'_Y:>D__ ")1_P /=O\ @H=_T<'_ .6GI/\
M\B4?\0EXC_Y^TO\ P*?_ ,K#_B8/@S_H'Q'_ (!3_P#EI^VU%?B3_P /=O\
M@H=_T<'_ .6GI/\ \B5WO[+/_!4+]NCXC_M+> /A_P",_CC]LTC6_&.G6.IV
MG_",Z9'YUO+<HDB;X[967*DC*D$9X(K'$>%?$.&H3JRJTK13;M*?17_D.C">
M/7"&-Q=/#PH5U*<E%7C3M=NRO^]>A^O-%%%?FA^VA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB5<* ?7-%%% !1110 4444 %?@1^V[_R>1\5/^R@ZO\ ^EDM?OO7X$?MN_\
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MK':3R>?'Y"QLK,&V2Y+GY1C) /AC]M^+XP?&+_@N1X;\*_\ !,V_T[PI\=_
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M_P!K#XJ_#;]J[]G']HRZ^$WQG^$SWJ>%?%HT&/5;&\L;M ES87MG(Z"6)P"
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJOQ5_X>S?M_?]%UA_\ ".T?_P"1*/\
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MS?M_?]%UA_\ ".T?_P"1*/\ A[-^W]_T76'_ ,([1_\ Y$H_XA+Q'_S]I?\
M@4__ )6'_$P?!G_0/B/_  "G_P#+3]JO^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
MOJOQ5_X>S?M_?]%UA_\ ".T?_P"1*/\ A[-^W]_T76'_ ,([1_\ Y$H_XA+Q
M'_S]I?\ @4__ )6'_$P?!G_0/B/_  "G_P#+3]JO^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJOQ5_X>S?M_?]%UA_\ ".T?_P"1*/\ A[-^W]_T76'_ ,([1_\
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M/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"OXV/\
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M?M_?]%UA_P#".T?_ .1*/^(2\1_\_:7_ (%/_P"5A_Q,'P9_T#XC_P  I_\
MRT_:K_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZK\5?^'LW[?W_1=8?_  CM'_\
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M9:OYR\5O^2GC_P!>X_G(_LOP#_Y(>?\ U^G_ .DP"BBBOS0_;0HHHH ****
M"BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_
MV/>L_P#I2:]TH _&G_@M3_R?7JO_ &+^F_\ HFODVOK+_@M3_P GUZK_ -B_
MIO\ Z)KY-K^M^$O^28P?_7N'Y(_SV\0/^2XS'_K]4_\ 2F%%%%?0GR 4444
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M *3 ****_-#]M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
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M;?1G=0PBGGCD4.X!&Y8P=OOP3\X:Q9V>GZO=6&GZDE[;P7+QP7B(56=%8A9
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M_P"1IB?\"_\ 2C^>/I#_ /(CP7_7R7_I)Y=1117[V?R<%%%% !1110 4444
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M2WEM*)4P1B2)#VQ0!]?T444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
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M^"B'_)^WQG_[*CKO_I?-7]-M?S)?\%$/^3]OC/\ ]E1UW_TOFK[#@[_>ZO\
MA7YGPG'?^YT?\3_(\<HHHK] /S(**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O8_^"=__)^WP8_[*CH7_I?#7CE>Q_\ !.__ )/V^#'_ &5'0O\ TOAK
M#%?[K4_PO\CIP7^^4_\ %'\T?TVT445^+'[^%9_B[_D5-3_[!T__ *+:M"L_
MQ=_R*FI_]@Z?_P!%M5T_XB]3*M_!EZ,_G'HHHK^U3_,P**** "BBB@ HHHH
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M^E\U?TVU_,E_P40_Y/V^,_\ V5'7?_2^:OL.#O\ >ZO^%?F?"<=_[G1_Q/\
M(\<HHHK] /S(**** "BBB@ HHHH **** "BBB@ HHHH **** "O8_P#@G?\
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M ,"?^8?V!D7_ $"T_P#P"/\ D=%_PM?Q_P#]!_\ \E8O_B:/^%K^/_\ H/\
M_DK%_P#$USM%']I9C_S^G_X$_P#,/[ R+_H%I_\ @$?\CHO^%K^/_P#H/_\
MDK%_\31_PM?Q_P#]!_\ \E8O_B:YVBC^TLQ_Y_3_ / G_F']@9%_T"T__ (_
MY'1?\+7\?_\ 0?\ _)6+_P")H_X6OX__ .@__P"2L7_Q-<[11_:68_\ /Z?_
M ($_\P_L#(O^@6G_ . 1_P CHO\ A:_C_P#Z#_\ Y*Q?_$T?\+7\?_\ 0?\
M_)6+_P")KG:*/[2S'_G]/_P)_P"8?V!D7_0+3_\  (_Y'1?\+7\?_P#0?_\
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M\]O$#_DN,Q_Z_5/_ $IA1117T)\@%%%% !1110 4444 %%%% !1110 4444
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MUG_TI->Z4 ?C%_P67NY[[]N'5+BXL9+9CH&G#RI2,C]UUXKY4KZR_P""U/\
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MFAZ?Y-M+/_I-RM[(8]_E>4F$.Z62->-V1\TZO^TO^TE_P3J_X*>_M"2?"_\
MX):_';XJ_#SXH:MH^O7GBGP?X65Q!K$6EV\$PLY"Y2\M754SO,3PS),H$BD%
M?HK]ES_@J9\6?VCOCMH7P9\3?\$J/VC_ (;6.L_:O/\ &OCWPE!:Z3IWDVLL
MX\^5)V*^8T0B3 .9)4'?- 'U_1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+
M_P"">_\ R1/5O^Q[UG_TI->Z4 ?C3_P6I_Y/KU7_ +%_3?\ T37R;7JG_!P9
M_P I(M:_[%?2?_1%?$=?T7P[Q1]5R+#4?8WY815^;LO\)_(/%WAW_:'%&,Q/
MUKEYZDY6Y+VNV[7YU?[CZ(HKYWHKV?\ 6_\ Z<?^3?\ VI\[_P 0O_ZB_P#R
MG_\ ;GT117SO11_K?_TX_P#)O_M0_P"(7_\ 47_Y3_\ MSZ(HKYWHH_UO_Z<
M?^3?_:A_Q"__ *B__*?_ -N?1%%?.]%'^M__ $X_\F_^U#_B%_\ U%_^4_\
M[<^B**^=Z*/];_\ IQ_Y-_\ :A_Q"_\ ZB__ "G_ /;GT117SO11_K?_ -./
M_)O_ +4/^(7_ /47_P"4_P#[<^B**^=Z*/\ 6_\ Z<?^3?\ VH?\0O\ ^HO_
M ,I__;GT117SO11_K?\ ]./_ ";_ .U#_B%__47_ .4__MSZ(K^CCPC_ ,BI
MIG_8.@_]%K7\G]?U>>!O^1)T?_L%6_\ Z+6OR_Q*SC^U885<G+R\_6^_+Y+L
M?MO@UPM_JW4QK]M[3G5/[/+:W/\ WG>]S4HHHK\K/W,*_F2_X*(?\G[?&?\
M[*CKO_I?-7]-M?S)?\%$/^3]OC/_ -E1UW_TOFK[#@[_ 'NK_A7YGPG'?^YT
M?\3_ "/'****_0#\R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KV/\
MX)W_ /)^WP8_[*CH7_I?#7CE>Q_\$[_^3]O@Q_V5'0O_ $OAK#%?[K4_PO\
M(Z<%_OE/_%'\T?TVT445^+'[^%9?CG_D2=8_[!5Q_P"BVK4K+\<_\B3K'_8*
MN/\ T6U5'XD3/X&?RAT445^W'\\A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?;G_!OG_RDBT7_ +%?5O\ T17[Z5^!?_!OG_RDBT7_ +%?5O\
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M_5YX&_Y$G1_^P5;_ /HM:_E#K^KSP-_R).C_ /8*M_\ T6M?$\9?#0_[>_\
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M:V:WU31=:L([JTO(6ZQRQ2JR2*>ZL"*U:* /@?Q=_P &XW_!/R36KK6OV?\
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MJ@JT:5_>>VCMWWM;\3-8/$/#RK6]V.CU5UK;:]]_(\$HHKZ;^'?["_P<\.?
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M6M?]BOI/_HBOB.OU_*/^171_PK\C\,SS_D<8C_'+\PHHHKT3R@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_J\\#?\ (DZ/_P!@JW_]%K7\H=?U>>!O
M^1)T?_L%6_\ Z+6OB>,OAH?]O?\ MI^A<!?'B/\ MW_VXU****^%/T8*_F2_
MX*(?\G[?&?\ [*CKO_I?-7]-M?S)?\%$/^3]OC/_ -E1UW_TOFK[#@[_ 'NK
M_A7YGPG'?^YT?\3_ "/'****_0#\R"I;"Z6QOH;UK6*<0S*YAG7*28(.UAW!
MZ$>E144!L?;OPY_:Q_84/[/_ ,1?$MW^P5I5E>/KOA^>Z\)0_%&\2PU>=7O2
MLD5N\;31PQ,27B21E82JN4  /SO\3OVG[K]H?]JR[_::_:4\$P^)8M6U:*XU
MOPUIFH/IL4]K%&D4=I%,H=X%6*-$#89L+DY))/E5%<=+ T*,Y35[ONVVE9:)
MMZ;?EV1W5\QQ%>G&#LE'HHQ2;NVFTDD]WH]-^[/M'Q=_P4=_8A\9_ GPW^SG
MJ_\ P36U ^&/"-[>WGA^U7XW78>WGNFW2NT@L0\@+<X8D#MBO(_V:=8_9R\(
M?LU?&GQ+\8M'T?6/%5]H]AHWPXTF\0-<PWEQ)*9[^/\ YYK!$@);NSHO>O"J
M*4<!1ITW"#:3:;]YO9WZMVOUMN.>98BK552HHMI-+W8K=<JV2O9;7VL>Z? '
MXP?L->'_ (=1^#OVD_V1=<\3:S;WTLT7BSPWX\DT^:6%]NVWDMVB:,A"&(D!
MW'=@\ 5;_:W_ &W-&^.WPV\*_L[?!/X*V?PY^&/@VYFO-*\-0:K)?W%W?2@A
M[RZN9 IEDP6 &!M#L,L,8\ HK3ZI1]LJKNVG=7;:3[I-V7W:=#/Z]7]@Z*LD
MU9VC%-KLVE=_?KU.V^$_QV\:_#+XI^&OB1<:WJFI1^'O$%GJ3Z<^KR1BZ$$Z
M2F(L=VT-LVYVMC.<'I7<^/?VN_#OQ6_;@N/VM/B?\&QKNA7?BYM:N/A]?Z^S
MP21%MWV0W!AP4R!G]UA@,%<$UXA15RP]&4^=K6S7;1_UON1'%5X0Y$]+J5M'
MJMM_RV/M/X__ /!2+]BG]I_XC7'Q5^-?_!.76]8UB>".!'/QXO8H;:",82&&
M)+$)#&O.$0 9)/4DGY]^"_QJ^"WPP^*OB?QGXL_9IL?%GA_5])U&ST+PMJFM
MG&C/.X-O.)VA<S/ HV@E5+Y)RM>745E2P.'HTG3A?EM:W-)Z>5WI\C:MF.*K
MU55GR\R=[\L5=^=HZ_.Y>TSQ/XET6 VNC>(;ZTB9][1VUV\:EL 9PI S@#GV
MKU[XE_MH>(?B-^Q[X!_91N- O;=_!>L:I?77B)]>>4ZHMY)O$30&,; G3)D?
M=Z+7B=%;3HTJDHRDM4[KULU^3.>GB*U*,HQ=E)6?I=/\T@KV/_@G?_R?M\&/
M^RHZ%_Z7PUXY7L?_  3O_P"3]O@Q_P!E1T+_ -+X:G%?[K4_PO\ (O!?[Y3_
M ,4?S1_3;1117XL?OX5E^.?^1)UC_L%7'_HMJU*R_'/_ ").L?\ 8*N/_1;5
M4?B1,_@9_*'1117[<?SR%%%% 'L7[!'[3VE?L>?M4^&?CYK_ (5FUG3M*^U6
M^HV5I,([C[/<VTMM)) YP%E592RY(!(VY7.X?5?C[]B+X%?M7_!KX7>&/V+/
MVHI;C7X?#>OW7@WP3X^T5['4]=@74KN>XC2YB+0&=")4V<!PF_*J25^'O@IX
M_P#!WPT^(%OXH^('PDTKQQHX@F@OO#FKW4UO'<))&4W++ RR12*2&5U.0P'6
MOL/6OV_?@!^S[\)?A?\ $3]EC]ES3]'\;V_AK7;;PWJ6L^/IM8?P=Y]_=1RL
ML'E1"29UD>2-YONK(!M<9+>-F%*O]8C4H)\^U_=Y=%*R:;OI=W:6S?6Q[^5U
ML-]5G3Q,H\BUM[W,KN%W%I6ULK)O=*ZM<^$71XW,<B%64X96&"#Z5]??\%Q/
M^3[KC_L1] _]((Z\#_9Z^(G[/_P_\1ZAJ?[1'[.]U\2+&YM EC86_C6?16M9
M]X)F,L44ADRN5VD <YS7LW[='[>W[-W[:":CXOA_8HN_#'CRZLK&SL_%O_"S
MY[V.U@MC&H0V?V2*.0M"ACR2""V[DBNBJJ[S"G)4VXI23=XV][E[N^EG?3TN
M<E!X=995A*HE*3BTK2O[O-U46KNZMKZV/E:OU(A_8/\ VNOV?;SX-?LM?"'X
M!:_>:%I_C?0O%GQD\;64*?9]5U1;B*1;='W9>TL82RCL\K2/M! -?%GQ:UC]
MG+1OV'/A=X$\'Z/H]]\2]1UC4]9\9:Y9(/M%A9B:2"TL)7'WF909BO\  -F?
MO5P'PG^.WC7X9?%/PU\2+C6]4U*/P]X@L]2?3GU>2,70@G24Q%CNVAMFW.UL
M9S@]*G$TZ^-@G#11<M&MVM$]UYM7\GT1IA*N&P%1JI[SDHZQ=N5/5K9^2=NS
M75GMG_!8+X-_%#X9_MV^/O%OCSP5>Z7IOB[Q1>W_ (;O+I0$U"V#J#+'@G*Y
M(ZXZUZ+_ ,$P_B=^P=I?Q>\#^&=/^%?B31?C#?F+3/"WCO7;X:KHMGK\^88+
MAM/C>!MI=PJAG<*S*Q QN'SW\7?VI]"^./[8FI_M-_$KX3G5M!U?Q/)J=YX#
MO/$,OEM;N<O:"Z1$9 1_RT1%(."!Q7KWP_\ VWO^"?W[/WBJT^,G[/O_  3_
M -43QQI<AN/#\WC#XCS7^FZ3=#.R=85B1K@H>5#LI! 8$, 1SU:.(>70H2A)
MRY;>ZTE>UK.\M5WW3_ Z*%?"K-)XF,XJ/->TDV[7O=6CH^VJ:_$^;?V@_"?C
MSP)\>/&G@OXI:BEYXETKQ7J%KX@O(GW+<7J7,BS2J<#(9PS X'!Z"OI#_@I_
M_P D/_95_P"R!V'_ *-:O!?!GQF\%:K\>M1^,_[47PPN/B/;ZY>WM_KFD0^(
MY-(>\O+AFD,WVB&-RF)&+;0N#TX%>\?M+?\ !0K]DC]HSX4Z-\/KG_@G_>Z5
M?^$/!;>'? NL#XO7,XTB(*WDR/#]B076QR&P[9;&"PS716CB%B*+5-OEW:Y;
M:JVEVG^&QS4)85X;$)U%%SM9/F;TDGJU%K5>>Y\A5]KZYJ7[._[?'[)GPD\'
M:Q^T[X7^&/C[X2Z)<>']2TWQU'<16&JZ?Y@>"YM[B"*0>8%&UHR-S,6Z *7^
M:M$^+?PSTS]FC6O@QJ'P(T^\\5ZEXEAU&P^(;WX6YT^T1%5K)8?*.Y'*EBWF
M#&[[IKMO@)\8/V"_#'P^M-$_:'_8\\0>*O$-C<2R-K>B?$2;3XM1C9]R0S0>
M4PC"CY=\; D<XR,UIBX3J)349*47I;EOM:^KM9WMWZF>"G3I2<'.+C..O-S)
M;WM>*O=6O=:=#Z&_X*B:;\'?#O\ P3F_9<\*?"OQC+XALM-;Q%;Z7K]Q8-:G
M4HTGA6ZN(XI/G2![D9CW@$IL)ZU\ UZQ^UY^UIXH_:S\=:;K5YX5T_PSX;\-
M:/%H_@OP=HQ/V31-.C^Y$A.#(Y)R\I +G'  51Y/59?0J8;"J,]VVW\VWTTZ
MZVTOL1FF)I8K&.=/X4HI?]NQ4>NMM-+ZVW/MS_@WS_Y21:+_ -BOJW_HBOWT
MK\"_^#?/_E)%HO\ V*^K?^B*_?2O@^+?^1HO\*_-GZ1P3_R)W_C?Y(****^8
M/L HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3
MW_Y(GJW_ &/>L_\ I2:]TH _ O\ X.#/^4D6M?\ 8KZ3_P"B*^(Z^W/^#@S_
M )21:U_V*^D_^B*^(Z_7\H_Y%='_  K\C\,SS_D<8C_'+\PHHHKT3R@JQ!I.
MJW6G7&KVVF7$EI:.BW5U'"QCA9\[ [ 84MM; /7:<=*986JWM]#9/=1P+-,J
M&:8X2,$@;F/8#J:_3'X\_#K]F#]@KX:_%+X(W/[$]SXMT'0;WPBM]XG\4>*]
M2M6\9O<0W<GVN![9DBMTB<R(@B##);?D@!>+%8Q8:48*+E*6R5MKI/=KNO\
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MSPN(EB(2YE9Q;3L[K3L[+\M[HTQN&CAIQ4974HJ2NK.S[J[_ #U5GU"OZO/
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ME^.?^1)UC_L%7'_HMJJ/Q(F?P,_E#HHHK]N/YY"BBB@ HHHH **** "BBB@
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M_P"%?D?AF>?\CC$?XY?F%%%%>B>4%%%% !1110 4444 %%%% !1110 4444
M%%%% !7]4G@BR\:GP7I!76K,#^R[? -L?^>:^]?RMU_5YX&_Y$G1_P#L%6__
M *+6OB>,OAH?]O?^VGZ%P%\>(_[=_P#;B/[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V**^%/T8Q_L7C?\ Z#=E_P" Q_QK^:?_ (*#K<)^W;\9%NI%>4?$
M[7!(RC +?;ILD"OZ<*_F2_X*(?\ )^WQG_[*CKO_ *7S5]AP=_O=7_"OS/A.
M._\ <Z/^)_D>.4445^@'YD%%%% !1110 4444 %%%% !1110 4444 %%%% !
M7L'_  3X6X?]NWX-K:R*DI^)VAB-F&0&^W0X)%>/U['_ ,$[_P#D_;X,?]E1
MT+_TOAK#%?[K4_PO\CIP7^^4_P#%'\T?TJ_8O&__ $&[+_P&/^-'V+QO_P!!
MNR_\!C_C6Q17XL?OYC_8O&__ $&[+_P&/^-9?C>R\:CP7JY;6K,C^R[C(%L?
M^>;>]=967XY_Y$G6/^P5<?\ HMJJ/Q(F?P,_E#HHHK]N/YY"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ^U/^" L>HR_P#!1C1DTNXCBF_X1G5<
M/*FX8\CGBOWD^Q>-_P#H-V7_ (#'_&OPC_X-\_\ E)%HO_8KZM_Z(K]]*_-N
M+?\ D:+_  K\V?K'!/\ R)W_ (W^2,NSM/%J72/?:M:O$&_>(EN02/8UJ445
M\P?8!1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O
M"_\ @GO_ ,D3U;_L>]9_]*37NE 'X%_\'!G_ "DBUK_L5])_]$5\1U]N?\'!
MG_*2+6O^Q7TG_P!$5\1U^OY1_P BNC_A7Y'X9GG_ ".,1_CE^84445Z)Y044
M44 %%%% !1110 4444 %%%% !1110 4444 %?U>>!O\ D2='_P"P5;_^BUK^
M4.OZO/ W_(DZ/_V"K?\ ]%K7Q/&7PT/^WO\ VT_0N OCQ'_;O_MQJ4445\*?
MHP5_,E_P40_Y/V^,_P#V5'7?_2^:OZ;:_F2_X*(?\G[?&?\ [*CKO_I?-7V'
M!W^]U?\ "OS/A.._]SH_XG^1XY1117Z ?F04444 %%%% !1110 4444 %%%%
M !1110 4444 %>Q_\$[_ /D_;X,?]E1T+_TOAKQRO8_^"=__ "?M\&/^RHZ%
M_P"E\-88K_=:G^%_D=."_P!\I_XH_FC^FVBBBOQ8_?PK+\<_\B3K'_8*N/\
MT6U:E9?CG_D2=8_[!5Q_Z+:JC\2)G\#/Y0Z***_;C^>0HHHH **** "BBB@
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M%?F?"<=_[G1_Q/\ (\<HHHK] /S(**** "BBB@ HHHH **** "BBB@ HHHH
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MET5KR[6[E.^X=I#"^59R2H!P!@8[G(_X4O\ \%K?^CR/A9_X2/\ ]S5]C44
M?EY^T'_P16_;&_:H^),_Q=^//Q7^%FN^(;BUBMYM0^SZI:[HHEVHOEV_EH,#
MN%R>^:XC_B')^,/_ $,WPL_\"-<_^.5^O5%=D,QS"G!1A6DDMDI.WYG#4RO+
M*LW.="#;W;C%M_@?D+_Q#D_&'_H9OA9_X$:Y_P#'*/\ B')^,/\ T,WPL_\
M C7/_CE?KU15?VGF7_/^?_@4O\R/['RG_H'A_P" 1_R/R%_XAR?C#_T,WPL_
M\"-<_P#CE'_$.3\8?^AF^%G_ ($:Y_\ '*_7JBC^T\R_Y_S_ / I?YA_8^4_
M] \/_ (_Y'Y"_P#$.3\8?^AF^%G_ ($:Y_\ '*/^(<GXP_\ 0S?"S_P(US_X
MY7Z]44?VGF7_ #_G_P"!2_S#^Q\I_P"@>'_@$?\ (_(7_B')^,/_ $,WPL_\
M"-<_^.5QWQ*_X(5?$7X;>+?"'A+5=7^',TWB[6&T^R>UGUDI$XC+[I-TH.W
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M_B')^,/_ $,WPL_\"-<_^.4?\0Y/QA_Z&;X6?^!&N?\ QROUZHH_M/,O^?\
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M,R/AE!VLI4XP017ZPT4GF68R5G6G;_$_\QQRG*HR35"":_NQ_P CXY_X4O\
M\%K?^CR/A9_X2/\ ]S4?\*7_ ."UO_1Y'PL_\)'_ .YJ^QJ*XCT#XY_X4O\
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MX?\ '^=&-R26A5=XF:/Y/,:-02BQ@?J+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?FE_P79_X+(V7[&WC
MWPG^P!\-?B]IOPS\<_$S1EU+6_B[XDL)I[#P/X?DFN(&O8884=[N^=[:=(8@
MNU&4,Y4%37??\$9OVE/^".^D^#H/V'_^";O[1EEXTU[3]-N?$7B>[GT^^&JZ
M].98DN]6OKBXMXQ/.\LT0)SP&55 1 !]WT4 ?E)^Q#^UK^S_ /\ !&[]I_\
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MRC@@_B*?I6DZ5H6G0Z/HFF6]G:6Z;(+6TA6..-?154 */84 6**** "BBB@
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M3JOI.D:3H&FPZ/H6EV]E:6Z[8+6T@6..-?154  ?2K% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P *3_9V_:CT[5?&#0--!X9U?0]1T:^N452[&&'4K:W><A SD1AB%4L1@$T
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M1_BS\-/^"[T7[17@VVM9F\8>#QX;\-S+<O)!(L,B3:<J7&FF.8H_EMN#!"A
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MO]%CMK0^5+*LL_F3*5Q"CE<9;:.: /+/^"E'QOM/A/\ M!ZE8_%?_@X$TO\
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M;Q7X*TW3-2\.:OJ"O]CU"TET^--UN7B?S(I P1$PNYI R>3>+?V9OVV/%_\
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M]@S]D/\ :%TOP'X:\;_!S5=:\3:GJ7A*RU1]+>WO"GV^W29 \MR%"PQQM)Y
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M-?%_P_U22^MKU)=/N9M.N=*U%UMI7*(UQ9J6A?9,%0@HI(H \.\6_MT?M$>
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M@36_AMXPM99])\0Z1<Z9JD,%R\+R6T\312JLD95XR4=@&4A@>001FOD?0?\
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MP@>*[D0(\K;0#E0#]2**^./!/_!?3_@E9X_^(&E^ ]#_ &D9X8=>UDZ1X?\
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M?L#?LH?$W5_@I\=/CRFD>,=&T:SU2;PQ#X=U&[O+J"Z=TMUM4@MW%W*[1O\
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M%C)1"8T*HQ1202H([OX)_LC_ +/?[.OQ!^(/Q3^#?P^_L?7OBIX@76_'E_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?+?_  5O_:,^,O[,7[.&
MB>/?@=XQ_L/5KOQO;:?<7?\ 9]O<[[=[.\D9-MQ&ZC+Q1G(&?EQG!(/YV_\
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MP62^)W_!/_\ 9\_:NM/AM\.="^$^A^(;O7AX+T_4M0TB2:1DD2Q$T8W3W#,
M9+AI8X8X7*1[V4@ _2"BOA/_ ()S_'3]KSX<?M^_&3_@F;^UU\?Q\6O^$/\
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MS[!XC\ :!>H);-=<O[V!7U3RVRKR+%,J*V/E:"%UPR U^C?CWX<^ /BGX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'Q)_P7I_Y- \-_\ 92;/_P!-^H5^25?TD45^E<+^(?\ JWE2P7U;VEFW?GY=
M_+D?YGXIQUX/?ZZ9_+,_KWLKQC'E]ES?#UO[2._H?S;U^MO_  06_P"30/$G
M_92;S_TWZ?7VW11Q1XA_ZR94\%]6]G=IWY^;;RY%^8<"^#W^I>?QS/Z][6T9
M1Y?9<OQ=;^TEMZ!1117YJ?M84444 ?%/_!4_]AC]HOXG?%_X2?\ !0O]A";1
M7^-?P/O+Q;/PWXAN_L]CXPT.\C,=WI4LW2&0J7\J1L(K2N25.UU\R_:,_:-_
MX+'_ +=/P6U;]D;X*?\ !,/5_@AJWC;3)=%\8?$_XC?$#2[G3?#5E.IBNI+-
M+)WFOI3&SK&Z*NUB'QQD?I'10!^?/[:O_!*;QSX6_P""5_PA_9(_8:T.T\1:
M[\ ?&WA?Q3X<T;6M2CT__A)I]+N6EN4>=\QP2W#33S98A [8R!BL[_@I/X#_
M ."A7_!37_@D]\2_@I+_ ,$^]3^'?Q#O/$_AT^'O!^J?$K0=0;5;6WU:QN[B
MY6Z@N1;PA$BE^21U=MGR@D@']%Z* /D#_@O5^RY\=OVT?^"3WQ6_9H_9H\#?
M\)+XV\2_V%_8FB?VG:V?VG[/KNGW4W[ZZEBA3;#!*_S.,[<#+$ \+_P4T_8B
M^.MQ^VM\-_\ @IM^S1^SUX9^,FI^$_!UWX,^(/PD\275I;2:YH4L[74,]A/>
M*8([JWN'D?;)CS%;:I!)!^^:* /B_P#9)^(?Q6^)OQ\T1?\ AR./@SX:M(KF
M75?B'XKU#P[!>V4P@<1PVEI8&6>4R2$(9=R*J%NI.*T?^"9/[+GQV_9Z_:$_
M:Q\<?&#P-_9&E_$SX\3^(O!%U_:=K<?VEIK6D48GVP2NT/S*PV2A'XSMQ7U_
M10 5\@?\$R?V7/CM^SU^T)^UCXX^,'@;^R-+^)GQXG\1>"+K^T[6X_M+36M(
MHQ/M@E=H?F5ALE"/QG;BOK^B@#\UOCO^QY\?/V._^"BWQ-_;8^$?[">B?M'_
M  V^.%CI4WC'PC%-ID6O>$]9L+<VXN[-=1Q'<V]Q&<R1HXD\QL\+&-_T5^P5
MXK^*/CSQCXA\1^*O^"6-I^SSH,>FPQZ+JFHZKHSZOK<C2$R1R6NF;OLT2!4/
M[R0EV;A1MR?I^B@#\B/VGO\ @DC^VMXZ_P""B?B;X%?#OX>V<_[(?QN^,7AK
MXI_%?53KUE&+*_L(9WU+2S9O,+B8:A=064KR)$RJWD_, LFWZI_X+$_L)?%[
M]JK0?A5\??V:O#?AOQ#\1O@7XY_X2+0_!?C%T33/%-C+&(;[2I7D!2%YHU39
M*XVJR8.W=O7[.HH ^!?@Y\5/C9\0_B=X5\+6O_!O;_P@H.NV8\5^+O%FK^%H
M+/0+83+Y]U:M;&2:_DC7)C6-$+, <J.:[OX-?LN?';PI_P %JOC1^UMK_@;[
M/\/?%GP?\.:)X?\ $']IVK_:K^UFD:>'R%E,Z;0P.YXU4YX)KZ_HH ^0/AG^
MRY\=O#W_  6\^)W[7VK^!O)^'?B'X#Z+X=T?Q#_:=JWVC4H+]Y98/(64SIM0
M@[VC"'H&)XKY]_8GTW_@IY_P3'T7QS^PMX&_X)SW7Q,TVZ^)6N:S\+?BG9^/
M-.L=#DT_4;IKB,ZJLKFYMF@9V,BQQN[@%8T;"N_Z@T4 ?E9\#_\ @C=^TS\6
M/^"#_C7_ ()X_M+SV7A3XHZMX\UKQ#HNL2W4%U:_;UUHZA973FV>95AG* .O
MS21QSME-R[:Z?PG\6_VO]-\*6O@#QW_P;;Z9J?Q'M;58+_4=(U_PG!X7OIU&
MUKJ.]D8R0PN?W@B,3R(&V?,1D_I910!\D_MD_%7X\^"$T#X5ZA_P2(/QT^&-
M]X3M)-:C\.:WH<ZZ1JBM(CV']E:DT8GA2,1%)D.!N92HQ7E?_!%W]B;XQ?L_
M_M!?'W]I/5OV7H/V?/AS\4KS13X'^!5OKEM>'39;2WDCN=2ECM&:VLVN&=2(
M8CD %6 ")G]"J* /!_\ @J%\&?B5^T5_P3K^-7P)^#GAO^V/%7BWX;ZKI?A[
M2OMD-O\ :[N:W=(X_-G=(X\L0-SLJCN17SY_P4'_ &*?VF_CC_P;WR_L/?"[
MX:?VI\46^%?@[1U\+_VS909O;&XTM[J+[3-,MO\ (MO,=WF;6V?*6RN?ONB@
M#QS]LC]E*Q_;(_8<\=?LB>(]4_LL^-? TVCIJ!3S!8W30CR9RH/SB.98W(!Y
M"D C.:^%=2^(_P#P6MUO]@Q_^"9[?\$U9X/B5<>!?^$$N?C0_P 0=,_X1);
MVWV%M<4B3[493;YD^S^3O$ASM./+K]3:* /SR^,O_!,?XN?#WP?^P1\$?@#X
M;/B?0_V=_B1I5SXXUMK^UM#%96^G20S7_ES2JTF^=BWE1!W&_H0,UZU_P4$_
M9F^-WQO_ &O?V2_BC\+_  3_ &IH7PR^*FHZQXWOO[2MH/[-LI=*F@279-(K
MS9E=5VQ*[#.2 .:^LZ* /D#]O;]ESX[?&G_@H3^QW\<?AGX&_M+PM\*_&'B>
M^\>:I_:=K#_9<%WI*V]N_ERRK)/OE!7$*N5ZL .:^OZ** /RP_8H\*?\%%/^
M":%W\5OV=O#/_!+VY^)_BGQ;\4M=\1^&OC;I_C+2;+3/$%OJ%P989]8FFD%U
M;O"#AXUCD8A,1J<JSX_P2_X)H?M^^%O^"!O[1/[&'Q.^&EO??&+Q[XO\3W^D
M:?::]IXBUHWEU;R1W*3&X\F!9=DCA)71E& P4\5^L]% 'R9^VS^S-\;OB[_P
M1B\7_LG_  \\$_VA\0-4^"<.@6.@?VE;1>;J*V<49A\^618%^=6&\R!.,[L<
MUY5^VE^QE^U[J'[/O['GQ3^ 7P=L_&'Q _9PU_0]3\0?#FZ\46FG2:G FD"S
MO+>"\E8VRS(X7:6;RR-Q#' #?H110!\$?MJ_#;]N#]OS]G?X':MJ7[%FH?#_
M ,5>$/VJ_"/B;Q'X-U+QYHU_+9Z!IURTEQJ/VFWN/(D 5\^2C-,=O"'-?5/Q
M0_8F_8R^-_BZ7X@?&C]D?X8^+]>GB2*?6_%'@'3M0NY$1=J*TT\+.54< $X
MX%>G44 ?"7_!0#]BK]K'P/\ MJ^"_P#@JQ_P3C\,Z%XD\?>'/!\O@[X@_"O7
M-773(/&GAQIO/CBM[MAY=M=12X96DPA"1Y.(O+DO^'_VZ_\ @JY\;?$FB^ O
MAK_P2*U3X=&XU2V3Q3XT^+'Q$TPZ;H]IYJ_:&@@L7DGOY#$'$>T(H<J6RH(/
MV]10!^;O[2'PT_X**_ '_@M?K7[>_P"S3_P3]O?C/X/US]GRR\%$V/Q.T/06
MM[U=5-Y(Q%_.)&"I&@XCP?-X;Y2*H_';]EK_ (*<_P#!9#Q3X.^%W[;G[._A
MG]GKX >&?%=IX@\6^#8O'UOXE\0^,YK5BT%F\MD@M;:U)SO&YG!*L-Y4;?TP
MHH _./\ X+F^ /\ @J7^T;XG\'?LQ?LM?LL:SXS^ NJ6:WOQFNO"/Q+T?P]J
M_B%?-E7^P$GO[A'MK9D2-YI(XW,J3>6&4*X;V[]@7XN_M@G4-*_9\^(W_!(>
M?]G[X<^'/#/D:#JD/Q:T#6;6V\CRTAL4M-/<RKN0N?,(VCRSN.6%?5U% 'YO
M:?\ #C]N+_@E;^VU\<OB7^SW^QAJ_P =/A#\??$D7C&"S\'>);"RU3POXE>,
MI>QSPWDD8F@N7Q()8R?+"A6!/7UG_@D3^QY^T!\#T^,'[6/[86C:=H_Q8_:#
M\?GQ)XB\,:3J*7D/AO3H8S#IVE&X3Y;B2&)I-TB$J2X SM+'[(HH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _/G_@HQ_P %IO!'[#G_  4N^ 7[+NO^
M-38^#==LO$MW\:"/A_JVHW5I$FF1RZ,;-[6W<S%[GS!*MNLS(H!E$2D,<G]O
M7_@ICX5'B_\ 8S_:)^!O[16H^'/A%XY^+6K1>,]6U2TN]#@OM*LK2Y6=;R"_
MBAFCB26WD/[Q%!"AAE64G<_X*)ND/_!=+_@G5<3,$C$GQ:0NQP-S>&;8*N?4
MG@#O63_P6[\!^$OB7^V-^P?X.\=:%;ZGI<_[0[S7%A=Q!XIC#9&9 ZL"&7?&
MI*D$$#!X- 'O'[,O_!8O_@GU^UQ\;8OV=?@[\9+_ /X3"^L9;[0M'\2>#]4T
M9M;M8P6>>R:_MXEN5"*SX0EMBLVW:K$=1^U]_P %*/V.?V&=8T3PC^T'\4IK
M;Q+XE1Y/#W@_P_H5[K&L:A&I(:6.SL8I91&"&'F,JIE6 8D$5\Y_\%E+2ULO
MVT?V#O%EI;1QZG!^TA]AAOT0"9+:XT^43PANH20(FY>AVC/2O"_AS#^W5JG_
M  <!?M>6_P"SUXX^"FD>,H_#G@]="C^,GA?5-1N9?#/]G*2=)-C>VVRW%T0;
MD'<#,T70A@0#]&_V0OVZ/V6OV[?!>H^./V8?BE#X@@T74#8>(-.GL+BQU#2+
ML9_<7=G=1QSV[<-C>@#;6VD@&O'? _\ P7:_X)?_ !5U'P1I/PA_:$O?%MQ\
M0+Z&UT.+P]X'UB=K8RW[Z?&]\#: Z<C7,;J#=>464>8H,9#G#_8M_84_;-^&
M/_!1;QY^W7^U/\6/A)<77CWX:6?A[5O#7PG\-ZCIL-[=V=VCVVI7"WMU<-)*
MD#2V^_=]TQ@ 8)/G_P#P:E_#WP=X/_X(D?"_Q3X<T*WM=0\6:KXBU'Q!=11*
MKWES'K=]9I(Y RQ$%K @SG 0"@#V+XU_\%Q/^"<GP#^(/B+X;>.OBGXFN+SP
M=J$MCXRO= ^&>O:E8:%/$<2)<W=M9O"I0YW!7;;@YQ7M.L_MF?LQ:'^RI<?M
MO3_%_3KKX56OAUM=E\8Z3%-?0'3U&6F5+='E<CD%%0N&!4J""!\7?LU?M#_\
M%*O^"E^B>/OV@/@5^U'\*/@/\*O#OC_7?#NA:1J/PM?Q)JES#83E)KW4I)]0
MM8K9Y&WR&-5^56!8MG<?E']C[Q(NO_\ !J?^T]:V'B:UU?2M-UCQY;:%>V%A
M]DMI+1KE9U>&W#N+>)VF>18@Q""3&3U(!^A>H_\ !>G_ ()7Z5XULO"-]^TL
MZ6=]J,6G)XO;PCJH\/0WT@!6UEU4VWV2*49PX:0"-@RR%&5@/H+]I7]JG]GC
M]CWX17?QW_:6^*^E^$O"EG)'&^JZ@[-YTKY\N&&*-6DN)6P2L42N[!20IP:^
M.O&EC^R8/^#9F\MH(]!_X5H/V4]]EC9Y/VK^QPT3#_I[^W["/^6GVG_;KXY^
M,LO[6-Y:?\$E[/6->\%Z;>R^![E[.\^,&F7EYH8\3C0;(:9]OAMYX)6N]AQ;
M'S%87+$G=A@0#].?V5O^"M7["W[8OQ1?X'_"#XI:E:^-#IIU&T\*^,/"6I:#
M?7]D,DW-K'J$$/VE  2?*W%5!8@#FO5OA[^TS\$?BI\:_B%^SKX"\;?;_&7P
MJDTI/'NC_P!FW,7]EMJ5I]KLAYLD:Q3^9 -_[EWV='VMQ7QG\5/V"_\ @J9^
MTQ^T?\"?C9^TU\<OV==/M_@Q\3;7Q':WOP[\$:Y8ZM=6K PWNFK/>:A<((KF
M%MK)M&YDCYP"#H_L ZI86G_!<?\ X* ^';JZ6*^NS\+KZTMI#M>>V7PRT32H
M#]Y5DPA(R 2 >HH ^E-;_;]_9.\/^*/C#X*U'XG7#:M\ ]/TN^^*^GVGAC4K
MB718-1M6N[-E$5NWVPR0(S[;7SF7&&"MQ7R9_P $4/\ @N?\+?V\/V?OACX'
M_:"\?2_\+[\6OJZ:KHNB?#;6K?2\V]Y?-#LO?LS6*_Z#!$Q_T@_/E.'^03?\
M$Q_%WAGQM_P7$_X*,ZUX2URVU&TBU#X76,EQ:2AT6YM= O;:XBR/XHYX98V'
M9D8=JT?^#75EB_X(;?!?3)& N+&X\3P7D.?FAE'B;5&*,.QPRG'H10![3_P3
MC^(W@W6_A5\4?$MM^VSJ/Q?T_1_C)XFAU/Q%XCT.XTI?"Y@D0RZ(/M1_>068
MX%PI$;!B1P#7&:%_P7U_X)<^*/&4'A;PQ\=M:U*QN=:32+?Q?I_PZUR;0)+Y
MY1"L*ZDEF;<YD(42!_+YSOQS7YX:S)\28_\ @W;_ &_V^%)NQJA_:9\9BZ^Q
M9W_V:==TP:CG'\'V'[5O[;-V>*_93]E:W^!D7[+?@&V_9X72S\/!X,T\>$QI
M@3[*=-^SIY.W;\N-F,^^<\YH ]$KY@^-G_!9'_@G?\ /BAXK^!GCWXY7<OCO
MP9J%E8ZUX)T3P=JVH:H9[JT^V0BW@M[5S=+]GQ(\D.^.+<HD9&90?I^OS4_X
M)PP?"=O^#@[]OJXU-=//CE+7P(-%,VW[4-*.C1_;/*SSY?G"Q\S'&?)SVH ^
MS_V6_P!NO]E7]M#X.7WQW_9O^+5KXA\.Z3<3VVMNMG/;W6E7,*[Y;>ZM9HTG
M@E5>=CH"005R""?)OA[_ ,%QO^"9WQA\8>"? OP:^/M[XNU'Q]=V=OHT?A_P
M5J\RVC75P;:W^WN;4+IWF2#Y1<F-BI63&Q@Q\!_9X328/^"W'[=4/P>6V'A<
M_"/PT_CQ=-_X]QXG-G/L+!?D\\V_G%\?-NW;OFW5W7_!L9\//!W@+_@BC\'+
MOPKH-O:7'B"#5=5UNYBA59+V[?5+M#+*P&781QQ1@GD)$B]%% 'I?[1/_!;/
M_@G!^S!\5M:^"WQ*^-]_=Z_X5C63QE!X3\&:KK</AM#_ !7\UA;2QVQ'.49M
MZX^91QGW7P[^TU^SYXL_9_B_:K\/?&/P]=?#>70GUE?&B:F@T];%%9I)VE)
M14VL&#8*,K*P!! ^'O\ @V8B\)S_ /!.[Q/<>(DMW^(5Q\9?%W_"Z#>!3=MK
MO]H2;Q=YYW?93;\-V)]Z^!-<BO3_ ,$ OVJH_A@DS_!"W_;?U$^'$TT2-$?
M2Z[II;[/Y?6U\WGY..)L\4 ?I_IO_!PS_P $E[OPQ?\ CC5_VD=2T70K2S>[
ML=:U[X>:[9VVLP)(J.^GM)9 WQ!8$I"'D"9?;L5F'N'[1W_!0K]C;]D4>#I?
MVDOCGI_A"'Q_;WT_A2[U2QNO(NX[.U%W<,\J1,EOMA96'G,FXD*NYCMKY"_X
M.8-7_9LE_P""$/C>6ZN_#DFDWD'A_P#X5>UDT1BDN?MUJUL; IQC[()B/+X\
M@2?P9K+_ ."E?@'PA\3/V[/^":GA3QSH5OJ6G?\ "7ZW>M9W40>-IK71+6Z@
M8J00=LT,;8/]V@#Z7\.?\%C/V ?$7P"\0?M.R?%/7-,\%>'-?MM&N]3UKP!K
M-I-<W=PJM;K;6DEH+FY$H8;#'$V<$=C5G]F+_@KK^PC^UK\7U_9]^&'Q0U;3
M_'4]B]]I_A/QKX-U/0+W4;5%+--:IJ%O#]H 4,Q$99@JLQ4*":Q_^"KG[:?Q
M;_9.\+_"GX??L[^&O"UU\0_C-\6-/\$>$=6\<+*=(T.:YCE9[Z=86625E5=J
M1*REVDZG!1OBG_@H/X-_;&^$'[<W[#C?M:?MV>!_B%K^I?M%V*Z!H'AKX0Q^
M'KVRM&B,5]*MV-1N));9A+!$\1C4.9$);* $ _0']HW_ (*I?L&?LG?$_4O@
MG\>?CQ'HOB_3/#MKK;^'$\/ZC=75U:W,[00"U6WMW%W,\B.!!"7E"HSE BEA
MQWAC_@N/_P $R/%OP8U;XWZ;^T68[+0_$$6A:GX>NO#&I1Z]'JDJ2/%9KI1M
M_MDLDB12LNR)E*Q2'($;E?'_  IX&\)^(O\ @Z/\6^,-<T*WN]1\/?LAZ?)H
MMS/$&:SDFUMXI)8\_<<Q%X]PYV2.O1CF'X+_  S\ )_P<^?&;QR/"-B=73]F
MG0KF._-NID2>6]6WDE![.T,$41<<[%VYP2" ?6_[&_[?O[*7[>_@?5_'O[,?
MQ.&LV_AS4VT[Q+I^H:9<Z=?Z/=*,F*YM;N..6$D D,5VMM;!.UL>(ZI_P<$_
M\$L=-U&_:#XX^(-1T'2KV2TU'QQHGPSUZ^\/P3(Q5Q_:-O9/ Z@CF1&:/'.[
M'-><_L]^$?#6I_\ !=S]M?P#>'^S]&\5_!SP7)XC%I*(/.=K.XMVN&;H)!$S
M /VZUYY<6O\ P59_X(#_ +'[FRG^#WQZ_9Q^$]F2;>>*Y\-^,;/1VN"<!E\R
MQN"@EY)!DD/8D\ 'ZMT5C?#GQSHWQ/\ A[H7Q+\.1W":?XBT:UU.P2[B\N58
M9XEE0.N3M;:XR.QR*V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /)/VNOV%/V4/V[O">E>"_P!JOX0V_BFT
MT'4O[0T.==2N["\TZYV[3);W=G+%<0DC 8)( VU<@X&,?PW_ ,$VOV,_"?AK
MX5^$M)^%-X]E\$_$%WK?PS^W^,-6NYM(O[EY7FF::>Z>2ZW&>7"W#2JH8!0
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MO\#_ -HW_AJ[X0? .7PWXU.KW>J&XT?QCK$&GF[NHI(IY?[,6[^PY=97X\C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>biib-20201231_g26.jpg
<TEXT>
begin 644 biib-20201231_g26.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
MV$D,OX(_\%Y_^"9G[//_  1$^+GP1\>_\$TOCSX]T/XFZ]>7++H/]OBZU&-8
M6A$%["8(TD022N\)C<,DQ4A5^20']N_^"Y7_  4YUW_@D_\ L*7G[2'@OX>V
M_B3Q)JWB&W\-^&+6_F*V=K?7$%Q,MS<A2'DBC2VD)C0AG;:NY 2Z_@G_ ,$P
M_P#@K7_P3A^#W[2&K?\ !1;_ (*FZ)\;OC5^T-J.J/<Z5J%MX;TF?1_#P'RQ
MRVRSZG"7F5<"/]U'';* L2 J)* /O;_@ZS_X*"_M4?!']B[X&?LL^&M?O/"G
MBWXR:7)=_$R;1+DVTH2UM[-9M.613E(I;F[;>%(RMN$)*.RM\T?\%?/^"7>G
M?\&ZGA?X#?MP_P#!/SX\>--/\:1>(?[%\7WFI:JLD&J7:VWVD.(D1/\ 1Y?)
MN4DMWWHR,@X(8M]&_P#!US^S/\2OVX_V*_@/_P %*?V:/ VMZII?A729-3UK
M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 9?A_P1X+\)3W-UX5\(:7IDMX^^\D
MT_3XX6G;U<HHW'D\FM2BB@ J*]LK/4K273]1M(KB"9"DT$T8=)%/!5@>"#Z&
MI:* *'ASPKX7\'::-'\(^&[#2K0.7%KIMFD$88]3M0 9/K7SOX%_X);_  &\
M)?\ !2?QE_P5'UW7M:\0_$+Q/H%MHVCVVKM";'PS:Q6T=O(+)%C#*\J1_,[L
MQ'F2@8$C _2]% !1110 52U_PWX=\5Z8^B^*=!LM2LY"#)::A:I-$Q'3*N"#
M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BO$OV"-4U/5_@UJMSJVHSW4B^-]819+B9G8*+D@+EB> .@[5[;0 444
M4 %%%% !7YI?MT?\%7_VF/%GQ4U?X(?\$_OV;;K7;+X8?';P;X4\;_$35_'D
M.B6-YK5SJMEO\/P1"":::.42K;7$Y"K$LCG;(-N_]+:_+'_@IY_P34TS1O'
M_:T_8:_;*\3_  U\0?$7]H;P1;^,]"TV.SUOPY+XC&OV5I#JTEA.,+>6\VR2
M2,2*LK1;'5=S$@'WC\&?&O[4OQY_9WUQOB[\&W^ _P 1+A+_ $W3X(]?LO$\
M>G2F'%MJ<,L:I%=1AG#B*1$),91U&:_/?_@I7X>_X+"?\$Y/V,?&/[6OB;_@
MO;J.NR^'H((=%\-I^S)X5@DUC4;B=(+:T1PKE=TD@+,$8JBNVT[:^GO^"1G[
M9/[2?[1DGQH^ /[6%[X7U[QE\"OB4_A2]\>>"K1K?3?$<9@65)?)9F$-RF2L
MT:G:K%0 ,'/DW_!0K_C/3_@L7^SQ_P $Y['_ $OP?\(HW^,_Q;A W1/-;,;?
M1;23L2;AV9XFSNBN V,+0!L_\%"/C]^WY^Q?_P $)['XPZQ\?S9?'VQT_P )
M0>)_&[>&-,D%OJ-_JUC!?*+1K?[(51;B6$?NAP@;AOFKK/V3?V??^"AC?&'2
MO''B_P#X+T:?\9?"6A7Y/B?P3I/P1\+V:WZ%' @DO+%VEMCN(;*\G9CH37T]
M^TG^SM\ _P!J[X57/P$_:5\"V'B?PIK=[:R76@:E<21Q7LUM,MW$I\MU9]KP
M"0IG#",[@5R*_,'_ (*Q_L:_LE_\$R/BM^S;^U)_P3R\ :9\+/B]JOQWT/PK
M;>&?!,K6L7C+1KMRE[93V2-LE3 B#2A1@S ,2SQE0#[Z_;._9L_;4_:"\0:%
M#^S3_P %"+[X(^'[*RF7Q!:Z)\.].UB^U:=G4QLMQ>DBU1%##"(2Y;DC'/SM
M^Q1\??VYOV?_ /@JQKO_  2Q_:I_:7LOCKHES\&U^('AKQ\WA2VTG5]% U 6
M1T^^CL\0NK'<ZR$;SF/G#E5^R_VDO@)\//VK/A-J_P  /B'XAUZQT[4Q:S7T
MGA/Q+<:5J,2QW"RQ,EQ;.LL2L\)!P0'"NIR,BOSH_8X^#7A/_@E[_P %T9/V
M'?V;O&EUXM\(_&3X47/B_P :P>*?)U'7_#=_9RF.WEEU0(+J6UE4;$AN7<*\
MA92-WS 'ZK5^77[-GCW_ (*A?\%@_#/C[]LW]F_]O[_A1OP^M?&.J:+\#O">
ME> --U2'6+>PD,(U/59[N-Y'6XF4J8HR%C"-C)Y;]*;7QGX$\:ZEKO@'PYX[
MTN\U;1XTAUW3]/U**6ZTMIT8Q>?&K%H2RAF7>!N"DC.*^ /^#8/Q#HW@K_@D
MK8_!#Q7J5MI_B#X.^._%7AWQ]9W4PC;2[V+5;FZ<3;B/+ BG0Y; P#Z&@#WS
M_@D)^W-XP_X* ?L6Z9\7?BOX8M-$\?Z!KVH^%?B-I%@"+>VUO3YO*G,8))5'
M4QRA23L\W;EMNX_3]?G9_P &TUC<ZS^Q]\6OCM:).= ^*_[3OC3Q=X1GG4@3
MZ9--;VR2)G^$R6DOX@U^B= !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU
M[I0 4444 %%%% !7PU^W=_P0S_8Y_:>\1P?%+P9\#+/3/&.M_$[0-:\>ZGIO
MC'5]'CUC3XM4MYM3:6*RN$BENI+99@DI02"1@RR(V''W+10!P7[-W[+_ .S]
M^R!\++7X*_LT?"C2?!WABSF>:/2](A($DSXWS2NQ+S2M@;I)&9SM&2<"JGPV
M_9'_ &>OA'\>_'_[4'@'X??9/'OQ0%@OCCQ'/JMW=2Z@EE$8;6-4GE>.V1(S
MMV0+&K84L"5!'I%% 'E/[87[%/[./[>7PKMO@W^T[X(N=<T.QUJ'6-.6QUR\
MTZ>SU"%)(XKF*>SEBD5U6:0 ;MIWG(->2_LP?\$4?^">W[*'QDM/VB/ WPNU
MC7_'>FP-#H_BOQ]XOU#7;O3(V# BV^V3.D#89AO10X#, V&(/UA10!\X_MD_
M\$I?V,_VZ_'^F?%WXY^$O$4/B_1]&&D:?XI\)^-]3T:\CL!+)-]F)M)T21/,
MED;YU8@L<$5I?L6_\$Q_V*O^"?\ /K.M?LS_  ?73=>\2 #Q'XMUC5;K5-7U
M, A@DMY=R22[,@'RU*H2H.W(S7OE% 'F_P */V1_V>O@A\;?B1^T9\+_ (??
MV9XR^+EQIL_Q"UG^UKN?^U9+"&2&T/E32M%!Y<<TBXA2,-NRVX@$>)?M'_\
M!$+_ ()T?M2_%[6_C=\2?A-K-EK?BR../QPGA/QKJ>C6OBA$&%74+>RGCCN#
MC(+$!VS\S&OK6B@##^&GPT\ ?!OX?Z/\*OA5X/L/#_AOP_I\5CHNBZ7;B*WL
M[>-0J1H@X  'U/4Y)K<HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I
M2:]TH \>^,W_ "/,O_7O'_*N4KJ_C-_R/,O_ %[Q_P JY2OR?-O^1G6_Q/\
M, HHHKSP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ(M/^/2+_ *YK
M_*OG>OHBT_X](O\ KFO\J^RX0^*M_P!N_J!)1117VP!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*^>OV"_#=AJWP<U:ZN9KA6'CC
M65Q%.5&/M+=A7MO_  @^D?\ /S>_^!;4 >;?&;_D>9?^O>/^5<I71_%33H-+
M\7R6EN\C*(8SF5RQY'J:YROR?-O^1G6_Q/\ , HHHKSP"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KZ(M/^/2+_ *YK_*OG>O<+;P3I+6T;&YO.4!XN
MV]*^RX0^*M_V[^H&Y16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U?; ;%%8_
M_"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I
M'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"
M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_
M #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\
M_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_
M (%M0!L45EV?A+3;&Z2[AN+HM&V5#W+$?B*U* "BBB@ HHHH **** "BBB@
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M OA)YXH)XH;B:QDEA82Q##M"9=BL,[@ >*_2N@ HHHH **** "BBB@ HHHH
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M -./_)O_ +4#Z,HKYSHH_P!;_P#IQ_Y-_P#:@?1E%?.=%'^M_P#TX_\ )O\
M[4#Z,HKYSHH_UO\ ^G'_ )-_]J!]&45\YT4?ZW_]./\ R;_[4#Z,HKYSK4\%
M?\CAI?\ V$(?_0Q6E+BSVM6,/8[M+XN__;H'O%%%%?8 %%%% !1110 4444
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MSE?D^;?\C.M_B?Y@%%%%>> 4444 %%%% !1110 4444 %%%% !1110 4444
M%?1%I_QZ1?\ 7-?Y5\[U[A;67C4VT976K,#8, VQ]/K7V7"'Q5O^W?U W**Q
M_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !K[8#8KP?QK_P CAJG_ &$)O_0S
M7L'V+QO_ -!NR_\  8_XUXWXL6X3Q1J*W4BO*+V42,HP"VXY(%?)<6_[M3]7
M^0&?1117P@!1110 4444 %%%% !1110 4444 %%%% !1110 5J>"O^1PTO\
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MC_R;_P"U ^C**^<Z*/\ 6_\ Z<?^3?\ VH'T917SG11_K?\ ]./_ ";_ .U
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M5Z^,_P#P;Q^/_P!J>\\%_MS>.?&'A7XT> [:#3[CQ;\/] \16FIVUO+ ES'
M;S3[9X;E/+G5@&\S9O905)859_X(\?&C_@WO\#?M0P?#G]@GQKXM\3_&7X@6
MES:#Q7X^\/\ B*YU2]MK:VDNY8/MNH6R0V\?E6S.54Q^88T!W$(!ZU_P\/\
M^"Z__2NK_P";<^&/_D>O0/V7/VR_^"L/Q7^.VA> /VE_^"+_ /PJ;P3?_:O[
M;^('_#1>A:]_96RUEDA_T&UA6:?S9DB@^4C9YV\_*A% 'U_1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0!X]\9O^1YE_P"O>/\
ME7*5U?QF_P"1YE_Z]X_Y5RE?D^;?\C.M_B?Y@%%%%>> 4444 %%%% !1110
M4444 %%%% !1110 4444 %?1%I_QZ1?]<U_E7SO7T1:?\>D7_7-?Y5]EPA\5
M;_MW]0)****^V *\'\:_\CAJG_80F_\ 0S7O%>#^-?\ D<-4_P"PA-_Z&:^2
MXM_W:GZO\@,NBBBOA "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4\%
M?\CAI?\ V$(?_0Q676IX*_Y'#2_^PA#_ .ABM\+_ +U3_P 2_,#WBBBBOV$
MJ.[_ ./27_KFW\JDJ.[_ ./27_KFW\JF7PL#YWHHHK\9 **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#J_@S_P CS%_U[R?RKV&O'O@S_P CS%_U
M[R?RKV&OT3A;_D6/_$_R0!1117T@!1110 4444 %>3_MD_"[]JKXN_"./PI^
MQY^U/:?"#Q:NL0SR>++WP/;>($>S5)!);?9;EE0%V:-O,SE?+P/O&O6*\O\
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M\@,NBBBOA "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4\%?\CAI?\
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M_D>9?^O>/^5<I71_%2[GOO%\EQ<6,ELQAC'E2D9''7BN<K\GS;_D9UO\3_,
MHHHKSP"BBB@#X=_X*8_LL_MKZ_X#\6^*_@K^VAJS^&];\3>'[@?#74_AM;:S
M]AE75-/7S+.YCDBN(XHWC%R\;^8N$D&4#%A[3^QA^Q O[+/B#QW\7/'_ ,9-
M5^(_Q,^)^H6=UXZ\;ZKIT-B+I;.$P6EM;VD'[NV@BC9@J LWS'+$!0/>:*ZI
M8RM+#^QT2\DE?;=I7Z7\^NP'@=E^P]]K_P""B][_ ,% ?''Q/_MB2T^'L?A3
MP1X2_L7RH_#\32^==7/G^<WGRRN77(CCVQN4)? ->M_%CP]\0?%?PVUKPW\*
M?B+%X1\1WM@\6C>)IM%344TV<CY9C:R.BSA?[A8 ^M=#164JU2<HN3O9)+1;
M+R_J_4#X \#_ /!*/_@H?X!_:0\6?M5:'_P5KTL>,/'.GZ?8>*+UOV>;$I=6
MUFNR!%C.HE(B%X+*H)ZG-?47[6GPR_:\^(>D:+<_L@_M.:1\.M4TVYF;5(=?
M\%1:S::O$ZJ%C?=(CP%&!8.A.=Q!&*]=HK6IC*]6<9SLVO[L>UM5;73:^W0#
MY>_90_X)]>//AW\?]0_;+_;!_:'D^+'Q9NM#_L31M2BT"/2]+\-:87WO;6-H
MC/M9V^_.QWL,C W/N]0\%?!#XN^&_P!JKQI\==>_:1U/6/!WB/1+&ST'X9S:
M:4M= N(%4374<WG-YC3%22OE)C=U:O4:*B>)K5)-R>ZMLMNR5M/E;\6!\2?M
MY_\ !,?]LC]M_P 4I;S_ /!2"P\-^"M)\:6'B;PGX1_X4K:WDFE7EF,PEKS[
M=$]R [.Q#J =V"#@5]+?LQ_#O]H?X9?#VX\/?M,_M(6OQ2\02:K)/!XCM/!$
M&@+%:F.,);?9H)I58JZR-YF[)\S&!M!/HM%54Q5:I15*5N5;>[%?BE?UUUZ@
M%%%%<P!7T1:?\>D7_7-?Y5\[U[A;>)-66VC4>$;PX0<AEYXK[+A#XJW_ &[^
MH&Y16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+7VP&Q7@_C7_D<-4_["$W_
M *&:]@_X275_^A0O?^^EKQOQ9*\_BC49I(&B9[V4M&W526/!KY+BW_=J?J_R
M SZ***^$ **** "BBB@ HHHH **** "BBB@ HHHH **** "M3P5_R.&E_P#8
M0A_]#%9=:'A.5X/%&G31P-*R7L16->K$,.!6^%_WJG_B7Y@>^45C_P#"2ZO_
M -"A>_\ ?2T?\)+J_P#T*%[_ -]+7["!L5'=_P#'I+_US;^59?\ PDNK_P#0
MH7O_ 'TM1W/B35FMI%/A&\&4/)9>.*F7PL#P^BBBOQD HHHH **** "BBB@
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M1PU3_L(3?^AFO>*\'\:_\CAJG_80F_\ 0S7R7%O^[4_5_D!ET445\( 4444
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M*N=D\,B%9()ER=LL;*ZY.&&37>T4 ?G[J7_!%W]J;X9,=+_8M_X+4_'KX?Z
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MOS ]XHHHK]A *CN_^/27_KFW\JDJ.[_X])?^N;?RJ9?"P/G>BBBOQD HHHH
M**** .-\ _!;0?A]\3_'?Q3TS5;R>\\?ZC8WFI6\^SRK=[6QALT$6 #@I"K'
M<3\Q.,#BNRHHIRE*3N_ZMH 5F:[X*\&^*;B"[\3>$M,U&6V.;:6_L(YFB.<Y
M4NI*\^E:=%";6P   , 8 Z 5G1>$/"<&OOXK@\,:<FJ2)LDU)+*,7#+TP9,;
MB/;-:-%*[0!1110 4444 %%%% '5_!G_ )'F+_KWD_E7L->/?!G_ )'F+_KW
MD_E7L-?HG"W_ "+'_B?Y( HHHKZ0 HHHH **** "BBB@ HHHH **** /"_\
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M6FV-TEW#<71:-LJ'N6(_$5J445]( 4444 %%%% !1110 4444 %%%% 'A?\
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M0"H[O_CTE_ZYM_*I*CN_^/27_KFW\JF7PL#YWHHHK\9 **** "BBB@ HHHH
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M??V2[72)_CE'<:;+K\D\>AV5E;W=]<7KPA#($CMK:0_*)$R6P/F'-9_[./\
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MRO/L^QE%2E5E)N:A[L8>ZFOB?N/Y;+1ZGZZ_\-.?]21_Y4O_ +71_P -.?\
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MAEMW(/OM-6*K:S_R![O_ *]I/_033BDY(F6D6?GW_P +N^*'_0S_ /DE!_\
M$4?\+N^*'_0S_P#DE!_\17*45^H_ZM<.?] =+_P7#_(_GS^VLY_Z":G_ ('+
M_,ZO_A=WQ0_Z&?\ \DH/_B*/^%W?%#_H9_\ R2@_^(KE**/]6N'/^@.E_P""
MX?Y!_;6<_P#034_\#E_F=7_PN[XH?]#/_P"24'_Q%'_"[OBA_P!#/_Y)0?\
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M $<#\+/_  4WG_QNOT4HIK,LQBK*M.W^)_YDRR;*)2<I8>FV_P"Y'_(_.O\
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MI.KW4D/B[PS?2FVNK6^261Q<2[C&R2L"RL2W+*A3]<* "BBB@ HHHH ****
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M=SSM!"RJY/DS1S$, 1'')D#FOT4HH _)+_@IK^W/^S#_ ,%D?"/P=_X)Z_\
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MOV)?AO\ LG>'S#(W@_PU#;ZK=P#Y;S4I,S7MR.^)+J2:09Z!@.U>T4 %%%%
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MAOA]\!K+P[H_P_\ AU\.K&SNM&TJ\OK$W=WJFI6]SJ5FLUS*Q,<#$2KY2."
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MKU'[:4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?-O[8GP"^+7Q4^)MCXA\!^$_M]G#H45O)-]O@BQ*)IV*XDD4]
M'4YQCGZUY/\ \,;_ +2'_1.?_*O9_P#QZONJBOH<+Q+CL)AXT81C:*MJG?\
M,^1QW!>5YABYXBI.:E)W=G&WXQ?YGPK_ ,,;_M(?]$Y_\J]G_P#'J^S?A=HV
MI>'/AEX=\/:S;>3>6&A6EO=P[U;9*D**RY4D'!!&02*W:*Y<RSG%9I",:JBK
M:Z7_ %;.[)N&\#D=6<Z$I-R5GS-/\D@HHHKR#Z **** /GCX&_L$_P#"F/\
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M!D-KJOB6UAE5Y+6>6:\DALQ,BE'>",LH8[-IP1]CT44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>biib-20201231_g27.jpg
<TEXT>
begin 644 biib-20201231_g27.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M([Q6B@C"%9&FVEB0R\  -J_L&?M2?M1_"K_@H9X__P""3G[:?QKM/B=K.D>
M;3Q[\-/B4- M]*O=5T62X%K<6E];VV(?/AG*A'C ,B*[MSP #[MHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **\2_8(U34]7^#6JW.K:C/=2
M+XWUA%DN)F=@HN2 N6)X Z#M7MM !1110 5RGQU\$_"?XF?!?Q5\-OCM;V$W
M@SQ%X?N]+\4PZG=_9X)+&XB:&97EW+Y8*.1N# @D$$$ UU=8OQ'^'/@3XO>
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M_P#%T?\ "COA=_T*_P#Y.S__ !='L\M_Y^3_ / %_P#+ ]KG/_/FG_X,E_\
M*CZTHKY+_P"%'?"[_H5__)V?_P"+H_X4=\+O^A7_ /)V?_XNCV>6_P#/R?\
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M4 >V*PK1PT;>RDWWO%+\I2_0Z<-/&RO[>$8]N63E]]X1M^)+1116!U!1110
M4444 %%<-^T9^TM\!OV2/A1J'QQ_:1^*.E^$/"NF,B7>KZK*0ID<X2*-%!>:
M1CPL<:L[=@:^;/V)?^"VO[(?[7WQ1F^!\/B_4-)\6ZMXQUC3O NEZEX$UO3D
MURPM/-DCE6:\M$B$YMXGD>$NKKM(* C% 'V917S=^V/^T3_P42^&?Q&T[P%^
MQ;_P3TTWXI:;<:(E[J?C/Q!\5K/0+*PN&FE3[$('ADGGDV1K(74! )5&2>*Y
MO]@3_@ICXW_::^//CO\ 8R_:D_99U#X-_&?X>:7:ZOJ?A=_$<&LZ?J>DW#!(
MK^RO8402)N*AD*@H9%&YF#A #ZUHHKX)N?\ @K+^UU^TG\2O%N@?\$N/^">L
M7Q;\$^!/$$^A:Y\3O%?Q(MO#FEZGJ<!Q/:Z8KPRO=HA.TW'$>1P""K, ?>U%
M?-7[2_[>'Q,_9._X)G>(?V\_C)^RY+I7BGPKX934M=^%<WC&&0VUP;E(&M?[
M2@ADC<#?N$J1,&&.!GCS[X&?MT?\%>/B;X\\)V/Q#_X(GV7A+P?KVI6:ZQXP
M7]IG1M0;2=/F=/,O!:1V:R7!CC8OY*E6;;M!!- 'VM17S9_P43_X*(6O[#UK
MX#^'_@'X-:C\3?BO\6?$+Z+\,?AQI>I1V3:I/$@DN+B>ZD5EM;6!&1I)2K;=
MZY&W<R\7^RY_P4S^-.N_M>6_[!'[?/[)L7P?^).O^&9M?\ 7.C>,8]=T;Q59
MP$_:HX+A88FBN80"S0LI.Q&?(!0, ?8]%%?%_P 9?VQ/^"Q6@_$3Q-9? S_@
MC_HOB+PCH&L7=MH^L:U\?-.L+[Q-:PR,J75O:BW?[*)0NY$F?=AAG% 'VA17
MA7_!.C]O3X>?\%&_V9K+]HCP%X1U?PW/'JUYHOB?PIKR 7FAZM:2;+FTE*\,
M5)5E88RCJ2J-N1?=: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MPO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH \A^,?_([
MR_\ 7O'_ "KE:ZKXQ_\ ([R_]>\?\JY6@ HHHH **** "JMGK>C:CJ%YI.GZ
MO:SW6GNB7]M#<*TELSH'59%!RA*D, <9!!'!KP/_ (*J?M8?$']B7]A/QO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^>OV"_#=AJWP<U:ZN9KA6'CC65Q%.5&/M
M+=A7MO\ P@^D?\_-[_X%M7D?_!/?_DB>K?\ 8]ZS_P"E)KW2@#QGXHZ=!I?B
MV2TMWD91"AS*Y8\CU-<[75?&/_D=Y?\ KWC_ )5RM !1110 4444 >>_M2?%
M[X2?!#X*:MXY^/'AN^U7P?\ N[+Q#;6?AF75U%K<.(7>:UACD>6 !_WF$;"9
M)!&:_%?XFG]A:]^,?Q-\3_\ !'_6M6L?CA-X[\,?\*0TSX1+J,%G<6S6UD=2
M2^ME46T5BKF[,GGJ@5AM/R;EK]ZJXWP#\%=!^'WQ0\>?%33-5O)[SQ_J-C>:
ME;S[/*MWM;&&S018 ."D*L=Q/S$XP.* /DW_ (+)_P#!5JW_ & _"OA;X*^"
M=?TG2?B5\2B8=+\2Z_;2OI/A:R#".?5KA41VG,98^7 JL68996"A),W_ ()*
M_M$?\$J/!;Q_LU?LL_M9P_$CXI>-+BXUKQGXHU/3K\:KXLU)(VEN+N:6>$*J
MJH<I%OPBY W,S,_WM10!^;_PW^.?PK_X);?\%0OVAM!_:X\21^#/!7QQNM+\
M8_#KQMJL+KIUY<16[Q:A8O.JE8YUE?<J,02B@G'F(&ZO_@EE++^U!^W!^TA_
MP4M\.:->0> /'5SHOACX8ZC?6+V[:S8Z9:^5=7\:R!6,$DP0QL0,X92 R$#[
MHU[PWX=\56!TKQ/H-EJ5J7#FVO[5)H]PZ':X(R/6K<445O$L$$2HB*%1$7 4
M#H .PH \*^$W_!1K]FGXQ?LI>(/VS_#VI:U:^!?#%W?P:U=WVBR&X@^QOLN'
M$$/F.ZKU&T%B <#M7Q?_ ,%-OV^_^"/O[5/[('C3X=_"W5O#7Q0^)WB[1Y[?
MX<Z/X0\)3W.NMK\J8L[B)EMQ+"\<NR1B64LB,GS%MA_4>LO2O _@K0M5FU[1
M/"&EV=]<Y^T7MKI\<<LN>3N=5!;\30!QW[(&@_%GPK^RA\,_#/QYOYKKQOI_
M@'2+;Q=<7$_FR2:DEG$MR7?^-_-#Y;^(Y/>O1:** "BBB@ KVRV\$Z2UM&QN
M;SE >+MO2O$Z^A+3_CTB_P"N:_RH R_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\
M"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJV*^6_B1\2_VP].^(.M
MV'A76MFF0ZK<)IZ?9M/.(1(P09==WW<=>?6NS!X3ZY)Q]I&%OYG;[CS\QS#^
MSX1E[*=2[M:$>9KUU6A]&?\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M7RS_P +
M7_;A_P"@_P#^2NF?_$T?\+7_ &X?^@__ .2NF?\ Q-=_]B?]1-+_ ,#_ . >
M3_K+_P!06(_\%_\ !/J;_A"-)'2ZO?\ P+:I;GPK97FW[3J%\^P87-VW%?*G
M_"U_VX?^@_\ ^2NF?_$T?\+7_;A_Z#__ )*Z9_\ $T?V)_U$TO\ P/\ X ?Z
MR_\ 4%B/_!?_  3ZF_X0?2/^?F]_\"VH_P"$(TC_ )^KW_P+:OEG_A:_[</_
M $'_ /R5TS_XFC_A:_[</_0?_P#)73/_ (FC^Q/^HFE_X'_P _UE_P"H+$?^
M"_\ @GU.W@K2W.Y[R^)]3>-2?\(/I'_/S>_^!;5\L_\ "U_VX?\ H/\ _DKI
MG_Q-'_"U_P!N'_H/_P#DKIG_ ,31_8G_ %$TO_ _^ '^LO\ U!8C_P %_P#!
M/J;_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:OEG_ (6O^W#_ -!__P E=,_^
M)H_X6O\ MP_]!_\ \E=,_P#B:/[$_P"HFE_X'_P _P!9?^H+$?\ @O\ X)]3
M?\(/I'_/S>_^!;4?\(/I'_/S>_\ @6U?+/\ PM?]N'_H/_\ DKIG_P 31_PM
M?]N'_H/_ /DKIG_Q-']B?]1-+_P/_@!_K+_U!8C_ ,%_\$^IO^$'TC_GYO?_
M  +:C_A!](_Y^;W_ ,"VKY9_X6O^W#_T'_\ R5TS_P")H_X6O^W#_P!!_P#\
ME=,_^)H_L3_J)I?^!_\  #_67_J"Q'_@O_@GU-_P@^D?\_-[_P"!;4?\(/I'
M_/S>_P#@6U?+/_"U_P!N'_H/_P#DKIG_ ,31_P +7_;A_P"@_P#^2NF?_$T?
MV)_U$TO_  /_ ( ?ZR_]06(_\%_\$^IO^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:OEG_A:_P"W#_T'_P#R5TS_ .)K:^&_Q+_;#U'X@Z)8>*M:WZ9-JMNFH)]F
MT\9A,BAQE%W?=STY]*F63<L7+ZQ2=O[_ /P"Z?$?M)J/U.NKNUW3T7KKL?1G
M_"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%%>,?1F/\ \(/I'_/S>_\ @6U'
M_"#Z1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_
M /"#Z1_S\WO_ (%M6'\3+GP-\)?AQK_Q3\7WVHII7AK1;K5-3:"X9G%O;Q-+
M)M4D;FVH<#(R<"NTK\?_ /@OOX4NHOVLIOB'^VE\$OB!X[_9TM_V=]6M? 8\
M*:?>7^B^'?'YFF9;_5[6U;(_<>4L<\JM$IQA<J[( ?JKX-L_"'COPEI?C;P]
MJ%])8:OI\-Y9NUT03'(@=<@$X.",CL:^1OC1_P %P?\ @E+\!OB9XD^$_CGX
M[>*Y=4\&:M<:9XQFT7P#K]_::+=0.4FCGN(+-HLHP(8HS@8-0?\ !$&W_P""
M1VH_##4_''_!,77/#8U/5-#TB'XE:-H&IWL307D,4FV673;I@;1F>2<>:D2"
M7;C+^6-OJ/[>G[:?Q]_9"MQ9_ O_ ()L?$3XW07.B3ZA<3^"+FSBMH)_,8&W
MF5RT[._WSY4,I(;H3Q0!ZK\#/'_P'_:8^%6C_'#X!_$Z#Q7X3U^V,^D:YH^I
MM)#.H8JP]5=65D9& 9&5E8 @@5OVBOBE\ OV3?@QKG[0O[0?Q N/#G@[PW#%
M+K6LR_:9Q;K),D$?[N!'D<M++&@5%8DL.*^4_P#@VW\(?#WPW_P39CU_P#\4
M-#\12>*_B'KNO>(-,\.65Q:V?A;4KF=3+HB07,<<T7V95C4J\:9+EE!1D9OO
M>>WM[I!%<P)(H=7"R*" RL&4\]P0"#V(!H ^)_@A_P %K?\ @E5\>_B[HWP-
M\+_M":YH_B/Q-<BW\+VWC3PKK&AQ:S*6"K';SWUM%$[LS*JH6#NSJJ@DXKT3
M]M7_ (*&?L"?\$\-4\/Z-^U_\;]5\*7/BFWN)M"C@\-ZSJGVE(&C64DZ?:SB
M/!E3ARI.>,X./@;_ (+"?M5_$3]K^3X9?LC?M0?L8^*OV=OA]J'QFTFYN?C[
M\2@EU8Z?):W#F*&S;3TG6VN;H95);F6"-4+[R%RR_LA0!\8_LR_\%F?^"3_[
M8GQVT3]F?]G7]J#5M?\ &_B*.Y?1]$E\$^(;'SUM[>6YF8S7=C%"@6*&1LNZ
MY("C+,H,7[1'_!:7_@DS^RE\9M=_9]^/7[3^LZ)XN\-7$<.M:5%X$\1WJV[O
M$DR@36MA)#)E)$.4=@,X/(('F7_!.'_C/#_@KK^T9_P4IU#-WX2^&C)\&/@_
M.WS1,MFXGUF[B/0A[EEV2K]Z.=USQS]R_M0_M!>"?V4?V<_''[2OQ&FVZ+X&
M\+WNLWZ!PK3+!"SB%,]7D8+&H[LZCO0!Y/\ L0_\% ?V"O\ @HX/%)_8U^.&
MI>+_ /A"Y+-/$WF>']7TS[&UT)S O_$PMH/,+?9YLA-VW:-VW<N?>G\%:-&A
MDDO+Q5499C>, !7QI_P;[?L_>-OAG^P3#^T7\:X2WQ)_:&\2WOQ-\=7,B$.9
M-3?S+6(;N51;7R6$9^XTL@QUKNO^"X7Q/\4_![_@DA\?_'?@J^FM=3B^'-Y9
MV]U;L5D@%WMM'D1ARK*D[$,.00".E '%V_\ P6\_X)&W7Q43X5P_M67'[S7O
M[$B\6-HFJ#PX^I;MOV8:N;?[$3_M^;Y?^W7V*/!&D$9%U>?^!;5\2>-?V4?@
MQ%_P;AWW[.(\)6!\/V7[+37<$<=NI4:A%HOVY;\#&#-]L47._O(2W>O7_P#@
MCA\4/%7QF_X)7? +XC>.+RXNM6OOA?I4=_>71)EN9(8%@,SD_>9_+WENY;/>
M@#WW_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/
M^$'TC_GYO?\ P+:MBB@#+L_"6FV-TEW#<71:-LJ'N6(_$5J444 %%%% !111
M0 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5
MO^Q[UG_TI->Z4 >0_&/_ )'>7_KWC_E7*UU7QC_Y'>7_ *]X_P"5<K0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7T):?\>D7_7-?Y5\]U]"6
MG_'I%_US7^5 $E%%% !7A7C3_D;]4_Z_Y?\ T,U[K7A7C3_D;]4_Z_Y?_0S0
M!F4444 %%%% !117S_\ ME_MPZK^S9X]\ ? /X1_!"\^)'Q/^)\]^/"?A6'6
MX=,MEMK*)9;N[N[R57%O%&CKC".SG(5210!] 45\>_\ !*?]I+]MOXR?"/P?
M9?M*?LW+;:)?>#FO['XK6_Q"@U(ZK.LRJ(;BS,,4\$K*[L&^=,0D%@2,Z_QF
M_91_X*3?&3XL>(?$?AS_ (*8_P#"L?" N\>#_"_@_P"&NGWLT4010);RZO<O
M*Y?<3&@" 8^;/0 ^JZ*^0O\ @EC^UU\>OB_IGQA^"'[7'B'1-9\7_ OQ]/X=
MU;QUHUFEG::[;",R1W3PK\D$P"OYB)A5^48!!SXO\'?C5^VA_P %,=/E_:9\
M,_\ !0G3OV=/AEKNO7MC\'_">F^&=,N]5\06=K</;'4KN34#NW22QN!;Q#:
M.>0&< _26BN7^"_AGXF^#?A9HGA;XR?$V/QGXGL;(1:SXJBT6/3AJDH)_?\
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MK,DB%H\D'=C-?;.E:7IVAZ9;:+H]E';6EG D%K;0H%2*-%"JB@=    /:IZ
M/@K_ ()X? /XT?\ !+C]@+X]?M-?M;W?AV#Q[XR\7>+_ (R>-M$T6X:32M#G
MGMA<&PCD'^L5%M@69<C+E59PBNWI7PH_:]_;I^(7_!,OP%^V!H?[%-CXF^*?
MBC2++5]0^$UAXLBT<?8;F4LK0W5[N5)1:M%-Y<O)8E#M/3Z>\1>'/#WB_0KO
MPOXMT&RU33+^!H+[3M1M4G@N8F&&22-P5=2."""#5N&&&VA2WMXECCC4*B(N
M H'   Z"@#\KOV[4_P""GW_!9OX%2?L!0_\ !-+5O@;X*\6:]IC_ !#^)?Q)
M\;:9<MIUA:7L-X4L+.T9Y+B=W@3:_"8!1MHDWI]]_MHWG[1'AC]CKQ\G['W@
M>;Q+\3%\(W%GX#TM=4M;1FU&2/R89S-=2Q1*(2XF;<Z[A$0,L0#ZQ10!\]?\
M$J?V,+?]@#_@G_\ #/\ 9<G@B&L:%X?2?Q9/&X?[1K-RQN;Y]X)\P?:)9%5L
MGY$0= *\S_X+4_LL?M*_MV_"WX:_L8_"'P9+/\/_ !I\4-,G^.GB1-9M;8:9
MX8LIDN9(1'),DTTD\JQ;/)63:8#OVA@:^T:* (=-TW3]&TZWTC2;&*UM+6%(
M;:VMXPD<4:@*J*HX50   . !7R_H_P +_P!IO_@H5_P3N^(OP _X*$_!72OA
M=XG\=V&N>'O[,T+5H=2CM;*16CLM0#PSRH9.5FV%^"@! Z5]344 ?DQ?/_P6
MQU[_ ()WG_@D+<?\$_OL_C&7P4OP[O/CXWCW3SX6.@>1]A;5P@?[69VLLCR!
M'Y@D;S, CRJ_2O\ 9;^ /A?]E7]FWP'^S3X+N9)]+\!^$=/T*SNID"O<K:VZ
M0^<X' =RI=O=C7>44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0!Y#\8
M_P#D=Y?^O>/^5<K75?&/_D=Y?^O>/^5<K0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7T):?\>D7_ %S7^5?/=?0EI_QZ1?\ 7-?Y4 24444
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MF'U#%?\ 074^ZE_\K-C_ (:J^*/_ $;I_P"7=!_\:H_X:J^*/_1NG_EW0?\
MQJL>BCZW0_Z!X??4_P#DP^H8K_H+J?=2_P#E9L?\-5?%'_HW3_R[H/\ XU1_
MPU5\4?\ HW3_ ,NZ#_XU6/11];H?] \/OJ?_ "8?4,5_T%U/NI?_ "LV/^&J
MOBC_ -&Z?^7=!_\ &J/^&JOBC_T;I_Y=T'_QJL>BCZW0_P"@>'WU/_DP^H8K
M_H+J?=2_^5G=?"[X[>.?'WBV/P[KWP>_L:W>%W:^_P"$@BN-I49"[%0$Y]<\
M5Z=7D/P<_P"1WB_Z]Y/Y5Z]7-5J0J2O&"CY*_P"K;_$[,/2J48<LZCF^\N6_
MI[L8K\ HHHK(W"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
M2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@#R'XQ_\CO+_ ->\?\JY6NJ^,?\
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M %%%% !1110 4444 %>V6UEXU-M&5UJS V# -L?3ZUXG7T):?\>D7_7-?Y4
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M/^-><_!S_D=XO^O>3^5>O4 9=G:>+4ND>^U:U>(-^\1+<@D>QK4HHH ****
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MQ[UG_P!*37NE 'D/QC_Y'>7_ *]X_P"5<K75?&/_ )'>7_KWC_E7*T %%%%
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M"VK3:9KVGP^ ->N1:W43%9(_,@L7C?!'568'L37FG_!+K3'_ &COV\_V@/\
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M^Q)'_P $^M4^#GA#Q-K6G/X[^(/C[Q?IUPUA96MY%=%+*UM6>2>9FA7:WW,
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M 'B#X;>"[;]DCPAX]U[68?BCHLWB.WUCXNWTJ6^AJ\GVR=!J%Z$$B#9M:/\
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M4 >0_&/_ )'>7_KWC_E7*UU7QC_Y'>7_ *]X_P"5<K0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7T):?\>D7_7-?Y5\]U]"6G_'I%_US7^5
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MV>?A!XZMM9^)GQ&C'^C^+-;LF+0Z)IK])H49MT\Z_+]W:1B,R_H;7P[\"?\
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M=6UO$L4:\=2%09/<UOT44 =5\'/^1WB_Z]Y/Y5Z]7D/P<_Y'>+_KWD_E7KU
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M2T_X](O^N:_RH DHHHH *\*\:?\ (WZI_P!?\O\ Z&:]UKPKQI_R-^J?]?\
M+_Z&: ,RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T_!?_ "-^
ME_\ 7_%_Z&*S*T_!?_(WZ7_U_P 7_H8H ]UHHHH *CN_^/27_KFW\JDJ.[_X
M])?^N;?RH ^>Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVH6L98K'>2*I9LG 8]3WH SZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K3\%_\C?I?_7_%_P"ABLRM#PI;I=>)M/M9"P62\C5BK8."PZ'M0![Q
M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q4=W_QZ2_\ 7-OY5E_\(/I'
M_/S>_P#@6U1W/@G25MI&%S><(3S=MZ4 >)T444 %%%% !1110 4444 %%%%
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M "H[O_CTE_ZYM_*I*CN_^/27_KFW\J /GNBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .J^#G_([Q?]>\G\J]>KR'X.?\CO%_U[R?RKUZ@
MHHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A
M?_!/?_DB>K?]CWK/_I2:]TH \A^,?_([R_\ 7O'_ "KE:ZKXQ_\ ([R_]>\?
M\JY6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OH2T_X](O\
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M1P-*R7D96->K$,.!0![Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM
M&Q4=W_QZ2_\ 7-OY5E_\)+J__0H7O_?2U'<^)-6:VD4^$;P90\EEXXH \3HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#JO@Y_R.\7_ %[R
M?RKUZO&?A==SV/BV.XM[&2Y80N/*B(R>.O->G?\ "2ZO_P!"A>_]]+0!L45E
MV>O:E<W203>&;J%6;#2NRX7W-:E !1110 4444 %%%% !1110 4444 >%_\
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M&-P+J5I7?,ULEV[6 ****]L HHHH **** "BBB@ HHHH **** /"_P#@GO\
M\D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@#Q[XS?\CS+_P!>\?\
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M?M8-"1'^[;S/LYDWL!@,=RU5/"UJD7)))+35I:]M6M?(#[2HKQ+]N/\ ;?\
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M;/)G2_%L)#)D;LK]E3;@C[S9SQCLJ]'%8V%;#0HQ3T[N]M]%HN^OHNP'P/\
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M]1TCPY<MI5E;6TKVDP2Y%M(##(9.3&9!'AG #7O^"L.E_'OQU_P6&_9*\ ?
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MHKQ;_AXI^Q1_T<)HO_?N?_XW1_P\4_8H_P"CA-%_[]S_ /QNC^S<Q_Y\S_\
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M*\6_X>*?L4?]'":+_P!^Y_\ XW1_P\4_8H_Z.$T7_OW/_P#&Z/[-S'_GS/\
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MT7_OW/\ _&Z/^'BG[%'_ $<)HO\ W[G_ /C=']FYC_SYG_X"_P#(#Z4^#/\
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M  DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\ T;QX%_\
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M_P"-4?\ #+_[-/\ T;QX%_\ "2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\
MC5'_  R_^S3_ -&\>!?_  DK/_XU7<T4 <-_PR_^S3_T;QX%_P#"2L__ (U1
M_P ,O_LT_P#1O'@7_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\
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M!?\ PDK/_P"-5W-% '#?\,O_ +-/_1O'@7_PDK/_ .-4?\,O_LT_]&\>!?\
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M*_@5KO[1O[1OCJW\/^%O#]OYEU=2_-)<2'B.W@C'S33R-A4C7)8GTR1\G_\
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MZ>4O_!2#_@H)'H/_ "!!\:](:$1?ZK[>=/E^VX_V_,V[_?% $7Q9_P""M?\
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MRJEE@=C(_ 4985[E^S__ ,%,/V8OV@?^"?$/_!2K2->NM(^'<?AB^UK6FU:
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M:Q6EA9F&.2P:*X91*DC3-,Z&0/A27_3>@ HHHH **** "BBB@ HHHH ****
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M_9M_X+*>'M&TZ^U:XU36+NZ_9<T^\OM5OYW+2W5W=W&JO-<RL>-\C,0H"C
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MWVO(Y.^X=M[@D8&YR_UY10 4444 %%%% !1110 4444 %%%% !1110 4444
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MG&YG9_KVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HKD_'?Q/_P"$*U>/2O[#^T^9;"7S/M.S&688QM/]W]:Q
M?^%__P#4I?\ D_\ _:Z\JMG>5X>JZ=2I:2WTE_D!Z-17G/\ PO\ _P"I2_\
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M1\8KJ'3O GP5T;6+874^I"W2:[BFOCF&*VM=X6:Z 91E6"[2675_9/\ CO\
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M'/'< )Y>XL5W8"LK'RW7?V3/VE=;_P"#87XX^(K[X,:OIGB3XD?%.[^+.F^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4DM'WVCZCIT4Y@;KE"ZG:>!R*U0 H"J  !P!7A'_  3L_;8_X;Z^ -[\<O\
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M_P""CGQ%_P""?W_"KOLG_" ?#_2/$_\ PEO]M^9]O^W2,GV?[+Y \K9MSO\
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M-ZC>:['XS_L>_P!%8W]OY6GO'&C&<S3>;:RE7"1>66/F*0* /U<HKXO^*O\
MP4Y_:=_91_91\7?M(?MM?\$_HO!FJ:?K6DZ+X \&^%/BQ:^()O%6HW\_D10F
MX%I;I8A9#'N=P_R%B 2H5NL_9U_:)_X*H>*?C!H'A7]I_P#X)Q>$?"'@[6Q<
MG4?%?A?XUP:M-X=*6TLL27-H]G";CS)$2#= [;6E#$;02 #ZDHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \J^.7_ "-MO_V#D_\ 1DE<96C^T_\
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ML&?'7]GKX@6'BWP?K'[6MD-+UNQC<0SO;VFHQ2;1(JME)HF7D#E./6OTHHH
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M=45-)O;HR36,DCQ0K/:MYEL2LPP$91N*@FOE[]FKXX>%_@O_ ,%$_@?\"?\
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MOUC)?^151]#\#XF_Y'V(_P 05^B/P3_Y(SX1_P"Q8L/_ $GCK\[J_1'X)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG>,O"NFZM;QOO2#4[&.=%;^\%<$ ^]7K2TM+"UCLK&VCAAA0)%#$@544#
MX 'I4E% !6?;>$O"EEX@G\66?AG3XM5NHQ'<ZG%91K<3(,85I -S#@<$]A6A
M10 4444 %4M?\-^'?%>FOHWBG0;+4K.0@O::A:I-$Q'3*N"#^57:* *VD:-I
M'A[38=%T#2K:QL[==MO:6<"Q11+UPJJ %'T%6:** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>biib-20201231_g28.jpg
<TEXT>
begin 644 biib-20201231_g28.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,GP=XZ\(_$'2Y-;\%Z]!J-I#=RVLD]N256:-MKISW!X-:U>%_P#!/?\
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M7C'XSZSJVG:'HLOQ#@\.K!)8VT=RQ,\]M-&VZ-W/S&/'E]6+ #HOV-?VEO\
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M&V5#W+$?B*U* "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
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M[-%IK[ZK'\/_  +I/AU=4DCV&\^QVD5OYVW)V[C'NV]LX[4 >A4444 %%%%
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M^"EG3P;X/TK21<OON1IFGQP>:W]YMBC<?<UJUYC_ ,-D?LW_ /11O_*1>?\
MQFC_ (;(_9O_ .BC?^4B\_\ C-']F9E_SYG_ . O_(/[:R;_ *":?_@<?\ST
MZBO,?^&R/V;_ /HHW_E(O/\ XS1_PV1^S?\ ]%&_\I%Y_P#&:/[,S+_GS/\
M\!?^0?VUDW_033_\#C_F>G45YC_PV1^S?_T4;_RD7G_QFC_ALC]F_P#Z*-_Y
M2+S_ .,T?V9F7_/F?_@+_P @_MK)O^@FG_X''_,].HKS'_ALC]F__HHW_E(O
M/_C->F0S1W$*7$+91U#*<=0>16%;"XG#V]K!QOM=-?F=.&QV"QE_858SMORR
M3MZV8ZBBBL#J"OSR^.W_ "6KQ;_V,=[_ .CGK]#:_/+X[?\ ):O%O_8QWO\
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MZ4 ?$W[<?_)?KS_L'6W_ *!7D%>O_MQ_\E^O/^P=;?\ H%>05^N93_R+*/\
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MK-5M9_Y ]W_U[2?^@FJC\2)G\#/S0HHHK]J/YI"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ]?_ &'/^2_6?_8.N?\ T"OMFOB;]AS_ )+]9_\
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MVC_]!%?%\8_#1_[>_P#;3])\._CQ/I#_ -N+-%%%?#GZ>%?GE\=O^2U>+?\
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MV**_&C^CC'^Q>-_^@W9?^ Q_QJMJ]EXU&DW1;6K,C[.^0+8_W3[UT-5M9_Y
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M*37NE 'Q-^W'_P E^O/^P=;?^@5Y!7K_ .W'_P E^O/^P=;?^@5Y!7ZYE/\
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MX V;^)+62'QOX)\=6_AZ]GF"2JEC]JN%*LDFXL8@-S&)2/NFO=:XWXX?L\_
MS]I;PG;> _V@?A/H/C'1;/5(=2M=+\0Z<EU!%>1!A%.J." ZAVPW4;C0!^=/
MCK_@GE^SW\+_ !7=^!/B7_P<R?M+>'=<T]D%_HVN_M/:5:7=L617420RPJZ9
M1E89 R&!Z$5Z#^P]^S)^SA\/?VHO#'C#P%_P7S^,'QKU:S^V_9/AEXI_:$TS
M7+#6=]E.C>;8P())_)1FN%VGY&@5SPIKC_\ @H?\8?\ @AYX;_:^\1?#_P"+
MG_!-Z^_:"^-:VMG>>.K+X:_!,>)M4T]'MXUMFOI3L5&,"1[5+E@@3( *Y/\
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M_P"0/GZBOH'_ (4C\+_^A8_\G9__ (NC_A2/PO\ ^A8_\G9__BZ/^(L\.?\
M/JK_ . P_P#E@?\ $/\ .?\ GY3^^7_R!\_45] _\*1^%_\ T+'_ ).S_P#Q
M='_"D?A?_P!"Q_Y.S_\ Q='_ !%GAS_GU5_\!A_\L#_B'^<_\_*?WR_^0/GZ
MBOH'_A2/PO\ ^A8_\G9__BZ/^%(_"_\ Z%C_ ,G9_P#XNC_B+/#G_/JK_P"
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M^0#_ %.XC_Y\?^30_P#DCRFBO5O^&8_^IW_\IO\ ]LH_X9C_ .IW_P#*;_\
M;*/^(B<'?]!7_DE3_P"0#_4[B/\ Y\?^30_^2/*:*]6_X9C_ .IW_P#*;_\
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M)[_\D3U;_L>]9_\ 2DU[I0!XY\88HH?&TJ0QJB^1'PHP.E<M75_&;_D>9?\
MKWC_ )5RE?D^;?\ (SK?XG^8!1117G@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !7T%::?8&UB)L8?]6O\ RR'I7S[7T1:?\>D7_7-?Y5]EPA\5;_MW
M]0&_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%345]L!#_ &=I_P#SXP_]^A7AGC-5
M3Q=J:(H %_*  .!\YKWFO!_&O_(X:I_V$)O_ $,U\EQ;_NU/U?Y 9=%%%?"
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M\9O^1YE_Z]X_Y5RE=7\9O^1YE_Z]X_Y5RE?D^;?\C.M_B?Y@%%%%>> 4444
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MBBOQD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .K^#/_(\Q?\
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M !1110 4444 %?1%I_QZ1?\ 7-?Y5\[U]$6G_'I%_P!<U_E7V7"'Q5O^W?U
MDHHHK[8 KP?QK_R.&J?]A";_ -#->\5X/XU_Y'#5/^PA-_Z&:^2XM_W:GZO\
M@,NBBBOA "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4\%?\CAI?_80
MA_\ 0Q676IX*_P"1PTO_ +"$/_H8K?"_[U3_ ,2_,#WBBBBOV$ J.[_X])?^
MN;?RJ2H[O_CTE_ZYM_*IE\+ ^=Z***_&0"BBB@ HHHH **** "BBB@ HHHH
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MZ#XJAUHI9&P+V\$,<TE[YAN0I9'5VW%BZ\UZ^5+F<TH-NVZBI6TEI9]_TMU
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M?M=?L^? []JOX!:W^SS^T1M'AKQ48+21TU 6L\=T)D>V>WD/W9UF2-D&#EE
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M'\:_\CAJG_80F_\ 0S7R7%O^[4_5_D!ET445\( 4444 %%%% !1110 4444
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MBBOQD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .K^#/_(\Q?\
M7O)_*O8:\>^#/_(\Q?\ 7O)_*O8:_1.%O^18_P#$_P D 4445]( 4444 %%%
M% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG
M_P!*37NE 'CWQF_Y'F7_ *]X_P"5<I75_&;_ )'F7_KWC_E7*5^3YM_R,ZW^
M)_F 4445YX!1110 4444 %%%% !1110 4444 %%%% !1110 5]$6G_'I%_US
M7^5?.]?1%I_QZ1?]<U_E7V7"'Q5O^W?U DHHHK[8 KP?QK_R.&J?]A";_P!#
M->\5X/XU_P"1PU3_ +"$W_H9KY+BW_=J?J_R RZ***^$ **** "BBB@ HHHH
M **** "BBB@ HHHH **** "M3P5_R.&E_P#80A_]#%9=:G@K_D<-+_["$/\
MZ&*WPO\ O5/_ !+\P/>****_80"H[O\ X])?^N;?RJ2H[O\ X])?^N;?RJ9?
M"P/G>BBBOQD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .K^#/_
M "/,7_7O)_*O8:\>^#/_ "/,7_7O)_*O8:_1.%O^18_\3_) %%%%?2 %%%%
M!1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\
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M1O);^\_:M^%CS32%Y7_X1J4;F)R3@08%?<E%8UL/0Q"2JP4DNZ3_ # ^%O\
MACW_ (*V_P#1U'PL_P#"<F_^,4?\,>_\%;?^CJ/A9_X3DW_QBONFBL/[-R[_
M )\P_P# 5_D!\+?\,>_\%;?^CJ/A9_X3DW_QBC_ACW_@K;_T=1\+/_"<F_\
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M\8H_X8]_X*V_]'4?"S_PG)O_ (Q7W311_9N7?\^8?^ K_(#X6_X8]_X*V_\
M1U'PL_\ "<F_^,4?\,>_\%;?^CJ/A9_X3DW_ ,8K[IHH_LW+O^?,/_ 5_D!\
M+?\ #'O_  5M_P"CJ/A9_P"$Y-_\8J6R_9)_X*[:=>17]G^U;\+$FAD#Q/\
M\(U*=K Y!P8,&ON2BFLNR^+NJ,;_ .%?Y ?'/_"E_P#@M;_T>1\+/_"1_P#N
M:C_A2_\ P6M_Z/(^%G_A(_\ W-7V-178!\<_\*7_ ."UO_1Y'PL_\)'_ .YJ
M1_@I_P %K)$*/^V/\+"&&"/^$1/_ ,C5]CT4 ?"W_#'O_!6W_HZCX6?^$Y-_
M\8H_X8]_X*V_]'4?"S_PG)O_ (Q7W317%_9N7?\ /F'_ ("O\@/A;_ACW_@K
M;_T=1\+/_"<F_P#C%'_#'O\ P5M_Z.H^%G_A.3?_ !BONFBC^S<N_P"?,/\
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M;B'2=8M;I[64Q726UPKF%_[KA2=I]CS5JOR/_P""D'["G[,__!%?PO\ !_\
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M1EM@8$JZL?T@\1>$?"?B^&&W\6>&-.U2.WF$MO'J-E'.L4@Z.H<':WN.:T0
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M2!8XXU]%50 !]*L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G>,?^11U7_L&S_\
MHMJ\$KWOQC_R*.J_]@V?_P!%M7@E?"<6_P"\TO1_F 5VOP*_Y&ZY_P"P:_\
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MZUZ516V&KSPM>-6&\7?4YL9A:>.PL\/4;49IIVWU[;GPK_PQO^TA_P!$Y_\
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M;PAXETW6O#^F> _A*MC97EY:S*S76H*U[ON)&B\V-$C:**)I3)LD(51^D-%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>biib-20201231_g29.jpg
<TEXT>
begin 644 biib-20201231_g29.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
MX.#TK^9/_@E7_P $5/V//VS/^"O_ .TY^PS\7=3\9Q>"OA%JOB*W\*2Z/K<,
M-\Z6/B :?#Y\K0.LA\DY;"+EN>!Q0!^O?_!2;_@M5\9?V(_^"M/[/O\ P3Q\
M%_![PQK/A_XPW/AN+5]?U2>X6\L!J6O2Z9(85C<(=D<8==P/S$YXK]%+76M&
MOK^XTJRU:UFNK3'VJVBG5I(<]-Z@Y7/;-?SG?\'#7[.\NE?\%JOV*OV3O@S\
M0=6\+/;> _ WA+PIXKAGW7VD%?$=U9VMZKJ%S-%A) P"_,F1BL3]L_\ 8N\,
M_P#!#/\ X+Q_LO3_ +&WQ9\<2VOCW5=$E\3R^*->%U=ZA]IUG[%J$4TL<<8D
MBN(6!96!Q(SL"/D"@']*-Y>6FGVLE]?W4<$$2%Y9IG"HBCJ23P![U'I>K:5K
MEDFI:+J=O>6TF?+N+699$;'!PRD@U_-Y_P %Y?VG_'/[57_!> ?L*?'+PA\7
M/&OP7^&Z6"M\)?@[;O-JFO2/HT>I2W*VX.)',DZJTI!,=M$Q3:Q)-K_@F%!^
MTM^R-_P67\%ZA^P+^PK^U)\./V=OB#J%GI'CWP;\5O!FH&SM#.&BDNGF*/&J
M0OY4Z3R/YBXDC+>6Q# ']'6IR:E%IMQ+H]I!/=K YM8+FX,4<DF#M5W5'**3
M@%@K$#G:>A_.[_@G+_P<!6/[8/[>'C3_ ()Q_M-?LHS? [XG^&#<Q:7I5]XV
M&KQZS<VK-]JMT?[';;7$0$\97S%FB$C@@*N_]&*_#K_@[H_8MM?A+:^ _P#@
ML3^SSXPN/!WQ+\+>)M/T/6M1TF1H)[WY9'L+U)$Z7$#1&(D_?B=%)Q"JL ?4
M^M?\' K^.O\ @K?'_P $J/V//V1_^%HW.GZB+/Q?\0?^$^_LZRT1X<MJ+F);
M"X\R.T7Y"QD0R3@PJ,E&?]%-8US1/#UF=1U_6+6QMPP4SWEPL29/0;F(&:_+
MC_@U(_X)T^ _V:?V$+']M#6KF/6/B)\<+8ZCJ.LR N]CI2S.+>R1V^;+,IGE
M;C>[HIW"%&/Y+77[0-A_P4Y_X*?_ !A^*/\ P4(_9H_:,^/'A?PUJ=_9>#_A
MM\%K*>XC\-0"\>&W298V!MHTBB(^3:9IBSN3A@P!_5Q#-%<1+/!*KHZAD=&R
M&!Y!!'451U'Q=X4T?4(M)U;Q/IUK=3$>3;7-[&DDF>FU6()_"OPP_P"#:?QS
M^V#^RO\ M9?%WX#_ !$^"7QQ\%?LNGPSJOB7P9)\:/"=[9_\(V;6ZB:-6GDB
M$"2/:23>:D1"R- KA1M-?(^O?"G_ ()7_MC:!\5/%/[$_P#P2V_:M^,#6$U_
M/J7QKE\6);)97KK),+AH%B:W$8SY@BD42>4%W*I)H _J7JMJVLZ/H-DVI:[J
MMM96ZL UQ=SK&@). "S$#DU^!O\ P1 _:=^,7QQ_X-O/VSOAA\5_&VH:];?#
MWX<^+[3PQ<ZI=--+:6%QX8N)!9J[$GRDD21D!^[YI484*!XU_P &^G_!"GX7
M_P#!6K]A?Q#X\_:G_:+^(VF^#_#GQ&O].\&>"_!NJ6UO;VNHFQL9+O4Y1<6\
MZO)(DEO$ %4@6YR2"H !_2GK?B7PYX9@2Z\2:_9:?'(VV.2^NDB5CZ L1DU;
MAFBN(EG@E5T=0R.C9# \@@CJ*_FH_P""H'[-'Q/\'?\ !83XO?'C_@J?^P1\
M<OCG\(-8GF'PWU?X>ZG=I8Z7IY,;6RK+!&R)Y4(9&MVDA/F!Y&#[MQ_2S_@V
M;^('_!,SQ/\ LY_$/PY_P36USXDVNE6WC"#4O%'@CXH7$,M]X=N+FV$42P/#
MN1K:06LA4EW;>DFXCA0 ?<O[8G[07_#)W[*'Q)_:?_X1'^W_ /A7O@?5/$7]
MA_;_ ++]O^QVLD_D>=Y<GE;]FW?L?;G.TXQ7Y'_"+_@[;_:V_:"\-S^,_@+_
M ,$%_B-XWT>VOFLKG5?"'C:_U*VBN51':!I;?P^ZK($DC8H3N"R*<889_2G_
M (+#_P#**#]I+_LA_B?_ --EQ7X+?\&^_P ,?^#@+QI^QIXFU3_@E/\ M%?#
MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,GP=XZ\(_$'2Y-;\%Z]!J-I#=RVLD]N256:-MKISW!X-:U>%_P#!/?\
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MO_Q%>+45^?\ ^MF8_P D/N?_ ,D![3_PMKX??]#!_P"2DO\ \11_PMKX??\
M0P?^2DO_ ,17BU%'^MF8_P D/N?_ ,D![3_PMKX??]#!_P"2DO\ \11_PMKX
M??\ 0P?^2DO_ ,17BU%'^MF8_P D/N?_ ,D![3_PMKX??]#!_P"2DO\ \11_
MPMKX??\ 0P?^2DO_ ,17BU%'^MF8_P D/N?_ ,D![3_PMKX??]#!_P"2DO\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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MY_:1^!G[5_POLOC/^SM\2].\5^&;]V2#4].9@%D7&Z*2-PLD,BY&8Y%5QD9
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MJO\ P2J_;!^(WP#\2Z-.!/HWASQO+XCT#S^?W>I:1J<LPG!P?E,D;#!(88H
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M'UBZTG_A&?,^S7#Q>9]MQNVDC.-AQTKDQ>.PN BI5Y63VT;_ "3 [RBO.?\
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M+#571]KHEYM*]NR;N_D!]'5J>"O^1PTO_L(0_P#H8K+K4\%?\CAI?_80A_\
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MM7Z)PM_R+'_B?Y(#8HK+L_"6FV-TEW#<71:-LJ'N6(_$5J5]( 4444 %%%%
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M8^(M1-M,M[INL0:,-2M3"1+Y?DR^7<1LK(64["&QF@#ZFHHHH \+_P"">_\
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MIGA_51/%IGAN31FB_P")DD3%4WW?V7R!*,B1<KC=D@'WM1110!X7_P $]_\
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M6/PQ>RM?B7\1?C[=73>'8=3N;=;E--M[.S4S7,J0NC/(,JC-M95^5G?^R?\
MMF?MP?LU_M/^!_V"O^"DG[+'PJ\)CXE1:@OPN^('P&NK@>&[V^LX&N9].FM+
ML">UF,"M(CMA9"-JJ3N*@'WU1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\
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M?_0Q676AX36X?Q1IRVLBI*;V(1LPR VX8)%;X7_>J?\ B7Y@>^45C_8O&_\
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M0 4444 %%%% !1110 4444 %%%% '5_!G_D>8O\ KWD_E7L->/?!G_D>8O\
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MRE?D^;?\C.M_B?Y@%%%%>> 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!A";_T,U[Q7@_C7_D<-4_["$W_ *&:^2XM_P!VI^K_ " RZ***^$ ****
M"BBB@ HHHH **** "BBB@ HHHH **** "M3P5_R.&E_]A"'_ -#%9=:G@K_D
M<-+_ .PA#_Z&*WPO^]4_\2_,#WBBBBOV$ J.[_X])?\ KFW\JDJ.[_X])?\
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MA"'_ -#%9=:G@K_D<-+_ .PA#_Z&*WPO^]4_\2_,#WBBBBOV$ J.[_X])?\
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M'Q5O^W?U W**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6OM@-BO!_&O\
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MBGXP\7_M)6NJV/QX\(^._%<NH6=U?#0)-5-W:P2#_1GL[B,1%AEC$=OR[FR
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MKJ_C-_R/,O\ U[Q_RKE*_)\V_P"1G6_Q/\P"BBBO/ **** "BOE7XS?M:_\
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MK_R.&J?]A";_ -#-?#\6_P"[4_5_D=YET445\( 4444 %%%% !1110 4444
M%%%% !1110 4444 %:G@K_D<-+_["$/_ *&*RZU/!7_(X:7_ -A"'_T,5OA?
M]ZI_XE^8'O%%%%?L(!4=W_QZ2_\ 7-OY5)4=W_QZ2_\ 7-OY5,OA8'SO1117
MXR 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '5_!G_D>8O^O>3^
M5>PUX]\&?^1YB_Z]Y/Y5[#7Z)PM_R+'_ (G^2 ****^D **** "BBB@ KS3]
MJC1_VM-;^'EE:?L:^,_!&A>*%UZV?4+OQ[I=S=V;Z: _GQHENZL)B?+VL3M&
M&R.17I=% 'R1^TAX$_X+<ZO\:M<U']E'X_?L\Z-\/Y9(?^$=TWQKX-U:ZU.%
M1!&)1/+!,L;DS"5EV@80J#R#4G[,W@7_ (+8:-\;M$U+]KCX]_L^:U\/8_M/
M_"0:9X'\':K:ZI-FVE$'D2W$S1KBX,+-N!RBN!R0:^>-9_91\8?\%,O^"EO[
M0OPR_:Q_;&^,'@[1/A9>:';_  V^%?PW\</H%K/HUUIT<QUJ7RE+7IEN?/C$
MF?W;Q21D\*B>]_LN?\$7OV>_V3?CMH7[0/@?]H;X\:[JF@?:OLNE>,_BQ=ZG
MIL_GVLMLWG6T@VR;5F9ES]UU1NJT ?7]%%% 'A?_  3W_P"2)ZM_V/>L_P#I
M2:]TKY^_8&\0:+IGP:U:VU#48XI/^$YUEMKGG'VEN:]O_P"$Q\,?]!J#_OJ@
M#S#XS?\ (\R_]>\?\JY2NE^+%_9ZEXQENK&X66,P1@.IXR!7-5^3YM_R,ZW^
M)_F 4445YX!1110!XE^W-^W)\-OV'_AE;>(_$.F7GB+Q=XCO!IGP]^'^B+YF
MI^)]4? CMH(P"0@9E,DN"L:D=69$;R_]@O\ 8'^(WP__ &<?BG??M1^((&^*
M/[0^HZCK/Q(;2,-;:,]Y;O#%I]OR0ZVT3E=V3EBP#,H5CQ_Q;_X)/_M<>,?V
M\M<_;S^''_!1^RT'7+K3SIGA33]<^"]MK:^&--( -M://?JB%CO+2K$CMYC@
MGYVW?2?[*GPF_:Q^%6GZU;_M3_M>67Q9N+V:!M&N+/X<6WAT::BAQ(A6">43
M[R4.3MV[.,[N/3E*C0PBC1J)MV<M)7]%[MK+=ZZOY ?%G[+GQ'_X*'_L5_L=
MP_\ !/36?^">OB3Q#XR\)Z9?Z)X3^(^E:OIZ>#[VT:24V^HW=S+,LELD:2!G
MB,;2,(NBL^U>]_X-L+77;/\ X)&^ 8=6E:2V_MK7O[)D((5[;^U;D;ER =ID
M$I_.MCXG_L'?\%//CAIVK_!?XG_\%1;!/AKKK36^L/X;^%%K8>(+K3920]B+
MD3-'"3&WEF=4W$#)7YB*]R\>?LCS:;^Q8W['O[)'Q0N_A#_9^@VNE>$_%&CV
M1NY]&CADC8R!/-B,KNJ.K,9 6,K,223G;$XBA4H.G>-YR4FUS66]V[^M[)=_
M) >S5\#_ +'.?VUO^"NGQJ_;4NQ]J\(_!:R7X5?#>4C,3Z@I\_6+E.V]9&\H
M.,[HIU]!7VHWA3QQ;?" ^!]+^(>WQ)'X;^PVWBR\TWS\7PM_+6]>W\P>9^\Q
M*8_,&[E=XSNKSG_@GS^QAX<_8%_97T#]FW0O%DGB*XTV:ZO-;\3W%E]GFUB_
MN9WFFN9(_,D*DE@H!=B%11N.,UPT:E.C0J6?O/W5Z/=_A;YL#SWXZ?L._M*+
M^T+X^^/G[''[0OAGP=/\7?"MAHGQ"LO%GA*;4_)ELHIH+;5+!H;F'9<I!,T?
MER!HF*JS9Q@?*OA3Q?X,^"EAX0^)OP]\$7_CSX;_  #UNQ^$/[,_AV>^2W'C
MGQW=R"ROM<EG*F-(8G\VVCF"NBD7CQC)45^BW[4GPZ^*WQ=^ OB/X6_!;XEQ
M>#=>\0V7V"+Q2]JTTFF6\K!+B:%593YXA,@C;("2%7.=N#YQ\=/^">'P^\=_
MLB^$?V6O@GXA?P"WPTU71M8^&>MV]DMW_9&I:7*LMM/+"S*+D,0XE#,"_FNQ
M.XYKJP^,BH*-5[M+;9)6NVM7I[JZI7\@'_LL?M=_%?X@_'GQE^R1^T]\)-%\
M(?$3PAH=AKT!\+>(I=3TK6M(O'EC2YMY9K>"5&CFB>&1)(Q\P!4L#Q]"5\]_
MLL?LB?%?X?\ QY\9?M;_ +3_ ,6]$\7?$7Q?H>GZ#"/"OAV73-*T72+1Y9$M
MK>*:XGE=I)I7FD>20_,0%"@<_0E<6)]C[7]WM9;7M>VMKZ[@%%%%<X!7T1:?
M\>D7_7-?Y5\[U[M:^+_#*VT:MK,((0 C/M7V7"'Q5O\ MW]0-:N5\;_!'X4_
M$0M-XK\$64]PW/VR*/RIP?7S(\,?Q.*V/^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#
M_OJONJ=6K1ES4Y-/NG8RK4*&(AR58J2[-)K\3S\?!'XH>"?WGPC^-VH+ @^3
M2/%$8O8".RK)P\:_0$UY/XG\;?$/0?$=^/B!X",D@NY/M%YX?D,T6_<=Q"-\
MX7/KVKZ8_P"$Q\,?]!J#_OJO%O%T\-SXJU&XMY Z27LK(PZ$%C@UX7$^90^K
MT_K5&-5-];QEMNI1:U_Q*2\C@_LQ4?\ =JDJ?E?FC_X#*]E_AY3E-"^(?@WQ
M&XATS7H3-G!MYCY<F?3:V"?PK:K,UWP;X6\3*5US0K>X8C'F-'AQ]&&&'YUB
M_P#"N=:T/Y_!'CF]M%'W;.^Q<0_0!N5'YFOC/J^18O\ A5I49=JBYH_^!P5_
M_*?S#VV:8?\ B4U47>#Y7_X#)V_\G^1UM%<E_P )7\1/#PQXH\$B^B7K=Z'+
MO./^N3?-5_1?B9X*UR7[+!K207 .&MKP&&0'TPV,GZ9K*MD694Z;JPA[2"^U
M!J:7KRW<?^WDF73S7!3FH2ER2[33B_E>U_E<WJ* 01D&BO(/1"BJFN:YI?AS
M2Y=:UJZ\FVAV^;+L9L98*.%!/4CM7/\ _"[OA?\ ]#/_ .24_P#\17HX3*,V
MQ]-U,+AYU(IVO&$I*^]KI/75:>9QXC,<OPD^2O6C![VE))V[ZLZNBN4_X7=\
M+_\ H9__ "2G_P#B*/\ A=WPO_Z&?_R2G_\ B*Z?]6N(_P#H#J_^"Y_Y&']M
M9-_T$T__  ./^9U=%5-#US2_$>EQ:UHMUYUM-N\J78RYPQ4\, >H/:K=>15I
M5*-25.I%QE%M--6::T::>S75'HPG"K!3@[IZIK5-/J@HHHJ"@HHHH *U/!7_
M ".&E_\ 80A_]#%9=:/A&>&V\5:=<7$@1([V)G8]  PR:WPO^]4_\2_,#WNB
MLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZK]A TJCN_P#CTE_ZYM_*J/\ PF/A
MC_H-0?\ ?51W7B_PRUM(JZS"24( S[5,OA8'A-%%%?C(!1110 45#<:A86F?
MM5[#%CKYDH7^=4;CQOX-M,_:?%FFH1V-ZF?RS712PF*K_P .G*7HF_R,:F(H
M4OCFEZM(U*\I_:<_Y@G_ &\_^TJ[2X^+/PYM?];XLMCC_GGN?_T$&O-OCKXU
M\-^,?[+/AV^:=;?S_-8P.@^;R\8W 9^Z:^^X!R?-L/Q5AZ]7#SC!<]Y.$DE>
MG)+5JVY\GQ;F.7U<AK4H5HN3Y=%)-_''I>YY]1117]''XR%?5E?*=?5E?BOC
M!_S _P#<7_W&?IGAU_S%?]N?^WA1117XJ?I@4444 %%%% '5_!G_ )'F+_KW
MD_E7L->,?">_L]-\8Q75]<+%&() 78\9(KU7_A,?#'_0:@_[ZK]$X6_Y%C_Q
M/\D!I450MO%'A^\G6UM=5B>1SA$4\DU?KZ0 HHHH **** "BBB@#\J_%'_!/
M;X:?\%._^"M/QVM/V_\ XJ>-8+WX6KI%K\%_ 7AWQ7)HT47AF\T^.2?5(3#B
M:X$UX)8Y)$?"20F-\XC5/I7]ES_@B#^Q%^R!\=M"_:*^$-W\2&\1>'OM7]G+
MK_Q,U+4+0^?:RVLGF6\\K1R?NYGQN!VMM8<@50_:D_X(%_\ !-7]LC]H/5OV
MH?CQ\-/$^H>,M:DA>[U&Q\?ZI9HACMX[=?*BAG5(?W<2 [ ,D$G))-7_ -ES
M_@AE_P $]OV.OCMH7[1WP.\'>,+3Q3X<^U?V7<:K\1M6OX%^T6LMK)N@N+AX
MWS%/(!N4X)##! - 'U_1110!X/\ \$_+2UG^"NK/-;1N?^$ZUD99 3_Q\FO<
MO[.T_P#Y\8?^_0KQ'_@GO_R1/5O^Q[UG_P!*37NE 'CGQABBA\;2I#&J+Y$?
M"C Z5RU=7\9O^1YE_P"O>/\ E7*5^3YM_P C.M_B?Y@%%%%>> 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?05II]@;6(FQA_U:_P#+(>E?/M?1%I_Q
MZ1?]<U_E7V7"'Q5O^W?U ;_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-17VP$/\
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MX]A)!2[ED''L-M>KU'=_\>DO_7-OY5,L;!1?+1@ODW^;8?V=4?QXBH_G%?\
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MB<'?]!7_ ))4_P#D#\K_ -3N(_\ GQ_Y-#_Y(\IKZLKRG_AF/_J=_P#RF_\
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MEM*1OMY0^&9&61"J.C97! /C#_A>W_!T7_T8[^R__P"%O?\ _P DUZ/^R/\
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M[Q_RKE*ZOXS?\CS+_P!>\?\ *N4K\GS;_D9UO\3_ # ****\\ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^B+3_CTB_P"N:_RKYWKZ(M/^/2+_ *YK
M_*OLN$/BK?\ ;OZ@24445]L 5X/XU_Y'#5/^PA-_Z&:]XKP?QK_R.&J?]A";
M_P!#-?)<6_[M3]7^0&71117P@!1110 5\,?\%G-&_;P_:*_9_P#'/[%W[-?[
M!]YXRT?Q?H-DL7Q"3XD:-I\-M.MW'.\1L[N6.5MHA W9 /F<=#7W/16^&K_5
MJRJ**;6JO?=>C0'@/[&OQ-_:\\3?"+4/#WQ[_8HN?AAJOA70K*T\-P7_ (_T
MS5T\02I;NK$-8NPM@K1Q ^8>?.XSM->)_$+]MO\ X*O>._A_J?PL\ _\$@=<
M\/\ CG5=/DLH=;UOXFZ//H6ER2*4-TT\;AKA(\[Q&JJSXQUZ_=5%:1Q-.-1S
M=*+OT]ZR_P#)NO6]P/E#]G_]G']HC_@FW_P2ET']G[]FCP?I7Q*^)G@G0BVG
MZ/=Z@MG9:IJ-UJ#75VJS321!(E-S<%"[(2(UR 3MKU7X\?%#]H/P#^SSI_C;
MP7^RB_Q)\3W$5HGB;P#I_B.SLFCBEB/VHQ2W),4_EM\OE[OW@)PQ[^M45$L0
MZE3GG%-MMO?6_31K3TL!^=WA/]FO]H;]NS]H/X9Z]\3OV(=-_9X^"WPF\81^
M,QX7FO=/EU3Q?XC@0K9R/#8CR[>" L[$R9:3<5&0V8_M']J3QU\7OAS\!?$?
MB?X ?#.7Q?XW6R\CPKH2.B1RWTK"**29G90L$;.)9#D'RXV"Y8@'T"BJJXJ5
M:<6XJT=EK;>[W=]>NH'PS\;/^"<_Q(^&W["?@'P+\$K./Q]\0/A_\7M$^)_B
MV._NX[:7Q]K,%]]JU(O-*0B23L[F/S#M410QD@*".R_9'\ ?'#XI?MV_$7]N
MWXF_ S6OACH>K_#_ $?P?X8\+^)[JS?5-1%K<W%U/?W4=G/-'#AYA#&ID9F1
M2Q"C&?K2BJ>-JRIRC))MWUZZM-^73L 4445Q@%:G@K_D<-+_ .PA#_Z&*RZU
M/!7_ ".&E_\ 80A_]#%;X7_>J?\ B7Y@>\4445^P@%1W?_'I+_US;^525'=_
M\>DO_7-OY5,OA8'SO1117XR 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '5_!G_ )'F+_KWD_E7L->/?!G_ )'F+_KWD_E7L-?HG"W_ "+'_B?Y
M( HHHKZ0 HHHH **** "BBB@ HHHH **** /"_\ @GO_ ,D3U;_L>]9_]*37
MNE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* /'OC-_R/,O_7O'_*N4KJ_C-_R/,O\
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MY_X<A?LF_P#11OBG_P"%L?\ XU1_PY"_9-_Z*-\4_P#PMC_\:K[&HH ^.?\
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M_P#&J/\ AR%^R;_T4;XI_P#A;'_XU7V-10!\<_\ #D+]DW_HHWQ3_P#"V/\
M\:H_X<A?LF_]%&^*?_A;'_XU7V-10!\M_"7_ ()'?LU_!KXEZ)\5/"_CKXBW
M&HZ#J"7EG!J7BXRV[R(<@2)Y8WKZC/-?4E%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'SI^V5_P5=_84_8*\;:7\+?VD?C'/8>+M;T
MQ=1TCPEHGAO4-6U*ZM#))&)Q!902E(R\,JAGV@F-@"2*Z']B_P#X*'_L>?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXM'TZ.SD=IHI96RUPP0!55N"-DGZ=444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7Y-?\% _A-_P57_:9_P""C5KX@^)__!+_ %#XN_LX?"Z\6Z^&
M_@#3/C#X<TFP\2ZNJJ5UG5H[RY\RX"$N(K5XE1<#.X-*)?UEHH \)_99^*O[
M3O[3/@KQ9X=_;)_8%O/@M;^2EC8Z7J'Q%TKQ -;MIXY5GPVFL1 $ 52'P6\S
MY?NFOA[]F&V_X*\_\$K_ -F/5?\ @FO\(OV [[XO?\(Y?ZK;? [XP:=XTTRU
MTIM.N[F6>WDU:&YD66"6V>=BR!<2!1&AP!(WZKT4 ?)_[!'[)'Q(_P""5_\
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M@W0!8T@7+AE5C@IF3]%J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S'Q8\1:QX9\.PW^B7
MGD2O>K&S^6K94HYQA@1U KIZXOXZ_P#(HVW_ &$D_P#1<E>=FTYT\MJR@[-+
M=:,#BO\ A;7Q!_Z&#_R4B_\ B*/^%M?$'_H8/_)2+_XBN<HK\U_M+,?^?T__
M  )_Y@>R_"?Q%K'B;P[-?ZW>>?*EZT:OY:KA0B'&% '4FNGKB_@5_P BC<_]
MA)__ $7'7:5^E93.=3+:4IN[:W>K ****]$ KPO]M/\ X*4_L6_\$\W\+0_M
M>?%^?PM)XUEO(_"\-MX4U357OGM5B:<!=/M9RFP3Q'YPN=W&<''NE?E__P %
MT/C7X>_9U_X*5_L$_&CQ7X9\1ZQI^@^*?',MSIOA+0IM3U&</I5E&!#:P@R2
MD%P2%'"ACT!H ^M?V1O^"M'_  3P_;J\;7?PR_9?_:9TO7_$UC;-<7'AJ^TN
M^TG4?)7&^1+74(()9%7(W,BD*""<9%?1=?C_ "_M'>!O^"MO_!=?]GKQ%^S#
M\+?$G@B[_9TT;7-<^)NN?$/2(] UG4-/OH$M[:QM["=Q=W,(D\Q7<H(XQ>,<
MJ6'F>P?\%'_^"C_BF/\ X* :9_P3@\!?MX^ ?V9-%TKP$GBSXB?%WQI<:6+R
M<SS^3:Z-I<>J2+;^<R S22D.50@K@H0X!^D%%?FO_P $^O\ @H7XIT;_ (**
MK_P3Y\0_\%%/ W[4OA'Q?X!NO$G@7XC>&KO1WU71+VTE"W.D:B-)8P2*T+>?
M',51_E9<,.5\A_8C_:N_:9_X*-C5O$OCW_@N/!\!/C$_C#5=-M_V<[;P5X=2
M3PK]GO9H(+26UU2,W6J.T:1R,X?K+LR&4@ '[#45^??_  56_P""AGQ/_9E^
M(?P/_81\'_M6> OA3XN^*%C>7GC3X\?$"&R@T_PUIMA GG7$%M>2I;/=W4Y*
M0Q2,R*001R'7S#X&?\%$?$7[-W[>?PA_9YM_^"NG@']K7X??&?4;O0;Q;&_\
M/OK_ (-UA+<S6MR#H[ 36=PZF%EE0>6VTJQ/RL ?JG17YR_\%)/CG8?"C]HK
M6=.^*'_!PII?[/\ :SP6LWA/X8:-X-T*YO-+7[+$&GOGN4GN;A99EEE4,(4V
M.J+N*EBG_!/[_@J#\8_VI?\ @EE^T-\5]2^+/A_Q-X^^!TOB[0].^)WA;2$A
ML/$IL-,-WI^MQ6LBM'&9%DC+0E2FZ,_*%;;0!^C=%?G/_P $P-0_X*2_M!_L
MT_"G_@I%^V=_P4$>P\//X-77-6^&/AOP!ID-CJFG+9R#[7?7:H)C<3 +=E8!
M%%$2(U3 8G$_8N_X>F?\%9O@I#^WN/\ @H;J7P"\)^,[Z\F^%OPT\$?#_2-2
M_L_3(;F2"&XU*YOXI'NYI?*+-&I6,#!7;O*( ?<'QU_;"^#_ .SO\8?A9\#_
M (AMJ@USXP:_=:/X/%C8B6$W-O;_ &B3SWW#REV=#@Y/&*]3K\M/^"R&A?M2
M:%\?_P#@GWX0\"_$+0-;^+47CW4-.D\9ZSH1@TZ;4CHL4-UJKV,,GRH"9KD6
MJR ':(@X!W5UU]XW_P""@_\ P3H_X*$? 3X;_'C]NJ\^.?PV^/\ K.J>&]6L
MO$7@;3-)N_#VL0VAN;:YLWL$3,,C#RVB?*HH)^9F!4 _1VBBOS+_ &^OV@H/
MA1^T#XFT3XG_ /!R%HWP4U'[29O"WPVT;P)H%W_PC\)53$NH">.:YNF8?.1(
MT((<!1CYF /TTHK\SO@A_P %5_V@?C]_P02^-'[9>E^.]#7XH_"O2O%>CIXX
M\,:;$^FZIJ&EH6M]6MK>X1X_+FB>"78Z%"Q;"A2$''_$+5O^"T>G_P#!,:S_
M ."KMS_P4:LM*\3:%\*+/QU-\'[;X9Z6^@WFG1V,=U-;7=PR?:'NIK<-)))$
M8T29VCA2-%5P ?K#7E?[2/[8?P?_ &5O$_PT\)?%1M4%W\5_']KX.\*?V=8B
M93J5PCO'YQW#RX\1ME^<<<5\J?MH_P#!0W]HOX@?#C]E#X)?L2:K8>"OB/\
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M?:2W&D'5[,6]SLCGD@;?&&;:=\3]SQ@UZ37X\_L??MN_$W]A?_@V4_9[\7_
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MUW^UE9:=XK^(_P"SMXZUWP!X@N].MA9VGB36K.^M[*SN#'$-L"2RWEJ)/+
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M\6^(O%OA:PGBU;981 ZC<PPPH(O*9I+LQ6I@#%/+R%.* /T,HK\X/B7\0_\
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M))_Z+DKM**Y<;AOKF%G1O;F5K[@?.=%?1E%?*_ZH?]/_ /R7_P"V XOX%?\
M(HW/_82?_P!%QUVE%%?58+#?4\+"C>_*K7V ****Z@"OC3]OW]E'X^_&S_@I
M1^QE\?\ X8^ O[3\(_"?Q)XNNO'^K?VI:P_V5#>Z9!!;-Y4LJRS[Y$9<0HY7
M&6"@@U]ET4 ?$W_!7#]C;X_^/O&/PA_;Y_84\$0ZS\</@CXOADMM#&J6VGMX
MJ\-7;>5J>D27%Q)'$H,;F1#(X"#SMGSR#/"_MO?L=?M!_#;_ (*$Z=_P4[^
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M3^)O&'@Q_P"T[6Y_M'1;N.U%O=8MY7,.\QO^[EV2+M^9!D9^OZ* /S(^&/\
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M5^P5I?[/D]UKI32O"UIK&FWEU?V*0QF.\NCIRB&&0N\R"'<[*J EOFP/=**
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M_@CIX\$>D^/+'Q%_POGX:>$?'5SK.BV^E0VJ/:ZC<Q//,MI+YC2E#N7<T,8
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M;K?B;XXVFE7GB6-0,O:VJVDPM@3N53<2+G&< $9 /K.BOD?PU_P5H\$>.O\
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MA+6+>XEA;2XKUH'.I7#>2S_NXT2)'C,C*6"$ _1*BOE']FO_ (*V_ SXQ_\
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MC\7;R73_ (;>-?#/Q%B\0Z?)JRIYBZ3>D6T!M[AUXC<;ED<[5! 9EW?VB?\
M@I/\:D_:OUC]AS_@G_\ LE)\7O'W@[1[+4_B5JNM^,8]!T'PC%>*7LX)[EH9
MI)[J:,>8L$<>0A#[CM<* ?8%%?+_ .Q+_P %$_$/[1OBGXC_ +/W[07[/=W\
M*_C+\)X;:Y\6>!9]?BU.UN[&YC:2UU&POHD1;FWE",#\@:)OD<9QGYL_9_\
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MEGC/P_?7OPR^"G@.#3?B7>V%A)=?V'9Z_P"%+"QAU6:.-6;R+>2/+. 2"Z
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M&WC75+=9]?NX 1E3&@^RD<9CDC('-?K;10!^*7Q'^&7P!_9)_P""M?[0T?\
MP4/_ &K?C5\#_#/QCUS3?%'PH^(/@3XGZOX;\/Z^@M#'=V%W-8L(EN[9P @F
M(/EY.0&3?]3_ /!,SPA_P3!\0?&3XM_&G]AW]K+XA?&7QE!X+M-&\;>+O&/C
MC5?$,*VCM-+:V\=[>KLE93#(=L<C^6K<A=XS]]:]X=\/^*=,DT7Q/H5GJ5G+
MCS;2_M4FB?'3*N"#^5/T?1=&\.Z;%HWA_2;:QLX%VP6EG L4<8]%50 !]* /
MP\\(?"WXG^,O^#7K]E3XP_"[X?7_ (MF^"WQ-TCXBZUX8TFW,UUJ6F:;KNI"
MZCBC'^L*I-YA']V)CVKU7_@L-_P46_9&_P""L/[#=G_P3O\ ^">WQ1M/BC\2
M_CKXAT&WTG1] L9Y)?#UG;ZE:WUSJ&H!D7[%'"EOL<2%6 D)QM5B/UWK-T?P
M9X/\.ZE=ZQX?\*:;8W>H/OO[JSL8XI+ELYS(R@%SDDY.>M 'Y?\ _!0?]I[X
M;_L7?\' /P#^+7QG?4(_"%M^SSK6G^)/$T=C+<IH4$NH%$O[KRE9D@$PAC>7
M&$\_<Q"@FM:\_:!^$W_!47_@N3^SMXZ_8K\5Q^,_!7[-/A3QAJGQ$^(6A1N^
ME"ZUNPBL+32X[HJ$FFRGFE4+#8SX.4?;]3_$#]A[Q?XR_P""J7@7]OF/Q=I*
M^'O"OPAU7P?>^'YHI#=7$]W=K.LJG&SRPH*D$YR>E?0_A[PQX:\(Z:-&\)^'
MK'2[,.SBUTZT2",,3DMM0 9/<]Z /@W_ ((B(@^//[<L@0;C^U]KH+8Y(%K:
MX'ZG\Z/^"$RJOCO]MP*H _X;@\9G '?RK*OT HH _$KP?^R_\5OVR?\ @B__
M ,%$/V>O@AI,FH>*M6_;$\;7FCZ9"?WE\]AJ^D:@UM&.\DJ6K1H.[.H[U+X5
M^+O_  0V^*O[.6[X]?\ !73]I;PV^HZ$=-\<?";QI^T+XH.HV4KQ&*[TFXTM
MRTEP 3)"R+'(D@X&X'G]L*R9O ?@>X\2IXSN/!FDR:Q&H5-6?3HC<J , "4K
MN''O0!^;'[4/@/X9?#/]L7_@EO\ #CX-1:BO@[0KK7K'PI'K)D-TFG1>%X$M
M5F\P!Q((E0$, 01@@$5W_P#P5C)'_!2C]@-@<'_A;_B 9'I_8QK[^HH _+?5
M/VO/V>/^";W_  77_:-^(_[;GQ"'P^\.?%3X;>"Y? 7B'6-,NFLM6-A;S6]U
M''-%$Z^8DAY0G..:_4+3=1LM8TZWU;3;A9K:Z@2:WE7HZ, RL,^H(-344 ?A
M_HGPQ_9L_8Y_X**_M*?#+_@HY^V1\<O@1%\2_BQ?^/OA=XL\)_%K6/#/AGQ1
MINH'S)(3+9,L!O+5\0OYI5]NP#*J"?K7_@GMX_\ ^"1/[/ND_M ?MK?LY?MA
M>,?']AINEZ4WQA^)OC_Q=J>N(R64-U]DABOKY,W3I&[H$A:3[\,8^8JM??OB
M+POX9\7Z:=&\6>';'5+-G#-::C:)/$6'0[7!&1]*GTS2],T6PBTK1M.@M+6!
M-D%M:PK''&OHJJ  /84 ?A?9?#O]I[P+^T!;?\'3OC']FW3$\,ZKKTDVL?!^
M'P^AUO1OA]-9QV</B<.#\VJ"%?M$JX.;>0_.B;@GT)_P6I_:K^&6A?'K]@+]
ML'P4D_C;P4/B5J.O17?ABR>^>XTA]+B>6]ABC!>7RK=GN-B@O^Z( W<5^J=?
M-G[9W[$?C3]IK]JK]FWX_P#AOQEI>G6'P2\;ZEK>M6-]'(9M0BN;'[,L<!0%
M0P;YCN(&* /C[]N_]L?]G+_@K!^TW^RE^R9^P'\3++XDZGX5^/\ H7Q2\<>(
MO"\<DUGX7T/1TG=VN+C:$AFF:<1HA.X. K*"Z!O*OC%\,O@1^R;_ ,%@/V@=
M3_X*$_M2_&KX)>#OC5=Z-XA^%7Q&\!?$S5_#FA:T\-EY%YIU]/8,(UNH''[L
M3$8CW'*^8@?]F=#\*>%O#$EU+X:\-:?I[7T_G7K6-FD1N)/[[[ -[>YR:EUW
MP_H/BC3)-$\2Z)::C93 >=:7ULLT3X.1E'!!_$4 ?G__ ,$UO"/_  2[\1?'
MGXH_&C]B/]KKXB?&CQS9^ (=$\8>*O&'CS5?$<$-A)*\UO;)>WJF.1@\3L$C
MD?RPS9"[^=O_ (-ED1?^"''P(4* #I^N9 'KK^I9K[FT70]$\-Z9%HOAW1[6
MPLX%VP6EE;K%%&/154 #\!5J@#\8?^"<6I_\$ZF_X-@_@%X0_P""H&K1Z=\.
M_$WBS6M-L-9F6]0Z;JX\0Z[<6MPMS9J9+)E%O*%G)5 2$8XDVMTG[$GQ[B^'
M?_!4CX6?LS_\$X/^"E?Q!_:;^#_B70-;N?B]HGC76_\ A)8/ =O!:[].N8=8
M\E3#YMQ^X6W+-TVMDNA3]=KRSM-0M9+&_M8YX)4*2PS(&1U/4$'@CVJCX9\'
M>$?!5DVF^#O"VFZ3;O(7>WTRQC@1F_O%4 !/O0!^''[,?PX_9,_8P^./QM_9
M6_X*4?MU_'KX ^*A\7-;\2>#;S1OC/K?AGPUXPT"^E$UOJ-JULZVSW'5)@3O
M#!5)9D=4_1'_ ((]^!_^">]IX:^)WQ<_8 ^.?C/XE6GBGQG%#XX\;^,_$&HZ
MK+J>J6MJF&CN[]%>Y58IXU,J%T)&T,2A ^MO$W@[PCXULETWQCX6TW5K=) Z
M6^IV,<Z*W]X*X(!]ZO6=G::?:QV-A:QP01($BAA0*B*.@ ' 'M0!\3?\%_\
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M)9O@AX0))Y)\-6O_ ,;H Z^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#6+6^M]Y7S[.X65-PZC<I(R*M5^0W[.WPEUGX-?\%)?@Y\3/^"<O_!*_X]_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&E?'/X/W<6J^#/COHOARUAN(M7\I8[J:330WD-:W(4>;:!@I547=@$-]744
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MI\/^&Y/#EYK4_AR/5])\3:(TWGC3]1LG>,N%E^9)D<.A.<,5C*=#^RY\!O\
M@I#X;^(]YX__ &Q_V[?#/B[2WT&>QT[P-X%^%\>CV-O=221,M^]U+<3W$TB*
MCHL>5C'FL2&.,?2-% 'Y_P#Q0_X)X?\ !8/XW_![7?V4?BY_P5<\$ZMX \5Z
M-/HWB;Q+#\"(K;Q)>Z9/&T5Q;@I??9(WDB9HS,L88;BP4$8K[4^ _P &?!7[
M.?P1\'_L_?#>&XC\/>!_#%AH.B)=S>9,+2TMT@B\Q\#>^R-=S8&3DXYKK**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>biib-20201231_g3.jpg
<TEXT>
begin 644 biib-20201231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY7_ ."L7_!6+X-?\$B_@UX<
M^-?QK^''B?Q+8>)?$XT2TM/"RVYFBF-O-/O?SY8UV;86'!)R1Q7U17XP_P#!
M[1_R8+\*/^RP+_Z:KZ@ _P"(VC]@7_HU'XP?]^]*_P#DROJK_@G-_P ''/\
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M\$W%OXSO=#&C66L-?(RP0V\@E\QHHSEO/(V[>-O7FOKJORA_X,V_^41^I?\
M98-9_P#233Z_5Z@ K\B/C;_P>/\ [ 'P;^,?BKX1P? /XF^(E\+^(KS2?[>T
M9---GJ!MYGB,\!DNE8Q.4+*6 )4@X&<5]G?\%K/VUQ^P%_P3/^*/[0>E:L+3
MQ$-";1_!K*^)/[7OC]FMY$]3$7:X(_NV[5_++^R7_P $MO'/[47_  33_:)_
M;[TK[6$^#EQI*Z3:Q+E=2!D\S5<G''V:TDAG//1J /["/V7_ -HCX??M:_L[
M>"OVF?A7<2OX?\<^&[76-,2XV^;"DT88PRA20)8V+1N 2 Z,,G%=W7XQ_P#!
MF1^VO_PM;]C;QC^Q1XHU;?JOPKU[^TO#\,DG)T;4F>0H@/41WB7#,>@^U1CZ
M]]_P<]_\%>?VR?\ @E3_ ,*/_P"&2=:\/V?_  GG_"2_\)!_;N@I>[_L7]E>
M1LW$;,?:YL^N1Z4 ?J]17\ZP_P""_P#_ ,'!/[8O[)UG\3/V&_V6;E-+\#:.
M_P#PL[XIZ7X'AOC?ZC'NEF%K!-O@2**%H]T<<<TO\;% X4?2_P#P;9_\'"?Q
M\_X*.?%S7?V//VS;31KOQ?:>'I-;\+>+M&TY;(ZE##)&EQ;7$$?[OS0)5D1X
MU12B2 KD L ?<?\ P4%_X+2_L&?\$Q?'V@_#7]K7QQKFE:KXDT=M3TJ+2O#5
MQ?*]NLK1%F:)2%.]2,'FOH[X1_%#PC\;OA3X8^-'P_NY9]!\7^'K+6]$GG@:
M)Y+2Z@2>%F1N4)CD4E3R#P:_D;_X.$?BU_P4A^*W[7=G+_P45^&?_"-7&E6^
MH6?PZ7^QH[/[9H8U";RIL([>9D_Q'!]J_2?_ ((]_M:?\'(6I^+_ -GGX6>/
MOV9OL_[/1T_0=/;Q'_PAENG_ !3*VD207'V@2[N;<1MOVY.<XYH ]A_X*=?\
M'/OCO_@GS_P4>UW]A#1_V/M(\46FCW.BQ+XDN?&4MK)+]NLK6Y),*VK@;#<%
M1\YSMSQG _7VOY_/^"U'_!=3]N#]C[_@L%XH_90^$>G_  [?PKIMYX<2V?7/
M EM>7N+O3K*:7=._S-\\S[?[HP!TK^@.@ KR7]LW]N3]ES_@G]\';CXZ?M7_
M !7L?"V@QR^1:><K2W6HW!!*V]M!&#)/*0"=J@[0"S%5!8>M5_)1_P '+/[4
MOQ3_ &W?^"Q7B;X%:?JLUSHOP]UBW\$^!]$\X^5%<GRENY-O3S);QG#/C)2.
M)3D1B@#])/'_ /P>X?L@:3XCFL?AI^QI\1-;TR-RL6H:MJ]CI\DN#][R4,^
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M]H_]G*XUSP)JVOV,6M07W@#297L;*:X1)9)8=*:.[M@B,S%I0 F,MP#7[X4
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MD"LW)(5C\IY[]I__ (.%/^#C?]B'XX^'_'?[6WP9T?P-X?\ %0>_T'X=^(/
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M'_!8?3]5\.V\[6.D_#K7+C7I(B0J6S+%"F_U!GE@ ![X/:N _8NUSP]\"?\
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M^QSJ^EZ]^R-\+=:T348+RSNOAWHLEM=6TH>.5#8PD,K#@@^HKTBOR1_X)/\
M_!K/_P .P/VVO#G[8W_#=/\ PG'_  C^GZC:_P#".?\ "L?[,\_[5:2V^[[1
M_:<^S;YF['EG.,9&<U^MU 'X^?\ !UE_P6!_:E_X)\^'?AW^SQ^R+XL/A37?
M'UI?ZEKWB^"U22[M;*!XHH[>U,BLL;2.\A>0#>HC3:5W$U\I?"3_ ()8_P#!
M4[X[?\$X'_X*1_M%?\%[/B#X5\-ZO\/+GQ9<Z,WBS6M30:=]G>589Y3J,$:N
MZ#88E1@K-L^8\5^K'_!:G_@BG\(/^"Q?PET'0?$7CRY\&>-_!DUQ+X0\7VU@
M+M(DG">?:W,!=/.A<Q1-D.K(R!E)!='^%OV5O^#1#XF^&K>+X>_M@_\ !176
M_%/PQTYY+BP^%WAA;Z#2[F[.YHY9TEN0B(LI#LD<8=^0)4SF@#XD_P"#-B66
M/_@K=JB1R,H?X/:RK@'&X?;-/.#ZC(!_ 5QW_!VS_P IH_&'_8G^'_\ TA2O
MU^_X(V_\&T'_  Z3_:XN?VI_^&U?^%@?:/!][H7]A?\ "N/[*V_:);>3SO/_
M +1N,[?(QLV<[\[ACG(_X*V_\&NO_#TK]M+6/VOO^&Y/^$%_M;1]/L/^$>_X
M5G_:?E?98!%O\_\ M*#=NQG'EC'3)ZT ?0__  7\\+>'_"O_  0V^-_@[0=)
MAM],TGP)9VNGV:1C9!%#>6BQ*HZ *%7'I@5^<'_!C'_S=%_W)/\ [GZ_9?\
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M_M*?;MSG'EG/3(ZT ?#'_![B#_PV?\&VP<'X87&#_P!Q&:OW4_X)9ZSI.O\
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MP3'_ &?KO]H#]I?Q:;:#+0>'_#]CM?4=>O N5M;6(D;FZ%G)"1J=SLHK@?\
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M!E_+:>*O NJO?:3>VUSXB:ZA-M.\:&5 DX7.W&00I*@&OG#_ (,;O!?AB_\
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MJ\^(?PZTR\\?>#]:M[BZTO4KOR\-<HT,JLF[&XQ.DB[F)4H,*/T6_P""(_\
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MZMI>F_\ !7>>UU'48()+[X4:U!91S2A3/+Y]E)L0'[S;(W; YPC'H#7[S_\
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M;6#)Q9B_C3<P'51*\)/IC/:F_P#!$?\ X-Z?^'.'QH\9?%[_ (:\_P"%C?\
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M>,].^)_AS2-%\ >"39>.IKO4XH$T2\MY)/M376XCR2[[I@7QN656&0P)[_\
MX+7?"+_@GI\9OV'M0\)_\%*_%!\-> I-=LH[#QG;Q/\ :/#VJRL8;:[B=(Y/
M*.9&C9G0Q[)&$F%)(_&3PU_P0%_X(?\ P)N_^&B/VB_^"['@?QQ\-=+S?OX4
M\*3:;;ZCJD2'<+59;?4;F:9F V,D%NLIR=IC/( /F'_@AWXF\(>-/^#BOX<^
M,?A]9"VT'5OB=XBO=$MQ%Y8BLY;/47A3;_#B-E&.V,5]A?\ !\%_R7SX!?\
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M-YC.S#:$_<;]BC]F[_ACW]D?X<?LL?\ "9_\)%_PK_P?8Z%_;O\ 9WV3[?\
M9XEC\[R/,D\K=MSLWOC.-QKX4_X+?_\ !MO\._\ @J_\2K#]I/X8_&1?AY\2
M+;2X].U>XO-(-[I^N6\6?),JHZ/#,@8KYJ[]R*J%/E#  _.C_@K!_P $=/\
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M]I>![OP[_8?_  KG^R?+\^ZM)_/\[^T;C.W[+MV;!GS,[AMP0#]1Z_.#_@[
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MX0#G!:5,9X(_.G_@A9^Q1_P6-_:O_94UK5_^";W_  4X\.?#/PUH_C">'7O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#)\'>.O"/Q!TN36_!>O0:C:0W<MK)/;DE5FC;:Z<]
MP>#6M7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^-/^"F/[&'[5/Q1_:+^!G[=W
M[&,_@S6/'7P+N-=CC\!_$.XFM]-URSU6UCMYS%<PJ[6MVBQ_(Y7:2PW$!-K_
M &77A_[6?[.W[5'Q=\1>'_&O[+'[<VI_"+4=&MKBWO\ 3I_!-GXATC68Y6C9
M3<6EP\3K)&4.V2*:-L.P.0: /CO_ ((Z_P#!3+Q!8Z5\&?V"_P!K+]DCQ!\,
MO$OC#PKJ-Q\)_%C:Q:ZKHWB^*R\R>\2&>':]K.D>7,$BD[5&6!:,/ZK_ ,'(
M7_*$KX^?]B_I_P#Z=K*N!_X)/?\ !,KXL-IWP3_;,_;:_:!UWQ9XE^''A'4;
M7X8_#V;P=#H5CX+?4 T-[))&K/->73Q#9YDK*%5N$R%*^D_\%3?^":/[8W_!
M1SPQXD^"7A3_ (*-6'PZ^$_BO1+2RUKP(_P7M=8FEEAG6=IAJ#7T$R;GCB.P
M  ;#R=QH ^I?V>_^2!^!_P#L3],_])8Z^4/^"I'P!_X+&?&+PSXTTO\ 8@_:
M=^'^B>$=2\.?9D\'77AIH=>O4,!6[@M]5D\Z&WEF!=8I#;_NV=3N7&X>L?L:
M?LQ?MF_ ?X9Z_P##G]I7]O.V^*?GZ3:Z?X+U#3/A5:>&Y/#B10RQ,V(;F?[6
MS;H&!<KM,'?><>#^)_V#O^"XOC7PU=?![Q%_P6=\,Q>&M0M6L[_Q7I/P&M;3
MQ%);,"KA&2Z\F"5D)7SHP&0G>H! H ]1_P""'_Q._9V^+G_!*SX-^+?V5OA_
MJ'A7P5'X;DL+#P[JU]]JN;*XM;J:WNUDG"H)V:YCF?S0B"3?NV)NV+\O?\'.
M5U\:?M?['NC?!:?3HM6OOVH-(BT.;7;8SZ?!KC(T>FSW$>0)%CDDDDVG@A6!
MR"17NW[0/[)/Q(_8._X(U7G[&'_!+G2?$S^+M'TFST'P%>Z?=@:@E[>ZI%]J
MU2:95"Q[3<7-U*X"JJA@H VBO2/VLO\ @G;H7[:?[$6@_LJ?&GXM:VOB;PU%
MH^HZ'\4-- &I6'B33HU\K68PQP9&D$A92>5FD4,I(< 'R5^UC=_M]_\ !'KQ
M-\)/VG=6_P""AGC'XX>!_%?Q1TGP=\5_!7Q#T/38E*:DSH-1TMK2&)K1HF4D
M6^64[E!8JIK]&?CU\:/!'[.7P1\7?'[XE7_V;0/!?AN]UK6)@1N%O;0O,X4'
MJQ"85>I8@#DU\8Q_\$J/VU/VEOBQ\.?$7_!3C]O?1OB7X*^%'B>V\2>'O W@
MSX;1Z##KNLVP(M;_ %.3SY=_EEF/V>-5C)<C@$@^[_\ !3K]AW7?^"C'[)^H
M_LDV7QPF\!Z/XCUK3I/%NH6NA_;I]0TNWN%N);"/_2(?(:5XX@9LN%564QL&
MX /#_P#@WJ^#'C?2OV,M5_;4^-E@(_B+^TWXROOB/XE9@=T%I=N?[-MD)Y\E
M;7;+&N/E%R0.!7-_\&SOGM^QW\6Y-:"?VZ_[3_C0^)O^>AO_ #K??YG??M\O
MKSC;7Z%>&_#NA>#_  [8>$O"^EPV.F:7916FG65NFV.W@B0)'&H[*JJ !Z"O
MASQI_P $LOVP/@M^T-\2OC/_ ,$ROVYM(^%>C?&?6#K7C[P9XL^'B:]:6>MN
MFV?6-.8SQF*>7[[Q.&1GY)*A$0 YG_@A"9A^T%^W<FC[/[ '[7VOFS\@GR_M
MI5/MF.V[=Y6<=_PK]%6944N[  #))/ %?-_[(_\ P3HT/]BO]AK6?V2?@O\
M&'64\2^(;;6+W6OBIJ%N)-2O/$>HQMYNM21JZ@R+(8V2/>"%@C4N2"YYK]H+
M_@GA^TW\>/\ @E_#^P%/_P %#-=T[QC>:5!IOBWXS-X4\^]URU$C-<1O;?;4
M:+ST(C8K<$[-RDL&(H ^?OCMXIO/^"[_ .U7X=_9N^ BF7]F3X'_ !#M->^*
MWQ01<VWC/Q!8,6M] TI^D\",VZXN%^7IL88B,WZ;U^??[//_  2X_P""IW[,
M'PV\,?!/X/\ _!8KPEHO@KPK;0VFF^'=-_90TF&,6Z'++O\ [2+%W.YFE;<[
M.[.Q9B2?T$H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_R1
M/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH ****
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M_EDZ'_\ (5'^J&9?SP^^7_R(?Z\Y3_)/[H__ "1_0Y17\\?_  _-_P""IO\
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M_EDZ'_\ (5'^J&9?SP^^7_R(?Z\Y3_)/[H__ "1_0Y17\\?_  _-_P""IO\
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MDS[>HHHKP3Z0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#PS_@IM_P H^/C'_P!D^U+_ -$M7\T5?TN_
M\%-O^4?'QC_[)]J7_HEJ_FBK]!X/_P!SJ?XOT/S#CO\ WZE_A_5A1117UY\,
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[4_\ !LM_R:M\0/\
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M*W2WL[2WC"1PQ(H5$51PJA0  .@%?G=^W';VOQ@_X.$/V0/@MXX@2[\.^#O
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MVNH4FMYXSE9(V 96![@@@U\ _P#!QS\6?!&L?\$2O'Z>$];M]9E^*">'M(\
M0Z;,)&UZYO=3LY8$ML?ZTM DDP"YRD9(K[A^#WA+4/ 'PD\+>!-6N3-=:)X<
ML;"YF+[B\D-ND;-GODJ3GO0!T=%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!X9_P4V_Y1\?&/_LGVI?^B6K^:*OZ7?\ @IM_
MRCX^,?\ V3[4O_1+5_-%7Z#P?_N=3_%^A^8<=_[]2_P_JPHHHKZ\^&"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]J?^#9;_DU;X@?]E!_]L;>O
MQ6K]J?\ @V6_Y-6^('_90?\ VQMZ^>XH_P"11+U7YGU'!_\ R/(>DOR/TGHH
MHK\P/V **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OST_P""MW[1/[?W@#X6^.O!$G[ EIXN^'<GB?PVWA?X@>%_B;I]M,%.K::R
M07NGWWE2)(UR#")(7D3$B,P158U^A=9/C;P+X-^)/AR7PAX_\,6.L:7//!--
MI^HVZRQ/)#,D\3E6&,I+'&ZGLR*1R* /CS_@E9^QQ^T%\)_VA_VA_P!M[]HC
MX4>'?AAJ?QZUS1)['X2^&-9BU"+08-,M)8#<7-S JP2WER\SRR&(%<Y.YBYV
M_/?[>4'_  5[_:'_ &X/@/\ 'SP-_P $=]5?1/V?O'FNZC [?'7PLI\3VUU
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M>>--?\):)J"W=MX:@D4);:=YZ_+/+&N[?(A*G< "=I9L_P#9?_9&_:%\4_\
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MM#O_ -IOX,V_B&_\->=_PCVLVVK7NFZAIHEV^:(+NQFAGB#;%R%< [17LM%
M'R)_P2Q_X),_L\?\$^/ACHGB2#X/Z+'\7)?#RZ=XN\;#5+O4[FX'F%C%!<7C
MN\,)PA,<0C0E1E>!6]^U[_P1P_X)T?MX_$:7XK_M6? >_P#%&N3:9#I\TZ>/
M]=T^%[>$L8T-O97T,)P6)W;-QXR3@5].T4 >!?LN_P#!,/\ 8D_8Q\%>,?AW
M^SE\)+_0]'\?64=IXJL[OQMK.I?:X8XYHD17OKN9K?"7$PS"4)W G)52/%-(
M_P"#;#_@C'H%DNF:%^R?J]E;(25M[3XO^+(T!)R2%75 .37W110!\K_M8?\
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M\9:CHDGB"R10BV]^+*>-;I0@";G&_8JKNVJH'U-10!YYX1_91_9W\ ?LT_\
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M ##_ %LS_P#Y_?\ DL/_ )$_6C_B*,_ZL:_\R;_][*/^(HS_ *L:_P#,F_\
MWLK\EZ*/]6\E_P"?7_DTO\P_ULS_ /Y_?^2P_P#D3]:/^(HS_JQK_P R;_\
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M(++90@CP1JV"(Q_SYRU_+97WO!O\&MZK]3\VX\_CT/27YH****^S/@ HHHH
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% 'R/_P %N/$N@ZA_P2_^*%I9ZI%)*\>C[44\G&LV)_D*_GMK^AS_
M (+@65G%_P $N?BC)%:1*PCT?#+& 1_Q.;&OYXZ_1N$/^1;/_&__ $F)^5<<
M_P#(VA_@7_I4@HHHKZH^,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K]V/^#>CQ#HFF?\$]8[:_U*.*3_A-M3.QSSC$-?A/7[P?\&[]I:3?\$\8
MWFM8W;_A-]3Y9 3TAKYKBO\ Y%7_ &\OU/KN"O\ D<O_  O\T?;W_"8^&/\
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M_4_-N//X]#TE^:"BBBOLSX **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1\?&/_LGVI?^B6K^:*OT'@__ '.I_B_0_,.._P#?J7^']6%%%%?7GPP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?M3_P &RW_)JWQ _P"R@_\
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M#K96ENCIO<(0[L6 16!P1N*_27P!UC]E?XH_ OXY_#7_ ()R^$O$G@?QY?\
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M_CT^-_\ UT\-_P M4K\DZ_6S_@UU_P"/3XW_ /73PW_+5*\/B3_D2U?^W?\
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MTNSE)K[FVB\5C\3C7>K9ONHQ3^])/Y;!11174<84444 %%%% !1110 4444
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MT?\ #+__ %/'_E,_^VUZQ11]=Q/\WX+_ "#ZCA?Y?Q?^9Y/_ ,,O_P#4\?\
ME,_^VT?\,O\ _4\?^4S_ .VUZQ11]=Q/\WX+_(/J.%_E_%_YGD__  R__P!3
MQ_Y3/_MM'_#+_P#U/'_E,_\ MM>L44?7<3_-^"_R#ZCA?Y?Q?^9Y/_PR_P#]
M3Q_Y3/\ [;1_PR__ -3Q_P"4S_[;7K%%'UW$_P WX+_(/J.%_E_%_P"9Y/\
M\,O_ /4\?^4S_P"VT?\ #+__ %/'_E,_^VUZQ11]=Q/\WX+_ "#ZCA?Y?Q?^
M9Y/_ ,,O_P#4\?\ E,_^VT?\,O\ _4\?^4S_ .VUZQ11]=Q/\WX+_(/J.%_E
M_%_YGD__  R__P!3Q_Y3/_MM'_#+_P#U/'_E,_\ MM>L44?7<3_-^"_R#ZCA
M?Y?Q?^9Y/_PR_P#]3Q_Y3/\ [;1_PR__ -3Q_P"4S_[;7K%%'UW$_P WX+_(
M/J.%_E_%_P"9Y/\ \,O_ /4\?^4S_P"VT?\ #+__ %/'_E,_^VUZQ11]=Q/\
MWX+_ "#ZCA?Y?Q?^9Y/_ ,,O_P#4\?\ E,_^VT?\,O\ _4\?^4S_ .VUZQ11
M]=Q/\WX+_(/J.%_E_%_YGD__  R__P!3Q_Y3/_MM'_#+_P#U/'_E,_\ MM>L
M44?7<3_-^"_R#ZCA?Y?Q?^9Y/_PR_P#]3Q_Y3/\ [;1_PR__ -3Q_P"4S_[;
M7K%%'UW$_P WX+_(/J.%_E_%_P"9Y/\ \,O_ /4\?^4S_P"VT?\ #+__ %/'
M_E,_^VUZQ11]=Q/\WX+_ "#ZCA?Y?Q?^9Y/_ ,,O_P#4\?\ E,_^VT?\,O\
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MU/S;CS^/0])?F@HHHK[,^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K];/^#77_CT^-_\ UT\-_P M4K\DZ_6S_@UU_P"/3XW_ /73PW_+5*\/
MB3_D2U?^W?\ TI'T7"?_ "/Z/_;W_I,C]9****_*S]F"BBB@ HHHH **** /
M*/VZ_P#DSCXE_P#8G7O_ **-?AM7[D_MU_\ )G'Q+_[$Z]_]%&OPVKZK(/\
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M'?V0/C[\=/#,_C?P)X/A70K>X^SOK>KZK;V%JTW_ #S22X=!(WJ%SCOBN?\
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MNC_A1WQ1_P"A7_\ )V#_ .+H]O0_F7WH/J]?^1_<SDZ*ZS_A1WQ1_P"A7_\
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MGS@4444 %%%% !1110 4444 %%%% !1110 4444 %%>G_ +]G6R^+7AGQ/\
M$WQQ\1+?PGX.\'QVQUO6I-/>\F,MPY2"""W0J979E/5E"CDG%=1^VI\)?V>/
M /CG7KCX2?%DRZC;:\+:Y\%2^%I+0641C8F2*<2/'*@*J"/E;]X#@@&L'B*?
MM?9ZW]'Y?YG2L+5]A[5V2]5=[[*]^G^6S/"**^D_A1\'/A'\(O@#H'QZ^,?P
MEU'X@^(/'-]=Q^"?!-K?36T"VEJP2:]N&@!E?YR J#@@@G.<KY9\=/%7PZ\=
M^)K&+X:?L^?\(#>1*UOJFD6^KW-VMS.6&QE6X&^(X.TH,@G![T0KJI-QBG9=
M=+:?._EL%3#.E34I25W9VUOKMTMMKOL>?T5]:>/?A]^S_P#LAW2?"'6/V7+K
MXJ^,--TRWN/'>MW>KWD%EI<\T2S?9($M1C"HRDRN<_J%^?X/$7P1U#XU?\)+
MJOPYU33_  /+?&63PSIFL&6YAAV<0I<RC+?/CYF&=OO2I8A54Y1B[='IK^-]
M>E[#K85T6HRDKWLUKIZNUM.MFSBZ*^DOVJO 7[.$G[*_PZ^.OP)^#USX3E\1
MZYJEG>Q7?B&XOY98[9@BEC(VQ22"<(HZXR<5\VU=&JJT.9)K5K7RTZ7,Z]!X
M>IRMIZ)W6UFKK=(**^G/V9_AW\#;;]D/7?CA\0OV9Y_B1K5MX_BT>SL+;Q#?
MV3QV[V@E+8M2=V&!ZH3\W7C%>2?'_P 9_"'Q7JUE:_"S]FX_#A[!94U2R?Q+
M>:B]TY*[2WVH Q%0&&!UW<]!4PK\]5P47II?2WYW_ NIAG3HJHY+572UO^5O
MQ//J***W.8**** "BBB@ HHHH **** "BBB@ HHHH *_6[_@C!_R9BG_ &-5
M_P#RBK\D:_6[_@C!_P F8I_V-5__ "BKQ\\_W+YK]3W^&_\ D8_]NO\ 0^LJ
M***^//O0HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O
M^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@#E?CK_ ,D1\8_]BKJ/
M_I-)7X$U^^WQU_Y(CXQ_[%74?_2:2OP)KZ?A_P#AU/5'QO%/\6EZ/] HHHKZ
M$^5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK0\*^%?$OCCQ'9^$?!
M^AW6IZIJ$ZPV5A90F26:0]%51R?Z#FO;_B+_ ,$[?CYX&^&NG>-$\,PSWD.D
MWM]XKTZ/Q#I\DNFI!-(,K&DQ=P(D#/M#%6W*<$$#*=:E3DHRDDV;4\/7K1<H
M1;2WLCP"BO5OV=?V9[;XQ>'?$GQ1\?\ Q#@\(>!_"$4)USQ!-8M=2--*VV*W
M@@4J99&/N N03U .A\6OV8/!>E?" _M _L__ !<;QGX5M-573=>6\T5["^TF
MX<9B,L1=PT3]!(IQN(7&<X3Q%)5.2^NVSM?M?:Y2PM=TO:):6ONKV[VWMYV/
M&:*]\_91_8X^&O[24FD:1K?[4^B^&M=UV[G@TWPU%H<]_>L8PS;G"O&D8*HS
M L_3WXKQ#Q'I'_"/^(;_ $'[1YWV&]EM_-V;=^QRN[&3C.,XR:<:U.=1P6Z\
MG_3^1,Z%6G3C4DM'MJOTVWZE*BOHF3]B'X:W?P*\6_%CPE^U?HOB'5/!VD6U
M_JF@:)H$\D:"9PBH;IW1<YW?=5ONGI7SM12K4ZU^7IY-?F%:A5H6YUOJM4_+
MI<**ZSX,_#SPO\3?&8\.^,?BKI'@W3TM))YM9UE)'C&W'R*D8+.YSPHZX-=C
M^UC^S'X=_9QF\(W7A'XM)XQTSQ?X=75['4X]$>Q41,Y50$>1V((&<D*>?NTW
M6IJHJ;W?D_SV!4*LJ+JI>ZM]5^6_X'D5%%%:&(4444 %%%% !1110 4444 %
M%%% !1110 5^B?\ P03_ -1\5?\ ?T3^5_7YV5^B?_!!/_4?%7_?T3^5_7FY
MO_R+I_+\T>OD/_(UI_/_ -)9^AM%%%?$GZ*%%%% !1110 4444 >4_MS*&_8
M]^)*L.#X0O<_]^S7X@_98/\ GG^IK]O_ -N3_DS[XD?]BA>_^BS7XB5\CQ%F
M.88+$0CAZTX)K51DUU\FCYS.J<)UH\R3T_4C^RP?\\_U-'V6#_GG^IJ2BOGO
M[>SS_H*J?^!R_P SQ?8T?Y5]Q']E@_YY_J:/LL'_ #S_ %-244?V]GG_ $%5
M/_ Y?YA[&C_*ON(_LL'_ #S_ %-'V6#_ )Y_J:DHH_M[//\ H*J?^!R_S#V-
M'^5?<1_98/\ GG^IH^RP?\\_U-244?V]GG_054_\#E_F'L:/\J^XC^RP?\\_
MU-'V6#_GG^IJ2BC^WL\_Z"JG_@<O\P]C1_E7W$?V6#_GG^IH^RP?\\_U-244
M?V]GG_054_\  Y?YA[&C_*ON(_LL'_//]31]E@_YY_J:DHH_M[//^@JI_P"!
MR_S#V-'^5?<1_98/^>?ZFC[+!_SS_4U)11_;V>?]!53_ ,#E_F'L:/\ *ON(
M_LL'_//]31]E@_YY_J:DHH_M[//^@JI_X'+_ ##V-'^5?<1_98/^>?ZFC[+!
M_P \_P!34E%']O9Y_P!!53_P.7^8>QH_RK[B/[+!_P \_P!31]E@_P">?ZFI
M**/[>SS_ *"JG_@<O\P]C1_E7W$?V6#_ )Y_J:/LL'_//]34E%']O9Y_T%5/
M_ Y?YA[&C_*ON(_LL'_//]31]E@_YY_J:DHH_M[//^@JI_X'+_,/8T?Y5]Q'
M]E@_YY_J:/LL'_//]34E%']O9Y_T%5/_  .7^8>QH_RK[B/[+!_SS_4T?98/
M^>?ZFI**/[>SS_H*J?\ @<O\P]C1_E7W$?V6#_GG^IH^RP?\\_U-244?V]GG
M_054_P# Y?YA[&C_ "K[B/[+!_SS_4T?98/^>?ZFI**/[>SS_H*J?^!R_P P
M]C1_E7W$?V6#_GG^IH^RP?\ //\ 4U)11_;V>?\ 054_\#E_F'L:/\J^XC^R
MP?\ //\ 4T?98/\ GG^IJ2BC^WL\_P"@JI_X'+_,/8T?Y5]Q']E@_P">?ZFC
M[+!_SS_4U)11_;V>?]!53_P.7^8>QH_RK[B/[+!_SS_4U^G/_!#>-(_@'XO"
M+C_BK_7_ *=8:_,JOTW_ ."'7_)!/%__ &-__MK#7L9'FN:8O,(TZ]><XV>D
MI2:V[-GI933IQQJ:26C/MFBBBOMSZL**** "BBB@ HHHH ^>O^"J_P#R8-X^
M_P!S3/\ TZ6E?C)7[-_\%5_^3!O'W^YIG_ITM*_&2OK<A_W.7^)_DCX;B?\
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M_P#Y15X^>?[E\U^I[_#?_(Q_[=?Z'UE1117QY]Z%%%% !1110 4444 %%%%
M!1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKYZ_8+UB_L/@YJT%
MMH%Q<K_PG&LGS(B,9^TMQS7MO_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_W
MTM'_  DNK_\ 0H7O_?2T 9OQU_Y(CXQ_[%74?_2:2OP)K]W_ (X>(M5D^"WB
M^-O"=XH;POJ +%EP/]&DYK\(*^GX?_AU/5'QO%/\6EZ/] HHHKZ$^5"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#TK]D3X[V'[-G[0&A?%[5_#\NIV6G
M_:(;VUMI DWDSP20N\3'@2*)"PY&<8R,Y'T#XO\ V6/A-^T)\,_ .@_LP?'N
M2;6(]$UBX\,^%O%^EO:WVK0B]N)9D6>,M$9E(D3;QN";LA<D?*OPN\8>&O W
MC"'7O&'PZT_Q7IHBEBN]$U*XEA2970KD21,'C=<[E93P0.M?2FJ?M?\ P?\
M@Y\._ ?C/X _ 2STWQ5#H>K0:)>ZGXOEU)O#7G7=PDA$7EQAY7#LZ-+]U7 P
MPY/GXJ%7VJE23YN^EMG:]]>O3IYGJX&I1]A*%9KEWMK?5QO9K3HM^J[7./\
MV8/'_P */$O[/7CO]DKXL^.X_"$OB'4[/5O#GB.^MY)+2.\@.&@N?+!9%90
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M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!P7[<G_)GWQ(_[%"]_P#19K\1*_:;]MG7]3N/V1_B+!+X
M7NXE?PE>!I'9<*/+/)K\6:^%XK_WNG_A_4^>SC^-'T"BBBOE3R HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *_3?_@AU_P D$\7_ /8W_P#MK#7Y
MD5^E/_!$_5KW3_@5XMBM=#GN@WBW)>(C /V6'CFO=X;_ .1K'T?Y'H97_OB]
M&?<]%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+7Z.?4&Q16/_ ,)+J_\
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M44?V]GG_ $%5/_ Y?YA[&C_*ON(_LL'_ #S_ %-'V6#_ )Y_J:DHH_M[//\
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M6/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+7VA]0;%%8_P#PDNK_ /0H7O\
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M*%[_ .BS7XB5^W?[<G_)GWQ(_P"Q0O?_ $6:_$2OA>*_][I_X?U/GLX_C1]
MHHHKY4\@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OTW_X(=?\
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MG(^<SC_>5Z?JPHHHKYD\H**** "BBB@ HHHH **** "BBB@ HHHH ***],^
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MVE3\QQV!%>-?L^_!B_\ CI\2+?P@FI)INF6T$E_XCUN8?NM+TV$;I[E_95X
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MR03Q?_V-_P#[:PU^9%?IO_P0Z_Y()XO_ .QO_P#;6&O=X;_Y&L?1_D>AE?\
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MW9%"BO>_B%_P3T^//@CX<:=XRC\-0SWD.E7M[XJTY/$&GR2Z<D$T@RL:3%W
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MPO%?^]T_\/ZGSV<?QH^@4445\J>0%%%% !1110 4444 %%%% !1110 4444
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M_'G]GG]L?XZ)\._C'^RKHVDW'CO5VAA\5>&M3N5U"TOIV.R9R[%)09",@J%
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MHNI^(?V(?'&CZ/;>=<S)I_EQ[U7.-1M6/+$#H#7Y'_\ "EOB9_T+7_DY#_\
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MC_A2WQ,_Z%K_ ,G(?_BZ/]5>*/\ H!K?^"I__(A]=P?_ #\C]Z_S.6HKJ?\
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M_)R'_P"+H_U5XH_Z :W_ (*G_P#(A]=P?_/R/WK_ #.6HKJ?^%+?$S_H6O\
MR<A_^+H_X4M\3/\ H6O_ "<A_P#BZ/\ 57BC_H!K?^"I_P#R(?7<'_S\C]Z_
MS.6K]8_^"-G_ "9NG_8TWW\HJ_,7_A2WQ,_Z%K_R<A_^+K]2/^"1GAS6?"_[
M(ZZ7KMGY$_\ PDUZ_E^8K?*1'@Y4D=J]C),CSK+L;[7%86I3C9J\H2BKZ:7:
M2N>MDV(P]7&<L)INSV:?8^GZ***^N/JPHHHH **** "BBB@ HHHH *\/_P""
M@/Q3T?X/? VV\8ZU^Q1XI^/<:^(K:*+P3X0\+VVKWD,A25EO?)N"$"Q[=I<?
M,IE&.IKW"O)_VR;/]MV]^$<</[ 6L?#*Q\=?VQ"9IOBQ;W\NE_8-DGF@"Q_>
M^=N\K:?NX#Y[4 ?#?C#_ (*)>%OB'XCN?&/C_P#X-I_V@M<U>]*F\U76/@GI
M%S<SE5"*7EDD+-A551DG 4#H*]!_8I_:G^'GQ'_:;\,^#-"_X(.?%3X,75[]
MM\KXE>)/A'I>EV6C[+*>0^9<P,9(O-"FW7;]YIU4\,:C_P"$=_X.@O\ HHW[
M$'_@H\5_XUZ!^RYHO_!>&T^.VA7'[9WC3]EB[^&J_:O^$DM_AQIWB&/6G_T6
M46_V=KP^2,7/D%]__+,28^;% 'U_1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TK
MPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 <M\<O\ DBGC#_L5M0_])I*_!BOW
MG^.7_)%/&'_8K:A_Z325^#%?$\6?Q:7H_P!#P<Y^.'S"BBBOD3Q0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *_0O_@A%_Q[_%+_ ']%_E?5^>E?
MH7_P0B_X]_BE_OZ+_*^KV>'_ /D;T_G_ .DL[LM_WV'S_)GZ"T445^EGU044
M44 %%%% !1110!Y]^U?IUGJ_[-?CC3-0A\R"?PW=)*FXC<I0Y&1@BORK_P"%
M+?#/_H6O_)R;_P"+K]6_VG?^3>O&7_8O7/\ Z :_,VOT+@[)LHS+!U)XO#TZ
MC4K)SA&32MLFTS\ZXSKUZ6,I*$FO=Z-KJ<M_PI;X9_\ 0M?^3DW_ ,71_P *
M6^&?_0M?^3DW_P 774T5]A_JKPO_ - -'_P5#_Y$^-^NXS_GY+[W_F<M_P *
M6^&?_0M?^3DW_P 71_PI;X9_]"U_Y.3?_%UU-%'^JO"__0#1_P#!4/\ Y$/K
MN,_Y^2^]_P"9RW_"EOAG_P!"U_Y.3?\ Q='_  I;X9_]"U_Y.3?_ !==311_
MJKPO_P! -'_P5#_Y$/KN,_Y^2^]_YG+?\*6^&?\ T+7_ ).3?_%T?\*6^&?_
M $+7_DY-_P#%UU-%'^JO"_\ T T?_!4/_D0^NXS_ )^2^]_YG+?\*6^&?_0M
M?^3DW_Q='_"EOAG_ -"U_P"3DW_Q==311_JKPO\ ] -'_P %0_\ D0^NXS_G
MY+[W_F<M_P *6^&?_0M?^3DW_P 71_PI;X9_]"U_Y.3?_%UU-%'^JO"__0#1
M_P#!4/\ Y$/KN,_Y^2^]_P"9RW_"EOAG_P!"U_Y.3?\ Q='_  I;X9_]"U_Y
M.3?_ !==311_JKPO_P! -'_P5#_Y$/KN,_Y^2^]_YG+?\*6^&?\ T+7_ ).3
M?_%T?\*6^&?_ $+7_DY-_P#%UU-%'^JO"_\ T T?_!4/_D0^NXS_ )^2^]_Y
MG+?\*6^&?_0M?^3DW_Q='_"EOAG_ -"U_P"3DW_Q==311_JKPO\ ] -'_P %
M0_\ D0^NXS_GY+[W_F<M_P *6^&?_0M?^3DW_P 71_PI;X9_]"U_Y.3?_%UU
M-%'^JO"__0#1_P#!4/\ Y$/KN,_Y^2^]_P"9RW_"EOAG_P!"U_Y.3?\ Q='_
M  I;X9_]"U_Y.3?_ !==311_JKPO_P! -'_P5#_Y$/KN,_Y^2^]_YG+?\*6^
M&?\ T+7_ ).3?_%T?\*6^&?_ $+7_DY-_P#%UU-%'^JO"_\ T T?_!4/_D0^
MNXS_ )^2^]_YG+?\*6^&?_0M?^3DW_Q='_"EOAG_ -"U_P"3DW_Q==311_JK
MPO\ ] -'_P %0_\ D0^NXS_GY+[W_F<M_P *6^&?_0M?^3DW_P 71_PI;X9_
M]"U_Y.3?_%UU-%'^JO"__0#1_P#!4/\ Y$/KN,_Y^2^]_P"9RW_"EOAG_P!"
MU_Y.3?\ Q='_  I;X9_]"U_Y.3?_ !==311_JKPO_P! -'_P5#_Y$/KN,_Y^
M2^]_YG+?\*6^&?\ T+7_ ).3?_%T?\*6^&?_ $+7_DY-_P#%UU-%'^JO"_\
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M]*T445^7GZH%%%% !1110 4444 >3?MR_P#)K/BK_=L__2V"OSLK]$_VY?\
MDUGQ5_NV?_I;!7YV5^M<!_\ (HJ?]?'_ .DQ/R_C;_D:0_P+_P!*D%%%%?;'
MQX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_R2KQ!_V,/_ +0CKY7C/_D0S]8_F?3<(_\ (ZCZ2_(^E:***_&3]:"BBB@
MHHHH **** /)OVY?^36?%7^[9_\ I;!7YV5^B?[<O_)K/BK_ ';/_P!+8*_.
MROUK@/\ Y%%3_KX__28GY?QM_P C2'^!?^E2"BBBOMCX\**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OO7_@G5_R;JO_ &'+K^25\%5]Z_\ !.K_
M )-U7_L.77\DKX_CC_D2?]OK\F?5\&_\CC_MU_H>[T445^/GZJ%%%% !1110
M 4444 %%%% !1110!^/=_P#''_@D+^SA_P %C_VH-&_X*=^(/AIK/B[Q-?Z!
MJ'@OQ!X\T%-7BTK2UTB!'T@^;#*NGS1N!+C"">*>)@S%65/JW]D?]K/_ ((+
M?$S]H3P_X(_8NU[X#S?$N]^U_P#"-1>#/"%I:ZDVRTFDN/)ECMD9?]&2?=AA
ME-XY!P?J;Q-^SQ\ /&NN3^)_&7P-\':OJ5T5-UJ.I^&;2XGF*J%&Z1XRS850
M!D\  =J7PM^SW\ O ^NP>*?!7P/\'Z/J=KN^S:CI?AJUMYX=RE&VR1QAERK,
MIP>0Q'0T =A1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
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M6;[K1V=FOEOB<OJ8:#DY)\KY9)7]UZZ.Z79ZJZNF<A1117H' %%%% !1110
M4444 %%%% !1110 5]Z_\$ZO^3=5_P"PY=?R2O@JOO7_ ()U?\FZK_V'+K^2
M5\?QQ_R)/^WU^3/J^#?^1Q_VZ_T/=Z***_'S]5"BBB@ HHHH **** "BBB@
MHHHH ^#_ (S?\%&/^"@_Q6_:R^(G[+7_  3+_8V\'>+;7X17-E8>//B!\3/&
M+Z;IYU.YMDN18VD$*&65HXG7?)G 8X*J-C2=C^RY\3/^"WGB#X[:%I'[7W[,
MGP'\/?#N;[5_PD.L>#/&E_=ZE;XM96@\F*50C[K@0JV3PC.1R!7C7Q1^%G_!
M9S]G/_@HQ\7/CG^P-^S!\)=;^&OQ*;2KC6+#Q?XYDMI-3U*UL(H#J4:( ;.8
M@>1(O[Q)5MXI-JN69O9?V7/C+_P6J\5_';0M _:V_8O^#_A/X>W'VK_A(/$'
MA;XC37]_:[;65H/*@9 'W7 A1LGA79NU 'U_1110!\]?L%VWB27X.:LVDZE;
MQ1?\)QK.5EA+'/VEN<U[;]B\;_\ 0;LO_ 8_XUY'_P $]_\ DB>K?]CWK/\
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M]B\;_P#0;LO_  &/^-;%%?B9^P&/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
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M+\T%%%%?H1\(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_DE7B#_L8?\ VA'7Q17VO_P3'_Y)5X@_[&'_ -H1U\KQG_R(9^L?S/IN$?\
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M_B:\]HH^H4>[_KY!]=J]E_7S/0O^$X\+?]!3_P @/_\ $T?\)QX6_P"@I_Y
M?_XFO/:*/J%'N_Z^0?7:O9?U\ST+_A./"W_04_\ (#__ !-'_"<>%O\ H*?^
M0'_^)KSVBCZA1[O^OD'UVKV7]?,]"_X3CPM_T%/_ " __P 31_PG'A;_ *"G
M_D!__B:\]HH^H4>[_KY!]=J]E_7S/0O^$X\+?]!3_P @/_\ $U]Q_P#!+35]
M.UCX2^(IM.N/,5/$6UCL(P?(C]0*_-JOT*_X(]_\D6\4_P#8T#_TFBKXWCO"
M4Z7#LY)O>/YGUG!6*J5<_A%I;2_(^NJ***_"C]H"BBB@ HHHH **** /%O\
M@H??76F_L=^,;VREV2HMAM;:#C-_; \'V-?EU_PG'BG_ *"G_D!/_B:_3_\
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M_P#B:/\ A./%/_04_P#("?\ Q-9-%'L:/\J^X/;5?YG]YK?\)QXI_P"@I_Y
M3_XFC_A./%/_ $%/_("?_$UDT4>QH_RK[@]M5_F?WFM_PG'BG_H*?^0$_P#B
M:/\ A./%/_04_P#("?\ Q-9-%'L:/\J^X/;5?YG]YK?\)QXI_P"@I_Y 3_XF
MC_A./%/_ $%/_("?_$UDT4>QH_RK[@]M5_F?WFM_PG'BG_H*?^0$_P#B:/\
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MXL^'MO\ :O\ A(/#_A;X<S6%_=;K658/*G9R$VW!A=LCE49>]>4_M&?L1?\
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M_2IA1117Z(?!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_R1/5O^Q[UG_P!*37NE !1110!A_$[_ ))MXA_[ =W_ .B7K\KZ_5#XG?\
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MC[_L5[O_ -%FOR$K]I\,?^197_Q_^VH_(O$7_D8T?\'ZL****_2S\\"BBB@
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MP84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?IA_P2F_Y-47_L8[
MS^4=?F?7Z8?\$IO^35%_[&.\_E'7P?B-_P D\O\ ''\F?;< _P#(]?\ @E^:
M/I2BBBOP<_:@HHHH **** "BBB@ HHHH **** /A[]NO_@J7^S+8?$;Q)^P-
MX1_8T\;_ +3GQ#L4@B\3?#+PWX!^VZ5IYG@2>$:G>7L?V2")HI4;?^]"[P"
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MO_T6:_(2OVGPQ_Y%E?\ Q_\ MJ/R+Q%_Y&-'_!^K"BBBOTL_/ HHHH ****
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M_&_AU-4M]$U"<RRZ<^</&';ETY&UCDGGG&*\JT=]*CU>U?78II+%;E#>1VS
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M._\ )F'C/_=T_P#].%M7Y55^X>&?_(BJ_P#7Q_\ I,#\;\0_^1U3_P"O:_\
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M10 4444 %%%% !1110 5^F'_  2F_P"35%_[&.\_E'7YGU^F'_!*;_DU1?\
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M%% !1110 4444 %%%% !1110 4444 %%%=)\,OA#\1_C%J\VB?#CPO+J,UM
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M %%%% !1110 5]__ /!(O7=(TKX-^)X=1OXX6;Q,&57/4?9XJ^ *_0;_ ()
MVMM/\&/%#3V\;D>)P 70'_EVBKXKQ _Y)JI_BC^9]?P-_P E##TE^1]6?\)C
MX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"OP
M_<2G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&
M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M_C9\-?B=8>(;#2]8A3Q3I2VTEM=Z2\Q"1%T?(E0MQO4]3P.&QRO_  3_ /\
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M0,JDJH!VA5SC&><UY7^TQ\(H/@/\=?$7PIL]0>ZM]*NT^R3RXWM#+$DT>[&
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M]1P7_P E+0_[>_\ 2)'W!1117\\'[P%%%% !1110 4444 >;?MB?\FL^/O\
ML5[O_P!%FOR$K]>_VQ/^36?'W_8KW?\ Z+-?D)7[3X8_\BRO_C_]M1^1>(O_
M ",:/^#]6%%%%?I9^>!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^A7_!'O_DBWBG_L:!_Z315^>M?H5_P1[_Y(MXI_[&@?^DT5?%>('_)-5/\
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M_P!KH_X:8_ZDG_RI?_:Z\KHH]E3[![:KW/5/^&F/^I)_\J7_ -KH_P"&F/\
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M_P!S2O\ T[6=?A77[J?\%AO^4<GQ'_W-*_\ 3M9U^%=?O7A;_P B"K_U]?\
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M_P!B?J?_ *2R5_.'7[5X4?[KBO\ %'\F?CWBA_O.&])?F@HHHK]:/RP****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OUN_X-[/^3;O&_\
MV/'_ +9P5^2-?K=_P;V?\FW>-_\ L>/_ &S@KX;Q&_Y):I_BC_Z4C[7P_P#^
M2EI_X9?D??U%%%?SH?OX4444 %%%% !1110!\S_\%AO^4<GQ'_W-*_\ 3M9U
M^%=?NI_P6&_Y1R?$?_<TK_T[6=?A77[UX6_\B"K_ -?7_P"D0/P_Q,_Y'M+_
M *]K_P!*F%%%%?I1^=A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_7M?^E3"BBBOTH_.PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M++@?Z+)S7\[5?M7A1_NN*_Q1_)GX]XH?[SAO27YH****_6C\L"BBB@ HHHH
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
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M2R5_.'7[5X4?[KBO\4?R9^/>*'^\X;TE^:"BBBOUH_+ HHHH **** "BBB@
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M2&[%I>ZGH^M6FH16-P2 (IS;2OY+9('SX!) !).*A^ 7[#O[4/[3_A6]\;?
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M)/=-([3X _LT_'#]J/Q=/X%^!'@*;7]3M;)KNYA2[@MTAA#*I9I)W2-?F8
MMDD\ UQFJ:;>Z-J=QH^I0^7<VD[PW$>X'8ZL589!(."#R.*_0S]CFZL/V7?V
MK?A1^Q'X2NX7\076LOJ_QBU.UD#>;J(L+AK;20Z\-%:*VYQD@SNQX*8KX(^)
M_P#R4OQ%_P!AV[_]'/7#EV:5\=F-6FXI4N6,H/6[3<U=ZVL^6\=-FF][+MS#
M+*."P%.:DW4YI1FM+)I1=EI>ZYK2UW32VN\.BBBO=/$"BBB@ HHHH **** "
MBBB@ HHHH *_3G_@W/\ ^/?XP?[^@?RU&OS&K].?^#<__CW^,'^_H'\M1KX[
MC_\ Y)+$_P#;G_IR)];P+_R5.'_[?_\ 2)'Z9T445_-A_0X4444 %%%% !11
M10!XY_P4+_Y,=^*O_8CW_P#Z*-?S[5_03_P4+_Y,=^*O_8CW_P#Z*-?S[5^Y
M>%?_ "*J_P#C_P#;4?BWB=_R,Z'^#_VYA1117ZD?F@4444 %%%% !1110 44
M44 %%%% !1110 5[-^R)\-/VMO$6J:A\0?V/]>NH-?T9HX;JST3Q%%::C+#(
M&;*P/(AN8LH RJ'P=N5[UXS17/BJ,Z]"5.+5W_-'F7G=75_O-\-5A0KJ<KZ?
MROE?R=G;[C](?^"BUSXJO/@E\5'_ &PM'\/0ZU#XFTU/@==O#:1ZY/#YO^FA
MO(_>-:B$'YI0,L>I/EX\#U/]K_\ 8W\=?"'P!\+OBC^RUXJNT\"^&X]/@31O
M'BV=K-=-A[N\\D6[8DGER[$DG[HSQ7S[\7?B5JOQA^)6L_$[7+"WM;O6KPW$
M]O:;O+1B ,+N)...YKG*\#+>'*6'P,*=>3YHOF7(Y047RJ+4>67DV]=7*3TO
M8]W,.(*M?&SJ44N5KE?,E-R2DY)RYH^:2TT2BM;7/M'_ (+1Z]\'KOX_PZ)X
M=^'VIVGBJ+1M*EOM<GUKS+>:R-D/+@6WV#8ZY3+[CG:>!FO*?!WAW4_^">'[
M5_@CQG\?O %AXG73]-@\10:'8ZD,.)X)?LCL[(0DD<OER[2IYC'K7@]O*()T
MF,*2!'#&.0$JV#T..U=-\:OC)X[^/_Q.U;XM_$G44N=7UB97N&AB\N*-514C
MBC0?<1$555>P4=>M=.$RBIA,#2R_FYJ2A*,VV^9MI)6U;BK<VSTT2.;%9K#%
M8VICN7EJN<9122Y4DVW?1*3OR[K76Y]V?L(?&C]D3XF?&WXB>)O"GP#\8V.O
M7WPWU_4/$&JZSX]^VM?PL$>Y3'D+MDD+9$F3M.>#7R%X.^ GC+]J3XG^(?\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OUN_X-[/^3;O&_\
MV/'_ +9P5^2-?K=_P;V?\FW>-_\ L>/_ &S@KX;Q&_Y):I_BC_Z4C[7P_P#^
M2EI_X9?D??U%%%?SH?OX4444 %%%% !1110!\S_\%AO^4<GQ'_W-*_\ 3M9U
M^%=?NI_P6&_Y1R?$?_<TK_T[6=?A77[UX6_\B"K_ -?7_P"D0/P_Q,_Y'M+_
M *]K_P!*F%%%%?I1^=A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_7M?^E3"BBBOTH_.PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^G/\ P;G_ /'O\8/]_0/Y:C7YC5^G/_!N?_Q[
M_&#_ '] _EJ-?'<?_P#))8G_ +<_].1/K>!?^2IP_P#V_P#^D2/TSHHHK^;#
M^APHHHH **** "BBB@#QS_@H7_R8[\5?^Q'O_P#T4:_GVK^@G_@H7_R8[\5?
M^Q'O_P#T4:_GVK]R\*_^157_ ,?_ +:C\6\3O^1G0_P?^W,****_4C\T"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'^ZXK_%'\F?CWBA_O.&])?F@HHHK]:/RP**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OTY_X-S_^/?XP?[^@?RU&OS&K].?^#<__ (]_C!_OZ!_+
M4:^.X_\ ^22Q/_;G_IR)];P+_P E3A_^W_\ TB1^F=%%%?S8?T.%%%% !111
M0 4444 >.?\ !0O_ ),=^*O_ &(]_P#^BC7\^U?T$_\ !0O_ ),=^*O_ &(]
M_P#^BC7\^U?N7A7_ ,BJO_C_ /;4?BWB=_R,Z'^#_P!N84445^I'YH%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7ZW?\&]G_)MWC?\ ['C_ -LX
M*_)&OUN_X-[/^3;O&_\ V/'_ +9P5\-XC?\ )+5/\4?_ $I'VOA__P E+3_P
MR_(^_J***_G0_?PHHHH **** "BBB@#YG_X+#?\ *.3XC_[FE?\ IVLZ_"NO
MW4_X+#?\HY/B/_N:5_Z=K.OPKK]Z\+?^1!5_Z^O_ -(@?A_B9_R/:7_7M?\
MI4PHHHK]*/SL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OVA_X(
M3?\ )BB?]CAJ/\H:_%ZOVA_X(3?\F*)_V.&H_P H:_/?$S_DFU_CC^4C[SPY
M_P"2A?\ @E^:/LNBBBOY]/W@**** "BBB@ HHHH **** "BBB@ HHHH ****
M /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH ****
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M **** "BBB@#QS_@H7_R8[\5?^Q'O_\ T4:_GVK^@G_@H7_R8[\5?^Q'O_\
MT4:_GVK]R\*_^157_P ?_MJ/Q;Q._P"1G0_P?^W,****_4C\T"BBB@ HHHH
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M'!/[1_\ T/GPL_/6/_BJ/^'!/[1__0^?"S\]8_\ BJ_6&BC_ %BX@_Z#*O\
MX,G_ )A_8&1?] E+_P %Q_R/R>_X<$_M'_\ 0^?"S\]8_P#BJ/\ AP3^T?\
M]#Y\+/SUC_XJOUAHH_UBX@_Z#*O_ (,G_F']@9%_T"4O_!<?\C\GO^'!/[1_
M_0^?"S\]8_\ BJ/^'!/[1_\ T/GPL_/6/_BJ_6&BC_6+B#_H,J_^#)_YA_8&
M1?\ 0)2_\%Q_R/R>_P"'!/[1_P#T/GPL_/6/_BJ/^'!/[1__ $/GPL_/6/\
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M@_Z#*O\ X,G_ )A_8&1?] E+_P %Q_R/R>_X<$_M'_\ 0^?"S\]8_P#BJ/\
MAP3^T?\ ]#Y\+/SUC_XJOUAHH_UBX@_Z#*O_ (,G_F']@9%_T"4O_!<?\C\G
MO^'!/[1__0^?"S\]8_\ BJ/^'!/[1_\ T/GPL_/6/_BJ_6&BC_6+B#_H,J_^
M#)_YA_8&1?\ 0)2_\%Q_R/R>_P"'!/[1_P#T/GPL_/6/_BJ/^'!/[1__ $/G
MPL_/6/\ XJOUAHH_UBX@_P"@RK_X,G_F']@9%_T"4O\ P7'_ "/R>_X<$_M'
M_P#0^?"S\]8_^*H_X<$_M'_]#Y\+/SUC_P"*K]8:*/\ 6+B#_H,J_P#@R?\
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M7_X+6_\ 1Y'PL_\ "1_^YJ/^%+_\%K?^CR/A9_X2/_W-7V-10!\0?$/]E?\
MX*__ !6\#:K\-O'W[6/PLO\ 1=;L9+/5++_A&9(O.A<89-\<"NN1W4@^]?/O
M_#@G]H__ *'SX6?GK'_Q5?K#17=A,TS/ 0<<-7G33U:C*44W\FCBQ66Y=C9*
M6(HPFUHG**E;[TS\GO\ AP3^T?\ ]#Y\+/SUC_XJC_AP3^T?_P!#Y\+/SUC_
M .*K]8:*Z_\ 6+B#_H,J_P#@R?\ F<O]@9%_T"4O_!<?\C\GO^'!/[1__0^?
M"S\]8_\ BJ/^'!/[1_\ T/GPL_/6/_BJ_6&BC_6+B#_H,J_^#)_YA_8&1?\
M0)2_\%Q_R/R>_P"'!/[1_P#T/GPL_/6/_BJ/^'!/[1__ $/GPL_/6/\ XJOU
MAHH_UBX@_P"@RK_X,G_F']@9%_T"4O\ P7'_ "/R>_X<$_M'_P#0^?"S\]8_
M^*H_X<$_M'_]#Y\+/SUC_P"*K]8:*/\ 6+B#_H,J_P#@R?\ F']@9%_T"4O_
M  7'_(_)[_AP3^T?_P!#Y\+/SUC_ .*H_P"'!/[1_P#T/GPL_/6/_BJ_6&BC
M_6+B#_H,J_\ @R?^8?V!D7_0)2_\%Q_R/R>_X<$_M'_]#Y\+/SUC_P"*H_X<
M$_M'_P#0^?"S\]8_^*K]8:*/]8N(/^@RK_X,G_F']@9%_P! E+_P7'_(_)[_
M (<$_M'_ /0^?"S\]8_^*H_X<$_M'_\ 0^?"S\]8_P#BJ_6&BC_6+B#_ *#*
MO_@R?^8?V!D7_0)2_P#!<?\ (_)[_AP3^T?_ -#Y\+/SUC_XJC_AP3^T?_T/
MGPL_/6/_ (JOUAHH_P!8N(/^@RK_ .#)_P"8?V!D7_0)2_\ !<?\C\GO^'!/
M[1__ $/GPL_/6/\ XJC_ (<$_M'_ /0^?"S\]8_^*K]8:*/]8N(/^@RK_P"#
M)_YA_8&1?] E+_P7'_(_)[_AP3^T?_T/GPL_/6/_ (JC_AP3^T?_ -#Y\+/S
MUC_XJOUAHH_UBX@_Z#*O_@R?^8?V!D7_ $"4O_!<?\C\;?@C_P $:OCG\;?"
M5SXMT#Q;\.;>&VUB[T]TOQJH<O!(49AL<C:2.._K78_\."?VC_\ H?/A9^>L
M?_%5^@7[%/@7Q=\/OA/J6B>--!GTZ[F\8:I=1P7  9H9)RR/P>A'(KU^C_6+
MB#_H,J_^#)_YA_8&1?\ 0)2_\%Q_R/R>_P"'!/[1_P#T/GPL_/6/_BJ/^'!/
M[1__ $/GPL_/6/\ XJOUAHH_UBX@_P"@RK_X,G_F']@9%_T"4O\ P7'_ "/R
M>_X<$_M'_P#0^?"S\]8_^*H_X<$_M'_]#Y\+/SUC_P"*K]8:*/\ 6+B#_H,J
M_P#@R?\ F']@9%_T"4O_  7'_(_)[_AP3^T?_P!#Y\+/SUC_ .*H_P"'!/[1
M_P#T/GPL_/6/_BJ_6&BC_6+B#_H,J_\ @R?^8?V!D7_0)2_\%Q_R/R>_X<$_
MM'_]#Y\+/SUC_P"*H_X<$_M'_P#0^?"S\]8_^*K]8:*/]8N(/^@RK_X,G_F'
M]@9%_P! E+_P7'_(_)[_ (<$_M'_ /0^?"S\]8_^*H_X<$_M'_\ 0^?"S\]8
M_P#BJ_6&BC_6+B#_ *#*O_@R?^8?V!D7_0)2_P#!<?\ (_)[_AP3^T?_ -#Y
M\+/SUC_XJC_AP3^T?_T/GPL_/6/_ (JOUAHH_P!8N(/^@RK_ .#)_P"8?V!D
M7_0)2_\ !<?\C\GO^'!/[1__ $/GPL_/6/\ XJC_ (<$_M'_ /0^?"S\]8_^
M*K]8:*/]8N(/^@RK_P"#)_YA_8&1?] E+_P7'_(_)[_AP3^T?_T/GPL_/6/_
M (JC_AP3^T?_ -#Y\+/SUC_XJOUAHH_UBX@_Z#*O_@R?^8?V!D7_ $"4O_!<
M?\C\GO\ AP3^T?\ ]#Y\+/SUC_XJC_AP3^T?_P!#Y\+/SUC_ .*K]8:*/]8N
M(/\ H,J_^#)_YA_8&1?] E+_ ,%Q_P C\GO^'!/[1_\ T/GPL_/6/_BJ];_9
MZ_X)Y_\ !3C]E7PW?>$/@)^T=\+-!T[4K[[9>V_]B75UYDVQ4W[KB*1A\JJ,
M @<=*_0:BN?$YQF^,I.EB,1.<7TE.37W-V-\/E.582K[2A0A"7>,(I_>E<^.
M?^%+_P#!:W_H\CX6?^$C_P#<U'_"E_\ @M;_ -'D?"S_ ,)'_P"YJ^QJ*\X]
M ^.?^%+_ /!:W_H\CX6?^$C_ /<U'_"E_P#@M;_T>1\+/_"1_P#N:OL:B@#X
MY_X4O_P6M_Z/(^%G_A(__<U'_"E_^"UO_1Y'PL_\)'_[FK[&HH ^.?\ A2__
M  6M_P"CR/A9_P"$C_\ <U'_  I?_@M;_P!'D?"S_P )'_[FK[&HH ^$_C%^
MQK_P5G^/OPXU+X2?%K]J7X6:MX>U<1#4-/\ ^$=F@\WRIDF3]Y#"CKB2-&^5
MAG&#D$BO"O\ AP3^T?\ ]#Y\+/SUC_XJOUAHKOPN:YI@:;IX:O.$6[VC*45?
MO9-:Z(X<3EF6XVHIXBA"<DK7E&+=NUVGIJ?D]_PX)_:/_P"A\^%GYZQ_\51_
MPX)_:/\ ^A\^%GYZQ_\ %5^L-%=7^L7$'_095_\ !D_\SF_L#(O^@2E_X+C_
M )'Y/?\ #@G]H_\ Z'SX6?GK'_Q5'_#@G]H__H?/A9^>L?\ Q5?K#11_K%Q!
M_P!!E7_P9/\ S#^P,B_Z!*7_ (+C_D?D]_PX)_:/_P"A\^%GYZQ_\51_PX)_
M:/\ ^A\^%GYZQ_\ %5^L-%'^L7$'_095_P#!D_\ ,/[ R+_H$I?^"X_Y'Y/?
M\."?VC_^A\^%GYZQ_P#%4?\ #@G]H_\ Z'SX6?GK'_Q5?K#11_K%Q!_T&5?_
M  9/_,/[ R+_ *!*7_@N/^1^3W_#@G]H_P#Z'SX6?GK'_P 51_PX)_:/_P"A
M\^%GYZQ_\57ZPT4?ZQ<0?]!E7_P9/_,/[ R+_H$I?^"X_P"1^3W_  X)_:/_
M .A\^%GYZQ_\51_PX)_:/_Z'SX6?GK'_ ,57ZPT4?ZQ<0?\ 095_\&3_ ,P_
ML#(O^@2E_P""X_Y'Y/?\."?VC_\ H?/A9^>L?_%4?\."?VC_ /H?/A9^>L?_
M !5?K#11_K%Q!_T&5?\ P9/_ ##^P,B_Z!*7_@N/^1^3W_#@G]H__H?/A9^>
ML?\ Q5'_  X)_:/_ .A\^%GYZQ_\57ZPT4?ZQ<0?]!E7_P &3_S#^P,B_P"@
M2E_X+C_D?D]_PX)_:/\ ^A\^%GYZQ_\ %4?\."?VC_\ H?/A9^>L?_%5^L-%
M'^L7$'_095_\&3_S#^P,B_Z!*7_@N/\ D?D]_P ."?VC_P#H?/A9^>L?_%5S
M7Q@_X(I?'KX/_#+6?B;K?C'X;3VFC69N)X;+^UC*Z@@87>X7//<U^PU><?M=
M^%/$?CG]FGQCX1\(Z1+?ZE?Z.T5G9P %Y7W*=HSWXH_UBX@_Z#*O_@R?^8?V
M!D7_ $"4O_!<?\C\V?#O_!"']HCQ#X?L=?M?'/PO2*^LXKB-9?[7W!70, <-
MC.#VJY_PX)_:/_Z'SX6?GK'_ ,57ZD_#ZQN]+\ Z'IFH6[13V^CVT4\3]4=8
ME#*?<$$5L4?ZQ<0?]!E7_P &3_S#^P,B_P"@2E_X+C_D?D]_PX)_:/\ ^A\^
M%GYZQ_\ %4?\."?VC_\ H?/A9^>L?_%5^L-%'^L7$'_095_\&3_S#^P,B_Z!
M*7_@N/\ D?D]_P ."?VC_P#H?/A9^>L?_%4?\."?VC_^A\^%GYZQ_P#%5^L-
M%'^L7$'_ $&5?_!D_P#,/[ R+_H$I?\ @N/^1^3W_#@G]H__ *'SX6?GK'_Q
M5'_#@G]H_P#Z'SX6?GK'_P 57ZPT4?ZQ<0?]!E7_ ,&3_P P_L#(O^@2E_X+
MC_D?D]_PX)_:/_Z'SX6?GK'_ ,51_P ."?VC_P#H?/A9^>L?_%5^L-%'^L7$
M'_095_\ !D_\P_L#(O\ H$I?^"X_Y'Y/?\."?VC_ /H?/A9^>L?_ !5'_#@G
M]H__ *'SX6?GK'_Q5?K#11_K%Q!_T&5?_!D_\P_L#(O^@2E_X+C_ )'Y/?\
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MK[&HKSSO/CG_ (4O_P %K?\ H\CX6?\ A(__ '-1_P *7_X+6_\ 1Y'PL_\
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MGNK;2Q;I-K$%LZ']VSNRIE3@IN0Y5S7G'[>/[&W[.7_!%3XI_LY_MM?\$_?
M_P#PKBWN?C-HOP^^*7AW2-4N39>)O#NIK*CM=1S2.)9X&BWQR'YM[[F)*+@
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MN;G5?#\#(^GS2S'_ %K!'= W_/...@#]#**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\$&?VA-)_;"^*OA7QCXP_X1"\<ZQX.\.2:79_93+!Y4?D22RMO7#9;=@Y'
MQ5K_ (*C_P#*N/XZ_P"S?],_])[2@#[^JM8:UH^JS7%OI>K6US):2^7=);SJ
MYA?^ZX!^4^QYK\G?^"H_PK/QOTG_ ()M_"-_&.KZ#;^(/&^GV5_JF@7SVM['
M:/H,?VA8)TP\$CP^9&)5(9"^Y2" :R?VX_\ @EY^SA^RK_P4&_99^'_[$-IJ
M_P '-'^..KZ]X,^+UGX&\07=M_PDNAP6<=\T$KF1G21A%-$9T*R@3[@X958
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M=^+?'/Q)TCP#X&T:;6Q;6,NM:C*T<7VJX17,<2!)&;"DDJ%^7=N'QK_P44^
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MI>&?$N@^,_#>G^,/"NK07^EZK8Q7FFWUL^Z.YMY4#QR(>ZLK @]P:O5\??\
M! 7Q?XH\<?\ !&W]GS6_%[R->1> H[&,RL2QMK6>:UMNO;R(8L>V*^P: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>/@;^P3_ ,*8_P""AOQS_;T_X6M_:7_"Z-'\-V'_  BG]A>3_8_]DV?V;?\
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M^^$/[+7P:\0_M!_'SQK#X=\'^%; WNO:S/;RS+;0A@H(CA1Y)&+,JJB*S,S
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M\:_'&A6^@2:[9>'4TG2_#^APR"5=,T^T620K&TJK([NY+LBM@,79^S_X)O\
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MX"9FT?P)X4L-#T^:10'FCMH$B\U\?QN5+L>[,37<T44 %%%% !1110 4444
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MUS2AI/C/3_V]/ GA_P")OAMX_+ET7Q)9+J,-];/&>8LN!*B'D1S1YYS7<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9M,1+N%EN$EN%>Y,\H,J&0QJ0@ H _1;XG?MA_!_X2_M1_##]D+Q:VJ#Q?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4>!%\+Z<-#%C]B&C"RC^R"VV;/(\G&SR]GR[,;<<8Q7YQ?\ !6?PIX9\"?\
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M]L7X;?%/PU9?&7X,?$6+P)J'Q \%6=GJ.C:O=V^OZ5;/J=BEPDUO+!=6-\C
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M$=SA49A\M?\ !N%;WNO_ /!,'3?VI?'$\;>*OC;X[\3^/?&M\[?ZV]N=5N(
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MT7]DWXG_ +)]_?RW%M^S[^T9XR^'6B//(7?^SK2\6>!2Q)+!?M3QKD\+&!T
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MMOXCM]*U;3M7M$:./5M.ENB(95='<R0DAV>1L9&TQ_HG10!^9?QH^"_[?O\
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M?LW7.J?'WXE^.=:\2^,;:V^)>IPQZ0EQ>2&VL$;2-02VE1(@KAAN*^<4W80
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M9/ ?P@^&NI:W;7^I0VCW1NKO5+YK5FBAE=R8TC#%@CL& V*[_?%%% 'YX?\
M!'7X8_\ !0?_ ()^>!] _P""=/Q:_89?4/ OA_Q5XA>W^.^C?$K2'L9K&YO+
MN_@F;3'D6^5F>58"@C.TL&/ ;'J'_!%[]ESX[?LF_L]_$/P/^T#X&_L#5-=^
M/'BSQ%I5K_:=K=>?IM[=K);3[K:615WJ"=C$.O1E4U]?T4 ?F!\,_P#@C_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>biib-20201231_g30.jpg
<TEXT>
begin 644 biib-20201231_g30.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
M_P!B'_@GW\%_&&K>-[KQ"-:\4Z=?Z2(XM,O&MA;B(2JS@P1&>X>6X;;&B(C$
MG+!0#]A?VM/V'_ '_!<#]D;X/^)?&7QT^(?P\\+ZSHUEXKN]-\ :O':S:E#?
MV$4J6T[RHZ%$$F1NC;GL*_-/_@RDT6T\-_%_]J[P[8/(T%A+X:MH6E(+%$N-
M94$D  G &>*_2[]JC_@H)^RG_P $(OV0_@]X)_:1'BK4M)M=#L?"&B7'A;2(
M[J21]/T^*,O(LLT>U2D8/4G)K\,O^#<+_@L+^R;_ ,$W/C?\;M1_:%T[Q=-'
M\6=6T6/PM_PCFCQ7)0Q7.H%O/WSQ^7_Q]Q8QNZ-Z<@'UK_P=J^&?C%JO[8?[
M/=W^T#X@\9:;^R+<2:=9>/K_ ,,>8\%E?MJDIU"66.,,#<?V?Y!MS(C',<WE
MJQWJ?!?V'_AM\'?#7_!PI\.-+_X-^OB#XU\0_""SLM,N_BY?O+>G3;>R,DRZ
MC#.]S'&98#;^28O.!_TJ3$9RBX];_P"#FB/Q!\-?^"QW[/O[07[:7PVU_P 7
M?LNZ/9Z6+K3[>U>XTP3)>S/J$#QY$;7#+]GD:-R#/$B1Y(4A?(=5^*7[.G[:
M/_!PM^S_ /$'_@@S\&[GPQH>@3Z(?B%J7A'P8VA::UO'J$CZC<3VL:QK';FP
M802,ZQ^<WR ,Q4L ?TP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,GP=XZ\(_$'2Y-;\%Z]!J-I#=RVLD]N256:-MKISW!X-:U>%_P#!/?\
MY(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_P#@GO\ \D3U
M;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH ***Y3X[?&CP'^SC\
M%/%OQ_\ BCJ$EKX<\%>'+S6]<G@B\R1;6VA::38G&]RJ$*O\3$#O0!U=%?F+
M\,/^"G7_  5.^-'[0=O\5?A-_P $QWU'P9X@^#FF^(O#OP^U7XXV-CJ=QIEQ
M?7!@U?RWM#;Q7,T>U?LKS JJIND!)"_</[6_PM_:A^-WPFL/"?[+'[4G_"E_
M$,NL07&J^*CX+M->G6P$4HEM8K>[81)(TC1'S3NVB-L YH ]9HK\R?%/Q _X
M*/\ _!,/]N']GOX7?%K]O5_VA? 7QY\:3>%-0\.>*/ NGZ7K.B3B$2#4K2:Q
M ,L,>5,JR JBC&,R!T_3:@ HK\X(/BM^WS_P4Y_;O^.?P2_9W_;$NO@'\+/@
M!K5GX:>[\-^$+#5-8\4ZY)"9;B662^1UM[>$@HJ1C,@96)[+V/\ P3U_X*$_
M&BU?]I3]E[]N7Q/I_BGXA_LJW:W&M^,- TA+ >*M!N+&2^LKXVB'RX+HQ1.)
M(X_W:EHP.I) /NZBORK_ &:V_P""S_[>_P"QDO\ P4T\'_\ !1.U^'>L>)]/
MO]?^'7P3TWX=:9>^'[>PADE%M87MU.ANIWG6+YYPP:/S@5'R[1Z1KO\ P7%B
M?_@@]8_\%8O"GP^L[CQ;K.BPZ;IG@_<[6Y\427_]F-!C<':!;E9)@NX.T"8#
M!F!H _0RBORP_:>\6?\ !7;_ ()/? +0O^"BOQ^_;Q3XR:'HNL:5_P +T^%-
MQX TRQL;/3[VYBMI7T>YM8UG62VEG1$WDK*/WD@PI0_J1IFI6&M:;;ZQI5VD
M]K=P)-;3QG*R1LH96'L00: )Z*_/W]IGX^?MJ?M=?\%0M3_X)G?LC?M$#X+>
M&?AU\.+3Q5\2?B!8>&K35-7U*YO)0MKIUI'>*T4$80K(TVTL2&7@ !M7]@S]
MJ3]J/X5?\%#/'_\ P2<_;3^-=I\3M9TCP#:>/?AI\2AH%OI5[JNBR7 M;BTO
MK>VQ#Y\,Y4(\8!D17=N>  ?=M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M].\9>._%E_KM_81,K*5MFO9I%MSM=UWQJKE792V"16UXB_83O/'G_!4S0/\
M@H/XX\3V<VF>!/A/+X7\"^'H$<3V^I7=W,]]J$SX"D&V:*!$!8?-(QP=M 'D
M?Q&_X)N_MF_!#]LOXB?MA_\ !,7]IGP-X7/Q@^Q2_$WX??%#PI<ZEI4FI6T9
MC34K22TGBFAF9&8O&?E9G9B2"BI\Y_\ !"K]GO6/%_\ P4)_;B^*/C[XPGXN
M^'M:O](\'^)/'\FG):V/B?6A;2R:Q!;0Q,R16UL\JVR(KMB)HL,<U]G_ +5_
M_!&C]A7]LWXN7OQP^,GA7Q=%XAU>R@L_$$_AKXBZOI4.KVT*>7'%<06UPD3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /GK]@O6+^P^#FK06V@7%RO\ PG&L
MGS(B,9^TMQS7MO\ PDNK_P#0H7O_ 'TM>1_\$]_^2)ZM_P!CWK/_ *4FO=*
M,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6OC#]O'_DX:\_[!MK_ .@5XU0!
M^FG_  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+7YET4 ?II_PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM?F710!^FG_  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]
M+7YET4 ?II_PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM?F710!^FG_  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+7YET4 ?II_PDNK_ /0H7O\ WTM'_"2ZO_T*
M%[_WTM?F710!^FG_  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+7YET4 ?II_P
MDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM?F710!^FG_  DNK_\ 0H7O_?2T?\)+
MJ_\ T*%[_P!]+7YEU^H>B_\ (&M/^O6/_P!!% %#_A)=7_Z%"]_[Z6C_ (27
M5_\ H4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X2
M75_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_
M^A0O?^^EK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_
M .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W
M_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?
M^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^E
MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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MGJW_ &/>L_\ I2:]TH ^&/V\?^3AKS_L&VO_ *!7C5>R_MX_\G#7G_8-M?\
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M"+?4M$L='T Q7.GV21M_H[MO/VF5F*@,=@R><#)'A_P"_;S_ &-?CE\9;?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0!\,?MX
M_P#)PUY_V#;7_P! KQJO9?V\?^3AKS_L&VO_ *!7C5 !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?J'HO_(&M/^O6/_T$5^7E?J'HO_(&M/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'SU^P7;>))?@YJS:3J5O%%_PG&LY66$L<_:
M6YS7MOV+QO\ ]!NR_P# 8_XUY'_P3W_Y(GJW_8]ZS_Z4FO=* /A']M^/48OC
MY=IJEQ'+-_9UMEXDVC&SCBO(:]E_;Q_Y.&O/^P;:_P#H%>-4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5^E>CV7C4Z1:E=:LP/LR8!MC_='O
M7YJ5^H>B_P#(&M/^O6/_ -!% %#[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'
M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\
M:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'
M_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W
M9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H
M-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[
M%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH
M^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\
M:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E
M_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W
M9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7
MC?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[
M%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK
M8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#+L[3Q:ETCWVK6
MKQ!OWB);D$CV-:E%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_V/
M>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 ?#'[>/\ R<->?]@VU_\ 0*\:
MKV7]O'_DX:\_[!MK_P"@5XU0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7ZAZ+_R!K3_KUC_]!%?EY7ZAZ+_R!K3_ *]8_P#T$4 6:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^
M2)ZM_P!CWK/_ *4FO=* /AC]O'_DX:\_[!MK_P"@5XU7LO[>/_)PUY_V#;7_
M - KQJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OU#T7_D#6
MG_7K'_Z"*_+ROU#T7_D#6G_7K'_Z"* +-%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->
MZ4 ?#'[>/_)PUY_V#;7_ - KQJO9?V\?^3AKS_L&VO\ Z!7C5 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?J'HO_ "!K3_KUC_\ 017Y>5^H
M>B_\@:T_Z]8__010!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\
MZ4FO=*^?OV!O$&BZ9\&M6MM0U&.*3_A.=9;:YYQ]I;FO;_\ A,?#'_0:@_[Z
MH ^*OV\?^3AKS_L&VO\ Z!7C5>O_ +<E_9ZE\?KRZL;A98SIUL ZGC.RO(*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_4/1?^0-:?\ 7K'_
M .@BOR\K],=&\7^&5TBU5M9A!%M&",_[(H VZ*S?^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH T
MJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?
M#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?
M]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#
M2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH T
MJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?
M#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?
M]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#
M2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJ@#2HJA;>*/#]Y.MK:ZK$\CG"(IY)J_0 4444 %
M%%% !1110 4444 %%%% '@__  3\M+6?X*ZL\UM&Y_X3K61ED!/_ !\FO<O[
M.T__ )\8?^_0KQ'_ ()[_P#)$]6_['O6?_2DU[I0!\+?MVQ10_M!WB0QJB_V
M;:\*,#[E>.5[+^WC_P G#7G_ &#;7_T"O&J "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_3W1=/L#H]H38P_\>T?_ "R']T5^85?J'HO_ "!K
M3_KUC_\ 010 _P#L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[
M]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3
M_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*F
MHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\
M8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"
MC^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^
M?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH
M A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&
M'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#GQA_[]"C^
MSM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A_L[3_P#G
MQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\ OT*FHH A
M_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT*FHH A_L[3_P#GQA_[]"C^SM/_ .?&'_OT*FHH A_L[3_^?&'_ +]"C^SM
M/_Y\8?\ OT*FHH B2QLHV#QV<2L.A6, BI:** "BBB@ HHHH **** "BBB@
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MM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 ?#'[>/\ R<->?]@VU_\
M0*\:KV7]O'_DX:\_[!MK_P"@5XU0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7ZAZ+_R!K3_KUC_]!%?EY7ZAZ+_R!K3_ *]8_P#T$4 6:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 ?#'[>/_)PUY_V#;7_ - KQJO9?V\?^3AKS_L&VO\ Z!7C5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?J'HO_ "!K3_KUC_\ 017Y
M>5^H>B_\@:T_Z]8__010!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^
M">__ "1/5O\ L>]9_P#2DU[I7SU^P7;>))?@YJS:3J5O%%_PG&LY66$L<_:6
MYS7MOV+QO_T&[+_P&/\ C0!\8?MX_P#)PUY_V#;7_P! KQJO7OVWX]1B^/EV
MFJ7$<LW]G6V7B3:,;..*\AH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K]0]%_P"0-:?]>L?_ *"*_+ROTKT>R\:G2+4KK5F!]F3 -L?[H]Z
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MX'_#C6OB]\6_%UGH'AGPYI\E]K>LZ@^V&SMXQEY'(!. /09H Z"BOBGX?_\
M!PU_P23^(_CW2/ >D_M-7.G?\)#>K:>'M>\2>"=8TO2=2G8@!([Z[M8X!DGA
MG95/8\C/VM0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_!/
M?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE 'PQ^WC_ ,G#7G_8
M-M?_ $"O&J]E_;Q_Y.&O/^P;:_\ H%>-4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5^H>B_\@:T_Z]8__017Y>5^H>B_\@:T_P"O6/\ ]!%
M%FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT;PG91S1VWAG2].A1]>O[C>5T^UME $]Q<.6&W&#EW<A5=A\J_\ !,3]DO\
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M_P#<U 'U-17RS_P\M_ZHK_Y<?_W-1_P\M_ZHK_Y<?_W-0!]345X9\!OVT?\
MA=OQ#A\!?\*U_LSSK:67[7_;/G8V+G&WR5Z_6O<Z "BBB@ HHHH **** "BB
MB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\
MI2:]TH ^&/V\?^3AKS_L&VO_ *!7C5>R_MX_\G#7G_8-M?\ T"O&J "BBB@
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MT_Z]8_\ T$5^7E?I7H_@G26TBU8W-YS;(>+MO[HH Z&BL?\ X0?2/^?F]_\
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MOB]I&F:C):OXCLM/@_T+3I7B97^SO.DGFH"-P*L,-&IKD_%/[/WPH_X) _\
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M155?M:B@#Q/X2_M__L]?&7QS\:? 7AF^U>WG^ >IK8_$*]U#2REO%(8)+AC
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M[Y_X;5_9F_Z*7_Y1KW_XS1_PVK^S-_T4O_RC7O\ \9KX&HH ^^?^&U?V9O\
MHI?_ )1KW_XS5S0/VM_V>_%&N6?AO0OB!Y][?W*6]I#_ &3=KYDCL%5<M$ ,
MDCDD"OSZKKO@#_R7'P?_ -C+9?\ H]* /T>HHHH *K:U_P @:[_Z]9/_ $$U
M9JMK7_(&N_\ KUD_]!- 'Y>4444 %%%% !1110 4444 %%%% !1110 4444
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MC_$[P-9?:O[<\#VOP&TO19-2WVLL<.+R"5I(?+G>*;Y0=PB*'AC0!]?T444
M>%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE 'PQ^
MWC_R<->?]@VU_P#0*\:KV7]O'_DX:\_[!MK_ .@5XU0 4444 %%%% !1110
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MNSM!YQC-=[110 5UWP!_Y+CX/_[&6R_]'I7(UUWP!_Y+CX/_ .QELO\ T>E
M'Z/4444 %5M:_P"0-=_]>LG_ *":LU6UK_D#7?\ UZR?^@F@#\O**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]E_8._P"3AK/_ +!MU_Z!
M7W/7PQ^P=_R<-9_]@VZ_] K[GH **** "BBB@ HHHH *\O\ VL_V/_@C^VQ\
M.+'X4_'S2]4N]&T[Q!;:U:Q:3KMSI\@N[<.(V,ELZ.RCS&RA.T\9!P*]0HH
M_++_ (*L?!'_ (-U_ O[3>K?$[_@HW\?+_P[\1?%L5M=ZCI.F_$/7_/\M(([
M>&0V&F._V=&CA7!,:ARK-R<FN:_X)A'_ (-HO^&Y/ __  []_:"\2:Y\7?\
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M_P"+_P!#% 'KO_"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\
M0H7O_?2U6UCQ)JS:1=*?"-X,VS\EEX^4UT-1W?\ QZ2_]<V_E0!^6]%?8E%
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MXQS0![=575-<T30XXY=;UBULUE?9$UU<+&';^Z-Q&3[5^6'[ '[!/[).D?\
M!;WXA>//V2?@];^%O _[._A6'P^9;75+RZ74/%>H12BYD#W,TA_<6LD]NZ#
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MI/X=?LB_ 7Q'^T%\4;F0:7X?LO,2SMANN-0N7(2WLX%_CFFE9(D7^\XS@9(
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M5=&5@RLI((((.#5RJ?AWP[X?\(>'['PGX3T.STS2M+LXK33--T^V6&WM+>-
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MD^'$OP\TH>'&LWB6Y_LCS%47 E$;>3Y@D\PRC9D$[Z_17]F_XJ7_ ,=/V>/
M7QMU7PX^CW7C'P7I>N7.D2$EK&2[M(KAH"2 24,A7G^[7Y<:M_P29^ 6C_\
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ME='4JZ.N0P/4$=Q530?#/ASPK9'3?"_A^QTVV+ES;V%HD*%CU;:@ R?6KM%
M&9X@\%>#?%DL,WBGPEIFIO;'-N^H6$<QB/JI=3M_"M)55%"(H"@8  X I:*
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MHHH *T_!?_(WZ7_U_P 7_H8K,K3\%_\ (WZ7_P!?\7_H8H ]UHHHH *CN_\
MCTE_ZYM_*I*CN_\ CTE_ZYM_*@#Y[HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#JO@Y_R.\7_7O)_*O7J\A^#G_([Q?]>\G\J]>H ****
M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
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MBB@ HHHH ^>OV"_#=AJWP<U:ZN9KA6'CC65Q%.5&/M+=A7MO_"#Z1_S\WO\
MX%M7D?\ P3W_ .2)ZM_V/>L_^E)KW2@#QGXHZ=!I?BV2TMWD91"AS*Y8\CU-
M<[75?&/_ )'>7_KWC_E7*T %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME)KW2O"_^">__)$]6_['O6?_ $I->Z4 >0_&/_D=Y?\ KWC_ )5RM=5\8_\
MD=Y?^O>/^5<K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7T)
M:?\ 'I%_US7^5?/=?0EI_P >D7_7-?Y4 24444 %>%>-/^1OU3_K_E_]#->Z
MUX5XT_Y&_5/^O^7_ -#- &91110 4444 %%%% !1110 4444 %%%% !1110
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MI/#S_#CPSX\G'BRUN/$FB6CS+ +"5K7[;C(C8EOFC0\$\;ATKTKP)I_P3_:
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MKB#Q9XCRG/,3@J-*DXTYRBFXSO9.VMJB5_DCPZ^95Z5:4$E9/S_S/I;_ (:
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MV)[+\?\ ,^EO^&@/A'_T-O\ Y(7'_P ;H_X: ^$?_0V_^2%Q_P#&Z^::*/\
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MQ5M;NVFH>RJW:Y7=;Z'$445J>#_!/BOX@:TOAWP9H4^HWKH7%O;KD[1U8YX
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MHU=?[-NN&&1]RON7^SM/_P"?&'_OT*^'/V"_^3A[/_L&77_H%?=-?U)X-_\
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MS#_G]/\ \"?^9#]@M/\ GE_X\:/L%I_SR_\ 'C4U%'^H/ G_ $*L-_X(I?\
MR(?VCF'_ #^G_P"!/_,A^P6G_/+_ ,>-'V"T_P">7_CQJ:BC_4'@3_H58;_P
M12_^1#^T<P_Y_3_\"?\ F0_8+3_GE_X\:/L%I_SR_P#'C4U%'^H/ G_0JPW_
M ((I?_(A_:.8?\_I_P#@3_S(?L%I_P \O_'C1]@M/^>7_CQJ:BC_ %!X$_Z%
M6&_\$4O_ )$/[1S#_G]/_P "?^9#]@M/^>7_ (\:/L%I_P \O_'C4U%'^H/
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MK5C5C!S_ 'D>5RC[O+&6MF[WYK)/6R3;Z,^H_P!O3XY_'S1/C?\ !O\ 9,^
M?CJT\$WGQ7U+5%U#QY>:3'>MIUO8VR3M#;Q3?NFFE#%07!P=N.6R.=\$^/\
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M_P"T<O\ ^?T/_ E_F0T5-]@N_P#GE_X\*/L%W_SR_P#'A1_J#QW_ -"K$_\
M@BK_ /(A_:.7_P#/Z'_@2_S(:*F^P7?_ #R_\>%'V"[_ .>7_CPH_P!0>._^
MA5B?_!%7_P"1#^T<O_Y_0_\  E_F0T5-]@N_^>7_ (\*/L%W_P \O_'A1_J#
MQW_T*L3_ ."*O_R(?VCE_P#S^A_X$O\ ,AHJ;[!=_P#/+_QX4?8+O_GE_P"/
M"C_4'CO_ *%6)_\ !%7_ .1#^T<O_P"?T/\ P)?YD-%3?8+O_GE_X\*/L%W_
M ,\O_'A1_J#QW_T*L3_X(J__ "(?VCE__/Z'_@2_S(:*F^P7?_/+_P >%'V"
M[_YY?^/"C_4'CO\ Z%6)_P#!%7_Y$/[1R_\ Y_0_\"7^9#14WV"[_P">7_CP
MH^P7?_/+_P >%'^H/'?_ $*L3_X(J_\ R(?VCE__ #^A_P"!+_,AHJ;[!=_\
M\O\ QX4?8+O_ )Y?^/"C_4'CO_H58G_P15_^1#^T<O\ ^?T/_ E_F>P_L%_\
MG#V?_8,NO_0*^Z:^&OV#[2XA_:%LWDCP/[-NN<C^Y7W+7]#^%N4YIDW#4J&8
M4)T:GM)/EJ1E"5FHV=I).SL]?(^KR6M1KX1RIR4E=ZIW[=@HHHK](/6"BBB@
M HHHH **** "BBB@ HHHH \+_P"">_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#D
MB>K?]CWK/_I2:]TH ^(OVY[2WF_: O'DCR?[.M><G^Y7CWV"T_YY?^/&O9?V
MX_\ DOUY_P!@ZV_] KR"OML'P5P;C<)3KXC+</.<DG*4J--R;:U;;BVV^K9^
M$Y[C\=3SG$1C5DDIRT4GW]2'[!:?\\O_ !XT?8+3_GE_X\:FHKI_U!X$_P"A
M5AO_  12_P#D3R?[1S#_ )_3_P# G_F0_8+3_GE_X\:/L%I_SR_\>-344?Z@
M\"?]"K#?^"*7_P B']HYA_S^G_X$_P#,A^P6G_/+_P >-'V"T_YY?^/&IJ*/
M]0>!/^A5AO\ P12_^1#^T<P_Y_3_ / G_F0_8+3_ )Y?^/&C[!:?\\O_ !XU
M-11_J#P)_P!"K#?^"*7_ ,B']HYA_P _I_\ @3_S(?L%I_SR_P#'C1]@M/\
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M?_DB>K?]CWK/_I2:]TKPO_@GO_R1/5O^Q[UG_P!*37NE 'Q-^W'_ ,E^O/\
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MM\>://??#KP/\6+:_P#'8CM&N(K*-DV6][-&H.8XGW9.#S(%&2P!Z7]F_P"
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M]?\ V'/^2_6?_8.N?_0*^V:^)OV'/^2_6?\ V#KG_P! K[9K\YXK_P"1FO\
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MF!]G3 -L?[H]Z^+XQ^&C_P!O?^VGZ3X=_'B?2'_MQT-%8_V+QO\ ]!NR_P#
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M?KS_ +!UM_Z!7D%>O_MQ_P#)?KS_ +!UM_Z!7D%?KF4_\BRC_A7Y'\_<0?\
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MEJ\)?]C'9?\ HY*PQ7^[3]'^1U8#_?J7^*/YH_0VBBBOQH_HX*K:S_R![O\
MZ]I/_035FJVL_P#('N_^O:3_ -!-5'XD3/X&?FA1117[4?S2%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!Z_P#L.?\ )?K/_L'7/_H%?;-?$W[#
MG_)?K/\ [!US_P"@5]LU^<\5_P#(S7^%?FS]CX"_Y$DO\;_*(4445\R?:A11
M10 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
M)$]6_P"Q[UG_ -*37NE 'Q-^W'_R7Z\_[!UM_P"@5Y!7K_[<?_)?KS_L'6W_
M *!7D%?KF4_\BRC_ (5^1_/W$'_([Q'^.7YA1117H'D!1110 4444 %%%% !
M1110 4444 %%%% !1110 5^E^C?\@>T_Z]H__017YH5^E^C?\@>T_P"O:/\
M]!%?%\8_#1_[>_\ ;3])\._CQ/I#_P!N+-%%%?#GZ>%?,/Q%^$'PZU7Q_K6I
MW_A[S)[C5)Y)G^US#<S2$DX#X'/I7T]7@_C7_D<-4_["$W_H9KYWB+,,?E]"
M$L+5E3;=FXR<;Z=;-'/B,)A,7%1KTXS2VYDG^9P'_"D?A?\ ]"Q_Y.S_ /Q=
M'_"D?A?_ -"Q_P"3L_\ \775T5\G_K+Q'_T&5?\ P9/_ #.3^Q<F_P"@:G_X
M!'_(Y3_A2/PO_P"A8_\ )V?_ .+H_P"%(_"__H6/_)V?_P"+KJZ*/]9>(_\
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MNKHH_P!9>(_^@RK_ .#)_P"8?V+DW_0-3_\  (_Y'*?\*1^%_P#T+'_D[/\
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M444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE
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M%O>\I=O(]S)>'L%D3FZ$I/GM?F:>U]K)=R2BBBNT]T*\'\:_\CAJG_80F_\
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MM-_LV[NYK^?S(X\;;:*0Q)OEC7S)-J9;[W!QZY7XV_MO_"KXA>/_ ('?#_\
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M$$B#9M:/]\,G8.M?HK\&?A'X0^ _PPT?X1> 6U$Z/H=L8+ ZMJLU]<["[/\
M//.S22'+'EF)Q@=JZ>BBOC<3B*4:=25TKOKU_K0 HHHKE *^B+3_ (](O^N:
M_P J^=Z]PMO!.DM;1L;F\Y0'B[;TK[+A#XJW_;OZ@;E%8_\ P@^D?\_-[_X%
MM1_P@^D?\_-[_P"!;5]L!L5X/XU_Y'#5/^PA-_Z&:]@_X0?2/^?F]_\  MJ\
M;\66Z6GBC4;6,L5CO954LV3@,>I[U\EQ;_NU/U?Y 9]%%%?" %%%% !1110
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M5'=_\>DO_7-OY5,OA8'SO1117XR 4444 %%%% !1110 4444 %%%% !1110
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M_P#AYI^V]_T6S_RV]-_^1J/^'FG[;W_1;/\ RV]-_P#D:C_B /&/_/\ P_\
MX%4_^5!_Q$O(O^?=7[H__)GZT45^2_\ P\T_;>_Z+9_Y;>F__(U'_#S3]M[_
M *+9_P"6WIO_ ,C4?\0!XQ_Y_P"'_P# JG_RH/\ B)>1?\^ZOW1_^3/UHHK\
ME_\ AYI^V]_T6S_RV]-_^1J/^'FG[;W_ $6S_P MO3?_ )&H_P"( \8_\_\
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M+(TJL54K1C"4>:,O>M)7:T2BY7NFG=+9^5_!Z*^@?V]/@+\(?A?+\/\ XL_
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M.;]KOX/^!;WXE>*OAG!<:-I0SK-UH>NV>HG3O4SI;2NR <Y;&T8.2*\X\?\
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MS1\)\?\ ]JSXZ?M.7MA/\7_&AO;;28C'I&DV=G%:65BIQD100JJ*3@9;!8@
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MY!XL?!@_6I_[8?J_A=\>+](?^WFE1117XT?KH5_/1^W5_P GI_%G_LHVL_\
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MP;/_ .BVK2K-\9?\BAJO_8-G_P#1;5=/^(O4BI\#]#^:6BBBO[!/Y."BBB@
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M_P#"('_R17[$> ?^4@GC_P#[$32O_1C5[I1_K_Q;_P!!/_DE/_Y /]1>%?\
MH'_\GG_\D?@'_P .]_VLO^C9/BG_ .$0/_DBC_AWO^UE_P!&R?%/_P (@?\
MR17[^44?Z_\ %O\ T$_^24__ ) /]1>%?^@?_P GG_\ )'X!_P##O?\ :R_Z
M-D^*?_A$#_Y(H_X=[_M9?]&R?%/_ ,(@?_)%?OY11_K_ ,6_]!/_ ))3_P#D
M _U%X5_Z!_\ R>?_ ,D?@'_P[W_:R_Z-D^*?_A$#_P"2*/\ AWO^UE_T;)\4
M_P#PB!_\D5^_E%'^O_%O_03_ .24_P#Y /\ 47A7_H'_ /)Y_P#R1^ ?_#O?
M]K+_ *-D^*?_ (1 _P#DBNK^!7[(G[67P5^-7A/XP?\ #)/Q3U/_ (1?Q'9Z
MK_9W_"(B'[3]GF27R_,\YMF[;C=M;&<X/2OW1HJ*O'7%5:G*G/$7333]R&S_
M .W2Z?!/#%&HJD,/9IW7OSW7_;Q\<_\ #RG]K+_I$_\ %/\ \"Q_\CT?\/*?
MVLO^D3_Q3_\  L?_ "/7V-17R)]4?'/_  \I_:R_Z1/_ !3_ / L?_(]5M9_
MX*,_M9:OH]WI7_#J3XIQ_:K:2+S/M(.W<I&<>0,XS7V?133:=T)I-69^ ?\
MP[W_ &LO^C9/BG_X1 _^2*/^'>_[67_1LGQ3_P#"('_R17[^45]A_K_Q;_T$
M_P#DE/\ ^0/D_P#47A7_ *!__)Y__)'X!_\ #O?]K+_HV3XI_P#A$#_Y(H_X
M=[_M9?\ 1LGQ3_\ "('_ ,D5^_E%'^O_ !;_ -!/_DE/_P"0#_47A7_H'_\
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M9;,HNX$;)WR,D$X.-?3/^"^__!,'6_$":=H/QD\2ZAI$NJ#3H?&FG_##7Y]
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M]UX U;^U+J'^RIKV%8+EO*BE6*??&BKB9'"XRH4DFO1* /R#_P"";/[6EO\
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M5\4Q7=Y<PG2?&.L)IL4MU')%.4TPW9L4#+(X $ "D@J%(! !^?W_  0)T/\
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MO/V8/V/_ -FW]C3X+6_[/?[-OPGT[PUX2@DEEETR$O.UY-+@2S7,LS/)<RN
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M@ >IH 6BJ>B^(O#_ (DMFO/#NNV=_"K;6ELKI)5!]"5)&:N4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <7\=?\ D4;;_L))_P"B
MY*\GKV7XL>'=8\3>'8;#1+/SY4O5D9/,5<*$<9RQ ZD5Y[_PJ7X@_P#0O_\
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MBT+3=",9<RNC^=-/=/+N0%I6 41@*HR2<;_@L/\ \HH/VDO^R'^)_P#TV7%
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MLQN </%,SCD9()H \<_X)2>*_P#@CY9_M;:KX5_9E_8E\5_LX?'8^!YH-1\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A7_!07_DC.F?\
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M\6^.?B:VBP:G<Z)X?LR(T2RMY\PO/<S;H_,<$1A0P!)R/,[OXF_\%-OV//\
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M<,SSI(H,Y9(UC0JR_1'_  7W_P"4-O[0G_9/YO\ T=%7S+/\5/\ @KW\3/\
M@FIH_P#P3U\'_P#!/B>^\7>+OA9:>$K?XY?\)OIR>%1HUUIZ6QUF1&D^UQW(
MM7+-:^22)LE/,4*K '5?MW_\%*/VO_&'PS_8C^)'_!/CQ/IOAF\_:5\2V<-]
MIGB72(+ZUCM[W3$G"7):/S-MJ\C2/Y#Q/)Y!4-AJV_VQ/BU^W=_P3!_9DTSP
MM:?M>7'QR^,WQY^+FA^!/AAJWC3PA8:78^'-0U 2+)<?9K%55K=!&SA'W;7*
M;BZ[E.E\:O\ @FS\7/!-]^P+\+_@-X:?Q)X8_9S\6VJ>--=EU"UM6@L;?2/L
MGVQHII5:0R2C<8X0[ OTP,UZ9_P6)_8M^,_[7OP#\&^*/V8+S2T^*GP9^*6C
M_$3X>VFM3>5::I?:<SYL)I.D:2QR-@G"[T0,54LP /GS]I[QI_P4L_X(]V'@
M']K+XQ_M^WGQ]^&M_P"-]*\/?&/PSXG\ :7I4FG07\ODC5=,EL41HO*E91]F
M<NK!U!/\2]]^T7\:_P!LO]L?_@ISK7_!.C]DS]I&;X,^$/A5X"T_Q'\4O'.D
M>&[/4M8U*^U!R;/3+47B/#;QB%?.:;:6)W+C'7SS]J?0/^"C'_!8W3/ 7[(G
MQ&_X)\:Y\!_AS:^.=*U_XS>*O&GC+3+XW5M82B?^R],CLI7>X,LJKBX941?+
M4D<UZ5^TA^SS^V_^RI_P4MU3_@HS^Q#^S_8_&+0_B;X#LO#/Q3^&Q\86>A:E
M#=V#G[%JMI<WI6WD40GRGB=@W4C.X; #G/V0OCO_ ,%&OA__ ,%N];_X)U_M
M6?M*67C[P)HW[,DGB_PSJ4/@^PTVYUJ=M?MK6/4+SR(]R7*+)<VC)"ZV[K D
MOE+([8X7]D3Q1_P5K_X*4?$W]IOPQ;?\%$)/A9X$^%/[3?B[P?X0U3PW\.=(
MO-7NH;2>,0:?(\T0C2UM(O)8/M:XG:ZD$DVV-08/V*O$7[4_Q0_X.5/&?Q,_
M:>\ :+X4U.+]CJ.UC\%:)X@75G\)6TOB2VDMM/OKN-5BENY1%<7A\H>6J7**
MK/L+M],_\$B/V7/CM^R__P -/_\ "]/ W]A_\+$_:_\ &OC;P=_Q,[6Y_M#0
MK_[']DN_]'ED\KS/*D_=2[)5V_,BY&0#S+_@IA\;+'X3_'RZM/BI_P %^],_
M9WTRZL+>7PS\-='\(Z'<:A!B(*]W=RW:3W,T<DH<JNR*/ V@L02(/^"7'_!3
M/XL?M7_L5?M W/B;XV>'O'WBSX(:IK.EZ-\6?"NC):6?BJT33S=6&J&U*^5%
M,3N$D2KY8,8P""<\]X-\!_MK?\$^O^"B?[1'Q?T;_@F_J_QWL?C9XHL]<\#_
M !%\)^)-(MKS3HTM$@_L>^.H31R6L$)4!9%+)MY /*IJ_P#!./\ 8W_;^\!^
M$?VTO$G[7GPKT?2?%_QQ\37FK^%[/P_X@M;JRNOM&E21+!#()-R)$[I;A[A8
MF;R]Y !S0!X]\#O%_P#P6M_:5_X)(6'_  4\U3_@I=!X3\2:/\.;[Q/HO@;3
M/ACH\MAKD.GI-(SZG,T(;S;M8'^6W6*.!)(\(SJ[-T_B/XI?\%>OVBO^":MQ
M_P %?? W[;.F_#"[L?AO<>.O#OP0T/P'8ZAHMQIMI;-<O!>7EVK74TUU#"[@
MJR+"9D11E#(WT%^R9^R/^T)\,_\ @@M8?L7>-_A]]B^)</P'UCP[+X:_M:TD
MVZE/:74<4'VB.5K<[FD0;_,V#=DL #BY\)?V4?C[X9_X((V_[%FN> O(^)B?
MLR7GA-O#7]J6K8UA]%EMEMOM"RFWYF95\SS/+YR6QS0!XU^W]_P5'^,MM^R+
M^R7\7O 'QCLO@3X4_:+_ +/N?B%\8[KPZFK1^"(+C2$OH[5(YU:%))Y7:!9Y
M05C$3/V++]#?\$\/!_Q1&JZA\2+'_@K?'^TO\.K_ $KR+"W.C:#(UAJ'F1N)
MTU'20@D4QB13"ZG&Y6!&#GS_ ,$K^V!^QM_P3<_9V_9]O/\ @FU<?&N/2_A3
MIV@_%WPI8>+M&6YT.YM+"SC5%@NY#;ZFC2"X5A'(0#$K L&KSG_@FY^Q9\5K
M#_@J%XF_;M\$_L$I^RK\++WX6GPW>?#TZGIZW/B_5VOEG74I=.TUWMK)8HPR
M9)$C-@C(D<@ _3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BN _:-^.7_"@/!%KXR_X1?^UOM.JI9?9OMOD;=T4K[]VQ\_ZO&,=^
MO'/BW_#S'_JBG_ER?_<U?*9OQQPOD.->$QV(Y*B2=N2;T>VL8M?B<U7&8>C/
MEG*S]&?5%%?*_P#P\Q_ZHI_Y<G_W-7M/[.7QR_X7_P""+KQE_P (O_9/V;57
MLOLWVWS]VV*)]^[8F/\ 68QCMUYX,HXWX7S[&+"8'$<]1INW)-:+?644OQ"E
MB\/6GRPE=^C._HHHKZLZ0HHHH **** "BBB@ KDOCM\(;/X\_";6?A'J'C_Q
M;X6AUJ!(I-?\"^(I=)U:S"R))NM[N'YX6.S:2O569>A-=;10!Y/^QI^Q5\ O
MV#?A WP7_9[T"]MM/N]8N=8UK4]8U.6^U'6=2N&!GO;RYE)>>=]J@L>RJ
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M$?C?P7X/N=-LO%OB_2]+FUF_6QTB+4=0C@:^NF!*P0AV!ED(!(1<L<'BM2@
MKPG]KG_@GU\*OVPO$NB>.O$GQ7^*O@?Q%X?LIK/3_$'PJ^)>H>'KHVTKJ[PR
M&UD"2J64'YE)&3@C->[5E:;X[\$:SJ6K:-H_C+2KN\T"14UVUMM1BDDTYF3S
M%6=58F$E/F ?&5YZ4 >1_L6_\$[_ -F/]@NQ\12? OP]J\^N^,KZ.\\:>,_%
MGB"YU;6M?GC4K&]U>7+L[A S;4&U 68A<LQ/N-9WA+QAX2\?^';7Q?X$\4Z=
MK>DWJ%K+5-(OH[FVN%#%24DC)5P&!'!/(([5HT %%%% !1110 4444 %%%%
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M"GG[&7PWMO!7PDU'6[;P?^TSX*\.0LFFMI%Y*([/7%M@=D,MI<, 3& 7\U$
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M\<_BKX0\&:E)9W?B?XI:QXILM*TJ=XH)T-Q=!X(B[R1E8A(&8J6"D(2 #?\
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M>YL+W4H+>1%DE%O+$65MH!0^:#Y8WT >D:5_P56_:V^ 7QI^'/P\_P""F/[
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M/&=M%9^,/"FFZM##)YD,6I6,<ZQO_>4." ?<5H0PQ6\2P01*B(H5$1<!0.
M!T%.HH S?#W@WPAX2:Y;PIX4TW3#>2^;=G3[&.'SW_O/L W'W/-:5%% !63K
MO@+P-XHU*VUGQ-X,TG4;RR_X\[N^TZ*:2#G/R,ZDKSSP16M10 5QWQ^@^/\
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MHJ7PI\&]7^$OBO5_%5K+<O\ 8=0GC$ LG,**SSS;Y%6*-%9V9PJJ6(%>S_\
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MOG\9:9:W&IVTEM>SP06LT2V4<LDR227$(#1JPP^XX4$CX2_9O_:(_P""B_\
MP4N_8RU/]OJ/]K[X,? KX)Z[::Y)8>#M0^$'_"42VNAV=Q<VTS:K<7&I6T7F
M,L$I=(T\O81P,D#Y*U75]3UO_@Q:6]U>^DN)4MH;=))6R1%%\2EBB3Z+&B*!
MV"B@#]0+;_@N1_P3%N_CKIO[/T/[1V-3UG7O[#T?7G\,ZDN@W^I[S']DAU8V
MXLY7W@J&64H6&T,6XKUO]L']N7]ES]@WX?6?Q)_:C^*4/AVQU344T[1+2*RG
MO;[5;QONV]K:6R233OZA$(7(+$#FODW_ (../AGX"\ ?\$$_BAX.\&>%;/3-
M-\%Z;X:7PI:V4(C72OLVM:=% 8-N#&4CR@*X^4D=":S_ (_7%CJW_!Q+^S!<
M_&=H7T9_V??$<_PW.H "%O%)G4WAA!^7S_L.P\<@;?:@!FL_\%2_ W[47_!5
M/]D'X<_LF_'G6AX9UK_A9%K\4_ U]IEYI-V+FTT.RN;!-0L+R**=-C/))$S)
ML;+%&;!Q^C]?FQ^VE!\(T_X.4_V+YM 6P'CA_A]X[_X2?R0OV@Z:-*G_ +/,
MN.=OF?VCLSZ/BOTGH ^5_CA_P6D_X)S?L]?&W5_V?OB)\<KN3Q#X95&\8GP_
MX0U35K/PT''RG4+JRMI8;3_:#L"G5]HYKA/^"('[47C?]HWX1_M#_$CXG?&F
M7Q7I.@_M4>-=,\+:Y?:HLUM::!;FU>UBAESM%LD;LR$';M;.<5QW_!M3%X;F
M_8 \877BV.T/Q$G^-GC _&@W 4W)UW^T9-XNMWS;OLWV?A^Q^M?$GP0=+'_@
MW _;\_X8[/\ Q(E_: \9)X:.B?ZO_A&C/I F,>W_ )9?V9YV<<>7GM0!^DMG
M_P %_/\ @E-?>,8O#4/[2LRZ7/J_]E0^.I?!VK)X9>]W[/)&L-;"SQN!'F^;
MY7'WZ^AM>_:O^ 'A?]I#PW^R/K_Q 6U^('C#P[=:[X8T.33+K9J5C;-B=XKH
M1?9V=/O&+S/-V_/LV\U\$>#OV9/^"GG[6/\ P39TK]G7P%\5/V-KGX->./A3
M!H^BQZ3\,_$1\K2IK)8X9(3_ &LT:3Q@JZOL.R5 V,KBJO\ P4?_ &=OBG^Q
MA_P3F_9F_;#LO$R^,OB!^Q;>:!=ZWKNE*Q;7_#AMX=,UJ*,L=VV:V\J5F8YV
M0N3DF@#] OB]^U7\!/@1\3/A]\&_BEX\_L[Q/\4]8N-+\!:-%I=U=3:K<P1"
M:<#[/$XB2.,AGEE*1J",L,UY=^U)_P %</V#_P!D#XJ?\**^+/Q8O[SQO'8+
M?WOA'P;X3U+7K_3[1@&$]U%I\$WV92I5AYI5BK*P!!!KYY_9.\4^'?\ @I!_
MP6R^('[97A?5X=:^&G[./@.U\"_#74H&WVM[X@U6,7FJWT+=I(K=H[1^F5D3
MCO7A'_!)FQ_X*8ZO\:OVNKG]G?X@_L]:5XM'[3GB ?$"T^*O@W6[_P 0!0RB
MP/FV>H6Z_P!G>2&%LNS:,3%20> #[J_:/_;;^&7QR_X)'?&O]L3]B;XXP:M:
M6/P7\6ZCX9\5Z#*\4^GZA::3=2(2DBK+;W$4J(VR15=2 2HXJQ^S#^V1\/?@
M_P#\$C_@S^V)^VA\;K;2;&;X(^%-6\7>,/$=RS/=7MUI5J\DC;07FGEFD)"(
MK.[OA5).*^8?$'[#G[0_[(O_  3[_P""AGQ'_:#^)GP^U2_^,/PT\3>*)/#W
MPST:\T_2]*OO^$:OH;N9(+N::17N2D4C$NVYD8], >3?'%-$N/V1O^"1-G\8
M5B;X72ZCX'_X2A-0Q]A;5!X8MO[)%P'^0J9?.X?C&[/&: /OK]ES_@L'^P)^
MU]\6(/@3\)?BWJ-KXROM/:_T;PWXP\(:GH5UJUHJEC/9KJ%O$+I=JLV(RS!5
M9BH4$UH?M#?\%9/V!/V6OB?K7P1^-'QU.G>--"L+&[N/"=IX:U*\O[I;W?\
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M'/A'_A--)CTO^T/LWEW(E\SRM^<*PQC(_O?I7*?\*$_ZFO\ \D?_ +97HE%
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MZK:^'K^._P##&I6.IW%CJ.BW: !9[2\MW2:%\ 9PV&VC<&P*]CHH ^9_@/\
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M\6!\?_'W@37- \?M8K977C?X?^,-0\/ZE>6R@!8KB6QFC%P %4 RAF54500
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MIH+^&X\':M<3ZG;3QWL\L]RDAO9)7D5Y9I&PS$#=A<  #UFB@#XFTG_@WO\
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MEJG_ &-4_P#Z36U?%]?:'_!.G_DB6J?]C5/_ .DUM0![Y1110 4444 ?#O\
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M>541%+.[M@*!R22>@JOI&MZ+X@LAJ6@ZO:WUNS%5N+.X65"1U&Y21D5\=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXXU^QBLM=\96?A^VBU74K:,((X9[M4$TT:B.,*CL0!&N -HQU-% 'QQ\#?\
M@DM_PIC]@G]H/]B#_A?_ /:7_"]]8\:W_P#PD_\ PBOD_P!A_P#"06C6^S[-
M]J;[3]GW;L^9%YN,8CZU8^*?_!*3_A9?['?[+_[)O_"^OL7_  S=XP\"Z[_;
M_P#PBWF?\)%_PCEI]F\GR/M2_9/M'WM_F3>5TVR=:^OZ* /DS]L__@FUX_\
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MHN=6%EX2\._#X:;H45E>Z?+:FWM%-V\D4OF2F:6YE,S2B.*(+$L8)^[Z* /
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M9+6=D)WI\RRLQ9CPJKT/[-'_  2?T_X#?LI?&CX0^*_CYJ/C/XE_M PZO/\
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>biib-20201231_g31.jpg
<TEXT>
begin 644 biib-20201231_g31.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K\/?AE_P=^_M$_'77M9T#]GW_@B+XT\?3:%*%U1?
M!OQ"N]2:U5F=4>5;;07,08HV-W7:<9P:_<*OY-O^" ?@3_@L#XX^+OQFB_X)
M)?&CP7X.U&W2P/C>3QE:VTJW4)N+O[*(O/LKD JPFS@)]X9)[ ']$_\ P2J_
M;Z^.W_!0?X.^(OB7\??V$?%OP"U+1?$ITRR\-^,+FZDGU&#[/%+]K0W-C9L$
MW2-'PC#,9^;/ ^EKGQ'X>L]6AT&[UVRBOKA<P64ETBRR#U5"<GH>@[5^;/QD
M^.W_  5R_P""?O\ P0N^.?QZ_;J^+/A;Q)\;]#GD7PGXA\)6ENMOI]A>2:?8
MV\NR*UMT,T$L]S,-T;9(3<6'RC\V_P!BW_@AS\!OVW?^"(WC[_@JG\=?CCXZ
MU#XT7ND>*?$VF>([GQ"9(K.72'N0B7(D5GG:9[1VDE9]P69=NTIE@#^E:JVH
M:QI&DO!'JNJVULUU.(;5;B=4,TAZ(N3\S'L!S7\[/P?_ &TOCM^V#_P:)?M%
M:?\ M ^+[_Q'JGPZ\5Z7X<TKQ!JD[37-SIPU/0[F&.:5B6E>,SR(&8D^6(P?
MNY/IO_!OM_P0N^&_[4W[)W[/_P#P4=_:0_:)^(U[KW@SQ:-9^%7A+2]4MH]'
MT.STK7YIEMGAE@D9Q/=V\\TAC>(E9P.'!8@'[Q5\;?L2_P#!9WX._MP?M[?&
M3]@3P5\(O$VC:]\&;[5K;6-<U2>W:TOVL-4&G2&$1N7 :0[QN ^7KS7T[\>O
M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
MV$D,OX(_\%Y_^"9G[//_  1$^+GP1\>_\$TOCSX]T/XFZ]>7++H/]OBZU&-8
M6A$%["8(TD022N\)C<,DQ4A5^20']N_^"Y7_  4YUW_@D_\ L*7G[2'@OX>V
M_B3Q)JWB&W\-^&+6_F*V=K?7$%Q,MS<A2'DBC2VD)C0AG;:NY 2Z_@G_ ,$P
M_P#@K7_P3A^#W[2&K?\ !1;_ (*FZ)\;OC5^T-J.J/<Z5J%MX;TF?1_#P'RQ
MRVRSZG"7F5<"/]U'';* L2 J)* /O;_@ZS_X*"_M4?!']B[X&?LL^&M?O/"G
MBWXR:7)=_$R;1+DVTH2UM[-9M.613E(I;F[;>%(RMN$)*.RM\T?\%?/^"7>G
M?\&ZGA?X#?MP_P#!/SX\>--/\:1>(?[%\7WFI:JLD&J7:VWVD.(D1/\ 1Y?)
MN4DMWWHR,@X(8M]&_P#!US^S/\2OVX_V*_@/_P %*?V:/ VMZII?A729-3UK
M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,GP=XZ\(_$'2Y-;\%Z]!J-I#=RVLD]N256:-MKISW!X-:U>%_P#!/?\
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M/1J*\Y_X7_\ ]2E_Y/\ _P!KH_X7_P#]2E_Y/_\ VNC_ %AR?_G[_P"2R_R
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M  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0!X]\9O\
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M %%>!_M5_'7]NWX?>/+'P7^R5^PSI_Q&T^?2$N]1\6:Y\2[71+2SG,LB?9!
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M.$'(9>>*^RX0^*M_V[^H&Y16/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM?;
M;%>#^-?^1PU3_L(3?^AFO8/^$EU?_H4+W_OI:\;\62O/XHU&:2!HF>]E+1MU
M4ECP:^2XM_W:GZO\@,^BBBOA "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K4\%?\CAI?_80A_\ 0Q676AX3E>#Q1ITT<#2LE[$5C7JQ##@5OA?]ZI_X
ME^8'OE%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM?L(&Q4=W_QZ2_]<V_E
M67_PDNK_ /0H7O\ WTM1W/B35FMI%/A&\&4/)9>.*F7PL#P^BBBOQD HHHH
M***Y/P7\9_!'CWXC>,?A;X?N9FU;P->VEKKL<L850]S:1W4?EG)+#RY4R<##
M9':FHMIM= .LHKQ?]K3_ (*$?LD?L02:18?M'_%7^Q]2\0K(= T6RT>[U"^U
M'80&\J"TBD<@$@%B O/6H_V2O^"B/[(7[;UWJ^B_L[_%A=3UGP^JMKOAS4]+
MNM-U*Q5B '>VNXXY"F2HWJ&0%@"03BM?JV(]E[7D?+WL[?>![9117SA\4?\
M@KI_P3F^#?QLA_9S^('[4&E6_C:;7(M'/A^QTN^OI8KZ218T@E:V@D2%M[*#
MO90,\D5-.C6K.U.+D_)7 ^CZ*1F5%+NP  R23P!7RK;_ /!:_P#X)J7/Q)7X
M;1?M&1_/K7]CQ^)F\/WXT%[_ #C[.-4,'V0G_;\SR_\ :ITJ%:M?V<6[;V5P
M/JNBLKQOXX\&_#7P?J7Q!^(7BFPT30]'LWN]5U?5+I8+>T@09:221R%50.Y-
M?.'P9_X+,?\ !/;X_?%31_A!\,?B_JMYJ?B._-EX;O+GP/JUM8:K< ,?+@NI
M;58F.%;!+ ';P3QDIX>O5BY0BVENTGH!]2445\U_M%_\%;?V&OV7/BOJ/P-^
M*/Q'UJ3Q9HT,$VLZ-X?\$:KJ;V$<T*S1/+);6SQKNC96QO)P>E*E1K5Y<M.+
M;\E<#Z4HKS_]FG]JC]GW]L/X8P_&+]FOXH:=XK\/37#6[7MCO1X)U +0S12*
MLD$@#*2DBJV&4XP03Z!4SA*G)QDK-=&!U?P9_P"1YB_Z]Y/Y5[#7BWPKNY['
MQ?'<6]C)<L(9!Y41&3QUYKU'_A)=7_Z%"]_[Z6OT+A;_ )%C_P 3_) ;%%9=
MGKVI7-TD$WAFZA5FPTKLN%]S6I7T@!1110 4444 %%%% !1110 4444 >%_\
M$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE 'CWQF_Y'
MF7_KWC_E7*5U?QF_Y'F7_KWC_E7*5^3YM_R,ZW^)_F 4445YX!1110 4444
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M&PM#+#)-+(!+*]\LFZ&663SV<_*ZN,_JK^T'XB^._A/X8W?B+]G#X;:-XO\
M%%K<P/!X;US73ID5]!YJ^<BW/ER"&7R]Q1F4KN !X-?F-\9_A#^VM_P4M\9?
M'7]EV_\ V)=.^'A\5>//"=YXH\;>*_'6F:A)X(%IINGN6LH[)I)+FYFABRC(
M8U"3E'926"^[ED[X:=.4N6/5J235W%:K=I=/FEN!^L$WAGPQ)XAC\97'A^P;
M5;>T:VBU5[1#<1P,P9HA*1N"%@"5S@D9Q7P/\#+W1OVX?^"T^H?MD_L\Z9"?
MAS\(OA[=>"=<\?VB@0>+];EF+M:6[KQ<P6J,"9>0'50,JT;5TO\ P6/\*_\
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MOA3Q]I0CU.$HIW36\[+):,KED.[<#MW#@XKR*%"4JBTB]+V<DOU6OEN!Y/\
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MNA6=G/J=U]IU*:UM4C>[FV*GFRE0#(^Q$7<V3A5'0"KE%%%VP"BBB@ HHHH
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MG_80F_\ 0S7O%>#^-?\ D<-4_P"PA-_Z&:^2XM_W:GZO\@,NBBBOA "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K4\%?\CAI?\ V$(?_0Q676IX*_Y'
M#2_^PA#_ .ABM\+_ +U3_P 2_,#WBBBBOV$ J.[_ ./27_KFW\JDJ.[_ ./2
M7_KFW\JF7PL#YWHHHK\9 **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#J_@S_P CS%_U[R?RKV&O'O@S_P CS%_U[R?RKV&OT3A;_D6/_$_R0!11
M17T@!1110 4444 %%%% 'YW?M+_L"_\ !2WPM^W+\0_VW/V4O^"CWPX^$?AS
MQM8Z99:KH.O_  _2Z@NUM+5(8I;QY91')<JWFA)U"2>4R1,S+&H'H_['_P (
M/^"O-C\8O#WQ"_:(_P""C_PL^)/PSC^U?VSH7A+X8Q64VH9MIDA\J[CE8)LN
M#%(V,[EC9>]>!:?^QU^S5_P5A_X*L?M'>'?^"A]W>^,E^"6K:+H_PS^#EYXC
MNK/3]*TJXTN"Y?6C;6\L;7$ES-,X\UB5 4(<XC"+:?LB_LY_\$HO^"NO[/'P
M]_X)ZWU_X2T_XX_\)%8?%+X.VOB.YO=/NM/L]+ENK?6U@N))&M9(KB)8_,R%
M<,R)MS+N /U&HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]Z
MS_Z4FO=* /'OC-_R/,O_ %[Q_P JY2NK^,W_ "/,O_7O'_*N4K\GS;_D9UO\
M3_, HHHKSP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ(M/^/2+_KF
MO\J^=Z^B+3_CTB_ZYK_*OLN$/BK?]N_J!)1117VP!7@_C7_D<-4_["$W_H9K
MWBO!_&O_ ".&J?\ 80F_]#-?)<6_[M3]7^0&71117P@!1110 4444 %%%% !
M1110 4444 %%%% !1110 5J>"O\ D<-+_P"PA#_Z&*RZU/!7_(X:7_V$(?\
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M[Q_RKE*_)\V_Y&=;_$_S ****\\ HHHH **** "BBB@ HHHH **** "BBB@
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MPA-_Z&:]XKP?QK_R.&J?]A";_P!#-?)<6_[M3]7^0&71117P@!1110 4444
M%%%% !1110 4444 %%%% !1110 5J>"O^1PTO_L(0_\ H8K+K4\%?\CAI?\
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M (G^2 R[/PEIMC=)=PW%T6C;*A[EB/Q%:E%%?2 %%%% !1110 445Y+^VO\
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M/,O_ %[Q_P JY2NK^,W_ "/,O_7O'_*N4K\GS;_D9UO\3_, HHHKSP"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KZ(M/^/2+_KFO\J^=Z^B+3_CTB_Z
MYK_*OLN$/BK?]N_J!)1117VP!7@_C7_D<-4_["$W_H9KWBO!_&O_ ".&J?\
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MNE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* /'OC-_R/,O_7O'_*N4KJ_C-_R/,O\
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M\>DO_7-OY5)4=W_QZ2_]<V_E4R^%@?.]%%%?C(!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 =7\&?\ D>8O^O>3^5>PUX]\&?\ D>8O^O>3^5>P
MU^B<+?\ (L?^)_D@"BBBOI "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\
MR1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH \>^,W_(\R_]>\?\
MJY2NK^,W_(\R_P#7O'_*N4K\GS;_ )&=;_$_S ****\\ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *^B+3_ (](O^N:_P J^=Z^B+3_ (](O^N:_P J
M^RX0^*M_V[^H$E%%%?; %>#^-?\ D<-4_P"PA-_Z&:]XKP?QK_R.&J?]A";_
M -#-?)<6_P"[4_5_D!ET445\( 4444 %%%% !1110 4444 %%%% !1110 44
M44 %:G@K_D<-+_["$/\ Z&*RZU/!7_(X:7_V$(?_ $,5OA?]ZI_XE^8'O%%%
M%?L(!4=W_P >DO\ US;^525'=_\ 'I+_ -<V_E4R^%@?.]%%%?C(!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 =7\&?^1YB_P"O>3^5>PUX]\&?
M^1YB_P"O>3^5>PU^B<+?\BQ_XG^2 ****^D **** "BBB@ HHHH **** "BB
MB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=* /'OC
M-_R/,O\ U[Q_RKE*ZOXS?\CS+_U[Q_RKE*_)\V_Y&=;_ !/\P"BBBO/ ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OHBT_X](O^N:_RKYWKZ(M/^/2+
M_KFO\J^RX0^*M_V[^H$E%%%?; %>#^-?^1PU3_L(3?\ H9KWBO!_&O\ R.&J
M?]A";_T,U\EQ;_NU/U?Y 9=%%%?" %%%% !1110 4444 %%%% !1110 4444
M %%%% !6IX*_Y'#2_P#L(0_^ABLNM3P5_P CAI?_ &$(?_0Q6^%_WJG_ (E^
M8'O%%%%?L(!4=W_QZ2_]<V_E4E1W?_'I+_US;^53+X6!\[T445^,@%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!U?P9_P"1YB_Z]Y/Y5[#7CWP9
M_P"1YB_Z]Y/Y5[#7Z)PM_P BQ_XG^2 ****^D **** "BBB@ HHHH **** "
MBBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@#
MQ[XS?\CS+_U[Q_RKE*ZOXS?\CS+_ ->\?\JY2OR?-O\ D9UO\3_, HHHKSP"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ(M/\ CTB_ZYK_ "KYWKZ(
MM/\ CTB_ZYK_ "K[+A#XJW_;OZ@24445]L 5X/XU_P"1PU3_ +"$W_H9KWBO
M!_&O_(X:I_V$)O\ T,U\EQ;_ +M3]7^0&71117P@!1110 4444 %%%% !111
M0 4444 %%%% !1110 5J>"O^1PTO_L(0_P#H8K+K4\%?\CAI?_80A_\ 0Q6^
M%_WJG_B7Y@>\4445^P@%1W?_ !Z2_P#7-OY5)4=W_P >DO\ US;^53+X6!\[
MT445^,@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!U?P9_Y'F+_
M *]Y/Y5[#7CWP9_Y'F+_ *]Y/Y5[#7Z)PM_R+'_B?Y( HHHKZ0 HHHH ****
M "BBB@ HHHH **** /"_^">__)$]6_['O6?_ $I->Z5X7_P3W_Y(GJW_ &/>
ML_\ I2:]TH \>^,W_(\R_P#7O'_*N4KJ_C-_R/,O_7O'_*N4K\GS;_D9UO\
M$_S ****\\ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^B+3_CTB_ZY
MK_*OG>OHBT_X](O^N:_RK[+A#XJW_;OZ@24445]L 5X/XU_Y'#5/^PA-_P"A
MFO>*\'\:_P#(X:I_V$)O_0S7R7%O^[4_5_D!ET445\( 4444 %%%% !1110
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M +]C_P"-T?\ #5?[67_2,OXI_P#?L?\ QNOT,HH_U>R?_GU_Y-+_ # _//\
MX:K_ &LO^D9?Q3_[]C_XW1_PU7^UE_TC+^*?_?L?_&Z_0RBC_5[)_P#GU_Y-
M+_,#\\_^&J_VLO\ I&7\4_\ OV/_ (W67KW[;G[1OAK4M,TC7/\ @G3\1K2Y
MUBZ-OIL%U*J/=2A=Q2,&/YVQS@5^D%>%_M8?\EL^!_\ V/<O_I,U'^KV3_\
M/K_R:7^8'S/_ ,-5_M9?](R_BG_W['_QNC_AJO\ :R_Z1E_%/_OV/_C=?H91
M1_J]D_\ SZ_\FE_F!^>?_#5?[67_ $C+^*?_ '['_P ;H_X:K_:R_P"D9?Q3
M_P"_8_\ C=?H911_J]D__/K_ ,FE_F!^>?\ PU7^UE_TC+^*?_?L?_&Z/^&J
M_P!K+_I&7\4_^_8_^-U^AE%'^KV3_P#/K_R:7^8'YY_\-5_M9?\ 2,OXI_\
M?L?_ !NC_AJO]K+_ *1E_%/_ +]C_P"-U^AE%'^KV3_\^O\ R:7^8'YY_P##
M5?[67_2,OXI_]^Q_\;KT2'_@I-^UE%$L7_#J#XIG:H&?M0Y_\EZ^R**[<'EV
M#P#E["/+??5O;U; ^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%
MC_Y'K[&HKM ^.?\ AY3^UE_TB?\ BG_X%C_Y'K@];_:\_:RUC6+K5O\ AV+\
M4X_M-P\OE[0=NXDXSY0SUK] J*Y,7@<+CXJ->-TMM6OR: _//_AJO]K+_I&7
M\4_^_8_^-T?\-5_M9?\ 2,OXI_\ ?L?_ !NOT,HK@_U>R?\ Y]?^32_S _//
M_AJO]K+_ *1E_%/_ +]C_P"-T?\ #5?[67_2,OXI_P#?L?\ QNOT,HH_U>R?
M_GU_Y-+_ # _//\ X:K_ &LO^D9?Q3_[]C_XW1_PU7^UE_TC+^*?_?L?_&Z_
M0RBC_5[)_P#GU_Y-+_,#\\_^&J_VLO\ I&7\4_\ OV/_ (W1_P -5_M9?](R
M_BG_ -^Q_P#&Z_0RBC_5[)_^?7_DTO\ ,#\W[7]MS]HV]\67?@BU_P""=/Q&
MDU6RM8[BZTY)5,\43G"NR>7E5..#WK4_X:K_ &LO^D9?Q3_[]C_XW7TQX!_Y
M2">/_P#L1-*_]&-7NE'^KV3_ //K_P FE_F!^>?_  U7^UE_TC+^*?\ W['_
M ,;H_P"&J_VLO^D9?Q3_ ._8_P#C=?H911_J]D__ #Z_\FE_F!^>?_#5?[67
M_2,OXI_]^Q_\;H_X:K_:R_Z1E_%/_OV/_C=?H911_J]D_P#SZ_\ )I?Y@?GG
M_P -5_M9?](R_BG_ -^Q_P#&Z/\ AJO]K+_I&7\4_P#OV/\ XW7Z&44?ZO9/
M_P ^O_)I?Y@?GG_PU7^UE_TC+^*?_?L?_&ZM:)^UY^UEH^L6NK?\.Q?BG)]F
MN$E\O:!NVD'&?*..E?H%150R#*824HT]5YR_S ^.?^'E/[67_2)_XI_^!8_^
M1Z/^'E/[67_2)_XI_P#@6/\ Y'K[&HKV /CG_AY3^UE_TB?^*?\ X%C_ .1Z
M;-_P4F_:REB:+_AU!\4QN4C/VH<?^2]?9%%#5T!^>?\ PU7^UE_TC+^*?_?L
M?_&Z/^&J_P!K+_I&7\4_^_8_^-U^AE%>+_J]D_\ SZ_\FE_F!^>?_#5?[67_
M $C+^*?_ '['_P ;H_X:K_:R_P"D9?Q3_P"_8_\ C=?H911_J]D__/K_ ,FE
M_F!^>?\ PU7^UE_TC+^*?_?L?_&Z/^&J_P!K+_I&7\4_^_8_^-U^AE%'^KV3
M_P#/K_R:7^8'YY_\-5_M9?\ 2,OXI_\ ?L?_ !NC_AJO]K+_ *1E_%/_ +]C
M_P"-U^AE%'^KV3_\^O\ R:7^8'YY_P##5?[67_2,OXI_]^Q_\;K+\)_MN?M&
M^.--DU?PK_P3I^(VHVT5U);R3V$JRHLL;;70D1\,#P1VK](*\+_X)[_\D3U;
M_L>]9_\ 2DT?ZO9/_P ^O_)I?Y@?,_\ PU7^UE_TC+^*?_?L?_&Z/^&J_P!K
M+_I&7\4_^_8_^-U^AE%'^KV3_P#/K_R:7^8'YY_\-5_M9?\ 2,OXI_\ ?L?_
M !NC_AJO]K+_ *1E_%/_ +]C_P"-U^AE%'^KV3_\^O\ R:7^8'YY_P##5?[6
M7_2,OXI_]^Q_\;H_X:K_ &LO^D9?Q3_[]C_XW7Z&44?ZO9/_ ,^O_)I?Y@?G
MG_PU7^UE_P!(R_BG_P!^Q_\ &Z/^&J_VLO\ I&7\4_\ OV/_ (W7Z&44?ZO9
M/_SZ_P#)I?Y@?!'@S]M']K+PCKB:U_PZ^^*=QMC9?*X3.1CKY1_E78_\/*?V
MLO\ I$_\4_\ P+'_ ,CU]C45Z.%P>'P5+V=&-E>^[?YW ^6_A+^WO^TI\1/B
M7HG@?Q1_P3:^(OA?3M4U!+>\\0ZE<@V^GQL>9I!Y*Y5>IY%?4E%%=(!1110
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MD5Q;R0'>DC*) [JG0?, ?H31110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>biib-20201231_g32.jpg
<TEXT>
begin 644 biib-20201231_g32.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
M_P!B'_@GW\%_&&K>-[KQ"-:\4Z=?Z2(XM,O&MA;B(2JS@P1&>X>6X;;&B(C$
MG+!0#]A?VM/V'_ '_!<#]D;X/^)?&7QT^(?P\\+ZSHUEXKN]-\ :O':S:E#?
MV$4J6T[RHZ%$$F1NC;GL*_-/_@RDT6T\-_%_]J[P[8/(T%A+X:MH6E(+%$N-
M94$D  G &>*_2[]JC_@H)^RG_P $(OV0_@]X)_:1'BK4M)M=#L?"&B7'A;2(
M[J21]/T^*,O(LLT>U2D8/4G)K\,O^#<+_@L+^R;_ ,$W/C?\;M1_:%T[Q=-'
M\6=6T6/PM_PCFCQ7)0Q7.H%O/WSQ^7_Q]Q8QNZ-Z<@'UK_P=J^&?C%JO[8?[
M/=W^T#X@\9:;^R+<2:=9>/K_ ,,>8\%E?MJDIU"66.,,#<?V?Y!MS(C',<WE
MJQWJ?!?V'_AM\'?#7_!PI\.-+_X-^OB#XU\0_""SLM,N_BY?O+>G3;>R,DRZ
MC#.]S'&98#;^28O.!_TJ3$9RBX];_P"#FB/Q!\-?^"QW[/O[07[:7PVU_P 7
M?LNZ/9Z6+K3[>U>XTP3)>S/J$#QY$;7#+]GD:-R#/$B1Y(4A?(=5^*7[.G[:
M/_!PM^S_ /$'_@@S\&[GPQH>@3Z(?B%J7A'P8VA::UO'J$CZC<3VL:QK';FP
M802,ZQ^<WR ,Q4L ?TP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,GP=XZ\(_$'2Y-;\%Z]!J-I#=RVLD]N256:-MKISW!X-:U?/W[ WB#1=
M,^#6K6VH:C'%)_PG.LMM<\X^TMS7M_\ PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
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M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
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M %*7_D__ /:Z/^%__P#4I?\ D_\ _:Z\YHK\R_UASC_G[_Y+'_(#T;_A?_\
MU*7_ )/_ /VNC_A?_P#U*7_D_P#_ &NO.:*/]8<X_P"?O_DL?\@/1O\ A?\
M_P!2E_Y/_P#VNC_A?_\ U*7_ )/_ /VNO.:*/]8<X_Y^_P#DL?\ (#T;_A?_
M /U*7_D__P#:Z/\ A?\ _P!2E_Y/_P#VNO.:*/\ 6'./^?O_ )+'_(#T;_A?
M_P#U*7_D_P#_ &NC_A?_ /U*7_D__P#:Z\YHH_UASC_G[_Y+'_(#T;_A?_\
MU*7_ )/_ /VNC_A?_P#U*7_D_P#_ &NO.:*/]8<X_P"?O_DL?\@/1O\ A?\
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MX275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^
MA0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_
M^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X2
M75_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X
M275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A
M0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH
M V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^E
MH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8J
M.[_X])?^N;?RK+_X275_^A0O?^^EJ.Y\2:LUM(I\(W@RAY++QQ4R^%@>'T44
M5^,@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!U?P9_Y'F+_KWD
M_E7L->+?"N[GL?%\=Q;V,ERPAD'E1$9/'7FO4?\ A)=7_P"A0O?^^EK]$X6_
MY%C_ ,3_ "0&Q1679Z]J5S=)!-X9NH59L-*[+A?<UJ5]( 4444 %%%% !117
MF'[6_P"RAX!_;/\ A2OP1^*OBSQ;IWAFXU2&YUVP\(^))M*?6K9%<-I]S- 1
M*;63>#(D;HS;%&X#((!YE\>_^"S_ /P2M_9D\23^#/C-^W3X T[6+20QWNE6
M&K'4KFUD!P4FBLEE:)A_=< ^U=M^S'_P42_87_;-E>R_9<_:M\$>-+Z.,R2Z
M1H^NQ&_C0#)=K1RLZK_M% .#SQ7,_LZ?LH_\$M/A'K'B/X$_LV_L_P#P@TW5
MO ,=G'XPTK2/#MC)?:7]I@\ZW-]*R-*7DA'F!I6+,OS9(YKYR\/Z-_P;J?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ J.[_X])?\ KFW\JDJ.[_X])?\
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M -./_)O_ +4#Z,HKYSHH_P!;_P#IQ_Y-_P#:@?1E%?.=%'^M_P#TX_\ )O\
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M:[U&C.QEC7R\;F\S(^Z: /SU_P""O7QG_P"#>/Q_^U/>>"_VYO'/C#PK\:/
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MI9C_ ,_I_P#@3_S Z/\ X6U\0?\ H8/_ "4B_P#B*/\ A;7Q!_Z&#_R4B_\
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M ".&J?\ 80F_]#->\5X/XU_Y'#5/^PA-_P"AFODN+?\ =J?J_P @,NBBBOA
M"BBB@ JK<ZWHUGJEKH=WJ]K%>WJ2/96<EPJRW"Q[?,9$)RX7<NX@'&X9ZBGZ
ME>/I^G7%_'9RW#00/(MO N7E*@G:H[DXP/<U^1G[-?Q4_;"_X*5_%KX-_M#6
M?_!0>T\$>)/$FG^.&TWP?X.\%:3>+X!CMI[*+[#<I>(\US).@B=S.4( 7RPH
M)9NS"X1XB,IN2C&.[=^S:V3[/_A] /UZHKBHO%DGP%_9^7QI^TG\4M/NW\)>
M%Q=>-?&)T\6-O<-;P;KF\\A680JQ5G$:EL9VC/%?E5XEL/BQ\:O^"F7[(O\
MP4$^-46I:5/\5O'^LQ?#_P %WKE1X>\)6NG;K 21]!=71GENYCDX\Z-!C9BG
MA<']8<KRLDGKW:3=EMT7R _8B66*WB:>>541%+.[M@*!U)/85#I>KZ3KEH+_
M $75+>\@+$">UG61"1U&5)%? ?\ P6V\.VNN?%;]GR?]I>761^R];^*-4/QO
M_LN6Y6U2X-M&-';4?L_SBS^U95F^XNX[B"8S7G/[*'A#]E:P_P""N'@74_\
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MLZQ0PQM)-*YPJ*!DDGL !4E17YL18S'5#%]F\IOM'GX\OR\'=NSQMQG.>,4
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M-YPA/-VWI4R^%@>'T445^,@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!U?P9_Y'F+_ *]Y/Y5[#7BWPKTZ#5/%\=I</(JF&0YB<J>!ZBO4?^$'
MTC_GYO?_  +:OT3A;_D6/_$_R0&Q1679^$M-L;I+N&XNBT;94/<L1^(K4KZ0
M HHHH **** "BBB@#\H?%?[8_P#P3U_X)*?\%</CS=?MP>+M$;5_C;+HOB3P
MOXOL=&;7-1T:UATZ*SDT>^@M(Y;NS >(3P$1F.:*7J#'@_3_ .RY_P %J/\
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M^!M^T?!W@[PG\//"FG>!? ?AJQT;1=(LX[32]*TRU6"WM($4*D4<: *BJ
M!@5I45O6Q.(KQ2J2;MW;8'"_$_\ 9J^"?QE^)/@;XN_$GP7_ &EXB^&VHW-_
MX*U#^TKF'^SKBXB$4K^7%(J3;D4#$JN!C( /-1?M+?LN? ;]K_X77'P;_:*^
M'=KXDT">X2Y2VGEDBEMKA,[+B":)ED@E7<P$D;*V&89PQ![^BH56K%Q:D_=V
MUVZZ=M0/ _V7_P#@FA^R-^R1X^O?BY\,/!6J7_C&^L?L,OB_Q?XEO-9U&.TS
MG[/%-=RN88^!D1[=V &)P*]\HHHJ5:E:7-4;;\P.%_9U_9J^"?[)WPV3X1?
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MBBOQD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .K^#/_(\Q?\
M7O)_*O8:\>^#/_(\Q?\ 7O)_*O8:_1.%O^18_P#$_P D 4445]( 4444 %%%
M% !1110 45^?GC_]J/\ X*M?M>?MG?%?]GK_ ()YWWPB^'_@;X*:K8:)XD\8
M_$O2[W4M0UO5[BSCNY([:VMW5(H(HY54E^6.UE8ABJ>H?LS?"S_@L[X<^-VB
M:S^UA^U=\$_$OP_A^T_V_HGA'X>WECJ-SFVE6#RIY)V5-MP87;*G**RC!(-
M'UG1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0!X
M]\9O^1YE_P"O>/\ E7*5U?QF_P"1YE_Z]X_Y5RE?D^;?\C.M_B?Y@%%%%>>
M4444 %%%% !1110 4444 %%%% !1110 4444 %?1%I_QZ1?]<U_E7SO7T1:?
M\>D7_7-?Y5]EPA\5;_MW]0)****^V *\'\:_\CAJG_80F_\ 0S7O%>#^-?\
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M[XS?\CS+_P!>\?\ *N4KJ_C-_P CS+_U[Q_RKE*_)\V_Y&=;_$_S ****\\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^B+3_CTB_ZYK_*OG>OHBT_
MX](O^N:_RK[+A#XJW_;OZ@24445]L 5X/XU_Y'#5/^PA-_Z&:]XKP?QK_P C
MAJG_ &$)O_0S7R7%O^[4_5_D!ET445\( 4444 %%%% !1110 4444 %%%% !
M1110 4444 %:G@K_ )'#2_\ L(0_^ABLNM3P5_R.&E_]A"'_ -#%;X7_ 'JG
M_B7Y@>\4445^P@%1W?\ QZ2_]<V_E4E1W?\ QZ2_]<V_E4R^%@?.]%%%?C(!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 =7\&?^1YB_Z]Y/Y5[#
M7CWP9_Y'F+_KWD_E7L-?HG"W_(L?^)_D@"BBBOI "BBB@ HHHH *X+]I7]E[
M]G_]L+X37WP-_:7^%FE^+_"^H.LDVF:G&W[J5<[)X9$*R03+D[98V5UR<,,F
MN]HH _/W4O\ @B[^U-\,F.E_L6_\%J?CU\/] !Q:>&_&26OC&VT^/H(;9K[9
M)'$HX56=R/4U?\+?\$*]#^(VJ6^L?\%%_P!NSXR_M'P6TRRIX.\5Z_\ V7X6
M>12&5Y-*L2J3,& .))&0@8*$9S]YT4 4_#OAWP_X0\/V/A/PGH=GIFE:79Q6
MFF:;I]LL-O:6\:!(X8HT 6-%50JJH    &!5RBB@#PO_ ()[_P#)$]6_['O6
M?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@#Q[XS?\CS+_U[Q_RKE*ZOXS?\
MCS+_ ->\?\JY2OR?-O\ D9UO\3_, HHHKSP"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KZ(M/\ CTB_ZYK_ "KYWKZ(M/\ CTB_ZYK_ "K[+A#XJW_;
MOZ@24445]L 5X/XU_P"1PU3_ +"$W_H9KWBO!_&O_(X:I_V$)O\ T,U\EQ;_
M +M3]7^0&71117P@!1110 4444 %%%% !1110 4444 %%%% !1110 5J>"O^
M1PTO_L(0_P#H8K+K4\%?\CAI?_80A_\ 0Q6^%_WJG_B7Y@>\4445^P@%1W?_
M !Z2_P#7-OY5)4=W_P >DO\ US;^53+X6!\[T445^,@%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!U?P9_Y'F+_ *]Y/Y5[#7CWP9_Y'F+_ *]Y
M/Y5[#7Z)PM_R+'_B?Y( HHHKZ0 HHHH **** "BBB@ HHHH **** /G[]@;Q
M!HNF?!K5K;4-1CBD_P"$YUEMKGG'VEN:]O\ ^$Q\,?\ 0:@_[ZKQG_@GY:6L
M_P %=6>:VC<_\)UK(RR G_CY->Y?V=I__/C#_P!^A0!X]\6+^SU+QC+=6-PL
ML9@C =3QD"N:KJ?C#%%#XVE2&-47R(^%&!TKEJ_)\V_Y&=;_ !/\P"BBBO/
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O=K7Q?X96VC5M9A!" $9]J
M\)KZ"M-/L#:Q$V,/^K7_ )9#TK[+A#XJW_;OZ@5_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%?; 4_^$Q\,?\ 0:@_
M[ZKQ;Q=/#<^*M1N+>0.DE[*R,.A!8X->Z_V=I_\ SXP_]^A7AGC-53Q=J:(H
M %_*  .!\YKY+BW_ ':GZO\ (#,HHHKX0 HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *T?",\-MXJTZXN) B1WL3.QZ !ADUG5I^#%5_%VF(Z@@W\0((
MX/SBM\+_ +U3_P 2_,#V?_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
M/C#_ -^A1_9VG_\ /C#_ -^A7["!3_X3'PQ_T&H/^^JCNO%_AEK:15UF$DH0
M!GVK0_L[3_\ GQA_[]"H[O3[ 6LI%C#_ *MO^60]*F7PL#Y]HHHK\9 ****
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MX*_Y'#2_^PA#_P"ABM\+_O5/_$OS ]XHHHK]A *CN_\ CTE_ZYM_*I*CN_\
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M])?^N;?RJ9?"P/G>BBBOQD HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!_&O_(X:I_V$)O\ T,U[Q7@_C7_D<-4_["$W_H9KY+BW_=J?J_R RZ***^$
M**** "BBB@ HHHH **** "BBB@ HHHH **** "M3P5_R.&E_]A"'_P!#%9=:
MG@K_ )'#2_\ L(0_^ABM\+_O5/\ Q+\P/>****_80"H[O_CTE_ZYM_*I*CN_
M^/27_KFW\JF7PL#YWHHHK\9 **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#J_@S_ ,CS%_U[R?RKV&O'O@S_ ,CS%_U[R?RKV&OT3A;_ )%C_P 3
M_) %%%%?2 %%%% !1110 4444 %%%% !1110!\9P_&O]H[]B+5-5^"?A/]B'
MQK\3;)]7N-6B\5>&G\NTD^U/YODJ#$YW1YVL<CD'C'6;_AY3^UE_TB?^*?\
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M6F:1KG_!.GXC6ESK%T;?38+J54>ZE"[BD8,?SMCG K](*\+_ &L/^2V? _\
M['N7_P!)FH_U>R?_ )]?^32_S ^9_P#AJO\ :R_Z1E_%/_OV/_C='_#5?[67
M_2,OXI_]^Q_\;K]#**/]7LG_ .?7_DTO\P/SS_X:K_:R_P"D9?Q3_P"_8_\
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M?[67_2,OXI_]^Q_\;KZ8\ _\I!/'_P#V(FE?^C&KW2C_ %>R?_GU_P"32_S
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M7LG_ .?7_DTO\P/SS_X:K_:R_P"D9?Q3_P"_8_\ C='_  U7^UE_TC+^*?\
MW['_ ,;K]#**/]7LG_Y]?^32_P P/SS_ .&J_P!K+_I&7\4_^_8_^-T?\-5_
MM9?](R_BG_W['_QNOT,HH_U>R?\ Y]?^32_S _//_AJO]K+_ *1E_%/_ +]C
M_P"-T?\ #5?[67_2,OXI_P#?L?\ QNOT,HH_U>R?_GU_Y-+_ # _//\ X:K_
M &LO^D9?Q3_[]C_XW67X3_;<_:-\<:;)J_A7_@G3\1M1MHKJ2WDGL)5E198V
MVNA(CX8'@CM7Z05X7_P3W_Y(GJW_ &/>L_\ I2:/]7LG_P"?7_DTO\P/F?\
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M3XV/,T@\E<JO4\BOJ2BBND HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HKYE_;&_9K_X**?M _%^QA_9S_P""A%M\$OAO:^'(5U"UT+X>
M6>L:YJ>J_:+@RL9[W,=M;B'[+M\L,Y<2[L BO&O^">W[2_[:GPP_X*5_$?\
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M ()#_L-_MG?%-?CE\6?A_K6G>,WTH:7J/B?P5XOU#0KS5+ 8Q:W;V4T8N8\
M >8"P4!0P  KT'PQ^PO^R=X)_9&N_P!A'P;\&-/TGX47_AR\T*]\(Z;<W$"3
M6-TCI<HTZ2"<R2B20O-YGFLSEB^XYH ^(O&&K^+O^#A/XI-\,? SZAHW[%/@
MKQ"I\6>*8V>WG^,6J6DP9;"R. RZ/#,@,DXP9G0!""H:/9_X.#]/TKX3>!/V
M3_V@)=-MK+P5\(_VM/!FI^*3%;A+?2-(5Y8OM! PL<<;>4@Z &1 ,5W&G_\
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M8(_ =_X?70Y?#FCW,VFQ1:>L8C6WA>T>*2W54557RF0J  "*^4-/_P"#;O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>biib-20201231_g33.jpg
<TEXT>
begin 644 biib-20201231_g33.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,GP=XZ\(_$'2Y-;\%Z]!J-I#=RVLD]N256:-MKISW!X-:U>%_P#!/?\
MY(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***X/6_C;_8^L76D_\ ",^9]FN'B\S[;C=M)&<;#CI7
M)B\=A<!%2KRLGMHW^28'>45YS_PO_P#ZE+_R?_\ M='_  O_ /ZE+_R?_P#M
M=<'^L.3_ //W_P EE_D!Z-17G/\ PO\ _P"I2_\ )_\ ^UT?\+__ .I2_P#)
M_P#^UT?ZPY/_ ,_?_)9?Y >C45YS_P +_P#^I2_\G_\ [71_PO\ _P"I2_\
M)_\ ^UT?ZPY/_P _?_)9?Y >C45YS_PO_P#ZE+_R?_\ M='_  O_ /ZE+_R?
M_P#M='^L.3_\_?\ R67^0'HU%><_\+__ .I2_P#)_P#^UT?\+_\ ^I2_\G__
M +71_K#D_P#S]_\ )9?Y >C45YS_ ,+_ /\ J4O_ "?_ /M='_"__P#J4O\
MR?\ _M='^L.3_P#/W_R67^0'HU%><_\ "_\ _J4O_)__ .UT?\+_ /\ J4O_
M "?_ /M='^L.3_\ /W_R67^0'HU%><_\+_\ ^I2_\G__ +71_P +_P#^I2_\
MG_\ [71_K#D__/W_ ,EE_D!Z-17G/_"__P#J4O\ R?\ _M=6M$^-O]L:Q:Z3
M_P (SY?VFX2+S/MN=NX@9QL&>M5#/\IG)1C4U?E+_(#O****]@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4\%?\CAI?_80A_\ 0Q6^%_WJG_B7Y@>\4445^P@%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_(X:7_V$(?_ $,5EUJ>"O\ D<-+_P"PA#_Z&*WPO^]4_P#$OS ]XHHHK]A
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M**_80,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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M?^%M?#[_ *&#_P E)?\ XBC_ (6U\/O^A@_\E)?_ (BO%J*/];,Q_DA]S_\
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M1U>PT#4_%'B7P<=>UC7]6N+&*\D,<$CK##;QI,B@GYCG=EMQ6/TW]ES]F?\
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MBBB@ HHHH **** "BBB@ K4\%?\ (X:7_P!A"'_T,5EUJ>"O^1PTO_L(0_\
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MQ  -3V'@7]L__@G=^W1\;OC1\-/V1-3^-'PY^-^J:?KD=YX1\065OJ^A:A!
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MTE_ZYM_*IE\+ ^=Z***_&0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 5]$6G_ !Z1?]<U_E7SO7T1:?\
M'I%_US7^5?9<(?%6_P"W?U DHHHK[8 KP?QK_P CAJG_ &$)O_0S7O%>#^-?
M^1PU3_L(3?\ H9KY+BW_ ':GZO\ (#+HHHKX0 HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *U/!7_(X:7_V$(?\ T,5EUJ>"O^1PTO\ ["$/_H8K?"_[
MU3_Q+\P/>****_80"H[O_CTE_P"N;?RJ2H[O_CTE_P"N;?RJ9?"P/G>BBBOQ
MD HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .K^#/_(\Q?\ 7O)_
M*O8:\>^#/_(\Q?\ 7O)_*O8:_1.%O^18_P#$_P D 4445]( 4444 %%%% !1
M110!^4/BO]L?_@GK_P $E/\ @KA\>;K]N#Q=HC:O\;9=%\2>%_%]CHS:YJ.C
M6L.G16<FCWT%I'+=V8#Q"> B,QS12]08\'Z?_9<_X+4?\$GOVM?CMH7[/O[-
M'QT_MGQMX@^U?V)IO_"L]=T_SO(M9;F;_2+K3XH8\0PRM\SKNV[1EB ?DRS_
M ."CW[%/_!+?_@L'^U#H/[0&D>)M0O/B+JFA:S'XYT3P%>W\NDLFD6T;Z-<2
M)#O>(#RYXF@,L>)F1_+>/YOK/]ES_@N;_P $]OVQ?CMH7[./P.\8^,+OQ3XC
M^U?V7;ZK\.=6L(&^SVLMU)NGN+=(TQ%!(1N89("C)(% 'U_1110!X7_P3W_Y
M(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0!X]\9O^1YE_P"O>/\
ME7*5U?QF_P"1YE_Z]X_Y5RE?D^;?\C.M_B?Y@%%%%>> 4444 %%%% !1110
M4444 %%%% !1110 4444 %?1%I_QZ1?]<U_E7SO7T1:?\>D7_7-?Y5]EPA\5
M;_MW]0)****^V *\'\:_\CAJG_80F_\ 0S7O%>#^-?\ D<-4_P"PA-_Z&:^2
MXM_W:GZO\@,NBBBOA "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4\%
M?\CAI?\ V$(?_0Q676IX*_Y'#2_^PA#_ .ABM\+_ +U3_P 2_,#WBBBBOV$
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ML_\ I2:]TH \6^*D>HQ>+Y$U2XCEF\F/+Q)M&,<<5SE=7\9O^1YE_P"O>/\
ME7*5^3YM_P C.M_B?Y@%%%%>> 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>X6UEXU-M&5UJS V# -L?3ZUX?7T1:?\>D7_ %S7^5?9<(?%6_[=_4#+
M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**^V Q_L7C?_H-V7_@,?\
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M &D?%WPK3Q?JME9:9XJ\ ^,(M#ULW<<RW*6UE<R(_P"\E$#JT:JS/%Y@ ZD
M'R=\;/V#?^"O?A[]O[XD_M9?L)_M4?!GP5X8^(5KI<.I>%O$WA2]NVU&2SLT
M@CO+L*"OVI?WD8DA:/="(ED#F-2/3/V7/AG_ ,%O/#_QVT+5_P!K[]IOX#^(
M?AW#]J_X2'1_!G@N_M-2N,VLJP>3+*Q1-MP86;(Y17 Y(KR__B'>\*_])@OV
M[_\ Q(%/_D"N^_9B_P""/'@_]CGXW:/^TI<_\%,/VK?&D/A>&\EG\.?%7XS1
MZCX?N8Y;.:!GN[<VD8=8UE,JDNH22)'.=N" ?:-%4_#WB'0/%V@6/BOPIK=I
MJ>EZG9Q7>FZEI]RLT%W;R('CECD0E71E8,K*2"""#@U<H \+_P"">_\ R1/5
MO^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH \>^,W_(\R_]>\?\JY2N
MK^,W_(\R_P#7O'_*N4K\GS;_ )&=;_$_S ****\\ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^B+3_ (](O^N:_P J^=Z^B+3_ (](O^N:_P J^RX0
M^*M_V[^H$E%%%?; %>#^-?\ D<-4_P"PA-_Z&:]XKP?QK_R.&J?]A";_ -#-
M?)<6_P"[4_5_D!ET445\( 4444 %%%% !1110 4444 %%%% !1110 4444 %
M:G@K_D<-+_["$/\ Z&*RZU/!7_(X:7_V$(?_ $,5OA?]ZI_XE^8'O%%%%?L(
M!4=W_P >DO\ US;^525'=_\ 'I+_ -<V_E4R^%@?.]%%%?C(!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 =7\&?^1YB_P"O>3^5>PUX]\&?^1YB
M_P"O>3^5>PU^B<+?\BQ_XG^2 ****^D **** "BBB@ K@OVE?V7OV?\ ]L+X
M37WP-_:7^%FE^+_"^H.LDVF:G&W[J5<[)X9$*R03+D[98V5UR<,,FN]HH _/
MW4O^"+O[4WPR8Z7^Q;_P6I^/7P_T '%IX;\9):^,;;3X^@AMFOMDD<2CA59W
M(]35_P +?\$*]#^(VJ6^L?\ !1?]NSXR_M'P6TRRIX.\5Z__ &7X6>12&5Y-
M*L2J3,& .))&0@8*$9S]YT4 4_#OAWP_X0\/V/A/PGH=GIFE:79Q6FF:;I]L
ML-O:6\:!(X8HT 6-%50JJH    &!5RBB@#PO_@GO_P D3U;_ +'O6?\ TI->
MZ5X7_P $]_\ DB>K?]CWK/\ Z4FO=* /'OC-_P CS+_U[Q_RKE*ZOXS?\CS+
M_P!>\?\ *N4K\GS;_D9UO\3_ # ****\\ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^B+3_CTB_P"N:_RKYWKZ(M/^/2+_ *YK_*OLN$/BK?\ ;OZ@
M24445]L 5X/XU_Y'#5/^PA-_Z&:]XKP?QK_R.&J?]A";_P!#-?)<6_[M3]7^
M0&71117P@!1110 4444 %%%% !1110 4444 %%%% !1110 5J>"O^1PTO_L(
M0_\ H8K+K4\%?\CAI?\ V$(?_0Q6^%_WJG_B7Y@>\4445^P@%1W?_'I+_P!<
MV_E4E1W?_'I+_P!<V_E4R^%@?.]%%%?C(!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 =7\&?^1YB_Z]Y/Y5[#7CWP9_Y'F+_KWD_E7L-?HG"W_(
ML?\ B?Y( HHHKZ0 HHHH **** "BBB@ HHHH **** /"_P#@GO\ \D3U;_L>
M]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@#Q[XS?\CS+_P!>\?\ *N4KJ_C-
M_P CS+_U[Q_RKE*_)\V_Y&=;_$_S ****\\ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *^B+3_CTB_ZYK_*OG>OHBT_X](O^N:_RK[+A#XJW_;OZ@24
M445]L 5X/XU_Y'#5/^PA-_Z&:]XKP?QK_P CAJG_ &$)O_0S7R7%O^[4_5_D
M!ET445\( 4444 %%%% !1110 4444 %%%% !1110 4444 %:G@K_ )'#2_\
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MBBB@ HHHH **** "BBB@#H_A7=SV/B^.XM[&2Y80R#RHB,GCKS7J/_"2ZO\
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M<V_E4E1W?_'I+_US;^53+X6!\[T445^,@%%%% !1110 4444 %%%% !1110
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MUK] J*Y,7@<+CXJ->-TMM6OR: _//_AJO]K+_I&7\4_^_8_^-T?\-5_M9?\
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M9?\ 2,OXI_\ ?L?_ !NC_AJO]K+_ *1E_%/_ +]C_P"-U^AE%'^KV3_\^O\
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MB9^T1<>$M"^%F@Z^"\%CK'B"W2>+[0  7$$7FG&,,Z(",,10!]R45^9/QO\
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M^-/@WXY^%M6O?AMXTUGPO9Z5K&C:OID8GN;"X^Q*D5Q;R0'>DC*) [JG0?,
M?H31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?!'C7]AK_ (+8
M^*;+6OB7!_P6AL_#OB='N+GPUX.T/X-:2?#MHH+-#:7$MPK7-PA&U7G8;EW$
MA#M ,'[,'_!9C5?&G_!":Z_X*O\ QN\!64&O>'/#&JG6-&TR1H[+4M5L[R6Q
MA$#L6*17$ZP]V\LRLH+[,D ^_J@T_2],TB VVE:=!:QM(SM';PJBEB<EL #D
MGJ:_*;XAZ[_P6V_9I_8/MO\ @K/XR_;HL?%NMZ9X>L_&?CC]GN?X>:?:: FA
MRB.:XTVVNXU^UPSV]LY;SR[EFA8'>#EOMSXU^(OVJ?VM?V2_ ?Q-_P"";_QP
M\*^ K[QO#I>O?\)/XU\,MJJQZ#=V$DX$%LK!&N2\MH1O.P*L@ZE: /H2BOAC
M_@@U^TG^UE^T3\%_CAI/[8_QU7XB^)_AC^TQXF\!V/B=/#%CI GL=.MM/5,6
MUE&B(&EEGD^8NX\W:78*N.;_ &HOC?\ MO\ [4G_  5FNO\ @F9^SG^U&/@3
MX6\(?"&#QOK_ (JTSPM9ZGK?B22>\%LL%J+U6BAMXR5W2(I;>KJ20PV@'Z%T
M5\%?\$XOVC?VQO"7_!0WXT_\$R/VJOCG:_&&W^'OA/2/$_ACXG+X<MM+OXH+
MW _LW48;0"#SAN#1L%5G1'=LAPL?WK0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-'_!1O_@HWX<_8@\.:
M'\/_ (?^"+CXA_&OXAW#:?\ "?X3Z/(/M>M7>.;B8_\ +M8P_?FN'PJJI&<Y
M(RO^"9/_  3[\7?LKVOBW]H_]J'QY#XW_:#^+]U#J'Q2\7PJ1:VPC4BWTC3T
M(!BL;9"(U'!<KN. $1-;]K[_ ()!?\$\OV\?C!IWQ]_:G^ UUXB\7Z3X=CT+
M3]:L_'&MZ4\.GQSSSK!MT^\@0@27,[;BI8[\$D!0)_V2O^"2O[ _[#/Q-N?C
M#^S%\'-5T#Q#=Z/+I5Q>WOQ!UW54:TDDBD=/)U"^GB!+PQG>$#C:0" 2" ?.
M_P#P0 N(/AWXP_;)_9?\3O';^+/#'[7/B77+VP8;9I=,U2.V>PO"IY*3);R%
M6[J%J+_@C%K^C>,_VP_V]OVK=+U2V7P/K/QR@TC3M?DG46LSZ-8/%>3K*<*8
M@94;S =N#G)'-?07[6G_  2'_8;_ &SOBFOQR^+/P_UK3O&;Z4-+U'Q/X*\7
MZAH5YJE@,8M;M[*:,7,>  /,!8* H8  5Z#X8_87_9.\$_LC7?["/@WX,:?I
M/PHO_#EYH5[X1TVYN($FL;I'2Y1ITD$YDE$DA>;S/-9G+%]QS0!\1>,-7\7?
M\'"?Q2;X8^!GU#1OV*?!7B%3XL\4QL]O/\8M4M)@RV%D<!ET>&9 9)Q@S.@"
M$%0T>S_P<'Z?I7PF\"?LG_M 2Z;;67@KX1_M:>#-3\4F*W"6^D:0KRQ?:"!A
M8XXV\I!T ,B 8KN-/_X-N?\ @C7I%E'INE?LK:U:V\*[8K>W^,/BU$0>@4:J
M !7U%<_LH?L]:E^S+%^QOKOPQL]6^&L7AB'P\/"VMSS7T;Z=%&L<<3RW#O+(
MRJB$2LYD#*'W;@&H ^*_^#EC4++QI^Q/\//V<_#ES%=^*?BQ\>/"6B>$-.B<
M-)=3?;1.TBJ.3&JQC<_W5\Q,D;AG]%Z^5/V8/^"+7_!/O]DGXNZ9\=/AA\,-
M:U#Q-X=LI++PA?\ C'QIJ6MCPW:NNQH=/CO9Y$M@4.S<HWA25# ,P/U70 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?%W_  42_P""@OQ7T;XK:=_P
M3>_X)V:18^)?VB?&.G&YN[^\^?2OAQH[8#ZWJC $!@&!@MR"TC%"58-''-]H
MU\?_ !D_X(+_ /!*GX^_&GQ+^T/\4OV:=0O?&/C"^^V>)-9LOB5XCL#>S;0N
MXQ6NH1Q*,  *J@#TH VOV>?^":O@W]CO_@GMXS_9,^$VOW^O>)O&.@ZW=>+?
M&^L2_P"G^)_$>H6KI/J-PY)PSN5"@L=B(H+,06;RC_@WI^./PVTO_@AS\-_%
M'B;Q);Z3;?#;1-9T_P =_P!H2"-M#GL+VZ>X6Y!YB*Q;9<-@A)%/>OI7]CG_
M ()[?LD_L":;KVD?LI_#>_\ #MOXFGMYM:2^\8:MJYG>!76,@ZC=3F+ D?A"
MH.><X&/)?C5_P0@_X)G_ !Z^+.O?%[QO\%M6MKGQ=J*ZAXWT/P]XUU33-(\2
M78;?Y][8VMPD,SEOF9@J[V)9]Q8D@'G7_!L)X1\0Z#_P2,\)^+M?TZYLT\9^
M+O$7B'3+6[&'2SN-3F6$X[!UC\P=B'##@U!^Q[_RL8_MA_\ 9+_ ?_I'7VSX
M\_9U^"_Q(^ E[^R_XE\"P1^ [_P^NAR^'-'N9M-BBT]8Q&MO"]H\4ENJHJJO
ME,A4  $5\H:?_P &W?\ P1KTK6V\2:?^RGJ\6H.4,EXOQ>\5^9)L^Z&;^U,L
M!V!R* .P_P""AO\ P3L^(_[27QG^&/[8W[*'QXL_AO\ &WX2F^A\/:MK&BG4
M=*UG3+M-ESIU_;JZ.8CG*R(=T9=R!N*.GPIXT^!_[7OQ)_X.%?V6(?VG?VE/
M"_C_ .(O@W0=>\2>+_#GPV\.2Z?H/@3P]':F.T8B:66>2>]NY65WE93@0*%V
M[37Z:?MH_P#!/O\ 9G_;YT'0M%_:'T#7)9O#%W-=>'-6\.>*[_2+S3Y9D5)2
MDMG-&6#*J@J^Y> <9YJ']BW_ ()R?L?_ /!/_2M9M/V8_A2-*U#Q).L_B;Q)
MJFIW.I:MK$BYVFXO+J225U7+$)N"*68A06)(![C1110 4444 %%%% !1110
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M[31->.MZ%X(OO&.IW/AK3=2WE_M,.E2W#6J,&9B$V&-<_*@P,?0/[57[(WP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>biib-20201231_g34.jpg
<TEXT>
begin 644 biib-20201231_g34.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT_X)M>,=5\#:QX8ET&_^-.JHESX8T>SO+1!+J\EO9)<WICLC*SG$ (>VW @
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M %*7_D__ /:Z\YHH_P!8<X_Y^_\ DL?\@/1O^%__ /4I?^3_ /\ :Z/^%_\
M_4I?^3__ -KKSFBC_6'./^?O_DL?\@/1O^%__P#4I?\ D_\ _:Z/^%__ /4I
M?^3_ /\ :Z\YHH_UASC_ )^_^2Q_R ]&_P"%_P#_ %*7_D__ /:Z/^%__P#4
MI?\ D_\ _:Z\YHH_UASC_G[_ .2Q_P @/1O^%_\ _4I?^3__ -KH_P"%_P#_
M %*7_D__ /:Z\YHH_P!8<X_Y^_\ DL?\@/1O^%__ /4I?^3_ /\ :Z/^%_\
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M /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP?QK_P CAJG_ &$)
MO_0S7O%>#^-?^1PU3_L(3?\ H9KY+BW_ ':GZO\ (#+HHHKX0 HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *U/!7_(X:7_V$(?\ T,5EUJ>"O^1PTO\
M["$/_H8K?"_[U3_Q+\P/>****_80"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!_&
MO_(X:I_V$)O_ $,U[Q7@_C7_ )'#5/\ L(3?^AFODN+?]VI^K_(#+HHHKX0
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MB@ KP?QK_P CAJG_ &$)O_0S7O%>#^-?^1PU3_L(3?\ H9KY+BW_ ':GZO\
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MBK_PY&N__)M'_#$7[//_ $"_%7_AR-=_^3:Q_P!;,N_DG]R_^2 ^Y:*^&O\
MAB+]GG_H%^*O_#D:[_\ )M'_  Q%^SS_ - OQ5_X<C7?_DVC_6S+OY)_<O\
MY(#[EHKX:_X8B_9Y_P"@7XJ_\.1KO_R;1_PQ%^SS_P! OQ5_X<C7?_DVC_6S
M+OY)_<O_ )(#[EHKX:_X8B_9Y_Z!?BK_ ,.1KO\ \FT?\,1?L\_] OQ5_P"'
M(UW_ .3:/];,N_DG]R_^2 ^Y:*^&O^&(OV>?^@7XJ_\ #D:[_P#)M'_#$7[/
M/_0+\5?^'(UW_P"3:/\ 6S+OY)_<O_D@/N6BOAK_ (8B_9Y_Z!?BK_PY&N__
M ";1_P ,1?L\_P#0+\5?^'(UW_Y-H_ULR[^2?W+_ .2 ^Y:*^&O^&(OV>?\
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M/Z*] _X9DTO_ **IXJ_+3_\ Y$H_X9DTO_HJGBK\M/\ _D2C_5/,?YX?>_\
MY$#S^BO0/^&9-+_Z*IXJ_+3_ /Y$H_X9DTO_ **IXJ_+3_\ Y$H_U3S'^>'W
MO_Y$#S^BO0/^&9-+_P"BJ>*ORT__ .1*/^&9-+_Z*IXJ_+3_ /Y$H_U3S'^>
M'WO_ .1 \_K4\%?\CAI?_80A_P#0Q76?\,R:7_T53Q5^6G__ ")5+Q%^R-X9
M\5:!>^&=9^*/B]K34+62WNEM[FS@D,;J5;;)%:JZ'!.&5@PZ@@UK0X7S"G6C
M-RC9-/=]_P#"!ZS17RS_ ,.A_P!F;_H?_BG_ .''O?\ &C_AT/\ LS?]#_\
M%/\ \./>_P"-?> ?4U%?+/\ PZ'_ &9O^A_^*?\ X<>]_P :/^'0_P"S-_T/
M_P 4_P#PX][_ (T ?4U%?+/_  Z'_9F_Z'_XI_\ AQ[W_&C_ (=#_LS?]#_\
M4_\ PX][_C0!]345\L_\.A_V9O\ H?\ XI_^''O?\:/^'0_[,W_0_P#Q3_\
M#CWO^- 'U-17RS_PZ'_9F_Z'_P"*?_AQ[W_&C_AT/^S-_P!#_P#%/_PX][_C
M0!]345\L_P##H?\ 9F_Z'_XI_P#AQ[W_ !H_X=#_ +,W_0__ !3_ /#CWO\
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M.DZ;\0]?\_RT@CMX9#8:8[_9T:.%<$QJ'*LW)R:YK_@F$?\ @VB_X;D\#_\
M#OW]H+Q)KGQ=_P")G_PB6EW^N^+9H9O^)9=_:MR:@@MCBT^TL/,/!4%?F"T
M?KE1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\ 2DU[I0!X
M]\9O^1YE_P"O>/\ E7*5U?QF_P"1YE_Z]X_Y5RE?D^;?\C.M_B?Y@%%%%>>
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M4K\GS;_D9UO\3_, HHHKSP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKZ(M/^/2+_KFO\J^=Z^B+3_CTB_ZYK_*OLN$/BK?]N_J!)1117VP!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHKR7]M?X0>!?VAO@3<_ +QW^TCXN^%:>+]5LK+3/%7@'QA%H>MF[CF6Y2VLK
MF1'_ 'DH@=6C569XO, '4@ ^3OC9^P;_ ,%>_#W[?WQ)_:R_83_:H^#/@KPQ
M\0K72X=2\+>)O"E[=MJ,EG9I!'>784%?M2_O(Q)"T>Z$1+(',:D>F?LN?#/_
M (+>>'_CMH6K_M??M-_ ?Q#\.X?M7_"0Z/X,\%W]IJ5QFUE6#R996*)MN#"S
M9'**X')%>7_\0[WA7_I,%^W?_P") I_\@5WW[,7_  1X\'_L<_&[1_VE+G_@
MIA^U;XTA\+PWDL_ASXJ_&:/4?#]S'+9S0,]W;FTC#K&LIE4EU"21(YSMP0#[
M1HJGX>\0Z!XNT"Q\5^%-;M-3TO4[.*[TW4M/N5F@N[>1 \<L<B$JZ,K!E920
M000<&KE 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2D
MU[I0!X]\9O\ D>9?^O>/^5<I75_&;_D>9?\ KWC_ )5RE?D^;?\ (SK?XG^8
M!1117G@%%%% !1110 4444 %%%% !1110 4444 %%%% !7T1:?\ 'I%_US7^
M5?.]?1%I_P >D7_7-?Y5]EPA\5;_ +=_4"2BBBOM@"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@OVE
M?V7OV?\ ]L+X37WP-_:7^%FE^+_"^H.LDVF:G&W[J5<[)X9$*R03+D[98V5U
MR<,,FN]HH _/W4O^"+O[4WPR8Z7^Q;_P6I^/7P_T '%IX;\9):^,;;3X^@AM
MFOMDD<2CA59W(]35_P +?\$*]#^(VJ6^L?\ !1?]NSXR_M'P6TRRIX.\5Z__
M &7X6>12&5Y-*L2J3,& .))&0@8*$9S]YT4 4_#OAWP_X0\/V/A/PGH=GIFE
M:79Q6FF:;I]LL-O:6\:!(X8HT 6-%50JJH    &!5RBB@#PO_@GO_P D3U;_
M +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* /'OC-_P CS+_U[Q_R
MKE*ZOXS?\CS+_P!>\?\ *N4K\GS;_D9UO\3_ # ****\\ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *^B+3_CTB_P"N:_RKYWKZ(M/^/2+_ *YK_*OL
MN$/BK?\ ;OZ@24445]L 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)Z
MM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I->Z4 >/?&;_D>9?\ KWC_ )5R
ME=7\9O\ D>9?^O>/^5<I7Y/FW_(SK?XG^8!1117G@%%%% !1110 4444 %%%
M% !1110 4444 %%%% !7T1:?\>D7_7-?Y5\[U]$6G_'I%_US7^5?9<(?%6_[
M=_4"2BBBOM@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_ ()[_P#)$]6_['O6
M?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@#Q[XS?\CS+_U[Q_RKE*ZOXS?\
MCS+_ ->\?\JY2OR?-O\ D9UO\3_, HHHKSP"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KZ(M/\ CTB_ZYK_ "KYWKZ(M/\ CTB_ZYK_ "K[+A#XJW_;
MOZ@24445]L 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_
M *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE 'CWQF_Y'F7_KWC_E7*5U?QF_
MY'F7_KWC_E7*5^3YM_R,ZW^)_F 4445YX!117E_[9?[5_P /?V)/V<?$?[2?
MQ-T_4+[3= CA6+3-)B#W5_=3S);V]O$K$#<\LJ+DG"@ECP#50A.I-0BKMZ(#
MU"BO@_\ 9K_;"_X*8^)_VH/'^C^//V$(7\/_ /"7>'[35])A^,-I/=>![:XT
MVT9I%B:V2.\79(;F5(I P9G1?,(!;TK_ (*F?'[XE> ?!/P__9I^ ?BN?0_B
M#\<O']GX4T37;/!GT2PSYVI:G&".6AMD8#NK3*P^[74\%55>-)M:ZZ-.RM=W
MM?9?\ #ZFHKX]_X*0?M+?M ?"[X@_ O]A3]DGQC:>'O'/QJUJ^LHO'>O6(U-
MM"TK3+6.>\N5AF.VXNF1UV>;E6*N#@L&7C8_BW^U[_P3M_;2^$/P._:1_:ME
M^,?PY^.-_>:'IVJ:]X9LM-U;PYKD4:/!M:S5$N+>=G6/:R[D)R",8=PP-2=-
M24E=IM+6[2O=[6Z/=ZV ^]**^9_VB?V9O^"@_P ;OC!J>H_#?_@H8/A1X B@
M@30M!\*_#ZRU#49Y1$OFRW5W>9VCS=^V.-<%2N2",5Q__!,[]IW]ISQ+^T#\
M=/V$?VM/'.E^./$_P1U+1S:?$71]&2P&MV&IVKW,(N;>+]U#<1JH#!, EF7D
MQEWCZKS474C-.R3:UNDVEU5MVKV8'V11577;F>ST2\O+9]LD5I(\;8!PP4D'
MGWK\M_\ @G=KO_!3C]NW]F+P5\<;S_@N/8>&/$/BZVO)G\$1_!;PK>75J(+R
M>W'41NX981)GRQ@/WQDE#"NM2E4<U%)I:\W6_9/LP/U2HKQ#]NCPO\?+G]BG
MQ5<? CXGZAIOQ&\,:"NM:!K-C&L7]HW]@!<&WEA'R-%=>4\+QGY<3?[(-=3^
MR'^T7X;_ &N/V8O O[2OA2W$%GXR\-VVHFT#[OLDS+B:W+=S'*)(R>Y0UDZ,
MO8^U3TO;]5]^MO1@>C4445D 5]$6G_'I%_US7^5?.]?1%I_QZ1?]<U_E7V7"
M'Q5O^W?U DHHHK[8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_P"">_\ R1/5
MO^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH \>^,W_(\R_]>\?\JY2N
MK^,W_(\R_P#7O'_*N4K\GS;_ )&=;_$_S ****\\ KS7]KK]GSX'?M5_ +6_
MV>?VB-H\->*C!:2.FH"UGCNA,CVSV\A^[.LR1L@P<LH!5@2I]*KDOC?\"?A!
M^TE\-=0^#_QU\ :?XG\-:IY9OM(U.,M'(R.'1@00RLKJK!E(((!!%72ER5(R
MNU9[K=>@'Y7_ ! \4_MO?\$H/%/QT_:'\&?M>K\4?"/@+QGX3L/%?A#XGZ)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?1E%'^J'_3__ ,E_^V ^<Z*^C**/]4/^G_\ Y+_]L!\YT5]&44?ZH?\ 3_\
M\E_^V ^<Z^B+3_CTB_ZYK_*I**]G*,G_ +*<WS\W-;I;:_F^X!1117M@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'S3X%UKXO\ [)%GJ'PKTK]GKQ%XYAGUF[U5
M-=T)DCMS]ID,GE8?G<G0GIFMS_AKGXX?]&,^._\ P)@KWJB@#P7_ (:Y^.'_
M $8SX[_\"8*/^&N?CA_T8SX[_P# F"O>J* /!?\ AKGXX?\ 1C/CO_P)@H_X
M:Y^.'_1C/CO_ ,"8*]ZHH \%_P"&N?CA_P!&,^.__ F"C_AKGXX?]&,^._\
MP)@KWJB@#P7_ (:Y^.'_ $8SX[_\"8*/^&N?CA_T8SX[_P# F"O>J* /!?\
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MX[_\"8*]ZHH ^;++]O/XF7_C:]^']K^QEXO?5-/LX[JZL4U"$S112$A79=N
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M[KQ;XWUB7_3_ !/XCU"U=)]1N').&=RH4%CL1%!9B"S>4?\ !O3\<?AMI?\
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MPK/P4_:4\&7>N^&CJ,-^;"S\0W^F/]HB#!&\ZPGAEP-[?+OVG/(.!0!\<_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>biib-20201231_g35.jpg
<TEXT>
begin 644 biib-20201231_g35.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
MX.#TK^9/_@E7_P $5/V//VS/^"O_ .TY^PS\7=3\9Q>"OA%JOB*W\*2Z/K<,
M-\Z6/B :?#Y\K0.LA\DY;"+EN>!Q0!^O?_!2;_@M5\9?V(_^"M/[/O\ P3Q\
M%_![PQK/A_XPW/AN+5]?U2>X6\L!J6O2Z9(85C<(=D<8==P/S$YXK]%+76M&
MOK^XTJRU:UFNK3'VJVBG5I(<]-Z@Y7/;-?SG?\'#7[.\NE?\%JOV*OV3O@S\
M0=6\+/;> _ WA+PIXKAGW7VD%?$=U9VMZKJ%S-%A) P"_,F1BL3]L_\ 8N\,
M_P#!#/\ X+Q_LO3_ +&WQ9\<2VOCW5=$E\3R^*->%U=ZA]IUG[%J$4TL<<8D
MBN(6!96!Q(SL"/D"@']*-Y>6FGVLE]?W4<$$2%Y9IG"HBCJ23P![U'I>K:5K
MEDFI:+J=O>6TF?+N+699$;'!PRD@U_-Y_P %Y?VG_'/[57_!> ?L*?'+PA\7
M/&OP7^&Z6"M\)?@[;O-JFO2/HT>I2W*VX.)',DZJTI!,=M$Q3:Q)-K_@F%!^
MTM^R-_P67\%ZA^P+^PK^U)\./V=OB#J%GI'CWP;\5O!FH&SM#.&BDNGF*/&J
M0OY4Z3R/YBXDC+>6Q# ']'6IR:E%IMQ+H]I!/=K YM8+FX,4<DF#M5W5'**3
M@%@K$#G:>A_.[_@G+_P<!6/[8/[>'C3_ ()Q_M-?LHS? [XG^&#<Q:7I5]XV
M&KQZS<VK-]JMT?[';;7$0$\97S%FB$C@@*N_]&*_#K_@[H_8MM?A+:^ _P#@
ML3^SSXPN/!WQ+\+>)M/T/6M1TF1H)[WY9'L+U)$Z7$#1&(D_?B=%)Q"JL ?4
M^M?\' K^.O\ @K?'_P $J/V//V1_^%HW.GZB+/Q?\0?^$^_LZRT1X<MJ+F);
M"X\R.T7Y"QD0R3@PJ,E&?]%-8US1/#UF=1U_6+6QMPP4SWEPL29/0;F(&:_+
MC_@U(_X)T^ _V:?V$+']M#6KF/6/B)\<+8ZCJ.LR N]CI2S.+>R1V^;+,IGE
M;C>[HIW"%&/Y+77[0-A_P4Y_X*?_ !A^*/\ P4(_9H_:,^/'A?PUJ=_9>#_A
MM\%K*>XC\-0"\>&W298V!MHTBB(^3:9IBSN3A@P!_5Q#-%<1+/!*KHZAD=&R
M&!Y!!'451U'Q=X4T?4(M)U;Q/IUK=3$>3;7-[&DDF>FU6()_"OPP_P"#:?QS
M^V#^RO\ M9?%WX#_ !$^"7QQ\%?LNGPSJOB7P9)\:/"=[9_\(V;6ZB:-6GDB
M$"2/:23>:D1"R- KA1M-?(^O?"G_ ()7_MC:!\5/%/[$_P#P2V_:M^,#6$U_
M/J7QKE\6);)97KK),+AH%B:W$8SY@BD42>4%W*I)H _J7JMJVLZ/H-DVI:[J
MMM96ZL UQ=SK&@). "S$#DU^!O\ P1 _:=^,7QQ_X-O/VSOAA\5_&VH:];?#
MWX<^+[3PQ<ZI=--+:6%QX8N)!9J[$GRDD21D!^[YI484*!XU_P &^G_!"GX7
M_P#!6K]A?Q#X\_:G_:+^(VF^#_#GQ&O].\&>"_!NJ6UO;VNHFQL9+O4Y1<6\
MZO)(DEO$ %4@6YR2"H !_2GK?B7PYX9@2Z\2:_9:?'(VV.2^NDB5CZ L1DU;
MAFBN(EG@E5T=0R.C9# \@@CJ*_FH_P""H'[-'Q/\'?\ !83XO?'C_@J?^P1\
M<OCG\(-8GF'PWU?X>ZG=I8Z7IY,;6RK+!&R)Y4(9&MVDA/F!Y&#[MQ_2S_@V
M;^('_!,SQ/\ LY_$/PY_P36USXDVNE6WC"#4O%'@CXH7$,M]X=N+FV$42P/#
MN1K:06LA4EW;>DFXCA0 ?<O[8G[07_#)W[*'Q)_:?_X1'^W_ /A7O@?5/$7]
MA_;_ ++]O^QVLD_D>=Y<GE;]FW?L?;G.TXQ7Y'_"+_@[;_:V_:"\-S^,_@+_
M ,$%_B-XWT>VOFLKG5?"'C:_U*VBN51':!I;?P^ZK($DC8H3N"R*<889_2G_
M (+#_P#**#]I+_LA_B?_ --EQ7X+?\&^_P ,?^#@+QI^QIXFU3_@E/\ M%?#
MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
M:5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^
M&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_
MZ#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &
ME16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^
M@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4
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M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\
ML>]9_P#2DU[I7SU^P7K%_8?!S5H+;0+BY7_A.-9/F1$8S]I;CFO;?^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_O
MI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V
M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$E
MU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (27
M5_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+
MW_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4
M+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^
MEH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:
M/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_
M (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?
M_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU
M?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]
M_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W
M_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -B
MBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^
M$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_
M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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M/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"\!VGVK^W?!^E?!>STF?4-]K*D&V[CD+1;)VAE.!\PC*]&H ^OZ*** /"_\
M@GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7< ?J-1110!X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO_P D3U;_ +'O6?\
MTI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVNG!BP_.Y<#/^\*[O_AX)^T]_P!(NOBG_P"!UI0!]645\M0?M\_M)31[YO\
M@G#XTM6S_J=0\8Z1;2#W*2RJP'OCFG_\-Z_M'?\ 2/+Q/_X<'0__ )(KDGC\
M#3DXRJQ371R7^8'U%17R[_PWK^T=_P!(\O$__AP=#_\ DBC_ (;U_:._Z1Y>
M)_\ PX.A_P#R14_VEEW_ #^A_P"!+_,#ZBHKY=_X;U_:._Z1Y>)__#@Z'_\
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M'+Y.RK1O_B7^8'U)17RG_P /!/VGO^D77Q3_ / ZTH_X>"?M/?\ 2+KXI_\
M@=:5V ?5E%?*?_#P3]I[_I%U\4__  .M*!_P4#_:>)P?^"7GQ2'NU_: #ZD]
M* /JRBOEW_AO7]H[_I'EXG_\.#H?_P D4?\ #>O[1W_2/+Q/_P"'!T/_ .2*
MXO[2R[_G]#_P)?Y@?45%?+O_  WK^T=_TCR\3_\ AP=#_P#DBC_AO7]H[_I'
MEXG_ /#@Z'_\D4?VEEW_ #^A_P"!+_,#ZBHKY=_X;U_:._Z1Y>)__#@Z'_\
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M=_XF?_"):7?Z[XMFAF_XEEW]JW)J""V.+3[2P\P\%05^8+0!^N5%%% 'A?\
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M_J;?_)#_ .V4_P#5_.KW]GK_ (H_Y@><T5Z-_P * _ZFW_R0_P#ME'_"@/\
MJ;?_ "0_^V4O]7LX_P"?7_DT?\P/.:*]&_X4!_U-O_DA_P#;*/\ A0'_ %-O
M_DA_]LH_U>SC_GU_Y-'_ # \YHKT;_A0'_4V_P#DA_\ ;*/^% ?]3;_Y(?\
MVRC_ %>SC_GU_P"31_S \ANOA[X O?'-I\3[WP/H\WB6PTZ73['Q%+ID37UO
M:2.KR6\<Y7S$B9D5F0,%)4$@D"MBO1O^% ?]3;_Y(?\ VRC_ (4!_P!3;_Y(
M?_;*;X?SE[T__)H_Y@><T5Z-_P * _ZFW_R0_P#ME'_"@/\ J;?_ "0_^V4O
M]7LX_P"?7_DT?\P,3X,_\CS%_P!>\G\J]AKCO!GPG_X1'7$UK^W_ +1MC9?*
M^R[,Y&.N\_RKL:^SR#!XC!8%TZT;/F;W3[=K@%%%%>V 4444 %%%% !1110
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M[Q_RKE*_)\V_Y&=;_$_S ****\\ HHHH **** "BBB@ HHHH **** "BBB@
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MN>^\7R7%Q8R6S&&,>5*1D<=>*YROR?-O^1G6_P 3_, HHHKSP"BBB@ HHHH
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MRKE*ZOXS?\CS+_U[Q_RKE*_)\V_Y&=;_ !/\P"BBBO/ **** "BBB@ HHHH
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M_P )+J__ $*%[_WTM &Q16/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\ WTM
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ME^(/_0O_ /DW%_\ %T?\*E^(/_0O_P#DW%_\77M-%'^J>7?SS^]?_(@>+?\
M"I?B#_T+_P#Y-Q?_ !='_"I?B#_T+_\ Y-Q?_%U[311_JGEW\\_O7_R('BW_
M  J7X@_]"_\ ^3<7_P 71_PJ7X@_]"__ .3<7_Q=>TT4?ZIY=_//[U_\B!XM
M_P *E^(/_0O_ /DW%_\ %T?\*E^(/_0O_P#DW%_\77M-%'^J>7?SS^]?_(@>
M+?\ "I?B#_T+_P#Y-Q?_ !='_"I?B#_T+_\ Y-Q?_%U[311_JGEW\\_O7_R(
M'BW_  J7X@_]"_\ ^3<7_P 75_PO\,O'&G>)+"_O-$V0PWD;RO\ :8CM4,"3
M@-DUZU15T^%\OIU%-2E=.^Z_^1 ****^D **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#S[]FOX,ZG\#/ 5[X0U76H+^2Z\0WVHK-;QLJJL\I<)@]P#@UZ#110!Q
MWC/X3_\ "7:X^M?V_P#9]T:KY7V7?C QUWC^597_  H#_J;?_)#_ .V5Z-17
MDU<CRNO5=2=.[;N]9?Y@><_\* _ZFW_R0_\ ME'_  H#_J;?_)#_ .V5Z-16
M?^KV3_\ /K_R:7^8'G/_  H#_J;?_)#_ .V4?\* _P"IM_\ )#_[97HU%'^K
MV3_\^O\ R:7^8'G/_"@/^IM_\D/_ +91_P * _ZFW_R0_P#ME>C44?ZO9/\
M\^O_ ":7^8'G/_"@/^IM_P#)#_[97&?$W1M,^&7B_P '>$+_ %.>ZD\8ZTVG
M6TT-HH6W81E][ R<C QQ7O->%_M8?\EL^!__ &/<O_I,U'^KV3_\^O\ R:7^
M8'7?\* _ZFW_ ,D/_ME'_"@/^IM_\D/_ +97HU%'^KV3_P#/K_R:7^8'G/\
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M8:';6L^H1M-(L:VZ&9U"E4S+*^=N0%SB@#]$J*^&/^"D?[4?[66O?MM?!O\
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M_:MTO5+9? ^L_'*#2-.U^2=1:S/HU@\5Y.LIPIB!E1O,!VX.<D<U]!?M:?\
M!(?]AO\ ;.^*:_'+XL_#_6M.\9OI0TO4?$_@KQ?J&A7FJ6 QBUNWLIHQ<QX
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M_P .V_B:>WFUI+[QAJVKF=X%=8R#J-U.8L"1^$*@YYS@8\E^-7_!"#_@F?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>biib-20201231_g36.jpg
<TEXT>
begin 644 biib-20201231_g36.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
MF\$&\?Q')I.K/J+2M=&^C^S&<N4/[N79][+YVUH?\%-/^"'_ /P\7_;E^"O[
M9_\ PT[_ ,(=_P *?N+"7_A&_P#A"O[0_M?[-J8OL?:/ML/V?=CR_P#5R8^]
MS]VOO>B@#\\_^"H7_!!;3?VV/VG?#O[?/[+7[4&M? _XY^&X(84\6Z1IWVN#
M45A1HXFEC62)TE$3&$R!F5X<1O&X IW[)O\ P2J_X*:^%?VE?!_[0W[<G_!9
M+Q5\3-.\&7DUQ:?#O1/"ZZ3I6H2/;RPJ]WY4RI-L\TN T)(900PK]"J* "OE
MC_@L+_P30_X>P_L?-^RC_P +J_X0'=XHL=8_M_\ X1O^U?\ CW$H\KR/M-O]
M[S/O;^-O0YX^F-)\4^&->N9[/0O$=A>S6QQ<Q6EXDC1'.,,%)*\@CGTJ_0!Y
M!^P'^RE_PPW^QM\/?V2?^$]_X2C_ (0/P^FF?\)!_9?V+[=M=F\SR/-E\K[V
M-OF-TZU\*?M"_P#!NW\5_"_[:?BC]O+_ ()6_M^ZO\ O%GCF6XF\7Z$WAU-1
MTZ[FN)1+<,@,BA8WE'FF&2.51(2R-& JK^GVF>(= UN:>WT;7+.[DM9-ETEK
M<I(86_NL%)VG@\'TJS<W-M9V[W=Y<)%%&I:261PJJ!U))X H ^'_ -B7_@E9
M^U/\,?$WCKQM_P %!_\ @I-XL^/\OCSP'=>%+KPS=Z2=,TC3;.Y9#.T$"3N@
ME=4V&1(XCM8@@X!KY8_9M_X-@_VG_P!F-/&_[/WPQ_X*Y>*]#^ GCNXGD\1>
M"]#\)1PZEJD<D7D^1+<F8K"6BVQRRP!#-&FTH@(V?K_HOB#0?$=J;[P]K=G?
MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M&E=EPON:U*** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\
M2DU[I7A?_!/?_DB>K?\ 8]ZS_P"E)KW2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \T_:K^#'Q>^.'
MPWM_#GP+_:=UWX2^)=/UB'4+#Q3HFCVFHA]B2(;:YM;M3%<6[B3+(=IW(A#
MK7P%^SU_P2A_::_:4^,'Q+T_]O7]LG5/$G@'PY^T=;^);SP5HGPN@\.VOCG5
M;31=%>VU&6<SSR?8@52$VT)\MI+21C)N.V/]2** /"OVX?V?OVQOV@O#VD^'
MOV3OVW;#X-1I#>P^*&O?A9:^)O[9BF2-8E7[1<P?9O+"S<KN+^<,XV#/C?\
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M$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@
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M]%W ****^@ **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **\>^,W_(\R_P#7O'_*N4KY/%\4?5<3.C[&_*VK\W;_ += ^C**^<Z*Y_\
M6_\ Z<?^3?\ VH'T917SG11_K?\ ]./_ ";_ .U ^C**^<Z*/];_ /IQ_P"3
M?_:@?1E%?.=%'^M__3C_ ,F_^U ^C**^<Z*/];_^G'_DW_VH'T917SG11_K?
M_P!./_)O_M0/HRBOG.BC_6__ *<?^3?_ &H'T917SG11_K?_ -./_)O_ +4#
MZ,HKYSKZ(M/^/2+_ *YK_*O9RC./[5<UR<O+;K?>_DNP$E%%%>V 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4=W_QZ2_]
M<V_E4E1W?_'I+_US;^53+X6!\[T445^,@%%%% !1110 4444 %%%% !1110
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M*CN_^/27_KFW\JF7PL#YWHHHK\9 **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W?\
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M])?^N;?RJ9?"P/G>BBBOQD HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% !1110 4444 %%%% !7T1:?\>D7_ %S7^5?.]?1%I_QZ1?\
M7-?Y5]EPA\5;_MW]0)****^V **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J.[_ ./27_KFW\JDJ.[_ ./27_KFW\JF7PL#
MYWHHHK\9 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#J_@S_P C
MS%_U[R?RKV&O'O@S_P CS%_U[R?RKV&OT3A;_D6/_$_R0!1117T@!1110 44
M44 %>8?M;_'OXA_LU_"@?%CX?_LT>*_BJEEJD2Z_X<\#R0-JT&G%7,MW:VTS
M+]MD1A&/LR,KN')4G;@^GT4 ?&_PZ_X+_P#_  2-\?Q2VNI_MCZ%X-U>T<Q:
MIX<^(MG<Z!J&GS#[T,L5]''\ZG@[2PST)K-\6?\ !?O]@#4_$ ^&7[)>N>)O
MV@_'UPO^@>"O@SX9N-3D<G@22W;*EI;P@_?E>;"*"V#BOJ#XK_LO_LT?'F>.
MZ^.7[._@7QG+$H6*3Q9X2L]19 .@!N(GP*V_AU\*?A=\(-"_X1?X2_#;0/"^
MF;]_]G>'='@LH-V,9\N%57..^* )_AYK7BSQ)X T/Q%X]\&?\(WKM_H]M<ZU
MX>_M".[_ ++NWB5IK7SXP$F\MRR>8HVOMW#@UL444 >%_P#!/?\ Y(GJW_8]
MZS_Z4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 >/?&;_D>9?^O>/^5<I75_&;
M_D>9?^O>/^5<I7Y/FW_(SK?XG^8!1117G@%%%% !1110 4444 %%%% !1110
M 4444 %%%% !7T1:?\>D7_7-?Y5\[U]$6G_'I%_US7^5?9<(?%6_[=_4"2BB
MBOM@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *CN_^/27_ *YM_*I*CN_^/27_ *YM_*IE\+ ^=Z***_&0"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ZOX,_\CS%_P!>\G\J]AKQ[X,_\CS%
M_P!>\G\J]AK]$X6_Y%C_ ,3_ "0!1117T@!1110 4444 %%%% !1110 4444
M ?/7[!?ANPU;X.:M=7,UPK#QQK*XBG*C'VENPKVW_A!](_Y^;W_P+:O(_P#@
MGO\ \D3U;_L>]9_]*37NE 'BWQ4TZ#2_%\EI;O(RB&,YE<L>1ZFN<KJ_C-_R
M/,O_ %[Q_P JY2OR?-O^1G6_Q/\ , HHHKSP"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KW"V\$Z2UM&QN;SE >+MO2O#Z^B+3_ (](O^N:_P J^RX0
M^*M_V[^H&7_P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%%?; 8_\ P@^D?\_-
M[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6
MU;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;
M4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10
M!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P
M@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_
M ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1
M_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'
M_/S>_P#@6U1W/@G25MI&%S><(3S=MZ5N5'=_\>DO_7-OY5,OA8'SO1117XR
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '1_"O3H-4\7QVEP\BJ
M89#F)RIX'J*]1_X0?2/^?F]_\"VKS;X,_P#(\Q?]>\G\J]AK]$X6_P"18_\
M$_R0&79^$M-L;I+N&XNBT;94/<L1^(K4HHKZ0 HHHH **** "BBB@ HHHH *
M*** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]T
MH \>^,W_ "/,O_7O'_*N4KJ_C-_R/,O_ %[Q_P JY2OR?-O^1G6_Q/\ , HH
MHKSP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ(M/^/2+_ *YK_*OG
M>OHBT_X](O\ KFO\J^RX0^*M_P!N_J!)1117VP!1110 4444 %%%% !1110
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MP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA#XJW_;OZ@24445]L 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCV^;]O\ W?D^7YN=OS;MG;->Z4 %%%% !1110 4444 %%%% !4=W_P >DO\
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M^ %Y_P#&:/\ A[=_P3H_Z.DT7_P O/\ XS0!]&45\Y_\/;O^"='_ $=)HO\
MX 7G_P 9H_X>W?\ !.C_ *.DT7_P O/_ (S0!T_[6'_!/K]C_P#;?FT.^_:<
M^#-OXAO_  T9O^$>UFVU:]TW4--$NWS!!=V,T,\0;8F0K@':*\G_ ."57_!)
MG]GG_@GK\*M"\06_P:T.W^+<WAQ-.\7^,X]4N]3N9@'+&&"XO'9X8#A"8HA&
MA*@E>!78_P##V[_@G1_T=)HO_@!>?_&:/^'MW_!.C_HZ31?_   O/_C- 'T9
M17SB/^"N7_!.8R&,?M1Z/D#)/]G7N/S\C%._X>W?\$Z/^CI-%_\  "\_^,T
M?1E%?.?_  ]N_P""='_1TFB_^ %Y_P#&:/\ A[=_P3H_Z.DT7_P O/\ XS0!
M]&45\Y_\/;O^"='_ $=)HO\ X 7G_P 9H_X>W?\ !.C_ *.DT7_P O/_ (S0
M!]&45\Y_\/;O^"='_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ P O/_C- 'T91
M7SG_ ,/;O^"='_1TFB_^ %Y_\9H_X>W?\$Z/^CI-%_\  "\_^,T ?1E%?.?_
M  ]N_P""='_1TFB_^ %Y_P#&:/\ A[=_P3H_Z.DT7_P O/\ XS0!]&5'=_\
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M .@SQ6=_PR_^S3_T;QX%_P#"2L__ (U7<T4 <-_PR_\ LT_]&\>!?_"2L_\
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M_P"S3_T;QX%_\)*S_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\
MLT_]&\>!?_"2L_\ XU7<T4 <-_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/
M_1O'@7_PDK/_ .-5W-% '#?\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S3_T;
MQX%_\)*S_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!
M?_"2L_\ XU7<T4 <-_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_ +-/_1O'@7_P
MDK/_ .-5W-% '#?\,O\ [-/_ $;QX%_\)*S_ /C5'_#+_P"S3_T;QX%_\)*S
M_P#C5=S10!\N>!_V?_@-<?MU^.?#EQ\$O",FGVW@K3);>P?PW:F&*1G;<ZH8
M]JL>Y R:]J_X9?\ V:?^C>/ O_A)6?\ \:K5TSX4^$=(^*.J?&"SAG&M:OIL
M%C>NTY,9AB)* )V.3U[UTE '#?\ #+_[-/\ T;QX%_\ "2L__C5'_#+_ .S3
M_P!&\>!?_"2L_P#XU7<T4 <-_P ,O_LT_P#1O'@7_P )*S_^-4?\,O\ [-/_
M $;QX%_\)*S_ /C5=S10!PW_  R_^S3_ -&\>!?_  DK/_XU1_PR_P#LT_\
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MM_\ : V^5_M^7YN/;-?HE0 4444 %%%% !1110 4444 %%%% !1110 4444
M%?'/QV_;2_X*E6OQF\3?#S]DG_@DW_PEGAKPQ>_9U\=>./BS9>'X-<<1J["Q
MM6ADE>/+;1,Y5"5([5]C5X#_ ,%"_P#@H1\*O^"??PFM/%/B;2;[Q1XU\4WP
MTGX9_#3P^GFZMXMU=\".UMXU!8(&9#)-@K&K#[S,B. 9O_!-K_@HQX:_X*$?
M#OQ5?7_PEUGX<^/?ASXKG\-?$OX=^(+E)[C0M3B&2JSQA5N(6&=DH5=VQ_E
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M ,$O?V='\4^;]O/P.\*FY,_^LS_9-MC=WW8QG/.<YYH YO\ X)1?\%%?%_\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^%O^"E__!(_]H']O/\
M:R^&W[3'P]_;TM? 6G_"[3ED\->!->^$\'B?3(];\Z=FUDQ3WT$33^5)!&@D
MB?RC;!T8,QQZU^R5^SE_P48^$OQ-N?$W[6/_  4JTKXO^&9-'EM[;PO9? ZQ
M\-O#>-)$R77VJWO)F8*BRIY6T!O-#9&P _1]% 'P[\5/^"8?[5GPT_:H\?\
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M]IW_ ()C?'V[_;3OO^"A/_!/S]K6T^%GQ"\2^&+?0?B#HWB?P>NN:'XGMK?
MMI9(O.BDMYXE5%$B,<J@4!<R;_M*B@#Y"_86_P"":/Q,^!7[3_C/]O;]L+]I
MT_%GXS^-/#<'AM=4L/#2:/I7A_0XIEF&GV5JLDAVM*D;M([98IG&YG9_KVBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>biib-20201231_g37.jpg
<TEXT>
begin 644 biib-20201231_g37.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
M/VFOB3^V+^R/X2_:.^+O[-FN?"'Q%XC^W_VA\._$DLSWND_9[^XM8_,::VMG
M/FQP).NZ%/EF7&X89O6[_6M&TNXM[34]6M;:6\E\NTBGG5&G?^Z@)RQY' K\
MC_\ @X4TC]IK0/\ @V^31OVR_%.E:W\4;?5_#J>-=6T2.-+2ZO?[0&YXA'%$
MH7;MZ1J..E?G7\?O^"1/@&Q_X-R?!W_!5#QY\=O'FM_$O2]+T=M T^YU=&T?
M2M'GU=+&'3[>W,>Z()'*LY=7&9MYQ\QH _J-KX^_X+/_ /!2WQ3_ ,$UOV#]
M2_:W^#'A;P[XQU"P\4Z?I!T_4[QS:_OW97W- P8.N!QGOS7Y0?\ !2S_ (*.
M_M4VO_!L'^S));_$W6(]=^+4TF@^-?%$=ZXO+_3-/-W%]GDFSO+3B&W\U\[I
M%CD5BPD?/GW_  5/_P"")7P1_P""?G_!$+P7^TS\$/CIXU;7?%C>&7^(^E7F
MN*^C>)'N[<W"O':JBB-X)B#"V6(B\P$L6+4 ?OY_P3R_:7\2?MD_L0_##]J;
MQAX=L=(U3QWX1M=7OM,TUW:WMI)5R4C+DL5'N<UZS8>(O#^JWUQI>EZ[9W-S
M:'%W;6]TCR0GIAU!RO0]:_G>_P""G7[;GQ]_9@_X-N_V-_@S\#/&>H^&X_BE
MX12W\3ZSI%PT%R]A9VT;&R65<-&DSW"%]I!982A)1W4_,7Q2_9QOOA%\/_AK
M\3?^"5?_  3D_;F^'OQO\):A;3ZS\0-?\$WQM=9B\AC-*J6ZOY3&81E8U7RF
MB:1) ^0: /ZQ[JZMK*VDO+VXCAAB0O++*X544#)))X  [U^='_!?W_@M;\4O
M^"1O@+X6>-?@?\+_  IXUC^(.H:I!</KEY/Y4*6L=LR-$UNXW;C.V<DCY1BO
MSW_X.#/VJ?VG_P!LKQE^Q-^P=\1M2UGX;:?\9O!?A?7OB7H\EM+9"+6=6O([
M*2*ZADVMBR=)F$,@&UI<L-RKM\/_ .#FC_@E3\'/^"5?@CX(> OV;/BQXVO?
M!7BBYUV>3P?XNUY;V*RU*V2P66_M@(T$;3I.BRA0%)@C([  ']25?G9_P6W_
M ."^%S_P1V^(_P //AU9?LBR?$V;Q]I=Y=Q2Q>.3I+6K0311"((+"Y,Q<R<$
M%<8Q@YK]$Z_GQ_X/*?\ D]#]ES_L'WW_ *<;.@#WW2/^#NFR^%7CW2?"?[?_
M /P2O^+?P3LM5DVIJ5]<2W4D:Y ,HM[NRL7DC4,"WE[F /"L< _KA\)OBQ\-
M_CM\,]"^,GP@\8V7B#POXETR+4-#UG3Y-T-W;R*&1US@C@X*D!E(*L 00/AC
M_@Z+C^"#_P#!&'XH/\95TTW:3:8?!)O-OV@:U]NA$7V;/S>9Y7G[MO/D^=GY
M=U?D_P"'_P!MG]K#]C?_ (--/ T?PL\6ZUX>NOB%\;=5\,Z1XCLYWAGL=!;[
M9<W"VLRX:)I+JVN(]RD$*T^"#@@ _I<M_$7A^ZU:70+77;.2_@7=/91W2&:,
M<<L@.X#D=1WJY7\CVK_LR:!:_LC> ?B+^Q!_P3O_ &WM'_:)L?[.UN7XQ)X4
MOFTK5YI4$EQ+;-;;GCA)<O;RQC>RA=[-O+#[ _X+S_\ !2C]OS5O^":7[(_P
M2\=:GK_PT\4_&7PW>3_&(W-M-H][=W%D]K9B&=-J26\,KS27$L. &W1C&T8(
M!_0IIOB7PYK-W/I^CZ_97<]J<7,%M=)(\)Z88*25_&I-6UG1]!LFU+7=5MK*
MV0@/<7<ZQHI/ RS$ 5^<W[%G_!L%^P7^PY\6_AO^T7\)_B!\1)/'W@&Z6ZN=
M8NM<A-KK<C0/%,DUL(<1Q-YC%5C8%<+N9\'=^0?[0?[1+_\ !1[_ (+2?&*/
M]NW]G_X_?&WX??#;7M;TCP?\)O@I9S7#Z3#9ZA]B@DFCC8&"(HC/+(FUY)Y$
M!;:-M ']3=K=6U[;I>6=Q'-#*@:.6)PRNIZ$$<$4EW=VEA:R7M]<QPPPH7EF
ME<*J*!DDD\ #UK\%O^#<#4/VS_V<O^"E7C+]G7PI^S-^T%X0_9?\8Z?J-]X8
MTCXQ>$+VW'AZZB"30,9WC$$<K 30-L8><&C9@608^8_^"+G_  3+\ _\%1?V
M]OVI?@S\</BOXST/P!I>K7=]K6A^#=72S?6;TZM=)9FX9XY%>*',\@0K@R&,
M_P ." ?T_OKFBII'_"0/K%J+#R?-^VFX40^7C._?G;M]\XK!^+GQ!D\ ?!;Q
M/\5- CM[Y]$\+WNJV2-)F*X,-L\R LIY5MHY!Z'BOYGO^#?O_@G))_P59LOC
M#^Q5^T?^TY\1K7X/_"6Z2^T3P9X<UM;>VDUR_DN($OGCD2166-+%W$6,;Y,@
MC,F_Z'_X-0OC;\2O&7_!-3]KCX(^)_%5Y?>'?!F@B\\-6-U<-(NGM?Z9J8N(
MXMQ/EQLUI&^Q<+O9VQEV) /T"_X(*_\ !8CXB?\ !6']GGQ[\;?CG\/?"W@E
MO!_BZ+2(5T:\F$$D;VT<N^1KASAMS[>"!TK[^AFBN(EG@E5T=0R.C9# \@@C
MJ*_F-_X-P/\ @C=\#O\ @JY^RI\5H?VE?C)XZM- \/>+(K?P[X4\+:XMK:VN
MIRV0+ZK-$R.L\H011QA@ H24'=O^7J?^"(G_  4H_:E_9&_X)O?MK?"C1_'$
M_B!/@7X:CU'X8WE[F>+1;NXN;FQD:)9-P\CS!#<K#]P-'*<'S&H _H_N_$7A
M_3]3@T2_UVS@O;H9MK2:Z199A_LH3ENAZ#M5ROY"_P!G#X3?"S]JC]D;QI\9
MOCK^Q#^V3\9?CIXON]1N/#GQD\&:-<ZEHUG>Q@K;;I06:Z(G7]^7W, 2D>PJ
M&/WHWQ:_;E^('_!I=\?O O[?7@3QWI/BKP+KVEZ-H-]\0]#N[+4-1T?^UM%F
M@=S=HLD_EO)-")#GY8T4DE30!^^^HZSH^D- NK:K;6IN9UAMA<3JGFR'HB[B
M-S'L!S5FOP/_ .#?/_@A1\+?VO?V-?@3_P %!OVC?VB_B-=ZGX/\73ZG\*/"
M>CZK;1:3H5KIOB*XF:!XIK>5G\^_@N99"CQY68 88;J_?"@#\L?VIO\ @NE_
MP4Y^$/Q,^(FG?!W_ ((3_$+Q/X#^'?B;5],D\>7>KWD,6LVMA<RPMJ%O$NG$
M^0ZQ-(K(TJ[3G=P:^@/^",/_  6?^$'_  6/^$?B7QEX*^&NH^"_$W@F^M;;
MQ9X6O]02\2W%RDK6T\-RJ1^=%)Y$Z_-&C!H6!7&UFY;_ (*^_#[_ (+S^.-<
MN;;_ ()8?$WX9Z1X(G\!"WU73]=VIX@GU<S70F-G)/;O!&K6[6JHSR)AU<_+
MPQ^/?^#+SXA_LTI\%/BW\%/!7PPUK0?BGI6JZ=>?$'5M5U5;F/6K?_28K7[.
MBQ1_9D@<7"M"V]MT^_S7W[(P#JOVT_\ @[%\=?LA^-[[3+G_ ()'?$67PO#X
MBO\ 1M*\9>,O$LF@VFLSVDI21K0G3;B.=< /\LA(5E) S7Z_^$]=_P"$H\*Z
M9XF^R^1_:.GPW7D;]WE^8@?;G SC.,X&?2OQ!_X/@O\ D@/P"_['#6O_ $EM
MZ_:WX4,J?"GPT[L !X>LR23P!Y"4 =#14%CJ>FZFC2:;J,%PJG#-!,K@'WP:
MGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *_/C_ ((H?\$(O^'/'C_XG>.?^&I_^%B_\+'M["+[+_P@_P#9']G?
M9I;F3.[[=<^=N^T8Z)C9GG/'Z#T4 <?^T%\!_AC^U!\$?%/[//QF\/C5/"WC
M'19]+UNQWE&>"52I*,.4=3AE<<JRJPY K\A(/^#67]M+X;?#GQ-^R/\ L\_\
M%D_$?A_X#>+[^2;6/!=[X2>28PR;1)$WE7:)*75560IY*2@?,F.*_:NB@#X/
MU+_@@U\#?#7_  1U\2_\$B_@-\3+SPO8^*VMKO6O'VIZ.NHW5WJ27UI=37DM
MNLT"L76SCA5%=1'&J#+;/F]Y_P""9?[$W_#NC]ASP'^QC_PLS_A,?^$)M[Z+
M_A)/[&_L_P"V_:+^YO,_9_.F\O;]HV?ZQL[,\9P/=Z* "OR?^.7_  ;+_$B]
M_;F^(?[</[#O_!5#QM\!]6^)>H7E]XBL=$\*/=RF:\N%NKM!<PZC:DP/<#S1
M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,GP=XZ\(_$'2Y-;\%Z]!J-I#=RVLD]N256:-MKISW!X-:U>%_P#!/?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9I=65I!#&MO(Z:@3]OW%=K?-O! 8YR:][HJ:F/KUN15?>4>[>NK>NN^O2VR
M^$/V7_V7/V@/VB/VS_"7[9_[17[,VD_!+P5\)-"U&Q^$'PGL[^TN;LW^HJ([
MW5KO[&!!#NA C6$98%58X*9?NO\ @K=^S?\ M ?MF_#OX??LG?"_PE)-X'\6
M?$73Y_C+KZZM;6XT_P .V<JW#PB.25999)I1'L\I7P83NVA@:^M:*3QU7ZQ&
MJDER[+6RW\[WN[ZO<"*PL+'2K&'2],LXK>VMHEBM[>! J1(H 554<     =
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ML 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O
M"_\ @GO_ ,D3U;_L>]9_]*37NE 'CWQF_P"1YE_Z]X_Y5RE=7\9O^1YE_P"O
M>/\ E7*5^3YM_P C.M_B?Y@%%%%>> 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?1%I_P >D7_7-?Y5\[U]$6G_ !Z1?]<U_E7V7"'Q5O\ MW]0)***
M*^V **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBO,/VM_V4/ /[9_PI7X(_%7Q9XMT[PS<:I#<Z[8>$
M?$DVE/K5LBN&T^YF@(E-K)O!D2-T9MBC<!D$ \R^/?\ P6?_ ."5O[,GB2?P
M9\9OVZ? &G:Q:2&.]TJPU8ZE<VL@."DT5DLK1,/[K@'VKMOV8_\ @HE^PO\
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M>3P;_P + LO#>RT9)#)=?:[U&C.QEC7R\;F\S(^Z: /SU_X*]?&?_@WC\?\
M[4]YX+_;F\<^,/"OQH\!VT&GW'BWX?Z!XBM-3MK>6!+F. WFGVSPW*>7.K -
MYFS>R@J2PJS_ ,$>/C1_P;W^!OVH8/AS^P3XU\6^)_C+\0+2YM!XK\?>'_$5
MSJE[;6UM)=RP?;=0MDAMX_*MF<JIC\PQH#N(0#UK_AX?_P %U_\ I75_\VY\
M,?\ R/7H'[+G[9?_  5A^*_QVT+P!^TO_P $7_\ A4W@F_\ M7]M_$#_ (:+
MT+7O[*V6LLD/^@VL*S3^;,D4'RD;/.WGY4(H ^OZ*** /"_^">__ "1/5O\
ML>]9_P#2DU[I7A?_  3W_P"2)ZM_V/>L_P#I2:]TH \>^,W_ "/,O_7O'_*N
M4KJ_C-_R/,O_ %[Q_P JY2OR?-O^1G6_Q/\ , HHHKSP"BBB@ HHHH ****
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M3_L(3?\ H9KY+BW_ ':GZO\ (#+HHHKX0 HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *U/!7_(X:7_V$(?\ T,5EUJ>"O^1PTO\ ["$/_H8K?"_[U3_Q
M+\P/>****_80"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BOS\\?_ +4?_!5K]KS]L[XK_L]?
M\$\[[X1?#_P-\%-5L-$\2>,?B7I=[J6H:WJ]Q9QW<D=M;6[JD4$4<JJ2_+':
MRL0Q5/4/V9OA9_P6=\.?&[1-9_:P_:N^"?B7X?P_:?[?T3PC\/;RQU&YS;2K
M!Y4\D[*FVX,+ME3E%91@D&@#ZSHHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>
M%_\ !/?_ )(GJW_8]ZS_ .E)KW2@#Q[XS?\ (\R_]>\?\JY2NK^,W_(\R_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%>2_MK_"#P+^T-\";GX!>._P!I'Q=\*T\7ZK966F>*O /C"+0];-W',MRE
MM97,B/\ O)1 ZM&JLSQ>8 .I !\G?&S]@W_@KWX>_;^^)/[67["?[5'P9\%>
M&/B%:Z7#J7A;Q-X4O;MM1DL[-(([R["@K]J7]Y&)(6CW0B)9 YC4CTS]ESX9
M_P#!;SP_\=M"U?\ :^_:;^ _B'X=P_:O^$AT?P9X+O[34KC-K*L'DRRL43;<
M&%FR.45P.2*\O_XAWO"O_28+]N__ ,2!3_Y KOOV8O\ @CQX/_8Y^-VC_M*7
M/_!3#]JWQI#X7AO)9_#GQ5^,T>H^'[F.6SF@9[NW-I&'6-93*I+J$DB1SG;@
M@'VC15/P]XAT#Q=H%CXK\*:W::GI>IV<5WINI:?<K-!=V\B!XY8Y$)5T96#*
MRD@@@@X-7* /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z
M4FO=* /'OC-_R/,O_7O'_*N4KJ_C-_R/,O\ U[Q_RKE*_)\V_P"1G6_Q/\P"
MBBBO/ **** "BBB@ HHHH **** "BBB@ HHHH **** "OHBT_P"/2+_KFO\
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M7T1:?\>D7_7-?Y5\[U]$6G_'I%_US7^5?9<(?%6_[=_4"2BBBOM@"O!_&O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P $]_\
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MW_(\R_\ 7O'_ "KE*_)\V_Y&=;_$_P P"BBBO/ **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 >%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
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MZ*^,_P!;_P#IQ_Y-_P#:@?1E%?.=%'^M_P#TX_\ )O\ [4#Z,HKYSHH_UO\
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MNK%);4S112$A79=V IQP<GZ5L?\ #0O[3W_2.?XI_E:?_'*]^\ _\I!/'_\
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MHH:N@/@W_AH7]I[_ *1S_%/\K3_XY1_PT+^T]_TCG^*?Y6G_ ,<K[RHKQ?\
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M:R;[:2:%6:)L8W*2/E..XK\XO"WQ0_X* _\ !5G]K'XYZ)^S)^VQ=? 7X1_
MOQQ+X#TB[\-^"=.U?4/$_B.U0-?SW+WRLL=O [HBQ1X$BR*6((S7H?\ P3>_
M;&_:_P#VJ_V;_CE^SW\2=:\+6G[2'P.\3ZSX'N/$S::R:-JFH);NVE:U);1\
MI!,Q5I(D R(G*J@<(H!]PT5^7W[97PI_X+0?L%_LN^*_V[H/^"O]M\0=8^'N
MDMKOB'X?>(_@YI.G^']7LXB&GLXFMS]H@;9G8ZOO<J%)0N6'KO[=O_!4?XC?
M"G_@F1\*?VF?V=_ 5JGQ,_:(N/"6A?"S0=?!>"QUCQ!;I/%]H  +B"+S3C&&
M=$!&&(H ^Y**_,GXW_$'_@I)_P $A/&'PE^//[2/[>\OQ[^%OC?XA:=X.^*^
MDZ]X TW2)?#TVH;EAU?3Y;)%98(Y5P\$FX%2H'+[X_TVH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBOCGX[?L;?\%5/CI\9O$WBGPM_P5@_X5+X)
M%[CP1X0\#_"K3;^>&$1J!+?7E\"\LA?>3$@" 8^8GH ?8U%?#_\ P2/_ &Y?
MVA?BSX:^._P2_;A\4:%K7C']G'XA77AW7_B)H&GK9V?B"R2%IDO'MX_D@G"H
M_F1Q@*ORC (.?#?V:/$O_!8K_@J1^S5J_P#P4C^!G[=<?PCLM?O]5N/@C\&X
M/ &F7VG7&G6=Q+! NK75RC3O+=/ RLZ,%C#"2,88(H!^I<>EZ9%J$FK1:= M
MW+&$ENEA42.HZ*6QD@>E3U\C_L9?MF_'3_@IG_P2ET#]IW]F^Y\->"OBEXHT
M26T(\16$USIFCZU:W;6MYOA4^8T6Z&5XT))VR1[B>37DO_!,#XY_\%#+?_@I
MS^T#^Q)^V[^UMI_Q3MOA[X+\-:MHUSI7@*PT.VM9]0C::18UMT,SJ%*IF65\
M[<@+G% 'Z)45\,?\%(_VH_VLM>_;:^#?_!+W]B[XFV7PXU_XE:)JGB;QI\4+
MK0H=3N-#T2R!7RK*VN 89+B:0,F^0$1C:0.25YWX0?'[]L7]@S_@IE\//^"?
M/[7O[4C?&GP;\<_"VK7OPV\::SX7L]*UC1M7TR,3W-A<?8E2*XMY(#O21E$@
M=U3H/F /T)HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO@CQK^
MPU_P6Q\4V6M?$N#_ (+0V?AWQ.CW%SX:\':'\&M)/AVT4%FAM+B6X5KFX0C:
MKSL-R[B0AV@&#]F#_@LQJOC3_@A-=?\ !5_XW> K*#7O#GAC53K&C:9(T=EJ
M6JV=Y+8PB!V+%(KB=8>[>6964%]F2 ??U0:?I>F:1 ;;2M.@M8VD9VCMX512
MQ.2V !R3U-?E-\0]=_X+;?LT_L'VW_!6?QE^W18^+=;TSP]9^,_''[/<_P /
M-/M- 30Y1'-<:;;7<:_:X9[>V<MYY=RS0L#O!RWVY\:_$7[5/[6O[)?@/XF_
M\$W_ (X>%? 5]XWATO7O^$G\:^&6U58]!N["2<""V5@C7)>6T(WG8%60=2M
M'T)17PQ_P0:_:3_:R_:)^"_QPTG]L?XZK\1?$_PQ_:8\3> ['Q.GABQT@3V.
MG6VGJF+:RC1$#2RSR?,7<>;M+L%7'-_M1?&_]M_]J3_@K-=?\$S/V<_VHQ\"
M?"WA#X0P>-]?\5:9X6L]3UOQ))/>"V6"U%ZK10V\9*[I$4MO5U)(8;0#]"Z*
M^"O^"<7[1O[8WA+_ (*&_&G_ ()D?M5?'.U^,-O\/?">D>)_#'Q.7PY;:7?Q
M07N!_9NHPV@$'G#<&C8*K.B.[9#A8_O6@ HHHH **** "BBB@ HHHH ****
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M_&']F+X.:KH'B&[T>72KB]O?B#KNJHUI))%(Z>3J%]/$"7AC.\('&T@$ D$
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M?\$%/^"5'[,WQ3T?XT_!#]FO4M#\2:%K*ZMIM\/B=XDN$6\'_+9X)]1>&8G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>biib-20201231_g38.jpg
<TEXT>
begin 644 biib-20201231_g38.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
M9[UC_@X(\5V/P[TRS2PLAH/@7R=6^Q(NQ(1="[6>/Y %!\]]HQU Q7ZRT4 ?
MG[_P5P_X(*?#K_@I[\$_ASH&G_&O4?!WQ'^%.FQV7A;Q\]C]K:[@"1!XKN-9
M(V8L\*2+(KAHG+D!@[ _,/[1W_!J9^T?^VWX.\,:K^V!_P %B?%GB_QYH'G6
MR:SK7@8ZA8VVGE4V6UM =0A9)-ZL\MPS,TV8P57RRS_M!10 5^=G_!;?_@@?
M<_\ !8GXC_#SXBV7[74GPRF\ Z7>6D447@8ZLUTT\T4HE#B_MC"4,?  ;.<Y
M&*_1.B@#\:M/_P"#1F^^+GCG2?$/_!0#_@K-\6OC7I.D3;K?2;VRFMI=A(+1
M+<7E_?&-6QAO+56(Z%3@C[__ &N?^"4'[(/[7'[!<7_!._6_!(\,^!-)L[5/
M!R^' L<WAVXM5(M[FW+A@S@,ZOOW&1990QRY:OH+QGXW\%_#CPU<^,_B'XOT
MO0='L]GVS5M:U".UMH-[K&F^65E5=SLJC)Y9@!R12^#_ !IX.^(?ARV\8^ /
M%FF:YI%Z&-GJNCW\=S;3A6*,4EC)5L,K*<$X*D=10!^4GPR_X(2?\%C?A#\/
M;']FCX<_\%^/$6A_"_2+466CPZ=\/@-3LK)>$@AF-WYL(5?E4)< (  H  4?
M0W[=O_!"7X&_M_\ [!GPX_8^^,?Q?\1R>)_A5HEO:>$OBQ/$MSJ37"6T4%Q-
M=1R-BX2Y\J-Y4WJS.B$2 KD_=%4=*\4>&=>N9[/0_$5A>S6QQ<Q6EVDC1'./
MF"DE>0>M 'YO?L-_\$=O^"H_[.WQH\ :S\?_ /@M#XG\>_#;X=W@EL_ ":#/
M$-8B2%XH;>ZF:[+&--R.%D\\ QJ !@,*?[7/_!O3X]U?]N'6O^"BO_!,[]N;
M6/@!\1_%1F?Q=:1Z$NH:?J<TY5KB0+YB;1*Z++)%(DR-*/, 0@5^G=4],\0Z
M!K<UQ;:-KEG=R6DFRZCM;E)&A;GY7"D[3P>#Z4 ?&'_!/3_@FM^W-^SO^T)>
M?M-?MO?\%3/%GQOU2?PK<:+8>$FT/^S-$TWSIK>5[E($G:-IO]'"!UBC.UV!
MS6'_ ,$E_P#@B!_PZX_:2^,G[0G_  T[_P )S_PMNX$O]D?\(5_9G]E?Z9/<
MX\W[;/Y_^OV_<C^[GO@?>]% 'P1_P1B_X(?_ /#HCQ_\7O'/_#3O_"PO^%JW
M&GR_9?\ A"O[)_LO[++>R8W?;;CS]WVS'1,>7GG=QS__  2-_P"" W_#K#X+
M_'#X0_\ #6/_  G?_"YM'M;'^T?^$$_LO^Q_)MK^#?Y?VZ?[1G[;NQNCQY6,
MG=E?T3NKJUL;9[R]N8X88E+22RN%5 .I)/ %0:-K^A>([0W_ (>UNTOX Q4S
M65RLJ9';*DC- 'XT? __ (-5OVIOV./A+XE\._L<?\%E?%WA#Q-XLG\CQ#=:
M7X,?3M.U+3A'M2&2&._ED2XC9IF2Z1]P65D"C)>OK#_@EW_P0,_9G_X)Y?L;
M^/\ ]EKQGK+?$>\^+UD]I\4=>O;'[$FI6IAEACLX(ED=H(HDGF*MO:0R2N^Y
M?D5/O*B@#\A?A/\ \&[O_!1O]B4ZS\,O^"<?_!:37? ?PRUK5)+T>&M=\#0W
M\]@[@*61S)Y;2%54-+$EN6VKD< U]'>*/^"-OQ)^(W_!)SQ]_P $V_C!^WOX
MH\;>)OB'JZ:EK'Q?\6Z&]]<I*M]9W6Q;1[S/E!;-8U3[1A ^1P M?=E% '@'
M_!+C]AC_ (=K_L)^!OV*?^%H_P#":?\ "%_VG_Q4W]B?V=]L^V:I=W__ ![^
M?/Y>S[5Y?^L;=LW<;MH]_HHH _([Q;_P0<_X+$:=%JGP_P#A#_P< ^.K7P1J
M4TXAT_5='O#=V%M*Q_T>*87SN%53M78\8P.%7H/IW_@C+_P1/^"/_!'3X<>(
M])\%_$'4O&OC'QI-;/XK\7ZG9):K,EN)/)M[>W5G\B)3+(Q!DD=F?+,0J*OV
MI10!^//[='_!KY^U/^W[\0M3\1?'+_@M-XKU?PZ?%&HZMX4\(Z]\-I=0MO#L
M=U*S"V@+ZRHPD>R+<$7(C'RCH/HSX"_L8?M8_P#!-#]B?X_ZQ^T+^WKX]_:>
MFNOA]/+X1T6_\,7,5UIS6EA>K]CLXOMEXTKW+2P( H7!B3AL_+]]44 ?F!_P
M:G?\$\OC3^PQ^P'J?C#X_:5=:+X@^*^OQZ]#X5O[1H;K2;&.$0VXN%?#)-(-
MTIC(!1'C#8;<H_3^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF[_@J'_P
M3D\-_P#!4/X Z/\ LV>.?C-XE\%^';?QG:ZSXAG\)LBW>J6D-O<Q&Q#OE(U=
MIT<LZ2J#"/D)(9?I&OC/_@NS_P %1==_X)+?L,O^T/X*^'L/B/Q-X@\40>%_
M"L%]+ML[.^N+2[N5NKD AI(HTM)#Y:$%V*+N4$LH!^)7_!>3_@FG\ /^"(OQ
ML^!_C7_@F5\=?'NB?$W7[JZ<:"/$(NM2A$+P+;7</DQI(JS2O)$8W#),5*JN
M$D4_8G_!US_P4 _:E^$/[)GP,_9'\':_=^%?%?QBTV2]^)9T*[:&;;;PVD;:
M<KH=PAEN;J3>%QN6V"'*NZGX,_X)??\ !6G_ ()M_!;]HG5O^"B/_!4C0?C=
M\:OVA]3U1[K3=2@\-:3<:/X>P<1RVHGU.$O,%P$/E1QVZA4B0%1(?N?_ (.M
M?V;?B7^VA^R!\ _^"GO[,?@76]2TSPMI#:EKFGQV6^_L-)U2"SO;6\ECA9]J
MP/$5E*,X0SAL[%9P ?.W_!7[_@F%I_\ P;G:1\!?VWO^">?QT\:Z?XM37CHW
MBV[U35%D@U2[2W6Y5C%&D8^SR^5<));/O1D*#@ABWZM?MC?\$L_@1_P7>\'?
M S]HKXX_%SQIH7@:/P(FM1>!_"E[' NIR:G#:743SSR*ZXB5=N%BW'>2'3&#
M^4__  65_P""HGAC_@X=T;X!?L0_\$\?@]XRU7QA<^(3K'BBPU+2?*BTR[>W
M6W6,R(S@PP^=</+<,%C1%5LG+!?LW_@OA_P51^+/_!$W]CCX0_L*?LJ6")XP
MUKX>Q:/8_$"Y52NBV&FV]O9F6WA.0UT_!5G^2, G#L1M /A[6_V:K?\ X))_
M\'*OPC_99_X)4?&/Q3K&GZ]J?AX>//#$NK_:3:07-U(-2TV],2JLL4=@@O-T
MB%H5F5\[HPU>]?\ !?GXM?%+_@H+_P %K_@W_P $5[3XGZUX<^&$]SI#>.++
M0KHQOJ-Q=EKJ>60<K(8K)(_)$BLL<CNY!S7DG_! W_@J/_P1W_8R\?:%I^J_
M#'XZ>//VC/B[X@M-*\3_ !4\1^&])DCBN]0ND1H8)'U9YH[;SI TLQ5IIR"[
MC[D2>K?\%]?AC\2/^">?_!<'X,_\%G9?AQK6N_"W[7HZ>,]1T6U\QM/N;3=:
M3P.>%1I+)HVA\QE61TD3(VDT >=_&'X7I_P;9_\ !=CX*^!_V0/B9XL/PB^+
M5KI"^,O"WB#5_M$4T-UJ,NG70<*J)*T($=S"Y&]')7=L)#?T9U_.5\=OBQI_
M_!R#_P %X/@CXE_8T\!>*)_A3\*;/1W\9^*-;T@V\5O;VVHRZA=2/RPB,JF.
MVB5OF>0$[2H)'Z<_M2?\%M-;_9U_X+$_#+_@E-I?[-$6O1?$*TTR>;QHOBEH
M9-.6ZEN5?_0Q:OY@C6WWDF5<ACG &2 ??E?GW^W%_P &[/[*_P#P4=_:^UO]
MJC]K3XR?$'4[2ZTBRL/#_@G0=4CLK'2EA@$<DA9TE:1W<%_D\I1G#!SS7Z"5
M^"/_  ='?\%R?CC\*?C;J7_!+?X$W^I>!M&&G6+_ !+\>:4%EU2]M+R!)C:6
M2>9&(XQ#(-Y,B/*V8]T:;C( <%_P;\Z;X\_96_X."/BA^P[^QS\9=<\;? /1
MQKL7B&::^$]F+>V0"VNG\L"%KF.\,5KY\:IY@:0C"MMJSXG\+7__  <-?\'%
MWQ+_ &1/VEOB5XH@^#/P5BUV'2O"?A[5/(B":5=PZ8\J$JZ+)<7DWFO-M+F/
M;&& ";?<?^#=#_@IK_P1G^'?C?PA_P $U?V$O@)\8;/QQX_%U-KGQ!\=>&](
MA;6[NRT^YO9)+J6WU*:2*,1P3+#!'&R(7 ZO)*?"]5\:'_@WL_X.//B?^U-^
MU%X \2CX/_&F#7Y]'\6:'I9GA>/5;N#4W2,957>"[A\F2'.]4VR!2K)N .K_
M ."/WC7Q_P#\$H?^#A[Q]_P1@\.?$[7]<^$?B&2[7PYI'B"]\T:;<?V0NMVE
MR@ "I*;??;R,BHLQ9&9<HFU__!UO_P $K/ _P[^#'C#_ (*3ZS^T1\1?$'B3
MQ!\1=,L]+\'ZGJT;:%HMK- Z.D$!1G#?N 01(J_.WRG/$'_!(7PMXS_X*P_\
M'&'Q _X+(^#/AUKND_"+PQ+='0M:UVR\I=0N?[&71+2V7DJTWV?=<NJ,PAVH
M&(+INT?^#L;_ (*V?LL?$_X,>+?^"7?AO3_%:_$KPAX_T>\U:>YTB)=,,:6S
M3GRYQ,78[+F/@QCG=Z<@'Z=?\$A]:U#PU_P1=^!'B+2=)>_NM/\ @9I=S;6,
M>=US(E@K+&,<Y8@#\:_#S_@D1^R3^SQ_P7:;]IK]J_\ X*L?M(>(+SQOX=LX
M;O3[U_%0LX] M)H[N62]6)]P%M T:(D0 AC52I4[EQ^F7_!N!_P5Y_93_:G^
M 'PX_P""=?PRT[Q;'X_^%_P4M+CQ+-JFCQ1:>R636=E-Y,RS,SGS;J+;E%RN
MX\8P?SX_;G^*G_!JAXA^-/Q"^*OC+]G+XNV?Q,TGQ+J4&M?#'P^9M,T_6]7@
MG>.3+1RO%;0RRJ26A>,A6+"+>=I /J'_ (,W?^"@7QI_:&^"OQ)_9%^-GC74
M/$*?#-]-O_!FHZM=M/<0:==^?')9&1R6,4,D"-&"3M$[*,*B*/V.^)_B^^^'
MWPU\0^/=+\+W>N7.AZ'=ZA;Z+IZDSZA)#"\BV\8"L2\A4(N 3EAP>E?D=_P:
M(?\ !.KXR_LR?!;XD?M??';X<7/A"Z^+=W8Q>$/#=_;O#/;Z1:F>3[08I/GC
MCFDN (P_S%+=7Y616;]%?^"H'BW]H[P'_P $]?C!XQ_9&L;RX^(^G>!KV;PJ
MFFVWG723A/FD@CP?,G2/S'C4 EG50 Q." ?!/Q;_ ."^_P#P5H^!?PUO/VD/
MBW_P0!\5>'OAMI<0N-7O]1^)(%Y96V0#+-$+#S(0-RDEX@%YR1@D?2/C/_@M
MU\(C_P $;-2_X+"_!3X6WOBC1M.L+=Y?!&IZNNFW4=VVJ0Z=/:RSK%.(VBDE
M9PPC82*JD8#@C^>/P3\2/V/?CU_P3C^(OBSX[_'C]I7XC_M62P:E<OX>.N7M
MSHUG8Q.&_M"[E=75[:.'>\OFR;C( @0 AC]E_LZ_\J4_Q=_['!O_ %)=*H ^
M@-9_X.V_C;KG[+6G_M;?"/\ X) ^-=3\':9=M:_$3Q3>>*I1H>B79NFBAM(;
M]-.(G9XFMG:1TB$4ERL6USM=_MO7?^"Y?[*/AO\ X)*:7_P5PU;2=63POK5@
M(]-\)JT9U"?6/M$EHVF*Q(7<MQ#,#+T\J)I<$84_ 'P,LK-/^#(?472TB!F\
M)^())2(QEW'C2[ 8^I 51D]E'H*^?+W]E;XP_M1?\&>7P[N/@QX<OM9O/AY\
M7]3\6:OI.FPM+//IT5WJUI.Z1J"S^5]L69L9Q'%(W:@#MO\ @I__ ,%SOVB/
MV]O^"-'Q'TCXW_\ !,3QM\,/!GQ+?1D^&OQ*AU&34=(U":VUVQNV@G=[6#R@
MT%K<&.8;EE:,J%'6OTP_X-E_^4'/P(_[!^M_^G_4:_)3]K#_ (+:?L[_ +5'
M_!N1I7[ WPG^#WC"Z\<^$/ _@_1_'=P/#_\ Q*_#EKI=[I\(U%KI6*A+F:&"
M&-<!MUV5.,?-^M?_  ;+_P#*#GX$?]@_6_\ T_ZC0!Z]_P %0_\ @G-X>_X*
MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?FM_P6!_X*/\
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MNE?/7[!=MXDE^#FK-I.I6\47_"<:SE982QS]I;G->V_8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
M&Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_
MXT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?Q_^(G@KXEZSHNO-XK\!_#*YOQI6JII5O#/;1N66.\LV3RY%DC=7BE,T1B;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:-S_ ,)UK(RR G_CY->Y?V=I_P#SXP_]^A7B/_!/?_DB>K?]CWK/_I2:]TH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
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M_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%%
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M7X+_ +/G_!5GP]H6A6]Q+<R1C]FW3YI[NYE;=)<7$\FHM)/*QP"[L3A57@*
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M1 =7\&?^1YB_Z]Y/Y5[#7CWP9_Y'F+_KWD_E7L-?=<+?\BQ_XG^2 ****^D
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M4?ZV9=_)/[E_\D![317BW_"VOB#_ -#!_P"2D7_Q%'_"VOB#_P!#!_Y*1?\
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M;Q1?\)QK.5EA+'/VEN<U[;]B\;_]!NR_\!C_ (UY'_P3W_Y(GJW_ &/>L_\
MI2:]TH X[6?&5UX>OCINL>,;*&=5#%/[.E;@].5!%5?^%FVO_0]67_@KF_\
MB:YGXS?\CS+_ ->\?\JY2OB,;Q+CL-C*E*,8VBVM4^GS ]1_X6;:_P#0]67_
M (*YO_B:/^%FVO\ T/5E_P""N;_XFO+J*Y?];,Q_DA]S_P#D@/4?^%FVO_0]
M67_@KF_^)H_X6;:_]#U9?^"N;_XFO+J*/];,Q_DA]S_^2 ]1_P"%FVO_ $/5
ME_X*YO\ XFC_ (6;:_\ 0]67_@KF_P#B:\NHH_ULS'^2'W/_ .2 ]1_X6;:_
M]#U9?^"N;_XFC_A9MK_T/5E_X*YO_B:\NHH_ULS'^2'W/_Y(#U'_ (6;:_\
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M/Z0- T&RT(:E=WOV*TCM_MFH3^;//L4+YDCX&]VQEF[DDU;HHH \+_X)[_\
M)$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@#Q[XS?\ (\R_
M]>\?\JY2NK^,W_(\R_\ 7O'_ "KE*_)\V_Y&=;_$_P P"BBBO/ ***@U)=0;
M3KA=)>);LP.+9IP2@DP=I;'.,XSCM0!S7BCXS^"/!_Q8\*_!C6KF9-:\8V6H
MW6C*L8,;)9" S;V)^4_Z1'M&#GGIBM3X@_$+P/\ "?P1JGQ*^)?BNPT+0-$L
MGN]6U?4[E8H+6!!EG=VX 'ZG ')K\+?AKI/["O@3XP?#KPA_P63^#WB/1OB;
M</XNC^,?B[XJ:=J4UMK]_)<VYTRXLK^$M']F2+>J/"8XX^<GY@[?<O\ P60^
M%VAZS_P1XTS1_P!FBPN/&'PZ\)WWAK4KNPT+57U,ZKX5LIHV?9.7=KI%C6*4
MR,[96(N6.TFO8JY;3IUZ5-R=I.U[:/5JZ=]?+Y/R ]J^!O\ P6#_ ."?O[0W
MQ+TCX3?#SXT7<6K^)'9?"A\0^%-2TJVUXCM9SWEO''.QR-J!MS;AM!KU#]J/
M]L']G+]C'P+;_$3]H_XEVWA[3[Z^6RTN'[--<W6HW3?=@MK:!'FG<^B*<#DX
M'-?FW_P7/_X*0_L,_&O_ ()Q6.E?LJ?&C0/%?C*UU_1=>\%P>$F$MWX6%I<1
MN;Z:-%W:>$C/D 2!&WSJ@'4#T_\ ;C^)?AKX2_\ !2K]DW]MC]J&V&G_  M_
MX0G5M-7Q%>PL^G>&?$5[;K)'+.<$0>:A6-9&Z>66) B+"EEL).$N644^;W7\
M3<5?31;WMMT>X'UQ^RI_P4$_91_;/U'6/#OP'^)$MUKOA]$DUSPSK6C7>EZG
M91OC9*UK>11R&,Y7]XH9,L 2"<5Q?Q^_X+"_\$__ -FWXGZI\%_B'\8;ZY\4
MZ%M.OZ-X;\(ZGJKZ6I4/FX:UMW2/Y2#@MNP>E?(_QQ_;;^ OQ>_X+Q?LP>(O
MV2?&^G>*HCI&N>&?'/BSPU*)]/U"&XM7F@T\W4?[N=[=A]I*JS!#+'G!)%?I
M#\2_'?P/_9>^&_BCXW_$/4-%\)>'K!)-5\3ZR\"0+(^ IED*C,TS81%'S.[%
M57)(%85L+1P]2'-"5IJZC>S3NU:_+KMIHMT!%^SO^TG\"OVL?A=9?&C]G7XE
MZ=XK\,W[M'!J>G,PVR+C=%)&ZK)#(N1F.15<!@2.172>./&OA?X;>"M8^(OC
MC6(]/T70-+N-2UB_E5BMM:P1M++*0H)(5%9B ">. :^,?^")'PK\86?A7XP_
MM::M\/9_!7AWX[_%"Y\6>!?!=S%Y4MGI#+MANY8AQ%+<@^85'&T(02&&/M^>
M""Z@>VN84DCD0K)'(H*LI&""#U!':N7%4J=#$RA%W2^_S5]KK:X'R'X<_P""
M[W_!,'Q'XDT_0#\?K_2K;5[I+?2O$'B+P3J^FZ7<R-]T"[N;5(D!Z[I"JX&<
MXKZ^1TD021N&5AE6!R"/6OS5_P""U7[6/Q;\1?L^>/OV6/%O[$'B?0? FNZC
M%HNJ?'+Q3"+SP]HMI]HB(U8P6"7%UA2!Y99(\2%"3Q@_?_P$\/\ A_PE\"_!
M?A7PGXO'B'2M,\)Z=::9KZS+(-2MX[6-([D,I(;S% ?()!W9!-;XK#TJ="%6
M":YF]&U+:VMTE;?9Z@=91117G@%?1%I_QZ1?]<U_E7SO7T1:?\>D7_7-?Y5]
MEPA\5;_MW]0)****^V *\'\:_P#(X:I_V$)O_0S7O%>#^-?^1PU3_L(3?^AF
MODN+?]VI^K_(#+HHHKX0 HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U
M/!7_ ".&E_\ 80A_]#%9=:G@K_D<-+_["$/_ *&*WPO^]4_\2_,#WBBBBOV$
M J.[_P"/27_KFW\JDJ.[_P"/27_KFW\JF7PL#YWHHHK\9 **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#J_@S_R/,7_7O)_*O8:\>^#/_(\Q?]>\
MG\J]AK]$X6_Y%C_Q/\D 4445]( 4444 %%%% !1110!^<GBO5?\ @IM_P42_
M;F^./P:_9_\ V[H_V=_AO\#M=TSP]#:Z)\/++6=8\1WUQIT-])=SRWI'V>$"
M=1&(^'7&1D%CZY^RY^P3_P %"?@M\=M"^)GQQ_X+#^,/BIX6TW[5_:G@/5?A
MEI.G0:IYEK+%'NN+=C)'Y<KQS#;]XPA3P37C7[<_[ WQJ\"_MB>+/^"@.@?\
M%TM/_9IT_P 865CI0TS5/ NBQV+06MNJ)%<3WMW%'J$BN9I$DG1I(EG,:,$
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MJ?\ B7Y@>\4445^P@%1W?_'I+_US;^525'=_\>DO_7-OY5,OA8'SO1117XR
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MXI/_ &C_ ,(OK]_\.]=L(K7&FW1N=T]T?)3=:BX0;NI<*/F(I^O?M\_LT?\
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M_:/\*WVO?:O(U[Q[\(9]+TFU\BUEN3Y]T\A$6Y82B9'S2.B_Q5]?T4 %%%%
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MM+ITHHKY.MB,1B9\U6;D^[;;_$]^G2I48\M.*2\E8****Q- K4\%?\CAI?\
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M+=#3O ZZWJ[P1J'F\NS\^4JH 4$X; &!D]J^=_\ @OG_ ,HAOC7_ -@.Q_\
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M^/2+_KFO\J^RX0^*M_V[^H$E%%%?; %>#^-?^1PU3_L(3?\ H9KWBO!_&O\
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M4*Z:TC?V3X-^UHC:)NC^?['96QAAD"YSFY<DJYKT_P#X)R#X#?\ #Q/XU?\
M# G_  C_ /PHO_A!?#W]J?\ "#>5_P ([_PEOF7/F?8?(_T??]B\CS_(XW;-
M_P V*PQ5&%6A*<'HFWHM+W5]?G:.FR7<#[SHHHKQ0"M3P5_R.&E_]A"'_P!#
M%9=:G@K_ )'#2_\ L(0_^ABM\+_O5/\ Q+\P/>****_80"H[O_CTE_ZYM_*I
M*CN_^/27_KFW\JF7PL#YWHHHK\9 **** "BBB@ HHHH **** "BBB@ HHHH
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MW_HZCX6?^$Y-_P#&*/\ ACW_ (*V_P#1U'PL_P#"<F_^,4?ZIYC_ #P^]_\
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M*7_X+6_]'D?"S_PD?_N:L&]_9)_X*[:C>2W]Y^U;\+'FFD+RO_PC4HW,3DG
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ML?\ !8#P]?#4M'_:R^%D,ZJ5#_\ ",2-P>O#0$5L?\*7_P""UO\ T>1\+/\
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M'<]%!8C)/IUJU0 453B\0Z!/J\GA^#7+-[^)-\MBERAF1>/F*9W <CG'>KE
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M*ZUJ-RFG^']*TJ.$37%M#%(@6:Y:9)'DY971MI&37=?\$@M%\2^(/ 7[6O\
MP2*^)GQ-\4ZAX<^$/CN_\)>#?$:ZTXUG3_"NKV4C65O'>'+">VC,GER]4)0
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M1V_5.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,[Q%X1\)^+X8;?Q9X8T[5([>82V\>HV4<ZQ2#HZ
MAP=K>XYK1  & *** "BBB@#.T/PAX3\,3W5SX:\+Z=ITE]+YM])8V4<+7$G/
MSN4 WMR>3D\UHT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6:TT+7K+4FM9)[))&;[/'<0A@R# :3;T6-%7Y _8.LOV?_V]?V=KK]L?]O\
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MZF:Y;2J.$ZL4UHU<].HKS'_AK'X;_P#0!\3_ /A/3?X4?\-8_#?_ * /B?\
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MU36H?''Q1T7P190Z5)&K6]UJ4CQQSOYA ,:%"6 ^;G@5[77YD_\ !S/^S?\
M!#XR?"G]GGQ7\3?AW9:QJ$7[2OA;PU'=7+R!ETK4[DB_M?E8#9,+>$,>O[L8
M(YKU']JC]FK_ ()-?\$Q_P#@G[XW\%:_^S==:3\-/''B#3;;5? 7P_GOCJ7B
MW5Y)X1:6%L$N$E:65X40H)45D5PYV[J /MG2O$7A_7GGBT/7;.]:UDV7*VET
MDAA;GY6VD[3P>#Z5<K\'_P!HGP-+^Q%\2/@+^UO^S+_P1R\6?LK7</QL\.Z#
MJ'BU/B1HSV_B#1[^X,-QI&H:99W\TLGG1_,&>/=&T>=X.#7V7_P7.\-6G[''
M_"+?\%G/@;XJTWP_\4OAA=VF@ZMHUW*T<7Q*T"\N523P[*J*S27&YC-;L%8Q
MLC,1A5>, _16BOSW_P""%O@&W_:9\*:U_P %E/C7XTTGQ7\5?CBLMO;#2YS-
M:^!/#UM<,D'ANUW &-HVCWW!PI>8#(8J9)/KG]MW_DR_XO?]DOU__P!-T] '
MHUWK&D6%Y;Z=?:K;0W%VQ6T@EG57F(&2$4G+$#DXK(32OA7HOQ"EU]--\/VG
MBO5[-+>>]$,$>HWMO'DI&SX$DB+R0I) YQ7YR_\ !!+_ ()C?LCV'["/P"_;
M;^)_@Q_%7Q43PA;:KIGCGQ%J]S++H=N%D2WL[-#((K:WAMV";%4!CO=]S.37
M@^O? []@;]NCP1XU^+7[&G_!"+XB_%'P[X@U+5+FU_:"N/B'IV@WNH:@DTJR
M:IIL^K:FMTT27"NR$*L8,>WR@%V  _4?_@H7^VYX+_X)V_LHZ_\ M9?$'P;J
MFOZ5X?OM-MKC2]&DC6XE:\OH+-"ID(7"O.K')Z*<<U[77X/?MCZNO[;_ /P:
M0?#7]J;]I>S_ .$I\>^'7TF#2_$VIW$DETDB^*(]'EG9]P\R66TCVR.^XL79
ML[CFOK+_ (*=_!SX"_\ !$#_ ()2_''XT?\ !,_X+Z=\,O%?BV'1-'N=9T"6
M9I(VFOQ9QW(,TK;)(8KZZ,3 KMDD4YX& #])(M>T.;5I- AUFT>_BC#RV2W"
MF9%/1BF=P'(YQWJW7X6_&']C+X&:-^S'<:;^QO\ \$7/VPO!WQ_T&S&H^!_C
MG>:?ID>LOXBC =;R_O$UZ1Y(YY PF3RW4+*^R,$*!^T7[/7B+XD>+_@%X'\6
M?&3PTVC>+]4\'Z9=^*]'9 IL=2DM8WN8" 2 4F9UQ_LT =5J&HZ?I%E)J6JW
M\-K;PKNEN+B4(B#U+$@ 4ZSO;/4;2._T^[BG@F0/#-#(&1U/0@C@@^HK\ROB
MW\&/!/\ P5!_X+I>.?V7_P!KNUN?$/PF^ 'PJT75/#_PTN;V6+2]7UO4V\QM
M3NHHV7[28HB855\JI P.7#V_V0?A?X>_X)Q?\%T=>_8%_9HN+K3/@S\3?@#_
M ,+"@^'C:A+/9^&M<M]6-E)+9+*SF"&>,.SHI 9V'18D4 'Z2ZKK6C:%;K=Z
MYJUK9Q/*(TENYUC5G/106(!)QP*LU^-G_!%;_@DY^QA^VO\ LP_$;XF?MC_#
MB;XC23_&[QEIOA[2=<UB[6R\/6BZ@WF?8X8946*>65GD>X \TXC4,!&!7U+_
M ,&['C'QIJW_  3YO?A9XQ\7ZCKR?"WXK>*/!.A:IJ]P9KJ33+"^9;5)'/)V
M1N(U[!$51@ "@#[NJM;ZUH]WJ,^CVNK6TMW;*K7-K'.K21 ]"R@Y4'MFOSZ_
MX.:]-UK6?^"=>@Z1X:\42Z'J-U\</!T.GZU#C?I\[:@%2X7/&48AQG^[7C__
M  5[_P"";W[+?_!,+]AJX_X*.?L/>$[KP1\8/@GKFBZO;>-TURZFOO%*3ZI:
MVEY;:O+)(WVY;D7#/(9 2S#:,*S*0#];B0!DFJVEZSH^N6?]H:+JMM>6Y8KY
M]K.LB9!P1N4D9!ZU^67[?O[-W@W]MG_@OA\ _A7\3K[6+;P?JG[.&LW_ (MT
M'3]3FLGUJR6_WC3IY8&600M,T+2HK+O6)HR=KD'E?^"KGP\^$?[,OQ?_ &:/
M^"4?[/W[-/CP? [X@:MXF\5?$KX6?!"41ZGXL2QM8GCT]#/>6X%JTC&6YC$Z
M;HU#* ZJ: /UVTC7=$\06[7>@ZS:7T22&-Y;.X655<=5)4D C(XJU7X[?"_X
M07/P9_;R^!WQ9_X)E?\ !)']H+X"Z?/XMCT'XWVOB'2-/LO#NL^&+E#$;BYA
MM]5NMUQ:2E)TD$:DC>69L*I^Y;?_ (*@_:/VEC^S9_P[O_:D3'C1O#O_  GT
MGPDQX:.VZ-O_ &C]N^T_\>!QYHGV<Q$/M[4 =S\#?VW/!?QU_;'^.O[&FA^#
M=4LM8^ __",?VYJ]W)&;;4O[;T^2^A\@*2X\M(RK[P,L1C(KV#6=?T+PY:?V
MAXAUJTL("X43WMRL2;CT&6(&:_'W]DO_ ()%_P#!-_X[_P#!9K]NSX7?%S]D
M_P /:YH'@J]^'5WX6TR[GNA'IT^JZ'<7FH.A24$F>X D;<3STP.*]:_X*#6?
M[!_[27[?6N?"*R_X)6^*OVK?C'X+\*:;%XQ2#6;>TT3PC97*R36EO++J5[#:
M0W4R2-, D9=TP2_[O"@'Z91R)*@EB<,K %64Y!'K2U^7'_!!4^)?#_[0'[8G
M_!/[QG\!]8\ _#WP!K'A6[\-?!SQEXIMO$1\-6^NZ5<S7FGK<PS3PR6DGD)*
MD*R.J+.RM\YDS\R_&;QK\7/V/?VL=5_X-P?V=?VG](T+X5?%WQ3I[:#XZO-4
ME;4OA;H^JK=3WOA2-RI0W-T(B+(.X<)= $EI@\0!^\->7_%[QE^U+H/[0/PK
M\+?![X/Z/KGP\UNZU=?BOXGOM62&Z\.Q16BOI[6\+2JUP9K@M&P5'VJ,G;UK
MH/V?O@+\*?V7?@KX:_9\^!_A.#0_"GA+28M/T73;<<1Q(.69NKR.Q9W=LL[N
MS,26)KXP_P""EG_*9S_@GE_V,'Q(_P#4=AH ^^[R]L].M)+_ %"[B@@A0O--
M-(%1%'4DG@ >II+*^LM3LX]0TV\BN+>9 \,\$@='4]"&'!'N*_)[P1^PK\"_
MVX?^"_?[9VB?M+Z5=^)/!OA_P]\.IYO DVI3PZ9JM])HA$%S=Q0NGV@VZQSB
M-')0-<LY4LJ%=_\ 8*BT;_@G)^VE^W?^RW^S]I=Q%\,/AKX-\/\ C_P/X%N;
M^::UT>^NM'N;F]@M][,R132Q(2N?EVJ![@'Z>:AX@T'2;RWT_5-;L[:XNWVV
MD%Q<HCS-Z(I.6/(Z>M6998H(FFFD5$12SNQP% ZDGL*_*_\ X)4_\$F_V,OV
M[?V&?"W[;_\ P4 ^'4/QJ^*_QHT^77_%?C'Q=J5S+);+-/(8;*R5)56RB@C"
MQJL(4J0P!"A47;_X*$?!SPU\>O\ @H)^RE_P1S\0ZIK%E\![?P!JOB/Q9X7A
MURY1O%<.DP1V^G:;=7._SIHHS&))%+DR!BS'>$=0#]+M(UK1]?LEU/0M6MKV
MV<D+<6DZR(2#@@,I(X-.U+4]-T>RDU/5]0@M;:(9EN+F4(B#.,EF( Y-?E]\
M2_V;?A)_P26_X*W_ +,-Y^PMX=_X0CP=\?[_ %WPE\3_ (;:1>2G2]2:VLDG
ML]3CMG=EAGA=@'D0#* #C?(7Y7]D?_@GE^S?^W'_ ,%5OVY-1_:Q\+S>-/#7
MAWXGZ+'H_@;4-0GCTD7LNDCS+^:")U6XG6-5CB:3(B5YBHS)D 'ZT7FN:+IV
MEG7-0UBU@L@BN;R:X58MK8P=Y.,'(P<\YJS')'-&LL4BLC*"K*<@@]"#7X_?
M\$QO^"7/[.'QS^,?[2O[+_[2=EJOQ ^$/P*^,UWH7P:^&'B/7[N72O#,%W"M
MY,R1B0&9PLL44;2LYB"2%,--(S4OV;OVD/B7_P $]/\ @E-^WGX.^"^O7]Q:
M?LX?&7Q3X=^#AU.X:[DT#3Y1:+:0*9=QD2UEN7E7?D'G/'% '["-KVAKK"^'
MFUFT%^T7F+8FX7SBG]X)G=CWQBK=?@_H?[(W[-?B[]BZW?1?^".'[8>J_'75
MO"<>KV/[1AMM/?6I_%+VPEBUA+[_ (2#S1#]I*N$"X\K V$\U^P?[ OB?]H+
MQC^Q7\,/$'[5_AB[T?XE3>#+%/'%A?PK',NI)$(YY'5"55G=3(0.!OXQTH ]
M=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MS'HK[J_X8W_9O_Z)S_Y5[S_X]1_PQO\ LW_]$Y_\J]Y_\>K]$_UMRW^2?W+_
M .2/R#_B'^<_\_*?WR_^0/F/]C?_ ).0\.?]OG_I'/7W57"^#?V:?@G\/_$E
MMXN\(^"OLFHVF_[/<?VE<R;-Z,C?*\A4Y5F'([UW5?*9YF-#,\7&K23244M;
M=V^C?<^[X7R?$Y)E\J%=IMR<O=NU9J*ZI=@HHHKQCZ0*\(_X*:?L3?\ #Q?]
MASQY^QC_ ,+,_P"$._X3:WL8O^$D_L;^T/L7V>_MKS/V?SH?,W?9]G^L7&_/
M.,'W>B@#X7T;]@S_ (+3Z!H]IH6F?\%S= 2VLK:."W0_LHZ22J(H51DZGD\
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M:7="MY+=S7,]Q(ZJK*(AL3]X2=Q QX[IO_!+C]M#]D[XH>-M:_X)B_MO^'?
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M+&;Q#J]_<M+-=R0"641ML\J+&]LB$'/.*^@:* /@O0/^"7/[:O['_C?Q6O\
MP3#_ &XO#O@KX<^,O$=SKL_PM^(WPZ_MNRT#4+EMUS)IMQ#<P2Q0N_S"V;*(
M<D$Y-?57[*OPQ_:"^%'PN/A_]IS]I0?%3Q;<:G-=W?B:+PE;Z)!'&X4):P6D
M#NJ11A>&9V=BQ+$DUZ510!X+_P %'/V%=(_X*#_LZI\%IOB=J'@K6M(\4Z9X
MF\'^,--L([N71M7L)A+;W'D2$+,HRRE"RY#GD5Y%\<_^"8'[5'[6'[(M_P#
MG]JG_@H1%XC\=:5XYTOQ=\,OB3X;^%-MHG_",ZEIY#V[2627<R7B[S(3ETXD
MXP5!K[7HH _.?X\?\$>_V[?VZ1X$U#]N;_@I'H]ZWPV\>:3XE\-^'O GPK%C
MI4\]G,'DGNT>],L]S)'NB1PZQVXEE(BD,GR_0GQE_P"">0_:/_;P\"_M9?'O
MXN_V_P"#/A78M<?#CX2)X?\ *L['Q"Y ;7+NX-PXO9T3*PH88Q =K*2P8O\
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MOCIX6\>Z)::=9/I/PPMO"UUI!B,CO<[X;JX6XG,HM9D8JJQR6H.U@Y4?5]%
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M5D! =6Y5AR#R"*TZ / /&?[#'_"7?\%*/!?_  4,_P"%H_9_^$0^%^H^#_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>biib-20201231_g39.jpg
<TEXT>
begin 644 biib-20201231_g39.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 9?A_P1X+\)3W-UX5\(:7IDMX^^\D
MT_3XX6G;U<HHW'D\FM2BB@ J*]LK/4K273]1M(KB"9"DT$T8=)%/!5@>"#Z&
MI:* *'ASPKX7\'::-'\(^&[#2K0.7%KIMFD$88]3M0 9/K7SOX%_X);_  &\
M)?\ !2?QE_P5'UW7M:\0_$+Q/H%MHVCVVKM";'PS:Q6T=O(+)%C#*\J1_,[L
MQ'F2@8$C _2]% !1110 52U_PWX=\5Z8^B^*=!LM2LY"#)::A:I-$Q'3*N"#
M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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MO?!"^^%GQC^$FJ6UE\1/AW?ZQ%J"VR741FM+VTNXE5;JUGC!97"J1C!&"C,
M?2U%%?"__!7_ /X+=>$O^"65QHGA3PQ\!+KXI^*;NUBU7Q+HMEXC&F1>&]$E
MNX[&&_NI_L]Q@S7DL<,46P%]LK;E$?S 'W11110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*MK*V0DI;VD"QHI)R<*H &3S5F@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^
ME)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBO)?%'Q-\<:=XDO["SUO9##>2)$GV:([5#$ 9*Y->=F.9T,LA&=5-
MINVEOU: ]:HKQ;_A;7Q!_P"A@_\ )2+_ .(H_P"%M?$'_H8/_)2+_P"(KR?]
M;,N_DG]R_P#D@/::*\6_X6U\0?\ H8/_ "4B_P#B*/\ A;7Q!_Z&#_R4B_\
MB*/];,N_DG]R_P#D@/::*\6_X6U\0?\ H8/_ "4B_P#B*/\ A;7Q!_Z&#_R4
MB_\ B*/];,N_DG]R_P#D@/::*\6_X6U\0?\ H8/_ "4B_P#B*/\ A;7Q!_Z&
M#_R4B_\ B*/];,N_DG]R_P#D@/::*\6_X6U\0?\ H8/_ "4B_P#B*/\ A;7Q
M!_Z&#_R4B_\ B*/];,N_DG]R_P#D@/::*\6_X6U\0?\ H8/_ "4B_P#B*/\
MA;7Q!_Z&#_R4B_\ B*/];,N_DG]R_P#D@/::*\6_X6U\0?\ H8/_ "4B_P#B
M*/\ A;7Q!_Z&#_R4B_\ B*/];,N_DG]R_P#D@/::*\6_X6U\0?\ H8/_ "4B
M_P#B*/\ A;7Q!_Z&#_R4B_\ B*/];,N_DG]R_P#D@/::*\6_X6U\0?\ H8/_
M "4B_P#B*O\ A?XF^.-1\26%A>:WOAFO(TE3[-$-RE@",A<BKI\49?4J*"C*
M[=ME_P#) >M4445]( 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S]^P-X@T73/
M@UJUMJ&HQQ2?\)SK+;7/./M+<U[?_P )CX8_Z#4'_?5>,_\ !/RTM9_@KJSS
M6T;G_A.M9&60$_\ 'R:]R_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z
M#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M4FO=*\+_ .">_P#R1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5X/XU_Y'#5/^PA-_Z&:]XKP?QK_R
M.&J?]A";_P!#-?)<6_[M3]7^0&71117P@!1110 4444 %%%% !1110 4444
M%%%% !1110 5J>"O^1PTO_L(0_\ H8K+K4\%?\CAI?\ V$(?_0Q6^%_WJG_B
M7Y@>\4445^P@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>
ML_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%%
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M^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\
M"8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"
MG_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0
MH I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\
MOT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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M\;6.F66JZ#K_ ,/TNH+M;2U2&*6\>641R7*MYH2=0DGE,D3,RQJ!Z/\ L?\
MP@_X*\V/QB\/?$+]HC_@H_\ "SXD_#./[5_;.A>$OAC%93:AFVF2'RKN.5@F
MRX,4C8SN6-E[UX%I_P"QU^S5_P %8?\ @JQ^T=X=_P""A]W>^,E^"6K:+H_P
MS^#EYXCNK/3]*TJXTN"Y?6C;6\L;7$ES-,X\UB5 4(<XC"+:?LB_LY_\$HO^
M"NO[/'P]_P"">M]?^$M/^./_  D5A\4O@[:^([F]T^ZT^STN6ZM];6"XDD:U
MDBN(EC\S(5PS(FW,NX _4:BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^
M2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\'\:_P#(X:I_V$)O_0S7O%>#^-?^1PU3_L(3?^AF
MODN+?]VI^K_(#+HHHKX0 HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U
M/!7_ ".&E_\ 80A_]#%9=:G@K_D<-+_["$/_ *&*WPO^]4_\2_,#WBBBBOV$
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O+_VL_VQOV?OV(?AQ8_%C]I#Q==:+H6H^(+;1;2ZM-$N
M[]GO;@.8HS':Q2.H(C?YR HQR1D5ZA7D_P"V3\7?VHO@I\(X_&/[(O[(/_"[
M?%3:Q#;R>#?^%@67AO9:,DADNOM=ZC1G8RQKY>-S>9D?=- 'YZ_\%>OC/_P;
MQ^/_ -J>\\%_MS>.?&'A7XT> [:#3[CQ;\/] \16FIVUO+ ES' ;S3[9X;E/
M+G5@&\S9O905)859_P""/'QH_P"#>_P-^U#!\.?V"?&OBWQ/\9?B!:7-H/%?
MC[P_XBN=4O;:VMI+N6#[;J%LD-O'Y5LSE5,?F&- =Q" >M?\/#_^"Z__ $KJ
M_P#FW/AC_P"1Z] _9<_;+_X*P_%?X[:%X _:7_X(O_\ "IO!-_\ :O[;^('_
M  T7H6O?V5LM99(?]!M85FG\V9(H/E(V>=O/RH10!]?T444 >%_\$]_^2)ZM
M_P!CWK/_ *4FO=*\+_X)[_\ )$]6_P"Q[UG_ -*37NE !1110 4444 %%%%
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M5/\ Q+\P/>****_80"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME;SE1"PD *_+D^J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!X7_P3W_Y(GJW_8]ZS_Z4FO=*\+_X)[_\D3U;_L>]9_\
M2DU[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7@_C7_ )'#5/\ L(3?^AFO>*\'\:_\CAJG_80F_P#0S7R7%O\ NU/U
M?Y 9=%%%?" %%%% !1110 4444 %%%% !1110 4444 %%%% !6IX*_Y'#2_^
MPA#_ .ABLNM3P5_R.&E_]A"'_P!#%;X7_>J?^)?F![Q1117[" 4444 %%%%
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MK/\ V]X?N8$M][73@Q8?G<N!G_>%=W_P\$_:>_Z1=?%/_P #K2NX_P"">_\
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M:OM^H_\ 0C^+?_",U+_XQ1]OU'_H1_%O_A&:E_\ &*^E:*\G_5/+OYY_>O\
MY$#YJ^WZC_T(_BW_ ,(S4O\ XQ1]OU'_ *$?Q;_X1FI?_&*^E:*/]4\N_GG]
MZ_\ D0/FK[?J/_0C^+?_  C-2_\ C%'V_4?^A'\6_P#A&:E_\8KZ5HH_U3R[
M^>?WK_Y$#YJ^WZC_ -"/XM_\(S4O_C%'V_4?^A'\6_\ A&:E_P#&*^E:*/\
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M%U\4_P#P.M*/^'@G[3W_ $BZ^*?_ ('6E?5E% 'RG_P\$_:>_P"D77Q3_P#
MZTH_X>"?M/?](NOBG_X'6E?5E% 'RG_P\$_:>_Z1=?%/_P #K2C_ (>"?M/?
M](NOBG_X'6E?5E% 'RG_ ,/!/VGO^D77Q3_\#K2C_AX)^T]_TBZ^*?\ X'6E
M?5E% 'SG\+/VU/V@?'_Q#TCP9XF_X)[?$3PQ8:C=B&Z\0:I=VS6]BA!_>2!>
M2HQV]:^C*** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_
M -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)KW2@#Q[XS?\ (\R_]>\?\JY2OHRB
MOD\7PO\ 6L3.M[:W,V[<O?\ [> ^<Z*^C**Y_P#5#_I__P"2_P#VP'SG17T9
M11_JA_T__P#)?_M@/G.BOHRBC_5#_I__ .2__; ?.=%?1E%'^J'_ $__ /)?
M_M@/G.BOHRBC_5#_ *?_ /DO_P!L!\YT5]&44?ZH?]/_ /R7_P"V ^<Z*^C*
M*/\ 5#_I_P#^2_\ VP'SG17T911_JA_T_P#_ "7_ .V ^<Z^B+3_ (](O^N:
M_P JDHKV<HR?^RG-\_-S6Z6VOYON 4445[8!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!X7_ ,$]_P#DB>K?]CWK/_I2:]TKPO\ X)[_ /)$]6_['O6?_2DU[I0
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MC'XFOHZO"_\ @GO_ ,D3U;_L>]9_]*30 ?\ #6'QL_Z,?\=_^!5M_P#%4?\
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M:=X.^*^DZ]X TW2)?#TVH;EAU?3Y;)%98(Y5P\$FX%2H'+[X_P!-J "BBB@
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M71/''A/Q)>Z+K%K;L6)@^U64L;21Y=R$DW*I=RH!9L@'R1_P3'\'Z9_P3_\
M^"R/QC_X)@?"/Q'-XO\  ^M_"RT^)MWXCUZ.WN?$&D:N][':/I^H:DB+-?*\
M<_GQ?:2\D:.@7Y6=F_3ZO#?V+O\ @G'^R#^P#8ZZO[-'PO?3=4\57*7'BKQ-
MJ^KW6IZMK,J[MIN+R[DDE< LQ"!@@+,0N6)/N5 !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>biib-20201231_g4.jpg
<TEXT>
begin 644 biib-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !2 7(# 2(  A$! Q$!_\0
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M.BJO:4XJ75HYW5]=U/Q7JBF>1W:1]L,(.%3/8"NMM/A',]INNM2BCG(SL7D
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>biib-20201231_g40.jpg
<TEXT>
begin 644 biib-20201231_g40.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
MX )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@UX1_:+^!GC3]GSX@27B:#X[\)ZCX=UM].F$=PMG>VTEM,8G96"OY<K;6*D
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MGPC\/(_B=>Q:SIOB^QLY;F36AIVG&:93/IURWEFW:T4 .!N1OE!R6 /Z%/V
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M$R-M('S':*_6"B@#\^/VT?\ @A1J/[8__!0[]GS]OW6/VN9-*N_@9;^&DNM
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MP!RIFLKE)4#>F5)&:LS30VT+W%Q*L<<:EG=VP% Y))/04 ?G%_P3S_X-]_\
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MQ(TG2EM+JUOH(WC^TBV:21?*D1V62!I&# @AU=4=?"/"G_!#C_@LY8^!+/\
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MA? '1_V;?&OQH\2^"O#T'C.UUGQ#/X495N]4M(K:ZB:Q#OE(U=YT<LZ2K^Y
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M2DLA)?66CZM;V=W!>2PQEQB!H LNPN%\\,241G'SC_P61_X*F^&_^#ACPE\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^57:* (--TS3=%L(M*T?3X+2U@0)!;6T2QQQJ.RJH  ]A4]%% !6/?\ P^\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,GP=XZ\(_$'2Y-;\%Z]!J-I#=RVLD]N256:-MKISW!X-:U>%_P#!/?\
MY(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_P#@GO\ \D3U
M;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_
M  3W_P"2)ZM_V/>L_P#I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_P""
M>_\ R1/5O^Q[UG_TI->Z5X7_ ,$]_P#DB>K?]CWK/_I2:]TH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME_Y/_P#VNL3XS?\ (\R_]>\?\JY2OSW,,\S2ACJE.%2R4FEI'_(#T;_A?_\
MU*7_ )/_ /VNC_A?_P#U*7_D_P#_ &NO.:*X_P#6'./^?O\ Y+'_ " ]&_X7
M_P#]2E_Y/_\ VNC_ (7_ /\ 4I?^3_\ ]KKSFBC_ %ASC_G[_P"2Q_R ]&_X
M7_\ ]2E_Y/\ _P!KH_X7_P#]2E_Y/_\ VNO.:*/]8<X_Y^_^2Q_R ]&_X7__
M -2E_P"3_P#]KH_X7_\ ]2E_Y/\ _P!KKSFBC_6'./\ G[_Y+'_(#T;_ (7_
M /\ 4I?^3_\ ]KH_X7__ -2E_P"3_P#]KKSFBC_6'./^?O\ Y+'_ " ]&_X7
M_P#]2E_Y/_\ VNC_ (7_ /\ 4I?^3_\ ]KKSFBC_ %ASC_G[_P"2Q_R ]&_X
M7_\ ]2E_Y/\ _P!KH_X7_P#]2E_Y/_\ VNO.:*/]8<X_Y^_^2Q_R ]&_X7__
M -2E_P"3_P#]KH_X7_\ ]2E_Y/\ _P!KKSFBC_6'./\ G[_Y+'_(#T;_ (7_
M /\ 4I?^3_\ ]KKT2&3S8EEQC<H./2OG6OHBT_X](O\ KFO\J^FX<S'&8^57
MV\N:UK:);W[) 24445]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4454T+7]"\4Z/;^(?#&
MM6FHV%W'OM;ZPN5FAF7^\CH2K#W!H MT444 %%4I?$OAR#64\.S:_9)J$B[H
M[%KI!,P]0F=Q'![5=H **222.&-I99%5%4EF8X  ZDFJFC>(= \1VS7GA[7+
M._A1]C2V5RDJAO0E21GVH N4444 %%%% !1110 4444 %%%% !1110 4444
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MCCEBG4JJ1,6^Z\8VM,H< _:.BL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBLNSM/%J72/?:M:O$&_>(EN02/8U
MJ4 %%%% !1110 445Y+^VO\ "#P+^T-\";GX!>._VD?%WPK3Q?JME9:9XJ\
M^,(M#ULW<<RW*6UE<R(_[R40.K1JK,\7F #J0 ?)WQL_8-_X*]^'OV_OB3^U
ME^PG^U1\&?!7ACXA6NEPZEX6\3>%+V[;49+.S2".\NPH*_:E_>1B2%H]T(B6
M0.8U(],_9<^&?_!;SP_\=M"U?]K[]IOX#^(?AW#]J_X2'1_!G@N_M-2N,VLJ
MP>3+*Q1-MP86;(Y17 Y(KR__ (AWO"O_ $F"_;O_ /$@4_\ D"N^_9B_X(\>
M#_V.?C=H_P"TI<_\%,/VK?&D/A>&\EG\.?%7XS1ZCX?N8Y;.:!GN[<VD8=8U
ME,JDNH22)'.=N" ?:-%4_#WB'0/%V@6/BOPIK=IJ>EZG9Q7>FZEI]RLT%W;R
M('CECD0E71E8,K*2"""#@U<H \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y
M(GJW_8]ZS_Z4FO=* /'OC-_R/,O_ %[Q_P JY2NK^,W_ "/,O_7O'_*N4K\G
MS;_D9UO\3_, HHHKSP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ(M
M/^/2+_KFO\J^=Z^B+3_CTB_ZYK_*OLN$/BK?]N_J!)1117VP!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-FD\J)I<9V
MJ3CUH;L@'45YS_PO_P#ZE+_R?_\ M='_  O_ /ZE+_R?_P#M=>+_ *PY/_S]
M_P#)9?Y >C45YS_PO_\ ZE+_ ,G_ /[71_PO_P#ZE+_R?_\ M='^L.3_ //W
M_P EE_D!Z-17G/\ PO\ _P"I2_\ )_\ ^UT?\+__ .I2_P#)_P#^UT?ZPY/_
M ,_?_)9?Y >C5PO[,WP%\.?LO? 7PO\ L_>$=9O=0TWPKI:V-G>ZD4\^9 S'
M<^Q57/S=@*I_\+__ .I2_P#)_P#^UT?\+_\ ^I2_\G__ +71_K#D_P#S]_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ J.[_X])?\ KFW\JDJ.[_X])?\
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MX6_Y%C_Q/\D 4445]( 4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?\
M8]ZS_P"E)KW2O"_^">__ "1/5O\ L>]9_P#2DU[I0!X]\9O^1YE_Z]X_Y5RE
M=7\9O^1YE_Z]X_Y5RE?D^;?\C.M_B?Y@%%%%>> 4444 %%%% !1110 4444
M%%%% !1110 4444 %?1%I_QZ1?\ 7-?Y5\[U]$6G_'I%_P!<U_E7V7"'Q5O^
MW?U DHHHK[8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "H[O\ X])?^N;?RJ2H[O\ X])?^N;?RJ9?"P/G>BBBOQD HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .K^#/_ "/,7_7O)_*O8:\>
M^#/_ "/,7_7O)_*O8:_1.%O^18_\3_) %%%%?2 %%%% !1110 4444 %%%%
M!1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5O^Q[UG_TI->Z
M4 >/?&;_ )'F7_KWC_E7*5U?QF_Y'F7_ *]X_P"5<I7Y/FW_ ",ZW^)_F 44
M45YX!1110 4444 %%%% !1110 4444 %%%% !1110 5]$6G_ !Z1?]<U_E7S
MO7T1:?\ 'I%_US7^5?9<(?%6_P"W?U DHHHK[8 HHHH **** "BBB@ HHHH
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M4 %?1%I_QZ1?]<U_E7SO7T1:?\>D7_7-?Y5]EPA\5;_MW]0)****^V ****
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MBW]L7/\ PC7_  D/_"2?VA_9_FM]G^T^3^[\_P K9OV?)OW;>,5C_P#&_/\
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MU7^UE_TC+^*?_?L?_&Z_0RBC_5[)_P#GU_Y-+_,#\\_^&J_VLO\ I&7\4_\
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M_P#1C5[I0!\<_P##RG]K+_I$_P#%/_P+'_R/1_P\I_:R_P"D3_Q3_P# L?\
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M(/)7*KU/(KZDHHKI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.GQF\3>*?"W_  5@_P"%2^"1>X\$>$/ _P *M-OYX81&H$M]>7P+RR%]Y,2
M(!CYB>@!]C45\/\ _!(_]N7]H7XL^&OCO\$OVX?%&A:UXQ_9Q^(5UX=U_P"(
MF@:>MG9^(+)(6F2\>WC^2"<*C^9'& J_*, @Y\-_9H\2_P#!8K_@J1^S5J__
M  4C^!G[=<?PCLM?O]5N/@C\&X/ &F7VG7&G6=Q+! NK75RC3O+=/ RLZ,%C
M#"2,88(H!^I<>EZ9%J$FK1:= MW+&$ENEA42.HZ*6QD@>E3U\C_L9?MF_'3_
M (*9_P#!*70/VG?V;[GPUX*^*7BC1);0CQ%837.F:/K5K=M:WF^%3YC1;H97
MC0DG;)'N)Y->2_\ !,#XY_\ !0RW_P""G/[0/[$G[;O[6VG_ !3MOA[X+\-:
MMHUSI7@*PT.VM9]0C::18UMT,SJ%*IF65\[<@+G% 'Z)45\,?\%(_P!J/]K+
M7OVVO@W_ ,$O?V+OB;9?#C7_ (E:)JGB;QI\4+K0H=3N-#T2R!7RK*VN 89+
MB:0,F^0$1C:0.25YWX0?'[]L7]@S_@IE\//^"?/[7O[4C?&GP;\<_"VK7OPV
M\::SX7L]*UC1M7TR,3W-A<?8E2*XMY(#O21E$@=U3H/F /T)HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BO@CQK^PU_P %L?%-EK7Q+@_X+0V?
MAWQ.CW%SX:\':'\&M)/AVT4%FAM+B6X5KFX0C:KSL-R[B0AV@&#]F#_@LQJO
MC3_@A-=?\%7_ (W> K*#7O#GAC53K&C:9(T=EJ6JV=Y+8PB!V+%(KB=8>[>6
M964%]F2 ??U0:?I>F:1 ;;2M.@M8VD9VCMX512Q.2V !R3U-?E-\0]=_X+;?
MLT_L'VW_  5G\9?MT6/BW6],\/6?C/QQ^SW/\/-/M- 30Y1'-<:;;7<:_:X9
M[>V<MYY=RS0L#O!RWVY\:_$7[5/[6O[)?@/XF_\ !-_XX>%? 5]XWATO7O\
MA)_&OAEM56/0;NPDG @ME8(UR7EM"-YV!5D'4K0!]"45\,?\$&OVD_VLOVB?
M@O\ '#2?VQ_CJOQ%\3_#']ICQ-X#L?$Z>&+'2!/8Z=;:>J8MK*-$0-++/)\Q
M=QYNTNP5<<W^U%\;_P!M_P#:D_X*S77_  3,_9S_ &HQ\"?"WA#X0P>-]?\
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MTU+6QX;M778T.GQWL\B6P*'9N4;PI*A@&8'ZKH **** "BBB@ HHHH ****
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MO[0^@:Y+-X8NYKKPYJWASQ7?Z1>:?+,BI*4ELYHRP954%7W+P#C/-0_L6_\
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MG_#;Q1\'?^"=/P'^%7CBQDM=:\/?!_PWI^KVDR%7M[J+3+=)8B#R"CAE_P"
M]J\D\&_\$"?^"7/@3XF:;\1="^ E^]IHFO'6]"\$7WC'4[GPUINI;R_VF'2I
M;AK5&#,Q";#&N?E08&/H']JK]D;X ?ML?"L_!3]I3P9=Z[X:.HPWYL+/Q#?Z
M8_VB(,$;SK">&7 WM\N_:<\@X% 'QS_P;O?\BK^V#_V??\0?_0--KSS]H+X/
M>'?^"I__  72\7_LJ?''QUJG@C0OV=OAMI>K^#7\!W4>D^)/$%QJD:/<W/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>biib-20201231_g5.jpg
<TEXT>
begin 644 biib-20201231_g5.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  D&!Q(2$A 1$A 6$! /$ X6#Q$0
M#Q -%Q,/%1$6%Q42%148'2@@&!HE&Q43+3$A)2DK+BXN%Q\S.#,L-R@M+BL!
M"@H*#@T.&Q 0%2T='QTK+2LM*RTW,"TK+2TM+2TM*RTM+2LX+2TW*S<M*RTM
M+2TM+3$M+2TW*RTW."TM+3<W+?_  !$( '@!+ ,!(@ "$0$#$0'_Q  <  $
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M&I=6EJ'5'4$'_(^<VYS54]7?$Q,7#,1$)(B("(B B(@(B("(B B(@(B("(B
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M[74%QKH/&<_Y*TG-\VNS!QKA,&57# ]A8?<_^9SYL)U:W#(QU958C@"0#PW
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M\O"0(C-<,M> 6A&WAFHKJ;@=S-<NGLRS2,.6@V5,2!5AQZFI1M LT*[S[EX
M=VIDG 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
61$!$1 1$0$1$!$1 1$0$1$!$1 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>biib-20201231_g6.jpg
<TEXT>
begin 644 biib-20201231_g6.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !5 .(# 2(  A$! Q$!_\0
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M0JJ.PJ6N&M5=27,Q-B8HI:*R$(.E+2#I6=X@U-='T.ZO6(!B0E<]V[4TFW9
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M*** $'2O./BUJVV"TTN-N7/G2 >@X'ZYKT?M7.:OX$TK6]0>\O?/:5@!Q)@
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M&JS<?$;48,7;>'[A=-)XF?()'KTQ6TJ4IPAR]@/0**Q7\5Z:GAO^V_,)M2.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>biib-20201231_g7.jpg
<TEXT>
begin 644 biib-20201231_g7.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "6 /H# 2(  A$! Q$!_\0
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MMO#:P+%;":2<'!9L!<>W?K66FL^,[E4ECTRW2*3!''8_C5/XH_\ 'QIOT?\
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M[:>ZB/\ L28_I4I-$Q4HZ&U6?J6LV^GH06#S=HP>?Q]*GFL_.B"-<3@ 8RK
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M@>QR*W:* .-3X9:4'!>XNV4?P[@/Z5T^FZ7::3:BWL85BCZG'4GU)[U;I"<
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M]MCTSXA7;78D1;N"-(6"$ACQZ?2@#-@N],URYO[G6=3>&19FCMXA,4\I1T8
M=:CGU>\N_ -O*+E_M$=ZL/G \L!T)]>"*M:5>:=X<;4+'680LJSM+"SP[O-4
M] IQST_6EUK[9<>#+62ZM4@FDNT?RHDQM7G&1ZT 6]=T5=+\):O(;F>XGN(U
M,KR-D%LCH.U5=1D&B>&M-MX+R: 7[1B29WSY:[06P>U;WC!6?PGJ"JI9C&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>biib-20201231_g8.jpg
<TEXT>
begin 644 biib-20201231_g8.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !W -@# 2(  A$! Q$!_\0
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M)T!2444 +2444 +2444 +2444 +1110 E+110 E+110 4E%% !1110 M%%%
M!4%X\J6<S6Z!Y@AV*3C)[444UN)['/>!M->ST^>XG&)KB0YYS@+D?SS1116E
..>3E4DV8X:"IT8Q78_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>biib-20201231_g9.jpg
<TEXT>
begin 644 biib-20201231_g9.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  C 'X# 2(  A$! Q$!_\0
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MM@''\S110T@N%I:01VT>V-1\H_EBG?8;<.7\I=Q&,_Y^@HHH458&W<<;2!@
M8EP.F.,=_P"M2A0%VXXQC%%%.PC#U#PIHMR&EDTZ'>3DE<K_ "(K.M_!VAM,
M U@I&>AD?_&BBLY15]C*45?8WK70=,LHFCM[&!$?AAMSG\34,GAS26<$V,0/
MMD#\J**)PBUJC>$G'X78M6>E65B=UM:Q1M_> Y_.KE%%:122T$VV[L****8@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>biib-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20201231"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20201231.xsd" xlink:type="simple"/>
    <context id="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40f86ad979b04ab6b1c5dbf39dc6ca3a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if78e92be0e5f40fa8335c122c201e968_I20210202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-02-02</instant>
        </period>
    </context>
    <context id="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6b7b9a353c2419ca9a01532a522a0d0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee2514a987784410a8165984f87269d3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if2987b04d4c240d88b84a50c04ca2df1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fdb048733b648df99bd7b1e5b1476ef_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4fe07a7c7dc0443dbe2b2303dcf1a9ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic832cd7b75cb4db1947131a9ca6ada7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i947f2882d6404d2ebbe95236b59c95ef_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifcf0372b542a4a81867022b7653fddbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id3b225a61fc749cf835625b8fa6246b6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ba23f55f1d1462cb337f7f348d52f17_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7685594c21ff48f6aa4a4ab8e67bd590_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3565d89e31c04fe69d700b215cbfe265_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic36a6dbaa4344c37a9dc77f2cda681cf_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic116ea7c17b449929c5b3e40bf3fc147_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacfecdd3de364249bf6dd9e13df58609_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia9808ec312874199952c2b8c5ee0b580_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id82ee39d50af4f5587e19230de06cf02_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic9925b2c3e594ae0812001969da2a99b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idae041b402f34f1db7c9617616121bba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c314d6d1f964bfe879cbff831677e6d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b238312a99c4acda7452e34a406431c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8631cd953f3488583e5a99f0aa067ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ideb28add0da94e2984281d36c212a6b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieafb8a83622d4c7d83aa7f731407ace6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia32b478b02b043de86c4b4db94343ae7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia04b4d5aa1794922b920009486d15ab9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59c8c0fefae64f87b0c7f553d3c884e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9730f32121bf4c97a3efb7cd327a3f8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7b0512c1ef74ccf9a55f06a601135a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02dd29564939484da19f114c7ad6568e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifba1e5d98e494036a7bb6347485e7fd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5dfc1fefbed7417cbbc28aa6ac0dd8b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iead28cb9adf24fb08e016c9daa3a77d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20ed583992094d77bff487c7db1d1673_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id631f87e609f40da8cd804801bbf81b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd77c6e9bea747df9f7e454828986d8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i399ba008e6b14b85b6ac84920d61a3c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f98217bbb834e0f8ebd6c2398b7661d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79a84661ca7648508fd93941bcbb997d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79397f44d5c042f496ceeab9b494a03a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b33fe470a0f4f07ae856080b1a72e21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id652954848994c64a952bdd912f71f14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if56588187b87454685183cbffc3ada80_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69e4e6dae85540218e42aba08c3a9ecc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7957fd5108f041cf86733aef419c0487_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icdeb7d5b926d493e962de8b221ba05e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccbf67b67a6f4ef8b20a95e69c600436_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a1a9b4290144caba8998988eecf9b58_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i004794513a2f4fcd8eace5db98fbe94d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7fbbd190dd9349c684025d6612613087_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i10bc4925779c4c62a721fcebc24cc43a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idd9ccd986ede408889b471271b8b92ab_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i71879223335b46f3bb3d2e9c89f29739_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0408f46008684d05830c8aaf3c8d10a9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia1627e985e4343de929ab7dfd5658901_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i70263815613a400b92f377b89a761d52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i743aafca54fa41abb7393b53cca04663_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if23b90bc2339453c813e349dde6eb88c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5788dc676f14d319251454a02fc807d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i918c175a6348429f80750ffad3e51592_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i561f5ec343c3430f81b526c7ba3bf33d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i127bbeecda744fa68a10a6e33a60cd1a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if96513171bce497b9a51c54f048f8529_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i77516ed4d6a7476c85c01147c2202ad8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic1a8269e77864460833b3ae44b188fbe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icff528a7cfce4bd8a0366f490246b62e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id60b675c71ae45dcba471a7e7fe41934_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib7d567bbbce0486f8cfdae0a70a3f4ee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i23b12db8472d48b2b53334bb866cc37b_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6de8222bfb764bc7976ec9ac1b1fcfee_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i32099e94310245729c8234363676b11a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i01ad07778ac849c8b2b4e37c57f5c8cc_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i71e785004dde49f0a56829b6f56ed277_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i4ca3a2e6fcb04f20be394cdde7a54e82_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i878381e1afac4f80a13bd087ea6d9e3c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ieb9c26e9c2e84acbaf8ec47d303849df_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib6054bf321ca4765a1d083cac2ace95d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i60249b902884484cb11d0cb33e879fff_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ide6cf3bb3d4e468189726437ef50fcc4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie6e22ca2059f4f898210fe8a9df07b93_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie81db584ecd34c3fb0bcfcd6b6c8bef2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i481a6d5bdbbe43a5980efa84e275da23_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8450111dafb6479dad6f805a7b7d9e08_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i084deb1b42c44169a52d93eca76466ef_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib5d4919f13974879958994e93ea3e69e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic1acabe726ab40d4b398592903594e20_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i837a6587aeba49309a36ff845c583cc1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaa3981c364664bbf965221342c3e8296_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i26657d5aeb394760be302cf4583f264d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i158387b1a5ea437bb6564f068f16da94_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8870b4b39a7c4f5db82e81c17a5045ae_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie609bb78211648bbb28efbdf966eede3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i946db844720d4aa7917f3e015d7ad5f5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic69589c021a84ef3b51246299f3819f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ece1a557c614598b419f009a522970e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0b527baa2064e4abdfd753f227e1770_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20d53eeb6bac423daeed8dd6132359a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b4148f6f0e64fcc8d46dde21febd1df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e23f9e905c04daca8cae6b8673c5e1f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id202dc9d694b43e7bb188183306ef1be_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredIncomeTaxChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i62315bf96a414f8f8bf19b192b4c0951_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i8ed6ef3bd55540debba7f93c76913164_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id1d08429d1c347878b82c18df8d582c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i434f35407e6e4c099ce33b8a068afd74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33ed7c967da142e892cae01133c8613e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie335a67b286c4619b0b5b87a19532f5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i31173508fedd4169a632723f6c55327a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68ae650937b24214a80dedf08e192bef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia457a1bccc154fcd8ff6932b1456cb83_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BIIB118Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i74d25f7562934bc8a1eebaf7750912d2_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibef78125dd7d4a94a4efe455cc442105_I20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="i931745da9c9741a7bcb5a4292c51f87a_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9f95102445b94a5183bbd60ea00497d5_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib0b20812b1ae4a52b980e45bc1c13af9_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i675123ee33df46f18f7d302db7babd89_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:PostacquisitionequitycompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i12ed3b5c3c244392982bf3e4a342675d_I20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="i2b0a4756e001463da2b40b89dfd99ab3_I20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="i217e491a4a2945fda8b6a3fb6e69f33c_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ic3ba7bb298ba4551bfaf50b04a063a19_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0826dcdf451640cfa9e62b8a90ea7c7c_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="iefe928ba270d49608bb021eb1ec31bd8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if38b01edc61441248c76861d6096cd34_D20180701-20180730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-30</endDate>
        </period>
    </context>
    <context id="i5655172610c049b7b1d99d51a603c7f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida412b4bccf941a7af64620b69dcf1ef_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7ae2c3b5bd774a9bb73adaf4ac185c0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e9e587add174faba8df37c45bf81a84_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i6599810683224f4f8d5b5a4cec91c8ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85a89db2076b46d08a583b581aa591ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5ec4e78cdf14e27b10a96f705b49b62_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7c7c39b59484f68a74bc30138f093c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8bc356d23184fcebc37ba9a22520399_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9f2c1d75d0244adbaf0ce60ba6f10c6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4671dcaaccbb4c73bc88e30c9c3ef796_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i611243e9e12c42aa8073bc846cf26e10_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i89219f9fbe1b4c1dbf921ccb2d9beab4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7d646b3f2acc46cfa9c025734b83a62d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i676dac9dfca9459aa08e07ccbde07b0d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38907cded92a4460972fcfcc8fc9a8e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0479de2c47942988bc6c58b22051c05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i239b75ed62774dddb59a70525b80aa50_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7ad45c8aa37643dda100435c30ec9812_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie627c15061db491694d9896f93024ce7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i808ab222eb14472a9a5315190f9d73f9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i43a5bf5f3c2f4bbfb702fcd685c5350f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icdcf0cf7d9d84f1b9a94c5e3ddfaf245_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i04860cd441c6444f8d0547cddbe88ec1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ef7c311e0124c438791428e3b4b41a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9fc945d8f6294b06ab322c83d51a8139_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7e8798dae8a4b08812a89a53e77047c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i15ac014fbb4e4c6db8de2f58e8127e65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e79a9c192ab4345a8831a1ec2ea4c7b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2acaf2f4edd94d2aa5d30476174c8ff1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9161ee6ab1b24fa0a4b4fb0e50c29fab_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7fc147b15e5c42138dac645bea65a6e3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i51cecc234a1c499e81996ec359a83235_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4cc67fa6b68546999e25a409116223a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6055a732a3c42339f265cbba96a4237_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b8355cc290044cc90da4d1eb56c12fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic228d3e552df4464b29306fc6585aa80_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i25bb90461ed2438a995263720a6ed66d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i793c32241e6a44aa9d8cbcf846f1608e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i21e1cbb7e7fd41b196a67213d407f8da_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia7dc62500324422c8b3e284eaa458c65_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3153e9337f7f46b180a951e086f83f04_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia30a842196f14402bb07dc592bab78e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0009c1183e6246eeb2ee54a841d184b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ea2097d09a44a509b495c405a069070_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5fd129491fd544708255c0bf9443922c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48d69c93cae04d3491b6586590a557f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i57ee1ffeca9640ecb4a25fa543737c80_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i92af91a220a14e519e257472f7b4627c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic7dc974c8cf545aaa99c23d6995ccf0e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie0b5853b0a7b4b75b8a727674c5976cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6420df982c54462fac44de3494b1078a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if92992eed3334e24956317197eb6249d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibfe618b1b7444265baadef360f6cfe7f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3274395ada7440579bbf98e82e662536_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4163b71d3ebf4640b1af4d523043b9d5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04b1f3407fd84deab1332035a3a31964_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id2f67a8c0aea4ef7ba8c99f1f5292a0e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3fbdc5541c854505baa5fe73b8b9fb16_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic369938897d44097803fd74cc0bf646d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b7d190fad4b4287ba2080a56db09bb6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e67ce0006534c9d90964417d4f29f9a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie8cbfde1864b4ae69989d769e587d576_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85145d7d92464b108b60ca4e887113f9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b2352931d6f4d8980b86773c3e2523a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7979d3870a264dd0a1528aafe4e9a00c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib08fe27eb1d045de9c81dadf75845b7e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibd3882c6c7e44816881d6d48c711cdb8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibb9ada749a894e289113c4d61f405d38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie042a2edd31046aca7dde1c59f969ab3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5a0d587886c43a485b4a1beaf2cb9a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied5ea019d4fd4c2f897fe2644f7c7ed2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icef4f9926f8d4814a9d013cf79e963e9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5d98281f667b40a595d97292a3d7d21e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i181d0ab423b0468a8a6f8b139f105d1d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5c81e1552b61450e83a94056dc340dbc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4ebf7dfae7004c2da140bd5817f77ab2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i67f197d8686c4e44bbee78953032d413_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23cac88653144474aa6d28fad81d8ecf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d5709855edc4dafb39167708c8ba135_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d2c2f06527b4022a893fa9bcb7e4e52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i22cdd79b3cf74f248c1f7221acba2a23_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iec8554a2c2be4400a7226435515b1cff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i466f28f7b774412c92456ab39ec8c2a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i31933ce497d64be0899c42e590f33e49_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibb7a44b1f0d049cabc406d3d7fb76dfa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2bc3ca49c80e494caf1f76203a66f71e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i836a100e66ca48e8a1e7ddee36e17253_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b4ad0dba054423b82e1cc5bf4358871_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28387800191b42c088cd25c6a9466a12_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3f5c2e8409c4870834b30b67f6c99d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icbd96336b17c48759b92af5b727a614d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c35b9c4f72240cb91164b21f3abd0a2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9e2ed02bfb06451f9fb5ae7fddafa907_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8f93424eda7546c9a3ac40bcfbfaa106_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie3ea9446ace44e788ee54818d9b37f3a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1fbc92ecd2ec466bb430e6dce8b804a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icf1efb62ce514836b55d3ee7a4ac1a5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26bd8f41008941b1be219ee8aba377f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib76e8e2921bd486fa43cf0f7bf709125_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9fc2e1129ed148b29526834ea34cc7e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5517906d4a214fd5a371d6c53ae66e73_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if66448bf19334d99863e008bc96d2313_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9b62d124ddb34cf3809af9802c175ace_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0132327259a94fb1975abd835ed78152_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5c90e682e5e417a967657ac50fbacf1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43014c84e32d490e8ca9d7d907dff83b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d4c2a4027e3422ea87ff6cc3b986145_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f6560ddf1da469783c308fbc59328d7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6c11246cbbfa46648ee949251e0eb821_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81d7562d98124ce596c58c5c77f902a5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie3f610d2c9e746d5ba0b20b191ecff82_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ife7ac8b29bb24df09106e8a94a348a10_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7f99591bb1b0401b8000095a52fab6f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bb76f2658274da7b4345880031c2273_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i72c66309e53f467ab518b51c5bce54f4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c98110a133446d0bd61f9284d0e58f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c311f0cc16744aeb4492070360e76b3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5fa69ae482814ac8bcd343ae4a224389_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6838460bdaca49d7b136d868993f4d08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ff66c8950bb4a7e88affcf110449d1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ea5f27bc85f4fddb4469f05a3b00215_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id4f9dcae88cc43e891f75bf74e4bf5c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib2a9f19b6d9f4f4a995ece66958a61eb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0863980b999348b5a5e8c88dcfc46890_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifd820ada82d04297b57bc8a5f70af4b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i112f6f59416148d2a921ea8b21ca66ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e510eea4c8c4271a8fe6ae31a7211f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c42c0c7a42943d7a9ffc85aa01e8a61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i400709e4fbb2431a8c60b9f0001721f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4bb52c820db94f3aa2e279e49e3f772a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia91f6946981c4e79a74688a13b7b6cae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib09a186083b44003b3551748e372ab96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i913629824c8f4387b3fa3d219d942aff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60e8aacd727c4737ad050b96fdf9c8af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec6a7b631471438e8fee99a379470ccb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2d8cb46beb3d4d47884b9ee3730ccea5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1bb4285e484a4003bbfb3010fd8b052b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idc03c10e08964a88b663a184122907a2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ica5f21c6cd2348a196b1a5aabce51c96_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1b9f7171e7754520b8801272436020bd_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic77265ab5c594a27b0736ca509460655_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8f40d69597314563b8de93e06ec34c1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i195b915d47274fca99fe4a792ac7ea69_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45223ed4352840169e55fb7523bb7c45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57f4c36386654c569a449f1f90ca2232_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9559172621a745278ce2779747432dec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b6b5a9481f349908c730396c050643d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifd59c1996ba049328473d73e6ebc2376_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia29bfccabbb4483d896c6bb788ec20c3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i63c7287b63dc4cd3a1a2ec95a9d031bb_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9dd5d205fed849349f4c94a2eb02cdd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:OtherRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a785963e61a4b4e817f15fa26f0d819_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:OtherRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iddf5ae537bd74ff9a59f2b74a8161266_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:OtherRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i87e510b249bf46dc94c9604a2b8b9a69_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29c0819a2f984821bb989e9609805bb8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3e58e40285c848e296a601009ac7f815_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i70ef21a6d03740f8aa272b7fdb22b854_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i34ea9f4eaaa24324b4547475bd116c88_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0eb160e00a5f449ca3dc21f07ab9ba0f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3976604c455244a68c5f8bc26ebe6514_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a6054a3521e4fad899551ca7aeb3026_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i18053bf504534e879bf5029dbb2066e7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9d72ff5a209c4e3b8fd84b931863f9d2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i609fe60df7e64f54a5f65e6a8167f50a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ContractManufacturingCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if028deb520d34a2aa081b6f9c3dac0e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16eea92696684f6f8f01944879fe877c_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i76d271b53e29411abc2a151b7350aeb7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c498e3888a34f50a02f1bb18e32ad14_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0293853038ec4dbf8d988ed6233a88a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie292720cdee34fa4a2f50bd921742df8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e983ff4043d40f0913bb5c532a2f59c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb36452ab02142988e739a2d7605d7ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB054Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i101d5553f62a4ad998a4e79cfea8fca3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1193619aae94660913bc904c7ad0ebd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia68ac17ffb634d7ea358cffd1d2ff11c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic1c8b3e3b2804596ba415198766ed335_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1f7617347de84315b946e8a49e9bd554_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia56ada61d04148c9aa29b83378b86afa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i725b0e19a3884b52a34ffa0720d25883_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14f3a2917b0f4c51b7e1a5f8612047eb_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB054Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2ad3e4569ba84e3ab10d4fb4ff676171_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4e82735011b489487c0fe39eb2af15c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife7148cb77ec48c4a82e74afba1044e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b88845b78404eafbfca745c512904b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11a386c121b94d3285b2e93991eee966_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31de162949914248aef0218bfb3cae08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia30b12536469448f9255d5e1df2de125_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa11cb31d8024230a65d4ab2be7a7509_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib868142b7926459283806400925364f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d4400d07ebb429faf284232b75c3fad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1295c3d9fdcd4cd6bd7a06e54f915289_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b1a4978f65a4ad194d0e7fd7c37d454_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia05d20dd706c4482ac970a02c04378de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i728ad60c42494777a77a89260395a79e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5360f78fa9cf47a49f8eb29cf63a6bb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b1e4d4d27f141faaceb13587dfc5353_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i109944c309984c92ba371b3ed38bc32c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7eca7f157f2643bb819b32bb8e7dc084_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i687ce2197ff242fb8d9744823666b4a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3e264b8e2f86435888156e14e7e26af2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6e51f6583c34ffea8242489d150dcac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9faf10577b784e7f8fe0df2ba091b6df_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc5ca70e7a0449ef9804d477da976c90_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c6ed8b6d39d4f95be135a06386353e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f12a8b2a02a45b5a3b5d20a2203d529_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if7b0ff43002742d382a430a6b312ac29_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i078713d9a8a24ed788012f01caca7e4c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22f29144216246c0ba14b7f3d524b07d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id37c27cce50943f586fccbb1bf987550_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i05ee55d0301d4a5296dbfd62c35d349f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic10b6933b9ab4178884a89b8aeef21e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50c85d1b3eb3432491fd04d440130a03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia29e9f9c6a0f4c099a0d0b872c4ab3e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0afc7497a10045ec82e92ec6f6142457_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i892b13c4cafa42ecb4c07f03ecf1b9af_I20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="i31f77918266b4800a5e937031d200d33_D20200608-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-08</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib982081d33b9432380d458461cb24794_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4596e7576e6f4acea88a866738dcf7c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4bbc25a9c5ac47fbbfd534ee97a1d39c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43d8fda27d15472886e7714ecfd74f13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i801a46869f664fecb61055c870823b33_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc1b899a302148ca9891b0255cc8aa0d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6b6dd5c2efe4f5396abf0aff9bfeccf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c421dee5311428bb63a943e6edd3b3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ff588847a4742dbb38528249abffe4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iddd13c0f2522452cb9725ea76f4505d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0204ca1f1214960bd167eb5e80b1a81_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic30eadf1122f4f10b6945f7d760771bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83bcad67dce847b8b91749bab6735d86_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i925b36a148674fc19a08cbd449595002_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i92764f5eb5834b79ae55dff4c1df9d03_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic89f75651f684c4e8666f45255e68b39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56a9f448c619444ab4fff72a5de9ba77_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if9f5fdb4ff554001875fedb563688ba3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe586d2389a346e4b21234342c93c79a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if183ac868dc34ca58fc0c53525b4c288_D20150201-20150228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-01</startDate>
            <endDate>2015-02-28</endDate>
        </period>
    </context>
    <context id="i648eef4285664a8dac0cdbc16d4a15eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7237b9cff6a4464cb92770b4bf1cbbc2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i51282ea551b1459695602c42c153aa71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90382b76ddef440099125efad57c3a58_D20101201-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-12-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="i2cc1602563fe4003b79c44b2d4563182_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc66d48ef7a8480184a55afd9eb1ca13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff949adf9ab740fbb27bef3b64e6be50_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibff8fc3255cf42698cf5d8a08d11df44_I20120331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-03-31</instant>
        </period>
    </context>
    <context id="i8be1727d99e64340bb2d309e36968ac8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib5ad52311e434feca77f912a91898714_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8a46f2c40caf49ea87719f6b7a9ee5bf_I20150228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-02-28</instant>
        </period>
    </context>
    <context id="i2afce0b61c084d69ab3183af171ee801_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i21ab402dc3c540aaaa74ab88707cd06e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i777e7a0559ef48fd8038247a2da5c7c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4f6df13a0ab4a20800b6bd00a5f821d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i665e4e826ccd4df0a58a999910a2c5ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5513569ac924bcd810dcccb4b75c1ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55d717cfc9ad47b288a5e9b60459b22c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81a1894f77974cf2b8aedcc04b6c5f86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3e9fb1cd6824fbb85da3d9df004f1ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a84817f64104c25b845cd16a8f0ab52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9959b5f071814b32bb44c12f7979e4f8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i368be994479c4748a98800a90058bb03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia668578daa974ee2b66900846a7f2aa4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8420ca71f3b4038bcfda28fcd31dc62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e3d526e5639439988a6a4d0a1596dbc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1444a522fb044ee7a105512067bac273_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ff8968812da45e2a9aa27638fc19580_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cd740912ac448feb53d1e58c59635f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f3019ec63604b1e9670c0bddc262a57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43d6eeff5022443a911867c6740b0321_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1018d5a2a449484ca302a3ba827164ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f82abfdb08f42288d72dca49fe6886a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9549e6582b0842b0bb8b80335d95f5c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6123894aef18412c8778f35bebcb4b94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if17d3f0012ad49839eb5e30af562ce46_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9c6df684829d457191dd58d3cd5cdf67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2dfeca1a2e48493283b2d3282a9abbda_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb8344f64bdd4767b10aa2100406065d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if324696bb41c43df9e57bee9ea0785b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i29edf7836e8242968b86b1318f81fb38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c9faf0348614580b6500e84022870f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i745ea53017d44a209cd4871e1fc8dbb3_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i58da0dc381ad4518baba0871c615c8cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c8cbdc550c74ee4ae87ae5b4bc3ac20_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9ccffca563b74d8792d57e3f776ccc3d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d0ec7fb81814c1188c3590687864a65_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i4877a3944c7c442fb949a47bf0f67c40_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SangamoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7391238241af432e81e836c4866c9d90_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i1533362d92634f39ba4a401c3f7026f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i8686b81ecb37418dbc5bcc179b1e109c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i265b3873c6154df1b98c0e68348adf62_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i304cadf22e1f4d51a2a058761d61f7e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9548c02f9465476885ffa4b8feb4449a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81d0fec390494bbf9e3fa14a10590ee3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i72fd8f14ca0e40fdb0a695a13b9d715f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0f26f772ded49dea5267467d918765a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfac85de776a4ccdb1c2c9949959fc1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba1524cdf8b541d993f6af6346716c26_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3984a0ac91e341979ac9c6a390e24ddb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2454550ae594d8ab5f93ecc8828eb34_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9e5d7ed77346446bbda233cc544e7a56_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if51c2fde97ce4501afc27d5c5035c4e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i970be973b11946e2ba4be4af29d27f00_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff4e5d22d10f47a4be988b01f0b8f5ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia5015e8fef3747c89a3ecb45e4b014c9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7a829cf79dbf4cf18de8842f672ff28c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2da81af0f6824d0fbb5054283dac56b3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c2e5836ef2c4728bf3267af3cd05975_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i341bf7c7b22846c3a15d2ca347a2a5e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i150073ed6ed44a05be7690bce055038b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib4fc26110cbb49bb95e0d829274d6717_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2e5f86d5a26a4fb599b079a5ce05a6ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie623c4bf0a334923b7419fe9e4036c4d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie26d559169994ab2bee2cc026fd0802f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic5bb44b7dbe04121b65a77c399136416_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3026bb704ae34186986b2cc13a1fa4af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifed04fdf163840848076059cbd6be57d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5681d70ef5e4ab1a40f14225017e26b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7eb0b3093eab4e4fbf121e5a890af5ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id6a22865ae984cd9a1584ed794eb45f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifeea6c57cc5b4032abf11ed3fd20204a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ad3e74dab6043a0ab76c58210d1d2c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f1921cf5b564c24a5b92cac02448a78_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib6b97f0e94db4a76838c9d49661b0f65_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i394788312749438ca5a0088d46557b6b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i43c9fc7dc1c74381a2af78f961d3d49a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifff3562287364307b49c65b486ab7f1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad27b646ce224aeab760a794d241f6b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78b4b25460674afd905c8bebb6f7495f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5f77bb62e04422484e61cd37ab61ae5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd5747821ef74aea809d0a7f45d8bd8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44254b6ac97b42949dbeef89bda488f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ef2acb849c6486f8fab7daf104f20fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia14add4a287f45888b55667cd3541758_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93f0f42e415041f8bcef0f0de00298ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib105aece693d4b43a0c52e39570beb9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe741caa88b64940868b7b3ab24c4a52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3844e07d48c84ee491e1b9f71aa66a47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfd0d7ea7b3a4afa9b4461ff7b726aba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2c6f6c468f64ddcb921d54c39e33bcb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f6909c22acb465098440df5033cb0c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i249f9f4c4b124dd8b673e35fc4455624_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia87d29e7890540bb8654a68a1d34708c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28e6c2c7dcef4706a9e8c029a70b1b66_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifbaabb3c8c67456798b662d69d200f72_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib34a3983473240ca94309b2221293726_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i82ea75f6631c448f8f22c298bec0c951_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i214f8c61e02b4bc78c01086f27fa4760_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f537e57d89f4823b4442dbfdb55895c_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i13d06bfb1ac54344bc9084f8e1ea171e_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:DenmarkManufacturingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="ic4652a3a2e7940719a658dd16032604d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i50d29a2be0b04648b7d97ec27df8f046_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i828bc1c45a6d4a98b00274ffc1f8eeda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:SubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i787eed6e9a344d8c908c09867efa7395_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:SubleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b65f5d0f33646d9bc123cea10741758_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf080c13135547c8af17c3b9569fb595_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:OperatingleaseassetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifa108c2a221547038bfc56b7a2800e00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i849ff223eb2f4be899ee0be3b39ab50f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d80f95e39cb4bfaba1e47004246e9e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e69090a5bf6448aacee4bfd8770c3e3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:LongtermoperatingleaseliabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45b85566626e4d3abc15fda2e07b56a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i923409ff6b114d4ab014bcd315beca62_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id224660fdd0047b996983e6ee2775abe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib639369018004754a9231ea3cb196a74_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib182bbc8abc342c796c4fe1951e63578_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icda291dcf88445d79798c83baf0cdab6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ied6fc4314ff74454a352c1254c20f4a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id270cfd00e264906938aa37712a47c2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie63cee825d9047dc912cec33b6578d0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6eb111e31f6244de805aec691711dc6b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6aadbc751f6142fb9d7d9b181bf75a09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c681c490eb24f0888c2d4a13e77ad8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i947c924e348b4937945183baa80b4090_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if61dd7a223a64fd789d0d20d60918b24_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2020SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i58e5df66246e4242a351e934e5d881a9_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A225SeniorNotesDueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i262058cabfd94b5ab32927e2ab5d4b39_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A315SeniorNotesDueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i6ddb930bb2d6431ea44a09daf6837686_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98decbb03ea4472c94a12ac0b39c7793_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2020SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b1c876d462a421f884f7da02f35aeb6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2015SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie421a618f95e4d26993d33169587ef01_I20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="ic07e15711c4c4d72879f1d4eddbaa8f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i522bc71323b84dfaa650873976042d71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i121fec5eb0a442788b9b201aa33e7063_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i02d9dc2f9e5647a79094565b056378cc_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="if4870972449f45cca77c7f81269fdbe0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51e142f8c61e4ef9aa6fcc66964b20a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51bbbbb29365442693577108f0597733_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:SeriesXPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic43dbda8223e4c34ae49a143d781adf8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0070294a197c45399f314f23509957dc_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i41af7ab14acc4fb1987d804ec0919188_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idbfd0586c39547f4bd2e2e1a5234c516_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8f5af4399029492c96f8e3642a945612_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="ice49d2ad46424ef199c6cb123804c5a5_I20160731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:ShareRepurchaseProgram1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="i29b72acd0c624e9a9e5f85ff7919818a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f24d77b87bc4232984dc260a26c171e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i709cfa41571a4ab8b7d4914c6efb00b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5d68ba226474425a9ad91c1d2d03c1a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25d8c73e458441d994c3c13f19832ae9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5acc9340a88745fd84cac5a88b2066cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2cdcecbf126d4b8099f5e7acda25fb2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85c3ebcbd89841a28e7480e4337c4988_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6f5a43994a74e30bc2c24fc58be7a8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38457c7073c148078d40e136da416dc2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29f346c927114584bd6128c5a5e41d52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie53527d45eb34a6b993b46ac83917155_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id971167191384986aec4598f9022d212_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b64d0eaf4c246fab3031182b58a6d37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7cf2db733a844ed99dc8f7222b3ccc49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bba1fded9e7415e8f0eecc9fc01fa37_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1d78be56f2654da88b7ee62f039e7477_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i863cc533cc0841c9a1fb1ddedc5d0abc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i520d25d1349b439588d438faa148525c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2706b4a26f7244ee86167f45ad4d537d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i05757bf43f664f91b75e8330e6981029_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic378ba6b90b54eb49686f7fbcd8d7d26_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i14c50d1ee35d466596e1a0bd0485826b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifcd9d8887f184f03b4f51f5d658bd9bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3946e2ed691746eea6486da676e10065_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89cc1e0b559548e1b327e6f439fb19d6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i05064dd261bf486d8e3bf1bba3b6c47e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0edbe632efef45cc957628ebc1d33d42_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7fa22ea433e141458d8691d0f27355c1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ide4cbacbf5734ef695d22154b1428d52_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="id59744b4317a46d5ab82e7521aa6b11e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia35f6885c958490aa4fa10a11e2ca2e6_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i903a5c782a9b41dc9edce0003cd86d67_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6757062bd137442ea0f58c866b089bcd_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i46ba77a8a8704925bcd95ae5bd41be65_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i20addfea8892477996faeb680a08f153_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7d0da88784044139ae3b0627adb1073e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ieedbbfb7ec1f47d98f528e19bea4741a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ifc4fdfb6dc344f2ba410b5f056357e3a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i255daee7862543c69e18f60f9dab28fa_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib03e8eced8bc40769f89224b7a3917b7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0835e29a53b74d32a686b04bc1b1b198_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib755e31f5e76447187fce9bda9cb4342_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8d38cf0e172d4e26924af47f88ae37cd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2c99beb651874e9494da14b27703de21_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i87a66bdab7bd472bae2b3efc40fee57c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i45c58c66b4a842ac9ad5f192b2a0e90b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae5eb4853f6f4dfe9344661c9aa220db_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i70d3de7bccd345f7a075fd96f73db36f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i98dca11e646a476986ce2b76bb838960_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i629d97b930eb4709852d599b96bd1336_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icca0c44aac904794a5af072f3936f72c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i268b5aee503541a1b2d10eb88d72b0fb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id83a5eaf6567467eb34c2a56b8b9b544_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1029aaf02d1e4e45bfea6b6f58c10380_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48908e834b734ebebfa2eebf3d33b0be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia8750b469f74471190cc2cf6076d21ef_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i286d43c7e7e34e99a914f5aa626a428b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie60b5c10ba06457f95296998f5fab4fb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i87ef982cfbdf41d3b4a5ae5f59e4bf33_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie7c767930933407ba05e420ac12e8ead_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iabe0551d164a4cf2b1e3b5a93ddbac8b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i553c1568915b41bd8a1f0a03726da4b5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie00db9b8e16a4be5b4796014ce7b9775_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2afb74941ee472f98e6628b9fc75769_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c0fbc5a8e674148b9ed9389f86047fa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i51da93958ce045aa9a3723e4939788a8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i978a8bf34b8a4498a033dbbeb035725f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5d9eb1cb8dad4f7bb71554081970672c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d9a8ab9362146acb873dbfa9866ab42_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d7efd2d47c945e197f5e3a194b14857_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="icf69f103a98a40ce90631e9f60d5754b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5182146502648bf94e1be9dce89213b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f97fac7edf9426d88a1e76bb48ad55c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i96f109ebcb514632b195259b16d76186_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d29238f9c3f411fa88ad3fefaaacf57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2d37f597e713494d9d43394bf06bab30_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7350a4e642e945d4b5a1646e257127f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8cf98ae6877747fc9a91fc7dc00a358e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib997cdf3cb144617bb5d6ff4986095ba_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia05aa73c81db48f6b204fa3c972243e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3653e8c908ef47bc8ad1352fd466e75e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba5bec6196eb4910ac31bcec98a0c3a9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3480fbb97844462e9008fb8c307b45ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a25527f05454792b6c3a170ae578dc8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i54cf49ddedf140a0ab09a33fe768f730_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5b0df0e7d12e4abda01cacd276a69d0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e0d61fcfcf945bea2cf06b84ae730ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6db7fc9d86d84cb6b0b36baee4a3643f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0a840f55f6d64ab182ff63fbceb3665a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i321f27bc93f84527866eb088a9a13ab8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7a7d16eb3f9c4249b12a16fbbf180e21_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0769ffe96e9e4c938ce1cbd317e37f42_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0390833128a4361842fcc8dc5e28d8f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4a49c0b0d08f4220b68f83ed9492b788_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:NightstarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4952db151b244967ad310f4684e13d15_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:DirectorsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e20d08747494db199b88c431d14e928_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="if0d36998038a4ff1aeee3c3273f7a37f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1c47bb693114834bbe5ba4a44e2234c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia82e3cb95d2d4a44b7a01995c91159a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7c1ad961cd346de9af30e39027d96bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2a2350cc1a754e1e8af5bc26001a39ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f065e3287da460f99889b0a7d3e9327_D20130101-20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28a8afaf854c4785ba7b167d54f6f8a0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i307bf919a041463693eb52f82fe704dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1af180b9ceba4128805321de34545ed8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i180576e386e14660b3b217b13f520f3a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b626c65959246e09aa12e28314bba0c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if59b671ae4d44f3b97a43ee65c799fc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb57f7f3d44e42c4a8e598bf54a94075_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id6d7f7d4fdc14cd4a16f3d306b79e0d5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94d4a650ffa44c1998500b69da6939ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a25395b7a6043aca656dfaf91b50a0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01b2d203f7de418d8494c28ba590c318_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9ef74f21f78441ffa5960a07e5974a49_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78b2e6ab84a14827b284ec4a34e34ebd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43f58504b3d04073a49321e74a6c17bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb3c0a4a765f431c99358d6639915157_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2b88b6b11d44635858d6a6d1dd65fd2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5279dcf6d19435dbf4f97f6c1923185_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3db70ce0acff40ddb1a8049995563df4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife7a28c7abae4f1c93ca334525d03c5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6556dcd7cdf41ecbef4a10fc43d3f45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i307d77a2fa40438aa59c8269e8e9b25d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibec2bce1b2964c0f98ad9f65944dee76_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if188b16b7c0a45a1a919112de323694b_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="icf6d89d5466147cd8f697b7487932bfb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2396dcccc314478d8ad44cb90e14d1e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3eed89417d914c45a6644792efcd83e5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0f3c645fd7d74b17a26a9b8652d2a6f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4a97d152e6b454f8ff1a1aaed64c1b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia726ac01887c4e3f8b260b50fdc0036c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i73be9e1394774290a72930a5f26e75a7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a8d0fe496fa4437a1c3009ee5b30517_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia220992660254d9a81341091dce24aa9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifad8db8e19694c21869ab3526b232850_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe08502e6aa446d09a87c817d769e4d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia976a78ea31f4adeb3848c2680c1fb1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibeae6620ceef4b6da93e2b0ac949cf2a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i13e408385075494cbe602b5be6d1c8e3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8e9fc07f4dfc4bc081d7e510e678bca7_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:ForeignearningsintheformofcashandcashequivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i60c4584fb70e4f31996559b7c3214b24_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:OtherForeignEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ib21ba4f090344f2f9805e82e16811047_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8fe3f12d8cdc4e1fb91fee9506338b3f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9237ad9c6c14888837dc3e87c024939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5daca379673646cba7a409b1982cb5ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie04b35230b3a4c1b86938c22cf535263_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DeferredTaxAssetLiabilityTypeAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0192f21805fe4e158b7667cad4964a5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d86e21f739f482d80d94fd171cf33bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26628f1182184eba96d1f455922e58af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c55c5c3bbab4bcc915d94071853367e_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2a5c5a093a604074b379ddadcb4304e8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8217e2c7737e464790a37fff8a75e2cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliAndSangamoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id44ba7c8ceb14c93b89739486052b804_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i36bea0a273e042b4977e70b6d39dce99_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i31f7c1fc4a6c450c9505e7b20773c69c_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="id2fc03f67f5645f1b013252212df9935_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i771406e8a3b34c93b5f87c9b46df7655_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79ec1427e45649d2851751c0d45cf674_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7585b972767d4bd6bbbd279b2e88eee9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e00ac4fc24f4e0bb5ded9386aef6231_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib74714c45267446986d21e121eec440b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i59c2a5bc4c964df2a0221f7f66aec154_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97799a59fdcc43b1bfbf8aa1dcd16b3a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4fce10d195874216b12663411fa5c489_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1662495653e1435689b93551c68ae54e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iffff7fb793694c20a0248c1ea9b22dfe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3dfe4622e95f4be3b13eb7b4eb5d7421_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id28d5f3f841240659df55d6cebaa2341_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1a76b88c18540f5b28ba2e5fbc3f6f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5bdb2b3168704d7e945362a0cc289715_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i747f7303e31143ec8231dc760b0cb79a_D20121201-20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="i71eb4f6064534d02b9b523b950ef4cb5_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="i45dbe435f7fd469798d0b243da615ec6_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i105821a34e0b4347b7fd8ae515422218_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9331add6801a4df791250e423365aaea_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i1d15cdc79395436f8ea70d371389138c_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ia2c9ea4c44b047fab182bf1e93960612_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="iff10bbc1b7204f9a899f2b15e8f5bb57_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i8b01dc3119ea40eaaabda1c48b7c9107_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i465d3d459afa478c9e3119d88d5627e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if47126e2c5154b45ab4cbefbf186b118_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i1e5d541771094deaba1fa696b580448f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if223f76ca1884559bc1cd766f260b0eb_D20130901-20130930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="i95a0cc3cf2744b12b943e07433857c3a_I20130930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-09-30</instant>
        </period>
    </context>
    <context id="ic9dc60a6f69e48f5a2a97af95fa37fb4_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5554faf4f05643a08aa9972d0ca3320a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66010d191b2a4b168f86fe9538abfa3b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia0993650b5ce4b56ba73d7e6d491c39c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8cbeeb58208f422997188aaf6d96b19c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i912e90e415414b2eb40263d0228aebbd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i46b16525b4ff43abb6399861bedb691a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3be23a7aefd749b688f0ea9bc6153af4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib08f91138dfb4499a6873f325caac5c6_D20190101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i12a519048d3946d6b1cae8db3bf6ea2b_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i04d3846e76534a968aa79c696280f29f_D20180401-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3f4b4db6bca74ad38b22a985c9cf4c8c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7cf41e8e7ce64d6b9af4dccfbd954c2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i685eb05651d54eb487dd05db4f014285_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i523d958a043b46abb2bf95ddabf9e48d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6770bed0636946adb09e5741c30e183e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i07e06dea69a4477c83eaaab76c26a1c0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6011115c7277467e81a492d53cc5c2de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i204866d0c938473fb367812907152221_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8095992b920b4752bea7ed0e25a7dec6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i307bd3b52c544217a250d6bec5afed5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0259bfa32ec47deb51fdd95ffd65e06_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5afe9f2f08fd4c56a2b406c9f04b9941_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8aed9a151f27413aad9ecb189295574d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4c7eb5801004aad9c424b58efad93ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i062dfb826bb543c0ab344580c2bc9f39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i329e830c9d924ad1abde877010ab5c13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie615c033847a4fdc95860b4e0bfd4d64_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i18853d4d37eb4076a332a07be0132022_D20170601-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="id74db4b324cc4118b5cddd07bff2bc26_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iecc638e4ad114ce2ad08351d98ed22df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7e2e7e20d974dde8d37743caeeb08eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i68ee0bf055a24fd6888b5ed314a45afe_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie154ef82e19b42d287f8709039383fa3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice90a1eb84854ab6838871533abeea35_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a57dff6854d41af89281f848dc03341_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib02062df52254e2a96f48ca5db08b037_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i238f01dc6276416eac270e2a8e9978df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4675956b4c7541689880490a770cb247_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i64566178ee6240c4bca091bed9507fe4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32a2842d092548499069b826f6c1c638_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie6856a51b4454c25b01425f5b605c021_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia6ee863c764240e8b24a01061fc43c1e_I20120229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-29</instant>
        </period>
    </context>
    <context id="i3ef12f56eff74ffba6abbdbbf71ce00c_D20120201-20120229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-01</startDate>
            <endDate>2012-02-29</endDate>
        </period>
    </context>
    <context id="i64dc4d43b5394b6b882e494448859c7b_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="ib4a6f7ae45f34f16a1e64ef99614a3f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d919fabed9048039865137149827503_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i295fd62c9b9a44a19b8f2c9cf5993d16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f272ab6a3b3497a8d35a3bdbf2a7afa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i897172e0b7bd4edda63f02e0d50f23aa_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="id583b49771574491a9a38091b81e5d33_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i40f71161d18144578dd8f72012056ddf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfa950bc28fd44ad8df6891d4c6166ca_D20131201-20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="if35d8e291e634b4fb356e7dd2eb4e57e_D20131201-20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="i55970ae847c94b61adb418c71761c6c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idced215bef924766890054dea8e163a5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2d07f2e384e64708858924ad5f63049d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14fe65b9d9ce412f9b5cb080d3a88a3d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic52a2fe62f214111bf27f2241c15e13d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b079cbb95c4416897c5c9f868e8ecbe_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i36b3ae17c9254af097d228dac7821a3c_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ic47c03e6e7be46888ccb47d76183eca4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ExpectedPaymentTimelineofMilestoneAxis">biib:TwelvemonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22a68eca818d4bfd974767e6d650ecec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77448f6c2bef4b2ea4eb496e64cae04e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i957831cfe2a145bab834e81558efd05e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AducanumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i933bc3e4859e442d998a3136c487cd85_D20191101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5cd0b9db93464b41b789d3e1ca413b78_I20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="i16f1d1f107eb4341ad1613ad1b5d5759_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i91a1d60eac014ca3be868d71ce1a4a4f_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i2dd3d46d9dd249b28b950c8de7e4732c_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="id7513df5070046c28b340530835d8133_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i65d03ca4620f4c52999c7becc617b0ff_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifeaee754376e4c77898d464920110368_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i751bdf5f146846a0a2d59925aa237c7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4aa757dc6dcd456f86823b48006f5e50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if55055ac245a4373b369623a07552bcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AducanumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43fa46a959704893ae8c17cdf1fcca1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia620d874c26f4526a51976fe0e5fd937_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i766a717009a042eab70c1b33dd98c33d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8eaae0c3c53245ed91bba34207199327_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd5e42a67c414bde9ae4844e15f78b39_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic085e896635e45e896872f4b67d23b0b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b27f85445594281810d4e11521c4fb0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4e1ee455bd644649ba9f949ccefc1a95_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib255acebc8bb4cbf9289671a4d33b082_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac6eab3ca24d4a599f6a591c887c3592_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a552a264841456ba32e800303b29c4b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a170e3656544b4d848f8f7740a81d09_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79fdfce753a6425b8f9b7ca88002a439_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifececb28512c40ee8412eff5d4625c9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7150facb4e24d09a7ef6a2fee36dfc9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3da3923fab24d76b979d1adf1a4a146_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cc247cbbe7443509ae3adc1934e986c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24be31960c444fa3abc4b582746b9496_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6cc07ab871bb4356b9e093f779247007_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2baef659c2bc4c41a82832bd90ac2e36_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibff57345bf2b4431834e26681459d492_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib9af8365f4d94f16920edbde69e7cbb7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96f46388dff4463e9fde50c812857bbd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe68292fbbe8447c8b94adbca7e5c270_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0916ba417dd84c7ba1d88322f8285810_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4626ac9e1499406f9c21d3df61161c1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85a3e7b4381945be8628c8dda3f341b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4af3774c88a4c69bdfb4f0b296748c4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibbd9ea049fb349888e438f5bf876864b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6587b6a9e7a4af3bde2b30568b9afb3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6988263d2c4242e89b4c6e3d6b3dffad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7c353d1945748a9b24ca8847773877e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13dba24b1b3b499ea5f5844129e61ac2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1973b2051d3340b1824cfc6b74a8aaa9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c819a830ca44238bc2e36f8b20fd54c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia331aa05ae08401980f6ff67ad3d9568_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib77580efa84d475392dddda68bff7041_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b205643e3ea42fcb8a65c552825bb63_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5aeffaf17ea24cf680dcae3471e1b7f9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i444f2f75d3b2489ab262daa8b78df9ba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98fe9583334144ef942f3d12e08913b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib6db9e6fd2a649c9889b826888da6372_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3ac83089e884263a9d4ae9da7e3efde_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d9eb2f85dd546a4ae15fc642f85d8af_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4630fecb0f6c47b2b848f15327791e4f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i002c6070bf8846dc9140030a63f37dac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i674d0e91669c40ff82a76bedb27e4e67_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0172f7c5c8b3448bb8ca832a1116f3aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib563770ab8184507a232435bea87086a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d67a017c4d1439bbfdeb2055dacff9b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i388f07fba6354ae6b12a5c8a48d28304_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c94a7c202e7466686a893e6fda06193_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4342c229637d452dafa8e4a45cb1a216_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic9714a1b144e4e9b81457f7ce371bbea_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iabe36228fc3c43b182afc7bd39a2d6bd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7dd05e22171d4dad869c4a37eb52a7f5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3e85dcda379e4e348325696cd2ec9cf6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2f84620186bd48dfaa02b13846091e74_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idf10b7ffe1994abcbd958c90d5c06301_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic16aea428adb4ba5ae3e7d508536706d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if67b659127c9421f89dad74f1278c337_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i745cdf1e889c4c16afb442fe563d25a2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id49704cf795948148f16dbae680341c9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9cfd775f332e45ac808c12b6838e769e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icbdc67c11df94e509edd9a7f39c16d8e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i89e40021e4994fcbb8133c1d5d3f6f27_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4c4f2b0a6a9c49f48c35940d82b38a6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6e096fa0fb0473683e284201e92aaca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8e2b3b8ba24b4036880ba37d5422da63_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8ae776ffb778432e982088a179ebb204_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9fca2b687f2f4872a9a845bb672960a5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia5dfc91e9f8241d894aa02ab5409f041_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1ae9621a79ec4f2a81baf7fc485474c2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c705be761834645b8c5978e3818b771_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f55339914bb4b2ab51133f2c27b01c7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib87a96b308944207b0abf485235389d9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i01ce7f756f854eff83de1460d06439a0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id3a2e9422f744e57a659fdc96c0a0d84_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie805016a199a4e4eafdf82e66b43ecd8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5a2d9c146e8546eb8940919a230b2410_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie1f37a240cd2462496769361d7d6aa4c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1cc07ea8987844bbae9f16026aa3eeb2_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7776337c87847de857073085287b7df_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1ee7c83511ad4b4a994502e07e77195c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5dc031b722984deaaab7026bf6193aab_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5416e51b85274f0bb17370851e4a3b1b_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2ad278057bef48a7b7423fcd6a012b35_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id87d95cb80ee488f95f41a5044d1b98c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i61172312032a4a168fbce9685cffadb9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1244a258e99d4f4bbccf06fe8dd8b6f8_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9edea67901754dfca2b56005c22d377d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5380e1ba1c7b486290cfbe6457fb3bd7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifd7ea2df93e7492991c4ca15c3f6e098_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3d05a3ba448a4750b45bb2d906497144_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="plan">
        <measure>biib:Plan</measure>
    </unit>
    <unit id="increment">
        <measure>biib:Increment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV80L2ZyYWc6Y2JmZmIzYzQ2YTI3NGIzZjkwYjk3ZGExZWNmZmU4YjAvdGFibGU6MGYzNTNiY2MxZmE4NDdhNTg3ZDQ2ZjI5ZTUwNzQ4ZTgvdGFibGVyYW5nZTowZjM1M2JjYzFmYTg0N2E1ODdkNDZmMjllNTA3NDhlOF8xLTEtMS0xLTA_0b496f3a-fed4-4e1a-a133-5d793a6c5767">0000875045</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV80L2ZyYWc6Y2JmZmIzYzQ2YTI3NGIzZjkwYjk3ZGExZWNmZmU4YjAvdGFibGU6MGYzNTNiY2MxZmE4NDdhNTg3ZDQ2ZjI5ZTUwNzQ4ZTgvdGFibGVyYW5nZTowZjM1M2JjYzFmYTg0N2E1ODdkNDZmMjllNTA3NDhlOF8zLTEtMS0xLTA_12273ac1-ce7e-4f4a-b09b-78e5e1b57e48">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV80L2ZyYWc6Y2JmZmIzYzQ2YTI3NGIzZjkwYjk3ZGExZWNmZmU4YjAvdGFibGU6MGYzNTNiY2MxZmE4NDdhNTg3ZDQ2ZjI5ZTUwNzQ4ZTgvdGFibGVyYW5nZTowZjM1M2JjYzFmYTg0N2E1ODdkNDZmMjllNTA3NDhlOF80LTEtMS0xLTA_ad8605b8-e8bc-4451-af0b-10ef0573f0cc">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV80L2ZyYWc6Y2JmZmIzYzQ2YTI3NGIzZjkwYjk3ZGExZWNmZmU4YjAvdGFibGU6MGYzNTNiY2MxZmE4NDdhNTg3ZDQ2ZjI5ZTUwNzQ4ZTgvdGFibGVyYW5nZTowZjM1M2JjYzFmYTg0N2E1ODdkNDZmMjllNTA3NDhlOF81LTEtMS0xLTA_6ece283e-cb61-4e71-94c3-5af2a0c840cf">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzEtMS0xLTEtMA_0467173a-da5d-472f-9329-91ddcf11f0a3"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzEtMy0xLTEtMA_42e23e41-83c6-43cf-9e13-6898f679ca19"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzItMS0xLTEtMA_5e727e9b-da1c-4acd-84c3-927c1bfa27bc"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzItMy0xLTEtMA_dfa4d726-6e4e-4b08-b1d2-01b787269381"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TreasuryStockShares
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzMtMS0xLTEtMA_6aa56020-140b-41e5-ba34-7e5b580f53a9"
      unitRef="shares">23800000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjYvZnJhZzpiMTVkNGJiZWRjMzE0ZWU4YjU2ZDM4ZGVhNTQyNjA2NS90YWJsZTo1NjczOWM5YzFhZmM0MTE0YTk3MWZmNTEzYjkzYjMxZS90YWJsZXJhbmdlOjU2NzM5YzljMWFmYzQxMTRhOTcxZmY1MTNiOTNiMzFlXzMtMy0xLTEtMA_627d7927-871d-4650-bbaf-679bdf4ed356"
      unitRef="shares">23800000</us-gaap:TreasuryStockShares>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i20d53eeb6bac423daeed8dd6132359a9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4NDA_d52adc0a-d056-48aa-8b93-a252ffbfe552">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id1d08429d1c347878b82c18df8d582c9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzItMS0xLTEtMA_ad4af409-6257-4ea9-b3d3-ccf967af7fb2">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i434f35407e6e4c099ce33b8a068afd74_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzMtMS0xLTEtMA_4bff1514-1ae1-4e6b-a173-1486c952833c">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i33ed7c967da142e892cae01133c8613e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzUtMS0xLTEtMA_a84410ae-3a67-4ef9-ba77-6a5bc6c42685">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie335a67b286c4619b0b5b87a19532f5a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzYtMS0xLTEtMA_b5830636-fc30-4f33-9693-e72e0cd18a82">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i31173508fedd4169a632723f6c55327a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzgtMS0xLTEtMA_e34daa41-0aaf-41d5-9215-985cd67eec58">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i68ae650937b24214a80dedf08e192bef_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzktMS0xLTEtMA_65586f9a-9daf-45a5-a519-b67f443aac6b">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i20d53eeb6bac423daeed8dd6132359a9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzExLTEtMS0xLTA_d522d9ed-79da-4f79-b808-2ce8de6a9d78">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1b4148f6f0e64fcc8d46dde21febd1df_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDEvZnJhZzozOWY2YjQ3ZDcwOGQ0MWM4YTRhYmEzZmI1YWVlMjMyNy90YWJsZTo3YmY5ZDJhMjM5OGM0MDNiYjc5NzFiM2FkMDE0OTBkYS90YWJsZXJhbmdlOjdiZjlkMmEyMzk4YzQwM2JiNzk3MWIzYWQwMTQ5MGRhXzEyLTEtMS0xLTA_1ed127fe-8322-4504-9fbf-d2bcead1f7cf">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic69589c021a84ef3b51246299f3819f4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTkvZnJhZzo3OTM1YmRlYzEyNGY0ZWY3YmMyMjVhNDIxMDcyZGY1MS90YWJsZTplYmYxYjYwMTM2ODY0ZmE2OWI0ODc4Yjg3MDU3NWExMi90YWJsZXJhbmdlOmViZjFiNjAxMzY4NjRmYTY5YjQ4NzhiODcwNTc1YTEyXzMtMS0xLTEtMA_ce455bcf-7b18-423d-aa4d-df4701d94a1c">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6ece1a557c614598b419f009a522970e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTkvZnJhZzo3OTM1YmRlYzEyNGY0ZWY3YmMyMjVhNDIxMDcyZGY1MS90YWJsZTplYmYxYjYwMTM2ODY0ZmE2OWI0ODc4Yjg3MDU3NWExMi90YWJsZXJhbmdlOmViZjFiNjAxMzY4NjRmYTY5YjQ4NzhiODcwNTc1YTEyXzQtMS0xLTEtMA_6a0af5d0-7c4a-4499-89a9-99ccd191037f">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21ab402dc3c540aaaa74ab88707cd06e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzItMS0xLTEtMA_bab008c1-85e5-49a8-8d17-62f301c653e3"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i777e7a0559ef48fd8038247a2da5c7c3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzMtMS0xLTEtMA_9f3dd0b6-fefe-4df2-b4be-810de88acdea"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if4f6df13a0ab4a20800b6bd00a5f821d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzQtMS0xLTEtMA_e89d515f-8350-4753-a174-a9d0bc4c4064"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i665e4e826ccd4df0a58a999910a2c5ce_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzUtMS0xLTEtMjQxODg_fa30f618-dde3-40dc-ba90-b2e4a6def973"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic5513569ac924bcd810dcccb4b75c1ca_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzUtMS0xLTEtMA_ab6645bf-a8c6-4423-9ca7-74ff251e6ce1"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i55d717cfc9ad47b288a5e9b60459b22c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjUvZnJhZzo3NGNhNWM2MmQ1Zjg0OGUxYWFjMGY2MGY2NzdmMzM3OS90YWJsZTo1ODM3YjFiMDliZjE0NTZmOGI3OGI0MWEwNGMxMWRkMi90YWJsZXJhbmdlOjU4MzdiMWIwOWJmMTQ1NmY4Yjc4YjQxYTA0YzExZGQyXzctMS0xLTEtMjQxODg_7ef7ae7d-815f-42b1-844d-34d42ada0080"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMS0xLTEtMTMxMzU_4631686e-fcd9-443b-a344-b69d241e1c2d">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21ab402dc3c540aaaa74ab88707cd06e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl8yLTEtMS0xLTI0Mjgy_416f1f93-333a-42c0-91da-a300950a4cb2"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i777e7a0559ef48fd8038247a2da5c7c3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl8zLTEtMS0xLTI0Mjgy_153276d6-3964-4550-9736-2093a173dce2"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if4f6df13a0ab4a20800b6bd00a5f821d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl80LTEtMS0xLTI0Mjgy_3abae926-ffdd-4d49-9992-75bc58879f22"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i665e4e826ccd4df0a58a999910a2c5ce_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl81LTEtMS0xLTI0Mjgy_cacfe58f-1820-4e9a-8a04-6ef078ee7946"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic5513569ac924bcd810dcccb4b75c1ca_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl82LTEtMS0xLTI0Mjgy_4685ffdc-563a-47ee-8d8c-71039fd5fb32"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i55d717cfc9ad47b288a5e9b60459b22c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTg4L2ZyYWc6NzIwY2Q1NDQyOTFiNDQwYWI2ZDJjNmNiODU5NTFhY2YvdGFibGU6MTY4OTQ5ZTE5YzcyNGQ1ZDg4MzkwOGFjZmQ4Y2ExMzIvdGFibGVyYW5nZToxNjg5NDllMTljNzI0ZDVkODgzOTA4YWNmZDhjYTEzMl83LTEtMS0xLTI0Mjgy_92f792b3-aa89-49c0-b3ab-031409a819f4"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id1c47bb693114834bbe5ba4a44e2234c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNzA_dabd3a6a-1cff-45b6-8845-824a093e53e1">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNTQ_9f998ee0-5669-4526-a3e7-3980eafec54f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNjU_9f998ee0-5669-4526-a3e7-3980eafec54f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0f3c645fd7d74b17a26a9b8652d2a6f9_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzItMS0xLTEtMA_9c8696cf-9be0-4b1e-89eb-e1c924aa1669"
      unitRef="number">0.378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic4a97d152e6b454f8ff1a1aaed64c1b2_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzItMy0xLTEtMA_7f393da7-a1a5-4ff5-a20d-9e9c9468bd24"
      unitRef="number">0.312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia726ac01887c4e3f8b260b50fdc0036c_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzItNS0xLTEtMA_0668fbaf-73ca-4776-9748-9045b9c15fd6"
      unitRef="number">0.275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i73be9e1394774290a72930a5f26e75a7_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzMtMS0xLTEtMA_2a2db1f8-6860-45c1-8fa7-b506f7306c32"
      unitRef="number">0.441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1a8d0fe496fa4437a1c3009ee5b30517_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzMtMy0xLTEtMA_30fba259-5dd7-49b5-9e88-4a66323727af"
      unitRef="number">0.336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia220992660254d9a81341091dce24aa9_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzMtNS0xLTEtMA_4b9f938a-6224-4b0e-a0d9-73b7cb554fbc"
      unitRef="number">0.324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzQtMS0xLTEtMA_25cb13bf-5839-40bd-9432-eeb2ce0f9198"
      unitRef="number">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzQtMy0xLTEtMA_12d1e6da-7b2d-4b2d-8ba1-1876378ff37a"
      unitRef="number">0.0246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzQtNS0xLTEtMA_fb455ca9-4847-4e30-be6b-26095ccbcabd"
      unitRef="number">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzUtMS0xLTEtMA_cdff5667-66f1-433c-acb0-2bed149a72a1"
      unitRef="number">0.0148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzUtMy0xLTEtMA_752a2d0d-4c0c-4526-b06e-e4a6a3ad2edd"
      unitRef="number">0.0253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzUtNS0xLTEtMA_922966ac-244d-4428-b6f6-2fb088665f93"
      unitRef="number">0.0230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <biib:AverageStockPriceOnGrantDateInDollarsMinimum
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzYtMS0xLTEtMA_7c0e90cb-6c57-42df-98bf-c6b718505e5d"
      unitRef="usd">257.83</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
    <biib:AverageStockPriceOnGrantDateInDollarsMinimum
      contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzYtMy0xLTEtMA_b3b885ec-1bed-4dad-ac98-528f7a58506e"
      unitRef="usd">228.59</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
    <biib:AverageStockPriceOnGrantDateInDollarsMinimum
      contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzYtNS0xLTEtMA_d22e304e-e521-470e-b43c-5272b70ad2fe"
      unitRef="usd">279.47</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
    <biib:AverageStockPriceOnGrantDateInDollarsMaximum
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzctMS0xLTEtMA_9e54c945-79d8-4fc3-9a27-404c09e7b202"
      unitRef="usd">325.40</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
    <biib:AverageStockPriceOnGrantDateInDollarsMaximum
      contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzctMy0xLTEtMA_44a83221-bea1-42bf-b758-9c7d2bef7ddb"
      unitRef="usd">331.18</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
    <biib:AverageStockPriceOnGrantDateInDollarsMaximum
      contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTo1ODRhNWIyOTNmNjg0ODJjOTVkMjQ3OWFlYWIxNjQ5My90YWJsZXJhbmdlOjU4NGE1YjI5M2Y2ODQ4MmM5NWQyNDc5YWVhYjE2NDkzXzctNS0xLTEtMA_03fef00a-5b76-40c0-8c11-032422e292a6"
      unitRef="usd">346.76</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ifad8db8e19694c21869ab3526b232850_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTplY2VmYzNjNTA5NzI0OGNkYjAyNDJlZjVlYTQwNDJkZS90YWJsZXJhbmdlOmVjZWZjM2M1MDk3MjQ4Y2RiMDI0MmVmNWVhNDA0MmRlXzAtMC0xLTEtMTM4MDg_0d6479ff-6b5a-4ac5-bb36-5c4d6816289c"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ibe08502e6aa446d09a87c817d769e4d4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTplY2VmYzNjNTA5NzI0OGNkYjAyNDJlZjVlYTQwNDJkZS90YWJsZXJhbmdlOmVjZWZjM2M1MDk3MjQ4Y2RiMDI0MmVmNWVhNDA0MmRlXzEtMC0xLTEtMTM4MDg_f5a7102f-29f2-4763-8aee-963250bb27c4"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ia976a78ea31f4adeb3848c2680c1fb1a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTUvZnJhZzpmYThmY2U2OGFhZjA0M2NhOWYxOGIwMjBkNzQ0ZmVhZS90YWJsZTplY2VmYzNjNTA5NzI0OGNkYjAyNDJlZjVlYTQwNDJkZS90YWJsZXJhbmdlOmVjZWZjM2M1MDk3MjQ4Y2RiMDI0MmVmNWVhNDA0MmRlXzItMC0xLTEtMTM4MDg_0294f2fd-afa3-41b6-bbd1-b05c48076192"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA2_50cbf961-19b8-4a0b-8235-e3f98dff2617">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6OWNkNWQ1NmI3YmE5NDY3ZDk1ZDc0OGJmMGJjOTU1YmMvdGFibGVyYW5nZTo5Y2Q1ZDU2YjdiYTk0NjdkOTVkNzQ4YmYwYmM5NTViY18wLTAtMS0xLTA_9b3675a6-db9d-4691-948f-062b96ec2962">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18xMTk_9c269e76-0d83-4ae5-a4a5-7c4fe8c1ae35">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18xMTk_e6fc9ab1-243e-4489-948d-2a9e7845d0c4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6ZTQ2N2IyMTM0MDk5NDZhNDgxZjRjNTg2ZWI0ZGY4NWYvdGFibGVyYW5nZTplNDY3YjIxMzQwOTk0NmE0ODFmNGM1ODZlYjRkZjg1Zl8wLTAtMS0xLTA_724f1d48-49ca-4058-91c1-802de5c4abca">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTAy_1758d416-8e9a-4f8e-b1ed-091e9590317c">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA4_cdcb5014-6cb0-48d5-bab9-958ffc0a1097">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6YjNjNGJkODJjYmZlNDBlMDlhYTNmYjIwNWRmMDQ4NzcvdGFibGVyYW5nZTpiM2M0YmQ4MmNiZmU0MGUwOWFhM2ZiMjA1ZGYwNDg3N18wLTAtMS0xLTA_e26a7735-6a13-48b8-bf41-6dea5a11dce5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6YjNjNGJkODJjYmZlNDBlMDlhYTNmYjIwNWRmMDQ4NzcvdGFibGVyYW5nZTpiM2M0YmQ4MmNiZmU0MGUwOWFhM2ZiMjA1ZGYwNDg3N18wLTItMS0xLTA_56a881eb-b98a-4211-8137-e7f42f42d05a">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk3_900c1f78-a12f-4cd3-b9f8-4a4eb5a8703a">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk1_107de00e-67a6-4db1-9ed3-976b515c63df">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTAx_747b4280-9f53-4a81-9065-090664567a41">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk4_b98d751f-21a6-4d89-9d6b-b972cfbbdd6c">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTAz_5cfccb7c-62e3-40a3-85c2-ab45ba8f12fe">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk5_80c13a0e-7876-47c8-b588-19aa825e6f41">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6NTBhZDhkYWI2YzJlNGI2M2E2MjFlODhmZDI1NjZmZGIvdGFibGVyYW5nZTo1MGFkOGRhYjZjMmU0YjYzYTYyMWU4OGZkMjU2NmZkYl8xLTAtMS0xLTA_822adaad-8b4b-49d4-97a7-77538321637b">Common Stock, $0.0005&#160;par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6NTBhZDhkYWI2YzJlNGI2M2E2MjFlODhmZDI1NjZmZGIvdGFibGVyYW5nZTo1MGFkOGRhYjZjMmU0YjYzYTYyMWU4OGZkMjU2NmZkYl8xLTItMS0xLTA_ade6adf8-ad2e-4948-bc5d-93048cb8bff7">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6NTBhZDhkYWI2YzJlNGI2M2E2MjFlODhmZDI1NjZmZGIvdGFibGVyYW5nZTo1MGFkOGRhYjZjMmU0YjYzYTYyMWU4OGZkMjU2NmZkYl8xLTUtMS0xLTA_fbc4abab-47dd-4c29-9931-1ae9a355f88c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTAw_5ae4364e-c961-4363-ba1f-c492dd8c1d40">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA0_2417c1ee-fd5b-4cb3-949c-9fa5b98a7588">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA3_7725f27b-0387-4b7f-b839-e1c2252ec95d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yOTA1_48928c16-0ca7-451b-8fd0-0bf035e907e1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6Nzk2MjA1ZjhiOWVkNDQxOGFmNDQ2MGI2MDRjYmQ1YzgvdGFibGVyYW5nZTo3OTYyMDVmOGI5ZWQ0NDE4YWY0NDYwYjYwNGNiZDVjOF8wLTAtMS0xLTA_acdcb982-ac2d-4451-a7e5-5fa19ae14242">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6Nzk2MjA1ZjhiOWVkNDQxOGFmNDQ2MGI2MDRjYmQ1YzgvdGFibGVyYW5nZTo3OTYyMDVmOGI5ZWQ0NDE4YWY0NDYwYjYwNGNiZDVjOF8xLTQtMS0xLTA_08a8425b-d0d3-43d8-b2c0-77f2cb932909">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGFibGU6Nzk2MjA1ZjhiOWVkNDQxOGFmNDQ2MGI2MDRjYmQ1YzgvdGFibGVyYW5nZTo3OTYyMDVmOGI5ZWQ0NDE4YWY0NDYwYjYwNGNiZDVjOF8yLTQtMS0xLTA_d9b89398-9a28-41b6-b34b-ae8bde70b393">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N180Mzk4MDQ2NTE0NDI5_3163de4a-148e-43c5-8885-d8f49292387d">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N18yODk2_052ea60b-046a-4f61-a12d-881594b67d28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i40f86ad979b04ab6b1c5dbf39dc6ca3a_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N180Mzk4MDQ2NTE0NDM3_d4667d0c-3952-4057-8c0c-f915d7bce113"
      unitRef="usd">42102640463</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if78e92be0e5f40fa8335c122c201e968_I20210202"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N180Mzk4MDQ2NTE0NDQx_6d8fa414-0501-42bc-9213-b467b606531a"
      unitRef="shares">152335731</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8xL2ZyYWc6NjIwMDlkNmI4ZGYyNGE3ZGFiMzA0NTFjNjdjMzljODcvdGV4dHJlZ2lvbjo2MjAwOWQ2YjhkZjI0YTdkYWIzMDQ1MWM2N2MzOWM4N181NDk3NTU4MTQyMjAw_8eab54a4-64ee-4d2d-b378-9f7c3e5d448a">Portions of the definitive proxy statement for our 2021 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:Revenues
      contextRef="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMtMS0xLTEtMA_6a0ed653-9f36-475f-9118-4e9e085a0ddc"
      unitRef="usd">10692200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMtMy0xLTEtMA_d75d01e0-2541-47b7-82d2-700b1f3acdd5"
      unitRef="usd">11379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6b7b9a353c2419ca9a01532a522a0d0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMtNS0xLTEtMA_bb196343-62ed-4852-b40e-5d323d7ffdd8"
      unitRef="usd">10886800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzQtMS0xLTEtMA_e3a3e877-3c54-42fc-9aaa-9086bd0f6877"
      unitRef="usd">1977800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzQtMy0xLTEtMA_efc48f75-a41c-42d6-aa19-8d9dc2a10c11"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee2514a987784410a8165984f87269d3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzQtNS0xLTEtMA_c740096a-486f-479a-83c4-68cba75c904b"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzUtMS0xLTEtMA_f947fba1-0902-48f9-b07d-8c0a0bf47db8"
      unitRef="usd">774600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzUtMy0xLTEtMA_c79804dd-b7ce-41a3-9472-2c58fa646b08"
      unitRef="usd">707700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2987b04d4c240d88b84a50c04ca2df1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzUtNS0xLTEtMA_c90658c4-4d94-447b-9994-0cd1981ebb49"
      unitRef="usd">585900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzYtMS0xLTEtMA_dbab5c81-4baa-4401-be65-4e1e8f4108fc"
      unitRef="usd">13444600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzYtMy0xLTEtMA_91199dfd-96fd-45c5-92a9-72a7831cb3ce"
      unitRef="usd">14377900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzYtNS0xLTEtMA_6f681e2d-1e3a-4251-a6b9-06f704c62b6e"
      unitRef="usd">13452900000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzgtMS0xLTEtMA_eef6523a-b8b6-4ee6-a006-553625085322"
      unitRef="usd">1805200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzgtMy0xLTEtMA_71b2c323-16ce-4bb3-b00e-77a5ecce6e12"
      unitRef="usd">1955400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzgtNS0xLTEtMA_858b18d8-74c2-4d7b-a345-d8981b130e54"
      unitRef="usd">1816300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzktMS0xLTEtMA_56f8f66e-b6e2-463a-9f1f-74d4fa9331ef"
      unitRef="usd">3990900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzktMy0xLTEtMA_2f7b9b2f-922c-44a2-9064-114bc5c8b105"
      unitRef="usd">2280600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzktNS0xLTEtMA_c8b3a1b1-31bc-478b-af12-458d5312879a"
      unitRef="usd">2597200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEwLTEtMS0xLTA_493d001a-31d5-448d-9eef-8a8cbf2b93e4"
      unitRef="usd">2504500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEwLTMtMS0xLTA_4e5f88d7-79be-4ced-b3b4-1e81c4875036"
      unitRef="usd">2374700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEwLTUtMS0xLTA_89157830-5e01-4c03-a866-cee49f428590"
      unitRef="usd">2106300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzExLTEtMS0xLTA_1ac5d9c5-36b8-4c39-b95a-140896767d61"
      unitRef="usd">464800000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzExLTMtMS0xLTA_8b31c47d-fba5-48bb-8733-fac9a2d3ebd8"
      unitRef="usd">489900000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzExLTUtMS0xLTA_04b25b28-b92d-481d-98b0-838dae1accfa"
      unitRef="usd">747300000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:CollaborationProfitSharing
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEyLTEtMS0xLTA_4cc55e99-f6a2-4ac4-9a36-a22dcfbc7d82"
      unitRef="usd">232900000</biib:CollaborationProfitSharing>
    <biib:CollaborationProfitSharing
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEyLTMtMS0xLTA_19047871-4441-4705-9043-97710f99b907"
      unitRef="usd">241600000</biib:CollaborationProfitSharing>
    <biib:CollaborationProfitSharing
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEyLTUtMS0xLTA_3e10c045-5a9b-4952-af17-09e75395fc8f"
      unitRef="usd">185000000.0</biib:CollaborationProfitSharing>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEzLTEtMS0xLTA_ad47f4d4-d55c-435a-b56c-80b0f46f5d82"
      unitRef="usd">-92500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEzLTMtMS0xLTA_a02358aa-eca5-40aa-a64e-6f9516d2e872"
      unitRef="usd">55300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzEzLTUtMS0xLTA_8f616f62-ee96-4de8-9e2a-b4dbbd6b4cd2"
      unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE0LTEtMS0xLTA_12ef2c84-5bf3-43fe-8e4c-a3b74b560779"
      unitRef="usd">86300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE0LTMtMS0xLTA_78e12663-3168-4f52-ae7e-d17196e32575"
      unitRef="usd">63700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE0LTUtMS0xLTA_0ad70e9d-a678-46b8-a71e-137ca12ada96"
      unitRef="usd">12300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE1LTEtMS0xLTA_662bc6db-6d0b-4a8c-a0e2-f0f6aa7cd824"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE1LTMtMS0xLTA_f1fadb9a-c5e4-497e-8133-789926d14f01"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE1LTUtMS0xLTA_21dda23a-239e-47da-9f04-b2b8d3ac7ce5"
      unitRef="usd">112500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:RestructuringCharges
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE2LTEtMS0xLTA_b9f9831f-2a96-4510-a4ed-eeeb49b8ecf8"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE2LTMtMS0xLTA_66288863-9f27-419c-9bf7-e1d0d612db53"
      unitRef="usd">1500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE2LTUtMS0xLTA_ab88dba6-a715-4149-a097-615ce683ebaa"
      unitRef="usd">12000000.0</us-gaap:RestructuringCharges>
    <us-gaap:CostsAndExpenses
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE3LTEtMS0xLTA_da22813f-66ce-49da-ad05-576c9c66bfee"
      unitRef="usd">8894500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE3LTMtMS0xLTA_0156f7b3-4eca-4e2f-96ca-49619d18fc41"
      unitRef="usd">7335300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE3LTUtMS0xLTA_5250c2dd-762e-49a2-ad92-dde4b970e035"
      unitRef="usd">7564300000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE4LTEtMS0xLTA_f1b6f877-f5cb-4cb7-87b2-f7bb9eb620cb"
      unitRef="usd">4550100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE4LTMtMS0xLTA_aaf2f99b-701b-48b8-a268-fad53fd08199"
      unitRef="usd">7042600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE4LTUtMS0xLTA_5da4dba7-872c-4af2-a074-707b41942b7e"
      unitRef="usd">5888600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE5LTEtMS0xLTA_d631a5ad-0f99-419a-9708-f8882a1bd5df"
      unitRef="usd">497400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE5LTMtMS0xLTA_cb31198c-5afb-4b79-ae46-82fa17c9ba26"
      unitRef="usd">83300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzE5LTUtMS0xLTA_6d62b742-5690-403f-b523-31c8b5833b3e"
      unitRef="usd">11000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIwLTEtMS0xLTA_de91a2f4-19eb-430b-a3a4-94b95e640379"
      unitRef="usd">5047500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIwLTMtMS0xLTA_e061a02b-dbe1-4f2c-b30b-b23750e0e3d3"
      unitRef="usd">7125900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIwLTUtMS0xLTA_ac052457-374f-4b5a-acca-d0b90f75b22b"
      unitRef="usd">5899600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIxLTEtMS0xLTA_d5c80daf-ad4d-4e58-a691-bb3ec1a6e7c9"
      unitRef="usd">992300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIxLTMtMS0xLTA_001fd664-fa1d-4311-9e67-9ffc8420a40b"
      unitRef="usd">1158000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIxLTUtMS0xLTA_655cb870-fba3-4264-ae03-49fe45df790b"
      unitRef="usd">1425600000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIyLTEtMS0xLTA_874c1b90-9013-4e90-b149-21ccec4c57ce"
      unitRef="usd">5300000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIyLTMtMS0xLTA_c6c2a85e-4fd8-43de-ab38-1e8b35f54ad9"
      unitRef="usd">-79400000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIyLTUtMS0xLTA_9de92976-7de5-4631-a0c0-d8e7f86ea466"
      unitRef="usd">0</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIzLTEtMS0xLTA_0c3f9af9-8954-48ca-b3b4-64e5692abfe5"
      unitRef="usd">4060500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIzLTMtMS0xLTA_23e4385f-0da2-423a-932d-457932858469"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzIzLTUtMS0xLTA_a264a1a7-39aa-4fc3-b41f-0354abc3522d"
      unitRef="usd">4474000000.0</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI0LTEtMS0xLTA_d73666b1-d083-4444-a42f-2d721496835c"
      unitRef="usd">59900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI0LTMtMS0xLTA_16f6adea-9953-4ff0-8e63-caa8643c6083"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI0LTUtMS0xLTA_39696b29-8b71-4168-b1d4-6fb7a1aa9066"
      unitRef="usd">43300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI1LTEtMS0xLTA_7d30276c-2f36-42fe-8d56-a35e9c945746"
      unitRef="usd">4000600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI1LTMtMS0xLTA_02b38495-3b55-4d5e-b123-c81f06e42aa7"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI1LTUtMS0xLTA_a4055183-d607-42de-ac78-50653ae3a2da"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI3LTEtMS0xLTA_0d399f58-471c-4b6b-906b-ef38d59f11fe"
      unitRef="usdPerShare">24.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI3LTMtMS0xLTA_801767ff-68ab-4415-9270-0fe64143be88"
      unitRef="usdPerShare">31.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI3LTUtMS0xLTA_d74ad986-b3f4-41ac-90a3-98948130bc39"
      unitRef="usdPerShare">21.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI4LTEtMS0xLTA_dd96bb7e-4dc5-4d5b-88e1-2e020536282d"
      unitRef="usdPerShare">24.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI4LTMtMS0xLTA_b0ab0aab-559c-4eed-b34f-d325eeae5dac"
      unitRef="usdPerShare">31.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzI4LTUtMS0xLTA_51743bd1-8b4c-47a2-a297-e85b4ed077de"
      unitRef="usdPerShare">21.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMwLTEtMS0xLTA_79556e69-4273-48cc-961d-bc083d8cef82"
      unitRef="shares">160900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMwLTMtMS0xLTA_6f35df45-1fef-4c87-8bb4-40177a6b55e0"
      unitRef="shares">187100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMwLTUtMS0xLTA_c97aa078-df90-44fc-ad10-c34f1711293c"
      unitRef="shares">204900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMxLTEtMS0xLTA_497ba59f-3ad3-419f-84bf-981fd717cfdb"
      unitRef="shares">161300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMxLTMtMS0xLTA_90c26f62-f30f-4616-8a5b-416126a1b026"
      unitRef="shares">187400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMTcvZnJhZzozNjU5NmRhNWYwMGQ0MGQ3YTMxODc1ZTdhZTMxMDJjZS90YWJsZTplZGViYzkzOWVkMTg0NTQzOTIzNmQ2OWIwNjhjZjkyYS90YWJsZXJhbmdlOmVkZWJjOTM5ZWQxODQ1NDM5MjM2ZDY5YjA2OGNmOTJhXzMxLTUtMS0xLTA_262b1bc5-76d0-49d9-a25b-5337bb89c94d"
      unitRef="shares">205300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzItMS0xLTEtMA_1f1a4227-36e6-46de-92d0-f5889ba8f287"
      unitRef="usd">4000600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzItMS0xLTEtMA_bd351670-df4f-46c1-8529-9f70297623f1"
      unitRef="usd">4000600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzItMy0xLTEtMA_82156a64-df9f-4f0f-96c8-b85976149037"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzItNS0xLTEtMA_39e0b859-211c-4cfc-b6ca-da4637599341"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzctMS0xLTEtMA_70f2c868-48f2-4f8f-aa26-9278f649dfcc"
      unitRef="usd">-2800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzctMy0xLTEtMA_0027d693-3e40-4257-92d7-cbd208fb52e0"
      unitRef="usd">8200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzctNS0xLTEtMA_b222add3-e57b-4105-9e36-bb226912b88c"
      unitRef="usd">-3900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzExLTEtMS0xLTA_a1e73acd-374d-4d47-b8f7-3455c1cf5aa2"
      unitRef="usd">-186800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzExLTMtMS0xLTA_021efb02-a2a5-443e-8c36-7678ac9b5b15"
      unitRef="usd">-26900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzExLTUtMS0xLTA_8683b4c2-9f94-4665-bec6-69cff99c40ff"
      unitRef="usd">139200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE1LTEtMS0xLTA_e1f31523-a79c-4b42-b17c-694eb87c3e61"
      unitRef="usd">-33600000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE1LTMtMS0xLTA_e5a4c352-6b0d-4095-8329-9ceb3e2db0f0"
      unitRef="usd">21600000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE1LTUtMS0xLTA_e5a66552-6b50-41a3-a139-6c7b4998473c"
      unitRef="usd">3500000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE2LTEtMS0xLTA_637eb254-3905-434c-8843-682ebd1303c1"
      unitRef="usd">33500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE2LTMtMS0xLTA_34bfaafa-e942-4fea-85c4-b78b72e5fd68"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE2LTUtMS0xLTA_64ab6763-eb43-4e4d-89a3-5994ef8c35a2"
      unitRef="usd">-5500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE3LTEtMS0xLTA_b658834b-84e5-4f36-81d7-3db2791fb83f"
      unitRef="usd">92900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE3LTMtMS0xLTA_dcf31c51-2534-49f9-a5ee-156563793286"
      unitRef="usd">103800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE3LTUtMS0xLTA_3694e81e-87c0-4eaa-a264-48ce1f70f68c"
      unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE4LTEtMS0xLTA_d207f341-f57d-4622-a0b2-a8062d316320"
      unitRef="usd">-163800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE4LTMtMS0xLTA_b9be0ff1-a292-4143-a2e8-1559cd369d67"
      unitRef="usd">105200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE4LTUtMS0xLTA_c897683d-fb17-44f5-8d90-ad6240e120d6"
      unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE5LTEtMS0xLTA_ee1fdc85-4f85-49e2-8b78-effdcf2bcedd"
      unitRef="usd">3836800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE5LTMtMS0xLTA_4dad0fe7-dab7-4cc8-924c-06864afc1b4b"
      unitRef="usd">5993700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzE5LTUtMS0xLTA_28d14a00-a0d0-4421-855a-a36756e584b6"
      unitRef="usd">4507200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIwLTEtMS0xLTA_787bc7bb-4204-4c2e-aabd-0a6e2bde7598"
      unitRef="usd">60900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIwLTMtMS0xLTA_c378b798-2f48-4bdf-a267-02839761fe53"
      unitRef="usd">-400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIwLTUtMS0xLTA_cac08277-8e12-4f1a-8e1d-ab13b7906337"
      unitRef="usd">42900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIxLTEtMS0xLTA_1ec2703b-17fd-411f-902e-597d33abecaa"
      unitRef="usd">3897700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIxLTMtMS0xLTA_49e055d6-e655-43ec-bf66-7c8cb3833c3d"
      unitRef="usd">5993300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjAvZnJhZzo2MTRjM2I0YjllZTk0ZWNkOWE1YWRjNWFiOWYzYTk2NS90YWJsZTpmMTczNDQxMWIwOGQ0MmYyOWYzN2E3OTI5NzQ5ODNiMy90YWJsZXJhbmdlOmYxNzM0NDExYjA4ZDQyZjI5ZjM3YTc5Mjk3NDk4M2IzXzIxLTUtMS0xLTA_59b1107e-3897-447a-a346-d47e82b8d207"
      unitRef="usd">4550100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQtMS0xLTEtMA_b1ef6ec9-2269-4bc6-aa4b-16e20f669f9a"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQtMy0xLTEtMA_f2ab034b-1d26-4a21-bf5d-fe211cba581a"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzUtMS0xLTEtMA_99d0ee14-a1b0-4902-a3c6-23dbe96b5e04"
      unitRef="usd">1278900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzUtMy0xLTEtMA_1ee8c363-2923-4df0-8312-9132261bf082"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzYtMS0xLTEtMA_b5be3808-c102-47f8-a474-7861428f70f2"
      unitRef="usd">1913800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzYtMy0xLTEtMA_adc00297-4535-47ea-9742-6e05a7d1fed1"
      unitRef="usd">1880500000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DueFromUnconsolidatedJointBusiness
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzctMS0xLTEtMA_10d01db8-ed9a-42c4-944d-58e32af077f6"
      unitRef="usd">413500000</biib:DueFromUnconsolidatedJointBusiness>
    <biib:DueFromUnconsolidatedJointBusiness
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzctMy0xLTEtMA_59aceeff-3129-4e90-b339-73c73f99435d"
      unitRef="usd">590200000</biib:DueFromUnconsolidatedJointBusiness>
    <us-gaap:InventoryNet
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzgtMS0xLTEtMA_e653f7c1-f03b-4a4c-ac3d-f9dd14dca079"
      unitRef="usd">1068600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzgtMy0xLTEtMA_8868d1dc-1c66-40b5-86b0-ba757f6234e2"
      unitRef="usd">804200000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzktMS0xLTEtMA_8daf8a86-434f-4566-8447-654b608e7ba6"
      unitRef="usd">881100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzktMy0xLTEtMA_fca07f8d-31df-48e0-beea-ace91f4e7572"
      unitRef="usd">631000000.0</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEwLTEtMS0xLTA_7b839713-7e0a-41b4-a83d-eff486d67d49"
      unitRef="usd">6887100000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEwLTMtMS0xLTA_c80b196a-bb23-4226-bab9-c2c1bff6c6d1"
      unitRef="usd">8381800000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzExLTEtMS0xLTA_1a422415-77f5-48a2-ab15-91e0f19a1de7"
      unitRef="usd">772100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzExLTMtMS0xLTA_e70db56a-4cf2-413b-b2e2-da25fe96d8cb"
      unitRef="usd">1408100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEyLTEtMS0xLTA_4b4acb3d-26b8-4742-8893-42557fb2fb21"
      unitRef="usd">3411500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEyLTMtMS0xLTA_ca3da1d3-b66a-4ea7-ab3f-adcc70bb5821"
      unitRef="usd">3247300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEzLTEtMS0xLTA_40cf13fc-a08a-47c5-8452-2da32ed84d88"
      unitRef="usd">433300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzEzLTMtMS0xLTA_f4db3866-c81a-44cd-88e9-d5b08eac4348"
      unitRef="usd">427000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE0LTEtMS0xLTA_8456b4aa-3dee-4405-af78-e6e5673d1670"
      unitRef="usd">3084300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE0LTMtMS0xLTA_b60aeaf6-0586-4e4a-a082-04b00dc87cc6"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE1LTEtMS0xLTA_a77c347d-93bb-422a-8003-f229c3b6995b"
      unitRef="usd">5762100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE1LTMtMS0xLTA_e6db83e6-e5aa-40cb-b276-048351308adc"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE2LTEtMS0xLTA_60d3d9d2-222c-405c-ad36-4e355ad8ff0f"
      unitRef="usd">1369500000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE2LTMtMS0xLTA_155fd86f-fa01-49d8-873b-a332ad51cfc0"
      unitRef="usd">3232100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE3LTEtMS0xLTA_2589f4c8-d412-4d4d-8dcd-d6fdb1db0f14"
      unitRef="usd">2899000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE3LTMtMS0xLTA_a00fca2d-5db8-45b7-ae7f-b0002884de59"
      unitRef="usd">1252800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE4LTEtMS0xLTA_faa9e37f-da62-402a-a4c3-8bf0c7e5f982"
      unitRef="usd">24618900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzE4LTMtMS0xLTA_4c3bfbb9-731d-4a3b-a946-1a752dbc3de8"
      unitRef="usd">27234300000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIxLTEtMS0xLTA_782c6424-0211-4dff-a35c-9f9f923a784c"
      unitRef="usd">0</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIxLTMtMS0xLTA_0ff4b27b-2e25-488c-9256-d7edf77b5427"
      unitRef="usd">1495800000</us-gaap:DebtCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIyLTEtMS0xLTA_140ca0ec-4250-4770-8edb-ebe5cfaff837"
      unitRef="usd">142000000.0</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIyLTMtMS0xLTA_ddc5a544-c843-4592-8ef7-19214d974b42"
      unitRef="usd">71400000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIzLTEtMS0xLTA_20372949-0c89-4fec-a0c8-ed490fe03ed4"
      unitRef="usd">454900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzIzLTMtMS0xLTA_3a279423-543a-4efb-ab2e-1c6af18ce8e0"
      unitRef="usd">530800000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI0LTEtMS0xLTA_d7991e02-8133-4de2-a4a4-735905bf19ee"
      unitRef="usd">3145300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI0LTMtMS0xLTA_030c49a0-dec2-46fa-be85-fa67757854bf"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI1LTEtMS0xLTA_e0b21e58-b8b5-4290-bd4f-f4b98edacb1f"
      unitRef="usd">3742200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI1LTMtMS0xLTA_6ca31f47-fcf4-42a8-9670-a932f0185a89"
      unitRef="usd">4863800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI2LTEtMS0xLTA_4c96d10f-26fd-4078-876c-1ddcbef3085e"
      unitRef="usd">7426200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI2LTMtMS0xLTA_493900fe-052a-4fe0-9d8a-7854720a1b53"
      unitRef="usd">4459000000.0</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI3LTEtMS0xLTA_e07459c7-22bd-4353-816f-e0ddf286a9fb"
      unitRef="usd">1032800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI3LTMtMS0xLTA_b68f8627-2bdc-4513-8d5e-f3b5a0c41b3c"
      unitRef="usd">2810800000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI4LTEtMS0xLTA_0f3e01ef-aa3e-4beb-a8eb-8bd227597d17"
      unitRef="usd">402000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI4LTMtMS0xLTA_4fff9cc2-fae6-402e-8c54-e0c32b16b397"
      unitRef="usd">412700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI5LTEtMS0xLTA_741a9778-b152-47d3-951a-71e87093a261"
      unitRef="usd">1329600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzI5LTMtMS0xLTA_d8c41ac3-757e-4c28-935b-72792430b02b"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzMwLTEtMS0xLTA_d38a796e-3e65-42f8-beca-b05d8bf96a8f"
      unitRef="usd">13932800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzMwLTMtMS0xLTA_1c137325-246d-4b3f-b535-f9f3a0219d16"
      unitRef="usd">13895200000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzMxLTEtMS0xLTA_8d3d3595-0381-4bfd-9404-ece022b41964"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzMxLTMtMS0xLTA_e107d668-bf4b-4363-8ad0-da57244c217d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM0LTEtMS0xLTA_92e92c83-381d-4397-abda-9366bf3e47eb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM0LTMtMS0xLTA_0d15d2dd-674d-4c72-b969-afa8595a1b54"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM1LTEtMS0xLTA_5919609e-77e5-4e59-a219-a6636d599344"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM1LTMtMS0xLTA_d55e24fe-01b9-439f-8bd8-68708ad5c891"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM2LTEtMS0xLTA_269205ae-1c89-4b02-96c1-7050e85f7c67"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM2LTMtMS0xLTA_2ecc3cca-b8f2-46fb-87fb-766257ec50a9"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM3LTEtMS0xLTA_5e63fb09-1653-41b5-9dc2-d35926845fe6"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM3LTMtMS0xLTA_b3019de6-5b63-4eb1-a70f-d10f4d7cb89e"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM4LTEtMS0xLTA_f778d447-7cac-41ec-971d-27a6f38282e6"
      unitRef="usd">13976300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM4LTMtMS0xLTA_69f368b9-17b8-4dea-854b-846e8d875120"
      unitRef="usd">16455400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM5LTEtMS0xLTA_3b336f2a-e52e-4224-8cc0-2f98a887f47b"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzM5LTMtMS0xLTA_17c77a46-7b49-4546-a9b6-424d471d87f2"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQwLTEtMS0xLTA_dc774520-ddf3-4748-b1b1-a6064e19556c"
      unitRef="usd">10700300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQwLTMtMS0xLTA_4b2a5c87-3a73-48f3-93fc-22ac9e63ae2b"
      unitRef="usd">13343200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQxLTEtMS0xLTA_e9949627-91e4-441b-a4ce-48224b4578ad"
      unitRef="usd">-14200000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQxLTMtMS0xLTA_ed48a5b9-51c0-4b9b-a68b-0bdbe5dfcd1f"
      unitRef="usd">-4100000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQyLTEtMS0xLTA_69e6b8cf-d4ce-401a-a1dd-3a2c12f293c8"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQyLTMtMS0xLTA_5b720d50-9863-4d41-ba53-1fae1cd3828f"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQzLTEtMS0xLTA_adf00792-8c40-44e1-8b8a-42fc88872972"
      unitRef="usd">24618900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjMvZnJhZzowY2JlM2FhNjc4NGQ0YWI3YTU3ZDJkMTg2ZjlhOTYwOC90YWJsZTpmZjgzMWUxN2NiZTE0MzFlODVmMjU2NDdhMWY3MDRmZS90YWJsZXJhbmdlOmZmODMxZTE3Y2JlMTQzMWU4NWYyNTY0N2ExZjcwNGZlXzQzLTMtMS0xLTA_3be81fb2-aac7-4502-9c5d-6aa2eefc90eb"
      unitRef="usd">27234300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMtMS0xLTEtMA_b86eddd3-7fe7-446b-8bde-cec12b3fcc35"
      unitRef="usd">4060500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMtMy0xLTEtMA_f3c1a507-cb6a-4bcf-8d7f-51f880d92bf5"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMtNS0xLTEtMA_2f799ea2-82fc-4b82-a6f8-3c4d75e06ea7"
      unitRef="usd">4474000000.0</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzUtMS0xLTEtMA_7eb482ab-bc35-45e1-91b9-6f0e90ce2507"
      unitRef="usd">457200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzUtMy0xLTEtMA_df35fbfe-6a43-4159-b866-da90a88715f7"
      unitRef="usd">464700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzUtNS0xLTEtMA_f296fdbb-0f27-4945-916e-686d448438f2"
      unitRef="usd">650500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtMS0xLTEtMjE2Nzg_90adba3e-5a47-43db-baf5-004027d3873b"
      unitRef="usd">209700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtMy0xLTEtMjE2Nzg_e954b077-19ac-4ba7-b274-6979fbc6ecd0"
      unitRef="usd">215900000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtNS0xLTEtMjE2Nzg_a262c99c-097a-45e7-b9b0-2257db73bc87"
      unitRef="usd">366100000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtMS0xLTEtMA_63355d92-b5fd-412c-8707-de5b818afaa9"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtMy0xLTEtMA_dd4357fe-c29b-49d6-85e4-9b14806e08a7"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzYtNS0xLTEtMA_1d2d0ceb-dabc-4ab9-9914-f027f71ea5de"
      unitRef="usd">112500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzctMS0xLTEtMA_7d3c922b-d393-4132-9bf9-7682d5cdc865"
      unitRef="usd">198300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzctMy0xLTEtMA_8337dcda-6431-4103-934b-7aed2d69a823"
      unitRef="usd">182300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzctNS0xLTEtMA_78175732-930e-4d2d-b79a-bed56132a6b0"
      unitRef="usd">157500000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzgtMS0xLTEtMA_37c67447-f12a-4f27-b7a2-e525c794058e"
      unitRef="usd">86300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzgtMy0xLTEtMA_74f7befe-bb19-42bb-a94f-5ae3d062cc79"
      unitRef="usd">63700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzgtNS0xLTEtMA_f77cdf18-cffc-4687-9d07-9dec17c4b193"
      unitRef="usd">12300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzktMS0xLTEtMA_77c6d651-0c5d-4984-8c1d-c8b46cfa0ef4"
      unitRef="usd">92500000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzktMy0xLTEtMA_7d935ce7-66ca-4aa7-9c76-92e430822a8b"
      unitRef="usd">-55300000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzktNS0xLTEtMA_328240c4-afe2-4994-9245-be4966bf97cd"
      unitRef="usd">0</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTEtMS0xLTM2NQ_f34621e5-e3ed-463f-8ed0-4407e3485c99"
      unitRef="usd">149000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTMtMS0xLTM2NQ_8db84ea4-58cd-4df1-b871-852fae018865"
      unitRef="usd">67100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTUtMS0xLTM2NQ_3f50fa7e-6b06-4710-860a-4bdf370299d1"
      unitRef="usd">108300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTEtMS0xLTM2NQ_88060e66-885b-49d8-9454-20a16635273b"
      unitRef="usd">681800000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTMtMS0xLTM2NQ_790c3b25-4a17-45ed-a870-55b73607ed9b"
      unitRef="usd">147300000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTUtMS0xLTM2NQ_26ccf3cd-f383-4626-b6a9-0ca12c908718"
      unitRef="usd">124800000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTEtMS0xLTA_30cb7239-3611-488e-9568-1a41dd14f35e"
      unitRef="usd">3300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTMtMS0xLTA_6b04d078-7607-4c26-a869-e8e597e1ef48"
      unitRef="usd">-77400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEwLTUtMS0xLTA_391ebe2d-540e-4793-8510-f6de8d7838b6"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTEtMS0xLTA_c21fdc8f-5537-4931-8c79-50b6771779a3"
      unitRef="usd">-131200000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTMtMS0xLTA_125ec36b-46cd-45e0-9251-7c2005a66680"
      unitRef="usd">-139100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzExLTUtMS0xLTA_f910a181-a802-47d2-8c0b-33386d1d5ae6"
      unitRef="usd">-55700000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEzLTEtMS0xLTA_ff790642-19e4-49a6-b535-1e653b1eddf2"
      unitRef="usd">-2800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEzLTMtMS0xLTA_0e7a01e1-6ef5-495e-98be-d26467e79a5f"
      unitRef="usd">-68800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzEzLTUtMS0xLTA_70dc3a63-ff89-4927-b81c-16b8e3ab9b9c"
      unitRef="usd">205200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE0LTEtMS0xLTA_7acce0be-21e2-4c4c-a9cb-e8abc1a5f102"
      unitRef="usd">-176700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE0LTMtMS0xLTA_af708612-518f-464a-95b0-b98379c9ace6"
      unitRef="usd">63300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE0LTUtMS0xLTA_bdb08695-9aee-470d-8743-5726611bd40e"
      unitRef="usd">-5700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE1LTEtMS0xLTA_2aadddde-f59b-4849-8c38-73511f8d87ae"
      unitRef="usd">316300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE1LTMtMS0xLTA_e5ea0823-a9b7-406b-ba16-cc478eb6c679"
      unitRef="usd">19200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE1LTUtMS0xLTA_bc65de68-59ca-4ccd-ae56-e4d1b9be2c72"
      unitRef="usd">52100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE2LTEtMS0xLTA_1977d2ab-dca4-47a0-9b71-e4587a5fb60c"
      unitRef="usd">154200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE2LTMtMS0xLTA_b9f9e3cd-6191-4abc-aa06-dfe8462f3453"
      unitRef="usd">240200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE2LTUtMS0xLTA_e3d2e145-d06a-49ec-9ae0-88fc7522fdc1"
      unitRef="usd">465500000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE3LTEtMS0xLTA_453c84d8-5e67-487b-b34b-a5746f3457eb"
      unitRef="usd">-67500000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE3LTMtMS0xLTA_31c5c724-9207-4126-9e52-57c0612d17a8"
      unitRef="usd">16100000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE3LTUtMS0xLTA_d3ae9f64-1303-4d63-bbbb-6dee289d51c0"
      unitRef="usd">321700000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE4LTEtMS0xLTA_e511d5df-f020-45f4-a424-108ead068106"
      unitRef="usd">-137100000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE4LTMtMS0xLTA_76605f8c-3a61-482a-8f2a-aaa4723779fe"
      unitRef="usd">-43300000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE4LTUtMS0xLTA_b3fdd135-6de7-404e-85de-5b675c156d0a"
      unitRef="usd">-135400000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE5LTEtMS0xLTA_b0eaa635-4317-466e-9ec5-fafa85af9042"
      unitRef="usd">4229800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE5LTMtMS0xLTA_abd0cb1e-48f9-427b-bb6a-68800ada09cd"
      unitRef="usd">7078600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzE5LTUtMS0xLTA_39eb8c9c-144b-4b68-a579-2c8021d43d20"
      unitRef="usd">6187700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIxLTEtMS0xLTA_8dc6c6f4-c9a2-49dc-9d43-46c24e3f3cb5"
      unitRef="usd">7299400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIxLTMtMS0xLTA_7c093993-588b-4a23-a138-fa031ffc7c41"
      unitRef="usd">6007000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIxLTUtMS0xLTA_9dbcf1c5-0779-4aa2-947f-fb383d9289a9"
      unitRef="usd">9173700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIyLTEtMS0xLTA_4da23522-817c-4e7a-91b1-d1fcc94c0438"
      unitRef="usd">6397700000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIyLTMtMS0xLTA_64c5dd73-8784-457c-b25e-1f9677d8a3f1"
      unitRef="usd">5252600000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIyLTUtMS0xLTA_08c16bd7-4d0b-4573-84e7-f73c634ee7fc"
      unitRef="usd">7694800000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIzLTEtMS0xLTA_8d0a459d-1024-4b8b-a043-4e4bbd41392f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIzLTMtMS0xLTA_b2809460-6941-4605-a048-56b227bd0b6b"
      unitRef="usd">300000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzIzLTUtMS0xLTA_cf8570ee-b6f9-4040-b978-7b9e12ab9a7a"
      unitRef="usd">1500000000.0</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI0LTEtMS0xLTA_3c3d81d7-1819-49c4-b384-0bf45d66ad0b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI0LTMtMS0xLTA_f497bf42-0610-4176-97ef-c623285c8968"
      unitRef="usd">744400000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI0LTUtMS0xLTA_833011aa-e426-4670-968a-9b19d59943d1"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i4fe07a7c7dc0443dbe2b2303dcf1a9ed_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTEtMS0xLTk3Mjk_8f9bd5dc-19b0-4dd7-979e-8a05d008e0bb"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ic832cd7b75cb4db1947131a9ca6ada7d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTMtMS0xLTk3Mjk_902fa7b3-57f3-4b36-93e4-40628cf9e4f0"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i947f2882d6404d2ebbe95236b59c95ef_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTUtMS0xLTk3Mjk_f48aa1d4-e61b-4716-a5be-3ecc7a088b87"
      unitRef="usd">462900000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ifcf0372b542a4a81867022b7653fddbb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTEtMS0xLTMyMA_12f7a1c5-cada-4566-90fa-0279cfde40b2"
      unitRef="usd">141800000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="id3b225a61fc749cf835625b8fa6246b6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTMtMS0xLTMyMA_f2bd6a26-c947-4cb5-bb20-82308d58c601"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i6ba23f55f1d1462cb337f7f348d52f17_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTUtMS0xLTMyMA_0a93753b-a6dd-428d-a3e9-98fc0eefacc9"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i7685594c21ff48f6aa4a4ab8e67bd590_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTEtMS0xLTMyMA_30c1fed3-e3b1-4cd1-af0d-cba65c926c51"
      unitRef="usd">423700000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i3565d89e31c04fe69d700b215cbfe265_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTMtMS0xLTMyMA_6ba37d53-e254-4804-ba28-2bef0bfc5784"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ic36a6dbaa4344c37a9dc77f2cda681cf_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTUtMS0xLTMyMA_f498cbc7-b481-4168-b2dd-d8417d2cf249"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ic116ea7c17b449929c5b3e40bf3fc147_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI5LTEtMS0xLTIyMDA_257ba48c-c7f4-4c7e-9e6a-84815d5399df"
      unitRef="usd">441000000.0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="iacfecdd3de364249bf6dd9e13df58609_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI5LTMtMS0xLTIyMDA_cbdf4517-8511-44b5-8b1e-7fa8909a7601"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ia9808ec312874199952c2b8c5ee0b580_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI5LTUtMS0xLTIyMDA_733f4f55-eab9-465c-aee3-eaea830f4feb"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTEtMS0xLTA_144bc972-cfee-43c4-8cbe-1ea89bf98bde"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTMtMS0xLTA_b4c5c68e-e88e-4053-9ce0-937997c12150"
      unitRef="usd">923700000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI1LTUtMS0xLTA_946bce5d-2563-4e01-9633-64c69584bf5f"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTEtMS0xLTA_0028c75f-e279-4886-9645-c4079546f49e"
      unitRef="usd">424800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTMtMS0xLTA_108cba38-fc41-49df-a42f-ff09d9e30703"
      unitRef="usd">514500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI2LTUtMS0xLTA_b85de27f-8dbd-4198-a2cb-1f550107a6a0"
      unitRef="usd">770600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTEtMS0xLTA_74723211-625c-4624-9b0e-1ed819569cdb"
      unitRef="usd">75000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTMtMS0xLTA_9bc3a2b8-f49e-4202-a91a-8b2698649062"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI3LTUtMS0xLTA_db9e763b-4d39-441d-9b6c-dabdbca6b341"
      unitRef="usd">112500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI4LTEtMS0xLTA_5f83b703-46b4-4674-8156-9cdc9fa85706"
      unitRef="usd">52000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI4LTMtMS0xLTA_a66bb1bc-e648-485f-b084-e680ba4ebb99"
      unitRef="usd">155000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzI4LTUtMS0xLTA_5c450535-86ac-4048-bd30-7208537b4beb"
      unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMwLTEtMS0xLTA_91f56fda-5823-45c2-919a-b2762a680e64"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMwLTMtMS0xLTA_f351d8af-89ee-4536-9360-266ac5669201"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMwLTUtMS0xLTA_48328eb6-b067-4244-abca-95d78b6a9d98"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMxLTEtMS0xLTA_ea794243-fb5a-4982-a419-5e69cf6201a0"
      unitRef="usd">74900000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMxLTMtMS0xLTA_c397f5f7-7e5d-451d-a289-9aee695faedd"
      unitRef="usd">479300000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMxLTUtMS0xLTA_1158e27b-6b17-45bf-a7d0-80cdcb479cdd"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMyLTEtMS0xLTA_eb6e40a8-156f-4299-b59f-ddb636cf1cbe"
      unitRef="usd">26900000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMyLTMtMS0xLTA_10d8f971-8279-468d-8291-0abe59e4c2d2"
      unitRef="usd">-27000000.0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMyLTUtMS0xLTA_c6dd2196-44de-4187-add5-e845855fb4c0"
      unitRef="usd">-400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMzLTEtMS0xLTA_a5b3efd3-2b71-41df-a7ad-7514fd7f6e92"
      unitRef="usd">-608600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMzLTMtMS0xLTA_593e2a15-f316-41b0-874c-7d5f14ec9c1c"
      unitRef="usd">470500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzMzLTUtMS0xLTA_2a5d2f14-e8d1-43a0-966b-56b95ea36856"
      unitRef="usd">-2046300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM1LTEtMS0xLTA_4d9da11d-e28d-468f-ae2b-459690e7b909"
      unitRef="usd">6679100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM1LTMtMS0xLTA_0a7fb270-65df-4f5c-bde4-69791569fc35"
      unitRef="usd">5868300000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM1LTUtMS0xLTA_5b2f390a-ac1d-4211-9526-e4677d612181"
      unitRef="usd">4352600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM2LTEtMS0xLTA_424c5030-1a6e-4a33-8bfa-e1d96d1d7016"
      unitRef="usd">4600000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM2LTMtMS0xLTA_12694025-4383-40d6-87f2-c3164b859bd4"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM2LTUtMS0xLTA_fa88a4d1-57be-4833-8f24-b9317ee4fac8"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM3LTEtMS0xLTA_1d20679e-e6dd-400d-b36d-efa1fff11eeb"
      unitRef="usd">2967400000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM3LTMtMS0xLTA_b72595d8-71eb-4788-a6ed-64642316432d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM3LTUtMS0xLTA_388aa909-686d-459e-a7ae-4c6fd4f7694b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTEtMS0xLTM0Ng_759cc718-e0da-4c40-8f01-44f6a204112e"
      unitRef="usd">1500000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTMtMS0xLTM0Ng_5480068b-800b-452c-ba8b-65f893313fcf"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTUtMS0xLTM0Ng_f5f9c264-e095-412c-879a-0c3e6222740c"
      unitRef="usd">3200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfCapitalDistribution
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM4LTEtMS0xLTA_da31919f-b8f9-4118-9516-a52006fa132e"
      unitRef="usd">71000000.0</us-gaap:PaymentsOfCapitalDistribution>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM4LTMtMS0xLTA_ea032372-6c19-4327-8459-b9c92e612d6f"
      unitRef="usd">4300000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:PaymentsOfCapitalDistribution
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM4LTUtMS0xLTA_3450eb10-c6ea-4129-8d1b-342cb6dccd0f"
      unitRef="usd">36400000</us-gaap:PaymentsOfCapitalDistribution>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM5LTEtMS0xLTA_42cc4b83-805b-496f-b901-37a25ad0be7f"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM5LTMtMS0xLTA_9a7fd22d-2538-40c7-889f-1155659519ac"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzM5LTUtMS0xLTA_6e66d137-aa8a-4456-8fef-afa47f54fd48"
      unitRef="usd">58200000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTEtMS0xLTA_add76988-1a77-4e6c-b882-d48263f1af34"
      unitRef="usd">14600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTMtMS0xLTA_37cfddd3-690c-442c-8b85-a6229932011d"
      unitRef="usd">3600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQwLTUtMS0xLTA_c8a41fef-4f74-42c3-9d3e-5d488d1bc012"
      unitRef="usd">-21600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQxLTEtMS0xLTA_286574d9-799f-44e3-a7f9-4af9527b940c"
      unitRef="usd">-5272700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQxLTMtMS0xLTA_e3743575-64a7-4f6b-9bb9-ce90f4bd44bc"
      unitRef="usd">-5860400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQxLTUtMS0xLTA_eafb6660-1ebc-4de2-867c-1e3703a423d4"
      unitRef="usd">-4472000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQyLTEtMS0xLTA_dc16848b-a616-4216-bd04-0781beba92ff"
      unitRef="usd">-1651500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQyLTMtMS0xLTA_d93868fa-758a-4baf-a9b9-e15f9c99895e"
      unitRef="usd">1688700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQyLTUtMS0xLTA_f15a2700-3309-4adb-a123-fa56b952dd22"
      unitRef="usd">-330600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQzLTEtMS0xLTA_21d461e5-a5ee-4cf0-bd37-dc52771bc65b"
      unitRef="usd">69000000.0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQzLTMtMS0xLTA_f28d2e34-dd2a-4915-87b6-0f328ed44ae7"
      unitRef="usd">400000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQzLTUtMS0xLTA_671a4e5a-0a50-4a22-ab33-5f3e3047c0ac"
      unitRef="usd">-18600000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ0LTEtMS0xLTA_e3df1643-c781-4311-80e2-11b479d7048b"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ0LTMtMS0xLTA_cad7d86f-d8ea-4615-a56a-3c343d543221"
      unitRef="usd">1224600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic9925b2c3e594ae0812001969da2a99b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ0LTUtMS0xLTA_13fc22c8-0393-477d-aee4-97a6c5f28b6e"
      unitRef="usd">1573800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ1LTEtMS0xLTA_ad4da943-c52e-4d02-af63-b8ab8ecebee8"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ1LTMtMS0xLTA_dbbaf1d4-ec84-49a3-a27b-2ee89db8fad6"
      unitRef="usd">2913700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMjkvZnJhZzoyOGZkNjgxMWU2NzY0NmMzYjYwYzMwMDAxMDJmMmU0ZS90YWJsZTpjMjIxYTEzMTNkYjE0ODcwYTdiYmFjYTdkODI5OTkzZC90YWJsZXJhbmdlOmMyMjFhMTMxM2RiMTQ4NzBhN2JiYWNhN2Q4Mjk5OTNkXzQ1LTUtMS0xLTA_6cca8dba-2e9a-4ffb-81e6-52f5642a017f"
      unitRef="usd">1224600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SharesIssued
      contextRef="idae041b402f34f1db7c9617616121bba_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMS0xLTEtMA_d3b7d754-bf1e-4306-b1db-87fc25ed9067"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idae041b402f34f1db7c9617616121bba_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMy0xLTEtMA_5edb59d7-16c8-4c1a-a7df-6f78426f18d9"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6c314d6d1f964bfe879cbff831677e6d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItNS0xLTEtMA_e646cc9b-65a2-47df-ba0c-a1428d0f4ea3"
      unitRef="shares">198000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c314d6d1f964bfe879cbff831677e6d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItNy0xLTEtMA_fa9cf6e0-ca76-4517-94d8-afd5a1555c26"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b238312a99c4acda7452e34a406431c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItOS0xLTEtMA_f3f1f7ce-3b5b-4903-a348-70dd9dd28e86"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8631cd953f3488583e5a99f0aa067ea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTEtMS0xLTA_680897c9-9d7f-4b20-9a46-ac0604e43e64"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ideb28add0da94e2984281d36c212a6b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTMtMS0xLTA_c9fcef3d-43f8-49d9-a781-08c19be2a4d0"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ieafb8a83622d4c7d83aa7f731407ace6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTUtMS0xLTA_34e86bdd-5bc9-478b-8338-ebbf26baba08"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieafb8a83622d4c7d83aa7f731407ace6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTctMS0xLTA_db09ed42-4a36-4497-96a8-5b9b1fd61c16"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia32b478b02b043de86c4b4db94343ae7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMTktMS0xLTA_8876fcae-fa64-4171-81fa-fd00cf9ed984"
      unitRef="usd">13343200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia04b4d5aa1794922b920009486d15ab9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMjEtMS0xLTA_5143037d-5937-463b-b6a2-dbd9dd24fa34"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzItMjMtMS0xLTA_0c79558d-873f-417b-b1e5-bdb6dec2f832"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i59c8c0fefae64f87b0c7f553d3c884e9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzMtMTMtMS0xLTA_442c2379-bf23-409b-845e-4cbbd1587d59"
      unitRef="usd">4000600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzMtMTktMS0xLTA_09455b8c-3930-497c-af59-8ca9ae655015"
      unitRef="usd">4000600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzMtMjEtMS0xLTA_bb404fca-c899-4f90-91f1-42b3d7a3d4b4"
      unitRef="usd">59900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzMtMjMtMS0xLTA_eab893d0-a794-4c95-9166-2db821fac8f3"
      unitRef="usd">4060500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9730f32121bf4c97a3efb7cd327a3f8b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzQtMTEtMS0xLTA_33b1e0e2-460e-4f2f-b769-8c6c62e922f2"
      unitRef="usd">-163800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzQtMTktMS0xLTA_5f1b4f09-5dc7-436c-8a1b-edfa929df531"
      unitRef="usd">-163800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzQtMjEtMS0xLTA_1f36ed60-57b2-497c-a0cc-e9ff76f98bbe"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzQtMjMtMS0xLTA_9f6f46e1-f41d-47ee-a350-7c2d8d106051"
      unitRef="usd">-162800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMjEtMS0xLTE1NDY5_25621e69-1ce0-4f77-a7dd-9b659a6c6638"
      unitRef="usd">75000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMjMtMS0xLTE1NDY5_ecd0f5d3-cb72-49d0-84d3-db812a8ce82a"
      unitRef="usd">75000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMTktMS0xLTA_cdb39b5f-e7cf-4979-9c1b-7f67b4875022"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="ie70bae3ad5d54f528b6056517e45ae1a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMjEtMS0xLTA_4b8a9a2f-f2e4-4d33-b5d5-aaee12fb379a"
      unitRef="usd">4000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzUtMjMtMS0xLTA_f55bce22-6eba-4c8c-a31b-bec4dc79b7d3"
      unitRef="usd">4000000.0</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTUtMS0xLTIyMDg_4608c08a-7084-45d5-8460-044d2ecce6ea"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTctMS0xLTIyMDg_293c7642-0453-4a51-a439-0b7f8385e26a"
      unitRef="usd">400000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie7b0512c1ef74ccf9a55f06a601135a6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTktMS0xLTIyMDg_98cbce5f-362e-486e-b835-4c14f26adfba"
      unitRef="usd">400000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMjMtMS0xLTIyMDg_c2d2b4ce-f2d8-412c-8a19-116a8c42c14a"
      unitRef="usd">400000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i02dd29564939484da19f114c7ad6568e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctNS0xLTEtMjIwOA_d45b1d75-d281-4cca-a647-03b6e0949b95"
      unitRef="shares">1600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ifba1e5d98e494036a7bb6347485e7fd7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctOS0xLTEtMjIwOA_91659103-59ec-4672-ae77-2d2a4879dfa3"
      unitRef="usd">60800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i5dfc1fefbed7417cbbc28aa6ac0dd8b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTMtMS0xLTIyMDg_1d9e2b2f-434e-4195-add6-47484dda89d3"
      unitRef="usd">339200000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTUtMS0xLTIyMDg_9238072c-8b33-4c7d-a58c-bc0fefe6bf1c"
      unitRef="shares">1600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if7609f5b3bca4d5ba6097ac0e73f1454_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTctMS0xLTIyMDg_72a084c1-62e3-4ad5-9eb8-0273039b1d7d"
      unitRef="usd">-400000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMjMtMS0xLTIyMDg_25bcad78-fd1f-4e3c-80ee-30affa49d745"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTUtMS0xLTA_673d7f7a-0b54-4944-bd62-f24d5a929866"
      unitRef="shares">16700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTctMS0xLTA_dcbfd9bf-7a19-4e11-821f-73a0fbc3c6a6"
      unitRef="usd">5000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iead28cb9adf24fb08e016c9daa3a77d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMTktMS0xLTA_7e0d5074-7e1d-412e-8cc5-665111aad021"
      unitRef="usd">5000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzYtMjMtMS0xLTA_b888cc7a-c51e-41ca-8ee1-01c648ed74db"
      unitRef="usd">5000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i20ed583992094d77bff487c7db1d1673_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctNS0xLTEtMA_f78b97f6-7720-41c3-805f-93c45f13daa7"
      unitRef="shares">16700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id631f87e609f40da8cd804801bbf81b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctOS0xLTEtMA_fd37426a-5e69-4a46-82b6-80ecc93845fc"
      unitRef="usd">121300000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibd77c6e9bea747df9f7e454828986d8a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTMtMS0xLTA_1c58b9b6-73fd-4919-a45b-209642294fa2"
      unitRef="usd">4878700000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTUtMS0xLTA_3268b655-d41d-480b-8098-cd69d044a19e"
      unitRef="shares">16700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibe9bf95ceee749ce8eb94f0af2cdf493_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTctMS0xLTA_b665eced-c700-4568-90b1-a9b4ba3a52b9"
      unitRef="usd">-5000000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iead28cb9adf24fb08e016c9daa3a77d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMTktMS0xLTA_3d5a4eae-4a17-4ed4-9c57-ad98b65fc9e0"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzctMjMtMS0xLTA_d683476b-0e2e-4fa4-b8b1-db2841e6146c"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzgtMTUtMS0xLTA_3d0705bb-e888-4591-b3e4-5a4b81a39856"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzgtMTctMS0xLTA_ced32f7d-2176-4175-881d-c3e254176547"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i399ba008e6b14b85b6ac84920d61a3c7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzgtMTktMS0xLTA_e6a54007-4c8a-4f52-a9eb-41bc55638983"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzgtMjMtMS0xLTA_5ac702e5-d086-4ffb-91d9-a8d4fa67fd5b"
      unitRef="usd">1279100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2f98217bbb834e0f8ebd6c2398b7661d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktNS0xLTEtMA_42f5e1ed-1613-4251-94e5-e412026cc662"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i79a84661ca7648508fd93941bcbb997d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktOS0xLTEtMA_9f05c2b5-186a-436a-b15d-d26c31ba0f5c"
      unitRef="usd">71000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i79397f44d5c042f496ceeab9b494a03a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMTMtMS0xLTA_0b0c7eab-0ec4-4f34-960e-e8fb2bb5a3c7"
      unitRef="usd">1208100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMTUtMS0xLTA_a8ba6ac1-9f95-4ec9-83d1-dd5eb3209b61"
      unitRef="shares">4100000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id888392d95a84e559d5be9d1aa49165e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMTctMS0xLTA_b68e96d0-30cb-4bc9-bfb1-f05692cdd03c"
      unitRef="usd">-1279100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i399ba008e6b14b85b6ac84920d61a3c7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMTktMS0xLTA_50141fb1-8170-4287-9180-4a8fa43d2554"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzktMjMtMS0xLTA_88b01fbb-20aa-4a35-8ab6-d90611cfaac0"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i3b33fe470a0f4f07ae856080b1a72e21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTUtMS0xLTA_cf3c7bbb-a775-477b-89b0-7308da57de38"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTktMS0xLTA_cfc8aeb7-98d1-4991-a949-0f70513ba71b"
      unitRef="usd">49300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i59c8c0fefae64f87b0c7f553d3c884e9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTEzLTEtMS0w_869e9f5e-9e2f-4f2b-91b3-29adde72841d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTE5LTEtMS0w_d27bd5e5-e2f2-4741-9242-ea7ff46186f5"
      unitRef="usd">49300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEwLTIzLTEtMS0w_e14c7b66-b721-49b9-8317-f402f0ce0491"
      unitRef="usd">49300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3b33fe470a0f4f07ae856080b1a72e21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTUtMS0xLTA_3c9c1c87-8f6c-493c-880f-17a8fb7f7b28"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTktMS0xLTA_65be729a-a762-4487-a466-0c71a1d7c2fb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i59c8c0fefae64f87b0c7f553d3c884e9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTEzLTEtMS0w_6ad377c5-2193-436a-a40a-0183c79f33bd"
      unitRef="usd">-53700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTE5LTEtMS0w_30ac9815-e8f7-4bb7-bd75-f33ebe6da24e"
      unitRef="usd">-53700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzExLTIzLTEtMS0w_08234b98-9916-4c8e-9113-1b643358b9af"
      unitRef="usd">-53700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEyLTktMS0xLTA_005553b8-08bc-4171-8aad-9fdac794ae3b"
      unitRef="usd">-204500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEyLTE5LTEtMS0w_8f2340b9-74d5-43bb-ab30-8e9431b75d5c"
      unitRef="usd">-204500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEyLTIzLTEtMS0w_f4a34f6d-403d-47c6-8537-98f94cda6b05"
      unitRef="usd">-204500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i59f32f978c114ab19917faf1ea3258d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzE1LTktMS0xLTE0NzMz_669ee8b9-14dc-48ed-80f1-4876ae3f458f"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i47815bc75e7a4befb716fba4531dd04f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzE1LTE5LTEtMS0xNDczMw_bdf5dd36-711b-4666-a805-d20432c1ada7"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzE1LTIzLTEtMS0xNDczMw_38450888-ef17-4bb7-be33-acfbccd8a382"
      unitRef="usd">700000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="id652954848994c64a952bdd912f71f14_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTEtMS0xLTA_29cd5ffe-900d-4943-aec0-085d934c8478"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id652954848994c64a952bdd912f71f14_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTMtMS0xLTA_d8ff432f-88ac-4d54-a6d6-c1f7e5f36db3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="if56588187b87454685183cbffc3ada80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTUtMS0xLTA_823532f9-2cd5-4fb9-92cf-9f09b2beaf3f"
      unitRef="shares">176200000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if56588187b87454685183cbffc3ada80_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTctMS0xLTA_b5633b01-1053-4435-8098-874dd1b4ddb9"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69e4e6dae85540218e42aba08c3a9ecc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTktMS0xLTA_63ce514a-422a-4caa-88b1-a02a149cc1a4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7957fd5108f041cf86733aef419c0487_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTExLTEtMS0w_b804ce9f-c924-422e-a6f9-41978432873b"
      unitRef="usd">-299000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icdeb7d5b926d493e962de8b221ba05e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTEzLTEtMS0w_ab7c2492-8550-482c-bba0-d7962d9740d5"
      unitRef="usd">13976300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iccbf67b67a6f4ef8b20a95e69c600436_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTE1LTEtMS0w_0db8a8c4-c360-4a73-8546-3da8c842d0b9"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccbf67b67a6f4ef8b20a95e69c600436_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTE3LTEtMS0w_a799dbcb-ada9-4b31-98d0-dc6f8fd95ab2"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a1a9b4290144caba8998988eecf9b58_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTE5LTEtMS0w_12c60f49-4698-4911-a1a0-4af6e0c069b2"
      unitRef="usd">10700300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i004794513a2f4fcd8eace5db98fbe94d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTIxLTEtMS0w_388daf79-76f3-4033-bb79-f3755feec8e9"
      unitRef="usd">-14200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTplOTMxNDA1OWIyMjg0YjljOGZjOWY1ZWU0MTc4OTkzMC90YWJsZXJhbmdlOmU5MzE0MDU5YjIyODRiOWM4ZmM5ZjVlZTQxNzg5OTMwXzEzLTIzLTEtMS0w_5ed4ac4a-da3f-4b01-a678-f978ed2e6a90"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMS0xLTEtMA_ef583f0f-beec-4596-96b5-c59651fc82bf"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMy0xLTEtMA_ad1e98e7-0668-4190-980e-34b52a828018"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i7fbbd190dd9349c684025d6612613087_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItNS0xLTEtMA_c1ede944-c5c2-48db-9c95-39d4809062c7"
      unitRef="shares">221000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fbbd190dd9349c684025d6612613087_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItNy0xLTEtMA_0ff4814b-78ba-4619-af15-99a02da2e0df"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10bc4925779c4c62a721fcebc24cc43a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItOS0xLTEtMA_8695d8f2-c139-43fc-b2e3-ce8200e6fc9d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTEtMS0xLTA_dae4eeb5-7eda-442c-a15c-5f12d5f63186"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd9ccd986ede408889b471271b8b92ab_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTMtMS0xLTA_6cdfe49d-679a-4cc9-a560-35a058889a24"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i71879223335b46f3bb3d2e9c89f29739_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTUtMS0xLTA_6932990a-d044-4fc2-b711-768064c5a0ee"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71879223335b46f3bb3d2e9c89f29739_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTctMS0xLTA_2b243290-f148-41ad-9a91-a7208ea2cc98"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0408f46008684d05830c8aaf3c8d10a9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMTktMS0xLTA_07f01686-881b-4f2c-9370-1abd19c38012"
      unitRef="usd">13039600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1627e985e4343de929ab7dfd5658901_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMjEtMS0xLTA_6a4dbbfc-023a-4780-b8ae-0adba6d784e5"
      unitRef="usd">-8000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzItMjMtMS0xLTA_d9b99a8e-8582-41ac-abe7-5d5f2d339d7b"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i70263815613a400b92f377b89a761d52_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzMtMTMtMS0xLTA_375d88e1-b531-4f98-9a4d-31ea4457e3a2"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzMtMTktMS0xLTA_485b417c-b4af-4800-a972-0d51a0a8b4dc"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzMtMjMtMS0xLTA_fe1e728f-7a17-42ce-b8e1-0fd28c666ffb"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i743aafca54fa41abb7393b53cca04663_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzQtMTEtMS0xLTA_ea90ce5a-8c9e-4e96-b0ba-124f2df4385c"
      unitRef="usd">105200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzQtMTktMS0xLTA_2ce38e9f-7500-4e74-bb0a-35f1e401efcb"
      unitRef="usd">105200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if23b90bc2339453c813e349dde6eb88c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzQtMjEtMS0xLTA_2ef1327e-9ff0-4b04-97bb-5cd118545943"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzQtMjMtMS0xLTA_99778351-eaf0-4c7f-9990-7c2ed3de5bc0"
      unitRef="usd">104800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzUtMTktMS0xLTA_164faa2c-2e4c-4225-898a-d7993bf5c884"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="if23b90bc2339453c813e349dde6eb88c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzUtMjEtMS0xLTA_da71c9a4-2f6b-4a6b-99a3-ef1dd00b7af4"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzUtMjMtMS0xLTA_2ef80d20-7889-4a69-9278-c85ad08bcff1"
      unitRef="usd">4300000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzctMTUtMS0xLTA_3a00dafd-b552-4ad5-9c08-e69ee52a2c1e"
      unitRef="shares">14700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzctMTctMS0xLTA_851107dc-6e95-495a-a1e2-cda626d18d40"
      unitRef="usd">3720900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if5788dc676f14d319251454a02fc807d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzctMTktMS0xLTA_d8e045e9-663c-460d-98fa-0d35f3a6a76b"
      unitRef="usd">3720900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzctMjMtMS0xLTA_bf12aca1-4f5a-46a1-b92f-7b2b0e598f03"
      unitRef="usd">3720900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i918c175a6348429f80750ffad3e51592_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtNS0xLTEtMA_879ee7ad-0d98-414a-96b1-0d1dfdaab3aa"
      unitRef="shares">14700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i918c175a6348429f80750ffad3e51592_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtNy0xLTEtMA_e3d94417-1784-4d16-bd8f-f14b74404e0c"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i561f5ec343c3430f81b526c7ba3bf33d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtOS0xLTEtMA_a71ca01f-3251-4674-b281-a72d55dc6e0f"
      unitRef="usd">121500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i127bbeecda744fa68a10a6e33a60cd1a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMTMtMS0xLTA_22d9775d-bd25-4a2e-8da7-a4f8b01a855b"
      unitRef="usd">3599400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMTUtMS0xLTA_c27bd346-a3ad-4ac2-9a19-4d2fd3650900"
      unitRef="shares">14700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ia942b55166ad455392b7fc91fe0e01a5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMTctMS0xLTA_2d683fcb-5a8a-41da-b571-fabfda36bdce"
      unitRef="usd">-3720900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if5788dc676f14d319251454a02fc807d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMTktMS0xLTA_4d935214-2477-4137-909e-e5d1b279a656"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzgtMjMtMS0xLTA_1709d07e-16ff-4a7b-a040-6e0fd4f5fd59"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if96513171bce497b9a51c54f048f8529_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzktMTUtMS0xLTA_564c8af5-e47a-4cfe-ac1f-78523c8007e9"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if96513171bce497b9a51c54f048f8529_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzktMTctMS0xLTA_2f75c3a4-5993-45ff-b74c-7f717c5a18f6"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i77516ed4d6a7476c85c01147c2202ad8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzktMTktMS0xLTA_00b20804-fff2-42c4-93e2-4da025a0417e"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzktMjMtMS0xLTA_05597185-3777-4e46-a2f9-775c8aa4acc6"
      unitRef="usd">2147400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ic1a8269e77864460833b3ae44b188fbe_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTUtMS0xLTA_d60e559a-651b-49ab-a1e3-15fdfc81163d"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic1a8269e77864460833b3ae44b188fbe_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTctMS0xLTA_e00fc764-4f4f-4810-9427-7af59b6d3f67"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="icff528a7cfce4bd8a0366f490246b62e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTktMS0xLTA_11c36647-d4d1-486f-a2ff-c23da0055103"
      unitRef="usd">110500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="id60b675c71ae45dcba471a7e7fe41934_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTEzLTEtMS0w_c8c39bff-d80f-4280-83f5-f58d3c8e1f60"
      unitRef="usd">2036900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="if96513171bce497b9a51c54f048f8529_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTE1LTEtMS0w_a0be81ff-9882-451f-ae30-6384e892a0eb"
      unitRef="shares">8900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if96513171bce497b9a51c54f048f8529_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTE3LTEtMS0w_32565517-e590-41fc-99e8-bbbd4b28f9ef"
      unitRef="usd">-2147400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i77516ed4d6a7476c85c01147c2202ad8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTE5LTEtMS0w_aed2259f-1ddd-446b-a55e-3e26a07cfa46"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEwLTIzLTEtMS0w_5606dde9-c17f-406b-adc6-02960af91ab0"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTUtMS0xLTA_3180426e-1358-4c04-8e3a-3d8787852b8d"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTctMS0xLTA_df546d13-a892-4a78-8b8f-caeedd73629b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ib7d567bbbce0486f8cfdae0a70a3f4ee_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTktMS0xLTA_e6bf00b2-7369-4498-a244-2a979bacc558"
      unitRef="usd">40800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTE5LTEtMS0w_0c08a876-c6b5-43ea-ab07-7198a7d056a4"
      unitRef="usd">40800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzExLTIzLTEtMS0w_6cdad9be-1f48-4075-ad2e-af2d42258694"
      unitRef="usd">40800000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTUtMS0xLTA_4e40a7d8-6145-4a4d-b9a6-c0c70c52ca3a"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i819f5bd5ad724f809a59b73db434367e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTctMS0xLTA_9f322c7f-a6bb-4609-8321-9bd16d444432"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i70263815613a400b92f377b89a761d52_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTEzLTEtMS0xNDc_93d98a0a-7134-4f62-a9e0-9cd47052e94d"
      unitRef="usd">-53800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTE5LTEtMS0w_5721b31e-155c-4e99-babc-20fca467b6dd"
      unitRef="usd">-53800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEyLTIzLTEtMS0w_36435a32-4a61-4a68-a19d-918e5843f4e5"
      unitRef="usd">-53800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib7d567bbbce0486f8cfdae0a70a3f4ee_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEzLTktMS0xLTA_1704913e-3c04-4119-bcfb-ad0746ca65cd"
      unitRef="usd">-191200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb7d2450d0074950bb9e4681ad83abdc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEzLTE5LTEtMS0w_98ba6799-64a7-4bd8-a74f-89771154d2f8"
      unitRef="usd">-191200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzEzLTIzLTEtMS0w_7cde9fd8-2e7f-4c0b-ad81-ee07b5a5fb36"
      unitRef="usd">-191200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesIssued
      contextRef="idae041b402f34f1db7c9617616121bba_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTEtMS0xLTA_c69b4b5f-ea40-4305-9621-13b948791b0a"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idae041b402f34f1db7c9617616121bba_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTMtMS0xLTA_7d79ef2b-eb74-4c97-9252-b21d4c1447b7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6c314d6d1f964bfe879cbff831677e6d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTUtMS0xLTA_97762a7e-df6d-49b5-92d9-748ff28b665f"
      unitRef="shares">198000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c314d6d1f964bfe879cbff831677e6d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTctMS0xLTA_b9e56e35-3de5-4c0f-b7a7-2e6086fe6c70"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b238312a99c4acda7452e34a406431c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTktMS0xLTA_bbcff1df-c46e-4430-96aa-a86610cd6e1b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8631cd953f3488583e5a99f0aa067ea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTExLTEtMS0w_680897c9-9d7f-4b20-9a46-ac0604e43e64"
      unitRef="usd">-135200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ideb28add0da94e2984281d36c212a6b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTEzLTEtMS0w_7cc4456d-1cbb-4dae-84c4-ae6cf59b94e9"
      unitRef="usd">16455400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ieafb8a83622d4c7d83aa7f731407ace6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTE1LTEtMS0w_23cfc941-0d81-4313-90ad-16f023092ee5"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieafb8a83622d4c7d83aa7f731407ace6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTE3LTEtMS0w_5311d5d2-40ad-47cd-a10a-b404e54f8fa2"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia32b478b02b043de86c4b4db94343ae7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTE5LTEtMS0w_85d8fd1f-997f-45e4-aee6-2df8dcb1282b"
      unitRef="usd">13343200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia04b4d5aa1794922b920009486d15ab9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTIxLTEtMS0w_54d8c824-74dc-4c62-9bbf-cfd90e474c00"
      unitRef="usd">-4100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozYmY2N2EwYzI1Y2I0Zjg2YjZmMTlhMmQwZDExZmE0NC90YWJsZXJhbmdlOjNiZjY3YTBjMjVjYjRmODZiNmYxOWEyZDBkMTFmYTQ0XzE1LTIzLTEtMS0w_97f8e8d4-1e4a-4232-80e5-81be9a0a0537"
      unitRef="usd">13339100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i23b12db8472d48b2b53334bb866cc37b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMS0xLTEtMA_e6bc581b-4803-4494-9246-066f2cef2ad4"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i23b12db8472d48b2b53334bb866cc37b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMy0xLTEtMA_75de622d-7480-4d46-954c-29eb13427643"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6de8222bfb764bc7976ec9ac1b1fcfee_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItNS0xLTEtMA_657aae1f-f69f-4ce4-a5af-fe31a2c566da"
      unitRef="shares">235300000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6de8222bfb764bc7976ec9ac1b1fcfee_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItNy0xLTEtMA_2d04f6fd-09fe-4556-8771-46c5af042a37"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32099e94310245729c8234363676b11a_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItOS0xLTEtMA_9a0a79d6-83df-4e8d-880e-4cfd752451ba"
      unitRef="usd">97800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01ad07778ac849c8b2b4e37c57f5c8cc_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTEtMS0xLTA_0200f2f6-8498-4642-b6e3-34eb1a59288b"
      unitRef="usd">-318400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71e785004dde49f0a56829b6f56ed277_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTMtMS0xLTA_87a973b7-c3ae-4f99-a7a6-4d0954c293a1"
      unitRef="usd">15810400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i4ca3a2e6fcb04f20be394cdde7a54e82_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTUtMS0xLTA_a0d9e9c9-b4fb-4785-87ae-71f0e4246d67"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4ca3a2e6fcb04f20be394cdde7a54e82_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTctMS0xLTA_5435908d-c2ea-49dc-b533-b1ba6ee3bc22"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i878381e1afac4f80a13bd087ea6d9e3c_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMTktMS0xLTA_a207a9b0-f506-4073-8745-cef0f374fea0"
      unitRef="usd">12612800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb9c26e9c2e84acbaf8ec47d303849df_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMjEtMS0xLTA_30eed16d-b071-4d59-90be-de1f3618d488"
      unitRef="usd">-14700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9925b2c3e594ae0812001969da2a99b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzItMjMtMS0xLTA_7e19166c-4b4c-466c-8e03-5b11db24b928"
      unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib6054bf321ca4765a1d083cac2ace95d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzMtMTMtMS0xLTA_964d916b-36f0-460f-869a-dba582027670"
      unitRef="usd">4430700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzMtMTktMS0xLTA_c071d6fb-b218-434c-aa22-c3a9dc952921"
      unitRef="usd">4430700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i60249b902884484cb11d0cb33e879fff_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzMtMjEtMS0xLTA_f90dc29e-f74b-435c-b49c-20e56134cc50"
      unitRef="usd">43300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzMtMjMtMS0xLTA_3428b721-de58-4cf1-a5f8-47d5f06e69c7"
      unitRef="usd">4474000000.0</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide6cf3bb3d4e468189726437ef50fcc4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzQtMTEtMS0xLTA_ceadda8c-6340-463c-8fbb-95d687793842"
      unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzQtMTktMS0xLTA_f0af5b3d-139c-43d0-b75a-48d0f1bb62e2"
      unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i60249b902884484cb11d0cb33e879fff_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzQtMjEtMS0xLTA_7cd5df1c-5a22-40c5-87c8-65e70048c0fe"
      unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzQtMjMtMS0xLTA_965db46e-57c2-40b8-b3a3-1d9d46af661b"
      unitRef="usd">76100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzUtMTktMS0xLTA_32a923d2-5668-4b65-875a-94ead912ff12"
      unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i60249b902884484cb11d0cb33e879fff_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzUtMjEtMS0xLTA_3c956a60-7e9c-47f8-8610-460ac560c7f6"
      unitRef="usd">13800000</biib:Noncontrollinginterestincreasedecreaseother>
    <biib:Noncontrollinginterestincreasedecreaseother
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzUtMjMtMS0xLTA_f907af7f-fee5-4c6e-a4db-bc9cf4d1459b"
      unitRef="usd">13800000</biib:Noncontrollinginterestincreasedecreaseother>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzYtMTktMS0xLTA_96cdb74b-5be5-49f8-af7a-cdd595cda473"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i60249b902884484cb11d0cb33e879fff_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzYtMjEtMS0xLTA_494ddb35-c3ed-4370-9966-c26d7ca206eb"
      unitRef="usd">50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzYtMjMtMS0xLTA_38f05d48-362b-4c0a-8e34-a58f66dfff19"
      unitRef="usd">50000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzctMTUtMS0xLTA_b860f7cb-0521-4e65-806e-2426171084f1"
      unitRef="shares">4300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzctMTctMS0xLTA_58f2f848-898a-4c63-9e07-f86c3902dd14"
      unitRef="usd">1352600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie6e22ca2059f4f898210fe8a9df07b93_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzctMTktMS0xLTA_3fa734bb-2f3f-487e-b23b-63cd773f4b9e"
      unitRef="usd">1352600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzctMjMtMS0xLTA_1392a74a-4b36-4d55-80bb-64cf055e9a75"
      unitRef="usd">1352600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ie81db584ecd34c3fb0bcfcd6b6c8bef2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtNS0xLTEtMA_1b3a786f-fba4-4cec-b4fe-296df1d22d1a"
      unitRef="shares">4300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ie81db584ecd34c3fb0bcfcd6b6c8bef2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtNy0xLTEtMA_74fddc02-57a5-4d6e-84fe-c8d991c8fdca"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i481a6d5bdbbe43a5980efa84e275da23_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtOS0xLTEtMA_6b4da7db-c269-4165-9458-3778aa72e4a1"
      unitRef="usd">92800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i8450111dafb6479dad6f805a7b7d9e08_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMTMtMS0xLTA_0fc4b517-c6b8-40d2-9e90-4264b8540338"
      unitRef="usd">1259800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMTUtMS0xLTA_808035ff-3459-4aa3-ab5d-15ecd083f4c7"
      unitRef="shares">4300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i6c492006c7894daa9fff4b14a663716c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMTctMS0xLTA_f3b90551-ad87-41f8-9fb0-1de16f55b1e7"
      unitRef="usd">-1352600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ie6e22ca2059f4f898210fe8a9df07b93_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMTktMS0xLTA_72211748-95c5-4401-bd4e-3aafcd7ab2ee"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzgtMjMtMS0xLTA_9c8546cb-e9ff-434d-b45b-17c1179248d6"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzktMTUtMS0xLTA_35a6e638-fe7d-4c7f-91b0-ae2e21d75d08"
      unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzktMTctMS0xLTA_ad877bef-0b2f-4f12-86c5-36edbed262e1"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i084deb1b42c44169a52d93eca76466ef_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzktMTktMS0xLTA_bcd74fed-ef17-46bf-8a68-57c73e0711a5"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzktMjMtMS0xLTA_07cda3c4-4bef-48f7-b7e5-aee37181146b"
      unitRef="usd">3000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ib5d4919f13974879958994e93ea3e69e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTUtMS0xLTIwNQ_27ba7549-0344-4401-9d57-2f9230711d46"
      unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ib5d4919f13974879958994e93ea3e69e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTctMS0xLTIwNQ_0c4b7db5-563a-4714-bfa6-90ee574b9a5a"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic1acabe726ab40d4b398592903594e20_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTktMS0xLTIwNQ_8547ba76-dbab-4efb-824a-3c6e2da12d99"
      unitRef="usd">171100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i837a6587aeba49309a36ff845c583cc1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTEzLTEtMS0yMDU_1ca84c1d-004a-4391-adb8-320f20e600e5"
      unitRef="usd">2828900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTE1LTEtMS0yMDU_0fe9b87e-a133-4d65-ad1d-ce2449c14161"
      unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i2c6cd0497ca5496080c151da8a89a136_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTE3LTEtMS0yMDU_ffcf4020-8af9-4a34-bd66-001c0aa6043d"
      unitRef="usd">-3000000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i084deb1b42c44169a52d93eca76466ef_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTE5LTEtMS0yMzM1_2c9477fe-ac36-4b69-9b86-170a22d5e497"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTIzLTEtMS0yMzM1_577d6faa-8e33-4a7f-b245-6023e1b9992c"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="iaa3981c364664bbf965221342c3e8296_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTUtMS0xLTA_19aeff9b-cbd3-4778-9a71-571809ddb0c7"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="iaa3981c364664bbf965221342c3e8296_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTctMS0xLTA_50444105-8102-45b7-8061-ab25c150617b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i26657d5aeb394760be302cf4583f264d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTktMS0xLTA_e94cd8a3-2d3e-4119-a72f-a7d4f603b3f3"
      unitRef="usd">41200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTE5LTEtMS0w_d55c5bc6-222f-4186-b889-c3c7969e20e3"
      unitRef="usd">41200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEwLTIzLTEtMS0w_0d5bc2f0-0f02-444e-b799-8157ae711b69"
      unitRef="usd">41200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iaa3981c364664bbf965221342c3e8296_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTUtMS0xLTA_f8a00b2b-8f66-41e7-9daf-0d31f9516045"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaa3981c364664bbf965221342c3e8296_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTctMS0xLTA_8d8c33b2-2181-47dd-9572-446a1506fbb5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i26657d5aeb394760be302cf4583f264d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTktMS0xLTA_0c2df6d9-d813-462a-a7f5-4e3b743175ad"
      unitRef="usd">-43800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTE5LTEtMS0w_3ce8ad74-81c2-4fdb-bcf0-00457557e0a4"
      unitRef="usd">-43800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzExLTIzLTEtMS0w_9b7398b5-182d-44fd-91f4-436148f4eabc"
      unitRef="usd">-43800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26657d5aeb394760be302cf4583f264d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEyLTktMS0xLTA_15c6b168-60e1-4e8c-829f-5ff3e3d9e873"
      unitRef="usd">-168700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i25edb9ffcaec47d78e2c523871518a40_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEyLTE5LTEtMS0w_aa844d86-ae7b-4d68-8ed9-e18b73194146"
      unitRef="usd">-168700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEyLTIzLTEtMS0w_de831df0-d1ac-41db-8ce7-8861ab445c94"
      unitRef="usd">-168700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i158387b1a5ea437bb6564f068f16da94_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEzLTExLTEtMS0xODQ_51d4ebb0-7483-4061-b470-f1bd4424189d"
      unitRef="usd">1500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8870b4b39a7c4f5db82e81c17a5045ae_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEzLTEzLTEtMS0xODQ_d3c72766-3faa-4e00-a09c-8238a8808666"
      unitRef="usd">104600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie609bb78211648bbb28efbdf966eede3_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEzLTE5LTEtMS0xODQ_16cdf586-fde8-41ac-833e-f7e0550ca2ab"
      unitRef="usd">106100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i946db844720d4aa7917f3e015d7ad5f5_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzEzLTIzLTEtMS0xODQ_8843c909-a768-4a11-9fd0-9326ebd8301c"
      unitRef="usd">106100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTEtMS0xLTA_b745bdf7-d07b-462a-b005-da4392c82e12"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i187c7347284c4f0e9dbeb83e324d2cf9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTMtMS0xLTA_d614b71f-cef5-4f51-883c-cf46e9981a90"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i7fbbd190dd9349c684025d6612613087_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTUtMS0xLTA_d2c86544-59a6-4a79-b163-9736341dddb3"
      unitRef="shares">221000000.0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fbbd190dd9349c684025d6612613087_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTctMS0xLTA_8182654e-2d6f-45f4-8308-8604f89a7a24"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10bc4925779c4c62a721fcebc24cc43a_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTktMS0xLTA_f335a532-431f-46ed-b38a-57af5c999295"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTExLTEtMS0w_3abc8fe4-7921-4898-8f7e-7a0838ca76e1"
      unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd9ccd986ede408889b471271b8b92ab_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTEzLTEtMS0w_68054bec-3c30-4832-8d70-3658e02a921e"
      unitRef="usd">16257000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i71879223335b46f3bb3d2e9c89f29739_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTE1LTEtMS0w_99f49d47-385e-4b2a-a62c-09dec8081228"
      unitRef="shares">23800000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71879223335b46f3bb3d2e9c89f29739_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTE3LTEtMS0w_176e9862-7127-4ef3-83c6-4ea9ba457bff"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0408f46008684d05830c8aaf3c8d10a9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTE5LTEtMS0w_902f12b3-6712-4b5f-b969-0b310f9b1d26"
      unitRef="usd">13039600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia1627e985e4343de929ab7dfd5658901_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTIxLTEtMS0w_364379e7-cefc-4515-8868-1a7eb5494041"
      unitRef="usd">-8000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzIvZnJhZzo4YTQ0M2M5Mzk0Yzg0N2Y0OWI2YzIyYjMwOWVkM2Q3Ny90YWJsZTozMmY3M2Q4NTZjY2Y0ZTAxOWM3MjhmY2VhZmJiYjdhYi90YWJsZXJhbmdlOjMyZjczZDg1NmNjZjRlMDE5YzcyOGZjZWFmYmJiN2FiXzE1LTIzLTEtMS0w_2f872f9b-e059-47b0-b188-f636e6fd83c8"
      unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5NDA2_3e3ba89d-5044-41b7-98a9-e1f0f50ca0ac">Summary of Significant Accounting Policies&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#x2019;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This standard became effective for us on January 1, 2018, and was adopted using the modified retrospective method. The adoption of this standard as of January 1, 2018, did not change our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the coverage patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Pharmacy rebates represent our estimated obligations resulting from contractual commitments to sell products to specific pharmacies. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from contracted discounts on product purchased or product dispensed. The calculation of the accrual for these rebates is based on an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimate of the pharmacy&#x2019;s buying or dispensing patterns and the resulting applicable contractual rebate rate(s) to be earned over the contractual period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product return reserves are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration with Genentech is within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;&#160;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech and the Roche Group. Pre-tax co-promotion profits consist of net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA include estimates that are based on information received from Genentech and the Roche Group. These estimates are subject to change and actual results may differ. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize royalty revenues on sales of OCREVUS based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our relationship with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize royalty revenues related to sales by our licensees of products covered under patents that we own. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Corporate Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of December&#160;31, 2020 and 2019, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#x2019;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities and Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Equity Securities and Venture Capital Funds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evaluating Marketable Debt Securities for Other-than-Temporary Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#x2019;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method of Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitalization of Inventory Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020, we capitalized approximately $93.8&#160;million of pre-launch inventory for aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease that we are developing in collaboration with Eisai Co., Ltd. (Eisai). If aducanumab does not receive regulatory approval in the U.S., we would expense this inventory as research and development expense and, under the terms of our collaboration agreement with Eisai to jointly develop and commercialize aducanumab, Eisai would reimburse us for 45.0% of the costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Obsolescence and Unmarketable Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4NDA_d52adc0a-d056-48aa-8b93-a252ffbfe552"&gt;three&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 to 40&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of the useful life or the term of the respective lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 7&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 20&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer&#160;Software&#160;and&#160;Hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ASU No. 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ASU No. 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ASU No. 2018-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Narrow-Scope Improvement for Lessors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and ASU No. 2019-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately $463.0 million and a corresponding operating lease liability of approximately $526.0 million, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the adoption of the new leasing standards, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include other amounts related to our other marketed products and programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to trademarks, trade names and IPR&amp;amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquired In-process Research and Development (IPR&amp;amp;D)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 24, Segment Information,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Flow and Fair Value Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Investment Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our derivative instruments and hedging activities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9, Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Translation of Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. For the years ended December&#160;31, 2020, 2019 and 2018, advertising costs totaled $111.8 million, $79.2 million and $90.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2016 the FASB issued ASU No. 2016-16,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;$0.5 billion, offset by a corresponding net increase to retained earnings of approximately&#160;$0.5 billion. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;$0.4 billion&#160;with a corresponding reduction to our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for uncertain tax positions using a &#x201c;more likely than not&#x201d; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#x2019;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. Legal costs associated with legal proceedings are expensed when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;above, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards did not have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018 the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard did not have a material impact on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This standard makes targeted improvements for collaborative arrangements as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjM0_b5a8f45b-dd72-4290-ad89-1035b37ea196">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODY3OTk_60896451-0a1c-4fd9-94c5-d6bf9accd589"
      unitRef="product">2</biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjQ1_a9400040-e0b0-493c-a8f6-c1f3849335d9">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzM0Mjg_28af3133-99b2-4f88-b5fd-f92b3f0c6dcd"
      unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjY2_59972f05-e39d-4198-a149-21d25a4a3869">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU0OTc1NTgyMTM1NzM_259bf04e-96db-4452-8236-a4c0f645de16">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This standard became effective for us on January 1, 2018, and was adopted using the modified retrospective method. The adoption of this standard as of January 1, 2018, did not change our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the coverage patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Pharmacy rebates represent our estimated obligations resulting from contractual commitments to sell products to specific pharmacies. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from contracted discounts on product purchased or product dispensed. The calculation of the accrual for these rebates is based on an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimate of the pharmacy&#x2019;s buying or dispensing patterns and the resulting applicable contractual rebate rate(s) to be earned over the contractual period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product return reserves are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration with Genentech is within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;&#160;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech and the Roche Group. Pre-tax co-promotion profits consist of net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA include estimates that are based on information received from Genentech and the Roche Group. These estimates are subject to change and actual results may differ. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize royalty revenues on sales of OCREVUS based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our relationship with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize royalty revenues related to sales by our licensees of products covered under patents that we own. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Corporate Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjQ5_7ad44380-f86c-4523-bd1c-ef79a6d1b75c">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzY0_2e5d5272-8e36-442d-b427-eebcb24e1835">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of December&#160;31, 2020 and 2019, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjI4_ec6af531-39af-4b3e-aa0a-5ae37f7d2374">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within 30 to 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#x2019;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <biib:PaymentTermsOfAccountsReceivable
      contextRef="ic69589c021a84ef3b51246299f3819f4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4MDc_cf128f8e-9d6e-4752-9288-9a0aec9b4a4e">P30D</biib:PaymentTermsOfAccountsReceivable>
    <biib:PaymentTermsOfAccountsReceivable
      contextRef="i6ece1a557c614598b419f009a522970e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4MTM_71f63176-744d-44cd-ad86-bc1a7de79347">P90D</biib:PaymentTermsOfAccountsReceivable>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzQ4_c591bf7e-2396-4d4a-a6e3-c5d7eb84bded">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mzk1_d59ebbb5-1679-4b6d-8809-e3030f6d029c">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Equity Securities and Venture Capital Funds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Marketable Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evaluating Marketable Debt Securities for Other-than-Temporary Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#x2019;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mjc2_b9c1a171-1aa0-4654-b5e6-85427aeae4fc">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjA3_0fe9c434-2d1a-467b-b0b5-413193359619">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitalization of Inventory Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2020, we capitalized approximately $93.8&#160;million of pre-launch inventory for aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease that we are developing in collaboration with Eisai Co., Ltd. (Eisai). If aducanumab does not receive regulatory approval in the U.S., we would expense this inventory as research and development expense and, under the terms of our collaboration agreement with Eisai to jointly develop and commercialize aducanumab, Eisai would reimburse us for 45.0% of the costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Obsolescence and Unmarketable Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:OtherInventoryCapitalizedCosts
      contextRef="ic0b527baa2064e4abdfd753f227e1770_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzI3NDg3NzkxNTU2NzQ_2717c0de-c735-4a8f-bc7c-3ac471158acc"
      unitRef="usd">93800000</us-gaap:OtherInventoryCapitalizedCosts>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1OTczNTY_6c061fe6-9f12-4a31-a184-dd1c57d61518"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mzky_2f829e09-ec0a-4385-8235-4bf22424b151">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4NDA_d52adc0a-d056-48aa-8b93-a252ffbfe552"&gt;three&lt;/span&gt; to five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 to 40&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of the useful life or the term of the respective lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 7&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 20&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer&#160;Software&#160;and&#160;Hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1b4148f6f0e64fcc8d46dde21febd1df_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4MzU_698569d9-3710-4191-8984-92812aa8260e">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU0OTc1NTgyMTM1NzQ_4b018080-ba44-4a95-8956-6d810b8be49e">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Asset Category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Not depreciated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 to 40&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of the useful life or the term of the respective lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 7&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 to 20&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer&#160;Software&#160;and&#160;Hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5&#160;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzIw_2be119f9-856d-4f39-bb0c-02b8a242a8d1">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ASU No. 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ASU No. 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, ASU No. 2018-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Narrow-Scope Improvement for Lessors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and ASU No. 2019-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842): Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately $463.0 million and a corresponding operating lease liability of approximately $526.0 million, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the adoption of the new leasing standards, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4e23f9e905c04daca8cae6b8673c5e1f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzM2ODc3_39757ca5-c5d8-409d-9e83-4601966959bf"
      unitRef="usd">463000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4e23f9e905c04daca8cae6b8673c5e1f_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzM2OTQz_d498f1e3-d324-45a9-b8ec-7ba2fa2a11cd"
      unitRef="usd">526000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjYw_4a896550-497b-4920-b0af-ca144a75dc6a">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include other amounts related to our other marketed products and programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to trademarks, trade names and IPR&amp;amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzIz_f2e39568-67d1-4926-8c62-a989bc2c18ec">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjIx_e256d958-0834-4107-9f0e-d918dbc803ca">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 24, Segment Information,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODY4MDc_cf82a576-3514-4296-9f1e-9b76339dc95d"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjAw_d8d95880-bef7-4447-9ceb-f162f3579d77">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mzgz_656d3064-fb07-42ce-b075-9f3f7b90cd17">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjAx_904f0851-431c-4a37-8a5d-078446ba52dd">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Flow and Fair Value Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Investment Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our derivative instruments and hedging activities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9, Derivative Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzEw_d6a6690e-470b-49ff-8fa4-e7ee03962473">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <biib:RoyaltyCostofSalesPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5NDE5_16d7c647-61d0-4247-9e2d-27a37dfebe82">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</biib:RoyaltyCostofSalesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjE1_1fd444c1-3dc1-4094-ba01-be31f3bc7f82">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzA0_35a35adf-9f89-4480-8104-913d94e90d2a">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5NDA1_d34e3c74-a0c0-408c-bf04-3f0c45dd1ee1">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. For the years ended December&#160;31, 2020, 2019 and 2018, advertising costs totaled $111.8 million, $79.2 million and $90.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU5NDMw_8b23c5cf-a4b7-46e3-90c1-b446a5962c57"
      unitRef="usd">111800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU5NDM0_6ddca70c-016d-489d-bf2c-ced1d108b36f"
      unitRef="usd">79200000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU5NDQx_93651b4a-d5cb-4c25-b044-ca49e81b37fb"
      unitRef="usd">90200000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5Mjg0_3c6cf1a0-aaed-48c5-a38d-f6db15a5b904">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2016 the FASB issued ASU No. 2016-16,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;$0.5 billion, offset by a corresponding net increase to retained earnings of approximately&#160;$0.5 billion. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;$0.4 billion&#160;with a corresponding reduction to our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for uncertain tax positions using a &#x201c;more likely than not&#x201d; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id202dc9d694b43e7bb188183306ef1be_I20171231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzYxMjgw_9fcc3ae3-1973-4a83-bdb8-132f4918f0da"
      unitRef="usd">500000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62315bf96a414f8f8bf19b192b4c0951_I20171231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzYxMzYx_00a76af0-39dd-4079-b424-f60077cde2a3"
      unitRef="usd">500000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ed6ef3bd55540debba7f93c76913164_I20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzYxNTMw_99760498-26fd-4739-b339-416dde29066e"
      unitRef="usd">400000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MzE2_96c1cd8a-c252-41fc-bdcb-f9928ea4a1d7">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#x2019;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. Legal costs associated with legal proceedings are expensed when incurred.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzY5MjQw_f28e0c4f-365c-494f-97c6-21882e2074dc">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzU0OTc1NTgyMTM1NzI_dfc745a3-2bcb-4ce9-a890-06d04be3d35d">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;above, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards did not have a material impact on our consolidated financial position and results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018 the FASB issued ASU No. 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard did not have a material impact on our disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018 the FASB issued ASU No. 2018-16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This standard makes targeted improvements for collaborative arrangements as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Adds unit-of-account guidance to ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzg5NTE_a686c6aa-3b7c-442c-a906-bfb4f7ac4a43">Acquisitions&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIIB118 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020 we acquired BIIB118 (CK1 inhibitor), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson&#x2019;s disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this acquisition, we made an upfront payment of $75.0&#160;million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0&#160;million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition of Nightstar Therapeutics plc&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the acquisition, we paid NST shareholders $25.50 in cash for each issued and outstanding NST share, which totaled $847.6 million. In addition, we paid $4.6 million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was $26.2 million, of which $18.4 million was recognized as a charge to selling, general and administrative expense with the remaining $7.8 million as a charge to research and development expense in our consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the IPR&amp;amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of 12.5%. We recorded IPR&amp;amp;D assets for BIIB111 and BIIB112 at their initial fair values of $480.0 million and $220.0 million, respectively. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reco&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gnized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for GILTI. Goodwill that is tax deductible for GILTI purposes is approximately $60.9 million as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our consolidated statements of income. Subsequent to June 7, 2019, the acquisition date, our results of operations include the results of operations of NST.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIIB100 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018 we acquired BIIB100 (XP01 inhibitor) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 investigational oral compound for the potential treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $10.0 million to Karyopharm, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB100 had not yet reached technological feasibility. We may also pay Karyopharm up to $207.0 million in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIIB104 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018 we acquired BIIB104 (AMPA) from Pfizer. BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $75.0 million to Pfizer, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB104 had not yet reached technological feasibility. We may also pay Pfizer up to $515.0 million in total development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIIB110 Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018 we acquired BIIB110 (ActRIIA/B ligand trap) and ALG-802 from AliveGen Inc. (AliveGen).&#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. &lt;/span&gt;&lt;/div&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $27.5 million to AliveGen, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB110 had not yet reached technological feasibility. We may also pay AliveGen up to $535.0 million in additional development and commercialization milestones.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia457a1bccc154fcd8ff6932b1456cb83_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEwOTk1MTE2NDQzMjU_39730354-366c-4a60-937a-dd2c89d05e60"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="ia457a1bccc154fcd8ff6932b1456cb83_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEwOTk1MTE2NDQzNDA_0531ea6c-aa5a-4fb7-99ee-961954ec1c2e"
      unitRef="usd">635000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:ClinicalAssetsAcquired
      contextRef="i74d25f7562934bc8a1eebaf7750912d2_D20190601-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzQzOTgwNDY1Mjc3MDM_4e3efba6-2183-4876-9c72-853d02d7a437"
      unitRef="product">2</biib:ClinicalAssetsAcquired>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ibef78125dd7d4a94a4efe455cc442105_I20190607"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzk1Ng_bc60674e-cbff-4490-b998-b33e5222fc32"
      unitRef="usdPerShare">25.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i931745da9c9741a7bcb5a4292c51f87a_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEwMjQ_7778c170-0ef3-4569-ac47-386165ea2bf6"
      unitRef="usd">847600000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i931745da9c9741a7bcb5a4292c51f87a_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEwNDk_e5f7895e-1282-464a-b9fe-ae5dccd883b7"
      unitRef="usd">4600000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i9f95102445b94a5183bbd60ea00497d5_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEyOTU_f57741b5-7d74-424f-9ef4-7d24b0d1c3ce"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="ib0b20812b1ae4a52b980e45bc1c13af9_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzEzMDg_3286c908-e46f-44a3-978f-7e9617b455ba"
      unitRef="usd">18400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i675123ee33df46f18f7d302db7babd89_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzE0MDQ_1dc1afff-e60b-46b0-83de-a1f69ecfd540"
      unitRef="usd">7800000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate
      contextRef="ibef78125dd7d4a94a4efe455cc442105_I20190607"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzIxMjA_d0ca0f64-2da1-4129-8089-7bb6861808a8"
      unitRef="number">0.125</biib:FairValueIndefiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i12ed3b5c3c244392982bf3e4a342675d_I20190607"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzIyNDE_0f51b0ce-63db-4b0b-b7e8-2b071bd6884f"
      unitRef="usd">480000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i2b0a4756e001463da2b40b89dfd99ab3_I20190607"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzIzMTA_c5bedb9e-550f-4ada-8732-a35055dcfa50"
      unitRef="usd">220000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="ibef78125dd7d4a94a4efe455cc442105_I20190607"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzMzMDg_880d2913-7eb5-46e2-95e8-51ed9998597c"
      unitRef="usd">60900000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i217e491a4a2945fda8b6a3fb6e69f33c_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzQyNjM_9fe5e89b-d5da-488f-b97e-0d6d16d968e1"
      unitRef="usd">10000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="ic3ba7bb298ba4551bfaf50b04a063a19_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzQ0NTA_6710f79e-291e-4d6d-b3e2-147239c035ec"
      unitRef="usd">207000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0826dcdf451640cfa9e62b8a90ea7c7c_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzUyMjI_c707b1f1-893e-4bcc-8f22-d781a328de39"
      unitRef="usd">75000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="iefe928ba270d49608bb021eb1ec31bd8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzU0MDE_a59e64e4-e1fb-4754-8554-2a2e6e32c389"
      unitRef="usd">515000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if38b01edc61441248c76861d6096cd34_D20180701-20180730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzczNDI_f833d29f-1da1-46f6-8e97-eec4a9d1ec5c"
      unitRef="usd">27500000</us-gaap:ResearchAndDevelopmentInProcess>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i5655172610c049b7b1d99d51a603c7f4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDQvZnJhZzpiMDE1NGY4YmQ2M2Y0MzZiOWU4ZDc0ZmE4MDBhMjExMC90ZXh0cmVnaW9uOmIwMTU0ZjhiZDYzZjQzNmI5ZThkNzRmYTgwMGEyMTEwXzc1MjU_d33d2298-286d-470c-b117-5287a74a652b"
      unitRef="usd">535000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzM0OTM_b1398559-a71d-43c6-b308-cb5133ec1f7d">Divestitures&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately $881.9 million in cash, which may be adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#xf8;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#xf8;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2019, we recognized a total net loss of approximately $124.2 million related to the transaction in our consolidated statements of income. This loss included a pre-tax loss of $55.3 million, which was recorded in loss on divestiture of Hiller&#xf8;d, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#xf8;d, Denmark manufacturing operations of approximately $11.2 million and our estimate of the fair value of adverse commitments of approximately $74.0 million, primarily associated with the guarantee of future minimum batch production at the Hiller&#xf8;d facility. We also recorded a tax expense of $68.9 million related to this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, upon the closing of this transaction, we sold to FUJIFILM $41.8 million of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, we reduced our estimate of the fair value of the adverse commitment associated with the guarantee of future batch production by approximately $62.0&#160;million based on our current manufacturing forecasts. Additionally, we recorded a reduction to our pre-tax loss of approximately $30.5&#160;million due to a refund of interest paid associated with a tax matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimate of the fair value of the adverse commitments is a Level 3 measurement and is based on forecasted batch production at the Hiller&#xf8;d facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ida412b4bccf941a7af64620b69dcf1ef_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzMzOQ_b10e716e-6e10-47b5-bb95-4b07599dad62"
      unitRef="usd">881900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax
      contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzIwOTc_6c4ba329-9d99-48b2-9b4e-40d7732533aa"
      unitRef="usd">124200000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzIxNzk_f85438b9-a7d3-466c-b322-17935072b662"
      unitRef="usd">55300000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzI0NzY_17622505-1878-4f80-a8cd-03fc4cb28fb6"
      unitRef="usd">11200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i7ae2c3b5bd774a9bb73adaf4ac185c0f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzI1NTY_a78b8dd8-3a7d-4cf8-8ee8-36c8781ccd48"
      unitRef="usd">74000000.0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzI4MDg_1ea877b7-eb9d-4bee-8957-63fd4e10b864"
      unitRef="usd">68900000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="i2e9e587add174faba8df37c45bf81a84_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzEwOTk1MTE2MzI2MTg_f3070b7c-9d6e-4f94-85fa-5d048d7296e7"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <biib:PurchaseCommitmentReductionOfAmountCommitted
      contextRef="i6599810683224f4f8d5b5a4cec91c8ab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzEwOTk1MTE2MzIzMTY_82569bf4-5249-459e-b563-886230b6eb15"
      unitRef="usd">62000000.0</biib:PurchaseCommitmentReductionOfAmountCommitted>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="i6599810683224f4f8d5b5a4cec91c8ab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNDcvZnJhZzo4MjAxOTZjNDU2NTU0MWNjOGViYWNkYzEzYmUxNTUwZS90ZXh0cmVnaW9uOjgyMDE5NmM0NTY1NTQxY2M4ZWJhY2RjMTNiZTE1NTBlXzEwOTk1MTE2MzIzMDE_f5bc465c-0653-4def-bdf9-ef07b5217610"
      unitRef="usd">-30500000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NDA_9377a03a-39ab-441c-b6b9-5f61c5fc5677">Revenues&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,742.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,905.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,312.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,126.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,438.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,253.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,274.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,273.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;604.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,877.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,426.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;675.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,101.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,668.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;694.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,363.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,096.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;849.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,946.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,041.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,892.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,025.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;839.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,864.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZINBRYTA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,719.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,832.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,780.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,748.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,529.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,946.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,648.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,595.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;787.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,264.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,052.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;933.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,163.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,097.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,724.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;481.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;481.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;795.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;795.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;738.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;738.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;545.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;545.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,900.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,792.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,692.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,713.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,666.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,379.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,800.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,086.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,886.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenues from two wholesalers accounting for 30.5% and 15.3% of gross product revenues in 2020, 30.0% and 17.2% of gross product revenues in 2019 and 32.0% and 18.4% of gross product revenues in 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, two wholesale distributors individually accounted for approximately 21.1% and 8.5% of net accounts receivable associated with our product sales, as compared to 24.1% and 13.9% as of December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;774.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,308.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,102.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(635.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,426.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,061.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(128.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(763.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(910.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;888.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;666.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,011.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,698.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(535.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,242.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,778.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(127.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(576.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(724.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;606.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;761.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,686.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,389.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(551.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,887.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,440.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(506.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(646.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;888.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;748.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,977.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 14.7%, 15.9% and 14.7% of our total revenues in 2020, 2019 and 2018, respectively, were derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from collaborative and other relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;719.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;774.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended December&#160;31, 2020, 2019 and 2018, we recognized $48.6 million, $383.2 million and $206.7 million, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result we are entitled to $500.0 million in a series of three payments. The first payment became due upon a regulatory approval of such product and was received during the second quarter of 2020. Subsequent payments are due on the first and second anniversaries of the regulatory approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other corporate revenues for the year ended December&#160;31, 2020, reflect $346.2&#160;million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $153.8&#160;million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NDQ_069a296d-09c5-4543-842d-f9069094bfdb">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by product are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fumarate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,742.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,905.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,312.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,126.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,438.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,253.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,274.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interferon**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,273.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;604.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,877.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,426.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;675.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,101.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,668.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;694.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,363.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,096.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;849.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,946.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,041.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,892.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,025.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;839.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,864.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZINBRYTA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,719.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,832.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,780.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,748.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,529.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,946.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,648.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,595.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;787.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,264.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,052.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;933.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,163.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,097.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,724.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;481.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;481.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;795.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;795.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;738.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;738.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;545.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;545.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,900.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,792.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,692.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,713.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,666.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,379.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,800.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,086.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,886.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;**Interferon includes AVONEX and PLEGRIDY.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="i85a89db2076b46d08a583b581aa591ef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMS0xLTEtMA_764a1af1-625f-403f-a56d-04e6a4ba8fcd"
      unitRef="usd">2742000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5ec4e78cdf14e27b10a96f705b49b62_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMy0xLTEtMA_37a7c0f4-eaa1-4823-b45f-ac6c55593e5d"
      unitRef="usd">1163400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7c7c39b59484f68a74bc30138f093c8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtNS0xLTEtMA_8c31f0c5-b44c-4615-b66c-3b798b492e3c"
      unitRef="usd">3905400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8bc356d23184fcebc37ba9a22520399_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtNy0xLTEtMA_a42169fe-9e4e-4764-b760-846b7ff9e371"
      unitRef="usd">3312000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9f2c1d75d0244adbaf0ce60ba6f10c6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtOS0xLTEtMA_fb1b50a7-1429-4c02-af1f-ea0384650de2"
      unitRef="usd">1126200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4671dcaaccbb4c73bc88e30c9c3ef796_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMTEtMS0xLTA_cf1b9545-0dc3-492e-8c8d-7e75676b8b09"
      unitRef="usd">4438200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i611243e9e12c42aa8073bc846cf26e10_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMTMtMS0xLTA_4e619517-1ec1-4fc1-8c97-aec366076b47"
      unitRef="usd">3253200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i89219f9fbe1b4c1dbf921ccb2d9beab4_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMTUtMS0xLTA_bb3a58fa-813b-459f-9145-b8264bb02a7a"
      unitRef="usd">1020900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d646b3f2acc46cfa9c025734b83a62d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzQtMTctMS0xLTA_c327372a-710a-4a97-9817-9c00ebe6dbd6"
      unitRef="usd">4274100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i676dac9dfca9459aa08e07ccbde07b0d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMS0xLTEtMA_4862dabd-3164-43e7-90af-17b9dfbcb00e"
      unitRef="usd">1273500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38907cded92a4460972fcfcc8fc9a8e6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMy0xLTEtMA_761009a0-9d2b-4d54-a1b5-f07d94259c62"
      unitRef="usd">604000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0479de2c47942988bc6c58b22051c05_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtNS0xLTEtMA_1ddce796-d666-45c5-a3c2-d3a1b941a0ae"
      unitRef="usd">1877500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i239b75ed62774dddb59a70525b80aa50_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtNy0xLTEtMA_77c8e186-7af7-4842-93e6-6acee6b8748e"
      unitRef="usd">1426600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ad45c8aa37643dda100435c30ec9812_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtOS0xLTEtMA_37995d0e-0986-4481-a0ce-9d8422f6e0a5"
      unitRef="usd">675200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie627c15061db491694d9896f93024ce7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMTEtMS0xLTA_020cf5e5-6c01-4e09-8a09-46c7800b7943"
      unitRef="usd">2101800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i808ab222eb14472a9a5315190f9d73f9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMTMtMS0xLTA_540a8738-caa4-479d-90f9-c31748d136b9"
      unitRef="usd">1668300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i43a5bf5f3c2f4bbfb702fcd685c5350f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMTUtMS0xLTA_925b53fd-9daf-41f0-91c6-8ecd44d011dd"
      unitRef="usd">694700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icdcf0cf7d9d84f1b9a94c5e3ddfaf245_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzUtMTctMS0xLTA_3742db96-54b6-4383-9587-e2df648391e0"
      unitRef="usd">2363000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04860cd441c6444f8d0547cddbe88ec1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMS0xLTEtMA_61e3f0a7-347d-4685-a3ed-6be8cb829b16"
      unitRef="usd">1096800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ef7c311e0124c438791428e3b4b41a4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMy0xLTEtMA_345f1f74-c72f-4609-8010-0c1dabcb3c7d"
      unitRef="usd">849300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9fc945d8f6294b06ab322c83d51a8139_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtNS0xLTEtMA_adb077bb-1c8b-4279-8b2e-92286e5c5b60"
      unitRef="usd">1946100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7e8798dae8a4b08812a89a53e77047c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtNy0xLTEtMA_549d9958-b61d-49e5-9f5e-c90483c2b953"
      unitRef="usd">1041800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15ac014fbb4e4c6db8de2f58e8127e65_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtOS0xLTEtMA_8f54e5b3-cf16-4add-955d-d844501706d7"
      unitRef="usd">850400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e79a9c192ab4345a8831a1ec2ea4c7b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMTEtMS0xLTA_ed16613a-a131-4feb-be5a-310321d5c781"
      unitRef="usd">1892200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2acaf2f4edd94d2aa5d30476174c8ff1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMTMtMS0xLTA_3ac78977-439e-447c-84c6-c60f57ae1a83"
      unitRef="usd">1025000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9161ee6ab1b24fa0a4b4fb0e50c29fab_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMTUtMS0xLTA_84d9ca70-eaf5-4b0f-8731-82e5ca0f5a1c"
      unitRef="usd">839000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7fc147b15e5c42138dac645bea65a6e3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzYtMTctMS0xLTA_fd8e9f08-c5a4-4849-a9c9-efb24b5ad06f"
      unitRef="usd">1864000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51cecc234a1c499e81996ec359a83235_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMS0xLTEtMA_6ddeb7ae-9dbc-4422-939b-5dd5ba9d2bdd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4cc67fa6b68546999e25a409116223a5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMy0xLTEtMA_c42b42de-2611-48da-88af-dc3190a6a7b7"
      unitRef="usd">103100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6055a732a3c42339f265cbba96a4237_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtNS0xLTEtMA_8085cfef-146a-409e-9194-8ad7be88d200"
      unitRef="usd">103100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5b8355cc290044cc90da4d1eb56c12fe_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtNy0xLTEtMA_e43c32b0-0a71-49aa-9778-d660f7dc96be"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic228d3e552df4464b29306fc6585aa80_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtOS0xLTEtMA_ee654e49-9d6b-40bf-b709-732fe0a364bc"
      unitRef="usd">97100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i25bb90461ed2438a995263720a6ed66d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMTEtMS0xLTA_f392bbd6-ac18-4869-9ca8-aee948887abf"
      unitRef="usd">97100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i793c32241e6a44aa9d8cbcf846f1608e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMTMtMS0xLTA_258156f3-36bd-41ee-8c5b-44ac3f49fa06"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i21e1cbb7e7fd41b196a67213d407f8da_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMTUtMS0xLTA_49b33b9b-d9a6-42a0-a9c3-fda89179fb63"
      unitRef="usd">92700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7dc62500324422c8b3e284eaa458c65_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzgtMTctMS0xLTA_0bdd13ff-e874-42d3-aac0-2a2500e9b8af"
      unitRef="usd">92700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3153e9337f7f46b180a951e086f83f04_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMS0xLTEtMA_b8ce3e19-c50d-4d12-85f9-cbace98e57e7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia30a842196f14402bb07dc592bab78e7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMy0xLTEtMA_0fd8706d-84b9-4821-942d-6966b5a4124c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0009c1183e6246eeb2ee54a841d184b3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktNS0xLTEtMA_7c01e63c-567c-48d0-9d66-6a5528b326b0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ea2097d09a44a509b495c405a069070_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktNy0xLTEtMA_66b6166a-cd3e-4575-98e2-11abd93e6954"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fd129491fd544708255c0bf9443922c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktOS0xLTEtMA_c0e9bae6-e727-484b-8bf4-83968d34a421"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48d69c93cae04d3491b6586590a557f3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMTEtMS0xLTA_be2f2f9c-358d-4ad2-b38a-75ef1fed0d7f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57ee1ffeca9640ecb4a25fa543737c80_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMTMtMS0xLTA_569f869f-157a-4754-8c7a-d2c02f2ac88a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92af91a220a14e519e257472f7b4627c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMTUtMS0xLTA_fde52ed3-5591-4e45-838d-af9b43183dc4"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7dc974c8cf545aaa99c23d6995ccf0e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzktMTctMS0xLTA_8a107742-3c22-46c3-b125-95c6dda5582a"
      unitRef="usd">1400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0b5853b0a7b4b75b8a727674c5976cd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTEtMS0xLTA_4ef8447f-c383-4d2a-bb25-80ed01d3f2d1"
      unitRef="usd">5112300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6420df982c54462fac44de3494b1078a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTMtMS0xLTA_49156896-4008-4856-897a-adf116d596b9"
      unitRef="usd">2719800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if92992eed3334e24956317197eb6249d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTUtMS0xLTA_592ca3a8-a344-42cd-bed8-b086370bc136"
      unitRef="usd">7832100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibfe618b1b7444265baadef360f6cfe7f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTctMS0xLTA_6425a6c7-e330-48a6-baba-10dd1a7bb337"
      unitRef="usd">5780400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3274395ada7440579bbf98e82e662536_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTktMS0xLTA_bb5e8faa-ab08-4469-8929-d391c72a08ba"
      unitRef="usd">2748900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4163b71d3ebf4640b1af4d523043b9d5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTExLTEtMS0w_646540a7-26ff-4689-8de6-cfcdcc065fee"
      unitRef="usd">8529300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04b1f3407fd84deab1332035a3a31964_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTEzLTEtMS0w_0e5faee1-595f-4d94-bb2c-08b20a505dc2"
      unitRef="usd">5946500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2f67a8c0aea4ef7ba8c99f1f5292a0e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTE1LTEtMS0w_c819ec60-2f58-484b-a0bf-9a040974b70c"
      unitRef="usd">2648700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3fbdc5541c854505baa5fe73b8b9fb16_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEwLTE3LTEtMS0w_0fa396e1-cdcb-4e6e-8b0a-db3943fcbc36"
      unitRef="usd">8595200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic369938897d44097803fd74cc0bf646d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTEtMS0xLTA_93906e60-bdae-4a41-af44-24d5c0b05f1a"
      unitRef="usd">787800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b7d190fad4b4287ba2080a56db09bb6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTMtMS0xLTA_2ef82cd8-0d54-4bec-945e-a460e2d987d4"
      unitRef="usd">1264300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e67ce0006534c9d90964417d4f29f9a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTUtMS0xLTA_20641709-b1ba-4ea7-ac84-bf6ebf0d0a82"
      unitRef="usd">2052100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8cbfde1864b4ae69989d769e587d576_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTctMS0xLTA_0b80143e-22cd-4264-b9ce-5e1f536cfd9e"
      unitRef="usd">933400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85145d7d92464b108b60ca4e887113f9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTktMS0xLTA_96ac0b28-dec1-4961-b66b-50b901a3bcdb"
      unitRef="usd">1163600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b2352931d6f4d8980b86773c3e2523a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTExLTEtMS0w_abd0bb54-6479-420d-a997-2537bdc7fd67"
      unitRef="usd">2097000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7979d3870a264dd0a1528aafe4e9a00c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTEzLTEtMS0w_c6d4cdd0-6465-4833-bc0b-966e266a4a79"
      unitRef="usd">854000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib08fe27eb1d045de9c81dadf75845b7e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTE1LTEtMS0w_6472ffb0-4de6-4e92-9333-8265db4542cf"
      unitRef="usd">870200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd3882c6c7e44816881d6d48c711cdb8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzEzLTE3LTEtMS0w_95247915-0e8d-42ef-810f-1c806bb98121"
      unitRef="usd">1724200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb9ada749a894e289113c4d61f405d38_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTEtMS0xLTA_90978123-1c48-4cef-b1e1-115af2db40ae"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie042a2edd31046aca7dde1c59f969ab3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTMtMS0xLTA_2739814d-a4f3-4ca0-a4c8-96f9bcfb3b15"
      unitRef="usd">481600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5a0d587886c43a485b4a1beaf2cb9a7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTUtMS0xLTA_bb369f5e-2bdd-401d-be35-8f71924c2c2f"
      unitRef="usd">481600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied5ea019d4fd4c2f897fe2644f7c7ed2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTctMS0xLTA_38814209-49c1-4719-871e-5307cd222e19"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icef4f9926f8d4814a9d013cf79e963e9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTktMS0xLTA_9ec6f78d-de9f-4fe2-9a1a-1281ec6d7398"
      unitRef="usd">486200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d98281f667b40a595d97292a3d7d21e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTExLTEtMS0w_400a93bc-8de3-4035-8945-f89ad8ba1fd7"
      unitRef="usd">486200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i181d0ab423b0468a8a6f8b139f105d1d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTEzLTEtMS0w_e6927094-cb87-4d6a-8af7-b1abea55c2de"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c81e1552b61450e83a94056dc340dbc_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTE1LTEtMS0w_861e5298-eaca-46b4-b896-e77b8d76b768"
      unitRef="usd">485200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ebf7dfae7004c2da140bd5817f77ab2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE2LTE3LTEtMS0w_83937202-e4ad-432b-88a4-9e9e885879ed"
      unitRef="usd">485200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67f197d8686c4e44bbee78953032d413_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTEtMS0xLTA_fad11740-b25c-4d16-9f9f-0fc1eb6b0e7e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23cac88653144474aa6d28fad81d8ecf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTMtMS0xLTA_90f627c3-8fce-4b1d-940b-da80ad01198b"
      unitRef="usd">216300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d5709855edc4dafb39167708c8ba135_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTUtMS0xLTA_e8a5cb4b-1f52-4f3a-b2f6-23e41e466a18"
      unitRef="usd">216300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d2c2f06527b4022a893fa9bcb7e4e52_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTctMS0xLTA_9d15fdb6-7089-4043-89b1-d09ab2ad3955"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22cdd79b3cf74f248c1f7221acba2a23_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTktMS0xLTA_708d4d47-0147-4a45-a7df-2e69f7b2069b"
      unitRef="usd">184000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec8554a2c2be4400a7226435515b1cff_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTExLTEtMS0w_0f386a0b-33e7-4c4f-adba-c7acf44ecbce"
      unitRef="usd">184000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i466f28f7b774412c92456ab39ec8c2a6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTEzLTEtMS0w_ac963c24-3a97-4428-8bb0-65780b8c38a3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31933ce497d64be0899c42e590f33e49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTE1LTEtMS0w_f407821a-6dc1-47cf-ba16-52bcda5c0f15"
      unitRef="usd">16700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibb7a44b1f0d049cabc406d3d7fb76dfa_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE3LTE3LTEtMS0w_85f47ba4-28d5-49b2-9ae8-712a6eae364b"
      unitRef="usd">16700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2bc3ca49c80e494caf1f76203a66f71e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTEtMS0xLTA_11fc8292-1c0e-4c99-9978-8a97342c01c2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i836a100e66ca48e8a1e7ddee36e17253_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTMtMS0xLTA_b26d1e7a-cf45-4048-8531-9f0a72ca64ab"
      unitRef="usd">97900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b4ad0dba054423b82e1cc5bf4358871_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTUtMS0xLTA_6a028fdf-2d81-476b-9a13-d4819b7af961"
      unitRef="usd">97900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i28387800191b42c088cd25c6a9466a12_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTctMS0xLTA_d1f33aef-dd91-4040-aca3-cea227811c99"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3f5c2e8409c4870834b30b67f6c99d0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTktMS0xLTA_571235eb-f912-439c-b5c1-1e14aa0f0b2d"
      unitRef="usd">68100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icbd96336b17c48759b92af5b727a614d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTExLTEtMS0w_52630954-3540-453b-b961-4b000691bbff"
      unitRef="usd">68100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c35b9c4f72240cb91164b21f3abd0a2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTEzLTEtMS0w_c762baa8-4ade-4418-9df6-cb291b3d0570"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e2ed02bfb06451f9fb5ae7fddafa907_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTE1LTEtMS0w_788b1ee6-5713-4e38-af9c-02afd380ebec"
      unitRef="usd">43200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f93424eda7546c9a3ac40bcfbfaa106_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE4LTE3LTEtMS0w_bf3a1aa0-7b82-4c90-a87e-f7518db9f845"
      unitRef="usd">43200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3ea9446ace44e788ee54818d9b37f3a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTEtMS0xLTA_670ed588-0dfd-46e0-80f7-9c485719ab20"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1fbc92ecd2ec466bb430e6dce8b804a3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTMtMS0xLTA_9b4ed0e0-e41b-4cf4-88a7-fd651d9899a7"
      unitRef="usd">795800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf1efb62ce514836b55d3ee7a4ac1a5d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTUtMS0xLTA_b6006044-8e8b-4a5c-8725-6fd12f3175d4"
      unitRef="usd">795800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26bd8f41008941b1be219ee8aba377f2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTctMS0xLTA_80832e08-0db6-4655-918d-a544123f1bfa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib76e8e2921bd486fa43cf0f7bf709125_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTktMS0xLTA_c8fb6d37-1d0b-4c13-87e7-b25f72f539bb"
      unitRef="usd">738300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9fc2e1129ed148b29526834ea34cc7e6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTExLTEtMS0w_b518221e-7b2b-43bd-9ecc-346cacba998e"
      unitRef="usd">738300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5517906d4a214fd5a371d6c53ae66e73_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTEzLTEtMS0w_393838c3-4152-441d-8e08-460a368688b8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if66448bf19334d99863e008bc96d2313_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTE1LTEtMS0w_c634192d-4558-4869-959e-faf1c3dc81d5"
      unitRef="usd">545100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b62d124ddb34cf3809af9802c175ace_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzE5LTE3LTEtMS0w_25b63534-c175-4029-9f1b-aa52bebe70b2"
      unitRef="usd">545100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0132327259a94fb1975abd835ed78152_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTEtMS0xLTA_f627db12-9f34-4edb-b142-07c8094fc4b4"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5c90e682e5e417a967657ac50fbacf1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTMtMS0xLTA_397a9049-d4d5-4a8c-8c67-d4a882294901"
      unitRef="usd">12200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i43014c84e32d490e8ca9d7d907dff83b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTUtMS0xLTA_4a3485ad-b30b-4b7a-8993-6373b5a9a181"
      unitRef="usd">12200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d4c2a4027e3422ea87ff6cc3b986145_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTctMS0xLTA_6e94d53c-3017-4f66-b145-6dd55610f896"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f6560ddf1da469783c308fbc59328d7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTktMS0xLTA_e3cc6c77-b140-4ca5-a62d-c0f5dd06e9bf"
      unitRef="usd">15200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6c11246cbbfa46648ee949251e0eb821_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTExLTEtMS0w_e032558a-5fe8-435e-9d3e-2a904a9fd125"
      unitRef="usd">15200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81d7562d98124ce596c58c5c77f902a5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTEzLTEtMS0w_162861b6-0ee2-4a36-8ca0-8062a46187cf"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3f610d2c9e746d5ba0b20b191ecff82_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTE1LTEtMS0w_f703e3e5-0ee3-41ca-a730-f2e893cbd744"
      unitRef="usd">22300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife7ac8b29bb24df09106e8a94a348a10_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzIyLTE3LTEtMS0w_be69dd7e-4140-4ab2-b703-72349970c983"
      unitRef="usd">22300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f99591bb1b0401b8000095a52fab6f8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTEtMS0xLTA_57556a95-019f-4a1d-9e1a-095ed7da5852"
      unitRef="usd">5900100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bb76f2658274da7b4345880031c2273_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTMtMS0xLTA_f2d309d2-3cb8-4c65-9f7c-34b5ccacb577"
      unitRef="usd">4792100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTUtMS0xLTA_4be2e776-979c-4e71-98eb-f0b269373661"
      unitRef="usd">10692200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72c66309e53f467ab518b51c5bce54f4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTctMS0xLTA_50938e99-5dfa-4d91-94c0-ae72d49c5560"
      unitRef="usd">6713800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c98110a133446d0bd61f9284d0e58f2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTktMS0xLTA_f314675e-181c-44cb-8e20-47ae85562958"
      unitRef="usd">4666000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTExLTEtMS0w_adcd602e-29b6-476c-9263-13500cfb8d20"
      unitRef="usd">11379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c311f0cc16744aeb4492070360e76b3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTEzLTEtMS0w_0d4b7386-ad4d-44d2-82c9-1a7a9d788d3c"
      unitRef="usd">6800500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fa69ae482814ac8bcd343ae4a224389_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTE1LTEtMS0w_a1f9f802-5c54-41f9-8a1a-22306b2399f8"
      unitRef="usd">4086300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6b7b9a353c2419ca9a01532a522a0d0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZToyM2FjYmI1ODI3YzI0MWY0ODBkZjQwN2I2YzhlMzM4My90YWJsZXJhbmdlOjIzYWNiYjU4MjdjMjQxZjQ4MGRmNDA3YjZjOGUzMzgzXzI5LTE3LTEtMS0w_53371154-bf3c-489c-8be6-00fbb9d44f1a"
      unitRef="usd">10886800000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzQzOTgwNDY1MTc0MDQ_a642b5b4-3eb8-4a2d-9740-0d220391f9a0"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i6838460bdaca49d7b136d868993f4d08_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzQwOTE_c5919aef-e09f-4da8-bf61-c6da87ac0549"
      unitRef="number">0.305</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i3ff66c8950bb4a7e88affcf110449d1d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzQwOTY_795e0241-9165-4a66-8d2a-f44380a9b60d"
      unitRef="number">0.153</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i0ea5f27bc85f4fddb4469f05a3b00215_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzIzMA_cbec50b4-4149-4d0e-9578-784aa7f15e78"
      unitRef="number">0.300</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="id4f9dcae88cc43e891f75bf74e4bf5c0_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzIzNw_23df41f6-f27f-4ecc-86be-c2eb4d7ec55a"
      unitRef="number">0.172</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ib2a9f19b6d9f4f4a995ece66958a61eb_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3Ng_cde651ec-427b-4602-a72e-eb21b54566a1"
      unitRef="number">0.320</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i0863980b999348b5a5e8c88dcfc46890_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI4Mw_d511ed4e-0faa-4fa2-84a6-c2808e1065a9"
      unitRef="number">0.184</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzQzOTgwNDY1MTc0MTM_2ad83e7e-b33d-4149-8613-4d6257c4905f"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables
      contextRef="ifd820ada82d04297b57bc8a5f70af4b9_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzQxMDE_d70e84e0-f177-49ba-8e1a-f29160564bd3"
      unitRef="number">0.211</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
    <biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables
      contextRef="i112f6f59416148d2a921ea8b21ca66ca_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzQxMDU_3f9c4b73-5cd7-4f46-bea3-6632e926faa2"
      unitRef="number">0.085</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
    <biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables
      contextRef="i6e510eea4c8c4271a8fe6ae31a7211f5_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzQ5OA_e521bee5-66ef-40eb-af19-075855c9f0a5"
      unitRef="number">0.241</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
    <biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables
      contextRef="i3c42c0c7a42943d7a9ffc85aa01e8a61_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzUwNQ_6c9321c5-8aa7-472e-9490-b894efcc4235"
      unitRef="number">0.139</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NjU_f54b9a46-53bb-430f-9c49-5b44608ea767">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;774.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,308.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,102.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(635.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,426.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,061.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(128.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(763.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(910.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,093.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;888.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;666.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,011.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,698.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(48.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(535.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,242.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,778.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(127.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(576.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(724.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;606.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;761.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,686.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,389.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(551.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,887.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,440.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(506.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(646.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;888.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i400709e4fbb2431a8c60b9f0001721f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzItMS0xLTEtMA_e4e69378-f0c3-4a09-923f-6c7ef8ebe61a"
      unitRef="usd">131100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4bb52c820db94f3aa2e279e49e3f772a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzItMy0xLTEtMA_d0083026-32cf-40ee-83d0-d806b56bfd55"
      unitRef="usd">1027300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia91f6946981c4e79a74688a13b7b6cae_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzItNS0xLTEtMA_d10a0f2e-f68a-4a8f-b2ed-389d8d27e6aa"
      unitRef="usd">40500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzItNy0xLTEtMA_df111f75-a68b-41de-bddf-b6f4e85fac24"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzMtMS0xLTEtMA_505b5a7d-9877-47ec-b685-0fdbeae3dc15"
      unitRef="usd">774700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzMtMy0xLTEtMA_588f90a8-1fb4-4d9c-b994-5b206cfb8ea9"
      unitRef="usd">3308800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzMtNS0xLTEtMA_254fc8cb-6c80-480f-855f-36977ad6a4c2"
      unitRef="usd">19000000.0</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzMtNy0xLTEtMA_b9b59cbb-073d-45c4-bb22-100f10ea3ede"
      unitRef="usd">4102500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzQtMS0xLTEtMA_07f089d6-f9d2-4ea1-9d13-78d7be5c8147"
      unitRef="usd">1000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzQtMy0xLTEtMA_caca5277-2c38-439b-a6a5-b5ee0d7d21ea"
      unitRef="usd">54000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzQtNS0xLTEtMA_7e66e104-fd9f-4e8f-912d-efbb682859f2"
      unitRef="usd">-1300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzQtNy0xLTEtMA_8ce8de4f-4a27-4ad2-b28b-9f76b540a7f1"
      unitRef="usd">53700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzUtMS0xLTEtMA_122c91d0-d8c3-4e44-8439-b47169235ac7"
      unitRef="usd">635100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzUtMy0xLTEtMA_d0f4547c-ae09-481e-bd4e-d4875122c74e"
      unitRef="usd">2426100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzUtNS0xLTEtMA_af217259-9f96-4e17-94e3-8488a7e1f068"
      unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzUtNy0xLTEtMA_6b658ddd-975e-40da-ba38-f7424e5a8404"
      unitRef="usd">3061200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i6b9a084281764753971f6d5b655ca8a4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzYtMS0xLTEtMA_d40119dc-7b5c-4eb8-b651-8562b44c6a73"
      unitRef="usd">128300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i3a3aca6afe274f86852e45206880d3d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzYtMy0xLTEtMA_27873341-0bef-4495-9cb7-202e3fab1a4e"
      unitRef="usd">763000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i0931f5eaddf647d59328ee59f4e5f61b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzYtNS0xLTEtMA_7fd28032-ee8e-4cc2-9ea2-84a7449be3ed"
      unitRef="usd">19200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzYtNy0xLTEtMA_c85f4120-1a09-4d27-85c2-9aa054e875e9"
      unitRef="usd">910500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib09a186083b44003b3551748e372ab96_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzctMS0xLTEtMA_addd70c2-511e-4080-8375-6b9ff8501b31"
      unitRef="usd">141400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i913629824c8f4387b3fa3d219d942aff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzctMy0xLTEtMA_11e764da-52bb-492f-bc21-588e74e4981a"
      unitRef="usd">1093000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i60e8aacd727c4737ad050b96fdf9c8af_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzctNS0xLTEtMA_25f1b91e-b4c4-429c-85ab-da371a7a808f"
      unitRef="usd">41600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpjOWYzN2Q2Nzk4M2E0MzI3OWY4OWZhZGMwNTY0ZjFiMy90YWJsZXJhbmdlOmM5ZjM3ZDY3OTgzYTQzMjc5Zjg5ZmFkYzA1NjRmMWIzXzctNy0xLTEtMA_c6d47f82-3614-4a19-9c62-226b3ba16e06"
      unitRef="usd">1276000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iec6a7b631471438e8fee99a379470ccb_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzItMS0xLTEtMA_63405e7a-ca9d-40ec-8e36-7071340cc70c"
      unitRef="usd">127800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2d8cb46beb3d4d47884b9ee3730ccea5_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzItMy0xLTEtMA_9b9c81b5-6cf3-4efd-a5c1-17a03a1b000c"
      unitRef="usd">888800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1bb4285e484a4003bbfb3010fd8b052b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzItNS0xLTEtMA_db3c6bad-d281-445b-9868-a6cffd460656"
      unitRef="usd">34700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzItNy0xLTEtMA_c1ffe047-8d3b-4492-b345-78b54f974201"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="idc03c10e08964a88b663a184122907a2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzMtMS0xLTEtMA_07a32b69-a31e-40a0-a781-26ba26e3ddff"
      unitRef="usd">666200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzMtMy0xLTEtMA_744f5ea4-1c7b-4686-bcdb-eb68ff1a3d88"
      unitRef="usd">3011500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzMtNS0xLTEtMA_ca05e07c-fed8-40b8-bd9f-009e44395b3e"
      unitRef="usd">20900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzMtNy0xLTEtMA_a9376dea-6398-44f7-8833-a927fcaeac87"
      unitRef="usd">3698600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="idc03c10e08964a88b663a184122907a2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzQtMS0xLTEtMA_981a731b-0e44-4792-8a7b-dee375978143"
      unitRef="usd">-300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzQtMy0xLTEtMA_3feb6c55-0e1c-4a43-a3a3-e17de2a6d377"
      unitRef="usd">54100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzQtNS0xLTEtMA_70cfebe9-c746-48a9-944f-2a807b81bf83"
      unitRef="usd">-5500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzQtNy0xLTEtMA_10f554eb-149f-4bf8-8458-f3f024ce9527"
      unitRef="usd">48300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="idc03c10e08964a88b663a184122907a2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzUtMS0xLTEtMA_c3c798a4-5b31-4d22-b5b4-dc9576ee751f"
      unitRef="usd">535500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzUtMy0xLTEtMA_d2706b15-49d8-40ff-afc0-f0b6674777d3"
      unitRef="usd">2242900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzUtNS0xLTEtMA_c5ac30b7-b752-4755-8f4f-ec19738e5e56"
      unitRef="usd">200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzUtNy0xLTEtMA_5f15d09e-fd84-41a8-b66e-6bb3eec11cba"
      unitRef="usd">2778600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="idc03c10e08964a88b663a184122907a2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzYtMS0xLTEtMA_bc79dffe-6998-4dd1-9890-c767ffb545a4"
      unitRef="usd">127700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="iafb1c83cdeb143e5bd4557e4152ef090_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzYtMy0xLTEtMA_39db9c88-0b5a-4a08-a6ff-69bc1a7b144d"
      unitRef="usd">576000000.0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i89c20345b5eb4e11b0d62930d8427048_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzYtNS0xLTEtMA_2908969c-55b9-46d6-b145-173155dc63db"
      unitRef="usd">20400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzYtNy0xLTEtMA_f38f302b-3904-48e7-b4ee-063b1c53b10d"
      unitRef="usd">724100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i400709e4fbb2431a8c60b9f0001721f4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzctMS0xLTEtMA_5349bcb0-7243-4753-8bf4-c5351755d231"
      unitRef="usd">131100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4bb52c820db94f3aa2e279e49e3f772a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzctMy0xLTEtMA_8050f4b4-b1e2-4e93-98fa-cc3374ff4b25"
      unitRef="usd">1027300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia91f6946981c4e79a74688a13b7b6cae_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzctNS0xLTEtMA_552717de-3cf1-498d-af8b-c1d5a7b24cb1"
      unitRef="usd">40500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkOWE1MGQxOTBhZTk0OWY1YTQzNzAyOTU2ZmY5M2MyZi90YWJsZXJhbmdlOmQ5YTUwZDE5MGFlOTQ5ZjVhNDM3MDI5NTZmZjkzYzJmXzctNy0xLTEtMA_ec4c1f0c-23e1-4018-a919-7bbef428c58e"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ica5f21c6cd2348a196b1a5aabce51c96_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzItMS0xLTEtMA_9f2936b1-ba68-4d40-a086-0d5ee6788128"
      unitRef="usd">109600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1b9f7171e7754520b8801272436020bd_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzItMy0xLTEtMA_9334e934-5ad7-4d9e-bb99-c27b4c58d6a1"
      unitRef="usd">606000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic77265ab5c594a27b0736ca509460655_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzItNS0xLTEtMA_2178b9b1-6a25-4fe6-b571-50a28af5bd75"
      unitRef="usd">46000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic9925b2c3e594ae0812001969da2a99b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzItNy0xLTEtMA_0a44aff4-e1c3-4d29-917d-9a9c1a8101bf"
      unitRef="usd">761600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzMtMS0xLTEtMA_87de97ff-467b-425c-8be6-855d6f92ca61"
      unitRef="usd">679300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzMtMy0xLTEtMA_db66a322-ff0c-4276-998d-53a91f2221af"
      unitRef="usd">2686700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzMtNS0xLTEtMA_a17e7462-79ac-4c2e-83f6-f1986d886593"
      unitRef="usd">23100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzMtNy0xLTEtMA_5faf8977-5ddf-4312-93fa-7875eb8c590d"
      unitRef="usd">3389100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzQtMS0xLTEtMA_a35201b1-b91b-4d65-8b40-64b8ff7707c2"
      unitRef="usd">300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzQtMy0xLTEtMA_1b55bed4-f87b-42dd-897f-2d9f74772a84"
      unitRef="usd">10000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzQtNS0xLTEtMA_a16344d1-25df-446d-84fb-4f0af6439748"
      unitRef="usd">1800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzQtNy0xLTEtMA_6faebd2a-4f5a-4968-a845-97836530fc10"
      unitRef="usd">12100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzUtMS0xLTEtMA_03680e2e-a29c-4461-aaf4-be7ece07336a"
      unitRef="usd">551700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzUtMy0xLTEtMA_21d8d10e-7355-4736-8a51-ccb284a14b91"
      unitRef="usd">1887600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzUtNS0xLTEtMA_783de352-e1d3-4d36-9ab6-fe778a133c14"
      unitRef="usd">1100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzUtNy0xLTEtMA_f58bc350-3f78-42cf-a2ef-13894f1c6443"
      unitRef="usd">2440400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i3f66415bc29a4084b53ec708b69a3bb2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzYtMS0xLTEtMA_ad79539f-1547-40da-b9a7-e5d540933d97"
      unitRef="usd">109100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="ia3d1c5b00f5944a097ed2d9f36eab6f9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzYtMy0xLTEtMA_887c648d-995f-4bcb-9394-04d42755cd18"
      unitRef="usd">506300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i38d73eafe45e4d3b88598164b6d1dd9e_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzYtNS0xLTEtMA_288ca3ff-110f-44b2-bdf4-b7e5e67e25f2"
      unitRef="usd">31500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzYtNy0xLTEtMA_406c20b4-8c97-4b7e-bdd0-de617ccf156d"
      unitRef="usd">646900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iec6a7b631471438e8fee99a379470ccb_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzctMS0xLTEtMA_083dc12e-5bd3-4f62-9814-8c2dae343f54"
      unitRef="usd">127800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2d8cb46beb3d4d47884b9ee3730ccea5_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzctMy0xLTEtMA_d9da0d68-3424-4cd7-a24a-3cbe2836895e"
      unitRef="usd">888800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1bb4285e484a4003bbfb3010fd8b052b_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzctNS0xLTEtMA_bd2bbacc-9c50-458c-9908-146fec39a9cd"
      unitRef="usd">34700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozMzA3ZTFmMTQyMTE0ZmNmODUxYWJhODllNThkOGY4Mi90YWJsZXJhbmdlOjMzMDdlMWYxNDIxMTRmY2Y4NTFhYmE4OWU1OGQ4ZjgyXzctNy0xLTEtMA_20bfdee0-d737-44d4-96f0-b9988c35d5be"
      unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NjM_301b2447-00de-4f72-99a2-777ffd5f6f3a">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8f40d69597314563b8de93e06ec34c1c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzItMS0xLTEtMA_94bf24c9-e5cd-48ea-a672-4e700dc17687"
      unitRef="usd">195400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i195b915d47274fca99fe4a792ac7ea69_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzItMy0xLTEtMA_043e833d-fb68-419b-81df-a0ae7684d0e0"
      unitRef="usd">197800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzMtMS0xLTEtMA_2305c86f-ff12-4ae1-ad38-469d71fb56f2"
      unitRef="usd">1080600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzMtMy0xLTEtMA_a7db5ddc-265a-4c9a-8560-4b4a59b39277"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzQtMS0xLTEtMA_7586686f-bc25-44cb-b1cb-986c4482ea53"
      unitRef="usd">1276000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTpkMTVlODYxOTE0MmU0YTg4YTk5MzA3MjFjMTllODY3ZC90YWJsZXJhbmdlOmQxNWU4NjE5MTQyZTRhODhhOTkzMDcyMWMxOWU4NjdkXzQtMy0xLTEtMA_a5e0c81f-868c-4aa8-9106-c1c07ca960e7"
      unitRef="usd">1198900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NTQ_76315981-623f-4a6c-ae43-8ee110d52442">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;748.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,977.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;748.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,977.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="i9559172621a745278ce2779747432dec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzItMS0xLTEtMA_ebec6446-e5a7-463a-ab56-bd96dcff1338"
      unitRef="usd">1080200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i3b6b5a9481f349908c730396c050643d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzItMy0xLTEtMA_c93cb881-346b-4e1c-84cd-0e8e13ed01ac"
      unitRef="usd">1542400000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzItNS0xLTEtMA_97df85a1-a3e1-4b41-a47e-a87f40dfdb03"
      unitRef="usd">1431900000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i9559172621a745278ce2779747432dec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzMtMS0xLTEtMA_77f15f1d-626f-41db-8e72-648836461ee1"
      unitRef="usd">897600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i3b6b5a9481f349908c730396c050643d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzMtMy0xLTEtMA_df0dc30c-3e83-4c77-9284-018a02519d6a"
      unitRef="usd">748000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzMtNS0xLTEtMA_4b06ae48-ce42-4306-a8b6-5592978f7d91"
      unitRef="usd">548300000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzQtMS0xLTEtMA_e1834f38-5293-4fab-acbd-e6878c145f15"
      unitRef="usd">1977800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzQtMy0xLTEtMA_213fea8b-1e43-4d14-a8db-917c757778bb"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee2514a987784410a8165984f87269d3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTozY2M4MDRjNTM1NDE0MDc5OWY2NmM2OGNkZDA4NWI1Mi90YWJsZXJhbmdlOjNjYzgwNGM1MzU0MTQwNzk5ZjY2YzY4Y2RkMDg1YjUyXzQtNS0xLTEtMA_c5f5cbd4-885e-4f47-8744-3b8023bcfe49"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzk3OA_0a92c5be-03d9-47c4-9446-c747a4548611"
      unitRef="number">0.147</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
    <biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzk4Mg_87ebe664-d74a-41d7-af60-5223cd39b7f1"
      unitRef="number">0.159</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
    <biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzk4OQ_54bdfad5-84c6-4181-913c-32e4e63da4fc"
      unitRef="number">0.147</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
    <biib:OtherrevenuesTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzI3NDk_b88bce9c-de1f-4a2d-a385-e1209a98891d">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from collaborative and other relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;719.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;774.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="ifd59c1996ba049328473d73e6ebc2376_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtMi0xLTEtMjA3ODQ_a5b00f64-559a-420c-aad6-72bf8b417e70"
      unitRef="usd">20900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia29bfccabbb4483d896c6bb788ec20c3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtNC0xLTEtMjA3ODQ_d5eb398d-ba15-4464-939f-175521476cde"
      unitRef="usd">106200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63c7287b63dc4cd3a1a2ec95a9d031bb_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtNi0xLTEtMjA3ODQ_f5c5fa51-5370-45b1-9c7a-f05a32a72c85"
      unitRef="usd">96400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9dd5d205fed849349f4c94a2eb02cdd4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtMS0xLTEtMA_7a6ceeed-6476-43f4-8735-623b90a204d4"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a785963e61a4b4e817f15fa26f0d819_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtMy0xLTEtMA_e2ec88aa-7593-4510-8532-a1c7cc4b74e2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iddf5ae537bd74ff9a59f2b74a8161266_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzMtNS0xLTEtMA_db1feb82-b271-4b31-88a5-df409d300b93"
      unitRef="usd">-8600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i87e510b249bf46dc94c9604a2b8b9a69_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzctMS0xLTEtMA_acbfa933-be31-443f-bc8b-62f6fef06e43"
      unitRef="usd">33900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29c0819a2f984821bb989e9609805bb8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzctMy0xLTEtMA_e0b43d4e-471a-42ec-b9bb-2bd7059bf985"
      unitRef="usd">17000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e58e40285c848e296a601009ac7f815_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzctNS0xLTEtMA_14be323f-e546-4cff-9e2e-1ebdef22ddb0"
      unitRef="usd">38700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70ef21a6d03740f8aa272b7fdb22b854_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzgtMS0xLTEtMA_fdbb93dc-5475-4dd8-b5c9-276823e776fa"
      unitRef="usd">719100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i34ea9f4eaaa24324b4547475bd116c88_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzgtMy0xLTEtMA_b7927810-f885-4dae-80ff-e9d0faa52d39"
      unitRef="usd">584500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0eb160e00a5f449ca3dc21f07ab9ba0f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzgtNS0xLTEtMA_9b517738-c901-4c5c-bec5-de7a9f6d6db1"
      unitRef="usd">459400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzktMS0xLTEtMA_ee75e8df-b447-41ee-8728-3ff134a6ee74"
      unitRef="usd">774600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzktMy0xLTEtMA_b2efdc22-c05d-4242-bd9b-36570a1dfde2"
      unitRef="usd">707700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2987b04d4c240d88b84a50c04ca2df1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90YWJsZTo0NGI1NmJmZmI4NTU0MmNiYjViMzE4OTQ4NmM2ZWQ1NC90YWJsZXJhbmdlOjQ0YjU2YmZmYjg1NTQyY2JiNWIzMTg5NDg2YzZlZDU0XzktNS0xLTEtMA_5e230af7-184d-48b7-942a-18e4a3fcb63e"
      unitRef="usd">585900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3976604c455244a68c5f8bc26ebe6514_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzE1NzA_39468b56-5d48-4ac1-b4c4-d9c95bd6c99d"
      unitRef="usd">48600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a6054a3521e4fad899551ca7aeb3026_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzE1NzQ_bd9f306f-abda-4400-9fe8-257272655be9"
      unitRef="usd">383200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i18053bf504534e879bf5029dbb2066e7_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzE1ODE_dccc3ce4-06b3-4e83-8da7-7c6281972cf6"
      unitRef="usd">206700000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i9d72ff5a209c4e3b8fd84b931863f9d2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzE5OTU_0a0781f1-d232-41c0-b38a-0faf9bd9b8ff"
      unitRef="usd">500000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Revenues
      contextRef="i609fe60df7e64f54a5f65e6a8167f50a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzI4NDM_0a9c2d7e-3b7a-4aa8-85c1-fdadb80a0cd7"
      unitRef="usd">346200000</us-gaap:Revenues>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if028deb520d34a2aa081b6f9c3dac0e9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzI4Mjk_1f2e7a0e-ea29-40fc-8a5c-5ea97ab6f4bd"
      unitRef="usd">153800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i9d72ff5a209c4e3b8fd84b931863f9d2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTAvZnJhZzowZjk1MDJlZTRiOWE0MThmOTBhN2Q4ZDNkMGM2NTM5Zi90ZXh0cmVnaW9uOjBmOTUwMmVlNGI5YTQxOGY5MGE3ZDhkM2QwYzY1MzlmXzEwOTk1MTE2MzIwNzQ_0a0781f1-d232-41c0-b38a-0faf9bd9b8ff"
      unitRef="usd">500000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzE0MDc_2345aea0-01f8-46f1-af1b-165d9639928c">Inventory&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled $26.6 million, $52.2 million and $41.9 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This transaction included the sale of $14.0 million of work in process inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we sold to FUJIFILM approximately $41.8 million of raw materials that were remaining at the Hiller&#xf8;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzE0MTQ_50e7d367-7ea3-4450-9a97-4ae220acbd14">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;460.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,068.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzItMS0xLTEtMA_98fe41ff-0f92-499f-99cd-35d13715067b"
      unitRef="usd">314900000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzItMy0xLTEtMA_7ee1bd99-51ec-4b99-9d20-4e58a3bad222"
      unitRef="usd">169700000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzMtMS0xLTEtMA_608a9028-2a0a-420b-b858-69fa1e0808e7"
      unitRef="usd">544500000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzMtMy0xLTEtMA_97132928-0910-419e-adb7-5fe72dcadeee"
      unitRef="usd">460000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzQtMS0xLTEtMA_9739c56e-f188-46ff-adc5-299e4403616a"
      unitRef="usd">209200000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzQtMy0xLTEtMA_2bfe87aa-b66e-4271-9ea2-c2bb8f505fe5"
      unitRef="usd">174500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzUtMS0xLTEtMA_82f4c293-f6be-49ee-a421-8fd01380fc22"
      unitRef="usd">1068600000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90YWJsZTplNWM0MmY4ZjdiOWM0MDRiYWJmZjdkNzJlNGQxZTk5Zi90YWJsZXJhbmdlOmU1YzQyZjhmN2I5YzQwNGJhYmZmN2Q3MmU0ZDFlOTlmXzUtMy0xLTEtMA_ade985f6-d2d5-474f-8ee5-abc8ca0e5318"
      unitRef="usd">804200000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:InventoryWriteDown
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzY0Nw_7d7d572b-77fd-4509-ad4f-485ddb5f7cfa"
      unitRef="usd">26600000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzY1MQ_f9b83923-0487-48a9-90f2-528aa56abfdb"
      unitRef="usd">52200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzY1OA_a46e44db-6492-44f3-95b9-e6ec34689ed0"
      unitRef="usd">41900000</us-gaap:InventoryWriteDown>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="i16eea92696684f6f8f01944879fe877c_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2Xzk3OQ_af585e43-8104-46ef-856d-cd41696eca44"
      unitRef="usd">14000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <biib:InventoryrawmaterialssoldtoFUJIFILM
      contextRef="i2e9e587add174faba8df37c45bf81a84_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTMvZnJhZzplZjA0YjExYWU2NGU0OTdjOGU0MzIxMzMzZGUzYzhmNi90ZXh0cmVnaW9uOmVmMDRiMTFhZTY0ZTQ5N2M4ZTQzMjEzMzNkZTNjOGY2XzEwNTk_f3070b7c-9d6e-4f94-85fa-5d048d7296e7"
      unitRef="usd">41800000</biib:InventoryrawmaterialssoldtoFUJIFILM>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwNjE1_a0cafe9f-72ab-4657-b5b2-9f091dc66842">Intangible Assets and Goodwill&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,257.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,379.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,881.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,497.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,084.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,881.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,527.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization and impairments of acquired intangible assets totaled $464.8 million, $489.9 million and $747.3 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of acquired intangible assets, excluding impairment charges, totaled $255.1 million, $274.0 million and $381.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The decrease in amortization of acquired intangible assets, excluding impairment charges, over the three years was primarily due to a low&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;er rate of amortization for acquired intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $115.0&#160;million impairment charge related to BIIB111, which was obtained as part of our acquisition of NST, a $75.4&#160;million impairment charge related to BIIB054 (cinpanemab) and a $19.3&#160;million impairment charge related to one of our other IPR&amp;amp;D intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2019, amortization and impairments of acquired intangible assets reflects the impact of a $215.9 million impairment charge related to certain IPR&amp;amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF), which was discontinued in the third quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2018, amortization and impairments of acquired intangible assets reflects the impact of a $189.3 million impairment charge related to certain IPR&amp;amp;D assets associated with our vixotrigine program, as discussed below, and a $176.8&#160;million impairment charge related to our U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan as well as other amounts related to our other marketed products and programs acquired through business combinations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of December&#160;31, 2020 and 2019, relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of NST and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Convergence Pharmaceuticals Holdings Ltd. (Convergence). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;amp;D programs with an estimated fair value of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$585.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For additional information on our acquisition of NST, please read &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BIIB111&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2020 we began experiencing third-party manufacturing delays that may impact our timeline for a potential filing of a Biologics License Application (BLA) for BIIB111 for regulatory approval by up to one year. In addition, we determined that forecasted costs associated with advancing the BIIB111 program through Phase 3 development and potential commercialization will exceed our original estimates. We reassessed the fair value of the program based on these changes in assumptions and determined that the program was partially impaired. We recognized an impairment charge of $115.0&#160;million during the fourth quarter of 2020, which resulted in a reduction of the IPR&amp;amp;D asset from $480.0&#160;million to $365.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BIIB054&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2021 we announced that we discontinued development of BIIB054 as a potential treatment of Parkinson's disease as our Phase 2 SPARK study did not meet its primary or secondary endpoints. Although we made this determination in February 2021, it was based on conditions that existed as of December&#160;31, 2020. As a result, we recognized an impairment charge of approximately $75.4&#160;million during the fourth quarter of 2020 to reduce the fair value of the related IPR&amp;amp;D intangible asset to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IPR&amp;amp;D impairment charges were included in amortization and impairment of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. The fair value of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of December&#160;31, 2020, the carrying value associated with our vixotrigine IPR&amp;amp;D assets was $177.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,757.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,706.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increase to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Elimination of goodwill allocated to Hiller&#xf8;d, Denmark manufacturing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(69.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,762.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,757.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of December&#160;31, 2020, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwNTk1_98f6a7e9-0a7d-44dc-b47f-c9ba0e007b65">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,394.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,257.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,379.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,881.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,497.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,136.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,084.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,881.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,527.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItMy0xLTEtMA_aa29a957-6997-4fee-954a-66da855b7553"
      unitRef="usd">7394300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItNS0xLTEtMA_1f48612d-f674-48e9-9857-4ab0e67de144"
      unitRef="usd">5136500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItNy0xLTEtMA_a00f6831-5605-4775-be5c-343be50dcb74"
      unitRef="usd">2257800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItOS0xLTEtMA_67af51b8-ace1-4c68-b1b0-9761bb7d6100"
      unitRef="usd">7379300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItMTEtMS0xLTA_af61b18e-4cb4-4b30-802f-1bcd1075d050"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzItMTMtMS0xLTA_bd70cae0-794c-45e7-8e4d-113c6ac7858a"
      unitRef="usd">2497900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i76d271b53e29411abc2a151b7350aeb7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzMtMy0xLTEtMA_edb25d0a-8e10-4eaa-9c51-ee7f7cf20763"
      unitRef="usd">762500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i76d271b53e29411abc2a151b7350aeb7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzMtNy0xLTEtMA_f60f44f2-3509-45b2-9d78-8db0ef95be43"
      unitRef="usd">762500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8c498e3888a34f50a02f1bb18e32ad14_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzMtOS0xLTEtMA_3b447a55-7f1c-4e70-9c3f-e80bca7a601c"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i8c498e3888a34f50a02f1bb18e32ad14_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzMtMTMtMS0xLTA_acada7d8-dded-48e1-836a-59662e239958"
      unitRef="usd">965500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0293853038ec4dbf8d988ed6233a88a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzQtMy0xLTEtMA_21cb51b7-a16b-4e8b-baec-779b9e9e3dc4"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0293853038ec4dbf8d988ed6233a88a0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzQtNy0xLTEtMA_a40400c7-b413-435b-9e1a-04bba1484ba0"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie292720cdee34fa4a2f50bd921742df8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzQtOS0xLTEtMA_860016a7-1eb9-4ee6-b050-0d0cba9b3f6a"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie292720cdee34fa4a2f50bd921742df8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzQtMTMtMS0xLTA_1a2dd759-52ec-4333-b120-49480e5694d3"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtMy0xLTEtMA_770df6ba-4ec5-4eff-b01d-7c3b84004ad1"
      unitRef="usd">8220800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtNS0xLTEtMA_7a5caff6-2e2e-4f72-83dd-183959e00ad0"
      unitRef="usd">5136500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtNy0xLTEtMA_4759a84b-6103-465e-868f-211e5d39b12a"
      unitRef="usd">3084300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtOS0xLTEtMA_375e558c-9594-453d-8c21-705cd15d4f2e"
      unitRef="usd">8408800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtMTEtMS0xLTA_1ac9ea54-a0b8-41fa-ae4b-72e15a8d44e7"
      unitRef="usd">4881400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo4NTIzZjNkNWJmODg0NDBkYWU1OTRiODE1NTdiOTVlMy90YWJsZXJhbmdlOjg1MjNmM2Q1YmY4ODQ0MGRhZTU5NGI4MTU1N2I5NWUzXzUtMTMtMS0xLTA_151afb73-51c6-4c27-ba5a-3d96f250ff3e"
      unitRef="usd">3527400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NTIwMTU_d1dc8568-13a6-4cfe-8ace-2bb33ca69898"
      unitRef="usd">464800000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzI3Nw_384ad337-d19a-4e1b-8296-1c00b94cd6ed"
      unitRef="usd">489900000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzI4NA_7edde50b-a6e5-4343-a068-a9b819871453"
      unitRef="usd">747300000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NTIwMjQ_e2efbc13-9e47-499a-929a-98087c7e35c0"
      unitRef="usd">255100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzQyMg_d9b9b274-a674-4a2b-b66d-4e82f6b0fce2"
      unitRef="usd">274000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzQyOQ_62eb7af9-9cf4-487d-9abd-5aaf00cff507"
      unitRef="usd">381200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6e983ff4043d40f0913bb5c532a2f59c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NTIwOTk_f60e8281-8e6f-4aa7-b5d6-850c67baf59e"
      unitRef="usd">115000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="idb36452ab02142988e739a2d7605d7ff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzQzOTgwNDY1NDU1ODE_d78c5c66-8764-4863-9562-93b33c00451f"
      unitRef="usd">75400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <biib:AmortizationandImpairmentofAcquiredIntangibleAssets
      contextRef="i101d5553f62a4ad998a4e79cfea8fca3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2Mzg2NDg_8af83f93-a30f-4fa6-9924-58773b46a712"
      unitRef="usd">19300000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ic1193619aae94660913bc904c7ad0ebd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzgyMg_8990040d-1e3e-4486-b294-5c0b8b099880"
      unitRef="usd">215900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ia68ac17ffb634d7ea358cffd1d2ff11c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzExNTI_8c45346b-ede7-458e-88d3-cd5573c1fefc"
      unitRef="usd">189300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ic1c8b3e3b2804596ba415198766ed335_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NDA4MTE_2c180697-775e-4e73-8026-9212a2f0a2eb"
      unitRef="usd">176800000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ibef78125dd7d4a94a4efe455cc442105_I20190607"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzYzNjk_7f8a7755-8ff7-4a1c-bd48-d89d1f9166a5"
      unitRef="usd">585000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i1f7617347de84315b946e8a49e9bd554_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NTE5ODA_83422eaa-0811-4406-b540-37f9fe387596"
      unitRef="usd">115000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia56ada61d04148c9aa29b83378b86afa_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NjM0NjQ_bae548d0-2ca2-4605-ac91-356db2c02e9a"
      unitRef="usd">480000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i725b0e19a3884b52a34ffa0720d25883_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NjM0ODA_8f76828b-5a23-41d2-a08b-1b9fac6d8d77"
      unitRef="usd">365000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i14f3a2917b0f4c51b7e1a5f8612047eb_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzQzOTgwNDY1NDU2MjY_c4cf34cb-89d8-4357-9c80-1c555315b338"
      unitRef="usd">75400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2ad3e4569ba84e3ab10d4fb4ff676171_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwOTk1MTE2NDg5NzU_809ed8cb-282e-44ee-b2ed-d923b11194ae"
      unitRef="usd">177500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzU0OTc1NTgxNjE1MjE_2c3d5f4f-33b0-4c37-bdde-b5775c7340a8">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzEtMS0xLTEtMA_d6dbd4be-e7a3-4787-8e0b-b3c709ed82bd"
      unitRef="usd">205000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzItMS0xLTEtMA_9f1e120a-6251-4a41-820a-edcf96d0acdf"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzMtMS0xLTEtMA_6c8ec636-6880-4660-8d70-b36d8445a148"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzQtMS0xLTEtMA_672614af-84e0-4f7e-ad6a-3b60801cdce8"
      unitRef="usd">225000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTplYjY0MDJhMmRlZDY0MGY1YWNjY2UxYTBmZWE5ZGM2OC90YWJsZXJhbmdlOmViNjQwMmEyZGVkNjQwZjVhY2NjZTFhMGZlYTlkYzY4XzUtMS0xLTEtMA_89a8e58f-fb79-4b8d-a41b-d7d59621527f"
      unitRef="usd">220000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwNjEy_726bfb6c-edc7-4664-84c9-6bef49e1e7b0">&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,757.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,706.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increase to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Elimination of goodwill allocated to Hiller&#xf8;d, Denmark manufacturing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(69.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,762.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,757.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzItMS0xLTEtMA_0d214b9e-8f14-4776-8a00-e6199d7ca258"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzItMy0xLTEtMA_fcb78abf-d953-4b06-8030-fc92d4e6ad6d"
      unitRef="usd">5706400000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzMtMS0xLTEtMA_0e6da53a-9acb-46dc-995b-0fc55b1dacb8"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzMtMy0xLTEtMA_24c962d8-76b1-4f8d-a1f2-786b2eb8ab3f"
      unitRef="usd">117500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzQtMS0xLTEtMA_f94dcae0-bd4e-4189-ac9e-7c1400ac30fe"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzQtMy0xLTEtMA_fbb38be8-c18f-44b1-870a-5785e793f7ac"
      unitRef="usd">69500000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzUtMS0xLTEtMA_cf336443-8245-4bf7-9dcf-50341769390a"
      unitRef="usd">4300000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzUtMy0xLTEtMA_dc823ad9-f096-41b1-8f62-e178195b22b3"
      unitRef="usd">3400000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzYtMS0xLTEtMA_9afb556f-da5a-4fe1-8909-fb1df33fcb51"
      unitRef="usd">5762100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90YWJsZTo0MmI3NDMyMmYyZWU0ZjBiYjAwZmYwNTYwZDc2MmE3ZC90YWJsZXJhbmdlOjQyYjc0MzIyZjJlZTRmMGJiMDBmZjA1NjBkNzYyYTdkXzYtMy0xLTEtMA_648a8b2f-d7d8-4033-b8b8-358ba91b93d8"
      unitRef="usd">5757800000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNTYvZnJhZzo0ODA3ODgxNzdiNmE0OTMxYWViMTI0MDg5YWNjZWY5Yy90ZXh0cmVnaW9uOjQ4MDc4ODE3N2I2YTQ5MzFhZWIxMjQwODlhY2NlZjljXzEwNDU3_2ff12343-4caa-4581-9984-35afdb920d93"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzcxMjI_c91bdaed-1393-4694-97ac-a9bfaa4e0da0">Fair Value Measurements&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,703.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in&#160;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,695.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,695.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,912.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value during the years ended December&#160;31, 2020 and 2019. In addition, there have been no changes in valuation techniques during the years ended December&#160;31, 2020 and 2019. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in Sangamo Therapeutics, Inc. (Sangamo) common stock, Denali Therapeutics Inc. (Denali) common stock and Sage Therapeutics, Inc. (Sage) common stock and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo, Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares of Ionis common stock were initially subject to certain holding period restrictions that have since expired. The fair value of this investment was a Level 1 measurement as of December&#160;31, 2020. For additional information on our collaboration arrangements with Ionis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$259.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 to 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 39.9% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to assets and liabilities that are recorded at fair value on a recurring basis, we record assets and liabilities at fair value on a nonrecurring basis as required by accounting principles generally accepted in the U.S. (U.S. GAAP). Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Beginning Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ending Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BIIB111 intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;480.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, we recorded a partial impairment charge of $115.0&#160;million related to BIIB111. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6, Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,509.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,054.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,003.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,897.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,365.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,536.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,515.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,553.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen International Neuroscience GmbH (BIN)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(86.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, approximately $110.3 million and $197.7 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, changes in the fair value of our contingent consideration obligations were primarily due to our discontinuing development of BIIB054 for the potential treatment of Parkinson's disease, resulting in a reduction of our contingent consideration obligations of $51.0&#160;million as well as other changes in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;probability and the expected timing of the achievement of certain remaining developmental milestones, changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2019, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of $61.2&#160;million as well as other changes in the probability and expected timing of achievement of certain developmental milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convergence Pharmaceuticals Holdings Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of $274.5 million. As of December&#160;31, 2020 and 2019, the fair value of this contingent consideration obligation was $259.8 million and $244.6 million, respectively. Our most recent valuation was determined based upon net cash flow projections of $400.0 million, probability weighted and discounted using a rate of 0.6%, which is a measure of the credit risk associated with settling the liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Biogen International Neuroscience GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of $81.2 million. We discontinued further development of BIIB054 for the potential treatment of Parkinson's disease based on the results of a Phase 2 study of BIIB054. Additionally, during the third and fourth quarters of 2020 we discontinued other programs related to our acquisition of BIN for which we had immaterial contingent consideration obligations. As a result, the fair value of the contingent consideration obligations related to our acquisition of BIN has been adjusted to zero, resulting in a gain of $101.5 million for the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the acquired IPR&amp;amp;D assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. These assets are tested for impairment annually until commercialization, after which time the acquired IPR&amp;amp;D will be amortized over its estimated useful life using the economic consumption method. In connection with our acquisition of BIN, we recognized a $110.9&#160;million acquired IPR&amp;amp;D intangible asset. We discontinued further development of BIIB054 for the potential treatment of Parkinson's disease and recognized an impairment charge of $75.4&#160;million during the fourth quarter of 2020 to reduce the fair value of the IPR&amp;amp;D intangible asset to zero. In connection with our acquisition of Stromedix Inc., we recognized a $219.2 million acquired IPR&amp;amp;D intangible asset. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF and recognized an impairment charge of $215.9&#160;million to reduce the fair value of the IPR&amp;amp;D intangible asset to zero. In connection with our acquisition of Convergence, we recognized a $424.6 million acquired IPR&amp;amp;D intangible asset. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;amp;D assets associated with our vixotrigine program totaling $189.3&#160;million. For additional information on our IPR&amp;amp;D intangible assets, including a discussion of our most significant assumptions, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6, Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzcxMTI_e67bfd95-2327-4981-922b-162810cab444">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other&lt;br/&gt;Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;627.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,703.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;477.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;217.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in&#160;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,695.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,695.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,920.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,912.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzItMS0xLTEtMA_cd10f8c5-effe-418e-a071-35e265ab5a17"
      unitRef="usd">626900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzItMy0xLTEtMA_d3fecf93-746e-4ef5-80ae-83b0213ad154"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2b88845b78404eafbfca745c512904b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzItNS0xLTEtMA_42b8428a-26f6-4dfd-9803-8bd2c8d3e7b6"
      unitRef="usd">626900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i11a386c121b94d3285b2e93991eee966_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzItNy0xLTEtMA_2472dbde-c2e6-4d80-9589-1dd065827023"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31de162949914248aef0218bfb3cae08_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzQtMS0xLTEtMA_cb535667-a42a-4d73-abc5-93551f7f9161"
      unitRef="usd">1301500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia30b12536469448f9255d5e1df2de125_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzQtMy0xLTEtMA_41f656d8-9589-4427-b668-56bf07ae5724"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa11cb31d8024230a65d4ab2be7a7509_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzQtNS0xLTEtMA_e2a6a92e-d5d6-4934-a18a-014fedd9651b"
      unitRef="usd">1301500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib868142b7926459283806400925364f0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzQtNy0xLTEtMA_3ba78d98-b3bd-471f-ae80-1acb69ec42df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d4400d07ebb429faf284232b75c3fad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzUtMS0xLTEtMA_a95e83ff-3c92-4b91-9d78-873d3fef5691"
      unitRef="usd">627100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1295c3d9fdcd4cd6bd7a06e54f915289_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzUtMy0xLTEtMA_65b7dd96-5d21-4aef-9471-ea242485d491"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b1a4978f65a4ad194d0e7fd7c37d454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzUtNS0xLTEtMA_c18acad9-61f7-43b8-a088-8679584e12f2"
      unitRef="usd">627100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia05d20dd706c4482ac970a02c04378de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzUtNy0xLTEtMA_749794b3-b021-46d9-a2e8-72c6463076ac"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i728ad60c42494777a77a89260395a79e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzYtMS0xLTEtMA_c49a4464-530b-4370-869f-f9f9f2d8d424"
      unitRef="usd">122400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5360f78fa9cf47a49f8eb29cf63a6bb6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzYtMy0xLTEtMA_e18d95b0-4167-4724-9b57-061e9c2fec6b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b1e4d4d27f141faaceb13587dfc5353_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzYtNS0xLTEtMA_24aa0bd6-9fab-44f1-8ab4-6bf4f8ab7469"
      unitRef="usd">122400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i109944c309984c92ba371b3ed38bc32c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzYtNy0xLTEtMA_4c1be5d5-2442-4be6-8da5-38754456edbf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzctMS0xLTEtMA_46711f17-aa3f-42b6-bea3-9d34a29e7d79"
      unitRef="usd">1974300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzctMy0xLTEtMA_33c1bfa4-626a-4e62-8e35-059605ed120a"
      unitRef="usd">271100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2b88845b78404eafbfca745c512904b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzctNS0xLTEtMA_e4510895-7423-4a00-94da-6d8431c3f6b8"
      unitRef="usd">1703200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i11a386c121b94d3285b2e93991eee966_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzctNy0xLTEtMA_11300379-eb07-4e3d-ab1f-1cea378bf1c3"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzgtMS0xLTEtMA_d84f7b2e-dd70-4850-8ca3-6c862b156222"
      unitRef="usd">20500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzgtMy0xLTEtMA_b502ef48-55a4-4a0f-a48b-cb66955eeb77"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2b88845b78404eafbfca745c512904b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzgtNS0xLTEtMA_34c8080d-25b1-4c02-a8c3-778db3800133"
      unitRef="usd">20500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i11a386c121b94d3285b2e93991eee966_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzgtNy0xLTEtMA_a89f711c-1a0c-40a4-aaf3-e643d1682483"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzktMS0xLTEtMA_806a739b-3782-4330-8ddf-bd46e3d8342d"
      unitRef="usd">28200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzktMy0xLTEtMA_74245496-3957-4144-98d5-6f2ceffdb65c"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i2b88845b78404eafbfca745c512904b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzktNS0xLTEtMA_3ed6fedb-c232-4e7e-be29-11e23520b106"
      unitRef="usd">28200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i11a386c121b94d3285b2e93991eee966_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzktNy0xLTEtMA_13f798d5-795c-4a8f-9832-39af49a0ef9b"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEwLTEtMS0xLTA_71d467a1-d888-4283-84fd-8efa540f00d9"
      unitRef="usd">4700900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEwLTMtMS0xLTA_5d4773d3-7bdc-4950-aecc-99d347908d3d"
      unitRef="usd">271100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b88845b78404eafbfca745c512904b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEwLTUtMS0xLTA_828966f6-bc35-4b48-b87f-b33ae18e184a"
      unitRef="usd">4429800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i11a386c121b94d3285b2e93991eee966_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEwLTctMS0xLTA_39a78fa1-edf5-48d2-944f-63870bf5edfa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEyLTEtMS0xLTA_7526de6f-a085-4280-bc0f-ffe704a30bb0"
      unitRef="usd">217200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEyLTMtMS0xLTA_0565a44b-d47b-457b-b40d-77a6a8901c64"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i2b88845b78404eafbfca745c512904b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEyLTUtMS0xLTA_e3da15e0-9ad6-4fe2-8a02-18e03717e0eb"
      unitRef="usd">217200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i11a386c121b94d3285b2e93991eee966_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEyLTctMS0xLTA_ec2e0f78-ee39-430c-9fab-98edead7d5f8"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEzLTEtMS0xLTA_1b640dbe-d2ee-4e4e-bf33-4b9b2d4a2147"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEzLTMtMS0xLTA_8380f8e1-2d07-42ca-b29e-0552737bc9ed"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2b88845b78404eafbfca745c512904b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEzLTUtMS0xLTA_0d0198ff-54eb-44e9-b355-54ca6a728f30"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i11a386c121b94d3285b2e93991eee966_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzEzLTctMS0xLTA_6c4357a2-a244-44d1-88b9-b8021244f495"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzE0LTEtMS0xLTA_efcfe6b6-88f4-4170-bd08-864f6882629c"
      unitRef="usd">477000000.0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ife7148cb77ec48c4a82e74afba1044e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzE0LTMtMS0xLTA_e4b2ee19-228b-45f1-a033-24a3bc4ede10"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2b88845b78404eafbfca745c512904b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzE0LTUtMS0xLTA_862f2072-8c81-46a7-bca2-c0cff111429e"
      unitRef="usd">217200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i11a386c121b94d3285b2e93991eee966_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphOTJhYWY0NjU1OGM0MTg5YTE0YWQ2ODk1YThjZjBhNC90YWJsZXJhbmdlOmE5MmFhZjQ2NTU4YzQxODlhMTRhZDY4OTVhOGNmMGE0XzE0LTctMS0xLTA_5c63bbbb-3844-4c9a-9a83-8b8f4aea178a"
      unitRef="usd">259800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzItMS0xLTEtMA_f7c598ff-f750-46e0-a98f-8421ff68151a"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzItMy0xLTEtMA_80c7b3d5-5ad3-4b0d-8d2c-6826585476e9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzItNS0xLTEtMA_a0afe955-c0a4-4c48-b44e-f8178ec2822c"
      unitRef="usd">2541100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzItNy0xLTEtMA_9df591c0-ec7f-4c7b-8399-fe2899d75f3b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib6e51f6583c34ffea8242489d150dcac_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzQtMS0xLTEtMA_9cd6e147-f286-4282-982c-a0250653e228"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9faf10577b784e7f8fe0df2ba091b6df_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzQtMy0xLTEtMA_3f4505c2-2445-4cae-a0ad-2d92307a1fb6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc5ca70e7a0449ef9804d477da976c90_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzQtNS0xLTEtMA_fcffbf16-57e5-4a6e-8f1e-f2d7fbe39140"
      unitRef="usd">1695100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c6ed8b6d39d4f95be135a06386353e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzQtNy0xLTEtMA_67a20bde-809f-41ff-88dc-c71ce8a948ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9f12a8b2a02a45b5a3b5d20a2203d529_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzUtMS0xLTEtMA_d79c8c30-3697-4b70-8c92-f1bed4b2dbcb"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7b0ff43002742d382a430a6b312ac29_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzUtMy0xLTEtMA_23180ad5-6378-41f3-a32f-21c979ac5bc4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i078713d9a8a24ed788012f01caca7e4c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzUtNS0xLTEtMA_79fe2fcd-7dde-4c7a-9963-eede67c8e49e"
      unitRef="usd">1013900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22f29144216246c0ba14b7f3d524b07d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzUtNy0xLTEtMA_2e4dbf76-eeb9-46a3-a613-90181013ec19"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id37c27cce50943f586fccbb1bf987550_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzYtMS0xLTEtMA_66a6a4b3-0e5d-456f-9d18-59e2e1f5aa29"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05ee55d0301d4a5296dbfd62c35d349f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzYtMy0xLTEtMA_60cdb715-232b-4ced-87a9-7d563e1878cb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic10b6933b9ab4178884a89b8aeef21e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzYtNS0xLTEtMA_7d14fda0-4a1c-4363-871e-931012b8f3a9"
      unitRef="usd">261300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50c85d1b3eb3432491fd04d440130a03_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzYtNy0xLTEtMA_f7b3f347-d038-4047-b3d2-898fec93d84b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzctMS0xLTEtMA_901b6218-93a2-44f5-b389-dbc159336cf0"
      unitRef="usd">337500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzctMy0xLTEtMA_f8dae1b1-6702-4c2f-80fa-05fed76ebfa2"
      unitRef="usd">7900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzctNS0xLTEtMA_7334c420-638a-4aa9-9ec8-449b74dbf6bd"
      unitRef="usd">329600000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzctNy0xLTEtMA_ed04b452-fdeb-41f0-a93d-babbf5f48be1"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzgtMS0xLTEtMA_f697a99b-5cc6-4b60-b7d7-1e99da8533c2"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzgtMy0xLTEtMA_45cba3c8-5738-410e-b36a-33c73c5b9eb6"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzgtNS0xLTEtMA_6dec33c2-ca5c-4d9c-b757-f8d468eb931f"
      unitRef="usd">43800000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzgtNy0xLTEtMA_44a92d08-9b36-46ac-afe7-761c18505a48"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzktMS0xLTEtMA_aabe7f96-a7d0-45d6-b49d-58199b622cfc"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzktMy0xLTEtMA_16c97557-acf9-40ef-b6f0-c088e3b03814"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzktNS0xLTEtMA_99995520-5b09-4b9e-b5fe-74b32ffaea1b"
      unitRef="usd">27700000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzktNy0xLTEtMA_c1fada28-cf4e-497a-8a05-4f3f5f2d1dce"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEwLTEtMS0xLTA_4fafd492-fb22-44ac-bdce-11588d4e4872"
      unitRef="usd">5920400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEwLTMtMS0xLTA_2d11687f-6915-4c15-a27a-63da7340a82a"
      unitRef="usd">7900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEwLTUtMS0xLTA_636d71da-528d-4a53-8244-f1af92d5fa20"
      unitRef="usd">5912500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEwLTctMS0xLTA_543fbce6-ae96-4e09-99f0-0dd8249aca4b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEyLTEtMS0xLTA_fc7293f6-0da5-445b-b56d-5858ac79fdf1"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEyLTMtMS0xLTA_bab018a0-7372-4eb4-9bed-e33141eda53b"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEyLTUtMS0xLTA_f72e2141-d173-4586-ab55-54f03d766716"
      unitRef="usd">8300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEyLTctMS0xLTA_b5566199-e0d0-4452-84d6-ff33992809e0"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEzLTEtMS0xLTA_65ed69df-1fba-4704-a7ee-880967f4be50"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEzLTMtMS0xLTA_5d9a3961-7948-402c-bde3-3d953909cfdb"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEzLTUtMS0xLTA_dea46ec7-7145-47ef-ba73-9a63ada8c973"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzEzLTctMS0xLTA_0bfd2987-3d18-4176-a684-3c412938ee76"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzE0LTEtMS0xLTA_aaaa7f39-3b99-4dff-9bbf-b79c62664f35"
      unitRef="usd">354400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7eca7f157f2643bb819b32bb8e7dc084_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzE0LTMtMS0xLTA_8cef8566-1021-4cb5-81b0-19edaf96816a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i687ce2197ff242fb8d9744823666b4a4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzE0LTUtMS0xLTA_295c41a5-18e7-448d-802e-29218e7a25c8"
      unitRef="usd">8300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3e264b8e2f86435888156e14e7e26af2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTpjZWUxNTJkYTBjMTc0YzU2YTgyZWY0NDQxNDQ2ODY1OC90YWJsZXJhbmdlOmNlZTE1MmRhMGMxNzRjNTZhODJlZjQ0NDE0NDY4NjU4XzE0LTctMS0xLTA_d043b114-5d45-44ac-b413-9dfe7a06f249"
      unitRef="usd">346100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzU0OTc1NTgxNTY0MTA_dab0d7a2-f8a0-4512-a0d1-059c6cd87d23">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$259.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 to 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphYWE1NTNlYjkxZmM0NGZlOTI0YTljNzVkNTViZjI4Zi90YWJsZXJhbmdlOmFhYTU1M2ViOTFmYzQ0ZmU5MjRhOWM3NWQ1NWJmMjhmXzMtMi0xLTEtMTEyMDc_1ca42066-20f6-4711-8d39-c9d64e12d0cd"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia29e9f9c6a0f4c099a0d0b872c4ab3e0_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphYWE1NTNlYjkxZmM0NGZlOTI0YTljNzVkNTViZjI4Zi90YWJsZXJhbmdlOmFhYTU1M2ViOTFmYzQ0ZmU5MjRhOWM3NWQ1NWJmMjhmXzMtOC0xLTEtMTE3NTg_2e9f7f93-e4e1-480f-8891-c93ee53c1dd3"
      unitRef="number">0.0060</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i0afc7497a10045ec82e92ec6f6142457_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTphYWE1NTNlYjkxZmM0NGZlOTI0YTljNzVkNTViZjI4Zi90YWJsZXJhbmdlOmFhYTU1M2ViOTFmYzQ0ZmU5MjRhOWM3NWQ1NWJmMjhmXzMtMTAtMS0xLTExMjA5_4d408373-abd7-4a3a-8f1e-d710793854a7"
      unitRef="number">0.0060</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <biib:TechnologicalAndRegulatorySuccessProbability
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NDU1MTg_cbfefd24-33b9-4887-8532-a0e0624ed260"
      unitRef="number">0.399</biib:TechnologicalAndRegulatorySuccessProbability>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzQzOTgwNDY1MzA5MTc_9c8269b0-7b55-402c-8c06-144e7f202a2f">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Beginning Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ending Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BIIB111 intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;480.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i892b13c4cafa42ecb4c07f03ecf1b9af_I20190607"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo3NjBmN2Q3NjIxMzU0ZjAyODRlZjFlNGE0NjMwYmJmMy90YWJsZXJhbmdlOjc2MGY3ZDc2MjEzNTRmMDI4NGVmMWU0YTQ2MzBiYmYzXzItMi0xLTEtMTg1NTY_2615cb68-341e-4d0d-b058-1d4db120e513"
      unitRef="usd">480000000.0</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i31f77918266b4800a5e937031d200d33_D20200608-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo3NjBmN2Q3NjIxMzU0ZjAyODRlZjFlNGE0NjMwYmJmMy90YWJsZXJhbmdlOjc2MGY3ZDc2MjEzNTRmMDI4NGVmMWU0YTQ2MzBiYmYzXzItNC0xLTEtMTg1NTg_e2d6c847-4965-4aea-b485-30f77a17ad1d"
      unitRef="usd">-115000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib982081d33b9432380d458461cb24794_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo3NjBmN2Q3NjIxMzU0ZjAyODRlZjFlNGE0NjMwYmJmMy90YWJsZXJhbmdlOjc2MGY3ZDc2MjEzNTRmMDI4NGVmMWU0YTQ2MzBiYmYzXzItNi0xLTEtMTg1NjA_fdd0b994-d7fd-4c8a-8751-342596968717"
      unitRef="usd">365000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6e983ff4043d40f0913bb5c532a2f59c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NDc1NjQ_f60e8281-8e6f-4aa7-b5d6-850c67baf59e"
      unitRef="usd">115000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzU0OTc1NTgxNTY0MDk_b7b6a68a-e584-4864-966e-af47fcdaf294">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,509.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,054.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,038.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,003.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,897.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,557.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,365.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,107.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,536.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,515.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,553.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzItMS0xLTEtMA_ae316169-1bd0-43ab-adef-cee443feaaa8"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i4bbc25a9c5ac47fbbfd534ee97a1d39c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzItMy0xLTEtMA_3f4d0c16-f073-4743-85ce-3e0066869c2b"
      unitRef="usd">1509600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i43d8fda27d15472886e7714ecfd74f13_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzMtMS0xLTEtMA_0be07fc1-54e6-4f10-886e-e1d12beaf941"
      unitRef="usd">1054100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i801a46869f664fecb61055c870823b33_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzMtMy0xLTEtMA_f02abd31-fb0a-40ff-95b4-ae4a4fc8ab46"
      unitRef="usd">1038900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ifc1b899a302148ca9891b0255cc8aa0d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzQtMS0xLTEtMA_6d4d41c9-6536-42c2-8951-06c7e8daba7a"
      unitRef="usd">2003100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="if6b6dd5c2efe4f5396abf0aff9bfeccf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzQtMy0xLTEtMA_ddf2fe0e-3b7e-4531-9c2e-5cb6069c1a3f"
      unitRef="usd">1897200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i3c421dee5311428bb63a943e6edd3b3b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzUtMi0xLTEtMjkxMg_f71a1839-dc9d-450f-b544-9df548237199"
      unitRef="usd">1557200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i8ff588847a4742dbb38528249abffe4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzUtNC0xLTEtMjkxMg_820c3b85-0d0b-42c2-95ee-a01aeaa5adda"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="iddd13c0f2522452cb9725ea76f4505d0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzUtMS0xLTEtMA_54312191-7dc0-4a38-8689-9a8ea9246911"
      unitRef="usd">2365100000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ie0204ca1f1214960bd167eb5e80b1a81_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzUtMy0xLTEtMA_99b0fd1c-2211-4953-9b36-d29b042413be"
      unitRef="usd">2107900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="ic30eadf1122f4f10b6945f7d760771bf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzctMi0xLTEtMjkxNQ_1dde538d-2009-4bee-bb5c-888a92ac0c3f"
      unitRef="usd">1536400000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i83bcad67dce847b8b91749bab6735d86_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzctNC0xLTEtMjkxNQ_c5c9dccb-5ea7-4495-8c5c-426011a5350d"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzYtMS0xLTEtMA_388da5f9-88f1-4930-8c15-57f6bdb48c26"
      unitRef="usd">8515900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo1ZjU2NDJlMDgyYmM0OGUxOGQwNzAzM2M5NjFiYmQwNy90YWJsZXJhbmdlOjVmNTY0MmUwODJiYzQ4ZTE4ZDA3MDMzYzk2MWJiZDA3XzYtMy0xLTEtMA_7a414a27-24d7-461e-9989-f9947152b4aa"
      unitRef="usd">6553600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzQzOTgwNDY1Mjg2Mzk_09e91436-dfc1-4f2f-90d8-f5879528c60a"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i925b36a148674fc19a08cbd449595002_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzQzOTgwNDY1Mjg2NDc_db24c87b-bb74-410d-a171-f925441a0348"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzcxMzQ_ed743172-c1a7-4933-91af-82278cd776c8">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.608%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(86.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzItMS0xLTEtMA_4a37cd2b-1f2c-454a-9e85-5dd1286bc835"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i92764f5eb5834b79ae55dff4c1df9d03_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzItMy0xLTEtMA_6d15f948-aaf9-4f6e-a2a9-3a09ffbd9319"
      unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic89f75651f684c4e8666f45255e68b39_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzMtMS0xLTEtMA_33cb6d2b-14f8-4e62-8ebf-130425588dbb"
      unitRef="usd">86300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i56a9f448c619444ab4fff72a5de9ba77_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzMtMy0xLTEtMA_b4436dd2-ec16-4bdf-aecf-c371b2ef5957"
      unitRef="usd">63700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ic89f75651f684c4e8666f45255e68b39_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzQtMS0xLTEtMA_0f97119d-7f62-4613-bb7b-8504320db8a0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i56a9f448c619444ab4fff72a5de9ba77_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzQtMy0xLTEtMA_e54f4883-a28a-423d-b80a-894e15e48db0"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia4e82735011b489487c0fe39eb2af15c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzUtMS0xLTEtMA_08ce28d3-d2a8-474e-9179-eb012939b565"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6cabfc2eff6e4b7c87d6b4c7420c0c63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90YWJsZTo2YzE4NzU5NGM3OGY0MWYyOGVmOGRlNTFiN2MxYzFhMS90YWJsZXJhbmdlOjZjMTg3NTk0Yzc4ZjQxZjI4ZWY4ZGU1MWI3YzFjMWExXzUtMy0xLTEtMA_c57f8659-ef3d-4b64-bf7d-60dee7cdad3a"
      unitRef="usd">346100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if9f5fdb4ff554001875fedb563688ba3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzE2OTE_e6b70ddf-2cdd-489c-9b96-5052c76a6ae2"
      unitRef="usd">110300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ibe586d2389a346e4b21234342c93c79a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzE2OTg_5c668cee-c7dd-4739-9df4-a3f717f356a9"
      unitRef="usd">197700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzI3NDg3NzkwOTQ0NTY_71d9d030-d487-471d-b094-6ac318e83554"
      unitRef="usd">51000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzE2NDkyNjc0NTQ5NzA_dc245a5a-9968-441f-a779-03102080009b"
      unitRef="usd">61200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="if183ac868dc34ca58fc0c53525b4c288_D20150201-20150228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM1NzI_7b947eb3-5c44-4bf6-8dba-d3fa1412aa74"
      unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i648eef4285664a8dac0cdbc16d4a15eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM2NTY_4cdea13c-0125-49ec-b123-788f380f327a"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7237b9cff6a4464cb92770b4bf1cbbc2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM2NjM_e04c3c66-9fdd-48ba-affa-64e38bab20b1"
      unitRef="usd">244600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i648eef4285664a8dac0cdbc16d4a15eb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM3NjI_ccd7782b-242c-4d2e-8158-bbf0a5dd98d0"
      unitRef="usd">400000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <biib:FairValueMeasurementInputs
      contextRef="i51282ea551b1459695602c42c153aa71_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzM4MTg_6f324ac4-40af-462f-8c22-2be3df826f42"
      unitRef="number">0.006</biib:FairValueMeasurementInputs>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i90382b76ddef440099125efad57c3a58_D20101201-20101231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzUwMzk_dada9aa0-60d5-49aa-abbe-7b8f56aea2c4"
      unitRef="usd">81200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i2cc1602563fe4003b79c44b2d4563182_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTMwNzU_46961842-6998-4ffc-99c0-3a7bc1827efa"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idc66d48ef7a8480184a55afd9eb1ca13_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzcxNDY4MjU2MDMyMjk_0dc688e3-b55c-480f-8df6-98f86a6160ec"
      unitRef="usd">101500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="iff949adf9ab740fbb27bef3b64e6be50_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTM3NTQ_80c9737e-c5f5-4b38-ace6-b07b813bbc87"
      unitRef="usd">110900000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="idb36452ab02142988e739a2d7605d7ff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTIxNTA_f975ab37-3474-4b9a-9354-554e328307e5"
      unitRef="usd">75400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="i76d271b53e29411abc2a151b7350aeb7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTIxNzE_3e9afb41-8d01-46ad-b79a-4fbb9c1d2b4d"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ibff8fc3255cf42698cf5d8a08d11df44_I20120331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzYzNTY_7fff92f8-b897-42a8-a1d6-a06cd7eedb5c"
      unitRef="usd">219200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i8be1727d99e64340bb2d309e36968ac8_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTM4NTU_7f925496-803b-4590-ae9d-edea0c2a6b49"
      unitRef="usd">215900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="ib5ad52311e434feca77f912a91898714_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzQzOTgwNDY1Mjg4MTQ_2d5c0b5c-b7f5-4462-a776-8e59a80642f7"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i8a46f2c40caf49ea87719f6b7a9ee5bf_I20150228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzY3MDE_8933ca5e-134f-4bd1-9790-d72a831b2ea5"
      unitRef="usd">424600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i2afce0b61c084d69ab3183af171ee801_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjIvZnJhZzo5N2VhNzc5ZjNkZWE0MTAyOGY2NmIyY2ZhMjdiMjY5Ni90ZXh0cmVnaW9uOjk3ZWE3NzlmM2RlYTQxMDI4ZjY2YjJjZmEyN2IyNjk2XzEwOTk1MTE2NTM4MjQ_f91e83e3-3f6c-40ba-861a-5e68cae11d3b"
      unitRef="usd">189300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ4MDg_84e4fbf9-b3a6-48fd-9572-604565369629">Financial Instruments&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,628.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15.9&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;733.8&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,057.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,058.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;636.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;502.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,965.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,562.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,560.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,965.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities available-for-sale as of December&#160;31, 2020 and 2019, was approximately 11&#160;months and 14 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,299.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,007.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,173.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized losses for the year ended December&#160;31, 2020, 2019 and 2018, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, our strategic investment portfolio was comprised of investments totaling $2,024.6 million and $393.9 million, respectively, which are included in investments and other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in our strategic investment portfolio for the year ended December&#160;31, 2020, was primarily due to our purchases of Sage, Denali and Sangamo common stock, as discussed below. These purchases were reflected as net cash flows used in investing activities within the consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this collaboration in December 2020 we purchased approximately 6.2&#160;million shares of Sage common stock. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of zero based upon the fact that Sage and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration agreement with Sage, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately 13&#160;million shares of Denali common stock in September 2020. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration agreement with Denali, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased approximately 24&#160;million shares of Sangamo common stock. This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration agreement with Sangamo, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the carrying value of our investment in Samsung Bioepis totaled 673.8 billion South Korean won ($620.2 million) and 670.8 billion South Korean won ($580.2 million), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ4MDY_d3ce39b3-ec6e-4bc5-877f-274be2f1f324">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;368.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,628.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i81a1894f77974cf2b8aedcc04b6c5f86_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzItMS0xLTEtMA_faa4430b-1f73-4f9a-afd1-6793e60b7f78"
      unitRef="usd">61100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id3e9fb1cd6824fbb85da3d9df004f1ff_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzItMy0xLTEtMA_59db27d4-ddad-4d86-936d-d158390d597c"
      unitRef="usd">384400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8a84817f64104c25b845cd16a8f0ab52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzMtMS0xLTEtMA_933dae92-835b-47f2-a01e-d57e0223aff4"
      unitRef="usd">37400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i9959b5f071814b32bb44c12f7979e4f8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzMtMy0xLTEtMA_d4711a54-2718-4d75-84d2-bd49ec4575c8"
      unitRef="usd">368800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i368be994479c4748a98800a90058bb03_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzQtMS0xLTEtMA_225dab2e-a1c9-47a6-90aa-2ead15fd7569"
      unitRef="usd">505100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ia668578daa974ee2b66900846a7f2aa4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzQtMy0xLTEtMA_f4e3ba69-7acc-488b-901c-2e0b38cfef84"
      unitRef="usd">1628500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id8420ca71f3b4038bcfda28fcd31dc62_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzUtMS0xLTEtMA_a1e936af-ba65-40f5-a352-32eb8dc65051"
      unitRef="usd">23300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i6e3d526e5639439988a6a4d0a1596dbc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzUtMy0xLTEtMA_942e779b-6d2a-49c4-b2bc-d0c4733841a7"
      unitRef="usd">159400000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzYtMS0xLTEtMA_7c92d76c-f3d4-4d2a-beb4-4833bb3af4cf"
      unitRef="usd">626900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2M2RkNDJkZTQ0NmI0Mjc4OGM4ZjA1Y2ZlNmE3OTY3Yi90YWJsZXJhbmdlOjYzZGQ0MmRlNDQ2YjQyNzg4YzhmMDVjZmU2YTc5NjdiXzYtMy0xLTEtMA_1d6495e5-b58f-4739-8f97-43ed328b158a"
      unitRef="usd">2541100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ3OTc_17e5332b-67bc-4324-90b0-382d9b5dff6e">The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;898.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;403.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15.9&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,168.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;733.8&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,057.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,058.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;636.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;502.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;503.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;510.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,965.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1444a522fb044ee7a105512067bac273_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzItMS0xLTEtMA_048d9713-c352-46a2-a9c0-187e525e0e59"
      unitRef="usd">897800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1444a522fb044ee7a105512067bac273_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzItMy0xLTEtMA_b5e8ed2e-25cb-42c5-b976-4eec3d41d586"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1444a522fb044ee7a105512067bac273_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzItNS0xLTEtMA_6f81d0ce-e50a-45fb-b621-c7488ff475b6"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1444a522fb044ee7a105512067bac273_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzItNy0xLTEtMA_ee73f516-ed49-46b0-bd05-0b5292ff505f"
      unitRef="usd">898000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0ff8968812da45e2a9aa27638fc19580_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzMtMS0xLTEtMA_2837cdb1-a78b-40a9-ac75-1e2c008ea100"
      unitRef="usd">402500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0ff8968812da45e2a9aa27638fc19580_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzMtMy0xLTEtMA_abc4001d-1dd9-46e4-b3d3-2eeff0317281"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0ff8968812da45e2a9aa27638fc19580_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzMtNS0xLTEtMA_35dea5d0-044c-4612-8cad-84107dfd524b"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ff8968812da45e2a9aa27638fc19580_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzMtNy0xLTEtMA_4aca9a76-eb57-4100-ad82-9a2c2e896932"
      unitRef="usd">403500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5cd740912ac448feb53d1e58c59635f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzUtMS0xLTEtMA_bfdb930e-5ee2-4aee-a58f-ea79837081bb"
      unitRef="usd">380600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5cd740912ac448feb53d1e58c59635f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzUtMy0xLTEtMA_9a0773e0-bb32-4691-9e9e-6145abdcf57c"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5cd740912ac448feb53d1e58c59635f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzUtNS0xLTEtMA_c262957b-fa6f-4d0b-8449-36b56749d49d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5cd740912ac448feb53d1e58c59635f4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzUtNy0xLTEtMA_cc7b1bab-1613-45fb-8df7-417e6b726dbf"
      unitRef="usd">380700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2f3019ec63604b1e9670c0bddc262a57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzYtMS0xLTEtMA_0a20bc88-573d-4d4a-9602-9d965cc22b9c"
      unitRef="usd">245900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2f3019ec63604b1e9670c0bddc262a57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzYtMy0xLTEtMA_19254ca9-1705-485a-afc9-682d45d8f3ac"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2f3019ec63604b1e9670c0bddc262a57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzYtNS0xLTEtMA_db836fcd-8bd3-4ccb-8ef2-14083eed59b9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f3019ec63604b1e9670c0bddc262a57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzYtNy0xLTEtMA_a4921b25-872a-4369-868c-b257454dbaae"
      unitRef="usd">246400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzgtMS0xLTEtMA_bf239143-ec45-447c-92ec-6be5d07a913f"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzgtMy0xLTEtMA_54c311ea-105a-41b7-8cd7-32c67ea46e11"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzgtNS0xLTEtMA_eb6a79e1-da28-4c03-bf0f-282898318abf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b4a50c62c444726b9e4bf29cffeea7e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzgtNy0xLTEtMA_2539bbc1-6ffc-4345-9f2a-6752399704c4"
      unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i43d6eeff5022443a911867c6740b0321_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzktMS0xLTEtMA_72de1db6-b630-4308-b01d-e806ac457920"
      unitRef="usd">122100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i43d6eeff5022443a911867c6740b0321_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzktMy0xLTEtMA_6fb92f38-cfd0-48cf-a776-534dbc338de0"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i43d6eeff5022443a911867c6740b0321_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzktNS0xLTEtMA_c730e091-1c9f-4f2d-bcc7-c5da7afe0363"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i43d6eeff5022443a911867c6740b0321_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzktNy0xLTEtMA_33c8be34-ed99-4579-99d6-0ad8763ffa83"
      unitRef="usd">122200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEwLTEtMS0xLTA_0af4fbff-690d-4c1d-95fa-cc4d4a8a5f50"
      unitRef="usd">2049100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEwLTMtMS0xLTA_986213fd-2342-4c62-b149-491679cbf6e6"
      unitRef="usd">2300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEwLTUtMS0xLTA_b40b5b8d-c837-4735-834e-4e344a58aa7c"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEwLTctMS0xLTA_c8c85aac-78c3-4218-a7a1-d01b0384d975"
      unitRef="usd">2051000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i1018d5a2a449484ca302a3ba827164ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEyLTItMS0xLTE0NDY3_e6cf92dd-c1b9-4e92-ba1d-8e357a117cbc"
      unitRef="usd">70600000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1018d5a2a449484ca302a3ba827164ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEyLTQtMS0xLTE0NDgx_fd30cf38-1b04-4bc2-9268-c8138e99c71a"
      unitRef="usd">15900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1018d5a2a449484ca302a3ba827164ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEyLTYtMS0xLTE0NDcy_4c18484b-4297-499b-b29f-8367f20957e1"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1018d5a2a449484ca302a3ba827164ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzEyLTgtMS0xLTE0NDc2_a60066eb-c773-4678-adb2-f77b870d9936"
      unitRef="usd">86500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i1f82abfdb08f42288d72dca49fe6886a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzExLTEtMS0xLTA_3eb82ad1-a597-4045-9fc3-d9f05c726567"
      unitRef="usd">1168900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1f82abfdb08f42288d72dca49fe6886a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzExLTMtMS0xLTA_bf1c383c-43e7-4421-be11-b39e95223c11"
      unitRef="usd">733800000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1f82abfdb08f42288d72dca49fe6886a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzExLTUtMS0xLTA_0698e527-27a8-4de9-b5f0-58f70958ad00"
      unitRef="usd">14900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1f82abfdb08f42288d72dca49fe6886a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo4ODVkYmY2ZmEyYWY0ZTE4OTc5NDgyYWZjNmI3OTk2YS90YWJsZXJhbmdlOjg4NWRiZjZmYTJhZjRlMTg5Nzk0ODJhZmM2Yjc5OTZhXzExLTctMS0xLTA_216a392b-19e9-4000-91c5-f5c00f59952d"
      unitRef="usd">1887800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9549e6582b0842b0bb8b80335d95f5c2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzItMS0xLTEtMA_aada3a26-47ad-4f05-a529-076d1dea900a"
      unitRef="usd">1057200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9549e6582b0842b0bb8b80335d95f5c2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzItMy0xLTEtMA_a63b9992-774b-4b77-b4b8-e28b7fecb477"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9549e6582b0842b0bb8b80335d95f5c2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzItNS0xLTEtMA_0dbd5d1e-97c5-4f03-8dc9-30ae67b83f5d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9549e6582b0842b0bb8b80335d95f5c2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzItNy0xLTEtMA_23c9519a-0c4a-422e-ad5c-43efd5749ada"
      unitRef="usd">1058200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6123894aef18412c8778f35bebcb4b94_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzMtMS0xLTEtMA_faabe316-ec61-4d42-8c67-d342bce04cc0"
      unitRef="usd">633900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6123894aef18412c8778f35bebcb4b94_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzMtMy0xLTEtMA_24940404-5d58-48b1-bead-befb1699c4d1"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6123894aef18412c8778f35bebcb4b94_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzMtNS0xLTEtMA_c0815a2d-2f74-4fae-a2aa-607f8a8a9af3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6123894aef18412c8778f35bebcb4b94_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzMtNy0xLTEtMA_17931a23-a66e-4643-a269-5b007f39301d"
      unitRef="usd">636900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if17d3f0012ad49839eb5e30af562ce46_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzUtMS0xLTEtMA_37494188-ad0c-4e48-89f9-e4df6f37006a"
      unitRef="usd">502900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if17d3f0012ad49839eb5e30af562ce46_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzUtMy0xLTEtMA_f0daffd8-6ec4-449a-bb6e-d304621320e5"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if17d3f0012ad49839eb5e30af562ce46_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzUtNS0xLTEtMA_a3594abd-4e24-43f2-8c49-02727d467b15"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if17d3f0012ad49839eb5e30af562ce46_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzUtNy0xLTEtMA_63b94350-6588-4c43-9564-d5f07218d84a"
      unitRef="usd">503300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9c6df684829d457191dd58d3cd5cdf67_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzYtMS0xLTEtMA_ecde79a8-769f-4e03-a540-a51a5bae50c4"
      unitRef="usd">510100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c6df684829d457191dd58d3cd5cdf67_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzYtMy0xLTEtMA_0a2eb670-699a-4b86-bba6-0e7684bdcd42"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c6df684829d457191dd58d3cd5cdf67_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzYtNS0xLTEtMA_71bfa28f-a129-440c-90d1-707d2f39906a"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c6df684829d457191dd58d3cd5cdf67_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzYtNy0xLTEtMA_621eff17-b499-4bd0-a5a7-1ef5e250dcc5"
      unitRef="usd">510600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2dfeca1a2e48493283b2d3282a9abbda_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzgtMS0xLTEtMA_ceb0d758-cc5c-438b-b834-45ac82f7f871"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2dfeca1a2e48493283b2d3282a9abbda_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzgtMy0xLTEtMA_06b8b529-6501-4007-befa-5892ceefb11e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2dfeca1a2e48493283b2d3282a9abbda_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzgtNS0xLTEtMA_ac2dd39e-c74b-4ceb-bed4-11b43b015cef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2dfeca1a2e48493283b2d3282a9abbda_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzgtNy0xLTEtMA_b6ae0944-c366-44df-8e8f-ae2d21716b25"
      unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifb8344f64bdd4767b10aa2100406065d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzktMS0xLTEtMA_639eb2ca-8ab6-479f-9a49-20429416724c"
      unitRef="usd">260200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifb8344f64bdd4767b10aa2100406065d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzktMy0xLTEtMA_3474daf0-fbfd-4234-8f49-7676e2f19564"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifb8344f64bdd4767b10aa2100406065d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzktNS0xLTEtMA_225bd31b-6b4f-4099-a438-3eccb64ce32d"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb8344f64bdd4767b10aa2100406065d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzktNy0xLTEtMA_1df68c8d-557a-4765-9ded-5e551370cf9f"
      unitRef="usd">260600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzEwLTEtMS0xLTA_337c4a24-3536-43b5-90fa-5b3c2a1a6014"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzEwLTMtMS0xLTA_ed6826c3-cacb-4079-831d-f445e01d1bd8"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzEwLTUtMS0xLTA_58737955-afdc-43e0-a496-7c37575f3561"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzEwLTctMS0xLTA_b236fda0-639d-424e-82f6-bfde061ce4fb"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="if324696bb41c43df9e57bee9ea0785b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzExLTEtMS0xLTA_52a799bb-aa76-4f07-b3aa-b1275b623288"
      unitRef="usd">218400000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if324696bb41c43df9e57bee9ea0785b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzExLTMtMS0xLTA_3fe60171-7bb0-4d1f-ac0f-459917141732"
      unitRef="usd">132100000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if324696bb41c43df9e57bee9ea0785b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzExLTUtMS0xLTA_4699352a-8d44-4da5-8931-504a23a51da1"
      unitRef="usd">13000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if324696bb41c43df9e57bee9ea0785b5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo5OWViNjViNmFlM2U0ZjAxODhmNWVkMTRiZjIxOWM1Ny90YWJsZXJhbmdlOjk5ZWI2NWI2YWUzZTRmMDE4OGY1ZWQxNGJmMjE5YzU3XzExLTctMS0xLTA_16c2f777-5402-4179-ba4d-758813ec6e9a"
      unitRef="usd">337500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ3ODQ_7fac16c8-fabe-42e6-bad3-a20af2fe5b46">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,278.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,562.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,560.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,234.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,049.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,970.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,965.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzItMS0xLTEtMA_84c06e90-8e04-4fc1-942f-84c0177539f4"
      unitRef="usd">1278900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzItMy0xLTEtMA_f955f0f1-4b93-4eaf-9353-8340726d8c50"
      unitRef="usd">1278600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzItNS0xLTEtMA_1a677462-a289-4729-a60d-ec353f685bdf"
      unitRef="usd">1562200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzItNy0xLTEtMA_4d33e1ff-205b-45cd-96c0-205b36b26ecd"
      unitRef="usd">1560800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzMtMS0xLTEtMA_9c2dec4d-20c5-4ee4-a609-ece229a0594f"
      unitRef="usd">722600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzMtMy0xLTEtMA_73508834-3896-488b-a2a2-8aaa27d9e54b"
      unitRef="usd">721300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzMtNS0xLTEtMA_4aa31144-c843-4db0-98e6-73034be571f1"
      unitRef="usd">1234500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzMtNy0xLTEtMA_84d4b89b-59ff-4004-bc72-0e28cda05334"
      unitRef="usd">1230400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzQtMS0xLTEtMA_1fa4372b-9734-461c-bfc1-b89f9809766f"
      unitRef="usd">49500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzQtMy0xLTEtMA_56314755-f215-4c14-b437-02b59d2d0c60"
      unitRef="usd">49200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzQtNS0xLTEtMA_4a6a3c1c-ff45-4213-841c-40ba34b14de1"
      unitRef="usd">173600000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzQtNy0xLTEtMA_c418a184-fc72-4e10-a115-c26da79438b3"
      unitRef="usd">173800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzUtMS0xLTEtMA_ae0a0c79-2bda-4ea7-9f00-434399ca68f5"
      unitRef="usd">2051000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzUtMy0xLTEtMA_e44ad2ca-d376-484f-8471-c1c57b5dcda8"
      unitRef="usd">2049100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzUtNS0xLTEtMA_66d4f8b0-c8d8-4522-92b0-6966e5a36870"
      unitRef="usd">2970300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZTo2NTMyOTA1YzBhYzM0NThmYWQ3Yjg3MjFlMjNiYjBjZi90YWJsZXJhbmdlOjY1MzI5MDVjMGFjMzQ1OGZhZDdiODcyMWUyM2JiMGNmXzUtNy0xLTEtMA_136bcdb4-aaf2-41e2-a8de-f2a1fc916b9e"
      unitRef="usd">2965000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzEwMTE_1d2e15c4-84f1-43aa-9769-a2472d53a2ba">P11M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzEwMjU_85a82449-444e-4996-b17b-3812f710efd8">P14M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ4MDI_9b5d8941-6d5a-4e54-ac20-2884bf6f4db3">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,299.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,007.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,173.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzItMS0xLTEtMA_ef5b6bf4-eaf5-4c12-a805-80628d9f3d8c"
      unitRef="usd">7299400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzItMy0xLTEtMA_b4680c3c-0165-4e42-8c3a-56a29f0be997"
      unitRef="usd">6007000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzItNS0xLTEtMA_f2845eb3-0415-463e-a627-17722f3c563d"
      unitRef="usd">9173700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzMtMS0xLTEtMA_c6be72f2-1b86-4037-93fc-711957530bbf"
      unitRef="usd">17700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzMtMy0xLTEtMA_22538285-1876-4457-90c1-fd1b4e2aa5d6"
      unitRef="usd">6000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzMtNS0xLTEtMA_ef2c5aac-d211-445f-b746-8ca01f2f97ea"
      unitRef="usd">3200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzQtMS0xLTEtMA_41e0410e-4f6d-424b-8a09-bff9278ff6d4"
      unitRef="usd">26000000.0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzQtMy0xLTEtMA_e38c02f2-6ca6-4dc8-87b3-adbd8c32434c"
      unitRef="usd">1500000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90YWJsZToxZWU2MmNiZWFmMDg0OWYzYjM1YmEzZTJhM2ZlY2ZhMy90YWJsZXJhbmdlOjFlZTYyY2JlYWYwODQ5ZjNiMzViYTNlMmEzZmVjZmEzXzQtNS0xLTEtMA_ec7349fc-f280-46f7-a08a-c41ed2f2e738"
      unitRef="usd">11700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="i29edf7836e8242968b86b1318f81fb38_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzE4ODM_23aaf3f6-4096-4b68-b7cd-26545ea1306c"
      unitRef="usd">2024600000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="i8c9faf0348614580b6500e84022870f6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzE4OTA_affa72ba-c14d-42ab-89a8-ff9466fff7be"
      unitRef="usd">393900000</biib:StrategicInvestmentPortfolio>
    <biib:InvestmentInCommonStockSharesPurchased
      contextRef="i745ea53017d44a209cd4871e1fc8dbb3_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzEwOTk1MTE2Mzk0ODA_e6fd7435-74b1-433c-85c0-339b71aa100b"
      unitRef="shares">6200000</biib:InvestmentInCommonStockSharesPurchased>
    <biib:DividendYieldPercentage
      contextRef="i58da0dc381ad4518baba0871c615c8cc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQzOTgwNDY1Mjg2MTc_0d88afb3-4c9f-42a2-833a-00e15683a2e5"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:InvestmentInCommonStockSharesPurchased
      contextRef="i4c8cbdc550c74ee4ae87ae5b4bc3ac20_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzEwOTk1MTE2Mzk1Njc_d6a6c5c9-c4bf-4e95-9413-b86614c6e882"
      unitRef="shares">13000000</biib:InvestmentInCommonStockSharesPurchased>
    <biib:DividendYieldPercentage
      contextRef="i9ccffca563b74d8792d57e3f776ccc3d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQzOTgwNDY1Mjg2MjY_e589b041-9bd7-4c5f-9f53-37961ee61e79"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:InvestmentInCommonStockSharesPurchased
      contextRef="i5d0ec7fb81814c1188c3590687864a65_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzE2NDkyNjc0NTE3Nzk_21b24d69-43d7-4cba-a361-ac0166801c8c"
      unitRef="shares">24000000</biib:InvestmentInCommonStockSharesPurchased>
    <biib:DividendYieldPercentage
      contextRef="i4877a3944c7c442fb949a47bf0f67c40_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQzOTgwNDY1Mjg2MzU_454ee840-8f4d-4796-b28f-8b8e70896fbe"
      unitRef="number">0</biib:DividendYieldPercentage>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="i7391238241af432e81e836c4866c9d90_I20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQxNzc_758b1eb1-33a4-42cb-adb5-2863cfeb4110"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQxOTc_f8f3f1b7-eea6-4a9c-9328-961f4718561c"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQyOTA_4c88c01a-ed83-4c5d-9abb-d950650aea32"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQzMTE_3e883ba5-3f22-40bd-8003-27ba98c7c4f4"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ0MTk_d492f79b-9e7c-49d4-be30-f1e3eeb713af"
      unitRef="krw">673800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ0NDA_3b4657d4-f201-42f2-8f06-8cbc5485339f"
      unitRef="usd">620200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8686b81ecb37418dbc5bcc179b1e109c_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ0NDg_7ff763be-99ac-491f-b185-7f1cde51bf5a"
      unitRef="krw">670800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8686b81ecb37418dbc5bcc179b1e109c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNjgvZnJhZzo4YmU3OWNjMDdlOTI0NWI1YTU5ZDE0OWJjZjcxYThjMy90ZXh0cmVnaW9uOjhiZTc5Y2MwN2U5MjQ1YjVhNTlkMTQ5YmNmNzFhOGMzXzQ0Njk_e41505a1-9d47-4e47-98da-bf916f11ea5b"
      unitRef="usd">580200000</us-gaap:EquityMethodInvestments>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwODM_e50ecbdb-b046-49b7-9e85-9d401507af14">Derivative Instruments&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts in effect as of December&#160;31, 2020 and 2019, had durations of 1 to 24 months and 1 to 15 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and fair value changes of excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;br/&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,979.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,892.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,892.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $212.5 million as of December&#160;31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; net gains of $0.5 million as of December&#160;31, 2019, and net gains of $27.3 million as of December&#160;31, 2018. We expect the net losses of $212.5 million to be settled over the next 24 months, of which $175.2 million of these losses are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of December&#160;31, 2020 and 2019, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18.3&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;118.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. The carrying value of our 2.90% Senior Notes as of December&#160;31, 2019, included approximately $2.3 million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3&#160;million for the year ended December&#160;31, 2020, which was recorded as a component of interest expense in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of December&#160;31, 2020, had remaining durations of 10 months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $21.2 million and $1.5 million as of December&#160;31, 2020 and 2019, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.2 million and $2.9 million as of December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our net investment hedges in our consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency contracts was $1,158.0 million and $793.8 million as of December&#160;31, 2020 and 2019, respectively. Net gains of $30.1 million, net losses of $5.9 million and net gains of $2.0 million related to these contracts were recorded as a component of other income (expense), net for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;Sheet&#160;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fair Value Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ic69589c021a84ef3b51246299f3819f4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzY0Nw_226d5997-76a1-4a3a-9005-9cc2b2052d41">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i6ece1a557c614598b419f009a522970e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzY1Mw_4d0d5d76-c365-42f5-970c-fc529c9539e9">P24M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i265b3873c6154df1b98c0e68348adf62_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzY2MA_320a2abc-a60e-48ed-aa97-4186a3f294a7">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i304cadf22e1f4d51a2a058761d61f7e7_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzY2Ng_8f823e1e-f869-4af6-a595-ff14e70a6d7a">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwNzM_bba846e2-c9fc-4927-a698-68128fb9bf4a">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;br/&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,979.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,892.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;250.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,229.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,892.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9548c02f9465476885ffa4b8feb4449a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzItMS0xLTEtMA_1bf47532-d900-4372-8ac6-7eb5f95ef7ba"
      unitRef="usd">2979100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i81d0fec390494bbf9e3fa14a10590ee3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzItMy0xLTEtMA_2e5389e8-5321-4421-b216-25ca16daed71"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i72fd8f14ca0e40fdb0a695a13b9d715f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzMtMS0xLTEtMA_e1b49c8b-dc2f-47fa-9831-f70b6ebf776b"
      unitRef="usd">250600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if0f26f772ded49dea5267467d918765a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzMtMy0xLTEtMA_970f279a-9b3b-4504-963b-7b88e7a0a1e5"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icfac85de776a4ccdb1c2c9949959fc1e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzctMS0xLTEtMA_c79e7d7d-7bbe-4e71-9a67-b114fb31f39c"
      unitRef="usd">3229700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iba1524cdf8b541d993f6af6346716c26_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTphZDI3YTBhZWE5YWQ0ZTFjODQ4YWRhMDJlMTQyZjdkNi90YWJsZXJhbmdlOmFkMjdhMGFlYTlhZDRlMWM4NDhhZGEwMmUxNDJmN2Q2XzctMy0xLTEtMA_b69bb3ef-e023-4f9f-989f-56cf789da41e"
      unitRef="usd">1892400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i3984a0ac91e341979ac9c6a390e24ddb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE3OTg_3a0de465-8c05-4139-bab2-b5b8fcc29d07"
      unitRef="usd">212500000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ib2454550ae594d8ab5f93ecc8828eb34_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE4MjQ_399f306e-2ac3-4876-bd27-9a42c608f5c6"
      unitRef="usd">500000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i9e5d7ed77346446bbda233cc544e7a56_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE4NTU_01edcace-cd75-4c9f-9833-dc2d925f8815"
      unitRef="usd">27300000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i3984a0ac91e341979ac9c6a390e24ddb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE4OTU_3a0de465-8c05-4139-bab2-b5b8fcc29d07"
      unitRef="usd">212500000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE5MjY_64c15284-1351-48d8-a5e8-d75993d3975a">P24M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="if51c2fde97ce4501afc27d5c5035c4e1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE5Mzk_26d2e484-8a2d-40cf-abf0-ca58ffe97d2d"
      unitRef="usd">175200000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="if51c2fde97ce4501afc27d5c5035c4e1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzE5OTg_833cf68d-edee-4422-bff8-8ccf745b404c">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwNzQ_b285fdb8-564d-4119-bcfc-431e8d7c6d6d">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reclassified from AOCI into Operating Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18.3&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;118.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(42.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i970be973b11946e2ba4be4af29d27f00_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtMi0xLTEtMA_2563533b-0a08-4991-9e45-123d65623031"
      unitRef="usd">18300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="iff4e5d22d10f47a4be988b01f0b8f5ef_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtNC0xLTEtMA_dca48a69-9a5c-4400-b930-8f9b785f834e"
      unitRef="usd">118600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ia5015e8fef3747c89a3ecb45e4b014c9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtNi0xLTEtODMx_4e686734-38e2-4b8e-a446-f15c0cd87e08"
      unitRef="usd">-42500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i7a829cf79dbf4cf18de8842f672ff28c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtOC0xLTEtMA_5d83ffec-caa3-4836-8728-6f6e35f090eb"
      unitRef="usd">-9900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i2da81af0f6824d0fbb5054283dac56b3_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtMTAtMS0xLTA_a4a0a8ee-7316-49c1-8f2c-5ef2f45ecbef"
      unitRef="usd">2900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i0c2e5836ef2c4728bf3267af3cd05975_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzMtMTQtMS0xLTMxNjg_37544215-f3e6-407a-a947-27fd4da3115d"
      unitRef="usd">10800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i341bf7c7b22846c3a15d2ca347a2a5e5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtMi0xLTEtMA_85cc5b84-5a43-430e-9e00-1709bf82b09d"
      unitRef="usd">3300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i150073ed6ed44a05be7690bce055038b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtNC0xLTEtMA_bbfac936-48f7-4b50-bb7e-6c331e34e950"
      unitRef="usd">-3300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ib4fc26110cbb49bb95e0d829274d6717_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtNi0xLTEtODMx_0295d74d-b540-4c15-868f-f3ff0452b676"
      unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i2e5f86d5a26a4fb599b079a5ce05a6ee_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtOC0xLTEtMA_0249bfdb-ca2b-4618-b6dc-fc959076faa3"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ie623c4bf0a334923b7419fe9e4036c4d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtMTAtMS0xLTA_247c96bb-2e43-47fe-8bc4-cea910d68ea9"
      unitRef="usd">200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ie26d559169994ab2bee2cc026fd0802f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpiMTExMmY5MGM5NWU0Y2M2YjVhZjk2Nzk4OWYwZDFhOS90YWJsZXJhbmdlOmIxMTEyZjkwYzk1ZTRjYzZiNWFmOTY3OTg5ZjBkMWE5XzQtMTQtMS0xLTMxNjg_5820fda7-e127-4bb7-826f-0833dd13eefe"
      unitRef="usd">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzI3NDg3NzkwNzc3ODg_c3339563-92a8-4c0c-a117-9617e38d57bf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic5bb44b7dbe04121b65a77c399136416_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzMwODA_f315ac0f-ba54-4685-8564-9f8539d1fad5"
      unitRef="usd">675000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzI3NDg3NzkwNzc4MTY_c3339563-92a8-4c0c-a117-9617e38d57bf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzI3NDg3NzkwNzc4MDI_c3339563-92a8-4c0c-a117-9617e38d57bf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3026bb704ae34186986b2cc13a1fa4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzEwOTk1MTE2MzQ5MjQ_63514ab6-7338-4fb8-aed7-8263ac0318ea"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQzOTgwNDY1MTk3MTA_c3339563-92a8-4c0c-a117-9617e38d57bf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ifed04fdf163840848076059cbd6be57d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzEwOTk1MTE2MzU4NjQ_27a45fb0-bb3e-4034-9f8c-df953ce565c7"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="i7391238241af432e81e836c4866c9d90_I20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQyNjI_758b1eb1-33a4-42cb-adb5-2863cfeb4110"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQyODI_f8f3f1b7-eea6-4a9c-9328-961f4718561c"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQzNzU_4c88c01a-ed83-4c5d-9abb-d950650aea32"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQzOTY_3e883ba5-3f22-40bd-8003-27ba98c7c4f4"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:DerivativeTermOfContract
      contextRef="ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzQ3NzA_886ddcbf-145f-4ca0-ab54-f00a477a2573">P10M</us-gaap:DerivativeTermOfContract>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="if5681d70ef5e4ab1a40f14225017e26b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzUxMjQ_41c2cfee-f8f5-4952-bbba-5cc8bf03f42c"
      unitRef="usd">21200000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i7eb0b3093eab4e4fbf121e5a890af5ae_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzUxMzE_345bc5b5-19a7-4214-9a69-b2db5eb7a2c3"
      unitRef="usd">1500000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="id6a22865ae984cd9a1584ed794eb45f1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzU1NTY_15667cb0-5637-436d-8859-a8ffb62431f4"
      unitRef="usd">200000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="ifeea6c57cc5b4032abf11ed3fd20204a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzU1NjM_a104fa99-8ba4-4fab-b78f-9ac448eba0cb"
      unitRef="usd">2900000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwNzA_bdeffa37-0bd1-46c5-99a2-097fc52c53de">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our net investment hedges in our consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.747%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMi0xLTEtMA_b8fd0578-6cc2-4f4c-870e-f521bdd32a02"
      unitRef="usd">-35100000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i5ad3e74dab6043a0ab76c58210d1d2c0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtNC0xLTEtMA_6648a8f7-7844-4a23-86f3-c0df73ff1d3f"
      unitRef="usd">25300000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i0f1921cf5b564c24a5b92cac02448a78_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtNi0xLTEtODc1_3e89dd5e-45a4-4e18-bc89-915d08bc9ef5"
      unitRef="usd">-3800000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtOC0xLTEtMA_416bcbee-420a-47b0-9852-d5f5a2a39517"
      unitRef="usd">4500000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i5ad3e74dab6043a0ab76c58210d1d2c0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMTAtMS0xLTA_11ae10ad-39ab-4305-841e-0a4f8dcb814d"
      unitRef="usd">3300000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i0f1921cf5b564c24a5b92cac02448a78_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMTQtMS0xLTg3OQ_9afdc7ad-a571-47f4-a447-beb6570a23a6"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ib6b97f0e94db4a76838c9d49661b0f65_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMTQtMS0xLTA_15cbfa92-41c8-4876-9f70-70829395f846"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i394788312749438ca5a0088d46557b6b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMTYtMS0xLTA_f46c4cb5-a05d-4a35-ab92-ef30a3f6e537"
      unitRef="usd">7000000.0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i43c9fc7dc1c74381a2af78f961d3d49a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTpjNDIzOWE0YzE1NTk0ZjE2OTY4NGE3NzY4Nzc3ZGQ1My90YWJsZXJhbmdlOmM0MjM5YTRjMTU1OTRmMTY5Njg0YTc3Njg3NzdkZDUzXzMtMjItMS0xLTg4Mw_8a8fbc1b-ea67-4f14-b068-727e6f7c6cfa"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifff3562287364307b49c65b486ab7f1b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzEwOTk1MTE2MzY0MDE_9088903c-9048-411d-be16-91986ef8f607"
      unitRef="usd">1158000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iad27b646ce224aeab760a794d241f6b3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzYzMjE_61be0b74-ec3f-4895-b490-3b621c0cd774"
      unitRef="usd">793800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzEwOTk1MTE2MzYzOTQ_a5deaed4-a867-473d-b5a8-5ad4dab92034"
      unitRef="usd">-30100000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzYzNzM_1344491a-5a8d-44b3-bc6b-11db9b134141"
      unitRef="usd">5900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzYzODA_23fa5cc7-656f-4fd8-b054-40a5a8e3914e"
      unitRef="usd">2000000.0</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90ZXh0cmVnaW9uOjA4MGUzYTdlYjcwYzQ3OTRiYjg4NGYyYzFiNjZkODAyXzcwNzU_566a05df-32ff-49f1-a328-5b18562bc421">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;Sheet&#160;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Fair Value Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued&#160;expenses&#160;and&#160;other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i78b4b25460674afd905c8bebb6f7495f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzItNC0xLTEtMA_b9517fc2-9857-4e40-aae2-4b86ee77c202"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia5f77bb62e04422484e61cd37ab61ae5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzItNi0xLTEtMA_4587a403-dbda-4b35-87f5-117953bad560"
      unitRef="usd">33800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="idd5747821ef74aea809d0a7f45d8bd8a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzMtNC0xLTEtMA_de55dc16-b9cc-4c60-8a30-0d18b0c69eb7"
      unitRef="usd">157100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i44254b6ac97b42949dbeef89bda488f5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzMtNi0xLTEtMA_6664fe97-7605-47e0-a473-aa3c54a5b671"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8ef2acb849c6486f8fab7daf104f20fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzQtNC0xLTEtMA_92f237a2-e300-48bc-acfb-54bb25cc5b30"
      unitRef="usd">35700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia14add4a287f45888b55667cd3541758_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzQtNi0xLTEtMA_2de8e332-8a7b-42e1-8d03-0b9cc6b2e707"
      unitRef="usd">1700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i93f0f42e415041f8bcef0f0de00298ff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzYtNC0xLTEtMA_59a89ffe-4e93-4a36-84a2-c913f9a87bce"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib105aece693d4b43a0c52e39570beb9c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzYtNi0xLTEtMA_10e0adf4-ed1f-4cda-8242-c4192ea127e1"
      unitRef="usd">2000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibe741caa88b64940868b7b3ab24c4a52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzktNC0xLTEtMTk2Nzg_f8825752-1847-4c96-aae1-2629c822accf"
      unitRef="usd">19700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3844e07d48c84ee491e1b9f71aa66a47_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzktNi0xLTEtMTk2ODI_e90597da-db69-4210-87a2-f3e9eb94d407"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="icfd0d7ea7b3a4afa9b4461ff7b726aba_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzgtNC0xLTEtMA_138668af-fa6a-4fc7-9943-cd95dde26c3c"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3026bb704ae34186986b2cc13a1fa4af_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzgtNi0xLTEtMA_63514ab6-7338-4fb8-aed7-8263ac0318ea"
      unitRef="usd">2300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia2c6f6c468f64ddcb921d54c39e33bcb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzExLTQtMS0xLTA_23ae9b7a-6a51-478b-9fd4-0ff2a5caee81"
      unitRef="usd">20500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6f6909c22acb465098440df5033cb0c7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzExLTYtMS0xLTA_25de18df-96ca-458f-be8a-0741db7263ea"
      unitRef="usd">8000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i249f9f4c4b124dd8b673e35fc4455624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzEyLTQtMS0xLTA_2a818dfe-9d4c-4141-bc24-f91ad1d3df1c"
      unitRef="usd">4700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia87d29e7890540bb8654a68a1d34708c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzEvZnJhZzowODBlM2E3ZWI3MGM0Nzk0YmI4ODRmMmMxYjY2ZDgwMi90YWJsZTplZDI5ZWNlMTNiNzg0N2JlYWNlMThjOGE4MWEwZjMwZi90YWJsZXJhbmdlOmVkMjllY2UxM2I3ODQ3YmVhY2UxOGM4YTgxYTBmMzBmXzEyLTYtMS0xLTA_045e4567-d49a-4e1d-813a-70f1c7fa72cb"
      unitRef="usd">2400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE3OTM_ff6e4828-0f5a-4d26-b7fe-df76edec1d2f">Property, Plant and Equipment&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,025.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;835.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;844.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer software and hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;903.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,084.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,193.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,838.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,782.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,590.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,411.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,247.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense totaled $201.9 million, $190.6 million and $269.4 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, we capitalized interest costs related to construction in progress totaling approximately $65.2 million, $68.8 million and $54.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of December&#160;31, 2020 and 2019, we had approximately $1.8 billion and $1.9 billion, respectively, capitalized as construction in progress related to this facility. For the year ended December&#160;31, 2020, we placed approximately $256.8&#160;million of fixed assets in service related to this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Hiller&#xf8;d, Denmark Manufacturing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. This transaction included $631.5 million of property, plant and equipment, which was primarily comprised of $312.5 million for buildings and $287.3 million for machinery and equipment. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE3ODU_f0e050db-e3cb-4e04-a622-4c7d3f35dc37">Components of property, plant and equipment, net are summarized as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,025.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;835.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,027.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;844.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer software and hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;903.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,084.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,193.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,838.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,782.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,590.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,411.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,247.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzItMS0xLTEtMA_d777a3c3-7230-4cc8-9a5f-6ea4c2daaabc"
      unitRef="usd">119800000</us-gaap:Land>
    <us-gaap:Land
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzItMy0xLTEtMA_967a6445-d869-47af-9e4b-e121f4b311b0"
      unitRef="usd">118100000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzMtMS0xLTEtMA_402c70ff-2909-42e4-90d0-27d37909ba2b"
      unitRef="usd">1025300000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzMtMy0xLTEtMA_049aa6f2-0fa4-44df-bc42-a0d367dc42fe"
      unitRef="usd">835000000.0</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzQtMS0xLTEtMA_e4f13eec-cc72-4e9a-b807-f2059caa45a6"
      unitRef="usd">104600000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzQtMy0xLTEtMA_9564dbe0-0bc6-4bb0-bbd5-ba99a70e119b"
      unitRef="usd">99500000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzUtMS0xLTEtMA_86d9610c-2bd2-4b87-8237-0a4daa68d41a"
      unitRef="usd">1027800000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzUtMy0xLTEtMA_fbf2ab3a-b9e0-483d-a92b-c970b9ca1439"
      unitRef="usd">844500000</us-gaap:MachineryAndEquipmentGross>
    <biib:ComputerSoftwareAndHardware
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzYtMS0xLTEtMA_1f68c328-4e5a-4582-8965-71e349031fb1"
      unitRef="usd">903000000.0</biib:ComputerSoftwareAndHardware>
    <biib:ComputerSoftwareAndHardware
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzYtMy0xLTEtMA_85d0909a-72b6-49bd-8d51-4df5b3fdbae2"
      unitRef="usd">798400000</biib:ComputerSoftwareAndHardware>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzctMS0xLTEtMA_d30d893e-b924-44be-97b6-75d3f7a8eee0"
      unitRef="usd">62500000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzctMy0xLTEtMA_42293d20-c16c-40ca-9f56-3f47f4c6f13c"
      unitRef="usd">58300000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzgtMS0xLTEtMA_beee5636-0dd9-4331-892d-54d473f535d0"
      unitRef="usd">1950800000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzgtMy0xLTEtMA_44a66542-163a-4a5a-b024-e1e545979a88"
      unitRef="usd">2084400000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzktMS0xLTEtMA_88438297-2ac6-483f-a8e3-88a6cb3721a6"
      unitRef="usd">5193800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzktMy0xLTEtMA_9ce2514d-bc2b-4aa6-97ce-0d59652f5ea8"
      unitRef="usd">4838200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzEwLTEtMS0xLTA_539f33eb-8f8a-4a46-8dab-c0da66194042"
      unitRef="usd">1782300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzEwLTMtMS0xLTA_01b29436-89b5-44df-afff-0892fc3a3120"
      unitRef="usd">1590900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzExLTEtMS0xLTA_ff79fd69-b206-4811-8c4a-8632e4e660c1"
      unitRef="usd">3411500000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90YWJsZTowYjMzMzQwYjJjNjQ0MDQ3OWQzN2RiMGY4NDA2YjNkZi90YWJsZXJhbmdlOjBiMzMzNDBiMmM2NDQwNDc5ZDM3ZGIwZjg0MDZiM2RmXzExLTMtMS0xLTA_018495b2-75af-463f-a0c8-811a02dda1c2"
      unitRef="usd">3247300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzI0NA_4cc560f5-8d71-43af-9d00-48f0314265c6"
      unitRef="usd">201900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzI0OA_faf49de7-9581-4e6a-bf11-4d78cbe3780f"
      unitRef="usd">190600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzI1NQ_2a52569f-91b6-4899-a08f-0a69c48b3268"
      unitRef="usd">269400000</us-gaap:Depreciation>
    <us-gaap:InterestCostsCapitalized
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzM5OA_73346dad-10ad-4aa1-88af-845ed2774634"
      unitRef="usd">65200000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzQwMg_83a7cf6b-109d-438d-a706-5234eb5b7aa7"
      unitRef="usd">68800000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzQwOQ_cb1e8c78-65c4-43ff-83a2-c6f99cad89c5"
      unitRef="usd">54000000.0</us-gaap:InterestCostsCapitalized>
    <biib:NumberOfSquareFeet
      contextRef="i28e6c2c7dcef4706a9e8c029a70b1b66_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzEwOTk1MTE2Mjk5ODY_29e02d5b-e648-4239-be99-e8ff10ee9ae7"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="ifbaabb3c8c67456798b662d69d200f72_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzEwOTk1MTE2Mjk5OTU_c041e163-8ecf-40f6-a46b-24c485e8a606"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="ib34a3983473240ca94309b2221293726_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzEwOTk1MTE2MzAwODQ_4cb029af-c4fa-49c3-9f6d-8ee271519381"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross
      contextRef="i82ea75f6631c448f8f22c298bec0c951_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzExMzU_81d8ee76-dd98-4373-a9a7-a9e5e0b1535d"
      unitRef="usd">1800000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i214f8c61e02b4bc78c01086f27fa4760_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzExNDI_7ec21d95-4214-4013-b83e-75a529900574"
      unitRef="usd">1900000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i82ea75f6631c448f8f22c298bec0c951_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzEwOTk1MTE2Mjk5NTE_97fc6c05-f191-4016-b857-9453d6692d2a"
      unitRef="usd">256800000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="ida412b4bccf941a7af64620b69dcf1ef_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE0ODM_e7a7e150-7b47-4b80-b17f-202fdcd25435"
      unitRef="usd">631500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i2f537e57d89f4823b4442dbfdb55895c_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE1NTM_805b6fb6-b543-4e5f-841e-868f1c39ed60"
      unitRef="usd">312500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i13d06bfb1ac54344bc9084f8e1ea171e_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yNzcvZnJhZzo3MjBkN2YwZWM4NjI0ZmU3OTdmNjNmNWRjYzVmYmFhZi90ZXh0cmVnaW9uOjcyMGQ3ZjBlYzg2MjRmZTc5N2Y2M2Y1ZGNjNWZiYWFmXzE1NzQ_c85932be-655a-4767-90e8-9b8c8bea4ac8"
      unitRef="usd">287300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5Njc_3525e829-3652-42df-ad36-329684347d50">Leases&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease real estate, including laboratory and office space, and certain equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our leases have remaining lease terms ranging from less than one year to ten years. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from one year to six years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from four years to eight years. Our subleases do not include an option to renew as they are coterminous with our operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance sheet location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;427.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMS0xLTEtMTMxMzU_4631686e-fcd9-443b-a344-b69d241e1c2d"&gt;Accrued expenses and other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;412.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of lease costs in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost primarily related to operating expenses, taxes and insurance associated with our operating leases. As these costs are generally variable in nature, they are not included in the measurement of the operating lease asset and related lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum lease payments for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic4652a3a2e7940719a658dd16032604d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE2NA_c369b594-109c-454d-a866-a690e3afdac0">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i50d29a2be0b04648b7d97ec27df8f046_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE3MA_988fc76d-d6b2-41ab-bef3-ec722ac5cd9a">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic4652a3a2e7940719a658dd16032604d_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzMxNg_d2e5f957-e28e-40f5-bb68-8d7816b5b42b">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i50d29a2be0b04648b7d97ec27df8f046_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzMyMg_df172522-d9bc-4b08-80a5-60bd8b6775e9">P6Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i828bc1c45a6d4a98b00274ffc1f8eeda_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzQ5Mg_cbf5e195-e3c1-48a5-846b-eeb00b0f266d">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i787eed6e9a344d8c908c09867efa7395_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzQ5OA_cc96ef11-a56e-41b8-bfb1-44d4febc7cd4">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <biib:LesseeLeaseTableTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5Njg_c7c78c0a-fca1-4ec3-987d-12da9e081b03">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance sheet location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;427.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMS0xLTEtMTMxMzU_4631686e-fcd9-443b-a344-b69d241e1c2d"&gt;Accrued expenses and other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;412.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;486.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:LesseeLeaseTableTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1b65f5d0f33646d9bc123cea10741758_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzItMy0xLTEtMA_6ccc50f1-3a06-4593-94aa-4e3e41e7b7ee"
      unitRef="usd">433300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="icf080c13135547c8af17c3b9569fb595_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzMtNS0xLTEtNzQ4_e34ee2df-af0d-4c37-b40c-fff774f173ac"
      unitRef="usd">427000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifa108c2a221547038bfc56b7a2800e00_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzUtMy0xLTEtMA_66eaff0e-5389-4240-a8b7-ada5fb179541"
      unitRef="usd">83200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i849ff223eb2f4be899ee0be3b39ab50f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtNS0xLTEtNzUy_2f5b7223-189b-4d8c-800d-7ae31fd0cef5"
      unitRef="usd">73600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7d80f95e39cb4bfaba1e47004246e9e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMy0xLTEtMA_4dca9f86-5b28-40a8-9228-f3c2d3e678a8"
      unitRef="usd">402000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8e69090a5bf6448aacee4bfd8770c3e3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzctNS0xLTEtNzUy_530591e2-334a-4f9f-80f8-c3adafe5d886"
      unitRef="usd">412700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzctMy0xLTEtMA_2cb8d196-65a0-4306-9387-807b659244d3"
      unitRef="usd">485200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzgtNS0xLTEtNzUy_122dfe5a-9dc0-43db-b752-91abedb1a762"
      unitRef="usd">486300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5Njk_2ae0a62e-dfbf-4497-bda9-7b186ae5f13d">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of lease costs in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i45b85566626e4d3abc15fda2e07b56a5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzItMy0xLTEtMA_5ab3a945-4909-4542-b225-601bedcc709b"
      unitRef="usd">5200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i923409ff6b114d4ab014bcd315beca62_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzItNS0xLTEtNzg3_811f764f-2d72-4684-b770-6ecff1a3d11c"
      unitRef="usd">6700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id224660fdd0047b996983e6ee2775abe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzMtMy0xLTEtMA_0a3e6430-f57a-4b51-944e-b1ad77ee4b5e"
      unitRef="usd">93100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzMtNS0xLTEtNzg3_f7b4040e-5c8e-4c42-b181-3e8ae327ce4a"
      unitRef="usd">84600000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i45b85566626e4d3abc15fda2e07b56a5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzQtMy0xLTEtMA_183bcd31-a33a-433e-985b-3deb3f7a90fd"
      unitRef="usd">1100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i923409ff6b114d4ab014bcd315beca62_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzQtNS0xLTEtNzg3_273b6793-eca4-430b-896f-325574c9fbe7"
      unitRef="usd">1200000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="id224660fdd0047b996983e6ee2775abe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzUtMy0xLTEtMA_0179b361-789c-4283-8881-16d18fe93029"
      unitRef="usd">21100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzUtNS0xLTEtNzg3_d7c31323-4a9e-4f25-9aaf-d93d0887ad05"
      unitRef="usd">23700000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="id224660fdd0047b996983e6ee2775abe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzYtMy0xLTEtMA_dc867004-2621-48e3-9712-f0a0b1c7ff7c"
      unitRef="usd">24200000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzYtNS0xLTEtNzg3_847b396b-5a08-4e80-a586-cf77463cfb27"
      unitRef="usd">25600000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ib639369018004754a9231ea3cb196a74_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzctMy0xLTEtMA_3a90691e-c453-4e83-a939-1c18607173bd"
      unitRef="usd">3900000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ib182bbc8abc342c796c4fe1951e63578_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzctNS0xLTEtNzg3_4f614f5b-6e19-45f4-83c5-5ebe6ec84d61"
      unitRef="usd">3900000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzgtMy0xLTEtMA_58ea32c2-ee86-4266-9b86-74da2298eeab"
      unitRef="usd">92400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTpkNTIyMjQ0ZGYwM2M0NTdlOTQxYjMwMDRiMmQzZjJiYy90YWJsZXJhbmdlOmQ1MjIyNDRkZjAzYzQ1N2U5NDFiMzAwNGIyZDNmMmJjXzgtNS0xLTEtNzg3_ef1db634-c3c3-4bfe-af74-46846748088e"
      unitRef="usd">86700000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5NzA_4cd12a0c-a48c-4429-9d2e-fb1ff4d98a55">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The minimum lease payments for the next five years and thereafter is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;br/&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzEtMS0xLTEtMA_2b7ef118-4971-41cc-922c-fc2485e32aab"
      unitRef="usd">95800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzItMS0xLTEtMA_11d09ecf-3c3d-4cbc-a97a-b8f5b2ac144d"
      unitRef="usd">93500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzMtMS0xLTEtMA_8129a822-5d90-4e92-8493-de2005d77021"
      unitRef="usd">82000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzQtMS0xLTEtMA_428a893c-79ac-4340-b392-8148c8ce15bd"
      unitRef="usd">75000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzUtMS0xLTEtMA_aecb219e-1065-4d93-a584-29c9f01afa0d"
      unitRef="usd">56900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzYtMS0xLTEtMA_90728556-dff9-4c26-a8b5-e58172d23f26"
      unitRef="usd">129800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzctMS0xLTEtMA_53cec26c-88e1-4b35-953f-5935bb3d7812"
      unitRef="usd">533000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzgtMS0xLTEtMA_7444dd40-ef29-4bf7-8bf7-9795330506d6"
      unitRef="usd">47800000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo0NGEzYjZlM2M4ZmE0ZDMwYmRiMzA3YzMxYzI5ZGFjNy90YWJsZXJhbmdlOjQ0YTNiNmUzYzhmYTRkMzBiZGIzMDdjMzFjMjlkYWM3XzktMS0xLTEtMA_d61ec27f-dd33-4eeb-ba32-9acf76c13871"
      unitRef="usd">485200000</us-gaap:OperatingLeaseLiability>
    <biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5NjU_7db86546-97fd-4320-a85e-fb9163defc41">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo3NjMzNWQ2MmIzZjU0MDExYWRkMzY3ODY2NDU1YTRiMS90YWJsZXJhbmdlOjc2MzM1ZDYyYjNmNTQwMTFhZGQzNjc4NjY0NTVhNGIxXzEtMS0xLTEtMA_f96ba46e-712d-443a-994b-fb2d25b9fb90">P6Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo3NjMzNWQ2MmIzZjU0MDExYWRkMzY3ODY2NDU1YTRiMS90YWJsZXJhbmdlOjc2MzM1ZDYyYjNmNTQwMTFhZGQzNjc4NjY0NTVhNGIxXzItNC0xLTEtOTI5_d15ce488-38bd-4a50-b3ac-03589262cdc9">P7Y25D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo3NjMzNWQ2MmIzZjU0MDExYWRkMzY3ODY2NDU1YTRiMS90YWJsZXJhbmdlOjc2MzM1ZDYyYjNmNTQwMTFhZGQzNjc4NjY0NTVhNGIxXzItMS0xLTEtMA_8b69baa3-4e3d-4e09-9826-b2297a345509"
      unitRef="number">0.029</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo3NjMzNWQ2MmIzZjU0MDExYWRkMzY3ODY2NDU1YTRiMS90YWJsZXJhbmdlOjc2MzM1ZDYyYjNmNTQwMTFhZGQzNjc4NjY0NTVhNGIxXzMtNC0xLTEtOTI5_2d00c353-2438-455f-a64e-a2b602e6008a"
      unitRef="number">0.032</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90ZXh0cmVnaW9uOjU3MDljYWU0NWRkODQ3NTQ4M2MwZTZiNzE4MDhlMWFlXzE5NjY_266eb514-2bcc-4eb6-a411-650bd7437e68">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo5ZTM5NGMzMjY2MDQ0YjY0Yjg5OTdjNTUwMmE3ZDBhZi90YWJsZXJhbmdlOjllMzk0YzMyNjYwNDRiNjRiODk5N2M1NTAyYTdkMGFmXzItMS0xLTEtMA_fdd67f30-f988-49a6-b45f-20638fd5221e"
      unitRef="usd">100200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo5ZTM5NGMzMjY2MDQ0YjY0Yjg5OTdjNTUwMmE3ZDBhZi90YWJsZXJhbmdlOjllMzk0YzMyNjYwNDRiNjRiODk5N2M1NTAyYTdkMGFmXzItNC0xLTEtOTUy_88b274a9-9da5-4d64-9b5f-84d2c10e9d3b"
      unitRef="usd">93800000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo5ZTM5NGMzMjY2MDQ0YjY0Yjg5OTdjNTUwMmE3ZDBhZi90YWJsZXJhbmdlOjllMzk0YzMyNjYwNDRiNjRiODk5N2M1NTAyYTdkMGFmXzMtMS0xLTEtMA_3f6440f1-af04-4904-8eec-41a8dc5bff1b"
      unitRef="usd">59000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZTo5ZTM5NGMzMjY2MDQ0YjY0Yjg5OTdjNTUwMmE3ZDBhZi90YWJsZXJhbmdlOjllMzk0YzMyNjYwNDRiNjRiODk5N2M1NTAyYTdkMGFmXzMtNC0xLTEtOTUy_793b41e9-7572-4b62-b447-914ba8aaf55e"
      unitRef="usd">35900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI2ODA_14349d57-aa25-4dc4-959a-93dfe4ed2645">Indebtedness&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our indebtedness is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,495.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,495.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;996.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,739.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,722.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,426.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,459.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion, as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0&#160;billion (2020 Senior Notes) as of December&#160;31, 2020, consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;$1.5&#160;billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;$1.5&#160;billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100.0% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to 101.0% of the principal amount plus accrued and unpaid interest to the date of repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred approximately $24.4&#160;million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable May 1 and November 1 of each year, commencing November 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our currently outstanding senior secured notes issued in 2015 (the 2015 Senior Notes) as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022, valued at 99.920% of par;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025, valued at 99.764% of par; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045, valued at 99.294% of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The original costs associated with this offering of approximately $47.5 million have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheets. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our 2015 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100.0% of the principal amount plus accrued interest and a specified make-whole amount. Our 2015 Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to 101.0% of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2015, we issued $1.5&#160;billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with the 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4&#160;million upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our consolidated statements of income for the year ended December&#160;31, 2020, reflects the payment of a $12.7&#160;million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3&#160;million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate contracts, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9, Derivative Instruments, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility that we entered into in August 2015. As of December&#160;31, 2020, we had no outstanding borrowings and were in compliance with all covenants under this facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total gross payments due under our debt arrangements are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our debt is disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQ5NDc4MDIzMzUyNTE_d0cf9d22-c9c3-4811-b419-d9f58cac6afc">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our indebtedness is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.900% Senior Notes due September 15, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,495.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,495.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;996.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,739.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,722.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,472.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,426.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,459.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion, as discussed below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:NotesPayableCurrent
      contextRef="i21ab402dc3c540aaaa74ab88707cd06e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzMtMS0xLTEtMA_a228b473-0fb2-4f24-a223-d5f9aa8c2c00"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="icda291dcf88445d79798c83baf0cdab6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzMtMy0xLTEtMA_3cc1b249-0233-44a1-9017-8e4a2018026f"
      unitRef="usd">1495800000</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtCurrent
      contextRef="ied6fc4314ff74454a352c1254c20f4a6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzQtMS0xLTEtMA_28f11399-52c0-436d-b494-edb785e34269"
      unitRef="usd">0</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="id270cfd00e264906938aa37712a47c2c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzQtMy0xLTEtMA_3c8f9736-f36a-452b-811a-bb64f0833262"
      unitRef="usd">1495800000</us-gaap:DebtCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i777e7a0559ef48fd8038247a2da5c7c3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzctMS0xLTEtMA_630adc71-8221-4070-815a-3dd6b66fd145"
      unitRef="usd">997900000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="ie63cee825d9047dc912cec33b6578d0d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzctMy0xLTEtMA_8caa189a-0887-46e8-8e54-3b3a491e405b"
      unitRef="usd">996600000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="if4f6df13a0ab4a20800b6bd00a5f821d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzgtMS0xLTEtMA_aedda25e-d4f6-4d85-969c-c0199f6f7c55"
      unitRef="usd">1741200000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i6eb111e31f6244de805aec691711dc6b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzgtMy0xLTEtMA_d52ee1ab-13f9-4bc1-81fb-3f67dccb9a42"
      unitRef="usd">1739500000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i665e4e826ccd4df0a58a999910a2c5ce_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzgtMi0xLTEtODAyNg_cd4685e3-bb07-4da6-858f-22bd30f0728a"
      unitRef="usd">1491100000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i6aadbc751f6142fb9d7d9b181bf75a09_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzgtNC0xLTEtODAyNg_67eb6412-fee1-4100-a8bb-778502a75a43"
      unitRef="usd">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="ic5513569ac924bcd810dcccb4b75c1ca_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzktMS0xLTEtMA_b4656ddb-d15e-4894-830a-d119a4df6e84"
      unitRef="usd">1723400000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i1c681c490eb24f0888c2d4a13e77ad8c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzktMy0xLTEtMA_cf40f960-afd1-40d5-805b-67f1d34ad217"
      unitRef="usd">1722900000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i55d717cfc9ad47b288a5e9b60459b22c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzEwLTItMS0xLTgwMzA_67ef809f-f32e-4bb4-a23a-c657e221a970"
      unitRef="usd">1472600000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i947c924e348b4937945183baa80b4090_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzEwLTQtMS0xLTgwMzA_6f06ec52-b530-42ae-b035-c33f154eae33"
      unitRef="usd">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermDebt
      contextRef="ied6fc4314ff74454a352c1254c20f4a6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzEwLTEtMS0xLTA_d3cd11a7-f468-4f0d-81b8-16b4bad83945"
      unitRef="usd">7426200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id270cfd00e264906938aa37712a47c2c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTpkNTE3ZGVkMDQ5NWM0MTQzOWRlZDhhYzViNDFiNjA0My90YWJsZXJhbmdlOmQ1MTdkZWQwNDk1YzQxNDM5ZGVkOGFjNWI0MWI2MDQzXzEwLTMtMS0xLTA_7d7bfdfe-f67a-400d-8822-d7cebec68bde"
      unitRef="usd">4459000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQzOTgwNDY1MjEzNjc_94bd5063-44ea-49c2-a9cf-55398e14d767"
      unitRef="number">0.02900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if61dd7a223a64fd789d0d20d60918b24_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2Mzc5NDg_3d3ea11d-6835-4cff-b5a7-a4f5f15a644a"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if61dd7a223a64fd789d0d20d60918b24_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyMjA_3d3ea11d-6835-4cff-b5a7-a4f5f15a644a"
      unitRef="usd">3000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i58e5df66246e4242a351e934e5d881a9_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxNjA_81c4b681-bdbb-4a0c-8fc6-57ac7e29fca7"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i58e5df66246e4242a351e934e5d881a9_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxNzQ_ccec51e5-0594-4e90-a6f5-7c90221563d5"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i58e5df66246e4242a351e934e5d881a9_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyMDI_2237045b-cd57-493a-a697-5cdcde4ae89e"
      unitRef="number">0.99973</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i262058cabfd94b5ab32927e2ab5d4b39_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxODE_8f1f1dd2-13ab-40d7-a31a-9017c31897ad"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i262058cabfd94b5ab32927e2ab5d4b39_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxOTU_b69590da-c0e1-4140-9f91-b4b8eab2768d"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i262058cabfd94b5ab32927e2ab5d4b39_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyMTE_c58b0e48-1cd7-4593-8a08-4ffe0d7481fb"
      unitRef="number">0.99174</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i6ddb930bb2d6431ea44a09daf6837686_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyNjI_4dbeba2b-0eb7-4598-ab5d-43578f31fee1"
      unitRef="number">1.000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage
      contextRef="i6ddb930bb2d6431ea44a09daf6837686_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIyNTY_b3350545-1d21-42ec-89c3-4c95b7385509"
      unitRef="number">1.010</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i98decbb03ea4472c94a12ac0b39c7793_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzIxNDU_cb4d3ebe-2779-4e21-82fb-3847c909386c"
      unitRef="usd">24400000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i43d8fda27d15472886e7714ecfd74f13_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI0OQ_ca8f5619-aa0f-4d9b-9fa1-fccca2cd3295"
      unitRef="usd">1000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i43d8fda27d15472886e7714ecfd74f13_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI4Mg_136d69aa-b140-432e-bae5-fe60c7c9f299"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="i43d8fda27d15472886e7714ecfd74f13_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzMzMg_ea40e7fc-9160-4502-a501-28084129669a"
      unitRef="number">0.99920</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifc1b899a302148ca9891b0255cc8aa0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzM0Mw_82985a06-b923-4d54-89fc-dcac79ed039c"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifc1b899a302148ca9891b0255cc8aa0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzM3Ng_6264740e-6a9f-4a55-adc4-a44ca060a375"
      unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="ifc1b899a302148ca9891b0255cc8aa0d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQyNg_f8c4ac70-26bc-4557-8871-ddd1553084f3"
      unitRef="number">0.99764</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iddd13c0f2522452cb9725ea76f4505d0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQ0MQ_105b2fcd-15f1-4cd9-a8b9-35c83c830f72"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iddd13c0f2522452cb9725ea76f4505d0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQ3NA_bb163ea2-61dd-4a61-ad86-28af61a7e5b9"
      unitRef="number">0.0520</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="iddd13c0f2522452cb9725ea76f4505d0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzUyNA_8fc89b40-042f-460c-9212-6b9cbcf4dbcb"
      unitRef="number">0.99294</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i3b1c876d462a421f884f7da02f35aeb6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzU5NA_6801e629-414d-4008-bc4e-7fee3f07243b"
      unitRef="usd">47500000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzk4OA_188b790b-d7e3-4aed-ab5a-412b4d877be0"
      unitRef="number">1.000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzExOTE_16e81ced-747b-4fbf-ab36-e18cefc1e949"
      unitRef="number">1.010</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie421a618f95e4d26993d33169587ef01_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzk0MDU_42f74c5c-f203-4300-a024-bc04f12116de"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzkzNjI_c3339563-92a8-4c0c-a117-9617e38d57bf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="ie421a618f95e4d26993d33169587ef01_I20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzk0MTk_d0f7bd9f-e738-4e6a-944d-657a2ef77ecb"
      unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzkzNzQ_c3339563-92a8-4c0c-a117-9617e38d57bf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzkzNzc_c3339563-92a8-4c0c-a117-9617e38d57bf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4596e7576e6f4acea88a866738dcf7c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzkzOTE_c3339563-92a8-4c0c-a117-9617e38d57bf"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain
      contextRef="ic07e15711c4c4d72879f1d4eddbaa8f6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzMyNDU_3a5695aa-df9a-4b62-a9f7-b87c90c38007"
      unitRef="usd">9400000</biib:PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain>
    <biib:PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain
      contextRef="i522bc71323b84dfaa650873976042d71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzMyMzA_1d6e0086-d534-414a-97dc-0937c67f9647"
      unitRef="usd">12700000</biib:PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ifed04fdf163840848076059cbd6be57d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzMyMTQ_caca74ee-280a-4fed-865c-c4ad7492f23f"
      unitRef="usd">3300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i121fec5eb0a442788b9b201aa33e7063_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI3NDg3NzkwNzk1OTQ_705efd68-8450-449b-b096-b99d513d37c0"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i02d9dc2f9e5647a79094565b056378cc_D20200101-20200131"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzQzOTgwNDY1MjEzODI_2f9c9bca-a5a4-4756-bc19-939161cbf58a">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="if4870972449f45cca77c7f81269fdbe0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzEwOTk1MTE2MzU1Mjk_e631bbec-e501-4132-8caa-c12e5ec5d773"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90ZXh0cmVnaW9uOmIyMTFhMDY0MGYxYzQ5NGRhYzkzZmJkNTliMDAwOGIyXzI2NjU_6568f297-eb3f-46d4-83a8-7b26e9f2c13b">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total gross payments due under our debt arrangements are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,750.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,500.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzEtMS0xLTEtMA_b5662a46-1cd1-47a2-bb59-956ca0c43b7a"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzItMS0xLTEtMA_351bd4ff-a075-4610-9976-31673cccbc4e"
      unitRef="usd">1000000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzMtMS0xLTEtMA_eedb4833-6503-4fa0-88db-ae69200ddc6d"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzQtMS0xLTEtMA_613fa663-9ef5-4089-90a0-393760a54b0d"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzUtMS0xLTEtMA_d9fa1f37-3741-4242-bac7-f885db7ca303"
      unitRef="usd">1750000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzYtMS0xLTEtMA_cf3315af-fa08-4ca4-b45a-ce2151a5c462"
      unitRef="usd">4750000000.0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermNotesPayable
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODMvZnJhZzpiMjExYTA2NDBmMWM0OTRkYWM5M2ZiZDU5YjAwMDhiMi90YWJsZTplZjFmM2Y1NTgwOTI0ZjhhOTk5OWM5YTg3N2JiMzA3Yy90YWJsZXJhbmdlOmVmMWYzZjU1ODA5MjRmOGE5OTk5YzlhODc3YmIzMDdjXzctMS0xLTEtMA_4b879dea-ae73-4fbb-9559-759ada22df6b"
      unitRef="usd">7500000000.0</us-gaap:LongTermNotesPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzMzNzE_d542b0ed-9365-482e-ad81-9663e3dfe203">Equity&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have 8.0 million&#160;shares of Preferred Stock authorized, of which 1.75 million shares are authorized as Series A, 1.0 million shares are authorized as Series X junior participating and 5.25 million shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences and the relative, participating, optional or other special rights of the shares of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.6 million shares of our common stock at a cost of approximately $400.0 million during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 16.7 million shares of our common stock at a cost of approximately $5.0 billion during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million and 14.7 million shares of our common stock at a cost of approximately $1.3 billion and $3.7 billion during the years ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018 our Board of Directors authorized a program to repurchase up to $3.5 billion of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately 8.9 million and 4.3 million shares of our common stock at a cost of approximately $2.1 billion and $1.4 billion during the years ended December&#160;31, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately 10.5 million shares of common stock at a cost of approximately $3.0 billion during the year ended December&#160;31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(186.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(243.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(240.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(104.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(318.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount reclassified, net of tax, upon adoption of ASU 2016-01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(104.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(316.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(243.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(240.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from&lt;br/&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQy_1b3ca3c7-b22e-49fd-b9ff-66bb63bdbb14"
      unitRef="shares">8000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i51e142f8c61e4ef9aa6fcc66964b20a3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzky_846a36e1-4782-4e9d-aa00-3e34c72e9a0b"
      unitRef="shares">1750000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i51bbbbb29365442693577108f0597733_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEzMA_d3369243-5d20-44d3-8c61-1c21e1fd8eb4"
      unitRef="shares">1000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic43dbda8223e4c34ae49a143d781adf8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzE5Mg_b31e8388-7a3c-4446-9b80-30fc01b84765"
      unitRef="shares">5250000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_196c85ef-7a42-47f1-9946-f26388ccdd41"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_228eadd2-80a6-4b34-90e1-c2e7bf43a7d1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_23a365f6-2ed2-441e-9eb6-140c8ed3568d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_69eacadf-6c1d-4bc5-8a7c-2fefc3cc7af3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_c8f90d7c-a626-449a-9ad0-d98b92c994ab"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzQzOTgwNDY1MTU3OTQ_daf5a04a-912d-4249-8c73-7864883fd80d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <biib:SummaryOfCommonStockTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzMzNjk_3d4551b8-2cb1-45f7-8e06-560f9db901a5">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfCommonStockTableTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMS0xLTEtMA_5e027624-37fd-4f4c-a690-1d0b29c38923"
      unitRef="shares">1000000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMy0xLTEtMA_ac92d319-c791-4e58-b9eb-560534394f5b"
      unitRef="shares">176200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItNS0xLTEtMA_3d6023cc-b507-48c1-bf99-6d5815954c24"
      unitRef="shares">152400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItNy0xLTEtMA_01d8c0c7-904a-40a5-995e-1644556378a4"
      unitRef="shares">1000000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItOS0xLTEtMA_3f2de498-02a5-4d34-8fdf-98ae2fe6a50e"
      unitRef="shares">198000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMTEtMS0xLTA_f4b7b4aa-baf5-4a3d-9aec-4550989243a8"
      unitRef="shares">174200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMTMtMS0xLTA_552cd5f8-51dd-4412-83f1-a22d74e2f0ad"
      unitRef="shares">1000000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMTUtMS0xLTA_6f4fbae2-902c-456d-a5f3-f27de77a4e46"
      unitRef="shares">221000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTo2NjVmODRjMmU4ZTI0NTMxYmUyZWM4NTNhM2U3M2E1Ni90YWJsZXJhbmdlOjY2NWY4NGMyZThlMjQ1MzFiZTJlYzg1M2EzZTczYTU2XzItMTctMS0xLTA_d29ef585-07af-444f-9d81-dcd6d6749efd"
      unitRef="shares">197200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i0070294a197c45399f314f23509957dc_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzIzMjg_fdbb6385-1e84-44a9-a66f-8e9fab3cf514"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzIzMzI_b2843ce5-0654-4480-9b15-568918e524a7"
      unitRef="shares">1600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i43c10b5da33b4fca9c90ffeaa1413a57_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzIzOTI_31c85977-d498-4e25-913a-73b0149c15e8"
      unitRef="usd">400000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i41af7ab14acc4fb1987d804ec0919188_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzE0NzA_dbebcadb-a653-49d1-ae63-bced7392d33e"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzE3MTA_0ce08ffa-af55-48a9-8b90-94f6a9ef86cf"
      unitRef="shares">16700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7872639da6844bb1ab9e213ec622d7b8_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzE3NzA_16aa521b-7ba2-40a8-8cb8-0c60e487de4b"
      unitRef="usd">5000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="idbfd0586c39547f4bd2e2e1a5234c516_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzE1NDY_7354644a-ecde-4f6b-8993-1551e5de0f8f"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzE4NTU_837ebcf7-8736-4cf8-af6a-9e41aeaf3e4d"
      unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzEzOTQ_9ee8abb6-98d5-4d64-941b-8499afe439ac"
      unitRef="shares">14700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i77acd15864b94ac39ef3c45f1c76498f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzE5MTI_0c31ae72-2ed3-40da-896e-c357740d3a1a"
      unitRef="usd">1300000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i87f9b0e1e2754962a619b3cba6e195ac_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzE0MDM_ada0edec-0be7-45e0-be7d-24a919d4da6a"
      unitRef="usd">3700000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i8f5af4399029492c96f8e3642a945612_I20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzI1MDQ_7663cc42-d1f6-4ed5-8eda-4b01e729a059"
      unitRef="usd">3500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzIyODI_6db39d19-22ab-4d01-a4dd-3313d2bb7977"
      unitRef="shares">8900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzI1MTQ_2b5d9353-15b4-4794-b151-fab0146187af"
      unitRef="shares">4300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie9f262004a1640feb50a587ed4d3f359_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzIzNDY_934597d2-d68e-4428-a497-d75e03ab19ea"
      unitRef="usd">2100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iff1ff5adc58b4f4ca0aaaa24dc93c64a_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzEwOTk1MTE2MzI1MjU_32b3148f-221a-4842-b395-9c340c37e44c"
      unitRef="usd">1400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ice49d2ad46424ef199c6cb123804c5a5_I20160731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzI0NzQ_0c4a80c6-83f8-4f49-9ab7-edfbb915dd6a"
      unitRef="usd">5000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzI3Mjk_5a5e1e44-480a-497b-9fc2-4bebe50f805a"
      unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic90f29c576544e949ee4484ed9dfc03a_D20180101-20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzI3ODk_1afd1849-1802-4451-a210-1be0dcd1cb92"
      unitRef="usd">3000000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzMzNzU_b8c9e755-3b8a-47da-8838-35f4ad691fcc">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(186.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(243.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(240.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(104.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(318.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount reclassified, net of tax, upon adoption of ASU 2016-01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(104.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(316.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(67.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(243.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(240.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i29b72acd0c624e9a9e5f85ff7919818a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtMS0xLTEtMA_24318b88-3103-4cc0-a1cc-35b750f95a97"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4f24d77b87bc4232984dc260a26c171e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtMy0xLTEtMA_4f60efd0-899c-456f-ba7b-77b5174740a9"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i709cfa41571a4ab8b7d4914c6efb00b3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtNS0xLTEtMA_f7103ebc-dc3a-415c-aed7-5b3a56814bcb"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5d68ba226474425a9ad91c1d2d03c1a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtNy0xLTEtMA_7604451e-4277-4a0b-9f4f-fcd5bcf8d2cb"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i25d8c73e458441d994c3c13f19832ae9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtOS0xLTEtMA_7fff9054-d927-4e06-a24a-f94e3e927cd6"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8631cd953f3488583e5a99f0aa067ea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzEtMTEtMS0xLTA_1b9fc7e3-d875-4c94-8655-b800b8e494b7"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i5acc9340a88745fd84cac5a88b2066cd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItMS0xLTEtMA_97974a58-c819-4f5f-a4ac-aec2b97d5cbf"
      unitRef="usd">-9300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2cdcecbf126d4b8099f5e7acda25fb2d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItMy0xLTEtMA_f0826394-d8ba-4186-b930-0937a7ba661d"
      unitRef="usd">-165000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i85c3ebcbd89841a28e7480e4337c4988_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItNS0xLTEtMA_54759a1e-25a3-4d1a-bef3-0c20a43e9029"
      unitRef="usd">-30700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib6f5a43994a74e30bc2c24fc58be7a8b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItNy0xLTEtMA_822c7e73-a6fe-4ec8-9a07-39bd42b7b9ee"
      unitRef="usd">-33500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i38457c7073c148078d40e136da416dc2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItOS0xLTEtMA_7267fff9-1c4b-497e-ae04-1d58809eb62e"
      unitRef="usd">92900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzItMTEtMS0xLTA_683d1f02-53c4-4010-aa7b-d27153965d95"
      unitRef="usd">-145600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i5acc9340a88745fd84cac5a88b2066cd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtMS0xLTEtMA_f35915e5-e00b-4c45-847f-32ea0a691417"
      unitRef="usd">6500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2cdcecbf126d4b8099f5e7acda25fb2d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtMy0xLTEtMA_d62e28c4-3881-40e8-a772-f6e7d213b52f"
      unitRef="usd">-21800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i85c3ebcbd89841a28e7480e4337c4988_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtNS0xLTEtMA_11171f38-9a7c-4626-aa8f-9694a9df930e"
      unitRef="usd">-2900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib6f5a43994a74e30bc2c24fc58be7a8b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtNy0xLTEtMA_3ca34fcd-75f8-45a7-9045-b213f70af084"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i38457c7073c148078d40e136da416dc2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtOS0xLTEtMA_576bef2e-9117-454c-b92c-8a1c4513208c"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzMtMTEtMS0xLTA_18c4819f-d79a-4d57-a3f7-127cccc2b434"
      unitRef="usd">-18200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5acc9340a88745fd84cac5a88b2066cd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtMS0xLTEtMA_beed4971-539d-4ff7-8cd5-1e9f23f07381"
      unitRef="usd">-2800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2cdcecbf126d4b8099f5e7acda25fb2d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtMy0xLTEtMA_60d99351-b99d-49ae-8e48-01689fbd52ef"
      unitRef="usd">-186800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i85c3ebcbd89841a28e7480e4337c4988_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtNS0xLTEtMA_2630fab3-063d-4ece-bce5-b4fda26f15cf"
      unitRef="usd">-33600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib6f5a43994a74e30bc2c24fc58be7a8b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtNy0xLTEtMA_44180549-8518-450e-83c1-bbd0c826792c"
      unitRef="usd">-33500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i38457c7073c148078d40e136da416dc2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtOS0xLTEtMA_21ab571e-e143-4331-8722-33906309c154"
      unitRef="usd">92900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzQtMTEtMS0xLTA_d6685044-af8d-4dd2-8cf0-9250e3658e75"
      unitRef="usd">-163800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i29f346c927114584bd6128c5a5e41d52_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtMS0xLTEtMA_955f4369-15ba-422f-8828-ab3b3d7424b9"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie53527d45eb34a6b993b46ac83917155_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtMy0xLTEtMA_ea9ad750-29a5-4bc9-ac85-f9da764056c2"
      unitRef="usd">-179000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id971167191384986aec4598f9022d212_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtNS0xLTEtMA_521f57f0-908d-43ac-be06-66f4077fe99e"
      unitRef="usd">-8500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8b64d0eaf4c246fab3031182b58a6d37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtNy0xLTEtMA_153f9498-45f2-441d-898c-f21e81af9e74"
      unitRef="usd">-66300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7cf2db733a844ed99dc8f7222b3ccc49_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtOS0xLTEtMA_d70f3a8a-40d0-4038-9a69-10d5e803d246"
      unitRef="usd">-46600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7957fd5108f041cf86733aef419c0487_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTpiZTkyYWViOTVlZDA0YWY0OTQ4ZDBlOTNjNWQ2ODRiZS90YWJsZXJhbmdlOmJlOTJhZWI5NWVkMDRhZjQ5NDhkMGU5M2M1ZDY4NGJlXzUtMTEtMS0xLTA_65eb87a7-cecc-4015-94fe-c77bfecdd7e1"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8bba1fded9e7415e8f0eecc9fc01fa37_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtMS0xLTEtMA_d72d0134-4bbe-44a2-9c6e-4e2b536f3a28"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d78be56f2654da88b7ee62f039e7477_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtMy0xLTEtMA_6835301d-12ed-4f03-95de-5b38308dd3b1"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i863cc533cc0841c9a1fb1ddedc5d0abc_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtNS0xLTEtMA_42cc7443-0d5d-48cc-b903-5d010ba120dc"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i520d25d1349b439588d438faa148525c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtNy0xLTEtMA_0a290f5e-a37d-44c6-abd6-9df878aeaf9e"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2706b4a26f7244ee86167f45ad4d537d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtOS0xLTEtMA_85acd05f-bb2a-431b-aa09-4cfb65286bcc"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzEtMTEtMS0xLTA_6204ab3b-11a7-42ac-bff5-ffdbfd79ce7b"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i05757bf43f664f91b75e8330e6981029_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtMS0xLTEtMA_592bdb65-3a50-4ecb-8ae9-17f2b9f8e579"
      unitRef="usd">11800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic378ba6b90b54eb49686f7fbcd8d7d26_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtMy0xLTEtMA_51de001c-ec1f-4f5b-b746-344d5450e8b7"
      unitRef="usd">88100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i14c50d1ee35d466596e1a0bd0485826b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtNS0xLTEtMA_7e9fb173-a7b0-4af4-b2f2-91f545f9966e"
      unitRef="usd">28600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ifcd9d8887f184f03b4f51f5d658bd9bb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtNy0xLTEtMA_c693b1a7-c14c-48bd-9d3a-a18fcd8cd6f2"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3946e2ed691746eea6486da676e10065_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtOS0xLTEtMA_749c25a2-3ddd-478c-b2e5-2caf60fd9dfd"
      unitRef="usd">103800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzQtMTEtMS0xLTA_495c77a1-3d35-4ffb-8a49-e2f7d7056a63"
      unitRef="usd">230800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i05757bf43f664f91b75e8330e6981029_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtMS0xLTEtMA_58453029-b5e6-49a2-ac23-d46d6e7338c4"
      unitRef="usd">-3600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic378ba6b90b54eb49686f7fbcd8d7d26_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtMy0xLTEtMA_b178f72d-f179-4b47-8573-770cc86ad392"
      unitRef="usd">-115000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i14c50d1ee35d466596e1a0bd0485826b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtNS0xLTEtMA_61df676c-2a7e-4216-a37b-7872a2326384"
      unitRef="usd">-7000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ifcd9d8887f184f03b4f51f5d658bd9bb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtNy0xLTEtMA_0b175fa5-27fd-4746-be29-67215fd1eb78"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3946e2ed691746eea6486da676e10065_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtOS0xLTEtMA_b5ebdd41-1898-4fa3-9308-00974743dc28"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzUtMTEtMS0xLTA_041e67ae-414e-4f2b-8587-38c5b0ffdc31"
      unitRef="usd">-125600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i05757bf43f664f91b75e8330e6981029_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtMS0xLTEtMA_0e2a3bdb-7971-4668-946c-429bf2b44807"
      unitRef="usd">8200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic378ba6b90b54eb49686f7fbcd8d7d26_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtMy0xLTEtMA_3ad08913-7995-4c94-9a89-2b1e3aa80337"
      unitRef="usd">-26900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i14c50d1ee35d466596e1a0bd0485826b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtNS0xLTEtMA_e36dfed1-d1ef-42de-9407-722b362d767d"
      unitRef="usd">21600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifcd9d8887f184f03b4f51f5d658bd9bb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtNy0xLTEtMA_3031d161-fb22-425f-a2fb-d30d743989df"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3946e2ed691746eea6486da676e10065_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtOS0xLTEtMA_3748b95a-623f-4679-8974-3e3ca39c2279"
      unitRef="usd">103800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzYtMTEtMS0xLTA_e61af562-7ce3-40f0-a272-a7a551b09070"
      unitRef="usd">105200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i29b72acd0c624e9a9e5f85ff7919818a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctMS0xLTEtMA_c1636e75-49b4-4a16-8722-b96eaf6a8e6c"
      unitRef="usd">4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4f24d77b87bc4232984dc260a26c171e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctMy0xLTEtMA_b6bd3a83-d025-447a-a610-969f7c645e84"
      unitRef="usd">7800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i709cfa41571a4ab8b7d4914c6efb00b3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctNS0xLTEtMA_ad31c5f7-5e19-4e85-bf39-47c464a89fee"
      unitRef="usd">25100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib5d68ba226474425a9ad91c1d2d03c1a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctNy0xLTEtMA_dae35d9e-6f69-402e-8899-71f32ce7103c"
      unitRef="usd">-32800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i25d8c73e458441d994c3c13f19832ae9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctOS0xLTEtMA_c6c0d0e9-fd0d-453a-b305-b41e70d921e6"
      unitRef="usd">-139500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8631cd953f3488583e5a99f0aa067ea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZToxMGRlODY0NzAxOGQ0N2I5OTAzMTNjY2EyOTIwNmNlOS90YWJsZXJhbmdlOjEwZGU4NjQ3MDE4ZDQ3Yjk5MDMxM2NjYTI5MjA2Y2U5XzctMTEtMS0xLTA_164cc4f5-439b-4b11-b277-4f42d73e3b60"
      unitRef="usd">-135200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i89cc1e0b559548e1b327e6f439fb19d6_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtMS0xLTEtMA_f7db62ab-ca7b-4c73-93e7-f9903746e8b3"
      unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i05064dd261bf486d8e3bf1bba3b6c47e_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtMy0xLTEtMA_ea8ea291-b042-4928-931e-d56f924f4a60"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0edbe632efef45cc957628ebc1d33d42_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtNS0xLTEtMA_c08c5b49-7e3e-4f25-8bc9-bd33db96504f"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7fa22ea433e141458d8691d0f27355c1_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtNy0xLTEtMA_f75c267d-596f-46ef-bb34-2af85cf6585d"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ide4cbacbf5734ef695d22154b1428d52_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtOS0xLTEtMA_74f67370-eb7f-4013-89f2-661440e85177"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i01ad07778ac849c8b2b4e37c57f5c8cc_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzEtMTEtMS0xLTA_3cd0dd4b-7609-43e2-829a-ac2e33081933"
      unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id59744b4317a46d5ab82e7521aa6b11e_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMS0xLTEtMTAwMw_8988b8d8-9d36-4e43-87ef-9daad52878a9"
      unitRef="usd">1500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia35f6885c958490aa4fa10a11e2ca2e6_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMy0xLTEtMTAwMw_2407194e-90b1-447d-b19e-363cba83d3b0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i903a5c782a9b41dc9edce0003cd86d67_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItNS0xLTEtMTAwMw_ff5b7c36-9982-4a78-a9c0-f7010ca4e1c7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6757062bd137442ea0f58c866b089bcd_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItNy0xLTEtMTAwMw_8038da5f-c6f1-4e76-a9f8-e33d34fbc1f6"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46ba77a8a8704925bcd95ae5bd41be65_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItOS0xLTEtMTAwMw_268b1162-cda5-4738-8951-373f068f66d4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i158387b1a5ea437bb6564f068f16da94_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMTItMS0xLTExNDE3_6aad2be1-dc2b-4dc0-ac9a-5e7d3b3e0a62"
      unitRef="usd">1500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i20addfea8892477996faeb680a08f153_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMS0xLTEtMTAwMw_8908fac1-fd2e-4b4c-ac65-f76cf38cb526"
      unitRef="usd">-100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d0da88784044139ae3b0627adb1073e_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMy0xLTEtMTAwMw_09bea457-843a-4714-9f06-75e7175f52e6"
      unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ieedbbfb7ec1f47d98f528e19bea4741a_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtNS0xLTEtMTAwMw_5e326e94-a603-4dc3-b5fe-f67f7e029b25"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifc4fdfb6dc344f2ba410b5f056357e3a_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtNy0xLTEtMTAwMw_d938600b-8eaf-4f89-a525-8b6f64431110"
      unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i255daee7862543c69e18f60f9dab28fa_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtOS0xLTEtMTAwMw_81c75975-54ee-4136-8f3e-4b601284efee"
      unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib03e8eced8bc40769f89224b7a3917b7_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtMTItMS0xLTExNDE3_f33707c8-1dba-4b61-9644-51593f71878f"
      unitRef="usd">-316900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0835e29a53b74d32a686b04bc1b1b198_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMS0xLTEtMA_c89347dc-7d1e-4781-8e41-d9f222aa2054"
      unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib755e31f5e76447187fce9bda9cb4342_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMy0xLTEtMA_8f4ec711-8759-4d3e-9a6b-248c3d69849d"
      unitRef="usd">97400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i8d38cf0e172d4e26924af47f88ae37cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItNS0xLTEtMA_3348eaa4-0446-4e8c-8616-0f92810ab539"
      unitRef="usd">5000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2c99beb651874e9494da14b27703de21_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItNy0xLTEtMA_155b21eb-c37b-4f88-be9d-b00baffc9e24"
      unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i87a66bdab7bd472bae2b3efc40fee57c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItOS0xLTEtMA_3ce58842-431b-4c70-af89-4f152885badc"
      unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzItMTEtMS0xLTA_7cf0d96f-8e5b-47cb-a215-5daf42af4b91"
      unitRef="usd">29500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0835e29a53b74d32a686b04bc1b1b198_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMS0xLTEtMA_d31d91b1-a7e6-4000-bfd4-7f600de28cf9"
      unitRef="usd">6700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib755e31f5e76447187fce9bda9cb4342_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMy0xLTEtMA_bfe99960-2d31-4641-8091-b578e3ab8ed7"
      unitRef="usd">41800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i8d38cf0e172d4e26924af47f88ae37cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtNS0xLTEtMA_81388eb2-eb2a-4369-b2c2-01933db0c722"
      unitRef="usd">-1500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2c99beb651874e9494da14b27703de21_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtNy0xLTEtMA_542ac343-9e8f-4783-bcee-5ff2dd444d1f"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i87a66bdab7bd472bae2b3efc40fee57c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtOS0xLTEtMA_f493bf50-80dc-47de-a7f7-2db148c3ccf7"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzMtMTEtMS0xLTA_3a0b7b9a-e93f-446f-9e68-11edd0f6f412"
      unitRef="usd">47000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0835e29a53b74d32a686b04bc1b1b198_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtMS0xLTEtMA_95da6103-d98b-4801-af92-690841dcfee6"
      unitRef="usd">-3900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib755e31f5e76447187fce9bda9cb4342_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtMy0xLTEtMA_6b320a39-0b8c-4dc1-b042-f4c805a551df"
      unitRef="usd">139200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8d38cf0e172d4e26924af47f88ae37cd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtNS0xLTEtMA_b5d6630a-986d-4876-badc-c7a23933fba1"
      unitRef="usd">3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2c99beb651874e9494da14b27703de21_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtNy0xLTEtMA_32b8b893-ce60-456d-8fb9-5a9e21065410"
      unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i87a66bdab7bd472bae2b3efc40fee57c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtOS0xLTEtMA_3c9f4451-0e64-4a81-83f3-11c3a78f0883"
      unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzQtMTEtMS0xLTA_477d4aa8-3681-425f-af68-302c28fa1519"
      unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8bba1fded9e7415e8f0eecc9fc01fa37_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtMS0xLTEtMA_bf290bb0-4274-4a78-987d-d358066d17e4"
      unitRef="usd">-4000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1d78be56f2654da88b7ee62f039e7477_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtMy0xLTEtMA_613a1a21-4ffd-40a2-a5a6-f4140f2b3b5f"
      unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i863cc533cc0841c9a1fb1ddedc5d0abc_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtNS0xLTEtMA_3577fdca-c0b8-4a8c-abfb-8e9684a59a39"
      unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i520d25d1349b439588d438faa148525c_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtNy0xLTEtMA_12d83d84-6ab4-44b7-bdfa-bb2d5ccd0cf4"
      unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2706b4a26f7244ee86167f45ad4d537d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtOS0xLTEtMA_014a974f-8ae8-48ed-8f4d-e7f57e5cc5d9"
      unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic5b21d6e3ac3441b8fbafacd9d61c082_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTozOTIzOWE0MWI5ZDg0NzlhYjFkNjc4OWQ5YWQ5NDQwOS90YWJsZXJhbmdlOjM5MjM5YTQxYjlkODQ3OWFiMWQ2Nzg5ZDlhZDk0NDA5XzUtMTEtMS0xLTA_b78d68ca-f589-45a0-afc5-018216b27185"
      unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90ZXh0cmVnaW9uOjMwODk0MGJkNjFlYjQ4OGY5ZjQ1MWIzMzQxZWFhZjRhXzMzNzY_071d84a3-887e-42bc-9dc9-7b4d5ed607d6">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from&lt;br/&gt;Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other Income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i45c58c66b4a842ac9ad5f192b2a0e90b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzMtNC0xLTEtMA_6e203272-cffb-4cbd-87a7-6083e9050d5b"
      unitRef="usd">-8200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iae5eb4853f6f4dfe9344661c9aa220db_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzMtNi0xLTEtMA_f38d5e7b-f39f-433f-8770-e8850ca1fa2e"
      unitRef="usd">4500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i70d3de7bccd345f7a075fd96f73db36f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzMtOC0xLTEtMA_84d6671d-f4ba-4826-a9b1-27436e0877d3"
      unitRef="usd">-8500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i45c58c66b4a842ac9ad5f192b2a0e90b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzQtNC0xLTEtMA_c929ac09-74c9-4ce8-b02c-41c10ccdaa85"
      unitRef="usd">1700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iae5eb4853f6f4dfe9344661c9aa220db_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzQtNi0xLTEtMA_d263d1eb-9c49-49d9-a954-f79d950d6935"
      unitRef="usd">-900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i70d3de7bccd345f7a075fd96f73db36f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzQtOC0xLTEtMA_239931d8-a532-4205-b87d-c2941eb98771"
      unitRef="usd">1800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="i98dca11e646a476986ce2b76bb838960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzYtNC0xLTEtMA_976d1b44-b95b-44dc-9f9e-14890d7e6e54"
      unitRef="usd">18300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i629d97b930eb4709852d599b96bd1336_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzYtNi0xLTEtMA_1cbaa7f7-fb26-4316-a650-08342b4e56c5"
      unitRef="usd">118600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzYtOC0xLTEtMA_da8a68d4-7622-481e-b9e0-35a3a61992d1"
      unitRef="usd">-42500000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i98dca11e646a476986ce2b76bb838960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzctNC0xLTEtMA_485fdf31-fa25-46ca-a724-2f63d7f1676d"
      unitRef="usd">3300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i629d97b930eb4709852d599b96bd1336_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzctNi0xLTEtMA_e32584c6-b396-4d73-b8dc-39e74c87e7ee"
      unitRef="usd">-3300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzctOC0xLTEtMA_7e46103b-1ac6-46b4-80e6-30f54525ed4d"
      unitRef="usd">200000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i98dca11e646a476986ce2b76bb838960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzgtNC0xLTEtMA_d10e10ba-da21-4936-be50-f05595749a9b"
      unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i629d97b930eb4709852d599b96bd1336_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzgtNi0xLTEtMA_573fe434-1462-41df-af6d-91497e25bf12"
      unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzgtOC0xLTEtMA_d8d1fd23-48de-460b-972a-edb907f7e381"
      unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i98dca11e646a476986ce2b76bb838960_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzktNC0xLTEtMA_2ef39db8-3abd-457b-9063-26f5ac9bb809"
      unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i629d97b930eb4709852d599b96bd1336_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzktNi0xLTEtMA_d51b998a-47a7-43d6-b022-9c55803cf7c0"
      unitRef="usd">-600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaa9037d613b9427a96ebc130b87ed19f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzktOC0xLTEtMA_19930005-8653-4b9d-98fa-85591f467791"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icca0c44aac904794a5af072f3936f72c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzExLTQtMS0xLTA_4a96c621-0628-44e2-a5e5-c822bf01d00e"
      unitRef="usd">2900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i268b5aee503541a1b2d10eb88d72b0fb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzExLTYtMS0xLTA_a0d4c407-2238-4f72-b38f-a52fbe8f72cd"
      unitRef="usd">7000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id83a5eaf6567467eb34c2a56b8b9b544_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzExLTgtMS0xLTA_3cc36891-b104-4db7-b108-cf224a09cbc5"
      unitRef="usd">1500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i1029aaf02d1e4e45bfea6b6f58c10380_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzEzLTQtMS0xLTA_6e0a504b-f8df-47b6-994a-2245c388b1af"
      unitRef="usd">18200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i48908e834b734ebebfa2eebf3d33b0be_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzEzLTYtMS0xLTA_259dc929-8b8a-45a3-bb48-9ca0531fa047"
      unitRef="usd">125600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia8750b469f74471190cc2cf6076d21ef_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODYvZnJhZzozMDg5NDBiZDYxZWI0ODhmOWY0NTFiMzM0MWVhYWY0YS90YWJsZTowODhkN2MzMTM0YTA0YjgyODdhY2ViNjIxZTYyY2E1MS90YWJsZXJhbmdlOjA4OGQ3YzMxMzRhMDRiODI4N2FjZWI2MjFlNjJjYTUxXzEzLTgtMS0xLTA_c74c6b50-ec9f-4034-bebb-7e0628718fd9"
      unitRef="usd">-47000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzQ5NDc4MDIzMjYxMjA_4b94b38a-5d16-42a9-869f-cecce3a2fbc7">Earnings&#160;per Share&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,888.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,430.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share for the years ended December&#160;31, 2020, 2019 and 2018, reflects the repurchase of approximately 22.4&#160;million shares, 23.6&#160;million shares and 14.8&#160;million shares of our common stock, respectively, under our share repurchase programs. For additional information on our share repurchase programs, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzQ4NQ_5cd6a47a-95b5-44d6-b2c8-e0d51c10d995">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,888.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,430.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzMtMS0xLTEtMA_1f1a4227-36e6-46de-92d0-f5889ba8f287"
      unitRef="usd">4000600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzMtMS0xLTEtMA_bd351670-df4f-46c1-8529-9f70297623f1"
      unitRef="usd">4000600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzMtMy0xLTEtMA_b01ca025-1e67-4c5c-9900-7ab2eb6ab097"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzMtNS0xLTEtMA_b218b854-b800-4a75-bd2e-31d7dc822922"
      unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzUtMS0xLTEtMA_8a3cbff3-1050-4688-8ded-33e7ef045cfb"
      unitRef="shares">160900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzUtMy0xLTEtMA_6e0f2cef-ae63-425d-9949-696ebecc7bc2"
      unitRef="shares">187100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzUtNS0xLTEtMA_8fac122e-1a81-4156-89ee-552ca859b843"
      unitRef="shares">204900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i286d43c7e7e34e99a914f5aa626a428b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzgtMS0xLTEtMA_22f0f8eb-b149-4aa9-9d94-8a5cbb421a82"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie60b5c10ba06457f95296998f5fab4fb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzgtMy0xLTEtMA_8a196795-6df2-42ae-920a-ac9adc85c240"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i87ef982cfbdf41d3b4a5ae5f59e4bf33_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzgtNS0xLTEtMA_af8924c6-7d34-4712-b662-90d8224f66bf"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie7c767930933407ba05e420ac12e8ead_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzktMS0xLTEtMA_c197aa5a-e20e-4cd4-8713-ecff5b19c3fa"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iabe0551d164a4cf2b1e3b5a93ddbac8b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzktMy0xLTEtMA_831beaf0-2fc6-4b6b-97e0-831ad2e606b0"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i553c1568915b41bd8a1f0a03726da4b5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzktNS0xLTEtMA_f62e92b2-16e7-48f7-bd1d-839034b0ae7d"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie00db9b8e16a4be5b4796014ce7b9775_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEwLTEtMS0xLTA_65430343-8f75-41d8-a613-e9f874158236"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ib2afb74941ee472f98e6628b9fc75769_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEwLTMtMS0xLTA_6e7bb9dd-c6b3-481f-8d3d-1545b260dede"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2c0fbc5a8e674148b9ed9389f86047fa_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEwLTUtMS0xLTA_160c3903-3c31-4be1-9daf-a3eb3a091899"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzExLTEtMS0xLTA_337a0fa6-1623-46ae-b17b-b6920ce485b4"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzExLTMtMS0xLTA_b08d945b-4910-4718-98fa-187743ca923c"
      unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzExLTUtMS0xLTA_490ad376-38f2-4b95-9473-a44318896128"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEyLTEtMS0xLTA_7576f9c4-ca1a-4cc1-a947-c226eb9ffece"
      unitRef="shares">161300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEyLTMtMS0xLTA_194e9bb4-2d0a-477f-a6fc-8e3e21239d3d"
      unitRef="shares">187400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90YWJsZTo3OTY4NjcyZGRjM2M0N2NhOWVlNWNhM2IxN2U3YjNjYi90YWJsZXJhbmdlOjc5Njg2NzJkZGMzYzQ3Y2E5ZWU1Y2EzYjE3ZTdiM2NiXzEyLTUtMS0xLTA_e1017e95-d10f-477f-9353-4e52faf915a8"
      unitRef="shares">205300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzEwOTk1MTE2Mjg4OTE_13b4db34-9405-4749-a88a-6ad622310341"
      unitRef="shares">22400000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzEwOTk1MTE2Mjg4NjM_217e794f-d88e-4446-87a1-236cc2653e2b"
      unitRef="shares">23600000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODkvZnJhZzoxYjk5OGNmNjAzODk0YTllYWJmMjNjMWMzZjAwYmY2ZS90ZXh0cmVnaW9uOjFiOTk4Y2Y2MDM4OTRhOWVhYmYyM2MxYzNmMDBiZjZlXzEwOTk1MTE2Mjg4Nzc_a9ae3497-e5c4-4669-a956-b575cea1248c"
      unitRef="shares">14800000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzE5_09e5e619-255f-43e9-8818-39f61e6305d8">Share-Based Payments&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;NST stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, unrecognized compensation cost related to unvested share-based compensation was approximately $207.6 million, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of 1.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have three share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Directors Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2006 Directors Plan. We have reserved a total of 1.6 million shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a 1.5-to-1 ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Omnibus Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2017 Omnibus Equity Plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;8.0 million&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under the Biogen Idec Inc. 2008 Omnibus Equity Plan (2008 Omnibus Equity Plan) as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;1.5-to-1&#160;ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a 10-year term and vest over a period of between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNzA_dabd3a6a-1cff-45b6-8845-824a093e53e1"&gt;one&lt;/span&gt; and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. As of December&#160;31, 2020, all outstanding options were exercisable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic values of options exercised in 2020, 2019 and 2018 totaled $2.9 million, $4.2 million and $4.0 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit realized for stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Market Stock Units (MSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MSUs awarded to employees prior to 2014 vested in four equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between zero and 150.0% of the target number of units granted based on actual stock performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MSUs awarded to employees in 2014 and thereafter vest in three equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between zero and 200.0% of the target number of units granted based on actual stock performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vesting of these awards is subject to the respective employee&#x2019;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our MSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant&#160;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;378.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;398.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the 30 calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in our valuation are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Range of expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.8% - 44.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.2% - 33.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5% - 32.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Range of risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.41% - 1.48%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.46% - 2.53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9% - 2.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30 calendar day average stock price on grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$257.83 - $325.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$228.59 - $331.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$279.47 - $346.76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average per share grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$398.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$378.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$378.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of MSUs vested in 2020, 2019 and 2018 totaled $26.9 million, $32.5 million and $26.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Settled Performance Units (CSPUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CSPUs awarded to employees vest in three equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#x2019;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between zero and 200.0% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the 30 calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our CSPU activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash paid in settlement of CSPUs vested in 2020, 2019 and 2018 totaled $3.8 million, $10.6 million and $15.1 million, respectively.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-vested Restricted Stock Units (PUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in three equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between zero and 200.0% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the 30 calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our PU activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All PUs that vested in 2020, 2019 and 2018 were settled in cash totaling $3.4 million, $10.4 million and $17.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Stock Units (PSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PSUs Settled in Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#x2019;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Participants may ultimately earn between zero and 200.0% of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our PSUs that settle in stock activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; PSUs settled in stock granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PSUs Settled in Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNTQ_9f998ee0-5669-4526-a3e7-3980eafec54f"&gt;three&lt;/span&gt; performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#x2019;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;achievement of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNjU_9f998ee0-5669-4526-a3e7-3980eafec54f"&gt;three&lt;/span&gt; annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Participants may ultimately earn between zero and 200.0% of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the 30 calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our PSUs that settle in cash activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; PSUs settled in cash granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Time-Vested Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs awarded to employees generally vest no sooner than one-third per year over three years on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;938,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;306.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;620,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(440,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,018,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; RSUs granted in 2020 primarily represent RSUs granted in conjunction with our annual awards made in February 2020 and awards made in conjunction with the hiring of new employees. RSUs granted in 2020 also include approximately 10,000 RSUs granted to our Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted in 2019 and 2018 had weighted average grant date fair values of $304.44 and $316.32, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of RSUs vested in 2020, 2019 and 2018 totaled $140.5 million, $131.5 million and $111.7 million, respectively.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (ESPP)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2015 our shareholders approved the 2015 ESPP. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is 6.2 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our ESPP activity:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares issued under the 2015 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash received under the 2015 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzUx_1fbd6c4a-b4c4-4f41-845d-fcac90c192f6">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45b85566626e4d3abc15fda2e07b56a5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzItMS0xLTEtMA_872107f9-fb7c-4d75-b62e-5ad323375294"
      unitRef="usd">80000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i923409ff6b114d4ab014bcd315beca62_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzItMy0xLTEtMA_356007b8-bf9c-4e0d-af81-7ef431d9972c"
      unitRef="usd">77100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i51da93958ce045aa9a3723e4939788a8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzItNS0xLTEtMA_ee41d05e-2c6d-4609-87ec-01fb83d9052a"
      unitRef="usd">75800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id224660fdd0047b996983e6ee2775abe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzMtMS0xLTEtMA_b76b65eb-fdd5-4f07-a48c-fb13dd599817"
      unitRef="usd">131300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3c2bb7707f074038b3be1bba9ce8463a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzMtMy0xLTEtMA_2939f3dd-92fb-451b-a9ab-5e52f8d651cf"
      unitRef="usd">148300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i978a8bf34b8a4498a033dbbeb035725f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzMtNS0xLTEtMA_22d57325-900f-49e7-9897-c3f6c79d70f9"
      unitRef="usd">105800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzQtMS0xLTEtMA_3db51c15-026d-4a25-a021-8c8320b2a845"
      unitRef="usd">211300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzQtMy0xLTEtMA_586b627c-79f1-42c8-821c-7e9e22f21306"
      unitRef="usd">225400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzQtNS0xLTEtMA_05c749c6-5e0e-492d-be78-fc21e5448d84"
      unitRef="usd">181600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzUtMS0xLTEtMA_a73f53ae-309c-4657-81dd-e3b26e6ff730"
      unitRef="usd">6200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzUtMy0xLTEtMA_58d3105f-b232-4a15-bf7f-3386bf67d9ce"
      unitRef="usd">8900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzUtNS0xLTEtMA_f9f50be5-e21e-473c-afdf-8edf790da9cc"
      unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzYtMS0xLTEtMA_e04e4a60-bf22-448b-a8e5-499d525edbd9"
      unitRef="usd">205100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzYtMy0xLTEtMA_fc871b1a-d9e0-4581-8949-4dc6628bb8f0"
      unitRef="usd">216500000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzYtNS0xLTEtMA_52d447bd-3ad9-4161-9553-2303ffe940b4"
      unitRef="usd">170100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzctMS0xLTEtMA_d9b20451-75af-4d8b-b0a3-25276dc01116"
      unitRef="usd">33500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzctMy0xLTEtMA_cdb35e5c-1d4d-42c3-ab08-257ba8a48d7f"
      unitRef="usd">35700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzctNS0xLTEtMA_d935bdd4-f912-42ca-b7b5-803eb2c5581f"
      unitRef="usd">27500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d9eb1cb8dad4f7bb71554081970672c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzgtMS0xLTEtMA_ba9bf324-a40f-46bf-a07a-110c3715b855"
      unitRef="usd">171600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d9a8ab9362146acb873dbfa9866ab42_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzgtMy0xLTEtMA_8a31bf67-f0ae-411c-bcbb-2f848ee25efd"
      unitRef="usd">180800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6d7efd2d47c945e197f5e3a194b14857_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo1YWRlMzZiMWFmMmY0NjE0YTcyYjNmMTJiMzIzYjc2Ny90YWJsZXJhbmdlOjVhZGUzNmIxYWYyZjQ2MTRhNzJiM2YxMmIzMjNiNzY3XzgtNS0xLTEtMA_d9663201-bbf8-45c6-a8be-47e85cc746e6"
      unitRef="usd">142600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzE2_b708e430-94fb-47a3-8221-084058ff22ec">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash settled performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;NST stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf69f103a98a40ce90631e9f60d5754b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzItMS0xLTEtMA_a2c5ab0c-78ad-4b48-bed9-c3a0930c76ed"
      unitRef="usd">40500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5182146502648bf94e1be9dce89213b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzItMy0xLTEtMA_a2794652-a626-48a1-905a-274160b7a5b7"
      unitRef="usd">30400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f97fac7edf9426d88a1e76bb48ad55c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzItNS0xLTEtMA_00f6b293-1683-46dc-874d-a799102a8972"
      unitRef="usd">27200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96f109ebcb514632b195259b16d76186_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzMtMS0xLTEtMA_ab927330-40c2-453a-acfc-6a0f0fa8e5e7"
      unitRef="usd">142600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d29238f9c3f411fa88ad3fefaaacf57_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzMtMy0xLTEtMA_d12d68c4-98d1-4791-aed1-7e5552fcd73d"
      unitRef="usd">134000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2d37f597e713494d9d43394bf06bab30_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzMtNS0xLTEtMA_5eb2efb2-1e9e-4e3c-b94e-5b0059d44467"
      unitRef="usd">126600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7350a4e642e945d4b5a1646e257127f3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzQtMS0xLTEtMA_896085c2-effd-46a8-b46d-bd6bd4dfe8f7"
      unitRef="usd">-1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8cf98ae6877747fc9a91fc7dc00a358e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzQtMy0xLTEtMA_c8dbc5d4-6529-45e8-baf6-795e92c96da9"
      unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib997cdf3cb144617bb5d6ff4986095ba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzQtNS0xLTEtMA_a8d8cbdd-3067-4e77-a58b-514752a16d8a"
      unitRef="usd">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia05aa73c81db48f6b204fa3c972243e7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzUtMS0xLTEtMA_b3ce81f9-806c-435c-a8d4-b353bad2d16a"
      unitRef="usd">-100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3653e8c908ef47bc8ad1352fd466e75e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzUtMy0xLTEtMA_efbcf3c2-cfe9-4f97-ba3f-8f4eb1febb17"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba5bec6196eb4910ac31bcec98a0c3a9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzUtNS0xLTEtMA_ce1a22a1-a323-432e-8f3a-10decd7bc1f4"
      unitRef="usd">3100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3480fbb97844462e9008fb8c307b45ef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzYtMS0xLTEtMA_22bc35a9-3ce7-4e57-9c41-981580e9a268"
      unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a25527f05454792b6c3a170ae578dc8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzYtMy0xLTEtMA_46bc10bd-3721-4bd7-85b4-e2f6d197e22f"
      unitRef="usd">15500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i54cf49ddedf140a0ab09a33fe768f730_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzYtNS0xLTEtMA_1c64a297-27f0-4cda-aff3-6fefe715c7b0"
      unitRef="usd">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5b0df0e7d12e4abda01cacd276a69d0a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzctMS0xLTEtMA_e0d5a578-0690-46bc-8038-b2b7f1cda04b"
      unitRef="usd">8600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e0d61fcfcf945bea2cf06b84ae730ce_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzctMy0xLTEtMA_c5a8e841-0e76-459d-8123-51decadd3c31"
      unitRef="usd">5500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6db7fc9d86d84cb6b0b36baee4a3643f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzctNS0xLTEtMA_fed6e50d-8fb2-466f-b483-d107f7d0dcae"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0a840f55f6d64ab182ff63fbceb3665a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzgtMS0xLTEtMA_90b354bc-ca7f-48d0-96b9-5992955199ef"
      unitRef="usd">13500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i321f27bc93f84527866eb088a9a13ab8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzgtMy0xLTEtMA_3ad61b0f-ea50-4ec0-8de1-4f8695102120"
      unitRef="usd">11500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7a7d16eb3f9c4249b12a16fbbf180e21_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzgtNS0xLTEtMA_f68ee06c-67b0-490a-943f-814b74510a50"
      unitRef="usd">10500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i0769ffe96e9e4c938ce1cbd317e37f42_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzktMS0xLTEtMA_d261de34-aa8e-405f-9bb7-a194aa82d0c4"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="ia0390833128a4361842fcc8dc5e28d8f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzktMy0xLTEtMA_a50cf45a-b687-4348-a2cf-5b1a39839eaf"
      unitRef="usd">26200000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i4a49c0b0d08f4220b68f83ed9492b788_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzktNS0xLTEtMA_596dc9dc-2587-42d6-9e90-56a29b9fa249"
      unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEwLTEtMS0xLTA_f03a3e57-abbb-478f-b365-73fdfd736af7"
      unitRef="usd">211300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEwLTMtMS0xLTA_5d74052e-28c5-441e-b906-6353303dac46"
      unitRef="usd">225400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEwLTUtMS0xLTA_808208f8-5066-4858-ba1a-74bfb2e12682"
      unitRef="usd">181600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzExLTEtMS0xLTA_492bd998-d809-409b-b6de-8ae62a3030c6"
      unitRef="usd">6200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzExLTMtMS0xLTA_ad276ed7-0381-448f-af52-a035e7a68ffe"
      unitRef="usd">8900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzExLTUtMS0xLTA_b351e9a0-2d6a-48a1-9be7-4082edd8dc19"
      unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEyLTEtMS0xLTA_a5336553-ca03-4639-97a2-d34c99f9e0f1"
      unitRef="usd">205100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEyLTMtMS0xLTA_e0d71895-ce9c-456e-b6fb-24bd75961d0a"
      unitRef="usd">216500000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplNGJlY2U1YTRkZDI0Nzk4OWM1ZDVjMzEzODU4NzQxMy90YWJsZXJhbmdlOmU0YmVjZTVhNGRkMjQ3OTg5YzVkNWMzMTM4NTg3NDEzXzEyLTUtMS0xLTA_ee6fe59b-7dff-415b-b2db-36ba7685f2f5"
      unitRef="usd">170100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQxNA_222b4fb0-5dc3-4159-9019-fc5cee5dea45"
      unitRef="usd">207600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzUzOQ_e5ab694f-a496-47f8-acf8-89005aa3dc36">P1Y10M24D</biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards>
    <biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzU4OA_6e076e54-6489-4b9d-8271-68a0d55206ea"
      unitRef="plan">3</biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade>
    <biib:NumberOfSharesOfCommonStockForIssuance
      contextRef="i4952db151b244967ad310f4684e13d15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzNjY_14eda07b-1ea2-42eb-b1d4-1fc8f37f0773"
      unitRef="shares">1600000</biib:NumberOfSharesOfCommonStockForIssuance>
    <biib:RatioOfNumberOfSharesReservedUnderPlan
      contextRef="i4952db151b244967ad310f4684e13d15_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxMzk_c8aa51f5-99c3-449f-8b90-e91cdcdeeb46"
      unitRef="number">1.5</biib:RatioOfNumberOfSharesReservedUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6e20d08747494db199b88c431d14e928_I20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzIzMDQ_a04f4747-7efe-4fa8-8365-dd7a988a5229"
      unitRef="shares">8000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <biib:RatioOfNumberOfSharesReservedUnderPlan
      contextRef="if0d36998038a4ff1aeee3c3273f7a37f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNDU_7da8c143-0e15-4bc8-9a8d-9269c0e689b7"
      unitRef="number">1.5</biib:RatioOfNumberOfSharesReservedUnderPlan>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNTc_83737e29-df8b-4cb6-9649-17845c7d9fd7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia82e3cb95d2d4a44b7a01995c91159a4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxODM_4b148e88-174b-4bde-b263-761b665a0057">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzNDAz_fbef932f-ac6b-475f-b79e-50f7bbf4191c">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia7c1ad961cd346de9af30e39027d96bf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzEtMS0xLTEtMA_b02f0139-0176-43f4-87ca-e2de704d66c5"
      unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia7c1ad961cd346de9af30e39027d96bf_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzEtMy0xLTEtMA_0383d6ce-51ac-471d-b3ac-aa7c70a72ad7"
      unitRef="usdPerShare">58.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzItMS0xLTEtMA_09e592d6-d590-4253-8452-893be2d5efa0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzItMy0xLTEtMA_0e622b1e-1534-4caa-8805-ef5cc81a6569"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzMtMS0xLTEtMA_64bf1d96-9eb2-4c90-9cdd-34253d1c7738"
      unitRef="shares">12000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzMtMy0xLTEtMA_f2309b64-1afb-41c9-93e1-058ab900e141"
      unitRef="usdPerShare">58.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzQtMS0xLTEtMA_5773816e-640e-493d-99ba-d010e2061560"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i40a1801e6f974222a0b0f5929a2f28e3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzQtMy0xLTEtMA_b12ac261-8123-439d-8d1b-4443df1d8627"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2a2350cc1a754e1e8af5bc26001a39ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzUtMS0xLTEtMA_9ed7b50a-486d-4074-8156-adb75d0f61d0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2a2350cc1a754e1e8af5bc26001a39ec_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpkM2E2NDBhZDBlN2E0Yjk4OTMwZjQ3NTFjZjI4MWI1Yi90YWJsZXJhbmdlOmQzYTY0MGFkMGU3YTRiOTg5MzBmNDc1MWNmMjgxYjViXzUtMy0xLTEtMA_8c792990-3a60-49ce-91d4-f45fa66425d3"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzM4NjY_a8fd1a90-f02d-4b22-8e70-d7fd9ef64851"
      unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzM4NzA_74475ab0-9b97-4352-a35e-98cb2c946bc7"
      unitRef="usd">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzM4Nzc_76dd7364-0b13-4da6-aa1a-f127f845ff84"
      unitRef="usd">4000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg4_8347a6c1-c9b2-440a-929e-1acf53fedf9c">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit realized for stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash received from the exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzItMS0xLTEtMA_4d51f2b4-6d87-404a-a740-6f783166c54c"
      unitRef="usd">2900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzItMy0xLTEtMA_5ae565b2-a5b1-49d2-be1e-a9bb8d2c1703"
      unitRef="usd">2500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzItNS0xLTEtMA_8081da3c-d115-421f-8096-ddb8d8a276bf"
      unitRef="usd">2200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzMtMS0xLTEtMA_d83c0cef-19aa-4598-8e14-9f1b2d1d0a61"
      unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzMtMy0xLTEtMA_2c3eb78a-27d8-482f-8fb4-45278c627980"
      unitRef="usd">400000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo2OThlZjc3MjVkYWQ0YTNkOGYyNWM1OTE0ODBiNzQwMS90YWJsZXJhbmdlOjY5OGVmNzcyNWRhZDRhM2Q4ZjI1YzU5MTQ4MGI3NDAxXzMtNS0xLTEtMA_4b557bad-46e4-49db-8dce-52af84d260f0"
      unitRef="usd">800000</us-gaap:ProceedsFromStockOptionsExercised>
    <biib:NumberOfEqualAnnualIncrements
      contextRef="i8f065e3287da460f99889b0a7d3e9327_D20130101-20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQyODQ_34cd242e-6492-4aec-a772-00ebb6002fbb"
      unitRef="increment">4</biib:NumberOfEqualAnnualIncrements>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="i8f065e3287da460f99889b0a7d3e9327_D20130101-20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ0MDY_653d53ee-8389-42ae-aea7-94ca5c6b565d"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="i8f065e3287da460f99889b0a7d3e9327_D20130101-20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ0MTM_6df86ee4-4bd0-4f63-a700-a5f8cd816840"
      unitRef="number">1.500</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:NumberOfEqualAnnualIncrements
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ1NDc_ab54c65c-d390-42b1-8eae-da397a4b58a8"
      unitRef="increment">3</biib:NumberOfEqualAnnualIncrements>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ2NzM_22d0141d-e1ad-4b82-813f-733aa39d288d"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ2ODA_8b01c210-815e-422a-9505-9dbf79140255"
      unitRef="number">2.000</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:ScheduleOfMarketStockUnitsActivityTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjQ_93470bbc-0b51-49fb-88b7-deaaad326c96">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our MSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant&#160;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;378.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;398.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.&lt;/span&gt;&lt;/div&gt;</biib:ScheduleOfMarketStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i28a8afaf854c4785ba7b167d54f6f8a0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzEtMS0xLTEtMA_55e16e0f-e55b-4b30-ba19-4e191752975d"
      unitRef="shares">183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i28a8afaf854c4785ba7b167d54f6f8a0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzEtMy0xLTEtMA_866b3c26-d20a-49aa-a6c4-268f9025f255"
      unitRef="usdPerShare">378.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMS0xLTEtMA_a453c414-1392-406f-a3c6-6be569fd62aa"
      unitRef="shares">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMy0xLTEtMA_5e5cc007-b27e-4389-873d-5a05fde0a71e"
      unitRef="usdPerShare">398.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzMtMS0xLTEtMA_3f169860-689d-4559-abb2-824084e628a2"
      unitRef="shares">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzMtMy0xLTEtMA_52ce774d-8bb5-46b9-96c5-1f1e7d8694df"
      unitRef="usdPerShare">375.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzQtMS0xLTEtMA_b51ffc6e-8030-4410-bc3e-e11a318a8a4c"
      unitRef="shares">33000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzQtMy0xLTEtMA_c2aa2a97-6cf3-4077-9498-8aac2ebc1b43"
      unitRef="usdPerShare">402.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i307bf919a041463693eb52f82fe704dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzUtMS0xLTEtMA_badf11df-d9a6-4e83-acb9-1453b1b6ad38"
      unitRef="shares">201000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i307bf919a041463693eb52f82fe704dd_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzUtMy0xLTEtMA_4eae62b8-bc3e-45bc-98be-21f27b394f70"
      unitRef="usdPerShare">388.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <biib:NumberOfDaysForCalculationOfAverageClosingStockPrice
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzU5NDg_758825a3-7995-4475-99a1-75c800ccde7f">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
    <biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjM_ae06a7a5-d16b-4685-b30c-4b6de6133f04">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in our valuation are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Range of expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.8% - 44.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.2% - 33.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5% - 32.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Range of risk-free interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.41% - 1.48%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.46% - 2.53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9% - 2.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30 calendar day average stock price on grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$257.83 - $325.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$228.59 - $331.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$279.47 - $346.76&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average per share grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$398.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$378.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$378.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzItMS0xLTEtMA_8ae4c2ee-ea98-4ef9-83e6-0d025b6f957b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzItMy0xLTEtMA_39d63b28-742d-4554-a464-774d5a9cdfa5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzItNS0xLTEtMA_a8e43bf2-e795-436d-baf8-98d4c2d1a574"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzYtMS0xLTEtMA_9322999c-3c96-4187-a79f-85f04ed4f813"
      unitRef="usdPerShare">398.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzYtMy0xLTEtMA_c6b16dfa-4707-4137-adf7-5c604d89497d"
      unitRef="usdPerShare">378.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowNWE3NzJiMWQzMDY0YjgxOTk0NjcwMDQ5ZTFkOGQzOS90YWJsZXJhbmdlOjA1YTc3MmIxZDMwNjRiODE5OTQ2NzAwNDllMWQ4ZDM5XzYtNS0xLTEtMA_6f632a87-9af1-4fb0-a6e1-c14290da8c77"
      unitRef="usdPerShare">378.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzYyNDE_7207434b-313e-47b5-ac38-07e165874697"
      unitRef="usd">26900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1af180b9ceba4128805321de34545ed8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzYyNDU_21455c02-9a4d-4e0a-bd7c-3c330c571210"
      unitRef="usd">32500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i180576e386e14660b3b217b13f520f3a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzYyNTI_c5cc2003-6877-4291-8d01-b72ef7a7e46e"
      unitRef="usd">26900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <biib:NumberOfEqualAnnualIncrements
      contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzYzNDQ_da065e3b-c3e9-493a-a944-aaeab21d6398"
      unitRef="increment">3</biib:NumberOfEqualAnnualIncrements>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzY4Mzg_5db1b7d1-ecb4-4483-af16-764b509ba0c2"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzY4NDU_4680e2b7-42fe-4836-bc6b-0c50b07bf301"
      unitRef="number">2.000</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:NumberOfDaysForCalculationOfAverageClosingStockPrice
      contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzcxNzg_da15c251-2a74-4fa1-aebb-3e7bfb4c7b50">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
    <biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzNDA5_527570b4-b964-4167-885c-e31d08ee3f24">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our CSPU activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2b626c65959246e09aa12e28314bba0c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzEtMS0xLTEtMA_5b472672-cb87-46f1-b8cf-745b508212a1"
      unitRef="shares">13000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzItMS0xLTEtMA_f50de499-1433-4dd7-83ea-d2ff737baa3b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzMtMS0xLTEtMA_e7f49a8e-596f-4fbe-82c9-ace15aefa078"
      unitRef="shares">13000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzQtMS0xLTEtMA_a909bdeb-1ba7-4a13-af3b-9b10bb5f699c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if59b671ae4d44f3b97a43ee65c799fc1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTowOWNmNzY0MTI0MWQ0NGI5YjIwNzgwYTczMDg5OTQwYy90YWJsZXJhbmdlOjA5Y2Y3NjQxMjQxZDQ0YjliMjA3ODBhNzMwODk5NDBjXzUtMS0xLTEtMA_d902520a-6105-46d3-b7d2-3e4c52963b71"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="i9223dc41966d407d8bd557ef8b037a30_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzc0OTM_4628d1fe-e70b-4081-bd84-4682aef84c95"
      unitRef="usd">3800000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="ifb57f7f3d44e42c4a8e598bf54a94075_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzc0OTc_9027fa0c-3213-4044-acc1-630ec32be4bc"
      unitRef="usd">10600000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="id6d7f7d4fdc14cd4a16f3d306b79e0d5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzc1MDQ_fb7197b3-8d4b-467e-8d3b-25cb787dcf82"
      unitRef="usd">15100000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <biib:NumberOfEqualAnnualIncrements
      contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzc4Nzk_cc62e94f-9e75-499a-a907-fb1b8635a125"
      unitRef="increment">3</biib:NumberOfEqualAnnualIncrements>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzgyNDg_318568f5-5459-4999-ab63-317d5b370267"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzgyNTU_86574ddf-1f3f-4d01-8aae-e76bf10418f5"
      unitRef="number">2.000</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:NumberOfDaysForCalculationOfAverageClosingStockPrice
      contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzg1NDA_072f8a58-36b2-4a9d-80c9-5abbdb8e7c84">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
    <biib:PerformanceunitsactivityTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMjk5_e13b08f8-2cf0-4101-bb65-0075390dca8c">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our PU activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:PerformanceunitsactivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i94d4a650ffa44c1998500b69da6939ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzEtMS0xLTEtMA_598330fc-0c26-435a-9bec-6e7c7507bd4b"
      unitRef="shares">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzItMS0xLTEtMA_efa5b434-1e52-4e0d-9bcf-8f96bee6fd43"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzMtMS0xLTEtMA_70f3266e-e168-4c24-98e8-e6c37e37a8d3"
      unitRef="shares">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzQtMS0xLTEtMA_de16597d-59fe-43af-82de-14d409b40dbc"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7a25395b7a6043aca656dfaf91b50a0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphNjZlZjFiZGZjNDM0ZTBlOTk5NTkzNTBmYjMwYTFiZC90YWJsZXJhbmdlOmE2NmVmMWJkZmM0MzRlMGU5OTk1OTM1MGZiMzBhMWJkXzUtMS0xLTEtMA_b202f552-9522-41f7-a9c7-5ffb9a9f85bc"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="ie5b557984c27427ca362f5595a84bb73_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzg3ODc_ce08f8f0-a25a-48f0-a8bc-9b86716b3584"
      unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="i01b2d203f7de418d8494c28ba590c318_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzg3OTE_65cf3805-b0b9-4a69-b740-77fb2d1a97bd"
      unitRef="usd">10400000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="i9ef74f21f78441ffa5960a07e5974a49_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzg3OTg_8d3959c0-9252-4aa4-a16a-7b369f12fe30"
      unitRef="usd">17000000.0</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNDM_5031c6ae-45ff-457e-8965-0f50a124b1cb">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNDQ_910bc494-a21d-4ae5-9889-8bc47afd48ef">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzk1MjQ_a7579045-bb2b-4b73-81c1-c864784ea4f7"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzk1MzE_cdeaef3e-2976-4521-8d86-08a4e27d6464"
      unitRef="number">2.000</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:PerformanceStockUnitsSettledinStockTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjI_d3775cf5-32d8-4526-8364-335d20dabf6a">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our PSUs that settle in stock activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;316.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) PSUs settled in stock granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</biib:PerformanceStockUnitsSettledinStockTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i78b2e6ab84a14827b284ec4a34e34ebd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzEtMS0xLTEtMA_2029c077-d898-4daf-aab8-6a5bc76d624a"
      unitRef="shares">111000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i78b2e6ab84a14827b284ec4a34e34ebd_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzEtMy0xLTEtMA_1c22ef4a-e4ae-4e45-b7ee-c720ef00cdff"
      unitRef="usdPerShare">316.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMS0xLTEtMA_94bb0b7a-efc2-49dd-9afd-60ee50e69cdc"
      unitRef="shares">73000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMy0xLTEtMA_31107894-bc5a-4a7a-9cf9-547a7e070226"
      unitRef="usdPerShare">293.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzMtMS0xLTEtMA_f411736e-ca46-465a-8160-72e097f4d125"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzMtMy0xLTEtMA_51769a62-d490-4ce8-94a6-a1703d9a6d06"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzQtMS0xLTEtMA_f9f2f502-085e-4c5e-b7e8-1558c07b8a87"
      unitRef="shares">29000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i9f1f55f29df34f5187def931d7cee5bb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzQtMy0xLTEtMA_72efb7ca-06b0-49d4-8729-e94bfaab2f40"
      unitRef="usdPerShare">323.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i43f58504b3d04073a49321e74a6c17bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzUtMS0xLTEtMA_30b05869-42c7-490e-84a2-1f1f3c829cf7"
      unitRef="shares">155000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i43f58504b3d04073a49321e74a6c17bd_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzUtMy0xLTEtMA_a62a60ee-dfa1-4352-adb3-f83f27f0b04c"
      unitRef="usdPerShare">304.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEwODM1_54226def-f0db-4d98-a529-6622cf730834"
      unitRef="number">0</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent
      contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEwODQy_5a651a61-34b1-449f-8d42-0c2d201f0f22"
      unitRef="number">2.000</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
    <biib:NumberOfDaysForCalculationOfAverageClosingStockPrice
      contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzExMTgy_a9c423e1-bbab-4885-b20a-ef894270349c">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
    <biib:PerformanceStockUnitsSettledinCashTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjE_21d7bf13-0ea7-4af8-8921-abd9e649952e">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our PSUs that settle in cash activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; PSUs settled in cash granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.&lt;/span&gt;&lt;/div&gt;</biib:PerformanceStockUnitsSettledinCashTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib2b88b6b11d44635858d6a6d1dd65fd2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzEtMS0xLTEtMA_8bb35e31-5311-44dc-8899-166ade73ec5e"
      unitRef="shares">82000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzItMS0xLTEtMA_cde2cbee-7ac0-4c30-a5e8-a40ead4a07d0"
      unitRef="shares">63000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzMtMS0xLTEtMA_6ec535f1-6633-4e20-8259-74c2f8c90395"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idb3c0a4a765f431c99358d6639915157_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzQtMS0xLTEtMA_3ec9a252-63de-4b54-a2b2-5fcb4a0eb160"
      unitRef="shares">23000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id5279dcf6d19435dbf4f97f6c1923185_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTpjYzcxODY0ZTg1ODg0ODhlOTZmMTIyMjhiMjcyZmIxNy90YWJsZXJhbmdlOmNjNzE4NjRlODU4ODQ4OGU5NmYxMjIyOGIyNzJmYjE3XzUtMS0xLTEtMA_230c8d1d-34c8-440d-9646-28f3216390c8"
      unitRef="shares">120000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyMDQ_94133f5e-4f96-4abd-8240-0d3fde2c97a5">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQ5NDc4MDIzNDAwMjA_974550b1-1890-43d6-9114-ab8e93418d84">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;938,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;306.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;620,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;318.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(440,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,018,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; RSUs granted in 2020 primarily represent RSUs granted in conjunction with our annual awards made in February 2020 and awards made in conjunction with the hiring of new employees. RSUs granted in 2020 also include approximately 10,000 RSUs granted to our Board of Directors.&lt;/span&gt;&lt;/div&gt;</biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3db70ce0acff40ddb1a8049995563df4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzEtMS0xLTEtMA_86722fb9-d9c8-4f54-91cf-8b2d5b4a20eb"
      unitRef="shares">938000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3db70ce0acff40ddb1a8049995563df4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzEtMy0xLTEtMA_d1d81716-1e32-425f-9583-ff0113126032"
      unitRef="usdPerShare">306.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMS0xLTEtMA_3d7def81-fe0f-4338-b42f-f9e4c5d0aac7"
      unitRef="shares">620000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMy0xLTEtMA_d535a514-8b7c-44b1-935b-6f83ea384d26"
      unitRef="usdPerShare">318.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzMtMS0xLTEtMA_7010cb1d-3592-424e-b750-4b7bd0d71e87"
      unitRef="shares">440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzMtMy0xLTEtMA_35ec7f97-ea96-429e-98fa-589afb023a73"
      unitRef="usdPerShare">304.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzQtMS0xLTEtMA_9b252fad-ca1e-47ac-ba73-319a1f4109a6"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzQtMy0xLTEtMA_be4d12fe-8c39-49ba-9dfa-cba10bc563e5"
      unitRef="usdPerShare">314.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ife7a28c7abae4f1c93ca334525d03c5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzUtMS0xLTEtMA_96716473-78d8-413a-a12c-1806e448235e"
      unitRef="shares">1018000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ife7a28c7abae4f1c93ca334525d03c5b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzUtMy0xLTEtMA_a906ceb5-cf55-4e84-82fc-e1e924e51b6b"
      unitRef="usdPerShare">314.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic6556dcd7cdf41ecbef4a10fc43d3f45_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyODE2_c2dfd109-d8fa-4cb8-b3c4-ad01329efc84"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i307d77a2fa40438aa59c8269e8e9b25d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyOTMy_742c265b-390a-4f8c-8d38-fdc2cc39547c"
      unitRef="usdPerShare">304.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibec2bce1b2964c0f98ad9f65944dee76_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyOTM5_3a81c85f-fb97-4295-a8ff-cde984d1d702"
      unitRef="usdPerShare">316.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMDEz_82b7001b-03ea-453d-8f63-d400bea8d42d"
      unitRef="usd">140500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i307d77a2fa40438aa59c8269e8e9b25d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMDE3_7a3a79bb-fbc9-4884-9b87-0f1aaac7ab5e"
      unitRef="usd">131500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ibec2bce1b2964c0f98ad9f65944dee76_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMDI0_f03c27c7-c709-4016-9061-d7637fd2af8d"
      unitRef="usd">111700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if188b16b7c0a45a1a919112de323694b_D20150601-20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMjM4_fc79e5bd-e327-4117-84b9-e1b3cf9dd837"
      unitRef="shares">6200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzIy_363a0a87-4d0a-4332-9562-bc63bff23f2e">The following table summarizes our ESPP activity:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares issued under the 2015 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;212,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash received under the 2015 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icf6d89d5466147cd8f697b7487932bfb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzItMS0xLTEtMA_0a1aa64b-06d3-4a97-b366-8305284f495f"
      unitRef="shares">212000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2396dcccc314478d8ad44cb90e14d1e7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzItMy0xLTEtMA_9e0f9180-82b4-4b45-a339-b282c9c899d9"
      unitRef="shares">204000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i3eed89417d914c45a6644792efcd83e5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzItNS0xLTEtMA_841f55a7-0d69-4823-a229-ed2687e3f703"
      unitRef="shares">170000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icf6d89d5466147cd8f697b7487932bfb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzMtMS0xLTEtMA_2b710ac7-45ce-4ae8-9f05-3ab208549983"
      unitRef="usd">48600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2396dcccc314478d8ad44cb90e14d1e7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzMtMy0xLTEtMA_f4d6a91a-0d0f-4a2a-975d-02dc7b055462"
      unitRef="usd">40400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3eed89417d914c45a6644792efcd83e5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTplZDFhMDRlMmY3YjI0ZjA0OTg3MDY5ZmNiZTkxMTljNi90YWJsZXJhbmdlOmVkMWEwNGUyZjdiMjRmMDQ5ODcwNjlmY2JlOTExOWM2XzMtNS0xLTEtMA_c1ceb1d0-a3e0-4fbb-8ff3-c41369daa2d7"
      unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzExMDgx_5109a545-e8e3-4d69-a1cf-1fe138dde481">Income Taxes&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Tax Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income tax expense and the income tax expense consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income before income taxes (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,290.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,725.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,877.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,757.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,022.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,047.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,125.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,899.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income tax expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;947.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;843.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,090.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,749.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,143.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,905.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,074.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;992.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,158.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,425.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Tax Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 35.0% to 21.0%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as GILTI or Subpart F income, includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) and base erosion prevention measures on U.S. earnings and reduces the effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2018, we recognized a net reduction of $34.6 million in our estimated Transition Toll Tax, an expense of $12.7 million to remeasure our deferred tax balances, an expense of $135.8 million related to establishing deferred taxes for GILTI and an expense of $11.0 million to reflect other aspects of the 2017 Tax Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transition Toll Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, we have accrued income tax liabilities of $697.0 million under the Transition Toll Tax. Of the amounts accrued as of December&#160;31, 2020, $62.0 million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unremitted Earnings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, we considered our earnings not to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences of approximately $1.5 billion as of December&#160;31, 2020, primarily arising through the impacts of purchase accounting. These permanently reinvested basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which were considered probable as of December&#160;31, 2020. The residual U.S. tax liability, if these differences reverse, would be between $300.0 million and $400.0 million as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Aid, Relief and Economic Security Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act adjusted a number of provisions of the tax code, including the calculation and eligibility of certain deductions and the treatment of net operating losses and tax credits. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the year ended December&#160;31, 2020, or to our net deferred tax assets as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the year ended December&#160;31, 2020, and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the net value of certain deferred tax assets by approximately $1.7&#160;billion and reduced the net value of deferred tax liabilities associated with GILTI and tax credits by approximately $1.6&#160;billion. For the year ended December&#160;31, 2020, the income tax expense associated with these reductions was approximately $90.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory, other reserves and accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,546.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,380.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,080.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,753.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,278.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,905.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(396.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(350.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,143.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,381.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(174.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,617.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation, amortization and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(227.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,941.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,484.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the valuation allowance between December&#160;31, 2020 and 2019, was primarily related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to deferred tax assets and liabilities, we have recorded deferred charges related to intra-entity sales of inventory. As of December&#160;31, 2020 and 2019, the total deferred charges were $142.2 million and $243.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. tax reform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss tax reform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, our effective tax rate was primarily increased by the income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above, and partially offset by the benefit recognized on the effective settlement of certain tax matters. Additionally, our 2019 effective tax rate benefited from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an internal reorganization of certain intellectual property rights and the enactment of a new taxing regime in the country and certain cantons of Switzerland, which we refer to as Swiss Tax Reform, partially offset by tax expense related to the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, the divestiture required us to write-off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the 2019 internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of $754.1 million and a deferred tax liability of $603.3 million as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2019, as compared to 2018, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of the Swiss Tax Reform. This decrease was partially offset by a $68.9&#160;million tax expense related to the divestiture of our subsidiary that owned our Hiller&#xf8;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from the unfavorable effects of the 2017 Tax Act and our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Attributes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, we had net operating losses and general business credit carry forwards for U.S. federal income tax purposes of approximately $0.6 million and $1.3 million, respectively, which begin to expire in 2026. For U.S. state income tax purposes, we had research and investment credit carry forwards of approximately $142.4 million that begin to expire in 2022. For foreign income tax purposes, we had $18.0 billion of Swiss federal net operating loss carryforwards that begin to expire in 2025 and $16.8&#160;billion of Swiss cantonal net operating loss carryforwards that begin to expire in 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries, net of the recorded valuation allowance. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to adjust or establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statute expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement refund (payment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance ar December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our 2020 activity reflects the impact of the effective settlement of certain tax matters. We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits as of December&#160;31, 2020, 2019 and 2018, are $68.8 million, $122.7 million and $109.1 million (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize potential interest and penalties related to unrecognized tax benefits in income tax expense. In 2020, 2019 and 2018 we recognized a net interest and penalty expense of $1.0 million, $4.7 million and $2.2 million, respectively. We have accrued $21.2 million and $20.0 million for the payment of interest and penalties as of December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Federal and State Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $25.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Bioverativ Spin-off&lt;/span&gt;&lt;/div&gt;On February 1, 2017, in connection with the spin-off of our hemophilia business, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders pursuant to a separation agreement. In March 2018 Bioverativ was acquired by Sanofi S.A. (Sanofi) and is now an indirect wholly-owned subsidiary of Sanofi. The spin-off of our hemophilia business was intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Our 2017 tax return position remains open to audit. Bioverativ and Sanofi agreed to indemnify us for certain potential liabilities that may arise.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzExMDkz_89c69bac-b3e4-4450-bbee-ca10e8d591b2">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income tax expense and the income tax expense consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income before income taxes (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,290.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,725.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,877.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,757.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,022.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,047.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,125.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,899.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income tax expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;947.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;843.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,090.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,317.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,749.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,143.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,905.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,074.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;992.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,158.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,425.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzMtMS0xLTEtMA_2cce673d-37a0-4cdb-8dae-44c34432c10d"
      unitRef="usd">3290000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzMtMy0xLTEtMA_12f357f5-1129-47c5-9277-b233865b968e"
      unitRef="usd">4725300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzMtNS0xLTEtMA_fbce5d74-bdd2-4f5b-8b53-8bc673d8de84"
      unitRef="usd">3877000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzQtMS0xLTEtMA_4e626d9a-8e1a-4c17-b09c-96399377d963"
      unitRef="usd">1757500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzQtMy0xLTEtMA_02d515a0-734f-4ec4-9b93-b64cf6bc5406"
      unitRef="usd">2400600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzQtNS0xLTEtMA_21f771f1-029b-4d61-9176-114c295ea297"
      unitRef="usd">2022600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzUtMS0xLTEtMA_a382e42b-a76f-4db7-bfac-0a0114a8bf13"
      unitRef="usd">5047500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzUtMy0xLTEtMA_7e524576-0d36-4bc0-b2ec-4f2f14f02b9f"
      unitRef="usd">7125900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzUtNS0xLTEtMA_f5105d03-4e0e-4970-9465-c5805d8981b7"
      unitRef="usd">5899600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzgtMS0xLTEtMA_f8123e42-1013-4610-8980-797e99fbb70f"
      unitRef="usd">647000000.0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzgtMy0xLTEtMA_367b0b4a-41a3-4a78-95cb-25b7585aaeda"
      unitRef="usd">947400000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzgtNS0xLTEtMA_8eb7384f-2abf-4be8-b3ea-7fe570dc0bd5"
      unitRef="usd">1131800000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzktMS0xLTEtMA_33b0cd9b-0a39-4b16-8ada-9c70f054a117"
      unitRef="usd">41200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzktMy0xLTEtMA_11c38630-19a2-4b38-b5f3-93d5e4a2902b"
      unitRef="usd">59100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzktNS0xLTEtMA_a18c6a7b-ee34-4265-9c0e-9cbf6ad41553"
      unitRef="usd">45500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEwLTEtMS0xLTA_f06e2975-e34d-405b-9e88-b3b7f92920be"
      unitRef="usd">155100000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEwLTMtMS0xLTA_eb3dfd45-71a2-477a-8883-2d5a43ba394f"
      unitRef="usd">84400000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEwLTUtMS0xLTA_6e9f9ddb-c4e0-42a0-9de6-eee5366b2dcb"
      unitRef="usd">140000000.0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzExLTEtMS0xLTA_e63e4adb-e8f1-46da-9f06-fa3402a322e1"
      unitRef="usd">843300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzExLTMtMS0xLTA_40d63c35-0e93-45b0-827a-e20793de75e7"
      unitRef="usd">1090900000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzExLTUtMS0xLTA_556ab62f-eb16-4214-8b36-c3724686dfc9"
      unitRef="usd">1317300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEzLTEtMS0xLTA_7fcdf067-d3fd-4005-a40a-b4230ca4b4ad"
      unitRef="usd">-1749900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEzLTMtMS0xLTA_b10ba749-6ba8-4734-8dd0-1a42a03e8565"
      unitRef="usd">1143900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzEzLTUtMS0xLTA_028b88d2-a7c6-4e3d-a63d-adb932c3ea82"
      unitRef="usd">-62000000.0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE0LTEtMS0xLTA_f54e17b3-b002-4eab-979d-e924073b80f7"
      unitRef="usd">-6800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE0LTMtMS0xLTA_e4555b88-c20b-473a-988e-af65be4515e0"
      unitRef="usd">-2300000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE0LTUtMS0xLTA_4fabe6e4-24f8-4cdd-8e97-a0a14050cabf"
      unitRef="usd">-7400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE1LTEtMS0xLTA_e64fb48b-d4f7-40d6-829a-622a804a33bc"
      unitRef="usd">1905700000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE1LTMtMS0xLTA_ea8cc356-dd56-4b17-b66f-514d9a6974b1"
      unitRef="usd">-1074500000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE1LTUtMS0xLTA_c8c61484-5fdf-4d98-95b4-bcc066363aca"
      unitRef="usd">177700000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE2LTEtMS0xLTA_98e5aaec-f643-4bd1-9c32-fdccfd4cf3c6"
      unitRef="usd">149000000.0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE2LTMtMS0xLTA_df7fe3ca-38e3-473f-9af2-fd6542d9ab6c"
      unitRef="usd">67100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE2LTUtMS0xLTA_faac5568-c663-4e78-a47d-0f093346d6a1"
      unitRef="usd">108300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE3LTEtMS0xLTA_32ffeb87-c4b3-45ab-801b-42ea83fdeb20"
      unitRef="usd">992300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE3LTMtMS0xLTA_db02bbd2-8a79-421c-bd9f-fac5840e22e1"
      unitRef="usd">1158000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpmZDBhNDEwN2ExZmQ0NmI1OTdkZjYyZDZkOTRkNmYxNy90YWJsZXJhbmdlOmZkMGE0MTA3YTFmZDQ2YjU5N2RmNjJkNmQ5NGQ2ZjE3XzE3LTUtMS0xLTA_f7bd9145-51df-4597-b5e9-145cc743be13"
      unitRef="usd">1425600000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:Reductionindeferredtaxliabilityundistributedforeignearnings
      contextRef="ibeae6620ceef4b6da93e2b0ac949cf2a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzE2MjE_0ce9a972-0c34-43a4-8537-1386610e72af"
      unitRef="usd">34600000</biib:Reductionindeferredtaxliabilityundistributedforeignearnings>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="ibeae6620ceef4b6da93e2b0ac949cf2a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzE2NzY_55738949-f871-4dea-a83c-26fac3a4d409"
      unitRef="usd">12700000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <biib:DeferredtaxliabilitiesGILTItaxcalculation
      contextRef="i13e408385075494cbe602b5be6d1c8e3_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzE3MzM_83bea6b3-fe96-4504-a527-ee3752eb110a"
      unitRef="usd">135800000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="ibeae6620ceef4b6da93e2b0ac949cf2a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzE4MDM_02d8d52a-b2e2-4696-9c76-0264cadcef63"
      unitRef="usd">11000000.0</us-gaap:OtherTaxExpenseBenefit>
    <biib:TransitionTollTaxRepatriationTaxRate
      contextRef="i8e9fc07f4dfc4bc081d7e510e678bca7_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzIyMjQ_1f019e00-8fdb-4c1d-b070-f003aed7efca"
      unitRef="number">0.155</biib:TransitionTollTaxRepatriationTaxRate>
    <biib:TransitionTollTaxRepatriationTaxRate
      contextRef="i60c4584fb70e4f31996559b7c3214b24_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzIyNzQ_502ea6ec-0de3-494b-9a04-c3dcc0a6f2f3"
      unitRef="number">0.080</biib:TransitionTollTaxRepatriationTaxRate>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ib21ba4f090344f2f9805e82e16811047_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzIzMzc_29dd9b65-0cfa-45fa-a027-d8a9c9135f5c"
      unitRef="usd">697000000.0</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i8fe3f12d8cdc4e1fb91fee9506338b3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzIzMzc_f74ad078-794a-4a0b-aa50-3bc757625071"
      unitRef="usd">697000000.0</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:IncomeTaxesPaid
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzI0Nzk_cabd9074-3cab-4f5c-ba6c-c1819442dcee"
      unitRef="usd">62000000.0</us-gaap:IncomeTaxesPaid>
    <biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzMwNTY_6e6b3b4f-2e58-4f33-97e1-6e6fe9b55a7b"
      unitRef="usd">1500000000</biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries>
    <biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting
      contextRef="ic4652a3a2e7940719a658dd16032604d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzM0Mjc_7efe14ab-3289-4624-bf51-ad02bcd7223e"
      unitRef="usd">300000000.0</biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting>
    <biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting
      contextRef="i50d29a2be0b04648b7d97ec27df8f046_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzM0MzQ_050f1378-a306-4919-8294-2d267ea103c4"
      unitRef="usd">400000000.0</biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting>
    <biib:DeferredTaxAssetsValueReductionInValue
      contextRef="ic9237ad9c6c14888837dc3e87c024939_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDE5OTk_bdb3475e-e769-4051-8195-ad16df7ecbf9"
      unitRef="usd">1700000000</biib:DeferredTaxAssetsValueReductionInValue>
    <biib:DeferredTaxLiabilitiesValueReductionInValue
      contextRef="ic9237ad9c6c14888837dc3e87c024939_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDIwMTM_48b3dea3-7a1a-4c53-b080-f5077016e101"
      unitRef="usd">1600000000</biib:DeferredTaxLiabilitiesValueReductionInValue>
    <biib:IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet
      contextRef="i5daca379673646cba7a409b1982cb5ce_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDIwMjc_714639f4-197a-48f2-995b-1f31f378b60c"
      unitRef="usd">90300000</biib:IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ5NDc4MDIzNDE2NDU_3e55b79c-9ed7-4d9b-9a0e-bbdcc73b051a">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory, other reserves and accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,546.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,380.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,080.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,753.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,278.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,905.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(396.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(350.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,143.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,381.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(174.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,617.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation, amortization and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(227.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,941.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,484.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the valuation allowance between December&#160;31, 2020 and 2019, was primarily related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzMtMS0xLTEtMA_e28c51d6-7418-4a0e-8e51-24a69b614877"
      unitRef="usd">113400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzMtMy0xLTEtMA_555581fb-312c-4124-aa5d-60687d6a9a19"
      unitRef="usd">106600000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzQtMS0xLTEtMA_574317a9-8f35-4e8e-a51f-e04df271029c"
      unitRef="usd">165900000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzQtMy0xLTEtMA_959e5889-bd34-4af0-b177-8cf8546747aa"
      unitRef="usd">162000000.0</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzUtMS0xLTEtMA_39a8eae9-59e0-43b8-b94e-e4e2ed5cfd69"
      unitRef="usd">1546000000.0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzUtMy0xLTEtMA_551fd103-dbc8-48bd-9be5-3b65db366981"
      unitRef="usd">3380000000.0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzYtMS0xLTEtMA_f561ce05-8ed3-4a18-aac7-9e28285ae247"
      unitRef="usd">2080300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzYtMy0xLTEtMA_6afce0aa-c244-4448-bdd0-5bb44079dc1d"
      unitRef="usd">130400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzctMS0xLTEtMA_4b455a2a-357f-4892-b8f7-3986c4fe256e"
      unitRef="usd">23300000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzctMy0xLTEtMA_05887139-66f0-4368-9bb2-8a49ddfb63e6"
      unitRef="usd">23800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzgtMS0xLTEtMA_50fb21e1-4079-4a1f-b336-8d62d6dba776"
      unitRef="usd">103100000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzgtMy0xLTEtMA_47e5a22a-a834-44a9-925e-a66ea8de950f"
      unitRef="usd">103700000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzktMS0xLTEtMA_5d9d636c-e6b9-4f36-b328-34cfc80c4685"
      unitRef="usd">1753900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzktMy0xLTEtMA_4f127311-63ec-414b-a06f-3091d3e0f92f"
      unitRef="usd">1100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEwLTEtMS0xLTA_113f09f6-d356-47db-b0b4-6f955406245e"
      unitRef="usd">2278100000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEwLTMtMS0xLTA_68307762-2008-44ea-9b87-e483a626c6a8"
      unitRef="usd">3905400000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEyLTEtMS0xLTA_28ae4b41-86d7-4151-8cb6-8fd64fa8afa1"
      unitRef="usd">396200000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEyLTMtMS0xLTA_3f627932-9aea-4ae6-a9b4-9e0094e3b8b7"
      unitRef="usd">350300000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <biib:DeferredtaxliabilitiesGILTItaxcalculation
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEzLTEtMS0xLTA_8483b184-6c2c-44da-b3aa-7f022a14f837"
      unitRef="usd">-1143700000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
    <biib:DeferredtaxliabilitiesGILTItaxcalculation
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzEzLTMtMS0xLTA_20cdc451-3325-4d8f-983e-44089e79382e"
      unitRef="usd">-1381600000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
    <biib:DeferredTaxLiabilitiesTaxCreditCarryforwards
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE0LTEtMS0xLTA_365d4acb-cccb-4d09-adad-2ec148552f97"
      unitRef="usd">-174600000</biib:DeferredTaxLiabilitiesTaxCreditCarryforwards>
    <biib:DeferredTaxLiabilitiesTaxCreditCarryforwards
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE0LTMtMS0xLTA_bea08f46-049b-476f-a23f-65d9181126eb"
      unitRef="usd">-1617200000</biib:DeferredTaxLiabilitiesTaxCreditCarryforwards>
    <biib:DeferredTaxLiabilitiesDepreciationAmortizationOther
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE1LTEtMS0xLTA_eaf7d7db-94a7-4026-b8f0-906b3ea04740"
      unitRef="usd">227000000.0</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
    <biib:DeferredTaxLiabilitiesDepreciationAmortizationOther
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE1LTMtMS0xLTA_93cefbc3-436e-49b2-85c3-aa1bed98bbf8"
      unitRef="usd">135000000.0</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE2LTEtMS0xLTA_220adcb7-994c-4155-b903-65a109a74bf1"
      unitRef="usd">1941500000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTpiMDg0ZjI3NjY0YWQ0OTlmODdjZGFhMWYxNmIzOGQ5Ni90YWJsZXJhbmdlOmIwODRmMjc2NjRhZDQ5OWY4N2NkYWExZjE2YjM4ZDk2XzE2LTMtMS0xLTA_c8c43e2b-99c8-4189-9a67-46f3aa417878"
      unitRef="usd">3484100000</us-gaap:DeferredTaxLiabilities>
    <biib:Totaldeferredchargesandprepaidtaxes
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ2MTE_7aaebb25-02b3-4646-ba56-c0c75481eb84"
      unitRef="usd">142200000</biib:Totaldeferredchargesandprepaidtaxes>
    <biib:Totaldeferredchargesandprepaidtaxes
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ2MTg_5db8a125-23fb-47f4-ac12-369e61e82e5f"
      unitRef="usd">243800000</biib:Totaldeferredchargesandprepaidtaxes>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ5NDc4MDIzNDE2NDY_4fb0fe2b-1e1e-4e54-aa77-a822d9bea350">&lt;div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Credits and net operating loss utilization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Divestiture of Denmark manufacturing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Internal reorganization of certain intellectual property rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. tax reform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss tax reform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzItMS0xLTEtMA_0b1541c4-6457-4701-ae63-90d29e64609b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzItMy0xLTEtMA_16595c6a-3072-45a4-b21b-74c2fe50aab4"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzItNS0xLTEtMA_f1755ad9-1948-43ff-8e9e-382982ac0ff8"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzMtMS0xLTEtMA_52cbaf73-f35a-4642-9acd-999c90d5cf40"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzMtMy0xLTEtMA_b514c663-8bf3-4cbd-9cc4-9ad1ebd5cfb6"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzMtNS0xLTEtMA_12439c51-c24f-439c-a5e4-7cf0b71f4597"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzQtMS0xLTEtMA_624373b4-e49b-4f72-99b5-454533935750"
      unitRef="number">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzQtMy0xLTEtMA_fc8dcff9-996b-4cf5-87d6-91efcf686f7e"
      unitRef="number">-0.045</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzQtNS0xLTEtMA_a4233754-96c1-4a33-a8d8-dfc8f178be06"
      unitRef="number">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzUtMS0xLTEtMA_5bd2afda-5e23-47b1-bee7-114225394177"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzUtMy0xLTEtMA_e2afdcd6-e999-4576-b883-1e4e0fffb6f6"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzUtNS0xLTEtMA_d5bd9ee7-7dd8-4435-aa1b-1961d949d62c"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzYtMS0xLTEtMA_227fc717-7fcb-461d-8b84-9487cd5609df"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzYtMy0xLTEtMA_95d9410a-20f8-4e66-8c95-d7fe164667cd"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzYtNS0xLTEtMA_c36fc0a2-08cb-4fa7-8709-c3811b0f6292"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzctMS0xLTEtMA_94f716fb-68a2-42ff-9253-2648e7785a49"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzctMy0xLTEtMA_c0798c3e-d661-4451-99fa-068dd2e87391"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzctNS0xLTEtMA_60e427b4-f92b-4ba8-995b-11760a68b618"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfAssets>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzgtMS0xLTEtMA_004ef53c-5272-4b9a-a310-e934a7720e73"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzgtMy0xLTEtMA_bb03c83e-e828-49c4-91ab-24ec3c944ffa"
      unitRef="number">-0.021</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzgtNS0xLTEtMA_bc5c8772-32ee-4a9f-bb72-38ad93ae0ef1"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktMi0xLTEtMTkyOTM_0ccd4b96-4d6e-4a1c-941c-77bc7af54655"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktNC0xLTEtMTkyOTM_875bb0b0-d2e9-4574-99e0-108176b0d426"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktNi0xLTEtMTkyOTM_9090f7aa-21ce-498a-a109-0fff6c258332"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktMS0xLTEtMA_34d99505-ac79-43b5-9d24-34deaeedde08"
      unitRef="number">0.013</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktMy0xLTEtMA_1f41fb2b-4096-4228-aeb0-455a074a2bc4"
      unitRef="number">0.015</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzktNS0xLTEtMA_004cc1c9-bd8e-4f08-8fb2-44d0ab6467ff"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzExLTEtMS0xLTA_b14e5385-2467-48c4-a5c9-6e4205c64bac"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzExLTMtMS0xLTA_bec9903c-c3f4-4516-ac3a-dcc00dfd96ef"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzExLTUtMS0xLTA_8646970b-299f-4678-80fe-4e86eb60c502"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzEyLTEtMS0xLTA_3cd18454-b54d-4f57-973f-7b9ea1e887ad"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzEyLTMtMS0xLTA_5bd84823-9ab0-433f-ad15-d619bf46bd00"
      unitRef="number">-0.008</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzEyLTUtMS0xLTA_65fd0937-286f-4d2d-a1ba-a4ad2a9a1812"
      unitRef="number">0</biib:EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE1LTEtMS0xLTA_d9c189bf-f8ff-47d6-9d05-5e69dd4a3093"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE1LTMtMS0xLTA_ba4c9310-81d6-47fe-82ef-94844dc85960"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE1LTUtMS0xLTA_1fb461ec-7fe5-4bb0-a60b-391a348a783b"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE2LTEtMS0xLTA_ecb72ebc-8556-4fb1-bdb6-1ca4305772c3"
      unitRef="number">0.197</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE2LTMtMS0xLTA_0251d717-e518-452c-8b90-c6cd27f46d44"
      unitRef="number">0.163</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4M2Y2MTJmZmQ5MTQ0MzgzOTMwMGM3NmI3M2U1YTgxNy90YWJsZXJhbmdlOjgzZjYxMmZmZDkxNDQzODM5MzAwYzc2YjczZTVhODE3XzE2LTUtMS0xLTA_b559fd49-8bd2-4b7f-9074-ad372d19d28f"
      unitRef="number">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie04b35230b3a4c1b86938c22cf535263_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzU4Njk_687cbc23-5f00-4034-a9ad-168fb25dbe7d"
      unitRef="usd">754100000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ie04b35230b3a4c1b86938c22cf535263_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzU5MDQ_1db464e2-dea8-44e4-be6b-25e0d3c36052"
      unitRef="usd">603300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="ifc3cfddad193493c8162b31bde88d1dc_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDQzMzM_7aafadec-9573-4d13-9537-6de7a1802c7f"
      unitRef="usd">68900000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0192f21805fe4e158b7667cad4964a5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzY3NDY_96ec8b03-edbd-451a-b919-973ec42df9f6"
      unitRef="usd">600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i0192f21805fe4e158b7667cad4964a5f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzY3NTM_01dcdd69-6303-4289-9730-620301cbc382"
      unitRef="usd">1300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i0d86e21f739f482d80d94fd171cf33bf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzcwMzk_224e5d43-9cc0-4f83-bfa1-f6bee991322c"
      unitRef="usd">142400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i0192f21805fe4e158b7667cad4964a5f_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzcxMTI_0eea5fa2-01cf-47af-999c-e0e577aa3292"
      unitRef="usd">18000000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="i26628f1182184eba96d1f455922e58af_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NTE1MDY_c866c90a-7ada-458a-add5-47b2fac74a3a"
      unitRef="usd">16800000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzQ5NDc4MDIzNDE2NDc_1dec2e5c-4cd8-49af-a439-274d29eb4ced">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Beginning balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statute expirations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlement refund (payment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Ending balance ar December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzItMS0xLTEtMA_c1424111-be85-40c9-8bfd-1cb0ac5b4fb5"
      unitRef="usd">129900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzItMy0xLTEtMA_516ffc6e-de73-448c-ad60-065e3ce21614"
      unitRef="usd">114200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic9925b2c3e594ae0812001969da2a99b_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzItNS0xLTEtMA_bdbd233d-57f1-46b4-835e-7d69cc9d72d3"
      unitRef="usd">66800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzMtMS0xLTEtMA_531562fa-afcb-4581-9a97-5cdc47bbb67b"
      unitRef="usd">1500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzMtMy0xLTEtMA_713d5649-fb96-422a-b241-20553bea2c68"
      unitRef="usd">5300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzMtNS0xLTEtMA_6f6016b5-b2e1-43d4-b5b9-f85ea1df5db2"
      unitRef="usd">500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzQtMS0xLTEtMA_d6aef71b-cd66-4542-a15e-7a16b850b33e"
      unitRef="usd">51700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzQtMy0xLTEtMA_6a092c46-342d-42b8-9091-4369b129d041"
      unitRef="usd">17200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzQtNS0xLTEtMA_cef2b627-3cd7-41c4-aef1-800107db3b63"
      unitRef="usd">58700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzUtMS0xLTEtMA_7cd23ff4-b89d-4730-882b-29150356efbf"
      unitRef="usd">63600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzUtMy0xLTEtMA_37176cf1-c50c-46d8-b26f-ac4ebc2d5586"
      unitRef="usd">10300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzUtNS0xLTEtMA_811a9c27-7b24-4094-8782-599e5900d409"
      unitRef="usd">13600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzYtMS0xLTEtMA_41d2db41-986c-44b6-a03b-dc0178ba7952"
      unitRef="usd">7900000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzYtMy0xLTEtMA_bebde395-90ae-4d7a-839f-dafcdac1d6ab"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzYtNS0xLTEtMA_3aeea948-b71f-4328-a8df-3c2659c67b95"
      unitRef="usd">2900000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzctMS0xLTEtMA_b2fdc9cf-0230-4fe1-b0df-4a25101de4ac"
      unitRef="usd">35900000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzctMy0xLTEtMA_f30c2261-f00c-4e06-bb3a-36221086f86c"
      unitRef="usd">3600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzctNS0xLTEtMA_abb00245-e817-4985-ab3b-53ffe464ab61"
      unitRef="usd">4700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzgtMS0xLTEtMA_c9b63bdf-36df-4de5-9380-b5d8a4102473"
      unitRef="usd">75700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzgtMy0xLTEtMA_019e9a28-a358-4509-af7c-2632b45a7fb6"
      unitRef="usd">129900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90YWJsZTo4MTY5YzU5OTljZDY0YTU2YmU4MGI1YjdmMjNjYjEyYy90YWJsZXJhbmdlOjgxNjljNTk5OWNkNjRhNTZiZTgwYjViN2YyM2NiMTJjXzgtNS0xLTEtMA_fdf6db14-40a2-4339-9ffc-258b18f0693c"
      unitRef="usd">114200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzkzMzc_a0f3bcc4-2f23-4e42-8a3e-cbdd1818ba12"
      unitRef="usd">68800000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzkzNDE_8b39d484-941e-44c7-b326-2683cf662140"
      unitRef="usd">122700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzkzNDg_c2583366-3bda-4f28-bed0-5c92f9563acf"
      unitRef="usd">109100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk2ODc_103faacb-ecdf-4cb3-afdd-0af4e8882a06"
      unitRef="usd">1000000.0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk2OTE_8b70672d-9018-4269-9e0c-b084a8fff327"
      unitRef="usd">4700000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk2OTg_6afc62f6-16ae-4555-9e89-1ad8c9f13e47"
      unitRef="usd">2200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk3MzI_92f47816-19a9-432a-a32d-add6bf058133"
      unitRef="usd">21200000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3Xzk3Mzk_85a65f7f-86a1-4d3e-8e5f-af8556ca93fd"
      unitRef="usd">20000000.0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTgvZnJhZzo4ZmFhMDliZWQ4MDM0OTczYjRjMjkyYmVhNDU1YjJmNy90ZXh0cmVnaW9uOjhmYWEwOWJlZDgwMzQ5NzNiNGMyOTJiZWE0NTViMmY3XzEwOTk1MTE2NDk0NDk_1d8f1985-a805-4744-8fc5-de79cd848031"
      unitRef="usd">25000000.0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwMzg_f1c585f1-52ed-4f26-9ab8-2fe5c588c03c">Other Consolidated Financial Statement Detail&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information for the years ended December&#160;31, 2020, 2019 and 2018, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid during the year for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;272.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;906.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,064.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,007.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-cash Operating, Investing and Financing Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2018 we accrued $300.0 million upon reaching $20.0 billion in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately $12.4 million and $50.0 million in our consolidated balance sheets as of December&#160;31, 2020 and 2019, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Property, Plant and Equipment,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Income (Expense), Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(187.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(200.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;497.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, net unrealized and realized gains on our holdings in equity securities were approximately $681.8&#160;million and $12.1&#160;million, respectively, compared to net unrealized and realized gains of $150.1&#160;million and $50.0&#160;million in 2019. The net unrealized gains recognized during the year ended December&#160;31, 2020, primarily reflects an increase in the fair value of Denali and Sangamo common stock of approximately $703.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;681.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,145.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,765.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $1,329.6 million and $1,348.9 million as of December&#160;31, 2020 and 2019, respectively, and include accrued income taxes totaling $709.9 million and $803.3 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwNDM_7874a6d8-726e-4220-aef3-b95099c1763f">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information for the years ended December&#160;31, 2020, 2019 and 2018, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid during the year for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;272.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;906.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,064.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,007.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzMtMS0xLTEtMA_4cb0aee1-60bb-4322-b811-acc5be7e183e"
      unitRef="usd">272700000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzMtMy0xLTEtMA_440525d3-1b0e-4c2d-af9e-5675ce3928c3"
      unitRef="usd">244200000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzMtNS0xLTEtMA_dab59983-c832-4d66-a038-44e4e954bc9d"
      unitRef="usd">243200000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzQtMS0xLTEtMA_4a868fb5-1d90-4145-b1c3-dcb6a3fade54"
      unitRef="usd">906700000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzQtMy0xLTEtMA_e481a6d5-dc5e-4448-b86f-140a399842d7"
      unitRef="usd">1064500000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo1ZmYzZmY2N2IzYzg0NGY3ODkyNmQ2OTljNmZkMGY4ZC90YWJsZXJhbmdlOjVmZjNmZjY3YjNjODQ0Zjc4OTI2ZDY5OWM2ZmQwZjhkXzQtNS0xLTEtMA_02a656d0-5816-42e1-b7a1-865b5ee3b52b"
      unitRef="usd">1007100000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i9c55c5c3bbab4bcc915d94071853367e_D20181001-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzI4Nw_613b93ee-e48b-4eee-ab6e-082e6bb0bc26"
      unitRef="usd">300000000.0</us-gaap:GoodwillAcquiredDuringPeriod>
    <biib:CumulativeSalesLevel
      contextRef="i2a5c5a093a604074b379ddadcb4304e8_I20181231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzMwNA_edb8f4e3-56e7-43d2-80ee-d3fd0567aed2"
      unitRef="usd">20000000000.0</biib:CumulativeSalesLevel>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="i82ea75f6631c448f8f22c298bec0c951_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzk2OQ_15f3ff55-c198-4522-ab49-ef44bed6173f"
      unitRef="usd">12400000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent
      contextRef="i214f8c61e02b4bc78c01086f27fa4760_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzk3Ng_7d830099-b385-46dc-a56e-3b4fac243183"
      unitRef="usd">50000000.0</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwNDk_61ff71fa-78fe-4cb9-aa50-52651e8c25b5">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other income (expense), net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(222.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(187.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(200.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;685.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;497.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzItMS0xLTEtMA_9e38a9f4-1c5f-4cd7-b130-3fb36eac1d5c"
      unitRef="usd">42000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzItMy0xLTEtMA_dfbe32b7-08fc-4d95-9b5a-fc19c9c6f80c"
      unitRef="usd">120000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzItNS0xLTEtMA_db9d422e-f3f7-45a8-8e5b-84a5bb9002e4"
      unitRef="usd">112500000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzMtMS0xLTEtMA_c0baeaf7-1f09-407a-ba48-96f79505e29f"
      unitRef="usd">222500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzMtMy0xLTEtMA_aab9263a-f788-4204-97ac-5a42406f5f34"
      unitRef="usd">187400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzMtNS0xLTEtMA_4b0f50b6-1d24-4fce-bc80-da9f38aaf1fc"
      unitRef="usd">200600000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzQtMS0xLTEtMA_b8e27167-c2ac-4cef-9677-45150c04dfa2"
      unitRef="usd">685700000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzQtMy0xLTEtMA_21d773ec-5e19-4839-a2e4-cbd664244991"
      unitRef="usd">204700000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzQtNS0xLTEtMA_3c98e586-0863-482b-8f61-f2cf42aca6cc"
      unitRef="usd">119500000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzUtMS0xLTEtMA_923d826c-38dc-4c39-b43b-01a0fc6eaaaa"
      unitRef="usd">-10700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzUtMy0xLTEtMA_ab4c268f-a2f2-43c9-9b19-18eb3ff08016"
      unitRef="usd">-7000000.0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzUtNS0xLTEtMA_329498c9-aef6-425c-9ab2-cb97e098fc01"
      unitRef="usd">-9900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzYtMS0xLTEtMA_f702b790-63ba-4ffa-bf01-4607916839d6"
      unitRef="usd">2900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzYtMy0xLTEtMA_fb491de4-7c60-4a58-8c42-df9454776f8b"
      unitRef="usd">-47000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzYtNS0xLTEtMA_a363a3fa-b663-4f91-aa28-eb559e260e72"
      unitRef="usd">-10500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzctMS0xLTEtMA_4e82753e-bf4b-48a2-87c4-c49092212e23"
      unitRef="usd">497400000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzctMy0xLTEtMA_3da5f00f-c8af-4e5c-947d-62112bcb58a9"
      unitRef="usd">83300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpkYjA0NjFiMDQ0Y2I0NzdlODQyZjM1MzQ0OTI0MmRmZC90YWJsZXJhbmdlOmRiMDQ2MWIwNDRjYjQ3N2U4NDJmMzUzNDQ5MjQyZGZkXzctNS0xLTEtMA_d44380c0-cce7-45de-94a4-46e33fde72e1"
      unitRef="usd">11000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0MDc_83f53fb5-9c13-448f-a45f-18b630f9e1ce"
      unitRef="usd">-681800000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0MTM_d4208bf4-90ab-4537-a5ae-0ddb50bfc0b3"
      unitRef="usd">12100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0MTk_b3bcae8b-1416-4c06-ac88-f3769549dfdc"
      unitRef="usd">150100000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0MjU_27bcd029-fae0-4142-815a-9f0d501991e3"
      unitRef="usd">50000000.0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i8217e2c7737e464790a37fff8a75e2cc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzEwOTk1MTE2MzE0NDM_6bc0d37d-721b-4334-9cda-a4f72f064a3f"
      unitRef="usd">703900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwNTA_916dc73d-3fcf-4538-9833-ef25935ad233">&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains (losses) recognized during the period on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;681.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzItMS0xLTEtMA_3168bac0-1012-49ac-a61d-98e4187ee3fa"
      unitRef="usd">693900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzItMy0xLTEtMA_47975338-2791-41f0-87ec-304cb34cc8c7"
      unitRef="usd">200100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzItNS0xLTEtMA_f00d2e2d-7c8b-4deb-8a60-a00fe1d96d17"
      unitRef="usd">127900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzMtMS0xLTEtMA_227e4f61-01ad-4f2d-8f22-30805179bc73"
      unitRef="usd">12100000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzMtMy0xLTEtMA_467cc4d4-319a-44a9-9c03-628b91a24b7f"
      unitRef="usd">50000000.0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzMtNS0xLTEtMA_0bf44139-5f6d-4e69-820b-74514460f349"
      unitRef="usd">-600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzQtMS0xLTEtMA_d7baec62-9325-4607-ac7f-7d8c9d03a1f0"
      unitRef="usd">681800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzQtMy0xLTEtMA_d9f8d033-065b-4138-8a55-b2b74dd23078"
      unitRef="usd">150100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i74ed8f8fda7b4b359c13cfe02034a083_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTo5NTY2NzYyNWU5ZDM0M2JiYWEwOTg0YTU1MzgwMjQ5Ny90YWJsZXJhbmdlOjk1NjY3NjI1ZTlkMzQzYmJhYTA5ODRhNTUzODAyNDk3XzQtNS0xLTEtMA_21bff74d-9bcb-45c5-8640-14f5aa8135b5"
      unitRef="usd">128500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwMzY_9d481d7d-147e-4025-9b04-5ac6e85cc22e">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,145.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,765.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzItMS0xLTEtMA_b3cf638e-75b1-4de2-bf0f-ba0b35c0cb42"
      unitRef="usd">1080600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzItMy0xLTEtMA_187cc441-2bd2-4fe7-b9c8-f84f4f7760e2"
      unitRef="usd">1001100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:Collaborationexpensesaccrual
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzMtMi0xLTEtMjA1MTI_51b6b06b-0c24-4015-9819-bcd010560991"
      unitRef="usd">389900000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzMtNC0xLTEtMjA1MTI_4111b44f-d6a4-4cd7-8d52-21ffab855b3e"
      unitRef="usd">281600000</biib:Collaborationexpensesaccrual>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzMtMS0xLTEtMA_3a2aa1ab-246f-4cbd-83f1-4afe7c79aebc"
      unitRef="usd">333800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzMtMy0xLTEtMA_b72c2da2-10e1-4ec4-beda-a28badac91c6"
      unitRef="usd">309100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzUtMS0xLTEtMA_62d4ae27-e3a7-45c4-8aad-cb867a9b329a"
      unitRef="usd">218500000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzUtMy0xLTEtMA_4abd140d-3786-4649-b6ec-da490c8b92b8"
      unitRef="usd">220900000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzYtMi0xLTEtMjEwNzk_9aa96f42-9ff1-4c24-aed8-d3e6633e3c1c"
      unitRef="usd">181500000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzYtNC0xLTEtMjEwNzk_fe1112dd-6afe-4cdd-83f9-cf3225261529"
      unitRef="usd">6700000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzYtMS0xLTEtMA_5f6179b8-2ed6-42bf-8823-ffc33a6dd87c"
      unitRef="usd">149600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzYtMy0xLTEtMA_a01ad3eb-877f-462b-8736-c64da223959e"
      unitRef="usd">148400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzgtMS0xLTEtMA_92aff3c0-a80c-44a5-85c4-f77204cdc159"
      unitRef="usd">791400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzgtMy0xLTEtMA_b27034a1-ea16-4776-955b-9a1fb3821003"
      unitRef="usd">798000000.0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i45223ed4352840169e55fb7523bb7c45_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzktMS0xLTEtMA_9ea83f1b-140f-460b-8119-90c8b22b2111"
      unitRef="usd">3145300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i57f4c36386654c569a449f1f90ca2232_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90YWJsZTpjNzc5MDdmZjcyOWI0OWFjYTZkNmU2OGZhOTNlNWQzMC90YWJsZXJhbmdlOmM3NzkwN2ZmNzI5YjQ5YWNhNmQ2ZTY4ZmE5M2U1ZDMwXzktMy0xLTEtMA_9e494ad9-8bd2-4de6-9516-48952f2fceda"
      unitRef="usd">2765800000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzE5MjM_741a9778-b152-47d3-951a-71e87093a261"
      unitRef="usd">1329600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzE5MzA_d8c41ac3-757e-4c28-935b-72792430b02b"
      unitRef="usd">1348900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwMDY_92d65717-6d60-452a-975b-95135f7cf01b"
      unitRef="usd">709900000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDEvZnJhZzo5YzlkNjExMDMxMGE0OWM1OWMyNjA0MmQyZTYxNThjMC90ZXh0cmVnaW9uOjljOWQ2MTEwMzEwYTQ5YzU5YzI2MDQyZDJlNjE1OGMwXzIwMTM_5324ea8a-d1a0-4390-824e-04cbcb0a2139"
      unitRef="usd">803300000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDQ1_37a1803e-fa68-4bca-be06-8422939d9f24">Collaborative and Other RelationshipsIn connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the collaborative arrangement, we may record funding receivable or payable balances with our collaboration partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaborative arrangements are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech, Inc. (Roche Group)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#x2019;s offer or purchase Genentech&#x2019;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to OCREVUS and any other collaboration anti-CD20 products in development in exchange for a royalty as well as our rights to GAZYVA in exchange for the compensation described in the collaboration arrangement. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCREVUS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0 million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Formulas&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a 30.0% share on the first $50.0 million of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;First Non-CLL GAZYVA FDA Approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the FDA&#x2019;s first approval of GAZYVA in an indication other than CLL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;First GAZYVA Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least $150.0 million or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $150.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Second GAZYVA Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share of RITUXAN pre-tax profits in the U.S. in excess of $50.0&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, was 37.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between 30.0% and 37.5% based on certain events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0 million of operating profits earned each calendar year. Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until First GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share of GAZYVA pre-tax profits in excess of $50.0&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, was 37.5%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,080.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;748.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,977.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ionis Pharmaceuticals, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2012 we entered into a collaboration and license agreement with Ionis pursuant to which we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended December&#160;31, 2020, 2019 and 2018, totaled $286.6 million, $293.0 million and $238.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2012 Ionis Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three gene targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, Ionis is responsible for global development of any product candidate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to $70.0 million to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to $130.0 million in additional milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;if we successfully develop the product candidate after option exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering into this agreement, we made an upfront payment of $30.0 million to Ionis and agreed to make potential additional payments, prior to licensing, of up to $10.0 million based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this $10.0 million developmental milestone upon the selection of BIIB080 (tau ASO), which is currently in Phase 1 development for the potential treatment of Alzheimer's disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080. In connection with the option exercise, we made a payment of&#160;$45.0 million&#160;to Ionis, which was recorded as research and development expense in our consolidated statements of income. Future payments may include additional milestone payments of up to&#160;$155.0 million&#160;and royalties on future sales in the low- to mid-teens if we successfully develop the product candidate after option exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Ionis Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018 we closed a 10-year exclusive collaboration agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (2018 Ionis Agreement) for a total payment of $1.0 billion, consisting of an upfront payment of $375.0 million and the purchase of approximately 11.5 million shares of Ionis common stock at a cost of $625.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing, we recorded $50.9 million of the $375.0 million upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining $324.1 million as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 11.5 million shares of Ionis common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of $462.9 million in investments and other assets in our consolidated balance sheets reflecting the fair value of the Ionis common stock as of the purchase date and a charge of $162.1 million to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the Ionis common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment in Ionis common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have the option to license therapies arising out of the 2018 Ionis Agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to $125.0 million or $270.0 million for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020 and 2019, we incurred milestones of $11.3&#160;million and $30.0 million, respectively, related to the advancement of neurological targets identified under the 2018 Ionis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 SMA Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of such therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering into this agreement, we made a $25.0 million upfront payment to Ionis and we may pay Ionis up to $260.0 million in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to $800.0 million in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Long-term Strategic Research Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2013 we entered into a six-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the potential treatment of neurological diseases.&#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For non-ALS antisense product candidates, Ionis is responsible for global development through the completion of a Phase 2 trial and we provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a $70.0 million license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to $130.0 million, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (tofersen), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made a payment of $35.0 million to Ionis, which was recorded as research and development in our consolidated statements of income. Future payments may include potential post-licensing milestone payments of up to $55.0 million and royalties in the low- to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of tofersen following the option exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ending December&#160;31, 2020, 2019 and 2018, we incurred milestones of $28.0 million, $20.0 million and $18.0 million, respectively, related to the advancement of programs under this agreement, which were recorded as research and development expense in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BAN2401 Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BAN2401 Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (the Aducanumab Collaboration Agreement). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expenses related to the BAN2401 Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aducanumab Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the period through March 31, 2018, we were responsible for 100.0% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for 15.0% of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for 45.0% of aducanumab development expense incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, we recognized net profit-sharing income of $33.8&#160;million to reflect Eisai's 45.0% share of the $75.0&#160;million milestone expense related to the submission of the BLA for the approval of aducanumab to the FDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a 55.0% share of the potential profits (losses) in the U.S., a 68.5% share of the potential profits (losses) in the European Union (E.U.) and a 20.0% share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab collaboration third party milestone expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;UCB Pharma S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Alkermes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for VUMERITY, a novel fumarate for the treatment of RMS. In October 2019 the FDA approved VUMERITY in the U.S. for the treatment of RMS. In November 2019 VUMERITY became commercially available in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, we received an exclusive, worldwide license to develop and commercialize VUMERITY and we pay Alkermes a royalty of 15.0% on worldwide net commercial sales of VUMERITY. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates, other than VUMERITY, developed under the exclusive license from Alkermes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2019, following the FDA's approval of VUMERITY, we paid Alkermes $155.0 million in milestone payments, which were recorded in intangible assets in our consolidated balance sheets and will be amortized over the useful life of the product. For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $32.4 million, $53.5 million and $68.7 million, respectively, in research and development expense in our consolidated statements of income related to this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alkermes currently supplies VUMERITY to us pursuant to a supply agreement. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by us or our designee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092 (gosuranemab), an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with Alzheimer's disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, we received worldwide rights to gosuranemab and are responsible for the full development and potential commercialization of gosuranemab in Alzheimer's disease and progressive supranuclear palsy (PSP). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we announced that the Phase 2 PASSPORT study investigating gosuranemab in individuals with PSP did not meet its primary endpoint. Based on these results, we discontinued development of gosuranemab in PSP and other primary tauopathies. We will continue our ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease, given differences in disease pathology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering into this agreement, we made an upfront payment of $300.0 million to BMS and assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#x2019;s acquisition of iPierian in 2014. We may pay BMS up to $360.0 million in additional milestone payments, and potential royalties, and we may pay the former shareholders of iPierian up to $370.0 million in remaining milestone payments as well as potential royalties on net commercial sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $62.4 million, $144.0 million and $97.0 million, respectively, in research and development expense in our consolidated statements of income related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acorda Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone of $15.0 million, due if ex-U.S. net sales reach $100.0 million over a period of four consecutive quarters, was recognized during the third quarter of 2020 and capitalized within intangible assets, net in our consolidated balance sheet. Royalty payments are recognized in cost of sales within our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes Inc., who acquired Elan Drug Technologies, the original party to the license with Acorda. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ending December&#160;31, 2020, 2019 and 2018, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were $44.5 million, $42.0 million and $36.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize zuranolone (SAGE-217) for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for the potential treatment of essential tremor and other neurological disorders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection of the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0&#160;million to research and development expense in our consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $875.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We may also pay Sage development and commercial milestone payments that could total up to approximately $1.6&#160;billion if all the specified milestones set forth in this agreement are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and will pay Sage potential tiered royalties in the high teens to low twenties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#x2019;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ATV enabled anti-amyloid beta&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; program and a second program utilizing its Transport Vehicle technology. Further, we have a right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this collaboration we purchased approximately $465.0&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Denali development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to the LRRK2 program are achieved. Under this agreement, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and will pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2020, we recorded $8.8&#160;million in research and development expense in our consolidated statements of income related to this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#x2019;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of this transaction in April 2020 we purchased $225.0&#160;million of Sangamo common stock, or approximately 24&#160;million shares at approximately $9.21 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of approximately $83.0&#160;million to research &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and development expense in our consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0&#160;million that was recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4&#160;billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $80.0&#160;million relates to the selection of targets, $1.9&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0&#160;million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we will pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2020, we recorded $6.4&#160;million in research and development expense in our consolidated statements of income related to this collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $92.1 million, $77.0 million and $48.6 million, respectively, as research and development expense in our consolidated statements of income related to other research and discovery related arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;Samsung BioLogics contributed 280.5 billion South Korean won (approximately $250.0 million) for an 85.0% ownership interest in Samsung Bioepis and we contributed 49.5 billion South Korean won (approximately $45.0 million) for the remaining 15.0% ownership interest.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0%, which reflected the effect of previous equity financings in which we did not participate, to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics.&#160;As of December&#160;31, 2020, our ownership percentage remained at approximately 49.9%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The former chief executive officer (the incumbent chairman of the board) and the chief financial officer of our joint venture partner, Samsung BioLogics, is currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, we recognized net income on our investment of $5.3 million, reflecting our share of income totaling $45.3 million offset by amortization of basis differences totaling $40.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2019, we recognized net losses on our investment of $79.4 million, reflecting our share of losses totaling $1.2 million and amortization of basis differences totaling $78.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the carrying value of our investment in Samsung Bioepis totaled 673.8 billion South Korean won ($620.2 million) and 670.8 billion South Korean won ($580.2 million), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $15.0 million development milestone, which was included in research and development expense in our consolidated statements of income. We may pay Samsung Bioepis up to $195.0&#160;million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2013 we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&#160;As discussed above, we have an option to extend this agreement by an additional five years. Under this agreement, we have made upfront and clinical development milestone payments totaling $46.0 million, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of $25.0 million upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling $75.0 million as intangible assets, net in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018 we and Samsung Bioepis announced an agreement with AbbVie Inc. (AbbVie) related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in Europe in the fourth quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended December&#160;31, 2020, 2019 and 2018, we recognized a net profit-sharing expense of $266.5 million, $241.6 million and $187.4 million, respectively, to reflect Samsung Bioepis' 50% sharing of the net collaboration profits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the technical development services agreement, we provided Samsung Bioepis technical development and technology transfer services, which included, but were not limited to, cell culture development, purification process development, formulation development and analytical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under the manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, we recognized $20.9 million, $106.2 million and $96.4 million, respectively, in revenues under the license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were $5.1 million and $85.0 million as of December&#160;31, 2020 and 2019, respectively. Amounts payable to Samsung Bioepis as of December&#160;31, 2020, were $99.0&#160;million. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the $100.0 million upfront payment related to the transaction we completed in December 2019, as discussed above.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="id44ba7c8ceb14c93b89739486052b804_D20170301-20170331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyMTc_9731b810-0398-453c-8c67-da8235ee38bd"
      unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="i36bea0a273e042b4977e70b6d39dce99_D20170301-20170331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyNDE_9c372f91-413c-4c4f-a426-f64cd2f90fa2"
      unitRef="number">0.240</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage
      contextRef="ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyNzE_9c7ee0bb-03e2-4035-b6ea-78ad2522452a"
      unitRef="usd">900000000.0</biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage>
    <biib:Reductioninroyaltyrate
      contextRef="ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyOTE_e5f3f39e-0d52-4a45-8330-6fa88dc00e38"
      unitRef="number">0.500</biib:Reductioninroyaltyrate>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="i31f7c1fc4a6c450c9505e7b20773c69c_D20170301-20170331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0MDc_e35cf9b5-bc03-437b-bb84-ae373bd0de4b"
      unitRef="number">0.030</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:PeriodOfCollaborationAgreement
      contextRef="ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0OTI_684dd954-eb0c-44a1-ba9b-bf6da395605f">P11Y</biib:PeriodOfCollaborationAgreement>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="id2fc03f67f5645f1b013252212df9935_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ0NDI_95f4dacc-787c-45a0-976b-dd305db45c76"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ0NjQ_16c4b3b7-1bb5-4780-ad5b-84b3996044d1"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionProfitSharingFormulaTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDU3_05fb4274-8ad4-4bdf-8247-b6f33b67df0a">Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ1ODI_16c4b3b7-1bb5-4780-ad5b-84b3996044d1"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne
      contextRef="id2fc03f67f5645f1b013252212df9935_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTphNzUyMDZjOWEyMjQ0ZWZlYThlYWU3MjljOWJjZmU0ZS90YWJsZXJhbmdlOmE3NTIwNmM5YTIyNDRlZmVhOGVhZTcyOWM5YmNmZTRlXzAtMS0xLTEtMA_8001e1e5-42de-4d63-bf7c-10ce5bc39224"
      unitRef="number">0.400</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
      contextRef="id2fc03f67f5645f1b013252212df9935_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTphNzUyMDZjOWEyMjQ0ZWZlYThlYWU3MjljOWJjZmU0ZS90YWJsZXJhbmdlOmE3NTIwNmM5YTIyNDRlZmVhOGVhZTcyOWM5YmNmZTRlXzEtMS0xLTEtMA_1d3cb2f8-42bd-46e6-adde-9ffd51993049"
      unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="id2fc03f67f5645f1b013252212df9935_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTphNzUyMDZjOWEyMjQ0ZWZlYThlYWU3MjljOWJjZmU0ZS90YWJsZXJhbmdlOmE3NTIwNmM5YTIyNDRlZmVhOGVhZTcyOWM5YmNmZTRlXzItMS0xLTEtMA_87861230-5b59-407b-9a80-2359cc41a56c"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="id2fc03f67f5645f1b013252212df9935_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTphNzUyMDZjOWEyMjQ0ZWZlYThlYWU3MjljOWJjZmU0ZS90YWJsZXJhbmdlOmE3NTIwNmM5YTIyNDRlZmVhOGVhZTcyOWM5YmNmZTRlXzMtMS0xLTEtMA_8dcfcc70-c408-4384-bc48-398b9af946f6"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne
      contextRef="i79ec1427e45649d2851751c0d45cf674_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ5NTc_ddf7d63d-a276-49d4-a007-c3f57a7c1aac"
      unitRef="usd">150000000.0</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne
      contextRef="i79ec1427e45649d2851751c0d45cf674_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzUxNDY_b162e53a-0ac0-4226-a234-1b6fddfbaf14"
      unitRef="usd">150000000.0</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
    <biib:SalesTriggerGrossSalesThreshold
      contextRef="i79ec1427e45649d2851751c0d45cf674_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzUzMDg_847ac47b-4d6e-415f-ac51-e7ec2f1213b5"
      unitRef="usd">500000000.0</biib:SalesTriggerGrossSalesThreshold>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODc2Mjg_d6c9aaa5-d1af-40ae-a082-219330cd0974"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:Futurepercentageofcopromotionoperatingprofits
      contextRef="i7585b972767d4bd6bbbd279b2e88eee9_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODc1ODc_37580f78-937e-4050-bc64-98e343be26f5"
      unitRef="number">0.375</biib:Futurepercentageofcopromotionoperatingprofits>
    <biib:Futurepercentageofcopromotionoperatingprofits
      contextRef="i8e00ac4fc24f4e0bb5ded9386aef6231_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODc1ODc_caa37035-f1fc-463b-82d5-7ed85f14bd87"
      unitRef="number">0.375</biib:Futurepercentageofcopromotionoperatingprofits>
    <biib:Futurepercentageofcopromotionoperatingprofits
      contextRef="ib74714c45267446986d21e121eec440b_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODc1ODc_edf8b72d-9a18-4a2b-9332-fcd2a860cd4f"
      unitRef="number">0.375</biib:Futurepercentageofcopromotionoperatingprofits>
    <biib:Futurepercentageofcopromotionoperatingprofits
      contextRef="i59c2a5bc4c964df2a0221f7f66aec154_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzU4NTc_45fd4880-2950-4af0-b8d9-48f22cc5f951"
      unitRef="number">0.300</biib:Futurepercentageofcopromotionoperatingprofits>
    <biib:Futurepercentageofcopromotionoperatingprofits
      contextRef="i97799a59fdcc43b1bfbf8aa1dcd16b3a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzU4NjQ_9772353d-1645-42dd-be24-5d02c5c131a0"
      unitRef="number">0.375</biib:Futurepercentageofcopromotionoperatingprofits>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzU5ODA_5c93600a-816d-486f-8b47-d6ce3e923e77"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYwMDI_16c4b3b7-1bb5-4780-ad5b-84b3996044d1"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PretaxProfitSharingFormulaTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDU4_aa76c2f6-54c9-4f6b-a5ad-fc71e78276bb">Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.891%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Until First GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second GAZYVA Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYwOTQ_16c4b3b7-1bb5-4780-ad5b-84b3996044d1"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpjNmFhOGM4YTViYTY0MGZjOWY1MzdmY2I4ZDZiOGExMS90YWJsZXJhbmdlOmM2YWE4YzhhNWJhNjQwZmM5ZjUzN2ZjYjhkNmI4YTExXzAtMS0xLTEtMA_d89542a8-52aa-4b44-abcb-733b444a6d99"
      unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpjNmFhOGM4YTViYTY0MGZjOWY1MzdmY2I4ZDZiOGExMS90YWJsZXJhbmdlOmM2YWE4YzhhNWJhNjQwZmM5ZjUzN2ZjYjhkNmI4YTExXzEtMS0xLTEtMA_9c8914a9-8952-4dfa-b8dd-03f7a86c5f78"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpjNmFhOGM4YTViYTY0MGZjOWY1MzdmY2I4ZDZiOGExMS90YWJsZXJhbmdlOmM2YWE4YzhhNWJhNjQwZmM5ZjUzN2ZjYjhkNmI4YTExXzItMS0xLTEtMA_c4fafca9-b18f-40b4-8d71-8638087820ef"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTcxMjY_d6c9aaa5-d1af-40ae-a082-219330cd0974"
      unitRef="usd">50000000.0</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="i4fce10d195874216b12663411fa5c489_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYyMjc_26046e1f-570f-48a1-bd8d-4dcf47addc5a"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="i771406e8a3b34c93b5f87c9b46df7655_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYyMjc_8cfba6f4-dc29-4bc8-99c3-b7f2de282680"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="i1662495653e1435689b93551c68ae54e_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzYyMjc_9a266c46-f1bc-4146-b07a-9af9d5b7484b"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:ShareOfCoPromotionProfits
      contextRef="i9559172621a745278ce2779747432dec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzItMS0xLTEtMA_10ccf37c-5bff-4ae0-b9ad-acbfa08b48d8"
      unitRef="usd">1080200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i3b6b5a9481f349908c730396c050643d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzItMy0xLTEtMA_245f921d-5531-43ac-8dde-756c0c4e9b49"
      unitRef="usd">1542400000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzItNS0xLTEtMA_87aa97c1-ac53-477f-af57-7ba72cc9a7ec"
      unitRef="usd">1431900000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i9559172621a745278ce2779747432dec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzMtMS0xLTEtMA_9d167efb-1f44-4876-908e-64ff2ac38f1f"
      unitRef="usd">897600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i3b6b5a9481f349908c730396c050643d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzMtMy0xLTEtMA_559d2a22-0dfc-4ecc-8ae3-b5831e43d442"
      unitRef="usd">748000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="i2b7ccdf6b3664acea438022f838b868a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzMtNS0xLTEtMA_4ba8e667-766e-4c40-85ef-fe66087cd189"
      unitRef="usd">548300000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzQtMS0xLTEtMA_4765fed5-a2d4-4c2d-b129-51609f8cfa02"
      unitRef="usd">1977800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzQtMy0xLTEtMA_66e3a679-5f8a-41a2-9d85-7ad2b4120fce"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee2514a987784410a8165984f87269d3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTplMTVjMzY2Nzk5ODA0ODMyODNjMzU0NjFkNDc0NWI0Yi90YWJsZXJhbmdlOmUxNWMzNjY3OTk4MDQ4MzI4M2MzNTQ2MWQ0NzQ1YjRiXzQtNS0xLTEtMA_e29e3db0-2702-4582-9e42-99833c771f99"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="iffff7fb793694c20a0248c1ea9b22dfe_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc2Mzk_40feffb2-3620-493e-acf5-89ddcfe6dfcc"
      unitRef="number">0.110</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="i3dfe4622e95f4be3b13eb7b4eb5d7421_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc2NDY_92165359-6573-4a7b-9fda-71c5553e74ad"
      unitRef="number">0.150</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id28d5f3f841240659df55d6cebaa2341_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc4Mjg_134e39c2-92fa-40c8-817c-0d69df77434a"
      unitRef="usd">286600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib1a76b88c18540f5b28ba2e5fbc3f6f0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc4MzI_b12d4185-36f5-4151-99cd-ce73e816015a"
      unitRef="usd">293000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5bdb2b3168704d7e945362a0cc289715_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzc4Mzk_3829156e-9c03-4827-a0d2-1409c229a8d4"
      unitRef="usd">238000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <biib:LicenseFee
      contextRef="i747f7303e31143ec8231dc760b0cb79a_D20121201-20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzg1NzI_31d91ab5-7208-48ac-9b71-75d6985f1dac"
      unitRef="usd">70000000.0</biib:LicenseFee>
    <biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments
      contextRef="i71eb4f6064534d02b9b523b950ef4cb5_I20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzg3MDE_2d42367d-f546-49bd-a74a-3ddd4de662a5"
      unitRef="usd">130000000.0</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
    <biib:Upfrontpaymentforcollaborationagreement
      contextRef="i71eb4f6064534d02b9b523b950ef4cb5_I20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzg5NjY_cf435754-65a6-4d90-b4ba-73e8f645dddb"
      unitRef="usd">30000000.0</biib:Upfrontpaymentforcollaborationagreement>
    <biib:AdditionalMilestonePayment
      contextRef="i747f7303e31143ec8231dc760b0cb79a_D20121201-20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzkwNTc_d36967df-fd6e-4852-a0ac-4d7150dc2617"
      unitRef="usd">10000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i45dbe435f7fd469798d0b243da615ec6_D20150101-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzkyMjc_a3a6c3cd-7807-4b39-9e74-e8fd7b23217c"
      unitRef="usd">10000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i105821a34e0b4347b7fd8ae515422218_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzk1ODU_8971fa7d-d32d-484d-bdd6-19fb86383237"
      unitRef="usd">45000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:AdditionalMilestonePayment
      contextRef="i105821a34e0b4347b7fd8ae515422218_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3Xzk3NjI_6709da2c-ddfb-4659-997d-70091f690863"
      unitRef="usd">155000000.0</biib:AdditionalMilestonePayment>
    <biib:Termofcollaborationagreement
      contextRef="i9331add6801a4df791250e423365aaea_D20180601-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDU5_15122d5c-5355-44e1-88d9-6166c8cd8424">P10Y</biib:Termofcollaborationagreement>
    <biib:Totalpaymenttoentercollaborationagreement
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMTQ4_7a94b565-d1c5-4d1c-8ece-9b9a7461eab0"
      unitRef="usd">1000000000.0</biib:Totalpaymenttoentercollaborationagreement>
    <biib:Upfrontpaymentforcollaborationagreement
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMTg4_856159c7-606c-4cb9-b41a-3d434f78e5ac"
      unitRef="usd">375000000.0</biib:Upfrontpaymentforcollaborationagreement>
    <biib:InvestmentInCommonStockSharesPurchased
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMjI1_270ad68f-6234-4578-905f-f9820028f2eb"
      unitRef="shares">11500000</biib:InvestmentInCommonStockSharesPurchased>
    <biib:Purchaseofcommonstock
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMjcw_21fae514-9e0d-4062-bb78-4019589e015f"
      unitRef="usd">625000000.0</biib:Purchaseofcommonstock>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMzAw_58367cc1-e21c-4dd5-82b5-05019999036f"
      unitRef="usd">50900000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:Upfrontpaymentforcollaborationagreement
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwMzEw_856159c7-606c-4cb9-b41a-3d434f78e5ac"
      unitRef="usd">375000000.0</biib:Upfrontpaymentforcollaborationagreement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9331add6801a4df791250e423365aaea_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwNDEz_5126ab12-3ef3-4365-9d39-1b9f08e660af"
      unitRef="usd">324100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:InvestmentInCommonStockSharesPurchased
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwNjkw_270ad68f-6234-4578-905f-f9820028f2eb"
      unitRef="shares">11500000</biib:InvestmentInCommonStockSharesPurchased>
    <biib:Investmentincommonstockvalue
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzExMDgw_8862d66b-b817-45f3-8cfc-95c90d2d402b"
      unitRef="usd">462900000</biib:Investmentincommonstockvalue>
    <biib:Premiumonpurchaseofcommonstock
      contextRef="i1d15cdc79395436f8ea70d371389138c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzExMjM2_961cd8e5-e52e-4bba-ac75-c98f338e212f"
      unitRef="usd">162100000</biib:Premiumonpurchaseofcommonstock>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="ia2c9ea4c44b047fab182bf1e93960612_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyMDY0_348d1175-eded-4ef3-a2fb-43dacd60ffbc"
      unitRef="usd">125000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="iff10bbc1b7204f9a899f2b15e8f5bb57_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyMDcw_66262bb0-0c65-4209-a0e7-8f5a4d00b308"
      unitRef="usd">270000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i8b01dc3119ea40eaaabda1c48b7c9107_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODQyMDQ_8dae4b77-ad4c-4cb0-afdd-4839b093ce62"
      unitRef="usd">11300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i465d3d459afa478c9e3119d88d5627e7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyMjU1_aa532543-9ad4-40b5-81c5-c5329d49fe68"
      unitRef="usd">30000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="if47126e2c5154b45ab4cbefbf186b118_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyNzQ1_8cb3ece3-33cf-4ed7-bd9f-3bdb1dd740c5"
      unitRef="usd">25000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="if47126e2c5154b45ab4cbefbf186b118_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyODAw_cff9c08d-7285-4672-80db-937e33daa8e1"
      unitRef="usd">260000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold
      contextRef="i1e5d541771094deaba1fa696b580448f_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEyOTY5_963b475e-c8d6-41a1-971d-3bbf0d9b46ac"
      unitRef="usd">800000000.0</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
    <biib:Termofcollaborationagreement
      contextRef="if223f76ca1884559bc1cd766f260b0eb_D20130901-20130930"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0MTM_19b9ee4f-cf70-440a-a151-abd1aad6ed8f">P6Y</biib:Termofcollaborationagreement>
    <biib:LicenseFee
      contextRef="if223f76ca1884559bc1cd766f260b0eb_D20130901-20130930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE0MzA1_207d9a92-4a48-49d0-b262-8397910c7ed0"
      unitRef="usd">70000000.0</biib:LicenseFee>
    <biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments
      contextRef="i95a0cc3cf2744b12b943e07433857c3a_I20130930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE0NTE1_426b0c7d-f3d2-4f44-b75f-820883af586b"
      unitRef="usd">130000000.0</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ic9dc60a6f69e48f5a2a97af95fa37fb4_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1MDM1_4d281cae-668c-4bde-817b-999f606ab6be"
      unitRef="usd">35000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="ic9dc60a6f69e48f5a2a97af95fa37fb4_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1MjE4_004c3b67-5b11-4e28-bf3a-cb09ea318210"
      unitRef="usd">55000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5554faf4f05643a08aa9972d0ca3320a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1NTM3_ab758885-1b5d-44d6-8f63-dd653cb21f48"
      unitRef="usd">28000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i66010d191b2a4b168f86fe9538abfa3b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1NTQx_eb5d6db6-4463-483f-8457-bff329c17ab4"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia0993650b5ce4b56ba73d7e6d491c39c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE1NTQ4_7be06651-c5e2-4161-a0f0-0b9fa60b5516"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:NumberOfProductCandidates
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0MTk_269f0318-ba5f-4925-938f-e5f6c2a9f5a8"
      unitRef="product">2</biib:NumberOfProductCandidates>
    <biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDI4_206eb8cb-3ce0-4534-9b9e-6c3410a0cb56">&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expenses related to the BAN2401 Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzItMS0xLTEtMA_8e8405d7-47f3-4459-8128-808bef4fa2ab"
      unitRef="usd">219300000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzItMy0xLTEtMA_2dd2e0c4-1d9a-42e2-aa0b-09403bdfb7b4"
      unitRef="usd">348700000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzItNS0xLTEtMA_00890c12-2119-467e-b97c-19c9ac326b2b"
      unitRef="usd">232000000.0</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzMtMS0xLTEtMA_07bd447e-a709-4b46-9c31-6c88ce65915a"
      unitRef="usd">109600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzMtMy0xLTEtMA_e338a6d8-e821-4533-bf8b-8c93e6133e18"
      unitRef="usd">174300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzMtNS0xLTEtMA_fc69d1aa-db1b-4b8f-8511-557c07c25fbd"
      unitRef="usd">116000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i8cbeeb58208f422997188aaf6d96b19c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzUtMS0xLTEtMA_c91d3147-f0e9-4ad4-b464-c023cbb13345"
      unitRef="usd">9800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i912e90e415414b2eb40263d0228aebbd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzUtMy0xLTEtMA_8cb3b2bc-7b9f-4934-b245-12a3a21c8b16"
      unitRef="usd">32400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i46b16525b4ff43abb6399861bedb691a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzUtNS0xLTEtMA_392133c4-5028-4d5d-a763-048135b65b31"
      unitRef="usd">10700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i8cbeeb58208f422997188aaf6d96b19c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzYtMS0xLTEtMA_516f7151-ef36-4819-95cc-e985ad104cd2"
      unitRef="usd">4900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i912e90e415414b2eb40263d0228aebbd_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzYtMy0xLTEtMA_5f1eddbc-1dfe-4ae0-a771-922280c74acb"
      unitRef="usd">16200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i46b16525b4ff43abb6399861bedb691a_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiY2M1N2E1ZDY2ZGM0YjE2OWM2OGVmNDRlMTVhM2YwMy90YWJsZXJhbmdlOmJjYzU3YTVkNjZkYzRiMTY5YzY4ZWY0NGUxNWEzZjAzXzYtNS0xLTEtMA_62fe7c4c-7097-4eb6-80a8-52feac4f337c"
      unitRef="usd">5400000</biib:Expensereflectedwithinstatementsofincome>
    <us-gaap:LossOnContractTermination
      contextRef="i3be23a7aefd749b688f0ea9bc6153af4_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODQ4NjA_39325114-56a2-4ce0-85c3-1af5d6cef4f6"
      unitRef="usd">45000000.0</us-gaap:LossOnContractTermination>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="ib08f91138dfb4499a6873f325caac5c6_D20190101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODQ5Nzc_2e526ad1-57d1-48d8-b972-4528f6c7a7f2"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PercentageOfDevelopmentCostsIncurred
      contextRef="i12a519048d3946d6b1cae8db3bf6ea2b_D20180101-20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODAxNzg_d414d757-ec4f-46a8-9f9d-ac021869fbcb"
      unitRef="number">1.000</biib:PercentageOfDevelopmentCostsIncurred>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i04d3846e76534a968aa79c696280f29f_D20180401-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5MDM1_b798471a-3b3e-44dd-aca4-ca643be20e14"
      unitRef="number">0.150</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="ib08f91138dfb4499a6873f325caac5c6_D20190101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5MTM0_2e526ad1-57d1-48d8-b972-4528f6c7a7f2"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzQ1NTc_dab8a7a4-5de1-4a49-9779-49a52ce20f97"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="ib08f91138dfb4499a6873f325caac5c6_D20190101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzQ1OTA_2e526ad1-57d1-48d8-b972-4528f6c7a7f2"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzQ1NzI_6632ab0a-8912-445d-9d01-541f58959466"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="i3f4b4db6bca74ad38b22a985c9cf4c8c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5NzA1_d44c64b3-0077-4211-a730-6592dee8289a"
      unitRef="number">0.550</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="i7cf41e8e7ce64d6b9af4dccfbd954c2a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5NzYz_25ac23c8-44f8-4f97-9000-526bd2109ddb"
      unitRef="number">0.685</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:Biogenshareofcopromotionprofitsorlosses
      contextRef="i685eb05651d54eb487dd05db4f014285_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzE5ODI0_6dd5b7a1-39fb-4624-bce5-20c72ed1f513"
      unitRef="number">0.200</biib:Biogenshareofcopromotionprofitsorlosses>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5NDM0_095c05f5-8847-4510-837c-26e6d644f18a">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total aducanumab collaboration third party milestone expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i523d958a043b46abb2bf95ddabf9e48d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzItMS0xLTEtMA_fd4fb3ae-ebdb-4292-8a6a-93a4028158d8"
      unitRef="usd">152000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6770bed0636946adb09e5741c30e183e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzItMy0xLTEtMA_16fd3ebd-890a-4f27-8439-1b67042a5da0"
      unitRef="usd">179400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i07e06dea69a4477c83eaaab76c26a1c0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzItNS0xLTEtMA_02828500-2072-44f4-83db-52c473c22658"
      unitRef="usd">264800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i523d958a043b46abb2bf95ddabf9e48d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzMtMS0xLTEtMA_df7f2676-51bb-4751-9cc6-ff97a792200e"
      unitRef="usd">83600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6770bed0636946adb09e5741c30e183e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzMtMy0xLTEtMA_80b77197-32b8-4dae-8311-913800fc8056"
      unitRef="usd">98700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i07e06dea69a4477c83eaaab76c26a1c0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzMtNS0xLTEtMA_cd13ee18-02ec-42ac-afff-51cfd82040f9"
      unitRef="usd">234600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6011115c7277467e81a492d53cc5c2de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzUtMS0xLTEtMA_47170db8-251b-42aa-93d3-a552fd6b4fbb"
      unitRef="usd">353000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i204866d0c938473fb367812907152221_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzUtMy0xLTEtMA_56f66db2-abff-4b0d-b28b-df5d5321fd56"
      unitRef="usd">27400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i8095992b920b4752bea7ed0e25a7dec6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzUtNS0xLTEtMA_a0b9e56a-700c-4d1e-8bd7-d0f41b74a99b"
      unitRef="usd">50600000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6011115c7277467e81a492d53cc5c2de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtMS0xLTEtMA_9b9cc419-a8b1-4a51-8d54-fb0ebaebcad4"
      unitRef="usd">193700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i204866d0c938473fb367812907152221_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtMy0xLTEtMA_b77fde18-a31f-4c76-9a08-bd876d5c2b74"
      unitRef="usd">15100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i8095992b920b4752bea7ed0e25a7dec6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtNS0xLTEtMA_0a65e195-44b0-43b8-a0b4-bf27a5fcd947"
      unitRef="usd">27300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtMi0xLTEtNTUzMQ_a3f63e1f-aea4-4a75-86ca-6b6fab2fcfcf"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtNC0xLTEtNTUzMQ_a7a4ccc3-f5b8-4fa7-b80d-1b3d0659c6c4"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzYtNi0xLTEtNTUzMQ_b9a9d93a-1a10-4e0c-bd93-fe957f09910d"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzctMi0xLTEtNTUzMQ_c1527754-73ce-4021-8053-726f05069c69"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i78bb225e6f554390b433e4ed84fca505_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzctNC0xLTEtNTUzMQ_9c8cd6f7-36b5-4434-b11f-8b3cd903518e"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i37c3b3faf445456090ef81552a332f5f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTo1M2JlNDBhOTVkYzM0NDBjOWEwNDc3Mjk5NmEyMmNiMy90YWJsZXJhbmdlOjUzYmU0MGE5NWRjMzQ0MGM5YTA0NzcyOTk2YTIyY2IzXzctNi0xLTEtNTUzMQ_03173601-ab19-42cb-a036-35eeb0418f84"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQ5NDc4MDIzNzc0MTI_09ade21f-fd1b-4912-9eab-ecc3046916af">A summary of development expense related to the UCB collaboration agreement is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i307bd3b52c544217a250d6bec5afed5a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzItMi0xLTEtMTE3ODk_8cd79765-e8c8-4d3d-ac70-19738b6887e4"
      unitRef="usd">58300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="id0259bfa32ec47deb51fdd95ffd65e06_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzItNC0xLTEtMTE3OTE_05eaec45-3fa4-42b8-9729-8be986bfa58e"
      unitRef="usd">31900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i5afe9f2f08fd4c56a2b406c9f04b9941_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzItNi0xLTEtMTE3OTM_b4cdb2be-f7a6-4540-a5cf-9860d44b7bbf"
      unitRef="usd">29700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i307bd3b52c544217a250d6bec5afed5a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzMtMi0xLTEtMTE3ODk_86512dce-6bc8-4823-9b25-3e3ef9512e0f"
      unitRef="usd">29200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id0259bfa32ec47deb51fdd95ffd65e06_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzMtNC0xLTEtMTE3OTE_8d63dae0-26e3-438d-a0eb-513a4650f37a"
      unitRef="usd">16000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i5afe9f2f08fd4c56a2b406c9f04b9941_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90YWJsZTpiZjdmNjdkMDdlYzk0ODFiYWZkZjU1ZjdiM2ExN2I0Mi90YWJsZXJhbmdlOmJmN2Y2N2QwN2VjOTQ4MWJhZmRmNTVmN2IzYTE3YjQyXzMtNi0xLTEtMTE3OTM_7580b524-995a-436a-9bef-0b8a265d0886"
      unitRef="usd">14900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="i8aed9a151f27413aad9ecb189295574d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIxMjg2_fa5c945c-8f57-4236-bb10-19a01aa6201d"
      unitRef="number">0.150</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:RoyaltiesPayablePeriodPostFDAApproval
      contextRef="i8aed9a151f27413aad9ecb189295574d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0ODU_0d7e4aca-1085-4a71-96aa-900bdcb8cde4">P5Y</biib:RoyaltiesPayablePeriodPostFDAApproval>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ib4c7eb5801004aad9c424b58efad93ad_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIyNDg1_b56775d5-7684-4c44-a91f-6556a6f4ac5c"
      unitRef="usd">155000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i062dfb826bb543c0ab344580c2bc9f39_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIyNjkz_15824e69-db6d-489a-90f7-565803483cc4"
      unitRef="usd">32400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i329e830c9d924ad1abde877010ab5c13_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIyNjk3_ae5ffee2-2357-4807-91fb-f8fcaff60c88"
      unitRef="usd">53500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie615c033847a4fdc95860b4e0bfd4d64_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzIyNzA0_9406c5d0-242e-4e1f-9d62-edfd1a4dede0"
      unitRef="usd">68700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i18853d4d37eb4076a332a07be0132022_D20170601-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTU3NDQ_fa58931d-cb3c-4fb3-927c-d902a466f084"
      unitRef="usd">300000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:AdditionalMilestonePayment
      contextRef="id74db4b324cc4118b5cddd07bff2bc26_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI0ODg1_52a6c494-84b9-4d97-a93f-8da0d70d45dc"
      unitRef="usd">360000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="iecc638e4ad114ce2ad08351d98ed22df_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI1MDA0_867ac744-6385-47b4-8c17-f466732ed1e8"
      unitRef="usd">370000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id74db4b324cc4118b5cddd07bff2bc26_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI1MTM4_3c2f9613-e0cf-4c0e-acdd-38c6788dcdf2"
      unitRef="usd">62400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic7e2e7e20d974dde8d37743caeeb08eb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI1MTQ1_d565ccdb-b9de-4a4c-a8d9-4f98f4a6440f"
      unitRef="usd">144000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i68ee0bf055a24fd6888b5ed314a45afe_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODUxMzE_e429d05b-7394-49e8-8f3c-4871a2998cc6"
      unitRef="usd">97000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold
      contextRef="ie154ef82e19b42d287f8709039383fa3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2MDI0_670250c3-4479-49e4-a41b-8788b08fdee6"
      unitRef="usd">15000000.0</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
    <biib:ForeignSalesRequiredToTriggerMilestone
      contextRef="ice90a1eb84854ab6838871533abeea35_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2MDU5_72a80487-2c63-44fe-809b-78653d7e4071"
      unitRef="usd">100000000.0</biib:ForeignSalesRequiredToTriggerMilestone>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ice90a1eb84854ab6838871533abeea35_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2NzA0_0fc014db-e6b5-4ada-ba9e-9b06c9dcba82"
      unitRef="usd">44500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i1a57dff6854d41af89281f848dc03341_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2NzA4_59f88629-1063-4b37-979b-5a8f2590e54f"
      unitRef="usd">42000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ib02062df52254e2a96f48ca5db08b037_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzI2NzE1_b6f9a976-6d85-4e89-acb9-46ba26c46fe7"
      unitRef="usd">36500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0OTM_0fd0aadb-d546-4252-b45b-790d9b32918b"
      unitRef="usd">650000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0ODA_fbf7a00b-06fe-4675-870a-c60759490e0c"
      unitRef="shares">6200000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA1MDk_2d4a5125-898e-493d-8dd7-98cdd05a17e5"
      unitRef="usdPerShare">104.14</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0MzQ_b1dd96df-daf6-455f-bd88-c4c6eee043e2"
      unitRef="usd">209000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0NTA_76f19706-7523-44d5-9442-2ed6770dfa2f"
      unitRef="usd">875000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments
      contextRef="i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NzA0NjY_72335eb4-6c4a-42ac-8a87-c828e2675b0a"
      unitRef="usd">1600000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2NjkwMTE_a5b51fc6-8f44-4caf-b3fd-c465fbf6eb97"
      unitRef="usd">465000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5OTk_72c2412d-7e12-4406-a7dc-f47b6985dc44"
      unitRef="shares">13000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5OTE_2d2ae93a-fd5f-42ad-baef-1c2a810975fc"
      unitRef="usdPerShare">34.94</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5NzY_b8776bc2-975f-43a5-a7a2-f32d76d469e8"
      unitRef="usd">41300000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5NjA_e4e1c05e-c579-4286-a1a7-915d08c17776"
      unitRef="usd">560000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments
      contextRef="i226946d21ec54ffe8a7889f0f6a8994a_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Njg5NDY_3e6d07c9-3889-4565-96fe-437d5c77e7db"
      unitRef="usd">1100000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i238f01dc6276416eac270e2a8e9978df_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODUxNzE_9a3f3425-0354-41ee-8a21-7377e8324d5a"
      unitRef="usd">8800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:Termofcollaborationagreement
      contextRef="i4675956b4c7541689880490a770cb247_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ4Njc_e146dbc8-596a-4222-a3ef-dd7d3450c644">P5Y</biib:Termofcollaborationagreement>
    <biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc4ODg_7404330e-454f-4cc8-b095-0bc21aaba5f3"
      unitRef="usd">225000000.0</biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementSharesPurchased
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc4NzY_d602a7b1-9ffa-4749-a4ba-acea14a8bad6"
      unitRef="shares">24000000</biib:GlobalLicensingCollaborationAgreementSharesPurchased>
    <biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5MDQ_6fa915b5-f93f-46e0-95c8-7bcbba833805"
      unitRef="usdPerShare">9.21</biib:GlobalLicensingCollaborationAgreementPurchasePricePerShare>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5MTE_d9eb94f3-a29c-48d8-91c7-65554e2ade40"
      unitRef="usd">83000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5MjY_5a3beab3-0b80-416e-853e-1f3de7c41655"
      unitRef="usd">125000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5NDI_ebfa9e7c-b532-456d-9443-af9fc5d5825d"
      unitRef="usd">2400000000</biib:GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments>
    <biib:GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5NTY_5647a580-c9c6-483b-9c40-c40a3ca29053"
      unitRef="usd">80000000.0</biib:GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5NzE_e85e6192-3d45-46ff-a68b-b903e0909d6c"
      unitRef="usd">1900000000</biib:GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones>
    <biib:GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones
      contextRef="i75cbc47327b1472abe5e7863eec32595_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2Nzc5ODU_6c7a67ba-f625-4f1a-882b-2a74597f62c4"
      unitRef="usd">380000000.0</biib:GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4675956b4c7541689880490a770cb247_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODUyMDE_b88da1cf-3e33-42b2-ab93-59564849e473"
      unitRef="usd">6400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i64566178ee6240c4bca091bed9507fe4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwMjAx_4daf2c37-9750-45c2-ae9c-804861320be5"
      unitRef="usd">92100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i32a2842d092548499069b826f6c1c638_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwMjA1_f25d5cfb-e61f-4d1b-9b45-783c2b959ef2"
      unitRef="usd">77000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie6856a51b4454c25b01425f5b605c021_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwMjEy_42eed90c-a657-4599-a61e-7f460c9fb4a8"
      unitRef="usd">48600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement
      contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNTc4_a2b4b062-c53a-4395-a0d1-d17ac91e5b50"
      unitRef="krw">280500000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
    <biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement
      contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNjEz_65759413-b0ab-46ac-a13a-faf969cd809e"
      unitRef="usd">250000000.0</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
    <biib:JointVentureOwnerShipPercentageByThirdParty
      contextRef="i3ef12f56eff74ffba6abbdbbf71ce00c_D20120201-20120229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNjI0_24606996-6a60-491a-bfc0-c266afd49523"
      unitRef="number">0.850</biib:JointVentureOwnerShipPercentageByThirdParty>
    <us-gaap:EquityMethodInvestments
      contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNjcx_5de001cc-74cc-494a-8572-0dc12533fa93"
      unitRef="krw">49500000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNzA2_857ebb98-4fbd-4c7d-8db3-8ba840deaf76"
      unitRef="usd">45000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia6ee863c764240e8b24a01061fc43c1e_I20120229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwNzI4_0dbcf831-05e9-4043-b75c-dd66d87f05ab"
      unitRef="number">0.150</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="i7391238241af432e81e836c4866c9d90_I20180630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMwODk3_758b1eb1-33a4-42cb-adb5-2863cfeb4110"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMxMDA4_f8f3f1b7-eea6-4a9c-9328-961f4718561c"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMxMTAx_4c88c01a-ed83-4c5d-9abb-d950650aea32"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i1f4ad926fe7c4cfbbdee89ac2e1ec180_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMxMTIy_3e883ba5-3f22-40bd-8003-27ba98c7c4f4"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMxMjA5_f8f3f1b7-eea6-4a9c-9328-961f4718561c"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i64dc4d43b5394b6b882e494448859c7b_I20181130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyMjEz_4543adb0-9141-469f-b6dc-bf7657d00ae7"
      unitRef="usd">675000000.0</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="ib4a6f7ae45f34f16a1e64ef99614a3f6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyNTk3_ed765be2-9e0c-43f7-bcfd-8964c771da0d">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i6d919fabed9048039865137149827503_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMyNjEw_02dd501f-091e-47e9-bc54-a58687d06b49">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i295fd62c9b9a44a19b8f2c9cf5993d16_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMTA4_8098ee5b-badd-49c0-ae2b-bcdb533148cc"
      unitRef="usd">5300000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i295fd62c9b9a44a19b8f2c9cf5993d16_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTE4MTI_d9aa4793-e4cb-45a1-8cd3-041e769cf367"
      unitRef="usd">45300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="i295fd62c9b9a44a19b8f2c9cf5993d16_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTE4MTc_25ea6838-05de-477f-bd3f-2342edda8e7f"
      unitRef="usd">-40000000.0</us-gaap:AdjustmentForAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i3f272ab6a3b3497a8d35a3bdbf2a7afa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTIzNDA_d64bab69-4f07-4b16-a621-db3623b0eb2a"
      unitRef="usd">79400000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3f272ab6a3b3497a8d35a3bdbf2a7afa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTIzOTQ_d61b332a-06d8-4214-8992-8015a337fbb6"
      unitRef="usd">1200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="i3f272ab6a3b3497a8d35a3bdbf2a7afa_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2OTI0NDY_f02d17fa-41ca-4d4c-93f5-2a5a08819b19"
      unitRef="usd">-78200000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EquityMethodInvestments
      contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMjk3_d492f79b-9e7c-49d4-be30-f1e3eeb713af"
      unitRef="krw">673800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1533362d92634f39ba4a401c3f7026f6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMzE4_3b4657d4-f201-42f2-8f06-8cbc5485339f"
      unitRef="usd">620200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8686b81ecb37418dbc5bcc179b1e109c_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMzI2_7ff763be-99ac-491f-b185-7f1cde51bf5a"
      unitRef="krw">670800000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8686b81ecb37418dbc5bcc179b1e109c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzMzQ3_e41505a1-9d47-4e47-98da-bf916f11ea5b"
      unitRef="usd">580200000</us-gaap:EquityMethodInvestments>
    <biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjY5MDQ_ac8b1eeb-f90f-46db-8390-29c9ff08f61d"
      unitRef="product">2</biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i897172e0b7bd4edda63f02e0d50f23aa_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzOTQ5_9e8323fb-9e6c-4c3b-9669-f40af5733d03"
      unitRef="usd">100000000.0</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i897172e0b7bd4edda63f02e0d50f23aa_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzMzOTk3_45b94ea1-06f7-473d-9391-495bccd3fa48"
      unitRef="usd">63000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="id583b49771574491a9a38091b81e5d33_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0MDk0_51b48939-7503-4545-8b42-06b9f6e32aad"
      unitRef="usd">37000000.0</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:AdditionalMilestonePayment
      contextRef="i40f71161d18144578dd8f72012056ddf_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0Mjk3_512054c7-aae0-4ac6-839f-480b241039d3"
      unitRef="usd">15000000.0</biib:AdditionalMilestonePayment>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0MjQ_2a4fe2dc-ed2d-4282-9dbb-ee54a7672018"
      unitRef="usd">195000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:Termofcollaborationagreement
      contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0NDc_b8140c70-e96b-452e-ba75-8d44fe57407d">P5Y</biib:Termofcollaborationagreement>
    <biib:ContractOptionExerciseFee
      contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM0NTUw_1de3efd1-8862-4799-88b5-c705ec1b1e21"
      unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <biib:Termofcollaborationagreement
      contextRef="icfa950bc28fd44ad8df6891d4c6166ca_D20131201-20131231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjUxNDY_f5d577f7-fc22-40d0-9d58-1833a2fd801f">P10Y</biib:Termofcollaborationagreement>
    <biib:Termofcollaborationagreement
      contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzQzOTgwNDY1NjQ0NjY_72f1aee6-923c-4297-93c9-2b6aef4b17f1">P5Y</biib:Termofcollaborationagreement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icfa950bc28fd44ad8df6891d4c6166ca_D20131201-20131231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM1MTM5_cee5674d-c968-4fd1-b68c-fe3a5bdbe352"
      unitRef="usd">46000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:AdditionalMilestonePayment
      contextRef="if35d8e291e634b4fb356e7dd2eb4e57e_D20131201-20131231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM1MzY1_edc0b1c3-d00c-4f32-a40b-ec6df05d82dc"
      unitRef="usd">25000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="if35d8e291e634b4fb356e7dd2eb4e57e_D20131201-20131231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM1Nzkz_4654bfae-0663-4bd6-87f3-af1481948c88"
      unitRef="usd">75000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM2Nzcx_ced8e982-5425-4d28-a3cd-14bde7734e20"
      unitRef="number">0.50</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:CollaborationProfitSharing
      contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM3MDM2_2cdfccac-d3c5-479f-8084-ca7ff4cfdbae"
      unitRef="usd">266500000</biib:CollaborationProfitSharing>
    <biib:CollaborationProfitSharing
      contextRef="i55970ae847c94b61adb418c71761c6c4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM3MDQw_513d1368-60bf-49bb-937c-7007bb618375"
      unitRef="usd">241600000</biib:CollaborationProfitSharing>
    <biib:CollaborationProfitSharing
      contextRef="idced215bef924766890054dea8e163a5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM3MDQ3_6811010b-fb19-4a38-b5ef-e55fdbb3f001"
      unitRef="usd">187400000</biib:CollaborationProfitSharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM3MDkz_ced8e982-5425-4d28-a3cd-14bde7734e20"
      unitRef="number">0.50</biib:EquityMethodInvestmentsExpectedProfitShare>
    <us-gaap:Revenues
      contextRef="i17b3475d15da4c8e8da864d4d4acb66e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM4ODA1_448408e1-dce9-4ff3-a7d3-55156f8ac0a8"
      unitRef="usd">20900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55970ae847c94b61adb418c71761c6c4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM4ODA5_7b858023-fd0a-470a-aa89-03b393f6cde1"
      unitRef="usd">106200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idced215bef924766890054dea8e163a5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM4ODE2_9c01f35d-8f08-49c7-b294-35dc449fcc7e"
      unitRef="usd">96400000</us-gaap:Revenues>
    <us-gaap:DueFromRelatedParties
      contextRef="i2d07f2e384e64708858924ad5f63049d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5MTY0_4bdd9ed7-337a-49e7-b8fd-01bd3f66ebd6"
      unitRef="usd">5100000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i14fe65b9d9ce412f9b5cb080d3a88a3d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5MTcy_c3c2393a-01be-4d0e-90b6-0476363da0e5"
      unitRef="usd">85000000.0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i2d07f2e384e64708858924ad5f63049d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzEwOTk1MTE2ODIwMDE_569e75de-cc16-425f-916d-2966cdea5db9"
      unitRef="usd">99000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i14fe65b9d9ce412f9b5cb080d3a88a3d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMDQvZnJhZzpiODlhZjczYjM5NmY0OThkOWVmNjJhYzg5NjNhMGJhNy90ZXh0cmVnaW9uOmI4OWFmNzNiMzk2ZjQ5OGQ5ZWY2MmFjODk2M2EwYmE3XzM5MjY4_138fd414-6a6d-474e-a268-92ec5a29ee99"
      unitRef="usd">100000000.0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzQ3NTI_02d5dd16-f18a-4740-bd9e-2e0351c835b5">Investments in Variable Interest Entities&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15.0% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;royalties payable on potential commercial sales of aducanumab, by an additional 5.0%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $75.0&#160;million upon the regulatory filing with the FDA for the approval of aducanumab. During the second quarter of 2020, we paid Neurimmune $75.0&#160;million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests for the year ended December&#160;31, 2020. In addition, for the year ended December&#160;31, 2020, we recognized net profit-sharing income of $33.8&#160;million to reflect Eisai's 45.0% share of the $75.0&#160;million milestone expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to approximately $200.0 million in milestones to Neurimmune in 2021, which includes $100.0&#160;million if launched in the U.S., $50.0&#160;million if launched in three or more countries within the E.U. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending December&#160;31, 2020, 2019 and 2018, amounts reimbursed were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $12.8 million and $22.7 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:Termofcollaborationagreement
      contextRef="ic52a2fe62f214111bf27f2241c15e13d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzQzOTgwNDY1MTY2NjY_b17abb04-2273-4a84-a082-9fed3cacceeb">P12Y</biib:Termofcollaborationagreement>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="ic52a2fe62f214111bf27f2241c15e13d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzMzMTY_8fab0968-4d7a-43f9-820a-e6a53e579736"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i1b079cbb95c4416897c5c9f868e8ecbe_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEzNjk_b6d585f6-885f-43c5-939e-18b68561a30e"
      unitRef="usd">150000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Reductioninroyaltyratepayableoncommercialsales
      contextRef="i1b079cbb95c4416897c5c9f868e8ecbe_D20171001-20171031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzE0MTI_51627e0e-684d-48b2-9943-079494e37b36"
      unitRef="number">0.150</biib:Reductioninroyaltyratepayableoncommercialsales>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i36b3ae17c9254af097d228dac7821a3c_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzE2Mzc_a9f4f579-8bc4-45f4-b0bb-33f9f3d8f064"
      unitRef="usd">50000000.0</us-gaap:PaymentsToMinorityShareholders>
    <biib:Additionalreductioninroyaltyratepayableoncommercialsales
      contextRef="i36b3ae17c9254af097d228dac7821a3c_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzE4NzI_a466904e-5854-41c3-b972-210b4acc272e"
      unitRef="number">0.050</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
    <biib:AdditionalMilestonePayment
      contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzM0MTE_6632ab0a-8912-445d-9d01-541f58959466"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQ1Njg_6632ab0a-8912-445d-9d01-541f58959466"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQ1ODY_dab8a7a4-5de1-4a49-9779-49a52ce20f97"
      unitRef="usd">33800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i27837e9cd10e410d9324a0de6843615f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQ1OTI_884b702e-be41-41da-ba2b-01da507bd8d5"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQ1OTg_6632ab0a-8912-445d-9d01-541f58959466"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ic47c03e6e7be46888ccb47d76183eca4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzM5Nzc_d00c53eb-d401-4be2-b184-aa9d27294146"
      unitRef="usd">200000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i22a68eca818d4bfd974767e6d650ecec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzM5ODk_69c3cbea-0752-4bbc-b93a-000836476c7a"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i77448f6c2bef4b2ea4eb496e64cae04e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzM5OTU_73dd4e2f-6ccc-4ed3-a28d-8bd7c5b742a3"
      unitRef="usd">50000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i957831cfe2a145bab834e81558efd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzEwOTk1MTE2MzQwMDE_4350c760-9f90-4e02-9f12-d3e8d011924b"
      unitRef="usd">50000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzQxNzg_5ee157fe-6c43-4489-ae4c-f978d12465bd"
      unitRef="usd">12800000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTAvZnJhZzowYjAxYzgzZDYyMGQ0YjM1ODU4MjU0NTliYzY1N2ZjZi90ZXh0cmVnaW9uOjBiMDFjODNkNjIwZDRiMzU4NTgyNTQ1OWJjNjU3ZmNmXzQxODU_e2160faa-fb2a-40ea-a647-c0e944d4a76e"
      unitRef="usd">22700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTMvZnJhZzplOWI4N2M4MjNjYjI0NWU4ODI3YjczYzUzOGZmYTk1Yi90ZXh0cmVnaW9uOmU5Yjg3YzgyM2NiMjQ1ZTg4MjdiNzNjNTM4ZmZhOTViXzQ5NDc4MDIzNTc3NTY_8e889dff-bab9-4c2c-8d44-687f77e43610">Litigation&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Aducanumab Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and an action filed by a shareholder on January 5, 2021, in the U.S. District Court for the District of Massachusetts. Both actions allege violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and are seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction. Fresenius Kabi has appealed that decision and was permitted to add a claim of infringement of the Danish counterpart of the &#x2018;510 patent, and the appeal is pending. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#x2019;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#x2019;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#x2019;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#xfc;sseldorf Regional Court relating to the German counterpart of the &#x2018;510 Patent. A hearing has been set for August 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#x2019; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%"&gt;Dispute with Jacobs Switzerland GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claimed additional payments were due for construction costs. We have reached an agreement in principle to resolve the claim.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Petition for Inter Partes Review&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#x2018;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#x2018;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Patent Office Oppositions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018 the EPO revoked Forward Pharma's European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TYSABRI Patent Revocation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. A hearing was held in January 2021 and a decision is pending. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#x2018;263 Patent. No hearing has been set in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annulment Proceedings in General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) have each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#x2019;s and Mylan Ireland&#x2019;s respective applications to market a generic version of TECFIDERA. The EMA&#x2019;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma. That case was heard in July 2020 and we are awaiting a decision. We intend to seek leave to intervene in support of the EMA in the case brought by Mylan Ireland. No hearing has been set in that matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i933bc3e4859e442d998a3136c487cd85_D20191101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTMvZnJhZzplOWI4N2M4MjNjYjI0NWU4ODI3YjczYzUzOGZmYTk1Yi90ZXh0cmVnaW9uOmU5Yjg3YzgyM2NiMjQ1ZTg4MjdiNzNjNTM4ZmZhOTViXzQ5NDQ_a7a57173-6e53-4cf1-860f-f8dee9ef0693"
      unitRef="usd">200000000.0</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzY2OTg_d1f79889-3deb-4b25-9d00-cb5ba99699e7">Commitments and Contingencies&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TYSABRI&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18.0% on annual worldwide net commercial sales up to $2.0 billion and 25.0% on annual worldwide net commercial sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;SPINRAZA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net commercial sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VUMERITY&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the acquisition of Convergence occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with this transaction at their fair value on the acquisition date and revalue the remaining obligations each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to these acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:13.5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fumapharm AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We were required to make contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached $20.0 billion, at which time no further contingent payments were due. During the first quarter of 2019 we paid the final $300.0&#160;million contingent payment as we achieved the $20.0 billion cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Development, Regulatory and Commercial Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our development plans as of December&#160;31, 2020, we could trigger potential future milestone payments to third parties of up to approximately $10.2 billion, including approximately $1.9 billion in development milestones, approximately $1.3 billion in regulatory milestones and approximately $7.0 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of December&#160;31, 2020, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If certain clinical and commercial milestones are met, we may pay up to $86.2&#160;million in milestones in 2021 under our current agreements. Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $200.0 million in milestones to Neurimmune in 2021, which includes $100.0&#160;million if launched in the U.S., $50.0&#160;million if launched in three or more countries within the E.U. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2020 we paid Neurimmune $75.0&#160;million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Funding Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $21.7 million in our consolidated balance sheet for expenditures incurred by CROs as of December&#160;31, 2020. We have approximately $593.0 million in cancellable future commitments based on existing CRO contracts as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the sale of our Hiller&#xf8;d, Denmark manufacturing operations to FUJIFILM, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Related Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December&#160;31, 2020, we have approximately $79.6 million of liabilities associated with uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, we have accrued income tax liabilities of $697.0 million, respectively, under the Transition Toll Tax. Of the amounts accrued as of December&#160;31, 2020, $62.0 million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue interest. For additional information on the Transition Toll Tax, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16, Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. As of December&#160;31, 2020, we had contractual commitments of approximately $9.3&#160;million related to the construction of this facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion
      contextRef="i5cd0b9db93464b41b789d3e1ca413b78_I20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzI3Mw_53509aad-6e97-40ca-931f-7a724162c540"
      unitRef="number">0.180</biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion>
    <biib:FutureContingentPaymentThreshold
      contextRef="i5cd0b9db93464b41b789d3e1ca413b78_I20131231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzMyMw_9a4d4af0-26f2-4a74-91f5-2373b306745a"
      unitRef="usd">2000000000.0</biib:FutureContingentPaymentThreshold>
    <biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion
      contextRef="i5cd0b9db93464b41b789d3e1ca413b78_I20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzMzMA_ca61d727-6a45-41d0-a182-72649e3ed546"
      unitRef="number">0.250</biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion>
    <biib:FutureContingentPaymentThreshold
      contextRef="i5cd0b9db93464b41b789d3e1ca413b78_I20131231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzM4Ng_e551ef41-2b53-4e35-b822-ec706b24c115"
      unitRef="usd">2000000000.0</biib:FutureContingentPaymentThreshold>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="i16f1d1f107eb4341ad1613ad1b5d5759_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzkyNw_62b16b8a-0766-4205-9cb5-fa86de3c5cf3"
      unitRef="number">0.110</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="i91a1d60eac014ca3be868d71ce1a4a4f_D20160101-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzkzNA_48ad354a-fcdb-4c3b-b0eb-7620ecb19b63"
      unitRef="number">0.150</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:PercentageOfRoyaltiesAsPerCollaboration
      contextRef="i2dd3d46d9dd249b28b950c8de7e4732c_D20191001-20191031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzE0MTI_2190628d-d2c3-4844-a8cb-3caadd9d55f3"
      unitRef="number">0.150</biib:PercentageOfRoyaltiesAsPerCollaboration>
    <biib:RoyaltiesPayablePeriodPostFDAApproval
      contextRef="i8aed9a151f27413aad9ecb189295574d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzQzOTgwNDY1MTgwNzg_0d7e4aca-1085-4a71-96aa-900bdcb8cde4">P5Y</biib:RoyaltiesPayablePeriodPostFDAApproval>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzIzODA_f884f67e-fcd6-40f4-b87d-0aac02b9fad7"
      unitRef="usd">400000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <biib:CumulativeSalesLevel
      contextRef="id7513df5070046c28b340530835d8133_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzI5MjI_3c1f6f48-6786-430c-8e15-6ccd8e9a0d0f"
      unitRef="usd">20000000000.0</biib:CumulativeSalesLevel>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzQ2MTg_ead357e7-99b2-44b0-aede-721223124c7d"
      unitRef="usd">300000000.0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <biib:CumulativeSalesLevel
      contextRef="i65d03ca4620f4c52999c7becc617b0ff_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzMwNzE_f6c438af-90f1-4eb8-9db0-46b027ab0e0b"
      unitRef="usd">20000000000.0</biib:CumulativeSalesLevel>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzU2Njk_4f5236c1-bd05-4404-ac36-6fd6909a3f30"
      unitRef="usd">10200000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ifeaee754376e4c77898d464920110368_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzU2NzU_155bb991-1990-42ef-8537-29f44551cd98"
      unitRef="usd">1900000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i751bdf5f146846a0a2d59925aa237c7e_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzU2ODE_3c5817c9-7bb4-4830-8544-4323eb79ffea"
      unitRef="usd">1300000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i4aa757dc6dcd456f86823b48006f5e50_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzU2ODc_42506cf6-c549-4775-a74e-428d2fc8a479"
      unitRef="usd">7000000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="if55055ac245a4373b369623a07552bcf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgxODQ_deff9409-bc86-4692-8634-2901b10012ff"
      unitRef="usd">86200000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="ic47c03e6e7be46888ccb47d76183eca4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgxOTI_d00c53eb-d401-4be2-b184-aa9d27294146"
      unitRef="usd">200000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i22a68eca818d4bfd974767e6d650ecec_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgyMDQ_69c3cbea-0752-4bbc-b93a-000836476c7a"
      unitRef="usd">100000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i77448f6c2bef4b2ea4eb496e64cae04e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgyMTA_73dd4e2f-6ccc-4ed3-a28d-8bd7c5b742a3"
      unitRef="usd">50000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i957831cfe2a145bab834e81558efd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzgyMTY_4350c760-9f90-4e02-9f12-d3e8d011924b"
      unitRef="usd">50000000.0</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:AdditionalMilestonePayment
      contextRef="i52be1e637a6d4c01a1729d497eb083b6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzYwNTM_6632ab0a-8912-445d-9d01-541f58959466"
      unitRef="usd">75000000.0</biib:AdditionalMilestonePayment>
    <biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzcxNjk_b357a2b9-71a1-409d-8632-1807bf3c0279"
      unitRef="usd">21700000</biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch>
    <us-gaap:OtherCommitment
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2MzcxODE_0e0b1d10-8f74-4409-a421-5fd2003d6023"
      unitRef="usd">593000000.0</us-gaap:OtherCommitment>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2Mzc1MTY_8071a6dc-a612-4bd9-af3a-c4de672e413f"
      unitRef="usd">79600000</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ib21ba4f090344f2f9805e82e16811047_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzU4NDk_29dd9b65-0cfa-45fa-a027-d8a9c9135f5c"
      unitRef="usd">697000000.0</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i8fe3f12d8cdc4e1fb91fee9506338b3f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzU4NDk_f74ad078-794a-4a0b-aa50-3bc757625071"
      unitRef="usd">697000000.0</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:IncomeTaxesPaid
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzEwOTk1MTE2Mzc4Mjk_cabd9074-3cab-4f5c-ba6c-c1819442dcee"
      unitRef="usd">62000000.0</us-gaap:IncomeTaxesPaid>
    <us-gaap:ContractualObligation
      contextRef="i82ea75f6631c448f8f22c298bec0c951_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTYvZnJhZzoyZDIyMGY4M2I4YWY0MWM5OGU5OGRjZWJjYWFlMjQxMi90ZXh0cmVnaW9uOjJkMjIwZjgzYjhhZjQxYzk4ZTk4ZGNlYmNhYWUyNDEyXzQzOTgwNDY1MjE5NDU_c992e45d-2438-4f60-8102-b76a4382ec5e"
      unitRef="usd">9300000</us-gaap:ContractualObligation>
    <us-gaap:GuaranteesTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMTkvZnJhZzo5Yjg0YWExMTEyY2I0N2FjOTc1ZjA1MzE5ZDM5ZGEyZi90ZXh0cmVnaW9uOjliODRhYTExMTJjYjQ3YWM5NzVmMDUzMTlkMzlkYTJmXzk4Ng_902531e6-8b4a-4f7e-94c8-e5b42845f419">Guarantees&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, we did not have significant liabilities recorded for guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:GuaranteesTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM2MDI_106919c7-c840-4e77-9900-e130503d0e23">Employee Benefit Plans&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;401(k) Savings Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of 21. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#x2019;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expense related to our 401(k) Savings Plan totaled $44.3 million, $44.8 million and $42.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Compensation Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of December&#160;31, 2020 and 2019, totaled approximately $120.0 million and $114.6 million, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was 1.00% in 2020, 2019 and 2018. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#x2019;s contribution. Minimum employee contributions are based on the respective employee&#x2019;s age, salary and gender. As of December&#160;31, 2020 and 2019, the Swiss plan had an unfunded net pension obligation of $75.7 million and $42.9 million, respectively, and plan assets that totaled $170.0 million and $127.1 million, respectively. In 2020, 2019 and 2018 we recognized expense totaling $15.5 million, $14.7 million and $14.8 million, respectively, related to our Swiss plan, of which $2.6 million, $1.2 million and $1.3 million, respectively, was included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The obligations under the German plans are unfunded and totaled $75.5 million and $59.6 million as of December&#160;31, 2020 and 2019, respectively. Net periodic pension cost related to the German plans totaled $6.2 million, $5.1 million and $5.3 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, of which $2.0 million, $1.4 million and $1.5 million, respectively, was included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <biib:MinimumQualifyingAgeForEmployeeBenefitPlan
      contextRef="i43fa46a959704893ae8c17cdf1fcca1d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzQyMg_8d243a4c-b3c7-417a-8a8f-edc36ec020bf">P21Y</biib:MinimumQualifyingAgeForEmployeeBenefitPlan>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i43fa46a959704893ae8c17cdf1fcca1d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5Xzk0Mw_455bc355-00a8-4f80-ad47-3359d37b4e9b"
      unitRef="usd">44300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ia620d874c26f4526a51976fe0e5fd937_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5Xzk0Nw_5a0a9104-3e39-4e2e-a930-e7a66518b5aa"
      unitRef="usd">44800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i766a717009a042eab70c1b33dd98c33d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5Xzk1NA_9ef5b34d-327d-4e74-9dd4-3203fd39c307"
      unitRef="usd">42200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="i8eaae0c3c53245ed91bba34207199327_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzE2MzM_2b3fa562-9b4d-4902-917a-72886591b883"
      unitRef="usd">120000000.0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="ifd5e42a67c414bde9ae4844e15f78b39_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzE2NDA_8da99fee-c1d4-49a2-bdae-2efb47c3843a"
      unitRef="usd">114600000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <biib:PercentageOfMinimumInvestmentReturn
      contextRef="ic085e896635e45e896872f4b67d23b0b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzI1Mjc_16b5ab52-81c5-42a4-a39d-53a64c5eda3a"
      unitRef="number">0.0100</biib:PercentageOfMinimumInvestmentReturn>
    <biib:PercentageOfMinimumInvestmentReturn
      contextRef="i9b27f85445594281810d4e11521c4fb0_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzI1Mjc_4264082c-e6cc-4f92-8b10-30584bbef1d2"
      unitRef="number">0.0100</biib:PercentageOfMinimumInvestmentReturn>
    <biib:PercentageOfMinimumInvestmentReturn
      contextRef="i4e1ee455bd644649ba9f949ccefc1a95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzI1Mjc_e20e9ddb-d513-43b3-a7da-8e751aa5c5ed"
      unitRef="number">0.0100</biib:PercentageOfMinimumInvestmentReturn>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ib255acebc8bb4cbf9289671a4d33b082_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMwMjU_f5725191-ab46-4610-bf4c-a9b4ca651b1d"
      unitRef="usd">75700000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="iac6eab3ca24d4a599f6a591c887c3592_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMwMzI_0c3e50af-9e6f-4c5d-bb3b-b8377d0c0ad0"
      unitRef="usd">42900000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ib255acebc8bb4cbf9289671a4d33b082_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMwNzk_1dd5b7c6-8110-4323-ae8e-c2cc48381d16"
      unitRef="usd">170000000.0</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="iac6eab3ca24d4a599f6a591c887c3592_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMwODY_0c6e6e6a-e699-4bd2-94ab-43ed83598335"
      unitRef="usd">127100000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:PensionExpense
      contextRef="i4e1ee455bd644649ba9f949ccefc1a95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMxNTI_dfdeed07-5e06-4593-bafe-7735b020f775"
      unitRef="usd">15500000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="ic085e896635e45e896872f4b67d23b0b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMxNTY_bd6a0608-92a3-4dfb-8080-273330c3d72f"
      unitRef="usd">14700000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="i9b27f85445594281810d4e11521c4fb0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMxNjM_ba0d41fa-5938-4e36-9ee8-9e3790b26a14"
      unitRef="usd">14800000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="i0a552a264841456ba32e800303b29c4b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMyMTc_38dcaa74-2633-4f8b-b97a-a0241c468fef"
      unitRef="usd">2600000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="i7a170e3656544b4d848f8f7740a81d09_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMyMjE_dfeaa615-3741-41fd-9cfb-379e3942f7be"
      unitRef="usd">1200000</us-gaap:PensionExpense>
    <us-gaap:PensionExpense
      contextRef="i79fdfce753a6425b8f9b7ca88002a439_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMyMjg_a513a291-21c8-4955-9884-4dc402ae0960"
      unitRef="usd">1300000</us-gaap:PensionExpense>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ifececb28512c40ee8412eff5d4625c9c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMzNTU_b39b01fa-736a-4eb0-ab38-b37b3b22c731"
      unitRef="usd">75500000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ic7150facb4e24d09a7ef6a2fee36dfc9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzMzNjI_ac1476c8-8834-4d3b-b9d7-304005213fba"
      unitRef="usd">59600000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib3da3923fab24d76b979d1adf1a4a146_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM0NTg_8eb68162-61c3-41d7-ac1c-843e1d0257b0"
      unitRef="usd">6200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i0cc247cbbe7443509ae3adc1934e986c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM0NjI_48b97008-61b3-4073-9cd6-0d9284e6021d"
      unitRef="usd">5100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i24be31960c444fa3abc4b582746b9496_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM0Njk_8bcae3f7-e9b1-40d6-bf2f-fa768f6d4271"
      unitRef="usd">5300000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6cc07ab871bb4356b9e093f779247007_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM1MzA_e436f49e-1f2e-45b9-854f-161058051220"
      unitRef="usd">2000000.0</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i2baef659c2bc4c41a82832bd90ac2e36_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM1MzQ_98dd41d6-0b7e-418b-8a53-d93cb66ff9dc"
      unitRef="usd">1400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ibff57345bf2b4431834e26681459d492_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjIvZnJhZzplZDU0NzExMmFhOTI0YWM1OGU1OGQ5Y2FjNmRhMTcxOS90ZXh0cmVnaW9uOmVkNTQ3MTEyYWE5MjRhYzU4ZTU4ZDljYWM2ZGExNzE5XzM1NDE_1c78aa01-625d-4bb2-b8b2-2479ee8a404a"
      unitRef="usd">1500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzI3OTM_73a849f3-da4a-4d42-aef1-9e2625ad6834">Segment Information&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables contain certain financial information by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,900.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,656.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;596.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;539.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,692.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,897.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,977.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;774.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,844.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,713.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,794.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,379.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,211.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,493.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,674.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,800.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,370.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,886.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,903.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,152.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,442.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, 2019 and 2018, approximately $2,180.6 million, $2,028.8 million and $1,748.5 million, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#xf8;d, Denmark to FUJIFILM. As of December&#160;31, 2018, approximately $646.5 million of our long-lived assets were related to our manufacturing facility in Hiller&#xf8;d, Denmark.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Property, Plant and Equipment,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these consolidated financial statements. For additional information on the divestiture of our Hiller&#xf8;d, Denmark manufacturing operations, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzQ1_613ed554-f42e-4db5-a417-2fa64e6f8a7e"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzI4MDc_570ada3f-938c-4d4e-96aa-fe85f3f8dacc">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables contain certain financial information by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.111%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,900.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,656.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;596.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;539.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,692.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,897.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,977.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;774.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,496.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,321.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,844.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,713.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,794.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;551.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,379.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,211.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,493.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,162.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,674.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,800.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,370.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,886.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,903.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues from external customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;585.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,152.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,442.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,601.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="i7f99591bb1b0401b8000095a52fab6f8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtMS0xLTEtMA_056c46c8-71db-45cb-a0a8-9a5d69ffd2ce"
      unitRef="usd">5900100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9af8365f4d94f16920edbde69e7cbb7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtMy0xLTEtMA_3dfe5870-74d6-40e5-a7dc-7f4e9fb66c7d"
      unitRef="usd">3656400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96f46388dff4463e9fde50c812857bbd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtNS0xLTEtMA_e7d64cc4-3a6f-4616-99e8-f036acfa9d9c"
      unitRef="usd">596700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe68292fbbe8447c8b94adbca7e5c270_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtNy0xLTEtMA_47881383-7451-416c-abbd-bbb66cabe69f"
      unitRef="usd">539000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEtOS0xLTEtMA_60db6cab-c3b0-446d-9035-4afc2dfa53f9"
      unitRef="usd">10692200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0916ba417dd84c7ba1d88322f8285810_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItMS0xLTEtMA_468d3a62-4ad2-40a5-abd3-ca3b32c96323"
      unitRef="usd">1897400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4626ac9e1499406f9c21d3df61161c1c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItMy0xLTEtMA_27652e49-f523-4ada-964e-9c266b6aa06a"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85a3e7b4381945be8628c8dda3f341b6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItNS0xLTEtMA_f8e47b85-e8e1-4a0e-a8b5-d95fc4f1054f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic4af3774c88a4c69bdfb4f0b296748c4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItNy0xLTEtMA_44260df2-48fc-4e01-a952-d9c651905d7a"
      unitRef="usd">80300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzItOS0xLTEtMA_41886a0d-b3f7-4e5d-b492-84b8cdd153c6"
      unitRef="usd">1977800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibbd9ea049fb349888e438f5bf876864b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtMS0xLTEtMA_3b62a454-8b90-4e7a-9877-3b9f22cc1ddb"
      unitRef="usd">733600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6587b6a9e7a4af3bde2b30568b9afb3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtMy0xLTEtMA_8d2cc2e9-8ec8-4f6b-9d1f-b19cf8d2d857"
      unitRef="usd">8100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6988263d2c4242e89b4c6e3d6b3dffad_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtNS0xLTEtMA_526c9d36-b939-4e0b-ba5b-2767c617fc88"
      unitRef="usd">32900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7c353d1945748a9b24ca8847773877e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtNy0xLTEtMA_cf0fa50a-174d-4ae5-b862-e6071b96b91f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzMtOS0xLTEtMA_d65f3d28-cfe5-42c8-928d-c7ec20ee936e"
      unitRef="usd">774600000</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="i13dba24b1b3b499ea5f5844129e61ac2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtMS0xLTEtMA_cf588b41-4c05-40bf-a3e3-8f6ce2ec807c"
      unitRef="usd">1496300000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i1973b2051d3340b1824cfc6b74a8aaa9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtMy0xLTEtMA_06109185-9935-4bc3-877b-41e6e4bd3ac3"
      unitRef="usd">2321400000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i7c819a830ca44238bc2e36f8b20fd54c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtNS0xLTEtMA_6b727bd8-67bb-459b-99f4-c94eefcb8683"
      unitRef="usd">16200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ia331aa05ae08401980f6ff67ad3d9568_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtNy0xLTEtMA_db51943f-f06c-46e6-ac7d-236eb210dc62"
      unitRef="usd">10900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzQtOS0xLTEtMA_c520a758-90ca-4f0e-8425-45fba92d514d"
      unitRef="usd">3844800000</us-gaap:NoncurrentAssets>
    <us-gaap:Revenues
      contextRef="i72c66309e53f467ab518b51c5bce54f4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctMS0xLTEtMA_9fe10ff5-eed4-476d-9853-444f294edfcf"
      unitRef="usd">6713800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib77580efa84d475392dddda68bff7041_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctMy0xLTEtMA_3cbfcc49-08d4-486b-9408-3f70987ebfad"
      unitRef="usd">3794500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b205643e3ea42fcb8a65c552825bb63_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctNS0xLTEtMA_85ad0a99-cea7-400b-88a7-cbcebc71d19b"
      unitRef="usd">320300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5aeffaf17ea24cf680dcae3471e1b7f9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctNy0xLTEtMA_b57107b6-bc6a-494f-9a8d-7ed3c041a844"
      unitRef="usd">551200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzctOS0xLTEtMA_0240376b-ff5d-4057-9fb0-33b6169a03ca"
      unitRef="usd">11379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i444f2f75d3b2489ab262daa8b78df9ba_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtMS0xLTEtMA_0874b523-99da-4bee-ba19-5105fd7f83d7"
      unitRef="usd">2211900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98fe9583334144ef942f3d12e08913b9_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtMy0xLTEtMA_e3845dd9-3e71-4fd9-9126-91d2c282535b"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6db9e6fd2a649c9889b826888da6372_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtNS0xLTEtMA_23834a88-0a5a-439c-8362-05ee2b7a6d8a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3ac83089e884263a9d4ae9da7e3efde_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtNy0xLTEtMA_82c506fd-9b9d-4128-8f2b-18d8b904eba5"
      unitRef="usd">78300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzgtOS0xLTEtMA_435a3ff0-7291-4d4c-8a8a-cc4b5beb362d"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d9eb2f85dd546a4ae15fc642f85d8af_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktMS0xLTEtMA_97befc69-bb53-4d55-8225-7d6ea1a99869"
      unitRef="usd">585800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4630fecb0f6c47b2b848f15327791e4f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktMy0xLTEtMA_c7b738c5-a95a-4357-a262-461c5c6fbf3e"
      unitRef="usd">9700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i002c6070bf8846dc9140030a63f37dac_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktNS0xLTEtMA_a685abde-f015-484a-9cad-606fcbb86209"
      unitRef="usd">112200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i674d0e91669c40ff82a76bedb27e4e67_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktNy0xLTEtMA_6d1ef973-bf0f-4e8d-b4af-d81a17a5e696"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzktOS0xLTEtMA_fdcb858d-69a0-46a3-b9d3-71845a2ca5f8"
      unitRef="usd">707700000</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="i0172f7c5c8b3448bb8ca832a1116f3aa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTEtMS0xLTA_e3c82dcf-9dfc-4760-84fa-5276e2aa3f36"
      unitRef="usd">1493200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ib563770ab8184507a232435bea87086a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTMtMS0xLTA_bb59b502-b03e-4b3c-89e6-0125d6e4938a"
      unitRef="usd">2162900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i9d67a017c4d1439bbfdeb2055dacff9b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTUtMS0xLTA_e4746b36-7760-486d-8a68-9574e3fcb132"
      unitRef="usd">6200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i388f07fba6354ae6b12a5c8a48d28304_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTctMS0xLTA_327a2fb1-223d-49e5-adfb-2f9cc9be589e"
      unitRef="usd">12000000.0</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i4fdb048733b648df99bd7b1e5b1476ef_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEwLTktMS0xLTA_be4c6992-1c10-4a00-935a-2dbfdbb2963b"
      unitRef="usd">3674300000</us-gaap:NoncurrentAssets>
    <us-gaap:Revenues
      contextRef="i5c311f0cc16744aeb4492070360e76b3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTEtMS0xLTA_df7af581-5657-44ca-8726-1859e7c8ffb8"
      unitRef="usd">6800500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c94a7c202e7466686a893e6fda06193_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTMtMS0xLTA_da3b7e29-276f-4438-a052-04c8cb377a68"
      unitRef="usd">3370300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4342c229637d452dafa8e4a45cb1a216_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTUtMS0xLTA_7c3bd239-9d41-4aa5-9ed7-62932e39f71c"
      unitRef="usd">281200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9714a1b144e4e9b81457f7ce371bbea_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTctMS0xLTA_c9d74227-c450-40eb-ac95-fee5a23cf31b"
      unitRef="usd">434800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib6b7b9a353c2419ca9a01532a522a0d0_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzEzLTktMS0xLTA_58bedd33-0fda-463e-a0d3-03d57d96f6b1"
      unitRef="usd">10886800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabe36228fc3c43b182afc7bd39a2d6bd_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTEtMS0xLTA_49b1cb1c-9621-4295-89a4-fac81e599957"
      unitRef="usd">1903400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7dd05e22171d4dad869c4a37eb52a7f5_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTMtMS0xLTA_4f92c4e7-b503-4236-9d0a-57b231fad7f6"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e85dcda379e4e348325696cd2ec9cf6_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTUtMS0xLTA_07df315c-6825-4c12-8965-e1bc1e99f613"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f84620186bd48dfaa02b13846091e74_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTctMS0xLTA_2c1c6bc9-bc30-479a-82b6-8e2ec18afe6a"
      unitRef="usd">76600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee2514a987784410a8165984f87269d3_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE0LTktMS0xLTA_c8ea9db9-fa2e-42fe-a136-fcad49017f27"
      unitRef="usd">1980200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf10b7ffe1994abcbd958c90d5c06301_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTEtMS0xLTA_245818e3-6ea2-43cf-9e3b-b91494730dce"
      unitRef="usd">457000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic16aea428adb4ba5ae3e7d508536706d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTMtMS0xLTA_7eb76c79-faa5-45d4-8d60-1bdc75e5a3c5"
      unitRef="usd">32700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if67b659127c9421f89dad74f1278c337_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTUtMS0xLTA_411d5046-00e0-48b9-8170-fa779f4b3c82"
      unitRef="usd">96200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i745cdf1e889c4c16afb442fe563d25a2_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTctMS0xLTA_41582e17-0e50-45da-93e5-4fe779665ccd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if2987b04d4c240d88b84a50c04ca2df1_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE1LTktMS0xLTA_18928a99-90c0-4c0d-b583-8a6c150a5cbe"
      unitRef="usd">585900000</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="id49704cf795948148f16dbae680341c9_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTEtMS0xLTA_3743daa7-7bff-4484-9ca9-b1f1ab64e035"
      unitRef="usd">1152700000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i9cfd775f332e45ac808c12b6838e769e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTMtMS0xLTA_2bb9c8fd-951f-4928-918b-f44b39a00fbf"
      unitRef="usd">2442800000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="icbdc67c11df94e509edd9a7f39c16d8e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTUtMS0xLTA_ec34e315-3bec-4e31-8485-c8a3a6b89043"
      unitRef="usd">3900000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i89e40021e4994fcbb8133c1d5d3f6f27_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTctMS0xLTA_5b24fe3c-b415-4f04-be89-873ddd606e5b"
      unitRef="usd">1800000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id82ee39d50af4f5587e19230de06cf02_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90YWJsZTpjM2MxMTcxMmFmMDY0ZDllODIxMGI4MTVlMmRlM2JkNS90YWJsZXJhbmdlOmMzYzExNzEyYWYwNjRkOWU4MjEwYjgxNWUyZGUzYmQ1XzE2LTktMS0xLTA_f690185d-9ec3-407e-a1ff-d5f99856dae1"
      unitRef="usd">3601200000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i4c4f2b0a6a9c49f48c35940d82b38a6b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzE5MzM_440f846b-0db3-4743-b8fb-306953b4533e"
      unitRef="usd">2180600000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie6e096fa0fb0473683e284201e92aaca_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzE5Mzc_af7a3f61-18c1-42e2-9774-0fab4aace640"
      unitRef="usd">2028800000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i8e2b3b8ba24b4036880ba37d5422da63_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzE5NDQ_a6ef2421-feb3-4c0c-b4fc-a6dc8a971cb2"
      unitRef="usd">1748500000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i8ae776ffb778432e982088a179ebb204_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMjgvZnJhZzpiZmUxY2JhOTUyMjA0YWFhYTU5NzgyYTgyZDNkNjEwZC90ZXh0cmVnaW9uOmJmZTFjYmE5NTIyMDRhYWFhNTk3ODJhODJkM2Q2MTBkXzIzMDk_6e4ef595-cd69-4994-8bc5-242400cc7964"
      unitRef="usd">646500000</us-gaap:NoncurrentAssets>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU0MjY_87d47e3e-2616-4e2e-b6cb-7b1b0bfd62e9">Quarterly Financial Data (Unaudited)&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,904.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,795.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,690.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,301.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,692.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,977.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;774.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,534.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,681.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,852.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,444.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross profit &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,080.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,927.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,361.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,639.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,392.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,606.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;703.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,060.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,399.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;701.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in calculating:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,680.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,880.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,894.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,924.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,379.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;517.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;595.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,489.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,616.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,600.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,671.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,377.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross profit &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,224.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,422.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,545.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,439.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,888.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,545.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,439.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,888.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in calculating:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1Mjc_1ae74079-c50d-4dae-bbe2-abf5e1616a44">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,904.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,795.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,690.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,301.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,692.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;478.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;419.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,977.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;407.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;774.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,534.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,681.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,852.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,444.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross profit &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,080.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,927.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,361.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,639.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,392.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,606.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;703.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,060.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,399.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;701.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,000.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in calculating:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;First&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Second&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Third&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fourth&lt;br/&gt;Quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,680.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,880.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,894.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,924.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,379.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;517.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;595.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,489.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,616.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,600.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,671.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,377.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross profit &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,887.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,140.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,170.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,224.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,422.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,545.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,439.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,888.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,545.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,439.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,888.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in calculating:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="i9fca2b687f2f4872a9a845bb672960a5_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItMS0xLTEtMA_07db04aa-7c4f-436a-8831-3689946eb245"
      unitRef="usd">2904600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5dfc91e9f8241d894aa02ab5409f041_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItMy0xLTEtMA_7cc23f95-b663-4243-943e-860d1ee15340"
      unitRef="usd">2795700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ae9621a79ec4f2a81baf7fc485474c2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItNS0xLTEtMA_58ebeeb9-f1b9-4a45-a9c9-1a424ed3e44a"
      unitRef="usd">2690300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c705be761834645b8c5978e3818b771_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItNy0xLTEtMA_4da0a5b7-7955-4c8a-8efd-b6fb33388ecb"
      unitRef="usd">2301600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5bb8cc2a155e45f19d0f68b22c0685de_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzItOS0xLTEtMA_3e29a612-ef6c-47b0-a2e3-cbe3399c40f8"
      unitRef="usd">10692200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8f55339914bb4b2ab51133f2c27b01c7_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtMS0xLTEtMA_af8f582c-5a3e-43ec-a878-b0949c87a832"
      unitRef="usd">520400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib87a96b308944207b0abf485235389d9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtMy0xLTEtMA_d40f3a05-8261-46f2-9e99-4835df0d5b29"
      unitRef="usd">478300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01ce7f756f854eff83de1460d06439a0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtNS0xLTEtMA_66db4928-6e58-4280-bc4c-c4d55a4e1a5f"
      unitRef="usd">560100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3a2e9422f744e57a659fdc96c0a0d84_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtNy0xLTEtMA_2b516a46-3f6d-4f26-85f3-4c03735a43f4"
      unitRef="usd">419000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1a7585179a34aa0aa02e17c494e49b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzMtOS0xLTEtMA_5fe7707a-abf5-4f86-a258-8ada778d206b"
      unitRef="usd">1977800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie805016a199a4e4eafdf82e66b43ecd8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtMS0xLTEtMA_1ca6cd10-04d4-49dc-acc2-099fa11c24d6"
      unitRef="usd">109300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a2d9c146e8546eb8940919a230b2410_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtMy0xLTEtMA_c9aaa2d3-b292-45eb-9b96-b945f82d2e9f"
      unitRef="usd">407600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1f37a240cd2462496769361d7d6aa4c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtNS0xLTEtMA_4e7d009a-b04c-4889-b0db-197fd3619e1f"
      unitRef="usd">125700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1cc07ea8987844bbae9f16026aa3eeb2_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtNy0xLTEtMA_bc9888a5-fb98-4114-a668-5e13ffb40c6d"
      unitRef="usd">132000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd36dc98481f4a4aa1b8c48355fa8a0e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzQtOS0xLTEtMA_a565085f-d711-4a13-b9c1-2a7f9068d70c"
      unitRef="usd">774600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtMS0xLTEtMA_0cd08d92-cfb2-4a0c-a192-e9d2a6cf98b9"
      unitRef="usd">3534300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtMy0xLTEtMA_4cc71007-fa59-4408-a199-ecc6db9d57e0"
      unitRef="usd">3681600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtNS0xLTEtMA_d110f119-31e2-4d66-a03f-e9a1062b98f4"
      unitRef="usd">3376100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtNy0xLTEtMA_ac2859d2-b1f0-4cca-932c-fffd22044c2d"
      unitRef="usd">2852600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzUtOS0xLTEtMA_61082424-b793-4f04-83c9-93edb2ec88d9"
      unitRef="usd">13444600000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMS0xLTEtMA_868f3bcf-bd41-4cd0-874e-b9e7a6eac3a3"
      unitRef="usd">3080000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMy0xLTEtMA_e02a9e0f-13e0-4819-a172-c922d853149c"
      unitRef="usd">3270500000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNS0xLTEtMA_8ecba11c-83af-4c5b-9efe-71417b9f874c"
      unitRef="usd">2927000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNy0xLTEtMA_bb7f955b-8dd2-4259-afc2-d669fdf6b779"
      unitRef="usd">2361900000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtOS0xLTEtMA_4eace0b0-5459-443b-adf4-f41a5aee20ae"
      unitRef="usd">11639400000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctMS0xLTEtMA_1e3e3715-5ec3-4624-992e-85bd57369a05"
      unitRef="usd">1392600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctMy0xLTEtMA_83770c2e-67a3-4572-9320-0f440d558e76"
      unitRef="usd">1606500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctNS0xLTEtMA_b54912fa-b9d3-4e0f-8d2f-d57302b9f6bd"
      unitRef="usd">703900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctNy0xLTEtMA_00ce2a1c-7afa-460e-a535-ff97e4050823"
      unitRef="usd">357600000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzctOS0xLTEtMA_9cf5b0d5-c61c-49f6-87a4-0e7d6bb4ca15"
      unitRef="usd">4060500000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtMS0xLTEtMA_d37c962d-8421-43dc-a784-c1000ce6aded"
      unitRef="usd">1399100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtMy0xLTEtMA_113433d1-7b59-47d7-80e0-9d388dbba293"
      unitRef="usd">1542100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtNS0xLTEtMA_7a539bd9-bc6c-482b-9d8b-f4f197b2e89f"
      unitRef="usd">701500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtNy0xLTEtMA_da690fae-ed6a-4c6d-82a8-76105c268a30"
      unitRef="usd">357900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzgtOS0xLTEtMA_1b9a353a-aff5-4a4b-ac40-f031b6bb4f68"
      unitRef="usd">4000600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTEtMS0xLTA_8fe4956e-fda9-4bfd-a01b-851184711ad5"
      unitRef="usdPerShare">8.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTMtMS0xLTA_354ddb90-c628-41be-949c-4a93051ff777"
      unitRef="usdPerShare">9.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTUtMS0xLTA_10615ec0-c93c-48ae-b122-0a9e14e255ee"
      unitRef="usdPerShare">4.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTctMS0xLTA_4991197b-a43a-45d2-86ec-cacf19e99ee7"
      unitRef="usdPerShare">2.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEwLTktMS0xLTA_c03fb85b-07eb-4a9d-8a10-878992c597b9"
      unitRef="usdPerShare">24.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTEtMS0xLTA_9373be3e-ee83-487d-ab67-63d295f81edc"
      unitRef="usdPerShare">8.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTMtMS0xLTA_2cf8e39d-7df1-413a-9c96-79b5806e174f"
      unitRef="usdPerShare">9.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTUtMS0xLTA_98a8ece2-c75b-4fad-aa99-6892ff3ae07d"
      unitRef="usdPerShare">4.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTctMS0xLTA_94c2e1ef-7fac-416e-85af-52aa1df4b6ba"
      unitRef="usdPerShare">2.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzExLTktMS0xLTA_860fa633-d142-441c-adba-d3065eb39a08"
      unitRef="usdPerShare">24.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTEtMS0xLTA_9a441885-c2af-4d5e-a1df-9fbb1dd1dffe"
      unitRef="shares">172800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTMtMS0xLTA_932075fb-fd36-4233-b17e-37bb5a916f97"
      unitRef="shares">160600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTUtMS0xLTA_7656fdde-77ef-44e5-ba13-df6b793617bb"
      unitRef="shares">156900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTctMS0xLTA_a95b6aee-4502-4933-bf1a-381001562d88"
      unitRef="shares">153700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzEzLTktMS0xLTA_c1350c07-82b9-4c59-a56f-3972d0321bfe"
      unitRef="shares">160900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9798097552734be1af7e1e808bd2c5fe_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTEtMS0xLTA_ab44a510-694c-45c7-a740-dd4b550f19e8"
      unitRef="shares">173100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iccc95fd70ec14f1e8f11129030013137_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTMtMS0xLTA_3f83a59b-f25a-45ec-8299-ccbb41606f09"
      unitRef="shares">160900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i74b60ff8ce5042e4b618864e7e793769_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTUtMS0xLTA_774a0777-9c4f-4176-ac7c-df39db02b595"
      unitRef="shares">157200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTctMS0xLTA_fa52f10a-7391-44f5-880d-cc9a32626b14"
      unitRef="shares">154000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzE0LTktMS0xLTA_b174a4f4-6dc2-4717-9230-70d4d46e5fb9"
      unitRef="shares">161300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:Revenues
      contextRef="ie7776337c87847de857073085287b7df_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItMS0xLTEtMA_b39f318d-340d-44f6-9bc2-36108985cbcc"
      unitRef="usd">2680000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ee7c83511ad4b4a994502e07e77195c_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItMy0xLTEtMA_64c7dcde-cc30-4608-a7f2-f2afd1d968f0"
      unitRef="usd">2880300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5dc031b722984deaaab7026bf6193aab_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItNS0xLTEtMA_12afd31f-e7d1-43ae-af21-20c2b06a0aae"
      unitRef="usd">2894700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5416e51b85274f0bb17370851e4a3b1b_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItNy0xLTEtMA_7e8cc5ed-b5fe-49b1-bc88-c549b45f756f"
      unitRef="usd">2924800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic828d3714b104574b1dbe27f39d0263f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzItOS0xLTEtMA_3af431e4-2bb0-4eb4-a47e-b9b1819b2aaf"
      unitRef="usd">11379800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2ad278057bef48a7b7423fcd6a012b35_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtMS0xLTEtMA_4100c309-0a98-4c03-9393-ee9bb55b564c"
      unitRef="usd">517400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id87d95cb80ee488f95f41a5044d1b98c_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtMy0xLTEtMA_de2b9391-c567-4f64-be49-35341f2625f6"
      unitRef="usd">576400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61172312032a4a168fbce9685cffadb9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtNS0xLTEtMA_7a328d97-7a39-498d-bcc5-96c63702302b"
      unitRef="usd">595800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1244a258e99d4f4bbccf06fe8dd8b6f8_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtNy0xLTEtMA_316de687-e86a-4801-9555-540cc6e7d575"
      unitRef="usd">600800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a8027d0c608463ab51bbf023bbbaa6f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzMtOS0xLTEtMA_62bdc50d-e6b8-4f09-81be-2b125a7febb5"
      unitRef="usd">2290400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9edea67901754dfca2b56005c22d377d_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtMS0xLTEtMA_5e36c376-11bb-49c6-a776-502acf2a2301"
      unitRef="usd">292400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5380e1ba1c7b486290cfbe6457fb3bd7_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtMy0xLTEtMA_3d5b24dc-b363-4a36-bbe1-e7f25810b15a"
      unitRef="usd">160000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifd7ea2df93e7492991c4ca15c3f6e098_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtNS0xLTEtMA_46f62ca6-e13a-46a2-9ced-7b6078026daf"
      unitRef="usd">109600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d05a3ba448a4750b45bb2d906497144_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtNy0xLTEtMA_39638832-cb23-49d2-8596-c54db9de4085"
      unitRef="usd">145700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03c4a47ed1aa468fb1cc00c8d7d2230f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzQtOS0xLTEtMA_ae3a9bfa-fdbd-4ae1-a435-c7e65cf7f5dc"
      unitRef="usd">707700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtMS0xLTEtMA_cf82b7e8-eca2-4721-9593-d7a80fa7bb8f"
      unitRef="usd">3489800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtMy0xLTEtMA_79f07107-6644-4550-9404-e82067c8224a"
      unitRef="usd">3616700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtNS0xLTEtMA_cbde5114-c05b-4d19-9c78-2508f402a89e"
      unitRef="usd">3600100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtNy0xLTEtMA_7e587a73-4db7-4afb-894f-84a207ca2e1d"
      unitRef="usd">3671300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzUtOS0xLTEtMA_b539c8ef-9322-4de6-be5f-6ea1e0b711fd"
      unitRef="usd">14377900000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMS0xLTEtMA_39dfce08-102f-4ec0-a97c-6fe195f05d8a"
      unitRef="usd">2887800000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMy0xLTEtMA_f12fa61f-347d-4d6e-b8f0-8dce21f1c03b"
      unitRef="usd">3140400000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNS0xLTEtMA_c67cd457-35c2-4bdc-98e3-c6fac4fc50f3"
      unitRef="usd">3170100000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNy0xLTEtMA_01e50ece-7e7b-4921-9bbd-d7faebc2bd59"
      unitRef="usd">3224200000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtOS0xLTEtMA_e605553e-fb73-480b-b14d-4ace6cf47e83"
      unitRef="usd">12422500000</us-gaap:GrossProfit>
    <us-gaap:ProfitLoss
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctMS0xLTEtMA_e6c0231f-1435-4772-b340-d9153187d369"
      unitRef="usd">1408800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctMy0xLTEtMA_e1acee11-0bda-4ca7-bbd2-86c9de4e3cfe"
      unitRef="usd">1494100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctNS0xLTEtMA_4de51ec7-07c9-4498-afb1-7b0c38e4a06d"
      unitRef="usd">1545900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctNy0xLTEtMA_9fa8f7f8-1a49-4b73-86e0-56d5fec4c1bf"
      unitRef="usd">1439700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzctOS0xLTEtMA_6db6a3c4-5afd-4af9-96ff-c1e1adcba63a"
      unitRef="usd">5888500000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtMS0xLTEtMA_1b9ce59d-9045-4c4a-a21d-d157b2c3bc09"
      unitRef="usd">1408800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtMy0xLTEtMA_e01817c7-7015-483a-b98f-3d1d0ca346b2"
      unitRef="usd">1494100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtNS0xLTEtMA_0a2e2f99-aa72-4b8f-a18a-6073c2c4986d"
      unitRef="usd">1545900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtNy0xLTEtMA_fbd9fc7f-257d-4a2f-a51e-a306ac0211c4"
      unitRef="usd">1439700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzgtOS0xLTEtMA_8c20aace-b061-4213-8dc4-89838383bbb8"
      unitRef="usd">5888500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTEtMS0xLTA_88396a64-d3e4-4ddb-975d-6680fde2583d"
      unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTMtMS0xLTA_24bfc3af-3031-430b-aac6-3d30f369783c"
      unitRef="usdPerShare">7.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTUtMS0xLTA_0c49bc7b-79ea-497e-bb5b-911f199d903a"
      unitRef="usdPerShare">8.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTctMS0xLTA_ec2fb9ed-a56e-4b4d-83a6-578a587a3d44"
      unitRef="usdPerShare">8.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEwLTktMS0xLTA_95aa40fd-37c4-49f3-aeda-092f941b515c"
      unitRef="usdPerShare">31.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTEtMS0xLTA_d9d20560-cf66-4ee8-b23c-98954e749a84"
      unitRef="usdPerShare">7.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTMtMS0xLTA_81c5dbbb-2efe-49b8-9309-4c33a904fa44"
      unitRef="usdPerShare">7.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTUtMS0xLTA_3e6e0735-a76c-488f-bc50-39dbf797f597"
      unitRef="usdPerShare">8.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTctMS0xLTA_01f79033-3606-47b7-8973-8375371e2471"
      unitRef="usdPerShare">8.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzExLTktMS0xLTA_b1f4c0b6-d103-4c37-bac6-518c034083b9"
      unitRef="usdPerShare">31.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTEtMS0xLTA_3bf747e0-20ef-41ce-ba6f-92751b87d95a"
      unitRef="shares">196600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTMtMS0xLTA_b52df3b5-6243-4979-a07b-e81601db9da7"
      unitRef="shares">190300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTUtMS0xLTA_dacb3659-a160-436d-919f-f9d4b718ac3c"
      unitRef="shares">184000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTctMS0xLTA_597f65b9-78ad-4f4a-8fbb-27b71b0da696"
      unitRef="shares">177800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzEzLTktMS0xLTA_b8d9c632-aff0-4499-8988-9d7a33bcd820"
      unitRef="shares">187100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTEtMS0xLTA_69cbf493-a28a-43c7-8a16-22465a25d64e"
      unitRef="shares">197000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1c9129d2428e4629976fa2f168f52b15_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTMtMS0xLTA_c3db8313-4e2d-49ec-bd01-08e618f17d85"
      unitRef="shares">190400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i620be7d2206145f48bcc2a8b850f0a3b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTUtMS0xLTA_20fb6800-c66d-4f2d-953f-5f7a59ed497b"
      unitRef="shares">184200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3b263d816fbd44d8a862638406100b0f_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTctMS0xLTA_db6c3451-0cea-4cdf-9f94-f003ca5cbe07"
      unitRef="shares">178200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i13dd2ed5753d41b4b61e2a2f19298031_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzE0LTktMS0xLTA_93256996-10e1-4701-8776-7e39007827ae"
      unitRef="shares">187400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNS0xLTEtMA_c67cd457-35c2-4bdc-98e3-c6fac4fc50f3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNS0xLTEtMA_c67cd457-35c2-4bdc-98e3-c6fac4fc50f3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNS0xLTEtMA_8ecba11c-83af-4c5b-9efe-71417b9f874c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNS0xLTEtMA_8ecba11c-83af-4c5b-9efe-71417b9f874c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNy0xLTEtMA_bb7f955b-8dd2-4259-afc2-d669fdf6b779"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNy0xLTEtMA_bb7f955b-8dd2-4259-afc2-d669fdf6b779"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtOS0xLTEtMA_e605553e-fb73-480b-b14d-4ace6cf47e83"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtOS0xLTEtMA_e605553e-fb73-480b-b14d-4ace6cf47e83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMS0xLTEtMA_39dfce08-102f-4ec0-a97c-6fe195f05d8a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMS0xLTEtMA_39dfce08-102f-4ec0-a97c-6fe195f05d8a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMS0xLTEtMA_868f3bcf-bd41-4cd0-874e-b9e7a6eac3a3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMS0xLTEtMA_868f3bcf-bd41-4cd0-874e-b9e7a6eac3a3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMy0xLTEtMA_f12fa61f-347d-4d6e-b8f0-8dce21f1c03b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMy0xLTEtMA_f12fa61f-347d-4d6e-b8f0-8dce21f1c03b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNy0xLTEtMA_01e50ece-7e7b-4921-9bbd-d7faebc2bd59"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNy0xLTEtMA_01e50ece-7e7b-4921-9bbd-d7faebc2bd59"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtOS0xLTEtMA_4eace0b0-5459-443b-adf4-f41a5aee20ae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtOS0xLTEtMA_4eace0b0-5459-443b-adf4-f41a5aee20ae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMy0xLTEtMA_e02a9e0f-13e0-4819-a172-c922d853149c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMy0xLTEtMA_e02a9e0f-13e0-4819-a172-c922d853149c"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNS0xLTEtMA_c67cd457-35c2-4bdc-98e3-c6fac4fc50f3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNS0xLTEtMA_8ecba11c-83af-4c5b-9efe-71417b9f874c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtNy0xLTEtMA_bb7f955b-8dd2-4259-afc2-d669fdf6b779"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtOS0xLTEtMA_e605553e-fb73-480b-b14d-4ace6cf47e83"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMS0xLTEtMA_39dfce08-102f-4ec0-a97c-6fe195f05d8a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMS0xLTEtMA_868f3bcf-bd41-4cd0-874e-b9e7a6eac3a3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtMy0xLTEtMA_f12fa61f-347d-4d6e-b8f0-8dce21f1c03b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTo5YWRlY2Y0YTZmZTU0MzIwOTVhZGJiYzAwM2E2NGEyNi90YWJsZXJhbmdlOjlhZGVjZjRhNmZlNTQzMjA5NWFkYmJjMDAzYTY0YTI2XzYtNy0xLTEtMA_01e50ece-7e7b-4921-9bbd-d7faebc2bd59"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtOS0xLTEtMA_4eace0b0-5459-443b-adf4-f41a5aee20ae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90YWJsZTowMWY3ZWI4OGI0Njk0ODEwYjM2ZDE0OWIyZWJjNzgwZS90YWJsZXJhbmdlOjAxZjdlYjg4YjQ2OTQ4MTBiMzZkMTQ5YjJlYmM3ODBlXzYtMy0xLTEtMA_e02a9e0f-13e0-4819-a172-c922d853149c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8zMzEvZnJhZzozMGQ0MTE2MTY5NWI0NTBkODNiZDFjNzE2YTRlNDVjYS90ZXh0cmVnaW9uOjMwZDQxMTYxNjk1YjQ1MGQ4M2JkMWM3MTZhNGU0NWNhXzU1MjU_67e8ccb1-057e-4b88-ac7c-1bf1141c2644"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMS0xLTEtMA_3d7def81-fe0f-4338-b42f-f9e4c5d0aac7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMS0xLTEtMA_3d7def81-fe0f-4338-b42f-f9e4c5d0aac7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMy0xLTEtMA_d535a514-8b7c-44b1-935b-6f83ea384d26"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMy0xLTEtMA_d535a514-8b7c-44b1-935b-6f83ea384d26"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyODE2_c2dfd109-d8fa-4cb8-b3c4-ad01329efc84"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyODE2_c2dfd109-d8fa-4cb8-b3c4-ad01329efc84"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg2_aca5d24a-146b-4dbc-aa83-d2e4f12e6dfa" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg2_aca5d24a-146b-4dbc-aa83-d2e4f12e6dfa" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">RSUs granted in 2020 primarily represent RSUs granted in conjunction with our annual awards made in February 2020 and awards made in conjunction with the hiring of new employees. RSUs granted in 2020 also include approximately 10,000 RSUs granted to our Board of Directors.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMS0xLTEtMA_3d7def81-fe0f-4338-b42f-f9e4c5d0aac7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg2_aca5d24a-146b-4dbc-aa83-d2e4f12e6dfa"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo3NThlOGFlODExMmI0OTY3OWEwMzI5M2MwMjU5OWYyYi90YWJsZXJhbmdlOjc1OGU4YWU4MTEyYjQ5Njc5YTAzMjkzYzAyNTk5ZjJiXzItMy0xLTEtMA_d535a514-8b7c-44b1-935b-6f83ea384d26"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg2_aca5d24a-146b-4dbc-aa83-d2e4f12e6dfa"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEyODE2_c2dfd109-d8fa-4cb8-b3c4-ad01329efc84"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzg2_aca5d24a-146b-4dbc-aa83-d2e4f12e6dfa"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMS0xLTEtMA_a453c414-1392-406f-a3c6-6be569fd62aa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMS0xLTEtMA_a453c414-1392-406f-a3c6-6be569fd62aa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMy0xLTEtMA_5e5cc007-b27e-4389-873d-5a05fde0a71e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMy0xLTEtMA_5e5cc007-b27e-4389-873d-5a05fde0a71e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzM4_565199ff-dcec-4c09-87e4-87594327fc27" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzM4_565199ff-dcec-4c09-87e4-87594327fc27" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMS0xLTEtMA_a453c414-1392-406f-a3c6-6be569fd62aa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzM4_565199ff-dcec-4c09-87e4-87594327fc27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTphYjVlYTdmMzRiYmY0YzhmOWM3NDgzMjMyYTc0ZjY5Yi90YWJsZXJhbmdlOmFiNWVhN2YzNGJiZjRjOGY5Yzc0ODMyMzJhNzRmNjliXzItMy0xLTEtMA_5e5cc007-b27e-4389-873d-5a05fde0a71e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzM4_565199ff-dcec-4c09-87e4-87594327fc27"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMy0xLTEtMA_31107894-bc5a-4a7a-9cf9-547a7e070226"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMy0xLTEtMA_31107894-bc5a-4a7a-9cf9-547a7e070226"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMS0xLTEtMA_94bb0b7a-efc2-49dd-9afd-60ee50e69cdc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMS0xLTEtMA_94bb0b7a-efc2-49dd-9afd-60ee50e69cdc"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzc4_f2233f5e-fe16-49c0-8d02-0bd274729343" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzc4_f2233f5e-fe16-49c0-8d02-0bd274729343" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">PSUs settled in stock granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMy0xLTEtMA_31107894-bc5a-4a7a-9cf9-547a7e070226"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzc4_f2233f5e-fe16-49c0-8d02-0bd274729343"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90YWJsZTo0ZTUwZjk2NGQyNjc0MjA4ODI3ODUyYTM1YzVjMmZiNi90YWJsZXJhbmdlOjRlNTBmOTY0ZDI2NzQyMDg4Mjc4NTJhMzVjNWMyZmI2XzItMS0xLTEtMA_94bb0b7a-efc2-49dd-9afd-60ee50e69cdc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzEzMzc4_f2233f5e-fe16-49c0-8d02-0bd274729343"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979598632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 02, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005&#160;par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,102,640,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,335,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the definitive proxy statement for our 2021 Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980316840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 13,444.6<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">1,805.2<span></span>
</td>
<td class="nump">1,955.4<span></span>
</td>
<td class="nump">1,816.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">3,990.9<span></span>
</td>
<td class="nump">2,280.6<span></span>
</td>
<td class="nump">2,597.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,504.5<span></span>
</td>
<td class="nump">2,374.7<span></span>
</td>
<td class="nump">2,106.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">464.8<span></span>
</td>
<td class="nump">489.9<span></span>
</td>
<td class="nump">747.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">232.9<span></span>
</td>
<td class="nump">241.6<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">(Gain) loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="num">(92.5)<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(86.3)<span></span>
</td>
<td class="num">(63.7)<span></span>
</td>
<td class="num">(12.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">8,894.5<span></span>
</td>
<td class="nump">7,335.3<span></span>
</td>
<td class="nump">7,564.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">4,550.1<span></span>
</td>
<td class="nump">7,042.6<span></span>
</td>
<td class="nump">5,888.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">497.4<span></span>
</td>
<td class="nump">83.3<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">5,047.5<span></span>
</td>
<td class="nump">7,125.9<span></span>
</td>
<td class="nump">5,899.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">992.3<span></span>
</td>
<td class="nump">1,158.0<span></span>
</td>
<td class="nump">1,425.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="num">(5.3)<span></span>
</td>
<td class="nump">79.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,060.5<span></span>
</td>
<td class="nump">5,888.5<span></span>
</td>
<td class="nump">4,474.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">59.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 4,000.6<span></span>
</td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc. (in dollars per share)</a></td>
<td class="nump">$ 24.86<span></span>
</td>
<td class="nump">$ 31.47<span></span>
</td>
<td class="nump">$ 21.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc. (in dollars per share)</a></td>
<td class="nump">$ 24.80<span></span>
</td>
<td class="nump">$ 31.42<span></span>
</td>
<td class="nump">$ 21.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc. (in shares)</a></td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc. (in shares)</a></td>
<td class="nump">161.3<span></span>
</td>
<td class="nump">187.4<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 10,692.2<span></span>
</td>
<td class="nump">$ 11,379.8<span></span>
</td>
<td class="nump">$ 10,886.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,977.8<span></span>
</td>
<td class="nump">2,290.4<span></span>
</td>
<td class="nump">1,980.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 774.6<span></span>
</td>
<td class="nump">$ 707.7<span></span>
</td>
<td class="nump">$ 585.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationandImpairmentofAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979737592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 4,000.6<span></span>
</td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(186.8)<span></span>
</td>
<td class="num">(26.9)<span></span>
</td>
<td class="nump">139.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="num">(33.6)<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">92.9<span></span>
</td>
<td class="nump">103.8<span></span>
</td>
<td class="num">(67.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(163.8)<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">3,836.8<span></span>
</td>
<td class="nump">5,993.7<span></span>
</td>
<td class="nump">4,507.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">60.9<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">42.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 3,897.7<span></span>
</td>
<td class="nump">$ 5,993.3<span></span>
</td>
<td class="nump">$ 4,550.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980850264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,331.2<span></span>
</td>
<td class="nump">$ 2,913.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,278.9<span></span>
</td>
<td class="nump">1,562.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,913.8<span></span>
</td>
<td class="nump">1,880.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DueFromUnconsolidatedJointBusiness', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">413.5<span></span>
</td>
<td class="nump">590.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,068.6<span></span>
</td>
<td class="nump">804.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">881.1<span></span>
</td>
<td class="nump">631.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,887.1<span></span>
</td>
<td class="nump">8,381.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">772.1<span></span>
</td>
<td class="nump">1,408.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,411.5<span></span>
</td>
<td class="nump">3,247.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">433.3<span></span>
</td>
<td class="nump">427.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,084.3<span></span>
</td>
<td class="nump">3,527.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,762.1<span></span>
</td>
<td class="nump">5,757.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,369.5<span></span>
</td>
<td class="nump">3,232.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">2,899.0<span></span>
</td>
<td class="nump">1,252.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,618.9<span></span>
</td>
<td class="nump">27,234.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,495.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">142.0<span></span>
</td>
<td class="nump">71.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">454.9<span></span>
</td>
<td class="nump">530.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">3,145.3<span></span>
</td>
<td class="nump">2,765.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,742.2<span></span>
</td>
<td class="nump">4,863.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">7,426.2<span></span>
</td>
<td class="nump">4,459.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">1,032.8<span></span>
</td>
<td class="nump">2,810.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">402.0<span></span>
</td>
<td class="nump">412.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,329.6<span></span>
</td>
<td class="nump">1,348.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,932.8<span></span>
</td>
<td class="nump">13,895.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments, contingencies and guarantees (Notes 21 and 22)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Inc. shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(299.0)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">13,976.3<span></span>
</td>
<td class="nump">16,455.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">10,700.3<span></span>
</td>
<td class="nump">13,343.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(14.2)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">10,686.1<span></span>
</td>
<td class="nump">13,339.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 24,618.9<span></span>
</td>
<td class="nump">$ 27,234.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DueFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DueFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089973316664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost, shares (in shares)</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974002664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,060.5<span></span>
</td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,474.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">457.2<span></span>
</td>
<td class="nump">464.7<span></span>
</td>
<td class="nump">650.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">209.7<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">366.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">198.3<span></span>
</td>
<td class="nump">182.3<span></span>
</td>
<td class="nump">157.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(86.3)<span></span>
</td>
<td class="num">(63.7)<span></span>
</td>
<td class="num">(12.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax', window );">(Gain)/loss on divestiture of Hillerod, Denmark manufactuing operations</a></td>
<td class="num">(92.5)<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">149.0<span></span>
</td>
<td class="nump">67.1<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Unrealized (gain) loss on strategic investments</a></td>
<td class="num">(681.8)<span></span>
</td>
<td class="num">(147.3)<span></span>
</td>
<td class="num">(124.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss on equity method investment</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">77.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">131.2<span></span>
</td>
<td class="nump">139.1<span></span>
</td>
<td class="nump">55.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">68.8<span></span>
</td>
<td class="num">(205.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">176.7<span></span>
</td>
<td class="num">(63.3)<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(316.3)<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
<td class="num">(52.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">154.2<span></span>
</td>
<td class="nump">240.2<span></span>
</td>
<td class="nump">465.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="num">(67.5)<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">321.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(137.1)<span></span>
</td>
<td class="num">(43.3)<span></span>
</td>
<td class="num">(135.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">4,229.8<span></span>
</td>
<td class="nump">7,078.6<span></span>
</td>
<td class="nump">6,187.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">7,299.4<span></span>
</td>
<td class="nump">6,007.0<span></span>
</td>
<td class="nump">9,173.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(6,397.7)<span></span>
</td>
<td class="num">(5,252.6)<span></span>
</td>
<td class="num">(7,694.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration paid related to Fumapharm AG acquisition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(300.0)<span></span>
</td>
<td class="num">(1,500.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of Nightstar Therapeutics plc, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(744.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from divesiture of Hillerod, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">923.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(424.8)<span></span>
</td>
<td class="num">(514.5)<span></span>
</td>
<td class="num">(770.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(112.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(52.0)<span></span>
</td>
<td class="num">(155.0)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(676.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">479.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(26.9)<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by (used in) investing activities</a></td>
<td class="num">(608.6)<span></span>
</td>
<td class="nump">470.5<span></span>
</td>
<td class="num">(2,046.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(6,679.1)<span></span>
</td>
<td class="num">(5,868.3)<span></span>
</td>
<td class="num">(4,352.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(4.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">2,967.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Net contribution (distribution) to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfCapitalDistribution', window );">Net contribution (distribution) to noncontrolling interest</a></td>
<td class="num">(71.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(58.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">14.6<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="num">(21.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows (used in) financing activities</a></td>
<td class="num">(5,272.7)<span></span>
</td>
<td class="num">(5,860.4)<span></span>
</td>
<td class="num">(4,472.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,651.5)<span></span>
</td>
<td class="nump">1,688.7<span></span>
</td>
<td class="num">(330.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(18.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the year</a></td>
<td class="nump">2,913.7<span></span>
</td>
<td class="nump">1,224.6<span></span>
</td>
<td class="nump">1,573.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the year</a></td>
<td class="nump">1,331.2<span></span>
</td>
<td class="nump">2,913.7<span></span>
</td>
<td class="nump">1,224.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of subsidiaries and affiliates</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(462.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoTherapeuticsIncAgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of subsidiaries and affiliates</a></td>
<td class="num">(141.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of subsidiaries and affiliates</a></td>
<td class="num">(423.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of subsidiaries and affiliates</a></td>
<td class="num">$ (441.0)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfCapitalDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfCapitalDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoTherapeuticsIncAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SangamoTherapeuticsIncAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977635240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th">
<div>Accumulated other comprehensive loss </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Retained earnings</div></th>
<th class="th">
<div>Retained earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Total Biogen Inc. shareholders&#8217; equity</div></th>
<th class="th">
<div>Total Biogen Inc. shareholders&#8217; equity </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Noncontrolling interests</div></th>
<th class="th"><div>2020 Share Repurchase Program</div></th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Total Biogen Inc. shareholders&#8217; equity</div>
</th>
<th class="th"><div>December 2019 Share Repurchase Program</div></th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>December 2019 Share Repurchase Program </div>
<div>Total Biogen Inc. shareholders&#8217; equity</div>
</th>
<th class="th"><div>March 2019 Share Repurchase Program</div></th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>March 2019 Share Repurchase Program </div>
<div>Total Biogen Inc. shareholders&#8217; equity</div>
</th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Total Biogen Inc. shareholders&#8217; equity</div>
</th>
<th class="th"><div>2016 Share Repurchase Program</div></th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Total Biogen Inc. shareholders&#8217; equity</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 12,598.1<span></span>
</td>
<td class="nump">$ 106.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 97.8<span></span>
</td>
<td class="num">$ (318.4)<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 15,810.4<span></span>
</td>
<td class="nump">$ 104.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 12,612.8<span></span>
</td>
<td class="nump">$ 106.1<span></span>
</td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,474.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,430.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,430.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">76.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interests</a></td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock pursuant to the share repurchase program, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock pursuant to the share repurchase program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,352.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,352.6)<span></span>
</td>
<td class="num">$ (1,352.6)<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
<td class="num">$ (3,000.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the share repurchase program, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the share repurchase program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (92.8)<span></span>
</td>
<td class="num">$ (1,259.8)<span></span>
</td>
<td class="nump">$ 1,352.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (171.1)<span></span>
</td>
<td class="num">$ (2,828.9)<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(43.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(43.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">221.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">13,031.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,257.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">5,888.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,888.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,888.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">104.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock pursuant to the share repurchase program, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock pursuant to the share repurchase program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,720.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,720.9)<span></span>
</td>
<td class="num">$ (3,720.9)<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,147.4)<span></span>
</td>
<td class="num">(2,147.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the share repurchase program, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the share repurchase program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (121.5)<span></span>
</td>
<td class="num">$ (3,599.4)<span></span>
</td>
<td class="nump">$ 3,720.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (110.5)<span></span>
</td>
<td class="num">$ (2,036.9)<span></span>
</td>
<td class="nump">$ 2,147.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(53.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">191.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">198.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">13,339.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,455.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">13,343.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,060.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(162.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interests</a></td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock pursuant to the share repurchase program, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock pursuant to the share repurchase program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400.0)<span></span>
</td>
<td class="num">$ (400.0)<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="num">$ (5,000.0)<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,279.1)<span></span>
</td>
<td class="num">(1,279.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the share repurchase program, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the share repurchase program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (60.8)<span></span>
</td>
<td class="num">$ (339.2)<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (121.3)<span></span>
</td>
<td class="num">$ (4,878.7)<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.0)<span></span>
</td>
<td class="num">$ (1,208.1)<span></span>
</td>
<td class="nump">$ 1,279.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">49.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(53.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to share-based payments</a></td>
<td class="nump">204.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 10,686.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,976.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,700.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089967831448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer&#8217;s disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; ophthalmology; and neuropsychiatry. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; acute neurology; and neuropathic pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This standard became effective for us on January 1, 2018, and was adopted using the modified retrospective method. The adoption of this standard as of January 1, 2018, did not change our revenue recognition.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the coverage patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Pharmacy rebates represent our estimated obligations resulting from contractual commitments to sell products to specific pharmacies. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from contracted discounts on product purchased or product dispensed. The calculation of the accrual for these rebates is based on an </span></div><div style="margin-top:9pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimate of the pharmacy&#8217;s buying or dispensing patterns and the resulting applicable contractual rebate rate(s) to be earned over the contractual period.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration with Genentech is within the scope of ASC 808, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs consist of:</span></div><div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</span></div><div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#160;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech and the Roche Group. Pre-tax co-promotion profits consist of net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA include estimates that are based on information received from Genentech and the Roche Group. These estimates are subject to change and actual results may differ. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize royalty revenues on sales of OCREVUS based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our relationship with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize royalty revenues related to sales by our licensees of products covered under patents that we own. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Corporate Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;1</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;3</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Liabilities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of December&#160;31, 2020 and 2019, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within 30 to 90 days.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities and Other Investments</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net on a specific identification basis.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Equity Securities and Venture Capital Funds</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Marketable Equity Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluating Marketable Debt Securities for Other-than-Temporary Impairments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method of Accounting</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalization of Inventory Costs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we capitalized approximately $93.8&#160;million of pre-launch inventory for aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease that we are developing in collaboration with Eisai Co., Ltd. (Eisai). If aducanumab does not receive regulatory approval in the U.S., we would expense this inventory as research and development expense and, under the terms of our collaboration agreement with Eisai to jointly develop and commercialize aducanumab, Eisai would reimburse us for 45.0% of the costs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obsolescence and Unmarketable Inventory</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4NDA_d52adc0a-d056-48aa-8b93-a252ffbfe552">three</span> to five years.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 to 40&#160;years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the useful life or the term of the respective lease</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and Fixtures</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7&#160;years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 20&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer&#160;Software&#160;and&#160;Hardware</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5&#160;years</span></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016 the FASB issued ASU No. 2016-02, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-10, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-11, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Targeted Improvements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-20, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Narrow-Scope Improvement for Lessors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASU No. 2019-01, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Codification Improvements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately $463.0 million and a corresponding operating lease liability of approximately $526.0 million, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the adoption of the new leasing standards, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include other amounts related to our other marketed products and programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to trademarks, trade names and IPR&amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-process Research and Development (IPR&amp;D)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 24, Segment Information,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow and Fair Value Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our derivative instruments and hedging activities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Derivative Instruments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Translation of Foreign Currencies</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Cost of Sales</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Share-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. For the years ended December&#160;31, 2020, 2019 and 2018, advertising costs totaled $111.8 million, $79.2 million and $90.2 million, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016 the FASB issued ASU No. 2016-16,&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;$0.5 billion, offset by a corresponding net increase to retained earnings of approximately&#160;$0.5 billion. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;$0.4 billion&#160;with a corresponding reduction to our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions using a &#8220;more likely than not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. Legal costs associated with legal proceedings are expensed when incurred.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings per Share</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards did not have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard did not have a material impact on our disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This standard makes targeted improvements for collaborative arrangements as follows: </span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Adds unit-of-account guidance to ASC 808, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969219272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB118 Acquisition</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020 we acquired BIIB118 (CK1 inhibitor), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases from Pfizer Inc. (Pfizer). We are developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder in Parkinson&#8217;s disease and plan to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this acquisition, we made an upfront payment of $75.0&#160;million to Pfizer, which was accounted for as an asset acquisition and recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB118 has not yet reached technological feasibility. We may also pay Pfizer up to $635.0&#160;million in potential additional development and commercialization milestone payments as well as tiered royalties in the high single digits to sub-teens.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Nightstar Therapeutics plc</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019 we completed our acquisition of all of the outstanding shares of Nightstar Therapeutics plc (NST), a clinical-stage gene therapy company focused on adeno-associated virus treatments for inherited retinal disorders. As a result of this acquisition, we added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. These assets include BIIB111 (timrepigene emparvovec), which is in Phase 3 development for the potential treatment of choroideremia, a rare, degenerative, X-linked inherited retinal disorder that leads to blindness and currently has no approved treatments, and BIIB112 (RPGR gene therapy), which is in Phase 2/3 development for the potential treatment of X-linked retinitis pigmentosa, which is a rare inherited retinal disease with no currently approved treatments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the acquisition, we paid NST shareholders $25.50 in cash for each issued and outstanding NST share, which totaled $847.6 million. In addition, we paid $4.6 million in cash for equity compensation, which is attributable to pre-combination services and is reflected as a component of the total purchase price paid. The fair value of equity compensation attributable to the post-combination service period was $26.2 million, of which $18.4 million was recognized as a charge to selling, general and administrative expense with the remaining $7.8 million as a charge to research and development expense in our consolidated statements of income. These amounts were associated with the accelerated vesting of stock options previously granted to NST employees and were fully paid in cash as of June 30, 2019. We funded this acquisition through available cash and accounted for it as an acquisition of a business. We finalized purchase accounting for this acquisition in the fourth quarter of 2019.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the IPR&amp;D programs acquired was determined through a probability adjusted discounted cash flow analysis utilizing a discount rate of 12.5%. We recorded IPR&amp;D assets for BIIB111 and BIIB112 at their initial fair values of $480.0 million and $220.0 million, respectively. Some of the more significant assumptions utilized in our asset valuations included the estimated net cash flows for each year for each asset or product, including net revenues, cost of sales, research and development and other operating expenses, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. These fair value measurements were based on significant inputs not observable in the market and thus represent Level 3 fair value measurements. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reco</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gnized goodwill in relation to the fair value associated with NST workforce's expertise and early research in retinal disorders. We also recognized goodwill in relation to the establishment of a deferred tax liability for the acquired IPR&amp;D intangible assets, which have no tax basis. This deferred tax liability is net of the related impacts on the deferred taxes for GILTI. Goodwill that is tax deductible for GILTI purposes is approximately $60.9 million as of December 31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma results of operations as a result of this acquisition have not been presented as this acquisition is not material to our consolidated statements of income. Subsequent to June 7, 2019, the acquisition date, our results of operations include the results of operations of NST.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB100 Acquisition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018 we acquired BIIB100 (XP01 inhibitor) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 investigational oral compound for the potential treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $10.0 million to Karyopharm, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB100 had not yet reached technological feasibility. We may also pay Karyopharm up to $207.0 million in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB104 Acquisition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018 we acquired BIIB104 (AMPA) from Pfizer. BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $75.0 million to Pfizer, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB104 had not yet reached technological feasibility. We may also pay Pfizer up to $515.0 million in total development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIIB110 Acquisition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 we acquired BIIB110 (ActRIIA/B ligand trap) and ALG-802 from AliveGen Inc. (AliveGen).&#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. </span></div>We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of $27.5 million to AliveGen, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB110 had not yet reached technological feasibility. We may also pay AliveGen up to $535.0 million in additional development and commercialization milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969843800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Divestitures</a></td>
<td class="text">Divestitures<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM Corporation (FUJIFILM). Upon the closing of this transaction, we received approximately $881.9 million in cash, which may be adjusted based on other contractual terms, which are discussed below. We determined that the operations disposed of in this transaction did not meet the criteria to be classified as discontinued operations under the applicable guidance.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this transaction, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods. We also may be obligated to indemnify FUJIFILM for liabilities that existed relating to certain business activities incurred prior to the closing of this transaction.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may earn certain contingent payments based on future manufacturing activities at the Hiller&#248;d facility. For the disposition of a business, our policy is to recognize contingent consideration when the consideration is realizable. We currently believe the probability of earning these payments is remote and therefore we did not include these contingent payments in our calculation of the fair value of the operations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this transaction, we entered into certain manufacturing services agreements with FUJIFILM pursuant to which FUJIFILM will use the Hiller&#248;d facility to produce commercial products for us, such as TYSABRI, as well as other third-party products. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, we recognized a total net loss of approximately $124.2 million related to the transaction in our consolidated statements of income. This loss included a pre-tax loss of $55.3 million, which was recorded in loss on divestiture of Hiller&#248;d, Denmark manufacturing operations. The loss recognized was based on exchange rates and business conditions on the closing date of this transaction, and included costs to sell our Hiller&#248;d, Denmark manufacturing operations of approximately $11.2 million and our estimate of the fair value of adverse commitments of approximately $74.0 million, primarily associated with the guarantee of future minimum batch production at the Hiller&#248;d facility. We also recorded a tax expense of $68.9 million related to this transaction.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the closing of this transaction, we sold to FUJIFILM $41.8 million of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we reduced our estimate of the fair value of the adverse commitment associated with the guarantee of future batch production by approximately $62.0&#160;million based on our current manufacturing forecasts. Additionally, we recorded a reduction to our pre-tax loss of approximately $30.5&#160;million due to a refund of interest paid associated with a tax matter.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the fair value of the adverse commitments is a Level 3 measurement and is based on forecasted batch production at the Hiller&#248;d facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969782072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by product are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,742.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,163.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,905.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,312.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,126.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,438.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,253.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,274.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,273.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,101.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,668.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,363.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,096.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,946.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,041.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">839.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZINBRYTA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,112.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,719.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,832.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,780.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,748.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,529.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,946.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,648.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,595.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">787.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,052.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">933.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,163.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,097.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,724.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">795.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">795.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">738.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">738.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,792.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,713.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,666.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,800.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,086.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,886.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenues from two wholesalers accounting for 30.5% and 15.3% of gross product revenues in 2020, 30.0% and 17.2% of gross product revenues in 2019 and 32.0% and 18.4% of gross product revenues in 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, two wholesale distributors individually accounted for approximately 21.1% and 8.5% of net accounts receivable associated with our product sales, as compared to 24.1% and 13.9% as of December&#160;31, 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,198.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,308.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,102.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(635.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,426.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,061.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(763.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(910.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">888.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">666.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,011.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,698.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,242.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,778.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(576.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(724.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,198.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">606.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,686.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,389.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(551.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,887.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,440.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(506.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(646.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">888.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expenses and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,198.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 14.7%, 15.9% and 14.7% of our total revenues in 2020, 2019 and 2018, respectively, were derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenues:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">719.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended December&#160;31, 2020, 2019 and 2018, we recognized $48.6 million, $383.2 million and $206.7 million, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2019, we amended our agreement with a contract manufacturing customer pursuant to which we licensed certain of our manufacturing-related intellectual property to the customer. In the second quarter of 2020, the customer received regulatory approval for its product that is being manufactured using certain of our manufacturing-related intellectual property. As a result we are entitled to $500.0 million in a series of three payments. The first payment became due upon a regulatory approval of such product and was received during the second quarter of 2020. Subsequent payments are due on the first and second anniversaries of the regulatory approval.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other corporate revenues for the year ended December&#160;31, 2020, reflect $346.2&#160;million related to the delivery of the license for certain of our manufacturing-related intellectual property under the amended agreement discussed above and the performance of manufacturing product supply services for such customer. We have allocated the remaining $153.8&#160;million of the $500.0 million transaction price to the performance of manufacturing product supply services for the customer, which we expect to perform through 2026. The value allocated to the manufacturing services was based on expected demand for supply and the fair value of comparable manufacturing and development services.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969838456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled $26.6 million, $52.2 million and $41.9 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included the sale of $14.0 million of work in process inventory.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we sold to FUJIFILM approximately $41.8 million of raw materials that were remaining at the Hiller&#248;d facility on the closing date of this transaction. These materials were sold at cost, which approximates fair value.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969209400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,379.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,881.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,220.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,084.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,408.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,881.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,527.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization and impairments of acquired intangible assets totaled $464.8 million, $489.9 million and $747.3 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets, excluding impairment charges, totaled $255.1 million, $274.0 million and $381.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The decrease in amortization of acquired intangible assets, excluding impairment charges, over the three years was primarily due to a low</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">er rate of amortization for acquired intangible assets.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, amortization and impairment of acquired intangible assets reflects the impact of a $115.0&#160;million impairment charge related to BIIB111, which was obtained as part of our acquisition of NST, a $75.4&#160;million impairment charge related to BIIB054 (cinpanemab) and a $19.3&#160;million impairment charge related to one of our other IPR&amp;D intangible assets.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, amortization and impairments of acquired intangible assets reflects the impact of a $215.9 million impairment charge related to certain IPR&amp;D assets associated with the Phase 2b study of BG00011 (STX-100) for the potential treatment of idiopathic pulmonary fibrosis (IPF), which was discontinued in the third quarter of 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2018, amortization and impairments of acquired intangible assets reflects the impact of a $189.3 million impairment charge related to certain IPR&amp;D assets associated with our vixotrigine program, as discussed below, and a $176.8&#160;million impairment charge related to our U.S. license to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan as well as other amounts related to our other marketed products and programs acquired through business combinations. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of December&#160;31, 2020 and 2019, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of NST and</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Convergence Pharmaceuticals Holdings Ltd. (Convergence). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&amp;D programs with an estimated fair value of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$585.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For additional information on our acquisition of NST, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020 we began experiencing third-party manufacturing delays that may impact our timeline for a potential filing of a Biologics License Application (BLA) for BIIB111 for regulatory approval by up to one year. In addition, we determined that forecasted costs associated with advancing the BIIB111 program through Phase 3 development and potential commercialization will exceed our original estimates. We reassessed the fair value of the program based on these changes in assumptions and determined that the program was partially impaired. We recognized an impairment charge of $115.0&#160;million during the fourth quarter of 2020, which resulted in a reduction of the IPR&amp;D asset from $480.0&#160;million to $365.0&#160;million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB054</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2021 we announced that we discontinued development of BIIB054 as a potential treatment of Parkinson's disease as our Phase 2 SPARK study did not meet its primary or secondary endpoints. Although we made this determination in February 2021, it was based on conditions that existed as of December&#160;31, 2020. As a result, we recognized an impairment charge of approximately $75.4&#160;million during the fourth quarter of 2020 to reduce the fair value of the related IPR&amp;D intangible asset to zero.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPR&amp;D impairment charges were included in amortization and impairment of acquired intangible assets and the gain resulting from the remeasurement of our contingent consideration obligation was recorded in (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income. The fair value of the intangible assets and contingent consideration obligations were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN as we engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies and awaited data and insights from mid-stage clinical trials of vixotrigine in other indications that have since been completed. The fair value of the TGN asset is not significantly in excess of carrying value. As of December&#160;31, 2020, the carrying value associated with our vixotrigine IPR&amp;D assets was $177.5&#160;million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span><span style="color:#679acb;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,757.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,706.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase to goodwill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, end of year</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,762.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,757.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of December&#160;31, 2020, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969504968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,700.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,541.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,541.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,695.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,695.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,920.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,912.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value during the years ended December&#160;31, 2020 and 2019. In addition, there have been no changes in valuation techniques during the years ended December&#160;31, 2020 and 2019. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. The fair value of Level 2 instruments classified as marketable equity securities represents our investments in Sangamo Therapeutics, Inc. (Sangamo) common stock, Denali Therapeutics Inc. (Denali) common stock and Sage Therapeutics, Inc. (Sage) common stock and are valued using an option pricing valuation model as the investments are each subject to certain holding period restrictions. For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Financial Instruments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in marketable equity securities also include shares of Ionis Pharmaceuticals, Inc. (Ionis) common stock acquired in June 2018. Our shares of Ionis common stock were initially subject to certain holding period restrictions that have since expired. The fair value of this investment was a Level 1 measurement as of December&#160;31, 2020. For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$259.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rate was calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success, ranging from 39.9% to certain probability, to the valuation models to estimate the fair values of our contingent consideration obligations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to assets and liabilities that are recorded at fair value on a recurring basis, we record assets and liabilities at fair value on a nonrecurring basis as required by accounting principles generally accepted in the U.S. (U.S. GAAP). Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:38.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Book Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Book Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB111 intangible asset</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">480.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, we recorded a partial impairment charge of $115.0&#160;million related to BIIB111. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.900% Senior Notes due September 15, 2020</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,054.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,557.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,107.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,536.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,515.9&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,553.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen International Neuroscience GmbH (BIN)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of year</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, approximately $110.3 million and $197.7 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, changes in the fair value of our contingent consideration obligations were primarily due to our discontinuing development of BIIB054 for the potential treatment of Parkinson's disease, resulting in a reduction of our contingent consideration obligations of $51.0&#160;million as well as other changes in the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probability and the expected timing of the achievement of certain remaining developmental milestones, changes in the interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, changes in the fair value of our contingent consideration obligations were primarily due to the discontinuation of the Phase 2b study of BG00011 for the potential treatment of IPF resulting in a reduction of our contingent consideration obligations of $61.2&#160;million as well as other changes in the probability and expected timing of achievement of certain developmental milestones, a decrease in interest rates used to revalue our contingent consideration liabilities and the passage of time.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convergence Pharmaceuticals Holdings Limited</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of $274.5 million. As of December&#160;31, 2020 and 2019, the fair value of this contingent consideration obligation was $259.8 million and $244.6 million, respectively. Our most recent valuation was determined based upon net cash flow projections of $400.0 million, probability weighted and discounted using a rate of 0.6%, which is a measure of the credit risk associated with settling the liability. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen International Neuroscience GmbH</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of $81.2 million. We discontinued further development of BIIB054 for the potential treatment of Parkinson's disease based on the results of a Phase 2 study of BIIB054. Additionally, during the third and fourth quarters of 2020 we discontinued other programs related to our acquisition of BIN for which we had immaterial contingent consideration obligations. As a result, the fair value of the contingent consideration obligations related to our acquisition of BIN has been adjusted to zero, resulting in a gain of $101.5 million for the year ended December&#160;31, 2020. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired IPR&amp;D</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the acquired IPR&amp;D assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. These assets are tested for impairment annually until commercialization, after which time the acquired IPR&amp;D will be amortized over its estimated useful life using the economic consumption method. In connection with our acquisition of BIN, we recognized a $110.9&#160;million acquired IPR&amp;D intangible asset. We discontinued further development of BIIB054 for the potential treatment of Parkinson's disease and recognized an impairment charge of $75.4&#160;million during the fourth quarter of 2020 to reduce the fair value of the IPR&amp;D intangible asset to zero. In connection with our acquisition of Stromedix Inc., we recognized a $219.2 million acquired IPR&amp;D intangible asset. During the third quarter of 2019 we discontinued the Phase 2b study of BG00011 for the potential treatment of IPF and recognized an impairment charge of $215.9&#160;million to reduce the fair value of the IPR&amp;D intangible asset to zero. In connection with our acquisition of Convergence, we recognized a $424.6 million acquired IPR&amp;D intangible asset. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling $189.3&#160;million. For additional information on our IPR&amp;D intangible assets, including a discussion of our most significant assumptions, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969150312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,628.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,541.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.3</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15.9</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">733.8</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,887.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,058.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,965.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,970.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.299%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,234.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,230.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,970.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,965.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities available-for-sale as of December&#160;31, 2020 and 2019, was approximately 11&#160;months and 14 months, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,299.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,007.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,173.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the year ended December&#160;31, 2020, 2019 and 2018, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, our strategic investment portfolio was comprised of investments totaling $2,024.6 million and $393.9 million, respectively, which are included in investments and other assets in our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our strategic investment portfolio for the year ended December&#160;31, 2020, was primarily due to our purchases of Sage, Denali and Sangamo common stock, as discussed below. These purchases were reflected as net cash flows used in investing activities within the consolidated statement of cash flows.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage. In connection with the closing of this collaboration in December 2020 we purchased approximately 6.2&#160;million shares of Sage common stock. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sage common stock and a dividend yield of zero based upon the fact that Sage and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately 13&#160;million shares of Denali common stock in September 2020. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased approximately 24&#160;million shares of Sangamo common stock. This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Sangamo, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the carrying value of our investment in Samsung Bioepis totaled 673.8 billion South Korean won ($620.2 million) and 670.8 billion South Korean won ($580.2 million), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980705816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text">Derivative Instruments<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts in effect as of December&#160;31, 2020 and 2019, had durations of 1 to 24 months and 1 to 15 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and fair value changes of excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount<br/>As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,979.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $212.5 million as of December&#160;31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net gains of $0.5 million as of December&#160;31, 2019, and net gains of $27.3 million as of December&#160;31, 2018. We expect the net losses of $212.5 million to be settled over the next 24 months, of which $175.2 million of these losses are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of December&#160;31, 2020 and 2019, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr><td colspan="45" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassified from AOCI into Operating Income</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18.3</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118.6</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.3</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Contracts - Hedging Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Contracts</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of our 2.90% Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of $675.0 million, which were set to expire on September 15, 2020. The interest rate swap contracts were designated as hedges of the fair value changes in our 2.90% Senior Notes attributable to changes in interest rates. The carrying value of our 2.90% Senior Notes as of December&#160;31, 2019, included approximately $2.3 million related to changes in the fair value of these interest rate swap contracts. In May 2020 we settled our interest rate swap contracts, in conjunction with our early redemption of our 2.90% Senior Notes, resulting in a gain of approximately $3.3&#160;million for the year ended December&#160;31, 2020, which was recorded as a component of interest expense in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of December&#160;31, 2020, had remaining durations of 10 months. These contracts have been designated as net investment hedges. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss). The pre-tax portion </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $21.2 million and $1.5 million as of December&#160;31, 2020 and 2019, respectively. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of $0.2 million and $2.9 million as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedges in our consolidated financial statements:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.888%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.1)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency contracts was $1,158.0 million and $793.8 million as of December&#160;31, 2020 and 2019, respectively. Net gains of $30.1 million, net losses of $5.9 million and net gains of $2.0 million related to these contracts were recorded as a component of other income (expense), net for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;Sheet&#160;Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Fair Value Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968128568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">835.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">844.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software and hardware</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,084.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,193.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,838.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,782.3)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,590.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,411.5&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,247.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense totaled $201.9 million, $190.6 million and $269.4 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we capitalized interest costs related to construction in progress totaling approximately $65.2 million, $68.8 million and $54.0 million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. Upon completion, this facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of December&#160;31, 2020 and 2019, we had approximately $1.8 billion and $1.9 billion, respectively, capitalized as construction in progress related to this facility. For the year ended December&#160;31, 2020, we placed approximately $256.8&#160;million of fixed assets in service related to this facility.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Hiller&#248;d, Denmark Manufacturing Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. This transaction included $631.5 million of property, plant and equipment, which was primarily comprised of $312.5 million for buildings and $287.3 million for machinery and equipment. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968118840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real estate, including laboratory and office space, and certain equipment. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases have remaining lease terms ranging from less than one year to ten years. Certain leases include one or more options to renew, exercised at our sole discretion, with renewal terms that can extend the lease term from one year to six years.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we sublease certain real estate to third parties. Our sublease portfolio consists of operating leases, with remaining lease terms ranging from four years to eight years. Our subleases do not include an option to renew as they are coterminous with our operating leases.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMS0xLTEtMTMxMzU_4631686e-fcd9-443b-a344-b69d241e1c2d">Accrued expenses and other</span></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of lease costs in our consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:30.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost primarily related to operating expenses, taxes and insurance associated with our operating leases. As these costs are generally variable in nature, they are not included in the measurement of the operating lease asset and related lease liability.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.07</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets obtained in exchange for lease obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968128568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text">Indebtedness<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.900% Senior Notes due September 15, 2020</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">996.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,739.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,722.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,459.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion, as discussed below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Senior Notes</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we issued senior unsecured notes for an aggregate principal amount of $3.0&#160;billion (2020 Senior Notes) as of December&#160;31, 2020, consisting of the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5&#160;billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030, valued at 99.973% of par; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5&#160;billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050, valued at 99.174% of par.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100.0% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2020 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2020 Senior Notes at a price equal to 101.0% of the principal amount plus accrued and unpaid interest to the date of repurchase.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $24.4&#160;million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our consolidated balance sheet. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on our 2020 Senior Notes is payable May 1 and November 1 of each year, commencing November 1, 2020.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Senior Notes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior secured notes issued in 2015 (the 2015 Senior Notes) as of December&#160;31, 2020:</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022, valued at 99.920% of par;</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025, valued at 99.764% of par; and</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045, valued at 99.294% of par.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original costs associated with this offering of approximately $47.5 million have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheets. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2015 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100.0% of the principal amount plus accrued interest and a specified make-whole amount. Our 2015 Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to 101.0% of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $1.5&#160;billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020, at 99.792% of par. Our 2.90% Senior Notes were senior unsecured obligations. In connection with the 2.90% Senior Notes, we entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. In May 2020 we used the net proceeds from the sale of our 2020 Senior Notes to redeem our 2.90% Senior Notes prior to their maturity and recognized a net pre-tax charge of $9.4&#160;million upon the extinguishment of these notes. This charge, which was recognized in interest expense in other income (expense), net in our consolidated statements of income for the year ended December&#160;31, 2020, reflects the payment of a $12.7&#160;million early call premium and the write off of remaining unamortized original debt issuance costs and discount balances, partially offset by a $3.3&#160;million gain related to the settlement of the associated interest rate swap contracts. For additional information on our interest rate contracts, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Derivative Instruments, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Credit Facility</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility that we entered into in August 2015. As of December&#160;31, 2020, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Maturity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross payments due under our debt arrangements are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:78.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,750.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,500.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our debt is disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968143176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 8.0 million&#160;shares of Preferred Stock authorized, of which 1.75 million shares are authorized as Series A, 1.0 million shares are authorized as Series X junior participating and 5.25 million shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences and the relative, participating, optional or other special rights of the shares of </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during 2020, 2019 and 2018.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes the number of shares authorized, issued and outstanding of our common stock as of December&#160;31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:13.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.6 million shares of our common stock at a cost of approximately $400.0 million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (December 2019 Share Repurchase Program), which was completed as of September 30, 2020. All shares repurchased under our December 2019 Share Repurchase Program were retired. Under our December 2019 Share Repurchase Program, we repurchased and retired approximately 16.7 million shares of our common stock at a cost of approximately $5.0 billion during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (March 2019 Share Repurchase Program), which was completed as of March 31, 2020. All shares repurchased under our March 2019 Share Repurchase Program were retired. Under our March 2019 Share Repurchase Program, we repurchased and retired approximately 4.1 million and 14.7 million shares of our common stock at a cost of approximately $1.3 billion and $3.7 billion during the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018 our Board of Directors authorized a program to repurchase up to $3.5 billion of our common stock (2018 Share Repurchase Program), which was completed as of June 30, 2019. All share repurchases under our 2018 Share Repurchase Program were retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately 8.9 million and 4.3 million shares of our common stock at a cost of approximately $2.1 billion and $1.4 billion during the years ended December&#160;31, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately 10.5 million shares of common stock at a cost of approximately $3.0 billion during the year ended December&#160;31, 2018.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.6)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(243.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.410%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(318.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount reclassified, net of tax, upon adoption of ASU 2016-01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(316.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(243.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from<br/>Accumulated Other Comprehensive Income</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089976649112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings&#160;per Share<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,430.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share for the years ended December&#160;31, 2020, 2019 and 2018, reflects the repurchase of approximately 22.4&#160;million shares, 23.6&#160;million shares and 14.8&#160;million shares of our common stock, respectively, under our share repurchase programs. For additional information on our share repurchase programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Equity</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969835448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NST stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, unrecognized compensation cost related to unvested share-based compensation was approximately $207.6 million, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of 1.9 years.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Plans</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have three share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors Plan</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2006 Directors Plan. We have reserved a total of 1.6 million shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a 1.5-to-1 ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omnibus Plan</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the 2017 Omnibus Equity Plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;8.0 million&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under the Biogen Idec Inc. 2008 Omnibus Equity Plan (2008 Omnibus Equity Plan) as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;1.5-to-1&#160;ratio.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a 10-year term and vest over a period of between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYxNzA_dabd3a6a-1cff-45b6-8845-824a093e53e1">one</span> and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. As of December&#160;31, 2020, all outstanding options were exercisable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock option activity:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.46&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.46&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic values of options exercised in 2020, 2019 and 2018 totaled $2.9 million, $4.2 million and $4.0 million, respectively. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.480%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit realized for stock options</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Stock Units (MSUs)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSUs awarded to employees prior to 2014 vested in four equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between zero and 150.0% of the target number of units granted based on actual stock performance. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSUs awarded to employees in 2014 and thereafter vest in three equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between zero and 200.0% of the target number of units granted based on actual stock performance. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our MSU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:58.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant&#160;Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378.09&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398.61&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.42&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.62&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,000&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.98&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the 30 calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in our valuation are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.713%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range of expected stock price volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8% - 44.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2% - 33.6%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5% - 32.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range of risk-free interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.41% - 1.48%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.46% - 2.53%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9% - 2.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 calendar day average stock price on grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$257.83 - $325.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$228.59 - $331.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$279.47 - $346.76</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average per share grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$398.61</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$378.08</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$378.85</span></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of MSUs vested in 2020, 2019 and 2018 totaled $26.9 million, $32.5 million and $26.9 million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Settled Performance Units (CSPUs)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CSPUs awarded to employees vest in three equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between zero and 200.0% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the 30 calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our CSPU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:81.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash paid in settlement of CSPUs vested in 2020, 2019 and 2018 totaled $3.8 million, $10.6 million and $15.1 million, respectively.&#160; </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-vested Restricted Stock Units (PUs)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in three equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between zero and 200.0% of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the 30 calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:81.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All PUs that vested in 2020, 2019 and 2018 were settled in cash totaling $3.4 million, $10.4 million and $17.0 million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Stock Units (PSUs)</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PSUs Settled in Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants may ultimately earn between zero and 200.0% of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSUs that settle in stock activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.39&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.35&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323.42&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,000&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.19&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> PSUs settled in stock granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PSUs Settled in Cash</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNTQ_9f998ee0-5669-4526-a3e7-3980eafec54f">three</span> performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yOTIvZnJhZzo5YWM5MTM4NjE0Y2U0ODkwYmRkZmYwNWYxMTAyMWE3YS90ZXh0cmVnaW9uOjlhYzkxMzg2MTRjZTQ4OTBiZGRmZjA1ZjExMDIxYTdhXzQzOTgwNDY1MjYyNjU_9f998ee0-5669-4526-a3e7-3980eafec54f">three</span> annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants may ultimately earn between zero and 200.0% of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the 30 calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSUs that settle in cash activity:</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> PSUs settled in cash granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Vested Restricted Stock Units (RSUs)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded to employees generally vest no sooner than one-third per year over three years on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">938,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.55&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318.87&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(440,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.45&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.46&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,018,000&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.46&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> RSUs granted in 2020 primarily represent RSUs granted in conjunction with our annual awards made in February 2020 and awards made in conjunction with the hiring of new employees. RSUs granted in 2020 also include approximately 10,000 RSUs granted to our Board of Directors.</span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted in 2019 and 2018 had weighted average grant date fair values of $304.44 and $316.32, respectively.</span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of RSUs vested in 2020, 2019 and 2018 totaled $140.5 million, $131.5 million and $111.7 million, respectively.&#160; </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (ESPP)</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015 our shareholders approved the 2015 ESPP. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is 6.2 million. </span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our ESPP activity:</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.523%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued under the 2015 ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received under the 2015 ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089966099032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income tax expense and the income tax expense consist of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income before income taxes (benefit):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,290.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,725.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,877.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,757.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,400.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,047.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,125.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,899.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income tax expense (benefit):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">843.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,090.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,317.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,749.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,143.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,905.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,074.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">992.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,158.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,425.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Tax Act</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 35.0% to 21.0%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries and collaborations to immediate U.S. taxation as GILTI or Subpart F income, includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax) and base erosion prevention measures on U.S. earnings and reduces the effective tax rate on income that comes from U.S. exports, called Foreign Derived Intangible Income. These changes became effective in 2018. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, we recognized a net reduction of $34.6 million in our estimated Transition Toll Tax, an expense of $12.7 million to remeasure our deferred tax balances, an expense of $135.8 million related to establishing deferred taxes for GILTI and an expense of $11.0 million to reflect other aspects of the 2017 Tax Act.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transition Toll Tax</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of 15.5% and all other earnings were taxed at a rate of 8.0%.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we have accrued income tax liabilities of $697.0 million under the Transition Toll Tax. Of the amounts accrued as of December&#160;31, 2020, $62.0 million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unremitted Earnings</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, we considered our earnings not to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences of approximately $1.5 billion as of December&#160;31, 2020, primarily arising through the impacts of purchase accounting. These permanently reinvested basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which were considered probable as of December&#160;31, 2020. The residual U.S. tax liability, if these differences reverse, would be between $300.0 million and $400.0 million as of December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was signed into law in the U.S. in March 2020. The CARES Act adjusted a number of provisions of the tax code, including the calculation and eligibility of certain deductions and the treatment of net operating losses and tax credits. The enactment of the CARES Act did not result in any material adjustments to our income tax provision for the year ended December&#160;31, 2020, or to our net deferred tax assets as of December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TECFIDERA</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 and September 2020 judgments were entered in favor of the defendants in the patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in West Virginia and Delaware. We have appealed the judgments in both actions. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. market and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA significantly reduced our TECFIDERA revenues during the year ended December&#160;31, 2020, and is expected to have a substantial negative impact on our TECFIDERA revenues for as long as there is generic competition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have assessed the realizability of our deferred tax assets that are dependent on future expected sales of TECFIDERA in the U.S. and reduced the net value of certain deferred tax assets by approximately $1.7&#160;billion and reduced the net value of deferred tax liabilities associated with GILTI and tax credits by approximately $1.6&#160;billion. For the year ended December&#160;31, 2020, the income tax expense associated with these reductions was approximately $90.3&#160;million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets and Liabilities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory, other reserves and accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,546.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,380.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,080.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,753.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,278.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,905.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(396.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(350.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,143.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,381.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(174.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,617.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation, amortization and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(227.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,941.5)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,484.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance between December&#160;31, 2020 and 2019, was primarily related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to deferred tax assets and liabilities, we have recorded deferred charges related to intra-entity sales of inventory. As of December&#160;31, 2020 and 2019, the total deferred charges were $142.2 million and $243.8 million, respectively. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Credits and net operating loss utilization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divestiture of Denmark manufacturing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal reorganization of certain intellectual property rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. tax reform</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss tax reform</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, our effective tax rate was primarily increased by the income tax expense related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above, and partially offset by the benefit recognized on the effective settlement of certain tax matters. Additionally, our 2019 effective tax rate benefited from </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an internal reorganization of certain intellectual property rights and the enactment of a new taxing regime in the country and certain cantons of Switzerland, which we refer to as Swiss Tax Reform, partially offset by tax expense related to the divestiture of our Hiller&#248;d, Denmark manufacturing operations. Although we recognized a loss on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, the divestiture required us to write-off certain deferred tax assets and resulted in a taxable gain in certain jurisdictions. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the 2019 internal reorganization of certain intellectual property rights, we recorded a deferred tax asset of $754.1 million and a deferred tax liability of $603.3 million as of December&#160;31, 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, as compared to 2018, the decrease in our effective tax rate was primarily due to the combination of the internal reorganization of certain intellectual property rights and the impact of the Swiss Tax Reform. This decrease was partially offset by a $68.9&#160;million tax expense related to the divestiture of our subsidiary that owned our Hiller&#248;d, Denmark manufacturing operations. We also had a higher effective tax rate in 2018 resulting from the unfavorable effects of the 2017 Tax Act and our sale of inventory, the tax effect of which had been included within prepaid taxes at January 1, 2018, at a higher effective tax rate than the 2018 statutory tax rate.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Attributes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had net operating losses and general business credit carry forwards for U.S. federal income tax purposes of approximately $0.6 million and $1.3 million, respectively, which begin to expire in 2026. For U.S. state income tax purposes, we had research and investment credit carry forwards of approximately $142.4 million that begin to expire in 2022. For foreign income tax purposes, we had $18.0 billion of Swiss federal net operating loss carryforwards that begin to expire in 2025 and $16.8&#160;billion of Swiss cantonal net operating loss carryforwards that begin to expire in 2025.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries, net of the recorded valuation allowance. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to adjust or establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance at January 1,</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions of prior periods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reductions for tax positions of prior periods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statute expirations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement refund (payment)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance ar December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 activity reflects the impact of the effective settlement of certain tax matters. We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits as of December&#160;31, 2020, 2019 and 2018, are $68.8 million, $122.7 million and $109.1 million (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize potential interest and penalties related to unrecognized tax benefits in income tax expense. In 2020, 2019 and 2018 we recognized a net interest and penalty expense of $1.0 million, $4.7 million and $2.2 million, respectively. We have accrued $21.2 million and $20.0 million for the payment of interest and penalties as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal and State Uncertain Tax Positions</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could decrease by up to approximately $25.0 million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Bioverativ Spin-off</span></div>On February 1, 2017, in connection with the spin-off of our hemophilia business, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders pursuant to a separation agreement. In March 2018 Bioverativ was acquired by Sanofi S.A. (Sanofi) and is now an indirect wholly-owned subsidiary of Sanofi. The spin-off of our hemophilia business was intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Our 2017 tax return position remains open to audit. Bioverativ and Sanofi agreed to indemnify us for certain potential liabilities that may arise.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969471704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text">Other Consolidated Financial Statement Detail<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplemental Cash Flow Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information for the years ended December&#160;31, 2020, 2019 and 2018, is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">906.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,064.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,007.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-cash Operating, Investing and Financing Activity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2018 we accrued $300.0 million upon reaching $20.0 billion in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately $12.4 million and $50.0 million in our consolidated balance sheets as of December&#160;31, 2020 and 2019, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Property, Plant and Equipment,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(222.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(187.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(200.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497.4&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, net unrealized and realized gains on our holdings in equity securities were approximately $681.8&#160;million and $12.1&#160;million, respectively, compared to net unrealized and realized gains of $150.1&#160;million and $50.0&#160;million in 2019. The net unrealized gains recognized during the year ended December&#160;31, 2020, primarily reflects an increase in the fair value of Denali and Sangamo common stock of approximately $703.9&#160;million.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of December&#160;31, 2020, 2019 and 2018:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">681.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,145.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,765.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $1,329.6 million and $1,348.9 million as of December&#160;31, 2020 and 2019, respectively, and include accrued income taxes totaling $709.9 million and $803.3 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969953128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text">Collaborative and Other RelationshipsIn connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.<div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our collaboration partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of PPMS and RMS; and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to OCREVUS and any other collaboration anti-CD20 products in development in exchange for a royalty as well as our rights to GAZYVA in exchange for the compensation described in the collaboration arrangement. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0 million. There will be a 50.0% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN Profit Share</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a 30.0% share on the first $50.0 million of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until GAZYVA First Non-CLL FDA Approval</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Non-CLL GAZYVA FDA Approval</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least $150.0 million or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $150.0 million.</span></div><div style="margin-top:9pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second GAZYVA Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN pre-tax profits in the U.S. in excess of $50.0&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, was 37.5%.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between 30.0% and 37.5% based on certain events.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share on the first $50.0 million of operating profits earned each calendar year. Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until First GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of GAZYVA pre-tax profits in excess of $50.0&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, was 37.5%. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ionis Pharmaceuticals, Inc. </span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2012 we entered into a collaboration and license agreement with Ionis pursuant to which we have an exclusive, worldwide license to develop and commercialize SPINRAZA for the treatment of SMA.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended December&#160;31, 2020, 2019 and 2018, totaled $286.6 million, $293.0 million and $238.0 million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2012 Ionis Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three gene targets. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, Ionis is responsible for global development of any product candidate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to $70.0 million to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to $130.0 million in additional milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if we successfully develop the product candidate after option exercise. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this agreement, we made an upfront payment of $30.0 million to Ionis and agreed to make potential additional payments, prior to licensing, of up to $10.0 million based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this $10.0 million developmental milestone upon the selection of BIIB080 (tau ASO), which is currently in Phase 1 development for the potential treatment of Alzheimer's disease. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080. In connection with the option exercise, we made a payment of&#160;$45.0 million&#160;to Ionis, which was recorded as research and development expense in our consolidated statements of income. Future payments may include additional milestone payments of up to&#160;$155.0 million&#160;and royalties on future sales in the low- to mid-teens if we successfully develop the product candidate after option exercise.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Ionis Agreement</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 we closed a 10-year exclusive collaboration agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (2018 Ionis Agreement) for a total payment of $1.0 billion, consisting of an upfront payment of $375.0 million and the purchase of approximately 11.5 million shares of Ionis common stock at a cost of $625.0 million.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing, we recorded $50.9 million of the $375.0 million upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining $324.1 million as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 11.5 million shares of Ionis common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of $462.9 million in investments and other assets in our consolidated balance sheets reflecting the fair value of the Ionis common stock as of the purchase date and a charge of $162.1 million to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the Ionis common stock. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in Ionis common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the option to license therapies arising out of the 2018 Ionis Agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to $125.0 million or $270.0 million for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020 and 2019, we incurred milestones of $11.3&#160;million and $30.0 million, respectively, related to the advancement of neurological targets identified under the 2018 Ionis Agreement.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 SMA Collaboration Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of such therapies.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this agreement, we made a $25.0 million upfront payment to Ionis and we may pay Ionis up to $260.0 million in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to $800.0 million in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Long-term Strategic Research Agreement</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 we entered into a six-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the potential treatment of neurological diseases.&#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the agreement. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-ALS antisense product candidates, Ionis is responsible for global development through the completion of a Phase 2 trial and we provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a $70.0 million license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to $130.0 million, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (tofersen), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made a payment of $35.0 million to Ionis, which was recorded as research and development in our consolidated statements of income. Future payments may include potential post-licensing milestone payments of up to $55.0 million and royalties in the low- to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of tofersen following the option exercise. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ending December&#160;31, 2020, 2019 and 2018, we incurred milestones of $28.0 million, $20.0 million and $18.0 million, respectively, related to the advancement of programs under this agreement, which were recorded as research and development expense in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BAN2401 Collaboration</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the BAN2401 Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai serves as the global operational and regulatory lead for BAN2401 and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. If BAN2401 receives marketing approval, we and Eisai will co-promote BAN2401 and share profits equally. In addition, the BAN2401 Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BAN2401 Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab (Aducanumab Option) and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (the Aducanumab Collaboration Agreement). </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments. Eisai has not yet exercised its Anti-Tau Option.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expenses related to the BAN2401 Collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:55.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab Collaboration Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Aducanumab Collaboration Agreement, we and Eisai will co-promote aducanumab with a region-based profit split and we lead the ongoing development of aducanumab.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, based on a pre-specified futility analysis, we discontinued the global Phase 3 trials, EMERGE and ENGAGE, designed to evaluate the efficacy and safety of aducanumab in patients with early Alzheimer's disease. A new analysis of a larger dataset from these trials, conducted in scientific collaboration with the FDA, showed that the Phase 3 EMERGE study met its pre-specified primary and secondary endpoints. In the first quarter of 2019, as a result of the decision to discontinue the Phase 3 EMERGE and ENGAGE trials following the futility analysis, we accrued and subsequently paid approximately $45.0 million related to the termination of various clinical trials and research and development contracts net of the expected 45.0% Eisai reimbursement of development costs incurred under the Aducanumab Collaboration Agreement. In October 2019 we and Eisai announced that we plan to pursue regulatory approval for aducanumab in the U.S. In July 2020 we completed the submission of a BLA for the approval of aducanumab to the FDA. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period through March 31, 2018, we were responsible for 100.0% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for 15.0% of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for 45.0% of aducanumab development expense incurred. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, we recognized net profit-sharing income of $33.8&#160;million to reflect Eisai's 45.0% share of the $75.0&#160;million milestone expense related to the submission of the BLA for the approval of aducanumab to the FDA.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a 55.0% share of the potential profits (losses) in the U.S., a 68.5% share of the potential profits (losses) in the European Union (E.U.) and a 20.0% share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab collaboration third party milestone expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB Pharma S.A.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB Pharma S.A. (UCB) to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expenses, are shared equally between us and UCB. Upon marketing approval, we and UCB will co-promote dapirolizumab pegol and share profits equally. A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alkermes</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for VUMERITY, a novel fumarate for the treatment of RMS. In October 2019 the FDA approved VUMERITY in the U.S. for the treatment of RMS. In November 2019 VUMERITY became commercially available in the U.S.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we received an exclusive, worldwide license to develop and commercialize VUMERITY and we pay Alkermes a royalty of 15.0% on worldwide net commercial sales of VUMERITY. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates, other than VUMERITY, developed under the exclusive license from Alkermes. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2019, following the FDA's approval of VUMERITY, we paid Alkermes $155.0 million in milestone payments, which were recorded in intangible assets in our consolidated balance sheets and will be amortized over the useful life of the product. For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $32.4 million, $53.5 million and $68.7 million, respectively, in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alkermes currently supplies VUMERITY to us pursuant to a supply agreement. In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net commercial sales of VUMERITY that is manufactured by us or our designee.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bristol-Myers Squibb Company</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092 (gosuranemab), an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with Alzheimer's disease. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we received worldwide rights to gosuranemab and are responsible for the full development and potential commercialization of gosuranemab in Alzheimer's disease and progressive supranuclear palsy (PSP). </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we announced that the Phase 2 PASSPORT study investigating gosuranemab in individuals with PSP did not meet its primary endpoint. Based on these results, we discontinued development of gosuranemab in PSP and other primary tauopathies. We will continue our ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease, given differences in disease pathology.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this agreement, we made an upfront payment of $300.0 million to BMS and assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. We may pay BMS up to $360.0 million in additional milestone payments, and potential royalties, and we may pay the former shareholders of iPierian up to $370.0 million in remaining milestone payments as well as potential royalties on net commercial sales.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $62.4 million, $144.0 million and $97.0 million, respectively, in research and development expense in our consolidated statements of income related to this agreement.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acorda Therapeutics, Inc.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone of $15.0 million, due if ex-U.S. net sales reach $100.0 million over a period of four consecutive quarters, was recognized during the third quarter of 2020 and capitalized within intangible assets, net in our consolidated balance sheet. Royalty payments are recognized in cost of sales within our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes Inc., who acquired Elan Drug Technologies, the original party to the license with Acorda. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ending December&#160;31, 2020, 2019 and 2018, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were $44.5 million, $42.0 million and $36.5 million, respectively.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize zuranolone (SAGE-217) for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for the potential treatment of essential tremor and other neurological disorders. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection of the closing of this transaction in December 2020 we purchased $650.0&#160;million of Sage common stock, or approximately 6.2&#160;million shares at approximately $104.14 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sage common stock acquired and a charge of approximately $209.0&#160;million to research and development expense in our consolidated statements of income to reflect the premium paid for the Sage common stock. We also made an upfront payment of $875.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also pay Sage development and commercial milestone payments that could total up to approximately $1.6&#160;billion if all the specified milestones set forth in this agreement are achieved. Both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and will pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATV enabled anti-amyloid beta</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program and a second program utilizing its Transport Vehicle technology. Further, we have a right of first negotiation on two additional Transport Vehicle-enabled therapeutics, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this collaboration we purchased approximately $465.0&#160;million </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Denali common stock in September 2020, or approximately 13&#160;million shares at approximately $34.94 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Denali common stock acquired and a charge of approximately $41.3&#160;million to research and development expense in our consolidated statements of income to reflect the premium paid for the Denali common stock. We also made an upfront payment of $560.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Denali development and commercial milestone payments that could total up to approximately $1.1&#160;billion if the milestones related to the LRRK2 program are achieved. Under this agreement, both companies share responsibility and costs for global development based on specified percentages and we are responsible for commercialization and will pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, we recorded $8.8&#160;million in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction in April 2020 we purchased $225.0&#160;million of Sangamo common stock, or approximately 24&#160;million shares at approximately $9.21 per share, which are subject to transfer restrictions. We recorded an asset in investments and other assets in our consolidated balance sheets to reflect the initial fair value of the Sangamo common stock acquired and a charge of approximately $83.0&#160;million to research </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development expense in our consolidated statements of income to reflect the premium paid for the Sangamo common stock. We also made an upfront payment of $125.0&#160;million that was recorded as research and development expense.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay Sangamo research, development, regulatory and commercial milestone payments that could total up to approximately $2.4&#160;billion if we select all of the targets allowed under this agreement and all the specified milestones set forth in this agreement are achieved. Of this amount, up to $80.0&#160;million relates to the selection of targets, $1.9&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones and $380.0&#160;million relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. In addition, we will pay Sangamo tiered royalties on potential net commercial sales of any products developed under this collaboration in the high single digit to double digit sub-teen percentages.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, we recorded $6.4&#160;million in research and development expense in our consolidated statements of income related to this collaboration.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recorded $92.1 million, $77.0 million and $48.6 million, respectively, as research and development expense in our consolidated statements of income related to other research and discovery related arrangements. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;Samsung BioLogics contributed 280.5 billion South Korean won (approximately $250.0 million) for an 85.0% ownership interest in Samsung Bioepis and we contributed 49.5 billion South Korean won (approximately $45.0 million) for the remaining 15.0% ownership interest.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0%, which reflected the effect of previous equity financings in which we did not participate, to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics.&#160;As of December&#160;31, 2020, our ownership percentage remained at approximately 49.9%.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019 we restarted recognizing our share of Samsung Bioepis' income (losses), and we began recognizing amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting requires us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences are amortized over their economic life. The total basis difference was approximately $675.0 million and relates to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;D for marketed products will be amortized, net of tax, over their estimated useful lives of 15 years.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The former chief executive officer (the incumbent chairman of the board) and the chief financial officer of our joint venture partner, Samsung BioLogics, is currently subject to ongoing criminal proceedings that we continue to monitor. While these proceedings could impact the operations of Samsung Bioepis and its business, we have assessed the value of our investment in Samsung Bioepis and continue to believe that the fair value of the investment is in excess of its net book value.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, we recognized net income on our investment of $5.3 million, reflecting our share of income totaling $45.3 million offset by amortization of basis differences totaling $40.0 million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2019, we recognized net losses on our investment of $79.4 million, reflecting our share of losses totaling $1.2 million and amortization of basis differences totaling $78.2 million.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the carrying value of our investment in Samsung Bioepis totaled 673.8 billion South Korean won ($620.2 million) and 670.8 billion South Korean won ($580.2 million), respectively, which is classified as a component of investments and other assets within our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Transaction</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in 2019 and $37.0 million was recorded as an intangible asset in 2019. Additionally, during the third quarter of 2020, we paid Samsung Bioepis a $15.0 million development milestone, which was included in research and development expense in our consolidated statements of income. We may pay Samsung Bioepis up to $195.0&#160;million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 commercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China. </span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2013 we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&#160;As discussed above, we have an option to extend this agreement by an additional five years. Under this agreement, we have made upfront and clinical development milestone payments totaling $46.0 million, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of $25.0 million upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling $75.0 million as intangible assets, net in our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie Inc. (AbbVie) related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in Europe in the fourth quarter of 2018.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenues on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended December&#160;31, 2020, 2019 and 2018, we recognized a net profit-sharing expense of $266.5 million, $241.6 million and $187.4 million, respectively, to reflect Samsung Bioepis' 50% sharing of the net collaboration profits. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the technical development services agreement, we provided Samsung Bioepis technical development and technology transfer services, which included, but were not limited to, cell culture development, purification process development, formulation development and analytical development. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the divestiture of our Hiller&#248;d, Denmark manufacturing operations in August 2019, FUJIFILM assumed responsibility for the manufacture of clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis. We no longer recognize revenues for the manufacturing completed after the divestiture date under the manufacturing agreements with Samsung Bioepis. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single digit royalties on biosimilar products developed and commercialized by Samsung Bioepis.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recognized $20.9 million, $106.2 million and $96.4 million, respectively, in revenues under the license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were $5.1 million and $85.0 million as of December&#160;31, 2020 and 2019, respectively. Amounts payable to Samsung Bioepis as of December&#160;31, 2020, were $99.0&#160;million. Amounts payable to Samsung Bioepis as of December 31, 2019, consisted of the $100.0 million upfront payment related to the transaction we completed in December 2019, as discussed above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089967823016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text">Investments in Variable Interest Entities<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including aducanumab (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017 we amended the terms of the Neurimmune Agreement and made a $150.0 million payment to Neurimmune in exchange for a 15.0% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. In May 2018 we made an additional $50.0 million payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalties payable on potential commercial sales of aducanumab, by an additional 5.0%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, now range from the high single digits to sub-teens. As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interests in the fourth quarter of 2017 and the second quarter of 2018, as applicable.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $75.0&#160;million upon the regulatory filing with the FDA for the approval of aducanumab. During the second quarter of 2020, we paid Neurimmune $75.0&#160;million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests for the year ended December&#160;31, 2020. In addition, for the year ended December&#160;31, 2020, we recognized net profit-sharing income of $33.8&#160;million to reflect Eisai's 45.0% share of the $75.0&#160;million milestone expense.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to approximately $200.0 million in milestones to Neurimmune in 2021, which includes $100.0&#160;million if launched in the U.S., $50.0&#160;million if launched in three or more countries within the E.U. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending December&#160;31, 2020, 2019 and 2018, amounts reimbursed were immaterial.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $12.8 million and $22.7 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969806968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text">Litigation<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aducanumab Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in an action filed by a shareholder on November 13, 2020, in the U.S. District Court for the Central District of California and an action filed by a shareholder on January 5, 2021, in the U.S. District Court for the District of Massachusetts. Both actions allege violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and are seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time. No trial date has been set.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in May 2035. No hearing has been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In June 2019 the Danish court denied Fresenius Kabi's request for a preliminary injunction. Fresenius Kabi has appealed that decision and was permitted to add a claim of infringement of the Danish counterpart of the &#8216;510 patent, and the appeal is pending. In July 2020 the Danish Patent Board of Appeal revoked the Danish Utility Models that were the subject of Fresenius Kabi&#8217;s October 2018 request for a preliminary injunction and Fresenius Kabi has appealed those revocations to Denmark&#8217;s Maritime and Commercial High Court. No hearing has been scheduled in that appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen (Denmark) A/S in Denmark&#8217;s Maritime and Commercial High Court alleging infringement of another Danish Utility Model. A hearing has been scheduled for May 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. A hearing has been set for August 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter PLC (Gedeon Richter) commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of the German counterpart of European Patent No. 3 212 667 (the '667 Patent), which was issued in September 2018 and expires in October 2035, and seeking damages and injunctive relief. A hearing has been set for November 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Dispute with Jacobs Switzerland GmbH</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jacobs Switzerland GmbH, the general contractor for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, claimed additional payments were due for construction costs. We have reached an agreement in principle to resolve the claim.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Petition for Inter Partes Review</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018 Mylan Pharmaceuticals, Inc. (Mylan) filed a petition that was granted by the U.S. Patent Trial and Appeal Board (PTAB) for </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. In February 2020 the PTAB issued a final written decision upholding the patentability of the &#8216;514 Patent and in April 2020 Mylan filed an appeal in the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit), which is pending. </span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 to 2020, we filed patent infringement proceedings relating to TECFIDERA Orange-Book listed patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act (the Delaware Actions), against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Limited, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Shilpa Medicare Limited, Slayback Pharma LLC, Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. (collectively, the Delaware Defendants) in the U.S. District Court for the District of Delaware (the Delaware Court) and against Mylan in the U.S. District Court for the Northern District of West Virginia (the West Virginia Court).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, the West Virginia Court entered judgment for Mylan that the asserted claims of the &#8216;514 Patent are invalid for lack of written description. We appealed the judgment to the Federal Circuit and the appeal is pending.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Court entered judgment for the Delaware Defendants on the grounds that the judgment of the West Virginia Court applies to the Delaware Actions under principles of collateral estoppel. We have appealed the judgments and the appeal is pending.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Patent Office Oppositions</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 the European Patent Office (EPO) revoked our European Patent No. 2 137 537, which covers the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. We have appealed to the Technical Boards of Appeal of the EPO and a hearing date has been set for January 2022. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018 the EPO revoked Forward Pharma's European Patent No. 2 801 355, which expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and a hearing has been set for September 2021.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Revocation Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent No. 215263 (the Polish '263 Patent), which corresponds to our European Patent No. 1 485 127 (the E.U. '127 Patent) and covers administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent expires in February 2023. A hearing was held in January 2021 and a decision is pending. In August 2020 a related entity, Polpharma Biologics S.A., also brought an action seeking to revoke the Polish &#8216;263 Patent. No hearing has been set in this matter.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of the Hague, Netherlands (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts, respectively, of the E.U. '127 Patent, which also cover administration of natalizumab (TYSABRI) to treat MS and expire in February 2023. The Dutch and German counterparts were ruled invalid. The decision in the Dutch action was affirmed on appeal and the German appeal has been withdrawn. No hearing has been set in the Italian action.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) have each filed applications in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) seeking to annul decisions of the European Medicines Agency (EMA) refusing to validate Polpharma&#8217;s and Mylan Ireland&#8217;s respective applications to market a generic version of TECFIDERA. The EMA&#8217;s refusals were on the grounds that TECFIDERA benefits from regulatory data protection. Biogen and the European Commission were granted leave to intervene in support of the EMA in the case brought by Polpharma. That case was heard in July 2020 and we are awaiting a decision. We intend to seek leave to intervene in support of the EMA in the case brought by Mylan Ireland. No hearing has been set in that matter.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089967776616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18.0% on annual worldwide net commercial sales up to $2.0 billion and 25.0% on annual worldwide net commercial sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013 and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net commercial sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. Under our agreement with Alkermes, we make royalty payments to Alkermes on worldwide net commercial sales of VUMERITY using a royalty rate of 15.0%, which are recorded as cost of sales in our consolidated statements of income. Royalties payable on net commercial sales of VUMERITY are subject, under certain circumstances, to tiered minimum annual payment requirements for a period of five years following FDA approval. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence, we agreed to make additional payments based upon the achievement of certain milestone events. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the acquisition of Convergence occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with this transaction at their fair value on the acquisition date and revalue the remaining obligations each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to these acquisitions.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumapharm AG</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We were required to make contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached $20.0 billion, at which time no further contingent payments were due. During the first quarter of 2019 we paid the final $300.0&#160;million contingent payment as we achieved the $20.0 billion cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2018.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of December&#160;31, 2020, we could trigger potential future milestone payments to third parties of up to approximately $10.2 billion, including approximately $1.9 billion in development milestones, approximately $1.3 billion in regulatory milestones and approximately $7.0 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of December&#160;31, 2020, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to $86.2&#160;million in milestones in 2021 under our current agreements. Additionally, if aducanumab receives regulatory approval in the jurisdictions where we have submitted filings, we may pay up to $200.0 million in milestones to Neurimmune in 2021, which includes $100.0&#160;million if launched in the U.S., $50.0&#160;million if launched in three or more countries within the E.U. and $50.0&#160;million if launched in Japan. Milestones payable to Neurimmune are shared expenses under the Aducanumab Collaboration Agreement with Eisai. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020 we paid Neurimmune $75.0&#160;million upon the completed submission of the BLA for the approval of aducanumab to the FDA, which was recognized as a charge to noncontrolling interests for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $21.7 million in our consolidated balance sheet for expenditures incurred by CROs as of December&#160;31, 2020. We have approximately $593.0 million in cancellable future commitments based on existing CRO contracts as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM, we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of December&#160;31, 2020, we have approximately $79.6 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we have accrued income tax liabilities of $697.0 million, respectively, under the Transition Toll Tax. Of the amounts accrued as of December&#160;31, 2020, $62.0 million is expected to be paid within one year. The Transition Toll Tax will be paid over an eight--year period, which started in 2018, and does not accrue interest. For additional information on the Transition Toll Tax, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be partially operational during the first half of 2021. As of December&#160;31, 2020, we had contractual commitments of approximately $9.3&#160;million related to the construction of this facility.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968076632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Guarantees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesTextBlock', window );">Guarantees</a></td>
<td class="text">Guarantees<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we did not have significant liabilities recorded for guarantees.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of December&#160;31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI http://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968102376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Savings Plan</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of 21. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense related to our 401(k) Savings Plan totaled $44.3 million, $44.8 million and $42.2 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of December&#160;31, 2020 and 2019, totaled approximately $120.0 million and $114.6 million, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension Plans</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was 1.00% in 2020, 2019 and 2018. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. As of December&#160;31, 2020 and 2019, the Swiss plan had an unfunded net pension obligation of $75.7 million and $42.9 million, respectively, and plan assets that totaled $170.0 million and $127.1 million, respectively. In 2020, 2019 and 2018 we recognized expense totaling $15.5 million, $14.7 million and $14.8 million, respectively, related to our Swiss plan, of which $2.6 million, $1.2 million and $1.3 million, respectively, was included in other income (expense), net.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the German plans are unfunded and totaled $75.5 million and $59.6 million as of December&#160;31, 2020 and 2019, respectively. Net periodic pension cost related to the German plans totaled $6.2 million, $5.1 million and $5.3 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively, of which $2.0 million, $1.4 million and $1.5 million, respectively, was included in other income (expense), net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968151352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</span></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain certain financial information by geographic area:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,656.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,321.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,844.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,713.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,794.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,162.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,674.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,800.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,370.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,886.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,903.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,152.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,442.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, 2019 and 2018, approximately $2,180.6 million, $2,028.8 million and $1,748.5 million, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 we completed the sale of all of the outstanding shares of our subsidiary that owned our biologics manufacturing operations in Hiller&#248;d, Denmark to FUJIFILM. As of December&#160;31, 2018, approximately $646.5 million of our long-lived assets were related to our manufacturing facility in Hiller&#248;d, Denmark.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Property, Plant and Equipment,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977420760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text">Quarterly Financial Data (Unaudited)<div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:36.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Year</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,904.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,795.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,690.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,301.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,534.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,681.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,376.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,852.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,444.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,080.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,270.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,927.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,361.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,639.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,392.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,606.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,060.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,399.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">701.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.60&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.86&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.08&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.59&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.46&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.80&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:36.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Year</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,680.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,880.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,894.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,924.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">517.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,489.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,616.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,600.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,671.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,377.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,887.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,140.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,170.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,224.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,422.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,545.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,439.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,545.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,439.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980509880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our agreements with Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics), we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe and have an option to acquire exclusive rights to commercialize these products in China. Additionally, we have exclusive rights to commercialize two potential ophthalmology biosimilar products, SB11, a proposed ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the United States (U.S.), Canada, Europe, Japan and Australia. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. This standard became effective for us on January 1, 2018, and was adopted using the modified retrospective method. The adoption of this standard as of January 1, 2018, did not change our revenue recognition.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under the FASB Accounting Standards Codification (ASC) 606, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates, pharmacy rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the coverage patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Pharmacy rebates represent our estimated obligations resulting from contractual commitments to sell products to specific pharmacies. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from contracted discounts on product purchased or product dispensed. The calculation of the accrual for these rebates is based on an </span></div><div style="margin-top:9pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimate of the pharmacy&#8217;s buying or dispensing patterns and the resulting applicable contractual rebate rate(s) to be earned over the contractual period.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other governmental rebates, non-U.S. pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration with Genentech is within the scope of ASC 808, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs consist of:</span></div><div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</span></div><div style="margin-top:5pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#160;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech and the Roche Group. Pre-tax co-promotion profits consist of net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and the Roche Group. Our share of the pre-tax profits on RITUXAN and GAZYVA include estimates that are based on information received from Genentech and the Roche Group. These estimates are subject to change and actual results may differ. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize royalty revenues on sales of OCREVUS based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our relationship with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenues</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize royalty revenues related to sales by our licensees of products covered under patents that we own. </span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization arrangements with Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech and Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Corporate Revenues</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;1</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Level&#160;3</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Liabilities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of December&#160;31, 2020 and 2019, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within 30 to 90 days.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide reserves against accounts receivable for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable Securities and Other Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net on a specific identification basis.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Equity Securities and Venture Capital Funds</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Marketable Equity Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluating Marketable Debt Securities for Other-than-Temporary Impairments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method of Accounting</a></td>
<td class="text">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our consolidated statements of income our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalization of Inventory Costs</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, we capitalized approximately $93.8&#160;million of pre-launch inventory for aducanumab, an anti-amyloid beta antibody candidate for the potential treatment of Alzheimer's disease that we are developing in collaboration with Eisai Co., Ltd. (Eisai). If aducanumab does not receive regulatory approval in the U.S., we would expense this inventory as research and development expense and, under the terms of our collaboration agreement with Eisai to jointly develop and commercialize aducanumab, Eisai would reimburse us for 45.0% of the costs.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obsolescence and Unmarketable Inventory</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period we review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are carried at cost, subject to reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yMzgvZnJhZzoyMDQyOGQ1NDU1ZGI0MjVjOWEyNzM0MjIyMGJkMTNiYi90ZXh0cmVnaW9uOjIwNDI4ZDU0NTVkYjQyNWM5YTI3MzQyMjIwYmQxM2JiXzQzOTgwNDY1ODU4NDA_d52adc0a-d056-48aa-8b93-a252ffbfe552">three</span> to five years.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 to 40&#160;years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the useful life or the term of the respective lease</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and Fixtures</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7&#160;years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 20&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer&#160;Software&#160;and&#160;Hardware</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5&#160;years</span></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016 the FASB issued ASU No. 2016-02, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a new standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative information related to a company's leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-10, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-11, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Targeted Improvements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ASU No. 2018-20, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Narrow-Scope Improvement for Lessors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASU No. 2019-01, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Codification Improvements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2019.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the new leasing standards using the modified retrospective transition approach, as of January 1, 2019, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, we elected the package of transition practical expedients, which allowed us to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases and initial direct costs for existing leases. We also elected the practical expedient to not reassess certain land easements and made an accounting policy election to not recognize leases with an initial term of 12 months or less within our consolidated balance sheets and to recognize those lease payments on a straight-line basis in our consolidated statements of income over the lease term. Upon adoption of the new leasing standards we recognized an operating lease asset of approximately $463.0 million and a corresponding operating lease liability of approximately $526.0 million, which are included in our consolidated balance sheets. The adoption of the new leasing standards did not have an impact on our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the implicit rate when readily determinable and use our incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease payments used to determine our operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable and are recognized in our operating lease assets in our consolidated balance sheets. Our lease agreements may include both lease and non-lease components, which we account for as a single lease component when the payments are fixed. Variable payments included in the lease agreement are expensed as incurred. For certain equipment leases, such as vehicles, we apply a portfolio approach to effectively account for the operating lease assets and liabilities.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases are reflected in operating lease assets, accrued expenses and other and in long-term operating lease liabilities in our consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have real estate lease agreements which are subleased to third parties. Operating leases for which we are the sublessor are included in accrued expenses and other and other long-term liabilities in our consolidated balance sheets. We recognize sublease income on a straight-line basis over the lease term in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the adoption of the new leasing standards, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of completed technology (comprised of acquired and in-licensed rights and patents, developed technology, out-licensed patents), in-process research and development (IPR&amp;D) acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also include other amounts related to our other marketed products and programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to trademarks, trade names and IPR&amp;D prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the potential treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but is reviewed for impairment. Goodwill is reviewed for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 24, Segment Information,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent Consideration</a></td>
<td class="text">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow and Fair Value Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Derivative Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our derivative instruments and hedging activities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Derivative Instruments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currencies</a></td>
<td class="text">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyCostofSalesPolicyTextBlock', window );">Royalty Cost of Sales</a></td>
<td class="text">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). Compensation expense is recognized based on the estimated fair value of the awards at grant date. We recognize compensation expense for the number of awards expected to vest after taking into consideration an estimate of award forfeitures over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense for RSUs is recognized straight-line over the applicable service period.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant. Compensation expense is recognized for the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the targeted payout level associated with the performance criteria expected to be achieved. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled. If performance criteria are not met or not expected to be met, any compensation expense previously recognized to date associated with the awards will be reversed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses and upfront fees and milestones paid to third-party collaborators. Research and development expenses are expensed as incurred. Upfront and milestone payments made to third-party collaborators are expensed as incurred up to the point of regulatory approval. Milestone payments made upon regulatory approval are capitalized and amortized over the remaining useful life of the related product. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. For the years ended December&#160;31, 2020, 2019 and 2018, advertising costs totaled $111.8 million, $79.2 million and $90.2 million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax consequences from the intra-entity transfers of inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the inventory is sold to a third party.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016 the FASB issued ASU No. 2016-16,&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately&#160;$0.5 billion, offset by a corresponding net increase to retained earnings of approximately&#160;$0.5 billion. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of&#160;$0.4 billion&#160;with a corresponding reduction to our retained earnings as these differences are related to intra-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions using a &#8220;more likely than not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. Legal costs associated with legal proceedings are expensed when incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed based on the treasury method by dividing net income by the weighted-average number of common shares outstanding during the period plus potentially dilutive common equivalent shares outstanding.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.<div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016 the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information on the adoption of the new leasing standards, please read the section titled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016 the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2020. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of these standards did not have a material impact on our consolidated financial position and results of operations and related disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Securities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017 the FASB issued ASU No. 2017-08, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. The adoption of this standard did not result in a significant adjustment to our marketable debt securities.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018 the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard modifies certain disclosure requirements on fair value measurements. This standard became effective for us on January 1, 2020. The adoption of this standard did not have a material impact on our disclosures.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018 the FASB issued ASU No. 2018-16, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard became effective for us on January 1, 2019, and did not have an impact on our consolidated results of operations or financial position.</span></div><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018 the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This standard makes targeted improvements for collaborative arrangements as follows: </span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Adds unit-of-account guidance to ASC 808, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</span></div><div style="margin-top:9pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Precludes a company from presenting transactions with collaborative arrangement participants that are not directly related to sales to third parties with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard became effective for us on January 1, 2020. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings, as of January 1, 2018. The adoption of this standard did not have a material impact on our consolidated financial position, results of operations and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyCostofSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Cost of Sales [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyCostofSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969242456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Property, plant and equipment estimated useful lives</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not depreciated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 to 40&#160;years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of the useful life or the term of the respective lease</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and Fixtures</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7&#160;years</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and Equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 20&#160;years</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer&#160;Software&#160;and&#160;Hardware</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5&#160;years</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089978169960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenue by product</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by product are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fumarate*</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,742.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,163.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,905.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,312.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,126.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,438.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,253.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,274.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interferon**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,273.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,877.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,101.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,668.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,363.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,096.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,946.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,041.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">839.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZINBRYTA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,112.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,719.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,832.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,780.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,748.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,529.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,946.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,648.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,595.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">787.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,052.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">933.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,163.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,097.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,724.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">795.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">795.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">738.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">738.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">545.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,792.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,713.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,666.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,800.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,086.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,886.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**Interferon includes AVONEX and PLEGRIDY.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change in reserves</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,198.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,308.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,102.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(635.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,426.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,061.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(763.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(910.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">888.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">666.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,011.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,698.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(535.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,242.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,778.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(576.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(724.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,198.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">606.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,686.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,389.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(551.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,887.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,440.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/returns relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(506.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(646.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">888.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheet</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expenses and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,198.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenues:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">719.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969431352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">460.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,068.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979225656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,394.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,257.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,379.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,881.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks and trade names</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,220.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,136.5)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,084.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,408.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,881.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,527.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization of intangible assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,757.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,706.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase to goodwill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, end of year</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,762.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,757.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089967884136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in<br/>Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other<br/>Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">627.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,703.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,700.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">477.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">217.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.315%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in&#160;Active Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,541.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,541.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,695.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,695.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,920.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,912.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of significant unobservable inputs</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant unobservable inputs in the fair value measurement of our contingent consideration obligations as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$259.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60%</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 to 2025</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Summary of gains or losses on assets measured at fair value, nonrecurring basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains or losses on assets measured at fair value on a nonrecurring basis, are summarized as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"/><td style="width:38.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Beginning Book Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ending Book Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BIIB111 intangible asset</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">480.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.900% Senior Notes due September 15, 2020</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,054.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,557.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,365.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,107.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,536.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,515.9&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,553.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.308%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of year</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980755000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,628.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.9&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,541.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Debt and equity securities, available-for-sale</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available for sale:<div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.3</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15.9</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.5&#160;</span></td><td style="background-color:#dddddd;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,168.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">733.8</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,887.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,057.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,058.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">503.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">510.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,965.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,970.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.299%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.898%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,278.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,560.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,234.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,230.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,049.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,970.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,965.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable securities, excluding strategic investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,299.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,007.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,173.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980026808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount<br/>As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,979.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,229.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,892.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as cash flow hedging instruments on our consolidated statements of income</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.685%"/><td style="width:0.1%"/></tr><tr><td colspan="45" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reclassified from AOCI into Operating Income</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18.3</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118.6</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9.9)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.3</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.2</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our net investment hedges in our consolidated financial statements:</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.888%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.1)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of the fair value for our outstanding derivatives</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;Sheet&#160;Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Fair Value Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued&#160;expenses&#160;and&#160;other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980766936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment, net</a></td>
<td class="text">Components of property, plant and equipment, net are summarized as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,025.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">835.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">844.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer software and hardware</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,084.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,193.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,838.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,782.3)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,590.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,411.5&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,247.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090081286104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LesseeLeaseTableTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases qualify as operating leases. The following table summarizes the presentation in our consolidated balance sheets of our operating leases:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">427.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVmZThmMWFkZWFmYTQ1ZGY4ZGE0YTViZWRlZDE2ZGU1L3NlYzplZmU4ZjFhZGVhZmE0NWRmOGRhNGE1YmVkZWQxNmRlNV8yODAvZnJhZzo1NzA5Y2FlNDVkZDg0NzU0ODNjMGU2YjcxODA4ZTFhZS90YWJsZToxODVlNDQ3MDkyYzA0ZDk4YTVjNGVhNWU1OTY4MzVlMy90YWJsZXJhbmdlOjE4NWU0NDcwOTJjMDRkOThhNWM0ZWE1ZTU5NjgzNWUzXzYtMS0xLTEtMTMxMzU_4631686e-fcd9-443b-a344-b69d241e1c2d">Accrued expenses and other</span></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Operating lease costs</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of lease costs in our consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:30.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.472%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating lease liability maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The minimum lease payments for the next five years and thereafter is expected to be as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/>(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock', window );">Operating lease weighted average remaining term and discount rate</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and weighted average discount rate of our operating leases are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average remaining lease term in years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.07</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock', window );">Operating lease supplemental cash flow disclosure</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to our operating leases included in cash flows provided by operating activities in our consolidated statements of cash flows is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets obtained in exchange for lease obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LesseeLeaseTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Lease Table [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LesseeLeaseTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease supplemental cash flow disclosure [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted average remaining term and discount rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969493368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of indebtedness</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.900% Senior Notes due September 15, 2020</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">996.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,739.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,722.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,426.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,459.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our 2.900% Senior Notes due September 15, 2020, were redeemed in full in May 2020 using the net proceeds from the issuance on April 30, 2020, of our senior unsecured notes for an aggregate principal amount of $3.0&#160;billion, as discussed below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Total debt maturities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gross payments due under our debt arrangements are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:78.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,750.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,500.0&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979537336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfCommonStockTableTextBlock', window );">Summary of common stock</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes the number of shares authorized, issued and outstanding of our common stock as of December&#160;31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:13.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.569%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.6)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(243.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.410%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedge, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unfunded Status of Postretirement Benefit Plans, net of tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2017</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(318.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount reclassified, net of tax, upon adoption of ASU 2016-01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(316.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(67.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(243.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from<br/>Accumulated Other Comprehensive Income</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedge</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Income (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969420184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,430.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969869000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in consolidated statements of income</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our consolidated statements of income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.6&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash settled performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NST stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expenses</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.1&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock option activity:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.46&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.46&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock', window );">Tax benefit and cash received from stock option exercises</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.127%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.480%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit realized for stock options</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock', window );">Market stock units activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our MSU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:58.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant&#160;Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378.09&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398.61&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.42&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.62&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,000&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.98&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock', window );">Assumptions used in valuation of market based stock units</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in our valuation are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.713%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range of expected stock price volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8% - 44.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2% - 33.6%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5% - 32.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Range of risk-free interest rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.41% - 1.48%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.46% - 2.53%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9% - 2.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 calendar day average stock price on grant date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$257.83 - $325.40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$228.59 - $331.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$279.47 - $346.76</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average per share grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$398.61</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$378.08</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$378.85</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock', window );">Cash settled performance shares activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our CSPU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:81.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceunitsactivityTableTextBlock', window );">Performance units activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:81.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinStockTableTextBlock', window );">Performance stock units settled in stock activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSUs that settle in stock activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.39&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.35&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323.42&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,000&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.19&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) PSUs settled in stock granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinCashTableTextBlock', window );">Performance stock units settled in cash activity</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSUs that settle in cash activity:</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> PSUs settled in cash granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock', window );">Time-vested restricted stock units activity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our RSU activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2019</span></td><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">938,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.55&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620,000&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">318.87&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(440,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.45&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.46&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,018,000&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.46&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> RSUs granted in 2020 primarily represent RSUs granted in conjunction with our annual awards made in February 2020 and awards made in conjunction with the hiring of new employees. RSUs granted in 2020 also include approximately 10,000 RSUs granted to our Board of Directors.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock', window );">Shares issued under employee stock purchase plan</a></td>
<td class="text">The following table summarizes our ESPP activity:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.523%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued under the 2015 ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,000&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received under the 2015 ESPP</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in valuation of market based stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Cash [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Stock [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceunitsactivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance units activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceunitsactivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Cash Settled Performance Shares Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Market Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfMarketStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time Vested Restricted Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979240232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income before income tax provision and the income tax expense</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income tax expense and the income tax expense consist of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income before income taxes (benefit):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,290.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,725.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,877.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,757.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,400.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,047.5&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,125.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,899.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income tax expense (benefit):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">843.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,090.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,317.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,749.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,143.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,905.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,074.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">992.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,158.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,425.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets and liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory, other reserves and accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,546.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,380.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,080.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,753.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,278.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,905.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(396.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(350.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,143.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,381.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(174.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,617.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation, amortization and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(227.0)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,941.5)</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,484.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the valuation allowance between December&#160;31, 2020 and 2019, was primarily related to the establishment of a valuation allowance against certain deferred tax assets, the realization of which is dependent on future sales of TECFIDERA in the U.S., as discussed above.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.459%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Credits and net operating loss utilization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divestiture of Denmark manufacturing operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Internal reorganization of certain intellectual property rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA impairment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. tax reform</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss tax reform</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of beginning and ending amount of unrecognized tax benefits</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning balance at January 1,</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions for tax positions of prior periods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reductions for tax positions of prior periods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.6)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statute expirations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement refund (payment)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.9)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ending balance ar December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974473208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental cash flow information</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information for the years ended December&#160;31, 2020, 2019 and 2018, is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">906.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,064.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,007.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other income (expense), net, are summarized as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(222.5)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(187.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(200.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">685.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange gains (losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497.4&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of December&#160;31, 2020, 2019 and 2018:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693.9&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized during the period on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">681.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,145.3&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,765.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089972731992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text">Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until GAZYVA First Non-CLL FDA Approval</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text">Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Until First GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second GAZYVA Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from anti-CD20 therapeutic programs are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,080.2&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock', window );">Summary of activity related to BAN2401 and Elenbecestat collaboration</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expenses related to the BAN2401 Collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.760%"><tr><td style="width:1.0%"/><td style="width:55.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of activity related to Aducanumab collaboration</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.873%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total aducanumab collaboration third party milestone expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock', window );">Summary of activity related to the UCB collaboration</a></td>
<td class="text">A summary of development expense related to the UCB collaboration agreement is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to the UCB Collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969519192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Geographic information</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain certain financial information by geographic area:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,900.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,656.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">539.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,496.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,321.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,844.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,713.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,794.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,493.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,162.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,674.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,800.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,370.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,886.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,903.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues from external customers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">585.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,152.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,442.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968148536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:36.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Year</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,904.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,795.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,690.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,301.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,692.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">407.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">774.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,534.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,681.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,376.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,852.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,444.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,080.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,270.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,927.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,361.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,639.4&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,392.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,606.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,060.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,399.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">701.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,000.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.60&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.47&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.86&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.08&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.59&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.46&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.32&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.80&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.8&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.6&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.7&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.1&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.2&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:36.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Year</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,680.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,880.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,894.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,924.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,379.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues from anti-CD20 therapeutic programs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">517.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,290.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,489.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,616.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,600.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,671.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,377.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,887.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,140.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,170.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,224.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,422.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,545.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,439.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,545.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,439.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,888.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089976807288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>product </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights', window );">Number of ophthalmolgy biosimilar products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433.3<span></span>
</td>
<td class="nump">$ 427.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485.2<span></span>
</td>
<td class="nump">486.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.8<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
<td class="nump">$ 90.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders equity</a></td>
<td class="nump">$ 13,031.6<span></span>
</td>
<td class="nump">10,686.1<span></span>
</td>
<td class="nump">$ 13,339.1<span></span>
</td>
<td class="nump">13,031.6<span></span>
</td>
<td class="nump">10,686.1<span></span>
</td>
<td class="nump">$ 12,598.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryCapitalizedCosts', window );">Capitalized inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 463.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">526.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentTermsOfAccountsReceivable', window );">Payment terms of accounts receivable arising from product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer&#160;Software&#160;and&#160;Hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentTermsOfAccountsReceivable', window );">Payment terms of accounts receivable arising from product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer&#160;Software&#160;and&#160;Hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember', window );">Deferred Income Tax Charge | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember', window );">Deferred tax liability | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders equity</a></td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentTermsOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment terms of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentTermsOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before valuation and last-in first out (LIFO) reserves, of costs capitalized in inventory classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979362120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer&#160;Software&#160;and&#160;Hardware</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer&#160;Software&#160;and&#160;Hardware</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089972025352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Jul. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 07, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ClinicalAssetsAcquired', window );">Clinical assets acquired | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member', window );">BIIB118</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 635.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Payments for pre-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate', window );">Fair value, in-process research and development, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Deferred tax liabilities, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | BIIB111</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | Post-acquisition equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair-value post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | Post-acquisition equity compensation | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair-value post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | Post-acquisition equity compensation | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Fair-value post-combination equity compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember', window );">Karyopharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember', window );">AliveGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ClinicalAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ClinicalAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Indefinite Lived Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121554379&amp;loc=d3e9972-128506<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121554379&amp;loc=d3e9979-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BIIB118Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_PostacquisitionequitycompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979737336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Divestitures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">(Gain) loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">$ 92.5<span></span>
</td>
<td class="num">$ (55.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration received for sale of Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 881.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax', window );">Loss on divestiture of Hiller&#248;d, Denmark manufacturing operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">(Gain) loss on divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">30.5<span></span>
</td>
<td class="num">(55.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Expected costs to sell disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Future minimum batch production for Denmark manufacturing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PurchaseCommitmentReductionOfAmountCommitted', window );">Purchase commitment, reduction</a></td>
<td class="nump">$ 62.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PurchaseCommitmentReductionOfAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Reduction of Amount Committed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PurchaseCommitmentReductionOfAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974278120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 13,444.6<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,905.4<span></span>
</td>
<td class="nump">4,438.2<span></span>
</td>
<td class="nump">4,274.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,877.5<span></span>
</td>
<td class="nump">2,101.8<span></span>
</td>
<td class="nump">2,363.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,946.1<span></span>
</td>
<td class="nump">1,892.2<span></span>
</td>
<td class="nump">1,864.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.1<span></span>
</td>
<td class="nump">97.1<span></span>
</td>
<td class="nump">92.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">Subtotal: MS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,832.1<span></span>
</td>
<td class="nump">8,529.3<span></span>
</td>
<td class="nump">8,595.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,052.1<span></span>
</td>
<td class="nump">2,097.0<span></span>
</td>
<td class="nump">1,724.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481.6<span></span>
</td>
<td class="nump">486.2<span></span>
</td>
<td class="nump">485.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216.3<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">68.1<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Subtotal: Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795.8<span></span>
</td>
<td class="nump">738.3<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,301.6<span></span>
</td>
<td class="nump">$ 2,690.3<span></span>
</td>
<td class="nump">$ 2,795.7<span></span>
</td>
<td class="nump">$ 2,904.6<span></span>
</td>
<td class="nump">$ 2,924.8<span></span>
</td>
<td class="nump">$ 2,894.7<span></span>
</td>
<td class="nump">$ 2,880.3<span></span>
</td>
<td class="nump">$ 2,680.0<span></span>
</td>
<td class="nump">10,692.2<span></span>
</td>
<td class="nump">11,379.8<span></span>
</td>
<td class="nump">10,886.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,742.0<span></span>
</td>
<td class="nump">3,312.0<span></span>
</td>
<td class="nump">3,253.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,273.5<span></span>
</td>
<td class="nump">1,426.6<span></span>
</td>
<td class="nump">1,668.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,096.8<span></span>
</td>
<td class="nump">1,041.8<span></span>
</td>
<td class="nump">1,025.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Subtotal: MS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,112.3<span></span>
</td>
<td class="nump">5,780.4<span></span>
</td>
<td class="nump">5,946.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">787.8<span></span>
</td>
<td class="nump">933.4<span></span>
</td>
<td class="nump">854.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Subtotal: Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Total product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900.1<span></span>
</td>
<td class="nump">6,713.8<span></span>
</td>
<td class="nump">6,800.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163.4<span></span>
</td>
<td class="nump">1,126.2<span></span>
</td>
<td class="nump">1,020.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604.0<span></span>
</td>
<td class="nump">675.2<span></span>
</td>
<td class="nump">694.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849.3<span></span>
</td>
<td class="nump">850.4<span></span>
</td>
<td class="nump">839.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.1<span></span>
</td>
<td class="nump">97.1<span></span>
</td>
<td class="nump">92.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Subtotal: MS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719.8<span></span>
</td>
<td class="nump">2,748.9<span></span>
</td>
<td class="nump">2,648.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264.3<span></span>
</td>
<td class="nump">1,163.6<span></span>
</td>
<td class="nump">870.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481.6<span></span>
</td>
<td class="nump">486.2<span></span>
</td>
<td class="nump">485.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216.3<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.9<span></span>
</td>
<td class="nump">68.1<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Subtotal: Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795.8<span></span>
</td>
<td class="nump">738.3<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of World | Total product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,792.1<span></span>
</td>
<td class="nump">$ 4,666.0<span></span>
</td>
<td class="nump">$ 4,086.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974920200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms', window );">Percentage of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="nump">15.90%<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 13,444.6<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">132.0<span></span>
</td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="nump">407.6<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 145.7<span></span>
</td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 292.4<span></span>
</td>
<td class="nump">774.6<span></span>
</td>
<td class="nump">707.7<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">719.1<span></span>
</td>
<td class="nump">584.5<span></span>
</td>
<td class="nump">459.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation, amount</a></td>
<td class="nump">$ 153.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_BioverativMember', window );">Bioverativ | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
<td class="nump">$ 383.2<span></span>
</td>
<td class="nump">$ 206.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_ContractManufacturingCustomerMember', window );">Contract Manufacturing Customer | Other corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenue from major distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.50%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">21.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.10%<span></span>
</td>
<td class="nump">24.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenue from major distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
<td class="nump">17.20%<span></span>
</td>
<td class="nump">18.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage receivables of wholesale distributor accounted in consolidated receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues In Percentage From Anti-CD20 Therapeutic Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ContractManufacturingCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ContractManufacturingCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979175512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Reserves for Discounts and Allowances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 1,198.9<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">4,102.5<span></span>
</td>
<td class="nump">3,698.6<span></span>
</td>
<td class="nump">3,389.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(53.7)<span></span>
</td>
<td class="num">(48.3)<span></span>
</td>
<td class="num">(12.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(3,061.2)<span></span>
</td>
<td class="num">(2,778.6)<span></span>
</td>
<td class="num">(2,440.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(910.5)<span></span>
</td>
<td class="num">(724.1)<span></span>
</td>
<td class="num">(646.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">1,276.0<span></span>
</td>
<td class="nump">1,198.9<span></span>
</td>
<td class="nump">1,051.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">774.7<span></span>
</td>
<td class="nump">666.2<span></span>
</td>
<td class="nump">679.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(635.1)<span></span>
</td>
<td class="num">(535.5)<span></span>
</td>
<td class="num">(551.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(128.3)<span></span>
</td>
<td class="num">(127.7)<span></span>
</td>
<td class="num">(109.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">141.4<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">1,027.3<span></span>
</td>
<td class="nump">888.8<span></span>
</td>
<td class="nump">606.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">3,308.8<span></span>
</td>
<td class="nump">3,011.5<span></span>
</td>
<td class="nump">2,686.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(54.0)<span></span>
</td>
<td class="num">(54.1)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="num">(2,426.1)<span></span>
</td>
<td class="num">(2,242.9)<span></span>
</td>
<td class="num">(1,887.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(763.0)<span></span>
</td>
<td class="num">(576.0)<span></span>
</td>
<td class="num">(506.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">1,093.0<span></span>
</td>
<td class="nump">1,027.3<span></span>
</td>
<td class="nump">888.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns relating to sales in current year</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns relating to sales in prior years</a></td>
<td class="num">(19.2)<span></span>
</td>
<td class="num">(20.4)<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="nump">$ 40.5<span></span>
</td>
<td class="nump">$ 34.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089966344584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues - Total Reserves for Discounts and Allowances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,276.0<span></span>
</td>
<td class="nump">$ 1,198.9<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">195.4<span></span>
</td>
<td class="nump">197.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,080.6<span></span>
</td>
<td class="nump">$ 1,001.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980730248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 13,444.6<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 419.0<span></span>
</td>
<td class="nump">$ 560.1<span></span>
</td>
<td class="nump">$ 478.3<span></span>
</td>
<td class="nump">$ 520.4<span></span>
</td>
<td class="nump">$ 600.8<span></span>
</td>
<td class="nump">$ 595.8<span></span>
</td>
<td class="nump">$ 576.4<span></span>
</td>
<td class="nump">$ 517.4<span></span>
</td>
<td class="nump">1,977.8<span></span>
</td>
<td class="nump">2,290.4<span></span>
</td>
<td class="nump">1,980.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080.2<span></span>
</td>
<td class="nump">1,542.4<span></span>
</td>
<td class="nump">1,431.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 897.6<span></span>
</td>
<td class="nump">$ 748.0<span></span>
</td>
<td class="nump">$ 548.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089973609992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 13,444.6<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">719.1<span></span>
</td>
<td class="nump">584.5<span></span>
</td>
<td class="nump">459.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Total other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 132.0<span></span>
</td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="nump">$ 407.6<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 145.7<span></span>
</td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 292.4<span></span>
</td>
<td class="nump">774.6<span></span>
</td>
<td class="nump">707.7<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Other Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (8.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_OtherRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_OtherRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980671672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 314.9<span></span>
</td>
<td class="nump">$ 169.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">544.5<span></span>
</td>
<td class="nump">460.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">209.2<span></span>
</td>
<td class="nump">174.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">$ 1,068.6<span></span>
</td>
<td class="nump">$ 804.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980926472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on excess, obsolete, unmarketable or other inventory</a></td>
<td class="nump">$ 26.6<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="nump">$ 41.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryrawmaterialssoldtoFUJIFILM', window );">Inventory raw materials sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory work-in-process sold to FUJIFILM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryrawmaterialssoldtoFUJIFILM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials sold to FUJIFILM</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryrawmaterialssoldtoFUJIFILM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089976946776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 7,394.3<span></span>
</td>
<td class="nump">$ 7,379.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets</a></td>
<td class="nump">8,220.8<span></span>
</td>
<td class="nump">8,408.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,136.5)<span></span>
</td>
<td class="num">(4,881.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,257.8<span></span>
</td>
<td class="nump">2,497.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets</a></td>
<td class="nump">$ 3,084.3<span></span>
</td>
<td class="nump">3,527.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">$ 762.5<span></span>
</td>
<td class="nump">965.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977071176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464,800,000<span></span>
</td>
<td class="nump">$ 489,900,000<span></span>
</td>
<td class="nump">$ 747,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,100,000<span></span>
</td>
<td class="nump">274,000,000.0<span></span>
</td>
<td class="nump">381,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">3,084,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,084,300,000<span></span>
</td>
<td class="nump">3,527,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,900,000<span></span>
</td>
<td class="nump">$ 189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,900,000<span></span>
</td>
<td class="nump">$ 189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets (excluding goodwill)</a></td>
<td class="nump">762,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762,500,000<span></span>
</td>
<td class="nump">$ 965,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">365,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets (excluding goodwill)</a></td>
<td class="nump">177,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | BIIB111</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | BIIB111 | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | BIIB054</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">$ 75,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationandImpairmentofAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB054Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB054Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089973835016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 205.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">215.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">215.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">225.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">$ 220.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089967862680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Changes in Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of year</a></td>
<td class="nump">$ 5,757.8<span></span>
</td>
<td class="nump">$ 5,706.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">117.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Elimination of goodwill allocated to Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(69.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of year</a></td>
<td class="nump">$ 5,762.1<span></span>
</td>
<td class="nump">$ 5,757.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089975105128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 2,051.0<span></span>
</td>
<td class="nump">$ 2,970.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">626.9<span></span>
</td>
<td class="nump">2,541.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">1,974.3<span></span>
</td>
<td class="nump">337.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">20.5<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,700.9<span></span>
</td>
<td class="nump">5,920.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">217.2<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">477.0<span></span>
</td>
<td class="nump">354.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,301.5<span></span>
</td>
<td class="nump">1,695.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">627.1<span></span>
</td>
<td class="nump">1,013.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">122.4<span></span>
</td>
<td class="nump">261.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level&#160;1) | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">271.1<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">271.1<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level&#160;1) | Fair value, measurements, recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level&#160;1) | Fair value, measurements, recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level&#160;1) | Fair value, measurements, recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">626.9<span></span>
</td>
<td class="nump">2,541.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">1,703.2<span></span>
</td>
<td class="nump">329.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">20.5<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,429.8<span></span>
</td>
<td class="nump">5,912.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">217.2<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">217.2<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Fair value, measurements, recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,301.5<span></span>
</td>
<td class="nump">1,695.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Fair value, measurements, recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">627.1<span></span>
</td>
<td class="nump">1,013.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level&#160;2) | Fair value, measurements, recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">122.4<span></span>
</td>
<td class="nump">261.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">259.8<span></span>
</td>
<td class="nump">346.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Fair value, measurements, recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Fair value, measurements, recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Fair value, measurements, recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089973472872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable Input</a></td>
<td class="nump">0.0060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable Input</a></td>
<td class="nump">0.0060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="nump">$ 259.8<span></span>
</td>
<td class="nump">$ 346.1<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089975374024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TechnologicalAndRegulatorySuccessProbability', window );">Technological and regulatory success, probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Reduction in contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000.0<span></span>
</td>
<td class="nump">$ 61,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,900,000<span></span>
</td>
<td class="nump">$ 189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,900,000<span></span>
</td>
<td class="nump">$ 189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Intangible asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 274,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,800,000<span></span>
</td>
<td class="nump">244,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 424,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember', window );">Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember', window );">Biogen Idec International Neuroscience GmbH | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquired intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember', window );">Stromedix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | BIIB054</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueMeasurementInputs', window );">Fair value measurement and measurement inputs, recurring and nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,300,000<span></span>
</td>
<td class="nump">$ 197,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueMeasurementInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Inputs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueMeasurementInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TechnologicalAndRegulatorySuccessProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Technological and Regulatory Success, Probability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TechnologicalAndRegulatorySuccessProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_StromedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB054Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB054Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089978425048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Gains and Losses on Assets Measured at Fair Value (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 07, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Beginning Book Value</a></td>
<td class="nump">$ 8,220.8<span></span>
</td>
<td class="nump">$ 8,408.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending Book Value</a></td>
<td class="nump">3,084.3<span></span>
</td>
<td class="nump">$ 3,527.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111 | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Beginning Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment</a></td>
<td class="num">(115.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending Book Value</a></td>
<td class="nump">$ 365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089972309048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Fair and Carrying Value of Debt Instruments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 8,515,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,553,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due September 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,509,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due September 15, 2020 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due September 15, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,054,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,038,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due September 15, 2022 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due September 15, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 2,003,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,897,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due September 15, 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,557,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member', window );">2.250% Senior Notes due May 1, 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due September 15, 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 2,365,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,107,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due September 15, 2045 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,536,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member', window );">3.150% Senior Notes due May 1, 2050 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090081264200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">$ (86.3)<span></span>
</td>
<td class="num">$ (63.7)<span></span>
</td>
<td class="num">$ (12.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of year</a></td>
<td class="nump">346.1<span></span>
</td>
<td class="nump">409.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(86.3)<span></span>
</td>
<td class="num">(63.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments and other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of year</a></td>
<td class="nump">$ 259.8<span></span>
</td>
<td class="nump">$ 346.1<span></span>
</td>
<td class="nump">$ 409.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089976143960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Financial Assets with Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 626.9<span></span>
</td>
<td class="nump">$ 2,541.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">61.1<span></span>
</td>
<td class="nump">384.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">37.4<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">505.1<span></span>
</td>
<td class="nump">1,628.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 23.3<span></span>
</td>
<td class="nump">$ 159.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089983095544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,049.1<span></span>
</td>
<td class="nump">$ 2,965.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,051.0<span></span>
</td>
<td class="nump">2,970.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">897.8<span></span>
</td>
<td class="nump">1,057.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">898.0<span></span>
</td>
<td class="nump">1,058.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">402.5<span></span>
</td>
<td class="nump">633.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">403.5<span></span>
</td>
<td class="nump">636.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">380.6<span></span>
</td>
<td class="nump">502.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">380.7<span></span>
</td>
<td class="nump">503.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">245.9<span></span>
</td>
<td class="nump">510.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">246.4<span></span>
</td>
<td class="nump">510.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">122.1<span></span>
</td>
<td class="nump">260.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">122.2<span></span>
</td>
<td class="nump">260.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Marketable equity securities, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">70.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities, fair value</a></td>
<td class="nump">86.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Marketable equity securities, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Marketable equity securities, amortized cost</a></td>
<td class="nump">1,168.9<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable equity securities, gross unrealized gains</a></td>
<td class="nump">733.8<span></span>
</td>
<td class="nump">132.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable equity securities, gross unrealized losses</a></td>
<td class="num">(14.9)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities, fair value</a></td>
<td class="nump">$ 1,887.8<span></span>
</td>
<td class="nump">$ 337.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089978660216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Contractual Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 1,278.9<span></span>
</td>
<td class="nump">$ 1,562.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">722.6<span></span>
</td>
<td class="nump">1,234.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years</a></td>
<td class="nump">49.5<span></span>
</td>
<td class="nump">173.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable debt securities</a></td>
<td class="nump">2,051.0<span></span>
</td>
<td class="nump">2,970.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">1,278.6<span></span>
</td>
<td class="nump">1,560.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">721.3<span></span>
</td>
<td class="nump">1,230.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years</a></td>
<td class="nump">49.2<span></span>
</td>
<td class="nump">173.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,049.1<span></span>
</td>
<td class="nump">$ 2,965.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979004760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Proceeds from Marketable Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 7,299.4<span></span>
</td>
<td class="nump">$ 6,007.0<span></span>
</td>
<td class="nump">$ 9,173.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">17.7<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974479976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br> shares in Millions, $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months<span></span>
</td>
<td class="text">14 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInCommonStockSharesPurchased', window );">Investment in common stock, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInCommonStockSharesPurchased', window );">Investment in common stock, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember', window );">Sangamo Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInCommonStockSharesPurchased', window );">Investment in common stock, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DividendYieldPercentage', window );">Dividend yield percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,024.6<span></span>
</td>
<td class="nump">393.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Samsung Bioepis, ownership percentage before additional purchase transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Samsung Bioepis, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620.2<span></span>
</td>
<td class="nump">$ 580.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 673.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 670.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DividendYieldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Yield Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DividendYieldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInCommonStockSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment In Common Stock, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInCommonStockSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SangamoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SangamoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089975414840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Narrative (Details)<br> &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Feb. 29, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 676,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30,100,000)<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Samsung Bioepis, ownership percentage before additional purchase transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Samsung Bioepis, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="nump">$ 676,600,000<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Forward contracts duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as hedge, excluded component, after tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,229,700,000<span></span>
</td>
<td class="nump">1,892,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,158,000,000.0<span></span>
</td>
<td class="nump">793,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due September 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain (loss) on derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 27,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward | Net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain (loss) on derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivative instruments, net, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain (loss) on derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979826408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments - Foreign Currency Forward Contracts Entered into Hedge Forecasted Revenues (Details) - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 3,229.7<span></span>
</td>
<td class="nump">$ 1,892.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">2,979.1<span></span>
</td>
<td class="nump">1,892.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 250.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980452024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Summary of the Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details) - Foreign exchange contract - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)</a></td>
<td class="nump">$ 18.3<span></span>
</td>
<td class="nump">$ 118.6<span></span>
</td>
<td class="num">$ (42.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivative instruments, net, pretax</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivative instruments, net, pretax</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980658408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Summary of the Effect of Derivatives Designated as Net Investment Hedging Instruments (Details) - Net investment hedge - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Net Gains/(Losses) Recognized in Other Comprehensive Income (Effective Portion) (in millions)</a></td>
<td class="num">$ (35.1)<span></span>
</td>
<td class="nump">$ 25.3<span></span>
</td>
<td class="num">$ (3.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Net Gains/(Losses) Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing) (in millions)</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974501736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments - Summary of the Fair Value for our Outstanding Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Foreign exchange contract | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivative instruments</a></td>
<td class="nump">$ 20.5<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Foreign exchange contract | Cash flow hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Foreign exchange contract | Net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Foreign exchange contract | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivative instruments</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Foreign exchange contract | Cash flow hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivative instruments</a></td>
<td class="nump">157.1<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Interest rate swap | Net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivative instruments</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Interest rate swap | Fair value hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Foreign exchange contract | Cash flow hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivative instruments</a></td>
<td class="nump">$ 35.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968158968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 119.8<span></span>
</td>
<td class="nump">$ 118.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">1,025.3<span></span>
</td>
<td class="nump">835.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">104.6<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">1,027.8<span></span>
</td>
<td class="nump">844.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ComputerSoftwareAndHardware', window );">Computer software and hardware</a></td>
<td class="nump">903.0<span></span>
</td>
<td class="nump">798.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">62.5<span></span>
</td>
<td class="nump">58.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,950.8<span></span>
</td>
<td class="nump">2,084.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">5,193.8<span></span>
</td>
<td class="nump">4,838.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,782.3)<span></span>
</td>
<td class="num">(1,590.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">$ 3,411.5<span></span>
</td>
<td class="nump">$ 3,247.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ComputerSoftwareAndHardware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computer software and hardware</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ComputerSoftwareAndHardware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089976127592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Narrative (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 201.9<span></span>
</td>
<td class="nump">$ 190.6<span></span>
</td>
<td class="nump">$ 269.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized</a></td>
<td class="nump">65.2<span></span>
</td>
<td class="nump">68.8<span></span>
</td>
<td class="nump">$ 54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,950.8<span></span>
</td>
<td class="nump">2,084.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">5,193.8<span></span>
</td>
<td class="nump">4,838.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment sold to Fujifilm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 631.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations | Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment sold to Fujifilm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment sold to Fujifilm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,800.0<span></span>
</td>
<td class="nump">$ 1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 256.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing | Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space | Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space | Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969852296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, contract term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Sublease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, contract term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, contract term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Sublease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, contract term</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=biib_SubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=biib_SubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969894056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Operating Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 433.3<span></span>
</td>
<td class="nump">$ 427.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 402.0<span></span>
</td>
<td class="nump">412.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">485.2<span></span>
</td>
<td class="nump">486.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">433.3<span></span>
</td>
<td class="nump">427.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">83.2<span></span>
</td>
<td class="nump">73.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember', window );">Long-term operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 402.0<span></span>
</td>
<td class="nump">$ 412.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_OperatingleaseassetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_LongtermoperatingleaseliabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969896712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Operating Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 92.4<span></span>
</td>
<td class="nump">$ 86.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">84.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">21.1<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(24.2)<span></span>
</td>
<td class="num">(25.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">$ (3.9)<span></span>
</td>
<td class="num">$ (3.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090081287208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Lease Liability Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 95.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">93.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">82.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">56.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">129.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">533.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="nump">47.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 485.2<span></span>
</td>
<td class="nump">$ 486.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969356712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Lease Weighted Average Remaining Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090076057672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Operating Lease Supplemental Cash Flow Disclosure (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 100.2<span></span>
</td>
<td class="nump">$ 93.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089971062824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness - Summary of Indebtedness (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,495,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">7,500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Non-current portion of notes payable</a></td>
<td class="nump">7,426,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,459,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Non-current portion of notes payable</a></td>
<td class="nump">$ 7,426,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,459,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due September 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due September 15, 2020 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">2.900% Senior Notes due September 15, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due September 15, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due September 15, 2022 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 997,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due September 15, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due September 15, 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,741,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member', window );">2.250% Senior Notes due May 1, 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,491,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due September 15, 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due September 15, 2045 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,723,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member', window );">3.150% Senior Notes due May 1, 2050 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,472,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089972265064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemptions percentage of 2015 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Redemption percentage for change in control provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain (loss) on derivative instruments, net, pretax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due September 15, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due September 15, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due September 15, 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due September 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemptions percentage of 2015 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Redemption percentage for change in control provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2020 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Costs associated with the senior Nnotes offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.973%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.174%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2015 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Costs associated with the senior Nnotes offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.625% Senior Notes due September 15, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.050% Senior Notes due September 15, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.200% Senior Notes due September 15, 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.900% Senior Notes due September 15, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain', window );">Pre-tax charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2.900% Senior Notes due September 15, 2020 | Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain', window );">Pre-tax charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2020SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2020SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A225SeniorNotesDueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A315SeniorNotesDueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2015SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2015SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089967955944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness - Total Debt Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">1,750.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2026 and thereafter</a></td>
<td class="nump">4,750.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total</a></td>
<td class="nump">$ 7,500.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980196984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 6,679,100,000<span></span>
</td>
<td class="nump">$ 5,868,300,000<span></span>
</td>
<td class="nump">$ 4,352,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember', window );">Series X junior participating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember', window );">Undesignated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram5Member', window );">2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost (in shares)</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram4Member', window );">December 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost (in shares)</a></td>
<td class="nump">16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram3Member', window );">March 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost (in shares)</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="nump">$ 3,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram2Member', window );">2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram1Member', window );">2016 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_ShareRepurchaseProgram1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980939656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Summary of Common Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">1,000,000,000.0<span></span>
</td>
<td class="nump">1,000,000,000.0<span></span>
</td>
<td class="nump">1,000,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">176,200,000<span></span>
</td>
<td class="nump">198,000,000.0<span></span>
</td>
<td class="nump">221,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">152,400,000<span></span>
</td>
<td class="nump">174,200,000<span></span>
</td>
<td class="nump">197,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089972067000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="num">$ (135.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="nump">10,686.1<span></span>
</td>
<td class="nump">$ 13,339.1<span></span>
</td>
<td class="nump">$ 13,031.6<span></span>
</td>
<td class="nump">$ 12,598.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(145.6)<span></span>
</td>
<td class="nump">230.8<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(18.2)<span></span>
</td>
<td class="num">(125.6)<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(163.8)<span></span>
</td>
<td class="nump">105.2<span></span>
</td>
<td class="nump">76.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, ending balance</a></td>
<td class="num">(299.0)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
<td class="num">(318.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="num">(299.0)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
<td class="num">(318.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, ending balance</a></td>
<td class="num">(299.0)<span></span>
</td>
<td class="num">(135.2)<span></span>
</td>
<td class="num">(240.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive loss | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive loss | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(316.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(9.3)<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, ending balance</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale, net of tax | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale, net of tax | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
<td class="num">(104.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(165.0)<span></span>
</td>
<td class="nump">88.1<span></span>
</td>
<td class="nump">97.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(115.0)<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(186.8)<span></span>
</td>
<td class="num">(26.9)<span></span>
</td>
<td class="nump">139.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, ending balance</a></td>
<td class="num">(179.0)<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (Losses) on Net Investment Hedge, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(30.7)<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(33.6)<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, ending balance</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (Losses) on Net Investment Hedge, Net of Tax | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (Losses) on Net Investment Hedge, Net of Tax | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded Status of Postretirement Benefit Plans, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
<td class="num">(36.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, ending balance</a></td>
<td class="num">(66.3)<span></span>
</td>
<td class="num">(32.8)<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded Status of Postretirement Benefit Plans, net of tax | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded Status of Postretirement Benefit Plans, net of tax | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="num">(139.5)<span></span>
</td>
<td class="num">(243.3)<span></span>
</td>
<td class="num">(175.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">92.9<span></span>
</td>
<td class="nump">103.8<span></span>
</td>
<td class="num">(67.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">92.9<span></span>
</td>
<td class="nump">103.8<span></span>
</td>
<td class="num">(67.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, ending balance</a></td>
<td class="num">$ (46.6)<span></span>
</td>
<td class="num">$ (139.5)<span></span>
</td>
<td class="num">(243.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency Translation Adjustments | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Amount reclassified, net of tax, upon adoption of ASU 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency Translation Adjustments | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">AOCI, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (175.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089973647064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497.4<span></span>
</td>
<td class="nump">$ 83.3<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">992.3<span></span>
</td>
<td class="nump">1,158.0<span></span>
</td>
<td class="nump">1,425.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">13,444.6<span></span>
</td>
<td class="nump">14,377.9<span></span>
</td>
<td class="nump">13,452.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total reclassifications, net of tax</a></td>
<td class="nump">$ 357.9<span></span>
</td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 1,399.1<span></span>
</td>
<td class="nump">$ 1,439.7<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">4,000.6<span></span>
</td>
<td class="nump">5,888.5<span></span>
</td>
<td class="nump">4,430.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">125.6<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">118.6<span></span>
</td>
<td class="num">(42.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089975864376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Basic and Diluted Earnings Per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 357.9<span></span>
</td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 1,399.1<span></span>
</td>
<td class="nump">$ 1,439.7<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 4,000.6<span></span>
</td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc. (in shares)</a></td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">156.9<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="nump">172.8<span></span>
</td>
<td class="nump">177.8<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc. (in shares)</a></td>
<td class="nump">154.0<span></span>
</td>
<td class="nump">157.2<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
<td class="nump">178.2<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">190.4<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="nump">161.3<span></span>
</td>
<td class="nump">187.4<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969407512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140090081282984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Share-based Compensation Expense Included in Consolidation Statements of Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (204.5)<span></span>
</td>
<td class="num">$ (191.2)<span></span>
</td>
<td class="num">$ (168.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">211.3<span></span>
</td>
<td class="nump">225.4<span></span>
</td>
<td class="nump">181.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total cost and expenses</a></td>
<td class="nump">205.1<span></span>
</td>
<td class="nump">216.5<span></span>
</td>
<td class="nump">170.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="num">(35.7)<span></span>
</td>
<td class="num">(27.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
<td class="nump">75.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">131.3<span></span>
</td>
<td class="nump">148.3<span></span>
</td>
<td class="nump">105.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Share-based compensation expense included in net income attributable to Biogen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 171.6<span></span>
</td>
<td class="nump">$ 180.8<span></span>
</td>
<td class="nump">$ 142.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979657544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Share-based Compensation Expense Associated with Each Share-based Compensating Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (204.5)<span></span>
</td>
<td class="num">$ (191.2)<span></span>
</td>
<td class="num">$ (168.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">211.3<span></span>
</td>
<td class="nump">225.4<span></span>
</td>
<td class="nump">181.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total cost and expenses</a></td>
<td class="nump">205.1<span></span>
</td>
<td class="nump">216.5<span></span>
</td>
<td class="nump">170.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">30.4<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">142.6<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember', window );">Nightstar | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">NST stock options</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_NightstarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_NightstarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089976929704">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Narrative (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Increment </div>
<div>Plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>Increment</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards', window );">Weighted-average period to recognize the cost of unvested awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade', window );">Number of share-based compensation plans pursuant to which awards are currently being made | Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under the 2015 ESPP (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 378.08<span></span>
</td>
<td class="nump">$ 378.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash settlement of awards upon vesting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash settlement of awards upon vesting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 131.5<span></span>
</td>
<td class="nump">$ 111.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 304.44<span></span>
</td>
<td class="nump">$ 316.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units | Share-based Payment Arrangement, Tranche Three</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based payment arrangement, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_DirectorsPlanMember', window );">Directors Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSharesOfCommonStockForIssuance', window );">Total number of shares of common stock for issuance (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember', window );">2017 Omnibus Equity Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Omnibus Plan number of shares authorized (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">PSUs settled in stock granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2020 primarily represent RSUs granted in conjunction with our annual awards made in February 2020 and awards made in conjunction with the hiring of new employees. RSUs granted in 2020 also include approximately 10,000 RSUs granted to our Board of Directors.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days for calculation of average closing stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfDaysForCalculationOfAverageClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfEqualAnnualIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual increments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfEqualAnnualIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share-based compensation plans pursuant to which awards are currently being made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSharesOfCommonStockForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSharesOfCommonStockForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatioOfNumberOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of total number of shares reserved under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatioOfNumberOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period to recognize the cost of nonvested awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_DirectorsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_DirectorsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969896840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Stock Option Activity (Details) - Share-based Payment Arrangement, Option<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, outstanding shares (in shares) | shares</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, outstanding shares (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 58.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">58.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974961624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Tax Benefit and Cash Received from Stock Option Exercises (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit realized for stock options</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089981171592">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Market Stock Units Activity (Details) - Market stock units - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, unvested shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(82)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, unvested shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">201<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 378.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">398.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 378.08<span></span>
</td>
<td class="nump">$ 378.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">375.42<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">402.62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 388.98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 378.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089966273512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Assumptions Used in Valuation of Market Based Stock Units (Details) - Market stock units - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Minimum range of risk-free interest rates</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2.46%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Maximum range of risk-free interest rates</a></td>
<td class="nump">1.48%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2.53%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum', window );">Average stock price on grant date minimum</a></td>
<td class="nump">$ 257.83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 228.59<span></span>
</td>
<td class="nump">$ 279.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum', window );">Average stock price on grant date maximum</a></td>
<td class="nump">$ 325.40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 331.18<span></span>
</td>
<td class="nump">$ 346.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 398.61<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 378.08<span></span>
</td>
<td class="nump">$ 378.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">37.80%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31.20%<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">44.10%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">33.60%<span></span>
</td>
<td class="nump">32.40%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted during 2020 include awards granted in conjunction with our annual awards made in February 2020 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2020 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2019, 2018 and 2017.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974088616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Cash Settled Performance Shares Activity (Details) - Cash settled performance units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, unvested shares (in shares)</a></td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, unvested shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969375544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Performance Units Activity (Details) - Performance units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, unvested shares (in shares)</a></td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, unvested shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969871784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Performance Stock Units Settled in Stock Activity (Details) - Performance stock units settled in stock<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, unvested shares (in shares) | shares</a></td>
<td class="nump">111,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">73,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(29,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, unvested shares (in shares) | shares</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 316.39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">293.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">323.42<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 304.19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">PSUs settled in stock granted in 2020 include awards granted in conjunction with our annual awards made in February 2020 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979387624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Performance Stock Units Settled in Cash Activity (Details) - Performance stock units settled in cash<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, unvested shares (in shares)</a></td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">63,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(23,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, unvested shares (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977374728">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Time-Vested Restricted Stock Units Activity (Details) - Time-vested restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance, unvested shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">938,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">620,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(440,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance, unvested shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,018,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">938,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 306.55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">318.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 304.44<span></span>
</td>
<td class="nump">$ 316.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">304.45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">314.46<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 314.46<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 306.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">620,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Director</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2020 primarily represent RSUs granted in conjunction with our annual awards made in February 2020 and awards made in conjunction with the hiring of new employees. RSUs granted in 2020 also include approximately 10,000 RSUs granted to our Board of Directors.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979994408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Shares Issued Under Employee Stock Purchase Plan (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under the 2015 ESPP (in shares)</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under the 2015 ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under the 2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.6<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 40.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2015ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979161512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Before Income Tax Provision and the Income Tax Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income before income taxes (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 3,290.0<span></span>
</td>
<td class="nump">$ 4,725.3<span></span>
</td>
<td class="nump">$ 3,877.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">1,757.5<span></span>
</td>
<td class="nump">2,400.6<span></span>
</td>
<td class="nump">2,022.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">5,047.5<span></span>
</td>
<td class="nump">7,125.9<span></span>
</td>
<td class="nump">5,899.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">647.0<span></span>
</td>
<td class="nump">947.4<span></span>
</td>
<td class="nump">1,131.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">41.2<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">45.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">155.1<span></span>
</td>
<td class="nump">84.4<span></span>
</td>
<td class="nump">140.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">843.3<span></span>
</td>
<td class="nump">1,090.9<span></span>
</td>
<td class="nump">1,317.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,749.9)<span></span>
</td>
<td class="nump">1,143.9<span></span>
</td>
<td class="num">(62.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(6.8)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,905.7<span></span>
</td>
<td class="num">(1,074.5)<span></span>
</td>
<td class="nump">177.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">149.0<span></span>
</td>
<td class="nump">67.1<span></span>
</td>
<td class="nump">108.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 992.3<span></span>
</td>
<td class="nump">$ 1,158.0<span></span>
</td>
<td class="nump">$ 1,425.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089978907096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="num">$ (1,143.7)<span></span>
</td>
<td class="num">$ (1,381.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">62.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries', window );">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</a></td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totaldeferredchargesandprepaidtaxes', window );">Total deferred charges and prepaid taxes</a></td>
<td class="nump">142.2<span></span>
</td>
<td class="nump">243.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">1,753.9<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">103.1<span></span>
</td>
<td class="nump">103.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefit</a></td>
<td class="nump">68.8<span></span>
</td>
<td class="nump">122.7<span></span>
</td>
<td class="nump">$ 109.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net interest expense</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductionindeferredtaxliabilityundistributedforeignearnings', window );">Reduction in deferred tax liability, undistributed foreign earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Other tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Transition toll tax liabilities</a></td>
<td class="nump">697.0<span></span>
</td>
<td class="nump">697.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Domestic Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforward, subject to expiration</a></td>
<td class="nump">18,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforward, subject to expiration</a></td>
<td class="nump">16,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">142.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember', window );">Earnings in the form of cash and cash equivalents | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition toll tax repatriation tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember', window );">Other Foreign Earnings | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition toll tax repatriation tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting', window );">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting', window );">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</a></td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember', window );">Denmark Manufacturing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Tax expense on disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetsValueReductionInValue', window );">Deferred tax assets, value, reduction in value</a></td>
<td class="nump">1,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesValueReductionInValue', window );">Deferred tax liabilities, value, reduction in value</a></td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet', window );">Income tax expense, reduction in deferred tax assets and liabilities, net</a></td>
<td class="nump">$ 90.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred tax liabilities, other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetsValueReductionInValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetsValueReductionInValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesValueReductionInValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Value, Reduction in Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesValueReductionInValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredtaxliabilitiesGILTItaxcalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, GILTI tax calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredtaxliabilitiesGILTItaxcalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductionindeferredtaxliabilityundistributedforeignearnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in deferred tax liability, undistributed foreign earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductionindeferredtaxliabilityundistributedforeignearnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totaldeferredchargesandprepaidtaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deferred charges and prepaid taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totaldeferredchargesandprepaidtaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TransitionTollTaxRepatriationTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transition Toll Tax Repatriation Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TransitionTollTaxRepatriationTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_DenmarkManufacturingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxAssetLiabilityTypeAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977017784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 113.4<span></span>
</td>
<td class="nump">$ 106.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory, other reserves and accruals</a></td>
<td class="nump">165.9<span></span>
</td>
<td class="nump">162.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles, net</a></td>
<td class="nump">1,546.0<span></span>
</td>
<td class="nump">3,380.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">2,080.3<span></span>
</td>
<td class="nump">130.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">103.1<span></span>
</td>
<td class="nump">103.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,753.9)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">2,278.1<span></span>
</td>
<td class="nump">3,905.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Purchased intangible assets</a></td>
<td class="num">(396.2)<span></span>
</td>
<td class="num">(350.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="num">(1,143.7)<span></span>
</td>
<td class="num">(1,381.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="num">(174.6)<span></span>
</td>
<td class="num">(1,617.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther', window );">Depreciation, amortization and other</a></td>
<td class="num">(227.0)<span></span>
</td>
<td class="num">(135.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (1,941.5)<span></span>
</td>
<td class="num">$ (3,484.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation amortization other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesDepreciationAmortizationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredtaxliabilitiesGILTItaxcalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, GILTI tax calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredtaxliabilitiesGILTItaxcalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980269096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets', window );">Divestiture of Denmark manufacturing operations</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization', window );">Internal reorganization of certain intellectual property rights</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">TECFIDERA impairment</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">U.S. tax reform</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent', window );">Swiss tax reform</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">19.70%<span></span>
</td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089968197816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Accounting for Uncertainty in Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance at January 1,</a></td>
<td class="nump">$ 129.9<span></span>
</td>
<td class="nump">$ 114.2<span></span>
</td>
<td class="nump">$ 66.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current period</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior periods</a></td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="nump">58.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior periods</a></td>
<td class="num">(63.6)<span></span>
</td>
<td class="num">(10.3)<span></span>
</td>
<td class="num">(13.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute expirations</a></td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlement refund (payment)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlement refund (payment)</a></td>
<td class="num">(35.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance ar December 31,</a></td>
<td class="nump">$ 75.7<span></span>
</td>
<td class="nump">$ 129.9<span></span>
</td>
<td class="nump">$ 114.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089966633976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">$ 272.7<span></span>
</td>
<td class="nump">$ 244.2<span></span>
</td>
<td class="nump">$ 243.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">$ 906.7<span></span>
</td>
<td class="nump">$ 1,064.5<span></span>
</td>
<td class="nump">$ 1,007.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977074904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 117,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(681,800,000)<span></span>
</td>
<td class="nump">150,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized investment gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,800,000<span></span>
</td>
<td class="nump">150,100,000<span></span>
</td>
<td class="nump">$ 128,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,329,600,000<span></span>
</td>
<td class="nump">1,348,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">709,900,000<span></span>
</td>
<td class="nump">803,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliAndSangamoMember', window );">Denali and Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Fumapharm AG | Twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Fumapharm AG | Each additional one billion up to twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">$ 20,000,000,000.0<span></span>
</td>
<td class="nump">$ 20,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_DenaliAndSangamoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_DenaliAndSangamoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_TwentybillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_TwentybillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089972029512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail - Other Income (Expense), Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">$ 112.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(222.5)<span></span>
</td>
<td class="num">(187.4)<span></span>
</td>
<td class="num">(200.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on investments, net</a></td>
<td class="nump">685.7<span></span>
</td>
<td class="nump">204.7<span></span>
</td>
<td class="nump">119.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(10.7)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(9.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">$ 497.4<span></span>
</td>
<td class="nump">$ 83.3<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089966611512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail - Gain (Loss) on Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">$ 693.9<span></span>
</td>
<td class="nump">$ 200.1<span></span>
</td>
<td class="nump">$ 127.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions</a></td>
<td class="num">(12.1)<span></span>
</td>
<td class="num">(50.0)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized during the period on equity securities</a></td>
<td class="nump">$ 681.8<span></span>
</td>
<td class="nump">$ 150.1<span></span>
</td>
<td class="nump">$ 128.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089979850680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail - Accrued Expenses and Other (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,276.0<span></span>
</td>
<td class="nump">$ 1,198.9<span></span>
</td>
<td class="nump">$ 1,051.3<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">3,145.3<span></span>
</td>
<td class="nump">2,765.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">1,080.6<span></span>
</td>
<td class="nump">1,001.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">389.9<span></span>
</td>
<td class="nump">281.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related Liabilities, Current</a></td>
<td class="nump">333.8<span></span>
</td>
<td class="nump">309.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued Royalties, Current</a></td>
<td class="nump">218.5<span></span>
</td>
<td class="nump">220.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">181.5<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Business Combination, Contingent Consideration, Liability, Current</a></td>
<td class="nump">149.6<span></span>
</td>
<td class="nump">148.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="nump">791.4<span></span>
</td>
<td class="nump">798.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">$ 3,145.3<span></span>
</td>
<td class="nump">$ 2,765.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974851272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - OCREVUS (Details) - OCREVUS<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage', window );">Royalty operating profit threshold for highest royalty rate percentage</a></td>
<td class="nump">$ 900.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Collaboration agreement term</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">13.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty operating profit threshold for highest royalty rate percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089975182040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details) - RITUXAN<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaAbstract', window );"><strong>Co-promotion profit sharing formula</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977037560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Profit Sharing (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of co promotion operating profits first fifty million</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of co promotion operating profits first fifty million</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales trigger gross sales threshold</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti Cd20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti Cd20 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti Cd20 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futurepercentageofcopromotionoperatingprofits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future percentage of co-promotion operating profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futurepercentageofcopromotionoperatingprofits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_NewAntiCd20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089971820568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details) - GAZYVA<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaAbstract', window );"><strong>Co-promotion profit sharing formula</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089972337752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 13,444.6<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 419.0<span></span>
</td>
<td class="nump">$ 560.1<span></span>
</td>
<td class="nump">$ 478.3<span></span>
</td>
<td class="nump">$ 520.4<span></span>
</td>
<td class="nump">$ 600.8<span></span>
</td>
<td class="nump">$ 595.8<span></span>
</td>
<td class="nump">$ 576.4<span></span>
</td>
<td class="nump">$ 517.4<span></span>
</td>
<td class="nump">1,977.8<span></span>
</td>
<td class="nump">2,290.4<span></span>
</td>
<td class="nump">1,980.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080.2<span></span>
</td>
<td class="nump">1,542.4<span></span>
</td>
<td class="nump">1,431.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 897.6<span></span>
</td>
<td class="nump">$ 748.0<span></span>
</td>
<td class="nump">$ 548.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089972064584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Ionis (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,805.2<span></span>
</td>
<td class="nump">$ 1,955.4<span></span>
</td>
<td class="nump">$ 1,816.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,990.9<span></span>
</td>
<td class="nump">2,280.6<span></span>
</td>
<td class="nump">2,597.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments', window );">Expected license fee and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Upfrontpaymentforcollaborationagreement', window );">Upfront payment for collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="nump">$ 155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totalpaymenttoentercollaborationagreement', window );">Total payment to enter collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInCommonStockSharesPurchased', window );">Investment in common stock, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstockvalue', window );">Investment in common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonpurchaseofcommonstock', window );">Premium on purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | SOD1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286.6<span></span>
</td>
<td class="nump">$ 293.0<span></span>
</td>
<td class="nump">$ 238.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Minimum | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage of royalties as per collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Maximum | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage of royalties as per collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments when meeting certain sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected license fee and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInCommonStockSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment In Common Stock, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInCommonStockSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstockvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstockvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonpurchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonpurchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totalpaymenttoentercollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total payment to enter collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totalpaymenttoentercollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Upfrontpaymentforcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment for collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Upfrontpaymentforcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SOD1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SOD1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089985238456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Eisai (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfDevelopmentCostsIncurred', window );">Percentage of development costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="num">$ (77.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfProductCandidates', window );">Number of product candidates | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossOnContractTermination', window );">Loss on contract termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfDevelopmentCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Development Costs Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfDevelopmentCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The loss recognized on termination of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 275<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84167019&amp;loc=d3e54681-109401<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089978619704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details) - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat</a></td>
<td class="nump">$ 219.3<span></span>
</td>
<td class="nump">$ 348.7<span></span>
</td>
<td class="nump">$ 232.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">174.3<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | E2609 and BAN2401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Total sales and marketing expense incurred by the collaboration</a></td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974067608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to Aducanumab Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="num">$ (77.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">174.3<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AducanumabMember', window );">Aducanumab | Research and development | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Total UCB development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152.0<span></span>
</td>
<td class="nump">179.4<span></span>
</td>
<td class="nump">264.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.6<span></span>
</td>
<td class="nump">98.7<span></span>
</td>
<td class="nump">234.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AducanumabMember', window );">Aducanumab | Selling, general and administrative | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Total UCB development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353.0<span></span>
</td>
<td class="nump">27.4<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193.7<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 27.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969315672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details) - Research and development - UCB Pharma S.A. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Total UCB development expense</a></td>
<td class="nump">$ 58.3<span></span>
</td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="nump">$ 29.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</a></td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="nump">$ 14.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977017784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Alkermes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,990.9<span></span>
</td>
<td class="nump">$ 2,280.6<span></span>
</td>
<td class="nump">$ 2,597.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
<td class="nump">$ 68.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage of royalties as per collaboration</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltiesPayablePeriodPostFDAApproval', window );">Royalties payable period, post FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltiesPayablePeriodPostFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Payable Period, Post FDA Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltiesPayablePeriodPostFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089980261960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Bristol Myers Squibb (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,990.9<span></span>
</td>
<td class="nump">$ 2,280.6<span></span>
</td>
<td class="nump">$ 2,597.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="nump">62.4<span></span>
</td>
<td class="nump">$ 144.0<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089974016488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Acorda (Details) - Acorda - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignSalesRequiredToTriggerMilestone', window );">Foreign sales required to trigger milestone</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income</a></td>
<td class="nump">$ 44.5<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="nump">$ 36.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments when meeting certain sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignSalesRequiredToTriggerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign sales required to trigger milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignSalesRequiredToTriggerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AcordaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089978920696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Other Arrangements (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,990.9<span></span>
</td>
<td class="nump">$ 2,280.6<span></span>
</td>
<td class="nump">$ 2,597.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration, shares purchased, amount</a></td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration, shares purchased (in shares)</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global licensing collaboration, purchase price per share (in dollars per share)</a></td>
<td class="nump">$ 104.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="nump">$ 209.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">875.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Global licensing collaboration, development and commercial milestone payments</a></td>
<td class="nump">$ 1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration, shares purchased, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global licensing collaboration, purchase price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Global licensing collaboration, development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsIncAgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased', window );">Global licensing collaboration, shares purchased, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased', window );">Global licensing collaboration, shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare', window );">Global licensing collaboration, purchase price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Global licensing collaboration, development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets', window );">Global licensing collaboration, payment, selection of targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones', window );">Global licensing collaboration, payment,first milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones', window );">Global licensing collaboration, payment, sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.1<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="nump">$ 48.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Amount, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Payment, Selection of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Purchase Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GlobalLicensingCollaborationAgreementSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global Licensing Collaboration Agreement, Shares, Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GlobalLicensingCollaborationAgreementSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsIncAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsIncAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089975158056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Samsung Bioepis (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="num">$ (77.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights', window );">Number of ophthalmolgy biosimilar products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,990.9<span></span>
</td>
<td class="nump">$ 2,280.6<span></span>
</td>
<td class="nump">2,597.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232.9<span></span>
</td>
<td class="nump">241.6<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">13,444.6<span></span>
</td>
<td class="nump">14,377.9<span></span>
</td>
<td class="nump">13,452.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="nump">63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266.5<span></span>
</td>
<td class="nump">241.6<span></span>
</td>
<td class="nump">187.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">$ 96.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement', window );">Contributions by third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 280.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_JointVentureOwnerShipPercentageByThirdParty', window );">Joint venture ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 620.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620.2<span></span>
</td>
<td class="nump">580.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 673.8<span></span>
</td>
<td class="nump">&#8361; 670.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Samsung Bioepis, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Samsung Bioepis, ownership percentage before additional purchase transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to increase investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Total basis difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Net profits on investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">79.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="nump">$ 78.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Completed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments by third party in joint venture as per agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_JointVentureOwnerShipPercentageByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture owner ship percentage by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_JointVentureOwnerShipPercentageByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Ophthalmolgy Biosimilar Products, Exclusive Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089977361144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payment to Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="num">(77.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">22.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember', window );">Twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payment to Neurimmune</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember', window );">Neurimmune | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember', window );">Aducanumab | Regulatory Milestones | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember', window );">Aducanumab | Regulatory Milestones | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089969440712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Claims asserted</a></td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089982917416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 58,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities associated with uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Transition toll tax liabilities</a></td>
<td class="nump">$ 697,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697,000,000.0<span></span>
</td>
<td class="nump">697,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember', window );">Twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember', window );">Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Total aducanumab collaboration third party milestone expense</a></td>
<td class="nump">155,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Minimum | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage of royalties as per collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Maximum | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage of royalties as per collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">$ 155,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes | VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage of royalties as per collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltiesPayablePeriodPostFDAApproval', window );">Royalties payable period, post FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember', window );">Aducanumab | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember', window );">Aducanumab | Regulatory Milestones | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember', window );">Aducanumab | Regulatory Milestones | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember', window );">Neurimmune | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion', window );">Future contingent payment for annual worldwide net sales up to $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentThreshold', window );">Future contingent payment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion', window );">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG | Fumarate | Twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG | Fumarate | Each additional one billion up to twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses on funding commitment related to clinical research.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales that exceed $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales up to $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltiesPayablePeriodPostFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties Payable Period, Post FDA Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltiesPayablePeriodPostFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedPaymentTimelineofMilestoneAxis=biib_TwelvemonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_TwentybillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_TwentybillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089966245704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMinimumInvestmentReturn', window );">Percentage of minimum investment return</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Unfunded net pension</a></td>
<td class="nump">$ 75.7<span></span>
</td>
<td class="nump">$ 42.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee benefit plan obligations</a></td>
<td class="nump">170.0<span></span>
</td>
<td class="nump">127.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension cost (reversal)</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH', window );">SWITZERLAND | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension cost (reversal)</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_DE', window );">GERMANY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee benefit plan obligations</a></td>
<td class="nump">75.5<span></span>
</td>
<td class="nump">59.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_DE', window );">GERMANY | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember', window );">Domestic Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan', window );">Minimum qualifying age for employee benefit plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses related to savings plan</a></td>
<td class="nump">$ 44.3<span></span>
</td>
<td class="nump">44.8<span></span>
</td>
<td class="nump">$ 42.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">$ 114.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum qualifying age for employee benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumQualifyingAgeForEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMinimumInvestmentReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum investment return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMinimumInvestmentReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089970810952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 3,844.8<span></span>
</td>
<td class="nump">$ 3,674.3<span></span>
</td>
<td class="nump">$ 3,601.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 2,180.6<span></span>
</td>
<td class="nump">$ 2,028.8<span></span>
</td>
<td class="nump">1,748.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DK', window );">DENMARK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089981326168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Geographic Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 13,444.6<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3,844.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,674.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,844.8<span></span>
</td>
<td class="nump">3,674.3<span></span>
</td>
<td class="nump">3,601.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1,496.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,493.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,496.3<span></span>
</td>
<td class="nump">1,493.2<span></span>
</td>
<td class="nump">1,152.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">2,321.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,162.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,321.4<span></span>
</td>
<td class="nump">2,162.9<span></span>
</td>
<td class="nump">2,442.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,301.6<span></span>
</td>
<td class="nump">2,690.3<span></span>
</td>
<td class="nump">2,795.7<span></span>
</td>
<td class="nump">2,904.6<span></span>
</td>
<td class="nump">2,924.8<span></span>
</td>
<td class="nump">2,894.7<span></span>
</td>
<td class="nump">2,880.3<span></span>
</td>
<td class="nump">2,680.0<span></span>
</td>
<td class="nump">10,692.2<span></span>
</td>
<td class="nump">11,379.8<span></span>
</td>
<td class="nump">10,886.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900.1<span></span>
</td>
<td class="nump">6,713.8<span></span>
</td>
<td class="nump">6,800.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,656.4<span></span>
</td>
<td class="nump">3,794.5<span></span>
</td>
<td class="nump">3,370.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596.7<span></span>
</td>
<td class="nump">320.3<span></span>
</td>
<td class="nump">281.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539.0<span></span>
</td>
<td class="nump">551.2<span></span>
</td>
<td class="nump">434.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">419.0<span></span>
</td>
<td class="nump">560.1<span></span>
</td>
<td class="nump">478.3<span></span>
</td>
<td class="nump">520.4<span></span>
</td>
<td class="nump">600.8<span></span>
</td>
<td class="nump">595.8<span></span>
</td>
<td class="nump">576.4<span></span>
</td>
<td class="nump">517.4<span></span>
</td>
<td class="nump">1,977.8<span></span>
</td>
<td class="nump">2,290.4<span></span>
</td>
<td class="nump">1,980.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,897.4<span></span>
</td>
<td class="nump">2,211.9<span></span>
</td>
<td class="nump">1,903.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="nump">78.3<span></span>
</td>
<td class="nump">76.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 132.0<span></span>
</td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="nump">$ 407.6<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 145.7<span></span>
</td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 292.4<span></span>
</td>
<td class="nump">774.6<span></span>
</td>
<td class="nump">707.7<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733.6<span></span>
</td>
<td class="nump">585.8<span></span>
</td>
<td class="nump">457.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.9<span></span>
</td>
<td class="nump">112.2<span></span>
</td>
<td class="nump">96.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140089973497528">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,852.6<span></span>
</td>
<td class="nump">$ 3,376.1<span></span>
</td>
<td class="nump">$ 3,681.6<span></span>
</td>
<td class="nump">$ 3,534.3<span></span>
</td>
<td class="nump">$ 3,671.3<span></span>
</td>
<td class="nump">$ 3,600.1<span></span>
</td>
<td class="nump">$ 3,616.7<span></span>
</td>
<td class="nump">$ 3,489.8<span></span>
</td>
<td class="nump">$ 13,444.6<span></span>
</td>
<td class="nump">$ 14,377.9<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,361.9<span></span>
</td>
<td class="nump">2,927.0<span></span>
</td>
<td class="nump">3,270.5<span></span>
</td>
<td class="nump">3,080.0<span></span>
</td>
<td class="nump">3,224.2<span></span>
</td>
<td class="nump">3,170.1<span></span>
</td>
<td class="nump">3,140.4<span></span>
</td>
<td class="nump">2,887.8<span></span>
</td>
<td class="nump">11,639.4<span></span>
</td>
<td class="nump">12,422.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">357.6<span></span>
</td>
<td class="nump">703.9<span></span>
</td>
<td class="nump">1,606.5<span></span>
</td>
<td class="nump">1,392.6<span></span>
</td>
<td class="nump">1,439.7<span></span>
</td>
<td class="nump">1,545.9<span></span>
</td>
<td class="nump">1,494.1<span></span>
</td>
<td class="nump">1,408.8<span></span>
</td>
<td class="nump">4,060.5<span></span>
</td>
<td class="nump">5,888.5<span></span>
</td>
<td class="nump">4,474.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 357.9<span></span>
</td>
<td class="nump">$ 701.5<span></span>
</td>
<td class="nump">$ 1,542.1<span></span>
</td>
<td class="nump">$ 1,399.1<span></span>
</td>
<td class="nump">$ 1,439.7<span></span>
</td>
<td class="nump">$ 1,545.9<span></span>
</td>
<td class="nump">$ 1,494.1<span></span>
</td>
<td class="nump">$ 1,408.8<span></span>
</td>
<td class="nump">$ 4,000.6<span></span>
</td>
<td class="nump">$ 5,888.5<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="nump">$ 4.47<span></span>
</td>
<td class="nump">$ 9.60<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 24.86<span></span>
</td>
<td class="nump">$ 31.47<span></span>
</td>
<td class="nump">$ 21.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="nump">$ 9.59<span></span>
</td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="nump">$ 8.39<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 24.80<span></span>
</td>
<td class="nump">$ 31.42<span></span>
</td>
<td class="nump">$ 21.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc. (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">153.7<span></span>
</td>
<td class="nump">156.9<span></span>
</td>
<td class="nump">160.6<span></span>
</td>
<td class="nump">172.8<span></span>
</td>
<td class="nump">177.8<span></span>
</td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">187.1<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc. (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">154.0<span></span>
</td>
<td class="nump">157.2<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
<td class="nump">178.2<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">190.4<span></span>
</td>
<td class="nump">197.0<span></span>
</td>
<td class="nump">161.3<span></span>
</td>
<td class="nump">187.4<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,301.6<span></span>
</td>
<td class="nump">$ 2,690.3<span></span>
</td>
<td class="nump">$ 2,795.7<span></span>
</td>
<td class="nump">$ 2,904.6<span></span>
</td>
<td class="nump">$ 2,924.8<span></span>
</td>
<td class="nump">$ 2,894.7<span></span>
</td>
<td class="nump">$ 2,880.3<span></span>
</td>
<td class="nump">$ 2,680.0<span></span>
</td>
<td class="nump">$ 10,692.2<span></span>
</td>
<td class="nump">$ 11,379.8<span></span>
</td>
<td class="nump">$ 10,886.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">419.0<span></span>
</td>
<td class="nump">560.1<span></span>
</td>
<td class="nump">478.3<span></span>
</td>
<td class="nump">520.4<span></span>
</td>
<td class="nump">600.8<span></span>
</td>
<td class="nump">595.8<span></span>
</td>
<td class="nump">576.4<span></span>
</td>
<td class="nump">517.4<span></span>
</td>
<td class="nump">1,977.8<span></span>
</td>
<td class="nump">2,290.4<span></span>
</td>
<td class="nump">1,980.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 132.0<span></span>
</td>
<td class="nump">$ 125.7<span></span>
</td>
<td class="nump">$ 407.6<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 145.7<span></span>
</td>
<td class="nump">$ 109.6<span></span>
</td>
<td class="nump">$ 160.0<span></span>
</td>
<td class="nump">$ 292.4<span></span>
</td>
<td class="nump">$ 774.6<span></span>
</td>
<td class="nump">$ 707.7<span></span>
</td>
<td class="nump">$ 585.9<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>200
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MOY\$/1N0/_$UYD_ZZ)C83UE*^6!/9M%5P[.,>,)#8R$8_'OD8YXD%@EX_%N
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MOEN)2HDBSYCF&7K0\ >2JA426_2NVHB2HVOTZ\,:77Q]B=2>2:Y07J'W>5%
MUM05^GIX>[/0,"3C>+'I7G_?OIY,O!X3]%Y4>J_0=U7&LW,'"^!R(D2.A.Z)
MU^.:;^8HQ%>(!"1P#&CU:G.<.LS7KS=//&S"4WK"QA^=\/>+T*R ^?7$JYH[
MX]O:QXV]F>1/=SBDE,Z7-XNG(6T'CH9Q/$_/<6NGOX@,<&=$Z(D(;0S#R3I3
M&K$J0_P%EBS%U1M/=**3T\@;G<8I5*IB!8=:Y"^;HL[R:H=8*:3._V+MT@)O
MS<L#RZ4I;8-GFS_J7$+!YY5FU2Y_+#AB2G'MC' [AF08D22(YF048 <LC:(Y
M'<77Y0TOYZ$[O,M3));>2'SDBC.YV3=D,RB70AP,6Q>?I36",$V#<2&L;!@A
M23"NJ[4#%J7Q(#IG?.(3G]C+YP$: 23R"NUXQ25, <.+9;  YDI+9GJ%BUKL
M&$Q Y]&(F@,6QG0>CZ@Y8#B83%5RHI9XJ;W]+VLSL89(EW2>C/@Z4$EJS7P;
M%=-XBFUZ8IM^9HH6!7L4LJ5[D&*;:W11"*7:?@))=O%*'1DB5HDZ4!1;%=JB
MEF<S+G*SPD'?-@,OKXL?0%-=(D,$ ;$,"E+I7->2FR3^" V1RV^^(C3Y-KM"
M:UZ!J/H$?;NJMZ!T:D,;@79KP^+NFX%%[CHE5BD[8+#HA*,0=*AA#(*)" R$
M _Z2"&RAAM$3*VH.[:KD3-62'VMZ RT>&)L[N%1YUA%W\L8V[V0Y9K1RP9:A
M-85=,$RFBAJ3GCSQ3^)^EEY#46\X!$%^P1K<N1\F)+92:V.",3UB=Q,\+))S
M>KWJP'[9 >U$R_I8J!N8ISNW^NC\>,:XZB!G8QR7\=KA!T^T$-Q+#DQ?(9XV
M8^7AY$&M029):G<.!RX.0\>$<^ B6)FG"J]7/-@O>3I1OI6B_-P"8BL-&D7!
M'(\IV;@XH,1:1AVX*$F2 >Z<4B]=L%^[_*SW7,)$:HA==%FZO$(5=T\=6W%0
M$!QT3,N&):&=IZ5==WB"4*]=L%^\=#EZY+ MYT=BFKT<*["M1EA ])]F]]2N
MH%NX-#V$\X:Y>0 FS@#8N@1$3FS7JHV+,8FLON_REZ3I9&)[H8/]2N>=Q=Q)
MQ]8=:4KL!3]Q9"I*QEQL9Y@"YRDNO8S!?AWSW2E=%VU"+[\\;[9<N;96CI4#
M%:=S&@S^X3%I6^%,='?2ZQOBUS<_ 966J(L*L54'#9:!58(.7+-FC)=_8NL3
M2F,Z0:*7*,0O47H21\G)M);Y8ZV9D=5:H$I41IQ(T6PWC.;FT,:U^EPNB:TK
M(DM1KSJ4KX,['-%PJDV07I\0OSX9,!]3OL\%*#%SNC-W,B/6 8 I/NL\P8%S
MI];ACX;!0*F=4^PU"@F])PH#BM 'V\,IWZ$"Z74#\>N&>Z;R#0(M5T%-J-Z[
M+Y1F64"9V>S(@<6E,\+MV].S;<L\L0)LPT(\IV.%Z_(&>Z"I"NJ%!O$+C75>
MU.9,\/\+0^0,PS@*-LI$@8RCX' &*C.9B$*O3<C26V2_-^?&/+MF3Z"U=OQX
M!EJK1ONC#2LV=<',[L9;>[UV('[M\(]KKQV8.])V@\=+^\#'!4OBL5Y<.V D
MH%/G@Z17"\2O%OY%P?FX.P3!$EM=UP5++%&Y=L!($$TNU[VZ('YU\4&*#+9;
M#LU[?FK<M^_0W[Y?<6X<V >]P1*$U_A<TP7$(6B2L?9R>DQ@[SXQ"\.^CX?^
M/OZQX]%N>UBE\^L5: 9D-@[LP&L-4P9VX3O)2N4+7]\^0W_[?$7X'#OO-(ZM
M]<N!(R0-K,IR^DN"J7/4</ !P;^5;W97OJ#T;3%\S7;:&Q1J54 <.SY%.&!!
M;)W=.&!1$ED+S6+P\:OD<M=\1%2P[:\KW7XV.CT]?:A\VWR>&SV_QV_6[>?&
MWDW[]?,]D[N\4JC@6W )V@6ZC6P_*+8W6AR:3VR/0FM1-I=[SC(N#0!^WPJA
MCS?F!:?/NG=_ U!+ P04    " # @T-2";NI93$$  ":#@  &    'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;)U7VW+;-A#]%8PF#_%,3!*\B?3(FK&E7O+@
MU!/7R4.G#Q )B6A 0 4@R>G7%P1IFB)!VHD>)%[.[N+L$1:[BQ,7WV2!L0)/
M)67R>E8HM;]R79D5N$32X7O,])LM%R52^E;L7+D7&.7&J*2N[WFQ6R+"9LN%
M>78OE@M^4)0P?"^ /)0E$M]O,>6GZQF</3_X3':%JAZXR\4>[? #5H_[>Z'O
MW-9+3DK,).$,"+R]GMW JS4,*P.#^$+P27:N045EP_FWZN9C?CWSJA5ABC-5
MN4#ZYXA7F-+*DU['OXW361NS,NQ>/WO_U9#79#9(XA6G7TFNBNM9,@,YWJ(#
M59_YZ7?<$(HJ?QFGTGR#4X/U9B [2,7+QEBOH"2L_D5/32(Z!C >,? ; []O
M$(X8!(U!\%:#L#$PJ79K*B8/:Z30<B'X"8@*K;U5%R:9QEK3)ZS2_4$)_99H
M.[5<<28Y)3E2. </2O]H494$? M6O-1_I:+2^(C!1Y;Q$H-+\/BP!N_?78!W
M@#!P1RC5\LF%J_1B*I=NU@2^K0/[(X&A#^XX4X4$O[ <Y^<.7,VBI>(_4[GU
M)SVN<>:  'X ON=[E@6MWFP.4XOY^NWFR02;H!4F,/Z"$7^M%J-2_'6SD4KH
MC?/W1+BP#1>:<.%(N$^ZQ)#:+U)*D,U!H0W%0'%P2_@.LRJJ8Y.Y]CLW?JLJ
M<UR&GN<Y\<(]=I,_A$5)DCC1.6QM\18&GC-O86?LHI9=-)G,/U2!!<C.LEBS
MO9K(7=QZCR=S]\ATQ:7D/[V#=KK22O"><BFQO "ZL$F<'011!$N CHA0DU5=
MKX%$%'\ #!N!%7JRY;:.FW2R<>D[22^S0U#BP/3LTTNRQ6W@I/84S]LDS'\^
M"1F2!=CJ,P84.-]A^1KO^7"!,(D'S"TP/W;Z;(<H&*2.;Z>;M'232;J_#3@R
MLX..6"JS:]]&-+$H$0SVSA#EPSYH/00%G=UU1C)M2:8_K^F^.?PWF.$MT20W
ME.Q0=9B_1CJUDNY5@I4%!0?E8@B*QDA#[^5(]"9IKPY"8)9]![JZ,DE1W:#D
M_QQJ::UGG3=82.H[J=?YP!X_BPGT@OY_?&V!7<;S#NR<9.?<AY,D_^0*4<!'
M"V.M]<5K6C91SF6*!S16%ASTHLXN;-@.8?-X5%'_A:P_K:B-X ^><TV(LPV6
M!,.B9,%%:1ITCK"&ZA 71MY\K##!E\8!!C].ME9SP)EQ_9HIP74;QW8:K+#0
M%>S5NM4LH;OXV.M7WI4%=>DY83\10U3HCQU'\*6A@=,=C2T-5BK#EB-(TGE?
MKY4%9W0-^G0L+4P4>0[L$7([37N)Q<X,/U+OQ0-3==/;/FT'K!LS5O2>WU:#
MEQD&7MS44]L=$KNJ;%.\U2YU%Z6[)%$/0O6-XGLS&FRXTH.&N2ST\(A%!=#O
MMYRKYYLJ0#N.+O\'4$L#!!0    ( ,"#0U))93,D\P8  #0=   8    >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&ULK5EM;]LV$/XKA%<,+9#8XHO>TB1 DV!;
M@+4+FG;[S,BT+40258IVDG^_TTLDV:3H;*@_V))\/#X\W=US1YX_2?58;830
MZ#G/BNIBMM&Z/%LLJF0C<E[-92D*^&<E5<XUW*KUHBJ5X,MF4)XMB.<%BYRG
MQ>SRO'EVIR[/Y59G:2'N%*JV><[5RY7(Y-/%#,]>'WQ-UQM=/UA<GI=\+>Z%
M_E[>*;A;]%J6:2Z**I4%4F)U,?N$SZZ95P]H)/Y.Q5,UND;U4AZD?*QO;I<7
M,Z]&)#*1Z%H%AY^=N!995FL"'#\ZI;-^SGK@^/I5^V_-XF$Q#[P2US+[)UWJ
MS<4LFJ&E6/%MIK_*IS]$MR"_UI?(K&J^T5,K&P8SE&PK+?-N,"#(TZ+]Y<^=
M(48#,)L80+H!Y*T#:#> -@MMD37+NN&:7YXK^814+0W:ZHO&-LUH6$U:U*_Q
M7BOX-X5Q^O):%I7,TB778HFN>,:+1*#[6EV%3M'W^QOT_MT'] ZE!?J<9AE8
MOCI?:)BX'KY(NDFNVDG(Q"0W(IDCBD\0\8AG&7[]YN$XWA^^@.7V:R;]FDFC
MCTZM>:N4*#3B507+/'-HI+U&VFAD4QIYM4&\6**DOA _MNF.9S"%U5:MJK!1
M54?9[A)3BN?D?+$;V\04(S&F\[ 7VT/*>J3,B?0S5X]"\X=,H$HD6Y7J5%A1
MMFJB,4H21O/X *5%S _(:#%[*/T>I>]$^2E)Y!;,!XDB$6!+@'N""J%M0'T3
M06VGZ "H12R*O+EO!QKT0 ,GT)NM0"LE<WCY.CV]OB$>TANA>"FV.DU0J>1:
M\=QJX,  Q "V?P#;E/)C;\J\88\Z=**^+7;@G%*]V'"%IJ&\()H'!\!,L<AC
M4\"B'ECD!/97;3Q(>^/XM&&,S,DC/,<'$%NI8"054&P'&/< 8R? ;U+S[ T
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MEQ#(;$L:0JF!Z9GA!IATS]S]AML#E*RR^E:>=J< ,M RM%(5!O09Q'#K+"'
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MXS8..(+;$F,3T$0$M38W32,@WCH@GC(@IZL;I56T><)OR^($P'T2+ZP([OU
M0?&$A2'"[ZNQI[N63S1F&OYUU_YUE?Z=A6GM5Q;+O ([Z%UAQ2V'6_-8Q/!>
MJ:TTG.JMG>HIG=JXL[-,G6Y(*XO](5WZ49;[RG)]=;>UDGK TTH*'.9WJVF<
M9IOW9+ JZ8E91_D;;/_2"'4%H-AUG\OS_@<=K!$T9-=/7.Q7"QM<P-G 78$X
MF+]GL9K#%#DV1EZ5R$TUT"*V;?/1-<3=:G%-&C8>?"$-#5F8%$^[7CY[+\JU
M-.XB8O8:H28 "LI>':P9MEI,([6:WF?8X.S%.C7)PJG'C$I,(V-[@LYBA3V
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M>#@P1@Z-D><0$B/J\;<1%E]3Y!B+<I1'-LFH)2E62]+7;%*<8%%+@FEL!+L
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MM(E%ZT*#[N$XR=]H8E'@L'>/S\VA$6I$Q;/J_*E=G:%F=.HZB.[U'(N60K&
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M@/W]/HZSZDW^]5'KKQ,]_C]02P,$%     @ P(-#4@M#AX#_*   V80  !@
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MI,:S,BCUC0WP^8K/ M4'O%9#$5,GT@Z9@C1K(GN42D)])EU5TT#1XA7=7"B
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M,5,1IG5XTT+2UFU[#G#!74M?:WX!<BA;I,BE]K8E?F/ =&5T"BJ-FJ\WE<>
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M]2:P+,"N ]-:6QR@%5D"W5*LR<N*M!-R42O6TQ K671SJIDUY6Y*/1DRZKA
MYZ^ZO)-Y>[=6'U::C:?CX2S0&^L2/MN!%B)251FY;W\99%OZRB@.X,"/!=-W
M:8ON)UQWH-RD]+1Z(6E?4B)-\<%UX "0^O<N3B1TC+.$2W<E>O-Z ]VXX.0>
M>6A"/#^&J#IDRVV!=[E#I_XAM$(N:W[DCTGB(7\JI.0M.:$XIPPHY$J7EBVC
M)<-5Z+9A-@PR'L'H;K1%8Y/T=]$XZAI]P<PT_C>*L11G16**O?7$OBE.-%UR
M5%W<U>/7D0^2P^W6P7O7HZ:U]V9#[+H1W:'TOWG7KF-1-S0NV4XN?*[K$=(
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M_\45J4 +9W"3PCE=)E/4C.LY^U2W[VXL1&(,]!Z^3U7$S_",[E4+T43V6IE
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M$88&X/M< ^WB VW0W-:__R]02P,$%     @ P(-#4J44%3Z-#@  %S(  !D
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M6D_8TLMKI*>L?9T^;.1ZU@T%]\?7':G=+85?YA4*M*_6VTR/M7\HHV]!-II
MVD$:_RRJB=?E -P*@9JW@Q>7[[^5V>;[5X=*EKR]LL[=_Y\Z5;=UM*D9I]/(
M'EUF4XQNC?CK*3Y7Y4*YLV$4?RX/T)DSI)0Y,!2-G*FZI/QZ5!FJ'LD?]2!$
M+N$^M4]1P3^D*9X[+A0-6TS)E9%^S2,2'-\Q#_2QK%(DFJ5R1D%( [G.DHB]
MJ<KL6[Q,E6L=>\-33#N21=GD::-M_TZ[]'Z;Z=VI\-^14NQ[EX[-_,#0>#[U
M)BWO3A;IYXXV=3"F V;=?>/2./=AH9NP&ZKKJ]+H#"7E,[^2WZ/V,#AU(? 0
MM;_:S9(]\8+36YGQ3^/]H68(>2[:"//W:=F!5WM4/ D=E/)55'RR<\CMMT%N
M2F^ZD%N9<A=@\ O_Y+,N3;*B7_+6M<P.5(B?1\'):3>C&?)#A\-" A1W*5.R
MPU1%X8!RQF[NRW5LJQ/./D#^E5^T[/M%^;'S8_V,[$U_DD (%@G9_FZ_O=O^
MU<.9_;%_M]S^R<1;6(G>U*5JB:V^-Y\> ?3QGR'8BU)O^*?_"UV6.N.O:\BJ
M#"W \Z6&T/4%'=#^+<B+_P%02P,$%     @ P(-#4JX9AYHC"P  %"8  !D
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M.3)*EVOAY2)7=5KIGY03IK)BU0Z4SBF,V6F_ 7)\9;77U&DE<N6<\!M9BOE
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M3BSNB7=;]6K*OV?^;HF5.3+P[O&EG(GQ:7C_LK6F0_ZQMB\JQ0M#J<2]DE:
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M.5SRH4'.VPA W6;1#=+>F9#G6@Q+,;KU^L<:I^#'"\0Z/O#Y!)]'9XC;X_:
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M>U/PUQGJ$V5I .Y/# J5^(,6:-YC>_%?4$L#!!0    ( ,"#0U)!%>QAP 4
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)57:V_;-A3]*Q=&"R2
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MO0(EA!0BEAC0E-TN+,1@%23!$013XL=IMJ87">/Y _M:\E3.9%PKELI,6O]
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MQV%ZJ[)]Q&/LIN$"O(=M\![N@/?D<(J]2:7;4,V98OJL:#=Z-D4^F/1%#34
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M<VO;9P0..&%7\4!:#=%1*?/T*7N%'1Q-D?BH 4/2+L);WT#\20K03;*UN(<
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M"QHIW:54%Z>LK"SSG%(P:G!7*Z0G-O=Q)U-L O3QE2 B__J761S%?R?G2\.
M#'(K]%KF#=/PID3=EXRZE%3'(JX!'#1/4TO'!#B]F+#WGQKV@CPIU6R[- [S
M"_RK=701>?+!1%"4#H4R-UNV1SMPCKC?IV!AQR+0-ZNQL#[?<G2(;4,<\>98
MMZ(Y./H$P0A80 7&X.L3\3K,BFKE_K:\X80&MYT<$@NM6,#(54YD&O_5CM F
MU#2,0=J<49:ZPM&>6C=*;4X!7#NZYAR6EYGRQ'IRB JD55!:U"FWH1K*'BWC
MV<X[N.\.I(J'QURYGX+]VXKO6P&MFIY&&7LZE>Q.JS5-FQRCN *"U^'^LSN
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MH!,L!9,@:)&#;HLGK J6NMK9+2*#.A^>!PJO>E*T/=''++!GE_Y'5P]HCJQ
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M! _U+4PVD5$*"DI9/6K0HQDQZET&L/Y!< JD[S8L!@3;QPKM\(V.66/_@5$
M#*!04G:40;F$O%W;68H-*.#*YCF=4#?*)\V0/>^^_J73!HE.PX\5?H5'5G7%
M;18$6)!UJ<I\=T5$G(N'P<V'F[NW-[S*CV_';V]"!;RP!DD\@],=9>0,.R5-
MU\I:S"1C8PX?L($5,%&:V_Y;HJLQN1E--#OV!,/7@FX:(_2H[ZZC[5?T6O
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MFOZERI<X)*ZWRE/Z<2%!3 I\ +['/\JM?\$)5GGQA<A[];]02P,$%     @
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M2Z.Q1IJP1\M(_*0:"*T:H\3'9OX._ZY_$+\J4<A;Z(6-92GGULE(%B87I<Y
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M*]=+#7 (C6_FWP0%PAJ):V:?)S'5D%9R9XD%!<)I@^^)Q-!:@M/SAOSEN93
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MGG8_FES'WPHVR^,O+F\QXVMTI%(ML'4R.CL="!=_Q8A?@JWYEX.Y#<%6_+$
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M=.N"EL,OSF:WE][M^/#'#:0 =,HZXDE0X.TY)#=;+P>BT+E>ID0O.?[^WA*
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M%@W ][&!(88?M$'Z[P=O_P]02P,$%     @ P(-#4J_E'^,6#   [B$  !D
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MMH[.=FS348,*D75B,GU1T,S11/J >!9S&=(R;Q<^T7;6<!)2O@9> B9-VLC
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M+<#SA04.FP]T0/<O'F__!5!+ P04    " # @T-2Q1K/F(4#   9"   &0
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MT_#?NXAV2LL6;S=[$<!][5!%TT8,S/\&=G\!4$L#!!0    ( ,"#0U+#9E+
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MSD?"I;=&Z2+8.KZI05L.MHI?2Y+(&!; \Z6UH;O@ _I7=S?_ 5!+ P04
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M(N:-TA4P6^N@0FD5=DES /.E"'Q(;].(H4P@9^(^B'WBBST&W5/W&R=?EQ!
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M7I<+XM)(G1;!;G&,O;$!AF(4-_ O1+EX -ZOK V[132P_U]S\B]02P,$%
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M'<,'II/I>EW>PT,(J**3N[@&VI3"?HG?ZK1\_#HKT=<YB%/)WO$^SU_?P4\
MZPQH.<JK#L!(EI/6:5M. -"SH#419/9.>,1Z7A;7J7&).8C1\P11A=Z:)2(:
M$FW')V#:'-?/$ !$6#;U:N9'IPT!8RJS0/5+!%FT.,*75,&$$H*2'Z"T3/4
M!^%(99=WZ3V!DO4I$C00/?//14O:U2*B=$U$WX)0ZNDH*0J(3T6UJ3<MGA#N
MNOTJYPYC@5* <Q%#M&7&"X--+#<DQ42(NH*]PEB;$B]OLFD]GL(8\%:6][ZJ
M<OQZ53=&T ) ZH9FPNN"UV^*@C\V"OYXD@1_8&IX#IM:(?<;(N+3([PGJ.:P
M*&%[RVUR,T+729!I$2XHEZ:? /-T';/D;YOLFA_$4X<3W:S6#%5"-P1MNESJ
MW8$%U U.E:X0K>BB(!8@>P!&/2]*NC\S)')TFQL0NZN-4!>@RGG5FDA<TJ*S
MHEW _=GP23!^79.43N/2LVYHD.XKDM2JZQI/<HXZ+*)>?IN6&QB1T7QL@RM
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M:F%Q1*W2$D2W]4T*4R_(JW"+&$G:N_E%Q)CYST\W2P!AUZ!CHW CDZGTR)/
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M0@1B<[@P"L^P"Q!CD%P1!R8-(M;US7ZFMQ8WNRD94\K8E!;9&T'2P1L9V=X
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MEJAH/VEHWQW%W_-QM7WQ_?W6=SN*P#0X!Z7E)DGSE)L6S=_,O8)<@<4:R!Z
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M?L(2PM30(;&1$[7261#E&L6 E+0@>3R8\S7,E? BC?+>5Q;DA<3@^(=GJ'8
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M0R>W;Q8)^'ZL]0:Y-HZ2@R,>3'%9\Y\ O3CP>>D<G0PA&/\MZ_\ 4$L#!!0
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M$,KL-,*/U<9836/Q\P1#-C!DGB'[@.%*-:V21&) 5< /?.\U\R20$^'<M*S
M94 J,ZA?,,@?:X3B?09@5$HO*?X;2V &*B5(:V8.*^]*S<1F@]HW].Q6TA@)
M08HPY[Z]]$EF<,\Z&BN+FC-AX!/Y9N&,UF0R"R_AB91%E-!J5: Q,,ZR< S9
M) YCN.&2T_R5L%6J-(0V"U-(+IW#H[),'*5*<!?Q9!I.:#>-,_)[K_/1T30W
MJ+=>LX;JWTG;#_9P.CP+JUX-?]W[-^4KTULN#0BL*#0.+\<!Z%ZGO6%5Z[6Q
M49:4YK<U/6VHG0/=5TK9@^$(AL<R_P-02P,$%     @ P(-#4IS,BO!>!
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MY** .L,PD4*0;^XHNEL5>M1CNII#WW.932@UP9$;1S]&H[B'1B]8&Q&%ML;
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M%;1>@<]KP\D8%][!]*/:_ U02P,$%     @ P(-#4AR%,"/#"   M!\  !D
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M!N$DJP'BS$<4%UP1_HRN281G#U_2CB^IGR]N;2#H/ M#H74S+2SH[@JS8%(
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MVX4$MA4-P/M9TYCU QGH/M2?_@]02P,$%     @ P(-#4L7&7Y4K!P  RQ$
M !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULI5AK;^.X%?TKA#M3V( J
MZVG9:1(@B;-MBMUV$&>W*(I^H"7:)D8679**9^;7[[FDK'$FCF>*?M&#(N^+
MY]Q[J<N]TA_-1@C+/FWKQEP--M;N+L9C4V[$EIM0[42#+RNEM]SB5:_'9J<%
MK]RB;3U.HF@RWG+9#*XOW=@'?7VI6EO+1GS0S+3;+=>?;T6M]E>#>' 8>)3K
MC:6!\?7ECJ_%0MA?=Q\TWL:]E$IN16.D:I@6JZO!37QQ6]!\-^$W*?;FZ)F1
M)TNE/M++0W4UB,@@48O2D@2.V[.X$W5-@F#&?SN9@UXE+3Q^/DC_R?D.7Y;<
MB#M5_U-6=G,UF Y8)5:\K>VCVO]5=/[D)*]4M7%7MN_F1@-6ML:J;;<8%FQE
MX^_\4Q>''UF0= L29[=7Y*R<<\NO+[7:,TVS(8T>G*MN-8R3#6W*PFI\E5AG
MKQ^:4FT%>^*?A&'#)[ZLA1E=CBU$TX1QV8FY]6*2-\3$"?M%-79CV'U3B>JE
M@#%LZ@U+#H;=)F<ESD49LC0.6!(ET1EY:>]HZN2EWW64S:4I:V5:+=B_;Y;&
M:D#C/V=49+V*S*G(SJM8"G!%,.G?+!3NM'J6#L:\J9C=O/@H/H%@1IR*^5EU
M1-<+L^.EN!J CT;H9S%XVX9.S1D+6*G -6.96KD9*U6#LK)97S 0P W]2W#=
M;3'#!HGM4FBW2<.'!NBL:_AH1F[+<(EG=)FRMVPBQ"U%(U;2CB[8'*/&RI*]
M8VF0S*(PPE,6%$D>IFYL6A08@RE@6L/BH,B+,&=)D$51.,$]2A+<GY3E->;G
M0931]W>L"&+(F+FQZ6R&.0^O?3\RY*[56C067HM*:"=LDA7.G!GN&>YQ$*=Q
M.&4+RZU@61PF+)^%,<MR:.PMS',,33.LB#-RQYLVS5(X% <17)SAGL8%WN=B
M):"V.M8ZA(_9+)R-O$:L(R>&DR2,1IWJX22<CM@P"5-<8=OH*#ZS* \+$A(5
M69B/6(SX%9T1,>1&;%+ P#B:0K\?/@$*.#U+W [ A'SJPA '&2(Z86<XD_><
MR<]RYDYM=ZI!N W!KNJBX"S@Q@@,$V!KR9>REE8*<XHGYU4L$ ZYDB5O+"!^
MK$ZU^D=4,@[8^JHEOV F-QTWS 6[<8)^B OSUYHN7#XJ,2BA%H&-4X^O:.)@
M^@Q+E?X<, 7V:=:QW!O(RU*WO#8LGA"Z8X(%EEC>K"5E\8 UJ.EQD&<3?$B#
M=$H8_#O&4-$UMR V0Q8TQ!Q\ B33",H7&WC[)RITE8L60,!=_4P(MKA,V3^<
M,7&4.O2D -5OO&[]+$YQX4TI''KSE- [C,-XU"'L5+C?P82DF$(:T9Q@F[T,
MUM%>7+ /K2XWSCS9._M5TC"=3<)DY)[RB&CQEX>?GQ[(&B)00=8@%'$X&;V(
M_3 &22;NZP2$A(2Y0%8MI7,K8'RKM)5?.B<1?K\CPR0IB(W#.,WI?L+)8R Y
M3L^0+W)O89 A/5!LD%OA5+.F].@R[?.)B"Z%W0O1O$2;PQ<91!@+V![@W&E)
M4*T_ S UL@3L4$XH\BL*O#0;=%4NS?.3>O@:S1SJ0"FTQ=.I/0N</'2!]2$F
MD+;?R'+#I,$"P*9R.AJV:BU56L.!29KU='_WT\/\_O'FX.JOX2(,B%05ZG)K
M:&?Y4CV+\$QZF?3I97*6^X\"1:U$^+V1AP@>U+)5EVP1&-L2U9R/FE(KQ52L
M5L*UC?WPJ?1SWH0;A.G_,H*RU&M#*,YOY*3O5NMOZO.BU^L$)S'RQ/MO;K[<
M^*(=@?$1\@"57=\XTC9W=0<Z&Z06,"IU1<F5'F0 Y(&[CFOD5/,Z#[56]FC"
M@N20.(81+3Y'>V\0RBSJ\!Q!0AOA,.<R<X,0?43+W+0K]'FM)GV=9B1HDHZJ
M24[^\0_3)$[^3#E4Z ;[H04..[PY0OB!$3 !YPCL"!(P=7<09Q$].@&87@ZJ
M,JP_O!W!?KOC4CL*4@]QF'"X^WP54T)&,X%$Y4'B]ITZJ.VK%=##%GN)$)Z8
M!/^F7ZWPJ=M'-,*R""KN7V,KGB&B[U%38 4@D"&N[\^PL>C96/PO;$1 EV(M
M&\*+IUM3N<>M:GU^:AOB#LKWER[[=%W:R2[@K.[3W?(K;G:M[W?,(D:^:=H9
M8I[MDF][G4M>^SQLV=\ 6YR54<:I*TAFK@.,8]H0=*5H_MA-!4XY)/N:#2?<
MD4.9;OB;&E#Z[I8!LE)5#F/48!,0OHI:409Y(05>HZQ@V*\S+(\!$:J4#$UA
MP1Y%U98_O'@X27VQ=14:Q9/>?!H2U'G*GIV%:R BEP<2>EX(:VOAV .DM]B>
MX8Y_IO<1E7R: FDL@TWW?M_Z<.J761 G VJ0OXWK*9R/CP[86Z'7[C>"07\$
M0/BS=C_:_ZFX\0?TK]/];XY?N,8^&U:+%98B<Z%YU?[7@7^Q:N>.ZTME<?AW
MCQO!42%H KZOE+*'%U+0_[^Y_AU02P,$%     @ P(-#4OHUPJ08!0  .0T
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MW(?[+:;+8\KRP:K<'0U.E+4J<\,Y\ 0T3<#O]+^W?" !]5GQ\3]02P,$%
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M>+QHP,;FP2<V7VC[H'5YOB1S^D#UY^5$FKM6B1*QF":*B01(.KMH7,'WM^W
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M=$1- ,$6 50*H)<"08N 6PJX72UXI8#756!8"@R["HQ*@5%7 ;\4\+L*!*5
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M(/_[0QQG^U^*"QS>WG/R?U!+ P04    " # @T-2GD_>X8L%   ;&P  &0
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MA*=$E>]].3%R4SQH"VGP>2R&:_Q$ F4-<'\II7F9V#>R_N@:_P%02P,$%
M  @ P(-#4CX8W!,P!   F!   !D   !X;"]W;W)K<VAE971S+W-H965T-C N
M>&ULO5AK;^(X%/TK%AII9Z1M$N>="I!XM!1*=RMH9U_:#RX8B":)&=N4[K]?
M.PEI2$P4;37[!6+GG/OP/3:^=(^$?F,[C#EXBZ.$]3H[SO?7NLY6.QPCII$]
M3L2;#:$QXF)(MSK;4XS6*2F.=-,P7#U&8=+I=].Y1]KOD@./P@0_4L .<8SH
M/T,<D6.O SNGB46XW7$YH?>[>[3%2\R?]X]4C/3"RCJ,<<)"D@"*-[W. %[/
M84I($5]#?&2E9R!3>2'DFQQ,U[V.(2/"$5YQ:0*)KU<\PE$D+8DXON=&.X5/
M22P_GZS?ILF+9%X0PR,2_1:N^:[7\3M@C3?H$/$%.=[A/"%'VEN1B*6?X)AC
MC0Y8'1@G<4X6$<1ADGVCMWPA2@1A1TTP<X)9)=@7"%9.L-H2[)Q@MR4X.<%I
M2W!S@MN6X.4$KRW!SPE^6T*0$X(JP;U4..-4.:.M#U@4NU;MBY13N6%:;ST3
M5JK*,>*HWZ7D"*C$"WOR(95VRA=B#!.Y"Y><BK>AX/'^ K_BY( 9N +%XX:2
M& P2'EZ-QJ8!GG:8HCT^\' %'BG94A0S\'F,.0HC]D40GY=C\/G3%_ )A EX
M"*-(;"_6U;D(3SK15WDHPRP4\T(H%G@@"=\Q<).L\5K!GS7SH=E@0!?K4BR.
M>5J<H=EH<8Q7&K#@S\ T3$,1T*B9OL1[03<NTL?-]-DA::3?--,?$&T,_K9U
M[C!0T">M<U?2[UKGKJ1/6^>NI,\^5O?[CRW=O#W=;U"Q56QQ*[5G7;(7,K3=
M4KQ%Z>\>V9QV.OAK+J!@RG',_FYP9!>.[-21?<'1$^$H$C_-Y6,$%<<(+QTC
M^_P841T2F0\O]2'O$*]]TW=,S>WJK^6M5X=9EN=J\!PV5L!<'U:MW2A@CF5K
MUCGL5F7-@U781 4SC&IL=RH8=#7O'#95P&P_T/QSV*P.@Y9MV]54[Q4XV_(\
M+3C'S97V1"'><6<B<0J1.(TB6?QG>9RY<PMW[H\5OU<X\OX'\6<^G-*BV[!2
MF)%7*XSCUL0UKJ-LSZ\J]49ARS0TNR+[.DK*N2+ B<)6X%11=PJ4V+85CU,%
M"GI5U"Q#^66)!D+)%9?W=9AI!K4LYRIKOJ&9:KW[A2[\1EU,<((3CE>[!HT%
MA:W@QXH9&N_70J,Q[&%(MCCYB0&V0Q1+5Z+)N^+H3<IW$W(F[WI"U>!96VI
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MG\JMX4S K2)Z6U54O5P!E\W,B[S7B3NVWA@[$>33FJ[A'LQ#?:LP"OHL):M
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M#3?XU(.R %Q?26E> _N:]'\>^5]02P,$%     @ P(-#4KI##P+0 @  _P<
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M88T+JF[X[@-4#O4-7\*IM/]H5^WU')044O&\ FL%.6'E$S]5@6@  O\ (*@
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MDRB[/$BQE<HV,,]WB8ER<6,/W\KCW/G_4$L#!!0    ( ,"#0U(V#TQ6,@,
M  L*   9    >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;-5676_:,!3]*U;4
MAU:BY L"5(!48-4J#0U1M7N8]F"2"UAU;&8[T/[[V4Y( PV,A[WL!?QQS_&Y
M/C>V^SLN7N4:0*&WE#(Y<-9*;>Y<5\9K2+%L\@TP/;/D(L5*=\7*E1L!.+&@
ME+J!YT5NB@ESAGT[-A/#/L\4)0QF LDL3;%X'P'ENX'C._N!.5FME1EPA_T-
M7L$3J.?-3.B>6[(D) 4F"6=(P'+@W/MW$]\S !OQ0F G*VUD4EEP_FHZC\G
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M+[Z'R85,S<5Q, @[<;>84<5!1]Q1JT3V"^_QY$*FOIKKUFI$'""U B._ I]
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M7;U=<3;G>6F@OE\((5\NRM\$-+\!F?P/4$L#!!0    ( ,"#0U**=Q=H$0,
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M3\Q]4K7__S35963:T<J4"1@N#:7O]HPS637X:J+%VK:\A="F@=IA;NY$E&6
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M7.W3;>83JO$)@AD+Y5J MZ%'O K\Y @>&0@Z*D%YEM N2[?(R/C -FU@6Y<
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MQY>IROA?V-:V_0BRC;%*U&"*0' 9_ME#K4,+,!B_ $AJ0+(+&+X 2&M ^EK
ML 8,O3(A%:_#DEFVF&FU!>VLB<T-O)@>3>ESZ<I^:S5]Y82SBR5J?L^<]G I
MC=4;*JDU\!9N0Q^ *L"6"!=%095RLR>$H;'A*\DLYL ,_$%=>BEIW3H2^(#Y
MBLO5,][.$BWCE>F2!V?.G\Q+,D=:_G2[A,Z;+KRACW#%JXK:P\QB2\FZD..L
M3NPL)):\D-@@@2LE;6G@0N:8/R>(2:5&JN11JK/D*.,2LQZD@Q-(^DG_0$#G
MKX8/WAV +U\/GQ[))FT*GWJ^]+L*?P*_TU$!G8_*4(V^?B007%H4YN\C+H>-
MRZ%W.7S!I2NXHS>QYT?R<(.96DG^'S40N?V3.DW#N1)T@I7N:/'!94H@=$(#
MNI5KI=V1T84.043=(-U#'1+"F?APW/EWOWB;CGJ#67S?+MN^53+JI<^-EH>H
M>M/&Z)D>HT:/T<_3XU2HC=M1%P]9M:$&AT(K 8U*$HV!OVAOT0Y\A5(AT&DK
MO6%OM*/3ODVZ)U.P&;=L^H<U&C<:C8]J%"2@^%W67< 'NN\,GH!$>Z0C)PW[
MY%=M@FGC<OIC10^GZ,\H\G2_T7OO=HH<;$8MF\E.B?=9!JU6"9K$K0M)H%[Y
MB]U YK()!VZSVKP=3OV5N;-^1F^*\ 1XH@D/DBNFZ78Q4&%!E/W>A&+6X9(/
M$ZO6_MJ[4Y8N43\LZ5V$VAG0]T(I^SAQ#IJ7UN)_4$L#!!0    ( ,"#0U*2
M\O<OR@,  !@1   9    >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;+V8VV[;
M.!"&7V4@]"(%6DND+!\*VT#KH+L!TFW0H-V+Q5XP,FT1E40O2=DIL ^_0TJ1
ME-B6D\#K&UN'F>',?.+OD2=;J7[JA',#]UF:ZZF7&+/^X/LZ3GC&=$^N>8YW
MEE)ES."I6OEZK3A;.*<L]6D0#/R,B=R;3=RU&S6;R,*D(N<W"G2194S]^L13
MN9UZQ'NX\$VL$F,O^+/)FJWX+3??US<*S_PZRD)D/-="YJ#X<NI])!_F-+(.
MSN*'X%O=.@9;RIV4/^W)U6+J!38CGO+8V! ,OS9\SM/41L(\_JF">O6:UK%]
M_!#]LRL>B[ECFL]E^J=8F&3JC3Q8\"4K4O--;G_G54$NP5BFVGW"MK(-/(@+
M;616.6,&F<C+;W9?-:+E0/H''&CE0)_K$%8.H2NTS,R5=<D,FTV4W(*RUAC-
M'KC>.&^L1N06XZU1>%>@GYE=<B4VS+82KG)M5(&(C(;W<%MR!;D$DW#XS(2"
M'RPM.."S [)0\+4PVK!\(?(5-&$T7%QRPT2JWV*4[[>7</'F+;P!D<,7D::(
M3D]\@YG;]?VXRO)3F24]F&7<@Y"\ QK08(_[_-GN9/S8W<=^U4VC==.HB]<_
M$.\K=D0A':6P6<"TYMBR?P&?*WQJ<N#W<<+R%8=8YD;A@XKW_I &GRZ-MYGA
M"_2!A"]6MG6B;GM'9F&=6>@R"U^$\QW\AAL:+JZE1BI_7:,37!F>Z;\[ENS7
M2_8[F_'1EH^UU0LW!>TE748;NFA69#8S&O2BB;]I\RR-HI;1J+9XE&549QF=
M&MF<Z026J',.%>]HU:!.8G N.L-ZR>%)Z931!JW&!T_0E!:CED48]@[0&=59
MCDZ^H; LD:/>&%O+443C.I/QN1"1H-'@X*20JG!=E/:8T/V,2.NG@G2G&<>J
M0/'B]SA$:%1Z%'^0#MW_*GZDT65"ST:OD5P2=K;E6K [D0KSZR4$PYU=U.\-
MGS+<-:*]_@&*C5R3(WK]6HK/UT/2J#*)S@:L46$R.#VPP0X+$@U[Y"FRP;.W
M7:/@Y(B$=P&[R@U7*(*@<&N!WK+UR[61-#)-1F?#U2@R&9\>UW@7UWAW@XT[
M=/3Q9-AH.3VBY2^FY4;KC1NMCY&BC593<BY2M#46=\_%KR%5A>SZ+:M,'NM@
M> !4(]NT6[;+F2.5^>H]0LD@K9(7_'2#(6U4F?;/QJM17]H]%+^*5[0SOX?1
MSL[:8T5:1F6^?NNUU?YG\(4I' HTI'R)7D%OB$%4^1I>GABY=F^R=]+@>[$[
M3#C#W*T!WE]*:1Y.[,MQ_6?([#]02P,$%     @ P(-#4NXV84]/ P  50H
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M>((:IXD;VE&3 34YB'K5B(JJID?<T$<SMG8]F82?H5&A.L:I492,%N\KQ'1
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M_,[_G$..,RBD>M%K (.VG D]#-;&Y+=AJ+,U<**O90["[BREXL38J5J%.E=
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M01H#W%\*H5\GYD;H_@&,_@)02P,$%     @ P(-#4BJD48\Y @  H 4  !D
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M'+5SH/.U4G:[<0FZOX7I/U!+ P04    " # @T-2:6_Z6CD%   ^(   &0
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M9[D>92^* :]8.%:N 4]LY&W)'G]]>SX,(,<&%:908X^PJ1( P@)GI%P' *8
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M)5:S8!*P$E9\*_%![[["OI[$^15:6G]ENV9O2L1B:U'7>S'%M5#-G;_NS^%
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MF+H7:ZCBWJ"*FU"%N%'>*H.F+1YV3(4F,#83.'\F<$J/XYV?^WV %VOPXI[
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M,\S5*P>X!JC]C#%YFN@FU;_$HO]02P,$%     @ P(-#4N5B:T@S"0  $D
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M:PVIA8NB%ADF,;R"T38!^DSJU^=XPQV:)CWYXGK*;L]H]QS2'"SBJ,1MQ[2
M<JSX-<\;AND=A*QHG1-A0W<PL!R>FL%L9N3<VR:T@&YBC5$D1.NHV2!GY#B_
MZ9CS^^6VAT2QG.L_M2$Q&P3KLMY!,4NZH758%/&Z9N95&<Z9!($_*,%94F=-
MM<']1WI+LK+BH"Y]IVF/U^;^?,=&6:XB8-?,APW<W^*4*J2W4JS4N07ST1[.
M:UKYWBC<07J;KFV_%!>[9C)^)[..H_JRS#),*YYK#:YS@#=.1F=2^[1K^W0R
MBMQMZR\L5GQV_])-Q77:X\G(F>R.C;[=).P9'<7QKIGDSW&U0A5A+(,AZI2@
MG7P4W[J3PY&/(E;7S*P_3S[3H1,L3_&RYSPQ&+489(-"3Y&]9R;[ [AF-DC+
M$-O.J1F!9R;27X[SEO[L..\IZO;,?->I>%%BW-AFT5&OP78.^6"PUDA_'\9'
M.TCU5M/(=3JK0[EEH&D5CMR>>E+\ZYGY</X= .8I9O3"@P&8IWC,&[JH_$$
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M2_#4UF06@^P@$"@^"_[E-9FE/_N4)E L&)A)[%.:DU=RLPU BH%)XJW<H-<
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M&H@/Z_UC0-M]*<0-#[?6"!7"AN:E@M N)[-KJ1UW/6:$YMJ@F/6ZCG56$BD
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M">.?L*YMVP&D*V-568,I@I++ZLTV=1YV )WK$X"H!D2'@-X)0+<&=-\*Z-6
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M):FYN9/;+[1UJ&_U+237[A=M6]FDAQ:U-K)LP6!!R43S3YY:(CX"2%M ^@*
MLS< 60O(7@+R-P!Y"\@_"NBW .=ZW/CNB+LBADPG2FZ1LM*@S3XX]AT:^&+"
M;I1[HV"6 <Y,[]=$T=,+H+I M^09MH#1Z!3--.R<RH92HP<[QP3Z2GA-7'3E
M$MT0]0C;N '>&[EX1 ^" ?;DBAK"N/X$6EHA[:9K-WV*'NZOT,DOGR:Q ?.M
M$?&B-?6B,35]PU2<HALIS%JC:U'0XEA!#'YWSJ<[YR_2H,8KNHA0AG]#:9(F
M'H.N/@S'8P_\^N/P4<";K MEYO1EP5#.740N90FI1#?AFBE%Q(K:V*+Y,SJ4
M:T..9ENB0HSFG0VYLR%_PX;KIPHR "@NV(855!3HF5%>^((=5I1$2?*K+R3?
M![O^W[ C]_N=^_V@GALF6%F7R/%M/Q/%]./I4E$*'Y"ABFH#<X9J'R%AU3C*
ML9>0,"R-\H&7D/=6&P<)&72$#,*$D*?O)R2L&@@9>0D)P]*HGWD)>0^6!0D9
M=H0,@WIF&ZJ@ +<YL5)L ;0(M *"#"J "9OD+64^0AK58Z?:G@ VT[0_C$;9
M)-X<$N 12T=1?WPL=NT1&XZC?-B)'3DXZAP<_:B#S9[P.3AZ95*6]J/\A7\>
MJ0Q'-H<>^><1RP?1<.#W;]SY-P[Z][MU!!+<"53$0G).E$85A:.7S:K>JC9^
M;<=X% WPL;F7X67_QO_X]KI']W 4)2^I\(N-^GXJ<+(_/"0?R7>![P(?'$3P
M3RM?.-U;D08]NMLE*KJK9(<;>2,YV,29>?8>7\*J,_A4_37M/2".4G]5>P>8
M#J-^,&OA_=D"9Q])Y"%=^S,"SG]>I/>E&H=+W ]%.JPZSR/\1J3#P"R+!F]$
M^AT@U/EPI&W%/A[9ERP<KEG^W'/Q#NKF_D$W:=\>!VO%Q,J=LZ'P+WA=4$1L
M*/<BD$\74GRK1=-!;IE9(UDK1(2H"=])EZ2P1P?TF<Y5#9UMHY+ 0?-H/9\R
MLZ9HS9P=-NIEQ>4SI3I"?ZZII@U4V^;7-K%.VA"U@OY%U.4<,CR 7)+7B'*V
M8G,. A+-*:)$"5B3M"#HHZVLTQ>],JNQEVO9K42@72Z^0:O7['NWW>L*K+;:
MEDR \U!@W)V @)U90@O,*L[ (F9[==Y\.V!*:]W18GC<]!>.(G@81KY-$A\T
MD"4%IVWGKH'"6ICF]-N-=K<#,]<3OQB_L+<&OO'T[-(G/\,#  R\FH:["XAX
M;U)S?0%]Y8I!9\KI$LQ+HB%\'*JY$6A>C*Q<RSN7!AIH][BFL'.4%8#YI91F
M]V(7Z.YEIO\!4$L#!!0    ( ,"#0U)*='HG<P(  *P&   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$P."YX;6RE55M/VS 4_BM6GH8$)$WI12B-1&&W!Z0*
M-O9LDM/&PK$S^Z2%?[]C.\TZ00/27AK?OLOYXIYD.VV>; 6 [+F6RBZB"K&Y
MC&-;5%!S>ZX;4+2SUJ;F2%.SB6UC@)<>5,LX39)I7'.AHCSS:RN39[I%*12L
M#+-M77/SL@2I=XMH%.T7[L2F0K<0YUG#-W /^+-9&9K%/4LI:E!6:,4,K!?1
MU>AR.7?G_8$' 3M[,&:NDD>MG]SD>[F($F<()!3H&#@]MG -4CHBLO&[XXQZ
M20<\'._9O_C:J99';N%:RU^BQ&H1S2-6PIJW$N_T[AMT]4P<7Z&E];]LUYU-
M(E:T%G7=@<E!+51X\N<NAP- >@R0=H#4^PY"WN4-1YYG1N^8<:>)S0U\J1Y-
MYH1R+^4>#>T*PF%^7W$#9TNJJV0K_D)QHV5G[)K;BM$;0>G6P?BWKPI@_KQE
M5RY,@2_LTPT@%]*>[$&V S4'H%8)8K4!*A3[4>G6<E7:+$:JP3F)B\[O,OA-
MC_@=I>Q6*ZPL^ZQ**/\EB*GX/H%TG\ R'62\@>*<C4>G+$W2)'@<8!WWN8X]
MZW@HUR&BBY[HPA-='"%:PD8H)=2&+I]T:9Y2G%NP2!EWB7ZB2,/PY*U  __4
M\[O_Z#8?C9,DR>+M&[8FO:W)H*VOABMGX1WMR2OM([K37G<ZJ/L0*G]'=OI*
M]FR@YEFO/1O4IC:P!O$!^=E'JY[WRO-!9;KK_W,#YN_ZB0\Z2 UFX_ND985N
M%89FTJ_VK?@J=*"_QT,?O^6&;JQE$M8$3<YG= =,Z(UA@KKQ_>A1(W4W/ZSH
M<P+&':#]M=:XGSB!_@.5_P%02P,$%     @ P(-#4KI>DF1G @  D08  !H
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MKBQVV7Z8XH\0:"> ^TNE[&[B'%2_5L-O4$L#!!0    ( ,"#0U+L)<P_A@(
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M;L/H(49BF9[XF?Y64MC/5:FB19;M-RBNM=9HW.F/9OO]VS.#=M%:&B=^&O\
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M-3G6:LG8R_1Y=#<R]839X^ ^PZG=S] _X'\.EP5P=I[XM!^+R"1011X89LZ
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MFV)7K2OFR#%M6WI)HE'4&XW]EW8!.E!QW(M>H^9=J'X+]4K\H!$_^(_X5!9
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M[%D#>_8].6_10GN*52K+-TFAN4P1<!C:,<U5XM:$0:G:%V18#&\M9[TK,^O
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M.VCYF#&:,.T$X/VC4O9UX!PT?VVL_@502P,$%     @ P(-#4AO^M*A8 P
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MD'2W#?>BQ<&>OT]"XVEN'PN\H($T /R^$T*_OI@.FBO?^G]02P,$%     @
MP(-#4B8H*-,0 P  5@@  !H   !X;"]W;W)K<VAE971S+W-H965T,3(R+GAM
M;+56VV[;, S]%<+80PNL\26)FQ9)@#99MP+M5JSH]C#L0;$91Y@LI9+2=/OZ
M4;+KN;FA+WN)=3FD>'@H,<.UTK_, M'"<RFD&04+:Y?G86BR!9;,=-02)>W,
ME2Z9I:DN0K/4R')O5(HPB:(T+!F7P7CHU^[T>*A65G")=QK,JBR9_GV)0JU'
M01R\+'SEQ<*ZA7 \7+("[]$^+.\TS<+&2\Y+E(8K"1KGH^ B/I^F#N\!WSBN
M36L,CLE,J5]N<IV/@L@%A (SZSPP^CSA!(5PCBB,Q]IGT!SI#-OC%^]7GCMQ
MF3&#$R6^\]PN1L$@@!SG;"7L5[7^A#6?OO.7*6'\+ZQK;!1 MC)6E;4Q15!R
M67W9<YV'ED&<[C%(:H-DTZ"WQZ!;&W3?:M"K#7H^,Q45GX<ILVP\U&H-VJ')
MFQOX9'IKHL^ED_W>:MKE9&?'7^P"-4R4-$KPG%G,X8I+)C/.!-Q;6B"-+4S1
M,B[@!#Y2)<'1C3+F&$BV:_F$QCJ(@:,*1!LG\' _A:-WQ_ ."'[+A2"-S3"T
M%+$[-\SJZ"ZKZ)(]T<4)W"II%P8^R!SSUPY"HMKP35[X7B8'/4XQZT W?@])
ME$0[ IJ\V3P^VV$^?;OYX ";;J->U_OK[E-/%TSR/\Q=H?<M%?V-DCG<:32D
M3;6@YKND-?#C8F:LI@OX\T!$O2:BGH^HMR>BS_12%50C5 Z"B@2I&C1FJJ H
MJ;3RE>:R *HY6*+F*G<UA(\K;G^#P8QV+<>==5*=>NI/=4_9TS@]ZW9(@J>V
M>-LH>OXZ\6O4=!L5)Z<M7Z^(]QOB_8/$;]"8<SA,?Q=9(,EV)<;)1_B,+;DE
MO7).&O'9RNZ[2%5T@Q:IDSC9I#ZI4&D;U8\VTK/M*>JDNY.3-LE)#R;G05)+
M$CX'_Z,XTNWB&,2=P0;W;53<WRZ.':ADT.EO\ ];+VZ)NO"=RT"F5M)6CU&S
MVC3'"]\3-M8OJ6E6/>Z?FZKCWC)=N%0)G)/+J'-*NNBJBU43JY;^79\I2UW"
M#Q?4^%$[ .W/E;(O$W= \U=B_!=02P,$%     @ P(-#4AOD'_CJ P  > T
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M$+4SH.]3I>S;Q@5HI\W1'U!+ P04    " # @T-2J?7PH7 "  "G!@  &@
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M<?&5L-1J1S\K2C_;H)\IC*H,3K1.K$K&T8[X:*_ZQC(BOV>\5#T5]R_5';]
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M%5 J)DHB(9LY"_\NGIAX&_#"H%9'<V(JV0CQ:A9?TIGC&4' (=&&@>+P&QZ
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M[1;Y'I0;J]B5$Z+(\:'@CTCD]N O?U-L[0(/FY&E>17>*P'_98!3Q[![8_+
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M%&5*B[0 @P<IX_DO>2D"40/ 1)L!00$(C@7T"D!O!X#[+8!^ >CO L(60%@
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M5=N.VC 0_9515*F[4I>0 'L3('%IU3ZLBJ#;/IMD(-8Z=FH;V/W[CIV09EE
MO"2V<\[)G!E[W-\I_6(R1 NON9!F$&36%H]A:)(,<V9:JD!)7U9*Y\S25*]#
M4VADJ2?E(HS;[=LP9UP&P[Y?F^EA7VVLX!)G&LPFSYE^&Z-0NT$0!?N%.5]G
MUBV$PW[!UKA ^US,-,W"6B7E.4K#E02-JT$PBAZG/8?W@-\<=Z8Q!N=DJ=2+
MF_Q(!T';!80"$^L4&+VV.$$AG!"%\;?2#.I?.F)SO%?_YKV3ER4S.%'B#T]M
M-@CN TAQQ3;"SM7N.U9^?(")$L8_85=AVP$D&V-57I$I@IS+\LU>JSPT"-'M
M"4)<$>)#0O<$H5,1.I<2NA6AZS-36O%YF#++AGVM=J =FM3<P"?3L\D^EZ[L
M"ZOI*R>>'5*^!%LJS5SZ@<D4?MH,-<Q1,%<8D_'"P TLRFT!:@4C5RINWTH,
MIF 5$ >>)V-HR%%1KZ9H&1?FF@3F:)#I)//_2'%+&ZZ@[6/IDR/.,D95A$5K
MU'(KBRE<?;J&3\ E/'$A7"3]T))A%W:85.;&I;GXA+DHAB<E;6;@JTPQ?2\0
M4J;J=,7[=(WCLXI33%K0B;Y W([;1P*:7$R/'H[0IY?3[\^XZ=3%[WB]SF7%
MUYK)-;JB&%\EJ>1-<@H"EH:&^=-KSL32K6/I^EBZ)V+YI2P3?BLT-P>^4G\S
M>*STI=R=EW/-;3OLW;<Z_7#;+,='4"=J/;P'33^"XH?670UZ9Z=7V^F=M3/F
M:HWRLP%#&QO=L3EAS?5.UP3I'''72$^<DCV:,&JC(:&D*\%3?_Z,I5=9-OH/
MEXG*CV:L=\QG?)"Q$M1K@*+;@WQ]U(FZC:26^0H;/2E'O?:]W5#@&VG+\U:O
MUM?'R'?-@_4Q72OE+?!?IKR3GIA><VE X(HDVZT["DR7?;Z<6%7XSK=4EOJH
M'V9T-:)V /J^4LKN)^X']64[_ =02P,$%     @ P(-#4M26-DJ) P  &PP
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MOG>[U*18X,49HX^ M;6EM_:ARV]G+3-2U.U0O!5,?BVDG5C(%);XGC+<C@B
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M(HP/5Y3X5!H!N+\0D./TQ!C(/DU._@%02P,$%     @ P(-#4B2)!%HD @
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M2(5NH'Y_X&IO++YH!^5KHZ?_ 5!+ P04    " # @T-27>_4<W\$  #5$0
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M;!9:"F<L8K#7H[W7HS.]CKA2,GW>*/Z<":1*=)>62U'HG#/W($5$0(2V@M;
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M-1<$"ZV\,X)@$37].P9A5D4[:6'=BH7$9G"#;"78;.$>05AH+F!Z8IV)*5
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MC;HS$U&.JOM?S..YXZ)@_>7L_P%02P,$%     @ P(-#4I>*NQS     $P(
M  L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2
M!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4
M+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(
M2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/I
MKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " # @T-2Z02$
M26,)  #47@  #P   'AL+W=O<FMB;V]K+GAM;,6<6W/;MA9&_PI&3SXS54U2
M$D5FXLSXTKB>21L?R\UY[$ 4)&%"$2I!.G%_?4'2LC84ZNMYV=:3+>JV! )8
MV+CL]]],^75NS%?Q?9,7]F*PKJKMN_-SFZW51MJ?S585[IFE*3>R<@_+U;G=
MEDHN[%JI:I.?1T$0GV^D+@8?WN\^Z[X\IP],I;)*F\)=;"Y\T>J;W3_?/!1/
MVNJYSG7U?#%H_\_50&QTH3?Z;[6X& 0#8=?FVZ^FU'^;HI+Y+"M-GE\,PNZ)
M+ZJL=/;#Y5D#^2CGMKU2R?F#=" 7@SAP'[C4I:W:5[2?+QWCDW(O[A[5E?FH
M\TJ5-[)2MZ6IM[I8-1_C?L4Y^1EM.>S^=H7XKOQ_BM$LESI3-R:K-ZJHNG(L
M5=X %G:MMW8@"KE1%X-K\Z1*<2]7JOE1[EON%MT/K!P9*:[RG79/E'>+EI&3
MI[ FUPOW[0LQ:R":-UAAEN*NR R!C !D=#+(:[/9$L@1@!R](>25S&61*='6
M2$L QP!P?#) <78O">0$0$Y.=ZNE71/(&$#&)X/\Y:]:$\@I@)SR0L[JS4:6
MSPW43*\*[=XFBTI<9IFIBXI")@ RX86\S%QY6=U>)T0I($IYB6Z<-VREJ[I4
ME"@,4!\=\#(]J"=5U#X/= :S-.X*QU.9\ID"(3^$S(*X<Z.(8M5\J;BTMNG0
M9+$0M\8LOND\IY1($"&S(3Y*78HO,J^5^$U)ZVI8VVU0/*2'D-D/'W7AE*!E
M[LQOJ[+^ 0YI(63VPHTJ]9-L!G7'Z) /0F8AN&'QU@U:GW\2]WG3R3:UKS'!
MMGD?A40^")F%\,G5.;\/01U_R-SSWQ4+-7?^+)3UF%#7'S+W_<TMJVBG%J%>
M/V+N]7^19>'"%"M<U7+C-%G2D"%"_7_$W/^W,,,K5YT6+I1Y/FR*$0P5V%60
MF8T2C_*[5]<CU/%'S!W_YVKM;J$W:MQWMC/:041( !%[@)#G<F[*KIMM^K .
M_*%[,<5$*HB85=",/FS5C;AUX81::MF8WPT"E#]HBY 3(F8G?'*CVE5[F1(A
M 43, G"Q\D:_%%QS=UV%K%P'HUP]](L->2%B]L)M+4NG4.43(2M$W%;8;'/S
MK)2X4H5:ZJIU/*4;(4N,F"TQ4ZOF%:[V=V_WZ]L(:6+$K(G_NEOIFF3^3'J[
M&UE)<?9'(>L%Q43&&#$; P;*?T84$TXO,4L$8XXH)I+(B%DBNUA5G#TVO;+]
M#P5#VAB]@3;:H+67#)EBQ&P*'+T*BHGT,6+6QY'P=5><%!,)9,0LD-XPMO>>
M(ZF,N*>9>N/9/LPQLLN8V2XPL!5G%!.99LQLFBZT[2T]9)8Q>RRRCW%[X9!/
MQLP^Z8+=7BRX2,'LCQ^CWEY$9)(QLTGZPM]>2"25,;M4]G%P+QQ2R9A9)3 @
M]H9<8Z22,;-*8$#L8R*7C)E=TA,"]-WQ"1+)A%DD,!;PBG*"1#+AGMF"@^PQ
MQ41BF9PT9)E03*28";-BZ.J>&(K?9?G2E,YN5"7I$N0$*6?"K!RZY/>"EOLM
M!RZ(,]OF-: :BM=_Y\_"C<P6=5;1Z&""?#-A]@W!/+S/!X6)Q#-A%H]7F%:5
M[L8+]T'B1MNFZ5!,))X)LW@(YJ.I7%?IPU),))X)LWCZJN:R-!MQ651Z>$TW
M:R#WQ&^T?.XP=_[>S5$T]9-B(O?$;[6J[CB;;4VFV._$<L]03.2>F#VHV6/B
MEAXC]\3,[H&3*MZ (T;NB9G=@S'IK%Z,)!2S3YXA3#HNBN&^K%/.I'GCHAA9
M*#[13-I0M ,[BHDL%'//I"%,OPDA"\7,%CJ.V79/=#<>LM"4V4+',6^E]M:3
MILA"4V8+X9M..Z0ILM"4V4+',=MG*":RT)1[RU?O9/1+._?VSTV1A::GV/JU
MP_1:^A19:,IL(8SIU4UDH2FSA8YANI M4XJN>T[A_F!N"QW!?!G444QDH2FS
MA8ZLE.PX*2:RT/0T"SJN/S*ETBN"F2 +)<P6.HK9]4@4$UDH8;80Q/0ZI 19
M*&&V$,:D'5*"+)0P6PBNXOFEB2R4,%L(+S8.*2:R4,)LH9?%QG^+?A.DH(1[
M\]F.<>8^;%&[>,@LQ6=7NK+9\46'1PE24/(F6Y*;>9E7M/:2N#;6M2.*"0^I
M,"OH*.8G+>>:GB](D((29@4=Q?R?$]":FC)%"DJ9%704<U9OMSG=Y)PB!:7L
MTW%D\?YUQ-Y-Q[EG*"924/J6>PS@&DN*%)2R3\=YF-VL]HV[)'Z354W''2E2
M4,J]^Z#;%/%O?7N*_),R^^>5D53)9FNO*<2L,AG%1 I*F17TBGF9N=?6>;O*
MOUOX]P[MIDA!*;."7C$?5)9+:]NUU'8)W=25H)O>4Z2@E%E!/=MBAN)*6IVU
MPR2*"0]/<N^5[L/<MR6"&0;X1"7WMNF^/3S##GDXEQXH/&H9G."L#6G['B@\
M@AEP[TGH!]W=? \4GL(,N#=2'RE1UW=^=6,2#Q2>QPR8970$]%%^;X\B>*#P
M;&9PB@UQ0V?V\JO[QID'"H]I!LQ..@)Z:6V]V7I37F$ CVH&W(?W^T&;% AB
MIKPCI0$\Q1DP>^D(Z+TJVX_S0.'1SH![DQP"]>9 0GS6G_NP/P8=>: X"<!I
MS/2H-VKXY2!9 303=W8 Y'HK[CQ0:";N! '>GMVA>'EXI=R'-1.,'B@T$W>J
M@ -0$'2&.&L =]J  U!_6\V-IU"<0( [@\ !:./X!\>RBSX]4&@F[BP"!Z"[
M=#+%JMV:]H<'"LW$G6  [S'W^U%H)NZL QB4[JT)83Z"D#LA 0:=>*#03-SY
M"3!H[('BM#7,9L*@4P\4FHD[@P$^">$U)IC"(#QI#H.#Q@3-Q)W% (/ZC0F:
MB3N/ 0;U&Q,T$W]Z P3J-R9H)NX4!Q@T\4"AF;@S'V#0E(+"' @A=Q($!/IG
M&\[M0:&9N%,B8-#0 X5FXDZ*@$&]<!EF10BYTR)@4,],,"]"R)T8 8-Z9H)Y
M$D+N1 D8U#,33)L0<N=-P*">F6#BA) [<P(&]<P$4R>$W+D38&HE?Y(,9D\(
MN=,G[),K]:[54E"8/R'D3J  <RYY>YI"F$$AY$ZAT)_EJ&^;90AS*H3<217Z
M3CN3.N"!0C-Q)UCH![U59E7*[=J;)(,9%T+NE OX;+:G4)AW(>P2+YRW+[<?
MWB]</2K4XG?W)=9=SV2>W9>B^?,2*$Z:B9=EG>?7[MKGXI.1BUU2]EU"^0__
M %!+ P04    " # @T-2W$_8KN,#  #X5   &@   'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QSS=Q+3AM!%(7AK2 O(%VWWA4!HTR81MF !<U# 6RY.TJR
M^R R@'.502:H_Q%J(Q=GXD_([M_G7^?'_?IP>%[N'X[+V:^GQ^?E8G>_KL?/
MT[1<W\]/^^73X3@_O_SF]G!ZVJ\OEZ>[Z;B__KZ_FZ<80IU.[\_879Z_/_/L
MV^_C_#\G'FYO'Z[G+X?K'T_S\_J/@Z>?A]/WY7Z>U]W9M_WI;EXO=M.OQ[>'
ME^GUAWUZ.7EW=G5SL3M=W=ANVGI0E$%Q^T%)!J7M!V49E+<?5&10V7Y0E4%U
M^T%-!K7M!W49U+<?-&30V'Z0!94Q "8YK %:FW)M *]-P3: V*9D&\!L4[0-
MH+8IVP9PVQ1N \AM2K<![#;%VP!Z1]4[ O2.JG<$Z!W=/]L O:/J'0%Z1]4[
M O2.JG<$Z!U5[PC0.ZK>$:!W5+TC0.^H>D> WDGU3@"]D^J= 'HGU3L!]$[N
MS1* WDGU3@"]D^J= 'HGU3L!]$ZJ=P+HG53O!- [J=X)H'=6O3- [ZQZ9X#>
M6?7. +VSZIT!>F?W9C= [ZQZ9X#>6?7. +VSZIT!>F?5.P/TSJIW!NA=5.\"
MT+NHW@6@=U&]"T#OHGH7@-Y%]2X O8O[L!*@=U&]"T#OHGH7@-Y%]2X O8OJ
M70!Z5]6[ O2NJG<%Z%U5[PK0NZK>%:!W5;TK0.^J>E> WM7=; +0NZK>%:!W
M5;TK0.^J>E> WDWU;@"]F^K= 'HWU;L!]&ZJ=P/HW53O!M"[J=X-H'=3O1M
M[^9N%@3HW53O!M"[J=X-H'=7O3M [ZYZ=X#>7?7N +V[ZMT!>G?5NP/T[JIW
M!^C=5>\.T+NKWAV@=W<W>P/T[JIW!^@]5.\!T'NHW@.@]U"]!T#OH7H/@-Y#
M]1X O8?J/0!Z#]5[ /0>JO< Z#U4[P'0>[A8!Z"W!9_K /RVX(*= !#<@DMV
M L!P"R[:"0#%+;AL)P <M^#"G0"0W()+=P+ <@LNW@D S2VX?"< /+?@ IY
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M^_NOEW\?]"^M5ZZG]S.6RS]02P,$%     @ P(-#4N>^E)+I @  !5$  !,
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M"5!+ 0(4 Q0    ( ,"#0U('04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ P(-#4@!Q0Y+N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ P(-#4IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " # @T-2;AR3-B@&  !!&0  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ P(-#4I(Y;D,U!P  XAT  !@              ("!:PX  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,"#0U()NZEE,00  )H.   8
M              " @=85  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " # @T-2264S)/,&   T'0  &               @($]&@  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ P(-#4@1R:P)Q @
M'P8  !@              ("!9B$  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( ,"#0U)&/0NKM0H  '8R   8              " @0TD
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " # @T-2A J3
M+*<,  !:5   &               @('X+@  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ P(-#4@M#AX#_*   V80  !@
M ("!U3L  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,"#
M0U+#X/'VL L  -H>   8              " @0IE  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " # @T-2Q4#F:.T&  !+$@  &0
M        @('P<   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( ,"#0U+WI0),$PP  #L@   9              " @11X  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ P(-#4H(R1[\I!   ^0@
M !D              ("!7H0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " # @T-264%Z?Z4+  "Y'P  &0              @(&^B
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,"#0U*E%!4^
MC0X  !<R   9              " @9J4  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ P(-#4JX9AYHC"P  %"8  !D
M ("!7J,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #
M@T-2\]>17P0,  #3)@  &0              @(&XK@  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,"#0U)!%>QAP 4  +P-   9
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M970R,2YX;6Q02P$"% ,4    " # @T-2R=WDOR,1   F0@  &0
M    @('BW0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M ,"#0U(:G/ZO9Q0  $P[   9              " @3SO  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ P(-#4FN30N+0!P  ?1,  !D
M             ("!V@,! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " # @T-2?WM]<O@C  #EA   &0              @('A"P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,"#0U)-)8LPW @
M %8:   9              " @1 P 0!X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ P(-#4K&8 '=<$0  BC   !D              ("!
M(SD! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " # @T-2
MK^4?XQ8,  #N(0  &0              @(&V2@$ >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,"#0U+%&L^8A0,  !D(   9
M      " @0-7 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ P(-#4L-F4L!B!P  QA,  !D              ("!OUH! 'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " # @T-23A[>K[T'  !\$P
M&0              @(%88@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( ,"#0U+8';KBV 0  .,,   9              " @4QJ 0!X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ P(-#4K+HESQ)
M4   _R(! !D              ("!6V\! 'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " # @T-2/MXKA_8"  !G!@  &0
M@(';OP$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,"#
M0U+HF5X5^@@  '$9   9              " @0C# 0!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ P(-#4@FB*2-\ @  . 4  !D
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M=#0P+GAM;%!+ 0(4 Q0    ( ,"#0U)%9AQF#@,  ($&   9
M  " @8#F 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
MP(-#4K7%+*$O!0  R0X  !D              ("!Q>D! 'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " # @T-2\;P3\<4#   !"0  &0
M            @($K[P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( ,"#0U)(?;W=#P8  -L3   9              " @2?S 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ P(-#4@!HI4 C P
MM 8  !D              ("!;?D! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " # @T-2'(4P(\,(  "T'P  &0              @(''
M_ $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,"#0U+%
MQE^5*P<  ,L1   9              " @<$% @!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ P(-#4OHUPJ08!0  .0T  !D
M     ("!(PT" 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,"#0U*Z8P(;3P,  +(/   9              "
M@0 H @!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ P(-#
M4I/P_M/H!0  WQP  !D              ("!ABL" 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " # @T-2C\7&'O\#  #P#   &0
M        @(&E,0( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( ,"#0U*M8-QG80H  ,E'   9              " @=LU @!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ P(-#4IY/WN&+!0  &QL
M !D              ("!<T " 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " # @T-2:^_E<[L%  "1'   &0              @($U1@(
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,"#0U*S;U\3
M[P(  ( )   9              " @2=, @!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ P(-#4CX8W!,P!   F!   !D
M ("!34\" 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #
M@T-2^ \A*&T$  #($P  &0              @(&T4P( >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ,"#0U)MI1$O<P(  $@&   9
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M970V-BYX;6Q02P$"% ,4    " # @T-2&0#-]NP"  #B!P  &0
M    @(&':0( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M ,"#0U*(S<=/2@<  % Q   9              " @:IL @!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ P(-#4LLL*1BY @  LP@  !D
M             ("!*W0" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " # @T-2<5AJ(/@%  #M'   &0              @($;=P( >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ,"#0U(;KGRS^0(
M .T(   9              " @4I] @!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ P(-#4GVS)6<,!0  VAT  !D              ("!
M>H " 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " # @T-2
M-@],5C(#   +"@  &0              @(&]A0( >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( ,"#0U(^ANG\_P(  #D*   9
M      " @2:) @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ P(-#4@KD>)3_!0  #R(  !D              ("!7(P" 'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " # @T-2BG<7:!$#  "("0
M&0              @(&2D@( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    ( ,"#0U()MML-R@(  '$'   9              " @=J5 @!X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ P(-#4G95W\.7
M!0  *QH  !D              ("!VY@" 'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    " # @T-2^!W_?%P&  !;'P  &0
M@(&IG@( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( ,"#
M0U(DOYR:H@(  )X'   9              " @3RE @!X;"]W;W)K<VAE971S
M+W-H965T.# N>&UL4$L! A0#%     @ P(-#4O+K>>Z$ P  _@L  !D
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M=#@U+GAM;%!+ 0(4 Q0    ( ,"#0U(:O*T[<P(  %P)   9
M  " @8F[ @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @
MP(-#4H8!B1$# P  I D  !D              ("!,[X" 'AL+W=O<FMS:&5E
M=',O<VAE970X-RYX;6Q02P$"% ,4    " # @T-2Y&@J%@X#  "V"0  &0
M            @(%MP0( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4
M Q0    ( ,"#0U+^OO9JN (   T(   9              " @;+$ @!X;"]W
M;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ P(-#4BJD48\Y @
MH 4  !D              ("!H<<" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX
M;6Q02P$"% ,4    " # @T-27RU+YIX"   B!@  &0              @($1
MR@( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( ,"#0U)I
M;_I:.04  #X@   9              " @>;, @!X;"]W;W)K<VAE971S+W-H
M965T.3(N>&UL4$L! A0#%     @ P(-#4OJ<X1JW!@  2"@  !D
M     ("!5M(" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,"#0U(%D_KM=@4  '<:   9              "
M@=3L @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ P(-#
M4KFW5JS^!   W!4  !D              ("!@?(" 'AL+W=O<FMS:&5E=',O
M<VAE970Y.2YX;6Q02P$"% ,4    " # @T-2]S.!8E<"  "^!0  &@
M        @(&V]P( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4
M    " # @T-2#/Y" AX$  !S#P  &@              @(%%^@( >&PO=V]R
M:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " # @T-2@DWB%/H$  "Y
M%P  &@              @(&;_@( >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX
M;6Q02P$"% ,4    " # @T-2#H1%G_P)  !:.@  &@              @('-
M P, >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " # @T-2
M36F1Q H#  !^"@  &@              @($!#@, >&PO=V]R:W-H965T<R]S
M:&5E=#$P-"YX;6Q02P$"% ,4    " # @T-2:&K9"J("  #5!@  &@
M        @(%#$0, >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4
M    " # @T-2F&*E+7P$  #X#@  &@              @($=% , >&PO=V]R
M:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " # @T-2\9?IM=\$  "C
M$0  &@              @('1& , >&PO=V]R:W-H965T<R]S:&5E=#$P-RYX
M;6Q02P$"% ,4    " # @T-22G1Z)W,"  "L!@  &@              @('H
M'0, >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4    " # @T-2
MNEZ29&<"  "1!@  &@              @(&3( , >&PO=V]R:W-H965T<R]S
M:&5E=#$P.2YX;6Q02P$"% ,4    " # @T-2%Y0BX0L$  !F#0  &@
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M:&5E=#$Q-"YX;6Q02P$"% ,4    " # @T-2M:_1E4T'  #I(   &@
M        @(&0-@, >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q02P$"% ,4
M    " # @T-2(21&3,<#  "R#   &@              @($5/@, >&PO=V]R
M:W-H965T<R]S:&5E=#$Q-BYX;6Q02P$"% ,4    " # @T-2'+3)PR4$
M$@  &@              @($40@, >&PO=V]R:W-H965T<R]S:&5E=#$Q-RYX
M;6Q02P$"% ,4    " # @T-2+!_VNKD#  ":"P  &@              @(%Q
M1@, >&PO=V]R:W-H965T<R]S:&5E=#$Q."YX;6Q02P$"% ,4    " # @T-2
M5"?]BJ,"  #(!@  &@              @(%B2@, >&PO=V]R:W-H965T<R]S
M:&5E=#$Q.2YX;6Q02P$"% ,4    " # @T-2B&0 JUP$  #F$   &@
M        @($]30, >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX;6Q02P$"% ,4
M    " # @T-2&_ZTJ%@#  #^"0  &@              @('140, >&PO=V]R
M:W-H965T<R]S:&5E=#$R,2YX;6Q02P$"% ,4    " # @T-2)B@HTQ #  !6
M"   &@              @(%A50, >&PO=V]R:W-H965T<R]S:&5E=#$R,BYX
M;6Q02P$"% ,4    " # @T-2&^0?^.H#  !X#0  &@              @(&I
M6 , >&PO=V]R:W-H965T<R]S:&5E=#$R,RYX;6Q02P$"% ,4    " # @T-2
M._)OT00#  !Y"@  &@              @('+7 , >&PO=V]R:W-H965T<R]S
M:&5E=#$R-"YX;6Q02P$"% ,4    " # @T-2J?7PH7 "  "G!@  &@
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M:&5E=#$R.2YX;6Q02P$"% ,4    " # @T-2\[ K#:X$   D%   &@
M        @(&V=0, >&PO=V]R:W-H965T<R]S:&5E=#$S,"YX;6Q02P$"% ,4
M    " # @T-2:3E'/I0#  #M"@  &@              @(&<>@, >&PO=V]R
M:W-H965T<R]S:&5E=#$S,2YX;6Q02P$"% ,4    " # @T-29F[*?T8$  "H
M$0  &@              @(%H?@, >&PO=V]R:W-H965T<R]S:&5E=#$S,BYX
M;6Q02P$"% ,4    " # @T-2EGA$E^4"  !X!P  &@              @('F
M@@, >&PO=V]R:W-H965T<R]S:&5E=#$S,RYX;6Q02P$"% ,4    " # @T-2
MU)8V2HD#   ;#   &@              @($#A@, >&PO=V]R:W-H965T<R]S
M:&5E=#$S-"YX;6Q02P$"% ,4    " # @T-24D*7EBL#  "<"@  &@
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M:&5E=#$S.2YX;6Q02P$"% ,4    " # @T-2)(D$6B0"  !X!   &@
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M:&5E=#$T-"YX;6Q02P$"% ,4    " # @T-2]V#3?[<'  "*)   &@
M        @('VOP, >&PO=V]R:W-H965T<R]S:&5E=#$T-2YX;6Q02P$"% ,4
M    " # @T-2=$P/5X$"  !&#P  #0              @ 'EQP, >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ,"#0U*7BKL<P    !,"   +
M  "  9'* P!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,"#0U+I!(1)8PD  -1>
M   /              "  7K+ P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" # @T-2W$_8KN,#  #X5   &@              @ $*U0, >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " # @T-2Y[Z4DND"   %40
M$P              @ $EV0, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..F0"9 %0J   _W ,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>940</ContextCount>
  <ElementCount>722</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>237</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010002 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020003 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030004 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040005 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>210061002 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210081003 - Disclosure - Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Divestitures</Role>
      <ShortName>Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210101004 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210181005 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210221006 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210281007 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210361008 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210431009 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210501010 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210541011 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210621012 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210671013 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210731014 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210771015 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210921016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210991017 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>211061018 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>211231019 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>211251020 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>211271021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>211291022 - Disclosure - Guarantees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Guarantees</Role>
      <ShortName>Guarantees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>211301023 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>211321024 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>211361025 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>220022001 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230033001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230113002 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230193003 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230233004 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230293005 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230373006 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230443007 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230513008 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230553009 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Leases</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230633010 - Disclosure - Indebtedness (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessTables</Role>
      <ShortName>Indebtedness (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230683011 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230743012 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>230783013 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPayments</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>230933014 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>231003015 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>231073016 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>231333017 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformation</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>231373018 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240044001 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240054002 - Disclosure - Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240094004 - Disclosure - Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DivestituresDetails</Role>
      <ShortName>Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Divestitures</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240124005 - Disclosure - Revenues - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails</Role>
      <ShortName>Revenues - Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240134006 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240144007 - Disclosure - Revenues - Reserves for Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Reserves for Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240154008 - Disclosure - Revenues - Total Reserves for Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Total Reserves for Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240164009 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240174010 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240204011 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240214012 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240244013 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240254014 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240264015 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240274016 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240304017 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240314018 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240324019 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240334020 - Disclosure - Fair Value Measurements - Gains and Losses on Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Gains and Losses on Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240344021 - Disclosure - Fair Value Measurements - Summary of Fair and Carrying Value of Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Fair and Carrying Value of Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240354022 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240384023 - Disclosure - Financial Instruments - Summary of Financial Assets with Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails</Role>
      <ShortName>Financial Instruments - Summary of Financial Assets with Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240394024 - Disclosure - Financial Instruments - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240404025 - Disclosure - Financial Instruments - Summary of Contractual Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments - Summary of Contractual Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240414026 - Disclosure - Financial Instruments - Proceeds from Marketable Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Proceeds from Marketable Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240424027 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240454028 - Disclosure - Derivative Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails</Role>
      <ShortName>Derivative Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240464029 - Disclosure - Derivative Instruments - Foreign Currency Forward Contracts Entered into Hedge Forecasted Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails</Role>
      <ShortName>Derivative Instruments - Foreign Currency Forward Contracts Entered into Hedge Forecasted Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240474030 - Disclosure - Derivative Instruments - Summary of the Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails</Role>
      <ShortName>Derivative Instruments - Summary of the Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240484031 - Disclosure - Derivative Instruments - Summary of the Effect of Derivatives Designated as Net Investment Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails</Role>
      <ShortName>Derivative Instruments - Summary of the Effect of Derivatives Designated as Net Investment Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240494032 - Disclosure - Derivative Instruments - Summary of the Fair Value for our Outstanding Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails</Role>
      <ShortName>Derivative Instruments - Summary of the Fair Value for our Outstanding Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240524033 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipmentTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240534034 - Disclosure - Property, Plant and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240564035 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240574036 - Disclosure - Leases - Schedule of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240584037 - Disclosure - Leases - Operating Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails</Role>
      <ShortName>Leases - Operating Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240594038 - Disclosure - Leases - Operating Lease Liability Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>Leases - Operating Lease Liability Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240604039 - Disclosure - Leases - Operating Lease Weighted Average Remaining Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails</Role>
      <ShortName>Leases - Operating Lease Weighted Average Remaining Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240614040 - Disclosure - Leases - Operating Lease Supplemental Cash Flow Disclosure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails</Role>
      <ShortName>Leases - Operating Lease Supplemental Cash Flow Disclosure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240644041 - Disclosure - Indebtedness - Summary of Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails</Role>
      <ShortName>Indebtedness - Summary of Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240654042 - Disclosure - Indebtedness - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessNarrativeDetails</Role>
      <ShortName>Indebtedness - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240664043 - Disclosure - Indebtedness - Total Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails</Role>
      <ShortName>Indebtedness - Total Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240694044 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240704045 - Disclosure - Equity - Summary of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails</Role>
      <ShortName>Equity - Summary of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240714046 - Disclosure - Equity - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Equity - Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240724047 - Disclosure - Equity - Reclassification out of Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Equity - Reclassification out of Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240754048 - Disclosure - Earnings per Share - Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings per Share - Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240764049 - Disclosure - Earnings per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareNarrativeDetails</Role>
      <ShortName>Earnings per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240794050 - Disclosure - Share-Based Payments - Share-based Compensation Expense Included in Consolidation Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails</Role>
      <ShortName>Share-Based Payments - Share-based Compensation Expense Included in Consolidation Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240804051 - Disclosure - Share-Based Payments - Summary of Share-based Compensation Expense Associated with Each Share-based Compensating Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails</Role>
      <ShortName>Share-Based Payments - Summary of Share-based Compensation Expense Associated with Each Share-based Compensating Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240814052 - Disclosure - Share-Based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails</Role>
      <ShortName>Share-Based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240824053 - Disclosure - Share-Based Payments - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails</Role>
      <ShortName>Share-Based Payments - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240834054 - Disclosure - Share-Based Payments - Tax Benefit and Cash Received from Stock Option Exercises (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails</Role>
      <ShortName>Share-Based Payments - Tax Benefit and Cash Received from Stock Option Exercises (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240844055 - Disclosure - Share-Based Payments - Market Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails</Role>
      <ShortName>Share-Based Payments - Market Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240854056 - Disclosure - Share-Based Payments - Assumptions Used in Valuation of Market Based Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails</Role>
      <ShortName>Share-Based Payments - Assumptions Used in Valuation of Market Based Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240864057 - Disclosure - Share-Based Payments - Cash Settled Performance Shares Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails</Role>
      <ShortName>Share-Based Payments - Cash Settled Performance Shares Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240874058 - Disclosure - Share-Based Payments - Performance Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails</Role>
      <ShortName>Share-Based Payments - Performance Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240884059 - Disclosure - Share-Based Payments - Performance Stock Units Settled in Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails</Role>
      <ShortName>Share-Based Payments - Performance Stock Units Settled in Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>240894060 - Disclosure - Share-Based Payments - Performance Stock Units Settled in Cash Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails</Role>
      <ShortName>Share-Based Payments - Performance Stock Units Settled in Cash Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>240904061 - Disclosure - Share-Based Payments - Time-Vested Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Share-Based Payments - Time-Vested Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>240914062 - Disclosure - Share-Based Payments - Shares Issued Under Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Share-Based Payments - Shares Issued Under Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>240944063 - Disclosure - Income Taxes - Income Before Income Tax Provision and the Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Income Before Income Tax Provision and the Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>240954064 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>240964065 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>240974066 - Disclosure - Income Taxes - Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails</Role>
      <ShortName>Income Taxes - Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>240984067 - Disclosure - Income Taxes - Accounting for Uncertainty in Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Accounting for Uncertainty in Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>241014068 - Disclosure - Other Consolidated Financial Statement Detail - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>241024069 - Disclosure - Other Consolidated Financial Statement Detail - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>241034070 - Disclosure - Other Consolidated Financial Statement Detail - Other Income (Expense), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail - Other Income (Expense), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>241044071 - Disclosure - Other Consolidated Financial Statement Detail - Gain (Loss) on Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail - Gain (Loss) on Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>241054072 - Disclosure - Other Consolidated Financial Statement Detail - Accrued Expenses and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail - Accrued Expenses and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>241084073 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails</Role>
      <ShortName>Collaborative and Other Relationships - OCREVUS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>241094074 - Disclosure - Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails</Role>
      <ShortName>Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>241104075 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails</Role>
      <ShortName>Collaborative and Other Relationships - Profit Sharing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>241114076 - Disclosure - Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails</Role>
      <ShortName>Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>241124077 - Disclosure - Collaborative and Other Relationships - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>241134078 - Disclosure - Collaborative and Other Relationships - Ionis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails</Role>
      <ShortName>Collaborative and Other Relationships - Ionis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</ParentRole>
      <Position>129</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>241144079 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails</Role>
      <ShortName>Collaborative and Other Relationships - Eisai (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</ParentRole>
      <Position>130</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>241154080 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>241164081 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Aducanumab Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to Aducanumab Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>241174082 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>241184083 - Disclosure - Collaborative and Other Relationships - Alkermes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails</Role>
      <ShortName>Collaborative and Other Relationships - Alkermes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>241194084 - Disclosure - Collaborative and Other Relationships - Bristol Myers Squibb (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails</Role>
      <ShortName>Collaborative and Other Relationships - Bristol Myers Squibb (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>241204085 - Disclosure - Collaborative and Other Relationships - Acorda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails</Role>
      <ShortName>Collaborative and Other Relationships - Acorda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</ParentRole>
      <Position>136</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>241214086 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>241224087 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails</Role>
      <ShortName>Collaborative and Other Relationships - Samsung Bioepis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>241244088 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>139</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>241264089 - Disclosure - Litigation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationNarrativeDetails</Role>
      <ShortName>Litigation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>241284090 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>241314091 - Disclosure - Employee Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails</Role>
      <ShortName>Employee Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>142</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>241344092 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>143</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>241354093 - Disclosure - Segment Information - Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails</Role>
      <ShortName>Segment Information - Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>144</Position>
    </Report>
    <Report instance="biib-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>241384094 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>145</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="biib-20201231.htm">biib-20201231.htm</File>
    <File>biib-20201231.xsd</File>
    <File>biib-20201231_cal.xml</File>
    <File>biib-20201231_def.xml</File>
    <File>biib-20201231_lab.xml</File>
    <File>biib-20201231_pre.xml</File>
    <File>biib-20201231xex1041.htm</File>
    <File>biib-20201231xex21.htm</File>
    <File>biib-20201231xex23.htm</File>
    <File>biib-20201231xex311.htm</File>
    <File>biib-20201231xex312.htm</File>
    <File>biib-20201231xex321.htm</File>
    <File>biib-20201231xex44.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20201231_g1.jpg</File>
    <File>biib-20201231_g10.jpg</File>
    <File>biib-20201231_g11.jpg</File>
    <File>biib-20201231_g12.jpg</File>
    <File>biib-20201231_g13.jpg</File>
    <File>biib-20201231_g14.jpg</File>
    <File>biib-20201231_g15.jpg</File>
    <File>biib-20201231_g16.jpg</File>
    <File>biib-20201231_g17.jpg</File>
    <File>biib-20201231_g18.jpg</File>
    <File>biib-20201231_g19.jpg</File>
    <File>biib-20201231_g2.jpg</File>
    <File>biib-20201231_g20.jpg</File>
    <File>biib-20201231_g21.jpg</File>
    <File>biib-20201231_g22.jpg</File>
    <File>biib-20201231_g23.jpg</File>
    <File>biib-20201231_g24.jpg</File>
    <File>biib-20201231_g25.jpg</File>
    <File>biib-20201231_g26.jpg</File>
    <File>biib-20201231_g27.jpg</File>
    <File>biib-20201231_g28.jpg</File>
    <File>biib-20201231_g29.jpg</File>
    <File>biib-20201231_g3.jpg</File>
    <File>biib-20201231_g30.jpg</File>
    <File>biib-20201231_g31.jpg</File>
    <File>biib-20201231_g32.jpg</File>
    <File>biib-20201231_g33.jpg</File>
    <File>biib-20201231_g34.jpg</File>
    <File>biib-20201231_g35.jpg</File>
    <File>biib-20201231_g36.jpg</File>
    <File>biib-20201231_g37.jpg</File>
    <File>biib-20201231_g38.jpg</File>
    <File>biib-20201231_g39.jpg</File>
    <File>biib-20201231_g4.jpg</File>
    <File>biib-20201231_g40.jpg</File>
    <File>biib-20201231_g5.jpg</File>
    <File>biib-20201231_g6.jpg</File>
    <File>biib-20201231_g7.jpg</File>
    <File>biib-20201231_g8.jpg</File>
    <File>biib-20201231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>206
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20201231.htm": {
   "axisCustom": 10,
   "axisStandard": 48,
   "contextCount": 940,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 1124,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 48,
    "http://www.biogenidec.com/20201231": 6,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 58
   },
   "keyCustom": 152,
   "keyStandard": 570,
   "memberCustom": 117,
   "memberStandard": 95,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210081003 - Disclosure - Divestitures",
     "role": "http://www.biogenidec.com/role/Divestitures",
     "shortName": "Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764049 - Disclosure - Earnings per Share - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareNarrativeDetails",
     "shortName": "Earnings per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794050 - Disclosure - Share-Based Payments - Share-based Compensation Expense Included in Consolidation Statements of Income (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails",
     "shortName": "Share-Based Payments - Share-based Compensation Expense Included in Consolidation Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240804051 - Disclosure - Share-Based Payments - Summary of Share-based Compensation Expense Associated with Each Share-based Compensating Programs (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails",
     "shortName": "Share-Based Payments - Summary of Share-based Compensation Expense Associated with Each Share-based Compensating Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icf69f103a98a40ce90631e9f60d5754b_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814052 - Disclosure - Share-Based Payments - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
     "shortName": "Share-Based Payments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ia7c1ad961cd346de9af30e39027d96bf_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824053 - Disclosure - Share-Based Payments - Stock Option Activity (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails",
     "shortName": "Share-Based Payments - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ia7c1ad961cd346de9af30e39027d96bf_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834054 - Disclosure - Share-Based Payments - Tax Benefit and Cash Received from Stock Option Exercises (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails",
     "shortName": "Share-Based Payments - Tax Benefit and Cash Received from Stock Option Exercises (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:ScheduleOfMarketStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i28a8afaf854c4785ba7b167d54f6f8a0_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844055 - Disclosure - Share-Based Payments - Market Stock Units Activity (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
     "shortName": "Share-Based Payments - Market Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:ScheduleOfMarketStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854056 - Disclosure - Share-Based Payments - Assumptions Used in Valuation of Market Based Stock Units (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
     "shortName": "Share-Based Payments - Assumptions Used in Valuation of Market Based Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i57041d1a814045c7be6ea6d6fd527f45_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i2b626c65959246e09aa12e28314bba0c_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864057 - Disclosure - Share-Based Payments - Cash Settled Performance Shares Activity (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
     "shortName": "Share-Based Payments - Cash Settled Performance Shares Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i2b626c65959246e09aa12e28314bba0c_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:PerformanceunitsactivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i94d4a650ffa44c1998500b69da6939ac_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874058 - Disclosure - Share-Based Payments - Performance Units Activity (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
     "shortName": "Share-Based Payments - Performance Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:PerformanceunitsactivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i94d4a650ffa44c1998500b69da6939ac_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210101004 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:PerformanceStockUnitsSettledinStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i78b2e6ab84a14827b284ec4a34e34ebd_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240884059 - Disclosure - Share-Based Payments - Performance Stock Units Settled in Stock Activity (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
     "shortName": "Share-Based Payments - Performance Stock Units Settled in Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:PerformanceStockUnitsSettledinStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i78b2e6ab84a14827b284ec4a34e34ebd_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:PerformanceStockUnitsSettledinCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ib2b88b6b11d44635858d6a6d1dd65fd2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240894060 - Disclosure - Share-Based Payments - Performance Stock Units Settled in Cash Activity (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
     "shortName": "Share-Based Payments - Performance Stock Units Settled in Cash Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:PerformanceStockUnitsSettledinCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ib2b88b6b11d44635858d6a6d1dd65fd2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i3db70ce0acff40ddb1a8049995563df4_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240904061 - Disclosure - Share-Based Payments - Time-Vested Restricted Stock Units Activity (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails",
     "shortName": "Share-Based Payments - Time-Vested Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i12aa11ebb73d46f6a5e8a7655a9a3d7e_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "if188b16b7c0a45a1a919112de323694b_D20150601-20150630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914062 - Disclosure - Share-Based Payments - Shares Issued Under Employee Stock Purchase Plan (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails",
     "shortName": "Share-Based Payments - Shares Issued Under Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icf6d89d5466147cd8f697b7487932bfb_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240944063 - Disclosure - Income Taxes - Income Before Income Tax Provision and the Income Tax Expense (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails",
     "shortName": "Income Taxes - Income Before Income Tax Provision and the Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:DeferredtaxliabilitiesGILTItaxcalculation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954064 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240964065 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240974066 - Disclosure - Income Taxes - Tax Rate (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails",
     "shortName": "Income Taxes - Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i4fdb048733b648df99bd7b1e5b1476ef_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984067 - Disclosure - Income Taxes - Accounting for Uncertainty in Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails",
     "shortName": "Income Taxes - Accounting for Uncertainty in Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ic9925b2c3e594ae0812001969da2a99b_I20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241014068 - Disclosure - Other Consolidated Financial Statement Detail - Supplemental Cash Flow Information (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails",
     "shortName": "Other Consolidated Financial Statement Detail - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210181005 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241024069 - Disclosure - Other Consolidated Financial Statement Detail - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
     "shortName": "Other Consolidated Financial Statement Detail - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034070 - Disclosure - Other Consolidated Financial Statement Detail - Other Income (Expense), Net (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails",
     "shortName": "Other Consolidated Financial Statement Detail - Other Income (Expense), Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044071 - Disclosure - Other Consolidated Financial Statement Detail - Gain (Loss) on Investments (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails",
     "shortName": "Other Consolidated Financial Statement Detail - Gain (Loss) on Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241054072 - Disclosure - Other Consolidated Financial Statement Detail - Accrued Expenses and Other (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails",
     "shortName": "Other Consolidated Financial Statement Detail - Accrued Expenses and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i45223ed4352840169e55fb7523bb7c45_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:Collaborationexpensesaccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241084073 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
     "shortName": "Collaborative and Other Relationships - OCREVUS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ie7879fe01aa94f84adbd555a7a199d32_D20170301-20170331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "id2fc03f67f5645f1b013252212df9935_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241094074 - Disclosure - Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
     "shortName": "Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "id2fc03f67f5645f1b013252212df9935_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "id2fc03f67f5645f1b013252212df9935_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241104075 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
     "shortName": "Collaborative and Other Relationships - Profit Sharing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "id2fc03f67f5645f1b013252212df9935_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i771406e8a3b34c93b5f87c9b46df7655_I20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241114076 - Disclosure - Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
     "shortName": "Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i771406e8a3b34c93b5f87c9b46df7655_I20201231",
      "decimals": "3",
      "lang": "en-US",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241124077 - Disclosure - Collaborative and Other Relationships - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Collaborative and Other Relationships - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241134078 - Disclosure - Collaborative and Other Relationships - Ionis (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
     "shortName": "Collaborative and Other Relationships - Ionis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "if223f76ca1884559bc1cd766f260b0eb_D20130901-20130930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:LicenseFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210221006 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i12a519048d3946d6b1cae8db3bf6ea2b_D20180101-20180331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfDevelopmentCostsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241144079 - Disclosure - Collaborative and Other Relationships - Eisai (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
     "shortName": "Collaborative and Other Relationships - Eisai (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i12a519048d3946d6b1cae8db3bf6ea2b_D20180101-20180331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfDevelopmentCostsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i27837e9cd10e410d9324a0de6843615f_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:ExpenseIncurredByCollaboration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241154080 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to BAN2401 and Elenbecestat Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i27837e9cd10e410d9324a0de6843615f_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:ExpenseIncurredByCollaboration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241164081 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Aducanumab Collaboration (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to Aducanumab Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i523d958a043b46abb2bf95ddabf9e48d_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:Expenseincurredbythecollaboration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i307bd3b52c544217a250d6bec5afed5a_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:Expenseincurredbythecollaboration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241174082 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i307bd3b52c544217a250d6bec5afed5a_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:Expenseincurredbythecollaboration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241184083 - Disclosure - Collaborative and Other Relationships - Alkermes (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
     "shortName": "Collaborative and Other Relationships - Alkermes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i062dfb826bb543c0ab344580c2bc9f39_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241194084 - Disclosure - Collaborative and Other Relationships - Bristol Myers Squibb (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails",
     "shortName": "Collaborative and Other Relationships - Bristol Myers Squibb (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i18853d4d37eb4076a332a07be0132022_D20170601-20170630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R136": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ie154ef82e19b42d287f8709039383fa3_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241204085 - Disclosure - Collaborative and Other Relationships - Acorda (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails",
     "shortName": "Collaborative and Other Relationships - Acorda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ie154ef82e19b42d287f8709039383fa3_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R137": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241214086 - Disclosure - Collaborative and Other Relationships - Other Arrangements (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
     "shortName": "Collaborative and Other Relationships - Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i7ba45b40cf69417f9bccf9942bb04760_D20201101-20201130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:GlobalLicensingCollaborationAgreementAmountSharesPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R138": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241224087 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
     "shortName": "Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i897172e0b7bd4edda63f02e0d50f23aa_D20200101-20200131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R139": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241244088 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i4fdb048733b648df99bd7b1e5b1476ef_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210281007 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R140": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i933bc3e4859e442d998a3136c487cd85_D20191101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241264089 - Disclosure - Litigation - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/LitigationNarrativeDetails",
     "shortName": "Litigation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i933bc3e4859e442d998a3136c487cd85_D20191101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R141": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241284090 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i2093a163235b48f4b3fa0b2166bb4321_D20190101-20190331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R142": {
     "firstAnchor": {
      "ancestors": [
       "biib:PercentageOfMinimumInvestmentReturn",
       "biib:PercentageOfMinimumInvestmentReturn",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i4e1ee455bd644649ba9f949ccefc1a95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfMinimumInvestmentReturn",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241314091 - Disclosure - Employee Benefit Plans - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails",
     "shortName": "Employee Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "biib:PercentageOfMinimumInvestmentReturn",
       "biib:PercentageOfMinimumInvestmentReturn",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i4e1ee455bd644649ba9f949ccefc1a95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageOfMinimumInvestmentReturn",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R143": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241344092 - Disclosure - Segment Information - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R144": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241354093 - Disclosure - Segment Information - Geographic Information (Details)",
     "role": "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails",
     "shortName": "Segment Information - Geographic Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "id49704cf795948148f16dbae680341c9_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R145": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241384094 - Disclosure - Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
     "shortName": "Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210361008 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210431009 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210501010 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210541011 - Disclosure - Leases",
     "role": "http://www.biogenidec.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210621012 - Disclosure - Indebtedness",
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "shortName": "Indebtedness",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010002 - Statement - Consolidated Statements of Income",
     "role": "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210671013 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210731014 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210771015 - Disclosure - Share-Based Payments",
     "role": "http://www.biogenidec.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210921016 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210991017 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211061018 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211231019 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211251020 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211271021 - Disclosure - Commitments and Contingencies",
     "role": "http://www.biogenidec.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211291022 - Disclosure - Guarantees",
     "role": "http://www.biogenidec.com/role/Guarantees",
     "shortName": "Guarantees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020003 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211301023 - Disclosure - Employee Benefit Plans",
     "role": "http://www.biogenidec.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211321024 - Disclosure - Segment Information",
     "role": "http://www.biogenidec.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211361025 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220022001 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230033001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230113002 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230193003 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230233004 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230293005 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230373006 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030004 - Statement - Consolidated Balance Sheets",
     "role": "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230443007 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230513008 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:LesseeLeaseTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230553009 - Disclosure - Leases (Tables)",
     "role": "http://www.biogenidec.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:LesseeLeaseTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230633010 - Disclosure - Indebtedness (Tables)",
     "role": "http://www.biogenidec.com/role/IndebtednessTables",
     "shortName": "Indebtedness (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryOfCommonStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230683011 - Disclosure - Equity (Tables)",
     "role": "http://www.biogenidec.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryOfCommonStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230743012 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230783013 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230933014 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231003015 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231073016 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040005 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231333017 - Disclosure - Segment Information (Tables)",
     "role": "http://www.biogenidec.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231373018 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "biib:BusinessOverviewPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "biib:NumberOfOphthalmolgyBiosimilarProductsExclusiveRights",
      "reportCount": 1,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240044001 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:InterestInSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i1b4148f6f0e64fcc8d46dde21febd1df_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240054002 - Disclosure - Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment Estimated Useful Lives (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - Acquisitions - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i74d25f7562934bc8a1eebaf7750912d2_D20190601-20190630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:ClinicalAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094004 - Disclosure - Divestitures (Details)",
     "role": "http://www.biogenidec.com/role/DivestituresDetails",
     "shortName": "Divestitures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ida412b4bccf941a7af64620b69dcf1ef_I20190831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124005 - Disclosure - Revenues - Revenues by Product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
     "shortName": "Revenues - Revenues by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ia7c7c39b59484f68a74bc30138f093c8_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134006 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i4fdb048733b648df99bd7b1e5b1476ef_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144007 - Disclosure - Revenues - Reserves for Discounts and Allowances (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails",
     "shortName": "Revenues - Reserves for Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154008 - Disclosure - Revenues - Total Reserves for Discounts and Allowances (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails",
     "shortName": "Revenues - Total Reserves for Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i8f40d69597314563b8de93e06ec34c1c_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164009 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174010 - Disclosure - Revenues - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "shortName": "Revenues - Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i87e510b249bf46dc94c9604a2b8b9a69_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240204011 - Disclosure - Inventory - Components of Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
     "shortName": "Inventory - Components of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240214012 - Disclosure - Inventory - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/InventoryNarrativeDetails",
     "shortName": "Inventory - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240244013 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
     "shortName": "Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:AmortizationandImpairmentofAcquiredIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254014 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240264015 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails",
     "shortName": "Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i4fdb048733b648df99bd7b1e5b1476ef_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240274016 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill - Changes in Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "id82ee39d50af4f5587e19230de06cf02_I20181231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304017 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ia4e82735011b489487c0fe39eb2af15c_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ia29e9f9c6a0f4c099a0d0b872c4ab3e0_I20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314018 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurements - Summary of Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ia29e9f9c6a0f4c099a0d0b872c4ab3e0_I20201231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i23b12db8472d48b2b53334bb866cc37b_I20171231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060007 - Statement - Consolidated Statements of Equity",
     "role": "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i23b12db8472d48b2b53334bb866cc37b_I20171231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "biib:TechnologicalAndRegulatorySuccessProbability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324019 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "biib:TechnologicalAndRegulatorySuccessProbability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240334020 - Disclosure - Fair Value Measurements - Gains and Losses on Assets Measured at Fair Value (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Gains and Losses on Assets Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i892b13c4cafa42ecb4c07f03ecf1b9af_I20190607",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344021 - Disclosure - Fair Value Measurements - Summary of Fair and Carrying Value of Debt Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
     "shortName": "Fair Value Measurements - Summary of Fair and Carrying Value of Debt Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354022 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Obligations (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails",
     "shortName": "Fair Value Measurements - Fair Value of Contingent Consideration Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ic89f75651f684c4e8666f45255e68b39_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240384023 - Disclosure - Financial Instruments - Summary of Financial Assets with Maturities (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails",
     "shortName": "Financial Instruments - Summary of Financial Assets with Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394024 - Disclosure - Financial Instruments - Summary of Marketable Securities (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails",
     "shortName": "Financial Instruments - Summary of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240404025 - Disclosure - Financial Instruments - Summary of Contractual Maturities (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails",
     "shortName": "Financial Instruments - Summary of Contractual Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240414026 - Disclosure - Financial Instruments - Proceeds from Marketable Debt Securities (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails",
     "shortName": "Financial Instruments - Proceeds from Marketable Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240424027 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeRemainingMaturity1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454028 - Disclosure - Derivative Instruments - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
     "shortName": "Derivative Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeRemainingMaturity1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icfac85de776a4ccdb1c2c9949959fc1e_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464029 - Disclosure - Derivative Instruments - Foreign Currency Forward Contracts Entered into Hedge Forecasted Revenues (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails",
     "shortName": "Derivative Instruments - Foreign Currency Forward Contracts Entered into Hedge Forecasted Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i9548c02f9465476885ffa4b8feb4449a_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i970be973b11946e2ba4be4af29d27f00_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240474030 - Disclosure - Derivative Instruments - Summary of the Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
     "shortName": "Derivative Instruments - Summary of the Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i970be973b11946e2ba4be4af29d27f00_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240484031 - Disclosure - Derivative Instruments - Summary of the Effect of Derivatives Designated as Net Investment Hedging Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
     "shortName": "Derivative Instruments - Summary of the Effect of Derivatives Designated as Net Investment Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ie215c6f8d19a49b09e42d9e80421319e_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ia2c6f6c468f64ddcb921d54c39e33bcb_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494032 - Disclosure - Derivative Instruments - Summary of the Fair Value for our Outstanding Derivatives (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails",
     "shortName": "Derivative Instruments - Summary of the Fair Value for our Outstanding Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ia2c6f6c468f64ddcb921d54c39e33bcb_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524033 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240534034 - Disclosure - Property, Plant and Equipment - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "shortName": "Property, Plant and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ic4652a3a2e7940719a658dd16032604d_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240564035 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ic4652a3a2e7940719a658dd16032604d_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574036 - Disclosure - Leases - Schedule of Operating Leases (Details)",
     "role": "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails",
     "shortName": "Leases - Schedule of Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:LesseeLeaseTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i1b65f5d0f33646d9bc123cea10741758_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584037 - Disclosure - Leases - Operating Lease Costs (Details)",
     "role": "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails",
     "shortName": "Leases - Operating Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594038 - Disclosure - Leases - Operating Lease Liability Maturity (Details)",
     "role": "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails",
     "shortName": "Leases - Operating Lease Liability Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210061002 - Disclosure - Acquisitions",
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604039 - Disclosure - Leases - Operating Lease Weighted Average Remaining Term and Discount Rate (Details)",
     "role": "http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails",
     "shortName": "Leases - Operating Lease Weighted Average Remaining Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614040 - Disclosure - Leases - Operating Lease Supplemental Cash Flow Disclosure (Details)",
     "role": "http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails",
     "shortName": "Leases - Operating Lease Supplemental Cash Flow Disclosure (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OperatingleasesupplementalcashflowdisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644041 - Disclosure - Indebtedness - Summary of Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails",
     "shortName": "Indebtedness - Summary of Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "ied6fc4314ff74454a352c1254c20f4a6_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654042 - Disclosure - Indebtedness - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
     "shortName": "Indebtedness - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240664043 - Disclosure - Indebtedness - Total Debt Maturities (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails",
     "shortName": "Indebtedness - Total Debt Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694044 - Disclosure - Equity - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfCommonStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240704045 - Disclosure - Equity - Summary of Common Stock (Details)",
     "role": "http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails",
     "shortName": "Equity - Summary of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfCommonStockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i5e9a4ee8449a49d88a3bbe9b29cab624_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i4fdb048733b648df99bd7b1e5b1476ef_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714046 - Disclosure - Equity - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Equity - Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724047 - Disclosure - Equity - Reclassification out of Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Equity - Reclassification out of Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i1029aaf02d1e4e45bfea6b6f58c10380_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "i6841825fce32422eb1457cf2ad6e770d_D20201001-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754048 - Disclosure - Earnings per Share - Basic and Diluted Earnings Per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails",
     "shortName": "Earnings per Share - Basic and Diluted Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20201231.htm",
      "contextRef": "icb3a3eb7d9cc449ebce025a800169b95_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 237,
   "tag": {
    "biib_A2015ESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 ESPP [Member]",
        "label": "2015 ESPP [Member]",
        "terseLabel": "2015 ESPP"
       }
      }
     },
     "localname": "A2015ESPPMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2015SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Senior Notes",
        "label": "2015 Senior Notes [Member]",
        "terseLabel": "2015 Senior Notes"
       }
      }
     },
     "localname": "A2015SeniorNotesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2017OmnibusEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Omnibus Equity Plan",
        "label": "2017 Omnibus Equity Plan [Member]",
        "terseLabel": "2017 Omnibus Equity Plan"
       }
      }
     },
     "localname": "A2017OmnibusEquityPlanMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2020SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Senior Notes",
        "label": "2020 Senior Notes [Member]",
        "terseLabel": "2020 Senior Notes"
       }
      }
     },
     "localname": "A2020SeniorNotesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A225SeniorNotesDueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A225SeniorNotesDueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A315SeniorNotesDueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A315SeniorNotesDueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses on funding commitment related to clinical research.",
        "label": "Accrued Expenses On Funding Commitment Related To Clinical Research",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AcordaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acorda.",
        "label": "Acorda [Member]",
        "terseLabel": "Acorda"
       }
      }
     },
     "localname": "AcordaMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Total aducanumab collaboration third party milestone expense"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Additionalreductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional reduction in royalty rate payable on commercial sales",
        "label": "Additional reduction in royalty rate payable on commercial sales",
        "terseLabel": "Additional reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Additionalreductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedTerseLabel": "Adjustments relating to prior years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdministrativeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative Space",
        "label": "Administrative Space [Member]",
        "terseLabel": "Administrative Space"
       }
      }
     },
     "localname": "AdministrativeSpaceMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AducanumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aducanumab [Member]",
        "label": "Aducanumab [Member]",
        "terseLabel": "Aducanumab"
       }
      }
     },
     "localname": "AducanumabMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AliveGenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AliveGen [Member]",
        "label": "AliveGen [Member]",
        "terseLabel": "AliveGen"
       }
      }
     },
     "localname": "AliveGenMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AlkermesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alkermes [Member]",
        "label": "Alkermes [Member]",
        "terseLabel": "Alkermes"
       }
      }
     },
     "localname": "AlkermesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationandImpairmentofAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationandImpairmentofAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change in reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumptions used in valuation of market based stock units.",
        "label": "Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]",
        "terseLabel": "Assumptions used in valuation of market based stock units"
       }
      }
     },
     "localname": "AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_AverageStockPriceOnGrantDateInDollarsMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average stock price on grant date in dollars maximum.",
        "label": "Average Stock Price On Grant Date In Dollars Maximum",
        "verboseLabel": "Average stock price on grant date maximum"
       }
      }
     },
     "localname": "AverageStockPriceOnGrantDateInDollarsMaximum",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageStockPriceOnGrantDateInDollarsMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average stock price on grant date in dollars minimum.",
        "label": "Average Stock Price On Grant Date In Dollars Minimum",
        "verboseLabel": "Average stock price on grant date minimum"
       }
      }
     },
     "localname": "AverageStockPriceOnGrantDateInDollarsMinimum",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB054Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB054",
        "label": "BIIB054 [Member]",
        "terseLabel": "BIIB054"
       }
      }
     },
     "localname": "BIIB054Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB118Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB118",
        "label": "BIIB118 [Member]",
        "terseLabel": "BIIB118"
       }
      }
     },
     "localname": "BIIB118Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiogenIdecInternationalNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen idec international neuroscience.",
        "label": "Biogen Idec International Neuroscience Member",
        "terseLabel": "Biogen Idec International Neuroscience GmbH"
       }
      }
     },
     "localname": "BiogenIdecInternationalNeuroscienceMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Biogenshareofcopromotionprofitsorlosses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen share of co-promotion profits or losses",
        "label": "Biogen share of co-promotion profits or losses",
        "terseLabel": "Biogen share of co-promotion profits or losses"
       }
      }
     },
     "localname": "Biogenshareofcopromotionprofitsorlosses",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_BiologicsManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "terseLabel": "Biologics Manufacturing"
       }
      }
     },
     "localname": "BiologicsManufacturingMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Subtotal: Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BioverativMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioverativ [Member]",
        "label": "Bioverativ [Member]",
        "terseLabel": "Bioverativ"
       }
      }
     },
     "localname": "BioverativMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb [Member]",
        "label": "Bristol-Myers Squibb [Member]",
        "terseLabel": "Bristol-Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "terseLabel": "Business Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashSettledPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash settled performance shares [Member]",
        "label": "Cash settled performance shares [Member]",
        "terseLabel": "Cash settled performance units"
       }
      }
     },
     "localname": "CashSettledPerformanceSharesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ClinicalAssetsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Assets Acquired",
        "label": "Clinical Assets Acquired",
        "terseLabel": "Clinical assets acquired"
       }
      }
     },
     "localname": "ClinicalAssetsAcquired",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.",
        "label": "Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment",
        "verboseLabel": "Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment"
       }
      }
     },
     "localname": "CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CoPromotionProfitSharingFormulaAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-promotion profit sharing formula.",
        "label": "Co Promotion Profit Sharing Formula [Abstract]",
        "verboseLabel": "Co-promotion profit sharing formula"
       }
      }
     },
     "localname": "CoPromotionProfitSharingFormulaAbstract",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_CoPromotionProfitSharingFormulaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-promotion profit sharing formula.",
        "label": "Co Promotion Profit Sharing Formula [Table Text Block]",
        "verboseLabel": "Co-promotion profit sharing formula"
       }
      }
     },
     "localname": "CoPromotionProfitSharingFormulaTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CollaborationProfitSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.",
        "label": "Collaboration profit sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "CollaborationProfitSharing",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expenses"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestones [Member]",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ComputerSoftwareAndHardware": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer software and hardware",
        "label": "Computer software and hardware",
        "terseLabel": "Computer software and hardware"
       }
      }
     },
     "localname": "ComputerSoftwareAndHardware",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractManufacturingCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Manufacturing Customer",
        "label": "Contract Manufacturing Customer [Member]",
        "terseLabel": "Contract Manufacturing Customer"
       }
      }
     },
     "localname": "ContractManufacturingCustomerMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual Adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ConvergencePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convergence Pharmaceuticals [Member]",
        "label": "Convergence Pharmaceuticals [Member]",
        "terseLabel": "Convergence Pharmaceuticals"
       }
      }
     },
     "localname": "ConvergencePharmaceuticalsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CumulativeSalesLevel": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative sales level",
        "label": "Cumulative sales level",
        "terseLabel": "Cumulative sales level"
       }
      }
     },
     "localname": "CumulativeSalesLevel",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CumulativeSalesLevelAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative sales level [Axis]",
        "label": "Cumulative sales level [Axis]",
        "terseLabel": "Cumulative sales level [Axis]"
       }
      }
     },
     "localname": "CumulativeSalesLevelAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_CumulativeSalesLevelDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Cumulative sales level [Axis]",
        "label": "Cumulative sales level [Domain]",
        "terseLabel": "Cumulative sales level [Domain]"
       }
      }
     },
     "localname": "CumulativeSalesLevelDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current provisions relating to sales in current year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "label": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "terseLabel": "Redemption percentage for change in control provision"
       }
      }
     },
     "localname": "DebtInstrumentMakeWholeProvisionRedemptionPricePercentage",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_DeferredTaxAssetLiabilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset/Liability Type [Axis]",
        "label": "Deferred Tax Asset/Liability Type [Axis]",
        "terseLabel": "Deferred Tax Asset/Liability Type [Axis]"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DeferredTaxAssetLiabilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Deferred Tax Asset/Liability Type [Axis]",
        "label": "Deferred Tax Asset/Liability Type [Domain]",
        "terseLabel": "Deferred Tax Asset/Liability Type [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetLiabilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DeferredTaxAssetsValueReductionInValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Value, Reduction in Value",
        "label": "Deferred Tax Assets, Value, Reduction in Value",
        "terseLabel": "Deferred tax assets, value, reduction in value"
       }
      }
     },
     "localname": "DeferredTaxAssetsValueReductionInValue",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesDepreciationAmortizationOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation amortization other.",
        "label": "Deferred Tax Liabilities Depreciation Amortization Other",
        "negatedTerseLabel": "Depreciation, amortization and other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAmortizationOther",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Tax Credit Carryforwards",
        "label": "Deferred Tax Liabilities, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxCreditCarryforwards",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredTaxLiabilitiesValueReductionInValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Value, Reduction in Value",
        "label": "Deferred Tax Liabilities, Value, Reduction in Value",
        "terseLabel": "Deferred tax liabilities, value, reduction in value"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesValueReductionInValue",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredtaxliabilitiesGILTItaxcalculation": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, GILTI tax calculation",
        "label": "Deferred tax liabilities, GILTI tax calculation",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "DeferredtaxliabilitiesGILTItaxcalculation",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries",
        "label": "Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries",
        "terseLabel": "Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries"
       }
      }
     },
     "localname": "Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DeferredtaxliabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liability [Member]",
        "label": "Deferred tax liability [Member]",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredtaxliabilityMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenaliAndSangamoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denali and Sangamo",
        "label": "Denali and Sangamo [Member]",
        "terseLabel": "Denali and Sangamo"
       }
      }
     },
     "localname": "DenaliAndSangamoMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenaliTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denali Therapeutics Inc.",
        "label": "Denali Therapeutics Inc. [Member]",
        "terseLabel": "Denali Therapeutics"
       }
      }
     },
     "localname": "DenaliTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenmarkManufacturingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denmark Manufacturing Operations [Member]",
        "label": "Denmark Manufacturing Operations [Member]",
        "terseLabel": "Denmark Manufacturing Operations"
       }
      }
     },
     "localname": "DenmarkManufacturingOperationsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Net Gains/(Losses) Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Milestones [Member]",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DirectorsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors plan.",
        "label": "Directors Plan [Member]",
        "verboseLabel": "Directors Plan"
       }
      }
     },
     "localname": "DirectorsPlanMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DisputedClaimsRelatingToConstructionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disputed Claims Relating to Construction Costs",
        "label": "Disputed Claims Relating to Construction Costs",
        "terseLabel": "Disputed claims"
       }
      }
     },
     "localname": "DisputedClaimsRelatingToConstructionCosts",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]",
        "terseLabel": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20201231",
     "xbrltype": "stringItemType"
    },
    "biib_DividendYieldPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Yield Percentage",
        "label": "Dividend Yield Percentage",
        "terseLabel": "Dividend yield percentage"
       }
      }
     },
     "localname": "DividendYieldPercentage",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_DueFromUnconsolidatedJointBusiness": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from unconsolidated joint business",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DueFromUnconsolidatedJointBusiness",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "E2609 and BAN2401"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EachAdditionalOneBillionUpToTwentyBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Each additional one billion up to twenty billion [Member]",
        "label": "Each additional one billion up to twenty billion [Member]",
        "terseLabel": "Each additional one billion up to twenty billion"
       }
      }
     },
     "localname": "EachAdditionalOneBillionUpToTwentyBillionMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change in Foreign Tax Rate, Percent",
        "terseLabel": "Swiss tax reform"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeinForeignTaxRatePercent",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "label": "Effective Income Tax Rate Reconciliation, Intellectual Property Rights Reorganization",
        "terseLabel": "Internal reorganization of certain intellectual property rights"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIntellectualPropertyRightsReorganization",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenue from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Samsung Bioepis, ownership percentage before additional purchase transaction"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Expected Profit Share",
        "label": "Equity Method Investments, Expected Profit Share",
        "terseLabel": "Expected profit share percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable equity securities, gross unrealized gains"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Marketable equity securities, gross unrealized losses"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "terseLabel": "Marketable equity securities, current"
       }
      }
     },
     "localname": "EquitySecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "terseLabel": "Marketable equity securities, non-current"
       }
      }
     },
     "localname": "EquitySecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected additional milestone payments when meeting certain sales threshold.",
        "label": "Expected Additional Milestone Payments When Meeting Certain Sales Threshold",
        "verboseLabel": "Expected additional milestone payments when certain sales threshold is met"
       }
      }
     },
     "localname": "ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected license fee and regulatory milestone payments.",
        "label": "Expected License Fee And Regulatory Milestone Payments",
        "terseLabel": "Expected license fee and regulatory milestone payments"
       }
      }
     },
     "localname": "ExpectedLicenseFeeAndRegulatoryMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpectedPaymentTimelineofMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Payment Timeline of Milestone [Axis]",
        "label": "Expected Payment Timeline of Milestone [Axis]",
        "terseLabel": "Expected Payment Timeline of Milestone [Axis]"
       }
      }
     },
     "localname": "ExpectedPaymentTimelineofMilestoneAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ExpectedPaymentTimelineofMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Expected Payment Timeline of Milestone [Axis]",
        "label": "Expected Payment Timeline of Milestone [Domain]",
        "terseLabel": "Expected Payment Timeline of Milestone [Domain]"
       }
      }
     },
     "localname": "ExpectedPaymentTimelineofMilestoneDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Total UCB development expense",
        "verboseLabel": "Total sales and marketing expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Axis]",
        "terseLabel": "Facility Type [Axis]"
       }
      }
     },
     "localname": "FacilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Domain]",
        "terseLabel": "Facility Type [Domain]"
       }
      }
     },
     "localname": "FacilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FairValueIndefiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "label": "Fair Value, Indefinite Lived Intangible Assets, Discount Rate",
        "terseLabel": "Fair value, in-process research and development, discount rate"
       }
      }
     },
     "localname": "FairValueIndefiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FairValueMeasurementInputs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurement Inputs",
        "label": "Fair Value Measurement Inputs",
        "terseLabel": "Fair value measurement and measurement inputs, recurring and nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementInputs",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ForeignSalesRequiredToTriggerMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign sales required to trigger milestone.",
        "label": "Foreign Sales Required To Trigger Milestone",
        "verboseLabel": "Foreign sales required to trigger milestone"
       }
      }
     },
     "localname": "ForeignSalesRequiredToTriggerMilestone",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ForeignearningsintheformofcashandcashequivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign earnings in the form of cash and cash equivalents [Member]",
        "label": "Foreign earnings in the form of cash and cash equivalents [Member]",
        "terseLabel": "Earnings in the form of cash and cash equivalents"
       }
      }
     },
     "localname": "ForeignearningsintheformofcashandcashequivalentsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ForeignearningstypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign earnings type [Axis]",
        "label": "Foreign earnings type [Axis]",
        "terseLabel": "Foreign earnings type [Axis]"
       }
      }
     },
     "localname": "ForeignearningstypeAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ForeignearningstypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Foreign earnings type [Axis]",
        "label": "Foreign earnings type [Domain]",
        "terseLabel": "Foreign earnings type [Domain]"
       }
      }
     },
     "localname": "ForeignearningstypeDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FumapharmAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fumapharm AG [Member]",
        "label": "Fumapharm AG [Member]",
        "terseLabel": "Fumapharm AG"
       }
      }
     },
     "localname": "FumapharmAgMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future contingent payment for annual worldwide net sales that exceed $2.0 billion",
        "label": "Future contingent payment for annual worldwide net sales that exceed $2.0 billion",
        "terseLabel": "Future contingent payment for annual worldwide net sales that exceed $2.0 billion"
       }
      }
     },
     "localname": "FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future contingent payment for annual worldwide net sales up to $2.0 billion",
        "label": "Future contingent payment for annual worldwide net sales up to $2.0 billion",
        "terseLabel": "Future contingent payment for annual worldwide net sales up to $2.0 billion"
       }
      }
     },
     "localname": "FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_FutureContingentPaymentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future contingent payment threshold",
        "label": "Future contingent payment threshold",
        "terseLabel": "Future contingent payment threshold"
       }
      }
     },
     "localname": "FutureContingentPaymentThreshold",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future royalties percentage to be received on sale of product.",
        "label": "Future Royalties Percentage To Be Received On Sale Of Product",
        "terseLabel": "Royalty percentage to be received"
       }
      }
     },
     "localname": "FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Futurepercentageofcopromotionoperatingprofits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future percentage of co-promotion operating profits",
        "label": "Future percentage of co-promotion operating profits",
        "terseLabel": "Future percentage of co-promotion operating profits"
       }
      }
     },
     "localname": "Futurepercentageofcopromotionoperatingprofits",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_GAZYVAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GAZYVA [Member]",
        "label": "GAZYVA [Member]",
        "terseLabel": "GAZYVA"
       }
      }
     },
     "localname": "GAZYVAMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "label": "Global Licensing Collaboration Agreement, Amount, Shares Purchased",
        "terseLabel": "Global licensing collaboration, shares purchased, amount"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementAmountSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of First Commercial Sale Milestones",
        "terseLabel": "Global licensing collaboration, payment,first milestone"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementOfFirstCommercialSaleMilestones",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "label": "Global Licensing Collaboration Agreement, Payment, Achievement of Specific Sales Based Milestones",
        "terseLabel": "Global licensing collaboration, payment, sales based milestone"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentAchievementOfSpecificSalesBasedMilestones",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "label": "Global Licensing Collaboration Agreement, Payment, Selection of Targets",
        "terseLabel": "Global licensing collaboration, payment, selection of targets"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPaymentSelectionOfTargets",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Purchase Price Per Share",
        "label": "Global Licensing Collaboration Agreement, Purchase Price Per Share",
        "terseLabel": "Global licensing collaboration, purchase price per share (in dollars per share)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementPurchasePricePerShare",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "label": "Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments",
        "terseLabel": "Global licensing collaboration, development and commercial milestone payments"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GlobalLicensingCollaborationAgreementSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "label": "Global Licensing Collaboration Agreement, Shares, Purchased",
        "terseLabel": "Global licensing collaboration, shares purchased (in shares)"
       }
      }
     },
     "localname": "GlobalLicensingCollaborationAgreementSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IPerianMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "iPerian [Member]",
        "label": "iPerian [Member]",
        "terseLabel": "iPerian"
       }
      }
     },
     "localname": "IPerianMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "negatedLabel": "Equity in (income) loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net",
        "label": "Income Tax Expense, Reduction in Deferred Tax Assets and Liabilities, Net",
        "terseLabel": "Income tax expense, reduction in deferred tax assets and liabilities, net"
       }
      }
     },
     "localname": "IncomeTaxExpenseReductionInDeferredTaxAssetsAndLiabilitiesNet",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "terseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InventoryrawmaterialssoldtoFUJIFILM": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory raw materials sold to FUJIFILM",
        "label": "Inventory raw materials sold to FUJIFILM",
        "terseLabel": "Inventory raw materials sold to FUJIFILM"
       }
      }
     },
     "localname": "InventoryrawmaterialssoldtoFUJIFILM",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInCommonStockSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment In Common Stock, Shares Purchased",
        "label": "Investment In Common Stock, Shares Purchased",
        "terseLabel": "Investment in common stock, shares purchased (in shares)"
       }
      }
     },
     "localname": "InvestmentInCommonStockSharesPurchased",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_Investmentincommonstockvalue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in common stock, value",
        "label": "Investment in common stock, value",
        "terseLabel": "Investment in common stock, value"
       }
      }
     },
     "localname": "Investmentincommonstockvalue",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments by third party in joint venture as per agreement",
        "label": "Investments By Third Party In Joint Venture As Per Agreement.",
        "terseLabel": "Contributions by third party"
       }
      }
     },
     "localname": "InvestmentsByThirdPartyInJointVentureAsPerAgreement",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "terseLabel": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20201231",
     "xbrltype": "stringItemType"
    },
    "biib_IonisPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ionis Pharmaceuticals [Member]",
        "label": "Ionis Pharmaceuticals [Member]",
        "terseLabel": "Ionis Pharmaceuticals"
       }
      }
     },
     "localname": "IonisPharmaceuticalsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_JointVentureOwnerShipPercentageByThirdParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint venture owner ship percentage by third party.",
        "label": "Joint Venture OwnerShip Percentage By Third Party.",
        "terseLabel": "Joint venture ownership percentage"
       }
      }
     },
     "localname": "JointVentureOwnerShipPercentageByThirdParty",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_KaryopharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Karyopharm [Member]",
        "label": "Karyopharm [Member]",
        "terseLabel": "Karyopharm"
       }
      }
     },
     "localname": "KaryopharmMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LesseeLeaseTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Lease Table [Table Text Block]",
        "label": "Lessee Lease Table [Table Text Block]",
        "terseLabel": "Schedule of operating leases"
       }
      }
     },
     "localname": "LesseeLeaseTableTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_LicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Fee",
        "label": "License Fee",
        "terseLabel": "License fee"
       }
      }
     },
     "localname": "LicenseFee",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_LongtermoperatingleaseliabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term operating lease liabilities [Member]",
        "label": "Long-term operating lease liabilities [Member]",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "LongtermoperatingleaseliabilitiesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "Subtotal: MS"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MajorDistributorAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Distributor.",
        "label": "Major Distributor [Axis]",
        "terseLabel": "Major Distributor [Axis]"
       }
      }
     },
     "localname": "MajorDistributorAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_MajorDistributorDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Distributor.",
        "label": "Major Distributor [Domain]",
        "terseLabel": "Major Distributor [Domain]"
       }
      }
     },
     "localname": "MajorDistributorDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum target number of market stock units granted based on stock performance in percent.",
        "label": "Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent",
        "verboseLabel": "Percentage of earnings of the target number of units granted based on actual stock performance"
       }
      }
     },
     "localname": "MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_MinimumQualifyingAgeForEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum qualifying age for employee benefit plan.",
        "label": "Minimum Qualifying Age For Employee Benefit Plan",
        "terseLabel": "Minimum qualifying age for employee benefit plan"
       }
      }
     },
     "localname": "MinimumQualifyingAgeForEmployeeBenefitPlan",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum target number of market stock units granted based on stock performance in percent.",
        "label": "Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent",
        "verboseLabel": "Percentage of earnings of the target number of units granted based on actual stock performance"
       }
      }
     },
     "localname": "MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune",
        "verboseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NewAntiCd20Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Anti-CD20.",
        "label": "New Anti Cd20 [Member]",
        "terseLabel": "New Anti Cd20"
       }
      }
     },
     "localname": "NewAntiCd20Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NightstarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nightstar [Member]",
        "label": "Nightstar [Member]",
        "terseLabel": "Nightstar"
       }
      }
     },
     "localname": "NightstarMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Noncontrollinginterestincreasedecreaseother": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest, increase (decrease) other",
        "label": "Noncontrolling interest, increase (decrease) other",
        "terseLabel": "Capital contribution from noncontrolling interest"
       }
      }
     },
     "localname": "Noncontrollinginterestincreasedecreaseother",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfDaysForCalculationOfAverageClosingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days for calculation of average closing stock price.",
        "label": "Number Of Days For Calculation Of Average Closing Stock Price",
        "verboseLabel": "Number of days for calculation of average closing stock price"
       }
      }
     },
     "localname": "NumberOfDaysForCalculationOfAverageClosingStockPrice",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_NumberOfEqualAnnualIncrements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal annual increments.",
        "label": "Number Of Equal Annual Increments",
        "verboseLabel": "Number of equal annual increments"
       }
      }
     },
     "localname": "NumberOfEqualAnnualIncrements",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfOphthalmolgyBiosimilarProductsExclusiveRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Ophthalmolgy Biosimilar Products, Exclusive Rights",
        "label": "Number of Ophthalmolgy Biosimilar Products, Exclusive Rights",
        "terseLabel": "Number of ophthalmolgy biosimilar products"
       }
      }
     },
     "localname": "NumberOfOphthalmolgyBiosimilarProductsExclusiveRights",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Product Candidates",
        "label": "Number of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share-based compensation plans pursuant to which awards are currently being made.",
        "label": "Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made",
        "verboseLabel": "Number of share-based compensation plans pursuant to which awards are currently being made"
       }
      }
     },
     "localname": "NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumberOfSharesOfCommonStockForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of common stock for issuance.",
        "label": "Number Of Shares Of Common Stock For Issuance",
        "verboseLabel": "Total number of shares of common stock for issuance (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesOfCommonStockForIssuance",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "biib_NumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Square Feet",
        "label": "Number of Square Feet",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "NumberOfSquareFeet",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "biib_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholesalers",
        "label": "Number of Wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_OCREVUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OCREVUS",
        "label": "OCREVUS [Member]",
        "terseLabel": "OCREVUS"
       }
      }
     },
     "localname": "OCREVUSMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OperatingleaseassetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease assets [Member]",
        "label": "Operating lease assets [Member]",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingleaseassetsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OperatingleasesupplementalcashflowdisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease supplemental cash flow disclosure [Table Text Block]",
        "label": "Operating lease supplemental cash flow disclosure [Table Text Block]",
        "terseLabel": "Operating lease supplemental cash flow disclosure"
       }
      }
     },
     "localname": "OperatingleasesupplementalcashflowdisclosureTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease weighted average remaining term and discount rate [Table Text Block]",
        "label": "Operating lease weighted average remaining term and discount rate [Table Text Block]",
        "terseLabel": "Operating lease weighted average remaining term and discount rate"
       }
      }
     },
     "localname": "OperatingleaseweightedaverageremainingtermanddiscountrateTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherForeignEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Foreign Earnings [Member]",
        "label": "Other Foreign Earnings [Member]",
        "terseLabel": "Other Foreign Earnings"
       }
      }
     },
     "localname": "OtherForeignEarningsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Relationships",
        "label": "Other Relationships [Member]",
        "terseLabel": "Other Relationships"
       }
      }
     },
     "localname": "OtherRelationshipsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherresearchanddiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other research and discovery [Member]",
        "label": "Other research and discovery [Member]",
        "terseLabel": "Other research and discovery"
       }
      }
     },
     "localname": "OtherresearchanddiscoveryMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentTermsOfAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment terms of accounts receivable.",
        "label": "Payment Terms Of Accounts Receivable",
        "verboseLabel": "Payment terms of accounts receivable arising from product sales"
       }
      }
     },
     "localname": "PaymentTermsOfAccountsReceivable",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedTerseLabel": "Payments/returns relating to sales in current year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedTerseLabel": "Payments/returns relating to sales in prior years"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of co promotion operating profits first fifty million.",
        "label": "Percentage Of Co Promotion Operating Profits First Fifty Million",
        "terseLabel": "Percentage of co promotion operating profits first fifty million"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option one.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One",
        "verboseLabel": "Until GAZYVA First Non-CLL FDA Approval"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]",
        "verboseLabel": "After First GA101 Threshold Date"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option one.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One",
        "terseLabel": "After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date",
        "verboseLabel": "Until First GAZYVA Threshold Date"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option three.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three",
        "terseLabel": "After Second GAZYVA Threshold Date",
        "verboseLabel": "After Second GAZYVA Threshold Date"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option two.",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two",
        "terseLabel": "After First GAZYVA Threshold Date until Second GAZYVA Threshold Date",
        "verboseLabel": "After First GAZYVA Threshold Date until Second GAZYVA Threshold Date"
       }
      }
     },
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfDevelopmentCostsIncurred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Development Costs Incurred",
        "label": "Percentage of Development Costs Incurred",
        "terseLabel": "Percentage of development costs incurred"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostsIncurred",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfMinimumInvestmentReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of minimum investment return.",
        "label": "Percentage Of Minimum Investment Return",
        "verboseLabel": "Percentage of minimum investment return"
       }
      }
     },
     "localname": "PercentageOfMinimumInvestmentReturn",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageOfRoyaltiesAsPerCollaboration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties as per collaboration.",
        "label": "Percentage Of Royalties As Per Collaboration",
        "terseLabel": "Percentage of royalties as per collaboration"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesAsPerCollaboration",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageParValueOfSeniorNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Par Value Of Senior Notes",
        "label": "Percentage Par Value Of Senior Notes",
        "verboseLabel": "Redemption percentage par value of senior notes"
       }
      }
     },
     "localname": "PercentageParValueOfSeniorNotes",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage receivables of wholesale distributor accounted in consolidated receivables.",
        "label": "Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables",
        "terseLabel": "Percentage receivables of wholesale distributor accounted in consolidated receivables"
       }
      }
     },
     "localname": "PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Table Text Block]",
        "label": "Performance Stock Units Settled in Cash [Table Text Block]",
        "terseLabel": "Performance stock units settled in cash activity"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Table Text Block]",
        "label": "Performance Stock Units Settled in Stock [Table Text Block]",
        "terseLabel": "Performance stock units settled in stock activity"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_PerformanceUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Units [Member]",
        "label": "Performance Units [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceUnitsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceunitsactivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance units activity [Table Text Block]",
        "label": "Performance units activity [Table Text Block]",
        "terseLabel": "Performance units activity"
       }
      }
     },
     "localname": "PerformanceunitsactivityTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_PeriodOfCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period Of Collaboration Agreement",
        "label": "Period Of Collaboration Agreement",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "PeriodOfCollaborationAgreement",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer [Member]",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PostacquisitionequitycompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post-acquisition equity compensation [Member]",
        "label": "Post-acquisition equity compensation [Member]",
        "terseLabel": "Post-acquisition equity compensation"
       }
      }
     },
     "localname": "PostacquisitionequitycompensationMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential future milestone payments commitment to third party approximately",
        "verboseLabel": "Potential future milestone payments commitment, approximately"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "label": "Pre-tax Charge, Payment of Early Call Premium and Write off of Remaining Unamortized Debt Issuance Costs, Net of Derivative Gain",
        "terseLabel": "Pre-tax charge"
       }
      }
     },
     "localname": "PreTaxChargePaymentOfEarlyCallPremiumAndWriteOffOfRemainingUnamortizedDebtIssuanceCostsNetOfDerivativeGain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Premiumonpurchaseofcommonstock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on purchase of common stock",
        "label": "Premium on purchase of common stock",
        "terseLabel": "Premium on purchase of common stock"
       }
      }
     },
     "localname": "Premiumonpurchaseofcommonstock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PretaxProfitSharingFormulaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pretax Profit Sharing Formula [Table Text Block]",
        "label": "Pretax Profit Sharing Formula [Table Text Block]",
        "terseLabel": "Pretax profit sharing formula"
       }
      }
     },
     "localname": "PretaxProfitSharingFormulaTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_PurchaseCommitmentReductionOfAmountCommitted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Commitment, Reduction of Amount Committed",
        "label": "Purchase Commitment, Reduction of Amount Committed",
        "terseLabel": "Purchase commitment, reduction"
       }
      }
     },
     "localname": "PurchaseCommitmentReductionOfAmountCommitted",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Purchaseofcommonstock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of common stock",
        "label": "Purchase of common stock",
        "terseLabel": "Purchase of common stock"
       }
      }
     },
     "localname": "Purchaseofcommonstock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_RatioOfNumberOfSharesReservedUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of total number of shares reserved under the plan.",
        "label": "Ratio Of Number Of Shares Reserved Under Plan",
        "verboseLabel": "Ratio of total number of shares reserved under the plan"
       }
      }
     },
     "localname": "RatioOfNumberOfSharesReservedUnderPlan",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "biib_Reductionindeferredtaxliabilityundistributedforeignearnings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in deferred tax liability, undistributed foreign earnings",
        "label": "Reduction in deferred tax liability, undistributed foreign earnings",
        "terseLabel": "Reduction in deferred tax liability, undistributed foreign earnings"
       }
      }
     },
     "localname": "Reductionindeferredtaxliabilityundistributedforeignearnings",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Reductioninroyaltyrate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in royalty rate",
        "label": "Reduction in royalty rate",
        "terseLabel": "Reduction in royalty rate"
       }
      }
     },
     "localname": "Reductioninroyaltyrate",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Reductioninroyaltyratepayableoncommercialsales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in royalty rate payable on commercial sales",
        "label": "Reduction in royalty rate payable on commercial sales",
        "terseLabel": "Reduction in royalty rate payable on commercial sales"
       }
      }
     },
     "localname": "Reductioninroyaltyratepayableoncommercialsales",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Costs, Percentage",
        "label": "Research and Development Costs, Percentage",
        "terseLabel": "Research and development costs, percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ResearchanddevelopmentassetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Research and development asset [Axis]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetDomain",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting",
        "label": "Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting",
        "terseLabel": "Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting"
       }
      }
     },
     "localname": "ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues In Percentage From Anti-CD20 Therapeutic Programs",
        "label": "Revenues In Percentage From Anti-CD20 Therapeutic Programs",
        "terseLabel": "Percentage of total revenues"
       }
      }
     },
     "localname": "RevenuesInPercentageFromAntiCD20TherapeuticPrograms",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RituxanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RITUXAN.",
        "label": "RITUXAN [Member]",
        "terseLabel": "RITUXAN"
       }
      }
     },
     "localname": "RituxanMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RoyaltiesPayablePeriodPostFDAApproval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties Payable Period, Post FDA Approval",
        "label": "Royalties Payable Period, Post FDA Approval",
        "terseLabel": "Royalties payable period, post FDA approval"
       }
      }
     },
     "localname": "RoyaltiesPayablePeriodPostFDAApproval",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_RoyaltyCostofSalesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Cost of Sales [Policy Text Block]",
        "label": "Royalty Cost of Sales [Policy Text Block]",
        "terseLabel": "Royalty Cost of Sales"
       }
      }
     },
     "localname": "RoyaltyCostofSalesPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty operating profit threshold for highest royalty rate percentage",
        "label": "Royalty operating profit threshold for highest royalty rate percentage",
        "terseLabel": "Royalty operating profit threshold for highest royalty rate percentage"
       }
      }
     },
     "localname": "Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_SOD1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOD1 [Member]",
        "label": "SOD1 [Member]",
        "terseLabel": "SOD1"
       }
      }
     },
     "localname": "SOD1Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SageTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sage Therapeutics Inc.",
        "label": "Sage Therapeutics Inc. [Member]",
        "terseLabel": "Sage Therapeutics"
       }
      }
     },
     "localname": "SageTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SalesTriggerGrossSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales trigger gross sales threshold.",
        "label": "Sales Trigger Gross Sales Threshold",
        "terseLabel": "Sales trigger gross sales threshold"
       }
      }
     },
     "localname": "SalesTriggerGrossSalesThreshold",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Common Stock",
        "label": "Sangamo Common Stock [Member]",
        "terseLabel": "Sangamo Therapeutics"
       }
      }
     },
     "localname": "SangamoCommonStockMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsIncAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsIncAgreementMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Cash Settled Performance Shares Activity.",
        "label": "Schedule Of Cash Settled Performance Shares Activity [Table Text Block]",
        "terseLabel": "Cash settled performance shares activity"
       }
      }
     },
     "localname": "ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_ScheduleOfMarketStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Market Stock Units Activity.",
        "label": "Schedule Of Market Stock Units Activity [Table Text Block]",
        "terseLabel": "Market stock units activity"
       }
      }
     },
     "localname": "ScheduleOfMarketStockUnitsActivityTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property plant and equipment useful lives.",
        "label": "Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Property, plant and equipment estimated useful lives"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment geographical groups of countries group other.",
        "label": "Segment Geographical Groups Of Countries Group Other [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "SegmentGeographicalGroupsOfCountriesGroupOtherMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due September 15, 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due September 15, 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due September 15, 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "label": "Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]",
        "terseLabel": "2.900% Senior Notes due September 15, 2020"
       }
      }
     },
     "localname": "SeniorNotesTwoPointNinePercentDueTwentyTwentyMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeriesXPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X preferred stock.",
        "label": "Series X Preferred Stock [Member]",
        "terseLabel": "Series X junior participating"
       }
      }
     },
     "localname": "SeriesXPreferredStockMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total cost and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses",
        "verboseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareRepurchaseProgram1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program 1",
        "label": "Share Repurchase Program 1 [Member]",
        "terseLabel": "2016 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgram1Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareRepurchaseProgram2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program 2",
        "label": "Share Repurchase Program 2 [Member]",
        "terseLabel": "2018 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgram2Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareRepurchaseProgram3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program 3",
        "label": "Share Repurchase Program 3 [Member]",
        "terseLabel": "March 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgram3Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareRepurchaseProgram4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program 4",
        "label": "Share Repurchase Program 4 [Member]",
        "terseLabel": "December 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgram4Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareRepurchaseProgram5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program 5",
        "label": "Share Repurchase Program 5 [Member]",
        "terseLabel": "2020 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgram5Member",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued under employee stock purchase plan.",
        "label": "Shares Issued Under Employee Stock Purchase Plan [Table Text Block]",
        "terseLabel": "Shares issued under employee stock purchase plan"
       }
      }
     },
     "localname": "SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solothurn [Member]",
        "label": "Solothurn [Member]",
        "terseLabel": "Solothurn"
       }
      }
     },
     "localname": "SolothurnMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StromedixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stromedix.",
        "label": "Stromedix [Member]",
        "verboseLabel": "Stromedix, Inc."
       }
      }
     },
     "localname": "StromedixMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SubleaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease [Member]",
        "label": "Sublease [Member]",
        "terseLabel": "Sublease"
       }
      }
     },
     "localname": "SubleaseMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]",
        "label": "Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]",
        "terseLabel": "Summary of activity related to BAN2401 and Elenbecestat collaboration"
       }
      }
     },
     "localname": "SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Activity Related to the UCB Collaboration",
        "label": "Summary of Activity Related to the UCB Collaboration [Table Text Block]",
        "terseLabel": "Summary of activity related to the UCB collaboration"
       }
      }
     },
     "localname": "SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfCommonStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of common stock.",
        "label": "Summary Of Common Stock [Table Text Block]",
        "terseLabel": "Summary of common stock"
       }
      }
     },
     "localname": "SummaryOfCommonStockTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheet"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of activity related to Aducanumab collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TECFIDERAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TECFIDERA",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TECFIDERAMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TechnologicalAndRegulatorySuccessProbability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technological and Regulatory Success, Probability",
        "label": "Technological and Regulatory Success, Probability",
        "terseLabel": "Technological and regulatory success, probability"
       }
      }
     },
     "localname": "TechnologicalAndRegulatorySuccessProbability",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Termofcollaborationagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of collaboration agreement",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "Termofcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.",
        "label": "Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One",
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one"
       }
      }
     },
     "localname": "ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold of gross sales to be achieved in any twelve consecutive months under option one.",
        "label": "Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One",
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in any 12 months under option one"
       }
      }
     },
     "localname": "ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time Vested Restricted Stock Units Activity.",
        "label": "Time Vested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Time-vested restricted stock units activity"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Totaldeferredchargesandprepaidtaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total deferred charges and prepaid taxes",
        "label": "Total deferred charges and prepaid taxes",
        "terseLabel": "Total deferred charges and prepaid taxes"
       }
      }
     },
     "localname": "Totaldeferredchargesandprepaidtaxes",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Totalpaymenttoentercollaborationagreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total payment to enter collaboration agreement",
        "label": "Total payment to enter collaboration agreement",
        "terseLabel": "Total payment to enter collaboration agreement"
       }
      }
     },
     "localname": "Totalpaymenttoentercollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_TransitionTollTaxRepatriationTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Toll Tax Repatriation Tax Rate",
        "label": "Transition Toll Tax Repatriation Tax Rate",
        "terseLabel": "Transition toll tax repatriation tax rate"
       }
      }
     },
     "localname": "TransitionTollTaxRepatriationTaxRate",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_TwelvemonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twelve months [Member]",
        "label": "Twelve months [Member]",
        "terseLabel": "Twelve months"
       }
      }
     },
     "localname": "TwelvemonthsMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TwentybillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty billion [Member]",
        "label": "Twenty billion [Member]",
        "terseLabel": "Twenty billion"
       }
      }
     },
     "localname": "TwentybillionMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_U.S.2017TaxActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. 2017 Tax Act",
        "label": "U.S. 2017 Tax Act [Member]",
        "terseLabel": "2017 Tax Act"
       }
      }
     },
     "localname": "U.S.2017TaxActMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma S.A.",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A."
       }
      }
     },
     "localname": "UCBPharmaSAMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undesignated preferred stock.",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Upfrontpaymentforcollaborationagreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment for collaboration agreement",
        "label": "Upfront payment for collaboration agreement",
        "terseLabel": "Upfront payment for collaboration agreement"
       }
      }
     },
     "localname": "Upfrontpaymentforcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_VUMERITYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VUMERITY [Member]",
        "label": "VUMERITY [Member]",
        "terseLabel": "VUMERITY"
       }
      }
     },
     "localname": "VUMERITYMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "terseLabel": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period to recognize the cost of nonvested awards.",
        "label": "Weighted Average Period To Recognize Cost Of Nonvested Awards",
        "verboseLabel": "Weighted-average period to recognize the cost of unvested awards"
       }
      }
     },
     "localname": "WeightedAveragePeriodToRecognizeCostOfNonvestedAwards",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_WorkinprocessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work-in-process",
        "label": "Work-in-process [Member]",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "WorkinprocessMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20201231",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "SWITZERLAND"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "GERMANY"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DENMARK",
        "terseLabel": "DENMARK"
       }
      }
     },
     "localname": "DK",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r865",
      "r866",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r868"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r870"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r865",
      "r866",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]",
        "terseLabel": "Asia"
       }
      }
     },
     "localname": "AsiaMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r611",
      "r612",
      "r619",
      "r620",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r611",
      "r612",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "auth_ref": [
      "r183",
      "r188",
      "r294",
      "r523",
      "r524",
      "r525",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r183",
      "r188",
      "r294",
      "r523",
      "r524",
      "r525",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r183",
      "r188",
      "r294",
      "r523",
      "r524",
      "r525",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r183",
      "r188",
      "r294",
      "r523",
      "r524",
      "r525",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]",
        "verboseLabel": "Equity Method Investee, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r258",
      "r393",
      "r397",
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r484",
      "r490",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r752",
      "r813",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/LeasesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r484",
      "r490",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r752",
      "r813",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/LeasesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r258",
      "r393",
      "r397",
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r254",
      "r393",
      "r395",
      "r754",
      "r812",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r254",
      "r393",
      "r395",
      "r754",
      "r812",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r427",
      "r484",
      "r490",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r752",
      "r813",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/LeasesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r427",
      "r484",
      "r490",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r752",
      "r813",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/LeasesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Equity Method Investee, Name [Axis]",
        "verboseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r393",
      "r396",
      "r815",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails",
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r393",
      "r396",
      "r815",
      "r840",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails",
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r358",
      "r485",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r260",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails",
      "http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails",
      "http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r727",
      "r729",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r23",
      "r44",
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r39",
      "r760",
      "r789"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails",
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r69"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued Royalties, Current"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r93",
      "r98",
      "r100",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded Status of Postretirement Benefit Plans, net of tax"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r61",
      "r341"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r98",
      "r108",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Cash Flow Hedges, net of tax",
        "verboseLabel": "Gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r98",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Securities Available for Sale, net of tax",
        "verboseLabel": "Gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r98",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (Losses) on Net Investment Hedge, Net of Tax",
        "verboseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r96",
      "r97",
      "r98",
      "r792",
      "r822",
      "r823"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "AOCI, ending balance",
        "periodStartLabel": "AOCI, beginning balance",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r95",
      "r98",
      "r100",
      "r180",
      "r181",
      "r182",
      "r618",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r88",
      "r98",
      "r100",
      "r618",
      "r687",
      "r688",
      "r689",
      "r690",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r45",
      "r526"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r151",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedTerseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r493",
      "r517",
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation expense related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r151",
      "r320",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r661"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as hedge, excluded component, after tax"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r280",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r163",
      "r239",
      "r244",
      "r250",
      "r293",
      "r611",
      "r619",
      "r680",
      "r758",
      "r788"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r83",
      "r163",
      "r293",
      "r611",
      "r619",
      "r680"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r663"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r274"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r271",
      "r300"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r275",
      "r278",
      "r783"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Estimated Fair\u00a0Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r275",
      "r277",
      "r782"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r268",
      "r272",
      "r300",
      "r765"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r270",
      "r300"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r270",
      "r300"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r494",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails",
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r639",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails",
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r27",
      "r340"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r480",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r480",
      "r486",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "auth_ref": [
      "r150",
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "terseLabel": "Reduction in contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Maximum contingent consideration in the form of development and approval milestones"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r591",
      "r592",
      "r595"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of year",
        "periodStartLabel": "Fair value, beginning of year",
        "terseLabel": "Fair Value",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r591",
      "r593"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Business Combination, Contingent Consideration, Liability, Current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Unobservable Input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r591",
      "r593"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Fair-value post-combination equity compensation",
        "verboseLabel": "NST stock options"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r158",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r154",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r146",
      "r153",
      "r156"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the year",
        "periodStartLabel": "Cash and cash equivalents, beginning of the year",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r146",
      "r685"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedge"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.",
        "label": "Cash Proceeds Received and Tax Benefit from Share-based Payment Awards [Table Text Block]",
        "terseLabel": "Tax benefit and cash received from stock option exercises"
       }
      }
     },
     "localname": "CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r161",
      "r163",
      "r197",
      "r201",
      "r202",
      "r204",
      "r206",
      "r217",
      "r218",
      "r219",
      "r293",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r602",
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative arrangements and non-collaborative arrangement transactions"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r74",
      "r357",
      "r769",
      "r797"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments, contingencies and guarantees (Notes 21 and 22)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r362",
      "r841",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r43",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquitySummaryofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Accounting for Share-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "verboseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r103",
      "r105",
      "r106",
      "r116",
      "r775",
      "r806"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r103",
      "r105",
      "r115",
      "r609",
      "r610",
      "r628",
      "r774",
      "r805"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "verboseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r103",
      "r105",
      "r114",
      "r608",
      "r628",
      "r773",
      "r804"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r222",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r768",
      "r798"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.",
        "label": "Construction Payable",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r428",
      "r474",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r121",
      "r754"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r165",
      "r562",
      "r571"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r562"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r165",
      "r562",
      "r571",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r165",
      "r562",
      "r571"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of notes payable",
        "verboseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r759",
      "r761",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r697",
      "r699"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Senior notes aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on senior notes",
        "verboseLabel": "Interest rate on senior notes"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemptions percentage of 2015 notes"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r72",
      "r166",
      "r373",
      "r376",
      "r377",
      "r378",
      "r696",
      "r697",
      "r699",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "verboseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred compensation liability"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r165",
      "r563",
      "r571"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r165",
      "r563",
      "r571"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r537",
      "r538"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxChargesMember": {
     "auth_ref": [
      "r857",
      "r858",
      "r859",
      "r860"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate action of a regulator resulting in capitalization or accrual of income taxes.",
        "label": "Deferred Income Tax Charge [Member]",
        "terseLabel": "Deferred Income Tax Charge"
       }
      }
     },
     "localname": "DeferredIncomeTaxChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r151",
      "r165",
      "r563",
      "r571",
      "r572",
      "r573"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r537",
      "r538"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r165",
      "r563",
      "r571"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory, other reserves and accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforward, subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r558",
      "r560",
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r538",
      "r555"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r560",
      "r561",
      "r599",
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "terseLabel": "Deferred tax liabilities, goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Deferred tax liabilities, other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "terseLabel": "Transition toll tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "verboseLabel": "Employee benefit plan obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r405",
      "r426",
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "verboseLabel": "Unfunded net pension"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r439",
      "r464",
      "r474",
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "verboseLabel": "Periodic pension cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expenses related to savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r151",
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r151",
      "r236"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract Type [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r84",
      "r86",
      "r641",
      "r734"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Asset derivative instruments"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r84",
      "r86",
      "r641",
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Liability derivative instruments"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r640",
      "r642",
      "r648",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r637",
      "r640",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r637",
      "r640",
      "r648",
      "r654",
      "r655",
      "r657",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r631",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "terseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Forward contracts duration"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r170",
      "r630",
      "r632",
      "r637",
      "r638",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Completed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenue by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": {
     "auth_ref": [
      "r2",
      "r4",
      "r6",
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.",
        "label": "Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax",
        "terseLabel": "Loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations, net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r6",
      "r13",
      "r17",
      "r539",
      "r570",
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Tax expense on disposal group"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Consideration received for sale of Denmark manufacturing operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory work-in-process sold to FUJIFILM"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Expected costs to sell disposal group"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment sold to Fujifilm"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r151",
      "r338",
      "r343"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "negatedTerseLabel": "(Gain) loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations",
        "terseLabel": "(Gain) loss on divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r21",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Divestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r480",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Country"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r479",
      "r483",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r169",
      "r718",
      "r766",
      "r800"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r169",
      "r718",
      "r767",
      "r799"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r117",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r194",
      "r197",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r776",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r117",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r197",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r776",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "U.S. tax reform"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfAssets": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to disposition of asset. Includes, but is not limited to, intra-entity transfer of asset other than inventory.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Asset, Percent",
        "terseLabel": "Divestiture of Denmark manufacturing operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "TECFIDERA impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r540",
      "r575"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee-related Liabilities, Current"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Share-based Payment Arrangement, Cash Used to Settle Award",
        "verboseLabel": "Cash settlement of awards upon vesting"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation cost related to unvested share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "verboseLabel": "Tax benefit realized for stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r185",
      "r191",
      "r193",
      "r216",
      "r294",
      "r372",
      "r379",
      "r523",
      "r524",
      "r525",
      "r567",
      "r568",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r692",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Total basis difference"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Samsung Bioepis, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r58",
      "r240",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r58",
      "r145",
      "r158",
      "r291",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method of Accounting"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable equity securities, fair value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "totalLabel": "Marketable equity securities, amortized cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r288",
      "r809"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r288",
      "r809"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gains (losses) recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainLossonInvestmentsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r663",
      "r664",
      "r665",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of significant unobservable inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "auth_ref": [
      "r663",
      "r664",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of gains or losses on assets measured at fair value, nonrecurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r663",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Fair Value by Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r663",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r474",
      "r664",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r663",
      "r664",
      "r667",
      "r668",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair value hedge"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r428",
      "r430",
      "r435",
      "r474",
      "r664",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r428",
      "r430",
      "r435",
      "r474",
      "r664",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r474",
      "r664",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r669",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r670"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Contingent consideration",
        "negatedTerseLabel": "(Gain) loss on fair value remeasurement of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r671"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r671"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments and other"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r474",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r663",
      "r664",
      "r667",
      "r668",
      "r672",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r673",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "verboseLabel": "Fair value, measurements, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r158",
      "r676",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r639",
      "r644",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Estimated life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r321",
      "r324",
      "r328",
      "r332",
      "r755",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r663"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Intangible asset, fair value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r328",
      "r756"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r321",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r328",
      "r755"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Net change in acquired and in-licensed rights and patents"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Finite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Finite-lived Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Acquired intangible asset"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange gains (losses), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Translation of Foreign Currencies"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r428",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r479",
      "r483",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r340"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures, Gross",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r640"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Gain (loss) on derivative instruments, net, pretax"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r640",
      "r647"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "verboseLabel": "Net gains (losses) of other income (expense) related to foreign currency forward contracts"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "terseLabel": "Gain (loss) on investments, net"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralBusinessMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards which include, but are not limited to, investment, alcohol fuels, low income housing, alternative fuels, alternative motor vehicles, hurricane relief, disabled access, renewable resources electricity production, employer social security, orphan drug, new markets, employer provided child care facilities and services, biodiesel fuels, low sulfur diesel fuel production, distilled spirits and the advanced nuclear power facilities credit.",
        "label": "General Business Tax Credit Carryforward [Member]",
        "terseLabel": "General Business"
       }
      }
     },
     "localname": "GeneralBusinessMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r310",
      "r311",
      "r757"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, end of year",
        "periodStartLabel": "Goodwill, beginning of year",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Increase to goodwill",
        "verboseLabel": "Increase to goodwill"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r158",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r158",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r312",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedLabel": "Elimination of goodwill allocated to Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r120",
      "r163",
      "r239",
      "r243",
      "r246",
      "r249",
      "r252",
      "r293",
      "r680"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "verboseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantees [Abstract]",
        "terseLabel": "Guarantees [Abstract]"
       }
      }
     },
     "localname": "GuaranteesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteesTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.",
        "label": "Guarantees [Text Block]",
        "verboseLabel": "Guarantees"
       }
      }
     },
     "localname": "GuaranteesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Guarantees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r637",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsForeignCurrencyForwardContractsEnteredintoHedgeForecastedRevenuesDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r151",
      "r333"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r151",
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r337",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "verboseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r62",
      "r158",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-process Research and Development (IPR&amp;D)"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r167",
      "r574"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r167",
      "r574"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r167",
      "r239",
      "r243",
      "r246",
      "r249",
      "r252"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income before income taxes (benefit):"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r111",
      "r151",
      "r237",
      "r289",
      "r770",
      "r801"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Loss on equity method investment",
        "terseLabel": "Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Net profits on investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to parent. Excludes discontinued operations.",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-sale, Excluding Discontinued Operations, Attributable to Parent, before Income Tax",
        "negatedTerseLabel": "(Gain)/loss on divestiture of Hillerod, Denmark manufactuing operations"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToParentBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r480",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r16",
      "r18",
      "r19",
      "r20",
      "r346",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DivestituresDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r541",
      "r552",
      "r557",
      "r569",
      "r576",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r165",
      "r192",
      "r193",
      "r238",
      "r539",
      "r570",
      "r577",
      "r810"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit (expense)",
        "totalLabel": "Total income tax expense",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Income tax expense (benefit):"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesIncomeBeforeIncomeTaxProvisionandtheIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r158",
      "r535",
      "r536",
      "r552",
      "r553",
      "r556",
      "r565",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r148",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedTerseLabel": "Unrealized (gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r206"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock options and employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r323",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible assets (excluding goodwill)",
        "verboseLabel": "Cost and net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r323",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Beginning Book Value",
        "totalLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r319",
      "r326"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "periodEndLabel": "Ending Book Value",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Total intangible assets",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/FairValueMeasurementsGainsandLossesonAssetsMeasuredatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r695"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest costs capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r109",
      "r235",
      "r694",
      "r698",
      "r777"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r142",
      "r147",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r51",
      "r308"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r22",
      "r80"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r81",
      "r158",
      "r213",
      "r305",
      "r307",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r53",
      "r308"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r52",
      "r308"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "verboseLabel": "Write-downs on excess, obsolete, unmarketable or other inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r123",
      "r234"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r291",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities and Other Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r663"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "verboseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r26",
      "r60"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r714",
      "r716"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r27",
      "r340"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating lease liability maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r715"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, contract term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r68",
      "r163",
      "r245",
      "r293",
      "r612",
      "r619",
      "r620",
      "r680"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r50",
      "r163",
      "r293",
      "r680",
      "r764",
      "r795"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r70",
      "r163",
      "r293",
      "r612",
      "r619",
      "r620",
      "r680"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "verboseLabel": "Liabilities associated with uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r38",
      "r761",
      "r787"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Outstanding borrowings"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Senior unsecured revolving credit facility maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r38",
      "r367",
      "r761",
      "r790"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Non-current portion of notes payable",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Current Maturities [Abstract]",
        "terseLabel": "Current portion:"
       }
      }
     },
     "localname": "LongTermDebtCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r172",
      "r365"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r172",
      "r365"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r172",
      "r365"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r172",
      "r365"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r172",
      "r365"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r172",
      "r365"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermNotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-current portion:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Non-current notes payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails",
      "http://www.biogenidec.com/role/IndebtednessTotalDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r72",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r357",
      "r359",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Claims asserted"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossOnContractTermination": {
     "auth_ref": [
      "r753"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The loss recognized on termination of a contract.",
        "label": "Loss on Contract Termination",
        "terseLabel": "Loss on contract termination"
       }
      }
     },
     "localname": "LossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r340"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r78",
      "r163",
      "r293",
      "r680",
      "r763",
      "r794"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distribution to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r146",
      "r149",
      "r152"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r101",
      "r104",
      "r112",
      "r152",
      "r163",
      "r184",
      "r186",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r203",
      "r239",
      "r243",
      "r246",
      "r249",
      "r252",
      "r293",
      "r680",
      "r771",
      "r802"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc.",
        "verboseLabel": "Total reclassifications, net of tax"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r101",
      "r104",
      "r192",
      "r193",
      "r615",
      "r627"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net investment hedge"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r379",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-lived assets related to operations in Denmark",
        "verboseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails",
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)",
        "totalLabel": "Total other income (expense), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "2.900% Senior Notes due September 15, 2020"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "verboseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r239",
      "r243",
      "r246",
      "r249",
      "r252"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r707",
      "r716"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r701"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseLiabilityMaturityDetails",
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r701"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r701"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r703",
      "r710"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r700"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r713",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r712",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r69"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "verboseLabel": "Cancellable future commitments"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r90",
      "r91",
      "r96"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r98",
      "r108",
      "r686",
      "r688",
      "r692"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r96",
      "r99",
      "r646"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": {
     "auth_ref": [
      "r89",
      "r645"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax",
        "terseLabel": "Gains (losses) on net investment hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r89",
      "r96",
      "r645",
      "r649",
      "r658"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "verboseLabel": "Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing) (in millions)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r102",
      "r105",
      "r108",
      "r113",
      "r372",
      "r686",
      "r691",
      "r692",
      "r772",
      "r803"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r102",
      "r105",
      "r608",
      "r609",
      "r617"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive income (loss), net of tax",
        "verboseLabel": "Net current period other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r639",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventoryCapitalizedCosts": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before valuation and last-in first out (LIFO) reserves, of costs capitalized in inventory classified as other, expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Capitalized Costs, Gross",
        "terseLabel": "Capitalized inventory"
       }
      }
     },
     "localname": "OtherInventoryCapitalizedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r69"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "totalLabel": "Total accrued expenses and other",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheFairValueforourOutstandingDerivativesDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails",
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Payments for pre-combination equity compensation"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r454",
      "r457",
      "r460",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Deferred Compensation Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r539",
      "r565"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other income tax expense (benefit).",
        "label": "Other Tax Expense (Benefit)",
        "terseLabel": "Other tax expense (benefit)"
       }
      }
     },
     "localname": "OtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Biogen Inc. shareholders\u2019 equity",
        "verboseLabel": "Share-based compensation expense included in net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Contingent consideration payments",
        "terseLabel": "Contingent payment"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r130",
      "r134",
      "r171"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfCapitalDistribution": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.",
        "label": "Payments of Capital Distribution",
        "negatedTerseLabel": "Net contribution (distribution) to noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsOfCapitalDistribution",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Costs associated with the senior Nnotes offerings"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r126",
      "r131",
      "r269"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Nightstar Therapeutics plc, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r132",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Total transaction value"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Investment in Samsung Bioepis",
        "terseLabel": "Payments to increase investment in Samsung Bioepis"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedTerseLabel": "Purchase of subsidiaries and affiliates"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Contingent consideration paid related to Fumapharm AG acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Payments related to issuance of stock for share-based compensation arrangements, net",
        "verboseLabel": "Payment to Neurimmune"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r427",
      "r429",
      "r435",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r474",
      "r476",
      "r477",
      "r478",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.",
        "label": "Pension Cost (Reversal of Cost)",
        "terseLabel": "Pension cost (reversal)"
       }
      }
     },
     "localname": "PensionExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r494",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and discovery services"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Net contribution (distribution) to noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r137",
      "r141",
      "r171"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r126",
      "r127",
      "r269"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/FinancialInstrumentsProceedsfromMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from divesiture of Hillerod, Denmark manufacturing operations"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r135",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Cash received from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTaxBenefitandCashReceivedfromStockOptionExercisesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Total other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net",
        "verboseLabel": "Total product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r20",
      "r101",
      "r104",
      "r144",
      "r163",
      "r184",
      "r192",
      "r193",
      "r239",
      "r243",
      "r246",
      "r249",
      "r252",
      "r293",
      "r608",
      "r614",
      "r616",
      "r627",
      "r628",
      "r680",
      "r778"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r61",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r350",
      "r844",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r60",
      "r340"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross",
        "totalLabel": "Total cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r34",
      "r35",
      "r342",
      "r796"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r158",
      "r342",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r34",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components of property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r34",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r40",
      "r762",
      "r791"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Future minimum batch production for Denmark manufacturing operations"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/DivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "verboseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable securities, excluding strategic investments"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r811"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized investment gains (losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r263",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r98",
      "r100",
      "r108",
      "r686",
      "r690",
      "r692"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayments of borrowings"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "verboseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r532",
      "r861"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense asset acquired"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r158",
      "r334",
      "r335",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r151",
      "r351",
      "r352",
      "r353"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r46",
      "r379",
      "r526",
      "r793",
      "r821",
      "r823"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r185",
      "r191",
      "r193",
      "r294",
      "r523",
      "r524",
      "r525",
      "r567",
      "r568",
      "r818",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r457",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r479",
      "r483",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r457",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r479",
      "r483",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r454",
      "r457",
      "r460",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r452",
      "r454",
      "r457",
      "r460",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EmployeeBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r394",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r159",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r110",
      "r163",
      "r232",
      "r233",
      "r242",
      "r247",
      "r248",
      "r254",
      "r255",
      "r258",
      "r293",
      "r680",
      "r778"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyProductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r711",
      "r716"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseSupplementalCashFlowDisclosureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasCashFlowHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r98",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Debt and equity securities, available-for-sale"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r276",
      "r279",
      "r282",
      "r283",
      "r284",
      "r286",
      "r780",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueofContingentConsiderationObligationsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofFinancialAssetswithMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Income before income tax provision and the income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of indebtedness"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r640",
      "r648",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of derivatives designated as cash flow hedging instruments on our consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of the fair value for our outstanding derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r493",
      "r516",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r493",
      "r516",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the details pertaining to each employee stock ownership plan.",
        "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]",
        "terseLabel": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r663",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r321",
      "r327",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r32",
      "r54",
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Total debt maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r61",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "verboseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r119",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "verboseLabel": "Geographic information"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r494",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r500",
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r75",
      "r161",
      "r217",
      "r218",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r551",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of beginning and ending amount of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r611",
      "r612",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r228",
      "r230",
      "r231",
      "r239",
      "r241",
      "r246",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelectedQuarterlyFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selected Quarterly Financial Information [Abstract]",
        "terseLabel": "Selected Quarterly Financial Information [Abstract]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharebasedCompensationExpenseIncludedinConsolidationStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofFairandCarryingValueofDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessSummaryofIndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of shares granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance, unvested shares (in shares)",
        "periodStartLabel": "Beginning balance, unvested shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance, weighted average grant date fair value (in dollars per share)",
        "periodStartLabel": "Beginning balance, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant\u00a0Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of vested awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Range of expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Maximum range of risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Minimum range of risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Omnibus Plan number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r502",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance, outstanding shares (in shares)",
        "periodStartLabel": "Beginning balance, outstanding shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Beginning balance, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r492",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsAssumptionsUsedinValuationofMarketBasedStockUnitsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsCashSettledPerformanceSharesActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsMarketStockUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinCashActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceStockUnitsSettledinStockActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsPerformanceUnitsActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSummaryofSharebasedCompensationExpenseAssociatedwithEachSharebasedCompensatingProgramsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsTimeVestedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share based payment arrangement, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer\u00a0Software\u00a0and\u00a0Hardware"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r161",
      "r163",
      "r197",
      "r201",
      "r202",
      "r204",
      "r206",
      "r217",
      "r218",
      "r219",
      "r293",
      "r372",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r77",
      "r180",
      "r181",
      "r182",
      "r185",
      "r191",
      "r193",
      "r216",
      "r294",
      "r372",
      "r379",
      "r523",
      "r524",
      "r525",
      "r567",
      "r568",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r692",
      "r818",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassificationoutofAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails",
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r216",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails",
      "http://www.biogenidec.com/role/LeasesScheduleofOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r42",
      "r43",
      "r372",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under the 2015 ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r43",
      "r372",
      "r379",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock under stock award plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r43",
      "r372",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r42",
      "r43",
      "r372",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "verboseLabel": "Cash received under the 2015 ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsSharesIssuedUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r77",
      "r372",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r42",
      "r43",
      "r372",
      "r379",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount of share repurchases"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r42",
      "r43",
      "r372",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Retirement of common stock pursuant to the share repurchase program, at cost (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r43",
      "r48",
      "r49",
      "r163",
      "r264",
      "r293",
      "r680"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r163",
      "r180",
      "r181",
      "r182",
      "r185",
      "r191",
      "r293",
      "r294",
      "r379",
      "r523",
      "r524",
      "r525",
      "r567",
      "r568",
      "r606",
      "r607",
      "r626",
      "r680",
      "r686",
      "r687",
      "r692",
      "r819",
      "r820"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Amount reclassified, net of tax, upon adoption of ASU 2016-01",
        "totalLabel": "Total equity",
        "verboseLabel": "Stockholders equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets",
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r379",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r709",
      "r716"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "verboseLabel": "Trademarks and trade names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r280",
      "r281",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Net Gains/(Losses) Recognized in Other Comprehensive Income (Effective Portion) (in millions)"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryoftheEffectofDerivativesDesignatedasNetInvestmentHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r76",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "verboseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r43",
      "r372",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to the share repurchase program, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r76",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r43",
      "r372",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Repurchase of common stock pursuant to the share repurchase program, at cost (in shares)",
        "terseLabel": "Repurchase of common stock, at cost (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity",
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r76",
      "r381",
      "r382"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r372",
      "r379",
      "r381"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Repurchase of common stock pursuant to the share repurchase program, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAcordaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsAlkermesDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsBristolMyersSquibbDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoAducanumabCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoBAN2401andElenbecestatCollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r428",
      "r779",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "terseLabel": "Unrealized gain (loss) on derivative instruments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "verboseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r534",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance ar December 31,",
        "periodStartLabel": "Beginning balance at January 1,"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions of prior periods"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlement refund (payment)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Net interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior periods"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Settlement refund (payment)"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Statute expirations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesAccountingforUncertaintyinIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "verboseLabel": "Unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r173",
      "r177"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpensesandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails",
      "http://www.biogenidec.com/role/RevenuesTotalReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r708",
      "r716"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r196",
      "r206"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc. (in shares)",
        "totalLabel": "Diluted earnings per share attributable to Biogen Inc. (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "terseLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares used in calculating:",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r194",
      "r206"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc. (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedStatementsofIncome",
      "http://www.biogenidec.com/role/EarningsperShareBasicandDilutedEarningsPerShareDetails",
      "http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3444-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "http://asc.fasb.org/topic&trid=2155896"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5558-128473"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121554379&loc=d3e9972-128506"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121554379&loc=d3e9979-128506"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "275",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=84167019&loc=d3e54681-109401"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=121557228&loc=d3e43603-110378"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "405",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=6500807&loc=d3e48068-110394"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=6501382&loc=d3e54053-110423"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "980",
   "URI": "http://asc.fasb.org/extlink&oid=6501382&loc=d3e54136-110423"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r862": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r863": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r864": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r865": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r866": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r867": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r868": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r869": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r870": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>207
<FILENAME>0000875045-21-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-21-000010-xbrl.zip
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M9CV*CMT($L91+#J,O*E6Z>PEYK/"BGM)J:]?!_HB,T(('% YE[A*#%&BLM%
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MU*T947%8@H$:E2BO1,$6:ON!?!B@R1JX#VK9>KX5/<HLZMG7F&OK<H]!H:W
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M_==S@_$"G6A%HUE+1!<XU *:M$1V/HCN+Z!"%?&_XL?R>8%.B(*A9&^<4M8
MM(5DLFPB,"*XF/T =AG=CA?H!#RKG>5D;:BA@B?!"9/3K**OT58U@+TCNQN;
MOS[9V>Z_&^A(Z5N%$8R8_ZH!E"%2,MY=,H04(@] Z=\2008_)R28I:QUM.P-
M>&8RS Z$/+KH"&3O#%-ZB5YD-"J%HE)3 TXE@N0R*(?*)Q4&(/H'XPBZT8NN
M%FT2)%V+ P@J&N>RHIH6+8S, ':<#<\1=+2)*!:?<K(964&Q0AGR+GJ7%#H7
MJKTS3.DE>BXPZUHY8_*@.!.@<14=V&!#C@,H530<1]#-QB&#-6DT1J$&=KHM
M$@<(I@:"EG^Z(L@2.H)N\L]$*::VZS!7!PX14\K&BG.0R#)7-8 IYEMR!)V@
MQXI<=)84RL"FX"AB,,$+GBX%G_M2JNB_H#=^^N[-)_R:IZ??W]*W<X_0C7;T
M8%2I*9HLRL";BAF@L 1^0%J%B#UARI+D)'\K*WM)F9I,2H:Y6&N!#23GK0XZ
M!28OS^Z@<>DEC%39ZTB: @ 8[PBQ<+5>59\KA]I_J3<\']&-K+0F@$T."PI5
ME N)2#P&1\/>&V?[4K_X;OJ(CN:1M+<4=+%,%3PHTEBA.&,56$IE ,F+=P)&
M)5%@M6W72(D2%B)I:XVR#BU:G?P 2AL/T$=THCB+J3Y@S H9@6L@>9Q2U=69
M9+ W\P5WU$=TLW^E4LG.@<[1@5,M '42>%J*E"IIWQ/*W'48L_4IV1A3*!(=
MIA"5K25 ;@N,'GQ?Y&"WA>^>/MK8?+*V.\CM":(P2ZN#B 4(3!378%14Z'PA
M)5)B511[Q93WU;!\R"S(>6<AIY*4Q)B@Q;!4DVKJRV3D'46/8Z9:6$<OXQQ9
MO$),)?A%[]GBP@"F"0;C"#HJD>LTN!)*,BTS3:M(7F51"S$&K2]+Y/::(,-S
M!!W-.Y"Q(ARM+KY"B2DJBCX$FRT;9RSVA"EW%+V00BHV!H7&0RD*M3,1L3)P
M0J7ZLLOD3CB"3B0CJ5C9!"9=!*_"*4==L-3@(C@*J\FB%5,NF2)V))KL<V"
MJ'T4HO@",4O$D O%GC#EKJ)':;%HF# F8!.3A'D9BM<5E!-D^Z_G?KV_>?_1
MVA\;O5\UZ$@R*C!HN!2K%7C,&(H(R.Q$[/N$0\@[NB6"##Y##1VJXF*(T6>P
M"-$1H";&:K)8F0'D,GXE4WJ)'A?'*!*C0"V038TI2 #H 6H0SU[ZT@BK^W$^
MU"U&F2O4E(RO4:([#9B*DEBAAL3)6^[+U%#W!!E\AIHK*9JHJ_>!0*%+\D)H
M>PQL"<7H 51 NQU'T%%1>]%O"@F,)0GX(D:4$4_:IJI%$>@!=, >CB/HILQM
MCIJU<X:\!J<X6DPB%GW)%E2AOLP==D^0P6>H 5,-I2('I22F+*A!D4@$'6H(
M2.;.,*67Z/E0=0HE^J;G&("(.<3DK+*F@!Z \M\8/UG[8[W_?J"K[MH9LXA]
M9S4 !$#TQ<2*10*(R+FN^+%T;J"C/4/%!96B<UPR%*QDD_8AJ)@CH1Y"7?RO
M(THOP4O%9%.5=Z:).=/ZH-F*B3(%!G8#F!<:BA?HJ$JQR:6$1&TF"*J!F'4-
MQFC,A ;- ,K1#,X+=$,4SN(! ,6:D 232J&PQ(-U3CO2N0X@F?56O$!'R8+>
M5XGM H4 H$U.!ESK;)H$U6QP (D@@_$"'16Z3=9F!M&+'HA53"F#89=4M59>
M7O%C^;Q 1_M- D)+655%0<I(&90OMH1*P9<Z@+KGM^,%NBE:3UDTO\ 6E8QI
MR%@EUO-&613W$"X6=OHMY![\L?&?M5_[[P4ZJG)K/6JEV'MA2>2(FMMN(;:>
M=3!N #.&M\./P<\(>0(LJA J!VVA,1K6.3NJH@=:JLE=(4HOP3/1QA!5TV@$
M)JL8<S$N>TRB$E /8$9H*%Z@&ZU8;779< 0E&B &%2V05>1#]3FE,H!:YX/S
M AWM**.2O+6>=&A$<8E:\5M'P03T&H;0X.PVO$!'^7_9.I(!WB9[065J76R!
MC*X6J2@<P-K^8+Q -W6LV7!1ABHI#T[75,EAZW96L&)28<6/Y?,"G1 EUF3!
M !<,#B1"0(L9%.5*%45-#F!J^7:\0#=5K"U+V-_R@AB 0XRM*5'4L22RH=H!
ME /Y=7(\GQQ-#G'6_[IS'147JI2381&)G$4A$H%5[$OF2%$!#F!6Z/8X,OB9
MH5PU5_(FL],011LX5RQS0,"LT?6E5-FUD*67 !I/)5;0<D=3:VQ+;'1BCDAH
M0Z@#F!T:DD?H1CM2\!S9)*.I0/05P>:J:J :E#!B *6'!^D1NB%+JMFPUB9Q
M$8] )CGCHP5&"SD'[DO-LF7P"!VE SH=DO(%T&BHQ8D?T,5G9Y&]YV#[+_ &
MY1$ZT9'5>Y#!7=LV(B@I16]9 !3AX(OP8<61)?4(W4PMBCXHVD I)#Z@VJ@2
MUA25R3HXS'VI3;44'J$3 )6VQII@7,($E702V$0U6,<E1'V14]!OD??@V7AM
M_?Z3<>_=05>E9')2[*-AQZ #)A^\"YB=JH2Y#F%_R.T09/#S16"5AAR!6TZJ
M<"9F3*U^K0JEUFCISC"EE^B95FH(09G %HQAC*%6G[,EB0 U#& B8#".H*.\
MD^J=5Z5471!\"M%FJV*E[)(UL80509;/$73#%)^U2 *?B:HPQ4-D3I",TZR8
MHM%WABF]1"_J$IRHNB1J#3*[Y+.+V>40:E(&7?\EW7 <04<;#:K7JIB<.( O
MCE"142(=-6<)](:PW6QXCJ";J406H=C6"8@,E*J25IXC)D +$;6Z,TSI)7IB
M[Y-+FDB3 J4IMCN;'#I3D7SM=SWJR['W[MW>NX*.RLD0!5^-=]$$*!@(++@H
M1+$Z&Q/ZO9_H=BDR^.FA8++W5B5VMH(/2$Y'^9,=29 )%7JM"H9F3CI:GLXB
M.K1";2U(9*FH-3]()D)1[&+/-RP-UIQTQ16K=54Y:Q\ D D@&164]8J#IWXO
M4P_.G'13';>B3\C0*F!#$R*Y6+#R AH#-O:[$LIPS<EM<>5T.KD@RIO]XT.>
MXR'/WL-_Q#@_G?&%R/OP_N69+M^^?-Y.]>6IT&@C>'%DV(IUE$#:^E;&-24)
M@HKJ@X:ZZ,V-!\>S]<G\9#:ATY/CV14)?.75K2D/,7*UM7J?8W**"#!PC%AK
MKA*IB,]Y5X9]."!NOSD>(HB*T543*$=7H98B\8)/53FTI)31?5C?7*:1V$W0
M5Z"FDE%&8,Y@.29=@Z,:@(&JRWVH9[!,([&CE .#J>I$OB09B8 I.<[L?7(1
MO6;J05BV5".QFWV#T=O6:#A)) .1'#J..<:2:P8);_HPM;]4([&;]9D2C<*"
MT10%)@5RS3^*GPP**U#Z<V, \<R-#,#)5!"28S\/42[?^0=P:&VJKRZ!]AIB
M$3-I-&,DHS.V.FZ#@.-&AM*-P.'9:<6,D&,&$S3&RA[9:@Q&Z^H:'+V/,6YX
M='P:-GP''#:W"F<YH%@JL"5($%$EF$=4FEO@, @X;GAT7",<H%10B:&VM7T9
M$S%[B0:JW#@MPZ/"\L)Q.9?U' ]/\41>6CL\/'Z#T\SSM6EYPG.>O>;Y]MFK
MJPO][UZNQ[/?<+XOB"TF36]@*NQFP")R)HNS+Y2@6D3#)@AXB6T-P># P/I-
M?OL,\\DI'JZ5@]/Y2;M87[!"$;4^@4]19^"0,$A '5%;"B1!  \'J\OCG^(A
MSY_PR>ELV@[\\*F>(.8IH8I@H@X>@K,I"(+%D7<N8T3HP?S@<MO$[F</;2N%
MA1ZKV$VHT4=G&)Q1,C)5L:4/?9.6VI)VC[!*5F)ZQE*J#.*R2&I@=JD"N^IU
M'[*7>F!_N\>95$(=O8J66NL;2ZWM38#(5N(@2GYY1?9RV^@;D>!)6V]2-"+!
M*]@8R%:TQ>A4$ABL=6!@W7[<>IW3)4ID..823,@0;,"BG"A"7TM-.>* L.HT
M;KU&Q#A[%$UA-00MHXMC94X);4@05,ZT4!I+.77?%U/XZ5S]=X!E2LP$GIAL
M@0(A1J#$XK6L0,7H!@96!Q+^^K#21*(&'4,$7,085,E*Z%A+).7,@ 96MQ+^
M^A K6=FL5>N6Y@%C).^MA(F@C4DJ8!]V'B^W3>Q^VP%6TCG:7)C$V[&C LX%
M!BU2OJK4A[TC2VU)NT<XIFR4!4>."5AK4D74@U4E@@D*X@ 1[EC"=]2LI.WD
MT]GG8A9YI,F31H?8$HETOI#P.@P!WL[BUG"-L5"J0=#@$%R;,:48100& ]:+
MEJ$R,+ ZB%NO#ZL<@O$.R667 $T@%:R7T:82>.6=&PY6W<:MUX>8;=4ZM:-L
MDB@-D83.<@Y*XE?1\41]J,6PW#:Q^TUZ:$M+DE6J[0P#5"EP,255Z[FEX?<A
MBVFI+6GW"-M8@F6L#(ZA6/&0+L76PLL774KJ0Q'5'MC?[G&.%421))>"U>"\
M %TX65:>LX6L\_+/D/^*APV=I_O,)W\<YPND/P)T+5]8XB><>?(:Z; WFV^3
MHZ1=@=!6^#.F).,10S*8 Z-/R[_M9MG N<[]:\X8RP6L,Q&4]HF=JQ2<D1@G
M9'!#&#E;)_L\^^UT-I,3_S%!FAQ.3B:]64MRH4*VWD;O'60GX2= JKHFE5&P
M,T,8/AT@=(UC*#F7M.@[HS'(> HQLPDA!0A@3>'<@PTN+4E]L8_Z-PD'CX]X
M-K\J"8[ENSR<'9^^>LA3.1_G_2'N7['DR6&"J*N%E%3,P2J;?%9.>;!]Z=2[
M/#!V,X=IQ&_E4CU9$?"8&<%&94R--E+T$7L0\R\9C!UET+F4=4J>4$';,@C!
M-C'GF;*QP?? J%YZMR;.MNK:;(;3O445D(^=WV_'AX=(QS/QBZ_YRE'747CD
M+UGT%(_FI].]#STXUO9F_#67[:5I1Y.HYHQ$!!!MB6+5O02X,7(V*ML>F/85
MF9;%P7B;@XEM>U?)D(M%C89SDM"A**NI#UGV*S(MBYM+I;ABE*M<HK@Y47:0
MVPH1DS*YE#YEN"PCF1;"\@D?+C3G?'_R:I [[T5W1I>\!$<:@8"C#E6[BL97
M5:).*_?6*Q)U5 &H5(?L;* 2H-:$+E714H!1>VV\7[FU?I&HFX68T$H[D &)
MM\$7<64Y>27^C"*E-M>__.[L[PM#/CD^P\.3LR%Z$I.R$H>!IJ8(T4@TFV)B
M@3!%Y8CZL-%O2?#KQHA;=I%!F>BRX,<F>?2"EDJ80XVZWRUF;A>_;CI#**Y&
MHQ<E&4#5B&B"..%:R(@)=7V0 W_3UV/A!_/Q[%7SOSSCUSP]'68^;&O?WI*<
M44 $:R0P=Q @."I:^QS[;4L[P[(;NZJ8M%>L%+H*D#+:DHVN*B E0E5[;5>[
MP[*;36$I>(E),SAG -#'[&JD;#P3>Z?[8F/_4FG\.CE^S0MQ<QV"YJMJI*]-
MR[NW%S0:HC5W$D@Y0.N,9JA88DK.Z8P!F:PROB?6_,ZRIAN_(3[!6:H-00D'
M8DCML4F%R"CO.?3$;]Q=UG2T*!!,K0Z-2AG84JREY:1;';VMJ9B+37G*6[6,
M9%F"(..CC7C*CZQZ_^.^IPQ'JNQ5J8$]5/$%KGK'OLV/!AG5V/>XX3(M8(S3
MT]K2 V:3Z=[E@3<WO.^8*JS*Q,+DC"H6T""JJ%NR2;8%L^(EK@R])!#>S!YU
MSR+6C4_>1ZB^QBI1 ( X["I>.^2+3;8J+A\J[[WC*<D1ST[>;9W=F,K]/SF>
MG5U!Z,7Q[.5D^FIVG'E^TWMK5;P>8((O)NB6?&<2:(VBTU [3<&*Q64*RSM<
M+H'9F!:ND^GDA/^8O.:R,95;L3>A0UZ;S_ED_NO9A4$^Q/G\XWAG8_KH JJ6
MY(.S_Y^]=^UN\\BUA']1SZH+J@KH#[.6G3@]GLG%8SOGO'.^ 064S6F9<E-2
M$L^O?U&Z^-:Y*#$E\J'HK-B61%$T]P:P485+?^W*YVLWJY/3MW=3#7$GEH4=
M""TC(F>883*D,3??^N<2:US -.,E KC%ZG9/5S*6'#):!Y6!2HBF->7,#FHX
M8 M\N6&U-[SYY^R@N_S@>WZSF)CF'C.U%+J:N>6QBPTW/U%*L4'2@0=L>3L
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MI2.!_K(XC9[%U!Y3% +-"8LDHTP4S8SJ O8D;H- ^4B@OSR:/JK%F@B<,I
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MWX(I7'HU1?>WF10&%;&8"X>:L>8YT/9A4/A8Z[=@"M.(B5$2A\10I'"664#
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MK3G6%%D@).VY%PCLOQJP(+;0NH:Z@,V:]]+F=.M7LR_5,%L[L6YMCF,OA6P
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M3F]>G5V]NH,\1[>:<@<9@7,&2K-].-(P,@BS4TZ/D?K(^T,4$I;<V1>*E8B
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MW.8B8Z!!PU,GB7,EE"=5+5LNHP.44A/LO[?<98#?B4GL+2VW&<2Q:2)K2*%
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M/REQJ%(90VOQI.K0(OG#X=..9G*Z&Z*11L"AT$OE)!!JIQ% B*[F_QY2<'U
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MLLL>V.1/Z=R\O_]PT8W*#UF*62I'1$I$+O.98$0$8:1<30#;$1=^&%_&2L8
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MFS ?;'\EI,UYZ-J*:BR"K'T5\[7<75!,#+HGYY]2F-]>^]MA<M(#'/:MVSL
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M7[WVN[_.#XX_PCO;U3V?X%U>WX3.*'S'SD=8^"HY.;YPX/D7!\>?+@" LQ,
MF'"/UX'O.R'AU?OC5F7)@!DC7#_PN&\K$2F;^1&Q(Q;&MN-3$?E:TLBG+][\
M]W]% ?-?7Q<!$PE0K8-;6/R1.?D^6L=92.NT.IV/K??6X>Z'@\-CZ\/'PZ./
MK<ZQ=7R ..$8P$"IDHAK'1Q:Q-M0+ZV#/>OXS]U9'#'!$*WM8SQ- &[/3=;W
ML5,U:3;.T"N7(#9>TI302A%;PZZVXJ0 2EECS7-+]P'<6X^Y]%\IK!T/3^PJ
M/L9WZOYM:_^#R>_<+;,^&[GX?UJ#@\5X\262U(]TX-N."EU0X-JST?BR \G
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M(DEGY\+M'']D[>-_QGC?EU!SX3'.;)]IL* 5 '?A!J$=Q8%TM:<8"_D+2X,
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M\LH,Z)[TFP+CH[K25.E'/AH-!JGYS?/QVH_Q7.D?KG%QHVD8U.&_:"V#5V9
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M(>)VU%O'[9H3[OH=XW8K%!CZ6X^M.I!E[<P4U?FIE("E(]]C-/= ?Y2]B$S
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M_]?WF+G%7^SQ%[/TO8IM/((UM.:SAN7))'R^W+XL3A5HN=YCZ593;A."GZY
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M (^0@K;@&CL^3D]"T$VAM'P\;IM3HL@FI1O;ITC'AT8K9P-_ O4&SG&7A2
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M$<Z CA%C+)2ZUVSL<S7..5J8!T$!=0RV8X[9G00? F7?5%ZJSG=/CC%IE._
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M=JY0!(Q?*[9\_6_G[-K92(-Q'-5B32W6S ? ^=%EY\OG*V<C]C 0LV9%"V5
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MEDPCR>7IE=86*.  /I][68Q1NZVMYB'-WY.>&$GK'H2 CC<B"(FF3[U]AKW
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M&G->7$5&7:$GEPH+J%QV3Q+SI)1W0(,\S#AVF%/^K-$2*J+VAV)C6$\M$RP
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MRHAU)92O$+9].Y1DDB?K$%YY?17)3C3O+O)R07:)O E=6D7D^-#PDL=)B3;
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MAI:]2)6*C9A%[F!;SJ)"QI462UY'*0#72"E9E?$V,.9I5)Y*)NS5<'O@ ".
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M_"J([.@JYPV**7E,I[_;$;(\I*KMM-IRI;ON/Y $1:1!@ 40DIE/_^VUAS.
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M JX-C8Z6_CXDNH;C#6?^_3C35DF);]DSO^!(K$:5%UWIH%ETT6M5[MG,C2G
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M%[9-LZM9>)L1R#D6G[A%;^(9_\;'.4]\-O.;0O?<L-WT*G(UN*6QA/P5XUG
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M"6*L(1V=\+V7E39)<?/-X:+."WQ^G^7:31X=?R ?)'K,^!$_!%OPD;X]??
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M+?PHJ-FE) B[?.'-SQ=>=GY\T9/RX)X"SMS:^8BDX66L$I8M;,_:9LD4X!]
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MZXA[H5L8"Q_AHVH"FVY-4<+I#*JF)R^.PKY/AVA>AW3'5153!,23W\4CNWZ
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MZ.D8=+_,(PSKDPD767)+#-B/@^1I25LTHXOWX5EWN8R;-I^G(-0)FKJ-0GI
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MG6&Q]W+S7HMO[S#HL_V;V>"^!>(%7AVGO;@#23P,!)L5GNDX#>!L8&PFY.;
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M^]N@E'>6.M'$>I2K8N+./_D*$K5!IT=5NA7\T4:^+R:W3IB5"I(L%@4M6_C
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M0_93D$;DT^BFW9ND=7B#>#D)/-PQH4FQCZM^2L?@UEM$;QHQFKZ^Y'IYPQ2
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M[G.&K;Z=95HY -E540GI%-?7 T615%[9Q.FLM*H!I*^.K4LM1;<+/?=8,BG
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M$N';\&0G$+5-[C!9#R^3Q\?'C_<?WN'DS(M?C[G?&^+?CGN 30I#9?$+Z>C
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MN$(SE=.%A(4B3FY(K/Q=/N"3%1KZ61%QH1AS$0)&_YW_(C@^I#8T?SV+:MR
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MA/9-A1PZS&@OM+_F1\93:>MUJO%2";A"H='/:8ZFWFC2]V.:\<I'R5U%X:6
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MMN)P1@FG-$MS5!:JR)8UPD8E,S$#D$>'6TVI(_>34DUC-0W!9LU*C\3<'07
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M/4OV7N0PX\>ILN3H=#-X=**:MXUH!1YB-8M4/LK6SR2_<.3IR3>48)=X[XM
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M1QPP7Y^EURD0#=;4>SAC-VOMU8Q-C[D72_\S#804NTY_$[-@Q8.6LO+*J^[
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M'%E@(?'?X0DWV*E=D(I,:^-B@F;-GES;"-![3[G>8*3<"?!85)L'P>.=A1T
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M3+=6=[H_G&+\D#_H\ >+@9L7F]Y\=<RGL3SFLY\2VM#@K!0-+81L96I:>7[
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M]UXQKGWPPOZ9!@)#(G4.#XM9PB/$Z*,_T]&U#+5B8IBL:][,L7N#CA"7*([
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M[<!ED0D91OF= [*V\OX#U2YHA&2$J<4/DW#XS<(&:MW35^" C@KN#N1]9/Z
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M>E'R4Z?]PHI O]$_&IL0A'V5'9)DP2BIJTP:QCC^$ BW>9Y#J<6!>ZN(M8(
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MSEG8"^(>&Z\W^A6O;Y_7&ZTUILJ.S.'#PV+)*HXJ3)9'Q&3IM^\K%@ZX@_J
MFZB[S5Z%Q[*'^])NM=>U=NW_OCPKR5?)O4,Z7\WV&E#1 ]B6YW2\VO<> WT
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MO*@U2@7>Q\U=F>WA2$R1ZOC_<,U06'"Q"_>*05[@MDR5W,@NN18!+'!H =6
M!DELD4T#!E>V(_#L;P)<Z%1_/!=N!#\$86Z]$T/>JZ9CTX)KUM<)R"/]@K0
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M#"85/,!:Q@$HMEYTRP/BX4@VT/2.[.9)*A 6** )Z9B54?O4M9P--=%S$5A
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M1>8JZ@^45!F;C+-'S98#@:J+^R"1^A26'V%R!"+3G#D#$C5?>Z-DB>\-&5B
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M9S +AT00?@?X:\H^N$@,;SU8EPFS(=BJ9!A=8I@ES?^O&=]N86Z2"J ")YB
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MC@Q3<T*I5\?">OPJP!9"!)B?P28-I.9R-0))(R%7[L0&&.:@+"S&5+.*,-5
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M%,<?/(#ZJGSPW/[EQDL2,2G3?B0X9Y[B4S <W(!#.XPH_:"H@U J\RC568Y
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M36&B6E"T0' M0%^BSR5:E$UE\)']/1G&\W:[UDQ-PK0D"8<?2,W+E0)EM)9
M6<0WS!W2W$]HDXER%62T:+G)201,^C&1N2AE0"8<DX*HT<J43GHY>8[9JVV"
M1-QP D7+IA<848*1EN^BMF'6;:_J$="OX43)JN7C;EHQDZDY68JJT":Q39AN
M0DNRQ<+]:8R!_HB3K52 7(;P,U.'$0XIH8MSK)21&S#+(+OHCH9.K]8OYM0L
M^<NZS;6<EC5*8FFG8[!SG;67P(:Y]5][4><6<_"0YYM.(^\Z2#:77FV297&5
MV(+1ZL2$1I^0%&.2$=(L"VF_Y85);BS->B[PDQ: @3H8XVZARG5!%>,SVQG-
M9]00]\$+X::U^.GTCO?5\9B<6-U",I7#0]$T=97T#/T0F]C6K6?G&/\L@UGT
M#D7R;R22O\#RVB$PHXI]7E,FT03_!7\%%5GNL$T"2>TE!D_[J0:2-%IBPU'R
M5:!/6I7;2[E7B/^11I;D.9@T6"7;)<T)GR1%2=%\):B>A<ZUH$DQ;I*Q&%!>
ME#\ >J?5R&$,AZ[V@6%^,K+9:Y0Y[&6H74.@H/ZJ^"6X@(J3O)'E3_'+TY&$
M!I;?2;%#<3?*P\GD6L_K&^N^W)0)*53RJY)!Y6&M)FA*>)C4JL'DLHL)[2UE
M(6B?#_)[:^% UC9IRJ=04AXCFCT38O(M"316I?N%Y?2<4I=[%\>$%KRO*)%'
MI4HFM0F8-^52G^!AEL7F"D!T+/"T&H39GSH0)Q.4FQV&"7]PMG>2KPD';A+E
M"LW\1Q,UD2W#.%1UKVOL(M?AX3I:S>$,:&!SQB.FE><AALK 6TG?Z1WP%CJ>
M%O'6KML7WGQ^MP%W%7#6 JY:S$O9AA7[9J62<M+J .H2<*)R&"!/,"NL"HWF
M0J.]W81&NU5HM#P1Q2HT^N1#HQJ2Z>5GKE,%ZU\K9GV3:@^;&/N=)<9^I]#8
M[S?W&-TL!7H/%T;V&%V63Y'3K?-9-W3+I:Y)WKR:(U6&?![#.X-5>G&V =Y
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M-V6X)2GI^$TV%4^DE/$6'5O.$X^GM1K/5NBK&FM;K>.>-^\2DEPKM&G3>.^
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ME*8![[;'8ZJWV"Y.?'SF?4<KEDA2QT,/@93,7A(;#ISP+^DZ'Y+D]-  @-4
M"BAM*T-*E<A'\I<5,#CK8C<BEX+NLX>M8I.J;X\.88AO*)R,FTA,#>NJ=F0G
M 8SDRPF2!]C"> >K[P?A\0F$6_4$:40<U 51_O^!J05VC]1P8+#P@ZO^_<8)
M,<!$9OW5P(\C@]L%&U^ QL>G+>N(8L3&GH.V)"I'Y^-.NJ;^H?A?XVVN?ZC6
MM_GK?/_0<NDJOP('NLH:&4F/#NO&<4AE?BC'U>E'%DCT,).V!OOX4T,=K9<
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M&J.6/( 0C ,&<&$L16Q@1I\6VOL\@GW!82F,-4(+&3D1=7E7K7.Q\UDH!)V
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M)A'VCWOVJ%!2YD#!0.J=JF=%=^ X#DB%M$=_QF&4DY):W'IXBR8.:58#E0:
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M.TY.&_M P1$.P51ZP(M4 [-H!1+T4>D43GT3^$#AJH#9Q6XY-4#<1",'=E'
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M9R B?OV$=[\4G5' FL2;A-[1R:1068AV4*%]6?$CK(3>XCQJ9<32+LBH&*U
MS:K+-)BHN2"BOE.UE-LAW"TXYS>]>C/G_]2#/NI1>67J=_-N*C>T"CK(TED\
M,6FT5#R<PJT>&C(GV!:S-L\T^(@4>A_H=^]^"'9GJHZ)XN^*#B:N<K1SV"9%
M78:R5D+=S(W"',H;(%J(8S3.V;&YFRP<V!R*R#^>G@/\<.W Y@^IE+]$)]K_
MMFRO8["9DV/1%]%:_VTX=D=K_/ZPYK3IWS/1J/K4U2VW;,IWJ*A7'@#''XT-
M?=@@&/[5F%:3.90K3&UJ(QK4S05X4O"!!?%>2935U8MYDC5G1Y*U*!5N2(J
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M,V ?S=+FF+^6(RG#V7&MX06 ;5':%VE71:CO, X@EN#IFX<"-OARP<?(&S#
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MWIO^B0B<P\?#;ZH7:R1<!.]DN5 5^C14)XVXQZL0V:>TG"FO)2'Z2H.!AQ8
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MZJ.G_O--5]B"TNJ9NL$?.H5O[1XB&!(*)!1,A0*7'D#W#?YEZ/\NRDXJOY"
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MZH;G^@B$U/9=F;^Q3#&\QGWRR]M#Y1:G.$=]JB>@:)"D23'*:7%UJ2ILH:K
M]_43VU6"9MW&GG) DY"U$&2=W%&XHK#5_;?EFQ'9+40P*[()L? BU<<X5CWD
MA4%L!+Z)+8I9FM6QI5JP<:AKJ5H@)75%DGI622JV8\^+7-7U ZQ:(8[4P R(
M"H ]/;0\U]9,!R35="V95=)*@5RG"B %<D4"^6<ID)ZOVZYG:JJ-R8Y9H6:J
MR',<-<38\F/+\&Q? X'4->D.6*K(=66PS_8K 0RN@B0)WM;WDVSG:;F;65S9
M*,16=NE.2N!:#+A^U3F_CD*;[)RMFD[@$> R?97L&5)U2_-\QW7<R-$/WEN.
M)4LLM0#MULOXI5BN62PK@N\%)B'R;J3& 2*JN!<$JN>:)CE9H8^,B. ME&:T
M/'\3^:U2^M9![Z7TK5GZ*C:O68%A!X9'KD(#"J/JD>I[@:9ZIA<A3*[,,$8'
M[UW+E5Q^N1']_3X*>(M&J'\:)R/E53\KBM>T/QZ9EF3MK63MC9V[I!MWS39,
MXM!B.'3?,,B'H6UCWU=C!QFJA4)+]9'IJ,@PHC .0C?RC(/WAKEX6ILDYSM$
MSJ7T+5'Z*@Y.-L!R/5=7+8OV4M!LE?S&5'W7U;78)RBIN43Z+%U&V;12R);+
MP:60+5'(*JIM8AU*:=FJC?Q M7S;@#@95]5\3,#1M^/0BP_>ZY[=T2357IX8
MO?J$DO2U MQ:(5(4)3]Q,4I&XYRV:?\MZ?=Q_C__95C>N^A0.<;I .4_E %*
MQS%9^S&<>B4;8B8,TI3^^%*OEY479-+DITD?X'%2#+,"]3^1E1V>9R/R;_CF
M)!WCZ$+LY&=R'.!@7*1?\F2$C[.[5(+;8N#V=YV_H\AR8RNRU,BV0]4R;:0&
MMA.JGA9HL>7$-N7OOC$EFN:U9.ZM)!5+8^Y2,-<NF!6U1YIAVAY"*@[!O*Z1
MGY!C8=6)?5MWR 9[+A%,V]Z$?4\*X;J#9_[&>1:AHB=%<V.B68NDB1W=B1U#
MQ=AW5"O"GNH3A%4#*PJ"R FL,"*B^3__Y1FZ\4ZJ!"M3"6*4Y,I/U!]C)<<#
MC(HQ_,6B:I@4W,*_R(]%$G%9D(I BQ2!)I9])-OY%^SF6;657Y)1[\\T"\AT
M?J*@CT_3X7A47&$RDC#I)W1+R;_&.>A['U"1%)\3%)!71O=P5@#Y3E-(( +W
MXPG*4_(VZ7A<$/RT1C2.@6,C]"S5#F*3* PQ5CULA2HR ]<BJH/FNO[!>V]:
M#*%4&-:)E9O4&*0HMU>4*Q7#];!N.(ZIFKKCJ58,ADWL8C727=UWL$FN'/O@
MO6-.B<^?)<I28M<CL4MS'$B);;_$UJ)^4.1JV(]4Y+A$8B$>%KDZ5G73#9%N
MH CYSL%[W5C@\I4:QZ.Q^U5POCID:>=$UY#E?;8C\.?Q @-E(0$)28M!DE[7
M!QS'"$(G"E0GT@+50AY1!31LJ+$6.PBY8>09UL%[=V'GJ%0*MMZ+,(\!4XKF
MLD6SXO>Q'J,H\)$:VMA2+9]0>T\W3=7U?-]P(MV*-7V#=DHIA.NG^5+<EBUN
M%3DW]"A"4)#:,'VL6FX$)>LT2PV,P(M,%+HA)NJTKD_SI4NGP$NJ;8[RL0CY
M"7LHOUU;YS?)Q1>LG_,(#:@V\8CMH02CQ<#(J-/RP(]]S]1CU4#@H[1U347D
M,E$QQH'E!QX.8^^9=[]DYEO/S*7PK4#XSNHZL>=YCDGN?\-5+=T/53^(717K
MD18YNA$%MDF8P"9X@)2OC9!N*5\OEZ^*::/ \Z( .6#\MHE\6;Z*--]5'=T.
ML>,1OH(0-8-O1T#^%G56#B>;I\D6RUO(PI]LQ@%M.'C-+8E4"R*56:?A$3(,
M3S=CU:%]</P(J2C2;-5VG= /'2>(,3YX[QUZ_O+J5<KNK2TG&.MN;R6E^472
M7/%Z3;>=V U,U<(A(G] @7L'?O(=W8]T+PXM_>"]>VB:"X?E2Z%MN="NNQ^6
M%-H7"6VE+-B&K85&%*FN8\ 5C QR!?N&&D78"GQ7PYII@]#:CM4ZH=VQULNG
M:9@-L!+GV6#]N;E2A5B;"L$SC]);MN$0""@A;#$(L^I:1*P'3NRYKAK;8:!:
M8>"JGAL8*N$B =E)Q]#"X."]=6C;6D>76L1^$))U:A%2H)<AT+7D7A0;4)Y'
M=34]@-J9GHH,QR/G*K+-.-(\W?>!DVB6L6CE'BFW+9?;=2H24FZ7(;<U72)"
M5A0@N'ZAKQV18A5IKD7$F.RE[EM&X.*#]_:AYWFMD]L=TR4N1CV<*PG3*%YQ
M=\3K0R7%,A"_13I#$X_.LS1K0I+L[/$L5+(;3@;'U)&-(A5*_D&X 5)]5R-L
M@L"0@?0@LJ.8J >^V[%DI,_&@6N3D3Y2_I8G?Q6;)S"IZ[X7JC:*"9L/7%]%
MV')4SXB1[H9^0+C]P7O/E*5Z6BEE2X_WD5*V/"FKN+<3.81>6X9J.[ZF6IH9
MJX%M0/)ZZ 6V9YJ!B2&\OOU!/ZWGUMQ.'V"B:&+!L4?HEXCZ81% _QDGHWOR
M*J_'$Y,?H40GQI2$PR_(1Z1Q?TN(^MPVA<J4\#'/!D>LVAA9WK+<6/&!GAOV
MOAOT"Q=G29KEY+"<DB'GY(ATTZCYE!-ZEL[PJ)>15^ 405J2M%4LAI>GC5:Y
M$?9UPA4M52?G0;5,+5"1B2S5M\B!P X!4"C48Q]JEBM#C_;%^+A.IX$$BC8#
M1:6^8,W1D68$:A1@7;5B(U0#0(O ,%U;PQHV(Q.<$;IA+]S$0^)!N_%@G<X(
MB0=MQH-:=D6HV89ENZKI6K%J!39241@B-=("7XM=.S",@#HY?%\Z.=:BB-54
M+^G;:(_*- W>"&QQ8\\'G.(X&4DH6@R*&JU_(SOTM C%*HJL2+6P[:G(\74U
M"$P<ZLC!;DAT&-^?5O!,>C9:S#O6KX=(P7RY8-8R(30]CAS'(H=))X)IZKKJ
M8\=5_3@./<O0D*41CJ ?ZK:W"7NLE, 6,G\I@2^7P)H[Q+;#P',U:+]MJI9!
M9!%AC?SDQ]BRH]CUF01:1&O?0/._'2/B)Z6SXQ5SA[QN@]=C2UGZ1KH,T Z)
M<QD/SO'H(B9@)>%I,7AJ] 7V7"O4 U]3"8F#?$GR4P!U&@P]#'%HA;8;0J2D
M[!*P-81A"91]HO&?%,DUB&0M3,D)#>396+7BR".</<(J"DQ/U;%'^%]L6RB"
MI -_T2A!*7_;2-@G*_%)85R#,%;TW8\PP4W74=T(VZKEF+J*M%!3(P^[L>=@
M9#G.UO00:SU])T>6AS')>*0M,:[/;5Q@C<YE:M/B@-1H!*R%9NRCV%<]W[94
MRPN1&IB!I3H6MAW?0$$,U8NM0\W19+C0OH0'K--,+^7X!7)<L7S#Q);IV;&J
M1<A0+:A'[IM&I%JV2_[V;,]R?)&BN*@<2W%MM[BNTZ8OQ?4%XEH+MC$<"^G(
M54T?(:*9AZ8:6#J17I/HXT%HVH81P;5KN=;"'71DL,TSE03E%1CW7RMH-,J3
M8#R"YG?**%/(TH.\Y5F_#[T&$AZ55DC3?SMUB(FT+#RJ[!O=VM;>9.>-C171
MAA+8%@.V1I_@R#4=QPET-2(7CVJ1_U1D&;%J1*ZA6[[CF79(>(B_<$BQ= /L
MDDHPJR&(%-;5"VNE-.A.[* ($U7!MXFPQK&F>M@QU1 AS[',T"$R+#N%M5DL
MEY_$+ 5PY0)8J0&F[_A.8/BJ%[BZ:D$_[D"/+-6) Y>H!\C7P!U@;:2$P.[2
M_$E^_R');G&JD'/?>0&-7ZUO8-$U70NM_^^567X7.*S[H=/,;:!I +@$Y\7
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ME:CE@>IKY \<FUYD^[&NQ_C@O6%UO&59H#:FV^V6^K9#&MH,\'BAR4B"QXK
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MLI[F/_^>#MS=!X%B3;NTNWN/=]<^#C*[_O4]\^/WO7(T_#3NE='PN#<\R36
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M-O)<:ZG$=,*,MGS+MBS]NA06+'^Z3,/B_6#QBN@VCD49A +TO.X;IQ#86\-
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MM^3%3@N<N3>8WL^XF9U#%Z+T(I J)X8%)"(%[[@'&X1V5J-C6K1*F"<NSAL
M[VO,S,YA"BX;+0-@D@X0>2(_J2,D'U*(7@=9%R=S+AXX+'[D$OU\"OPT,]X?
M3/S@7;^N9/73O09-EZ]<EU]:I"V:N W!X+P05\7*8)@D#1ZPSJA%L%QI( $>
M7?%U"X7>V%:B"?'U<?GWGP-O$+PS!&<BVVL= @\1LD8+:%6!P&R=*F=9\)A#
M<(Y\O%HD&&Y0>SSJND'MCE";R6D543$E%5CM8UVK9"$DR< (9I6L)JRUX[*M
M5%H2E'8''_-X4A]HTM&]5_YX?#IXU_NQ/\PG_:<HI#M8"?XMW]2CM<G97IZ\
M'Z:9^1KM+$8[>Y_F1;;C16GR$:"L(*6MH@#'G8<@C!:>W#QY_E8&WAW:6H.L
M=X/ILF ZMSM)*IZL+V!=[=90T\'JFH'0I!:4UDZTOL\GK\<;\)8%O)DL1RN%
MS4%3W*L-H$ $'Z('IY*Q07N7G-W8UD:W0I1[Z>4<TY,[37:/)R,_R>_H+_1G
MCW;3Z0^;[_Y#XTFCG*50SN=Y29Z]<40T$DI0'M!9 1ZY Y6UBT63H::U;WC-
MZH:FQQ^W'F]P?"@XSJ1WE,X450R8V@J&I,/!"^O ^4R 5,7GE#:VT;@MV81W
M!V&WLJ;,!L9E@7$FQSE7-@L30 =.<ER% MXD!I;%% .!,%8PMI;,I0/N8/(^
MCYZ@W.Y$?<E/P]$\O4QM<<XH=$=WZ+H^]B?]-K]I468YNZ*Z@\[(O 6N=*%
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MV.*(<TAN.\4U>$4&TL5S646VX4UA/R6%?7-.K1UZ+P6 >W,3>)D4T@C0D1,
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M0"+Z9)+5!9*MHULTK[D [4%&B3(IE$+P>H0AQ.(=60W8W09V=$ZH(*+,RE'
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M]>. FR73M><!=36\]59J(1)&DZSTWA0C.3+C8];M/.!!P#T;RB21XKN0$JA
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MDCYI;AUQ6G$"@)#L #TP&C1S+.K LZ^IH'76\ K&:S-4B^S$<0>9^>ERWPK
M#PW <\EXY:+0.DC"F17C/9 <4$<H,R)HM+G"QXUG4FSIN@7'>JES1=XZ5'6H
MEFDD[R +7XWD\HSD+!TOJ L6Q[+L3:4)>*^)CUH2M([))Q4=AU2-Y#JJ<T7>
MM1FJ19#W#E+Q%7F7AKQS.7EJN !O#;&6J7(F42*6,4&85R"$--ZZO$K(^\C2
M\2]Z)Z>I.W"-OJ5/Y>_4ZJ>.&Z98SL!HLF/$ERWV6J?NO)R94=?$5RM2AZH.
M51VJ.E1UJ%9OJ!XVY7H-B][N='JAD(BFPN5YX0_S5&-GS#0J=5Z,.I_/IU8I
ME5(*;P@U/I3C>1DQSD5B<W1!6W!)^(UGG,*6K(G5-=3C"KEUJ.I0U:&J0U6'
M:M6':B5R9I5SWA/GG$N4F<P%4&^)AB@)B++%F1>4F&1!,*]E+"=J5=*YKHI<
M,7=MAFHELF45<^\)<^=29!F<@*PB 2KPAPZ*&"G*1F?90HA.>2I7#W,?6:+L
M8'B<^JN5^>)2"^^J05@#@U"'J@[5HQZJ57G&XYTRBRW>N(^M;(][G9CZ@YW_
MCMK#\\8>5EZW&*]CL_P-]N?SWN?W2MF4#/K3#&(@8%(DAF:&?VGEDL@@32X+
ME5>D^JFJZP^+\'6HZE#5H:I#58?JT0W5 R]YJM3R?JCE-$V#[PN?]\[>^YAE
MC$(1S9@GH)0BSE!)(J<@>& N.EW)Y1HJ;,76M1FJ!U[45+'U?K!UFHZYP%9A
M0%)C#$F97:P834(0%[(/(1HG#%\A;%W;;(R^4JN>NT[91'2S]3*%=.)3OR78
M9JLHQ?>D:'ROCYI"QKU[*E#4L3?RG=0JG;JX.NR=/BVC,.AUVG%\94VA:;$M
M$:.2W$HP8*R%H,!9R7V,EO&L66;P?O>[=N5J7KE;-SF^!3Q-H:E4A7,;HLPY
M$4MI)& !(2D%2JB1T0H(!@G\76^X=1=ZLV0FLC1H6!1>'P09_G<9,V"!D5\Y
MQ/R:R]TS7'Y%[':[H3,JLORMUR]MVQX.^VT_&CH<A</>?J];6M?O=;!31[O8
M3D3;>LC[XD [.^0]FIS1B\[$&!<(1 G$J:A(8%DGF86*7E2@_2Z7K_*Q;_"Q
M+)4TAAGMC08)RLBRH9O/.0@7T6>\'F J\[I#0)CM.6VXD"7K3G@HI='96V)Y
MR,1F:CWWR661-YXQK>[LU.='  >5=U7>=:>\Z\Y@L3*LY0!JF *JETH(3QEA
M5 H"("0QU!J" QLC\_C#VQ)B8Q5.*YQ6.+T7.%4V0=G_,!DI@7)F$G#G'34(
MIS:%4-W8M039N0WZ14B2@2/ .?X(SJ%#ZQEQE#L&-@3FH+JQ%6@KT-YS\E=;
MJ7.4C)I,@85LE!;"I0S,!@I&7X^TW]K(LH+K$I(QGZ9+][RA$)+-)%@.!6(3
M<2I;@H.J#0AN=+-'C[5;]/OSQ!56*ZS^$+"Z2$E-+/4TTENN(EB1K.(Q&<\Y
M0Q(KD[P9?^V.3F)O.+E><795<':V1-IY'3A83M!-H00,#\3C ).HRX!;#33*
MC6=,;%JM[NQTWT> MS4;<PON=F4Z)@2?E?9*HWV'E!%BJ+,R*1L4I2!43<<\
M#":PV<[BT1MG I @%&*"TP+1 101$3\UP",MX4,NMDRE7I5Z5>IU]^7,MX;$
MJ4=;2=C* ZZ8D3!M;?3!$Q<=NKA>,&)-1!(65#8Y6ND\1\!%#J:OR-E4S*V8
M6S'W.]U=X9BS'KBE#" X[XRUQAJ34LC62U/=W35&VMDNC(RC"<V (*NL(6 9
M(SCPA>1FE6B@RA:D97134UK=W8JW%6_OB^,BD=46)!..9\@AFN1"DM%;DWVR
M$&O69EW@=7>6M1'&1)>U)5IE479=%,1[_&<66LJ,MM0DB_ *5Q1R5A9;4;6B
MZO<>2Y.L@Y0, /ZVT1@G/**IYQ8IK>(W7#M36>Q*PNPL:2-3!!? D>A$)E J
M/9W2AI2-ZU+D23E+&Q:KC'H419[-(NR?FQF%OV/[X[-_X(^+)L\]*Z0RP2;*
M^NP?OO_SLVD_ZVUK<MO=KHMG].]0EA>4?9-2RX70.\$&G.-\;75[PS0H)WD.
MC],@%9QM)G5SOF=N=UTWM%T'FXH?-(=[;EW;S\E[N,:&G/8&[:*$3YNC0ML?
MTR]G[3@\OH#ZN;LFBD9GMSB/+1@-K[]EI03Z*U&7)3+_\[@_VT#A*!'?3^XO
MXC(V^:GKG+GSP<;/EWIVTNY>/%V:+8D-^%(&U_8TY_NSS]C1,9*AL>SUFXW;
MGR)RIG[Y%K;+K51[6L?]PA+^IYUR,IFYF%QV(&-&T@Y.^A139"HF^5YO/#LL
M8-OJY=8_?G9KW9$7A2 UA^^Z9U=-R,7UAP7I=+R]_O"_VZFCT9_GNP?_W-EO
M[>Z_V&IM[[]LO7G[_,WNR]WMU[L[;[X74A^F!R\.]M\<O-I]N7VX@\T_Q%][
M._N';UH'O[9V?G^[>_BN15I/RO"TNZ,4?UJ/3CW9[;;PV9URDOGU33YQ_2.$
MK F&%[R:?%((DKSLC$W[U/";&?PWA K[UG&G@_3TXH]?8GMPVG'G3]O=IG'-
M35^R)WS+#""WZ!@D)YO83)X_N;S57/J" XZO<;YE%;_V,MUBUU[[UF/%EM#V
M5D_]]C7!KW_G[=L*1M2V_M!MA2VXY5,?OJUZB_%UT2VYQ>2ZR%5L2:/7I*VP
MI<6ZZ);:XE:N35LUNYTU7(IN*;C14R?;VWWAJA8NM+'Z6][IQA/\^TWOK@YX
M3;MF;]*U,4M;P<[]AKY0ZO=3&>1>^.O:7GX]@-?6-*^W0%[T3DYZW;N3!GZU
MWSO[LMI['26SC4TNKK3K-(&Y4]>.I-UM_@[NM#W$SZN\YN45PNADU"DAOT9(
MO>8HLT9<O9/3?CI.W4'[8VH^Z?0&@RJ]>>F]3D.''XY%EUR_BQVX$Q&M-SP=
M]I,;C/KG%:"ND$UO.,&FY^W>4>JV=KMAJ_EWLW1DDG9LUM3K7\;SJDE!5BG.
M2_%RRK414WN2=ZT0=<U\NV(>74V-.;T!-;[)26W7)4ROR)FNA2S'ZZ]N,+]N
MU/,?48+;)[U1=WA'&OI8A52GV2I.LZ5_]=&-4IWGCW&>_R"G23!SD],D;CKA
M[F;M^QT+Y"YV(F9&!RU <P,!,DTV^N2-2()#Y"';4J[)3#T98EIOV?O\[N0=
MW^<[9_@=]H[OTC\_'/%W'_X\V3OL'.^=_'Z&;?O4M.'+>LL/^^T_/[P3[PZ?
M?]C[\,>'=Q^PC2__;.^?O/MT\.^=\S]?/O]K[[#I+_W/Y]V+LV:'>]OO4Y9&
M9)J)3RD0D%81J[PD ?^2+ ?#?;[M1F\+8.X=%JK_73WZ=RGFDH%JP=KR&W=U
MC;'GZSKQ>P:>6B*^%,@ZGT*6BRQ9DS2A2IFR9QHEUM!$!'C)G>$&1_=Q0%;E
M%5?P"IV]CSCHL1Q<9(,R0+F,2C&NF*#C'1&O5N_*(.Y,'?=G#"*P%),%0,H0
M. $3/;'!2B)L!$,M53SHC6><LRLV,UPG9:S\X0?A#W<&,)4I+ 6:9DR!Y@R&
M@2?:>$= ,4M<9I)8ZRB/CB<:\VV."JC 5(%I&8X-]0$LEUK; $%QISEZZ,D'
M#B& <-6Q64.X.I@Q*:.LC"9S$IBP!$0.Q/,D2$B&4YI4#C8^#L>F0M8Z0]9"
MN_U)SUE42;@@ )@WV;OL0K11L4 -OQZSZDXHJP13>W.'"4>7("4OB4X1:17P
M0!R3@<C,>)19"684>GQ M^#F.Z%4@*H M8P#>:,-B$9&I9B &F.L!\VX1J3R
MECM_,TY5-Q591<2:G<JK0LP);"1*VW*<44!'4"I*A'14ED%W'#:>,;6)Y'K-
MPU0_2,QXP7W8-3/:<BZ$D!Y4%MZ+R),-QF9NM?A&3J@&C>]0(V?'XBHKN+74
MD4@!".3 B=>,$:T,51!0+U-:=!OVU5+$2B'6F4(L=$;7K<&E[FB^-M U.X"6
M>PX(7I1D!B7_["*QSC+B-*<F.8[LPMQB0_.*7A6]EN  4?1Z,BA*C3(0D0T+
M&HQS6003&74WK):IF+6*F#4[SY7J3)DRBAC#/-(M'H@5FA+F2JHS"$,9;T["
MHL)NJ;5V@"IRK3-R+<*['%-<)VMD @$B)LNM\SKF*)4TEK(:6UX3H/HPBRTK
M!]'[' CEPA'0AA)O7"+41>]4U :2W'AF%CD8M<)3A:=E1)8-3TG8**G+D*4T
M.C'+!8V)JI#I-S)?E5BM.E[-(LO1>FN=2<1(PXLS&(CS21,99>91X/AK/R%6
M;.6(U=HNV+I:.??3L-7&&7Z2;K! :TWCWI/JCV_.FY5(.E3Y5OE6^5;Y5OE6
M^5;YKHQ\%TEK4:Z$85(QX?!AWO(LM/;&.JU8E/S]2W1@+&64D?+'=WDRO_5[
MN3U\U1L,JC>RD#>R=ZG.16@9C4F,>"D8@6P-L0XB$2PY *F3<'SCF=PTQFS)
MQ9R1JG05U*I\?TSY+F TDM>1@Z214@U64N]M F68BT8X'T,U&BMB-&:Y03#2
M ].!>'"9@*&4.*LYH5$R1YWQ$$,U&A74'IE\%UEX)V+D*4HM103FP2N6N..9
M66X-%:R"VFJ VEQ</B>6-#>9:,<T 1X2\848TQRY"4JIG/T20>V11=X/RM[A
MK4O[AD\B\:TG9>_PGS9;W30L!ZX-W:<:G*^07>5;Y5OE6^5;Y;M.\ETD> S"
MN1R<A.R .>^UL,)+$8*CH)2X 66^S(L;BO%BGF'L-@2C,.7]-#S(A^Y39<P+
M,>;?+ZWJ3L[2D*0C)MA$(%E%//6., Z9QPS"R%#.79=;O 8!*J)5^5;Y5ODN
M6[X/&YFO%OD!+/(L,,]#$B;93+2D%"VR!N(]=43(S!)0EG+PU2*O\ *5S(6W
MU <NA 7DOH:)),#&F%3RQMQ$Y:Y9J5)U[SYT;VX="D^9":X3L3FC[GD*Q&KO
MB0R1,2-!6A!EZ\B;[W!4E6Y=<C55U1Y U6:I&FNU-D(RDEQ1M: SL=92H@..
MHXA)^D"+F8,K]@*IB9K%%.G%^"3<1F6:A4%%FW*_=]+J7EH;U+HX4[$F:RIF
M5_E6^5;Y5OE6^5;Y5OE6^5;Y5OE6^:Y6:/Y;)SSX=ML_O;SWPX5[U^Z&?G*#
MA ]K?O=*L*-&,Q:*9KR]%+1G"K)S/!">(!#@7!)CC2-16RM\EL$8N.4A#E4;
M'T0;[R!J7_7N8?3NP_RA!)H%ZX#PK#P!AS^L=8*DS"+BJM<NH][!EJ@ZMX(Z
M=V=1^ZIS]ZYS>_-),D,CIT0;8XO.66*Y-B08Z2(U/N3,EJ1S?Q.WC^W!:<>=
MES:E;ZMI_6;]9OWF^GSSD27L7J?343\<H[DJJZ="[^2D5]K1"W^U\,)@Y+K#
MUK#70E/6VG/XQ58QCZWFF(K6W+V_]7M'?7>RV7)#?$A-ZU525^5;Y5OE6^5;
MY5OE6^5;Y;O\^NDK#VYS%KB7DBGE(D@I+/<Z!\MRHHDR)Q<NYSPLL9]1_[S9
M.WM\G-MV^.^HW:\'NBT8"PJ7#G03CM+H<B0X6IR BY+80 U)RJ8DN>.!H8_&
M8$O7BND56Z9P!SIVX^UM+JG?'ZXS2A?:]P+=TKTT/.Y5/5Q<#V>GDQG)&-4Q
M$)6L)&"E(XXE3D)TBJO(3 2Z\4QL:DZW;%7%%5/%++4Q,2BM,H,HF.62@01'
M>0X&A[6JXLJKXJP4()I$029+E!*!@**16),=H5'(+)QR6OFJBI7</Q[Y+@)U
M1F?K:4+;I"58Q9UBUHO@G4H,K=:=[A1:H>X^H&XN$^PSXRZXLN<T$@Y0^%?9
M+YQHSW&,)<(>%<N!ND>7#QKBM#U)W6'-!U7(K_)]]/)=,%YFF0E,2Z<$&. V
MH],@:<XNBB29M#<YM.&*,^9FR!&WNW&,0?'EJ(_R_ U[U8MO)FVI)G0!$WHT
MW&_,Y\YP#_UV;5/2+J)W8,NIXN"(59[A/UG,T3DOG*OQLU6L7;P#E?M6]?Z5
M'':B@C/VNGW2&W7K48X+*^#Y5 &3B!: :<*T 0*1*>*CR20S\!J 0J*A%NZO
MD/W[6A.E8EFF($"4_VDVS$NN@O9.^"S$3:)G5>?N7><.9D:OU.P[RC(17*+O
MJ,H.5]PPXC2/4L:@$LUH]#B[8H_V:O4JF5\W^2X"9HQK[U,*T:'UR4X9QZA3
M20BG:(C,W5M\K.+<W>#<_,%LG$>KM8Q(*;@DX'@B!@>6.,C&4^:,E$TJ0%I;
MMQ1;+L%_F#*4ZE;?J^;-ZE("PF@4H(@3Z%R#"YQ8QRP2?)ZC4)):2J_QJZL9
M7+YS?0>*-]U"LYK#Y2KEK$B%1V5$#IY(9QP!%AWQ4C.<<3Y')Y2/(5V?+JIZ
MN7R]O.-"E1KT>E!-G#O\,5HA.0/"06O41*&)I3:1)"/S7%NGI*I1K^J(/S+Y
M+J].I2+=0R+=7(D*T]1&JA-A*F=T!+0GC@(E)<88(<L<I5TBTCVZ.I4;KUM&
MK3&U0J5B?95OE6^5;Y5OE6^5;Y5OE>^JR'?!"LQLE62":>9# JN]=9(%"9F"
MR49R6U<L+\TA_.M29D@J",9E21)H1R#D1%Q@F6@<)1$,15\1'4)3EV:M7&G$
M':A873JT7#6<RP5E+8-P0*2U@H#,F7@-@>BLF0[2,9/5QC.^R4#7THB54T6M
M)5,I0E1.@U;!R$ 9#E7@G'(7357%E5?%63*(4L^IH4!RSIP #T"L2/A7=)1+
M1X'I5%6Q<OO'(]]%H"[9S!6G%!Q30'/RDCII= $_D86LK&/EH6XN&T2EM)H9
M280N>>]4"L1XM@3M&3H%#EP(2V(=CRX1=.,%RS415,&^RG=]Y;M@H"PP9[BR
M26NC !0U0GCA$H!GQF2?:DWUZAC/G;-7<Y&SJ&A"^^F(DLP3L,Z7/<8$83+'
M' QC2L0:.5O!6J8[4+E:R[0T!9S%S!*E.6@%!#)D H918H%KHEV6UBOT1Y2N
M59LK9 "O4,6<)3=.AQP2^&@<%4IEL)2#\HHO;OVJTMV+TLV=[,<"#A%H@@X_
M0Z53N;B,F00NHJ/H4+*RQQ5CM"Y6KG3^$<AW$31#1NB5ED$S9!,R!N\ _]1)
MYP3,"JB+E5<>Z'8^-YLRO*%G[X,)PGJ$MF@HT@MN*#$B2Y*EB2*8Q+*B)3B&
M)JMR_!5<K7SG)2C5L[Y?U6-3U7/4)\-0]:PQG(!D2#*2H$0) \E8[FCR5[O6
MU0XNW[^^ \6KJY5712G%5"D%EPKIO29)6DJ Y4"L389X[R-X;K)-^?ID457,
MY2OF'9>IU,#7PZJBG-G'%#F7-A,68R0 RA,G92(B<>6H#ME!7:]<??'')M_E
ME:E4J'M0J-N=>>%2415CLB0PC5XX+5 7@R*46T5=MLQY6A<LWY6&[0Y*+4KX
M>KGRJ!M3?_)W[[31/M>-LQ*6<97*:0=?74M3*KY7^:ZB?!>+GQEFL_11NJ@Y
M9$/1C;=>B^A!@%#ZEI4I!6&N"IA]84G;S=>JZ5S,='Z:KT\1S%#@*A$FI"$0
M*!"3A",B&FW*\BYOXL8SNL6K@[!T!;QBPYWOU[Z;$-AK=+(IMJXJ>3<J.:M8
MB5F"BDP09VPY'E8;8KS))+B48M1"<>NKW[[*:NEUE$I[[T.BI?C!A!Q=HDY3
M)S*D.S.*50'O4 %GU2M)^5S6=Q'4-4L K"&. Q#NK+;>A2"EV7@&=,M4[:NL
MO\JWRK?*M\KW<<MWD:@ZTA\.DD9*-5A)O;<)E&$N&N%\O,DNH)7]/#3[F<L;
MTD"-,UJ1H+PD()(CSE---+/&Z4BE<E#I3X6WQR3?10X;$C'R%*66(@+SX!5+
MW/',++>&"E;A;07A;2Y7J$)TT?I$6 9#@&I)' XH<9E'X%P:99<&;S]BHM"=
MN7YLDH(U)UCAN\IW%>6[RCG!YN)!4VTPV/F4^J$]J"9R41-Y/I\3A 04B;XA
MBD$Y@0\B\=:A/T"#ID'RX(0K.<%:O[M\!5S)G&!5R;M1R5E.T&;!>="9..4]
M 44M,8(S8GUD*@+^)WC-"5;>4>5;Y7M?VY=2KH1A4C'A\&G>\BRT]L8ZK5B4
M?)$%6]64/+0IF2Y9_K3_,KRW(EKCJ".:B;(SBN+$V42)#1$TE3Q9B!O/I+@B
M!E*7+%>8J_*M\KWUUK#?GQVL9F1Y9F26)I2:,R]8(DS*0"!92[SS 4<M!P=*
M>Q6K#:D8]UCDNPC&W4&*L&+<TC!N+E<H% CI1*G"5JS\,,0Q&XEE)DD#I9A7
M+@'C'EF:\$7OY#1U!ZY1JW[JN&&*9:/K)KF 1@6G<>O4G9>-L>NZP0K@5;Y5
MOE6^5;YKO;[G&GZWW>GT0K%_36[[>3%]\]9QYU/Y,U52MQBI^WQI;UI-P3*1
MB"B+78$Q]%M#+AM&4 TJ."4#^JTX:G7-:P6W*M\JWRK?*M_'+M^5".!7\G-/
MY&<N:F^-=TI;2Q0X3<II"L1IR,18K1F3$'DVE?U4='M4\EV)T'U%MWM"M[EX
MO0XQV8R8QE/9!S#0XM891E*BVDLGLQ=J:>BVME%[?:52/7>=LK9GL_4RA73B
M4[\EV&8YF-+>($;O>_V8^F3<B:<")1I[(]])K=+V7R97A[W3IT78@UZG'<=7
M'AL 7;E^HL22"O90G@5D%KT.5C&MF&*<>>_>[WY7X7;SRMVZDO 6:'-Q^$ 3
M2 K*HGV0F20'E("@DEC%&6'"6S#:,D_=+6NR[T(]'H8DW+<^KV3"\G_O<=@6
M&*Z50[,K#CNZ7R@K%0_'O0Z*=;#SWU%[>+[;#9U1D>5OO7YIV_9PV&_[T=#A
M*!SV]GO=TKI^KX.=.MK%=B(2UJV7%P?!V>'@.FJ;,O<D>0W(N*PFEDM./&<1
M @/0_K;'*ZX/"%:"LQC!44$PB"JR;!7XG-!8!I^S$4QIG52\'A4JE;E#+9ZM
M^+1:*^YT(C&K2,!ZI#(\6J+!Y,R-5TKFXC>9+?I8=;@2F4IDOD%D[@RR*F59
M#MC-UM)ZFZ1*0A(1DRQ!HDR\=IKPI*A1.:F@:5G>SBK45:C[ :%.>BX0U[BS
M-H +T6F0/ EP0!4(%JK/MI8 .*N \CYD],4S": 2 1"46.4<<48I1D-4B=UV
M@_$*@A4$5Q<$%UG#@\J 6!>M%%F ,=*()!$1,W6.*IV^$;GZUM*="GQ+B-A_
MFNW]9ZBQ.EAB8\D/>H[(YT 1%ZBBD$ D!>CG"GE%?O"Z!3T5\BKDK2[D+1*K
M3YX;[!V-SD+BU@ W+ H5D 8XY>7->-\WSU^N&+@L#)ROD0@ 4D7"0ME**KI$
M# 0@#AW?+*W'L;>(@6H3I%QTB[?UP<(:LK^>#%T9LT\N>^.,4)Q'"+H4>SJ=
MM6! M0M)U9C]PR@RFRHR%R$'"XS04N*$GKD@ECK4:Y4I%]3R5!8G\T46)Z^/
M_E8N\^-QF86VF;DU7$W=M\IJ5AX,Q6PW&L%8E)$3*! (.D3B&'7$ _IU$K+)
MCB,8;EJMKPCL5SRL>+A^>+A(-$MP#]IXRCT%$9-1 3Q$)/L"A$NZ^G9KC(*S
MU3U&1I,CR\3:$M^2J;AU21$>LXG!,VZX+_&M31SU14O@*Q96+%Q=+%PHM$\+
M]DGGF+9@.?>68P,M&!69=-[6T/ZZ0-_N++0O(9I@.! -,1 (BA/K?28A1TL3
M: B4;CR#2OXJX#T*P%L [R!'9'U&"^$5F)BM]5%[EJ1GH%7*E?RM,0+. OM(
M^4PR$0A+X APP8FA21+#?+*..BJ%'I,_8=>IN*U9-_ES,W'P=VQ_?/8/_''1
MLKEGA53FT40GG_W#]W]^-NU.O:W>5F^[R6UW:\P8_3MKQHLU>Y-2RX70.\$&
MG"-@M+J]81J434"'QVF0BCUK4*79&C2WNZX;VJZ#3<4/FGU!MZ[MY^0]7&-#
M3GN#=@&[I\TNH^V/Z9>S=AP>7YC4N;LF2$=GMSB/+1@-K[]EI03Z*]&7)3+_
M\[@_8Y1'B?A^<G\1E[')3UWGS)T/-GZ^U+.3=O?BZ=)L26S ES*XMJ<YWQ\/
MPHZ.30F2DEZ_V47A:7.R9/D6MLNM5'M:Q_W"QOZGG7(RF;F87'8@2V3&@9,^
MQ53.<DKR/5KIPV+MRK&9__C9K75'7A0BVNS;ZYY=-2$7UQ\6I-/Q]OK#_VYW
M@T9_GN\>_'-GO[6[_V*KM;W_LO7F[?,WNR]WMU_O[KSY7DA]F!Z\.-A_<_!J
M]^7VX0XV_Q!_[>WL'[YI'?S:VOG][>[ANQ9I/2G#T^Z.4OQI/3KU9+?;PF=W
MRA[GUS?YQ/6/$+(F&%[P:O))8:CRLF\[[5-#,+_@N]BWCCL=I*<7?_P2VX/3
MCCM_VNXVC6MN^I*^XEMF +E%QR YV?AC\OS)Y:WFTA=<>WR-\RTCS;67Z1:[
M]MJW'BNVP(A;/?7;UP2__IVUK;6MMVTK;,$MG_KP;=5;C-LU::O<8G)=Y"JV
MI-%KTE;8TF)==$MM<2O7IJV:\35I*^J6@AL]=;(EV!>N:N%"&[<N:+4WV5%L
MS'H>,*BM&[?Q[W<5^PU]B]3OIR*T7OCKVJW$?AB!O.B=G/2Z=R<-_&J_=_:M
MC1W713+;V.3BFKI.$^@Z=>U(VMWF[^!.VT/\O,IK7EXAC$Y&S>DZC9#PP:D_
M%E?OY+2?CE-WT/Z8FD\ZO<'U1^W\D-)[G88./QR++KE^%SMP)R):;W@Z["<W
M&/7/*T!=(9O><()-S]N]H]1M[7;#5O/O9H7%)%W:K+/6OXSG59,ZK5*<E^+E
M5'$CIO8D7UPAZIKY=L4\NIIJ<OH]5%-\N7;JZPSP%4G@M9#E>)G2#>;7C7K^
M(TIP^Z0WZ@[O2$,?JY#J-%O%:;;TKSZZ4:KS_#'.\Q]E1WM]K=B_6CW^]Q-N
MC9:(+[9"G O/>/0&-(]@//=2" '>&Z5"$-HW9::Z;EL_5R>Z=X*MY;_#_N&?
M'][A]_\\W/YT\.\]L??A^.0=+^__5_O=AWC\KOUEG>C>^9\?PN<_7QZQ_9/]
M#W]^>-W9>[DCWWT.YP?__/-#TU>\=Y__VO[/Y]W)SE\[P[WM]TGY( WS! P5
M!, "L1P4H4IE'E+F+L+W;?YU(\Q]\*KX6RKF.I:^WZ"K:XP]7]>WWS/PU-+V
MI4#6^12RM(RIK.,OVU%3 A'1RDH(A-ODF0"N%8C' 5F55URU6WQ,AG/NL\>!
M]D%;K5*P+C#/<L@I7:_>E4'<F3KNSQB$DMJYQ#+)RI9#MLHB8^GPGTDPQX-4
M*KJR[XS<$FNMC)4__"#\X<X IC*%I4#3C"GP2"&K' FU.1&04A&C-2.@ B(4
M!>[*$KC;;NU>@:D"TX,"D^#4VF1!,,I!:FZ#X0*$$DHKSYBKP+32P'0PXTQE
M_:VV$>%(1.1,R41B#$6("CEJB8/+/'(FJZ_8JZ\BTRIH[8^ 3(OLH4*9BU1K
M;5PP@+CDN8<D=) ZRV!"N!Z:ZAXJJX11>W,'FE).:>8900JL0<X$G'B5!!&0
M/'/2<F/\QC/!S!7; O_-)BH5H"I /2AUTBQI(RF%&!.44QND,MQZE:5*D6M]
MLYAPW?-D%1%K=OJHT<YJX34)PB&9RM82IYTB$&F)$',K'-MXQN2F8?26>YFO
M"G+](*'A!7<EA^"$XTGEX-'SY]0G82&@SFLGD67S&AM^$(V<G23J:$2/-5CB
M(7L"B,$$E301S3)-P$%%I6^W*?FJ*&*E$.M,(1;Q<6X/+G4/\;6!KMFYH!*$
MM-1$$GAR!&P,I%02$,^\4RD)'_CMMQ"OZ%71ZT$=(*.-,"PQEUV ;*ACPD=J
M='(*+;3X1H"F8M:J8];L*$_'*;I GI(L*;H]5 ND6R!)2)EFH2$G1]$!XIN*
M\1I;KLBU%KPK>1NX0B^")P,N>)=-"J"CH,*@6<XUMKPF0/5A%EL6-#6[PA%/
M2SX^2DLL$FH2$\M",1/!& 0JV-*56:V:[OX(^+0 / 5KN?0\B"0MN$0-XY0R
MJVQTY<ST&Y8;5V:UBH U"RWKQ"Q3*A#P@#_*7R910:1G+'H.WG+3,"MIS<K5
M$ZWMPJRKE7,_#5MMG.$GZ08+L=8T\#TI7__FO%F)K$.5;Y5OE6^5;Y5OE6^5
M[\K(=P$'QBLJP6?!67"@E70L4B.""]R%9&5\_Q(=&$,99:3\\5V>S&_]7FX/
M7_4&@^J-+.2-[%TJ=+$*(KHCG@B5*7HC-!.CK"/1.VDXY5KI<KK9)@AZ102E
M*ET%M2K?*M_O6F0O4_0VY^":6+PVB0?)A=%,,N. 5J.Q(D9CEAP,5+.HLB>>
M,T- 0"#.<5Z*)6T,5G++634:JZQTBG*PWE)N#("!4&*/-'@ADM&HB_D&2E<U
MZZXT:RZ;E2V-@=M$L@:/FB4#\6 ##D*2BJ&B!5GHF%AT!7Q5JX=9'  IFFQR
M=-J#%](&)D).E%,!#EVA:LM61.-F#I  ;KSFC,0D35DVR8B3&?_246:JDK)!
M-[9,PQ9]>*5[9 F7@[(U?.O2MO"3!$SK2=D:_J?-5C<-R_ET0_>IYF0J9%?Y
M5OE6^5;Y5OFNDWP7H,PQJ9"%]R)" F68L9HK$#IE27,(L+ GVE",%_,,8[<A
M&(4I[Z?A03YTGRIC7H@Q_WYI-7](."F="40)*"D#$8C)WA,KHS):6V& ;SS3
M:DM6'[4"6I5OE6^5[[+E^[#YF&J0'\ @S](QF;HLD4 1)FP@("(E7DM'P$2:
MF?>*IVJ05WA9TATD8ZY9GU15[SY4;RY?HT.4,;- 9,E_ @UE5XI@B)))4PHF
MT)S*OJ WW]>J*MVZ9&JJJCV JLU7JLGH024B=2BJY@WQP@G"HHV@7%:*^<;*
M+;AFIF9IOCX:>GS*<:,QS6*PHDRYWSMI=2^M!VO]_7F9:X\IU3.I\JWRK?*M
M\JWRK?*M\JWRK?*M\JWR7<_(_+?.)?3MMG]Z><./"_^NW0W]Y 8)'];\[I5@
M1XUF+!3->'LI9B^XLUQ$3J12AH!7)7 H';&07+2,Y\SX+8\>K-JX7DLHJM[=
MM][-;Q<6K%1.4:)3R97I;(A1K%GYZH)4-.BL-IZQJ[:1KDJW?*6[L[!]5;I[
M5[J]^55-VF5=3O),DD!0B3B(GOA@0X;(0%J_+*5[9*'[E^W!+&0_[-6 ?47K
M*M\JWRK?*M\JWRK?*M\JWRK?*M\JWT<0L+\H/=QK=WO]9BOOL7/W<A*X^+7?
M.YGW!P?7[>?]?^,-P6N,8Z$8Q[M+ 7VK0O1ETQ;I2XS#9D-<UHZ$&*65(3K0
MH@;T'WL=?E7,U5#,N8@_6(C1"TF"2)& T)18JQ0)7$4='*<J^8UGDEZQNTNM
MT5^N0MYYD7Y5R*4IY-R.2R93&<$0H;@G$*@C)@D@3IJL5$2@978)"OG($@&O
MT^FH'XYQ<I?=E$+OY*17VM$+?[7PPF#DNL.2'Q@>IU;1G59S4'%K[J[?^KVC
MOCO9;+DAWCX8UHQ!A?PJWRK?*M\JWRK?*M\JWRK?9;N,@T):!U^&<0)83JD*
MVJ#K[UP)W8!GX)02FJFPL-=X6'S$4?^\.3RQX<F#[?#?4;N?8G4$%W($PW#O
M\.W4$?1&T:R#)U1R1B"5&FBJ$N' %=.,&LAE&_DK]KJN@9DE1TJ_7\5NO,_U
M)>W[PW5&Z4+Y7J!7NI>&Q[VJAHNK89BJH3299P.&&&M<J<X4Q":J238J"$MY
MC PVGK%-(?F6JJJX8JJ85.*\A+&ES9!Q"#FC.1EG8Z;:VSO=<KZJXKVHXMRJ
MH.RT .\)SR(3,#H1SX4G2H2HM4",M:FJ8N7VCT>^BT!=SBQGZ6*0QD.&X*C#
M_SC$8$50X"K4K3K4S66!F+#<:4#"X84B$&4A_XA\"D*F4B;KM%P.U#VZ1- 0
MI^U)Z@YK(JB"?97O(Y;O@H&R9%CTTD *44 0V5,?<HC*JV!\RGSA0%EC+&?(
M$;>[<8P^\>6HC_+\#7O5BV\F;:G&<P'C>33<;PSGSG /;:<73AN52?8.T&-/
MY92XG BW*F86.8_,U<#9"A8$WX'&W:0@^!)YG6C@C+9NG_1&W6'5OT7U[WRJ
M?QIRC(%R(K63R%U5(J;H7S#16A9,CL'56M\5,G]?:R(8YE24/GJ?0#AI#4W9
MH69R+:/CBY<65IV[!YT[F-D\Y2$Z'7VIV[4$F)+$@C1$:&V<TSR!8QO/++]B
M#X%J]"J57S?Y+H)E!B1EC$67O0)MHXLJ&RJ=]CK:1,V]Q<4JS-T-S.T=SN)B
M- ?PDFD2E#<$:.3$)DL)< 7>2*!"F!(7X])6J%LNOW^8ZI/J5-^KYLW*40PU
M5,B<B0")#,,Y09R7D3")[AHU(D-S$G0]>GT%5.]>2E*FA^A4:[A<G9S5IF3A
M+962$1>-1M:?#;'94\)B8BI+Z5G2UV>)JEXN7R_ON#ZEAKP>5!-GI2F:<\8T
MH/[)( D CI>/D(AP+H>HG><IU9A7]<,?F7R75YY2D>XAD6[^H+& ;K8*GB3D
MD 0$1.)!>L)T0 2T'$Q42T2Z1U>>LL@Z957+4RK65_E6^5;Y5OE6^5;Y5OE6
M^:Z*?!<LO^1!A4C!ZN D6$4-#4RRZ(PSUC&AZCKEI3F$?UU*# GI5%+"D)QT
M)!!T)I9Y2ESBB;.H9:0E)4NW9,W'KEAIQ!WH6%TRM%P]G"6#2@Y(^Y0)]3P3
MR(P3HX(D0J7H4^2*)[;Q3&SB%*R;.:Z<*E(#,7GF@0< IJR3/%J1@M,*E$HW
MV5VUJN)R57&6#?(A:L@IDI29)J!\)L8I0Z0.6B2J&7.RJF(E]X]'OHM 7; T
M<QND5A(@6; IE0VE4[0Q!RKJ0N65A[JY=!#5(3H1@$"A'F"R)EXGB>P_"8V#
MQQ#]E@-UCRX3M,A"Y9H)JF!?Y;NF\ETP4N9E!,ML9L)J,-I:::Q%PRJ2$TG9
M5&NJ5\=X[IR]FH;.=L_V?W_/M7=:@B54 (P+QVR4FO!LN2B>0@15HV>K6-!T
M!VI7"YJ6IH1A7@EI *^CET0JX0AH!L1GIXBE*4D-WCI95RRODAV\PJED+CB?
M-%?. XW@A372<DN%1*7D-SE,K.K= ^C=7_-Z9R04\Z=(],X32-D3P\$1$53B
MT3$>K47CI]D6J]:O$ONUE^]"RY:%=DH:[9)W8 6U3JB<#<@@C0B!U67+*X]U
M.Y^;W1G>T/.]EV_?L^ ,!!8)I65?/V'+LBUOB. T<YH4I4EN/..;AILM6^%N
MY98NWWE!2G6S[U?[V+SVT9RL+SL&XU")LBF11.U#90R) ]C @"EVC9]=S>'R
MG>T[4+ZZ?GE5%%/,*V;.(0/EE!B7R[X" GWOJ!1:21:H<XJ"B-<GD*IN+E\W
M[[ATI0;"'E8;Y50;/^^Q]SQ8T#JCG0QEXVFO+$&[J0C3U'$>94(,KJ&PZID_
M,ODNKWREPMV#PMWNYTMP)[6.*KOFC&5T"YS.Q'.01%$N$O/66A[J:N:[TK+=
M0:E3"5^O91YU8^I/_NZ=-AKHNG%6WC*N8#GMX*MKV4K%^"K?593O8N$TYX0U
M#$DF^@C@?;9*<LX$.A$B&6YO&4XK"'-5_.P+:]INOE;-YZUK5[;?,^M2SM:3
MX"-:3JT-L4XS(C6.FHW1T[(?(-WBU4E8N@)^36+O0/MN0F*OT<FF$+NJY-U6
MLFR_EQ0 &)7$,,H)2*_+B;&,.,]E8!+_U+[Z[JNLEEPIJ:-TR0L+6E&?!.4A
M@S0B<P7QKHQB5<![*&G9?I\LA&B<(#R*1( Q2YSF&7]$R(H*+[+8> :L&L7*
M^JM\JWRK?*M\'[M\%V$_,D5O<PXN!=!1F\2#Y,)H)IEQL'@-;V4_#Y@_/'L?
MI0S2!T4X+SM0,*.(-\:2((*VRB9.4Z4_%=X>E7P7@#<-*9IL<G3:@Q?2!B9"
M3I13 8Z:Q0]5J_#V@/G"L_<T(KCQ3 G-);P"D(C7UA+#I'9),^:571:\_8B)
M0G?F^K%)"M:<8(7O*M]5E.\JYP2;BP=-M<%@YU/JA_:@FLA%3>2G^9Q@-HY2
MSSTQ62ET )(F-KI,:!0L6XDZ!K+D!.L98<M7P)7,"5:5O!N5G.4$331!",\)
MQQ$CH&,D5NI"7Y4K*<'LO:PYP95>"7H'2<'IVI>JB@^MBK/L( T\9A4MB88)
M HH[XG26!)+P&@33TD7T'T4]N+92_RK?*M\JWRK?1RS?A2C0]V<&*P5:&@6:
M2Q&*D(R+&@@ZFNB$Y.B)#R6D3D%J*76B#BH'JACW2.2[",;=07JP8MS2,&XN
M3VB]%M9X29CAD0""'+$L P&A&)@,R?FP!(Q[9"G"%[V3T]0=N$:MTJ?R=VKU
M4\<-4RP;83<)!N++QCJM4W=>-LZN:P<KD%?Y5OE6^5;YKO4:GVMXWG:GTPO%
M_C7Y[>?%],U;R9VQD:SD;C%R=SX?PV<R*,^4(8HF1B"90 RWF<B<11+1)J/%
MQC/\PI:NR;0*;E6^5;Y5OE6^CUN^*Q'(K^3GGLC/7/3>.0,0C2(N:5\VT37$
MI&A)8L9KP2RPYK":RGXJNCT>^:Y$"+^BVSVAVUS</B8C6,R41.8" 18],2%I
M8HQBS@/(8&%IZ/;(HO?;<;+-7R^WNNFLY4(H&UIB%UI'HW8L:W]JL+XB=I5O
ME6^5;Y5OE>\ZR7<!QLRD0>??,R>3 Z&]5U)!ILIDIJ*S\'X7B;*^X4*_XUXG
MIOY@Y[^C]O!\MQLZHR*]WWK]THKMX;#?]J.A\YUTV-OO=4L[^KT.-O]H%UO4
M3X.ZG_:"_+EPYT\3_OSIX.7O[R6+D+RG1(,1!,KF@QXT)9GY","!&1N10M=#
M=E92&8W1M/BMUND 649O>#(L,.TD!>E25<955\;/\\H81=!<*T5$V> >$J7$
M45L2EL(X8ZA1JCE:&K945<?*/:I\JWSOU)PD1:WW&L>#*3#>>VY2]C%;I5**
M251SLNKF1,Z;$Z9"S-(HDF,R!$J,U B12-:)2DF#X\X7<Z*N.*RYJF.%N[64
M[P)P9T$A8P;0G$9P3ENFLTB4R:A=E%E6N%MQN-N]Q)Z- 1$L+3MX*X0[QQBQ
M.5)B!5?)1R,H"TN#N[7-!NDKM>RYZY2,SV;K90KIQ*=^2[#-5DF1WB )Y'M]
M5!4R[L13@1*-O1%J1JNT_9?)U6'O]&D1]J#7:<?QE<>&2%?NJ,6,#EH@)AE
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MHRAD8YUV',J&QPN&B"K45:A[%%#'J ]@N=3:!@B*.\U9#LD'#B& <-5G6TL
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MCS:\Y^[,4_\];N+&6>&RJHP+,0XQN"1R_30MPK*,7"^\+3?U+75>_WIA(PH
MJ)  ZT>#GY#-U[L?-UIZ&VP\O!+9!!@WL$X?+UWT"!E]LD.HAK2L;4R4P?@(
M%W(AKKR/*L"K'3S$SMAA_UX^W"ZD6@L$$A8/.(Z(H+ LGQE5F4 @Y6:0S=%9
MFW<S*'*2%?=@A*E<?0LHB[')\Y1LP23QB+CT60?#UDYVOKQ1G%)B5X@0B2W
M(*?PRVIH4EF(DI2FV[3L<NYJQ0P@89/?,E8  QON(1XI1E!+1H9:<^%HDQ(<
M)C)_*'#:S";:PU<@'/"':C)LVB8GT4,?:< <]5YX/&S2M\'4OXKE=#E1!0K2
M<[/#%_5D@OX#QB,P*]&'0FA0E#+M8+) AS;%D% /']4#D1V,CL%LZP&JQ)++
MZA2TD8> *K5%A0DJ /\"H>_ W&2(<=%A9!.8,#;WKIK9)EJ@6).$_,!_>3L=
MB)X.7,)^P7TF-A>D_D&?MV*A9(UCR8C<B;(7M <=50!&B0*5.9#DL9F,\9F'
MTP?%@:\7"ZKPHG-)-G_= F&/\*X _B@=>UL1ZI$I" Y1F=SWM4AI4F,^ )UZ
MA5"TU-/D1EA.E2Q7 [T#2FK*9HRBIL8W'EME:Q/BN>OE1FQW2+M"MZC*/B_
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M#W/TMN7'R>+&%@W@'2#%E Y2JW5#!IXEMV> CY%,PL_[C]RT)=(!4^W])-E
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M$T-$=JN\^J!W"8X._Z"FCM3&GN@5 )DJ[T[9B]*P&JN!KFD+N-$%W[7&@"\
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M&SJ4:%@+XU"X#E.6CPG3L*@=-KV9-#5X@ N&OQ&'!FP]X9>4BOT(34M]0!=
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M<:  Q6Q'6*@Q4@*Y6QO\=%E/8+C=/7;Y4Z>]M2+@1> LA"ZA.J2A^4.*P6\
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M,!1I,310/3328G!QF7;T=$0G/H;DYA/@)4#[&LS3F4;_TY6\9D!4;0/7$C%
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M9RLA_]3A+AGL4B6$,&^5.>LT5PX$RWWWYW61#_R3]S.8?+S#5H>$Z3?:239
M;R;OL4Q@_:OZX9M-XP%#T"*$Q(:!LC<*T1R,WK,6JDR@7 8+)W3[9(*I0M %
M_!B2JW[?<U!Z[)I<#ZMC,EJCO5$LV#N.'8(&82GZO7R4$/1E"_1M"[M[GU7U
M#<\5FFX!#E&WS-]B#:3PZ<5H%WVL4Y/+,R/9.VODDBNPHR)\VBHH&K9DAV7
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M=B">T+2]77>&'LO\K#AI< Z$_R',W,NFD42/V(;OB>SP/AM)/HBZL_HCJSK
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MY"]+)$GFSKIO'_XLI*MK-*&J4(T61<)>L42Y?I0M>M&45()=74O)?,HO?7(
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M@*Z9@:QOY,%%%_.)#6ZX"Q:(MIGF!@%;DO\KXR,IB%["6I:?BLW:]B;B*=%
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M#JTV:.V;I#6?G3%-YVQ"!*#* &AUU"[H&@-?MLKMH+6O1&M3E[@NP-&EH*A
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M>;U=CH[7N(X3Y%HF^3&]$IS\*:-X*&"X)$^VDJPF2<9LT6 QLN\26:1RU-2
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MK&2^=95T!1KXS7VE\!.([ZBH5+U5R[]5-=*^/*2=NN=($B?.$T4L%[3E9:&
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M4>#1:IH+V\->IH2E@0"R ^3@RKT@L#P@%"X>9<KP]0P^ YA+]896+Z!L"%P
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M 8 ))^0$Y\B$)#B8HXH84_E'Q=3 5!C#G-T,*0FM-5>6*TZ#<TP+JBDW0!R
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M98TJOBIN/8$ $WRR\\WK-@&(2W^BO9E/)*;9G)+K&!.G6DC)K0ZY:6!PGLC
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MCT8S^TT+>D^'WJ=_[%PTO<>-C5VV%Z5/A@;8L,09H*N&(F=)0#HR 5!.E'=
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MYC>N^<[:GDW)*NK ;!.>/5D+GJRQ&H$CRZ5,*2D7EU:982OFVA6?/G6[7)P
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M"5K<.5I130RH1K\XMKW!-8&)1XM#<"#O+G@AL%<\1FZC5C8*QYUGN5!C%8?
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M3C7X/ 'X-";Y422.&Z\="IXFQ%6RR&A&4%+8R>AR*6$'_$C@&6>P[\>.GI\
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M#=PD$X1;)Y%B#$0H.8UL#&4<@(%E9$3'W'/GIJY<O5AUU)@&G>NZ<]YD^%;
MT2T:]K3J,W$RT:=E>+,SF$4T_^MPV)D@_:779WOMW)LSQ*/C<>/0&ND67$P_
MG6WM[)\TUW=!5+^SQL[:XR'=,LA"?]@>5'T6"ELV%LQ"<7]H2S%@GD(BDFF.
M-==822R,=T&Z*%1XS 92;R8T^C@8]X4W >.HLEPDEW.V6$0<LY+@>Q22$<Q'
M(857L[.W*D,X!KHTJGA^"J "GN)DP?/I%CGG+@&8U5[T.:>]ZA]4]AOJ=F+E
M)IXCVBAMX<[-/E;N%7PB*W3A0I^YH/-FYT<<M53Z[\K+^94"GV#1/D;7&]I>
M-FN$7HDRV.*P"W\4/^#5')ZT^[U8+GAEQ+;M47\(,_&^U?VKN]_R_0(F"TA^
MJW^0)PB>"CX*K&9Y\I/QN 5(!Q</\4=L=X^7<R!TF'*KIWR'3H!_][[#W+M6
MM]^"1P>!!O@+P[$1_O>P$\NVFN5P?X)5:O5'=KA[/ +$W-0JOW#=\,L(BN]%
MVQ\%4T\ZL0>C/BZ.SZU<%OE+XZ[*RT_#\7S66K%,)#7EQ";.:-0DZKP/#1;;
MFV!PR34UE@Q/XC ;8ZUKM=R[C;*I=R,.#KKA0D"WQH]P8:>K?+ZU$%I59.7O
M80]84#_N7$2BW[0I/VT>;NXIH1V)CB#&+$><>H=L< )1+9E/T7%"\-+JK"C+
M/[,8/408B #J('./6<EX8L:!M\$Q\2RIO%=Y#75CEPWOG>7A;2_V%GBE22>6
MB%,H1BL1M\8CPZC.7"UQ1;20Q"^M\EF% _Y9!2?Z![EGX_%(DR8W=4J3FHUH
M.PZJ:O_-[H\JOE:B%4#;<C$\SGM#;4"VSGX9U3VVK7"]V'SOG5R6&2#Y66!2
M5)[[Y%R(41OK:231 W)46]OD?&N;3",)TG,PNK_M:6G>=KIK'F2L%V=+VD5O
M4//VQ.JL>?9ECWNM/286Q: 9N  B(&.=0\$(+',W>,OHTJH29E8K8#>B<-O=
M(=C4_P>(#8;S!%[X;1ZF_U"YF(?ISRT7;X_I9S=Q=X]%K8&["L02I<#N74 :
M8X:H<M9H#RN5>([ARQD%^\8QC++9YQ6FM5)LE7&'<WHZ"FO$<B4R';],7>"_
M<INYBH:4#3K/F_^UA[G19K4S/;K096F\WZ[R8I#<\N!NN>4.1*C<&*OB/;,G
MP,7!28S5+'Q9V5XI0FY'6+5$O3PK)81?31ZX0P/1XN/M+1AA&D8M&Z^/@6:/
M[L &\.5&W7F+,.R-G@2^<E-KTDB)\#+I0(SEQF$3.7"1J#&GA!$S.X%Z_K[!
M.[%WM)7&&_=O#PE8\VQM3VL9@G<)$7#WP4)8C*P3'"6,+5?*9B<W'XJ_IF=P
MR3WZDSUU2Z%S64ZG-^,Z<3 )"]7>7-GMMS?N1'0Y%-H_[F8_?]02MPQASMN0
MN.)&\"X:V)]%[DJ<S=6E;E+P9'G\K4ZE:5,8,E)9GKUD *G287E71F_A7A?]
M/?\YW3UMU*\.7WS%NGZW/1Q<_Y7GZ5QV1VSZB)BY-$D3/P]Z%ZEK^Q$Y )WO
MR"88\SO;/K&G_:4_IG$80'AT>:%S-L^52;CV45-ZNK18>-+*)H0<;BJ7_EWI
MH>=/P;CL0HVG..AE</Q'*Z:H$[$AVF2Y" "3X)T)%T,,1(8H]M32ZDZYHPDP
MF]&M"@39U6OMY!U%CWAA5;B_Z-';TFE+T7N_N?7G1K/8;'Y8*=::Z\7VE_?;
MF^N;:Y\W-[9?QQ,TMW8VMHN=K>+#5G-[ZZ_-];6=C?7BXV9SK?EA<^VO8GL'
M7FAL-'>VB]')D>*W#Q7^Q'"YT]VXC?<D0%66*K=VQ])I8->>&RT,EUXPZ5(^
M3("M6+J!"[TDMEQ-QSC?Y[I#]^?!@1U4N1[G&ZQS-ZG/YJ4[L.TQ*07%:@.9
M@>]F(]4NF^3-FY*4A-0D*!R3B-PZ8CE.A%,J,%&12O>8&QI?.H"X[=RZ;];6
MQEOV;K[\S/NSG'CJ4XPHZ200-X(BYYQ%PGOM$F:)4[^T2LF,4QKG&[295,^S
M_BHZ[!@V+%K'(T\N$4JBL-I@FX2-=SC.4Z__8ZS_V<8>X\)YX00"_T$A<!HX
M,KDZO:/!B>B U/K,:6?%/,Z7_P:_II2-*LFC%_O'.67V1VR?EEP6V&H&I5G)
M9A-;_B7^C:"MI+5E^#['^\?M["N&";Y2#OWG^YW P'*V)!#8LSAU@>.\E5#E
MLI7(-\:ZT0;9[\LCZGVW;;(R?;N\/EC1HW'NW!A_9]/IZQ#]\A"?%KOSIO3<
ML!VDI51+4%"CN0_&$J%Y#,KPZ, A(K,CW7-IZUK7MRZT\],0-#?E++*U?KES
MMU%)3/@PWN5<RT3Z5ZAU\  U)LV=W3TBI%3>820D S5F,B -- =9G9*3E#.2
M@U2SSMK=&\53#K][H7+%(XX9M0#C) :60A8#;A\AXZH6A_N(PV%CSQ+,DS4&
M:9?WPY)UR"F= -H]YSHZB[V;7<'T0:@^S<=OB%IYQRP#ZP)T' 9D8JYD1($
M .F3QIG9Y<^F96/; _X/VW$K->/@(EY=[?!O=M8ND/*FDBJE\[<#XWJ?3P>]
M.6GQ)SFNY4),R0)N8!<(RJX1,L92A(U*7E#PE +XU!%TZCC[C[UAO,E?6K38
M\4YI7-OMT0&NTMOO#X]@T'"1?A5PKP*TH]2]F=&WF:0@M3JVXUM@82_HP;O;
M0NRC>%<U*Z/A3!6G]#E4?=R/[\9__"NT^L=M>_JNU2D?K_S2Y3..,/L7H:(5
M7(6+1K4H1]<?O;U2OG7I8.7H/;XB.+OV;;Q"[OF>8-??]*9OWC18$"VN7LE8
MQ0IC])6,E:^ ;_9*QOJJ!):M:'6_J]9C_57&2N@*D.-7,MC7-+%/-5:F[[=:
MMXQ5ZSM==69%:6DN=XL:<8I7WX[[XR@#>C?:7K_8F$J!+L#[N+U5-R6_9)_R
MG,>< YC]/W[[JXRY__Y?KO?'ZN?Q=G 9'2H=G6+*TRDV1Q&AC9+BYE?^KB)1
MOQ>_P5=&WE[_2KV-QVT>7Z_*[%6ICDF#I(\B&55P\WRM.K'?+W; $8%IJ=?K
MF=:K.C)0KD_Y[F,MTBW- 7ZIOG]_=:MBM ^1TCL)*KN]B.9])W9^&:9"6>^>
M>&IS/.PYI_799N]9!#,'+1=A]E[GU.G'J'O[P-GY9?'N:<'N#2+=&U;4!V'<
M&YZWYP*XMXIQ-:>K.=W"X5T->;^ZDSJ[RG,9":ARI6+_]UQ,;=;.[Z_4NOXQ
MD6SVG"YPZ_JG?_CYJEO?X]S6G:I;EX4!JHS(M9!+%&=9_MCM74V3@5>VTH[]
M^3<\;3[S6=526(_5[U>?1#6J?GW87-\\V_H*8SG;(,V=[_C;X0;=VMGE<"_6
M/(/?9YY]^_,3:9Q>KG[=P(W#AMC=^7S8V/E"MG;@'CN[HGFX#\_E&?R&[X?O
MW]:_G)4]5"_Z #J= A9*(^D]13QQC[3"$25!B0N!48OITBH3<U2^KGO;O[2]
M^+5ZV\]^QCD03-C HN+!.HDYL]@Z);W0E.!  O5X[J8<-7"]$'!--"*4DFN;
M>Q JS3GBEC*D96+(XY 42XD$ENN@B6MK6=6]YU\30KTV>)J'8>%$#"4^"2<D
M]S2?^S346X\I!QE7^O[]0VJ@>BF@.N_0Z$FNRV%"$!%QD7/<8^XWYK5!AHB
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MGLX7)3R!M2%@+L'Y @_  V!HF:A*EBN)K]ELK%?\X2O>7-_<4]%3$HP BD+
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MS+/Z@"[ILL#I;'#Z:52+(9I5]C"RC($6PUA$1@N'6(B.)64-Z)]K&Z0H,4L
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M,M@+N&11+%$)B)O\4(<=_#MOX,?+72@<\CB'[.[M.\8$%EP@$G(S2!H]TM6
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M'U3KC%PU3)7'UY=8!]IYOW?_)2/%%ID"@+X6**S? V_=VJ21GX>=ZS3] ^#
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M049*%EE(D6(V$-_5^*G-+'P]5\1Y(:E3EF,)DAM'!]) 1^JET_AV^O1@W^]
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MP-B0D 2M##C9"Z2M\HBFF#SS7MD\/7U%#KD@]9WS]3H9'.! K:0RMV&TR-B
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MK164.*2<I3DY22/MG4;82QPYR,'(W2,0.W?U9 G'4H)Z4K= 2R^OFP27 A;
MQ\P(KA)W@48:"1P:XUX0.=!-,"NZR;,R#FEL[>TK)KCDW*+H0T0 L0YI8Q@B
M0I H0L1)IUGTD1'2FDD9&5Q_Q6./*R(3//!>+62":Y]/!5'6!P+<P)T!99V!
MA&.>BT2\DF!@I:*"/#LC\,;NUWW-%&CFN9ND8A)QGS0H(-(B$\&4BC:QR .8
MM>OD?JUC^JE76J4\69-$J@0WDEI)C&/>61F)$=;GPP<D'!S^^,RM<OCS4Q\N
M<EM>$Z.VSDED=,@9E)*#Z@G:A.;&V!0Y,]:#_LD7K'\^$3:*_CF_V6F[VV"T
M,$ )17/7?3#K<; @1F5$/@\]A'\R2VQVJK+[Q6A&CVDHX*G842C@69P\]:WZ
MO@T61]A*A%U4B(N($?PE(,JM(29PL!J!&M@X!+G' ND^:()<=NHU;_)<HE/0
MW9L_ %!6V#+9[!_T 2)S\L:+FB8Z"9L XDV.[.9.^S+IR"2GUG AR3"?!.MB
MFKQ8T('4MS[M*RF9]YRB0!)H9Q$DLXX LMQA K!K+!8F<]28V92/Q'2!P&8R
M4/[LG\2AHY2820*W#SSH7L/DP:N>S22))E$)R@.W1'*<HA/8YLPJ "Z6F#!%
M*WUN!MB&9V[OR^"8"<0@2JT#313VV_(0$&.$!>J<,DKEV=]FGB9)2B0!" 8O
MM,MM-RRV\!_EP1OF);?5X>O+PQ^;6E<.?Y[HEV<Z.1$,$]DKXSCBRG#DB" @
M@G/(51*M;,JVZ1CM\N4LDJ>B1M%'YP4>%]FQ9Q@71@60F%)'Q#G5 !Y&H:!
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M:<6)T)3)6NX_1WGAJ$U.<<-)C%S19'24DFIGDE="23-GGM9I['6#[>_7^*T
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M"<*3@VIKZ ;=@6W754T?@Y<67BCH=KS4C(/-M&V/:WZ:BY\^S\ISL!]@]8E
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MTADDC*%&"&),S'MOE_5.K-5WA<4 HR11Y;QA27-!E98R.JRU-98PZ^IM\*I
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M,E=+OJL:?]V7V\K'V=_X?4Y34]@<%+8Q*_6PB?!X@T1!&(PX%0SE#NI(&^9
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MR!AG48 ''2F61,AZK^5ELL"SWVNYA IJ3;-(FIAJ&D>H]502E&M6(\YRC;M
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M70R/X/&E5KY8B+!.@1I'CW2L;J;&;&S91^;L<8H:E))WV@S^O,ZM6[^/M*P
MKYO#OW,+^%^-@\^[AG&%G?,(.Y'C>9-#6CL%/&ZM#8Q*;^0M2QC(:NK.&[K
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M P XK,43>%CXTE&!65F Q4B11&7A#>=P>_7:GS9O8K1."^&$8WM>RP(3X&"
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MZIFBKN^H(%JI9U8RD)4,Y+RYO(XZK9UTA 3.)9"W3-^L#"0$H'2!5C*03]_
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M"6@9Q2Y"@"_$O"M\Q;5?)M>NO'!A7MBX],+H6$B!"Z1(IME*6:2U9H@&83F
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ML2$[ 33@+:Z@/K>-11EK@&^WP@! 8)15=@DAYVNU5G&/<.N3#S5\'/#JXND
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M0=@CZ&3-;L>]$D2Z?Y%*0)J3W4/)L-%2*F0Q!UB1GB98,4CBH&2AJ2$"IP(
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MSGK=[RU09>#"_(9L["8E!B0.(%KW;#U=XH>NW%78F6]A4'T%UPUS J@#V]C
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M5_>Y7)=7@_>E0'ZAV[P_J\"/0;\_M*C:ZS!QGZ<XMBD)D).(QT)@"M379^3
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MR7F0A16>:N^"UC4)/"H)-+>V#[6CDD2-$<.P^\RQB PC D7!G(<?BFC(VEM
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M6N EQ/<3E5;G/![)OJ_QSHWW?^?L?O#.(OBUP]S]G$]=:U@7QB^-)SK;S>/
MP29&.(QUE>1,-BPKE1/;Z668O8ITW2H4L$Z+_53IV]_>^=X6A$KK"$4L)H9
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MQ;E=A5*@8A&?)RD9-O)1^@H:8O)%#WICR@F5(TBPYK[I6J@R GGS)\Q@)_T
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M'UDV?H2MQX\\JN=9CQ]9CQ^9&S]R[3B1A?$C,2GL%/< A6).SQMM0W \8@$
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M^H,N&.Z9.4_/41>+_>];I!TX]Y([AC!6"G%*"+**822%H2%&3;6QE\Q/7U#
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MYTIY4#?66J>DI](2C]?<>0^K>V:'VU!-M< 8-B*78/'$D68 C03U7#%/J10
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MTES]9AF11RD7,W&9.@W@N_UAJ?1,5:JD-$75VKTS5_1>"=+I>. _E;S&*L9
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MNE["M'C9./L;9+EN!7RK.K/Y2T_ 8?-[L]#J=E/ 'V?7T,EPW#MNO>GTXRG
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MM-2@,*7C)F<4EDOA4P5361EG80(ASFT;*:<\_'A4QK:FU &@V7I9P1.??6C
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M+@&M3'"YMQ33925(Y:2Q1>YHD5M)2JIRZ[B@A!?,WV=+Y'98X:O19(+E]I=
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M@FK]_("K#[$C_-W0_-0]X;46F\-OBTR$'=B(HG]%OW?=&6='0:9VRUUB%]U
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MG0.NL!X!)]3WL9)S%R1AT JAX %]<>W<$*V6GP:B?GOGS<:KS>W>ZZB6'KO
MV!Z"^#N9-M-E1.]EJ$WHSR:]_PL*MK?I9M.).1H@^?QQK/_L/9V_X%DLQ0/3
MULX9%LAVM4F,W^T//\Z&$8L=["UP0WOJ$$04$&::D(SO9ESO[<;;FIOW$>1E
M&"8W]OZ 3RT6&:4IZO#S:S7N8PP)^35&4X$8T_'$:@UEX5"/@XR_.# YQ H7
M)CF]^[]PH"DQB7=+2T-"7IBG#$O<FHV#Q5=;8I,("0 "-R3U9LAX:!'@@^*U
M<,:);'9'ZSW2*ZCHL2+O/<4O_@M_BA\_ZX(*]">362IXQ\+9<$:XH>[+27\<
M)TS$.DO" @,>N=C5WW(?%LS/0)0^4D=A'I7X H%VR<]A6GF(FJ$FMPB6U%#E
M LT]38/HG\$6=@<1;)R\#7N<+JO'U6_\S]LXC2G\\U\3^!8J@^.H=%^T):E_
M(AA25#\->=9D4MN<FVK8GQSUWDVC$;LSLFXP"2@/]3G+J+?B=2;<#8ZD#V\Z
MOP7_FH2,)@KYB*N[?"/6%W?N*"(8N5!+%.@=RS0FM3I!XCO!PHMI2M0K:Z/:
MZ1_'1.[\"\TOMDO]^$EP<_EO2.31HE]K );B&K JX"16_J==&)S%$JS.C1/[
M/!\E-;<1OSIVGT>?$DKUTGVMW::$5S^9Z8\NBH#Y/6D X^<H[B:[&][FZ@T>
MA43*YY%)=@5L:2*EYK'7$]0U/!YE)[QK?.[C9?G$!'#\WY_?V\OF.?X6QW0Y
MWZMA+%%81J=@D%UUMKZIJ2^+QWNRC>=PM32?V[>OLBR"V9)LBLW_%YSI\K?)
MQ WL:.Q[;^"00DU]/+5N* @O_\/AK(AKY%D42LO/SD6IL3$[G,&"'O?!)8D,
M>ND/<(> T]Z C8*P6Z]?O>@]G?_=96;AW8_F4H:Z_)R66UUE4?8XKY+5A3]=
M:74MF,<+IE>K)PB+&JWVWZXDT2N)I<,@CY9<;N]8)BJH_:L4]ALT_E6G0B).
M_[[*$[WW"-R/<C?_GO5[^^KX9_ S:_'!P(;Z7WBM*;S68J1G!_A/N4'ON3JU
MLV%??<)HCW9':N!K,@HQGFZ0*Y1+3 +7SH:3:&R%L/F=XT'[G4A+B 9-4I,9
M/A:D6<PI@63J5$IB^4\=,FHBYREJ]%(-P/1[$2/Z&R;&8L*R,8K4E5J31H1,
M:C#58"6/'3).$]0Q\-1!&Y5NHSQK;8BGSBN%$'7=O3>Y,D837CSL&?X:F:L>
M=A#N_QF++ ,C1B_AOL-'J[J*Z^LJBE5=Q8-:SZJN8E57L5!7<4V=Q.+T8"8J
M1K17BC%JRDJ: M%7C++>&%7HFT\/?HCF"RC9$Q"OL97A9<Q P:9^=F/,)[I>
M=Q[-HS5L&GL=M>S<J/;N^X$_D]K^8E/S6U"H?8,YQU<OUBZ:.2E=UTE\39+D
MJ#=OK8<WZV&]\6@<)ZV&$I, &1&K3E(1P2V1724AVA 'U"H=I:654BA2$&ZH
MJ(P5H=2_D$4L];]C!UC3$P!&09M@/MN,%LY;K,"9_@=[@1Y0(]>/Z SX^T!5
MBE5%13+N&,FH\44F>.XST##.2>=S+LFUD'$A<AE,6;"-P3  +[>97!@[8U(J
MLZVX,:E'ID-QH3_')I:>-O4[/X6W5=%%<?67,B,]Z;V%?YR#MJ\38(]33%WR
M,C%/!H<;_)2:%H!8:B\)BWBFXS2[+;7E#1#5.@MLB7FUP>BP;R8+HYSAIQC7
MQ @*7#(]FHV':]WGKT7J07>^1;9HQCR$4+V=Q4F!<XM(;DS;IJ\"()3JM,[A
M0T]@&:9_$M&@0#IBZ5A+LS\-&D.$Q4A-53\#'X:W>NVF$9T(3S^T]F*V%[W\
M-^YSWYT^3A[LQ$!$;^=L@(%)4._'RKC9M _L!([\]M"L]YZ&#Y^EL(@"1S]M
M1\QB@6]^"(N;+L0Y4I!S/SCWR. I.1:394]?[V\\CQ/D'V ?3X@OA/JY!]"A
M@TDZ(+):W'4W%R/(8HU(N<8*VN3M:1U!CA&4SF]: -9DBH62XI!@P/$V=0A[
MYVU4.53DO>/#4+\#DG%Z=#;H^=DQU@ Y3,7VK#K#VI^F.]:''K&PROVM%R^W
M-[?>;(!XUIA) FI[Z?0XU$DU:50D@CJVK4+IY:!W.L8,;QO6Z<U.T."L&]1B
M(':AAK7)?C0O&L/<0'/C_B ^+U)XHN%AD^7M5&K%@%R3QFVG(;Q,@;,7_;&9
M]:=QHQ=^V83KNWGCGT8"_JFFYBA[K[Y@6@-#AFT >"Y)U1[[7@BT9;@8N'B"
MTB$>S>-UK *.&+QD,\<B$M-)S5J7) BOWY]!W)^Z$OMD-I[,$F9>" V/9X>]
MUV/PSC"YVTA?)/%:R+KQ,>BBR;3!<HN!Y$(*NA927Z,A2/I/P]'I,+6Z]RX<
M::#J35CL*=;];<3Z0R#K.D>&W8L@N?\$UI@>&;P&M<-:;V/PR1WW7D7,@- M
MT'LUM?C!\1!9;$&I1 ?S!=A"JJYN6L-Z*@Q<7[CV]>?I>KK;GPB[,>J]>[NQ
MEA[\:G:"+#X%OIX"U_T9I018E7#%CC(#-[*3BRHMWFWG[>[\DCM/BE^!W0!;
M<7T#?S'&#1@MZL>TC+=P$*/S^A]'_<&)ZNW V8<M:M[P[4"=:01;BO>(N_!V
MMN2>=C8)R+3U4J^Y*#VWN:CWQV"D,<K_S]9:;W\4*VXOG$&X\_[["SM>W^\]
M,-X **5SVLT.!<K[YPR6<.&^3^%XGB6K 8$D:K2.:-@WQ+79U/<^NVVM;'./
M>7(-7X@UK36]1H%_@]OOCD*#YG#N.>^QPN8_?91(?14?-O^K^,1'F@_=JRM:
MRKI:^I(7;$!"/L[L81!MH>HC;&TP_Z9'=80'+FH#/)=HY=@W@STIX3X!?0RN
M;G4^YE1/&OS.3K62:U=03SM:T,J7UV\]SC/:OT#?RP_C$L[JI=%2A^/1;&@G
M[6DU7T['M.S4PR3!MIEH42NDZ$SCU(8C#\ QTW DJ(G@% :M7[ST)"=?>6:/
MPG1:K/K8"QT/O;V3IF/N<9)G-(AX!$Y?_HY/MU[O/6NJ(=$M6%8"4_8*4O48
MJ6H+.C@ET4BYM5MR4W?D(EU&2M]'V*^@8X.?.NE4=29V@7>*:J:IF+F0N0Y/
MKIM"0+R6-_,$'N09[P1\I1 CJ-^^/M"7HW'H[XA&P+\FEYRNR(L>8:P^W:75
M2B5;7[A=A$Y8\-:^XI NG$^WD.J&=4V/H2%D_\/;C>=OFH:0-TV![VVB<@^2
M$KN%FE7HD?C?WA\[S_\$#\7C,*-YY.G7H\%)LH=! 9ZL]73HHYYV&KJ2:8A0
M+&TM=Q)===E<B-8BN2]<%DB[8"4GT39,G_X+?[%0O]>FPQK(G&6,4H!<8[VB
M3)6 81;%O_"?Z7:I:":(1F6/05F#L=K4]PP5$LAY:"YYFFC@6> 7E* @.F,L
MZ.(RN_S8#="0;DT@QOA"?W!_V)5K1>*Q)E2S4#/?EIGF ;8]0O(%;#3P"-H3
M>MY$[:._%3JJ+Y[7Q3/I['PR-ML7NZ0RW4WCN?<G">MH5>=S@SJ?<E7G\Z#6
MLZKS6=7YS-7YW+ENY^&I^K>G_4D=68K9MJ%*^=B-/Y)RN)'&3]9C<EGKLO[Y
M&%"R%_]4AS.WUMMU& C"=/"D][15= 5_MM:MZT^!['2+IXV)S)\U#FVG"Z=Y
MT!M$OW@Z9\8\ZRJU%!E1J9IA<S8U1VOU,_'&VZCCY_L*)O.HN&N- ;Q@/M3&
M2-B]8$7<Q8CHM!LLL1?VZT6'RR[V0*0T^C@UAH67C=]J#8AA^^JUVD?C \][
MC,GY4>,+U#M=[T_\;:/HD2SL6)T.K[$#7+.K\7$_3^!A8SB<#8+O_'H>QN:/
M5%\QQP&-2?IN>&E2YW&Z#@NQ\_>C\:=)1UB\W>@];?X5&3B&-[=Q#^!?(>3]
M=.YWSV+P(!0N)2F# ;.ZDS(1UDWVN7WTO$.<6GOF5]*?<X+*?$YZ*#SNAI,F
M%YX74A*(AM/;"+5MO:=;.QL8G?$(DA-NT8B?9E%-B^&%Q32?M.)G?A/@?MBD
M"'RF8D4/'"8Z+TG6-$05)0"LI7-'6!)F$X*X6!;&;,,Y:1[0I.?'H^/N4%QX
M#]5!Z5FO6[QJL='L2YB?-PG+"L^K:QD&#H\XB.78;!!$7L+0:G9W9Z,^;8/
MI+73HL_:/<07A#6'SZ,CA5&.?K>E./0W1U@I=:KZTP9P(S4VO(_0TL,0IL(S
M_^K5S9WE-2)239>[2H\W2/(Z82Z\ZM>%!.U,GP +W169CU/J)63@!$[6@@+7
M<!.#YM4[J&>Q%?@B]EFJR OXP@:1XZ8Q&(>QC"'6U@Y:J*TNF/O[H_X@&C,U
M^%?H.+X,_*MIQE'&S,9Q_/3)&.562*&V<VPT=BVF KK9('7\A*JZ66W+S#W%
M?0$[!XF[AC<^#3ACB^!A-5*9\]XM!Q%KT<' !(]E@O>*ULX?.EI[\:/0VMLQ
MIQ? VL&D-X,P_N'AP+9_J*=LG/VSN7VV _?>*;?IA_<?\IWW.VSOCW?PWYN/
M_[S_Z^.']R\'.Q___K)S8<K&7Y]V<+K&Q\/S#Q^/COZ!:SZ<?Z+_[,-_?\":
MCG>//KQ_=[:[N77VW_,/Y=[^X8$M?"6%D!FQ3F=4ERR3-L\SHYE64G*$U;S0
M\2$U%;D$.BPU+8I*<<X8]H8HX6SES")4>^<@$MY YRCN@-Y^_?,7UNM<KO.*
ME+F6E"@O*BZ\XD91+P1PU?UTJ/RH MHW:31A/=WW9]&XR9M\I$/88JZ3S#4B
M!(-S*]04S@:#WN@45"1.-0O*9X @,,<*_&M0.F.\4S"(Z^1,,Y8MS;I4 T2T
M/\.;)*C*Z7@T6.^U4SO#8].,5-4.ZDQ&XT@/L!HOIC&/U2?7(IM/VR)V^"RL
M%Q9X:?O-<(;>Q>*P+F.!V:R6A'(*3*HK(2UQ!?!<0> ?8?0266R\V=Y].3=@
M*<ZO;L3%-)'XR]$8/54U ,=L8$_!NMAUT[?8W_SN9']4YL]CSTC3>).5OYQP
MWR8[IP>,L%PJ93/N9)71W*A,DL)GE:I*6O#2,)H_^;T02_IN_D\(FX1-!LLG
M[7)OZ*87YY;.3I!,;C7)[4[$D8F;SN6ZA&SVC\#>P\+@AC#D+T<7.V= %U+A
M^"R?9R7W949513-9>):5!#08R7E%F0+#;5D[ENZ,8GL4$@$=Z:TOZ#"LY *>
M__G.QH%1O+!5664<G(J,%C;/5"'*K"HY6-K$64;!JRC9U\F%H+%<V/J5='@D
MU$%W#P\<8X7S%/PJC>V:CK!,B[+,G*ERKDMJBH)=+1W6>[5->L&0:$,&\Z#@
M<?";&1T. SAE@*N<1&3K0$S]&TYE6X^/"0F VNS"R)H;@TDUZL7!C+"N@>D]
M3;]\%O'1VJ9G$NODTU<F,SU!]+PP*PD>;GL8.VP-M!24Z+RHBN^6X;N=I<@
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M98YAG<M3?[=3,:568,(R:4J0*8862I2"E AMKTP)5NU*Q7QW(OC[0 IKP;H
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M")%UMCM([T)"<.RI^<>(I?/9MY?8__Z)GH>$@7NZ=7W_:3B=S?_EI]_M_[:
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MY=IGS9S /SJL,$NL.&?/2\6*Z\:*I[V3B@LF")9),I$1*2 1R+Q,3N">:J
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M4W#0DTFESIH'T"25(^>E!DY<2)$8KZG!Q%7'9L\(=9N>@U+AH,+!)^% 1*I
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M:DNU>P;;S& S(VB3);2.,96<S:!EX,UL#:=A<5R&#]]H&(!/HV'ZNP/P7ES
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M?G4IX*U,>_7P1,]BN^#26U]ID[L+T&)EC,LK# O(%*^8]<>X-++#LE8F+SA
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M7+*+]4[<98S&((7 4QZYO]B\O^)U:TLO7K?^SD_B>_SG:'X\VO__4$L#!!0
M   ( ,&#0U(Z=/P_72\  *PN @ 1    8FEI8BTR,#(P,3(S,2YX<V3M?5MW
MXSB.\/O\"GWU-'/.I"O.M5)GJO<XMUKOYK9QTC4]+W-DB;8Y+8MN2DKB^?4?
M0.IF2R(IV6YIUYXYU4EL KP ! $0 /_V'Q\SSWHC/*#,__:I]]/A)XOX#G.I
M/_GVZ?7E]N#+I__X^4]_^MO_.SCX^^7SG77-G&A&_-"ZXL0.B6N]TW!J_7!)
M\)LUYFQF_6#\-_IF'QS\+("NV'S!Z60:6D>'1[W5;_G7B^.SD]-1[_3 Z7TY
M/S@9G9P??#D:C0].7/>LUW//1A?G7_XZ^3H^<PZ/SH[M@R_CL7UP,G:/#^R+
MTZ.#,Y?TW//S,[=W0032C^!KX$S)S+9@8G[P]2/X]FD:AO.OGS^_O[__]'[\
M$^.3ST>'A[W/?[^_&XJFG^*V'O5_6VK],>)>TO[X,WX]L@.2-!]1.EIJ/J)L
M0GSJ$N<GA\T Z.BP=W3<2]HC-JK 3_T@M'TGQ>\SWX]FY0!NR#^'BSGY#(T.
MH!7AU$GA]$#+ -C #5.8_*A./\LO/UEV&'(ZBD)RR_CLFHSMR .0R/\]LCTZ
MIL0%QO$(LL92@]S7H<TG)'RP9R28VPXQ6KJ?_V192%,ZFS,>6GX!>&P'(S'8
M@(<"[."P=X!K+KG@CCEV*%@[/[D"T&?BA0'^=9"A^.DC<#]]-A] %!Q,;'M>
M?Q!Y0#F0^)/Z@\FQ>._BXN+S!_)LY3"*+"C:'^"O![VC>MU6\;)YW_#700*W
MB3%D^[7>&!*X-<=0OD5-AI*'?)" .)8+'$OO;+VQ-!M'TT&4BQ)#<B0 V.UI
MG0X#D"(3]O;989$?\H5V1P8JP.2/^IMQ&67$.1RL30:3ATS_6G,X+J'U1Y(
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M>C?R"!L_SD6LGS^17S2DD!:?AF+H_"E<M*842["C(93B3W?5SA)Q>:FO6-#
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MD\,)"!;#F<I/9C" T.8+@ZG^8_!P^?SK2U]-I]56K5/HB7 'I>6$L/$X O%
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M(T=9=4NXT4YJG%M;N"U)3H]G I:.'_3G<X\2MS^QL=-E1\(S"0B'V4I[SY_
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M?. <8"-\9\Q]AT$;ZL2U\71!%>Y[6+J6Z'()5EJU+B'1Y@CHQ$>7=ZW7-_2
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M$&?\[3.L8^!,0?W^^4__'U!+ P04    " #!@T-2'##K74P_  "@P@( %0
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M<4%P1'W0&JM$B*H3-3L,[T[,&RH)XIF"M3546_%<X)&#BX2)DHFB*#7.VWU
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M4,\:/;Z^V?1NF2\SW.;#4#' @R!4U\KQ@JFLN==G\)LX;V97/ZBCG:W=5-?
M;@,L(>5--30.DN/FALI(:@>0U61Q^"G*8\U5E$NMDY.-G5T?(5Q3^%;1SEQU
M!6R+8!?7?WO$1"W:?T7Y%Q%)H<.66SW?]-?,_;3-<"=)4B()&#S1*G!>8WZ
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MM\A939%/Q@4C(S>JSLG\,:A'Y9D>RZ\'3L)@^BSGJ^X#^>IL+>3;A9$G%'7
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M>N#!4>]M M/<*9>3V0@RL+DB%@-/1!FPU.N<V.P ;DSN5#'V/#B2*:VE<B>
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M/8G(N1"62Q4/8%E]"RSO(\O>DVXW(I-+9$8E!=9K&F8M]HG2,7""QD^:Z%5
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MS,E%FT(;692U@BWG#IT-6D9X-BS>D['5+XF[2*UG\GXE29U?G*]*TXAH,)O
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MN=4F9Y%M[#)_8@N,YV2*]:+FL WYUGY60^#V-,&VQ'L<\ZL;_\/UK!EY'<[
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M9)?$=I5-22XE!LZ+F@NMF=?.,[ &=4050NEB)+R(8H3CZ6B+FH5MJ.U@G.X
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M'!;7Y31^!M?AM](6^K"Z?;84?@>O\N&2%Z6[.%MTD?DXIW_DW\G3JN[T)[S
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MY&JZ0/[_X_0)W/5/EC5Y#D/46)@4DK0_$WK@UI&S+8I3Y'%+_VP,>&\49Z9
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M3-.G3E^ZT$SH$)+S.4;>)?_SA-M7'$5E=FA>L0UU1VHZ, 3BC^85+?C=H?O
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M%A^5MB?'Z!"+N"NAVTBM-9$?R;:;?[Z:CI=9]DKQ:+)F1?D:9BN%@8V!E5"
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MN\DXW7PRBUM0GDD5I!!,*Y%8T(8^&0YDZNE$)N(A-ZH[9.>J0SO*OD-=YP:
M%Z(X(<!K5GPH!$O74!&MW(184]M2X7T&[FW <ZZ*L)6<.Q2!W*[R.D#H,2L7
M2!E3;1:IZS+!BLB<))\" SE'HLN9\Q#&H1(.&E.\ARR/G4YPFRU^KV;SU_N-
M.(2!J(I)C"LZN&A_4@P\K<@)2#H6DW/N$BC;!.AH8?8].%[-S&\AZQZ%&6MP
M+3MB#4#6,Z"^&=IQ NIM*!R@%WO(_[ :XCU(B#PPS2UGVEG+@M>164^H0&91
M\&#[Q!$#ZH=6C&W$WCJ@?FO9+$+%L+ANO D8FZP2+YE.TX2BMF_2##(9N%9&
MZ167R/VP)E6;WW%XP[ 5#9/V,NP0XGJ5$MD=>6FPCG")RT>>49?":&6.:5DB
MBSI&)A) -,I)%%T<A$V 7KPB-)5XZX_\U\GXTQRG7R8/%/7R$<:@LXC9!V:B
MLF0_JYIL8H&)@,;*7(05P_I0#'SABV>]FW0W!I*Z7, ]=&\7(Z_VOGI[XID-
M+]V&(E^Y;I-:2EY2S$D6[76**G*N;$H"5%9F6='VQ-.;7[39G#@64H>B:K\*
M;9$%$P4K.G/4HN@HNU1C];YHJU*[4 D-:)=I-;*.4RK 0B#O/'N952R6?/8#
ME)I5*"<1BMJ&ZZ=#45M+MX.1\=\P'55_^@X0+V050Y LNQJ'(3.'!<3("B9C
M8Y#&09?IA(^0O'BV]Y-MCWJHFZ22ZW9A%Z"XP0":^2@EG6ET7GH,@:$O1L<D
MN.H367H(X\73O(=4^R5EDK)!%-I*$UD.-8T,B8@H:6$6DTU*!?2#$JYWS; [
M@P]X-UEVN"I:B7U:6Z>2H&/(7<V]4)S69"R+/&%,(=J<^Y0LGLI=P5Z?Z^ZR
M/)6[@I5VCP_"7,6; +8V9=2%UE,CY%#/&0TV! ]&V#Y# 9_ ="(W!ELQ_72G
MX9TEWN%0WP!MF8 Z %S/>X,GT9U$J]_=N1RF(WL0<7!ML06<2R"8D#7.I91D
MY%-+.N8T1N%DAMQI,OG!M62[CKH'4I)MY-]!.3[@#.F!GU^-\T_X#2\GBQY5
M/__UE82VS$2/+J *9-2: K1D";Y6E=)6NBAG\\5:47JHR !LA[<W&[(YZ4M%
MA]#!1[RD/_KT#QSC%"X7?:;O#U^ZP;H,H%J?I?4F,ZX*OT[O\*8X)I2+TB7A
M3)^PPE8HSTF#^M'3(W5W_AFG[R;CVS#\M5Q6]!T38G&9Q2!KPE;.M?L>.=JZ
M%)6T,8A='-HAX,Y)<YJ3<<P+D=M\O]^@]A*??V]\.;+Q^=TN2H:M:+6)G7<R
M8LFH!.ABHB=O2 :O15 F&9G67IH,65L+COZ%M;@$\ZMO]--/]+BJPO2'M9 .
MZ "LO>:OQO,/I.J-V=OAS=UXW5<**XP#U[X(#B9'U#EAT-+EZ#G$9*T1ZQG?
M3QXM=*'.X;P.E\#E&YA]_N5R\N?=V(K&] ][63?&=UCK"LF*1R$B*EM+@M$[
M#]9D@:IV&I:F^+4D;[WJ;7E]2P@C:=$89SM1]>#O-Y'^9D2KM9P:(C<F9Q^3
M+O0O!ZI(YS$6X4N4%YNP[2.CW1O+KGE*<WD-:#(K BF<M44 @O86HM1&@(M9
M8='9P<73./>1W<>K+U]@^GU2[O]PCVUB\+.;RWGX2E:DCT&DQ 6 "U8+FX-Q
MI+LQ)H- O\.+P6_9<\(3/>_MF!R,JX?1>BD][44 # .2GYK)7@P$DI7DK?8B
M).ZZU#AMP+/W#=OD^CRLC[^I2'L59]<]47.VL=A:0Q0]6<5! @.>ZO!$:9V(
MQOO2Q<M] M,11@8UT(-'5W&-A-XA#O)N,L?9[_"];FO+2MBB0C6X!),U%4TK
M&<C]JDVXDBSH_Q][[[K<QI&LBSY1[JC[Y:<LV[,=X;&T9<V:<\X?1-9-XAH*
MT ) V=I/?[( 4J) @.P&NH &R(D9#DE0W7GYJBHS*R]*"ZZ;S%380LL)^F$,
MI:O9L()N,=3N.XL3J0C6M >#I4,05$$-GI/++9A+G."=>&R2EGN/ALO1];Z"
M;9%1<8_%[]6CW[BTPA6EE -N(B/>D($WG$,LWF-P,M QVWK+?TC6Y>WZ!XJ^
M17>K6^KN[TL3PY@V-CC0N4ZFDTR DS$ SU:9Z VSK,G.OXV8TVX'ARIL!Q;V
MEG9#!%1V)T*;''BTD$T=XA)E B]XAA(2BF"8X[Q-OM4](BY2X[VEV^ 0^'%W
M^VVZS/.\6,7!5A'X]#;/8PVH?,@3J1,+66E(@=&Q9Q-M>)(T)QGQFK5,R)KX
M -U)O(S#H9%*FH/G5XSYU:<:1IVP4&()W(+5CE9'72*>!P$6$8NPOJZ2]E#Y
M3M E F-/<3?(XOR1KG526K8<4PP,0I0<%%/DOW@>P>ED9:J5 ?P(L9&CYG.V
M5WE_T8XEL_-'/E;91H:9$J+B0!B5U?NQ$!R+8&16EA5TF37Q+QZ2<JH\SH.5
M^RA8>@NY41CA.T7WIFAWH:ME^N8NPDZ3N7FHXA[%P8%2/R8J0C%9:[*B0^:!
M;&%MP!-=8,B\UD%;,JV;^)C'1<,3&9K' D,?80_>,3E/KV;SE<?[_J_9VQE)
MZP\Z+V\MVY]O\ON_Z/^_KK_>C0LP2@OOR0>66(<7QUJIG W$D$MM=R:2??(2
M;-^7G]I^W%=MLR/*?, ;B ?TDC[SBN(_K_XFXG^]^K*#;OKPKK.TL%'ZJ* D
MG4#I7&UB7L!9Q9EC0D0I>L.E/QV7AIS&FFBXT?PZNYFO*/__\OP1NNLG=V-.
MR'F*J09U5MZU\ Q<J U@+3+:CNG34OI"J#<5%P:@MEH8,,:Q(OR5$/H>\43D
M/_$K%TRR6^)$L+K84EUMGNI( X)U='SEV]'!K+(3K!-$GGK3)<!@4&D.&,=X
M@-$*RXK1>DYNP//7V?Q'=&:67-(2N CU+K"V"W<.P=2YY^3:F^S[[Q'=WW\)
ML#B"Y =L<[I&LN1;D:SOD.QYX<8H!D(G4R-R%ARS"FI6HZY@CKGCOO#$FRX!
M (-*\Z&J]1"W8<O;^YKW]&]6/IE+V2GC-$2N:IV <(#.>#)R,/D<D7/3I'O,
M-F(N)8!UL* ;94G<I^FN,5<'JIH. MM*UHF&@!VLMB=P<(#,&UV.;Z&.^VPM
MBQFR<[FZ.1Y<T1QR3*YDE43&)C<>QT3"4T._C@2$/J)NT6[H^UEU>T!9I:V@
M ZNR1YY)L*8VNR+K%>GLRS;GHD4+W3^@Y#1Y$H>JZ$&%YR'R/=:8L/MYYG_@
M?%U].E""_H/G#9Z4_SC%&XGXWCJ3 B,=**NL5X%Y,LX"TB_)L!-N\NB3VR3?
MQ^@DT4.;B?;USMO4[U0&1,>\8L'FR%LLN4;)]SOO]DTFM"M?0*\*F*W/X)VG
MU:2L-)P,;.Z;3*,=?RI%'P1T3J7H(^X&.?<]<G]"[;[&8E6<K..320:K&;PB
MUA)8S@SK-/C]6:1C#0>5P50R=*3[.QEO<?Y?>'V3WY1[!^E$T$%9)!W#@CGR
MRWA2U0QS4(Q61>?"Z)SN%)%XXD7GK?3!1=D\Z^Y=3OG3YRKAM_.KF.^A,:7H
M?:QM&KD--6KBP!N10!OFM8BTF1WCA-Q)WWD#I:4RA@YM_TCC/_$_^=\?26QO
MY[,O5]6OVTUU$)P+IY"V,5;3T+.J(3T.Q4ENZ&RLK<D[;1I[DW#>*#FB^!M,
M\GJ+7RO%BV_C"*<?5NW&Z9P+$DTID&0DNNK YJ!1@_7%TUE7%#EX+7:6702=
M-T@&%?> X>_U63C/[_'OUQ]Q7D_#K^OIE+_@_/KK:[R^ID\_7=U\>C5-_YY?
M+>F8+&_*M]X:_YKBI]E\>?5_<UJ):[&XJ6,.5CS]D>DQ/^?YU9>5J_B/=7::
MY*P6T_EZ!:B$TA",%1 UL9^\E1%5-POE:#2?-_#&K."'.#:';F>5AM]GB\6;
MZ7>ZOHNR4DS<+O'O229WD!?K045.L@Q>@.?.@-<\!1NCM]C$<.I*X'FCKJDZ
M'L+&'ASN)V[?E-?SG*YJH."V;]3?5Y]N/OTTF\]G?]5]&C_3)\NO$\6C$4(C
M$+T$<6DLA,@,'>!&D/N7R QLTL&Z#Y&7 9]F:GD((3=P@4R>?YH8J:*TDE!<
MZE[(7 *GI /&E&6L:*]RDW;6#TFY##@<*.*'2O=#[AL3G15+1B>0.CE0S@4R
MX80&GI+5+%HA=9L:VGM$7(:B]Q;KEH#;P.':=0)$G9\7C5/ R.,G*R<%\#YH
MR'10:9L<SWB$VL=15+X-N*![BW8LE6];[\2EKU,VM -N0^W\D3.X1#L56<!)
M!X&Y^#9FPLB3AWHIN$OR4!]!'R]5I M5SSIYJ)?:NN6,["/S(R8/1:DQ5:1C
MS9TD$Z7FSRG@B-Z3N:(T-C$'QYX\U  (?41]E.0A1*9839E-(=\ZN<@M0F!*
M>31<)-VDO]:(DX?ZJ.C)Y*$^\FUPI7_?8+VE2*DDM4 .SM=[8ND*\5?3F<@I
M1:95X;QYE.""5'Z@A)M7.*]W,F51)>]J!9.HH[TX8$D&"K,8C)8NEB.D:UR2
MP7>@D)O?S-\KC>A"U[-N=]!+<5TKW/>1^C';'8A(U.@L(*=4"V98@N * ^YH
M^[)T8FE_A!C@^-H=- %#'V$/G9OUJBKBH6'"$Y9L!(*.MJ8V.P\^<052,F<8
M1S)]NQ:/;GO^J>-]^PI_-JSDANY+\&05JTPQ9+0.1$I$G&(&,/L 05@3N"&7
MQO&.:AU+3?!@NNA5#MQ'D(,OV:=J$D5!YFS*0-#.H$P-/2O:I#@Z)XISQ1?7
M3<NCJ?!LH^4A!3E\?3_[@;J[CA7.5U[)#)5(VY5F#APO"83U2F8G<M&IZ\:\
MY?D7LC$?*KF6387V:%-B8E)<8@3I14W>UI)(3PQD9MPFH8-AL9/2SZ5AS&!Z
M'+!73!\EC*I73)4*8\E!DI[V1QL$N&@S&"=1%1FL4K8O>D;<*Z8U=MHJ8.AC
M9,\.%HE,&I&BA\"D!,6M!6=+AB2D+DI@RKQW1[-1]@YICI9&0F_88Z9S"S:E
MG'"J.-!2UTBF">"*E60$9Y$=;9<HN]DBY]WV;F]#I;7,&X01'YO1[4N6*I4(
M;E4)'6T!'U0 EJ+#8E+Q;:9R/$+3I<23AQ)[@P[;C\_$[4)<R^CR":;</Q5B
M'DR7O<;<[Z.(!@'GQXD,S$1F:3?3R+ F9=6B(HN02;FH;5:Q-$E%/ %*G@@]
MGP8D?>3?!!SK N8?IU[':)1DMAZO9#,K3P<M>A9 FLSK0&4==9/;R:W4C&WF
M>"^-/<#"H>)NTF7@8<'%NZO%?U;(UY[1&8J2/*<ZE2RQ"*$V7'%&2#3"%#2-
M)C?L)NI23(S!!-^@VO,[;:]GT]60HWOI&5UH:WN!O9NX4UUB#Z7*G1@92 ]-
MKK0?H=&$7&,Q"(4;39N;1$ 4&7+)&9,R'DNCP1['QLB35]NG@$@?\3>T+U8-
M4O["S[<G'AV31E@I0!8G0 6M 6-.P&O2%SGQ);5I1K&=G%,$-H92V0X#XP!Y
M-[ P?JS+6V=UY*R$$!Y2;0:H%,9Z@\C!Q^!4[0+OA&Z!@(>D7(HU<:"0&W3*
M_9&BNS2L#C2UM!VV$74:F^%0A3VJ_P.DW> 8V$I;T8$QXSF40%N<RH7<GI3H
M.QY=0&LPLR:'P/$0\(1%< P ]!%R \6_RU]FUU]J\?6/I=FW:21.,*.% ZY4
MK0C4#((H$@H*K9.TUH8FMN&C5!W?&CA<<;-64C]%^]3WLR5>U]/QG[B\F=/#
M\V*@1JJ//'GPEJI=N=AHKIJ#=4Y:9U%XA8&C2\S+9*Q,@26TD_[\]-7%+_]S
M4_M"["'KVW\YB"RW4;$AJZ*29M$QK7)45C"'F+4LGMF8F=1Z\I">_62Q,L[V
M0M\/_WY N6RC:$,ZUOOHN<B1.3HZK'4B"%%]BR0X\W@GG8>T[2>C(9H>[WC2
M@'+KU>A8&Z9D"*GXX EB(N00&;?(;+;:J#39\<P#;:5K7"S>E#^7L_B?W[\5
MSYLL%-=VE?A:)XP+ =Y@@"0LKXE0-3F^B;&TC9J#6\D1@7E.9]/JL7]^1')9
M7]TL/\[FM7O4Q#G:ZZ(7H$64E6$%'EEMG.HL;8%1/DAR&*BAW*-DG< N.!@)
M#YK*#2?X!F&";=35-F)$F>%89,R.#.$8Z\Q+3C8+L5^,ST1UE,XVN9':3=*E
MPF$/@3?P&[91]N9FN5CB-)%=.RG!\VQ% $>4$.O: U:D%I^4])(LV-ADWLX3
M=%TJ*/85?8-TJ!55[_+GFWG\B(O:-_7#'#]]W\36G=OYQ&7'DY &H@EN/277
M<XX@@C=69RY-;')QV9&^2T!*"U4T2)=Z/\^XN)E_O7_F1;+<".(39)F1?8>0
M>+UW"=D"%K,*O1>GR.OFK(FI\0A-EX",H43>L(WQK[/Y=^B^*:]GGS[-IBMZ
M)Y;K$E6H%E TH"Q/Q+FG'2[*8 HJAJ%I0^/=I%T"-@960(-[BS_CQYQNKO,M
MVS]]70EA?4,3?7(H:N/E8A&4B +010;"::V\U^G!(.F!CI7=-!VKKUN# V0@
M08^EN]MJIWMX(-; ?O(N\H!D3Z]XPFP 5]%=IC*/!KUW39J\[";I5/>>@RE]
M$TS#"+]%DZ>ME-W&^;O0UO(^]#'B3G,O.I0B.^'C "T<&RE!2S31*DB!U22.
MQ, YI2&R7!AR$Z5NXO,>'R%/W)N> B!]A#]X*>I6PO3M=1[+*I54V]SRR$%)
MK0 Y'< ZZ1*T%3F4;GU#'GW-\2W/X=0Q:R++H3N);*=,W15&2N>R* A(. ;%
M:BFTHK6JR#!F+*(PO%L;D4=?<]E:WD>6QUG+\I8REP-C]%^(6==+?R1CNO;!
MT.B-9<ALW)PUT4O+\CEH>1]9#EX"OI4R<5?OX<G&9>@AZ$+N;9'$L):QMJ)/
M7!+)V98#M"R>@Y;WD>7@!=Q;*>-W4XIK';)G&F0I-4Z>,X12![W1?B.30DO[
MS %:YL]!R_O(LD',\%LIV/T0R+HPD+#FN4<HCDQ-I4J"D%4$C-%9PXJ4LDGY
MY$Z*+LZK'T3T#>ZA[M-S5_#;@:*FJ<T/2#J1 S^,SC;36X<1>(OLYH>4Z<*R
M\*F -<F3(Q%*[5QD(6!R)I'M64R;\H8C0> I#_U8".@CYR;MV^=7>?'JQROS
MNT;CSEEI-0-;QPPIAP4"9PA62.M5TJALFYN"W32=]OIH'Y4]:.<^C+P']]U7
M=/T_6^DJ3 M.QB@(;<JZQ1 *E. KOSIC<49TLP-WO^1L%3NH](;VU?\U37EQ
M]6&ZFNN^C3C!"DM,!#)L"J?-S&H(3G#@@F'"G&36NI-JGWK3>>MW4#GN-.4&
MKDA8Y_;^>?/I$\Z_SNY?3Q^<X/S80P?,=>Y,^V;B>.%>(I,9:>6)J+P4UGE=
M8A!>:ATFO;C83^ZO8KSY='-=$?-F^3'/Z1V?Y_EC-3]J_73MSU&GA1ZLBI[O
M&5 [AW"XH;#DO4,N$TM)*XV:?"W#4Y%1!<&<LI.]WGB89=3Q9;]_RR/P-NHL
ME8&T&M[GDP249!BF4IBS:'DRI86YU)?00TW&5V]>__9JN9Q?A9ME]8[?S][B
MO':WJR.2W^/?[V;7U[_.YG_A/$UX](&C"<"SJ(ESVH/+=5!I"%ED.AFE:!)=
MZ$'C\4^FILC:-#A;::M!]GQ'N=Q1/HE,2^92H/-;DR?&,@-7Z-!UQ@2;'2],
M-)E,V9/.$P"LE<XWL=5082U\W7K ?YQ=T],6ZP.%:+R^J3GA;^O<=U+)#T+[
M8S:M:58D>7KBA[O&%),<A4V\9""SHM2ZU@*(,8'PG">!3.C0QBT>A/S+1>,)
MU-L@*OO80OHIEUF]8XC5M;DJ5^NN;M_7ES>AEM@C^&S("V%UMH3/F8X-9BTF
MCLB;(/, FB\7CL=29(-Z@TW"?B4A=MCK7]_,JR#?YOG5+'WCQ5@RY:/)D$TL
M]0(E0D@L0%+:NH@Y!]/DE!Z2B<M%Z<E4W>"2LXL-LO4D6(MV(E$:63L619$1
M%*8$9*PD.@.XR_0Z64*3^64'TGVYX#RF0AM48?0UCY5U65F#-8V+OA1GR<WS
M=82HT$H6=-GBZ/R99F)9W[SGF*1!0ZYOJ:UCO"056AM FV2$SL5GU2: T(/(
M8Y6O'#=NT$I+HREUN;OA7?L*E;_9M)9UK6YYF?8B11&!%69!)1'JP%T+7G!F
M&)UE$MNDJC]&U:E28]IA85>NS,$Z:1 ^V*#I]DZI"U$M4V:V4G7BK)G#M3=K
M)?JCX2)R3_C7$FQ!LCA8;86K7 0LW-EH>'";PY#.#@]=4VB.!(<^$F\ @PZ;
MY.UEL9>:245;8M!.U>S]! &]AU"/9!8%%Y*=R*8YU67] !KM;[_LH8ZVMQYD
M8?]K.L]X77M/_#;]DA?+NG[^0;*HY^M=*^024R)'FV0AR<NNO3;1D52T]X8\
M;,&*:=)SLB^AH[Q8VT?GNY$UO,+:;DQWA!'=KW'Q\=?KV5__.Z</>>TOWY60
MV4(;L$20DM<6SKR PY1!1BX0.2._N?7VU(7.9P"OP=75X+ZB<T[&7;_X_W-#
MRZ5\O9I^>+58<?/+W_66)J=ON_\^US9W)5,Q*1VXK#(G89"\R: @MS>SHHI3
M-9Q^RG#!<:3P#%;&Z87<"VH-[FCN">/GJN&<?LI3^F;Y]AJGBU?IOV_69]%=
MQ:CUQ2;/P#M/<D="L>/D_:M2)!%J<Y"MC88.9#X#Y ZMK ;W*/>H?3\G^J[7
M8^0VJ40745DT(%FIMSTJ  :FH4[D<%I'(K-)]_MNY#T#* VEG &O/A;SY>3U
MFCYB^I=2<KR])'Q37J79YV_S"'4R001+&Z>6 I0K&1 -F2ZQ3KV6,MK2)3Q"
M[[L''/II$S1=";K8T&H3C0QH1W:A[RY]OP.%/4*M@V#G%/'6-BKM@9<#]#&@
M?]N#4L5,,(H+*$+1AFNB!I<PDJWFC4(L(FA["8C9$9$="V#ZJ.'(0'EP@!;O
M;')6DXIK(YWB$WB2 / <O3'D:GO;)6UIF /J9+9-*^7V.9P.T<R \=KNM))U
MCV37QSMS#ZWRS 8+C-5Q>&2104B\U/B?31D5X[Q+0&U *&U0^ SQ=(B.=FY-
M30KX-C/T9C?+6>E@-AY<67;HBP<L-1M4!ANU9^1R%>E,))4S9:T.FM?^\"D&
M&W-)<C(,"<-FY'[?%-_<+-]TH>/-]'M<[%Z*4)1"U:YP8+FJG<22 I0QD'.!
MDO'HR3=MTN:A%4.'QC[^(,V2^T9/K0&_^I[;2><3H8-T7BJ0)3!0@;:)X&E3
M0JFT3]IS'IOTU-Y)T?$C'*- X69 9!B--;C871/S'O^^I><VY#=Q60H41!:B
M=J"$8A 0$V1RXLF$D9Q^TP)(.^AY@=%@VFHS?C)/;_)BDB,3)0@$H;(%1?8/
M.)\]<.>X\9;^(YLDI]\1\ *3_?71HDSL;LN[A>MB@M+[&$,@ UE7>]F1O1P%
M.?#,)&68B\6U*?[:I.0%*0-HJ,&-X1]Y^3V@/.$AZEQT!-K",N'7"PCD5@,7
MI8C,"Z</FY@S]ZEX@<J!FFEP^[<IH:YR65]1!#HA96VLX[,6H+*K+2Y= E&0
M(PO$$FMT3!U ];$*.$8)ON/I^SPJ/X(7JHA 7H.I(R1#\.!L*F!TUH8+RZ)I
M@N!15GX<$1R]2D'Z*.EH*?]=B'HI!>FKO4ZY__N(_FBX2"$I1?X ^8R%[+Y,
M7D(=00J&<^L2L[57V9GCX:!2D.'AT$?B;3.NNV6(FZR,,9:!%HSHE=* 8RE"
M8"A5RE9FU;IUV$A3^@?0[Z'I^WV4T[8^I%,^N$Y)NE#%HKRG+Q+!R820A48Z
M=*43L745^3C3]YM":7#5G*9"[8CYTYQS@\627QN$!G)?!*#2&H+PW+NL-,\O
MJ?IGM@I.+]!>L&H0E]W785H90C5HK&T40'M$[2(L+;@0$R1DJ79*D<+(%DOB
M$**?GV=Z-!6/")ZWVT07ZEMZN(>1?QI7^'AP&0BG!^BZR07H05S$J#3:9*%X
M10L=N0:TW$-)"IESI0369&KQ&)'ZA)-^KD#MH^(1 ?367DDZ"U>T RVCK84Z
M'M!S =P(XX205L0FKO]A9)_^XJXE2 ;"YQX:WAD_&#JU%.=3LIT79'"MYM;M
ME26Z^8QA$CX?I6PC=U.)P@4K*C)9E"UDM^EL14!F3,Q*\<EC-!XJLY4EN5]^
M[?8G-9'?-BHWI$CX3-DF(8),*CCM<G220.F24RP;\T"*#^D]5)8_X8(6US3]
M?'5]0ROJ[N.WMQ\?DLN\WYN:Z&(?+C=TY71 &V(TV60E-)*NBL(B?60AR1P?
MZ*KC.P^,+$V75ZF^@/:^/W.\F9.X\N+.K:\]9>OV2/[[:OLLFT1\O\C.(H9B
MZIA,6L=UN%H$SXL"30HEISX0,IM<O@[%P$'3FOZX^513AF;S5V&QG&-<3DBS
M.<M$!I4FYU1972!8GB'2]F8-+XRG^-0"V/[H$Y1'GP(C/TQQ.DR^#4+[/^;]
MA,B#\Y*!$C6C4'$'+C$R&W1*(JJ<69OVKR?*R!I")8_F4?61Y]"#UW[.T]FG
MJ^D/G#G-K*]5_]+57@ZKR&3V1%YDB0P83,RS3HMYR\.?XW(^5,8-?,%_YZL/
M'^F4??6%4/TA$[I)AF_*BN,%N0V+)9W$)(;5H3Q1Y'R8VN5?\?I%8^WRSQ48
M9#$I5GEODH+9B\HC;P@'*W5V+(TT@,_/#];3]VU1DPB<52!\JIQ["<$XTFZ@
M[8PSS[5H<C6PFZ0S!\9 LFX0HZ<C;+Y*EL'KU^O!A"NP_G@'=F?;Y_06O]8_
M?C6?X_3#ZM\M)BKHZ@;7&)RBHX^A Y1UY&4()ON(+H8FS6</)_WX!]E00'A8
M3W1,+1[K,+MU(Q_LG]]3F2>",1LUT>E3G0+BBP./QD'*66>MZ$6E2<A]3WHO
M!G''T%>#[6['";V+\(DIR@0K R#C==YNTG52EX-L)8;(0K2^29U33SK/_'AL
MJ94&M4U_QH\YW5SG-^5 OV2='D#;;"G2)]"YVH%6D^M8+&W$S@FE,P9LTV)Y
M6#:.-I?DE*[@"! PEKJ6 QG_Z>OV!ZSN=W/,G@X#!D'6=OU%)%K?3@*SQ:JH
MBX^B3;/'=CR=*G/IE$C=3-T;"6):)+MNI>P/_'8CW(6^EKE,3Q%XFFRET2"B
M$U(/5.<I8&=H00J3:+DR3::8MF1MF\A %*5E*;7S5+P<N#V1<G2V:.NCQ:'O
M%MZ3>/\KUQ9F[^CK_"I6@[S./OX7:6SQ+0U:6A&\ :LYG0JBEI/'Z,%PCR'D
MQ,MF'?:.RX8N;QO+[<.^"IJUE.Z ]X8K O^)\__DY0.2I&0!59*@N=*@LJK]
M2$P"X6)P@DOGT792^/;G7Y**!Y#@T&N:=K0RFW^J#0F_T_5G7BZO,[G7JU_=
M5:-YQ[!H#I;;!,IQ";YVH+'6ZLALR$R'3GKN_,I+4GT;.>^,BC7.VOL#Y_-5
M1<V ^5$/GMDD$^IQRC=RGDC@TG/2A@^E=@7U":W*,3%CM)/H'N0\/<9#7YD_
M"-'O)>4M3QE$KD]1MYGIE[C ;).7UJE2M&=.1",SD[62%?WD<3H/E]W^.9,[
MG]5(CAWR)KF4@AMK1;%,E3J@&;5@R#6WFOD4MTCS\,S)A\]<_2;4WU1CF2SO
ME;5\VW5J74E7-[?7L^EB=GV55I]^*\A?S,K![6);D]1(PPWEM@$47Z)W+F>F
MO%,\.2R$&Q%3U*B3DGD+4(8E[L"N%@2"V==,1_'\RQ4=G-^(O4_:J^O5@U9^
MVKL<9Q^FM:A^W7SY]6RQO->MR!G:N9G4P'1MJ9A*!N\#@4H@;4W&>YZ;W. ,
MS,?!H8+UFVYO4QX0<M?%% M*&6L%JT_DQWK'P9.% Z%P1=]$S6671O3] P:=
MR#M! ?,)T?@@3C"\"EMTD.A$Y1]Y^::\Q[\GVDIFR?P%'D@,BB,CRS=P""QI
MR81F239I=-R/S!?@-5)IB[9(@TCN-7Z^6JY[M;SZ-+N9+B=,&YVD%B!L5* $
MN8'!H@">6>)89!2\"5(;\?.\(3T&D R8WK(*-SRZ.N^LN-^F*\I?3=.W3K')
M<&&X3'6]2E F" BBWB[&PG,=?A%+MV#>G@0\3R0>364-$F ZR8^.@MNVYG=7
M*YN62G%99A8<D*S(4M$I@9."I&BRLD4XK4N3^JMAR'^>L#TA!!JT'_Z>'3&,
M;-=)$E'8K*4WM/]C >68 8S,@W<B^N1L9J:)I="$FV/E=8T)W*>'Q5BRO-:1
MG6^QGM]O^5S=><M@A)'*@(BFWHLH"V@L!Q9*(#,G&E4:CA;92M/ILZQ.!IBM
M$T8.5UP#!VT':;>W;5V(:YDI]2AUITF3&DR7W3!R@"*.CA9>F,LF(R2&&13G
M#$).$:25TEJM36DS)^L$*'DBN^DT(.DC_R;MD!:9'OB1?*.?\Y=\/?N\ZON\
M-BYO[]8M9SXSR\ %44U,R<!'#&!88L%:[GEJ<@'0@;;CNQ #:O-!WZ)A5=$@
M-/UG7O7P_ >Y)'.\)D)?I4\D\5K LIK@>>M=WZ5=2<G0UFF@RM(7$@%@80%0
M6)F-)CYDDPX)O:B\) 2U4T^#G>>'5LN63D$E$P-$1_NK,@@A" 72H]8B\6*Q
M2;W":5M<MT/"WL(]5F[4EBOTFT^?</YU5AZ]2W^U6,SB5;U*^>MJ^?$7C!^W
M_?GTP]OY[,,</RV&S9-H2F*KO(GCR76SW1L:4<AH$I9EI1AS7EA/'E=)&%11
MN"V/HBFQ8[@6^QY?P< XR4:!*UF"\LE7FY*^*&F"#5)DW6;.R%GF59C"C*P=
M/I@HD2P?9L')J$"0R+R0)#3=I$S]N>15]$'CGGD5?538P'C]Z69!W"X61%JH
MI=<U!2M_1K*-\O77[])Y/T>B.]:/%W<6$YE2M4=57GS_LPECH69A!N <4QWB
M1K)B)4&A(U6P)+RU31SG8=EXWL ](21:%+/URS(1)+E$E )Z3;ZDJ-0J\BHU
MDT$Y(VA9MJD1?F:)0^UWUKU4VJ W2*N<D#KUP6E!KD_F!A2M)0@F&6!D1R:4
MS$75I CS)7&H :3' )(!,SH.RD(127&?"CF>H8:5$W?@N1*0C?;!.BY0ZJ?<
MU.>=.+0/$H^FLO/)MTC&ZD@KAC-7XX$L@=/20/2)DR2%S:')5(.7?(N!-M73
MPV(L^19W)OVK^#\W5XNK;S=XP4?E(]GFT=2)$MP+H&5L(5L6'#FE(?HF\^MV
MT'-A>19]@++#!SM$80V<J6UDU6_G^:ZJN0N!+?,LGJ3P-+D6@^BS T8.5\9)
M4".D\D:+ I'5+J$N%O!8)]N%+(V5WGALTD7Z1&AY(N?B-&#IHX.A6T?\41LU
M+I8XO[V<*Y&LQCI?"!7G-44M$QE,04&6,Q;G&9>=7("-!Q_?M!]8[K.!A-:B
M0N\OG*?W],<KK"IN#+)@(:!<91J2XZDQTP)DSGA;Q[^T:1%UGXH7>^)PY32(
MB.V0PKVVT3]]?=A5NG+PG8UI>GN-TWOM5+KPU-+P:,'4B=KG[8^530=L+(IN
M8-0TX2WY(+33''24&50Q!5S0=.#7AB?&1CH<FNR:YP/>IYKQC1N[??3;LH:Y
M]HAZ\[DR=&L[!&8$RU:"6V5#%:7!,3(@G&%8)"O!FB:QKIT4'=]2.[W"=]T)
M'*2M!I;>'8^K->:B]$2,K-ESGF@IY)1XYX!Y9Y.T7GO?Q'6[3\2+G7>P:AJ4
M\VXLA2[4M#30QF!:[:^>'7H^0+8MLI=_I"IH6Y30AC2"H<;N%?@<-'"'(L9L
MI$Y-)OB,P YII>@^(ATZ2+.CY6B(G)B( 9@QCD@2IAY&#JPUS 3-0HD;A3 C
M;]IZB,@[M&CM(Z^A^^YV:@QL6.1.6D,<QCJ]TAOPLA@PC%DR+J2.F[;@6;5=
M'DJ]@\MRZ/7Z&A<?;]O"WF\9NQI[<U?MXIQ#%2/PR&OE%*>=J5@!KJ3H4F2:
ML]1)U4^_ZWP5/; <A^[/<X^F^\AS"3,G-4%*6M=J)DV^;\ Z!K)24Z*RW5;Q
M]N>?KSH'D-?0F5+=.SI+9X+DWD+@TM]Z?IE+2$$YH5/D,9Q]Y^P&BAY0J@.F
M+W6@LNX]MT1&(6.T,8/)CHC,VD$P-D)FR914E+=L"-5_?^.E:GY/F3Y4O#Y(
M\3^$=][>S.-'7.0J@5O:5-(B:Q_!ZQ#)=#"<CA.>P">NDG36.M%-WT^\Z'S5
M/*0$'VK7'*G$<X@&^!V>VJB0LE<3?,VS)G,X1>^X,@DQ!V6$CEY&%;S;5OOX
MX/F-;VUVQ7A__]X!*D<N,&DHSE6XH@,7(H-DK+"V6!E-DYJ[PTD_2B7#'[/I
MEY57M'KWXOUL/3SXV^<UT/G';/G_YN7]&J&2@RT:@99DS8&09#IKE,"E9DKK
MR![$$(Y8R[ /1R.\OA@6V7L5,#3'QM#QDHT)LNM0_?O9-^HJP6_*!EN3(+)1
M@A6H(Q5 1:4@J.Q!2*N]]B$$QSN=W'N]_ME [T@:&CS7[78,\7:I5?-E0;;,
MX@:GR_>S?W^\BA_71+^:Y]<W\]K!XOKK3_EJ^N&?F&KYL+<)90$L57!<>0A2
M.I#>&DVV#R;5S4H<E*SGA<'3:73H6-(/G"S>%.+CTVSM*O\ZF_^VJ#S$/.$Z
M>RPZ ^=TK"KO!(0<#5CC!&9F38ZL/^AVON\9HVD8'0P=KWI7Q4&[Z@^4UDY=
M\R\Y_8L,_GD%_<0+)/]9<"@&:XL=<JQ#%@J,<D5)G9W9S '= 9-N[WM>,&F@
M@Q:5>?M*Z$>^7MTL/\[F*W/0U"Y/FFGPA!%0I4Z 4#$#$TXZK ,.61-787!.
MG@U<QX&% <-W/S#TH!W30X;")D.__/WY:KXV#E;VZB18$;AP#(36AL[\J  %
ML^"=MDPR5Z)M,A]I, Z>)YB/KON=4<H3[-"K+_4"O/846['")UJ56(P*4#A#
M4,8R0&XMH,7"7<VXS4VZ=PW)Q/.$\BD0\!#-]F1H7N?7+G[Y.\_CU2(O?IO>
MA1*6>/W;=#F_FBZNXG_A]4V>"!:=RB+6^T$%*B6RJ0J=0DCVE,XFFM2F._0Q
MF'M!_ZD1\W!5N$%\^E_^YZ:VOYW>5.KB?)W2/E%,9J>-AAA8[=Q1)TL91N1I
M[5/-10NY8Z7E8Z]Y-J@:6.(/L> /2^$DN7^Z^?0>YQ_R\H[,S3S%?Y",ECFM
M)/-F'7BX=Z&^@GDD3B8J*!&2J.7(E9&L%7CAB*],!HTQGIG2+<-H2*J>%]).
MIL\M0?'#;EK^B7\/QXE$HS3C'B(39(1$DJ?7SH/&HAA7*LJDNB%S0*J>&3)/
MI<\MR!SFON9G_+KX=39_C=?QYOJVBN?VUNGU]6Q!-O":@?E5S!/#$WKN$3#3
MUJXR"@@N6>!,,X66^^"[)=;N\_;GA;3F^MF"J/8E\+L$1C;%U?+K;]/%<GZS
MLB?>+#_F^?N/.+VU1]<IZ3\8H[_BU7QMA[(0@V!%@)15R%6^6-/1DPHD;$=?
MT8[*<SF(W6>S#LX(55L6TW'FAM:LSU^O9W_]4DJ.R_K3O^@OWL_6::&W>0&N
M*,MU]"#K[%,5(ZYS38H7*(W1-H?3#6/NPL&S@_QI=+\%Q<-<E>T34;X?AGNW
MZ@ET:S?1R3=A6)!K+2&*>DTL9)V74A"R848)M#[Q=ATEAN;FV:'[])C8@O1A
M[LV:'%,KA^);)&XC-VSUX<^XS-]/+LT9(U,/@4GMZ>2R"-['0GCVR3JN172G
MZ;=R+ D\SQ4U!LGWPMZ657CXQ5_UAFHZ44X_W\R_7>&L+]EWEE8L)L8A"IT)
MUL9+4,YQ\$:26RZ(<,>YMZ;-'=]^]#X_A!]!KUOP>/C5W;=F*OMWXEDW4&'9
M8K1UYKNOW<AM">"$%&"-98YGJ8J731 Z% ?':M9]:J2>1.-CZ<G]0XN03%N_
MUMY#1A5)C+) 8%Y!Q&1]]%Y$VV13'5<7I:/"X+'.27W4T;Z/3A=JGE7GI%[J
M>;RASCZR;:]QYTN6)="&RI0FJK0&CR+7,:62"8DQZ'"NFN[3.6E 1?<1Z= E
M/S]?S7.DSQ?WBI.UBLH8U$ 'J )EH@27DH,@N3.!,2-2M^3X+0\_>4EW+V'/
M!I34T 6 KTC:]LVGZ56X6:P]P/OUY4*RZ +Q5FH;1E&KR 1QF4H*/$:NZ6&=
M5/C86\Y7EX/)KL54P!_ZQ&H>G72Z@+&U2*)4<-FH0>:09)(EH3<MMMN1-2L_
MI?FUOT+.I4%Y%YY>&I3W;U#>"RO':/*\CZ+/I4&YB$4H+!(\LW0$:.2 PD;0
MD:',UFJAV\Q$.QOP]FI0/CKL]M'OD?J+9E=TT,Y"YC4:&;(%-,%"X<9*KBUR
MBQV3^<;17_3TBNO0I;2/U(<VNCLT7#3.J>AR!M2>C%(N.(1B*_>":VZ33[Q;
M[O$8&U>."R #:Z-%\&0'6<5'I<DH!5.;^2E?,:QL@"2EK;W!$@M-9GF_ &EG
M3&8 337LG_I4FTB31.;$N56L@,K60U"T1?KZ6Y\4#ZE;I^LQ-]\<0D-[=N'L
M(=ZA;8_.'2,EF6<V)@%:TFFH3!VWAMZ#TSHHS"48U2VQ>\1=.(\+@3V%._0V
MT*F=-^<J\L D1,/IH$NT]X>4 NC,LM$Z6@S==H!QMD8?S7G11B,-9ISLGM&3
M6/%*.'+HD$=B6S'P6A6(RG.-)23435+M+WVBTB'FQS#:&K!-SF*^G+RKTEC/
M=TV!<:8",!V)B-H-USNO0*$5T3$MD^HRC9L>>@\N]-,F5'YXZ_,,.^\O^ $W
MD6]$W$T&Z4!&CPAQ=QP,OT$\'<P]0 .;.CQ ? /:D9OD")N5EEY ]);,69L-
MH%<(T1;'%=/)QRZ#T<:AQ1U1S>&5V$=J ROOMICZEA!OLC<ZTSDC:P L%D_?
MD9WA/5-&H\%BNPROZJ2^']Y\O'/Z(-G/AA#<@)'#%2'KHN-;0M"RY+C3P*0Q
MH&2^G>CA2S1!.')E.EE@W31X_\UGJ,&]!=<@G'=;MK+:4IAS0G-C(>9JEWD1
M@*CS$(.1G#MI$F_2&.T>#<_30#I4&0UZ2=Z2<NL'="&FY77Z#]2<YAY\;]UL
MU_$!@FVW"]P21:Z\MK1_@;6TG2E+#A\Z1,B)B%)*E-PFI?\(6G[BPKB-DOO(
M\WBY":LMBW8UVOG>3._.-#(<A94&P7 KZN[% !/3((NVUI-_[GB3 <,]:#Q^
M:.4 ;79+(SA8%0WF3C]-ZON_9G>D&I0QE@(^"[T.)8<DZ,RSEDS0C('9)AG4
M/6B\;-3LIXJ3[#7O"0!W$.>"W)12:JNA1!:TUIFVV! @T2\YCTF[<,P.IMNI
MO'#D[*F.G3="S4=XW8LGOXK+JR]7RZ^##O-ZY/F-QGIUY6ACP%<=:.M%]I'%
MVDPN!U9GJV! XP47K&P9\/7(FTX^ZHL7982S@3RE*&JKQ@A!"DN.< I)(YUZ
M95SMC'\?:M37H5U1W]PL%TN<IMI^8G9]_>ML7C^<!,682X'V?I7K<N8<O*:-
M0R5%3FHR2;5QY]NP,\(;M6$Q/72OW %0<3RS<A^NUKWH)E$QEWDM6XN.&))U
MLJQ(&8KT1J5$^V/J$CL^)<S7G)P1P@>$6#O4[X&/4U0&/,'0CYU.)@Z=B84;
MT"124(5)"*Q8,@ZC-I(,C9R[7%L?'>T_LO$"]=,BHT49UV.=4.[9G=]ZN*>)
M+#H:9Q.X5:=9X10X3F*,EF>1,U?<M*EOZ4WJ"U[;:[A!PMBA0B2IE7RUO)E_
M'S@P\4DX\H4+L(2KNMQ,R\P4$*$(+*S6<33)<V_ RPNJ1X"1,<V!VVE#&4XR
M1*W!H*Z-AZRC=9PB%)-"D*&FG(P2]$_8V"<5[4;3NKM-<]4RNX*[W($[J43;
M9PWAR@CD3RKPUB0R8ID4+"5&F^C(9=^1U3/:CT;GXK= TPB]H8X<3Z)6OO@B
MP'!G:Z>T CYP#\4I[KBRQ/THW:2._)W12CD25$^SLGKA;%1M![KT4?V155$<
MEPPM8,TU5<$YP!(L")F]*2+E9(YYR=N"QY=E=>BR.A'>1M669M>LND>Y14<[
MA4\<R&HPM2$^@^ B I=D1[!BHC>GL; '9?-E@;5>8.U0=XKXS%/<;G&^'^57
ML>)EH3V%*T/'-9I0QP'6JEIE-%?$<SB-63@PHR_KK/4Z:XF\<8>$'F<S%>VB
M%*!];4XB@B8VLP/G@M9%6&X:A?1/X7?MH8;!R@R*(#$SD0$).80GB>!DB! L
M"[FV>^2Y353H&;9=/RC$<Q*-CZ7M^H\-V+BWR;K,0#M>P^*!+/JL4AU7[IF-
MP6)JLCE<6.?/7D!XM/-G'X6,*GKQ2,N"+CR]=/[LW_FS%U:.T3UQ'T6?#8BC
M<RYJ#DQR#ZK&%M''##:B4D+SA Z?-WA[=?X<'W9[Z+<!9G>W9F$FL6B,(<)J
MC]2D:^J&Y>18:2]#-DS%)J5_E]Y(IY?".S?2Z:.MG;F\S0LVWN/?/^4I/;XZ
M6+4!V;L<\]67G*KL[S'U+70U:#G'WF]O5.PQC#0V2D%"%"7G) 3769F WEB4
M*CO%B_7TJRVE($/(Y7!L;#;$;5+1\]1+&FFZ%V\;"HW9,F&88<AM[<7H8A(Y
MBNAYB(9TM$6A3[WNY 4^A$QN:TO#N"I-S$+4EI,(*7B>G+="B7'5H_Q^\@*?
M)^=@_C&;?EEW[;N7#N<MYEQJ6T]!;J$*LF8"^P@<-0^R=HQ19S9H=1N;([0,
MAET#QYNF>C"*QE0HU)W;V^1&Y7R0H@20V0=0Q2L(VELP$HU0*1;%VDRP/!:'
M9[12C@#5XZ^J/7 VIM2[GL.8)S*D8HS44$*TQ&=AX",*\%Y&KZ16S)S9\7.V
MQ4N7M)P.0-DITH/VYG/=A?D;GTIRR3C3A'JR$\BG$X!<&_!)>2>S8 ;'E7K?
MD\&7U722U70 RL94J/4DG[=Y&O=83<HB)F20/&T7BM@$;XL'%U %;ITH+)W7
M@GK X\N:.LF:.@QK8\KZZ6W;9FX%6L$AN>)J+U0)OLZR*H9ED9GW0AVS;UQK
M'VJ4JMA(7%K92S_C,O^*5_/_PNN;?'\%:0*F0;0094R@6,UI0;*F. K")F-<
MX9GM@GO)X8QVRK,)(C7#X5DYQ=W%,9$^.2ER 41.IT149'?5EL$Z,YNL=(4+
M<:EK\8P6X!A6P A7<R_XGM42?K18:9L@R*;+-;DD:&)?%>/ *>$ M90*BU L
MG29KYU@2>%G,XUS,+8%\QK&UIP6!7I>H98TO.@-*:0..J0(V.OJ$E6C<N,K(
MAY; RXH>YXIN">1SC._5.JP.4@C"2J\Y!%_[\K@BP9'#!%BB%!$C)Y6>UW+N
MP_[+6A[G6FX&X?.,*#XM@^RMS9%Y<"4%4%87<$8G("T:8[UA8TLD:^8OG[("
M42B=M*M3/*OOI[Q87<!F\%DG89CU/+;IN_L,*Q /BOB=1./CK$#TR5N98@3.
M0AV5F'C=.7(=K.)4L)IY[EXJ$(<%PJ,5B'T4<B[%6UUX>JE [%^!V LKQZCB
MVD?1YP+B:(N)B6QCS$R""JS4.4)D-/L44?*<N#]-5_W1@+=7!>+HL-M'OP-B
MMI;K3#8K5>XFH19#YXHM8*WPH%*(X$(AFP>+#P(5:MPPZQ\6_SSR_!&ZO\T5
M-QM6ZJ>K(7RU6-Q\6OM*_Z)?7TVK,[02YZRL&5O]^7?N!BT@V_OMC2K+AI'&
M9LF9"<Q)QH+V2@43G=0\9X;!)Q:YLEM*SO:FX^2U:)@R%FL">.L8J,@T!.[I
M-++,:C)CK=3C"NS_?O):M&\AB'M:_^7OSSDN<_KYZ@MA=IK>X3)/"D_)JQS
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M=[JF!!@G+(M:%*4&!,XSV[#:ZN,A</1X\U+ZYLZJQ(V1*D'T3I+Y'C)9[DE
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M"*BXMI$D:CLE43SWY-9>0'@TN;6/0LXE+[ +3R_)K?V36WMAY1@)@OLH^FQ
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MO_SY]NW=18[30B6.4 )WH&QQ@#EGB$4(Y4HD@WRC:GK'U=K&@X]OA!XBY-E
M$CI6D.FW*7V;W^/?>:]@T?U_/DC09R<]&\$;3*2,D&/@.2NGO;>1R:Q$C=Y$
M+LMD!V4'R&=U'!\JI=N'#"VK;;1M2$RS[*QB#LE$55I;GZ1C/AM')D3.3DP>
MI?( N:V__2F7V3Q_^_7;^>S+5=T[<9J6'[___I>_ZWUC/B!^.=";A];08%+8
M4*MABA5N;6"H5&("2Y&93$9:%BQ'Y2;#R^, +/R!\SDNK[X,I. 'CQM::X_3
MNZ&*@H8);1CW,2AKDQ?%H))<*]KA2_&3QQY\F*E%SWP]S^EJ^9J>^[6L2T2^
MNZO2&%M(() $>:K*RCJ#00G0V6LNE3$%50O3ZW&R#C(_WI$W%:MVKT@#)<_I
M-4ND/\5P=7VU_'HS35<UYR3<+'.J>+_Z,,TXI[_^L)A$%Y@H3 '30H(2TD*0
M5D+!*((+7& RG4R5 X@XOEDS($9^,'..I8D&,=S-S>ZG/"5%+%_/ILNKZ0U1
M^(8\_/75XZOTWS>+90V)O"D_W[))__#58I&7O]_Q.G'"HN=H(*7(J[.>P7O%
M <E:4<(S*5)JL="&9N0BT#D*+0_M=OW\<(E=Y<4_?OO]_6_TJXC7\69]63[1
MSD:#-@!3=7H;$09.Q@C"V<(S2I$W.SCLV.4ZO_(B4--0R@W:"ZSKNC:A/<E2
MR:18 (TN@\IU3K,- 4RFW=68R!C#%OO0=G(N A<#2GS HO1UHNT<IXN51-_/
MKJ^)MG?Y,]*1NT)H_1&7F0ADSN0@0895'PP6P>F M',%9Z1E)4G9:3OH\K:+
MT'@;V38H9+YW4OW^?;?ZUWW#Z]>UX?7+G>%5R/\O$@/P*.D(JU<+7K(",@NC
M(P:?69-@;']2+P)*1]+40VSIP4SDO'B+5VDB@[8:&8)")NOEMP.'#B')8'(B
M7S=L;B,#6[AK.BX*%8?(^*'*30/[DEC\/)OC_&NZ*O1YGL:\^'R;$X$QSFZJ
M*?WAUKM;W(3%5;K".?W#B63".PP6I*]%QICJ]:52H(V(WJ!(-H<#K-"]";L(
M )U<8P_19P^,ZBQ66;__^E]__J_[0839=)Z_Y/D"KV=E2Y"!R)Y-M_#RD&'B
MSG ?,$/4U4X3A>SU),ERSV2SR62*]]V&PS4G]7(0.BZM/L2L&V3'O(L3+-:M
M>NZB8K]-;[M6D:RXH2,\Y'J.)V; 661@.:,S/42I9;?[T6[ONQST-)#O0PCX
MH2!PSZS;3J=,460B!H0KCNC,'E (.MR]UM(YKT+L5H+:XZ47"89!);TE3+=W
M='E%Z&;0\1YU#P#]:IKN,?-'7DZ4X2E8[Z"HVA6J& U!9 &,#F=FO#/%=KNA
M.(B,RX'-\;2Q!4@'UK7/EGA]=SK2N3?_D!<X39_G^3/Y"LOJ-$PB-RYGG@C?
M,8)B-H.O*47*BL@"8D3L9M1T>-GE@&)HR6Y1_<'QW:V'W[H<^_IZ]E<=N3MA
M/"B!5H.U-1DY%P'H<@#FM>$BZ!1EDV!O!]HN BRM=+$%+P<W)ZWIP^M[K9R^
M76O5?8^<P%@OM;9]/M$2BXF)$]5U8E),'D)R#D0VJ@Z%UJ&TB0;N0^UE8:JY
MOK:@;,B \WHEK"Y%)L()SIFW$)0C\-=^VTB2 )ML+LPC*[9)A^GMY%P63@Z7
M^!8@'!P=WFZ.KVF3DKL@0P:K#!V==&*"QQQ!BV05"PZ+;XV&39HN%1('R7X+
M+O8.(7^[)%UO5=,/O\\6B_NLDT45> F6(^C",Z@@%4$V..!&"(_:,8)NDZOI
MG21=%"H&DOP64.P=V7V4ZU>?:@QO(FS 6LD$(? :="83VZG(P*18Q^ Y[5.3
MLO5':+HH6 PE^RVXV#MZNOMLVXGA/V_"?Y-=]'Y&?OS5K3$4LK/>LP(:$X)R
M'L%Q^F)3RI;Y$@JVOLK>@^R+0M<1-;@%@'O';N_(_]=TGN/LP_3J_ZY8N$WI
M6;S_B,M_SVZNTV^?/F-<KDWRJR_Y+NL#@^ E2PV<ME%06EE Y 5X3?N(KK D
MF@!O/W(O"G!'T-B69+V#\XUWD/V]%B-/\;I:<:^FZ;?I,L_S8GD;L9PPH8MU
MR8(O28'RS-$BT0JT9L64$)3(33I''$#S<X#<X+K;@KN#*W%WTKXF\\WT7@;*
MJQCG-SE-K))>.4:0\,S6<;]D'Y#Y"$87GWA$@=@DJK@'K<\#9P/I:@N^!HA2
MQWG&1?YMNHOZQ3OZ?#;%</WU+9D$5[6S =?6>HL1;+&>=F,=R!^Q=/87F4E2
MEEAJ9+CM0>U%8:R]OK:@[.#8]E:!K)MD.*:BS*E.]0N:%D!,$'1)@(KGHI4V
MFC<9P;";I&,UKSFVS]A?WJ=N1;,UB>1;,<^W9NJ(+'.K2,O)<E"*N/$N.$#M
M(\^&J^+]7ODY#UYUJA8T0^GSL>2<P^3:JEAJ*W6W[1VZT+>]$<T^^C]%NYD6
MBNJ,@0.D? HT)&E<*)@@>S+7%3.N-H(E8CW/6*++P@VP"YR@%<T80-!'N WZ
M$543^OHZQ^4-7K^=SVCG7'Z];<T2&4/&H@"ODB,'S1MP7G H*B2?'3-%^Q;V
MPVZ2CF=OME'?@Q*'060_\ 0(HJ3F@;V9_YGG7Z[B>@F49'-VEHQ;%*56=!*'
M(ENB1XD@;**CLHLMV:G5]C8"+L0\&$2^ \]SN*6GAFAN*5K<8KL+44-/;MA)
MS?%G-!RNJ(=:'TC* _?5WTV<HUT'+>=@A,]U'RK@3)UX8WTRAD?E1)<S8(RJ
M?V3 PI$TWT>X@T^&^N7UK[_]_,N[5W?-_NEU12<//BD$I9%\XNP9[6:U4#>X
M&(/J9.-M//BXDQ(&DO5L($$UZ\[RYQ*7ZX&F>%U3+/_\F/.2F'Z5TDJZ>'VO
M9>I/7^F'S[,%7O]C/KOY7*/SUS?I:OIA:Q[=8@5V;PMFA@C2(0E)FE6#U4#2
ML[4+C9!"\#:VWS'8NQ!K8L28&+";P[VLT.X$WVM5V87LEDUU]Z3[--UWQPBE
MA]G!1\-! X=[7_*U2)$[[L%&0P>8M0702H3(Z0!3+*&03:+YHX+O$RV%+QB]
M?=0_?(QP^@GG__DG3F\*QN5J*,1W(F_MHF2#P:QX[?I5)X^@ *=XJ"$1F66Q
MQ6X.X]H9)'SZ;<>_>#R*WF8MA3YPF.A=G7NY7@[11,N"A60+.4;5&'8,':#P
MC,@B\OA@/N*WMUZ(";>_) =LF?2-B%M4=2%CZ+C/O?<?/]*SIP8V=7B ^ 8.
MZ-PG)Y?L_W_VWJVYC5Q9%_PK$_..O7&_1,P\V.[+]([NML=VKQWGO# 20,+B
M.1*I15+N]OSZ25"B+-&D5$6B*(K2ZA6V+G0AD?D5D ED?EDB5\PJ3BN0Y9P%
MXP)3H0A7?'9!=PGECL.*#QS:M#5B'ZTU-MX?I*F+JXL;061M?J"<9R$%Q73R
MAD$EA[42N2PY>M^I/TPG\]T;^; G-SOK?MI"<8WWQC_@GSN" $\J9BF8Q4I?
M94)AL<C$#!2KM474MMG=R;V1GZ$%=U9<:Y_WE_NDS(O;NV '@FL/#"QFIB$D
MYFFV#&T,7.1 6W\WII(M YR(7]-,APW9^[;)M,K&Z"!5KYR7K4,]0:9+$U,\
M8ML]]'B MW=U7^]L[8%)*Y.K935%>^9+ 8;.N2P-[1@>CM&Z#V6P'-"X?=0W
ML%%)66>U:\?%M"28G\$DU[_PWU?CKW!>&Q/?["(*(7DN%8L.R _ I)@WQ9%2
M0K39RQ*LW\7B'<<_<,Y*(],]@(8A]-[0_UJ*O"SX7B.-736<*A*+C9X5(:L:
M!# ?LF="Q)!<L%S);AOX]C&>O\D;Z6^ X_/--;MUM9,Y@A<>64F.HKXD(HM>
M&2;)4<PY"R%LZN!F-ZJ6/AU7KJWF&U+S/BC8G2/8+N(->0'XB'Q/<]'7R)I=
M,+*G*0ZUB-P]M'?)18P4>&H;2,R S&O#R7N*,A3:SKP9I&/-DR#ED3NUIP%*
M'PL, )!?<8(S.'][1=X.SE=;G^.H8[6<-(XS[=$QST5A*8B89=0J#W,%NU&:
M(ZF]V]5FT]8*'R#7ZB/.R:E*9S?21*."I_]8@E)3O8UA7LC:?L ;Q8OA.@]2
M_'M?C-.R^QXJ'J08XJ:*^,W5XFPZ&R^^72]T(:,%F9A#ZRF.]H*%5#03F0=R
MIU$!#MO [)XX)^96-M!Y0\+][5*M/)@.<@WI3&X3["G3Q?8SWJ-XV$/S!UDC
M;N2S(>N2:=DRE4];!QX9"!68,EE0P)U I$'ZB1X6$9TRL X#B#X*;WT66;LV
M2"Y<%2LM5KN7YNA43)4ZA]P5$<E=\84<8B=,D+GPXKOET&]Z^N'W_3:*G[;4
MV@!.'LT)YXMQ>E=IWV:K^CM$;1#H??-&J,HAJE@H/#'Z(3=*6UETEUOW_MF6
MFZ1YYJ9OI^D!EO-ELFAEMZ=/GO_7U6P\S^,E"?XJF2=;+C()%7.EN:\3CIF6
MKZP,"!<-H!S$Z7]$KA.!1$OM-RR+7(EW<P)^'[ A"PL.)0/C(X4[Q3*@=8I%
M=#DJ+"J704IC-@ES(C#86\];RTW^K_]<T\SO].WR%\N?UYE_Q/)_U+__^OC;
MK9;^_OOO_XCCZ1><C#.F_Z I_^=227=HIMY-+RZGDWK?-?VA*W+MF'"'?GC5
MSOZ>L//QQ>4Y/N8.[#?@?WZ?Z7T-W(QZ#QD'F#/^L\!)KJ[>./_?_^<XN))C
M5C%&IW04T:,K$H6*O*;O:3MJ-OL]['Q#D]C&AFL/:VV?AV1=T[W+AKPKJV16
M3@LKHM*TV>;$#0\A%#WJ)/4>>GUSM]_>7Y.$,WKZ9/%M?)?+K8W6>PW5VB:[
MSW/-8MYD2)P"*5I?=9!D)"NTDURGS#$)-6HPX[[V7-X3OYM.YM/S<8;:J'4\
M@4D:P_EM$<[U*+M8L/O#F]ALQ[FL60F-<,H&\B4HON44V];I**YL2M)S84<[
MS6HPNRS/[W9ZO_H.<5@;;9K7^@HH(V9'X69R7@?4M WE@$9GC0(YANZ6^G&&
M@]GKT]7EY34%')R_@_G9+^?3OW^K_2 OEG5!>ZR7K44XK+UWT<L:'B04GPS%
M%-$)C9X'(4N(4KL00Q&8NN.AOX8&P\N?,*L58U_W\5]V'^RP&'AXKNOK= A
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ME(_,6:VMXEY+UXPNZL035'KAX;$$E3YV.5AV0A>A7EJ"2B]#=4I3V$7+!X-
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M#53[  R<E,PZPX4RF&UJUH/Q=M07[K'L;H$!>QMW$>-$>QOWLL"6MKB[J&_
MWL8!O%0>D38J5TO#:SIWP,(4R>@%QL!YVY;E3][;N(41^VAMT-[&WH:@;0(F
M:\RN.<7LWN7 /$B9N06@W[4RWY'T-NZE^ZV]C?LH;M#>QM9[ ]HH%E%J<ARM
M9]$+QQ*2*^$UURYTJ:M\3KV-=[;@SHH;AG3D/LE&O1Q Y0)+AIQ_G4IFX%5D
MJ: $#CZ;];O%5WZBQK[2WG9I6.3V,"]'%Z%>&C]1+T-U8JG91<N':ZZC8X D
M!;,ZE[H#&>:M3PPT(J9D/3<OI;-*>\OW46[K(Y)/[W\2M\Y^XE(+P] $57U-
MVJU<E"P#CSJD$C!UH]?X_LQC81;JI>'I_NII3=;_Z<-O?WY\\S]7[5VT-<X8
MD9G(@38:GB2#E,A%*5K8[)S).76SU+WG/G]K[:ZFK>_5P8F>?A[/83PHT=.]
M$0Y$]+1]5FM$3V0K $C*\:RUT!Z*2!QTD,:3H^5X!Z*G>V,=$=&33Q2P40#
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MB+=O_I2:"_I7/Y_C)&+".>U?]SKO#9H=VD2R V65MM?B6C:JR5R)H% $P[4
M#3+[E(7"FB3G7>J0C=I$QB/*8E4JIB)\84$6BHL1)'UUPS&'P4NK1)<0]/EF
ML=[P%*_24=Y^N]\5DT"B%#A:ORRJZ[RX(&EA$UYDYVWA%KL3UVT?YYE?P/9!
MT0^<=(VTW[I*XT8TLNGYDC;O[_'B;#R9KZ*/^;0LN8QQ) S/SF7.A)$4=A0;
M&84:)'/=LA2%'LZ[/A!Y=,07#I:V%FE^7GLMY/@&T?$;;2'WNG",HK&5T]HP
M#KP6L@!%J,EKEJ/4BA#/><=^<8\.]<*!TL@&#<_U!CS[1!^4TYRBVU0B.<Y)
M,1]3K#ENM7.S<@6ZT#&\)G0<#JM'@H9C2>BXSN6\/=[[O?Z#:O9ZM*>,!5&*
M9)D;K E8-6DO>N9+ K2!HGP]2,O$!V0ZH7N37FC9F(&[O]4&N(3?(MK-0447
MX89,Z'A0NJ=)WVAFRVX8V<,0!T=+MMJ*R@[ -2WMM*H'>D6 LU22B4(71;\\
M$90\DH[Q-"#IH_\!P/$)S^E77W[%"<[@G-;7-_F"E#U?7*^N-P[G*F.A@!$N
M0F)H*\,3+:(,D%OF1%#!I"!S[G(QU]\7ZR/EX8.#AA9>]Z &,T_C7)"-'"0T
M> !PD0G4Y#$:1.:E &:T!BN+SQQ?Z9N&\V2:V*5Q\L=V.HTN0KTT^J9>ANI$
MXK.+E@]&WX1@<];<,ZN-8]JF3" GHSF.V>=@0@G-F!>/G+ZIO>7[*+?YV:&D
M-0HF^>8JZ6:[$N11V66S7DG":&XUJ]3++$2=G 7I079KU+3Q\<="$]1+[].F
M2AL@]V,+4WN*B0<TU:?A3(,.C-P0FFCB25HT7 V3_7'JQ2G[G%_L;ZD!BM)[
M]WKH(.YK<<K^EMZW)<<.9CJ"XI02$F;M BW-M?I5*F !M:<@G].:79(M:I!P
M]BA0M5M+C@."JH]UABQ.T<$[:WADR5J@#=S09NLP,>$UYSH7R7E'-^4Y%:?T
MTOZVXI0^JMOJK!Q1TML;\O%@<G4!\1@2W1Z1YLF3V_IH:RVA#35YRZA02$$!
M3T80(@?!94PA04ANKX2V1^0ZHB0VJ:QP*#V+N5 4B$4P<$8RRZ5#$0IJ>!%)
M; \D/'@HUB4C6#(@F';<,*A4K,Y&T-EF(WTW.N!33SKI@Z6>22=];/!DV6Q)
M(??&.U8RI\ Y:DNNB\U,^2QT1*.D+'V <NK9;/OBI:U%6CMX#_ H:0 K0N0,
MP)./6]M1QV E0W#!>N>%S]V*D4^6O6IG:#32^@"):]WXUFRP6(H(3$*MPXW9
M,_ 9& \FQ^Q\@6%(6%X"6]XNH!K.>@.<?0UP/NBS*:0?RP1-B<)Q#RP*Z5CV
M27JEO==ZF/OXU]S(?2'[Q&AXZMS(K1=?07OAO TL&.UI$A$9B*R8UR84E4..
MN@O[_&O.0$\\/)8ST,<N![LP[B+42\L9Z&6H3C?'NVCY<!!0PM1C(::7(.=>
ML!!$8E+Q'&U1,I?6.4;'FC,P@.5[*+=]A+8ZI5NU@8[6QD@A 4_9,DW;*_-)
M*):=H?^$299WXXY=?_*Q9 KTTO:TE:H&2!)X*)/6QWJ JPT3HIX56=J4?&U7
ME14WJ)3+9MV*KP4/PV[YK:TV6'2^+<&VBW"O!0^[V;)7+OLNACAXP0,$M*E$
MQXH4F5X1&1A$<+4W TI)?^1D3@0E>Q0\# >2/OH? !P?<8[TP#-:6>]T[K@Y
ML[[9/M$#)@&&A:*7!T6*A1@BLSI%VCPS%!QDC^H@V[$5-_2RYG184PS@R?2K
MOT"KI%6F,'+=:FYF/<,VP)FB!VN7HDK8I?WLRRJ/V0=!PYEG@)5G<T:5RHDF
M6!1SJ,A5-YZSD&QF(;M,WAQR@$$(DD\]=78?3WA_2QU!ZFP7<5]39_>W])Y9
MCKN8Z0A29W,6BEXCQ1)RQ[3SD4$MB'6T.2?)31%\$"_Z*%"U4^KL(4'5QSI#
MILY:Q6EPKIA$U"2'50PR;0DT8^M ^^+<6D'7*:3.]M+^MM39/JI[#JFS]-&_
MWKT]AK39!R1Y\I39KEI:2Y<M+G$C10H\>ZT<1&TH3->9HB>O,>W'__B 3$>4
M*IM,3"H6P4JH@6(0FI;7DAD:'DO)$2C*>.&ILE$7\!D-N<2UD[:E=250 %V[
M=$E#TX/HU6NJ;$\L]>5GZV&#)TN5];47"5",[)RC^4N.M05-8@JCE2",RZ87
MD=^II\KNBY>V%AF"):9]?)Y2DHY[Q[R)Y-\ O0-!%,,"5\6!#"[95UJ_XX+L
MD:#AJ5/7NER?0 K)*&^8*TXPC5XRL-DR^AFXB*1]'U]ON0^"EAZWW'VL=OA[
MRP["O=YR[V;+?A>8.QCBX&C1WEBM F?")V3D= ;F%;TQ*',V/('!]2*69XN2
M/6ZYAP-)'_T_T2UWC+37.Z.9$<8S[:(@$24R\@QX;>/LO1^$^?$9WG+WLN8.
MM]Q]3'$P4I^@54H4KS(3) 6HN=(\(.<L1ZY0"&/],%D0IWXSN8_WLK^E!LC.
MZWL^WD7<UYO)_2V]YR72+F8Z@IM)E[3/VB:6H%[\(RVHD:;!1#1H:$M7Q70I
M"'B>J-KI9O*0H.ICG=8WDW^]>_OA#&87\.G-C32)IF8,[>:9HV0Z6EJ4O52,
M>U 1%8!$V^F@\X=''_\M92]+3)NI\7CN*M^<_V^<7>!\T&O(]4$.=,/XX-S6
M+@]3#JF@X#EDHXM47@H?$L_6($;OH,/EX?IPQW0OJ&A^%AR%>)Y@;@5GGGM=
MFVA&Y9#^LH.<Q!W-O> '<G;IP?"%5OZ/TV]POACC_,V<?GR_)9G"S#F@8 8*
MQ3B99A44.EH/LI4$CQ1RM]O!C@,^]SN?'KBZMWP.88_6-X6W<GV ;S5F(>'&
MT_QA.E_\\M.;-Y>7L^E7.!])8X))M'D8E9>!C&+@:>TO&+PW7@O1L2"OTW O
M%2_M;7'H\Z:?_TGG5WD\^?(F_?MJ/,/\V^3#;)IP/G]'LQAIT%[6WAH4%.=:
M:I+)$2$?-"J%465E;*=N[VW/H1Z6^05B\="6;GA.<;WL3LGI68SA_)>KQ=4,
MU_F'2,"+B_&2*.;S]//9>)8_P&SQ;?E^_3.^@ 6>?QL)P& M)H8A5#IFHUD4
MO# 7E(VA**G7;_6V;9'["_,"(?@D=GP>1$#%J4RQ5F'!YYI6Q(%%4P*3M/;3
MNZ4%5X,<>KQF4^R]H#XQ&IXZFV(KFP6"@(P"F1>.)J&X85YI9$$KSV5$]*%+
M8=0K$5!//#Q&!-3'+@?L'/.X4"^-"*B7H3JVD.FOY8-!P #%R$G5=BB&A(O!
MUL8HD7%I2]8B*BN[5"0=H^G[$@&UMWP?Y;8^MO_77W_\_/&WS_]C=6[MDI((
ME4Z^-B1..C,(V=->&RBL2(;35#LYX?>?>RPD0+TT/6VCIH.E%&A5A(6 C&=>
M6R$&SJ(VD?F8!<DD0["#9"6=>DK!+AM\.TL=04I!%W%?4PKVM_2>M[^[F.D(
M4@JD+-846=.S:C.^)("V4ID8*I]3K<<L9A".AJ- U4XI!8<$51_K-"<IO+GX
M7&VZQ1C#-6=8%.V\R4D6*_E>3BB3D!!*ZD@=?^^YQY],T,L&TS8*/)Y,@K>S
M\7PQ/?_C&\[FG_Y]-8YQT)R"[<,=*+N@XWS7BY1-SI(K'X4@1Q9B0)]"I6C1
M-E2RR@YY!ML'/J*,@VQ]E*;RRG,=F<Z*,P_<L:*U 4_^-^A!SF*/(>.@Q2V1
M,TE*=,",-Z;N'>360JE-PRP:,(4K,4B3A9=[']@'L2WO _M8NG6*PP.M2!(8
MCT#[C[6<Q J.0F>C%)/191_1Y "IVRY^J@U@=@%,2ZT_CQ+G*)7#)#+S-@BF
M15RR&"J6%*++VIO(7R_EC@ND1X*&I[Z4>SBXLY!4J9- ;BFX<\!9X";0LEVD
MX-8(IP>A6CGU4[Q>".ETBM?'4D=PSM)%W-=3O/TMO>>!RRYF.@)TA61="O1V
M2Z!-09NLF3=!,I=1H=1%T-MWLJC:Z13OD*#J8YW6IW@_'BO<".5%D-$D8,HY
MSW0*2 HHY$(4GKGG(IORZ'G.@R,<_\E>+[M,6RNU==3W6\V>ALF*>U5P"C&"
M9QQUI>0,M/5*#"SD@KD(R9/JQG-U[[$G;-/=U;?UE3U\V5<B 6#8HJ][0QRJ
MY&O[O-8+OHR-5E%<S9/4,=J08C0Y\5 H .?@NQ1\W1OLB Y?A<"(B>*];&*E
M_;:619LD YX%#S9+*0;A)3Z&P]=;2KE*);?]I&7^WV=(KS NQI,O[W!&)IQ\
M OK(9]+'_&QZGD<@BDA*%!944$QKH2@0J7S%D%P06GF9<Z=UL8$PS_RDK \>
M?Z &/*0=6^^TOTQG./YR+=%'O#[]_3S]/!M_^8*SVZF,!"AA#*^\QKIR)9?
MO"NI,F-RY6D/@74>\2U0ZS;>2T73 -9HSAO>E0O3<(W<<,D4M[%F-P::O^4,
MP0MAZ(\87>?5Z06PD^ZU!#6WR #)8@,<Q06TSJGLF=.A-J7AEGDED)60+?!2
MI/&#<!^]'MWO#-DC0<-Q']UK;R%8[5F)PM6.Y:'FUUAF<HG%A)##,&P(IWYT
MWPLAW1)P>UCJ" Y7NXC[>G2_OZ7W3<#=P4Q'@"Y,60+'R)Q*A6FND$4C/;/1
M%L-]RH:KDT75;@FX!P15'^LT3\!='D3="%*LC139:I:$!Z8SU\SK7%@&*Y/C
MUH/HUF[H[E./_SBWE_ZG+91W/*FWRY_<5=B@![M;1SO0&6^WV:X=]SI5DZEJ
MB9 L.LK@O?6(*@@(3JBL.QSW;AWWB$Y^/1?)8G(L "2FI5;,1T,.(08NT*&P
M,,@><30GO[^>3R.<_SY.=>.8?+G')O7FRPRO-X>+Z=5D\>D,9CC_<#5+9T 1
MR2@8H2WDQ*S-IA*S"!9B394*%( 5+PMWI=/"N;L,S_R0I0_Z[JW!![):Z^/=
M3F*O"YQ U"M>TD^L=<F2=A>0J%G!K*+6UH7<C3]GE]%? 3:0I5J[=)T$7HGZ
M84:?^X"SY01&WO/ )?D_KF15?9C,@#9")H-S-F94*85V -LHPRO,!K7: ,?'
M#U8PC'A40O)"<G$A2#AA6+"6,S HH40$E0;I4_6@5"\09.VMU9#9ZYH7^9+4
M1GOU)/]P4_L'X?GS])X.*RW9A,(N87561GCFLZ.PBU/L18%68HJC%01\^J];
MS+K3\"\02 >RU8_HTL/OBJN7X\Z;\1&_7)W7!W^CR59R/)RE\89D@A$WQ?$2
M+7/)%Z8Q(X/*!QXBZ;A(%Z7JEO0QM*0O%;-'A8 ?X6V>LF;4YIAS/?A2&OEU
M.T,?76'%>Q#:9Z'#("4I+[=F=+ ]O*&E?P2IW6L-_HRSBVE)=U\\6+UXHV)J
MTHS1-<_*UMR9FE1;J\\@>B,"%BC=JD8?&N4%@J:MYG^$A#M L'J]PG["FD=#
MOWA?/L/L"]*2F[7DR5"([6UM_&6A,.]C8CD'3K)+'B-O&+!ND^.EPNJ UOL1
M>/Y@P'N3SL:TSM8OWY=?QK/YXKL;4%,";UV!^4B:D&B;ERRF8NL+53G%*!9/
M$ !-@AQTMRX0P\CW"M0GL_:/  Y/ ^!/EYC&99R6R:QOZW'EG1DI*80JH?9/
M%)4^,7D&V4262E18DJ,HK>%-1E_Q7N'[5+;><$B]-\?E 'EDN8 0W I6G*JL
MG:7R:%G-0'IC% 3NY"!QS&O>Z=Y!S1.CX;CS3GT"5#H9\L[KJ^H4O:K%6%9L
MU@8#)AOR$+@^];S37@CIE'?:QU)'D!G81=S7O-/]+;UGBN N9CH"=&'4.BER
M*0R*6H=00STC+<,$7&A5O):#M*8Z"E3ME'=Z2%#UL4[K)(5/\ 4_G^$,+O%J
M,4[SWR9I!?6@D^8N,UOJDNPHG(H:@''#$SJEBU;=.".V#O$,,E+[6&;:7*VM
MDYU^P@F<CS?+E54H$1W-LDB@J1I/4]69$?QSD"K15+M1_CXPR D;O)5JV[_?
MDR]P,5T3[#96O9$PNIBC5)8%N>R<K6NZ 4CFN>.99LZSZG9:UFFX$X9!>W6W
M[A^X3(&>W5Q<P23G\3Q-O^+LVVT/[%#)3Q*3-$>FN7;,6UJN$@(&R4MQLELS
MU$<&.F$0M%3QUN2>@U<H?(*+^=7DR]OQ%"_'PY8G;![J0+4)'>:Y5I@@K) %
M9'8V)5T2!R%-$,&D;*SGVG0H3-@\Z#%5)4@C94VDQ0CD%&LN67#@6%+%11."
M_:%;T8E5)?PV^8KS93_.^=MOWQMR_C;YKRFM1_^BGU_-<-G^^G:U'\4LM P^
MUG1V"B(2T,:/GM0794A""<RN6XNG'09_[D?T/?!VG]IK8#NU]LGOBO7^[TG-
M)1Y??N^M?G<.(V-Y3)+"!L$Y,FUK+RR,B?D 2LJ01>F8VM9CT)>*HZ'L,L!I
MT,__OAHOR+E8G$WS'?B/- T/.A;F$BVL&J(FL31GM#$!#PK(MQGD$F:+/"\0
M22TM-$#%P&:QEFB?WT/[*#N70W8$:5D\39Y$CE8&9JQP4*PS=IU =$@H;9#P
M%5R-K=BZJJ"SE&^Q3&F'OJ6+6]7:W%'<* >4)&UBB?M*O2H,\[7FQJ&+3B:N
MO>U6']52JA<(P:>U;,/2A)5&5SGDGZ<W6;O;5FZ1N1<4J3.?K:8M7T4&D.O5
MI2E*>BQ\W;5OLR!V%? %@G%0&PY0)[!9K)_&I> ,)XE>E\7?B)-W,)M]JVGD
MR]II4N9?$QK_O/[H^@FC7 3XJ!,K;EDQ5@2+24G&@^>0M'!:V,-MSOTG\(*Q
M^B08:%U.<"W"Q7(2X]M)1)B/Y_EV)G QG2W&_]_RR.L29^-I'F'2,@(M\T;5
M<U"4B@6,BJ'DS@1/NX#NEN.XHP O$'<'LU?#^H25\GY;DG3^/IW/?R'%;EG4
M_\3%^_+3^.LXXR3/W\]^&L\7LW&\6NINE&U0M*AG)G6HC2"\8<%7+UA:"KZX
MM":5(5;*_45_@5A](KLW+'#H-8.15A:D@4Q2:7)"O \L9F>9,^0 .X=2KE_"
M'A"<K_AK:+V&)0BWEYOY?UU=B_++=/;FSMH]\LH(XTBF7!0GP81G06ID7/K@
MI$PYQT$BE:T2O6 HM;%2RQJ I4/PYU75W_OR_O)L<0;G%]/S+]_>CJ?S\<7X
M'&8?9M-\E1;S94'KG%3T<?SEC!"?T+A4"/$\QNH.J$"!E,DLH[1)T2\=[W8;
ML=/P+Q!%![+5!GCMEX.T&TF%*P#2T0I*$M*"&K5@WL7,E-;9. _6HN@$KQ=)
M*+(KO(:WU09X#4Q]!(;BEJPH(HZY-E EZ:(+R$C,8!&*0O5*?73 7;"=M39@
M:>=;BMOCPQE>PCC?B//F)EOGS7R^K)16R$V.DAF.@6F0))R)]9@E>V6MMQSD
M$%!Z2*@7C*1FMMH I/UHCAYH$&YT- 9"9BY;H+TX.!9Y<LP6ZP*X1 [?"V_+
MOO/NU4CK&]"P\VG_]8G;?#&^@'M=L%:[ZE^79):[I<)WEL3-/$?SD?#!IEB3
M4FF_I26R\C4D7SG2=18Q6ZYYQ\Y!3>5ZJ:A[0NMN0.J U$ A>.-#RJRFM9)D
MQC PSC"NBX[HY"LUT!XH:J;Y#9C8CQOH'04$,YKH^\LJU,__5,3.\1?$D9#6
M\.@TDU'7A!*CF->TLAHE*Y5@ &.[ 6+K$"\5#6UTO@$*>Q]F[T-Z5C"J8 )G
MF0+#V@\K,P]"LJ)L0I-SS&X0]_D%T]L-%:<UM/0&E.Y]'OY+-1/^3BHBP1:D
MHW$\Q^O X,/R-O.W29HAS/$GO/Y[E)/2*BG.D =R$$5)#!+08LNS31)J1^%!
MLBAZ2_J"$3FL53=DV.YWKK[EKFC5$I?>ES*^IJRG51UL<#XRY<%6QA9D465D
M19I0,BI%"_T>&8V;QGR!.!K2*AO0L]^Q^3UVJ>]2T9([*EFD8IRJ="DT=U60
M@8B65E=EO/ J1]&M2'/[&"\5'8VTO@$-#4ZYO^+DBB)$7PP$B)+E4LDILB@4
M#4AD7&%*(48->9!,@94 +Q ;>]E@ QCV/J;^Z0IK.L*RBA27=4ACDBI:'G2H
MMWLJ"J;)TV*QMD&+@>:K:':9#W+9OU&:%PR3_:VS 3-[9[>35)^G]V5Z=S6;
M79]%5?U<?S."XB 4#LR56I:D">4^)LFLSA1X1J?L,&TJ.\KWLG'5W((;D+9W
M;OL %'$@P><"H=(D5,)T[E@(I$!.#HV*N7A:?8< Y2NEY-ZH?6(T/#6EY'RV
MN*."S>''CS]%_!,N<$E&)EPREA?-9$X4Q!8M6<Q9L8A6Z2B4=JY+ @/)<0?V
M]-TZY/<5](0(*7OA:_H$=FY81U[EWB;73\L-LI-D/>@I.R'Q89$.RT!Y6--.
M![7+89'C.2H+&5A6Y.YJD9%Y;RE.TIB<<=(*,,\9,5O8)8\5,'W,T9Z+;D5R
M=).MNLZ+Q@/:4J.BXBJ/AH\4']5P2;NL$A@33>J6\OG82(>+(%J;9#J4/AOR
MVMR>UL-X]B\XO\*WWY9G]._.83Y?@CLJZZ2A>$1(3^&)3)J!29PE9VF3!11N
M&#J)K1*]<,^EK<4&8"JY%>SZLN</A/G5#//[R4>L(>^8WH):OOC79!KG./M:
M%?';Y/)J0;\FW8W/Q\OCW+NSNGGYNLQK2-[MH2;V- 3=C?"S#97'8/P!^)L&
MFY^SAB.HP@QDQW2T@?F2$I.2)J<XQ+1.X?P20?T(/_@SPW0?FP^ Y>K?3.@C
M8US1J$8=2BJ"/%=.>Z+F$FD_$I)!5IA :!7=(-SS/TAR^&/CXS#R#^6L^UAH
M #?Q)K<(\V=,9Y/I^?3+M^NJM1OQK+4J"9%8H%>,Z5P,BX;\8Y#91\&E]7:8
M.ZV'Y7J%4W/K#; >;>[N$+P2R*VIA;8US]H[YK67S(:DG<3B3(Y#0.K4V_CL
M$WOL;ZF&E'6W!=L].<.[B/O:QF=_2^_9<647,QU!&Q\55%8))>-0;W4MU+X!
MA3.P A"#%]F%DT753FU\#@FJ/M8Y^-%J4M'[B+2Q)T[;L+>5ZXY[<OD,^7K!
M J1N[5V.YVCU(';J==[:1\FM><1_N:I,U;5LA/S *M*JH*R^&*MX5=(F[ Q3
MH7)K!GH9@'Q[9A.)!\+DM-Z4<PL&'A_KA?LT0UBD(=MI!_%N3\@>%W"S/[,3
M=)[B['(06W7'P1Z*;KV)=!(TN5Q<E)HEA[3&&4$[*H5V# UMK(YVVZ3LD2-A
MBR=Q'$#HH]_6 +A3Y?6]'GFU:X+S=GDM:4IM8B8TS=IK5C!8=,$9);I1;C\P
MR.%\AX'L,1U F5L=A<8=H.Z4PHPG_X+9^/K\:($S^O'/I*-E2O<]H;KU>^KV
MX";=G7:8PUHO)Z6$C"(8IY.B_V-01B>7?)3@HK!FU'LV@]AAC_9;O9Y_.*MT
M:;3E$\B04]$*N,XVAB0$O3O6HS0AJ=S-.&VZ:VU\^K??;_-E$[<<12Y,&$N[
MA%%UETB*0<JYH*)?PEJ)5IM8_1&YAB.'R":H(GAD1G%:TR(OS$=OF3$I8D+O
M:?J=-HCC(H=H:>?N? ]]E-DZDMQ<]EVKNN=W>HD(Y86T6K 2*<+5HF0&,FI2
M _T))9&<W?R!3L.=D-W;JW> D\GO/13^&$^F,YKYLB#V;'I.SY^/K %O52!Q
MT-1+'7*&0R;/B/Y042KZO@Q2(/2P6*<!D@%,T+J'[$>L)*.DV?%D-OT&YXMO
MM'[A)7RKNJAG*RM6HSF0XSO27H D9ZJF(0K2 D5-,?',DA(QY]HB;;U\8>M2
MT6?<TX##T IOW>?I.P?6K*?0P:=20#)"M6/:Y\QB5)Q5/DCM.&UYIELWB%TE
M."&\',0(K0\D'R#O$T4Z'[AD%'2GVB>/UCG#$T-EG!,F%QV[44T?$V7B :R_
MER(':'G4C4H_64#,M4S:Q-H>G2/S*@26O)2FE%1<X<-DC!UE(X0AG8SV!FG=
M7.B[3SPM97E@E[][S:EZS;/K<NC%].?Q',:CF#(%3EPSDGK)'YR8UP*8%0$3
M(=SDCDUR^XY\&L@87ND-6P-="SM=D%2TA5V?Y_[ 6UY)-L=+)'^>?F_:^^;R
M<C;]9\G;>?YMQ,&$F+TDA/O:O4-:6A>M8+SD"#S7F^*.H-E?F%/"T8%-T[!W
MSUHS\=\F;\<TF56*(PE^"9,QSC^?P>+-#']"TMP%*2Q_GK[%OVA5G<RGY^-<
MWY%MYY CZX+R(2-+&<G92I9".&,D<SEPL%H)&[KE9 PJY@G!\7C,.4 'H.^I
M#]LDO,YG2%[)#!)91E2U%4AA] K5+F[!R*"B*^N^=&L>C0?E.Q0YQI!>U1"F
M>&H2BX?S[&3PNN@BF2Q!L'HQRCP&SH3ED%V]M<$N5=ZGDE#=T.R=LJ3[J/\(
M\EB[B/N:);V_I?=,:-W%3$> KEA4BL)FQDUM]FA%9F"49RX4%SB&$NP@-Z]'
M@:J=LJ0/":H^UFF=W[2,56^Y$:S.4CK&09"W5CAM[98FCC3IDF70?KTV=AOA
M[O>''G_N<R_M3QNHKO7E])]X-1M?7%Q-\$:80JXU2,59K)1D6KK$/*C,I-7%
MD]L6H]"=[+C^Y!,VYEY*;/U2OLE7"297%Q!7VTZ*V:+5S&$]2])5&+-TE "S
MD@6$Z79=N/[D$[;H7DIL?3W<(8>6@F,,OG@FD4(L76I!J-.1H2;Q,H245#<"
MZ^=0BM ^&AA"S8=%P2J[MH. +Z2^H)>M^J>5[Z#H)ZDO"#%XEV)@7)&TVO/(
M8LB&><%SS,H$HT^\OF!8(/31;VL ?,0O5^?U ]]^R(B7-@+78%G@IE)C)T%B
MI5I$5V@K"U$XT\T=WS[&,587]++&M+TJ&[KGE>GNW9US\M4NM\2T+S9@#IXE
MD\FQ 7)'0,C,(D"V.G!O<S,&VVU"G*(CT$SI#=/ MLFTHCOL(%5K*MGMXAR>
M1K:-N1ZQ_QZZ;DP/^X!T DK225EF@P.FE?6,D$[KEL B@HB\0)<\GZ-$P .T
ML(<$0!\5M][M?SAET%!3"TUA7G):X'**+-"LR%(4CVJA?5KOL'9T1S4MU?W@
MB4P?7;4^8[OMA'6=I?&94$V?PVFY=366<%40"W>1YFEJEG%,COP,U,PH[R!'
MP05T/$'M--XI;M]#J;MU:N[C(MZ\ %V$[!7/=QWY"6+Z(>S6#Q=[*+WYU4I7
M82O7M74\,8'9,EUCGR@U9S0#;6F+"[B>*7"4R'@HQC\:8/31=6M ?/X;S[_B
M!86_9[>GV\YY"-*Q["J3"N><^:B!Y1(UFH(JNVZ'OC\^^\"Q_3 6F+937^.X
M_M."G)TZTU]Q^F4&EV?C!.=+$".70-L>.290/1[C(_.H"[-:)FFB+!:Z='3N
MUIIFFQ2GZ!JT4WO#.HZE4-=Y9'=%6H&]@U"M(_NMTCQ!?Y@VUIH.I>K&@?UV
MX8(L1EL7&980F:XIL2!)N,C!*PP)<NY"V'N,]G^HV\L!S=]'PP-D9/U\-9M>
M(DS^FI!25J?.0GB_3 4QCG8Z+)*!X)DVJYA=0)'1#\)-N4&6PQX'-++2M*V*
M&SH :7HU6<R^C?[KPXCFX0%,8%89))>UUIL'4UCR!JPV KC<4/<_7VEXCND_
MODR__N?-$Z^-?//-NGV_C_J<S;FC[K:^LXTYGWZG9WQ94H_<'[D;D]"=?]V$
M)VB;-&LL0$YK:YW318+2Y$"'E'71WH3$7;8QCC;+M;MN_JQ).Y4G<@_6I0>>
MUEAW#TN[IDN1I>1)<I"5;"0C@.0A5F8E@F;!,.HF=U_=?J_[FL,DW]Z1IAT9
MQAYZ7!/M=I9W3;U)6@C*1! .M5,4_B74WAD/V@=P>M11\H;Z;0'F/H\?6O^]
MX,ZYYC8FD"));< 'I0MB74JD4IF'A^SQPT#[^5!OK^;C"<[G;]*_K\;SE59N
MBH^**"8[29N#!@H8I:YE^DJRHJ4C,7F&]9.2-L[40T(U3?VY.3CY93I[,YE<
MP?E_3V?G^6\R^I^X^%29*/ZZ_#R5_.WX_)QD& E:Y%7(FEGN#-/""1:]<21^
M1%NDH\4J/@;:!G(</H&T&4H>3!0:T!I#TURO3N#(ZO-*C312SHD8 F>NJ)K*
M+ 0+658J''*Y0#OG9;<>DH^-=.)@V$VC0Z<,/HK46L#[\S\),7_'*P=K)$G+
M0-4)F.AK0I2EX$E$3EMQT64WWO-=I#EQV QGF=;YR=\Y+MZ7CTMJI)J'43GX
MWMWE9!Q)GE&CHH6N5$JDRNP?7/ ,M26$8'(A=KNPZCC@J0!D"/VV)BN[E>O#
M-2$6"3>>Y@_3^>*7G]XL:2B^POF(0DR>$\7\QM3]+G##0I2YFMA%4H; W#$W
MM<MPIV+_]KIMF-6P/G7R^^-XL@3D]R6M)OK0 G:-T[NE/!_K5^_+^ZM%94^:
M+WNR_3_C+V<C8:WP(B&M8I&498)F@>O,3+8ZE: 4&#NDW]YF&B> P".P;\-K
MM^7[].[JHF9\4P"ZW$Y_KX1,HQB%<F" A7JRJ)$'!I9KEIVS,J#5TJI.2].F
MIY\ #MIHKB&GV1J[*[E+6_#X^QCB^'R\^/8+X7:2Z!-O$DWAFFH&=23<A<+
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MOU?)[L75\O-L/EE^6UFQE$(%ZBGH4 K:"2;!12ZA-&4-EBKJPU;UC,HE ^_
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MZR2E+%$G&3QC3"I!DN6TLG*O7C]WY7KRUL#9NZZF=)-/<F>QB2I28J('PH+
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M"PG$X)0;I(GXKQ$-;!_.']/$JJC68*'<<^!\':WI2V'>(#($ER6(K$4)\]7
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MFW!'# 7UP^O/._>U2RX<4H(VM-T/=J[V<X!G)*YI$(&W,<Z2X*#9_+6X=MG
MH4XOH6.7%[M+1J,#1F+9/V*AT9$"N:^?80#6'S1]R$("3_CX1,Y1ES4\8=MQ
MQ+/(NPS^%#+U$H0)=+"^KF.>]VG#V$QZ^4L@/=]TS6<M'QBUB1"4X6+2_]?A
MWE'Y:+ V\W"3L\F+$:-96QXJR[NO#,UT=RV@@S @7 RR6%%Z>,UTF0@XFL*]
M]WVO%8EK7>[OVM>XI(N1<5^?/I>YK,#3'[HWZQEV3;T\K<E<GW/.E<-<'_C_
M-0,A7=N!N,0>^!3VD[NVYHF]]"6&HDMKD6/>3>H==T=!]Y[ST23>9F/M$(#R
M?]CX7O9DDOM@V\KSL5N>'+F?O&/JTPS;N9)J:3=C%BTRF-EZBY32Y,VUU^-0
MR;H^+7,:@^"#JMNA/6W4W=Q79G^X_SBZ>IH<QL1W#-42T$>^7[(3K]=@:KO6
MM,3=5>.'!Q5H9'10^/7UA(SG"]UU#QK1_<$L75#85 5/Y+*?<CN)6"Q\W?V9
MZ7V<'\(#459M>-NQ^]&+8KZ\L9*]3XFK46&0)Z./K##&+"L\5-2"+[XIC[JU
MA&_Y/.SM_+4RON7<8#1MV/CHFP#ET[2,(\;)Z39WDY_Z3506M(2-0_P=N.KC
M,3M88EE\F!!>=2'DEW4HUJ(A^E!;*)R6']I,R#SB1G_WJ1]B[!R5#TGT6S8:
M]+4!'M4:]PDG9<PK+ZB8149PD[\#H!5XT:9]SUV/!B)0E>PT2UCOD=_]<ECE
MJS%2DF#N97QY1:VT0G2T]$/"A<28Q(<$X/_7Q*%-FC(@^0N9MWV[N@5Y[*.8
M:$3'6!.FODS2WTR>+4=V7TA!Z/'&$R(Z]G$;D(:N?<=5*YW'/9K4LH6H =SD
M%96R9I^\R?F["54\8[;F6-^,8G'JGP'-8:M<J\WT?:JJ&,NC9&MIU\&,_IJ2
MBLLE/YF*L#_][/R6A+@>SJU*"TY@EZ/EL)]ZU YWOZV5F.H'R]<K!8U>8'[V
MXU(K90O]J?+)XU-F$_L'1L-IR'7>L><)."WL2[.;-DHGI NJ4A<'0SOGHW/F
MNQ*7N<SXP^1!M#YEMU M+QQ!9*^L:I(D=@QN1:=UV+5*E%C6U6I(=O3_C/JB
MX1714%NQ4;?\0J4G1F Q5R906X$J/#>^*H1!NKF\'A$U^C6@K-C0:\4@)NW*
MV@\MY[ZO?5K!]O;V /"S/O4J*N=@\,E@'>]D0BT1N,9<A;9XYE:J_5V:IP7Z
M,50N-MLR_ZL:"XN-@.] ZC)<:D$)%^QCU[:W!E$Y>SIY+6WM$WW:E-\WO+%0
MK/_RV$.LO/O[N:RX^1='W[3D%R],H"W&H(9/#>D;^C&75LQ-6-ZE943XI*LC
M"\"+*"UJ(G##BQ6^H"6$#VY#+IW@TU$\1.#7Y5TB\$];N&FX\@49NEF'7RG9
M&-J>59_Z0PVIT[U\)'F3T=U8>_@$A5==BR "?QB7Y/#4T40@U9P(,)XN@,_(
M Q.) -D"$<",[SWTZ9,-$-71V+9PFW=&$ *-B4 H8@]9103N^XY_@0?M520=
M!#VI.A$*N7D>&DAEK-*0N40S>;[MP00V3@YHH=[VV*OK8I_^6B">TK/J@Y E
MS#W@9**]4N3,BC3=CO(F R7@1])Y17D#IS0O]>LKU")H[:7D9K^7;+RMUU']
M+JDYEF1]Z'X$=I"1VZXW49.3V1'Y\CF?Z\''6'31"[14_]>%*!IUP< *Y=/,
M<W#XSQQDAV"(>U!+?)SL,M7Y'08%9O+OB2"'&QK'WM>#Z ;.K$J><)W5)]=O
MYV%GK1\:U**59'E!!D"%I "++K5HBOO!X(QD5>9]\X*:$)VUC2FN$$.-#VO,
M >[/@H9Z4J?);^ $SO3< ZPSI\:Z/@I],DA-E7N\/9/O<](C7Q!?PGL P7D-
MD1&!G_Q=,!PSR3F7JQ4)=$)$0$B'G CXGI_.3/8^;D=)+.(OJY(QZ-L<:&Z=
MJX1>#NGFC8.]'>L<=L^T*7GV]ERDJEGW:#4KE_OL\QF=?[AK> ?WLS?F^B32
M^G_(R4%>/4,QC4)LUPYGDF5-W,,LQ_MY91^4:X'8H^[SOF2@H@:HPE>;K%#.
MO#-HU>ASN,;!/WPS3@\:C($^J+A,/X0LPD)C6UOZ3_M2UI<R3 W'N[).2T/&
MVX)\&7[I8_C/$X?G%6&W5F?,C$7;&M,^9*G7-?,:4QIM1]%TNP="%H5>MOJ(
M"(H;Y;@']*GZ,LL"9 !^.\)(_!7M4_((;_=#;AN<S6*;^\,,:X3^IURHL[[[
MVP7HM;J=R[IH)JH%Q0CJ&_*4(WU/NT%W^4.( ,1\U]JQ*:&8IM@TJVVN]RU$
M\N'<X6>=D#WN+421:Y7@?()L#]*[2:3_]^O&NT.6BX@:H6=.++I4;0T\]C7U
M"=/3/-M5'\S2T&RQ_YA=_PMN H!:V>-<95.WE@-8'J:.#S?E9YF)3PU(N9S/
MZ2K">&N.48^=L\M=)N@'_^38Y7='R]!KJK&WV1Y/WUF?<EI$R7?LKMM*-SM"
ME=JX-J$9'JUPB6\**GI,>>R;WQ:<#NR8:P)?BG$&>"X5?)2+#U7W*X7I>[)4
M8[(\F<9W3)F]QA:>(UWJZE)ZYB1$;&MZOMP+"3D_'[_#K1^O7[]?R)_?'$2S
MDGI(_HD0.I$9UF,3\4#C.9Q=O$\@OGOW5,Q.G@A\TIXGO S&YQ'X+AQQ;40
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M0'2$MP_BYKTC1I4#P_:L'X21$.EO1FPVOWL<TVB!B'L1NAW4:3\GQXE N5K
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MN5LTD< W,OKH*_P_#!;WRT 2R)_P9 T,SFN1.E&9Q[.@?TE0"GYU256J3]K
M4J'(EVF_J3<4NG(#F;W( '+1>%,F7?_A="<L6Q!30O?LDT^P-FS]+#^U$QRG
M08)DP0>XYY!7NJNK-HD?]0:\Z# AKS0*]")GW^H*"Z0."]$0OJ.86H6*.AR9
M8S]?Z&*$E%=+/+,5O\W<D+'MZ/$YN4?)JV9NQTL$*,[W2FW!W>V@+ F;[SG7
M=&@_,;RLN9U>JIW9^BU0@*WP)_27\BI6Q<WZH\*#P%L_X[)LAVQB%)YJ:S'X
M^#\*&D+I7SP)+.F6FX)\G=/:PW]:;U%&Q/N[8OS<@S[J?0*6O4'W (UEID)A
M%XK'*'7_Y*N[-\:1G[_KR8D0^H.NE<1[>Z2+>OA_ PFP&.@*8Y(FM^0687E$
MH*$WON<E=OIXW6G^HLK9*QC*0W/C.F;^PI1403^[_UR\W5-9,4!K";UC&UPX
M@'GZ,59+R^>SXP!H:WM<,'5+&FOI(=X-M:-JS57A>Q-2P2&J*<OJNT$C0)5L
M(MA+/L#3X8APOFAL-?=9) )17BZ>J'UN5%R_(8/N/^A^GTV$A"1UDCPRMIT7
M%ZDEC65'\W75]E&VI11[:8WHF>Y*&'W4[>#MWZ%X)OPJ>/)/ZK;RW@0\ 4SC
MKTG/[^-3,<W97J/7]?B?\W[Y\1R5M!M:SO&F[]?4@M6T5N-$;@UGW#DK02V;
MWDSH<JQE,.!B.HAR"U9N7',\$,^#_I';NK-W8#@<SCZ%*Y#V.)NH'0TZ48BP
M<DQQT4]66PR_T?5<'+0@(81X@*Q#.1*!:6ETL%#4XA[L93V]!Y>[9)&**E1\
M(,XU/\> ^8KF?33WYF<6,X:\R6$??8TC;_I?TA6S,XVG3T,;J<;19H.["6ZN
M(Z@PL GB48AC BEE')_N,64RO?P0V,E#P5=G)YNOV0.P]PQ_V[ 90V;=T$G2
M_4&E4],Z^7E6U23,8-.LH6%T6*NW)>O^@TR?_.Z77WEV82SA4XC+2I 7)L6!
MCFAHS4: BBJC?U 0&SO_[?=I7*I_OE*]2B>C]EW8<S_X(5CX(NN1Z;V,VN#C
MQKM'LE)=CT0SQV(MJR<2J_"IV=)'C@LE"=5:SGO9G6?COZNT5[ICX*Z97RE7
M[L^(VI,EU69\)<_!UP\KV<RSN7-96^9Z3EK'+@]0MDK=D-VZ00Z*T$A*OT&>
M$?D]_&U@!@0>@ZHK*'[D%GJE>3A4&\1JU_.![;$1766$T^+;/9^,OEV8;??O
M3.U83FPC3HCQZTXQ]XLN<.2UL.?XZE#Q<\-0:\329%>5WK:L]1VF'H/ZT2M,
MMQW$U!0B(P=C/,5Y.^Z#MCG+SJ_AF:,QX.0=JHI5>*=VT0=(8,WUNXJ*K +J
MWYP9Z_N<*2)BG$VDF;DW[3;WR(_S$A=@\<J"RJ&2E^NT5^:G[0ZV42YA7S@M
M%<\_?K/@V?<Y0%2%<2DRPQBS+FQD4]N<,BL1N806A&1$]Z.:H,:).N.0JH:3
M\$13Q/LSP<(_.?#X0]Q3I0'I$'H>@U_;VPX/,+J3=.6  !'06 L'A4KOK75[
M7+*5AHUB\JUX'[7H7PIYK*:YY$M[-_/N'Y\X"C;I55TB0,D4ND9@X1RZB&,F
M CR%A,O"I"HDC"0P@<_UPYT%XM5BQHU&W4Y68:OAZ+LO:^E>Y_..F<J5D'*B
MZ,K\BSGJ+SAW3+(+6G4MK >AGF3R]<!16,DKPE155-H^W6#KLBZR$$S"_@0V
MMSF1L5#&H.LJ+5'UVU%?R!J>D0_J\_3]CE!]2,;Z=8#=[@H6O50DQ(-_&FK,
M%7LY4G3&D )KJ/9F<.,!+6^#K.E(Q3=Q&O4_4G*1&MT_XK&Y'5 5KY7;T_5M
M7P1<EC.[3,$< 4+)X9G)Z+$>9UF>8K?2><*<X;)5N%0!+-_@(Q.TY+OS&A<>
MCV+?(0(S[(0[D]TP&\B%=!Q*&1Z'N@5_"CY5A7!<_)OG)@A\^SCP14\)#K&<
MZI<JA)<8A?^&Y6I'+PJA\_V.L[#CQ9DKRUG3EADE,S,/;:44K[6U&M7T<MBG
MOY]W4P,QO.6GY@$_Q3D>V^%<%O/%MXP7W>_\4RLUX%]6,OTX+6JA8?4\!J-V
MHU \0CKM(AXOSA6_9RUXW]8)8=V:LY+ZFMR@M(=3;VJ H>=[P=PCGIWPV-5V
M1<WOTA!.&6U>M='H6I,[+8@@=-!5O@(FGKQ_.#;N03TVV^<C3R_.;<)_!$,[
M[Y;@$M'Z58?2Z[%%66S?1OB#&K@L4KKJI*7DKZ3<BXZZ":#4 I CJ3.L-\-_
M$"1 E^Y7T:BM$S(YP]VA?P04DRJ2OZ(\=Y:V]T?Q0X.!*#)#N<&J>,ND],PO
MVM _X1_#A^PDO'A"N?:R/NZ;*%4Y9>T/:&8_3V=S" #M&SLY9DPJ_QG'"-7,
MXW,;8\,;X6=0Y1#M<-V4&+>EC4Y-264<HG7%7PQ*KE?4Z).ZS&&N[W/YG;D^
M1\S_W.GS%>)&+6<&]A*^GL#/Q#;W_7#N1ZG_*W(K[D"@JS90=[$P%G#RS6&$
M(_Q_ZO[TP/=,B<!1NPX1"$"?_IZ<RMQ_:$P*X'_W@_P[P?MB[XF %WS]MO20
MCF:H0O12+_H.3-_5?+?+((26IU3^=^E5!9[H"$A_%\/V8_*J8,&@QEY4P@2"
MEB#P)"?7ME+C\[ 2WU,UR^=-CV*N&//>!RD& \%YY$L+%Q5=NF:XG<J0T^AW
MGS)UZO:LYG_B&Y!(^ *"H):E#>DJ8$G+7\@2&_<8$]DVL*CI-^XQMO^YP![!
M@A%86P8_.0LY)A_>J=:YNCF=Y[/:/WE+9;^O(%6FII8AY 5B'SD=F,"29747
M4=Q^7GBZ&UNBYL+1EFU)V!14Q7-H$G1:J0DK)P>-R!147'LWJ>S%PWLG_[.=
M,[DWYKV+3W C;8?Y7*4EU.GE^T2@$0X*SP\?X_MG>IY4=I=^"9]CI\7Z,& 9
M"U 5$4AYCQRTJS_;74(RH9=V:3=:! =: \XR7V>E:SEYWD^C8U-@5A,O1?9I
MVYBT_#PRF54Y8Z?<?CWDI06*LOC'H;(H2K>#PHE-#4D?72%^JYY_(Y]P ;[Y
M!W? -/Z$)]$5X_4%-G9>>$R6KH*#5AOP\');IR5$?Z.B 4#!W@9A%>L;.-5C
M1NQ*0S1F%H:&"E^9M#=L?)5!:&#<_@2 7PK.@)*" I?38$$!R)0E!JW2Q\H<
M#<'(MR=XR9=QHI+%_4<IJ2M$@-P,.40R>2P:FWN;=_V#'GA?Z^@,&.0TUJ8,
M?Q@^7* 6O<3= V'=F,C@/3QZ8VW=F .Z*7"+W9?%I^:M58_:Z<%8SF&3:5*Y
MX\6':4D2&"[[_!!1VA\WWI64^WJPK=(?!C&KKZM_N=K2E.F0H-8A,]@% (+&
M((#:#U9M)X*]FKM !)AM-_F^3S]8;_ )JANZZEWXA\KX!P"P&0-.>=#5DJVA
MA=-6%^R7SHGAEQ26STU*OROY9+-6"K7RMY%K?'"I\9D'+OA)B?L2]LYQ_B**
MWI7%>&7JR=WO/G[U+^267W1>Z>AXV/\@BEFBR)%SUX=2[,WJ@U"ZL-T#(A"1
M^G8Q>%>JW\<J$3HE!\,%A*Y@UWKM>'$(S+H<7G0Q:\0RB#E7!9);>FLFW(]&
MS&QGB#Y])E&^[VO8Y!8*>VM2GS":T7&2[%[C-,-18ZS"SW/1WYRAM?_%5Q-#
MU8R*"0>-A@IA-='6$S5/9 \'I'^MO*7U>D4>>94;]!JD0VT;\1PYMDW=E0--
M4"I5OB9J5C_V]*J06'=EA8@*$PT%FYIP](Z\K56#,TPD64:'CSNV,7/^VU*?
M0IXJVZT&<>Z[6<^G56":-F<;X0^(0"<"2UK)M^)=<)QD$RE4I1OVXK=2L:K=
M\R[9YPRN$WY4(FN6;VXV\O*X]CA3I,UJ,]_,N9"<YS[)..!H=V!>,L=-_AA*
MK$E/?F\J>:)3GDV^<&_7\G-1NQ$6$8FJ/8G784@K54+,%(#0<L=YV*>LT@(>
M"5JO$+)DZC*^OQ>V^<#UIMD^E:%DV% NM(*A9S9U7FC:K71U(M!N7C&>&?W,
M/CRN1LMG<1YW6XN[^H^!5QW<[<&0RYK';-U@<G: )B; !W9-P,/Z39.#>__^
M'>TP2'V6K5X*["YU7(*YCSM$*5S_+  9A*,\ET'URM'.;;HO/?J0&+)6N\\8
MC_CRU*=]>^X)9A?#L[W;&SL[];UD]HZ[/T76I)FFOHRB)#3Y]:O[D4 4C7"4
MFG#".3V!E@A@7CA"V +UEAX4OFEY$I"VY;'O1+,Z$/9;]M=U-;#BY9#PO@('
M'YY0\JY'@CEU[6="$7L[W/0)@X5Q/3W8Y[;U[ 3!.1(8@.4(M*3M(U3X/_Y$
MUOY!#J F;D\2X.&LI,1ZG'ID*$8$$$*G2JA!W"A!<('$FFFG/D3 'DZ8MYYC
MO(B>[RRX-JQ<AW%NX7,^Y"ZX,=(05/ PX?QYT!KO3-("1IO1'TZ2*D^EA6)0
M+$+HZ[BP^CHO#DB0=W:X<21B]1='STV66'[-B%/LF( K7OGB$XG:-7LT7.(^
M;XM:1YNWS['NB,3\4VR>7]MIX1.KW28]4I:X1+O85CGS;!D98NC5A'6S#[3C
M03VB:"NRK0KR.CE1@C_5 ;O .%)#_HT%*!(6H/ZV>6#_T>89)_"=%9"$H0_B
M+Q>D8.9/>4:)P"7\U-G]<T$BT->"@VX^)P+%?M"ZR:3P7OB^9SOGV2P16'\X
MOG5TFN),.+?!6^"'IA3@I]R/B$"'4-]E^7,'..FZBDU2&B[VGEQ%[DVN0[=?
M$H&KFTO(JA)")AJ6@T+#2KR?GR<1@2XB  I7[YW?5R@A4)[6'58<D^I<AO\>
M<H)4#&^M(EV0/!<I1&!Y-E3ZB"1V1YHKIC8/! 8NCAMQQ:>(FF4BL"^+)M4!
M<#J=Q(?6T<G_;+_\=U.=.7%^_Q:>)#7L0U 7;$>GZK#J HV?:UAPE/^%R'AA
MR@:A,^3!M(4>5>"4K@/9USY!LJ5VDO5Q=+B7H^<0- +'#B8"O,B?@3#YSH5'
M]QW$!P(JP^_V!-DI7J_07RQK!N4/">%"L"'=*+KDT[T&Y,5KK]8:'T(J1_OC
M[S/P"6E'_IF/&A?2GTBW;,4U$H&;?O"%=M(Z)T-):\; B64G1(63$/=K&1'
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MMON7\]%@&KP=#E*!Y\<FY3"5#_^@H]WV?'^>S9)^(]3_;J9PV1_=#E&&9T3
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M-A:FT*D*%_E(,5 :N#*18?+?#2<_T>"]5N>J (OE).Q>A)PV!1@NN,:*=:(
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M%$M&F'T:??=D<C.(;G^.E'Q$63Z$ZY;#2[.KO0TLN_MR1J]CGAUW_Z>.+H/
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M;G80=Q3<@X)9')%.=BCX)->.W EB 0> TSP8%@0$;(N"3W+="& Z6G(H6!(
M< AL?H,M?X,1D-NG>9)R4!>/TTP<1G8P!R.?F)@HHQ+$W1&"0'!IH@;% F;%
M* =U<K%P]@" ,YM/"^D_'-M_<]0_;?PWR\G8GD$;-T_'#$39]@OW5W309  0
MW4+YYLDOG.4+ "AY  #GAW[A6!(!@!@U;L4=O]E#>3)??HOMV4' W"<._5G^
M)<&_47[KC_M$W$_W,%X_R\1B//$;&.H(1<(8X:@U 6'D^OM)_%]F_&L]KJ#.
M%! 8!/65S:B'FF5VSC:HX7:VLCN-5-HY_T>#^%]D^[MR-J]1A>SU$4!NS@V<
MZR 'T)?:  PR? #=)![5 OHY;JJX>B?Y78 ^PY>S>7]:_B(M$BWLY :W.TT&
M!.2T=!C!2)C;6=MI_A\F@ <0 ^0 -4 /, /L !? #X@ $L!50!ZX 6@ .H A
M8 :  5O "8 ![H W<!<( (* )T 4$ ,D *^!#" 7> N4 )7 >Z !: 4^ ;W
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M9+M/]0^>CM+X2\)>..HW+%?D1-,7#+)W@^?=4]58(R*I*^ &.Y^ZEZ6Z-87
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M!+ZMTE.9'3Q@N< 9O$V]S,,0UH@'3"WS7S;RFYQB5V\++3YRVSCJ;MEJ27H
M^/VTZ]H7J(Z;^2Q[6@K>D45B<5FIC:A_Q4UX0.R39LJQKN-ZM]R3*3Q@=3<,
MLOH6<K0=8'6K5DP0'H!ARNG!W4":LVKQ )%-/* B\#/\J@JR:85-PD%3+,^2
M_:M)-U^K*IH@&&=XCL[WHQ2F%[@^1+/&Y0_V,.2B=FV/E4D^4Y*QA3U)'"8
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MMEULR4PN,6Y!V:<A%E14'[W@*796_28]ATU(HN?ZY5'%^995 '>,ZS6^.CA
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M.B*>R?808)L(&/JK,=2>UW6"%7&12A^>(_'L0AMQW1.,(FK+,$A;)2.T4/Y
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MKGQ,OGP&CV)H>$1A^A0??Q67;\=PS7MV#&Y'6X+\GJ6)'U^!4HZG78W3?\1
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MR%,9&XREZR4\? GG1X:]+N<;GM7-"4GL4'P=I]D9B#MR+T->U+E$4J=C '@
M2&1(]FARK@,/&(M>?7K^&T%0[\WTHNQ2H;4^G6Y47]A=]5K2^HSD'4GR^+Z?
M]$N)]T$K1[.; KOT;V.<R@S(N*S);;&M6:DW)D@\P&_AG=*([T8I 9D:.$,V
MWG7[^Z<?=@!'TU-EM#0V1N;XF/E4,KVZYRIA9&ZR,&SPB-]%__S3,JEH(M&
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M2% M'F0]% D:&I)R<3\/AV,SOBJ@2Z0MC_/WSS*%2\5HS08OD]^0O>0<T79
MO[WWU*%:06<.$C@0M)]5C<G*6<'@UD!8(0^OF%;3MQ^@/SPAGP(TW <)[H)
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MY^Q^.Z1U!27OUNH ,U9G%W"M]4*X"]SJ3G@*X@ORJT1746\MWK$>O14F74M
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M+AW1E$\V@P.=C(4EGSA'KU\\ %[R)E#.>;*T&_&-LDI(+>31WQK1PXKOYA\
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M[]>\WA!8K-0]+Y@BQW+0WE5_%VT5$([Q?>T'3J;H1[J\?P#8B70E[Q_70*?
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MVW<OEV]<^.S*QDL)THT45A:D*YOX.CBQY4/XG0I^5G!^D#P<+H@VV#^BN6<
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M>N(>G&J)W'3-:/CH4K+-M+K/XR[IBV'OY%'ZW,;%QV'7[A^&#7=;0E74YYN
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M[XFC*71 $U2SWQ\Q>#G=/@';DW9D,C[:OTPFNTAZRV9&(T7%.AWKQ.H,SC1
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M&5$!%/J1ZF(58,B];_3Z"X/!!E;?(TRD-!04)1;"OOXS?$\DI&2,0IBH9*V
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M8L'>L3>05 @(2.B@(!W!&B 4Z2FDD-X;(20$0N^]]R:HV!5[+VOOO:UM+=^
MJZOLOK=_WN>N[GL9!9([YW?.W/,[]]PR<^?#F0^706.<[!SM0 ,&#  Y /]
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M] HC!O?6U&FSGYU]:&!8H)T7#!FSFD(D!T?K:(&7NE)"G#S"\,Z>7@A7]_!
M7Q_O:/\U=A#,&HA[N%]$8!3:)QKK;P\A^$/_K-8Z6DMMPIU\?,(1H7X1T82
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M^][Y8P7^"?G^O\OYYA"$GK,Y4"<]7W,3L-Y*X./W:@.(OY0%DWZ.-_]N'L
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MM:]--*DI+KF3,+]BHZHA'E&BS]HFH1? (_3%@W/4/KN%'9D<U!1!:;IJH;;
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MB>2;\I1\1%(:HS2[2\&(')@AE&>OS4@5R5XXZ">_B]\*6Z :&&\X9:_*0/H
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MNYIPQAO7;&/@TEQQ[6S\0LNLIDOX X:V];,)@=.&UKXBA V*JG$FBD @SCP
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M@H:[L-/T8J4/PDQGD#6H+'I'V33T;_KMQ%PLBC%VV3&</V/LY/GX5W3>\=W
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M7D'9M\''U=LJOFS7B195WNM)P<X"_]F.*RB$'FI>LT$&7]FPQO\8'&!MFX!
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M@4UI8 F.5LS6U0E<*R4\(]\*/H2-YL=#+Q0/\B?!3R6]Y;U#=H5Q^%[HC?.
M@M+_K[/L3<1=]2;>((*G;>5M0$W@LKE/T C,"FXM9E_182X,-S9I%C</'[7B
M )=!")][@H<B5/Y_=: .U<DX-XA7-)4<,4G&*>1$D?W1TSACR <*#[!O4S(3
MP]G7* ]6C&._IVZ>NY)CH2[]OV)&UE:R9[,7J4-8M]@+V+-8K>PQJ.DL"NMV
MP5^L"M:A!#:KDM4=2F8Q655S3K'NLNR)HR:*N57"4"UD,L3G6>.9J:+?B =,
M?Y%[_E6FAS!QHX:Y7& .V<:,$3C-B6#F"B:/*%LL0ZU]I5S( &KTS(F,2/44
M^#O&;"4I[R/#6?XE_AICMJPO9!YCH?36[./T[]+*$65ET#NL($4N76B!,%;3
MLTV!<!]ZJ/Y!7B@]4'<R/I0>KIVXO)GNK_&9C:$=5_Z;Z!_2OC>_EP_0;C9F
MTI6TUCH8C$2CV+"Y$AK&<C).1>.9#B_WI"&,7V=[48^H?]H5@\;JK95'T,JZ
MD+0?M/EM-Z"WJ0^:5^7\HEYL<(^;3?V[;DYP+_68K=9MD/).O7-$55U032[7
M"M\I;,"WI#=R"M@+5"N30'VSYDIWPV>N7RU=@K@;2)3ZH>*GGY!7HV;\,UYK
MJUP4 7"JT%_V&?&+Y"Q]B )7GI9\0!_(S)4LPDZ*T8AUN.B .V(&WF-ZF92!
MZ_HG90_H@F7%A'C!/&DRT9GH)ME(/ *\+*X@H3,8HEKRG'771-/)0P$)PE<4
MS^ECQ"RR9:2%VJ620<9W_B3Q-N9"_#O10>:*BF?">\RH]'9A(#-^7:"@G9FY
M]+2 R,R8-B2L8]H3AR9(O$EXAC=%E"[,QOT0P@2'RS\*M +WM(_\&WS.6BN_
M@#]Y:3[?B[=_&HG_A">T5P^R15&J?=P,8:)R&VZ]H$1!*E_ %\A]TQ;RSDC?
M1+_CQ4H!_A>Y/R4UTSQY('&DO0[0)BPS[>!8!&3C+*R +]%'E(%X[;JX+0CN
M.XTT.I,+5,?XHSC?U>Y3'W(]Y+/MRDNPIWX?9P+_1JT!\Y1WUS:W] SW@T66
M>H6[TI2W9HBSS?!AR1M.I"%NZC;.5)G]I%BY3["AXS/;R >V96/*>67-&TJC
MN64-\U-S.,9:TYHLSL0:X))JMK)ZQ50,>X/L](@2T4VV\IE4B,$$S(7'5MT'
MD0ONZBH@V$T)VBFPY,@PC1?\XZ(;FG#DJ$FK='H$_I_QBA->,?R$22GG]9Z(
MT3"S#H($%6S0_(7:G[1'3<,X1.Q3<;"^B\@J(O;$I$"-&W;#R+.$7OJ-N+_(
MKW1B?#/THN8&H2*?IMY"]$B:K/Q(O!P1J/A&PB]R5EPF[9XT3WF"Q!A1@HVZ
MK717TB_-#_HFR!EU(1V7UZ+\DVY,3%+(Z0?"-?(J^L.%5GD._=&D4?(]#/M7
MR4=I"_FYI"7J/OYX\!>5&Z\^]YC"P@M.:).OXYX,'R?;PA4M#)?^XH(FOI2^
MY;RRUP%V:>+E)XA859OL-3A:.47Z(==-+I$\3W"0!8I_KK1*%XGSO9]+#HAA
M$V](0,(9=N6CQNMC"6^5MW1O0'L44=JR'*&L37UT(TR:K *OG"&)49J\:\3;
ME,<F'A.[BQ+L=8 ^U57;.0)1&6,=!XJ4&\VO<\9*/QG/Q#^3Z QSPE1BN1[F
M'2IZ6C5SXH#(1;3&KO)4%2U\@JOB7%-^Y6GYK/KCV1HIJ'99/%_\V986MDKT
MT(I>\$H48:R9J!?&B>RU+ZJZH;D,C9Q>YU.A+^FTO:JL2_.J?@R6QN18/* I
M0?=,OV"'YW',!^'18^Z8ZN'[_J]8?U!^U*^#TA!U-6=@]TI"K2S$NBU#ED*D
M/F:4B8VZ&-1H3$1?GE=I/(\9/];+X(*QG[938+4-V!SX*UL,;GZQS?(!]VC+
M?-,%?-<ZKN$= 1P4J^\C_)H79AA'^#XV37>4E#RBR$=J7*CN\.75NZFE16?-
M9*HUE6[,H=Y<^T+/H;DONU2UBK9Y[N<J$"UX+%YS@+[)KN9:]W->P\06+&>H
MR,.T@D/<?,(PG1.P%EP5ROZRK$+[FGUS[@[M1_;UL4K53[9M1)&$U;LD=Z#?
MS#A)>*'.&"0F;([43Q!U1]_3+1"-7S9;,R3LFZO2V$2N8]N41)Z/74VUW-)<
M@[)-->HCA3,-.2IARJXJ?^7&:(1VK2(E\(CZE/S#7*$:*&\:>USAQXNR5P^V
M6S:8GT.33 XF7L$M?8_A= I.5ZJ?'.VA >JN!I:KONLNS@U2R36KQUZ1S^/9
MOQ0BS'RUP1\ZVJBHHQ7(]+XU!2GSM&>LL6LNJH]4SP[T5269W\P=KSRKC1M[
M79;&BQM12(?NB%)=V9B.PG)M9F3K3B O'M(<!<H.3VYT!W_V#6N8!9T[;4D3
M"](ZG-HN(<M&%(+7Y0*)+MW5/A>JROC9$@>[&[^VL0ZQ)'QE?0DRW3>Z+A@U
M=QJF(0 I'4YM 3B(7<WJX*"WET:TZC"X#%-3/W9EW.V&,;A1*U_6#N%V^<ZM
MP>(#IVGKIN-, ("^CAPTHN#U;<_(CB6]+6/(Z>D_&Y>2K7'0.BKY]4I)30AE
MG<\MZTT*?)JQ9CGY(P!0%40OMZO%K6H6O"2\J9>5FLZIO\'RWW"_UH<U=F6P
M]0_F!Q];-9KY;IK6*F3>!P"T3_[-E;"]+2+AN^(;C<U"4OJBNN."!QL$-9,$
MJ6'7JSOY#WU0EL7\*].TU6/XPWE9<^P_5=&\4\DHUC1<5/2FW:E]+-^V(=+F
M(=L=)K3LD<WUB3(ODB5.:S:W28:SO/JO_]3"YBD&E^*,!I^JCVG6VA!=;>Q[
M:[$V-VRM^8-F^Z*GIE+-GFE<4[><-ZQ\_U70-TWUMOO%6?5-UK8T<XW)\CGV
M>G6#.2LLQ#S+='[1#R/4\'A:A[%=7@.8I)*R'4=4Z?9!>HDD\\,.>EE:0OTV
M=87;JM+>P\## ;N[Y:!%\[3=L:!!QX*>)A , -#E8.UW#TJ#=FI ?V4>[]\,
M&9V@[9L)#5^%ZID$JPQXV%D+KYCWIG,B?)?CVZX)\.'QU<XB(4=4R;.!2<@7
MF:1M^U':A,)>+'K#JO5=6S#C ZZVG\.TNL]H'X<Y.:&@O1DS_&6I[]+8=M71
M7T&XGKFH;PYQ]L:?W7\02U>-[>@D[@KH:/,B37*?U;J<Y#"AK95*"@< 5/M9
MKG8%WO:1?C'C:6\7??_&?5V%].ZHH?90NC5 V:*G-[C/;E;2S1.>-8L9PZND
M\N"_?5@2V/<G[VW&\1X.S[BQL7,A;TE4=>M;[L$ 5/-&+L]]49,+MVZB;^,9
M;@0 H+C_KRK^N?6';$;&CFZ%E+'1U.$IV1,E:[DK<0PH; H6#[C[-]R6>$T$
M-B0*Q<,JY#]U8VNV-BYC6]=I#7.CJ7VCFA@E:/ZJD@0D-:Y3 =W=ZE\H]TRD
MUWN*9@$ <NM_ZF#O+7-=QNZNI::]&QO;-$9.E*@YU, /2&M & +<0^I'Z5(F
M:NL6B(;G&3G@7W5P.FAF\<N>2Y"(LO[JE[ UP!+Q L1"T"L<!/D%"BG<B1Z"
M7X@[CMV <EEZ'N>#OC5Q+'$)9L9^KXI%T O=2952N,"B!.]'+A4^@5Y$G<;&
MP<]C2@K:D'W8YQM.HA/PZ?Y/T&\)A1,0># !MC>A5$]H[116>!%3S.,K&<3W
M AQX.ZD9_05ZD5R0SX'_09D:>PJ)IO3Z3T'>H$YT?(J]20W832I.8A>V#Y9^
M9$\QKJ^ LT[P7E4>9"E01L@H%B0O#>;&2EY_'KZ/Y;<D!OZ ^=*1B-G.% Z=
M*<R4C6WS*IDEN:G?5M8BWL&% ">+C,@T4)E0F;L"HA:TQCR&1?#/^DE@L_ES
M'&=@<[G1@YC\ _KM+9>+M+K=5>C2 ,T.3G!Y@VH $5 Y1G$Y9Q5XI=P]9@[D
MOK1N\4,(4](W_B#VH6#-SH(\2EUY\YG"+%N-#EK\T;*+'5R&-MZ&KZZXK0_.
MAH+F: ^LPX!WJWL7EX!GJ4Z-I^-R!2X#REQ6IW/SN(*R5KK66O2K<1^KN)18
MYPA#EC^VFK.Z*Y>:56NO@DX:?7U?5-[3+Q@?BQOD/QN8F'-Y1U<3,W]'7[1V
M3%%L5S-S5TE?VWSH^7+WIC%9GL"2.N;:Y,HW-9Z^2. )<_%X-_P8_IGM*Y$O
MBN,;S.C-9<$:9TQKQ5,F&/L)1(+VXZ,A+S.?$CCPY.@]Q"8DR6<T*0_U8^QR
MV@3,M+Y#\*60SGH:XCQ,K@:@4A&I#!AZ+_(WY##6"UV;Z8PC8Y>O^8*OPUD6
M91.FX,EC[E*PA)-;@R$[<!]JS\*8^#M*&L*+,$C[A.PFRL%4=!"I)/TEIIX<
MN/H7]B3YYD(1]A'%9XR9\IP:UZ,%<9F>-3Z02F: _$_8?&8@50\_SO0#A2,A
MS*"T&ZA7S*C5\S"SF*N\+Z+O,EW&Y%/3F?[=+L!:<;QU.\@DDLG@$(AP%R40
MYB6X6SD=?D$P<\LU))P/6I6$TO*.>P>A''CI8WRHW1QNY]4*-RVCFEWIJ?XA
M70?ZILHE.T/V*WJ!XV!4^9S43PA7:6]4%3)2(EY0ARB4>([^1OW*'=-QL^RF
M=8=%4O'"@I4D59XV_B)Y@O5ZP?"74*!;D1H&^Z7QB?R-F*92+5@&>Z:\.?H*
M;27G68=WZ8N6E^8SY;\:GXKYP!MU;<0L4*VMK+P$ K64;F;#9A@O1"+A\PVN
M\T]".W3JT3MI4,[5]N[2#7V>YKCRC.Y\T1/@@O9D0E_ES>8-94?!#?5-*=^@
MB34#$<]AB=9O\S=#I ;!Z%J:CG.TN8DTL^BP@4KJ+=TE#"475.#QK909E=]+
MWU N04 I#M1JV,YP&:T2L=_C-#T*>>G_,P"VI(F,IX 5^CQ"!E0I&$5<!(?@
M9,1/2-^25Z33J"O)"\B-&/C*PY1*['&/Q93KN"W_5Z1QC6'86=C4JM$X3QR2
M]P#OC,=CP?@OA,KB%X2_B>F;XHC'26$KIY($I)?N-I*6_,\).,VM_@CJ(^VS
M5H&91=_,S<%ZTN68V3@/^E#1('X1_6G2*H('PRUL!>$*(VS>>P*),>:?E-U0
M!T?Z"*R:<%2>((KCB";P=Z(N8WA\S\)^;!5/G9B)J^7-6D'')W.[YT%Q BYJ
M9&:K387WJK+47HC7RC6L+ZCI\L_(L^BE,EO!7LP&:6:" KM)$A;Z%_:=N'SN
M:\QI<9(]FR-@;/-TU2KX"6,\:P;BE3X:\08U2>>;_PH=J G=>!.S4B4.S<4<
M56+FJM&%"OLIC.T(U-!P22F%W:_+9N8@QMDTB!5(=\N>_#!4C,E_8Q ZS3 [
MY +ZLMYS;B1JA89J5QF0MUU&I2-L=3N6<1">T?P.;D04-\#RFI&,VN3X'2BI
M;4Q(%NIW-7G.$62\UI[:3*DL8U&>-(&%+HVCN;'(Y5^@!E9-)3'G.NL:^,J&
M8^Q F%/00_8^^&W7'=S5B-#_*V*!,9TQ%V22Q#$B($W448P*F BB85@1R=DO
M&?>1OV*_,]>A54$1S+V8DZYAK.V8W?^D;) A@GH-O4\\BN:%'45^2"O#^8+)
MM*WXE5G?Z(Z$R-AE=#31;YF1_A?Q^LRCC(U$P3^I[;U^'/D(Y;%P#V4)%4LR
M4@34OT 4REU:1)8+-86F7(^A'J#=7#:!-I<^<68ES9W6,O)>NDND\3QG00^)
MQ7U/Y).><;=6)I/3N&F9GN3CG.\Q!LI&3G]@-D7+(<YX2DGFI-NS^65"DSR)
MWT[TD8D(?*)1J@'FD!PDO(Q($E/,6_<WZ9.H)^ 8.4@4,(-#.B:T/TL['L_5
M2WA_$297>>-W$AA:>H6&\$I],)U!A*O\UJTCWE/<#<@C_E"DSX@@,F7VG8,&
MBAO.*+R5^"#K*?PD?(V%7/Z8X&B:GG:-(-2_7UM/!%15+OV3.%[W:_I' DG!
MM"?ZG]B?;?.XNW"J9BF.@?O0H"O/Q&^I5:6EXX]9?ZX-(4140Y?""2%F^709
MOE]A/U^6+14S"]\PIXJZ2XZC+HG<RZ$E\<)!X%^;\4(,V'>UO[ 2&K5XC_ E
M;,C90?P+%O]_1;DDW2(,K>QF1 J:P#N0+P0!4$LQCG\.7I:RBR]%3EFEXM-1
MJL5K^7?0*J=KP@34QW_&*T=2Q!^/2J>[\YK0C8B7O!C,7T4D[GOLM^0[W-WX
M25'7N7WX;[[;N9\)(J<:WF/\ZY$6BC=S9Y">4+]QCI*-\$$.F;*DD,]93FE+
M!G"<J!Y1WISQ5([O4LYR:J=3)><"M=!>!TAD9[%EE)_LN>Q&V"'6';:A0,9J
M82,W@5@T=D)D&XO!#O"YR5*R79S26+]83^R)'LP:+]E,"6->%U^"C696B[WS
M#S&+1%E)"N9*H3'B)W.I<(+/%N9"P0TG)R:5;[\Q+NACO-=.)5,89S0.T'B&
M0K4SWXF1HDQ-O,GP4TR)J&2XRI<N^DB_+X^<_(RQ7&RPJP4,=\L5TF/Z=W,L
M9"M]I[$XCT)'Z<L2$^AQNFWAE^BAVKY%7-HC;>+DTW1?L?T7Q1^DLQK[2'AZ
M27T79!E]>FUX[B?:'FM?PE6:R-(53J3!S'\O\J%--GI/EM**Q?89@+E>\[6P
M$O.G6E,RIP*BPI2U9.Y2\H#C-^Q3' 9%A'HJL)"YGA>56=!9#BE*,_2?.@#]
M-(.F>@)LPRQ1;@75E6]3F"&LS-GR)MCZ#6&RF_"'(3MD#.0&3Z7<%_FW U3V
M"?GFGY1]F]ZCN(:X@(Z4'T5YESV0[4&79:1(_\ H8V52)VQC2*"D'2?T#)-Z
MX\XXD"2U>/^1%M).REX2GJ)BI:^(':6W)5])&>D"R732V_77Q(5DVO)&T2?R
M8X];XCCR2P>Z2$O9;Z\#/)4F,L<AR9(<9FSI;#&,69&V5:1D0M=O$9YF(I:'
M"4%,DH=-*&>6.\@%Q_X]E:8N$'\3QB*&Q*Z"[R5%HB4"4=HD80S_2\PN 9V/
M"7['_\SW\D#RO_*C'#3\5=R_['4 GNB#4HZ(%,U1G"N^+_25G]I"$@3)6F-F
M\R'2;<$EO-O2Y1Y^O$:IQ$'&?<^'V]58T1+#+?B0,$/?5UPHR*WR3?W(S]32
MUUEX/$UPT&7N%_4)]T%NM>JJ@X3SD&^_84)N$&IKD^%I@GVVTT7/^(/5QU*Y
MO&9SP[HP[B'3HB AU\<XX,[A].K>.S X,_CV7(GIK;Y>L WXUORY."8WRE12
MVI^48OA1_GW51/V?E>.7W-,S0#6N@48!Z/APDG*"_-.'K$3T9XMSA1P(,L57
MHG+Z#0W@M8EW]=Z0+U$#NF<PWI)>'1+>Z1JDGP6O BQ3[T,.C#P+O=DT'1Y3
MT6" (I0YSE6GD6<2HW7)J.]1H=JIF E+LC1<S"G7F=J;& $ IT3C0T842F<(
MQMTOOU!EP'=G^^O&$X )"HV*."W2K,XGMOD]5!TD39AY6WV#V UHD,,HL?8Z
MP+6J:IJZ?)9N,NU>%D;#I;MO_$,]@;X^<IKR/!WD1U &T^DSK2IG>B3@L+2#
M8?]2D,MU^;R\,KKF*F]-YDWU1N[WC5'*4]SZ"+Y"R,WR"Y+OXZZ<2514<,&
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MEYJ\KD[*[M9FJCMRIT\T@L_L5"0WJGZF;XX<585DWMDTKNS*R77C*T/RZJS
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M\@;O$H!M](#?"/ACP5DIH.F[.;#\OU2DA)F2'QY@RCQ6$+^AC[6VR-Y.F\4
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MN-_"7#K><*YZ?VYT8(\[[:Z<Q;II;2:1L%8(UAX+4B>0F(?HBEKXHSU-,B=
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MM-[5QO/]/VOVZ2YWO9!>5K]KW<]1*WT:\+)-LB;+YFU6$E?#U"B6L%F%K<_
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MP+Q=ZB=W8R'I(9*?[)A-&M%ACO.Z33C"#768*O#F&=N/Z#>"SM5\S35@OVA
M!0%9+#]% K"DA"1SX/^[U2B9R7^T:9[P ?^^[T]LE/_%81K*!^S:KNB<A$-&
M0'T,QX3-2A96P,R0;Q(D%+=*?=#TM$]B1Z0LLD:X$.;Z'L F0C*'Z<@=4-WZ
M4>NDBC&85!<5V_%]"KF,R*#("B5(T6M)@J@E+4>4CE^)],:W"M[YXH+MR!>'
M&4@J=+/544.JOJ-_I%IB\,!GRJ]J"?2=TCY5>U& N%'^<,M%8;=T><0%;*\H
MQ#<)O8RM<Y@!WX5_MO#5]QI3]#Y*>>T#;)L\RAQ%GR-=9; 4MHH7:UYMV2IT
M4'I$\#!O:;*O/9HEW. P$^8CGYH_J2F=S;H.I4UKN>"$;*SA'8TKZ:S97+A*
MU&(<2'V$'])\CW 37%*L\IV,_!!/^X]R0T\W:]56@[=U 8JK/?\31,FP]E+J
M=TE\X^F"7E%8C5VJ%,\UD,-?"$"5T6<,V2T1.\R$7@OHEG.-,ZLRY,VUPX1&
MX(M93'Q%/&PDDZ-SO70IE!/)2K45C; Q6GZ-L<&K6$)D9=LVX/<X#RT^]>_I
MC7*[F@[&'(!@XC*DQ !##M-NQZ VE/DX>:5J&>M,Z&O9+?99KQ"Q@#O%]@P^
MC0>8C76G^$=EI189OX1_HCJ'OX8@T\?RQ^U8K/'C_4IJ4%KSEX1JI1_Y$5[+
M10-\E>T;;!/_F^E^[0!V7&HQ\P0[><^-&>BNJBNZ*.1R#EF]"9F3M$JQ$=X:
MND%J"S6M_2;\ 'ZS^TU0#VXVK:FY(!^2W#/52+_PG V 9%/5?"U9U)A]1U4F
MG)38*6=@C)#WDA+T]MJ[PEADO9VCX'=(6(W63-/W2T*K[VO#N%+]<=7Y2IYF
MIV)S=IIR0'HK<9-LE[@X9%@\BC]9>PH?%FRR"T8-L-[XW<*LE8O/5F\Q5W(7
MZCV-#A6_-,NTE[-N*5>HX(1G,E>Y0PA'["S>M78(7X];V:6@:Q&>46+YO35,
MO,WXNK&$4ZL[5IM8(5:WF!9GD15MNH<),NEA54-(B.B8+')M W99>-0N%[F'
M!AO7F8_VW!#],M9V!'#6ZRJ;@RNLU9OJ%F<M4414?TB(EN[0'@^9*R(JH+5B
M3"9>;5>)U*%W%*^Z9%63X9UM/$(H;463E"@K7EI737J??L,LHO!C#(8TVOK
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MV>*9PRG4>\*]#9VT/IP@)]"%F#O[&(,KF%L\B8DA'S=36.WPWR&V["^0Q=7
M14#O8U_(?VOM!M]0^E3OZF.H,L6(; 6-+N.R6NAL24+1?$:3R"-E'_,>]BFX
MG1V'*ERW<MY!EXZ>)]VL73]P@GS ;%UG2ZDWO)5.HFJT(\Q66JN*5^A'OR7?
MF/(GTUO\)MB/-8JGNJ[F4)&(([=(2]H]^Z^2QS7[U:XEWZN?*5E(N68^P?B+
M^MF % CI&S3NR3)&@[PGZ#9K@^BNRWO.3%1ZQ(XH')S<OYQ4U6-?4T:.:?LL
MCJ4$-=8RYE(+:R+R']'V&6XDSV=XJ#V"Y,QK4D>7\^PA0<OA'J+CWN8^'6G6
MR'7+.=+-/K.HGGR\PXY>1?FGL2=_.RW6LCJI@7Y>EQ(4R$3EUB[][$I,L2\'
M8I<E=]V"5E0$F83@S:J9PBRPAW"2U@U*2)J\DR"#PD_Z'231Q!LP4,JXY3P(
M7F.;]D8!(]2EG:< C#:N.@_(IMW 8X (^@AU /!G-.2^ L*8K8D9P';6H0V3
M@&K.)&<F.(4+[+'E+^)=[Y#PI_".&[?RWO+Z,!_>:UXC93?O&Z\S=QE_%>]8
MPA!_&^]QH(*_ES_?.0*(XD?M_IO;C5/:?;C-&*I_S&T2B-!/W"%42;9P[R&]
M.]QY-O#E^%\\-O0^< GO*S3)>3&_ 7BW2\7A*[^W?N3P%>MUG1RQ+ <YR^F0
ML$D-G(<B<TX6-QP_&9_+'1;<#ACA)2!GG=[Q?X=H.P5LM0EL><FN-CS7MK#;
M=7;P)?9%=0+Q$&>A@IS=R &DJKAKW!DB4\!V[EXLS^D23PM?'.EE76MZU3*/
M];">KSG%>F<Y!WUC+S5^(HYC5^J69T]A/U9YQ!5P&+(5 0NXP<+#3CMY+LC/
MD5FLF)YUS86L;>W_:'YGY3>'01M9>%TA(85USP1E$=AE.E'L1\X,98[__SAC
MXKM.==RK@O'#]<R7.].:'C._#SBJ6<RO75RPB36_15)UF%56I]G^A?6M&H_5
ML3LT$?YJCEC:[R3GJ@57>PO%_J4#=?'"]^5MBG3\;B6/#V.O")&5#MA4DE5F
MG<"!8A63AB;1HOR"$05CC\,W^"7;W",2JLC/:TMQ/N69?#N&4&_R-():VN6*
M!/0D_5[& W0<<WKT;B2$%;W^.FQA[W%X O_!K>A6XS,XOVHV87]PK609 AON
M!JX2W<+-+:]"-%QCAC/\F/LHV@4.X_FOAZ #O":'_T')_%5=D*!9,--BCXZB
M.5('Y!Y2SS$@*^ G93J8"(=M0Z QJ#VJ']H*S5[O#7X$2QR.@VU ?V<>RI?]
M-#LCU5*-Q T^)YG)EL +1<32;HB%WTP_ $W$4J.L0!VZ=]UC,!J9Y+ ;7 @M
MZZ A%OU;TWKXH/:@. CZH,YB]4(;%;=*GH+]LJWI:\ -XK\W#0+/A('KFH 1
M095##V" L]M'X.=U)ZII\ ++.1$;VE0M8KX"]?K%)>O!.>K&K0:@5;%F4SJP
M60*OJP+6X0T.S8 [0F^W@?/; >,8I&W>);P,'JD7,3>!TRW+BFL!V-"Q=1;@
MJK&/_)?_3"Y8%\*_)-([U/#'T(*VH_"4@47&?"B@FRL,!W/:4AF#@*'A9O$*
M8(XE-ZV-OU]_*[*-+U1YK9O'AR4;'0Q\G<"A_I%F?FF\^K5J0GD0ZJ)PJ?R3
M:I;1JEX6Z"6'B%=2*\33R8_#=<)8V@J?Z9B>T6)'0Y^Q3?7>JFKR>/4&Q3!E
M&E(@>T6=2;DK]:,MSG\NEM*#-M\0/F:@X2OQ0.9C[Q."6C;/#D>G<=/KRI4.
M;*DJ2I[#/@8+I(WLGY3QXE^<\'Q[43ZG<7, ?H7[9U@'%L8U>TO0@[P .ST2
MS/M4RY*/P:^5FV2+81)$D51"K\C6HDM0:5Z^,!'\EM*,70-U81L%V:"7=SKR
M";ABUP0K 5*-5C8DV:K(E/P26X%B<;9PC!0LO("CN<-X(N:3LECP%OUWXT-4
MB31Y.R,;X8UV?=!7\*3EG/2&YH"\3>*J^ANX(9(I]A%1X3B9+'<R)I9D)BL$
M[B+'C2CR$'ON]0/N0B&[48@%?; X2-TL$V3?Q:+J#,!%^%1/(MS&TS6Y.PB"
ME\K8Y"6H4>:T,0")$[WS&H.=,*'=86@N_-G<+NEM7B:CBN?6C_ MPF++>T(R
M]I?Q2\X_@D+MAZ06=(WR?NA+^(YTQ&L_=$B88G<2W(W\;4Z0I'3_(9LEVMGV
MDF\EG-H44G4%*ZB-S0'1]]5)22G(D#8JM!L&%+9>!H@L^I_=.9",8IH'%NN2
M']A8]?:RARP7_<F* V57M1NK:K:O4@T0=?&IBKGD74%OI1FT\1Y?1$:&R<8)
M.\76:U)-MTAKL:U&=W(@TZ@S4^++XC3SJ(3,)B5,ZXU[+?N',2^H11+!5'G<
M%^K9L38[!&/<</7.:I"U3J#5OV!!C%?:#-;?I76JFVS_S+F*#/;^.([T.B<S
M:)LXDCO+XRS>R[UCHQ#,X%U4?3/Z08O0H[H><)@Q6^,"II2\4 X#OS((\FC@
M8-Q$R2U &31;M ,H]AC&[@*Q-KO1S< ZE9_!67@7G:YMP6_0D]4NV.D29\4^
MP<BVI[)$M"76(/Z"M&PX)U3"-1Y-F#TDMQE#=H),9;5^DW(0*=)<5$RD]:O2
M95[%!ODS2>*V/"DH*HL-$=OAH@U&_+*@P4,K$" --E^0M9!:N4!7;\R#/VC<
M]3-I0<H!#:5XF=Q/N3O]F>2Z[$?,?9%8$KBA"%\GK/(0H#\%@.WO\'$8473J
M[.H>PP+U+LL=ZFFE5S6GJ$,VH'N8#DB2U=$QB&BNO'6# W94_-&#B2KP-;;6
M<#F2H-BN/=\6!+NILYH$U"+%7W4Q11&R<-.9=$?Q77U43)BP7G4H\!N6)W/Q
MR$.#A8"M%VR#O,>!EO*25DY2P^<RL*JQMKEB>R[-'%45F3K9<)J8&*G5.I!1
MOWIE(?6^J[^4SU!8K18";#4^KSF-6,[^7O^41*Z*K('(TEPKTT+*D<U[]1K:
MLLAL]3>ZQ0]1;&1N<$V05+&763%QA.N!U37-8+QCE]5U,,,KSUK"F)T[VHRW
M6)Z;TW2%K.N1BU2WV0U^.?)U', U4\SB8E;'L39>%[:PX2@0S3I76PZ,JUQE
MGL<_L&.588"O2[FOC>/C$<>5U_AR/U]9)+_1M4!4QS]C/4WP#)@@0.L',24K
MH"9/T%LA-LU%S^1(](/(BQ2F)@E9$4%7O(&S_.9*B5"=:[GP+OC8.E@0 7H*
M)M?=DYUG'K;HI9LK%E2'B(_D_*E[*+)/F:>&<45$H&*9X.?Z3Y)>M,*5+%P'
M7[*N0O="_FA#G8OV,3/3_$)]H;S+J%$*LP=U/G+'Y+VJZY)3$9/E#%'!^N>2
M"=@/5Q[>C.+6.C0&7H8FUHZ8KS*=S91JAW*6<8Y^539%:U _2F:I?!1]X4=D
MSZ3\]0?$J"C.%<3=L6G6P\AK^#HZKW9'HYGQRKR@+J;<R]!HIF<[::T-N<F!
MROV:M'"#C*Q(7M\J7BE)<.5A8WB$]7FD&2%Q]O>^* DBQG1>+9M9(&X]7/XT
MG=,(5=Z)VU0[B? ]Q*TZEASEW:K-HQYP/*\(8R"KT\2SV%).1>]$@H5HTW&-
M:"DH;K&0#J7G-H129L;Y6O90P1 7XPRZC?<>C3/CA=-,^4K6J]7G1>.Y*SDV
MW0?H7823[4;&Y(*5S5L9G/0E==^9UG$3S%SFNY!Y^INLI]X'U;^QOS@%RI9P
MO=?X"!?SQ.SS740>0LAJ2^+%Y;<U+>8Y;CU<>Y3G'+O;E,I+"7ZF.\Y3>^]3
MS>8]<BJ4>O(WKY'CB?Q+;$)G*AI%&-<:@(CR(QNGP7]OW5XS MO%LJJC(4/P
M0>T%:*7W3J4#V.6$28K J#5C6#/P+WMQ!T\RI6JPI4"T/^]G@[,P?^M"RS5\
M>JR_L4JP)[A>\P[E>@\JLI!PIT;Q"/R[U1)L(?@/ZV+[596NBMF\1W$D[W@]
M2W8H[:9EI:0[=I)ACZ@Q&-:$XPW>.^5=@F:G?>+E2(M5O* >.L2J;4\PO*Z*
M:7;3B?+4=4_5M]+:S;AR5LP5@[4L-#A-O5?,\6Z3V^ 'G:Z*S(+)5@Q!"$QD
M4=J^U-I6Q36=,J_/D]>5&TZDR4SOM(MBCN@A)12\1;U2-LY[4-8F4CH]$P5C
M#E;5Z =D'!'<W5A\L[!S>%*I*N-8GT=Y1>+ICE^5A/"+S26$!O_9M2!YIOL[
MXU:JV:Y1]8S!6GE80F)CQ+!=#ZNN%G8.S2.<S+C<.X'X-O%A>P<Y/OQMTS3*
M __ &AM:EX>W80K#:#]#V<,ZNBI-G,:=3;3?V4 C%P(#IVFG,D:[^^BQB6?;
M$AA_A+]H&&3.\(\WWV9Y>.3I+K%I]MD*+>?IJJNB7%X%<>K(1LZ%PMC^*DY#
M!K,K@V-,;&R=R#D2?JF>PEWIGV :X)H\4.U>GIM]B]S">[@Z7*C@MQ)N#\^'
MYQ?:]H5"A(RD3C?P;B*E>0PL"C]4EP+^Z9]8W0(\]6C4' >.V#^0'05VKF[$
M;P.CA%U#SL+DPC]Z$W"?C- .;^SWQ+RF>^B'\+[:'.2-?ZIQ)S+98[_Z!>SH
ML$@V#<I:_0;?!+82](-,>4[AS!ZQ]&3&AO9"R?3$C*:YHI#P]AH]+O'?9O@L
M>.9Q7>V.ICI$2$OA2VO<L?-0%8$W\$'K6SB[^XUZ=49HVU[%P<3TQFQ9>'BM
MY9GXIO]F0Z80]7BLJL,V.I1)GJ#SUN1CI? "0L6 KOIZX:)NDB$P(Z[-6>N1
MF-EP0OD]O-&2(KOIGZ._*+[L\49EAS]RX$H0P:(U4FP9;#I?7_%GX=<]3RM?
ME@2V#1.ZRXB:YZ2L"C,P3)E7=;Y\"_4&:='65?0#%'[8<N8=NIW[*4XZ:\/9
M_:5#Q&.CI>6'2 ];<RJ[*5/4^PEBJCN_B51)*RK+I131!].B:#SFO(T4Q@66
MR3V7S>#DGOY2W,KA[1HJO<0!FY^6/^1(55F5CSDC/ +A'>??TDSR(F[(%@HU
M@ZL+O4J_P?WF/I75Q2L_Y5]X%9L]\KEDJ6!&T_JR,'2AXD5%,>+-=:@RP[22
M>.)SZ$!J,V4K-#$TG/8+#'3;R?P$;#G16I"H9 \3BUKDXH:1DD?2&CFG?(5X
M#_M#997P:7$LX0%NO_D^F2I("3E$"T:VN9&86Z&EQ[/SEYG^-^19R#5.K.<6
M']<MD<65S56[L>Y54!2Q1?E5/Z6EF]>2!D2,D!BJ&8MR6\>X  \=R\BS;9DW
MZ%T@;\BHXQ;=K"%)DTI=JQG,'^7-.D%A<U68"D^I)<V2Y0<_I\X3_G2;QLA$
MEQ\UYA+Z5@W0\F]V@K4#138M&@E00J]'F&O+/IN9!9\KN_2Y*2N)0M4?P7I*
MG:3*]2[]AR#UZ)(=GW:_Z'^?GS.47+NXL+8G37RM^&F;"T-95M8PM:"BTL%T
M,;F5N$";&1Q$"99)7 _2^[!M!R'*KT*O7CGUYW_%^XCVJ_2#F,$87^'.$#'G
M5)$+REBNQ(O)''8))3'H*.=_]/DN?_,4K)@#=J23!'8/2/Y%O&Q^0+4BKQ A
MM(C_LFVD4ZC[\BV,_73'I LL&T9/4#C[*"O71<;MY6S=UTOXBU7;]9QDQWIG
M(I-+V<%">THOVTACT"9S)N8UTID<?M)4Y@SNI VCK+^Y9I=DSD/>IKWV58L0
M8V<Z 8)_&I\1;\%9V!@Y$#I$3:2,0OZY?;04<&]B(F,F&+ AA/D-&'%9SG$'
M_AS=4U$K8[=_KEHJG620$L1BED!*&B=\2@DBJ_&L'6>I28+["2UT)W1SX&7F
M!KC-^35;#1[>K2JG&E+:+E=\UXW35U51U0*43?BJ^$*.)-7)RG>,IQ#%MQ+F
MTLJ$08$4AD50ZGR*/1L.WM52AC?,;'U:L;#FI@ZJ5)G*$1UAI?X6B4&\IHG+
M22/O5?3&JZDG):\#;1D+\+?.[2P+(M_YJ?1JIZ'5J[RH%=<>JKC7N R^7%51
M Q$/$-V-C[)WDQVUZ^-74:,4V0'WZ<UB'V<Y*QCMW2DHW3'TM&6P[)_>?[0.
M%9D='-BS\F[3!:(#H;EV578 J<.8$S="N:$N#]#2HZ4.SBSF!T'-P!7NZH*F
M1BHWK-A9O9X+E@JA9=R+Y1<(!)YKU<HL%<]"E,6^X:^FK/E/OB[0QSM- T99
MJ?U'V;.J8AI*V26$"ZJE[!.D#> ?'$]R:Q7"Z:8NWWZ:&TSKBDW@/F=L]E_#
M.\QR<7S,O\*)[3,S[1GWZAV9G4R2<C;+FOD%F,#J9/$JM>PP]OSMD]E?V7MC
M1CEG."2_(]QSW"#'D_SI/)O>"#H+BJF]R/@=FBJO9S2#/;P+S# PJ0)E300G
M9-JQ;@%[8Q:P+P%TORS.9\#=L8>WF3_6,XFV0%Q?(Z>-BF2R0GJ.,)/;Q)B'
M+RK7,AX*KF1D,>^AYFB8]0'9XC>5$P!]=-1S=X)E75\IGS5O+#BU33U'6DC;
MHOC,Z:,OE!TOVT7_+)%MZV-.%B5'3V+YXE/7[V6;4(GC?TX)7>RRI<RO66GN
MIYPUE4GD5*ZAG'V/%J8-+_U)]U4MW+:$D2J[%F5A:L2<]0#[#^R)(Y5S")G:
MB9&+6ZW-TRG6C4;Q+<K?M9UL3ZK1A):FTW3Z+>EB^BGU@BA?YF)9S_H85I-H
MO&,QIP"=V[F2]*[WK4E&[ND4BN,HFUL:6&;J[_74DDNTW\P;TE?08W0?-XTQ
MNI70^IFL6/%9QRS.,O1ELQCE%/CK^<C)HI.X% DK=6:,P+?+V<5),%QY+6T?
MO):8%DF"WI!_^I*@L[3W]J70959F4R^,5Z;HM/"\JM>8!.HE4NC'H4S2QR(>
M]"<%3YL-/J)Y13P'#]&_^UJ!!YE?[,O IYP-C7W@07JXMA@D,*8+^* 58P_M
M(/",6558"QQ@N6W9!G2S)T84 QWLQSYCP#G.P_^HA;SQ#2;@3\!*LXE_!UB%
MIO![@(G4FWR,?[_@!I_%/Y-Z@B_@[X^8S&_A#_NT\-_RN^S+@"Q^73V?=QA_
MK8[AZ7 W))U'QJ(H9WG;!='Y7WGY:%SJ=)X*V1K.Y5V TWVR^=Y0I'T9_P#X
M9YV..Z <5&5RE0H/F,BERFCD]]Q2B3Y_/9<GZM],X^[$3X0OY/TF^,O'GJ=&
M^O^CUD$%M=<YUZN3E36<PX99T#"G54LC;^#4J?KSM)S#\KLI'[@SI./#CG'+
M1#.]?_*F"^[;E_%.P(+::(Y7PTGE%(YU[1YH/F>*>2.I@?W=(,F;R+'6G$PA
M<P#%N[!2SEOI..]K7 -^^3^J#&'7/&4?[)RE4+('6[U &5O:\!=I"9M9LR)7
MRJXW9J<LXDS2R,)6<#!YC7<K-U3$_(]:C88;+#*/_&?B=DE/43GWEKBXY&*5
MGRBDW#YGN7!9I3+Q-O:%N"KDJ^ J^?I:$GJ*]MCF%W*%M4/_5%):P12]$:^N
M6L*=*WQ'Z*GDXW^3PK-9V%[RZ\1T02]U=X@!;:/7KXU =C&/V:Z&[W+<]8M$
M0]0[P@]"%6TWQP.GT$45+5@9(SOKB*",&9%P!F6QPD)\$"4[=>UR^! 'L]T
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MX%>ODHWF/M+.E$_A'U?:*&8(N]A%2C<QJSQ 522-S_BJ7BL/B7;7."I3_9^
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MN&FC9%!PJ\%,YXLD=;[%3_['Z'R:0%9JYD5U*1J-(_R+U5-U&I<2S5[\J:6
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M4KB(_UHE+54*3W!>5%X4]U5<HG"EYJSMS'2Y)78&CZ]<&SA%_!08ZZ910N!
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M_::=>>99[_O_KU7HG#P'S5K? \X^]Y4<Y/IQ+^C<;05%059N>@*[!ZU9;8O
MPNV6>Z-6(B[_6(TVH6 A]S('H38^=[*+8.^[F')7PO0V;GD:>."N*Y MB*\V
M34"/("ZL#H43D4/+H<AP5.V/9]$_HC$A<1E_1]-]*%GOH?M=XK,/HOML_I.;
MC=;OZL__#MV\20ZYACZQVAK6B?EJ>1&B!;-_R:<H*28D^%E:,9'K\W-&.]'%
MY<.L>D+5@?$<"/[@KO*\W?AEFTH@O^**5N^!_83[=#D/88VE+]F(LL9^&D"E
M[?2(]'A$+?/!.BZF+@IHVW^B("QTU?9,BB)R:OU&\HVXSI5\LG7RN:5'2 V9
MOM]%D#SSCOIGDI_['?;X%]D<A'5P(0>%V>[?2SH3M7;[9Z2 .(?U7Q /)U6M
M;"?&I2_Y:0OQV^PSWUTGW(8H_#B$Z5!']UV$(Q&Y]I4$<[1AGY*0%__EMEK"
MRJ3*=5?PE]("5D[C&[.V_H3%U^;9?1^/;X.Y^$YB3T37NN7AOH_SMCN.VY;X
MWKYEN,W)1[9YX%:FC:]KQZW.O+9R#K<O=_E/;;@L"/;["5P#O-_W<_2O21^[
M=J(U*2OL=J!?I+GL+<=LR,!M^R<F,NOT.AY&FAN^\A+F7OZ-GVYC(V E/_R*
M/83\QB<<T9,1[/H]DIIYQ;8.]4TV;.\:%"+W7UO;4,?S1M=1T*X0Q<J[Z$D8
M;=EWF!Q$S@_9V&]0N[Q[888\J$L9W)R/L;5&P"$Y>XXB/X*F;84CRV'X=<FH
MC7#]K^^C9A WEMF@U:BE/^@P</0F;RO(142@R]>P=8@9FVGX"N2:/23X'!*W
M=3^"CKRS;B?2"P7Y]1W4I^A/EJ6C )K]PVGT<\P[7G/YF;@?G$<@#W#?V AA
M/V+;]V3"KF,#MOK")=C%ZQ(0",RC7W]!1F,N+:.B4)BQ']]'<S!:MR.ES]TE
M#DY,@O>D56;)YP'?[]Q31 R1;CQ=>#0R;U4S?5E<Z7(K*BSYW(]EE >9Z=_^
MAUR?=]%UI/B);Z.]5]'U0.1^#*,V-'P'LG!?9.;&%%IU;.<J-O7[)/?E*11!
M^CM+%I&]LL]_:R390Q2N7Q4^"AZVHQ>N#O]NWS3]URC"]BO42W'?;?R\H"#Q
M["HH94/JW/)BTO7,ATN"B2?RUGVWB_@!;*\+A/9YY(3M%2HB1KIO0T%M?-%V
M.$6;)-@P2"Y(G5L52TK/M%M>2TS*Z5BB))1#7+^KQ3^"JYUG*6'Q8[;>E,^2
MENZM(<-3*)9/H#+]_0UB8GMFXZH0PID<ZO)QPC?Y44NNX9$PJ^\_PW^&N.9L
M1;R9VF_31[R=SMJ[GUB1F;:MA_ @.VQ#-F%';L:J:'Q!OG3Y+=QMZ.S2%3@Z
MXH/O(W%NJ'><6O 3V:4V+H0E.<?WG"/\/>^G;20\+1^^P05W'W)G51 N%89;
M\07V(>*;I<'8#F3E]U)L#>JFDPMN$73=@8NX<NB=/2Q<+4RPS0\7!@_8L 9[
M!;%QE2V6AERR8C%V(^KKI03L?U"/OY_%KD;7.S[%(%"R ^58+]2Q/;Y8/NK"
MM@W8%-3C#3]C/T6O7^6#&4(C5JS$L-$'EW(Q59AO?_@O3 _&9]$B /ZGU+B<
M#8LLKW?^L731HK\M^K]?_W\__^WO[_SCO]Y][_T/_OGA1Q]_\NEGGW_QY5?_
M^OJ;?_]G\;????_#CTN6_K3LY^4K?EGYZV^K5J]9NV[]AHV;-F_9NFW[CIV[
M=N_9NV^_E?4!&UL[>P=')V<75S=W#T\O;Q]?/_^ P*#@D-"P\(C(J.B8V+CX
MA,2DY)34M/2,S*SLG-R\? @4!D<@46@,%H<G$$ED2@&51B]D%!67,$O+6.QR
M3@675\FO$@A%8HE4)E<H56J-MKJF5E>G-]0;&TSFQJ;FEM:V]H[.KNZ>WK[^
M@<&AX9'1L?&)@Y-3AZ9G#A\Y.GOL^(F3I^9.GSE[[OR%BY<N7[EZ[?J-F[=N
MW[E[[_Z#AX\>/WGZ[/D+L.AO?_O[W]]YYQ^6&;S[WGOOO_^!90X??O31QY91
M?/K99Y];IO'E5Y9Y?/V-92+_66R9B64HEJE8QF*9BV4P+R?S:C2_S^;_&<ZK
MV5A&X^+J[N'E[>L?$!02%A$5$Y>0E)J>F9,'1:"P>%(!C5',9)57\/@"D42F
M4*JUU;4ZO<%RR%=G_'^.^/L97QWRY2DMQ[2<TW)0RTDM1[6<]?P%RVDO7;:<
M]^HURXEOW+QYRW+H.W?OWK.<^\'#AX\>/;:<_>FS9\^?OWA[?B#?L1&([9R>
M"UTC;DM=LBXH7 BS2@_VN#Q0WB^+J>M1I#=T*B#-K0IL1Y.,W-<@(0\;A.2)
M6CYE1L.EG9"5LR[\U=X:WAK>&MX:WAK>&MX:WAK>S&#K]%SD$G%'YIQY0>6$
MGU6[LL95?K(!9:2N5YUL[-+F-K5ID.U-:GQO@Y(\I)>3)S1B\HRTJN XEUMT
M^J\&Y-LW HG%(':.N"-WS+R@=L =JW8JG=!Z20:UH;5]M?&&[KI,<[L!VFJN
MQ?;HU>1AK9PT(9.0IOD"TFPIGW;RKP84_VUP"K^C<,BXJ+7#'J^U9T[JW$1#
M=?[5 PU1NMZF%&.3 =*FK\'V5EL,"@5Q7"@E3'%$Q,-% LKL7^UW@XWS"XEC
M^%V57?JE&AO,"<.!XJD&!\&(R5,]U!&B;36GF QZ2$=U#;9/I28-B96$,9Z,
M<+!,0CA$%Y$/_]6 8MOO!IE]V%VU3=KE.BOT*?->QDRK-6^\VTG:U192VV!*
M::RI@W2J+ :9ACA8I2*,<!3X\1(989(J(1WZJP&EQ2"U&.1V8?>JK5.OU.]%
MGF[=19OMV\T>ZG.0-K:$Z&L;4IM5==!.60VN5Z0E#/#4^&&6"C]:I"",%\A)
M!_]JOQL.. /E@=#[M?M2KIEWPLYU;R.?F-I2W-GCJ*AK"C.JC&DMTCI8A[@6
MU\.O)O1SM(1!IIHP7*@BCE*4I+&_&E!MW0ADULY ;17R0+\KZ4;KUOQ+PYLP
M$Y.;2LW=SDIU8T2#U)C1(M+#.ZIT^&YN#:&797$46QPT#7&(K":-_-6 :LOO
M!NV>H$>F;?&W>S9DGCJ\&MX[L86EZW)32<W1)H$QJX5O0+3SZO"=Y;6$;J;%
MP:@F]E&UI &RECSX5P/JS1N!?+\ST.T(>-RZ(>KBV)K$B;F?T8WCV\H575ZJ
MJJ8X(]>8W<PQ(-O*]?B.LCIB9[&.V%U82^PIJ"'UDFK(?7\UH-FT$:AW.8*&
MC=ZW^G\+.G)R:5S7J9]QU6.[.8)N/T5%2X*>;<HUE]4C6TL-^+82/;&=H2=U
MT.I(G10=N8NDHW3_U4#UAHU M\GV4<>O+J=FEKGV7UJ29#BY@B :MV*7]P5*
M2SN2M,4MN?JB1F1#D0EOIC<0FJA&8@NEGM1*,I#;" 9*^U\-U*[;"!I_W7=I
M[(=](Q>^]3+=6)HJ.[D:7SYIRRP>#N;3>Y-EM*Y<-;4=44UN0^L(+9@Z? M.
MCVW&&]!-A'I4$\GX5P/ZWS;>[OMNT\$S7^ULN?NMG_+&BE3.Z2UHQA$G.F4B
ME$4:2>81!G.$V'Z(!-4+ER%ZD')X#TH![<8H(5TX57X77OU7>]+VW<J9$Y\L
MZ[CUU3[M\Q_\*V^M22HZOQ=*.NF&QQX)IZ$/)1?##F:4Y8_GE.>.Y7.R1Z'<
MK%$X+W,$R<L81E>F#V/X?[6CDQ_^N^?Z)[_JGG]M)0 _^Y;<VQ)+OFJ7@3[O
M X6?CD3GG4@@9!U+(Z<?S2Q(/9)#2SZ23T^:@18FSL 8"=,(1OPTJNBO!B0[
M?@,"N_V [^'[1.@1>U/BF7M.ZDV:%0>S)X2QT@%^AJZW$F[LJL0WMG,+VEI8
MM*ZF8GJOF5XTV$!ACA@(Y>-ZK&"R&BV>>M/>&MX:WAK>&MX:WAH69*AR]WDB
M<HNY*77//2_W),[* E@'Q5&204%J;:\@W]A5A6ELYU/:6BH*NAO+:/T-187#
M!FKQ>!V)?:@&+SRLP(JFW[17!N%+@YO/$[%KS"V96\YYI3OAF,*W;%(6+AJ2
M)%;WBG/JNT3(QG8AL:V93^DV<PH&C*6TT3H&8ZJF@'U$0>3/BHC"F3?M3X/
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MR++[TU[N_M7D?IR6.H#6% Z^:4"QY3<@L1BTNUV!::O_G=Y-X:=GMD:/GMV
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M0LD>@RO%HW"5?,$!R1\&V0$[H-WO!>KWACYNW1=W8^! ZMD9U_3I$V[8GJG
M$N-@G$#5F:D16@P5#9BF,LON3:\E]9"J*?T8#7T0H68.P3250U"-8,$!R9:?
M@-!Z&Y!;V8+:/1XOS+L"[_;LCKQP\$#,T5,'L@>..Q%-$_XL=7^L^/_]C^C_
M^$+8D:&M:(+6EUE4)09BV\O; $0=I1M;0^M%5A?WP:K++7$7')!N_@F(K+8!
MU9X#P+##]7';-M\K(SL#CYW8%35\?E]^\U&' LV8/T?8%ROE=&1J2YMAAF(S
MUDPW$BS[*ZF-J"_HP-;1.E&ZHBZXKJP;IF,ON%<&R=ZMH'J'%3!O=KC5M\GU
MU-&M'J/GM\:WG=L%KS[L0!>.!E24]\5+F9U9&D8K7$=_^43 C#<13,1&G)'2
MC*ZGMB(,A6TP0TD[S%"ZX(!\XT] OG,ST&_:\[!CK?6YR756X^?6^K;?W)1<
M>WH72CCC5,@>"ZXH'D@4T;NSE04=<"VI#5V+:\'J,<T$ [*)9(0W4AJ@9IHI
MWU1DSC<5-RXTH-CP$]!NV@ :5VV],K)BZ^3I%5:=-U<'Z:YO2A.=WH-F'7:E
M%TZ$L0N&D_FD_APQO@<F1W<C58A.C ;6@=-"VPG5^6VDVMRV EUV*[TNN[5P
MP0'5VJ7 \-NJ.[T_K9XY^=V:[NO+[/6/5X6*KVU-9YVQ1M)FO2C$0Q'%N(D4
M-FHDFP<?RJ^"#,*%>0,H<4X_1I+=AY-F]A)D&3UD>5H/59'635MP0/O;DB>M
M/_YT_.@7W_9>7;RI_LDR)\GCM6&L&[M3J><=H?A3?CC4;$P!;":%D3>569(]
MF5N6.0%EI8_#RU/'4)R4,4Q%\BB.FS1*X"6.D"L31B@+#C3\\.]S$Y]\.7#Y
M\R7&Q]]NDX$5SN5/-H?0;ELGX*ZX9R'.!\/R3\>@LTXFX=..9Y!2CN50DH[F
M%R0<A=+BCR!H<8=1]-@93&',#(X1/4TLBGJ#+O=__-'0[(>?FAY^\;,"?+^#
M U8YTE_L],<_<(Q$W/)-S+T6EIYV.3HGZ6)B?OSY-&CLN2QX]-E<1-29?&3D
M&2@JXC0<'7X:B0Z?0V/"YG#8T%/X!3<\\<$[36<^_%()OEK!!4NW%8(-M@2P
MWP/QS"T@YY%_>.J]T)CX.U'QT;<2DB)OI*2$7\](#;V>E1YR+3<]^%I^1M!5
M:&;055AFX!5$5L 5],NR%QJHW+X8<.W6@')/*\#U=G]1Z1MVOS(HY1HO'':N
M(IY\G)W)G"Z%5XX7$Z3##+IF@%JLZR67U7<3.*8N+*^Q$UW5U(D4-W? Y2T=
M4$UK.T3?V@PQ+*BWAK>&MX;_I0;^2X/M6E#N805XGNZ [Q-ZORH@^1H_%'J.
M%T,ZSDEC3K,@E1-,K'2XJ$#37UA4UUM0:NPFEIN[<-PFBZ&Y REN;8<KVMJA
MU6W-D+JV!JA^0?UIX+B_O)'@!@1>(0^$ODG7A4&0\X((XHG*I)(93C9O@H64
M#C.)FOZBPKH>>DE#%YG5V(FO:&Y'\]O:D.+V5IBRHP5:VUD/U77J8+J.A03X
MVQ8#GL50X?;R-H ;$'D$/Q1[)]Z0^.=?$(?B3PKBB@Y7IG,/<J"2819.T\\L
MJ.MA%#5T%90VM1,XK:T8?D<+4M+5#%?WU,.J>ZKA-=UJ>&WG0@)5+PTV:P'7
M]>5M %<@=@M^*/5,N"GSS;TH"\*=DD05'A$F<R8K<T4C%2C5 (NDZV$6-G32
M2YK;2.SV%FQE=Q-*VFM":/JKX9H^!:*Z1XJLZ5Y(?QIX+B]O [@"J6O0([E[
M_"VE=\XEI3]F3A%&GY4FL*=$F8(Q/DPQ6(&O[651C9U%1<VM!:S.)B*_IP$G
M[==AU ,*I'I C-+V"M UW0OI3T.E\SX@<G(!,N? QTJWN-MJS^S+&E_T&4TP
M]9@JMFQ:GL8?E^3+A@08;6\%J;Z]E-YB+BSMU!=4]-:01 -J@FI0A%$-56*U
M?3QL=<]" E5;%X/*EP:G?4#LZ +D3H&/52ZQM[7NF5=J?)!G:P,I)VJB2F:J
MD[D'U;GB81E2T\G'US>R"UKT)<6=6CJ[3U' 'Y"0Y4,\O'*8@]?TLPG5O0OI
M=\.!M8#ON ](')R!PC'@B<8YYDZ-6\;5.B_X.8,_\51]!..H(8E]L"ZWJD\)
MU[0(L?4&+KE%6U;8)2\NZQ,6\@8K:=)A-EDY7$K6###)VMZ%! 1_&*H<+ 9[
M9Z!T\']:[1A]5^>2?JW> WK![(<_W1Q&FVU.8H[69U=U:J!JDQ1=7\,GM,@Y
MU$YA64D?MX0SR"X2#9?0E2-%5/4 @ZKM6TC_8[#?"Z1V3D!MY_>LQB'JGL$Y
M]8;9/?]2JR_Z=&<8::8CA3%@RN2WUN2K]0IDO4J$:Q954CJYG**^,C9[L+A,
M,$QG*D>H1>I!*D/;MY#^- CL]@*9K1/0V/H^T]E%/FAP3+[5XI9SL<L7?FH@
M$G.P.ZFPIRF#;];GJJHU<(-$AFGFB4B=9?S"7@:O;(!:P1\B52B'267J01)3
MT[>0@&#+8L"W7@N$MGN PL815!_P>6&P"7_89)]PL],UX_R@7^[QL1C82%]B
M85M;6J6^(4>IT$'U51I4$TM.Z&!(:#T4$;.?(. .8@2*(2Q7/8#C:/H6$A#^
M81#9[ %*:P=0:^4-&JQ#'[;9Q5[K=TT^.QF0.C,5">L?BJ<W=J7RM"U9"E%#
M?AVG#ME85(UKHZ@+NG'*XCZDHF( II -PL6: 625MF\A_6D06^\&ZOWV0+_7
M\WG3_L"[W381E\;=HD\=#XP?/Q(![1B/H^H'DKGRK@PYKR6OML0,-Q48L2TX
M/;D#J6-T0VK8O7G5HKY<K;8O7U[=NY" </-B4&6U%DCW[P+:/;; N,OM8?M>
MWVO#-H&G9]V##IWR3.F;#4*:IZ)HFK%$CJ O4\KJR*]F-*/JR29\([:>W(K0
MT]NA=:6=>3I>5XY.WI6EJUY00+3II6$=4.S9"70[#SQOVNYTJV^7^]EI6[?I
MTW;A V><,YM.>&&UT\%%@I$X'KLO0UK4 =%06]!UA$:\$6,BFQ$-M&9H?7%+
M?GUY:UZ]J#7'(&M;2$!L,0CWK@7J'=M _99]#SJVV%P<WV%[^-1NC\&+5C'-
MY^WRM,?=B(*I("9K)+Z289D#M0NJ)K:C:C"6=\*R^]?#&JD-^6:&.==4VIAM
MXEH2+B@@V;@82':N!C6;-[]HVK#S^M#Z7;,G-NX;NKC=M^7:GL3J\S90P3$W
M<ME4"+-P)(%'&<@2$7J@<DP74HWHP%9#VXBU^:T474X+39_57&S(:&;5IS=Q
M%Q20KE_\ZH9*_;KU][I_VW#RR*HU(Q?6VK;>V1)4?6-7BN"<#;STF">9=BBL
MF#2>Q,$-9_-?WDJ ]2&D^3V8E[<17MU$R.PLT*1W%&I3.YC5*>VL!05DZQ:#
MZC7+G[7\LO+\Q-*?Q\[]O*GM]FJGFD>;0H77]Z26GK.'44_X$/&'(^GHR10F
M?#RK/'\TGYLS#*_,&D)590QBA6D#!%%J/UF<W$>5)/8QI F]);*%!!2K%P/C
M\A^O#2[^;N+,?Y:VW_II>^WS5:["1UO"2F]8I11<<,W'S@5@D,=C2) CR;3L
MZ4Q&QE1N2=HDM#3E(*(L:0+-3AS'E2>,$SEQ8Y2*V%$Z-V:4L:! S<]?W^_\
MYJM#IS[YK./FOU?HGB_;+0)KW,H>[PPMN&V?@+WJE0F[$ K).1.#S#B5C$T]
MD4%(.IY#2C@&H<3-P@MBCR*I,4<PM*@C>'KD#+$P8J: $3Y-6U O&K_^^-#D
MA^]VW?CDZ[IG__E-#);O*0,;70J>[0_$/G"-@MT*2,R^%IZ><CDF.^%B4E[<
M^71HS+EL6-39/$3D62@RX@P<%7X:A0H[C4&'SN$Q(7-$;/ IRH(Z-/#!.SV'
M__F>_NEG_Y& [U:QP,I=5+#= 0MLO6#/O(*R'@9&)-\+BXF[$Y,0=2LQ*>)&
M:DK8]<S4D.LY:<'7\M*#KD$S J_",P.N(C-?/G_POX++]KM,6% ]H^__K?[$
M^Q]*P1>+R\&/O]' VJU8L,<*"IP<,X&71R((\(U^'AH0_C0Z..1Q?&C0H^3P
M@(=I$?X/,R/]'N1$^C[(B_*YGQ_M?1\:[7T/$>-U#Q7C>0\3NY  >]-7@'5@
M.6!Z;@/EWK:@PM_[>45PQ'U.9.IU5@+T/#.+<*H(P9BE$]G39%KE07RQ:!S#
MDH\BN:IA>)5F""JJ'LR7U0[DJG3].35U_=D&?5]VD[XSMWG>O36\-?RO-93^
MM\'/ZW=#1.IU=CST?&DFX50QG#%;2&!/4ZB5!PG%XI>&$62%Q<#7#D)%-0,O
M#7GJ.HM!WY]=K^_):=*WY\Z_5P:VQ<#RV 8J/&T S\?K165 ^'U>:,KUBAC(
M!78*_E1I7N%L$89]B$[A'R0S)*/X4N4PAJ,91%;6#,!$=7T0F;XO7UW?FZLS
M]N:8C:WY9J-Y 8'R/PQLMVV ZVX#^%Z>+ZI\PQY4!27=J(S(N\B-Q\VQL^BS
M3#CK$(/ GZ#2)*.D$M40CET]@.+I^N!"0R]4;NS)US9TYQE,;?DFDPG28-9#
MYQ_@6 SE%D.YZS; <ST !!X>0.@=^E 8D'A3$)I[B1^#.<U-HQUCYY=-EV J
M)Q@%DI&"(M4@@573C^'J>Y%"8S=,8>J"U#1VY!L;S1!C8QW4V*B%S;]7!H[%
MP''9"BI=#@"AFSL0>X8\DO@FW!('YUP61:+/5"45'.=FE\ZP$+R#)43)")VN
M&B27UO;A*@S=**&I"Z9L[(34-3="#"UU4$.S!E;?K( ;F^8;J/C#4.&\%50Y
M6P.1BQN0N@<_EGG'W98%9%V1AB'/BN/()ZHR2@Y70"HF65C1:%&!:I!:4MN+
MY]1WH07F5H2BN0FF:]7#]&T:N+Y5CC"T2)#U3?/M#\,*4.&T%0B<K('$V0W(
MW0*?*#UC[RC],JXJ0^#G%5'$4Y(4QE%!;OD4%R48+24I>PL+:]O)9<9&?&6C
M$2UIJ4-JV[2(NG:9)1'*T%J%JF^>;Z\,%18#UW$+$#I8 :FC*U"X!#Q1>\3<
MU?BD7=<&02]H(W!SZD3:K#R[;%R X/>5XY5MQ52=F5;2H"=QFJKQPE855MDN
MP^@Z!&A=1R5&W\K%&IKG&^#^8> Y; $B>RL@<W !*B?_IUJWJ/NU7BDW= %Y
ME^K"T*=T"91I;4[QD 3&[^!AE>8RLJZNB-&@H;*:Y61^FY@HZQ 0:CLKL+6=
MY3A]&PMO:)EO?QHJ[;< L=U^H+!W!AI'O^>U+A$/])Y)-^K]L\^;PA G&I+P
MX[59Q;UR"-\R0(6>0]1I2FD-,D9ILX#&;>,5B#LY%&U7*;&VBTFJ:R\A&5KF
MV^\&:XO!;C.0V.X'2LO^7VWO^Z+.*?R^T2/A:J-?QMG6L/RCS4F887U&<8<J
MC]\@1BBJ*W&ULO*"AJK2XN:*(DY;6:&PLX2NZBJDUG05%M2U%Q;H6^<;X%D,
M7(N!;[L92&WV ;5E_Z^U]7Y6[QAZI]$]]G*;7\KI[HBLJ;9$3)\QK:BY.J=2
M)X<I%$),K8!',G+*&<VE+%8;@\GOI#(5793BFBX*0]=!*=2WSK<_#54VFX#,
M>B_06/;_.ANO)R:'H%NM;I$7>OSB3PY&I8YUQJ,[&U,9#759/(T:(A?+4#45
M0H*1R:<UT;FE;60.KX-0+NW"L6N[\*6Z#D*)OFV^_6ZP6@$$UIN ?/\>4&W9
M_^NMW1\VV_M?[W8-/3<2$'%T-")EL#<.U=*:7*@S9G)EM7FR2C6BNE2.JZ>+
M"QI)PN)6;%5%.[)*W FOJNU$5N@ZT&Q]VWP#E7\8A%8;@7+?;J#;:PM,5J[W
M.FR]KPRZ^9V9#O*?/!B6W#,8@VSH3**KF],K!,8<*5L'TQ9J,7J2BFQ"*QC-
M,#F[+5\F;,^15[?GB^K:87Q]VWP#?(N!9S&(]VT ZMT[@6&W]=/FO8ZW^FQ<
M+TRZNQX_[N\W,AV:U#8:#=?U)]"DG:GE%2W9XB(S1$VJ1^G0>J(1JJ.;<VI9
MS9DU@I:T6DUKIMK0DB.;?[\;]J\ TMWK0?6.[:!AQ[[[G;L/7!ZSL3EYPM5^
M<LX[H/=82()I*A*F&HTKJ!Q(9I7T9 HH'7D*="NR&M),J,MNHM6GF\M,*2:^
M.<FD;$QL:#"GUAH;YQNHVO@5X.]=#A0[UH*ZK5N>MFS=>7UPY^ZY69N=DV?L
M7?K/N(8UGO1)TQX-1@@.15'*)A)*J2/I/%Q_OAC1C5+F=1"T66W4VO26DKK4
M%HX^N5ED2&JNUL<W-=3/-R"P&(0[?P;JS:N!<>.&N]T;-YT]M'W]U.G=^_HN
M67LUGG>(UIYQS1*<\D&7'@VE%DS&E^)',[C(P7P!I \IS>G!*S*Z**JT3H8F
MI:-,F]3.JTYLEU4GM-?,.R!<_]6KFSJUZU<^;5FSZM+HZI73<^O7]U_>;M-X
M;:^_]K)M?-5%YUSFG#>FX&A8 >Y00@EB(I,-&<GGY0PAJS(&<**T?K(DN9<F
M2^PIEB?TL!5QW57*V&[9O .B=5\!Y;H?@?&WGV[U_;STR(EE2P8NK]G2=&>+
MH_;V[J"J6P<2F9=<<BFG?='88Y%D^.&DPI=W$+(.YK/2QQ'E*:,8;M((D9<P
M7,"/&RJLBAUD"J('.<*H@2K1? .2-5^!FE\7/VI?LOCDS+^_'+STT_*F>ZMV
M:A]M=JUZN#N$>=LND7+9(QM]-A ..Q6#RSF>3,HXFDE-G<DK3)J&%R5,H4OB
M)O',F(/DLNB#5%;D1!$[8KRL/&R\@C/?@&+E%\#TXQ<7QC[_>/C"O[YNOK?T
M-^V+57NKP&8WYI-](90[3G'H:[[IT$MAN5GG8N!IIY-12:<RL DG<PFQQZ'$
MZ&-(<M0LEA(Q2R@(/TJFAAZAT4(.%].#9\H*YQO0_?#A];Y/WA\]]N'[S7?_
MM5@+EJZM JOW,<$V5_)SFP#T _=(R.W A,SKX:E)5V,RXR\EY<1<3,^/.I\#
MC3@'@86?A<-#SZ(0(6>PR.#3!%30:0HZ<(Z."9@KPLZWNZT?_V-D_(._M9[_
MZ",M^.:'*O#S.B98MX<,]CBB@:,7Y)E/4,:CH/#$>^$Q,7=BXR-O)26&W4Q+
M#KF1E1I\/2\MZ!HT/> :(L/_*BK#[RHVT_<*(<OG"B7;^S(M9[Z-]+V_J/70
M^^]4W__D4P%8_&,I^&4-!6S>@0+6!_*!JU,:\/:(!X&^4<_" L*>Q@0'/TX(
M#7R4$N;_,"/"[V'V'\\?(%'>]^'17O>0+Y\]Q'C<Q<>ZWR7%S;?6X7<7U1Q[
M]Q\"\-EGI>#[[RG@MY4HL'UC'K#9F0J<K6*!IUTX\'<,!J$N 2#*S1?$>7B#
M)$\OD.KE 3*\W4&6CQO(]7$%^;ZN .KK\@+NY_P"Y>_T'#OO0.&:3P!][_>
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MC#,-Y59.Y0D$![.EXHE,M70\O58VEM8@'TMM50RE=2FZ,[H4K9GS"Q2],OP
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MR;:.(,WRA2?3SA[DV-N!/ =; '6P 0C' P#C: WP3O,)X%9^ ' [O@98A^6
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MOX!HZ[= O74I,&Q=?K]MQR]7!O>OF)MQ7'EPVFUW]YB?6\- 2+BZ*SI5T)H
M*S.G$6CU.87X.E@9H@;+S=52JC(T)>)D%4^:H)++XU0&>9RZ6Y8H[9$EBUX?
M8%@,+^]02C8O!M6;?GAAWKCD5N^6)6>G]GUWY*3MBJ%CKCM;IWQ<=&/!H9+!
MR&1.3WQ^84<*EM":58!H@A3GFM'L] 8R-\E8S(^MYPJC##)19'V=.,+8)8JJ
M[1/':%X?*+88>!N^ /(-WX"ZM8L?MJU9?'%LPS='3^[XS^A9FY5=<Z[;C<>\
MG933@4&5$^$)Q2.QV:3!9"2R+Y.8VY-/2^M&%2=VDLIB.HK*(SJXW- .&2^X
MHXX7U-G)"VX9J@PU#?%?%RBQ& 3K/@?J-9;]?^6_K@^L^&+V^*^?C)S;^GWG
MA?UK&\XZ[%7/N;E4G? +9,Z&QE)FHM-1AY(@>9,9Z+2)?&+".+H@>HQ<&#Y6
M7!P\RF4&CLI*_<?TI7[C7:5^PQ-E_KWCK-<%2BT&R>I/@&[%I_<[?OSXU/2W
M[XV>^^7+SJN;EQFO[-FDNFAKS3_O[%%RUBN$="8@#C$7GI9S*BXWY60J+.YD
M+CKR!!(7>IQ$##I61 DXRJ'Z'1'1?(YH+9GHWD<&:=XS,Z\-E/_\ 5"M^.<+
M\W<?7!C[_+_&SG[S?L>-%=_4W]JX4GECU_;*ZP?L2JXY>Y&N>84@K@;&9%\-
M2TZZ$I,1>RDE-_)"#B3L' (>? :/#)RCH?U.,;&^)[EX[Y-BO-<)-<'S1(.E
M]M<&!$O?!;IO_^MR[\?O3!S]\.\=-_[]D>'!BN\4]S>LYMW?M;/XOHT]\;Z+
M)^*^=U#V_<"(Y+OA<;&WXI(BKZ>FAE[-R0BZ LL.N(3-\;M(SO.Y4 CQ/E\&
M]3S'@WF<$\'=SZH1;F=UKPTHO_O[U9:/_C8Z\L&BSKF/_J%_\I_/9,]^6<)]
MOG%MT?,]NX@O;&WAP-4M"_CX)C\-"HIY%!$>\2 ^*N1>:FS@G:QX_]N01-];
MJ"3OF_@4SQL%J1[7B]+<KI6ENU[E9KA<%64Z7Y%GO:Z'AH\7C72_OZC]X/N+
MZFY^\JX4?/ME!?AU*0-L7DL ^W; @;U5)G!S2 (^;M$@R"OL181?T+.X /^G
M*4&^3S)#O!_GA7D^@H6[/T1'N#T@1+K<+XAROL^(=KI7%N-XEQOK<+<J[G6-
M-O_7HM;^=Q?5'7GO;Q+PV?L<\.-7A6#U$CS8M@H&K#9G /M="<#5*A+XV(:
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M[/(;5T7ZY=A$^8EMH_ZPOTC[;G>+_A7SG#%I-\IX@WW+>(%[S^C'OV?>=?K
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M1+VU^6,R:?O=[*OME,5WF__W?T276SIN]</FE?4/VY=_ 0X*,F![2 [P2O)
M4U\(;KHKP<-L$[C9*0#3Y2!06"K@PM<$O%@''&(-P"[=&&SS3<&ZW!RLZBW!
M\J056+3;@/E5&S"[:PNF+]"#>1SSTVP*\]G\*^:]U3?,F/5WS)#M#[M!VQ_V
MTP''G3)@IR@'A$/RP%1=")[:*X%CLA'8M@K@YGP0Z P5(',U@1"H [@H0\"F
MF(!=GCG8EEF"=:TU6+78@.4Y6["X@@&+.W9_S ?M?YJ_M?]F_LE^PNJK_6N;
M;_8O;+]AG]A]=WC\%X!#,S@<D /207EP^Y_5&9[Q1O"VV0D<_ %PHZH G:T)
M9*$N$,*- )]H"@Y9%F!?9 UV5;9_;!LQOVU.V_^ROH#]8=6#_6;UU.&SU6N'
M2:LIAS>V7QR&,%\=^^V_X>YBO^'O_,5_&?#[Y("V7Q[8AQ> S[$5X&>X 7RM
M=@#?<3]XD8Z FYLF, 2Z0 DQ^N,2:_;3*<WJ.R[?]IM#F=T7;!WVL]U)ARE,
MN^,DI@LW8=N'?V?["O\:,XD;LOOL] _VB_,=AZ^$Z[AOA*Z_ /P.&2#LD0/F
MGEG@K30?_-'V)S)8#R*+[2"TWP<^+LK 86K^<O/6_<X(-/Y"C32?(B99?R1D
M8SXX%6/'<56.;QV;\&\<SCB-82\[O\+>=1[&CC@/8"<(?0Z?B3=Q7TC7\%](
M%YR^D,\[3P^<T RD77+@OFL6^/[[=(;Z,@C16PL2LZT0C-D# 4Z'OPMHZI^]
MV#H?/?R-QUFA%F]H<3:CY'3[E\1\QV%".7[(J=[Y.;[5Y2GN K$?=YO4AWM!
MNHO[0.[&?Z)<<OY$;2=\HIUVF:*U$J<'SMME@+H3;>,[Y2#@X#R0J"V!")W5
M$&FR&<)M=GV3X!0G TFJX[YNVF/>/D8C[&"+(=<HVV>,9(?'U&Q\'ZF8<(]8
M1;I#:*;<<CY'[7'NHMUP?D*_2GA+[R1,,MJ('YDMI(_,1O)'9@-E>D! ,S"V
MRX(WVCB"#LR%R*.+(59K)<09;?@>:[5C,@J[_UTH0>55$//XH!_7\ DOP**/
M'8KI=8MSO,E,(]R@YY&N44NIE\EU](ND4\Q.XD56!['7]2SIE>LI\@>W1LH'
MMUKJ![=*V@?7"OK$M,!EFPRXHDU<@#8.R;XY$*OR[U^/7?X[V6#=IV3SK>,)
MF#VO8O!* ^%TC7^"/ UZ_006/?Q@NVM>D?A+'HDNG:Z9E'/,0GH;O9+52FMR
M:Z&><V^F=GLT4H<\:FGCGA6,<8]2YKA'$>N]>^%? !'-\&\+]?]W16#O;$A0
MG@^IFDN_9>BM_I!ANG$TW7KG8++C@7]BR.JWP]P,K@?Q+"[Y!]B?]PEU.L.-
M)9UBI]!.>.0P&]U*W>I8=1[5S%9V)?,*IYS9SREAO>44N+[CY+J]8V>[CWMF
M_<5_&=AH^PK8(@M1>^0A66D>9*HO^I2CL^)MKM':X5R++?T9]OOO)+JH78]F
MZE\,Y5B<"_*U;_4/=FH61)+J>8GT:J\,5@6[T*/4HXI=Y'["*]_] C?/_9YW
MCL=K;J;G&Z\TS[=>*>QW'!1[.D!&&Y?7!K2%HMLB=O<L2#\TYV>NZH*)@N-+
M1HOT5PX4F6ZXGV.[MSO56?52/$WO7*2GQ4D)WZXQ2.14(PPC5_C&TDOXJ:X%
MWKF>.5YE7IF<1N]T3CLOE7.+E^+UBI?D]=H[@?N&&\]]ZQ7W%T!%9WNC#52,
MMN$$!3G(/#C[6X'*O/$2C84CY=I+^\L,U]\NL-ES-1-_M".9HGLJSLV\,=+;
MKEKB[U06+"85BJ+HN?Y);IF^69ZI/L5>2;PZ7CROC1_+N^$3PW_!C^:/\:)\
M7GM'^KSAHKRF W1T-A]M@*$;T?:#GJ,Y^V=]*E:>\[KBZ+S!FF,+'U3JK[M1
M;+7[0JZC2ELZ2;<IB656'<O!E$8*\ 6A0:1L<3@]+3#>+2D@@QWG7\B-]JOF
M1?B>\@GSO2H(]1OP"?4;XTO\7O,D?F^X?P-,=#_XHBTX?+TTI*+G:?Y>N8]E
MBK->U1R>_;3AZ/P[-7IKKY9;[FHO=#C2DDW4J4UCF)8E>6(*8OGXK*@ 4FIX
M*#U!$NL6(TYE1P3E<26!E?Q@48M/H.BR0!3X!#7&#Q2-\0)%K[T#16^XTP%7
M=+8_VD(CUZ%M?)O,SZ+=LN^K]LD.-QZ4^^>$\KR>>ITU%ZO,%4Z7VBLWYA.T
M*[-I)H5I[K;92=ZXU'A_8D*,F!8=&>4:%I[L*0[-X8HD97S_D&:!;\@%@2#D
M(6J4[QLRQO,3O_;V"W[#G0ZXH[,#5DE#S%HIR-HB_:UTI\R;.@69@9.[9>Z=
M4IK;U:2]NKW.;&=+)>9P38G3\9)\JG%.MJM-6KJ78T**KTM48A M-#["-2@F
MP5,8G<451);P>!$-/MR(#@$G\I[ *W*,SPT?XWF'O?;FA;WA3@<\T?T0M%(*
MXE=+0>Y&J4^56Z5?-6V6ZC^[1>I6VZ$YETX>7]769+*]H=;V4'D%_EA^"=DH
MO8!EE9#+=HC*\B%(TD74P-0PEE]2G <_,=W+*[[(VS.NCN\6=\['-?XV:HSO
M'ON:YQG]ANL9-3WP0K=!R HI2$)S%*R5FJA=)_6B=25ROV.#U/5S!V=WM&FN
M:#EIM*VZR5JQJ-91(ZN*:)!4QK",+O:PEQ3PG +SA&3?[!"&=V:,&SLCE>V6
M5L!EI-7P:*EM/&I:#^J5-SWE#9>9^,:+F3 ]X*U C\=E4I"V'/E5N@)YT[04
M>7Q^/G+KXCJI2Q?VR[=UJ"]K.&.XI>R4U?Z<9JQ:2H.+7DPMS3RTR@TC*N?B
M!*5^1&YQ,-6C,)+%*DAVI^7GL4EY55XN>:U<0MX-U(B72\Y;+U+&6PXY_=VT
MP'>I%$0OD8+L)<A4U4+DGU-SD3L7YR+7KJY&VJ_LD3MQ275)9:?^QH)S%GO3
MVNQ58D\Y:X>=H)B(&EVM!?4<K%>MP,F])I#$J(J@42H3F2X5.6Y.Y14>CN6G
M/!TJNE O/!S*QCWPA:B"Z8%HL10D+$:^%"Q 'M7/06ZUS4&ZKLQ&SG<O1TYU
M*\C67E=95'Q59UWF);-=\9V8P^$=>,W LV0#01O3S.NTIXW;*3Z6?E+D1#H1
M1G1N3J X-F?3[9O*&9BF%J9M\S74$-.F\2,+4S/!LJN>'D@6(I V'WE2/@NY
MW2R/7#TGCW1TR2.G>A<C=;W;9$KO')Z??4MK=6*W\?:(ZS8' J\YJ@JN$+4X
MEQB&KA<]S&@7>-;$S@ [I_-AC@X=\4YV'5D$F_8RHE5["\FBXRIJD&C>/D&V
M./V98M$Z/8B>APSER2"]-7+(U5-RR+E.6>1$SVRD]M$"I/3Q9NF<1P?G)#W4
M7![YP'!3T#VKW8)>K!+GCHL:ZQ9-BWK37=_E)L\$WR,TQW:'6MEVQ]M:=6?9
M67278\VZ6QQ,>ZXZF/0,8DUN3#@:=?W &5_]B9_.UV19Y$&)--+5*(N</2.#
M-%V10RI[YR"%0XN1K*$M,HF#BG,B!C66!@[HK_-Y;K&=_<Q^+_.ILQ+E">TH
MX8F[!J[?6\N^7ZAGVQ]J8-D?;VS>GV5JTE]N9ORDQ=SHZ15SPZ?/S0W[Q\WU
M'WVWTGOT<UI/<A"DNUH:.=<BC31UR"#E-^20W(=SD+2QY5)QKW?(AHT=GA<P
MIKF<-Z:_SGW,;"MMU':7RRAN/VZ4I&0_RCIB.\I1M1KUU3 ?%1\S&8W6,AI+
MT]$?*]35?5VGI_/ZK+[VFUNH$7WML<_ZVJ/?]*9SJQ1!.AJDD*8V*:3LBC22
MW2N') [-1:(_KI4*^;A+SF]2:;[7I,8RUTF]-91)TTW.4];;L%,."K93+GNM
MINC[S3]Y*)I\XBD9?@I0UOL4IJ+S.>'H\<_9:L>^E*EK?&G24/_:J:GV[8ZF
MZM<QU+MI==8@2',+@I1U(DA6MQ02]T@6"?NQ$!']7"?-_[E3SN.7XESZ+]7%
M+K^U5SC^,5J#^6.QP0KL-IL!?JLQD'<8 '.G+GCNT@:?/<<@<*\Z1.Q7A>0#
M*I![4!DJ% _#B4-*<%[I$/2B'D[K1"."E)]%YU]#D-A["!(\((WXPQ(I#JR1
M9L)661+LD\>#\GP[T%QD!7K+3,%DA1%8K=(#^S7:X+3N.)#7:P!CHQIX;E(!
M_F9E"-QR""*V'83D[?LA=\<^*-^Y%QIW[H%S"KOA_+0J6M'YE]#YMQ$DZ F"
M^'R71]QAD10%5DH[P489.]@I9PD'9IG D=D&H#E/!_06' ?CA1I@N5@5,$N.
M@./2P^"R[!#0EJ/%<,4^\%ZY!X2K%"!T]0Y(6+,=LM9N@Z*U6Z%FW1:HGU;.
M>71^-SK_'P3Q&D80)L@B+K  P<)2*2MT6YC 9AD]4)#5@@-RZJ \ZRBHRQ\&
M+7E%T)]] $SF[ /+.;L!,U<!'.?N )=YVX V;PMXS-\$_ 4;('#A.HA<N 82
M%ZV&;%3NXNF ^1X9,#XL!U;*L\#NZ&S ZRP$9].5@+?;  ZD[6#GO@>L_0Z"
M1=AA,$U4 :-L-3 LU@"#:DW0;SH.>J>U0/<"ZH8VZ/3I@,X(ZKTNZ'Q!_=8%
M]/UW?=#Y9 BZ'XRF!Q:[9<!4Z=^5D5G@H#(;G+46@HO)2B!@-@#>93LXN.X!
MC,]!L Y1!HOXHV":J0[&A9I@5'D,#!NTP."4-NAWZ(#^-5W0NXMZH0=Z[U"?
M4;_T?NFCGQF!W@=CT']K,KW_,I@KRH+=(3G *<_^;X6(;+022+8;@."\'?#,
MO8#E*0(F6!FL8E3!(DT#S/*/@6F9%AC7:8-QBPX8G=,%P\MZ8'A;'PP&4&\,
M?AM,&?Q$W[X:@OZ$"?H54S!\:09&TP%+-(/5 =G_UB (2O) U5@(=,.50+?>
M &3<=B#0]@+>2Q&PHB. B50#ZV1-L,S1 HL2;3"KU@73)CTP/:T/)A<,P+C;
M\+?Q$\,?QJ-&WXPGC3X;_S#\: )&;\S >-@<3)Y;@.ETP&J7#-CND_UO#8)\
M4!Z8_ZX'Z:\ -\OUP'38#A3R7G#Q/ 1.?BK@$*H.=O''P#9#&ZP+=/]8E>O_
MLJPW^&EQTNB'>;OQ=_,NXR]F#TRFS%Z:3)A-F(R;?S=^;0ZF0Y9@UF\%YO>M
MP6(Z8(UFL-\C"X3=<D#?+P\>J@N H[L<.&;KP<-^&[!<]@#5]1 0^2J_G8,U
M?N*BM;YC4W2_VN7H?\:4&'ZRK3:>M&DV^6A]QO2#U66S]U9WS-Y:O3 ;M7IO
M-F+US6+ ZH]EGPU8W;8%ZQN8Z8&-@@PX*L@"&>6V;Q9P5>8#7WL9\$W6@K?M
M5F [[?[-HBE^IWNI?"$':$RYA&M/."7HO<=E&+YS*#!^8U]A.F97;SZ*.67Q
M$M-I.8RY:3F$&;!\AAFW>F3[U>8NYK=MM]T?S!4L8#H=I@>V:(9_UT'H:/]G
M[YD% N5Y(#RV!(2&J\'/:O-/ON.N+QSRP8_N'BKC3('F:ZI8^Q4IQF"$D&(\
MY)1C.H KL7CF6&/5[W#"^A&VW:;/_KKM/?LGF-O8MY@>[!?[:]C?V$['W]BS
MN-\.K?CI 6:G#!"WROSWTWC>+CD(4)H+P1J+0:R_\F>0^<9/ 78[W@L(^U]S
M6<HCGMX:@ZXBG:?T<,-'E 33!\0,B[N$?.O;SN6V-_'U=C=PK=@NW"6':[A>
MATNX5XZ=N"G<.?Q/W"FGG_@FPD]\/>$G;CJ 1;L5!>V<GBA?M.L%*\Z&,+4%
MOR-TEG\.-UGW7F*S=300OV?(CZ;TE,=6?\#VU>EU$QO=9$2;7Z<E6U^E9&$N
MDXKL+[A4.9XG-./.$=J=SCC?<#[M/.A\DO#!N<GE.Z&6^)U01?KN7$Z>'CBB
MVX".=G\NVCL#T#QA!^0A6F7>M]CC2S[$&JX:B[+<.!3FL/-Q$/G073\W]1X>
M3_<:1V1\R2/,XKQKG,TY1JI]&RW7\12U%-]"KG-N(IUV:2!=(=:1'A&KR6^)
ME>2OQ!+J5V(A[2LQG_;-93K@M%D:6&C?XV] N\XV&8C:*_<[7GG.5)+&PC=)
M>LM?))JN[8^QV]$;2E"\$<14O^S'T3W/]S,^PQ5;GF)'V9YP3\0VNF;BZYB%
MSM7T*F(%[02YC-9)*:'U4HIHHY0"^F=*#N,S.8OYA93!FAX0-DF#&]J[?=$<
MDBW2$+M;]GOR(?D/Z:KS7F5H+7Z69K3J7H+-]NXHIX.70FEJ[4$>.J?]^<8G
M?$26#=YAF!I.K$.%9ZI3J7NN2Y%;&2F?U4#-99VE9;-ZZ)FL85JZZQ0MU>T3
M-=G],R7)_3-Y.D!$OW]/M/,*T=X9CN9)4)#YG'Y [FWVD=E#>1KS'V;IK;R9
M:K7U2KSC@8Y(LFJKQ%6G*8AK7"OTMZST%6-*^5&.A=PDIUQ.%C&+74Q)]ZRE
MI7B<9B1Y7&,D>@PP$CP_TN/84[18]B=J#/L393KH+8@T<%9*@PCMO%$;I=!;
M#^G)[+VRHP6'Y)X5J<RYFZ>SHBO38DMG,G;_Z3CBT>9(IG:MA&U<'B2P+ H(
MQ.3YA3MF">*=T_CIQ&3O DH"MXH>ZW62&>UUF17I]809P7W/B/">I(=[3]'"
MO#]1IP-4=#]PT;X9C';>F/52O]*V2+_/4Y >+MDG\ZA,:?;-0NWEEW/,-I]-
MM]_7DD0X6A=+URJ/]# J"N59Y(H#,!F!$H<488QS@E\**4:02XWT*6>$\9N9
M$OX%EIC?QQ+[O&,&"R89P3Y3=!1M.D!'>S=_N12$K$*[]UJI[YD;I=X6;9,:
MJ-@I?:]24?YZZ?%EG04FFUJS,7L;TIQ4*A.I6D6Q;H:YD5R+]# _VZ208(>X
MX$CGJ, D4EA -E4L+&4$^3>R OP[7(7^=UW]A6]80N$D0^@_21?Z3]&F TRT
M=PO0#&%H[TY:)?4Y=ZW4:-D&J2>UFZ1NUQR<=:7BV-*SQ<8;3^3;[*G)PBF7
MI)&/YR6Q##+B..9)T0+;V(A AXBP<">)))X8),ZD"H.+&;Y!=2R?P'.NO*#;
MJ#$6/^@C@Q\X2?<13=&F Z[H;#^T=T<N1R!U!?*Q8 4R7+42Z6M8)]5=OW_6
MA6J-):WEAAOJBZUWE^<Y'B[((FIFIC'TDY(]S6(3^#81<0'8D.A0)U%D+-$O
M(HW"#RND<T-KF)S0-E?/T![4*Q8[=)+!D4S2O4*F:-,!=W0;!*#=.V8I AE+
MD?&2Q<CS^H5(;_,:Y&K37KES]6J+3E3KKZLNMU0H*L8J9>>[:*3DT/1B,]U-
M(]*\K<4I_O8!B6*\;WRTBW=<"ID=DT=SCZYBND:WLIC1UU'#3%;T),,U<HKN
M%C%%FPZPT?E!BQ&(7XQ\S5F(/*F<B]QOFH=TGUR)7#BY6[:U^>C"^@:]M64U
MYCMR*^P54TN=U>**J#H1^:[&XAPORX L7XP@(\B1FQ;A[)&21&(EYU#I215T
M:M))!CGI&FH(-4FG)DS1:'&?J-,!+MK])8L02%Z /"^<@]ROF8/<;)F#7&E;
MAIQMVRG3W'ID?F6+SNJ"1M-M&768 PG5^*.1%60M<1G34%C,-O<I]+'QRA?9
MN^>%X1DY"01J=A:)F%5&(62=H#EE748]ISIE35"=TS]37%*G!SYH]X]8@+S-
MF(WTE<HC-^MG(U=;T?[?O@0YV;%-NO:<TMSB,UHKLEJ--R>UV.R-:G)4%C<0
M-86U##U^M8<QIXIGZ58AM*672[#DTC@\H23#&5]20G0H;B)ABR^2[$N>DNR+
M/Y"PA5^)#GG3 ^%\Y'?L'*0_5Q:Y73D+N=(T"VD_(XN<NK@0J;NT6:KLHN+L
MG$[-9<D=AANBSUHIA+1A%86M!%7>29H6^X2;/JN9:T)K\K<@-H38.-7'V#G6
MISO8U17C;.L:G:SK+J#Z\5:U[YVL:GXXV51,#\1SD*$4*>1ND2QRK58.:3\I
MB[2@_;NV:QY2=F.]5-[U?;-2N]06Q5S57Q-RV6*;\*+=/EZGTV'/\Q0U9KOK
M<<HY+SV7L[Y&^#-B,^R9:$M,6YJU=5N1K45;@YUY6Z>=V9E'=F:GQ^U,6[_;
MF[;\P4[G1Z0T\C +06Z4RR =C3)("]J_JR_)(L6W9B,YO2N1E-Y=LC%W5.:'
MW-99X7_3=*-WC^U.CV[\?L8-LA+Y.NNH<Q='T_&:0,O^6K">S=5H \NK:<9F
M5XM,3:XVF!E?[30SNO;(S.CJN)GAY>\6!I? <CH#20ARLQ!!.FNDD)86='Z'
M-%+8)8=DW)N#)/0O1:*>;)<6]RO-]GM\?#'WD?%JMW^L-]$>.NX@]A'W.#U@
M'G1XP#Z,N2]0L;X?K&9^/TK#]'[:<:/[15H&#QJT]1]TZNCU/=+6O_].6_?>
M%UV=NW_TIW,7W0:7RQ'D5 ."5/_[5,!E:23MUBPDYO%<)&QXM53@R$X9GQ&E
MV>QAS47,88,5Y&&+=<[#]IL=A@G;[89I"M8OW/=8O.#M-QT6*1H/1R@9#"<I
MZPWG'=$9J5;1'FD[JO6R!S5R5&MX2N78BY^JT[E6C""G:Q&DYB0Z'^V_J3>D
MD:@'LY#@]PL1__%U4MQQ!1FW]TJS:>\U%KB\UUOF^-YL%>:][5KK#[B-YA](
MFTT^,+<9?>#LT)_P5="9$._6FHC9<^QC^CZ-C\7[U28;#JA.GC]X=*H7-7I0
MY>/4M,Y4(DAMT_]AVR[CHLS>/H!?,T-+2W=W]U##T#ET=W=WAX!(EX2(B" H
M@@IV=[O&KN[JKEUKKIVHUW/\[_/"15]\/S/[ZG?.=<XM^[M%@)$] -W' 1HO
M4*#\.CL4O!>"S/<RE*0/:K3H#_H<81\M> (^VO'[?'(1\OS$$G&=#Q1SF@^7
ML)^/D[+[G")C\SE'UO)+B;S%ESH%LR]M2B9?!Y2-OHZK&.*LJ@$>4-/'\VIZ
M>/>G9F9(_@Z2?YCD_P)0^B= SBLN2$$AB$4I2A@JTP)0F\T;C3G<T8J+U.=%
M#NC&9X?>_#88*&B)X4(6&+O8%%-$C#%;U !+Q/2P3EP'VR2U<%!*$\>E-'"3
MM#KNEE'#$S\U2LZ@YP#)/PU0\CM QAV ^,^<$($"$(AB%&^4H[JA&LT1]=CL
MT(3=&JTXZ,CD-$-G+F/TY#)$7VX]#.;1P4@>+4Q8I($9O*I8R*>,U?R*V"R@
M@,L%Y7 UL4Y(%F=_:OE>DG^"[/\W@/1; %'/ (*0!M[("VXH3'% 28HM*E#I
MJ$XS15V:$1JSZ:$%FS;:L&N@/;L:NK"KH">'$OIR*& PARQ&<4IC(J<D9G&)
M8PF7*"[A6HQMW(NQCUL85_T4VNO2T-Z(#5T)3S,.9%ESH8\+/_KXB2(K6@H]
MTN71M5@%G9:HHWV[%C+[=9"Q6@\9D_IHN]$ ;;89HLU>([0^1IPS1JN;Q&,3
MM'I-S)N@-1I_)3[;H,D[!IJ^_0ETT*&AHP$;NA,L$P[TM>1"?V=^]/,51=](
M*62E*J!'@0JZUFB@4XLV.BS71?MA?62N-4"[:4-D;#%"QFYCM#UL@K9GB6NF
M:/.0>&F*MI],O]BBZ3P#33XPT.P5$\U?_ 0ZDC6XZ-'02^_?WU()H'-AL",_
M!GF+8D"8-/HF*2 K3Q4]*C71M4D'G;OUT&G( !W7&*'#>F.TWVR"]CM,D7G
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M>V2EO/61#0I61_8J6AZYK&AU^!]%^L&/2A8'4&6A;_=P\Q# .+F# U, K;,
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M&AH3Y'7U1C"LUAB&U;!G6#4/AE4)Y;!*B1Q6,8?#*I01M40ST48L(GJ)E<0
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M+%JZ(31)IBXD4SPC.%^N*KA,87I0C5)Y8)-*66"[6DE@GWI1X*!&0> >S?S
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M.GD'8+D;&$FVW>B@ +I'1- ^H@2M(SK0/#H<&D?-H7YL M2..4+UF"=4CH=
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M+W )SREIS^B?IWA'S68_\?A?L.IZ8-6TJ1V$G"Y8L2E8F?%@I1W!2OB Y4>
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M,&[F[#-NX^PU7L39;;R4L]-X@+O#9"MWF\E![E:3B]Q-IG=YZTU?\P;-6/Z
M&2M8\R_84:1O,72LR<'K\0(\'2N-^Z/E<&VD&BZ--L%9<VN<L'#!80L_'+"(
M8/9:)#*[+#(Y.\SS.=O-RSA;S:NYF\T;N)O,6[@;1K?SUH_NX0V.7LD?,-_
M7V.^A[_*_(Q@I<5O@F46+R3Z+%C)WC&LY!*BYQL^Z=-R\G0"+:\VP"\3>?C!
M4@H7QBOBA)4!#DX8@ST3)F/'!$]FZX1@9I-U#&>]=3)GT&HJ=\"JD+?&:AIO
ME64-?Z5E(W^%Y5S!,LN%$GV62R5Z+==*]ECND%QL>5QJD>5UJ4ZKI]+M5A^D
M%UBSTFW_8NA8]S5I_SZ9/)\3<,&)P>E) ARSE<7>2=K8/GDD-D^VP?K)KLS
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M8HY?"P1M!*9L!>QVD#[I&I-5UST J!X&Y(\QD#DE"<G38DB<5H+@M!;XIXW
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MD4XU[F$F[J"9M.:12B=I]9#6<GK^ '[&9AHR>W$5IW#YTTG(8WR'M[A(3[U
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M]L!RXT L-8Y$KW$">HS3L-@X&XN,B]!E7,%T&M<R'<;-S +C=F:^22\SSV2
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M\0+GQ;/(I$XA6ZN@1ATU6JC1Q4.UCST=H<X$=5;A,N?&18[)!>;B'(YQ5ES
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MC]TFI,4>$:7&72;/D4_)KZ+46+D"08'BGK"3B?3=9 T93US8?^ED'$VD-E9
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M0G#N62$H]TGR/I__* 3GR(7@;+D00LYDT>J0&3)"ND@#*:,UD/$QBZ5Y6JZ
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M8E#LDX0BGPP4^N:AP+<4,K]:Y/FU(==_ #G^*Y$5L F9 0>0$7 >&8%/"=+
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M&!7UP;!H%=D%@\+3T"^\1?X+@X*[,,R7S[.26KTL_1NH5T;R2#IU$VC1(K.
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M5>0I4*&G3 6>6N5#@O)BQB@W=E@Y<3.5%;=,F?',+O&;E1Y_D]+B[U%J_,_
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MQ@#M=?KJ/R'P<W]$D<0@ YAZR'CLF( =$[%CLF]?RG3LF!EK%<!G%EB'4,]
MP SZ8_IB ,>;=AV?97Q.(:.>_ >UTLXZ4.G;!Y2)V4FTV0,]=:(W KU! SZ=
M(S48FD1Z8I(]*^DS^U+FD7@MP(Y%YJP48N,D^N2D3.MFQ&4(78;Q2_GPDE.E
MQ<3$(K,?A?&YX$,U-Q.>YEXP'K/;B %,9KF1DZ^$HS=PHD^GT4>7ZG_L1Y&O
M)H)/5L/YUQ*GISFL,V//2K0.*5MG#@EGKCB#\7$&'SY]/9^!N)]ZB,^_IB9\
M74$_Y_&1--H<2YN=$ZS]-_ZS?#I'ZB\G[D7Q[D/Q)>-F?\@_SRLA*=Y 0KH9
M.[9BQ^4IUF%A6^G<RQ"^!8&;80^;R>8W,E=M>%HU^+NHS[H/*YXV.Z>C?Z[D
MM]C7OE-\^L[RZ;E(/^Y!&3DGUM0)1LYM-1O5;_2SSFN]F?&RE[%R*^/D5H+]
M%IR\A\;M7B7MVL)G&!\[#JG,G,6#[D2S!V<>_<]4XK?*I_<<G\Z-^G$?RHGW
MY)QX1LG(F:W[]>-^#;.!_"'\\3"+_L/TR6$"[B%\<8BYXB?$YH/,F0?O5/YT
MZSZH:'3;F-+]S_21K4WZUSK(;OUX-LF=^O%\$K/W9*06,O++OD_HQ]^1>3'$
MV@OR&@OTJTPZK^"+EU'Z(G/%41KV_,W_4G_X#GP/M_HKG.;/BB7[3X.I%^A3
M,O"/R-A_0][^'HSB'0;GFPR2UV$_K\"G7B)HCGKO1UFI9PB6G^+ )^FPQV"O
MCV@GIMV-B3_%U(^]]YZ8,T!-#6+G"?4'<P^&V8-ASH+XO0*\YX&^"[]["S[S
M)ASS-17K!5C",S"(I[#C<>PX H]Y&*;U$ SL)PR:!V&!!PG>^[#C'MCJ703/
M'03,[02(.0WT%BRY66_CSK]Y=9O?(#'G<%[NJS^8<S _E'46IG'?DPJ#F4;2
MAAB^F0ICST5^*;)KD=V,[ YDC_']+LDP\B<A?SJA,1?YBPF3D[UW7%Q',&W3
M%;J:JU=ZJS+FM)*O""WK#(Q+P(7 G -J]H"8VYH,![_;V^6!V&Y#KAO$8WL&
M\O/Q6QGVUQ(BS=Y]&%=Y]V'TT99![SZ,2[W[,.82PDO@T*O0<196;"2\KL4K
M^WQ[,#X$__#NO3!G<)X&WO2%T#V^T";#\&[!NAQ?7 ;GW@+7W0RWVZQ,I!4@
MMPRY-=C?J/-AD^?!_LZ%VYU-C)Q%C*S#CC.PXS0M)3+6\.]\K:;U)],*<WKK
M"KVLY43:<G2?=,(]('?Z0M\, U,#.%^F!A&(/!OR7" 6I#!<LY!;X+L/I)J6
M-B"W%;F=R.Q!Y@!3IV'\T[VG4"SDG05\<QY2Y] SL^G%6434+'T"CGMA[@&Y
MR]?VS;XIR$P+JWW3TS+&R%)\L80^6:PXD JRD5V AE)D5]'B>N2W(+\#F6.0
M.8 %$_'&3*)UL?>$CHGTQ@0B8CR>'J;'AXCX(6)S&/W#WOJ<M27M;)]NI@EO
M>=PL#;,4Q-(4@<Q($(W<>)#*B,Q&=@&16(K\*N37(;\9>1U$1@^],H@E4XC8
M>43+"GIJ'5>W8.$.(N@^\ ++_U<\'O?"E)Q-67B5;RDR2P2S*?)9FN6'W% D
MVKWUAW'R(#L!I"$_6_W8T:L2Y%<BOPYY+<CN)$+Z^/]X+)JI47BQC1YL)9):
MZ(]F>KZ9N:+9^TM,YC2BX][^/]747UCR9C*E3>1Q$/2S'/<R[?<0%]T*1[8#
MV2/UAT3DIS$RLM%1@(Y2=%0AKP&Y;42KJ8B,HY>F8MD"1I*YB^@"(NAJ/G4;
M> 3\"OS9^[OAYZ)OA;D]F*5_DHWT!HPQZ5FXE:JU!?FIU2\$^1'(=ZB)V&@D
M1AL9*PU*1T\V.@K048:\:N0VX94.5>"E<GJJC%XMI3]*&)G%1'V1]@!S O$K
MX OPO??/'HO1.XVE91#T.*P_U;6PY#5RO1Y[ZL("5!L4JAI_NZK]G.B)0D\<
M>I+1DX&>7/04H:<"/74\:_-6B0KHR7SZ(X\1D^NW3CE^EV+Q+G _>!Y\#+[5
M*68/#CHGF3_-D89U@A90S^L:TN5*WBNW^ZDL(DAEH>$J#;:K),BEHL!H%0;$
MJR @1?D!F<H+S%=N8*ER@JJ5'=2LK*#1R@P>5$;P#*6'+%5:R)E*#=FBE) =
MX%XE!S\#/E1RT-=:@8Y9Z!PF_1I#RM$&&DS=@]?E7"_!EB)L*7 $J, >HOR(
M".6%.90;YE)V:(RR0A.5&9:FC+ <I8<5*2V\4JGAC4J)Z%1RQ#@EV:8KT;94
M";8S%6?; G8JUG:O8FQ/@P\4$_&5EJ)C&OH&2#6Z2(F;3>T%E/.Z&%L*>"\/
M6W*<?LIR!BK3$:I,NTT9MDBEV:*4:HM3BCU9R?9,)=D+E&BO4(*C07&.3L4Z
M!A43.4.>R&6*<IXEM_,RN9R[P4$Y(W\.?BM7Y)^T$!V3T6>VJ[>3#C> *E#*
MZP)LR>6]+&S) &GN *6X@I7L#%.2TZ[$2*?BG1[%.1,5ZTQ7C#-/'E>9HEWU
MBG)UR.T>D,L]34[W4CFCSI0CZE*P4_:H^V1W/RV;^P,>X=WHF("^GCBK!E0+
MRGVUESQLR>*]=)"*/4G1_DJ("E2\.UBQ[@AYW Y%N]V*BHJ3.RI5KJ@<N:*+
MY8RN4:1GE!R>?CEB)LL>LU"VV%,5$;M!X;$W*BSF@$)CG@2_4ICG"\TVM; X
M:Q]0,Z@F%2[EL0!D8TL&[Z6").R)C_%3;$R /#&!BHH)DRO&+F>L2Y&Q,7+$
M)LD1ERE[7(%L\96@21$)S"P)XQ66,%<AB:L5G'B1@A*O4V#"'0I(>%P!\>\H
M,/XSS3#W@:&OP^P! I6@".2"3.Q)X[UD;$D L7%^\L3YRQT?*&=BB!R)-MF3
MG+(E12DB*5[A2:D*2\Y5:'*I0E+J%9S2H<"4006DSI)_ZDKYI;(:II*0II!T
MIL WD]\"GVE*@G7;PBA2\#I0!@I2K/I/.M=30"*VQ(&81#]%)?K+E10H1TJ(
M;*D1"D]S*#3-K>#T6 6E)RLP/4O^&47RRS!_M&^C(1"53 A*)N0@DU4AD\P@
M8Q\@\4S_!?A<$\V]:-"REC3Z 92 O+03ZC^\GP!B0!2O7:G^<J0%RIX1HO"L
M" 5GVQ68[91_#H&5DV!MW,DUQ8,*ZP"/7'.(@SE($K*0"T'(987*W<OG'@%D
M+]F?:PA]7>G67J0*WQX@(R;#U']X+Q%;XGB,!B[>BX2^V;,#%)X3K."\< 7D
M,\D5,H$4,<"*")HB#"W*L39Q%)/+%T.0BR%-Q:S&Q60&1>32123HA0\#;"CX
M0F/-?BAS'Q@HR[+V &6A)YWKR2 >>'CMYGHDHNUY<* "?P47!<F_A(6FE,F\
MC(FN@HFFDL%32:=5\J5*N%7E2"T&$E-)-E!)/E]!IE(!(2DG<RS#AK(OU6/V
M0R&[ZH0:4*;9@X3.1!YC>.U&KQ,*;2]"/Q0VN,Q/_A4LK%4LM-4L.+4L+'78
MT>"V)IB&5*NPU$!_-$#>&_H!)+D!LE@/2:O;"2 DM<=8$+Y4)UW7 ,KSK1I0
M#OHR^'HRCW&\CJ(Y3O3:RZ0P1+(<R*^6!;\>CML([V]B<6W!%ZVFP(\O.HB+
M#GS1@?,Z2JR#7LP?]MN)B79(\B@(5!LDK15RU/(R^-)['E!-D;4/R%L#HKVI
M/,87$P-TJ;/"JO^$UL'!&] -1R=90!;HP(XN[!@=:BWXO0YKX1L;8VW^&TM#
MQE9QK=TZZ**/F.@C+GLAICWPW3'/2]V?><\#JO3M \HKMFI B68/4I55_[&C
M-Y3P]F\S.N6KP0!3#\'%&B#1&6?VI= OX[%C(G9XSTIA0IF281V$/1G#)T.L
M)Y&E32(F)A*7$QB?PT^!CU0W<B^8KP:47&WM 7*9^@]Z0TSMI]NGT]1@!KU)
M'G)DU4-,XN>MB9",S<*.N=BQ #L6L< L9G)91,<NHD$+$;2 +RQ@GIAW"9^#
M+,^!H,YZ5]6TM0R]>3RFT>8XVNS"=3;:&VSTCO/IG.339^HOIO8RUY?\FGT:
MBWW)\')\LI+$;#5VK(VT-JB>SJ ^#0>?AN!3$;9VOK2&_CB%^7(5K.;DGZO:
MG ?4:)T%E("OW?C91GN#AGWMG.%+LHV^D?MR5OJ2</.'R)%ZR,A9)=Y:"'VS
MGO&R&3LN99QL89!MQN&;NB P<.[UITB7D,U?Q%QUX1&5XN]LW)348^W!L3.=
M!$[SM7.1?JR_C.P).<='@OZY_T0_GE%B2)+Y0[&I%]Q O.YD_MC#6-G#_'DS
M@VPWC=U%9^[ <3<R/FZ$V=QPC_+1G8INC]F#@XE!\WQ^/;$.,K(/98M/CR&#
MIA;BK;G(.K=CMWZL@XSLU3"UB4/XXQ'&RL/,&8<9 (?PQ8,X]P$:==]62.:M
MRIA@W0=ESB$.6>;S[UD^O:8.<H5/W\@9K2?^1L[(N20GWB-C_GAO]H.8301F
M+\@+Q,CKQ,<Q8N-U)KQ7Z?Q7&*<OTK%'\<7SUWKOOS#['TS]P?P>JOE-UF_@
MF7\B=_Z*_/US;_9;HM^0O;]'AO\V[.(8@^15@O4E&-91 O7G,*-G8'\_PX%/
MXL#'X)A'O/>B7(99-V+>G;"K)^#5'WG/WC#U#W,.YS6^^L,WLNH/YK=(3!W
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MPR].Z7[)Z,E 3QXR2Y3B5Z-DOU8E^?4HT6^"$OSF@E6*][N0$7XMN ,\"3X
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M,7*#0><SAND"P6EJO?@DA27K(3,4G7?2OPT.R&!^=_=ES9*J/MEZP>@.0G7
M$=-E></&PI#?!$LX=-@6X\@=A S3)Y%@!KABS.C^@2RDG"&)ZD^11.(!(D_6
M2^ HNNXDX)HV$;AG0(:7YP'+W-V7M8MA?8K5 FC^MZ1T>^QQ\V%WQ)X3=)FJ
MDI:;[R#D"G2O0(;J9TG1 R/[!X*8> HKI@_AI(*3.+&T%RM0=-U)-PQ//@6<
M+T&&=W9?UGT$Z]<LYS=I-I@;+%ML2<\NI]>>&[8:8:F1=Q!*-;I#K$)UU2M0
M/70Y:N3MP4F<E' 2+:6<1,K8_2B%N!<EDW?=2<#]X 3@>6(&<,V:!ZQO[;ZL
M_[#ZI&$!M]FXW-CD76$*>G9Y;+;C$8.I.J71HYNE6E0;7XWL8*F0G50EJGOD
M[0%&CNM%RDF]"#FM%Z[@]L!5TJX["7@>F "\C\\ [IGS@'WV[B^-\ZH'';/9
MK9ZWM;'@8HO=M<]GL)Z(JDW5284!W3CR!H&C1;;2;[X_P*LQ(V\/.FM51.B_
M1^FJ5C$[86I>QYT$O/=/ +Y'9P#O\_. \XW=7]GG5)R)/%/7%'].X_2M<NB=
MAP(J6V%$;JZ.2TRH%-> ;&3J44U4W8W[@QOO#W!MM1I"&UQ#;J_6T-JJM.P[
MZG?_U F_!Z8_^:?_F0^ ^Y7=5X,SBX9[IF*\T5=U.N\&E\*9$9#8BL(B:TV,
M;[YY@V"\^0;AYOT!6H\;O3V ZTG-U7IJ<Y6>?D=]%[SWGE]#TYZX'GKR_=]]
MLW9?;'\HLW%P"MX8?ULM]6SW")V9?KY]] 8A4O\?-PB8!-Z$26),V"3*]._[
M@U2-D=( ,];=4<.1B7?_%+O_\9]CC[SW3>/TC6VG[SWB'+H?)VMZ3\(+;;=P
MW-E>EK/DY@T":O0&@3QZ@X")XJPW;A!0%GQLY 8!82'&X69RO-I,O:,&8Q/N
M_JQARF/?-CXPMVMHR@K?EU,S56<?JZWO>I]%:]PBI<8RM)10@8D<J+21? @G
MWE/KQGI0'K0;[46Z,+Y:%Q;Z59P?[L3[JYV$ ,Q!"E0YR,$[J3<QX:[^EDG3
M>WJGO!2\<.]J[8\/9W"_F%5&.3T/@^O=4(?I.,!!M>8*D$W%DIJ&,ADL5:FH
M2,)4Y0FXNC2.T)3$D-KB&$I7%,7H1V\1(GC#B3#1>"=UI";\H[-MTK3(X*37
M#=?N7\6__O1>ZK=O'<-<7%H"O["QNOK,?G3E8!:AM"^/6M132#_15<K,[ZQ@
MYW7 .+GM-=R<-@3W6!N2E]V*YF>U8@69+7CAT6;2'=7<.'%\K'O"0Z8O)KTA
M!-.7T,#+&['7Y^U%_+#J2-776_-*+Z45G_@LHR+W_+'J[.%\1.;98M21TV7H
MC%.5V,-#U;A#0PC\P4$DX< @FG!@ $M,&R"0TOK)Y#LIT3SAG]:ANZ:+P7TO
MT\%3[^/!F\MJP<+U57^LW5'ZR_;]QW_8EY%Y]5!V^M=9>0>O'#^Q_\O"PGV7
M2HOW7JPLV?-%=>GN+^!ENSY'EN_\'%VQ\S-<Q8[/B)7;/Z54W4E -^-NH'OI
M4:!^;S:0+5]S7;@YXS)G?_5I1AZC@UZF3-%K'0DZWA6G43Q12ITO0J 'PEAF
M,(1BAT.UW$@0SH\&JT71 $P:"U0J8H$*33Q0;HQ[RLVQL?:WX6_#_S[#DS<-
M[\X&\A'#IHPO.6G5IYBYS YZJ2I)1S@2#)PK3B=[HE2J+T*D!<(X1BB$9H>#
MM?71 )P?"U2+8I A[J]4)/P5VH2OW)APEIOB8PWH(8/^Q4>!9NYLH%BVYE?1
MQHPOZ_?5#+&R6&W,(DV26>U(L#"N&(ODC=(H_C"Y+AC"T\-!##,:0'+B?@0O
MX:L6)GTP:<I7J4QY*W0I9X4A9:TP)L8:T#\!&68]"K0CAJ5K?A5O.'*)NQ<^
MQ#[";F6=T"9958X$&^F.<8B^"(,4"%$IX2"Q+AK ,N(^%#OI17!3WAIA@P<F
M;?14J9J<%;HF2Z6^P5!I3(XU8'C\;F"8^0C0OC,;*)?<-.Q!#-8?9K>RC^N2
M[')'G(-P1^OQOC"+& S1R)$ F1KSX>A)+YK5X*FM;W+7")M=,%F+JTK38JG4
M-ANJ=(T:F"$YUOYMT+T]8EC[JV3]T8N\78A![D%."R=7G^24.N+<&G>4A_6'
M.810D#&Z#TIX"74-'@RCR55;W^*L$;8YJN7MUBI5NP&F:=' =$W*:D-JK(T:
MC"_<,*@6K_U%\LG1BX(=B$%>&J>E/MN0Y!8YXCR8.\I'^T-<?#C (L1\=:2D
MAT1M=&'I+0XDI]T.%W;::A1=AFIEAZ9:W:JHT39)X8;46 /&QVX8]&]!AD4W
M#,)MB$'!7DXS-].0Y!4XXH(*3T2 ](<$^+"?@X][&<0&-X7<,G(38T.QNZP(
M88\!+NM1PY6="KBZ38+0-HL0^M18NV%X_H9!#1FDZXY>%&U!# IW<9KY&8:D
MX+@C+BSS1$2(0%"$B_AYN,3(78RSCMAF(U*[+!A6GPDE.JFNE?;*:Q5=XEIU
MFP"I;>8A]0UC#1@?O1N81@QS(,-'D&%MYD7Q)L2@>#NG67#(D!3F..+B8D]$
M4AT(2K!1GW#TC5*+G8'OL%#(O48\<U"#$0[]:P?#1ZO:N6AM,P>M;QAKP/3H
M7:,&PTV#;&WF)>D&Q*!D"Z=9M-^0$F<YXM("3T16%0C*4%&O!-LP^C:'@^LV
M,8@#.@IC6$84G!;@)?U<G+R;@U.ULW#:9B9.WS#6;AB>@PRS9P/-0LBP)O.2
M[!/XH&PCIT6R%_JFR;#'%7GNB+(L$%#6QCP*;*-#@FVW"'%]>B[AS,@.A$_C
MGV%3)2>99'D/G:3JH!$U+74$?>-8 Z9'[@)FR& <,7RX]IIL=>8EQ1KXH.(3
M=HMLISZE.&A/J+/=$6U1(*"MCGDTV$:["MMAD&%/*J"YG\<CGV?Q^&=I+/$
ME2'KH=0I.RE432N9HFL::\#\+\.;LX$6,LA79UU2K:H94J]BM2JWZ!HT>VT)
M0[HK:LKS!\UE$9<!U6128SM5<DR?4((99(SN'YA0X@$B5]I+9"LZ"0QU&X&F
M;1IKP#S]+F!Y]A%@&C$L6'M-\7'6EYKEU:?TRYAMVG7:1N-62\J^UQYS'_&Z
M+:4Q"S1K:M68#BDT^W-DJ'Z*!#N($U.'L%+> %8B[<7R%5W8>E4[EJ5M'FO
M,FJ8#DQOS :Z^6M_42W/O*Q?##MM_I#>85ZJ:G:N-J8"FZU>YU&_Q5(6UT.?
M@P*:_P70[,^ '$3H\T#+2/VU,F8_4B'L1<H474B1JAW%T[2,-6!Y^"Y@?68Z
M,+_^)M#/6_N+=O'1*^8%E6==[U"[?7.EK;%Y.K]OF]/BR [J+.5QM1'5(-:A
M6NHUR+8Z-:H3K\1THQ2$'KBBKJ=&R>FN44DZ:Y2J=KA$TS+6@/6ANX#MZ>G
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M:46R6CGR$J$@BM<?#U.-.6&VZ5A(:,H.JTR989,I(^BQ9'C]MPTH(8/FV8G
M\.*CO_N?>N+3KH<>;_W\\5>"WS^_Q/S'J]ND/\P]POYR41'I_-H:]*E=.'C?
M$6I5UW%F:7L)M["E2I#?A!#G-F*EV0TD>6:*KCB2Y"K3DQ(HC?)PRJ8XD/"K
M;A?0/# .Z)Z>".Q//?A5T]3[VS^=.CWT_6-OF/]\?ID4O+&-_>.\=-)7*XZC
M/M]47GUN+[S\]%%,T6 >(;^_B)+34T[+ZJYA'.U$L=([")Q#[=3Z VTL[OXV
M 2^M3<;?UZ;G[VUS\&X7T-\_#AB?F/!]Y+Z)[3V3[PE=G?J$^<_'YTC!S&4L
M\/9FXB^+TI#?K<V$?;4]O_32_I*1EQ$YYW.JLX8+$$?.E*$.GX9A#IZJQ>T?
MPN+W#9*(>P;HI%TGZ\D[^T7D'?U*RO8^PVT#YOO&C5S)M#5-'!\:F#3)],<#
M,Z1@QFP6>&41$;R_KO;/%=NK?MV85OSCKO2\[_9G97Z3GIM^)3O_X.7\POV7
MBHOW7:PHW?-%3=FNSU'E.S_#C[Z$V':! =MZH;YZ\WE1]:;SRIK;]9UCXKCV
MR#WC@NT3QIO.39@B =-F,,&SKQ' [ \08.&R"K!Z;2'8O"GGSQT[,G[;M^?@
MKX?3TJYE'MCS4^ZAG3\6I&__H?3(MN\KCV[Y#IZYZ2HJ:^-5?/:&;RG'UG_#
MR%GW#3=W[=?BO-O5Y?WGN$#R[G'&_G^.%_\R90H#//(8'LR<"0=S9Y>#)>_G
M@U4?98(-RPZ!;1_O [O7[@('/MD.,C9N =F;-H&\+1M P=;UH&3;NC\KMZ_]
MHV;'ZC]0.U?]CMOU\6_DW2M_8^Q9<;U^[^T*!O\YSM@V?IQH>-QX.KAO(A8\
M/JT:O/)D,7CWA1SPX:OI8-GL-+!F[DZP\?VM8/O\36#/A^O!@8_6@O3%:T#F
MDE4@9^E*D+]L!2A:OAR4K5@*8"N7 ,3'BP%FU2) 6KT0T-;<+E-RW#C1R7'C
MJ#^-&X\!]]]5!9Z<<@+,?/ H>/W1_>#=&;O PN>V@A4O;@!K7UD'-K^^"NR8
MO1+LF[,<''Q[*3CRSF*0_>XBD/?>0E#X_H>@](,%H&K>?("8_P' S'\?D!:\
M!^@?WBZ ?&@\0#U_#T"_^S! KIP):K;-!8BTI0!Q9".HR=O[:U7ID1\JX,>_
M*<657BZFPBX6L&H_R^>A/\T3X<[GR(CGCJG)PUEZRME,<]V9HP[:F2,^VNF,
M*/UT1A/]5$8GO?MH-ZT]\];];;AI0$$&-&3 0 849(!#!M2^90"=L1$@<_?]
M B_._!Y6?>*K"DSYI5)RS>?%#/2%@GK\N7PA:3A/1CF3HZH[?4Q//Y5E9@YE
M.EE#1_VLH2-Q]M"15G9/9@>[-:N#U9C=P;Y5 #UM/,!"!BQD0$,&U-9W 6[O
M,H!+W_0G]EC:-61!UG?PJL(K,'3EQ0I2[:>E=.RY(@[I;(& >CI?2C^5IV(.
MYNC8@]F6^H$L%_=D9A JQ>O);.6U9K=R4\=:>;&<6P<PD 'WW#T !QDP*V<!
M[)9W 7'/,D ZM.E/0G;:S]@3V5=1%467X4C8YS "ZD)%'>%L"9MZNHA/'SHA
M80T<5];WY^IY?<<L_+YLMZ W*RSLS6H2MAYK%J9RFH21W"9A,._6 2QDP$,&
M F3 00;"YG<!9?<R0#VXZ4]*9MK/Q./9WV++BK]$(:H_@^,PYZJHI#/E3-I0
M"8\U4"CF]N4K^;UY.E%/KE7<?<PCZ3X6D[;E-$A3>0W2")3_>(/4DW_K  [Z
MV9X &8B0 0\9R)O>!?2=RP ];=.?=1EI/U-RCGU++"ZYA*V&?XK"X,[6D*FG
M*AG,@3(NMZ]8).@I4(B[\G6RSCR;O#/7IVC/22A3QQ.*<'Y"Z3N14#JA; 4)
MQ:T">,A A RDN0\# F2HVS 7,+<O \P]F_YD'$S[F99Y[!M*?LDE8B7\ A:)
M/X,DT :K:9R^"HZ@IU0HZ2Q2R#M.Z%3MQ^WJMKR@IB$_I@F=B&H]!5&MHS"J
M-1?%-,:BF/I6 0)D($$&,F0@KGP1,-;/!>PM2P%GY\8_V6EI/S/3L[^AYY1<
MI)8@SI/@A--8''V@ELKM@;'$G>4">7NQ7-U:H->UY#OTC?EA0[@P9' 7A8RV
MXI#!5!(VZ$K">DUI1'>K !$RD)^]!U @ WG%BX#]R3N NW$)X&W; 'B[]UVK
M/Y#U+2NS^!(]'WZ>6DDX340Q^C$D7C><(6VOY*E&=H/-17I38X'''"D*F-W%
M 8NE)&#1EP;,FK*@65D>,LIO$R!"/\M1( ,5,E"7SP+U:]X!_$\6 ^&F]4"X
M8\\O@KV95WF'BRYQLFLN,(H)IZEP1C\!S^]"U<G;JNNU3>4R4T.QT9HH\MG=
M)5Z[N<QKUY7[[*H*GTU>Z;=**@,6<570=*L "3)0(4,=9* OFP5XJ]X&PC6+
M@'C])T"R9?>ODIU'OA/O+[@LR(!]6G\<=YI10>^GHOB=.+*\!<'6-U1*K<D2
MB]-7ZG:9R]TN387'):_R."157KL(YK,)JOU6?G7 <JL ^::!!AF8RV9"\_];
M0++J(R!;NQ8H-NZ\KMB6_H-B=_X5V<'*S\19Z+.\PKJ3K&IN)P4G;T8S# F8
MQ!$LLWC-Y4ZOJM+ED<+<+F&UQ\FO\3JX-3Y[/=QGX\#]UELU:JB[:> LG0F$
MR^8 V8J%0+EJ-="LV_:[=M/!GW0[<K[1[BN]J#F,.*_()?:+RMDM+*0L0J08
M74B>RU2M\RNJ[ %1M=/'@[O=]0B/DXWP.EBU/CNSUF=CU/JMMPI0( ,-,M A
M W?)"T"\9.0%VP*@6?$Q,*S>\J=I?=I/EBV97]EV%WQF/UAYRIR':E65,"."
M:IF#CC-I"4RW!*T(<FNM(1;2X6>@7!XZRN.BH;R..I377H?RV6X7H-X_'M A
M P,R\!8]#Z2+W@3JQ?.!8>D*8%FY\5?[VMU7W9L/7_+O.C8<3"_H<N74)@R%
M#)>\0JKC(DTB>IV;21:'*$1KF(2W!TAXIY>$<[M(.(^3A/4Z2%B?'<IVJVX8
MGKD',"&#8.%S0/[A&T"W\ -@7KP4.):O^\FW>MM7X4U[/TOM/CB0/'2\*9"%
M\-ORZ49=J40BA1L9?*(;S^8'D2QS&$6S!S 4IQ=+=KFQ)+<+1_0X\02O T_P
MV6X5J(,,#,C FCL=B!8\"\W>KP'#_'>!?>&BWWQ+/_XNNFK]I:9-FX>[]NSJ
M:#Z0&XT=A=N\N74*:Y&8HX/I"0J<LT;"\9>)#:$JGCU0PW+X$'27!UGG=J.H
M'B>*[+6CR3[;K0*TJ>,!$S*PWYD.)!\\ S3OO0(L'[P-//,7_!Q9M.2KYH]7
M?-J_=47_X(Z=#9UIQSR-Z=6ZZ#&*P%<@H#B@N=>$MI7HF9[C>JVO0 G]%A4Z
MO15<EQO&=KNJ&5Y'#<UG@]?YK;<*T"$#"S)P((/LW:>!_IV7@&/N[%]#[[W[
M==/"#R[TK_I@\-PG*]J&MV\/#^S-LG0>JI0V91(9\>-<=*A44>9#&O,\#'NF
M1^/*LGE<Q]5N5Z'4XRP1>!UE7)^]@NVW5K("EEL%&)"!_<S=@/O.PT Y9P8P
MSWGA#]_L5ZZFWG[CT]X%K_>?6SR_Y?-5ZR+GU^^UG]F>HQS85U'?G8$CM.<R
M84TEXL($4IT3H1F.AJ3FC)#+?,3AMQ[3^ZUY2K_UA"1@*10&S46\H.E6 29D
MJ'_Z;B!\:QK0OO$X<+SZ]$^Q5Y[_K.N-Y_K.O?-ZTZ4/%X4N+=MD_7SU0<6%
M#?F<X>TPPM !'+SG&+VLK927WU@KS4Y2E$?B?$U&W* ^& OJ#GO"^B.6L"%+
M%S;D*,/Z7%E$=ZL "YHW>9!AY-+7^/+TW_PO/':I[=E'^X9G/=5X:<Y;@6_G
M+;=\M7B;_/+*=,ZE3TX0/]T&0YP^B"GORZ$4=)6R<MH0O*/-1%%Z(UMRL%$N
M/=!HE^YKB,OWAQ+*@ZZX,MT25V88;AW@0 8!9%"]>!]P/'O_MZE'[^\_\\C4
MQB]?>-[_PYOOF7]\;Y7L^X]V<KY;F4&\LB$?\?G.BHKA]-K"H5Q<;G\).;.G
MAI[>B6,=Z*#7I[4+N7O;M+P][5[NKK9&WNYDLV!OL$F8YFD2W2K NW<<$#]U
M-S \,_&7T$,3!_JGW-5X:?I#OA^??\ET_8UYLNOOK6%?7[23^-.JP[7?;,ZM
MN+2WN."S],K<<[GPS#/%Z/2A:MR! 0QQ7S^5O+NOGKJS5U:WH]=$V]X;J-O>
MVU:WO:V+OJ.QBW&K@&#*."!_ZB[@G/;/WJ;)_V@<FG*/]\=''C6 %UZ5@C<7
ML, 'JXE@Z;;:7];MK_A^^]'";])RCUU.+SAR,:?TT&=%%?LO5,'VGD?6[!XF
MUNXXRT!N.R- ;SVMQ&P^;8;R8S:=;D5O'AJZ94 R>1PP/C2^-S)Q7*I]XCCO
MIU,FZL&CCXO!S%>98,X\ IB_ @%6;JCX8]/.@E]VIAW[*>UPQO<9F0>^S3FV
M[^N"O-U7RO-W7(:/O((HV@+]L+7I"W;IQB]$9>L_5Y=_\KFYXI//_!7K/DO>
M,J"8,&[ <]>X1.*><>Z>">-U/]PW102>>((!7GH9#]YY%PX6+2H':S[.!YO6
M9X$=6P[]L6]'VF_I>W;_FIVVXUK^@:T_EQS:_&-5^L8?D!GKOR<<7?<=+7/M
MU?JL-5?%V:N_51];]:TEY^-OW+?LC'G<N&3@KG'.YKO&:4[=_0\!>& *#3SU
M*!:\^D(U>.^-$K#DO5RPZL,C8,/2 V#;RCU@SYH=X."Z+>#HADT@%_IAJV#S
M.E"V=0VHWK;J3]3VC_\@[ESQ.WW7\M_J=R_[3;QGZ77UWB77#;>LT35^G#/Z
MSW'JKO'CN%?N_@<53)N$!L].JP*O/UD(WGTA&RQ\]1!8/F<O6#MW!]C\P1:P
M<\$&D+9P'3B\: W(7/PQR(7^@BU8MAR4+E\*8"L60T/K(D!8M1#4C9SSKUX
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MJ< Y<Q6X-"OGCR'4<@ZARAZ$LE\@E 0+A:)@K5@@;%O@ 7N6,4%^#0E4-Q)
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M#CWF.CO@M4((>)M$@(,Y!"HNABB--9!@N!V2+>4@B: &"61#B&990Z@G\5=
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MYD*YPF*H55GQNU%]W==6W:U#QTUVO3YE(_O@N+W.]<-4VW-UKK3CY7R/QH+
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M$Z<M/A''K<:((S;?B0/X<>)+NQ^._Q F''MG :C8^<49<R#L$P>2H@2P-)>
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M2JOM_M.'G/3::NC6#67NSN6%/JS\G&#/C(R8@,24]-#HQ**HT/B&.$'\J?C
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M448,J/LE@*DA"6SCU<#$;087TBX@N^T#)W]EL(]2!UR:-E@7ZH-EM2%8-)F
M6;LIF)XW!Y-;V)/V8T\U8CEM\M-JS'S:<M#JEW6?S2^;^[C?-K?P8'O5;F:
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M]TT3,YP!,,(<=&1$0'>_"!@IB(*)JCB8Z$B J<4B,"$N!T/66M#SV00Z$=M
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M1&H\H2;K/B#G&-US+C.][5AO<9/89M7M<,;FJGV/;9?#@.TYAQ^X#B+@VYP
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M-PY*8/EW&>H\O%/D:)/*PD,-!FLJ:ZVD"BL=Y+-*J6K)1:[Z,?E\L["<0)O
MK$A[GXQD)X^T?(I;2HT+*^4X@Y%R"V/$A97T@^H:/T'AQ/XDN4=/.G&CIOX'
MH&/[T&<.FH@60<\RA-&=8C%TO48<=36+H[-')5'[T>W"S6U*\VL.ZZTJ:;38
MEEU/D$VN(:O&5+)TPLIXQ@$E?I9>16%X;GXBD9V72Z+G5E&I.4=IY)SK&)^H
ME,P)BDOJ3Q(C>=*9F3#EQ(J?<OQO@(VM0Z (>I. 9>\<(72C7!1=:L#R?ZLH
M:C^Q$+6<W")<=V+_W+)CVBMRV\PVIQ[&[XUM=%8,.\C0"*ASU_>J\3%SKPJQ
M9E7&V]'*LXC.917.Q+(VLGW9-8QADD/QI+-3WJ03*6O*D9(^3:2F33O\-^".
MK4,HEKVQ_-]3B%!7C0@ZW2B,CAT30LUGYJ'ZLQN$RL_(B>>?UEB2UF&\/J[=
M9F?8,<=] 4=HJOQ6-VW.82]#1I/ C-(8:^UT*!-'.%A.P#6T.M@>O.I@TS#D
M8%,W[8"O^.5 */YE[Y#_VYZ8]YOPWP!?% U$(W0_"Z&K90AUU@NAHUCV:SPI
MA*HOB:'2RZM17M<>T;1+!Q;&73!8'7;.:HO_&?L]GJ<I_X^PNP".\N["AG_N
MW8V[N[N[;=S=W5V(NY,0(D",! B$0(!@08,$=W=M2TLI%(<"Q:WH^4[:I^\;
MZ#OS3><WNUO)];=[=Z^;S-0R;W>.?<;.8I?D';6><=NG^T9MFQT8MFTX)'A\
M+"QPV_&PP/''80%;,#QH/4:$K,*(L!&,"%^"X=_#:H ;LP#.+  XL!Q@?!W
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M]?/7NM9_HJ[E$]2W?(A&5O?0^'N'%P-L7@VP@L[A?-J#64<!IIX'*+L*D/N
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MX/>&Z QT[0=H/ 50]!- ZBV \ < OF\!W!' "07 CM;"$F484QJ'(6HQNFC
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MB/SB/1Z%WAMBT&LT%KU6QJ'G2!QZ? _]*#-2EL%DZOXYTA._>T_=4X/Y5&7
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MH.]A"IV%0@8>U /\W %P=C8+CBW@P(%A#NQ:+@I;5F@P:Y=;\HTL=958N#A
M:<["2)VN^4DF[7,S;9K["QSK>RO<J[H;?4H[VP,+9O:'YLX8CLCJV!"5T7$P
M.KWC=E1ZQX>(S#8,RV[!T)QF#,YMPJ#O83J=A1* 6TVT!M2&3\QEX. B-NP:
M8<&6U4*P;HTJLV+4C&?1*F>Q><O]%+J7AFNV+XXW:AY*MZP;G.)0.5#F6C*W
MSBM_3JM?=E]O4/KL1:$IO>LB$GOW1R3T_AZ1V/-76%(7AJ;,Q)"T=@Q*;\7
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MXZ\[-;G7KFAR?WZE9?<3ZMG^@ ;6E]'(]@R:?.]X'\ .VH,U=!TLW@@PF\Y
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M'3,R#%O:IY@W3B^SJ6VIYU8VM[J43NWU*&P<\I[2,.J;4[_++ZOA$GGAF]V
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MQZ+"KPY%A6A77(@VQ05H79R/EI-A),";5(#?\ZG[TQH<I?R]U'^WMU#W;A6
M->V*L+S=B+6HC<LW,-U;M*\Y5*9S:IQ21T.J>DM=KL[4FA+#^NH:T^K*:985
M%5TV)>7S[0O+5G"GE&YURBL]X91;^M QM^RS0UX9VN65HLV4$K2>4HQ6DTV<
MA2=T/5PMIMY+:W!P*O5.^NJUF;K/FAF\L'R6'"SN-&#FS[+C[9OA*=S5'BS5
M/CU:8=JT9+7&YFSMVJE%!I4-52:E]4T6174SK:?4S+/+J1[A9E9O=DRO/N:4
M7GV?'C\Y9%2C7685VF16H'56.5I-AG%T%G)H'ZC_'Y]8 YK_UAD ZZG_+>]F
MP>)>:5@P6Y?I[[7FZ>IV$VKO#)"8-C-2OJ$C4:6Z/5.SO#5?KWAZN5'^M :S
MW.8.J\RF?MNTJ4L<DAO'N(F-AQT3&^_2XT?[I :T2VY FY0ZM$ZM0:O)OM)9
MN#VQ#U5T#F@/=G30'G11[^FEWM$/,#!7 OKF:3)=<RW8[7.<!9K[_<3J9X?+
M5O7$*Y5UIZD7=N;IY,TJ-<B:46>2WM%JD=P^VSJA;;%M;.L&^^C6@P[1K;?M
MHZ=_L(N9CC8Q+6@=UXQ6\5/1<K+G:0"_T3Z<G%@#ZM];*7]-'\!2ZJ#SZ*MP
MST)1F#6D"FU#IJRFA5R^N@7>(I7S0Z1*!F+D\^>FJ.3,R=;(Z"_239E=;9C8
MVV(2V]-C'M4]9!7>O<XFM'L_^=TFM.N]=6@G6H7-0LOP#K2(:/O68WI?^H'.
MXI%F6H.9U'TI?_D\@$'J@-W4@]N6"L*T90K0.&+ U"RSY2E?ZBY8M"10+&\X
M4CIK<:)"VJ),E:2A HVXA94ZT8--!N$+.HU#Y@^:!LY?8QXP?Y^%__SKYO[S
MWIG[ST5S_SEH'M"'9H$]W[I30.])=0#[Z QNH?Z[FO(7+03H'P;HH!Y>OYH-
MU:-24+%&&XK76++SUSCS9H_Z"J6O#A-+7A4G';\R33YZ19YRQ(HRM9#EC5J!
M(S-U_4;FZWLO6VWH-;+'R'/DFJ'GTK=&'L-HY+$8C3T6H;'7 C2:[)=RNAZG
MT1IT ZRC_*64/V\)P*P5U'^IDI12#\S?+ IY6U0@>XLQD[[%GIV\V9,W?G.0
M8/2F*-&(3<D2(6/9,H%C)?)^&^N4O#=VJ'IL&%!WW;!*TV7C;BWGC5<UG=>_
MU7):BSJ.HZCKN)JL_-:YB7- >S VA_: \A=0?O=*ZI_K *JH!T_9!I"RFQ<2
M]TA#_%YMB-EKP43N=6:'[?7E"=X;QA>P)U[0=T^&B->>0G'W/352+KO;9)QV
MSY5SV+U"WG[W3@6[/3\KV.UZHVBS Y6MMZ&JU3BJ66U%]<D.TSG<1N=_->W_
M(LJ?31UX^GJ ZBT !3L 4O<!1!UF0]!Q$0@\K@#^)_3![X0->)]T8SQ/!K#=
M3D9R7$XF\SJ>S.5W.%DA:'=RFK#UR3X1RY,CHA:GMHN9G_I1S/S$&W'38RAE
M<@1EC ^CK-$AE)ML5P_MP0* )93?3_EM&P!JMU+^;H"T@Y1/E3#@% O<SO,!
M]P=1</A!">Q_U >['VW ]B<WL+X2R%A=B68L?DYCF?U<R#;YI9YC=+6+Q_#J
M,(_^KUMX]:Z=Y]7[Y3FO[D\HH/,#"FE?1F&M2R@RV1A=?\OH_,VC]>^@_#I:
M^\*]E$\]/.H$=?"S "Z7 &RN<,#DAB 8WY8"HSMJ8'#7$/3OV8#>/5?0O1\
MV@^B0>M!.J/QL)A1?]C$4OVCCZ7R:"5+Z=$^EN+C.RS%!Y]9"O>1K7 /.?)W
MD6>R%90_G_)G4G[]=LK?3^M_#"#R#'7P"P!./P)87@,PI#ZN\TP M%Y(@,9+
M!5![J0DJKXQ Z;4U*+QQ ;DW?B#S-@*DWJ6"Y+MB1N+]-$;\KWF,V(=UC.B'
M$^0I(_(.&9$WY/6W%M+Y[Z+\1LHO.D#Y-/>(\P#>/P X7 4P^QU ]PZ VF,
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M6[L!5M'Z+Z3\GA& YE& <JK).>, "50-0_<">%$?Y1YC@?EI?C ](P$F9U3
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M+]X_G ,J8,R3'J?^$X#G;6#Z,X##<X -K;KI:X#Z34#G74#\D+[_4R71)T;
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MI,D!'0*R6>=8Z@90=PYUG:@[GKK6MP"3.X#^/?IP>G/A)1TN-&IN/,R 5\8
MK]+SO\;-\>N:3:GF/TQQ$7Q+\R+B+B[,K.#;K-!;K_'Z$Y'^@Y7L;QV:'!#K
MGL-XQSU&?>JZWP"F4=?V:<"2NH;45=&JR_]-K_\6>4< WF4YWF,Y/C#AAM@:
M^-@>^-09^-P3^)+E^(J+P%<<^%\O [YA W_#2GWS/K__PJOT%XOV#N> \LYR
M#%P! F\"LQFV*7>!L<\S]M154U=+H_L>^4B3@QG)A7Q!OE+PGGK MX;<F%H
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M\]IT-O!M"MQF)6[?)E^0/XGT@"4;.2]3-T?S=IS=; /^FOLQ8-IIZE/3_#%
M34WEM9'\"V\!32[DSD@^Y![]_K,ZP/,T2B_0)+Q$S_\J-^BOLQQO^A(N/F]Q
M\+_%1GYK"_#V6:)Y4N?[OY[0:=(\'<4XIQP%0JGK<0%PO,3X7P5,;[#M-2=B
M'LV_O/SP9,I(/N2MA_D0!0V*"OC8</BM)5]RL_P-R_$M%^;OV#>^KZ*)8.>^
MSP#?Y\WOOTU8COOW4<IXI[%]PUEG+];7\3KU1YY*4CUZ(N:-$:W_.)7RWW(A
M6L OC,GOYB-O"M'\"S9!(V]+U3PAH_D78QALB8TIO4I>I^.T'/'[9B.?-:=$
M)N+OIT*B_I_YAT=/9FC>D#'\E,P9.OVK^(,.]3<6^%<ZV$??QO'#2/[A4PR?
MDAC.?1B-H/']%AA^0F8&AI\*"<7P"17-&SHTIT,T3^HT\_X+\3N6\OY]O.\:
MJFS"3]C&^^_#?1S#=[C(T-QFB-ZAWG</WE?R$,U3*A^.Y"+>TI3AP4D,C=_7
M'\%D)!8/\T$!K%,TZY-*G3QJE#'DM;Q_"^_?P?MW\[XK\!D&6*]!UFL'/L)!
M?(#3>)>N_QTZ]K>H^@;OH(GZOT=X#<,G-%YXD O2Z.H0Y<C5X$&;_ 8':LZD
MYGS6(I3-'D^=#&H4\/[E> ]UCYS,Z.9]5[+;K.-]-_.^>]@*1W&/L7B&@^AI
M_HVG\"-N83A+I;G>?@1)E]K"PQ?0R(F*L31F'<=2<QICYDX]/[R)2)8]B1I9
M^!>*\"S[QEW4<XBV\OZ=O&\/[[^*PW<#KK--KN( IY'3> PW6)+7<1[?/#A#
MI'FW[ME_\."%-_+A,OSY(,4GPR=LDW?8+UZ#/?5FL#Z>U JB3@PU4ACA;$Y1
M1;B,2FK44Z.-&HMYOV5478-3&,()QN(8CN,(2W*(@_H VV,_HZLYTZ1A[R,\
M>-B,P^D^IYG/- _DR35#7XNQ-&+];%B+R=1SQ25X4R>4/3Z.&FG4R*5&,36J
M.!(:V /:J=/%^Z^D^@:.D!W8R3_9SHEUJ^PNML@_P9#R%PQJ2=BD+6'C(VAR
M,#^13TPY!9AQRN/T?XOENB%7L9ZF."_8XI3,"<<4<W%8Z8\#VA'8IYV /3KI
MV*6;AQVZI=BNJL%653.VJ#HQI+<,@WIKL5%O&];K'\(Z_0L8T+^+U>K/L,KP
M=ZPPY/KP",O);YQ>O[3BE#J.4Z$MIW].^><U2Y!F*5+IX[#^*.Q73\!N@UG8
M;C@/6XV",&04C4W&2=A@G(GU)@58:U*. 9,ZK#9=@'[3I5AIUH\^LR$L-]N/
M7O.SZ#9_&ET6'V.QY6_H'"6AXR&6P_Q _0_& \]-YM(SA=H3Z#4XO>VUX;)J
MIHT=IB;8;&Z+C9:.6#?*'6NL?-%O'8:5-K'HLTG!LM'9Z!U=A.XQ55@ZI@E+
MQG9B\=@^=([=B(7C=J-]W"FTC7L2+;8?H,GN%S3:<98C];9_\S7K_OI4+D4S
M@'/DH!,]'\NRF6799"M@_1A#K!YGC96VD[!L_"STV'MAJ7T@ECA$8M&$!'1,
M2,?""7E8,+$,;1/KT#)Q 9HG]:!QTEK43]HAU$XZ+M1,OBY437Y'J)C\DU ^
M61+*'C)IF$^XY#_/I>6:._W>;/H,5VKS^X C]U>,3=]$/?1,LL"2*>/1.=49
M"Z?-P8)IOFAU#$6S4PR:G)+1X)2-.N<BU#I7H=JY1:AR7B)4.*\6RIRW"B7.
M1X3BZ8\+1=-?%PJF_R#D3Y>$/ W.?_,>ZWV'^H]Q^W/ DUNNN< :EF4YEYKN
MZ?2>3CKH<#9!V_2Q:)XY%8VS7%$_:QYJ70)1[1*)*M<$5+BFH]PU'Z6NY4*Q
M:X-0Y-HI%+BN$/)<A\0<MX-BMMLE,<OM%3'#[7LBB>ENDI#N.H*+)+Q!K2>I
M?8;^>Q>W'>OGL>Z:W,<<^DXW[K5=Y&AR-43];!O4N$]$U9R9J)CC@;*Y?BB=
M&X9BCU@4>:2@P"-'R/,H$7(]:H5LCW8ATV.YF.ZQ44SSV"^F>%R0)7N\($OR
M^%9,])"&F2L)#Y@C"2^QSM>H?YS+_%8_^@QN.Y:R+ M9EA8/^@W&I6:N&A6>
MEBCSLD?)/&<4S7='P7QOY'L'(]<["CG>2<CRSA0RO N%=.\J(=6[54SV[A$3
MO=>+\=Y[9''>YV2QWL_)8KR_ED5[2V+T_&%BYDF"AN>H<R6 8X%+_& @8\#/
MBUB>%I:EGN6HXM:PS%L/13YF*/"U19[?5.3XN2++?QXR_0.0$1"!M(!XI 2D
M"\D!^4)B0(40'] LQ@8L%6/\U\JB_'?+(@+.R,(#[LK" KZ4A?E+X@/\)#'<
M=Y@[U+A(_[^/6^'U(9H3,?2<+$\#RU+)<I0P-@7^.L@-,$%6X!AD!$U">O!,
MI 9[("7$#TDAH4@,B45\2(H0%Y(CQ(24"5$AC6)$R&(Q+&2-+#1DIRPXY+0L
M*.2.+##D"UE@L"1J" HB@</<HL8Y^O]=9 WI"F,,6)YJEJ>$<<EG>;)"E$@/
M-41JF#62PQV0&.Z,A AWQ$5X(S8B&#&148B*3$)D9)80'EDBA$;6B<$1G6)@
M1+\L(&*[S"_BI,PWXBF93\1G,I]P2=3@&T9"A[E!C=-1P#:R,I*>DS1H\B\L
M3Q[+DLEK:H2(Q$@UXJ,L$1MMAYB8:8B*<45DK!<B8@,0'AN!T-AXA,1F"$&Q
MA4) ;(W@%[M0](E=*<Z/W2J;%WM<YA5[2^89^ZGH&?.GZ!DMB5Y1(T1*XN.L
M][$XCLE88!FWX@M(3;0F_T-]EB>9W^/Y9S%Q>HB,-T5XPEB$)4Y&2.),!"?.
M15"2+P*30N&?% N_I%3X).4+WDF5PKRD-M$SJ4^<F[19=$\Z*LY.NDD^%F<G
M_B'.3I#$V?$D3A+=R6.L_\%$]H4$C@=NPYM)!<DGR226?\8P(S1%!T&I1@A,
MM89_F@/\TIS@F^X&G_1YF)\>B'D94?#*2()'1@[F9I0+[ADM@EM&K^"2,2C.
MRC@LSLBX(<Y(_U"<D?:[."-5$F>D2.+,%$F8F2P)YZBS)X5CDMOO3E)'O1*2
MS<_Q_'ED&A#,+;%?EAS>V6K,R[& 5\XX>.1.QMS<F9B3.Q?N>;Z8G1<&M[QX
MN.1E8%9>,6;D-0K.>4L%I[P-PK2\@\+4O*O"E+SWA2FYOPE3LB5A:M8(F9)P
MDCK;TCDF21OUJD@!2>?WF$SZOFSJYP*>!?0^1;IP+3:&2[$U9I788V:)(V:4
MN,*YU M.I8%P+(W"M-(43"TKP.2R6DPJ6XP)96MA7[8?X\NNP*[T'8PO^448
M7R0)XPN'L2^0A"/4V*0Y'40:LX9/!N7P<Q*)H$WS+Z3OH'5U*P.F5\HQK5J-
M*35FF%PS!I-J)F!BK3,FU,Z&0ZTW[&M#85<;#]NZ;(RKJ\"8NG:,KEL-Z[K=
ML*J[B%%U;\"JYB=854NPKB*5DF!=(0F:MP6M81T[\MD722')(+'\>3 MVOQR
M8#8MTO0Z8#(MBEV+-L:V&6),FP5LVL;"NFT2K-JF8]2".;!<X >+!9$P7Y *
MLP5%,&UOAG%['XS:M\.P_2P,VE^&8=L/,&JADVBFDV@:9AOKM[R4OI=Z%227
M)/%[> 7;@)9Y3CW]/RWKY#;J=P#6B^D!E^K J-N06,"P9RR9!'7/#.(!_9Y
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ML&JG"JHN5%[U2>56WZOLZA>47?6)LBNMRC&HL"JWW*J?$OH>!_O!YBII!5C
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MGZ)SG3*/"J.PZQ'W)Q'TUR&>K_N*[UMMF()S;"UC80/]< OS$'Y.I?FBJ&O
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M^I"B,A8K(F.CPC+.5VC&50K.N$N!&<\K,/TC!:5;%9)FQ^$4^S9YLQ=HV.2
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MOF6\YN#K)$R/'("?^GK!ZS8AS4"?$U!1!J!Y"1=%D,=BAS\VXX^MV+$=?^S
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M2;(_G];<C6KV@G0ZE(EY5NXD:FFYOD/Y?(L2^@95]!4*\',4X:=TDG^BVCY
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MI*WG3%IZ@TE#?PRIZT\G@?X24M4/)A7]3:2LGT&*^E6DH'<*> Q\($5=)CS
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M!;,6K0.RYFN (,L$,O4!+;Q6QW55R%5"L7)VB,,0)I #8FTG\.@+'BY\<L'
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MKE,%\GH5\%Q_&N@;3@%S@S*P-R@!=Z,B"% B-_T-P%HK SX[Y,%;80ZPCRV
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M4HFP6DX(VV9S8.\"!GHLR*"\F@#JZ^Q!?Y,UF&^U +OMID#8:0SD789 VVT
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M C;(0A3:_ZGH<R-__RRH.#;_8\/I%1.MFIM&.PT/W&RU/--79V]QKLS%J;:
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M[W.D@F"%M ]LD"/#CEG.<&">'1Q?: 4J2TQ :[D!&*[4!<M56H!=K0Y.:]2
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MM  6?5Y;[94#:X49@#LZ"YR4YP%!<S&X&*\ @OT:<*9N CQ[.^ B=H-]XC[
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MX"V@!/X""A D* ?A@FL@7E 6TH5608&0%%0(K82F99+0^3^!MS()J+I<X&7
M _[&O!!@)0"!SL(0X"D.K*"5P$R4 ;_\M<"H50"?3F7P'E(%KW%UH&_7 /I>
M3? \J@6>Y[2!=E,':(^QU[I ^Z@+U*]Z0/VA!Q30^X'-4T#WZ_\ /DK_K,%7
MCQM81KP09"$ '$=A"*:)0U" % 3&R4) KCPPJY3 KTT5&.O5P7=4$WRFM,%[
MMPYX'](%K]-ZX'5-'^@/#8#^T@ \/QB"YQ=#H/TP^DX#HZ]4,/I, X-/_\/?
M:Z#I<(&?+C>P#7@AQ$P PNR%(8PB#B%,*>#$K(:@+ 4(+%<!5K,Z,-=I@=^P
M#C"VZ %CAS[X[C<$GQ-&X'/)&+SOF8#W<U/P>H_-F7VG?S?[X@EFGSS!]#T=
MC-_1P6@IX*M( KHV%["TN8&CQPOA)@(092<,4>[B$,F0AO#(-1":K@C!)6K
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MX#=V(8$Y_CPF8.Q3>.#PUV#V\'S04B!G&8)Z?G2_GX2N3?"@LSMYT;%#/.C
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MF''I@ VW)CARJX$;CS)X\BB"'Z\\!/&N@4@^64CFDX8\_I50S;\".O@E85!
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M@J/TZ(*[]+BBCVZ))>"85 JVR:5@M1A$X+.0AM##8H2NUQ+P&2"AXSU<Z.
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MQGG99>996?56Z9F==BD90PZ)Z5N=XM,/.L>E_^:<D/'6+BEKP2(Y&TQ2<\
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M@<57L7L61.RN!>'<MOR#Z*U_(3:3]>4HXHSYVPU?/;$7GK@>'K@>KBY,XAS
M)DZS!#\[9 A_L"\6Q:3 >6W7*O;2KHO[PK:/]\QVA?A3FQ&)QS:;)![9C$L^
ML#DD>=_FO-1MFSM2UVU>2OUB^T7R9ULB<<6.B%]&E^P(#W&G(O;R6%\:B(<D
M$!\9BOA/?B8#]XB_.8WX.C(^>WFQWKJ'"[YT2Q9YYI+'>>1<P7LPLU'B[HQV
MR=M."Z5O.BZ5N>&XDO^;PWK97QRVR?WL,"'WD\-I^4L.-^3/.[R0/^/X6>Z4
M$^&?<"(RQV<0J6,SB.31?R$S,.N[8^;WP<P=A.,(DP<2KD&1,"/:AQ ;^LM
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M -E#L<F/Z G%(N_^83[N_WJL7SA9_Q36OPC@\3. W6\ )K>Q]GT Y=\!% B
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M[0@/LB^XN%\NHF?H"_KZ7^U8OV;RJ=@$0#S./>@<@,LE@&E8VP!KJV%MV7L
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MX=Q[NC#_8PZOP[J%2W$-!C!_#V+^6PG@.BP(,X<EP&E8&1R']<!AM05,7^T
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M>#'Z,OF9%#SA?%T%\&T<X>3(C?\JFWP&A;V/.@3@@[6G_P!@A'-6NX:]OP[
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MTQ36.CO L+,G-3@SF#8P(YJ^=$8BH\\ID]GC5,!:Y%C.[G:L$^AR;!6:[[!
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MV*@C8L-C/#!2/V[H7YQ6WB0O\OUSJB5H+5U<D9KBO&P:3BN<<%S;&X=U0G%
M)PY[==.P6S<7.W6+,:)7A>UZ#=BF-P];]!=B2+\7F_0'L$%_*]89[,>@P1FL
M-;B!U<I/L-+P-_0;BN@S$K'\,7ZC[A>\W+S):>V6#:=\2WI/3K=/F HX9:#$
M8>5X[!MCBUV&+A@V\L=6HPAL-D[ 1N-TK#?.Q:!Q"09,JK#&I!&K3-JQTF0Q
M^DU78KGI)O2:[<92LY-88OXT%H]]']WC?L&"\2*Z-'1JN#>-4^T,3L6.O.S,
MHM=P8)W-R\[!J:K+LC9&S$VP9>PT;!COB,$)GE@S(0@K)T:A?V(BED_,P#*+
M?"RU*$6/10T66;2@>U(7%DSJ1=?D0<R?/(+V*4?0-N4RYDU]'7.G_8#F:2*:
M+,FT?_B2E]M79_,2Y@:<]P".\74?RX 1>WHN*PG633;$ZJD3T3_-%KV6SEAB
MY8O%5J%8:!6#+NMD=%IGH<.Z &W6Y9AG4X^Y-FUHL5F,INFKT3!]"^JG'T"=
M[074VMX1JNV^$ZIFB$+E(^S4?.S$RYX[+\$^O+S[L<8F.[SHO3G-KV5N^FSU
ML<36'-UVENB:X8B.F1YHFQF UID1:+&/1Y-]*AKM<U!O7XQ:^VK4.#2CRF$!
M*AWZ4>ZX22ASW"N4.CTAE#@]+Q3-^DHHG/4W$?_!213><>7EV%>]!G.4E[C=
M9 LO_0/>JO4/UG=.VICO:(PVI\EHF34#3;-=T##;!W6S0U S)QI5<Y)0,2<#
MY7/R43JG'"7.#2AR[D"A\S*AP'F=D.>R2\AU.27DN-X4LET_%[+<_B*BD.7Z
M#Z]ZLNR@YIDPC@&68"-D(R]S*_E9#W/3X29#BXLA&EPGH-;5!E5NLU#AYH$R
M]P"4N(>CV#T.A>ZI*'#/09Y'"7(]:I#C,4_(\N@1,CW7"NF>(T*:YPE)JM=U
M28K7IY(4[S^%%"]12"8I&EYB#BZ'LJ2*4J_!;"6#,<!RQK& <;0PCEI/ U1Z
MC469ER5*O.U1Z.V*?&]?Y'F'(,<[&MD^B<CTR42&3R'2?2J1YMLBI/AV"\F^
MJX5$O^U"@M]12;S_TY(X_X_)'T041O%3<YLZ%]CVHW'J^X"&DECCL@1;RC@Z
MF)MZ_K[<3P_%?J8H\)N,7'\[9/O/0::_)S+\ Y$6$([4@#BD!*0A.3 /B8'E
M2 AL%.(#NX38H!5"3-!62730$4E4\%5)9/ 'Y#<BJA B@]3<8 [.4N\0]4?H
M?S>2E2R_%O'GUFC6V<Q'4; V<H.,D!4\$1G!-D@+=D)*L!N2@OV0$!R"A) 8
MQ(<D(RXT&S&A)8@.K1>BPN8+$6%]0GC89DE8^"%):/@524CX>^17(JH00L+4
M/!W!LI?MWD_M[1GT_ID<BV1A&NM<?E[..'+#Y<@('X/4\'%("K=$0K@]XL-=
M$!OAC9B(($1'1"$J,A&1D9F(B"Q"6%0M0J/:A>"H7B$H:I,0&'U $A!]2>(?
M\Y;$/_IG(DK\HT0A0,,5:IQ(YGQ$W2TLQ0?H\WM5]^'0C]<Q'\6,(R-60%*T
M >*CS1 ;,P71,7:(BIF-B!A/A,<&("PV'*&Q\0B)2T=P7 $"XZH1$#=/\(M?
M*OC&;Q!\XO<)7@D7)5X)KY.?!*]X44V<*'B3)^,Y%M+5ZT!#!<#J(F )::<?
MKV)<!?Q=*F.,3=!#5((Q(A(M$)9H@Y!$1P0GNB$HR1>!2:$(2(J%?W(J?)/S
MX)-< >_D%GBF] @>*>L$MY2]@FO*><$E]17!)>5'OA<%U^1_.,?C'V*Y.:+:
MBT,/OI)E^"+:H[DE[ ?&D<N<)#&6B#0M!*<9(C!M' +2I\$O?29\TYWAD^X%
M[XP@>&5$P3,C"1Z9V7#++(-K9A.<,Q<)<S('A%E9NP6GK+."8];+Y)[@E"D*
M3AD:TD7A-,? /K9_&W4'JWA.5@-=I*F2GH>?91;3>_/W(7D2^.88P#O7%)ZY
MD^"1.QUN>4YPS7.'2YX_G//",2<_'K/S,S KOQB.^?5P*%B F05K,*-@)^P*
MS@BV!2_"MN [P39?%&SS1,%.1:XH'&,[=[/]FZF[II[]T,!SDM37J_>AI#*N
MJ H@@/&XE>C N<0(LTO&8U;I-#B5SH!CZ1PXE'K!OBP8,\NB85>6"MNR DPO
MKX%U^7Q8E:^$9?DPII:?PI3RV^0;3"U[B*FE(J:6B,(T<JA8LQ>GD=Z[A?W0
MRG.R5;,/I1E(H"4(94S>C&EVG10S:@U@6VN*Z;46L*FSAG6= ZSJ7&%9YX=I
M]>&86I^(R?4YF%1? 8OZ>9A0OQSC&[9B7,-QF#?<A'G]5QA;]P#C:D6,JU&S
MMTIS/]0\G@\=[(=.]@,I)1GS@6A^%M#.'!![6FC+>5J8-&\,+-K,,;%M,B:T
M3<?X-B>,:_/ V/9 F+5'P[0]'2;M)3!N;X91^Q(8M@]A3/L1*-NO0]GV.93S
M[F-,*ZMG%7-%[*#^1AY_I>JYO-WT_[3(U3WT_R21A!)/XD2LB04Q[=&!T1)#
M&"XQ)Y.A7&)+9L-@B1<)A?Z21.@MR8/.DEIH+UD(Q9)!R'OV0=IS";+%[Y*?
M(%\D0M&M9BO;.;"0.5C"Z\,RH&$YYP3-O4!1M,I^JX Y9#J9M)H>= TP9JT4
MN@/Z4 P80;9V'*1KIT)8RT)H+?WE "_^ [SXK.5)O9:#:"T3O)8'6T-_M^8)
MGOPO ZMH#%?]Q8:+HVQ8Q!=J]U!W+G7*U]+_#G(^6 \$;@1<-P%V9#+]N=EF
MZF\%=+?1AVYG\;N=A?!V$S*!L @<9N$SS")HF!>984X\P[GJ!R!M9W*W\P#;
M::RWT>MNI5'=\B=A#)O%T3687FJW#[ /:,US^4\3J!,\#+B/ #,8_I1=U-\-
M*/<"VO3H+*(YJ<B(+F$<AQC'8<9QF'$<81Q'610=Y87H*"?:HZH'DW,@'6$"
MC_  1VBL#],\'_J%_$U$]1K,>O4:3 %M>=).C@'^4W=JS:36Y$/L_R. P7%
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M2/"9@C@?6\3XS$*4KSLB?/U(*,+]8A#FEXI0_UR$^%<@.* %@0&+$1 P"/_
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M7N<HI8WS4G*'GY+&A2IQ7(P2QJ4H?ERVXL87*W9\C6+&CU%49Y<B.P<4T;E
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M<1M)\NVAMN3T3@;<.VOM.W4(Z#LWDRA0\!WW(2_Q/?QQ^W=: ?9LZC>)>K6
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MR+S+K3+^Z"D(E6TN9$1&]N:,S(W<1ZQ>P#</^DL/TU8>)C9^17S^BD'@$1K
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MQCZ&5WT$"_T !_X# [Z+@=Z!2;\-YQXYA^,E^QJ,1^US$/\]!V+,Q=C6H_P
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M#CBFI(#;E1AX40F!;RDQZ%LE!5F4% CW!^\4_/X@:<8.4N%U7)?P?G;NE6M
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M&Z=A4+AFPQ[(%-R_GFRM[C7(/3J,ME@?6;)INGT="B:;#0WJFX4?9M FT:4
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M#O+W:R*_3H\4PAA21#Q6#KI1#,Y(,8R;Q2"+8E"^D@N0 %S4B&R#-NI=AG$
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MO7[^*R4Q$ ]&091U&B+?4Q!I14),?@+D$88<@3J([V-$02R>!)+)!&VI0GQ
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M =Q*XG%V<)9%P3D5!6=3!'@0GD7.0/W'H5Y_DX63*?O!Y;2#GW<:0<P'O&R
M? W@119DL@KX$ #]80=]99)>AM"N68Y02,+ +@$#R"HP&@D8<"5 @26 20D
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M#-H ^J!*0$*)7VP&E?%RA'D"8OF]3F"78$I&Q M&P)<L\"<.,N&%8EA!+O3
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M%T)!L6P9)245R("&EB@%$ ,#(R,32(*%E94-A,'. >+@X@:!S$L$1 (R :&
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M#<&?9R0#R;*K/=;\WE7H28\0SD_:V;2HB/4<6B.1RZ2 6V0 5 3200;00_%
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M6C62 !Z0 TB=F&ZR+4\D@90)<S( :G>8?/T'%9-<)P.8DP)JQ=  +92D3=
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MO*CSRX>[#3,VO9NY&]6G)FSW-65*/]C:09. 5"C=WW>I2^<F'[7URI:^<9J
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ML!'[Y]YU[RP.?V-0".,(:IY6MS^D*9M]XL[08$W#N.(% ;O+Y@Y7"4B!V:R
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MDI_798SK<WIQ).,A)#YTS2$*M1WV_1S&GL(;.)H_QJP;KC,KJ\G/KK\7PDQ
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MU[HC)EGGE<*I[U>J:[]'["VS?/9:@4TDR?9<D(V)@#Z[$<(&"[([P\ICXAI
M:Y&E6CQ'7FQ"=#]06E?3,)?;<65V=F/+E;X_,/'7!_G3^[WRG_H&OM!5[BDS
M65 3N7#U"^R:VHJ1:TG*]0QG!><]XE>=L45W81<U59D^_)S,/9@O)I!0V!K'
M^<;LA+1D>%I4(',70"58:JF! W!9&51WL50*_&+=&*(-;ZR_@G],O2'^9L<?
M1(]MMQ*LM0YX3 @3G]]^SG< I(:IWM8@KH1OQL4_]<^41SMZRDV'[K?BAZ:E
M^8:X#N56QS]:.NWFA[U=*BN0'$0QA3!",[PQB0UG9FA[ T.9W.+99B @L2HI
M]<>@S4C8]^9'"\77+?/;#/QU)<7$KI_+"^!==@4]&<\Q5*/%#9K:1]2]H('<
MMV]>ISHF3&]$:NKX$F:XGJ,B4///WZ,MN,@## 4=#9@%_QZT$);4;AX,P0"D
MTI1>1\/49CDTBB'!5H@-97*DT4UH'YY!MYN;Y5.>ZDN\BPY"M_Y F,&8"M)$
M8D'\\@39J@*L<LSONU+7,%H=T)%-6U0HT#%Z-_!:8W7X(!8)=701LE,CD/,
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MV5BAG&U0Q)X?-QL4W-46A5QM8^7L:6?EYFE+(OK;DW !#B1DT.<?HJV#%3'
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M1PNRVA/LM\;'+ASM R$%K@DW\?&#AD2C(_ X?Q]$K"_,'1(8&0C'K(DV#G*
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MM1^L-7P>(4'_,3?3^CM ZKM&_H,Q .W)1] >"N#?]4Y"O[)17^D_G2W_V!S
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MXC,$!,IOZ?EL!46!00-LMX$&(AN SQ#0(#K^U\]0T)#F13V?@]$1>-"P1Q=
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M,VG+6E5CM*+IL1*_2;NV/5'E<KOBE'R!V8X214+HHM.% ?)I8P877A&? %
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M9D82TO?1&<%!T3ND]$KO0QVGZ#9V,2UX^F+XV?INNJO>BYKW].SAP35W&;=
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MP)(>PG&+]W@RB2AP.O &774PK&<6IFC/&$L:=L* 1' 5NZ_/ WT%9^[RS_?
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MURTS+\+/LNT3/<,W5KL2#A)6F(!E9PA_ZN^E_$5DZ_HBI,3GVL5>6X@X]1G
M'::(;6P[A3W8$6'"X<I:747^N">-7?C?>&Q=1)DSP<TV/<6?<-Q"#O])7&IV
M\7Q-H%9] !QG;F4+VPJPL?TYQC?8>UNE0A4NOZL,GX>[UA9>BL,3FSC)S80%
M]5O#Z01>K="3A&_3QP'ZF1?8E :6X&C%;%V=P+52PC/RK>!#V&A^//1"\2!_
M$OQ4TEO>.V17&(?OA=XX#R@H_?\ZR]Y$W%5OX@TB>-I6W@;4!"Z;^P2-P*S@
MUF+V%1WFPG!CDV9Q\_!1*PYP&83PN2=X*$+E_U<'ZE"=C'.#>$53R1&39)Q"
M3A39'SV-,X9\H/  ^S8E,S&<?8WR8,4X]GOJYKDK.1;JTO\K9F1M)7LV>Y$Z
MA'6+O8 ]B]7*'H.:SJ*P;A?\Q:I@'4I@LRI9W:%D%I-5-><4ZR[+GCAJHIA;
M)0S50B9#?)XUGIDJ^HUXP/07N>=?97H($S=JF,L%YI!MS!B!TYP(9JY@\HBR
MQ3+4VE?*A0R@1L^<R(A43X&_8\Q6DO(^,ISE7^*O,6;+^D+F,19*;\T^3O\N
MK1Q15@:]PPI2Y-*%%@AC-3W;% CWH8?J'^2%T@-U)^-#Z>':B<N;Z?X:G]D8
MVG'EOXG^(>U[\WOY .UF8R9=26NM@\%(-(H-FRNA82PGXU0TGNGP<D\:POAU
MMA?UB/JG73%HK-Y:>02MK M)^T&;WW8#>IOZH'E5SB_JQ0;WN-G4O^OF!/=2
MC]EJW08I[]0[1U35!=7D<JWPG<(&?$MZ(Z> O4"U,@G4-VNN=#=\YOK5TB6(
MNX%$J1\J?OH)>35JQC_CM;;*11$ IPK]99\1OTC.TH<H<.5IR0?T@<Q<R2+L
MI!B-6(>+#K@C9N ]II=)&;BN?U+V@"Y85DR(%\R3)A.=B6Z2C<0CP,OB"A(Z
M@R&J)<]9=TTTG3P4D"!\1?&</D;,(EM&6JA=*AED?.=/$F]C+L2_$QUDKJAX
M)KS'C$IO%P8RX]<%"MJ9F4M/"XC,C&E#PCJF/7%H@L2;A&=X4T3IPFS<#R%,
M<+C\HT K<$_[R+_!YZRU\@OXDY?F\[UX^Z>1^$]X0GOU(%L4I=K'S1 F*K?A
MU@M*%*3R!7R!W#=M(>^,]$WT.UZL%.!_D?M34C/-DP<21]KK &W",M,.CD5
M-L[""O@2?409B->NB]N"X+[32*,SN4!UC#^*\UWM/O4AUT,^VZZ\!'OJ]W$F
M\&_4&C!/>7=M<TO/<#]89*E7N"M->6N&.-L,'Y:\X40:XJ9NXTR5V4^*E?L$
M&SH^LXU\8%LVIIQ7UKRA-)I;UC _-8=CK#6MR>),K $NJ68KJU=,Q; WR$Z/
M*!'=9"N?28483,!<>&S5?1"YX*ZN H+=E*"= DN.#--XP3\NNJ$)1XZ:M$JG
M1^#_&:\XX17#3YB4<E[OB1@-,^L@2%#!!LU?J/U)>]0TC$/$/A4'Z[N(K")B
M3TP*U+AA-XP\2^BEWXC[B_Q*)\8W0R]J;A J\FGJ+42/I,G*C\3+$8&*;R3\
M(F?%9=+N2?.4)TB,$278J-M*=R7]TOR@;X*<41?2<7DMRC_IQL0DA9Q^(%PC
MKZ(_7&B5Y] ?31HEW\.P?Y5\E+:0GTM:HN[CCP=_4;GQZG./*2R\X(0V^3KN
MR?!QLBU<T<)PZ2\N:.)+Z5O.*WL=8)<F7GZ"B%6UR5Z#HY53I!]RW>02R?,$
M!UF@^.=*JW21.-_[N>2 &#;QA@0DG&%7/FJ\/I;P5GE+]P:T1Q&E+<L1RMK4
M1S?"I,DJ\,H9DABER;M&O$UY;.(QL;LHP5X'Z%-=M9TC$)4QUG&@2+G1_#IG
MK/23\4S\,XG.,"=,)9;K8=ZAHJ=5,R<.B%Q$:^PJ3U71PB>X*LXUY5>>EL^J
M/YZMD8)JE\7SQ9]M:6&K1 ^MZ 6O1!'&FHEZ89S(7ONBJAN:R]#(Z74^%?J2
M3MNKRKHTK^K'8&E,CL4#FA)TS_0+=G@>QWP0'CWFCJD>ON__BO4'Y4?].B@-
M45=S!G:O)-3*0JS;,F0I1.IC1IG8J(M!C<9$].5YE<;SF/%CO0PN&/MI.P56
MVX#-@;^RQ>#F%]LL'W"/MLPW7<!WK>,:WA' 0;'Z/L*O>6&&<83O8]-T1TG)
M(XI\I,:%Z@Y?7KV;6EITUDRF6E/IQASJS;4O]!R:^[)+5:MHF^=^K@+1@L?B
M-0?HF^QJKG4_YS5,;,%RAHH\3"LXQ,TG#-,Y 6O!5:'L+\LJM*_9-^?NT'YD
M7Q^K5/UDVT8425B]2W('^LV,DX07ZHQ!8L+F2/T$47?T/=T"T?AELS5#PKZY
M*HU-Y#JV34GD^=C55,LMS34HVU2C/E(XTY"C$J;LJO)7;HQ&:-<J4@*/J$_)
M/\P5JH'RIK''%7Z\*'OU8+ME@_DY-,GD8.(5W-+W&$ZGX'2E^LG1'AJ@[FI@
MN>J[[N+<()5<LWKL%?D\GOU+(<+,5QO\H:.-BCI:@4SO6U.0,D][QAJ[YJ+Z
M2/7L0%]5DOG-W/'*L]JXL==E:;RX$85TZ(XHU96-Z2@LUV9&MNX$\N(AS5&@
M[/#D1G?P9]^PAEG0N=.6-+$@K<.I[1*R;$0A>%TND.C27>USH:J,GRUQL+OQ
M:QOK$$O"5]:7(--]H^N"47.G81H"D-+AU!: @]C5K X.>GMI1*L.@\LP-?5C
M5\;=;AB#&[7R9>T0;I?OW!HL/G":MFXZS@0 Z.O(02,*7M_VC.Q8TMLRAIR>
M_K-Q*=D:!ZVCDE^OE-2$4-;YW++>I,"G&6N6DS\" %5!]'*[6MRJ9L%+PIMZ
M6:GIG/H;+/\-]VM]6&-7!EO_8'[PL56CF>^F::U"YGT 0/ODWUP)V]LB$KXK
MOM'8+"2E+ZH[+GBP05 S29 :=KVZD__0!V59S+\R35L]AC^<ES7'_E,5S3N5
MC&)-PT5%;]J=VL?R;1LB;1ZRW6%"RQ[97)\H\R)9XK1F<YMD.,NK__I/+6R>
M8G ISFCPJ?J89JT-T=7&OK<6:W/#UIH_:+8O>FHJU>R9QC5URWG#RO=?!7W3
M5&^[7YQ5WV1M2S/7F"R?8Z]7-YBSPD+,LTSG%_TP0@V/IW48V^4U@$DJ*=MQ
M1)5N'Z272#(_[*"7I274;U-7N*TJ[3T,/!RPNUL.6C1/VQT+&G0LZ&D"P0
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MAA%5;JL?C^G,@=7<PU(W@:TG<:NB"98+N(_!4\T;\0HOM>DV_O!DI64V/A,
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M^U88S0^R?5IHP_MM/ 09Y 7_I039J9_4++)KQLL*&X1QED8IRWF1JR-_%GL
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M;(/"*5"@N<MO:F#!P,I[M!+06CT.XREH6F\0+?!#.&!61/%'_/I<Y[SY^'?
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M";"]R1\PO9# =%OL[HQ+F0O*MT=F9S?A&C;&Y$;CT=:0'#;!8!X-YDJ8.6>
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M:T*L=TM*UDVJV9\"_">BSYN.:TKG_:4V>VE&X_4\4S2RQ&L.#IJ:E *+Z,J
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M49H(M9 L%MNF9 B_"KX&O.-?YQUR G.;.+G'?E<5-7_:.5O=WQ#2NE5E5G-
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M[M98X_IZ_(9GL =G?6=]:\_.G^AM=D08&WG+J7??ABSAE?U%%6N 0_OS1=Y
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MH5#+3 ;?YTC-$&N.TVG=(_:'->&R$9X-./48G_6%8CR0P&HMGK1["JLFHVA
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MEKB1+V-.W#<14E1D[@3!W3OJ^T^!OZ4^Z;P*-$0'-/<#%1L>U28#6[W"#7U
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MK5/=9/MGSE5DL/?'<:37.9E!V\21W%D>9_%>[AT;A6 &[Z+JF]$/6H0>U?6
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M;1AE_<TUNR1S'O(V[;6O6H08.],)$/S3^(QX"\["QLB!T"%J(F44\L_MHZ6
M>Q,3&3/!@ TAS&_ B,MRCCOPY^B>BEH9N_USU5+I)(.4(!:S!%+2..%32A!9
MC6?M.$M-$MQ/:*$[H9L#+S,WP&W.K]EJ\/!N53G5D-)VN>*[;IR^JHJJ%J!L
MPE?%%W(DJ4Y6OF,\A2B^E3"75B8,"J0P+()2YU/LV7#PKI8RO&%FZ].*A34W
M=5"ERE2.Z @K];=(#.(U35Q.&GFOHC=>33TI>1UHRUB OW5N9UD0^<Y/I5<[
M#:U>Y46MN/90Q;W&9?#EJHH:B'B Z&Y\E+V;[*A='[^*&J7(#KA/;Q;[.,M9
MP6CO3D'ICJ&G+8-E__3^HW6HR.S@P)Z5=YLN$!T(S;6KL@-('<:<N!'*#75Y
M@)8>+75P9C$_"&H&KG!7%S0U4KEAQ<[J]5RP5 @MXUXLOT @\%RK5F:I>!:B
M+/8-?S5ES7_R=8$^WFD:,,I*[3_*GE45TU#*+B%<4"UEGR!M /_@>));JQ!.
M-W7Y]M/<8%I7; +W.6.S_QK>89:+XV/^%4YLGYEIS[A7[\CL9)*4LUG6S"_
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ML43G7<;EV&B[*;HYZ"F28ODJDT?QC2791C3K2=<J@RKQ6ML1?5KDVZ8S.M]
M5MUUK8?77LMM8K'S?>-4O-@N0;L*0TBER^?4]A5?[MUH-60][/S/\B#Q<MML
M\[#(?YOLC8&!ZKH0/>%URI*C?>/\V;"$8-L)M%GXU!VEE!UE+P:^TJNJ2EH]
MF5_(N[3G.%;Z1,D??CB+21XFFLB]G9TDG2A41]U1E$M9WF)@G/+1=DDUAU[0
M#U-HS%W-]^GQG-G$.I8-3R[^R9TJN$VR%7B+R[-JQ"KISZA*^73%?>\D]23
M:^OJ"DS8M^)<]2[Q\"8QY:JD B^BOY(>%5UFSY='5GOR ,6)S$NB<2I>Y#/I
M&R#&VU[E"19N?ESZ0GUL^=S*(L"SX2QI&=""?J>^THP1+F>6::Q5P9POH&.F
MC> 8>#12+7D!X=[#E%2X?%-L\5KBR-*V\D0BH9Y4M1<_B"RA^.(Q@F;Z&>QD
M91&[#Z-E0/SUZ)_(N9*Q:(_78\4V-&3#D\++UM5+RDOK:E+JHBI=S-?@)M(^
M4R5_&0TS/*_H9B%Z3?HGWJ!N?,11<2IA\#JCL,4>K3]7D-W&Z*TL<6VQK<TO
MO]*X ]I3;:B/Y]VE\JV7RW\RZRW5Z7KN!^.M"*UHE3[0:Y=\.5&^[F>^_=)G
M/=W%XWNV6#O+CG5F0Q.KC*VW>9$40Q._G,\X6_<EW8:;4T.-R! Y&KN\5LLC
MM+WKI'FI:R;TS"F*[+]AG5[Z;9D4-%;N[QG./4H^W=Y>/I'ATNR0=HISN$X?
M,5FXW;S>JUOV7+=NS1W.A+)U73^XOZN":A3\#^1>,%+XEO8O5RL9Q<HI6R:+
MYIY.&Z_H$\K"+JGSI7*/#6"9:MCJ,L9[6E/G778@<X%%R:6QFS3E_ [>",Y>
MX7,!4/I#0A-/2JV13Y8>"].IQBF.>RS1E %^*\_0G 5%';&, >$K\T3V1+$<
M&,<%)/^QEPA&R]I*IXD.*1)2AJ0;5!/";!4O@+\\&@ %&#T00EZE?-.VF5:J
M6F:T,MZJ4U67V&;U&U8M+Q=84A(N3-&04Q(E8G!1Z GY"\C60Z=>![OW[:_&
M,'9K/J4,2S9$T^=BDY4MS+OH:68OYSQ:6RSC_T%)R7O$56A0*"0?CT[V %2_
MD1<KS)5[S1=;_$E;33?TBZCUQCV*;H;28&'L9UOUY47G>0]TBY*31&+MV-!(
M629^SD.B8F' \N:*U.;)S2G5)8T1NB)*:GV@_ (]K78Z8RP+MWPLBN)^-YU-
M>BE<9>@)'2==K\OVX"I?X3>6W2EWZYG:U%*5V%FM[2/'M;'D;K2\YAPZE[FB
M(:QP&S>B=D&213C>_#)D2.IAJ/&@*W7:4<NH9:7]@TTS*\'E;MIY)* W0K:4
M6MOI3OO,>-VZH+"$T]$X)BE<0%BOA0Q(#ICD'B1E@/9/;[^XO:RVP4%RMLH6
MORV;0S9+C\B5M'LT-\5;5E0!367@[D_X#B0))4&?P50IYC8+[E#-ZZ$(^JFW
MZD>+O!@PME^\D3U.<E(:RZVAYLG>"N;E[U0<%AU/T*@.2#N"MFK^4FQSLX>:
M /_N>=S/_)FUN_A[!=?1'4*)R"P^(PZ0!%)0Z33IZ_Q9<GOY8,)D9;ER=1"B
MOJ\^X>8)K@%=.S>QZQ0NUB*N5CD/R> SE=]% \)\U3DR(N:KU^5E2+<!W?&X
MPDW3$Q2J>@SN<0O0W(6^=I"9*+*@9B:[ TF#YW&7(\5"$W\[DD-:+_R,9.8N
ME8B1DOC)\CD(.VBX:C2"N85KO)">]@SZ>>,(RR362 ,#<N&XZ+L$ [PRW;;J
M1X*]VE.Y4\6EQ-.X#3)O8E3@164*/M,M!FC!9K8):;SZ07,88UM=(5C&>F5=
MQW_)#;;<JX[@[S1/RJD5R8T1<10I74\.W*A8J>6[)0)S\/+6D]3"CDA3$WU=
MVQC-5N;;9I"?R4EJ.%BUBG>O[J^<2<+!FH2XB9)3)GE@G<))C[FEJC<3XM92
MBGF9P#27]J*7J_%A>G5^Y9UDF]HRJL)XWDU+LW<+;>K>QQZ6)-5X!5;*!XV)
M;IGJ:FU)XP8UN<RHSU3?J9JB=@ 0LI+KH8F@G:G8 HYG^6;- S]S=T<_AWX+
M%8N\D!AIH_-J])#*MZ%-T4Q-T&4JR?1_58ZJ,):%DZJVY]J4?P5L^?LS39K%
M(BQ:#R)2[J+1T"_%$N?SR%; KUXE&\U]I)TIG\(_KK11S!!VL8N4;F)6>8"J
M2!J?\56]5AX2[:YQ5*;Z/P%OJNN<W\.'P<EUB>)M,@D^)'DC;Y&_D\U7+&-I
MY(7*565JQ7;5U@R)*E)]<?$=]0O-2/_3FFM@H<L$Z -TK':><!!\AMT6SX'R
M9>\E+*B'*9,>@2Z4;I6GP&/3SRE'PIF+A:K[<*?_$N [_*^+,Q2%%%@=!/:Z
M%/2%L$G[0S91]$NK9O1)Y,2-DO]DLXG ]'SY6[Q]L9WR,_:?/P*$8U4N8> *
M=&M-&>^<%43=!04U$FF1\*S%GOY37&9:6<*6SC6ZI3V03]*OC'JB]-8Y^7/5
M;835)0UTPAY;#G(/M2B0>GYQTT;)H.!6@YG.%TGJ?(N?_(_1^32!K-3,B^I2
M-!I'^!>KI^HT+B6:O?A32P'G1X\+LI#7T3D@B178MJVB?1+N:6;^3Z':&AS2
MG*1[K;>BRA53S'I_7]4ZPWP7JH9-[-&_Q_AE6@V.A5;^$E9@B\@5%!A+H&TO
M],6J6';)YS C]Y_P!]AQ(>R#XHND XX\_+PJ5O<=OD#9":R&G]/9 @,RB36>
M?!*)Y6PH6(+@?&HR [DEB@H?0-.D,3X@^E)1Z[@.VP[X:/^ ),XE=1NXE7>"
MOQ0:(=A&^A>J$/7D_PN=D'0DO8!S99O#J^!/BN<^(N2HNM#Q$3JH^4+\"_A(
M3JM,P"K9#%Z=QD:>2?+1M"O@_'0P4+D[20:^5H\+MX7V P(?)GQ0\]EI.O(8
M:L,_JA* 066]ZKZFE#N@EFMN5!<"D\'$O!/ <7!WTG3-!B@B[ VX'CKA0X7N
MP@RG2,0#F83/5.S%>Q4WE&*\@3M,-1?/KUJM.HE]SG-1=V/MB:N!'BPI;(WF
M,/K=)P>:CZYQJH:M: E&E@/F+(6+(M;4PBE6?#$V5TU6[C1P<KM5*_21B7'J
M?;II82#PG7CIDP+*\:U.&G@\)D.ORM0-!^2]\NSZ<O9%Q<3:ELIFQ?6:]EPO
MY15S:\(]]3AC<U@,4*%O](G5O-&"3HW0,IR&\J0[VM_) V5MK8_9%'EI<T&E
MI\*Y <RYKG2O79K0IQ)8CH9-4=\R/O-QT>AUOYSZH S"7:,V'2QCBQX;GU:>
MI?]C#"2[E[XQU-*,F:?T]UG#8_OU0=S5P7_IFH6XYQC=-.DN>YIVARH;Z#)4
M4&Q$/OJ#M'/T<7I?)E!*T2WA^&92=%-XOV.IVAKAOT%OM;.DTSP=B4,*T'Z0
M: #<U4=TX]D[A$G:?NY>6H8VF+^_9!MQ7'@\8XBH%#^-G4",ECD'G<0'%3K/
M(+Q5O<!A'%ZGN:MZ@+\3!PK*\762=BH)KY9^+!F%3Y5G961@EQ2[8M9@_:K(
MH$[,I+[J&875:5H<,K$-$$<U!G-0]?!KT1]J&J4+/0[,*DY$FX#!])LH3\./
M*41YH&^0!%6!?SR3T)70 P<]^A8^HTQ"NI!/O+M('6I#_HF(4/NB?4@F.BZ=
MCRQ&/L4$(#G(NR VHD4^>Q8B=Y%?#MO13'2D8B7,,CCPR+!4OXULA<OUPXIR
MX$B=0_HP.%:;''T'%A+JH QX.[[5LPP)P!XXW$&.8Q,5[I"D=C;W.62Q3B;/
M@0#+\L(7$,7T(ZT?DAF+HTW0;OU@T$)XIL[+LQI>25@<?B%EV&OY"?"?YM-<
M(WB]R9>T$SS5,*JP'MQ6:TTC@:=KYD>70PM-VX*&0;6&0L]B.$+[UG$F,A)?
M(9(W5I79,-;5WZH45?#KI*13N5MK1]&"DW;5 ,PC$>?-C[AZ?\"4*52YWC2<
MEAZU[="+567"U?6!9!)C1NU]VL3RQU83XUAN1HT3NS%)9M[ @R(VF\*$;?YZ
MPPG)3;<9>I&";O>W;C'@*/AB_<-"Z84UUSF-Y1F6;MZZG"/F7,&-I!G&WV+;
M"-"P45KCC^F9BOEN<;H(U4,[CM9?<TP087DOQ&E-YJ?B864FTTD)DA-B[)&-
M2^PW".6K(\+U:4J:OU#GK0YSHV@]-4%V^X@4*(:O,WLI1-3GIBAE5>E38[ J
M-GN)P59MEYBJGPA,"_^MFZR9ZU^AG0/ZN4%$%%1M_Q>.P0V\Q\;=4":UU/ 0
MVEC*TK^ WF5[ZQ[ -@FOM0_@PO"GQ =XN7\%80O_<FO#!4B9?0QV"_F'5V;0
M$1\I5_2'B ,EKW77B=*L0>TM_%I"(_$:+PG?2DS!GOH+\"2,<-N"#6(+[,58
M+KJ)^U;?;I93.G6O34=*]NF&&]=D-1.?#(4)<F*T?GJX&4_5/O-/QWJ)2VZ'
M,0]\K7T'>A_#N>VZ!_7[*:FZL#IS"5^;;]V=E4FD6+H38O%R4WLX'QLPK/=/
MPB;KKKM=1'<27^QWH@;<FS[4Y5^ZK.)9Q]B*)_D=K<](L:EOFI=0]\?,;71@
MLH(9=29NAG=QS3-AM?-(<['TN,T8PR\5A>[0D4R"*KAMT53W?)^6>?0/J?V-
M9UBWHC_7EW!?!'.L-X6>WEI+L:3-N=SX5I%F4Z/? RRD-;>Y,KW*K[1$LS/R
M=C0%<-'4J/KO_&O1VVJ7B=*"BVH2)"^]EYA>R-<Y]QG6J09LA^E6:#;11K7,
MX^\H#VU*%^;DS6HH%7U-.5L7)=D>3;..D]4&+S)?51B\UQC[5)W.=_0-P U;
MJG8+-)\J;2J6!91M:E@N3\WMK#N@(*646/]1 M%.EJ6J3<&330W ".]U!H.&
MYC)&UPT^M-U!/(;+*>\;7@+]95'UZ9KPW)!:N69GRE\U2M!S\4.S"-P4])]1
M A5X;]);X+]<W+0GX/VVOXE01$+!ZP^B+TH?U@5APW)>6)GHO>1]%CXZL'B9
M28'"03<,5E3@O4>W%16XI&AGH&R[$'PU6DWQJ#NO?U]:6YNOU^9TU=3J#B9#
MYG;M]<4"XRKML* !_54BRGNU[F^\T85%0-A=.P8>C#F1G]3-J;E<*K2NM'S+
M02R/S-IDANFN\?1BB>&Q(33HF'Z.[KCW&2U/*W;1$:.)J786[!9VM+RIKZ+D
M>W[.LN8*_[0GO0/5#7$I76RJ2UAWVWW&-W_79B_N>/?J>JXPPZ&J9E!Z>4&_
MJ4K%*KNU?%VU*._*DD\4FS2H^POM1]RHCK6LT6&Z5CMNLG]4(R@XX-Y7>UE"
M<CAO25:$+UQLG S,*N,N74[?GE?5\YOY-,V^:P8G-'9GVS7>OK"J9IJ0[Q];
M?U^2Z7[=6B9/=_0V?5,I%Q[2O]9TEXWK;>5>S?VW>Q3?DKJQPU]8'BMJG2[.
M"_-O/"05^T?64>7;W'_5C%%-<@2,%P&+3:#N(_BMM+_[M/AY;DMGOM0EM:JM
M5B:)=6Q&Y&?#9C5D* O\PVNGJ7YXS#??!=8[[C%< A4VS3H;V*LTJ:M ^2DW
MO?V#:E^J<VNH&HSYT10 1(;^J)^LF>.?6/,<G.T1;KH!.3I^T'^%@VT>:WE(
M4,F73@?H0N[4MO.P:\JOEH5P;LS-1GM8''JO;@*\VC_.\@/^Z5%A_(:0G!ST
MBY%#MB[$3716R?8.7P+(>=;ZC"A/&6H.Q=_&'&V(PNFA%VK]L<_^?I90K->C
MVIB.53NEZ?JQ>;;E!!6]6&)I%QH_YYQM=3>24TXVP8;\F%WU.OW<T&M60/O+
M/]%L)7Y[R S_$#.=J#HO/-!61XS"V.N0BD>%GCV+JG^7NEAUU*F5,Z$,AA_I
M)V\)6T9[5GZ$]Y+U+CU"U,)WBY@BZQ#O\1JC^J%XLL92\J::W+6I0D@AU014
MWZ,7@Z[48E8&MYOQB9M:]IQS3$!.JQ%<$"\/[Y<&R@,]ORH_JA>O&BQDLM&.
MWZ6+N:CY2,5_?!BX2#HL)#@JVL;_*<(OUE7IP=0A?HAB0GB,^+.JU?.E<HQ&
M,? Q+THJ;4\OHLIPDTL93=ZL1JMXBK7L?,J \E+I#.9\]<34<.XYH#+LB6A(
M<]-S2!$"&?OCLI507.OI_/N0P'"TQ 'J4 56T* CK'+2'>A;22J]"UZ<LI;3
M"M>&M0I?PY\\+\L)1+#B2J:=_D.+)?>0/DJ_L2A4ARBCRC9K]S"AZDKB9_$J
M6BZ1F!+*MN*-805".^RNYRG9"\QA^>IT]WIILRG[9^UUW?F"+JN' BB-L<@9
M9ZML3$>*YU'CC5.3AUCK]45A#@*9UN!Y6,;&ERT[DMK6L:GI4%9MFY/./C^S
M&9<_+)G2<(N14#F]+J1H"85>8TW6,G^:SH=^YS_5O_(<E TC7BSS3!$MQYI"
M,C6]7[5+\]*[*N2B8ONVH_1G%1'-H44EY#7U/<D)3$K-X]!3?(GQA^<NZ5KM
MSZ57J?\6!C5>8;!+P[6IK&>5KO*Y7!5Y-%TL\**]+5PNGL+ZGN0K<^.'A'@J
M6\37W,LU)<IQ2SQ)?E5/&E90)Y-_$HGT^_01LDC67M8(VC;N('=<X3C!9X%_
MXF$)78P'_ZOPE7NX4X%T=6J/N>(<2UT_G#2,TX_=IL[G'9>\9<0*GE&[V'7B
MZ04>_+G2LD1[T5WYH>!>V3<5UYVC+M?0NUZ6'A$_J1561DD#T4I2FPP0'Z#^
MEN^AM#+;E6/RJ[E\%2NA30BK'P272)]H].Y"E0DJ[V05S]<$62>77=!L1&97
M,<&Y(BOE+U!-WDF_#=[+6\/^!I4D+!1D07>"%TJ^P IWF?(RXMSA5G!/R[&\
M*3FBG0Q/K[ 0G<(5I"IB)NDYC8$WY,UE_8//B=_-3\4&@EY)/+% =[4R%-W7
M[I(_W"JRC"B>7!,)19?]-#\4/*GZ:I*1%E/]C&-S6Y@;]#WQ AY/YQ=T7(P2
M6]U!Q0[<L8V2JVOU-V<6;FIV %M*=S0,"3(K+]01U5LI7E:OW'F,:^;+\?.Y
M@T91T$K1O[JW[H@BDRALO9O#Z:TSG2I8V;4"G%8RV"[E7ZYXUN)1G4TN:WB9
M<X%A7SL0=Y/K;LD. D2$X8H[)O^NS6LIYP85%AF;^:-*BS2N@I>54?Q1HF?D
M655,Z4C:S^S5\@SVF-A\Y1%^:H "L(H_N-R$EBL]FYXR5U1Q#!3V=7(],);W
M-VT%;Y(@@[FILD.TF7,R>ZPT53 JYI%BNI@;D*3VE;NZ? .MZMQ&C$9FJO1_
M,UZRCZG^L,F\,=S9W,>"N(K+ JO(G"47BR1O8XPRHUP6X*C\J(ITG:YIU^0W
MC"'+1&3M$EJ,^)&RF?%)6LS^SMXF.U1^A[=*$92Y0WA9N3_F;VF@FK+HE>*1
MQM_5 S@(^=2MKWJA]B'*R2_5KQ0,VE6@GO6(>4;C7#Z'\U5S('.N@ GRHOLD
M?T,NBP[+/T/?7!<#8^&AVKJ*8]AC/*_Z(W9;KJ3^C:UC_<WPQYAEI>P:S"&C
M@^^)OHC.$X]&=RU:*G='+:[9:BY::5U=]L?,QC15F:9VV6:RWMC +*9=,?!+
M=[,J]:D9]CPWG7OT#)&'=L(BLPS"'[I6JIYC:VN^E]8WKD.O5/QHF":;0LJH
M\V4<H6ZWNI8&,$D6^_2UW$+3@L4GA9!AQB*9])WVLRM;!>'':I 2L+,%+2W_
MWAXBK:\N;5$PTBB7&O4E%QB-=5WI-,[RFBV+S8+7I@.+TJ6X_A]7B<J5V&P>
M(_FG$(4SI$.E8O$SN7ME-NV"HI;L6)RD&D\?FSJ@7L>>&PEHY'RR[W5()YGJ
MA"%7E,G&7<+LJK^@(-%-LJ_HB81'2Z-^EDUB4HI:Y6<YYE1'Y0[^]4A7]6EQ
MGN\AT$7NX+0#WJXN,D"\0(9&\UXPB?5(."0<XD93QXCW\=L*;TGW"7^G=,G?
M2O"(&ZHTN8?O1N"U:KK34VBG)D8?S*8('@&;N)#(*MC -TI<*8'"7NF^0B_Q
M/7E9BK,L5SDIHE/Q0777MT]]%;CE/!F\ XW0_F9\5OJK^]AQ*F?^>BZB^H_L
MRS^F/ED@$D4"'<D6R7L-&!$F/P,*?+6JYQ#@O A<"'<0/V@O$:9J [,*Z>.=
M81]"=I!HO!!D2_YAP4UD0_("\0YD1_@7V2GDM*](-1]YXIRM@=!AA#LUV,!6
MOJ*?TK_CS65EZD.K#W$>ZZKS _@;M8:D+:(=Q+;P$](W^'-?II*'SW!F 5^Q
M$%Q/OEKGJ<RE::T_N033ID91'<X^:SZ2MX.WTS0]*4GXS, (UTMC=(.^Y8H[
MVN'.&L",1^-32<=;NQ1WJ>;FO=SQC$6-S*H3K'=UU_/*N6^L:4FCA<'F0^%9
MDDW&4-\PA5"WU-D"!!!SX$L 6+A$-DHSO!1B=6DV5>96U(%2LG..'11/GQ*_
M"O9B>X1L1@+Y&J]B5"X)="C!GBFKH0%E6F6/=+K*DW2<N5\]B_J\_"XPD3DQ
MNTTSBY,<GP[&\%>':"&+.-R+@DR5VSKTH8/J$K!&ED>O$W^4HZS1C$N* 8ZR
M?*SR,N]YUGOU'"$_[AJ@E4P/20:GRH:\J-!5Y0N'9\@.C9=&).[C,T4WI..$
M ?1!&5WTJ2Q)?EBR)2M3F2(#XSBJ#XKJD&G /E65%PW<!Y@=[>'+X'6@0I@A
M#Q)>$CU4%-#.23A*4BE/^D55E7E!ODK-C)NJM )$\"MUHV:S%T]S$OSIF ]/
MAHO58GXI^$XX13@;8M$<10>AW24')%+HW\P 62;L'[M>409CP9M5]?!=+S+P
M XES!"$.LDJUF;M#*Q.4\9NTB5106$;<+/$0>Q'I&1NE[OB!V&QY!1X3;%5N
MP4YX48 4+,.Q%WR GE;-X] LV_EG>67F!Y3/@F#3]N(MHH7&\HQX28AA9,Q[
M6:UN2W")<I26XT51;R=F.>X&)=A!Y6IV1>,&/HG+:(B@&/BY=9G%&<)$JUWZ
MOV*1^7/,7NF0\4JPET*NW^&5KD[6MCB>!^?B9ND9O*:PDWT/%Y<RJWFXIC*P
M@(?7D2>FSL>7T4=%7<3WL_T"9N$?^ WNXXEL28$=E;BBE$KV(8V5"]@3D%.D
MI*J-Z&BJ,/\F&L_H3]F":ME?HIK1VWQ9P#@L56SK'H@]DL^W.X;WJ$O%I\!]
MM'K6-"B2.:OR&;2.W9/O"L_E>:7XP/6"2U&QB(.X=]$;Y(RLWCT'7:K<;S\?
MLVKFB"X#WMRWS+G $/]JQ2<-)-R1)P?GBWN3>\'3TM;(1U";?.VBH[!&><>=
MA.B!<'LZN@S<('RN_"@-9<2JSLJ("@]UL_Q [E:@7/$EV4\3H J+; 5#U,V+
M5D(YFN'N$K@6--GW(=?@N<(9BO& E XI)VGLRS7*KYI-N2ZJ(= K:5!]&]P4
MR=8,@](7=8(IT+_N6F@GW&]_$_%"B@4,F0J#:>_E2[&6\A&*Y9@D9X>R!_--
M*E#M1C]'+@!&HF<6Z34L=*-[/30"M3J,@I>@+/X=Z2)C&DTHDQI.EIGD9OV'
MG"Q%F^YUX@_E&>V'B//J8.W(117 /X2#>P?(PT,=7&%O+),OD?C57J*-D^JL
M!\I<9>MJ_+*_R8^9J8F[E7\;ET6L4AGT;Q;% \ZZ1/<FS4^BRR$>NHB/9=N9
M'Q=6D":8'4L7%%E-4,6+C [C!=+9.+IQ,NU6:*HADVWG<U+?RN]R^5OWGT1H
MLTK7H"18/D:["GYU@6%-=4?A"X,'Y6+&0GT7PR9NEGXXNS;472?D^_K<UKX2
M_7;)U)KE,VUMM9GJ$F:UCD?E5B&Z ,;(PECM0]:*=(L6XA;';M9.$[B$_$O\
M([;SN46P95$N&!&M;+'5$XLTHQ@-^'M.?N5&_#&OI$"&#PI(:=]PG4@9NQC/
MEJP(V8*[R][[G,&G*4M=5N(+U*]M[^%1H)%^'#TN]JKX@#Z2+,T_A-Z734PK
M1D_)@9A[Z#[EL!#I_[+4Z[,'?0IDN1S%[,"Y=AX8#WI GPY_5GZLR$2"5-?R
M Y!L]8K4FT@)P(C1(!Q-2$@>T@S:^NQ [D S71Z@B? L.S:Z%YE(4T T&"K?
M YV&+^5M@8?#/U/YL#TR-<8)SD'\0MS@=J3:YP+\"5GB.@HQ(7?L>E!/=!+U
M)^BFO5?. ;=I-^:)P9]:C]3%T )"$S,6*L0?A(R&]N/E/MO@*.REZVSX'<:U
M.XYL1Y]0.S4>EK_*)VM.F;/S%H*.IGDIW\%<P[KHVV"+OC#X/31)-\MG,S1
MO'1U@E7X#KOG2#'67/6HR5APLZBW<69)4]:X^C45C/__72*1(T=985IMP S+
M"=8/C]/F6?QVQTPC(M$M=#$L4-97C:W_64X4?JT[5K4C4UFKH(Q,V&P=31=%
MG+"HV7\'C#.]Y-WP^&*DB2XYKM'_D4]8N%%W6EU865++I,PL3+32:(<S7M5$
M,8F$</,[#B4",EGYM$7OC3ZB%L\I^IO29XZ?=2N5/!L7;3_PL6*SY2>KL:#+
M8L?9F1%OMN&]BC]A_"D,CO TG! O6W1&WR7S\5RH Q37G/RT&O4*&RNQ"J17
M3#3=$HXL&&%R$2U/WV%,E"3&IQMBI1_"7^F#Y/L6K=6%*E=Z.FF3U$N=R(12
ML\GF$7X!VE N-XZ7D_,U!E@!IB?K=RN-<>]T%U0MX0/:^^I_%BTA_@.^>/H3
M(6",DPEO@^IM/?'Y\)FRCWJ#QIH_46\+NJ:]T4G!]KC5VB[P3[B . PI%^GP
M/_!8SV0\$U[IM F[@43:,C$=LK_,H$O"1'G]VM\8EE:G96$%<17$<FQ:>"!^
M%WVR* </04]Y1F--Z!&GV]@B=)-M&S8!-9<%:%,,*7F8UE7_*DU-#.C_CJO&
MSVL_A5.PG]I)BY9B942F)XC>P_N=?J-;L)>V@^@ZS+?@3K>^P#'3TEE6?#WQ
M9[M=^<;%MBT;J@\$NS3^H<WR(=4'L3:[)EKY?-#NG?F,Q#S_DA%6=A:,ZHPL
MXV0,M>=7KDPL;/4@CXOJ:]I%ZPUZT3"9Q?(AUU;R>*XZRW91BSW9%"W[NH!O
ML%/GY4-M^TG-&1DMOZAE"3>;?C.BHL(:5K+S@M;5V?.L/F4U'<*?KCO,ME*=
M_2'#'67$@H^Z=\"#_+$M>8P5Z2>;-K)>)V0U7.#F1MZI6\6_%22QYH@L/EGF
M'])JU]O&K8HTARGZ 77A0IKV!9B49VIRY_6G9S5L%<CBG]6]%>5'$M8A26)0
MEF6KC.:3:K(HEKM^-2A5KQQR=)V:I(5'M>,@+&]B0X%D1=K#^O'2;_&MM51Y
M6F1F#5LQ$.1K+E#9^A0;4]6#;G/T9 W-0:?=!DVTF47DP(VYR^I.J>1IQMIU
MZMSX NM\8$KD DL@<#YHO"E8L\8GQY $+G.+T$FA 8?MQ$=XJ4T)O@-1YZ;5
M&N"Y:;%6*PS$V]9,@Y=%_#8'P;L#OQL3X4\^H7HYDN@6JMV-K'&X2^0@_]G4
MXN%H6.Y4*T)TI4VL64I <9\L4<2PB"<F+LX-_&U L%\^N;J]V&JW NU\C.WP
M&[^(V=GLPJZC5Y<'%75EKVEZ7.9>X*B+J]Q?TJY82%95CF<8Z"RRH>@8NY/A
MF,P0C.-\"55*;HF\/8XK?RI&+77+/56ZI#&S\%:E'_&@]#5IM^QUU1Q:/!VB
M@,PKA2^9CEQ=TC[>1"$S=)ZX1+K2X[SBI8K7FYDIIEKJFW*_,]QP?I&2=5C:
M5CZ>2Z%555\53"H<37LINI&TD),@/15R0C1,.=[CNOP;L+E;F4KP"VL?9H'"
MO]!K^26BW9*"DA2)A)I2J9:%%OA2/BIF)]:PMJIFAJ""*T"VQY#< 3S7N2WQ
MC^*GE91.4IY$\)QN59=X7N%]-9_"+V< Z?D0.5H3F3B=60Y&AR3P+T,<CT<R
M#CS8X1'W%E74S$W9B-)A558,6B"*S+^.QI%7E:Y$ _-^59]$ Q-V,$+0R)"9
MO!]HOL=SZ5E4W?8P)L,T:)F81#8>@OHR%AM."AORYNLODB>7^.ONY!%5+=J7
M"3)Z+/$U^%]>//[+X[4T#?O3>F^Q;>-6<U@"4'\,_)W66GM?.#EGK74D:7G1
M#XMGGFUEARDCP8L&&2C!-[CK=54>[R1#1'JK6Z2\R][4&S^L/0+$4I-;.((M
MV?K&+21RX9_ZD;F?*HY;XQ-&4:^;N<%[N($&CL='B5%+;J-5TK/_F.>2R 5L
MD$^5EEP41#!65X94=W.FD-?FW.7_PTB,,XD[N',"M\GOB(K<? &FPJ\%*#E>
MRC$>KTBM^$]37GV65,<OIW)I-E4/F1',[3D9W"RN(,Y%N$Q8$FB1E4A7N66H
MLU50T^Z"3LH9PYR21CJA?EL!LH)Y$TD0YV7E&=I6_IIL"=M?9(ZMX[^7-@8F
M22<J7KO15<7 0./8G$N\*3JD<!'_M4I:JA2>X+RHO"CNJ[A$X4K-6=N9Z7)+
M[ P>7[DV<(KX*3#63:.$P(%Z1:9<'J)=D.>GB%8&%)U3QK,/EFM4\15C22QU
M9M9T>A_ BUG'M=$L"7@J>@Y^=ZM5'(35=8YIM7 D_CF[#18K0@L(N)/UO!2&
M!\O3JK;#3S([::'(PIA*]G\()>"(: JRPZU788_.K9V<,L,P'A^=2=6SY/R\
M>MT65D3Q6>WGLLV5R=JH3!?J.,(:X\2>@#\*V" LQ8/<ULI[,*TU+&E"G05+
M3V^JG2([G?.E1LW<6L0TWRB+J)AEBLG82YEA6!M]CY6FGQ70+3BL%;AME_OA
M>VJ6)P!MK>C!-,^6%%E6]K;&\\S4PO3ZK-)7Y?;6VQEZ<K*%$;V1N<;X(@ 4
M9.ESW?;);A)[:_;1*G.HJ(AQLF"'=#>[H'02 ^8-KV25# END*^F.XN?,_A1
M]^7^W&A_9]5U$>I\ !Q4E)A?5W\K783,ICRI."%IH-\FE=$-K.?4MR53>$[,
MAC2]L)=;'J60Y@E+_(<KJZ7_.'_0=*DLIH+R#Y2)T,KJ?-H-,419S5Q*:V!,
MY;"*L]FK^-&I/_A:47"4D[A'6NSW2C%><<IE = -=!@.E>1RSH&^%3-XYT73
MJP\(SE,!*B0Z6T1B*B574U.X6V0_(K>*W)31?H=DK]0'76+5>T%87U(X3RH#
M'I=ZRS8)GE5ZRA]1..1PY=3"-71"E9:RDS-;W1Y9*;@/_/);)7T#FES(JE]P
ML,XC+U_S2WV]:#THX_\J^PC>('=6IT&+"KY1;T&-*6FLS?!?D?/YAV&C7Y-T
M!K+01:,J10:UP=E?M9FJWP4UVA'\R-*)1!/I8V4?,:. 1I'A/<EWF49\4<0;
MW@7LDI])4HY)7!J4%[$IA#IK=$V!JB#OK"6)M[08,8\@<2L2C2OS7Y%3#<7)
M,D:K?DK$>MX4[04_1'R$(%Q6*"FX'_XI V_ZI+R>*VGTX[D6)=7/JOY5[FN]
MF]]"*K9L20ZGGS;51P!<B4'D5RW.U<6Y;%:.(VSQ^=S:G,.*?_C\@C^<MT)1
M:7S56G%=97/>).DY\I]$NF(QHRTL4G6/R_%>K[DDVNBH@;\I-"B%22X=)A>S
M=U8TLN_QYI.<*\\)FJC[<RO%ODQ!PF/9"&YRZ#OE&&&^]PJ@5'K \0!T1M4*
MOZ-:R"FRF8PLFB/K/'L<XT_%$/<Z^T[."L$9WKD$DOBW\%'H@)PD=?3N5/^M
MV.SX"SP,6" C:2+;)#E$]>:N8G8R(OC'*R:QBX0OLW_R^B2SXC^*/&6D4*GT
ML>*,=Y?RGEKAY*^Y"Q:!X16_Q)O%JTE,Z5Q&"_6 #"B?P'217\M.Y1Q01L?3
M!#VJ Z&VDCZ@Q-NH> S.=:K4S((^:US+\M5[1.LK?P,B^G9RNV9261(]0;,T
MJX]M#T;&_X\A^";DI=@$;?1&%&-AG1,."!$JD%(R":L5/BE_C]731U8?PEBE
MJZFK,.^L!<P#Z,^XY;Q9Z(V0XZ(6](@W*L] MSDM4S]&EZJ[BGQ,<X6I93%&
M 4U<%6V 2]TIN7I1YFI&ETX0MYCKJE6'U FO$/7>D&P+OM1IMUJ*K5?;%&RK
M3Q-<*WE3^YOZIW*2-;%D'SG&0LHLI*\UF>+&<"H-!T-(PA#]"&^J+$:[V.F<
M>@YN5O*DHW/_XGV0%1=Z4A;(SY32BJXJ"RLWI\>IWE,61F\!-C,& S>"[=QV
MCV+XB.B^/0V;KNB0WQ#.*1GDGA==K<@@^TAZJQ\6S9=)J;JT?Q049GQTD0KF
M^@7J@8/"; \>E" ];3^(W%+UR Q<,0GG-/,;J1Q2H' ]HZ@P5GR1G9XV23:=
M5[+XD4(OK G,5MM+7GO(-1\5K0[CX!. 1IK!LF&%L9F<1HZ\>C;O.V][ 2BD
M"7ZF\L2_Q/F+-;)#TM.!]LH-"KH' IQ4ASID0C=!7XDMW5WXB)7'?"*65MEQ
MZJ7#\I?SXV26E"\B&X7[8@_I(N6#P%$*AGJ31[WZB&:U@PZ: .T0VU.ZE0HF
M3F]3D2M%+$0=DO>#*P)&I50)3,!0U$7Q#<VE@*OR=/"&1[WJ*?3183M(0B:+
M\DE<^!+C*+4;F5MQG+$+"<JCL^\C,<GW^/Y(<91:M!W! W;+BI%!CPZ5&_+;
MX8[F(AHJW%35H7O"""1_U5DK8NFQVG>Y[UE-VH!D%6\JH8VR%Y[$GP58I2UX
MJ<=2I1D[[O!+4XDM$H95.M6LH1\GK;'L+[]&FV6FY]8RC<;;R3Y<9P,I\E_A
M,-WW *;DFW:)1ZUR-I'D.%,S#/N/=PDXFSN3FJ8Q%/J4\D%**2G;'4JLW)C0
M!WM3G,/]$&_&5;]"-(V[SS44ZQ1/LD6)48HM7);2MJ20DJ"*+']2TJ*NJB:R
MM !.#4KPU6QE_AWV%AK%G>R7!DN$R:XL=)KTFNUK;+]J.2=&NK)Z*=E;;DMI
M*]ZCL-#;,X\I/[%6Q?>K1=QK89V::4)?/S_P@F2+JQG>I=#8I:++ "[;300P
M[I$62J+8H45[I&^X;9D3Y;V"4?%3E2R1*2Q*72SU]YNH(<M_N"Z#K*IO=AW(
M&G <RXG?)QA?'2!<+3Q6^%C<(<8SDJ0UTOBX/GF+?$[HO\ISRDF^7X#YZKFN
MNT&])L5N"+X.@<P(KH?<I:J:SU<D%'H+.Y0%Z3O$1U3DN"#9&#44>E8A 7;Y
M?E3] $>[7M$LA1CVLV%G^" #9(\!IU8>YAK ]H*U_&?@M_0D42R4'GM.LAW:
M%*J5%\ ^OH]5?\'[7)\!0TBV?1+4B%RG/V9&X;LJP]AO\74%OCP0KT@;$OS!
M/L8JQ-U8=VBXC(-5^!Y0QF$^KI^!:/2G/0^:AQZD2_[7R0LJ+K#ZC$3^:6Z)
M 4TS\'_J\V-#13MT$:&SI?W:"-_5BGXBP_6#^@1>;6\!=V,H18O?R7E0^@G_
M4/ U=P9A5^J1?)E(KR06EQ,"RL2@D407XYI7)G&;>\.)HHT7!RV\JCVB.$Z.
M1SC%.TI'(G?+LW.2T;2JG\G!Z!K*D:A/V%C&/X%7,0WGGE<Y/D(8ZK0&WRP=
MLLDCQ*I^4CRXL*J^9 +X@-R;K87J:;N2ZF ?YNLH%+[ C0]L1VH$)[W*T J)
MPNDAEJT@V^S#4X'RZ@+U)'I5L0,PFWDSJU\SDE.=^%[SF/<C:@QX3K@EL "Z
M)&GPRH)?R.N<)Z(+5'ML%V"IFF=5(D4VS[8H2]DN&)WY2'50^&]BDOJ.^&5D
MOV:T;%C@;#!+$>P5!ZU08<Y^R%3@I2T7%4#)E?W2QY+3A6URGLP^,UEQ3BY(
M.*2R5QR,C%7_'WMW%=5VNC;\OWO/?D;VN.R9O3O63J>=SM3=!8J[N[N[Q-U(
M0H! 0D@(<0\0$D*"NVNAT)8:=7?7^TT[\\RSWO?_7ZO0.7D.FK6^!YQ][BLY
MR/7C7H""K-ST!'8/6K/:%H&%VRWW1JU$7/ZQ&FU"P4+N90Y";7SN9!?!WG<Q
MY:Z$Z6W<\C3PP%U7(%L07VV:@!Y!7%@="B<BAY9#D>&HVA_/HG]$8T+B,OZ.
MIOM0LMY#][O$9Q]$]]G\)S<;K=_5G_\=NGF3''(-?6*U-:P3\]7R(D0+9O^2
M3U%23$CPL[1B(M?GYXQVHHO+AUGUA*H#XSD0_,%=Y7F[\<LVE4!^Q16MW@/[
M"??I<A["&DM?LA%EC?TT@$K;Z1'I\8A:YH-U7$Q=%-"V_T1!6.BJ[9D41>34
M^HWD&W&=*_EDZ^1S2X^0&C)]OXL@>>8=]<\D/_<[[/$OLCD(Z^!"#@JSW;^7
M="9J[?;/2 %Q#NN_(!Y.JEK93HQ+7_+3%N*WV6>^NTZX#5'X<0C3H8[NNPA'
M(G+M*PGF:,,^)2$O_LMMM825297KKN OI06LG,8W9FW]"8NOS;/[/A[?!G/Q
MG<2>B*YUR\-]'^=M=QRW+?&]?<MPFY./;// K4P;7]>.6YUY;>4<;E_N\I_:
M<%D0[/<3N 9XO^_GZ%^3/G;M1&M25MCM0+](<]E;CMF0@=OV3TQDUNEU/(PT
M-WSE)<R]_!L_W<9&P$I^^!5["/F-3SBB)R/8]7LD-?.*;1WJFVS8WC4H1.Z_
MMK:ACN>-KJ.@72&*E7?1DS#:LN\P.8B<'[*QWZ!V>??"#'E0ES*X.1]C:XV
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MMY5!$9LHQ:HZ0GF-%B.H4Z(4]3)DG5&$-#?P468C%]U87X%I,LRG/PT5MJN
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M&N"=YA/ K?P X'9\#; .RP'5?0-@^.T!12&.@!'M\X*:%/:(F)EP!P/+N('
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MH9;QSJF%]1;?X?8:U^T^CGOH/HH;=Q]P>N-QFS#A><WE+?LB\2W['.DMYV^
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MN1E<"^)97/0/L#_G$^ITAAM+.L5.H9WPR&$VNI6ZU;'J/*J9K>Q*YF5..7.
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M3%BD@1F\JEC(IXS5_(K8+*" RP7E<#6Q3D@69W]J^5Z2?X+L_S> ]%L 4<\
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M-;CHT=!+[]_?4@F@<V&P(S\&>8MB0)@T^B8I("M/%3TJ-=&U20>=N_70:<@
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M;6ER3FSN=HM;MLHCNFG**ZII-RNBZ1PKLNF15^32#YZ12]$CJO%'F,D.CRL
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MJ6J(&5^USB&V<KMC3.4IQ^C*^PXQE>_L8RJ1&5N)=@MA,L#= H!?JTGO;*+
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MJKZ8Y%)YN9-+^>59+J57][F47KSF4GK^]C]6?7L&-@'4D_SB_\^/O #@^P>
M\W4 QF-VL'['#_1WXF#V7@&,WVN X0<#T/MH1M'^:$/1_.1(4?_D3E6=]Z,J
MSX=1%3['T^0^9]%DOI33I+\N8Y/\.L F@>O8Q'$'FQB>)&X1]_ZC9R- PPZ
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MC5,*!\V2"M9:).1OH<?E'[6,R[]%O+:(ST=SPFPAC 6XE4G.H1C@:#7 G@:
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MRE_API<]Z"V<-A DGM0?*1V_/%XNNC=-*:(G3S6TNUPCL*M!VZ^K4\^G<]B
MU;G!T+-SKY%GYV]&GAW/C#S;/QEYMJ&A9^M_72//P\EO,V@"F"7Y$WVD^ZT
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M1 Y.1S3A<-08DX^.Q:1C=K [YL+8'/-A)AP+X5@=B^%:'DOEC3N>QQMS?+K
M_/ALP:CCW1(CCJ^5-#M^@/A9TNS8GY*F1]Y+F1QFI0GA5]:0_A+2GT_Z]0-
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MA9VRSH7]<DZ%.^0="\_*.Q7<)_Z2=\IGY9SS_LOAI,_?R5I32+Z3RN_63V=
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M;OW=3)?^&:;3X'>FW? 5TV;(,O.)>=\P= [TT)3T1]-22\O]25IJ#QMSL=]
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M.@EX8(D4>Y?D8?>2$NQ:4H4=N@W8KMN&K;H]V*P[A$VZ$YC378,->ELPJ_<
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M*NH5D$R23-THZH;1N@9D4C\;<,T3P5&F"?M\7=CF&\.FP!K6!8ZP*O"$94$
M+ HC8%Z8 +/"3)@6%L.DJ %&17TP+%I%=L&@\#3T"V^1_\*@X"X,\^7SK*16
M+TO_!NJ5D3R23MT$6K3(+""(MM5'1N]50/]-&VU=J@KS<FV8ENO#I-P,QA6V
M,*IP@6&%-PPJ0J!?$0.]RC22#]W*&BRI[(9.Y0IH5VXC)Z!5<9.\ >WR;Z%=
M]@=TRN08HU:'XNXP4J2X,HBDL,\QM&>AU/:E/7(OH3[MB4TE8%8CP*!>'7H-
M2Z#;8(@E#1;0:;2'=J,;\8=68P0T&Q.AT9@-]<9RJ#:V0:5Q%,J-<U!J. 11
MPQ6(ZU^$4OUG4*K[D?R! ?:SF7KE1$:D>4!\/N=A$<>@%/"HH/>JIC[MHAG]
MN4$+L*1=!9I=6E#KTH-JES&4NZR@U.4(<9<G1%U<9+MX,'4QN5WL0%<]H9'O
MHI'MW$=H'#MHV-I90;=_3WY%%W-<2XI)#G\EF=I1I0N[0MXU]/\-U*>N&?VY
M :VSSE) LU\)RH.:$ ;I^X=8> VQT!BB[Q^FOQSFB6:8"]PP)_DP$SK,AH;Y
MB\,KR YRFI^]!0R^2[[AHO S6JA76;IPAYBT#(BK6M@#\FWB'&P#;/GK9KW4
M'Z#^"#TH_;G2! OA21:=*UA\KF ANM(0F&(<TRPXIGG27\63WBHN;*LXV5:Q
M8ZO8V"K^\BIZ[NDC_.S#Y%7^WN?D+NJI649RF.\DQ95!S3P.V6<W6E,[ZIKQ
M5_67 ]KLAMHJ0,24LGCF L\B?+TZL(%QS.DJ_CELX9_%-C..+6X+MP@K%I]M
MG&C;F(NM;' KO>[6O?PYQV,+QV/S^^1K5'.X"ICO-.8[NH/' ?OL,43]<>JO
MI/^> ;2HJ;*1NEL(T\D"G\4GV<-\[*4IV*>Y<*7* 7W@H"F+(L9QA'$H3HB*
M[6G%UZ8?92Z.CA(V<H2^_S -_6$ZFL,?SE^9D\5\Q_?Q.&"?O117Y;"_9M35
MV\2QWW[?_LLA<I30LM,R+.R)<'CQ('-RACDYQYR<9U%^D47Z9=O%NW5XTKG"
M _XJ!_IJ-V$NKC(75\_S?<Z+*R]!QBF;LHQC, FPW( SA\R"NOK\F-9!0*S8
M?SFUN/]R;R_DZB(<5MJGA3T*Q1T[CRD#CS,G3W!LGJ91N,,XGF51]AQ//,]S
M?C[/P7YAF#"I+QPFE\ACR. XQW*,@Q1W1NWD&L3^&K"O6NR?^/RBYL.+&K>P
M<$7*,_B?.W7N[8G<^_:25P3@-<[7_W!L%.9%\<VM[W..?LB3PD<\^#YN)>SP
M)]L(Y^?'YQ:OQE!>O"-#9_ZN$#D]-\^J))1^-!Z_TF/^B'Q\CW)ZTUI\35_W
M)7W=Y_2YG]'G?D+']C$=W8=T>1_07?Z7KO9=^LRW.%B*^S#^Q<!?X[NOXBY>
M@?SONU,4WQ3Z[+SO%A;]OS!_58;B"I7?Z.]^@BM^0  UHZB7@D^13:=8A/?I
M+]^EOWR;OO]-QO$?QO$ZX_@GXWB%<;Q$%_L/NM#GZ13OT'/?IFM^FDE\DI^X
MQ>@?I\M_C"H*'B4W_]<>R&_S5V4LP1<P9;\<J.>-]YB+-Q''?J0S]ERV7\ST
M5\Y?F7%[_ALR.ME^+]L?9OO+V>XTI\=Z3I-MN,:)?(6Y>(A_7V*/+[#5\_3<
MBNR?7>3<?3'\/']5A(@9TV+N#-@?*_;%E5K^U(FD1B+;S\!UY'%Z%'-*5K+E
M.ESFN%RB[[_ .!179IQE' _2<9_FF)SD07R<N3C*GQQFA(<X.@<XH@?NNR+C
MP&(,"GW%72G_F9]B:GB"OO\&<W$-]NR#)S6"J1'-]I/9=@8/$QD/S6(<X[@<
MY?PX@B:VWX&#C&,_X]B'28[$6BXA6SDS'N"2<II945RS\B)'Z0MZ^-_GK\90
MH/@_F!7ZGV#ABW&>GC_41+C(7#S(>7$2EM1Q9A]\J1'*]F/8?C+;SV0/\]A^
M$;9SGFYC'%L9QV;&L8EQS&$9-G!NS/+OM?SD&K:RFAF;GM^Q^A K.<-78N'_
M@E;PY:+^XSRD+BTN.4<Y+_;S&-G+8V07;*GC1@U_:H0S[EBVG,+V,SC[\JA1
MA!G&L9IQK.*X3'%^K,  ,[&<?]9@C!&.SE^W<HX9NH4ASN9!SKH!'G&#U%?P
MC@;P))>5"UK4YN->'MH[E13;XAK4T^/L,J.. W4\J1%(C0AJQ%$CA1J9/!KR
MJ%'$GE=0IXX:+6RW!_U\U<N>+V5FNCD>BGN).G@4M NOHUWT%=K$OQ'Y//]0
M;#'K+6QY[^+C1MV%?Q*8T11CE;(65@H&F! L,29RPC*Q-X;%P1A4BL2 4CSZ
ME%/0JYR)I<HR="L7HTNE$ATJ#6A7Z4"KZB!:5%>@26T.C>I[4:]^&G7JUU&K
M\4_4:GZ)&JW?B'R>)[BD/LCE?2]/-7-D%5]/\!0XRGB6Z:A@F88.!C6,T:=I
M@QY-5W1I^:)3*P3M6E%HTTI JW8:FK6ST*2=CT;M,M1KUZ)6IQ4U.GVHTIE
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M>/\.S4/V8N2N8 BOT75P[FU,9-?0)U>AY0JLVHK$R^BE2_41//YO6'C<BRW
M[ 'YI2^TS="ZUSL,P]'EI#?CD)^._ +D5R*_D5YN1_9H9(_1E<3'Y<3I5LU
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M[5>QXR5X_PNPJ>=A5S^';S^+'4]CQT]AMT\2N(_#5!\E:!Z!XQV&<Q_"BI_
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MXN0%*DI9K<+4"U20>I7R4V]57MHAY::]!#[E^7=<.^[=CKP6O8NSK/TOX\$
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MM&;T0U%B.M /;7/T!"JB-TPA?78%]KODU\^$WL\$W\] [R=P^ZNL@HHY[F7
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M.I3F[E>*>Y*2H^8K*6JU$J(N5'ST-L5%[U-L]".*C3H&OE!<U'=:A8XYZ)P
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MFB5SK W<Q23JQ3< DN\B,J:B]\%7FH;L,3G67J0&4 F*01[7LD Z2 ;Q7/-
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M9M.+LXBH6?H$'/?"W -REZ_MFWU3D)D65ONFIV6,D:7X8@E]LEAQ(!5D([L
M#:7(KJ+%]<AO07XG,D<C<Q +)N*-F43K8N\)'1/IC0E$Q'@\/4R/#Q'Q0\3F
M,/J'O?4Y:TO:V3[=3!/>\KA9&F8IB*4I IF1(!JY\2"5$9F-[ (BL13Y5<BO
M0WXS\CJ)C%YZ91R63"%BYQ$M*^BI=5S=@H4[B*#[P LL_U_Q>-P+4W(V9>%5
MOJ7(+!',ILAG:98?<D.1:/?6'\;*@^P$D(;\; U@1Y]*D%^)_#KDM2"[BPCI
MY__CL6BFVO%B&SW82B2UT!_-]'PS<T6S]Y>8S&E$Q[W]?ZJIO[#DS61*F\CC
M.## <MS'M-]+7/0H'-D.9(_4'Q*1G\;(R$9' 3I*T5&%O ;DMA&MIB(REEZ:
MBF4+&$GF+J(+B*"K^=1MX!'P*_!G[^^&GXN^%>;V8);^23;2&S#:I&?A5JK6
M%N2G5K\0Y$<@WZ$F8J.1&&UDK#0H'3W9Z"A 1QGRJI';A%<Z58&7RNFI,GJU
ME/XH8606$_5%V@/,"<2O@"_ ]]X_>RQ&[S26EG&@UV']J:Z%):^1Z_784Q<6
MH-J@4-7XVU7MYT1/%'KBT).,G@STY**G"#T5Z*GC69NW2E1 3^;3'WF,F%R_
M=<KQNQ2+=X'[P?/@8_"M3C%[<- YR?QICC2L"[2 >E[7D"Y7\EZYW4]E$4$J
M"PU7:;!=)4$N%05&JS @7@4!*<H/R%1>8+YR TN5$U2M[*!F906-4F;P.&4$
MSU!ZR%*EA9RIU) M2@G9 >Y5<O SX$,E!WVM%>B8A<YATJ_1I!QMH,'4/7A=
MSO42;"G"E@)'@ KL(<J/B%!>F$.Y82YEA\8H*S11F6%IR@C+47I8D=+"*Y4:
MWJB4B"XE1XQ5DFVZ$FU+E6 [4W&V+6"G8FWW*L;V-/A ,1%?:2DZIJ%OD%2C
MFY2XV=1>0#FOB[&E@/?RL"7'Z:<L9Z R':'*M-N488M4FBU*J;8XI=B3E6S/
M5)*]0(GV"B4X&A3GZ%*L8YQB(F?($[E,4<ZSY'9>)I=S-S@H9^3/P6_EBOR3
M%J)C,OK,=O4.TN$&4 5*>5V +;F\EX4M&2#-': 45["2G6%*<MJ5&.E4O-.C
M.&>B8IWIBG'FR>,J4[2K7E&N3KG=@W*YI\GI7BIGU)ER1%T*=LH>=9_L[J=E
M<W_ ([P;'1/0UQMGU8!J0;FO]I*'+5F\EPY2L2<IVE\)48&*=P<KUATAC]NA
M:+=;45%Q<D>ERA65(U=TL9S1-8KTM,OA&9 C9K+L,0MEBSU5$;$;%!Y[H\)B
M#B@TYDGP*X5YOM!L4PN+L_8!-8-J4N%2'@M -K9D\%XJ2,*>^!@_Q<8$R!,3
MJ*B8,+EB['+&NA09&R-';)(<<9FRQQ7(%E\)FA21P,R2,%YA"7,5DKA:P8D7
M*2CQ.@4FW*& A,<5$/^. N,_TPQS'QCZ.LT>(% )BD NR,2>--Y+QI8$$!OG
M)T^<O]SQ@7(FALB1:),]R2E;4I0BDN(5GI2JL.1<A2:7*B2E7L$IG0I,&:>
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MESVF@@P*6-BGP";=4FRS78SML BQO28^;D#/Q9_6UA.'U?64"R,[# F;>T[
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MKPRIZ!0C56UW$G",&)Z!#*_?,*A65/8)=_(;>%FVT5V,N-P7EM2& F)<S"O
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MF^Q"^?$.3!!MPX5'YOX:*R4Z,O-76-G1<BL_6F:31HJLZNA8 J9IXX'YJ?N
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MF-@9KU2X8^5:;ZS4[(V5.+V!,I?' V4O<[DMY>[;!MB0@0<9>*.&MP!SVW+
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M :B:-Q\@YG\ ,//?!Z0%[P'ZA[<+(!\:#U#/WP/0[SX,D"MG@IIM<P$B;2E
M'-D(:O+V_EI5>N2'"OCQ;TIQI9>+J;"+!:S:S_)YZ$_S1+CS.3+BN6-J\G"6
MGG(VTUQWYJB#=N:(CW8Z(TH_G=%$/Y712>\^VDUKS[QU?QMN&E"0 0T9,) !
M!1G@D &U;QE 9VP$R-Q]O\"+,[^'59_XJ@)3?JF47/-Y,0-]H: >?RY?2!K.
MDU'.Y*CJ3A_3TT]EF9E#F4[6T%$_:^A(G#UTI)7=D]G!;LWJ8#5F=[!O%4!/
M&P^PD $+&="0 ;7U78#;NPS@TC?]B3V6=@U9D/4=O*KP"@Q=>;&"5/MI*1U[
MKHA#.EL@H)[.E])/Y:F8@SDZ]F"VI7X@R\4]F1F$2O%Z,EMYK=FMW-2Q5EXL
MY]8!#&3 /7</P$$&S,I9 +OE74#<LPR0#FWZDY"=]C/V1/955$7193@2]CF,
M@+I044<X6\*FGB[BTX=.2%@#QY7U_;EZ7M\Q"[\OVRWHS0H+>[.:A*W'FH6I
MG"9A)+=)&,R[=0 +&?"0@0 9<)"!L/E=0-F]#% /;OJ3DIGV,_%X]K?8LN(O
M48CJS^ XS+DJ*NE,.9,V5,)C#12*N7WY2GYOGD[4DVL5=Q_S2+J/Q:1M.0W2
M5%Z#- +E/]X@]>3?.H"#?K8G0 8B9,!#!O*F=P%]YS) 3]OT9UU&VL^4G&/?
M$HM++F&KX9^B,+BS-63JJ4H&<Z",R^TK%@EZ"A3BKGR=K#//)N_,]2G:<Q+*
MU/&$(IR?4/I.))1.*%M!0G&K !XR$"$#:>[#@  9ZC;,!<SMRP!SSZ8_&0?3
M?J9E'ON&DE]RB5@)OX!%XL\@";3!:AJGKX(CZ"D52CJ+%/*.$SI5^W&[NBTO
MJ&G(CVE")Z):3T%4ZRB,:LU%,8VQ**:^58  &4B0@0P9B"M?!(SU<P%[RU+
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MBF</U+ </@3=Y4'6N=THJL>)(GOM:++/=JL ;>IXP(0,['>F \D'SP#->Z\
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M<:+ IR WW"._.IJ3=RS6-;\GAI/S(IJ7\3*2G]H?[I7\.M0G\4VP3\);P4R
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M"AC*(/U;%61^JH'LN/K_ H;;_N.@I2@">IB'@;HX&.A+@*'U0C!P7@:Z;FM
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MGG<A*8M?2TOS/$)/\>AB)'F^IB?PQUWB^3^H<?R?Y%C^I',,?\HQAC]-_&_
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M)J\-6)VT(W!ETLF@Y4EW@I<FOP]:G()!@ZD8,)"&_G/3T*\_#7W_]?W_$5U
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M^Q@YI8D^?QHQM* !@POK,.A[F$)GH9"!!_4 /W< G)W-@F,+.'!@F .[EHO
MEA7JS-KE%KPC2UW%%RX.4)RS,%*[:WZ2<?O<3.OF_@+'^MX*]ZKN1I_2SO;
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MEK?:!,UOS1,RO;U:V.3V/A'C.[=$C'__2]3P!DH87$<I_6LHH_>=\8DS0-?
M0KH&NBB_:2+_$$#V*8#X"P A/P)X_<8!UT?"X/Q(%AP?:X+]8Q.P>6+'6#WQ
M8,S_#&29/HUF&S]-91L\*^#H/:OEZCR?R:/]?(A7\\48K\;+4[P:+Y[RJO^)
MO.I/D$_M"0JH/D;!R=;0-;!H-4#/)H#FB?S# %EG .*HAP?]#.!.7=SN'H#U
M.R&P?"\%9N]5P.0O73#\8 9Z'^P8G8]NC.8G?T;]4P2C\CF9I?1E"DOA2QU;
M[FL76Q:7L*5QG".%/W*DOK[A2'Y&MN1'\N%;PW0-SAX#F$;YY4<H_RQ #,W=
M_QJ RTT *\HW>3-Q'T  ]% ,M%$6-*CSJZ(.**$Q4-$"670"*?1B)#"$$<-X
M1@1S&2&L802QDR6 2UG\N)W%AU=8O/B&X'_T;P283OD5$_GG*/\*@!_-W?$.
M@-E# -UG )H(H(8<RA2B3'&001F01$401W4005T01A,00!O@11?@H!_0EW22
MP0!6D!EDF&PE9\AC\OH;;73]5=+Z9T_D7P7PI;G;WP<P?DS9E*_T!4".QB!-
MQ&D<HBA(F2+ 3V/A06E@HP+EJ1$=8D)LB3L))DF$W@1Q.J&+']>0/>3H-U#+
ME$%MHD=TS1G4LF&AF@L+%?S9*!O#1NDL-DJ6<U"BF722>628BQ(KR08>E!@G
M>\A1'I2\P(N2-\D3\H[@!)Z_2=%S*>2CYWPHC?S?T#9A4-^804,C,O'<DH5:
MCBQ4]6&C<B0;%=,Y*%_,0=D&,H.+LOUDB =E1\A:7I3=3';RH>PA/I0[0WXC
M?Y WY L?RN._^(D RJ$@*GQ'A_*-J/^;Z#%H:L"@L2D+]6U9J.O)1JTP-FHD
M<U MGXLJ-:25!U5Z>%%E/EG"ARJK^%%E QDG^P10Y03YD=PG+P50];/ 5U44
M^***@I]54>BS"@K3H\A[]6^A >6:ZC!H0?W;4IL>)^[+3-R7<F6C<1 ;#>(Y
MJ)?#19UR'M1NXD7M67RH/8?6;T@ M4<$47N-(&IM%D*M74*H?9A<$*:F+_Q9
M^[GP!YV/0N]T4/BM#HJ^T48Q(OY*!R6>ZGX+32C?BOJ^+?5O>W4&[6@<]K06
M=K0?UKYLM(SBHGDZ#YH6\:))'3\:MPF@<8\0&LT71J-ALDKDB]$&T<]&VT0_
M&>T7_6!T6NR=T0VQU\9_BCXW_DOTJ3%*/#%"J<=&*/W("&7N&Z/,+9-OH05U
M;#OJWD[4MUV(&XW'W9 >Z6RZ>+#I$Y^+]DD\:)?']\6F0O"3=9/07]8S1=Y;
M]8N^M5HH]MIJF?@KRS42+RPW2SRWW"WYS/*XY!.K7R0?6CV6N&OU7NJV%<K^
M;HGRURU1X3?RDQ4J7+#^%MJH4KX\Y<H >A%?%0;]=1GTLV"ACS,;O?RY'SUB
M>-^Y9?"_<BT6>NY<)_K4J57LL5.WQ!^.\R0?.BZ6NN^X4OJNPT;I.PX[9&XY
M'I&YZ?B#S#7'/V1_<GBG<,D!E<X[H,I9<L8!58\YHNHA)U29#.TGYBX-Z$V=
M+X Z=X@\8!BM19@1\R7$EO4NT)/SPC^,]XE?LL!#GRG"=[TKQ6YY-4G>\)PA
M_9M'G^Q5]T&Y*V[+Y']T6ZMXV6VKTD6W_<KGW<XIGW&_IW+"[8W:$3?4..B&
MFOO)7K+#'37'/5!C,G26I?E/Y%/?"J/N'T7CB5&&+S$ZS.MH<^9)I#/[?D0@
MS\VP.(%K(9DB/P452UX*J)4Y[]\B?]:O4_&4[QSE$[Y#JL=\5J@?\=F@<<A[
MI^8![^-:^[RO:^WR>:&]W0=UMY+-9(RL\T6=4;]OH1MU?S_*#Q$$C*;'>!I/
MD@R\25:%QTD&S)U$6]:U!!_N#[&1@N>B4\1.1>9)'PLOES\<UJ!T(+1-=5]P
MM\;NX &MG4'#.ML#1W7' [?H;PDX:+ IX++!AL GAFL#/QNM#J23&X2&*X+0
M8&DP&@P'H_YDZ$F9@=3W(OD $V@<*<+P(4T,GJ3+P.T,=?@YPYRYD.[./9D:
M(G@D*5Y\?T*6[.ZX(L4=,=6JX]%-&ILC9VB/1<S66Q\^:+ V;+G1:-@&XU6A
MNTU7A)XU71;VP'1)V >SQ6%H.A2.)H/A:#P_ HWF1:#A9.A#ZQ_"3^O/A:\I
M// \@Q<>9@O O1P1^#E7'L[G&3/'<YVY![,#!'=G1DML2TN5W9PR16E#4IGZ
MVH1ZK=7QT_56QG49CL3,,UX:/6RZ.'J-^5#4-LO!J..6\Z-N6\V-?F<Y)QHM
M^F/0?'8,FO7$H$EW+!I/AOZT_N%<6@,&GE'7N)G+AJOY/'"E0 #.%TG#\6)]
MYD"1/6=G@:_@EKP(\0TY27)KLK*55V84:8RD5>DL26G27Y3<83R8--MT(&&A
MQ=SXE59]\9MM>N,/V73'_V;;&?_:9E8"6LU,1,L9B6C>D8AF[8EH.MG?^T ?
MM9^H;]VAWGFU@(&+Q5PX5\H')\HEX$"%#K.SPH:SI=1+8'UQJ/CJ@GBYD2GI
MRL.Y^1H+L\MUYV?6&\S-:#7I2^LV[TD=L.I,668S(V6C77OR/OO6Y)_LIZ>\
ML&M)19MIJ6A%+)M3T;PI%<TFP^")?0!XEDY=AWKG9>K?9RK8<+R*!PY5B\&N
M6DW84FO)7E_MSK^J(DAL:6F,[*+B5.7YA;D:<_-+=&?GU1AVYS:;SLJ>:=&>
M-<=Z>N:P[;2,=?93,W8[-&1<=*S/>&9?GXEVQ*8N$ZV(15T&FD^&H=2[XZG[
M9U'W+Z3N7P%PK(8%!^NH^]=3]V]4@PV-YNQ5]2[\2VL#Q(:J(F4'*I*4^\NR
M-'I*"G5G%54:MA<VFD[/;[=HGC+;NC%OD5U=[JA#=<X.Q\J<<TX5N4\<*W+1
MKB(/;8@U/;>LR$&+R3"<\_=7C3O4^7XHI>Y/O>]0/<">J2S8UBP$&UN48;3%
MA+6LV8EO:*JOZ$!]N$Q?;8)25W6&^HS**3JMY66&S67UIHTEK1:UQ3W6546#
M=N6%JQQ+"[8Y%1><=BHJ>.185/C5OJ@0;8L+T;JX *V*\]%B,HP$>),*\'L^
M=7]:@Z.4OY?Z[_86ZMZM_+"F70&6MQNR%K4Y\ Y,]Q;I:PZ5[IP:I]C1D*K6
M4I>K/;6FQ*"^NL:DNG*:145%EW5)^7R[PK(5#E-*MSKEE9YPRBU]Z)A;]MD^
MKPQM\TK1>DH)6DTI1LO))L["$[H>KA93[Z4U.#B5>B=]]=I,W6?-#!Y8/DL6
M%G?J,_-GV?+TS? 4ZFH/EFR?'BT_;5JR:F-SME;MU"+]RH8JX]+Z)O.BNIE6
M4VKFV>94CSAD5F]V3*\^YI1>?9\>/]EG5*-M9A5:9U:@558Y6DZ&<706<F@?
MJ/\?GU@#FO_6&0#KJ?\M[V;!XEXI6#!;A^GOM>)V=;L)MG<&B$^;&2G7T)&H
M7-V>J5'>FJ];/+W<,']:@VEN<X=E9E._3=K4)?;)C6,.B8V''1,;[]+C1[ND
M!K1-;D#KE#JT2JU!R\F^TEFX/;$/570.: ]V=- >=%'OZ:7>T0\P,%<<^N9I
M,%USS=GM<YSYF_O]1.MGA\M4]<0KEG6GJ15VYFGGS2K5SYI19YS>T6J>W#[;
M*J%ML4ULZP:[Z-:#]M&MM^VBIW^PC9F.UC$M:!77C);Q4]%BLN=I +_1/IR<
M6 /JWULI?TT?P%+JH//HJW#/0A&8-:0";4,FK*:%#KQU"[R%*^>'2)8,Q,CE
MSTU1SIF3K9[17Z23,KO:(+&WQ3BVI\<LJGO(,KQ[G75H]W[RNW5HUWNKT$ZT
M#)N%%N$=:![1]JW']+[T YW%(\VT!C.I^U+^\GD @]0!NZD'MRT5@&G+Y*%Q
M1)^I66;#+5_J+E"T)% T;SA2*FMQHGS:HDSEI*$"];B%E=K1@TWZX0LZC4+F
M#YH$SE]C%C!_G[G__.MF_O/>F?G/13/_.6@6T(>F@3W?NE- [TEU /OH#&ZA
M_KN:\A<M!.@?!NB@'EZ_F@W5HY)0L48+BM=8L//7./-DC_H*IJ\.$TU>%2<5
MOS)-+GI%GE+$BC+5D.6-FH$C,W7\1N;K>2];;> ULL?0<^2:@>?2MX8>PVCH
ML1B-/!:AD=<"-)SLEW*Z'J?1&G0#K*/\I90_;PG K!74?ZF2E%(/S-\L GE;
ME"%[BQ&3OL6.G;S9DR=^<Y! ]*8HD8A-R>(A8]G2@6,E<GX;ZQ2]-W:H>&P8
M4'/=L$K#9>-N3>>-5S6<U[_5=%J+VHZCJ..XFJS\UKF)<T![,#:']H#R%U!^
M]TKJG^L JJ@'3]D&D+*;!Q+W2$'\7BV(V6O.1.YU9H?M]>4&[PWC#=@3+^"[
M)T/8:T^AF/N>&DF7W6W23KOGRMKO7B%GMWNGO.V>G^5M=[U1L-Z!2E;;4,5R
M'%4MMZ+:9(?I'&ZC\[^:]G\1Y<^F#CQ]/4#U%H""'0"I^P"B#K,AZ+@P!!Z7
M!_\3>N!WPAJ\3[HQGB<#V&XG(SDN)Y-Y'$_F\MF?K!"P/3E-R.IDG[#%R1$1
M\U/;1<U._2AJ=N*-F,DQE#0^@M)&AU'&\!#*3K:KA_9@ < 2RN^G_+8- +5;
M*7\W0-I!RJ=*&'"*!6[G><'A!Q&P_T$1['[4 ]L?K<'F)S>PNA+(6%Z)9LQ_
M3F.9_ES(-OZEGF-XM8MK<'68J_?K%A[=:^=Y=']YSJ/S$_)K_X""6I=12/,2
M"D\V1M??,CI_\VC].RB_CM:^<"_E4P^/.D$=_"R RR4 ZRL<,+XA $:W)<'P
MCBKHWS4 O7O6H'O/%73N!X#6@VC0?)#.J#\L9M0>-K%4_NAC*3]:R5)\M(^E
M\/@.2^'!9Y;\?63+WT..W%WD3K:"\N=3_DS*K]].^?MI_8\!1)ZA#GX!P.E'
M (MK  ;4Q[6?\8/F"W%0?RD/JB\U0/F5(2B^M@+Y-RX@^\8/I-]&@.2[5)!X
M5\R(OY_&B/TUCQ']L(X1^7""/&6$WR$C_(:\_M9".O]=E-](^44'*)_F'G$>
MP/L' /NK *:_ ^C< 5!]#*#TB0?DJ??+HB1(4>>70'400ST003,01GL01$_@
MQQ#@H0]B#A8""Z<!\W?GWTAH4OB"X'_TT/F;2OG%M/=IIRB?UMWS%P#;&T!K
M#J#Q $">\J4_ &4"9?)1I@@(H3CER5">$E QII]E0"R),_$GL82^%"%] .
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MF=$$9];R>'_NDKA(_D6QB4(+8K+$!J(+).9$54C/CFR0[8EH4^@*[U&:&;Y
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M_UU@O0_3?V\F*V@).DDC*<VE[^3/L@J52"LR0DKQ:"253$9BZ2S$EWHBMC1
MB"X-%R)+X\7PTG19:&F!/+BD2A%8TJKE7]*K[5N\2<>[^*#N_.(KNO.*W]*9
M5_23SKQ"27M^@:3U@/QAGD@:/A.UOX3CH9AC@7:@C=20 GY/Y[8\N5Q ?*4:
ML566B*ZR1V2U$R*JW1%6XX/0FA AN"9&"*Q)$?VK<V6^U>5R[^IFQ;SJ;J5G
MU7JMN57[M-VK+I'7M=PK?]1RKY"TW,LEY9PR4CK,%<;@>"&PBUOO->7T_F5
M$RGGYYQ*^KYJ^IXZ(+Q!%R&-)@AJ&HO ILD(:)X%OV9/^#;[PZ<Y0IC?G"!X
M-6>*'LW%XISF>MGLYL5RU^:UBEE->Q0SFRXJ9C3_CV)&XP^*&?628D8=J944
M,T<XSY@?HOX66L.^:LTY(*"6%/%[.K5CFH#05GJ?=AGF+U3CG_\BNLK8J\,2
MGAWCX='IB+F=;IBS:#[<%P7#C4/;=5&J,&M1OC!C4;7@O*A#=%S4+YNV:*=L
MRJ)SLLF+7I!-[OA>-KE=DDU>0-K^YB2CO[>>(Z21O;.!3I14D!R6)HFE":=Q
M\UL$>"RE(^W5P<QE1IBQS!K3ESG >;DSG):[P['/!]/Z0C&E+QZ3^[(PJ:\,
M$_I:!?N^/F%\WS;!KN^T8+OB6<%V^;?"N%Y)'-=-EDJB[0B':SE;+@#ZV]@[
MJ5E'"OD]K8.MLA@([ 8\E].1T;%/6T-7ME8/]NM,,'Z=#>S63X#M>F>,6^^.
ML1M\,69#.$9O2(;-AGQ8;:S'J(W=L-PX"(N-QV"V\6F8K_\*YFLEP7R K"&K
MA]E+[<$EG"58U[9.]@SJ9M$LQO<"(7W _-6L/]VZ(TVL QW[Z&T"S'?HP72G
M,;&&R4X'&.]T@M$N=^('PUU1,-B5#O7N,NCO;B<#T-N]'[J[KD&UZR/H[?@3
M^MLEZ&\C6X?91KV!9< 2:M:1 NHFKV(;#  ^U)U-I^ZT#;"G6[?9"Y@=  P.
MRZ%[3 ]:1XVA/&H-Q5%[R(\Y03PV!\*Q $X_G *.<?@=8Q<[1M=YC.[WV!GR
M,K<K=+Y'Z<"/D,/#;*#F"M:U;?7PR9R,#6P#UM=_.S"'+MUY/^M/I\Y-*TQ/
M FK>2N<\(%S0X51#QWO1E'!K_)@#<=;\9RE.@UR"+VN.B&H>!V.@+[,1+Q\D
MM-F7/^?O_$FDOUA-W26;& /6-X^Z"=0-8ET]C@+3J>E 36MJ&C\&Z-&M*Z[2
M=3]!;HK D[J$Y;C%<MRVYO94LSUV NZR'/>X/-_C]'^/P_Y9-O:S%+A'R__L
MO\F/_"S]1??@R!MR]@&I1]@&IX!Y-.O3+S+^EX%1U#2Z >@^"8A/:S(RY'GR
M+TV&1 !>U 9>U@?^QPCX-ZW+&]RVOST->)?E>$_SR"J7@ _8\3]@P#]D8WYX
MC7Q$?B;2 UHU)W,8IO3C0 2UYU-W^LBI&(O;;/L[@-:S(YJOD#?(VYK3*2,G
M1309DH]DP"=LFT\9DR_,@*]H7;Z="MQG.7[@5N%']HV?6H"?UQ(&^)=;A'_Q
ME^\?4'$(R&3=HQAK[^O #-;7CO4UIZ[^"X#\GQD936;D\Y&G91[-CCPX)<*R
M_*H"_C :.1VB^4^ZW+II7B<G<7J6.O[QA,PK#Y#D-B,9  V:SW9D*G$G#Y\*
MT60D2OY+1D+S9,BC)S,>OBWD(H9/A[Q&__T%W?1O_)_T%[]B^+S(7T^%:%E"
M$LQ&LA'FQ/J!"Y?@0GQ))$G%\!,RFNQ, VG'\"F5Y;S_:OR.#;SO5OQ"%_XS
M#N,GG,$/N$J=9Q\\G?(M@_3HDRE?C?#7J0P5M95&_&0X@OE(+#09(D\,9XCB
M69\LUJ&8.M74:*9&!^^_%-^AC_<?X+TWL7FVL];[>-]C;+*+=/&W\2'>POO\
MC?=XAW=XIW=&<D:/(NE35T>?L=#C-PW&(VTRB?5SHZ8?:Q%)K13JY%*CC!JU
MU&AA#3O91;IY_Q6\UUIVU2%VG9UX'8?P*F/Q,J[A!;S(8?09(_(K[O&N#[G[
M")(A=?6T(,E$?M,FZ@>Q^)&Q^ ;.U/3$IPAF?>*HD\Y:%5"C'/^#.KS$OO$"
MR_$\>JBQBO=;CSMLDZ>P%[?8+V[B$F[@&9;D0SS.R%V!YCFF_QO)2#'\XAO-
M"W"T!?917;:I(76M&,-)U'1ES_)A;<+Q'!)YQRP\C4)J5%*CGAIMN,X^>I5]
M] K[QF6VR6.,Q07VBW,XSVC<QBFVP$GA.QP7)1R323@J_T\DTY$'S@SHR#G5
M?,:R?"K384R-6<^QN"<XXBEQ+F[* G!-%HTK\A1<4N3@HJ(8YY55.*MLQ!FM
M=IS2ZL))[14XKKT>1W6VX;#. 1S2/8L#G-SVJ=[&'OW[V*66L(-L_P</,C(F
M'.J<XCX8!;QNSNG/4,1S.BH\I6V.Z[KVN*PW$^?UY^&,.@0GU7$X;IB&HX9Y
M.&Q8BH-&-3A@U(Q]1IW8:]2+W<9KL--X,W:8[,,VD]/88O($-IN^A8WF]['>
M7,(Z"PEKR8 &\V$T_QC5_=&<,L=SRN6R<X=3_@U^?]Q<CDN&ACAC,AK'S:;B
ML+D[]EOZ8>^H".P:E8@=5AG89EV K=;EV&Q3AR&;-FRR68*-HU=B_>B-6#MF
M%P;&',?J,5?1/_95K!CWK;!LG"3TDIX1ND=XD!6:P*G>D?K3J<TEY^PD.D$[
M+K76>C@PV@*[QT[ =MM9V&(W#X/C@['1/@;K[5.PUB$; PY%6#VA$JLF-&+E
MA [T3>@5ED]<*_1.W"9T3SPL=$V\)"R9]"^A<])7PL+)DM!.%DSZ3WY@O=^G
M[G.NP'5WX(P;E_09W-]QV=DU08EM$TPP.,D6ZZ<X86#J'/1/\\=*QW#T.<9C
MF5,Z>ISRT.U4*G0YU0J+G5J%1<Y=0H=SO]CN/"2V.>\76YW/B\W.=\7&Z9^)
M#=/_%.NF2\,X_\TW4[@,4?\VI_7'Z(B/>%*;9=DR"]C$[<!Z)T.LGFZ#%3,G
M8]DL5W2[S$>7:P@6N\:@TS49"UVSA';70J'-K5)H<6T4FUT[Q4;7/EF]ZT99
MK=L>6;7;&7F5VU/R"K>/Y>5NO\O*W"0-8JD&UV$^8_Q?Y/)VPX?.@XYXKR8;
M,H_:_-EJQF2%JSYZ9UNBR]T!B^;.0(>')Q9X!*#5,P+-G@E"DV>ZT."9)]1Y
MEHHUGG5BM><"6:5'CZS<8YV\U&.GO-CCI*+(\TE%@>>'BGS/7^7YGI(LS^,O
M1 T?,@;W6/\K=,/'N/W9SJW8>I9EE3?WF(Q)EZ<N.KU,T3[/#JWSG=#L[8X&
M'U_4^82BUB=&J/9)$2I]LL5RGR*QU*=:5NS3(BORZ9(7^*Q1Y/EL5^3X'%-F
M^]Q09OJ\1WY19/A(\@QO2?8H;\_A]H>:%[G=.!C&&'#[LYIEZ?7G_HHQ6>BC
M1*NO$1K]QJ ^8 IJ EQ1%3@?%8%!* N,$DH#$X7BP RQ,+! S ^LD.4&-LJS
M Q?+,P-7*=(#MBC3 HXH4P*O:B4'OJU,#OQ)D10@R1_@+\F21_BW%[=EU#Q+
M-[R'<'N./I9E"<O2SI@T!XJH#S)$=; U*D,FHBQT)DK#/%$<YH_"L' A/RQ.
MR U+%;/#<L6LL%)91EB]/"VT0Y$2ND*1%#JD3 @]I!4?>D4K+O0-K=C0'Y6Q
MH9(B-D22$UELL"2+(R^QKM>H>2H&V!'-/3:W&STLRT*6I3F8+HSQJ0S31UF$
M)8HC[5$8Z8S\J#G(C?)%3G2(D!4=(V1$)XMI4=EB2E2Q+"FJ5IX0U:Z(BUJN
MB(W<I(R./* 5&7E)*R+R-?*#,B)24D1$2'(-D>&23,.SF@P=-8_%#Y_,6<5M
M^1*6IY7EJ>4VK)QE*HY6H2#&#'FQMLB)FX:L.#=DQ,]'6GP04N,CA>3X1"$Q
M/D.,CR^4Q<95R:+CVN21<;V*\+B-RK"X_5HA<8]I!<>]K!4<^[TR.%92!,=(
M\A -T9),PQW6]2)U#]&1;^)V?'D"T*')R+ \Y2Q+$:^Y\=K(2C1&1M(8I"5-
M1DKR+"0G>R(QQ1\)*>%"7$J<$).2)D8EYXL1R16RL.1F>4ARMR(H:;TR(&FO
MTC_I@M(O^06E7])W2K]$2>&7(,G]-<1+,@VW&/.SU-Z;"JSC5KP[F5Z#U+!,
MA?QY#C]GI,B1DFJ(I#1K)*1/0%S&=,1FS$%,I@^B,D,0D1DCA&<F"Z&9.6)P
M1IDL,*-1YI^Q1.Z;,:#PSMBMG)]Q3CDOXWFE5_JWBGEIDGQ>Z@-D\U(DV7QR
MG3$_2?V=W(*O3@<6:[)"I(+DD#3^/#$3B,W61W2.!2)S[1"1.PWA>:X(S9N'
MD+Q !.5%(C O4?#/RQ1\\XI%[[PZV;R\13+/O-7RN;D[Y7-RSRC<\^XIW'._
MEKOG2'+W;$GFGB7)YF0.<YFQ/ZHYH93-\<!K.ZDEQ22#/TO(Y9X['P@KU$5(
MD3&"BD<CH'@B_$MFP*]D#GQ+?>%=&HKYI;'P*DT3/$L+A+FEU:)[Z4+1K62E
MS*5DNVQ6R2G9C))G9#.*OY3-*))D,PHEV<P"DC_,>=;U(#5HE=&=Q[% *D@^
MOZ<4T/<5T_N6T?]7R.%=J<:\*DMX5=G!LWHJYE:[8$Z-%]QK C"[)A)N;$"7
MFAQA9DV%,*.F57"N62XZUFP1I]8<%Z?4/"5.J?Y<G%(EB5,J2+DD3AWAI.:4
M5 G;@5J=M(?UI(1D\7L"M<,JJ5]#_U]/_]NH"Y<F8\QJML',9@?,:''"]);9
M<&Z9#Z>68$QKC<74UG1,:2W&I-9&3&CM$1Q:!X7QK4<$N]8G!;N63P6[)DFP
M:R0-DFA7+XGCB>9M15NIL[R"?9'6L(H4D%3^+)K: 0V 5S/@MH#^NT/$Y$7Z
MF+C8%!,6CX'#XHFP7^R,\4O<8;?$%[9+PC"N*Q%CNW(QIJL&-EV+8=VU'E9=
M!V'9=1V62SZ"Y:(_,*I3$D9UD(7#[*OF^D"+WD5+V$C-,I+)[_&-; /:L_GM
MK/\B^N\N8&(O,*Y/ >N5:EBM-,.HE6-@N6HB+%9-A_FJ.3!;Y0?3_BB8]*?!
MN+\41OUM,.SOAT'_'JC[+T&__QVH5_X*@SZZB.5DV3 [6SDO46MA$_LBR6>=
MDVG7(Q8"OHOI_[NIOYSZJZA/"V^YGAY\DP+J(37TATRA-S0:JJ$)9#ITASR@
M,Q0([:$X*#?G0#%4"_E0-\0A>NZADQ &GX,X^ W$31+D&R4H-@PSR#KVT :V
M4K.,9/![]%*VP3+Z_Y7TGP/ I W 6-I$RZWTX/3H>KM%*/?J0MC+S?!>;D#W
MC27<?.V;">SG K2?$_Q^3BS[V=#[V8C[-?\<S@%"C[GW4_([H>?>,XSF3<F+
M6=?:[N&3.0DKV ;\*UX;-*=RJ+^-^KOHP?<!AO3GJB/TP;2L.*DD>EQHZ&]/
M<6-\FN4XS7*<83G.<C-PEA/]V8SA5X2?Y<W/L@)G:>S/TKB?^8E(?]'7SQ@P
MSJ7436.<(ZCKO1UPW0-,8=''4=/\!&#P,/]RD?I7R.,:6(ZK+,<UQN.Z^?!F
M^(F)P),LQRUN0&YQLK^M>6TZ&_@V!6ZS$K=ODR_(GT1ZP)*-G)>IFZ-Y.\YN
MM@%_S?T8,.TT]:EI_AB@IJ;RVDC^A;> )A=R9R0?<H]^_UD=X'D:I1=H$EZB
MYW^5&_3768XW?0D7G[<X^-]B([^U!7C[+-$\J?/]7T_H-&F>CF*<4XX"H=3U
MN  X7F+\KP*F-]CVFA,QC^9?7GYX,F4D'_+6PWR(@@9%!7QL./S6DB^Y6?Z&
MY?B6"_-W[!O?5]%$L'/?9X#O\^;WWR8LQ_W[*&6\T]B^X:RS%^OK>)WZ(T\E
MJ1X]$?/&B-9_G$KY;[D0+> 7QN1W\Y$WA6C^!9N@D;>E:IZ0T?R+,0RVQ,:4
M7B6OTW%:COA]LY'/FE,B$_'W4R%1_\_\PZ,G,S1OR!A^2N8,G?Y5_$&'^AL+
M_"L=[*-OX_AA)/_P*89/20SG/HQ&T/A^"PP_(3,#PT^%A&+XA(KF#1V:TR&:
M)W6:>?^%^!U+>?\^WG<-53;A)VSC_??A/H[A.UQD:&XS1.]0[[L'[RMYB.8I
ME0]'<A%O:<KPX"2&QN_KCV R$HN'^:  UBF:]4FE3AXURACR6MZ_A??OX/V[
M>=\5^ P#K-<@Z[4#'^$@/L!IO$O7_PX=^UM4?8-WT$3]WR.\AN$3&B\\R 5I
M='6(<N1J\*!-?H,#-6=2<SYK$<IFCZ=.!C4*>/]RO(>Z1TYF=/.^*]EMUO&^
MFWG?/6R%H[C'6#S#0?0T_\93^!&W,)RETEQO/X*D2VWAX0MHY$3%6!JSCF.I
M.8TQ<Z>>']Y$),N>1(TL_ M%>)9]XR[J.41;>?].WK>']U_%X;L!U]DF5W&
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MX\A_W.,8BD[ABVOQQ54*POX8;$^%(Y?R2RF_AO*;*+^#LGN(Q"'*FT]YB_#
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MBBF_&L\V4W8G9?=1]@AECU/N8L)U)9Y?3Q?93E?9"\=%=)^K=0O_OXEOWDC
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MY?E_J7Q_JPT%?HR5\%T03OQ%FG,WZ PP!'I8)G?R>1NVM&)+B_\,-?E[J"'
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MU6DA_!2I)6C^I2S"EK'868X=*VF3*2;9U4PN:VB3-:;#E=LWVZP> ^L8C"\
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MP_@Q42@P%*1#$5B').$>](W "[@?D<4JQ/[XV(V?T(._/5%GLPFB75D"R%6
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M%>4-0=FC:!CN'@JV0Z"QP6BU@;#* ;#@_K!T5UB^*_TH/)>HOQCID+<!TUR
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M-Z*^:>BVI7C5#MDOA?D/GOO@^S_XF;<K &Y&/)77+#9QWKTRQ-T@E62A-Q5
M ^7JHWN84Q)XQ(-''.QCDW UOQOT.0I#Q7B4/Q76, ?#QQ+4T0]U7(.62: @
M, Y :_C3?>&^$Y[WX#F(A>(\1*O8W+GL'?3G&@R^+&TM=!%!"L+3.2,08X8C
M*@H%CV"T2R!BJE6(_O@)G;[B$SI7(!+WQ@3BA4%U*?[OB;L6H4T60D,+T$+S
M82WS8&'\6=!\#PC/0_!S*&KH?_> A(J'II7BX7$92:,\)4  : .&*-L<95NC
M7#N4ZPB)+JC]8)0] A8Z'M8Q#?_F0\8*6&TX+":!/"!E(JQH JQ^/(GV?W2>
M05$@EA\EELVG CXM\"F)#]<SH(OIL,]I:)-IL(WII(.R#<'?'&5;H6Q;E.N
M<EV@A<$H>R3*G8 I?29>>0JS1,,I!E/];K3:?DS[7POW?PP1]W3^-TU<?SX5
M+!7+YM,%GZ[XSQ7\9XO1T,5HQ-SN:!-W\!@-'J/("#+,4;X5RK=%^0XHSP7E
M#H&UCH:E3*;^T+PK6LD%K=H/%M47MME7>-K-:^&Y1,[B42=>K']>?Y[_F"26
MRW^NX:X*=QT&D20@1P,Q9@PD-4 #,G0APPCEFZ-\*Y1E)\P^..&J UC90S-]
MH(O>PC-50_!I/) 'MBW 4^$*.%OQZ,=UP'- "^""3)$4N40\]S$0K[GKQ%TW
MS'@H7090 %0@0P!H0HX>Y!A#A@7*LD&9O:DGV/"5(3;0F#4T:H66[8Y6[@9+
MMQ0^@^@ [KXG''WY&4G=B F7@B[#M#(30_IXN&/#Y>&RR8M<57M<ZP67Q Z<
M;$D*Y<NA?"5 %5"''&W(T8<<$\CIAG\]4:X#RN\/[8S B.)!IK!8$[2',2S.
M"/W#$"..(495_JPLOC/2" B$C$7RHC4P[CS_ O0%[ %;7+.!Z]X=GW>3DR1+
M:5FRE%0@"PEER%&#' W(T8$<0\@Q@QPKE-D;[_JA%P\%NW'0U"RTFC?NB@#C
M9* $O?PX\),P*\_/KO)%^?,@;Z*R:+DV=]$= #L5GO= K('KYH"ID@29*,J0
ML;P\&<LJD9&,"AE)"\A06HOTI?4 $]*3MB1=:5O2D78B;>E!I"4]FC2EII.&
MU%)2EUI- LE$$D@4",^(5L,,H4:?A:LDET/^+!5^[@G<;(0I?8'>@ W0#=?,
M &/ 4$6"]%6D24]9CO24%$A701E0)1T%#=)6T"$M!4/25(!F%&P >U*',RQ0
M&$5J"E-)5<&35!1"2%D^GI3D]Y*B7!,IRMXF19DWI"C-:"GD3X,,=QZ>\+4O
MZJ*PC>=>S %CP !\]-0D2$=5FK15Y4A+18$T591(4UF%-)0%I*ZL10)E?<"4
MU)2M256E#ZFH]"=EE5&DI#*%%%06D[Q*$,FJQ)&,RAZ25JXG*>6K)*G\"TDJ
M,>'/D9,A9P3DNFH@S@!L $L-GG=!_0$]0%N N%\@0QH".5)74R"!FB()5)5)
M55655-4T2$5-EY0%QD W4A38D8*@'\D+AI&LP(-D! M(2A! $@(X@P+$O&KP
MX53A[*C"8U'%G 'Y$R'/#6Y./W$.R HPQWLC0!^?Z0!:ZE*DH2Y+ZNKR)! H
MDJI B534E4A97864--1)44.;%#0,2%[#G&0U>Y",IA-):0XA24V^81].JB9&
M $W,1!KPG33 0?UKX#7 :#;*'PN9@_DZ((3-MD WGO\!#'!=%]#2E"!-#6E2
MUY C@88"J0(J@)*F(BEHJ9"<MAK)ZFB2M(X>2>F8DJ0.?#9=>P#!@BX_2A*C
MGRYF()T- !Q@;7#0_@8%OP4O)MR7Y@ZY ^#ZVHMS0!;B_(\^H ,NFEK0@:8L
M"33E2 U0T9(C)6UY4M!1(%D]99(R4"4) S28@8XH8<$73!@B>#1$4&J(@,$(
M<9[A<@#.JB&<5 ,XP/KPEO3>@QOF3GQM!.2Z\/U7!F@'P$S_S_R/M@YTH"U#
MZMK2I :HZ$B3DJX,*>C+DJR!/$D:81 Q@6&;H5'--$5?-D,\8=Y3G(L9#B!0
M,O,"X,>:I@/P%DS P1B>)'^JM[YH/9*SD6@/5C? !.\-P$47/+1T)4D#$.A)
MD(J^!"D92)*\D13)&$N3I"D&4G,,,);HX-UAW%;0A15/Z)F(-O)8PY>WQJQC
MA5C3:C& 4;D[O)1N^_$=>(X6\*;-&8WAZY'P%0?Q.B +P!@\],%#!SQ@9B3
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M??@>,,A'?:4&B)VIX6*9?\V_3"716A3N?/U]G\QR\/!5%AT9[PN#\D7A/JC
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MWF4ZBW6=QC;WG\H2@,0N@^TPEF8I&*.V]16P#,Q9>2/-68E'+U8Z9Q K]IK
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M%R/O&N<C5R[-0;H>S4/J/F^4+8$C2S- ;GTL*.T, _7#'- [S02+<U2P5Z4
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M\^@\8)U<!$'G5D"(QGH0&.^$4+O#P"/+ =='!?QY.N ;;0S>219 R[+YX5&
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MS?M<++_T3>7Y=:,UVKOOE9N>&2RPU;J8X631F$1VK(RA4XJ$+*_LL$"_-)Z
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MMD8=K->J@,,Z92"N5P3W#>> L4$! C;*0<BF,Q"]^10D;SD).5M.0.G6X]"
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M <R>GP735V=_FDR>^VH\=>Z3T5?%#T8_%2>-X.R? )O-4F"!.E@?F@6.1^<
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MB%!< 9&:&[Y%&N_Z&(X]]H;G<NXEFZ8]PO W?>C)L[U#CL3?<$ETN>J<01[
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M?+3(D_H1)/*>),*#11+^L$Z*#MME2;!_KB.<6&@#9Y=:@.H*(]!=K0^F:W7
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M/K4$GW=6W[WGK.>\OEM_\ +KM]Y@^<H;S%[^#\# :_#6Y *V)C>$Z_!"M)$
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M_\G:&_#0_WC0??]KP;?]_@J^R?H8<(W]@W$Q&.AG@X%RD@-N)SA 7@JPY(G
MP>N(D^>"#-S=^;B[BXT%H=1&#,K(TC_+O.6_%'$T/^3&&[].S[1YGE3B\B2V
MEOHPLM7W7F@OZS9G(_MFT"3G.GM'Z)7 0V&7 B^$GP]X%'Z&_3[D%.=;P-&0
M!<;!4/":#0/JOC#P6,K?:PC#C9>T]M=O)'!!,3X3%88"4&TENE#CO/)+#4W^
M746@YHNB*)/'.2GV]]/R/&XEEGM?CVU@7H[J9%^(6,\Y&[8I[%3(5,1QSMZH
MH\$GH@\'_QYS@/,R:C;\"V=WQ'?6CL@%QK9(H$]'@N=2($".")&X_5-Q=Q?@
MZU&!N[M6GQ\:+(3GFQQ7O&^BR+VH8VK^61%F>J<HP?%Z3A;E8GJQSYGD:M:)
M^);@([$]80>CAB)G(\=C]H3/Q.T*.Q2_(^Q2PK:P)_'349\BMD1_#9J(^<$<
MBP6?T5CP7@H$XC7\:LZ,7^\ X^M1@\]GDR[OSS93H4\==A*O.MW6/&YA:-RI
MXYA>K8AU/%>81CF1D^][.*,\8#:UGK,[J3UB1WQ?]'3L2-S6Z*T)DU%[D\:C
M3B=OBKJ?O"GN?<S&^+G0H83YP(&$GWX#"0N,I0 ;=VX<GI^-F[<<[T>#,A>T
M:?/,=QL+ONVU6?ZTST7V7I>W^K46MNFYVBB'X^7)E -%V;Y[<HL#9S*K0Z;2
MFB,G4[IC1A,'$X83)I*&XG>F#,0=2^V/^T]J?]*;^'7)'R-ZD[\&=Z?\8':G
M_/1?"@2O(4("GI^'>ZL*-V\S_I[5I<G]N<^0_^6@I>BC(6?I__31U2YT!)B<
M: QW.%"30-E5EN&[K:@@<'->1<AH=GWDQHSVV(&T_L2^E$TI/<G;TCJ3#J:W
M)U])[TA[F=2>_B&J+7TNI"7]6T!+^G?64H"#YR;AWBW$:O&>M"D0?ZY3YWH_
MI,?[=,1\V;U-CBNO#M)43_<PC0^UA=KO;HCUF*Y.]9THRPT<*2X)&2RHB>S+
M;8GKSNI-;,_<F-J2OB6],7TVHS[]?&9#UM.4ANQW,?79G\/JLN?9==G? I8"
MH;B[?_5>,6[>>MR\G7+$^0$5TNL1'>X_)TP$?I^P6W%AF*)RK-_/:%\7QVY[
M2[3[9'VRSTAU5L! >5%(;TEE9$=A8UQ+?E=20^Y@:FW.9$95]N[,BNS3695Y
MC].J\M_&5>9_BJC,_QI4F3_/7@J$X[.0+D& 4MR\3=($Z%U#F-N@2'PQH<'U
M8-J ]]H6&\G3HQY*!X<8ACO7!=MNZ8QTW]22Z#W0D,'JJ<D/::\LCVPJJX^K
M*VE/JBI:GUI6.)917+ SJ[#@9%9AT8/TXN(W\<7%'R.+B[X$%Q=]#5H*1.)S
MD(F;LP*OHW4E ?IE"!\VR1'^FE(AWMFIPW-IVEKB^*2;XKX1'_WI ;;-6&^$
MVU!'O%=O2QJKO3&7TU17$E%;71-;4=F:5%*^+K6@;%-&;NE,5G;IL:RLLKL9
MN16O$W++/T3EE7WAY)5]#5X*1.-SD(V;\]<G\3LDT<*@%'HS*4MXM$.>\-L>
M#>ZS.RS%#TV1%7:.>^MM'@ZPWC@0YMK7&TOOZ$QA-K5E!]<T%T64-U;%%M4W
M)^;6]J1F50^GIU5-9Z94'<Y*KOY/9GKMZ\3TF@]1&=5S(1G57SA+@5B\!WFX
MN^O$$'0O1_/#$NC%E"2ZNV\ENCRKQG5BC[G8OAD7N>DM=-W1,:;E^N$0E\[!
M:,^FOB2_FI[,H++.@O#"]HJ8G-:&A/3FKI3DIJ&TA,:M&7&-!S-C&Z]E)K2\
M3DQL>A^=U# 7DM3PA;,42,#/OU"$ (VB"/I$T:=Q$?1DUS+TVV%1=.Z0"NGP
M?E/1G;N=UDQNIVEOV.IOWC,1[-2R*9):NS&!43:8'EC0GQ>:O:XT*JVG+BZQ
MJR,IMG,@-:IC<WIXQVQZ6.?E]*CN5PG1G>^C8MKG0F+:OG"6 LEX'TIQ^[<*
MHP]#0NCV5GYT?:\ NG1<&)TXIDC:=]A8>'J_@^S('HI&WPZ&:=LTV[YN2[A[
M^42<=\%H*BMK)"<X96-Q>/Q0373T0&M\^/KU29SU$RE!Z_>EL-=?3.$,OHP/
M7?\A,FS=7$A8[Y?@I4 ZWH=*(?2M2P#=V<2#KF[G0^?W\Z%3IP71P=-RQ)F3
M!H+C1^VD!PZYJW;,^AC5[PZP*=\9ZEJP/<8S<SJ9D;PU*R!N<R$G<J(J/'2\
M)3IHK"^.-38>[S^V-\%O[$("<_QY3,#8I_# X:_![.'YH*5 SC($]?SH?C\)
M79O@06=W\J)CAWC0@0M\:-=%6<+F\[K\&\Y8K^@^259L/.:E6W&8:5%P@..8
M.1OEGKPWD1Z[)X,1L:L@@+.S,CAP1W.H_XYU$;XS8Y'>,WNBO'9<B/+>\3S<
M=^8+AS'U+=!OZ_> I4 1/_K02D0W-Q#1N:W<Z,@>;K3W&#>:N<R/-M]8B8:O
M:_+T7K%8WGS)>6WE>9I&X5D_H\S30=9))R.=8DXDN(4?2Z<%'\WW81VM\&,<
M:69Y'^YC>QX>#Z(>WAM,.7(1>\&F'9YG>1Y88-!GEP:51'2W!_?_*!$=W4Y"
M>V9):.H4#QJ[+H"&[DJBWKMJ7"UW3(6K;CE(%][T4,J\X:N=>(UM''TUW"KT
M2KP]^W*:"_-ROIOOI0HJ_5(SG7JIS]OCTH2/VZ5]ON3+EWW)EU[BK[_2W<\#
MS?T<4)?RM!FAJX,('=],0'MV$M'6PR0T?)X']=T20!U/5A$:GVCR5#PV7I;_
MI^V*]$?D-0D/O56B'@9HA3P(,PA\$&?B_R#-PN=^OC7]?J4=]7ZSH_N#/F?R
M@W$7EP=[79T?7G!U?O#,U?G^G(OS/7#Z7VYU(W1Z%*&]VQ#:LH^ -IXDHIZK
M/*CYY3)4^V8ML>2-)D_.:R.AE-?6XC&O7:3#7M/6!+WV5V2]#E%EO([1\'Z=
MJNWY.E>7\KK<P/U-HY'KFQYCYS>;3!W?[C!S>'?"S/[=?7/[MV_-[%[_-+-[
M!4LZ/X30[&:$MNY$:,,1A+HN$%#]+6Y4\56,4/!U+3'CJSI/PE<#@8BOEB+!
M\X[BS'F/E3[S/JOH\X&KJ=\BUKI_2Y G?\M0=/E6I.STO4;%_GN[FMWW 76;
M'YLUK'_LT[3\>1Y[I&GQXQ/V94D'QQ&:PM=@PP&$.L\@5'L#-_@S;I0-RPG)
M($N,!A7N$-#E8X&IH"_8"GN"JY@'T,1=P4_2"8)6.$"$E!W^ <0:,E=90I&,
M.?X!P!0Z5IO T!ICV++6$/9A9]8:P",Y WBZI&U;$=JX!\\_@5#U%83R[R*4
M]I,?Q8$8(12DB0&@0/(%#6Z<IKQN8,'O#/:"]D 6L@&:L"4P1,P@4-0$PL2,
M(%;, -*6ZT*^N#9426A"FZ0&#$BJP\0*-=BQ0A6.8:>7-(+WH OO0?4%A/)N
M(Y3X$J$(X$9L$";X@@2!BJ\%&92X'$"+VP8,>2S G-<$[/@,P9E/#SSX=<!+
M0!/\!=0A2% 5(@25($%( ;*6R4')LC70(+P:NH5E88.P#&P1D8&I)77C/:@Y
MBU#N383B_T2(,X>0'R!$ P'D"J($>UA!M(+51%-0(AF !DD7]+@TP81;%2RY
ME<&.6P&<>>3 G6<-T'EDP(]7&MB\*R&"3Q(2^<0AFT\,2OE%\3=!4>CD%X&>
M)8&;*A&<]+G  Z,;\8"W!1]X.PJ"%TT$/-GB0(U? 91<:?"HE@&W]M5 7K\6
MR*-RX#HE#ZZ[%,#EH"*XG,*N*('+ ^R%,KA\Q+YA\-^4?KJ XE+^7H.+[C_W
M0;P->(!AS@<,!T'PI8J -TL<Z#$KP3-[%= J5@.E=2UX],F#^X@"N&_!?W>'
M$KCM5\;%I@+DB]A=52 _P]ZK 7D>@[\M8-_)H#I/!I6E@#M> UG[GWL0##T>
M8)KP <M.$)@>(L#P$P??*"GPSI !K](UX-DD#[0>1:!N4 ;JA I0MJN"QUXU
M\#BJ#A[G-,#]%O:7)KB_P[YJ@3MH_<2^N8/F%W=0_^P.:DL!#Q4B>&C^<P^"
MJ<,-@49\$&0C"$%N(A#@*P&L,"GP3UT-C"(Y\*E3!.].%? :4 /ZJ 9X3FD"
M;9<6T YJ _6T#E"OZP+E3SV@O-;[09G3_T99T/]" ?W/5-#]0 7M=U307,K?
M:Z"ID\!/_9_[("'ZO!!F*0AA+B(0XB4!P1Q\S!+70$">(C"K5,"O51T8Z[3
M9Z,.>$_J@==V??#:9PCTXT8+GI>,OWO>-_E*>VGZF?;9[ /MI]D[3S!^0P?#
MEUZ@_]P+=)<"%&4B>*F2($"%!"%JW!"IRPLQY@(0XR@"T31)B Q8!6$Q<L#)
M4H:@4@T(:-!98';I__ ?,/K.&#69]]UJ]M5GE\47[T.6G[W.6G_TNFWSCO[,
M]A7]H]USKY\VSWS \B]?,/N3 <8/&6"X%* J$<%7B01!N*\B<>?%:?- HHD
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MG8@BC(HJP Y1>3B*75G2X S>_T/X^9_#\V\B%/T(H<#W",_F03001F20(#B
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MW#='6#OO"&N6 O;J1'#1( %%G01>6ES@8\ #OE9\X.LJ!%[>(N 9(@[4Y)5
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MQU7\:::OS,,4CO+M^#CMZ]$91I<B"BW.A5;9GN8T.9P(ZG(^&CA /APPZGZ
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MCQH$\JI .*\B)/+)0R[_6JCF7P.= JMA6$ 6M@O(P!'!57 3N_\O??@,-![
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MKXLV2.Y),HWKRK2*ZBRT#>NH=N2TM;H$MJUW8[5N=O=OW>_AUWK=P[_MK6M
MVT\'=CO8!+6#Y6*0A-"#(GP-</N>Z$1H=CU"VX=Q_^/VV3 EB/JF5Q,ZIG2X
M&K98"E5.ND@6C=-D<T;]%--&@C02-T;HQFZ(-XH83#<+&<BW8J^OM&7U-SLP
M^OJ=??HF7;WZ9EWI?5?QXQLGG[X?=HP^L/+K XO%WF?@LXC[_TP+0H=P?^_
M_3LY]FL^[L]=/*AMMQ1JV*5!JMQIRE\TXR"6O8TBE3KENS9A:Z!R].8PC;#)
M6-W@B53#@/$\4[^Q<@N?T29K^FB?'773A+W'IED'C]&K#AZ;7MM2-_VPHHV
MN><(F"[V&._#Y5J$CN%KL'L0H2UX#S9NP?V)^Z]I/Q'5'%R.R@\J$PH.&/)D
M[;==ECSK)A&WUVM5Y![6VI#=(4KL7='JS)W)6KX[<O2\=I094F<:3=QGUIF1
MMX];N,SLLW">N6KALOVUN>NV'R:NV\"(/ V&B]W!9_$TO@;[^Q&:PGLP,HG[
M$_=?\SZ$*HZ04/ZI92CGU!J4?DJ'E'C2@B_ZA+-PV'&:>-!Q/RG6L>#5C*-1
M\EY'DY1H1[+5/(Z4:I(/-V@['UZGZWAX7-_^\*R^_9%K^O:'WNC9'_RI:W\
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M@B'N?U-M(ICIX4<3$AC9<H&^!P_H,GE!*XH/-#+X0;U4 -0:!4&M&QO$1H5
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M5\O#*^<LSTE]LOQ#ZIWE"ZG7EG-2+RQAY3,K6/G4"E;\90V23ZQ!8C&P5B"
MTQH"N.'^IN)'N@H1O/!^T"VY@>;"!QX^@D .$0:7!+'OSCGB7YW*).<<&U9^
M<NB0^FC?+_W>?ECFK=VDS!N[&=G7MOM7O[0]M>:Y[6]KGM@^6_O([M.:^W8+
MJ^_:@\P=!UAURP&D?G> E8N!W5H"D''GTJ0(?W\&P$^1"$R\'_YX/Q@.O.!-
M%9RG!PA_ID8O?T])6_'&O5#J);E*YKEK\^JG+MUKGS@/R/WI-*KPT&E*\8'C
M'J5[CL>4_W"\HO(?QR<JUYT^*EUQ7E"XZ )R%UQAS3E7D#U+!IG%P G/I:S
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MS*))DDR:."FG\4@KC4N6H%$ZA^Q'5] S]/L_+-P$, ?W?^ED_;-8_PJ SZ\
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ML4S!;L<&!=L=!Q5M=MQ0L-GV1L%F*U&P&2/R-EO^Z1">"[8OQ#7 ]5^&\U^
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M0Y-X^Q--XLT+FOBK+S3QW\D_+,'CKP/7OP[K%QS ^B>P_GD S\L ]M< S&\
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MR>Y_("J8-M6T_Z2L1Q%9$XJ(VU"$ZTH1T6"*B,131"B'1@0KT!S421'!'C2
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M?D)D&G)#$7]]2J4>X4F/C/SU/&;O?Q%Y+2 *F+7ED)0V$*XA$"$K($QG(%0
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MW)_/PL:Q[H9"W ?%>+^/&; S#S-/GBC,SI.'FGQ=J,BSI$IR'>F%.1[,W.P
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M//H7HH)97UD2QR$!1$8*^Z$(1$('>V(!1!370P370S *B$ JRH=O[ KXPF[
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MJ/6(,^SS ]3?3FLZ2.WE __48(J&F(,M]/_;@(#M KR&E? 8'@OW$4NXCCC
M9<0-SB/^F#,2@=D[$N&T(QN..TH%^QU-PHR1;HGMR(!D^L@NB?7(68G5R!V)
MU?#W4JMM#Z666T69Y99_.,K\[Z3^1K9[Y3J>CYLX#K9R'- J9ZEJ,+2(P7L!
M#_IBIX-RS#@T!G:'QL'VL"6F'W: S6$W6!\.@-7A2%@>2<&T(_F8>J0:DX]T
M8-*1E9AX9!@3CIS"^"//8_SA;X7Q!_\6QAT0)>/V_\.^?F +<[YV ^?$+:I[
MH=@'NX%<:B8> D*/ EZTA[/H2Z?3OD\^J\#X\V,P[OQ8C#T_#>;G9\+LO"M,
M+_C#Y$(4C"^DPOAB,8PN-L'PXA*,N3@$Y<6C,+CX+ PN? 'EN;^@/"M"^<0_
M;&?NUS'OO<QWAVH?#K7SCP#)].+AIP'OL]2G)[>A/9UT!3![BC[XN@)Z-Y70
MO6$&G1N3H7W##EHWG*&XZ0?YS2B2 >G-<DANMD&XN1*XR0/?H-^^22-_XQYY
M0,1_LY&Y[]^NWH=3QW874COE">I?H/XEYO\J8$U//O%9P.0Y0$EOKGU'@'!7
M%[A+SW_7G!<]>OY7Z?E?F\,%(1=F;_!B_"87(V_RI'NS2_6GPLD!<HU\1'XF
M#XDXRBKV^T)5#8AM+V*[4R]2G^WUHJXC=2VI._X%P.@.H,]FR-^@UW^7O"<%
MWF<<'XSA8M@4^-B"BW)KX%,G+LR\@2\8QY>\&'[)"?\K#KJO-I-CY ;YA/Q$
M?AUED:H&Q%^5,.=IEU7W05'_)N# ]DZEKCEUQ[S)MJMT/U357\AGFEK(EP(7
MY%I<D!H WQF!AHP+Y&G S_; ;UPL_\Y%XA^\&/S)"^!]3CSWV>'WF>C[%+G_
M#OEPE+FJ&A"[*ITYCZ2V%]ML?Q>8\CI@RG]F\*&F_O*H#J+:#\(NI;&F%OE5
M50^14$N'QU,"?YO0+# GHAUQA_J)J8Q#]:>[Q&6:^V&.:.Z#N3R*:#25'GLR
M_361T??#EJCJ#_XDEF21LO^?]8>3Y()F+\@=\@D>X@?\C;_^H^9Q_[\03>EO
MC2= 5!)MOH<J#D?B32))&BDBM60>Z=;48M3U!]6>E(?829W]>("CU'@"?^(*
M_L!M_([WF*9OF:X_1FL=/Y$?R0__A3B67M_,G/DP8R[&0I1/XJ=VQ)V$D$1-
M/:B"-(WFX@%Z&'\_CSQ G4W4V8Y?L)LZ!ZEQDL>]@.]QG>JOX6L.G*_X+[[@
M-S\GG_T/Q GT^N.,F ]#B&/X:C >HJXU8V%_"/Z:>E &VUI,W5H>K97M64"=
MI=1929U!?(,AZHQ09R]UCN)3YN(37,-'> D?<!"_QV^\PTR]I:E2O2%HD*@9
MK7M8&# ?>LP'?;\I\V$TA7TS$Z*>)_[6#L,?BB3\(LO%][)R?"UKP.?2-GPJ
MZ\8GLEY\)%N%#V3K\;Y\*]Z5[\1;\H-X0WX*K\HOX:[B-NYH?807M7_$;5T1
MS^F)N*DOXL9_(4[3ASB5_M]""G&2+L2)C&D<^\?4"K\9S<8]I3^^5D;C,X-T
M?&Q0B/<-JO"V01/>,.C :P:+\8I!'UXV6(N7E)OP@G(8SROWX9;R.&Z.N8AG
M#6_A&<,/<=7H)UPR%G'11,1Y$U$X]U^(-@IU.5&%->.8IHN_)QGAQPD3\:6Y
M+3XV=<,[)B%XS30!=\RR\()9"6Z9U^"&>0NNC^W$TV-[\-2X?EP=-X#+XS;C
MTOB=N#C^$,Z/?P)G)SR#)R:\B9,3OQ..63P0CDP2A4,:#C[&Z&G,:?;A3)[V
MY M; 5]8ZN#3289X>^(DO#S)$;<G^^+9J5&X-C4%EZ?EX>*T,IRWK,-9R[DX
M8]F%4Y9+A).6*X3CENN$HU;;A"-6>X5#5B>$ U:7A?W6=X0]UE]*=MK\*1FQ
M$27#9#O9]ABB V-PY-3CS*G6%7C'A=.^DQ2OVNCBMLU8/&UKBTLSW'%N9@A.
MV\?CA'T&CMH7XK!]A7#0OD'8;S]/V&N_0-ACOU2RRWZU9(?]1LF(_0[)=OO#
MTJWVYZ1;')Z3#CE\(MW@^*MLG:,H'20#3L3Q'U2W&OY$W4\YQ;_I1__/2\YS
M7L#U.7)<<3+"V=G3<-)Y-HZX^.& 2Q3VNB1CETNVL,.E6-CN4B79ZM(HV>+2
M)AER[I9N=%XN7>\\(%OGO%4VX+Q/OL;YE'RURS.*E2[O*?I=?U(L=Q7EO6ID
MRQ[C ?6_H?Y[0?1;H=0F5_C^@H^ TQY*'/&TP#XO>^SR]L2P3RBV^L0)0][I
MP@;O/,DZ[U+)@'>-=(U7LW25UWS9"J\>>;_72OERKXV*95X[M99X'=/J\;JL
MO=CK->UN[^^U%W@_U.KR$15$_CB_>/ 2%,A++Z?U&]%<Y\< 9WG).Q%"O^&O
MA]T!8S$<.!V;@URQ(2@ @T%1PIJ@)&%E8):D/[!0NCRP0KHLH$ZV)*!5OCA@
M@:+;?[G6 O]![4[_[3KS_0_IM/M?T&T+>$FW->!KW;F!#[3G!HI:1-'R&#_Z
M\')(__\BO>\U>L]SB<!QOAY@/#M#M; US!0;PRTQ$#X;JR)\T1\>)O2&QPM+
MPM,DB\-RI0O#2F1=H=6R^:%-\H[0#D5;:(]V:\AJG9:0+;I-(?OU&D/.ZM>'
MWM:O"_U"OR[LOFYMF*A-M![GVP#@+;;[.6I?2@5.I;']?-W%G[=$2[ NR@BK
MHZ>@/\8!RV(]T1,3+'3'1 M=T<F2CNA,:5MT@:PUJES>$E6G:(J:I]40V:U=
M%[E"IS9RDUYUY![]RLC3!A61-PS*HSXE?^B51XDZY=&B-E^U'O$E<_YJ'/ ,
MO>]Y+GV.<=FQEZ_;&<OZ>/J=>"66)TQ$3\(,=">ZH3,Q0&A/B!#F)21(6N+3
MI$WQN;*&N!)Y75RUHB:N6:LJKDN[(G:Y;EGL>KV2V)T&Q;$GE$5QSR@+XSXF
MO^D7QHNZ1(=H/^)?' <OL<U7,^@Y<X##]."[R&9>\E<SKMYD?2Q*&8>N%!MT
MI,Y!:ZHO6E)"A<:46$E=<HJD)CE+6I5<**M(JE24)35JE21U:!<E+=4M3!S4
MST\<,<A-/*;,27I*F9WTP9CLI%_ULY-%W9QD42<G2=1^Q(?L]]O4NJ2J0]%[
M[B^BWR(;\H$^QK4H71?S,\PP+\,2+9E.:,SP0EU&D%"=$26I3$^4E*=G2$O3
M\V7%:67RPK0ZK?RT-NW<M![=[+0U^EEIVPTRTHXHT].NCDE+>Y?\;)"6)NJE
MIXDZ&K15O,M^N$&M"]0\5DSO7T;O3P9*N-;/Y5HW1X'6'&,TY4Q!?:X]:G+=
M49D3()3E1 @E.?&2HNPT:4%VKBPONT2>DUVCR,IJU<[(6J2;EK5*+S5KJT%R
MUF%E4M9E96+66^0G@Z0L48_H$AVBK>+U)(X%YN )MOUP.<^%2GH^+H=750 +
M"NDW"J1H*#!$38$%*@OM4%[H@I)"7Z&H,%0H*(B5Y!:D2',*LF59!47RC/PJ
M15I^BW9*_D*=I+P5>@EY6_3C\@X:Q.8_J8S)?YW\J!^;+^K%YHFZ1(=HJWB9
MY\!5YN 4VWZ@FOW Y><&TE\+M/.S!OKRJE(ERDK'H[C4!H5ELY%?YHW<LF A
MNRQ:DEF:)$DOS92FEA;(DDLKY(DE35KQ)9TZL25]NM$E0WJ1)?OU(THN&(27
MO$+NZ8<7B[H1Q:*.!FT5S_,<>))]<)QMW\-EY]8F]D,SL)2O<[DLK^+G)55Z
M**@R0V[U-&17.R*SQAWI-0%"6DV$D%(=+TFJ3I,F5.?)XJK+Y-%5]8K(J@ZM
M\*I>G="JC;HAE?OT@JK.ZP=6O:P?6/F]7E"EJ!M4(>H0[6 --W@.G&,?'&;;
M=[8 F^;1=[9Q+/*UD;&4,9;<1BUD-AHAO7$24IOLD-SD@L0F7R0TAPIQ33%"
M3%.*)*HI6QK15"P+:ZR5AS2V*8(:EVH%-*[7]FO8H^/3>%;7I_$E7>^&;W5\
MZA]J^]2+VCYUHM8CKC$'I]C>_=0?[J#OZZ3WIC7J)'7SZ;OHR]/;!"2V*1'?
M/@ZQ[=:(Z7!"5(<'(CL"$=X1*81V) C!'1F2H(Y"24![E=2W?:[,N[U'[MD^
MJ/!HWZ7EUGY&R[7]!2W7MF^T7.?]K>7:*FJYM8H*M[EJ+JKNRU/=DT;]S0LY
M)RP">FB+YO6P'_B:0Y)(Y")=A"TV0<CBR0CNF8&@'F<$]OC OR<$?CTQ\.E)
M$;QZ<@6/GG*)6T^3U*6G6SIG\1K9[,4[9$Z+3\D=%]\B7\D<NQ_('1>*<L<%
M_W"&8^ @VSK<S1PLX9S0J[H7B?W0QW% 3YZV H@A02LD\%FIA-?*L?!<90F/
M50YP7^4&UU5^<%D5#N?5"9BS.A.S5A<+CJOJ!?M5G<+,52LE=JNV2Z:O.B&Q
M67538K/R2XG-BK^D-GVBFN5JCK'?][#M0[1 JZG9LXHY6,,<T(_GTJHFKJ?_
MWT#_2V\^9Y,V'(>,X# T ?9#UI@YY(@90^ZPVQP V\V1F+XY&3:;<V&UN1*6
MF]LP=?-R3-F\19BT^:A@L?FZ8#'TF6"Q\;XP<8,H3%PO2AYQ@.W?SK8/TJ(O
M7PO,7Z>IP="BIM$>1M$3^XT +CN F;N :7MT,66/$2;OF8!)>ZUAL=<1$_>Z
M8\+> (S?&XUQ>]-@OJ\(9OL:8;IO,4SV;8#QOH,PVG<-AGL_@='N/V"T2X31
M3E%XQ$[J;V3;5PT"W=1NHATLI68F]6+IQP/W VZT[3,/T8,?I0>G/S4^J0/#
M4X9D')2G+(D]#$ZYD4#HGXJ!WJE,Z)ZJ@/:I=FB=6@GYJ9V0G3Q+[I)[D)]X
M",5Q\=]L9M[7,M\];'<KVURQ&\BF9CQM:=#H'AAZX%-L_Q/ .'IC(UI5@\M2
M:%W5A_2*,80KXSG)61)Z[:OTN%>Y"+O&"^XUU890GO#7V-%7V;BKAPG]]I5/
MR6]$_#?KV-?+V/;VG4 UVYQ+[8230/ 9ZE-SY@5@ZB5@+'VYX=. WK. [#EZ
M[=OT_+?I^6\; \\SCA<8QPN,XR4WX [CN,.+\<N<[%_F)/,R!_G+;.#+/.C+
M=\@W_/T?Y.$H?=O4^W!J#P+Y;'/B6>JSK6ZTY3.N 9,9NME-0'D;T'Z1VG?)
M:T15"WE3P060/O"V$?"N.1>E4X /:!8^X@+]$\;Q"2]&_^+%[U^<]#YEPC]E
MYW[Z)!>/KY.OR<^C=.T!ZIFFPM.<!Z@=PO:Z/:/> V-!79.7 /U7V':5YCOD
M Z+:B_()^515#Y'2E.@ 7RFY.&9.OIM HV+-Q?H<X!?&\0L7!K]R(OZ5D]YO
M[/3?.+!^9P-_9SY^_W"41HZS(O9U"O,==AUP9YYMV=Z);*\1=74?U5\^T=1?
M'NT'^4ZS)^3?M1 9CZ<+W#<$'IAK[HEQTCP71/5\DDK-_3";-$]*94>+UT81
M#2SHLR>"9RH=\61"SPTGXDNB23HI(76D[7_6'_[SGI@G-'M!;M.KOT^W_1T>
MT+$_JGW\^;]J((;T^@9C(2K,^=,X31RJ_2@>)(PDDWQ219I))^DA_62 .INH
MLWUT'\9?.$B-$_@#%_ ;KN,7O,H4?4'G_]MHK>.>IN9Q3\/W&D1C4XACC.GS
M"51,(#90[XD))'&:>E IM>JH,X\Z"_ [EN)7K*3.('6&V"7#//X>'O,PN^H,
MOF8NOL0+C.!C=N&/^!>__:_1ZI#(3]1\I&&T]F&D9"X,(&J-89^8\=.IC]6#
M(JB90KU\MJ>2.HW,;CN^89]\A674687/L8XZFZFQ@\?>S^%S'.\Q%^_@!M[$
MVWB=4;W*H[S"H[VLJ50]CCA6GW%H,Q=RB$H]B/I&C(6Y$*8SOZYL9Q UXZB7
M2:UBZE0S]F:>'AUX%XNHT$N=U3Q=UU-C*S5VX27FX@7FXC:NX29/YAN,]#K[
MXVGJ/241<4WZGX@3%8Q#\Z@;$\9AQ'PH3?&G[A3\H'# YU(O?"0-QWO2)+PI
MR\&KLE*\+*_%B_(6/"^?CUORQ;@I7XX;BC6XKMB$IQ7#N*;8CRN*D[BD=1D7
MM5_"!=W/<%;O=YPQ$'&*G%2A%'%"P^C#AR>JN<]3^U=S.7YC'-\HS?")GB7>
MTIN#N_K^>,$@&L\9I.%993Z>5I;CFK(.5Y1S<6E,)RZ.Z<%YPQ4X9SB()PRW
MXK3A'IPT.H831D_BF-'S.&S\&0Z8_HY]9B+VD-W_A<@I5O7(H1^L@,\YM7S$
MT_J]\7*\:ZB/NT;C<<MD!IXQ\\ 5\U!<'!N/LV,S<&9<(4Z.J\#Q<?4X.KX5
M1\9WX=#XI3@X817V3]B O1-&L&?B0>R:^ 1V6-S B,6'V#KI9V'S9%$8(INF
MB,+&QQ"GJ[>X?>[(:7 6IW*^/L^?GYNBC:<M3/#D9$L\,64.3DSUPY%ID3AH
MF8S]EMG88U6,7595V&G5@!&K-FRW6HAM5KW88KU6&++>(FRRWB-LL#XIK+.Y
M)@S:O"FLF7Y/6&4K2E:2%:1?C:#B_@Q.>[.!]WG)>\D3>-:#ES=GKK7M)3AK
MH\1QVTDX.,,>>V=Z8N?,$ S;QV*K?1HVV^=BDWT)-MA7"^OLFX0!AW9AK<-B
M8;7#"F&EPP;)"H<=DCZ'(Y)>AR<ERQSO2)<X?2U=[/1 NLA)E'1K6*CA%TZG
MGU+W53_Z+7KP2^0)7^ $+W^'9NEASZRQ&)DS'5N<7;#)V1_K7"(QX)*(U2Z9
M6.F2+_2[E G+76J%7I<68:E+EZ3'99EDD<M::;?+5ND"EP/2+I>SLODNMV4=
MKI_+VMS^E,US$Z6M_\4/+LP!]9^G_[X:!IP-YQJ7[_?SLYWN"FQQ-\$&SVD8
M\'+"*B\O]'N%8+E7+)9ZI0@]7MG"(J\B8:%7I:3+JT$RWZM-TN&U2-KFM5+6
MZK5)-M=KC[S9ZY2\R>M918/W)XIZ[]_E]3ZBK$Z-M,Y;S==>ZGTXST8"%V/8
M?G(@"M@1RG6VOX!!7T.L\IN$/O^96!K@AL4! 5@8$(FN@ 1A?D"ZT!Z0)\SS
M+Y7,]:^1-/NW2!O]NZ0-_LME=?[KY37^.Q75_L<550%/:54$?$!^590'BG(B
M&R5 S6=L[\ML^[58]D$"O0Z7'KL35/4/KC$9QXH@ RP-'H]%(=.Q(-09\T-]
MT18:BM;06*$Y-$5H#,D2&D(*)74A%9*:D 9I54B'K#)DB;P\9*VB-&18JR3D
MB%91R!7MPM"WR<]:A:&BHB!4E!-9H8:/>(E_GGJ7J'V2E]@#:< (7S<RCI7,
MQY((/2R(,$-'A"7F13JA)=(339%!J(^,$FHC$X7JR'2A,C)/4AY1*BF+J)66
M1,R3%44LDA=&K%;D1VS5RHTXI)T3>4D[._)U\J-6=I2H(/+LR%%D*MYE6V_2
M_U^@[K$,KO.SZ#GI00?IA7NY+%P0HXVV&&.TQ$Y!8ZP]ZF+=4!/KC\K8<)3'
MQ@FEL2E"<6RVI"BV6%(06RW-CVV1Y<8LE&?'K%!DQFS6RH@]H)T>>U$G+?85
MG=38>]JI<:(B+784^2/>X#AXADNNL]0_G,-QR*7H$%G-6!8SKK8$&9H2#%&?
M:('J1#M4)CJC+-$')8DA*$J,%@H2DX2\Q$Q);F*!)#NQ0IJ9V"3+2.R4IR7V
M*5(2-VDE)^[33DP\KY.8>$<G(?$[OA>UB(+('W&78_ :VWPZF_V03[_%9>@&
MTD\OW,6XFOF[VA0E*E/'HRS5&L6ILU"8ZHG\U$#DID8*V:D)0E9JNI"1FB=)
M2RV3IJ;6RY)3.^2)J;V*^-0-6G&I>[5C4L^2%W6B4[_AZT.MF%110>2/>)'Y
MOD2MXZJ]0/2_6TO9#Z27[]N8ESKV2WFF/HHSS5&0:8F\+ ?D9+DC*\L?&5GA
M2,^*$U*S4H7DK!Q)4E:)-"&K5AJ7U2:+R5PJC\I<IQ69N5LK(NN,=GC6\]IA
M65_S]6]%>*:H0AZAX;EDC@5J'2D"=G'I29N&-54<BQ7, ?-1R=B*\G20FV>"
M[+S)R,B;@?1\%Z3F^R Y/P1)^=%"0GZR$)^?)8G-+Y)$YU=+(_-;9>'Y/?+0
MO %%2/Y.K:#\4UJ!^;?(EUJ!>0\407FB?)1<-=?3>4X6T/=2?Z2:YP-MR0K2
M70LT,(Y2YB2G6([T8D.D%D]$<HD-$DMF(;[4$W&E@8@IC41T:8(069HAA)<6
M2,)**R4AI2W2H))N64#)&KE?R8C"M^2DPJ?T)OE<X5-R7^Y3+([B6R3*5%QE
M#D[2 NRC_K8&]@,M22_I;.(X8"R%-?2=S$M"I0'BJL8BIFH:HJKM$5GMBHAJ
M/X35A"*T)A;!-:E"4$VN$%!=)O&K;I3X5"^0>E6ODGE4;Y>Y5Q^7NU4_2SZ3
MNU7]*7.K$F5NE?]PD?D^2HU=C>R'5IX/M",]I(U4S:7O:J'O8#R1C;H(:S1&
M2-,D!#?9(K!Y-@*:/>'?' B_YDCX-"?"NSE+\&PN$=R;ZR2NS?,E+LW]TCG-
M6Z6SFH]*G9J?)O^2.C7](75J%*5.#?^@VA-U@.T?G@>LGP_TT8HL7,"Q0$KY
M/J.3WI>?!W=(X=NAA/?\L?":/PV>\V?"H],%[IT^<.T,A4MG+)P[TS"[LP"S
M.JL%Q\XVP;YSN3"S<[/$KO.PQ+;SFF1ZY\>2Z?-_ETQO%T>Q;5-SG/V^A_I;
MJ+>F&UC:0^^YA/VP%"@@222"^!*7I3J8O=0(LY9.@.-2:S@L<X3],C?,7.:/
M&<LB8->;"-O>;$SO+8=U;PNL>I=@6N]&3.T]($SNO4P^P.2EOPJ3>T0UB]4<
M9+Y'V.;UU.Y?QASTT?^O ,I6TO^O8@Y6T__3*KH3A[6 S8 ^K 9,8#E@@6D#
M-I@ZZ(0I@^Z8/!B(28-1L. $.V&P$.,'ZS%N<"',UPW ;-U>F Y>A,G@6S!9
M^PM,UX@P74U6B8**/0O4S\190^VEU&RC3M4@D$=KF$C+'C8$>&T&G+90G_Y\
MTC8)S(?U839L M/AB3 9MH;QL".,1CQ($ Q'8C%F)!/*D0H8C+1!?V0%](9'
MH#M\&CK#+T)G^[?0W?80>EM%Z&U1H[H?:Y#M[F,[.U4U&-K!0NJE;N<XW,$^
MV G,W@5,IS>>M(\>_ !@>$@.O2,&T#YL JW#$Z$X; WY82?(#GM"<C@4@NKB
M>Y@3R^%ZLIBP,8=HK \]S4F 1OG@;QR$XK_9R)RO&OBG!E,R J3O!J+W WZT
MIG/XU>E'J'\,,#T)*.G/=<X*D)RCOSTWAI@!YR<1&\(%Z04N2"YP,7"!D_R%
M4O6#D"Y0Y#P;<YX^]_QK_,X]\H"(HZQEVWN8[[G#G).IG<EVQM"+^Y^@_BGU
M'A@+?M7D F! ;ZZX2H_-YN 9^NQG](#K]-G/,HYG+;@8Y,+\)A>'M[R!VQ'J
MC:&WJ]1_HNGV!G[.!MVBN;_%7-SZA?P]RC+FO8TYKV2[L]G>..H&G*7^!?4>
MF E7 *.G #U^5:JJOSQ/7B)WR,M2X*X.\(H2>,V8"[+QP/_1++S#Q?G[JHW:
MJANV>3'\D'WR(0?\A^S@#YG(#UX@G_/]+Z-TL*]KF/-<MCN>VH%LZQS-'ICQ
M-]CWMYA[5?WE94W]Y6W5/A3ROJ8N,5H/D7-AS)Q\SIQ\:0Y\3</RG3U-"_.A
MNEGW1XZ-GSC9_<P^^9G)_IF)_?DV^7B4.J8GGVU/O @$70.<GZ4^=<=25WF7
MN7^\_O+)8_M!OM;40K[7U$)^4CTO1 '\I@_\R9P\L- \'U5U(W^<YGX8U5^,
M>?27:U3/!'EZ%%%K//WM6+K1L1K?K]J#84^\1CVWB%2H[P&I)BV:^H-J+\B*
MT?J#^IZ8;607U/?$G(!Z+\BS>(@WZ)N_QE_XX]_UCS\T_ ;U/2BJ/1FB'KV^
MW(3O5)AJXE#M1W$EP22!Y$"]'Z4>ZKT@JGM1EE%C)?[&(#6&J#',8^_![SC"
MXY^A7[]*C1='*P_W^$Y5Z_@.ZJ>4?*-Y??1>-*#7US'DNS%$]:JJQUB265#?
MDZ.J!Z51JY Z5=1IHD8'-;IYY%YJK*+&.FILYC%W\)C[V57'\05S\1E=_[_8
MD1]3_4-&^@&/]/[_0!Q#KZ^O!U&JPY_T-;48U7Z4&?R6!S5#\2L2V=W9U"FA
M3@TU6J@QGQJ+J-%+C5746,_C;<&[[).W<8B]<!JO,A=W>0+=X2!ZD9$_SZ,^
M/UJI$G'K,40C;>9"PG'!X2'G>RA'<_$[<W$/L]DN/WR)*'S*<?$1\JA31HTZ
M:K108SXU%E%C.356\_@;>,QMN(F]' W'\ QS\12>PQ5&>)D9N\3>NZ@9+8\S
M6OO@=#?ZV%\.:5%+!W\(AM2=P#;:4=,=;W%<O(HX:F50IX!'+6>6ZW =<SE=
MS<<U+*9.'S764F,(Y]DG9SD^S_"_4XSD!(]P7/(=CDK_PA&YB,,*$8<>0S17
M/V;G=_*M$4\]3C>?*;3QOM08KTNGXB69(V[)O'%='HYK\D1<5F3BHJ(0Y[4J
M<%:K'F>T6G%*NQ,GM'MP7&<%CNJLPV&=;3BHNP_[=4]BG]XU[-%_';L,OL,.
MY4,,*WF-&L,SZ3%4CSK^G=/;UY,YY9 W^/-=$PGN<(P\IV>.IPQL\*32&>>4
M 3@])@HG#)-QU# ;APV+<-"H$ON-&K#7:!YV&RW +J-EV&&\!L/&0]ANO!M;
M38YAL\EE#)G>Q0:S;['._&\,C.7U@:QYC/N\W'QO17T[:L\$GK/EY6 :<&6\
M'!>-#7':;#*.F3O@X%A/[!T7@EWC8[%C?"JV3\C%U@G%V#*A"D,3&[%Q8ALV
M3.S&.HL^#%BLPUJ+8:R>= @K)YW'BLG/HV_*%^B=>A]+IXK"$@T]&G[E9>8S
M!_6VPYLNP&6^GN-T?Y*7P:.3]+%_\CCLFCH=VZ<Y8XNE'S9:1F"]50(&K=*Q
MUBH/JZU+L=*Z!OW6S>BSGH]>ZR58:K,:2VPV"XMM]@J+II\6%DZ_(2RP_43H
MM/U=Z+ 3A?;_XAZG]?>I_3PO,5=]N,[GU'K,'=C/R_ N.RULLS7!)KNI&)SA
MB#4S/;'2/AA]]M'HM4_&4OM,]#@48)%#.;H=ZK# H16=#@N%^0Y]0KO#!F&>
MXTZAU?&X9*[C4Y)FI_<E34Z_2!IGB9(&-4*]AB_9[M>H>SV EW9Z\.-DOS_7
M=Y[TG7,$##H98M4L"_3-ML/2.2Y8[.R';N=P+'".0Z=S*CJ<<]#F7(16YRIA
MKG.CT.S<(32Z+!4:7 8D=2[#DEJ7(Y)JU\N2*M<WI)5N/THJW,11RA_A*DH^
M89M?I/X5^N_3O.0?C%#M_^#ZCI\-,#=]K@98XC86W>[6Z/*8A0X/+[1Y!F.N
M9Q2:/1/1Y)F!!L]\U'F6";6>=4*U9ZM0Z;E(4N&Y2E+FN45:ZG506NQU45KD
M?5=:Z/T]$:4%WJ+D<=YG_I\+ 2[R4G^<E]F]L?0ZT<"Z,*YQ&<=B;QUT>INB
MS6<JYOK:H]G7#0U^_JCS"T>-7QRJ_%)0Z9>-<K\BH=2O2BCQ:Q:*_!9("OWZ
M)?E^FZ1Y_OND.?[G9-G^+\JR [Z5904\E&8%B"HDH_B+DC>I<YUM/QNKKL'L
M)$,)7.,RGJ6,8WZ@ JT!1F@*M$!=H!UJ@IQ1%>2#BJ!@E 5%H20H$45!&2@,
MRA?R@\J%O. &24[P?$EV<*\T,WB#-"-XCRPMY(PL->0V^4J6$O*W-"5$E*:J
MD:BX&TSOSW:?IO:!%'H=+@,W\'4%?^[FYZUA$M2'*%$3.AX58=8H"W-"<9@'
MBL("4! 6CKRP..2$I2([/$?("B\1,L)K)>GA;9+4\"72E/!!:5+X+EEBQ"E9
M0L1SLOB(+\A?1)2J2-#P(I>?E^C_3U![;X:F!L/77O[<R<\;&4=5I '*(LU1
M'#4-!5'VR(MR14Z4+[*B0I 1%8WTJ&2D16<)J=%%0G)TM9 4W2I)B%XLC8]>
M*XV-V2&+B3DIBXZY(8N*^9S<)Z(T^C%N<1Q<2.)<0-U=]+^;<]D/9$D6,(_Y
MJ&$<I7&Z*(@U06[<9&3'V2$S;@[2X[R1&A>$E/A(),<G(#$^0TB(+Q#BXBN%
MV/@6271"MR0J8;4T(F%8%IYP7!:6<%T6FOBI+#3A3[X7I:/$JWF6X^"L:C\2
M]7=PV;>1'G@E6<3WS8RK@G'D)VDA*\D(&4D3D9ID@^3D64A*]D!"<@#BD\,1
MEQ*'V)0T1*?D"5$IY4)$2J,D+&6!)#1EI30X99LT*/6H+##U:5E ZB?D#VE@
MBO@/R:+T*?;[:>9_/S6W<\FWKHSG(UG ]_7,1PGSD94N16JZ$DGIXY"0;HFX
M# ?$9K@B.L,749FAB,R,041F"L(R<X30S%(A.+->",SLE 1D]DO\,K=(?3,/
M2WVRKDF]LSZ2>F?^3D2I3\8_7&:_'Z?6GA+5\V X)] .+",=?%_#. J9D[0\
MKKES]!&38XJHW"F(R+5#>-X<A.5Y(20O",%YD0C*3T1@?B;\\XL$W_Q:P2>_
M7>*5OUSBD3\D<<\_)'7+OR)U+7A?ZIK_J]0M3Y2,DJOF MMYN(CG)#4WT8.O
MHA583.;Q?05CR2VG]Z9=BBS606BQ$8*+)R*HQ!H!)8[P+W&#7ZD??$O#X%,:
M!Z_2-'B6%L"]M$IP*YTGN)0N$^:4;93,+CL@F55V2>)4]H[$J?07B5.)*)FE
MHEC-F7SU<WFVU]%[-ZF?Q[* -#=S+#;2=S&>.,837"V%;Y42WM7F\*J>"L]J
M.[C7S(%;C1=<:X+@4AL%Y]IDS*G-Q:S:<CC5ML"AMD>86;M>F%&[3["KO2C8
MUKTIV-;\)-A6BZ/858D2%<?9QCW4V*)Z)@VMX5):@(X.>E^^%K8!*?PLLI7>
MC[]W;=;%G!8CS&Z9@%DM5G!JL8?C7%<XS/6%_=Q0S)@;![O6#-BVEL"FM0'6
MK=VP;!W M-;=F-IZ'E-:7\64N3]B2HLH3&D6A:E-:@[5\/K$XV_H4#V3E^?#
M0GK/;O8#R29Q_#F$>-(RSEH@@=T" TQ?8 KK!1:P6F@#RX6.F+;0G01@2G<D
M)G<G8U)W/BRZ:S"A>S[&=Z_"V.X=,.\^ [/N.S!;> _F75RQ=JH92_8RYUOG
M VNIMZR'\])2YJ!7?2]0*HGLH_\GSL2.3.V38T*_$N/[S3"N?Q+&KI@.\Q5.
M,%OA =,503!9$0OCE9DP6ED&PY6M&+-R.90KML%@Q0GHK[@%_?ZO8;#\ 93+
MN7KN5;.CDSE8S!S0DBZB1@LM8=EJGH]K@5C:LB#Z<E<RDTQ;3P]*^VR\20'E
MD!(&0V;0'YI$ID-O:!9TA[R@,Q0*[:%$*(;R(1^JAW33(@B;^*6--+4;:60W
M?$3H==>+$-:IV=RCKL$LT]1@JJF5MY'^<S,0NI5]L UPH%VV'*;^"/5W @:[
M)=#:HP=A#SWNGK%D"N$B< \7(WM]221))YQH]G!0[6'#]O"+N^EU=[U*:%!W
M_D7$450UF/Y'-9@A]@$U4Z@53C_N16OJN!>PVD]]-L.(_EC_*" _3G][@H;D
M! W!"2[&3XXC]-JGN"@]Y<Q)CXN@TYR 3W/R/<T!?UKUAXAX\%/\\LF;Y$M^
M[W<BCO(?-9@=G(^H&4$];^HY\BN6U!MW$C"D3=8]"T@N4/^2ALN,XS+CN,(X
MKM(D7./"_"G5HIAQ/!/(18'J)F5.<M?G$N;B.AMVG0=XYO_(/7*?__8A%C.\
M%N:YC&W.H';4,<#G%/6I.8VI,[\(**FG]:C^<H.H:B&W5/M15#41.?""'O 2
MC=(=&J:[]/RO30?>9!QO<6'X%B\X;W,">ILGW=L<%V\?(=?)QX1]\O8OH\^C
MJ6"NLXZJG\?K>QYP>I+ZFGN0#)YE[A_57U2UEU<?[4/1U$/>?50/84X^IE'[
ME\HHT;!\Q07[MXSC.R[2ON?8N,=)X!Y/NGL<7/<H=(]]<H]?O/<IJMGVG!,\
M!]AF_\N< Z@[E;JF;*?^B\R]:O_+ZQJ]1W60SS2UD"\?VQ<R6@N1 #_I +\R
M)W]PK#ZP4M_(/_IL5-7],)R(Q7[-,T%.:9[1>I..TTQ3=S#5U$$>W0.BVH,1
M2I*@O@>DG#1 O1=$77]0WQ,S2(;(,-3WQ!R!:B_(0[K0OYFXOQCLGX^>2?H8
M/VCJ#U^I/*_46%-W4&&DB4.U'\69!$!]3TX&U/?#J&HQJKT@'3S^(CR@[[]/
MW_\GUE%C,Y5VX%?LQR\XCI_H?G^@ _^>R?N.[[YA5%]K-%6H[DM1[<D8W8.A
MI?+Z!D1/4W]0U6.F$ >H]V"$\]O);$\N=<JH48N?Z;=_I-^^1[_]/7W_M_3]
M7V,]C[V5Q][%EA_B\<_@8^;B0]SE</D*[S#2MWFT_R-O/,;KJAAT="$*<KZ3
M$AU-/L93<SISIMJ#$<@VQ5(KG3H%U*C IZCGL)C+-G2RE8OQ'N-XAW&\B0T\
MYC:\@CUX&<?P(BYP*#_'4^@C9N1GGE(BKO\/1#V!_?'HT;O2T7S\#&-J3J&F
M(]OD3;TP:B6P'9G4**1&)7NZGAISJ=%)C<746(YGL0;/8!.>P@BNX@"GD-/L
MD:=PGM\Z.[I+YB^B?IJNBE,:1FL?"HS&H7KLS2^,XPOVS4<8Q[;9X#6.BSOP
MIU84=9(9=S:/6D2-2EQF'$\RC@N,XQSC> )]//8 3F(+1\1N'&4N#O-?',0+
M'"6?8Q\55*-V#]1/MGF$ZD\N_<73^IZ2IQOC^5!'58Y4L!>-. 5-8MMFLE<]
MV*9@MB>&.JG4R<$)%%.ADF=!/7N_E3J=U%E"C94\[@;L9"Y&A(/8+CF+;=*;
MV"+_!)L5OV"3MHB-.B(V/,8#(_7CAO[%:>5-\B+?/Z<J06OIXHK4%.=ETW!:
MX83CVMXXK!.* SIQV*N;AMVZN=BI6XP1O2ILUVO -KUYV**_$$/ZO=BD/X -
M^ENQSF _!@W.8*W!#:Q6?H*5AK^AWU!$GY&(Y8_Q&W6_X.7F34YKMVPXY5O2
M>W*Z?<)4P"D#)0XKQV/?&%OL,G3!L)$_MAI%8+-Q C8:IV.]<2X&C4LP8%*%
M-2:-6&72CI4FB]%ONA++33>AUVPWEIJ=Q!+SI[%X[/OH'O<+%HP7T:6A4\.]
M:9QJ9W J=N1E9Q:]A@/7V;SL')RJNBQK8\3<!%O&3L.&\8X8G.")-1."L')B
M%/HG)F+YQ PLL\C'4HM2]%C48)%%"[HG=6'!I%YT31[$_,DC:)]R!&U3+F/>
MU-<Q=]H/:)XFHLF23/N'+WFY?74V+V%NP'D/X!A?]W$9,&)/SV4EP;K)AE@]
M=2+ZI]FBU](92ZQ\L=@J% NM8M!EG8Q.ZRQT6!>@S;H<\VSJ,=>F#2TVB]$T
M?34:IF]!_?0#J+.]@%K;.T*UW7="U0Q1J'R$G9J/G7C9<^<EV(>7=S^NL<D.
M+WIO3O-KF9L^6WTLL35'MYTENF8XHF.F!]IF!J!U9@1:[./19)^*1OL<U-L7
MH]:^&C4.S:AR6(!*AWZ4.VX2RASW"J5.3P@E3L\+1;.^$@IG_4W$?W 2A7=<
M>3GV5==@CO(2MYMLX:5_P%M5_^#ZSDD;\QV-T>8T&2VS9J!IM@L:9ON@;G8(
M:N9$HVI.$BKF9*!\3CY*YY2CQ+D!1<X=*'1>)A0XKQ/R7'8)N2ZGA!S7FT*V
MZ^="EMM?1!2R7/_A54\N.ZAY)HQC@$NP$;*1E[F5_*R'N>EPDZ'%Q1 -KA-0
MZVJ#*K=9J'#S0)E[ $K<PU'L'H="]U04N.<@SZ,$N1XUR/&8)V1Y] B9GFN%
M=,\1(<WSA"35Z[HDQ>M328KWGT**ER@DDQ0-+S$'ET.YI(I2UV"VDL$88#GC
M6, X6AA'K:<!*KW&HLS+$B7>]BCT=D6^MR_RO$.0XQV-;)]$9/ID(L.G$.D^
ME4CS;1%2?+N%9-_50J+?=B'![Z@DWO]I29S_Q^0/(@JC^*FY39T+;/O1./5]
M0$-)7.-R";:4<70P-_7\?;F?'HK]3%'@-QFY_G;(]I^#3']/9/@'(BT@'*D!
M<4@)2$-R8!X2 \N1$-@HQ =V";%!*X28H*V2Z* CDJC@JY+(X _(;T14(40&
MJ;G!')REWB'JC]#_;B0KN?Q:Q)];H[G.9CZ*@K61&V2$K.")R BV05JP$U*"
MW9 4[(>$X! DA,0@/B09<:'9B DM071HO1 5-E^(".L3PL,V2\+"#TE"PZ](
M0L+?([\24840$J;FZ0@N>]GN_=3>GD'OG\FQ2!:F<9W+S\L91VZX'!GA8Y :
M/@Y)X99("+='?+@+8B.\$1,1A.B(*$1%)B(R,A,1D44(BZI%:%2[$!S5*P1%
M;1("HP]( J(O2?QCWI+X1_],1(E_E"@$:+A"C1/)G(^HNX5+\0'Z_%[5?3CT
MXW7,1S'CR(@5D!1M@/AH,\3&3$%TC!VB8F8C(L83X;$!"(L-1VAL/$+BTA$<
M5X# N&H$Q,T3_.*7"K[Q&P2?^'V"5\)%B5?"Z^0GP2M>5!,G"M[DR7B.A71U
M'6BH %A=!"PA[?3C58RK@+]+98RQ"7J(2C!&1*(%PA)M$)+HB.!$-P0E^2(P
M*10!2;'P3TZ%;W(>?)(KX)W< L^4'L$C99W@EK)7<$TY+[BDOB*XI/S(]Z+@
MFOP/YWC\0UQNCJCVXM"#K^0R?!'MT=P2]@/CR&5.DAA+1)H6@M,,$9@V#@'I
MT^"7/A.^Z<[P2?>"=T80O#*BX)F1!(_,;+AEEL$ULPG.F8N$.9D#PJRLW8)3
MUEG!,>ME<D]PRA0%IPP-Z:)PFF-@']N_C;J#53PGJX$NTE1)S\//,HOIO?G[
MD#P)?',,X)UK"L_<2?#(G0ZW/">XYKG#)<\?SGGAF),?C]GY&9B57PS'_'HX
M%"S S((UF%&P$W8%9P3;@A=A6_"=8)LO"K9YHF"G(E<4CK&=N]G^S=1=4\]^
M:. Y2>KKU?M04AE75 40P'C<2G3@7&*$V27C,:MT&IQ*9\"Q= X<2KU@7Q:,
MF671L"M+A6U9 ::7U\"Z?#ZLRE?"LGP84\M/84KY;?(-II8]Q-12$5-+1&$:
M.52LV8O32._=PGYHY3G9JMF'T@PDT!*$,B9OQC2[3HH9M0:PK37%]%H+V-19
MP[K. 59UKK"L\\.T^G!,K4_$Y/H<3*JO@$7]/$RH7X[Q#5LQKN$XS!MNPKS^
M*XRM>X!QM2+&U:C96Z6Y'VH>SX<.]D,G^X&4DHSY0#0_"VAG#H@]+;3E/"U,
MFC<&%FWFF-@V&1/:IF-\FQ/&M7E@;'L@S-JC8=J>#I/V$ABW-\.H?0D,VX<P
MIOT(E.W7H6S[',IY]S&FE:MG%7-%[*#^1AY_I>JYO-WT_[3(U3WT_R21A!)/
MXD2LB04Q[=&!T1)#&"XQ)Y.A7&)+9L-@B1<)A?Z21.@MR8/.DEIH+UD(Q9)!
MR'OV0=IS";+%[Y*?(%\D0M&M9BO;.;"0.5C"Z\,RH&$YYP3-O4!1M,I^JX Y
M9#J9M)H>= TP9JT4N@/Z4 P80;9V'*1KIT)8RX706OK+ 5[\!WCQ6<N3>BT'
MT5HF>"T/MH;^;LT3//E?!E;1&*[ZBPT71]FPB"_4[J'N7.J4KZ7_'>1\L!X(
MW BX;@+LR&3Z<[/-U-\*Z&ZC#]W.Q>]V+H2WFY )A(O 82Y\AKD(&N9%9I@3
MSW"N^@%(VYG<[3S =AKK;?2Z6VE4M_Q)&,-F<;0&TTOM]@'V :UY+O]I G6"
MAP'W$6 &PY^RB_J[ >5>0)L>G8MH3BHRHDL8QR'&<9AQ'&8<1QC'42Z*CO)"
M=)03[5'5@\DYD(XP@4=X@",TUH=IG@_]0OXFHKH&LUY=@RF@+4_:R3' ?^I.
MK9G4FGR(_7\$,#@.*$Y2F[:=AD4#3<DYYN,\X[A@3+A ?I(+U$N,XS(7)E=X
M,;J2J7XP]17FXLH6PH-<H:&__#6AH[GT$ N9[T;FMIC:*?N \,,<@\>H?X+Z
MM.<F[$+]\X#THJKN0JZI]J%HN$Z>)3=IDIZC2;E%4_"\.0T"%\0O,XZ[7(R]
MPHOR*YQP7^6)_RH'V*MLX&N7R%OD._+;: VF= ^0SO9&4-?K#/7/<?Q1TYB:
MNM<T6C<U=9>7-'M"[FKJ(:\_JH=(@'>U@0^8DX_9-Y]. KZ<2;A(^HH7OJ\X
M$7[-D^\;-OH;CHMOV(AOWR"?H9PYS^1'4=3VH:X]=2<]!1BQ?3JJ>L]_[T-1
MU5P^TNQ!>?SY)/_>%\)Q\J,>\"O[Y@\:E;^8C[_]@8<<&P\Y&8H\ <5MFN>B
M7B7/:_8:/*H]F(QZ;I&>6[T'0_5<5-4](*IGDA9#_3Q0U5X0U7-!5'\C1G5/
MS&JR_O_S%]$-C46Z3O5=,@?PD-[P 9WG?:;R3X:O>C:'JA*BV@WR*]2[0515
MB4^AOCM$O1O#0(-24Z%1[5!Y=)>.ZBDAJJ>4YHU69QZBCL=OI:?NY/%[>/P^
M'G\-C[^!#GH;U793XS#NT:M^AZ?Q#=Y@TK[%E_R6JA*B>AK'YYIJR-N/*A*C
MU1#53@C%8Q4)U=-*9D#]E)!@ZL53)X,:A:-WI]Q# X\_CT?NXO%[>/P^'G\-
MC[^1';:=;=L[>G?*^[A(1_T\_H\M?IU1JNY,N:M!=8?*"U _5U9=A7A4D9"-
MYN,^S/D-*[9I-GY@+KY#!'.71(UL?,)>^A!5/'X#CS\/;S&.UQG'JXSC+M9R
M$&_BL4?8"P=Y_#.XP5P\PW_U%"._QBQ>A?H^ILN/(4K^\P\2_0(M:AJQ;19L
MTPSJN>%=CI0W$<-VI%(CERTKP2W&<9-Q7&>_/,U^N<8XKC*.RQC@2-B,"^R3
MLSC**"[B%*,ZP4P=9\^I[J=2U=&.:E"]'_TC2% _#/A[S:#_$/K4-&.^+*GG
MQ/9X4RN4;8FC1AJ/FHOSC.,LXSC#.$XQCA.,XQCC.((5.(1U')G;L0_[L8?_
M8A>_O0,?,#L_C=;SMFO8ID&U,^8WU<UO/,$^Y&3\ADQ5')6SC8;4G(!+L*6>
M,X_DAY,(ITX"1UPZ,YU+A1+V?"5;W$"=5NIT46,IC[N:9\D0_]O-$7*<Y]$5
M#/)T'V"&UW)LJNXW6RW\PY^<9+[FR?V>&2<DU68\53&:D^"3$EV.;&,>83(U
M9U+/C4<,X-D7B6$A$=LDZ=@BR<60M 0;I558+VW H&P>!F3=6"/OPRKY.JQ0
MC*!/<1B]6D]BF?;+6*K[#7KT'F"QOHA%CZ&JRGS$2>ZEJ>H=(1?X_M187G@X
M$1_4,<!N+7,,ZUAABZX3-NIY8KU^$ ;TH[#&(!&K##*PPB /?08E6&Y0C67*
M)BQ1SD>/<BD6*==BX9AMZ!IS$)V&%S#?\ [:C;[%/,XDK62NR3]\.5E=]+[.
MB?8".6X''+ "=G+2VV8BQ:8QAA@PG(A51K;H-W9&KXD/EIJ$H,<T!HM,D[#0
M- -=IOGH-"M#AUDMVLSF8I[Y0LPU7X'FL9O0-'8O&L8]@?IQMU$W_DO43'B
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MF]Q:86S[@=@NOXV.!P*W#&*V]"L$'998=)AZ[UEKVQVT<K/]E-JM\&^D!BF
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M1E:FW'&%W DYN!._W$6"?C<)^CUP[7OQRWGT.$]B<)Y!YSR-^CR!?9[*GJ?
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MC4&MJ@_J5EW05-4&SU9-\')5AVQ35>A1583>HO*P1U06]JK*PK]4>;CE1[E
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MX6!@0E8RL"+L#)P(&P,_PLHHBK P2B/,C$H($Y,.PLADA# P[T3HF9T1.I9
M9 5+/$+#<@VA9GF(4+$T0QJ%G_%($M1W$ES#4(V?D2GPKR/XDSN!EVWKP T!
MDW0]])<RN)&RT#?BT#>"G&0(%SLUPLI"#W4Q(4S,[ @C"P\D882!11*A9U5
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M-( *=2"=1\(EZK3H+0D W:%B:$ 9"F"!!MSY5URFHP!UZ#DH"07 6Z, D6C
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MB=[B1*11 /30)#%BT.X#0H4"Y)!PB0)TBJ !XRC$;C2@"P5(1P/08?D#1B@
M:JK%XZ^@9BE2^^ H.1%@B<W[H[][2E1;20'X:]8N/L?B4VZ7OOG'V\_+]!<-
M+WG*VIAQ=*?&&E%^3B9J4H,4GV-.O'RCQLU'XO-/("5B ,F^'8(0<_&*%( Z
MJ$6?+2((ZC#8E 2 .CP,)P%H$ /ND0#XB0'M%&@ .4I04B1%H#QK4BY1>NM#
M D!=5[E, D =)U72H &YQ  LR21U"=4,9S0 [6!DH 'H\Z8^]#;);A0 ?YJ:
M&( V&/&##L0 M,&(Q[\P)D:0 /!UX"DQ<(O)ZVS;XQ.;M>0=J=;/Z-EQF?X+
M--C\JN9967'1_;NYV3?1P0<=H3MTUHGRL-+^->,3'^SYD>@T0AQC21*]@""^
MQ%60*#VB3PS81@+@)0;$D=9!?$CRE!1 W(PQ'A( :G< /2H0Y#HQP(T$@-H-
M/DT"0/GV120 E&_?N0H-V$$,P*/7=D0'!?!' ]!63@YJ_P'A1 $^ZZ&+0 '0
M,3.D@!;T?O$<&I&UEACP%@W 7_QKPJ;FEM7;LT3TT$TGG^.)*;=+7O4N7^O[
M?TJ]BL=^_R(Z&]N_^?>?ZXJR4\\E1)\X%AS@<_B0RWYB5[WTX!99'F(ME"<N
M *U?"$)!#$!'*P$1WZE(( 406RWHD&N$9#BO(0&X$0-L2 #;B &1) "4\442
M/((($@.:N=  .F+ C_4D11 #\/O_%8!45"A *<G<.4H,&".9P-%N+,G&:CD*
M\!)MIZ+/L/"G45P<10/&?8ATBM4!#< /^+ +R:CI[=A[).)R0>.2S[JT#ORK
M]^*6Z;^/9KY-C(T,#0X.C1'__OV]Y*A ]WUV5F;&^KI::@JRDJ+$6Q+&JU$'
M>>B=^I,D2H]:BTF/59#UQ$R0F.KH_8)#I$40 TAW/5" 6I+='83X_&A,F030
M15R$+0D M<,<1@) [1=D4Z,!J*W9)I+H$?0Q.?K0E&1#X0S:1D0?4;U"SP\D
M.^E1+,0 ?C3@'9H+- !?OCB/,?'+:)L?C,Q<XEKVL^"X2UD/JEH&2 R:9?H/
MHY&>UOK:BK+B!_FYV5DW;F01GP661;K;;MV@*B<IPL_)0D])4(N51(!6*I)Q
M@U(H)5( \>!=PK5J) +<)040&S$])$>>R'EB)LQ( *C38=+]'Y1/<H4$8$8,
MJ!%% [10DC9& R2( :0[*RPH0 ;)X0X*\&[KOP#@3Z(WB-& NAW_ H#/_.LN
M *V TC:W)<+3D]4WF3EXA"1<*:S[PXM'@\M/'?WOH,&7CW*N)I^.C3Q.<(+<
M7 X<<"&V8ASU%$2YF8@65^*@RE"2D8?:62$]%$&=BLRHD@ 4B+DD"=Q ;P>@
M+Z^1C(MROG\!^$3JK*%$17+NB@:<(O\7@$<R: #*C!\@.5=!W^(_S8T"E*(
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MF"&Y6H*^UW&,!(#R0+))3!#4\?$;DGE.E!@PY8(&,*!$E;@2C4 !'I*$EZ$
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MBGG:CV./>;F9:)_T2%Y/^< WX<%D'AHZX7!41Q_3W>' ')(XO6TL\J:UFT/
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ME8X$'YH++W7$ONAU2Q6GU3+)R%Z]OV#KA\KU@FO+8SR$MIWK97\RW5AP1-I
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MZA#,=:C/F^50[3Z0B968[A^;>MR?<^I]0*Q%ND/3_C4/-$^NO>Y:MM7KA%_
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MV/>Y14-V<)C:L4AE4Z4#<PD115G2H (BF;H!Z!?79PI[!A_?'PGE\AR2R2?
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MUS:W;>Y[/ YYGO0Z[7W6Y_R:B[Z7_:ZMO;7N[OH'&YYL_'G3*_3; %#@(,P
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MET>41Y9'E4>7QI1@"W'Y^!Q"9FPJ445*)$LI@C@VE4J+I4<Q0IEHEA_;C>/
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M8=&$#VIGPB+ AWKTT-2Z_/;_Q[-=^$69_'$ 7PLQ0"S$(!0%$4$01$)%$4%
M$.GN9;N[NWN737;I3E%$L+OC;+TSSN[N_O$[]NX/>+^>>6;VF9G/=V9)@=+^
MNB:2@'K8=I#T%/*@>BJY*/N'J9K\./:6@4NA+GNF7T)Y.;/%<)ER<[@/ 6R
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MYNT?_=(2Q?D^HO />J8KI.#%'00Y-J^WY;XL9U-Q(T6:L]JC#BRQ+"VN<9.
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M7P7^ME-5][S0>_OTVH34+3T[;/080T>U=5'(T]9)U4COOJ8JTP*7K":>;#(
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M'F2+HE3[N!G"1.4VW'I!B8)4OH OD/NF+>2=D;Z)?L>+E0+\+W)_2FJF>?)
MXDA[':!-6&;:P;$(R,996 %?HH\H _':=7%;$-QW&FET)A>HCO%'<;ZKW:<^
MY'K(9]N5EV!/_3[.!/Z-6@/F*>^N;6[I&>X'BRSU"G>E*6_-$&>;X<.2-YQ(
M0]S4;9RI,OM)L7*?8$/'9[:1#VS+QI3SRIHWE$9SRQKFI^9PC+6F-5F<B37
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MU54'"><AWW[#A-P@U-8FP],$^VRGBY[Q!ZN/I7)YS>:&=6'<0Z9%04*NCW'
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M?6)$ <M:LO.WYDUK\BR:F?RFP;L$N+:S+K],$?RN=EP%V.MQ[72@=-+W^MW
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M)R9GP9N'B)1<=/V7\JT%137FU+%%WZJ/1BTN85G&>2\HVF#P&.=$(O&@;;/
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M,L&K2:_B<[*J/J1X=EI?34VJ=2:_*C+8(7M"(W$^GK-(_7U99EZQ'/N74F1
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M]@&:0JOVU(?ETZHM/T-/T-H,;Y<MH\WL:U%& >OYZU!YA5F\$\ %P!B>1^I
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M:*"D?ZDH#N=;!CAP)3<ZZZGG*%>=ZV=WE?L^WW?E#=XE -OH ;\1\,>"LU)
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MZQ 7')^9@$SD)M4G;T\YGGH[[5/&O,RU63[9B3G%N?@\87X=H+]@?^'9HCO
MM\4Z8!/(6J@[+*@DJ30/#D:@D,0R%DI<KD;78]HJ>K';<"/X?80CQ&.DT^0S
ME-/44[23]..,H\QQUF'V <Y>[@AOB#\@Z!&VBQK%U1*%E"LCR<L40&6&*D8=
MH'&O7%>UO'IN]>^:=[4/ZJ[4'VO8V]C?U-0L;2&WPMK2VT,[W#LMNN9W_>A^
MUG.U=[QO:$M+OVR LK5D,'-;^';/(:MADQU:.U[NG!HYMFO'[K8]\KW4T9)]
MF?O##VPX:'EHX:%?AU\<F1H[.KYCHNVHXACU>.F)S),AIYQ.+SNC?>;YV<OG
M]I_ONB"_2+A4<#GRBNO599-:DX^NG9[:?KWZ!N5FX:WPVPYW%M[Y<'?RWM[[
MC0](#],?N3^>__C)DT-/:Y^AGD>\6/7BS<LCKRI?8]^DOG5_M^#=L_='/M1_
M1'^*_+SZ\_LO$U\UWPJ^VWY__J/K9\XOHU_#O[/^637:3W2[9CGHLV<?F//8
M4,]HZ=R5\U;/7[E@^4)3X\4F"Q<9+=9;_&/)^Z6/3">7G5I^9<4ML[LK[ZZZ
MO?JZ^16+\VM.6HZMW6^URWIHW8!-[_I.VU:[9OM&AP;'6B>-L\)%\F<U<-U9
M'HP--$^:%VTCW9OI0_.E^I']R9O(FRD!M$!F$"=8$"()5895A]=&U$4V1#5%
MM\5TQO;&;8T?3MB3>##I:/*9E,NI5].NI5_/N)5Y)^M^]N.<9[DO\][F?P1\
M*?A1I 74!6F#?A?_ '^#?(%^A+TO>5/Z"OX<\03YL.PNZE;Y%/H*YG3%$>QN
MW%9\!Z&.*"=QR$0*D@JD9=!C&8',#2Q;]DK.0LXO[DO>=?X)P2YAIT@C9DE0
M4H L3NZO<%":J0Q5W]1/-=<JCU?MJ>ZJ4=72Z^#U60T1C9Y-ULV+6_1:/K8^
M:IML/]&QKW-;5V=W78^BE]='VX+K1PZ MP(&L[:E;(\?BAF.W!&V,W0D9%?H
M[K ]$7NC1N/V)>U//Y![L.@0['#Y$=(8>UPX(3]:>:SA>,>)_I,[3QTX?>S,
MA;,WSCTZ__;"]TOZETVNK+YJ-^EU+60J\7K>C9*;A%O<V^H[]7=;[W7?[W^P
M_>'.1WL>[WMR\.F19Y>>/WSQ\97>:Y,W%F\=WFU\'_PA[F/FIZ+/L"^(K\AO
MI=^!/])^AOQR_FWZS_SKS-*=G 71GYBC;^!FF&0$FEL^#S^?N("XD&A,,*E8
M5+88LB1O:9)IZ#*OY;8K/,S\5P:LVKS:Q]S#PF'-6LOE:Q=8Z5E]M7ZU[K[-
MY/I3MH?L=MKW.30YJIQXSF27,E>@6Z9[K$?@!D]/>Z\U&Y=Z&_EH^7SR?>EW
MW__ZIHN;3P:,!>X+&@G>'K(EM#.L);P^HBI2'26/EL:(8H5Q@GA^ C]1D,1/
MYJ?P4_EI@G1AABA3DB7+5N2H<BOSJO_HA8:"IL+FHA9@&ZB]N!/<!>F&]L!Z
M2WI+^^!]B#YD7UD/JKN\ ]V&::YHP-;@-'@%04SDD9AD,@5+1=*@] )&%C.1
M%<'>Q-G M>>MX9L*Y@IUA)]%+\7W))/2T[(C\MV*K<H.5;U:J1%4TJOPU64U
ML-JBNKSZS(;4QJ2FA.;XEOC6A+:D]M2.S,[\KN)N1 ^^E]DGW5+?WS>P=^NI
MP=O;W@\9#%OLV+@S<:1T%V]W^Y[#>^_NT]Z_YD#P0= AWN'>(V?&WDXL.>I]
M+.\X\T3GR1.G7IY9>-;M7,IYS 7UQ>V7SEY^?E5_<O4USZF8ZP4W,#=YMZIO
M=]T9NKO_WM'[IQ^<?WCAT;G'IYZ,/=WS;,OSNA>\E\A7&:]SWF2_37L7\][_
M@]U'DX^?/EWY//1%\K7PF_.W#]^W_2C^:?QSZ%?LK[N_4=.?_VNZDED&^BFS
M:7,J#5H,VXV:YJKF,>>7+<A?&&/L9;)FD<&B-XNO+-F[M,F4M8RQG+("8U:\
M,G55X&H'<U,++8MG:RY:[EO;:26W)JX#VL2M][:UMEMH]]/^F<-5QS&G;<Z-
M+F)7@AO8/=4C9(.;IZ67\4;MC6^][_E<]!WSV^'?N:EZLS" $H@,*@Q.#8D,
M]0MS"5\;81II%/D[ZGWTDY@;L>?BQN-W)_0GMB1I_JP#8BH\+3\],2,X<T/6
MNNQE.08YWW*?Y]W(/P785["EL*Y( ,2#BHM3P$$0%^AJF!'L2\G#T@OP_8A>
M9&49$U5:GH8.P-A6F%1\QS[ G<;O)#02N20$.8VRB6I-FT?[0+_..,SL9DG8
MY9QTKB_/@C^+_TQP5C@DJA93)(72<)FCW$3^17%+.:;J52LT^$I 57BU<\VR
M6NW:9W67Z@\T]#96-K&:42WYK?%MF]M=.BP[EW3-Z?K9_;[G6>^]ONM;+O>?
M&SBY]>C@V+;#VP\-'1H^O&-\Y[&1T[LN[KZ^Y_[>EZ-?]NL=,#YH<<CE<,"1
MI+'B<>*$[&CGL?W'KYQX>VKN:;LSX6>+SM'/-UTX</'.9=TK-E=C)M'7ZJ;&
MKK^^N>)6V&WTG9:[9^_K/(A]6//H\1//I]QGDR_L7])?77WC^E;^[O6'V(^]
MG_6^9'WM^_;IA\]/TJ^]O_\L@'_\B$?QM#.TC-,UM&[JZ>$I6@V54+^8UD8%
ML6)H$U0.C$/[13V8>(!>1//WUF*8T!?\&*>211X/=E"+!*6G JBYO%-#M50$
MM[AVDEK-"68NHUYCQT.S:,XL<,( ;2NS9>-B.I;QZ-LHQ;,2=>\[Q46E/'&2
MLDE^=KL/!2K-JU%1MH@=Z*^ILX66D#AJ!7]1_"':7*Z65R#M"6O+E_MDIY:1
MNX%D]X8#Q]W)L35O!@^3.97IU:'DVZH5M).4>-E[<!KEO'A'W&LJ61#KR:.!
M.3F?O4A%_;JW.TC%7<^/]I)X;89; :3CC=#*+V3[FB_4[>2MFI%B!"58$1CG
M1/DI)FUX2/W ??UQE'AB5^HM9^+1[8LG@HD/MBP>6$YRZ"S0W"#5-$]1VLE6
M=9D@#?F8ICN625'(&!NRJ0I^_@<<,>E([XT7Q+!1MW$#8NX.PRU?B5T#ONJG
M)/.N.O(UTL[F)\!),J#F9LQ+R@9E@L<3JK^@ZWT1X?-9[>N3A/L3 4>^$=[M
M>]#WF>BSXX5:A[AKP(IL0<KN# !&D!<V/(Q!DI^I[WL(*)^%X^\J",-365//
M"57GW(XL(#1-J/N6$>[O@ZE\B<!A& E'FM<74'28=*JE,L: O+7*W<.?LE^T
M\U4R_SK5\RJ7-T8Y?+")>X12UB/F/**D*I,X=I0*TFPVES)1-,9Z2]T0(V/A
MJ4\W*/^YL_>%/X_"/WEE\9\0*.! "8?%N=]=Q-[+/J18S39CW29<8JE9CH7U
MK%5,2;22>82YU&.2*6<<>D;DAJM ES"<6/G4OA]LI!3=9<0:$V?(7K*\A3C\
M">8)_KZ"G4PH3S?J-',=)\;#G3F;A7QRG1/?\.O"'79^+6:4R))6+>[H8SY6
M/9$.,\L51KB]S"720, 5QE$1,&H9HXH/<6]EB#AZCW/8HN[F\Z6LAO8E>Q<R
M+S7M:<]F>M6I)73&X2H-=@\#K]H+F,/PEFV/K&"L$('<K1CF7-(C+=;;H>AS
M9BR]_CV[3S-]NC/:W!AM;8YB$L.ST:+B&/U5S>+\*/I^U?6(!_2M4A^WW?1#
MO+,/+K/0^[Z<^<;DC:3MVL$8';S7ZLQ8U]LM:J*/M0LKC.FLQM2\+GI*U?D(
M*#U9?LT-0"_G?[]_A37_6,>964RK@_=&)ACINY-;HN@'MGT3GJ,7].[%E-"=
MVG+R;.FSZS01.O39*E\W4[J+X-=]+>:^BRFGO1A73F3N_,:8?:BVF4]'[%XD
M7$LW'FQ%3]'N=>OGCM F&G^&]]'.:=)<;]"^"Z_>,E'<(P\>>R5[2RX:VB9=
M1O9I]!5#R.%\B? 6658^+H!2#'.->3\HW>$D;@U5Y9;(\::]O6$G'^96'55+
M#W&2MBO%']A^#9ZB=%8V3RIXP-R)NL#G,_US['GNC,FPW9RGC%;7D^Q61L-4
MFTPJUTQX2[JEZ=O*13?%F^J7"-.%95P\_PO_6MDYW@X>)#N"B^/\")O%"6,W
MN::PE[,\K@5)ZVJKQB;%!ZI*!V>+9JM+:H\)F(IV3A+?6[8*>8TW2]R=Q>),
M"M>%(ME[>#*7%ZQF]M:KKR1WV]5'>&*#9L; 'F%V?5V-C'^K^@';AR?1Q"/>
M<$L4ES//<**D'B%/V/[";!<%:P/7Z,H.2?1 _>$<$:ZGH;]&<*)]K)K)3VHV
M9<7PYM11$2LX=ROO9=JSSRA7A:!9Y\2_74*94[R0RUWB<[O:#N4(?V\?W-(B
M2-PR557'N]EEQ^1RZUJ$<!R'6'<NHX5=J#D78L)"RTI=9C$E_+1+A\6PPYT'
MN<*&O=O[SO+?#E^J/,\C#9@PSG#]N[)+[W-LFYD9GNRE-7'!AU@VBGKG\\PX
M0> E/?&B4ST'+@MCQYK[S/EMHQV5-CS'X?T,+\[;+;=*P>P[[9?3+[&NU<.#
M\<P/*HYS%]-,..M,?)T9B;ZGM3J3E-CY6K.%%/;'/[4AH:E/Y!.D*5BWM(*,
M2^.++2G>096"P]0$YR!>$.W>J8;:!>P+NQE5?JS]G?KJ*N9EI8?2@FE%722[
MR.B'3DFJ&46I$Z),AFO@#X$QP\OI-;>303P95&,L7;,KI#)4[-3^5=4@S%(X
M*;SXERD6TF\\"E1'?)X;E3I?V,$Q#\3PR]B&3AU<,^:W$VNJ5U=)1Y9IBM2[
MVTXJCRNUY6;R=)F8O$KJ*$F$6(@7BVQ3,@1?^5\#WO&N<P\Y@3A-[+QCOZN*
MFS_MG*WN;PAIW:HTJSD@_2;;5PDE64@$*G=PHH@F-T[>+X"+3P<(>;F" B<G
MC@>GY>B+RLE>P/ OM67'U98!A;*E3&HD\VYP)<9(#&ITBJN$7]1GDCWY;^28
M !?N:]%%Q]_L2>ZAB>^5P*$#PQ:J@8&TYJL*\YY9DD#IL;;SA$9Q2V-7L:%0
M55.4-,%GJNYM?LR52><Y3K+%O+T33I6Z^Y8/@51Q.\>:U\@/#I+%2BFT-P3_
M2QS6;@P2"$,:]B25\#VKEF[NY0;*C1QWL6/X\G&.9NL$:OMIY8\#*YL$\O*1
M"=$OZ:I!')XD^MZS'F0A^-6R/6D%[V?-B\UE7&/%8<<F]@I!P &+=AZQ?\OQ
MYF]$22VM@4RLY"^N-2=.5I17WB*E%0ZK.LAS$^SDV>2G_G?%KZ@6#C"!+^WB
MOM:V>E99W[VF=TQRS9EZ-&,'#U%CSK#&C&M>TR\4&BJ/T@?B!3(9O=,?(=Y
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MVBZ!NV^EF/-,GTQ5S!HE76BHT.R<O_<WUFOKG@XK[/<>M=0?]Z!-@DO$/VM
M QA$_:JYD9=(T7)W]UCR83[D\6-,_5'4^<$*FP.O]BZL.+R+U.Z%96ZSEP!P
MJ)XOV#H\JW4@_QVAM_9'9![QDW*OVP\R1B!^;(-)O1!X[A/FVO&Z/3$5L(._
MVQ!8JUUT<2MNT>"2B@]X^RY^/HR0W2B-^$K<IO[F-DKV%#+NU;"-\6:G)2P.
M'K]K)6L^_F[K1F8? 2@V8.80YU:,,LV)U_+IC#>D(Y&IC'OD%^YDIAZUXLY=
MII39<RJ':<IX-&+"&&)L;EG/ -$/"9\R[.DEF&:& =T[#TW_15\>4<%80C=W
MN\/(HD?>3F0$2@)/'*)?$R%V5-*9@EU-X_18_B;!=KH3]PU:3;?E[,^5T3>P
MA>%[Z$!6AEL:_0!S]LT#]/55X\>M:4?5'X:U:61E4&,.+4&VFX^A14L0Y3Q:
MCL@U9X1&X]\/7T0;YV)<;](]6%MNA-""6@./#E'O-9*VUU*;:R\TS*;2JZ)X
M@52FZB9*0.V5J[)?4^](+,)(-&\!W!5#V\-QF?I&E6_9/X&ANG;K;2NBO&K+
MJ+M/N=@XSO6GW*Z-*&NDSM6<R_:FIBD\0S]0#XM]7<UHB5SIM2=4G1&W\5)*
M^S;J8 XEK^]H[0-*<.<:3AXEJUF!?$11UK[+:J3<U9B&,J@YTO,NYZA?>4>N
MS:-4':H>JZ3X[+FWE49^.;RT5I]\NC^6K2 _[JQ#>E,<FZYFK:#PJH^$KJ'.
M4=B[J*A;^6<FBRE1)U\=>45^-68S,$ZN'MU0$T)&#ONR[I#Y6S(0G>3+[8#,
M+13?^L4A%RG'5/XN152,H/_":_%S[+4#2A$9E]ZW3^B(NUF5S_^%)S-[>(\(
MP?^'J[.(CBKAUBCNT#2--"YQ%R(03X@0-T(("4F(>RKE7E?KWG*W5%7<W8'@
M[MKP(\'=&G=]/7[#,]B#L[ZSOK5GI_PB_S;3(^UO]#8K/)2%O&77NVY%EG!+
M+U)$:N#@OCRA)^#7T8A_X%W4;L6N\/A@+_\2+[_L*?J 5[@E"/G)8VTX@SCR
M1EU>P16 _05KX2;AKKT+!9,%GNTP=A([I?'@[^>K "-Z 85+WR)?$45J.>((
M-VQP@&G0?A<)=!F\=.Z<($3=O'L(^Z+T;IO+/R>[KWJ&GI8,\JC(1]%0R3=D
MK>#0Y@Z8C1T.,4-C:*_+>B@:WG86Q(MKD-$B;(W1H^4D?YSNFW( G:*^SLU#
MW!3G2A;"J/1&RC?HMNA(R$HH 6<XOP7_08Z=2<?VM17OBN$SF[R:A]#4NNF*
M+B3'^"^' 6MT=XHCH&>J<RG;H$TR4_  >$VTR'D0+.///%V K1T(W9F)ONNV
M:3J.G&O]+3\)WVBXPQZ %YE/%35!)'W=INO@+95_<"I(E'"= 7 A9G.JCG]\
MSQ\[3*AP9'S3."2W]XI\$ES27L_Z 74TTHIF0O/-[IN*04S;'#P37"%K==X,
MG,.7G)K!IQP]NV,BZK?O0&,:,G<'1Y8&S^NS8N5 B6V7"R7@@?JB35/ 0$-?
MT%'@G@)W]@ T^,/#NS5?*+?[3ZD&J,3:2H6<-E>LEBEH)QD9DG9Z1_XOT6G&
MSJ33@A?,YX%'\-GL4J=BOB4W^Q!;?9#GT7=!"7.OU2#R<JY*-")E<HET5-S
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MH)];)%_:P> RH,<M1*X=):6AE/.I,+:FC/,^;65U-G=!]&1M,'>K?[GB&W?
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M-&G"SP[ETJ>8P&(?KD(8-YJKWI3;'VLA)58<&7 @-Q%2S:LHSZN>84,T5Y*
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MG]'WA2*Q?T AODY0Z<9'?_$!ZS_A8S B[]3:U#V&^:J=YCN44PJ/:G9AAW1
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MO>$T)A1=>X'^)S155D]O!GNXYQFA8&(YRIP(3LBP8=X"]D0O8%T":#Z9["^
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M$*H9*X;<7YC6R*/LUAA8ZAQE;=M.QA)^4DL_ZR@EJZF>\[7H80.?'YF^J"Y
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M(&7V,=@MY!]>F4%'?*1<T1\B#I2\UETG2K,&M;?P:PF-Q&N\)'PK,05[ZB_
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M#;2J<QLQ&IFITO_->,D^IOK#)O/&<&=S'POB*BX+K")SEEPLDKR-,<J,<EF
MH_*C*M)UNJ9=D]\PABP3D;5+:#'B1\IFQB=I,?L[>YOL4/D=WBI%4.8.X67E
M_IB_I8%JRJ)7BD<:?U</X"#D4[>^ZH7:AR@GOU2_4C!H5X%ZUB/F&8US^1S.
M5\V!S+D")LB+[I/\#;DL.BS_#'US70R,A8=JZRJ.88_QO.J/V&VYDOHWMH[U
M-\,?8Y:5LFLPAXP.OB?Z(CI//!K=M6BIW!VUN&:KN6BE=779'S,;TU1EFMIE
MF\EZ8P.SF';%P"_=S:K4IV;8\]QT[M$S1![:"8O,,@A_Z%JI>HZMK?E>6M^X
M#KU2\:-AFFP**:/.EW&$NMWJ6AK )%GLT]=R"TT+%I\40H89BV32=]K/KFP5
MA!^K04K SA:TM/Q[>XBTOKJT1<%(HUQJU)=<8#36=:73.,MKMBPV"UZ;#BQ*
ME^+Z?UPE*E=BLWF,Y)]"%,Z0#I6*Q<_D[I79M N*6K)C<9)J/'ULZH!Z'7MN
M)*"1\\F^UR&=9*H3AEQ1)AMW";.K_H*"1#?)OJ(G$AXMC?I9-HE)*6J5G^68
M4QV5._C7(UW5I\5YOH= %[F#TPYXN[K( /$"&1K->\$DUB/AD'"(&TT=(]['
M;RN\)=TG_)W2)7\KP2-NJ-+D'KX;@=>JZ4Y/H9V:&'TPFR)X!&SB0B*K8 /?
M*'&E! I[I?L*O<3WY&4ISK)<Y:2(3L4'U5W?/O55X);S9/ .-$+[F_%9Z:_N
M8\>IG/GKN8CJ/[(O_YCZ9(%(% ET)%LD[S5@1)C\#"CPU:J>0X#S(G AW$'\
MH+U$F*H-S"JDCW>&?0C90:+Q0I M^8<%-Y$-R0O$.Y =X5]DIY#3OB+5?.2)
M<[8&0H<1[M1@ UOYBGY*_XXWEY6I#ZT^Q'FLJ\X/X&_4&I*VB'80V\)/2-_@
MSWV92AX^PYD%?,5"<#WY:IVG,I>FM?[D$DR;&D5U./NL^4C>#MY.T_2D).$S
M R-<+XW1#?J6*^YHASMK #,>C4\E'6_M4MREFIOW<L<S%C4RJTZPWM5=SROG
MOK&F)8T6!IL/A6=)-AE#?<,40MU29PL00,R!+P%@X1+9*,WP4HC5I=E4F5M1
M!TK)SCEV4#Q]2OPJV(OM$;(9">1KO(I1N230H01[IJR&!I1IE3W2Z2I/TG'F
M?O4LZO/RN\!$YL3L-LTL3G)\.AC#7QVBA2SB<"\*,E5NZ]"'#JI+P!I9'KU.
M_%&.LD8S+BD&.,KRL<K+O.=9[]5SA/RX:X!6,CTD&9PJ&_*B0E>5+QR>(3LT
M7AJ1N(_/%-V0CA,&T =E=-&GLB3Y8<F6K$QEB@R,XZ@^**I#I@'[5%5>-' ?
M8':TAR^#UX$*888\2'A)]%!10#LGX2A)I3SI%U55Y@7Y*C4S;JK2"A#!K]2-
MFLU>/,U)\*=C/CP9+E:+^:7@.^$4X6R(17,4'81VEQR02*%_,P-DF;!_['I%
M&8P%;U;5PW>]R, /),X1A#C(*M5F[@ZM3%#&;](F4D%A&7&SQ$/L1:1G;)2Z
MXP=BL^45>$RP5;D%.^%% 5*P#,=>\ %Z6C6/0[-LYY_EE9D?4#X+@DW;B[>(
M%AK+,^(E(8:1,>]EM;HMP27*45J.%T6]G9CEN!N48 >5J]D5C1OX)"ZC(8)B
MX.?6919G"!.M=NG_BD7FSS%[I4/&*\%>"KE^AU>Z.EG;XG@>G(N;I6?PFL).
M]CU<7,JLYN&:RL "'EY'GI@Z'U]&'Q5U$=_/]@N8A7_@-[B/)[(E!794XHI2
M*MF'-%8N8$] 3I&2JC:BHZG"_)MH/*,_90NJ97^):D9O\V4!X[!4L:U[(/9(
M/M_N&-ZC+A6? O?1ZEG3H$CFK,IGT#IV3[XK/)?GE>(#UPLN1<4B#N+>16^0
M,[)Z]QQTJ7*__7S,JIDCN@QX<]\RYP)#_*L5GS20<$>>')PO[DWN!4]+6R,?
M06WRM8N.PAKE'7<2H@?"[>GH,G"#\+GRHS24$:LZ*R,J/-3-\@.Y6X%RQ9=D
M/TV *BRR%0Q1-R]:">5HAKM+X%K09-^'7(/G"F<HQ@-2.J2<I+$OURB_:C;E
MNJB&0*^D0?5M<%,D6S,,2E_4":9 _[IKH9UPO_U-Q LI%C!D*@RFO9<OQ5K*
M1RB68Y*<'<H>S#>I0+4;_1RY !B)GEFDU[#0C>[UT C4ZC *7H*R^'>DBXQI
M-*%,:CA99I*;]1]RLA1MNM>)/Y1GM!\BSJN#M2,750#_$ [N'2 /#W5PA;VQ
M3+Y$XE=[B39.JK,>*'.5K:OQR_XF/V:F)NY6_FU<%K%*9="_610/..L2W9LT
M/XDNAWCH(CZ6;6=^7%A!FF!V+%U09#5!%2\R.HP72&?CZ,;)M%NAJ89,MIW/
M27TKO\OE;]U_$J'-*EV#DF#Y&.TJ^-4%AC75'84O#!Z4BQD+]5T,F[A9^N'L
MVE!WG9#OZW-;^TKTVR53:Y;/M+759JI+F-4Z'I5;A>@"&",+8[4/62O2+5J(
M6QR[63M-X!+R+_&/V,[G%L&61;E@1+2RQ59/+-*,8C3@[SGYE1OQQ[R2 AD^
M*""E?<-U(F7L8CQ;LB)D"^XN>^]S!I^F+'59B2]0O[:]AT>!1OIQ]+C8J^(#
M^DBR-/\0>E\V,:T8/24'8NZA^Y3#0J3_RU*OSQ[T*9#E<A2S ^?:>6 \Z %]
M.OQ9^;$B$PE27<L/0++5*U)O(B4 (T:#<#0A(7E(,VCKLP.Y \UT>8 FPK/L
MV.A>9")- =%@J'P/=!J^E+<%'@[_3.7#]LC4&"<X!_$+<8/;D6J?"_ G9(GK
M*,2$W+'K03W12=2?H)OV7CD'W*;=F"<&?VH]4A=#"PA-S%BH$'\0,AK:CY?[
M;(.CL)>NL^%W&-?N.+(=?4+MU'A8_BJ?K#EESLY;"#J:YJ5\!W,-ZZ)O@RWZ
MPN#WT"3=+)_-T #QTM4)5N$[[)XCQ5ASU:,F8\'-HM[&F25-6>/JUU0P_O]W
MB42.'&6%:;4!,RPG6#\\3IMG\=L=,XV(1+?0Q;! 65\UMOYG.5'XM>Y8U8Y,
M9:V",C)ALW4T711QPJ)F_QTPSO22=\/CBY$FNN2X1O]'/F'A1MUI=6%E22V3
M,K,PT4JC'<YX51/%)!+"S>\XE C(9.73%KTW^HA:/*?H;TJ?.7[6K53R;%RT
M_<#'BLV6GZS&@BZ+'6=G1KS9AO<J_H3QIS XPM-P0KQLT1E]E\S'<Z$.4%QS
M\M-JU"MLK,0JD%XQT71+.+)@A,E%M#Q]AS%1DAB?;HB5?@A_I0^2[UNT5A>J
M7.GII$U2+W4B$TK-)IM'^ 5H0[G<.%Y.SM<88 68GJS?K33&O=-=4+6$#VCO
MJ_]9M(3X#_CBZ4^$@#%.)KP-JK?UQ.?#9\H^Z@T::_Y$O2WHFO9&)P7;XU9K
MN\ _X0+B,*1<I,/_P&,]D_%,>*73)NP&$FG+Q'3(_C*#+@D3Y?5K?V-86IV6
MA17$51#+L6GA@?A=],FB'#P$/>49C36A1YQN8XO03;9MV 347!:@33&DY&%:
M5_VK-#4QH/\[KAH_K_T43L%^:B<M6HJ5$9F>('H/[W?ZC6[!7MH.HNLPWX([
MW?H"QTQ+9UGQ]<2?[7;E&Q?;MFRH/A#LTOB'-LN'5!_$VNR::.7S0;MWYC,2
M\_Q+1EC963"J,[*,DS'4GE^Y,K&PU8,\+JJO:1>M-^A%PV06RX=<6\GCN>HL
MVT4M]F13M.SK K[!3IV7#[7M)S5G9+3\HI8EW&SZS8B*"FM8R<X+6E=GS[/Z
ME-5T"'^Z[C#;2G7VAPQWE!$+/NK> 0_RQ[;D,5:DGVS:R'J=D-5P@9L;>:=N
M%?]6D,2:([+X9)E_2*M=;QNW*M(<IN@'U(4+:=H78%*>J<F=UY^>U;!5((M_
M5O=6E!])6(<DB4%9EJTRFD^JR:)8[OK5H%2]<LC1=6J2%A[5CH.PO(D-!9(5
M:0_KQTN_Q;?64N5ID9DU;,5 D*^Y0&7K4VQ,50^ZS=&3-30'G78;--%F%I$#
M-^8NJSNEDJ<9:]>I<^,+K/.!*9$++(' ^:#QIF#-&I\<0Q*XS"U")X4&'+83
M'^&E-B7X#D2=FU9K@.>FQ5JM,!!O6S,-7A;QVQP$[P[\;DR$/_F$ZN5(HENH
M=C>RQN$ND8/\9U.+AZ-AN5.M"-&5-K%F*0'%?;)$$<,BGIBX.#?PMP'!?OGD
MZO9BJ]T*M/,QML-O_")F9[,+NXY>71Y4U)6]INEQF7N!HRZN<G])NV(A654Y
MGF&@L\B&HF/L3H9C,D,PCO,E5"FY)?+V.*[\J1BUU"WW5.F2QLS"6Y5^Q(/2
MUZ3=LM=5<VCQ=(@",J\4OF0Z<G5)^W@3A<S0>>(2Z4J/\XJ7*EYO9J:8:JEO
MROW.<,/Y14K686E;^7@NA595?54PJ7 T[:7H1M)"3H+T5,@)T3#E>(_K\F_
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MNTO<C20$""2$A!#W "$A)+B[%@IMJ5%W=[W?M#///.M]__^U"IV3YZ!9ZWO
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MPD+>8"5-.LPF*X=+R9H!)EG;NY" X ]#E8/%8.\,E [^3ZL=H^_J7-*OU7M
M+YC]\*>;PVBSS4G,T?KLJDX-5&V2HNMK^(06.8?:*2PKZ>.6< ;91:+A$KIR
MI(BJ'F!0M7T+Z7\,]GN!U,X)J.W\GM4X1-TS.*?>,+OG7VKU19_N#"/-=*0P
M!DR9_-::?+5>@:Q7B7#-HDI*)Y=3U%?&9@\6EPF&Z4SE"+5(/4AE:/L6TI\&
M@=U>(+-U AI;WV<ZN\@'#8[)MUK<<BYV^<)/#41B#G8G%?8T9?#-^EQ5M09N
MD,@PS3P1J;.,7]C+X)4-4"OX0Z0*Y3"I3#U(8FKZ%A(0;%D,^-9K@=!V#U#8
M.(+J SXO##;A#YOL$VYVNF:<'_3+/3X6 QOI2RQL:TNKU#?D*!4ZJ+Y*@VIB
MR0D=# FMAR)B]A,$W$&,0#&$Y:H'<!Q-WT("PC\,(IL]0&GM &JMO$&#=>C#
M-KO8:_VNR6<G U)GIB)A_4/Q],:N5)ZV)4LA:LBOX]0A&XNJ<6T4=4$W3EG<
MAU14#, 4LD&X6#. K-+V+:0_#6+KW4"]WQ[H]WH^;]H?>+?;)N+2N%OTJ>.!
M\>-'(J =XW%4_4 R5]Z5(>>UY-66F.&F B.V!:<G=R!UC&Y(#;LWKUK4EZO5
M]N7+JWL7$A!N7@RJK-8"Z?Y=0+O'%AAWN3ULW^M[;=@F\/2L>]"A4YXI?;-!
M2/-4%$TSEL@1]&5*61WYU8QF5#W9A&_$UI-;$7IZ.[2NM#-/Q^O*T<F[LG35
M"PJ(-KTTK .*/3N!;N>!YTW;G6[U[7(_.VWK-GW:+GS@C'-FTPDOK'8ZN$@P
M$L=C]V5(BSH@&FH+NH[0B#=B3&0SHH'6#*TO;LFO+V_-JQ>UYAAD;0L)B"T&
MX=ZU0+UC&ZC?LN]!QQ:;B^,[; ^?VNTQ>-$JIOF\79[VN!M1,!7$9(W$5S(L
M<Z!V0=7$=E0-QO).6';_>E@CM2'?S##GFDH;LTU<2\(%!20;%P/)SM6@9O/F
M%TT;=EX?6K]K]L3&?4,7M_NV7-N36'W>!BHXYD8NFPIA%HXD\"@#62)"#U2.
MZ4*J$1W8:F@;L3:_E:++::'ILYJ+#1G-K/KT)NZ" M+UBU_=4*E?M_Y>]V\;
M3AY9M6;DPEK;UCM;@JIO[$H1G+.!EQ[S)-,.A163QI,XN.%L_LM;"; ^A#2_
M!_/R-L*KFPB9G06:](Y";6H'LSJEG;6@@&S=8E"]9OFSEE]6GI]8^O/8N9\W
MM=U>[53S:%.H\/J>U-)S]C#J"1\B_G D'3V9PH2/9Y7GC^9S<X;AE5E#J*J,
M0:PP;8 @2NTGBY/[J)+$/H8TH;=$MI" 8O5B8%S^X[7!Q=]-G/G/TO9;/VVO
M?;[*5?AH2UCI#:N4@@NN^=BY  SR> P)<B29ECV=R<B8RBU)FX26IAQ$E"5-
MH-F)X[CRA'$B)VZ,4A$[2N?&C#(6%*CY^>O[G=]\=>C4)Y]UW/SW"MWS9;M%
M8(U;V>.=H06W[1.P5[TR81="(3EG8I 9IY*QJ2<R"$G'<T@)QR"4N%EX0>Q1
M)#7F"(86=01/CYPA%D;,%##"IVD+ZD7CUQ\?FOSPW:X;GWQ=]^P_OXG!\CUE
M8*-+P;/]@=@'KE&P6P&)V=?"TU,NQV0G7$S*BSN?#HTYEPV+.IN'B#P+14:<
M@:/"3Z-08:<QZ- Y/"9DCH@-/D594(<&/GBGY_ _W],__>P_$O#=*A98N8L*
MMCM@@:T7[)E74-;#P(CD>V$Q<7=B$J)N)29%W$A-";N>F1IR/2<M^%I>>M U
M:$;@57AFP%5DYLOG#_Y7<-E^EPD+JF?T_;_5GWC_0RGX8G$Y^/$W&EB[%0OV
M6$&!DV,F\/)(! &^T<]# \*?1@>'/(X/#7J4'![P,"W"_V%FI-^#G$C?!WE1
M/O?SH[WO0Z.][R%BO.ZA8CSO86(7$F!O^@JP#BP'3,]MH-S;%E3X>S^O"(ZX
MSXE,O<Y*@)YG9A%.%2$8LW0B>YI,JSR(+Q:-8UCR4217-0ROT@Q!1=6#^;+:
M@5R5KC^GIJX_VZ#ORV[2=^8VS[NWAK>&_[6&TO\V^'G];HA(O<Z.AYXOS22<
M*H8S9@L)[&D*M?(@H5C\TC""K+ 8^-I!J*AFX*4A3UUG,>C[L^OU/3E-^O;<
M^??*P+886![;0(6G#>#Y>+VH# B_SPM-N5X1 [G 3L&?*LTKG"W"L _1*?R#
M9(9D%%^J',9P-(/(RIH!F*BN#R+3]^6KZWMS=<;>'+.Q-=]L-"\@4/Z'@>VV
M#7#=;0#?R_-%E6_8@ZJ@I!N5$7D7N?&X.786?98)9QUB$/@35)IDE%2B&L*Q
MJP=0/%T?7&CHA<J-/?G:ANX\@ZDMWV0R01K,>NC\ QR+H=QB*'?=!GBN!X#
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M^%]%9?A=Q6;Z7B%D^5RA9'M?IN7,MY&^]Q>U'GK_G>K[GWPJ (M_+ 6_K*&
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MQHUX#>-?>3TEC,WH_QL9MJ$9#LT%-IK!UV CB"QV09#=81 Y:X(_S0!XGI;
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M;G@S&=?]/<A=(5Z$:S%\W+4T ?9JH1_F6IV_[;5S0INN._XV5X:%F/87HIE
MS'(I*%PM!4W+I1Y=GHO<1OO_E9?+I<Z,[)S=,**\K.R%UN;L0:/]B<^MU,*?
M8O4#^@GFO,<T.X]_W/&,A]Y$<I\_S?F!A.GX(-;-_D&ZI^V#(K;U@WJ.95^[
ME\7#7HY%WYB7Y<W7WC.!E"524+D$>71F#M)S;39RJ6\N<OK-2IFZ-PKS2UXK
MK\X:.[X]?M1(,?25I;KPI9T>=P1OZCI"MJ8-L^R)PUXX_+"?,W983,0,1U.L
MAU-I%B/Y=+.1:J;IRU:FR<MK3.-7 TS3P7=,TX&_@[P%R)/F64AWASS2V2V/
MG.J?B]1\6"-7-+%K4<;$D75Q$UH[)1-&A_PG+-6\/MAILS[@#<D?2&:$#TPK
MQP]L6[L//O8V$X$.EA/A.+.)1"?CC]G.AA]+7?0G&XEZD^>(NE,W23I3HZBQ
MOWI>*8WTM,HA'1?ED!-WY)'*-PND\K^NET_[MG=IS#>5]2'?M7?Z_3 ^R/EA
MH<+\@=$D_7#4=OI)U,?^I!O9_O0PL?KE;6;VR]_"^%>(E<'O&!N]WZFV.G_R
M,%I_*NR. ?I"\Z<=J_GG%NKV7]UNDD8ZSLHBS5VR2/E#>23W]V+I9-@\)PKV
M+Q6CG5L 6ML\P6 /'<P47<#FB",XJ&* H&$%U./FP-(V ;:.(?CHZ8%(7QO"
M#(]!G)$FI!EK0+Z).I2;JD&]F2J<F='Y4])(TP5II.RV#)+Y7 Y)A.72$;!M
M=B <6,R#(ZO=0',C!72W.X'Q+GNPW&<-=@?- 7_(&(B'#8!V1!?<5+3 ZRA:
MD-4T0*2N!J$:JA"KJ0*IQXY SG%E*#Y^&&JT9M)\5@HIO8X@&0\1)/;3'*E0
M6"GM#YMG<6#7?"8H+B7"T56.<'R=+>AO,@?3K<9@O5T?['?J %[AW_4'#:#M
M40?7O:K _F_M01F$!PY#R'_K#HJ0J'@ ,@[MAP*EF91=0N??09"H 001PWPI
M'U@J[0:K92BP11X/N^=AX- B"U!=:@S'5^B!_BHM,%VC"59KU0"S[B@XKC\"
MSAL. WGC(:!O4@2WS0? :_-^$&S9"Z*M>T"R;1=$;5. I.TS =(.67!2G 5D
M]07@IK,2.*:;@&N[&SA.2N!.4P<F6P=H0B,@A9D#(<$:\!D8<"S @D.Y(]C7
MXL&NV0DPIYW!]CSACTV7RR^;N\2?UH/$;]:OB5,VX\3WF GBF-U'X@AV\J_^
M;P:*V@+PT%X)7)--X&VS&[AX)?"DJ@/+4P?H?D9 #K4 EW@;<,JP UR^ SB4
MX0!;XP3VS<Y@=YKP!]/I\MNVB_C+YC[IA_4+TA>;UZ2/MN]);^T^D%YB/Y*&
M'";_"LAH!F<T UUU ;"U5@#?:!/X6.\"ON,A\"*K@[N;#C %QD -L0!2K"T0
MTNP!G^<(CJ5X<*AQ_H-M<OEM=YKX&]-)^H6Y0?YA^Y#RS6:$,F7[AC)N]Y[R
M"ON!,N@X07GB^)'Z-T!!,Q .S@*FR@+@'E\!OH8;P<]R%_AB#P&?J YLE@ZX
M\8R!$60)E&@,$%.PX)R+!WR)\Q_':I??#DVD7_:GR3_M+E!^8KJIWS']M,^V
MKV@?[-[2QK#O:4..'VB/<1/T^_@)QM\ 9;LLN* 9W(XL +[F"A#J;P21N0($
MV"F"K[,:>--UP(-C#*P 2Z!%8("4Y B$;*<_3L4NOW%5I%^.392?V#;J#_N+
MM.]VM^A?,<\9DW:CC#?8MXP7N/>,?OQ[YEVG#ZR;SA-_!50T _' +/ \/!]\
MU?^?M1BQZ4X(ME4$D9,J^%)UP,O#&#Q\K8 IL0-J/.XW*</Y%Z&0^,.IDO(-
MUT#[ZMC*^.QP@?D)V\/Z:/^,-8Y][3J,>\?J=QIW[75^[W:#\-[]JLO? 6V;
M+)#WSP(OI?D0@/:+$.WU$&:R \)L#D ([BB(R-H@<#4&+Y[53X]@^V^L:/P7
M6HK+%#F7_)%82IL@U#+>.[6PWN';W=[@NMS'<(_<1W!C[OU.;SWN$,8]K[N\
M8U\BOF.?)[WC_ W0T0RTO;. IS@?@E260;C6.H@VW@[15OLAPD$%)"['?XD8
MAM\$7I:?N 'V$Y[A^''7!.(;>B9UC%+(>$6J=!UV:70?(ISQ&'2^XOG<^3[[
M,>$5^[;+6\XUXAMN)_D-]RSEM7<K]>^ @69@[IX%O@?F@>3(4H@^OA;BC;9"
MO.5>B+,__"O*6?-+*,W@H\C#XIVOK]V8=PA^A!U#&G)+I3UCY++Z::7N#REU
M[/ND4UZ]Q$[N;>(M[Q[B"]X5\ABO@S+&/TT;Y9^@C_(;&7\'S*VRX*8@!\)_
M^[_R$H@_M@:2#39#BL6NW\F80U\2\.H3T63=-Z&N9B^#^)A!OT!\/R^"]("=
MR.AUSW2[R2IDWV!4<KMHC;PKU#,^ERC7!!<H_;YG::]\6^@O?1L8+WUK6"]]
MJUBO_NJ_#)X[Y2!PSUR(5EX,R9JK(!T]-S+-=G[+L#WP,<U1Y4V2B]9(#-/X
M61C7NB_0'W_'3T+NYL4PKW%2/"YYY'AUNI7PVEDU@C/,DWZMC O^)QF]PF;F
ML+"6-2RL=!L6EKJ/^!?/ %C_KD=MEP,QVKWC#B^"-(V5D*VW_G>NR;9/N59[
MWF7;'WZ9X:SQ/)EN\"#:T_IFJ #?%1A$ON@7P>K@)WBV<3.\3['S?9H]*OP:
MW!L#ZMS.B6I<NP.KW(8"2SU>B H]7XCRV"\"<MC#?P6N6V2 NTWNO]^92U1:
M")D:RR%/=^WW L/-$X7F"F.%M@<&\_$J#]/)^K<2W*RN17GC.B5"RIE ">ND
M?PR[29#"J^/E^%9YE0C+.;6!)>S6H"+/J\$%["?!N9S!H"ROH: ,[E!@&O>%
MZ&_^R\!']T?XKMF0?&@!Y*@OA4*M59]+]#>\*S/=-E)FO?M)L<.1.SE$O:Y4
MEE5GG!>N+=*7?$(2S*H/BF!7"Q-X9;X9?D4^!0'YO*J@'.\6<2;W0DB&]_V0
M5-Z .)D_&)S$'PQ*Y \%_@VXH1D$FV4A4D$>TM#S,U]MR>^28RLFRW76OJXR
MVC188['C09F=<G<^0?=B)MWR;+*GXXE8'W)=A(A5*0EEEP3'\O-%J7[9_KFB
M=-_RX!1!8TB2H$.2(+@MB?=]'A+K.R".\1L,1@7]#?J2+P-^:,>)WBD/&8KS
MH/#HHA]EZLL^5&NM>E5OL/9I@^GV.U68P]>*G74Z<FD6)]/='>L3O4F5L?ZL
MXL@0=FYH%#]3G.27$I0M2A"AB83UDBCAV=!(84]H1,!S27C \Y#P@ %Q>,!@
M\-^ .YI!N%$68G?.@JR#<Z'XR(*OE:J+W]5K+AL^H;ORGV:C;3VUMDH7R_':
M;844\Z9L5X>J-"]2<:(O,S<VB)T1%<%+#D_PBY-DB*+$A>*PX!I)2/#I4''P
M];!@\;/0X.#G(<'! V)QT&#PWX 'FD&T7@;B=\R"G -SH/3PO$\UR@M>-ZLM
M&CBMM?3>2<.M70W6ASJJ<%HM)22SVGPFMC2+3<Q+\V%F)(D\D^)#>;$QL7X1
M46FBD(A\<5!8E20@[%2H?]C5,+_P9^C'YR'"T &Q4#(8_#?@N4D&@M:AO1<]
M/_/WR?^I4)PST7!HWLO6(_.>M*LMN7W:8//E$U:*;74.QQLKB:85Q73[@GP/
ME\QL'B,I7>@1DQ+B'9X4[2N.3Q8%Q.8&^\:42_C1)T*]HR^%>L?TA_*BGX?P
M(P?$/A&#P7\#'+3[B]$,*>@UNVCOK!_5^^3'3^R3?]%^2+[O@LKB&^?T-IUO
MM3APL@FK65-+,"FNH-EEE[@1D@NX])A</_>PK&!N<$:$P#\U4>B3G!7$32H-
M82<U2CR2.D/=D_LDGHG/0SCQ V*OV,'@OP$NNA]"UTA#.GI^E.Z6^U*O(#=V
M>J?L\\M[9'HO'UEXI5-GPYFSYOL;3MEIE#<Y&>7646Q3JUR=8LLYU/ 2@5M0
MH8CCEQ?&Y^7$^7.R,T3NF<7!K,QZ,2.S/82>=5?,R!@(9J4.!KDE#_T5^*R5
MALC5TI"%'A<5.V0F3VR6&3F_4?J?&UNEN[L.+SA_67M]2Z?IWNJS&+7"5KQ!
MQ@FR=7PC$Q=>YTD*JN8S_2J$GMYE$F_/DA@!JSC-GU94*"(7U@81B\ZB;@<1
M"X<"*;E#@=2L%Z*_ 3]T?NPJ*<C?(/V[=J/TN[954L^O+T'NW-HD?>6FXKRV
MZ\?7U%\UWE5ZT48EJ\-1-_$,T2*BE8X-;G$G^#5[T[P;_5T]ZL5L9EVT-Z4F
MQ8=8G>_G7%TCQ%>?$>)J;@H=JT>$3F4C0D+QB/_?0. *:4A"^W_Q:JDOS<N1
MQQ?G(??NS$.NWULOU7[WP)SFVQJK*GH,=^1=MSJ<? 6K%7618"+NI-KZM;OA
MN&>]B.YG?&F,T\&NY-9(3\*I9"_<J3QO[,EJOMW)-C[F5 ]JA&_7-.J#K?L[
M"%TJ!1E+$*A:@CQNFXO<OC('Z;HW%^E\O$;JY*.]\M4/U987WM??FM9K<3#F
MEIU&2+>3OM]UB@6WRQ7C?I6#HU\1N) N!U&<+T4R'"\FL^POYKG;7JSRL+YX
MVM/J4C=JQ,.JXQW;^LP[SM] ]&)T/RQ$^AMG([?.S4:N=,DC[0_G(2T#:Z5J
M!O;*%SU76YKQ3&]C7+_9'LDCS!'_/KP6]S[9T.T>RYQ^EV-+ZA5@G7J#\ YW
M(@F8.\E$ZSMY9,L[U53S.VU4L]X>JGGO2XKI[4FZV?5)QM] R@+D>84L<OOD
M+.12YRSDS,W92-.S^4CERPTR!2_WSTM[J;8R9D1W<\BPZ1[?%]:'.4..&JZ#
M1!WJ(,/098!MBA_PL<0.!-K8#D1@K :2L!8#N0YF@Y6.)H.G<,9#UU #.*.!
M"9SAT\].?S.>)XO<K9=%+K7)(:<ORR'U=V<C9>.+I7+'-\NEC!]8&/U.?;7X
MG=X6P3O3/>QWUH<8;[%'26^=-9W>TK0=WKKK8=YZ&UJ_%9I8O LU,WT79V'\
M+L/28+S86F^\P4;W?;N-SH>;MCH?7MIJCW^T^9L'Y0ARY80,TMHN@]3>D$.*
M'LU&,C\MDTK\O%T^\O.A14%?-%;SO^AN]OABK$#_8K7?Y:O](=Q7IR/V7RFJ
M-E]9&A;?.,=,OPFTC+X%Z>A_C]33_9YLH/TCU_#XCPHCS9_-QAH_SYNH_[IC
MHO9K^*^ZZA'D]&EII.:R-%+0*XND#L]!XGZOE@[[HR ?@'9N;U!=Z0K:ZRE@
MN-49+'9B ;/'%G#[+8&H: IT)2-P5]8'[A$=\#^J!2&JFA"CK@ZI&JJ0KZD"
ME<>.0/-Q93A__#!T:_U-VPD$J>E D/QN!$E^)(U$_5P@%0QKI 6P?18;]L]G
MP)&E1-!<Y0AZZS!@LM$2K+:8@OUV0W#:J0<D!6U@[#X.[GLTP'NO&OCO5X&0
M \H0<_ 0>C.B"'F'#D"YTGYH/+P/3O]5;1N"%%Q%D*1["!(ZB""!L$C*&U9*
MLV"C+!D49N/AX'P[.+K8$HXO,P']E09@NEH'K-8<!_MU&H!;KP;$#2I VZ@,
MKIN4P&OS0?#=LA^"M^Z%R&V[_EM?R-ZQ$XIW[H#*ORJ\@'[_M]#Y3Q#$[XLT
MPH$%4C18*NT,:V3L8+.L)2C,,H:#L_5 9:X6:,[7!-V%JF"TZ B8+SX,-DL4
M ;OT ."7[0/B\CU 7[X+W%?L!.[*;>"_:BN$K-X,T:LW0O*:#9#Y5X!5D 4;
M)3G 'I$'XK&%0#-8"0S+34!S5  RY2"XL(\ WE\#',*TP"Y1#VRR#,&JR!@L
M*TW!HL$,S$^9@UF[!9A>L023VU9@\MP*C%];@_&D]2^3+]9?S;Y;?S3_8?76
M\J?U&ZOI_=\,CLKR0-%8"$S]E>!JL0F86 6@D@X"R?T(./MJ@*-$&^SC]0&3
M8036A29@56$&EO468''2$LS;K<#LJC68WK$!DT'46YL_)I.VW\V^VDY9?+?Y
M?_]'=+FEXU8_;%Y9_[!]^1?@H" #MH?D *\D#S3UA>"FNQ(\S#:!FYT",%T.
M H6E BY\3<"+=< AU@#LTHW!-M\4K,O-P:K>$BQ/6H%%NPV87[4!L[NV8/H"
M/9C',3_-IC"?S;]BWEM]PXQ9?\<,V?ZP&[3]83\=<-PI W:*<D X) ],U87@
MJ;T2."8;@6VK &[.!X'.4 $R5Q,(@3J BS($;(H)V.69@VV9)5C76H-5BPU8
MGK,%BRL8L+AC]\=\T/ZG^5O[;^:?[">LOMJ_MOEF_\+V&_:)W7>'QW\!.#2#
MPP$Y(!V4![?_69WA&6\$;YN=P,$? #>J"M#9FD 6Z@(AW CPB:;@D&4!]D76
M8%=E^\>V$?/;YK3]+^L+V!]6/=AO5D\=/EN]=IBTFG)X8_O%80CSU;'?_AON
M+O8;_LY?_)<!OT\.:/OE@7UX ?@<6P%^AAO UVH'\!WW@Q?I"+BY:0)#H N4
M$*,_+K%F/YW2K+[C\FV_.939?<'683_;G728PK0[3F*Z<!.V??AWMJ_PKS&3
MN"&[ST[_8+\XWW'X2KB.^T;H^@O [Y !PAXY8.Z9!=Y*\\$?;7\B@_4@LM@.
M0OM]X..B#!RFYB\W;]WOC$#C+]1(\REBDO5'0C;F@U,Q=AQ7Y?C6L0G_QN&,
MTQCVLO,K[%WG8>R(\P!V@M#G\)EX$_>%= W_A73!Z0OYO//TP G-0-HE!^Z[
M9H'OOT]GJ"^#$+VU(#';"L&8/1#@=/B[@*;^V8NM\]'#WWB<%6KQAA9G,TI.
MMW])S'<<)I3CAYSJG9_C6UV>XBX0^W&W27VX%Z2[N _D;OPGRB7G3]1VPB?:
M:9<I6BMQ>N"\70:H.]$VOE,. @[. XG:$HC060V1)ILAW&;7-PE.<3*0I#KN
MZZ8]YNUC-,(.MAARC;)]QDAV>$S-QO>1B@GWB%6D.X1FRBWG<]0>YR[:#><G
M]*N$M_1.PB2CC?B1V4+ZR&PD?V0V4*8'!#0#8[LL>*.-(^C 7(@\NAABM59"
MG-&&[[%6.R:CL/O?A1)47@4QCP_Z<0V?\ (L^MBAF%ZW.,>;S#3"#7H>Z1JU
ME'J97$>_2#K%["1>9'40>UW/DEZYGB)_<&ND?'"KI7YPJZ1]<*V@3TP+7+;)
M@"O:Q 5HXY#LFP.Q*O_^]=CEOY,-UGU*-M\ZGH#9\RH&KS003M?X)\C3H-=/
M8-'##[:[YA6)O^21Z-+IFDDYQRRDM]$K6:VT)K<6ZCGW9FJW1R-UR*.6-NY9
MP1CW*&6.>Q2QWKL7_@40T0S_ME#_?U<$]LZ&!.7YD*JY]%N&WNH/&:8;1].M
M=PXF.Q[X)X:L?CO,S>!Z$,_BDG^ _7F?4*<SW%C2*78*[81'#K/1K=2MCE7G
M4<UL95<RKW#*F?V<$M9;3H'K.TZNVSMVMONX9]9?_)>!C;:O@"VR$+5''I*5
MYD&F^J)/.3HKWN8:K1W.M=C2GV&__TZBB]KU:*;^Q5".Q;D@7_M6_V"G9D$D
MJ9Z72*_VRF!5L L]2CVJV$7N)[SRW2]P\]SO>>=XO.9F>K[Q2O-\ZY7"?L=!
ML:<#9+1Q>6U 6RBZ+6)WSX+T0W-^YJHNF"@XOF2T2'_E0)'IAOLYMGN[4YU5
M+\73],Y%>EJ<E/#M&H-$3C7",'*%;RR]A)_J6N"=ZYGC5>:5R6GT3N>T\U(Y
MMW@I7J]X25ZOO1.X;[CQW+=><7\!5'2V-]I Q6@;3E"0@\R#L[\5J,P;+]%8
M.%*NO;2_S'#][0*;/5<S\4<[DBFZI^+<S!LCO>VJ)?Y.9<%B4J$HBI[KG^26
MZ9OEF>I3[)7$J^/%\]KXL;P;/C'\%_QH_A@ORN>U=Z3/&R[*:SI 1V?ST088
MNA%M/^@YFK-_UJ=BY3FO*X[.&ZPYMO!!I?ZZ&\56NR_D.JJTI9-TFY)89M6Q
M'$QII !?$!I$RA:'T],"X]V2 C+8<?Z%W&B_:EZ$[RF?,-^K@E"_ 9]0OS&^
MQ.\U3^+WAOLWP$3W@R_:@L/72T,J>I[F[Y7[6*8XZU7-X=E/&X[.OU.CM_9J
MN>6N]D*'(RW91)W:-(9I69(GIB"6C\^*"B"EAH?2$R2Q;C'B5'9$4!Y7$EC)
M#Q:U^ 2*+@M$@4]08_Q T1@O4/3:.U#TACL=<$5G^Z,M-'(=VL:WR?PLVBW[
MOFJ?['#C0;E_3BC/ZZG767.QRESA=*F]<F,^0;LRFV92F.9NFYWDC4N-]R<F
MQ(AIT9%1KF'AR9[BT!RN2%+&]P]I%OB&7! (0AZB1OF^(6,\/_%K;[_@-]SI
M@#LZ.V"5-,2LE8*L+=+?2G?*O*E3D!DXN5OFWBFEN5U-VJO;Z\QVME1B#M>4
M.!TOR:<:YV2[VJ2E>SDFI/BZ1"4&T4+C(UR#8A(\A=%97$%D"8\7T>##C>@0
M<"+O";PBQ_C<\#&>=]AK;U[8&^YTP!/=#T$KI2!^M13D;I3Z5+E5^E739JG^
MLUND;K4=FG/IY/%5;4TFVQMJ;0^55^"/Y9>0C=(+6%8)N6R'J"P?@B1=1 U,
M#6/Y)<5Y\!/3O;SBB[P]X^KX;G'G?%SC;Z/&^.ZQKWF>T6^XGE'3 R]T&X2L
MD((D-$?!6JF)VG52+UI7(O<[-DA=/W=P=D>;YHJ6DT;;JINL%8MJ'36RJH@&
M264,R^AB#WM) <\I,$](]LT.87AGQKBQ,U+9;FD%7$9:#8^6VL:CIO6@7GG3
M4]YPF8EOO)@)TP/>"O1X7"8%:<N17Z4KD#=-2Y''Y^<CMRZND[IT8;]\6X?Z
MLH8SAEO*3EGMSVG&JJ4TN.C%U-+,0ZO<,*)R+DY0ZD?D%@=3/0HC6:R"9'=:
M?AZ;E%?EY9+7RB7DW4"->+GDO/4B9;SED-/?30M\ETI!]!(IR%Z"3%4M1/XY
M-1>Y<W$N<NWJ:J3]RAZY$Y=4EU1VZF\L.&>Q-ZW-7B7VE+-VV F*B:C1U5I0
MS\%ZU0J<W&L"28RJ"!JE,I'I4I'CYE1>X>%8?LK3H:(+]<+#H6S< U^(*I@>
MB!9+0<)BY$O! N11_1SD5ML<I.O*;.1\]W+D5+>";.UUE47%5W7695XRVQ7?
MB3D<WH'7##Q+-A"T,<V\3GO:N)WB8^DG14ZD$V%$Y^8$BF-S-MV^J9R!:6IA
MVC9?0PTQ;1H_LC U$RR[ZNF!9"$":?.1)^6SD-O-\LC5<_)(1Y<\<JIW,5+7
MNTVF],[A^=FWM%8G=AMOC[AN<R#PFJ.JX I1BW.)8>AZT<.,=H%G3>P,L',Z
M'^;HT!'O9->11;!I+R-:M;>0+#JNH@:)YNT39(O3GRD6K=.#Z'G(4)X,TELC
MAUP])8><ZY1%3O3,1FH?+4!*'V^6SGET<$[20\WED0\,-P7=L]HMZ,4J<>ZX
MJ+%NT;2H-]WU76[R3/ ]0G-L=ZB5;7>\K55WEIU%=SG6K+O%P;3GJH-)SR#6
MY,:$HU'7#YSQU9_XZ7Q-ED4>E$@C78VRR-DS,DC3%3FDLG<.4CBT&,D:VB*3
M.*@X)V)08VG@@/XZG^<6V]G/[/<RGSHK49[0CA*>N&O@^KVU[/N%>K;]H0:6
M_?'&YOU9IB;]Y6;&3UK,C9Y>,3=\^MS<L'_<7/_1=RN]1S^G]20'0;JKI9%S
M+=)(4X<,4GY##LE]. =)&ULN%?=ZAVS8V.%Y 6.:RWEC^NO<Q\RVTD9M=[F,
MXO;C1DE*]J.L([:C'%6K45\-\U'Q,9/1:"VCL30=_;%"7=W7=7HZK\_J:[^Y
MA1K1UQ[[K*\]^DUO.K=*$:2C00II:I-"RJY((]F]<DCBT%PD^N-:J9"/N^3\
M)I7F>TUJ+'.=U%M#F33=Y#QEO0T[Y:!@.^6RUVJ*OM_\DX>BR2>>DN&G &6]
M3V$J.I\3CA[_G*UV[$N9NL:7)@WUKYV::M_N:*I^'4.]FU9G#8(TMR!(62>"
M9'5+(7&/9)&P'PL1T<]UTOR?.^4\?BG.I?]27>SR6WN%XQ^C-9@_%ANLP&ZS
M&>"W&@-YAP$P=^J"YRYM\-ES# +WJD/$?E5(/J "N0>5H4+Q,)PXI 3GE0Y!
M+^KAM$XT(DCY673^-02)O8<@P0/2B#\LD>+ &FDF;)4EP3YY/"C/MP/-15:@
MM\P43%88@=4J/;!?HPU.ZXX#>;T&,#:J@><F%>!O5H; +8<@8MM!2-Z^'W)W
M[(/RG7NA<><>.*>P&\Y/JZ(5G7\)G7\;08*>((C/=WG$'19)46"EM!-LE+&#
MG7*6<&"6"1R9;0":\W1 ;\%Q,%ZH 9:+50&SY @X+CT,+LL. 6TY6@Q7[ /O
ME7M N$H!0E?O@(0UVR%K[38H6KL5:M9M@?IIY9Q'YW>C\_]!$*]A!&&"+.("
M"Q L+)6R0K>%"6R6T0,%62TX(*<.RK..@KK\8="25P3]V0? 9,X^L)RS&S!S
M%<!Q[@YPF;<-:/.V@,?\3<!?L $"%ZZ#R(5K(''1:LA&Y2Z>#ICOD0'CPW)@
MI3P+[([.!KS.0G V70EXNPW@0-H.=NY[P-KO(%B$'0;31!4PRE8#PV(-,*C6
M!/VFXZ!W6@MT+Z!N:(-.GP[HC*#>ZX+.%]1O74#??]<'G4^&H/O!:'I@L5L&
M3)7^71F9!0XJL\%9:R&XF*P$ F8#X%VV@X/K'L#X' 3K$&6PB#\*IIGJ8%RH
M"4:5Q\"P00L,3FF#?H<.Z%_3!;V[J!=ZH/<.]1GU2^^7/OJ9$>A], ;]MR;3
M^R^#N:(LV!V2 YSR[/]6B,A&*X%DNP$(SML!S]P+6)XB8(*5P2I&%2S2-, L
M_QB8EFF!<9TV&+?H@-$Y73"\K >&M_7!8 #UQN"WP93!3_3MJR'H3YB@7S$%
MPY=F8#0=L$0S6!V0_6\-@J D#U2-A4 W7 ETZPU QFT' FTOX+T4 2LZ IA(
M-;!.U@3+'"VP*-$&LVI=,&W2 ]/3^F!RP0",NPU_&S\Q_&$\:O3->-+HL_$/
MPX\F8/3&#(R'S<'DN0683@>L=LF [3[9_]8@R ?E@?GO>I#^"G"S7 ],A^U
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M33%%Q!BS10VP1$P/Z\1UL$U2"P>D-'%,2@,W2JOC+ADU//Y+(^0,NO>3_%,
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MHKK.H/S:P=#LFG%69O66B/3JHQ'I-3>)UZSTFKFPC*HOH9F_@*FD^Y>0[MW
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M67N=<[(N..=D/W7*R?[LF)N-#,(^-^>_,)J+_)G !K>+ "Y6T^!T(SL<;>&
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M:'6A5<3BPG(QLPOKQ$TO[!8W^?UW<=/SS\1,SGV0,#Z+4O-M'B!W@-S!Y>L
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MYEKM=<Q9G0GF/MUQYEF]4>8#O1&?=WK#/JBWDACZSO>_T(MD!Y+N'TG6$2\
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M<#6?3>]J-;O.U39VK6M#')K7ICDTKA\D;G"H7WW!J7;E$Y?:Y6_</QH;(G>
MY+>0_"J2G[L'(/$PR2<]W/LWTL'_H(#5%0XPO<<'QO?$P/"> AC<UP*]!\:@
M^\ &M!\Z@=9#+XK&HT"*^J-(BNKC9*KRXWRJTI-:JL*33IK\TQ&:[--9FLRS
MX\1MFO235S3IQY_^8SFY_VUD_M5; ?+VDORC)/\T@-=Y ,8E (MK /JWJ:#[
MB@^T7RT$C=<RH/9:!53>:(/26R-0?&L)\N\8(/O.':3?^X'D!Q9%_$,B1?1C
M'D7D4RUEX:<NBO#GU52ASYNI@G/'B.O$X_]8NAZ@ENP_G^0GD=F'D;U[_@%@
M?P7 ] : SET M5< *M]X0!$%01[%0 9E0!*50!PU0!3U8"&:@C#:@" Z C]Z
M 1\&PP*, V[,!BZLIG!B!X4=5U'8< .QAT+#X_^QB.07DOQDDL\Z1_+)WNED
M[\:W 33O R@^ Y#["B"%["23EV0*DCP1DB=)\N1(GC+)TR!9>D!*.M#0%@!=
M"#\BDD@GR@GR!P"2AP_)P>/4?Z"Z#@6UM"BH36CI45#-A(JJ="HJ>])0,92&
M"@EL*)?#AK+E1 ,[RK83O<0*#I1=S8$R:XD-G"BSA=A-'";.<J+L3>(IYQ?9
M=YR?9+]Q?)!#S@^RR/5>%KGG0TV2K:-.03U"]_MW([(>6RIJNM-0/8B&JK%L
MJ)S)ADHE[*A4QXZ*+1RHV$TLYT3%5<0:8CT7*LX0.XB#Q&FN+XK7N#XI/N9Z
MK_B6ZXW25\[72LC]2@EY7BGB@I?SH(X:!0U(SS4DO=^0?#?2)Y]65-1WH:&N
M/PVUH]A0,Y4=-0K94;V: ]6;.%&M@^CE0K4AKF]JH]Q?U=9Q?U';R#VGMHW[
ML]H^[H]J)[C?JUWA?JWVB/N%^AONY^I?>9ZJX8(G:LCWF'BDAOP_0GV2;4QZ
MKJD\!<W)=PMR-A;F5#1SH*()DX9&+#8T2&1'O1R.;[KEG%]TZ[D^Z[1R?]3I
MYOZ@,\#S7GL5SUOM<9XWVE,+7FMO7O!*>_>"%]K'%ORC<W'!$YT'"Q[HO%YP
M3^<+WQT=%+BM@X*WB)LZ*/0C-/Z>+4U!*ZE_WX70-0AR'K9V5+0FYV$9Q#9G
M'LOQP32#\YU)$==KXVKNET:+>5X8+5WPW*AWP3/#%;Q/#%?S/C9<Q_O(<!/?
M \.=?/<-#_/=-;K =]/H/N\UHU<"EPV_"%TR1.'?#7'A!4,4.3_/__*MQ0'I
MI',[RI K3<[%A=Q-)TOJ%P<GVGNZ+]LKVPB.YS;)G$^L<[D?697QW+=<M."N
M10OO'8LNOEOF WPWS8?YKYN/\U\UGQ:X8K9-\"^S@X*7S,X*7C"_*_2;^:N%
MI\SG1$^8H]@Q<Q0_:HX21^;Y7[[]0D!GPET"T$N!T*1\]C2FO':SHSYS\6![
MZ!3,<=<QCNLF(X/GFGTA[Q5Z%=\ENT:!/VS;!"_8]@B=LQD4_LUF]<(S-NM$
M3EG/B)RPWBUZW/J$V%&;:V(';9Z+[[/Y)+G;!J5VV:#T3F+'/&@G NA$NK>'
M$* /^>XG#7/^RO#*3Y?RV,>"<L?;F7;-TX_]3_<(K@NN20O.NN3PGW8N$3SA
M5"-\S'&QR!&'=M'##LO$#C)6B.]GC$GLM9^2W&._36J7_2&I'?:_2V]E/)*>
M9;R7W<1 N0W$-#$U#SJ0;%?2_;_W[P#R/5@4WH3(P*-@5;@59$CY*X!./>?O
MQ7[*-X3[&#.6[[!7FN !CSSAO>YEHKO=ZL1VNBZ1V.[:(;G5I4]ZL\NPS(SS
MA.PFYQFY#<Y[Y*><S\A/.M]5F'!YH[C&!15'75!I-?F<#YU)MB?IO0&D?X?P
MP2>6(#P-%X&;+!FXR-*&,RQKZK%0-_:#P0'<>P(C^';Z)PIM]<T4V>Q3*+Z)
M62&YP;M>:LJK16;2LTMNK<=R^7&/4<4Q]RFE4?<=RB/NQU2&/6ZH#'F\5!GT
M^*HZX(DJW_7/@VXDVX?TWF N>!?.#8^C>.!>%!]<BA:%TS'J<"3:C+HORI%]
M1SB3>TM8*/^FD%CAJ:!4T<G '(F)@!*I-?[5,JO]&N56^;8KK/3I55K!'%9>
MSERKVL_<K-;'/*2^C/FG>C?SF7JGSYQZAP^J=_BBVM)YT(.;S( =/K+8X$XT
M#?Z.XX"+\=SP6[PP'$E4ACV)1M1M\?;L,[&>W%-1@?QK(R*%UX0GBHV$94@,
MA^9+KP@NDUL>5*?0']BLM"RP2Z4[8%"MTW^-^E+_39IM_ONT6OW/:S4'/-9:
M$O!)LRD0-1<'HL9\Z$5Z=S %'I,?+]?BJ7 AF1W.I'#"L11!V)NF -M2]2F;
M4FS8)A-=N=?$^_&-Q+*$AZ)CQ99'I4KV1>3(+ LOENMB52EVA#4JMX6VJ[:$
M]*DO"1G1; R>UFX(WJ6S*/B,3EW( YW:D _:-:&H]?\T?X0^5/@:!G G!N 2
MZ;YGTFAP+(,=#F3PP_9,6=B4I4.9S+!D6Y/FQ+4JA<DWF!0BU)<0)=H3ERC9
M&9,ATQZ=+]<25:ZX)+).I3&B1:T^O$>C-GRE5C5K4J>2M5VW@G52KXQU5Z\L
M_)UN603JE$:@-OG4^M'W'[&O2?>^03K?.=)]CV=1X4 .&^S*X8797"E8GZM)
M69-C3AO.<N!<GN')VYL6*-25$B':GA0OT9*8*MT4GR/7$%>B6!=;K5(3TZ16
M&=VI61Z]0KLD:D*W*&JK7F'4,?V"J-OZ!=%O] JB4:<@!K7GPP" 1Z1[7R$S
M.$VZ[^%<"NS.I\+6?-+]"\5AHE"=,E)@0AO,HW,NRW%?T)GE+]B:$2:R)"U&
MHB$U6;HN)4NN.JE0L3*Q4J4LH4&M..'_V#H+L*K2[NW?^Q1Q.(?N#B4,,  E
ME);N[D[I%"0$!!%!14!$! L5L;N[<W1TW@EU=!QCS+%''=W_A3&O[WS?-=?O
MVOO .?M^UGIJW<^<8>::%B=UCRA([!^5E[C5/#?QF'E.X@WSG*3GHW.2/H[*
M26)'$B.^A0T![E _?)]!?HN\[T'RGCM+&6PJ)>]?IHSETXS04S:6TUEB+YA?
M-$4XI\!/=E9>F&)];JQJ37:R1N74+.WRK$*]TLQRPZ*,NN$%Z2VFN6D+1V:G
MK1B=E;K9/"/UL$5&ZB\6&6E_FF>D?1B5D<:.S$QC1WS+QW#@5A+U _G.8X7D
M^<K(;Y ''RSG866% GJG&Z!KNCFGK=R6/Z?,5;JQU$=<5QRB4%T8K5)1D*A1
MEI>A79R;IU>04V:8FSUC>/;49M/,J9TCTK.6C4[-VFB>G'G0(BGK1^*I>7+6
MWZ.2L]A1*5GLR&]Y26/A>BKU0RYY_Q+* 95=&\E[K:IBT%<MAT4UNEA0,XK3
M4CV1/ZO26:JNPDM451ZD4%X6J5)2FJ!>6)RFE5>4HYM=6&*065 ]/#V_R20E
MKWU$8M[24?&YZ\WC<O>;Q^9>(1[3_?M1<;GLR/A_\9#&PH_4#R<+@'WDO[=6
M4PYJR7,0B^K$:*_71FO]"&96G16OKM9!LJK&0V9:=8!<<66X4L'T.+6<BA3-
MK/*I.NG3B@Q2RBJ')98V&L>7M)G%%/>.C"H>'!U9M-<\HOB2>431H]$11>]&
M11:Q(XD1WW(W ;@T-!8I![LK*0=UE /R?SU$^RP9M#:IHZG)A*EK&L^M:IPD
M,:UABK!HII]L7GVH8G9MC&K&C"2-U)I,[:3J KWXJG+#F,KZX9'3YYJ&5_2,
M"*T8&!E<L7M44,6%4<'E#XBW(X.GL2-"IK%FWW(KA=8$\O\':0QLH]@'&RD'
ML\EW41G<TB*%QE85U,XU8BKGCN&4M=KR"UM<I'+G>(NR9@?+IS5%*B?/2E!+
M:$S7C&W(TXF:6:8?7E]K%%+?,CRPKMO4OW:UF5_MSA&^M>>(^R-\9_QEYE?#
M#F'Z+;\,K0G%Y+VI#S:1_JHYE /RH'/G PT+^*AI5T!%ASY*.T8Q!1T3>-GM
M3A(9"SR%*6T!XL3YX0JQ\^*4H^:FJH6W9FN&M);H!+;4Z/O-:3;T:>X:YM7<
M;^S1O-W$O?F,B?OL>\8>36],/&:QQAZ-_\LE&HN':1QNKZ<<D/[2>92#=O*>
MY$.KNH'2Q6(4]F@A=XDID]5CR4GMF<Q/7#Q%,J[;3QC='2H;OBA:(:0K23FH
M*TO5?V&AAD]GI;9G1Y/NE(X.?=>.E88N[5L-G=M/$7<,G=M>&3G/9XV<Y_TO
M9R@'>V=0#BCW*RGV[@[* 5F1.O*A1<N!G!5"9*Y416K_,"3UCV'B5MIRHU:Z
M\,-7>DF&K @2!JZ(%/DM3Y#S69ZNZ+DL7WG*T@HUEZ4-&DY]"[0<^I9K3^K;
MHF/?=X*XK6V_Y*6.?0^K:[?X$WI?.3*=<C +&*#X>SO)_R\F_]]'_I]\:.X:
M\O_K>(A;+X_H];J(W# "81NLF. -#MR ]>Y\W_5^$E[KPZ0\UL<*W=:EBES6
MY<@ZKBN3GSQ8KV@W.%_99G"IRL3!3:H3!H^J3EA[2]5ZX(6:]>J/ZE:K6(UO
MV4-]L('Z?SGI+R3]YF7D?U>1_R0?FK:1_!]YP: =,@C8J0J_G4;PV64!SUTV
MC/LN9X[;+B^NRZY GN.N2,'D78D2]KNRI&QV%0LG[)PA8[6S53Q^YQ+9<3O7
MRX[=>5AVS,X;LF-V/)>SV/:WO,565H%0_,J65J"?\M]-^JV4^UJ*O7@]D+$5
MB-U)^GN!*8?X<#XB!Z<CFG X:HS)1\=BTC$[V!US86R.^3 3CH5PK([%<"V/
MI?+&'<_CC3D^76!^?+9@U/%NB1''UTJ:'3] _"QI=NQ/2=,C[Z5,#K/2A/ K
M:TA_">G/)_WZ :",8L_:#L21=O!!P.,H>>!3/%B=E\*X"_(8>U$+8RX:P^*[
M,3#_S@:C+SECU"5OC+@< K/+<8S)]QF,\?<ES+#OZSE&5]HY!E=6<?2O[B8N
M<_2^?\C1N_R:JWN)Y7U+'^FWDW[CP)<SJ%U _ '2)VV/D\"DLX#E=PQ&715@
MV"]"&-U0@.$-+1C\.@SZ-T=#[Z8U=&\Y0.>6)[1_"X+6[5AHWLZ$QN]E4/M]
M%J-ZIYM1N;N.4;Y[B%&Z=YU1O/.44;S][G_H)/TFTJ\@_9S=0,(ATC\!N)\!
M["\"X[X'S'X"#&YPH/-0&EJ/Y*#Y6!7JCW6A^F0XE)^,@M)32RC^:0_Y/]T@
M]\P?LE20B)]G0/2B##(O9T/XJ@?2KS9 ZO41XB=(OGK\/S23?N46F@-[@,0C
M0,AIZO\+@.UE8,R/@/%U4)R ^GU Y2\!E-Z)H/!> 7)_JT+\MS9$'PPA\\$4
MTA\M(,E.@(!U!)?U!EC:D%G:#-E2HHF@A+,TT%GJ9)8$V(O_4$WZ^:2?1+D/
MI;R[7P)L?@#,27L8:6O= 93^ .3? +(L Q$K!2$K(CTYTE,B/35ZC@YA2)@1
M8PD[8@H13%!AP%)1P,XD:.%C:=*S6_X'UL"480V-"?*Z>B,85FL,PVK8,ZR:
M!\.JA')8I40.JYC#817*B%JBF6@C%A&]Q$IB@-A(["#V$R>)*YP/"G<X[Q2>
M<=XHO..\4F0Y+Q59[O\/UHCTAQM]9NC>P)S:8L.P.F[4GB .JQ''8=4R.:QJ
M,5%-S"+F$IU$#[&,6$VL)[9R/ZKNY7Y0/<Y]IWJ)^T;U=\Y+U:><9VKO.$_5
M6.X3-98WQ&,UEO\MK+$APYJ2SQW"Q)"NHQC6V)IAASE3;OPXK'X4A]5-Y;#:
M^40%E]6N)^9P/VHOX/ZMM8C[7JN/^TYK)?>MUEKN&ZW-W-=:N[FOM(]P7VA?
MX/ZI?8O[2/L)]P^=M[S[.BS_K@XKN/,9B6]A1^B"'46>?Y0FV-'4#G-38CS#
MCIS,L&9>'-8DC,,.3^1\&);-?6=4ROW+L(;[VG 6]Y7A7.X+PP[><\/%O&>&
MRWA/#=?PGAANX#TVW,%[:'B0]\#P'.^>X4W>;:/'O)M&;P4WC%B):T:LY"]&
MK-3/_X(=3=ICR/^/50%K26VQ&D90?XRG_ACCQKPW#^2\&17#>3$RG?OGB +N
M$[,*WB.S>MX#LV;>?;,V_CW3+OY=TU[^[Z;]_-NFZ_BW3+?Q;YKMY]\P.\/_
MQ>P&_P>SQQ*7S?Z2NCB"E3YOQ@K/F;$R9_\%.Y;T+17 3B!LU<#:4R[LS/#1
MUI)Y,]&1>6;EPWDT/IQS?UP2]\[8;-[ML26\FV.J^3?&-/*O6;0*?K;H$/QH
ML5CB!_/E$E?,!R0OFV^6_,Y\C]1%BQ-2YRU^E#H]YH'TB3%O9(Z.8<6'Q["R
MAXB#GY'["FNE"':B+-A)<F =E< Z:X!U,L0KQ]%X/,F&N6?OQMRR"^)<MXGE
M_C0QG7=E0K[@TH1RB8O6,R3/6\^2.FLU5_J,5:?T*:LEPA.6*V6.6ZZ3.6JY
M7738\I#HD-5%\7ZKN^+=5B_E=EJQ\MNM6(5M5JSBUG_!3B1M>R%IBVA*T[V[
M$EY-T<)#M^&X[3(6UUP<F2O./IR+CN&\LPZ)@E.3LR2/3RJ2.FI?(3QL7R=S
MT&ZV:+_=//%>NX6R>VS[Y';9KI;;8;M)?KOM7H6MMJ<5-MO>5-Q@]TQIT.Z#
M\H =J[+F"ZN_@;4G;2?R_N[28+UD\,Y;%H^\E7#+4QL_>([$!2];YK2G.^>8
M>Q#OT)08B7UNJ5)[7'*$.YU+1-N=*\5;G>KE-CLVRV]R;%/8X-"MN,YAN=):
MAT'E 8<=*JL=CJFN<OA)=87C8[6ECN_5^AQ9]5YBR1!.K-I76 ?R_F[DO<E_
M/_.3P%U_*=SV$^&JGS+.!1CC>( 5<]#?F;/'SY>_PR=<<JMW@O0FSPS1>H\\
MV4'W,OF!*=4*JZ<T*/6[M2BO<.M06>;:J];GNEJ]UW6+1H_K08UNUTN:7:Y_
M:':Z_:75X<9JMA,+AICR7U@GTO=D\-R?_%8P@Y]"^?@^1 KG0A1P--0 ^\+&
M,CM#)W.V!'ORUP<%2ZX-B!&N]D\6K_2=*K?<IU"AS[M<:8GW#)7%7DVJBSSG
MJR_T7*31X;%"<X''!NTVC[TZ\SS.Z;1ZWM%I\7RMT^S%#J$]^U^PKK1D^Y#G
MI*7]IPCR?%%<G(D2X%BD+/9&Z6![]&AF8Y0M9VVD&W]5N+_D\M (85](O+@G
M*%U^46"NXL* $N4._TK5!?[UZO/\6C1:?3NUYOCVZ<SV7:L[RW>G7J/O*?V9
MOK_IU_N]T*OS8X?0K?7_A,Y7AK:6%^3_?Z5M[E(,<#J>@Z/Q/.R/%6%[O 8V
M))AA(-Z:LS+6F=<7XR.Y."I$V!41(^X(3Y9O"\M2G!M:H-(2,DVM.7B&QJR@
M)JV&H#:=^L >W=K U?HU@=L,J@./&58&WC"<'O3,8'K01_V*8'8(O6]A/8$_
M* <_1Y/7(<]U-)D\7S('__X_H@L4=B1)8V.R*@92C+$B>3RG-\F!MRC!4Z(C
M+E X/S92W!J3(-\<E:[8%)FKTA!1HE8?7JDQ([Q!JSILKDYEZ"*]BM"5!M-"
M-QN6AAXV*@G]V:@X["GQP; XG#4@]+_E4\^$ =_' :>H10?3R FG YO3)#"0
MKH05&4;H31_++$JSY[6G3)&8E^PG/2<Q3#0K(59N9ER*8EWL5)6:F$*URIAR
MC8KH.NUI47-T2Z(6ZA=%+C<LB-QHE!]Y<%A>Y-5AN5&/B;\-<Z-8@R_H?^6=
M'XW.2!H9B< QTM^;14YX*K NDX>560KHG:J/15/-F?8L&^[<#!?!['0?J8;4
M$%%=2K1<37*B8F5BAG)Y8IY:64*91G%\C79AW&S=O+AV_9S8I8938]</RXK=
M-SPS]M+PC-A'PS+CWAMEQK&&A,&W_!D(7*>1<9:<Z"'2WYE#3IC<V.H<!DMS
MY="=IXOVO)',W-P)W-G93H*&J5Y2M9F!,E49$;(5Z?$*I:FI2L6I.:H%*<4:
M><E5VME)LW2SDMH,,A)[C=(2!X>E).X9GIQXD7@P/"7QG5%*$FM(&'S+PQ#@
MQWCJ!\K_/M+?2HYXD JAY71=7"!&1Z$6YA69,;,+K3@S"QSX,_+<)2MS_873
MLL/$)5-CY0NSDI7R,J>J9F<4:F1E3-=*3V_034V;IY^<UF.8F#HP+#YU]_"X
MU//$_>'QJ6^-XE-9PR$24EF#K]RG&?(]%6#'* >[27<3N<'55!3VTK6S1(1Y
MI>IH+C-&0^DXSHP2>][T8C>)LD)?87%!B#@_/UH^)R])*2LW4R4C)U\]-:=<
M*RF[3B=A:JM^7%:W84S6ZF%163N'1V:=(>[1_1NCJ$S6,#J3-?B6VU' !2I&
M#U$.=A31.)@&K"!7W$77>>5"S*Y0P<SI1I@Q?0PSO<*65UKN(BB<YBV=5Q8D
MFEH:*9=1DJ"85IRNDER4JY906*896S!#.SI_CEYD?I=!>-XJH]"\[<-"\DX1
M=XC71J&YK"%A$/8-O])\.)-!_5  ;"DC)UH)]%4#;57 [&H)U-<HHF:&/BIF
MC&9*:R9R"VJ<^#G5GI)950'"],IP<?+T./G$BE2EN/)LU>AIQ>H19=5:866S
M=8)+._4#2U8:!)1L-?0O.6'D7W+;T+_XE6% ,6L04,3J?\N/U _'LX%=)>1$
M2;^_EIQ@'=!"U-=S43E3#M,:=%#<.(+);[3B9#=,YF7,G"*14N\GG5@7*HJK
MBY:-KDU2B)R1I1Q64Z@67%VI$5 ]2\NOJEW7IVJYGE?E9GW/RF,&GI6W]+VF
MO]3WJF#U_LUW-!\/40ZV4?[7DO[2!J"#G'DC,7TV4#)'C((6#>2T&B.S=2R3
MVF+'36IQX<?/\9:,;@Z2CFR.%(7-3I +;DI7")B5K^PWJUS5NW&FAF=#FY9[
MPU)MMX:-.JXSCQ"_ZKC6/]=QK?NHXUK+_@]G* =[J \VSJ <-%(.FH&Y+< ,
M<L=%\\F-+9!&1KLR4CL,D-0QFHGOF,")[G#D1;1["$+;_26#%X1)!RR(E?%M
M2Y7U;LN1]YA?IN0VKT[%9=X\-:>YO>H.<]=K3)Y[B+BF,;GEF<;D.1\T)S>S
M_\,1FH?;J>_7DG[?''*C\X!9"\@-DCN>N@A(6<Q#?(\<8I9H(ZK7%.&]XYF0
M7GM.X!)7KO\2'[[/DF )KYXH*?>>)*%;3Y;(>7&QK./B&OE)W2V*=MV+E6RZ
M!Y4G=N\G?E*>V/549>+"OU4F=+*J$SK^R]YRR@&9HI6DWT5QMY#VC&Z@> F0
MOA2((J,4VB^#H%6J"%AM"+_5YO!>/8'Q7.W(N*_VX+BM]N<YKP[G.ZZ.$TQ>
ME2YIOZI VF95I7#"JMDBJ_Y%XO'] [+C^O<25V3'K7PB.W;Y>[FQRUCY;QDZ
MG5M#^DO::"Z0.6OH(4>^C!QY/SEB<J<AZP"OC7Q,V20'UTU:<-EL#*?-8^&X
MQ1:3MS@S]EN\&-LM09R)6Z*XUEN2>99;<OCCMDP3C-G2*&&^N5-R])95DJ.V
M[)(:N>4[R9&;'DF-V/A6>L0&5FBV_K^LI_Y?2OH=7>3(*?;*%>1(UP#)ZX$(
M<N<^VP"G7>2*]TACPEY%6._3@>4^4XS?/Q;C]MMB['X7C#G@#?,#(<SH [',
MR /IC-F!(H[I@5J.\<'YW.$'EW.-#F[C&AX\RS4\<)]KN.\-SV OR_^6E:3?
M1?IS>H&:_B^G0INH#[8#?KL!EWWDB@\!%L=X,#LIA,DI11B?UL;PT\88=MH"
M1F<FPO",$PS.>D'_; CTSL5!]]Q4:)\OA];YV= \WP/U"QL8M0O'H7;^=ZB=
M>\FHG?F;8#E?63ST[:P^H';5YU.A]*U -&G[[R?]P\#$8Z1_"C YQT#O.P'4
MKPJA\A\Y*/^H#N6?#*#TTP@H_CR>L(?"+^Z0OQ8$^>MQD+N>#;D;51#_.A_B
MFRLANKD+,C<O0_CK8\C<> .9Z^__H8WT9ZX&2C< F11[#,7M3]HNQX$)IX'1
MYX%AEP"=JX#*SPSD;P@@=T\$\3T%B.ZK0^:^/H1_F$+ZP1A(/;"%Q$-7\!\&
M@/<P%MR'.6 >U@ /V@D2>4@/?WB9^ -X]/0?&NE7TX9.I78"L0>  -)V)FUK
MTAY%VH8_ )J_ (J_ N+;@,P3#J1?2T/BM1C\UPK@OE8#7ND0PXC1A#7PVHGP
M):@H>$T;T6M:?%[3A'M#8F](Z*^3Q'?_4+'QRZD4]7D@Y=R%M*U)>\1_ /UK
M@-I-0/YWTKX'2%"S>>\ AN52:2Q)B("/<H02W6L0^H0I,8Z81'@1M"FR5!2Q
ME ^6!A]+DXZE3F>W_@.K-9PPHD>0^U4V!BL_&JR<#5CQ%(85!3&L,(YAI;.(
M8J*::"1:B0YB,<-*+27ZP4H-$IN)7<1A?)0ZA[^E;N"MU$.\DGJ-%U(LGDNS
M>";-,L^$_PNK:PA65Q^L#J%.;5$=26VQ!JOH0NWQ9UBY:(85IQ$%1 513S03
M;407L818P7P4KV'^%F]@WHNWXYWX /X2G\8K\2]X+GZ )^)7>"1FF8>R+/-@
M"#F6^>,;6 -=L 9:E$9"EURXKBGE93SEQ8':X\VPRN$,JY3$L(HY1"GS4;&&
M^5MQ%O-.H95YJ]#!_*70S;Q66,J\4EC%O%18Q[Q0V,H\4]C'_*EPDGFL\"/S
MA^)]YJ[B*^9W)9;Y38GEW%+^S,UO8(=I@AVN"M9(!>PP:L=PZA,C"VJ3+;7'
M':QV,/-!,XYYJY'!O-$H9%ZJ3V>>J]<SS]2;F:?J\YDGZ@N91^I+F(?J*Y@_
MU-<R]]4W,_?4]S!WU(\SM]6O,K]JW&>N:;[B_*C)<JYJL=PKQ/=:+._R-["F
MI&^F2$-) >Q(-8+Z9.0(>FV-#\;.>#/,CWEA&,D\-4AF'NGG,'_HES+W]*N9
M._H-S._Z+<QO>NW,+;UNYE>]I<P-O=7,-?V-S,_ZNS@_ZA_E7-7_GG/)X![G
MO,%+[AE#EG?*D.6?-&0%)_X%.Y*T1\N"M9"CX:Q$4%[&#L,["PL\'VV'1R,]
M<,\LA+EM%L?<-,U@KIL6,#^;E#/_,:GE7#5IXGQO,H]SR:23>]&DAWO!9 7W
MG,D@]XS)5NYIDP.\DR;G>,=-?^,=-GLF.&#V46*?&2NYYPN[S5BIK[ 6I#]6
M"-9*!'8"M6.B,MY:Z^"II0GNC;/$S;%.^&6L'ZZ.B62^&Y/,.6^1S3EK4<P]
M;3&=>]*\CG?<?#;OF/E\_A'SA?S#YKV"@^:K!/O--PKVF>^6V&-^4F*7Q76)
M[19/I+98O)?>9,$*-WQA_3>PXV1(7P#63HJFM P^V,OAJ9TR?I^HBU\FCL)E
M&SN<M_%@3DT,9HY-C.4<GI#&/6B=R]MO7<+?:U4IV&U5+['3JEEBAV6;Y#;+
M;JFMELND-ENNE=YHN4VXP?*P<)WE%>& U0.9559_B?JM: 99L^+E_X*UE@!K
M2X[3@8OG3GS\X22%.Y/%^'&2"BXX&..DHQ6..+HP^QW].+L=(K@[)B?PMDW*
M$&RVSY?8:%\FN<&N6FJ=78/T6ML6X8!MA\QJVR6B?MM5HA4VF\3+;??)+K4]
M+]MK>U=NL=TK^6X[5GX1T?4O6!N&](&GKN3YW(&?W/GXWDT*YUP5<&R* ?:[
MC\$N]\G,UBF>G$UNP;QUKC'\M2[)$JN=ITKV.Q5*KW J%RYSG"&SU'&6J-=A
MGFR/0Y=<M\,R^2Z'=0H+'78I=#B<4ES@<$MQON,+I7F.K-)<HM6)5?R6H</F
MMR[ [^3(?Z0E_H(?!Z=]!#CJ)8N]/MK8[CL*&WUMF$$?-\YJ;S_>2J]PP3+/
M>,E>CS2I'O<<8?>48E&7VW1QIUN=;+MKLWR;:[O"/-<EBJVN:Y3FN&Y3;G8]
MIC+;]9K*++<_51K</A"LRLPIK/*WL)-IZZ+XKY/WO1@$G"#O=RB(B[T!,M@:
MJ([U0:98$V3%K ATXO0%>/%Z_(,%B_RB)3M]DZ3;?3)EYGOGB^=ZE<FV>%7+
M-WLV*C1YSE-J].A6GNG1KUKGL5FMUN.0V@S/']2K/1^K57G]3;"JE9]1^0KK
M#-SU!GX@_=/D^PY%4)T=SF!;J!36A:E@5?@P+ L?RRP)F\3I"G7G=80$"-J"
MPR7G!L9)SPE,E9D=D"V>Y5\D-].O0J'.KUYQAF^+<K7O0M5*WV5J%3X;U,M]
M]VN4^5[2*/5]J%'J]TZ]Q(\=0HU0_<I?;L!O_L!W8>0YH\G[QY+7H"UW0Z0
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M+@6;V1<5;&<]5+!M?*=HV\#^#_OR:2Q2SOM)>U$CS8590#5I%\X!4N:1]UP
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MCF?2?8AGO.@&UWCA<YYQYP>^<0?[#P,4>R_IMI$-J__T/2#R?G,I!PN X(6
M!UE5AS[ >CD/8U>(,6:%*BQ6ZF/T2C.,6CD6(_MM,*+?&6;]7C#M#X9)?RR&
M]V=@6'\)8]@_DS'H[V3T5JUA=/OW,CK]_V%T5CYE=):_Y^@L8_]A>0.PD'2;
M2;=R/I#;3N.@B\8 ^7&?98!S/S!A#6!!OMQD@P2,-LK!<*,J]#?J0V^3*70W
MC8'.)AMH;W:"UF9O:&X.A<;F!*AOR87:EBJH;)D'Y2W+H;1E!Q2W7(#BYH=0
MW/@6BAM8YBO=+30.*-_U%',QV=%TBCEJ!>!/NJ[DQVW)EH[90AZ8?+'>+D!M
MCP24]HFAN$\9"OMT(+]_.#$:<ONM(7? $>(#WD081 =2('.P",*##9 ^L B2
M!]9!XL 1XE>Z_Q.2^]\1?W]B <7=N(C6 ]*>2C''KP6"-@)3M@)V.TB?=(W)
MJNL> %0/ _+'&,B<DH3D:3$D3BM!<%H+_--&X)T9">X9*W#..- F2 7)6=J$
MSM*D.TL3[APE^BP)G*6'GB6_?^XWXBGQ[!.S*?;IE//<U4#B>IH']#;WH>_@
MD*X%Z0XG7>UC@#)]5/8L('T!X%WF4-%!GO][6>"*$G!5 _C! /@/>?Z?Q@,_
M#Q6H5!Q>HT7X.BW URL)ZNCK*X$;%-@->MB-&\1OGZC^>@9$.0_=26-P'\5_
M"# G7:.3@";I*EX$1)<!B1] Q3]!'\>O7."F%'!+3*9  ;BM2H6I#G#7&+@_
MA@IE>^ 1M>,1M>,Q+8)/:,(_H:0_H60_V48<(4Y\HHARGTK]';X;\")M^^.D
M?YKTSP/JERCWI"LD7>Z0[M 9S!WB/O''E_.0AP+2$))!H9S\J0@\IYR\- 3>
MC ;>4L'\GHJDOZ. #[3Y?*!V?*0)]Y$"_TA)_[CQ$Y_/',CS2Q.,'EB8$):$
M(^%+1!(I1 Y12E3C(QKP-^;@/=KP%@OQ%WKP!LOQ&JOQ"NOQ MOQ'/OQ#*?Q
M%-?P! _QF-[QB#[]D'CP+UA%\MGRY/E%A(#NN</HIV.(280G$4HD$%GX@$*\
M0P4]K8ZTFO 2<TFKG;06X4_TD=9*TAHDK2WT[#V4KA.XAQ\H=??Q.WWB-K7^
M-WK2K7_!*JM1.\CSRRI];H?0 *SD*+"\B907MT_G01\13=JI%&<N:992;%6D
M-9-B:B:M^:3025H]N(MEI+6&M#;2LW?A5QS%=5RB(707/U%V_D-17.6PN#($
M][^P:HK4#O+\"K*$,N6$^D1L\L]YT%M);[P2A.&9( &/!9GX@U^ N_QR_,Z?
M@=_XC;@I:,&O@C9<%W3A%T$O?A+TXS^"];@BV([+@D/X3N(B+DC>P3FIES@C
M9'%*AL7)+YSX JLI!JM.GE]-1,A_/A-2,L![^=%X(6>#QV(WW!<%XHXH&K=$
M*;@ARL8OHF+\*)J.JZ):?"]JPB717'PGZL %40_.BU?@K'@0I\7;<$I\""?$
M%W%4[BX.R;_"?@46^XB]Q!X%EOD*JRL-5HL'5E>2H'9H*^ O#4T\41F.NTKC
M<%-Q,GY6],(5Q5!\IQB'"TKI.*N4B]-*I3BI7(D3RO4XICP;1Y7GX[!*%PZI
M].& RFKL4]V$O:K[L%OU+':J_8:MZL^9S1HLLU&3939\8?T76 /2I^6%'<;!
MWT82>*,O@T?4CEL:6OA1PPS?:4[ 66U7G-3VQU&=2!S22<0!G4SLT\W''MTR
M[-:MPD[=F=BA.P?;=!=@JVXWLUEO!;-);QVS06\GLT[_!#.H?YU9;?"4TV_P
M@;/"D/:H+RS[ CN,]$UH6M,2=V<$+3TF?%S3%^*ROA).&QGAZ+"Q.#!\,O88
M>V*G<3"V&<=@BW$R-AE/Q0;C F:]\31FT+B:66O<P*PQ;F56&W=R^HU[.2M,
MUG"6FVSE+#4YS.DSN<KI,7W$[39[Q^TR8WD+O]#YA2']H:^YW1E'2ZPE\-TX
M!N=&"7#"3 X'1NE@U^B1V&IN@XWFKEAGX8<!\W"L-H]C^LU3F17FV<PR\T+.
MTM'EG-[1,SA+1C=Q%H^>SUTTNIO;-7HEK]-\(Z_#?#]O@?E%WGR+^_RY%G_Q
M6\:PGYCS#>PH6NY(^YH-<(&6UQ-V5.M;<[!WG A;QZMC@Y4Q!JS'H]_: <NM
M/=%G'<0LL8ID%ELE,(NLTCD++7,Y'9;%W';+Z=PVRWK>/,L6WES+3GZ+Y5)^
ML^6@8+;E;L$LRS,2C59W)&9:O9:HMV8EZKY0^X678VFIIR7ULB/INY#G(Q^^
MD[:<S;926&NKA'X[ RRUM\ 2>ULLLG=%I[TOTVX7RK39Q7#FV25Q6FTSN7-L
M\WFS;<MXLVQJ^(TVLP0S;=H$=38]$C-LUDC6V&R7JK(](55I>TNJPNX%P4J5
MV[&2W_+$FK8STC]+_ON@!["#V$#W XX\K'"4QQ(G'70YCT"'LS7F.SNBU<F3
MF>,4R#0Y1G :'>.X,QU3N74.V;P9#D7\&H<*0=7D>HGIDULERR<ODBJ;W"]=
MZK!%NMCAJ+#(X;JPT/&9L,"1E?Z"U%?^H-Q?=06.TQ:WQY>\#K&:[I=3.Q:[
MB=$Y10/SW8W1ZCX.L]WMT3C%C:F?XLO4NH5P:MRBN56NB;SIKAF\<M<\?IE+
MF:#$989DD4NS5(%+IW2>RW)AKLM&F1R70S+9KC^)IKH^E<ER_2#,<F.'D/[*
M'2HY+E+LA_W(^P^=OQ#+Z'XQ;7?MGC*8ZZ6*9F\C-'J;H][;!C.\G9DJ+R^F
MPBN0,\TSG%OJ&<<K]DCE%WID"_(]BB5R/:HDL]UG266Y+Q!FNO?)I+NO%Z5Y
M[!>E>EP1IW@\%J5X_BV3XLD*O^4FC8&SY/_WD_86\IZK0LASTGT'Y:/55PI-
M?DJ8Z:^'&?XC4>5OC0I_!Z;,WYTI]O/C%/J&</-]HWFYODG\;)],099/@42&
M3X5DFL],Z12?^<)D[R4RB3Z#H@2?O>)XGTO$(^*]*-Z'E2&$7[DVA;P_^?_=
MI+^!RJ_EX4/G+U1C!@!-@0+4!<FC.D@;%<&F* L>C^)@>Z8@R)7)"_+F9 <&
M<;("([@9@?&\M( T04I KD120)ED8D"=='S 7&&L_V)1C/^ ."I@-W%!-C+@
M 5W?B:("6)DO"(?X@7)^E/S_#M(?C*8ZG\J>!73?'$QU;B@75:%R* _30$G8
M<!2&CT%>F VRPYR8S# /3GJH/R<U-(R;'!K+2PQ)X<>'9$O$AI1(QH3,D(X*
M:1%&!'>+PH-7BT-#=LF&AIPC_J#[MZ+0$%84%LS*?.42]<,ABGLKZ:\>.@.*
M >;2?0/EHYK:,BU2A*(H5>1'&2(G:C2RHJR1'N7 I$1-89(B?3D)D2'<N,AH
M7DQD$C\Z,DL0&5$D&1Y1+1T:T2P,CN@2!86O$@=&[! '1)R1#8BX)PX(_TL4
M&,X.(?.5\Y3S?:2U*0Y8D4">,YYR0/<SJ/R:1NTIC)5!;JPRLN+TD!XW JGQ
MEDB*MV<2XER9N#AO3DQ<$#<J+I(7$9O #XO-$(3$%D@&Q59*!<0T"?UC.F5\
M8U:*?&*VB;UC3A%WQ3XQ;T0^T:S,$+Y?.$TYWTUQKR?_W4>T$8V)5&M36XJH
M33F)4LA(4D!JDC:2DDV0D#P6L<FVB$YV9B*3/3GAR0&<T.1P;G!R'"\P*8WO
MGY0GX9M4+NF=V"#ME=@N]$A<+N.>N$4T)?$D\;O(/>&UC'L"*^,>SPH]OG",
M<KZ=]-:FTGPD6HC:%/)\R:1/U_14/I+2Y!"?KH&8C&&(RC1'1.8$A&4Z,"&9
M4YB@3%].0&8(UR\CAN>3D<SWRL@6>*2724Q)KY=R2V^3=DE;)G1.VRSCE':<
M^$W&*?65C',J*W1.^2\'*0>;26\5V8#.#)H+&9_/@/*)-/I9XE0&,=DB1.2H
M("Q7'R%Y(Q"49XF /'OXY[DROGG>C'=>$,<S+Y+KGI?(<\O-XKOD%@N<<FLE
M''+F2DW.Z96VS]E(')&VR[DI;9_]4MI^*BMMG\5*3_K"T'G<>M);F@/,I_*[
MGB@CIM+KA#SR?07D.XJD$5BL /\2;?B6&L.[= R\RB;"H\P1[F4>C%N9/^-2
M&L9Q*HWC.I2F<R>5%O+L2JH%-B4M$A-+>B2MB]<3AR2MBF](6A<]E[0N_"AI
M7<#^P_:AL[!<F@_Y-!:)*J*0=-,+@>@2\MYDU7PK^/"LE(5[E1K<J@WA6CT2
MSC66<*JQAV.-*R;7>#/V-<&,74TTQZ8ZA3.A.I=K53V=-[YZ-F]L=3=_3-5:
M@475?N)G@47EGP*+B@\$*[ H_\PFLD KBVE=)AJ(::2;4TK>F[3#R*+YS2#O
M60\X-<A@<J,B[&=IPVZ6,6R;+&#3- $3FAQ@W>0.JR8_C&\*9\8U)3!CFJ8R
MYDUEG%%-C9R130NY9K-6<TUG[2&N<$T;GG!-9_[-,ZUG_V%M$:U+%;0NEP,U
M1!'=IU<!,:0=.).\7Q/@2)9UXCP^+.?+8ER;*L:VZ6-,FRDL%HS%Z 4V&+7
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M)?1W;B<GH;?S4>CM> M+MG\'_6V_0W^K8IYM8UP7J3E$VL9Y+-"FR]GG]#5
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MMQ;,N'5AVFT0*]PF,.DV*RQWWR*,N^\7QCQ."Z,>UX41CQ>%(<DGPJ#G+\*
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M$*8S=3"9Z8'QS"0,9[; 8.88#*8?@?[TZS!8\34,IGZ#X13=Q*0"FSHY%SN
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MH^HP&].#Z9@13,:L8#SN"*-Q"0S'_6$P'D$2H3^1A243I=";:(;NQ!!T)M9
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M2;8">ZDQ2T:HTT'J:-%*22Y)94F>D U(:9?"\T0(SM=!H-P0_G(+^!4XP*?
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M:X*92A!-1=#4L=:1)]/@>%,AKU,A45,A3U/(&J>\P8+P&?B+YN/?2>@:"[I
MJ]F'1)M+:7,>;<Z NB?2G)B)Z(>?VQ$9-C- @;/AEG-(>.:0@,QEH9_+XC:/
M27T>$_T\!O8\.G8>@N;QQ?F0VGFG 0CLO-U\%G(X]V6^^P?P9^\=8L/HZ^6Q
M8\R/-: "VIQ)FY,FHQ^]+JBB?0X<?+X4L C>OYC$;PD)UU*2G64D&B>1B"R'
M]Z_(L(K_9K"MP,DK!JR;;5;0'RLNYC.0V.5DSB<]!S[BNU]K"OH&P!C:W#)@
M[0,J@B)GT>;D&>A'KY-FV!;#04^2_.#(I&DD67#*4TA"UV#'J0XK^3H]ADF7
M!?],%L)UQ;X]*?ABG3D:&7*_COXX$Q)_!MGS&9#6TW\-OM0$=/:#=K,/"+>5
M3B4&9C$&YZ$?O4[T1M"$(+@YB25R *)(5UGL_*7S\<<%X=:^E(NQ8SW^V(@=
MFXB-S>:X- )\$XW<1&R:8V$WTA\;R=XW' :O\OF/-8R)W?B["7]7\+$\VIQ*
M",6@U[E6"C]3\C\'?82U3"UDHS?I)O'QU40N-W41DO&K0DG*29"W$1_7F021
M&-U.;&RG3[83=#>BZ,9E7+^01_KC>OKC>EC-=>^I#W^WX>]J*'DA'TE?#?^G
MO4[TAEV$[S?Z])F]*-OTKWM1=OCJ$[M':B)!TFWXY';ZY@[B] !V'" V#M G
M!QA<!VCD 83?Q?BX<Q]@?-QY5%V+I'K\78+NS#.D^//0OQ[]E_GJ/=?[=-WL
MJ[F86LB=^G%OR$A-9*0><HAX/4R<'*%O'B=1?XJD\"D6X:>(SZ<(M"=1]B2-
M>X)&/'D '%'+*?0!NG//MTZF<6-B^'4^O;?X=/+1?[DGYQ']>&KL$R?40T;V
MB!CB^A(^>14[WL0?OR!&WV)1>)L!^ [!]LM3 <Y]%R>^>^>_U1_,GA!S/TP\
M7#A+WZL4=EKONQ>E3Y_#8_X W_X]/.:W\'[KI-"5\.4U>A<V] YL[!>PLV,P
MM5=AIB_CO!?@W,]CM/FMV&=@UZ;N\;0/C_MJ$"?:\ ,\\ULY8*0>/IVJ3^&Z
MG\ Q/U0S>KKT-GSJ&'S[5>QX"=[_ FSJ>=C5S^';SV+'T]CQ4]CMDP3NXS#5
M1PF:1^!XA^'<A[#B)W#N!^&9(Z>"FC-2[C[!AK^"SV7N XF &;MH3P*69]&6
M$EQ;BXXVY'?C^@&Z8+SOA(Q9>@@[?H(=#V+'0>RX#SON81 =8/#<">?>3\#>
MSJO;^-9>&/ZM>/56--[BPQ[]>#*&^2'D7WB[,IBN=? -#VU(I0UYM*$<NQMT
M+[S_ +S_3NS8CQW[X)>WP;=OA??? L>\&0:Z&SMV,HGL@'-OIT]NX-]U?.I:
M+-V&YZ[!NU?K'_\\&>-JWQX,\V/,K_C*;8?D3SLBT./RW@.R5QG(+\3>2H9A
M(RR^'=ECD#P6V</(GHSLZ<B:JZM@O%?@C\OAW)?!TB_5!KQQ-3VSFV?W,+T\
M!7X#E__6NP=C!+_SE?..^(:9V0:V4R%, 0[D1V-W,K*SF1Z*D5^-["9DMR.[
M&]G]R!XB"B<A:SHMGT,O+"8B5C*-GHX5%^@LOK$.:6?@N=/IO=/T.O@2_ "7
M/^[%*[ZA=J=ONC'#\@I\L05?;&2,K%<L\M-TH7*16$KD5R.[B>EZ%/)'T_M]
MR!]$_D3D3L<#<^F-I5K-OU5\8B56KL!3)^%-<Z[*,B)XJ;>R^#=PW LSO$WY
MU6R_N\+?FHHO,DL!<7&6[.AP(S\!^1G(ST=^&=)KD-^DD[%C!78LQPY8-O(G
M$9TS\,0"+>3J KXU'^OGTJHYM'"VMXKV4_ !^$8ST6_P %/:;E*!*UC^+@9G
M,]6>SK6U+ &KF2].5B1Z/.A(PN9,=!2@HQP=->AH0L<HS<...?3+;.)C%G$Z
MDV?3^>0TG<*K<XF82[%N.YXR.XH> ^\0T:R7C%/S.U7[F<JN97K?P%*S#IP"
MEO-Z*<O/XK  +0J,0)<3/;'H24%'-CH*:6TY.FH9H4WH:==DOVY-\AO01/\)
M&N\_0\,!"S44<++&!9ZE@<#-&AMT@_J#]JLOZ(AZ@X^I-^1S\#=P7#>C<ROI
MV+E,J6NBK=K' J;Y.2S#LR*EF?8@S0RS:UJP6U-"XC4I)$T30W(U/J18PZ&5
M&@JMTV!HB\:%=6H@K%?]84/J"Y^JWO!Y&A.Q0MT1ZS3:ME&=MNO58=NO=OL1
M\ ;X OP=P/VCK3TP9\31?M*Q^6 FSZ=R;1*V3,"6"8Y0C;<[-&2/UCA[HL;:
M,]1OSU.?O42]]BKUV!O4[1BET8YN=3G&J=,Q6>V1<S7*N5RMSC/5XMRH9M?U
M:G3M!T?4X'H3?*4&]S]XS1R!O@O,GZ)(.Q:SU,X"4W@^GK1LD/<&L*4_*D#]
MK@CU.IT:XXK5:%>*NEQ9ZG05J-U5IE&N6K6YF]7J[E2SNU]-41/4&#5+]=%+
M51=]FFH]EZC&<ZVJ8O:!AU49\SKX@N??@^/:BJZST;N2)78^*>FT-*OV,9!"
MCLGU,=@W&ENZ8D+4X7%HE"=*K9X$M7C2U.S)5:.G6 TQE:J/:5!=S"C5QO:H
M.G9(57'351F_2!7QC*2$BU2:<(U*$O>J./$A\ KXC-=_!_!N=)V!SF6DHK-9
M8B>!<3SO34<WUSMX?Q1VMB8$J#G!IL9XE^KC8U2;D*R:A$Q5)^2K*J%,E8DU
M*D]L45G2:)4FC5-)\E05)R]04<IJ%:9>H(+4JY2?>JORT@XI-^TE\"G/O^/:
M<>]VY+7H79QE[7\9#_I!-Z_;N=Z*+5!*-6!+;4J8JE,<JDR)4GE*@LI2TE2:
MDJ.2U&(5IU:J**U1A6D=*DCO5W[Z).5ES%-.QLG*SCQ/69E7*#-SCS*R'@0O
M@$^4F?4WKL.[T;/:U*%RB$/2O\$\>#>/':"5:XW8 K56-:C("%99AETE&2X5
M9<2J("-9^1F9RLLL4&YFN7*RZI2=/4I9V;W*S)F@C)PY2L]=H;3<<Y2:>[E2
M\FX&#R@Y[WGP,<__RO7C.A?]*]$W)Y]^ &-)_T:#4?FF]D+;>:\*6\I <4Z
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M&JNHJJER5RV6J_ITL$G.ZIO O7)4/Z/(JM_*6?5G<%RGH']^B74?UEC0!5I
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M3-J<#'6/[44_U-DQB/[Q4O!$$J[))#I32'JFDFQ,8W&=!L^=SN(R(]TJ.,_
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M,8WGDUB&)_#>^/! C0^.T%" 4^/\/!KP2U2_7[KZ_'+5ZU^D'O\*C?&O57=
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M-EG\K&-\[PMUT\Y6=#;X]@'ET^9TVIR "Z-HKP.]X7#S0-RID1H,(293#UF
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ME*> XC+Y%S?(S]P\40S7+)EC;> N)E$OO@&0?!>1,16]#[[2-&2/S;'V(C6
M2E ,\KB6!=)!,HCGF@>:X"HD_R\*D+TD1&%E-@67.Q10[I9?A1G(=%8%AE;
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MZ4B3WDMH"20A"2&]33*3Z3W3,[WWWGLOZ;V0A!+  H(%*XKE?G\)[/W\]WL
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M[[2;AA>!^\65/]O>RCZC6P@9TFX8)&6^D!3Q/WL0/K;-5H_KLK#P?28Z<<!
M)9_2D>EG-23>L(P@'!+A)?T"O+3W3OO3]^!4X'_B1> 9,<R!#!]"AGW6A"C/
M%966C.ZD;NY!FAU";(>5A^TQU>-.&EB$4SH&^:R&1K^@J..>$Y&%IW@DR4DN
M4=IWI_WI?W#JGZ.&62M_ML_)/JU?0&\00P9QCBLJ*_*%%-4W]B"RT3U(IT6
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MFZJ3"@.Z<>0- D>+;*7??'^ 5V-&WAYTUJJ(T'^/TE6M8G;"U+R..PEX[Y\
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MZ@CZQK$&3(_<!<R0P3AB^'#M-=GJS$N*-?!!Q2?L%ME.?4IQT)Y09[LCVJ)
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M'ZBE<'MK&*(N&$?64<E7M96+-*VE,EU+B=+07*0U-A4:34T%-G/3";>Y\43
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M5=V"8A@:$1Q+JH9O3\#$SGBEPATKUWICI69OK,3I#92Y/!XH>YG+;2EWWS;
MA@P\R, ;-;P%F-N6 _:N;=?9:1E76>E%%QDYM6=I)90!:@VWBXR3M1$HVB8L
MW91"L>T)!,\5JQ9[8Y4*7[1<YXN66GW!,J?/7>;TVLN=7G.YRV.H<+EO%^!
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MYUQ[% N"C0L\06HI"^36D$%EHP-H;\6!D90E6.PR ]Q>(R#*& !95@]<Y'2
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M$,IZC%#L*$*AF ,?EHBP88TX!;;,LX?=BVU@_S)S4%MI!+IK],!DG398;=
M_)_YP^;_S!^86Q6 LTT>O+;+0> .&0B7DH:$G7L@8]=N*-B]"RKW[(*:6:FZ
MA-6_AU!T/T)!@! /)(1HL%#8 ?.PAM5B)K!97!]V2VB#_#QU4%V@"EJ+E,!@
M\7XPE=P'5DMD ;]4&HC+]@!Y^6Y@K-@)G)4[@+]J.P2NV@KAJ[=@+Z--D+%V
M$V3-"KBM$0;F-E&@RHD#14<2&.9KP=5N![B1Y8#M>@"8/KI #S,!6H(5D#-Q
MX%QH#T[ECD"L=0:'1O)O^S;J+T([;=KNC,NTW67Z%+Z'\1/WG#&.&V!\P0\Q
M/MI]8@S8C])?.7QFS 9P5@L#"W.@R8H#%7-@FZX%=_P.X)+V 8>E!JY>>L ,
M,05ZG#50T^V G$\$YS)G<*HA_R(>HDX[M+I,V;?3)PEGF).$RZR?=K=9/_!]
M[*_X ?8(88@]:/^)U4\<83US'&7/!KAC#NRMHN B.P=HVI+ ,5D''K92X.F\
M#WA,->!XZH.KP!R8,;;@DFH/U#PG()>2?SE7TZ:<#M$G'5N9/XGMK)\.9UPG
M[*^X_2#<<?MN]XKSF3# ^> PY/;:\:/;,Z=/G%[GD5GYZ^"*.= Q!X:6)/",
MUOV=!_DX8EN,K@X\K@%P BS -0H'S!0BN.20?E%+:%/D*OJD\T'63Z<6UPG'
M=K<?Q#.<<8>K[M_M[W''"/V\CPZ#O+>.'[C/G8>Y#T@?>3WD3[,"W%7"X+9%
M!!@R<\!50Q*\#->!GY44!#C(@Q]-';PXAN#A:PGNX7; 3G3ZS<BB3+D4T7]2
M*UD3Y :W<=)A]^].QWG?',]Z?"->\QQS>, ?<7C-'W <X/>1/GCVDH?X/91A
MKVO4V0$>YL#!'%B8 U=-$OSTUX' 0@J""?(@(&N /]L0O+RLP"/$'MSC2-/L
M#)=)9@'KATN%VSBUGON-?-CC*^DX?\SIK/<7Q^L^H\2GON^=WOB^( _X]%+>
M^]ZDOO>[2GOO=]%E=L #>V^[;Q8!-N; 5Y7\.P<),]L!$3AY"'?6@!"&$03P
MK,$[T.&W1S1ERCV5,<'.<_O.+.-]=:GECU&;O3^3C_N.DL[[CSC?#!AR[@M\
M17X3T$M[%WC#Y5W09?J[H'.,=T&GF;,#GI@#%W-PDYX#OLJ2$*:]%J*-=T"L
MS3Z():I#%,T00CG6$.#C\-L[C/K3(Y$U[I[M_I5=PO_"J/'Y,QO\1&T/^DB^
M*/A(NAO\AOPRY('+ZY ;]->AEYC]86=8_6$GV:]#C[G.#GBM$ +>)A'@8 Z!
MBHLA2F,-)!ANAV1+.4@BJ$$"V1"B6=80ZDG\%1!$F_")=?WND>[QA5/H,\JN
M"OC(:!(,TTZ$?J!<#A^D/(YX[/(R_ ;C9>1%UHNH4ZXOHHZ[O8AJX[R,;.:\
MC)@-\,8</# '[MXY$+)_,<1C^3]5?RMDF,M !EX5TIST(8EN^6<N]2O4AS81
M$.'ZS3O9\S,OS^^36X5@B-D8]M[E9.0 M3NZS^79WSG<!?;SN ZW9W%'W)_%
M'>8^CSW$ZXNIY_5%SP;X+!<"/G:.X^^> Q'[%D&RZBK(TMT"N6;2D&>K##E$
M7<BDF4^EN!*^Q_*IG\."78<#X_B#/ID!;SQ*0E^XU4<]91V+?<BX''^'^33A
MSPSN).=Q4BOW<5*CQY/$>L^G"36>3^,K^<_B9N.O@Q?FX+-K#I:]%T(ZEKWS
M=#9!D<EN*+)6A$*"UF0^R?1;-A/_*95+QHYM[/Z(*/ZSH-3 7I_\\!Z/JMCK
M[H>3KKAUIEQTNYMZ@OLPK<7C85H#_U%JC=>CE KOQ\EEWD^22GR>)LP&^/YQ
MV" "_E+B$"^]$,O_*Z!(9P.4&NV$,@OYZ3*<^K=21\-/133K@5PWQY?IOHR'
M\6&>/1$)05>#LB(O^)8D=/(;4D]X',\XQNO.:O:\GU7GU9M9Z?,@H]3W85J1
MWZ/4 K_'R?G^3Y)F _R6"8$WYA"T71R2L-R;I[0,2K760:7^=J@VE?U18Z,R
M6FVO.UA%-GM9YFKW((]/OYD6Y-D5%RWHC$B-;A?D)[7Z5Z4W^K1FUWM?S*WR
MO9M;ZG<ONS#@?E9^8&]&;N##M.S 1ZE908^39P/\,0>?]2(0LDT<4G?/AT+%
MI5"!?39J=+=.U1OM&3MHJ3!TR$[C]2%G@W]J&/A;Q3SZI1Q_S],IX8*C<0DQ
MC1%9R;4AI9GE08VYQ0&=^06!=_)S!7=SLX+O96<$]V:F!S_(2 M^F)8:_$_*
M;/QU\,4<PK",D[Y['I0H2D+U@550K[7I1Z.!U$B+F>R[(SBEYZV.NG<.NN"N
M5')<.@M]/(]D!0L.I<3$5,6EI11'%6;EAM?E9X:>*$P+ZRE(#;^3EQQ^-R<Y
M_'Y64GAO1E+8P[3$L$<ILP$!6+;PPQPB-XM!UJZY4*ZP&&I55OQN5%_WM55W
MZ]!QDUVO3]G(/CANKW/],-7V7)TK[7@YWZ.Q(#"H*BLRNB@U.24K(2\K);8Z
M/S[F:%%,[,W"V)C;^;$Q=W-CH^]GQT;U9L9&/4B/C7R4.AL0^,?ASSQJHRCD
M[I2 ROT+H4%QV62+ZNK1=LWU V>,MCP_;R%]^Y2==M<1LLW)1A;U<"V/5U/F
M%UA4&!J5E1.?G)21G16=6I$?EMQ:&)QRK3 TZ79^6.+=W/#X^]D1<;V9$;$/
MTB-C'J7.!@1A#OZ80]QZ42B0F@,U<O.A:9_D]V.*RX<[U5:]OFRP^N%ED[W=
M9_&:9TXX6QUI8Y#K&]W=2VN] [(K@B.3BF.2HO+3,P4YI7E^V<T%WME=A;Y9
M=_(#TN_F!J7<SQ(D]V8&)SY,#TEXE#H;?QT",(=$C.(=XE"_=^[O5ND%7T[)
M+1KH4E[<UZ.Q\G:W\>Y+EVS53YQQM&@\X>)<T>;FEM?$]TNI#PR/JHZ,%U2D
MI'F7%F7S2@[E<4K.YW.+[N9ZYM[+]LZZG^6;\2##/^UA6D#*HY39 ,$2(0A:
M*PRI6/XOQ\YTC5+B$\=W2 Q?V"71W[-OSH/[*LN[>PQW=G9;'VB]Y&!6<Y9*
M+.Q@L]*.>7C'M/J'!#>%QW@?3$IVK\_/8-4U9-/KSV8S:NYGN9;U9KH7/LCP
MR'N8YIG]*-4K\W'R;$ (YA"*G2$R,:JQ<T3+9M&QS@VB[VYL%'GZ;+O(K2=*
M2R_TZF\_?MM2^>!U@G'I93(AZP*3'G^&ZQ'2X1O@TQX:[GXL(8YQ)"^9TE:7
MZGSD3)ISZ\,T:L/#-$;5HU1VZ3\I;D6/D]WSGR3.!H1*"D'4<F'(P]Y=#1N$
MI]M7"@]?E11Z^FPQZGFU0[3KI?+BCF>Z6YH?FBM4WL/KY_8XV29=IY/#KW)<
M_;J\O;@70X*8Y^/#R>=RHXEGZ^+LSW7&$\X^BR<>>YI :GJ:0*U_FN!2]2R>
M4?8L;C8@''-(^/-;UB4(#B]'3\_-0_=ZYJ&;;R6%+K[=,>?D&Z5EA_MUMM2\
M,)4K>(;32OG'T3SR <TAX)Z;B\<=+PZK)]B+<BO>GW@K3V!WJS[$MN=,J,VM
MUZ'XBZ\B""=?1A*/O(AR:GH11:I_.2L0N5@(TA<)0366_]LET.V+$NCJW;GH
MW(>EPL<_[)C7^%YA5>6 UH[\=\;[4]Y8:4?V$TP#7I'Q'B_8SJP^O@NE+]B5
M^#R>BW^>Q[?IJ_>V?-'I8_FRW]OJWJ"?S=6!0-RYMT'XCK<"PM$WP;,!,7_N
M!<U'?4VBJ*=#'%VZ+(Y./YB+CHPN%VD8V;&P?$1A;>XGS9W)'XT4(H>MM *&
M"<:\(6<KYA"#0![R<"(.!5+P0S%TJZ$LEMEPE:OQQV,<HT]W.28#[SGF3X;=
M+>Y\]+"Z-LRWOC#D-1N0-!]]J!1"=X^(HHMGQ-#)Z^*HY>E<5/M]E5C)]YV2
MV=\5UR>.:^V,&#?>'S!NI<X;M]-CCCN9D,?IE@[C7%O<N#_!\D<DT60BS<EP
MHH2D-]%$T?UQCJKSXR5-?^0CS?C-%ZK)LR\NIO?'&+/Q.P^A!X<0NM0N\O<.
M0N,=,50Y.%^H\-=:\8S?NR7C06E=..CL\ ,C&2Y8*#$ IT8"1VU[H.G;@)NQ
M!7B;&4.(Q9__@4$'<FVTH JG"6UVZM!%4/_=3]#X^9F@\_D;07_PA]UL/*M"
MZ$H;0NVGA='!:\*H[)$HRIE>))0"&\1C8._B8%!:Y0T:F]Q 3XH&IM*.8"V/
M!WLE+'RJF@)+'0L?FKH0H*T%D;KJD*)_  H-5:'62!F.&BO!91,EZ#-5A,^F
M*K\G9N5Z$T(GCB-T\")")7<02G\IA!)@B5 X;!#UAYWS>2"WE DJJTF@M<$>
M#+?:@/D.<\#M,@+B7EV@RFB!JYPZ\.55(4A!&:(5%2!-61Z*5/9!G:H<'%63
MA0OJLM"K+@/#&K/1@?7@X!F$BJ\CE/H$H:CO(D@ DD*>L%*$!9O$*9B' ^Q;
M; LJR\Q!:Y41&*[1!8MUFH#;< "(FY2!ND41"ZSRX/E_LX=(J;V0^G]SA^H]
M.^'P7BDX)2T%UV5FH_$D5O\*0BF]"(6]1L@?Q! '%@A188FP ZP2L8%-8J8@
M-<< 9.=J@_)\==!<J +ZBQ7 =,D^L%XJ"X1ETN"\? _0_V_VX+-J&X2LW@+Q
M:_[,%C9"Z;J-4+=^ [1MF(W2"]CSWT8H] 5"7M\18@%"3B N9 L+A4PQ#WW,
M0Q,VB:J"E)@BR(CO X4Y,G!@SA[0DM@)^A([P'3N-K":NP7LYFX"IWD;P&7>
M.N#,7P,^"U9!Z,*5$+]P.60L6@[%BV<#2.N%P4%*!&SWBX.5A@0X&$J"L]4:
M(!&W@C-C+SCR]X-#L"K8Q6'MS]0%FR)#L*XT!JL&4[!L,0>+XQ9@WFD)9EU6
M8-IC#:9]-F#R 6/,9LITW&;<_*?-9\LIZR'K*9M!Z^D9^>M Q!QPF(.MF@0X
MZ4L"U7(-4!VV <5E+Y \%,!1H 8.L=I@EZX/N )CL*DP!>MZ<[ Z; F6QZW!
MHA/;JEVV8'X;!V8O<6 ZA/]E-H:?,!_'?[&<P U;3^+>V4SB7]O.#)#7"8,C
MYH"7%P>[ Q) UI,$NOE:H!.V 8TJ#52N(I "U<$Q6@?L4PW!+L\$<.7F8%MG
M!3;-UF!]S!:L.G%@>1D/%G?LP/P5 <R'"9,68X1OEN.$CS83=@.V$X27N)_V
MS_$S Q3,P6F'"-AA#D05"7#160(LT[7 QF\#)ED&Z&Y*0/73 %*$'C@F&X-]
MCCG8E5H!OM8&;)MP8'/,#JQ/$\#JLCU8WG4 R]?$:8M/Q'&K,>*(S7?B 'Z<
M^-+NA^,_A G'WED *G9^<<8<"/O$@:0H 2S-)>!NO!:XMMN!XR0#;*8R,+PT
M@1JJ#Z0$4W#,L@2'8AL@5.,!WT@ W%$'L#WM"#97G,#ZOO.TU5OG">M/I,^V
M8\Z#=M^<7Q"^DQ[:CY-O$W^0;\X"T# 'TG81L)<3 ]I^"7!7EP2^P5KPLMH&
M? <9X+HH@RM/"QA!AD"+,0=2NC4X%>+!H=(>[ \Y@MT19\"?)OVVO4J9MGE$
M_6DS2!W#C5 '"5^H?0YCM/O$KRXW';_3KSA_IW?- KBL$0;R-A%PDA$#EIS$
MWSF(G^X:"##?!OYV,N!-5@:>JS:X^1H!,\(":,DX(.?]WWRP@?1W-FAWFC:-
MOT;_,Q/\BG_/^$ 88;P@?F;>=?K"ZB:-L2^1Q]AG*6/LSED .N9 P1PH>\2
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MW(8(&JLNF4FK*7!SKJGG.M:<YA%KGG,=*T>XI.)1=VK^9XY+]A<W1L87]DP
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MH"&N"'ISY,%40A9LYNX%AWF[@#IO!W 6; ._A9NQ+_X-D+UX'51+KH6C2]9
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MUEO<)+99=3N<L;EJWV/;Y3!@>\[A!ZZ#"/@V)\ WD0#70 9<#1ELJ\E@\]^
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MFK_'4P 'RK<FIL@" Q0 '10%#5H/%51@%%"5D:&Q2*(>(X;&C A:,D)HSQ)
M=Q8O^K.H-+( 4T@A:60#]I!ALH%L_P^TIYYG:<%":RLVVMD01P[:>'+1,H07
MS1/YT31/&(VKQ=&P30KU^V50?Y$<ZJV41[V-"JBW71%U#RBA[BGRDS+JWB//
M55#W \%_*:,>,:3GQJCZV?2_T('&8&7.0CMS-CK2.!SM.>C@SD7;0%ZTCA-
MRVP1-*^00-,6:33NE47C07DT&E%$HW5*:+B5?O9>%30\IHJ&EU31X+8:&CPE
M[PFJ4>X$530BIJC^V1PUWEO^%SKJT!J8L=#1E(4N- Y7&PZZ.'/1R8\7':,%
MT3Y#%&U+)-%ZJBQ:=LJCQ8 BFB]11K-1%33;I(IF.]70]) ZFIZE(W*=/-9$
MT[?D*Z&?;_8WS4^6J/W6&K5?V*+.]]")QF!OS$)7(Q9Z&K/1RX*#GO9<]/3F
M18\(071+%4.7 FETK)5#^W9%M.U30=LA-;19H8[6ZS70>EP3K?9IH=4);;3Z
MB3S00:N7Y),.4N97:]3Y:(-ZK^U0_T\'U'_@A ;?0V=M%CH;4+X>"WWUV>AO
MS,$ &RX&N-/Q"A9"WP1Q],Z508]*!72;IHPNW6KH/*"!3DNTT'&U#CJ.Z:+#
M3CUT.$S.ZZ/#;?VO#L_T/SE\T'_OB/KO'-#PA2,:_^&,)K==T>0W]_]"%QJ#
M.ZV%'_7_('H>2N.(L.1BN LOAOL+86B,! 9ER&) B1+Z-JBA=X<F>O9KH\>0
M+KHOUT?W=09?W+8:?G;;9_3)]93Q7ZZ_&;]Q>V+\PNV]\5,W-'WBBN;WW-'B
M-T^TO.R%EF=]_@O=*'OBWMS$?8@(=1;&Z+ QWI2#\0Z\&.\CA#'A$AB5+(?A
M^<I?0ZK4/P>U:'\(Z-)[[S]@^-9WV.BU[VJ35SYCIB^\=YD]]SYF_M3[1_,_
M?/XPO^_SSN*.-UK?]$*;'WW1]HP?VAT+0+N#@6C[/7379-!?E<%PZGP3OQ.2
M1.-),V)CF@T/IKD+8DJP^)?$.+F_XK*4WT27:KZ,;-1]%M9A^"2TS^11\$*S
MAT$C%O>#UEG>#=QF=2?PD/6MP(O6OP4^L+D2\,;N<@ Z7 A IV-!Z+0_&)UV
MA:+3ME!T_!YZ:# 81/G1U+<F_OP]D]8C1X^->19<S'/F_YCC)_8F,U+V65JJ
M\N/D LT'"=5Z=V);C&]&=YE=CYQG^6OXL,V5L-5V/X9N<K@4NM?Q0LAII[.A
MMYU/AKYR.1J*;H="T7UG.+IOB4"WC9'HMBX*7;^'/K0&890=3UUGXAY$'G7_
M0MJ?$A/VAQ([WI?%7B)/"D*D[^<E*MW,RM6\EE9F\%-R@^FEQ':K<W&]=J=C
M%SB>C%[F?"QJK>N1R&WN!R./>.R/_-ES=^13KQV17[S'H]![0PQZC<:BU\HX
M]!R)0X_OH1]E1LHPF$S=/T=JXG?OJ7NJ,Y^J]%FOJBVYCZI=!.]4!$C\5A*K
M\$-!AN;YW$+#4UG5YL?2FVT/I<QRW)\TQV5/XI#[SOB57MOCQGRVQN[UW1Q[
MWF]CW!]^Z^(^^H_&H]]( OH-)Z+OHB3T69B$WM_#0.K=L=2UTJEG%%#O+I>A
MWJ?$O&W08IY,-6;?:;+G_;7!1^Q2=:3"Z;(4K:-%>48'\LLL]^0VV.W(:G7>
MFM'MOBEMP'M#RE+?M<EK U8G[0A<F70R:'G2G>"ER>^#%J=@T& J!@RDH?_<
M-/3K3T/??WW_?T07D/@__R2$3D8"M:\L:J$E-+)J2?@\51:>MZ@P]]IT6;^U
M67$OM7B*GFH,E3]<FZ"YMR++:'MID>66PFJ'C?G-KFMS9WJNRN[W79ZY*&!I
MQJK@Q>E;0A>F'0Y;D'8];"#]=>C<# SIR\2@WBP,[,["@*XL]/L>AM'.)%%V
M'K6?B3L"]6+PKD4"'G7(PN^=:LP/G6:<TQUN(H>G!\OOF1JKN:TNW6BL*M]J
M;7FYP\J2!K=EA6U>P_D]?@OS%@0-Y(Z$SLG9&-Z7O3^B-_NGR.Z<%^%=N1@V
M,Q=#9N1A4$<>!K;GHO_W,().12IE%P@"5@G!AR9A>-$N G>[Q.#GV0IPKM>$
M<[3+67COC "Y;:W1&AN;4@Q'&W(ME]>4. Q7UKHM+)_F/5 RR[^_:&YP3^&2
ML,[\=9$S\G='M>=?C&HK>!;96HCATPLQM*4 @Z<58! )^!Y&T>E,%P(L%H O
MM?SPQW0^N#Z+'Z[.%H1+<V7AQ%Q#]H$^1Z$=W7ZR8S,CU$?;D@Q'IF59+FXL
M<EA05^4VIV:J=V]51T!G>5](1]FB\.DEHU'-)3NBIY:<C6DL>1+56(H1#:48
MUE""(22XH1@#OX>QXH"9U !+>>%%(Q>NMW/AIVX^RN>',_.EX/ "??;N>?:"
M6_I\9-;VA*DMGY5@L+@]PV+^]'S[_N9RU^[&>N\9]:T!K;4](<W5@^$-52NC
M:BO'8ZHK3\545?X1757U);*J$L.K*C"TNAR#J\LPZ'L83V<AAQ>P@@.WFQGX
M>28'+O;Q4#X?'!N2@'V+=%C;!FWY-PQX2:WL#U$=[HW5F]^99MXW(\^NJZW4
MM6-ZK5=+<XO_U*E=P;4-\\,KZY='E=5MB2FI.QY37/\@NKC^<V1)'8:7UF!H
M634&EU5AT/<PD<["% Z\JZ$62$WT4A<;3L_EPK&%/'!@B1CL6*K%&ANVXEL]
MY"ZY='Z0\N#<:-W^OA33KIYLV_;.(N=I,ZL\&]J;_*I;9P:53Y\;5CQM661!
M\UAT7O.1F-SFN]%YTSY&3FFBSY]&#"UHP.#".@SZ'J;062ADX$$]P,\= &=G
ML^#8 @X<&.; KN4BL&6%.K-VN07OR%)7\86+ Q3G+(S4[IJ?9-P^-].ZN;_
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MN,MN0_%_N@[&?W5=D( N\Q+1J3\1'6<GHL/W,(C6/V9B#?@!\P0H7PA>5XC
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M96TOKI>SN714SN;B'W)6YS\I6IQ%9?,SJ&IV&M5-3WWK .W!IHDS0-? _+4
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MVUUO%*QWH)+5-E2Q'$=5RZVH-MEA.H?;Z/ROIOU?1/FSJ0-/7P]0O06@8 =
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MJI4P;99>;/-\@^BFE48133N,PYLN&(=/?6X4,14-(QI1/[(!]:+J47>R/U(
M+M&U>*B:>B=]#5_?#C RB[IO%W5OZH&ML_F@J4\6&OIUF>I^*W9YGRM/T6Q_
MP2F]X:+9/?&2&=UILBE=>8J)G64JL;,:U*-F=FB%SYBG&]JQ7#^X8YM!8,<Y
M@\#V9_I!;:@?U(IZ1#>X!75")KD]<3W0M;"7]F SS7]U)W7?7EH#^BK>-I>Z
MUP +JA9(0/F@!I0,FK'R%SAR<A9X\V7,#Q%*'8@139R7+!DW-ULV>FZQ0OB<
M6N60_C:UP+Y^3?^^$2W?OJTZWGUG=+QG/]7V[D%M[V[4]NE"+9_.;UVELWBT
M^I][@1/WP9;.GK@'17M ]:AIB+H'=<&"I2*0MU0)<I89,!G+;%FI2]VYB4L#
M^.*61 A&+4D0"1_.D A97" =N+A*SF]1BX+WHMG*'D-+5=V&-JNY#IU2<UWX
M1-5U$-5<YJ.ZRP"JN\[[UGE:@WUT_C?/I&N1\A?. ^@=I#V@[)IE %.HBZ:-
M\D'R&BE(7*L%\6O-F9BU3JS(M=Z<L#4A/,%K8OD#UJ0*^8[FB7B-5HB[KVZ6
M<EG=(^.T>EC68?4F.?O5)^7L5SV6LUN!"K8CJ&B[#)5LEW[K6"VM 9V!M90_
M3)5L#LV]8RGM ?70XC4 &531HC<#A&T5@9"MBA \K@>!X];@/^[*^(S[L[S&
M(SCNXXD\KN-9?$[C)0(.XPU"MN.=(M9;AT0MQS>*68P?%[/8^DC,?/-7";,Q
ME#+=B-*F&U!FLHG[D6.T_R.4/Y_R9]'<IU(E*Z,>FKT)('X;0,A.ZH#[N."V
M7QQ<]ZN RP%#<#I@ XX'W<'^8"!C>S"*97THE65Y*)]C?JB&:WJH@\?XT )>
MPT/K^ P.'^$S./205W__%P&]?2BDNP>%=7>CR&1;NP%6T?HOI/R>$8#F48!R
MJLDYXP )5 U#]P)X41]U.,8"L]-\8')&'(S/*(/167TP/&L-AN?<P.!\ .B=
MCP'="^F@<Z&$T;K0S&A>[&>I7US%4KNTGZ5V\1Y+]?Q'MLI9Y*B<0:[R:>29
M; WE+Z;\/LJ?3FM?27//W0&0N(_F?XCF?Q3 GNJRZ3D W4L<4/U9 !2OB8'B
M;PJ@\)L.*%PW!_D;3B!WPP_D?H\&V9L9('.K'*1OM8/4[2&0O+,%).Y>!(E;
M;T#B=V3$;Y#?D#79$LJ?0_EM:_^Y!Y5'<T^D>8<< _ X!6!+V<:7 +2N "A1
M)Y>^R06I1R(@\5@*Q)\H@]@3'1#YTPQ$GCJ \#,?$'P6"0+/,X#_127PO9P%
MO*^6 ??5'N"\O >LEU^ ]1R!_?1; Y3?L?:?>U!3]E#^$8!@RG:C;*O+  8_
M ZA3MOPM (E[ *(O&!#^( ""'T6!_Y,T\'Y2 LYG+6 ^&P%\MB4>A#X(/Z<#
M?*$W_\^TV9_IXOI\F#PA2'__6[,HOX[R\VG?DVCN(93M2MD6O]#:WP!0ODUS
MOP\@\@> P$L OB\ 7&0#E?S_W7^0(+)$E>@2<^+RO]_!H ]#I'%@S__N/= $
M\2'Y_,U]F$8Z>X6T]\DG*/\BY=.\S2E;^PZ P@, \<< 0L\H]Q70O_\][J1[
M(1-CD2/J_[L/8D\"2#*A+P1(ZX&T'KB;_$1^_S]0S@A07I_H 4H; HJ9 0K:
M,<CV8A#"20HI)+5D.NDF\\AB&L9RLH9L(CO( 7**_$(>DM?D"_G_^4N1\I5U
M )6T:1RZ@)(T)A$K&H<;@WPA#'(3:3QY#+(J23.92?K)(%G*(+,*D-E MI(]
MY!BY3#_Y'GE)/L-G&O%G%F$3#C*?N=]"5<I7IXZKI@ZHHDGK,C$.6@MQ)P9%
M A@4CF50,)-!@1)23]I(#Z&U$%A$EI,U9!/920[1]IPCM^"3P'-X+_ 1W@HB
M\U8(F3?"?V-]#S4H7XOZOA;U7 UZ5*'72A/[8P<HX\V@9 2#$K0?8OFDBM!:
MB-%:B/61!60)6<5\$=O ?!8;9SZ*[6<^B)]FWHK?8%Z*/V6>B7]@_I1 UA-)
M9#V61/:C_P?4H5P].2(#J#.!7NO0V="D_5!SHWT*9E QGD'Y;.:K?"GS6:Z>
M^2#7RKR7ZV;>R<UEWL@-,:_E1IB7\FN8%_*;6<_D][">RI]@/5;XE?5 X0ES
M1_$#ZY8BLG]70LX-)>1>_Y_?)D$#>4!C22+^#Y.)U[061B: ^@XT'E_FHU84
M\TXSC7FE4< \UZAB/=5H8CW1F,%ZI#&;]5!C/NN^QA+6/8U5K#L:&UFW-7>R
M;FH>9=W0_)EU5>LQ^P>M#]R+VLAS7AMYSVHCWYD)6M]"$RFZI*E[6U#WM1(!
MM*;7UK0OEKKPT=P*7INZPS/C$.:140)SWRB;=<>HE'73L(YUPW Z^YIA%_NJ
MX1S.%<,ASH^&RSF7#==Q+QJ.<\\;'N0Y9W21YY3Q0]YCQN_Y#QNCP$%C%-QO
MC$+[)ABAT-Y)T)SF;BT$:$.]TT$0T(G&XR@-?]FKPG-;0WAH8P^WK7WANG44
M<\4ZC779.I]]P:J"<\ZJD7O&JIWGE%4/[PG+>7S'+!?S'[%<Q7_8<DS@H.5N
MP?V6IP3W6MT6W&GU6GB;%8IN(9NM4&P3&:/GDZ$US=V.\IU8@&X\@.Z"\-%=
M%)ZZRL!=)PVXYFP./[BXPSF74-8IEP3V,><L[F'G8MZ#3M5\^YR:!/8XSA#<
MY3A;:*?C N'M#DM%QAW6BFYQV":VR>&(^)C#K^+K')]+C#JBY"I'E%I)CRO(
M\G](_ OMJ/L[_?,K;F^]J?_[L. V=?&['L)PQ5,>SGD;P0E?)^:PKS]KGT\T
M9[=W*L]VKSS^<<\RP<V>=<)C'BVB&SQFB:US[Y=8XSXD.>JV4FJ5VR;I%6[[
M9$;<+LDL<7\LN]C]L^R0.\H._D-F@3M*3X:.-'=7@ \^ />I>UX/H<X5S('+
M ?QP)D *C@3KPKX06V9GB#=K:W 8=U-0 M_ZP$R!-0&%PJO]*T57^C>*C_BU
M22[U[98>]AV07>2S5&ZASSKY!3Z[%.;[G%&<Z_- L=_W@^)L7U3H]45Y(M?S
M#]E_H0OK[]O;3RC_1CC Y2CJ.U$,G(C@PN%P<=@=J0'CT9;,6)0[:UU4$'=U
M9 S?\O!4H:5AN:+#H27B0R$U4H,AS3+S@V?*S0WJE^\/6J0X.W"U<D_@N$I7
MX'&568%W5&8$O5?I"$+E]B!4:@]&!7J4GPS=Z./4E]: /FZOQ% ^=9XC"=2Y
MXMBP*U8$ML2KP(8$4V8TP9FU/-Z?NR0NDG]1;*+0@I@LL8'H HDY4172LR,;
M9'LBVA2ZPGN49H8O4.D(6Z':%K99;7K88?5I83?4F\+?J$T-1U6B3)2((E'X
M%]+'_0OZ>+M)\[] V<>H\^RCC]P=]+@E21#6IRC JC1#6);FP%J<ZLU=D!+&
M/R\I3J@O,4VL)R%/LBN^5&9F7(U<>^PTQ=:86<K38N:I-D4O56^(WJA1%[5?
MLS;Z%\V:Z%<:U3&H1E2),E$BBO]".H=_TAFX1OW_-.4>I.ZY,XORJ?NL3^>#
ME9FRL#1+#X:R;5GSLSRY_9G!?+WIT4*=:<EB,U*S)=M2"F5:DBOEFY*F*C4F
M=JC4)?2KU20,:U3&K],JC]^C71;_@W9IP@O-D@34(&JE":A"E(G2OR9^]?1A
M!)U#ZO_'*7\O=<_Q/( -9%4.%Y;F2L'0%&T8F&+%ZLMSXW3G!O#-S(D4:LM.
M%&O)RI!LRLR7:<@HEZ]-KU>J3FM3J4CM52]-&=(L3EFC79B\2SL_Y8+.E)1G
M6E-24",_!=6(*E$ARO_Z0/MPE[KW15K_P]FT!OG4>PNI^Y.E^0PL+!"'>44:
MT%=LSG05.7-F%/KRMA:$"3;GQXDVYJ5)UN;FRE3GELA7Y-0JE?Y_A)T'6%77
MVJW'6KM0-FQZ$;" 8 <L@"B@]-Y[[[WW*H**@**B6,'>>^]18XG1Q&B2D_8G
M)[WW;GI9=VS!Q)-[_GN?\[QG[8VXQIS?K./+7,N"16,J\E?8EN9M&E^<N\^A
M,/?<A/S<N^0+A_Q<:3RQ+<B5QI(Q9/1#O@MG7V [W&$,KM#WG:YD&]![[2*#
M_+RVVA#]M6.QO-9)Z*[UD"VN"=!JKXY4M58FJALK,HWKR@O,JLLJ+"M*&ZQ+
M2SK&%)4LMRTHWC ^MVB/0W;1F0E914]/R"SZS"&SZ,_Q6462;5:A-#:[4!KS
M*%]'L2^D [<8@\<JZ/EJ&0-N ;?6 ^NX!5M9KX]EC398VC156-3D+EO0Z*=L
M;@C7J:^/UZ^I2S.JK,TS+:LILRBNKK,JJ%HP.K>R9UQ6Q3J[C/)=]JGEIQQ2
MRF\[))=_PNL?XU/*)-O4,FEL6IDT)JWT;SZ/&\Y)WF ,SM6P']#_[FYA#,C*
M)J"G184E;9;H6# );0M<Q:8V;T5=:XAV54N,7GESBD%Q4XY)06.Q>6Y#]:BL
M^E:;]/JE8U/KUM@FU>X8GU![PCZN]DGRL7U<S>]V\372N/AJ:6Q"M30FH4H:
M_9 /DX9SDH\S!J=8_P-M[ <+V0;TP3VDLT,+"SK-T+S('@V+9PHUB[SD%9V!
M6B6=4;J%'8GZ>0LSC;+;"TTS%E1:I+8U626U+AX=W]H_-J9EJVU4RS&[R)8G
M["*:/[2+:/K--K))&AO9*(V):I!&/\K;;(>G. 8NL@V.M7(L= )#B^F]2><2
M[ON7BJCO-D)-[SA4]CH)I;USQ*(>/T5>3[AV=G><*F-IFCJU*\\HJ:O,-'Y)
M@T7,XDZKR$4K;<(6;1X3LNC(V.#.Z^.".M\?&]3QZYC@A=*8X'9I=,@"R>91
M7J$5N<&^=X;^^Q#UM].#K^L!>DG;,J":6_*R5?HH[K="8?]DY*YV%;+ZY\O2
M^X,5*:NBM1-7):OB5F:KHU<4&T:LJ#4)[6LW#UZ^W#)@^:"5W_)#UK[+KUK[
M+'_7VJ?W%VN?;LG:9ZED[;M4LO+M^AM-7O0R^]]QQG]O-V.PG#&@[F+:DH;5
M])[THSGKM9&YT13I&\<C=9,SDC;-%>(W^<MB-X8KHC;&:X5O3-<)V5"@%[2A
M2NV_OM7(9WVOR?QU&\V\UATP]UAWA;QM/G?@9XNYJR6+N?UDU7^BR4F>8Q\X
MQ/IOZV,,^AF# <: VI4;@=S-0-(V(':'&C$[K!&U<Q(B=KH@;.<\(61GD!BT
M,UKFOS-9X;LS1VO^CC(=KQU-JKD[ENJ[[UBG=MNQS\!UQR5#EQUO&KAL_<EP
MUA;)>-80&91,'N6*)A_)=M]-_4UK.!;6 XL&@;HMC,%V^L]=]/^T:4$'M>%_
MR!A^A\;"Y_!4>!^>C?E'?.!U)%3P.!(GSCF2+IM]I$CN>J1.,?/((N7T(VNT
MG([LUG8\<D%GVI'7M*<=^D%WZ@%)-66?I#=EKZ3_*&?9!PY0?POUUVP EE*[
M>0?[P%X@ZP 0=P0(/@YXT9.ZG57!Y:P99IVSQ<QSTS#C_&Q,/^\#YPMA<+J0
M@&D7LH4I%RJ$R1?;Q(D75XH.%[?+["^>D8V_^()L_/G[<KNSDL+VC*2T/2UI
MV9[ZFZ-L_QV:LUB,>^]6ML%(#BCG*)!P$@@]0P]ZGAZ<GGCJXS+8W]"#W0U3
MV#TQ%K9/3,&XFRX8>W,^QCP9BM&W$F%S*P_6M^M@=7LI1MT>A.53QV#QU#.P
MN/6M8'%3$LR?D$3SZY+L47:O&3X+U<<V;V?=JP^S#U [\1SU:4_G7:'^-6 *
M/;G=4\"HNW*8/*\+HQ>,8/B"%0Q?=(#!B].A?LF3!$.?FQ#]EPN@]THS60G5
MJWN@^^KCT'GM(^B^\B=4+TE0O?  X2%#U%_%=N_<-YP#RF>]DQX#0JXR_K3J
M,^G')ST-C+T'6/R+/IR^7.]U!;3?4D'YMA$4;UM!_HX]Q'>=(+PWEPL@-T0?
M<#/T 0?<A^SL'[&#?W2(BS,K\/$WP"?2_\4:ZB_>/YP#*F#,DQZG_A. YVU@
M^C. PW. #:VZZ6N ^DU YUU _)"^_U,ET2=&P&?T_)_3\W])S__U;.!;;DJ^
M8SF^Y^3W/0?]?3;T#R> 'Y\'?OJ>2/_!4NHW\H\++P#)US5G@ "/NX 3ZSR>
M=1[U!NO^#NO^/B#_F-J?D1_(?<U5052\MP$Q!7X>#?PZD9M#EY$S& DC9T$6
MD2%R:N3<Q9?DE[]HIGXQ8Y_"NH>QWA[4=GP5L&6=S=]CW3\"M#6Z_&M@*/'S
M?\N%:,Z%Z!'#D3R(YFS*=.(]<A;D83DXZ*7C(\_ O/P7D@G]K8D#O3[1I^]7
M.O*VKL2'1)%T4D+JR4+22U:3C60KV4,.D1/D/*'W![T_WB9?D)___SD0<VJ;
MT^.:VK(:XR'ILDR83KQ(&$DF^:2:M)(NLH*L)4-D!]E'CI(SY#+^Q%/X Z_A
M-WR*7_$C?ADIR:/\\@B2%?6MQC"$]/PFO*KY77<:)*TYD&2!_(TXDDW*2"/I
M&(E%/]DP$HO=U#V(WQF+7W$1/^$FN\P+^!X?X3MV'$TVYAOR]2-\\PC2&$W>
M@W[?Q@*2A>5P.8PF#>>#]-@>NI&0M--8ID*V4PUA+)1+\*>R#[\K!_"K<A _
M*[?C1^4^W%<>Q7?*L_A&<0U?*I[%YXH/.'Q8$FT)'^I*^$#U .&?2+;4M36!
M-([^V]J89;%B7.S9/LXLCR?+$\(V2L#OZAS\HB[#C^H&W%<OQ'?J;GRC7H6O
MU.OQI7HS/E?OPF?J0_A$?1H?&5S!AP9W\:[!^WC3\'N\9B0)KQA+PDLFDO"B
MB22^\ \D!^H[T._;ZT,:3P\^WI3=FK$8.YGE<<4OH_QPWS(*7UNDX0N+0GQJ
M48V/+%KP@<4BO&>Q#.]8K,';%IOPIL5VO&ZQ'Z]9GL0KEI?PTJ@[>-[J7>&N
M]??"TS:2>(O<M)%D3_P7I$G4GZR"-(G>=RJO4S7?+?#'!#O<'^^$+VP]\-&X
M$+PW+@%OC<O&OVU+\8IM/5ZT72 \;]LE/&>W0KAGMU9XQFZS\+3=;N&I\4?$
M6^//B3?'WQ1OV+\N/N[PE>R2PY_R"PZ2XAPYZR I1U \1)K&^CLJ(#D)D&;P
M.D.%/YP-\>U42WP\V0%O3YJ%5R?YXE]3HG!O:BJ>GEH@W)Y:*=R<UBC>F+90
MO#:M6_;XM%6R*],VR"Y-VR:_.&V__,*TDXISTZXJSCK^2W'2\3/E,:??M X[
M2=H'R0$-CO^)Y*P]G-YUY53':?8S-Q$?S]+&!\X&>,W)&L_-F(:G9WGBIDL(
MKKDF")==L\3'7(O%\Z[5LK,NS?+3+IV*DRZ]RA,NJY7'7 :UCKCLTC[L<D3G
MH,M%G?TN=W3WNGZHN]/U9]5V5TEOZS"J+?] FB4.ZW.Y^7 >\ :GMI>\Y'AA
MM@Z><3?#$W,GX(J7&R[,\Q?.S(L63GJERHYYY<F/>)4I#GK6*?=[MFGO\URB
ML\>C3W>7QSK5#H^M>ML\#NAO]3BCWNSQI'K0XQWU!H_[!NL\)8.!8=1K/"7]
M1]'H:U++G_D ;P8"SW/9>YK76SX*7/,VPD5?6YSVGXGC =["X8 P<7] @FR/
M?Z9BIW^AUG:_2NVM?HVZFWT7J@9]N_4W^O2KU_L,&JSUV6.TQN>$\6J?:\:K
M?%XS[O/YUGB9KV3<ZRL9$<.>80P>(KES:?,:7G)?H.][BA[\6@2];ZB(<T%J
MG @9C<-ACM@7[B'L"@\2MX7%R#>'I2H'0W.U-X24ZJX+J=$;"&Y1]P<O-E@9
MU&?4%[3>>%G@#M.>P"-F2P,OF7<%_LM\<=!7YIU!DEE'D&1*C(G1HT@>P%=<
MXMZ@_MT8^MYX>@URAI^/1:AP(&H4=L=,QK;8V<)0K)^X,292OBXF4;DF.E-G
M552A:D5DA?ZRR :#GHB%1DLC>DP6AZ\QZPS?8KXP[*#%@K +EFUA]RQ;PC^W
M; [_TZ(I7#(CIL2$&#]$\Y\:/F$,7HYF_+GD7Z;_/9,"'.7G_7%:V!EOABV)
M#MB4Y"*L2_(65R>%RE<FQBF7)Z3I],3GJ;KB2]6+XVH-.V-;C=MCEYBVQ:PR
M;XX>M&R,WC>J/OJL55WTTU8UT9]85<?\;ED=(UD0,V):$RV9/.0']L$/PNC]
M6??KJ?3^&=QG9U(_#=B9+,/F%&-L2+/#0/H,856ZE[@\/4C>DQ:M7)*:K+,H
M)5MO84J1NBVYRK EJ<FD,;'3K#ZQSZ(V8<.HJH3=5A7QIZS+XV]9ER9\1'X;
M59H@61!S8E:6()D^Y#NVP]OTWL^P_E>H?YJ^ZW NO3]]\&;ZP/69AEB=/18K
M<IS0FS-7[,H.D"_*CE0NS$K4:<O,4#5G%*@;T\L-Z]+K3:K3VLTJ4WLMRE+7
MC2I)V6E=E'+"IB#E"9O\E/?)KU;Y*9(EL2A(D<R(Z4.^YACX=RS;@?5^C/HG
M"H!]A?3^>=3G]_Y<-?KR;=!3,!5+"F8+'06^L@7Y8<KFO#CMAKPT55UNKKHZ
MI]2P(KO6I"R[S:PXJ]NB,'/-J+S,[=8Y&<=LLC.NVV1EO$M^MLK*D"R)17:&
M9$[,'O)Y*.<#MOT3C/\YZA_AEF<7V<0M:3^_+RO4P]+B45A4,@D+2UV%UI+Y
MLL:2$$5=<8QV=5&*;D51MGY989%A<4&U<4%^BUE>_A*+[+S^49FY6ZW3<X_8
MI.9>M4G)?9O\9)6:*XU*S9$LTG(D<V+VD(\Y#I]+&<Z%:?)0!ROH^<C:,NJS
M+$O*=-!1888%E0YHKIPI-%1ZB365@?+*BBBMLO)$G>+R3+V"L@*#O-(*H^R2
M1M.,DD7F:<4K+9.+-ELE%AVR3BBZ8A-?] ;YT2J^4+),*)0L$@HD\\0"R>PA
M[W$,WLD8SH5I\E#[:H#!:N[WJZA/+]I>K4!SK3$:ZFQ16^<L5-7-%<OK_.4E
MM>'*PMIX[;R:-%5V=9Y^1G6985I5O4ER98=90F6?15S%X*B8B@-64167K",K
M7K.*++\_*JI,LB06T:62.3%[R)O<^CZ9,YP+.T+]70WTO?3AR\B".NZY^;VF
MR1!5S:-1WC(5)2VSA<(6;UE>2X@BNSE&*Z,I62>M*5LON;%8G=!08Q3;L, D
MNK[7/*)^HT58W3[+D+J+HX+K7AX54ON]94B-9!%:(YF'5DMF8=62Z4->XGB\
MILD'LMX'&MD76]@/FH$NTL3/50N TG9]%"T<A?R."<CMG"ED=7J)Z9V!LM2.
M2$521X)6_,(,G=CV KVH]BIU^((6H] %W29!;>O, MKVF/NWG3?W:WO!W*_U
M.W._%LG,KUDR]6\BC9+)0^YEL1W8]L=8[SW4VTA+LKP=Z."UMH.^@YX\ITL;
MF=TF2.^Q16J/$Y)[W(6$'E\QKB=4%MT3JXCL3M4*Z\[5"5E:K@I<VJ3OU[7$
MP*=KP&A^URYCKZZS)IY=SYEX+O[&V'.19.S523K(0LGH(4\R!F?9!H<T>:C%
MP !92EJH7=%-[TU/G+Q20/PJ \3V6R.Z?R*B5L]"Q&HO(6QU@!BR.E(6N#I1
M[M^?I?#M+]::WU^GX[6J4S5W5;^>^ZH=^K-7G5:[K;JK=EOYM=JU3U*[+I,,
M7'LE [>>O]'DPDXPYGNI.]@#K.AE#$@MM0M7 JGTQ-'KZ?\VZB!HDPD"-HV#
M_^!4^ VZP6?(&]Y#P<*\H1C1<RA5G#N4+YL]5*5P'6Q7SAI<H35C<*NV\^ )
M;:?!.]I.F[[4=MH@Z3JN(VLEE>/ WYQCGSM$"[2-NFNIV;T*:.X'RFA5LZ@=
M3VL4LA7PW@',W:4/]]T6F+W;#FY['.&Z9S9<]OA@UMXPS-@;+TS?FRDX[2T5
MINUM%J?L[95-VCLDF[CWJ'S"WENR"7L^ESOLDA0..R2E_7:R3=)ZB"8/M9OZ
M&ZF]<BVPD+K5].)YFAP0_7#X+L"7GMS](.!\1(8IQ]28?,P2DXZ/Q\3CCIAP
M8C8<3OC _D08QI],A-W)/-B>K,'8DXLQYM0ZP>;40<'ZU'7!^N3'@O7Q/T6K
MHY)H=42261W^FP/4W\QZKUG'L4!;VDC=8NJF[06BJ.M_%)A#3^I\&IAP#AAS
M40'+2VI87#*'Q>5Q,+\\!6977&%ZQ1LFCX?!^/%D4@2CJ\TPO+H"AM=V07WM
M,?(N#*[\!H/+$@P?DX1'T9Q%6L>Z][#>+3O9!O3AF4> V)- P!G&G[K.%P&'
MR\#HJX 9[:K!+054=_2A<\<4VG=&0^O.1#(3RF?F0?%,&.1W4R&[6PKQ[D((
M=UFYNX>!>S3T=VF<[](D/R-!N/,W&S=P+&[A?*3) 1T"LEGG6.H&4'<.=9VH
M.YZZUK< DSN _CWZ<'ISX24=+C1J;CS,@%?& *_2\[_&S?'KFDVIYC],<1%\
M2_,BXBXNS*S@VZS06Z_Q^A.1_H.5[&\=FAP0ZY[#>,<]1GWJNM\ IE'7]FG
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MDR6AG2R8])_\P'J_3]WG7('K[L 9-R[I,[B_X[*S:X(2VR:88'"2+=9/<<+
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M;];%SKMTT;2#.C+M<AV>?E('I]^A S,>T_Y9KVK?[$]TGHM5>US_$U_!^TX
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M<4(A$_<H:.(%!2_\5"'C1*SSK0HU&+/J)/+XL&,OT$JP  R"3CYO@+M\GE2
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MP-<V@^7X>1ST\+[)Y("H<]X:]/\&^"DF;+ODOPL-N <-OL]),PZXR'( C7O
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MP5AN]LNIG^+U ::8NYS,E#P;3D_J%$P/BX,K$YXBZE %1Q,<G7#TP3'"B%@
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M="Z7?^=V^79>*)_.&^35^3#XJ[PZOI%W.]%S&U$CN!".;?5H?S &5R]H _6
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M!#1(08<&*AI1?T4+<E6T(1>EWM1/J2_U51I(3DHCR%%Y MDKSZ0^RI[42SF
M;)774T_E'62C7$S6RBW47?DN=5=Y358JC*P!?CI,.&0NU^$[<>#FPOT9B[\C
M@*%PE0?ALP&XI[^Z!/57DR=7515R4=6@OJIZY*QJ2HZJW<E!S8[LU1RICV
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MM]' $, %\AQ<1#D@<[PW1!':0T7Y'V7(E1M#)(DBX3"@7& *G(RIX#$=/&:
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M.:2J54LJ6N> 9Z2J^1E@%(*R/2%O&D*D,7!WA@(('<D1[WL!/<#'"I]W RS
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M5N-$/YY:83:R0D#2/0= W-T-3J_E>P"QOXEH/=(@<]$Z(%N@.]Z;@8LQ/C,
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M>4J  - &#%&V.<JV1KEV*-<1$EU0^\$H>P0L=#RL8QK^S8>,%;#:<%A, GE
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MGM S$6WDL88O;XU9QPJQIM5B *-R=W@IW?;C._ <+>!-FS,:P]<CX2L.XG5
M%H Q>.B#APYXP,Q(@-<JN*:$>^5QGS2J*6&)":4[!GEK\.B!P=1.632P]-84
M*90OJNF- +HW;*(W9N!>_%"!8-R'8,46 5#/ZW_D84::H4^*]X)9 69X;P0>
M>I"G!0CP6A5RE?"9'(J50@B+20+?!^PPT?66$DTL3FB3OGQQ'W31#XW8SU1T
MR$T_!-']^,8&>"-]$9PZPU-S1"#F "_2_H-P/<Q0\5H@VVZB?6 \!V0('CJ
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M:?ULKT^Q<Y=^C)OW7W']DB*=>*$AV?#12J6,]=//9 ,MM[)A=AO8..<(-FU
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M!-$1=P,3XF^RTM.N,?)R!CU*"_LI=:6];FUEYXCMI8UN7?DUE+Z,2O<!R70
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M:0J96B90H&T,93K3X4JC+-+6)8=4WY!'\G\ME$F%S3.C8>^"8#B\W!<4UGC
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M*H  )6+3= #66AGPWB$/7H?G /OX @@^LPQ"M=:"T'0[A-D?!#Y% 7B^:A#
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MT+"(_.#HF*S I(0T_ZQDB5]Q:H)??5J<WX5TL=]@4@S[>G04^TYH%/M^R%2
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M@J#E.T&((IH2<-X@ _A=<H _/!-(Q^8 56D!>&HL YKQ&J#9;08/RDZ@L@^
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MF(0!+I=ZP2_,N],GQJ^5)@EL],@*KJ,6"ZHIM6$5Y,[P,O)0>"'Y?D@>Y7%
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M]/TS/^4>GS=>>&;92(G6AMOY)@<&TK'*78D$_988BF6-D(XOX[.)!;P@:G:
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M]E$7J%_U@/I##RB@]P.;IX#NU_\!?)3^68.O'C>PC'@AR$( .(["$$P3AZ
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MY,N7?<F77N*OO]+=SP/-_1Q0E_*T&:&K@P@=WTQ >W82T=;#)#1\G@?UW1)
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M_<]4T/U !>UW5-!<RM]KH*F3P$_]G_L@(?J\$&8I"&$N(A#B)0'!''S,$M=
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M)$.PY=(#%VYMH')K@B^/&@3RJD XKR(D\LE#+O]:J.9? YT"JV%80!:V"\C
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M$NQZI,!V"!N3!INI56"S&SLD S9G9,#ZINR"]5^RWVW>RWZU^2;[V09D/]K
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M^9\?!.1^_/B7C?AUV(G/8/7^_V\^YQ9"WO<1(C]#R!'XD"V((DN01J8@CXQ
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M6>PX=EG\A_%#\7F3U^)S)E_$/YJ ^'L36/[N%U,0>_L/T?\&YK_FRQ/ 68X
MK@I$<%,G@KL1%[C9<H.+!Q\X,07 (7(9V*6*@$VA&%A7+P?K5HD%JU[)GU9#
MDC\LQU9\LYQ:.6^Y>^57R\,KYRS/27VR_$/JG>4+J=>6<U(O+&'E,RM8^=0*
M5OQE#9)/K$%B,;!6((#3&@*XX?ZFXD>Z"A&\\'[0+;F!YL(''CZ"0 X1!I<$
ML>_..>)?G<HDYQP;5GYRZ)#Z:-\O_=Y^6.:MW:3,&[L9V=>V^U>_M#VUYKGM
M;VN>V#Y;^\CNTYK[=@NK[]J#S!T'6'7+ :1^=X"5BX'=6@*0<>?2I A_?P;
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M]PAI/_E)2/O1[T+:#[X*:MTG0O^V=G(/K@&8OP5@]N3\#V/]TP#1%S&#_P?
M]3< A^>",/T5#VQ>RX/5:TVP>&,$IF^F449O'2F#M^Z4[CM_FO:[<)KF^P2Z
M^OMLNNJ'2H;RAS:&TL<E3(6/HTSY3P>9<I^N,^4^OF+*O?_*E'U'_F'YY#&P
M&: 1ZY=@_;0S %&7 7RO <R\ 6!]#\#R,QLP,H(1D09]H@RZF/DUB2&H$PM0
M(7:4$G&FY(DW)4N"*6DRBR9),FGBI)S&(ZTT+EF"1ND<LA]=0<_0[_^P<!/
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MNU3)-KG4*F!TJ4_0\/(Z08/+^X4,+M\0U+_X6DCOAV_"NN>)B.XY(CK5ICZ
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M4#]>2JD=;Z94CO=1RL='*:43ARBEXW<IQ:,?: J'"5WAT!\8WZU>]->GHX8
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MLXHY6,,<T(_GTJHFKJ?_WT#_2V\^9Y,V'(>,X# T ?9#UI@YY(@90^ZPVQP
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M;(81_;'^44!^G/[V! W)"1J"$RS&3XXC]-JG6)2><N:DQR+H-"?@TYQ\3W/
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M^=B)ESUW7H)]>'GW8XU-=GC1>W.:7\O<]-GJ8XFM.;KM+-$UPQ$=,SW0-C,
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M4(3[Q2#,+Q6A_KD(\:] <$ + @,6(R!@$/Z!N^$7>%;P#;I#OB>BX!NHQB]
M%)YD#HY2;Q>UAU)I"-+H0OG:SI]KF8\BYB.=<20$ZB,VP 11@1:("+1&>* #
M0@-=$!+HC>"@8 0%12$P. D!P=GP#RF#7T@3?$*ZX1VZ%EZA.^$9=D;P"'N!
M?$M$P2-4%#Q5A(@X'Z59&:+V!A;%*[-X/O)U'DU+)3_/8WPID72!83H(#S5"
M:.AX!(=:(BAL!@+"YL _S!-^80'P#8^ 3W@"O",RX151#,_(>KA'=L$M<C5<
MHT;@$G4*SE&W,2?J&[X^A'.D.(H+>8(:!U0K0]1>1Y/2E\>Q0%JRV0^,*R>9
M+I#]%!XM1V"4$OY1YO"+F@R?Z.GPCG:"5[0;/&/\X!$3"O>8.+C&IL,EMA#.
ML;68$S<?L^-6PBEN.QSC3\ A_CGR%1SB_H9CG C'6#6JIR6KGI2SA;IKB]1W
M!W7RM;& #B"'%3!_%\]80I($^"3HPS/!!.X)$^&68 771'NX)#K#.=$;<Q*#
M,3LI&DY)*7!,SH-#<A7LD]LQ([D/=BE;89MR#--3;I OR /8)HNP35)S-$U]
ME]8F:J\N5]\=U,[7.IK'0L:21K,0S5@"&(M;NC;FI!EB=OI8.*5/@6.Z+1S2
M9\$^PQTS,_PQ(R,"=AF)F)Z9#9O,"EAGML(JJQ?3LC9C:M813,EZAGR&*9GW
M,353Q-0,5J[D(',^3/WUU%Y1H[X[J)54\WU>)9T88PFG@?,II!O.EV)FG@'L
M\DPP/6\B;/*M8)T_$U;YSK#,]\:T_!!,+8C%E((,3"XH@45A$R86]F!\X4:,
M*SR$L85/P;SP$XPM^!/C\EG3J\@3L9?'WD*M 9K5WD:@JUF],Z6\2;TSA=V*
M(,;C7@4X,DZK<FU,*1^#2>5FL"B?A(GE-IA0[HCQ%6X85^&/L161,*](@5EE
M 4PJZV%<V0VCRG4PK-R/,957H*S\"(85O\.PG/ZB3,T.U>Z<!IISFK,>&O?V
M]O_<F1(^ESG@[^8P+EO&-9F8-^K"I-&0C(5QXQ08-=G"L&D6\82R*9C$PZ I
M!_I-5=!KF@_=IM70;MH%1=,Y*!I?A5;C/6@WL(JO5S-ZAU0KL+R#YP/-V=R%
MS ')6JC>F1*X@.. S.3OII%QQ*A+!OTN?>AV&4&G:SRTNZ9!JVL&%%W.D'7Y
M0=H5":&+ ZV+G=C%1G0MYT!7/7J3EG;^"[P0?D/N$U:R[>+HDX)7\;A+%O$C
MS=U!^<LX#GJ!,'[5BS@2*S*!&!.#/@&*?ET(_6. ?E.>T!,)"Y]^%@+]O CV
M<U+KBU>?Z'UUA"Y\.9WG<EKZ7MK*99\#2_\@XBBJ59GEU%[(8S?U R4TR^FK
MZ4C7 KZ#P&QB32:LH_YZZF\ %#P<-M%];V+AN9%%WR86A)M8!&ZR)DZ$Q< F
M3O2;F(M-'-2;VM6/@MU(%[Z!%G?]A^173DCB*"O9WB4K>"Y0MV* ?4"-V"&>
MBUL YZW =!K6B4RC,1V[_@Y MI/ZN\D>@; HW\,X5+M4]C*.O2P ]]FHM^?N
MY\5_/R?[_3RQ]W-P[V."]_%@>VFW]]#&[[G'XSP@(GJIW<YV5K-MN=2-IU80
M=5QVJ^\,FKB/_7\ T#T$"$PEBWM>Y,C)1\A9 -$8G&:_G&&_/,%^.<M\G&<!
M=%ZU;9>3X'F>_.>9B_-LY#D>Z-PSY%/"7)Q]J%Z5V<SK,[43J1N\'W ]I+XS
M: +U#*FGHUJ->8*<)T]J5D>ND*L:GJ)9>UH;>,: YH!&X>9XX#;C>)Y%V@LA
MZC\E^&(U8:>_R*2^<):O=\A7Y+?159FB74 RM4.IZ\ZVV5)S O\92W)H_3^V
MS@,\KN)J_Z^L7E9:]=Y[[[U;U2J6K6+9EBU9MMSDWGOO-BZXX (N] YQP)1
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M3N#]F&%BD<_RT"^9HB*Q42#?]T8O]VEN<IQ&XC/ (#_ P#;  #?  #/ P#=
MQSM ( \0W -\N1^.UP]QGPJAFPJ)FO(B M?L0X<^BPZ!LQ/<#7QMQ7+\L(*O
M<>V )H_F7M%B^#>?QZ!7,!3)C&X>R*AY\*AY<,MA.-TP@_PP?'N8@64NG&HN
MMIA;@Q!$<S'@7'XX!X(_!U([&](ZZW<,QA\AWQ/\%NU;8ML+M':-;1W*=*0'
M:5XKE2/92#R?A:Z6?#&I!^*(:!5<>Q6)WTILL=)L7Y-"TK$2OKV23G4%MEC1
M9)OL7($QEQN;?0X3<)#*I9#4)?\ \#O$8CVA9=,&?K8)-;?0)Z!N&U*]#1]L
MEQ*YAB&^B,<V8PT*^-PGP>/J2+*#'MO08QMZ;$./[21BV_')=@:\[71NVVC<
MVPCXK2MLCR3>0EQN)G/>1":]$4:ST:*MFVW3-/-WXC*HZ+B]^(#P*82B)R/A
MB.\!\!$9:U"N1@Y?*0X(R>=A$K_#Z'$$/8Z0'!XUDC*2@J/$Q1%B\\@\VZ.!
M#A,35Q.7AUZA/++Z@Q;K7J#%X Z"U76(_N@([>"8E'J-%'$<?%SH/K(&A9]#
M6$AX?B;&W,CU3@S [M*-),0W$1\WH\<MQ,8M^.06.MR;L<7-./1F%+_I+@3>
M?R.LZH9OM8SZ#5&W"> V@54*3AHXD93M2]EN(_,NM\KXHZ<@5+:YD!$9V9LS
M,C=R'[%Z =\\Z"\]3%MYF-CX%?'Y*P:!1V@ O\*)#U/PPX_P^F]<_Z798$\$
MNP7<\AOH"V\!WWXZK>M==HSS]OF6D3F)1^WRF'U^XJ)LIY:,S(?\UM%V>NN+
M$(7?DPS^GMCX P/@'^F 7Z8!O(PM_G0GP@]>_KOZ3A.#8%=2SVPPH\'T!=/U
MPA68C]DQ1M:#/*<KUI[HI]-;7['/A1CK0JQ/E4&/#[#'AR3('Y&(_).V^C&=
MWR?$Q2<8_!,,]ZFQ&L'1/@?A9)\/,?;&&$^L-4XI-?;#&.=Q&$^,,4Y+-=:"
M3(.CSH8I+1">A#VNT=<PK2]I*%_H*KCC4>L)"Y_@O'_"5C_$.!_ I-_G6R,G
MDQKS$,9>D-_8YR#^>_[!F(LQS@0QGA2;KG_#,;_5:#!:*=O8B])'V8.4/9MR
M%^@]Z]-2UL"9-]F?EG( ,URCOQ*LKQ(\KV#(EV&S?^27QAD<QOZ7W]JQC3F(
M7_X?.OP@-WT%O_M,8?H8KOL1'/,]E5-^@]Z ;[^F'NK1IS^CQQ_1X_>PR!=A
M8,_#,I]%CV?@_4_#$I^"(?\/P7P1E,=X]RA:_DK?6==^/&B?_S#67]Q\A0[_
MML]!?(AOWI&)N@3J+]CB93CF2RJD_"KT;Z*TL=BPA[+[*'N0LF=1]GS*7DJ]
M5NL"+/@^N.YY.H][:,AWZ0ZPC!4A?](MU&SD=%#C&3_&&1@G[#K08UH?0/2.
M/:Q>("Z>EB]88> D4$(6NI?0-&HHNYFRQU)V-Z5/IOP!/#^3^LRC_"7P]=5X
M80OH^^A.KM%)$(]CBVLH\0@6/4QMC7-VC6<.&>LOC'-WO['/OQA;OEZT-ZU'
MB<\+]C48=RF*.J2 D4OYI3#H6B*NF3J,I?PNRI]$^?U$XA#E#U/V$B)B+=&Y
M#<Y^$(L8JT+NH'M_5%OQY!8B:[-^6G^QT3I79UMJ]8R]"3Y@[WINQ1;7$Q?7
MT49.*$['\,EA>/\AE:%_+?HW:0_QL4N=8$P$8RH80V#,H^QEVL"_=6BPFE^N
MQ!8KL.(R&O02(FPQN%?*Z\XT>0_J3E,^3U=[FY.MZ[V6N#A*&SDH?^H3#E8"
M.!E@Y(-1!D(M&$VTB#:M0H^5ZM5R]%B*'HMI+XNX,Q^MABEA+I:;3<UF$J5#
M>ELS:&G&L[&-%5_&]26Z]\?ISGY)5W(KU],,.\?0YR!=W1ZY4HHW]@K$NE&4
MF@A.)G4I *-,"XF/^6H$IPV<3G F$J$#X,RF_"7T).OQTAY-P9)]1,XD_#$1
M?QBSG,:91+UVN12$_8U#L1ABSC+L'@LEMV/(V4%JLA&[K'+PH&YF\(+!BM8<
M)5.?+' *P"D'IP;41BS0!E8743J9\J=3]GQ:SRKN[$"[HQKG<+,Z'![2V%%_
M4+O3)VIWMOPHCQMS,'$,88GP7N0@KW=P;T,(J0=V66@:I=DN7IKAZ*N!4:&:
MZABK/J<437+*5J]SH28XEZO;I59=+DT:[S)6XUQ[--:U7^UNL]7JMDQCW+>H
MV?VPFCQN5(/' ZKW?$GU7A^KSF2Q2CWR,%WY':D,R1D,]<:?7QAN-Y."K"(M
M6TA:- N;#/@X:Y*G23T>_NKR#-=XSSAU>*6JW2M;;5Y%:C55:(QIM)I-8]1H
M&J\&[\FJ]Q[2:._%JO'>I&J?0ZHRWZ *\P,J-_]>Y;Z?(A:K5"#WI]JVWY[*
MLRV#W9D+WS/VP)""S"4M&\0FD_#7>%\WM?F8U6(.4K,Y4HWF!#68TU7GFZO1
MOL6J]:U2C6^#JOS:5>DW015^@RKS7Z!2__4J#MBOHH"S*@R\3P6!SRL_Z)\J
M"++\*/<RO-] "GJ\&.[/T+:5U&<U[Q=R?R8VF8*=NDD#VD*<U!A@TN@ /]4$
MA*HZ($:5@<FJ",Q4>6"!2H/*5!(T6L5!+2H*[E)A<+_R0X:5%[I&.:%[E1UV
M6EEAYY49_COD0V5&6)05;I.[C+4X8!^%T^ZMP _(2GCV//28GFU; S*..&F*
MEFK"/%01:E99:)!*0B-5%!:OPK!4%83E*#^L6'GA5<H-;U)VQ#AE1?8I,W*V
M,J)6*BUJMU*CKU5*]#U*CGE:23'O<_VW4F(L5KF=>I\&]S#IYZY:V^FLRZ$H
M<PV*4$A^E0,M2I?JT:,\QE5%4=[*C_)77E2H<J)BE!V5I*SH3&5&%R@CIESI
M,?5*BQVKU-B)2HZ;J:2XY4J,WZ'X^).*2[A;L0E/*3;Q/<4E_L![B^(1(]T[
M!?Y!^.P.TL]U]<0"KV=S;RJ?=:%C"S%22[R6)#DJ-]Y+67&^RH@+4EI<I%+C
MXI42GZ;D^%PE)90J,;%6"8FMBD^:H+BD&8I-7JKHY&V*2CFNR)0[%9[Z/\AE
M1:1^I\A4"_<9PZCS"3#W0P6VP?/7&NM0>#T+72:CQWA\U$2L5.&S0F(U(\5=
M*<D^2DX.4&)RF!*28Q6?DJRXE"S%IA8I)K5:T6EC%)76K<CT:0J'((5E;%%H
MQC$%9]ZNH,PGD+=Y_:U",BT*1:['_L? W >GWMI./!KK4(P_5:/+Q'KC+!*I
ML9)<CYC))T;2LEV4D&%2;(:?8C)"%)T9I:C,1$5F9B@BJT#A614*RVY42/9X
M!>?T*RAG@0)S-\D_]XC\<F^3;][CR-_EE_<-]RQ6.6.D_^#O@8ILAN.OA%LO
M@%M/)_6;@![MI*+UV*D<F^3BF^0B1T7G>2HBSZSPO$"%YH4K)"].P?FI"LK/
M56!!F0(*ZN5?T"&_PBGR+9PG<]$&^11=+>^B6V0J?A3YJTQ%7_*>S!&Y%IRK
MP=\%/=TXP;X.!9X_C?<]W&_#)J/Y3@FZ9F&S!&P24>:FH!)O!9;X*: D1/ZE
MT?(K39)O:9;,I<7R*:N5=UF;3.63D#GRA#1ZE.^7>\4-<JUX"/F3W"H^D7NY
MA?OD,=3W *G_#CC]^C[;.I0Y</Q^WG>ARQCL4L5W"K!5&CZ+Q3\AHQWE5^,I
M<[59WM6!2(1,-?'RJDF79TV!/&JJY%[;(M?:"7*IG2FGVI5RK-TKA]JS!#<D
MH?8E7O\3^5ZC:BS6TX*O,O8C]4MKIMG6H<Q"IO)^//HT0-/*^ [N52)VB< N
M 2WP_V8W>39YRZW)3ZY-H7)IBI%S<XH<FW,UJIE ;D;AYB[C,3<()+X9,MD,
M66N&.#1!#)K@W4UD<$T6':;.>\#</(,Q8B;Q.(O^<99M+TX;]VN@)87HDH:>
M,>@3C&W,%.W9Z2KG\28YC/.E$Z,S'Q=IZ\S&T<&.(X#'$43C"*QQ5&;<(@2R
MW %Q["!#&DO&-);LK1T=VBVV,V' W##7M@[%>%KQ(/2TB_>-T)$R=,E&OP2^
M%S8@^5&DUQ3)90J<KH]$8S*#_&22C\FAMHGM20Q D_(1@GA2FVUASZ1YMD45
M$X]*O?"KWJ<(>+A_#SKT6'35'-M>H+4CZU"0R4NP >^K%](>^2R%(B*AB@%\
MUX1>KHAFD>3,(L&8:3+^N$!C#C06.2(,,$/88HA&- -_S,!P,XQ%/FMI;)#J
M00C=M"?HA"\CWQ)X%NW"3)N6V]:A+#36H2"=O&Y 2J"&Z4@,GP?A4F_$%1TU
M(DM(!)>0""XA&5OL:UN3LI@!;G$R@BT6T;DLPA^+<.I""EFXCX8/L9P/69T'
M&1S^FD'!HFVK;*?4CJQ#Z=U$6T JD.S-4AS78.[[(*X(R>1/8KS?B!X;T6,C
M]MB('AO18R,\=R.#S 8&OPW-",&T'H.NWVX['V4MF?,:,NG5,)I5%FTV3JF%
M@LXE9/J@Y>V$;[7QE)X]Q  2@O@@KL;:$ZI!TD[';I>K1@2_7.7&/?38CQ[[
MT>, "=D!!MX#Q,5^;+&?P+J*REX%T=]'7.Y]GL;P,6+1.G 7@-D/QCC*'7V0
MON!J*0EZ'GH$^_]X#HILZT].V>=#?B[&_,AI;'*:.#U#8GP6/<XEV/Y =([.
M]ARV.$N0G07HS,T(1/[T>]8].8NIQR"X76#6@U-TDOZ8,D,IT^>TY/SS-2BW
MV>="1L2Z)\<^-V*<5W*/ PFJN_V,$I+2^XF-^_')!0:B^['%_3CP/BIR'WW5
M?7]"/M$0=>TY3E<!;@EXJ81,V$W4_Q;)Z39[^7?;YUKNMY.@A_2SO3BR_8%X
M9#[$6+/QE"O$"3U^1]+^+ /_<\3G\PP$+] (GL>ISU'X<]CBN;]K(MACSM$/
M4,<,ZA4!I@_N<AJ9>QG9C_.8?EH/\EN[&/,A(V>3O'C%7,C(::IOXIO+Z/$N
M;>4]!O]_$)_OTT8^("X^H.(? O3A;W[&_8WU(,8>$./I,<:9I,9^&.,\CCH9
M:T%L>U'Z8$G3]35,XTM8QQ>PGL]A0/^"17X*&_L87O41+/0#'/@/#/@N!GH'
M)OTVG'OD'(Z7[&LP'K7/0?SW'(@Q%V-;C_(#?.8;..87JJ3\1LKNH.P)L.<I
MNHP>;Z/'6^CQ)DSR=5C?7]'C+W#,5V#6+UOWHMR">>Z'93[#OW]8YSZ,U2]/
MV.<@C&?[WOE_Z/"UG*F3M_X)KWH?KGL96[RI8LJOH>PQ^J/&48\)>@$]GD./
MW\'K?@N_O(0>3Z+';V"D%V&HC\&M'H6E/TRP/L"[^RGA/NM.(=O\A[$&PW@R
MR9DK=##F &BMUJU-K\M3?Y8?6!'@)(&10_EEE#T:R[;H$?1X"#T>P"\7-$C9
MLRA[/F4OA=FN!74K3>8JN/L)FM+--*G[=8[ .4O-1LX"-=9B&.=A7&W7P3@'
MY/TKYB">)BXNR@>L8&P6 T8:Y>?CW7*:8AUECZ'D#LKNH2Z3*7^ ^LRD_'EX
M8"GEKR,B=H!Q2(>Y>PBM#M!HKB(B]A%-QHDRAACK+XSG,'\NVW*FE^VA;C2O
M"W*PKL&X'5O<;#T'(QZ,#,HOH&85=%=UE#^&\L=2?A?E3Z+;[*?\(<J>1V0N
M0X,-E+\;SQRC6[^)=Q?0[$6\]>E_K,%8(8MU_N?W]F9G-/E[[=W0.6QQBK@X
M1ANY&MY_ )_L@_?O5B'Z5V@[?MFJ)J*P'8Q.,":"T0_&3# 6:"7_EEEWI1S0
M(FRQ@%K-QZ/#M)2Y1/L<L V9BQC'#/V/J^T,D#M=;$=#&5WO4>N0X &FF?J$
M@!.C];23M?#^5>BQ K\L5RV6;])BVNTB]%B 'O/PRUSB8S9W9UI7ANPF<H]K
MFG4'T2.:JM>(YB^MSX7JL\LS##,/T[W?Q5!S/=?CO#^(/@PAU-.94DQ@^E&G
M,'!BJ4L*=<FF#H7@E(-3"TXC.&W@=*+!)' &*7N85RO42RD]6++;NHKG@L;C
MCW%$O['[;D0>#[ ](.TF8]DCJ=!!TK)=Z+,)759AER5RHV[>X 7@[7!*CZ,^
MJ>!D@U,(3CFUKZ65-(+5#DXWFDRA[)E$BV$A8]?.?J+GC)J)["8BOI&^HI'>
MKE&VW8 /A3/L,-R?8:@]$F?; [,9?5:1%BW"+G,8!@>=/, T@Q<$5B0H\>"D
M@9-#ZR@$JQRL6K":P>I0DT.O&AT&53]JONI&K5&MXQ[5.)Y2E=/=JG1Z4A7.
M[ZC"]6O$8I5?@GLS0]M)TL #R'9>KXNG_G3Q<['/H!^YG<E176Y>ZG#V59MS
ML%I<HM3LDJ FES0UN.:HWK5(=6Z5JG6K4XU;JZK<NU3I/E7E'G-4YK%2)9Z[
M5.QY4H6>=ZG ZS?*]WI;^:9O$(L*D+O!/,>P=HQT8U^V\608; #?7T"*/(1]
MIF"3;OS5YN.B1B^3ZKS\5.L5HFJO:%5Y):K"E*YR4Y[*3"4J,56KV+M)1=[C
M5. ]6?G>LY3KLUPY/CN493ZA3/.=RC#_C])]WU&&[[>(19G('>"?AE<?)M78
M!=??P'4Y[X=)Q::AWT12Y0[\U42<U/BZJ]SLHU)S@(K-X2HRQZK G*Q\WTSE
M^18HU[=<.;YURO)K5Z9?KS+\9BC-?XE2_;<J.>"8D@)N5V+@124$OJ7$H&^5
M%&114B#<'[Q3\/N#I!D[2(77<5W"^]FY5ZX!D>J@#^7!SBH,,"G/WU>Y <'*
M#HA45D"",@+2E!Z8J[3 $J4&U2@EJ$7)P=U*"IZFA)!%B@_9K%B2LIC06Q4=
M^IBBPMY0=-C7B@FS6.5&ZGVBS+X7J(I4L]*V1'LF?+^/(;\3/<:@!U1.)5$.
MR@GU4$:(C])" I0:$J;DD!@EA28K,313"6&%B@^K4EQXDV+#.Q43T:_HR/F*
MC-RHB,BK%19ULT*C'E5(]%\5&OVEPJ(M"H^R6,_E/0;NOEK[>;#( E*>&150
M$_3H($5O)$8JB=="TL/,&%<E1YJ4&.FG^,A@Q49&(@F*B4I7=%2>HJ++%1G=
MH(B8#H7%3E%H[+!"XM8I*.Z@ N-N5$#\K^0?_Q>N7R@PWJ(@Y Q81\#? Y?=
M1.JY IG/Z^G<Z^6S=G2LQU85.? =8B0MR5'Q<9Z*B34K*C90$7'A"H^+55A<
MBL+B<Q0:7Z*0A-$*2FQ78.(D!23-D7_2&ODE[9=O\@TR)S\D[^0_RYSR.>\M
M5KF..E\-K]]ET( 6^SH4N/XT=.E!CS;\4X>ORHB17'R3@F]B4MT5GNRMT&0_
MA22'*"@Y6H$IB0K@0_^4(OFEUB"M\DWKE3EMEKS35R'[9,HX*Z^,"_+,>)'K
MQ[PG:TMG'#?.!@9S!]1P_5C;.A3CS]3]</TNJ%H+GX]&SU+\E8U-$K%)9(ZS
M@C*]%)!AEG]FH/PR(^2;&2]S9II\LO+EG54I4W8STB.OG!GRR%DN]YS=<LN]
M3BZYYY%GD0_DFO.]W'(L.D[]]Y-V;X/;KX5/+X'GS^ZD34!+.M%K#':IP2:%
MQ$DZ-HG#)F'%#O(K<)=/OK>\\_UER@]%8N15D"+/@EQY%);+K;!1KH6=<BZ:
M)J>B)1I5M-U&'(H8F8O($HK@%D7?R*'08CN7QMB/1-J]>B)M BHRT]B+TV/;
MB].$72K0)1==D[%)%/X)@CJ9*USE66:2>YFOW,J#Y5(>)>?R)#F59VE4>8D<
M*N#^%<:/(>H5D.>*+0BY= 5$I!S>7?XN M\L)Y?JM#VM:!-\?N54V@0_F<%U
M,N_'<G\T=BG&1IGX)Q[_A.$W/^QBJG>1:YV7'.L85.H87.KHR.IHP'4$;AV=
M71T.K*."=7W(/-NC9NO("$9#BD:3K=22-=:20=9:=,#8CP3NAD';.I1Y4*'I
M7'MY/P9=*B?#/?E.,G:)PE>!Z.--]=S;G36JG0&M#<[=YB^U,KBT,N"UTIFT
M$KRMQL(J%&[M16836'"*%KC_&+C_&(A0,]E;\]?6>9A] \0"N&MGV]:AS!TF
M'KF.FX7:W"]&EPR^$XL^(53)C*\\T,FQE^2G%TXW@4&^!UOT8(MN;-&-+;J-
M#I8.MYL&UXWBW134M<JVL:(3$C<>4C8.[C\.'3HLV@WVIGGV=2A0TIE(+Z];
MYF,#[N>@3^(<?&#LPZ$H3VSD-)T$9SJ\<I $8QJVF(8M!OQ^6I/2CRWZZ=SZ
M\4<_1NNG$E.7(F1&4R!U?9#$R:_3"7[%@&2Q[@4RSJ0USD.9MY*O<>U8CLN6
MT1:0%#Z+1"]_:*(7WW5"-"+S1R&NMC4I\]!C'GH,DP@-Q]D6/@[3B.;BC[DX
M="Z5FK.-1D>F..L"E7V%@?D+ZUH48R_0E>M0NM?3-R.E2 82S;V M<0@XH3H
M2EEC"/98C3U6H\=J]%A-;*QFP%_-X+^:N%A5:]L :$RXK:3 %<?H"&F?RUZ0
MEGYJ/1=EXP9N;T8]FL[$K?@ 52MHRED[B $D$#$ACL;:DYW(+MF2S=WVUS^*
M$T)\[$*/W>BQ.P)AD-E-Q[:+3F:7\:@N#&L<@+J#N-Q.^]SV(4GKO[7:.#Z&
MLJ=09OM>J=IX2L\!VN%!^@'$1"B/&EE_<@09F0_YN1P?$7QS@C@]B1ZG:">G
M,FU_&#B%+4X16">IY,FS? <R?]S8D_.U%H [@&KCC"<E@Y%/>0F4%70"?+HU
MAY%S4$;F0FZRSX6,7*W[<61;)S(R/W*'D^V,DGO0XQZ2H'N(SWOH^._!%O<0
M=/< = ^\_^[G^=['&J2.7=2M'LS"ZZ0DXRP4L$Q7KD$QYEKNTD_GDACS$E?N
MQ;GR?))'1N9#B)/_(4:>HLT^16Q<HJT^31MY&EM<PK&78#*7'D7^IA[JVD0]
M2[B5>HOM*<FFD;F7G\^#C.S%>=).S)ZZ8D[D=S^;"S'VR!AK0M[ 'F_2?[U%
M__DV\?D.;>0R#>\RE7^'BKWSY,^XO[$>9.1,TI&GYAK[8:I@9\WVO2B]^H),
M_W.8S;]@5)_ ?#Z&<7T$&_H ;O</&*?QU_W+L.NW<<[?J<#K*/<:G-M8_V&(
M<1:HL0_D@GT>X+_G0(RY&!]]#[_[&A[Q.=SN$Y50_FC*;H&?CJ?<B7H#/?Z&
M'J_!N/Z7SN+/UE,-UL%=MV**?: > ^MZ3'2O_9DH;\'EOT,LN.NG.8B;?J:#
ML0[B,VSQD;S \^=746"EZ"_*TQ_AN2^J7L_!9)Y!CTO6,T&G4O9T$&;CI@6$
MP7+*7T=8;*?V!W#C2<+G5K1X$->^I#NQG+$'Y?8KUF <OT('8P[ >!#R&S*F
MM=ST KSJ&6SQ%-SN":7K4?C4PZK4 ["S^]#C/'K<"^NZ!\9W%PSP#GCN[>AQ
M"WK<!#N^@<[D'#XY0X.ZCF^=)(".P[F-O2?&^9^'[6LP]B+&6:3&&I"W_F,.
MPA$\$UC^X$2 D4CY6323(MU(;)S#'F?PRVGBXUI8YDE-IOP!RI\%7Y]/^2MT
M2!NQQ%Z\<IP(N85N["'MP&/;X=S&R;I;[.LOC)-V/[+/OSQG#WFCB8VLP;C!
M>@Y&L$XIFI*2*3\;!EVL@]ACO^HH?PSECZ7+[*+6DRA_@/)G:C/VV A;7\^[
MM7Q[-:483XY9!M]=J@^M9U^,K+\P3OTU\(TU((_:F^+M]J[H)+8X0EP<H(WL
M52CUB 4C%?USM D]-J#'.N)T#>UE-7Q[)2QX.;&Z%#V6$!^+0)C/-XS=,7.H
MP2PB<"8H,_0F$?2M]7G0(_(\7<FCSM*]R,VC;-/.MOD/8WAP ].;^@2 $TY=
MXL%(I?0<]"^BMA6:!]^>"Z.? _.>A1Y#V&.&IE'V7+0Q5H9L(6(.<=<XR?5^
M(N@EO/<OZZXWXQ1DX_H$7<@O&69N\9&NY7J8KFV/LS'_ >_3*' ]P313IR!P
M(L&)!R,-C!R0BM0/[Y^*'GUJ)"K:L$07.'V4/X1&"XG<=>K DNU$3IOU9)=+
M1-+[>/'?UM.8#7F8(?^.(-L16$>Y[J6+WT):M 9=EI JS:._F$E\#LH7K!!P
MHL!) "<-G!P0B\ I)SIKB8PFL,:",X&R!W@W%\U6$L$[B)[C?.-VU1#QU?0P
MU?0^5;*=1O1+4HZ;2'U.,,0=B+8M UU+U[K42$>PRW0WQE0'-^SH#9X_6*&@
M1%.G1.J33C3D@%4$5@58H\$: ]9XRIX,QDSN+E49_B@ENDJL+>M7R*NT],\1
MBU7NBF%(A$<>3<('R";CB#;NS0^W_8EJ"C;I]G+06!</M8SR 2\ K##08JA3
M(ECIJG+(585#L<I'5:ET5(-*'-M5Y#A!A4Z#RB?QRG7>J!SG0\IVOE&9+@\I
MP^5E9;A^H@PWBU5N8TB[-DTZE$$,,M2O8VA9FDS:13HV -_OQ4<=V*39VTFU
M'IZJ<C6KW"50I:[A*G&-59%;D@K=,I3OEJ<\]U+ENM<JVWV,LCRZE.'1KW3/
M^4KU7*\4KX-*\KI!B5X/*L'KCXHW?:($DT6)R$W@G\BF'>39SF)=DTMN:ZP!
M2;6M >DRTG7\54><5)A=5&CR4KZ7KW*]@I3M%:$L4YPR32E*-V4IS52H5%.E
MDKT;E>0]3@G>4Q3O,ZPXGW6*,1]0M/D&19H?5(3Y947Z_@NQ* JY'OQC^;;G
MX6R&ZZ_DNH#W,ZY8 ]*,;ZI)$4OP38ZOFS+,WDHS^RG%'*)D<Y02S0E*,*<I
MWC=/<;YEBO6M4XS?6$7Y35:D_QR%^Z]6F/\^A02<4W# !04%_%Y!@9\J.-#"
M/;@_>$? WFWL!2HGW43FD0(.PFU[T6,LOFD@3BI)APJ(U\Q@9R7Y>RG>WZPX
M_T#%^(<IVC]640')B@S(5D1@L<(#:Q46U*K0H%X%!\]44/!*!83LD7_(&?F%
MW"??T!>0C^47:I$_<EV1;3_23OCL>M*^9=7VY]&0]O1 V=IR\ .Q4D:,Y!$C
M:5$.B@MU5U2PMR*"_106'*S0D"@D02&A&0H.+5!06)4"(87^X3WR"Y\AWXCE
M,D?LDD_D=?*./"]3Y+/(A[PF2T!.EMGV(VT?;5N'L@2J.H?7_>C4Q6<MZ%A+
MG)02K[G$2 J^B8EQ45BDEX(CS J,"%1 9#@2)__(5/E%Y<DWND+FZ$:98[KD
M'3,H4^P2>9&D>\:=E$?</7*/>QIYE]??R3/68CV7QMB/M T>NP9NO1B9W?C3
M>:QCL%$-OBG!-]G8)!F;1"4[*BC>0WZQWO*-]9<Y+A2)D4]<LKSCLV5**)57
M0KT\$\?)([%?[DF+Y)JT52Y)U\@IZ2XY)CW)]1WD*^XQEH^V[4?: @58;3R7
M!YD)O^Y#EW'HT40*6(V>Q>B2B4T2:#?AV,0_S54^*2:9DGUE2@F25TJD/#&2
M1VJFW%.+Y9HV6BYI8^64/D6.Z?/ED+Y)2F<D2F=43&>$3B=;2/\2YY)+--KV
M(VTBY5T)IUZ S##VXD#;.]"K"?VJT"4?ZIA:@1^P23 V\<UUEE>VE]RSS'+-
M"I1+=KB<L^/EF)VN43D$4@Y&S#$F+B#)N9#67#A6+GEL+HEZ#LEQSIL(7"_;
MHD/@[P1S0[=M'<H\9#H\?R)T>2SW&]"E#,J8#85.Q&81V"0 FWB7.LN]V%-.
M13YR**+S**(3*:(1%Q$T1010,8%=S ^+X?[%$.MBB&$QI*D(PE!$\E]$QE:(
M#H46ZY^BMQOGXDZVK4.9BTQ#>E&_C?LUT*/"L9@,76/P3S!V,Q,_GK5.<JKQ
MP%$,*E6^" ->%1UK%0VYBD9=14!7\>4J*E<%8:]::7O4:B7$I0(24O$WJ?P+
MZSS,7M3<.H5XA)XO'J1-#-JVCG0;>W'0I8S/L[%+(KJ$HZ\?=O%"'Y<6!M4Q
M\,MF>%T3@TI3 &29CJR1!MQ(X#;2Z32B;"/.;9R&0>&:#7L@4W#_>K*UNM<@
M]^@PVF)]9,FFZ?9U*)AL-C2H;Q9^F$&;1)<"=$E%QVCL%(@^WMC&E:JIB^2G
M$[X]GD%^/+8PUJ1T8(L.!N$..I,._-%!3'2@]%A QBY"C(4%QN)ZR%DKW+\%
M'5HLV@'V>OLZE 4+;6?"=L^C6MPK0Z=,/H_#E"'H::8Z[MB+Q,4F4['%% ;W
M/J^?UJ1,,M:D8(M)-)Y)^&-2L^V!1Q,IM!=RWPNQFP!A[(&,=7]NW1.T!>PU
MB^D?,=4<9/)2U%R"F[F7A^J)Z!7&=WPIPGT87$/FV@6;:;:Q)@4]9J''+/28
MB4]FTJG/Q!9#-* A_#%$@ _-M!WX.IWV.0B1G 8Q'/C4NA9E ]1OE;$.A; =
M0,8C=4C1:GR 1/"9+^'DL0*\$5EIORZWRS(2T65P_F7HL9386,K@MI0VLI2X
M6$HC6D(;78(!E_#EQ0?HA""U"R&J\S^RGHNR#M66;D1-I(=NI&DS_3(F2R>A
MC.+JAW@@,L1(,K==(5M_+D8B2EO9ZF,_+S8>R;-M"C4F0 VC;]Y) )*Y;Z1]
M;KA,('ROE5MMTT23")?673090C=K+^UP'WTAXG'E^I,K]^-<_7^(=7\.-CE"
M>SF*'D>)C:/XY*BQ2!1;&)O!CM!7'3G!]^[C-\3EH2\U;$R5@=D.1O4ANB[*
MB<5E <? 'YE?N?),6&,NY)S^>S^.]9DY^FENY!9\<YOQT$9BXS;B\W8ZVMNQ
MQ>T$V>U4[#;\<>O3?.]##5"W<>#6@I</5CP$(P LCRO7H(R<"3NR%^=>_><S
M<JX\G\18)_+C.:KH\3AZ/$XR=I%$Y2+]YD5L<1''7Z12%_GBXZ^HBWK6\[;P
MK.V9/$'VLU"L<R\C:U#NLY<],L=R43_-A_S'/AS]M%=FY/S4OZ#'J[39OS+H
M_XWX?)TV\@:-[74<_%?&K[_^?!V((<:Y(,:9I,8S48S],-GPXC)]0];^!<SA
M,YC+I["FC^D@/H+'?$ C_0?,[ET:RF48V=LPPK\3/&_@Q+_BH+_ (/\$>_^#
MWOOQ6;#&S,M#]C485Y[#^9.,TG=PFJ\4"%XT6*FPH@+*KZ3L!OT-9O$J3.,5
MF,[+Z/$'6-=+Z/$"G.HY]/@=3/2W<)I+\+O?$$0707D,QSRB_X7+?V7%OM^.
M;:S!./TS'7YZ)JL'S-17K\$C_A_<[B5X_[/PW*=A$T_"9IZ 3=G.!)UH_2OZ
MP[#8A^BP'K">L+""FF^DCKMQY1%<>CVA=)Z0^BWA^I$5]P;[_,>Q*]9@?&_'
M-N8@C'THSUN?Q^H-5B X46 DZP)\ZI<PI7MA-G>AQQW8XS;XU*WPNIOAES?"
M!J^';Y]%CS-T8M=J,\WI*CQR$@Y]&\W6>&+MZ_#X[ZQG@>Z[8@V&]2Q0V8[;
MO7(.XI?8XBYL<1L<\V9X_PWXY(SRX.6EE%I-V0W69Y(<A?T=ACT?@ML=A 7O
M1X]]Q,<>F/I.8F,[-=U* ]Y,B1M 6$\TK9/M^<LC:S NV\/WDCWLC3F(6ZW-
MTC@'PP26/Q8-!R.>6J7#H/.P<@GE5U%^/>6/H0L=JTW$R 9B=1UZK,$OJ[2$
M\M=K&=H8IX0LLLX4/0Z'OFP]^V*N768C!KXQU6A,==YI[PZNM7=Y5V&+7=8U
M&$%@1(*1@/[IU# /:Y<P5%3":$>#U@Q&.QA=FH\>P_AE#O_/XAO&[IA!;#&
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M@--29,IQMY_?5GP<V(:N4W8!=0&>!""? WAB #XI[1;-G+\3\(\L1JH 'S;
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MS\@4^&D#_J0I\**W"=P0,$FW07_)@QLI"7TC GW#RTZ"<+!2(LQ,M% 7 \+
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M"PV0A0;(0AT60G7H#W59_-=/0X*.W@45[ *K9"<XDVK@L.T 1VC["+0!AP1
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MU<O6D:+V][C82SRR<"..OPT<Q668R);Z#2"01PSP_7UL,A'O<DS*$0SOVT2
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M?>!?NX<(WS)^=;_GVM]T\A(QX*K@[TIK3US!3@*MWDUT$!M"J/8;.]& S80
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M1(![*";HT( 0%$ 2#?!" 731@,,H@"L:8(@"W$ #MJ, 1&;0)A1@"#V+":
MN%TH !L:< 8%H$6']KZ@)020$L7VH>T@HL"VEX06)4)\&!S[VY85%0/',@?2
M[PN*RVK>O&_O_33Z[8]G?ROT[Q"V^P\A$B/5R1==C+:NHT)DECEU:XDXL/[O
MWKI+E'^)<$TBVH"P0ZF+#&H#XB8J'R%#&;VI: ":"2+S /%#\4 $0$]2PFC
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M>+#G1:33"&&,)5'T H)X$E9!I/2(!B% CPC 30BX3%P'X2%)&3& L!D37$0
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M76+[T^5&5X]ZMMVP3>W&1JMB=KJ(Z<ZJ^>3-TMX)9+@E>SV^ZV!YIU)@K>K
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M@/\ LEVMK<>'?A[H6H^*(QONO%.MVZZIKNH3L=TD\EW.&D#N_P Q"%5SC
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M=_\ $C]B6?XS?M^>!?B]XH\00W_AGX7:-<P^%O#"VKJMKJ]R0LVIRR;]LC"
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M[VM2*NX> 9Y(!T=O.*<-%UQ(2DH2KF'GYV+G[<VG8VWC;.UI"U=Q=_6P=@L
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M[5#G</;(]>C\..:$YJ3D5/*T^\SX;/7<[P)V\?*2Z[+Q2O-J&NV*1J.G !4
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MMCJ4*=:2Y5HPV5W(BK!>?O*H]_R-1H_\Z:%LYK["L\_D.][Q1EITRD+=HO"
M8]Z\'IO^45@"3$_I8,LT!R?8^4@S:G<VCQ^>&EWEJ^ S8'#&.(L&S%:O./PM
MT8 &2FL[]T?/T8W*C&0/X;RLY,(CJ7ZYLH&")W$/B<1\ME9\1RNX=/2*B\.8
MLU^7^B]UGD775(X<\D1_;(BTH!Z$E7[!P_)^OWN\"$0L-XP;4?^@LN$O8 <8
M$'!2"^RGBX3Z[>E=.[<;'=EX:NH)J -)_,4&9YVRI5'9Z5ZR>_<01>8=0WV]
MD9RW2[Y^!;!EO5<^.2D[66Z]N'O;\Y'EX93D1C1KVJ)ZFHU,2E]4],Q.RO?
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M?VC)UH$W].MUDF^71:ENU(14C637,_!\RH\!./\_%_3/_P!02P,$%     @
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MFHJ"@HKZ.H0&'Z]S,3 SX!,7.P\[*_Z1%>+C$Y)5EI:45M;7T-!WL'$("ZO
M_00HP'^3T^!%=*H[57WGG4V3Y_\E,[_M.AS@8GRKQCY=_=56=Q-RRXXJU8-^
M0NEZMRRHD63C5"?WV-..4=RCO^Y<=;5_<^0+BQ#5Q>&]WC'$+GK+;#38/J.P
M;."XFO;6]E3UZ&W43J,Z@:N<_*[J6"3EA._>;%;^5N=9J/[43[=EW66'DK-"
MSI,C(G=^A[].E*EIC@MP@,,>*G\Z8_L4NQ^WJ*0 (Y]MWD<^'ALUZOPU=1D.
MDUN]R+CZ+,<V+_<EBQC_S[YLMA@.Y<G'JV#[E3+V64^7G9#$KW8RD@%6^=5W
M5\KL9UL/,2^QB\I1,=_;]XXW@Y]01;5_*U[>]R@X9PN3OGHU%(5!5Q]LAWR4
M]QL[F^&2Q=B&XN5@:;!U2AQCZ)$A71W*QO52MWQ2"*%686%YAU[(0NA5)!?8
M<,=,U\Y ONS''[%M5'UX8683K?;4CH^2 L4P$>IER"GA096IN$M+7=)5X[EL
MG2;,XD/8*YZ]G2V?D/'?TC:S";#)-6-1XBI/T2PS]O00#V"\]C5'U4C0?*A)
MZ)7)_=/_-3ON!@*-N194&9KE)YZL;!I+35#Z4 9-3='R!,.=__.TXS.\,I'B
M5QN(B  'I-SV:;%HHUEX5%]..;YD%,)3F;A@$7LS2(>GV;:N>#W?3.0OCP(&
M!@-:LEQH4GA#2 6-#YG/O+IP<WI?]O6R\I#)9S4Z=!12+BD^0M,W^T0_^D>N
MR-WLFN +>L0M(=B<8BIYGW)\AV6R><+FR<B>X>MJWP\?YMX9?/TT6:CG0\O]
M\T,U?/UV:\.G>?/L![+WMZB0V26?YG9I?+UX&W.1NV0:WI7]30]_D#9K1AIM
MD4]AN#A;^M^8WF2&,MQA"O%XJKY 7Y3>+ZWG,60=8AF?T>_E(BS<5FB[LFI5
M57GY\;%3C5LF_2!EYL(G:U'97@._@$>BG(US%EXR>[/[M-7NIJEYULY-'W\Z
MQ?_<';^K_[DX;%;VV<#T!P:;N3G?FV\_+ :FWN7F*3"QIH<'J[LXIXRX\%@V
MZ]H\[.+"L%;LD;O-7+9OGLH_M*31?,;(^UI7LZGNF4/@W>SQ7J1&7/,+L06(
MQ?[9I)SXL[E?1#=>OH&\_J56X@4%T6&$:I;@C,89>0-9;+W?U1G%,UX.^Z8(
MW7GY>&;J476V\4000;IHD5#<.G-2H0SU@I.'L:EY4;*HTTVSOM2<%9.!)VA(
MA21/U5$RK_#:._(UW>MOC.E=) 8>;+R]WYS@Q$#$!Z=]^SWC.,3T<6.Q-953
MQ>O\;)(Q)E?9U#7NSA"@2>=1!IEV8^4D_&,ZE>Z!AJ_K8!X=10O7KWNQKMY]
MC1P;+L]H@VR+A2TFSJ/;@[<9X6;GS8=R B _)\PJ+(3I<@!$1R1V+.1$TI:9
MDQ)99D T.&C)G_TR]XLO"X\:#IB45+M>ZT]_[HB9E'B0C!F3?_S>[1<O\4+5
MN?=(%5Q#4+=MBM*HM>R(+@Y:\GG&[%?NPU2FCWJ)(M17+W# WWH)I@'!0#C@
M\6V1,[49EQ$))\XD$S&_!R4#N<AD3SDNUB=:Z&GZ&1:K!^$/DT;J++U:J _[
M,F'2NOR=1%MU%*D9*-"V1#=KCS-:"6;$FOQ+^&BE/\YZ@]K(Z%CAX&&^ANJ:
MDJR(=\O<R_(%N>&GFRR;>P6E%6=]FRCOD^^9G((.HM^2KH+$.X"SD<PGLO)(
M2>A,TL9.$6$RF#V)C7+ZD94ZNQG=RO.[7KN[VZ,TE*=,ATGT2\^/W+G=%BJQ
MD*^DRZ6;[%GT(2D<2Z%I?O&VX[.QGZ4]&=&?56=3D2'>*W27:\/)R/0(:.I&
M/#<5M"-EX@8.D(HB3=?)BMI<9BAXNKPI@0.$3*_6L&.%)N./;I>Z(+1W$V]V
M&,\]X'-.-CJ230'D"@&[EN/\!AS@FP3:YD(8W&Q')IUF]YDE ]:B^LQU/U!H
MUX]4')\Z .5S=>PNXKU*?U95;+0G3TS-;>]IU/A$R1;JW!4'$.* MD4OL6TY
MEMG&I\-'D#<=6)^]P9BPI_,I3OE63^K#]T7>[PTV%QY+)6XF(SMW<8#G?#.Q
M>N!P^3S1UT]"!!+2W<!UER#Y@TM?'KVD02788K-NCO]EU?I#>2^F9^\39V+G
M7E(-TCUB;W;J9:(()\E[$N(7L,(GJ.)<C:T\8L5X#R8:,VWC@)KL6VCGV/C2
M9FJ./,QR;#BK(@[(PQP,5Z8?:_FM@E$.^P(XX!/LM\,^$^(3QR[-%&@R?V&Q
M#, !(=J861S@M+&]G*ZE/$7Y U&=MBK&',_9B U:[O_A%H]T58"'O@RMJ72/
MUQHJ16-_:H,Q% @*Q/?^@WX,91CU^0?$WRI'\&^5J^B3="E%YMS;XO(TA>*
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M9/WC5D*.2/38\X6-]"$=-@^C$NI5+3\])?\]C@SR3$'>1>K$_0:=0FYD5MP
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M)U[!<U?\=9>%VT>#B0L9OT#4?J]@WE"I)J7GZBDY_CQ<CTE%F2E(*+# >T;
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M)FN>]19^R1,8SJ8?F.(+ASA.JD4$%)6+24]0TW$7CVR_R]@0D(\3RJ9U]RM
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M@SFBL6?GVC$Z$Z>^[92JA$3L%7TX.K3D^!XNP&&Q6Z"T[%4>W<H1ET_IB>!
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MHCXIW222UKTB:JE;X/_R!I;=(<.;^M7COZQ9K=-:JC4AT4]&D5M -I>9=/%
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M&@ED6;JD%%:LBL"#TV_!6DX*WWYX.E!L4*FP45V06JW])7D8QC]N/@=9U-R
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MZ0U+'?6(T;)?^2NQOI4>VQ8%&DXND4D<L_/2X!TEU=-->)K.#_A!&6^1&AZ
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MZL8A<68U"-P)6*/[4J\_L(,O6L&:81CT%UP-'HBR_(P'J"1#=,CP0&T_5NE
MH,X'#]S+P0-^D#33#[@G1]:9<.C/?JS:Q0OQR\[=B\,#1JPX-\_=96Q,L QN
M$0\XOESQY<,#]]O/&@\%-\R@LUD;L-0N/+!BJ3&:#E_B/24RA([S7W V96)U
MO>'0S]":,3Q * P+;MQ</\O%!1@7F]=)4,0LPC]686)&/1MQ4K$7G'U->. .
MVY#5/,J-E#<$NH]D.U^KY:=8XI5I7>P_\8*&I=&&53AE39:_Q^WC-$'K6,X(
M,J5I3;6-"NO:Y*4Q(@H.N&V!K%=9V-Z=3U8Q%>QM[]XEHU2>S,-I-LWS#Q#2
M8,B!I.J])I$NW;-N@P:#TRWGI&C("AOM '1#27^A,8#YB_CE$&0=2+B/7RA"
M?S9VZ/1U+_D77G D_0;OE73L[U+C@0XOR%P$'K JR6J&UG2O^5LF7UX; Q^O
MK_&&-:Z(@,<@*S;-T%JE-7HX-A*)!Z8;,[<C3HB&SW1ZW2"J)A3=1^+FOU/M
M5?&  QXXXCA[8WU>!]T9/MC^\K(K]Z(%VZ^P_PH/A+V91XV'!>.X5&M[(;,<
MWHR-S5FAK$>S%YR-CS'+&[[KEYZ[#ET2=#-AU$/^H/M$/ZE"/@00#;.%KR,^
MYFFY0-R\TA-YQ9L769!M:)8JM8V^NRTX'F6[$8-";DKRNTZ6$OSM-)N+WV$4
MDAXL1Q4Q!WKI3J1-(=^CV'\?LAL;V"AX7 ;-#!@]@0<V-&4N#HP#BOY$D<GR
MA<KY;Y.#FQ&;]FVM>(!!?FIE'O7N-!E,>9_"EOI$ ?*YU<T2-<J @O&&+B""
M(VO:5 \$L;3L<4JAX 6Z8D/]U2).4(ZRY!LF@3/..X7,]>'''C]-CYWE$_F'
ML1P/D>?"CWBA>8/2PJ%+G(KE2:7N*SK3V*A%#NKRQ_TY<E".E;*Y]J+>NY."
M_N,ZCS/"T6[L3!-^\1E3U;M'Q3G(<Y;8D]V\56GAH(A4!.NVB ['X9'0\[RT
MS.#=EY$XK6[K^G()8YOYA#]/GX?P7Z4W TZ6DC*5OVW.)LU8V^EL6=MR]UCJ
MM@6%,-,S%=B]6T]]C2K>=C*SS[_-H1.@W,1=I+TF8VRX6?,J93"!A^65/#/,
M!.%Z(!WU5C_LYT.OXHHW5L2:S14,0PI%[D)<$<T.X*D7AU?(UL6M&0\-X\KB
M5O1-5&7&LGI)7AWWNCPJMO;C':DL+GR23;E)07.G,D3:MB"G:$6H[YE3M;.W
M\Z.R[=9^&L3X7!C[G7_]"4]V_\Z3JG=*T]TW3P5"SL8'+7=GXGWG5V"]GM%/
MBQ1S571+:IRA><@SBX\&NFG>MTU6C6EDNT5XG_KA&!1=;3O=PK'1;$LLF0[F
ML&I?G-;FZM9)U+%\YSYC;',;DV'Q:SL^.E^QM[FP.<+3E,WLW8@X(QB8EE;U
M40[<YV+=80%^>ET>,YX4B>.4K&+% RXA/3V8D'M*MXUWV [HBP[0WK!.D >E
M@OQ-FCEM+"G]L'70"![P"L,^L2\26P;'K'2)5PN(SW;L7&*$?A*N!KRN!3FI
MV+"4P3T?P@.4@U@)/ "CQ0/%4=BMB,<XWHYCC,?%Z&4F)(K_P:9]' 9GEDN
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MOT3;PN^+:H[7K+"I,JH[=S[+W'3RL<AQ4Z@C>[W6OT>Q&)IMH<^,=(EH.>F
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MFWAG[KPW[\Y:\^:M]7:RDYV5?4[^?__M^W+VH4Y1%X +!CKZ.@ ='1WPF/8
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MR'D4)G1H&"'-\_-,+]Y6&_1T3(9EY[+%QFVW;AW;=U\;>%P?ZO&(')2US3R
M+;*Q_GUU!E;,:L]J*'Q.S3C6.W5QR#+E&VN58X;HN5\]K^48ER@JA&&MR&^>
M,JV]ZF$N.Q)?2P2:"S/G\UO&&C7@$\]]F(:4RK8WQ;^T;5 !6CZZ3H;<>QJD
MNXA/6X#3B:<MAES"HJ.E8M)YA7>^C]E_O]&SJP;FOVCHF\IYY\'L(GR+"I0&
MI7EU>(\\LW+Z)2%OH%D@$'8IJFTYE0FA1?#%/IHU]OGJ6<:?F< ]_4PE>5;]
M?8_Q$0QW,>1YF-@CX==G@ 6Z&=2'/1#+QAHW8GOPZOLB%<^^V=6T5_/VCQNO
MZD)6O9HUJ0"HB[W=]"3#*C5^Y._39C64<HFS;PL[X=PBG/%!34=)Q?C(0?;:
MT5O00\UU$E#Y\US!J7C)HQL(\5:7VN9HB(Y"P8RL <5[%J5<BKM5[A)Z_WAS
MH/?X1]0E$X>47YQQM#*K*I'\V65<83,D1K+6J/Y9Z8'O3Q+.UM]26IX^IFLX
M*-3\UB!;4*\XO'?=4P=I8&9^3;^KLG0:KD:Z2\X.@-"K9\?$B*>9UCR\G['S
MN5C[R"&5K4-S;O/G#G^O>F*?R!/COC.GB)9_TE=0 E"WG^H^/DJEA;K\O'VD
MP<@5PR'$8TH,"FI"ZL%8OO'%7^S!CI-G>X=_> Z,MI12@8!Y*N!2=A4U\MTO
M&:3Z.2M@V-B'Q-H_5.*PU@:M/=HJ=<)5MB%9V07A&$_G3C_.F<S7_LF09;XO
M1_QL,0'D4T?M,^.#N5]F#=W"7%=5/K]S3(DYWOR=['EX<?6:4%;!![E>]JF^
MA1W36SV+(TTR^ %R;AHFYNVLP\AV#TF4]YY+K/8QXC'_>\WR9DN<0+>&<0$,
M1DB$<1E&!4449)SWR?BX?%@@OI4_2P4RO?XB6@\MDH;YH:T'N/=%60M.'J4.
M^F%(-,D0=UB%$P@Y(G&,XL>:R<D4V2[? -%1@IJ=<_W$-I<44C[JNS85R$M9
M_@B]F.%0R+Z@8'FBG= ^TCF<SM*'2ZVA_,"#X:5C[T5+!(;)G.LG78A8_P3[
MN]T8OA]\ZZ:8^: <?S^=#1Y[O84()J$3WAH(/0UN<8 ]5=2=%K:U%EV1?JN0
MH%?R8?GJ2?OZ3ZV8:7FLSKLMQJSN[BUF2*CE D^=K?KYZU;N!]-']J##2:U-
M[&&ZC<=3DA$-?Q81JB%<X7,MZJDZ3@*)6*M[)83+DD'OWFQ9R8=938[!L7=D
M8E[B"% ,8X)HHN+8Y.63>Q?9?SW]ZO*.GC(<%$>C+9;]4.PC%'/_(FBVOB?E
M9[E(2QXKX0,5X.WWX4C5B+P,^9I]4D!A$L.=XFF2P=&W(X1L<T+*O"RX!^6%
M515,V=$KLMWGH2VR\RBC002E0G?:J]]XYPA:'&0%.9H<F*.4K)M?,H&\@^MP
M'A-I<&.#$.;CN\!&1ZAP8@UP^V)4V"OD8"\&&WAH3!3G$H+6C9^<AM" :-NK
MIA ?+RRZ-9SKHG=CRUCQ. \=L?2LPT/1D*Q!\)S/JQ-ICC7*1$'O''DBD'1>
MO1UMF4X%*HQAT(5L!\FT-BI0+]/Q(W9YCS+^!9EPHCK$T1%)!<)@/8QUGO@T
MC$]<3AOD'.E.>=EI+PFCAN:S.@O%M[+V$_G): .2+6U=GQ(>&'-3_J#.;R_!
M?EUNC(2T^+VU$DY]!B<N./UY,X]RUQ0GN#1Y8M&=O')?7,=K9W.$"K?/.L>E
M\?SLF3]$A"23X?@D:9\5RX-5*/:!>C&EVV+W!#1T?U2C<T T<43_RHU?/3<Z
M#T4GMQ$D#M;%;50'8@K:^JV#MWP&6> Q*?,FRV%QYO8#C0OYY N!B,Y2IZ?.
MS@$N 6+65H\CU'C)C30178-6V00I'?/ ]VAMM]&M!UERD;]\?$2T(]<-OM8/
MO]EU6(OEIP(F)?WU2BB_JOZTV1F4UOS5_'A2XHE0?OQ5^C69_X&"OH.<(@7[
M8!%+/I%-)L%G)R^'\TW>0.IC8@2=2QG^2EY??O,]2LCY33:9QKHB:JE GV:+
M$/0/#;0^L$ 2CK&!-%!*DH(GY'%B$3-4H(8*+(I/2"D@D,$./M--QZDR\JZ6
M+^>.9[^[<?_<A-#@A@3>'.*.W3>@?*QJV)^NH%3Q^;@<UQP4^Q!D0!WC48GA
MYW Y^I%(VZV^0CS#<0S(CA<W-.-$8?5"D(RP+OC(!>AY:+N$8 ''':42WT!\
M0I?.XEN#KV5\[-T8J]</E#ZRYQ!-:9[$<^@SO;N04;5T3J(;CLU0BB[3&'\]
M;)23$(K1-V\ZEO]VH?."YL,>]<>D2.RJT1D9P?5M3"R2N4D%_YT*U*9V:R<O
MMWWWD<VPX'O=V\:_Q,/S<[WOQ?WXVG#D6UCM2IA=O<W6-J&,/;;K"8:<J^MY
M$NY:WPJ+X*4"VQPX74,L/'I;M'%,\1K@-G/_9=4IY8$KH( +_&D']**OH:]:
M^ B7:=BL8XZMXU5X>,<GJSLEL\LO3*^.TVDN2QLW5(+Q+F1X"S_I'%:@)E1M
MQ)]HKVP5H98"Y>!9'7-R^9,\*GMCX\Y/GAGY5LZ_YEB22:>QW)?/3-_;E:M#
MZN?P!QKWS[--Z6S/U2Q3 8(4&RGKW!$Y^@;J0!S1!W^-YI+6I ]UQ%*!Q!M;
MBZ@&+/EW8_*\JR1_X:F;>LL!VY"O:*P-Z%B.;Y=XUAJZ;@3)!%=/MMO*)--6
M1>(M"?3ESYSU%"'BV,LU>]8GA_?= \OG(NJ!9UKZ(^T5T\8"POGZ*!F6)#9E
MN=63OA6TUB:, '5+0*W?P:(I9XQT2>":+O2!$,&'"M"+(ZRI0,QYDBJ-F7=T
MHX[&ZVGIIX#"KX;=I,2PT582;8$F>32A*Y^7D(@D,8HK9>CF[C^*@S6&$*[E
M_2"ZA3X=5Y?Y&N2F/^RUI6 =H)TW@=$7F):HC[UVKIOIPT<B"Y&WY3D91N,9
MV0Z7R$GA8NB@@KN335I?'2#NJ>X^G,<Q_8^"G[S_-A4?Z,HIX!OAN7Y"^+53
MS!)4O'?H\=+^:+/A[Z*3N1G2:XB68&HA '3Q*>672=#7$9#\(ZS T$SR>+_B
MQRZGC^$,VE<T3G6/'Z.)]"1_&N\+)I>K7\$P%U_X6VV?!#:]\3QB CJGIESM
M?3',B9,8A1EBG2*@VV<R$DKOUJN^K/"4RAW3+:S2*Q* <HI:+H![?-Y.HD^U
MR :EM?-&+_DM$H^EE*NW]]_Q]P@))D?9A=Q$-"R4/Y*UNM[@Y9U93W!!_:$"
M\KT#UQH#G!S H[H'[)#W:*P=*!F.S:;\5C6.\'*5<EN8O2+5%]DSLW.W@7'R
MF3"_8-=46/@".0'EP2H3B_ZVFK!4X;%_;G'NNA6R-R=#_\;O.&>?E_<N0EM[
M#$@>A,RE)+,E>-><9R<7>Z]F&2;I@2%"3-.IQ9K9:BS$^:K@:TNN,RX7HQTM
MBEQ(D@AB\%RX)7&XSBWV0>*C\ F4R,X0X8KN%GD-32C N!R I+Y3.D:F,\L$
MJNUNG;!=NP.:]]V$%)JO0:K=6J>@;FS3Z/86MB0GHDZZ<_'A:&&]<9;$LZ,S
M.L]" #7+_,D^MVG8I.^X9 7"9;T6$DY3'<6H.VWZ<'-RC$0CLQ$G5.#G'':(
MTG3(1CX_WS!$$-HE?;1,!&_9@4_,SOE#L1#(,5\+#Q68S/M,<[W9214JP"!
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MMQS=SD_F,$"#$Z_J!@1RXK7#-6C2N+1(*7>"9X7W]9*?X#7/?XLT2M)R49^
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M!NE@\^U7FM9Q*<,(IJX;37R;;+9])K^Y?>/*<0:7^(+33GLU/7F6ZQBWC71
M:=4)%XKQFME_= @N1U$$]#S!Z'MYS47D+\?EKR#3$/H5R&:2BN4X G=SO"?3
MAZR0V^"/_'B@<!B\F>98&.SKY266[ISJFL0:I9T1QK80FB466WQ5KR CM24W
MU+W=6!F/?O >_"M$GL8-P<T5$GF 0L9N*'OEK\4#!:N--SH%L3E%&E !E73^
MNP+Z'QJ>M9V^MV8I[ -F)+28,6_9H^N^$A 1" X-"=S'OS*>:0]L[@L(&(GH
MO>9,V<EDKCAUHT5R4?50.5W3HJY<IK81'$*K>$9Z#X:L[VFUY37[$'@W9XF[
M"]L=2:S=U9X6T, Y&2LU[HQ,8'9P*4_/&;_4\^W7;KWP$I4ZC+-8Y-^F<1MU
M"9_ZD0 FN;6!W@H+$0<4=@/N/J8OV;PN3"?HGEGT'6HFI=GB=IYXN>]:Q-I[
MCC;9%WPRID7:E)@%OJ!>BE^B7PIS)F[W8F*S$/$:\M_UB]V/4M,$7W/#_@@J
M>A>E!VA<1CS6KC B?SVNHK%21=P#T5HW6^NAF_=4_KP:D&Q>GYFM'YKX:25(
M\*^J@ W!*M1@AKOE^S#MAKG).O3>SAI4.L5LQ<=DI60$(@*B<:%[V8NR#8'3
MG?BH++DSD4MY >^Z9VD84?)*Q:TAO\%0X$8IU04F3\80NR<.HK?DOC:/V9J?
M !ZU)NH&N]BK&TF*<JNJ/A?UU3]S6:V23TLN6L6Z0'.BR5@]9+HI[!?N;9'*
M "]J]C#'B"'^KR> M.NM#(%U9]*C)O;<VN</11VY&=\UB^AO#0^'_^\;N]#N
M7'1O-,*-(0^*3D=@HW<+ 2'XUSWCI?X7=YYO:\L*3^]_,]=:UK]^S[6=V?N\
MQ&@R3YW(S7R3Q">Y&B< 24^JO++3ILB%G9?AO&OALKIA;\H0[19*F%AAAQ6D
MUAG:0V).I,W-QC0]UV2VSVQ;R4K;O^LE?BCM%;6CDEIYC[]H7/3!@\ZO31[U
MI/D:!J<L.?(". 7C?'\21*3;!"^'7(8.=#^'E6EP&U8>0"S'P)NOL TCIE=,
MO$="3@ .0R7QI16>'*MVLDOC/$'\49._-2JQ;8^-7O87Q/UNL/K;]=3[Z>W@
M:_Z.ZO*;P<&%=FM9\,*%I@%3/MLU.WBF5[[^]V[%H)?SUV'L6,"%""NQV\]-
MYB4),)F<$%6[]+17$YO++6HMS60'H_2'O?XSDBBFEN/Z[+VK]H^()L4ET,G
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MJ-Y== #\"CRK<1];D5 X= *0<;1)"+:,5#;U#A1<H7SD,QV1^2W3%W;*%2Y
M<QE7A,: G";8L5X:0Z.)N/='Z:YG2*GWEEL\,5DTK6[KXO10-I-T][ZQK+5"
M <8&OGD"2 HVG&5O&EZ]KXKR,,5EF9OV;;1"V']*YL53WW1=D,Q[_;^WTX&)
M690# F_B"0"G3DDH]CP_4TX;%I]G1LIJ68FL)\T3I0]\L!!\*N5.AW$AMN\$
MP*EI>^&IL%,4<7 SMQ'$B6UU1BU""L!7+5".F>Q.A0'&N^/H727WW@GQF1,
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M4U9-V/\FI^PYP'T@1L(9S.P;'J('(=6#"$_(M','PR]A.N]JJ.#=72"R-*K
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M5Q$4;%;Y].6,MBKAAR+#(;'XP,_ A^&<1'B^/S0X_(M-@NVWNMFEA^UO^[<
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MY6*?"\?< &"AAYENV(N"Q:T#3<T:;5TNR]=FNEP 1CMU,OT_ %!+ P04
M" #!@T-2%0[PDYT)  !$#   %0   &)I:6(M,C R,#$R,S%?9S$X+FIP9^65
M>SR4^1['GS$SQD@[QB6J5Z8R)!9-<EO5+$71(F*40H7<C7LA.VJIW*^1H=R2
ML*@)4Y2)7#*M=3<A1AGCEL)HQC#F.6//GNWL:_\Y>_X[K_/Y_?,\K^_S_7[?
MS_-\?[\/^!8<!Z0MS,S- (AHG1<M !0"F!],C8_NM'-W]?0G^A(]O-R#=YK[
MNVKM)."T]N$ < 2( >!PN 1<0@J!D))"(I%2FZ5$VOPW!(%+2$@B)#<*;):2
M_%NI_Q38 BD"  @<\IN WP41@\+@X@@)I.0F" "%_$M_"4H#8A H5 P&A<-A
M,%$D2A0#8&BXS"Z<L;BLS07$[D"Y_=?2"B6431XWR=OV+&!U+@9=1TIN45#<
MNDU%=8_:7O4#NGKZ!H;?'3EJ:G;LN+G%*3M[@L/I,XZN;NZ7/#R]O(-#0L,N
M7PF/^"DF]L;-6W'QZ1F9M[.R[^20BXKOESPH?5A63GE24UM'??JLOOE52VM;
M^^L.>F]?_\ @X^W0\/L/$ZQ)]M3TS.SB$F?Y"Y>WPE]%BY#%8# H#+&!#!&[
MO/$^:!A\%TY<QM@&<2%0=O?^:Q)R)FF%CYN0RCJV"_(7@WHDMV /O%=9W*#^
M#?H_8[[^7T'_P?P',O@20$L &H ?%"*B1T.@: @X#$A!(:(;*!K  ZN?3PYH
M+M<Z/+UDH^Q[,@Z;>-9'3ZRMBAEZ.B,1,-1-LGA4E%ENI/JQAGA6GV+Y,2=O
M:ILW)\R!ZL#?2ENX?9K4URX4<P*!Q7CVZB2&35J!@0!?%O.SK9#8[,+"_.F)
MP\^.\?.%$+SPZ.'')_@T)"F5U&Q_ 02L,2O(RR#0IO:U@O1JJS9;H"(T!@&D
M_<WU@Z1Q%28(*!;/99)R0&!<%@181^;D:+D+V7R$0(6 65X$@>ALDN!B2I6-
MT$-T;0T"::C_.XKM!*J-\]%L:;WI2?L0 V7UE_OSI"5>[QR//A9(GD_,[,T+
MM51]H?1PQM)\KR:YGI_G$>^F$>IIA+PCJO'BI;"6[4J[B5JL7E?U$-<>=_G@
MDJ$>7O1<M@UUX"2$'0\<[/D>058#.*: DF<!M%,.""^*_AK:UHA*K<LAWNMN
MP6/EO]CA?[(62(- K\UR9J,$Z08^??_S2T([;N6,#FDZKB(!4V(  DFD&1U#
M7,2IC4Z&(%"7XLB?N[>C$P10%MDRKQ65_>+NA$?+P= =7=\;Y?_ *(NUL*E0
M+;Q2XJ'[J9+WL>'N';>24[?O,[ZM\9XK#"AW_F67JU]L'*NS<(>909"Q #%W
MM* \THR/OVS>&:D=VS"OC6\P2TXVM0UXL'XW7W^!VA.Z?M@M3$_Z7?NF!@-.
M%L$7W9[=A]&>8BR4GXX(L\U(=V[M#ZN;:?5Z,$BT;ODU2;'_I%\#/2@Y:SK7
MZ6#<1<J3[ X-[$LG<?1UV5W9AIHC2M%N:P-1SAG>N,QJ@^!F;H\**9)&'SD4
MIGZ@3!=9JG5&7[Z6GU$KR+I'M&<;EPZ9ANCA\RBX@,JUVL3;79;MD<M3GE^6
M52FE)O)[.9&+^<IDFGK"L@/;I\N481E7:J9E)<NFZ<1[T[]S:6B(\'UQ\$W8
M%F[W&ZG@+>$/3-X'/#@H'?!->-=61%K:<+U7;PDR4C_<CGNU\T!>J$-?)8/$
M,)GIC=F!]QS)S*50 BGU# 9GK?7F44ZAS-4UEBW=K$LSLOP1UA![V>9:OO>;
MV:R2SL_!2WN9HY/^C$DFF3M'99T+H$?,5N]U'*RQ]=,HK:#Q+.8\O#<_M^KE
M4]4KFRP+E)Y/X*U0ST1?S[E73C;_0/&O7,HY2A2U?IZ:<Y,2XVJ=FTOV'R10
MKG;@FV8:&X\DW4T5L^3X<A)A%_:[&,#"-LVEFB_+XPK-G#O+K ;.)H;1]OLY
M<1W]*@9\GOG?5BLSHG?G8^L&^!$N!![#,CEBU=C#J"F/[^N@RZ*%/N7Z1756
M=[,J4.[Z<,H(NWKU]H_#A[S.-4^YCS/YXJ+=<ZX8!+KA4:&H\3X0@.&7,Z,.
M:5_'O$]A):)N$2<EMO<2UTLTPT5_2(WV6;0'CFW1L? 1G%CRR(MJ&&MTR%O0
M<G[$N-^7>&-?);NMY^[+//%9,XFI9)VT^;.OI&>:0P8J;<Z,\<[.5^?;=7H-
MA)1T;7?N]*EKS-ILY)Q]XH[U-[T!=A6)98B'.Z4#EW>79ZET^[6:EFD1[E>1
M?W1PBI5,SLR<J-?M2OH4%.MZ#68Q6_Z07F#>?]Y@)AFWPJ9F?1=4[ZV^/'I(
MEI!(CO I)IB'4(^479Q44%!L"GJ3@R4[>%5FC!#6F&6V&'EK@"KY& 0*/PVE
MOOL\1V-OY;8QVTI</;::>)DMW'SB:.0XV, @/0M7-*LI5C1V[,Y('^/YK\Y1
M1V<=J8NU _5%,;&)[G5/=FG)QZE _6':AQY=V:IKTVZ%.UFSH[ C[,64W,\9
M7I4U$6?M+T<1*:U6AY1#]ZB$+CPSZM ,L?;GSM5F,=IX>N7Q,@B<&'H4&5"Z
M<@2!(,Z][- ]@3&X7RG>'VY(OOJKAMNPCQ!#4/M0NMU+X=)P/3'KT[RF?_:$
MGQ9!Z=O<CB5L,C+L.IJ5J%.PQ\#6:I^1V[;6#^\*RNC[_$Q-+=N9E!X?5ET8
MS>F+3$N'AD&SQ7R5)S,[9W1X77L,! *:/N2T9"W-IX06Q1C?:(*N@8#^GFF'
M&?LO0^45:$^.VI**A\^9*EYC=?7KKA&+_HG23Z.#J[/WZODAC_(7,BV?O!F^
MHX#QG!YBSO :IZ@NW'+7A$QY;"8I9"1YM6Z$5\N9N5"_E)[GZ"S@CZT>?N/T
MPE] 5R"_&ON%AXKU4GR\*15R. <[L:A+GPW6WS- Y?A1^6FVQ15[#,_H^]7U
MJ$R]K>1^CK@7K'&O\\_#.?!U.-U_'T[2K6V^PS&!MP#Z<<4IY:2JY^>5?KQP
M[BU=IJ7/;J:&G!XQ-FA>%<?#M=B&%G9LR:B/$*PIG5F_%K4^(!@!@5O5T#5U
M*N<5"*B*#GEKC5E=/!F?PD=PX3R> X<HW)WRL9S9A1+D;EC5PWZAIQ#/PKQ5
M8(ZZ=-)6XO&4"M)!_!)19%/%I_C%*R"02CKO0@HEZ8' !S4AO5*P  (=-)%'
M)5FS4R:$QE_[%O];VR/_HUU1*&;(,"V7M"A'<B<(KY!83,&M*+-2SC&1T2N_
M>Z[IR\U"FX! .%INXH%)=&!>X(K#H&U"J95T9!O.:L0)FQ*V*0N7,(IM9(4\
M:4GA1>N6N5M33-=%/CJT6SA= /V81@HY">$>I]6K 6M8EU$Y("I=^U,\<+A#
M@6<*8-P2UD0.^Y<$L82-!+'EXP_W%8M%X\&A?P!02P,$%     @ P8-#4DMC
M9S?(. $ AMP! !4   !B:6EB+3(P,C Q,C,Q7V<Q.2YJ<&?L?0D\5.W;_Q&E
M"-E"RA2*$HJD(M.&)"0Q99L*"2')/HR2)6LI%#&69"?+D'7LE"3[EF5&9#=C
M&8?9_J?G?=_?HYY^OU_/^W^7YWW?QN=69XYSGWNYKN_UO:_K.O=A]#"&@2WG
MU#34 *9U3,!5Z =@S *<)\WMKUL %@#T86+T Z>!=4Q?/U]_K_OZ86'^^GL]
M"PLSRX;U&S;\5E@W;80*ZX8-&]DW;F+[^H'^MYF=;?/7@Z^5_,NEZ]8S,Z]G
M8]W RO:G/XQ*@'LC<R7+.V8F46 =-Q,S-Q.C%H!!;5S_6_.8@'_],*UC9EF_
M@15J!COT!]@M4/.9F:%&KX=:#)WUA,X#+-SK>78=/+F!5_<:JZ@#G]R]QPD;
MQ4[E5O%?;"6*RU^_<W\3VU8!0:%MN_=(2.[==TCAL.*1H\=.GU%54S^K<4[O
MDKX!XO(50S-SBQN6-ZVL'>\Z.;NXNKG[//#U\P]X&!C^Y&E$9-2SY]&)22^3
M7Z6DIJ7GY1=@"XO>%)=4U]36U3<TOGW7UM[1V=7=T]N')XQ\'AW[,CXQ29I?
M6%PB+X,KJU_[Q00P,_W;YX?]XH;ZM>[K'+!^[1?3.I>O?\#-LG[7P0T\)W59
MKSGPBLK=V\AWZG%";M4F,?F+1/[K=UK9MHH?PN\F?>W:;SW[N8[=_W?U[&\=
M^[U??<!F9B9H\IBY 3A HR8&JEFHRDP#S.)/*OF  H0P187J3.2:D2?:GP"G
MB-4$@@E[;:3HE+;BXXUC&S4$[[+,V!V[48&BO<0-OT$3M="]1H39+"(OP;YA
MQZFY>A61/I1Z@BNBRC [=T]X,O-LL8>2E5C0Z,X(Z3?,;=XJV,2R?K(++8<!
MW+#O:QB^!2](F9XC/5$GZ=S?'6IIZUZO=J;HH,S$1=?/^N&#9XRWANHC+IS<
MN4YJ3)T!^(3!A\."<K*C<=@=_1,WP"OPH/9*P]Z/;<.%'T/09+@X1X_PLIO9
M4>G@1TS+N_DKJ=:TU(IU7BWH_*X4B@$5 8;9F!&7U=M$.V51NF;VAQ-8>T8E
MQ>(4"C1,S>T/;CR887Y +-1FC $\0!)OVU-Y%$=P=3!.E""(H.B93GJ)DVY@
M;5^.;_- R9-VEPR8?#J;>UHHTO.H:+!\7LCLNZ2CXIPWF:<G)1.]V7Z5?URH
M! 9P?\[U=)UA=QVZEU('$_;B0IT ?2DR-TOJBR0:=#92CQ66E$0;118$6RDJ
MDB.#\TTNUQV(&$!\-G7Q^Q0PE(3%,P LIA[6[S*\'(""I].;&$#NAQB2?TWW
MUNY-!-MC7 %;2[;FF!VY27TN3?^T'EMK<?Y>1/+#>VPGQ42]500A:;J3 #5"
M>8K.3.P.8@#FMH@:9YC(K;)UJRZU6ENKZ:OUJZZ&KH/J,3JQX5(A6=OA$P?K
M^Q7-WJ\[);SH2,BIA?<ND%5!$\)0'S/!.27>5:K&T%TCT[74-'Q0R2F"F&[Q
M-'$VSK):+6GL<4^BI/@]9!2.> [6JTE^24M3V>OU%E=H7RO;VWT&1 SCO'%<
M"DU:BK6LM851JU]J!3JRXKJ.#"J=4,7&OK$2UW_>-'NCFFF75"X#6,\":D&_
M$;17N.&DPQ4[00P#8,%UJ,C0/\#8<PRF\#CO0RW!*MO;;BEK9:1G#U@:A,Y_
M>?^&.YP@A7BH?UO1CD/R*7,7>O@^;+VRON<P/ R&90!!7MRX^RAAREGJY3(2
M\I[*CDF#P!#[^+="H5*E0>C2[5&!]6IA@I);[NM'EHO1V04HIZE,M$C<5>06
MU*8.E>V7P3 3$!-O#(KA$=4[8-KJ,;7'0CKV# J[2E]P8-$2MYN-W]@A"5-2
MRYI YW/-L%-NHA!$6-#24!\7?1,>38RZ\G$FHDP"/S7T<%4E#Z4VMO=R??[E
M_-VO=HB=;VJ8NW-$#QF+S$MYP "&\TW7T3*4KU!0]!XT46V'$0%3SV&GL1\E
MEJ9.FJMV=D?>*Y Y-5&BGQEU\5F0G?WAX:+G>PB<BN_,@64& &, 58HXJU3<
M\*=GN.'HONV'^QA '3<Q0[M5JR#ZI6YE$<[:SVHG[[LJY50!U+7\A?UB-S]+
M6T[AB'HX4%* REO]I=*?SF9%X0)/GP;5LR:CT7Y?P!AB4T.;M4^-@-P]/J[4
M?AU[X6</!:W,JK,Y%7//V*=2K2BGO/H-U:?=7E'O$/VGF5222&J: 3$(4 )>
MFR6G%'23HT9=IOG"UH)PU0?[)^/Q^:.?%<4(8?UFJI!X/H>:;*,B,H%\75$,
M3?1$)WT=5;9+63?%E'J)Q !J84(3W0CXU?QBS;#<"7*D78OX!U("SY/7M_KJ
M3ML!L/2[NJJ  T:H0"?4</"YA4#EG/!XR8X^[?I5$YOS-A&1Q\OV>:NUQSF:
M*I#<E\ESX%%B^Q40DXVZ3;3M?!5TPTZBJ("8Y!8:?\_WT[!EW%C%LQQ)&M2.
MSZU4#P9P58 !?.SR/C;$^@E<0!(CH[);LGKMR]OC8QE Z\&F^DS7EATVFM.F
MB@P@?B"*S@PCI58(H-_*$^=HWEGPQ7,&,X 9+:B> 2P*YS& 2C/Z(<^U1PJY
MJO_%YQ4,I,($FS,T7\KD6(L(1JJ9V5:QDK(#<Z=QGUW*&4".).YY///:_B2M
M/<@*E&2&_3K[TV=C<6](H1A'&QMHM.LGD=)L_;<YY5L4;+ZYJ!8W+]#* *86
M&<#XGL*_:E?^!YQ-+UH6.=@^:VMKT3ES>4!S-,'(CJG>;:QD7P-)ENJ[B%ZE
MP5<W_9+N_["SF$Y8O:$!1B;I<.[-)C8["R.S)ZL=KXW +M>+3EV9E4Z;F0J/
M-W1E@@UTU:"AU6'K,0@T=X+PJ4 &L.N$$.XZ"4?;,(TC0CPE!+;VX);N">B?
M7Z?_Z6G$#R:@^^25BH,,X/'U9?J;;4#6>ER(I:^$B?5[U@N5PF:?/*V^K<'*
M:FB>RX?^)F>>7^$O9JG^IY]70)R%P#_W5O<%:W+Z5H-@_\(O^QRF3/C-0!C]
M) \#Z)X>6N4'8'\56?K^M)"S<YRTYDN/&<-. @>E5O/.)I%Z[)KUC1QJTS!\
M/?4 T0\SS.7O)9#7>E=KWZ>3KR8,;4OJUA=<#>?F=M4-=Q7!9JGR ;IK"N*I
MUR<&,'^3?IP!O&:';)Z-:8ZI+L61 ;Q- I?IE;(,("$+<$&RXSX_!UWHE0:8
MU=U2SJ^_IU5\$.M;6_C#+!B 6/D<S4V5VGS+X'@4-709MS0JL'"(*5>5[P+3
M3Y8-\(?HS[))T/1,0,Q/ZY;!=\<_71'39?IN!O"H(HP!(%,8P$F%W.^^^)/M
ML@]&?[X,,;3L#=F_ZZQ./7Q^ORG4.&;$H;D5UBH&8(Q880.B R7CU_U,R4>9
M,0#1NCG:;87DM;!1G()N5.%:)> :+W5RKD%MO3_3?5:HMV=P2Q1%NJ\1?]@P
M>H5%$^IZ/GK\TI_J^6_E#P+B7NZF/M/" /:$C0Q1 !S=KX!I "7# ,(M\4,4
M)D/T^-.LOFK0A &(M]3@R.L*(+J^UZC@&T'\6M;("31!9.2\TB TFD^1[S]N
MJ./3/;'^)XO@/YEKA=R?KFJ]&1A%/[4*IWEA:"Q==6N/_ER;A'Z?S]^G4Q\.
MJ7=C+K2R,>8P;L=]AK'2')"?)==9_ZQ7HYD41@T2P"U5=D7<^#?#?G/=6LNN
M=^F8"]5G&))4*:JOUI_I]QI<A/3N'K0&XY:E>35#TWWA3_7\M_*=>& GET9A
M17!J-#P,/;V. :QN^\CJ1"RE:V#\T=/K(:N8>+'(AAWO0GT"YV0 /6SM#.!,
MLMW'/XKU&AF!9J<7W3@'#::I+EK^A/#WD/2/RM^?Y:ZZGZZ$/XR 7&$?9P!+
MJ^A%7J-O#_]<>V[\D*5=HOX-'QRU(8%&P9;JT(_B-Z4F!@*2/U&D%/\&4(;Z
M,2.PE:VRZ*E[\>S1:R3DPL0:"O+S/5^#)_JYWX#-G^OX;[5])QK=&=U_,%(G
M=G17SZWL\=H!?<&?0G]X;B!3UG=H_CQ5B0%<E=*A\424_D"FU\B'T3<6"KCU
M/13]@\+TC^;9Z*>K ;XW9M\=_[DV_6TZ,];,IMZ_P4-GLQ+])!'=S4\_Y;TG
M,5 2^)F2.?0[.ED9_&[QO&76T-33O]NFCC_1\[5P8E#W+0G[,_W^Q6'^CW(8
M8X$9'Y(_G5^BFCWIU8";>R&VI$FKK\?\$]Q-D@$XR?OT/K?FZBDEW$>= Y6V
ME)<L*!R7&>ZW/ADS9N9]\31]?IE.M#^W@"L@XOK0NCA<$R2(S%U]J]MQ1LE+
MN Q:!I+.FJ/7#:'FHG;\WU>2_^I %H5\G9;. "S#^I7P'/X-F%XTH2)J1';3
MI)RR\VKALP^'SST;VIQ[-D.<)_O2L\_ZMP5Y #$5+E(.G3V9 ;#4T#!T61OX
M>B]1>BLOAUZ-P)098>:T&C$R+74B#E9RHV=7>06V,'QPH :5F;D2<H\K?X.W
M2G'BZVP5">H1+'B+ 0C)*'LDI3S0.W.L!HS%2E94'IJ3^D!!8DJ;YE$Y@V[/
M^XM>C$2OQ PCJ )2]$U/*&HH9&O%)I0\+4'B&.[A[&!WM8#[T ,G+7D=$M^X
M<X&!8I1S:]5M2H6^/JIXY\Y;@<!JWU<A*DLB?V$ 3]1)D'(B&<!IPR7W^;!^
M#%T+UH C,Z%I'#>92[YGDUC?[_C#S3\"FH?LRHXY]-0[V3&;Z]_X6#D"_T0L
MZ2 5LG2[/&%TG []/E31MX<_'Y):ZP?+"OS&*_:GVB./^A$M2/?Z >&\P-+Q
MLT;X;P8E:]_?6.;'];_;D5>I=W_'A^B?;&S.7MKK"KD&XA/\[@Y#)V+8Y:Z(
MS,4Z1$V\V/(3B.CMB^.Z89Y]RW1?)#O'L258*3\:A!T/SNCR$PE.US1'95&N
MH:XQ -\BDM>X59'IC2>)LWGMSH7Z9,S@.?@@:GA9WQ ][? 5%>!UE)M8J1Q9
MC>[#O=9*,6P/, /GT ..]SVD%-R.\X-AY%=2%)VI[N658MRPNY'.Z86YK,[5
MH2Z5SCD(!MH35M-4W>RG?:&:MLY5LVLX">?(&[22+-+M;N5'P,13NMVO/J$-
M#T9,ZE.\>'DUA?U\W3TTD*N+/;0-OC<12=L>]V;X\NF:;$CX$8HA7R"))G,;
M73,,P1P*W#5IQ+YJ+@"V!6?1+'"YZS,X@8?Y&W0C]#3O=#T.V3-&;VN-M,D0
M?,53FDX-^D#L?RR\Z%P&)^>#-10[J@B)RW\)V8LF'VWW.@"Z$_KPREHI)TGK
MND]U3EMRP)[LQO5[%[X)3GLD5Y![8-=9<?,+K#4PHMTE.%$]%EWIM8V$G@Y)
M!^UJ1IJCO)':X,/$'N30Y2$==AWAQ@6KA3Q5!VR2/VW/D?X;TV[>9T][A:+T
M07^*BE<CCKW,B'("I=VQR+7>U49'0R%,P*;-J,$NKX+_?-Y3D_;WX-D.5)L2
MGRK+(RD(:#>=INSUZL!@)>ID>Q7)S: OY=@XAHTJ0!3 CQ5;O0*]P<@V2(S
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M_)<\ ("ZK^[K*UPJ]H X?.1S"S2>RZ>D.]B\)#8INE\U7,'&B?W13%GHII'
ME05R%BV)OM\UA^Q$<O%7P/5*U&_;D3P8WMJ2@30^<0UKTK3P1N^%YW&;*>OO
MGS*,!Q$$SVL5@JX.83XY)X]Q/-^91Z(\@.C.[XDJ?WQYRU\C3G[#<"HZ$'PU
M.8%2O/.!W)IQ0LA%DF7>)F.MMQSXGY, ]%>[D%//N%M!:&G'80UE14>AT,]Y
M8G)CIXOBL^!KZOO#6UK^VBEL?ZTK;>1_.,#9V=^&5GZ)\+]?A"UK2\@ICO$#
M)Q7]9!(, GQ^RSBYDD<228]T$ 7/D;P?GKC:Y--@6/3#G2EN_#5P[@Z,OP)>
M5!-C8RO37Q7E,KBS\W)=PGAKX^8H.?='<J<X9PS1@EX'>J@'<PO;#S4K+-ES
M3WZX]K% RI'2]!Q>-O0IQ#U?!.#7A'I5E8%CGQ2 \7B)6V_* %LNZ2SV4[UF
M/\BW]7V"%6];;!PM[8X-J-7/T,<3?_-N\:^^7311=+^B8HBU/$K99[3DB1LF
M(Q6_!!$]\',/E:73!U":X)-$$QN1@YT( 9<AV2@+ 1N;VSJ-/@G'M=QAWVP
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M" . 3?I<)D6^+NY44!.Z+)!:Y(UFL:D<$6JX"HA\@PJ(OX,*,16<5.%BHN]
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M>.R3P7MHMID*F%HL]!/+YA5B7X2-.#%Q%"ZPEPL5%9V&4=L=A/MTJ%;-! D
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MW37H>^E1->8*[<VD2VOGQMY(+OJXZ!PJ?>;S//L 4I"*:Q++M%F='5AGC 5
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M5_=OWO7,9% F'%[<9FE0Y.[IGRNHO6RU&H9NV'2?N86^@PQ@O20$D<S"L-N
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M7E,;-5TK297C2[9MO?*'#CMEUV]K"17X_6#M=S4-VW\DM7%M6\F_MM8@]G!
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ME_5)?,H@4H=$V=?\*#CF3"GA_(B_>YA'RD/HRQ.G-*<(E6U-%- \NC0].4!
MO4'<H+[91J+\:L/;<\DQ]U8.JIYY*<AM*M=$IC('M =Y:K'XTYFO7I]U8*LM
M2F%L8? >]%</(<9"&5[,O>8NX$SZI'P$Y&89+'V9 \H^3K8E# VCF4 3!X2*
M EW]E6V@";PF'LG>ROGS3]^C7;EP:'5*B+4E\EMQ&_S/*AC@(I*+AL^\@U$*
MJEDO\CB@GD38QIS%G\7+O+#?ZL!(:M0VUHZ77#Y:,$L/Q') T!,<T/@KD]_*
MIT6XG_4/U=[]9ELA]D^CP?^"_46U\/USQR=':HD#,OL,BCQ27"/.Z(A^_=-^
MT<>NSBY(U[!]Y0EN98E1*ZW;VE_N1E.? 4[LR,OH\6OH1B<29DO@# <4?KUG
MB0QC_PH/()S%_%F\?YP#^K.2!0>T"Q,-F]/D8ZU;P<JXB'*3%L-F\?]6!.7]
M5L>$>11ZD(M'^L$; W;L;BXTF6T%,]:._5;\ _M;'? _F';=CZ$'YX"P!]&4
MKSE_%E_R_Q_K__.LY\$2Z\Q>_E@(O?W5X_'))G\;2[[EI'ISC]]-@^\;LGY;
MF%M@<X['8>\G8QT)<T_NVO(_Q$'^XP[> <31>$AYC<4'%[-U^Y>67GO%RKHU
MF>FA S5X_+ OI_"\(7-50!_C#+HM&:O01-G%!2@J8Z+L[P0,ZW'OT'G*1FW2
M)^(!6:E+B:PGPED<T%.?A2VCD-H0N]G\V(?RG],U:B'$TG5=H=CQ\HW[^F+^
M^CHD$B26>0:RURT#WOEIZPL'%"@OU?Y3T#=^NEB?IPAYLP;CP,I%!OC0Y7WE
MN:#3-MKL5,EGQKG(F1<Q;^\*&4;&K^%BL'PH2:9*+[H4"28].S+>U=)?. ._
M.SZ68KSY;#;+_] $_QSZS_'2<K/P%E9+;10M Z#"75?+T;7]&$?=86(0XDOE
MYL;F_$]G=UWB_34I72FPX<>2LO(J\T>VML;[3Q&_*B9NLT3_.[K/(>6"XN<%
M4_G;?U^OM/Y_-TMW_$T7\/]M1-T.3O[2I6DO?Z7WL#@U^@^US\-N?XS_3W;[
M__Q)JYHBACP/&$X<'J<^#VX[VV<=VA04M/\\*NY%&U74?_Y:H>H-HZHAI<>Z
M3^9-,KSE9U\5_@L6AR2.5[0UFE]Q*0<\)\;W HTW+TPUC4D^_JI=^WGO-LKG
MM^A&9\;5X#;,3E0/&TS]H<)^3VG)^/ T=OW$2-*7\*2@HCP)\.0;.-/;B-4U
MOFPB1G\K:'/U#IIT"1%OR1A:@/WYM3M>T80_#9M7UPT@KSM[\Z^G3=Z-APFW
MA."8Q^#)>%4]O SJFY_UV?'0ID9Q#<LP@\#NH4=L&9S;> GFD^?N-_UU9UXZ
M /%K 76T _DJ'54#ICO1E QH<7HO6SYL\ZP*^^1/IBKX1MLUMI0$.MD4M6^&
MM:O.D'$;U3V\O;4;$KMO(?W<I)[]@4';MX^V>,2?<D!MA?R(X:HVJ#P4T00;
M6KWQ5"*JCJ:YINMQC$UO5>Z$/M-<V!)Z@!0F>:)+@UT;MAQ>'%";_CY/:R:D
MO..VYV^SX8T.=[1@0CKPDP,ZML+V,HAVO#I5E,,^B.NV&T_1MR6C*\02JP?Q
M:L%ZC7MAS+*OY57X%R:O/!-5PP<?,'20FC0A"E2)2P_A"6;HHHI^S;;X?@ZH
M5L0V$ .(AL'_!5<WH5>J@ALJ8-06!0[H@6TF36BI4YF0$,(!Q9OC:DE,0;%&
ML #!%;R-C-X%J)\N?PPEMWT?F '3OS6@!PD:B^N9?XXYG"('%'V Q6V4N30.
M:/H.@P/"$+_>'=]O\67:Y@8^I'IEJ#APIGZ9Z-<T*0@N?&[\Y&[=A\LS]6MC
M@Q6I2Z@@"\1+E#PKEN#,@IVMJ2\'G$IO3,I+,#S6)EA[!CPZZ.*LM#=E\=90
M,><,>65T):5:#DT,W<*LKW)-QP9 YSB@%9,N#BA?![?:1$GG@&2".2"FL,2-
MWC4L8,X!E>.N@-49VBZK1+!'SZKHNL]O(_@F\R3 2\5,4$8()/M@ V58.1)7
MZ5.;@5;O&"]C^>%_^-QYUAW2S1N ^+/#4"'94W,S(<47S>7ZG3T1X3+IQHP@
MZ*I\P_6.TN'@T"0=8X9W4>9"^KV_RW%QA]?_UT\\_S.L_Y6]1R08M=JT$5A9
M4P27;3XKDVU:_-MGE-79.SF#HW'2>J>>/E3@=0+%@Y21]J1W2Z^2UI\9*E_8
MJ?"JQ>PW:Z^Z;X5'WCAM_D3NF95<JP&O^?]$B/5W0L3\@!$*/^!DBG6@B0Q:
M6EJVX\,R7[R+->!2_:-UV0AAYAG6ZQEO/9)*9K!KHWS\C^":F3[O@9597F_9
MPR)\[%!)\,6]U^[?05Y@O6%JDS))$Y08.I::$ISA&%N^:#4B6L4(VB\M:S&?
MM3:?-8B(0(F[#2<3Q)JQR6S-"AHX]NI,61DH"69&J=P9V[2/13\T(9WCN\R6
M0AX&T-2J<^(*#]=V/E(;]0LZM1]^CS5FHE^RN*3^Z7<R]K\**Y<RY2?M=[1=
M3)&HOW+L^^B%AAMTE8;WD7^._R(,[Y!UQYOSO</GVL@IB>4W:37W5?[;>NA_
MR?Q2[#V)$1J[5/D7G\^2.?XS@V AG_3$ZY>7QYPMN6]D]@\;MI*0I2ZJ6!.V
M=.,38C>[9VS?H$^ @'9CC<WWH;$%(_W-1^I2/277_58#_Z@M^.OASXZN/=HG
MZNN;S>3N';<RL8OFB]AI8.02[/H)OY-Z.2M8NZ'&,I6>/N['>IYGQ)<Q5EQB
M/+7L:?F_+G9EE1"++H?'("'%X#\ L.E'&B(><43#_'#T"KQH9>7#.TK6XQ_;
MNAQCF[\V-F47%1$.,.1K4697=9^Z?\-HC!+>O^AF6/3[LV1:[>'7\='#P]LA
M!BW-#_9K2IFI30CY.5B@:5.M:%&(,Y6X1"2UU,5)M@5-2=EH8>"5!D)/=H[J
M81SO^S;P:=2@/_D<0E[!)S2/E^?%':!K^,KG19;GN:TM.O6'Q.CE^2Y<TDW\
M< IGV;?&$#CZ147;K.37RW8)U->=X;[LCW<30HYV"/+WL;57'% JH<LH?(4#
MVLWU:K=F]#W8ICH'!&G9DA1KZAD:;T*)#IHD(ST+?@07MD BCU87WA\S78N
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MAB1J7W%#E,7$-'Y7>K:,]"D^W>XN?0KFFIC8W=2?R--_<Z8&'#U>1GS(%"C
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MO<D."=A0&^E)BK5.&U.>?=RXHH2'\<V(7>JXK!;9?ZL"*<50!'A,!X@M7,*
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MUN&?6EKYC>DZ(;:E,LGVF)?@-_?0^Z#0EC>+7=0IDF4T$CY9>=!3*8@#,OE
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M3W]?$L'_/I*EU@Z*-&($4\B=3CD(X.!],JW7<>][#<9/MRF'1X6L<4 5F*B
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M8]1"&6L_+=8/^><+,7>A7K%R1.N/<SM.:.V7B1=ADMSR!TLP;9VQBWF*T*;
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MPA49IBQ<\!G8A7YT]DX[Z:P^-)>W_JD[N,P,V(F(#TSIQ/>=K!CS70:NV%C
M>B%5U7/9%)TWO.V<KD\@\RF6GO![9N.5SMRT8X-=X,^_U#:\M /#R,OP658$
MF7L2Y%:ZR@I9^WZC<_I>#TZ$<3PE/.ZTNFYXLRK60BV%=FI9(N3+0;V#7K,*
M]&16M)9XP$_,_^E"K=M1IA6]7Z?R,'J+4M*A9SUR\V15_+8$MNCD$V1;'28@
MNP9,=(#OWHFZ/@+O?0>?#60"YMT+X7_,%>+D!;^[/CX/QX^U3^2R?TSH$'/A
M'';3[U.DG0&WLAP+X;TNV)[7;)VD*+$W-["JS@J%:D6LO#K&!!QOGW3SCF3=
M2PN&!181)G\<>!N_,#HQ?$,Y$" %Q[XBEC0G'1G(+YQ /D]<YK&#^E&R_!$-
M<Y2/J>CK71Y[M79D5F(B<C)\0!7/51;5:+SP#&789+/"CQK^<7@'^9E=H?DU
M)L!Y(CGB?-,#Y _KA?GH=*HEX_L9&IC"B0I_RY\*TAEY-K;Z>:BF+\1/95XE
MA NZ,A\3T'!_(?ZF-SZ2#HXI&2C.,C5'JB]$CJ.J9#3 VKC=D9(7EX83E.?L
M',$UJJT&PM9C2*7H .KI29H'J\XB\+?50H2J,9SASOS5[V<\22]"3%K&U*MF
MZWH!/-?B@5J]>9=07A1W8L&L8EO)I.6/8_$K5D]^X1U'W+2T*BN6NPR!JE%Q
M7/Q%KK!V*ZM 1B](+,/>Z 5B,K!/7)X)*':P_O [!DL12FC8<V<GE\0"SE[9
MB./Y9?"(%<6&W890(WJF8@MV=%^<K:IGX-6^%5^Q]@%HS?J_DX,+L/,_89FQ
M3H<-(>L25@NH)TQE'Y*D.@.694\TN)J>;9D1KY*,KXF6B^XPL=DUQ;0-"EO\
MT/3^PHN@"=>1,5,5-G:,/C"_:C@/48$)2-$X:%8GL#29,.C1O],9:MYJF:M7
M./%(I]=D3P73<S:^]NY5$1DES^_P7AG?93*B#R4WS@1XK%-.B*TBJ:=L7U/*
M2.8_O<:XP%6-9PH[QEX6;<J*.->FB.TBV'*\W$NYB*,45E5V0(!>^]-@UM[$
M;!R-W6Y=L"/M]X3C)BEFX03XB,V:!&?$YF%L5DY1E/]J/\N#R?1G:%?;0A(G
MR]\ 3(!G>/ZB4$DXIO/L*T.;IL#3WW?48RS"2*<N">.S4&Y_X>]1-O./8WV"
M0[=_MQ!]@K"#&9"(AD@ECPF ;)B 4\ %/2!C7\%R/Q+NAOSI3M:CO]!(THW(
MMS/&(:2FP3GO:)=)34O#VSDOC%KAH$N)28O0UR]D@D:;)O\>*A'IL:NQV_Q5
M<ASS8E*?5<2;93R];9W^[T(J5E<[_YG9FOYS2#&AQ:1N/(J@0HS%^17/1B%E
MY?3WS[@^ZG_]DT&>WDU%#P<&M+*>MA'!P8<)J.DG' B2-^_#?WI\>;) [DJE
M./B1+N,<VT[V'_L/,9NFJ4@080+T5\&4HQ5, %YD&[+Z)HBDV(GFD2/5=;ZR
M52O7L+U>'ZQ2;-\^-\DG4B'LG;&@\AWF^&G9@_T'^I]5E__JMO!/(7_"'Q#H
ME8:"5(G#H3>[]KX=?::P7^@'#B%F,VZ(+>U.^ZYP]U"K3<NQLJ6_YLD#Z/]+
M$XK] W1H2F_KHK 07L^,%:>CGSY65#T,,PT*-3]W:<T^&6#VNZ=:@ ,F8_@:
M3[X%5># 8N.VDU=!GL<S)4 /0EQ6U;W[RT%G*<6XI^N%L.]@_C<-=3SF$#'O
MVE_<!S^WGBF16I#[>3\R1ODW:IHJ8'Q9S3T2HM/1R5_<NSWK\S#^EK=?]-$Z
MX#'^\@@)\=<\ROT(!HB"TAX"'5JZN5AO?Y^A2I)WU>=?MY_<#EKLVR ?L>I^
MT"P(/4Y\6Z[K@D,(@9-UC7ZJE7MG1)0GH-:>S#NSUVK+G$W>&GB[]'5?V:,C
M? ^N@-O^B_CQ/X'X47H,4=T?"Q'150N:122]5$W"\<J2 D**5C2-@_:C;Z<;
MR;O'IJ2-;,R4LI+ZSF<*=XD9'DA1Y"18EM!.YQG;>=(XR[[NU<6M.VP8CO]2
M42AQR>V1<.;D*DVF*OZA;LJ3Q>LIP<.RB.!MLQ$]/H>KW+Q)7A:(QEIO8[6K
M'\9FH$$%\-:;C",T0//C-@SQ%GP<M]E:D2"@UH'<?T@#SNN0<5^&S)'7'Z K
ME^!WZ#RJ&"8+C:8HD[S;3U/ZL0F=O&*0P7+.-=16SER>>L#7C$+"W>D;!Q<O
MEC];UQ_P)]RK:!Y4<8OQ^&K*4[O\9?DJUY.K!^52)'<?XQ TP=C95PO)OR@H
MJE)XNST%B/?D6QB!LA]!F#7<S1!=,74A1Q3TR.<G;D3(C])^2AMV-.4VE+GL
M^#6;[DE/O4@3P\)&]5X]93 !<;1AZ/@6ZH]-9D.+=JZ.L$0%\E<PQH%5!G4=
MF$/V]YD (1C_>$)],NOIJ:B=*VX_V?UM7?3G,'OJR#JRJIC@2%6%C4JRD3A;
M@$E[P,3] 0D-'Q\EKOMRFF'LC41M/N-/O9;M&+6\'[*DSS*X315K&K^A^YRO
M/C !!7;_X$ZKM(*K,MZO?%N'_[N"=."KHG^Z1/#_:2(K56MS4OCA$]QSM&'D
M6&KJ\ <1A/.4Y.+O0LD7HF-6;OWM5)7"Z[#Q$[U7^:7>_=_%#3XZ<X)(GUOQ
M]G[?L:'=]EM6WA:T&;_:BJ]*L@E6%M]_^\]GA]C:&-\P;%!MJAKT !&]2L?*
MN.W<'((J%Y6EOEHKM.A_P7YFBBIB#=:ZHUS_VSZ'SBTB_%%-M-]01WU=W-9*
MV;46 9=W#K97-R?9QWJ?Q/10!.S.W62SG?"/I2D4>&OE'1N@J17;>4D^Y&#L
M37P]_^NS7/'S978PSM1CX'\;'X\#LIL_;H6$Q(86$T=JT*O8$G'^25#?0@3,
M@=2[HZ4:-(]_UQ5$<'05=BQ[U70.?KSFBF4QU_#\#:^EM\@"D"43D.#*!(RP
MX'*O/Q-0[U4()-ZXFF.+9,&4N)Z'/,J*.4S P9V9?I_H L3WYIK?$YZU%K=K
M*\CZ7;.JK]HI?A^%2L3&6V2WT3[6C.153JZ#?/_FJ[UG&#Q0A6J*"3''C&(9
M4O(6Q9LQ=2JSUTW.]IGMW--8"3< _UD_]2 $U!IB$#J_:\6I;&YCLU%BM]=3
M[#UY=68L=-OM.;3A0%P)X>3E[Z/33>?6:.GSD?VK/Z%G2TQP*%95V5D5;G@S
MO:Z_^(3Z4K;[H!'_H:7/L,7%L]>'T!YED):=@? @\F/BO3SI/,-Q#K2;9+3J
M4H/SI4P!\+0/ON18D].;X>!I'9N*[.LC'X[6U[[0[/,/.!R<'BUA= 11%JGH
MX;F7ABS]V5FR9/UC:O+&0^RGNJ<7C(K?6$D+K"EY;:3JDT-&&[FCU1+1[F )
M=();^K=,"FPG>,]Q*-)'V\.8L;' _N" <3YLT*6]OM!)B$+'GFP\6F(T>02=
MWCBMN;I7B'^TW1X]LW".;9!F0&$G*N-HOF*=\!B&,.GTW5@Z&KOBW;[[-369
MV"\&;Y6"S^;!Y(=OH-] ^3/;7K+BG.7[\+,=8O7WGK!TG7[MF PZMB9:SS?(
M-\HO.S3LT"GSUQ[S2>W*)8N7I 7,RI-M&BUY3_:AK@[TVA^([= 9*9:(+.S/
M@&,G(%*-@##&=R: :(%(F0%R!1TH3E$M:S3QYL__8'T"J5:AN&+,,HD$FF@V
M]L'W.%+L++*3FU4=C\+;3%X[>=15\9-!7=>5NNGEVJBRQ3)TM7(O)5E].QD]
MDP%/2B [R8+;G[Y9.FF_YMM-!+&^*7Z*"8AY #V_"SH/;U5IU(_PE]C=AL3/
MG*L<U1U8?O;)UGJQ^SC2FPDXD$M_4GURL!N/3&#(0T]]#N4FPQ,A?.MEU] [
MQ@^/W^H/#(#8#JGZ^J)\9P8W9K3STZ_U"+^3L)%]'=LJ'.W""4Y+1;<?1V^5
MW]DK!R&)*QC:+580,9[3+<76$2:IXE"G,YW$%7(A4;5(]]/&:G9'+6DJEPD8
MDI"XQP1T>X^\>2GUW HWXYJA=?-/^_-O]H>(S,$%X7> /S-QZR\4._C'[5OJ
MAGJ1ZF0P7ZM_((8\(6(,)BUOO$#/IF JBQ..1Z$?-%^@%!'?.W=F,8#0JTVU
M7-V*.NZ>\>J1P7NW>K+-/+^"2C1VWJ*/+/1YKA\T&;RAMN:)HCW?&TS>E6.(
MHQE<"D3, D69I8M+(QHZ'MT]A5!CHDI>\:\]OP;S2D1K1)\:31%-M../5Y25
MIW 277!QC? @A@"_\+1'79 :%>+'H>!?+!Q]39 A8X/.03">9M#T5S832!XW
M0$DLD&?LR^ <';;NX61P!9#L6^3<"4(LV#5"&<=^+-C9:18?G"6)/)4M6J@-
M::,2]#[]JFV48,GRF/4 P\(;;C+:A\$>!QNU2DKV^>IT26K\RI:7)[M]2G(!
M[HP7;JQZ6=_T#4,T-E.F OH"R:O+)YH'=R#3RF>7)I2S*5$D]"RZ\Y/H M:Z
M$\,3_E+3\>L>1Y-_^,$5Y+2.]2V'C)37! 6WL*L!N?YBP1&*!%8H/(["(:D!
M3,#@2B1M#37ZN+?7%#1H3Z6^FXTY.&'\]D5;H4>!PO,\ $#0> F2@"2:]U-4
MK;LP:2#M8888HZ=9$TV$/_B@*CNCYV^45;:M$N39BOPNGC$C:-@C*>)<K'J#
MD+33*/,2YW'KF6B6K&O?M[GY>^49-9\=R2#^E/OA9I[2EEZ-Y5/OE;3\^AIH
MUWH=X861TR*[7B!YZ!7'^^$OH%%EO$;&C5[LMW/Z>7/7-K7\OD=\]UY'4(Y#
M:&)J>*U6E,P2_!#:&R4U$U[54A_79@]O,RC]YC8<?*Q[G]OS^;4C^VDK1]TM
M=Y_0&J0( 1'E2G%B%V[?GECJ<]_8<60"V+'$V\3PY.577FF'MN?K=ZE?,4E[
MW51N>$\IQ9Z!06_5XYK\FJ/I;]"S19@JQ1;34+4$.ZNZ*/RZS(S,R[ '(%D[
M)L#+*TA;@FU4KI(MYM"FA+WG%RN4-I@;/EL$J25ZPC0IVV!W5,*.(8*3(KNM
M2C.+/L202C64=?S3D31]/<NA)IA^4H&%1%+)XU*O@-S<FLVP ;N-[6O3J[ F
M?1&30Y?%KVF5GE< AOF*U(151TNA[_5;THN8@-E\>)7B:OL'Q8>ZAKC'* '*
MQ")A" 8,5^VIT7-;OJQ>,F? >)?^1?WI?O:4+922+ L.Q.3")N==2>5HX.HT
M<6,AL]!#3#D*MT(Q\U2]+_?Q2ZL4Y_,$I:\C:\@JLU5+ZEG&E[WKSX#L(-&?
M2]G9RJDF3I_ZNHI@QKT2Y47'#7M=:^>.R&,-(HM<MG-!0(I  \/3ECXP#MU%
MOM38*U<3*3\>"NGE&-SM-09G*ZV]F -6 5<5J&=@/:(;#K2CE*"#HVMU,F:=
M]1WQ.];HT/D)^Y) )N!,CU*.A:*.021=V%K&KL;;]'MA3O3X]-744WH:7 &W
M3/)_G,A/_C;\Q\<J/B,3P>(,2:A*;!\)_;C,9_[N\P_M$JKR6Y."KOUCXCNO
M^8___5;FM3Y]'&?7>JJHT"*&ER'2G>]1][':PMOIK'G9J>L'?9^5/M,VOV^O
M%/1=&8].@7.'(&/AA]6@G!^^'?=V1OF'5A#L$Y^[WF-7E'UT;S;F;"? C*B,
M#6&ALJ0]]Y@[UJ(;O;^6A11IE;4W[OF0S^\:4J\K;SEW=?5?KT@P'2(,2D6%
M/SMQ-.7N+>&[M_DO D0V=E:+J<H8+P@?EI*MA8#J8_NL+=R\Q0;*1X_X!FKN
M)M]>YVGY*,$N91J)H!U!UT#B/A/'NE*%.LZ@INI(J@ESA_5XGBT$19L"(LM$
MYB'$&K0'BB< #QZ?]3JCAFDB=M5(?]Z[C(>OF-7142#AB>NU>><KQF@J.M('
M&_7?F(J!7EQL)QU_H'<MN878WVD6GW=V0E<9/WV,/EEH-?'(5Q'W8@HL8+_U
M]PB>_M>X?XWEC=*+LMK>Q]@^GV5;]F#S4IY<4=$<--6_U9@\<_!FXU#_D2M_
M:DC5ZXM )8$]3<$W1^:(_JU WGZ\BB??N%-GV\\)H*T??R_"]7M 2JRE#]R]
M7XAFT(" T MH]R:ZQ@0O85-57O*J3VU+/6B_;E@:%9M^D7\$[M%DUO7R4;,$
M_154EJ%0G_HM3'+^^]U!@M1(T7GU]#&O$.D8SSW%U8D9^9%C)/=N)D"D%S=]
M31/#D;LROU2;,'B>DW_I\]Z.!,ID<*M,37\(-QCL>(';Q$;(1W1T8'^:QA;7
M:X!2)T!]9F9F<']-S<-CR1K<T@'O+&]> '!>,ONCXT):?SZ%:&?Y9UV^YOZ=
M,DUO+OV%\OBO&\IGX=76-"$7LBT]?YM$XMMIJX,)D!K5)7QH\%F=H2(O8B\3
MH,=3P5NEU?A^0>8@"II?4^!4<VC3(M/L2U>S;/QQZ2SGPL;^M.815J8RHZ>D
MJ:D$8R:L6VHQ&Q/3%L8DWURY$>WX'8^M;Y4"-&V4&3T7/%N KD03U#X@]U'"
MNC(I05WWT=E1LVI2MJ_4;.JR&V%7B@4_KL^?Q3<K3Y=^ WNPD/D0V95>=NYN
M(3228E"T$MB1X[-M(1'/Z/]T>OJ*E0TQ8D+*4^Z)=^F*N!<+2<0A-PW-FG7
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M"@5U!WZ6W6(;'?A_UOX1.,@N]R(3L+T'WQ)B8=2_>OD[)9H^LWF=5)QG><5
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M7O^[!FZP$14)0<18AHABY^2GZA6(VK61S:BWON*W>6#A"534$\Z=:WMCPTQ
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MK^WQ_\S2NU),6.DL[86\5N1_8^^]HYIJUWW1*"@" M*5%FF"(B!2E1(;3<2
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M8>3[0M5QW8FB-R9'7NU94Y2WY_L@XGTJHNG?'O\_=I/<GSCHOP\.(NP&R"Y
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MS2-/<4+ON-O8WZZQFBD.F^$H7GXW[TU#1,JY?RI(@%'Q4P&B,6M^KS^#F &
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MWV%WEDA"Q8-%?;Q^F8=7F]+Q[#;D;/]ZJ48/$>%YS.V!V7? /$Q#A2-X5:1
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M9>!Y 6'=.!=+>X17!;'TJKO/VD$!(O[(>Y\*2FS_=%3$#MF;+9VJ-XC$X%,
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M;?U^9W#X.V^[WR';FV1$S36OWSVY0<A\KP"Q]NX7 FHE#7&'8%P#Q0,AD28
M$G^XL:#EPI;1#W*>6K5>.6M/F>M=/$J+67.ENG?A;3A?7(05V6VS#0(>P-_W
MKL=*X4U8-F57_&)T:#T5!*W1^O(4G\0B+*YIE;F]>)1X9+W3CQ2CCHYB7B[*
MGQA/K+&?^T9'3T72U&(ID0EX]8=ISF9;2Z5,!CU*\QD!")%"#U]'GUA$6_H>
M(03BBO[?W4?EOHN5U-EAQIKL1,M!.O2R;G<02/Z5)8DY 0$]-5\>XRC:/QL7
M5!0[9Z:.AZ]/KUT^]Q)Y=G3/KKM2*TFOQZ1Z8A:L+G(A)-"V^NT6APB4,J[+
M@:/89ZBZ3 @K *E=YGL>O'RW8[,C$"Z*N]\@$N5^5MOB5"?<[K".]3@W]GE>
M-G :-?6)_.(;S5"8/T&4J!<G-?8_*]HY.OMUW>#<CHW2&PW0Q\F54E.*_'6W
M8"W3Y259K7F,M^$5H6AUGFJWL%4A3;LGDR/T][-//26-1V3879[1GYB9>?5D
MT=OA2MAE"\2JU-^M[#N\V I4Z/#;;>BW8^Q&J#*<H1_\S;'.G"A=KZ]FO>V#
M:?E9C],3E979,_IW#EUM>W#1K&[+G)')JL4DKJHI')YD##&YMJ*\%N(&*P/\
M3O1O,L KEQPV5%F8_GCIDW+Y//"OL3[,YB ,"%/O:2?F4O="8A-L@$<$"$A7
M\A;+_3EQ'=XQE(&4Q%EV 9)^(U+)$6G'-&#,=[Q@7F8Y<7M=E/0C>X,I"RVS
M:JX<AR^JSH'UD+P7"*I.)*IQQ3E7IG'BMI#':A\H^OGNR4Z<E>/#QC;MHLSJ
M?Z.-&CC- SGFTAO%[ZVUDUM%A"-W/Z3(6F1?YU5Q_>$.+N95M(E&T8K<^M3$
MX\G4M7SE8/$TJA3.U,"6,O1(\O*LSR'ACX;+IU7'<TG!)^$O(PBOJ1L$B#!1
M*SM9#IY/*390_$!Z$W,S"AF@LOB!.3@UO:GG_SQUM&+!'SP/.]/DJNN:?%@#
M$^)I8R'O/P5,ORJ(9%-#I]O:9Q8G&PAI[L-$\##JK4@7"?80\93):]I0P6/<
M8F^Q&<O_4VJ'-G[?FU 9\6KI$/<#FZK6_X4K'G/8OV./:/_V;I[(OW9VPY_E
MS_)?JKA;LK",K&LVHGC#2;XA[C=W.K!#>31@/&)KWL5.W>O-8JB4S!WE[ZY;
MCJ7[;]6MG-IYXY3B5DNM2T?=%Q/^P@:/K%R2.HWN,U^B3&9%H*1P#J^8]N#9
MM$=69D_W$G-?O;6G^/>*.VZ)TJ_7N%XRU+&*_Q993YKK8[0"BEQ9J+\JL*Y+
M-TI?LR-*WV /7[3RW<T/;I]?QMA)2L1<LD#);U,9?72CU0M-X@O9J)6IGF0F
M?\C80N=..OZ&8^D:Y+BI/ T).F=-I]GR.H"ST5)I7QZ2RT+>N.L_Q-4Y-IWV
M:R1E'+M5\L[Q1ZF]HZ+6]8V/M[L4+OU>]OP9?.K;P3S;()VS,0^1TD[R^TP?
M6_8>_*Q[/_7%6]W[I"T C6FMS'9BB<QW<:0"!8BF0Q030/032R>C+YW8K?C#
MRR/9KNBDWZ)_2M[KJ,[M&[KN2/Y<]7O( \L$UO0QM: (G;2?#:SUA1?&-5]G
MWMO8'K*'[_%L0]CL:>J/A=Z9=P&F4 /([$*"ATG" -F%%."CPY=89+4/-BT5
M;WE6P/R>!@H0W2U% D22U+7\S=JW716/](?EK-7:)Y>X4]Z"^D%VB5W',J>=
MPX ^,8JT7WUS'U1(TA]X^=\C0H T%'CCG4B2G=IF:;,,7E%=_\D G@!!<<(B
MP\/@0%[UN?J:J12TK6\^'':13*ENS,K9S"8 C<@&Y+EZ(+$[%XKL\;5DV7>_
MM;(.>A)RG*9<9'G(KNGFJY'OQXR;'9:DN=LK9LHZL=#VZKDQYC"D@\U T>X5
M6[XV'1:!R=KZL @)0P8FKB$PN\%'Q*<N6Z/ \:181:Y5[?-LF:/F%,UWFMIY
M>VQ:[Y/,;0P <@" 79C*8A^=0(6A* %\49TM*2"]_EC'"'/,1G]O>/F)38UI
MVA.A'=T2I>&MW1E:A'"OME2M+.5;,51V+NS?2P))" $B@'A-S0:D/A_"] H0
MLC:6Y%.*7<AKA9*/9;R#W>NF^B*W]4=M>[(7)L_Q^F-;-LB?CI6-E2K7K4[E
M*\.M=X*U&),(\SUB+"S*$-)=F+,_!5;:Z,TZE>$M6=77^.KV#-5MGXX[I'<=
M;.UIDPJQO-^4#YW)2YSXW.V//PA7HX$_HDAL:NJIAG3LYQYS5J-90KTDB?HA
M*9>FR6K"YOT/OLA0,&\?#-;Y.FG7F"7JY&\L2419?Q>W7"73_1X1,V:+)\%Q
M[NO*:A&HCDUFH7ND8C%JI(!FOCP7 QE7>IR %LAEOEE'&W;X/A][2_6<N;\Y
M?Q/3_J18W+--.N=-/Z- %^+R#DPFDFW/=18@'I87(G[]UEL48D>OR/Q"! ]A
M(/-H]@5>641U0AVN8Q 7W;5;?_86]LEM1XW4'_N5O?6VRVY2VB&^+B[NTX=W
MS4-7D!D K9+::#^WR"2MQO6Q^U=V)0R#B[3);O2F$[C@KEYQEL&8ZP37.AP_
MO?W#Q*7/IZ97-\-LLF:0C][F00U^)D*]X?X2MAX45RX7P[MC8PX9L\UYMT@!
M<*>GHY3;HAYXAR@%Q.LW?*Z_K:]GGS!X,?A*QL]'W[ B-RN25QME,\^L.?$H
M;)B]!QKFA'/MWC3 VD68HM9DIH$C/P>BH^J=H[M0,NJ3<Z;51J4R!Q1?Q(4$
M:8A=6TX]UAU;?OXY(KKR/^,5Y8L8 L2R7 .:(X(6(.Y32%OUOCP#DH F/U>.
M[V&GF-NS2XL^647#X0MS'FZ^P\1"7FB(5_\2RDNWNG\W>R7ES+W3"-ONR6\D
MGES(9!^(&G]ZS AY@J01]BZ_O8!P-NJ$@='OCP9%4J?"SN8M5X? N+#L,_QI
MC'#,L[\<7($I L (U1N["[C2M_L\(\A8 T >.FM..7\>AF06W*\+7.E)1E.6
MS0:<)4S)9339*2SAI@Y+WNT!"L[]6+M%;G?QNF=V,1J\:*/,G?JEHGEI9W0/
M,P*%?JJE<FGP*(KAOC$"NM"0>3A=,:-#@JO8#"4QHO5UW/F]H/_#!FR939DQ
ME//;.O$K<\EE6Y+!JZE5KL]T$&S/)JZ\.'N&=XNO":E)0;I97-EA!U"QBYJL
M9E '#A&SVJ19GH8;MEQ]/+LK<U1_WSO*G@&YK 3S=0?5OXJ>U!7Z3M%[GT5A
M\L4T66//40W\7,YJ?@^QMJBL6X!(B;19;6/"6L_79%5<D<R^%]@+3O7H#9XJ
M=$KQC?#_4;+GJ/QI!RW)/OK2? RKCCX\-\2$O9HB7\R48QE$%#D%16+#8PB7
MT"K[&<H^:.>XJ;,AK9&9&WTV-D+YLP=D%%W3DSP12T/AWB-XX_NSN-SNPO8J
M8ED0N]:;2J5Z;W?QVJN4'W7FLKJK_-[3W;$(K4(3ZW!;EEE:  ,M\97=DECT
MR+,O_!3@=[Z6'"Z<NDD[8SSODK]Z_.J]PAM"?MQFPW@][A9AAJJ(HMT0(#;:
M6'!AW8D[Z0.YP>:"C??D%23]XF"3&Y=F-X^%1NCOC(Y!N9)&$UK.->5]NEHJ
M/3CJ59HPY>%Z,\:8HXE'\^X1Y&"_M$F .&L=R3[-N]77@Y'WP<N#UJ4V*K=[
M%2AR&_91)%JMWRV%ER1D6L?*'X@\_54>K86(R;/%8T" +^;*<8'LV;4@9@YF
M;FND>*D5!,6O2#GU#J0$WI]NB.QC2""/M=<GS<M^6436D?5+&1L\Q+=Z2+UL
MFR!2C/EB[JQ9PVFD&P]&WR>14QICC,E,*U4ZQSF $59=#4V9J"IWOIZ)8U^N
M/72RZ&-+L=''[<'QZ\BUSVV>2]5\KLY G:1">E)IP#GDM"$#/6?/TF'OGR H
M0DUT]X0*0ZZ'9#4CN?J68946Y<W(NKM'\ZD#1L[RHR\.C PF#:2_ERI#!:*7
M-Q,L8+*/<A,@1CUTA:HKAC?@QLBSLJUC%59NC"'C0\03'0J>!W8G<,^W_^I?
M<VU'TN8!=3$'V_[G.BKN=/<Y==B?PD0K[A NB;].E5X]C6:&Y?K34"GB<'#U
MF$ R&F\QRV?,C]2,GVQI]PKR.]8L;45L23ENN'WY&D*N9FT+4ID_B50VK8:V
M1')E4>Q:7ID)5@97U[N?V7YCR2S?;)90R3 T4#T^C7ZK4GW[0H08Y?KWYY;#
M[;>%&Q $Y@AF/>3&%\OF>'-W\,H)ROQA*NB"A'1XU9U#XDR#QS:Y(*?GMTCW
M +#!=NV3[$U^8PW"F;.&VSSD3OELND$2NIATZ=<PI8DYS)5S(J-D[H'(N0C.
MVD UF]&U&?(?%C+:?%B>$I*O+/-SCID9>>FW+<F\>)+\<9^,T<=':Y)#[R)M
M73'F -D&P/+<V7T=4!*8RUAX[K.?CNFION8Y\_ V2_FY(F70,\<SIDKH@G]D
M:)38$^]I[P-5+SA'N1F].X9HR*=97 5+]N#*E"FTOPLI!YPE0EL\*3@+J*8^
M*UE-AX7J<=@<?_C$0CH\1&?OU3M&;,D<[SL_>$1.QNBJ4ZTQ0FI$3&^1VHD$
M3Z"GI=@WH!H6D68_!S\L_!:M$$)=TZ'[M4-N,H(HC7=-<AKYU-1PW5[XBS$%
M&U*>"-/%$6F/4PX3L^$?-0IAE$2K1S9DS5>"C*],]J:5>X*_[E[*:%.-"G^(
M]QFQBF"MG3XPQM6OW&M58Y.]9GK?)]=F#<,=-S(M&)DGTM,K^"<0/)G['0$K
MNX!H]R,QC<2Y35$<'[PJKSCB<1OF80;Z\'@'#!5>[X\12=Y^)O#L:,;X/0WO
M%^6- 6*M6L?]]S?;9W(/K:2/^;,"1.V:CEQ6&E]LS4I+1MIDP3@!PKMV#+^?
MB5[+/17OVPP"E.\RLZ(+\QU](K>E;FL%_]C7O>5[^L''",[7U&7B7]Y<LS&-
M;<:2BB6(X+=!RN5X=ZB/A7%I;H"B0:K=.*.&<\3+3JNEK;7UQDX/2N<UA1OE
M:H<5Q>8*! A_PRPBZ(+:""T> 8GSY1Q)*)S>F(&]VU%2!HUU(>5/3FY_<.M,
MBG/ZZX8VV?V;'=70YA*;-CQ[8?%"9,3$_;F:)-R.6L([4H/=U7)N%/S/%8"\
MTP]* :,/C1OJUZ,4H1)&44<\P#1MR+M?&&K0/^_?[7LFK*;?LNRFW8[T3?;^
M3"*TO:_S&Q;2,8];Z5#B.H("%<IR9 'I)H"D$SW&RTW)_V-N5.03@]OA\F1I
MYY30AXNK]CS+/4DAGS!%Q-RVQ8EPY<I7KD1*PO&'LOFO26 YB6Y(94HH[^._
MX$_SA_NF%S0;%]NH&MA?T4OGIA;]E MV56<!M)6L?,'\,OB)+YX :I(%" 3@
M#[7Y/+2'C;K'D#ZS%I/N6.*)>V9:6>(]?#$C1,/3]'9.38J"FP'C:-]H+,HI
M8E@9,NQ2ZBA86=&&(SF-+?QJ38RWK>T8UTP-63X6:7)>\VG0"4,M72W)D",=
MBKQ2&ZL@?<X>0L]CCA^ADZU E&WS9PEY-KW6K(>*],<)B([,G@%OK7PVJ^=)
MU%-A91^_H]3>@XLCA%$,Z :D*Z :7I5PUA*> [7N7 /#Y%G%$?T(;')+8B4#
M^JDOWKG!QX!SXGM8X:9BKUNYDD_M;C?N.._@+K:*#5,;ZCJ^#7_ZRO#<)R82
MB;_(N^8'+G5C))TN()/:5L'53S'SO*&V312K<KT?2QCIS"_?7@5FGT_U,U+8
M=4041"8CP:/#TP-LA^;7'5M64D8K&5H**LY&YIO-YMK1"*(*SI#Q4XD[*Y/S
M(Z*IJ<"ET>QZU/5-9VRC3IV6/4^_E><@\NY*=097\1ZNP!$\V\S@&0R?F&P3
M(.:LMRRX9%H6V;_8JS5[X!#YX8_7B3&Q\T=$GU<>A(3X8D@!8NO*YH<(8,9'
M@!@_3>D0(.ZN3N6.P+\=Q'WCRP/=PY!N4S=ICM0$=%IR''!);AQ%XH>8DCFV
M+[: %')NIDZY\4Z A;4NA(4MI9'7MG)'])18%WN>=Q-N1<[%;X!DI8GH+Y2,
M<R7>JZFVK<6LAS^MEB=:9XB['G71\,X7Q=M:8=F]T_LM1+Y$^$--O7QQ4/*V
M6AV3I/CEBOZ=)M=IV\CR8.GI XLOIOV23=)77;;:]DD+7(/O8>7RQ7Z!(G08
MVY2089>]( &Y^;!,"[H?72K')*FM&V,>FS"="7$5]@K26\K;(EE;<0TKMOGZ
MH^L)QR'TRH)6+\([7W7>K0X5O#[O&7!R&I.HTX-1L5*_0 <VX-P9<C8:-5XW
M(X3SG<V@T@T-#<,W5$?&'>7N;]KCOTT(07@U@C$D3)- 5[0L89BHQ%7GJ!$&
M,74-GWH6,HK-1PU,*RW)K!!6D-GNPVE"RT>""V&\S)B5,C>Z>_1LWL3U4XW?
M7_+R2+02Y$:N.^?H $=\Y4"_VFZ,J,V66>@T1AIGX(/L87TK-$S]^?:,]#O3
MRM>)"JD,!7]#K$;8U"WC)KE5OQKD64UQ)%HM2K1-NXH; 45S+D [D?%J^I"4
MT#>E5]D1#*EY7=,%B>9C]6\N30VUM_IH_=C9];XB>C1((_G#.UTV\:T].PVJ
MXWCP!W]+S4NP(MF7B/30X=1C"Y?0HM1O @2VW5G_A5F3X@&O3OV/^58.H<\!
M?8^]%WOR]EC'_0LWS_VO%*F\7P+$6Q'V[3>FTS.>?7RQ)-:13O'RYBV)O;.]
M+_K"TGNNA>2]FA 1LDXXNN*E"./4GWE9:1AHE=_*'JDWE]PO#EYPO"1 //?C
MVQ?_:%..K">!NP2('_;]1'!!BG*;GU/#@I$]8CL I<*^"=J*G$-R7'!N;"2,
MM<M)TQR&?69E?;N&Y<"">##[<GEH=*C\X)%#9XP>G8/C!6O6J-@84QJQ]O&#
M+RVSMR[<_Z9@Y./INP?T\?*V4]M5$K'MQ4O<MKV;X\>5WB2&I#SP-+Y\.8AK
M])FWWFB3F4R#Z)CWRR_EB\[?6\.#@2WC[E\^S;<*$&N_X4^.M(7',%%OBSGH
M2;QES/FQ_71KKR->7C,F-<.Y*F/2<BS)RW4M%AM%HM8,W\8+"1#Q44 8*;EX
M>U,]-/'PLP A=<GVAO*W;T-GIUV:C3X1MRCOTCJ.#;BDQBO_B0NX=?1S-"8X
M9VZ6=%F N+!L>UCU51##.JLF-V9TB<#K6(3K$"?+AWFD&L$<K\]:R+!!\B=F
MC2&_DIYJRM03Z/2L2-:19@>/]X8?X^.5!B2-! CK79_UOL/=%YDT#[-:QQ,0
MS %C%5!<VVC2W##' F_$RR6(?2:NMI$.PF)+ AL_'/=X:[(4;C2CWSV(F-%L
MWNZ 6$_?]P@1F;?,1UE4IO0>?F"IV_2 J3#?=)1 S#]S=,=-I4M/9OKU0[=J
M1U:EF)"$W@__[<>0?S.DOU^E,ODC/9$8:#WPXCO_)9E=P!=!\1T>WPV:]+1)
M\"^E!M=AAD."5(PQW@BM9Q$N#^WZE&^FWXDT7;X*N[1O4 \H2Q-9614M!9$Y
MZ&^4R[=HUK(]:KL*NMU_M\?/>-DJ!UUVO8?+5KT3E;7QN5N_2&/(KVVW35Y/
M[UM2E*FXT/N@:.:IG*2CUD_YSIFIS]K^?JP -I-7CCI%A73MYV4Y9C@,?UW7
M T]<&=,]T<;BB]*K2B9Q%4[R&SJIJWA3QEF?/<&*&5BQVT%"?2TR)W;WOMRS
MO5QGPD9#@,B[VP8K\MF],#1X?**ZW204V,=2O4<"V4U! .+TPQ"]O+R=EOZ.
MFQZ;6KL=&CE7.OXKPT[<*3#1_UGS+;\#F_JV=Z\:$D+I +1\:I/A'#SFPKE@
M7R_F+6IEE]>123J0;J6Y,B.F,1K6A@ZU.H^KWD>ZB0YY?.)%3?8E;Q$WF;#K
M\D)A\R\[W$KYO4!]Y/Q*9B2$U]!AA-\)N9:?\"6\IJI\[]#";P//5I\<\?W:
MHEU<XA\I;B(B[!2I6C&MR3?^D+>]=BNJ87=30ILX\]FY!M7(KI;#=:JMHC^_
M?)]C/)/.C=/*N*DB>W71L$$GZR=),80@_.8G!H%[J"_EVS9J<'+$M'GN^!<3
M3E-*OG)B0K+LNO?;/N[<<_*9UME8E#:*]H0(>L'>8Y+]'%9H._Q1R(=CZ5B-
M2V*@DMO6C>#2Z-^@XVP]DHA&K>E/2LF 6$]P(UG+I4> B-9-\9MIDT;SQ7Q
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MV5B<.J2GMO6Q&?/.1F 5-63*EVIG4$<EV)^A=,Y6K@/OX0HFAF\ G:$'20L
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M&!]X-02-(6IIR8@ F./1#<S5"K[M")@WO+CEQK<-5UG31Y2:UDLU)O)J!4
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MR 1S5X#!Y25')AU(X:E6E>.=A)),A'"$5(- I82@8DGS-'<59R4.H!\B\-C
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M<1R-S:U<C$]*OEXT] GNX>U:NP>0*9W(,C9R\1A.$(HJ2"VRY72?04CN.H*
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MD)!#;$0'_J[7?%":JRU=%K5J;]QFO5QHET#E&ZNKYD3]!?LGIK2FIT;:T];
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MMXUO-,'(%VV]P0X<Y&6<J/K$+JS7A&ZE[G]>XU.!HBLI#DG7^QT/$:H:,,J
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M)J1"&6Z/VKWC09M==M1;?X'4!P8M59YK2A8YTW+6Z15&ZG-5)@GC#]-XM?'
M>*]^?&V+1G;$Y(A(D4HRV<]ON*NQYKIZOZJ.7Y.I%UH8B)<H"/LK@>O/$!/T
M+$  ^=M(<6)/.%D0DVGJH*NMF#$U9MLV@"URA=&;B$BO?W2;_4=P*Y<>1%CH
M@]TST^C'6"\D+/1U55IP>YXU]BK^SW='/*%7TO,J?J%?.4J(#I@$#Z9:CT]$
M49)S_TX;+!>V?##-]',%R77<4NQIL@FD0VQEC]D/9W*%2LN<'5^,>1S@J,L7
MI<\BR; &V"939U8.&G<9/&]63,X/3FW-^QN;)/#75D) H@@I8G1=-_WK&<B9
M(\\[%1VOJ8K)+:4GDP+FFU8F6-@=?H>>D#DIG;KI7]53GBH<:6;>;UM:AFUF
M4 +B=.K C44=3\X_XBX?70@A8DBV'I)GM\+&2AZBE<^YY,P-2R$.^2WQTC3D
M:JERI@3,&=,)Z_"X&0S1W+DBSY%9AN^DRCZE=7>R8I)XP*#O$K4YY3P>/JUN
MMH9(CM<:BS.:/OMV3.9YUPF+P/$] !_>E.@O<Y=YJXE0J^ZQY8YW=NIV[S.%
M!W>0UQH%9G-'/E;X8;'^,O4?<1.P;.UX+O]&CZ+8.%@I'=H3*)F-E\FA\L#^
MZ]A%Y"S4-Z/44O6^NQ$"0C(Z&^[R0($V*.461#O,O?)O6^HD^1^'#]:D]6'>
M C(:X"$V)W]M.J)UW5B0<+YD2LF>NJQ#YYJ&?'W4=HBUZ12G1LH2=1U@5@-O
M+2.-UA!:?GU%K/*XLD#,T?Q"'V4=O@IMF:XZ4^4;G!3PY>%V8E8<JN]EX+0"
MI9Z^Y8\K?&O:XULEC%#H(E9;,VG RRQ7-9=8K*$*'L_.>KTH3VAITBY-I?%4
M6M"]&TS=!D:4&]XX*GP*68.>Q'5V63XQ,5=XDVYTJ'Y*1?C9_PSDJ@_E0\=!
M?*X\SF:<S))H<!,=?S4TQ"^_OFS<I62VP]/[HM1G9J"I]PU>;[<,AKNQ@R1R
MZSYNXU<IG,JQU6BJY/5A&M7R$[8-*'3X[$@C7\459<\2).+I_\S"Q6YF2^B-
M,12JB1A(5%8NC *&$SB<$)S323T^AJ:*.%8.Z'TIS/D)<4#"#Z[6 R4G,I7A
M'C3"<,Y7=1GP0P?F5(X_L1/O_G:_LR476J47HOTN*LDJORJ]:WP.Z5.CUA^S
M%C H5&$IF!L@%$JDJ[1_T86//&U@=ATSVMCZLR]?D5*VL.4YD2+2"NOHWVGC
M?^ ?U*DECLZ_3>;FNE^="A(X;+PPWBTZ9&ENTB]XB;5%@#JI,P>MHO0O.NJ<
MHX^8QC(+\IKD K55MV]#_C4)OUP*Z. Y@N4F!S/1^?PFO?5#=;O.L^^APIN,
MP\&U<EL?<7@>^8XU\1U$*V@O?QSWV:H'"=](^Z2I30LTSG!;P,Z&M-^X.CM\
M_R>X<R/:I D*%SH=[/5"?.JBHCLU.OP\/6]_C>G@$3_* <[IWP/ \/.B.-D+
M9Q1WIKVS#W>]?3DA%W.'_X)AJLVO**ZP?MNG?^71LPZK&UFN)D8E;J&Q@?9S
M(.L;V0&$&C&Z1+EZ<GL*KYT^UY)#<%# UM8J4_V]+74"[Z@W:=A"V&->$U%C
M,CJKW,:5ZWM ^!6ECE:RR=##US6E#!(\?W=<TES!@NAC^(9X+&D4U@WXNMGB
M"EYFKSO3!?X^[ MO("$P7K2E;BALI"ZJ.VQN3'=!-6+]8Y"1$MO;TMD4A1EZ
MBX,CP$0K"&!.D=?\87R8HZ6GM85%>[0^:*XJNR!*2[Z$@>]$#4 +_[12QUU?
M,\NQ[Z?4T9IJJ&[_+%6=KI/0%5OY]R?%$4+CPM TD_9FM4>W>C-0VAVQ\_!P
MQ.2Q=NJ,VB%6>!+)J^POVI;L;F"(-CO!5C'RLE?JV:ZWGR(,PNU9R:'6%GUS
M([%]\N2D>QA%Q:I]2LE18THHH4@YXCNE%V\K(B$6N+)]QS01FC?X([4]Z!YP
M@DDO_WV+U8H\2KM8,@=/>@Q0:3/6I[.<6F89]KER-<H\JXIB)\G\VATR#M='
M\,QYK2A-M^G>I50J_-Z=-X6&+VD)>),N+D22I/ <55^]@%Q#23Z@QC(7 SZC
MOJ7E,.;0N2%&/&_*JH[S0FFH-OH#FW&*M0[$%0>_/'U73!)K(J@#M42Q("3.
M)A>-:@_PE%@(F /"5IM2&#X$_HO5.OELG,N'@<IN=957Z=X%C*D\>$TM367J
MG T6H&9-!T]QO,!M:DHV'^'::;#X"5S,- J9$C7+,HW>;!C[(MSR,:U\KQ'#
M..4IP:2DTM,._?HF\7-S8Y+(2,W37VE>*4(,+?(??2JBH.(^&,3&HA+"O^1'
MF4Q J6OHZQ^WK;RYO++;5$MC&G9%8]U#-PF O2"JD_A#0VUJ:%G0:9T$K+S5
MY@0)Q#-T91*/-/E91/DYN:TPIR-B453E*8:RWO7\*+<&_&VE>Z4>+T$TMAV:
MB#/_K4+L#5&-%&J;(<7'..@KYE_PXY7.#A((R#"0,/X>T,U=O/AVT_&%.,DM
M<8SPE*.\I;YZE]*Y'T^ZSV/N1D:.?/B19$%^-,?IU-%7*,7=GP?2(%K10)00
M)4G;P&>@%EIIT-G,*R7M!L"\^!LL&W[D>BG'9V/^)PR10JY7J%$5SU=!\ _'
M&S@7UJ-&J*V5,#9"^[,"Y*JU),H0+=!PX7U(?$.TV.7IB6 (KZZH%N536YLQ
MK8@H$SKP8<*DYV0GV*&W-::<!8QE[(GE)_V)=@P=&N'J/S=DQ(%,C!W278BR
MSP4CJK<M!6N\E'9_;-U@8,DPO]?Y+:.?\G,=G;DV83HS*"57]S<+M&_SO-UW
MR-S4)J'5:.R;)WL8EI;&&>BK+M:$@C=/,[@/C(UNE!6NB\X9'FALG=%LK"JG
M@._OUB!KN2<2']XWVY:G=]2 #_9Y$@(4G-?C_&"0\/KFICDY=E2@6TEHZ(P
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M=[Y5S) B@(4=84O' >?\KO 2BMU44J?09A.R^7'K?_Y_Z6UR,_4_4$L#!!0
M   ( ,&#0U+F ;+48\P  ,/Y   5    8FEI8BTR,#(P,3(S,5]G,C N:G!G
M[+MW5%-=UR^ZZ;U*;Z%*%Q41!20H2A$1&[WD4:0+V&@2$@5I(D1 X1$>B%($
M1$2ZTD*H(B+2.TE 5! D$0D;DNR<[?O=>\][QCW?./><<>X?=XR[&6N/#62M
M->=<L_Q^:^VPI]AD0/RTC;T-P,') ?P%_P#LGX#H\:OA5_P /P"^.-BS@#7
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MOBQ__?9]997V:_/W%GT;W-G]HQ<'P,7Q?U[_7;TD8+TX_ZP!WQ^].#BC_GQ
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M**W@L#?]^::\BZW]'HV@0QS?L'(8V3*F8@ L^A2H3\9.<RT&I(EU&J6Y-)\
M!SH75,>A8:G/\\$'5R:/=[[4K.*7F.O\$FZK%75-T_1W .J3:U]XF@*6J90
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M*LXI-W[ZB7DNX@6*&L;'E/Y&O\BJ@ #T$5C<".;!T59/! Z294K5OZ49S+S
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M<*1,XQ5SMP4W-9G/O7[I?@%"FBW_E',7WK!"8(=/87RPQ%BX?)4C&\HZJOG
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M5Y[-KD[=F]?[L @?S72DS#!J3[Z8W/<OCZAELT[BL_/>1F<^2^U)5UH1SBQ
MY;M4F)I4V&=G-[P;GQMW<3I,Z/)12&OG7,0:X%(7?3$TCB'PUJTVL,83LRU9
M3<<]QX\E$U>?>B IK!4,6)?[YA+:J@FQ>@4YADQ$W!CKW.)$D/$M$'=#\CVS
MU?O/-9%_O';]/>%#P@,B>%J4DAG85&7#@&GI^*;!O-B76*A/(2H2",0@ZHB
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MVS/CZ1EFY;FF2XL:1%T JN1J(X,\E:5(*X'WXV]614STKZE4O*]T_=F*=O!
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M_^#)>H:O2;OHIJ.91=&:&*_/ACWULDJ9AR919_URJ_A'LEPM!NYUO>DP2G[
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MIV03CT'J(!.B.+(8.G??DWZ'WG=S^]#Z74CLNO$&@H* ^ ([(+*&H#1M(N
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MM8T+D+$W2!9/UJ'QX\E\!GJJ:$5T_M\I!N;:QM]I1\:X,2TL#SZ&W-;;BH2
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M[ P0%8GL!$4P+>IP:( ZU)>KCV-:$%+;6U*MIZ"29FV(_YH%\48LQ9 J*)E
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M*FJ86G"P8VH3?"_DDF']\!=LX59E7E5/+E_/[8(X%N,556FKN\]49JIT*;K
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MF^&*.^Z%A=5&)KU+>?.K\1C4GY-%?R3\_@1(B+A_@Q[D^/\4>GR5'34CV])
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MI3;6GWU#UJ(50EMMQ8GUL9?R_0B!G@VE+K==+[W$=XH6Q N'W4^(^-[^O5W
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MQ+\5E &\*W?/Q[M_LK:^/(@(UW_]PJ1I=?QBMXY4\5_UXDHM'Q[.8XX<12H
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M$XRMHW%O\!A.ZX4COP-B9=*6<U..L*M_4?*X<3_,4F(,)BL$O6L2>,>T;]-
M?&"K\/ID]ZC:TU2>.]+.59=/.PH==]OPH1]+!'P(;"$X!I0K-!3-]KBUY*>:
M#,4%&-/[N9SQ6S^V[EUY13+KQ311QZ?,K5%*JMR7VT42W4"C$?S:7Y[L.;@_
M,Q5!,, ]'%WC2WLC NA\H4(U1.NKPAL-IHI]WS37.9OKI.:,UYQY&^K<B$_1
MAC!LQ763>XS+XRA&-5'^HE=Z#5F#$@8VA>*.?I9:7Z(?#2<8A5O*KJQ0KBZB
MB#=K"O6Q]CMEA9(PUA=?JY.NHGC8@#V(RL4JD3+)FN8N:/MO!5<F[1BV <N_
MVQ/F/WNH?>!*ED%Y=WB(M?<4!(S($,"-%& (.$VC(]/E%BUQ+3AV<T/U\" J
M3&3XA.+RA<:X;;]N<O_'BX='8SZ\_23I5@]^01[9AR;J!HHW_$0V@?;4$#<J
MU]F:3D;GC /1S=L^"]M-)L.Y<LVIS\JW6EIJ[9Y.6F0>FGO>D7=0B&%U5X)A
M/8E\!G1+3GL00-AO!48QIH.Q3F5NLSF2?P'D>'\^X@Y@-04_:?6C0O!,;[DS
M04[+72Y+.LE*C86O;7MDI")LU&L0U2!*/V,!L!$J5P)!=J0#$^_=-'B)C"VR
M CC_FB9C^,)MT4WZB=Z"&0-WK>5?QWG]J4-WA66^7!"U,:>_](]NU. @(2Z,
M :5-O$\^"]0V6OEO\4G,F7\4$- **:]K4\R$,$!N,1*,EC? K_N!B_9 CF/+
M%5.IG"QTYB *W#^@Z1DJ6%$?2[B*[$E:2'\QBPV[5&Q<Y!I[K+3)-T^/4^&^
M1>+$DV154NFR+" 3HQ*^PD+A0!S[HR=Z^Z[-6OSCGA L3^TYTK.^X:OER;E#
M5.7C<^_>OTBV1HLY_S[S_.SEF>_\P_/9G =V1,$I*-*J]B".4$ Z/A1Y?#_;
MBL*C81S30'PA0A/(>K]4KXC6+$9W$G/#I!]0#"=6-JHE*A+,K^5S$$9*OK(:
M6VU5E);!COH;-7%,6 -NC;M/WHENUKMOIEPR;AQF]]FHNJ)4*9Z4U.7\\^]Z
M.G@<E&@&3@+V338&6R$(&OQ#&239%9<]"+,6P2E\V*EM+6*J>XUB9G7HG.=Q
ME[-''9Q#HPA.U?=X7'QM.IB-*%!M".(=Y23"$:2#,W($6B(>"7M@!(CS-!N"
MJ_IFRTTL)M8-H0DTR=6C9:\]W>=B#_!<U.FK"9(J3?RQ4O4N^J+XM"<@9D;E
M*OVCO[P=JN$RC!"-\HCGT,?O06)1$+3)3\]ZOG%S(_(:^^7:KV^, B\<_5X=
M-RL:R:ZMZI,J:B_9MK586@YE! S,AE;4#/+]X3>K!PH.<*N\:'GEJ?Y%'5%U
M5!H=Q+G?H?UD$H&*(]Y  \(\X51/BJMU_.'Q)L\\ #?%-E8HVAV3.NP]GF?
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M._.,""FAI(B8%<%;UX?L'DI]Q>38ZX!B<\T+B0Y;T^0CH"N?[D -B:>''0^
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M;;%O?6[3?-6SM17]:VX2Y:WM>]3&UB-@+Y]G%[%N,9UPK>'\2WOHO6U(.?,
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MU9JG/#HZ,V%_$[)+E-R:2]-P=AWLG+)Z$)*A]J"']!,'&@O/A700%> ZCPK
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M9;71P&0.8#W8>'7.0++G^42 T<2I<]956O;O'X:V(-8^G'0^=[0/2P(=/#G
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MAUV)QT_U<&A0/]M6[F.:2N9)16L1@9TC(RH8]38"S1+.A_/X>WHP?&R"R:8
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M9RD.O#6/DL.',@E\(,&#+E;T=NK_XNZ]XYI:MW7A("I8 )$FH$0%!41 D:*
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MK#L-GJ7@U_$&$8!U. 2'%MA^*3G^U20\+N1F_H\5JSO"M_O\F[Z]HV7S7)N
MP;B9FH&Z3B'!@57$1%Q\*F=)^Z&D7 ,82IO8$NS^5?)(<=(QN;TA)K6+?)VF
M*B^TE?<X )3+<_BY%W( Y;1"XWYB0;5KGC9)19ICP0H6JO=69WBS8S;+5O:
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MSS$GTN5)G00,T6)RBQ ^ ?RRM0)_N1ZG72/.?LR?OSYB@+.)B[L?UB%;B?5
MW^)VOG*9?[;:HVH81S:BJ'$0'#VICJ,+6YY6RE^)W$+L957?OHWMBX@],1H?
M?IQSPLG^[!O9R&@S]6,34JPLL\@@4 ;=C"WFH/&FDI,&$1-?A-5ZY2*YS@:+
MU@)\*+WNFMX,A8"ITOMRGY)D"ZODEXMEMC]7ZGZ'KUYPVN&@'1DQ)2(:I4>P
MY!)*!Y6+\G1.AQXO1[>XAMPC61 O&1&:3?&7T- S7]4M?V9XW$:5VJQN_.#!
MY=J;V$ST66+0JRK'>[*88Q2D?G^^R;4EYYPA3>7[01K#$V%KWKEE'B8^[ADF
M GX9-U4/WS\5>*P^PV'_GNSC,);[U^#)0.E.Y,@6>"B=:$26ALB?+A&Q/)A6
MWA09S,G^(-XJ_LA\7)'MB_/J<=.'4=T&HI,[JNK<3-M8J"\B&+"PR=T)%+ '
M1S0)-Z)+7%/LH8E2I!^/?NAZ]LFTNN)5\JQ$+E;*6/C8_0MD^'UT5VH9K@XQ
M%#]E4 \\QW+!302VFOW02YK$>[W+>[\D)7E-11M<W>(0]_C^];)3\B#&\!I<
M =T-$$T-**+(Y5!2V1S9AYX%V/M)U(Y+O-0J[QOH1'ZI")$(U0Y]%:WT@C,
M?/3XI@I14\+_P#:DTS].80ZB1P"B!11M6*(A,*30H+! O(Y\629TZ"LIN4)V
M0/Z]+.F\9]</5^?&[^&(*-=#%B4!3V'Z/[_1+Y(0_K034XXWOI!27VUT6+&.
M/'N\&,<Y>KH\^^@>IEQR7%P<;^&0V8CFX0L?M#X&[_DL=@S&5,O<\USD#[N-
M?[@.2X"Z<^&(9?L:""!6D5ER_YBD5[\RT\GE%--9%.(X4'&+ >.B04 KANF+
M[*C_5Q,BE8BA0>C2_@S8LCT4&MT+=ZT]@&(,+;X3@J!?O0\9L/2>;T]P*\9
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MB)JF7[KD$-Q>\74M5@-R='-\LT3KX<=:2X?E21G?/Z2^F_.P>&)&5R#?I2=
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M)L.;--M+W ESJ6QH3M'&U7!>W"%E.?SE%6=1;!2B[-9^=4>SADOZG$13L8P
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MU(UY&7'&GO=;Z7R^G[.;XB_SDB>N'%4Q,[VYU26_FM.J04'7(?0JG@&C7:I
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M%GP+X11^*9_O>A]*U3EMV-+<+MYS>:N<Z8?A.\*#J#Y.0=KTOF/382&;!]>
M$5'\*D&=:#1Y''T12N>/X!3+FG/.#P2]E049L$-[VAM\)?E%9"S]"C8%+A7&
MR:V1OE7]B*RP8UX?! ]NDE)!MBG2[A(,[PGL2%*+R@4BU#RF$=6L4:_R2? %
M7D)/?WC<[.CL9;;95"?B:%:\XA>V6:?QMH/1]7F03!92D07JJL']].Q[%#?J
M7LI@4XTHI9VTIV>VRPO3,@XG\?S,\75V=CXS^L6O_&:9EO/46GY"6T[DCXL?
ME%Y?N^H("L$AU@(Y3Z8[L.Z"NLB ?=^<AQ?-$>)WW_9$P9!&KA-9"-(0+T$R
M8 %Z$TD,6"G@3-MUB]"NTM7E_+BB5HX=MCP)6="IE1LN+JA,F)NY+L:\M//?
M6Y7&\1P[\1&Q]M032SY4LLL/\3R0TQ%OIFY?4<)1]PT#\Q6D@_2E4Q YE(+3
M.&F1C<68;4'HN8__;5W!@')MEMH<?\PRM:JCP>;GM\YC+3[.BN(B@>J)?.?F
M:W/%Z_8^D[U@D:HVGRI(4R*)UEH)?Z4L$?U/Z.Q(C$GUWJ[NGHG^N4-:EQ&)
M2#^W]JGGXG/!RY=K<[',-,Y)S M<.0I[./ZV@H?&N*.C=L'S4=22H4PS!>92
M]\N+_VK@D[LJX=0'*&0)T27?.MMKV-X]V*8$_-$GJ%OJ;<CU8]U3Y^&XQ>$D
M;9&(QQKZJ KD42]_X B<IS-_3.632TV/^_Z4L'$/PK@-;<[#N_/NX ^CMHN7
M(D['E%[6EQ(7OR+QM;GC;.Q;IX&D<9PU7-U(MJ'^]KG<GT\<3)\8>NB;ZG>,
M5>:32W>*YSF>P_E5+M)NT-."&@S@=SN M$6,IVV^E\WB$6?)>V8XL<(I3M:V
M[&-U4RSY]RGR/;VWZ/$UXA2U^E5R7 ]*U1;]0G\NNDO'Z,>Q1>Y3#WS9'>,&
M&#!'1(0Y.=P]?<SK_?A9;/F:W"'J52E6EX+T9OFJ[R^^M]P]8N S#<)16J2L
M>MP13(CRH?SJ\%_!:5'^$AF%90H:D.US:B=>=@E],(EJ*^1].W5,%21D-]68
M3$J,U1@[TI3DHRMK&I5_^L^\RA3'^%V1+7@[Y2AI-;(2XR/AXJ-9.^/,3+:C
MY./#=2[$E9<-HY-L?EY.G,Q\8.RGDRL!O^9F[FEN4-?A-H$)!(7FD27[PS\V
M37_*Q&M);8QD)<X9/INYFW8O0\=#C 7NM7D%HT")(G7B$4VZ@I:"38IYA[+N
M:#TJ[96EBA'RI]SZR1H?>*?7GFKH7XRY&_"L13+?Y&GN+52TVVR)4T_);=.F
M$\],1SRG$SK/UX>+-<=>7E?7C%NK<%E["ASJ-74F6SD+023:R[&!C#R:3MJ7
M%4Z0PF1^*0ZT%%+RWENH43;%Q2ML;U);RX*0>X(H1L50^,@1Q##P7&%BBT")
M3KOW(8W;.@<ECM3>LW[1J3-=Y3:URDO3'HP,KG+,]2NCU!T_"YR^#-ZX^5F^
M^?-EV.$IE9+5$R@U4F1COC?*8,KRT3A2LNKQ>3PKOM'NPDO.SQ$L*)M<MN>-
MM]J%7^:(# J'^I44E84L^2V31Y,U% -^:S:K>&*_+GX&9U&YN$P>7O*+6-4E
MBKX>)+<%U7UJ-O*&1S)??B2RK>L^RP^,K373=MS,X"6!Y??QTI%6DOT;K9R$
MZ4$77G%A:@%/FXO0!\)/W]E2$7H^J*R=EG*F"@E/'DBU=C:S[PJ=#3KVRT7>
M.S7"TW<P,5J[5<Y+65[R 8\Y6?^BH8DSSJ+\LTEU;%Q-QH/"8[:J/>D>R=]2
M>DQZ6NW&MCQ]?/9!@B)G-@!=:(=<8RYFP#!:$'7@1,:4_L/(G!N>HRZ0 2MG
MP,B]JU_YIAJ!$2SUB0-$I#H,NORQ%[%V&(BHR.X2%2I$5*K1R8-_&@.OF>#8
M&L9-(A.(M"?@@B[-8.URFU@:]A9"X5]NX_PS"WH2^X\KY69:@&_&#-AA[-EG
M$UB<. ,6C+:C7X%@:WN:/BJAT(Q<$W/ DME2(6E5:F_B&H:=OMD/+ LBP%"'
M"J#1*N,V!?Z1UM.MSD/W!T3_?2/</_F!0\RJC@,Q#99$4OG<$70N9.DF97>G
M@C(DM7=Z$,N6?9 1]="#@^O0@^#6#%O ZI;U*"HF"+YFT [6Z*Z]-H12X]#6
MY+^G1@/J(YH4_7.-%$TXLCZU<(Y@8$]\V92;IZ;\_GPU\6KY:\[E?I&C%GYQ
M,[%,'G8C/WZ:MM=2FZL?5&')Q?1(D!4<@;.?1W/34#V;NM6"^J1]9:6.O#$%
MHPMKARH?X^5E+!25Q-8%Q?1[FU5K/W"\14R^PD[4P#?>(SD8,+S4?"H-7<U,
MODN/ 28*4@^#2G96"KMO3)K(]T$TKC+?\<NENM62L4PEU;QZNGYYA0VAW\_8
MGUJ;\_JTK3IZ6LSK(?(R9!$3%5;H=P6XC_YITS481S3$1L:#)RBA^%_Y!9LG
M1/4H09AMT%SU1)6,(-M%W/)\=_W7LW+LQDDQ,7<':5R[WRU!$D??L^QNFP6[
MK$0&5:0@?ML)<DI"GY8DIZX.!NQH.[;414]U7V%3UK"9=Y#_!\P/WN>(N]G_
MC;H"*GO^2FWO+C"_#DQ/KP++?/:[LPF-$EMY0>"-KP!1<PUQ]"=VVA5)>TJ#
M) /&;/U?;@G^AXFCUN'_D@(J5><VG<V:5T6&0.E_D+#[>J,L@B$)W@ G%J"[
MZ2E3?K=&.L%?0[-.%5&>SFOZE\*FSF(=)+;GZ178Z0WP/ ,VI#$ ;)29TQ$-
M![ES9R\'R %/T+:SH,A@KAJ3:MW(.!#5OSOI!O1#UFS#,6!VZ:!@.ICC"4+4
M@:J.@LRP>Y^7(+*) 4O89B%'7-K&[@,UN^#$,?BF+G8-LM#P[B3=/ /VV9(!
MB\6"W4A$MR;9@V,;X /OT]/#0-<Z(&J#A::@2;^U2H.,3MZ=440LQ@,SKKOO
MB^[<,/RW&[P#[*80243DM!\3Q*B[&;#;E0R8!$!/BZ2X1.YDXK8M(,+&LT[G
M!FSO,6#Q)& 6/GRY<Y;&MPV_!OS+1L"'?B%F:,CMH/^?- !S V*T3I$4'0;,
M(3)("!*Z 6YD@  77/ 8!\C-#)BT7Y]CI6OTI; Y?A[2F ]F68(!$\TB)H%M
M\N&02Q>:\EK'3PK'FS@@'E@B;6<]K+<#I<QVM-L)FFDK59'S5I#'SACM./W?
M#X*[\U(S')#_.P$440SMJ!%X<)(TNT2>('F\'L8V#SV#:!VRB:QXR3$Q(MR1
M/84G.?'J!F]4NZ<-<Z/H\]<_W-2E;SZLVP'(=Z$ [P/J1+&.R-TR%E2J+.H9
M.$0J?ZW23P_^!(GEXD%(VBI]+XV;==T(S5<1>]AXH0UWJ8!0J6'V'/U;\>X.
M>G03@J@+4,[#"6H?P"X!S>#20YVO*SX%Y+5,I7#5FI:O+9Q/5"]Q3;^K]6;5
MZ_G:7/ 'F9;@!'B[%^@*$6[K3HJ4*XUKA-Q$(7Q$_T0P5SV<.H3EID02D$,>
M.YB&%//Z_=2K>>6W7-[CQX1_4]_[RN5^])ZPZ'W_Q]-S5>O@H2#(039S(7"K
M_ 3,)VX?Q&9<=I,@?V,70)&KA'O;^T 4_G#OD*W7NZ=6O?%(A-K&GA :!'G5
MF&5@%803#82I#ZFID33F_WT\\N^'U?ZO.OH/*#OK@<W$[(>DU<=,X)<\!YVW
M=-LV^!WBL]JA52L:79*6M8 ^\5"E7-F@TO&I.W9=X+:A.OHF^CT/;0,]AESS
M 7B!Y71'Q(Z%)'!]\T_'T#F3IK2P0O@$<L=P.Q+R9>F&W2%SS5C(@:DO*-\-
M_UZ;]2]_3#^#]5CH8@>PR^EVN!T+'F_COPIA*#N<'L9-Q$___%$):G #+? .
M>%<UMR&RE67SVA]#M>>O1FFT<H@(M>U,B/!0]X+Z_UE5#)5JR,6%@%:Z/9PL
MM0CLG,4Z+I'40%;O7<?) 'Y5YD")*I&.P<PQ8%S8Z?1(NF_DG/ 6DATQG1I/
M1\7/'(%NM%Z\^L>5H#3:KLK6A%2M.1V#<%J%(KD82NP_J9-\D+V84=S]3K(&
M1[U:\%;QOCD. N.8)[8G1J-&+"PJ,FZJ'_^<@3WO451XV/BJ&MF& BG9?2G$
MN68"UQUZ'L)AU1]]A@)P# /E&P:LM*M5A7TN;L[GZF8,1)9SRB;J";%7U*V/
MB0C =G[^LV7JG;@O"J]E+2]-#.0[9SM<;!*EB2JV.[O]5.D9'802P^]*2+),
M\='X.$"#)5.(;WK^!BEEN34>O]W-N:78XCZLJZ3Y8O.D=1C%5X^ICQ3%AHI"
M]HU*0A)\E@L"N#7-=86CT*U5H<9CHO]&%[Q(_YHN_(/?TGH&-Z(F&# ^BC5*
M.#/7\8*_[#P3/P/VR1'YQJN0>(_N !""%D$^E!=6"R#,::O;_/[I#7]7,A,9
M#B](-/ZSAU_[C]J9QC0:>M2MP8UJ0S/Y6OY&49O$8?;H?M=+;RFV?^;T<?\?
MG3YU^8JR/*[,M3XI-'B/"'!DP\/C*HPOZM'@7_M^QS^M_@F(P/OWQ]I0VD%U
M-E.P#D+K^;)TD M^&.ARX* N%J/NXR$A4/[*W=C2YJA^RF5FQ$;'YP4&C-,G
MRF@"';3N"C$M\@%:\G]6L-K/]Z^2&=Z4QGD.[-2C5Y4DY2X%A%R<)&CQ/6S^
M38ZJ^7O3=X*B0*LF?&<+_E-SI>8XT(J0WMF6;CO[E^5)L4HJM/]8[%(53QZD
MJ$X@AP4G]#IKI4^ /2I2%)/WTOU.>26=/%XLS9QV/D.5$=;?=!TE$C@9,&^Q
M%_WIQC9>5;4LMV J^I0A*N1/=5:TJU0 I4W/P]Y'#*=/=/I7720='-0-ND4L
M#ZX2]_48#HOSL-_K&7]?%5DJO2I\]'KWRJL;12P7<X02J%*H2U $C7L!4V4!
MN> @K@17"QRA*041D,0W\^!AHB7]4^:3I#LF'&?OF*4Y?[U0_.AIR,13=6^
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MUPS;A]EQE[V2I!?ECBTU:JWU>1ZK:4^:K7V/3%1HJ;U8L#W2RV\FA<O[4$L
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MP_2L1<H5KRN99E\3GLX:?S955!Q6E YP]2@<J:N;M7:.#E>Q_';L7=L^,YN
M.W4!-SH7*+^LK1W_DAX8-@X%SQEEDK)R3/?4B=N<454;L PTZAGX;_3 Z7^G
M!UKINT"9.6\6T-.]R-Y>":>&SL"7EX,V8 ^\-^F!:7^F-6 W+WSX'V\ "'SU
M[EH[[#"PW]M%R1KQZ%Y3GEO'A_J4O$54?B 47R25#$$A]E.L"SF &47=@$T
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M@9N*#U$I$ET25VRI571R+/R>$]Q<$2[469Y@R7'_R-'ODT!3"J1(D$OMG<1
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M4GT>8!R=&9Y@/WG[SU#=>RJOQEDG!KK,KNC6N,4,U>ZY=Q\]./U_K_+^/V_
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M4I*^V07EW/QIO2VDL.*^T W#^>?H?';7^A13P)#-Y4]"",S6YD"Z^=!I>_4
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M1D+'52G[:4@R H)9]"7JZOUZ<5I!:QF8TSHF"H53@4'WWI6:7O-9!C*%<J1
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M>G$#!BKQML-#"8OSKV@ F[MZ/-V>M!KYR_,72B PEO?!WI' !,:%#*U(\I#
M>X:4CY12[_-DW9C6D!!8\1?(_4P0"2@VEW(.1A^T92! >[HCZV4E/$Q/GO6\
M_A%6*+!LHKD$W;'_]<Q,3L?VT:QB[N]WGQ@\OS)]=JNAW;HD_2;5L-TG L?U
M%J/(,&+>*043R4.RZ<7U]CF!>B=W*&9YVKX^[7Y@62EH;SZ?E$[DPL2QHEDH
MO*+HJY"_N1U81T\&WU,W8/0ZUK,-F(<\5@!S'73=/9KQ@%RC(?5-@V5A4@.?
M$75[Y;:0<5OIEE5H^./TYZ>]LV_B77U &7S;* ^]T0>4@U-HC$O#&$LP+2?0
M";4'%$-2%Q^VQ;P*/-_D/GK3^Z5:E]0@WY+H76&M]FO-L&QLZ^\09[H9XE+P
MGH@X8H4J4QE.Z0&=G([TKQ#GX^:1Y<#5X-2>^3%DVE0'/9T8A/U8VN\YY[0!
MTQ?80@/FH8QAVPVJS3RDT]O/@M70S\-][*,.7O$8XQ!:!6Z+\2OA5]25'XQA
MDSPGZ7:"L*ET2[*1\=X6*WMGU>C-=3L LG0Q77X&)W8$#^&SZ]V*$[O&)'TB
M5_V@,*U-RM/@+<L)G;_AKQAS?K93OJ%7%G<@15WR?FF34!="4? CPP *DRGD
M*2:_*CT##&+8!Q+I4*0+\<8.$@R;3R+)68(X:CE&: *Q#?">KLU>J<!:GGBQ
M13;<Q/Z!R*&09%L3P1MH@&X-O6*E3^48EVW#[6*> EFY@7/D:@JG^"\\/UO1
MRT[ISL]9,OJXMW<?C]SDR.["LO-LAZT7M8_LRK>RF*N5X^A$./L,A[*%R^D(
M,( A!XGNNP'C4F4>U!.JZOU]36.Y7CM] R;GTKVD.XQYNP$+"'+Y.O@(([I9
MO,4H4>.8_#UD&R9_^02RQ;C>DU3\&"L[6!ESUK*RMRU=,]%+"(>.ZC1(]?TY
M<KZTUNBBR(3Y)=[DAK;7]Q&:#:I HQAB_#6QTF8^#X#RY*^0#[>J4[8@M8B>
ML?4,2!5JNET]X.\'V]&ZXDE@_%\3/LZ]),BDL#+7^LC2I[]O[W>J$_XA_D^T
M_M!YWAJ3?U=^E_]1WB>_^;+=[2>5\1F_;3C%9VXNSKF[V;I<)EW2-GL!_IN,
M1C'IV/[_30!02P,$%     @ P8-#4M$TL HWSP  S/H  !4   !B:6EB+3(P
M,C Q,C,Q7V<R,BYJ<&?LO'=4$UW;-QJD-T/O$*0C3;H"$E!I(F)#FI!;4:J
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MJE7;!:411_/$ ZRYQ.15S4*GOH3;SFJU A]M^C0NA4_?.*_T"P>*M$&Q/\"
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MW\?A8WZKR3%/\_1*GY$N/;\T*/".AD"KE%\7,WC\7VL< -+" $L2(=*'-)!
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M\#>31Q\9[51.LNZM(G?)]GQ[LA)P"Q=KO'L;<^I=X<5-S^L?"Y2=)8RV=N?
MC)9Q@+$91_8@J$%F(VS7*G@P\1I02GW!H'X"">$XNBHXSH/A+AO\Z,0US7(W
M+#=BEV(/ECO^/8(^2<]+_IRR7YP2K]@8J':F-R*QP,IM+UE0AZ!Y)W4W%Y8D
MO";,-L22)<$^*AQ['@]X8^D&4,#!R2M/L3W.W&*666MT?*SEF\T+/[I9-K_R
M1NN@B@[E;5('5IYCQHX *EB0J6Z>!JGMQ-=F"HF? [,[48]L,T\>'WWQ^=4]
MSTMO)'(4;.\E/576OG_H5H/57[L)*ZP'B^K\@24IJ:IG&CL*)KR*/:*N%"@%
MLFOERJK22%LUMK8V$_$;"4F7\EU4B@K\U78_4X>0O $_G0>;*@9%_=DG.>9,
MVSN=$#@6%(8F+TQL7.)T.S#4)]--.RT3GI19NH]>_.XOL2X@:O_P_KB-LLS>
M.Q.::=>CEG'3K:!DVA]('VK%)*YQ&?V@V/)B%YRF?^>[?B$E6/PC1U?-KJA:
M+3_)\5"KWKF71;D7KPS #EI%-#W>88,A?NW6_(AVBXSMW%\W37VM5EWR;EG7
M:>'!"=?(]Z,'H\7GSARN[U<I2HA_?6R?3N''8\)?%#FR0Z#D-@^6(<&]@0U'
M3ET%5:B@#!$(!A%CUX: PTCZ#C:<A9AIJF[BP2S7J+'%Z_;H#<O84H7X]3<?
MZ.L(ABL"T,5S[!"L8^-(B%D%$QDOB4V=EQ,6S=:' %=D YKH.#$"UW[+]NJ+
MYQ;'<Y<<0VWRVI"^$2H3$-HTK7H4.3'9\L$],-=CXI".FI2RAYI*HQ/B'XBS
M%W-D)D$Q-@&=Q"RF;$PK@N*7"8F6/>">R; Q388-D79O[.S'$\%'% J]'#I"
M! KD930M7P]9ST.KKT"DY9;#(=L?2K3L5[1%J%K#L\KM@,+JP"" V&M;$MZ8
MW4LL'W:1<SQ?NV?;LO'-B.RN2^[''OK.-@?Z3%CE";UM-KGJT]+0>H!_+NA#
M_>/"40CN.JD)KV?_>=I+]@/?(63^\$A/XDLD_6PBXA1C@_5ERG&<!6\)>"N,
M__0K_U>'[??I+ML0U8RKJ'P>3(1(&_&>F66E,N9 "4 <\HRO0!XM3^/S+T+,
M-8)((A2#7BU%R_G25>%U'*><$;D[UJ:NB_7//LB%L :\QZYQ ][M]SS<G?%Y
MX<*\'.M'IIO&HTR!5,/VIW657XN\J[\%W.\J:TK<-#5]ZC=\Y9+%>R>UC\*O
M$0I86A9"KML>2](<!453F,6@F#@!(* <=;Q.?UL2SN98.CY*NE3]S'K&B36Z
M>N33[GPIO4\T \V0Y1=IB_T<Z:N@0B9'VML3,N1^2&T/;B;;UFVD%DD_A^U1
M__P+?V[L<3<5TMG4]E=PL./'^._S17VCV^IUXW4_FQ):?,T')9YI&)Z[]&XU
M24":I/%3%X;!)%)!21X,0#)#0)%OM U AP?KQ=XN#K@'\H5U,EHI-7!X7>U$
M2?&,::4GOK[IAQ#NPMS=3KW8,H]=^2T-Z*X76%(-LAG;!U6PJ][<8AXL AK-
M&)OS<UV8M!E((*>*.FANVQW-EG-Z^LOD4[=;&47P49:R?/3PWZ8TDMNZ[JFQ
MGUQQER*1N+S(D>'O3WZLG_B\'&*)W#YEKHK3ON&$V(F&!KPIB1;D/D'2[B/A
M2-H#HJJC-A5UAF,^8G*.0:#DZ1\.]*P)_*J="(Z8E'@HOLM7+W)7<940V34^
MKH[6[L$S#D+Y<!EWPQB"CUT0V11A!N'(71:#QL89:324_FFVC"GE5I!X<SGR
MKJ#P4&J%NE,OIF'8"8$G,GSA@&85F0 8;I"0F79">";A.".!@DVWNQ@?K,#<
MG.+6O:")2B6^6/+7#C5F/,G5>A7^3QM?VDOD'G"8RH@,6T>PHP%[L@IA_0;D
M8MG,L%Q.TL.DB;>UWX*%[-+S6LI]; (#G>)$_'46:G_,65IZ_4WR^3& 7!>4
M@_E^">,H4$$1Q-4_=P(XQN:B2?%ZG#[9L)._<B' 10X:H3'(:M/%X-Y>8LN>
M>^8,V,4O^Y0(PW8&_,P:;PA#N<9VFR9^\6#".7+\H-@@,VHIN/")5SO5HZNA
M9";HULUAD]YE+C,O4"G6Q"?KZRD:CLB#1>$!7>&U-/89#.DRQ'I_$@5P$H"L
M1V.SM[!9YHY^V\P8DU.Y*:57Z&E[)5;9V\H*_@?5VB)_B_=A;!DH,D[R##"T
MB,C=ZA)V:YQF#08&C&DWMZ2EU$9T^_O[)-COOEWN?UTMWY/&@ZDDVB\B,DTZ
M0VAPA8B2S_G)2M.K[?LY"3:CZ>=NG_![>YIL9$C:N]OMN!/B'EZ"2+N%9_A1
M;R'A%[&AN$PD X63#L>*;^4>OU!!KD([\I]L: B6$0FUQ5S<Y;M\K!BF"3.
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MR734K&CPAM<0Z\L0W)P66=-$9UN),0/GV+#9#@1K,VH2HG6[, R #7/783S
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M#N&8(QJZ.-_&Q1N@BZ??CNW;V)V&UA+;P*<H,.K\> /P^3(;MHVP_^XP@7B
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M.6?7_[UR?(% PE]IW$;J\R^E]O]CQ5A7"E76."!2W)L&K'/C6_U/TP\3(74
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M1E=)?[/4B?(@BVCX(9\PS(O=U?M"'JLM0>S??CB**8D?1O=C+.A)$+Y(TM>
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M0I;4UC#AZT:(-2^[TZ>GH6F[?RZF74,ET="E0Y-BZ2T/_S;=IS _8&I]/';
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MD&_D#,I3NT4<K7 72GL.S=\UXBK*CYXX5U@4C3[R]DF>0G#4T)ZKCI7'T&?
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MX0U;5^<'TX?+!I&(J[MRV1!'G3UI+_OR'F*?IL]2"DM_I@]B2GO'D.%_<:.
M](^X*>KA?]-.@43[(H$LT(HO&VXSA4UB@SU)2EZ^SB\SJ"R=C[;:@J:*I887
M9=W:8NZ=DX:<'_[$<&&F8V_%"DSZ/5V'\;(&#R@7L"&[607WL^</,,Y_BH(*
M=//--.6*")2.I7\^HA^_6UXH[8ZAI!!="W6#]H8L1FQ+H0"$74!%&>P,P;)@
M+T53TDZQ2WY?L>AHLT_#.<[]N^G.3;8BBZUTE NP![W?/Y$:H+6+PAW%4"_Z
M_E/R"%DK6WX.)UVQX>=)M#OG)U?I%_GK\X8/SP\?OAG>Z?PIWQ-ZT*PL2T;G
M?+V9R?M,\XX.HS.#"94JKJ[HJ_.JE\] 19Y^,-)7+NU]L&J3+2>7\ZDLL<8/
MZ[_@Z3@%C,ZV J6(D/4+B&O,S'H!]_J3$=JBO64%4@ZLKQ$=GY9/=>8B/<],
M>5UPK]F^9H0A1K,D*U#?UY!E&S'<;,A-%]F+_5Z'^X$RV>J5#'>G>#8D0*.F
M4K:J_;70I&IVLI1!G9T[?Y69]H;0N@A#6("%. /0!=80S*//:G+;KM&"HV-F
M7)NRAD_-;-AKV*J7/*KS"#*3MXB]'%;R0LK?+!TC_V/CI0E]J,962<4#FK2P
M@#E$NTJU8H:C^":AO"A;9MH4+7D**4JS'6M!RR5?H\A\CSFOE]6K99I>/7:"
M^=/2HT_+\)?=GW\1F3E7>XJH$;131:B'0)_NF_UT0OO#A<SH !F.8VK/8[,>
M<TZ*4Y (H/'ZD;060$!+'.70]];5!R&"DN[U/)WV[F!,V?T2D]UPO(ZU][I8
MVZ/>%'B^(YGF?.:-\L/-V\2Q*"OK:$3>0\3[-\DJ-Y^TW!*\^BK@P(^H!&/3
M[SBCPDB'[V9^U#>T/60IJB\S4_,(<??=]3HD 1Z+@F?3\HR*P^:V,Y7.SQBY
MZQZ?-"S,\I/4*9E52@CBIOH, ;^ N)C(2J.?9$.:!8PF0RDJZ1YO_(MT*'7K
M)!;F7K'&NP00.]6DF_6D*81^O?^D#<X0C#8<+% "G-F0Q\5SJCU$4':IB1XY
M<P^_G1HW\/-NR7JCO7I0G[LC9J;M?%19OPN,;(+E'!^U<QAS@Y>I1)Y.W+OL
M=;0+VDP_V/_C2O.1<I[]4X>):EZ(]0FI5Y04/3$S+WX9N?ZRZ0H/^02C=WU6
MWMZF%UZ.YS-#=]\\95OY5%A26=GOJ<.<NIG2^W[/>7DE.[_;A55%(P:3W$U%
M0N@^22TRK V_,SMF;9F+IN" C;M<.;#D(4R=;_UVQ$;I^XU=S3L&4)N-#?E0
MG  1OCCJ-YG"D)ED0VBR6>W-R/W?3UO8N ]G: X63L@-7;RQ)S!K-^&%4,?<
MJV=Z 96-VV4-1=&<_@FK[5ANE%/@F_ED814GWUR;MRF<JN=+Y1Y>_5BJCSW1
M?"]@>G@(7EK4!D1CRC<6DRG]34"Y6<U](A;J#V_H6\@0HRC7B29,&0]E=E2&
M*01SW+DK)&\TN?_L+:BG(T(DN(WY, \D,6I.%O=+Z]*F':8+<0\#"S2?:7)=
M5C[%O7[>53_SJI\/02'/7MEON:U#S;=T^ L-79]%7GX,=\:,6E.MR(AV9"R6
M*Y,62<1'#HN4NM@*9^6/VXS,';(O"Y8Z%>U=H%A2NK-*0Z="GS<=?ZJ9@.$?
M=SE *X1"\5K)7 W!049*XF/MQP_RESWVV*O-S3F;NO6 .A*%$$6W(DN1+:2]
MFCC[HM!R*'3B\ZNL\O6ZIA Q-L3WU:Y?H(HYAI-W:E9MJG^-.0-+R3'S,.Y^
M3^(QTI][7]CW2"W0[LZ]F?O7?MY26,D^JWWV^['R5[=F[J0^-"VP2L;J)C'+
MM+A1LN2-)_42Z'Y\Z5*X7R9-@^B9\G"JN=*OVP>GG.EZ(FQ^] Z03AS7UF%#
M3N+:WT,V6?6YS)RWR8UPLFG<Z!0!'W%TQ=?#>!4YG-"GU_)\U.1!A+1426>A
M!.+>A;P9VWZI/(O"':L=74F^1]/\/$^^RA2KKY8N&O8^E>LS-V6M>"W@C9FI
MTH$7;PX:=[TOF.MW7,#3CLPR,$.@!;JUE,V&O'6GUF,%X9/AF!7 UH 978UA
M11;AMAC(EN5-N:F_9>9^9@+-<9NR,VP(4F;SDMS;*,8BG?Q_<"LLX\J_2@8N
M B8_ 6 ?L& ?G,$^/,_;2@O%3K]J H8_L0Q9=XC(3;F3VY'![7JTRY*'_[0>
M[>\W^U-M_U*>3Q;(GJ8,%MX@>PQ(@VR(;#;%F=5Y9KN(1<GPFLJ_^G0^0PCX
MW,7/X@+_@_VZO3]XE &GX:<#+ 7-D9]@,=M9[A*23R@*EN2-9B0_XV3%Q\I
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M&"[S4""J1*-E:-E7@I>OI*YP5:><'G-7<(6XW%*L2G]IWS"]\SZU#JT--,K
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M4I%7_,YKTQX^! >*ZT_R7(^SQ.YV8Q"VNKWD,=;-J?B',UOT)2(X"K V@5$
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M,3(S,5]G,C,N:G!GU+QG5%-=US8:>B?T#D&*@( (B'@+$AM-1,1&$V*E"MB
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MHV/C$Y-3]/F%KXO?OO]86F;^VOC]A[4);/W=T8L'QL?S?U[_6[VD(;UX=^9
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M4"Y9<+BRMO)<TI2!KI^X]A6MUYGW:?CO^ ZD#/(:%8]BG$8FM1D!Z\P%UA,
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MW<K!3FH=5%<.$%9QC'76FVW80P0H301<6DR"*W&7<0'<VE4-?\J3[UNND>]
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M4DFW+QAU4CF*;-8,MQ89Z +HC*>""( $BE0L4!^J8 G113,<!Z9>M[>+BT+
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MC?\^<_5,&Q^L6/>-FW$SLE%IG>67=-M$69$]?]N ^OTA(@334_CZK>*]Q.G
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M_WW#5K,K3GP9V(_@G!6-./41Y&ZLS< G\@!'Y+(:D[PXBH1"T!>M: H(F"S
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M+];T@-"ZP-5J/9CYUNV<)KJ,EW8,N \WX^EDZN.D5^<]%A!;)P)J8X/ K ^
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M!_'6-QQV[1%RM4>FD*474OA"== 436%KEK>UQV%Z)JVI>HU2]*53=D8$:4>
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MOS9?)V:/KVO>U4$I:8^H.9LG2IY-98=JJ4<#ISR&$30GB0"!47'&84#ZCX[
M*2MU)+D9'#=:/>@R936_)-)'&5X,W)7M,3C-=[3&Z$+OE[.0<W<^/='#]YX'
M\;L%A]>'>8\#9C$.T-TLV:VQR* >&J$5V^E01R"<;GIZ".5C%'X#ED&&[[G2
MR<BJ&YOVO^1[L#363K&YS/VV1&[5G*^')WH?#1>E6%M#&XI<H>I;S*#&9E1N
MY466*$Q/WWV(](,K*F;V_NLX1Y2!39; :%<P#Q&2F%LGX1R>DQ3$:#]')+JI
M1Z"D!TL2;,TF,4HJ=UM/R/2=V]?1RR/:U./?H-8W6Y<J@F,8Q4'6#1@'@2Z0
M<U_9'V!N<"'T9QSMHGI,)KBHA_6JY!ODD&)8\X;M=T&O8Q-C/5+;U5P3\@.W
MVWL<>C9VST#,%=Y&HEW  \H>\^W@,UI 3MS&-(MQQN4.IS1N0J0XVXR*7I!0
MNM6E..J$PIW@.SHY&]<$DP)D/UL(*<3=GU8[WV:+G1OT\#82H*7CBT>#,NQH
MA.R PBO;50+XXI4F0JX]6+^[SP&V78F+C ?D%9O7B9//8#03=0& Q!BHD>.K
MB2+9THDMT"I'BVQ)]9*?-3;I"G9)SJJC$#I5!5MC]GFH@_1AD246SN&))\.W
M6L-1CS#-@7#&AS[5>H$ITO8@F"4MD3!J\N+&@%^Q;T2@X%&^>P=3_7@"K$*$
M$16@<;3A:%>*,, AG?Q)_+89&.TR20X?;N'3_QVE1:\HIG)PF+Q9JS:L_.BL
MV'G+HM3A^QV-"L<+F[5\JLBDX7B&"SME$^*# )1)S>I81*GL6J)A"(TT:9E8
M_!9ESGZ!WN^3F5YX;XH?/3LT_P"-18:\02T?RKSI>M VA@=J6*O)Z?4A0+^B
M+KTVSPW*.%<^<.LU5W<YH=(A%R7S."],@')DPRXEW]/17]\H]K73R*C3ZPY5
MWP-7IA)"16T@><-6.^/^@PU0&)\1&+I<_^T@BF8#&UUBDMNISY@V7F!N1'0G
M1:(/[B*1J>RH%Z/1K;XNXTL9^F%C9RC\1\6W)8]T!%_9E71Z_3J3R)@N \Z"
MIA0#:L 1U&5:X#PWI5- ;,;H *TEG;-'WS*ULG0<X65O];W]AL@]4\D+G9ZE
M)39**GKMVFN'0#_(PSR/:?3&W-R$C-[@[%[',%59DM_P%<1170JF.1_8RLE-
M^LVJG1_TN-152H6R-$_U8@^?"+Q:D\9X:2,3-@R]!_A0$/.KH!)N-4._CU*E
M+5)]Z??;F^6@-(%P?X'=+D%A(3ZQY$R.M,0D^7H":=K3[=K]J1G$Z6:R ,]8
M4!Q"? Q 7,3:Y1P0V<AU,%%3./U8V6P7Y82,<**RR4.8#,BAB4W(UE!YT5=
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MPBI3H1Z/#B[K^/EF57KX38%AN=C_7W^L]'^O__K%O3GR_P!02P,$%     @
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M[[5(1XZ3L>ULF$#D&#+1)+Z4IV,E)VOW7'%Y^-<T"8\/LQ_Z)S^K+,H2!K#
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M+<+7%R=WJG:GW1'4"X[ /@CMF*'HBX VPY<-ZSC+AK5#$2B F6]' 39L&$4
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M4FC.FBEZPR T3SI\[5,_90U!M4$ :GBF"8)^;A0),2MO(O4]L:;I9L2\WMH
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M.GCPM>O@K1OZ7RT4O_&V(J2QY$2$9(LIMFWO,,@?3<L!!00)  %EKNK@O++
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MG6_U-Z;UY6C#RJZOSCG^*B=OXYYJJ47Q5L PH9@.+-4V%#B 7%VC%;;*#_1
M[J\+3V)&4Z<IL^3L@5;^%P.B8_OMO#6#UU\'5G4?F4F7=C3CDK^WATL 6SO
M5!A>F$71*6-$\BLB]<S&=)XKP$%#=-GXTL**[HHORV-*CBRZSUNT7 D6;]"I
MLMY_)DUS"W:"!Y,_>MR@TV1/O6%77=H[M]G/_NJ];]9"SMO$?=SUU#)UY(U=
MLD#(8MN.(\FYI'KCU0W&"6_,,*INAREET(57^'V*J7WSU43DJ1KD:I^$PQ9$
M0];/<^<7^A,'VWE="TV][O==AM*V&D1I(+ZT@INR7]!8XV?#A$W9,/X!IF[C
M?3VZ+7,?:A(_B5K*FEGH8P2!V#\LXBUD8P& B(:"AQO;)DLD)[!AU%\X!-.;
M-L \LL'4T0/<Z^71Q.L09-!F:##T5JOF/J>1@C]L[<14*TDH>T?-]B AV)D&
MA3P7MJ/<7! B\U;0M%>A:4G,@\'*8ST0LQ9U7"6N8M6G0&$0-5W"L,%,-RH4
M]CQ)S9]$#9J6E7DH^#8U?TR7O7)^R%X[[B)7J2J5Q[(P\(],XAJ4ZA)J&^T!
M+BD#-\_RTHSI W9],,P1-%2:8B\1 T(G%BAZ26A3AB*V[3K:BP*7B*S"JG0:
MNZ-B$6>':W6/VM;NRY3=6,PXJ.+S+',)<</-C3,UAU".).=@J18#DWB0?Y&A
M (%]NCNMH(HDMF&NYW:\I$OI+KUG]52I^]/K\:9'][LIO4A6+;A2T5RD?WKC
M(\;:L>G-"_@GU$/(5"$;3,E0NIK)0(<>H(%@2F=Y41$=NH$7,[<C [VH1XRW
M)DSO%6=\+?"PNW3Q2*7:Q^"RC%;#[8AD)#F-*(Y1P;9IF,5 YIL&VAC10&'W
MG#J04/:ZN!R-HH7$[XQK'2"YS09YV#8-/);NNWJ182-J;@O3C9FTAD7R,L47
MZ+*0<0+!=LP>5C*6X@=!7BCS\J'H>.9%T@1^DA3$\"F-P+)ARB :]!ZHC<*N
M*(3WS81,'0>3(<IJVD6D6@X .C;YTJ54"&/"F8I<"V4H[H +9_<-__92ILY.
M>)SN82EKQ6U]N'2A-MSL*E><=^P2"5#18XHAR3BFV#"E)W$;S\.T'&D*7$#(
M.P2!VC1,R;7L,GV/)+.\Z.@PW\W]%W12+3-M?=#5HF_*Z,62', 6XPZVC8"O
M1:XQ:((7:#(]>H"N<?)OK A>,L"D/LY,A8 VRCE71UV-.%\MZ">X<N!0QFK*
M#>M/J>C"%W\,R'JKEQFND*,?05[!XO[TK DR[@([](+<%<KV)F!K3:1V?75Q
MO^WNZDV86)UG7%\XO:.KP\<9UY9T-(A)C(%RTU,$-2""*=&[X+AZF,&QC#D$
ML(J]_%KV @1"#\&*XL&PB5\Y59DN)OSA@TN'ZI#PT--//&(+PO$SA=O@_ZPW
M-?*(Y#=8ZEE'R+G;SH&P7Q#C\TW'&$3FM&&4ZFGY[ZKGY9CJG^KO%A<9[1Q6
M$-UXG.958JNS=""6;Y=_7\Z2/#  "E9#1<9Z'$O.)+WOA;B- ! -3V0ZS,,E
M+2E8@;:8@].FIBLI]HU/&C["XC,UAX:L%E_R3+Q:/V>OR3OOPI3) OE+J%P@
M7PJMFHQ-PY*?H930T:_0#N/K[Y[[J73N7SG_\ 15MW;&_(S__O*AI@S9&?TS
M%]^^$[>&[-XVCJ2>@T_E4."KSZ@&=%MJ.#&"@I)B7AF^U@QDW]&NBP^NHT[9
M3-UJ4&J7"PDIFI-1R)[8]Z6Q%#  ^?\>:_P%",%,:=:KL%! $\>44K$$9FEE
M](21W[8-PV&:9H9%,WZ@<EOGK:FDWT?MO\IPP)\HAB]+[;>X:(?Y"05^!=:'
ME(2M2UB]3X6# M&,PX",QTC-@*"_<&E@+CK<8V/U2/YY0=-IC\]7X_ !K32I
MQX5'K8X&K3K?X-BJ9THQ0/XXB"&T?9RR;45-1X/\/VG#W0W8E O>)L8I(;\=
MG*[%7FRT#_OH?-@F U?=N^BIFCW0+"<@PG>%5(:J,V:*#Y!MF3+1;20NI!\A
M'2ECYO\R4A[)J5XK<Y^I%:TH6/JYM,,_3&+ +'DE\4DXY<I,1*;2X=A=J,+S
M/($T?Q4)01JEP18.3">2ZHB(G=,?15^^/2]1'OFJX_P0^DU-;WV]1UCJIU1R
M!SS_QN;,(==!*0\-'9E5$J"7P)2RG1]@BAG3CP)6# ',EVR^@D-C+<I=A1-,
MBX^7M%]-^-?1Z3X>D6>MO) \;J!=JX9(9S ,B/9@Y59 M2$32[U%:$=.^H+\
M3C1<ETDWGA" 458VHW8V$*<<BF2,SPO;.S0?/E!>:?O/@ZT[B>Y2SU"FA<+>
MOR'9=X%:FCV$?Z%; F ,92V7&@!?$7F;\G#'Q"IROO=$P^&6PIOA[LM1UQ3+
MX[55<9_%M75NF7[D-?R.IUJ0H(K+%"/1]6GTN))EHA#&)'*+G@HTS@LZ:'>R
M85)FMI1F=;OYQI&#&?*RJC%N/]*G^Q\=J9;R+]G;B/LH?K>>*3-.P77B  T\
M4X:7/,"4#D<ER(\U4NO7[II$#C@-!J.[A]>#C=T=N0JDY.W5TUYNR3G;GI)0
M\3_"\1,KBY$I82KX0J)/ -ID["37O&\*O%TOQ;GA!-#;/K=W%!R4_#8;H+\T
M;MG^5K6"3VRF_7NHK5I$D*KQMB^JWZ4G-$4>RU2,A08@ RKSJ(GA5F]-/,6Q
M/>^X$M-W/BW4SHCF,3T=H+\L<QZILU^_-'U*+?39=^ZU _R($F2M!E-ZV(.5
MCR57(B%D]'@*M3HHW2S3J>V@']7DUZ+E=VTX>]GC"7;[< #X3UKP3N9US_AC
MK7)[$1B7GZ2U+C9LS^K? _^_KP8Q/%AOD8&.J7C1,%/[BOU?.CI _F]A=JOE
M=XKC.10SI>\\*8JX@?J^^=A72'$+]>()H,*&\=IBVVYACC*U@.E2;)LNR$U:
M]MXS&)]_A0T39T85\^1<;*YINJ]NE'WJAXU*JM7>N3.)FW579^5#]&$W4-30
M_KR%@4D/"(4#+QDB8 ]2+FQ  <TUV-THD^B3"SCZZ*X]$@PLV6R->W>UZ;#[
M+NUMU/TB%8'I@($DIBY4?7B%L6U=)'$V[)KCE,>\2_)>P(#JK!NNI-V.41XU
M2WS@[W)C"7= _%V*6M?WN<"^FH^XH,OW^.MGL.19.*!%8(KA*:0TYC[(WT99
M#ULXT9>K:3VXKI&IGYT(I<A0N[C:QD9=\Q_T4P>+ZT=>9VIVWCCSODTQ*-%3
MA*!:TOX;)8\ C*M!$3, S[B &?&&T30AZO1:&!.#Z,I5SO:-6Q@-(8_,JLA=
MBGBPCE"WN]U\(>C^Z:H0V#(4+;@Y0]K?4[0$4$29ML,4B^W 2]2R;E,0B=<:
M42+^RGN;MVSR;K(>-<P6?X%Q%KTFQ32E)J<<ON;C^2H8RU0*A60NIR([B+'*
MA_[N8JP@:VP[4:*169T(L3N]Q_7:_A14*/BYZY9_,S&QY+"Y0?K +;:?T$_2
M&A#%MNU#ZRX@ 6VH*E^F<8&"*N2!!/?U+&I*A_BLDJ#[>%!3\<A!;&7.R9HZ
M[],U)-_96\NI[4IO9!\L-=J"(A"Y>U"'Z45(@$*1]2!_!*49V15(TVY71@YN
M&/JOWTG,.7.XN/HL^F-GU\3J1URL[,^(DKV($A35+B;P''6<*19!MDVLR5?;
M6*]AP^[G>O75ID;-WM[OJJUS57$QD8M&Z!@ 5&U7LQAFV+;P/'HNJPRR5AFB
M)B%1SRR4,GTT9)LQ3CM7C;.HR37]>*W9%7]#^ML1OR113MG1TT],<Q"O4=00
M7J;43_H%5BD(0Q^%Q UCZ@\W>2!PH Q3LN8#36?J-4[2/5HMRVW2X?O7:H-C
M6R&OIA][OEOH/H0U1X9@D_'4@(1$S!'F":!L06^R=WX-W]FGT=GP6'Z\ P%_
M5M.']!@EYR]DZ2H2I&KTOQ1EQRWL<WV?$C5E8?X2JB#&6/(+E#S6+_0!41Q[
M#9568#AB=@(O1'(@4GT*R[QJ=D3]QS'H6VYRBMF'K53Y!A^<'335;'^ER4H'
M\/.,C022,-IJ85:O?>?N8G_"R]EEZ3\'"XH&WIP2TML_W<U9J;?O7,J]LZXW
M[KI\CV#*__7=9:"7H8^6!C(8*'0X</,V19"0$A%^.-*J(X*^(43_8UU:X%@C
M6[2[D.Y_$):*_'I^%O4DPXUHC26_4=9E%3;Q0F/\!MH6$)/RW9L+\^;YY,#)
MI@.YP?7Y=[(>[A8],$/HW\%]C1SA=!NU$#K+Q]N&E/Y[L@PE#6?<?:QP*-(?
MG@(A7H149#2E+D?TP^C&;T327F\WCVM<.H."<'U18RVU>8ZHSU#J58'\3G>\
M'4H<W$$C1/)[(H^Y]!Q0:#-<KCL'P<.[#4OU3K-UI2+YQ\NKRR\D3FFI^0JI
M7-[_-N,>&?<3UX841UXEX5#4L\C$%AU@@[9 ?P+@&,[V>XIO@<HFBVO]:;Y7
M)>+!;XU/1D?7"A.B>W]\_O")DQL6C[P.]A,WBY%=)(:B AMVWNO /?-[8UCR
M&C&MX>=J;0DX1N*#='ID;CC"5'KM54OH=)2<BWSK]/)7CL_2J_@AA>WAQ/P"
M];KPC*%]DCG:TN.F7N TA) ^8JMP\7]K7RZ**=7A/!1VC=I2^X_*,%J]0FY$
M8\Q\4*W0/[DS;J9>]*M0L]F;7$^Q."0,+515[0CH(YSNU"3*-6G,\ZOM/YQS
M<\'^O>R?1U(VCM>5'[2@FUE/6@Z!(RBJ;TY'(RY66;%E+-1<&8T:8;J5+9D$
MZ>IL+0UZ+8]E-=B\J-Y%!;GER77>M)M]P_7W< 8/X8_;1#_<]#3(-TA#V $D
MR-R=M/H.^!ZT?8R<N3SS=()3EM.0(7]%[;1"W8.(:%>S%]_<9V1_*&0[I[YQ
M&B.>09(GL;N6 ZTX!N\*]@]V)'#S OT]-/04II\-J[5E*F048UI)_" \LGVE
MQUR4BHS=QBK-P"'FU$GHR&[P6L?SC;@ON;ZQ?_;R@>PX1[W7DZ,]?7_&_V[F
MLV%?1##<V FD!QLV#!9:*#=#A0^B=0]N1T:# G%47EM6'CJ05MC9(D#=5C:H
M'4-;(>/DG#<NUB1/+:M7BNS:C<[=N=6?25BWF#@E1'R I'IC 77?U2U(R9/
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M2$/@P_/C_-V&JEG17OE'#KDVG5$S.7?+:>XS<859:U[QJDF#WL2JT</Z$F0
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M$]#Y_A%_Q-SN97PVD9E:_+,3 I ?6N_R\<-$]BL>#&(\?34N/%A:_.<PR,7
M5Q2=Q(D0PZ^==MMNQ<HSII.:IR'-5@5%KPB@%CBJ*V(UJK=TU.0_MEW^[_QL
M^.?$1R>!"B1VC+8MM^F+$P]F8!20 </=AJQF"ORFE<!9FZY#6%F^VE,5M@X7
MD!89<$4PMQ9 ?--K,0\7DP"400 MP(YN/@&L2EKR8,+LVK!#^77?_W:#(8=(
MI[##2Q'+8^+<1TH,&1*:K<&#R=!".'ZZ$*0*K'K(DQ,X7]80Z!J2*,#R@1RH
MTJ$KNA RN 6GC>L&%CQ1.X%93\C+'PPX080F IG O>I&A7.B_!.X+[^B].N
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MQ'NYR/N)R!Z+P\#<J^7PE:HJNLGI1/3VV&UI3L?J*Q(_G7AT!G\.A<<7:T0
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M*]4/M<D/,ZNB#;U79YF:8Z^O72_ORCQ\Z*=MOWQR%Q=M&3_HX;LRZY3F@A)
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M]BY1.(>C"NN!C;CH!<VC^/F'/%@]Z013+.P0X1N<_)<#IDA.!@_FB.F?83:
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MI,C$77O",F+(65:WWI.-UU+;_1';J" !V_[">I.?68-5\,WLMH6F#Y&4D9D
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MVLZ<>7515RJT-FO3(Z4?P"UC,I(IQYBGF8U@^-DR4$U YR1V%T.4,D JXBJ
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MY.L'N^]8)XV?[B0_V5)8F7O@Y[XO*QV/)V#K?8/O*11!@<H!/ ET,$KXI"_
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MSEY>4/[0B:@[JA,%!5?7?#ACAY8QU\FJLALE@3ZI$WXN"E)2RM.9?17G>"7
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M#SZ,O)LOT"T+'./;/QV5WD^]Y3D(_+W7>.5>]_,_4NEVN?\UBFC^9Q3Y7T-
MIK1G0W:W?MX]-(XZ2'+'/"_Y=P!0_4J[DEJ?;3SY/LUJ(Y99O=Y\3KQ?8)(G
M93.Y=4IF9.L;$9.35H?6O,S@8L6&\)@?J)\0<BEKD3B'V8+Y/=;-@+;!['59
M&$;>5C"+8).AN+]I07^\^_-9T-@'YA(JK^'KC.#K6MS_$!@S4'\KU[Z!!AHY
MV,2EJ&52..01,L5+'#?X_4C_\"Y_$[=C2MA'4AF0,T2D"A!IV+NP]RY]^?U
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MC2!&G_#(OKCG_85TAE7<+1O*]WC?'UX&I6%W!8C!7FBC([TS#%N"+^$&XP>
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MJ68'NC&= (X_83.14.3S]/M+\\'/S;[/KS+Z0W7^:4E4 QS<L'.N8S!P*0^
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M+DX[IZ&.-7D/*:VL59JWO*HZWP!MT8&UI\O57NGS#"*7Q@8F0G!L6,LR_#"
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M'A=8_8LM"GD/07[RL:V2@:WJ]8SB1LMZ4;-/V98[E;"6V K>5XGO_[JJOM!
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M0UY6_0K):)RVM;;$RS<"0[]'(15A^!#RV/IN)/!>((%W"0]ZF!W"%>I#&*8
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MI= 5!B;^UUIRM$7VP+A@;;['NKFN>F."8T6JMOWC8SN5/;S>3)77(ZE#_TH
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MRL*L003N6JD(K";_6>VENL$?4%)_>*0#^0UZ]D(DZAQCC?5MS'*8)5[G\5Z
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M">R#1:J1)F,]BJ=GTM[T(-Q&&(P13X(<Y\1ECLSBA2FW]TZ:FR^G.C0]:FP
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MH=M+G@<T]MYK]*DLI40$'5K-G?BJE?F7?/^CNWRW TL3L,JSXOSN!_+I-.&
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MA]1*BC/9GRP/C\ FG'0\_1]T97!]YW3H;%AM$=:)Z9IL$26?^#-8[L>BZ(,
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M:C9UVR7M.\H!*A\E9TX)01$%D_N;%XW(E"6R8T_:@$V5D,X\;QR0Z8=A\Y'
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MVEEUD'T>O3_P,HW"2;V5FU*O6H@<O!Y#GC85W:OH>DGMW!F/8?[8" :PWR^
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M'B.Q](6FE-X6+BQ\M==]&3UG:] #/&[7L0&0JN-L18%I5+X0.]6@ELB2TS0
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MUZL<SAZZL.F%]&F2VH9ESG_I>#/>4?2?QS;O9;'%()EP^% O<=:B$UC2"S3
M= 1J-2#,OGSL#HI>M1<(]FAERR[ A?Q\.6\:]G]%]Y;Y3U\T'ZO,&RI>[0%'
M)R,4)NXI#'!A4**?:@(ALX-X+2YL#Q&$B.0")'0]@O;J!<[K(68 SG'HB8BL
M2US8$PP79@*LWW56JO,DK<HW#;=,!%\"8R3..Z >R86]([(A:CJ$/VN"T>HP
M6(-"X2)J 0MVHZA0;;LQ((3M<^UI<H17D^D<+!>6A5C5X,)<$72HVM/0SP]#
M^G^B@]_BVY()"%&1+AP;X@_%<"842,N0@6=<&.ON;\\M]_O'#F-#BGX-8K@M
M *=L"?*V2GX TMI+$"[*0.7I@@<!#L3MQU'@\-JA/Y($-KYOV9^,7=WG!;!X
M()L0DVAEG_^&*K9_;/NRHH*#)2+C9H.'R'T[@&SOHX2A@(O>Z-F%P6$N;,2W
MLNT\%&\*J+O_;U%N_YHTBA603:@%J1D$8_LGR*G<S1#A?*@'^!9Q"-Y+$>T'
M_VZ]VSHB#>%I6#P[(Q)JVWP,1 P[!%A3F ? 7WR8XHEE1PM!W*F]][@L>':>
MC5U8)^9?$=?^A=593$A4\K+YC<#M1UGW KV8)K16QFJ/#BSP.%.4X&(GT;6$
MY/4[T[)BWI>7Y]6/S2"6?2K?W+"7CR=\CX!CS0$50<"%\X)(Q@/%\S7PZ$'9
M!G@$BF:.B\#S>2DAYU >-(-P[9.9IQW?^R=VUJ8Z#-47(!,7I%J+HHK.PS=_
MY^WU^J_-0D!5O>T$5=5ZO:J&ZU6EBP>5<6&\6X"6<\4$EL 2'LJ5>_MF5@W8
M$9/K8UD&E!<3[)BCB-&DGU"%[\D^^WN":^<G"IY]A0!KS->77KNMZA*F%ZM)
M"U*0+<;VTM_&V_@:,;O@+"ACN*/.D)$X2 =Z0"[?F EUX?;@*(&_\$ PQ>TO
MB2]#3!Q<L6 K+.KPQ7!APU 9X:!!# 3T:QM6G_[M*LU\"$:@S &5LA,8,/E.
M7*H2H;?\:1S.\CKQAROP&#2XN(.S@&>FKZ:ON:?]!G>T/W)9U_\FNI6BR"34
MJJ$@E!*N5T$=F::PTDG<",7/GS\]1B6MBB!IA#9\SFTT.YS$)(U!X$]XKE/]
MOP)/7JN\U6CKKI[E[MOUGWY(Y0GH^XDEQU7P@MLOOPVN3CW">2'#-%F_L*?7
M*Q+U&%2A[\9G7GT58%/>I3A>9575XQHW8MW,9P-7Z3_&B%.3/E,86'..MQU?
MA&7OPU%7&G!##@WXDJP:.%.A- KD<Y60[U(LFEI";)^\YS:4FUDD']MPU!?A
M)O_39>]/<S_VRA7Y"@MWUN'@6B+DY$3<9W@]#G)R*T BT.)[$:DXJ+Q:I"_4
M*SO _?+7XF0IDC1Q7JC%US!T)'<K[T.W!]^A1NB?9Q[ AB\%8/<PW1@JQ=UJ
MK'YS-ZT91$25=++PJ/W3R:GW"8Z2;S:'V*1"F?(AA)([B.3X8*TNE,=528IO
M6##?] C<IC"3V5I/Y%?''>H?MFYS4\GQ70NI4ZA0;7FP7=6QL>/381C"Y[<5
M.H$!%%1$U8;OH)S?#C-6<!C56&+H2@>V(BQR3C!IK^+WY@(]"^,OTSX?=ZH^
MW$ MD=M4^^<K#!(H  T-K!ZZ5\K!W6L'GR6OG(>M3\F'A*#&I:S[.!%K:/ )
MX<G,7#OSN"IHJI<+]!,RH%P>P8PA8EI08Q8&;(4%U,YVU)CG$RY,C'@$<KP.
M[==_J]K^%&HMXH!%ZI9U%6:PKL*(8*0U,U6%Z0P,D5@N:T(; OUP+(A8>JA#
M7L.\O'2-\!-*9 ?7R2 =#Y'!<BB7+%HL#?V?9*)_9IM],7\5CG4"X,QE-G)!
M\S9F'@+1!D0;HLL=2A&1".)C1^8$E&0<P!H+Q)I2MFD!^RX7=N@B9.1:-HXC
MV&/"C%5E"K/?K&\8]V0O_&<W ZWGOS^1Q;\>O_EK!@D9":QA_ ?.6-EIT) /
M@V68!I=HO/4 [U3P@>_%;C=+>]2NNM9J91M]L<FYTR!?<"[K\\=#Q<ZOX0_6
M%_9O&05J4%*]><4$B-XTD/8';^5\]DE>J"-/-!C]D.\TW,^NMVF=,-B/^A%M
M9G!-(9<#N1OY(9X&D8G[53K%3&)>H%HOY*^=#766S,)11'A>H('WK=-?G$?+
M4$X&NQ9Y]_)>?KC_FL6 UR48;-,_3A/IFQ7*P?0'BO6\+OFNK&P!\D7?6(W=
M&\7)_/2SLO0_NZ!C?;D SUIY*@M"OIQA6\OF6TUUFI<6,B4E5\3]"!'_9_TZ
MOD9"JB>IYMX9W-81,1<?=J@=X%/,SOT3#0H?18:&<2"%4H)_<UNH"2J@%&!0
M4?\4*^F_J];U=9=W^+UN6<U:/Z:^91'\0126B=L2CJ?Z?+(^-IU!,JXA3-7^
MQ3R0?0UIWANH):I2CL]SON&8^#&_<<A'7R->\/!?*1&*SB+I!C]MDCRM\D7R
MA8:DP %*V&W/+Z_A[T 1R.&EB*Y$<?;N'AWI:0F8I@Y!=>J.G^[97K;!VZG.
M:9\^">"%I)ZWIB%B;]-XV+:?'N[E)2_]PD*#>5UWT6F!&YFEU$J-:@N?Y*]K
M'L3WS!A=1M A2]_PP"Z)6<I30NO+N"/^;4'SH^C]8 .)9M(>!@A4J1";YAPH
MZ"<53A_\SOD5=#4F*]A-6?N\V6QQR:8)>]=C*''P*F'Q2WKK0!SLFA"9,(@A
M0_X[<'<TZ8G.YD KF[MYDT*&XL.]\2_L/QE$2T<X#]^WDM P$(91/IXZ\&#L
MFJ=EU-F)B]GC21[FR1UV;249\4!>F^3PU]M^M]0.=Z=+. ,:*J[6+7V&LH*=
M,S]+C5-S61BP%MC%A3FA[E=MX;P.Y@>[$_'[B@"1Z;ZUP+O]?J;NFONEBZJ?
MIK<I:*=[*N"5>%N?GE-?] X"6&>AV(0@V G#DM"V@-*(^@*/]S59<R],49*J
M:5Q5RF&U$D,Q_P1--?I>AN?XQ2,^/=/4E!^EY;^"#K..!M<C-@<K!7^U)LT9
MTUF,XGC*V\?IS$[4[D,-Y&W+Z2?K$UMO1[,B'SE^43SZ\4'A_!T>__DY"'(9
M-Y@..M&(61++PIBNAS2]FV.(O.]1A)SM#$7);?"47!VY.77"UGUA]1OE:OOL
M#U: ,V8#\>;<988'W6FVB8)]HGDS>U2=OA-/2Q@9]M_;4M+L$7'P_AM%_A/#
MMCC\+WKR-!=V"_D(59A43^COJ^'":)?@ TT4+SP\-&O4L.+@*(I'[UVSKZ-$
M6DG[7?&V]!;?#VKG?&5_\#R#'4L,]K;@,Q)F32A;G>]@GO#I7+OK.^U]/G%?
MR::5[<J>T>/T16RV]8+/5/&L/S"+8HG.0&$"-"32-/UJX3O\ BZ66K&-J*PA
M56V1ZX:'ZC;Z!W2U);N,'$]_<N3FS>,48POF*Y82A"T0AMWB8!@7Z/#&DRJ-
M3?KTRY,KJ<=Z%=N*<XZ^6<V[\43K&>QND:I$B';?CTM@#:FX;Y850'-C6#-U
M:3LPE=^+N##123M%9O.HF]SEV;6\#Z5[-8<D?[4.6M9:&3@E9 2]ON\VCF<J
M"M40(Q [U\=&$'ZE3:G;*SN72$)^:0PNK,XWZ?Q&5\&:;F&'FA.VL7WB;F(Z
MU^A^??NOV.8A$Q0P^L7SOMFE;BX!*=<+&AZV=D\8+C8:O2C/_.#Q(Z?(8CY
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MN'V\:?8"_>OZ22Y-SE-*EU*W8&G.R.0F$XHBLE-<>E#'#C<9M+Y9\*LNH.I
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M[P7-OI=_8UEDF_'RR(!DC<CSX*0L_=MXW'>L!Z9MA_=\Q?;90VXC0G05^[?
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M<OJM *N//H+?._=U&^8FF'M3"_N-SDPEFS"JJ'!A3)LAQAE^F,D%D)?F2Z#
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MG4GL(.9()P7>%#Z>\SSR?GA; /P%Q%3XPK$U5LR#"C.7X16H#A0HE9I.Y2D
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M#DPS<&<6*8/ORT#)PM7!%7IV*7OF-(D]5.@3*E/4:S&%]?9X6S*UP<#4KFU
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M;,EVM;F;PLK]=__'=<6N@<@:M73!+>+7)5!OM1T-[H2H&;,7N)JC+6P['P3
M39"Z"ZN%?ETL+:97MO'HJ?<M)<L:OH.^N1C<!Y_E<16I3Q+WI)[ 8= B=.5O
M$+1 T]-,H#8?!I5YP8YLVU8;-U;:3%<\KQTO6SO<$!SD$I-ZFAPVO3E;YH2W
M1^Q+I92'WPO"TU\\X3DOKD SA 5[V$5"*2,.CULD()8.MGAPU+C>8!83E5*R
M@S)HHMI%ZUCK(H1A, $'LLT;Q0L=:;Z \57<XJO]YU@(M@-!Y&B+=0P45>PT
MR*%C%G?Q,;P+8$^7MIHSR]:#V/B+-."AY5%%Z]')P4(L-LI@7 UA86J/36FC
M@'J$+N=,PNMI5A]/6_BMT 8T)]L)A[PL.4"[X+SC0M!0@?.[HC/O!AK4/ *N
M/+/L+,Q/XIY6D=Q9E@YC+ZD*)Q'U#G&4&QE$FBE-*'\ %&>:I5/1*<YI9D@8
M=1(\#=[F^:#]\]I'A%<@O]Y[5=W[/\<?+7<=M-Z@+J%\43E4-98;SP*'%#RW
MV_O\_<.<G!:-YPM<KM+';2SQR?HP=8VX#846LU);E9Z3Q4&W&0I-EY'37FQ$
M[^M"@]913A"@!:N=27%^RW%._$N1[F;TXB_=,Z0E#7^Z'*SJ2;Z6Q?1SZE X
MT8G/Y!O6#]]$JF%O#WJQK8H868?WV:)9<+E?RZ74@*C-^A;4MH^OB%LQ[U3B
MXXXDW/WOK,3_-F7___&'N\OS%0X!V\A;@-9+E.L0GRO]H'V )Q&/%R4N=4*
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M,")HK8,0\>_DD1'$!+5SRZY&]1W.#S='?I]-TX.@=9DRWLRU U$\(RR!B<[
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MGGW:V/^'5^SZXQ\CM?G YIB7>H7.C\=F)W/V?X6II/&,_V^!X,)^+Y05?J'
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MJ#;AW!/3@BUGOW ^E_9^[<AZ9*1P*@Z?V(\NF'X3Q=]BW4&0 .BE:#F*MQ1
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M>_N N(I,LOBI>$F$&KX778_B;ZD42J.?87G<.%"%=XZ_$X2S*]O)J%&<[=,
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MZSK257*I+ 3&FUUP$B2.GB+TEIGRPCG/ =A;*KGS6/.(68<7 _\DX6#"X+/
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M(?ZKIZ!UM.==^4NM!+0NUZ]^^DMH"58A1H 19YX$4LO0$)2,EV(>I2'O@BK
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M8RIS+5>@N(/.GMHS]MM'E;HP[7VBGZ6JE[C5?/YLPQUK/ZY$WX15$J!AS)1
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MBU&O79]_S[^V^B)I5&E[+*6P2+OQ3O;H'NE\?=DI*Q]P#D)(+=A:7-+?VE>
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MGC%\\6@%BM/3BF&A*'NGL6L=<3NUJW2)KBF1@?D5:3GKHE,QDZ7_-BAOZ<O
MUJ'[K;XU9<3(8,N-@MFO6CF'Y$8>W>.."RI+0BM1Q'@\#Q2228*!K;9MG3L)
M)VNR%A0Z3CR#X6-&_SOWT?]7;/H]A(N99\].@")!39:-Q8?'TY?C+LDZI3Z9
MUFU1,_(H@GVW<F_\_"^S_VVH E03E-ZQ],<T_UYG%#F9*<6@A[9.A73*H^]0
MPQ.MPVE2[K0OEEJ97QMNO9X)IS(E^+4+ E8DJQIZONSMJ3TTIS9'V&XD&&#)
M97BJL[.I'>T=JPIYJ7KN+R\601^AR=&3J+:$C&W# U:'P[MS@(Q@NMN#M5&/
M4_N:\K9"<AQZTFKKO57<;TER[."(>$5PG*"*]8^[T6G$5,+^?4'<"")?SF-D
M'*J69AUS^Z6R=]#U0<42=]>DZTMZ$@+['T8H_'T74@^5#($]//64RW1_'[*A
M.I5 [FC-:C-.?A:O(M<=R#")<A,PS[1;NAT_.Z*L_VA!\VX=]^57;^9.S?Z)
M!044&%? 46S]%;PB @9.RG7*3;5?I>HOG07.[/07"=8'QUGTW'@L>RY_X-HE
MD0]7*D?*9RO/P?;=^D*BGJX&AET  ]0Z1+6XO]6P84Y4;)<N:1G9VVRS(#44
MTD>RK<^MT:;,%&E_^OZ&RT_(1@E)/8W#D9J^K:.@+CHU0'<E&GL !0^YS88)
M'%G"*C4EF0WP=!9C*SR(Z!<C5>#[\[)+'O8_D_F5DG8K*EFY6'\2H.N'OC3:
M?F.)#0.,[?"T_"XOF5V$#O54+M6^BQZ,253FUVRON9,W_7-/;7OAX^_.<8<9
MCN G$E0Z@S83W9$<R$ 4YW04OJM@8:,RWXNW](;F#=^A4).%GK+!"/]9JH @
M!(JM[EU(8Q(AI%$#]A%J44PIC:6F]3G&&2S1NIWC)=H Z'C-C/S,U ^EX+D_
M3-9$#=JUW<QO/#NC$?)HG[J(KFO"/F$GZZLVB#^L.L*UX;FS]'@:;Z+8^AB4
M[?@[ 0T*0U\OOT>V5:>[P\JC<Z+,_ZR28>^J^H3$,6%UR946#67F!D,:'<=J
M(?A#6N[M:X.L5<-ZC0V,-<YJU1HF-@#W*-5PBT3#^D*4+==I67N7SJQA\=::
M^1][E#[Y?1,]CQEDE4",VYI5@9 *8L-@B#U LF_-6,/^8//M(BF:8=^C5STU
M\P8U)A>\+0<EZ[J.$#FZ6O_)2&-^9V4A1*)<0(%82-217+H*ZVE[8,02B9]Y
M!7"]!=E<D;B$UW&=8EI@_?6R%CTC;.+7O#W/A3B$^72U)S[,).WC6VO ^&"&
MBJ#$&O\<2[S(-%W>G+.@A[,(!(H=$]% RRI_P12E%CTBBUB<2_9H>ON@R_RP
M6VSSHKUWZL/R-!/9?9D91=[;+Z?Z,-RT-Z5O +[N(JO13?-05;-DG[%MU@F]
ML/K&0OG>;WV57I(?%/*CE.)S3-, +E D@2::2:X&-*MP1#&9-;=9; I"%-CL
M]56A_2X<[SHPNGEY(BSL'^=FG %_V;&\=^\027</0]A.@'$KJAL4Y&#(KN+E
M,/K Y;'C-/!>=1!"!L@L\> TW&CH0(3OO26O^<C^K/)S1ROKA9;0-MS8[]T9
M"'"/><S_0-;L]%9G3:8>^HS0!\<ZS6B1]_T+':16<YW#0W*TL?<' HV71#"I
M_SGQ_$]H?(D0T(*6Y$OJ&HE^^ ?RSYG@!?TN"%L7L6&_CO\.9ZC^QK/TS'\^
M_%=E_=O<NU%-D4SQ8?HA5EF[/5^O,2]:N&[,VJ^*>>JS>;7J6DQX1D2<ZF$_
ME_1S34_/!EZN;78H;<V9N2:@=T0M.\$@9?K&CJ$T!Q$S1*IEP]99##6T00.@
MSS!#ZXZB52CIAXH"MCO4);ES$19#^C7&9E7W6AT5_ME0T.%\C3[ RF;#_*OO
M8U696,;I*#[*SHQU+,W&PSC+VAY1$1EA]"S/53[4[UR1>]:,I&G3%2'%1NFW
M6D=4LVUAT2X;B0QI\!.R*;^K+3P!6[\9;Q0Q)-KOE>PQEM=_H7VLK&Y\CZ-&
MVE>]]94TVPC/$EC8;.0_";Y.C'U8HC267$2J3>YS<IG5>$<2:LC$]L>$B(CB
ME@CP*,+IJ;#M]]/[U.<V<BUMIJ\IC1R[^Y'K4@K2P]4&?A"<05)/H*:'Z3]H
MX!-:Y#+^?KNM6/IVG'R@(C8-K;,<YV+7GO7.29-T37OTMJ/4QSR[W8D4@^NV
M@9A> O4D=KKB+]=!U%5A/K)A?%/.4^T.,!H\/2+3[<>YB=_[^"_F+/H,:+:9
M</P:?RWY;./]4.R*-,=7-DP0>04[\X.<W$=*A=?[0\N93)HI,@%:;KP<I@EY
M@I-M>(B^\U])^KQ[]L3(D95^L_24,_OF:N=2N*/R-^!04CD*!>EMS#A!KH&0
M29+$2 4?\"*E:V0AE77N,X/+OT]VZAZ7/S]NN%Z69960$=_#%\+\&/S#2Y=+
MC%+6[0)#*P'88N9>X#R9(28&A'?_0;M9&J67SJ54K6\LGRY75"/#^,9_'])N
M^I\,#*R-08%--DS3Q8T-J]GT9,-&<WU7?>4@_7?8L!R="NST3B4;MNI8??N9
MF"HPQ(9I?"3\WH3_>G.FE9!!^F4-L6I?J,;M7='_A9X#[2((4'G?!PW<3OUO
MSOQ'?0P\K,Z&O0EF5GR+^2\_K3<?6X*X;!CXS-%6VGWNWV/N_Z?&0<%27;"[
MZC%-+%S,,/BP8.?$[@^Z$'4AJ8IZRZVUI8#B$;7L><'VD"NNONF2[QP;QH^
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MI!03,09R H[?T@26DI:"%;02[]<(6QV].EUIV@R+JAYMA>F^2/L?VJ@$0(?
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M'>MGM&I"*-[H82.5T+2A]8_<-KI:'3W O@BN[ I5SH30V%?,CD>B>%&"^3O
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MT^3?\R1PT&SP)[!]+W!Y@P=; KS!@8$%=#6N!,&L\ZV^\AKYH@),1O\0^JP
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M>PZ5&G[XKDPN"I,U'2M_K'S-MZIW:AO>%)LP@N1N"6GDBX4SJ;7#6KQWY1N
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M7]Y54&AQB']\4514ZX0Z7,;WAS/BSZ2E. 4\/D]86JH0P*J*TOB;[BKS\1B
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M.IV]YNSH)>4SAW8KD_9,C6"VE?U';FLD2@&>P#3R4>7V=F!DTQR^*?=K[;@
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M&6LWB9KLW0A\V8;DRL!G441440%Q621+ +O7POU,XLL$UL.7Y: [/0WG*Q%
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ML8G@/MAP#F"%N40(.1WEE<#KFTD+,?N].A"M;?*G;+(^['-G;GE[@\!FLD?
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M-CO-E4^I.(N8#B*:;%^N.)P%1M?5M\RMCJ;-&D*2YNQN;J:)#><@T':T=5]
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MJ?"L65@W;5EY]O-33N#CY!2G/2K8']_[.!;5('""9?E8-67&76+0\?4CI-'
M^MCE%&:8;H8@.KELP=7^X;/ O[^OJSX.]0^\FK^GOB[!)T/_UP6'S7BOXS+_
M:@<TI,F'KFUI__LT#U]U,;AG-0G5X,]P+(.,N+DX:3!9 4@BL7?%!Z&DZV,B
M/UY:% D12=8KO[3=UG_OU[]V60A\38*IZWA!WS02DE'F"9:P,&VT5Z@T31.W
M8C")(N$&'EHP.$NEA,>6N)O?4+KGV*OH=T3K>?M;A\)7WQ1')AXX",RI,0[P
M%S.X^1N(0#RH_'4#L4QB^KNV#L/<C)8"9U*YTWW0 06[?=/A2Z:W5D8#UYB]
M6RQ-'DU/ALT[4Q,<PD3^BNV;)J8 M2.0A"Q/:(Q)HI#K29WC*-$HX)V9V-\F
M>Z-GA!C5:HG!X!6?^(1$0^#IL\RX<7Q)K #RKHE:R,P!K&?H=*R1J6O4W7.+
M*7YR;S*W'ZK:HY!,OV9_M&H7 KH!9\NPA>CEY%=.V;,8/'I3/8JJ8Y?629,E
M7^F37:+MT#M7.I4[_&OI=XU,I&"[4K+*89LX966QYKC.FX0ZJXZ^L?Q_Z&%"
MX. ,S,QR>C DYG82L\BFCOND^<+LY)ZIJ,@SF=+V52$*)J%B]7/9JV'+TLVM
M(ILTO<BN!W/(TV28@9^)E>TT$LLI\=^[W=;NY!?5E.2%A]=.0.5;?GSC"87.
MHNZB=P'T!IH"S@ >3,-?40SRY3^MXJ.!4[I?3$R+3/%)]62E_3]T,7Z[AS)L
MSO;UVJBD7[.?-VX>BN">>[ENGUG\?=<5([.$DO$Q5[?J4:V0/1=GTV.ESR,$
M!BK_KZG(_[]\"73Q:TK]T:3Z<]-V;B 6+'JC+L00(2E9GJW!XPV$=P=ZW?&&
MA[1GI2_YQ\&B[SB!#MH/LPX@6>.7%9T 91($-Q"C-5X;B&+6R+=P7#(DN8'(
M.C*-XLAHHG\5&+&.DKG4W H(7\I<X_X@@\[S-W\Y6F#%UU_Q22\SLA//7[QF
M/-E D,B=H:.>;&/8?_U&H8N-H&WI]\C&%7(,JWV0,A44%'$@?.=%[2LJ\EN;
ML:?'QMXP)N,6R$P,"CS00.!<!4=F#-_II*!JUY)QXI ':!,;*(#'*8$9/)'!
M$*6AD/TMO?43<AF+ A=4C!+H18@+_?DS5:A.@+2: -#I.N,'@5'C:5E*J,S4
MAVD, FBW$.CPE')?2-OJ8X%17IZ?DC=Y?UEWNUB=J([)$SC#/ADW@T]!-] 8
M7IP3N%&2S7/<D&SKW@$]SV2"6,C-+Z17S.'TX.#:,UGM)TQ*UZ=FI-+3VY15
M]_^YUC:'X.I]T6<@S0^E![O4U7+./-< ZB]IXH(+4IN2)Z8H>23/;$^FW>JH
M,]N?7T@*F0Z;1A:2<GLG#CFR9.I9V1T>4LR&A\2@2-7!MO7M!-VV4!\_J3!U
M4G9%7462]X77\D\) FP?[N/F&(X_G/22KX2"*@4U+!$GEB)A2ZOVHBOJ79_,
MDO.\[21Z^8XQ8]?82LJ$QU14QYD_V[P?%;8G.&SB"#@L[LH@%(_9O @B_3WN
MUMY44C#CD!P_5$-'5N&L>8,$$@WF6_12%/,T<6R6?1$,?]E3"IWE5IE8A-)#
ME=S:4+DWGHT'7D5/:[X]+/[ ND.T1,Z7$H$LB1& I&@4 A-C;:8"R7%3('X!
M58AER!"9I2%AM 42R8+8PU%[!W^Y"^O44O.79F^$;WMR+3Y44?R#X2-SC8,)
M?$FX':^&-/7=COY6TEY7R(_.O7ED_*.2XJU$1?%?Q =HOS[P #+%[% @H=XS
MA;</:UI3-TCVQZ0TKB4M^_3[W3"H\"D=VS_R6"UOW,E_6^X]G=,@AR=T Y5*
M]D.!6K@FCGH4AFW 0BZOTG62"8BO+)@0"(;K[%Y89V0MR3161O14N(HH5"0O
M#UQT#?#8<[[6HDE.)(%+:!6%#H$_.49 FT,K"NO!C&UH*@(H)T"R(V?;^%%,
MO<O"W^[CMC]VWE!D=N[Y)G_B28;ZEE]$MC&W!#+D^/)Z6K=Q7S2CIL<9RK8L
M6M)?7Y9O]MKT5VL5/?!521 Z2VD5DEZX\ ?.^K>ZPFYA [298CWA+V_ 2);'
M*CNXOY 5V8F)&PB8,F"92/2R*S@AEA-=-P7]U2LI6W<6;3LAUQF]1M$!U<LZ
M":/?>()XEB'["LNRS'25L86IUAD&B3);BH_)NC:4W% ;:T;'7KT[]^+U0]4S
MA"<7NV-F;J,]OQ-EX>=&\+IQ*&X\V=LSD5^_.>F3KF$\I"_66A&)^!.J?^"(
M/J-[-46[..]$0=QMAD?_OQW.C"[KZ@-Y@\#2/4)O\,!2KYD9T,6&H?B2+R_8
M P6GM=W/RWI^'H_^+>7H^3B. ;,\\MRI0?(2#,Q_4TG!(M.Y4')>)/<Z>EW!
MB8%KNKV!N%["D^-9;TY5KWXE_,>*#=]RI["+HX/U9Y8MQW",>7VW^MX3,EH-
M!XN'ZCR3;JE6['BZ+?'1/<=ZI=.\O_K'W%:<+WA7NMR_MT-HO9%L2/;&+^?"
M^)N-#G%BQ?E4EU&(FXCQ9@/;IXN4="=HT<>^?>3X9S<IABY]5M_R,ILGO,0Y
MP^M!2V'WT\G@0=*R JI=1PA<=4VS9*YU D+8XTD=KM+59=K8"CNK*X<^>"ML
M%7JDNQLCG&44*\_J84\P/=\1QU%TY^7 ZBC#\RW#9B9 .X:;5$&UD6L8!&KT
MP-72GY2=WS[9;"Y]=^W=M\VM.+AQ.8/O>N$Q/P/2L5%:V))!/4II_FU='7)]
M):_OZQIMWJ<L9&Q6_T<9(XTC@NLCU*E!4@2>$-F'XX3=^6KD-SG54\S$)9@5
M86KO0EDZ%^@A7ONFWH;=+7CH4G.U 4.E9C(/P17C-@!75N5X/61%M#\A 2?/
M3'S\PA7R!4NQ6I67:,UW; 7-.DV[GNYHWQ3;ORFQNTW_EUAB?5%0KJQ,WN6J
MX!M:3UK=)QSLJ_]&KUW:\M!DMQB.7W+.%? FP+Z[8P7P(HX2V6&OF\ 0.A$,
M2%EFA$#*Y7:AU[T";P3&7+_5,)@3N#?'T^B;1.)$NL'7/>6=H=0TMM(_M/_X
MQ0^)HS_Y&X=0S#&<XA2X.E/)V\[ZDI'V8J*>F'RSHN* 0LA<6/=,H/+-G]+C
M\U/FA[V3SV_Y;76.+U3YT0YS<>BONH;DRVYICW/T3CP)^W1<<9!QM2JTJJCE
M]=N, +_C+%O)1.=SW7LR!->([_%4] SR[@;B"A[4#.W") 'U(\N'647L1#"6
MN:N'THBF;""2/'=47EFI"SGX8[UC<G(Q[V'+YY++M9<^=G1M$3_XQYI^VU$L
M)A(27YK>0'02[P DG4[4)DB)FVYV&%+D/H:LZ/EVH916<;!*K-'\&5AJ_$QZ
MR"C(/#9B'^G-'<?#F$-BS%?"+RON(P?LS"\.Z.7$Z;L[44<G/NUMD)5\*>]K
M*AZ&NVQZ>[YR9#874K#CAP-N-D\7MO<1,S'>"*'., Y&Y32&_J0]YUVD*[LJ
MC!5EJ8':Z2'W[%6"[T5Z[YS$I/$VS=5CHJ<3'-?;6&LS^M_:5N,\]$%26:#W
M^FS[E,10?91F_M$W,<$NJA?!;_/J HH_CRN);2"2;XH=_$&S_Z+?8QR<UC >
MN*WSH_*G6'&;'E2):\[%PI32/(M3%IHK79N.+]HL:_SHX@E=@)OWF)O&WT,]
MZME.:!AA<)B+J'1/Z=8C"Z^CXCL+=%D1+V[H-<P$SAUV<;G[T.FCNK*(W,63
M#P^^V]GD&(&F%]($F@U9/WG"TAR8,K0I0E8O@YV 30S<[L4"999_PK/A%0>P
M6NN@5,/@KZ6*I[R;+$MO">N2#_</7S:^8W0;E[M@]!E/'*TN>Q;4,-+PV=HV
MS6;XE/>.'?(V @*IN*(7@533!WDY5<"VJCJ-QU>U_023C7QK=V[#>4 6W#P>
M7\Y+%:!7;R!J1<FO&N+Y:C_QZ "1%J"=+,G;M>!<"_@%Z01ZY\K<>N+T>?G5
MQ*GE+=:W_1 >)A]$PE"OG2')6G88]RV97@'CN4P5QR4J") '/2F>DG6G^IM%
M8E]<LBJ);757C\[]V2;Y<N),S4LK\>QK]TPZ1%N/"RQEMKYV4WZA/W=RU&(^
M/W[/6*W\9%/IX<^WO+/MA^H8WA]-;6W(=Q:I?I^<90:2K)1TY6VVDY4A1XX
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M1V+VU:.H_KL^ 15!3S<01^:N3\@^G)=[.W/0/NAL9,1UTJSL'X+P!H*BP!M
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MZ@M<B"J)G\ZD.DX)]JC[U :VH7SZ_WD!H_]__<\N8&/L?P%02P,$%     @
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M!;5J-C!*FJP:),P^Y%IM5\99X:KX*Y-[_PK1G&^D7[%&DT#&J7#(T*T;^YD
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M !_?I?LD%3,TI;?)A*=NKAIK.7Q+1_K /=KIEZ_BIRUB;"T\/;;W^1/+OBO
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MUF/0-I]S'11AFL#E0!2Z5G].^7/*B^H'[_,27OZPM[.SL!!(34^/W'+'B94
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M;V_H^."%5K>8.9082P.8IGM62L[&:G\[T/+]$Z&H41'?NO-90N_T/ZNE9Q!
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MEHA\& 6_0&)J\D1[J+CU8!@U-AY?#< Q UTY^ZIC0AW'U+7Z&K![K;:>:]Q
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M""S/_+L10)>J?=O +U6H0WPH,OWVCU#XGYK_$+DCO"/^MM$)W 5/BM#@8,%
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MT+%W3W*X(^6L:M'>#'-GL3*'&(>+.ZWT 7(:H=J2(YW?%H!8&&5K\\:N<TZ
M!33KQ"3?[HB=(ROSS!*PZMP)HE-B?4&.9$E)7M]QPH9ZP4!]?2X=T@X0PX?Y
M$N[E[.:68RW9\G,(8A(-*8XY-]5I4AFVV:'@^>(+18>ZP*VZFZ8W"1R@MJQM
M&L9RO-?>BDM^0%(F>"U-XEG]S"1<QPS:!:P)I\$W8!ZZ5J=O8>K%ZKH=]='Y
M<L']"?GR3LP=;8VGHX>W,E?E&.,L;]")@:<I=")2(I2'%Z\R49W]4TH<5(GK
M=.C]P4EB>7E-TU&8Y4:OLB,;/_T?]MX\'LK_WQL?22),9 EE*B39*EO9I@U)
M$HJLDV1/4LK(F$O)OH6BB*F$9!F[0B9[A61G+&-&M" S:%S,=E_S^9QSOI_M
MG._W^[OO<Y_[_![GCVMFKIEKKO?V6I[/Z_UZO]Z?;RI\26QVH>(C#6RV[4?C
MFM-D8AT_*-SVG^MUE85&[%AX^(]#3^#1P&0D6V[P1H+\U,*\<@Y:#T)U'!B<
MK<8,Z&>:4D<M^B]G#_RH'#R'FN>[';9?L1EV^.V[)$:=63[U"=!\%7)4!NZT
M1-0R?CV[0TZ2 [MKWJP>'&LIX7/2T>J1)C/@L!SQR'"1Y^S*.Y[#Y[;R/H&4
MK1%'=5D((R8E83=C=K-R=E*%O\0N)]TA;%U.$D>/-J=)>LPX=L,5GJ#FHJ\K
MGSO?H;Y_>C7^JOA0^B^Y=B]KC$ XSZT P\MZS(%=Z(Z6)(D:0+1Q4\Y1FK6/
MD5QY5E1$8*&F_!AI_&0/?J0ZZLATF9U2]>03]K-SPE)-V5+4L9HM8%#S34EX
ML-*CFW1;;]$L#JQ^^O!8:!<D]=& [\)=HZVL$@R2L>6['V1*FGPI* $G=-(I
MT1%>;_J>2V@2IJ[!;BPA@GA-?^@C@>J,B'%1>\/*Q&@S-F,4^T\9Z;!RZCV]
M)XNU<P[Y^NT?1UG7NDXHA(N^_UJC,#0:>&8#?Q,ALD$,U*1V-!,VUO/F;S*$
M-ZTIEJ0^=RA!WO#S%VN5H?5''$D=&V1!G77NMR%C+L=^%T#VI_@:B=7D(,8>
M="%;T!_"AZJL9Q@)QGGL(%+*0 VB]G<=\L+SF?J@,W6A?8N7I%_N^+>R,>"R
MY6?,BI\!^Y;J(UDAZ_;4RKVA @Q-H'$;TF-AQ&[J9@QMX2U2&JOC0ZP.I^/*
MO=GJX.L7WS,"&T(KJ^=G1D]-*S:=ZGR-4(EP_1 +6_O(G4WY"R)O]Q<6=@_O
M.^QO8]I+"G\7\/YWD]*K?#6W!)?CV*_QB_CLV;^=/!'XY=<_SNR]&?S]Y)\7
M[X&_-Q7W!SA;\?NIOSV\X]R<_'OU">!R.OMUS6+!WSX^@6=__0?RZG]O$ '>
M+4BQ0MXS"X<*WV%_<_;B=X^[2CRG^-N2[J(J%IH9I%@.;#MV]U<C.+4MHT?]
M*04N]KW,WGY4^M+Y'+A6T8O<YX%'4COV\:8Z:Z.#F.(:E)JY"FH4/:"6QC]?
M3'6QE&7N?SU0[,>T\]0- \@*I7VN0AX61]G='?=9:=([C_9&C[7-R[J!8?R-
MJ"IX$PK43:>7LUYH \25=A+5;M1/OLWA3:5MVU03JK(U&R><57MLFXMQK7RJ
MD-]TU"5;XL?.EDM#P0P8AIN+4P^M0G]%38\AN/N#*O 8(T60/CK/@0T;"1!8
MS_M04=;CKE=3?Y2*G&(["6LU)]UK08 J ]A-3'X.+!Q-\,*+-%/PMW$5'-@<
M0,E4SA%!F%)-(]U3#.+G4_:+@ ^#3,^YC@E^I)%:+4'=6;9 SY0ADN*2-.D_
M,M2$VZSZ'%U_R)/:_O:617OL\PPO(J]$5D/ZE:',7'L9L;-\NXX6'4T]C+AN
M=1XR> 8HR(1L>BN#2"*0MPXL6\YWR8V>8;?1^-)'\',&7],L*\::4Z=/9U;K
M79J_X9H:._S78MZ-*D5%SFG[AV=4#70."3:WRWR@*'^(#\VM$Z23?K- _PG\
MT.]#MC1B]0)E4'&7*FN"I8_ON:Z29I!DXS3_ST**^;0)@5X'HHZN[N,G!LXU
MN; KW,;].ZE6SFQH_7W(8,EOTXNA.;#8^=ZA%F)$D7ML>_"N H_W;]WZ5YX(
MK?VSX5YP0<?<H9A*AOTFOI1%[8O%X7>:G\X?EJ,9N_VVO-]FXSDL^QN 8HOZ
M39W/!AD)]-H23:1T'^\T&(<:B,[ZYX,.T=U-\WK"-JUE1">#V#RI0S$?LOE?
MX$__+KT";/A9^1Q3,6]X7'%,5\HXY_*+D#1YFD3!W^Z[?@/?^74;/\MPLWFR
M#8%&$0(74Q!BE&A1K:1AT[=#,L7]>8Y=QXRKTD]DS!R]YF+;]SGL77N=CMD/
MW]>L-,+D(T*IU)P5^@8PXD\WI]K=U3X0(?+:[;EJ;<S1?3;SJ?XX[^UV6,/"
ML:^_QJS]CU7]/VY5_Q/S%?][QV_REQ5^J?UM-K-U)[F__RZV$G_C#[&7L,Z_
M-R_RA^#*H@^_UT;8B@.WE,0%MJ$B5*P?\^7)OWU^P?NE]A_(4/A/,LS_6??V
MGQP#])OC+V.&48;8QENMK*C&+H=-?NLHTP#YX*#E(]&MW43'1-]1@*PX #7Z
M#.26&M+"#+[\KO._8I5)EL&4;TJO2E/&X_<8%)QX-X67^!B</?!YH/M K83S
MH?Z*T]UFP#V19YDS(58S(;; K(@E!X8$%NW_]J45N_0S![:TPH$IIJ_"OBLW
M>%;)>58A_FNN_)T"XC2);VI'6S+*1TURFG2C-AX2JJ<YOS)HYT^Z1A>;J5[3
M)KP\_*L+3?G.@2WO<>' 2.:F3(5: DM0BK#2.^0E^R?2#@VT@#J> SL:L<!:
MKIIBJSSX0M-YJG5/Z]1*BF1";8$J6HL']T_3^*=D,Q?X%N\E4]Z3[X.ESP\5
M;FZ^_:\^U+R0 _OT%/(-H6J(WU;TCV[TWZK='V2D,)!!-#82K9<^]MY]*A9&
MT_OG%9^&BQBZ/@Q6Z\>%2*N?/SKU(3H^6V_))>NW[:_D*3-V'YDE/NCJ/:(;
M>>6I[66MDHZ(%>V"O_33_\2\8!+& ^J@F5_G!96=46W^JW+N_SHO^&#5R _2
M1ST2!7@(W=<%_1^OJQ#]S;J*-[\]HSOMI$&:5 .<47@6JS(?IM)DX /2L"\@
MBZ3QJ_>;J$>T$18/^N#HFS,YL&/:2_7&B:T7]AP]J^@Q4:O4U[5/$]/M8]#M
MXR>Q"&E&P"^R"8G3/9$EPQ=+A@65D'!^0?PBFTFKL 5-8I(F,=,8\5]U9253
M?)6&3>,VCVO&R@MM&E&+![T!^N8HJ'$2U0AD5[Z+Z ,+66=YTB<X&NJ3Y7_/
MEQ28$57AV?_:^-7TM>;'0#>)F8;\S%O_ZY?B0-&A=B8+&E@W]F']3GI.)SVO
MQ_2__CI^>ZK?TE1T)'*:R[(;70RIGFS3A[]R[F:4YSVW_5O'-A4XV&&Z+J=?
M&82<KLKH_PZ@H"W$DQ8-_@U0J!2"79#H=OX***P)2EV$SYZ.3,LE;D'=T$NX
M=7TH\O0K0N)'Q\@[_,E^DT[UN4?TSP8I;96;"9.^7OQU\%9N2510(;$UY%:*
MX8/'Z8+E8ZHAF+;C2NI2UW[LV'9%^OO> >Q1=A<@@;RL 2JC6O'A0*4VCBDN
MU]<HIT#;C9N*[,,@)A?XO'7C)K?.YY?'S>DJHY.T.U.?Q(Q]/!,FU2$HX,%2
M!*,8RJ 2_2'KD2K!$S%J3>RCJ-4/2LJWVHD:ZSP0*0Z]8L7N+1L]60SS3NT4
M+;JK?O-S[(^6R:F[C]VL;_TTTR]V"!DQK&/+W/Y>:3>%GX?&8WT$=S\$;U(5
M:>XG X[M(%0X9T=0++>#+RV =H<BN1W])2X=31G7-,?:;"G3/4:]HSFFHUF?
M'B!"<#TD(HDMT,&08H]G)$858@=(ZY_0;K1'DK.W2YI59<ZB*A1:9<[P%=$B
MQ]PLWSSVF]K65QC9U'MVNEO%3)=:F!NB=JBJSO(E[ZA/7C'>ZY:0M\[K(J*]
M0E*U3MWK\\TU3U1-+*NP]NRWR%*[N0?/N1DO=H)+='/0T)\,\+*[Y<2CFMGN
M)05!@;51L3\WYDH=X*_-.,:(LU>J";1>]\J&Z<3:Q,!B/P!4$V%>BG;[/#>!
MO3AU)>+"D,%%L4%A5)O+KH:SCQU&3;=&$B4>FDJ?'S 3?>+AH9!B<99Z?V=T
M@I&W_O/EV#<3U36Z?D&K//38\O)(V_6B]X[,FJ/60QQ@8Z"SFQD5U?H-*S4!
M)OJ/+$Y1Y'7G5B%+;% CK$0_$Q\76<VP6XA(OK\C"JM9-<QL?<]PI!":NGDP
M5T'?$B8"S"7_'*@_1'$^X*?OV"<7O$O*MK? 7EYCBTK)V>0'%TPOJF2*'G&E
MB60&F1=7,?"UW_$-Z;Q/GA'D("''HZ@G%L#="V\7[KH(@&H,%7:''C:5YC^E
MU&*HVS0AT,\?_=,QLB\YSUY#(][&^8!6P-%U^]UW8JCCY4A[HRT8+6I[(Q"!
ME0;U)S.#XDRHN*BY2K]=RK*J:=6E"J+*AN^.6V7TB48]/7UWKTTF9JBG54W*
M66'MV^*%0(@!!X39]4C^6XB'_M!O3MR;$!+^C*"?7&#=,+SN#Y9Z06*2K0VY
MD&;(<9?>)4%@.X5"6O'!XA=YU6/WX._^BQZ#'90AIB2#K@[Z,XR]H [5ZH[)
M<?XT/S6XBS84C3$D6SB>C3*MJV+H/A"S\/13L/[<L>?^4T#EXA7E5YX^!V^!
M,=JGU49+$1X]+L$4[CR+;C@'YF&>- JWH[$(3)5W!JH-.U&;367GLALI8FVT
MISPCSX6>;I%]E&4G?1#_V$@*2T)1K8$$42^2I $OI"2YZ 89W[XCZIDW*/ X
M21V]Y8S+1?NQ@\("HNSY^NZ*1[JE6X6"U,X9J/DD7S-3J!S(Q?LY#+V#5[[
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M8+Q@C?!.J!:"0INYCY<V:JN(]R_/)NB83<=<V8'..(_P?7+!Y"Q=WD"NC:#
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M^$'N2\V-.V)$C&@:$4JR9_FB6UUGS_A545L5_8/-['5#_"ZMS?569_"780)
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M2,@[I2GU*6"@?EA?P\IF&V*\6"^X>Q[R);-*, (:=^JM:,>:!B>D07?JQ'1
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MDR4[J=X=_CMC/A2XWQY^Q^23=G699D"\N_$4TD.#R,\6H$'*4GABJ*0R*2H
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M?+40R-A$6.]#+.W%7_;/&[C0=\7OBL+FC[M2!!0]WIJ(\5EOM!,R\H7&Z3
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M5--XJ7#\(Y*>MV<1,7+Q4_EH@I<0>&2=803J _K=$<0'\V Q3;R.;E95=,E
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M(T^2J-;[6)09-Z_L_"XY?-+<[ 5208P(U.=868)/< Q9E' -FY)G.&QZ(E^
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ML/+^'7^Z.2F0]9;@3QAO9 @"<?&I9'\2D8'G'C)T^19KEW6A,?=;4[JAP)+
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MI^;L2?=_EZ$Y?20I(K]S&EWVV?R>*+]B.Y(Y@E[T3Z>NNC_[<NBP.5J3T-:
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M3F_2(M__X&<MK)W;*9?;1&0<'H+:.TGXTO_79X01P9\YQ!%4TLI\.&I.#8#
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M1ZJZ_&O[#Q.7PISZMAN?)AS?(C[;//23729$UZIA+[/+JHWH\R.382QWJ#/
MSOG2>5"_VL1Y&V2.';[32YZ.SC%-SL]*[IQ]]+K;)=*P_.TCQ3GIQTL&+"@>
M8GC1Y6=CF7M!S6'>*&W=3=DY4_[E6]]<[DLXI%P\:.S3<0:UQ2FJ?3Q;>J?0
M4;'WM***(,DS([N'D)\H%$9,#)-L_:/@I\%7UWA<X?TLJULE^&\6%M$I+[Z;
M@^9%9W]V9-3NPDQ2@[DP,3-(8 J IY@2_;$EF*#WD>0='.GF8]')FPY-OT4Z
M)3U+T.V6XY6T] 85-R[C&TS[E1A![+0EC!/=((*E0-EC-7 &M!96-0ZFG'E7
M9IB9T.X4<[+8#E8T_T@9>_":N;"F'W,#A\2%B6K+TT4I4"\CF?J@ 1/>C!?2
M=C%)39%CUW1]<].(&+]T^EJ(T7:-^H&0<BT+[:@MI '4<#EU8P;N*R  !4&D
MOOF11JGC%30-?+:[SEZ:A4>AS??O??:OM9DV^_<A#_-ALZ7+/V[RN6GIWIVZ
MT^\R2FTL]?.T@I*65[]Q\N! QY/3I?R!#X[O2![/XC/P35<XJ])ZZ_K3E/&)
MVE:;?)(Z+;;QW7P_P.'/I0TTD85QHAYXWF4D#$1> K9A@&:K<773W>R"39%F
M0HWY7E_LE+13-K1+7VUQT8Q?PH/*UO=92IY0']/ 2DJ;]Y9I^H_RXRIQESW<
MKX50+.UFKN1TKJN\(PDS75\Y _!ROA++ &H2+7<TH!'15_MSQ#5$9T=95K 0
M&'NI%&_10_ :OG1&0:28^&3GK+Y<S&Y7L:/-L2P1Q#GV6YPF:S<]8)9 DV'H
M5-'UDRB>4MU.]!QPQK@HDB]A7 [3GO\I0N;*F4VS=P+H7[ZJ(]Y</?C\>4KQ
M>$ \)7[%O*MT-B'QA]MS9.F-A*=77Z9_JAQM$WX]<+F];S"HYYT'8]IYB52/
M7)'3@91ZX>TV+NR,W!5<-V<'C0N+);H(AN,VTU'1:;2>I%R,DD7)5^U36E=/
M'!=3N69=@=,W6Z?<(*.X^4.[(^=#ZE'V*ZS)<!EMLH74AYL9J:[:^B#Z=7*O
M#N)M-U!Z4T(YANCDLN O?!Y.2&H95/\ $D9:J/),9UP]1PORQ%.@Z#DP>!0N
M9.LA[H]W=\W.[*[2ST\QRH@3DUNYG#-_P8C?M*V_1N'B9(/M8<^*&G&T5PRC
M=!45W#%Z^F%F],333K.G7EU1Y0%5Q1Y6,^@!%^PM@&D-+BQR^$QY9ZDWF7O1
MAS VU7#!!P.4[\GV=;3Z;SEY/*AO*IR!MW<.KF,>98]LK2(: *YP@2F'S>S4
M:MYAH@!8B]P^G8R\I_9NCQ;J0</^S U6CPWV?'QDN$_OPLH&]MSK6KV:M7.Y
MA+6LV8_&V%'(D:'R1V .L '/9T*)P**R@"O*FWIGH[&[#2_'*B=I1V=,CD]F
M!MLSE;!B5>Q4I,L\#VL;L<?Z0B6M/-13;2;W6QV?6F$C3Q'/!Y.^?L&]-Y-'
MVIS,K-Z].\MGW]3<P]12XFC,9T]/JF;0>F*5[;+EW5K/3Q,B2@;?^9YGN@4L
MF>D%&;1O_'V-*UED%94.?)#JXM2D<V%?]+"HW2PU@#K/+F'+-Q!CA:8%V17%
M>G\$;G^-QZ8\_\T0[;^<;K%'O<>OJ#CL7)M+A]S,0,XGOIO%MU;R"(*Y>Y:X
MY&.UF_#3?17YX<=[@&C.A0D#:KC0#CT1L(,M*6)GL[:$0V8'&:VE)Q1;EN)7
M> :YL-X2_"I?3FQC!/X]J9W_0!K1 YG\QPI,M1*'W^(E-IB.G+49]11BN-N;
ML"S5\XGQVR)N7*U-_7*YT6NTS/%#?'YC3L5*C"'J6>1/VW$=M1F\*$MS6."%
M][#K736B$"9D"&.[1\"ZN_U^P*.5>^UZ%=\HQS2\%&W.SO%H6QT-5WPJOZN_
M"FW"F)[P'?YQ-N'@<\H3]ZR"?IU:>])GTK<?@J!L0C'3#%VUL3>$.+*>?B(K
MHL28$)9L&B5TH6,9C0[/HT8]UBXZNM.PUX.9%F>P:"PE>90TO8Q#LRZ"KDPK
MW!!. :QAZ@SA6ADZ?#I[Z4#H'/84A;@#K*I?9NU7R;N.]\NQ30R<DXM$QC]-
M>_ T-U[N#K.<$5\--F3@2 XJ0-_/!O,9G,;Q#5\P#A]0IWC41PF)DJ^-!F76
M'QER_]ZP=[/D(Z5/;;+3%MES;@5S:92AHLZ!LKQ:IE>LMU84NB>=2;IMM#]3
M71WNKX%M.Y/B]9/:7FSP&2@DLIR1+&'>44$JWE^GXR5&)7&DI:'5[JF25[V]
MON]LP+D&=$RVTD%, 6I8L#GV'K$(Q1*6841U 6A!,?=4P1Z6<]YT/_$^RX#R
M\$%9>;>OY=W'>T,HY_8NQ&Q_?4KV"L_X\V!YYF;.Y^V<5G*1=T@MK]'.K0;&
MG5;VMR]>&?+*/*9JKS'R8K0]P/(84O'-U,:;7%BI?!,^VA81DT%SSF()N4Q2
MFL.VF)F\1'>@^VT>S(EM6HJ3>%4[@*9/7 DYMN>PP=L7RNK'B_R3O4P'?7J,
M!FW0F;/XN(T16>'-/:\VWO92%!B*@BM+7N]*2"[UKQJL#?M,?*O99$9/9V2P
MWZH)]E%LJ-I(RD-C>U1=<:"IIQ#*!*V]B2/]7L0NZ?0G./Q(CKH60XY= #@)
MWL/3SG6S4VL/SB0[Q%)J> V[?5&BK"-?7_7EDG^8&Q^I%G S2+JQF'B!/Y0'
M8Z[?R=L!O'6=)=%U1W#9H_/]"$;$0Y-[%$23Y]6AQ4N=:A'WRZKV/,C3E]AS
M_!COSMWILJJ$CRTP5S>G2;*PCB)N0$JG6QTNB-6"9*#C@!MR^\&=Z*VJ%)<:
M2K B6D5!PA>-+6Y^':CQ:MN^"Q)'-TAN#\SNS ]+YX_#+4YV/:Z14YHM"W(;
MK/*M[#.OE1"-S-97\$&XS%-E]CANL\X%$U8S<;E!XD2:+ED,$]O$A=%,R#Q-
ME(C,A%']RJ^^%1G/XH;.:<:%/TG]\,!)*N20TH]<-L_I;L3LLKVI7DEE5=>8
M:]><:YEU7%^2?[%^HS.?^2D9,4GK4*P.N(<NSQ!EARCK;,.UZ6PKH1,?LI0R
M#G25L/6G5?9USV=6[APT),F&%V:[N_AM8<%RG\3X$+U?6#-6NHDN^3(-J")1
M2'1J->O([#A%:6O;@_O8$[QI,&T34%3S]4/TX:M.-CP:[P76O<BK?<#7QG<G
M2E'OXX4HKSBO>?3!N9EE[2B3XX&AZ.-/LW8W9XR[]%M9UY"=71?[/ )_-K>U
M*S&J(6NFL [2"'5*N^=:W@?-M%M0#*+S3R[D.6!"=-.5T]G7"CZ<>SPYMO%=
M7J3.5\(C*)Q7BNW79 1_J5:G\33 :<;YIG5#PDR?@Z64(.)#<;FED3%ITS>7
M\TPF!L_B%CW%CO*_/& )=[ </C'U.8/0+A^0;M4A&]]9$T?.948M6K<I^CIY
M&2KI=T:E=)>1E=SMRS.7K&SG/AY(>T<ZL,R%_3F0JMW/#D..$2'(_'9\D@L[
M22A#+ZYE^3Y.7ENY[&/"UP$?XE"CP-.U68 DG:^_;IYCY;"+N#!G JB(OUL=
MQ+3@D)"%7-AL2SK850>4Y@^6MF<U\;$"75]S8?5;?AZWKTW,R:1F?$L>QSZS
MH1RZ=F=4@GS@Q"0E#(+=^6V<+OA;$M0O]_""!^5 @,9/MG[2B#L2_>J!&A.C
M?;3?/OK-:8H!.DFV;8,5?^'.EL=XC=YJ'N9U**0XA_0FQA+YN;"189P.*$);
M'(ZIS' 3Y[V/VZ7KZ9[C463O_HBLDQ40J*BZXB/FWQRI(:(;G9?7&:0YN_:S
M7L5@,?,HR_]+K2H&"HP(3 .646%';?<DJ-12JQ(R8_05.V-S10IKM#YAH=],
M\4J4T4ZI;R\%"5/_QO9!G?WL"BCN(3H WXX/K%E9FH#ZRY/>(_B5769K9H^=
MG).&NF!(AN7#JH?L?G)A+26 7W1(A#:419$0W.4A+E?2GYHH3'<O[SR]I:Q5
MHTXQW>\"Q]9UCW_L6:*><-ZC >\;:9$*X;_O=_P]P8'UA=#)EN"<9."7J7!.
MB!(%;!F!F-\;H&9-Z^QA8?"& +4I^4!:K21;6VFQ;;2<E4#8!?E*2Q 7EIY*
MU$7_Y5DM\3YR*&<M_<9ULG8O4-'!A0FQ8LRA5M0@%?XV&^,'9P,7UNI!2V1'
M^:-6CRD]+2 ,FT)E\P'?6IRAHN/>-@'O3#LX!E8\[-5$,'TE?4D#*K8Y=FKX
MSPL[R7]>]KF(DSW'V81S@X0'TXS5^?\F'5WHTE8:J1&U^5JMFS&5T/.S_U-A
M6\Y@PV:;@T-'>V3=-X]'-N>DGX"M)W3HR<9]\RRO,-,3;OP]<PF*2W]? Q+"
M_;Y.M$(2@=ZG'7B N\Z.O4,<,T+0B1\A 63]">_Q:V&X:Y S&R&OPN_ MP)H
M3R?&(@CAYL9W]-[9\5P,Z7QY9Y[:H&:3K7^2<(]5QSYV@NQC[,"''I-%JJ-T
M]*2/QEQ! X</3U-J<#@*%K[F?,%O) [7P'<BW?""H..<D!W-N?>A[P!;QRJU
M!^-D]R'_B_$.JYM'-@TD/#"549^$;U,S_2;1!-!L4?U7$:!"?/E=;YQ<_V4W
M/II/ ^5;&7H#+8QQ^1PA0^[GG)2NOU=4\Z%KUN2N(^-8DS1<'4<8PCT*[O/:
M(8%'/+5WN(X^K$$VMM([6T8.E-FK<G;<?*UZ<C7G$F=$CGFC;,%XG8Q.>Y^4
M)0SW^I^?6_)/1A8,:\*$R+L55[V6BU+.N>MPRH'X^Q-4@3-R03F=([(")WT_
MQ87)5!N XRL/A,T<[H[]79K+_Y7"?Y>,!'T$47\A"HKWOS I!Z'.RA/J/TJO
M)C**V1G+R#[T2%-LHXH2PP^,IFL8D[?;N7N^Q![^(FK^5:7GRMA@ZX['&@,M
MQ=M61F_3;CF\<C!E0H.CP0=BDO18SAXHDN+'<X1(U'#L/'B9V _TP?N8LHLW
MV2G,>2007X[<KSGY_ )O"Y)V$1[#A16+-LX_[(]]C^@/XFP^!GUYE$J\[W!@
M";\'=!I>.AY_/U=MQWE*/>MRRZ&3J+9'"F839][?*Q''<_@\Z9,,=S"0?LN4
M_0+I@@#W&K20^U;;FD(!JK<DF#O,.NZ0 N^CNE2< @!&Q/XKS:K"I]H$CSB;
M13?VM+#\U+DPJW5<6&+-;=XUJA%<@G"1^@IH0 ,-TD ]1)YGN;#[*1P1;Y8<
M<H!(GT'T<=H8D/L!X,J"YCP7EN#@0D[QA 4#:XO%_[MFS_[NC,3?!@7.[5]:
M!&P7-D-MPZ6*#',@@SQNN B-UOOD53$"AL!+)[!BQ+/8]_=#Q;5C$R$>>6>Q
M##P2\S73PTK_[8#UP"AQ#+8B./7;N;"IJT4S%G6HA:/N &-[&!>F*U(KROZ!
M!Q,G>*O78'_S_XG)D 1(L82$8@_1$$WDN[MJ!<&[3"^0.+PU!8SK,<1Z#^/W
MV(&W&8$A9[.=&+D/%%OW4YJE-0]'&#)?U_14D&/@Q:3WI'Z[>O\A'O9+G-"4
MSN&.Z\N&?DKVB,;C/O:G1,9.W;?(.2I]/.RZIEG%%]Y)TQCB<"JJF RYC,@@
M*$1!L21;F<:8@,M=?1LYT06<KG[+S,'":]9FLD?J"Y+TK<1X]MZ=TKLM.'N"
M>03W&2X(>""V8!K>HV@H9!1<?!F-+&,_&4F,!-Q,5"^_[0GH.Q\]\>U]B!'K
MJ4N%?=:8FPB)'PUY1$@8RW'M7#2,-Z.6+MK A3W$TTQFYOL%1FW[^X8P/]I&
M"'6'*9X6I@;ET9[)JQ:%9E%\4MT'+TF?N\,_!GWQ-NL,]!<U0RSCO:]&Z!O@
M;+:FWQLF1SESOG!:P,<4?%_SB4T-ALUX'^=%[QZK0X%O(ZXX;&.\L "G>):&
MUG#KGR066I/(;S7#U>Q5AWOR/=]X'&Z29\D?;_.\]5FG\WMO.80Q3B.QJULA
M]@B&, 3^YXS#97P+ &-ITWL;%:I/ :]5QF(]=XKU3%AN4!S=;<6S5*#)$8Z%
M3+RZ"[G@#W .UB0[R(W9>!X84>S*&3?Q>7>@?\8$H49=0"+:C\JK-T^HW]S^
M?.?S%&N?6@*ABH1_0W@)C!BR$%S8*R<N3![R*,H4A!DR-"+G02SK!1ZR7SZ2
MHDR;9*WF<F%W('LF2,+I@HOXE173^41H(&+9>L$\$#H:C !L ?B*%I(+$S5@
M*< A\%A2!L9FN3"6/9R^"W.+$VS)A;V'^J:-A[.7 RD5I )[ 4(7P7_E'=(Y
M^TC; %(.$=R"7+D"-"(_ Y/CR%H4Z^[BLLB2X._UT3)PHM!0@8*#)Y BIOL"
MC38CI)5E:RYL'318E07!L!42BY7U$R*X1SJXM-J[?ZGN3S:-!1]J0Z)+!U*9
MPX>XL/&[?^SS7]N-\)2S BSPDKY:?T'^I<[ZQR"*"SO=PCE/XL*:((S:X1J&
MG.Q&L3;!66^1%/@D<G$!3T9P3JZL1J[R_EZC.1+RHZE+D!_U<6%@U6]]P,O2
M94UR<!;,<0A5X4@SU$G(B7ZO[[<^T4M=VS-A"=!V POON;!P8"W]_B. ):[P
M3/[X+3.YUNPWBQ#>*%?;C&"41Q[XA9\TC#_Y'?.^0-);U+GZ0MK;M\^#7\Q_
MB@/+2C,/#AGTWL@2=/)1L/(;%R6U>5D-]0Y-!ZA/Y9'!<]C#$&"_0<[G($<.
MTUK8FUYR8;6Y=YA"9ZOAS<2%HQYXQO84"$K59\FT9Z 3Y]X%@&Q)&3J8*H$7
M\=#<M<!KA'"^YO@EI&53K?%#8#![E?AARP\(X;;_G8I87ZH-:6&94,A5'3<#
M2X=M_-)'Q$;*Z%8O;MZ4/A/#V.]_ K;E"!J+8'8CZ8A/@D%IQ<!_OMW:,6TM
M#? E\7N<5<*WDYU_EOW>OS0IS(R."O526Z'VVMT7V^O,J_,RTCUCKC6NVA:I
M.46PXL)"(=?.)G-A"D0VQ((NR-47$(M"S1U0HA(I^VX$L#<"8_'(%1X:%[:L
M%<Z%3;9P3 0YA@O)2MW$D6=<V ^(2SYZ<V'7TSEBL9PL@ 4%N8R/R%^^"N/"
M+"IB.5A@[ LTK&(5TFKL_O2OOY6R3YX7^&+-,;* QH#@_ZWR?T.5Q;\GMK?A
MBPWJ)9"A>!$5ED4P93SA*'5_5+K-BI-RQ0P482BN&G"$X%N +QZ"S!^UWAJ?
MC\S."Q?N5EBL;W5H]R!T&NED35^62W0Z\BF_H[$EX7)[__2T<U_IE\ZT-W:8
M](:?3_+S"W*%/DQNC@S<3^A]%OQK@OJZ%>L\W&#M%HBK;@)UMC@D]A!XC*G)
M,F6_1(XXMZ=A<ENJ7.M0&TFY:"F>;FO3F#Y/;Y[K(9<.[C6<<]KGYV8SIF\N
M9A*LRU0%ZJSF 7?3Z'[Y.B/B<!*\%-_0U%/;A=^--0&-MR6]FN:8E$!MSOB>
M/QMZ@F/]])ENE8V,@^8U;%<NI_./W]\4REW[?:+31A#<\*'I Q1" RE2O"R6
MX(#)JN/LLMZ.WN'N3SNG/';0?*&[VT+KD^F6UB-W]SVRGB+TW>+P)]%=&3$@
M]156C*[)VIG.B 4]G?+8N20Z(18KM['@25:@1M%G[15S?Z4)M=.R[X_%7=RS
M>!*.ZH!L,,R%T4S;C&TX_#](ZB5>P,CQ'GV;=4CZ OH[L1B*S%;H81PV/QW^
MU\@0,]F\.RVLN3/C< [B,9S_T'%K%7M4L_>*E#,4SV&XL'B?^!4=3PAXCI,I
MP#-(/CI@_E9;!F]TS_HF<2FB,(QM"S'DWFF43F_'+CQ]6I1]"S6.<JZ'BW@S
M Y;7$?OZ 18(,0#N ?P_+TWT@M]"A.0*P??BJ"![560D5=725-3#+1(FNG '
M-HR=J)GX#6,7+MMQJ*;=G)/.:QN*[ORM!,\:;K*F^S^+>7D/V"X=(_A9Z<AO
MH&HW @QE<V$1N"M!B0Q_B"YT()8DOS+XY=K"#/7VKN O#\P&IQGK>\R5(4%@
M15[X<-LR)V:><T*."ROP9.4XT][J!*SM+7GTWQU$?1Q_KT-/,SK-*-T:M>_\
M[FN^!'O.YRYHR#7#F4M*K3J0@W]8%&4'M;)ROZ&7SD-R_['3V@31HQURT4^O
M2VD=C0\[77A'SUA/9.G/1K">E*KA90D;<_@/,V]C?4$S6AMCI5L'ACT*2A#<
M':2ZEA"\F-,??UKU%A3X?O/.(%96O-O0M$-H8\1V$><ZZ2.[ '=V$G$8#Y3.
MUPE"@Z-),!))LXJ-Q OYJB"H2"^:083VB<Q3SMF!"9WUJ4X#C46(A 79MI*H
MDK."&[[P]OC^6]O4I$[04S@&2<#,$')\;<>6&'$L,)%3,\JQ_&@]ME+.BIH!
M(CA7H(8%#O]M5R_I9;%NZW%AEWM7K#\O_WK7=R.LR8XSR#X9!X4M9;#? JF@
M)@PR&AB[T8V<W:O)"46/592S^_&YK#MM4"^._-.3T/XQ0_CG."K1-I5_+68S
M7HO9D*N[\VG$>2A^:R0>.D&!:OYV4E&+""XE<BK+%[)_N4RL?[\RM#8Y=_+O
MZEK[_.#\R2=::O]+%X%&)LKP'Q,C9H-#MI=.>A$*TD/EFJ?E;N2HOA_[&C^,
MI)F_4&5LH(?-MFK6QX(*YXLS;%@(>F*X+UMQ=J9_<"C)566AG9%[,6&AQS#Y
M6V!"77G)XU>*(BD3_"=UL.QT8/@I(%JKC!N04F:7ZFP&ZNRK76DI%^A62<Y9
MIB]!:]TNAT%/E5<78Q0>5C!MK%4-8X\4MTQ6O;*DO//N,V:(L FXK:S@+SA9
M+"390MK 14KM@]?L7.H0K*=:-=-NP"/5.:]C_XH*%X:IM:@ZI['L=E);Z/(V
MR-:;6H Z'JQI^@ FK %5&%_P*FNHOMB&?(EE25?^0I+8$F9@<BY78<]F6?'O
M- /63F/.9GLN;$,*?2B)Z3,-%ZC6HN&M:+<'7R":'>3 5WF!NYHI/6B;>"?B
M5RDQ^Y'4BYO-4@YJ1-<9PIAED2U@T"B9CV5)VQ9&UWUO2QA80NYT8_2_?A@\
MIHUR*ZF(< DUB5.L\C*P*+WC^'R[H$CAO[-K*Q;K G7:!&KU9^R*M<+_&A#O
M@$!4ZC'0J\ZQ7*SY]8YQ>2\=&G/EP 59R*>I=Y3J6.@U$(2 SY&/N*3J0'<0
M'$6M2*J;,C>;0*%,\LI!R.C^63^@(.G(5%HD>/)OL>PKS1H:3RCV_;W0>&IR
M[LD*(8[=@/AQ=J\@)U3I'_H4 ]7-V,[_"U:>_9_A)O$><D&["=+["X B0YP^
M_Z=;MM #XA@4>S1"0 ,YOW7G/_:Q65E'LP2&\1&U.[YJKZ/#ZU91X6HJMGWY
MRR:BMF]C?G0N[)J1+#R;%Z<PE[<YW_8 SS @"M15D&FFK>JY^6@&0 ]HAH<@
MO5Z\KGX+'J.;_SQ;$J>//+QK8:6C6?"GDZ79-_X9P)4(2F>QA(!A1&P^#C&#
MWZI.C)12*[S1HZ,,ME#0^!V#=MM]Q(_.F?9U-&#K&D]]'0[=+<*P%X;!8.__
MO=V]_Q<V_S^'S5]WG_S+$XJCY%][POK73L*9I@ ?/I>#^(DUQTQ=IR=B-6G7
MD;=L;+]MWKHTDK$L&Z1T[*"(<\4EQDI4^/G+!\>_GSSZ7?7KA8TY?[C^FWG$
M]:49&T2I0,7+$#D5Y2Y#D1T&YD;#_+"XR)C.N4Y.O]: Q)N)4,NMPAU'G?U.
M;)8)491HOW6FBR#=5;KU:H_ P]=-)4*7%:M;.BX^+Q_1>[;K35J.'7COU+NO
MXQTJ?N^,$(YBR9U:\>Y.4GEWQOSVZ.VZ8O>/";@T%>1H)V)U@OBQ-N#7F[;[
M.HIDQOR/#6L;M-]N_+-3#/V.-"BY)N+<5S9J;),]9.K-D DV95Y-3GUQ\W6K
M=J%*HZ"0,0_5=\OFCZF-KO>^?>%M0>XB#I>3"P,:@'XE ]#H-=9$?"[,6ZI0
M-*9:=V2>WZ,_X_B)04)?]9LXM);[OL3]-F<R!5;LA&Z:-"#/8-XQ(KJ$&*[(
MDI8ZP8T_R#MGO7T%@NT:CB,?[(-[]$H_WQO6NI/://[HV&#4 =F8PZADI""+
MEPE /:V@HX#=!?+"9UM?8=UIY7=\ 8GR$$(M'+SKRT9;=LZY%E=6)DQT3FN4
M?M?JVM'8/K'RS$HY,V6IF*'/SM(1QO7!B[,@CW&'AYC>XL(VDR/RANP.(/+O
MJ_97^U2KGE)4N%)DH.PCLU'.I]+\?4CP92_Q!YM/^R:J!2WN3RWH-=J?8KPT
MJ,$;R:DGT\P%'\)+450EN@3C*MC-E$!A97MKX5/)+MDJ99FCQL'F0<^\==5.
M=0Z)&&Y[GW]7!I^R04%D.1JKPE2"PCJ(1CSP3'D<Q#V=9YFO*PN_9/&WQ6F<
M/^S?FV<1-'AWT9LZP_1F8=B/\Z^] T\P^3%9E-+\Q%"OTG9OVR+ZUM=/7KO[
M,T;Z]9(I-\8^[-0(#H\Z.PI[$KD$?",SH/ PM(R=@.5C&@/U<*B=7!AK_Y!D
M>3=0")3H]#(0:JYMB]45K$] T-7)+Q?AY0A6$A(2MW*ITEQ8EV=3()FUXQW'
MS)TFSVEM#^/<<:_H3.!YH=]I7KK<J\\<F#MY"P41Z7 Z%R:!U6/J@BD,B,5#
M -P' OV6/6U'*#+<0:Z[VGY;Q*NI@",%2T5"K9+1?K?*YYOO! :.Q>6)]M1*
ML:ZQ\["GF$=FX#NU_9A[6EZQ3+JN5ML)AJ+IZSLQ?C9I8G<,LO-P%XV0NUW/
MM<3MOF8]L?:#D)H,'S8$P>Y4K5'V>!@UD1)[OTHJD:F+23KXDJ:3XN)W M6X
MK</HUJW@FWZ2F6DQ&N5G'JS?I.,H+RW.A-#Z&-,4>QML'R%' E  [B&XHP\3
MUH+<4"MG#QJ;T7'XJPG9%(%KZZCS4L(K^^(3;SA?@/77M%F[J KHW[_L_J;6
M&$6IK6%8>9?EF@3PM 'N"%!)DR4<QC  U7-9.'#M?)(-&$C%\T_A3G[U$V(:
M3EMOR5=KW>)1J'NUT[!=-OQ0CNFQ*3ZX+W8_'17!"J 1&G2.TLM#4 VVGXM'
MF$I45$.<0_"KDMSLET9R)4=F3=4:9SOFO[TKF_28Y*%X@P?HR#)3EK#%,"]+
M*, 4[D%CW,6017#*]<0CP2%U4;9^)2_]C IL.KZ,1NSS/LN<J"STB&SH\DB.
MRO2?'2]K\V=J3E_1UF6,L2NP8DPA#%R7^(YVGC"*V(TAV<>> 8%AP6U4IC_Q
M#7&?NLI"T\XM:D\T+-=)[OR8Q<-P8;\D#J?ACH$OO$>\^Q,Y?#\S0)Z&1(:J
M*3QB"?7_M/?M\5"V7[]3<DJ:Y)P8Y9CC4Y1RFDY"DDHHIRDEAPE)&!DS2@@A
MYZ*,"$E,<I@<QUDER3E#9I <)S/*N)F9>_;M>??[[N?W^SW[>=]W[_U^/ONS
M]^^/^V.&VW58ZUIK?==UK6NM6%;F^]>/#^]!F]0<3?BXJM3U()4_A-W< )F+
MNZ]G$16"\4A:&0_VQJ^%? =G$M%<4T4<)THTY0(%*U8)OSPC2SJ]I8,8G6Q2
MM=39-&M:Z?>C9L'G,$16V7KI.W",S ]N!E98%4Q$.R(*N?-'I;SD.',@GL B
M1B^C,5*>I;O>5L7J[I,5T9 9OA&^=^K^_IZ=*KHOCYB9?3I[<RASS:"R8ACE
M\G4('4U=+J(15W?JD]E"QR! %=M98L./?S>>SX-].8K@;G%X"FF'VX6@RNJ=
MQ?7< LT01.?!.IZ3E[O(:99_^'RJ04KPTR_HC7U_F8]CW4(Y,#Q \T?D^3&;
M*=<65Y,_?D/EWB!QXA  X5LX9 _7_A3-&?\9RD"9X)IP<J\'&K9Z#SGH.6O"
M=Z(U[Q=J[&6E+VB.X/\F>?O(I $G<1\/-E2'_U!]<@;4\/KLA=--[OWZS7U;
M>X!FNG&BK?/4WUG 33O2)F?7 MLX03='];<9Q_EMG)K2$*;D51]L7-F_*LO>
MSSG/?4VFY>.E&D3!SX-XQIE0FTV8E-9,?(*<-0,?42?Y?$PW_$I5]@?=UZ/Y
M$\9#^T[?50LX=!2&TE)7R5KN/M?@HG?Z;7\FQ2NR#KXG:LQDR?3SZ0'7!?]P
MHTR.+[>\017?)$SV1%+BFI#; Q]]8S04AN9BDO%R!I%UAU[.F&I$.^ZY>EUD
MI&E+@&7H=[F'^4D#(_YN\UVW5\]]#S@I6NN;F^^CDD_ ]WX]S#W#M&D,\YA8
MC^GAP2" P1R9P!6%O9B[S5\?'6M\<5S54+MK869;ES\LYA%E]<&]!7LCNP\1
M8PV[UB/*<%UX81[L*A'0,J#O9YC32M/"O')FP8V,5*9.?O$HRD:Y[VAOIU+7
MC1\+%X<3U?@.PK9JCN%I3\E2#3J<]6@"6T!O4HTC@6Y=RTXIF5&0K6E@^I9,
MW'</98>9Z!0<>..J+KJ+L$#PT!':Y_N)!R,$8@/8AR!#=W$=PBCL@%IH!#\C
M$,O=% \K$@,?CY4;=T$VKXUX!;?I_O I8=GL>!%>D^HK[ YCJ5:T]+358#+/
MU.5=J^]?H*0&D=+'#N.JAZ9)=#$:8BN^R0P20C76?H"184ALMHF@"M.8IGDT
M8I659 %I0F0DS>)J[87A4V5MODU)PN,#-<5OD<X<'+<4MQWL:C !_!C4"?4!
M.5N@<.+9. \FHIIU97I/K8:<GGQ+YX.-PM=WWG9X1T: NS H4)C*@_%G^%$F
M)Z?Z*9 +^P#JBC'0'9]?E;10@=\V[%S<)MJ72TI.'LD1HH=?S +.?@FXM,M^
M7VHN02]N:A%7];.R,87ER#@=\2_^VMVF>>3K[B9+'?W%>V0)4S%\LT\.<&CQ
M6_K(D4$ZT7%LW$?*_HJ$[?$2)?6#VA4P29@\J4T7V$WD;'^-"6['2_)@GJBH
M?7-##O-AQ4#>A&!<G3MV*-W3ZN-/+?!F_IOC>A6[7[[,>6<\?9_[B.,_3@;4
MU3A2QRYP*T'!DVO$YL1(I!!^7*2W[FI50GK-6&W [2'Q./,D\ZR=OY4KO7D@
M0#FBN3OEYS0=TBC\-MQXLA^94NC(?8+W0E%NPJ.HY<26IP'OAVX)5C;LR&BE
MGQX[9UQD77'*I^+M\T05X8LJNTYO4&P:*YKT=I-6?I[YP)E2O]AG5NSC=)J]
M\ 5AAV^2= -BV,?6L_N_,E9CF\UG@K6Y\QTN/5AD\;S#N98B;U>9$'=25=+4
MII,/W'1>T**$RM(.4M!3"$#=;X&^7B\<4&',.P-&;/ALT!J2;I3G_?H+QZ"W
M80>:\@I4CD!=?*CLV^R@>"7X49^"M+\@QI$K#UQF!^':LE6YJ?M1E !:8:N1
MR;%QO[N*R8,K9QA@Q,TR+Z9CARPFKVK;JTBW^$FC*\>6&#F3DDP41Z*/M0IQ
M# D.(-_ XTWE.=H#G/W,8Q-^<14A='#G#"C&>#)D.(]>*M#ZH>1.VM[<\^&<
MN4KJ&Z7"CTZ7GR@SSWU4,;5LUW%\\55YD956@O:K>AK.50*.2+?*F(IC7.%Q
MML?48OM:JJPFO+2K5GU>"(G358*8%9UDF4EYS4]XWT5*(_@>N0D>4Z<[WC.!
MD,=DV$:T4+=P%.-C]G<%S:161;]H/1F@14RJ4G\R?;!;Q8M]QHR]"6Q!"@12
M1_!G!WVQ-OA" -U\F]N5NGMIPAHWT7/V8\E;7X$+WZBJIVT.'BI%L]YQ[R'1
MNO&$*H\(,CIQ^"?K.:,C$M%DNIE@_KD"*861K7QTW<_7X^'7N=_@%:UE75H"
M(C>_*"N?VK#:%=+_HN]"@G>)NLM\R=,:K[ #JQM^+G*VJ]$$[Y.O$0&-1?HN
MQD@'SKB::1/KSH!'!J)D,<E3[PW3RVXG!H9H;!1X5S?K<N6PP)<!@7VBN&R'
M*8<%2\80:Z$/3WN+VE%B[,^VP1RS[:\@;@%.X^]GI&?#?C,GSM+]'OF4I-!%
M68?$,/O<5Q1N:"[;5W:5,O>F)/NT&^$C0W0S'O[=/D5H).GNK?2J^/BN:76X
MM,^L*X0CL79D.K5?],/_O.P0^]*!?]C$:/IC#82!29P6R<I&POM 6;JF_,++
M_"RU#8FV8__C^&WM]^.WG/Y7(V?[2O67ZS)'N_G:=;2IUY-\-_G:#D?=A+\H
MFLF!=R-BR65(C@06UT<6,5:!W$1^S4&_!27&= S]59T?LJE3>+_)UN$4&X<H
M]*.I"RK9@9N5GD[8VXI4*;N=Y%HS(E@FY=QT'LQM1'<8SK("(OW']U28; ]%
M;05(%_J4!@I(=9D.F5:SM*!X'?GOR9:R^^(R&BDP/HIZ:<U;RL!EF=J+09:J
M/U8LT624Z0(\W!@."5K>>JP (,AZR/2@VSV#)-;Q5]DD?.?L6EATK*X3*Z1L
M3Z#/M5I%LP=S*KMW8;1>"L\%N$ZRG6:0E1X)>+1?N((8($9$U\#O_J*'GAL"
M-=%!^R0JLIL'U<T:'NMREM&/GRNJLXMW)HY(_@J4F(HO.9?[I-='-:,FP^K6
M2=9L6#@D>*PY;@;9FTA);#F'X:,YT)]Y,&I;:DC1BQ4$*:]@Y!:?RND!MVH;
MK;1TIT>.5+%RXOLG/SX=V5B]7I4#M6#./@>V9LOVF4I@3W+?:H%*@&!+@Y2+
M4HN"=-RX>T.<=L3SI$?3Z(K:3,NR'>^R9 *^^WXZS[?,+YG99G_>).$)>3P>
M9*.8?),$67R3$02Q$9$(!4XPDP@*T]G.7@BX5L.>N6-VS(X(SD5:X.!U!P?-
M-];GNN[U5.A9F'K$DY3(RC0-XDM<$[),,!I_N3NRIB,RHV,M\4&=PR1<_"N0
MT0$:#-![Y>*#':H5.Y&I]U[MY>1H'7Y8]R2YE7 S]^DI]]NIJ\J_^G)KJX:"
M:DF/% 39AW M>;1"N@<S@]7")+1"\SS)L6:ZLMHU)7VD%^+&Z0J?E';NN.7Q
M*:5K$FVI+A8C*UFUY]-M,J6#%MU&3305Z,'N97BPDOI!&>\=?G'7 YVX'B?[
MK/OFI,Y(_[S%.JOO=,ZG,V/4_S6VQ#7/[%BK79K=V7J[],[<-WT^X0S=$1)K
M)Z*2GAB!1=.0L4-X>(,J5F]HY (0/-FI?<"HK_#CC%*V<,DW#9)47XY=LDGG
MT[CWL.(;""$D+1M9 8]%>A,V@U\0I ZZ>2'V^!!.X<*8$\<04C><W?KQ2B<R
MY_;*M\T76VF.GF:&Y_EO.'!WWU'ZVE+L6[?YYHQR&VO[#[,FO:'/>3"'K^'V
M?[O_IU-AK.:;@5/O*[FJ)67U)2VV:JO(UNC*T_\:=-3P%P5*'!84KY\/QC-G
M=;D!?E,7\7]X[>PHH&;IY"7C/';CWL^@L;1]P 4%! 0J)Q77M[5"\/0,M@/'
MA!N#]$"(@;UX\5O<HVSKSTJ1;GWZCR*^HK[:[',:&6E]=7ATZ4-<\HV<=&,^
ME"[8A:^2YDAT0-RK%$S\A5? -6\C1_-@XSH,;@'Q>0LSJC>4R#?B[%7UH%?+
M^GK2F,Y[T8]%$G<B]')7[VVDVN*&4.73C8L4(DV*Q#8&>^3,H^K.7ZI(ZCLC
M5=YQ2]6\*C0$_O7I-8MA@:T7#VLTIB$?$[89V[+]\$WJQK;,/E8TPX-^FRR!
M5:+IR@*G6]IPVP!"[N&UCIB<VKZ%W3$Y_9>&=]7&[DF"J=L-BBL)*!;?!C:?
MU_R<NOUTWD@F:VS/Q5)2 ^A(H>'BP2%P([<2M]NS1C6:+8?%,4@M15W]':V9
MB_>Q>[AE!Z.]5X]2!-P3;_BTU;4\N"(__P$B=PRU(K@CD4)@B?>!&KA>Y#9H
MYGN89YC7*@M=T*AAJ2I3K/U0XA9\=67"P:'->;G3_2E=85Z;&F[M,4A_7W_L
MNG^4<T+T6(,,#Q81A)R22R>PSAI;\V"%>]#9HE8Z3WOKW.6,-.>[PH)GPMD%
M9%/<#LP*BP&ILASL6:!\DCH,:96/6;3"%F2TJU$]P^].R2^DP 7O# 7%?BT[
M7,^+,9.)L@-37X^:*7S^8'%]GY1?'9V#IHV0I9PQFX?::J[6T/-SO[IXEE';
MAVXTMO*GC8O6GTF&N?UFN7.H!5IAAVNS\ (<<:"3;8(>$H;'@ C<9U.5BJ$%
MY>LGB[2*E TV*9RZ"6,C\D)\'DQD2X8:FYPL4E/I1#]?R!H8GAW&-OY*!-0$
MZ?[,$5;%[_!M,6;;S&T(]D6".H-U(A./\TC^A=:OAK<<NZV$>G1$%1B^RSCY
MOF)#!5P)X&,Z@9NM&'G@YLYQ_+ NU$#)+UWY&5-UX-@+(-=%N@6WH;R7KN7K
M5KND=#P+[=P9_^IFK[K1:X<'@R2.F&Q?AZDF]R7>$P7_]!.XTLZ#5114C4G7
MPQ_YT4NJVGV?*47%#S-D K^8V^V_,H'GO#)G=(!=!,B1ZRL><LX[+?.RO]^N
MVFG8<]6OT,[C"SP?CX;?PU>0VA$"7C6(A1:V<Q<CU*&RG\,]YAS=6+5CM;YJ
MZ2NNZ]L8)XFS0*S'^:7("Q/O!Y:@P<UID%NY&<TP8AUZ"S'NV5>L542;<,!$
MXOU,9X+ +=$]^CS8UHL6SZ/399X_#"OI=7*_JO[NRZXW1Q %.K,[9)5OO,S3
M^G@#MDR\BZ<EJU,K"71=YD]P\[/BHBP;)B$F\2Y.\N3D/<:GU.8#V;K'J]^>
M6=!K?8@D&@.&I3*WDU/=)B4']_IE.FH[-F36KVU8J<>M;]9YK?M03:=YL&O$
MNSA3;@G>PX;2USPFPD!&5-#W62-;TL&-I/Y I]F"&E)E1M?;.KB$5</-SJH#
M1@X[Q9-6?#H@;\=KHA._P05#.A7G4EN!+G:1L@(&?WA*/.Q]KD)ZLU%(2V"#
M8.:J.+A5G =+-<9Z\&!$>24>S,9>,MVIP##57:+_>7J1B9Q+XUK+N&ME$9 R
M'AW%,2MQ7AW*6!-]VC4Z(HE][[KIVG5UV-7D&S"%M'IG<B,/MKJ[ ;+F94XV
MD+/M.?^B])"7ZM]Y\=H,XNF(\TQL4 9\=U'4L4=/BFBW8Y<1?RC.2/S\U@DT
M2^38+!V^?O9B$&Y[WW7?Y!]R<;D]5>=-.L6 V'[B\S\-S?P/II1D+CZ@+AEW
M\F"N3!Y,8SVQ8A<$NCZ2EQ<12Z7GR&I=Y&\>3AR;GU";FMVP4H,V,G\%0IKC
MS0AN9W^U7](^UG0[J,3CLI=4M^HMLE3S,=43"\1A6U\A=M<39L*'6/^4N!JP
M=(.9Q#F^.\SNA0$&:<*\@\ ']N#V]?WP,S["F.NTC6BV5.E8VY]%?7YVU#D$
MLUJP-"%6G+)4W"#@M'_$N^9T6NGLTNR.L<=^(5Z&].S!.<GD0X)YFAN%U@9B
M-9Y,*Z>$^DP-_=PH:F#=5Q$J4U&O9'-WD+))F+^^XHA2?)CD>9C@ZZ*9W.<;
MW_PB;L+H'AVX-G3+1L@K*'CH$-MLJI2P\V9G]NEI.WZRN&.J;>UAR+@H_KYE
MLK:[#S39S8.5HCG%T[?_^&WA[;&)$A[,%\RQA.S1",PA A@"S45MP69Q_,RU
M^HG_C7"&O]Q4L@=0*R_Q$ZA'"DRHWP5%27DJY[85#^8\LGH^[0^?.\<O81?_
MS5+>1,F!FSB*W.<-.^80@J AP&?#1$95VFA1O78\<<]+2FK)VRCD[AYHO^7Y
MML.*L:MX5@@D^;K@.X(@#^:%DN)<&P %OWBGIU-^/ YEO _LEO"^W=2+S1)2
M2C\F^6M),=4YK\(W^(WZX0=W[,R'*^Q_E5V(_2UUEVK*;##W%CM\:9&2Q=K'
M?4+VT169S1;E/C>&AY3.4DQ6Z_MHY4R=O *9:?4S9:%R]UW:!Y70V^N9V>A/
MD*0O LJZ'/$1EAF05<"YQ,W&";@">%0O?V/?C\2$Y<ZW>3\G,/FJ8]]9%LYO
M+":U[MV]^=MAI5E']00U\<VNG_2\34KI*]<%[V)W<!_\P(JR [%.7!('/6'D
MQ+7M,+R6D@,XMO?(GTC*<W1JOVHIS(<M=Q%XN+RY2$8P_1698@X*(]GBN'X>
M3/Q'PSZ.)1!6?!&3<;[,";%M+EN<Z0(FK$WEOCC+/U.1N?_MF1R="[Z4C3^:
MPTT3<S/;W"3-#KXOO%K1=[S$KW&KU7A'8^(]I)#IUF$L#$#1K+0%FRA!Z6MA
MZ=$%OK$'2T8/,&3DV8_*]2R<0O6DM"ZDH/8A.=O@H+#A6NP\G*T_%T7?O3>_
M!\B?\-M[YDF:*#?_H=Y(?EB2F0;FE9WJJ.K 2KDWF!,@119L0%S$[DBD\1<D
M^2,BW1B-#(Z]\,O1& <;*8B:8B($O>XMNU>Q5+V/W5WDX*ZS6!% EE'(\@*L
MGG%$  0-J(!OQMS\/.)).66P_8/VI,ZGX9"+WX)T%MJ>/GY4IIR,?I7[)B K
MSGIF>76%[\X@_AKB3H,B-^\6GM+GP$ ^90H>9GRC2*5,P.E&:4OZJR[/DQ&[
MW+<=N/AET;/S :/1K6Z(]7Q]&PO71*U*3%0&,MA66*DZID*9#D$T]0TQOC)+
MQE4HQK._R2M$XOC=UA_#;YG)-S1G8C4MW/9*?,L7KNA]4QX:](OO'?XJ) U(
MEB,WFKZ_%CZ<,OYU.GJ<*>XD[Z+#L2N:<[/U51;S88=]'+/OT7JB.OK-XZ#,
M\ISZBZ)S^1>KK:NH#L5\Q8#>NH9#+2^J+1$O$Q7^]NMGS+^J6TAXPOXTZOZ?
MI___-Y[^_W7IYS^[0H59^5MV#'#^R"Q4RG?JDEX)J+8:?M9,<CK\+S/H_B$>
MSNC/@N,VGE3/;?BR\>\LP^(_7 ))GJ"N>..(2WPZL>K$>W]U]0+V=[;!Y6^O
M@) @\U]ORX-MYS2NQ*KGDB_#7OS@P29[46O?J1^>_^%S 4J$;_HV](;L7_:V
MCBC^6G!Z#OY3</XI./\4G/\*P4&H8WZRUJ\.A6/$VU;6/!:NL(\"FLV@4,U;
M]+M;Q.TS)2%!I)M/5[;VRJ T/EF>V0IK[ A(XL$VHT 1)Q[,/(E1SH,)(\#O
MQ+(7.?#[@83A*Z#(A@FYR2(THC*C^7VA._2F6(STG;[(\,W0ZM\"R2,_)&)Y
M+X"+/-B];U2.6\-L;K5:>&-_2FJ1&6F@#?\0(8)O45C/*HV?F3.5PH\?,N#!
M9/) F15P\PC4Y=G?NWQ/!MK"^LQL6+XN_U90CV_<#[A"!33]N/+FS=T<-56(
MI!)_TA:QQC./;:#S;[7T-C!(G+V+'$D2F) W[@&*I^"9L<CQ1#RMA/PK$"&"
M9#R!UL8#AZ_Z9[E9&?A_J:$7#CC]R8C\J=L;X/BF\S@Y#*E98?L WHL0K6<]
M0;]<P5:K9/1)Q+2ZKUC6; NBX;=:X^(='N)Z0'YF<)RI%E9YD',HISO8ZQG0
M;%7BB#FLB1:^DVH4T&?\QSY7A_ZD3P2C@\RPIZX9)D82@-.0-FG7_)&I#G9U
MDO^E9-]AK/:?TCWQ'V@EN6(M@;\V1?W7<GVF$,*+,H$61Q4/UM./U>+!FF_Z
M@7O-_X%8[()89/G-Q=6?< [_?XY_B.'JX/]>BQ$>2?Y'FA\G\"-IE4DYQ[EE
MH!0L#X9OWHU?W='0D5N5%]5R>7$A)R]L(1EBQC0H0>9(D<!$)6A,VY'<+G/.
M'CR@[<=56)^=,IZ=V=">2^*;) #G>#"&(W7->)U:%CS8ROY+8^![),/!Y\22
M$[N;0AJ_TJ4?.84'3N3+/7J2<D> /^R]V14G^+%MR<7\RK40U/SM/T.6EO^:
M=?9?QW/DH5NH""K#3AX]Z4MBG(93/,8_4&=J3*J>^=\ =_CMZKVVR\Y_*[UE
MYS>W6L0_MO;+(0(K,C$/'[%I)VS3U9>=[ F$"\X.5CG&;9CJU/=M^QS0S^=*
M-O^_2VK_5ZF9_X:;C*>54@*_.;#PE7[-K9FROV< CS\9]/J0H,"6'>SD6+1.
MY\2/%^WK!6J_K=^4AJP#K9+\*V1]@) >_>&-'(><ZR8T?F9I?:9*/-CH &N_
MY)<_?=<<V+->AC%I,Y*>R'@=):,$BHGS8.\&6"82_V%J.$C_OT'\MXMWD8)D
MVDND'%8E8.(K'^LQ$. G6E467%B# KPB,NX>?=!R5=E'V9\Z2#Y1_ [I1M@(
MU(ZO-(=9'6<61)@^#39XL-_J!>TM3.^8\E028"+T[?\?37O_EM_O=GI\?KS(
MDP>##/4[#SL-!&2HY2*&HL)CO_!@D;K0-$J@:;S[?1J)/%B PY=^!S,-?4_S
M]"?G':Z6K&Y8HC:C(A$,>VO$A&O,2^QE;E&#O/>8=,09\Z%;708M IIQ69=P
MM^(YD9366X=DB$7JN97_'J)9?S:*VMCU_G)2ZZ]\>G*LE[*7W1E7E*Y_>K1\
M&[_IIZ6^,Y4):\USAVAI?&WZ.K+R-D>%:(FW5UM8T%SO6N%:J"14>Y?19#3=
MGS%TEMGU*7[\744\HJ6F,$97J>?5@-K;1Z,E3[:?2+SQG99GJ<IY?A8F,$I(
MAB0MC0<3Q2+8T+R;O)&>B<,B+(7^94EN-M: ,7^*S%2+$B@S866,XW=:WR3,
M!/GHD5.O5K*M.F7<CA6T=Z2^#$<4UI16Y\Z<-3] >N4X_+SW?FYH<>0#H^Q8
M$;'D,,.!EYP<[@,>[*IN.)+AB*1$L'*X)4@_\D92J[5T$W5'("J2O!FK6>)M
ML*<0P)_LS;MG[>^SY9SBQ5+'JTG?IM)ZJI)27(8XVT7,F+KWC?G9ZV4W=C>H
M8JV9IY^-=]\S-2(S,B*P)VKZXCUL&*5$=Z6+3AV8F\VAGA^SG>O/I,+XS<YL
M6-.3OG]+>#G$&"E0?6V%J;IZ_=S4EG=UV#:]MUO-#RXZ:"Y)@YOG(4\J B+E
M.; 1SSCM)POVHOA!A3&L/O!T7'W76\"'*6C&3"_BU@=,G$@S>V6EE;%U9;OU
MKEU#@MZR\D'71QL@.O+; 5/LBRU02UW<QSR8AWQP6V9&1(,FV-MP@*'6TGV_
M9O"A=?WW)-6\Z\17QEIY*];?VWMV7A'6G)3)@??Z&#GW!,;X[NH-C',JK$QM
MNY4^M/F[-#@?J>;%,H;HN'[?_2&NF5".Y(BA(% MN%Y]',&PT8WNY1@-&,.9
MYD<_XQ0OSAK6]S\$:EL,>K/0Q4[?TLVEM__8^^9DXYLR[4X-">Z-O\S#L;%H
M7F'79V.3G0'HM:FGL=:J[S*7IG9OI7[EO_^>59RVI-:N"^PB<<2/L:*!K@DR
M18GU!-@5R!1I;=CS=M]75Z"VS6'I6$&CTGDIUHT.?7_'UF?[#I1RDJVR&Q$N
M TXE 69E_3Z_XKZZ#<K5OL9UHK6;7Z5<*6U3TTX B!_)@"(/UB;<( 9VHRIW
M,5 )^\E28#=>N$$#_9 #'ZA\:O8CSI-EWZ7=55+R\=[C5Y.!=K&GTHR>1"0W
MWD RK/& ,FEAO3RZ)40GC"Z]FQTPFS&F 4PR!ZUM(<T?F;#6UCN&.<-],Z%M
MJ*U[]9E/;M6%W"0E/EF5K6<TPN%#'S1I"$ Y.*'.:3U:"&I$PU-!A/NB81<F
M$=PNF]=OC)A$B6/\7)*[;:M33I,][0-K;9ZZ)PL]^ZG,_N1ZC'.1J []DSGX
M 2^ =Z,".@9T=S:2LZEG641WZRQAJ[&T_W;OFH%/SP*T^AK[K)531FO?+7Q:
M"#DHVPB#J?,MGYR8$+%0F)N[%:O^L"[9HLE.8DNRY0QL\:S7[:J,DF'5PMPY
M^Y7T7H_.MY6/KYYH:FK9H_@3E85BV.EN]4)5=G,D.UGNZT5)P,\4^AQ6BJD6
MB3TR41+0?,9['\4)Z'1X<^( RP NIVFU4R,;GRHG&' 5D9IP=+J)O!%/2R(P
M7&S"">7$!;2GL1(-1=%M-OQ:V(J,,L3EZV<&UM.?G+ V<H@=,[^\J==2SBG=
MY>7[G4^NEBDBBE/_8O-]_;&M96Z]<[FH*9>*3K\QYK+1QT>EVBS]$K+FWE1-
MD.1-L@EHC&_:A*<],!4!]D]2XP@5-BUR[8]OL>E^;4BI.NO)L!,N;FUIKO;U
M5E%95VVD^'8K7Q:VXY=31BAP"63?1 H/QH)\YHCS'MPWH#8FPKX&B,P'MK,0
M0I@XE(#5JD]II6WAK/1/O^Y'\Q*LI>(#BWNW&[BQWT-#9\YG*E,J,C<9MA53
M6V22G53>VN[;U2Y3$+SAW;3\W #N,*Z'P# CAN/+!3G;#=FL5D _<S"1?8JC
M#V (8AX %7[?=VJP4M1W\ MJ#FZ<J*GU^6.QOVQ,B^()V4UW;2@K* %0$E)7
M5Y&T;()@G0.3:LNT3\D#6EIJX/&5\@9-KNK5O:(?5W8XZ0W;:&U1#KWD._JH
M94O%V2J<ZV'3%R_7"DKR9])MBN8=T^J?5F!^ZN@47.BY>6/?Q\,[A[Y/<^14
M&-/-",$& ; ?*6RJ,!OOGH-Q8O4QJY*>#9M\3)$+-4+[:,A<V7?RXY)DO(1O
MD)9_LJ7R$*0T^']C>"Q0B]='=LO$ 121#IIG'[!DQ%\&3+%680'P>QEM;O,&
M,;<_OX[7M:X..G9(J">R22L6)C@O_Y2>G8>69Q&")1@G[^1"L$^I:.;(3K%S
M#E-#'#%X,V%K!6IDA!79#VFFI\&.*;B.GUZ.YW&R(OZ!JO= '003O'7EIJ6G
M77!,)C+EHV?_]C@9Q(N*_^E>QE\\&U;7"U0/0^O]W3"N?<R$05C8P!B:8&4Q
MNCN0XOKN_97DN ;EUYFA<#X 9UFJB/YR.5+^Q^)3>J&%FTBE[+%#9\X/A4%Z
M^AHW'TE+6+.)R.%&0X/.(E>X9\3OIR.MJYG2,3^F^Q:CBHFGW6-TEM'S<7&8
MUI]UY<>%NS>DG=]T6/#KKS."4VH+Q]B.ZQF&&2<6*7A6'A=2TGXV]U]S#O5!
M#"^T!PH9I-:&W:3'UXV/Y7GW-%^-HKB?N*A:A9$R2%PL+_<1K9A\N6Z_.4?+
M&8@6/PH;%-G/K#T\B-U/@\>Z&C4P@Z-RR;W/K68YN_(NODNG1 ^_WJG/7'WU
MXH33I4LG:\JXBDSI>UBU"> RB>D1I4\_9Q1RKXHY=^#LIS(+0\-H071H OHX
M3 "6 S%G>!K<O C->91;C?=&ZP+JTAQ)/E8#8R7J%_1;[Q1\\STN0:UOOT@G
M?HN/6Y[SP XYCZCY\P_5/9O+56KH&L&3'E]0#">90#A%FJ4*R$$,V,Y-^55+
M59@E".)T,;83R_FED6A-FQ+@IGRWT1$1C6K34ST?C\&.^[]_>(C8<U*=;\D*
MW(QF!X 0;+R($.+(KZ=@@=:A*4ZM@XEP!"*8YD>&L&C3B"O(C'&;+1<Z65FU
M(].WSOKL?AUCK]92[GY#)I<T[^/AB=O&($2IU50SAB)_T0VM9K$CLUK7\R)+
ME:>G;X;[^=JHJ67V_+6=(^]$TDJ1C OX<)0L_KJ)#2AL,H&B]($2T<W=\-+N
M1*I8VU,JJ[1*Z-S8SM[CV][U"$LV=]]JU.F=JTV5(+!,8V&K1JS=ZT>[FSYS
MWR"OVFS'?2 P3NO>SX0F%5ZG/7YE/+0$V;)F-RKF]=O82/>.C3IN\?G!&QT\
M5!Z/!!A)N=FT4QFGB("FQWKT\R;(?;I[ ]\B!7Y54$UIXL%V@!M,BW.H6(.W
MKPGT,67_$/\#V6N7Q)("Y3]8;5>.#9K6.=ENES@_X.'][U7[5><;)P)*:BVK
M9-IC)..$+AR@LOJK%42JHZAV3'(K@N1H]516MW2J^GRZLGV2BS8%QJ1K)59;
M?!AZ1WVSR)&* (7CQFT ".'3][ M@0C6FU[M.O@D=2,&:<U(:*"<R+G2[UOB
M<R]83$,D8'>JKW#@F5!Q5"4D'.T$QH5B/*!R()]&W#"+9-A2%8@15NB^4:P^
ML[*$#A+P>7-GVA.5*'-2)ZV+4[\$O6M2WEO4HH\FC5._Q+%<N2D\&!H%:%);
M=!-1K^57$HQ#&52:=4+)2ZPE-P>GB,Y,+PJ8%,7-#2W<QB7ZA;[ _E3)O.:V
MV^Z^,,*X1@_L03<@/F//%ECF8C*.5_1?+^#[5-%0=3$7N_-!WEWXQ)XU^Y1\
M3\=;AJ8Q!4[#%*>"=]H^NRY,_G[ G??E#'_LO[,[C!0QA4R7V[\$!3#.(RE+
M[/$.^F/V>2\>;"O9G1J)VRU ':=SHW(HT6T^KE^7,@SOCAR=$-60WI \_"[D
M@D#2D=7+;#)KNAQ8#T^^#ZV /5A;1O""X$0G7&K6=!>C-1W<8FB=6O7Z*\K+
MX<QHQQ6) '/94YV>KTO/JVL=ZMB_H@+I06'V27R3-_X:#T:Y @JMXMG:'-E!
M8B698C"!;\D' GBPS2?Z+-ZZW.YVK:W:$<;1.]R3J'HPV+DZC?7L_,Z[7Q !
M 'H"M; ,+<)(: A!6&W&(MV'&=31HH!@P"-NP85<,7=#T3'CF:"<#&W\<CQU
MVO/JI:#)6=21EG&X\ @F%B4] J!.)]IG[Y)8R[UX0D?YR --"X&)@SO%$S1/
MA"-W0A0:X\$ #=T%R>= WV1WHX\Y*Z[/C1G<MCBBU[:VTA(O,4O*7ZXWY%XW
M>]K\6[2;\)9SERS>M?@I^KNHT<68>JQKW*=X&ME4'X"<:W[W-WUTSH82CGJO
M#])#5Q*S8F&0+=^G;&9;['2B6Z[%)T29/5K+[Z=[M]%*QF\P-I\(^+4T:/8A
MS)BG(]R++KX[D@RY4I:Y;H;NSMOP&C!.-31K)Z!C'-Y. +1)[=1X,L.:JV#D
M-]S@=R]H1_"#2ANX9_>5<;I?AR7V0<JP>:52\OGRG^<LE9S%JQ,6]\N3S\\U
MI#SW,A3(VIKXS"N(99\^7R7B9"%U<!)E9@?;\*OX/VW<_OG\GWLV/)U$K$H$
MHM@"D)'.I=1MKU]L1RZISY%9H@0>S*P2HX)5D^+!ZGI_X1_Q!Y$WDK_Y0@OB
M-9H'FWDW'ULZ1'/@Q \A6:)XKJP\IEJ7$^]U^\[<^O6BE[]?(;J';[)&^A"
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M;21WSWINV4._=J$T(#[;K%_MA?3&I2.,K);?+P]?$VK0  @3*ZT'.4HY,[;
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MW]02RJD+(Y#7%L @M"9N-:"O[QJI,FSBC"7'Y\,I3[,C&:[:2#OF<;2<1OY
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MQJ\I/1O!>-%3@12>?6.Z.C@XVJG9:5SRM*]6@++P2$EF51#</,\@LBZL)[&
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M^X<40VP0$MQA ?$"S =87^37NY L"1(E@%X08O3>('@:.<].%Z(AIFK+:EF
MP1HI.&?=!+UI$)PG&;K^X?/\.H)BA0#5"QG&"-JY,23,K+P(E'>$VM;;80MZ
MZX.@%;(:33 ?'Q92[:/;]X0R<T*9B^8WCJ0U(5W\9,=AM'F@](7_^$3]9QN/
M%-OQ4VKRPC*V\K(U%HA_8,Z>PQ"=@/CH>'0$-:=K<U(*XK^-#S?HA Y.^(PJ
M48X0R(]'KWPY[W5&,LO>M,6;,U-"5,G@_:#A++S[D@1R2H$0;/M3X0:]4D8(
M.4.AQ )C,*O,PQ,D=!OE^M8D=1,*ABS%S:]5'-PQJ/DP+*9\R^;<<Y?I.@^G
M\<-I>_KJ=.\ZU5<WG."8\?Q<]3)K!(:[%O+<ZTE_3WN)KM!'A.A?'FE'>(><
MOQ*.N$C9I/WX:CY&$ZIW[^,N_+:;L=MBM#'99N0M%W\7E<$"> CD88>I:5HT
M9082 /EAS_@)II'3%+_OXF_>P_.$PS%H7Y^]E"%2ZEO)L$@>%D\W/&"U4/7Z
ML[@WK=]A]![3_:.9W>GV^.]SUV?%:;\2K!5?)'!&:S6_JBSYF>U0MNK^I"V_
M-GSKP(%7KD-W;NE_LI#_POT>(8DE)R+$VTVP'4HC$&\4-0?BX\>#>)2YFKWS
MZB)W$L/ _$7$K;+7AE,6M)&5,]_V9PCO^T;65/)>>AN[T,L0N0M))C!$'.Q@
M0YK!:MLR$^A&UL,5R/FKV$Z%[[N%5T=?MI-@G0\8[7IYF7\)W9C-[AG94:@<
MJ_Q=&U;O<FA X+6BUM5;'U<B.$4Z%'^K QA,. D29 $@DNH-\:R2-T$U%M"-
M3<UQ?PRQ^;12&KK*A80J*\9S<Z8.E-@55M7^VH.[/O.H=5]POJUR1GTUNNTM
MMJ,<68?M@2O870=F#@OP@V?3P2;_7N?NV/+ $Z-Y395VC,\FB5N\VM7]UFZ=
MW\7U(E%&(FCHZ0%RA_6Z^L71WTQ^RVR>D#3_X:&-XE_KY[\O>1L@=RX>DL.I
M/K! [$7#$\8(HKF8Q4CR$Z00DOR,(&>N2D)=8AP:UKU*P7>E:9SVL"OW^*D:
M#@WKYMI*?<Q0R+:1M1+@41X;4T"K=A923L+Y< GW0 >&CVTPV>2A>N*(;?H#
M.CKQL624AC-=]$#70T_^N@+D(R[NP>@B!8MN3/60!:*00'$1 I5*B7A0:[,#
MF6"\IY"*=Z2$=6'CC -#O22I6U^9E6_)O,+A;Q?=5&_H4(I35!I]_VEBBWV'
M/ @-D2C^/NL(>A!H0I3%KS^ 72R)ZI/"B'@>,=Y7L>JUQS@NK;[ Z8B'AT4(
MCYO:7,6O&0,#^Z<=3K_ZD>M<XH#+#Q^&) GB0=S]^R2(HVPMZ.:LAV@0M5HY
M2N;<+<7A&6H\#V]9:CX^2J@_^/@0!0C\<4P:/V2LR4$M=X QE%5P^X'P'[94
M(88X!\0W0 U8],HJMF\FV;95YTYY/HP9TNU>8E+3/*2#=9T2?UXDXP@L(* 0
M5.=>BZ5?PG3<AEGO;P(G3@ 4LZVI<^#62V#O-4JXJ7LQ)2KOSGSL48$5^HZ,
MI-M)^2;_/_P]&",*BH@3O 0.+B!2MMNXK6LF:0,>[J.J=?6Q415^[6YN3F$F
M^U,+W.[+9]B168!LN,D"(D&WU9LL).F7^STC4GIRI=F,$79D).YJZGG7/F>B
MME;'T?W6CA:(QX4"!/+#0HHKZ2%2*!![ Y> I*!P(KY8_NT4Q^M%Q%*T.<>%
MZFHO49X;1IA 99>E<SF $J )<"%.8F8)E!.H!P2XZJW)4!9IYF O%=MU)[QP
MWCDIV&]>+T6LJ\$XZY)Z[;E+]B'R:2D/FWX515R(K#%6%F5O0MYS4M#N5I29
M>.M3\X5A>27*L*K[DW..G^JIN[BG6NH1W)4 )AA#Q%*L@\']R+5U:M%[V<%>
MV/UUA9(8493I^5ER]N![WN>#PN,J-EZ:01NO JI[#L^D2SJ8<LC>W\/!AZT;
M9,B-+,ZB://C!/)+ N7,YG2>*\A&171;^5!#BB-%5V0QI8>7W!<LVJ\&B3;K
M5%NJG$G3W ).<&'RQ\P,NHSW-!AVUZ>]=9OM\]O7_WK]YGFKN*;=2UHF#MRQ
MRQ8(:6R'&9*<2VHP6MNDG_#"C*#J=Q@2!MV%<K]M&=JW7WX-MZU%K@V(V6_!
M-&3C/&=^D1]AJ)/;M<C$\\' %3AMJ\.4!N9+J[@INT6-=5X6(&C" G@'&;HM
M#_1HU@QEU&3A)&HY:V9Q@!X(8?\P"7>0+04@(@H.'DYLAS2!G, "*#]Q"(87
M=9!Q>).AHP>Z-\BB"==AR*!-UZ#KK57/]:61@AJW=J)K%,04O2)F>Y$P[$R#
M0YX#2ZPPYX?)_$EX66]X61+C0)#B>"_,K(4=U@AKV'U3D""$FBZE6V&F6^2*
M>I^DYD^BADS*RSWD?%K;FM*EKYX?MM..N\A1ID;A.EX4\$<J<1U.=0EU+78@
MAX2!VZ6*LHSI_38# .8P&BY-L4X$_^"OB_-Z26@3NCRVXSK:<UY(++P:J]IE
MY(Z*19P=J=,]:EVGG"F]N91Q0/7&L\QEQ"TW-_;4''P%DIR#I5@,3A9"O$MT
M.1CLT]RI!=4DD4US/3>STFZ%2%KOFFV9^]/K\29'5=P4GB>K%5RM;"O6/[W9
MA+%T:'W]7.@#ZB%LJIN;#/%@FKKQ(%$/U$ P)+,\*0BB;L#%S.WP $_*8:.M
MKR;W2S(^%7C8.%T\7*7>%%2>\=YP.RP924XCB&)4L1T:IM&P^:;!#GH46-0S
MMP],*']54H%&46_&[TQH[2>YS09Z6+<./I8<\+Y(MQ(VMP9THR<M@7!NAN@B
M31HV3@#4B=G#3,;.^\*0%\Z\/"A:(>,BZ6OA)"F0?J,L#,L"%"$TY#58%X%=
ME0L=F+DY908EPY35I)M .3X(ZECE2Y918(PIQ)#G6"Q'<?I?.*L\\MM3D3+[
MU>-T+U-1*VZKT>E"7:BI-T><5^PR"5358X@@R3B&R,A\;^)V(1?C^&AKP")"
MUCX0TJ9B2J]EE^M[))GF146%^/Q2N:"3>CS3^@:Z1OAU.:U$G W<HM_#=N +
MZY#K="K_!:I4KQZH:Y3\&[NW4-S?N"'.5!6//I)SKIZR%G:^AM^7?W7_P8RU
ME%N6'U+11<__&)#UUJ[076%'/XR\BL7]Z5WGIT>".[2"W-7Y[5^@M26!TOW)
MQ?VNNZL7_NO: OWZXND=71T>]KB.I*.!#$(TG)N>(BC^80RQ_D6'M4-TMA7,
M09!9XNG;K@3B\;WXD_,>=*OX5=NJ=!'!QD87HMJPX/#3#UPBBX+Q,T7;T/]?
MW]3((Y!?8REG'6#G[C@' 3]AQN>3CC$(S^G *#10\]_6+,@P]GUHB"PI/K)S
M2$YX\W&:9ZFUSO+^6)Y=7N6<95EP$.*O@8N,Y026G$EZUP]S&SXP2BB18;\@
M)'Y\'LO7$7U@VL1D-<6NY4ES$Q"?J3D\?'+I!=?7EQOG[#2Y%UP84ED0;RF%
M ^))H=:0L6E8\C.4 CKJ)=I^8N/M/[ZJ72JKYQ^>H.C6S9B?\5.I&&[-D)[1
M/W/QS5M12]CN'1-(RCFAJ9QYH;5G% .:-264$#:/DF!<';G6!F;?TZZ/#ZJG
M3%E-W6E6Z)2Y>;-X3DHN^ZORQY8RT #B_?M:XR] "&)(,E^&!(.:.(:$ZG%P
MEEI.2QC];=T\$J)I:E@\XPLI=G3=F4KZ?=3NDQ2;T!/YT!4)%8N+-I@?<.!7
M8F^0DK#U"6L/*$(07Q3]$"CE,5H[R.\G6!:0BP[UV%P[G'^>WV3:H\\[KM#_
M/57B<='1DT<#UYQOL6TU,"3H$&\<S! ZFJ:LWZ.FHR#>']21GF9LR@4O8Z.4
MF[_M':_%7FRQ"VER/F25@:OI7[JDECW8)L.WE^<JJ1Q5;\00'21;,Z2B.D@<
M2%]\.E+*U.]%N"R2?5^=U .&5I0\?UE?&=$O1&S0-'DU\4GH_-69L$R%0[&[
M<(7G>@)K_C(<AC0*0^ULF"XDQ0$1.Z<_AKYR=T&L(OPE\?PP^G5M?T.#1TCJ
MAU0R42C_UJ^9@ZY#$AX:.E)K)% O@2%AO3#($#&B'05/TODP'[-Y"@Z.MRMV
M%WUE6#0Y:;_\ZE=/H]WP"#][TA/)Y0;9O-?8VQ4$@%$>S-Q*N#9D8BEW\)W(
M21^(UY&*ZS;N*<3[8Q0532E=S80I^V(IH_."=O9MA_975%E?CMFZE^@N\0QE
M4B3H]1N6?1>LH]K!^!?NXD$C.&NYU(*%E>%WYQ_N&)\,7^@_T7RHO>AVJ/M*
MQ#7YBGAM-5R?J+;.'9,F;L-OA10+$EQQ&2(DFCZ5%E>Z0A# &(=OT5+!E@5^
M>^TN%B!A:CW?ML]FH67T0(:LM%JTV_?TZ<^/#M=(^)4JM>":1",;&%(3\[@N
M'*A1R)#B)@\R)$-1";+C+92&]4CC\$''H2!TS\A&D)&[ T>!A*S=OK076S+.
MUK9BJGZ'V7Y@I3%2I0PY'UCTKZ V&3O)L>"3(M2IE^+<? +L[YQ3&H.&Q+_,
M^NLO3QSO?*-6R2,RT_DMV%H]+%#-:-L']=FE-SA%%LN0CX4G((.J"ZBO(^^]
M- OG'3KSS!08/@MIP39'J![3T_[Z*U+GD3HJ^F7I4^K!S[YQKN_G190BZS08
MDB,>S'PLN0H)(Z/'4ZBU(<DVJ2YM>_V(5M]V+=]K(]DK'D^PVX?\H<MI03N9
MUR_%'WLOHX3 N/P@K7>S@#UK?U_X__UJ$-V#^089X)!:*!QB8E>I\I%(A'B_
MA-BL5=PKB6>3SY2\]Z0X[!;JVZ_'/@+R6ZCG3T!5%L!MC>VX@SG*T *GR[ =
MNA G:<5KSU!\_E46(,J(*.'*N=A6V_I@WY%LV^]6JJDGE>;.)/ZJ]YZ5O:D/
MW$)1@C_G+0Y.>L H''Q!WPOU(F5"!N70'$,]+5*)-W)!AQNZZX_X TI_O8][
MZ]UZR'V7^B;B0;$JW[3_8!)#%ZX^W(+8CFZ2* NXYC#EL>"2K 0:4)QU0Q6T
M.S&*8Z:),7XNMY9Q^T7?IJAW?YL+&*AMP@5>N<_;,(,ESPJ!6GB&2.$\*8VA
M#/O;&/-A.SOZ2@VU%]<].O6C"Z$0'FP35]?2HFO^G69[H*1A]%6F9M>M,^\Z
MY ,3+^W%JY5V_D;)(D"C&FBO*5A(OX 9]0*HFC!U>B6(B49TYRIF^\0MCMTD
MC\ZJRCB%Q6P@]MG<;;L0^.!T]4U@!8X6W)PA]>];M 1HKR)UAR$22RP4JV/>
MG4<D7FM![?535&K;LLJ[S7S4/%OR$6 O?D6*;DU-3CET[<:EET%8AD(P+',%
M!4DDQ"H>_'N*L8JLM>Y""8=G=2%$[O6;Z77\*:B4\W77K?AB;'R<S>H6J9%3
M1 7_F:0U*(SM4$;K+B)!;;@J7Z%R0/RJY,$$]XTL2@I1=%:!WWTBL+5D] "V
M*N=4;;W7Z5J2S^R=E=1.A=?2,<LMUM!>F-S%U&/Z$6*00'@#Q!LVWX;L#J!J
M=RHBAS8-_3;N)>:<.512<Q;=U-7]=:T)%RO](ZQ4"5&*HMA$!YRC3#!$PLC6
MB;7YZIL;M2S@0:[G0%UJQ.Q=%5=M'6_YI40.*IXX"*I9KV713;$=H7FT7&8Y
M;*UR1&U"HIYI\/STT9O;] GJN1J<16VN2=.U-M?"6Y)?#OLF";-+CYU^8I*#
M>(6BW.1F2/R@76"600#Z*"QN"$-_I-4#@8.D&.*UC52=J5<X<?<H]2RW2?MO
MGVH,CFW=?#G]^-+;Q9Z#6'/D36QR(<4_(1%SF'$"+%_4F^Q?6"_L&M#H:GXL
M.T%$"#VK'4!ZC)'S%[-TY?$2M?H?B[/C%I5=WZ5$3%F8OX KB!&6_!PEB_4-
MCB&(8J^AT@H,1TU/% J0[ F4&T7EGK4[PGX3&/0=-QGY[$,GU7B&8LX.F6AV
MOM1DIH.%"_3-!)(@^N3BK%[G3N32YX07LRN2?PX4% ^^MA704YGN8:_24SZ7
M<O^LZZU(EV]A#-F_OKL"]M/UT9)@!AV%#@5OWYWGQZ>$A1X*/TD,HVT*T/Y8
MEA4XU$H7[RZF^QT 4I&?SL^BGF2X$2RQY->*NLRB5FYXCM]@QR)B4K;GU^*"
M>3XY8+)U?VY00_Z]K(>[Q3&F"/U[N$_AH^QN8Q8"9WFX.Y"2?]\LPTG#&?<
M*QB,]!-*@1$O0B(\:KX^1[AQ;/,W(DG)R\WC&H?.$+^0OK"1EOH"6T0?G'I5
M8;_3G>B$$P=GX"B!_([ 92XY!Q99C53HSL'P,+)YN<%QMKYL;[Y914W%A<0I
M+74? =4K*F\R[I-Q/W =2%&D-PF'HIQ%)K;K@)O41=H3$$=WMMM3<@=2-%Y:
M_YSFXRT6#WUI>3(VMEZ4$-7_O:_Q SLG$(^\#GTF_"I!=I/H\G(LX+SG_OOF
M]\>QY'5"6O./M;I2:)S$ ^OTR-QPE*'PRK,.W^4@/A?^QO'%SYP;RR_CA^6V
M1Q+S"_;5AV8,*XOG:$M.F'A"TS!":L)6X^+_UKY<%$."Z#P<<HW27G=9=02]
MKU)F5&/<?$B]R"^Y*VZF0?B30)OIZ]Q+(G%( "U07>, ZB,<[]4FRK1J+/"J
MJQS*N;UH]T[ZSR,)*X?KBC'MZ#;FD_:#T"B*XI-#;,'%*LJWCP>;*Z)1HPRW
M\F7C0%V=K>4ASY7QK&:KYS6[J$"W/)FNVS:SKSG^OIPIA/''78(O;GH:XAFB
M(FQ $FSN+FH#46@/VBY:QER6<3K!,<MQV)"WLFY:KCXF+,K5]/D7]QGI[W+9
MSJFO'<<)9Y#D2>SN\<'W.#KW*O8/=C3@UP7:.WCJ*<QG%E!GS9#+*,&\)_%"
M0N&=J[WFPA1D[#96848(9DY=>&)VL^=&(<^H^[+K:[MG+V*D)]@:/)\<[1WX
M,_'W,)\%?-R+X<1^17JP@!&HR$*Q#2Y\,*V+N1L>!?'%4;BMF7GH &I15SL?
M95O1H&X<?1(9)^.\>;$V>6IE7]7>79NQN7MW/F?B-RR^V@H08I 4+RRXSV=M
M"U;R%-A$L>XE4.SU<.9F7Z!]JQ,Y.LU"-+!YU-O5781K;1_/\"G1TYN\:42U
M;ANG735NVB;$#^,FKF/P7F:Q@'<E/]:5R82$>DB-NJ]R00XK"%X=AZ[6AS9,
M"%\ZTV"D;!.ADJ9;O.^P<G[]VV^<S1#,@CO@_$NNA"$W(I94&P\#(2XX.F)>
M_2R4:S?$?)E*?[UC[/PB" 8@T0CB>W15?V#-RJV<9R[LR%EKA>K[54K[U9X+
MM1'(JTA04V_=D6)-.P#*T'7  %0KI30%H^]WQY-Q)N]4TY'AAW4--6ZU2QEG
MSVO=O#D=?EZ_?IY7<ZURRYHAL07GX5)L1W.!%"A(OP7+A#0W#1]QH!9[*4/=
MU.CO)6\J'OGG! 31'BVHG6(!UCE]3;:ZI$A]_;^XTPH>/X&L07;AIW$T;1#>
M0RXM9JZI8.5*+BKNWC-#LX#3=LKJO[-QY1Z3LQT1.H=RI!\\YS_0.8^F=#VV
MNKV%8TA:0WQY\P3PJ'<G"F !5Q&@!JD#*^T_9]1,Y1EOO5"*6E8Y6MO?4R^Y
MH+R_)I;3*BHA>[Z^)S&QZY]WYX2^HJ9&: @*-T.*@V8%(A=0,NA[8 )EJ_//
MY[3K"RUM1N]E6T-K_,^1OEKN]SC[J^C%*=%K-].:UK2W'""!XJ$@4R,JEO:6
MLA[[X8NKW7RYK_MY?G&[M.O'U0#>]S(+!#N"/P[4U%B#43FG"O,1[+(:M S%
M_:.U>9Y[>SMEU7OC:A,WBC.VF>::_1^J!Q3'M*3-;/OP,.DVXH?X^?_U L;(
MW(AQ<Q3KZVG2/6)-]7$>\J8T,%1S35W4!5R,'P0CT=1=+'5'\E!+4>0=MM]X
MAD+Y?&&J.WX]@6XV"WTQ5Z)FY]%59FQ+W<+_L "BHG?'=<Q4<>FY;-=% <%>
M&O91T*?$WD,#2^4**V@I&@(,HH01491;I<0T/4CP#QB[B!)F*-54CQR #J!:
M&TKM&ZKUSS2G&K1]NOWL\A'(-N4S-W/_&:L[*3@XI&)S5:G<1!2H$[9&IQ_'
M3*$$ZUB %*:_V:P@^T M/<JE<82S+\I@1=@T0J2.J#?YS7<FUM0FXUN<,CK!
M"2RA&V.FD)1;#6LL@,H-\1A0;OX@RBH^,$_$*/M[B5"\?=T#/'I?V_Q)ZZ)5
M500H-+V[PIFZBOB'I"30;0=@SX@[6@+_N]MU$-NAR$]YO&/D)4&)SWEE%T[?
M5!O9!N?]IL<^:LY$F.:.ODP&]FM/:YN='O9$.M8F+_ ^*OYB+WTOPX'+59''
M/+[DY7W-\+N=[5*4T-S#6![P)O%T[=Y+[LOU?IQ7<!?J !GSNBW" RPYFP6P
MM:K#\:!!S6%((#PGZO#"C!-4\P=!1;ZTJ983@6B# (G:T%_\:JY$[8\9C,]K
M71&9#QZH<FRWB0..EN* DRZ6B%&@>CW]HY=\3T[W].<3 MFY<6_LQ41&]I-C
M=YVF--D%C<Z,W//@J:U$.,0,CW/R<M75VLG??KWVYCE@%N< S^'\]W!_$UAI
M5T[H;BZ-.1R5[SP3NZ?T]JM3.R(9[Z>5/8F*/?6:S]F3-9\+K*MV*HI],90;
M0!VGM.=?#WMM3J>7VVDN9BX1VE0UN08UL@KJBBS_)1M;X7/0KK-=,B";TAM_
MCWET[LR-UB.2CL0??<R=KWN^[YB.QXF?8[.$FULD=PQ:9MXNKWR0/]S:;N1&
M6_1.]3)-I'-"L&]F25S*M.!LY'C)OTVZI^257_/ PV:OJM*.L #C]=RI[^J9
MQZ2&GCS@C/8OC4?+S0MQN1W))Y/X_)HM6]IW8L]4I<_*M)U^#A1&#O\7WZ/_
M']CTT0J+>![&\>%OXPPI_/'74R?#="NRIC.=;J35-]^=410,<(F#TPV\X]^2
M5D@TLU7DG_,!LYH<"#>8*SQL-4/?F_5V_N7C)'#A0T:CV3$GE3?8SBDPF@6<
MY(9.V\'%UX6#F@=9/\.NSB&7+I6@K8R2;G\-O'[:,35(<KQL>_?!.I)2WX[
M?NE@ 9F9<(B+_X_/ISA>(JS>\&8\HL,H0HT;ANC_WP&.+( _8'Z'*8#8U=)C
M 2)>NI:(_SO^?WV\RZGT:J5[QP3T!='+J%/NV-YBU.\![)/H/99Y5^]:.SK9
MWID:)WCL!+\3=;24V%;Z+^7*]%59J;OWB]2&1\.PU&4]YMW@)=L6[0</_@<1
MK1FZ^ 32]D'LMV("PS*\3F*7!?R9? J+:_Z#!?2Q_4_XC/7_'?^_;_Q&KA&.
MH;X@-__JYY^&?!.MRP6G4MZO]FM*5'F947P@ZZ>$U3F')2\BRBES<?7&42/G
ME[:SE>:>T\#+9.V)_^R0F./'YE>Y+MD#SR@!SO6CAM(+69!8_O7ZIA\(OYL!
MTRQ@_A"EE[GG.0MH+^_!D@NSLVL8$F,% ;XSL/.&5*16LV,7OTTT87W\6,#6
MHA#SCSC;(DE2;^VWGG1_B/>MZI[+J=P7>BS>^C<7IAZR%$HKL?&^B%(Q%[]\
M[ZT[06. \,W'@^&P]5>Z0>"M0S="AB%"9@$IBA+@H<I+GW(G4@/KY"IEG ]Z
M7ZL6EFFH0FJQ !N<;\>@V2'/ \7-L7X3_,6M=J&7;P>.Q)RSC:VM/]9S^Y]0
M?,=@?+/#FC;9(16QMQ5FQ5Q9H-F"F=Q"$!%L1J9B#H!EI?X7/ )V?EV:SM=?
M^ B)#C&?J<R]ICQ=Q/U3^-0D4EI>_O9I^X;24V_GTN8FW+6CUP\T<-"V%@F]
MP0]90(U19Y#W8DXO0JKW.>ABD7S,,,C=P^V5L$YFL1:]T?';G6&;9/8RM7<+
MK7+D'89D+,0[2ZU92,^BW"5B98-KV[!=1NQ">SW":SJ-"W"*E5K*SD?56QO2
MC4+53[RX_,GM1,Q9[3D,MR^*MQ87@Q&G['2D.4\X4:ZGQ_E(Q>$OCZ47B8\[
M6L7,G6H*NWMTZO6IDJ?U'#<U<AFC,-,HQ0Q['6.670<CZ <Q0X7584D8SG#%
MG86>9[=O4_$+@$>*B99N:? !.:LJM^RYA6_7SWLD*5N>IS?VN7=<>;UP8[G/
M9*?9&35?$[2K\8U[92#\Q[H'/1KSD5#EX3N.J.7N>O5N#'UJHQU!V7A2/.OO
M7E!4LUGK7)_1IV6YL72"H^=N=Y0"Y@[#"L13\#0D+-"O58(L-C Z<I"H*$N=
MZ- VTYX/2V^U@KR>!1BV?0B89KO# EH:GJ0OVUQM/=K'7(DG<I^06+&U-;HV
MF[TQ*PFUF(EQK.$GO6F?F'F$( 0/*GR$=@=\LK<EN)@DI^O_T>/8VN:]_@)L
MR-V 6TF'=3MZEMCJ\XOO!WS&_/VMGR<+N!P\6;,06DK!+CCTF#35,?<89G71
MVN4I;TO*7\6GZLO^LM...,^1?KIJCEO=6F;7FN;&K,!(,*[#X#F)<>4-]"FR
MRQ@?TXJB& :%#(2=24T1C+HXLE'4O:T/2'X[E1K$2=Q_^@.;THU\F%&\8;YE
M =<=OE[HQ,ICV#'3!(E:1 )6_# IM1FJ6OA&35V86NPZLG.@VH/D49,Z5YS!
M4>4]TW4E9L%2EZ33+/PX+[4@PU][8:>A'1=4OU+/L9TU7]H-SR"#0?BA)" )
M<-!AHM6H<E)W[DG%<@.[S8$KR*X*,QZEV)AB80NEY-W/TQ _"I9CM!E\3!"\
MPGRYR/Q>Q\1))>41=Q:/1S$6UQ8O'HQ^] \+0#Q;@JD[JA!5S;VNNH 5PG:(
M$X*:VN66(W$)VS@AD-Z5$8ZP+YBM?/5E>];Q,ON8,/G]5;=9VGT^TX>4@/5-
M&6@ R:<"[R_O'(,=)3AY),F'?M2PN[EX_T>]HF'[A;GT'E3=Z\;9V3ZS90<]
MXOR;QK&62S-OQIV'3-H4=MS])LZ9#W&*/ KXQ +\D=-"M%O,5%.A("HW[1&8
M%S"_*D<?JQE^3C\\8129UK<L6%?+LW66J2^REZWO_?=& JCNT(429;C"RP>C
MQ:B;J3=_-([IF<LO)T6%W,U2)W;S=5Z_&G$#JQ=AMN/3AEZ&XU^!ZO.0X(,#
MM5%K$W07:'A-UUS,#Y*=N*<=+(::KLW%)J!/WBKN-EV/>2?C_35%N<>T_JI%
MVK,(S2OBU#M%9A$1];._2E_^;GB*<(0^8BGG'":M:5\(XZ9(BMS"F9S('PEC
MB$N4SS5%LWZ1^8^#TZK-*F=N?_ ^AIK3U,KF.'84[XO_B$]#UD^\QZ9@*5Z$
MR9PN;+5#VC8+D#A^(*X21/6:[Z?TIZ0ASR5'^6DD.!@Y,K+J6KB:KCM?D<DV
M_66#>%-;U7@]X9;?X6*\3_/8V_XZVN1]EQ9WD$#4#I*MK^%1!E3-Q^8-MR5>
M%5X.NKJO!_$[@ 7H))1$Z_&@G0CKI%$^%D!Y"GI#L>>PI(O83N]YW!_!XRP@
MVFEP;1T)H:^P ,()W+]WV[_R8?\KX^_#>?G?!\&XAQ<7C_QIR,W\[8*L@7'.
M+C4!8O+]ARY0^A_&6#/VF4NS@.>CB)VQ2]#G$1;PHP=!W];\#UWVPO\P!O'?
M17.Z2S=Q8 &%TMC-+T7_WGW^?Z7_WR6]=<@""Q"HJTUN_J3V6$F [IQ "X71
MK/E!%D!ZX3B[3&,?/Z\#R^5,^O4A\F+__&4TW5+<9?%?8%6B#]1;1,:81E'E
M>I#\:.1= _^Y/6VU=1/>V0??*'X?-GG-J,ETC;CSZNP>.=6Z\ F&1"\164M*
M19(+$<(,$[K*@;?0X<::NE]!#)-[5T;?ZEC.Z$8)%J6?VO3?Y\3Q_=C^IJMU
M%+TUB2 X!QZ;8 &!.!'PZM;\#D/;0=H5)!(G"OD/.RA:O_%U7RH9/2(9[WHM
MUPW(=FEW,SJI4QVQ]F,IY':AM6!,&EIGI7[[YY/U /_?[B:0X/8HTH8%!#B
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MQR><DK[=?6AIFN6RHE95G1;;ZR/Z[J?S09ZR@&5 \V7R?VNMO;0Z,(AN@_8
M+[:S,9]B?4U0<7_&H#*^E7;]+*+C2H-SKJ^+@>X_!@<3+[5$^%?;R'B?7Z][
MJ@M$FK\H6VZV)$S]]K3B=VWP'FA\YGAW.=.B[$JN=F)VN+J+];D//R<%A)1B
MC)-!921Y&@ON:T@/[DU!!F@CDU *K1=WC<RUP7*J@W-3<T;>YA5=C88XJ2'V
M*Q; /0GK3BSE)'*REWRC,NK-OW[%$(A() $,NZ*SG'^,$DR#]1*WA9"%LRON
M5J4ZG;=N82ZH!1ZTN9(,,+E?5D$*T^$;@_-0G _5[N)(<*N]),Z_0+5MJ+)
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M04HF5"":(U0(%2@:K@4(N_MC[7#ZUY'..YJ]=PY;MD_M#M%;2.\S$*,]"Q3
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M2U/&!1$F\$]Q9>V?*W;?78OD-,,\_@KDV<IX=/^C\-IC&-%LR)4-Y>]@<>2
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MYWC]YJXHW^3_[TS^_QC?_#]FH37O,?X;$$!C<OD;*Y?2L0')0+G3R'=&+LP
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MO@0]CH7&B#K2/"/5F>VF<S+C)AZ$>/?T2H%HCN=@F'0O^NJ;V?ZKUU8>_<6
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M/=P@8<0I&*-:Q C+NP'2L9-^[QUEG[K=:QO S#_+!DT7#TI5A.DR:=_/N8@
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M<>,9VH(+<#G^^RC^-(+I[!//]@%6F1(V@&<L#0PZB,7UW"1C)\"P%F428^G
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M\FTTU#6[']1GR*YWY,\VT1"IW_]$&^0.7+M*^!9C.S]_QR6NSB)4H>O#O.*
M*[X- >ILP>@^+-](Q(7!+9@G"50/?E&.L0#,BB)>L;VVBR68[7/SF_2]5Y\>
MDWHM2$][].ZWXINS-LCEN3.IRD=4#ER]Q[MV+FW#B@E),;Z!+0KV0#%RE2''
MEI:BC27]@R='XSHV#-WT4UOEAG_*.7D@1@S^F#87[/KT5D^I*<,BT4'CF?QD
M^3D\8@Q)>4< +J"3MV#\#LPIL )J)Z=EH)6W^%%TPYL8@2Y%-[RL?[04'4=W
MJ7L8+"4B)>0QCIJW;-+I\-K%L[G' A/ZGTDA]S74A*(KAQ!D)HOMWZSLFD)-
M[J>M(@0_4]U]=)>5TC7U=,X?ZI6PSJ6^NW9QU5KX=&+Q=:U7CKX0UP /C-%1
M5/(4J@U1#:5] :9\#6@?Q@CH<2B@1J2VF# 4$+LF/&:<3^OI&;!>Y@*/U9VQ
M5]EEU<)%62<%IBXY_?!M1TY"41[_"M<6@ OHXZ66+!GZSA5YO8QTE $\2E@G
MNTI<_!IL^&AC%^Z^JLX]HK9TU595,VT D5-XVLAI,;C D/[M64CH&Q?=^J\/
M5*ZXZ;1>3?VT\\%!WCOBEC>/9'SG&W;J1LA"N?LUK@YUG^2_O<#YF038(<<'
MIVBC%<#7J0Z&?K>'.F,8B_A>Y_9G[J_7D&?VIT*;WDK])S+2.E8\J<=Y2SG9
M$*HD[,(%$)(1LJ:Z_BR]7FH(GL#_CE3+1@->G1YZJ9ZLVPW=M(]=;[OX4D;S
M0N,]FU9C#AVHX[\*?_.[,EX54O4&1BR/*5O#>55'N!?=-=95 /4%URXDL/3;
M$/8>9%0].+.I<BA=ZRWJ<?!YY]6TAC85P< *3BN)4O:?;(ASP^P<, UA[9L%
M:[L("O51!M8M!Z#D**<S^">ZL?[^7%U#EMLE-\KZX5<[G%B'2]4=XH2_"TQ<
M<NKT$-J>0\0.(T5P 94P;A\)L,>-W^FA6N"[IC[?WH(ES1H"_9W.+>8EG\NT
MHM)?S3X,XB$VAM.,%'.M3"[MVIT7P4R%6LAF!Z F2<Z<9"0%PO$U%S$>C/6$
MNAA=%,VQK +L/B%P"LAP2O/X)K3LNOM5X8)?S^,J*^73NUB98\(\S)TRJQ"W
MM('BAA0#3E>D$;97E=?I.UDG9MC:8"]0J!A(D(V4C<7JVHTN=\\?S1JSKVI-
ME0@.^BGXD7WW9<C#[E!" =(7LCA=,GV#Y8?]?!39@%Q*@$P^->\*T%=<O-2J
M@O< /X1XKSNX]FGU!KU*JB'C&@PN7O>CH8^U:-88W!CFV?2UP 0RX%R10P !
MZDO\;?9A3BM6G*T^RO9%=@?%6 /DCA >W;6C3D;<O:1"F\BUC67T;<<V]7BJ
M<LB34RD4I30Z[CH2CX1XO2S;J1[ T0-9/)%6;5CYUJ%Y E<*+LB^FN[,[7\F
M+=U0.&AS5M63C3]ZU.?B<:7Y.+.<EZW[&$9L&5YF"4AF]/>0!9&4?&35"+[+
M5H7J0=)/9H<R!+K($IX \U'XITL&FY=36*:K[C:R/UU4]TDHQ=TJ?S>['2LV
M.,UK^E-$:BZI8A:C/X+AG</MB'RWV Z!1*QR(-&^/XS*\9S6-CWM!^0=K'G?
M$E8JLO]IG.!>6,R,3"=VH! )$@$29;9Z#G<7N:,$S*/U6C;8(MHN1":1SQFG
M]X9)V[DN_Y"GG)U[.']G7^:GQUJUN^!?CI(!!\*4"1,'C@!_/^*V34CN+!A%
M1:1A]1H 8A)V;Z0V[9['WOJA^N;G9*]J4F)%T(^,\Y<?V!4\./CCZ@]8;*\%
M)I%U ==F@?0+@7/'*UC\W Y"C2&^D[S'WT.8R'#*,$1+@PLG>,]^7]+34Q:Y
M3?Z!TAW^-E ]F;(COB0,TQ9;QK0""UCV&'LPHC2 4-^SU',-J.R255AKN."W
MZ72?.D8/U[:(%Y+D*J:\3'EI\ED'>REESWE1N\N/'L =7C82)O4A\<ERY3&*
MHZ9!@ ;E$EF2[>(7E&T)7#+;1QRT>[XZW265V]S$?TSRV,S_'+N,PU\YMH$3
M6\XUA+Q=UW< U!<F:8N2ZT2__H8#U>[:?)GW,C5YZ<;_"\)L.LFB)'?:E$V\
M>\$I,K798:UM?/I!1\-!N].9QN(Y<FQ-0BIB[=:LQA:,M&L+EA@=+C-9*WK1
MK9+-C_P15:G99A0#62KO]I444?C__O)-4AVQ':<8Z4LIK*]8V((I&<YXSL)K
MH_+#E^Q37O=]/7?XDF^\.3Q<9LUB^]4$C#6#%WJ5BA#\0PH<#N;V,6-PQU7(
M-?,:(4\^V2<ZFA:.C-W]&LBYDV>2AC<(6>[R#X\-*GG3EN\-^N8Z,>VS\U3+
MFUXO;[CG-#W[]V<8Y$];6P&]<)/FW-1^[N4ER#O_(8#N+5A=,D>*P"Z#8!1C
M@8-@H72W8(3O6["/>1O;-^]Z_D*NB3ELP6!Y&WN02TX4E&3D%%<2#5JUJBT4
M[F$9C;-7EH8M698K2$4BG#H9BE]16$>#]DA)Y.^?+:@M&!8BR<+S2$]2 D[2
M3!+7#LE'1*!C&[1-(KQ8&IO>AS<*T002QZ'AT(?HN>-S'V(J,++AC_OFPT]D
MO)PK?O:2^V71-Q;3/Q(9J/&ZQA7M?*\(&?WG2RC+;M+=S>;V7],>KC2J$[]Y
M/$1J"T9.P;7C__O'UQ:T>[D#71%H4!3W:1U7<_!$\1;L;O\6+&M_3;R;FV;0
M]2;_PF,Y'KZLP5T'G5F%]1O0_W>6@^8 ::Z?+8-@\H!6C**/QDYIIH<J(BM[
M[ ,FQ8G7B;)$O_>V3]-J+"E)/ /.ON\3)DGG2]_)+O=;J^;@O_1/N3%O@4Z0
M">IS7F*5H<2-0GKI)S%GA4'KTL4[LW#.:XP,]9.+P>B@OIK$Q&+Z#?%//G6-
M5X4R=G #]L),BQO)H.9Z!RD1S8>DU%1O[^_I[T&F(\3-A# NX*F2W_D:72OW
M6H\/KP7:&KG5-^J\QQ:'O6[X22R45+M/7O?YU".DHK&D:U[Z9Q);Z:7WI,S9
M/#S(6+IPEK;WS_["MU\F^&(4^+&A4+^0+9#"^=+ =%:TO\=Q3AXI9'OCIA)7
M"S1ORW^4&X'5 (O+(U_WGALLB7S^3*SK>^1^O55+QWU[KVLY'Q \NW%DCMP%
ML0)X._J>\E&(85"R("[=OP>S!TRX2<SO26X5BT2BW^>='S,]3<TW.8#1QP5_
MK3C1/5[U]F$7R>2.WB2G"R GFNI2Z"8LE79EA:&U,MN?W-[7$Z\DED_8#<-\
M9U^8[0"T(Q]'?@?UK8T_N1<Y&M]&^_/*]Q00<:AH&#L>R@U9H!4M9Z43,4[B
M"J-8=_0[^V&1CE-4[_<:/81=&)61?V(JEP#^RE+GMF--.>76C4G?I^NJSO.?
MUJ)[?K5W^T[R[1/@"KY@%#"[0.L2C '48C[& YQAR%DPI!9Q\#6QP#F[)EJ!
MC6*IKD^N36I6R&'%RZN7A^ON*]/;S6QV(M]*6BD-U%WL+L]X=;CJT]Y_?(Z^
M22UP"FGGJP'0I%W!(XNHWTJ]W6=VC*^",S]>%+INP /^K&![<9+-5+DSN+IW
M$"S<^8%39AI$#=K>]"LQ7P_: Y,K--EFZHP*5X*'#W>U=8B^]N9%X%1!QJ=!
M&7]53ZF?OV3DV)*'6O0@\F^+!S4[0+F/RGN!=_>XQQF]OSWV,'SZAB=?$[PQ
MQJ\%WTW2?Q#H.W0+K^9,='@?D12JG+!U:IN5& L//!'C!KPKB(HM:5@4F2J3
M_Y$[_N]K\,='R-/:Y^+,3D&BL(\\C$Y! &<0\21X>;W4-?5F (ZJREP]E,"+
M*HG"7NVYB8Z@H@]#MK0722G!58\M\;!$?B.JD/0-AH,=>(B!IA21?[=J 949
M1;GC,\\_%/J%E*.O3WU2S[0(]R-*1NP2?A3!<2[_$/:1*\(XP7GWAH86](^^
M/Y(>7-/4.C27;Q/V].?NX4>_AJ1Y-AB0H.3!=$I_!JGA%ULJF?:K8\:V'@Z/
M+*.IORGW<ZIQM>9IK&WZ[ABI=NA+F:K/PX&&]V5Z-T_N39N!AO)1$AE,'M>]
M"Z'AQ"W8G<,GD#4_*DFESW>0)-A2C'3(U8L88\RX81R%2*Z'=XH9T4H2L0<7
M%7P3N5+]#'BGJVY]7K+$=W]SRZI!]7OD*,;39-1A:VM'E5_B$$N5>18#83RA
M -=_Q+1ZA,B?,87B?.G:X9*:^\M['9[>>W#_RW%3WMDXY/:J9B2=M@5+",(%
M:U:82KP%KZLQ^CO;Y)+^33UYW3KHM/3=<Y!F76CMG;^/1?3?,UTC^;4S"SL"
MKBM80/QA,#)>\X%6Y9+'Z;<9,"153LEI=KN(I5PWY_0B%'6VI[,_0(/-C>SO
M6!\CB;8*1XI#(W&G)][+0X_?B8;&KJ-S;>1ZIN'U5=T?>!V*I,AS6"Z,R!5V
MV!8N)Y=T@SR5P%2%.-^SN0)4BG%P NN\WQA7A5&2_#RJKN]PE'WN%,HHYDQ0
MZ.&HU<>7<BT:=K;_#-O<" W9.0T/#-]A(UUZ\>R/"U\6+ 4A5[CSMA4!C"6;
MJKU^=Y^*AD_XY_IU90VAZLYZ7HQ2U8+Q(,_!FM$YA"HB/8%EC&O3( 40)ON9
M3AR2F?H$VVC8U(MU,A G8RI"0\DD)_5V3BI7RC1K-C1.7G2YZG?4].KR[,_+
MUDXBFR4NFROWV-JTY/KLSE:%H7^RU4]MO<=&K0\1']V^/2O>O2YOP+,AQ8*Y
M!"* "W1]KC#N.5O_^S]]\7Y&]+^Z+9B@5:7+AXQ^F?5DO:M5[_,/[&@Y$*K8
M83;&$X_Z)& XCZXBX9&4QUA^SB.,+E#+A!)G_$ON$&*'F2;;!/C7<'<.$NM[
MB&T*T$X(U:4O'LL5<--6NTGPN1E_UHLX_4;Q+>PH!?MGU*Z>@N0%LR\WC+58
M4/K4N9N]7-.5D-N_BW/%PU9-#FCWFTJ<1/"!15RA%98>=X  G PD3*APA5BA
M[VRIO-0R>@REH;@\_7$]S]NN-ZBWKN<5?JH4[E.;_RGZI7Q?P6NXV0E(^Y&<
M%YAM^)['::W 48J430!ZW^M40(K2FD?IDYU<&.]1C!R[1'3YQVKDV>V@ *]Y
MV.V5=5C <'/* H8]@+$"?0 !IC4TPGKN]X'M?>U;L #R?30O^P@#?V4(8P\4
MT>!WS306N(H MS7^>T_$M0C#=,'<Y8F/@NI[-Z*.\V3CAJ&@=+Y?$-=V$'.*
MD4TC=Q/&(Y@U8"(CK_M"I-Z0)8.8WN(U=]^I\V!%4=W@Y%1/3'2SFL_!3W=Z
M5#8"IA-GCZR/?J"2X6#)^6P+AEFB[QN77OS10>Z(>BIC2(N2L.&P%BMG"2P7
MR-ZG<M0GN[_MG-I9_%1$.A1O<1G&L_8<WM$OB-$%"7/ZH.$B\Q+8 313_VW!
MTJ^#N@RCLV!Z1:27-?&(>X#K]8)W"Z<7CA4A%H5?S5Y#S*3B _ZA01TCMK0;
M<_MP3A6WXPX.L(/0D@:Q2Q&5AI3D&H/)IXB#MV-W=$>I ?^>M18'QH:5!O \
MQ'8I'0BI[DQT%A+J'O%$NB\:60&^"6R3-^Z+R@C@=8%71*D9BU5F(D_+^EG[
M]-,7GK L.[OH[P(_M^>D$,Q",(0EAVO[B(1Q=3&^L:>1@F[8?N-1 @TE9>6E
M^\7O@DVIM VK\H!+%L_!)*,\>10R;-?S_-$6SG.L%*[-'D=I0M82,TF>))F>
M[4H*?6;2C*0W#"F:;*)BZR.]^F;!<EV#QN6T>_DW2O(OBXAE@,>MIOXA.^'C
M,5U<*'C'OXF48V[@NR;/@3'M),%PM, LB/5[9>0D-3-3OJCU],9J>_PKJ:>%
M.6O(Y)9#U$K!/T66 "&Y_';SP27:F%W=6151.YN@D_RHL-DX,S&HO?W[X7@D
M4><N_QP+'?B\X?A>UTD*MN1O$5?P_-M6$PYQ1RDO5S&AVQ<6L5I>MK8C#<8^
M!^"62 PWYF?HU_J0V9U!^E;&*YS/3TZK#YF2ZA[+-WLBQ/GY=SQ@T_+YZ$#F
MZKG<"@7QI063X589L!DR^Z-@&>MX, CI>>=M3G'+T<W,>[?)2AAU1@E=A)90
M.G&.(?]NK>"^;J_U39[#IS]5?\H2YZ=$<:K*G[0(4&+PDB49RZ:[7WTNMWSA
MX!AKK'+KN2A,3;LQ=.4DH@!1#X_C[L8<X53C*+E;,'$S,8O2RH0Z[8KHGO:'
MB^KFM_-O>\C=U74,.2@@*9C#(\K#=S7.(@+R <?#5FSI(B;OU9LX:@@8YQV-
M\U)@;4*#)8X@ _LGYKA"4*C>.<8IPJIPIPB[DCM6Q#&7P"!*$V8G;8_7^?>!
MNL[C;GTAX4IA%E*5C[.4+SR=R^><'@I7U/6R(X[4327F3R[PY<]>_OW[X^&J
M_M*]P\,7!*C<5*"'>8.3B:.\)-65=.B#FK_H#QF]E#-H2:X.&F11(])--1B!
MSD!_$L;^]8+ URPIW6P=_M41ALA&,3KXX^&W0IMC7"'ZW'9%*]02ZQ7W.Z*!
MN/23=2VRIX>I$)Q7;-2-2&U%,NZ4O%-1>V2$]D[27OS1-_0J^+>D;/9*A_Q&
M6D4LBZ8O OIV;?H/M+A0I_9<['MZQ#7@:*JI1;)Y?=MNQ#G"^<&U/MEV76W+
MH>=U]7>/G@H*%.Y1"OS]]CGL1"(,*S>!,>&4M(BP3KKAVH9:#W$*;G<"W\HJ
MK8]6 U@$_,7H6DCRD$N/+SRU(^%O0+P,ZTQ90D$4_%MJH\9W N!*F*RDYB8R
M%ID[.%48Z6QPJLV<YEA4:1%!3==HC;F_;ZVQT&W<,T,N[PO1MW'\.6DYA3="
M9K,$?10[0:Y&W$?Z5TZ6,8/ +1B5M-L_.CRY35]QP76VWBM6*2GHM'8!HE;G
MIO1.<_Z-3!J_)N_<RA2)V<-Y2J*4(^K(2\4L=>Q'G)1.J^H"5@9JX@7F(J,G
MI45?*=L%1)L/#$;<:6R<E-S]VK_3[]ZR^(Z:^-^*7UH/80Z#$MM%N-JN(OWV
MH+C"4JR+[ !0C;)RWRG:* 4K@[$$Y#K[T!WYLG7 1)1<?O@:4U3%K50)NW3>
M4F7Z5JNG .?)=_8!:HBH=;A^4HMAR1]Z+/)9].A1?XG&;-9*E1A]^5: >T3'
M)CS-X+,!2O)W;O[]1Q^C1O-&>PU0"0\?W3S%AJ+_]KDAPQ85R)N:&7(]A#2D
M M(3.;E(T^C&*TV ._9(=2MK,9+QAFB)-K%[62VCS,\QT:^/RYO:M:D\9%?U
M/6C>F()PC<]#.:Y@*+#O=)PXX9TWSV+E@DME4YT[_ PP^T0VG3JC/-K^GXB=
M\[Y+VFO@\DE>0"8@#BF/HSQU);"E(!(QCHSSV"Y1\#Q@X ]9G&U+ZPNTK1J]
M[C9L'/S.U/S=M.NT;E_^$YTG%BTO?-4N2$IDJD[.:"Q9,Y;UDW' )7PBH1;)
MEDK@"CLQ!)@%()+FSNO6!'YX&3GFM@6[EPOGF6H+)-DU)3NO7NJ8G\92@WJ-
M;"NR?CO\FUS]-G2A/JN;.WJ<DB-L(_II]Q[4A5,4?$ 1E2 0:=7F:/L: O23
MP=G!JW(QL8>[CTD4L+HNP% ?8%@E[%><.-*[?[QC#M]-GG#C"MNSPMG1("_M
M!2/,C:&1$&(0DK%)3L(8SHGMV+0W;"T*&/W6T!\ZHLZW(BIC?=WJ$F?[&/T)
M$ 'E?G]J92I9#GD5GHD] N;XTPB[N^"9IB%SR%T!QN7O"]\$!CSV6UX9\/CI
M>&#.04ONM.7WSA>\BR%2D2;M9H8U[D;=9K)#X8&W'QB[+=PY]"V-/"M,B8M=
M^/=?JF)+_I>JV,,\#".VW!:,MMX#CR=7!56FF4F 8UT>,M^76U5_'T7(FOI3
M4L@LMX[67;EW%'+^E767,\X^/]/JF5'ZX&%F_0:1%5["ECS"E41,K/9RA=KF
MT+(86\897!TZ_EV+SQP:=.&JCJW-[.^V/<GGUOVA.>NSOIZZIDJ*I9J(-/V>
M< 1V"]8K[=#YO4_AO7'.[6L//O[CBY"QZ2B4!D@)=7]?@58==Q0NOWGP*:AN
MRB#^\*^R[313 </>V:;5D(=^-3O"J=R7P"SBU)F:LY#L:* G\6I:1T\KG%&\
MDEA_W"#JR7R:6LMJ7_&TI^T63$4@_$8&[*-R)5?P".L,]SM2F;N'[3K$W8L)
M'>7JLHT ?&>J 2$!*8^Q?I&N39;QUQ9^XO+I+'>TJG=5Y!FI16W#Y$[E-%8#
M0">T! 7NP6>P-5X' &=8M&2'JDRJQ(>3#W;!/_BY34U-3/7X^^^PD#XKJ5ET
MX6T:/PQV$[:GE)>&!(\)S,&[T?&XJH8G-%R2AS$#?:_%*(IAU;$9T;4%4XA4
M/HZL;S&A_"FY]L9CREI>7S2-SWI^[S1?LOPWJSY'+"_D8NZ50?M;FB"#B;<(
M4ZTN^QP6PW($[U_/2?D<);T0F*R1=31#,G*/]K\O?M>:$NG+^UU4'IY[;_SC
MH.FN4PO:6<C:E8^6:@64Y'M"&ED8P\ M6/=OWLK_0ZF'__:PMS'P$$800HC^
M9% ;L20!2'69:8T8/(-WXAG&B%T-]]]8^X;&EG2]\B?*R>[P>^)]=MDKL>+'
M^)?N Z]@&=\%_B3E5?AM3E]$O5P8'?.7KI"N##3^)-%S6<VZ0WRN0J&UONBW
MK.V;Q??U]3DUNQ1HR^'W>31@LIX"ZB1]G!]B D4)84M"?F;#TL8X<.+9,H@.
MCLJ<0.8[,V6,':"7&'9P\!_+ND+!QJV'Z*M5.W6VN/,MKU)<STYB9 ;7$(Q@
M;1=8LR3Y(Q2Y4Q#&PV<2Z@K3 2+M$G<'Z$O%[_R3:U2H!!179-UHS*E8#K<Y
M.4:T.].G8J4N==5122L..VVU_UR\\]/#53M=[$XIUWNL. \:L)ICS;9@EQOB
M8QJT_?F&WK9TBCZ(>UK-.TC20E[KYV/? HT ;>8 :.[#.HQQ!J^QS'#MK8TC
M7$$032-GA1@<]QU8D;L\1/\:$7'2-77PN">^SX0O&7R6"@'J^-VX-@.2CY@(
M5X@,6#$98"VPC%-B.U4#5XR7TVD?PAR;<H.4!2^BJL>=K>:C'+]WP2Z-O_G;
M?':EL>DY?'@/JE-!/%6W1>$;T==O_5;4G3?AMQX^(>!S>"4:5X\IUP>3H.Q#
M>4 &(!^9L.$*WV7M]B<#%Q&@9G]'+SJ#(,4U"#!N>/$FP$.3U)A//EV3;M]4
M3QPR ',OY%9U/O#FX\EYEG='YF0>5\0DYAH0T4VJT6!+XJDK'<@TXU]M)-G6
M1NXA0*Z=;E\\QK8N^GUGUX>&C#PYIYNF#4L^NJ'O?WH?[)0_<A 6AWWKK\!,
MI@EZ_#HU&J3OE6FNE.5Z12?MG?$;+3MX/2HJQK?$U1I7ZM[%M^M%U.O\DZ5I
MQEDH&-P!G5G(!QZ#"#(IJ/\N>GLA*0]"8&=#)J4H6@1EE]](!2F/@3464GS1
M3.(]_^[YYC2RXWMR:*"*5:A2H?,QR2/'M>+?5_)RVW$\N&!]4'^,_JR(.V1\
MXE<J9A_$1=C&S]@B9L4&KAYO8O12SA@YA9Y99"81G><EBK+BIIN#=-Y>XOT7
M_X79?[$N<PMFUYQ&$WI@ZF"^]W;X"4&5^!-=D?ULJ2'F-(!F2]LP[;\C _63
M9\5&#,2T.^4F<^I;\\H_*UXY,QHQ--'DM5L[*7)W$MQR]WRK#J3W"&XOE)"Y
M>[@SB(9^MJ3'5/L@&K/#UJC==389^'6!5!BHJQFPB>E_XW:Z3WTMS>6BT;C\
M3F'8,DH#$D8GKLT8Z1F%NX9,)! -"+6S&5B=B<56#9L0Q:A:SEM#6R?[Z@L"
M3WXR EF5S>NQ&\_A(XND7;\5L"7\Z;AW+FU1MY$#0>I-%KDAZY>>$BE:/[&'
M TD[M\^9HXFM%0P!FOY2#M0[5<9ZSPE$I[+62-Y%\(]1IQCR=*R3@]Q%D?0*
M]47'X<$PT; \YTFUL\,]598RAUSN$!K6Z0XT/&@X1<U+(="8U3YS>.7(R2EJ
M9A%#%+U;?^GV/$/F6_Z8[4WY;*-Q^JC445K7T\:@3D,8=LA_<_1^F4UH2''
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MGMNYBJO&52]YU\\P"2=:AWY%%3!^]M3*]_XR7%F[(!"'4> D(:GVD(><,C/
MSA" .EP=DAH2B>O(]V7O)X\7.C%1S,O-'?.Q)?TAR#YR<TB.\E<O_=$6$A,*
MP_&>V$$"@%J1F\"8@>:LV.+UC[HFG:X-)=> =!?P<L#Z*,.CY2\G)[SXO<O1
MXJ^S?EX\.M(E/#5F_2_CD"9<05S;/EPP;@)'91:Q=F._(8&+;BA1;+^1:\.+
MH]G%E1V1KQG7[Y9X3%N?^%;@\\:P)ZL@WS]MID5,-4C]Y\E+CLST[:HYG-PM
MV'4$N!^=@J,\(]3[=EN'HY(*E88,G[DY,Y:,789*!O<9/]JLBZ@N>7+SHHVE
M]S[B,9QJKON[BZVKI<L502$5WM6M#9E^US->??]R-V<X0V8O<$IIEQ_OQO8M
MM/$%,VCL$*+Z6QY+_@\"N$(_PJQEY&48]BE:@[9 +Y685%<66%!&;C@MQB2%
ME4Q?Z36]P_2D?L[[Y*!I[2WZ.8?CS6F&&%H!#AB-((AQ#V+V@RMOV#K@9R!Z
MWK]U#]MZL*ZT,I>O4"9IX=OJ-\=+S?5/I/DS:AY.5'VK7"[D!X4 ?6I2?2@-
MF43:R=:@TBWIYV;(O[%*]77Y/AJJ)IUI7X_TJ[__ ML(9$9P"-"7WD;[=L?"
M>PCU>+:T2)OKKWMKYC>#V4(4_7O^K]^][P_4.53?1^\:'NQ4>3AZ\\';I,AA
MV:D<Y,4!"Q@VU@\!6&_!ILJ8#L,8?^ 75Z@2HEQB ZU*[ .,;E)4N1MHWD46
M';K2!+C/3 4W!:G/T0_Q2MQRW_ODG*65X_6(X T<)1,G:JH/*>8Q \F6[*"&
M=)VP.9_0E:\[;=S?J1N(4KA/7RZ).%:X:%^X3\<CL#E^1U1Z_6F].:+&4K0F
M+P%$4=#@9<B+3 V!(98#G0QD@MC^\ZR0AS]CBY8 58_K?7VU=[[2IT.?>O^K
MA#P\'H]M2V7%8C2!DL0U_0PG,AQS#5BGJ>?-X9.YAM4#M&'QG/+QW7SZ:N7E
M96$2+MYB$CZB=[+.RB-/VY]$[&'[0$U<8U_E5)*\W,@3_<P93FU!%_?8$#L\
MB$9*1LNP$0 3+GX%M.,.J+"D'[JJ#?\YTJ,Q:7/\H4W/[4]'I5VTTT- M0AZ
M&<N6?1&,J,"UV9)"]L!IR+M<&3"?W!F-N(N1 69N:[:<*G?S72).ODJBN=,.
MN[3V2Y;?<$ZX^P +OHPSL][>T@\9B1SW(':\< _G ](;/Z6,2B!+KE4F9T<J
M.K>T CM)J3J&06(KV.D'AG5CN^2?Z5GC#EWY)7PH+JR/C=N^E1([.DFFPX$M
M&/,/Y\D6+$A7JH.DR#X!O(7S8$Z/8*P P-W/P[#*)??/?*#\N\M+2C,;V9J9
M3A^]\3<%;3CU4!QR8^W?SI9FNACQ[4)T"R3@(@H/I8)G$!E6BBR@&LR*,60+
MN6)XVYK4@HOUS6DV,IG4KHIR>U?5_=-%S<V])E]=3^<LX*H(2X>V8*(.E9C@
MT2T8%8+ [;:04K/GDFH9\"_<3I8<TVIJ="=+'+.!'?BY@5RL5J:3%\:46!QI
M'BH"<$"-%W"5]5GBD7^94#N)T& $(]CJH\Q#N'9KSGW."Z9^+7G*PW>)>]OL
M^DKMTA;,N9%<&)KPAR")%8WDG=-H<P^D"'2Y2^KZ=GBH C\FU3]XZ=D'5ZC'
M=6C]4'JAU<.G]*9-8*_"PN_G\+M8V6V6 HF_? M6"[^K@X0(T$0>5[B8B@<=
MHY5$O*B*A!0D_]Q(RZGG_J5'._PT,E?E0_C.[BCJ56 _U]M1*O,/CB?YE&*/
M<KM<2R#D8<X^V<0HB,RFKA4J,)S2@]?&@WX-S^<.=^B]^&&10GWT"?/S4GL1
M#U%>9M'@@L G G"6#*IYDX'S*%AD>T<WN<[B5Q=! 21?&OHQVA)1"F+\:S^7
M_)G$'#4.OYM.E]N9.ZM)%O=6W2A1R7B*2$, YW&33E0<W78./0FY; D+[4\2
MK4>D_CT5SM#_:&8 7!@S198O2*AW#;\4,CWB,BW3_Z0ZY5&U;AKK>AILH_(C
MK@9-Q]$($T1:9=O*E!QS>(@=58&Q 4:6[Y>@_7#B5P>W[QXV#_4QK!74';R3
MM3)?\/5Z[M6^*DU-[0@*:0G2K' "5XA4!,G1C$2]CH/4[<W6"-F):W?GW/^Q
MT50=B*KGY'T+(L7@<N8+'Y-G/\RFP<"R'A)@I:O2@P3.]2?C +OKG.>5:RN[
MV ?PEJV ?I?MD=/.KX?^?3C4.Q6PH^]U*/[)R,N_J"^_Q,4%:68JN#857#!^
M<A$-NL\AI[;K0[X.S,,)F6G^QNH#LW<I_8F0R)Q0UVZJY2QGT['>1(>]$JK-
M]QR__ U*,M=S6CL,C=R(^1TR\N!(UIP 786Z78+K&*?8!T0R2CJXBMD=>?G#
M7"6\TR#&]J7!;.30/T6-R-[$O'GKAQTOCG?(9)28L_0P_% ##\ 0VHE?D)?<
MP$T1.\ST!LFG"GOL *.[6+F>HO&I&6O5\\25<-W.=:FS:9GIRHZ'YJOW91Y:
MNR_- V48ACE7:/LD<0)(!F+<.8^P>K@V)U.ILDC>KFB#3:/4%AOXQY2*%NN8
MURA%B]!@871LEE&6NM_77OEKC547++7IJ+@M&#]&AG6<+0'@ECC K&(*^P0%
M)^KL9[S?O6_^O*ZN[J!@2\_'69:*>]_=[.S,P/+_FU.K___Y?WF06Q/_ U!+
M P04    " #!@T-2/JRWWOVX 0 K50( %    &)I:6(M,C R,#$R,S%?9S,N
M:G!G[+MY/%3Q_S\ZDF2=[&NF0BHAV2HRJ9 DK=:8BD@:4TG(<HKL6RC:IZ)4
MTF3/.HV]Q(2RQLQ0)(8SE7$T9X[?V^?[^_WN'_?[Q[WW<1_WKWMZS#1EWN?]
M6I^OY_.<8[%_D8U;M=_.P0XGLDP$=Q+\P2W.X&1M?"FGS^#.X, ALCB$VX-;
M)K)T++TO6SJ6BRZ]BRU?+KI\A=B*%?]YB4NL!"_Q%2M62JV4D%PZP"=I*4GI
MI7\LG>2_EBX3$Q45DQ1?(2[Y?_M8?(^36RF*B)F*BJS#+9,3$94366S"$8"-
M8O\Q3P3W/P^19:++Q5:( S.DP!?*5P'S146!T6+ 8O#3*/!SW'(Y,?FUQC8K
M% Z?$E]W47'K]<PG*[5W%S.4CG3!.B:G+\5(2"JKJ*JIZZ[7V[!QDZF9N<6V
M[3OV[+6UL]_GL/_HL>,NKF[N'CZ^9_S\SP:<"[X<<B4T+/QJ[(VX^(3$I.2L
M[%NW<W+OW+WW-"__V?."%R]?E926E5=4OJNJ;FAL:FYI;?OPL;OGR]?>OOZ!
M0<[HV/<?XQ,_)W_Q?O_Y.\>?1Q;^+?DE@A,5^5_'?^N7'/!KV5(.Q)?\$ED6
MNO0%N>5B:XU7R-L<%C]U46'=UNLK%7=G/BEF2&B;'(&53E_JDE36,>7H\I9<
M^X]G_]<<B_E_Y-G_=NS_\&L0)RTJ I(G*H<CXH3HT^0-N/__]?_]BW9[$<=^
M38)=C&))\#YZK+<FTL>C<5J34,=3HR2%-/GNGH;V(+]D'XJI@,7,,1NH4-:4
MOV2O-&<;O641Q^ 2?I^D2Q*GWQIA]V@O<(NXQ$'B2=(_,T(J87YV_R+N^\=_
MA9A$QR).7!-\VX+.SF?)D:,ET.T\O<1(M;$B&T^!?D,]L>=T6>[1,T<^Y?38
MF'[>SUZV]TRO'>YF@CA! F*\)9;TH?)_QL11!8UC/!HW%W9FOZD9W5>O\^NS
M>1%/?'^/3EUZL\'YCT;W+UDU)SGNLUN)R]&NB]X;/>A"%+=6 /N>L#I,7L0M
M;^W-FFCT(#1[NELK>9T-90;+#^=_K@T,,'=KE_>:<7N@_"WYALDRU6M0H*+K
M#SRJ.;^($PL7ED#LVT0X;Q''R0JAX0<6<0WABS@)(U2',%0MZ3TK4.&[9I9>
MU##F5Y5.94Z2%"8)\ 4ZJC++_X40GP2P8&>C@8CC7XRLC/-?D^10B$.+IP[2
MR5_OE*5I[IO4+2K9[*3J=J6VTR;R&F.7^%^R;;0CL-B>SN;0"!!C*W02NM9;
M;XB$XA,7<0%0$FMEF5.H]^=:Q]-\Y7]*33E;A&]FL%YCS<2.\(F6G)<_(C]_
MDK+_$4>)YRSB8LH@1O\\JQ38'!/C$;F#@AS3]PW9<YDJ:YI1_- JLN7G;ONA
MCC?,^TQQ/P8]VOH<#LO>0.N@(FL(J,J$ UA5];-ZHH&0@HGWU&[DA39XG/ME
MP=]AFGY92'$V+#;[\:JM0V?]=BW3+#W_UOL:^F_]W+ ]8-4(Q.@DEA,:H"&%
M(\(8(OO.H/6#ZLKXN1N?YUC*[4\,"Z$7@7%-Y()^SWWJQ.&/(XXJZ?99)S\^
MV1V[1OP7'E7&8Y(:KT$0#!=QIV4"^36?HU4\D)8)A][+4TJ?9^9<2AS$.AJ:
M3GPL;K/[-J$1SG^C@*T\!7)U@:<"%O.O\D);%G'RD:M*8)UZ5=[=SV,]KT/Z
MZ)YQRC=/A#\;5$U^\,DU"#_<&4YKP2.;)E!%!4S*D8@J)!P59D-L4&['>V\3
MTLVBMLZ_9\F?ZBYZ_:&J_)W#CY):1_O "QTK_6RE%%_YG,^+\2!60NP/T,(6
M4O(BCN^FL8AS<C$5$>RTC095:PJQ.4;(!A;7%AA6^!DZ14W&=.%;(\N^6%%&
MG0S'1UH;BALODZ=?STF<7'9R8+E9F?NV[Z)3)"^(\0F"C]$&&S$),FS"R<V@
MGY$A[2G[8G5TM+V.Z$(.MO7\<M:G7'[#\=/F#X=_BO[M3$9J, DSL(T\C]C*
M0K2=;X"6?KJ(JRA(*2O4>/(T+-N%][S8YZ1!T>.RGG*RG<R4I/]RS\&"CU6;
M&Z_G-$<[1MHOXF(?@44T$GQH=O TY3H1=L!?,_]GD%]D\M-<&=-(<.O3*]\3
M&QJN^R'0T?>'@\8RNQ,;<PZ"5K$_SIOE<L'F/2#QX1####-U1Y<)7Z$0+2!:
MIQ[^JSY<5W^7$WB_OR._U%G2.$MWDZP@W&XD#S=/NT5D9]/+6U%-5[(@."R"
M'P1.412YPLU*;G2GQI$[876HKM]3J1<&]\X^]1Q>[URB;;S;JDJQ%#=T,36C
MD8@8T)HIR(:"%OR0?$\3"SY*BF?!*6%\O/C0X*0ZQ+>Z8NV76AF:1C'*U7B[
M/7-FQ?1W[F0S#CKC+<4+2AD#D!1@;0E_8ZY_6#1YD]3OH'-&[?$]LTR)HQ^S
M7F_;J7^0K@BQ;[+*"U#-N#'"(($]T4@:A/A^V$=$SIRZNKZ !I! C;*BP]AT
M0";_T=6/;D%G*C4JOL_,TP9_X3;0;M+99:0R/531DQ\JO!MI4@@QMM2OM!VC
M)V+:2$K TQ/]SIR%$+'B'N\&+#RHS=UGW[)V2M"CRQT_C!Z6I77F1Y^,]$ 6
M :**OT#E8>4"WGPKMJP[#QZ/\UF?]SJ@VB^;(S5?69[F6*-J\,@Q5_)QEO;F
M]_C39T7G?R>C-2"A5^ALNO4&$-*2#,5(,>'32'S>6:JB%2%__9O<1YH.VB5]
MIDRS-5FGI-.YRXL===:^OY0V\?+0NTW6+F#-/]!^#23X,!W1RT 58YN(I7K3
MK%&2A&>8IQ/,SPX/5*9QSLY,R'_S>)VEH+U%)TA/M!P7S>\B=>9RZT U_ $&
MQ,Y110A#!6S\=!<$I_"OO*M)P>0>!AZ"S2H>]^4<:9,?&>='E-U\]<E]V0=Y
M6PG#Q/3O"5 W"['(PZ3PHR1$/W>ZCC9%5:DU>1Y DJLGG(,#1O2=Y-0,C#B/
MS",\^\>N^$ADMS]4W_G)8M>G?/&5CPF/E7@3J/(8)IE&@QC:BSA?+WW^ WB6
MT4[4='X9-L-L[,@;F3(ZG?F:7YE]M[8Y>?<^\R=7N!/AV\>H[31D4RNZ6D1P
M'DG@?_M"/$U$=.H3SJB?K5]OK5G)6ZZEF>'^U<JI,+_^0%* =*&./NZ6:4#B
M</[0>-#QDWD3>,2 Q%V:%P$\VK3>X^AF%NR:,;";(H4\FFJM\%X/^V>0SY^L
MB#U>45Y66UE5<9?\D#L8$MAV0C59Z6A":I#+&D(-';9U1C:V@-R)G1%F&$+G
MG%>A:\M@IV9ZZNQEXSSW0)G(U+=[*&MR/YW-VTZQ2JL)&^J[]^\7?0/$[J O
M[(U^MH@[$^N^B.MVLJ:[OL#1VC+2Z'#8(FY:!*:,$9+KY1@P?I22F-N K:OM
MABK+?'N<'CTFCX>EPFJ&MU,/'BK)P=U>P_97XH>BRJ7\/L);%52!.)K!%7]V
MKJ&G:<]N,H'QFI9$+)_-&"CZ[GQ4[LH[;4$%E]1N-)T+AFL%C[F$=<M[A$\A
M2IT^]Y2U[(D _?S!IBJO?6I6':YZFE'WNO?Y6_T%4Z:!>&81-ZC-F><&"BS#
M]/EW$=>+^@C4:JU1WFO:]&YHO"';3K5QPY%=.>8&&M?VR:9NO>@U'&T,:O(N
MH8*.&E#ZAUJ(Q?;)9N1_M(:Z"(%C(_Q!3\_NR]WO&Z[-R8WH-AK_M/ZJ^F^>
M!0>S4*4)_@=0T<= NV8LXN(=>FN)_F" 3Z Z=/@F%/1S8P1]FC3@;=?1=+YU
M<)SYQOX9+IIVF-3Y%BQ:ZC\&@UAA-/W0GV?"UQ#F!!UUA,W3%W%P:?W&R6CQ
M>(3URW@FYU3@\B'VOJ=Q><.:%SN,>,6[./;=X#MD*JJIQ_N#26[G!7L),XCG
MAYS49YOYC[2R/>'*E#+R]O/ISZ2WVN4J]ZVR%]!-)5SVAGU5?+I/\ONR]X2+
M8&<;B%U&?^N/*JBT#N(!_/2UJH_??H5DVY.=]Z?LA[\V_ZZK_MBE[)>T[VC=
M/L9X?3IBS]O30-2H5T1\QNP;!57^GR-)G"D#RMY'8>IZ6=V_EC]2]@TZ=.?[
MD6._\2OHF71DF_UH'ZJ8,%K)#?4W0A5=.514VU7]>/T3?W@2*LXK%?C%FTG4
MOGR;/N+GS-,DG!/J@:CLQ'JI\"7E@M%%W, $QS^#[D<IQ9CVSI\O\WD$=&W.
MY").\>/@WILGHAX[UMR_J$$9RGXP=@_')R ;^U!-P1@ %2:J&.$EO&$*]0OV
M\6R?9P0_;:K7J>+=JBAQY$_I>V8=T#_'/F\A9M\97&GE+SK'IU.9B($]JG*4
MSQ9FT-EOO3<(;UG+@8UD60W5Y(D$^8$YYC)/;^_1V8,E][QZZ)]85LQ*01[N
M,NVG[#7)WZ0A"_YW82Z1366)!UGOB/ZZB%.:CC1XW&J4&3"A[QCRXMNJ_4-#
M-JI;G3?B'KZ2_2QE?%PLH<CU]V$ OYNQ+W3%11R9A6QV3:H7"_CWNF^'4>/P
M:1;#6KS+:NR'[:7(9S79%.>MGBT7F*FWTG6WRR7CA#J\11RJQ1&L";#6OM?*
M*9@.X"EX]FA?*CZG7D'S*?A@B!_Y?8AY[6IJ?=0N6C'$OD6"+Y"F _^#(.-/
M8!^.T8U:'PY)<])#L;J9E8 Z%^P]G=.Y_52RPZFJRLRNF%J>]#[MX)JX-?([
MJ/TFV$K04,MGA GURW[2I8KH?M#RL-:FPP'%!<E6Y%&6U- YB\&Z 6>60_T/
MS4:)TT,G#ZQ[(R(]X/.3M )BYY#>4J8Y@D-. E)T)ZNT(H%-5/,.\YO:_27C
M!KDY+NY'_A\;2TI)RJK-U[F?D^3DTMV,@[:(_,Y%%8]BLM>$643V?3#%D^@^
MK&2H=!'71 X] =<JRP__BB8XB@9LJ"Z-YRX+[]N ZOPJV+1=7$VS+PLYBN&7
MILSY7]59[D@I/PSIRF^84>%>#-AQ_*,]UB,2770=:_/ADK*I< @1+= 8G17&
MHA:+N.=2DEAL]'J(44>'[6=!.Z\<@Q^5"^01Y\;2D<E]Z_IJ%<Y?OB]P\#!.
MRG*\].J31)N\_A-MZ=?;'N//">.([&=0,0553'F?JV4ES+0VZT<R+W-C/;J>
M)7%## SN6]HVOV;XVNIL<<<95[GT<V-/^*-*EIBD0& (QHF5*(>I@77O,$HQ
M<X_T"@DA<X;U&CQ.N"J<< C*++L_&/ TW4SK?&0.4P\WIH0VA5DVDU2)[&LD
MV"-B6*KQT8ZJ=\[QUD0O(^][ZTX[KT*"_-/MT\,8VO.]E^S7][RS-VQ1._NE
M;\Y?X D:WY+H2Q@J;;9>P;/@GH'3^UJ*4:OJVFIX)JWPP'@CL\KM^$B88EP5
M;M=CG?MY"_<WM2['11\'H:= I7C^!.#[G/C:".']B9/# /4<STPL0"._*[C#
M&/-N!K_P[Q F404*[8 P$V*_(DH88OK1[=:&-5E.Z\*XJ",G[<I7<KF3LK]8
MGF?B[>'][UPV;@[B5;2*5&J_0I=&W*SP#N"*#PAX(CN3JE3NG PMJR<@9%.*
MQ E[^->$(_SC65I'0:+Z5M/^UX.*KD?Z1$2?7C@E/Z,AZCI.0-4VPA.CY7W<
M;%[PZ(^XM$%$JY63-:E>U+DRQLDCRJX[\!C3+B1F!.9]3-K>PKN)'YI%-AJA
M2GOX8+C$N* Z%4B!X'!8]:3>UV=9!&G$=4^E9YJKYVV<X=N]GY+E1 T7?'W3
M+#885'5Y_J$P  9'A$Z'OD2Z5QNUL(J935YZ-EE168'*'D5I/YKV'12]?]I'
M/'V??)9E$ V(5&3['H!IJ730AH@AE%0OXUST\3)3ZIRZ48R5L8AN3I?'!JU+
MBA<<O89/&+?JD,5GDH7W@54_(88A\?0B#@\QY*T@#CZ.5<J*JR42&Z"5C,(P
M(Y>>R_M.UY5&Z"6V'?AY_;O)[I+\9Q_^2,<-;1;%X>L7<7X9@_[L4&XL[+Q;
M^&01YT],-(]>#V<D%M5R+8Z5MGV7IRDFOK<ZDK<L0^-:VT<;7/+,U )@AK'K
MH+, QJPK>97\?5_- M9W'6EWYOFE^,W^'OQ&,<\-RL/N;2P5Q]YE>&#7?XK^
MKN$##V.+B3[._51^/J]RNF!L=J!U]$K1:T3#@VQQZ,OERSWU'1?7O:KXB;;?
MCGIWZJL-;>M_(^B%F@@5@ T0&#'G(L_QL$*>ZRAKV@QN;8K6Z3-,ZRQ^$Z@E
M7_%H_/=IW%8'[8V;^W&^_UQ_5PEL(Q41>PX3V:;G)J1>)B2H[RRXSA&^(/_=
M5[N1<CKEY+V+O:,W!E?N&EQGG'7?.%7SD#BW;YH% #@*:Z*7T;EXMM% :P.U
MU*+94>;HJ'B:*5UFLG(P.8#N7_&NOB:Y=[ONP.6.8H]#GF?U<&R%9C]LF @'
MSX)1[<-$-KD MKY\J@?RX6I[E72CKD]^3HV^1,\8U)88/B'[&V>W*;\6V7-Y
ME\9"OZQ=F*"508#W92"ZLXTD]0 "H)X8@R#YEQS1^.]9_;.GY_Z%QA:=?E=<
M&V.;HS8:<B O/_GUZ^UB-K3Q;$Q*,$:V!$-4\SA/?]2Z.-"*_XC H\>%Z+\P
MN+;505/]X&W]34%K@M:N5%OC_^XQ?NI1,D:ADVF(42BJ&<Q^*.4H+#U/]P^W
MEHE4Y*V>AN"D/1!;/Z+?T."[&+=YN&/0E/$C-<AUV;"O9LN[YNA* !42=/:K
M/A+LDM%_.WH;TM/0JZZ2%FGQIOTQ,G2PNSW%KCI]PW/'P@O3GS(=%=NNE!J[
MNJL$BTGOLNY^2A>%SI.0[4P^+"PDDB6(I_'(.OL&&1,7"C?@[[!VL\J.$U?C
M0 'HQH;>#PG*KAX<=,>E-SC$^IG)F^R5L/D01L.DVD%^ECC26LPRS*<!D%[B
M]7]&2;5FH\<"QJ[U!^3\&1[,V_2IUV+0,>I^9V)U4/KQX(1#C.7)?T6$^"[2
MVN@1.GQH  6D8ODE'H0J0ORM/-NT,8MKK]$][#K'P\4*>UW"V8?6QV7(%FKK
MK]WN>@2O3THEE<RCJP%,BD4A?1R*4J0\ L%$)^0A+[8IUR,2DAV%F=?S;YL6
M[NOFENLG&9#OU'UZ,+ 04:QXZDQHFX:;Z#^/IW0]XBG:D"<F54:'#U &\:#M
MN4ZPGO?7:*LP>^_*% X4%VD#,UYWYDFWGZ\Y75Z2+AIV/?]6@LNV#:'&DK:1
MPI?H(=!-WVH/YQ$2K[HVI*G8EJ[T]Y+M;6<T^&7$9JP?#] 35UN0D-<*Z]P@
M.I^5C (J$;-T+>H#O0SB>@E(0',O_PW^+P&UZC9=Q*F=,XH(X"SBY .N>DZ6
MOBGPRW*PIK[P*%5TD&S<XFJCU9=JYZ,[;Q0"X@WF(,,7(E,0W83TZ%4_"25^
M59PA2TAM<D=S2X59AXB1X\ZRBA3EAD_FT@<6YL:ZKQ&]-M FGM'9E23X$IY;
M*C"<)&D03[(&K".,)!'2;C?4GZ?@!$<]X[;4O=JC-35@8/ FY<EUC0W%GHWZ
M,3=*XRD&UK%+@A)B ]6<1(4/T5)ZHIM)%2UWGS:/"=+,(V;%$)IMJ7+F5,SR
MK2<\G(,D]KYSB_U$4SUV=O2FDLLN7YPP^RE=F\ZN![3Q("C:Y=^10L*TCV!U
MF)0#C]A,*K:Y.+K3TRO98;I,Y$(RG_^!HJ!]PJLVJ(3]=J_[NK9;5<<6],>
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M9>W_!H,89X*>-8W^!*8K%/<O-PZ3'2:%I30_TC&V2*D-+6I*"7VQ\L\/AF;
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MYEMN?FR,P;^@[:-] )VUB$/5F8LXV??"BMKM A^H\3*8-" 2*S'JBT'P<3M
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M;.;8[I)IV_3/TV/AT#OO-TE;.R74)/U.C(4Q&TAPJ'.Z]?]@[[NCFOJV=:.
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M.J8@+TN*R-?$L$E\A/<3 ()SOYA,"-W]DKWGZ@C[T3KA7Z;&P$_&FT%'H30
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MB#Y?=1=C[ODDIW4DJ86B^A6S__&'V>HG1;LN"#DCKR",7?>"A;E'9%]0X1<
M;0BN^0(@.#1IR)OAR:U\$ HPTE'T!R9HOD*N4$62KPD,XU4&*P'P!,! \!"Y
M@B>7HXQSN>A*&W(7S^MKP^6OWR=T:L6^0197 \Y7Q4 "3Q(4+:!' *&JN5!9
MA9M]?9I_>,7DK)O@:77-39=HS?%G5L)E/+VON6MP'Z95+QU!.?R>BQ>N;X2X
MUXZ5<&M9? ME.;R:U+.\U/(OLXP'B8,H;&W0$*0#C&!(&'!HEJ]Y4N@)-%L)
MK@L*O\5D3>ND4?SFZ+3:KE'B7N]#3>W:8DL?(#7A(?$G .(H>AEF?8-N$$VQ
MP3"2U+PY^_I,6)?G>KO58R/^FD%O2N_7<3XD/-0Y0MEMXB.__Z &49 *^!,(
M&'8PY+_.N8%6G"3;/FREG7ZKW$^,W$;_.W4YZ?'[K&XYE-^[_5%NUB=]4L-E
M%>?[._A! <3 X[8"30H4QH<\)? 6@P@&$$!7!)L8N#F82H3X@1\7-81\ERU%
M1EQ\.Q>QM/3))>13DNEE%-M='S0V9]#XRF+,B1L-)A"!-^;KP!5^FFS)L:R*
M0<2UE]9\?)']L5KFZ>QH5^2#"=597I:3E[CW-C4[:,;>'OV-V@#0,_+6<B9:
M:IM>@E?@MVHL"U]X3<[.)$P][S/<2'^SI\[ TH8!FY H..$7AS(!Z G$,BN^
MLC&7)+AG6((12JT4U3C(GFA!R?H+]^9MC6[L PM/5M22ZR//G8O0-!J\4CJ<
MO_;E=FSN.U\1+,L'/C8SG"24RGZ&@^9UG)_K2B6AB^CD:IIJG7[ $]O'G2_'
MP,N5V<3C\B&5L>UZA3X90^)GGMLHW3:7.EF<2_AA!0'[)T(JU'N\]A@X+I3B
MK*0H44T5SD75'#P[L&>ZQ%#57ZK[[F)-&$?P& *;+ <!W TV^R=WHAQ@.P8?
MYE:SB2P7GA/0=$RXUC.RPXDS?<=@,_4FSONEU8O?;C<4CKPV7Y6-QB#IQ0Y/
MU6<O4=QX).%ZIB 1HN.%%'I.$C>.W9"NQ3%NTL7P0HR/?2#D>UR,/YEZ3:*M
MJDNMZ\)858NPA<(.G$AOD!$.CDD)*D6P(!JHW9V,WQ&9WSBVK6K0X"MRZ^Y3
M.]Z0;]MN[HJ.#C4ER)U[7^Q_^>%>+8V%+J;D==-='-O&:[06_:T_.8$FB)OS
MMQ[IN_9-;++-M;V9L^LI]H*5+[(]%G6'D(9@G_$,8OKQ-S@R"OD*LE7N6=1Y
MQ,WL9*94^OA$Y)7/.P8?*931XT,CW[TZY%"P\_(;OT6"<&TAM$:$'+^I".C_
M/01&0_PS&U^.!M,OSA"M^*O Y6+GRU_.FJY_A+ZO<V9^VO^,HWYH?&?#,1""
ME356?#.V2SL&#DZTBV#D^;$=[.I,IJT[R['Y%'^7\LRK,VTF[[AVH8(7#)D[
M+U/?JQ_\8FT_P"O:$B"_]NF15X\EG#;"KIV4Y&"A-_N!9CPOOI_@;3 2+FPC
M5MG?8_LQG0L?TUJ>!XU,%UT^&])\,:H2'%N[ S@TL(D;O&G#P4^7X)-$UCFH
M'\.00B-100@9R'JVK&PVV LW@2W6[%ITE+?6K3I,L>GFD/G5KN;('/&SK_28
M]GL;!A;@?,51H:P!*,?#X,+Z1;! ]/"!\7IJT\S&(+?<P&N#60:A405?:!4S
M02_$K[3IWB5MW[_/45WYNX.4)O@4:,J'!JS?GA7?0JRB\I6UO" :*9[2<4*Y
M)H]4)W-V]]A8\66BY<A0A_D1M;<<6ZXW1W]%P&O2(ONXT1RK-@B"P%D[E:;L
M.;?(HL::"EJ <3752]W8037@ZX9WUW=*WZZ]LK[74FII7"@3R)Z^=96)&O%N
MJYCL,<KW]66HVKJ7Y^,NV2]WO8_ER@RR,P[?I_927%8JZ33IU.U:B1/>6(D3
M=HOASO8;I/WM.*'$'4*6Y>=W:Z8+MRP!_ T=?PH5KO> B'3^O^0\2NL(E5T@
M:]B)&J(-TR 98U>2'HF'/_ B>*HX$O/K;"Q>!6@:J69#-D_B.>?9G3]>]8*V
M+3,ZN^FU,7&&G0L'83$PT@ 6-$/V_IH02KG3HTKH?K8 X=KIS/)T.?NTDE+T
MXR_OD<^<"_E*9*'L50BI"_ C;AVL&(@O=4)HI\^M)A0. <UF*\%R'OH];\]J
M72' O:M*]CXXVV[BLT!J6$D-P;PF-LV N^!31"86TF+05_=)-_[E+K^B !Z^
MKV"LF6D;_88LHVPEMCLRS,^\93,,E!;*\,!;],-H4'-]>;90OZ^$PE !LTML
MF<HU==94^YNC(Q]VW"];?9!?5\UM9K@3[XYS)KC[(=*+2*.Q0QMN<8B-FV-K
M/^,P/)? G,'D<$D%-\_ 1<=F$2SURBY^T/3,#0K;AY)J@$W^0662^8KK=_%A
MB]*"PB &=EU7T,O K%_#<G)[9F3$1;#()0::G3<VQS.$U/<,OU:01:$_12($
MU0V;A,/M<%G0A6F:I[&2)AW*GAP:&;J5E"%KS#NZ8.DW.^YSJ]L_.3@W9?7E
M(P@BA1U%3>3[%0)-CJ;Z3,_P7;DV_0WP@)=/[$\OG3M/Z1?O$>N[\J[MW5;Q
M5]%Q^&1!'HI^E\:^G-T!^8?1S6K[P974Z$?L&%I+MV+D_IYY:6W3H*+[*B>R
MAIUT4_1RG,(M<<\)J%W.CN\,ERG0HR<AV#XN[**QG8EQ@T3I!I2[UV1-0X(!
M66T#)^^F W8^X)N3O,38NBZ9W TVTC)&;=N*7ID(SX!8H:P:]-,$W!9WPBK^
M2E)!"^8G<D->>'AE7W!5\!Z;VL,/6+HD-_56;Q3*8-4PT+2&0H^C51+X\C3A
M.A?C5D0*4.775'*-@=SZ2[FF.ZYN.].VL^I>Y9NL+VV7N'UN;=5P$VUA^#:%
M5)_Y1D$--$6H< *P <)>BJ+P*X)M0QKU.\IF"2G,>BNG;/1;ZHS!Z"/XZ:P
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M/O\H)Y'"48/#76U*U*=SK?M:;Q\/T2),UY996-%3]Q^&Q5 M(I/X"C3N;S
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MRTC\3HI@BM1Y#6K)>1:SM"""9=KR6P07NT6PB46A+5QX[#_O,>K/_85PR_V
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MNOPM^1>-:_8;M7PJZ*L.]&-ZG@@V>VP!RU-;( IV&4[?_=/.0RN^#S,;3-L
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MKC?1>VIS7V<Z&=6I/%F-<4M>V$S38D/FY6]_F<?_8XQAU&"[H;1C'HR7/$>
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MN5EA=>]2FR/.SB!:(N5,9W!*IK>[99%-KF^@5X>($9^I75C:7R=2AEB0G6S
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M0=;";AQ-DV?W!L>"N-W^ _6A_N SA6=@KOT6I)!,-B,Q9+\3;LH4/<D#3%E
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M%:M]SLQ \TYL2CX;Q'\UT#+@R%VY?O_%"=)B7[&QAZ4\8B2AUUC+2_;/[?P
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M[6>#)MR,6-58YLE[6^\QL.XOC1)&OP'JY' 3?2*L9O7.R2-H^X&90(9@$LO
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MRF,<*HA$SGIEA93T=IL;>Q\^<7A_@_B30[:>[_<,#[D'&(=LRI-T%F(IZ<3
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M;N.>5U/[&*^GFV+VV0NZF!IPI2'XW_77PBMU?B0M2;F/"?6Z3>%' 'W@MJ:
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M5 0+5 GY684R:D2N&G\!?L'^C 3?!UYG6Q_^*E@#*I<B 8.63:W0>+9W<K!
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M>[ PWL!XIK( >R?@59H6F,L\Q\#"UC+W[%DUO#DNJI[!4UNV '1K,#D:3S(
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MLJF8\;B[DEEJDM+%=L*;1+7\FBA>69KB7FO[8#9JO$,$?:>HH!:IR_R*(L>
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MKB_TC[KP/J#:N^NVS5[@_VR!Z+GQ55EMWRF!P]=/^J#5,DO1!F8N56T>,C5
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ML^33S>X>Q!"R#-LL,S),"?] %<V%7ZW+8'=7T]>4QM946,!TZUY?^7[UR+F
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MF9;%9;<95^YA4+L16EOUSNM] $GZ>T'(S8H;3Q?7]V[$[NBR/+4>4=_FGRQ
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M-G.[F?&<.Z/E2N5-H^,.<;]E.&EJY3G/GOCWAL7TOW;KXX[_]I'Y=W;^5]O
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MCNPJ'\TV3BEG[EC+0--RJ2P,<B@-6DOF[@AVA<2M82'PB[5U,ISGP<*T5,F
M&39%_3Y9@*)[D'VAP]C@U"5+\7-+G28^Y\+:ZYG:R6'( >LC-GT+\=L-=<]"
MRL[!]@$5"M)WCJIFW85])L'==+KK@/F)VNB)L<N2ZU@6FS9AKC=%F*;,MS'=
M5K8:6^F5I#W'2ID<8#MS"EEK7HP'&TBB9JH48GQQ9B%KDE67E([<Z"^T5.K8
M*5D1D!%F=TI6*AU<A,1@*D6@#\Q$PC:>!HE<-: ![5NFC(F0QPI[&Y+B5-?&
MV#V;-V>1$[:2[<HMUG5-C(5<:WO4L^:KR=-,NUBA7S+V P98)"6>&>I05ASU
M:NVVZG<.GXN^5UY:@\ER$I:ZYS67SPGFI^'%@(8K .TEMLRXU7<XOP&^+#'X
M"(W:O)M%IKN%_W(Y'-AG@"V"L4)&NT'XAE;HW0FM,2]<_>7U<JMO87A2:">V
M<3V68L7)@P/!X7QPOMV7FNTL9"O%<+))O6#L@[]?]G>E;_%C#=EBK[:.:5\(
MVWS#6?J913T"]>+A7SCE]*^FGTX.-.\3^9EG&G/EK6-GZ+7JM]<8E<=2-[?I
MA'TS5\^=/3?;1HXTW<1_ 4D&$VA ?-FHEW4OSR;K0\Z40MVFSY2NY3W8F#FW
M4T[;U-6O?UWMEU2V!-^^2 I\@RM$?!?LT"?D0M5,KB7^ QGI6R?'N\H:*\O.
M:43+@;8M2@_3)[)(5D%*62^7*J0/C!]_YA>X.=8N:*/X(00__G75U<J7TY=<
M,[WD*RZ-N<I.]-,OSWW=9%/^(%HU)IWW [[&>]QI$)8"Q*%%#I8?8XA2I :C
MFP6(4F)S@5 32O87%CEZ^]G4L)7\#Z,BD9(7_.']Q=EG:-E?]]H;3J(J"#/>
MW+U @YSI=J@+*!_@R2S6PRY]J_L3O]N=C*S;'AQD\47/.NUNS?Z\-[G,0)7>
M/:G!2KKL]WCOV<J[6N\0?+>7==O@4:Q,\NP1(-PPE&G.3?9DFV^2,?XW<C5+
MH?' +6^A)H[JKIJB7NN/1FD*.\]U>OE\UTRY+-%Q/^O,]M/:K^&?RPL0[2BR
MFR]WZW(0%.8N-.5B[M)C<)?)+/.^VMMO56E2;?%33T[);?S;P68?DR31 B?2
M>WUP*WE&F:L)7_F\B3Z;S*F%3Y0(KL6=!)/S<!YL9/2VLH' T%*XENI;%P<D
M#5B5Q&VWG<$[F;*FA)Y.6;[7X!)XRO'<DV#&N/U,&5N3AKT+:9X'^_7#J8J_
MR"+!]BU5*?3*RB\XM)#ZCWFKG0*$4\.F3\:\^:1]"/ZZOW+V_Y^/U[> V #)
M\S\93<<'='[FE'I7G!H>R:S1[*G7R*/]6GBKS<GAI]>AH$'4JE_=0WV,MSDD
M)S"HV=O=\":KOTR/&*3SFTO3C0L*4AM^J&1+R89;Z,K>UU*_:?X-S9-7@,2:
MN HK05DGA],'A^"*TP1Z:3:A*;N N'2]1-;+@<:Z+>10HJRE8:-N9]3GTYV:
ME(*$<^U=2):ZT=8=-%2)1I3(HS#$U_2"5]-.1F0/_HL7GOT5A;[:DY23Q=OH
MGZ]8*LHM,>'P?UXS0/; 4KB<,RMY0+Y;YF+<@%*JL29YH>4R>V:SRM+.]!A8
MB51#'T,N;>Z72-4CE48^/"%U#ME*&GI F^5)=4#B7EQ]GAD_VF3;F C+N TI
M[X+;!^;1=/6@H#Y#RRMAIH]Q:LF#YGZRU?,[YLYXC^,RZM%GM$@?2>!>44AL
MF&N*P_+C('V(0I72YUW,#5ZI5I*-P5['57?6Q!PK2E6<J]C2JNGPZM'2&\57
MZ]9*),_%<9TA,7CTVR18:.B] !$-+'SQ/JB: S#TD3_L^Y>OYKT=&CXW6CYL
M%1K_ROS1Y$8S31U\R@VR"-J-&D-F6>S'K,7!93PVW%#9C)\]T.;4![9C8I7>
M9JKF4OPMVD[>7N5Z7:/LMWL7N%JN#PCOU(46<J"U.U]"7TQA51_AR-O=*T!<
MDV>O99]V'BLG*L0/)9'DDP9N/-VK;XQKM/&\M.0\<6;PC=!VA-#,CK^R#^G?
M<>S$:_ .L2H:L3&W8.J&4:&6O;U+?RH_?;9?[[[\O28O7PEK[3L''6./NI:N
M/OG;&B_6(IW DX?] -,6$45^/I-\#0-N#V+:O@@VIU.;$CV/@7)<4\]]/B^"
MRJ>,*";F!?QG8FKI,V&X^.M=]R)'OF7Q1UZ&H4W(M+);MQ>9U7"H5K$ 9A!7
MWMF*O08=0]Y@8LS&-J;>,GM5YU-])><CY!ZM>?!;S=VL>YM=FH\>%(D5;0%H
M^6C6*>J0/R2AS%4/AGW;LH+FX!,<,(Y-@G0_N7XI'57'/+&F6TOW+TMP._@6
MNU9Y%FY4/VN^_ZZF^S7[Z5HW#]4-K&?AN6.>R\BHA6GMVD.+U%$G1W.5-%W^
M#\6#>B$F3WX]1W9C0+T8GKRV!>Q%G#E-@!@<H*.3#$AK>,? IQ<S@%A3K=)G
M+IKU%+W%:.NS1^]JA.:'N29?#)>K"QCAB5@:H6GQQ%("3ZJ[,5T6*"+-B'%M
M*;PC[(DLR>Y8GC<)^X,2PVF+FYW+GK>K?5<9?J1Z?\)V_R*''9/"Q$_'M83F
M2CBN_!R\*)S8*#3M);7,OIXTG-%F)$ @<89L@*$-0X3S^($;8T?[# =G80)\
M-['XW XY1]JC+1L?_?2QV+C#&:[?M+OE2I-,":XU](7,LA-F3>3D@.AQ<F*I
M"YJ>D-[R,+7/,UT^ZA+'QM-#-FQ7DU^-[,@J_@=:$!_!1D69Z(Y+R/69.-,+
MT&?*+8_>]<T=>O7][;[?[(57'[CU!1RWN&<F+6*'V)%;+]0;)O]7=D[_T[%>
M@9/!?UFGA/^ *EF,)WOX)MA7G IV:W#2H&07<HRR0RA:;2.)HF,W+[U^?F]7
MT]9C%CPW?C) *P!8UE@*F9-2#OL/QNT&6^ :=;W'^2TL_E<V;QTH;\ \/HL!
M0SRJW3_K.6F?C9L]^VA'T</+1XV836M[D:,[M(3FB9!$B!QL65,IJ!.[LDMT
MA"FJCDV,KA/#.?;@@MXVO!BLJ3 VE:J^BQ\($3XJ>BGYD0;E("7J::'ZM9 T
MGBR*T\;/(-.*!0A9\E4X@/PYJ\$87[8VI&\:SQ9BG*U\X=C5CU=DC3W:&F(]
M<G_+F]T?>^\D&2U59+>*7SX!%?<'Q=2@Z/IBNHV@;>/RS4=Z$[M=)$W;]^!^
M(.UOA_GX^G<B<(_A5(15640DO@U=C)TAC7='D$O-VR20Z\!,!JJ1)#4<O-NB
MJK JY==>IU8'.;L7=WMVZQ21NL[@QAX;3F!9/F0FEZN&\^/?J9/&P_I+O,[(
M81HE;2+*>MGK*P\Z*2N_2CMI\6S/Y:OW+5*W#6OTZ+]G+K;N^8!Z:7!*]"N:
M65NPTM-3I\Q_A=\>W,UP8UX<Q\1@-V#/IG8S9L/P&X/)S4H:S_3K$N3<?71T
MY<ZR)ZB$7=+YFU,>$W6ZS\-"8\T,O@V_G?^(?)F@R#O))C9D@W[^;"(C.F=<
M5X;^^=ZC+%9YE%:2KO')%*3VED/R#.6)U7;KA:+E%KT7(W"*>=,<2.=SS=;L
M<Y[ED?+I#SE2M<WJ/1K:E;>>19=^_T]!\Y4VI/> +WI8GY[#DYGD'&-7,&/8
M02<_ZP?HB_Q@6Q^(3MG@%5\Y^2ZNGR+<+7[YW3/9,?R9=0ZL;+(6<,$7W$'@
M2<_#54L%UN,13X &:[0OL'8*I1SH+%K&0H=?6W Y.VX)VF=^>,"1V,TY7$S=
M]^2<2T*JSON8BY<$B(J'IT0GS7GR-K,P-4-1%CFPFHDHMGKIZ133)$!$0EL&
M GSC[&_9/:S0SW*O8D90MN5IV.0!6T87=]\3^YB<(!/',#6%8%!:@Z:1 )8M
M><B+CI[9/QZ,NTU'13S3K0(?L&W;E%2D31]G/KH@ENW(?_%0N]M@^'-SSHV\
M=8?$N6C;K7';&>Y7$UTV':_Z[?V%6Q'[X[+H5'$0V\ 1/<Y*BYXQJ+;=?&_8
MH]]#^$KW64K8NF<38>C] .TK9GB1<Q TYHKBG/CQT%;>M:+>.DV02B<,FVC3
MM[_Q>>9]6,PG76OTLD7Z5A%FSKG=>?RAF6.WL9"8$/<VOATHH\[XP84XDEA,
M;3NPN_G\;V @*ZVI_/R.OCY,58*' G'HQ^HWV0[)Y\2>)Y]LI%[GJ!&+<Y\C
MFV;!K?9,F+\+W^>GDR]1%7A*L,FJ*<'[S?@OKN'L&:+@O <[J!'MW5]SR%^7
MV9Q\(E%'^L",M3OKI8Y9^)6K=DW1  QYM!'D>IXK:Y(GHVX9S\!',G35CU2S
MGY4%L4K,V(Y Q8\QZ?N3^P)VB9E>?QZ2$,;^5GH%?[B,\[.,AA$""7;E [@C
MM-$=T'('9#*K'_ ]*W6]_]S^[=K=)E).I7]9Y_W?Q]_'?Y?#?GR2IX(4(#33
MZ$3N-B/LLM]G+\YZ,LR':,"2"7F= #&T$P;7OJ1,[&UZ!>\AC";"A!BV!&19
M"<2A'[/*9&VPG]IH;@MHKBSP(1VG(4 4NSX7('Y4B2]0YO4',Z$3?71-_H--
M,,NR_F2?/3!GZBI J(M3&6D3W5,)9'YC&NBZI/8R3CMA1AQ4'T?QY'(X7V(X
M2V .5QQJ);.L\H'X1;38 E-Z'LL6ABOZ&]S^J@,G6_1>-BO</+%'=PNNV!17
MVZQ'TYZ]Q8O]A$-R@X('H/6B_.(M_!B\"8BL'[@)R8-XG)E^$D[9J# M^:FB
M2<H=,Y/S-J<U=$[ZOPMH4T.]Q!816@D4 6+</K+LMANGF1^G!JKG#TUYK7_P
MLH&]JZ-YW*9\9[3Q&B\+5X?K7W-2ZQ]4[&T@72%U ^ .WVBT)R &-*P!W*TU
M.8U@/AV[$6R"I"3:]K5%UNS=EN;&L=51/8,_>K]]>$ R=30RN;[%:65Q/UB\
MOX/V"1 E0!]ZX5EOF"GTNE^IG_"ZT\\W:ZI_8)>3U;?1K353$PK0=!C>=B:$
M]($*[D WEK#)EO#/O7GJP,:I94ERK(EOSA!V*EUDGC+6YKZ\#G!WT#QA(FUB
M>OF2W>9[==_4PKPT.>/P+\[CNU#%))ZL,L<1!+@;*)X"A*@!D+2OKI;6'=^/
M7\,6&:W@:52IR/M1#:0KDY]J7)3M4?STYCGFW9XK9Q$HDM+-DLPIYCZ/?05E
M/>6/FF[H3MK/O=ID4WBR7S4F_6H18Y-04T^;$?FMX^"KWFMW27JGU9C\3PX)
M1$]>/3MF)IQ[ *8QOP&T,G2Q";J0&B93KZ3?VJG?.J8,IM%KMRS[7WG3D//#
MANIX@OU!';EO[V#%X\5'B%U[MR$I\TVH0G.F!S> =Y(UV40%U;OCT9ZDV#K%
MU XK,(V15V/ID?,]79;1;AA_LNS=%WUZN*9#LM/1"K/-(ZDWOM*$?EEL.';H
M]<"MUN2<T>$?B\L%I3*C1<X6VY[:3:A=OB/\+58U90D#1W88N[M9=S]'EU\"
MP,1!(?A(LZIB#[0A.*=9R3<2I\@ 9)H*S@?;GJCL50KL@8:%B]M,;LZ)&4FI
MTRP.N2:LCX'6*L)GJ>4_S.)'0JOP%.)&DW60/OC69+?7Z^]CN]EK\OUTTN6*
M%>6[NMK1OYEY"QMQS[PD=3'5ZQB3"%1VFNGF3SIE#@':G3>ZM*=3.FN?5&@5
MMQ^P$^L(."#J.8<$M7*8E30RJ*D_XS>.'-9GH"(#,1O<(4FHFWLU^>4'I9%N
M3NUA2HN1HL6ALI]V29A1VR0_[*-;W?4P,T9REGMQWFP,!W9#A#3N,%A+%R!D
MO)9?Y;,A;&RZ3Z1_WI2V_XZ.W!]!^\ISTR37!:WB%;].%I+OUMDAJQK*/1?\
MS'<X!EI'80TPG;F6]6.:<"VX4W M[0C;-,=/(^U4M^_XQ@6C2K=1[H?+Q<?,
M@T8<WG_$NZ8C^#]>)T]35*IJGJ'B'4N]P$QIJTL5XE>/[FF2[:+M51FOQ5^'
M \/*5 SJ)K..=(-;,6U$"@H2RV*A+4&O<4E_JYZ%O,!$^9".UKZIG0YM-];U
M[G%4L^+&)$;_]LVR2_L;-@Y;E%:?J,]QJ>Q#7]$'MP@0S+MT D7T6!^Z%"?'
MGIC']-DZ/6CN(3U*&ZBX2_J@WF92?_>A^NM7I&*3*-E5RT4PP=?@EW[E1P%7
M]Q/CZI19./PV]K-JD@=<.;SHBIH[!0@?,-[FT2$W3X<;"GX>6&&4GN)O_G&?
M^:\!=R )3F'C^MO*K6-K^"DFA]C$UK2*_G1O:A0>92U7K#/KJ]X1T#M:KE9J
M'^\SJ5/?L7'O!T.V.3.*,1N/E@.N$<&MY!BT^ZQ$76)>,,&F'V<[7KN>87CH
M(B,4)>DT8B:DIB&:-,'X=E"8EM>")YX2[4"QCA-!K>Y$@):INAI,>XL[SG],
MI)O'0@HXA\\UHB30";/1K*#X_&"+T,E6AG:P:_N'W>9E)BW\_F_)D>M\>2?Y
MI3@,"P.);V?-<BSA[+/>AQ+A85FI+Z%5[,M(M2?!A)-;O)[N^F:I)6UE+-TX
M[N&6.-YTW;P;Q3JHOZ1$]D%Q3?_Q.O'WFU_0/)7=_GYT(!HV@GX+:OU/0K.I
M"K\0)[,MQ@0[K9CEE?LU\LO]HQJ[@ U">UL0^#O_6VCU#2Y?31 &U4S]Q5S9
M=EC6<#D%FTIFV2*73  98*"<*$"\.C7P_3Q,/]]#P*^?V.4SR#LP7!V])T"0
MX@4(RV1:J8T9_BO> #_F+D#,B97!G\.Y_LG,X?4RFA?A#4P/H1>DSFHO&6%E
MT#F9K.<OXW8<%U\:YVSBUP+T$KPF+QCTA35<#B1%!D]CY?5JY#A4)K4<\ [1
M*N#4/CN*O=KE]^WJ"0 W\.G74N3*Z[<"1#(!$K>!M<0J!L W5D+P#>OZ2[UW
M35$Z3G\I\)ZHN9?U:G=7;E_A5*Y8AZJY4'\-@?.=7U*SB;N6)UL*#H\3UGK>
M&DVAQB\ R*QG]]EO\HU>A&QZ<T-FL]"ETO",NE5MADLA\(4^P8EMC(<52BF)
MMX'82%5>641J%3:XHJVJHDGW[+0Y.SJK8/1V?I.5<,75KDV&9VTVO;K^T-'H
M-<-2R?S!S3GMI_RW)H9TXG H)-FYTL#H/DN)/T)H@8SZ>.9TEVW4YEMOYFH_
M5%3U%RQP.V<VAA#\1$H/FU\KV>"L=M]=:'''Z^'IJJUC.49W/=Y0K$*OO7BK
MJ_[N;*K:+?F#-YY/OEMYPJB-:@3N8%G'! AP*S51%Z#!VEHL@QY=Q,:TIBM$
MDWYAA&M(MQ%53YKGAQ]/-(Z$J ;L+ R@S&NO.2V$S, ?P'] B^-0K/62YM"*
MYX0Q_#>0 @_/2N!0"&&FNBX_JCQ'.W+;=ABTG7GG<L.M.IHNG+?#X&1.YYZ#
M>YXC1Y66<F!'<($1J!D.5RAJ?/;.V)J^FB &585GV6LB1/-6\K[F[-!1X+FK
MU._V:[K<1S\U2\7"5_=?X%V&8V V8H,)*^!Z @VN@*MO%%;I5;\).CN80)N,
M\X'4ON_3RS-\N'AV6E@&DV7 *DS>?/]"\G&I2)/SEWR42\[E\.0[(+'-\*#I
MX"86E^-5 5IQ-8/]#Q/.\]_4;*(G.FDKZAT>\5"8&[E=_"ER^ZJM<_?*?[M1
M*2Q]8]5R.%?;!1JT!R3?:O(K M#154'QY+(LK@Y*PM#E\*PU5S1-(;5KD75$
MB_AQ/A*1M?J.VGT+U<A77E6:L;J4V4/]WOHO+=?YZCYM;'\]_OK^J[!CYG)+
MF^"J=XZET$@> ACV,W"4"C_B$]%NR$VH\&<F7W V#'0L(($7/\?\PK.53)#J
M2@_P]@OQP7^</]X[0GKVJO7Q^5-N:'I.PS Q$JB(J:?& ZP3OJ &@2G$DF['
M;CSRG.=3SEY/R!D*#G)BE;5O3 ]]Y/W+JV! OOCA4PVI/.ZWQ[%V:JC"@8%^
MIRM/TJ.S0N1J:[3.>TS>V[(EZ541#>EO8_W6O7S9G*>AH-3RYJ:J11J3=/TE
M2B?LR*RF3U]RY!-_[ -  GT!$T:LL.<I]'%^E/)S KQ(,N#^1C9N5TJ-B%\>
M1CXMSU,&O"P1VI'[(D !Z:MBKZU4=^IV\3&*PW;E6\29')8M!]:[$:W3Z$+-
M-I1X+;4>,^1& V(4ZE&BG0OL'PKV S:OS4--+BZZ2(1><0YPE$#8A*:-K5HF
MNH6ZY5+,@9S1%A,9M>"KT0??3]W:8"Z,LK'QK.I/?.%<,%:9[S34/!?;ZUS9
M;^AV0%9>3=JOGM1)')*AQ\0 M"<HELLF7\X:?KJ>7FEW)%H&6D6,W8 SV9?0
M-P2ZG:OX8OWD@>.K-Q-KW1+V7A9>DQQ&OV2F:@R[Z2P\7@R^%5O>-M/ 5F9@
MF0]8$]C8;G3KK*)'G4IO8.UYID[- ?>JR!"B:[2BS:5GCHY?0\-,>H6/;]2Y
M<$ITYECMV^]C\I](.&O&@9/*NNB3I?>G(,[$P>3A)J6TD$V$57:'-#BKZR[Q
M[PL0OH1X:JG;C Q#?WB([*8]S=UT>-+A<YULL$R3._/--$6RID#^6>^;'$^7
MT25K+;LEJ:V$MV+HU3A#L);MU41F>54P-6D/QEWL'=^!%W/!/OK/N_E3"KJZ
MX]\+IU9_.6MN\C2U0G_C3&[<FM4)^%RH":_TR421*\M38Q&B+B3I[CX!8I\[
M_6"W)+[<N/!=;F<2LEW48!6[NZ4;U(:A@,0YP=J-[Q4@RH-X4A-8"9Q:\;M(
M2/JV?:, H6C ]W5F,5\5ZUR:"M5Z8?;XT)61/+6AZHD+JPP7W)C?N-Y@) ?+
M3R@@^_A&/I,M9),B%S(*U)W8E[=/+,T'GV18M'SYE=J[*EWKJM6]8LDWR>_7
MBPGCAN"D,0)[QI'@=I@J>D%KR[A26(G8G\]&T1Z8N'NM6_MXR,R0E^9]ZD"U
M49[_MT?-ZJ9.LY(1&NZF9)#/\J6WAG.%@@<XM^-/6N#475F1-JPYIY/#J0?V
M&E3J1NP\<##VPH,?!U6SZ$3I[Z:[66/$<:3XU"?LCUL%"?;IWK]*?B9-C)U!
MJL2&YFNO1E[W_(6[#0>$"!N(,_&#__#F$PW)"C6)(0IAF44)[<U%Y67/O)Q]
M:FMB+[65:\\H_65OX_UG']KS_I"$!%<(Z@?*C)D[7_ .@4A6)C?(HH2E6_[4
M/XA??=&K^)N^[V5WSCF,LHI&SY-P0H;B>S5\\D [L4*?N96=0YMM>;J_";T>
MY\9_ZHJ.N5B5BIR9]J@XWC>RV;NWM1F7FZG8MFFOX2^5S=B=39,[@E4Q'NW0
M_KEA4E-!=P:C2A&OKG6]U?^&"TY^@HR)/S+O!JE\@YT/LYY,?P&B@VPN0'RM
M0M.[L"R;V65C-*]Z 8"L2(5H>A7@25C>@5TZ"M/*<5F@*0#Z@EHX0YZ["PO?
M5NU?!*;/'B;,EMK)$W@L_T%#+1NUA.$18#2[,KL&?$ ?F.EFS=(7$TJI15/+
M"N$!B?OM2N?O8[9,2&AEIA[X[NCLE;\N3VU<+;DSR*Z+IS80B)7E;6.1[Y8-
MDTRY-BQFRI>O7#G<A\OAFX8]P]8X/ A#;(H*L --=;L<7B?=G)@(*A^H*Y]#
M>S?FFDN(2-X_6\<I3Q/7>EG9V5@7#"IS88G=^ @N,-$\?WXMFNX%> "-WWMX
MQA<%B+4Y'(4'? +_@1O'6X#PG!]FJOJ.M:6H=CW&ERT<P"D&PGK2"*;R4F\N
MS<\"U_+?VZKYIM$Q<0\O+RCN<T'<]N6>@KI55_$+ #>L$O21*BL_SA5J,U6N
M[OFU5V=$YU.;R17A(NFUTNH;IBS4;R1$["%%F*R$MR,\G#C\)V+1-RI/1H#@
M),+_)PVY\'87LQ:4CD7IQ^"ES7U?>^X<OL95X+SJO'6BQ^S;,2>M=*/'R2?N
M)]>@<W]@63=$>5(EY\H_ZP<0*>0SSS;M:!Z;.DUJQ,IYEU6L3W[\Y*F^>/BK
M@PXLX\LT?ZS;4/! PS(A<@L8[\IX:HI%=F?K9:TO3XOU5NW,G#>K3]N_[MAN
M,OXF<Q(F%4\@ Z !+LMT7Y# N3  _W$#9GI DW%PA"3F RR1@KK@?^([^J+2
MTHBE^D.[$[E%1J8_D6-O,SG/^7?)]%> 1W<84.K+T^F>\05M(*TO@809WQG?
M4@'"^W8%Q@NMW37_8&;8V'>TV'IP.&KZC (D7@&;A8\9VH ?<R(P%:_DX+:E
MG4IM;6M9;HW/==SVPD^%H&SN(=)2A0FV:E/#;C%&?K.LN'ZL38Z%AB1@BBP\
M BZQL4U48=QVME>S$_9N#3:XO$ZZC^?(&G?NM7=,B;:[D#[5L^52Z&K:$Y:6
M4 T_BWR1 +H3AO=S0OAOX7N$N?/*#G91GTTL8;>O7>1H4M 50%GIU^+AR:4?
M'*SV5=[2C=FN$<TQDMP7F.8!Y=T-^I1(!J'5%]2<9/;0NU<%8\?/UE4M)IIH
MCZ.C75WVG2V^Y)#SV6!)?FI=Z8LC&[-$A+2ZZ&'D"SA?<(!5S;D.'F&@"6AE
M$Y?UD72TF,=N3[S:E\EHR[/]E*TC,^IWG2R5BU]J[R\2?^T0!GO@*H821+-G
M)K..'.%GDJ^244T,@@B8N,T;Y13=%>J'3C&X9['.7JI-YUIQ\Y1=STG[[)T'
M4490$XIE8<^/QZWB'@K>,<EY_H7G'\B>M7OWN0RUP6M9/(OY=+0E?G@$LUOC
MF\\SRU?W_<LNV%1?.(4P_$DL%"!FBD1G_+C*.%-^\EN<NXD-*KQF^YJ[V]X%
M4(LD#[F>SL:H=Z:UCR!'YY55LVOR.;%P(,/DHV$G< 6=-+:%GVZZ%^HQ7K9/
MK-FFBXP-L$+%G-_\N:Y9S_M2561 _UGIQF%ZNO'2N7$_T74;D:?Y!!B>?0>Y
MG"56X"*L02^C"4KHQ&L&^5&19ZWD4B7RQ39*Q_MY7T_N7D,KJ+BEY9V8P-R#
M6%*G 3PI+N<'_RDD-8IO)(NC:5EG*=B9[XM!/3_ZI7A[$VLN9G]?]/]@L&Q7
MESN@>MJM*\5L^&!O]IR-K;A"*>@%A\\)ED(,F19W!%K;P=8?]YZ-#8C,IAZ$
M]O8MR!5F=*>=RW"L>.KMY%$_YQ8<;KM]7MC\(36J'WP*UP<AH$$#OQYGQ39O
MU(\EEQE^BZZEU>(GC[*M:P!)G+G?>N)MW^UQ[L\8F_;2]Y^3JCWW0B5:/7T9
MR\'S7T)K\%\ "0,!(I%80FS11;6:RGTQCM?U.EHMW?PQQJN5VJ(2%^P^LL:V
M8768B4P3FH4!"/_8CD,_EKCRW*N$TU$,,NE(%? 6]7B9]7[Z;7*TWD*W?DCH
M QUC^]4A'R/&SEQZK7Y_Q*A_W<'Y62&HD<J":T]4W?IB4(:&!;73[DRPHA^X
MISJAXTW,6/NT9V4H0ZU&+<K5Y^.]'MNL)A$UKCQ)_/CJ/O(+L423Z<R2X+2!
M@>@6XE!3&YF5#.('SM7T3'Y&%_]\PQFC?/C6+=^1F^E?!HXH>$R]2O+JT1)B
MP+0F9N8#.[Z96D)L0E/T:4DIKX.I#.+,T/A3]5:**?&*IZ0 $:];<##&KM!B
M7*4CT+/W7=+.RJ^)4L<<[,F\VZSN-@&"0$04R'!L^,^_@FB&B_U,$.>9!ENT
MZ>&7[++R*^LY?1X5]P^ZIJ1$%-X@*:\6_RIU/L\,@;^-;\"R+*C# YQ-8 ,#
MI>(,--@;4*6#O58Z1GUK0MG&C3$<H+CD-F!3>\7XTGXR4]'IO671=?7#>4D*
MZ3. MV\$54J N-8-;K>?66+=G*1/5" ;9R/2YG!G87[B:Y"7V1>XZ>8&3M6V
M#._K[>JIC.VJC"F[T\/J:]?W3A/+_C?GL>O6\BO1E\@4UW$D4_LM[R#HSQK@
MFEO41'1ZP_6J_-J+L=,4#=_[<&E3M/AZ<SR..T8V)M->8"O(S"LL8\Y;MD(3
M)HHL)T 4+U@IA\J7%4.-A<2+]WNWHR;31?U3KYH\2*#YN02;:N<W_#IO].3,
MD[2MZ77+ H0!D$9^SPJ.T6^XZK"QMV6O5I[F3\IBR<]GZ24P3L7X0!3TPC%@
MCM%'7MI" &_.,C,%B*-N H2>[GX!XKXV3 1B\O!CQ 47 6)N &:R2_($\%8:
M\X< 8485('1OZPL0R5Y] D3L-'RZE84*ZK'PQZ:[^;;T[LG\15CM)Z,OE@Y>
MKN@KH*5<_R&>OVY!#>'I&7D\W?FI'H5Q=63..7._J^+60X8'@HWK<J8DCLK:
MF F)+\'<%ZX^O@)$D[$GNC3[A0 AD<9U@Y24&6OR&+>)K"1^!E>(F3J!*IED
M(CFUCT?)B\Y5WIN\?BPOF7/NPC^%D:YA'_HJ-F$?808F.H0$2FK1^ &I(\&1
M3= :ED\>R?K5ZMWQV845*6J^#D.1"7,OP_8)$(,=G(T"1/0Q^ 1!H"]'#$XO
MV"!B2)[Z&++F$YFN#35S-2DFG"=+U"OS7X<JNKC//+JH-;O;[H\ #8HFAF^
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MMD>'6NH)$/X[)<D!UM$7*SQ4!IJ!,FHDS'UA=>,KC], E=^N4+E?A'#B>IA
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M^ YL15 ;$=R1F@.?Q9Y?82KZG;RF8(%PA\@B\9"LMI/LJ+KJ7&L)K.%(6L7
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M:4;AU/?+/])2.:F]8VN<@RI3K;+GKYQ6U]!.57YL.T4 MRK4"Q!QZ!)[G@Q
M:ZO')#[;"+6PW>[P1*_D!$=:<J\IH*]4)EH$\P8W,7! B.)#CL&JI6_L_31L
M"W&(2!_@28?2]-OL+S*H$KA3A<4#NNE?3US[YKPNWF7J>,7]K(OM]\E52Y8;
M#3&0.)4K?0X:@T'/99@<B9?N)YJS6Q]PUYDQ,%'0YFA@A[5Z<[GJSF=>RE$/
M(,<(6F/W!X>)&WM7UZWL,O@,6D%F=X#R@&,&)K*"ZK'#2L:-*P_8AJ&]-=#G
ML@KH8U]=9TG7D$GN/&[D6BRL84J.Y7"U>+??P7 ?%C [[(-:Y4:_@RIV#=Z%
ME0$\G7A5DSR-&V/\!S-COA3D\G[1>1.R]M/J1;^#J(T0!5VQ#H#E\8P,5Y+G
M/6#PXA78C>'7FHC1!8B[=<K!O,H K+2C7J;DKY+6D'@]X=R89)6>R2<#?G#Q
M,N:_PFWE:@$-\/A**EHQRN#NEF6(Z,;2;I:?\ZA;PZIM+<K=;V78J+VU[)U>
MNUC';QMM/KP-_1^OHN+YI8&P#!<@FDB)Q"+[)C"0%#FV$YRE4>\2-Y8FOW6@
M2 IA>WPT(KR/:[U]J^XA/]$UYZCA(&^IZK"Q\$,"ZC6T%P^+^5+-!(!6115&
M7R.NQYER,4W 6AQJ(  C%4S@.O68?@"N]SVZR-U_7$]C9!/^<N)#M_M[GR/3
MR9=G$TW_$9= 0_U-<AE\_T.L 3L6-@8OBM.J8LTV/^9Y>,@GOYT>J&C%%CO7
MI9\;69**D=;IV_+VHG:#U.0@F58<I,L]A^\CEA!XTD>.;1O'@%'C.\=)\>4_
MVDEW2K<IH-R>W+2J+K-(J5RB"=4& JQ3R,%%3F0/X(N"H8]EBQP,I;=/0_JL
MB>=C&\ F>H;+V:X&GAFMHZ;TOJ)>5MS>K24/0XI>7._Z^/3H!?N4(:!!H0;]
M+_HW#(?CPYJ0ED\MJ?W6%1?H@FY"K2K58/-;BF*:^G>^U_@LX;[8WJXW\:!K
M0U?#^+83K5E1B$ 4RV+(?":(>PWJ);,L^2?X&1:?:DZ::N)4RR^6H>F*_8.&
MG6\D*,I6,RT_YXVWU:T\4[H/Y_PA4U6@81\,[(_Q.X(CS=ZQ4?&&'=\7L-%U
MB-ZY 6C'@-M^[YGG9B*%#I'J83?5]JQKD:H[P4;SI*P: 19&@!CVI8DR8_[1
MS?"4I/NRK\8^D#Z;.*;J&VMLO&:Q<?G.*B7NS1+<$%?E[D3LQ0MS^W/><TVQ
M>U86@V^XH _?9MYY;7[M2NL,J&&4PSZ-$C_0>I=[P)T#J.#T<W[4R?9^3"KV
ME%BWJ#>'=5$[YO%$7>VFRSNI6)BPPG=@LR+.H,WX+LZS;?PB]+5.3VHSN938
M:FXE0,12IC:POM\<4;Z]NBU5BC*L=72SV'IVDJ,K ;4'=YO_I 9FS2(P'8S(
MQOF -N,1:6A)P(T8&81?]<EWDW&+:"+OT*K0?!!S9&M6C5]S1\*;Y!<_5RU[
MT8-6GBF*F+%3*X LWLJ3M9U>>(F2R"9*RFA2OG$;=MW48<:RLN/6LN(-#;L*
MC67>7!=33%'?Y7O3[K1Y)[8PC:?LP=T6W,3QZ\-KP<-?:52:[I;& >SLO+S@
M>,;-%\CFQ/-#MJ=J:],!-;VTW*TELN9F;M8-1+^18UI"/Y#@YACF7@:58@Z)
MT>FWE1E])H 47@[KPML'IKCM_YDNZ6KNY]EJ^_F#QNJQ_ZN][PQJ*NK6CB*B
M%.E=C 4!I8DTI04+(B(&0:E"5) 6,*(H06(.@O02 045,2ABH1@% DJ+=!40
M 0$)0@HVD, )8CB2=@_OS^_?-W._^_VYF3G)9";)K.RU]GJ>9^]]U@I!3=YN
M-IR5AF1$ZZ=7SL)P^P7*ZB)I6ZYS*Z8&U698A!H#V+A$B^:(MC@['U. M9$;
M4&K9--)H>O[!LM/KY'M7BI0,<,;6B(?>\_3_[_O4_]= SI2'=M9SJ/QCHCY:
MK4DV$Y?(4 9>Q530UOHSOOK!XFWLU/QK;./KL26TS,L/'4F(J>\?=Q\CBA&4
M#S3(Q%E07)A*FRVF ]/7A%?O.ME<CBXW=ZFP_VL7N5SEMS?^]EZ+.>JQ[F(X
MSXT".-JR*>8?-APCR'06V,?R^&+$H[]B1$'=;9@'4/\TJ_X%/%K%B/[7PAX!
M*57T">87_6, $RWHGV2,=7?>6ZFA'4I9!?WL+(15T#",XN&QR\6CMW+_C2K[
M.>F2J(B3/69[W!$?$:L;;?[0QF1$;M8L0)C?#(NFPULH!RDW*O,J=!MK%C_(
M-2CBJ@6)&0:5??N;7'DK3>DR15WDEWIWRP)%PTAM(]@\RH>S("\IZESTLXA[
M%8FKU'A>N>_M2I3*3^EU&I6\?$>)HO2N' U-K2730T728@0_G/B%H1[I>9+K
MW<Y ^A.L0 E,!U*DR-DTN+?@>(2V@S==\^18X9I\?50S(>&:"W\;'-I^J-.T
M<5SW$DU*)"G XB"W6OZEZ,M,LLHO]08]RK?K^4971L&./YM/F84E):\YWQFO
M\[,;G;0,=%6@QCXLL?4*U7.H\O(N+\;POG..345N.9CM<[=M[G2DGL'Y"?[!
MB%@LL'PLT!/FVZG",U(+U*GTB^V4OXY27K1W;7NPF;K*Y ?UP>R^Z*?F.<&)
M&#/?1W9(HYRLUM< O9\ISSG'E1%M./S)@G8#4]]2 XKXWL)[E,M(^9DK&/F8
M *=:'2O[8P8A0XHFK'.O7<ZKSAU=2-JI*1NQ'V$@L>C/CN6D@@#+E.,,MO/V
M<[$129UBA+JQ92-I7296@5=F41'\IN'/XZ]V-=]?C[=^Q;.;/6@&*.9CXAHA
M)<84VJD_NPJDL6*[JVQ]H">3&E#ZTU,"=RXZF3-B,5'F9SSYC'Z94BAQM$"$
M[5[-22]3K#@CX_U4L ?*Y,>NK%*")V!"C'S5ST'R0P,)%T%UCAR+K-3#XC,4
M\:AC@W]AL6)C7![8_ZIRFU/>Y.&-B"P'+Y3)Q%.\U*]DU7\'N"B1M"=%- +4
MT;J0B61P"4C%5*/;24F;=N#6T_==>X:_9N<ZI7-64HQP:PBJW*O&<^^UN[50
MZA#N_75,TKM>F()B/B&K$_7@P:]TD("2>*4@NK-?G=@?J!GE"=NWD2"AD_0%
M>M3VYTA#0\WK/&W/[8\FQMW.<X^F\YM;O</;S1'$_-%[82@JT :H$H<G-PMS
M[,Q-2I_A&]M6JG5(9810:R:"'K?'&CIC<7;C+:YW"_9N/_S2)5TF;Y4F-"Y:
MKQJ^DH2%U:)5 DUA$RH"&.>YVEN?'#S;G,\"4II6E;5CJ\:2\[9$ U>V*<7]
MN:D_?GYKAL+QU<I-Q::0=8]'T91U&SH'J&.D(SDV2UUH^K:.V(5)ER1=OX"L
M]#-/QT(IA6O<&TKL$GXDV )9#! #0-OGWY+36W0AMRE<-G$S^0084A7]!-\5
MH,RJ:P3"'TTX?M?+B4\SHAL]E(H^=&$7]A<@2?P,6RDR$O5U\ZH@5?;U*3%"
MJJ?DZTQ#U&C2VX;"XSEKKN!/9]W6N_9NX)\Q]49"J>1IQP7:>#MO !+RMW;4
MH5;3F$48!9%5^Z5'Z&>G3N&WSGS0#M/_@[1:J,P*"05:CKJ_.WS^!C?06HQ8
M2X>L64NP9^[GXY/> LJU 5<Q:@37E6KQBF&3FZK?4&O!G++HG7$-2OLN;[QT
M@'?N<*MW]NY@HY)2PUU28\@:"F<56,,KAS19.+HIDYP&<R9*5DS896.U19.1
ML,<;2RDG<C5VVVPZ/G!K0>[*;5!*H/!C[C<KM8-,9_ ,:R0)]O#7LSZ_:-*)
MV.-FZSJB@"F[%50;_2[DS/P."NV_Y\Y%2C<&,L0(5)UY?X1W4>?GU0F:$)([
MSE=N]PMX<H=G@Q-L70[HOS7X99]1:N]K:IRVR6Q<4!;S]&GOV9.  PH,1/]S
MF2<!O]MAX!X*J+JF+_/I85KO.:U7'J<HA_)G&LD[NO;</Z1NF/6KK_-/60S]
M2FVC"L#Z1P-/,)9M3 75,2C1_E(1L@AV*TQT2Q^)$3WZ!\2(;SO_F63PYV=[
MZT4$^.TJTC_D73$B,H2QJ(@2;,#\ 'SH.KVC]XR+)WKF\OQ])@^]U3Q;DM_I
M5QZH*4;D7H)Y%$6#MKC*&\O]^89?2U2!1>26Y#@I3BG_*O$]S+-0*58H#?@'
MT9D@WKJ]H8"Z*??,-;W;<82A23N/(Z^,K"[T[/BW)3<SBKYZX="A:T3:;E2$
M?-(DK,82F^!$'/07-X9BZY!YY#9@K)[)$1 -DR\,O&?WJ_@UUQHX3YBN+6[
M,^:==M]'Q)7(#PH-3PY93IB,^P_@6(TU3?4N').J;_(;!VQ2O+TV[KZY;\WE
MM97>'2C0D9P]:<DES<+TL7J^*W/>G&TZ^YW=*$:D;-KM%=2 F1T=.W>A9"$H
MWGQUQ?U4L[UK5JJ+'^7/0\;R E57GMP0*CP $$D#8H3TQW^7 R)ZVDBL^62Z
M<<_O/'_,UT.%5^_F*61J-0CO1G&FLC0X@N[P3>A;$G^5I[R[&#=H-87M.IY3
MSMWH-*W0Y*8=CW3=*K#TSK<9]('@VUOVSUT]GW=PWUS;<P$1^LM$C=&8IAE
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M@UOA)7,/?5XM]^W%VB##L6EX:DAR"L:4>1BH6C:>&5S:P/<,Z?2T/E28ZD;
MGS0.(;TGR$7+N49*M=*-^S^4Y24MJWF\3H^=M;5Y!E40"RSY*4H!&Q210)#
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MJT:&6ZLCOFN3N:T.3QMV45<]"^5[KCLMO.#Z>SB#A_#'34(0;FX.Y!^A(9P
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M\V<5_89U]OH;UT92J9HG^;M:>#O/?(92U"(6T $+&;[.RS_8L)G:$^,8>4\
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M@@&:%-H9)*!*O]QI5U'_QL_JC+D46'F'J:Q-6S&3U@WU;-U=WM'SZ;8!6[J
MZ<1YAO.?C"2*X#S@]TR%TW'1H"[PY#F2T=\66T(:$SG0*GUFQ_L',5\RU;.L
MIYUJ0C35^WDFJ_;J\F1"8XF%[9W0!ZZP^%I9%FS?>[5M>))"6RU1 A-X<_O6
MKR=/LKN=HK[;2P^_NR#'2M"*4/2E!4B@4:VFNA_+,-I3\"TC<R3/A3LZNK13
M?1KA@6^-W WXG2[QAHL>+W\^6X=-*'"=E3]YWZ$F_66^_M 0XU[BS@'^L_;;
M=H?"8-=@A"SV)D8QN-FW"-OB?@# 3W%A(\.MI.#.>.E!#[ICJRM2FJ27_JR<
M.6*C/4G*4MLB^LM<OTI+6I?X1A@=!QP,H I&F&IANQ_@FC5!.?3NW@ZB/-;(
M;704+=3<M[V\CT:N2_2N'DOA8>TH;;CV+O:8W'DS_M-N1#1;E6Z_TAH0J20+
M!+[P_317:R@875(UEG#Z_)$):[Y-$B=&-3)V.RU/$'<2R3D@I('"7V$[UVKC
M&DTQ7M#!;G0V%=^)BZD]:9 $:OH0JW3N*:>CCUQ6-.P0-8E,N'^\4)KOJGAH
MCK1NTL^"IKK.6.,CY 0%%"/C'KR5U,Y,"[C^XILXRNH6R;.[K52[/$NK<U="
MM_J/55=_*SY;@=)_:>[@;^3?V0JVPG\[6<)$_3;W[A^JY_\EV8:[-<?PY:,]
MP97!:1*FGZ<.RK7#;"PP$ 46U>;"7FAR81EP+NRFW>^.;04'!H^TN\O09Q*-
M]Q6A-3ODM6N>Y?M*2SC[9 5^.7S,O_39D6WEQPJB+"T]E>GFVQNA)Q4-^<!!
M*2ZL&ZKJZ\+?'_/.<C1M^JM,]H]9]"WDU515ABE7UT1NR+=[&GG6UA &@]TY
M^W.IEVU<"Q82P',X3H_5K[Z;P4\ \:TY2@QL9# %)_U-W^5Y)H[7_&Z!CWZ1
ML<R^O:UJR:]VSUGQ;34OOM8J4K4K($"\<YN/E)@,CQD9)FB.@IK6VHV;B^/"
MIB$5_'D ]YLCGI]Z4O_)K<_8H;3^SY9WEZ,KK"_N'3G&V +GP;54@^^72Y]E
MT'!CID'Z>Z[7OG,GNJP8_G<,2DFYNJQ'+R8YMR&_EIM5:5]-6.5UX\*&2_!K
MFW)%N[O^(HR(\L!8"V*+L48A>K&S4:VR[X??[M$R/46D[>.+41,[YM[W-/U8
M4>-YERMR7'-Z,1).MR>.1E.MVL==*0LY^W)(+5/G^JL6^>8^ 8[V<8KN-K^H
MJ+@X:[==+\\Y'-N0&TAJ50DSS6 Y8P=!&4X:1N79G Q6:J#A)!4I,?<N'S!H
M7E-&5<_+?-BO>OJSE7RB^YF6#0?50LU,7.(8HF%P.:)?DC3 5.1EAG(2="<%
MO8*#*KJRF&D,\;$S^C<*N\QU-<4/2'\)B3D>WO!3*IZ1P?P$9/JQS"; ;EQ%
M4M-.4!FH-/ND,M!P(;@(G:#[QNAHW(6ZC>YGMD59?SFW]SY/Y/G1@^=SX4?[
MW+59>[ CD.55(>\UN"G5TEM/TSL33>$^^[W! W2MX4V!)J5=3]#L3%O^G$/V
MR'2R2)O2OG!,9SNNA@NCT<A$07?,%0:<+>'@BQ*832\-*1PCML5;#3VM,'/^
M;MJ5O%7.5GKO]\EF.<50T]JGK_$1"&FV'&.&XA#&2*5,?TG]UJC6O[VQ?\*+
M>4RL(\CP"RWPD(/<04]5]7*$%R$&!S?=AK[8>9:#1UPY"*K-W9Q<=:P[V[B_
MML^B1$%V=>(JHX[X7BH()MKSB&&F%&&!"9VDVXF2^EOP5?#6I%"X'(*,UP?E
MZH&DDC=ECV\&,&[TVZ&UGXP,!ULJW#E\O%5";N_[L!KRWB])A&]_BLB/XLXO
M0MH=P1(8QWV36C&!!(<@[ETK)/9'].?7!<?K;_]-DQ_M_7Q!LV'<SWD-,-RG
MQV&(^$4D&+I:!>Z;>BA"YW]*G+<X_][1@K.<,J+GI#A[X\<&NRU)A3YX3SRR
MH?[>NX"9L7/MU^5/1.QX>CE&\[PXSWA41__\8!?[,AT>#ZJA-T^UFFX ""_0
M&HX'6O628JJRG:ZDC$\],!V*"_2:3@C=_;:53P("EIUT#5H1HY7I!#0SC-J(
M-8X+[R3EA1M5/_IA+DPA-_ANNO/\V\V:Q[Y\XB953ZYL/;C/%#PN,QIUGM<5
M<K1Q4"_(&D/?^/=Q'F$4Z:D=^FO\S(*GZ'!MU39'_5U!=1>\#H3<%#X59$P=
MW)L=YO;^7J*FE24G FO,O@N4,@Y05FCFK).3<^#F5PSUV)M4;2,KNIKA8:#^
M;7EUR@YO]NB):WF6R75'5K+V!ZLTH7*Y,%_<Z'X$R09)[XQAPQD",\W80W2E
MLD $'[KFP[L]V%9-9>L+*8(JE\/M-Q.4+(,(![M>"M[OH<))!YAJ'$*C-'LO
M(Y@F5X8Y28>W%V>/[W;"N/GZ<9[D^>QMV9'H]3S\X$K;=/C#"Y$\21H"9;AF
MDX96EC=VR.]%)/@)0OF(9[%"=[FPBGAG; ^>&70%GA"($"%>[+T_L9V3VV#"
ML@9'</ %C&\Q>O?05QV^;TIP^DC_K?']OO=&]<8BU)*,WX?RI&P@BST21C)2
MF?N!"GR5'F3<=BQ5]LT*.B+.V"+?_#G0>W*(;:JG;>!Z3& L9)0OI@\I3^'=
MI5S(.]V]"/N"N-RKBVMV1WB+Y=-8<G1"Y);BZ1G0M+'#N'2\-@3B/J(=M0A_
M'9)F.U9K *(\",\[Z)^XV(E]GR84?59*"R*J,C,NU45.);T"7?&[=1K:TU[>
MB-?P9.E@WQHF+<Q2X'(^+DGMV7@QM@4046A=A"[NK+U][GJF/[OB04A0<US^
MU@U!%J\2G2YMD,*@R$BVA!6S@_/HZ3"<$LV6]$!&K;21*N>PVP=_PL.9M1EU
M:=U79K*HOE^3F]Z17I/J?PD5$C<S?<K),=T$!#"O W *+BQ'_'7Z'5%A+X93
M^\V#/-_E+-T=>$/=N@_QAKKRQBW,=V,<Z0%3O?$XSWE\1"VJ:H'I;E17*6;0
M-J[9:NW#>+N'+\?'N7/O6<[(TDNU[Z[&U/HSE$EI<_I' (EDE(T'ZNI4F%.-
MLN$&,A<5PVF4"0,V\. Y(R<[V@6VZKNNS>ZO[Y#X@'V&4_1=E&1L0*\;Q"H!
M2J?*WU#Q!F<>W_%W#-#:R^I[;\)_-]+=E24'=I/@"R$L4Z])7MTD,>O2'H\=
M[1^*"4C?+^^*)I":-EK?LS\7[0@/=8XY:Y=Z?[CH3[$0P0JP>7+IVA".*5*W
M[K"_WX;0:<LZ.E6NH],P&(:Z^?&O@RB83L8B*+2^!'4I)]/8&A%A>@ [;@KK
MKXZW%@ZNLX\J"=3,=N9IMGY:X>RB#A^_)EH=-%D)__,[096>=W1&;S)+Z58)
M.GGWW^U)SILO5P ^"F?X6FD:$E@6,/)R.^R.WM^ETCG$\T21$9])03W?XLPR
MJ>A$O;2V,VFR+)L@*1J1'C$+7UZ&1EN8GQE<]O>!V6&B'\=01&=J>OQ9_=LN
MW7F/S'/ETR8G0T3^%:8]ZYY$?KRC*M[!P.#1F J51JS;R?OD*02^%,%/B)FO
M4+TWD)( \Q])JZMON+"FFC]%I\&M=U5!; ".K@T]W'OP8UP8/GN2+>0#&_G/
M2Q8_F\_:\RKUW5,?9FV\;^".ZFZ7SUKANSY2J'[YM$!C*>.( <<.(MT9<GW4
MI 4CNB.%Q!9AY"20.6>H&1TB"DW#>(D&#U_FN%&S0W"\47?1.\G[Y4;*T9MW
M;-?Y)4-Y"SH V(%<6&1=G'7?PX"WS2+(SV7 @W0]8@=2:@RH;'$AM)9*O&6H
MA7NGTI@K-=Z2Z8G+NC<ED?NW2^;:"V^$<?@&JQ_#S2O\;-P&_4I*'X2NR-PL
M\<JG[W]O)J7WIDWFVH[!DEFMT[GH+PD1FD5R?&(#8A.-'ISG"'(2_*4C[3&C
M'Y19H7G0*VT98(% LD!V_K>UE5@"KJ+J5=YD>O@'.8^D]S>^U+\*.BC;CJF%
MA@6&+GCO3VO,G4+X+([R,A$,Z?) E@&P9_(H:T_"'H+)5SR%(-WUC'!5=_59
MT'F8>,A;V8>WSE[U.Q>*?3)HP-@2IE31J'CW1D^@8-)MI^R'$ONY,+1ZL%CS
MC&*QP6G@SC,?%SWPOI[;\<^HD9,^*]+#SSPC+QV.G/)X7'8@[>JVK2)8;W!B
M<GW+!%74PC,6+\8&F"2P#=_0>V.,-2DV/>ZMU/&9A.I=#>9*5<FIWM=JQ<]A
MF50;_"X'Y2>*GW?:)8>*#KPH\*0J\IX>\->]:W2N\E5]%6+6X>7GO'>BK+DM
MC@Q"CTX"9 #T,SKQ"/K52'PL6WA"(YL9/M0HYK4T=]H;O.B;D6[Y5?KU):%H
MUJ4Z[Z#S^S2-7ME]E9)BK-!VT.?!C8R;="'*/3C=_.1Q?4X),NZ6)7!U8O-
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M.Y*3VE'2Z-I3])Z.(I$/]1<H</&3STRKK\91JEB9N=O/^*K3+QT;EZO9^5G
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M[H?HK10\S8IEAQW+$>.4@:88*524J0QPY<F<?N,6^C2SFO][09';Y-'S6=0
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M#@EEY\7[AI1)N7M\>W'*E;Y>$0AZGU"LW44EO)>M>(^_"Y%S&B[>VAKF_+.
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MSH(!M:#*!)W 41=B+G)A;6%(T*R,Q;P(894Q&L$\!(SG@9\R$/0SHJ3:C@>
MN\*[*_29=M3]OCE3^.M$UT.Y5^IK]9.CG8;.[$Z9$S^6_"&(S"!EL,6"F<^!
M2YTVG'@<N1JAU C_!J/VMV+WVZ!DQ[P9/[:.Z3'?J<9:;2[Y;E54#*[OWRSU
M#2=6;7/7 ]RLPPK">'+RR#69GDA!- $%=M,KW^;O;\BRCSV;&0&[KG;_GK"D
MZB$8"]\ZH?+1V"W7"2"T9(T_+W@V%W3=;;8N'7^CTCPX8+M@HM.7P_9]:1&:
MNY3#-Q[4NU$$!+<VPNG1T0L8#8K)EMX3GZKJ#Y;J]A@@:YS\:-I39LFMDEX;
M.N)>2-F;P6"PIN*'_^3R 2&B'8A5Q6DNC  IW[0;U8,8CW7Y@EI;25IUU/PS
M8%F%!/M>\-;F+,Q+[K7\=%+ST>Z=<FHY33RGSSI^;7-Z'WA$9K3A.<N*M&]Z
M%6U4>R7AU8>;'3MYE^-:P<WQ+"^P'ZZ E67;<9(0'M:!R&@EY7ZV T;S"A45
M.[1F/&$0_L'FF#N]F>D=^4OD2LCVR^I(O=ZW,&WFE;:30LP4@,/:-]),'Z-J
M3S;A8@Q[(A/&>Q;J=D3'//^HWF5]_7+?<6S/M>N-$LH'03T:B@]S>%TY84YS
M4HG>J,@L%%LBE3G32,='$S F4]H!S: 28SRMIIY"V[Q5:\\>;;_\\Q7F5ZY=
M=M!Y34+HH+6<8UDVX*98EBM0S/S&B<+PLVR!J19]DGHYU<8F?U#KJM#=7WK]
M0DSRN@66G"Q4S2[9VFS=)M*3T,9+[1WSQ)$)J(J,1%-1MAH]@"T%+G>X[P6:
M&0**O,<^9I,14261;^+*6#2+?+&N$T'?^BIWNA_-?-M^5P,"Q6V< J*7G\Q4
M4O/BB ;3C.&9%(6YPXACV;X:,+Y^]YD5QGC?4V]Z;)F_1VW&RHU>Y1VJXALR
M+4_S>'J2$5=4N3"1U]!%\H$\ULD/V'[RY&CK850T5O#&3<D<Y=?CZJ4W<E*.
M/J.YYMA-(:QQ5YW]0#E<\RV$)RXN1Z>>M2>:FB2 QK<$R53JJYQ$=NUO%]I'
M<4<=$A-TN,KS2!Y63Y^DKM#NL$0AT#,S50([$=4R-#F=]DE>C&]?H"7=(+XZ
M:0O)FY234#+;I[4\^MY/RB-KT_;S=IG!BX&V9I;C-#C=%D&*[IC<P-[TA*W!
MP=.TJ^'W45)Z9R#&%67HV16=.$%^/O_8@7(-UZ?U9/RZ2C-?S,>D"<<H7/-1
M=W@L@N[ A8W4DR%1XW]_K3/Z)R1'"6Y1XZ"OB+[1SN0=&:PBK>1WXJG-GIH3
MKTT4.O"UT:V]P$Z9]B12-!7!EM#LQ&]=Y/\Q(0G8%7GE:/:17WYJT S8IZFV
MZ?HU-8F)M_QM[[LV*KD(\V\/-<D#-V:PK-BW.2\0%Q01U *:!D,4%,=+)4G[
MN@0.5>EFN\(--7T[HQ"?29W;?"/M^F[.67]],\8L![I?@!^(D'=I0R9ER41M
MJ;Y#)O+[W!Y_GKI\<<[5U5G=:82@8FW^*O'PESC %10I LH9!NZ<E#*L[#RN
M\D-M/CJHNRWK)Z<@\7N@D6/EF[K4TW[,7>*',B\EW?',/ S7(C^*6^MD?N$4
M^X%;L4U<&*3;O EAP88:]_TQVA2;V2J&]TU%6N9KBQ',I';,K9B:50GE-$M!
MN1X8!A5"10*[U[TOW^=X<',9CER@'RS_FBYL>BB5TD84U7U"Z:A$I\^P5-_;
MRVRP4P@Q/9_Z?G]")M\BH0\U2J0^@R0E<G2J":40B-IBFA0X!>>?O3W](5EE
M1\FE^JHX2JY:J/41%7=</2I#OI8M?H4LG03=ZA&B>IQ VT<U8/#C0Q$4S\,[
MWE0&"-@4"P70>/QU>3?UMQ>?P"1OC5=5E4/LXJAQ(K$& )[YD). E<7<911$
MYWZJ#I !5$\-ZBDH'!M52?0^[^ A7G.\H^V[F75+Q?V<?-[!;^N.YYL-$O@1
M#[XF+!%RYO]RD+OI3VZII<&;"U/%%G%AJ"4N[-OE-T-_-Y#V:E*:+?41@V(4
M-Q.WZ02ZOJT6Y9\E53^.S'<USNRWE6XYHFZY0!@]X[^1U?.(D=@5!]L=B8\T
MUBGP-5!2[6<;7!#("]H7B!/)TNH7M;IF8$#UX4C"1B_&4=7#T6E] \5Y94=X
M!\0^VY\4;#7=1B]-[L?H4%B*^B.O;P9<\'KPQ&.P)I=78ZBLSTPN1YGN&(%Q
MUCJ +FAQN?R<V:F_6.ADM2]FK2C0"+?YD_U9VYC<G;*P+;!GD+C.!27I#75K
M0!E29$2_,'G5NT@O2R$2^3UVWRO1JX-K?TXJ*T5 +/#M)/0DA]FH-=F2KGXZ
M"I+M* X.<N=/XF K+NLZ/7$1--G!A97YL5\<_\OW0MZ9NO^8NUB>)*525UJ0
MX7!^O8!M;#1]G%D,&>;X*#J*U-NZ?VY.VW_;X46]DGUOEYIXP>6-(R=2-O;<
MEI+D 309NF#+,%$6XCUX<",75NHSA-BFSIB,0E".>>,W9MB%?Z".EI8DYF<,
M=3TE:4K=#+JT/+CA)0E[LAM5!:\>IBGD0NRGHC,1X8V27]41C&@X<+U0X4:[
MP]STF:O2<W?DKGA1E98VC]!%F]T$*2OMHDJ8L_UZKN\6C7&%(Q,^#LL+2Z43
M0QT*NF+G><,?%"NVL=NF>.,6"GF_3 +;:Q>FJ:AU^B%,9[YA&+S/Z,1++)9A
M[DS-O^N_6CGGDK<)HHV&T<>,[UW@_,!FMF,($-Z:0+ZFB"T)5++L?7#T$Y-B
M8'\$>;'U[J;#;%\&O;K.,+UBXVF2P"\JL23E.2!K.M2M?L#3$KJ+0V&NZ&/$
M!2*I$]PT-H4+-0"5.%&-*E[#IAL N_SV+4]\G\YF7+?(']N8GVPM<92@N;]=
MLU)DX;ULN=8HXK$+DBV%9 K\#_;>,ZRI;=L?CJ(B**("TI180)"Z4:J4J B(
M;$!Z)R(B @(B58%$0(KTCH(2:=()':0%Z45$>B<0>D\ (9#V7_'LLX^Z]]GG
MW'O/^]P/[_V0)UEK9:[91OF-.><8@VJ2D7M2IZ&KBP15ZZ03> 7L.O2RIR">
MQRO#[//>Z@K4S73 ,Y!+LEDCVK;";T:2,X0"*F&^0QN$'R73TQ!$\9+;(E6D
MVI5J<Z=\XN62 N/& 3&YJ\I1&"97H2NGM0*',!8EOF$O!A-@8Z@B_6;$Z(B&
M-P7$ ;=R&#FBC/4+]Q&GDS6T3L,7US/D&-GH%X\VD-ZZ<.]W?Q[7;S05S?/\
MJ?>23VUIRG,(MZPJ-II,KV .C%DSWF%JG14V!#O4)VN#/N"0_PYWIKR!B2';
M^DC6+PF?1KTRY_3O-JJA9@\P9+#LH7\[6=#O^?VBJG[$CVNL_]17XT]6$ 7^
MQ"4Y9M\,A WXFUL\N6::K-L^J/O#FN$W;[<SX^EYI-PRR;)%P2M*W9W,0?25
MD3YI7.]\0W1B[M VF,D#TW&"W&"$;D$>=/=M@!3/AF8\7\EU0>)5JT490\3=
M[7@K$E?\>]N+51'G+!A.S]V\%CBLUH[GA/5BW7P]>;";]0ENWIZT4SEG.!5[
M!*=+>K;>7NX_6U[BS<RO>/KA_I1,$.C006O-:Z<95^8)(L2CI&C9$T^QRY.T
MP)P4E+Q5-JD<<#F,T*ZLCELBSWHG80SSTZ,,SP3EJXK6W3D$VI\,  Q+D>?0
M,N4&.GE&<C>"48BHF)Q8L2Z4^G3&QT,F<W-V;+3KB&#$[:I7M$JT1]N?Y%[?
MNLU'TX"R!.-Y-5:R"!SNX0:X^8]=!Y=.XC.@9:IV%DUD7MS!B;QLD]'D@W<)
MBF-A;<?Y,^[9:6FJ[M<YL28&M)5W99$@1F0B1<,X>>O! .5_A YQG5%36B(Y
M4T"K HFY)B:W+5\3.UYS1\^Y\G(67'D.PF02&4@1*"OP,&H2D-!UC+X4T%$A
MX.^'EN+URSGBO#V>.F8J..^\)MR*7GUR^W/4?9\7*Q_/@J20*BG/Y:_ZD@]+
M KJGSQ]GQUCO<+QMJJ1/?BR))AYS*']O_Y@#&K5R<;[C ESFF';9F"/4;/&J
M>NP[:[V14P'O1X<-#8W33KFZ1N0Z7C_)IQ-ZXAI]]CL 2X/VZ?VF(&I?E%!
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MH+9>@15CX56>Z(6;<1*:!>XK&+TS],W[6(28]9=IT_Z'F46/P'Z"6@#"<M
MFM)%.&3T+<@#"U&[&;&A-PTT!1"?[SV31$ASL-QO_7IS"?OTHC,KSPN/EE?:
M^6.;X9[:?,D/ZW88#^$U)IO?3D*/0Q?08&'S0G)/[P,/[RE"X+H0O=CL\8/M
M\8\BV(U!^>J7#UK8<HGC%7&([?@J7%>C+2&4LW[G<DZK_.=UP0[F6T&YYX[J
MM!4+*CE&79FHKF70UBSKG>_)6[^O:OM>Z8.WB5_$>]>3,M-.%DLV]'O/QFZE
M^R??2.)(>,$1D[I>T:X9,Z*^Z1#7ZZ:2,SX^K#1^#%69DI);XX+N^K0##F$B
M<N$S<AF4'$8>- _4U],<"T@VPM_8O5OTG#%.C/-:6UV'1?0"B"8.#P;T"=V0
MNT4C!72X]NQ2T>(>)"@O>31;<5_\BOXO;;62]\T,Z:8*NVC&PB53BO,:8Y?F
M;$]GUE_Q;-=SX4AX\]22W4DG-E[ \;:PA(9:;'3^N+J' /$KJFM#SNLKPA]Q
M2)[9/;'>C WO3?OR:Q=+"T-QC5]:X:C!Z(6X>T;7CE19L=&$SR.Q.6;X,Y/H
M%VK6R43K@&LX6"F[FI5N8L-._,GA.I7.ZD-B(Z^GA>EX1X^4US_,>^BH^$CB
MO/BEJ<6-^F-O+A ZKJM\4&F^;>/96;[N9'JQIZCTC>.QRY5!W88.&=,>;\&-
M(D?Q3 U.(QG>9%Y%C.YKD[$VKDBYC(CK; =^/;0RL[48_BP<HQ0[R0!NO-<U
M51[$V[^%+FIL7IL;3S&_!+YJ9ZG]W/VSP/X@[/*]+-UYS50V)['^#PBAZ,K@
MF+15@?%-:9GT!W'^PBH3;2+56W ._$Z]*Q14?06;^-$(.?(@:LU4O^E8@0H;
MZTV[(,&BT%$F'R6=V ,<FT%\&>$M Y_XFUU.FA2&G#3F88X:KUEUR\\K[W-*
M3*S: M1A12#]SXA"6. K^(<H(Z3ENG7,-.D2?$UAN%T2T?%5L%N1"B;,H6]1
M7()YT&FKX+<I;?+<-;QSD,WAY:W;*-E:&7B;#<Z!%.*&VI->'FV[_&NB3-[5
MIV$<;]V;3/DC0GJ\>J)<80$?<:O/\)XLK+?MA=I61A9G'-%W 8LG"8K'I:Z<
M0FP"^(!+7)QE"['$N!_^)8<:$^ 2?(-WE@(:D0X@DA'D Q30IX"__U/,RZ>7
M_!0^W?P^)?PKK3=D09?J6<F,VCU.[OX$F=\"["Q>\GW(G]3 #,^4I:. ;N1*
MD@\#UEQKP'88 #@@&120-V3S'.%@!G&# FH)!?^]:%9F*NGZI,8>BSD*JRA"
MO@DI<6+<)4&(P#M>,PX)0>;CR;(/?R^FI@C^H?WG2*FOX%V+%-"D!K$5]A$8
M>%D4;EKYMW(V-GP4T!UW)K*?@0/QA"H%%,FX>KJ!# =DW7[XG,+V$8U=H/_A
M'/)_+ZBMJ;SG6X?8XF^ 3P9!B8'PAW/@S3TXG@E0TN "(WB7"-&]^_=B"4&0
M/BY@V)+UJ)EWM2B@&06"\B^ ' 4P51UB-X+TVQA6=CW?ULO"%=<+%]X-/VEX
M8A.\NQ+[:5 ?&$)5_1>H%0MJU*(VPX%)L\.IMW4OS;J[<">JW4E+L'V $ X]
M8R#8 !:TXUYJ'^LF:%1N0A0>I@3A%?8._V6 4<-^,G,-6U++;!.S)K1NOOGO
MF]Q,8TL)H;-ORQ!N'MP1ACE"N>HSN==?%1\\4]2(R,KD2WF3?DFF'([G. N0
M<\0?SJ5T$0Y20Z@ <GGH\K<0PY6V4PY#(F1UKB[RQWAJB.%>:%\2,#5M/")[
M!!'21=IN2^@:6G(/*/W/3/9_,Q.N$.$9O*UA CYT^5OP%C:D%:D&,C.U#EEA
M_Q:,-T0?I\$!;S,. P8 4#,]KS?<43NO]PH :#VG_OBO0_)Z?1^2%X/2_#[5
MU$3U,;(PI">>/"/W)O4I$:75"73EBW(9R^XL;A28OF#XBD4-,'U=T.32/]R"
MUH/7=>'UJ"N;Z..H,<#N>$E6OJ3(K#^!B/$#QO/HAP_EQ651:TN687P1U5'2
M=;HTW(B[ E,Y$#P?[ZHF;AZ#>BY_EOP)7C23$.!=FB-R LQH;#L!"?@UOBEB
MI*9$S=E\@_M4BL3X[$MCD3G171 [(0H[<D1%_9W%AFS9)G'ET7"8FU6(A70G
MS!,_N,V']R-(>[KAGV:0&U"EG6C_+=4\UB9J0#$HZ\CUG(6$FP;%";;N9PIP
M1I_N:T&=BAZ-'3GU:/=U3*&HIO/H;&5-'CQ( E]21@').']8G>G^J-:IIYK0
M%9^8&#=6A&K(VRZ/W1LB=-4EK*$P&@>LY2_@X"]XL-L9'AD*\NG)8^,M,HN]
ME_=CQ0JCHICOZ3\C9K"?YL![&).J40_7 ]'E\/H&+**IP!I-0S2<-E5NX'!6
M4"V/TV"N\:N2FWA7K,(IZTKV"+PG>GE]XTSX ?H^'&*5DV! 'H%3LTC3$97Q
ME[#^VPXG/6_VH0J)MM93MD/ODKI45-;>H2H+/;+V^_*5G7@_=\]G69I'4C^<
M_(4"8B,+X_4!?;I2/-7)2J9;Q* .&^'!QGUV1-XI:\_K[ZN66LM$6V9N+(KJ
MW-<]:G1#TBI+.E_67KS]^.,GFCMG>F!?9THJ]49V3(U56[>>C!7>R#/H#SE-
M 3WETN<C5!?&E=GOS!5I&'./+G1E4I%,&!PLIA%* 1VB@.YW/8==+<&JS3=Y
MJ>J8*K3$)_SJEI=A/#3*O<I0K0U;?!\C>L?D])F*V2)I] %J*-Q,4CSP"G
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M.05%M>TCJ&] @U[^]Y)[OBWP+7X _4\&H:CP!'B\N0?&GP3P"0>_0X$I4!T
M431_+PGYJ1L 0!$!  H@_>KB=R.ZM?_>X_#?BY+?X= D^D((_CR2 CH/'I&&
M$\D!Y .H3_Y_,E  -@04[H+N2P <LL"IX!!X/+\%P?*0[XOIH.]6?<-XV-3?
M"P+@T(T*#C7(AW/^!@ZA #A,!L"AR.:YE/?_&,K?BY*N3Z/V6.[!L8I0*CC\
MQQ2L0 J@Q#=R")*O,#4.X_M:#I+OJO Y4O*CB5M82+']AU;RK%<'] OYU*ST
M>[4&K>17=]YR)/5HQ*59TAEF#H^HR,C(>8;GM-EJ(E\\R>#A<<MV6QT";$G2
MV:]_MA+W[_MO8$1&DWHF'$;VXV;">0E7!]\@UO3#_XZG:^*W 94317I* =U=
M=B#MK_:I':7]:,(96J^-#.QXO/DFZDE,9N\3NSQC>Z&RO3(84](TKF_SS4T+
M/95+'8J\Z+X_@^B5\)]PJ ;OGP+1\-\@;%\?,,U87A)] 1I_/OYOT_Q_-L!_
MP0887,P'%/E9#XV][;]%TDV&IN])$KU7(<LC$-(!?>^DQV2%R&P'H7JMY"Z8
M@Y7Z\;G2/)@.TK8*:EL[O_!FW\O&>[R!V\5/RH5747-KAH#$FN_JV?^SK;<E
M\?.=9;P":0F)UY^#>6!8":%@'*1U%J!90N]&!(!E]\5+;._$;1B9WBA2Y&>.
MDC3)N<1VUK?O!)0'WT*F.TBXL(1FJQ;(>P@YF"=4#;:VS@8DO,H[98R7NH#U
M^_B5N=&.4D-BNEJ;J/.=[&'3=CS;WD10?2TGXTL5W2#7M6AR]>=<84E67[ON
MQ-"=8MM44QFH>A/C47=H XP.NQK^0A;\;L3ZF5ZB3=P([*VY?>%U.WJ&'([S
MSUFN@4 'G<@0/",V%1,>5GT!)])BQD)P+9]475R7%?#87L00CO8J78C<5EJ*
MFKW&%O$+6RMH$*IH,T6G')L'Z7"HJ!>WN>'9':UAZI!?":FQ?XH&H-\EST.D
M7%EQRZGP,-B!<+UPU2J"7J0'PUA9^3-/(FSC2" [=PCVP[Z"4?VSD_J2V"/;
M^TBO(5;@TUTX[;K:DWT.1'VYY%(')GPJM+)?)!50'QU\,Q\BB>E+Q^K2?'UN
M(1^F%+D_DLTFZ!_LG&@'4%V)8T7%'6<+K=N,Z>.UZU?FD8$H[&WTD"JFO/&M
M+68G3/[(^!@^N%$2^G# A=.!P_;4^[E?]T5%F*:(@!YGTY:ZH8K+5R*QM-N:
M1?W. "-P,51U3PVD!ZFIV%<KP#/9C<Y^/"P9W:Z];]2O3GI>BF616<N?Z8AZ
M1DFH5):;"M3T*_][R!F]\**WAE*+J=&V:B4U)0N.*!IYD.<%4@+Q./J8/#U>
ME<"JY*7D,5=,\&KZ;'_1KJ=V=\9M9C-DTG5_N#\<,(OJ17S)0CB',#*7N_+*
MU9:P4L<L//).%!F#427$'A!@$@N?S?:_6_B^[XYZ/\NPIA&_3DI*C'Y56:)S
M;V%(SF!B=,SH'%H?:>JQG)^LR*SG?]T4"L@7(3- _Q2&47<@>)[$]E/9-JI_
M2H3 MH+:>J+'AMRQWH.T+M7!48!H8H:+P?R[%5GPW:33+,:&%%"$')KDH?);
M@%[$+LTX!3180CTU$-[X$E'7U0D8HB@;2,*-WT7QO*P 3J,>)HIK>4GF6NAM
M=Q$Y/&YLO+1X'I0\7Q8V)7&:V' _.-K;-]($N7J!8 [K0A69YD="6D38QZR+
MEC<TN (L+5/&T29FU>>.>E\H"U+8>,G$4R!OWFG%WY=,*ZW"75G^?INX)>'/
M56.4_>;L6%*;0'GZ]M;@EZT1@5:4%7@4N6U&RG')4ZY''()Q>^68])@SV9B!
M^[8ZWLJ3#Q?1OIXQ:0YKB[MC>/V.Z?6SD2:#3>MX?NB*$!:,D<_"1F.0S<%O
MKS1R"&9QI=]+8NQ?N_EK=VZ0;*L0E^2NJ49[2_Y5'P')D'JEA,PEY=A%CQQH
MWXBTJSG_YY"';9T"I>UK\1Y&V_(^*=4YVY:D,L@#Z"BS;<"V$SZ<-U#9?V)<
M/&6/X6O\\ C\2CMX\;%B->*B.JO,XRNA'4D>TVY$9L2V+ E!/JN!S6F!,V5\
MP)UY<T]-]19VS?=IMNK=%_<YPXN:SKZ8]"T-?'3<T3>!2X0^BS_?-G9E+6_G
MY5W1GOR%;*UYXY;8\6<YIO8>I2R^V :,@W?M%4](#^R2I]A@O/87EP[%RI[U
M ;KS3#>?T#R*U!V,4&*_SC:C"PU!<-2RD+L0C,A:?D\K7$U\P!:#E,A(*>>
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M#?VI;G%.9:5R-W1Z7("M(K-^IKOYCVA^S@\6OX#>H 4X ?F0 MHZ 65MAC"
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MHO S/28C.69K@X1;N_%3C(UV"M3T<SZ%"_)R^(_8YLU)"BA0%HPE[PTV))W
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M ,+O=S  4J"S$N:%!=#P$X% '?L]^&[_6_ 5<O\,OG4YIB:FU6][S<BN.CP
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M&I!1S2&48>VPEG=.2H\]S,U,/S1?OW4U)T)_CP5;&(CG@<Q'DB"=+X/RG>H
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M.P5&?R3UQ9!=LLU4#CQ]F2MW+.3VN\!W!Z],F0@E(8>Y+R)RH'IFBTME?I?
M5N"T,I&LPL:KB&]*3J/N>1OF^5 ]Z(<-[Z 2N:%("O4[4X!^C"RYN(+@VMZ7
M% ZK^JYV;3Q W[BG1-MM:6FTL>SADJ'[,J_\\:=&QRY?;N#NU#9J?Y$QEE\:
M-I)UC!:QI4K8H/,E4H*HH20+@']RK2V';Y@H\SI!RVJ5W>2N%?8$LT"OO66:
M W5-7T39"]R:5\H],OR,1WLE]BFL)+89,H2QK"&#Z]!\%G/>2=%ORZH2)C6*
M:[@/WOW,5AFA87WYPBWN6IFZ5I)9ZIYH![M<Q$?/>-VQ5WB%2"=M1=OT_L0Q
M_;$9>%1[8:F3^%BXI][54]C'2I8YVDI)WF[YQ!)C!H;)L0_P<3*$$;XER7RA
M956623:R8H1@;0R"8:0\A.Q[GRB$D6#E&!9%H"GUKBU8A(F;=N-PW29GKYW(
M1:[HO=>4&0"QD9:C\*1;&!R@"$EZLPW82#R?6VF Y*VSC )NJD9)NR^X[85M
M+$^=:YP49\0#(0>A"[LC/I"@E&E&.G.WSW&FD(]6XU8 "Q0B,C62%8K03L/-
MFSS_JG_S16:CZ_T+XL_?[=06Y_&T[&I=%7QI\[$O;9__2<Q1IX<=4B4%F[QZ
MVJOF'8ZEQ*[3PZ!B2\V3+[/ SBF9;15O1^+]/$MZ= 8J_8CX :P[T=.8&D^"
MCJ.)??[\G:%T&X+/LNN25_:93"6/Z(L3)F/SS<)FT26V-E%.M.J/TGMT+PVC
M</<IKHP<=55'")\B0&>X&\W+FZWT*6W@Q6BQQG"!9WGS'D$QJN$$^?-=[XV%
M)S7K]GK+M\MO8B<[B6+D#,IO9$5L!%/!I]_*G-#6:^'T7:+Z,:7_UH$7#9S2
MA<W5G!,/'YS3E^D.I?-S4]I"&R0;MN"-7.?JI_,TDA>VO(,79=>5GDCIH9UB
M#HX30?#=$.'15$=F4[/1YYXL(8UO:@LZ\1%!=C+95IJK$2;F*]A'YJ/<Q*C3
MY%)I';VKEK'F#^)?IN?-.LAHZHW./5I6Q6.N 77F+AE$;07^Y"3;OR*M]+LY
MS[2ZKJ4G657I; B:4+*+<T[8QL7M.Q@S9K:&N<B( SA?.-:.!1*D1NJ30QOZ
MR'+!"&A:1QIUH'Y#F<MU=?C"?!SHII&8E[A'PF$>89_MN^>U)^A"U/@LNC45
M3M#LH6ME?ELUG8?#^1O$8Z*BFNRA6A)6H5^S"OQ6S;$<$$=\)&H/4\J*;D,Z
M@W43J,B6K7?FM78RV3@[*DZLM/6QB\Z0;GG#)D2,6$M+T(FY\_%PSH-HE29K
M?=FV2SB#1-L>J--:ET)GJIU(17*+IXJ^T<N4N#A#9+ZG>X]^:T%E,1$VV$.
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MKOU\+KB#VA*M[+9E?4W8ZLTW!NP/9A0.75S/MK[M5MZA^'@#9P(! :<=8X&
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MK:XW2AIH]*O])>\"+E[YTK:G5>7GC'ET^C.B/WE,=5)LOA)XPY<7E)@HAU>
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MH'RBCLRU3&"D^ 9]_-V%W_RW>NX@AX?KTM&A^B%GU%ZSDTVDGU6*)J(F<Q"
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MF\H+GJ_!JA<(._%>[X$Y_SYPEV3:3F01Q?JGTSW- F=?Q0ASE[:S@A1D+Q-
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MXPWR8^:O$A(V!?[#@P\B.0_\L9MP[83?\H[PR>JQ_R09%<$8<(<4OE\E#T&
MP^GK!QC5K)JQEIK-]+]#]SF1X/OAQCTVM72_^[>[]DO;&+S;?W:ITD^:J"5
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M4QZ'ZE-$B[O1.*<R '\:GQ!8I_>;%"S,$EGW;Z^-%#'^U?[1X#+H,I-Z&14
M;Z^A@(%C IHL.C=Y1A4,P+=\-<?9^K;LOTG0B\ WMB.ZU^T7)&/A()^FP8!#
MW],X#E3[74S:>#1!#AG9,H8SMU.^6]S:ZF63VJ!SZV5'7E0V99>A4AJ!4J<N
MRISFR"X.@1E.#B(<\*3K&I657O>.ADGKW"AOB^U$X:KVRV[:E43GGLE6._G
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M(^T62R7HRM.>XPMC2UXBG_U-VAWV))G[(-5=WK@))'\P$!@!Q<";W3CR[93
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M[4-)3)E#XJN1NHRRNN?SH5.FH4L#DD2RS]7XE\)]Q]Y61'QY_5U3%;8^S+Z
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M/PN$C"#,;=AG@9'?<_<BJC:17>.[CJ5@'KD:B\LS#+X@AS34B4P,3V*G?=T
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M-#[YH6W1#S QU/;!T4RWQJ 8M&SX;>R]0#O BF:HM_3DV&'#&-^F*(1.&9_
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MPY0$/1#G0-PJT4GGG.56W\;Z-W1>&R=^/?9,Y,L5M5&5XT-";OQHJ@J^#PM
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M+>WVA!3$/QPY^/*#/7;8Q?_2L-6Q@$@5K&=C;;.P]%#LC=K]KL??I2G4#.
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MV7)1SVU;/=[[GO\8MQ3?DR!*%T9'%<C6^9$N]0L??!8;D-_U2D=!,Z^3:X+
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M^I37)62"5,S^WQ.SO<6RA#%)FF'OQU,3H]VW*N!%TL4GUW?LLQ1E>6XV/BF
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MZHF2J_=1OM0;')-KZG"DFT>S1NU^@AX+%LNWP<?0Q7:+@'TD,>Q5/."*I>A
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M.T2$NXI^KZK"Y.O ^B],N\OQ9K6]GRX6!FN<O(W[6U<KEJ\:A@G'=&.I#N&
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MD/LS!N5+-37?F;*\4Y;SJ=C'T?V"::W6N[#*G$ZSG]$9"'(V01*C@25J6R5
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M3(!7FJ*:)\4OG6XV5W>,W9=M6+K?5+VHZ?57[A808L%$*/^2JR'(#4\B-:1
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M2;HKW!]Z@)B\<.7E*[/0_#P/[PKDYU5--JR4X]_59?3VOR_2KOQH=\(F:4Q
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M12#LI*E [#A+/\9(]93GX2\!,O*WSPHMV-KV 8W*35VKK&:6*\J:;TRHF6Y
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M\'TS^G-(J\OFD%?[W&?B(/W<D;A&'RUXM1^3VBR_A:5,3O1A#A[HO<P'Y/B
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MAUVMBX+TB73!UDGLAO>8B!HOSJYVC\PW'K;V%W1/J=L/_DPNNCJOFG8M;ZO
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MPG1V=7G\-78[72X!)K.?T5;;TS]NU-F/K_[0\UQ7]//S,K]V76.I3GKSJEN
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MYEG<L = UT:HTPM1W&U41[9JIE?LW$@ 97A:7>%\:/0/U [K6XUGK]TY41$
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MGNY(PT4)LW#)ZC;]\2_>4S%FUFE?8K=CX\]#A4P3W 2:=KUVF0/0^6$!0UK
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MZHJ.EFNG.Q.G$G>JO=AX:_#MW)H'9^Y<?*,:1H@EO$=MFH'WPQTFJZ'!9U#
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MVFZ:J--8,]_6W$%H_)S_][[7\!_U'E:EB?+C(Q?[>:WK)AOLNM_";/^MXO1
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ME_N,\8!X(L,4A%0P+;0$$Q7N(W@'H=T@<B8>?R:,U;'19R]V8XWE:7\/JG1
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M,5-<MC)'*HZ%@\1&''4[!,RUWMVP_+A0,&0?\.)LMT :[)4;=+9EW%-]U6L
M07=:*P&=H+?.3;EHCGP'DV]L@11S$=4PK,N][U[VX<N> DVR7'&:YO0CK*,1
M^\[15[9W(E:=3,0C4_+D[&5:UM$@5<QK,-)M7TERGQ-CL0[QGR:77^6\L9W^
M\;A;J\OAEE'$;5EPQ+C@K9$\(J,K@8<ND 3=(Y,I?1 2)+ RMM<$O1*NDQ[>
M]1$!M4^^.;=QGVQ1=XZJL!!Y=_#BKF+"*1F990'6,VY2+4 81 EUU&&H)^O2
MK\U$W<X677I>QA2%[_* "[=V6LP5JD:YB$[/SE #W^S;M(K9P9%'1'H;:?H&
M#_"D,05XP(%NGP[T!9T;PRNOI%]Y[]F5&BQ;'1_ [,T?21!F785\<[_!HN"J
M(<L<**516B[GPJ(^FEH@6WV[54SOC ]NRX8<M7=6]-HD"!&/-9N01DX1WM$V
MS8,)Z#5HCU?69LSMD87%14]H8C'#RB_,:U"S R-$&YR'*M^V0Z<#WN@-$?II
M#&MT?S7K*S,MCFDY1FS(A&H\1P?M*CJ- D;1&]V^5C4554MM%ZMPM):W4G!]
M8Z6OGG[YH=3%<#S",FM:&(1[R*^53)\1;S@(HT><QBLQ-P_K,$S(C-)NNB_M
MUL+7Z1]XTQSOF= MV9/+43FWRK :+6BB--7ZK9P!_Y+C  53T ">G8%445,W
MV$#_]P*V+EXG3/\4T[;5!5?02*TE!>5_H[XKJ/9Z45.=;.6R^MW!M>N$=PFG
M*;-3_\M?EO!?44#>P/\"4$L#!!0    ( ,&#0U*-V=!T^7   "B2   5
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M^(H3=[B:*D+G1A*C-/^^J< PGA2#8D7#_(DMF*)-%]8F&7;T]O.,@W#D_ZE
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M@_T03S5<9,S'L*0TXH=>F-MP@Y$""73;>0'1DW-8;D+4X2ECX]5DF\9G#9^
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MW.SRUN'\=[Y[U.0Y/^Z=#DAQQ&\M:-U@T*:4MEIRRCR S<?U1XB)^KMH:Q.
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M]]W=O?>S]_.^>[^?YX_%NEBSKFNMW^_Z_K[?WW485+$^1SIAR+R1"&Y4C!*
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M:.QTX<U]PHI-ARHKGEWT:J#0!@@+9B/9W+O6$OBQ%L?90T[#TKEL67RM&]D
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M>I/Z*]&+%A.B>LS,EP^(OXWZ.ETZP=5GG>3>XP&TYU0$V?"\BS;W*5QX#"'
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M2G86L:T06QG'I!9"WPE-)/YS9_?]PNC!JSU@1XG#=^M"QV>KOR^Q3JYGVO&
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M6^EM]5ROP\S4L7U6'[#6-)+,N)S4YZ>GMD4YE1:F;+NB"/"_%@P->1@"V#\
M75DRW(0J";:R,U1G+ 9NRQY#"6MS# (>NH#FA\K+KF\LJ#"WNNOQ?H]!O(W*
MC<^S1EWN&NA+;P"LZ; 8NI'*N$ALW BZTMP_[,#T9->ZK+>EMTDVM6%039I'
MWY]J/7WVHNQ5_W,F9^^?>OUEF?BQ'4$HQD4<,0N[D:$V262;6#WN=_!7'T).
M>=#>6#=N5+^8M&AVAZ2!/J]TVC56;^;.5>!ER)G*&!0DMO0EI;ICTC9C%?:3
M^?F._7659TI+P7KZA_V*U\UR *EO4FV3#]F[/=$O-- %Y$I&4YL=Z"5S<SV#
MP2@I->IN)Z=)>BE<,BI=-?.RY4GX@;=G11_.^_ ]X:=30 /7(X7,[$EKQBSK
M"F/DM3UN,UC '*YS5 O?\>7^CF3;X*+#[[?$'O0LB&F;MW]],*[,?<Z%?(S[
M&XH6A6984WK5Z%_O,3N&(NK%O(XP]2,N9!8R;O" :*S'4R_7>M]GE7+KC U[
M/UF=.C+Y,</_Z+&MHC5<^U_O)X=UAGOW&OB)0SGV[61U#RKCT#2H=B[.E8[N
M4VO:=:F\DE*U,$>*D#,\95R:LU5@.=_UT(^A[[?M/1YFKD ]WPWS2UD4#28;
MC -$ D4.:\7>QSG*3;DF0ET+UK&GTE6Z+I!5_6-K!M\4:0U+/7NH<& K()P#
MS#T0(_6.0BMS:=2>:6CEU#"J=_N0'@5/\D]MVK6J]!J=*C\!MRH;)#8$WLC-
M7(RIC[_X=F1O:/.9#:&O]YR;(8#ZV<.$>F]M:,45!K51<2-3E9S@S>C?WW65
M!ZSC ><ME+U7!8GT9Y<YW0FXE>?D5G\J/,XZ<-&>9;"4I\6]0CW?F$KR0!82
MZX-XP*I^,"4HH#B3S+R9GWMO4/!:=-B3@<-G:N+ O0]&[]-<7^%T\;4K4+1[
M/$"1K#%!E:G",)SL2LJ9OH\J(F+F4 C_[F,=.PAKG&]21P=[^CZJ;#? W/MM
MR_09AWEIE9" ;H[\RB&D^!<4PZ)M)5B)[GAVH:,)I\64N76UU:D@PLHPYK!;
M^/#S:X37ZVY=K \[@FNFS!00IB)XP%E*#7[1''T!G&5= [69RC35Z4D*';VL
M%ADRS3&N4" KM'\]UW$FROI$@Q=&I,_HJ%/.HQS2W9?' #ZIF9M$'K!\Z?L:
MY>;RO:LLLZ&6P"K'L+LZ+MJ-TU(+\1?8#U/9MAI"IRYOXE_:&A[NT[6&QLK0
M>[0LM!:FVX41S5$H^(_RN#6I7["[<[WD-G^XFN]^L/)0\JYKW(H*@UNCZAO6
MM2=?7DZ/)0K[=]#P4T%,-6B5%#=I/3<;[V$M O( NG;8U75!#>G:C-%ZS"JK
M["_& HPYW\>&9AO@:&,Y[3/BYI=XEV;RT'=*=]&#?1YN@C$/.(?O']WSK@C=
MAS3I5DVME[GB['_%CC$:.3T7]<;8(>[HT?C>-[*G6G*$R2,T!?>4")8FW/S+
M2U*'8<U5=RCB_@9)QJ@?8:I,H&Y76>9X^NU*RL^S*._ST=;*C+<_WBJ>&KKY
MW/H]9RR$ROZ"7? M#+//0ATH&9@ 95'E=:=!U0B.!*5I^Y@QLD,V#^^A';MX
M]8P57M2A3%TK[+'E_+E.=^?VRLT;!JS<1\5&K):^U8<;S4$RHB"QSV N6QEJ
M35^I)R<4BD/V6F5Z^-)>TML.?_#&?,VZTF4IMU,MR=SHQ8N"3RECPSP@# -7
M&G/'>6"P%]>R*S^7.FCIYZM!UO3/$8AW-_!35WPBH[*XJOX].96;2CE+[&6S
M+$%-F4DF UE3Z)&^*M+IWG+"TPG[BF?#%QL?(S0Y'0?&&PDM;X_QAP#T$&.G
MI2X/?4"OT$6 ^D2Z4/,$>DT/*J+*@[VSU?WA6W<[!Q]=9PV'_KWDPH#Y3:F!
MN9L%EF4K+L#HWP9ZTPEA%,9A8@@/$*ZZY*KZK'AH.@R2[_@69'DGMW_ ]+%3
M9H%X@*""#BP5@^SC_?6A%1+P!\L9:@UO].E:-QAKN%,[#OE/!,J$:E>Y/H6I
M[:$/I<GL@[N.E8IY1LO^%M[C>I+S9.NV.<34<;8R%N"6&$L10XE%V6%:WZAB
MZ\SD9T^[T^6YVZ!V\5,QHR>L1<OD^T>H1:-W+F[B'R:"^D&0*;I?"&JCT!'0
M]<?=Z;AW:*$J0]@62_N@COE36,? X>%\VUHYF<DI1K]5)T<.XJ\@6#+5;FGI
M6K1_]<$7VVWW6W=7T;.NB[%+V<+FMX3&8&6&,K1B,_P43[CWR)N_\  YW K<
MF\"D"/HA$0=GIT-DI$25Y<4H?]3(BUKC1XS7AY?OOU4S?,>K@EM H27A"_RF
MVH<U9>B$9E2$/M._K;XDW^N1_W =3J6Z_5J4DZ_&0:1G89)>O%'EG7B?XUHC
M)AJ]P((RM)) XVY?6K4%-SX.A!U<H 8TIQM4H6G!F"&W[(9^RNJ)]OZ/8)A%
MYR#+T+SCFYCEZG-D^UB\L791<OR.JR(S+U[@B/8W(3A\'D;U"K'X"KKM6>=!
MET6?I_3<NV5,^]O%P2X3MIW%]^Q].RX%^*G$EPG^%BXJ+GU&1L-R?LM_R8[%
M_[</7N__ E!+ P04    " #!@T-2!K9K(0%J  #4B   %0   &)I:6(M,C R
M,#$R,S%?9S,T+FIP9^R\!U137;<VNNF=T#M$>@<5$%] @HTB(E:JD%=1:0(J
M(BTF"M+%""@HO!"E" @8D28UABHB(EUJ H@*@B2 86.2G;M]S[WWO^>[WW_&
M.?\X9XQ[QOTW8^T1!GNM/==<SYSS>?;:A/.)0P4DCM@[V0-<W%S G_ /P/D!
MB.^_$';^(G 1@ \NSA1P$.#F^GW\/G/_/GAY?I_Y>'EY>/GY^/G_;@)"@G 3
MX.<7%!$4$OY]P)]$181%?__R>Y!_Z<K-Q\/#)RS +R#\'SXX;P!)02XJ=PP/
MEP; +<G%(\G%Z020L(U\?YO'!?R?!Q<W#R\?OP!LA@A\09T$;#X/#VPT'VPQ
M_->;\-\!7DD^*?5=^_FE3YP3T+@JL_MVQE-!S0/59-F3@S0ML_/7XH2$Y>05
M%)6T=73U] W,+?98[OW#ZN"AP_8.CDY'3IT^X^;NX>GE=^'B)?^ P*#PZQ$W
M(J.B8^+O)"0F):>D9F8]>)B=\^AQ;F%1<<FSTK+RYZ]J:NOJ&UXW-K5W='9U
M][SM?3<T/#(Z-OYI8G)N?N'SXI>OWY:6Z>L;FS\96^#VK]_SX@)XN/ZOXY_.
M2Q*>%_?O-1#X/2\N[LC?%TCR\JGOXI?:?T+@W%5IC=VW!64.9#RM)@MIFIVD
MR9Z_-B@LIV4^ITW_/;6_9_;OFUC<_]+,_N^)_8]Y30*B/%SPXO%( BB S2I,
MU0/^.S9B!R4138M<6Y6FC_N.74=,;$&":0NN2)>G1^1/H_E9!YI'<D<]\T\L
M>H?PO=^?NL<R8O+J7TKL=N+G*4A0@.H*&B'NV9JP+J5!0MKT(C)6?"1DZ TX
MZZKH-76DX7A>&NE5<@O3\+[PR[R]0EN)3BM<;&D.0#8@A1'O46C'<?%M&F .
M?8LA20][8^Q\F*X_;-1BN2"25ZX[\B?3YB2[2JP_/8]W1M.A?>=[_R\#/$O!
M!$DP9L M:7_S^.7"MM=GR1>UAXQ>(<X<N!:C%E^'O<RZ *YR +YK'" ."]](
MI.T/5@R[J<T(].XD*&_^\1DM!":UNV5_#RO]Y.M4^FFJ[Y6A]W6S_49;9F*#
M]8XN74GO4'LXP'D*J#[P)FPJ$A),7U@##0@]Z'NV5B.VYKY+:OKT/8_GK0D2
MCS5J<AQC[Z=<TW*+GO2OO9'I=I-\R:?YR,5;J)*@JK)@)?M,FL/SY?JQ_HB]
MB:.ANJ?-'&,T/K/>QW+UXZQ1 AP@Q/0>I1[!4M)F'@[D +6(M#66PW.,%=TW
M9Z[?L%.I>-6B_\-?%OO$ORA\>9@2Z&MFDZR88NMQ%]F<M42BA36P))KG2*LN
M3%WL  >@G:!,'F2D@.FQQ"BSKB)/\,R<L>GI>KS#QY7-*FQ@]L1<MI!BY]:-
MC7[U]'EM?YXDOF2!-5E,"%,*=I(_5AR:1C8T=+M^DB:C!5M<BH(I_&%UP2%^
M9T=U&X*=&2]'^?/5[]@OO@D4I[]&Y! M-M=ZB/&^DNQ"B#]JF($!;VO/!]A:
MTPJ*YF9"-I?N1(KXQX9HUW;K7OR3N/ANRJ,<H%(WB5]<(2%W#L![FHU'71X
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M-3@NAS#G\8Q5-@%"84+ F[0IW[%-O !+!]3WM^A8VCFQC#P?YU24?CM.(WG
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MAZO@B@[G;7(S3I9ER@P$BQBPJ^+<($H3Z8VI7-07[Y06]%/+I%,GAE]\>?W
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M*_X&BZ[Z]!>>,[V!.GUEJZ$G[1,:M\_J6[L*Q"_9(15PY'TH:BZEP7)EC7G
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M*C+>6&Q&IJ*HZ20IK":.K&MS$W;?%$AFQH)%W;,Z8%+%LY)*#)H>FK@UKF]
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MOZ,4]4NALNE?HRP,SNHQI9#V]NTUN,QCV__?8T25KE8Q<5 ?Y24Z;M7F(/,
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M6O_?EAS\UR&IK^UJHVR\UL^"8]_"<%?W,3NH\+#0Q,&ESXE\:P&0(P 6M 2
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M=TD 9,FSJ;!P@UVP"&PK.B( N))[27RYWN_WE]'(K'Z,(N9K"SY( $3NM!$
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M+,9@[%^34?A??*$% _\'4$L#!!0    ( ,&#0U+3?7P/*'$   &:   5
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M1>05%)64M3?KZ.KI[S#=:;9KM_F!@]8VMH?L#I\\Y>3LXNKF[GW^@H^OGW_
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MP/.#PQ@/+M 'Y^Y5KT<:'T+K8JZ%1\$B<71!6TX6+I"1V]H@0E]1-ZD<Q!W
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MFCLF]1^O/#ZS$[9+_B3(T3]B<S69@*14;*8F0[ %"QF&+;!8^_"C6/%*+J"
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MZ,-* + ._S?OI+I\R[7,#,Y-D)K?(,]YB]> QXAE&6S9*%I',T8B?+3C2-G
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M6SY:R@G@SU3PK,_\IL1_=4VM&4G.'&2[#_X*9JG_(G+T3'\\X)FF*)&_1&3
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M%P/.VU3T_ZRW^*A4KWVN[X>5BRIURH#>(?7P=*UZB:.C_-;CO)N*_S? _IL
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M^4JX&DPNQE*"[+WOM=R])'7CH'=BN<=/0MS%EU9^<X&^UO[W%N-8VV]]7)K
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M :1DDA+V'8L!F7$6C9&D0 _L_.0*59BY V,T:\Q.6_XB?+JBXDU5SU1?14Q
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MHI7_AQ^^R/Q1C@#^#[[*.LL;]_L+2/3OKQA6]3TX,#D=$@7W!*K7#L/CC:B
M/R3H LB)&-)#HK-PV*AV%,O2W8>[8:+>QU;G.NJ3?^'LGL^KM_@<%U>V.YU[
M&\P;:ELI9NFF;EYX;U66GC$A3%U?QE"%GM*&'KD#*4V%/H(,7 RSU.B7OH]>
M'<GR?>4F@MEM[5H;D%P6^R$[86;&Q;Y=?6>__+3TXV3!GWB66/A)KU"X.,Z)
M".PS"_=0(@\U1V@2=XT3$?:?*K^*F[\A/%XQN=*(K'@=Z#X?"&\($J6!Q$(@
M]Q2-FO8J!]^]>73@YU:>Y#63K$L.KI=N33L8&B -S^J>K[.=$.9G&= @_@_1
M\Y\(U+7I\;4QKAS0C+%KUWUF\U[J&B5Y/Y?IMGN["S?P?5?ZY!_E*^LR>LBJ
MC'@IK^/.BAD2N*E_&BJ;#79R8!5^<: BEH]=CG!$;[R$&6HF<NN=ST-WDP6_
MV.G"J51]D"^S9BM2[4?"Q(ZM9]]PS]JK&Q@O942 .]C5"/(K=$7NNP\L1^:.
M[^NP L?"@43GR32_9GT-NMB#UI?YXR-3#==<O5SE2F*&'RT>$FCW:3# KPF^
M<DWUC'HU]G7T< 9/3EHVOU!.3L6)(Q,Q!A=/780="%X?ZBW(RWUM%L_EQ+9_
M/F\Z=SN-11T8G<N#;P5[<-P(5^2(.RB@!"D9'BGVDR N4SK2B$X,SJ(1F[MY
M7*U;*I,+/;0J\ABU:?EO'&.]I]NDU+:0FSPGGD\KLF."-@;U(W8AR)EV:I 7
MGH+]N$UM3?MR &_>8% &LVGA<@C3TO:(G> 'O)?=EVC+MZ?Y3!KDE:-W"D5V
M,^JWIQ_V3%$[4/_&JX@Z%N!O-\9%(?(3Y,$QB5D(62/7VEHR1CI.]=2=? %D
M7*X&S%^.82)W1#6O73^TJ:_8.4GAL75E\U,KX=*74H^E07^ R+R&:[ ,4L<J
M#X&; #F0GPOO(G. +A/EG:-?3L%%Z.B-RB0[1V0%A"7O[>K=;3\F=ASK,$J@
M966E[WV^=^J;(0.H8&;,\'X8%^NY@2,_0M!,COST$@/*5,XM32";(JK1IR0=
M0;SLG5B^DYN3$ABWPPX:'+G^7EHI'VJZ!=AY=W8>&FD;?P HFF#+G9A-U3F
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MC$SZE+XV^P6H]N5D'O8<'7O L*@DQJ2Z5_/G[IVO/1X][+]YI7@R>)NH#8,
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MTA4?JFJ9]/SPQ%5::?A)/Y9Q:QRDZ<B96#Y); F4H\F!?/NA5N2QGQ+V?^7
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MZSOGK/._ZYRU[K">K)E%GCU[[V>7WV]*N)^Y5$#BB(V]#<"SB0<XC_P!W)^
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MT+23HMO$D;KC.2FDRL0FEMY]X=<Y>X36X^T7>3C27("\G11<?H]"/P[&MFA
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M\2QC$(&[!U0$EI+^7.UM=X'?HZ7^\$@'TFL,[4(X^C1]F?GML^4P$U7K]DZ
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MLJ[ X&\.Z3JF,0]"1R')PP>2%4C4!"Y _TY LST9?>S=RVQ]0\BM3@E'NHQ
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M27L^=$Q#J.%XQZW+.M_#PX.X[5'1F^KDIY6'/QU]>#=^$@OKI')W"2C"$-B
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MN<@HJ_STQ'(O8,2XRA>LP"(-^"F2-BH^Y3^CHTYR";$!CK @%)KF$T2:-:=
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MO$X]U#F2\MM.4%Y3#:G7 9%+">1=KV0IXGUHL"Y+N/*6!E0UWMU9X[$!SC_
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MG,0;2YY07D$3+L[@:\*^^'):-P.17\WA:FXO:7]DZNCU:92_MW4<6^@^_;:
MX1(6II'=$&*@;?:JWOID!B!%W(W:!XC0J]A[B:]RAF\KRL*M\P@HT4T@M#Z2
MJ>R3WDK=]OQ,Y7I/#TNOGFZMB]V)K^L]79;I4I<$WZP8>:@OS:8OD-PW=J@I
MF:E!48>'$3EOP0E__&+A:HA4^0,<6X;,A^@55Z<V%$8=[9/K^9AV]W0$N7;%
MV_K'U:J6]1$]KL1QMW]PEQ+3G&(*EJF+@2"B%KKY;$U1JJ1?4SX.KPF-C25O
M"LW4TBM+(\91I'L"1SE:^ED*_CY?-"[J'DB>F-2UUYG.FT4)ZYM9:0.$,\;"
M('=^';SIWB@?+,)RGV0*_9^VK3I58)Z C;YR:XG&WH \6:>+_>\]@]^K;K[2
MRZ@K;1RD7N2"["1,$;.4)!?>Q/<0G9%<";>>N8 B#0\[,U\09#_2%NS:V5Z,
M49DT]G#S5V/Z4WVV[^.3]KWY]/9NR0?-J>/Q (\0+0:>5&6.O13,_T![ H[M
M&QR'K=PK<"H_N9RU<,D:N1 P[GW,/HQYJ[M'_]/=B%OV-X_&-^EX^Y5BEI/Q
MZ!9#QURVO403:4.,14^*\1*XV*)6@UEXK,%L.R]40*D_$9$\T5&UWKWZB=:.
M&B7Y,I\=A%UI(DG8 H'?##L(@LC;FTT,Z%U4?F$S3FU4P[EM/+ML  ]4/.H.
M//)<?ROMV)/:0][[]UCX7'F[._'8A!CH:D5D;_,P'"K7X &EC\E0Y)KK58.)
M7RBHV3\+;FI?#K6YV5(YCKK/+G"/C6[HXQ<G;Q?$!GV27:)Y@]EY^1]&=,B\
M)Y01X!48X6)O_G&XD[>('PT[25XJ:LG@42NY>_O#,RN19:*TG%!'6[]3HO:T
MMWL#$IO=;6=%Q_QP(2D[6FHWMMMCH2A%" XV=4M[B*[@2<2D#IJZ+\_C6M8'
MBAY/*_,,RC[Z]_3-W:3<4[8V6[XZZ=2*$NYKS&F#7M04-Z FC7V.5<1*+IDS
M(E''R1AHUWV>S%C[G5K?(,-3OM"$.7YQP,S*NUG\'M/&^XPYJKI*E3$^<>8Y
M5BH .XHNL"6KP]P!YJD.4!XE/:0>M>VP<<Z'5K>:S-%QMF8413YRWH[;!>ZK
M[T<#!H]E^E)D3RX(;$=;;J)W22.RFH(32#E>.32)M%WRB+I_R0J(FH1;PX*_
M#.#/4E&$>,!OAI\1-21?FAKKE#)6>7I)J=*#W37RM8^:^#?1$M[DJ!>B@G$4
M]>(A0E-/1RO'MQ*K#'NQ-L%G,L)I9:./_"AZ18S2HBM;BT?N,FZMW.VTXL?7
MZ3O4C$B"GU&6*\^7/$7@)]P&JP@(<!.?+WK,]&_E^0[BDRS,9&(Z=S^&6OQF
M7&*G-MQWC:$=",C;>KS@@69!<K?7M>KWQT&ZWW__19C_'7]X<?=_ %!+ P04
M    " #!@T-2NXXO?5]G  #'AP  %0   &)I:6(M,C R,#$R,S%?9S,W+FIP
M9^R\!U03;;LV.@@("!)ZAT@3$! 5$5] @H4F(J+22UY%J0(V>L@H2!<C(/ *
M+Z "(@)&NM(B741$>B<!!*4G@&$PR>0?OWW*M\_9:Y^S]SG_O\Z_SA[6,VMF
M\93[OI^[7-?, 'N430&$SII9F@$<NSB /Y$?@+T&")Z\%GCU.G =0 X.]@1P
M&MC%\?OX?=[U^^#B_'WFYN+BY-K-O7OW/QH/'R_2>';OYN7GY=OS^T"N!/CW
M"/R^^3W)OPS=Q<W)R;V'9S?/GO_PP?X "/-R4':%<W(H ;N$.3B%.=AM !J1
MD?L?XG$ _\O!L8N3BWLW#R(&/]*A6@@1GY,3$9H;D1CY;23R>X!+F%M$\?#)
MW:*V5WB4;HD=N9_RG%?Y5'FS^,4^JHKNU=M1?'LD)*6D953WJZEK'#BJ=TS_
M^!\&I\^8FIE;6)Z]=-G.WL'1R=GCVG5/+V\?WSMW@X)#0L/"HQ_$Q,;%)R2F
MICU)S\C\ZVG6B_R"PI=%KXI?5U165=?4OGM?U]+:UM[1^;'K4__ X-#PR.C8
M^,SLW+?YA>\_%I=H&YM;/^G;T,ZOWWIQ )P<_^OQ;^HEC.BUZ_<>\/S6BV-7
MR.\.PES<BH=WBYRTY;ER2U3IR'U>L5,IS\N;^91U+U+%K][NVR.A<G1&E?9;
MM7]H]G]/L:C_E&;_FV+_NU[C@  G![)YG,( !F Q7R2J _\S-F(K.19+#5E?
M%:6-N _?18UMP[Q)<S9HZ^=G)2]C=S-/U0]F#3GEV,Z[^'-_/IEX3#]H_-;?
M,JP6XK<)F)>'8@-IH1X9'V1Z)L%\JK3\9KS@H'__!VC:1MIYXFSMA>PD4D5\
M T/S\9ZWV<?YMF,M5SA8HFR@^0 ID/B(3+T 1C<I09FT;;HP+?"#MI4I36-
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MO:IWPGEXW*4+5V]1E&-;!*X]4],*D]O#)" Q$'.4,.YG@EP$IIFQ*IB7"OU
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M-_X:O#:5T3&P+5\V5/:S*J3&X7"/P"L%C:LW/RV%<0DW*_Q4!?#X4#*\EPU
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M[K,PCV\1HLHPS;PGH>@D3\,K-N4OY0J4YW?G7A952BF14T^5RA@^LTC;GSA
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M@M)MV!70J0(_@G3 +X)887)P@.3>_OZ%=9958-C=:X>>A2S/*Z:8.7_#=JV
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MS5> 9V8GM5H)M1P DB3/4"GF^F<=BXJPYQR"-?SNB^1._7C?\279FGO*\RM
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MT*@0;M)1V-8DU;J8/^]VEQBDI[../_T^W7_5X?:G-(4#(KIK.HF [AP1U#.
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MR/M.F=8S!(8;3Q5BY]7V5G5WULC.;-.IC.:UB8S+F*[IC(]O__/U<=1G[-@
M$TWGA^1XF#8@9@:K@+L)QM%76W]_3+X\T]!DVJ+8&%+I>YSZ^;".^[&?><\.
M25X*3*Y;TEUU@D7R^P(L3!D$YBOZ<O3;3RX.T\7>;B>%I1V2+Q_0  1;%&;(
M#F1?(JBMM82@<EXU]GW$9;68J:HZ@U5//,2Z6A4UNV*JXG_DIZZQ+;6[WU;T
MJ [MD-]O_ZX,(=VFPK"P\%\O8$PM3:' 08*WAWG'@"W#ZVS?17HMI)YEX:PI
MXFQV)PB#8VP0&.NRNQOR(JYS_2J#5(JG2??<RI;C6/LGX4^66QD93UAJ$_:%
MKF&_.4";ZD7*9?Q8?N'Q#)=9$=$N)N%^P(?XKMT]<\4J"S@Y)AH,H(>V8>E7
M"]N2#6#1WV#T+%8<VEI9,; 3WHEMK"UTK*TP/%I_SZCIP[7'?^R![9,^\K-U
MCMI<3R(B(16=I<[@;\.">J%++-8!_!A6M)H#R.&[Z_?G9.RL8D4ZOQG@?1=I
MM"!N$2Y1W68P^L5[(MK"+O5+S#9<W!FP@&6&'\/0K]8N<0 &/RQ@1 _\UJ:H
M>L<R'K_-UU."?M';S<^]ZX7=[^1V9GF)GTK=Z_.\]Q;1?U*WBG0X (2CTB<.
M _]_M\L@@:(J3'^P;NHI0X_-?.X0QEK1&%@#IWW&A]YK3X1;9 WF)@(ZNN.Z
M^X_T>V!.5"7."-[/_^0H?S/5B<]%5< RMB#WMG;8C=9F.7I(EC%!  QL.U(E
M=LYMOL:']SSQ5#6@8%F]2KY#H&5P *Y&320>M!B9D S:8Z2Z3!PZR+"\$Y#G
MS1QK..B/,_*3J0KY*:SATJ;[/A7ZN-0>GG;GCCK/6I,T<.*P-'!&G]"&5V%X
M/OIMD'A32?_(QX,B&5DQ+QVE) 9T:-$;9\:TN45-CP[<=!>H*D4[1?4/\PKR
M55<Y*%][L?3R*; _Q@D9X^SFYOX*L-"\+:ZCOC#*.#+[[$3TEL)KSP^M2Z2V
MC&_S:%/MK-%^RIVH_51D6;U55>J3B5(/]@"].?MRZ M+%JO807LV;8[<I*[-
MUZN5GE.==_@OW;A(3T&'UF99OPQZ5^Q-]MZIHU<:]\B>:/OVCKW^><O7=8OA
M&.GC7(>1YAK!'X53F'9X4MPK'&;K,'"EZ=9ZQ3Q3HG5$]-W$G+2<1<ZQB.&"
M?QET2\%SG_J>N_6>Y8644#^SY:RQKYII^^3Z'M[AO>5;&(M3FD;QN>[)IE&%
M?.H/-S2O1Q\M3YE4:#KR%"!%]/\'WZ/_']CV)?/,Y$3/FML'8[B*ADN>U:6-
M.71K*<EZC_NGKJ:<IOLBC$"CGLP6DB.O]X^D(ID'6?PO"0M4YOY%S.^3?I/:
M/&A8T@,+QPA36?/>'.!NIC,'>'9P'?[M]CGW]FX.,*TYQ &^'T=J:G,&$;0/
M)OR6-B"L%)0F_BWYM^3?DO^YDH9+OY:/?)W?^J3-]'CQ'D7GRZVLOVJ5]C]I
M=#*H1892][O#74U>'."(8V1!&!:2HL)V.0C&O#A5R0$*MC?U_Z>GM'_7ON%U
M(0_0E:[58D;L<$K&2-S$"H7YV<?U#%93Q7U/C+F-&QRHMQ<X;M_"LT_CMN$Q
MW=Q73C/K+80H#H!>2S9JHRI;RG[WW#E0%>"K@G4<:#S\O"LT2'3-7NWPM3D[
M(:.GJ<PTL?[KNZRV\LPL.\-B<FP2SA4WSU+'=Q"J1KI*]2]=5M5%'A^X<$N%
M^4TS,#"+NTT=N#LVF?#VXWHK"C3XMG1@%J7P&6?(SFW48E@S0QD[BW7:GOM@
MJ]"WO>@S'N\),3O_;*I@A:<]VQ\;5O;4@I_E@Q-@8(F6NW&F YI- _K-W/NS
MR2G!XXN'XH[>[BX4/9 F*-.]-VKR?O>#XS&WE>JZ>C"5SIL[$,C:1ST,6[1E
M9S;KXSOPF$\6^HP@VT$#2[D%C%RCC/\8NEW)W&152W:A5ZTR'H.7&(R6UW^C
M\NRVY<^:NIJFFI2?'Z<U8T^CI,OW7@Y6WW9'6=QV7^&P\QT+U#0FUE.@KUDI
M3/A@M,.GQOT%[O-9.Q_["Z3T]PMD:)\_FA:2J_:"*5-LI2J'P-YU#I"F54SX
MO%[" >;MRVZ6"2.*17* =U)#Y*7(8<):_DC]O]3Z_V*-?VY]^0F+ET YF=[%
M :I(%/3G@8/@K1>0(;OD54"@"54!)+9?=\."JO95H''/::7+!X,N9HTI=\W=
M/U['JWQCA22+N8"*Q]+[J>7$&$N),$L!6 [?>VVA<K%^K?:3K3&W :KFX7.W
MPV(KN]<?*^3K-,A<]+2WP&UNIVN"ITFUDR/+OV8YP)CI##4182E_T'$9!"&\
M[+RJYIN!M66S(-!VR_.LY2_BAD_>>64_>6]XF=OJK?7MW6OKG64JBSDB; 1[
MTW*8ED*,AU $*=&8+.Z3LXT^65.@UO;2NZV->_J'UNT]([+K$N[U=FTZ'ZTP
M^WAY5GXC461A  NN<  -I[,<H'S%E0/TIWO.>_ZSM?P+^/U7:ZCW9:#N>@R!
M%HM6:L:$9;:1JD(A:>L3H!P#;R!6%@M%!M,,Y.R?>RR:':7K)10NO);7B&7R
M\+ZW.M_@]S)#YYE-*"35-=,%*?UBH2%/0A)S<[-)OED'.CE8=?-3@.4VG!=X
M-_#'S9Y=$C6=?7.)VGJE\)EU0*)QAZX'*@J_E4#!0/K((J:P\_7)M.?'<6:?
M\-N:IF(X@% $!Y@IK<YN)MV8MBYH;:AZ5V854^A7?EWK<I!)O,O/LVI%Q+(P
M BP8QSJ&X*_+S0J0/CNQ60&G#<;D+Q!0N./DJD9+T4_&;(>VWN?A$H1+^V</
M)OL&'69^L3WH=3JU[V/_4P#_<EZQ.7U&=/N(YR<3A\A%I?&;.>^9'X,S=..S
MK37B%^R"+V^-Y8T24"MQ[L#0K6ZI+K:A7XM,"?<7#*(I8Z@.HL(\281ZTD?1
M>OJ-R?B;I=L^EE>LGD6E0UNY6F28U< _JP2-_\QEK/BD3_R7:^@L*MT%#6IO
M?H8QC9$*(]%".PW [5\+64?/X;0&_*LQ\<X[:"SA)H.6^5NU2^],EK_BDAX_
MS#NO[)!A\RY08/.+]&L$BE4C_W30V*SMYM81A$'..F$DIO^3=C./J=I;QK\]
M,Y^[*;E'ABLMW\M8B%U3.!3RU>Y#C.I-L<.^. 1G1WG!?5BI1E$6#E+L-VY0
M<L 2Y<:\XO&R83D!-E+,<7 MR67J_327 ??A\ OQ*B,^*;/7O\3*)-,7.\CT
MXT10VW9YA64.'0 I2% R&%HMI>HTO=]?2V=[I<%BMZH_?3-'ZH]F$9B!F5]V
M&XTWIH43#29V*'X3>:G,LU:Q&2+_) <[]V)?>]0F:(+[BO>D%[EWR$%:BA_/
MNC@HLPOJ>B*#/C<&<8 ##0;0%LRLE9+T6<P__L#V[ZM_7_W[ZO\]5SVR"Y-.
MSJNRSE:'1>,9DA-1MN6E1_Z5'N@2039#O8,D8"D*QLUXW<%++*I:#*T%6$RX
MA&&LTHR;AB[QHK9+;1.2_Y(3-M,@I,W#Z&9N[K(7P^/UZ.4DEM-B#95N3TS!
MZV:Z,)JC];ONEE9W;\^DS!D+VW64Y-KOV?%(NX[;<K>VUM>>R/56<@*IMFMY
M$2FIXB":$=1)>!W4CKF#1EF*C8?ELCKD+/<P]K^RL+[Q8CZJLW](/X!DN.'?
MNV>=SSGH3$!#"?B-N?D55PD\2JHI["#?QKRV3;&4A?3I*(J*9]O!$0OG69+8
MA)_B\Z;B"9>N<+6VP#2-J^.=Z6ISKS]<I3S:;<=V8EX!M9"G)]&)G<M2[9AJ
MI^4.>EFG*G<MRXFY'F=A2G_EN(>Y$EQ5S)]Y/5#9MB(DUF;CV)R-I^F5VY:5
MN0@Q:]V$8AS@YZ%?02S57R3V#I,?#Z<)="?"AEI$+9L8T0L_R%H_\D^YV']V
M@Y;8>>3S0:".$T*2 LOB.4 -<2F:%0II@-AIK(KK?,98;1QT@C92E[(V.J:Q
M^]R444UGW:FON3T*-KLV3C0S%&<'R9>#[J+I;DYBN*N?+)Q8SO@Q,C_N/'W!
MI"X@]""=U%97$A3$,_:^YJM2[/47LB&QUNPO-BJ+TP10N[:E-X90:Y!(H#W#
M2A#\2JV/CT .K'UA@C30@&;>%!CFC]M]94J1=3-BXFRY7;'%B*G^CM5+8D"\
MUN'C9 ?HVLC-'B,FC"Q_J"NH=?K4K%(I?_MQ/[. *K)%LQ)!9$N.0PR_FF9]
MXN=.=^(N\<8?TER_-3>Q?\R_W_[2_2>+^."OG=;_8HV+[KSLQ-I\.V2,:/R:
M6D5H)\5Y[J*O)-\DQ9,$2DIP!K,&\98"0VB[M(7Q$Y4LEWZW8 ,5R$\D\5**
MRR/;KW?YOUXN)E>L+%U&X,428KRC^,$I ?#&=)-IE]M*!S9ECUE&ZE/H* ,N
MVUX=?DWLL6]MVGQIR-S9OJ.Z3>HIQI(;>S7O^?(K,93:L3482+*,.0<V,<I:
M,.6FR9;F.%EPN7A^2IT$RURZ-AD6W9JUM&>WRT2'9M)KOQ=:+FH//8[$TT^3
MG"'M(8S_YO>LRROT=&8:F,Z2 ]MH3A3R[8&%WYWI08R]MD$S:-G%VAJ#BY+L
M!$$_A\BPN;2#']KMVH%CQUI0?1'_-W 9#VLFE X+IB+IYPP[%])_"7<0T+!:
MF.Z,9V7N8L\,F0LRK",KGGV9=:;1:-QF+L.\>X_3SL-IILZ)IXQMMK=$_ YB
MGD.6\#UN.[L8;^Z-!1J-6*KX/EBF>:1YZ(O?U'[0VC(S?VQ#MF*"9#G_14V_
M6_#0VXW\F]B9,L2%HF()E(.(%^7]GBIGV=JS &P8BN+)R\[ &6E24W ^LZ*J
MCD['&:H562Z#5,>!Y9]JL7MI8?WVEWE7KE6JFZQAVH/&K6>UVM!CZLPC=,VY
MFKC0:4S*<,3S)S/OYLKO8]U\^[RC3U9F3 Y;)4E5.4N\O7<W^>WI>XK [_K_
M%4[])Z'YG_^?5/V3QK-Z"A:R1SQM\U? [O260C@&!I)ZTL$!4+\P(O" I]@M
MW9FNMM[XM%Y?IEL<\]I ;%G^Y$$AC;*@U_;2'&";]_KE)"#;=NDR:_-[2NOF
M'7 _1I3@2P5W=,7#JM^'";R0Z8U"G#KH0>]W3WIQOK&^TMT\V?E$/2G!B[77
MNW_OSZ3&7=K6@GL]O)@:X'G$@P(031[@/S5S(W\GAO6VCZW$6*(6QK9GTE=H
MMTA)!L:ENV^.9QLJY;WJ5<E/=;BY^O%G[GMEWI^JANZ^=PG1A(OH."Q2MT$=
M5 OJ+E*^@I3"2'9TVTZC&5TL4AAXRZ SH2_G:X;W1/A-=+QR+YU(<_#NFXA_
M%J[P-OVCW6#4!WF>M87_)?^@OC:--_8PH@V7!KSPW=VA!6F9=0?<^&C9/S%2
MRP%:+TX3?XL>X "WCF]Y*/.$ P@28S'?3?C9OVRA[9;R'.#I('I]"/ YX4JF
M/P(OPM''"=33A+^E_I;Z6^I_J]1I_<83TZQWP\,C9Q*^W+A[V"+=^?O_D/>F
MJ6-D6$")I8,?X0#5QPI8%T .,,L!NARE.IWIUGQ5.>+@??^M UM3Y&=^!DA;
M]00IA>,OJM4HVH8L#%&^<P"Z/V'IVC15D8JSIW. Y7#6<1<PZ72->X #MA)\
MS_"<;"V\WJ6W&*B1RO5%5Y+K:W,3F\0!_)+-9WN711F5-+[".]\&KH"[9P)T
M;>L'OS1+OGHY4G^F.5?CM(#( =X90T'_AQ]MKAV'KK'+C:E1U.K>%NJH&9:[
MNV@2\GW#4+0N[BK2L[9UU#K*NF%'?[#]_+9Q\;:=_;0_UYZ*$D913&?ZR-(U
MNB\JJED*S)OME7>EO' *J1]I)T@UEQ55'CF@/2+V\LA.RS-=W$T'$7-0D/))
MRLBHA&2&<OR\)Y!,%EQRKX*;,/MEI([@Y<,!5F=1[-\R,YA_1P?B6.9.'( D
M3UCYE/=OW:(73P4(E54<8(,1![.%,/_6S4K\6^1OD7\O4E1I/W>H?];\])\1
MGR;O2W" ?_4ZZ7]PP&](X)$YP,))I"YS 'C$%C+@ +\?D'\2D"@>28)??T'N
M1%"S9N8&UW?TZ!@! MLX #[F'[KA'. ?A1#@@Q1ZN,  0L)S^2:A9!\&8B.C
M7X:M(OB9(<@/+7=Q .HSVW_H>Q+^)R&$=7& (@<.@#!PE@=Z40R9%H;PTY5P
M7_4..[N0 _3>PZQ_/_%O76=$[G\2^A_G];LM';F5"F5@O_ _)?S';='WMRG^
M0Z:XGB,"EB/U).1-E@&3?W3=IN<K0D5V&0W\ 0=_'LF+Z3S/J&HJ4/#P'#?9
M^"R0UOE^#TKESR-MSUQ:U IR$^?_M;:\PLRNM_3&D:NZ*&7BT!:PS"O\VG2O
MM,_RY>*VP@7#L:/T-$%!8[T*F^O\.@=>M28"D!G[!9F61:4'&4!2SK/.\8WF
MK).0.QA7L@B;9HV<I!/:4 *+O]E3Y06NMOZOR8_\7ZE\<]5,L9=U3[O+?<)4
MY]J:$R3A1Z'2K;*#9K^6S0:!6A_,6B%L7]6^K4W]S1H+;B-,9F;A^U,?_"(#
MSA[DO?0 I<>5&"?T@?=1H'4KB7Z2M/G+<U+6L+ ZZW38*68[6%TXC]=E,,N>
M^F8YIWQ,"(T8/FN?YU;(%.VV%G[G?T%'Z^#3-HT;SST\]H@9,!\A*/DS@8+&
MFR/X_Q3!BY3<S,W^;^R]>513S;8O&NP0$)&^E=B B(BH"*@@L4- Q'R(TD-4
M1 2$J/00LA0%E"Y*JR!$103I(KW2)/0@B"@(2 *$A+Z)) AA0;J[V/><=[YO
MOW/WWN>]<<>]=[SWAV.D<(V52M6LW_S]9LV:E>T7MZ]K9 $,Y[2@9'PPQW(=
M8V8M:O4MCAXY*CQ0PRG\;3GYZ<:VIF+]?IV=#C >_DW-)-N!5PBX Q1'FA%"
MA>0V_Z2">("9W;S8=V=6+J"T(<Y(343Z-BMKW%R%T9H=HO>_PPZ/::  IIH@
M@/7K\Z^H_[EQ&+2#&WXWD07;_O:<;!Q+FJ[SP%@J"'X93&49-I.Q#VD\J<Y?
MY=ZNES_9>3.NN13]:H4%+*G=/VPFNX"JEP"UJ7/>+-]1XB=F$1KN-#"=BE7K
M]L-''1\;%NE[5=GO5E-Q/R)XO%SR=.==S?@3XQN>%*?>N=H:8G?;Y-8GZQ@/
M] WA@3+;>#[$;<K0+:2!99/ORB/(N5 Z/E;I:Z7_D=V63/9[;]>-]TULI)P&
M!S.>YLLUO%1Y&J:ES!<IYGB[0%-Y"N'6H4,VN 1:"F";+9N_5N9Z5*JJ\H>5
M4I^R4\7%X$9G-M].UA Z> +I8$RP_1GJ%5I9,=N5/?]]<?WPU)L:,;ZH.B<D
MR)6]#MQ%DG1C:G?%UECE#=96/JH1RT&)A<:YF+WQBDG]K6\^5K^Q[%[7_F9%
MJS_6=QRXGKPO.6_O*></)]C1S*Y'\(ISU:P8]OIO)&^"&%>X=TG< L5T"F'@
M&H<VK:!U-)+[M3QD.E6N_7PI/BXCE'"R.4BX20 #]QDP6)P#H"76F/\3S[0(
M9%8VM!UXA=PVJZH$YKL5>F;"P^WE]#YF=N^]<M/YZ^M'/OJ_QC].>@;M-S'_
MV*R5X^6L@?UL0&B3J,DEO"2AYRDSRVQ#'MYH)ZN19MNPF;AG,&BR)0T156.0
M94KW[[[$6%)_2FD_X"*2M.[*)L6332_V?\Q%N,/)KGQ1798&O1GWB'0+ /=L
M)S0B1+NV,,+H(/&H1QK%H:JI4RDL87A(+3$TXD*D<J#/L779U[R.&_>?+1^V
M0EK.I5>O[#!.>A.]XLN&T#(\*HA*FV=L1'.4L:T"6*D;%9+IT:UGG-U=>H0?
M7^OV(XE/_Z*XIJVRK]R)'PM_NB_5O[YML/I-G%+R>,?&5;7JBL638:8FP3IS
MZ2Q'=AZ8\6I6A&/'[Y##;]'+.,P^6K"[!^.-+B3/?#OLH]NJ9I5UIKPD\IA\
M("S\E.SL%=V'.0;RZ$0DRT&HEZLH@#V;T%E=3ERQ_="/P_RE.66D+8#M:N5K
MK.P0W?N&^/0OH:*O"' O@2O#H;LW2L Q5YF3<VB.$.A.?PR*T-SZC?6XIUB9
M^>*1Z6\K?UK.>/3-[/8@_.*WY\UMBXC96_AYE,)UY9P'Q>K@<-)- >R1ZB[>
M"^Z!521C?;:G9Z9:Q#7K+,^**H<9*_+S+<*=\4%-,X2)=87;-EZ<PR4A1K*!
M4H KLYL=_)&7?X0P8,VV2Q]%-"+(C0W68A1 8O8IQ<M8A*62AF [E:9[G$,7
M[C&C)4IF3+77C0B1*GD)1&7^,+42R3C#/ -Q>"O.7F?,%O :Y]A4()*&VAH4
MXQ3^VY$50/)]!W&7L+Q;U^!3 =].=Y=D;9N;,UXM7JA#G%L,DS!A+CWM\1-7
M[6L9/'1M8T95T_W,',_[NC:Y_WN$ ;.J!3"<.3";#NQ+^-/G%YC]$AE3;Z*Y
M-_XVBVME85*QK:M=C"&.0A")[<[LCV4L;K>VYVS_FIR+.NE6SK','C2X:WKG
MOM2WZM.2'T2$*C=>KT9"]BJ.&'D-@5+4G#5K=A0>BQAYA2INTB<JXIN)BJ6L
M^29$)'8'SJK;Z-@]\I7D\C*"QT&+9]X[#K;=&&NY(4E[":.^097!&W54,4Z@
M:^#(?"1"10\?Y?#;J?[N.Y!PIK3R4TJ?6;8M^9M3OLF1BT*F<9&*=@O'^QN,
MX6MUEK ]>(B)ME!C$6+ [2[*;NM^[/:AH.K&5.S^;C^)R#NWS$=)I1X5EQH*
M?2<O7 _7CS[ZUNQ0+=VU2C<"Y2ID$]4[+LJX-X\.3;=5'BC4*RE?+>I?OQA_
M3.JR_?4[[76R;L<VA$2#*+[X3P$LR<<!&#C+,N"_S"9D"V">B A\V633O*A'
M"&*NE&,]@-'X4:@3FQ:?X\]<I3:)!:/'D[=M=L_<*:<L7B,5U'*,L!;^N@>L
M1<>]X#\W6>K4E:Z!\ES--2:YZX\?A'GN-F,)BL?"L-/0$Y6/),[M[A:Y0/N
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M9QV4VIBRNN@BBV^2,\]#"F6*Z_WZYF2^[>B!XL2/N3MB'\3O7<=8Z_ );'W
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M/ Q13SNJ=..KA?2'9\G;M89RBVQMQ"M>)9/GLZO0H<:DB/O<95X.\01$.)#
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M(0S)%R%Q?&^E=GM DE;%C:7:/;'+B!)*$)DZU/8"%IN_S70#O*5V/=N4%R>
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M6_P1+ST)[>FHQV&A\O 8,43B.P&,O2B K<^'NE/,=8<FS;H@"#O*KZ:TOQ#
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MKTTHL[88B:RJ?+_BKO*'G^XMD\Z.08?/0]Q+/3>@"<1&8SSFX&*8G71M=%V
MP?K6Y;X ],2*3< AM=OXVCM \.=CQXP'6CVGLL!C(P,J%@5AU=9/5:)^Z Q]
M!=9MU*B'0RS.G5<!L;@%6UM41\T9_,T?NG/.Q_6<C^3]<*'_$6)>Z'3)>]F[
M8A5?-;9B@[+=U_@UV_@F37C>0)U9F)1N\5E;_HR!)3/PT2)FNVYCP!\?IJ9O
M5Y.,;I95^;V)7CG^,_;<'DSOS3%.!86+Q&;LN^S:<5%31_TJ!&S2)_]Q-GKE
M_\-L]%S"[8(EK6-EC'/=6C&AC]..C60>G-YUL%%+<R1<9(/J9CWM2RQM=G$V
MZ/O'CYH3KP4P3T\Y]J4.UW=BR5$,WWU23U=P"ZV?[CNW/GB9F:1=MX+CB[YG
M]8S@YT8Y,E[ )C1FHQO!"R5YQ!&W&:,'.F?_W-U11!ULNAJYV?OIW2WGS@;>
M@<6=;/W2)HZ(4-TM@$690Z)S3XV\.^>4BWG!+'\CTRWS>9I^NDZZ,:'PPEWT
M6_)5::VR;NVJ;9O)Z4S9B\9.O+0:70@MKS-M&>IT%,66G0O!G*4G7@J[SW/!
MW)T69V*L!][LO\@,B/:M1/9X#].1>S,Z)RXZ?DF\^]7 [ ;'G8Z>:QQ9.P0B
M@,T-T;9+LVF@6$&0H57/$L@];;3;=32NW^% -NQ3N+S\ZNWH$OB^FW>+/VQY
M"*;BKA=H7J.)6B<D'2-H*)I4,$K,AS][!'J1GL)%@QK9;JS6>C@EE'T8+.6<
M=#X%L*+HA&9 ,BB*'I MH;FQT>-@846JT.==?>WB%:PBL_:VT?DTGB?A"X*,
MYV\^-B)NS4X#Q=YCQ)DXG#]BHQV8: U$A\0)8,V42;QEJ7ZN=N:FJAKIK"/5
M#_3K/JV?&)5E=S6)4<F(D>488PF,)B^=N,4A*+7NYM@TL,V?X=HD>J &\>X4
M6LKQ8B9F5GTP_LRF'>=;?<PFU5US+*25G!*K2X?;R9\I@=Y'+,H+/ZHFYI]A
M+M<]M .S"NNSICBWC8: )@--V4]R%5.=571?W%!+=;P3[5R(+VHK-&<'%EMX
M60 :CA/ F)<$L$BB;/IIT'%T-LR@,5,TT\O:9U@[$:GJ_+5\?-OFV+;(HX.Q
M']V_*MK9V')ETVF57!DO=A+(H9$>JHKPXI=0<.Q7A\L'/5T.=AL9LG3-OOW"
MN&-%_$JJ$G[YIV@=?>&JK90SO_4B]]$AG@9G.^8:+P_CFON9.3]JP)6.1X>K
M*GP_LK?G9!7R<=J!0I\)?;/1DFCJQ>O7KN#4I-8)J0[37UNS%334U09[\;7;
M97O*"0%#J9;RF?6LE#C.(6Q?FL$<CH8&U;]6<_1FV"(T>*P'8090\5FR/(%!
M"&";>:3'-_KB<Q/$<&5B_;&/+:O/;K[^Y6O^RT \-!"W$>'#.WAO4OFB<!:C
MQ@2 /V&@N7H<'5"L,5.:V*=GSSUV>X:,?^Q:4A9M;LM(V%7YLCU=^WI$(-Q
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M(!];.I(N40YXKUUJ$.GWK0S.<&:7M$JL^A=T'E&]W"4C@.TUY&9$C=_SZA+
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MG3*V!SN$"K?NV"L+ _<AR:-X4'G]OE*J$]CRON-@QVSYXC9'3QH/9T<:M%!
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MX9-]EG4T9"J6G\S6;S=D>LO>2SW?6%NWZ\O)$O4/">??*(\<7[&!1?!"@[U
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MM ]/XP%2-NJ>N#>U6.?"'JKO_-3QKKG<QPT5^W:ZBB2*B^?NN*HOJ-"](ZF
M*U?]I0>60M(W]R,W'[V$0D*E3,T26)O6AC=^JP5/S4WK=^";>  D2YJED:V,
MW9S+RS$^3I$Z(;<E'LU\?]?U*?, _XS?9X!9>4EJ,;4C/ ,E"5MAS3ZVFV(U
M69GY:=8FL[ZFQ@<.C$:L6QR(#M=*L?>A9VT4NZWBL/6UM"WH#V_,(-"3D$Q
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M^.+6[=E+&9<.O;F%+7GPVXQNLG2&XX$$^D[T63SA=\^R."<.7&,7%RPR?OX
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M4&#1CY$.2Y41I2E\FW(4(^X^CKZ$^?3C3H#$IE7,@[N@-@\0ML>3K^!V0UO
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M)=Q?J[QB@_)J8!%9J@<1U'I_/O!>LHLZY=\-SJ7WO+'^D^&9O_/;'R$6!86
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M_<D;W8]RNRZ$K0Y,.>YQP%4>E: .?TRH+TUV) A[85G)S >K/OB_\H%V%'_
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M!?@%_WSY,\@_==W!S<G)S<^SDX?_WWVPFP!A7@[JCE!.#B5@AS 'IS 'NPU
M(S)R_T,\#N#_/#AV<')Q[^1!Q!! ?E EA(C/R8D(S8U(C%P-1ZX#7,+<(HH'
MS'>*GK_"HW1;3.]!\@M>Y6-ES>(7^FDJ^E?O1/#Q2TA*2<NH[E53U] \:'#(
M\/ 1H^,G3EI8GK(Z??'293M[!T<G]VO7;WAX>GG?O1<0&!0<$AKY,"HZ)C8N
M/B7U25IZQM-GF2]S\_)?%;PN?%->45E57?/^0VU+:UM[1^?'KD\#@T/#(Z-C
MXQ.S<_-?%Q:_?5]:IO_<V/S%V *W?__1BP/@Y/B_CG]5+V%$KQU_UH#GCUX<
M.X+^_$"8BUOQP$X1\_,\5VZ+*ND]X!4[EORBK)E/6?\"3?SJG7Y^"96#LZKT
M/ZK]0[/_.<4B_D.:_=^*_3]Z30""G!S(XG$* QB !;V,5P?^.[;25DHTEA:T
MOBI*'W4;N8<:WX)Y$^9MT38O3DM>PNZ$CM4-90X[9IU?</;E_FP>?\@P8.+V
MWS*LEM*ODS O#]46U$8EF>Z#;B3 ?*KTW&;\[B'?@29PQE;::?)TS;GG">3R
MV'JFUF/^=\\/\VU%6ZUPL$390+,FV;\TB4([1XAL5 (SZ%L,8;I_DX[U2;K&
MH':]X;S \T*UH;^8)A=8);MZ$I]S32M;MNS_[+'8Q[GD0Q(&0_OL8LSK1F^^
M;'SOTGQ==4"[''7YV)U0A<@J_$WH&KC*!KCOL($(/#*10.,1*)15VZ@-.K>1
M9#>/?,7R@3$M=ND__ O&W*P*QB:[R[6<[^F;:V_I[^JO/F73'O,)<X@-7*6
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M1*.P=Z-2#2VOUK1&T+ WW72/#,X45\)9'--UY*;2P@?J;3-T*8%VP1_4L>_
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MPP<2FGV101HE,31+_U@V@#*5=\1_+,?9/.^<<%V8NM ^GYI7561^\#QOA(!
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M8YW+>V35^W6?TI7AONY6-)% [>Z+)52<QHF!-;2+S5A!@Q*>N>RT-TNC)*$
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MR[VI1:8O!ZKZ&XDK'7<64&L+XUOEVY-.:-I%6U 103LF6,8"J,7T8 .M9]E
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M;QRDDU=8M$Z8?V&N 4552UI32VUS$_@"J<H9I1?*)8>8GJC9>_5=>L+-.]W
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MS?1+X-IT>L?@EGS)<,FORJ!J^P,]@J\5-*[>^K0<PB7<K/!+%<#C@RGP+C8
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ML9\E;GVVT>T2VNJ'KSUP6%-;5).2.\>3#0\3:!>Q8QD,<7I!-(S&CV'D-]D
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M(UFO[Z$G.$_1#[T(H4M>^E+U%+K[,IB? ;NJIIZJ3MSTB1.17Q=2<*$?W.E
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MA2#-9,DI \Q\&%^49OF&79U4GW'W(9WQ<?=@?K+!:<+:A//N[JY-AITH/5O
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M(?V7 UV23'P:_#)&]E%@64T?\ML4S"P7.  MZ64NB!0$N GX(0,"@AA!_Q<
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MQ$3=W@];0)#;XSRR.[?NW/G_ (:+N?\ 4$L#!!0    ( ,&#0U+VK)5?=Q4
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M4S.RI:N[I[>O_\O U['QB<DIU/3,[,KJVOJ/C<VM[9VCXY/3L_.?%Y=7?[A
M !CTS_A?N<AON&[AX(!Q('^X0+<"_S0@Q\%E$<&C4#: V'A3LHJ&X\/NIKZO
MZ21@$S,\I++U&26D9A=?X3CZ@_8WV;\&%O%_(OLOL/_FF@6(P:";S0.3 XK
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MNX&(P9&LM@+-SW^X?V)T2N@]K#?UVOR70_]S ?N6!@W.-#33UUB1!D2?>B4
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M?PJ>)ASY=S\U_G^DB)WY#U!+ P04    " #!@T-2 Z$_%@ 8  #7&   %
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M%B8PI;)?%RIO=1=DC& %J7A@=[+62<!^*_&XS.'EN@%*W$<4\W$P3T'=?+5
M1[\R1L5;2WAVT_VL[20RSQ>:8<H+I*XDFIJE3+#RJZ@[M^4V#AR?&8&AM20
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MMQWWRJTH#XFW^TZ<!G^-*.\*AYR!F=YZ/_1._'+H")VY.+,6>'$SZJ*=JP"
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M=6*J>53I#-A#0V'!+W:]@-Y#=!_NW.M)5E]X%S;;](8\ G5;B?JD=<C@*I5
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MC*5KZ@2:AOZHRS$:VPEUN#DW0I[*;A@&=3:=Z&I:#U.WO@=NI3.73URIK"Z
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M!,X_@%HEH'4";,7E!\^5%ABXP160SWE@$61\T5!UD^2D S#VDGH;=*4(T)H
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M=N]63T^X>%'1B$+E\U/Y^R@NBA=ED'[5R?WD5RH3*T@WX]7;P=@],-9>QL'
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M,_LH[O'1'#0T?$1QIXTW'Q_W@R#V";KL-V_4FX*;)C]\_92J!+V+ .'$I;&
M-,8$HL0)84P3!X;(8?(/&A$OL3F1<JHC*\:>X(S*K[CXDU=Z5X37 0#E6N8K
M@)_RHM+[)RK)MAU_GX3:C'R' '!DYFPB)NZV /OP;_#339UX>SCF/ ?%D+1W
MLJ]).>N<QON$<_;Z'@O\G4.U!P$(RHE9?EX5Y0IGU7W^^V-*'W7807E=\+=U
MNK?ERQLN>>U7S/B",VDVLCB!S(L81"[R(':8' 'NNHB$W(U=9N$.&%2X^3D/
M/NT>+V\"ENAV8),Z75Z"YT9)E5CUFU(38*TGD'<!VFH*B%(5/$E=+=;*PSX
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MD7F0!)F0G,5]B+. 0R\1:>Q%/,U"9!+FTWGVW")[ZNJSR[V AAU>.ZCI<<A
M+!P3Q1<- ,S;K)ZJ:K6!:N?QT[9&/=7KI.GIF4L&EAG#2][6N*,!"W@B+0CF
M>0%$ :,PI8D/@R!B6>"3+,#4K!E:Y^GSBV_YSE]XL37])+N Z7V2 T%P_$E6
M4EDTZ'NTM5KAI_/X:6OPG.IU4B7GS"4V,OB53Z,Z(HU"2F(?A1#SA$*4<@&S
M) JA_&83PG'(*27#T_;;8>9FW!^GF-=.P]'Y^3M4];[B\5@Y_J"'P#0R^_X8
M!7<I][N1WC#/_EC;_N3ZDZL'VLTK57&D4*W->4%?/^ G_,#+'ZOMP^.F2NA:
M>&'DJZ,32#@)(8IB#^(P]2!'Q*>98-RG6O6/M4><&S^\7^+\J:PJ1ZTWG!E:
MV%?QU;2[;:+FVAI?536:=L+>@$9<4,M[4V=E6K34=<&Q:K]?'71:JUX7@Q-;
M7_O&B0L-[_J@5D6-ZG)^'_]\YE1^A']=+>5CU(',=[SABP1Y'J+"AP2%5(6.
M2(X2(H1>$ <>\>2&7V0F'#6!S'-CN>]*-15ZPAMQ0;E9T?\!S^N<<O"RDWVB
MLK$&DZ^Y2YK7E+K>?8TO%=MI*-W1_ :TNH.]\D!I/X,2L>93-8OBL 9B_W.4
MA36?!VL%80<,/=!PYM(>Y-^>N0II*AZ^<"E)ZS9[_:U@>4E7VV)3]2B1E]X^
MJ=\6/$4T]$(&/:[*#F >0.+'L>JQ&&#/SWQF%E ^2(JY+3U*B7\%N113/M4P
M 778-&C:W*[!=6V'5_+?@)T&H%+A9E<&]54=I.W5 +4>H%;$HGD^!D>K)OL@
M0:8UX\=@=6+:CWK8J'I9W\2O>9$_;9_VC<B_\\UV72R2(!6>""@D04(@"OT0
M$A8AF-$@Y 0E'I&V^I":61>'G-_10*=(D;2XGVJQ)0.V<H-U)?B@FD^7D>]G
M/1=H.B:X#HS?!&CD!7N!P7<7, XJGV4%SNE+:/6]G;8R-PU TBRE=?DY;U%.
MZZI6%TIJ7;]O $,?!V/<ON!\J2J#?%JMU?E2)PWHE_6J+ \#-=YQL5KS>_SG
MPO<B1'@2P"A!"43<"V$:L%15/O11E 6<9_HAJY:$FIM=VU]VY4%I K9'D64&
M7&5K*C66A3>8(,=+QYG0LIU24(H+2ZG6S4&^9*79<>39#2"5=D"J]P9S9[ 6
MO<$<3K1>33J79FN;9=![US];8TVW1EI&YV =M?WL(;NA5;G!JDU#F:L/H%X#
MNC4SFC ?GWF(QCR%,<]"B *<P(QX&<0>YXR(-,Q\@PZS>H/.;:U48L..W.V*
MV97<Q([7A%YG2V0?4-?;(@TL![6NU0359(-D']RI-DE60#;<*9FAU;];TGS6
MA#LF,^T.=TV&]PY@\Q_;IR>\?OTF[M8KMJ6;)KSS.R_Y6N[//A=UX<O/Q7O5
M]6*9,[6TO*L;<?YXY'Q3WJOE1R6B5WGH"T3\.*.^!ST2I! 1G,+,YQ@*$9 L
MH%E,$ZY-^[:EF]OZ4 >ZKQMU0-[H(W^07]Q>H[;S*2B53@;<9GUV-5:6MYPS
MU^?/M6K*+=<H!QKM0*L>:/63/X"NAJ!1$=0Z@M\K+;4J.$PPKP:+VUO.[T2K
M8#O/*P&J=!?PW,SVNIEMPR^VM.54=(5][YIJ?=#I%E]7>!VLTLX&&5J,Z.DI
MK_RJY6W!]C%P<K?X(2_I<E5NU_R6E)LUIIM%$',:!JJ)G9=$<KDF#*8\BR'C
M@1^%*(DQ-^II9S3ZW);CCO!58\T#\<%>?O![JX%A++W9W.B=YSM#W/%B:A/L
M 36.!H!FM^J1B0 3UT$:@,UI9:0A#QG&>,K)U>:KW^,_W_&"BWQ3UN7=Y!_N
M>(&7E;>L4$U#JW@<%3U5E'R!TB2FG'HP%DA %*(4IBQ@, FQ_$\:D)@9A2Z-
MD&5N;/B5;W;A2U7\K)31C.[&3(P>^4T$MV,J[&JAW/2@U>.F+5VI_KC3I:++
M5AOP\<K,&'.C!4QM,N48<2;E30NX';.HC4<.X]1=Q.GGXGF[*;](FW;IMTU*
M><2S-/(@PYQ!:2-&, M4N&> .,H\(8(@,<MX[AEM?F%._[%=J1W>G4HA4#M
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M762 ODX'9_T&MPU8#Y2UJL[#OE49_A__Y&N:E_P3YPL2!2&B60 C[ <0^4$
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MK;BG+TDP4U^U56?3@'D9ZM8>!?.;^KCKU6!?S:LZFZECW#H-&^2R8/. T1Q
MMP[QBZ._L7?\&BK77>57GS# 3W(O)Z-\7"W9-U%EN5<M!.Y7[_@M?<SYB\JU
MN"U>[__@RQ>NSOTXW:H(K5_E)N6Q_*U@2B#%P=\*O@B#%",4IY"25*6IJQ)>
M/J90"!%@QCEGW*1PET71YN>)_Y(_Y54@0%WE1?D;U6^_W/[7?_[U%FQ6@'"
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M"(89)U[H"Y(APP!K[;'G=US6V1<JCT:K"6A5 94N?0U31\Z&'K4X0=@QV5S
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M\#<I=*.-R:4:-_H/&,9E'_(2/SRL>5TX])OXSE]XL>55]M:"<9SBR,<PB;T
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MA^'A6OQS=!,>/4O6.@>/EV2 CZ@1X)ZOG\IOXK19RB(*Y/]-?0$S/\ J,3Z
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MAG&61=1U,\0+QI&.;@T&I.W>AA<X@^]AL/5=-\$,6XCVP-G0U6>[QX]><O;
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MR!DALE!%RH13#L69=J;&%761JYV=[C503V%IN:EX.T)#;QCN@P/^-$:"VLJ
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M&-57'3X6S*0-%7F4486ILE)]O=#&U(BZ,1.T=MX!8ZDI?V1LM>.12X!>9N-
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M?9$44805Q(G)\J,HT1]]G,!<R#2*$&$I2]VR_(+:-[WISDXD?KEH5*O!NO'
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MP"R6 B)99!#GJ81,8<H30E6*E4L\X6?&U'A+OT&96Y#A";]=,#(\J /S8>,
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M\9 8SE]XL[CD5SW"5<U.[I%<89:HI.!I"@5&#*)4Y1#'$8510;(\P40BY+0
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M7Y?SN9%*E\]TO6IDU%OE]%G*BYBD.8)8"<T8L<2:,?($QB+37*%)(V6I]3*
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MMG/;T]OD;JUO"U,]&_N!GGP]&@^ ,"+W3XWI#BM&3KUAL2HW%,(#DUL';;/
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MO5RT+QOVGY*OOR[?_7@NFV2H688(32(<0<RQIF&!"TAQDD&<"ZY_0UF$G>I
MW&;.U*AX5P%!3^XKP'OFWX&JL=_,.^76 [\"R)Z=9T>[XW7)P-2[EQG;N-(O
M4F&\V4^,O0-?=GWT[GH?>==-O@W:(2HI>UKT*K65;T/O7+7E&Y_JQ\9?]6V?
MU/UJI=_;^@!(?;@(,R4S00B,$JP@PEQ"1BB&B&59JB?@&4IS%Y(]V<K4N//!
MK+VQI8'5Y'[NC*V#V/[O3:+H^AM=@/V;?(YXG>X!.Z:\&=>!"7!X2)T9\")D
M(8GM=$.C\M5%7P]IZ/+%?NSRRX::S4PIJWM6K5>4KV<$Y=3L[L(HBE,C2Y5
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M#U_Y6"S%??%>:KOG*5_)*F/I9W7YI2_KO%C?%[=ZC11FG5QHVRPDB500"9%
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ML&Y$KU)V5/47\A5X-EJ 5ZV&2S+*@<:TF\"F'J)IN*Y5"#0:@48ET.@$&J5
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ML]6I1)_?"6TM'_@I7]7W>3M2N[[MH(^\_3[&0/Z/V9JOE3^HBU>I#S9:?]
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MI7ZC;(,&FIH$7XIU%6VPJ7G#;.#=%R8UDBGV4525"3ZN]!23Y>:6:7*A?+/
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M-%OWSF1G6\3:%PMPH*!@60@150)2*3,8"9F@B N"0WMGS$>"N='!+IWLC5Y
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M2=_%DVKJ0<\EM4:SXO%16?=EM52K7Y0[H@AJ6P!%6*!\(!L!-H<7GNJ;TS>
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MLU1 YM-4.?<I39/(F-.,NUT:U74$;RHK[;3HH*QEUX7+JA];3'7S(3 @Q4F
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M5E:-'T#DQ3*2!(7$-XI$MNQW:01R$!"02D(=)U9=DP";O3*6*6I,A\",7R8
M=F*RJ20&!Y%!(_,-Z*!=B^TPK,X.)J<1=(9=SQLL9X?'B[@XR]>'D=7O),OU
M_?2O^3OEU_TD=?A=N=W4 =**)+]MQ);\O:)>2'V2$L@\?6^"^Q&D1)$7CZD(
MDY![R*<V;&7:\=+H2LM=UWFJJCSQO?#*"MI+7U5XN@%/E09VU&4\(&;<-07,
M$Y-7C?"G%N&#W.!C%^$O&N%O_0A;<Y@M7"Y)S+CO65G,%I%3&K-^WVF]XB8)
M<779K*U\D)-<USSX5I197:5OJW,_*'_Q4U9N5QAQPGB20AR&*40HEI"PB,(@
MYLJ'([[O,RN><R78TGBPKVQOH]P-V*M7ERYI% 2MAN#/@XY *VFY;>5LT,VX
M]#6&<F*NG7D4715K'@SY##6=[65;0NGGP8@:5H@>WO[0' :%S*J,82L>4N+Y
MB,(X8;%B=$0@3CF"C,1)["4I2W6<CGE6KT/35IP\0Q*O>B_./AU\!RS$$":$
MI5!(@2#2AR[4DP(&3(0QQ@E.HM@VJ<,0N.:Y0^@ ,+.E8Q@(LVQ)'N4H4_]<
M[[A>#[[IU,PZE\Y)IC)=ZKW(MTJ^M7[,?5+]EU"YS:VP;WWF_ FG6KW,D?#B
MB6'4]RXKR?W]1M3%AK_*[^*GR'?BY JJ%%X:T1CKP$4/HA1)B%'J0TZE$!Y/
M_3 VBEZTZG5I1FPCI+ZK_[0I=.)).QXP@]J,(IP#.#%[',NK3<,6S2GO[EJA
MY)(XS#J>E5.LL#BE&[N7AS'1:3WL#TJ%6\9VC[NUSKAPJ;YQ8RO6@2;[/*%>
M)#B*"88RK!*W"!\27WGGODR\,&!A$'K8AK!<"K<T7JOWADNPV>LH.- ?$" '
M#4%153MGYS*_UAN<=F3H=+3-./.UQG!B:GU11[X:NHYBX%RA^K;.45OSK%:O
MFW?6'0U/ ;Q+MG8JWZRD/@6RI]P_21\#0_OWV;V_;M22]%249/U5ZBO.53!/
M'<+SK5AG[/E@4"&.0\7]!*8D5!Y]F(0P92R"04 C1#D/0VQENPX18FF4WTFZ
MKR9[E2"@$KZ)8K.\&C!D5,PH>VJL)Z;F+LP;T"IP%O(;4*L!_FS^G,0@'H.G
MTPL*0^28]_K""*1>7&X8T]; 9#5"-2J.MU=U&HBO\JW>C]&U6WWN!R%AVITG
M/D2<4\60:0(])IGO(8DHLN+%ZUTNC04/YQGK^CR#-8("U?NC94*:ZX";49Y;
M&"<FN%K8&_#B9*A*-Z-XKI7988898WR<II&YWNN\N6*,47B1$,;\33OJH5E&
M5[^O"TK6GS*F3<'\_JU.9DQURD2=L_I^(ZKCG&_[*"7UW#XCL8@IC@E'D,0A
M5BX[0I &@L+83T@22I$R:G0W:Z0<2R.I6A.P;E51)-71Y0;LH_:>M!:'M-&C
MDDF/'<M^JIMQA";FOV9P]EJ (S7 7@]EW1V"*_4P74]![70\>',=JZ[-NH!Q
M.1+H?\OQ,5ZX'*%:KV:ZL6J-4K9;O4*-;7Z69<L1!NU:YJJY 0M<MT;UV^+Q
ML<BKT-NJW;+MC:\0DZGTE7$="AKK<@<))"+TH9?P*$*A#&1J= G1HL^E+5R=
M^RMJ)6*5W&W)@VHM*O=K%Z\6J_J'-BN4X6 8K$;N(9YZ:Z%;LA[4(K<U#VJI
M]Y1F6)S(!E&+]<0]LC.M'4X0MELE[+#J71$,FYJ/_>UT.V)ZRU<'!D(T12?V
MF2C>JN;O1=G>V8RY]&1$H/"(I[P3+J$N6@-C$OB4<L_WN=6=S?[NEL;EK;3=
M1-RUP)8A$/T@F^V0N(-N8HZ^C-H$-SG-4'$:Y-#?X[S1#4;:OPAK,'MK&*'\
MSQW9J+FY?M['KG[,9;%YK):M0]'Q6UK6VX,H\5.:>A$,8NI#A"2#./93&"8L
M243H8<X3&X:Q[']IE+,7OQ-$WE$ '#0 ?[8Z6-X(L!TA,WJ:$/>)^<HMY-8,
M-A XEY1F*\*L'#<0GU/2&]K,,!9\__BT+IZ%^"$V/Y4+?J&:X;KZ.IK0LC9#
M;ATZ\+8HM^5;\I1MR?IPDW651"),<<Q@XJ% L:6GZPD2 GF(@R@1L0Q9NLIU
MP)K@=^:D.9&X1I,<UY/\A=#33?B.G+7WW=0]9=WZJ$QK9$>L4PVZ&0&_YAC.
M7\MV7Z/V4!'TIKFM#SHZN*/IB>%U2>=3B3HK[4^,]^GR,'5W8XNC=<7077TH
M-B_KWQ[F0MD5];PRE<!OGK^I*782B^\S/R B"F <"Z%SQJ:0(F6<1R)A01A+
M$43!T*IJ,^IAPUSS7*7ZL7M\))OG??*6<^N.^%O_70!2EH6R4G0@ZU_9]@$(
MPA[TBTJ8"R_G]_J"ADZ 89L)YE6^,K-5;?%?SFNO>5H)?3=':S%31;A7&(EI
M2LG-J<@KU:![A;&Z7+SN-8097O5NV]2/NE---.5] H($36@*)1,4HD2'5U/U
M-\%12*) ;Y9;;8>?[V9I>U)5U.[V4$E-2SJPLM(%7,W6@O%H34S6PX :5&WN
M,@ZNR\B=Z6GV^G"7M3U7^*WGZ8%F^%GN67$<R"A-=35+92RCF&.(0^[#@.(T
MP6$JA77UX;,=+="0O6"]6MJ=YV$U- Q'0_7:EIO.$D#*!_"^MO@=6FJ]T#@U
MI<[W-*^MTZOM"V.D_^G!B528$+S4=\2:H2Z5;5/=$6NVF_/[6UVVMRI#N?)"
M$F+IQ1"C@$-$_!!BGQ.8B!"G(0UH@JW.O"S[7YI]4<EIG5S$"G$S3ID0QXG)
MII6\O@7[2RL\D,7FU^8B[%X!<-# :4:2(= Y3EMB)<+<N4V&X',F <J@9@:4
M<2N4*;$_ XZ\$$<B]J%/N8"(^AQB[OM0DL!G"0FPEQ@Y/B]:7AH75<)9'ZV_
M!*R?<$;!,#&5&"-@5\[MG+9CZKD=M3=?0;=S:AQ5=#O[P#"SXK,@^DBZC@!\
MVE7^3%5^+(EE$,0)ACX*D9J-K*KGY$$B,(HQ%4D@C>X,7>MH:9.S(R>H!&T\
M[ &%W2YB:V8IN$!LXGD\#"SKA?\:$BY7^(M]S;J47]/X=,V^^KR3$@K\-N??
MQ3;;"/YNMU%60'TL64<+KT*I($VB&"*,??6_T(=$1A@RD?) AA&AR(HQ;#I?
M&HO4@K99(+HW-/3-C')'U"^V!5 FU8L2"^T!VPT@VRI"Q/X&QZ#A,]P2F6A0
MIMXH.2G$P ').6@D![7H^T0]M?23%60PPFS"J@S]_;]F:08C9*[49S!K8V!R
M\PL)>72RR#="^<'B-*-/N4^D%7G,BZ7BQ"B*"42^0!"C)("QGTJ>$((1L\H)
M,4*6I9'EUVOYSP"M%.JD46LTLDQ3/F+XS-AQID&9F"PO)S7;YZ=M!N2%-M-D
M.7, J].$XR/$F3?'^'C<7J05=]#DT%MD9\I6M%4MWCPWE<.^BW7=ZT/V].:Y
MEFV?[/Q3<]+_YOE<8]^S\E_5 ?]*<$YB(1+HIX$N)<@PI+X,H8B25/U)E2EK
M57MB/M&71NV7BL9T:\O0YWT5OBX$-_H7#>T<*A^T.%2_/=LZT& T44J6#ON,
MGYC9>K+,#V?BY<?DF[DVO /N^,V-M-O[@K-)/_/=P[E'Y>4]QMDE&) ZX\-N
MN]L(G65*":-S<]3'-A^*S6V>[\CZG\5FS?_*N%!K\0^R%N7= ]F^_UL?\P3>
MFVR]UC$188H9#U,.8QXG$$E$8"H#"A/*(BRY\'#(C1-KN)!H:8M9K5.5RJY6
M"CPU,1?*[@&DT@O\U2JF2\^!4JL&MDHW("KEP/\9_.8!6BMHD3W"R0CW+SJO
M,FX3KR7_VP^913J0N8=NIF0A\PVA7481EW#WYAMQTM%\V4A<XG*4J\1IPP,6
MV</J_9DH2;+M<Q-93+EDA!,*B9<&$%&/0.*C!$9)(' :8)'&H?'">:F7I2V&
M'2N]%=0R7KL?5(.UR@54\_DRDZ!DL3RX0&LFRF\1JAC^+(2.#IB-@.DEYXLO
MST>XU^0_(M&K#SOP/CYGBGRW12[T*71913SX.) 8)0R*(%"^A1\JWT+HZRU8
M$,X0B:/0/&G?]?Z61I:-#7,0&>QEKB(F2JOX$E/0!YC[XZ"<QYB?&<41%O@X
M-.>UKX>C.LYLOHR1E5%\IIG7,WDOZ]1KT/:\-H"5_\BY*+/[7%_O_K9ITG%5
MA^5-2KB4^%[B^1Y,L2XQ&C$.L>=%D$O*?"(C$0G/F).O];8T1N[*:\$75T$U
MX%R74$W,N%U1P5[6.E7G]41[ ^"S(%N7,,Y$M4=P/NWAK.+"?G/$KZ:P]++K
MU4;FXU93?8Z8U?BEX3>W[YH+H*M81BQ,L814<N7]8^1!FGH)C"7EL3)Z,>'2
M[H9FMWF;KWBF6LW%5N>7)L_ZT,+^9O8>-Q*DB+"$0!_)2.&FRU,D"84XC*ED
M41Q18>02C$5MCM7F2Y%#UI0#?&H*.A<2Y(Z@-#M,'@K0Q&O,\85VMS?83]5U
M?6]]W_[LM]5/-3MW1_W%,^X*7I6''#M)',0A(P)*$>K=SSB$-$XQ3)F,$R^6
M2<BCL<6NRL66^ZO%&U_0JK1-6N0.IJGG]_E"5LJMG"2%D!DN4Q>P*E\I*8^9
M]B:%J\Z\-31NCVY_"*;W&K-].G(_I1&+E+T4,IW6(M)\0<,(DI0D3!E2$0I"
M.Z/I7#?+,YY^/*C5OU[MN!(8E'N);2/5SH!J1AQC@9K\Q$3!<I!ODG3NEP%P
M&Y1UII^9PZ<N:_HRT*GGV0';3T=%@[YM"IEM]1T,12^K2/A>S)($LC31-3+U
M13$A AASX47Z#ED<&%60O]+/TDR%XP)93Y6H[06'LA;98BNE!U^#/2@WJ$U,
M!6<!<XJ4Q7:3&\1FVFC:Y^;05PL?"1?ZLN%[G;U1GZAN'T36EC)47JCJN+JR
M4<705/$SQ=Y4JT$O]>M"2L&V0+4A_DN'W#0#4=]O[ [4Z=N_@;L'H>\UMD)E
M.5OOM$P/^DI/]DAW:O*U=R5U[M&.B[Q]R#8</I'-]AELBF>RKA:%*K2GTD<U
M6@+U*!4/9"WK-\1I(<=-%9ZI!%)JU+%!Q6Y;ZFBAYOD_?OO12DFJG+HU<FHQ
M6"N=!==EMEZT>_)% C66^MY2I8$BZ+)89[S:Z2OWT>NJN_IBTV_@MFQ%D>#N
M/W_<OOG^<2_57B3U\*:N^EHWVM-[F]/UKVR]WK_G:E/Q^L??NYW8\_I\&XG7
M=3C:0C1X?)@]K--)?I6_%P4O;W/>Y((N?Q1KOO+]A'./(YBP!$,4QPRF$1(Z
M#)<')/(8"8Q.9*YWM;RUL>:@:DK<Z*@]Q1#ZLU;347'!?]>?O+ZSFW4*OTM
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M@+%,$X@"D4 2AQ)ZE/G(8^K[89&-W7*IHZ59*@<Y*[<+:$D'EIB_B*T93[A
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M8/,P"7T_81"GQ(<H\E)(0X:AS^/88YAB%AN6@)D([GD.QN8#W'37VRF(DV^
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MI=B*\D/V4WPKLGQ[]U?Q3:@O(-^^VXF[O]2?SXJ:U?_4 \WWFF#," IC&)*
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M]1XRC8 CA/(-0N"Y$=*)@:9N?'1>UQ.-C@8N=FQLU(>AB-6W0OM_IP+5=TT
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M=-_@=6=S=ESV6=3*\!3JTF6S&?RU:FM[K/\AR&J!TU!R'"60(-T-*\Q#B(,
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M1'=V2E"$$TRC+#+J(3 XRMPHNQ>R[_)AZRV< M+4KK\2GM$M\$-D1C@1'83
MKQU[:J")+<X!75_;AD,7.^^=K#29O!/MGQ_+6\9T[</ZLV"B^-;$/[$\D!&/
M$ RHR"$BB$,:YBE47W] U=^G$>)V/9M,AG4XKAR9%GH9P6HKI/4^PF6TC3<
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MT.!R!WI\5ZP$4P^MM:G6O9D,I93B2, PU2>:/,409RR%09KS+(@BDL3(HD7
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M5SE=5SS*L3Q^43]7-5G^M*HVS[]4:_6[SH0LRHW@G1Q5J5/-?E).PEWY=R6
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MHP1BD7(8)UP@%*11QHU6Q)-/G]M"M9//XLCS%60&9\G7 #%V0,I6-)<RE:_
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M*I9>,;D,'=7 K%"<$OS+53G3OI>:::NSQU'U=_#S=*DW"9Y7W7R#3GEA)*B
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M"KX7*\?(N@G(E./=\E]I;O#%S<O^-_3-ZP*:^?*+DT6\^8-KGYQ1ZZ4-AJ(
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M$J2H''5&6"VK',S<)67:\^SQH7*DL)L S$WRHZ Y9FI!1VO++6%D1%@/R?E
MO-.$F"I9M:?#I-JQ<@5GY6 1-W LO*\O7XY =APR%TU2/ *5Q6@:7 @F890I
M6.9$>^X,=5-&75>DMA!XC9.1JJNE)BS5^V5IG;W^5HI 2WO@DLGXO*MKFTDJ
M!9$,>2AC'42B% S+%%BPP>*/=.)5RNP?(ZJ%H&L4=(TF^29P=-F^_VVIP/]0
M>A2\RW]=;:<5SHC.+H:(1EF795$&?UG#9&G++E)D+&!L6<5;>HRJ%J*R49 T
MGNP;N/9P>] EKH;+R;YE"O4?W7P^,]Y0HP(!CCY":4^.[!"C@(:@K21)$V5J
MX&D?XEH(W4:!U>B::,)075*NJ&?61PYQF VAB0;GE0""_S,2-_)(J]BD)^&D
M<MPV"DX.DF@36'BU>_%E*_M+H,\$;K"1<P*&1((A9Z!@K100E?72IQ1DKM*_
M^V&26@C@1L'+2%)O8*^ZEJJX%@/$($E(*D(D'GTW;0T8ZSS8R%UF^/]<I_7[
MO=1,6XD[II-SM*P; ,QN=G=,(N48/"@;(WKWGH)/O.1#95"(]6Q<E>3A$Z:G
M5RM)';UBY$G2;"#W<S'LM?3!6,2/ZS[\_:R?H]!7VWD8EZ+Q2A*N12Z%5^4
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M>=.F+Z>&Y/$::R>?>8>Y%YL5>DOHW__1#Q,"BZ1WOXHS&E00WEM009=B/NW
M8NP)EFL3A18^Y#H]Y9]"Y;09SJG!.9K^&L;HQ0":-XN/&[_J8N>6V[DA)SD/
MER+0>PE)9(W\0%3,H5"'[(4@(*-FN:1]&:V2@S^$V&DSH5,C=FQM-@3<6Y[W
MNXP_^9R6ZV_OYVZQ1A9+;=]P%7,61,@>/PQ4Z@@8C/(RV$F6\-0I@W+FH4I0
M_P0:I\V03APUC:6[!C*E=U;@PYP1&[00(@.S-I76)*FT',W R]PO7'O1R^=Q
M0X\#9;7K&%/;SG$TUV9@='D[_?[+ZS-/T%^A2D'D89@H[,%K3R'FS'0..MM*
M.:<G$CKM78RI$3JF%AO:V>]Q8F[T_9AY9VSP%@%4.CL)A3ARN/1 $6N8#SQ3
M_VS^YPW*IKUK,3T<C]!3P_A[Z)*(Y=19R0PDC/9* VA>EI>%[)0P(OCL;1VW
M<D\")[YC,34<QU!;0ZB\XS,_Q)^APGF9,DK-(7]2"S &37_FAE&=8E:^RFVT
MO2F<^#K%Y,'.&(IK*-1YW2^O\SAD<.\1YDQK;ZBD&6)@I1N-L.4&J$2OF7,2
M@S7.5IEO_40Z)RX/F<AJUE!B.\9S?Z&6:2 A>1; D.*SR&C!$BY!!J9)9)G%
M.M-M]R=Q/X#^HYP055)=N]5)NUF3]PL2O6>?,9:SF200AA,PCG)0,C,7I,E9
M5TD9/9W41D9W5JU.&DM3315XX$;P(7W>+,.96Z&O<FWL[<Q*%6R9<.JT$R"H
M1NZHM! ,LT)R'56LTI;C^Z0U67,T&CP>WK+'T%1C"<K?ND5?RJ>&EH9G_1Q5
MAY:=2!="8.#*=&7!T>%PT4CP1&;)%*.&5G4=[R>KR>*AVJ@;04/M^(777=XW
MJ]4&)8<KZ6V_.,5WG ]%4%2E0(*SP,N6(6C4Z%YP!YQ'FJRU&AV9VM'T_:0U
M62A4#7[C:JJ!\!EM]VY)O<L#_=GJZ)R7H&C@Z*$8CDL(XRN=DZ>$&'1NJZ03
M;Q/29(U/+5P=I84V#=F]]CEXI[1P#$(6N5PX*B&8-1!8EL1&$HRN<V3R'<*:
M+,]Y#B-VM)8:,&'O+Y?.[A[=JVZU[:A9ND\'(34GE$)6OG3.% P,QS^"Y2A
M96V250L:[Z6JR3J;VC[;\?IIR-)M><+@Y^70T/4TE3:PBQ7*<]O5];)'\SU2
MG47AA1*9@$JL].)W!"S+!IAQ64J7/4^A(B8/H[K),IS*F'T&_;81^%[;$JX%
M]D/^_3X&:;:&))-!$PRVA,9@RW.K@"OEHT\A^U!EK-@3Z6RR+N<YMO6Q==C
M+K^_-&<J6J$]"M [C\YS++-0<V+@L@O9QIQ1F-/FIYNLT*D%S$J::^#LI+!5
M_BM'Z5_</ V-WXIO$] P#]<R%O'F#ZY]\GU:=N7D_6:[ALM>\?C%F<-]YP,:
M^5]R3J@$SJ6B^!_(G,K](V+!EKHZ)BG/QE#J8A6K^[QL3AOXCWQFTS!"&E@_
M6ZK?Y>N<O%L<)3,T(0DY1FW1I"0([@180B/(P$6DSF=.JQC_"KQ,FY48>25,
MK>LFCC>/8U<$%X@6&J0M7?28,V"3=<ANR,)ZEX6LDCVK#^)JJ8Z6S/F3]'<P
M7#\/FP;RO5PW %D;T>-S%EGFY4"..@8^2@XZ!))*MU$GJQS6UX=LM4Q'4Y!]
MBOZ.A.POB^NYC'_^^8[P41Y_'WXU_*;\RP\I_U3^_NN'-S?>X;O^-"TPV A_
M#OWY]B4E>]//NUAR)I<B7O6[,MB;/*RZ\\_S6Y,(?-?Y 6V4[;#VG2?^?$7K
M;2YV#[X#FV/I3E_7:8$*^].1LS<O7O,N#X4<NW.![1LO0T*5+?>E]U9FR8#P
M@N'FJSR$&$U*.3I79X[Q7M0=/7[TXB6?AKZ-@DO!HC&0RRT[88G "#5GX$DH
M)[G)1E?IM'Z3C&GKB\9'Q9WYH8<+O8$$U7"$=E4*]7[9GR[=^<G7KO19<L:)
M,!RCQ3(\PX(CI2,\%^@4&\F3J5(X]#!)C4#I $7?-W/V>*DWBY]7_;GK%C/M
M=93>4W!4HX@<EV"8)*"9X)2RH(VI8X >(6IB#(VD^+WP=( 6)D14<54>8$3^
MELY]6LZ4HM9(:B$&I4#H7"Y0&!16*/-]/"?B=A'M7?_G^Z]I$2&'J+*O(M<V
M$2)VG/#D#*,D@::$@,B$@_-EM"/&K5XJPX(41R!$/ $A]=J'/B-"#I%KFPCA
M.TZBT#)&@F;6EFZ_@63POF0WJ">$4D48]T<@A#\!(?6N<#PC0@Z1:YL(83M.
M) _<*2-0+.4X+S$-3E.4%Z+><)NT,/D(A+ G(*3>@=$S(N00N;:)$+KCQ"6M
M+9>I()R4RW(&K)01M$Q:$J^2B=_-PWS_-1,?I#PC0@Z1:PNQST5 N,TF7 Y4
M7PW^?#+")(6NO!-&XY;I,#[T:!4%DYH8K:Q354HX'Z6JD<;G(T30H\F^ 2#=
MXF&WR'P,3BO-(<N,3'#4M@O!0V:!JA2MDZQ*X<2]U#22>CE>V[</>(\6?0/X
M>7_QWB'%N3.F)@=&M/3 %9-HHR/!U14L9&0GFT2E4I6J'>\2,RUZ1M#QG:K%
M(P7>QKG^U:W7"R>>*>++W1V7RTKR,8*)P@&EF0C)8XRV2HGW'4JFW:?&!\QQ
MHFX"+2<Q=D4!;O[>=?'-8G<M8L>.9X%0S2TPA_Z;X)&"%Z7>4E)+%64LBRK=
M%1ZE:MHH?'P4C:>"-A 5PN9\,R]GQ$.]=Q'5,IVEQ:K[DK83G7:L$2FUX4F"
M4R6Y8(3%R",*8"QJIIBB(E1IJ;DWA=-&\Q605D4U3:#N0UJC=%+\Q2T7W>)T
MM>-#BY1EE &2119$0D%YCI8Y$(WN9<B$QBI;W_WD3!O[CX^G$83>!'@^E6+F
MS?+;]9V<$RZ5P7B#RHPK *TL.$8M<!*9"#DQ76>@_3VT3%NV.#YLCA5W$YAY
M/PCO(@E*O6=2$<BE.Z&P2H!EQ*&.><A>RDA3I6XL5T1,6RE8(1H[5, -A.Z_
M][B9+M;X5/S$Z<7(B8M\*$E,EJ;367&,*"E#\QA+MU53N(F&:5:E=/HQHJ:]
MG3@^>$93P*2V9K5<SUYN/39TT+:W%K87<=[ED]A_'O13<F6,1FD(JIQ)GD&$
MI##L1'DQ03!J$-IAL+ 'I/!]U^"$W]V&TKX$-=+K[O"$=!7)3VB8]N%GM^QX
MQJA2Z A>:0J">0TN^@ T")%U<A07XG-A:<HL=1T(/ %?!^BC<81=#7K>6>+,
M>.(L<MS,K<&E&2AX;R0$(9D2J4P;WV<K',=NW2*N7=0= HRGV+5CM-2 \W7O
MI15T(&T(D*-5()Q$5T*A T!%:2'$LPVZ2@/XNZ0T<J-XQ*/:PZ3< $YN7V9^
ML[A[E^ #.I"O^^4?;AEG7!J;94Q@DL+U)IT!;XD%:4TRR4F3;)7;O$^DLY$S
MW0-AT3^?CAJ X% XLRK=&U.<2<>"S0EC7%X:R2M6S&P,8&@Y?TQ69%;O9L:.
MB&G!4U7;]Q77'R+Z9F[#WI4-RF_;CN%]OQQTMM[V-BO&_E-_?TP\XT1RXED&
MJY+',!N7ITGX%>X!5G!<LX)7ND\V!OG3'BD_*V"?7]W-0/W]LL_=^FV_6LVL
MU5I%YU!Z9IA^J<$8]$A%YAD=4LM4K)-JO21AVN3&<T+N0+$WD9]_Z("S<#.,
MJO[DOLZ4)M9D[L'D+)"U<NK@D@"9J(N1>Z9YE0;#^Q W;:3PG# ;7553UYG?
M-+W=SO1V.Y'&G4C[PO8L>@S?C4*^5"S5T4F"M>6Z<HGEF2?&<G83@@]4G3_A
MI=.>0S\'M*JJH8' X:)7\L6V?B'+TG#Q>DO;U4-^P+_M^BM3%2AZN1FC,5ZN
M;U %+D4#C+$07)!$Z"KU[&,Q,.W9^'-:R4E4WDZ7XQM% ]O@;3?5,LZ2ESD8
M22&;4(H'<%LP@@0@^!45243+ZM=JW*1IVM/XY\3E6(IIHOGP#6;^P\TWZ8*7
MEWTY/RX#*F?)4!N$T)"IQKTB&0*>1 >16ANI5HPJ5AUN#Q W[4'^9+@;0U5-
M '#@YNHJ71PZ8JT+5Z\VRQ+J;R/K89F5R1Q"&1TA!99 L&Q1D%X!D8QZ'JFS
M>I]C_\-2-WL2.6U[X6=/T-1070/^YHW%MN/J:IF=G/>;Q7KF<45D9CAP@G(3
M3#(4GE,@933&Q! HJ5)LNP]Q$T_^GLPPCJ&K=IS @:5MSO[NFKK%=[=-[0NN
MDV0N@"*9E$KV#)8( I%SZ;35/-:IXWTZJ1,/ 7]V4UE/CPT8S <X'/R4^QE,
M1%'FE :JG041@P>;RP2:1 4MJ1XOTC,"]6%*)QX'W@!.1])BNS#=+L3AE^^&
MFJ#5+U_3,G3HU<R8RLIFW#E,C!QCNIC!&84;26)<6Y=EXE5N(#^=U(G'@C<
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M7C?A5]X%+BR,KVD9[!Y+9UE'P0@?(&",'8U7@NHJ;9$.(7;BBR*UK&!MM34
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M&(TT"JSRY3)=)&@R8\%(]"#HT!+3>@U&\P2148,2,B;5=<(>I*P-4W:4_O?
MU.'*F/JR_8LW;UY0:G89N)"SU.52B/.4E7*0!(YG9$1J@NM-1&3F>[[5W<>V
MAX$C]-6/(KRIU?[[T+9H[9:7P].\=AK#$)?++46K$ECA*3"9. 8)Y6+0?EU>
M;CUXX@%T]51_C "G5OZ_EXL/G\_<\OP2N8%[0B1PG0@2GSDXEP*4]I ,W3MC
MR'Z]Q&X_>>))<_74?Y0(I];_^]S]=[H +F?"E>'5H*3Q)<-N<5-T"8*A$;VN
MR(AP>^G^^E.G/=&JJ/>#13>USD_FW9?T:UI<F"OF-97&@J+&@8BE[M.42\2(
M5Z*8=,3MI_6;SYVV(4Y%O1\AOH;BAVL1_<>$,G7K-/_V(87^=%%:15UO_[HM
MJ*,T.4,<Y%2Z&@8IP-.0@7G%F;2)R5AEF.V!]+92%ON,@6U-C?Z8P-VM=!]%
ML!JA124KMED'L+*<MQ$I1 C4:5VIVO% BML(DJKBZ7@,'Z#<J3?>]SU&"5=+
M/PU7W$-_7OHQ##Q?E%_IT@D;#4%45)>&R*S4BEK@'G>7H".11.[GA^WWPA\.
M;X?HOJ^LB 9,Y)L%\I ^HNJ&%NYO=Q.UA]494D9165]:BB80VD8PPA=6LK')
ML.*LU#""C]#42MW1,^S18VFF79#MEJ1!HJPU :)W"CGB#KRU"22AB6LK? C[
MW)T="V8M[*>CZ7X_3!V@B 90]3$-/5PPK$I+-S]9Q)-XWBVZ<M(X#$O:]BRZ
MJ ZU*J!D- >"01H:?HRY+/<"@J3>:\E3R%4*VYY$99.H.P0=MX]NJZFJ 1Q^
M0"TA 6?(UK7*Y!U/EU=Y7&G@IR$&@EZ!T1:<8@X4BRFQX).YG28;!WU[T#9M
MV%L/<V.K9>I(X((?MXC7FBF[TG!TV!=RS$J84@Z*/B:(*!6N&J9!"B>IBY*F
MV]-&'X@ OO.B5J:(5G3!1I=WP]C9K;0@@XA:*]!&11!.&PQ;0@*O=(XBN>#4
M?AG=[[YJFCUN?)7NB94#Y#LU6K;GTG1G(VDD,5"1@1=74W#<9"RS&4J_=BM8
MH%H]Y5"?3NGIU%#6W1/]0R37AL[9)>519,\Y4)+1 ^.6@/<!*><L*N4S(UD]
M0>=L2D_C>71^B.0:\%WOV43?7MYG24*AMRT\R"0IB(3[ITDF \U&,_3%3=#/
M57AX250KDUBGJ3X\3#<-X.Q^9_S-XOVR#\CB+#KNJ$ ?W\HR)Y(E 0XWW:$<
M0@7E4(Y5<D#?H:N-+/?Q -@K-#I,&U-O7)=]5D]B'$3DYKN!6:N_?BXG^&<=
MLEB^?Y>O,8NLO^S/S],R=&[^6S=/JW6/LIX)[5C*A(%F*96FZ+A@@P_ C..>
M:26)W\_;&9>NY@KAC@/BU)J;&K0O\:==</-A7,AJ5V429U[$X)4)D"TIK59-
M!!,-+CZ-40ESSD2R7Q!V__.;*Z<; 40C2+*![?$>V7P\0ZF^7W8AS33W(I"@
M@/F$PC$4O=(<'$0M,B&6)2NK;(Z/4M5<C=XX6^-XFF@ 5A?F]%._6Q@7W*75
MK\L>-WII @OX8H@2S:40AH!U'$,6D057S@='JO1E^AYAS14"C@.N4?711"?,
M86[D(VS-!/<YTTP@^"&EICTXIA@XBR%02MDF6:5[SO<(FW8$7C6$C:J/!BS8
M 84^%X>)Z">^[0O/5Q^;44>\(\R#]\Z4!*\#YU29@$2]]VC :1TTCLO&M)/U
MJF^]$^AZZGC@M>N6_^'FF_1F$5-&CW:=RL"0^*;,%#GM_'P[6'!5FC24B0T?
M4"8SIVBT*3"(3.-F$5T 2X.$+*UEFG :S'YS:P]Y^[3#^.K$$M6UT*9!O5HS
M;R+*OLN=NV3U(J J"VPWD[!,"5FM-N=%+H^*J:Q (JQ(P)+"%4BH $^$ N&S
M)I&PP.AS=;6IQ>.T0P2?TQ0W@9(&%M"KW6L_N:_7>/VU[^,?W;R4-MUF\.)7
MLTB%]3P8H$(A>P2Y=49:,$X[4VR%WFMPS).7P\$43SS>L!JZGT>%HV%U]'9(
MK\HLLO70'_B@]D<W_OU([8X>ING(]D;#SG[]Z5<CKEQ0QD<#BM A8<Q+7\@$
M-$1J!+J.\G;3BP?\I_N>?K29Z5:?^Y6;_[KL-Y]7ES,-!]>C3.S:I+B;[5KN
M-MS3NTLKXUR9/)VT%"!<8N!+7_NDD](IZ$QHE>+]8PF?L##D:)3<,33/J<0?
MP]X<T77MOL=4L#XU>JP]#"]%?#FOLA"-)""DQQV%: \J.N-P0PM*[G=OJX81
MNE6<^\+-W2*DCV<IK8<:[HMCNROHKEY\>Q+HMU42SNE@>=9 &2LCQ$KM#>,1
MK'%9NC)M,%1)0S\3?ZV9M*=@[CLW2)J 1 -107VQ# 6JUJ7,LD7_4PH+0F4/
MCE,&G ?&K(PJL"HAQ/.PU]3MES:0_>RK[\DP:V#Q/8G!W]WY13N/)+6V1A&@
MCI34G0]@ WIZ2=JL%#I^VE7I>G<@O?_HR^/IT#O&W3X0!U.?%+Q*BW.W_/MO
M;K')N)=OELC@%5,7%^@$RRHF 5KD<D]4.S0QQD!0S@L,**3?LWQ[G[=-"\MG
MT7E?4P$-&-#Z:_LJ<6>3B\YS MFG6#K=6;#4)$B6<1VX,2)5:0KTC#PV=:/R
M?Z@?<QC@&EB+-[A\G,F7R&<7=]_,B V61I&!26Y0'Q1MCLP<$I?,*T\#?J"Z
M-_,$@O_1W9D#$?B83U,+#FW _BY'[Y?]EVZ%7[SNEZ6^XU?<N=\M+D3R>UJ_
MRY_<UYFR*I;[="!,0DMD;:EILA:2T<9[%94355H['$'S/_H6,1KXGP44;>#_
M2KJ_]^M[6;]B]V_+;HVN[!^+68A)4VLEY*'?E(_EKHYT0#55DD47**L%_H,(
MGO82P@^$_/IP>#KL[1;VBW1:[NU\FL+I&2I<=W5_LTRIC2PHB(X0$,[@(G?9
M0526,,\9E:Y*F\8#Z9WVSL0/B?U*8&C XK_?E/OHJU0NLW7KHI$/J:0FROQO
M_/-\<WYR7JH,M[_'Y3:S7I$DE00?@\5]C5'<TF0&K3R&7/S_9^]-E]M(DG31
M)_)[8E]^2JI2C8ZII+J2^O3M^4/SV"2<I@ U0*I:\_37 P0W$*020 8R6#/6
MUB5PR_3EBPAW#U\\MZY)O')O2J<MWW@N.&\+@ X0OE-X9)O]6DJ.M:ASU\_/
M% N<8>"@G:X]GU"!B\Z#\\[(B$I*V2IQ97]JIRTC>2Y(;P^$J</R;^;?20&+
MY8\E_EEKFI<S/%^M%N?I8O'Z;__[S>LW;W\_\X*GDK,!DT.=\5%(@LY&P,"\
M$3[[H(;EZP]XV;0E(KWCLHG*IH;@KN,D7:[K9-Z7[9/$1.1>%0DR!5.'AQ)C
MQM-)@A:]4%JIX@=A<9^W3ELS\BQ V4R)_68'?LBT#B\/RT2^^=N1\@!WTS+2
M@-7-PU\3,E\1>&HJUM]G%U]>7:XN")C+F_0L5D(B\1>@4\[7IO@.0K8"2L(B
MDD[)F29E,P/I.[X5T).ON4U^]3*YDE2=A>8DJ&(S8/$!8G#&2&=K;_4)Y-#)
M;.@6:'K8)ZB!JOK?B=;WFT?M1YLGC+PK[:+KQ'N3CD9:GDN][Z4C!Z4']"R
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M!JG]D1=,4^_52/]C"'%J('S\X\V[#R_^\QK#7&/4D0Q2;T2H]\D1?)VW:XS
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M.#4.?IU?S"Y^_'V6\A^T<5:=?,XW\JEWVMO1Z]69,S(P(PP(U.11QI# B\C
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MGO-8@O>2#QFGL_<)]A.ZIHWA-X-7"ZU,G*\WU,Z\#?-85E1$K6EGK9FKT65
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MG),."BH3E;,:MV_G?M*A;]!K)P?,L3K>U9!O?(%W$&?\:;\PP94HWDDZ7J4
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MF, Z+2R/Z(O9:I_W6$SV_H,G5_JQ>EJ,)+0.3)CK7?+M31HQ<6JY#@J$#L1
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M0EN6(3D,1DH!4GJ2@K2"+(,B_T^5A(Y''5F36LL6S(Q[O3C^RA@)%AT<?OW
M.NRP"NO-\C9U[8[]+*S G!EMD"61;4 #P4D-QB;K7<E)F":W @/S,>Z%ZO@+
MXOQ@>'&AZ1 =4_=[<,MP]2P]4T_!L\HFL\!KK9&O!<]:@A.8((CD3$X%56@R
MQ6/$P/5V)2WNB%B\#I?5"_OX!7'YICZ"$/#Z^]TO_#2;KEY>B\E??U]3^3,N
M)I^GX2Y_-),9R"[70G)-NY,0!;S3Q+_Q0FIO%/=-I-F.I9<;WAZ"[)U)X^-"
M9.2&KQ]JYZ)5T0>2Q**3#EB6%*:C1/ Y<,!@5>V<8)3;IWYAKRZ9MV_MI$)A
M9 C,3M5'#R#:M+O"@)EB6PC,N#II(((7%-Z&)*T)6I>\5Q76_C :NROFD1K;
MUOD1XAM9Z[]/II.KZZLUX=8J1T0B%.YK3F$BP/M@P*1LE<V<E[VF,.RE]P=O
M'EGSQ^AM-H001^^Z_'OX=H]TU**89#(P+>J0;8X0)3HH.K-ZJF6%W*>+VW[Z
MO__F<8XD!]/_T4(</\__;D_<U+>LS* U#E%2Y%S0FSH)W8(+Z('K*%20PN3M
MB5X[.T4\]?QQCZ [<QF&TL/86=Z/65B7A18R>\(G!;FP6 =H90BR*& Q.LZ"
M5KGLUW%BUQO&V3X&T]OS.#A"B&,CX>.7V7Q)S[K*=]RLNZU%IK@4 JQ+J_Z!
M-4N#)2C&%6,9VJ+V['>WZQ5=8>$8W<T&%V0'Y^M/'1!\F"S^N5HL*7+I:GIL
MC/4BS9"]C,)*VCN+DP*]Y>&)%F5MSK8V1(U[%=39#C6X%KM"Y'VY;19L(+<M
MD=-F<\UB0Z7!Y2!IP1HAN%.9IR:7FL\1U=\)WW&JWXFI$_70 :9^G<V15MLO
MW]*7&E;0EW^%>5Y;;%VXX<4Y2!1*T"; :J-10Y(RAD7E,BW%W )3SQ'5"Z9.
M5?WVL?!0>N@ 4[]-Z5FX6'X(2_SX5_BZYB*5'%-4J79#(?&(>FH>33UT$)*"
M3Z&4;)*-]#0YO:04#8RC 63? 8+J8,^M-MX$?XPH%(C"ZN@\$R!$:VIOO.Q=
M)E,NF]BBQZ2,FV'0K9]UDL:ZP]R] 5,D FD$AIH!8<E5$+H>KVGP7&M)7* *
M33IL[2)H[!WP-$4_BYLCI3[ZX0%.)[/YV]D2%Y_^FKV?38B3R137!;T_7^.G
MO^C?[S<?UQ;9Y3K!SC,PMC 2FB/6;+ @F?!2EYBRW_-8X?"7]X2@8U4^.Z/\
M.[!.CVWV3;=P<@5"* C1UOI-K@6Y"HJ#1J^*C 4M;U(I]C0YX[:4Z'1G'$!S
M7>)OO6B]X"%E%2B0-M6]5 IB\'7"L0\R9L]$;I*7M(N@<6W;$,K^(7Z.D'P'
M"-HP@/G58LW3W2ZPF;@9D^.Q)& RQ3K\P(.KW3BU9M9H'J3*L8VK]4/:>L/5
M,2!XY'L-JY$.0/9V-LVW7&UB7RE92;[.JPLD(D$Q=406H3@KC:X5,=L#BX8!
MU1.TC'OHT 1$ITJ\ ] \6UUUZQ1\P,N5S&JKGI51=QQY2K6%JZYY5U*2>1<*
MP3$;F<U,,]_(6!U#[K@]E3KUS<Z@^0[P_00;ZX5O273*)P2E WWPT4 H]930
M<&&,C5YDV=!Y>TS1V)%I>S@\[=V=J)L.0/:H$(^XV@PA02$=^0I J['.JTL6
M(M>U/Y#.P65>L#2Y+-]-4A?.W*DZW]Z(AU% !U"ZJ="\K5C;; TW64J*8XPN
M@9-*@DJ>G!:M,B1GK&3&B"R:7',_0].X3>,ZW5F'TF&_<-SXSH4<YUPB)'2T
MMH1/$#AWH(I0M+:8U&UZ-3U+U;CV;3#=[X>I(Q31!:IN+FI_^?85IXM-CASC
MAF)LC>1*N$QFOXZ+M4J3X2;[+[WB/#2)59^DIDL4':/M'7?DQXM^Y!*8NVKO
MIWLP/OXN8KUG6:W F"(WNI!5]X63O I"\+PV(?/,)J:M<8-52IU"Z+A=,SO;
M5L^J]=%+?'9QLAF3F()/)DK@GE5>> 97,V5$)M>9UJV-9K":G^=)&:\(['Q@
MF#71R_AE1!_#U>)Z^OGU9+:87$TNP_S5YSGBO:-O+:WDBA 19:2PWCL%/L5,
ML7U!VEV,S-MWJSNGCC[_IO%0-*1"9ZUDVX&S=F\/N-T8WMPV4;;"D5BD)\^A
MSE%RQ)8KHO9Q43P*98-034[1GJ5J+U#Y?Y'M<W@]=@7*#UB7:SWO61?Q\(NB
M74J%,3 AUB;<*=<C'P%&,IF*)Q//&J5+[B:JE\/=DW6_$U4G*J(#4/TQG6.X
MG/P/YLVY][OI/<E=1!EL"*@@8TU%]\283Q1\^2*C89Q)F9I<>OV KEZRN8>&
MUI#JZ !=#U/_'N2JUSC__K HGX+AV=8!%'5P/=,./*=0GUNN0S'%6M-DK/+^
M)/;2>G%X<]9$25W ;R.SAZV%+X*0,6AR=&4.)"Y%GP6.')@*4AD58O&-RSD?
M$M1+$\-V.^4)"N@*2+<"NM]Y\<TDQ,DE;?\7,CN.V2K '#TYJT90Q*,8%.^#
M*"K+T*8#^;X$CINQ>PZ@#:B@#H#WE!=POR<D+M_/<1F^7>3DB'RO(6'-I;<H
M:\D@<2@CMUH9'DL3/VU? L=-1VH'O"8*&KN^9=BQBM&BXHCD*7!![-:Q=BH7
ML%Y):4+FN'UZV\LPS&9W^,/#<5RU=6 H]Y^UR%+,AH<"F&HA4&01:FT0N;0A
MNIK]RFV3C))AIV$VNPAK9RK;J*@#[.T];C&P9%SVM)R\,A0^J4R!.WF]+K(Z
M^TEJ<DY:0&_0<9C-SI#;(:^)@CH WIW$/N'\ZEW9'*A?9&>YT3Y#L+7\WV*I
MD[<E04-K1B%7%+YQ&/*0H/U.@MG+0]8@&N@ 2:]F:7+'R_^Y#I>3\KVVQ5X5
M"N$OW]+E=<9<!VO,IK4.O-"[/Y%;F^HH/8\URS34F79>@K<, 6MB%TE0AM3$
MI!U+\'Y(?(&7$F?18 =(O0NXUBUT?KHF*J;I^]/QUVSY;-7;XB(6ZUD@/]?J
M>C,=:YL=H3TD881B)!KA]TDN.2%P'H2/_7#] F]$QM3WBYMTLB6B=5>IS::T
M^&5UMI\GT^5L913JKZ>P(%%]P#]QNKJ]'W9"RF $M9RLTD9J'4QD8<7[G&,B
MA-<^SX4 'VU"*$XK+Q)C(37J9/-WG,@2T"@NT1/7F:)237+U>35,CV-AWF!I
MD_;S[XDLIR'[C!-9#H'(R#GE&VMWT]$I$-V:8I0@4ZH-X0/Y@(Z(]QA5DCZ$
MO9R@O3)L[[_X;SN7Y2 @S ;0RHAH2FN:+UY=7J[IKXOV)J4T::]DU [(N[*@
M DJ(.2!(6704.68L^C&R%AMH+6CS_CS[\W]MWG$#K\U7V_!ZCI+QDFZ/U^EL
M8 'W ))?_OAPH1)YVLX'"CF%!)6=@1!,]<&SRYEYJ]T3EY6G@H+>/ X(AM/?
M-B .%>:H6?BW5/_'Z_<7UF:?6=; 92:V*3H$S[VOLUBMB4AL/-5,XU0(T)O'
MR1QL!X%#A=G!$<Z.IEF:&5^\=&!-;9H5/(+SA=7Z/&8YRZA=DXNY$WK;O<3Y
M+\>X)@-JKDO\;1I2,BL5*D.Q1)WS:),@T: &%+J8H@R7;2*\%]7;[B!E[]O;
M[A#)=X"@?3JI12VE=3&0OI4'I9@'BDP+,"NR$4'&$+ %F%YN;[N#0'!$;[M#
M--(%R)X[4T?R[PIG&C2&>'-W$R0S8"5Q8[7(WC7I''!Z$=I+'$ESRJ8YG!Z[
M N561K<JUI3:"JL&';5VE(&C" 2L"R5RY)P\TNY2ZD>ZYSU(Y_NFU!^B@,&
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ME$1G&7=V^P;H1YC8\:8NYC(T0<<0HNU@6]JUK=_8U!2$-L)"8CZ!4NC 21;
M)*>Q2&3&-SI9/W$8]QG2KU^<2W645KM"Z!,37:WBP3&I(6.0H(I+$)W*U0GP
M@259N&I25/ <4?VY3\>I_I#AW(?HH0-,;0V%WC"T-N&%.V%95""<Y[7YCH"@
M,X/ '3.*2:E#DQ8/SU+5"ZI.5?[SX[E/T,2H*5<;=I[KT!Y5#I:\#C"%^%"1
M/$CO+0+314:4+CO9Y(SOU D+9^BTU?5F.I1.>P;HIOF[S-[J(,"7VHO"U<0
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MNE$/VDYSG./F83#:1%-_W[3'IX:!]I'[N"=EG21 'B/'#K(@K8I9$5K!1Z5
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M1^,:'L$*I01ZTCIOTMW@(1D=.-_'Z?G1W=#QTNU@I[K?Z>W-_1:M7(<HBT[
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M@TWRT:#7@3HF/DM6/][+D7K?[IHXG!(ZA53MC4><&!Z*3.C IY1HS04.D4B
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M3^2N^+J'L"@)H7!%OXF:RR:=N-L=;^0Q!&,BZ.Z8X^'%V84QWXZNO_+J3?F
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M..F\1JS!!,LVF:3:S/]L0T[G]GY@4 Y<6#X 0LY+3Z[*G291,9=Y71P='3%
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MG)Q (YQ+38Q<+Q.!;LGLS;]GI$B?IE^JT%Z^?_/VQRF75[U.H22EN#3 UWM
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MM,PV%4&VL"XK-G4/K$=/]W1,A'KK;.,)9S^?Z5![^8/K/_=A+K\3SK4OC/D
MQJ=$*N82H.6U?TXE+K(,+#59/[S5Z3J9SG0@7N[:PN$%T\7M?(>0>R^3Y:1X
M%%*I#)PS<HAM\1 4UZ"CEDI*1]?*<6H4[C_?N(AK@(RG,D4#B*E']+V:?24V
MSA??)I(YH2UY+4'6!F$A,S@G'(28'>,A11Z;/+H\?*1QAP2,@+']A-$CK/XQ
MGZ=_3R\NKB)]G'VL;NK5/TT<\24)0[Z89I4V3!!\J576F0>=A33-'XR?/.2X
MTP)&@-Y0 NL1C(\\<3(FK% N IJ8016IU\.+(24CN4,ETMU.H*,_T(P[9& $
M* XDKAZ16'WDS=]M$I^5O_2_5_*<I>LH__TGDLYON,SIY@_\/E^N)C$6E:4-
M4&H#GY+: ":)X(LS3)7,8G''<@P/)6;<D0CC>)%'!4"/2G!5K:2#T3QB[4B5
M$A23!H)U@5!7 N?(ZD2:S@H0F]4?CF%D=Q9"CU"ZIX3<1&&0@B\BI-1&?9_K
M3A0#.I'*A))-X4TJ?8:J[6]6E3@"R X4S^Z(\U>(F^6/N*)SM ->[:?B@:&.
MQ4):SR+TTH'/1$IFS)9HM,ZYR4S2^PXS[A2$$:"UJP#VMUZU16H0$#W I1M)
M_>^LLE9(%LB[E4F1GUL?C[S  L45HM4X94P3:&U_Q$X&NQ\GXWRHB+HHL[F?
MGD?B_I_R !YC+A1_@4&A045=P!7A(:9@"DIK2VI2;'/PR;M,5A\,JJU: UK)
M=_R[><?YE[FXY*(AWS;Q]<I-#IYN'0A9R:RE8#K<R3H>9>+HL=/70Z&N(??'
M[CV_GUL/O/\D983,)0$WCFX;)!+1<P]<>9:#9%FE[29([O*M76:GFR!K<!GT
M":X_,ATF7LW,?/%YOEA-_W?]^TV4SLB3Y2&!]4:!2L60GVLEV67NLRM!V5 .
MP-BC7]YE]OD(4!M.(N/?E(]["!-MLU^;92WH[E?9.0ADD2&'I)AB 2DP.YY;
MUV5*^#B^VDZ2.!A6=^+:EM5\F]:$82KU[GS8\%5XCYWV"!5V5@837$"P3!E0
M(9-MP5(@1J&]T,%YUZ3PIV&%W?<>E>_?41G\+L?Y+!+VK[1[]6=.=8MP78AU
M68L@;OWPQ#-B"T4AM5G>D\EU=7I1W29LG8G1>^G:!)\#G+W?ZKQ=L';7AAU;
MJ%TD4;8A^M9&MQMV91)+D<$E ]K+ZC4P"Z%8K*VPUC%N,;598G7(H?O-\[7&
M[B!B/!G0;B:CW_J)/S93AE=3O)A(XG IY-\$I6/U33349FUP4?)4**+/<C3[
M^]3A.UD;.0*(!Q7KR8#Y>YY@.7$B.&NU!9;J&Y&MDS=UJ%ZZ<S$7+;5JLGIR
MMV-VLI1R!(#N*:I#HY^C0?&O>0T7ZI3.<)$W)3^W<@NS=#.],$'!4*CZ/AHJ
M$V3)=5 [AQ*U9U+RPN5H/L*.M(P;R8\)ZI9"/QDC3'S_,K_:#/2F;%Z8.-.,
M%R\@<D>N$T8+R(T 4:0((B+SODELN^=YQZT*&Q/!APIO[#3[-C36GN^+"_JQ
M2[QXNYA_R8O5MW?3CY]6RW>9#H6S:_5,*?HBR.%7!4W-]"5 GQC=3E811^I.
MTCLE90_DWX<\U;C%9$-C<URA=5#:N.^U4H? 3!=UB6BMEJ?H5!F1M/ *K- U
M.N42*$QE(.MX#2>+)D>J)P?B+@'C5K+UYC4<)-YNC/"]Y%Z7"4R4\]$B!C#1
M%@I!K21-90B&*Y%$Y!C4D^\#.WS?N"MUVAK.X1A](B;Q]T\X^T@_\')&#%R_
MIZWSRL)Q]%Q&"*ERLF0'Z$P"R:1-4DBZ#NQ81O#^(X^\;F=,NS> #+NQ=$^2
M.;U.R6U^YFU>1)+/I";A@B9W):*M?>0A #)R7#B7CB=CDMMR(?;!1QEY7<]H
MGN5P\CD1V[DN9?FQA'XY29;YNI$(?)&.7&8I(6@LD%.0/(J2Z#/'LIIW#SOR
MAI\Q[>5!<NLX??3[U:Z%Z>SC]V4+RTF4Z((NY._J2#Z+T@B(1@!3.JT;1U*;
ML63;'W'DU4#'1>+!,AJL#Z=EO=*+F[M4_S6+>;'"Z6SU;7IS.N PU4P[?=7P
MM4[[4WJ$2JCB+!8K*%[)+(/RKH 3@H#L$C-1!5%\$]UO6 EUQY*7!X;\O?P[
M7EPFDLK5U/3EVRNYT%_4>=3X>3J[\I/SZG(Q6[Z;7US\>54,/=',LN R@QRY
M)$ZA U=XK%6)FJ6LH[F[%&T8GK4FK-\:JEU0>M?(=@6'#MS6!^B?".F%R+8.
M7S6>8D%7R3 6-'<\*VV,S$WB^0?.,RX8^P+-=O-U=Y+@WD DEV0Z3^]7N%@U
MGDR^GM&Z?)>7EQ?U\OR3A/3[Y:)*[^WZ#/33;S?O9\L)N4 81*R-R8:#DDI0
M[,@=<!:-\5P:U6:RVC#''[<"\!3!WA(?_1KI^ZE^2]0N[J&9*Q]9BAIXP4 Q
M:Y3@O/9$<_*\F%C,C^!]-)UXX/#CEA.>CT8,@8U^]>%ZDO=V-!LA+',L4 QM
M-=&L+3B.'*Q2T@1KHF=-IGH-<?AQJQ=/41_:8:.?;L,'2']WO;/\-NVO\<LR
MORDOOGRYF$8,%_FJ8X3^ZO7T\W2UR31YIYRPM>J>C #=E)QNRHQD'H3V*0ON
MBPE'U))#:!FW.O(4E>9HR.E>A^Z_3M_GU>HBKY\$_FNZ^D0_7P5WN?HT7URU
MEWH22*@IVF(\V9&Z6!L3K[_S)4GE0Y1-WG<&I6+<FLQ3U)LCH.74O+ GB2\R
MIN0,@V $KZ4RK!8?"&!6>"=#]AJ/F7#:CXIQ2T1/456.@);N+Y>)%HEG@1&\
M8PB*U50=IEHPYDV)HBA3CKE3;]R"T%-$\4X2/##9^G*66C[*KFL=?B<';GXQ
M317^?TYG2/*XZBA?Z^35Z^0^S[#;?_A #Z][4C/04^N;&^7Q/PYQU8[T]@95
M;\K/Q_HQ]L0IG@RQ$42HD[Q"[15%\@UXHA,Z%R,+31X8!SG]H2;S14KKF!PO
MOG_)JUF9+SY?-\UL'@<_D,A^H__POR?!NL1"#)!"$?5J4%#[PR$*+SG7)OG0
MI)]OYY..^Z9U?&S>M:5M13M@V=5X-O9#C:[W*GC9]2N.;6_OHZPKJQM-DAHC
M YVCH1M=%,"J^"ISRX-"54*3>*0+J_L^?LKI\B*_*;_C\M.?%_-_O[_\\N7*
M(\>+'ZJY7(OQAX(6<L*M20&"(+4DIX?,@90&R-]*6LH8<ILN@#W/>PX6>!><
MWK7 QQ!S!XF*'V2NS=-?\]G\>N'-59G1IO7K#I5,&J^CU9"-36M^UGY&#99)
MCEFGXFUC,.]RW'&+!GK"<C,A=U')_0\*<FMG8MV;_35O"M)_T"-K3V(@#XRQ
M0L&MYHE"4A4K/9&4-G.EF[QJ/GZL<=_OQP?G@$+KRIYN]K7?&AA\2[T<*D47
MA8=<1VLJRS0XP36PXHHLI19P-MD\N/T1QWU*'Q^:C81Y%N'736_HVD.Z&:+N
MWX\P]!&.';[MPYFNPKN<BTU<*^ Q$I95B>!*9F1WO5&,V2Q\DY?9+L*[.M*#
MOFOU%J>IKO4ID7.?2@%91"!_GD=R@B*"2K4J3&;;: 36G7.<0SBV"Z[NFN)#
MQ-*!6W"C?^F: N22EZ+9I@8]4\CH$]HZ$L;QI)0,J<GU__-1SB$\.@Q;!PEG
M,'B-=YG_A8L:#GX]9"CZ_E]V[ OZ<6J[NHJEB)$<2U?WK5M0GM5B?":!0O-(
MW^E,:3.BKHNK^(?[_=OE<CK+R^6+^#^7TTTAZF_?;OQI[8U/C% ^%KH%C&41
M%&9;C4"$["4+QH7"8Y,6S5T/>@Z7^2[(?#BN:B#8$6_[Y6(U>;N8U\+0-XOW
M>?%U&O.+OZ?+28J".29JZ@+7.^LSN,0=<<QP:0)Z$[;I+Z'/OP%*^M-=0#YT
M@'$!UU;<\P%YWP=VEJ2(&PJ6?\P_XW0V24QSP[!F83VY-UF1WOFB("7!L@I!
MBJU*S7<!T,^G& =%PPCV9Y0<R.6QASS]>?D9R8O)_\R?0UY,HF2,9TXL<*FN
M84\60DP1?)3!.9^--^DI#^Z>SQU=Y(=*:3X,RSH((>^QG6LU<-D%R[@'IA7%
M*^NGQV $!.LQ:"95+$WZ>1\XS[C!Y%&NFB$ETBFPZF\7.6\TKF2E.>>F3E@F
MM6-: RH3@!E-<7>NSS!-_.HG3S:N7S.(_+? U/["Z.&2^O()%Y]??-P8W:P,
M)FT,!.'JCJ7"B0[/(#C%+'/*%>>VOJ=N?71_6#A ;G>OK?V9.#H$L-:KK[Z]
MKC]VK2$LTZUM,RE\"&1UM4=P5B;@Q2(316%4VZT_ON_3QWU0/\H-- QG>X/&
M1E&DUCR@#<0!74!9H<DEPP)2%V%5,C&9[8:/WO_YX]B)@23VF/SW8-_8"'@_
MOYBO/ETN9AO#9J,1/I$E<VCKS"IG 47DD!,39.NX=&F[X=MW/K@CF>\CI?E
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MYQF7VYS1S5JO;U=:E ],R00E*5Y[)Q:(Q45PQH3,G-!%#W*YL?N4QRDO/#Q
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ME8O>U^H'2XAVDC- Z;WU'E4L;;(Y/U*_V[LM%K)(]>V6%"K7NA(!+GL.).6
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MG*HF@,.GJX)D3B20(L&B))]4.P8^F0P^VTP."+(0!GD"^O>H[]O'A=M?7Q,
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M3:K(-*60K N5=V7#6RX1O"^"=E&VRG.?LASD&?>Q%IFFE(1EY!8Y'14%G*&
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M"IA ++%/>YF"47KM&62*U\EC-1E<X **- EUSC';04*-H9L*B>-/K!Q*[1-
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M?":S+]$:<$[1Y*7BX*J/J.H)+HI4Z?&Y=)1]!W;'PCX"'1L-WU"'!E5B]DI
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MJZ6^)"5%'D-0$'0VD+3E#E%'NF/;9:#MI6G:GC#-3-VQI- OH.Z=4*.5TLQ
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MY<60?()!,-@N.YVM.CX(3F3FU-[R'D;\=3&__;K\L3R42ZQ_L&MV,Y&M2<(
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M]!K#,GYI+UO,]>)>W37#M(?(,"!JZE] <8=!EE3/-S2&;Q'P14$!U4@E:CO
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M,IZ1FU1-)6?7O!Q"6,2.*6Y(JE!P,02%132=D3RU.N?P R785V-$F)(QGK1
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MH:MD#UX0S#^SZXK^XN39?P!02P,$%     @ P8-#4C?S"2J2!0  F2$  !<
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M'H]SBRM2U8-XI\NK&Q]B>*DX L@:_[*;@2*/1B%L?J9#!;JMX<JK3'1RU0;
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M4]Q(B82;1S W4E"M&V#.&H%HHL&\O.H;%WWT%FID-H.&7M=F"1++_J@VJ''
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MFG=(O$OKMQ[,@_RC-.>)6>T>LP+"FJN;RL5L".':^K@%5H6 /9WGVQ %(0W
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MWLV*;OQ'[VBXO@-D[BN'Y2@@V6%^U@A]I#URD=A90]=(+!,8GGM ]7+Y$>;
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M7)+O0!89JT#<Y <5$A#>Y,*R[UF[ ?'BV3QW38-,Q"M5EM6=[E6T4=(K[()
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M*DRN& J#Y9 5-2[OEN0'_E#6!CI;4Y5V04=*GJ#B<^-[+5ZRB!-!?'Z4NXS
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MU@P !3=?CK27E48A5N+M4U1LE]QY2'%T-DYF.YD>NX$9:G)$' ^<1^RD1JE
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M'MT2V-O/5("WKVM<&]+S5<F$V8Z+YK +-:7ON3A<[K9K4S\HR__H6O<UA3-
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MB9:VH4B#%[ONUW?FS,SNDKK$+OI0L7Z*%5$D=V?G?F;&Q6E;C*%>93(S32(
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M/^MN4_[R-U!+ 0(4 Q0    ( ,&#0U)E1\(; 5D' #2"3@ 1
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M+3(P,C Q,C,Q7V<Q,2YJ<&=02P$"% ,4    " #!@T-2^GTY[*\C!@#"F@D
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M,#(P,3(S,5]G,34N:G!G4$L! A0#%     @ P8-#4ND]2LWA30  _U0  !4
M             ( !-]<< &)I:6(M,C R,#$R,S%?9S$V+FIP9U!+ 0(4 Q0
M   ( ,&#0U)C._F]TW(  "!V   5              "  4LE'0!B:6EB+3(P
M,C Q,C,Q7V<Q-RYJ<&=02P$"% ,4    " #!@T-2%0[PDYT)  !$#   %0
M            @ %1F!T 8FEI8BTR,#(P,3(S,5]G,3@N:G!G4$L! A0#%
M  @ P8-#4DMC9S?(. $ AMP! !4              ( !(:(= &)I:6(M,C R
M,#$R,S%?9S$Y+FIP9U!+ 0(4 Q0    ( ,&#0U*K^PY8Q%8  *18   4
M          "  1S;'@!B:6EB+3(P,C Q,C,Q7V<R+FIP9U!+ 0(4 Q0    (
M ,&#0U+F ;+48\P  ,/Y   5              "  1(R'P!B:6EB+3(P,C Q
M,C,Q7V<R,"YJ<&=02P$"% ,4    " #!@T-28_JOND7(  !3]0  %0
M        @ &H_A\ 8FEI8BTR,#(P,3(S,5]G,C$N:G!G4$L! A0#%     @
MP8-#4M$TL HWSP  S/H  !4              ( !(,<@ &)I:6(M,C R,#$R
M,S%?9S(R+FIP9U!+ 0(4 Q0    ( ,&#0U+H.JY_$\<  &[Q   5
M      "  8J6(0!B:6EB+3(P,C Q,C,Q7V<R,RYJ<&=02P$"% ,4    " #!
M@T-21ZH$N#G1   ]^P  %0              @ '072( 8FEI8BTR,#(P,3(S
M,5]G,C0N:G!G4$L! A0#%     @ P8-#4K^E#FYV%P$ 24T! !4
M     ( !/"\C &)I:6(M,C R,#$R,S%?9S(U+FIP9U!+ 0(4 Q0    ( ,&#
M0U(H,R'N>*X  %;3   5              "  >5&) !B:6EB+3(P,C Q,C,Q
M7V<R-BYJ<&=02P$"% ,4    " #!@T-20#"!9%W9  !A @$ %0
M    @ &0]20 8FEI8BTR,#(P,3(S,5]G,C<N:G!G4$L! A0#%     @ P8-#
M4O!/=,0.NP  DN0  !4              ( !(,\E &)I:6(M,C R,#$R,S%?
M9S(X+FIP9U!+ 0(4 Q0    ( ,&#0U)#FA#(5/H  %8K 0 5
M  "  6&*)@!B:6EB+3(P,C Q,C,Q7V<R.2YJ<&=02P$"% ,4    " #!@T-2
M/JRWWOVX 0 K50( %               @ 'HA"< 8FEI8BTR,#(P,3(S,5]G
M,RYJ<&=02P$"% ,4    " #!@T-2)U0L T"@ 0"Z_@$ %0
M@ $7/BD 8FEI8BTR,#(P,3(S,5]G,S N:G!G4$L! A0#%     @ P8-#4KB9
M,&51<P  %98  !4              ( !BMXJ &)I:6(M,C R,#$R,S%?9S,Q
M+FIP9U!+ 0(4 Q0    ( ,&#0U('=U^:9G$  $J5   5              "
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M &)I:6(M,C R,#$R,S%?9S0N:G!G4$L! A0#%     @ P8-#4I-(H3>!8
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M              "  >G)+P!B:6EB+3(P,C Q,C,Q7V<X+FIP9U!+ 0(4 Q0
M   ( ,&#0U+[7%IU9P<  .\'   4              "  1OB+P!B:6EB+3(P
M,C Q,C,Q7V<Y+FIP9U!+ 0(4 Q0    ( ,&#0U)+V6%)R"\" ("P%@ 5
M          "  ;3I+P!B:6EB+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" #!@T-2:EA2&_*9 0#B11, %0              @ &O&3( 8FEI8BTR,#(P
M,3(S,5]P<F4N>&UL4$L! A0#%     @ P8-#4JYEJU?)'0  :J8  !@
M         ( !U+,S &)I:6(M,C R,#$R,S%X97@Q,#0Q+FAT;5!+ 0(4 Q0
M   ( ,&#0U+68]?T20@   FG   6              "  =/1,P!B:6EB+3(P
M,C Q,C,Q>&5X,C$N:'1M4$L! A0#%     @ P8-#4DX]*@]8 P  $@H  !8
M             ( !4-HS &)I:6(M,C R,#$R,S%X97@R,RYH=&U02P$"% ,4
M    " #!@T-2WHS0JC@(   G*@  %P              @ '<W3, 8FEI8BTR
M,#(P,3(S,7AE>#,Q,2YH=&U02P$"% ,4    " #!@T-2^\<"W$,(  "3*0
M%P              @ %)YC, 8FEI8BTR,#(P,3(S,7AE>#,Q,BYH=&U02P$"
M% ,4    " #!@T-2-_,)*I(%  "9(0  %P              @ '![C, 8FEI
M8BTR,#(P,3(S,7AE>#,R,2YH=&U02P$"% ,4    " #!@T-2:7EDE1U]   !
MG , %@              @ &(]#, 8FEI8BTR,#(P,3(S,7AE>#0T+FAT;5!+
4!08     -0 U -H-  #9<30    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
